cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	39.72	6.55e-153	2.62e-145	1.08	0.88	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	38.48	6.11e-148	1.22e-140	1.06	0.87	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	38.05	3.68e-146	2.15e-139	1.07	0.87	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
LGG	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-37.4	1.64e-143	4.69e-137	-1.02	-0.86	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	37.4	1.64e-143	4.69e-137	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	37.4	1.64e-143	4.69e-137	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	37.4	1.64e-143	4.69e-137	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	37.37	2.12e-143	5.65e-137	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	37.33	3.19e-143	7.96e-137	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	37.29	4.77e-143	1.12e-136	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	37.21	9.77e-143	2.17e-136	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	36.82	4.19e-141	8.38e-135	1.06	0.86	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
LGG	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	36.76	7.04e-141	1.34e-134	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	36.66	1.87e-140	3.4e-134	1.02	0.86	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	36.62	2.61e-140	4.02e-134	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	36.62	2.61e-140	4.02e-134	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	36.62	2.61e-140	4.02e-134	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	36.6	3.23e-140	4.78e-134	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	36.39	2.38e-139	3.07e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	36.39	2.38e-139	3.07e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	36.39	2.38e-139	3.07e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	36.39	2.55e-139	3.08e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	36.39	2.55e-139	3.08e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-36.3	5.71e-139	6.62e-133	-1	-0.86	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	36.29	6.46e-139	6.62e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	36.29	6.46e-139	6.62e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	36.29	6.46e-139	6.62e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	36.29	6.46e-139	6.62e-133	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	36.21	1.33e-138	1.3e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	36.21	1.33e-138	1.3e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	36.2	1.52e-138	1.35e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	36.2	1.52e-138	1.35e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	36.2	1.52e-138	1.35e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	36.18	1.85e-138	1.61e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	36.17	1.96e-138	1.67e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	36.16	2.19e-138	1.82e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	36.09	4.59e-138	3.74e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	36.07	5.54e-138	4.35e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	36.07	5.54e-138	4.35e-132	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	35.92	2.21e-137	1.7e-131	1.01	0.86	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-35.81	6.41e-137	4.84e-131	-1.01	-0.85	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	35.6	4.87e-136	3.61e-130	1.01	0.85	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	35.43	2.67e-135	1.91e-129	1.01	0.85	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	35.35	5.48e-135	3.85e-129	1.01	0.85	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	35.28	1.11e-134	7.64e-129	1.02	0.85	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	34.94	3.13e-133	2.12e-127	1	0.85	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	34.7	3.3e-132	2.16e-126	1	0.85	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	34.61	8.13e-132	5.25e-126	1.02	0.85	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
LGG	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	34.4	6.05e-131	3.46e-125	1	0.85	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	34.4	6.05e-131	3.46e-125	1	0.85	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
LGG	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	34.4	6.05e-131	3.46e-125	1	0.85	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	34.12	9.6e-130	5.26e-124	1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
LGG	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	34.04	2.08e-129	1.12e-123	1.11	0.84	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-34.02	2.52e-129	1.33e-123	-1.11	-0.84	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
LGG	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	34.02	2.54e-129	1.33e-123	0.99	0.84	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
LGG	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	34	3.07e-129	1.6e-123	1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	34	3.29e-129	1.69e-123	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
LGG	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	34	3.37e-129	1.71e-123	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	33.92	7.4e-129	3.47e-123	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	33.92	7.4e-129	3.47e-123	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	33.92	7.4e-129	3.47e-123	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	33.92	7.4e-129	3.47e-123	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	33.92	7.4e-129	3.47e-123	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	33.92	7.46e-129	3.47e-123	1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	33.79	2.67e-128	1.23e-122	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
LGG	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	33.78	2.73e-128	1.23e-122	1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
LGG	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	33.78	2.73e-128	1.23e-122	1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	33.68	7.47e-128	3.02e-122	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
LGG	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-33.59	1.83e-127	7.31e-122	-1.11	-0.84	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	33.58	2.09e-127	8.28e-122	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
LGG	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	33.53	3.38e-127	1.25e-121	1.1	0.84	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	33.53	3.38e-127	1.25e-121	1.1	0.84	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
LGG	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-33.53	3.38e-127	1.25e-121	-1.1	-0.84	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-33.53	3.38e-127	1.25e-121	-1.1	-0.84	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
LGG	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	33.52	3.79e-127	1.37e-121	0.99	0.84	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
LGG	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	33.5	4.43e-127	1.49e-121	1.11	0.84	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	33.5	4.43e-127	1.49e-121	1.11	0.84	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	33.5	4.43e-127	1.49e-121	1.11	0.84	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
LGG	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	33.5	4.43e-127	1.49e-121	1.11	0.84	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	33.5	4.43e-127	1.49e-121	1.11	0.84	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	33.5	4.69e-127	1.56e-121	1.1	0.84	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	33.49	4.99e-127	1.56e-121	1.1	0.84	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-33.49	4.99e-127	1.56e-121	-1.1	-0.84	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
LGG	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-33.49	4.99e-127	1.56e-121	-1.1	-0.84	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-33.49	4.99e-127	1.56e-121	-1.1	-0.84	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
LGG	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-33.49	4.99e-127	1.56e-121	-1.1	-0.84	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-33.49	4.99e-127	1.56e-121	-1.1	-0.84	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
LGG	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	33.44	8.13e-127	2.52e-121	1.1	0.84	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-33.42	1.02e-126	3.15e-121	-1.1	-0.84	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	33.41	1.13e-126	3.41e-121	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	33.41	1.13e-126	3.41e-121	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	33.39	1.4e-126	4.2e-121	1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
LGG	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-33.37	1.68e-126	5e-121	-1.1	-0.84	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	33.34	2.23e-126	6.6e-121	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
LGG	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-33.32	2.88e-126	8.42e-121	-0.99	-0.84	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
LGG	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	33.3	3.53e-126	1.02e-120	1.02	0.84	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
LGG	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-33.28	3.96e-126	1.13e-120	-1.1	-0.84	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
LGG	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-33.27	4.54e-126	1.29e-120	-1.1	-0.84	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-33.27	4.62e-126	1.29e-120	-1.1	-0.84	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-33.27	4.62e-126	1.29e-120	-1.1	-0.84	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-33.25	5.44e-126	1.51e-120	-1.11	-0.84	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-33.24	6.36e-126	1.73e-120	-1.1	-0.84	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	33.23	6.62e-126	1.78e-120	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	33.23	6.62e-126	1.78e-120	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-33.22	7.64e-126	2.02e-120	-1	-0.84	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
LGG	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-33.22	7.79e-126	2.05e-120	-1.11	-0.84	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	33.19	1.05e-125	2.72e-120	1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
LGG	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	33.11	2.2e-125	5.63e-120	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	33.11	2.2e-125	5.63e-120	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	33.11	2.29e-125	5.79e-120	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	33.11	2.29e-125	5.79e-120	1.01	0.84	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
LGG	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-33.04	4.47e-125	1.11e-119	-1.1	-0.84	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
LGG	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-33.04	4.47e-125	1.11e-119	-1.1	-0.84	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	33.04	4.62e-125	1.14e-119	1.1	0.84	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
LGG	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	33.01	6.13e-125	1.51e-119	1.03	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
LGG	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	33	6.49e-125	1.58e-119	1.18	0.83	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
LGG	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-33	6.53e-125	1.58e-119	-1.1	-0.83	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
LGG	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	32.98	8.26e-125	1.99e-119	1.01	0.83	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	32.94	1.28e-124	3.04e-119	1	0.83	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
LGG	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	32.9	1.78e-124	4.16e-119	1.2	0.83	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
LGG	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	32.88	2.32e-124	5.39e-119	1.01	0.83	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
LGG	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-32.83	3.6e-124	8.28e-119	-1.1	-0.83	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
LGG	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-32.83	3.6e-124	8.28e-119	-1.1	-0.83	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	32.83	3.78e-124	8.42e-119	0.95	0.83	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
LGG	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-32.83	3.85e-124	8.42e-119	-1.1	-0.83	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
LGG	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-32.83	3.85e-124	8.42e-119	-1.1	-0.83	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-32.83	3.85e-124	8.42e-119	-1.1	-0.83	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-32.83	3.85e-124	8.42e-119	-1.1	-0.83	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-32.82	4.09e-124	8.69e-119	-1.1	-0.83	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-32.82	4.09e-124	8.69e-119	-1.1	-0.83	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
LGG	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-32.82	4.09e-124	8.69e-119	-1.1	-0.83	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
LGG	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-32.82	4.09e-124	8.69e-119	-1.1	-0.83	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	32.82	4.19e-124	8.87e-119	1	0.83	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
LGG	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-32.8	5.17e-124	1.09e-118	-1.1	-0.83	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
LGG	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	32.7	1.44e-123	3e-118	1.01	0.83	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
LGG	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	32.66	2.11e-123	4.34e-118	0.99	0.83	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
LGG	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	32.65	2.39e-123	4.89e-118	0.99	0.83	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
LGG	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	32.59	4.25e-123	8.59e-118	0.98	0.83	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
LGG	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	32.59	4.25e-123	8.59e-118	0.98	0.83	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
LGG	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	32.57	5.11e-123	1.03e-117	0.99	0.83	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
LGG	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	32.53	7.72e-123	1.54e-117	0.99	0.83	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
LGG	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	32.41	2.52e-122	4.91e-117	0.98	0.83	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
LGG	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	32.4	2.84e-122	5.51e-117	0.99	0.83	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
LGG	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-32.4	2.93e-122	5.66e-117	-1.03	-0.83	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
LGG	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	32.32	6.3e-122	1.19e-116	1.02	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
LGG	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	32.21	1.84e-121	3.46e-116	1.01	0.83	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
LGG	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	32.17	3.03e-121	5.6e-116	0.98	0.83	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
LGG	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	32.17	3.03e-121	5.6e-116	0.98	0.83	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
LGG	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	32.15	3.38e-121	6.24e-116	0.98	0.83	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
LGG	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	32.12	5.03e-121	9.19e-116	0.98	0.83	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	32.11	5.53e-121	1.01e-115	1.01	0.83	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	32.02	1.3e-120	2.36e-115	1.02	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
LGG	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	31.99	1.73e-120	3.12e-115	1.11	0.83	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
LGG	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	31.98	1.89e-120	3.39e-115	1.02	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
LGG	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-31.95	2.59e-120	4.63e-115	-1.07	-0.83	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
LGG	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	31.92	3.49e-120	6.14e-115	0.98	0.83	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	31.92	3.49e-120	6.14e-115	0.98	0.83	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-31.84	7.89e-120	1.34e-114	-1.03	-0.83	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-31.84	7.89e-120	1.34e-114	-1.03	-0.83	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-31.84	7.89e-120	1.34e-114	-1.03	-0.83	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-31.84	7.89e-120	1.34e-114	-1.03	-0.83	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-31.84	7.89e-120	1.34e-114	-1.03	-0.83	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-31.84	8.08e-120	1.35e-114	-1.03	-0.83	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-31.84	8.08e-120	1.35e-114	-1.03	-0.83	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
LGG	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-31.83	9.24e-120	1.53e-114	-1.13	-0.83	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
LGG	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-31.83	9.24e-120	1.53e-114	-1.13	-0.83	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
LGG	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	31.81	1.08e-119	1.79e-114	1.02	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
LGG	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	31.77	1.62e-119	2.67e-114	1.11	0.82	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
LGG	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	31.74	2.16e-119	3.54e-114	1.02	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-31.74	2.17e-119	3.55e-114	-1.02	-0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
LGG	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-31.73	2.53e-119	4.09e-114	-1.03	-0.82	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-31.73	2.53e-119	4.09e-114	-1.03	-0.82	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
LGG	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	31.66	5.15e-119	8.3e-114	0.99	0.82	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
LGG	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-31.62	7.34e-119	1.17e-113	-0.98	-0.82	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
LGG	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	31.59	1.02e-118	1.63e-113	0.98	0.82	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
LGG	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-31.59	1.09e-118	1.73e-113	-0.99	-0.82	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	31.58	1.2e-118	1.9e-113	1.01	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
LGG	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-31.56	1.41e-118	2.11e-113	-1.03	-0.82	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-31.45	4.39e-118	6.18e-113	-1.02	-0.82	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
LGG	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-31.39	8.41e-118	1.16e-112	-1.18	-0.82	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
LGG	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-31.39	8.41e-118	1.16e-112	-1.18	-0.82	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
LGG	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-31.38	8.74e-118	1.21e-112	-1.11	-0.82	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
LGG	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-31.35	1.23e-117	1.7e-112	-1.06	-0.82	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
LGG	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	31.31	1.86e-117	2.55e-112	1.19	0.82	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
LGG	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	31.3	2.02e-117	2.75e-112	1	0.82	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
LGG	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	31.3	2.02e-117	2.75e-112	1	0.82	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
LGG	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-31.28	2.4e-117	3.26e-112	-1.02	-0.82	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
LGG	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-31.26	2.9e-117	3.91e-112	-1.13	-0.82	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
LGG	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-31.23	4.14e-117	5.56e-112	-1.03	-0.82	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
LGG	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-31.14	1.01e-116	1.35e-111	-1.17	-0.82	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
LGG	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-31.12	1.3e-116	1.74e-111	-1.14	-0.82	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
LGG	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-31.09	1.79e-116	2.29e-111	-1.03	-0.82	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-31.09	1.79e-116	2.29e-111	-1.03	-0.82	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-31.09	1.79e-116	2.29e-111	-1.03	-0.82	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-31.08	1.92e-116	2.43e-111	-1.03	-0.82	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-31.08	1.92e-116	2.43e-111	-1.03	-0.82	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
LGG	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	31.07	2.05e-116	2.56e-111	1.07	0.82	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
LGG	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	31.05	2.5e-116	3.12e-111	1.11	0.82	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-31.05	2.69e-116	3.33e-111	-1.02	-0.82	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-31.02	3.37e-116	4.09e-111	-1.02	-0.82	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-31.02	3.37e-116	4.09e-111	-1.02	-0.82	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-31.02	3.37e-116	4.09e-111	-1.02	-0.82	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-31.02	3.37e-116	4.09e-111	-1.02	-0.82	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
LGG	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	31.02	3.58e-116	4.33e-111	1.18	0.82	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
LGG	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	31.01	4.03e-116	4.87e-111	1.02	0.82	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-30.97	5.85e-116	6.84e-111	-1.02	-0.82	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
LGG	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	30.97	6.08e-116	7.09e-111	0.98	0.82	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
LGG	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	30.96	6.55e-116	7.51e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	30.96	6.55e-116	7.51e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	30.96	6.55e-116	7.51e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
LGG	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	30.96	6.55e-116	7.51e-111	1	0.82	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	30.96	6.55e-116	7.51e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	30.95	7.17e-116	8.19e-111	1.03	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
LGG	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-30.9	1.21e-115	1.32e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-30.9	1.24e-115	1.35e-110	-1.01	-0.82	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
LGG	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-30.88	1.53e-115	1.64e-110	-1.1	-0.82	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-30.85	2.06e-115	2.15e-110	-1.02	-0.82	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
LGG	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-30.85	2.09e-115	2.17e-110	-1.17	-0.82	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	30.83	2.48e-115	2.57e-110	1.01	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
LGG	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	30.81	2.9e-115	3.01e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-30.8	3.43e-115	3.46e-110	-1.03	-0.82	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-30.77	4.58e-115	4.52e-110	-1.02	-0.82	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-30.77	4.58e-115	4.52e-110	-1.02	-0.82	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-30.77	4.58e-115	4.52e-110	-1.02	-0.82	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-30.77	4.58e-115	4.52e-110	-1.02	-0.82	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-30.77	4.58e-115	4.52e-110	-1.02	-0.82	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	30.75	5.63e-115	5.49e-110	1.03	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
LGG	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	30.74	6.3e-115	6.12e-110	0.99	0.82	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-30.71	8.5e-115	8.11e-110	-1.03	-0.82	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-30.69	9.91e-115	9.37e-110	-1.03	-0.82	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-30.69	9.91e-115	9.37e-110	-1.03	-0.82	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
LGG	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-30.64	1.66e-114	1.56e-109	-1.02	-0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
LGG	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	30.61	2.34e-114	2.2e-109	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
LGG	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-30.56	3.88e-114	3.53e-109	-1.07	-0.81	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
LGG	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	30.55	4.19e-114	3.77e-109	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	30.55	4.19e-114	3.77e-109	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
LGG	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-30.55	4.2e-114	3.77e-109	-1.07	-0.81	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
LGG	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	30.55	4.57e-114	4.09e-109	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	30.55	4.57e-114	4.09e-109	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
LGG	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-30.53	5.2e-114	4.64e-109	-1.16	-0.81	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
LGG	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	30.53	5.29e-114	4.7e-109	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-30.52	6.09e-114	5.26e-109	-1.03	-0.81	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-30.52	6.09e-114	5.26e-109	-1.03	-0.81	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
LGG	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	30.49	7.81e-114	6.55e-109	1.09	0.81	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-30.46	1.06e-113	8.59e-109	-1.01	-0.81	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-30.46	1.06e-113	8.59e-109	-1.01	-0.81	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-30.46	1.06e-113	8.59e-109	-1.01	-0.81	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-30.46	1.06e-113	8.59e-109	-1.01	-0.81	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-30.46	1.06e-113	8.59e-109	-1.01	-0.81	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-30.46	1.06e-113	8.59e-109	-1.01	-0.81	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-30.46	1.06e-113	8.59e-109	-1.01	-0.81	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
LGG	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-30.46	1.12e-113	9.03e-109	-1.16	-0.81	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-30.46	1.13e-113	9.08e-109	-1.17	-0.81	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	30.44	1.43e-113	1.14e-108	1	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	30.44	1.43e-113	1.14e-108	1	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
LGG	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-30.43	1.54e-113	1.23e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-30.43	1.54e-113	1.23e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
LGG	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-30.42	1.75e-113	1.38e-108	-1.12	-0.81	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
LGG	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-30.41	1.78e-113	1.38e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-30.41	1.78e-113	1.38e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-30.41	1.78e-113	1.38e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-30.41	1.78e-113	1.38e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
LGG	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	30.38	2.46e-113	1.88e-108	0.98	0.81	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-30.38	2.62e-113	1.99e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-30.38	2.62e-113	1.99e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-30.38	2.62e-113	1.99e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
LGG	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-30.36	3.18e-113	2.4e-108	-1.13	-0.81	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
LGG	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	30.33	4.17e-113	3.14e-108	1	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
LGG	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	30.32	4.81e-113	3.6e-108	1.07	0.81	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	30.32	4.81e-113	3.6e-108	1.07	0.81	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-30.31	5.23e-113	3.87e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-30.31	5.23e-113	3.87e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-30.31	5.23e-113	3.87e-108	-1.01	-0.81	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
LGG	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	30.3	5.55e-113	4.07e-108	1.06	0.81	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
LGG	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	30.3	5.55e-113	4.07e-108	1.06	0.81	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	30.3	5.62e-113	4.09e-108	1.06	0.81	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
LGG	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	30.3	5.62e-113	4.09e-108	1.06	0.81	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
LGG	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	30.3	5.62e-113	4.09e-108	1.06	0.81	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	30.3	5.74e-113	4.14e-108	1.06	0.81	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
LGG	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	30.3	5.74e-113	4.14e-108	1.06	0.81	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-30.3	5.74e-113	4.14e-108	-1.06	-0.81	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	30.3	5.74e-113	4.14e-108	1.07	0.81	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	30.3	5.74e-113	4.14e-108	1.07	0.81	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	30.3	5.74e-113	4.14e-108	1.07	0.81	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
LGG	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	30.29	6.16e-113	4.4e-108	1.07	0.81	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	30.29	6.16e-113	4.4e-108	1.07	0.81	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-30.29	6.19e-113	4.41e-108	-1.06	-0.81	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-30.29	6.43e-113	4.57e-108	-1.07	-0.81	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-30.29	6.54e-113	4.64e-108	-1.02	-0.81	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
LGG	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	30.27	7.67e-113	5.42e-108	1.08	0.81	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
LGG	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-30.26	8.46e-113	5.95e-108	-1.16	-0.81	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
LGG	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	30.24	1.03e-112	7.25e-108	1	0.81	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-30.23	1.18e-112	8.23e-108	-1.02	-0.81	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-30.23	1.18e-112	8.23e-108	-1.02	-0.81	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
LGG	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-30.22	1.34e-112	9.37e-108	-1.05	-0.81	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
LGG	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-30.19	1.9e-112	1.31e-107	-1.01	-0.81	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	30.18	1.97e-112	1.35e-107	1.02	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
LGG	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	30.18	2.04e-112	1.39e-107	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	30.18	2.04e-112	1.39e-107	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	30.18	2.04e-112	1.39e-107	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-30.17	2.15e-112	1.44e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-30.17	2.15e-112	1.44e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-30.17	2.15e-112	1.44e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-30.17	2.15e-112	1.44e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-30.17	2.15e-112	1.44e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-30.17	2.15e-112	1.44e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-30.17	2.29e-112	1.53e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
LGG	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	30.16	2.49e-112	1.65e-107	1.06	0.81	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
LGG	cis	rs2739330	1	rs2739330	ENSG00000273295.1	AP000350.5	30.16	2.51e-112	1.66e-107	1.02	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23901432~23907068:-
LGG	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	30.15	2.74e-112	1.79e-107	1.15	0.81	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	30.13	3.25e-112	2.1e-107	1.02	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
LGG	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	30.13	3.43e-112	2.21e-107	1.07	0.81	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
LGG	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-30.12	3.6e-112	2.32e-107	-1.01	-0.81	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
LGG	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	30.12	3.92e-112	2.51e-107	1.06	0.81	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	30.11	4.19e-112	2.67e-107	1.06	0.81	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	30.11	4.19e-112	2.67e-107	1.06	0.81	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	30.11	4.36e-112	2.77e-107	1.06	0.81	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
LGG	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	30.1	4.57e-112	2.89e-107	1.06	0.81	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
LGG	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	30.09	4.94e-112	3.1e-107	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	30.09	4.94e-112	3.1e-107	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	30.09	4.94e-112	3.1e-107	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	30.09	4.94e-112	3.1e-107	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
LGG	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	30.09	5e-112	3.13e-107	1.06	0.81	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-30.08	5.76e-112	3.6e-107	-1.03	-0.81	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-30.06	6.84e-112	4.21e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-30.06	6.84e-112	4.21e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-30.05	7.79e-112	4.77e-107	-1.01	-0.81	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
LGG	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	30.05	7.82e-112	4.78e-107	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	30.05	7.89e-112	4.79e-107	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
LGG	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	30.05	7.89e-112	4.79e-107	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	30.05	7.89e-112	4.79e-107	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	30.05	7.89e-112	4.79e-107	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-30.05	7.91e-112	4.8e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-30.04	8.54e-112	5.1e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-30.04	8.54e-112	5.1e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-30.04	8.54e-112	5.1e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-30.04	8.54e-112	5.1e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-30.04	8.54e-112	5.1e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-30.04	8.54e-112	5.1e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-30.04	8.54e-112	5.1e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
LGG	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	30.02	1.08e-111	6.42e-107	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	30.01	1.12e-111	6.67e-107	0.97	0.81	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
LGG	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-30.01	1.14e-111	6.74e-107	-1.16	-0.81	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
LGG	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-29.99	1.43e-111	8.42e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-29.99	1.43e-111	8.42e-107	-1.02	-0.81	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-29.96	2.05e-111	1.2e-106	-1.02	-0.81	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
LGG	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	29.94	2.46e-111	1.44e-106	1.06	0.81	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
LGG	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-29.93	2.76e-111	1.6e-106	-1.16	-0.81	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
LGG	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-29.9	3.84e-111	2.22e-106	-1.02	-0.81	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
LGG	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	29.9	3.84e-111	2.22e-106	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
LGG	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	29.89	4e-111	2.32e-106	1.05	0.81	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-29.89	4.11e-111	2.37e-106	-1.01	-0.81	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
LGG	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-29.87	4.98e-111	2.85e-106	-1	-0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
LGG	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	29.85	6.09e-111	3.48e-106	1.07	0.81	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
LGG	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	29.81	8.85e-111	4.9e-106	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	29.8	9.96e-111	5.47e-106	1.02	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
LGG	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	29.79	1.16e-110	6.35e-106	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
LGG	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-29.78	1.32e-110	7.23e-106	-1.16	-0.81	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
LGG	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-29.77	1.37e-110	7.4e-106	-1	-0.81	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
LGG	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-29.71	2.49e-110	1.32e-105	-1.16	-0.81	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
LGG	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-29.7	3.02e-110	1.59e-105	-1.02	-0.81	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
LGG	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	29.69	3.17e-110	1.66e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	29.69	3.17e-110	1.66e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
LGG	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	29.69	3.17e-110	1.66e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
LGG	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	29.69	3.17e-110	1.66e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-29.69	3.35e-110	1.76e-105	-1.02	-0.81	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-29.68	3.6e-110	1.88e-105	-1.02	-0.81	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
LGG	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	29.68	3.75e-110	1.96e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	29.68	3.75e-110	1.96e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
LGG	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	29.63	6.3e-110	3.27e-105	0.97	0.81	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	29.61	7.64e-110	3.95e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
LGG	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	29.6	8.53e-110	4.4e-105	0.97	0.81	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
LGG	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-29.54	1.56e-109	7.95e-105	-1	-0.8	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
LGG	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	29.5	2.4e-109	1.22e-104	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-29.49	2.66e-109	1.35e-104	-1.02	-0.8	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
LGG	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	29.39	7.66e-109	3.85e-104	0.97	0.8	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
LGG	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-29.38	8.49e-109	4.25e-104	-1.04	-0.8	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-29.38	8.52e-109	4.25e-104	-1.01	-0.8	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-29.38	8.52e-109	4.25e-104	-1.01	-0.8	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-29.38	8.52e-109	4.25e-104	-1.01	-0.8	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	29.37	9.45e-109	4.69e-104	1.22	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
LGG	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	29.37	9.45e-109	4.69e-104	1.22	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
LGG	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	29.35	1.14e-108	5.64e-104	1.23	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
LGG	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	29.34	1.19e-108	5.92e-104	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
LGG	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	29.33	1.4e-108	6.9e-104	1.22	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
LGG	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	29.33	1.4e-108	6.9e-104	1.22	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
LGG	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	29.32	1.48e-108	7.31e-104	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
LGG	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	29.32	1.53e-108	7.54e-104	0.97	0.8	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
LGG	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-29.21	4.94e-108	2.4e-103	-1	-0.8	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	29.19	5.88e-108	2.85e-103	1.22	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
LGG	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	29.17	7e-108	3.38e-103	1.22	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
LGG	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	29.13	1.06e-107	5.09e-103	1.23	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
LGG	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-29.09	1.75e-107	8.37e-103	-1.01	-0.8	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
LGG	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-29.04	2.7e-107	1.29e-102	-1.06	-0.8	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
LGG	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	29.03	3.01e-107	1.43e-102	1.09	0.8	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-29.03	3.02e-107	1.43e-102	-1.02	-0.8	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-29	4.33e-107	2.05e-102	-0.99	-0.8	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-29	4.33e-107	2.05e-102	-0.99	-0.8	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
LGG	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	28.97	6.02e-107	2.84e-102	0.95	0.8	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
LGG	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	28.78	4.2e-106	1.94e-101	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
LGG	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-28.76	5.23e-106	2.42e-101	-1.07	-0.8	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
LGG	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	28.74	6.7e-106	3.09e-101	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	28.54	5.31e-105	2.42e-100	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
LGG	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	28.5	8.34e-105	3.8e-100	0.95	0.79	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
LGG	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	28.5	8.34e-105	3.8e-100	0.95	0.79	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
LGG	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-28.46	1.31e-104	5.95e-100	-1	-0.79	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	28.41	2.22e-104	9.98e-100	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
LGG	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	28.4	2.3e-104	1.04e-99	0.94	0.79	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
LGG	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	28.39	2.51e-104	1.13e-99	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
LGG	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	28.38	2.77e-104	1.24e-99	0.95	0.79	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
LGG	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	28.38	2.77e-104	1.24e-99	0.95	0.79	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
LGG	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-28.38	3.01e-104	1.35e-99	-1.08	-0.79	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
LGG	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-28.37	3.09e-104	1.38e-99	-1.13	-0.79	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
LGG	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	28.36	3.48e-104	1.55e-99	1.21	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
LGG	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	28.34	4.63e-104	1.98e-99	0.96	0.79	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
LGG	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-28.33	4.98e-104	2.12e-99	-0.99	-0.79	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
LGG	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	28.32	5.42e-104	2.31e-99	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
LGG	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-28.32	5.61e-104	2.39e-99	-0.93	-0.79	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
LGG	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	28.29	7.16e-104	3.04e-99	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	28.23	1.34e-103	5.55e-99	0.96	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
LGG	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	28.21	1.72e-103	6.58e-99	0.98	0.79	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
LGG	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	28.19	2.05e-103	7.76e-99	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
LGG	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	28.19	2.05e-103	7.76e-99	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-28.19	2.07e-103	7.81e-99	-1	-0.79	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-28.18	2.46e-103	9.29e-99	-1	-0.79	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
LGG	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-28.16	3.06e-103	1.15e-98	-1.15	-0.79	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
LGG	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	28.13	4.14e-103	1.55e-98	0.94	0.79	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
LGG	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	28.12	4.55e-103	1.69e-98	1.21	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
LGG	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-28.11	4.91e-103	1.82e-98	-1	-0.79	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-28.11	4.91e-103	1.82e-98	-1	-0.79	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-28.11	4.91e-103	1.82e-98	-1	-0.79	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	28.1	5.8e-103	2.14e-98	1.22	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
LGG	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-28.08	6.85e-103	2.53e-98	-1	-0.79	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	28.06	8.1e-103	2.98e-98	1.22	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
LGG	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	28.04	9.91e-103	3.65e-98	0.93	0.79	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
LGG	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	27.99	1.82e-102	6.68e-98	1.17	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	27.99	1.85e-102	6.78e-98	0.96	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
LGG	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	27.98	1.9e-102	6.96e-98	0.95	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
LGG	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-27.96	2.44e-102	8.89e-98	-1.07	-0.79	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
LGG	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-27.96	2.51e-102	9.12e-98	-1.07	-0.79	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
LGG	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	27.95	2.62e-102	9.54e-98	0.94	0.79	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
LGG	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	27.87	6.4e-102	2.3e-97	1.02	0.79	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
LGG	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	27.87	6.4e-102	2.3e-97	1.02	0.79	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
LGG	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	27.87	6.4e-102	2.3e-97	1.02	0.79	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
LGG	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-27.85	7.52e-102	2.69e-97	-0.99	-0.79	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	27.81	1.23e-101	4.38e-97	1.16	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
LGG	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	27.81	1.23e-101	4.38e-97	1.16	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
LGG	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	27.79	1.42e-101	5e-97	1.02	0.79	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
LGG	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	27.79	1.42e-101	5e-97	1.02	0.79	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
LGG	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	27.79	1.47e-101	5.17e-97	1.02	0.79	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
LGG	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	27.79	1.47e-101	5.17e-97	1.02	0.79	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
LGG	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	27.79	1.48e-101	5.22e-97	0.97	0.79	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
LGG	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	27.76	1.94e-101	6.8e-97	1.17	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
LGG	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-27.75	2.17e-101	7.57e-97	-1	-0.79	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-27.75	2.17e-101	7.57e-97	-1	-0.79	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-27.75	2.17e-101	7.57e-97	-1	-0.79	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-27.75	2.17e-101	7.57e-97	-1	-0.79	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
LGG	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-27.7	3.94e-101	1.37e-96	-1.02	-0.79	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
LGG	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	27.69	4.28e-101	1.48e-96	1.02	0.79	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
LGG	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	27.68	4.45e-101	1.54e-96	1.02	0.79	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
LGG	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-27.68	4.62e-101	1.59e-96	-1.14	-0.79	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
LGG	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	27.67	5.13e-101	1.76e-96	1.02	0.79	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
LGG	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-27.66	5.55e-101	1.9e-96	-1	-0.79	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-27.65	6.31e-101	2.16e-96	-0.95	-0.79	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
LGG	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	27.64	7.49e-101	2.56e-96	1.01	0.79	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
LGG	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	27.63	7.98e-101	2.72e-96	1.16	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
LGG	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	27.63	7.98e-101	2.72e-96	1.16	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
LGG	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	27.61	9.94e-101	3.37e-96	1.16	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
LGG	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	27.6	1.07e-100	3.63e-96	1.17	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
LGG	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-27.59	1.24e-100	4.19e-96	-1	-0.79	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
LGG	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	27.56	1.74e-100	5.88e-96	1.23	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
LGG	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	27.56	1.74e-100	5.88e-96	1.23	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
LGG	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	27.53	2.29e-100	7.72e-96	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-27.47	4.41e-100	1.48e-95	-1.01	-0.78	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	27.45	5.63e-100	1.89e-95	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
LGG	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	27.44	6.16e-100	2.06e-95	1.16	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
LGG	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	27.43	6.77e-100	2.27e-95	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
LGG	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-27.41	8.57e-100	2.87e-95	-0.9	-0.78	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
LGG	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-27.41	8.57e-100	2.87e-95	-0.9	-0.78	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
LGG	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-27.32	2.13e-99	7.07e-95	-0.95	-0.78	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-27.32	2.13e-99	7.07e-95	-0.95	-0.78	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	27.3	2.74e-99	9.11e-95	1.16	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
LGG	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-27.3	2.76e-99	9.16e-95	-1.01	-0.78	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-27.3	2.76e-99	9.16e-95	-1.01	-0.78	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
LGG	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	27.27	3.57e-99	1.18e-94	1.15	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
LGG	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	27.26	4.23e-99	1.4e-94	0.93	0.78	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
LGG	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	27.22	6.37e-99	2.09e-94	1.16	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
LGG	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	27.17	1.01e-98	3.31e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	27.17	1.01e-98	3.31e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	27.16	1.14e-98	3.72e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	27.16	1.14e-98	3.72e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	27.16	1.14e-98	3.72e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	27.16	1.14e-98	3.72e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	27.16	1.14e-98	3.72e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	27.15	1.26e-98	4.09e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	27.15	1.28e-98	4.16e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	27.15	1.31e-98	4.25e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	27.11	1.93e-98	6.26e-94	1	0.78	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	27.07	2.96e-98	9.51e-94	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
LGG	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-27.04	4.24e-98	1.36e-93	-1.08	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
LGG	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-27.02	5.09e-98	1.63e-93	-1.08	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
LGG	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-27.02	5.09e-98	1.63e-93	-1.08	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
LGG	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	26.99	7.04e-98	2.24e-93	1.05	0.78	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
LGG	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	26.98	7.83e-98	2.49e-93	1.05	0.78	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	26.97	8.98e-98	2.86e-93	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
LGG	cis	rs1799949	0.931	rs9891977	ENSG00000198496.9	NBR2	-26.96	9.57e-98	3.04e-93	-0.97	-0.78	Menopause (age at onset);	chr17:43360030	chr17:43125610~43153671:+
LGG	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-26.95	1.09e-97	3.45e-93	-1.01	-0.78	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
LGG	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-26.95	1.14e-97	3.61e-93	-1.08	-0.78	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
LGG	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	26.85	3.04e-97	9.44e-93	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	26.85	3.04e-97	9.44e-93	1.01	0.78	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
LGG	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	26.85	3.17e-97	9.84e-93	0.94	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
LGG	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	26.78	6.54e-97	2.02e-92	1.16	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
LGG	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	26.76	8.14e-97	2.5e-92	0.94	0.78	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
LGG	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	26.68	1.94e-96	5.92e-92	1	0.77	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
LGG	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	26.62	3.73e-96	1.13e-91	1.05	0.77	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	26.6	4.75e-96	1.43e-91	1.01	0.77	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
LGG	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-26.59	5.28e-96	1.59e-91	-0.94	-0.77	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	26.59	5.28e-96	1.59e-91	0.94	0.77	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
LGG	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-26.5	1.32e-95	3.96e-91	-0.89	-0.77	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
LGG	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-26.45	2.17e-95	6.46e-91	-0.9	-0.77	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
LGG	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	26.43	2.81e-95	8.37e-91	1	0.77	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	26.42	3.05e-95	9.05e-91	1	0.77	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
LGG	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-26.42	3.16e-95	9.35e-91	-0.9	-0.77	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	26.39	4.38e-95	1.29e-90	0.97	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
LGG	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	26.39	4.56e-95	1.35e-90	0.93	0.77	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
LGG	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-26.38	4.88e-95	1.43e-90	-0.93	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
LGG	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	26.36	5.83e-95	1.71e-90	0.92	0.77	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-26.36	6.22e-95	1.83e-90	-0.94	-0.77	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-26.35	6.8e-95	1.98e-90	-0.93	-0.77	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
LGG	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-26.33	8.12e-95	2.36e-90	-0.9	-0.77	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-26.33	8.12e-95	2.36e-90	-0.9	-0.77	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-26.33	8.12e-95	2.36e-90	-0.9	-0.77	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-26.33	8.12e-95	2.36e-90	-0.9	-0.77	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-26.33	8.12e-95	2.36e-90	-0.9	-0.77	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-26.33	8.12e-95	2.36e-90	-0.9	-0.77	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
LGG	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-26.33	8.36e-95	2.42e-90	-0.9	-0.77	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
LGG	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-26.32	9.48e-95	2.74e-90	-0.93	-0.77	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
LGG	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	26.31	1.02e-94	2.95e-90	0.93	0.77	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
LGG	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-26.31	1.05e-94	3.02e-90	-0.9	-0.77	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
LGG	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	26.3	1.13e-94	3.25e-90	1.11	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
LGG	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-26.29	1.32e-94	3.8e-90	-0.89	-0.77	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
LGG	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	26.28	1.34e-94	3.85e-90	0.93	0.77	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
LGG	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-26.26	1.66e-94	4.78e-90	-1.12	-0.77	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
LGG	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	26.26	1.77e-94	5.07e-90	1.02	0.77	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
LGG	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	26.26	1.77e-94	5.07e-90	1.02	0.77	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
LGG	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	26.23	2.41e-94	6.9e-90	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
LGG	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	26.22	2.83e-94	8.09e-90	1.18	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
LGG	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-26.21	2.87e-94	8.2e-90	-0.9	-0.77	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	26.2	3.16e-94	9.03e-90	0.97	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
LGG	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	26.2	3.45e-94	9.86e-90	1	0.77	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
LGG	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-26.19	3.52e-94	1e-89	-1.17	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
LGG	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	26.17	4.53e-94	1.29e-89	1	0.77	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
LGG	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-26.17	4.69e-94	1.33e-89	-0.9	-0.77	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	26.15	5.48e-94	1.56e-89	0.9	0.77	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-26.15	5.64e-94	1.6e-89	-0.9	-0.77	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
LGG	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	26.14	6.08e-94	1.72e-89	0.94	0.77	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
LGG	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-26.12	7.55e-94	2.14e-89	-0.89	-0.77	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-26.12	7.97e-94	2.25e-89	-0.9	-0.77	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
LGG	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	26.1	1.02e-93	2.87e-89	1.16	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
LGG	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	26.1	1.02e-93	2.87e-89	1.16	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
LGG	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-26.07	1.35e-93	3.81e-89	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
LGG	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-26.05	1.73e-93	4.86e-89	-0.88	-0.77	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
LGG	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	26.01	2.6e-93	7.31e-89	0.92	0.77	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
LGG	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-25.96	4.2e-93	1.18e-88	-0.91	-0.77	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
LGG	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-25.96	4.56e-93	1.28e-88	-0.89	-0.77	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
LGG	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-25.95	4.95e-93	1.38e-88	-0.9	-0.77	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
LGG	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	25.94	5.4e-93	1.51e-88	0.92	0.77	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
LGG	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-25.91	7.79e-93	2.15e-88	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
LGG	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-25.91	7.79e-93	2.15e-88	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
LGG	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-25.91	7.79e-93	2.15e-88	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
LGG	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-25.91	7.79e-93	2.15e-88	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
LGG	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-25.91	7.79e-93	2.15e-88	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
LGG	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-25.91	7.79e-93	2.15e-88	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
LGG	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-25.91	7.79e-93	2.15e-88	-1.16	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
LGG	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-25.87	1.18e-92	3.25e-88	-0.89	-0.77	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
LGG	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	25.86	1.24e-92	3.41e-88	1.05	0.77	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-25.84	1.52e-92	4.17e-88	-0.9	-0.76	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
LGG	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-25.84	1.64e-92	4.49e-88	-1.17	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
LGG	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	25.83	1.77e-92	4.84e-88	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
LGG	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	25.82	1.87e-92	5.11e-88	0.93	0.76	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-25.8	2.44e-92	6.65e-88	-0.93	-0.76	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-25.8	2.44e-92	6.65e-88	-0.93	-0.76	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-25.8	2.44e-92	6.65e-88	-0.93	-0.76	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
LGG	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	25.79	2.61e-92	7.09e-88	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
LGG	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-25.79	2.79e-92	7.55e-88	-0.89	-0.76	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-25.79	2.79e-92	7.55e-88	-0.89	-0.76	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-25.78	2.9e-92	7.86e-88	-0.9	-0.76	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.857	rs9608229	ENSG00000273295.1	AP000350.5	25.78	3.03e-92	8.21e-88	0.99	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	25.77	3.51e-92	9.48e-88	0.96	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
LGG	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-25.76	3.77e-92	1.02e-87	-0.89	-0.76	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-25.76	3.88e-92	1.04e-87	-0.9	-0.76	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-25.76	3.94e-92	1.05e-87	-0.9	-0.76	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
LGG	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-25.76	3.94e-92	1.05e-87	-0.9	-0.76	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-25.76	3.94e-92	1.05e-87	-0.9	-0.76	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-25.76	3.94e-92	1.05e-87	-0.9	-0.76	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-25.75	4.15e-92	1.11e-87	-0.9	-0.76	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
LGG	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-25.74	4.74e-92	1.26e-87	-0.88	-0.76	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
LGG	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-25.73	5.23e-92	1.39e-87	-0.9	-0.76	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
LGG	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-25.71	6.09e-92	1.62e-87	-0.88	-0.76	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
LGG	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	25.69	7.63e-92	2.03e-87	1.02	0.76	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-25.68	9.1e-92	2.41e-87	-0.9	-0.76	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
LGG	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	25.65	1.22e-91	3.21e-87	0.88	0.76	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	25.59	2.36e-91	6.19e-87	0.96	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
LGG	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-25.58	2.7e-91	7.07e-87	-0.89	-0.76	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-25.58	2.7e-91	7.07e-87	-0.89	-0.76	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-25.58	2.7e-91	7.07e-87	-0.89	-0.76	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-25.58	2.7e-91	7.07e-87	-0.89	-0.76	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-25.58	2.7e-91	7.07e-87	-0.89	-0.76	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-25.58	2.7e-91	7.07e-87	-0.89	-0.76	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-25.55	3.73e-91	9.73e-87	-0.9	-0.76	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-25.55	3.73e-91	9.73e-87	-0.9	-0.76	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
LGG	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	25.52	4.9e-91	1.27e-86	1.04	0.76	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
LGG	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-25.51	5.3e-91	1.38e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
LGG	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	25.48	7.88e-91	2.04e-86	0.9	0.76	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-25.47	8.66e-91	2.23e-86	-0.9	-0.76	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-25.47	8.66e-91	2.23e-86	-0.9	-0.76	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-25.47	8.66e-91	2.23e-86	-0.9	-0.76	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-25.47	8.66e-91	2.23e-86	-0.9	-0.76	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
LGG	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	25.47	8.8e-91	2.27e-86	0.82	0.76	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
LGG	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-25.46	9.22e-91	2.37e-86	-0.89	-0.76	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
LGG	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	25.46	9.44e-91	2.43e-86	0.91	0.76	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-25.45	1.09e-90	2.78e-86	-0.93	-0.76	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-25.44	1.14e-90	2.93e-86	-0.96	-0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
LGG	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-25.44	1.22e-90	3.11e-86	-0.89	-0.76	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
LGG	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-25.44	1.22e-90	3.12e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
LGG	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-25.44	1.23e-90	3.15e-86	-0.9	-0.76	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-25.43	1.24e-90	3.16e-86	-0.9	-0.76	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-25.43	1.24e-90	3.16e-86	-0.9	-0.76	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-25.43	1.25e-90	3.18e-86	-0.9	-0.76	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-25.43	1.25e-90	3.18e-86	-0.9	-0.76	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
LGG	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	25.42	1.49e-90	3.79e-86	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
LGG	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-25.41	1.66e-90	4.22e-86	-0.9	-0.76	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
LGG	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-25.41	1.67e-90	4.25e-86	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
LGG	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	25.41	1.69e-90	4.29e-86	0.82	0.76	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
LGG	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-25.4	1.79e-90	4.54e-86	-1.12	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
LGG	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	25.39	2e-90	5.06e-86	0.82	0.76	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	25.39	2.04e-90	5.16e-86	0.95	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
LGG	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-25.37	2.37e-90	5.98e-86	-0.89	-0.76	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-25.37	2.37e-90	5.98e-86	-0.89	-0.76	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
LGG	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	25.37	2.5e-90	6.3e-86	0.82	0.76	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
LGG	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	25.37	2.5e-90	6.3e-86	0.82	0.76	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
LGG	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-25.37	2.56e-90	6.45e-86	-1.12	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
LGG	cis	rs1799949	0.832	rs2070835	ENSG00000198496.9	NBR2	-25.37	2.6e-90	6.54e-86	-0.98	-0.76	Menopause (age at onset);	chr17:43022008	chr17:43125610~43153671:+
LGG	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	25.36	2.82e-90	7.1e-86	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
LGG	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-25.36	2.88e-90	7.22e-86	-1.16	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
LGG	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	25.34	3.4e-90	8.52e-86	0.82	0.76	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
LGG	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-25.33	3.83e-90	9.6e-86	-0.9	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
LGG	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-25.32	4.32e-90	1.08e-85	-0.89	-0.76	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-25.32	4.45e-90	1.11e-85	-0.89	-0.76	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
LGG	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	25.31	4.79e-90	1.19e-85	0.92	0.76	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
LGG	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-25.3	5.44e-90	1.36e-85	-0.98	-0.76	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
LGG	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	25.28	6.51e-90	1.62e-85	0.89	0.76	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
LGG	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-25.27	7.43e-90	1.84e-85	-0.98	-0.76	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
LGG	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	25.25	8.61e-90	2.13e-85	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
LGG	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	25.24	1.05e-89	2.59e-85	0.91	0.76	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	25.23	1.17e-89	2.9e-85	0.94	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
LGG	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	25.2	1.51e-89	3.72e-85	0.82	0.76	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
LGG	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	25.19	1.72e-89	4.23e-85	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
LGG	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	25.19	1.8e-89	4.44e-85	0.82	0.76	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
LGG	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-25.18	1.86e-89	4.58e-85	-0.91	-0.76	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
LGG	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	25.17	2.22e-89	5.44e-85	0.89	0.76	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
LGG	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-25.16	2.28e-89	5.58e-85	-0.88	-0.76	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
LGG	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	25.16	2.29e-89	5.61e-85	0.92	0.76	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
LGG	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	25.16	2.43e-89	5.93e-85	0.9	0.76	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
LGG	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	25.15	2.52e-89	6.16e-85	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
LGG	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-25.14	2.94e-89	7.1e-85	-0.89	-0.76	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-25.14	2.99e-89	7.22e-85	-0.89	-0.76	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-25.14	2.99e-89	7.22e-85	-0.89	-0.76	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-25.14	2.99e-89	7.22e-85	-0.89	-0.76	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-25.14	3.04e-89	7.33e-85	-0.89	-0.76	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-25.14	3.08e-89	7.41e-85	-0.89	-0.76	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-25.14	3.08e-89	7.41e-85	-0.89	-0.76	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-25.14	3.09e-89	7.42e-85	-0.89	-0.76	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-25.14	3.09e-89	7.42e-85	-0.89	-0.76	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-25.14	3.09e-89	7.42e-85	-0.89	-0.76	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-25.14	3.09e-89	7.42e-85	-0.89	-0.76	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
LGG	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-25.12	3.53e-89	8.46e-85	-0.88	-0.76	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
LGG	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	25.12	3.8e-89	9.09e-85	0.92	0.76	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
LGG	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	25.11	4.16e-89	9.94e-85	0.93	0.76	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
LGG	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	25.09	5.3e-89	1.26e-84	0.81	0.76	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
LGG	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	25.09	5.31e-89	1.26e-84	0.81	0.76	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
LGG	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	25.07	6.07e-89	1.44e-84	0.87	0.76	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
LGG	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-25.06	7.25e-89	1.72e-84	-0.86	-0.75	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
LGG	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	25.05	7.78e-89	1.84e-84	0.88	0.75	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
LGG	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	25.05	7.84e-89	1.86e-84	0.81	0.75	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	25.02	1.05e-88	2.49e-84	0.94	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
LGG	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	25.01	1.23e-88	2.9e-84	1.13	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
LGG	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-25.01	1.27e-88	2.99e-84	-0.91	-0.75	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
LGG	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-25	1.31e-88	3.08e-84	-1	-0.75	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
LGG	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	24.99	1.47e-88	3.46e-84	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
LGG	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-24.99	1.51e-88	3.54e-84	-0.9	-0.75	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
LGG	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-24.99	1.57e-88	3.69e-84	-0.87	-0.75	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
LGG	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-24.98	1.69e-88	3.97e-84	-0.87	-0.75	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
LGG	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	24.95	2.28e-88	5.33e-84	0.81	0.75	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
LGG	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-24.94	2.47e-88	5.73e-84	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
LGG	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-24.94	2.47e-88	5.73e-84	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
LGG	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-24.94	2.47e-88	5.73e-84	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
LGG	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-24.94	2.47e-88	5.73e-84	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
LGG	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-24.94	2.47e-88	5.73e-84	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
LGG	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-24.94	2.47e-88	5.73e-84	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
LGG	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-24.94	2.47e-88	5.73e-84	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
LGG	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-24.9	4.15e-88	9.59e-84	-0.91	-0.75	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
LGG	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-24.89	4.56e-88	1.05e-83	-0.88	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
LGG	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-24.88	4.69e-88	1.07e-83	-0.84	-0.75	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
LGG	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-24.88	4.75e-88	1.09e-83	-0.89	-0.75	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-24.88	5e-88	1.14e-83	-0.88	-0.75	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-24.87	5.26e-88	1.2e-83	-0.88	-0.75	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
LGG	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-24.87	5.5e-88	1.25e-83	-0.98	-0.75	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-24.87	5.51e-88	1.25e-83	-0.98	-0.75	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-24.87	5.51e-88	1.25e-83	-0.98	-0.75	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
LGG	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-24.86	5.94e-88	1.35e-83	-0.98	-0.75	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
LGG	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-24.86	6.13e-88	1.39e-83	-0.98	-0.75	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
LGG	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-24.84	7.23e-88	1.64e-83	-0.91	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
LGG	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-24.84	7.51e-88	1.7e-83	-0.98	-0.75	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
LGG	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	24.83	8.2e-88	1.86e-83	0.8	0.75	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
LGG	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-24.82	9.24e-88	2.09e-83	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
LGG	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	24.82	9.25e-88	2.09e-83	0.8	0.75	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
LGG	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-24.82	9.66e-88	2.17e-83	-0.88	-0.75	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
LGG	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-24.82	9.66e-88	2.17e-83	-0.88	-0.75	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-24.82	9.66e-88	2.17e-83	-0.88	-0.75	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-24.82	9.66e-88	2.17e-83	-0.88	-0.75	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-24.82	9.66e-88	2.17e-83	-0.88	-0.75	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-24.82	9.66e-88	2.17e-83	-0.88	-0.75	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-24.82	9.85e-88	2.21e-83	-0.88	-0.75	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-24.82	9.85e-88	2.21e-83	-0.88	-0.75	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-24.81	9.99e-88	2.24e-83	-0.88	-0.75	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-24.81	9.99e-88	2.24e-83	-0.88	-0.75	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
LGG	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-24.81	1e-87	2.25e-83	-0.88	-0.75	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
LGG	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-24.79	1.25e-87	2.78e-83	-0.92	-0.75	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
LGG	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	24.79	1.3e-87	2.91e-83	1	0.75	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
LGG	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-24.78	1.41e-87	3.14e-83	-0.8	-0.75	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
LGG	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	24.78	1.44e-87	3.21e-83	0.88	0.75	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
LGG	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-24.77	1.59e-87	3.54e-83	-0.93	-0.75	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-24.76	1.73e-87	3.84e-83	-0.91	-0.75	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
LGG	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-24.76	1.79e-87	3.97e-83	-0.9	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	24.75	2.09e-87	4.61e-83	1	0.75	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	24.75	2.09e-87	4.61e-83	1	0.75	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	24.75	2.09e-87	4.61e-83	1	0.75	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	24.75	2.09e-87	4.61e-83	1	0.75	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	24.75	2.09e-87	4.61e-83	1	0.75	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	24.75	2.09e-87	4.61e-83	1	0.75	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
LGG	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	24.74	2.27e-87	5.02e-83	0.99	0.75	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-24.74	2.28e-87	5.04e-83	-0.88	-0.75	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	24.74	2.36e-87	5.2e-83	0.94	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
LGG	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-24.72	2.7e-87	5.91e-83	-0.98	-0.75	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
LGG	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	24.72	2.7e-87	5.91e-83	0.99	0.75	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
LGG	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-24.71	3.24e-87	7.05e-83	-0.98	-0.75	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-24.71	3.24e-87	7.05e-83	-0.98	-0.75	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-24.71	3.24e-87	7.05e-83	-0.98	-0.75	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
LGG	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-24.7	3.28e-87	7.11e-83	-0.98	-0.75	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
LGG	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-24.7	3.28e-87	7.11e-83	-0.98	-0.75	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
LGG	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-24.7	3.31e-87	7.13e-83	-0.98	-0.75	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
LGG	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-24.7	3.31e-87	7.13e-83	-0.98	-0.75	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
LGG	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-24.7	3.31e-87	7.13e-83	-0.98	-0.75	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-24.7	3.31e-87	7.13e-83	-0.98	-0.75	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-24.7	3.31e-87	7.13e-83	-0.98	-0.75	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-24.7	3.31e-87	7.13e-83	-0.98	-0.75	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
LGG	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-24.69	3.85e-87	8.29e-83	-0.9	-0.75	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
LGG	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-24.68	4.38e-87	9.35e-83	-0.8	-0.75	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
LGG	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	24.64	6.46e-87	1.37e-82	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-24.64	6.47e-87	1.37e-82	-0.92	-0.75	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
LGG	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-24.64	6.92e-87	1.46e-82	-0.88	-0.75	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-24.63	6.97e-87	1.47e-82	-0.88	-0.75	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-24.63	6.97e-87	1.47e-82	-0.88	-0.75	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-24.63	6.97e-87	1.47e-82	-0.88	-0.75	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-24.63	6.97e-87	1.47e-82	-0.88	-0.75	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
LGG	cis	rs9637599	0.967	rs7661312	ENSG00000246375.2	RP11-10L7.1	24.61	8.64e-87	1.82e-82	0.87	0.75	Metabolite levels (small molecules and protein measures);	chr4:88279855	chr4:88284942~88331421:+
LGG	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	24.61	9.23e-87	1.92e-82	0.99	0.75	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
LGG	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-24.59	1.18e-86	2.44e-82	-0.88	-0.75	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-24.57	1.36e-86	2.81e-82	-0.88	-0.75	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-24.57	1.36e-86	2.81e-82	-0.88	-0.75	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
LGG	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-24.57	1.42e-86	2.93e-82	-0.89	-0.75	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
LGG	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-24.57	1.44e-86	2.96e-82	-0.88	-0.75	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-24.57	1.44e-86	2.96e-82	-0.88	-0.75	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	24.57	1.46e-86	3.01e-82	1	0.75	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	24.56	1.62e-86	3.33e-82	0.99	0.75	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	24.56	1.62e-86	3.33e-82	0.99	0.75	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	24.55	1.84e-86	3.76e-82	0.99	0.75	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
LGG	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-24.54	1.93e-86	3.93e-82	-0.98	-0.75	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
LGG	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	24.53	2.22e-86	4.53e-82	0.87	0.75	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
LGG	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	24.52	2.37e-86	4.8e-82	0.94	0.75	Depression;	chr6:28317705	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	24.52	2.44e-86	4.95e-82	0.99	0.75	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
LGG	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-24.52	2.48e-86	5.02e-82	-0.91	-0.75	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
LGG	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	24.51	2.77e-86	5.61e-82	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
LGG	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-24.5	2.96e-86	5.97e-82	-0.91	-0.75	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
LGG	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-24.5	2.99e-86	6.03e-82	-0.98	-0.75	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
LGG	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	24.49	3.48e-86	7e-82	0.99	0.75	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
LGG	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	24.48	3.64e-86	7.31e-82	1.16	0.75	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
LGG	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	24.48	3.68e-86	7.39e-82	0.94	0.75	Depression;	chr6:28303421	chr6:28176188~28176674:+
LGG	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	24.48	3.88e-86	7.79e-82	0.98	0.75	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-24.46	4.39e-86	8.77e-82	-0.88	-0.75	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
LGG	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	24.46	4.59e-86	9.16e-82	0.94	0.75	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
LGG	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	24.46	4.61e-86	9.17e-82	0.98	0.75	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	24.46	4.61e-86	9.17e-82	0.98	0.75	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
LGG	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	24.46	4.8e-86	9.55e-82	0.93	0.75	Depression;	chr6:28301886	chr6:28176188~28176674:+
LGG	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-24.45	4.91e-86	9.75e-82	-0.88	-0.75	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	24.44	5.69e-86	1.13e-81	1	0.75	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	24.44	5.73e-86	1.14e-81	0.99	0.75	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
LGG	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	24.44	6.02e-86	1.19e-81	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
LGG	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	24.43	6.08e-86	1.2e-81	0.81	0.75	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
LGG	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	24.41	7.99e-86	1.57e-81	1.16	0.75	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	24.41	7.99e-86	1.57e-81	1.16	0.75	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	24.41	7.99e-86	1.57e-81	1.16	0.75	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
LGG	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	24.39	9.37e-86	1.83e-81	0.93	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
LGG	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	24.39	9.43e-86	1.84e-81	0.93	0.75	Depression;	chr6:28323463	chr6:28176188~28176674:+
LGG	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	24.38	1.12e-85	2.18e-81	0.98	0.75	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
LGG	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	24.38	1.15e-85	2.23e-81	0.9	0.75	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-24.38	1.16e-85	2.26e-81	-0.91	-0.75	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
LGG	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-24.37	1.19e-85	2.32e-81	-0.89	-0.75	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
LGG	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	24.37	1.21e-85	2.36e-81	0.99	0.75	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	24.37	1.25e-85	2.43e-81	0.95	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
LGG	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	24.36	1.32e-85	2.56e-81	0.99	0.75	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
LGG	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-24.36	1.32e-85	2.56e-81	-0.98	-0.75	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
LGG	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	24.36	1.35e-85	2.61e-81	0.97	0.75	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	24.36	1.44e-85	2.79e-81	0.99	0.75	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	24.36	1.44e-85	2.79e-81	0.99	0.75	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
LGG	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	24.33	1.88e-85	3.64e-81	0.98	0.75	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
LGG	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	24.33	1.88e-85	3.65e-81	0.91	0.75	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
LGG	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-24.33	1.97e-85	3.8e-81	-1.11	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
LGG	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	24.32	2.09e-85	4.04e-81	0.87	0.75	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
LGG	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-24.31	2.26e-85	4.36e-81	-0.88	-0.74	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
LGG	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	24.31	2.32e-85	4.47e-81	1.16	0.74	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
LGG	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-24.31	2.36e-85	4.54e-81	-1.1	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
LGG	cis	rs9399135	0.967	rs11757577	ENSG00000232876.1	CTA-212D2.2	-24.31	2.42e-85	4.66e-81	-0.88	-0.74	Red blood cell count;	chr6:135070327	chr6:135055033~135060550:+
LGG	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	24.29	2.77e-85	5.33e-81	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	24.28	3.18e-85	6.11e-81	0.99	0.74	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	24.28	3.18e-85	6.11e-81	0.99	0.74	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	24.27	3.47e-85	6.65e-81	0.98	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
LGG	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-24.25	4.27e-85	8.16e-81	-0.91	-0.74	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
LGG	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	24.25	4.31e-85	8.24e-81	0.86	0.74	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
LGG	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	24.25	4.34e-85	8.3e-81	0.93	0.74	Depression;	chr6:28327262	chr6:28176188~28176674:+
LGG	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-24.25	4.38e-85	8.37e-81	-0.88	-0.74	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
LGG	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	24.25	4.43e-85	8.46e-81	0.9	0.74	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	24.23	5.58e-85	1.07e-80	0.94	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
LGG	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	24.22	6.13e-85	1.17e-80	0.98	0.74	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	24.22	6.13e-85	1.17e-80	0.98	0.74	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	24.21	6.8e-85	1.29e-80	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
LGG	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	24.19	8.64e-85	1.64e-80	0.98	0.74	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
LGG	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-24.19	8.72e-85	1.65e-80	-0.88	-0.74	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-24.19	8.73e-85	1.66e-80	-0.88	-0.74	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
LGG	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-24.19	8.73e-85	1.66e-80	-0.88	-0.74	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	24.19	8.91e-85	1.69e-80	0.98	0.74	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
LGG	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	24.18	1e-84	1.88e-80	0.99	0.74	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
LGG	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	24.17	1.04e-84	1.96e-80	1.16	0.74	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	24.17	1.12e-84	2.1e-80	1.16	0.74	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
LGG	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	24.16	1.25e-84	2.34e-80	0.88	0.74	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
LGG	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-24.13	1.58e-84	2.94e-80	-0.87	-0.74	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
LGG	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-24.13	1.58e-84	2.94e-80	-0.87	-0.74	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
LGG	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	24.12	1.9e-84	3.52e-80	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
LGG	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-24.11	2.06e-84	3.82e-80	-1.1	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
LGG	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	24.11	2.14e-84	3.96e-80	0.86	0.74	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
LGG	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	24.11	2.14e-84	3.96e-80	0.86	0.74	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
LGG	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-24.1	2.34e-84	4.32e-80	-0.91	-0.74	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-24.06	3.39e-84	6.21e-80	-0.91	-0.74	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
LGG	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-24.06	3.58e-84	6.55e-80	-0.88	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
LGG	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-24.06	3.59e-84	6.57e-80	-0.9	-0.74	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
LGG	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	24.04	4.36e-84	7.96e-80	0.9	0.74	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
LGG	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	24.02	5.74e-84	1.05e-79	0.98	0.74	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	24	6.81e-84	1.24e-79	0.99	0.74	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-24	7.03e-84	1.28e-79	-0.98	-0.74	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
LGG	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	23.99	7.59e-84	1.38e-79	0.96	0.74	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
LGG	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	23.99	7.63e-84	1.39e-79	0.91	0.74	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	23.99	7.81e-84	1.42e-79	0.94	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
LGG	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-23.99	7.85e-84	1.42e-79	-0.95	-0.74	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	23.99	7.87e-84	1.43e-79	0.98	0.74	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-23.98	8.01e-84	1.45e-79	-0.98	-0.74	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
LGG	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	23.98	8.27e-84	1.5e-79	0.88	0.74	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	23.96	1.03e-83	1.84e-79	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
LGG	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	23.96	1.04e-83	1.87e-79	0.77	0.74	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
LGG	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	23.95	1.11e-83	2e-79	1.16	0.74	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	23.95	1.19e-83	2.13e-79	0.98	0.74	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	23.95	1.19e-83	2.13e-79	0.98	0.74	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	23.95	1.19e-83	2.13e-79	0.98	0.74	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	23.95	1.19e-83	2.13e-79	0.98	0.74	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
LGG	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-23.93	1.47e-83	2.63e-79	-0.91	-0.74	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
LGG	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-23.91	1.71e-83	3.04e-79	-0.97	-0.74	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	23.91	1.75e-83	3.12e-79	0.89	0.74	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	23.91	1.89e-83	3.35e-79	0.98	0.74	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	23.9	2.02e-83	3.58e-79	0.98	0.74	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	23.9	2.02e-83	3.58e-79	0.98	0.74	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
LGG	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	23.89	2.15e-83	3.8e-79	0.85	0.74	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	23.89	2.15e-83	3.8e-79	0.85	0.74	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	23.89	2.15e-83	3.8e-79	0.85	0.74	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	23.89	2.15e-83	3.8e-79	0.85	0.74	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	23.89	2.15e-83	3.8e-79	0.85	0.74	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	23.89	2.15e-83	3.8e-79	0.85	0.74	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	23.89	2.15e-83	3.8e-79	0.85	0.74	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	23.88	2.58e-83	4.55e-79	0.97	0.74	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
LGG	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	23.87	2.75e-83	4.84e-79	0.85	0.74	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	23.87	2.75e-83	4.84e-79	0.85	0.74	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	23.87	2.75e-83	4.84e-79	0.85	0.74	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	23.87	2.75e-83	4.84e-79	0.85	0.74	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	23.87	2.75e-83	4.84e-79	0.85	0.74	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	23.87	2.75e-83	4.84e-79	0.85	0.74	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
LGG	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-23.86	3.16e-83	5.55e-79	-1.07	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
LGG	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	23.86	3.2e-83	5.62e-79	0.85	0.74	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	23.83	4.07e-83	7.12e-79	0.85	0.74	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	23.83	4.07e-83	7.12e-79	0.85	0.74	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	23.83	4.07e-83	7.12e-79	0.85	0.74	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	23.82	4.61e-83	8.04e-79	0.85	0.74	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	23.82	4.66e-83	8.13e-79	0.98	0.74	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	23.81	5.1e-83	8.88e-79	0.98	0.74	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
LGG	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-23.81	5.5e-83	9.56e-79	-0.9	-0.74	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
LGG	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	23.81	5.58e-83	9.7e-79	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
LGG	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	23.79	6.85e-83	1.18e-78	1.16	0.74	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	23.78	7.37e-83	1.27e-78	0.97	0.74	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	23.78	7.37e-83	1.27e-78	0.97	0.74	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	23.78	7.37e-83	1.27e-78	0.97	0.74	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	23.77	7.99e-83	1.38e-78	0.98	0.74	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	23.76	8.92e-83	1.53e-78	0.97	0.74	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	23.76	8.92e-83	1.53e-78	0.97	0.74	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	23.76	9.36e-83	1.61e-78	0.98	0.74	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
LGG	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-23.75	9.74e-83	1.67e-78	-0.89	-0.74	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
LGG	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	23.74	1.1e-82	1.89e-78	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
LGG	cis	rs9637599	0.967	rs4693209	ENSG00000246375.2	RP11-10L7.1	23.73	1.22e-82	2.08e-78	0.86	0.74	Metabolite levels (small molecules and protein measures);	chr4:88265916	chr4:88284942~88331421:+
LGG	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-23.73	1.22e-82	2.08e-78	-0.89	-0.74	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
LGG	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-23.72	1.39e-82	2.37e-78	-0.95	-0.74	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
LGG	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-23.7	1.8e-82	3.07e-78	-0.9	-0.74	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
LGG	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	23.7	1.83e-82	3.11e-78	0.97	0.74	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	23.7	1.83e-82	3.11e-78	0.97	0.74	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	23.7	1.83e-82	3.11e-78	0.97	0.74	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	23.7	1.83e-82	3.11e-78	0.97	0.74	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	23.7	1.83e-82	3.11e-78	0.97	0.74	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
LGG	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	23.69	1.86e-82	3.17e-78	0.85	0.74	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	23.69	2.02e-82	3.43e-78	0.85	0.74	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	23.69	2.02e-82	3.43e-78	0.85	0.74	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	23.69	2.02e-82	3.43e-78	0.85	0.74	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
LGG	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	23.69	2.07e-82	3.51e-78	0.79	0.74	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
LGG	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	23.68	2.12e-82	3.6e-78	0.89	0.74	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	23.68	2.13e-82	3.61e-78	0.99	0.74	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-23.64	3.38e-82	5.68e-78	-0.96	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
LGG	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	23.63	3.85e-82	6.45e-78	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	23.58	6.21e-82	1.03e-77	0.97	0.73	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
LGG	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	23.57	7.54e-82	1.26e-77	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	23.55	8.62e-82	1.43e-77	0.98	0.73	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	23.55	9.09e-82	1.51e-77	0.97	0.73	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
LGG	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	23.54	9.9e-82	1.64e-77	0.84	0.73	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	23.5	1.47e-81	2.42e-77	0.96	0.73	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
LGG	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	23.49	1.64e-81	2.69e-77	0.87	0.73	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
LGG	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	23.49	1.64e-81	2.69e-77	0.87	0.73	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
LGG	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	23.49	1.73e-81	2.83e-77	1.06	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
LGG	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	23.48	1.97e-81	3.22e-77	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
LGG	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-23.47	2.22e-81	3.62e-77	-1.12	-0.73	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	23.46	2.35e-81	3.83e-77	0.97	0.73	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
LGG	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	23.42	3.84e-81	6.24e-77	0.96	0.73	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	23.41	4.2e-81	6.83e-77	0.97	0.73	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	23.4	4.41e-81	7.15e-77	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
LGG	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	23.4	4.48e-81	7.28e-77	0.84	0.73	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
LGG	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	23.4	4.84e-81	7.85e-77	0.84	0.73	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
LGG	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-23.38	5.54e-81	8.96e-77	-0.85	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	23.37	6.06e-81	9.78e-77	0.96	0.73	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	23.37	6.5e-81	1.05e-76	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
LGG	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	23.37	6.57e-81	1.06e-76	0.9	0.73	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
LGG	cis	rs853679	0.517	rs17711344	ENSG00000199851.2	U3	-23.35	8.05e-81	1.29e-76	-1.2	-0.73	Depression;	chr6:28109824	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	23.34	8.7e-81	1.39e-76	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
LGG	cis	rs853679	0.517	rs2273564	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28089816	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs1853097	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28090857	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393888	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28091439	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs3734573	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28091659	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9357063	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28092227	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs3823180	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28093966	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368551	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28094014	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393890	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28096077	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9366715	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28096855	chr6:28015568~28015777:+
LGG	cis	rs853679	0.598	rs9380054	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28099759	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.547	rs2116981	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Parkinson's disease;	chr6:28100173	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368552	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28100648	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs2281588	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28104824	chr6:28015568~28015777:+
LGG	cis	rs853679	0.542	rs34131763	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28107222	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs35193936	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28108492	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs36078605	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28110254	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393891	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28111382	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9468286	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28111650	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.516	rs7739216	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Parkinson's disease;	chr6:28112168	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs35512245	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28112175	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380055	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28113851	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368553	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28114487	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368554	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28114933	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713137	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28115743	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9348793	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28116411	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.586	rs6905516	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Parkinson's disease;	chr6:28118700	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.586	rs6905522	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Parkinson's disease;	chr6:28118701	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.586	rs9468290	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Parkinson's disease;	chr6:28119896	chr6:28015568~28015777:+
LGG	cis	rs853679	0.542	rs6934769	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28123153	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs17711801	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28124529	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.527	rs9461433	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Parkinson's disease;	chr6:28127394	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9468292	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28127577	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs1947863	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28131566	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713141	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28133900	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380056	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28136698	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380057	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28136856	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs1947862	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28137418	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs6941992	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28138363	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.516	rs4713142	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Parkinson's disease;	chr6:28138569	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713143	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28138981	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713144	ENSG00000199851.2	U3	23.34	9.31e-81	1.46e-76	1.2	0.73	Depression;	chr6:28139012	chr6:28015568~28015777:+
LGG	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	23.33	9.88e-81	1.55e-76	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	23.33	9.88e-81	1.55e-76	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	23.33	9.88e-81	1.55e-76	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
LGG	cis	rs853679	0.517	rs7755442	ENSG00000199851.2	U3	23.32	1.09e-80	1.71e-76	1.2	0.73	Depression;	chr6:28071237	chr6:28015568~28015777:+
LGG	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-23.32	1.13e-80	1.77e-76	-0.9	-0.73	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
LGG	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	23.31	1.2e-80	1.88e-76	0.95	0.73	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
LGG	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-23.3	1.35e-80	2.11e-76	-0.94	-0.73	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
LGG	cis	rs853679	0.517	rs55747925	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28076559	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs56310871	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28076704	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs34716816	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28078391	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380049	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28080757	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380050	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28080760	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393885	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28082231	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393886	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28082261	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.515	rs9368549	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Parkinson's disease;	chr6:28082269	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs56364346	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28082984	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9357061	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28083994	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368550	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28084025	chr6:28015568~28015777:+
LGG	cis	rs853679	0.542	rs2295594	ENSG00000199851.2	U3	23.3	1.36e-80	2.12e-76	1.2	0.73	Depression;	chr6:28085319	chr6:28015568~28015777:+
LGG	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-23.3	1.4e-80	2.17e-76	-0.88	-0.73	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
LGG	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	23.29	1.56e-80	2.41e-76	0.91	0.73	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
LGG	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	23.28	1.64e-80	2.54e-76	0.9	0.73	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
LGG	cis	rs853679	0.517	rs3757187	ENSG00000199851.2	U3	23.28	1.66e-80	2.57e-76	1.2	0.73	Depression;	chr6:28139876	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs3757185	ENSG00000199851.2	U3	23.28	1.66e-80	2.57e-76	1.2	0.73	Depression;	chr6:28139998	chr6:28015568~28015777:+
LGG	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	23.28	1.67e-80	2.58e-76	0.84	0.73	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
LGG	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	23.28	1.74e-80	2.69e-76	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	23.28	1.74e-80	2.69e-76	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
LGG	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	23.27	1.85e-80	2.86e-76	0.91	0.73	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	23.27	1.88e-80	2.9e-76	0.91	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
LGG	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	23.24	2.65e-80	4.08e-76	0.91	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
LGG	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	23.24	2.77e-80	4.26e-76	0.91	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
LGG	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	23.23	2.9e-80	4.45e-76	0.9	0.73	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
LGG	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	23.23	2.95e-80	4.53e-76	0.97	0.73	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	23.22	3.09e-80	4.74e-76	0.9	0.73	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
LGG	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	23.22	3.09e-80	4.74e-76	0.9	0.73	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
LGG	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	23.22	3.09e-80	4.74e-76	0.9	0.73	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
LGG	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	23.22	3.09e-80	4.74e-76	0.9	0.73	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-23.22	3.27e-80	5.02e-76	-0.89	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
LGG	cis	rs853679	0.517	rs4713145	ENSG00000199851.2	U3	23.21	3.68e-80	5.63e-76	1.2	0.73	Depression;	chr6:28139049	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380047	ENSG00000199851.2	U3	23.19	4.56e-80	6.96e-76	1.2	0.73	Depression;	chr6:28070115	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393887	ENSG00000199851.2	U3	23.17	5.33e-80	8.11e-76	1.18	0.73	Depression;	chr6:28091242	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs6922063	ENSG00000199851.2	U3	23.17	5.33e-80	8.11e-76	1.18	0.73	Depression;	chr6:28126588	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs2275508	ENSG00000199851.2	U3	23.17	5.33e-80	8.11e-76	1.18	0.73	Depression;	chr6:28126953	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-23.15	7.24e-80	1.1e-75	-0.91	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
LGG	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	23.15	7.34e-80	1.11e-75	0.85	0.73	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
LGG	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
LGG	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
LGG	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
LGG	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
LGG	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
LGG	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
LGG	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	23.14	7.45e-80	1.12e-75	0.9	0.73	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	23.14	7.89e-80	1.19e-75	0.9	0.73	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
LGG	cis	rs853679	0.517	rs9393884	ENSG00000199851.2	U3	23.14	7.94e-80	1.2e-75	1.18	0.73	Depression;	chr6:28079011	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	23.12	9.2e-80	1.38e-75	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
LGG	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	23.1	1.19e-79	1.78e-75	0.9	0.73	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	23.1	1.19e-79	1.79e-75	0.95	0.73	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	23.1	1.19e-79	1.79e-75	0.95	0.73	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	23.1	1.21e-79	1.81e-75	0.9	0.73	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	23.1	1.21e-79	1.81e-75	0.9	0.73	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	23.1	1.21e-79	1.81e-75	0.9	0.73	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	23.1	1.23e-79	1.85e-75	0.88	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
LGG	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	23.09	1.3e-79	1.94e-75	0.9	0.73	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
LGG	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	23.09	1.3e-79	1.94e-75	0.9	0.73	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	23.09	1.3e-79	1.94e-75	0.9	0.73	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	23.09	1.3e-79	1.94e-75	0.9	0.73	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	23.09	1.3e-79	1.94e-75	0.9	0.73	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	23.09	1.3e-79	1.94e-75	0.9	0.73	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
LGG	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	23.09	1.37e-79	2.04e-75	0.9	0.73	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
LGG	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	23.07	1.6e-79	2.38e-75	0.84	0.73	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	23.07	1.6e-79	2.38e-75	0.84	0.73	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	23.07	1.6e-79	2.38e-75	0.84	0.73	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
LGG	cis	rs853679	0.517	rs12174753	ENSG00000199851.2	U3	23.07	1.72e-79	2.55e-75	1.19	0.73	Depression;	chr6:28074687	chr6:28015568~28015777:+
LGG	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	23.06	1.79e-79	2.66e-75	0.9	0.73	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	23.06	1.83e-79	2.72e-75	0.9	0.73	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
LGG	cis	rs853679	0.517	rs1904840	ENSG00000199851.2	U3	23.04	2.39e-79	3.55e-75	1.2	0.73	Depression;	chr6:28140454	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368555	ENSG00000199851.2	U3	23.04	2.39e-79	3.55e-75	1.2	0.73	Depression;	chr6:28141189	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393893	ENSG00000199851.2	U3	23.04	2.39e-79	3.55e-75	1.2	0.73	Depression;	chr6:28141484	chr6:28015568~28015777:+
LGG	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	23.03	2.45e-79	3.63e-75	0.84	0.73	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	23.02	2.93e-79	4.33e-75	0.96	0.73	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
LGG	cis	rs853679	0.542	rs9393892	ENSG00000199851.2	U3	23	3.53e-79	5.21e-75	1.18	0.73	Depression;	chr6:28113616	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs6932109	ENSG00000199851.2	U3	-22.99	4.14e-79	6.12e-75	-1.18	-0.73	Depression;	chr6:28110525	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-22.98	4.62e-79	6.81e-75	-0.92	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
LGG	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-22.97	4.7e-79	6.93e-75	-0.9	-0.73	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
LGG	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	22.95	6.41e-79	9.43e-75	0.95	0.73	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	22.94	7.13e-79	1.05e-74	0.91	0.73	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
LGG	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-22.93	8.06e-79	1.18e-74	-0.83	-0.73	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
LGG	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	22.91	9.54e-79	1.4e-74	0.83	0.72	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
LGG	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	22.9	1.07e-78	1.56e-74	0.83	0.72	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
LGG	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
LGG	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	22.89	1.16e-78	1.68e-74	1.14	0.72	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	22.89	1.2e-78	1.75e-74	0.95	0.72	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
LGG	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	22.88	1.26e-78	1.82e-74	0.9	0.72	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	22.87	1.45e-78	2.1e-74	0.9	0.72	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
LGG	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	22.87	1.5e-78	2.17e-74	1.15	0.72	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
LGG	cis	rs853679	0.517	rs1904841	ENSG00000199851.2	U3	22.86	1.62e-78	2.34e-74	1.18	0.72	Depression;	chr6:28140307	chr6:28015568~28015777:+
LGG	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	22.86	1.66e-78	2.4e-74	0.9	0.72	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	22.86	1.69e-78	2.44e-74	0.89	0.72	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
LGG	cis	rs853679	0.517	rs868987	ENSG00000199851.2	U3	-22.85	1.82e-78	2.63e-74	-1.19	-0.72	Depression;	chr6:28142370	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	22.83	2.23e-78	3.23e-74	0.95	0.72	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
LGG	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	22.82	2.56e-78	3.68e-74	0.89	0.72	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	22.82	2.62e-78	3.78e-74	0.95	0.72	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
LGG	cis	rs853679	0.517	rs1340004	ENSG00000199851.2	U3	22.82	2.64e-78	3.81e-74	1.2	0.72	Depression;	chr6:28135913	chr6:28015568~28015777:+
LGG	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	22.81	2.94e-78	4.23e-74	1.14	0.72	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
LGG	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-22.8	3e-78	4.31e-74	-0.87	-0.72	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
LGG	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	22.78	3.87e-78	5.55e-74	0.83	0.72	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	22.78	3.87e-78	5.55e-74	0.83	0.72	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	22.78	3.87e-78	5.55e-74	0.83	0.72	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	22.78	3.87e-78	5.55e-74	0.83	0.72	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	22.78	3.87e-78	5.55e-74	0.83	0.72	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
LGG	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	22.78	3.99e-78	5.73e-74	1.13	0.72	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
LGG	cis	rs853679	0.517	rs4713135	ENSG00000199851.2	U3	22.76	4.79e-78	6.86e-74	1.19	0.72	Depression;	chr6:28071808	chr6:28015568~28015777:+
LGG	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	22.76	5.02e-78	7.18e-74	0.9	0.72	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	22.76	5.02e-78	7.18e-74	0.9	0.72	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
LGG	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	22.75	5.57e-78	7.95e-74	0.84	0.72	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
LGG	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	22.75	5.71e-78	8.15e-74	0.83	0.72	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9295761	ENSG00000199851.2	U3	22.75	5.72e-78	8.16e-74	1.19	0.72	Depression;	chr6:28180209	chr6:28015568~28015777:+
LGG	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	22.74	6.33e-78	9.02e-74	0.87	0.72	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
LGG	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	22.73	6.52e-78	9.29e-74	0.91	0.72	Depression;	chr6:28240757	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	22.72	7.86e-78	1.12e-73	0.88	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
LGG	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	22.71	7.98e-78	1.13e-73	0.88	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
LGG	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	22.71	8.35e-78	1.18e-73	1.15	0.72	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
LGG	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	22.7	9.34e-78	1.32e-73	0.98	0.72	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
LGG	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	22.68	1.14e-77	1.61e-73	0.83	0.72	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	22.68	1.14e-77	1.61e-73	0.83	0.72	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	22.68	1.14e-77	1.61e-73	0.83	0.72	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	22.68	1.14e-77	1.61e-73	0.83	0.72	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
LGG	cis	rs853679	0.517	rs12332979	ENSG00000199851.2	U3	22.68	1.2e-77	1.69e-73	1.19	0.72	Depression;	chr6:28173770	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs67878650	ENSG00000199851.2	U3	22.68	1.2e-77	1.69e-73	1.19	0.72	Depression;	chr6:28174809	chr6:28015568~28015777:+
LGG	cis	rs853679	0.569	rs9348798	ENSG00000199851.2	U3	22.68	1.2e-77	1.69e-73	1.19	0.72	Depression;	chr6:28175233	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380065	ENSG00000199851.2	U3	22.68	1.2e-77	1.69e-73	1.19	0.72	Depression;	chr6:28176973	chr6:28015568~28015777:+
LGG	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-22.67	1.25e-77	1.76e-73	-0.7	-0.72	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
LGG	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	22.67	1.32e-77	1.85e-73	0.9	0.72	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
LGG	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	22.66	1.4e-77	1.96e-73	1.15	0.72	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
LGG	cis	rs853679	0.517	rs4713146	ENSG00000199851.2	U3	22.66	1.52e-77	2.12e-73	1.19	0.72	Depression;	chr6:28143758	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393894	ENSG00000199851.2	U3	22.66	1.52e-77	2.12e-73	1.19	0.72	Depression;	chr6:28144784	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	22.65	1.61e-77	2.25e-73	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
LGG	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	22.64	1.82e-77	2.54e-73	0.84	0.72	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
LGG	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-22.62	2.21e-77	3.07e-73	-0.89	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
LGG	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	22.62	2.27e-77	3.16e-73	0.83	0.72	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
LGG	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	22.61	2.37e-77	3.29e-73	0.88	0.72	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	22.6	2.8e-77	3.89e-73	0.88	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
LGG	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	22.6	2.8e-77	3.89e-73	0.88	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
LGG	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-22.6	2.89e-77	4e-73	-0.95	-0.72	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
LGG	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-22.6	2.89e-77	4e-73	-0.95	-0.72	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
LGG	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	22.59	3.12e-77	4.32e-73	0.9	0.72	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	22.58	3.47e-77	4.8e-73	0.97	0.72	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	22.58	3.62e-77	5.01e-73	0.9	0.72	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	22.58	3.62e-77	5.01e-73	0.9	0.72	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
LGG	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	22.57	4.08e-77	5.64e-73	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
LGG	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	22.56	4.21e-77	5.82e-73	0.89	0.72	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	22.56	4.21e-77	5.82e-73	0.89	0.72	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
LGG	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	22.56	4.49e-77	6.19e-73	1.14	0.72	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	22.56	4.49e-77	6.19e-73	1.14	0.72	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	22.56	4.49e-77	6.19e-73	1.14	0.72	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
LGG	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	22.55	4.64e-77	6.39e-73	0.9	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	22.54	5.37e-77	7.38e-73	0.91	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
LGG	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	22.54	5.43e-77	7.47e-73	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
LGG	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	22.52	6.41e-77	8.78e-73	0.9	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
LGG	cis	rs853679	0.517	rs9468297	ENSG00000199851.2	U3	22.52	6.55e-77	8.97e-73	1.18	0.72	Depression;	chr6:28151096	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	22.52	6.59e-77	9.02e-73	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
LGG	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	22.52	6.61e-77	9.04e-73	1.14	0.72	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
LGG	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	22.51	7.29e-77	9.95e-73	0.84	0.72	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
LGG	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	22.51	7.43e-77	1.01e-72	0.9	0.72	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
LGG	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	22.51	7.43e-77	1.01e-72	0.9	0.72	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
LGG	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	22.51	7.8e-77	1.06e-72	0.82	0.72	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
LGG	cis	rs853679	0.513	rs9468296	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28145952	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4711164	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28147378	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4711165	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28147406	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713148	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28148143	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9348794	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28149979	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9295758	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28152885	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs17774663	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28153120	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9468298	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28154567	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9295759	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28156691	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9348796	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28158424	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs11552219	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28159056	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380058	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28159666	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9357065	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28161802	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9357066	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28162053	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393898	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28162598	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368556	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28163375	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368557	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28163759	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380059	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28164580	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380060	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28164825	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs35227624	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28164948	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380061	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28165025	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9368558	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28165528	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.587	rs9393899	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Parkinson's disease;	chr6:28165750	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713150	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28168434	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.527	rs4713151	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Parkinson's disease;	chr6:28168578	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393901	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28169019	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs3173443	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28169249	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713152	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28169676	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9348797	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28169755	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9380062	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28169791	chr6:28015568~28015777:+
LGG	cis	rs853679	0.542	rs9380063	ENSG00000199851.2	U3	22.49	9.53e-77	1.28e-72	1.18	0.72	Depression;	chr6:28170075	chr6:28015568~28015777:+
LGG	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	22.48	9.79e-77	1.32e-72	0.9	0.72	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
LGG	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	22.48	1.01e-76	1.36e-72	0.96	0.72	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	22.48	1.09e-76	1.46e-72	0.9	0.72	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
LGG	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-22.48	1.09e-76	1.46e-72	-0.75	-0.72	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
LGG	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-22.46	1.26e-76	1.69e-72	-0.91	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
LGG	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	22.46	1.35e-76	1.81e-72	0.89	0.72	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	22.46	1.35e-76	1.81e-72	0.89	0.72	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	22.45	1.38e-76	1.84e-72	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
LGG	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-22.45	1.46e-76	1.94e-72	-0.75	-0.72	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
LGG	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-22.44	1.54e-76	2.04e-72	-0.85	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	22.42	1.91e-76	2.53e-72	0.92	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
LGG	cis	rs853679	0.517	rs9393896	ENSG00000199851.2	U3	22.42	2.09e-76	2.76e-72	1.18	0.72	Depression;	chr6:28159925	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs9393897	ENSG00000199851.2	U3	22.42	2.09e-76	2.76e-72	1.18	0.72	Depression;	chr6:28159932	chr6:28015568~28015777:+
LGG	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-22.41	2.3e-76	3.03e-72	-0.75	-0.72	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-22.41	2.3e-76	3.03e-72	-0.75	-0.72	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-22.41	2.3e-76	3.03e-72	-0.75	-0.72	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-22.41	2.3e-76	3.03e-72	-0.75	-0.72	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	22.41	2.3e-76	3.04e-72	0.75	0.72	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	22.38	2.96e-76	3.88e-72	0.91	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
LGG	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	22.38	2.98e-76	3.92e-72	0.82	0.72	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	22.37	3.32e-76	4.35e-72	0.94	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
LGG	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	22.37	3.61e-76	4.72e-72	0.86	0.72	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	22.35	4.13e-76	5.4e-72	0.91	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
LGG	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	22.35	4.22e-76	5.52e-72	0.75	0.72	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
LGG	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	22.34	4.84e-76	6.32e-72	0.9	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
LGG	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-22.34	4.98e-76	6.5e-72	-0.82	-0.72	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	22.33	5.37e-76	6.99e-72	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
LGG	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-22.33	5.38e-76	7e-72	-0.75	-0.72	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-22.33	5.38e-76	7e-72	-0.75	-0.72	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
LGG	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-22.33	5.38e-76	7e-72	-0.75	-0.72	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
LGG	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	22.33	5.48e-76	7.13e-72	0.85	0.72	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	22.33	5.48e-76	7.13e-72	0.85	0.72	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
LGG	cis	rs2739330	1	rs2739330	ENSG00000218537.1	MIF-AS1	22.32	5.89e-76	7.64e-72	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23894426~23898930:-
LGG	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	22.32	6.17e-76	8.01e-72	0.91	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
LGG	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	22.31	6.59e-76	8.54e-72	0.94	0.72	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	22.3	7.24e-76	9.38e-72	0.89	0.72	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
LGG	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	22.3	7.48e-76	9.68e-72	0.76	0.72	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	22.29	8.36e-76	1.08e-71	0.91	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
LGG	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	22.28	9.21e-76	1.19e-71	0.84	0.72	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
LGG	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	22.28	9.37e-76	1.21e-71	0.84	0.72	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
LGG	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	22.27	9.95e-76	1.29e-71	1.13	0.72	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
LGG	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	22.24	1.49e-75	1.92e-71	0.74	0.71	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
LGG	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	22.22	1.7e-75	2.18e-71	0.89	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
LGG	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	22.22	1.7e-75	2.18e-71	0.89	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
LGG	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	22.22	1.74e-75	2.23e-71	0.84	0.71	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
LGG	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	22.22	1.81e-75	2.31e-71	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
LGG	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	22.22	1.81e-75	2.32e-71	1.11	0.71	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	22.22	1.81e-75	2.32e-71	1.11	0.71	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	22.2	2.14e-75	2.74e-71	0.88	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	22.2	2.28e-75	2.92e-71	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
LGG	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-22.19	2.32e-75	2.96e-71	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
LGG	cis	rs853679	0.517	rs9393895	ENSG00000199851.2	U3	22.19	2.32e-75	2.96e-71	1.17	0.71	Depression;	chr6:28159843	chr6:28015568~28015777:+
LGG	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-22.19	2.5e-75	3.18e-71	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-22.19	2.5e-75	3.18e-71	-0.83	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
LGG	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	22.18	2.66e-75	3.39e-71	0.76	0.71	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
LGG	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-22.18	2.81e-75	3.57e-71	-0.82	-0.71	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
LGG	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-22.16	3.21e-75	4.07e-71	-0.77	-0.71	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
LGG	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	22.15	3.6e-75	4.56e-71	0.76	0.71	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
LGG	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	22.15	3.92e-75	4.94e-71	0.82	0.71	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
LGG	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	22.15	3.95e-75	4.97e-71	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
LGG	cis	rs4713118	0.587	rs61471148	ENSG00000199851.2	U3	22.14	4.06e-75	5.11e-71	1.18	0.71	Parkinson's disease;	chr6:28069254	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	22.14	4.38e-75	5.5e-71	0.9	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
LGG	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	22.13	4.46e-75	5.61e-71	0.96	0.71	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	22.13	4.69e-75	5.89e-71	0.89	0.71	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
LGG	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	22.12	5.41e-75	6.78e-71	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
LGG	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	22.11	5.54e-75	6.95e-71	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
LGG	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	22.11	5.79e-75	7.23e-71	0.84	0.71	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	22.11	5.79e-75	7.23e-71	0.84	0.71	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
LGG	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-22.11	6.12e-75	7.64e-71	-0.77	-0.71	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-22.1	6.72e-75	8.37e-71	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
LGG	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-22.09	6.91e-75	8.61e-71	-0.77	-0.71	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
LGG	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-22.09	6.99e-75	8.69e-71	-0.77	-0.71	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-22.09	6.99e-75	8.69e-71	-0.77	-0.71	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-22.09	6.99e-75	8.69e-71	-0.77	-0.71	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-22.09	6.99e-75	8.69e-71	-0.77	-0.71	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-22.09	6.99e-75	8.69e-71	-0.77	-0.71	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-22.09	7.06e-75	8.77e-71	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-22.09	7.06e-75	8.77e-71	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-22.09	7.06e-75	8.77e-71	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
LGG	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-22.08	8.3e-75	1.03e-70	-0.77	-0.71	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
LGG	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-22.08	8.3e-75	1.03e-70	-0.77	-0.71	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-22.08	8.3e-75	1.03e-70	-0.77	-0.71	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-22.08	8.3e-75	1.03e-70	-0.77	-0.71	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-22.08	8.3e-75	1.03e-70	-0.77	-0.71	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
LGG	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	22.08	8.38e-75	1.03e-70	0.74	0.71	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	22.08	8.38e-75	1.03e-70	0.74	0.71	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	22.08	8.38e-75	1.03e-70	0.74	0.71	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-22.08	8.4e-75	1.04e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-22.08	8.4e-75	1.04e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
LGG	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	22.08	8.41e-75	1.04e-70	0.81	0.71	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
LGG	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	22.07	9.38e-75	1.15e-70	0.83	0.71	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
LGG	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	22.07	9.5e-75	1.17e-70	0.82	0.71	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
LGG	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	22.04	1.19e-74	1.46e-70	0.99	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
LGG	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	22.02	1.48e-74	1.81e-70	1.08	0.71	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
LGG	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-22.02	1.48e-74	1.81e-70	-0.84	-0.71	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
LGG	cis	rs853679	0.517	rs9380052	ENSG00000199851.2	U3	22	1.89e-74	2.31e-70	1.22	0.71	Depression;	chr6:28096845	chr6:28015568~28015777:+
LGG	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	21.99	2.11e-74	2.57e-70	0.75	0.71	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
LGG	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	21.99	2.15e-74	2.62e-70	0.85	0.71	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	21.99	2.2e-74	2.67e-70	0.85	0.71	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
LGG	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	21.98	2.31e-74	2.81e-70	1.09	0.71	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
LGG	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	21.98	2.37e-74	2.87e-70	0.84	0.71	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
LGG	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	21.98	2.54e-74	3.08e-70	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
LGG	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-21.97	2.73e-74	3.3e-70	-0.77	-0.71	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-21.97	2.75e-74	3.33e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	21.97	2.76e-74	3.33e-70	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
LGG	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-21.96	2.84e-74	3.44e-70	-0.77	-0.71	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
LGG	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	21.96	3.04e-74	3.67e-70	0.74	0.71	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
LGG	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-21.95	3.3e-74	3.97e-70	-0.75	-0.71	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-21.95	3.36e-74	4.03e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-21.95	3.36e-74	4.03e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-21.95	3.36e-74	4.03e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-21.95	3.36e-74	4.03e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-21.95	3.36e-74	4.03e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-21.95	3.36e-74	4.03e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-21.95	3.36e-74	4.03e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
LGG	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-21.95	3.46e-74	4.15e-70	-0.76	-0.71	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	21.94	3.56e-74	4.26e-70	0.9	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
LGG	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-21.94	3.79e-74	4.54e-70	-1.11	-0.71	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
LGG	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-21.92	4.57e-74	5.46e-70	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-21.91	4.95e-74	5.92e-70	-0.86	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
LGG	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	21.91	5.08e-74	6.07e-70	0.74	0.71	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
LGG	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	21.91	5.09e-74	6.08e-70	0.91	0.71	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
LGG	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-21.91	5.1e-74	6.08e-70	-0.76	-0.71	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-21.91	5.1e-74	6.08e-70	-0.76	-0.71	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
LGG	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	21.91	5.15e-74	6.14e-70	0.82	0.71	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
LGG	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	21.89	6.35e-74	7.57e-70	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	21.89	6.77e-74	8.05e-70	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	21.89	6.77e-74	8.05e-70	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	21.89	6.77e-74	8.05e-70	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
LGG	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	21.88	7.09e-74	8.43e-70	0.83	0.71	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-21.86	8.98e-74	1.06e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-21.86	8.98e-74	1.06e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
LGG	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	21.85	9.67e-74	1.14e-69	1.12	0.71	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	21.85	9.67e-74	1.14e-69	1.12	0.71	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
LGG	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-21.85	9.78e-74	1.15e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-21.85	9.78e-74	1.15e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-21.84	1.11e-73	1.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-21.83	1.25e-73	1.45e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-21.83	1.25e-73	1.45e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-21.83	1.25e-73	1.46e-69	-0.88	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
LGG	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	21.82	1.4e-73	1.64e-69	1.12	0.71	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	21.82	1.43e-73	1.67e-69	0.95	0.71	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
LGG	cis	rs853679	0.517	rs16893666	ENSG00000199851.2	U3	-21.82	1.44e-73	1.68e-69	-1.15	-0.71	Depression;	chr6:28086929	chr6:28015568~28015777:+
LGG	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	21.8	1.65e-73	1.92e-69	1.12	0.71	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
LGG	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	21.8	1.65e-73	1.92e-69	1.12	0.71	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
LGG	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-21.8	1.65e-73	1.92e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
LGG	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	21.8	1.7e-73	1.97e-69	1.09	0.71	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
LGG	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	21.79	1.95e-73	2.25e-69	0.73	0.71	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
LGG	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-21.78	2.05e-73	2.37e-69	-0.76	-0.71	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
LGG	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	21.78	2.07e-73	2.4e-69	0.87	0.71	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
LGG	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	21.78	2.07e-73	2.4e-69	0.87	0.71	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
LGG	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	21.78	2.23e-73	2.58e-69	0.81	0.71	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
LGG	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	21.78	2.24e-73	2.59e-69	0.73	0.71	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	21.78	2.24e-73	2.59e-69	0.73	0.71	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
LGG	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	21.77	2.39e-73	2.77e-69	1.12	0.71	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
LGG	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-21.76	2.71e-73	3.13e-69	-0.76	-0.71	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
LGG	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-21.76	2.79e-73	3.21e-69	-0.77	-0.71	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
LGG	cis	rs853679	0.517	rs9283884	ENSG00000199851.2	U3	-21.75	3.06e-73	3.53e-69	-1.18	-0.71	Depression;	chr6:28167882	chr6:28015568~28015777:+
LGG	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	21.74	3.18e-73	3.67e-69	1.12	0.71	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
LGG	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	21.72	4.07e-73	4.67e-69	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
LGG	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	21.71	4.34e-73	4.97e-69	0.74	0.71	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-21.71	4.34e-73	4.97e-69	-0.74	-0.71	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	21.71	4.44e-73	5.08e-69	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
LGG	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	21.71	4.79e-73	5.48e-69	0.84	0.71	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
LGG	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	21.69	5.43e-73	6.19e-69	0.87	0.71	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	21.69	5.43e-73	6.19e-69	0.87	0.71	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	21.69	5.49e-73	6.26e-69	0.83	0.71	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
LGG	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	21.69	5.7e-73	6.5e-69	0.74	0.71	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
LGG	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	21.68	6.06e-73	6.9e-69	0.87	0.71	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
LGG	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	21.67	7.02e-73	7.99e-69	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	21.67	7.02e-73	7.99e-69	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
LGG	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	21.67	7.26e-73	8.26e-69	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
LGG	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-21.67	7.3e-73	8.3e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
LGG	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	21.66	7.61e-73	8.64e-69	1.1	0.71	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
LGG	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-21.66	7.82e-73	8.86e-69	-0.84	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
LGG	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	21.66	8e-73	9.07e-69	0.85	0.71	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
LGG	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	21.65	8.45e-73	9.57e-69	0.74	0.71	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-21.65	8.47e-73	9.59e-69	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
LGG	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-21.65	8.96e-73	1.01e-68	-0.76	-0.71	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
LGG	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	21.65	9.03e-73	1.02e-68	0.86	0.71	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	21.64	9.36e-73	1.06e-68	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	21.64	1e-72	1.13e-68	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
LGG	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-21.62	1.25e-72	1.41e-68	-0.76	-0.7	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
LGG	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-21.62	1.25e-72	1.41e-68	-0.76	-0.7	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
LGG	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	21.61	1.42e-72	1.6e-68	0.87	0.7	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	21.61	1.42e-72	1.6e-68	0.87	0.7	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	21.61	1.42e-72	1.6e-68	0.87	0.7	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	21.61	1.42e-72	1.6e-68	0.87	0.7	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	21.61	1.42e-72	1.6e-68	0.87	0.7	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	21.6	1.54e-72	1.72e-68	0.87	0.7	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	21.6	1.54e-72	1.72e-68	0.87	0.7	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
LGG	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	21.6	1.54e-72	1.72e-68	0.87	0.7	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
LGG	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-21.58	1.96e-72	2.19e-68	-0.76	-0.7	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
LGG	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	21.57	2e-72	2.24e-68	0.85	0.7	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
LGG	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-21.57	2.17e-72	2.43e-68	-0.76	-0.7	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
LGG	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	21.56	2.24e-72	2.51e-68	0.87	0.7	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
LGG	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	21.56	2.26e-72	2.52e-68	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
LGG	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-21.56	2.37e-72	2.64e-68	-1.08	-0.7	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
LGG	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	21.55	2.52e-72	2.8e-68	0.82	0.7	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
LGG	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	21.55	2.63e-72	2.92e-68	0.86	0.7	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-21.54	3.07e-72	3.41e-68	-0.74	-0.7	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-21.53	3.29e-72	3.65e-68	-0.74	-0.7	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	21.51	3.92e-72	4.34e-68	0.83	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
LGG	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	21.51	4.03e-72	4.46e-68	0.87	0.7	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
LGG	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	21.5	4.36e-72	4.82e-68	0.85	0.7	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-21.5	4.47e-72	4.94e-68	-0.9	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
LGG	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-21.5	4.69e-72	5.19e-68	-0.82	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	21.49	4.94e-72	5.46e-68	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
LGG	cis	rs2739330	1	rs2739330	ENSG00000225282.1	AP000350.6	21.49	5e-72	5.52e-68	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23926900~23929574:+
LGG	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-21.49	5.15e-72	5.68e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-21.49	5.15e-72	5.68e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-21.49	5.15e-72	5.68e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-21.49	5.15e-72	5.68e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
LGG	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	21.48	5.53e-72	6.09e-68	0.83	0.7	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
LGG	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-21.48	5.87e-72	6.46e-68	-0.73	-0.7	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-21.48	5.87e-72	6.46e-68	-0.73	-0.7	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-21.46	6.71e-72	7.38e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	21.46	6.81e-72	7.48e-68	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-21.45	7.81e-72	8.56e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-21.45	7.81e-72	8.56e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-21.45	7.81e-72	8.56e-68	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
LGG	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	21.45	7.94e-72	8.69e-68	0.73	0.7	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
LGG	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	21.44	8.61e-72	9.42e-68	0.84	0.7	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
LGG	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	21.44	9.03e-72	9.88e-68	1.14	0.7	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
LGG	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	21.42	1.09e-71	1.19e-67	1.21	0.7	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
LGG	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-21.41	1.17e-71	1.27e-67	-0.76	-0.7	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
LGG	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-21.41	1.17e-71	1.27e-67	-0.76	-0.7	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-21.41	1.2e-71	1.31e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-21.41	1.2e-71	1.31e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-21.41	1.2e-71	1.31e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-21.41	1.2e-71	1.31e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
LGG	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-21.39	1.47e-71	1.59e-67	-0.8	-0.7	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
LGG	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-21.39	1.56e-71	1.69e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
LGG	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-21.39	1.58e-71	1.71e-67	-0.74	-0.7	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
LGG	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	21.38	1.69e-71	1.83e-67	0.84	0.7	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
LGG	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-21.38	1.72e-71	1.86e-67	-0.86	-0.7	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	21.38	1.76e-71	1.9e-67	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
LGG	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	21.38	1.77e-71	1.91e-67	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	21.38	1.77e-71	1.91e-67	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
LGG	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	21.37	1.81e-71	1.93e-67	0.86	0.7	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	21.37	1.87e-71	1.99e-67	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
LGG	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	21.36	2.05e-71	2.18e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	21.36	2.05e-71	2.18e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	21.36	2.15e-71	2.28e-67	0.95	0.7	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	21.35	2.2e-71	2.34e-67	0.82	0.7	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	21.35	2.38e-71	2.52e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	21.34	2.48e-71	2.62e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	21.34	2.48e-71	2.62e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	21.34	2.48e-71	2.62e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	21.34	2.48e-71	2.62e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	21.34	2.49e-71	2.63e-67	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	21.34	2.62e-71	2.77e-67	0.94	0.7	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
LGG	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-21.34	2.65e-71	2.79e-67	-0.83	-0.7	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
LGG	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-21.33	2.74e-71	2.89e-67	-0.91	-0.7	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
LGG	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-21.33	2.83e-71	2.99e-67	-0.91	-0.7	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
LGG	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	21.32	3.33e-71	3.5e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	21.32	3.33e-71	3.5e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	21.32	3.33e-71	3.5e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-21.31	3.41e-71	3.57e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-21.31	3.41e-71	3.57e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-21.31	3.41e-71	3.57e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-21.31	3.41e-71	3.57e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
LGG	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	21.31	3.48e-71	3.65e-67	1.22	0.7	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
LGG	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	21.31	3.56e-71	3.73e-67	0.95	0.7	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-21.31	3.61e-71	3.78e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-21.31	3.7e-71	3.88e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
LGG	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	21.31	3.79e-71	3.96e-67	0.83	0.7	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
LGG	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	21.3	4.22e-71	4.39e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	21.3	4.22e-71	4.39e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	21.3	4.22e-71	4.39e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	21.3	4.22e-71	4.39e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-21.3	4.22e-71	4.39e-67	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	21.28	4.81e-71	5e-67	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	21.28	4.97e-71	5.16e-67	0.94	0.7	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
LGG	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	21.28	4.98e-71	5.17e-67	0.9	0.7	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
LGG	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-21.28	5.09e-71	5.28e-67	-1.08	-0.7	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
LGG	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-21.28	5.15e-71	5.33e-67	-0.93	-0.7	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
LGG	cis	rs524281	0.731	rs11227452	ENSG00000255320.1	RP11-755F10.1	21.27	5.4e-71	5.59e-67	1.11	0.7	Electroencephalogram traits;	chr11:66291634	chr11:66244840~66246239:-
LGG	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	21.27	5.69e-71	5.88e-67	0.87	0.7	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	21.26	5.88e-71	6.06e-67	0.93	0.7	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-21.26	5.94e-71	6.12e-67	-0.93	-0.7	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	21.26	6.24e-71	6.42e-67	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
LGG	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	21.25	7.22e-71	7.41e-67	0.74	0.7	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
LGG	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	21.24	7.42e-71	7.59e-67	0.81	0.7	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
LGG	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
LGG	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
LGG	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
LGG	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-21.23	8.24e-71	8.4e-67	-0.93	-0.7	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
LGG	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	21.23	8.53e-71	8.68e-67	0.9	0.7	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
LGG	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-21.23	8.63e-71	8.78e-67	-0.93	-0.7	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
LGG	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	21.23	8.89e-71	9.04e-67	0.82	0.7	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
LGG	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-21.23	8.96e-71	9.1e-67	-0.93	-0.7	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
LGG	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-21.23	8.96e-71	9.1e-67	-0.93	-0.7	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
LGG	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	21.22	9.68e-71	9.84e-67	0.74	0.7	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
LGG	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	21.22	9.94e-71	1.01e-66	0.95	0.7	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
LGG	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-21.2	1.14e-70	1.15e-66	-0.9	-0.7	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
LGG	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	21.19	1.28e-70	1.27e-66	0.93	0.7	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	21.19	1.31e-70	1.31e-66	0.94	0.7	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	21.19	1.31e-70	1.31e-66	0.94	0.7	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	21.19	1.34e-70	1.33e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
LGG	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-21.19	1.38e-70	1.37e-66	-0.82	-0.7	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
LGG	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-21.18	1.42e-70	1.41e-66	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
LGG	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	21.18	1.46e-70	1.45e-66	0.9	0.7	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
LGG	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	21.18	1.47e-70	1.46e-66	0.82	0.7	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	21.18	1.48e-70	1.47e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
LGG	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	21.18	1.49e-70	1.48e-66	0.83	0.7	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
LGG	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-21.18	1.53e-70	1.52e-66	-0.9	-0.7	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
LGG	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	21.17	1.61e-70	1.6e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	21.17	1.62e-70	1.61e-66	0.83	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	21.17	1.71e-70	1.69e-66	0.89	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
LGG	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	21.17	1.71e-70	1.69e-66	0.93	0.7	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	21.17	1.72e-70	1.7e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-21.16	1.77e-70	1.75e-66	-0.8	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
LGG	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-21.16	1.86e-70	1.84e-66	-0.92	-0.7	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
LGG	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-21.16	1.88e-70	1.86e-66	-0.83	-0.7	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
LGG	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	21.16	1.92e-70	1.9e-66	0.79	0.7	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	21.16	1.92e-70	1.9e-66	0.79	0.7	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
LGG	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	21.16	1.93e-70	1.91e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	21.15	1.97e-70	1.95e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	21.15	1.97e-70	1.95e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	21.15	1.97e-70	1.95e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	21.15	1.98e-70	1.95e-66	0.94	0.7	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
LGG	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	21.15	2.01e-70	1.98e-66	0.84	0.7	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
LGG	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	21.15	2.04e-70	2.01e-66	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	21.15	2.09e-70	2.06e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	21.15	2.14e-70	2.11e-66	0.93	0.7	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.516	rs6931858	ENSG00000199851.2	U3	21.14	2.19e-70	2.16e-66	1.14	0.7	Parkinson's disease;	chr6:28110633	chr6:28015568~28015777:+
LGG	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-21.14	2.24e-70	2.21e-66	-0.89	-0.7	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
LGG	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	21.14	2.26e-70	2.23e-66	0.84	0.7	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
LGG	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	21.14	2.33e-70	2.29e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	21.14	2.33e-70	2.29e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-21.13	2.58e-70	2.54e-66	-0.83	-0.7	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
LGG	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-21.13	2.63e-70	2.58e-66	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
LGG	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-21.12	2.78e-70	2.72e-66	-0.93	-0.7	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	21.12	2.86e-70	2.8e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
LGG	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	21.11	3.1e-70	3.04e-66	0.75	0.7	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
LGG	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	21.11	3.1e-70	3.04e-66	0.75	0.7	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
LGG	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	21.11	3.1e-70	3.04e-66	0.75	0.7	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
LGG	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-21.1	3.43e-70	3.34e-66	-0.73	-0.7	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-21.1	3.43e-70	3.34e-66	-0.73	-0.7	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	21.1	3.43e-70	3.34e-66	0.93	0.7	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	21.1	3.55e-70	3.46e-66	0.94	0.7	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	21.09	3.81e-70	3.71e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-21.09	3.84e-70	3.74e-66	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
LGG	cis	rs2282300	0.739	rs10835647	ENSG00000254532.1	RP11-624D11.2	21.09	4.04e-70	3.93e-66	1	0.7	Morning vs. evening chronotype;	chr11:30291721	chr11:30044058~30084343:-
LGG	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-21.08	4.47e-70	4.35e-66	-0.73	-0.7	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	21.07	4.93e-70	4.76e-66	0.93	0.7	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	21.07	4.95e-70	4.77e-66	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	21.07	5.05e-70	4.87e-66	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
LGG	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-21.06	5.38e-70	5.18e-66	-0.93	-0.7	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-21.06	5.55e-70	5.34e-66	-0.93	-0.7	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-21.06	5.56e-70	5.36e-66	-0.81	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	21.05	6.11e-70	5.88e-66	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-21.05	6.33e-70	6.09e-66	-0.82	-0.7	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
LGG	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	21.04	6.58e-70	6.32e-66	0.82	0.69	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
LGG	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	21.04	6.67e-70	6.41e-66	1.12	0.69	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
LGG	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	21.04	6.77e-70	6.51e-66	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	21.04	7.19e-70	6.9e-66	0.82	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	21.03	7.28e-70	6.98e-66	0.93	0.69	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	21.03	7.81e-70	7.48e-66	0.93	0.69	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	21.03	7.81e-70	7.48e-66	0.93	0.69	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
LGG	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	21.02	8.28e-70	7.93e-66	1.1	0.69	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
LGG	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-21.02	8.32e-70	7.96e-66	-0.81	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-21.02	8.45e-70	8.08e-66	-0.83	-0.69	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-21.02	8.45e-70	8.08e-66	-0.83	-0.69	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-21.02	8.45e-70	8.08e-66	-0.83	-0.69	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-21.02	8.45e-70	8.08e-66	-0.83	-0.69	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
LGG	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-21.02	8.46e-70	8.09e-66	-0.75	-0.69	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	21.02	8.86e-70	8.46e-66	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
LGG	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	21.01	9.3e-70	8.88e-66	1.12	0.69	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
LGG	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	21.01	9.3e-70	8.88e-66	1.12	0.69	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
LGG	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	21.01	9.72e-70	9.27e-66	0.83	0.69	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
LGG	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	21.01	9.79e-70	9.34e-66	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
LGG	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	21.01	9.81e-70	9.35e-66	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
LGG	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	21	1e-69	9.58e-66	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-21	1.05e-69	9.97e-66	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-21	1.07e-69	1.01e-65	-0.83	-0.69	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-21	1.07e-69	1.01e-65	-0.83	-0.69	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	21	1.09e-69	1.03e-65	0.83	0.69	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
LGG	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	20.99	1.18e-69	1.12e-65	0.9	0.69	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
LGG	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-20.98	1.3e-69	1.23e-65	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-20.98	1.3e-69	1.23e-65	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-20.98	1.3e-69	1.23e-65	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	20.98	1.31e-69	1.24e-65	0.82	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
LGG	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	20.98	1.36e-69	1.29e-65	1.12	0.69	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
LGG	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	20.98	1.36e-69	1.29e-65	1.12	0.69	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
LGG	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	20.97	1.4e-69	1.33e-65	0.93	0.69	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	20.97	1.44e-69	1.36e-65	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-20.97	1.46e-69	1.38e-65	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	20.97	1.47e-69	1.39e-65	0.95	0.69	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
LGG	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-20.97	1.51e-69	1.43e-65	-0.92	-0.69	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
LGG	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	20.97	1.53e-69	1.44e-65	0.9	0.69	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
LGG	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-20.96	1.63e-69	1.53e-65	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
LGG	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	20.96	1.67e-69	1.57e-65	1.11	0.69	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
LGG	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	20.95	1.75e-69	1.65e-65	0.82	0.69	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
LGG	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	20.95	1.77e-69	1.67e-65	0.92	0.69	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	20.95	1.78e-69	1.67e-65	0.93	0.69	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	20.95	1.78e-69	1.68e-65	0.92	0.69	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	20.95	1.83e-69	1.72e-65	0.92	0.69	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-20.95	1.83e-69	1.72e-65	-0.89	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
LGG	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-20.95	1.89e-69	1.78e-65	-0.92	-0.69	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
LGG	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-20.95	1.89e-69	1.78e-65	-0.92	-0.69	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	20.95	1.92e-69	1.8e-65	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
LGG	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	20.94	1.94e-69	1.82e-65	0.74	0.69	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
LGG	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	20.94	2.01e-69	1.89e-65	1.11	0.69	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
LGG	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-20.94	2.1e-69	1.95e-65	-0.83	-0.69	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
LGG	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-20.94	2.13e-69	1.98e-65	-0.92	-0.69	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
LGG	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	20.93	2.28e-69	2.11e-65	0.92	0.69	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
LGG	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	20.93	2.28e-69	2.12e-65	0.83	0.69	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
LGG	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	20.93	2.36e-69	2.19e-65	1.13	0.69	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
LGG	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	20.92	2.46e-69	2.27e-65	0.74	0.69	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-20.92	2.51e-69	2.32e-65	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-20.92	2.66e-69	2.46e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
LGG	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	20.91	2.68e-69	2.48e-65	1.12	0.69	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
LGG	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	20.91	2.77e-69	2.56e-65	1.18	0.69	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
LGG	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	20.91	2.86e-69	2.64e-65	0.91	0.69	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
LGG	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-20.91	2.9e-69	2.68e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
LGG	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	20.91	2.95e-69	2.72e-65	0.92	0.69	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	20.9	2.99e-69	2.75e-65	0.93	0.69	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	20.9	3.02e-69	2.78e-65	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	20.9	3.02e-69	2.78e-65	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	20.9	3.02e-69	2.78e-65	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
LGG	cis	rs2282300	0.739	rs1616223	ENSG00000254532.1	RP11-624D11.2	20.9	3.12e-69	2.87e-65	1	0.69	Morning vs. evening chronotype;	chr11:30317236	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs1717772	ENSG00000254532.1	RP11-624D11.2	20.9	3.12e-69	2.87e-65	1	0.69	Morning vs. evening chronotype;	chr11:30318586	chr11:30044058~30084343:-
LGG	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	20.9	3.27e-69	3e-65	0.91	0.69	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	20.89	3.37e-69	3.09e-65	0.92	0.69	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	20.89	3.37e-69	3.09e-65	0.92	0.69	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	20.89	3.37e-69	3.09e-65	0.92	0.69	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	20.89	3.59e-69	3.3e-65	0.92	0.69	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
LGG	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-20.88	3.78e-69	3.47e-65	-0.81	-0.69	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
LGG	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	20.88	3.89e-69	3.57e-65	0.92	0.69	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
LGG	cis	rs172166	0.694	rs188105	ENSG00000199851.2	U3	20.88	3.91e-69	3.57e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28103615	chr6:28015568~28015777:+
LGG	cis	rs172166	0.611	rs203882	ENSG00000199851.2	U3	20.88	3.91e-69	3.57e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28110724	chr6:28015568~28015777:+
LGG	cis	rs172166	0.694	rs1770131	ENSG00000199851.2	U3	20.88	3.91e-69	3.57e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28118635	chr6:28015568~28015777:+
LGG	cis	rs172166	0.694	rs1631552	ENSG00000199851.2	U3	20.88	3.91e-69	3.57e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28121921	chr6:28015568~28015777:+
LGG	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-20.87	4.29e-69	3.92e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
LGG	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	20.87	4.34e-69	3.97e-65	0.8	0.69	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	20.87	4.34e-69	3.97e-65	0.8	0.69	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
LGG	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	20.87	4.34e-69	3.97e-65	0.8	0.69	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	20.86	4.77e-69	4.35e-65	0.92	0.69	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	20.86	4.87e-69	4.44e-65	0.82	0.69	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
LGG	cis	rs172166	0.694	rs203893	ENSG00000199851.2	U3	20.86	4.97e-69	4.52e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28094288	chr6:28015568~28015777:+
LGG	cis	rs172166	0.652	rs476167	ENSG00000199851.2	U3	20.86	4.97e-69	4.52e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28098110	chr6:28015568~28015777:+
LGG	cis	rs172166	0.694	rs203892	ENSG00000199851.2	U3	20.86	4.97e-69	4.52e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28099418	chr6:28015568~28015777:+
LGG	cis	rs172166	0.611	rs203883	ENSG00000199851.2	U3	20.86	4.97e-69	4.52e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28110578	chr6:28015568~28015777:+
LGG	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-20.86	5.01e-69	4.55e-65	-0.92	-0.69	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-20.86	5.01e-69	4.55e-65	-0.92	-0.69	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
LGG	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-20.86	5.13e-69	4.66e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-20.86	5.13e-69	4.66e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
LGG	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	20.85	5.22e-69	4.73e-65	0.83	0.69	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	20.85	5.34e-69	4.85e-65	0.92	0.69	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
LGG	cis	rs172166	0.694	rs203884	ENSG00000199851.2	U3	20.85	5.59e-69	5.06e-65	1.05	0.69	Cardiac Troponin-T levels;	chr6:28109596	chr6:28015568~28015777:+
LGG	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-20.84	5.75e-69	5.21e-65	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
LGG	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	20.84	6.1e-69	5.53e-65	0.94	0.69	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
LGG	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	20.83	6.49e-69	5.87e-65	0.72	0.69	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
LGG	cis	rs2282300	0.739	rs1222216	ENSG00000254532.1	RP11-624D11.2	20.83	6.51e-69	5.89e-65	1	0.69	Morning vs. evening chronotype;	chr11:30324505	chr11:30044058~30084343:-
LGG	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	20.83	6.7e-69	6.06e-65	0.81	0.69	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	20.82	7.17e-69	6.47e-65	0.92	0.69	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	20.82	7.17e-69	6.47e-65	0.92	0.69	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	20.82	7.41e-69	6.68e-65	0.92	0.69	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	20.82	7.41e-69	6.68e-65	0.92	0.69	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	20.82	7.41e-69	6.68e-65	0.92	0.69	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
LGG	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-20.82	7.74e-69	6.98e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-20.81	8.2e-69	7.38e-65	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
LGG	cis	rs172166	0.694	rs203876	ENSG00000199851.2	U3	20.81	8.32e-69	7.49e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28078895	chr6:28015568~28015777:+
LGG	cis	rs172166	0.694	rs203877	ENSG00000199851.2	U3	20.81	8.32e-69	7.49e-65	1.04	0.69	Cardiac Troponin-T levels;	chr6:28080846	chr6:28015568~28015777:+
LGG	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	20.81	8.36e-69	7.52e-65	0.91	0.69	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
LGG	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	20.81	8.36e-69	7.52e-65	0.91	0.69	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
LGG	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-20.81	8.57e-69	7.7e-65	-0.92	-0.69	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs1933343	ENSG00000254532.1	RP11-624D11.2	-20.8	9.43e-69	8.47e-65	-0.99	-0.69	Morning vs. evening chronotype;	chr11:30289445	chr11:30044058~30084343:-
LGG	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	20.8	9.86e-69	8.85e-65	1.11	0.69	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
LGG	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	20.8	9.86e-69	8.85e-65	1.11	0.69	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
LGG	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-20.79	1.01e-68	9.06e-65	-0.93	-0.69	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-20.79	1.04e-68	9.36e-65	-0.92	-0.69	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
LGG	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-20.79	1.04e-68	9.36e-65	-0.92	-0.69	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
LGG	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	20.79	1.06e-68	9.48e-65	0.9	0.69	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
LGG	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	20.79	1.06e-68	9.48e-65	0.9	0.69	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
LGG	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	20.79	1.07e-68	9.59e-65	1.11	0.69	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
LGG	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-20.78	1.15e-68	1.03e-64	-0.92	-0.69	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-20.78	1.17e-68	1.04e-64	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-20.77	1.27e-68	1.13e-64	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
LGG	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-20.77	1.27e-68	1.14e-64	-0.92	-0.69	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
LGG	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	20.77	1.32e-68	1.18e-64	0.92	0.69	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
LGG	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	20.77	1.37e-68	1.22e-64	0.82	0.69	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
LGG	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	20.76	1.42e-68	1.26e-64	0.93	0.69	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
LGG	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-20.76	1.49e-68	1.33e-64	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
LGG	cis	rs2282300	0.739	rs1222211	ENSG00000254532.1	RP11-624D11.2	20.75	1.54e-68	1.38e-64	1.01	0.69	Morning vs. evening chronotype;	chr11:30340692	chr11:30044058~30084343:-
LGG	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-20.75	1.62e-68	1.44e-64	-0.92	-0.69	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-20.75	1.62e-68	1.44e-64	-0.92	-0.69	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	20.75	1.65e-68	1.47e-64	0.92	0.69	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
LGG	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-20.74	1.78e-68	1.58e-64	-0.92	-0.69	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	20.74	1.82e-68	1.62e-64	0.92	0.69	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	20.74	1.82e-68	1.62e-64	0.92	0.69	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
LGG	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	20.73	2.09e-68	1.86e-64	0.82	0.69	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	20.72	2.12e-68	1.88e-64	0.92	0.69	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-20.72	2.13e-68	1.89e-64	-0.92	-0.69	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
LGG	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	20.72	2.16e-68	1.91e-64	0.8	0.69	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
LGG	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-20.72	2.23e-68	1.98e-64	-0.82	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	20.72	2.32e-68	2.06e-64	0.91	0.69	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
LGG	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-20.71	2.43e-68	2.15e-64	-0.82	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
LGG	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-20.71	2.6e-68	2.29e-64	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
LGG	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-20.7	2.8e-68	2.47e-64	-0.81	-0.69	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
LGG	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	20.69	2.96e-68	2.61e-64	0.92	0.69	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	20.69	2.96e-68	2.61e-64	0.92	0.69	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	20.69	2.96e-68	2.61e-64	0.92	0.69	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	20.69	2.97e-68	2.62e-64	0.93	0.69	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs1222219	ENSG00000254532.1	RP11-624D11.2	20.69	2.97e-68	2.62e-64	1	0.69	Morning vs. evening chronotype;	chr11:30322798	chr11:30044058~30084343:-
LGG	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-20.69	2.98e-68	2.63e-64	-0.84	-0.69	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
LGG	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-20.69	3.24e-68	2.85e-64	-0.8	-0.69	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	20.67	3.66e-68	3.21e-64	0.92	0.69	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	20.67	3.66e-68	3.21e-64	0.92	0.69	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
LGG	cis	rs2282300	0.739	rs1717775	ENSG00000254532.1	RP11-624D11.2	20.67	3.75e-68	3.3e-64	0.99	0.69	Morning vs. evening chronotype;	chr11:30328707	chr11:30044058~30084343:-
LGG	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	20.67	3.81e-68	3.32e-64	0.9	0.69	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
LGG	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	20.67	3.95e-68	3.45e-64	0.92	0.69	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	20.66	4.22e-68	3.68e-64	0.92	0.69	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
LGG	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	20.66	4.28e-68	3.73e-64	0.83	0.69	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
LGG	cis	rs853679	0.55	rs1237875	ENSG00000199851.2	U3	-20.66	4.31e-68	3.76e-64	-1.1	-0.69	Depression;	chr6:28205232	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	20.66	4.34e-68	3.78e-64	0.92	0.69	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	20.66	4.34e-68	3.78e-64	0.92	0.69	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	20.66	4.41e-68	3.84e-64	0.92	0.69	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
LGG	cis	rs992157	0.737	rs3731860	ENSG00000261338.2	RP11-378A13.1	-20.65	4.58e-68	3.99e-64	-0.76	-0.69	Colorectal cancer;	chr2:218292256	chr2:218255319~218257366:+
LGG	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	20.65	4.67e-68	4.07e-64	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
LGG	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
LGG	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-20.65	4.86e-68	4.21e-64	-0.92	-0.69	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-20.65	4.87e-68	4.22e-64	-0.92	-0.69	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	20.65	4.9e-68	4.23e-64	0.92	0.69	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	20.65	4.94e-68	4.27e-64	0.91	0.69	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	20.65	5.01e-68	4.33e-64	0.91	0.69	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	20.65	5.01e-68	4.33e-64	0.91	0.69	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
LGG	cis	rs172166	0.694	rs9295760	ENSG00000199851.2	U3	20.64	5.24e-68	4.52e-64	1.04	0.69	Cardiac Troponin-T levels;	chr6:28179607	chr6:28015568~28015777:+
LGG	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-20.64	5.34e-68	4.6e-64	-0.92	-0.69	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-20.64	5.34e-68	4.6e-64	-0.92	-0.69	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-20.64	5.34e-68	4.6e-64	-0.92	-0.69	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-20.64	5.34e-68	4.6e-64	-0.92	-0.69	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-20.64	5.34e-68	4.6e-64	-0.92	-0.69	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
LGG	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	20.64	5.47e-68	4.71e-64	0.91	0.69	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	20.64	5.48e-68	4.72e-64	0.91	0.69	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	20.64	5.48e-68	4.72e-64	0.91	0.69	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
LGG	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	20.63	5.65e-68	4.86e-64	0.92	0.69	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
LGG	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	20.63	5.89e-68	5.07e-64	0.69	0.69	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
LGG	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	20.63	6.13e-68	5.27e-64	1.09	0.69	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
LGG	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	20.63	6.18e-68	5.31e-64	0.92	0.69	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	20.63	6.18e-68	5.31e-64	0.92	0.69	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
LGG	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
LGG	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-20.62	6.33e-68	5.42e-64	-0.92	-0.69	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-20.62	6.35e-68	5.43e-64	-0.8	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
LGG	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	20.62	6.47e-68	5.53e-64	0.92	0.69	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
LGG	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	20.62	6.47e-68	5.53e-64	0.92	0.69	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
LGG	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	20.62	6.54e-68	5.59e-64	0.82	0.69	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	20.62	6.55e-68	5.6e-64	0.92	0.69	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
LGG	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	20.62	6.75e-68	5.77e-64	0.74	0.69	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	20.62	6.77e-68	5.78e-64	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	20.62	6.79e-68	5.79e-64	0.93	0.69	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	20.62	6.79e-68	5.79e-64	0.93	0.69	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	20.62	6.79e-68	5.79e-64	0.93	0.69	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
LGG	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-20.62	6.86e-68	5.85e-64	-0.84	-0.69	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
LGG	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
LGG	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-20.61	7.04e-68	5.99e-64	-0.92	-0.69	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-20.61	7.26e-68	6.17e-64	-0.86	-0.69	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
LGG	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	20.61	7.55e-68	6.42e-64	0.92	0.69	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	20.61	7.55e-68	6.42e-64	0.92	0.69	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	20.61	7.55e-68	6.42e-64	0.92	0.69	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs1933342	ENSG00000254532.1	RP11-624D11.2	-20.61	7.65e-68	6.5e-64	-1	-0.69	Morning vs. evening chronotype;	chr11:30291278	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs2225909	ENSG00000254532.1	RP11-624D11.2	-20.61	7.65e-68	6.5e-64	-1	-0.69	Morning vs. evening chronotype;	chr11:30308197	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.702	rs2211018	ENSG00000254532.1	RP11-624D11.2	-20.61	7.65e-68	6.5e-64	-1	-0.69	Morning vs. evening chronotype;	chr11:30308532	chr11:30044058~30084343:-
LGG	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	20.6	7.9e-68	6.7e-64	0.92	0.69	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	20.6	7.9e-68	6.7e-64	0.92	0.69	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
LGG	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-20.6	8.14e-68	6.9e-64	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
LGG	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-20.6	8.17e-68	6.92e-64	-1.08	-0.69	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	20.6	8.32e-68	7.05e-64	0.92	0.69	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
LGG	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	20.6	8.34e-68	7.06e-64	0.91	0.69	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
LGG	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-20.59	9.28e-68	7.84e-64	-0.86	-0.69	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
LGG	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	20.59	9.36e-68	7.9e-64	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
LGG	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	20.59	9.58e-68	8.09e-64	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	20.59	9.58e-68	8.09e-64	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
LGG	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-20.59	9.6e-68	8.1e-64	-1.08	-0.69	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
LGG	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-20.59	9.66e-68	8.14e-64	-0.91	-0.69	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
LGG	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-20.59	9.66e-68	8.14e-64	-0.91	-0.69	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	20.58	9.74e-68	8.21e-64	0.91	0.69	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	20.58	9.76e-68	8.23e-64	0.92	0.69	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	20.58	9.76e-68	8.23e-64	0.92	0.69	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
LGG	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	20.58	1.03e-67	8.67e-64	0.91	0.69	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
LGG	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-20.57	1.13e-67	9.47e-64	-0.91	-0.69	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
LGG	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-20.57	1.16e-67	9.75e-64	-0.91	-0.69	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
LGG	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	20.56	1.24e-67	1.05e-63	0.72	0.69	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
LGG	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-20.56	1.26e-67	1.06e-63	-0.91	-0.69	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	20.56	1.27e-67	1.07e-63	0.92	0.69	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
LGG	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	20.55	1.37e-67	1.16e-63	0.79	0.69	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
LGG	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	20.55	1.4e-67	1.18e-63	0.92	0.69	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
LGG	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	20.55	1.43e-67	1.2e-63	0.9	0.69	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
LGG	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-20.55	1.46e-67	1.23e-63	-0.91	-0.69	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs1222215	ENSG00000254532.1	RP11-624D11.2	20.54	1.55e-67	1.3e-63	1	0.69	Morning vs. evening chronotype;	chr11:30326049	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.696	rs1222214	ENSG00000254532.1	RP11-624D11.2	20.54	1.55e-67	1.3e-63	1	0.69	Morning vs. evening chronotype;	chr11:30326148	chr11:30044058~30084343:-
LGG	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	20.53	1.71e-67	1.44e-63	0.92	0.69	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
LGG	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	20.53	1.79e-67	1.5e-63	1.21	0.69	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
LGG	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	20.53	1.83e-67	1.54e-63	0.79	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
LGG	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-20.52	1.96e-67	1.64e-63	-0.8	-0.69	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
LGG	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	20.52	1.98e-67	1.66e-63	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
LGG	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	20.52	2.01e-67	1.68e-63	0.91	0.69	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
LGG	cis	rs2282300	0.739	rs6484478	ENSG00000254532.1	RP11-624D11.2	-20.51	2.17e-67	1.81e-63	-0.99	-0.69	Morning vs. evening chronotype;	chr11:30284893	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs10742237	ENSG00000254532.1	RP11-624D11.2	-20.51	2.17e-67	1.81e-63	-0.99	-0.69	Morning vs. evening chronotype;	chr11:30289112	chr11:30044058~30084343:-
LGG	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-20.51	2.17e-67	1.81e-63	-0.92	-0.69	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	20.51	2.26e-67	1.89e-63	0.91	0.69	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	20.51	2.26e-67	1.89e-63	0.91	0.69	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	20.51	2.26e-67	1.89e-63	0.91	0.69	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
LGG	cis	rs853679	0.55	rs1233701	ENSG00000199851.2	U3	-20.51	2.26e-67	1.89e-63	-1.09	-0.69	Depression;	chr6:28200948	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	20.51	2.29e-67	1.91e-63	0.91	0.69	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	20.51	2.29e-67	1.91e-63	0.91	0.69	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	20.51	2.29e-67	1.91e-63	0.91	0.69	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
LGG	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	20.5	2.37e-67	1.97e-63	0.91	0.69	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
LGG	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	20.5	2.37e-67	1.97e-63	0.91	0.69	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	20.5	2.37e-67	1.97e-63	0.91	0.69	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	20.5	2.37e-67	1.97e-63	0.91	0.69	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
LGG	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	20.5	2.39e-67	1.99e-63	0.73	0.69	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
LGG	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	20.5	2.41e-67	2e-63	1.15	0.69	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
LGG	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-20.5	2.42e-67	2.01e-63	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-20.5	2.42e-67	2.01e-63	-0.82	-0.69	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
LGG	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	20.5	2.43e-67	2.02e-63	0.92	0.69	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
LGG	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	20.5	2.47e-67	2.05e-63	0.84	0.69	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	20.5	2.58e-67	2.14e-63	0.92	0.69	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	20.5	2.58e-67	2.14e-63	0.92	0.69	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
LGG	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	20.48	2.9e-67	2.41e-63	0.79	0.69	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
LGG	cis	rs4853012	0.793	rs6723185	ENSG00000217702.2	RP11-287D1.4	20.48	2.97e-67	2.47e-63	1.11	0.69	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74130583~74135395:+
LGG	cis	rs4713118	0.621	rs10484403	ENSG00000199851.2	U3	20.48	2.98e-67	2.47e-63	1.14	0.69	Parkinson's disease;	chr6:28065745	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	20.48	2.99e-67	2.48e-63	0.9	0.69	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-20.48	3.08e-67	2.55e-63	-0.78	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
LGG	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	20.48	3.22e-67	2.67e-63	0.91	0.69	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-20.47	3.26e-67	2.7e-63	-0.88	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
LGG	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	20.47	3.27e-67	2.71e-63	0.92	0.69	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	20.47	3.42e-67	2.83e-63	0.92	0.68	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	20.47	3.42e-67	2.83e-63	0.92	0.68	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
LGG	cis	rs172166	0.694	rs536704	ENSG00000199851.2	U3	20.47	3.43e-67	2.84e-63	1.02	0.68	Cardiac Troponin-T levels;	chr6:28124825	chr6:28015568~28015777:+
LGG	cis	rs2282300	0.739	rs1765133	ENSG00000254532.1	RP11-624D11.2	20.47	3.52e-67	2.91e-63	1	0.68	Morning vs. evening chronotype;	chr11:30317853	chr11:30044058~30084343:-
LGG	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	20.46	3.61e-67	2.98e-63	0.93	0.68	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
LGG	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	20.46	3.97e-67	3.28e-63	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
LGG	cis	rs4713118	0.512	rs2622319	ENSG00000199851.2	U3	20.46	3.98e-67	3.29e-63	1.03	0.68	Parkinson's disease;	chr6:28152623	chr6:28015568~28015777:+
LGG	cis	rs172166	0.694	rs1150666	ENSG00000199851.2	U3	20.46	3.98e-67	3.29e-63	1.03	0.68	Cardiac Troponin-T levels;	chr6:28156150	chr6:28015568~28015777:+
LGG	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	20.45	4.04e-67	3.34e-63	0.91	0.68	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.662	rs9380046	ENSG00000199851.2	U3	20.45	4.06e-67	3.35e-63	1.13	0.68	Parkinson's disease;	chr6:28062721	chr6:28015568~28015777:+
LGG	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	20.45	4.25e-67	3.51e-63	0.91	0.68	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
LGG	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	20.44	4.51e-67	3.72e-63	0.92	0.68	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
LGG	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	20.44	4.53e-67	3.74e-63	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
LGG	cis	rs2282300	0.739	rs7926465	ENSG00000254532.1	RP11-624D11.2	-20.44	4.98e-67	4.1e-63	-0.99	-0.68	Morning vs. evening chronotype;	chr11:30311469	chr11:30044058~30084343:-
LGG	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	20.43	5.1e-67	4.2e-63	0.91	0.68	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	20.43	5.39e-67	4.44e-63	0.92	0.68	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
LGG	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-20.42	5.69e-67	4.68e-63	-1.08	-0.68	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
LGG	cis	rs2282300	0.739	rs1222210	ENSG00000254532.1	RP11-624D11.2	-20.42	5.72e-67	4.7e-63	-0.98	-0.68	Morning vs. evening chronotype;	chr11:30340578	chr11:30044058~30084343:-
LGG	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-20.42	5.75e-67	4.73e-63	-0.79	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	20.41	6.53e-67	5.37e-63	0.8	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	20.4	6.98e-67	5.73e-63	0.91	0.68	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	20.4	7.06e-67	5.8e-63	0.92	0.68	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	20.4	7.27e-67	5.97e-63	0.93	0.68	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.621	rs9295755	ENSG00000199851.2	U3	-20.4	7.28e-67	5.97e-63	-1.14	-0.68	Parkinson's disease;	chr6:28065396	chr6:28015568~28015777:+
LGG	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	20.39	7.75e-67	6.36e-63	0.81	0.68	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
LGG	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	20.39	7.85e-67	6.44e-63	0.91	0.68	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	20.39	7.94e-67	6.5e-63	0.92	0.68	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	20.39	8.11e-67	6.64e-63	0.91	0.68	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	20.39	8.3e-67	6.8e-63	0.8	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	20.38	8.92e-67	7.3e-63	0.91	0.68	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
LGG	cis	rs2282300	0.739	rs1631451	ENSG00000254532.1	RP11-624D11.2	20.38	9.05e-67	7.4e-63	0.99	0.68	Morning vs. evening chronotype;	chr11:30327586	chr11:30044058~30084343:-
LGG	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	20.38	9.43e-67	7.71e-63	0.91	0.68	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	20.38	9.43e-67	7.71e-63	0.91	0.68	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
LGG	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	20.38	9.43e-67	7.71e-63	0.91	0.68	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
LGG	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	20.38	9.43e-67	7.71e-63	0.91	0.68	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
LGG	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	20.38	9.43e-67	7.71e-63	0.91	0.68	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.621	rs9295756	ENSG00000199851.2	U3	20.38	9.47e-67	7.74e-63	1.14	0.68	Parkinson's disease;	chr6:28065618	chr6:28015568~28015777:+
LGG	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	20.37	9.77e-67	7.97e-63	0.9	0.68	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	20.37	9.77e-67	7.97e-63	0.9	0.68	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
LGG	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	20.36	1.08e-66	8.81e-63	1.16	0.68	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
LGG	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-20.36	1.14e-66	9.3e-63	-0.82	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
LGG	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-20.36	1.14e-66	9.31e-63	-1.06	-0.68	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
LGG	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-20.36	1.16e-66	9.49e-63	-1.06	-0.68	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
LGG	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	20.36	1.17e-66	9.53e-63	0.91	0.68	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	20.36	1.18e-66	9.6e-63	0.91	0.68	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	20.36	1.18e-66	9.6e-63	0.91	0.68	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	20.35	1.2e-66	9.81e-63	0.91	0.68	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
LGG	cis	rs2282300	0.739	rs1222208	ENSG00000254532.1	RP11-624D11.2	20.35	1.24e-66	1.01e-62	0.99	0.68	Morning vs. evening chronotype;	chr11:30339830	chr11:30044058~30084343:-
LGG	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	20.35	1.25e-66	1.02e-62	0.59	0.68	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
LGG	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	20.33	1.51e-66	1.22e-62	0.92	0.68	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
LGG	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	20.33	1.53e-66	1.24e-62	0.82	0.68	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
LGG	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	20.33	1.53e-66	1.24e-62	0.82	0.68	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
LGG	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	20.33	1.53e-66	1.24e-62	0.82	0.68	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
LGG	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	20.33	1.56e-66	1.26e-62	1.06	0.68	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
LGG	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	20.33	1.57e-66	1.27e-62	0.91	0.68	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	20.33	1.61e-66	1.3e-62	0.92	0.68	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-20.32	1.66e-66	1.34e-62	-0.91	-0.68	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
LGG	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-20.32	1.67e-66	1.35e-62	-1.07	-0.68	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
LGG	cis	rs4713118	0.662	rs9380045	ENSG00000199851.2	U3	20.32	1.68e-66	1.36e-62	1.13	0.68	Parkinson's disease;	chr6:28057501	chr6:28015568~28015777:+
LGG	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-20.32	1.72e-66	1.39e-62	-0.78	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	20.32	1.8e-66	1.45e-62	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
LGG	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-20.32	1.82e-66	1.47e-62	-1.06	-0.68	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
LGG	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	20.32	1.82e-66	1.47e-62	0.9	0.68	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	20.31	1.88e-66	1.51e-62	0.91	0.68	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
LGG	cis	rs2282300	0.702	rs4379811	ENSG00000254532.1	RP11-624D11.2	-20.31	1.92e-66	1.55e-62	-0.98	-0.68	Morning vs. evening chronotype;	chr11:30273213	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs3858428	ENSG00000254532.1	RP11-624D11.2	-20.31	1.92e-66	1.55e-62	-0.98	-0.68	Morning vs. evening chronotype;	chr11:30275003	chr11:30044058~30084343:-
LGG	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-20.31	2.01e-66	1.62e-62	-0.82	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
LGG	cis	rs4713118	0.662	rs9357060	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28056708	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs9468271	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28056792	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs9468274	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28058299	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs9468275	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28058358	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs9468276	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28059910	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs9468277	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28060612	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs9468278	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28060704	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs13218430	ENSG00000199851.2	U3	20.3	2.07e-66	1.66e-62	1.13	0.68	Parkinson's disease;	chr6:28062059	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	20.3	2.26e-66	1.81e-62	0.91	0.68	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.616	rs9348789	ENSG00000199851.2	U3	20.29	2.51e-66	2.01e-62	1.13	0.68	Parkinson's disease;	chr6:28057708	chr6:28015568~28015777:+
LGG	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-20.28	2.56e-66	2.05e-62	-0.84	-0.68	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-20.28	2.73e-66	2.19e-62	-0.91	-0.68	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
LGG	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	20.27	2.98e-66	2.38e-62	0.82	0.68	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
LGG	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	20.27	2.98e-66	2.38e-62	0.82	0.68	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
LGG	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	20.27	3.02e-66	2.41e-62	0.91	0.68	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	20.27	3.16e-66	2.51e-62	0.91	0.68	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	20.26	3.19e-66	2.54e-62	0.9	0.68	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	20.26	3.22e-66	2.56e-62	0.92	0.68	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
LGG	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	20.26	3.37e-66	2.68e-62	0.79	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
LGG	cis	rs2282300	0.739	rs7925340	ENSG00000254532.1	RP11-624D11.2	-20.26	3.43e-66	2.73e-62	-0.98	-0.68	Morning vs. evening chronotype;	chr11:30258861	chr11:30044058~30084343:-
LGG	cis	rs4713118	0.621	rs9368548	ENSG00000199851.2	U3	20.26	3.52e-66	2.79e-62	1.14	0.68	Parkinson's disease;	chr6:28066959	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	20.25	3.61e-66	2.87e-62	0.92	0.68	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	20.25	3.66e-66	2.91e-62	0.9	0.68	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
LGG	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-20.24	4e-66	3.18e-62	-0.91	-0.68	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	20.24	4.17e-66	3.3e-62	0.79	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
LGG	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	20.24	4.18e-66	3.31e-62	0.9	0.68	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
LGG	cis	rs172166	0.694	rs1225716	ENSG00000199851.2	U3	20.24	4.18e-66	3.31e-62	1.02	0.68	Cardiac Troponin-T levels;	chr6:28145968	chr6:28015568~28015777:+
LGG	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-20.24	4.21e-66	3.33e-62	-1.05	-0.68	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
LGG	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-20.24	4.21e-66	3.33e-62	-1.05	-0.68	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
LGG	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	20.23	4.42e-66	3.5e-62	0.9	0.68	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
LGG	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	20.23	4.52e-66	3.58e-62	0.91	0.68	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
LGG	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-20.23	4.55e-66	3.6e-62	-0.9	-0.68	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-20.23	4.55e-66	3.6e-62	-0.9	-0.68	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
LGG	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-20.23	4.55e-66	3.6e-62	-0.9	-0.68	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-20.23	4.55e-66	3.6e-62	-0.9	-0.68	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	20.23	4.71e-66	3.72e-62	0.91	0.68	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	20.23	4.71e-66	3.73e-62	0.91	0.68	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
LGG	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	20.23	4.74e-66	3.75e-62	0.89	0.68	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
LGG	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	20.22	5.11e-66	4.03e-62	0.91	0.68	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	20.22	5.11e-66	4.03e-62	0.91	0.68	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
LGG	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-20.22	5.33e-66	4.2e-62	-0.82	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
LGG	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	20.21	5.75e-66	4.53e-62	0.79	0.68	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	20.21	6.07e-66	4.77e-62	0.91	0.68	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	20.21	6.07e-66	4.77e-62	0.91	0.68	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-20.2	6.13e-66	4.82e-62	-0.9	-0.68	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	20.2	6.2e-66	4.87e-62	0.91	0.68	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
LGG	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-20.2	6.67e-66	5.24e-62	-0.81	-0.68	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
LGG	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	20.19	6.83e-66	5.36e-62	0.92	0.68	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	20.19	6.95e-66	5.46e-62	0.91	0.68	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
LGG	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-20.19	7.14e-66	5.61e-62	-0.9	-0.68	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	20.19	7.18e-66	5.64e-62	0.91	0.68	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	20.19	7.28e-66	5.71e-62	0.91	0.68	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	20.19	7.37e-66	5.78e-62	0.91	0.68	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	20.19	7.37e-66	5.78e-62	0.91	0.68	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	20.19	7.37e-66	5.78e-62	0.91	0.68	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
LGG	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	20.18	8.02e-66	6.28e-62	0.81	0.68	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
LGG	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	20.18	8.02e-66	6.28e-62	0.81	0.68	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
LGG	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	20.18	8.02e-66	6.28e-62	0.81	0.68	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
LGG	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	20.18	8.02e-66	6.28e-62	0.81	0.68	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
LGG	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	20.18	8.03e-66	6.28e-62	0.93	0.68	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.629	rs203890	ENSG00000199851.2	U3	20.18	8.17e-66	6.4e-62	1.12	0.68	Parkinson's disease;	chr6:28054470	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	20.17	9.05e-66	7.07e-62	0.9	0.68	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	20.17	9.05e-66	7.07e-62	0.9	0.68	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.91	0.68	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.9	0.68	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.9	0.68	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.9	0.68	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.9	0.68	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.9	0.68	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.9	0.68	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	20.14	1.21e-65	9.42e-62	0.9	0.68	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
LGG	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	20.14	1.29e-65	1.01e-61	0.82	0.68	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
LGG	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	20.14	1.3e-65	1.02e-61	0.8	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
LGG	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	20.13	1.38e-65	1.08e-61	0.9	0.68	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
LGG	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	20.13	1.39e-65	1.08e-61	0.84	0.68	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	20.13	1.41e-65	1.09e-61	0.93	0.68	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	20.13	1.41e-65	1.09e-61	0.93	0.68	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	20.13	1.41e-65	1.09e-61	0.93	0.68	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	20.12	1.51e-65	1.17e-61	0.9	0.68	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	20.12	1.6e-65	1.24e-61	0.91	0.68	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	20.11	1.66e-65	1.29e-61	0.81	0.68	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	20.11	1.7e-65	1.32e-61	0.94	0.68	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
LGG	cis	rs853679	0.55	rs1225598	ENSG00000199851.2	U3	20.11	1.72e-65	1.33e-61	1.07	0.68	Depression;	chr6:28193021	chr6:28015568~28015777:+
LGG	cis	rs853679	0.55	rs1150689	ENSG00000199851.2	U3	20.11	1.72e-65	1.33e-61	1.07	0.68	Depression;	chr6:28197321	chr6:28015568~28015777:+
LGG	cis	rs853679	0.55	rs1225599	ENSG00000199851.2	U3	20.11	1.72e-65	1.33e-61	1.07	0.68	Depression;	chr6:28197412	chr6:28015568~28015777:+
LGG	cis	rs853679	0.574	rs1233705	ENSG00000199851.2	U3	20.11	1.72e-65	1.33e-61	1.07	0.68	Depression;	chr6:28198669	chr6:28015568~28015777:+
LGG	cis	rs853679	0.55	rs1233707	ENSG00000199851.2	U3	20.11	1.72e-65	1.33e-61	1.07	0.68	Depression;	chr6:28205175	chr6:28015568~28015777:+
LGG	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	20.1	1.98e-65	1.53e-61	0.81	0.68	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
LGG	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-20.09	2.05e-65	1.58e-61	-0.79	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	20.09	2.11e-65	1.63e-61	0.92	0.68	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
LGG	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	20.09	2.12e-65	1.64e-61	0.81	0.68	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
LGG	cis	rs853679	0.55	rs1233704	ENSG00000199851.2	U3	-20.09	2.18e-65	1.68e-61	-1.07	-0.68	Depression;	chr6:28199145	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs9368547	ENSG00000199851.2	U3	20.08	2.33e-65	1.79e-61	1.01	0.68	Parkinson's disease;	chr6:28060289	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs183244	ENSG00000199851.2	U3	20.08	2.33e-65	1.79e-61	1.01	0.68	Parkinson's disease;	chr6:28064060	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149950	ENSG00000199851.2	U3	20.08	2.33e-65	1.79e-61	1.01	0.68	Parkinson's disease;	chr6:28065261	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149951	ENSG00000199851.2	U3	20.08	2.33e-65	1.79e-61	1.01	0.68	Parkinson's disease;	chr6:28065309	chr6:28015568~28015777:+
LGG	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	20.08	2.39e-65	1.84e-61	0.92	0.68	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
LGG	cis	rs172166	0.694	rs2791332	ENSG00000199851.2	U3	20.07	2.53e-65	1.95e-61	1.01	0.68	Cardiac Troponin-T levels;	chr6:28141010	chr6:28015568~28015777:+
LGG	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-20.07	2.55e-65	1.97e-61	-0.91	-0.68	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
LGG	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	20.07	2.57e-65	1.98e-61	0.81	0.68	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
LGG	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	20.07	2.77e-65	2.13e-61	1.04	0.68	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
LGG	cis	rs4713118	0.629	rs203889	ENSG00000199851.2	U3	20.06	2.91e-65	2.23e-61	1.12	0.68	Parkinson's disease;	chr6:28053997	chr6:28015568~28015777:+
LGG	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	20.05	3.16e-65	2.43e-61	0.89	0.68	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	20.05	3.29e-65	2.53e-61	0.9	0.68	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
LGG	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-20.04	3.5e-65	2.68e-61	-1.03	-0.68	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
LGG	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	20.04	3.5e-65	2.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
LGG	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-20.04	3.65e-65	2.78e-61	-0.89	-0.68	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-20.04	3.65e-65	2.78e-61	-0.89	-0.68	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
LGG	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-20.04	3.65e-65	2.78e-61	-0.89	-0.68	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	20.03	3.99e-65	3.05e-61	0.9	0.68	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
LGG	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	20.03	4.08e-65	3.11e-61	1.03	0.68	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
LGG	cis	rs2282300	0.739	rs35883696	ENSG00000254532.1	RP11-624D11.2	20.03	4.26e-65	3.25e-61	0.99	0.68	Morning vs. evening chronotype;	chr11:30224860	chr11:30044058~30084343:-
LGG	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-20.02	4.36e-65	3.32e-61	-0.89	-0.68	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
LGG	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	20.02	4.61e-65	3.51e-61	0.89	0.68	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
LGG	cis	rs853679	0.55	rs6901017	ENSG00000199851.2	U3	20.02	4.8e-65	3.65e-61	1.07	0.68	Depression;	chr6:28184805	chr6:28015568~28015777:+
LGG	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	20.01	4.86e-65	3.7e-61	0.89	0.68	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
LGG	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	20.01	4.99e-65	3.8e-61	0.83	0.68	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
LGG	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-20.01	5.03e-65	3.82e-61	-0.89	-0.68	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-20.01	5.03e-65	3.82e-61	-0.89	-0.68	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-20.01	5.03e-65	3.82e-61	-0.89	-0.68	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
LGG	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-20.01	5.03e-65	3.82e-61	-0.89	-0.68	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-20.01	5.03e-65	3.82e-61	-0.89	-0.68	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	20.01	5.07e-65	3.85e-61	0.9	0.68	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-20	5.43e-65	4.12e-61	-0.91	-0.68	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	20	5.76e-65	4.37e-61	0.91	0.68	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.513	rs149955	ENSG00000199851.2	U3	20	5.89e-65	4.46e-61	1.02	0.68	Parkinson's disease;	chr6:28068447	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
LGG	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
LGG	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
LGG	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	19.99	6e-65	4.54e-61	0.89	0.68	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
LGG	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	19.99	6.19e-65	4.68e-61	1.03	0.68	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
LGG	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	19.99	6.63e-65	5.01e-61	0.85	0.68	Depression;	chr6:28314871	chr6:28176188~28176674:+
LGG	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	19.98	6.71e-65	5.07e-61	0.9	0.68	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	19.98	6.73e-65	5.09e-61	0.93	0.68	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
LGG	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-19.98	6.93e-65	5.23e-61	-0.97	-0.68	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
LGG	cis	rs4713118	0.629	rs203888	ENSG00000199851.2	U3	19.98	7.32e-65	5.52e-61	1.12	0.68	Parkinson's disease;	chr6:28053811	chr6:28015568~28015777:+
LGG	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	19.97	7.68e-65	5.79e-61	1.03	0.68	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	19.97	7.68e-65	5.79e-61	1.03	0.68	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	19.97	7.68e-65	5.79e-61	1.03	0.68	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	19.97	7.68e-65	5.79e-61	1.03	0.68	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	19.97	7.68e-65	5.79e-61	1.03	0.68	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
LGG	cis	rs853679	0.55	rs9295762	ENSG00000199851.2	U3	-19.97	8.14e-65	6.13e-61	-1.08	-0.68	Depression;	chr6:28187640	chr6:28015568~28015777:+
LGG	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	19.96	8.42e-65	6.34e-61	0.83	0.68	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.857	rs9608229	ENSG00000218537.1	MIF-AS1	19.96	8.99e-65	6.76e-61	0.86	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23894426~23898930:-
LGG	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-19.95	9.47e-65	7.12e-61	-0.81	-0.68	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
LGG	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	19.95	9.94e-65	7.46e-61	1.04	0.68	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
LGG	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	19.95	9.94e-65	7.46e-61	1.04	0.68	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	19.94	1.11e-64	8.33e-61	1.03	0.68	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	19.94	1.12e-64	8.4e-61	1.02	0.68	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	19.94	1.12e-64	8.4e-61	1.02	0.68	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
LGG	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	19.94	1.12e-64	8.4e-61	1.02	0.68	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	19.94	1.12e-64	8.4e-61	1.02	0.68	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	19.94	1.12e-64	8.4e-61	1.02	0.68	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	19.94	1.12e-64	8.4e-61	1.02	0.68	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	19.94	1.12e-64	8.4e-61	1.02	0.68	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
LGG	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	19.93	1.17e-64	8.73e-61	0.9	0.68	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	19.93	1.17e-64	8.75e-61	0.81	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
LGG	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	19.93	1.21e-64	9.06e-61	0.89	0.68	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
LGG	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	19.93	1.25e-64	9.37e-61	1.03	0.68	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
LGG	cis	rs4713118	0.513	rs149958	ENSG00000199851.2	U3	19.93	1.26e-64	9.41e-61	1.01	0.68	Parkinson's disease;	chr6:28045839	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs156738	ENSG00000199851.2	U3	19.93	1.26e-64	9.41e-61	1.01	0.68	Parkinson's disease;	chr6:28046247	chr6:28015568~28015777:+
LGG	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-19.93	1.27e-64	9.49e-61	-0.83	-0.68	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
LGG	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	19.92	1.31e-64	9.81e-61	1.03	0.68	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
LGG	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
LGG	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
LGG	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
LGG	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
LGG	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
LGG	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
LGG	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
LGG	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
LGG	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	19.92	1.35e-64	1e-60	0.83	0.68	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
LGG	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	19.92	1.39e-64	1.03e-60	0.81	0.67	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
LGG	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	19.92	1.41e-64	1.05e-60	0.92	0.67	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
LGG	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	19.92	1.42e-64	1.06e-60	1.04	0.67	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
LGG	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	19.91	1.51e-64	1.12e-60	0.91	0.67	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	19.91	1.51e-64	1.12e-60	0.91	0.67	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.513	rs156739	ENSG00000199851.2	U3	19.91	1.53e-64	1.13e-60	1.01	0.67	Parkinson's disease;	chr6:28045632	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs149961	ENSG00000199851.2	U3	19.91	1.57e-64	1.17e-60	1.12	0.67	Parkinson's disease;	chr6:28047791	chr6:28015568~28015777:+
LGG	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-19.91	1.58e-64	1.17e-60	-0.96	-0.67	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
LGG	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	19.91	1.58e-64	1.17e-60	0.9	0.67	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	19.91	1.58e-64	1.17e-60	0.9	0.67	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	19.91	1.59e-64	1.18e-60	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
LGG	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	19.9	1.69e-64	1.25e-60	0.89	0.67	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
LGG	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	19.89	1.81e-64	1.34e-60	0.9	0.67	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
LGG	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	19.89	1.81e-64	1.34e-60	0.9	0.67	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
LGG	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	19.89	1.81e-64	1.34e-60	0.9	0.67	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	19.89	1.81e-64	1.34e-60	0.9	0.67	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.513	rs149959	ENSG00000199851.2	U3	19.89	1.85e-64	1.37e-60	1	0.67	Parkinson's disease;	chr6:28046076	chr6:28015568~28015777:+
LGG	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	19.88	2.02e-64	1.49e-60	1.02	0.67	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
LGG	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	19.88	2.1e-64	1.55e-60	0.9	0.67	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs1765139	ENSG00000254532.1	RP11-624D11.2	19.88	2.17e-64	1.6e-60	0.97	0.67	Morning vs. evening chronotype;	chr11:30332178	chr11:30044058~30084343:-
LGG	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	19.88	2.17e-64	1.6e-60	0.82	0.67	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
LGG	cis	rs2282300	0.653	rs12800124	ENSG00000254532.1	RP11-624D11.2	19.88	2.19e-64	1.61e-60	0.98	0.67	Morning vs. evening chronotype;	chr11:30218318	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.696	rs12578061	ENSG00000254532.1	RP11-624D11.2	19.88	2.19e-64	1.61e-60	0.98	0.67	Morning vs. evening chronotype;	chr11:30227818	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs34224414	ENSG00000254532.1	RP11-624D11.2	19.88	2.19e-64	1.61e-60	0.98	0.67	Morning vs. evening chronotype;	chr11:30229494	chr11:30044058~30084343:-
LGG	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-19.87	2.3e-64	1.69e-60	-0.91	-0.67	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	19.87	2.37e-64	1.75e-60	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	19.87	2.37e-64	1.75e-60	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	19.87	2.37e-64	1.75e-60	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
LGG	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	19.87	2.4e-64	1.76e-60	1.07	0.67	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
LGG	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	19.87	2.43e-64	1.79e-60	0.95	0.67	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
LGG	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	19.87	2.43e-64	1.79e-60	0.95	0.67	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
LGG	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-19.86	2.5e-64	1.84e-60	-0.9	-0.67	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-19.86	2.64e-64	1.94e-60	-0.85	-0.67	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
LGG	cis	rs4713118	0.621	rs4713132	ENSG00000199851.2	U3	19.86	2.66e-64	1.95e-60	1.13	0.67	Parkinson's disease;	chr6:28066257	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.621	rs4713133	ENSG00000199851.2	U3	19.86	2.66e-64	1.95e-60	1.13	0.67	Parkinson's disease;	chr6:28066263	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.621	rs4713134	ENSG00000199851.2	U3	19.86	2.66e-64	1.95e-60	1.13	0.67	Parkinson's disease;	chr6:28066343	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-19.86	2.67e-64	1.96e-60	-0.9	-0.67	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	19.85	2.89e-64	2.13e-60	0.92	0.67	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
LGG	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	19.85	2.97e-64	2.18e-60	0.81	0.67	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
LGG	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	19.84	3.06e-64	2.25e-60	0.83	0.67	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
LGG	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	19.84	3.06e-64	2.25e-60	0.83	0.67	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
LGG	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	19.84	3.06e-64	2.25e-60	0.83	0.67	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
LGG	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	19.84	3.06e-64	2.25e-60	0.83	0.67	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	19.84	3.33e-64	2.45e-60	0.92	0.67	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
LGG	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-19.83	3.52e-64	2.57e-60	-0.9	-0.67	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-19.83	3.52e-64	2.57e-60	-0.9	-0.67	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-19.83	3.52e-64	2.57e-60	-0.9	-0.67	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
LGG	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	19.83	3.52e-64	2.57e-60	0.9	0.67	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
LGG	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	19.83	3.57e-64	2.61e-60	0.83	0.67	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
LGG	cis	rs853679	0.55	rs1233699	ENSG00000199851.2	U3	19.83	3.64e-64	2.66e-60	1.06	0.67	Depression;	chr6:28201380	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-19.83	3.71e-64	2.71e-60	-0.9	-0.67	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
LGG	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	19.83	3.73e-64	2.72e-60	0.81	0.67	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-19.82	3.83e-64	2.8e-60	-0.81	-0.67	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
LGG	cis	rs9322193	0.923	rs2184370	ENSG00000231760.4	RP11-350J20.5	19.82	3.86e-64	2.82e-60	0.92	0.67	Lung cancer;	chr6:149843242	chr6:149796151~149826294:-
LGG	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	19.82	3.95e-64	2.89e-60	0.83	0.67	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
LGG	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	19.82	3.95e-64	2.89e-60	0.83	0.67	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	19.82	4.15e-64	3.03e-60	0.9	0.67	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
LGG	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	19.82	4.2e-64	3.06e-60	0.91	0.67	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
LGG	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	19.82	4.23e-64	3.08e-60	0.82	0.67	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
LGG	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	19.81	4.66e-64	3.39e-60	1.03	0.67	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	19.81	4.66e-64	3.39e-60	1.03	0.67	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	19.81	4.66e-64	3.39e-60	1.03	0.67	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
LGG	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-19.81	4.67e-64	3.4e-60	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	19.81	4.67e-64	3.4e-60	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
LGG	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-19.81	4.71e-64	3.42e-60	-0.9	-0.67	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.653	rs67745574	ENSG00000254532.1	RP11-624D11.2	19.81	4.72e-64	3.43e-60	0.99	0.67	Morning vs. evening chronotype;	chr11:30213292	chr11:30044058~30084343:-
LGG	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	19.8	4.76e-64	3.46e-60	0.9	0.67	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-19.8	4.79e-64	3.48e-60	-0.9	-0.67	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	19.8	4.84e-64	3.51e-60	0.9	0.67	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
LGG	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	19.8	4.84e-64	3.51e-60	0.9	0.67	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	19.8	4.84e-64	3.51e-60	0.9	0.67	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	19.8	4.84e-64	3.51e-60	0.9	0.67	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-19.8	4.85e-64	3.52e-60	-0.8	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
LGG	cis	rs4713118	0.662	rs149969	ENSG00000199851.2	U3	19.8	4.92e-64	3.57e-60	1.09	0.67	Parkinson's disease;	chr6:28009959	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs202908	ENSG00000199851.2	U3	19.8	4.93e-64	3.58e-60	1.01	0.67	Parkinson's disease;	chr6:28043773	chr6:28015568~28015777:+
LGG	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-19.8	4.94e-64	3.58e-60	-0.96	-0.67	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
LGG	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	19.8	4.98e-64	3.61e-60	0.91	0.67	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
LGG	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	19.79	5.33e-64	3.86e-60	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
LGG	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-19.79	5.38e-64	3.88e-60	-0.9	-0.67	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-19.79	5.38e-64	3.88e-60	-0.9	-0.67	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-19.79	5.38e-64	3.88e-60	-0.9	-0.67	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-19.79	5.38e-64	3.88e-60	-0.9	-0.67	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
LGG	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-19.79	5.38e-64	3.88e-60	-0.9	-0.67	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
LGG	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
LGG	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	19.79	5.38e-64	3.88e-60	0.9	0.67	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
LGG	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	19.79	5.42e-64	3.91e-60	1.03	0.67	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
LGG	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-19.79	5.42e-64	3.91e-60	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	19.79	5.57e-64	4.02e-60	0.81	0.67	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
LGG	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	19.79	5.58e-64	4.02e-60	0.88	0.67	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
LGG	cis	rs2729354	0.817	rs2848626	ENSG00000265566.2	RN7SL605P	-19.79	5.6e-64	4.03e-60	-1.08	-0.67	Blood protein levels;	chr11:57516515	chr11:57528085~57528365:-
LGG	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	19.79	5.77e-64	4.16e-60	0.78	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
LGG	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	19.77	6.64e-64	4.78e-60	0.9	0.67	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	19.77	6.86e-64	4.94e-60	0.89	0.67	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-19.77	6.88e-64	4.95e-60	-0.89	-0.67	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
LGG	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	19.77	7.09e-64	5.1e-60	0.88	0.67	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
LGG	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	19.76	7.62e-64	5.47e-60	0.91	0.67	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
LGG	cis	rs4713118	0.513	rs149962	ENSG00000199851.2	U3	19.76	7.65e-64	5.49e-60	1.01	0.67	Parkinson's disease;	chr6:28048140	chr6:28015568~28015777:+
LGG	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	19.76	7.76e-64	5.57e-60	1.11	0.67	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
LGG	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	19.76	7.76e-64	5.57e-60	1.11	0.67	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
LGG	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	19.76	8.04e-64	5.77e-60	1.03	0.67	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	19.76	8.04e-64	5.77e-60	1.03	0.67	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	19.76	8.04e-64	5.77e-60	1.03	0.67	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
LGG	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	19.76	8.09e-64	5.8e-60	0.92	0.67	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
LGG	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	19.76	8.11e-64	5.82e-60	0.89	0.67	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	19.75	8.18e-64	5.86e-60	0.89	0.67	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
LGG	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	19.75	8.46e-64	6.05e-60	0.9	0.67	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	19.75	8.46e-64	6.05e-60	0.9	0.67	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	19.75	8.46e-64	6.05e-60	0.9	0.67	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	19.75	8.46e-64	6.06e-60	0.78	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
LGG	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	19.74	9.38e-64	6.71e-60	0.9	0.67	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
LGG	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	19.74	9.47e-64	6.77e-60	0.81	0.67	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
LGG	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	19.74	9.68e-64	6.92e-60	0.9	0.67	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	19.74	9.72e-64	6.95e-60	0.91	0.67	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	19.73	1.07e-63	7.63e-60	0.88	0.67	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
LGG	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-19.73	1.08e-63	7.68e-60	-1.03	-0.67	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
LGG	cis	rs4713118	0.662	rs156744	ENSG00000199851.2	U3	19.73	1.08e-63	7.68e-60	1.08	0.67	Parkinson's disease;	chr6:27999496	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs149946	ENSG00000199851.2	U3	-19.73	1.08e-63	7.68e-60	-1.08	-0.67	Parkinson's disease;	chr6:28002253	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs149947	ENSG00000199851.2	U3	19.73	1.08e-63	7.68e-60	1.08	0.67	Parkinson's disease;	chr6:28004655	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-19.73	1.08e-63	7.68e-60	-0.9	-0.67	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-19.72	1.14e-63	8.08e-60	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-19.72	1.14e-63	8.08e-60	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-19.72	1.14e-63	8.08e-60	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
LGG	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	19.72	1.14e-63	8.08e-60	0.9	0.67	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	19.72	1.14e-63	8.08e-60	0.9	0.67	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	19.72	1.14e-63	8.08e-60	0.9	0.67	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-19.72	1.14e-63	8.08e-60	-0.89	-0.67	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	19.72	1.16e-63	8.23e-60	0.9	0.67	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
LGG	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	19.72	1.23e-63	8.7e-60	0.89	0.67	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.629	rs149899	ENSG00000199851.2	U3	19.72	1.24e-63	8.82e-60	1.12	0.67	Parkinson's disease;	chr6:28052201	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.629	rs172165	ENSG00000199851.2	U3	19.72	1.24e-63	8.82e-60	1.12	0.67	Parkinson's disease;	chr6:28053036	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.597	rs172166	ENSG00000199851.2	U3	19.72	1.24e-63	8.82e-60	1.12	0.67	Parkinson's disease;	chr6:28053042	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-19.71	1.28e-63	9.07e-60	-0.89	-0.67	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	19.71	1.37e-63	9.72e-60	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
LGG	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	19.71	1.39e-63	9.86e-60	0.9	0.67	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
LGG	cis	rs507080	0.733	rs497678	ENSG00000255239.1	AP002954.6	19.7	1.42e-63	1.01e-59	0.84	0.67	Serum metabolite levels;	chr11:118697172	chr11:118688039~118690600:-
LGG	cis	rs2282300	0.739	rs12577729	ENSG00000254532.1	RP11-624D11.2	19.7	1.46e-63	1.03e-59	0.97	0.67	Morning vs. evening chronotype;	chr11:30235830	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs34044331	ENSG00000254532.1	RP11-624D11.2	19.7	1.46e-63	1.03e-59	0.97	0.67	Morning vs. evening chronotype;	chr11:30242939	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.667	rs10734405	ENSG00000254532.1	RP11-624D11.2	-19.7	1.46e-63	1.03e-59	-0.97	-0.67	Morning vs. evening chronotype;	chr11:30252203	chr11:30044058~30084343:-
LGG	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-19.7	1.46e-63	1.03e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-19.7	1.46e-63	1.03e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-19.7	1.46e-63	1.03e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-19.7	1.46e-63	1.03e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-19.7	1.46e-63	1.03e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	19.7	1.46e-63	1.03e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
LGG	cis	rs172166	0.769	rs149965	ENSG00000199851.2	U3	19.7	1.5e-63	1.05e-59	1	0.67	Cardiac Troponin-T levels;	chr6:28050911	chr6:28015568~28015777:+
LGG	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-19.7	1.51e-63	1.06e-59	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
LGG	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-19.7	1.51e-63	1.06e-59	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
LGG	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-19.7	1.51e-63	1.06e-59	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
LGG	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-19.7	1.51e-63	1.06e-59	-0.64	-0.67	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
LGG	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	19.69	1.68e-63	1.18e-59	1.03	0.67	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	19.69	1.68e-63	1.18e-59	1.03	0.67	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
LGG	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-19.69	1.72e-63	1.2e-59	-0.89	-0.67	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
LGG	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-19.69	1.72e-63	1.2e-59	-0.89	-0.67	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-19.68	1.74e-63	1.22e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
LGG	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	19.68	1.75e-63	1.23e-59	0.84	0.67	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
LGG	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	19.68	1.78e-63	1.24e-59	0.94	0.67	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
LGG	cis	rs2282300	0.739	rs35229181	ENSG00000254532.1	RP11-624D11.2	19.68	1.81e-63	1.26e-59	0.99	0.67	Morning vs. evening chronotype;	chr11:30220151	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs34234618	ENSG00000254532.1	RP11-624D11.2	19.68	1.81e-63	1.26e-59	0.99	0.67	Morning vs. evening chronotype;	chr11:30220154	chr11:30044058~30084343:-
LGG	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	19.68	1.89e-63	1.32e-59	1.13	0.67	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
LGG	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-19.68	1.91e-63	1.34e-59	-0.89	-0.67	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	19.67	1.97e-63	1.37e-59	0.89	0.67	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
LGG	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-19.67	2.14e-63	1.49e-59	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
LGG	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-19.65	2.52e-63	1.76e-59	-0.88	-0.67	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-19.65	2.52e-63	1.76e-59	-0.88	-0.67	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
LGG	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-19.65	2.52e-63	1.76e-59	-0.88	-0.67	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs10835648	ENSG00000254532.1	RP11-624D11.2	-19.65	2.56e-63	1.78e-59	-0.95	-0.67	Morning vs. evening chronotype;	chr11:30298959	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs7952339	ENSG00000254532.1	RP11-624D11.2	-19.65	2.56e-63	1.78e-59	-0.95	-0.67	Morning vs. evening chronotype;	chr11:30305797	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.739	rs1222221	ENSG00000254532.1	RP11-624D11.2	19.65	2.56e-63	1.78e-59	0.95	0.67	Morning vs. evening chronotype;	chr11:30321191	chr11:30044058~30084343:-
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	19.65	2.62e-63	1.83e-59	0.83	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
LGG	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-19.65	2.68e-63	1.86e-59	-1.02	-0.67	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
LGG	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	19.64	2.78e-63	1.93e-59	0.81	0.67	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
LGG	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	19.64	2.81e-63	1.96e-59	1.03	0.67	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
LGG	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-19.64	2.91e-63	2.02e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-19.64	2.91e-63	2.02e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-19.64	2.91e-63	2.02e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
LGG	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-19.63	3.13e-63	2.17e-59	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
LGG	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	19.63	3.19e-63	2.22e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
LGG	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-19.63	3.22e-63	2.23e-59	-0.88	-0.67	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-19.63	3.25e-63	2.25e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
LGG	cis	rs4713118	0.513	rs156734	ENSG00000199851.2	U3	19.62	3.39e-63	2.35e-59	0.99	0.67	Parkinson's disease;	chr6:28039579	chr6:28015568~28015777:+
LGG	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-19.62	3.61e-63	2.5e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
LGG	cis	rs2282300	0.739	rs16920406	ENSG00000254532.1	RP11-624D11.2	19.62	3.7e-63	2.56e-59	0.96	0.67	Morning vs. evening chronotype;	chr11:30194611	chr11:30044058~30084343:-
LGG	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	19.61	3.98e-63	2.75e-59	0.89	0.67	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	19.61	3.98e-63	2.75e-59	0.89	0.67	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	19.61	3.98e-63	2.75e-59	0.89	0.67	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	19.61	3.98e-63	2.75e-59	0.89	0.67	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.513	rs149897	ENSG00000199851.2	U3	19.6	4.2e-63	2.9e-59	0.99	0.67	Parkinson's disease;	chr6:28038872	chr6:28015568~28015777:+
LGG	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-19.6	4.38e-63	3.02e-59	-0.89	-0.67	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
LGG	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	19.6	4.6e-63	3.17e-59	0.9	0.67	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-19.59	4.63e-63	3.19e-59	-0.82	-0.67	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
LGG	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	19.58	5.52e-63	3.79e-59	0.9	0.67	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	19.58	5.63e-63	3.87e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
LGG	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	19.57	5.94e-63	4.08e-59	0.81	0.67	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
LGG	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-19.57	6.13e-63	4.21e-59	-0.78	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-19.57	6.13e-63	4.21e-59	-0.78	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-19.57	6.13e-63	4.21e-59	-0.78	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-19.57	6.13e-63	4.21e-59	-0.78	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	19.57	6.17e-63	4.24e-59	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
LGG	cis	rs2282300	0.739	rs67670125	ENSG00000254532.1	RP11-624D11.2	19.56	6.8e-63	4.66e-59	0.96	0.67	Morning vs. evening chronotype;	chr11:30193367	chr11:30044058~30084343:-
LGG	cis	rs4713118	0.513	rs149954	ENSG00000199851.2	U3	19.56	6.93e-63	4.75e-59	1.01	0.67	Parkinson's disease;	chr6:28067468	chr6:28015568~28015777:+
LGG	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-19.56	7.04e-63	4.82e-59	-0.65	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
LGG	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	19.55	7.21e-63	4.94e-59	0.89	0.67	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
LGG	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	19.55	7.34e-63	5.02e-59	0.82	0.67	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
LGG	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-19.55	7.51e-63	5.14e-59	-0.95	-0.67	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
LGG	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-19.55	7.86e-63	5.38e-59	-0.79	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	19.54	8.1e-63	5.54e-59	0.8	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
LGG	cis	rs853679	0.55	rs1150692	ENSG00000199851.2	U3	19.54	8.1e-63	5.54e-59	1.07	0.67	Depression;	chr6:28206179	chr6:28015568~28015777:+
LGG	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-19.54	8.22e-63	5.62e-59	-0.79	-0.67	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
LGG	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-19.54	8.41e-63	5.75e-59	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
LGG	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	19.54	8.76e-63	5.99e-59	0.8	0.67	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
LGG	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	19.53	9e-63	6.14e-59	0.8	0.67	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
LGG	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	19.53	9.75e-63	6.64e-59	1.02	0.67	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
LGG	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	19.52	1e-62	6.83e-59	0.89	0.67	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
LGG	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	19.52	1.04e-62	7.08e-59	0.8	0.67	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
LGG	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-19.52	1.09e-62	7.4e-59	-0.78	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
LGG	cis	rs4713118	0.662	rs175954	ENSG00000199851.2	U3	19.51	1.1e-62	7.5e-59	1.09	0.67	Parkinson's disease;	chr6:28043807	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	19.51	1.11e-62	7.55e-59	0.89	0.67	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs34855782	ENSG00000254532.1	RP11-624D11.2	19.51	1.19e-62	8.09e-59	0.96	0.67	Morning vs. evening chronotype;	chr11:30203923	chr11:30044058~30084343:-
LGG	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	19.5	1.26e-62	8.59e-59	0.88	0.67	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
LGG	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	19.49	1.42e-62	9.6e-59	0.9	0.67	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	19.49	1.42e-62	9.6e-59	0.9	0.67	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
LGG	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-19.49	1.49e-62	1.01e-58	-0.87	-0.67	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
LGG	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-19.49	1.51e-62	1.02e-58	-0.89	-0.67	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
LGG	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-19.49	1.51e-62	1.02e-58	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
LGG	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-19.48	1.58e-62	1.06e-58	-0.89	-0.67	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
LGG	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	19.48	1.64e-62	1.11e-58	0.89	0.67	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	19.48	1.64e-62	1.11e-58	0.89	0.67	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	19.48	1.64e-62	1.11e-58	0.89	0.67	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	19.48	1.64e-62	1.11e-58	0.89	0.67	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	19.48	1.66e-62	1.12e-58	0.83	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
LGG	cis	rs4713118	0.513	rs149989	ENSG00000199851.2	U3	19.47	1.85e-62	1.25e-58	0.98	0.67	Parkinson's disease;	chr6:28030406	chr6:28015568~28015777:+
LGG	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	19.46	1.92e-62	1.29e-58	0.91	0.67	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	19.46	1.92e-62	1.29e-58	0.91	0.67	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
LGG	cis	rs4713118	0.662	rs9393881	ENSG00000199851.2	U3	19.45	2.11e-62	1.42e-58	1.11	0.67	Parkinson's disease;	chr6:28055973	chr6:28015568~28015777:+
LGG	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	19.45	2.15e-62	1.44e-58	1.01	0.67	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
LGG	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-19.45	2.23e-62	1.49e-58	-0.67	-0.67	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
LGG	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-19.45	2.31e-62	1.55e-58	-0.91	-0.67	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
LGG	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	19.44	2.47e-62	1.65e-58	0.92	0.67	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
LGG	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-19.44	2.47e-62	1.66e-58	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
LGG	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-19.44	2.47e-62	1.66e-58	-0.64	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
LGG	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	19.44	2.49e-62	1.67e-58	0.9	0.67	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	19.44	2.49e-62	1.67e-58	0.9	0.67	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
LGG	cis	rs2282300	0.739	rs7942129	ENSG00000254532.1	RP11-624D11.2	19.44	2.62e-62	1.75e-58	0.95	0.67	Morning vs. evening chronotype;	chr11:30203145	chr11:30044058~30084343:-
LGG	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-19.43	2.63e-62	1.76e-58	-0.88	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
LGG	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	19.43	2.89e-62	1.93e-58	0.9	0.67	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	19.43	2.89e-62	1.93e-58	0.9	0.67	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
LGG	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-19.42	3.03e-62	2.03e-58	-0.89	-0.67	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
LGG	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-19.42	3.08e-62	2.06e-58	-0.67	-0.67	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
LGG	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-19.42	3.08e-62	2.06e-58	-0.67	-0.67	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
LGG	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	19.42	3.22e-62	2.15e-58	0.92	0.67	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
LGG	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-19.41	3.29e-62	2.2e-58	-0.79	-0.67	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
LGG	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	19.41	3.47e-62	2.31e-58	0.9	0.67	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	19.41	3.47e-62	2.31e-58	0.9	0.67	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
LGG	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	19.41	3.54e-62	2.36e-58	0.9	0.67	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
LGG	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	19.4	3.68e-62	2.45e-58	0.72	0.67	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
LGG	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-19.4	3.72e-62	2.48e-58	-0.83	-0.67	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
LGG	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	19.4	3.96e-62	2.64e-58	0.89	0.67	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	19.4	4.03e-62	2.69e-58	0.89	0.67	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
LGG	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	19.39	4.29e-62	2.86e-58	0.83	0.67	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
LGG	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-19.39	4.33e-62	2.88e-58	-0.67	-0.67	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-19.39	4.33e-62	2.88e-58	-0.67	-0.67	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
LGG	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	19.38	4.57e-62	3.04e-58	0.9	0.66	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.513	rs149941	ENSG00000199851.2	U3	19.37	5.07e-62	3.36e-58	0.98	0.66	Parkinson's disease;	chr6:28033255	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149942	ENSG00000199851.2	U3	19.37	5.07e-62	3.36e-58	0.98	0.66	Parkinson's disease;	chr6:28033832	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149945	ENSG00000199851.2	U3	19.37	5.07e-62	3.36e-58	0.98	0.66	Parkinson's disease;	chr6:28035075	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	19.37	5.3e-62	3.51e-58	0.9	0.66	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-19.37	5.37e-62	3.55e-58	-0.89	-0.66	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	19.37	5.43e-62	3.6e-58	0.89	0.66	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	19.37	5.43e-62	3.6e-58	0.89	0.66	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
LGG	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	19.37	5.43e-62	3.6e-58	0.89	0.66	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
LGG	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-19.36	5.73e-62	3.79e-58	-0.64	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
LGG	cis	rs4713118	0.513	rs149944	ENSG00000199851.2	U3	19.36	5.75e-62	3.8e-58	0.97	0.66	Parkinson's disease;	chr6:28035040	chr6:28015568~28015777:+
LGG	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	19.35	6.55e-62	4.32e-58	0.64	0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
LGG	cis	rs4713118	0.662	rs149901	ENSG00000199851.2	U3	19.35	6.69e-62	4.41e-58	1.04	0.66	Parkinson's disease;	chr6:27997725	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs464312	ENSG00000199851.2	U3	19.35	6.69e-62	4.41e-58	1.04	0.66	Parkinson's disease;	chr6:27999813	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.662	rs469228	ENSG00000199851.2	U3	19.35	6.69e-62	4.41e-58	1.04	0.66	Parkinson's disease;	chr6:28002926	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.54	rs469227	ENSG00000199851.2	U3	19.35	6.69e-62	4.41e-58	1.04	0.66	Parkinson's disease;	chr6:28002927	chr6:28015568~28015777:+
LGG	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	19.35	6.72e-62	4.43e-58	1	0.66	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
LGG	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	19.35	6.83e-62	4.49e-58	0.93	0.66	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
LGG	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
LGG	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-19.34	7.17e-62	4.7e-58	-0.89	-0.66	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
LGG	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-19.34	7.18e-62	4.71e-58	-0.67	-0.66	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
LGG	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	19.34	7.6e-62	4.99e-58	0.91	0.66	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.662	rs149948	ENSG00000199851.2	U3	19.33	8.32e-62	5.45e-58	1.04	0.66	Parkinson's disease;	chr6:28007039	chr6:28015568~28015777:+
LGG	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	19.32	8.82e-62	5.78e-58	0.85	0.66	Myopia;	chr6:28302807	chr6:28176188~28176674:+
LGG	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-19.32	8.88e-62	5.81e-58	-0.83	-0.66	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
LGG	cis	rs4713118	0.513	rs1225591	ENSG00000199851.2	U3	19.32	9.3e-62	6.08e-58	1.02	0.66	Parkinson's disease;	chr6:28180974	chr6:28015568~28015777:+
LGG	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-19.31	9.95e-62	6.5e-58	-0.67	-0.66	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
LGG	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	19.3	1.08e-61	7.06e-58	0.78	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
LGG	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-19.3	1.11e-61	7.24e-58	-0.67	-0.66	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
LGG	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-19.3	1.16e-61	7.55e-58	-0.83	-0.66	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
LGG	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-19.3	1.17e-61	7.63e-58	-0.89	-0.66	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
LGG	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	19.3	1.17e-61	7.67e-58	0.83	0.66	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
LGG	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	19.29	1.29e-61	8.44e-58	1.12	0.66	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
LGG	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	19.29	1.31e-61	8.55e-58	0.79	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
LGG	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-19.28	1.39e-61	9.03e-58	-0.67	-0.66	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
LGG	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-19.28	1.39e-61	9.03e-58	-0.67	-0.66	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-19.28	1.39e-61	9.03e-58	-0.67	-0.66	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-19.28	1.39e-61	9.03e-58	-0.67	-0.66	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	19.28	1.45e-61	9.45e-58	0.82	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
LGG	cis	rs2282300	0.739	rs34951229	ENSG00000254532.1	RP11-624D11.2	19.26	1.66e-61	1.08e-57	0.95	0.66	Morning vs. evening chronotype;	chr11:30243619	chr11:30044058~30084343:-
LGG	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-19.26	1.69e-61	1.1e-57	-0.77	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
LGG	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-19.26	1.69e-61	1.1e-57	-1.03	-0.66	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
LGG	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
LGG	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	19.26	1.75e-61	1.14e-57	0.88	0.66	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	19.26	1.78e-61	1.16e-57	0.9	0.66	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	19.26	1.78e-61	1.16e-57	0.9	0.66	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
LGG	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-19.25	1.98e-61	1.28e-57	-0.67	-0.66	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
LGG	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	19.24	2.16e-61	1.4e-57	1	0.66	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
LGG	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-19.24	2.18e-61	1.4e-57	-0.68	-0.66	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
LGG	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	19.24	2.24e-61	1.45e-57	1.02	0.66	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
LGG	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-19.24	2.24e-61	1.45e-57	-0.63	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
LGG	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
LGG	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
LGG	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
LGG	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-19.23	2.47e-61	1.59e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
LGG	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	19.23	2.52e-61	1.62e-57	0.9	0.66	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
LGG	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-19.22	2.65e-61	1.7e-57	-0.68	-0.66	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
LGG	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-19.2	3.29e-61	2.11e-57	-0.68	-0.66	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
LGG	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-19.2	3.29e-61	2.11e-57	-0.68	-0.66	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
LGG	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	19.2	3.36e-61	2.15e-57	0.77	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
LGG	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-19.2	3.42e-61	2.19e-57	-0.83	-0.66	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
LGG	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	19.19	3.59e-61	2.3e-57	0.89	0.66	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
LGG	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	19.19	3.64e-61	2.33e-57	0.89	0.66	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
LGG	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	19.19	3.72e-61	2.38e-57	0.89	0.66	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-19.19	3.88e-61	2.48e-57	-0.89	-0.66	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	19.18	3.97e-61	2.54e-57	0.91	0.66	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	19.17	4.59e-61	2.93e-57	0.88	0.66	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
LGG	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	19.17	4.85e-61	3.09e-57	0.86	0.66	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
LGG	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	19.16	5.28e-61	3.36e-57	0.78	0.66	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
LGG	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-19.15	5.6e-61	3.57e-57	-0.87	-0.66	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
LGG	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	19.15	5.63e-61	3.58e-57	0.89	0.66	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
LGG	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-19.15	5.63e-61	3.58e-57	-0.64	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
LGG	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-19.15	5.64e-61	3.59e-57	-0.63	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
LGG	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-19.15	5.81e-61	3.7e-57	-0.67	-0.66	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
LGG	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-19.14	6.36e-61	4.04e-57	-0.68	-0.66	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-19.13	7.05e-61	4.48e-57	-0.67	-0.66	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
LGG	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	19.13	7.06e-61	4.48e-57	0.9	0.66	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.887	rs4870139	ENSG00000231760.4	RP11-350J20.5	19.13	7.19e-61	4.56e-57	0.91	0.66	Lung cancer;	chr6:149575182	chr6:149796151~149826294:-
LGG	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-19.13	7.19e-61	4.57e-57	-0.63	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
LGG	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	19.12	7.72e-61	4.89e-57	0.88	0.66	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	19.12	7.72e-61	4.89e-57	0.88	0.66	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	19.12	7.72e-61	4.89e-57	0.88	0.66	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	19.12	7.72e-61	4.89e-57	0.88	0.66	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
LGG	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	19.12	7.72e-61	4.89e-57	0.88	0.66	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	19.12	7.94e-61	5.03e-57	0.77	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
LGG	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-19.12	7.96e-61	5.04e-57	-0.89	-0.66	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	19.12	8.22e-61	5.21e-57	0.9	0.66	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
LGG	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	19.12	8.39e-61	5.31e-57	0.88	0.66	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
LGG	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-19.11	8.65e-61	5.47e-57	-0.78	-0.66	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
LGG	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-19.11	8.96e-61	5.67e-57	-0.88	-0.66	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
LGG	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-19.1	9.44e-61	5.96e-57	-0.82	-0.66	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
LGG	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	19.1	9.53e-61	6.01e-57	0.74	0.66	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	19.1	9.67e-61	6.1e-57	0.74	0.66	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
LGG	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-19.1	1.01e-60	6.33e-57	-0.67	-0.66	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
LGG	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-19.1	1.01e-60	6.33e-57	-0.67	-0.66	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-19.1	1.01e-60	6.33e-57	-0.67	-0.66	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
LGG	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-19.1	1.01e-60	6.33e-57	-0.67	-0.66	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-19.1	1.01e-60	6.33e-57	-0.67	-0.66	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-19.1	1.01e-60	6.33e-57	-0.67	-0.66	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
LGG	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-19.1	1.01e-60	6.33e-57	-0.67	-0.66	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
LGG	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	19.09	1.05e-60	6.59e-57	1.01	0.66	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
LGG	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	19.09	1.05e-60	6.63e-57	0.83	0.66	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
LGG	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	19.09	1.05e-60	6.63e-57	0.83	0.66	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
LGG	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	19.09	1.08e-60	6.79e-57	0.85	0.66	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	19.09	1.08e-60	6.79e-57	0.85	0.66	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	19.09	1.08e-60	6.79e-57	0.85	0.66	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
LGG	cis	rs853679	0.506	rs1150693	ENSG00000199851.2	U3	19.09	1.1e-60	6.9e-57	1.07	0.66	Depression;	chr6:28206812	chr6:28015568~28015777:+
LGG	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	19.09	1.11e-60	7e-57	0.88	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
LGG	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	19.09	1.11e-60	7e-57	0.88	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
LGG	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	19.09	1.11e-60	7e-57	0.88	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
LGG	cis	rs2739330	0.857	rs9608229	ENSG00000225282.1	AP000350.6	19.08	1.18e-60	7.39e-57	0.87	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23926900~23929574:+
LGG	cis	rs4713118	0.662	rs149900	ENSG00000199851.2	U3	19.08	1.25e-60	7.87e-57	1.11	0.66	Parkinson's disease;	chr6:28046819	chr6:28015568~28015777:+
LGG	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	19.07	1.3e-60	8.14e-57	0.82	0.66	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	19.07	1.33e-60	8.33e-57	0.9	0.66	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
LGG	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	19.07	1.34e-60	8.37e-57	0.88	0.66	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
LGG	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	19.07	1.34e-60	8.37e-57	0.88	0.66	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
LGG	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	19.07	1.35e-60	8.43e-57	0.77	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	19.06	1.48e-60	9.22e-57	0.82	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
LGG	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	19.06	1.53e-60	9.53e-57	0.82	0.66	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
LGG	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	19.06	1.53e-60	9.57e-57	0.78	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
LGG	cis	rs4713118	0.513	rs149975	ENSG00000199851.2	U3	19.06	1.59e-60	9.94e-57	0.98	0.66	Parkinson's disease;	chr6:28018562	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149972	ENSG00000199851.2	U3	19.05	1.73e-60	1.08e-56	0.97	0.66	Parkinson's disease;	chr6:28015449	chr6:28015568~28015777:+
LGG	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-19.04	1.96e-60	1.22e-56	-0.78	-0.66	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
LGG	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	19.04	1.96e-60	1.22e-56	0.87	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
LGG	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	19.03	2.16e-60	1.34e-56	0.65	0.66	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
LGG	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-19.03	2.18e-60	1.35e-56	-0.88	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
LGG	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-19.03	2.18e-60	1.35e-56	-0.88	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
LGG	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-19.03	2.18e-60	1.35e-56	-0.88	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
LGG	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	19.03	2.2e-60	1.36e-56	0.85	0.66	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	19.02	2.25e-60	1.4e-56	0.9	0.66	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	19.02	2.27e-60	1.41e-56	0.87	0.66	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
LGG	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	19.02	2.38e-60	1.47e-56	0.89	0.66	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	19.02	2.45e-60	1.52e-56	0.9	0.66	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
LGG	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	19.01	2.63e-60	1.63e-56	0.79	0.66	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
LGG	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-19.01	2.68e-60	1.66e-56	-0.9	-0.66	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
LGG	cis	rs172166	0.637	rs1233691	ENSG00000199851.2	U3	19.01	2.74e-60	1.69e-56	0.97	0.66	Cardiac Troponin-T levels;	chr6:28186119	chr6:28015568~28015777:+
LGG	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-19.01	2.75e-60	1.7e-56	-0.88	-0.66	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
LGG	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	19	2.81e-60	1.74e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
LGG	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	19	2.81e-60	1.74e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
LGG	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	19	2.81e-60	1.74e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
LGG	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	19	2.81e-60	1.74e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
LGG	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	19	2.83e-60	1.75e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
LGG	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	19	2.83e-60	1.75e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
LGG	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	19	2.83e-60	1.75e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
LGG	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	19	2.83e-60	1.75e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
LGG	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	19	3.01e-60	1.86e-56	0.74	0.66	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	18.99	3.1e-60	1.92e-56	0.88	0.66	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
LGG	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	18.99	3.1e-60	1.92e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
LGG	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-18.98	3.48e-60	2.15e-56	-0.85	-0.66	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
LGG	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	18.97	3.86e-60	2.38e-56	0.88	0.66	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	18.97	3.88e-60	2.39e-56	0.88	0.66	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
LGG	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	18.97	4.15e-60	2.55e-56	0.9	0.66	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
LGG	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	18.96	4.26e-60	2.62e-56	0.69	0.66	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
LGG	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	18.96	4.43e-60	2.72e-56	0.82	0.66	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
LGG	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-18.95	4.74e-60	2.91e-56	-0.85	-0.66	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
LGG	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	18.95	4.9e-60	3.01e-56	0.92	0.66	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
LGG	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	18.95	4.91e-60	3.01e-56	1.03	0.66	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	18.95	5.06e-60	3.11e-56	0.93	0.66	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	18.95	5.21e-60	3.2e-56	0.82	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
LGG	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-18.94	5.73e-60	3.51e-56	-0.87	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
LGG	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	18.93	6.12e-60	3.75e-56	0.74	0.66	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
LGG	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	18.93	6.35e-60	3.89e-56	0.88	0.66	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-18.92	6.99e-60	4.27e-56	-0.82	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
LGG	cis	rs172166	0.637	rs1225592	ENSG00000199851.2	U3	18.91	7.78e-60	4.74e-56	0.97	0.66	Cardiac Troponin-T levels;	chr6:28182464	chr6:28015568~28015777:+
LGG	cis	rs172166	0.637	rs1225595	ENSG00000199851.2	U3	18.91	7.78e-60	4.74e-56	0.97	0.66	Cardiac Troponin-T levels;	chr6:28183562	chr6:28015568~28015777:+
LGG	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	18.9	8.45e-60	5.14e-56	0.86	0.66	Shingles;	chr7:38346957	chr7:38343894~38350022:-
LGG	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	18.9	8.82e-60	5.36e-56	0.87	0.66	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
LGG	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-18.89	9.33e-60	5.67e-56	-0.7	-0.66	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
LGG	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	18.89	9.41e-60	5.72e-56	0.83	0.66	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
LGG	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	18.88	1.02e-59	6.18e-56	0.82	0.66	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
LGG	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	18.88	1.02e-59	6.21e-56	0.89	0.66	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	18.88	1.06e-59	6.45e-56	0.93	0.66	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
LGG	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	18.88	1.06e-59	6.45e-56	0.84	0.66	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
LGG	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-18.87	1.17e-59	7.06e-56	-0.75	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
LGG	cis	rs853679	0.55	rs1233701	ENSG00000216901.1	AL022393.7	-18.87	1.21e-59	7.3e-56	-0.93	-0.65	Depression;	chr6:28200948	chr6:28176188~28176674:+
LGG	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-18.86	1.33e-59	7.99e-56	-0.9	-0.65	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
LGG	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-18.84	1.66e-59	9.98e-56	-0.82	-0.65	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
LGG	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	18.84	1.7e-59	1.02e-55	0.74	0.65	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	18.84	1.7e-59	1.02e-55	0.74	0.65	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
LGG	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	18.83	1.81e-59	1.08e-55	0.87	0.65	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	18.82	1.95e-59	1.17e-55	0.85	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
LGG	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	18.81	2.28e-59	1.35e-55	0.87	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
LGG	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	18.8	2.41e-59	1.44e-55	0.89	0.65	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	18.8	2.65e-59	1.57e-55	0.87	0.65	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
LGG	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	18.79	2.78e-59	1.65e-55	0.74	0.65	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
LGG	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-18.79	2.83e-59	1.68e-55	-0.83	-0.65	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
LGG	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	18.79	2.84e-59	1.68e-55	0.87	0.65	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
LGG	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	18.78	3.12e-59	1.85e-55	0.95	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
LGG	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-18.78	3.21e-59	1.9e-55	-0.76	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
LGG	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	18.78	3.21e-59	1.9e-55	0.88	0.65	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
LGG	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-18.77	3.32e-59	1.97e-55	-0.7	-0.65	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
LGG	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	18.77	3.38e-59	2e-55	0.87	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
LGG	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-18.77	3.67e-59	2.16e-55	-0.74	-0.65	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
LGG	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	18.76	3.76e-59	2.22e-55	0.88	0.65	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	18.76	3.76e-59	2.22e-55	0.88	0.65	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
LGG	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	18.76	3.98e-59	2.34e-55	0.93	0.65	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
LGG	cis	rs853679	0.55	rs1237875	ENSG00000216901.1	AL022393.7	-18.75	4.12e-59	2.43e-55	-0.93	-0.65	Depression;	chr6:28205232	chr6:28176188~28176674:+
LGG	cis	rs172166	0.637	rs1071893	ENSG00000199851.2	U3	18.75	4.38e-59	2.58e-55	0.97	0.65	Cardiac Troponin-T levels;	chr6:28199857	chr6:28015568~28015777:+
LGG	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-18.75	4.46e-59	2.62e-55	-0.83	-0.65	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
LGG	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-18.74	4.67e-59	2.75e-55	-0.92	-0.65	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
LGG	cis	rs853679	0.55	rs9295762	ENSG00000216901.1	AL022393.7	-18.74	4.68e-59	2.75e-55	-0.93	-0.65	Depression;	chr6:28187640	chr6:28176188~28176674:+
LGG	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	18.74	4.99e-59	2.94e-55	0.97	0.65	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	18.73	5.2e-59	3.05e-55	0.92	0.65	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	18.72	5.76e-59	3.38e-55	0.87	0.65	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	18.72	5.76e-59	3.38e-55	0.87	0.65	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	18.72	5.76e-59	3.38e-55	0.87	0.65	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
LGG	cis	rs172166	0.637	rs1225597	ENSG00000199851.2	U3	18.72	5.92e-59	3.47e-55	0.97	0.65	Cardiac Troponin-T levels;	chr6:28194309	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	18.71	6.42e-59	3.76e-55	0.92	0.65	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
LGG	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-18.71	6.45e-59	3.78e-55	-0.78	-0.65	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
LGG	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	18.71	6.79e-59	3.98e-55	0.84	0.65	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
LGG	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-18.71	6.8e-59	3.98e-55	-1.06	-0.65	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
LGG	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	18.71	7.03e-59	4.12e-55	0.79	0.65	Depression;	chr6:28363475	chr6:28176188~28176674:+
LGG	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-18.7	7.38e-59	4.32e-55	-0.86	-0.65	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
LGG	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	18.69	8.4e-59	4.91e-55	0.92	0.65	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
LGG	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	18.69	8.47e-59	4.95e-55	0.92	0.65	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
LGG	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-18.68	9e-59	5.26e-55	-1.01	-0.65	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
LGG	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	18.68	9.43e-59	5.51e-55	0.88	0.65	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
LGG	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-18.67	9.82e-59	5.71e-55	-0.82	-0.65	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-18.67	9.82e-59	5.71e-55	-0.82	-0.65	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
LGG	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	18.67	1.01e-58	5.89e-55	0.83	0.65	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
LGG	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	18.67	1.05e-58	6.08e-55	1.04	0.65	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	18.66	1.16e-58	6.75e-55	0.84	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
LGG	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	18.66	1.18e-58	6.87e-55	0.82	0.65	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
LGG	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-18.64	1.37e-58	7.93e-55	-1.08	-0.65	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	18.64	1.43e-58	8.29e-55	0.87	0.65	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	18.63	1.52e-58	8.77e-55	0.87	0.65	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
LGG	cis	rs853679	0.55	rs1225598	ENSG00000216901.1	AL022393.7	18.63	1.59e-58	9.19e-55	0.92	0.65	Depression;	chr6:28193021	chr6:28176188~28176674:+
LGG	cis	rs853679	0.55	rs1150689	ENSG00000216901.1	AL022393.7	18.63	1.59e-58	9.19e-55	0.92	0.65	Depression;	chr6:28197321	chr6:28176188~28176674:+
LGG	cis	rs853679	0.55	rs1225599	ENSG00000216901.1	AL022393.7	18.63	1.59e-58	9.19e-55	0.92	0.65	Depression;	chr6:28197412	chr6:28176188~28176674:+
LGG	cis	rs853679	0.574	rs1233705	ENSG00000216901.1	AL022393.7	18.63	1.59e-58	9.19e-55	0.92	0.65	Depression;	chr6:28198669	chr6:28176188~28176674:+
LGG	cis	rs853679	0.55	rs1233707	ENSG00000216901.1	AL022393.7	18.63	1.59e-58	9.19e-55	0.92	0.65	Depression;	chr6:28205175	chr6:28176188~28176674:+
LGG	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	18.63	1.65e-58	9.55e-55	0.75	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
LGG	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	18.62	1.84e-58	1.06e-54	0.87	0.65	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
LGG	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	18.61	1.88e-58	1.09e-54	0.69	0.65	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
LGG	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	18.61	1.98e-58	1.15e-54	0.86	0.65	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
LGG	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	18.6	2.22e-58	1.28e-54	0.85	0.65	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	18.59	2.34e-58	1.35e-54	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
LGG	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-18.59	2.43e-58	1.4e-54	-0.73	-0.65	Breast cancer;	chr11:743813	chr11:779617~780755:+
LGG	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-18.59	2.51e-58	1.45e-54	-0.66	-0.65	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
LGG	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	18.58	2.58e-58	1.49e-54	0.82	0.65	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
LGG	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	18.58	2.6e-58	1.5e-54	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	18.58	2.61e-58	1.5e-54	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	18.58	2.61e-58	1.5e-54	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	18.58	2.61e-58	1.5e-54	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
LGG	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-18.57	2.95e-58	1.69e-54	-0.63	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
LGG	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	18.57	3.13e-58	1.8e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	18.57	3.13e-58	1.8e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
LGG	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-18.56	3.23e-58	1.85e-54	-1.06	-0.65	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
LGG	cis	rs853679	0.55	rs6901017	ENSG00000216901.1	AL022393.7	18.56	3.36e-58	1.93e-54	0.92	0.65	Depression;	chr6:28184805	chr6:28176188~28176674:+
LGG	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	18.55	3.61e-58	2.07e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
LGG	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	18.53	4.41e-58	2.52e-54	0.82	0.65	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	18.53	4.57e-58	2.61e-54	0.81	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
LGG	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	18.53	4.7e-58	2.67e-54	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
LGG	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	18.53	4.72e-58	2.68e-54	0.67	0.65	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
LGG	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	18.52	5.11e-58	2.9e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
LGG	cis	rs853679	0.55	rs1233699	ENSG00000216901.1	AL022393.7	18.51	5.5e-58	3.13e-54	0.91	0.65	Depression;	chr6:28201380	chr6:28176188~28176674:+
LGG	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	18.51	5.57e-58	3.17e-54	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
LGG	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-18.51	5.66e-58	3.22e-54	-0.87	-0.65	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	18.51	5.73e-58	3.25e-54	0.9	0.65	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	18.51	5.75e-58	3.27e-54	0.86	0.65	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
LGG	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	18.51	5.75e-58	3.27e-54	0.71	0.65	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
LGG	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	18.5	6.14e-58	3.49e-54	0.88	0.65	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	18.5	6.2e-58	3.52e-54	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	18.5	6.39e-58	3.62e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	18.5	6.39e-58	3.62e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	18.5	6.39e-58	3.62e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	18.5	6.45e-58	3.66e-54	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
LGG	cis	rs4713118	0.662	rs149970	ENSG00000199851.2	U3	18.5	6.69e-58	3.79e-54	0.99	0.65	Parkinson's disease;	chr6:28012442	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	18.48	8.07e-58	4.55e-54	0.88	0.65	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	18.47	8.72e-58	4.91e-54	0.88	0.65	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
LGG	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	18.47	9.24e-58	5.19e-54	1.06	0.65	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	18.47	9.24e-58	5.19e-54	1.06	0.65	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	18.47	9.24e-58	5.19e-54	1.06	0.65	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	18.47	9.24e-58	5.19e-54	1.06	0.65	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
LGG	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-18.47	9.38e-58	5.27e-54	-1.08	-0.65	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-18.47	9.38e-58	5.27e-54	-1.08	-0.65	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
LGG	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-18.46	9.54e-58	5.36e-54	-0.92	-0.65	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	18.46	1.04e-57	5.81e-54	0.86	0.65	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	18.46	1.04e-57	5.81e-54	0.86	0.65	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	18.45	1.09e-57	6.1e-54	0.86	0.65	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	18.45	1.09e-57	6.1e-54	0.86	0.65	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	18.45	1.09e-57	6.1e-54	0.86	0.65	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	18.45	1.09e-57	6.1e-54	0.86	0.65	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
LGG	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	18.45	1.12e-57	6.27e-54	0.82	0.65	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	18.45	1.12e-57	6.3e-54	0.85	0.65	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
LGG	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-18.44	1.17e-57	6.56e-54	-0.62	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
LGG	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-18.44	1.18e-57	6.59e-54	-1.07	-0.65	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-18.44	1.18e-57	6.59e-54	-1.07	-0.65	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
LGG	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	18.44	1.2e-57	6.69e-54	0.67	0.65	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
LGG	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-18.44	1.21e-57	6.79e-54	-1.07	-0.65	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-18.44	1.21e-57	6.79e-54	-1.07	-0.65	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	18.44	1.22e-57	6.83e-54	0.86	0.65	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
LGG	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	18.44	1.25e-57	6.98e-54	0.88	0.65	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	18.43	1.34e-57	7.5e-54	0.86	0.65	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
LGG	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-18.43	1.44e-57	8.04e-54	-0.89	-0.65	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	18.43	1.44e-57	8.06e-54	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
LGG	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	18.42	1.44e-57	8.07e-54	0.85	0.65	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	18.42	1.47e-57	8.23e-54	0.86	0.65	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
LGG	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	18.42	1.55e-57	8.62e-54	0.88	0.65	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	18.42	1.55e-57	8.62e-54	0.88	0.65	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	18.42	1.55e-57	8.62e-54	0.88	0.65	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	18.41	1.61e-57	9e-54	0.86	0.65	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
LGG	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	18.41	1.65e-57	9.22e-54	0.67	0.65	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
LGG	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	18.4	1.8e-57	1e-53	0.68	0.65	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
LGG	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	18.4	1.8e-57	1e-53	0.81	0.65	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
LGG	cis	rs853679	0.55	rs1150692	ENSG00000216901.1	AL022393.7	18.4	1.8e-57	1e-53	0.92	0.65	Depression;	chr6:28206179	chr6:28176188~28176674:+
LGG	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	18.4	1.88e-57	1.05e-53	0.8	0.65	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
LGG	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-18.39	2.1e-57	1.17e-53	-0.97	-0.65	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
LGG	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	18.39	2.21e-57	1.23e-53	0.86	0.65	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	18.39	2.21e-57	1.23e-53	0.86	0.65	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	18.39	2.22e-57	1.23e-53	0.86	0.65	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
LGG	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	18.39	2.22e-57	1.23e-53	0.82	0.65	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
LGG	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-18.38	2.22e-57	1.24e-53	-1.07	-0.65	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-18.38	2.22e-57	1.24e-53	-1.07	-0.65	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-18.38	2.22e-57	1.24e-53	-1.07	-0.65	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
LGG	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	18.38	2.23e-57	1.24e-53	0.67	0.65	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
LGG	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	18.38	2.39e-57	1.33e-53	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	18.38	2.39e-57	1.33e-53	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	18.38	2.39e-57	1.33e-53	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	18.38	2.39e-57	1.33e-53	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	18.38	2.39e-57	1.33e-53	0.86	0.65	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
LGG	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	18.38	2.47e-57	1.37e-53	0.86	0.64	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
LGG	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-18.37	2.53e-57	1.4e-53	-0.82	-0.64	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-18.37	2.56e-57	1.42e-53	-0.82	-0.64	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-18.37	2.71e-57	1.5e-53	-0.83	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
LGG	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	18.37	2.73e-57	1.51e-53	0.69	0.64	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
LGG	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	18.37	2.74e-57	1.52e-53	0.56	0.64	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
LGG	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	18.36	2.78e-57	1.54e-53	0.94	0.64	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
LGG	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-18.35	3.33e-57	1.84e-53	-0.81	-0.64	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
LGG	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	18.34	3.43e-57	1.9e-53	0.69	0.64	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
LGG	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	18.34	3.79e-57	2.09e-53	0.68	0.64	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
LGG	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-18.33	4e-57	2.21e-53	-0.85	-0.64	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
LGG	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	18.33	4.19e-57	2.31e-53	1.07	0.64	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
LGG	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-18.33	4.2e-57	2.32e-53	-0.69	-0.64	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
LGG	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	18.33	4.21e-57	2.32e-53	0.81	0.64	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
LGG	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	18.33	4.21e-57	2.32e-53	0.81	0.64	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
LGG	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	18.31	4.81e-57	2.66e-53	0.85	0.64	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	18.31	5.01e-57	2.76e-53	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
LGG	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	18.31	5.14e-57	2.83e-53	0.86	0.64	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
LGG	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	18.3	5.38e-57	2.96e-53	0.88	0.64	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
LGG	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-18.3	5.48e-57	3.02e-53	-0.85	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
LGG	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	18.3	5.61e-57	3.09e-53	0.86	0.64	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
LGG	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-18.3	5.68e-57	3.13e-53	-0.62	-0.64	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
LGG	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-18.3	5.71e-57	3.14e-53	-0.96	-0.64	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
LGG	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-18.29	6.25e-57	3.44e-53	-0.75	-0.64	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
LGG	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	18.28	6.68e-57	3.67e-53	0.82	0.64	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
LGG	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	18.28	6.75e-57	3.71e-53	0.69	0.64	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
LGG	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	18.28	6.86e-57	3.77e-53	0.81	0.64	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
LGG	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-18.28	7e-57	3.84e-53	-0.68	-0.64	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
LGG	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-18.28	7.2e-57	3.96e-53	-0.76	-0.64	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
LGG	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-18.27	7.52e-57	4.13e-53	-0.73	-0.64	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	18.26	8.34e-57	4.57e-53	0.86	0.64	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
LGG	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-18.26	8.46e-57	4.64e-53	-0.69	-0.64	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
LGG	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-18.24	1.02e-56	5.57e-53	-0.69	-0.64	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
LGG	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	18.24	1.05e-56	5.72e-53	0.96	0.64	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	18.24	1.08e-56	5.9e-53	0.96	0.64	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	18.24	1.08e-56	5.9e-53	0.96	0.64	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
LGG	cis	rs853679	0.55	rs1233704	ENSG00000216901.1	AL022393.7	-18.24	1.1e-56	6.02e-53	-0.9	-0.64	Depression;	chr6:28199145	chr6:28176188~28176674:+
LGG	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	18.23	1.21e-56	6.6e-53	0.73	0.64	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
LGG	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	18.23	1.23e-56	6.72e-53	0.91	0.64	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
LGG	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-18.22	1.36e-56	7.39e-53	-0.86	-0.64	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	18.22	1.36e-56	7.39e-53	0.86	0.64	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
LGG	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-18.21	1.49e-56	8.08e-53	-1.07	-0.64	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
LGG	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	18.21	1.52e-56	8.25e-53	0.56	0.64	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
LGG	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	18.2	1.58e-56	8.61e-53	0.85	0.64	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
LGG	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	18.19	1.72e-56	9.32e-53	0.86	0.64	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
LGG	cis	rs2487048	1	rs2487046	ENSG00000226334.1	RP11-217B7.2	-18.19	1.9e-56	1.03e-52	-0.86	-0.64	Intraocular pressure;	chr9:104929948	chr9:104927553~104928892:+
LGG	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	18.18	2.12e-56	1.15e-52	0.87	0.64	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
LGG	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	18.17	2.17e-56	1.17e-52	0.68	0.64	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
LGG	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	18.17	2.18e-56	1.18e-52	0.72	0.64	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
LGG	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	18.16	2.54e-56	1.37e-52	0.86	0.64	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	18.16	2.58e-56	1.39e-52	0.86	0.64	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
LGG	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	18.16	2.6e-56	1.4e-52	0.85	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
LGG	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-18.16	2.6e-56	1.4e-52	-1.06	-0.64	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
LGG	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	18.16	2.61e-56	1.41e-52	0.68	0.64	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
LGG	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	18.15	2.63e-56	1.42e-52	0.83	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
LGG	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	18.15	2.92e-56	1.57e-52	0.81	0.64	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
LGG	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	18.14	3.1e-56	1.66e-52	0.96	0.64	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	18.14	3.1e-56	1.66e-52	0.96	0.64	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	18.14	3.1e-56	1.66e-52	0.96	0.64	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
LGG	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	18.13	3.44e-56	1.84e-52	1.03	0.64	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
LGG	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	18.13	3.48e-56	1.86e-52	0.72	0.64	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
LGG	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	18.12	3.7e-56	1.98e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	18.12	3.7e-56	1.98e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	18.12	3.7e-56	1.98e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	18.12	3.7e-56	1.98e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	18.12	3.7e-56	1.98e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
LGG	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-18.12	3.91e-56	2.09e-52	-0.85	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
LGG	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-18.11	4.14e-56	2.2e-52	-0.69	-0.64	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
LGG	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	18.11	4.16e-56	2.22e-52	0.81	0.64	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
LGG	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	18.11	4.19e-56	2.23e-52	0.69	0.64	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	18.1	4.57e-56	2.43e-52	0.8	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
LGG	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	18.1	4.77e-56	2.54e-52	0.68	0.64	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
LGG	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-18.1	4.77e-56	2.54e-52	-0.68	-0.64	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
LGG	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	18.1	4.97e-56	2.64e-52	0.68	0.64	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
LGG	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	18.09	5.36e-56	2.85e-52	0.85	0.64	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
LGG	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	18.09	5.41e-56	2.87e-52	0.68	0.64	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
LGG	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	18.09	5.41e-56	2.87e-52	0.68	0.64	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
LGG	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	18.09	5.51e-56	2.92e-52	0.68	0.64	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
LGG	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	18.09	5.54e-56	2.94e-52	0.85	0.64	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
LGG	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	18.08	5.72e-56	3.03e-52	0.68	0.64	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
LGG	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	18.08	5.74e-56	3.04e-52	0.55	0.64	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
LGG	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	18.08	5.92e-56	3.14e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
LGG	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	18.08	5.99e-56	3.17e-52	0.86	0.64	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	18.08	5.99e-56	3.17e-52	0.86	0.64	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	18.08	5.99e-56	3.17e-52	0.86	0.64	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	18.08	5.99e-56	3.17e-52	0.86	0.64	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	18.08	5.99e-56	3.17e-52	0.86	0.64	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
LGG	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	18.07	6.3e-56	3.34e-52	0.96	0.64	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	18.07	6.64e-56	3.51e-52	0.96	0.64	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
LGG	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	18.07	6.68e-56	3.53e-52	0.68	0.64	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
LGG	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	18.06	6.98e-56	3.69e-52	0.68	0.64	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
LGG	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	18.06	7.04e-56	3.71e-52	0.96	0.64	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
LGG	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	18.06	7.18e-56	3.79e-52	0.68	0.64	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
LGG	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-18.06	7.21e-56	3.8e-52	-0.85	-0.64	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
LGG	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	18.06	7.32e-56	3.85e-52	0.79	0.64	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
LGG	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	18.05	7.71e-56	4.06e-52	0.87	0.64	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
LGG	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-18.05	7.92e-56	4.16e-52	-0.83	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
LGG	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	18.05	8.55e-56	4.49e-52	0.56	0.64	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
LGG	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-18.04	8.63e-56	4.54e-52	-0.83	-0.64	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
LGG	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	18.04	8.8e-56	4.62e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	18.04	9.35e-56	4.91e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
LGG	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	18.03	9.6e-56	5.03e-52	0.86	0.64	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
LGG	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	18.03	9.77e-56	5.12e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
LGG	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	18.03	9.81e-56	5.14e-52	0.87	0.64	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
LGG	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	18.02	1.07e-55	5.6e-52	0.74	0.64	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
LGG	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	18.02	1.08e-55	5.65e-52	0.56	0.64	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
LGG	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-18.02	1.1e-55	5.71e-52	-0.66	-0.64	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
LGG	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	18.02	1.16e-55	6.04e-52	0.96	0.64	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
LGG	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-18.01	1.21e-55	6.29e-52	-0.96	-0.64	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
LGG	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	18.01	1.29e-55	6.68e-52	0.77	0.64	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
LGG	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	18.01	1.31e-55	6.78e-52	0.56	0.64	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
LGG	cis	rs853679	0.506	rs1150693	ENSG00000216901.1	AL022393.7	18	1.34e-55	6.92e-52	0.92	0.64	Depression;	chr6:28206812	chr6:28176188~28176674:+
LGG	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-17.99	1.54e-55	7.94e-52	-0.92	-0.64	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
LGG	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	17.99	1.57e-55	8.08e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
LGG	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-17.99	1.59e-55	8.19e-52	-0.83	-0.64	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
LGG	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-17.98	1.65e-55	8.49e-52	-0.66	-0.64	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
LGG	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	17.97	1.88e-55	9.63e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	17.97	1.88e-55	9.63e-52	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
LGG	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	17.96	2.12e-55	1.08e-51	1.03	0.64	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
LGG	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	17.96	2.14e-55	1.09e-51	0.84	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
LGG	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	17.95	2.27e-55	1.16e-51	1	0.64	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
LGG	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-17.95	2.28e-55	1.16e-51	-0.84	-0.64	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
LGG	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	17.95	2.43e-55	1.24e-51	0.73	0.64	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
LGG	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	17.94	2.52e-55	1.28e-51	0.85	0.64	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
LGG	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-17.94	2.55e-55	1.3e-51	-0.71	-0.64	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
LGG	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-17.94	2.57e-55	1.31e-51	-0.67	-0.64	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
LGG	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-17.94	2.73e-55	1.39e-51	-0.78	-0.64	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
LGG	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	17.93	2.94e-55	1.5e-51	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	17.92	3.2e-55	1.62e-51	0.84	0.64	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
LGG	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	17.92	3.29e-55	1.67e-51	0.79	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
LGG	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	17.9	4.03e-55	2.04e-51	0.68	0.64	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	17.9	4.03e-55	2.04e-51	0.68	0.64	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
LGG	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	17.9	4.13e-55	2.09e-51	0.78	0.64	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
LGG	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-17.89	4.49e-55	2.27e-51	-0.79	-0.63	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
LGG	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	17.89	4.5e-55	2.28e-51	0.67	0.63	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
LGG	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	17.89	4.63e-55	2.34e-51	0.85	0.63	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
LGG	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	17.88	4.78e-55	2.42e-51	0.55	0.63	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
LGG	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	17.88	4.78e-55	2.42e-51	0.55	0.63	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
LGG	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	17.88	5.29e-55	2.67e-51	1.01	0.63	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
LGG	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-17.87	5.6e-55	2.83e-51	-0.89	-0.63	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
LGG	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	17.87	5.75e-55	2.9e-51	0.84	0.63	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
LGG	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-17.87	5.82e-55	2.93e-51	-0.89	-0.63	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	17.87	5.84e-55	2.94e-51	0.89	0.63	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
LGG	cis	rs11647589	0.911	rs7194098	ENSG00000260762.1	ACSM5P1	17.86	6.1e-55	3.07e-51	0.8	0.63	Blood metabolite levels;	chr16:20453028	chr16:20586550~20607107:-
LGG	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	17.86	6.25e-55	3.15e-51	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
LGG	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	17.86	6.36e-55	3.2e-51	0.92	0.63	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
LGG	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	17.85	6.84e-55	3.44e-51	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
LGG	cis	rs11647589	0.689	rs8045136	ENSG00000260762.1	ACSM5P1	-17.85	6.86e-55	3.45e-51	-0.79	-0.63	Blood metabolite levels;	chr16:20442599	chr16:20586550~20607107:-
LGG	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	17.85	7.24e-55	3.63e-51	1.02	0.63	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
LGG	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	17.84	7.36e-55	3.69e-51	0.79	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
LGG	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-17.84	7.86e-55	3.94e-51	-0.89	-0.63	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
LGG	cis	rs2882667	0.652	rs874115	ENSG00000253404.1	AC034243.1	17.83	8.43e-55	4.22e-51	0.75	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944367	chr5:138744434~138753309:-
LGG	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-17.82	9.14e-55	4.57e-51	-0.76	-0.63	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	17.82	9.71e-55	4.85e-51	0.69	0.63	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
LGG	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-17.82	9.77e-55	4.88e-51	-0.77	-0.63	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
LGG	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	17.82	9.87e-55	4.93e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
LGG	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-17.81	1.04e-54	5.2e-51	-0.78	-0.63	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-17.81	1.04e-54	5.2e-51	-0.78	-0.63	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-17.81	1.04e-54	5.2e-51	-0.78	-0.63	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
LGG	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-17.81	1.04e-54	5.21e-51	-0.75	-0.63	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	17.81	1.05e-54	5.24e-51	0.79	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
LGG	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-17.81	1.07e-54	5.32e-51	-0.75	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
LGG	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	17.81	1.11e-54	5.55e-51	0.88	0.63	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	17.81	1.11e-54	5.55e-51	0.88	0.63	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
LGG	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	17.81	1.11e-54	5.55e-51	0.88	0.63	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
LGG	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-17.81	1.12e-54	5.59e-51	-0.82	-0.63	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
LGG	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	17.8	1.23e-54	6.14e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
LGG	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-17.79	1.31e-54	6.5e-51	-0.82	-0.63	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
LGG	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	17.79	1.38e-54	6.84e-51	0.83	0.63	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	17.79	1.39e-54	6.88e-51	0.83	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
LGG	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	17.79	1.39e-54	6.89e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	17.78	1.53e-54	7.59e-51	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
LGG	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-17.77	1.68e-54	8.31e-51	-0.69	-0.63	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
LGG	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	17.77	1.7e-54	8.4e-51	0.83	0.63	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	17.77	1.7e-54	8.4e-51	0.83	0.63	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	17.77	1.7e-54	8.4e-51	0.83	0.63	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
LGG	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-17.77	1.7e-54	8.42e-51	-0.82	-0.63	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
LGG	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	17.76	1.8e-54	8.88e-51	0.71	0.63	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
LGG	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	17.76	1.92e-54	9.43e-51	0.56	0.63	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
LGG	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	17.75	1.93e-54	9.52e-51	0.78	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	17.75	1.93e-54	9.52e-51	0.78	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
LGG	cis	rs11647589	0.906	rs6416611	ENSG00000260762.1	ACSM5P1	17.75	1.96e-54	9.64e-51	0.79	0.63	Blood metabolite levels;	chr16:20459768	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.815	rs7194852	ENSG00000260762.1	ACSM5P1	17.75	1.96e-54	9.64e-51	0.79	0.63	Blood metabolite levels;	chr16:20461954	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.815	rs11646536	ENSG00000260762.1	ACSM5P1	17.75	1.96e-54	9.64e-51	0.79	0.63	Blood metabolite levels;	chr16:20462274	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.723	rs9937581	ENSG00000260762.1	ACSM5P1	17.75	1.96e-54	9.64e-51	0.79	0.63	Blood metabolite levels;	chr16:20462581	chr16:20586550~20607107:-
LGG	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-17.75	1.98e-54	9.75e-51	-0.82	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
LGG	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	17.75	2.06e-54	1.01e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	17.75	2.06e-54	1.01e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	17.75	2.06e-54	1.01e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	17.75	2.06e-54	1.01e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
LGG	cis	rs11647589	0.689	rs12599141	ENSG00000260762.1	ACSM5P1	17.75	2.09e-54	1.03e-50	0.79	0.63	Blood metabolite levels;	chr16:20440775	chr16:20586550~20607107:-
LGG	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	17.75	2.09e-54	1.03e-50	0.55	0.63	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
LGG	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	17.74	2.22e-54	1.09e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
LGG	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-17.73	2.46e-54	1.21e-50	-0.99	-0.63	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
LGG	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	17.73	2.48e-54	1.21e-50	0.55	0.63	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
LGG	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	17.73	2.51e-54	1.23e-50	0.84	0.63	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
LGG	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	17.73	2.55e-54	1.25e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
LGG	cis	rs2487048	1	rs2487048	ENSG00000226334.1	RP11-217B7.2	-17.72	2.73e-54	1.33e-50	-0.86	-0.63	Intraocular pressure;	chr9:104929542	chr9:104927553~104928892:+
LGG	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	17.72	2.82e-54	1.38e-50	0.82	0.63	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
LGG	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-17.71	3.22e-54	1.57e-50	-0.78	-0.63	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-17.71	3.22e-54	1.57e-50	-0.78	-0.63	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-17.71	3.22e-54	1.57e-50	-0.78	-0.63	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-17.71	3.22e-54	1.57e-50	-0.78	-0.63	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-17.71	3.22e-54	1.57e-50	-0.78	-0.63	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-17.71	3.22e-54	1.57e-50	-0.78	-0.63	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
LGG	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	17.7	3.31e-54	1.61e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
LGG	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-17.69	3.81e-54	1.85e-50	-0.78	-0.63	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-17.69	3.81e-54	1.85e-50	-0.78	-0.63	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-17.69	3.81e-54	1.85e-50	-0.78	-0.63	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
LGG	cis	rs11647589	0.724	rs7499667	ENSG00000260762.1	ACSM5P1	17.69	3.95e-54	1.91e-50	0.79	0.63	Blood metabolite levels;	chr16:20437198	chr16:20586550~20607107:-
LGG	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	17.68	4.09e-54	1.98e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	17.68	4.09e-54	1.98e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	17.68	4.09e-54	1.98e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	17.68	4.09e-54	1.98e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
LGG	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-17.68	4.21e-54	2.04e-50	-0.89	-0.63	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
LGG	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	17.68	4.35e-54	2.1e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	17.67	4.63e-54	2.24e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
LGG	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-17.67	4.84e-54	2.34e-50	-0.82	-0.63	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
LGG	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	17.67	5.01e-54	2.42e-50	1.02	0.63	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
LGG	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-17.66	5.12e-54	2.47e-50	-0.78	-0.63	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-17.66	5.26e-54	2.54e-50	-0.78	-0.63	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
LGG	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	17.66	5.37e-54	2.59e-50	0.78	0.63	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	17.66	5.52e-54	2.66e-50	0.78	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
LGG	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	17.65	5.72e-54	2.75e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-17.65	5.74e-54	2.76e-50	-0.67	-0.63	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
LGG	cis	rs11647589	0.678	rs6497489	ENSG00000260762.1	ACSM5P1	17.65	6.18e-54	2.97e-50	0.8	0.63	Blood metabolite levels;	chr16:20460042	chr16:20586550~20607107:-
LGG	cis	rs6452524	0.618	rs10462394	ENSG00000248112.1	RP11-78C3.1	17.64	6.27e-54	3.01e-50	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:82919376~82921119:-
LGG	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
LGG	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Depression;	chr6:28399886	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	17.64	6.5e-54	3.12e-50	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-17.64	6.82e-54	3.27e-50	-0.68	-0.63	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	17.64	6.88e-54	3.3e-50	0.84	0.63	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
LGG	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	17.63	7.1e-54	3.4e-50	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
LGG	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-17.63	7.14e-54	3.42e-50	-0.92	-0.63	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
LGG	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-17.63	7.14e-54	3.42e-50	-0.78	-0.63	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
LGG	cis	rs11647589	0.648	rs7192310	ENSG00000260762.1	ACSM5P1	17.63	7.27e-54	3.48e-50	0.79	0.63	Blood metabolite levels;	chr16:20465373	chr16:20586550~20607107:-
LGG	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	17.63	7.43e-54	3.56e-50	0.85	0.63	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
LGG	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	17.62	7.71e-54	3.69e-50	0.56	0.63	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
LGG	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-17.62	7.96e-54	3.8e-50	-0.68	-0.63	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-17.62	7.96e-54	3.8e-50	-0.68	-0.63	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
LGG	cis	rs6452524	0.618	rs1871203	ENSG00000248112.1	RP11-78C3.1	17.62	8.02e-54	3.83e-50	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:82919376~82921119:-
LGG	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	17.62	8.18e-54	3.91e-50	1.03	0.63	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
LGG	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	17.61	9.27e-54	4.43e-50	0.68	0.63	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
LGG	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	17.6	9.64e-54	4.6e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	17.6	9.64e-54	4.6e-50	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
LGG	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	17.6	9.88e-54	4.71e-50	0.67	0.63	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
LGG	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	17.6	1.01e-53	4.83e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	17.6	1.01e-53	4.83e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
LGG	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	17.6	1.05e-53	5.01e-50	0.68	0.63	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
LGG	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-17.59	1.08e-53	5.16e-50	-0.84	-0.63	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
LGG	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	17.59	1.1e-53	5.22e-50	0.68	0.63	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
LGG	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	17.58	1.22e-53	5.81e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	17.58	1.22e-53	5.81e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
LGG	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-17.58	1.25e-53	5.92e-50	-0.73	-0.63	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
LGG	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-17.57	1.32e-53	6.25e-50	-0.84	-0.63	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
LGG	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-17.57	1.32e-53	6.25e-50	-0.84	-0.63	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
LGG	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-17.57	1.32e-53	6.25e-50	-0.84	-0.63	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
LGG	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-17.57	1.32e-53	6.25e-50	-0.84	-0.63	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
LGG	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-17.57	1.38e-53	6.54e-50	-0.84	-0.63	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
LGG	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-17.57	1.45e-53	6.89e-50	-1.05	-0.63	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
LGG	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	17.57	1.45e-53	6.89e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	17.56	1.52e-53	7.18e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	17.56	1.52e-53	7.18e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	17.56	1.52e-53	7.18e-50	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
LGG	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	17.56	1.54e-53	7.3e-50	0.67	0.63	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
LGG	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-17.56	1.57e-53	7.41e-50	-0.83	-0.63	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	17.56	1.57e-53	7.41e-50	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
LGG	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	17.55	1.73e-53	8.16e-50	0.85	0.63	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	17.55	1.73e-53	8.16e-50	0.85	0.63	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
LGG	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-17.54	1.84e-53	8.64e-50	-0.77	-0.63	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
LGG	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	17.54	1.9e-53	8.96e-50	0.93	0.63	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
LGG	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	17.54	1.92e-53	9.03e-50	0.72	0.63	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
LGG	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	17.53	2.03e-53	9.53e-50	0.55	0.63	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
LGG	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-17.53	2.03e-53	9.54e-50	-0.67	-0.63	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-17.53	2.03e-53	9.54e-50	-0.67	-0.63	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
LGG	cis	rs4713118	0.513	rs149878	ENSG00000199851.2	U3	17.53	2.12e-53	9.95e-50	0.91	0.63	Parkinson's disease;	chr6:27910960	chr6:28015568~28015777:+
LGG	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-17.53	2.14e-53	1.01e-49	-0.67	-0.63	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-17.53	2.14e-53	1.01e-49	-0.67	-0.63	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
LGG	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	17.53	2.15e-53	1.01e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	17.52	2.26e-53	1.06e-49	0.68	0.63	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
LGG	cis	rs6452524	0.618	rs6867727	ENSG00000248112.1	RP11-78C3.1	17.52	2.31e-53	1.08e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.618	rs7723639	ENSG00000248112.1	RP11-78C3.1	17.52	2.31e-53	1.08e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.618	rs2306336	ENSG00000248112.1	RP11-78C3.1	17.52	2.31e-53	1.08e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.589	rs6882386	ENSG00000248112.1	RP11-78C3.1	17.52	2.31e-53	1.08e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.618	rs6860752	ENSG00000248112.1	RP11-78C3.1	17.52	2.31e-53	1.08e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:82919376~82921119:-
LGG	cis	rs11647589	1	rs7201498	ENSG00000260762.1	ACSM5P1	17.52	2.4e-53	1.13e-49	0.78	0.63	Blood metabolite levels;	chr16:20438127	chr16:20586550~20607107:-
LGG	cis	rs6452524	0.618	rs7722924	ENSG00000248112.1	RP11-78C3.1	17.52	2.44e-53	1.14e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.618	rs6452503	ENSG00000248112.1	RP11-78C3.1	17.52	2.47e-53	1.16e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:82919376~82921119:-
LGG	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	17.51	2.74e-53	1.28e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	17.51	2.74e-53	1.28e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	17.5	2.81e-53	1.32e-49	0.68	0.63	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
LGG	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-17.5	3.06e-53	1.43e-49	-0.67	-0.63	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-17.5	3.06e-53	1.43e-49	-0.67	-0.63	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-17.5	3.06e-53	1.43e-49	-0.67	-0.63	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
LGG	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	17.5	3.07e-53	1.43e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs255561	ENSG00000248112.1	RP11-78C3.1	17.49	3.2e-53	1.5e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-17.49	3.23e-53	1.51e-49	-0.83	-0.63	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	17.49	3.33e-53	1.56e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
LGG	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	17.49	3.39e-53	1.58e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
LGG	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	17.49	3.43e-53	1.6e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs3899556	ENSG00000248112.1	RP11-78C3.1	17.48	3.57e-53	1.66e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.56	rs6895174	ENSG00000248112.1	RP11-78C3.1	17.48	3.57e-53	1.66e-49	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	17.48	3.57e-53	1.66e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	17.48	3.57e-53	1.66e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
LGG	cis	rs853679	0.517	rs9295761	ENSG00000216901.1	AL022393.7	17.48	3.76e-53	1.75e-49	0.92	0.63	Depression;	chr6:28180209	chr6:28176188~28176674:+
LGG	cis	rs11647589	0.798	rs9923280	ENSG00000260762.1	ACSM5P1	17.47	3.82e-53	1.78e-49	0.79	0.63	Blood metabolite levels;	chr16:20465155	chr16:20586550~20607107:-
LGG	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	17.47	3.85e-53	1.79e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	17.47	3.85e-53	1.79e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	17.47	3.85e-53	1.79e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	17.47	3.85e-53	1.79e-49	0.77	0.63	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
LGG	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	17.47	4.04e-53	1.88e-49	0.75	0.63	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	17.47	4.09e-53	1.9e-49	0.73	0.63	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
LGG	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-17.46	4.3e-53	2e-49	-0.94	-0.63	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
LGG	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	17.46	4.32e-53	2.01e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	17.46	4.32e-53	2.01e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	17.46	4.32e-53	2.01e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
LGG	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-17.45	4.74e-53	2.2e-49	-0.67	-0.63	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
LGG	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	17.45	5.1e-53	2.37e-49	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	17.45	5.14e-53	2.39e-49	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
LGG	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	17.45	5.24e-53	2.43e-49	0.83	0.63	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
LGG	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	17.44	5.69e-53	2.64e-49	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	17.43	6.22e-53	2.88e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
LGG	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	17.43	6.26e-53	2.89e-49	0.87	0.62	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
LGG	cis	rs6452524	0.618	rs6452502	ENSG00000248112.1	RP11-78C3.1	17.42	6.53e-53	3.02e-49	0.79	0.62	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:82919376~82921119:-
LGG	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	17.42	6.65e-53	3.07e-49	0.76	0.62	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
LGG	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-17.42	7.14e-53	3.3e-49	-1.06	-0.62	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-17.41	7.24e-53	3.35e-49	-1.04	-0.62	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
LGG	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	17.41	7.66e-53	3.53e-49	0.67	0.62	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
LGG	cis	rs11647589	0.784	rs1910803	ENSG00000260762.1	ACSM5P1	17.41	7.96e-53	3.67e-49	0.78	0.62	Blood metabolite levels;	chr16:20464412	chr16:20586550~20607107:-
LGG	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	17.41	8.01e-53	3.69e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	17.41	8.01e-53	3.69e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	17.41	8.01e-53	3.69e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
LGG	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	17.4	8.19e-53	3.77e-49	0.63	0.62	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
LGG	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	17.4	8.28e-53	3.81e-49	0.82	0.62	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
LGG	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-17.4	8.4e-53	3.87e-49	-0.67	-0.62	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-17.4	8.4e-53	3.87e-49	-0.67	-0.62	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
LGG	cis	rs6452524	0.618	rs1993948	ENSG00000248112.1	RP11-78C3.1	17.4	8.47e-53	3.9e-49	0.78	0.62	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.618	rs2075685	ENSG00000248112.1	RP11-78C3.1	17.4	8.47e-53	3.9e-49	0.78	0.62	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:82919376~82921119:-
LGG	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	17.4	8.5e-53	3.91e-49	0.78	0.62	Depression;	chr6:28273214	chr6:28176188~28176674:+
LGG	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	17.4	8.5e-53	3.91e-49	0.78	0.62	Depression;	chr6:28273215	chr6:28176188~28176674:+
LGG	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	17.39	8.98e-53	4.13e-49	0.84	0.62	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
LGG	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-17.39	9.06e-53	4.16e-49	-0.75	-0.62	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
LGG	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	17.39	9.23e-53	4.24e-49	0.74	0.62	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
LGG	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	17.39	9.57e-53	4.4e-49	0.77	0.62	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	17.39	9.85e-53	4.52e-49	0.77	0.62	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	17.39	9.85e-53	4.52e-49	0.77	0.62	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
LGG	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	17.38	1e-52	4.59e-49	0.63	0.62	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
LGG	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	17.38	1.02e-52	4.68e-49	0.83	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
LGG	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	17.38	1.04e-52	4.79e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
LGG	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	17.38	1.07e-52	4.89e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
LGG	cis	rs6452524	0.648	rs27364	ENSG00000248112.1	RP11-78C3.1	17.38	1.09e-52	4.99e-49	0.78	0.62	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:82919376~82921119:-
LGG	cis	rs11647589	0.911	rs9923452	ENSG00000260762.1	ACSM5P1	17.38	1.09e-52	5e-49	0.78	0.62	Blood metabolite levels;	chr16:20457882	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.911	rs71373192	ENSG00000260762.1	ACSM5P1	17.38	1.09e-52	5e-49	0.78	0.62	Blood metabolite levels;	chr16:20458840	chr16:20586550~20607107:-
LGG	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	17.37	1.14e-52	5.22e-49	0.66	0.62	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
LGG	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	17.37	1.15e-52	5.28e-49	1	0.62	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
LGG	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-17.37	1.19e-52	5.45e-49	-0.83	-0.62	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
LGG	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	17.37	1.21e-52	5.56e-49	0.87	0.62	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
LGG	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	17.36	1.29e-52	5.88e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	17.36	1.29e-52	5.88e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
LGG	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	17.36	1.36e-52	6.2e-49	0.74	0.62	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
LGG	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	17.35	1.37e-52	6.28e-49	0.77	0.62	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
LGG	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	17.35	1.37e-52	6.28e-49	0.74	0.62	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	17.35	1.37e-52	6.28e-49	0.74	0.62	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
LGG	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	17.35	1.38e-52	6.32e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	17.35	1.38e-52	6.32e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	17.35	1.38e-52	6.32e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
LGG	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	17.35	1.44e-52	6.58e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	17.35	1.45e-52	6.61e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	17.35	1.45e-52	6.61e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	17.35	1.45e-52	6.61e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	17.35	1.45e-52	6.61e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	17.35	1.45e-52	6.61e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
LGG	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	17.35	1.47e-52	6.68e-49	0.74	0.62	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
LGG	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-17.35	1.47e-52	6.7e-49	-0.94	-0.62	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
LGG	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	17.35	1.51e-52	6.88e-49	0.74	0.62	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
LGG	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	17.35	1.51e-52	6.89e-49	0.73	0.62	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
LGG	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	17.34	1.6e-52	7.25e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	17.34	1.6e-52	7.25e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	17.34	1.6e-52	7.25e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	17.34	1.6e-52	7.25e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
LGG	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	17.33	1.75e-52	7.95e-49	0.87	0.62	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
LGG	cis	rs853679	0.517	rs12332979	ENSG00000216901.1	AL022393.7	17.33	1.79e-52	8.14e-49	0.91	0.62	Depression;	chr6:28173770	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs67878650	ENSG00000216901.1	AL022393.7	17.33	1.79e-52	8.14e-49	0.91	0.62	Depression;	chr6:28174809	chr6:28176188~28176674:+
LGG	cis	rs853679	0.569	rs9348798	ENSG00000216901.1	AL022393.7	17.33	1.79e-52	8.14e-49	0.91	0.62	Depression;	chr6:28175233	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380065	ENSG00000216901.1	AL022393.7	17.33	1.79e-52	8.14e-49	0.91	0.62	Depression;	chr6:28176973	chr6:28176188~28176674:+
LGG	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	17.33	1.8e-52	8.16e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
LGG	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	17.33	1.86e-52	8.42e-49	0.74	0.62	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
LGG	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-17.33	1.86e-52	8.43e-49	-0.9	-0.62	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
LGG	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	17.32	1.95e-52	8.84e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	17.32	1.95e-52	8.84e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	17.32	1.95e-52	8.84e-49	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
LGG	cis	rs853679	0.517	rs1904840	ENSG00000216901.1	AL022393.7	17.32	2.08e-52	9.41e-49	0.91	0.62	Depression;	chr6:28140454	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368555	ENSG00000216901.1	AL022393.7	17.32	2.08e-52	9.41e-49	0.91	0.62	Depression;	chr6:28141189	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393893	ENSG00000216901.1	AL022393.7	17.32	2.08e-52	9.41e-49	0.91	0.62	Depression;	chr6:28141484	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs868987	ENSG00000216901.1	AL022393.7	-17.31	2.12e-52	9.6e-49	-0.91	-0.62	Depression;	chr6:28142370	chr6:28176188~28176674:+
LGG	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	17.31	2.14e-52	9.68e-49	0.99	0.62	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
LGG	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-17.31	2.15e-52	9.73e-49	-0.74	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
LGG	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	17.31	2.28e-52	1.03e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.618	rs4266384	ENSG00000248112.1	RP11-78C3.1	17.3	2.5e-52	1.13e-48	0.78	0.62	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:82919376~82921119:-
LGG	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	17.29	2.64e-52	1.19e-48	0.79	0.62	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713135	ENSG00000216901.1	AL022393.7	17.29	2.76e-52	1.24e-48	0.91	0.62	Depression;	chr6:28071808	chr6:28176188~28176674:+
LGG	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	17.29	2.78e-52	1.25e-48	0.74	0.62	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	17.28	3.08e-52	1.39e-48	0.74	0.62	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	17.28	3.08e-52	1.39e-48	0.74	0.62	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
LGG	cis	rs6452524	0.618	rs10051445	ENSG00000248112.1	RP11-78C3.1	17.28	3.1e-52	1.39e-48	0.77	0.62	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:82919376~82921119:-
LGG	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-17.28	3.15e-52	1.42e-48	-0.88	-0.62	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
LGG	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	17.28	3.2e-52	1.44e-48	0.84	0.62	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
LGG	cis	rs11647589	0.689	rs59318790	ENSG00000260762.1	ACSM5P1	17.28	3.2e-52	1.44e-48	0.77	0.62	Blood metabolite levels;	chr16:20438062	chr16:20586550~20607107:-
LGG	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	17.27	3.22e-52	1.45e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
LGG	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	17.27	3.37e-52	1.51e-48	0.73	0.62	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
LGG	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	17.27	3.41e-52	1.53e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
LGG	cis	rs853679	0.517	rs4713146	ENSG00000216901.1	AL022393.7	17.27	3.43e-52	1.54e-48	0.91	0.62	Depression;	chr6:28143758	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393894	ENSG00000216901.1	AL022393.7	17.27	3.43e-52	1.54e-48	0.91	0.62	Depression;	chr6:28144784	chr6:28176188~28176674:+
LGG	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	17.26	3.72e-52	1.67e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	17.26	3.72e-52	1.67e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	17.26	3.72e-52	1.67e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	17.26	3.72e-52	1.67e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	17.26	3.81e-52	1.71e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
LGG	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-17.26	3.87e-52	1.73e-48	-0.66	-0.62	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
LGG	cis	rs11647589	0.834	rs1910802	ENSG00000260762.1	ACSM5P1	17.25	3.99e-52	1.78e-48	0.78	0.62	Blood metabolite levels;	chr16:20464245	chr16:20586550~20607107:-
LGG	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	17.25	4.28e-52	1.91e-48	0.73	0.62	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
LGG	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	17.25	4.4e-52	1.97e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
LGG	cis	rs853679	0.517	rs9393896	ENSG00000216901.1	AL022393.7	17.24	4.41e-52	1.97e-48	0.91	0.62	Depression;	chr6:28159925	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393897	ENSG00000216901.1	AL022393.7	17.24	4.41e-52	1.97e-48	0.91	0.62	Depression;	chr6:28159932	chr6:28176188~28176674:+
LGG	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	17.24	4.77e-52	2.13e-48	0.74	0.62	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	17.24	4.91e-52	2.19e-48	0.73	0.62	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	17.24	4.91e-52	2.19e-48	0.73	0.62	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	17.24	4.91e-52	2.19e-48	0.73	0.62	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	17.24	4.91e-52	2.19e-48	0.73	0.62	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	17.24	4.91e-52	2.19e-48	0.73	0.62	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	17.24	4.91e-52	2.19e-48	0.73	0.62	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
LGG	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-17.23	5.19e-52	2.32e-48	-0.66	-0.62	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
LGG	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-17.23	5.35e-52	2.39e-48	-0.89	-0.62	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-17.23	5.42e-52	2.42e-48	-0.83	-0.62	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
LGG	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-17.22	5.98e-52	2.67e-48	-0.74	-0.62	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
LGG	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-17.21	6.14e-52	2.73e-48	-0.66	-0.62	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-17.21	6.14e-52	2.73e-48	-0.66	-0.62	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
LGG	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	17.21	6.23e-52	2.77e-48	0.72	0.62	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
LGG	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	17.21	6.35e-52	2.82e-48	0.73	0.62	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	17.21	6.35e-52	2.82e-48	0.73	0.62	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
LGG	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	17.21	6.4e-52	2.83e-48	0.74	0.62	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
LGG	cis	rs853679	0.513	rs9468296	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28145952	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4711164	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28147378	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4711165	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28147406	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713148	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28148143	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9348794	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28149979	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9295758	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28152885	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs17774663	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28153120	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9468298	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28154567	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9295759	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28156691	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9348796	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28158424	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs11552219	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28159056	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380058	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28159666	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9357065	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28161802	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9357066	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28162053	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393898	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28162598	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368556	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28163375	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368557	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28163759	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380059	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28164580	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380060	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28164825	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs35227624	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28164948	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380061	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28165025	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368558	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28165528	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.587	rs9393899	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Parkinson's disease;	chr6:28165750	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713150	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28168434	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.527	rs4713151	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Parkinson's disease;	chr6:28168578	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393901	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28169019	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs3173443	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28169249	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713152	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28169676	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9348797	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28169755	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380062	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28169791	chr6:28176188~28176674:+
LGG	cis	rs853679	0.542	rs9380063	ENSG00000216901.1	AL022393.7	17.21	6.41e-52	2.83e-48	0.91	0.62	Depression;	chr6:28170075	chr6:28176188~28176674:+
LGG	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	17.2	7.05e-52	3.12e-48	1.02	0.62	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
LGG	cis	rs853679	0.517	rs9468297	ENSG00000216901.1	AL022393.7	17.2	7.27e-52	3.21e-48	0.91	0.62	Depression;	chr6:28151096	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-17.19	8.01e-52	3.54e-48	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
LGG	cis	rs853679	0.517	rs1904841	ENSG00000216901.1	AL022393.7	17.19	8.31e-52	3.67e-48	0.9	0.62	Depression;	chr6:28140307	chr6:28176188~28176674:+
LGG	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-17.19	8.34e-52	3.68e-48	-0.89	-0.62	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
LGG	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-17.18	8.58e-52	3.79e-48	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
LGG	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	17.18	8.91e-52	3.93e-48	0.54	0.62	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
LGG	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	17.18	9.24e-52	4.07e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	17.18	9.24e-52	4.07e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	17.18	9.24e-52	4.07e-48	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
LGG	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	17.17	9.37e-52	4.13e-48	0.74	0.62	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
LGG	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	17.17	9.49e-52	4.18e-48	0.71	0.62	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
LGG	cis	rs11647589	1	rs11647589	ENSG00000260762.1	ACSM5P1	17.17	9.54e-52	4.2e-48	0.77	0.62	Blood metabolite levels;	chr16:20438294	chr16:20586550~20607107:-
LGG	cis	rs4713118	0.699	rs573179	ENSG00000199851.2	U3	17.17	1.03e-51	4.52e-48	0.99	0.62	Parkinson's disease;	chr6:27881898	chr6:28015568~28015777:+
LGG	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	17.16	1.04e-51	4.56e-48	0.98	0.62	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	17.16	1.04e-51	4.56e-48	0.98	0.62	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	17.16	1.04e-51	4.56e-48	0.98	0.62	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	17.16	1.04e-51	4.56e-48	0.98	0.62	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	17.16	1.04e-51	4.56e-48	0.98	0.62	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	17.16	1.04e-51	4.56e-48	0.98	0.62	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
LGG	cis	rs853679	0.517	rs1340004	ENSG00000216901.1	AL022393.7	17.16	1.11e-51	4.88e-48	0.92	0.62	Depression;	chr6:28135913	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.699	rs200978	ENSG00000199851.2	U3	17.16	1.14e-51	5e-48	0.99	0.62	Parkinson's disease;	chr6:27885390	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	17.15	1.21e-51	5.3e-48	0.8	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
LGG	cis	rs6452524	0.618	rs1478487	ENSG00000248112.1	RP11-78C3.1	17.15	1.22e-51	5.34e-48	0.78	0.62	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:82919376~82921119:-
LGG	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	17.15	1.26e-51	5.5e-48	0.99	0.62	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
LGG	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	17.14	1.31e-51	5.74e-48	0.75	0.62	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
LGG	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-17.14	1.35e-51	5.93e-48	-0.76	-0.62	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
LGG	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	17.14	1.36e-51	5.97e-48	0.74	0.62	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
LGG	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-17.14	1.37e-51	5.99e-48	-0.73	-0.62	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
LGG	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	17.14	1.37e-51	6e-48	0.93	0.62	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
LGG	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-17.13	1.51e-51	6.59e-48	-0.68	-0.62	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-17.13	1.51e-51	6.59e-48	-0.68	-0.62	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
LGG	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	17.13	1.51e-51	6.61e-48	0.73	0.62	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
LGG	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-17.13	1.51e-51	6.62e-48	-0.66	-0.62	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
LGG	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	17.13	1.55e-51	6.79e-48	0.74	0.62	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
LGG	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-17.12	1.74e-51	7.61e-48	-0.66	-0.62	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
LGG	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-17.11	1.76e-51	7.68e-48	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
LGG	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-17.11	1.8e-51	7.86e-48	-0.65	-0.62	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
LGG	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	17.11	1.92e-51	8.36e-48	0.71	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
LGG	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-17.11	1.92e-51	8.36e-48	-0.7	-0.62	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
LGG	cis	rs6452524	0.618	rs6452501	ENSG00000248112.1	RP11-78C3.1	17.1	2e-51	8.71e-48	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:82919376~82921119:-
LGG	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-17.1	2.03e-51	8.82e-48	-0.66	-0.62	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-17.1	2.03e-51	8.82e-48	-0.66	-0.62	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
LGG	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-17.1	2.1e-51	9.12e-48	-0.89	-0.62	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
LGG	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	17.09	2.22e-51	9.67e-48	0.74	0.62	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	17.09	2.22e-51	9.67e-48	0.74	0.62	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	17.09	2.22e-51	9.67e-48	0.74	0.62	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	17.09	2.22e-51	9.67e-48	0.74	0.62	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
LGG	cis	rs853679	0.517	rs7755442	ENSG00000216901.1	AL022393.7	17.09	2.29e-51	9.94e-48	0.9	0.62	Depression;	chr6:28071237	chr6:28176188~28176674:+
LGG	cis	rs6452524	0.618	rs6452504	ENSG00000248112.1	RP11-78C3.1	17.09	2.33e-51	1.01e-47	0.77	0.62	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:82919376~82921119:-
LGG	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	17.09	2.35e-51	1.02e-47	0.72	0.62	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
LGG	cis	rs6452524	0.618	rs6452506	ENSG00000248112.1	RP11-78C3.1	17.09	2.4e-51	1.04e-47	0.77	0.62	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:82919376~82921119:-
LGG	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-17.08	2.48e-51	1.07e-47	-0.66	-0.62	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
LGG	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	17.08	2.56e-51	1.11e-47	0.79	0.62	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
LGG	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-17.08	2.6e-51	1.13e-47	-0.66	-0.62	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
LGG	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-17.08	2.64e-51	1.14e-47	-0.88	-0.62	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
LGG	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	17.08	2.64e-51	1.15e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
LGG	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	17.07	2.74e-51	1.19e-47	0.87	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
LGG	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	17.07	2.79e-51	1.21e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
LGG	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-17.07	2.81e-51	1.22e-47	-0.88	-0.62	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-17.07	2.81e-51	1.22e-47	-0.88	-0.62	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
LGG	cis	rs853679	0.517	rs55747925	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28076559	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs56310871	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28076704	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs34716816	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28078391	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380049	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28080757	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380050	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28080760	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393885	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28082231	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393886	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28082261	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.515	rs9368549	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Parkinson's disease;	chr6:28082269	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs56364346	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28082984	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9357061	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28083994	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368550	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28084025	chr6:28176188~28176674:+
LGG	cis	rs853679	0.542	rs2295594	ENSG00000216901.1	AL022393.7	17.07	2.86e-51	1.24e-47	0.9	0.62	Depression;	chr6:28085319	chr6:28176188~28176674:+
LGG	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	17.06	3e-51	1.3e-47	0.74	0.62	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
LGG	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	17.06	3.03e-51	1.31e-47	0.7	0.62	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
LGG	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	17.06	3.03e-51	1.31e-47	0.54	0.62	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
LGG	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	17.06	3.03e-51	1.31e-47	0.72	0.62	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
LGG	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	17.06	3.07e-51	1.32e-47	1	0.62	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
LGG	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-17.06	3.17e-51	1.37e-47	-0.8	-0.62	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
LGG	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	17.05	3.37e-51	1.45e-47	0.66	0.62	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
LGG	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	17.05	3.4e-51	1.46e-47	0.7	0.62	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	17.05	3.4e-51	1.46e-47	0.7	0.62	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
LGG	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	17.05	3.52e-51	1.52e-47	0.98	0.62	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
LGG	cis	rs853679	0.517	rs3757187	ENSG00000216901.1	AL022393.7	17.04	3.77e-51	1.62e-47	0.9	0.62	Depression;	chr6:28139876	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs3757185	ENSG00000216901.1	AL022393.7	17.04	3.77e-51	1.62e-47	0.9	0.62	Depression;	chr6:28139998	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-17.04	3.89e-51	1.67e-47	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
LGG	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	17.04	3.93e-51	1.69e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	17.04	3.93e-51	1.69e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	17.04	3.93e-51	1.69e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	17.04	3.93e-51	1.69e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
LGG	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	17.03	4.12e-51	1.77e-47	0.83	0.62	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
LGG	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	17.03	4.19e-51	1.8e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	17.03	4.19e-51	1.8e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	17.03	4.19e-51	1.8e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	17.03	4.19e-51	1.8e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-17.03	4.21e-51	1.81e-47	-0.77	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
LGG	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	17.03	4.25e-51	1.82e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
LGG	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-17.03	4.46e-51	1.91e-47	-0.83	-0.62	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
LGG	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-17.03	4.54e-51	1.94e-47	-0.89	-0.62	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-17.03	4.54e-51	1.94e-47	-0.89	-0.62	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
LGG	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	17.02	4.8e-51	2.05e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	17.02	4.83e-51	2.06e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
LGG	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-17.02	4.84e-51	2.07e-47	-0.69	-0.62	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
LGG	cis	rs11647589	0.636	rs7186805	ENSG00000260762.1	ACSM5P1	17.02	4.85e-51	2.07e-47	0.76	0.62	Blood metabolite levels;	chr16:20465841	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.636	rs7186307	ENSG00000260762.1	ACSM5P1	17.02	4.85e-51	2.07e-47	0.76	0.62	Blood metabolite levels;	chr16:20465843	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.834	rs6497491	ENSG00000260762.1	ACSM5P1	17.02	4.89e-51	2.09e-47	0.76	0.62	Blood metabolite levels;	chr16:20468691	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.834	rs1827711	ENSG00000260762.1	ACSM5P1	17.02	4.89e-51	2.09e-47	0.76	0.62	Blood metabolite levels;	chr16:20471046	chr16:20586550~20607107:-
LGG	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	17.02	4.98e-51	2.13e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
LGG	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-17.02	5.04e-51	2.15e-47	-0.67	-0.62	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
LGG	cis	rs853679	0.517	rs17711344	ENSG00000216901.1	AL022393.7	-17.01	5.15e-51	2.2e-47	-0.9	-0.62	Depression;	chr6:28109824	chr6:28176188~28176674:+
LGG	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-17.01	5.17e-51	2.2e-47	-0.79	-0.62	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
LGG	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	17.01	5.2e-51	2.22e-47	0.54	0.62	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
LGG	cis	rs853679	0.517	rs2273564	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28089816	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs1853097	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28090857	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393888	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28091439	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs3734573	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28091659	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9357063	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28092227	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs3823180	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28093966	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368551	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28094014	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393890	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28096077	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9366715	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28096855	chr6:28176188~28176674:+
LGG	cis	rs853679	0.598	rs9380054	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28099759	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.547	rs2116981	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Parkinson's disease;	chr6:28100173	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368552	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28100648	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs2281588	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28104824	chr6:28176188~28176674:+
LGG	cis	rs853679	0.542	rs34131763	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28107222	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs35193936	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28108492	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs36078605	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28110254	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393891	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28111382	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9468286	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28111650	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.516	rs7739216	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Parkinson's disease;	chr6:28112168	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs35512245	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28112175	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380055	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28113851	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368553	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28114487	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9368554	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28114933	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713137	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28115743	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9348793	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28116411	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.586	rs6905516	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Parkinson's disease;	chr6:28118700	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.586	rs6905522	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Parkinson's disease;	chr6:28118701	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.586	rs9468290	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Parkinson's disease;	chr6:28119896	chr6:28176188~28176674:+
LGG	cis	rs853679	0.542	rs6934769	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28123153	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs17711801	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28124529	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.527	rs9461433	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Parkinson's disease;	chr6:28127394	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9468292	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28127577	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs1947863	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28131566	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713141	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28133900	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380056	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28136698	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380057	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28136856	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs1947862	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28137418	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs6941992	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28138363	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.516	rs4713142	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Parkinson's disease;	chr6:28138569	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713143	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28138981	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs4713144	ENSG00000216901.1	AL022393.7	17.01	5.39e-51	2.29e-47	0.9	0.62	Depression;	chr6:28139012	chr6:28176188~28176674:+
LGG	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	17	5.7e-51	2.42e-47	0.73	0.62	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	17	5.7e-51	2.42e-47	0.7	0.62	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	17	5.7e-51	2.42e-47	0.7	0.62	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	17	5.7e-51	2.42e-47	0.7	0.62	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	17	5.7e-51	2.42e-47	0.7	0.62	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
LGG	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-17	5.9e-51	2.5e-47	-0.88	-0.62	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
LGG	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-17	6.05e-51	2.56e-47	-0.79	-0.62	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
LGG	cis	rs853679	0.517	rs9283884	ENSG00000216901.1	AL022393.7	-17	6.13e-51	2.6e-47	-0.92	-0.62	Depression;	chr6:28167882	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	17	6.17e-51	2.6e-47	0.7	0.62	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	17	6.22e-51	2.62e-47	0.7	0.62	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	17	6.22e-51	2.62e-47	0.7	0.62	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	17	6.22e-51	2.62e-47	0.7	0.62	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	17	6.22e-51	2.62e-47	0.7	0.62	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	17	6.22e-51	2.62e-47	0.7	0.62	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
LGG	cis	rs853679	0.517	rs6932109	ENSG00000216901.1	AL022393.7	-17	6.24e-51	2.63e-47	-0.89	-0.62	Depression;	chr6:28110525	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9380047	ENSG00000216901.1	AL022393.7	16.99	6.27e-51	2.64e-47	0.9	0.62	Depression;	chr6:28070115	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs9393895	ENSG00000216901.1	AL022393.7	16.99	6.47e-51	2.73e-47	0.9	0.62	Depression;	chr6:28159843	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	16.99	6.51e-51	2.74e-47	0.7	0.62	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
LGG	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	16.99	6.58e-51	2.77e-47	0.72	0.62	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
LGG	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	16.99	6.59e-51	2.78e-47	0.99	0.62	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
LGG	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-16.99	6.77e-51	2.85e-47	-0.65	-0.62	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
LGG	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	16.99	6.8e-51	2.86e-47	0.7	0.62	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	16.98	7.08e-51	2.98e-47	0.7	0.62	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	16.98	7.08e-51	2.98e-47	0.7	0.62	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	16.98	7.08e-51	2.98e-47	0.7	0.62	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	16.98	7.26e-51	3.05e-47	0.7	0.62	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
LGG	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-16.98	7.41e-51	3.11e-47	-0.88	-0.61	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
LGG	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	16.98	7.72e-51	3.24e-47	0.7	0.61	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	16.98	7.72e-51	3.24e-47	0.7	0.61	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	16.98	7.72e-51	3.24e-47	0.7	0.61	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	16.98	7.72e-51	3.24e-47	0.7	0.61	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	16.98	7.72e-51	3.24e-47	0.7	0.61	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	16.98	7.72e-51	3.24e-47	0.7	0.61	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	16.98	7.72e-51	3.24e-47	0.7	0.61	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
LGG	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-16.97	7.89e-51	3.31e-47	-0.92	-0.61	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
LGG	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-16.97	7.93e-51	3.32e-47	-0.66	-0.61	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
LGG	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	16.97	8.08e-51	3.39e-47	0.67	0.61	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
LGG	cis	rs11647589	0.642	rs1532842	ENSG00000260762.1	ACSM5P1	16.96	8.63e-51	3.62e-47	0.76	0.61	Blood metabolite levels;	chr16:20468067	chr16:20586550~20607107:-
LGG	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	16.95	9.58e-51	4e-47	0.7	0.61	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
LGG	cis	rs853679	0.517	rs9393884	ENSG00000216901.1	AL022393.7	16.95	9.77e-51	4.08e-47	0.89	0.61	Depression;	chr6:28079011	chr6:28176188~28176674:+
LGG	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	16.95	9.82e-51	4.1e-47	0.54	0.61	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
LGG	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	16.95	1.01e-50	4.21e-47	0.84	0.61	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	16.95	1.01e-50	4.21e-47	0.84	0.61	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	16.95	1.01e-50	4.21e-47	0.84	0.61	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
LGG	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-16.95	1.05e-50	4.39e-47	-1.11	-0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
LGG	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	16.95	1.05e-50	4.4e-47	0.86	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
LGG	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	16.95	1.05e-50	4.4e-47	0.86	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	16.94	1.14e-50	4.74e-47	0.75	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
LGG	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-16.94	1.14e-50	4.75e-47	-0.83	-0.61	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
LGG	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	16.94	1.17e-50	4.86e-47	0.7	0.61	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	16.93	1.19e-50	4.95e-47	0.69	0.61	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	16.93	1.19e-50	4.95e-47	0.69	0.61	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
LGG	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	16.93	1.2e-50	4.98e-47	0.73	0.61	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	16.93	1.21e-50	5.05e-47	0.7	0.61	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	16.93	1.21e-50	5.05e-47	0.7	0.61	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	16.93	1.27e-50	5.27e-47	0.7	0.61	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	16.93	1.27e-50	5.27e-47	0.7	0.61	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	16.93	1.27e-50	5.27e-47	0.7	0.61	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	16.93	1.27e-50	5.27e-47	0.7	0.61	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	16.93	1.28e-50	5.3e-47	0.69	0.61	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
LGG	cis	rs11647589	0.642	rs7193826	ENSG00000260762.1	ACSM5P1	16.92	1.4e-50	5.78e-47	0.76	0.61	Blood metabolite levels;	chr16:20467260	chr16:20586550~20607107:-
LGG	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	16.92	1.4e-50	5.79e-47	0.84	0.61	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
LGG	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	16.92	1.45e-50	5.98e-47	0.87	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
LGG	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	16.92	1.45e-50	5.98e-47	0.87	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
LGG	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	16.92	1.45e-50	6e-47	1.09	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	16.91	1.47e-50	6.03e-47	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
LGG	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-16.91	1.49e-50	6.13e-47	-0.79	-0.61	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
LGG	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	16.91	1.52e-50	6.24e-47	0.87	0.61	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
LGG	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	16.91	1.52e-50	6.25e-47	0.73	0.61	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	16.91	1.52e-50	6.25e-47	0.73	0.61	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
LGG	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	16.91	1.53e-50	6.3e-47	0.65	0.61	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
LGG	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	16.91	1.56e-50	6.38e-47	0.73	0.61	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	16.91	1.56e-50	6.39e-47	0.69	0.61	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	16.91	1.56e-50	6.39e-47	0.69	0.61	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	16.91	1.56e-50	6.39e-47	0.69	0.61	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	16.91	1.56e-50	6.39e-47	0.69	0.61	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	16.91	1.56e-50	6.39e-47	0.69	0.61	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
LGG	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-16.9	1.7e-50	6.95e-47	-0.77	-0.61	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
LGG	cis	rs853679	0.517	rs9393887	ENSG00000216901.1	AL022393.7	16.9	1.81e-50	7.38e-47	0.89	0.61	Depression;	chr6:28091242	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs6922063	ENSG00000216901.1	AL022393.7	16.9	1.81e-50	7.38e-47	0.89	0.61	Depression;	chr6:28126588	chr6:28176188~28176674:+
LGG	cis	rs853679	0.517	rs2275508	ENSG00000216901.1	AL022393.7	16.9	1.81e-50	7.38e-47	0.89	0.61	Depression;	chr6:28126953	chr6:28176188~28176674:+
LGG	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	16.89	1.83e-50	7.49e-47	0.73	0.61	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	16.89	1.83e-50	7.49e-47	0.73	0.61	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
LGG	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	16.89	1.95e-50	7.95e-47	0.53	0.61	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
LGG	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	16.89	1.98e-50	8.06e-47	0.86	0.61	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
LGG	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	16.88	2.04e-50	8.33e-47	0.74	0.61	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
LGG	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	16.88	2.06e-50	8.38e-47	0.71	0.61	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
LGG	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	16.88	2.06e-50	8.38e-47	0.73	0.61	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
LGG	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	16.88	2.09e-50	8.52e-47	0.71	0.61	Height;	chr11:118703185	chr11:118688039~118690600:-
LGG	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	16.88	2.09e-50	8.52e-47	0.71	0.61	Height;	chr11:118703207	chr11:118688039~118690600:-
LGG	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	16.88	2.09e-50	8.52e-47	0.71	0.61	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
LGG	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	16.88	2.16e-50	8.79e-47	0.73	0.61	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
LGG	cis	rs11647589	0.834	rs2271060	ENSG00000260762.1	ACSM5P1	16.88	2.23e-50	9.06e-47	0.76	0.61	Blood metabolite levels;	chr16:20471301	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.834	rs2271061	ENSG00000260762.1	ACSM5P1	16.88	2.23e-50	9.06e-47	0.76	0.61	Blood metabolite levels;	chr16:20471429	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.834	rs1700801	ENSG00000260762.1	ACSM5P1	16.88	2.23e-50	9.06e-47	0.76	0.61	Blood metabolite levels;	chr16:20474158	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.834	rs1354577	ENSG00000260762.1	ACSM5P1	16.88	2.23e-50	9.06e-47	0.76	0.61	Blood metabolite levels;	chr16:20474341	chr16:20586550~20607107:-
LGG	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-16.87	2.27e-50	9.21e-47	-0.69	-0.61	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
LGG	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	16.87	2.27e-50	9.23e-47	0.99	0.61	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
LGG	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	16.87	2.37e-50	9.63e-47	0.73	0.61	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	16.87	2.4e-50	9.73e-47	0.72	0.61	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
LGG	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	16.87	2.41e-50	9.77e-47	0.81	0.61	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
LGG	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	16.87	2.45e-50	9.93e-47	0.87	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
LGG	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	16.87	2.46e-50	9.98e-47	0.93	0.61	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
LGG	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	16.87	2.48e-50	1.01e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	16.87	2.48e-50	1.01e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
LGG	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-16.86	2.51e-50	1.02e-46	-0.82	-0.61	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
LGG	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	16.86	2.61e-50	1.06e-46	1.09	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
LGG	cis	rs4713118	0.699	rs200969	ENSG00000199851.2	U3	16.86	2.75e-50	1.12e-46	0.96	0.61	Parkinson's disease;	chr6:27891675	chr6:28015568~28015777:+
LGG	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	16.85	2.78e-50	1.13e-46	0.69	0.61	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	16.85	2.78e-50	1.13e-46	0.69	0.61	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	16.85	2.78e-50	1.13e-46	0.69	0.61	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
LGG	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	16.85	2.86e-50	1.16e-46	0.73	0.61	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	16.85	2.86e-50	1.16e-46	0.73	0.61	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	16.85	2.86e-50	1.16e-46	0.73	0.61	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
LGG	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	16.85	2.97e-50	1.2e-46	0.84	0.61	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
LGG	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	16.85	2.99e-50	1.21e-46	0.98	0.61	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	16.85	3e-50	1.21e-46	0.97	0.61	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	16.85	3e-50	1.21e-46	0.97	0.61	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
LGG	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	16.84	3.07e-50	1.24e-46	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
LGG	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-16.84	3.12e-50	1.26e-46	-0.67	-0.61	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
LGG	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	16.84	3.21e-50	1.3e-46	0.84	0.61	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
LGG	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	16.84	3.33e-50	1.34e-46	0.73	0.61	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	16.84	3.33e-50	1.34e-46	0.73	0.61	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	16.84	3.33e-50	1.34e-46	0.73	0.61	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	16.84	3.33e-50	1.34e-46	0.73	0.61	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
LGG	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	16.84	3.4e-50	1.37e-46	0.54	0.61	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
LGG	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-16.84	3.41e-50	1.38e-46	-0.73	-0.61	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
LGG	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-16.83	3.6e-50	1.45e-46	-0.72	-0.61	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
LGG	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	16.83	3.64e-50	1.47e-46	0.83	0.61	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	16.83	3.64e-50	1.47e-46	0.83	0.61	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
LGG	cis	rs853679	0.517	rs4713145	ENSG00000216901.1	AL022393.7	16.83	3.66e-50	1.48e-46	0.9	0.61	Depression;	chr6:28139049	chr6:28176188~28176674:+
LGG	cis	rs853679	0.542	rs9393892	ENSG00000216901.1	AL022393.7	16.83	3.75e-50	1.51e-46	0.89	0.61	Depression;	chr6:28113616	chr6:28176188~28176674:+
LGG	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-16.83	3.78e-50	1.52e-46	-0.7	-0.61	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
LGG	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	16.82	3.82e-50	1.54e-46	0.67	0.61	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
LGG	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	16.82	3.86e-50	1.55e-46	0.73	0.61	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
LGG	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	16.81	4.24e-50	1.71e-46	0.79	0.61	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
LGG	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	16.81	4.45e-50	1.79e-46	0.69	0.61	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	16.81	4.56e-50	1.83e-46	0.69	0.61	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	16.81	4.56e-50	1.83e-46	0.69	0.61	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
LGG	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	16.81	4.64e-50	1.86e-46	0.73	0.61	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	16.81	4.64e-50	1.86e-46	0.73	0.61	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	16.81	4.64e-50	1.86e-46	0.73	0.61	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	16.81	4.64e-50	1.86e-46	0.73	0.61	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	16.81	4.64e-50	1.86e-46	0.73	0.61	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	16.81	4.64e-50	1.86e-46	0.73	0.61	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	16.81	4.64e-50	1.86e-46	0.73	0.61	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
LGG	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-16.79	5.41e-50	2.17e-46	-0.54	-0.61	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
LGG	cis	rs853679	0.628	rs9368560	ENSG00000199851.2	U3	16.79	5.52e-50	2.21e-46	1.02	0.61	Depression;	chr6:28192182	chr6:28015568~28015777:+
LGG	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	16.79	5.57e-50	2.23e-46	0.52	0.61	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
LGG	cis	rs853679	0.628	rs9368560	ENSG00000216901.1	AL022393.7	16.79	5.59e-50	2.24e-46	0.91	0.61	Depression;	chr6:28192182	chr6:28176188~28176674:+
LGG	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-16.79	5.74e-50	2.3e-46	-0.65	-0.61	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
LGG	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	16.79	5.76e-50	2.31e-46	0.71	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	16.79	5.76e-50	2.31e-46	0.71	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
LGG	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	16.79	5.77e-50	2.31e-46	0.72	0.61	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
LGG	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	16.78	5.97e-50	2.39e-46	0.53	0.61	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
LGG	cis	rs11647589	0.834	rs9933872	ENSG00000260762.1	ACSM5P1	16.78	6e-50	2.4e-46	0.76	0.61	Blood metabolite levels;	chr16:20473849	chr16:20586550~20607107:-
LGG	cis	rs853679	0.517	rs12174753	ENSG00000216901.1	AL022393.7	16.78	6e-50	2.4e-46	0.89	0.61	Depression;	chr6:28074687	chr6:28176188~28176674:+
LGG	cis	rs11647589	0.553	rs7195201	ENSG00000260762.1	ACSM5P1	16.77	6.63e-50	2.65e-46	0.76	0.61	Blood metabolite levels;	chr16:20467280	chr16:20586550~20607107:-
LGG	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	16.77	6.72e-50	2.69e-46	0.81	0.61	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
LGG	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	16.76	7.22e-50	2.88e-46	0.72	0.61	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
LGG	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	16.76	7.31e-50	2.92e-46	0.7	0.61	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
LGG	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	16.76	7.31e-50	2.92e-46	0.7	0.61	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
LGG	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	16.76	7.6e-50	3.03e-46	0.52	0.61	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
LGG	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	16.76	7.68e-50	3.06e-46	0.72	0.61	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	16.76	7.68e-50	3.06e-46	0.72	0.61	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
LGG	cis	rs11647589	0.834	rs9806821	ENSG00000260762.1	ACSM5P1	16.75	8.08e-50	3.22e-46	0.76	0.61	Blood metabolite levels;	chr16:20473857	chr16:20586550~20607107:-
LGG	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	16.75	8.31e-50	3.31e-46	0.76	0.61	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
LGG	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	16.74	9.01e-50	3.59e-46	0.65	0.61	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
LGG	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	16.74	9.32e-50	3.71e-46	0.82	0.61	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-16.74	9.32e-50	3.71e-46	-0.82	-0.61	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
LGG	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	16.74	9.44e-50	3.76e-46	0.87	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
LGG	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-16.73	9.96e-50	3.96e-46	-0.74	-0.61	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
LGG	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-16.73	1.01e-49	4.01e-46	-0.88	-0.61	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
LGG	cis	rs11647589	0.552	rs1632600	ENSG00000260762.1	ACSM5P1	16.73	1.05e-49	4.17e-46	0.76	0.61	Blood metabolite levels;	chr16:20476182	chr16:20586550~20607107:-
LGG	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	16.73	1.05e-49	4.18e-46	0.71	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
LGG	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-16.73	1.05e-49	4.19e-46	-0.73	-0.61	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
LGG	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-16.73	1.07e-49	4.24e-46	-0.65	-0.61	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
LGG	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-16.73	1.08e-49	4.3e-46	-0.67	-0.61	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
LGG	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	16.73	1.08e-49	4.31e-46	0.73	0.61	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
LGG	cis	rs11647589	0.641	rs9922446	ENSG00000260762.1	ACSM5P1	16.72	1.1e-49	4.38e-46	0.76	0.61	Blood metabolite levels;	chr16:20470093	chr16:20586550~20607107:-
LGG	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	16.72	1.11e-49	4.4e-46	0.82	0.61	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	16.72	1.11e-49	4.4e-46	0.82	0.61	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	16.72	1.11e-49	4.4e-46	0.82	0.61	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	16.72	1.11e-49	4.4e-46	0.82	0.61	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
LGG	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	16.72	1.14e-49	4.54e-46	0.7	0.61	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	16.72	1.18e-49	4.68e-46	0.69	0.61	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	16.72	1.18e-49	4.69e-46	0.69	0.61	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
LGG	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-16.71	1.21e-49	4.82e-46	-0.86	-0.61	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-16.71	1.21e-49	4.82e-46	-0.86	-0.61	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
LGG	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-16.71	1.25e-49	4.96e-46	-0.66	-0.61	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-16.71	1.25e-49	4.96e-46	-0.66	-0.61	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-16.71	1.32e-49	5.21e-46	-0.65	-0.61	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
LGG	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	16.71	1.32e-49	5.25e-46	0.81	0.61	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
LGG	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-16.71	1.33e-49	5.25e-46	-0.69	-0.61	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
LGG	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	16.71	1.34e-49	5.29e-46	1.09	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
LGG	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	16.7	1.35e-49	5.33e-46	0.82	0.61	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
LGG	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-16.7	1.39e-49	5.51e-46	-0.58	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
LGG	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-16.7	1.42e-49	5.61e-46	-0.88	-0.61	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
LGG	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	16.7	1.48e-49	5.85e-46	0.86	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
LGG	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-16.7	1.49e-49	5.87e-46	-0.74	-0.61	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
LGG	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-16.69	1.51e-49	5.98e-46	-0.75	-0.61	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
LGG	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-16.69	1.52e-49	6.02e-46	-0.64	-0.61	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
LGG	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	16.69	1.61e-49	6.35e-46	0.54	0.61	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
LGG	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	16.69	1.62e-49	6.39e-46	0.7	0.61	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
LGG	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-16.69	1.63e-49	6.43e-46	-0.86	-0.61	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
LGG	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-16.69	1.65e-49	6.5e-46	-0.72	-0.61	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
LGG	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	16.68	1.67e-49	6.56e-46	0.52	0.61	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
LGG	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-16.68	1.81e-49	7.11e-46	-0.82	-0.61	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
LGG	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-16.68	1.85e-49	7.26e-46	-0.72	-0.61	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
LGG	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-16.68	1.85e-49	7.26e-46	-0.72	-0.61	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
LGG	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	16.67	1.86e-49	7.31e-46	0.86	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
LGG	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-16.67	1.86e-49	7.32e-46	-0.72	-0.61	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
LGG	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-16.67	1.86e-49	7.33e-46	-0.83	-0.61	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-16.67	1.86e-49	7.33e-46	-0.83	-0.61	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
LGG	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-16.67	1.9e-49	7.49e-46	-0.65	-0.61	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
LGG	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-16.67	1.92e-49	7.54e-46	-0.68	-0.61	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
LGG	cis	rs172166	0.637	rs1233708	ENSG00000199851.2	U3	16.67	1.96e-49	7.69e-46	0.9	0.61	Cardiac Troponin-T levels;	chr6:28205441	chr6:28015568~28015777:+
LGG	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	16.67	1.97e-49	7.74e-46	0.95	0.61	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	16.67	1.97e-49	7.74e-46	0.95	0.61	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	16.67	1.97e-49	7.74e-46	0.95	0.61	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	16.67	1.97e-49	7.74e-46	0.95	0.61	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	16.67	1.97e-49	7.74e-46	0.95	0.61	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	16.67	1.97e-49	7.74e-46	0.95	0.61	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
LGG	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	16.67	1.98e-49	7.77e-46	0.86	0.61	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
LGG	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	16.66	2.14e-49	8.38e-46	0.53	0.61	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
LGG	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-16.66	2.16e-49	8.46e-46	-0.87	-0.61	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
LGG	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	16.66	2.17e-49	8.53e-46	0.86	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
LGG	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-16.66	2.24e-49	8.8e-46	-0.74	-0.61	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
LGG	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-16.66	2.26e-49	8.86e-46	-0.74	-0.61	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-16.66	2.26e-49	8.86e-46	-0.74	-0.61	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-16.66	2.26e-49	8.86e-46	-0.74	-0.61	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
LGG	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	16.65	2.29e-49	8.97e-46	0.82	0.61	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
LGG	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	16.65	2.35e-49	9.23e-46	0.78	0.61	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
LGG	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-16.65	2.4e-49	9.39e-46	-0.66	-0.61	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
LGG	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-16.65	2.42e-49	9.48e-46	-0.73	-0.61	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
LGG	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	16.65	2.46e-49	9.63e-46	0.73	0.61	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
LGG	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-16.65	2.49e-49	9.76e-46	-0.72	-0.61	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
LGG	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	16.64	2.58e-49	1.01e-45	0.7	0.61	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
LGG	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-16.64	2.58e-49	1.01e-45	-0.93	-0.61	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
LGG	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	16.64	2.61e-49	1.02e-45	0.73	0.61	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	16.64	2.61e-49	1.02e-45	0.73	0.61	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
LGG	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-16.64	2.71e-49	1.06e-45	-0.66	-0.61	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-16.64	2.71e-49	1.06e-45	-0.66	-0.61	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-16.64	2.71e-49	1.06e-45	-0.66	-0.61	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	16.64	2.78e-49	1.09e-45	0.65	0.61	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
LGG	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	16.64	2.79e-49	1.09e-45	0.81	0.61	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
LGG	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	16.63	2.87e-49	1.12e-45	0.86	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
LGG	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	16.63	3.04e-49	1.19e-45	0.84	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
LGG	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-16.63	3.1e-49	1.21e-45	-0.72	-0.61	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
LGG	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-16.63	3.12e-49	1.22e-45	-0.52	-0.61	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
LGG	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	16.62	3.21e-49	1.25e-45	1.09	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	16.62	3.21e-49	1.25e-45	1.09	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
LGG	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-16.62	3.23e-49	1.26e-45	-0.66	-0.61	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
LGG	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	16.62	3.34e-49	1.3e-45	0.96	0.61	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
LGG	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	16.61	3.55e-49	1.38e-45	0.79	0.61	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
LGG	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-16.61	3.86e-49	1.5e-45	-0.86	-0.61	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
LGG	cis	rs11647589	0.834	rs1505100	ENSG00000260762.1	ACSM5P1	-16.6	4.24e-49	1.65e-45	-0.75	-0.61	Blood metabolite levels;	chr16:20470350	chr16:20586550~20607107:-
LGG	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	16.59	4.35e-49	1.69e-45	0.7	0.61	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
LGG	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	16.59	4.46e-49	1.73e-45	0.82	0.61	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
LGG	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-16.59	4.69e-49	1.82e-45	-0.82	-0.61	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
LGG	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	16.59	4.76e-49	1.85e-45	0.73	0.61	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	16.59	4.76e-49	1.85e-45	0.73	0.61	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
LGG	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-16.58	4.86e-49	1.89e-45	-0.73	-0.61	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
LGG	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	16.58	5.02e-49	1.95e-45	0.72	0.61	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	16.58	5.02e-49	1.95e-45	0.72	0.61	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
LGG	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-16.58	5.19e-49	2.01e-45	-0.68	-0.61	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
LGG	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	16.58	5.21e-49	2.02e-45	0.71	0.61	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
LGG	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-16.57	5.31e-49	2.06e-45	-0.73	-0.61	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
LGG	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-16.57	5.48e-49	2.12e-45	-0.72	-0.61	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
LGG	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	16.57	5.69e-49	2.2e-45	0.95	0.61	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
LGG	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-16.57	5.86e-49	2.27e-45	-0.57	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
LGG	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	16.57	5.87e-49	2.27e-45	0.81	0.61	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
LGG	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-16.56	5.91e-49	2.29e-45	-0.65	-0.61	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
LGG	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	16.56	5.92e-49	2.29e-45	0.75	0.61	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
LGG	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	16.56	6.09e-49	2.35e-45	0.95	0.61	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	16.56	6.09e-49	2.35e-45	0.95	0.61	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
LGG	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	16.56	6.09e-49	2.35e-45	0.95	0.61	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
LGG	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-16.56	6.28e-49	2.43e-45	-0.66	-0.61	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
LGG	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	16.56	6.41e-49	2.48e-45	0.7	0.61	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
LGG	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-16.55	6.81e-49	2.63e-45	-0.72	-0.61	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
LGG	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	16.55	6.93e-49	2.68e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
LGG	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-16.54	7.27e-49	2.81e-45	-0.86	-0.61	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
LGG	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-16.54	7.42e-49	2.86e-45	-0.89	-0.61	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
LGG	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	16.54	7.61e-49	2.93e-45	0.53	0.6	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
LGG	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-16.54	7.64e-49	2.95e-45	-0.87	-0.6	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
LGG	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-16.54	7.76e-49	2.99e-45	-0.86	-0.6	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
LGG	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	16.54	7.8e-49	3.01e-45	0.7	0.6	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
LGG	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	16.54	7.93e-49	3.05e-45	0.53	0.6	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
LGG	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	16.53	8.34e-49	3.21e-45	0.66	0.6	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
LGG	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	16.53	8.66e-49	3.34e-45	0.79	0.6	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
LGG	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	16.53	8.77e-49	3.38e-45	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
LGG	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-16.52	9.02e-49	3.47e-45	-0.81	-0.6	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
LGG	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	16.52	9.14e-49	3.52e-45	0.73	0.6	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	16.52	9.63e-49	3.7e-45	0.7	0.6	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	16.52	9.63e-49	3.7e-45	0.7	0.6	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	16.52	9.63e-49	3.7e-45	0.7	0.6	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
LGG	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-16.52	9.65e-49	3.71e-45	-0.95	-0.6	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
LGG	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	16.52	9.83e-49	3.78e-45	0.72	0.6	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
LGG	cis	rs4713118	0.587	rs61471148	ENSG00000216901.1	AL022393.7	16.51	1e-48	3.84e-45	0.89	0.6	Parkinson's disease;	chr6:28069254	chr6:28176188~28176674:+
LGG	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	16.51	1.08e-48	4.15e-45	0.82	0.6	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
LGG	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	16.51	1.08e-48	4.15e-45	0.7	0.6	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	16.51	1.09e-48	4.17e-45	0.79	0.6	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
LGG	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	16.5	1.13e-48	4.35e-45	1.09	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
LGG	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	16.5	1.13e-48	4.36e-45	0.72	0.6	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	16.5	1.16e-48	4.45e-45	0.78	0.6	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
LGG	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-16.5	1.16e-48	4.45e-45	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
LGG	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	16.5	1.21e-48	4.64e-45	0.74	0.6	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
LGG	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	16.49	1.25e-48	4.8e-45	0.99	0.6	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
LGG	cis	rs79349575	0.721	rs9904645	ENSG00000248278.1	SUMO2P17	16.49	1.27e-48	4.87e-45	0.69	0.6	Type 2 diabetes;	chr17:48892303	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.594	rs1985785	ENSG00000248278.1	SUMO2P17	16.49	1.31e-48	5.01e-45	0.69	0.6	Type 2 diabetes;	chr17:48890426	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.685	rs1124829	ENSG00000248278.1	SUMO2P17	16.49	1.31e-48	5.01e-45	0.69	0.6	Type 2 diabetes;	chr17:48890435	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.721	rs1008834	ENSG00000248278.1	SUMO2P17	16.49	1.31e-48	5.01e-45	0.69	0.6	Type 2 diabetes;	chr17:48890646	chr17:48874860~48908983:-
LGG	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-16.49	1.32e-48	5.06e-45	-0.82	-0.6	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
LGG	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-16.49	1.34e-48	5.14e-45	-0.86	-0.6	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
LGG	cis	rs79349575	0.87	rs12941262	ENSG00000248278.1	SUMO2P17	16.49	1.35e-48	5.16e-45	0.69	0.6	Type 2 diabetes;	chr17:48889675	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.778	rs12950328	ENSG00000248278.1	SUMO2P17	16.49	1.35e-48	5.16e-45	0.69	0.6	Type 2 diabetes;	chr17:48889699	chr17:48874860~48908983:-
LGG	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	16.49	1.36e-48	5.22e-45	0.86	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
LGG	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	16.48	1.42e-48	5.44e-45	0.7	0.6	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	16.48	1.42e-48	5.44e-45	0.7	0.6	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	16.48	1.42e-48	5.44e-45	0.7	0.6	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
LGG	cis	rs11647589	0.641	rs1394676	ENSG00000260762.1	ACSM5P1	16.48	1.44e-48	5.49e-45	0.74	0.6	Blood metabolite levels;	chr16:20477880	chr16:20586550~20607107:-
LGG	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-16.48	1.51e-48	5.76e-45	-0.73	-0.6	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
LGG	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	16.47	1.63e-48	6.23e-45	0.8	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
LGG	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	16.47	1.64e-48	6.25e-45	0.86	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
LGG	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	16.47	1.66e-48	6.35e-45	0.97	0.6	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
LGG	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-16.47	1.66e-48	6.35e-45	-0.65	-0.6	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
LGG	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	16.46	1.7e-48	6.48e-45	0.68	0.6	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
LGG	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	16.46	1.7e-48	6.51e-45	0.86	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
LGG	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-16.46	1.82e-48	6.94e-45	-0.77	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
LGG	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-16.46	1.82e-48	6.94e-45	-0.92	-0.6	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
LGG	cis	rs79349575	0.749	rs519537	ENSG00000248278.1	SUMO2P17	16.46	1.82e-48	6.94e-45	0.69	0.6	Type 2 diabetes;	chr17:48893778	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs832410	ENSG00000248278.1	SUMO2P17	16.46	1.82e-48	6.94e-45	0.69	0.6	Type 2 diabetes;	chr17:48895503	chr17:48874860~48908983:-
LGG	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	16.45	2e-48	7.63e-45	0.77	0.6	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
LGG	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-16.44	2.11e-48	8.01e-45	-0.74	-0.6	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
LGG	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	16.44	2.11e-48	8.02e-45	0.7	0.6	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	16.44	2.11e-48	8.02e-45	0.7	0.6	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	16.44	2.11e-48	8.02e-45	0.7	0.6	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
LGG	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	-16.44	2.13e-48	8.11e-45	-0.62	-0.6	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
LGG	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	16.44	2.16e-48	8.22e-45	0.7	0.6	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	16.44	2.16e-48	8.22e-45	0.7	0.6	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
LGG	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	16.44	2.17e-48	8.23e-45	0.53	0.6	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
LGG	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	16.44	2.17e-48	8.26e-45	0.69	0.6	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
LGG	cis	rs79349575	0.783	rs28409394	ENSG00000248278.1	SUMO2P17	16.44	2.23e-48	8.46e-45	0.68	0.6	Type 2 diabetes;	chr17:48920756	chr17:48874860~48908983:-
LGG	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-16.44	2.23e-48	8.48e-45	-0.85	-0.6	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-16.44	2.23e-48	8.48e-45	-0.85	-0.6	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
LGG	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	16.44	2.24e-48	8.5e-45	0.64	0.6	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
LGG	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	16.44	2.24e-48	8.52e-45	0.78	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
LGG	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	16.44	2.24e-48	8.52e-45	0.78	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
LGG	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	16.44	2.24e-48	8.52e-45	0.78	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
LGG	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-16.43	2.43e-48	9.22e-45	-0.85	-0.6	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
LGG	cis	rs79349575	0.777	rs28517720	ENSG00000248278.1	SUMO2P17	16.43	2.51e-48	9.51e-45	0.69	0.6	Type 2 diabetes;	chr17:48899394	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.756	rs2643361	ENSG00000248278.1	SUMO2P17	16.43	2.51e-48	9.51e-45	0.69	0.6	Type 2 diabetes;	chr17:48900100	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.749	rs2546491	ENSG00000248278.1	SUMO2P17	16.43	2.51e-48	9.51e-45	0.69	0.6	Type 2 diabetes;	chr17:48900554	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs962272	ENSG00000248278.1	SUMO2P17	16.43	2.51e-48	9.51e-45	0.69	0.6	Type 2 diabetes;	chr17:48900921	chr17:48874860~48908983:-
LGG	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	16.43	2.55e-48	9.66e-45	0.72	0.6	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
LGG	cis	rs79349575	0.783	rs318095	ENSG00000248278.1	SUMO2P17	16.43	2.55e-48	9.67e-45	0.69	0.6	Type 2 diabetes;	chr17:48897372	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs318096	ENSG00000248278.1	SUMO2P17	16.43	2.55e-48	9.67e-45	0.69	0.6	Type 2 diabetes;	chr17:48898008	chr17:48874860~48908983:-
LGG	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	16.42	2.57e-48	9.73e-45	0.71	0.6	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
LGG	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	16.42	2.59e-48	9.8e-45	0.7	0.6	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	16.42	2.79e-48	1.06e-44	0.7	0.6	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	16.42	2.79e-48	1.06e-44	0.7	0.6	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	16.42	2.79e-48	1.06e-44	0.7	0.6	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
LGG	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	16.42	2.8e-48	1.06e-44	0.64	0.6	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
LGG	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-16.42	2.83e-48	1.07e-44	-0.87	-0.6	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
LGG	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	16.41	3.1e-48	1.17e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
LGG	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	16.41	3.11e-48	1.17e-44	0.53	0.6	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
LGG	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	16.41	3.16e-48	1.19e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	16.41	3.16e-48	1.19e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	16.4	3.22e-48	1.22e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	16.4	3.22e-48	1.22e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	16.4	3.22e-48	1.22e-44	1.08	0.6	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	16.4	3.24e-48	1.22e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	16.4	3.24e-48	1.22e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	16.4	3.27e-48	1.23e-44	1.08	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	16.4	3.36e-48	1.27e-44	1.08	0.6	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
LGG	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-16.39	3.65e-48	1.38e-44	-0.85	-0.6	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
LGG	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	16.39	3.74e-48	1.41e-44	0.7	0.6	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
LGG	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-16.39	3.82e-48	1.44e-44	-0.92	-0.6	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
LGG	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	16.39	3.86e-48	1.45e-44	0.77	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
LGG	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	16.38	3.96e-48	1.49e-44	0.84	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
LGG	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-16.38	3.97e-48	1.49e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
LGG	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	16.38	4e-48	1.5e-44	0.64	0.6	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	16.38	4e-48	1.5e-44	0.64	0.6	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
LGG	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	16.38	4.11e-48	1.54e-44	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
LGG	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-16.37	4.43e-48	1.66e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
LGG	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-16.37	4.44e-48	1.66e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-16.37	4.44e-48	1.66e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-16.37	4.44e-48	1.66e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-16.37	4.44e-48	1.66e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
LGG	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-16.37	4.59e-48	1.72e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
LGG	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	16.37	4.68e-48	1.75e-44	0.85	0.6	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
LGG	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	16.37	4.79e-48	1.79e-44	0.78	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
LGG	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-16.36	4.88e-48	1.82e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
LGG	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-16.36	4.89e-48	1.83e-44	-0.82	-0.6	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
LGG	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-16.36	4.97e-48	1.86e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
LGG	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-16.35	5.47e-48	2.04e-44	-0.76	-0.6	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
LGG	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	16.35	5.53e-48	2.06e-44	0.52	0.6	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
LGG	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	16.35	5.58e-48	2.08e-44	0.87	0.6	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
LGG	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-16.35	5.63e-48	2.1e-44	-0.78	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
LGG	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-16.35	5.63e-48	2.1e-44	-0.78	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
LGG	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-16.35	5.63e-48	2.1e-44	-0.78	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
LGG	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	16.35	5.64e-48	2.11e-44	0.94	0.6	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
LGG	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	16.35	5.72e-48	2.13e-44	0.69	0.6	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	16.35	5.72e-48	2.13e-44	0.69	0.6	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	16.35	5.72e-48	2.13e-44	0.69	0.6	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	16.35	5.72e-48	2.13e-44	0.69	0.6	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	16.35	5.72e-48	2.13e-44	0.69	0.6	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	16.35	5.72e-48	2.13e-44	0.69	0.6	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
LGG	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	16.35	5.87e-48	2.19e-44	0.94	0.6	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
LGG	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-16.34	5.97e-48	2.22e-44	-0.64	-0.6	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-16.34	5.97e-48	2.22e-44	-0.64	-0.6	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
LGG	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-16.34	6.02e-48	2.24e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
LGG	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-16.34	6.27e-48	2.34e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-16.34	6.27e-48	2.34e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-16.34	6.27e-48	2.34e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
LGG	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	16.34	6.37e-48	2.37e-44	0.94	0.6	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
LGG	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	16.34	6.39e-48	2.38e-44	0.73	0.6	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	16.34	6.39e-48	2.38e-44	0.73	0.6	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
LGG	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-16.34	6.48e-48	2.41e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
LGG	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-16.33	6.73e-48	2.5e-44	-0.65	-0.6	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-16.33	6.73e-48	2.5e-44	-0.65	-0.6	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-16.33	6.73e-48	2.5e-44	-0.65	-0.6	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
LGG	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	16.33	6.86e-48	2.55e-44	0.96	0.6	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
LGG	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	16.33	7.07e-48	2.63e-44	0.78	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
LGG	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-16.33	7.18e-48	2.67e-44	-0.65	-0.6	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
LGG	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-16.33	7.26e-48	2.69e-44	-0.74	-0.6	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-16.33	7.26e-48	2.69e-44	-0.74	-0.6	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
LGG	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	16.33	7.27e-48	2.7e-44	0.77	0.6	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
LGG	cis	rs11647589	0.834	rs4603548	ENSG00000260762.1	ACSM5P1	16.33	7.29e-48	2.71e-44	0.75	0.6	Blood metabolite levels;	chr16:20472639	chr16:20586550~20607107:-
LGG	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-16.33	7.32e-48	2.72e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-16.33	7.32e-48	2.72e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
LGG	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-16.32	7.37e-48	2.73e-44	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
LGG	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	16.32	7.9e-48	2.93e-44	0.65	0.6	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
LGG	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-16.32	7.96e-48	2.95e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
LGG	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-16.32	7.98e-48	2.95e-44	-0.65	-0.6	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-16.32	7.98e-48	2.95e-44	-0.65	-0.6	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-16.32	7.98e-48	2.95e-44	-0.65	-0.6	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-16.32	7.98e-48	2.95e-44	-0.65	-0.6	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-16.32	7.98e-48	2.95e-44	-0.65	-0.6	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-16.32	7.98e-48	2.95e-44	-0.65	-0.6	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
LGG	cis	rs79349575	0.783	rs62075818	ENSG00000248278.1	SUMO2P17	16.32	8.02e-48	2.97e-44	0.68	0.6	Type 2 diabetes;	chr17:48904965	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs9912829	ENSG00000248278.1	SUMO2P17	16.32	8.02e-48	2.97e-44	0.68	0.6	Type 2 diabetes;	chr17:48905387	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs62075820	ENSG00000248278.1	SUMO2P17	16.32	8.02e-48	2.97e-44	0.68	0.6	Type 2 diabetes;	chr17:48905809	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4294857	ENSG00000248278.1	SUMO2P17	16.32	8.02e-48	2.97e-44	0.68	0.6	Type 2 diabetes;	chr17:48906029	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs61576918	ENSG00000248278.1	SUMO2P17	16.32	8.02e-48	2.97e-44	0.68	0.6	Type 2 diabetes;	chr17:48908231	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs903567	ENSG00000248278.1	SUMO2P17	16.32	8.05e-48	2.98e-44	0.68	0.6	Type 2 diabetes;	chr17:48902956	chr17:48874860~48908983:-
LGG	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-16.31	8.31e-48	3.07e-44	-0.64	-0.6	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
LGG	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	16.31	9.05e-48	3.34e-44	0.53	0.6	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
LGG	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-16.3	9.05e-48	3.34e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-16.3	9.57e-48	3.53e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
LGG	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-16.3	9.8e-48	3.61e-44	-0.82	-0.6	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
LGG	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	16.3	1e-47	3.7e-44	0.72	0.6	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
LGG	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-16.29	1.01e-47	3.71e-44	-0.77	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
LGG	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-16.29	1.03e-47	3.79e-44	-0.82	-0.6	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
LGG	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-16.29	1.06e-47	3.9e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
LGG	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	16.29	1.07e-47	3.94e-44	0.53	0.6	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
LGG	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.08e-47	3.97e-44	-0.81	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
LGG	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-16.28	1.12e-47	4.11e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
LGG	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	16.28	1.12e-47	4.12e-44	0.69	0.6	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
LGG	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-16.28	1.15e-47	4.24e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
LGG	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-16.28	1.18e-47	4.33e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
LGG	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-16.28	1.22e-47	4.49e-44	-0.64	-0.6	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
LGG	cis	rs853679	0.527	rs9461443	ENSG00000199851.2	U3	16.28	1.24e-47	4.55e-44	0.95	0.6	Depression;	chr6:28226851	chr6:28015568~28015777:+
LGG	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-16.28	1.24e-47	4.55e-44	-0.69	-0.6	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
LGG	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-16.27	1.26e-47	4.63e-44	-0.82	-0.6	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
LGG	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-16.27	1.26e-47	4.63e-44	-0.63	-0.6	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
LGG	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	16.27	1.28e-47	4.7e-44	0.72	0.6	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
LGG	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-16.27	1.32e-47	4.83e-44	-0.77	-0.6	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
LGG	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-16.27	1.33e-47	4.87e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
LGG	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-16.27	1.34e-47	4.9e-44	-0.69	-0.6	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
LGG	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	16.27	1.35e-47	4.93e-44	0.87	0.6	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
LGG	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-16.27	1.36e-47	4.98e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
LGG	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-16.26	1.42e-47	5.19e-44	-0.62	-0.6	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
LGG	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	16.26	1.43e-47	5.25e-44	0.86	0.6	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
LGG	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	16.26	1.52e-47	5.56e-44	0.76	0.6	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
LGG	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	16.25	1.54e-47	5.64e-44	0.7	0.6	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	16.25	1.54e-47	5.64e-44	0.7	0.6	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	16.25	1.54e-47	5.64e-44	0.7	0.6	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
LGG	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	16.25	1.55e-47	5.66e-44	0.86	0.6	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
LGG	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	16.25	1.56e-47	5.69e-44	0.69	0.6	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	16.25	1.56e-47	5.69e-44	0.69	0.6	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
LGG	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-16.25	1.57e-47	5.75e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-16.25	1.57e-47	5.75e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-16.25	1.57e-47	5.75e-44	-0.73	-0.6	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
LGG	cis	rs9532669	0.889	rs9549302	ENSG00000176268.5	CYCSP34	16.25	1.58e-47	5.76e-44	0.7	0.6	Cervical cancer;	chr13:40843278	chr13:40863599~40863902:-
LGG	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-16.25	1.6e-47	5.85e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
LGG	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	16.25	1.61e-47	5.89e-44	0.76	0.6	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
LGG	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	16.25	1.63e-47	5.96e-44	1.07	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
LGG	cis	rs853679	0.517	rs16893666	ENSG00000216901.1	AL022393.7	-16.25	1.65e-47	6.03e-44	-0.86	-0.6	Depression;	chr6:28086929	chr6:28176188~28176674:+
LGG	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-16.25	1.65e-47	6.03e-44	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
LGG	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-16.25	1.66e-47	6.07e-44	-0.72	-0.6	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
LGG	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	16.25	1.67e-47	6.08e-44	0.69	0.6	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
LGG	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-16.25	1.69e-47	6.17e-44	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
LGG	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	16.24	1.75e-47	6.38e-44	0.69	0.6	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
LGG	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	16.24	1.8e-47	6.54e-44	0.7	0.6	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
LGG	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	16.24	1.85e-47	6.73e-44	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	16.24	1.85e-47	6.73e-44	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
LGG	cis	rs79349575	0.783	rs4793992	ENSG00000248278.1	SUMO2P17	16.22	2.24e-47	8.15e-44	0.68	0.6	Type 2 diabetes;	chr17:48930845	chr17:48874860~48908983:-
LGG	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-16.21	2.34e-47	8.5e-44	-0.6	-0.6	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
LGG	cis	rs79349575	0.749	rs318093	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.88e-44	0.68	0.6	Type 2 diabetes;	chr17:48911992	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.749	rs46521	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48911167	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.745	rs170319	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48914169	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs318090	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48914390	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.721	rs3744608	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48915871	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.651	rs4378658	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48916008	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs12453374	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48917484	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs12453394	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48917608	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.811	rs12601072	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48920636	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.749	rs58838744	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48921540	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.811	rs60708039	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48922011	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs55771415	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48922575	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs2088139	ENSG00000248278.1	SUMO2P17	16.21	2.45e-47	8.9e-44	0.68	0.6	Type 2 diabetes;	chr17:48922748	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.715	rs62075844	ENSG00000248278.1	SUMO2P17	16.21	2.47e-47	8.95e-44	0.68	0.6	Type 2 diabetes;	chr17:48925027	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.749	rs957557	ENSG00000248278.1	SUMO2P17	16.21	2.47e-47	8.95e-44	0.68	0.6	Type 2 diabetes;	chr17:48925859	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4255820	ENSG00000248278.1	SUMO2P17	16.21	2.5e-47	9.06e-44	0.69	0.6	Type 2 diabetes;	chr17:48919221	chr17:48874860~48908983:-
LGG	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-16.2	2.67e-47	9.66e-44	-0.66	-0.6	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
LGG	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	16.2	2.78e-47	1.01e-43	0.69	0.6	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
LGG	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-16.2	2.79e-47	1.01e-43	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-16.2	2.79e-47	1.01e-43	-0.72	-0.6	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
LGG	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	16.2	2.82e-47	1.02e-43	0.52	0.6	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
LGG	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-16.2	2.84e-47	1.03e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-16.2	2.84e-47	1.03e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-16.2	2.84e-47	1.03e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
LGG	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-16.19	2.96e-47	1.07e-43	-0.64	-0.6	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
LGG	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	16.19	3.1e-47	1.12e-43	0.69	0.6	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
LGG	cis	rs11647589	0.834	rs1394677	ENSG00000260762.1	ACSM5P1	16.19	3.1e-47	1.12e-43	0.74	0.6	Blood metabolite levels;	chr16:20478195	chr16:20586550~20607107:-
LGG	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	16.19	3.12e-47	1.13e-43	0.69	0.6	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
LGG	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	16.19	3.16e-47	1.14e-43	0.63	0.6	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
LGG	cis	rs79349575	0.716	rs46522	ENSG00000248278.1	SUMO2P17	16.18	3.18e-47	1.15e-43	0.69	0.6	Type 2 diabetes;	chr17:48911235	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.729	rs62075824	ENSG00000248278.1	SUMO2P17	16.18	3.36e-47	1.21e-43	0.68	0.6	Type 2 diabetes;	chr17:48909317	chr17:48874860~48908983:-
LGG	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-16.18	3.41e-47	1.23e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-16.18	3.41e-47	1.23e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-16.18	3.41e-47	1.23e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
LGG	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	16.18	3.44e-47	1.24e-43	0.69	0.6	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	16.18	3.44e-47	1.24e-43	0.69	0.6	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	16.18	3.44e-47	1.24e-43	0.69	0.6	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	16.18	3.44e-47	1.24e-43	0.69	0.6	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	16.18	3.44e-47	1.24e-43	0.69	0.6	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
LGG	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-16.18	3.47e-47	1.25e-43	-0.69	-0.6	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
LGG	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-16.18	3.47e-47	1.25e-43	-0.69	-0.6	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
LGG	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-16.17	3.54e-47	1.27e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
LGG	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-16.17	3.58e-47	1.29e-43	-0.69	-0.6	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
LGG	cis	rs79349575	0.749	rs12601672	ENSG00000248278.1	SUMO2P17	16.17	3.58e-47	1.29e-43	0.68	0.6	Type 2 diabetes;	chr17:48929131	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs17635252	ENSG00000248278.1	SUMO2P17	16.17	3.58e-47	1.29e-43	0.68	0.6	Type 2 diabetes;	chr17:48929588	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs56046215	ENSG00000248278.1	SUMO2P17	16.17	3.58e-47	1.29e-43	0.68	0.6	Type 2 diabetes;	chr17:48931395	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4793991	ENSG00000248278.1	SUMO2P17	16.17	3.67e-47	1.32e-43	0.68	0.6	Type 2 diabetes;	chr17:48924439	chr17:48874860~48908983:-
LGG	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-16.17	3.87e-47	1.39e-43	-0.85	-0.6	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
LGG	cis	rs79349575	0.783	rs4399576	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48932473	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.687	rs12602179	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48932672	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs17708633	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48934258	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs9747646	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48939520	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs62075852	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48939814	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs12601858	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48940115	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.715	rs55724082	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48940517	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.749	rs8182364	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48940663	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.681	rs56080003	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48941687	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4793995	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48942037	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4793996	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48942235	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.715	rs4793997	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48942310	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4793998	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48942537	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.749	rs2270574	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48944908	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4794000	ENSG00000248278.1	SUMO2P17	16.17	3.91e-47	1.4e-43	0.68	0.6	Type 2 diabetes;	chr17:48945393	chr17:48874860~48908983:-
LGG	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	16.16	4.06e-47	1.45e-43	0.92	0.6	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
LGG	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-16.16	4.08e-47	1.46e-43	-0.64	-0.6	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
LGG	cis	rs79349575	0.811	rs1057897	ENSG00000248278.1	SUMO2P17	16.16	4.2e-47	1.5e-43	0.68	0.6	Type 2 diabetes;	chr17:48928147	chr17:48874860~48908983:-
LGG	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-16.16	4.23e-47	1.51e-43	-0.69	-0.6	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
LGG	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	16.15	4.51e-47	1.61e-43	0.91	0.6	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
LGG	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-16.15	4.56e-47	1.63e-43	-0.85	-0.6	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
LGG	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-16.15	4.69e-47	1.68e-43	-0.72	-0.6	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
LGG	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	16.15	4.78e-47	1.71e-43	0.71	0.6	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
LGG	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	16.14	4.96e-47	1.77e-43	1.06	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
LGG	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-16.14	4.97e-47	1.77e-43	-0.85	-0.6	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
LGG	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	16.14	4.97e-47	1.78e-43	0.69	0.6	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
LGG	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-16.14	5.04e-47	1.8e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-16.14	5.04e-47	1.8e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-16.14	5.04e-47	1.8e-43	-0.86	-0.6	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
LGG	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	16.14	5.28e-47	1.88e-43	1.05	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	16.14	5.33e-47	1.9e-43	0.7	0.6	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
LGG	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-16.12	6e-47	2.14e-43	-0.9	-0.6	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
LGG	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	16.12	6.47e-47	2.3e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	16.12	6.47e-47	2.3e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
LGG	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	16.12	6.47e-47	2.3e-43	0.73	0.59	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
LGG	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	16.12	6.61e-47	2.35e-43	0.81	0.59	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
LGG	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-16.11	6.79e-47	2.41e-43	-0.69	-0.59	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
LGG	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-16.11	6.79e-47	2.41e-43	-0.69	-0.59	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
LGG	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-16.11	6.87e-47	2.44e-43	-0.91	-0.59	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
LGG	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	16.11	6.92e-47	2.46e-43	0.63	0.59	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
LGG	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	16.11	6.93e-47	2.46e-43	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
LGG	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	16.11	7.16e-47	2.54e-43	0.69	0.59	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	16.11	7.16e-47	2.54e-43	0.69	0.59	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
LGG	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-16.1	7.58e-47	2.69e-43	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-16.1	7.58e-47	2.69e-43	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-16.1	7.58e-47	2.69e-43	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
LGG	cis	rs853679	0.55	rs34477097	ENSG00000199851.2	U3	16.1	7.74e-47	2.74e-43	0.94	0.59	Depression;	chr6:28229408	chr6:28015568~28015777:+
LGG	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-16.1	7.88e-47	2.79e-43	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
LGG	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	16.1	7.95e-47	2.82e-43	0.53	0.59	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
LGG	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-16.1	8.07e-47	2.86e-43	-0.66	-0.59	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
LGG	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-16.1	8.13e-47	2.88e-43	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
LGG	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-16.09	8.27e-47	2.93e-43	-0.64	-0.59	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
LGG	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	16.09	8.65e-47	3.06e-43	0.64	0.59	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
LGG	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-16.08	9.2e-47	3.26e-43	-0.73	-0.59	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
LGG	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-16.08	9.33e-47	3.3e-43	-0.65	-0.59	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
LGG	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-16.08	9.33e-47	3.3e-43	-0.65	-0.59	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
LGG	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-16.08	9.42e-47	3.33e-43	-0.69	-0.59	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
LGG	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	16.08	9.86e-47	3.48e-43	0.86	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
LGG	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	16.08	9.86e-47	3.48e-43	0.86	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
LGG	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	16.07	1.02e-46	3.59e-43	0.69	0.59	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
LGG	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-16.07	1.04e-46	3.65e-43	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
LGG	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	16.07	1.05e-46	3.69e-43	0.52	0.59	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
LGG	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	16.07	1.06e-46	3.74e-43	0.72	0.59	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
LGG	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	16.07	1.06e-46	3.75e-43	0.63	0.59	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	16.07	1.09e-46	3.84e-43	0.63	0.59	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
LGG	cis	rs79349575	0.783	rs62075838	ENSG00000248278.1	SUMO2P17	16.06	1.15e-46	4.03e-43	0.68	0.59	Type 2 diabetes;	chr17:48919070	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs62075839	ENSG00000248278.1	SUMO2P17	16.06	1.15e-46	4.03e-43	0.68	0.59	Type 2 diabetes;	chr17:48919072	chr17:48874860~48908983:-
LGG	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-16.06	1.16e-46	4.08e-43	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-16.06	1.16e-46	4.08e-43	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
LGG	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-16.06	1.19e-46	4.19e-43	-0.56	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
LGG	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-16.06	1.21e-46	4.25e-43	-0.84	-0.59	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
LGG	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-16.06	1.23e-46	4.31e-43	-0.77	-0.59	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
LGG	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-16.05	1.3e-46	4.56e-43	-0.86	-0.59	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
LGG	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-16.05	1.3e-46	4.56e-43	-0.86	-0.59	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
LGG	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	16.05	1.3e-46	4.57e-43	0.71	0.59	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-16.04	1.39e-46	4.86e-43	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
LGG	cis	rs79349575	0.783	rs15563	ENSG00000248278.1	SUMO2P17	16.04	1.39e-46	4.87e-43	0.69	0.59	Type 2 diabetes;	chr17:48927831	chr17:48874860~48908983:-
LGG	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-16.04	1.4e-46	4.9e-43	-0.64	-0.59	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
LGG	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	16.04	1.4e-46	4.92e-43	0.94	0.59	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
LGG	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-16.04	1.41e-46	4.96e-43	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
LGG	cis	rs4713118	0.539	rs510987	ENSG00000199851.2	U3	16.03	1.59e-46	5.57e-43	0.87	0.59	Parkinson's disease;	chr6:27879739	chr6:28015568~28015777:+
LGG	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	16.03	1.63e-46	5.7e-43	0.8	0.59	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
LGG	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-16.03	1.64e-46	5.74e-43	-0.82	-0.59	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
LGG	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-16.03	1.67e-46	5.85e-43	-0.69	-0.59	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
LGG	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	16.02	1.71e-46	5.99e-43	0.96	0.59	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
LGG	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-16.02	1.78e-46	6.21e-43	-0.64	-0.59	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
LGG	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	16.02	1.82e-46	6.36e-43	0.63	0.59	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-16.01	1.92e-46	6.7e-43	-0.63	-0.59	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
LGG	cis	rs853679	0.517	rs9380052	ENSG00000216901.1	AL022393.7	16.01	1.92e-46	6.7e-43	0.91	0.59	Depression;	chr6:28096845	chr6:28176188~28176674:+
LGG	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-16.01	2.03e-46	7.11e-43	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-16.01	2.03e-46	7.11e-43	-0.71	-0.59	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
LGG	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	16.01	2.07e-46	7.23e-43	1.05	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
LGG	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	16	2.1e-46	7.31e-43	0.72	0.59	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
LGG	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	16	2.17e-46	7.57e-43	0.69	0.59	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
LGG	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-16	2.26e-46	7.88e-43	-0.66	-0.59	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
LGG	cis	rs4713118	0.539	rs200951	ENSG00000199851.2	U3	15.99	2.38e-46	8.28e-43	0.86	0.59	Parkinson's disease;	chr6:27868152	chr6:28015568~28015777:+
LGG	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-15.99	2.43e-46	8.47e-43	-0.69	-0.59	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
LGG	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-15.99	2.45e-46	8.55e-43	-0.68	-0.59	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
LGG	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-15.99	2.45e-46	8.55e-43	-0.65	-0.59	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
LGG	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	15.99	2.48e-46	8.65e-43	0.68	0.59	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
LGG	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-15.98	2.64e-46	9.18e-43	-0.71	-0.59	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
LGG	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	15.98	2.69e-46	9.37e-43	0.71	0.59	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
LGG	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-15.98	2.81e-46	9.78e-43	-0.65	-0.59	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
LGG	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	15.97	2.99e-46	1.04e-42	0.63	0.59	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
LGG	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	15.97	2.99e-46	1.04e-42	0.63	0.59	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
LGG	cis	rs4713118	0.539	rs200967	ENSG00000199851.2	U3	15.97	3.01e-46	1.05e-42	0.86	0.59	Parkinson's disease;	chr6:27894349	chr6:28015568~28015777:+
LGG	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-15.97	3.04e-46	1.06e-42	-0.78	-0.59	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
LGG	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.06e-46	1.06e-42	-0.84	-0.59	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
LGG	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-15.97	3.09e-46	1.07e-42	-0.72	-0.59	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
LGG	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	15.96	3.36e-46	1.17e-42	0.69	0.59	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
LGG	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	15.96	3.43e-46	1.19e-42	0.72	0.59	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
LGG	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	15.95	3.67e-46	1.27e-42	0.69	0.59	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
LGG	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-15.95	3.79e-46	1.31e-42	-0.63	-0.59	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
LGG	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-15.95	3.82e-46	1.32e-42	-0.85	-0.59	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
LGG	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	15.94	3.92e-46	1.36e-42	0.72	0.59	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
LGG	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-15.94	3.92e-46	1.36e-42	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
LGG	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	15.94	4.04e-46	1.4e-42	0.67	0.59	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
LGG	cis	rs79349575	0.783	rs58591767	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48948714	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs59270107	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48948823	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs62078370	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48949474	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs11079844	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48950972	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs62078372	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48951627	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs12602933	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48951918	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs4794003	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48952542	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs12602746	ENSG00000248278.1	SUMO2P17	15.94	4.24e-46	1.46e-42	0.68	0.59	Type 2 diabetes;	chr17:48954379	chr17:48874860~48908983:-
LGG	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	15.93	4.46e-46	1.54e-42	0.69	0.59	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
LGG	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-15.93	4.75e-46	1.64e-42	-0.79	-0.59	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
LGG	cis	rs79349575	0.749	rs1057902	ENSG00000248278.1	SUMO2P17	15.92	4.86e-46	1.67e-42	0.68	0.59	Type 2 diabetes;	chr17:48928226	chr17:48874860~48908983:-
LGG	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-15.92	4.91e-46	1.69e-42	-0.63	-0.59	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
LGG	cis	rs200986	1	rs200986	ENSG00000199851.2	U3	15.92	5.02e-46	1.73e-42	0.86	0.59	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28015568~28015777:+
LGG	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-15.92	5.06e-46	1.74e-42	-0.68	-0.59	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
LGG	cis	rs4713118	0.513	rs200971	ENSG00000199851.2	U3	15.92	5.28e-46	1.81e-42	0.85	0.59	Parkinson's disease;	chr6:27891126	chr6:28015568~28015777:+
LGG	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	15.9	5.93e-46	2.04e-42	0.67	0.59	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
LGG	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-15.89	6.58e-46	2.26e-42	-0.72	-0.59	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-15.89	6.58e-46	2.26e-42	-0.72	-0.59	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
LGG	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-15.88	7.33e-46	2.51e-42	-0.64	-0.59	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-15.88	7.33e-46	2.51e-42	-0.64	-0.59	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-15.88	7.33e-46	2.51e-42	-0.64	-0.59	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
LGG	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-15.88	7.6e-46	2.6e-42	-0.89	-0.59	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
LGG	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	15.88	7.67e-46	2.63e-42	0.77	0.59	Depression;	chr6:28364057	chr6:28176188~28176674:+
LGG	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-15.88	7.88e-46	2.7e-42	-0.69	-0.59	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
LGG	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	15.87	8.16e-46	2.79e-42	0.69	0.59	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
LGG	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-15.87	8.53e-46	2.91e-42	-0.78	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
LGG	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-15.87	8.54e-46	2.92e-42	-0.64	-0.59	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
LGG	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-15.87	8.63e-46	2.95e-42	-0.66	-0.59	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
LGG	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-15.86	9.72e-46	3.32e-42	-0.67	-0.59	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
LGG	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	15.85	1.01e-45	3.43e-42	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
LGG	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-15.85	1.01e-45	3.45e-42	-0.77	-0.59	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
LGG	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-15.85	1.08e-45	3.69e-42	-0.83	-0.59	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
LGG	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	15.85	1.08e-45	3.69e-42	0.7	0.59	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
LGG	cis	rs853679	0.513	rs13437444	ENSG00000199851.2	U3	15.85	1.1e-45	3.75e-42	1.09	0.59	Depression;	chr6:28103220	chr6:28015568~28015777:+
LGG	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	15.84	1.14e-45	3.89e-42	0.89	0.59	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
LGG	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-15.84	1.14e-45	3.9e-42	-0.68	-0.59	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
LGG	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	15.84	1.15e-45	3.91e-42	0.84	0.59	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
LGG	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-15.84	1.19e-45	4.04e-42	-0.89	-0.59	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
LGG	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	15.82	1.36e-45	4.62e-42	0.7	0.59	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	15.82	1.4e-45	4.76e-42	0.67	0.59	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
LGG	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-15.82	1.4e-45	4.76e-42	-0.76	-0.59	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-15.82	1.4e-45	4.76e-42	-0.76	-0.59	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-15.82	1.4e-45	4.76e-42	-0.76	-0.59	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-15.82	1.4e-45	4.76e-42	-0.76	-0.59	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
LGG	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	15.82	1.42e-45	4.81e-42	0.85	0.59	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
LGG	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	15.82	1.42e-45	4.83e-42	0.72	0.59	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
LGG	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-15.82	1.44e-45	4.87e-42	-0.68	-0.59	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
LGG	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-15.82	1.45e-45	4.91e-42	-0.67	-0.59	Breast cancer;	chr11:825777	chr11:779617~780755:+
LGG	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	15.82	1.48e-45	5.03e-42	0.66	0.59	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
LGG	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	15.82	1.49e-45	5.05e-42	0.63	0.59	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
LGG	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-15.81	1.55e-45	5.27e-42	-0.9	-0.59	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
LGG	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	15.81	1.63e-45	5.52e-42	0.66	0.59	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	15.81	1.63e-45	5.52e-42	0.66	0.59	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	15.81	1.63e-45	5.52e-42	0.66	0.59	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
LGG	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	15.81	1.64e-45	5.57e-42	0.69	0.59	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	15.81	1.65e-45	5.59e-42	0.69	0.59	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
LGG	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	15.79	1.9e-45	6.43e-42	0.69	0.59	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
LGG	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	15.79	1.92e-45	6.48e-42	0.64	0.59	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
LGG	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	15.79	2.01e-45	6.79e-42	0.66	0.59	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
LGG	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-15.79	2.02e-45	6.81e-42	-0.9	-0.59	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
LGG	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	15.79	2.03e-45	6.85e-42	0.76	0.59	Depression;	chr6:28402301	chr6:28176188~28176674:+
LGG	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	15.79	2.03e-45	6.87e-42	0.76	0.59	Depression;	chr6:28386473	chr6:28176188~28176674:+
LGG	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	15.79	2.03e-45	6.87e-42	0.76	0.59	Depression;	chr6:28391932	chr6:28176188~28176674:+
LGG	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	15.79	2.03e-45	6.87e-42	0.76	0.59	Depression;	chr6:28399846	chr6:28176188~28176674:+
LGG	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	15.78	2.08e-45	7.04e-42	0.91	0.59	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
LGG	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-15.78	2.18e-45	7.36e-42	-0.77	-0.59	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
LGG	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	15.78	2.21e-45	7.44e-42	0.76	0.59	Depression;	chr6:28379133	chr6:28176188~28176674:+
LGG	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	15.78	2.21e-45	7.44e-42	0.76	0.59	Depression;	chr6:28379168	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	15.78	2.25e-45	7.58e-42	0.67	0.59	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	15.78	2.25e-45	7.58e-42	0.67	0.59	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
LGG	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-15.78	2.28e-45	7.68e-42	-0.77	-0.59	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-15.78	2.28e-45	7.68e-42	-0.77	-0.59	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-15.78	2.28e-45	7.68e-42	-0.77	-0.59	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
LGG	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	15.77	2.34e-45	7.88e-42	0.71	0.59	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
LGG	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	15.77	2.43e-45	8.16e-42	0.67	0.59	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
LGG	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-15.76	2.56e-45	8.61e-42	-0.64	-0.59	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
LGG	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-15.76	2.6e-45	8.73e-42	-0.83	-0.59	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
LGG	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	15.76	2.65e-45	8.91e-42	0.71	0.59	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
LGG	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	15.76	2.77e-45	9.3e-42	1.04	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
LGG	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	15.76	2.8e-45	9.38e-42	0.68	0.59	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	15.75	2.94e-45	9.86e-42	0.67	0.59	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
LGG	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-15.75	2.99e-45	1e-41	-0.72	-0.59	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
LGG	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-15.75	3.05e-45	1.02e-41	-0.85	-0.59	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
LGG	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	15.75	3.08e-45	1.03e-41	0.83	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
LGG	cis	rs6452524	0.837	rs1479569	ENSG00000249664.1	CTD-2227C6.2	15.74	3.16e-45	1.06e-41	0.81	0.59	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:83012285~83013109:-
LGG	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	15.74	3.18e-45	1.06e-41	0.67	0.59	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
LGG	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	15.73	3.47e-45	1.16e-41	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
LGG	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	15.73	3.48e-45	1.16e-41	0.73	0.59	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
LGG	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-15.73	3.5e-45	1.17e-41	-0.71	-0.59	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
LGG	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-15.73	3.63e-45	1.21e-41	-0.75	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
LGG	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	15.73	3.73e-45	1.25e-41	0.66	0.59	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	15.73	3.73e-45	1.25e-41	0.66	0.59	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	15.73	3.73e-45	1.25e-41	0.66	0.59	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
LGG	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-15.73	3.77e-45	1.26e-41	-0.76	-0.59	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-15.72	3.87e-45	1.29e-41	-0.76	-0.59	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
LGG	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-15.72	3.93e-45	1.31e-41	-0.7	-0.59	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
LGG	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-15.72	3.95e-45	1.32e-41	-0.76	-0.59	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
LGG	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	15.72	4.14e-45	1.38e-41	0.71	0.59	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
LGG	cis	rs2945232	1	rs2945232	ENSG00000173295.6	FAM86B3P	-15.72	4.21e-45	1.4e-41	-0.61	-0.59	Schizophrenia;	chr8:8240516	chr8:8228595~8244865:+
LGG	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-15.71	4.27e-45	1.42e-41	-1.07	-0.59	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
LGG	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	15.7	5.02e-45	1.67e-41	0.75	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
LGG	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	15.7	5.13e-45	1.7e-41	0.62	0.58	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
LGG	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-15.7	5.18e-45	1.72e-41	-0.71	-0.58	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
LGG	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-15.69	5.7e-45	1.89e-41	-0.7	-0.58	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
LGG	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-15.69	5.7e-45	1.89e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
LGG	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-15.69	5.71e-45	1.89e-41	-0.7	-0.58	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
LGG	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-15.69	5.74e-45	1.9e-41	-0.55	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	15.69	5.8e-45	1.92e-41	0.74	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
LGG	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	15.68	5.85e-45	1.94e-41	0.66	0.58	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
LGG	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-15.68	5.89e-45	1.95e-41	-1.02	-0.58	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
LGG	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-15.68	6.07e-45	2.01e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
LGG	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-15.68	6.07e-45	2.01e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
LGG	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-15.68	6.07e-45	2.01e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
LGG	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-15.68	6.07e-45	2.01e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
LGG	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-15.68	6.07e-45	2.01e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
LGG	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-15.68	6.07e-45	2.01e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
LGG	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-15.68	6.07e-45	2.01e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
LGG	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	15.68	6.08e-45	2.01e-41	0.73	0.58	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
LGG	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-15.68	6.15e-45	2.03e-41	-0.76	-0.58	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
LGG	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-15.68	6.26e-45	2.07e-41	-0.55	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
LGG	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-15.68	6.43e-45	2.12e-41	-0.75	-0.58	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
LGG	cis	rs79349575	0.783	rs2112617	ENSG00000248278.1	SUMO2P17	15.67	6.56e-45	2.16e-41	0.68	0.58	Type 2 diabetes;	chr17:48899763	chr17:48874860~48908983:-
LGG	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-15.67	6.78e-45	2.24e-41	-0.68	-0.58	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
LGG	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-15.67	6.88e-45	2.27e-41	-0.83	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
LGG	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-15.66	7.31e-45	2.41e-41	-0.76	-0.58	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-15.66	7.61e-45	2.51e-41	-0.76	-0.58	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
LGG	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	15.65	8.03e-45	2.64e-41	0.62	0.58	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
LGG	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-15.65	8.64e-45	2.84e-41	-0.84	-0.58	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
LGG	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-15.64	8.94e-45	2.94e-41	-0.68	-0.58	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
LGG	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-15.64	9.2e-45	3.02e-41	-0.62	-0.58	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
LGG	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-15.64	9.41e-45	3.09e-41	-0.75	-0.58	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-15.64	9.43e-45	3.1e-41	-0.76	-0.58	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-15.64	9.43e-45	3.1e-41	-0.76	-0.58	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
LGG	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-15.64	9.52e-45	3.13e-41	-0.85	-0.58	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
LGG	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-15.63	1.05e-44	3.45e-41	-0.68	-0.58	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
LGG	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-15.63	1.07e-44	3.52e-41	-0.69	-0.58	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
LGG	cis	rs683250	0.629	rs681259	ENSG00000254551.1	RP11-727A23.7	15.62	1.09e-44	3.58e-41	0.71	0.58	Subcortical brain region volumes;	chr11:83222984	chr11:83209431~83213379:-
LGG	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-15.62	1.14e-44	3.73e-41	-0.75	-0.58	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-15.62	1.14e-44	3.73e-41	-0.75	-0.58	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
LGG	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-15.61	1.23e-44	4.02e-41	-0.74	-0.58	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
LGG	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	15.6	1.34e-44	4.37e-41	0.76	0.58	Depression;	chr6:28428413	chr6:28176188~28176674:+
LGG	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	15.6	1.34e-44	4.37e-41	0.76	0.58	Depression;	chr6:28430971	chr6:28176188~28176674:+
LGG	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	15.6	1.34e-44	4.37e-41	0.76	0.58	Depression;	chr6:28431469	chr6:28176188~28176674:+
LGG	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	15.6	1.34e-44	4.37e-41	0.76	0.58	Depression;	chr6:28432562	chr6:28176188~28176674:+
LGG	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	15.6	1.36e-44	4.44e-41	0.61	0.58	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
LGG	cis	rs11647589	0.531	rs67450218	ENSG00000260762.1	ACSM5P1	15.6	1.37e-44	4.46e-41	0.69	0.58	Blood metabolite levels;	chr16:20436061	chr16:20586550~20607107:-
LGG	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	15.6	1.37e-44	4.47e-41	0.62	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
LGG	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	15.6	1.37e-44	4.47e-41	0.62	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
LGG	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	15.6	1.37e-44	4.47e-41	0.62	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
LGG	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	15.6	1.37e-44	4.47e-41	0.62	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
LGG	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	15.6	1.37e-44	4.47e-41	0.62	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
LGG	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-15.6	1.4e-44	4.56e-41	-0.68	-0.58	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
LGG	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-15.6	1.43e-44	4.68e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
LGG	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-15.6	1.45e-44	4.73e-41	-0.84	-0.58	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
LGG	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	15.59	1.54e-44	5.01e-41	0.84	0.58	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
LGG	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	15.59	1.54e-44	5.01e-41	0.83	0.58	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
LGG	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-15.59	1.56e-44	5.09e-41	-0.84	-0.58	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
LGG	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-15.59	1.63e-44	5.31e-41	-0.6	-0.58	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
LGG	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	15.58	1.68e-44	5.49e-41	0.84	0.58	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
LGG	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	15.58	1.74e-44	5.66e-41	0.62	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
LGG	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-15.58	1.78e-44	5.8e-41	-0.62	-0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
LGG	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-15.57	1.88e-44	6.1e-41	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
LGG	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-15.57	1.89e-44	6.14e-41	-0.72	-0.58	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
LGG	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	15.57	1.9e-44	6.17e-41	0.83	0.58	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
LGG	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-15.57	1.97e-44	6.39e-41	-0.67	-0.58	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
LGG	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-15.56	2.07e-44	6.73e-41	-0.69	-0.58	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
LGG	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-15.56	2.1e-44	6.83e-41	-0.85	-0.58	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
LGG	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-15.55	2.31e-44	7.47e-41	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
LGG	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	15.54	2.51e-44	8.14e-41	0.76	0.58	Depression;	chr6:28407125	chr6:28176188~28176674:+
LGG	cis	rs79349575	0.716	rs595767	ENSG00000248278.1	SUMO2P17	15.54	2.56e-44	8.3e-41	0.66	0.58	Type 2 diabetes;	chr17:48880625	chr17:48874860~48908983:-
LGG	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-15.53	2.78e-44	9e-41	-0.63	-0.58	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
LGG	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-15.53	2.8e-44	9.06e-41	-0.73	-0.58	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
LGG	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	15.53	2.94e-44	9.51e-41	0.62	0.58	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
LGG	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-15.53	2.98e-44	9.62e-41	-0.64	-0.58	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
LGG	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	15.52	3.08e-44	9.96e-41	0.79	0.58	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
LGG	cis	rs4713118	0.516	rs6931858	ENSG00000216901.1	AL022393.7	15.52	3.23e-44	1.04e-40	0.85	0.58	Parkinson's disease;	chr6:28110633	chr6:28176188~28176674:+
LGG	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-15.52	3.27e-44	1.05e-40	-0.83	-0.58	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
LGG	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-15.51	3.44e-44	1.11e-40	-0.76	-0.58	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
LGG	cis	rs46522	0.585	rs79049364	ENSG00000248278.1	SUMO2P17	15.51	3.54e-44	1.14e-40	0.68	0.58	Coronary heart disease;	chr17:48937629	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.811	rs80032154	ENSG00000248278.1	SUMO2P17	15.51	3.54e-44	1.14e-40	0.68	0.58	Type 2 diabetes;	chr17:48937630	chr17:48874860~48908983:-
LGG	cis	rs11647589	0.784	rs1700804	ENSG00000260762.1	ACSM5P1	-15.51	3.7e-44	1.19e-40	-0.72	-0.58	Blood metabolite levels;	chr16:20477047	chr16:20586550~20607107:-
LGG	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-15.5	3.79e-44	1.22e-40	-0.77	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
LGG	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-15.5	3.87e-44	1.24e-40	-0.73	-0.58	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
LGG	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-15.5	3.98e-44	1.28e-40	-0.83	-0.58	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
LGG	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-15.5	3.98e-44	1.28e-40	-0.75	-0.58	Depression;	chr6:28422360	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9380045	ENSG00000216901.1	AL022393.7	15.5	4.08e-44	1.31e-40	0.85	0.58	Parkinson's disease;	chr6:28057501	chr6:28176188~28176674:+
LGG	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	15.5	4.1e-44	1.32e-40	0.62	0.58	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
LGG	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	15.49	4.34e-44	1.39e-40	0.73	0.58	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	15.49	4.56e-44	1.46e-40	0.73	0.58	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
LGG	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	15.49	4.57e-44	1.46e-40	0.62	0.58	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
LGG	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	15.48	4.67e-44	1.5e-40	0.71	0.58	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
LGG	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-15.48	4.7e-44	1.5e-40	-0.73	-0.58	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
LGG	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	15.48	4.7e-44	1.5e-40	0.64	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
LGG	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	15.48	4.81e-44	1.54e-40	0.83	0.58	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
LGG	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	15.48	4.81e-44	1.54e-40	0.83	0.58	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
LGG	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	15.48	4.87e-44	1.56e-40	0.67	0.58	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	15.48	4.87e-44	1.56e-40	0.67	0.58	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
LGG	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-15.48	4.88e-44	1.56e-40	-0.74	-0.58	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
LGG	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	15.48	4.95e-44	1.58e-40	1.02	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
LGG	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	15.48	5.03e-44	1.61e-40	0.64	0.58	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
LGG	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	15.48	5.07e-44	1.62e-40	0.67	0.58	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
LGG	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	15.47	5.17e-44	1.65e-40	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	15.47	5.38e-44	1.72e-40	0.83	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
LGG	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-15.47	5.46e-44	1.74e-40	-0.61	-0.58	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
LGG	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	15.47	5.54e-44	1.77e-40	0.95	0.58	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
LGG	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	15.46	5.93e-44	1.89e-40	0.65	0.58	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
LGG	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-15.46	6.02e-44	1.92e-40	-0.61	-0.58	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
LGG	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	15.46	6.12e-44	1.95e-40	0.75	0.58	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
LGG	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-15.45	6.28e-44	2e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
LGG	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	15.45	6.41e-44	2.04e-40	0.6	0.58	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
LGG	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	15.45	6.5e-44	2.07e-40	0.66	0.58	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
LGG	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-15.45	6.54e-44	2.08e-40	-0.63	-0.58	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
LGG	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	15.45	6.63e-44	2.11e-40	0.7	0.58	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
LGG	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-15.45	6.86e-44	2.18e-40	-0.72	-0.58	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	15.44	6.97e-44	2.22e-40	0.82	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
LGG	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-15.44	7.16e-44	2.28e-40	-0.72	-0.58	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
LGG	cis	rs853679	0.527	rs9461443	ENSG00000216901.1	AL022393.7	15.43	7.78e-44	2.47e-40	0.82	0.58	Depression;	chr6:28226851	chr6:28176188~28176674:+
LGG	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	15.43	8.33e-44	2.64e-40	0.87	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
LGG	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	15.43	8.33e-44	2.64e-40	0.87	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
LGG	cis	rs11647589	0.651	rs7195862	ENSG00000260762.1	ACSM5P1	15.43	8.43e-44	2.67e-40	0.68	0.58	Blood metabolite levels;	chr16:20431561	chr16:20586550~20607107:-
LGG	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	15.42	8.69e-44	2.75e-40	0.85	0.58	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
LGG	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	15.42	8.94e-44	2.83e-40	0.87	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
LGG	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	15.42	9.17e-44	2.9e-40	0.71	0.58	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-15.42	9.17e-44	2.9e-40	-0.71	-0.58	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	15.42	9.22e-44	2.92e-40	0.73	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
LGG	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-15.42	9.27e-44	2.94e-40	-0.8	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
LGG	cis	rs1475911	0.708	rs11701371	ENSG00000184385.2	UMODL1-AS1	15.41	9.55e-44	3.02e-40	0.7	0.58	IgG glycosylation;	chr21:42103862	chr21:42102134~42108534:-
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-15.41	9.83e-44	3.11e-40	-0.82	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
LGG	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-15.4	1.06e-43	3.34e-40	-0.76	-0.58	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.539	rs200988	ENSG00000199851.2	U3	15.4	1.06e-43	3.35e-40	0.83	0.58	Parkinson's disease;	chr6:27851575	chr6:28015568~28015777:+
LGG	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	15.4	1.13e-43	3.57e-40	1	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	15.4	1.13e-43	3.57e-40	1	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	15.4	1.13e-43	3.57e-40	1	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	15.4	1.13e-43	3.57e-40	1	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
LGG	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	15.4	1.14e-43	3.6e-40	0.81	0.58	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
LGG	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	15.39	1.18e-43	3.72e-40	0.87	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
LGG	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	15.39	1.2e-43	3.78e-40	0.62	0.58	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-15.39	1.25e-43	3.93e-40	-0.62	-0.58	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
LGG	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-15.39	1.26e-43	3.95e-40	-0.69	-0.58	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
LGG	cis	rs79349575	0.783	rs12603969	ENSG00000248278.1	SUMO2P17	15.39	1.26e-43	3.98e-40	0.67	0.58	Type 2 diabetes;	chr17:48957057	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.783	rs12601955	ENSG00000248278.1	SUMO2P17	15.39	1.26e-43	3.98e-40	0.67	0.58	Type 2 diabetes;	chr17:48957058	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.594	rs62078375	ENSG00000248278.1	SUMO2P17	15.39	1.26e-43	3.98e-40	0.67	0.58	Type 2 diabetes;	chr17:48957612	chr17:48874860~48908983:-
LGG	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	15.38	1.3e-43	4.1e-40	0.62	0.58	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
LGG	cis	rs4713118	0.621	rs9368548	ENSG00000216901.1	AL022393.7	15.37	1.43e-43	4.5e-40	0.86	0.58	Parkinson's disease;	chr6:28066959	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.621	rs9295756	ENSG00000216901.1	AL022393.7	15.37	1.47e-43	4.61e-40	0.86	0.58	Parkinson's disease;	chr6:28065618	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-15.37	1.52e-43	4.76e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-15.37	1.52e-43	4.76e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-15.37	1.52e-43	4.76e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-15.37	1.52e-43	4.76e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-15.37	1.52e-43	4.76e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
LGG	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	15.37	1.58e-43	4.96e-40	0.7	0.58	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
LGG	cis	rs11647589	0.651	rs7498385	ENSG00000260762.1	ACSM5P1	15.36	1.59e-43	4.99e-40	0.68	0.58	Blood metabolite levels;	chr16:20435517	chr16:20586550~20607107:-
LGG	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	15.36	1.65e-43	5.17e-40	0.77	0.58	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
LGG	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-15.36	1.68e-43	5.25e-40	-0.73	-0.58	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
LGG	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	15.36	1.7e-43	5.3e-40	0.83	0.58	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
LGG	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	15.36	1.7e-43	5.3e-40	0.83	0.58	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
LGG	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	15.35	1.83e-43	5.7e-40	0.83	0.58	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
LGG	cis	rs4713118	0.621	rs9295755	ENSG00000216901.1	AL022393.7	-15.35	1.92e-43	5.99e-40	-0.86	-0.58	Parkinson's disease;	chr6:28065396	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs149948	ENSG00000216901.1	AL022393.7	15.34	2.05e-43	6.39e-40	0.81	0.58	Parkinson's disease;	chr6:28007039	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9357060	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28056708	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9468271	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28056792	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9468274	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28058299	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9468275	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28058358	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9468276	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28059910	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9468277	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28060612	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs9468278	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28060704	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs13218430	ENSG00000216901.1	AL022393.7	15.34	2.12e-43	6.59e-40	0.85	0.58	Parkinson's disease;	chr6:28062059	chr6:28176188~28176674:+
LGG	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	15.34	2.13e-43	6.63e-40	0.51	0.58	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
LGG	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-15.33	2.17e-43	6.73e-40	-0.72	-0.58	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
LGG	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	15.33	2.18e-43	6.78e-40	0.87	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
LGG	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-15.33	2.21e-43	6.86e-40	-0.61	-0.58	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
LGG	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-15.32	2.45e-43	7.59e-40	-0.61	-0.58	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
LGG	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-15.32	2.45e-43	7.59e-40	-0.61	-0.58	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
LGG	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-15.32	2.45e-43	7.59e-40	-0.61	-0.58	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
LGG	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-15.32	2.45e-43	7.59e-40	-0.61	-0.58	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
LGG	cis	rs79349575	0.756	rs4793605	ENSG00000248278.1	SUMO2P17	15.32	2.53e-43	7.85e-40	0.67	0.58	Type 2 diabetes;	chr17:48958507	chr17:48874860~48908983:-
LGG	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	15.32	2.55e-43	7.91e-40	0.62	0.58	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
LGG	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	15.31	2.66e-43	8.25e-40	0.7	0.58	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
LGG	cis	rs11647589	0.651	rs6497485	ENSG00000260762.1	ACSM5P1	15.31	2.67e-43	8.28e-40	0.67	0.58	Blood metabolite levels;	chr16:20428511	chr16:20586550~20607107:-
LGG	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	15.31	2.7e-43	8.37e-40	0.99	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	15.31	2.7e-43	8.37e-40	0.99	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
LGG	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	15.31	2.71e-43	8.38e-40	0.66	0.58	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
LGG	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	15.31	2.73e-43	8.45e-40	0.88	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
LGG	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	15.31	2.79e-43	8.63e-40	0.99	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
LGG	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	15.31	2.85e-43	8.81e-40	0.77	0.58	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
LGG	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	15.31	2.89e-43	8.95e-40	0.7	0.58	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
LGG	cis	rs4713118	0.662	rs149901	ENSG00000216901.1	AL022393.7	15.31	2.92e-43	9.02e-40	0.8	0.58	Parkinson's disease;	chr6:27997725	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs464312	ENSG00000216901.1	AL022393.7	15.31	2.92e-43	9.02e-40	0.8	0.58	Parkinson's disease;	chr6:27999813	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs469228	ENSG00000216901.1	AL022393.7	15.31	2.92e-43	9.02e-40	0.8	0.58	Parkinson's disease;	chr6:28002926	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.54	rs469227	ENSG00000216901.1	AL022393.7	15.31	2.92e-43	9.02e-40	0.8	0.58	Parkinson's disease;	chr6:28002927	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	15.3	3e-43	9.26e-40	0.66	0.58	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
LGG	cis	rs4713118	0.616	rs9348789	ENSG00000216901.1	AL022393.7	15.3	3.02e-43	9.33e-40	0.85	0.58	Parkinson's disease;	chr6:28057708	chr6:28176188~28176674:+
LGG	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	15.3	3.09e-43	9.54e-40	0.83	0.57	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
LGG	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	15.3	3.09e-43	9.54e-40	0.83	0.57	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
LGG	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	15.3	3.09e-43	9.54e-40	0.83	0.57	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
LGG	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-15.3	3.23e-43	9.97e-40	-0.69	-0.57	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
LGG	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	15.29	3.46e-43	1.07e-39	0.87	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
LGG	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	15.28	3.68e-43	1.13e-39	0.75	0.57	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
LGG	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-15.28	3.82e-43	1.18e-39	-0.67	-0.57	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-15.28	3.82e-43	1.18e-39	-0.67	-0.57	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
LGG	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	15.28	3.92e-43	1.21e-39	1.07	0.57	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
LGG	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-15.27	4.08e-43	1.25e-39	-0.81	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
LGG	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	15.27	4.08e-43	1.26e-39	0.66	0.57	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
LGG	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-15.27	4.2e-43	1.29e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	15.27	4.24e-43	1.31e-39	0.71	0.57	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
LGG	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	15.27	4.33e-43	1.33e-39	0.77	0.57	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
LGG	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	15.27	4.39e-43	1.35e-39	0.88	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
LGG	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-15.27	4.41e-43	1.35e-39	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
LGG	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	15.27	4.41e-43	1.36e-39	0.86	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
LGG	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	15.27	4.41e-43	1.36e-39	0.86	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
LGG	cis	rs4713118	0.629	rs203888	ENSG00000216901.1	AL022393.7	15.26	4.48e-43	1.38e-39	0.85	0.57	Parkinson's disease;	chr6:28053811	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs149961	ENSG00000216901.1	AL022393.7	15.26	4.65e-43	1.43e-39	0.85	0.57	Parkinson's disease;	chr6:28047791	chr6:28176188~28176674:+
LGG	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-15.26	4.65e-43	1.43e-39	-0.83	-0.57	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
LGG	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	15.26	4.71e-43	1.45e-39	0.62	0.57	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	15.26	4.71e-43	1.45e-39	0.62	0.57	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	15.26	4.71e-43	1.45e-39	0.62	0.57	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
LGG	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-15.26	4.73e-43	1.45e-39	-0.5	-0.57	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
LGG	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	15.26	4.82e-43	1.48e-39	0.62	0.57	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	15.26	4.82e-43	1.48e-39	0.62	0.57	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	15.26	4.82e-43	1.48e-39	0.62	0.57	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
LGG	cis	rs4713118	0.629	rs203889	ENSG00000216901.1	AL022393.7	15.26	4.83e-43	1.48e-39	0.84	0.57	Parkinson's disease;	chr6:28053997	chr6:28176188~28176674:+
LGG	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	15.25	5.09e-43	1.56e-39	0.62	0.57	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	15.25	5.09e-43	1.56e-39	0.62	0.57	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	15.25	5.09e-43	1.56e-39	0.62	0.57	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
LGG	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-15.25	5.19e-43	1.59e-39	-0.69	-0.57	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
LGG	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	15.25	5.22e-43	1.6e-39	0.56	0.57	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
LGG	cis	rs11647589	0.651	rs7498473	ENSG00000260762.1	ACSM5P1	15.25	5.34e-43	1.64e-39	0.68	0.57	Blood metabolite levels;	chr16:20435638	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.677	rs7498421	ENSG00000260762.1	ACSM5P1	15.25	5.34e-43	1.64e-39	0.68	0.57	Blood metabolite levels;	chr16:20435714	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.677	rs7498484	ENSG00000260762.1	ACSM5P1	15.25	5.34e-43	1.64e-39	0.68	0.57	Blood metabolite levels;	chr16:20435907	chr16:20586550~20607107:-
LGG	cis	rs11647589	0.677	rs66465511	ENSG00000260762.1	ACSM5P1	15.25	5.34e-43	1.64e-39	0.68	0.57	Blood metabolite levels;	chr16:20436010	chr16:20586550~20607107:-
LGG	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-15.25	5.35e-43	1.64e-39	-0.82	-0.57	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
LGG	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-15.24	5.64e-43	1.73e-39	-0.62	-0.57	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
LGG	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-15.24	5.72e-43	1.75e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-15.24	5.72e-43	1.75e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-15.24	5.72e-43	1.75e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
LGG	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	15.24	5.9e-43	1.8e-39	0.89	0.57	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
LGG	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	15.24	5.91e-43	1.81e-39	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-15.23	6.43e-43	1.96e-39	-0.72	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
LGG	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	15.23	6.44e-43	1.97e-39	0.72	0.57	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
LGG	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-15.22	6.86e-43	2.09e-39	-0.77	-0.57	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
LGG	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	15.22	6.89e-43	2.1e-39	0.87	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
LGG	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-15.22	7.18e-43	2.19e-39	-0.92	-0.57	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
LGG	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	15.21	7.55e-43	2.3e-39	0.89	0.57	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	15.21	7.55e-43	2.3e-39	0.89	0.57	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
LGG	cis	rs4713118	0.629	rs203890	ENSG00000216901.1	AL022393.7	15.21	8e-43	2.43e-39	0.84	0.57	Parkinson's disease;	chr6:28054470	chr6:28176188~28176674:+
LGG	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	15.21	8.03e-43	2.44e-39	0.87	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
LGG	cis	rs2945232	1	rs2945232	ENSG00000253893.2	FAM85B	-15.2	8.34e-43	2.53e-39	-0.68	-0.57	Schizophrenia;	chr8:8240516	chr8:8167819~8226614:-
LGG	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	15.2	8.38e-43	2.55e-39	0.62	0.57	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	15.2	8.38e-43	2.55e-39	0.62	0.57	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
LGG	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	15.2	8.81e-43	2.67e-39	0.84	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
LGG	cis	rs4713118	0.629	rs149899	ENSG00000216901.1	AL022393.7	15.19	9.16e-43	2.78e-39	0.85	0.57	Parkinson's disease;	chr6:28052201	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.629	rs172165	ENSG00000216901.1	AL022393.7	15.19	9.16e-43	2.78e-39	0.85	0.57	Parkinson's disease;	chr6:28053036	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.597	rs172166	ENSG00000216901.1	AL022393.7	15.19	9.16e-43	2.78e-39	0.85	0.57	Parkinson's disease;	chr6:28053042	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	15.19	9.26e-43	2.81e-39	0.68	0.57	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
LGG	cis	rs11647589	0.684	rs12051080	ENSG00000260762.1	ACSM5P1	15.19	9.35e-43	2.83e-39	0.67	0.57	Blood metabolite levels;	chr16:20428968	chr16:20586550~20607107:-
LGG	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-15.19	9.89e-43	3e-39	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
LGG	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	15.19	1e-42	3.04e-39	0.85	0.57	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
LGG	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	15.18	1.01e-42	3.06e-39	0.73	0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
LGG	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-15.18	1.01e-42	3.06e-39	-0.73	-0.57	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
LGG	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-15.18	1.01e-42	3.07e-39	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	15.18	1.03e-42	3.12e-39	0.7	0.57	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
LGG	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-15.18	1.04e-42	3.16e-39	-0.93	-0.57	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
LGG	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	15.18	1.06e-42	3.2e-39	0.62	0.57	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
LGG	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	15.18	1.11e-42	3.36e-39	0.7	0.57	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
LGG	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-15.17	1.13e-42	3.4e-39	-0.6	-0.57	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
LGG	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-15.17	1.13e-42	3.4e-39	-0.6	-0.57	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
LGG	cis	rs4713118	0.621	rs10484403	ENSG00000216901.1	AL022393.7	15.17	1.13e-42	3.41e-39	0.85	0.57	Parkinson's disease;	chr6:28065745	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-15.17	1.13e-42	3.41e-39	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
LGG	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	15.17	1.15e-42	3.46e-39	0.62	0.57	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
LGG	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-15.17	1.17e-42	3.51e-39	-0.7	-0.57	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
LGG	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	15.17	1.17e-42	3.51e-39	0.69	0.57	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
LGG	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-15.17	1.22e-42	3.68e-39	-0.79	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
LGG	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	15.16	1.24e-42	3.74e-39	0.77	0.57	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
LGG	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	15.15	1.47e-42	4.43e-39	0.5	0.57	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
LGG	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-15.15	1.51e-42	4.52e-39	-0.68	-0.57	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
LGG	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-15.15	1.51e-42	4.54e-39	-0.71	-0.57	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
LGG	cis	rs8062405	0.72	rs9926245	ENSG00000271623.1	RP11-435I10.5	-15.14	1.55e-42	4.66e-39	-0.66	-0.57	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28364700~28365333:+
LGG	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	15.14	1.61e-42	4.84e-39	0.97	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
LGG	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	15.14	1.68e-42	5.05e-39	0.86	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
LGG	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	15.13	1.76e-42	5.28e-39	0.61	0.57	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
LGG	cis	rs4713118	0.662	rs9380046	ENSG00000216901.1	AL022393.7	15.13	1.79e-42	5.37e-39	0.84	0.57	Parkinson's disease;	chr6:28062721	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	15.13	1.82e-42	5.44e-39	0.64	0.57	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
LGG	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-15.13	1.86e-42	5.57e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-15.13	1.86e-42	5.57e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-15.13	1.86e-42	5.57e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-15.13	1.86e-42	5.57e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-15.13	1.86e-42	5.57e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
LGG	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.12	1.92e-42	5.74e-39	0.61	0.57	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
LGG	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	15.12	1.95e-42	5.84e-39	0.76	0.57	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
LGG	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	15.11	2.11e-42	6.3e-39	0.8	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
LGG	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-15.11	2.12e-42	6.32e-39	-0.73	-0.57	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
LGG	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-15.11	2.14e-42	6.37e-39	-0.87	-0.57	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
LGG	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-15.11	2.15e-42	6.43e-39	-0.48	-0.57	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
LGG	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-15.11	2.19e-42	6.53e-39	-0.84	-0.57	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
LGG	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-15.1	2.32e-42	6.92e-39	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
LGG	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	15.1	2.47e-42	7.33e-39	0.61	0.57	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
LGG	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-15.09	2.54e-42	7.54e-39	-0.96	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
LGG	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	15.09	2.55e-42	7.58e-39	0.7	0.57	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	15.09	2.55e-42	7.58e-39	0.7	0.57	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
LGG	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	15.09	2.75e-42	8.15e-39	0.61	0.57	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
LGG	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-15.09	2.77e-42	8.21e-39	-0.69	-0.57	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
LGG	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	15.08	2.86e-42	8.47e-39	0.63	0.57	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
LGG	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	15.08	2.92e-42	8.66e-39	0.64	0.57	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
LGG	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-15.08	2.93e-42	8.68e-39	-0.65	-0.57	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
LGG	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	15.07	3.12e-42	9.25e-39	0.59	0.57	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
LGG	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	15.07	3.42e-42	1.01e-38	0.85	0.57	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
LGG	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	15.06	3.49e-42	1.03e-38	0.83	0.57	Depression;	chr6:28251492	chr6:28176188~28176674:+
LGG	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-15.06	3.51e-42	1.04e-38	-0.74	-0.57	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
LGG	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	15.06	3.62e-42	1.07e-38	0.76	0.57	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
LGG	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	15.06	3.67e-42	1.08e-38	0.98	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
LGG	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-15.06	3.7e-42	1.09e-38	-0.82	-0.57	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
LGG	cis	rs853679	0.55	rs34477097	ENSG00000216901.1	AL022393.7	15.05	3.96e-42	1.17e-38	0.8	0.57	Depression;	chr6:28229408	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	15.05	4.03e-42	1.19e-38	0.7	0.57	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
LGG	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	15.05	4.03e-42	1.19e-38	0.99	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
LGG	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	15.05	4.07e-42	1.2e-38	0.6	0.57	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
LGG	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-15.05	4.21e-42	1.24e-38	-0.75	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
LGG	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	15.04	4.39e-42	1.29e-38	0.86	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
LGG	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	15.04	4.41e-42	1.3e-38	1.04	0.57	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
LGG	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	15.04	4.41e-42	1.3e-38	1.04	0.57	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
LGG	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	15.04	4.56e-42	1.34e-38	0.7	0.57	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
LGG	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	15.03	5.14e-42	1.51e-38	0.75	0.57	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
LGG	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-15.02	5.26e-42	1.54e-38	-0.62	-0.57	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
LGG	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	15.02	5.43e-42	1.59e-38	0.95	0.57	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
LGG	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	15.02	5.5e-42	1.61e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
LGG	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	15.02	5.65e-42	1.65e-38	0.61	0.57	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
LGG	cis	rs4713118	0.621	rs4713132	ENSG00000216901.1	AL022393.7	15.01	6.11e-42	1.79e-38	0.85	0.57	Parkinson's disease;	chr6:28066257	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.621	rs4713133	ENSG00000216901.1	AL022393.7	15.01	6.11e-42	1.79e-38	0.85	0.57	Parkinson's disease;	chr6:28066263	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.621	rs4713134	ENSG00000216901.1	AL022393.7	15.01	6.11e-42	1.79e-38	0.85	0.57	Parkinson's disease;	chr6:28066343	chr6:28176188~28176674:+
LGG	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-15.01	6.2e-42	1.82e-38	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
LGG	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	15.01	6.21e-42	1.82e-38	0.66	0.57	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	15.01	6.21e-42	1.82e-38	0.66	0.57	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
LGG	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-15	6.42e-42	1.88e-38	-0.54	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
LGG	cis	rs853679	0.513	rs13437444	ENSG00000216901.1	AL022393.7	15	6.62e-42	1.94e-38	0.94	0.57	Depression;	chr6:28103220	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	15	6.74e-42	1.97e-38	0.75	0.57	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
LGG	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	15	6.95e-42	2.03e-38	0.65	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
LGG	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	14.99	7.32e-42	2.14e-38	0.6	0.57	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
LGG	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	14.99	7.48e-42	2.18e-38	0.64	0.57	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
LGG	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-14.99	7.63e-42	2.22e-38	-0.73	-0.57	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
LGG	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-14.98	7.9e-42	2.3e-38	-0.62	-0.57	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
LGG	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-14.98	8.37e-42	2.43e-38	-0.96	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
LGG	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	14.98	8.51e-42	2.48e-38	0.7	0.57	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
LGG	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	14.98	8.55e-42	2.49e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
LGG	cis	rs79349575	0.756	rs62078385	ENSG00000248278.1	SUMO2P17	14.97	8.89e-42	2.59e-38	0.65	0.57	Type 2 diabetes;	chr17:48967647	chr17:48874860~48908983:-
LGG	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	14.97	8.91e-42	2.59e-38	0.75	0.57	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
LGG	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	14.97	9e-42	2.62e-38	0.7	0.57	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
LGG	cis	rs79349575	0.655	rs62078384	ENSG00000248278.1	SUMO2P17	14.97	9.03e-42	2.63e-38	0.65	0.57	Type 2 diabetes;	chr17:48967101	chr17:48874860~48908983:-
LGG	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	14.97	9.05e-42	2.63e-38	0.61	0.57	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
LGG	cis	rs1475911	0.708	rs8129075	ENSG00000184385.2	UMODL1-AS1	14.97	9.52e-42	2.77e-38	0.69	0.57	IgG glycosylation;	chr21:42103320	chr21:42102134~42108534:-
LGG	cis	rs79349575	0.721	rs2291725	ENSG00000248278.1	SUMO2P17	14.97	9.53e-42	2.77e-38	0.66	0.57	Type 2 diabetes;	chr17:48961770	chr17:48874860~48908983:-
LGG	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-14.96	9.68e-42	2.81e-38	-0.57	-0.57	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
LGG	cis	rs1475911	0.671	rs12483409	ENSG00000184385.2	UMODL1-AS1	14.96	1.04e-41	3.01e-38	0.68	0.57	IgG glycosylation;	chr21:42101792	chr21:42102134~42108534:-
LGG	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	14.96	1.04e-41	3.02e-38	0.51	0.57	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
LGG	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-14.95	1.13e-41	3.29e-38	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-14.95	1.13e-41	3.29e-38	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
LGG	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	14.95	1.13e-41	3.29e-38	0.73	0.57	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
LGG	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-14.95	1.15e-41	3.35e-38	-0.72	-0.57	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
LGG	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	14.94	1.2e-41	3.47e-38	0.7	0.57	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
LGG	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-14.94	1.2e-41	3.48e-38	-0.63	-0.57	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
LGG	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-14.94	1.21e-41	3.51e-38	-0.81	-0.57	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
LGG	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-14.93	1.38e-41	4e-38	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
LGG	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	14.92	1.49e-41	4.3e-38	0.81	0.57	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
LGG	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-14.92	1.49e-41	4.31e-38	-0.72	-0.57	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
LGG	cis	rs71281886	1	rs71281886	ENSG00000229759.1	MRPS18AP1	14.91	1.64e-41	4.72e-38	0.68	0.57	Breast cancer;	chr3:48311088	chr3:48256350~48256938:-
LGG	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-14.91	1.64e-41	4.73e-38	-0.59	-0.57	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
LGG	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	14.91	1.7e-41	4.88e-38	0.81	0.57	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
LGG	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-14.91	1.73e-41	4.98e-38	-0.72	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
LGG	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-14.9	1.89e-41	5.43e-38	-0.69	-0.56	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
LGG	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	14.89	2.06e-41	5.91e-38	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
LGG	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-14.89	2.07e-41	5.94e-38	-0.63	-0.56	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
LGG	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	-14.89	2.1e-41	6.01e-38	-0.59	-0.56	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
LGG	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-14.89	2.11e-41	6.04e-38	-0.59	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
LGG	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	14.89	2.14e-41	6.13e-38	0.97	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
LGG	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-14.88	2.26e-41	6.47e-38	-0.78	-0.56	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
LGG	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	14.88	2.34e-41	6.7e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
LGG	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-14.87	2.47e-41	7.04e-38	-0.74	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
LGG	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	14.87	2.47e-41	7.06e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
LGG	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-14.87	2.49e-41	7.1e-38	-0.61	-0.56	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
LGG	cis	rs8062405	0.823	rs7202948	ENSG00000271623.1	RP11-435I10.5	-14.87	2.49e-41	7.12e-38	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.824	rs7191618	ENSG00000271623.1	RP11-435I10.5	-14.87	2.49e-41	7.12e-38	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.754	rs3859172	ENSG00000271623.1	RP11-435I10.5	-14.87	2.49e-41	7.12e-38	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28364700~28365333:+
LGG	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	14.86	2.75e-41	7.83e-38	0.6	0.56	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
LGG	cis	rs1475911	0.708	rs66994219	ENSG00000184385.2	UMODL1-AS1	14.86	2.75e-41	7.83e-38	0.68	0.56	IgG glycosylation;	chr21:42101537	chr21:42102134~42108534:-
LGG	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	14.86	2.82e-41	8.02e-38	0.62	0.56	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
LGG	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	14.85	3.05e-41	8.68e-38	0.63	0.56	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	14.85	3.06e-41	8.68e-38	0.62	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
LGG	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	14.85	3.09e-41	8.78e-38	0.87	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
LGG	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	14.85	3.09e-41	8.78e-38	0.87	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
LGG	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	14.85	3.17e-41	9e-38	0.65	0.56	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
LGG	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	14.84	3.33e-41	9.45e-38	0.67	0.56	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
LGG	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	14.84	3.43e-41	9.72e-38	0.69	0.56	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
LGG	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-14.84	3.45e-41	9.77e-38	-0.7	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
LGG	cis	rs2282300	0.956	rs1717779	ENSG00000254532.1	RP11-624D11.2	14.84	3.46e-41	9.8e-38	0.83	0.56	Morning vs. evening chronotype;	chr11:30355151	chr11:30044058~30084343:-
LGG	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	14.83	3.88e-41	1.1e-37	0.62	0.56	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
LGG	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	14.83	3.99e-41	1.13e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
LGG	cis	rs4713118	0.662	rs149900	ENSG00000216901.1	AL022393.7	14.82	4.04e-41	1.14e-37	0.84	0.56	Parkinson's disease;	chr6:28046819	chr6:28176188~28176674:+
LGG	cis	rs1475911	0.708	rs56185023	ENSG00000184385.2	UMODL1-AS1	14.82	4.15e-41	1.17e-37	0.67	0.56	IgG glycosylation;	chr21:42101428	chr21:42102134~42108534:-
LGG	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	14.82	4.22e-41	1.19e-37	0.62	0.56	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
LGG	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	14.82	4.34e-41	1.23e-37	0.5	0.56	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
LGG	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	14.81	4.53e-41	1.28e-37	0.61	0.56	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
LGG	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	14.81	4.56e-41	1.29e-37	0.83	0.56	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
LGG	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	14.81	4.56e-41	1.29e-37	0.83	0.56	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
LGG	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	14.81	4.58e-41	1.29e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
LGG	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-14.81	4.69e-41	1.32e-37	-0.61	-0.56	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
LGG	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	14.81	4.82e-41	1.36e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	14.8	5.18e-41	1.46e-37	0.62	0.56	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
LGG	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	14.8	5.19e-41	1.46e-37	0.92	0.56	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
LGG	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	14.79	5.58e-41	1.57e-37	0.84	0.56	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
LGG	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	-14.79	5.67e-41	1.59e-37	-0.59	-0.56	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
LGG	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-14.79	5.77e-41	1.62e-37	-1.04	-0.56	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
LGG	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	14.78	6.21e-41	1.74e-37	0.65	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
LGG	cis	rs8062405	0.824	rs4788083	ENSG00000271623.1	RP11-435I10.5	-14.78	6.32e-41	1.77e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28364700~28365333:+
LGG	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-14.78	6.35e-41	1.78e-37	-0.62	-0.56	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
LGG	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	14.78	6.43e-41	1.8e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	14.78	6.43e-41	1.8e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
LGG	cis	rs8062405	0.824	rs28698667	ENSG00000271623.1	RP11-435I10.5	-14.77	6.71e-41	1.88e-37	-0.66	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28364700~28365333:+
LGG	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-14.77	6.74e-41	1.88e-37	-0.61	-0.56	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
LGG	cis	rs4713118	0.662	rs175954	ENSG00000216901.1	AL022393.7	14.77	7.05e-41	1.97e-37	0.82	0.56	Parkinson's disease;	chr6:28043807	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	14.76	7.88e-41	2.2e-37	0.63	0.56	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
LGG	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	14.75	8.26e-41	2.3e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
LGG	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-14.75	8.28e-41	2.31e-37	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
LGG	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-14.75	8.28e-41	2.31e-37	-0.52	-0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
LGG	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	14.75	8.38e-41	2.34e-37	0.62	0.56	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
LGG	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	14.75	8.55e-41	2.38e-37	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
LGG	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	14.75	8.77e-41	2.44e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
LGG	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	14.75	8.77e-41	2.44e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
LGG	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	14.75	8.85e-41	2.46e-37	0.73	0.56	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	14.75	8.85e-41	2.46e-37	0.73	0.56	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	14.75	8.87e-41	2.47e-37	0.73	0.56	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
LGG	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	14.74	9.02e-41	2.51e-37	0.62	0.56	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	14.74	9.19e-41	2.56e-37	0.62	0.56	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
LGG	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	14.74	9.22e-41	2.56e-37	0.64	0.56	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
LGG	cis	rs8062405	0.824	rs240702	ENSG00000271623.1	RP11-435I10.5	-14.74	9.27e-41	2.58e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28364700~28365333:+
LGG	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-14.74	9.32e-41	2.59e-37	-0.6	-0.56	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-14.74	9.32e-41	2.59e-37	-0.6	-0.56	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
LGG	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	14.74	9.67e-41	2.69e-37	0.64	0.56	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
LGG	cis	rs8062405	0.824	rs62034326	ENSG00000271623.1	RP11-435I10.5	-14.73	1e-40	2.79e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28364700~28365333:+
LGG	cis	rs4713118	0.662	rs156744	ENSG00000216901.1	AL022393.7	14.73	1.01e-40	2.8e-37	0.81	0.56	Parkinson's disease;	chr6:27999496	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs149946	ENSG00000216901.1	AL022393.7	-14.73	1.01e-40	2.8e-37	-0.81	-0.56	Parkinson's disease;	chr6:28002253	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs149947	ENSG00000216901.1	AL022393.7	14.73	1.01e-40	2.8e-37	0.81	0.56	Parkinson's disease;	chr6:28004655	chr6:28176188~28176674:+
LGG	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-14.73	1.02e-40	2.84e-37	-0.6	-0.56	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
LGG	cis	rs8062405	0.824	rs153106	ENSG00000271623.1	RP11-435I10.5	-14.73	1.03e-40	2.86e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28364700~28365333:+
LGG	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-14.73	1.1e-40	3.04e-37	-0.74	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
LGG	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	14.72	1.2e-40	3.32e-37	0.96	0.56	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
LGG	cis	rs2980439	0.807	rs2980438	ENSG00000173295.6	FAM86B3P	-14.71	1.23e-40	3.4e-37	-0.58	-0.56	Neuroticism;	chr8:8237303	chr8:8228595~8244865:+
LGG	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	14.71	1.24e-40	3.43e-37	0.58	0.56	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
LGG	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	14.71	1.27e-40	3.51e-37	0.83	0.56	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
LGG	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	14.71	1.32e-40	3.65e-37	0.71	0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
LGG	cis	rs8062405	0.792	rs12446550	ENSG00000271623.1	RP11-435I10.5	-14.7	1.35e-40	3.74e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28364700~28365333:+
LGG	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	14.7	1.37e-40	3.79e-37	0.62	0.56	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
LGG	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-14.7	1.37e-40	3.79e-37	-0.7	-0.56	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
LGG	cis	rs8062405	0.824	rs4788084	ENSG00000271623.1	RP11-435I10.5	-14.7	1.4e-40	3.86e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28364700~28365333:+
LGG	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	14.7	1.4e-40	3.87e-37	0.75	0.56	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
LGG	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	14.7	1.45e-40	3.99e-37	0.93	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
LGG	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-14.7	1.45e-40	4.01e-37	-0.62	-0.56	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
LGG	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	14.7	1.47e-40	4.06e-37	0.58	0.56	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
LGG	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	14.69	1.52e-40	4.19e-37	1.01	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	14.69	1.52e-40	4.19e-37	1.01	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	14.69	1.52e-40	4.19e-37	1.01	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
LGG	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	14.68	1.66e-40	4.58e-37	0.62	0.56	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
LGG	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	14.68	1.79e-40	4.92e-37	0.5	0.56	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
LGG	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	14.67	1.84e-40	5.07e-37	0.95	0.56	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
LGG	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	14.67	1.85e-40	5.09e-37	0.96	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
LGG	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	14.67	1.86e-40	5.11e-37	0.76	0.56	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
LGG	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-14.67	1.89e-40	5.18e-37	-0.72	-0.56	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
LGG	cis	rs8062405	0.824	rs62034319	ENSG00000271623.1	RP11-435I10.5	-14.67	1.89e-40	5.2e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28364700~28365333:+
LGG	cis	rs916888	0.61	rs199529	ENSG00000261575.2	RP11-259G18.1	14.66	2.14e-40	5.86e-37	0.74	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46267037~46268694:+
LGG	cis	rs2282300	0.91	rs528292	ENSG00000254532.1	RP11-624D11.2	-14.66	2.18e-40	5.99e-37	-0.81	-0.56	Morning vs. evening chronotype;	chr11:30368163	chr11:30044058~30084343:-
LGG	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-14.66	2.2e-40	6.03e-37	-0.72	-0.56	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
LGG	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-14.66	2.2e-40	6.03e-37	-0.72	-0.56	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
LGG	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	14.66	2.21e-40	6.06e-37	0.92	0.56	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	14.65	2.25e-40	6.17e-37	0.72	0.56	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
LGG	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	14.65	2.28e-40	6.27e-37	0.69	0.56	Breast cancer;	chr11:750849	chr11:779617~780755:+
LGG	cis	rs8062405	0.789	rs240704	ENSG00000271623.1	RP11-435I10.5	-14.65	2.29e-40	6.29e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28364700~28365333:+
LGG	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-14.65	2.31e-40	6.33e-37	-0.69	-0.56	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
LGG	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-14.65	2.37e-40	6.51e-37	-0.72	-0.56	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
LGG	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	14.65	2.38e-40	6.52e-37	0.6	0.56	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
LGG	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-14.65	2.39e-40	6.55e-37	-0.7	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
LGG	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-14.65	2.39e-40	6.55e-37	-0.73	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
LGG	cis	rs8062405	0.754	rs62034323	ENSG00000271623.1	RP11-435I10.5	-14.65	2.43e-40	6.66e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.824	rs62034324	ENSG00000271623.1	RP11-435I10.5	-14.65	2.43e-40	6.66e-37	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28364700~28365333:+
LGG	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-14.65	2.46e-40	6.74e-37	-0.8	-0.56	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
LGG	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-14.64	2.5e-40	6.84e-37	-0.72	-0.56	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
LGG	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-14.64	2.51e-40	6.87e-37	-0.63	-0.56	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	14.64	2.7e-40	7.39e-37	0.63	0.56	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
LGG	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-14.64	2.7e-40	7.39e-37	-0.61	-0.56	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	14.64	2.71e-40	7.41e-37	0.74	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
LGG	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-14.63	2.77e-40	7.57e-37	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
LGG	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-14.63	2.84e-40	7.77e-37	-0.79	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
LGG	cis	rs2282300	0.956	rs1717773	ENSG00000254532.1	RP11-624D11.2	14.63	2.86e-40	7.81e-37	0.81	0.56	Morning vs. evening chronotype;	chr11:30361607	chr11:30044058~30084343:-
LGG	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	14.63	2.93e-40	8e-37	0.69	0.56	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
LGG	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	14.63	3.01e-40	8.22e-37	0.91	0.56	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
LGG	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-14.62	3.19e-40	8.69e-37	-0.74	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
LGG	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-14.62	3.26e-40	8.9e-37	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
LGG	cis	rs6908034	0.769	rs6916589	ENSG00000228412.5	RP4-625H18.2	14.61	3.38e-40	9.21e-37	0.9	0.56	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19802164~19804752:-
LGG	cis	rs2282300	0.956	rs2685286	ENSG00000254532.1	RP11-624D11.2	14.61	3.4e-40	9.26e-37	0.81	0.56	Morning vs. evening chronotype;	chr11:30360041	chr11:30044058~30084343:-
LGG	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-14.61	3.4e-40	9.28e-37	-0.78	-0.56	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
LGG	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	14.61	3.51e-40	9.58e-37	0.93	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	14.61	3.51e-40	9.58e-37	0.93	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
LGG	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-14.61	3.6e-40	9.81e-37	-0.6	-0.56	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	14.61	3.61e-40	9.84e-37	0.6	0.56	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
LGG	cis	rs4713118	0.662	rs149970	ENSG00000216901.1	AL022393.7	14.61	3.68e-40	1e-36	0.76	0.56	Parkinson's disease;	chr6:28012442	chr6:28176188~28176674:+
LGG	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-14.6	3.76e-40	1.02e-36	-0.87	-0.56	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
LGG	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-14.6	3.8e-40	1.03e-36	-0.7	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
LGG	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-14.6	4.09e-40	1.11e-36	-0.8	-0.56	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
LGG	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	14.59	4.22e-40	1.15e-36	0.75	0.56	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
LGG	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-14.59	4.27e-40	1.16e-36	-0.66	-0.56	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
LGG	cis	rs2282300	0.956	rs594937	ENSG00000254532.1	RP11-624D11.2	-14.59	4.37e-40	1.19e-36	-0.81	-0.56	Morning vs. evening chronotype;	chr11:30368585	chr11:30044058~30084343:-
LGG	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-14.59	4.49e-40	1.22e-36	-0.91	-0.56	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-14.59	4.49e-40	1.22e-36	-0.91	-0.56	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
LGG	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-14.58	4.67e-40	1.26e-36	-0.71	-0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-14.58	4.67e-40	1.26e-36	-0.71	-0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-14.58	4.67e-40	1.26e-36	-0.71	-0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
LGG	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-14.58	4.7e-40	1.27e-36	-0.72	-0.56	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
LGG	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-14.58	4.72e-40	1.28e-36	-0.73	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
LGG	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	14.58	4.78e-40	1.3e-36	0.93	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
LGG	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	14.58	4.84e-40	1.31e-36	0.73	0.56	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
LGG	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	14.58	4.84e-40	1.31e-36	0.75	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
LGG	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	14.57	5.07e-40	1.37e-36	0.7	0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
LGG	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	14.57	5.32e-40	1.44e-36	0.43	0.56	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
LGG	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	14.57	5.32e-40	1.44e-36	0.43	0.56	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
LGG	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-14.57	5.56e-40	1.5e-36	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-14.57	5.56e-40	1.5e-36	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-14.57	5.56e-40	1.5e-36	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-14.57	5.56e-40	1.5e-36	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-14.57	5.56e-40	1.5e-36	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
LGG	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-14.57	5.56e-40	1.5e-36	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
LGG	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-14.56	5.63e-40	1.52e-36	-0.73	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
LGG	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	14.56	5.65e-40	1.53e-36	0.89	0.56	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
LGG	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-14.56	5.72e-40	1.55e-36	-0.78	-0.56	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
LGG	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-14.56	5.93e-40	1.6e-36	-0.62	-0.56	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
LGG	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	14.56	5.98e-40	1.61e-36	0.63	0.56	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
LGG	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-14.56	6.03e-40	1.63e-36	-0.71	-0.56	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
LGG	cis	rs2282300	0.956	rs654710	ENSG00000254532.1	RP11-624D11.2	-14.56	6.17e-40	1.66e-36	-0.8	-0.56	Morning vs. evening chronotype;	chr11:30372756	chr11:30044058~30084343:-
LGG	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-14.55	6.3e-40	1.7e-36	-0.71	-0.56	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
LGG	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-14.55	6.4e-40	1.73e-36	-0.79	-0.56	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
LGG	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	14.55	6.49e-40	1.75e-36	0.49	0.56	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
LGG	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	14.55	6.61e-40	1.78e-36	0.62	0.56	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	14.55	6.67e-40	1.8e-36	0.71	0.56	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
LGG	cis	rs8062405	0.789	rs2106480	ENSG00000271623.1	RP11-435I10.5	-14.55	6.74e-40	1.82e-36	-0.65	-0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28364700~28365333:+
LGG	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-14.55	6.77e-40	1.82e-36	-0.69	-0.56	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
LGG	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	14.55	6.82e-40	1.84e-36	0.64	0.56	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
LGG	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-14.54	7.35e-40	1.98e-36	-0.74	-0.56	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
LGG	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-14.54	7.41e-40	1.99e-36	-0.71	-0.56	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
LGG	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	14.53	7.66e-40	2.06e-36	0.74	0.56	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
LGG	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-14.53	7.91e-40	2.13e-36	-0.71	-0.56	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
LGG	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	14.53	8.29e-40	2.23e-36	0.93	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
LGG	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	14.52	8.75e-40	2.35e-36	0.66	0.55	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
LGG	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	14.52	8.8e-40	2.36e-36	0.69	0.55	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
LGG	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	14.52	8.86e-40	2.38e-36	0.79	0.55	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
LGG	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-14.52	9.03e-40	2.42e-36	-0.71	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
LGG	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	-14.52	9.14e-40	2.45e-36	-0.59	-0.55	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
LGG	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	14.51	9.32e-40	2.5e-36	0.64	0.55	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
LGG	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	14.51	9.38e-40	2.51e-36	0.74	0.55	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
LGG	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	14.51	9.59e-40	2.57e-36	0.7	0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-14.51	9.67e-40	2.59e-36	-0.73	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
LGG	cis	rs7829975	0.511	rs1401390	ENSG00000173295.6	FAM86B3P	-14.51	9.7e-40	2.6e-36	-0.59	-0.55	Mood instability;	chr8:8278888	chr8:8228595~8244865:+
LGG	cis	rs7216064	0.601	rs35453056	ENSG00000278219.1	AC145343.1	14.51	9.75e-40	2.61e-36	0.66	0.55	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.628	rs62084702	ENSG00000278219.1	AC145343.1	14.51	9.75e-40	2.61e-36	0.66	0.55	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68101538~68101639:+
LGG	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-14.51	9.77e-40	2.61e-36	-0.81	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	14.51	9.91e-40	2.65e-36	0.73	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
LGG	cis	rs7216064	0.636	rs4638	ENSG00000278219.1	AC145343.1	14.51	1e-39	2.67e-36	0.66	0.55	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68101538~68101639:+
LGG	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	14.51	1.01e-39	2.7e-36	0.69	0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
LGG	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-14.51	1.01e-39	2.71e-36	-0.68	-0.55	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
LGG	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	14.51	1.01e-39	2.71e-36	0.75	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
LGG	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	14.51	1.02e-39	2.72e-36	0.63	0.55	Height;	chr11:118737823	chr11:118688039~118690600:-
LGG	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	14.5	1.04e-39	2.79e-36	0.64	0.55	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	14.5	1.04e-39	2.79e-36	0.64	0.55	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	14.5	1.04e-39	2.79e-36	0.64	0.55	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
LGG	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-14.5	1.06e-39	2.82e-36	-0.86	-0.55	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
LGG	cis	rs7829975	0.511	rs1543238	ENSG00000173295.6	FAM86B3P	-14.5	1.08e-39	2.9e-36	-0.59	-0.55	Mood instability;	chr8:8277287	chr8:8228595~8244865:+
LGG	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-14.5	1.09e-39	2.91e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-14.5	1.09e-39	2.91e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
LGG	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-14.5	1.09e-39	2.92e-36	-0.62	-0.55	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
LGG	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	14.5	1.12e-39	3e-36	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	14.5	1.12e-39	3e-36	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	14.5	1.12e-39	3e-36	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
LGG	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	14.5	1.12e-39	3e-36	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	14.5	1.12e-39	3e-36	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
LGG	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	14.5	1.12e-39	3e-36	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
LGG	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	14.5	1.13e-39	3.01e-36	0.85	0.55	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
LGG	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	14.49	1.18e-39	3.14e-36	0.68	0.55	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
LGG	cis	rs4713118	0.669	rs200997	ENSG00000199851.2	U3	14.49	1.22e-39	3.26e-36	0.76	0.55	Parkinson's disease;	chr6:27844037	chr6:28015568~28015777:+
LGG	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	14.48	1.27e-39	3.37e-36	0.7	0.55	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
LGG	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	14.48	1.27e-39	3.39e-36	0.63	0.55	Height;	chr11:118737916	chr11:118688039~118690600:-
LGG	cis	rs1475911	0.708	rs56109792	ENSG00000184385.2	UMODL1-AS1	14.48	1.29e-39	3.43e-36	0.67	0.55	IgG glycosylation;	chr21:42099950	chr21:42102134~42108534:-
LGG	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	14.48	1.3e-39	3.47e-36	0.64	0.55	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
LGG	cis	rs4713118	0.629	rs203887	ENSG00000199851.2	U3	14.48	1.32e-39	3.52e-36	1.01	0.55	Parkinson's disease;	chr6:28053491	chr6:28015568~28015777:+
LGG	cis	rs7826238	0.594	rs2948285	ENSG00000173295.6	FAM86B3P	-14.48	1.33e-39	3.53e-36	-0.59	-0.55	Systolic blood pressure;	chr8:8273016	chr8:8228595~8244865:+
LGG	cis	rs2282300	0.956	rs1222212	ENSG00000254532.1	RP11-624D11.2	14.47	1.42e-39	3.79e-36	0.81	0.55	Morning vs. evening chronotype;	chr11:30353096	chr11:30044058~30084343:-
LGG	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-14.46	1.58e-39	4.2e-36	-0.63	-0.55	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
LGG	cis	rs8062405	0.824	rs4788085	ENSG00000271623.1	RP11-435I10.5	-14.46	1.66e-39	4.4e-36	-0.64	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.824	rs28772958	ENSG00000271623.1	RP11-435I10.5	-14.46	1.66e-39	4.4e-36	-0.64	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28364700~28365333:+
LGG	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	14.46	1.66e-39	4.41e-36	0.64	0.55	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
LGG	cis	rs79349575	0.715	rs11657238	ENSG00000248278.1	SUMO2P17	14.46	1.67e-39	4.43e-36	0.62	0.55	Type 2 diabetes;	chr17:48908272	chr17:48874860~48908983:-
LGG	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-14.46	1.67e-39	4.43e-36	-0.62	-0.55	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
LGG	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	14.45	1.71e-39	4.54e-36	0.6	0.55	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
LGG	cis	rs9532669	0.926	rs11147831	ENSG00000176268.5	CYCSP34	14.45	1.76e-39	4.66e-36	0.64	0.55	Cervical cancer;	chr13:40978593	chr13:40863599~40863902:-
LGG	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-14.45	1.79e-39	4.73e-36	-0.9	-0.55	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	14.45	1.82e-39	4.82e-36	0.68	0.55	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
LGG	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-14.45	1.83e-39	4.85e-36	-0.71	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-14.45	1.83e-39	4.85e-36	-0.71	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
LGG	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-14.44	1.91e-39	5.04e-36	-0.59	-0.55	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
LGG	cis	rs4713118	0.662	rs149969	ENSG00000216901.1	AL022393.7	14.44	1.91e-39	5.04e-36	0.8	0.55	Parkinson's disease;	chr6:28009959	chr6:28176188~28176674:+
LGG	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-14.44	2.01e-39	5.3e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
LGG	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-14.44	2.02e-39	5.32e-36	-0.62	-0.55	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
LGG	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	14.44	2.02e-39	5.32e-36	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
LGG	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-14.44	2.06e-39	5.43e-36	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
LGG	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-14.43	2.08e-39	5.48e-36	-0.43	-0.55	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	14.43	2.08e-39	5.48e-36	0.43	0.55	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
LGG	cis	rs7216064	0.636	rs62084696	ENSG00000278219.1	AC145343.1	14.43	2.12e-39	5.58e-36	0.65	0.55	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.684	rs7406031	ENSG00000278219.1	AC145343.1	14.43	2.15e-39	5.66e-36	0.65	0.55	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68101538~68101639:+
LGG	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-14.43	2.26e-39	5.94e-36	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
LGG	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-14.43	2.26e-39	5.95e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
LGG	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	14.42	2.32e-39	6.11e-36	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
LGG	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	14.42	2.33e-39	6.13e-36	0.65	0.55	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
LGG	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-14.42	2.35e-39	6.18e-36	-0.69	-0.55	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
LGG	cis	rs950027	0.596	rs2467865	ENSG00000259433.2	CTD-2651B20.4	-14.42	2.39e-39	6.28e-36	-0.6	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45330209~45332634:-
LGG	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	14.42	2.4e-39	6.3e-36	0.62	0.55	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
LGG	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-14.42	2.48e-39	6.53e-36	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
LGG	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	14.42	2.51e-39	6.59e-36	0.43	0.55	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	14.42	2.51e-39	6.59e-36	0.43	0.55	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	14.42	2.51e-39	6.59e-36	0.43	0.55	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
LGG	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	14.41	2.54e-39	6.67e-36	0.79	0.55	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-14.41	2.67e-39	7.01e-36	-0.69	-0.55	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
LGG	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	14.41	2.74e-39	7.19e-36	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
LGG	cis	rs916888	0.61	rs199529	ENSG00000262500.1	RP11-259G18.2	14.41	2.77e-39	7.26e-36	0.79	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46243606~46245044:+
LGG	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	14.4	2.85e-39	7.47e-36	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	14.4	3.07e-39	8.03e-36	0.68	0.55	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
LGG	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-14.39	3.28e-39	8.59e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-14.39	3.28e-39	8.59e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
LGG	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	14.39	3.39e-39	8.86e-36	0.74	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	14.39	3.39e-39	8.86e-36	0.74	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
LGG	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-14.38	3.45e-39	9.01e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-14.38	3.47e-39	9.07e-36	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
LGG	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	14.38	3.51e-39	9.16e-36	0.72	0.55	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
LGG	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	14.38	3.55e-39	9.26e-36	0.61	0.55	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
LGG	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-14.38	3.7e-39	9.65e-36	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-14.38	3.7e-39	9.65e-36	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
LGG	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-14.38	3.73e-39	9.72e-36	-0.69	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
LGG	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	14.38	3.75e-39	9.77e-36	0.62	0.55	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	14.38	3.75e-39	9.77e-36	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
LGG	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-14.38	3.79e-39	9.87e-36	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
LGG	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	14.37	3.83e-39	9.97e-36	0.62	0.55	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
LGG	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	14.37	4.01e-39	1.05e-35	0.94	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
LGG	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	14.37	4.09e-39	1.06e-35	0.43	0.55	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	14.37	4.09e-39	1.06e-35	0.43	0.55	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
LGG	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	14.37	4.12e-39	1.07e-35	0.61	0.55	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
LGG	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	14.37	4.13e-39	1.07e-35	0.58	0.55	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
LGG	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	14.36	4.23e-39	1.1e-35	0.79	0.55	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.923	rs2184370	ENSG00000268592.3	RAET1E-AS1	14.36	4.28e-39	1.11e-35	0.7	0.55	Lung cancer;	chr6:149843242	chr6:149863494~149919507:+
LGG	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	14.36	4.3e-39	1.12e-35	0.62	0.55	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
LGG	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	14.36	4.35e-39	1.13e-35	0.74	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
LGG	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	14.36	4.44e-39	1.15e-35	0.79	0.55	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
LGG	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-14.36	4.58e-39	1.19e-35	-0.68	-0.55	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
LGG	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-14.35	4.73e-39	1.23e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
LGG	cis	rs7216064	0.684	rs62084675	ENSG00000278219.1	AC145343.1	14.35	4.84e-39	1.25e-35	0.65	0.55	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68101538~68101639:+
LGG	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	14.35	4.88e-39	1.26e-35	0.61	0.55	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
LGG	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-14.35	4.93e-39	1.28e-35	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
LGG	cis	rs9322193	0.962	rs2275045	ENSG00000268592.3	RAET1E-AS1	14.35	4.97e-39	1.29e-35	0.7	0.55	Lung cancer;	chr6:149842775	chr6:149863494~149919507:+
LGG	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-14.35	4.98e-39	1.29e-35	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-14.35	5.08e-39	1.31e-35	-0.62	-0.55	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	14.34	5.13e-39	1.33e-35	0.68	0.55	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
LGG	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-14.34	5.14e-39	1.33e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
LGG	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	14.34	5.53e-39	1.43e-35	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-14.34	5.53e-39	1.43e-35	-0.63	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
LGG	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	14.33	5.67e-39	1.46e-35	0.99	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	14.33	5.67e-39	1.46e-35	0.99	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	14.33	5.67e-39	1.46e-35	0.99	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
LGG	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	14.33	5.67e-39	1.46e-35	0.69	0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
LGG	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	14.33	5.82e-39	1.5e-35	0.63	0.55	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	14.33	5.82e-39	1.5e-35	0.63	0.55	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
LGG	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	14.33	5.82e-39	1.5e-35	0.63	0.55	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
LGG	cis	rs6452524	0.711	rs1478486	ENSG00000248112.1	RP11-78C3.1	14.33	5.88e-39	1.52e-35	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:82919376~82921119:-
LGG	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-14.33	6.13e-39	1.58e-35	-0.69	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
LGG	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-14.33	6.15e-39	1.59e-35	-0.86	-0.55	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
LGG	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	14.32	6.35e-39	1.64e-35	0.67	0.55	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	14.32	6.51e-39	1.68e-35	0.68	0.55	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
LGG	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-14.32	6.57e-39	1.69e-35	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-14.32	6.57e-39	1.69e-35	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
LGG	cis	rs7829975	0.509	rs2945269	ENSG00000173295.6	FAM86B3P	-14.32	6.67e-39	1.72e-35	-0.57	-0.55	Mood instability;	chr8:8258056	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	14.32	6.72e-39	1.73e-35	0.69	0.55	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
LGG	cis	rs950027	0.596	rs2467853	ENSG00000259433.2	CTD-2651B20.4	-14.31	6.97e-39	1.79e-35	-0.6	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45330209~45332634:-
LGG	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	14.31	6.98e-39	1.8e-35	0.63	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
LGG	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	14.31	7.09e-39	1.82e-35	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
LGG	cis	rs7216064	0.532	rs8065296	ENSG00000278219.1	AC145343.1	14.31	7.09e-39	1.82e-35	0.65	0.55	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68101538~68101639:+
LGG	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	14.31	7.14e-39	1.84e-35	0.84	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
LGG	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-14.31	7.15e-39	1.84e-35	-0.89	-0.55	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
LGG	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	14.31	7.22e-39	1.86e-35	0.79	0.55	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
LGG	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	14.31	7.26e-39	1.87e-35	0.92	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	14.31	7.26e-39	1.87e-35	0.92	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	14.31	7.27e-39	1.87e-35	0.68	0.55	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
LGG	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-14.31	7.33e-39	1.88e-35	-0.77	-0.55	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
LGG	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	14.31	7.47e-39	1.92e-35	0.7	0.55	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
LGG	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	14.31	7.48e-39	1.92e-35	0.93	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
LGG	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	14.31	7.5e-39	1.93e-35	0.92	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	14.31	7.5e-39	1.93e-35	0.92	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
LGG	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	14.31	7.54e-39	1.94e-35	0.75	0.55	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
LGG	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-14.3	7.75e-39	1.99e-35	-0.65	-0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	14.3	7.83e-39	2.01e-35	0.67	0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
LGG	cis	rs7826238	0.509	rs2948288	ENSG00000173295.6	FAM86B3P	-14.3	7.88e-39	2.02e-35	-0.57	-0.55	Systolic blood pressure;	chr8:8257782	chr8:8228595~8244865:+
LGG	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-14.3	7.95e-39	2.04e-35	-0.74	-0.55	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
LGG	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	14.3	8.03e-39	2.06e-35	0.89	0.55	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	14.3	8.1e-39	2.08e-35	0.67	0.55	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	14.3	8.23e-39	2.11e-35	0.62	0.55	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	14.3	8.23e-39	2.11e-35	0.62	0.55	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
LGG	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-14.3	8.3e-39	2.13e-35	-0.7	-0.55	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
LGG	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	14.3	8.34e-39	2.14e-35	0.98	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	14.29	8.56e-39	2.19e-35	0.68	0.55	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	14.29	8.56e-39	2.19e-35	0.68	0.55	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	14.29	8.56e-39	2.19e-35	0.68	0.55	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
LGG	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-14.29	8.58e-39	2.2e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
LGG	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-14.29	8.89e-39	2.28e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-14.29	8.89e-39	2.28e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-14.29	8.89e-39	2.28e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
LGG	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	14.29	8.96e-39	2.29e-35	0.61	0.55	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
LGG	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-14.29	9.14e-39	2.34e-35	-0.8	-0.55	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
LGG	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	14.29	9.33e-39	2.39e-35	0.69	0.55	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	14.28	9.47e-39	2.42e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
LGG	cis	rs651907	0.557	rs7651721	ENSG00000244119.1	PDCL3P4	14.28	9.62e-39	2.46e-35	0.43	0.55	Colorectal cancer;	chr3:101674739	chr3:101712472~101713191:+
LGG	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	14.28	9.66e-39	2.47e-35	0.62	0.55	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
LGG	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	14.28	1e-38	2.57e-35	0.75	0.55	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
LGG	cis	rs172166	0.516	rs1225618	ENSG00000199851.2	U3	14.28	1.01e-38	2.57e-35	0.73	0.55	Cardiac Troponin-T levels;	chr6:28161935	chr6:28015568~28015777:+
LGG	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	14.28	1.03e-38	2.62e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
LGG	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	14.28	1.03e-38	2.63e-35	0.65	0.55	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
LGG	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-14.27	1.05e-38	2.68e-35	-0.82	-0.55	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
LGG	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-14.27	1.06e-38	2.7e-35	-0.77	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
LGG	cis	rs1930961	1	rs6004657	ENSG00000100058.11	CRYBB2P1	14.27	1.06e-38	2.7e-35	0.93	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25448105~25520854:+
LGG	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-14.27	1.06e-38	2.7e-35	-0.65	-0.55	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
LGG	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-14.27	1.07e-38	2.72e-35	-0.58	-0.55	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
LGG	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	14.27	1.07e-38	2.73e-35	0.67	0.55	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
LGG	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-14.27	1.08e-38	2.75e-35	-0.62	-0.55	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
LGG	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-14.27	1.08e-38	2.75e-35	-0.62	-0.55	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
LGG	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	14.27	1.1e-38	2.81e-35	0.42	0.55	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	14.27	1.1e-38	2.81e-35	0.42	0.55	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
LGG	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	14.26	1.15e-38	2.93e-35	0.74	0.55	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
LGG	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	14.26	1.17e-38	2.97e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
LGG	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	14.26	1.18e-38	3e-35	0.64	0.55	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
LGG	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	14.26	1.2e-38	3.05e-35	0.81	0.55	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
LGG	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	-14.26	1.22e-38	3.1e-35	-0.56	-0.55	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
LGG	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-14.26	1.22e-38	3.11e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
LGG	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	14.25	1.29e-38	3.27e-35	0.7	0.55	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	14.25	1.29e-38	3.27e-35	0.7	0.55	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	14.25	1.29e-38	3.27e-35	0.7	0.55	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	14.25	1.31e-38	3.32e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
LGG	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	14.25	1.35e-38	3.42e-35	0.98	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
LGG	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	14.25	1.37e-38	3.47e-35	0.92	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
LGG	cis	rs67383717	0.643	rs72756397	ENSG00000175611.10	LINC00476	-14.25	1.39e-38	3.53e-35	-0.65	-0.55	Parkinson's disease (pesticide exposure interaction);	chr9:95790861	chr9:95759231~95875977:-
LGG	cis	rs950027	0.62	rs35861938	ENSG00000259433.2	CTD-2651B20.4	-14.24	1.41e-38	3.56e-35	-0.59	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	14.24	1.45e-38	3.67e-35	0.67	0.55	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	14.24	1.45e-38	3.67e-35	0.67	0.55	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
LGG	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-14.24	1.46e-38	3.71e-35	-0.65	-0.55	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
LGG	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-14.24	1.46e-38	3.71e-35	-0.65	-0.55	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
LGG	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-14.24	1.46e-38	3.71e-35	-0.65	-0.55	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
LGG	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	14.24	1.47e-38	3.72e-35	0.88	0.55	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
LGG	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	14.24	1.52e-38	3.85e-35	0.73	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
LGG	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	14.24	1.53e-38	3.87e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-14.24	1.54e-38	3.88e-35	-0.68	-0.55	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	14.24	1.54e-38	3.88e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
LGG	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	14.24	1.54e-38	3.88e-35	0.63	0.55	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	14.24	1.54e-38	3.88e-35	0.63	0.55	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
LGG	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	14.24	1.54e-38	3.89e-35	0.42	0.55	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
LGG	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	14.24	1.54e-38	3.89e-35	0.62	0.55	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
LGG	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-14.23	1.56e-38	3.93e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
LGG	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-14.23	1.56e-38	3.93e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
LGG	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-14.23	1.56e-38	3.93e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
LGG	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-14.23	1.56e-38	3.93e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
LGG	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-14.23	1.56e-38	3.93e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
LGG	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-14.23	1.56e-38	3.93e-35	-0.72	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
LGG	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-14.23	1.57e-38	3.96e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
LGG	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	14.23	1.61e-38	4.07e-35	0.98	0.55	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	14.23	1.65e-38	4.17e-35	0.68	0.55	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	14.23	1.65e-38	4.17e-35	0.68	0.55	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
LGG	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	14.23	1.67e-38	4.21e-35	0.7	0.55	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
LGG	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-14.22	1.71e-38	4.32e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
LGG	cis	rs950027	0.62	rs2461700	ENSG00000259433.2	CTD-2651B20.4	-14.22	1.74e-38	4.38e-35	-0.59	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45330209~45332634:-
LGG	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	14.22	1.82e-38	4.58e-35	0.73	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	14.22	1.82e-38	4.58e-35	0.73	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
LGG	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	14.22	1.83e-38	4.61e-35	0.61	0.55	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	14.21	1.89e-38	4.75e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	14.21	1.94e-38	4.86e-35	0.67	0.55	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	14.21	1.94e-38	4.86e-35	0.67	0.55	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	14.21	1.94e-38	4.86e-35	0.67	0.55	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
LGG	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	14.21	1.97e-38	4.94e-35	0.61	0.55	Height;	chr11:118760944	chr11:118688039~118690600:-
LGG	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	14.21	2.01e-38	5.04e-35	0.61	0.55	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	14.21	2.01e-38	5.04e-35	0.61	0.55	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
LGG	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	14.21	2.01e-38	5.06e-35	0.59	0.55	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
LGG	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	14.21	2.02e-38	5.07e-35	0.96	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
LGG	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	14.21	2.05e-38	5.15e-35	0.42	0.55	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
LGG	cis	rs4373814	0.857	rs11012783	ENSG00000226083.4	SLC39A12-AS1	14.21	2.06e-38	5.17e-35	0.57	0.55	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18136489	chr10:18001786~18010562:-
LGG	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-14.21	2.08e-38	5.22e-35	-0.63	-0.55	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
LGG	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	14.2	2.11e-38	5.3e-35	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
LGG	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	14.2	2.14e-38	5.37e-35	0.61	0.55	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
LGG	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	14.2	2.15e-38	5.38e-35	0.69	0.55	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
LGG	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-14.2	2.18e-38	5.46e-35	-0.65	-0.55	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	14.2	2.18e-38	5.46e-35	0.67	0.55	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	14.2	2.25e-38	5.64e-35	0.65	0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	14.2	2.25e-38	5.64e-35	0.65	0.55	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
LGG	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	14.2	2.28e-38	5.72e-35	0.63	0.55	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	14.2	2.31e-38	5.77e-35	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	14.2	2.31e-38	5.77e-35	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	14.19	2.32e-38	5.81e-35	0.68	0.55	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	14.19	2.32e-38	5.81e-35	0.62	0.55	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	14.19	2.33e-38	5.84e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
LGG	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	14.19	2.36e-38	5.9e-35	0.89	0.55	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
LGG	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	14.19	2.36e-38	5.91e-35	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
LGG	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-14.19	2.38e-38	5.95e-35	-0.77	-0.55	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
LGG	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-14.19	2.41e-38	6.01e-35	-0.68	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-14.19	2.41e-38	6.01e-35	-0.68	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-14.19	2.41e-38	6.01e-35	-0.68	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-14.19	2.41e-38	6.01e-35	-0.68	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
LGG	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-14.19	2.42e-38	6.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
LGG	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	14.19	2.44e-38	6.11e-35	0.73	0.55	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	14.19	2.47e-38	6.18e-35	0.68	0.55	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
LGG	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	14.19	2.51e-38	6.27e-35	0.89	0.55	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
LGG	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	14.18	2.56e-38	6.38e-35	0.67	0.55	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
LGG	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-14.18	2.56e-38	6.39e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
LGG	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	14.18	2.57e-38	6.42e-35	0.61	0.55	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	14.18	2.57e-38	6.42e-35	0.61	0.55	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
LGG	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	14.18	2.59e-38	6.46e-35	0.63	0.55	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
LGG	cis	rs8062405	0.964	rs11860513	ENSG00000271623.1	RP11-435I10.5	-14.18	2.6e-38	6.5e-35	-0.63	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28364700~28365333:+
LGG	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	14.18	2.66e-38	6.63e-35	0.75	0.55	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	14.18	2.66e-38	6.63e-35	0.75	0.55	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
LGG	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	14.18	2.67e-38	6.66e-35	0.6	0.55	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
LGG	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	14.18	2.68e-38	6.67e-35	0.71	0.55	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
LGG	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	14.18	2.68e-38	6.67e-35	0.71	0.55	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
LGG	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	14.18	2.77e-38	6.9e-35	0.62	0.55	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
LGG	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-14.18	2.77e-38	6.91e-35	-0.62	-0.55	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
LGG	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-14.18	2.79e-38	6.95e-35	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-14.18	2.79e-38	6.95e-35	-0.7	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
LGG	cis	rs4713118	0.662	rs9393881	ENSG00000216901.1	AL022393.7	14.18	2.8e-38	6.98e-35	0.81	0.55	Parkinson's disease;	chr6:28055973	chr6:28176188~28176674:+
LGG	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-14.17	2.84e-38	7.06e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
LGG	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	14.17	2.89e-38	7.18e-35	0.66	0.55	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	14.17	2.95e-38	7.32e-35	0.61	0.55	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	14.17	3.04e-38	7.54e-35	0.68	0.55	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	14.17	3.07e-38	7.61e-35	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
LGG	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	14.17	3.1e-38	7.67e-35	0.61	0.55	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
LGG	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-14.16	3.3e-38	8.14e-35	-0.83	-0.55	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	14.16	3.38e-38	8.33e-35	0.67	0.55	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	14.16	3.41e-38	8.42e-35	0.67	0.55	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	14.15	3.44e-38	8.5e-35	0.67	0.55	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
LGG	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-14.15	3.48e-38	8.58e-35	-0.63	-0.55	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-14.15	3.48e-38	8.58e-35	-0.63	-0.55	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
LGG	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-14.15	3.5e-38	8.64e-35	-0.58	-0.55	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
LGG	cis	rs1150668	0.835	rs1233696	ENSG00000199851.2	U3	14.15	3.51e-38	8.65e-35	0.73	0.55	Pubertal anthropometrics;	chr6:28175232	chr6:28015568~28015777:+
LGG	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	14.15	3.51e-38	8.66e-35	0.63	0.55	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	14.15	3.61e-38	8.91e-35	0.67	0.54	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
LGG	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	14.15	3.62e-38	8.93e-35	0.75	0.54	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
LGG	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	14.15	3.71e-38	9.15e-35	0.65	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	14.15	3.71e-38	9.15e-35	0.65	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
LGG	cis	rs11148252	0.512	rs9526950	ENSG00000235660.1	LINC00345	-14.15	3.74e-38	9.22e-35	-0.7	-0.54	Lewy body disease;	chr13:52600328	chr13:52484161~52484680:-
LGG	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-14.14	3.88e-38	9.56e-35	-0.77	-0.54	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
LGG	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	14.14	3.95e-38	9.74e-35	0.69	0.54	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
LGG	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-14.14	4.03e-38	9.92e-35	-0.86	-0.54	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
LGG	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-14.14	4.05e-38	9.96e-35	-0.58	-0.54	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
LGG	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	14.14	4.09e-38	1.01e-34	0.64	0.54	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
LGG	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	14.14	4.11e-38	1.01e-34	0.62	0.54	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
LGG	cis	rs651907	0.557	rs3094297	ENSG00000244119.1	PDCL3P4	14.14	4.16e-38	1.02e-34	0.41	0.54	Colorectal cancer;	chr3:101680416	chr3:101712472~101713191:+
LGG	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-14.14	4.18e-38	1.03e-34	-0.69	-0.54	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
LGG	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	14.13	4.23e-38	1.04e-34	0.61	0.54	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	14.13	4.33e-38	1.06e-34	0.61	0.54	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	14.13	4.33e-38	1.06e-34	0.61	0.54	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	14.13	4.35e-38	1.07e-34	0.68	0.54	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	14.13	4.43e-38	1.09e-34	0.68	0.54	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	14.13	4.43e-38	1.09e-34	0.68	0.54	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	14.13	4.43e-38	1.09e-34	0.68	0.54	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	14.13	4.45e-38	1.09e-34	0.67	0.54	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	14.13	4.55e-38	1.11e-34	0.68	0.54	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
LGG	cis	rs6452524	0.901	rs10079680	ENSG00000248112.1	RP11-78C3.1	14.13	4.58e-38	1.12e-34	0.7	0.54	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:82919376~82921119:-
LGG	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-14.13	4.59e-38	1.12e-34	-0.93	-0.54	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
LGG	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-14.13	4.59e-38	1.12e-34	-0.93	-0.54	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	14.13	4.61e-38	1.13e-34	0.67	0.54	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	14.13	4.61e-38	1.13e-34	0.67	0.54	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	14.13	4.61e-38	1.13e-34	0.67	0.54	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
LGG	cis	rs6452524	0.905	rs7736289	ENSG00000248112.1	RP11-78C3.1	14.12	4.65e-38	1.14e-34	0.7	0.54	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:82919376~82921119:-
LGG	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-14.12	4.98e-38	1.22e-34	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-14.12	4.98e-38	1.22e-34	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
LGG	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-14.11	5.22e-38	1.27e-34	-0.72	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	14.11	5.25e-38	1.28e-34	0.67	0.54	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
LGG	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-14.11	5.31e-38	1.3e-34	-0.62	-0.54	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
LGG	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	14.11	5.35e-38	1.31e-34	0.69	0.54	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
LGG	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	14.11	5.57e-38	1.36e-34	0.67	0.54	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
LGG	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	14.11	5.63e-38	1.37e-34	0.73	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
LGG	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-14.1	5.67e-38	1.38e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
LGG	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-14.1	5.72e-38	1.39e-34	-0.69	-0.54	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
LGG	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	14.1	5.76e-38	1.4e-34	0.97	0.54	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
LGG	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-14.1	5.78e-38	1.41e-34	-0.92	-0.54	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
LGG	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	14.1	5.94e-38	1.45e-34	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	14.1	5.99e-38	1.46e-34	0.67	0.54	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
LGG	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	14.1	6.06e-38	1.48e-34	0.59	0.54	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
LGG	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	14.1	6.13e-38	1.49e-34	0.67	0.54	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	14.1	6.18e-38	1.5e-34	0.61	0.54	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
LGG	cis	rs950027	0.62	rs1145076	ENSG00000259433.2	CTD-2651B20.4	-14.1	6.19e-38	1.51e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45330209~45332634:-
LGG	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	14.1	6.24e-38	1.52e-34	0.61	0.54	Height;	chr11:118764443	chr11:118688039~118690600:-
LGG	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	14.1	6.25e-38	1.52e-34	0.61	0.54	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
LGG	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	14.09	6.36e-38	1.55e-34	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	14.09	6.63e-38	1.61e-34	0.68	0.54	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	14.09	6.63e-38	1.61e-34	0.68	0.54	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
LGG	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	14.09	6.63e-38	1.61e-34	0.68	0.54	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-14.09	6.63e-38	1.61e-34	-0.68	-0.54	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
LGG	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	14.09	6.64e-38	1.61e-34	0.61	0.54	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
LGG	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-14.09	6.89e-38	1.67e-34	-0.71	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
LGG	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-14.08	6.95e-38	1.69e-34	-0.69	-0.54	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
LGG	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	14.08	7.06e-38	1.71e-34	0.6	0.54	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	14.08	7.42e-38	1.8e-34	0.67	0.54	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	14.08	7.47e-38	1.81e-34	0.61	0.54	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
LGG	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	14.08	7.49e-38	1.81e-34	0.69	0.54	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	14.08	7.49e-38	1.81e-34	0.69	0.54	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	14.08	7.49e-38	1.81e-34	0.69	0.54	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	14.08	7.49e-38	1.81e-34	0.69	0.54	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
LGG	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	14.08	7.55e-38	1.83e-34	0.61	0.54	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	14.08	7.55e-38	1.83e-34	0.61	0.54	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
LGG	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-14.08	7.55e-38	1.83e-34	-0.91	-0.54	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
LGG	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-14.08	7.57e-38	1.83e-34	-0.77	-0.54	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
LGG	cis	rs172166	0.516	rs2791333	ENSG00000199851.2	U3	14.08	7.65e-38	1.85e-34	0.72	0.54	Cardiac Troponin-T levels;	chr6:28143336	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	14.07	7.89e-38	1.91e-34	0.67	0.54	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
LGG	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	14.07	7.89e-38	1.91e-34	0.59	0.54	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
LGG	cis	rs172166	0.516	rs2622322	ENSG00000199851.2	U3	14.07	7.92e-38	1.92e-34	0.72	0.54	Cardiac Troponin-T levels;	chr6:28149665	chr6:28015568~28015777:+
LGG	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	14.07	8.05e-38	1.95e-34	0.63	0.54	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
LGG	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-14.07	8.11e-38	1.96e-34	-0.71	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
LGG	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-14.07	8.11e-38	1.96e-34	-0.71	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
LGG	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	14.07	8.18e-38	1.98e-34	0.87	0.54	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
LGG	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-14.07	8.31e-38	2.01e-34	-0.63	-0.54	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
LGG	cis	rs1150668	0.835	rs203869	ENSG00000199851.2	U3	14.07	8.36e-38	2.02e-34	0.72	0.54	Pubertal anthropometrics;	chr6:28073041	chr6:28015568~28015777:+
LGG	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	14.07	8.4e-38	2.03e-34	0.56	0.54	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
LGG	cis	rs2729354	0.693	rs2584862	ENSG00000265566.2	RN7SL605P	-14.07	8.4e-38	2.03e-34	-0.86	-0.54	Blood protein levels;	chr11:57474483	chr11:57528085~57528365:-
LGG	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-14.06	8.64e-38	2.09e-34	-0.69	-0.54	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-14.06	8.64e-38	2.09e-34	-0.69	-0.54	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
LGG	cis	rs651907	0.535	rs36060163	ENSG00000244119.1	PDCL3P4	14.06	8.67e-38	2.09e-34	0.42	0.54	Colorectal cancer;	chr3:101642119	chr3:101712472~101713191:+
LGG	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	14.06	8.71e-38	2.1e-34	0.56	0.54	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
LGG	cis	rs79349575	0.715	rs1058018	ENSG00000248278.1	SUMO2P17	14.06	9e-38	2.17e-34	0.61	0.54	Type 2 diabetes;	chr17:48922889	chr17:48874860~48908983:-
LGG	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	14.06	9.03e-38	2.18e-34	0.67	0.54	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	14.06	9.03e-38	2.18e-34	0.67	0.54	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	14.06	9.12e-38	2.2e-34	0.61	0.54	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
LGG	cis	rs34787248	1	rs34787248	ENSG00000199851.2	U3	14.06	9.16e-38	2.21e-34	0.95	0.54	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28015568~28015777:+
LGG	cis	rs2486288	0.539	rs2433601	ENSG00000259433.2	CTD-2651B20.4	-14.06	9.19e-38	2.21e-34	-0.59	-0.54	Glomerular filtration rate;	chr15:45424227	chr15:45330209~45332634:-
LGG	cis	rs79349575	0.691	rs28528789	ENSG00000248278.1	SUMO2P17	-14.06	9.26e-38	2.23e-34	-0.61	-0.54	Type 2 diabetes;	chr17:48909254	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.715	rs999474	ENSG00000248278.1	SUMO2P17	-14.06	9.26e-38	2.23e-34	-0.61	-0.54	Type 2 diabetes;	chr17:48910303	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.715	rs9894220	ENSG00000248278.1	SUMO2P17	14.06	9.26e-38	2.23e-34	0.61	0.54	Type 2 diabetes;	chr17:48911792	chr17:48874860~48908983:-
LGG	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	14.06	9.33e-38	2.25e-34	0.61	0.54	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
LGG	cis	rs950027	0.595	rs2486288	ENSG00000259433.2	CTD-2651B20.4	-14.05	9.46e-38	2.28e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45330209~45332634:-
LGG	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	14.05	9.46e-38	2.28e-34	0.88	0.54	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
LGG	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	14.05	9.78e-38	2.36e-34	0.69	0.54	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
LGG	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-14.05	1.01e-37	2.43e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
LGG	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-14.05	1.02e-37	2.45e-34	-0.61	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
LGG	cis	rs172166	0.516	rs1150670	ENSG00000199851.2	U3	14.05	1.02e-37	2.46e-34	0.72	0.54	Cardiac Troponin-T levels;	chr6:28162781	chr6:28015568~28015777:+
LGG	cis	rs172166	0.516	rs2021826	ENSG00000199851.2	U3	14.05	1.02e-37	2.46e-34	0.72	0.54	Cardiac Troponin-T levels;	chr6:28164978	chr6:28015568~28015777:+
LGG	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-14.04	1.09e-37	2.62e-34	-0.61	-0.54	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
LGG	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	14.04	1.1e-37	2.64e-34	0.62	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
LGG	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-14.04	1.1e-37	2.64e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
LGG	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	14.04	1.1e-37	2.65e-34	0.66	0.54	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	14.04	1.1e-37	2.65e-34	0.66	0.54	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
LGG	cis	rs950027	0.62	rs2467862	ENSG00000259433.2	CTD-2651B20.4	-14.04	1.11e-37	2.65e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	14.04	1.11e-37	2.67e-34	0.67	0.54	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
LGG	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	14.04	1.12e-37	2.69e-34	0.61	0.54	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
LGG	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	14.04	1.14e-37	2.72e-34	0.67	0.54	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
LGG	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	14.04	1.14e-37	2.73e-34	0.68	0.54	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
LGG	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	14.03	1.16e-37	2.78e-34	0.67	0.54	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
LGG	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	14.03	1.16e-37	2.78e-34	0.97	0.54	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
LGG	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	14.03	1.16e-37	2.78e-34	0.62	0.54	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
LGG	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	14.03	1.17e-37	2.79e-34	0.67	0.54	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
LGG	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-14.03	1.17e-37	2.81e-34	-0.68	-0.54	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
LGG	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-14.03	1.2e-37	2.86e-34	-0.61	-0.54	Height;	chr11:118758322	chr11:118688039~118690600:-
LGG	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-14.03	1.2e-37	2.87e-34	-0.71	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
LGG	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	14.02	1.26e-37	3.02e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
LGG	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	14.02	1.28e-37	3.07e-34	0.72	0.54	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
LGG	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	14.02	1.29e-37	3.09e-34	0.97	0.54	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
LGG	cis	rs950027	0.62	rs2453533	ENSG00000259433.2	CTD-2651B20.4	-14.02	1.33e-37	3.18e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45330209~45332634:-
LGG	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	14.02	1.33e-37	3.19e-34	0.61	0.54	Height;	chr11:118742526	chr11:118688039~118690600:-
LGG	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-14.02	1.34e-37	3.2e-34	-0.71	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
LGG	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-14.02	1.38e-37	3.3e-34	-0.71	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
LGG	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-14.02	1.38e-37	3.3e-34	-0.73	-0.54	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
LGG	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	14.01	1.39e-37	3.32e-34	0.97	0.54	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-14.01	1.41e-37	3.36e-34	-0.97	-0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
LGG	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-14.01	1.41e-37	3.37e-34	-0.83	-0.54	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
LGG	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	14.01	1.43e-37	3.42e-34	0.61	0.54	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	14.01	1.44e-37	3.42e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
LGG	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	14.01	1.47e-37	3.5e-34	0.6	0.54	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	14.01	1.48e-37	3.5e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
LGG	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	14.01	1.5e-37	3.52e-34	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
LGG	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	14	1.56e-37	3.68e-34	0.62	0.54	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
LGG	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	14	1.57e-37	3.7e-34	0.65	0.54	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	14	1.58e-37	3.72e-34	0.67	0.54	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	14	1.58e-37	3.72e-34	0.67	0.54	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	14	1.62e-37	3.8e-34	0.67	0.54	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
LGG	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	14	1.62e-37	3.8e-34	0.6	0.54	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
LGG	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	14	1.63e-37	3.82e-34	0.68	0.54	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-14	1.63e-37	3.83e-34	-0.62	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
LGG	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	14	1.64e-37	3.86e-34	0.61	0.54	Height;	chr11:118761813	chr11:118688039~118690600:-
LGG	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	14	1.67e-37	3.92e-34	0.42	0.54	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
LGG	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-14	1.68e-37	3.95e-34	-0.96	-0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
LGG	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	14	1.69e-37	3.96e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
LGG	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	13.99	1.7e-37	3.99e-34	0.57	0.54	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-13.99	1.7e-37	3.99e-34	-0.57	-0.54	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
LGG	cis	rs7267979	0.657	rs6107073	ENSG00000125804.12	FAM182A	-13.99	1.72e-37	4.04e-34	-0.64	-0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:26054655~26086917:+
LGG	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	13.99	1.77e-37	4.16e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	13.99	1.77e-37	4.16e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	13.99	1.77e-37	4.16e-34	0.97	0.54	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
LGG	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	13.99	1.78e-37	4.17e-34	0.61	0.54	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
LGG	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-13.99	1.79e-37	4.18e-34	-0.91	-0.54	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
LGG	cis	rs7267979	0.546	rs8115804	ENSG00000125804.12	FAM182A	13.99	1.79e-37	4.19e-34	0.66	0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:26054655~26086917:+
LGG	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-13.99	1.8e-37	4.2e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
LGG	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	13.99	1.8e-37	4.21e-34	0.66	0.54	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
LGG	cis	rs950027	0.62	rs1153862	ENSG00000259433.2	CTD-2651B20.4	-13.99	1.83e-37	4.29e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45330209~45332634:-
LGG	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	13.99	1.84e-37	4.29e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
LGG	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	13.99	1.84e-37	4.3e-34	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	13.99	1.84e-37	4.31e-34	0.61	0.54	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
LGG	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	13.98	1.88e-37	4.39e-34	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
LGG	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	13.98	1.88e-37	4.4e-34	0.71	0.54	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
LGG	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	13.98	1.89e-37	4.4e-34	0.61	0.54	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
LGG	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-13.98	1.9e-37	4.44e-34	-0.61	-0.54	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
LGG	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-13.98	1.92e-37	4.48e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-13.98	1.92e-37	4.48e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-13.98	1.92e-37	4.48e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
LGG	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	13.98	1.93e-37	4.5e-34	0.61	0.54	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
LGG	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	13.98	1.95e-37	4.55e-34	0.69	0.54	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
LGG	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	13.98	1.99e-37	4.65e-34	0.61	0.54	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	13.98	1.99e-37	4.65e-34	0.61	0.54	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	13.98	1.99e-37	4.65e-34	0.61	0.54	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	13.98	1.99e-37	4.65e-34	0.61	0.54	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
LGG	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-13.98	2e-37	4.66e-34	-0.59	-0.54	Height;	chr3:53085518	chr3:53064283~53065091:-
LGG	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-13.97	2.09e-37	4.86e-34	-0.77	-0.54	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
LGG	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	13.97	2.1e-37	4.9e-34	0.61	0.54	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	13.97	2.1e-37	4.9e-34	0.61	0.54	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
LGG	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	13.97	2.12e-37	4.92e-34	0.69	0.54	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	13.97	2.12e-37	4.92e-34	0.69	0.54	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
LGG	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	13.97	2.13e-37	4.96e-34	0.91	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
LGG	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	13.97	2.14e-37	4.98e-34	0.67	0.54	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
LGG	cis	rs950027	0.62	rs1426932	ENSG00000259433.2	CTD-2651B20.4	-13.97	2.16e-37	5.03e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	13.97	2.16e-37	5.03e-34	0.67	0.54	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
LGG	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-13.97	2.17e-37	5.03e-34	-0.71	-0.54	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
LGG	cis	rs2729354	0.729	rs2258835	ENSG00000265566.2	RN7SL605P	-13.97	2.17e-37	5.05e-34	-0.85	-0.54	Blood protein levels;	chr11:57476115	chr11:57528085~57528365:-
LGG	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-13.97	2.19e-37	5.08e-34	-0.68	-0.54	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
LGG	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	13.97	2.21e-37	5.14e-34	0.88	0.54	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
LGG	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	13.97	2.26e-37	5.24e-34	0.61	0.54	Height;	chr11:118781100	chr11:118688039~118690600:-
LGG	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	13.97	2.26e-37	5.24e-34	0.61	0.54	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
LGG	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	13.97	2.26e-37	5.25e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
LGG	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	13.97	2.27e-37	5.27e-34	0.73	0.54	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
LGG	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	13.97	2.28e-37	5.3e-34	0.61	0.54	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	13.96	2.33e-37	5.4e-34	0.61	0.54	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
LGG	cis	rs172166	0.538	rs149956	ENSG00000199851.2	U3	13.96	2.36e-37	5.47e-34	0.73	0.54	Cardiac Troponin-T levels;	chr6:28068473	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	13.96	2.4e-37	5.55e-34	0.67	0.54	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
LGG	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-13.96	2.41e-37	5.58e-34	-0.58	-0.54	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-13.96	2.41e-37	5.58e-34	-0.58	-0.54	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
LGG	cis	rs79349575	0.679	rs9894239	ENSG00000248278.1	SUMO2P17	-13.96	2.42e-37	5.6e-34	-0.61	-0.54	Type 2 diabetes;	chr17:48920597	chr17:48874860~48908983:-
LGG	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-13.96	2.44e-37	5.64e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
LGG	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	-13.96	2.45e-37	5.67e-34	-0.57	-0.54	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
LGG	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	13.96	2.48e-37	5.75e-34	0.61	0.54	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
LGG	cis	rs6452524	0.901	rs1580309	ENSG00000248112.1	RP11-78C3.1	13.95	2.58e-37	5.97e-34	0.7	0.54	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:82919376~82921119:-
LGG	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	13.95	2.59e-37	5.99e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
LGG	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-13.95	2.59e-37	5.99e-34	-0.7	-0.54	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
LGG	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	13.95	2.61e-37	6.04e-34	0.61	0.54	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
LGG	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	13.95	2.64e-37	6.09e-34	0.61	0.54	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
LGG	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	13.95	2.67e-37	6.17e-34	0.61	0.54	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	13.95	2.67e-37	6.17e-34	0.61	0.54	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
LGG	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-13.95	2.67e-37	6.18e-34	-0.62	-0.54	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	13.95	2.67e-37	6.18e-34	0.6	0.54	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
LGG	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	13.95	2.68e-37	6.19e-34	0.61	0.54	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	13.95	2.68e-37	6.19e-34	0.61	0.54	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
LGG	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	13.95	2.69e-37	6.22e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
LGG	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	13.95	2.71e-37	6.26e-34	0.59	0.54	Height;	chr3:53085313	chr3:53064283~53065091:-
LGG	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	13.95	2.74e-37	6.31e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
LGG	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-13.94	2.82e-37	6.5e-34	-0.71	-0.54	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	13.94	2.86e-37	6.59e-34	0.67	0.54	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
LGG	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-13.94	2.86e-37	6.6e-34	-0.51	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
LGG	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-13.94	2.89e-37	6.65e-34	-0.44	-0.54	Height;	chr11:118791319	chr11:118791254~118793137:+
LGG	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	13.94	2.89e-37	6.67e-34	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	13.94	2.92e-37	6.73e-34	0.66	0.54	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	13.94	2.92e-37	6.73e-34	0.66	0.54	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
LGG	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	13.94	2.93e-37	6.76e-34	0.64	0.54	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
LGG	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	13.94	2.95e-37	6.78e-34	0.73	0.54	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
LGG	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	13.94	2.98e-37	6.86e-34	0.61	0.54	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	13.94	2.98e-37	6.86e-34	0.61	0.54	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	13.94	2.99e-37	6.87e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
LGG	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	13.94	3.05e-37	7.02e-34	0.61	0.54	Height;	chr11:118746590	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	13.93	3.1e-37	7.12e-34	0.67	0.54	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
LGG	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	13.93	3.14e-37	7.21e-34	0.68	0.54	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
LGG	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-13.93	3.18e-37	7.31e-34	-0.84	-0.54	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
LGG	cis	rs7267979	0.727	rs4815431	ENSG00000125804.12	FAM182A	13.93	3.19e-37	7.33e-34	0.65	0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26054655~26086917:+
LGG	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	13.93	3.2e-37	7.35e-34	0.59	0.54	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
LGG	cis	rs6452524	0.935	rs10942321	ENSG00000248112.1	RP11-78C3.1	13.93	3.21e-37	7.38e-34	0.7	0.54	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.836	rs1478484	ENSG00000248112.1	RP11-78C3.1	13.93	3.21e-37	7.38e-34	0.7	0.54	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs7714710	ENSG00000248112.1	RP11-78C3.1	13.93	3.21e-37	7.38e-34	0.7	0.54	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs11750799	ENSG00000248112.1	RP11-78C3.1	13.93	3.28e-37	7.54e-34	0.7	0.54	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:82919376~82921119:-
LGG	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-13.93	3.3e-37	7.57e-34	-0.62	-0.54	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
LGG	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-13.93	3.35e-37	7.68e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
LGG	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-13.93	3.35e-37	7.68e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
LGG	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-13.93	3.35e-37	7.68e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
LGG	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-13.93	3.35e-37	7.68e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
LGG	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-13.93	3.35e-37	7.68e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
LGG	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-13.93	3.35e-37	7.68e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
LGG	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-13.93	3.35e-37	7.68e-34	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
LGG	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	13.93	3.38e-37	7.75e-34	0.67	0.54	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
LGG	cis	rs950027	0.62	rs1153860	ENSG00000259433.2	CTD-2651B20.4	13.93	3.38e-37	7.76e-34	0.58	0.54	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45330209~45332634:-
LGG	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-13.92	3.42e-37	7.86e-34	-0.68	-0.54	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
LGG	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	13.92	3.47e-37	7.97e-34	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	13.92	3.48e-37	7.98e-34	0.66	0.54	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	13.92	3.48e-37	7.98e-34	0.66	0.54	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
LGG	cis	rs950027	0.62	rs2486274	ENSG00000259433.2	CTD-2651B20.4	-13.92	3.49e-37	8e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45330209~45332634:-
LGG	cis	rs950027	0.62	rs1145080	ENSG00000259433.2	CTD-2651B20.4	-13.92	3.49e-37	8e-34	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45330209~45332634:-
LGG	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	13.92	3.51e-37	8.05e-34	1	0.54	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
LGG	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-13.92	3.53e-37	8.09e-34	-0.89	-0.54	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
LGG	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	13.92	3.55e-37	8.13e-34	0.74	0.54	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
LGG	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	13.92	3.56e-37	8.15e-34	0.64	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
LGG	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-13.92	3.59e-37	8.24e-34	-0.86	-0.54	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
LGG	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	13.92	3.62e-37	8.29e-34	0.6	0.54	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
LGG	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	13.92	3.72e-37	8.51e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
LGG	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	13.92	3.72e-37	8.51e-34	0.68	0.54	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
LGG	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	13.91	3.83e-37	8.77e-34	0.67	0.54	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	13.91	3.83e-37	8.77e-34	0.67	0.54	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
LGG	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-13.91	3.85e-37	8.81e-34	-0.69	-0.54	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
LGG	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-13.91	3.86e-37	8.83e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-13.91	3.86e-37	8.83e-34	-0.57	-0.54	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
LGG	cis	rs7829975	0.511	rs2955578	ENSG00000173295.6	FAM86B3P	-13.91	3.92e-37	8.97e-34	-0.57	-0.54	Mood instability;	chr8:8279561	chr8:8228595~8244865:+
LGG	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-13.91	3.98e-37	9.11e-34	-0.44	-0.54	Height;	chr11:118786602	chr11:118791254~118793137:+
LGG	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	13.91	4.01e-37	9.18e-34	0.63	0.54	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
LGG	cis	rs6452524	0.935	rs7718472	ENSG00000248112.1	RP11-78C3.1	13.91	4.02e-37	9.18e-34	0.69	0.54	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:82919376~82921119:-
LGG	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	13.91	4.08e-37	9.31e-34	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
LGG	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	13.91	4.1e-37	9.37e-34	0.65	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
LGG	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	13.91	4.11e-37	9.39e-34	0.65	0.54	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
LGG	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	13.91	4.14e-37	9.45e-34	0.42	0.54	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
LGG	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	13.91	4.14e-37	9.45e-34	0.42	0.54	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
LGG	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	13.91	4.14e-37	9.45e-34	0.42	0.54	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
LGG	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	13.9	4.16e-37	9.5e-34	0.63	0.54	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
LGG	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	13.9	4.17e-37	9.51e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
LGG	cis	rs2980439	0.783	rs2948305	ENSG00000173295.6	FAM86B3P	-13.9	4.17e-37	9.52e-34	-0.58	-0.54	Neuroticism;	chr8:8241055	chr8:8228595~8244865:+
LGG	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	13.9	4.19e-37	9.56e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	13.9	4.19e-37	9.56e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	13.9	4.19e-37	9.56e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	13.9	4.19e-37	9.56e-34	0.62	0.54	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
LGG	cis	rs4713118	0.588	rs200994	ENSG00000199851.2	U3	-13.9	4.19e-37	9.56e-34	-0.84	-0.54	Parkinson's disease;	chr6:27846035	chr6:28015568~28015777:+
LGG	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	13.9	4.27e-37	9.74e-34	0.74	0.54	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	13.9	4.27e-37	9.74e-34	0.74	0.54	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
LGG	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	13.9	4.32e-37	9.84e-34	0.98	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	13.9	4.37e-37	9.95e-34	0.66	0.54	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
LGG	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-13.9	4.41e-37	1e-33	-0.92	-0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	13.9	4.45e-37	1.01e-33	0.66	0.54	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	13.9	4.45e-37	1.01e-33	0.66	0.54	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
LGG	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-13.9	4.52e-37	1.03e-33	-0.9	-0.54	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
LGG	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-13.9	4.52e-37	1.03e-33	-0.69	-0.54	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
LGG	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	13.9	4.57e-37	1.04e-33	0.68	0.54	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
LGG	cis	rs651907	0.557	rs59596156	ENSG00000244119.1	PDCL3P4	13.89	4.6e-37	1.05e-33	0.41	0.54	Colorectal cancer;	chr3:101675373	chr3:101712472~101713191:+
LGG	cis	rs8062405	1	rs1987472	ENSG00000271623.1	RP11-435I10.5	-13.89	4.6e-37	1.05e-33	-0.62	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.895	rs56186137	ENSG00000271623.1	RP11-435I10.5	-13.89	4.6e-37	1.05e-33	-0.62	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28364700~28365333:+
LGG	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-13.89	4.77e-37	1.09e-33	-0.7	-0.54	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-13.89	4.77e-37	1.09e-33	-0.7	-0.54	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
LGG	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	13.89	4.77e-37	1.09e-33	0.6	0.54	Height;	chr11:118749988	chr11:118688039~118690600:-
LGG	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	13.89	4.83e-37	1.1e-33	0.96	0.54	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
LGG	cis	rs651907	0.557	rs3864012	ENSG00000244119.1	PDCL3P4	13.89	4.87e-37	1.11e-33	0.41	0.54	Colorectal cancer;	chr3:101678779	chr3:101712472~101713191:+
LGG	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-13.89	4.91e-37	1.11e-33	-0.68	-0.54	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-13.89	4.91e-37	1.11e-33	-0.68	-0.54	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
LGG	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	13.89	4.92e-37	1.12e-33	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	13.89	4.96e-37	1.13e-33	0.97	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
LGG	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-13.89	4.98e-37	1.13e-33	-0.63	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
LGG	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-13.89	5.03e-37	1.14e-33	-0.7	-0.54	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
LGG	cis	rs7267979	0.745	rs6132845	ENSG00000125804.12	FAM182A	-13.88	5.08e-37	1.15e-33	-0.64	-0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26054655~26086917:+
LGG	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-13.88	5.11e-37	1.16e-33	-0.63	-0.54	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
LGG	cis	rs950027	0.62	rs1145093	ENSG00000259433.2	CTD-2651B20.4	-13.88	5.11e-37	1.16e-33	-0.58	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45330209~45332634:-
LGG	cis	rs950027	0.62	rs1145089	ENSG00000259433.2	CTD-2651B20.4	-13.88	5.11e-37	1.16e-33	-0.58	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45330209~45332634:-
LGG	cis	rs950027	0.62	rs1049518	ENSG00000259433.2	CTD-2651B20.4	-13.88	5.11e-37	1.16e-33	-0.58	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45330209~45332634:-
LGG	cis	rs950027	0.584	rs1145086	ENSG00000259433.2	CTD-2651B20.4	-13.88	5.11e-37	1.16e-33	-0.58	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45330209~45332634:-
LGG	cis	rs950027	0.62	rs1153857	ENSG00000259433.2	CTD-2651B20.4	-13.88	5.11e-37	1.16e-33	-0.58	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45330209~45332634:-
LGG	cis	rs950027	0.62	rs1153855	ENSG00000259433.2	CTD-2651B20.4	-13.88	5.11e-37	1.16e-33	-0.58	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45330209~45332634:-
LGG	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-13.88	5.27e-37	1.19e-33	-0.7	-0.54	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
LGG	cis	rs651907	0.514	rs34301719	ENSG00000244119.1	PDCL3P4	13.88	5.31e-37	1.2e-33	0.43	0.54	Colorectal cancer;	chr3:101699149	chr3:101712472~101713191:+
LGG	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	13.88	5.34e-37	1.21e-33	0.7	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	13.88	5.34e-37	1.21e-33	0.7	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
LGG	cis	rs34787248	1	rs34787248	ENSG00000216901.1	AL022393.7	13.88	5.36e-37	1.22e-33	0.84	0.54	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28176188~28176674:+
LGG	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-13.88	5.37e-37	1.22e-33	-0.62	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-13.88	5.37e-37	1.22e-33	-0.62	-0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
LGG	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-13.88	5.41e-37	1.23e-33	-0.7	-0.54	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-13.88	5.41e-37	1.23e-33	-0.7	-0.54	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	13.88	5.41e-37	1.23e-33	0.7	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	13.88	5.41e-37	1.23e-33	0.7	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
LGG	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-13.88	5.43e-37	1.23e-33	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
LGG	cis	rs4819052	0.851	rs9977178	ENSG00000223768.1	LINC00205	-13.88	5.47e-37	1.24e-33	-0.59	-0.54	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45293285~45297354:+
LGG	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	13.88	5.5e-37	1.25e-33	0.67	0.54	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
LGG	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	13.88	5.56e-37	1.26e-33	0.6	0.54	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
LGG	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	13.87	5.66e-37	1.28e-33	0.7	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
LGG	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	13.87	5.79e-37	1.31e-33	0.66	0.54	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
LGG	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	13.87	5.83e-37	1.32e-33	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	13.87	5.83e-37	1.32e-33	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	13.87	5.83e-37	1.32e-33	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
LGG	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-13.87	6.01e-37	1.36e-33	-0.68	-0.54	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
LGG	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	13.87	6.01e-37	1.36e-33	0.67	0.54	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
LGG	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	13.87	6.03e-37	1.36e-33	0.68	0.54	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
LGG	cis	rs172166	0.561	rs149976	ENSG00000199851.2	U3	-13.87	6.12e-37	1.38e-33	-0.72	-0.54	Cardiac Troponin-T levels;	chr6:28019998	chr6:28015568~28015777:+
LGG	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-13.87	6.15e-37	1.39e-33	-0.58	-0.54	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	13.87	6.16e-37	1.39e-33	0.62	0.54	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	13.86	6.19e-37	1.4e-33	0.62	0.54	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
LGG	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	13.86	6.27e-37	1.41e-33	0.7	0.54	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
LGG	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	13.86	6.27e-37	1.41e-33	0.7	0.54	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
LGG	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	13.86	6.27e-37	1.41e-33	0.7	0.54	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
LGG	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	13.86	6.28e-37	1.41e-33	0.95	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
LGG	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	13.86	6.28e-37	1.42e-33	0.74	0.54	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
LGG	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	13.86	6.29e-37	1.42e-33	0.68	0.54	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	13.86	6.29e-37	1.42e-33	0.68	0.54	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
LGG	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	13.86	6.29e-37	1.42e-33	0.68	0.54	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
LGG	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	13.86	6.33e-37	1.43e-33	0.72	0.54	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
LGG	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	13.86	6.48e-37	1.46e-33	0.59	0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
LGG	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	13.86	6.49e-37	1.46e-33	0.64	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
LGG	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	13.86	6.81e-37	1.53e-33	0.62	0.54	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	13.85	7.07e-37	1.59e-33	0.6	0.54	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	13.85	7.07e-37	1.59e-33	0.6	0.54	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	13.85	7.07e-37	1.59e-33	0.6	0.54	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	13.85	7.07e-37	1.59e-33	0.6	0.54	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
LGG	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-13.85	7.07e-37	1.59e-33	-0.41	-0.54	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
LGG	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	13.85	7.1e-37	1.6e-33	0.72	0.54	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
LGG	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-13.85	7.11e-37	1.6e-33	-0.61	-0.54	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
LGG	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-13.85	7.12e-37	1.6e-33	-0.76	-0.54	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
LGG	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	13.85	7.21e-37	1.62e-33	0.61	0.54	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
LGG	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-13.85	7.21e-37	1.62e-33	-0.62	-0.54	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-13.85	7.27e-37	1.63e-33	-0.62	-0.54	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
LGG	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	13.85	7.33e-37	1.65e-33	0.68	0.54	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
LGG	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	13.85	7.35e-37	1.65e-33	0.6	0.54	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
LGG	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	13.85	7.41e-37	1.66e-33	0.41	0.54	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
LGG	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-13.84	7.55e-37	1.7e-33	-0.64	-0.54	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
LGG	cis	rs4819052	0.851	rs8131143	ENSG00000223768.1	LINC00205	13.84	7.59e-37	1.7e-33	0.59	0.54	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45293285~45297354:+
LGG	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-13.84	7.6e-37	1.71e-33	-0.41	-0.54	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
LGG	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	13.84	7.67e-37	1.72e-33	0.67	0.54	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
LGG	cis	rs6452524	0.935	rs6896953	ENSG00000248112.1	RP11-78C3.1	-13.84	7.91e-37	1.77e-33	-0.68	-0.54	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:82919376~82921119:-
LGG	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-13.84	7.96e-37	1.79e-33	-0.68	-0.54	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
LGG	cis	rs4820294	1	rs41280035	ENSG00000233360.4	Z83844.1	13.84	7.96e-37	1.79e-33	0.71	0.54	Fat distribution (HIV);	chr22:37658031	chr22:37641832~37658377:-
LGG	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	13.84	8.03e-37	1.8e-33	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
LGG	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	13.84	8.03e-37	1.8e-33	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
LGG	cis	rs6452524	0.935	rs6868416	ENSG00000248112.1	RP11-78C3.1	13.84	8.21e-37	1.84e-33	0.69	0.54	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs1478485	ENSG00000248112.1	RP11-78C3.1	13.84	8.21e-37	1.84e-33	0.69	0.54	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:82919376~82921119:-
LGG	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	13.84	8.27e-37	1.85e-33	0.72	0.54	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
LGG	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	13.84	8.28e-37	1.86e-33	0.68	0.54	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
LGG	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	13.84	8.29e-37	1.86e-33	0.61	0.54	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
LGG	cis	rs7267979	0.78	rs6050679	ENSG00000125804.12	FAM182A	-13.84	8.31e-37	1.86e-33	-0.64	-0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26054655~26086917:+
LGG	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	13.83	8.39e-37	1.88e-33	0.59	0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
LGG	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-13.83	8.49e-37	1.9e-33	-0.72	-0.54	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
LGG	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	13.83	8.5e-37	1.9e-33	0.59	0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
LGG	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	13.83	8.5e-37	1.9e-33	0.59	0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
LGG	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-13.83	8.6e-37	1.92e-33	-0.81	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
LGG	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	13.83	8.6e-37	1.93e-33	0.73	0.54	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	13.83	8.6e-37	1.93e-33	0.73	0.54	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
LGG	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	13.83	8.64e-37	1.93e-33	0.61	0.54	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
LGG	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	13.83	8.66e-37	1.94e-33	0.7	0.54	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
LGG	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	13.83	8.68e-37	1.94e-33	0.59	0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
LGG	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	13.83	8.82e-37	1.97e-33	0.6	0.54	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
LGG	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-13.83	8.96e-37	2e-33	-0.57	-0.54	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
LGG	cis	rs79349575	0.756	rs937301	ENSG00000248278.1	SUMO2P17	-13.83	9.08e-37	2.03e-33	-0.6	-0.54	Type 2 diabetes;	chr17:48968914	chr17:48874860~48908983:-
LGG	cis	rs79349575	0.756	rs3848460	ENSG00000248278.1	SUMO2P17	-13.83	9.08e-37	2.03e-33	-0.6	-0.54	Type 2 diabetes;	chr17:48969752	chr17:48874860~48908983:-
LGG	cis	rs950027	0.62	rs1719246	ENSG00000259433.2	CTD-2651B20.4	-13.83	9.16e-37	2.05e-33	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45330209~45332634:-
LGG	cis	rs11148252	0.532	rs9526975	ENSG00000235660.1	LINC00345	-13.82	9.2e-37	2.05e-33	-0.66	-0.54	Lewy body disease;	chr13:52681669	chr13:52484161~52484680:-
LGG	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-13.82	9.27e-37	2.07e-33	-0.69	-0.54	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
LGG	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	13.82	9.32e-37	2.08e-33	0.96	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
LGG	cis	rs6452524	0.935	rs7736296	ENSG00000248112.1	RP11-78C3.1	-13.82	9.32e-37	2.08e-33	-0.68	-0.54	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:82919376~82921119:-
LGG	cis	rs950027	0.62	rs1145084	ENSG00000259433.2	CTD-2651B20.4	-13.82	9.9e-37	2.21e-33	-0.59	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45330209~45332634:-
LGG	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	13.82	9.95e-37	2.22e-33	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.887	rs4870139	ENSG00000268592.3	RAET1E-AS1	13.82	1.01e-36	2.24e-33	0.68	0.54	Lung cancer;	chr6:149575182	chr6:149863494~149919507:+
LGG	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	13.82	1.01e-36	2.24e-33	0.61	0.54	Height;	chr11:118791319	chr11:118688039~118690600:-
LGG	cis	rs7216064	0.655	rs8078543	ENSG00000278219.1	AC145343.1	13.82	1.01e-36	2.24e-33	0.63	0.54	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68101538~68101639:+
LGG	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-13.81	1.03e-36	2.29e-33	-0.57	-0.54	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
LGG	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	13.81	1.03e-36	2.29e-33	0.7	0.54	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
LGG	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	13.81	1.03e-36	2.29e-33	0.7	0.54	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
LGG	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	13.81	1.03e-36	2.29e-33	0.7	0.54	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
LGG	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	13.81	1.03e-36	2.29e-33	0.7	0.54	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
LGG	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	13.81	1.03e-36	2.29e-33	0.61	0.54	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
LGG	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	13.81	1.04e-36	2.31e-33	0.73	0.54	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
LGG	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	13.81	1.05e-36	2.33e-33	0.41	0.54	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
LGG	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	13.81	1.06e-36	2.35e-33	0.89	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
LGG	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-13.81	1.07e-36	2.38e-33	-0.61	-0.54	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
LGG	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-13.81	1.08e-36	2.41e-33	-0.63	-0.54	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
LGG	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-13.81	1.09e-36	2.41e-33	-0.92	-0.54	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
LGG	cis	rs79349575	0.721	rs4794004	ENSG00000248278.1	SUMO2P17	13.81	1.09e-36	2.42e-33	0.61	0.54	Type 2 diabetes;	chr17:48961109	chr17:48874860~48908983:-
LGG	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	13.81	1.09e-36	2.42e-33	0.6	0.54	Height;	chr11:118786602	chr11:118688039~118690600:-
LGG	cis	rs8062405	1	rs7187776	ENSG00000271623.1	RP11-435I10.5	-13.81	1.1e-36	2.43e-33	-0.62	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28364700~28365333:+
LGG	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	13.81	1.1e-36	2.44e-33	0.6	0.54	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
LGG	cis	rs172166	0.585	rs149963	ENSG00000199851.2	U3	13.81	1.11e-36	2.46e-33	0.72	0.54	Cardiac Troponin-T levels;	chr6:28049354	chr6:28015568~28015777:+
LGG	cis	rs7267979	0.789	rs1983974	ENSG00000125804.12	FAM182A	13.8	1.13e-36	2.51e-33	0.65	0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26054655~26086917:+
LGG	cis	rs79349575	0.783	rs1994970	ENSG00000248278.1	SUMO2P17	-13.8	1.13e-36	2.51e-33	-0.61	-0.54	Type 2 diabetes;	chr17:48936765	chr17:48874860~48908983:-
LGG	cis	rs172166	0.56	rs203878	ENSG00000199851.2	U3	13.8	1.14e-36	2.53e-33	0.71	0.54	Cardiac Troponin-T levels;	chr6:28081218	chr6:28015568~28015777:+
LGG	cis	rs7267979	0.816	rs443009	ENSG00000125804.12	FAM182A	13.8	1.15e-36	2.54e-33	0.65	0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26054655~26086917:+
LGG	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	13.8	1.15e-36	2.55e-33	0.58	0.54	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
LGG	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	13.8	1.15e-36	2.56e-33	0.88	0.54	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
LGG	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	13.8	1.18e-36	2.62e-33	0.82	0.54	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
LGG	cis	rs6452524	0.935	rs1017794	ENSG00000248112.1	RP11-78C3.1	13.8	1.2e-36	2.65e-33	0.69	0.54	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:82919376~82921119:-
LGG	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	13.8	1.2e-36	2.66e-33	0.61	0.54	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
LGG	cis	rs6452524	0.901	rs1600362	ENSG00000248112.1	RP11-78C3.1	13.8	1.2e-36	2.67e-33	0.69	0.54	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:82919376~82921119:-
LGG	cis	rs4819052	0.851	rs2838839	ENSG00000223768.1	LINC00205	13.8	1.21e-36	2.67e-33	0.59	0.54	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45293285~45297354:+
LGG	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	13.8	1.21e-36	2.68e-33	0.61	0.54	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
LGG	cis	rs7315956	0.963	rs7960641	ENSG00000257139.1	RP11-320P7.2	-13.79	1.24e-36	2.76e-33	-0.65	-0.54	Testicular germ cell tumor;	chr12:70216357	chr12:70180338~70202004:+
LGG	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	13.79	1.25e-36	2.76e-33	0.86	0.54	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
LGG	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	13.79	1.25e-36	2.78e-33	0.63	0.54	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.851	rs58644915	ENSG00000223768.1	LINC00205	-13.79	1.27e-36	2.81e-33	-0.59	-0.54	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs12626188	ENSG00000223768.1	LINC00205	-13.79	1.28e-36	2.84e-33	-0.59	-0.54	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45293285~45297354:+
LGG	cis	rs8062405	1	rs2008514	ENSG00000271623.1	RP11-435I10.5	13.79	1.3e-36	2.87e-33	0.62	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs55991577	ENSG00000271623.1	RP11-435I10.5	-13.79	1.33e-36	2.93e-33	-0.63	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs56358680	ENSG00000271623.1	RP11-435I10.5	-13.79	1.33e-36	2.93e-33	-0.63	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28364700~28365333:+
LGG	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	13.79	1.34e-36	2.96e-33	0.61	0.54	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	13.79	1.34e-36	2.96e-33	0.61	0.54	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
LGG	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	13.79	1.36e-36	3e-33	0.61	0.53	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
LGG	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	13.78	1.37e-36	3.02e-33	0.6	0.53	Height;	chr11:118773873	chr11:118688039~118690600:-
LGG	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	13.78	1.39e-36	3.08e-33	0.41	0.53	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
LGG	cis	rs4819052	0.851	rs2838848	ENSG00000223768.1	LINC00205	-13.78	1.4e-36	3.09e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2838849	ENSG00000223768.1	LINC00205	-13.78	1.4e-36	3.09e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs7275870	ENSG00000223768.1	LINC00205	-13.78	1.4e-36	3.09e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs7275874	ENSG00000223768.1	LINC00205	-13.78	1.4e-36	3.09e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45293285~45297354:+
LGG	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	13.78	1.4e-36	3.1e-33	0.63	0.53	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
LGG	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	13.78	1.42e-36	3.14e-33	0.67	0.53	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
LGG	cis	rs853679	0.723	rs1736904	ENSG00000199851.2	U3	13.78	1.42e-36	3.14e-33	0.87	0.53	Depression;	chr6:28251492	chr6:28015568~28015777:+
LGG	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	13.78	1.43e-36	3.16e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	13.78	1.44e-36	3.18e-33	0.66	0.53	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
LGG	cis	rs651907	0.557	rs7645391	ENSG00000244119.1	PDCL3P4	13.78	1.45e-36	3.2e-33	0.41	0.53	Colorectal cancer;	chr3:101642662	chr3:101712472~101713191:+
LGG	cis	rs4682868	0.581	rs4682869	ENSG00000273328.4	RP11-141M3.6	-13.78	1.48e-36	3.26e-33	-0.62	-0.53	Monocyte percentage of white cells;	chr3:42882472	chr3:42809414~42908105:+
LGG	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	13.77	1.51e-36	3.33e-33	0.59	0.53	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
LGG	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	13.77	1.52e-36	3.34e-33	0.73	0.53	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
LGG	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	13.77	1.54e-36	3.38e-33	0.6	0.53	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
LGG	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-13.77	1.55e-36	3.42e-33	-0.43	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
LGG	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	13.77	1.57e-36	3.46e-33	0.41	0.53	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs12629954	ENSG00000244119.1	PDCL3P4	13.77	1.57e-36	3.46e-33	0.42	0.53	Colorectal cancer;	chr3:101641779	chr3:101712472~101713191:+
LGG	cis	rs950027	0.62	rs872192	ENSG00000259433.2	CTD-2651B20.4	-13.77	1.57e-36	3.47e-33	-0.59	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45330209~45332634:-
LGG	cis	rs4820294	0.926	rs62236671	ENSG00000233360.4	Z83844.1	13.77	1.58e-36	3.48e-33	0.7	0.53	Fat distribution (HIV);	chr22:37673298	chr22:37641832~37658377:-
LGG	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-13.77	1.6e-36	3.51e-33	-0.63	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-13.77	1.6e-36	3.51e-33	-0.63	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-13.77	1.6e-36	3.51e-33	-0.63	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
LGG	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	13.77	1.61e-36	3.55e-33	0.84	0.53	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
LGG	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	13.77	1.62e-36	3.55e-33	0.6	0.53	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
LGG	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	13.77	1.62e-36	3.56e-33	0.63	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
LGG	cis	rs6452524	0.935	rs6880566	ENSG00000248112.1	RP11-78C3.1	13.77	1.63e-36	3.57e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.905	rs6884981	ENSG00000248112.1	RP11-78C3.1	13.77	1.63e-36	3.57e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs1580311	ENSG00000248112.1	RP11-78C3.1	13.77	1.63e-36	3.57e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:82919376~82921119:-
LGG	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-13.77	1.63e-36	3.58e-33	-0.43	-0.53	Height;	chr11:118761813	chr11:118791254~118793137:+
LGG	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	13.77	1.64e-36	3.61e-33	0.66	0.53	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	13.77	1.64e-36	3.61e-33	0.66	0.53	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
LGG	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-13.76	1.72e-36	3.78e-33	-0.59	-0.53	Height;	chr3:53069965	chr3:53064283~53065091:-
LGG	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-13.76	1.73e-36	3.8e-33	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
LGG	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-13.76	1.79e-36	3.93e-33	-0.43	-0.53	Height;	chr11:118764443	chr11:118791254~118793137:+
LGG	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	13.76	1.81e-36	3.97e-33	0.6	0.53	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
LGG	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	13.76	1.82e-36	3.99e-33	0.41	0.53	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	13.76	1.82e-36	3.99e-33	0.41	0.53	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
LGG	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	13.76	1.83e-36	4.02e-33	0.97	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
LGG	cis	rs172166	0.561	rs149971	ENSG00000199851.2	U3	13.75	1.85e-36	4.05e-33	0.72	0.53	Cardiac Troponin-T levels;	chr6:28014374	chr6:28015568~28015777:+
LGG	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	13.75	1.87e-36	4.1e-33	0.94	0.53	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
LGG	cis	rs9890032	0.57	rs8068504	ENSG00000266490.1	CTD-2349P21.9	13.75	1.9e-36	4.16e-33	0.48	0.53	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30792372~30792833:+
LGG	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	13.75	1.95e-36	4.27e-33	0.84	0.53	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
LGG	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	13.75	1.99e-36	4.36e-33	0.6	0.53	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	13.75	1.99e-36	4.36e-33	0.6	0.53	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
LGG	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	13.75	2.02e-36	4.43e-33	0.6	0.53	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
LGG	cis	rs4820294	1	rs929039	ENSG00000233360.4	Z83844.1	13.74	2.03e-36	4.45e-33	0.7	0.53	Fat distribution (HIV);	chr22:37675504	chr22:37641832~37658377:-
LGG	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-13.74	2.04e-36	4.47e-33	-0.63	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	13.74	2.04e-36	4.47e-33	0.63	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
LGG	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	13.74	2.07e-36	4.52e-33	0.6	0.53	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
LGG	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-13.74	2.08e-36	4.54e-33	-0.91	-0.53	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
LGG	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-13.74	2.09e-36	4.56e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
LGG	cis	rs4819052	0.851	rs2838842	ENSG00000223768.1	LINC00205	-13.74	2.1e-36	4.59e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2838843	ENSG00000223768.1	LINC00205	-13.74	2.1e-36	4.59e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45293285~45297354:+
LGG	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-13.74	2.13e-36	4.64e-33	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
LGG	cis	rs4819052	0.851	rs8130285	ENSG00000223768.1	LINC00205	-13.74	2.13e-36	4.65e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45293285~45297354:+
LGG	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	13.74	2.16e-36	4.71e-33	0.61	0.53	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
LGG	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	13.74	2.17e-36	4.74e-33	0.41	0.53	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
LGG	cis	rs6452524	0.935	rs1382376	ENSG00000248112.1	RP11-78C3.1	13.74	2.18e-36	4.76e-33	0.69	0.53	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:82919376~82921119:-
LGG	cis	rs651907	0.557	rs7651406	ENSG00000244119.1	PDCL3P4	13.74	2.21e-36	4.82e-33	0.41	0.53	Colorectal cancer;	chr3:101674452	chr3:101712472~101713191:+
LGG	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	13.74	2.22e-36	4.84e-33	0.86	0.53	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
LGG	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-13.74	2.23e-36	4.87e-33	-0.8	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
LGG	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	13.73	2.28e-36	4.98e-33	0.6	0.53	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
LGG	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	13.73	2.3e-36	5.01e-33	0.57	0.53	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
LGG	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-13.73	2.3e-36	5.02e-33	-0.44	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
LGG	cis	rs4682868	0.581	rs7630617	ENSG00000273328.4	RP11-141M3.6	-13.73	2.3e-36	5.02e-33	-0.63	-0.53	Monocyte percentage of white cells;	chr3:42880157	chr3:42809414~42908105:+
LGG	cis	rs7216064	0.531	rs62084683	ENSG00000278219.1	AC145343.1	13.73	2.3e-36	5.03e-33	0.63	0.53	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68101538~68101639:+
LGG	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	13.73	2.37e-36	5.16e-33	0.67	0.53	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
LGG	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	13.73	2.37e-36	5.16e-33	0.61	0.53	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	13.73	2.37e-36	5.16e-33	0.6	0.53	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
LGG	cis	rs6452524	0.935	rs1580310	ENSG00000248112.1	RP11-78C3.1	13.73	2.39e-36	5.22e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:82919376~82921119:-
LGG	cis	rs4820294	1	rs4820294	ENSG00000233360.4	Z83844.1	13.73	2.4e-36	5.22e-33	0.7	0.53	Fat distribution (HIV);	chr22:37675036	chr22:37641832~37658377:-
LGG	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	13.73	2.42e-36	5.27e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	13.73	2.42e-36	5.27e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	13.73	2.42e-36	5.27e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
LGG	cis	rs79349575	0.756	rs2291726	ENSG00000248278.1	SUMO2P17	-13.73	2.43e-36	5.3e-33	-0.61	-0.53	Type 2 diabetes;	chr17:48961892	chr17:48874860~48908983:-
LGG	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	13.73	2.45e-36	5.33e-33	0.73	0.53	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
LGG	cis	rs950027	0.62	rs1145077	ENSG00000259433.2	CTD-2651B20.4	13.72	2.53e-36	5.51e-33	0.58	0.53	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45330209~45332634:-
LGG	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-13.72	2.54e-36	5.53e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-13.72	2.54e-36	5.53e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-13.72	2.54e-36	5.53e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-13.72	2.54e-36	5.53e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-13.72	2.54e-36	5.53e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
LGG	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-13.72	2.6e-36	5.66e-33	-0.67	-0.53	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
LGG	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-13.72	2.63e-36	5.71e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-13.72	2.63e-36	5.71e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
LGG	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	13.72	2.68e-36	5.81e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	13.72	2.68e-36	5.81e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
LGG	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	13.72	2.72e-36	5.91e-33	0.58	0.53	Height;	chr3:53091453	chr3:53064283~53065091:-
LGG	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	13.72	2.72e-36	5.91e-33	0.73	0.53	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
LGG	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-13.71	2.75e-36	5.97e-33	-0.43	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
LGG	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-13.71	2.77e-36	6.01e-33	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-13.71	2.77e-36	6.01e-33	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
LGG	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	13.71	2.78e-36	6.04e-33	0.54	0.53	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
LGG	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-13.71	2.81e-36	6.1e-33	-0.43	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
LGG	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	13.71	2.82e-36	6.12e-33	0.6	0.53	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	13.71	2.82e-36	6.12e-33	0.6	0.53	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	13.71	2.82e-36	6.12e-33	0.6	0.53	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	13.71	2.82e-36	6.12e-33	0.6	0.53	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
LGG	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	13.71	2.82e-36	6.12e-33	0.6	0.53	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	13.71	2.82e-36	6.12e-33	0.6	0.53	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
LGG	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-13.71	2.83e-36	6.14e-33	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	13.71	2.83e-36	6.15e-33	0.6	0.53	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
LGG	cis	rs6452524	0.905	rs6896548	ENSG00000248112.1	RP11-78C3.1	13.71	2.88e-36	6.24e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	13.71	2.88e-36	6.25e-33	0.67	0.53	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
LGG	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	13.71	2.89e-36	6.26e-33	0.59	0.53	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
LGG	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	13.71	2.89e-36	6.27e-33	0.77	0.53	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
LGG	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-13.71	2.91e-36	6.3e-33	-0.6	-0.53	Height;	chr3:53084188	chr3:53064283~53065091:-
LGG	cis	rs9890032	0.618	rs1979507	ENSG00000266490.1	CTD-2349P21.9	13.71	2.93e-36	6.36e-33	0.48	0.53	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30792372~30792833:+
LGG	cis	rs6452524	0.935	rs12109517	ENSG00000248112.1	RP11-78C3.1	13.71	2.94e-36	6.38e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs12109514	ENSG00000248112.1	RP11-78C3.1	13.71	2.94e-36	6.38e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs1011979	ENSG00000248112.1	RP11-78C3.1	13.71	2.94e-36	6.38e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.901	rs17284211	ENSG00000248112.1	RP11-78C3.1	13.71	2.94e-36	6.38e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs1382374	ENSG00000248112.1	RP11-78C3.1	13.71	2.94e-36	6.38e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:82919376~82921119:-
LGG	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	13.71	2.97e-36	6.44e-33	0.58	0.53	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
LGG	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-13.71	2.97e-36	6.44e-33	-0.52	-0.53	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
LGG	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	13.71	3e-36	6.5e-33	0.63	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
LGG	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-13.7	3.05e-36	6.6e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
LGG	cis	rs4819052	0.851	rs2838840	ENSG00000223768.1	LINC00205	-13.7	3.05e-36	6.61e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45293285~45297354:+
LGG	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	13.7	3.06e-36	6.62e-33	0.86	0.53	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
LGG	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	13.7	3.06e-36	6.62e-33	0.86	0.53	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
LGG	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-13.7	3.08e-36	6.67e-33	-0.59	-0.53	Height;	chr3:53094335	chr3:53064283~53065091:-
LGG	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	13.7	3.1e-36	6.71e-33	0.66	0.53	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
LGG	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	13.7	3.11e-36	6.73e-33	0.68	0.53	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
LGG	cis	rs2019137	0.539	rs4849181	ENSG00000274877.1	RP11-65I12.1	-13.7	3.12e-36	6.76e-33	-0.69	-0.53	Lymphocyte counts;	chr2:113234393	chr2:113237595~113240825:+
LGG	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	13.7	3.12e-36	6.76e-33	0.6	0.53	Height;	chr11:118747911	chr11:118688039~118690600:-
LGG	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-13.7	3.15e-36	6.81e-33	-0.59	-0.53	Height;	chr3:53093751	chr3:53064283~53065091:-
LGG	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	13.7	3.2e-36	6.93e-33	0.65	0.53	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
LGG	cis	rs8062405	0.964	rs62036614	ENSG00000271623.1	RP11-435I10.5	-13.7	3.25e-36	7.03e-33	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28364700~28365333:+
LGG	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	13.7	3.26e-36	7.04e-33	0.63	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
LGG	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	13.7	3.27e-36	7.07e-33	0.6	0.53	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
LGG	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	13.7	3.27e-36	7.07e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
LGG	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-13.7	3.28e-36	7.09e-33	-0.67	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
LGG	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	13.7	3.31e-36	7.15e-33	0.86	0.53	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
LGG	cis	rs4682868	0.611	rs7614670	ENSG00000273328.4	RP11-141M3.6	-13.69	3.36e-36	7.25e-33	-0.62	-0.53	Monocyte percentage of white cells;	chr3:42879906	chr3:42809414~42908105:+
LGG	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-13.69	3.36e-36	7.26e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
LGG	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	13.69	3.37e-36	7.29e-33	0.65	0.53	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	13.69	3.37e-36	7.29e-33	0.65	0.53	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
LGG	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-13.69	3.39e-36	7.32e-33	-0.58	-0.53	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
LGG	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	13.69	3.43e-36	7.4e-33	0.62	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
LGG	cis	rs950027	0.62	rs1617634	ENSG00000259433.2	CTD-2651B20.4	-13.69	3.44e-36	7.42e-33	-0.58	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45330209~45332634:-
LGG	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-13.69	3.46e-36	7.46e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
LGG	cis	rs950027	0.62	rs1346267	ENSG00000259433.2	CTD-2651B20.4	-13.69	3.53e-36	7.6e-33	-0.58	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45330209~45332634:-
LGG	cis	rs651907	0.557	rs11712748	ENSG00000244119.1	PDCL3P4	13.69	3.66e-36	7.88e-33	0.41	0.53	Colorectal cancer;	chr3:101664718	chr3:101712472~101713191:+
LGG	cis	rs7829975	0.511	rs2980426	ENSG00000173295.6	FAM86B3P	-13.68	3.67e-36	7.89e-33	-0.57	-0.53	Mood instability;	chr8:8288087	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	13.68	3.69e-36	7.94e-33	0.66	0.53	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
LGG	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-13.68	3.71e-36	7.98e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-13.68	3.71e-36	7.98e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-13.68	3.71e-36	7.98e-33	-0.57	-0.53	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
LGG	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-13.68	3.71e-36	7.99e-33	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
LGG	cis	rs7267979	0.789	rs4815429	ENSG00000125804.12	FAM182A	13.68	3.72e-36	8.01e-33	0.64	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26054655~26086917:+
LGG	cis	rs853679	0.76	rs9468317	ENSG00000216901.1	AL022393.7	13.68	3.73e-36	8.03e-33	0.81	0.53	Depression;	chr6:28230678	chr6:28176188~28176674:+
LGG	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	13.68	3.74e-36	8.03e-33	0.41	0.53	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	13.68	3.74e-36	8.03e-33	0.41	0.53	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	13.68	3.74e-36	8.03e-33	0.41	0.53	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	13.68	3.74e-36	8.03e-33	0.41	0.53	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	13.68	3.74e-36	8.03e-33	0.41	0.53	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
LGG	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	13.68	3.76e-36	8.09e-33	0.61	0.53	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
LGG	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-13.68	3.77e-36	8.11e-33	-0.65	-0.53	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-13.68	3.77e-36	8.11e-33	-0.65	-0.53	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
LGG	cis	rs172166	0.538	rs1150686	ENSG00000199851.2	U3	13.68	3.8e-36	8.16e-33	0.71	0.53	Cardiac Troponin-T levels;	chr6:28193493	chr6:28015568~28015777:+
LGG	cis	rs1150688	1	rs1150688	ENSG00000199851.2	U3	13.68	3.8e-36	8.16e-33	0.71	0.53	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28015568~28015777:+
LGG	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-13.68	3.82e-36	8.22e-33	-0.63	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
LGG	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	13.68	3.85e-36	8.27e-33	0.67	0.53	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
LGG	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	13.68	3.85e-36	8.27e-33	0.67	0.53	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
LGG	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	13.68	3.85e-36	8.27e-33	0.67	0.53	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
LGG	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-13.68	3.89e-36	8.36e-33	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
LGG	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-13.68	3.96e-36	8.5e-33	-0.66	-0.53	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
LGG	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-13.68	3.96e-36	8.51e-33	-0.67	-0.53	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
LGG	cis	rs8062405	0.965	rs8049439	ENSG00000271623.1	RP11-435I10.5	-13.68	3.99e-36	8.56e-33	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.851	rs2838844	ENSG00000223768.1	LINC00205	-13.68	4.01e-36	8.6e-33	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45293285~45297354:+
LGG	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	13.68	4.01e-36	8.61e-33	0.99	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
LGG	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	13.68	4.01e-36	8.61e-33	0.59	0.53	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
LGG	cis	rs8062405	0.679	rs72793818	ENSG00000271623.1	RP11-435I10.5	-13.68	4.03e-36	8.64e-33	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28364700~28365333:+
LGG	cis	rs853679	0.76	rs11967137	ENSG00000199851.2	U3	13.68	4.04e-36	8.67e-33	0.92	0.53	Depression;	chr6:28231986	chr6:28015568~28015777:+
LGG	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-13.67	4.07e-36	8.73e-33	-0.56	-0.53	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
LGG	cis	rs950027	0.62	rs1719245	ENSG00000259433.2	CTD-2651B20.4	-13.67	4.07e-36	8.74e-33	-0.58	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45330209~45332634:-
LGG	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	13.67	4.08e-36	8.74e-33	0.59	0.53	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-13.67	4.09e-36	8.78e-33	-0.6	-0.53	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
LGG	cis	rs853679	0.76	rs11962305	ENSG00000199851.2	U3	13.67	4.1e-36	8.79e-33	0.92	0.53	Depression;	chr6:28232159	chr6:28015568~28015777:+
LGG	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-13.67	4.11e-36	8.82e-33	-0.8	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
LGG	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-13.67	4.12e-36	8.82e-33	-0.67	-0.53	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
LGG	cis	rs8062405	1	rs62037371	ENSG00000271623.1	RP11-435I10.5	-13.67	4.18e-36	8.96e-33	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs8055138	ENSG00000271623.1	RP11-435I10.5	-13.67	4.18e-36	8.96e-33	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28364700~28365333:+
LGG	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	13.67	4.19e-36	8.97e-33	0.57	0.53	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
LGG	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	13.67	4.2e-36	8.99e-33	0.62	0.53	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
LGG	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	13.67	4.31e-36	9.23e-33	0.6	0.53	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	13.67	4.31e-36	9.24e-33	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	13.67	4.33e-36	9.27e-33	0.66	0.53	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
LGG	cis	rs4682868	0.552	rs6771233	ENSG00000273328.4	RP11-141M3.6	-13.67	4.41e-36	9.45e-33	-0.62	-0.53	Monocyte percentage of white cells;	chr3:42881205	chr3:42809414~42908105:+
LGG	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	13.66	4.48e-36	9.6e-33	0.6	0.53	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
LGG	cis	rs7315956	0.963	rs4761186	ENSG00000257139.1	RP11-320P7.2	-13.66	4.53e-36	9.68e-33	-0.65	-0.53	Testicular germ cell tumor;	chr12:70232545	chr12:70180338~70202004:+
LGG	cis	rs7216064	0.589	rs7213585	ENSG00000278219.1	AC145343.1	-13.66	4.54e-36	9.71e-33	-0.62	-0.53	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68101538~68101639:+
LGG	cis	rs7267979	0.738	rs2892409	ENSG00000125804.12	FAM182A	-13.66	4.55e-36	9.74e-33	-0.63	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:26054655~26086917:+
LGG	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-13.66	4.58e-36	9.8e-33	-0.73	-0.53	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
LGG	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	13.66	4.63e-36	9.89e-33	0.61	0.53	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
LGG	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	13.66	4.63e-36	9.9e-33	0.62	0.53	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
LGG	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	13.66	4.66e-36	9.96e-33	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
LGG	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-13.66	4.67e-36	9.99e-33	-0.65	-0.53	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-13.66	4.67e-36	9.99e-33	-0.65	-0.53	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
LGG	cis	rs651907	0.557	rs3806654	ENSG00000244119.1	PDCL3P4	13.66	4.71e-36	1.01e-32	0.41	0.53	Colorectal cancer;	chr3:101677685	chr3:101712472~101713191:+
LGG	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	13.66	4.74e-36	1.01e-32	0.6	0.53	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
LGG	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-13.66	4.78e-36	1.02e-32	-0.63	-0.53	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
LGG	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-13.66	4.79e-36	1.02e-32	-0.56	-0.53	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
LGG	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	13.66	4.82e-36	1.03e-32	0.72	0.53	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
LGG	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-13.65	4.92e-36	1.05e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-13.65	4.92e-36	1.05e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
LGG	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	13.65	4.98e-36	1.06e-32	0.6	0.53	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
LGG	cis	rs8062405	1	rs62036626	ENSG00000271623.1	RP11-435I10.5	-13.65	5.1e-36	1.09e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs62036657	ENSG00000271623.1	RP11-435I10.5	-13.65	5.1e-36	1.09e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs12444171	ENSG00000271623.1	RP11-435I10.5	-13.65	5.1e-36	1.09e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28364700~28365333:+
LGG	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-13.65	5.14e-36	1.1e-32	-0.93	-0.53	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
LGG	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	13.65	5.14e-36	1.1e-32	0.59	0.53	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
LGG	cis	rs4819052	0.807	rs7283915	ENSG00000223768.1	LINC00205	-13.65	5.16e-36	1.1e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2838850	ENSG00000223768.1	LINC00205	-13.65	5.16e-36	1.1e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45293285~45297354:+
LGG	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	13.65	5.22e-36	1.11e-32	0.95	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
LGG	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	13.65	5.22e-36	1.11e-32	0.47	0.53	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
LGG	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	13.65	5.22e-36	1.11e-32	0.67	0.53	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
LGG	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	13.65	5.24e-36	1.12e-32	0.96	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	13.65	5.24e-36	1.12e-32	0.96	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	13.65	5.24e-36	1.12e-32	0.96	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	13.65	5.24e-36	1.12e-32	0.96	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	13.65	5.24e-36	1.12e-32	0.96	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	13.65	5.24e-36	1.12e-32	0.96	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	13.65	5.24e-36	1.12e-32	0.96	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
LGG	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	-13.65	5.31e-36	1.13e-32	-0.55	-0.53	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
LGG	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-13.65	5.41e-36	1.15e-32	-0.46	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
LGG	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	13.64	5.46e-36	1.16e-32	0.43	0.53	Height;	chr11:118758322	chr11:118791254~118793137:+
LGG	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	13.64	5.49e-36	1.17e-32	0.6	0.53	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
LGG	cis	rs8062405	0.964	rs78613234	ENSG00000271623.1	RP11-435I10.5	-13.64	5.53e-36	1.17e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs62036624	ENSG00000271623.1	RP11-435I10.5	-13.64	5.53e-36	1.17e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs3088215	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs28403629	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs61737565	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs4788099	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs9972693	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.964	rs9972768	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.965	rs56040780	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.965	rs62037363	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs7205323	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs4788101	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs62037364	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.929	rs11150609	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.737	rs11861132	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs11861174	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs62037367	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs7198606	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.929	rs11864750	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.964	rs7193733	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs8055982	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs7498665	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.964	rs11864107	ENSG00000271623.1	RP11-435I10.5	-13.64	5.57e-36	1.18e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28364700~28365333:+
LGG	cis	rs7267979	0.789	rs2260197	ENSG00000125804.12	FAM182A	-13.64	5.58e-36	1.18e-32	-0.63	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26054655~26086917:+
LGG	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	13.64	5.63e-36	1.2e-32	0.65	0.53	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
LGG	cis	rs8062405	1	rs62036617	ENSG00000271623.1	RP11-435I10.5	-13.64	5.69e-36	1.21e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.819	rs7279136	ENSG00000223768.1	LINC00205	-13.64	5.72e-36	1.21e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45293285~45297354:+
LGG	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-13.64	5.74e-36	1.22e-32	-0.57	-0.53	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
LGG	cis	rs8062405	1	rs56404918	ENSG00000271623.1	RP11-435I10.5	-13.64	5.8e-36	1.23e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs55719896	ENSG00000271623.1	RP11-435I10.5	-13.64	5.8e-36	1.23e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs55830740	ENSG00000271623.1	RP11-435I10.5	-13.64	5.8e-36	1.23e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28364700~28365333:+
LGG	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	13.64	5.81e-36	1.23e-32	0.63	0.53	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
LGG	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-13.64	5.85e-36	1.24e-32	-0.59	-0.53	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
LGG	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-13.64	5.94e-36	1.26e-32	-0.65	-0.53	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
LGG	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-13.64	5.95e-36	1.26e-32	-0.43	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
LGG	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-13.64	5.95e-36	1.26e-32	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	13.64	5.98e-36	1.26e-32	0.6	0.53	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	13.64	5.98e-36	1.27e-32	0.66	0.53	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	13.64	5.98e-36	1.27e-32	0.66	0.53	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
LGG	cis	rs200972	1	rs200972	ENSG00000199851.2	U3	13.63	6.01e-36	1.27e-32	0.73	0.53	Urinary tract infection frequency;	chr6:27891059	chr6:28015568~28015777:+
LGG	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	13.63	6.06e-36	1.28e-32	0.65	0.53	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
LGG	cis	rs8062405	1	rs4788095	ENSG00000271623.1	RP11-435I10.5	-13.63	6.24e-36	1.32e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.964	rs72793809	ENSG00000271623.1	RP11-435I10.5	-13.63	6.24e-36	1.32e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs62036620	ENSG00000271623.1	RP11-435I10.5	-13.63	6.24e-36	1.32e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs62036621	ENSG00000271623.1	RP11-435I10.5	-13.63	6.24e-36	1.32e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28364700~28365333:+
LGG	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-13.63	6.26e-36	1.32e-32	-0.64	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
LGG	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-13.63	6.29e-36	1.33e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
LGG	cis	rs4819052	0.684	rs914216	ENSG00000223768.1	LINC00205	-13.63	6.29e-36	1.33e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs914218	ENSG00000223768.1	LINC00205	-13.63	6.31e-36	1.33e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2838829	ENSG00000223768.1	LINC00205	-13.63	6.32e-36	1.34e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.885	rs9980676	ENSG00000223768.1	LINC00205	-13.63	6.32e-36	1.34e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2838836	ENSG00000223768.1	LINC00205	-13.63	6.32e-36	1.34e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45293285~45297354:+
LGG	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-13.63	6.33e-36	1.34e-32	-0.67	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-13.63	6.33e-36	1.34e-32	-0.67	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
LGG	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-13.63	6.33e-36	1.34e-32	-0.67	-0.53	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
LGG	cis	rs853679	0.76	rs9357067	ENSG00000199851.2	U3	13.63	6.39e-36	1.35e-32	0.92	0.53	Depression;	chr6:28242515	chr6:28015568~28015777:+
LGG	cis	rs853679	0.76	rs967005	ENSG00000199851.2	U3	13.63	6.39e-36	1.35e-32	0.92	0.53	Depression;	chr6:28242910	chr6:28015568~28015777:+
LGG	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-13.63	6.39e-36	1.35e-32	-0.79	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
LGG	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	13.63	6.4e-36	1.35e-32	0.6	0.53	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
LGG	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-13.63	6.54e-36	1.38e-32	-0.6	-0.53	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
LGG	cis	rs853679	0.76	rs9393910	ENSG00000199851.2	U3	13.62	6.71e-36	1.41e-32	0.92	0.53	Depression;	chr6:28240414	chr6:28015568~28015777:+
LGG	cis	rs853679	0.76	rs9368563	ENSG00000199851.2	U3	13.62	6.71e-36	1.41e-32	0.92	0.53	Depression;	chr6:28240780	chr6:28015568~28015777:+
LGG	cis	rs853679	0.76	rs9295768	ENSG00000199851.2	U3	13.62	6.71e-36	1.41e-32	0.92	0.53	Depression;	chr6:28241324	chr6:28015568~28015777:+
LGG	cis	rs853679	0.699	rs9468318	ENSG00000199851.2	U3	13.62	6.71e-36	1.41e-32	0.92	0.53	Depression;	chr6:28241753	chr6:28015568~28015777:+
LGG	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-13.62	6.79e-36	1.43e-32	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
LGG	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-13.62	6.83e-36	1.44e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-13.62	6.83e-36	1.44e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-13.62	6.83e-36	1.44e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
LGG	cis	rs4819052	0.851	rs1999335	ENSG00000223768.1	LINC00205	-13.62	6.9e-36	1.45e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45293285~45297354:+
LGG	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	13.62	6.94e-36	1.46e-32	0.59	0.53	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
LGG	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-13.62	7.06e-36	1.48e-32	-0.61	-0.53	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
LGG	cis	rs4682868	0.581	rs13068366	ENSG00000273328.4	RP11-141M3.6	-13.62	7.09e-36	1.49e-32	-0.62	-0.53	Monocyte percentage of white cells;	chr3:42880528	chr3:42809414~42908105:+
LGG	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-13.61	7.31e-36	1.54e-32	-0.59	-0.53	Height;	chr3:53080524	chr3:53064283~53065091:-
LGG	cis	rs4819052	0.851	rs2838834	ENSG00000223768.1	LINC00205	-13.61	7.32e-36	1.54e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45293285~45297354:+
LGG	cis	rs853679	0.76	rs2299029	ENSG00000199851.2	U3	13.61	7.33e-36	1.54e-32	0.92	0.53	Depression;	chr6:28231053	chr6:28015568~28015777:+
LGG	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-13.61	7.39e-36	1.55e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
LGG	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	13.61	7.41e-36	1.56e-32	0.63	0.53	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
LGG	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	13.61	7.49e-36	1.57e-32	0.58	0.53	Height;	chr3:53073584	chr3:53064283~53065091:-
LGG	cis	rs4819052	0.851	rs8134392	ENSG00000223768.1	LINC00205	13.61	7.5e-36	1.58e-32	0.59	0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45293285~45297354:+
LGG	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-13.61	7.52e-36	1.58e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-13.61	7.52e-36	1.58e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
LGG	cis	rs73086581	0.891	rs73084555	ENSG00000229539.1	RP11-119B16.2	13.61	7.57e-36	1.59e-32	0.98	0.53	Response to antidepressants in depression;	chr20:3913153	chr20:3888239~3888868:-
LGG	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	13.61	7.62e-36	1.6e-32	0.93	0.53	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
LGG	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	13.61	7.67e-36	1.61e-32	0.65	0.53	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
LGG	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	13.61	7.71e-36	1.62e-32	0.59	0.53	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	13.61	7.71e-36	1.62e-32	0.59	0.53	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	13.61	7.71e-36	1.62e-32	0.59	0.53	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	13.61	7.71e-36	1.62e-32	0.59	0.53	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	13.61	7.71e-36	1.62e-32	0.59	0.53	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	13.61	7.75e-36	1.63e-32	0.59	0.53	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	13.61	7.75e-36	1.63e-32	0.59	0.53	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	13.61	7.75e-36	1.63e-32	0.59	0.53	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	13.61	7.75e-36	1.63e-32	0.59	0.53	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	13.61	7.75e-36	1.63e-32	0.59	0.53	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	13.61	7.75e-36	1.63e-32	0.59	0.53	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
LGG	cis	rs7267979	0.816	rs6037158	ENSG00000125804.12	FAM182A	-13.61	7.77e-36	1.63e-32	-0.64	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26054655~26086917:+
LGG	cis	rs172166	0.561	rs149973	ENSG00000199851.2	U3	13.61	7.83e-36	1.64e-32	0.72	0.53	Cardiac Troponin-T levels;	chr6:28015835	chr6:28015568~28015777:+
LGG	cis	rs172166	0.561	rs149974	ENSG00000199851.2	U3	13.61	7.83e-36	1.64e-32	0.72	0.53	Cardiac Troponin-T levels;	chr6:28017318	chr6:28015568~28015777:+
LGG	cis	rs2980439	0.607	rs2980419	ENSG00000173295.6	FAM86B3P	-13.61	7.86e-36	1.65e-32	-0.55	-0.53	Neuroticism;	chr8:8256619	chr8:8228595~8244865:+
LGG	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	13.61	7.91e-36	1.66e-32	0.6	0.53	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
LGG	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	13.6	8.07e-36	1.69e-32	0.67	0.53	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
LGG	cis	rs4819052	0.851	rs2838845	ENSG00000223768.1	LINC00205	-13.6	8.11e-36	1.7e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45293285~45297354:+
LGG	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	13.6	8.18e-36	1.71e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	13.6	8.18e-36	1.71e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
LGG	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-13.6	8.28e-36	1.74e-32	-0.6	-0.53	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
LGG	cis	rs8062405	1	rs4788102	ENSG00000271623.1	RP11-435I10.5	-13.6	8.47e-36	1.77e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28364700~28365333:+
LGG	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-13.6	8.51e-36	1.78e-32	-0.88	-0.53	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
LGG	cis	rs4713118	0.866	rs9468217	ENSG00000199851.2	U3	13.6	8.53e-36	1.79e-32	0.8	0.53	Parkinson's disease;	chr6:27758688	chr6:28015568~28015777:+
LGG	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	-13.6	8.56e-36	1.79e-32	-0.56	-0.53	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
LGG	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	13.6	8.81e-36	1.84e-32	0.59	0.53	Height;	chr3:53072864	chr3:53064283~53065091:-
LGG	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	13.59	9.03e-36	1.89e-32	0.59	0.53	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	13.59	9.03e-36	1.89e-32	0.59	0.53	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	13.59	9.03e-36	1.89e-32	0.59	0.53	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	13.59	9.03e-36	1.89e-32	0.59	0.53	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
LGG	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	13.59	9.08e-36	1.9e-32	0.95	0.53	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	13.59	9.08e-36	1.9e-32	0.95	0.53	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
LGG	cis	rs4819052	0.807	rs4819047	ENSG00000223768.1	LINC00205	-13.59	9.09e-36	1.9e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45293285~45297354:+
LGG	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-13.59	9.12e-36	1.9e-32	-0.68	-0.53	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
LGG	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	13.59	9.13e-36	1.91e-32	0.73	0.53	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
LGG	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	13.59	9.16e-36	1.91e-32	0.6	0.53	Height;	chr11:118808920	chr11:118688039~118690600:-
LGG	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	13.59	9.46e-36	1.98e-32	0.6	0.53	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
LGG	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-13.59	9.49e-36	1.98e-32	-0.61	-0.53	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
LGG	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-13.59	9.62e-36	2.01e-32	-0.43	-0.53	Height;	chr11:118760944	chr11:118791254~118793137:+
LGG	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-13.59	9.75e-36	2.03e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
LGG	cis	rs7315956	0.927	rs4567514	ENSG00000257139.1	RP11-320P7.2	-13.58	9.83e-36	2.05e-32	-0.65	-0.53	Testicular germ cell tumor;	chr12:70237903	chr12:70180338~70202004:+
LGG	cis	rs4713118	0.505	rs156740	ENSG00000199851.2	U3	13.58	1.02e-35	2.14e-32	0.72	0.53	Parkinson's disease;	chr6:27992657	chr6:28015568~28015777:+
LGG	cis	rs4819052	0.851	rs7276828	ENSG00000223768.1	LINC00205	-13.58	1.03e-35	2.15e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs4819046	ENSG00000223768.1	LINC00205	-13.58	1.03e-35	2.15e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45293285~45297354:+
LGG	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-13.58	1.03e-35	2.15e-32	-0.43	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	13.58	1.03e-35	2.16e-32	0.66	0.53	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
LGG	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	13.58	1.04e-35	2.16e-32	0.95	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
LGG	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	13.58	1.05e-35	2.17e-32	0.59	0.53	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
LGG	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	13.58	1.05e-35	2.18e-32	0.59	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
LGG	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	13.58	1.05e-35	2.18e-32	0.62	0.53	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
LGG	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-13.58	1.07e-35	2.21e-32	-0.59	-0.53	Height;	chr3:53064759	chr3:53064283~53065091:-
LGG	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	13.58	1.07e-35	2.22e-32	0.87	0.53	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
LGG	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	13.58	1.07e-35	2.22e-32	0.87	0.53	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
LGG	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	13.57	1.08e-35	2.25e-32	0.67	0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
LGG	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	13.57	1.09e-35	2.26e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
LGG	cis	rs4819052	0.851	rs2838837	ENSG00000223768.1	LINC00205	-13.57	1.09e-35	2.27e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45293285~45297354:+
LGG	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-13.57	1.1e-35	2.28e-32	-0.59	-0.53	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
LGG	cis	rs853679	0.76	rs11962305	ENSG00000216901.1	AL022393.7	13.57	1.11e-35	2.3e-32	0.81	0.53	Depression;	chr6:28232159	chr6:28176188~28176674:+
LGG	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	13.57	1.12e-35	2.33e-32	0.94	0.53	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
LGG	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	13.57	1.12e-35	2.33e-32	0.61	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	13.57	1.13e-35	2.35e-32	0.66	0.53	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
LGG	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	13.57	1.14e-35	2.35e-32	0.6	0.53	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
LGG	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	13.57	1.19e-35	2.46e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
LGG	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	13.56	1.2e-35	2.48e-32	0.73	0.53	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.868	rs10071617	ENSG00000248112.1	RP11-78C3.1	13.56	1.25e-35	2.58e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:82919376~82921119:-
LGG	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	13.56	1.25e-35	2.58e-32	0.59	0.53	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
LGG	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	13.56	1.25e-35	2.59e-32	0.56	0.53	Height;	chr3:53073764	chr3:53064283~53065091:-
LGG	cis	rs8062405	0.754	rs151179	ENSG00000271623.1	RP11-435I10.5	-13.56	1.26e-35	2.6e-32	-0.64	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28364700~28365333:+
LGG	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-13.56	1.26e-35	2.6e-32	-0.56	-0.53	Height;	chr3:53074760	chr3:53064283~53065091:-
LGG	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	13.56	1.26e-35	2.61e-32	0.64	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	13.56	1.26e-35	2.61e-32	0.64	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	13.56	1.26e-35	2.61e-32	0.64	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
LGG	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-13.56	1.28e-35	2.64e-32	-0.43	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
LGG	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	13.56	1.29e-35	2.66e-32	0.61	0.53	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
LGG	cis	rs853679	0.76	rs9357067	ENSG00000216901.1	AL022393.7	13.56	1.31e-35	2.71e-32	0.82	0.53	Depression;	chr6:28242515	chr6:28176188~28176674:+
LGG	cis	rs853679	0.76	rs967005	ENSG00000216901.1	AL022393.7	13.56	1.31e-35	2.71e-32	0.82	0.53	Depression;	chr6:28242910	chr6:28176188~28176674:+
LGG	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	13.56	1.31e-35	2.71e-32	0.59	0.53	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
LGG	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	13.56	1.31e-35	2.71e-32	0.59	0.53	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
LGG	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	13.55	1.33e-35	2.74e-32	0.66	0.53	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
LGG	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-13.55	1.35e-35	2.79e-32	-0.67	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-13.55	1.35e-35	2.79e-32	-0.67	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
LGG	cis	rs4819052	0.851	rs2838865	ENSG00000223768.1	LINC00205	-13.55	1.37e-35	2.81e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45293285~45297354:+
LGG	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-13.55	1.37e-35	2.83e-32	-0.6	-0.53	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
LGG	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	13.55	1.41e-35	2.9e-32	0.95	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
LGG	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	13.55	1.42e-35	2.92e-32	0.59	0.53	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
LGG	cis	rs853679	0.76	rs11967137	ENSG00000216901.1	AL022393.7	13.55	1.45e-35	2.98e-32	0.81	0.53	Depression;	chr6:28231986	chr6:28176188~28176674:+
LGG	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	13.54	1.47e-35	3.03e-32	0.58	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
LGG	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-13.54	1.48e-35	3.04e-32	-0.67	-0.53	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
LGG	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-13.54	1.48e-35	3.05e-32	-0.7	-0.53	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
LGG	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	13.54	1.48e-35	3.05e-32	0.41	0.53	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
LGG	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-13.54	1.49e-35	3.07e-32	-0.68	-0.53	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
LGG	cis	rs4819052	0.808	rs2246697	ENSG00000223768.1	LINC00205	-13.54	1.5e-35	3.08e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.788	rs4819051	ENSG00000223768.1	LINC00205	-13.54	1.5e-35	3.08e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45293285~45297354:+
LGG	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-13.54	1.5e-35	3.08e-32	-0.67	-0.53	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
LGG	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	13.54	1.5e-35	3.09e-32	0.59	0.53	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	13.54	1.5e-35	3.09e-32	0.59	0.53	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	13.54	1.5e-35	3.09e-32	0.59	0.53	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	13.54	1.5e-35	3.09e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	13.54	1.5e-35	3.09e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
LGG	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-13.54	1.51e-35	3.09e-32	-0.65	-0.53	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
LGG	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-13.54	1.51e-35	3.11e-32	-0.69	-0.53	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
LGG	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-13.54	1.51e-35	3.11e-32	-0.69	-0.53	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
LGG	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-13.54	1.51e-35	3.11e-32	-0.69	-0.53	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
LGG	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-13.54	1.53e-35	3.13e-32	-0.85	-0.53	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	13.54	1.53e-35	3.14e-32	0.66	0.53	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
LGG	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-13.54	1.53e-35	3.14e-32	-0.59	-0.53	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
LGG	cis	rs7267979	0.702	rs449801	ENSG00000125804.12	FAM182A	-13.54	1.56e-35	3.2e-32	-0.63	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:26054655~26086917:+
LGG	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	13.54	1.6e-35	3.29e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
LGG	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-13.53	1.61e-35	3.3e-32	-0.41	-0.53	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
LGG	cis	rs6452524	1	rs2126988	ENSG00000248112.1	RP11-78C3.1	13.53	1.62e-35	3.32e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:82919376~82921119:-
LGG	cis	rs853679	0.723	rs9366718	ENSG00000199851.2	U3	13.53	1.63e-35	3.34e-32	0.92	0.53	Depression;	chr6:28237724	chr6:28015568~28015777:+
LGG	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	13.53	1.64e-35	3.37e-32	0.47	0.53	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
LGG	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	13.53	1.64e-35	3.37e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
LGG	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	13.53	1.65e-35	3.39e-32	0.73	0.53	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	13.53	1.65e-35	3.39e-32	0.73	0.53	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
LGG	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	13.53	1.69e-35	3.46e-32	0.47	0.53	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
LGG	cis	rs6452524	1	rs10474093	ENSG00000248112.1	RP11-78C3.1	13.53	1.72e-35	3.53e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs10473868	ENSG00000248112.1	RP11-78C3.1	13.53	1.72e-35	3.53e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:82919376~82921119:-
LGG	cis	rs8062405	1	rs62037365	ENSG00000271623.1	RP11-435I10.5	-13.53	1.75e-35	3.58e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28364700~28365333:+
LGG	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	13.53	1.75e-35	3.58e-32	0.57	0.53	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	13.53	1.75e-35	3.58e-32	0.57	0.53	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
LGG	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	13.53	1.75e-35	3.58e-32	0.69	0.53	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
LGG	cis	rs7267979	0.816	rs6076358	ENSG00000125804.12	FAM182A	13.52	1.79e-35	3.65e-32	0.63	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26054655~26086917:+
LGG	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-13.52	1.79e-35	3.65e-32	-0.59	-0.53	Height;	chr3:53070344	chr3:53064283~53065091:-
LGG	cis	rs4819052	0.851	rs2838833	ENSG00000223768.1	LINC00205	-13.52	1.79e-35	3.66e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45293285~45297354:+
LGG	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-13.52	1.81e-35	3.69e-32	-0.67	-0.53	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
LGG	cis	rs8062405	0.755	rs4788073	ENSG00000271623.1	RP11-435I10.5	-13.52	1.81e-35	3.7e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs17640009	ENSG00000271623.1	RP11-435I10.5	-13.52	1.81e-35	3.7e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs55792032	ENSG00000271623.1	RP11-435I10.5	-13.52	1.81e-35	3.7e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28364700~28365333:+
LGG	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-13.52	1.84e-35	3.76e-32	-0.85	-0.53	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
LGG	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-13.52	1.86e-35	3.79e-32	-0.66	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
LGG	cis	rs4713118	0.699	rs200969	ENSG00000216901.1	AL022393.7	13.52	1.89e-35	3.86e-32	0.74	0.53	Parkinson's disease;	chr6:27891675	chr6:28176188~28176674:+
LGG	cis	rs6452524	1	rs62374373	ENSG00000248112.1	RP11-78C3.1	13.52	1.9e-35	3.88e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.561	rs4331874	ENSG00000248112.1	RP11-78C3.1	13.52	1.9e-35	3.89e-32	0.69	0.53	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:82919376~82921119:-
LGG	cis	rs7267979	0.844	rs6115188	ENSG00000125804.12	FAM182A	-13.52	1.92e-35	3.92e-32	-0.64	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26054655~26086917:+
LGG	cis	rs853679	0.76	rs9393910	ENSG00000216901.1	AL022393.7	13.52	1.92e-35	3.92e-32	0.81	0.53	Depression;	chr6:28240414	chr6:28176188~28176674:+
LGG	cis	rs853679	0.76	rs9368563	ENSG00000216901.1	AL022393.7	13.52	1.92e-35	3.92e-32	0.81	0.53	Depression;	chr6:28240780	chr6:28176188~28176674:+
LGG	cis	rs853679	0.76	rs9295768	ENSG00000216901.1	AL022393.7	13.52	1.92e-35	3.92e-32	0.81	0.53	Depression;	chr6:28241324	chr6:28176188~28176674:+
LGG	cis	rs853679	0.699	rs9468318	ENSG00000216901.1	AL022393.7	13.52	1.92e-35	3.92e-32	0.81	0.53	Depression;	chr6:28241753	chr6:28176188~28176674:+
LGG	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-13.52	1.93e-35	3.93e-32	-0.6	-0.53	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
LGG	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	13.51	1.96e-35	3.99e-32	0.58	0.53	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
LGG	cis	rs853679	0.76	rs2299029	ENSG00000216901.1	AL022393.7	13.51	1.97e-35	4.01e-32	0.81	0.53	Depression;	chr6:28231053	chr6:28176188~28176674:+
LGG	cis	rs950027	0.62	rs1617984	ENSG00000259433.2	CTD-2651B20.4	-13.51	1.97e-35	4.02e-32	-0.58	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45330209~45332634:-
LGG	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-13.51	1.99e-35	4.06e-32	-0.69	-0.53	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
LGG	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-13.51	1.99e-35	4.06e-32	-0.69	-0.53	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
LGG	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	13.51	2.01e-35	4.1e-32	0.65	0.53	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
LGG	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-13.51	2.05e-35	4.18e-32	-0.56	-0.53	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
LGG	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-13.51	2.06e-35	4.2e-32	-0.43	-0.53	Height;	chr11:118773873	chr11:118791254~118793137:+
LGG	cis	rs4819052	0.851	rs7276591	ENSG00000223768.1	LINC00205	-13.51	2.06e-35	4.2e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45293285~45297354:+
LGG	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	13.51	2.08e-35	4.23e-32	0.59	0.53	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
LGG	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	13.51	2.09e-35	4.25e-32	0.69	0.53	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.588	rs200994	ENSG00000216901.1	AL022393.7	-13.51	2.09e-35	4.26e-32	-0.74	-0.53	Parkinson's disease;	chr6:27846035	chr6:28176188~28176674:+
LGG	cis	rs4819052	0.819	rs34818688	ENSG00000223768.1	LINC00205	-13.51	2.1e-35	4.28e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45293285~45297354:+
LGG	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-13.51	2.11e-35	4.3e-32	-0.62	-0.53	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-13.51	2.11e-35	4.3e-32	-0.61	-0.53	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-13.51	2.12e-35	4.32e-32	-0.61	-0.53	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.789	rs6076347	ENSG00000125804.12	FAM182A	13.51	2.15e-35	4.36e-32	0.62	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26054655~26086917:+
LGG	cis	rs6452524	1	rs6452524	ENSG00000248112.1	RP11-78C3.1	-13.5	2.15e-35	4.37e-32	-0.67	-0.53	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10043018	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs10037501	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.904	rs6452525	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs7716931	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs7721416	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6882220	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6452526	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6452527	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10055844	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10077862	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs9293332	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6868817	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs10042018	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs10036418	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10055948	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10037872	ENSG00000248112.1	RP11-78C3.1	13.5	2.15e-35	4.37e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:82919376~82921119:-
LGG	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	13.5	2.15e-35	4.37e-32	0.62	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
LGG	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-13.5	2.17e-35	4.4e-32	-0.61	-0.53	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
LGG	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	13.5	2.19e-35	4.43e-32	0.57	0.53	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
LGG	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-13.5	2.19e-35	4.44e-32	-0.63	-0.53	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
LGG	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-13.5	2.21e-35	4.48e-32	-0.61	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
LGG	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-13.5	2.28e-35	4.62e-32	-0.67	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
LGG	cis	rs8062405	1	rs8062405	ENSG00000271623.1	RP11-435I10.5	13.5	2.28e-35	4.62e-32	0.61	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28364700~28365333:+
LGG	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-13.5	2.28e-35	4.63e-32	-0.69	-0.53	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
LGG	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-13.5	2.29e-35	4.63e-32	-0.43	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
LGG	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-13.5	2.29e-35	4.63e-32	-0.43	-0.53	Height;	chr11:118749988	chr11:118791254~118793137:+
LGG	cis	rs8062405	1	rs3888190	ENSG00000271623.1	RP11-435I10.5	-13.5	2.29e-35	4.64e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28364700~28365333:+
LGG	cis	rs916888	0.773	rs199448	ENSG00000232300.1	FAM215B	13.5	2.32e-35	4.7e-32	0.77	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46558830~46562795:-
LGG	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-13.5	2.33e-35	4.72e-32	-0.69	-0.53	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
LGG	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-13.49	2.39e-35	4.83e-32	-0.92	-0.53	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
LGG	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-13.49	2.44e-35	4.93e-32	-0.66	-0.53	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-13.49	2.44e-35	4.93e-32	-0.66	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
LGG	cis	rs4819052	0.765	rs2838852	ENSG00000223768.1	LINC00205	-13.49	2.46e-35	4.97e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45293285~45297354:+
LGG	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	13.49	2.52e-35	5.09e-32	0.87	0.53	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
LGG	cis	rs6452524	0.935	rs7703318	ENSG00000248112.1	RP11-78C3.1	13.49	2.53e-35	5.11e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:82919376~82921119:-
LGG	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-13.49	2.56e-35	5.18e-32	-0.45	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
LGG	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	13.49	2.57e-35	5.19e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
LGG	cis	rs853679	0.723	rs9366718	ENSG00000216901.1	AL022393.7	13.49	2.58e-35	5.21e-32	0.81	0.53	Depression;	chr6:28237724	chr6:28176188~28176674:+
LGG	cis	rs7267979	0.816	rs376742	ENSG00000125804.12	FAM182A	-13.49	2.58e-35	5.22e-32	-0.64	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26054655~26086917:+
LGG	cis	rs8062405	0.754	rs149299	ENSG00000271623.1	RP11-435I10.5	-13.49	2.59e-35	5.22e-32	-0.64	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28364700~28365333:+
LGG	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-13.49	2.6e-35	5.26e-32	-0.55	-0.53	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
LGG	cis	rs4819052	0.851	rs2838831	ENSG00000223768.1	LINC00205	-13.49	2.61e-35	5.26e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45293285~45297354:+
LGG	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-13.48	2.62e-35	5.28e-32	-0.59	-0.53	Height;	chr3:53097932	chr3:53064283~53065091:-
LGG	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	13.48	2.66e-35	5.37e-32	0.61	0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-13.48	2.66e-35	5.37e-32	-0.61	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.819	rs8134084	ENSG00000223768.1	LINC00205	-13.48	2.69e-35	5.43e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs7281263	ENSG00000223768.1	LINC00205	-13.48	2.69e-35	5.43e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45293285~45297354:+
LGG	cis	rs7267979	0.789	rs6083820	ENSG00000125804.12	FAM182A	13.48	2.7e-35	5.43e-32	0.62	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26054655~26086917:+
LGG	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	13.48	2.74e-35	5.52e-32	0.95	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
LGG	cis	rs8062405	1	rs80275162	ENSG00000271623.1	RP11-435I10.5	-13.48	2.76e-35	5.57e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	13.48	2.77e-35	5.57e-32	0.65	0.53	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
LGG	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	13.48	2.84e-35	5.73e-32	0.57	0.53	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
LGG	cis	rs7267979	0.789	rs6083810	ENSG00000125804.12	FAM182A	13.48	2.84e-35	5.73e-32	0.62	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26054655~26086917:+
LGG	cis	rs8062405	0.755	rs56209193	ENSG00000271623.1	RP11-435I10.5	-13.47	2.94e-35	5.92e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28364700~28365333:+
LGG	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	13.47	2.96e-35	5.95e-32	0.62	0.53	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
LGG	cis	rs7267979	0.753	rs404148	ENSG00000125804.12	FAM182A	-13.47	2.97e-35	5.97e-32	-0.62	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:26054655~26086917:+
LGG	cis	rs8062405	0.755	rs12447461	ENSG00000271623.1	RP11-435I10.5	-13.47	2.98e-35	6e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs111693583	ENSG00000271623.1	RP11-435I10.5	-13.47	2.98e-35	6e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs7186573	ENSG00000271623.1	RP11-435I10.5	-13.47	2.98e-35	6e-32	-0.63	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28364700~28365333:+
LGG	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-13.47	3e-35	6.04e-32	-0.58	-0.53	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
LGG	cis	rs916888	0.773	rs199451	ENSG00000232300.1	FAM215B	13.47	3.04e-35	6.11e-32	0.77	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46558830~46562795:-
LGG	cis	rs4713118	0.911	rs9295746	ENSG00000199851.2	U3	13.47	3.07e-35	6.17e-32	0.8	0.53	Parkinson's disease;	chr6:27762285	chr6:28015568~28015777:+
LGG	cis	rs6452524	1	rs7710900	ENSG00000248112.1	RP11-78C3.1	13.47	3.07e-35	6.17e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	13.47	3.1e-35	6.22e-32	0.65	0.53	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
LGG	cis	rs7267979	0.844	rs4423675	ENSG00000125804.12	FAM182A	13.47	3.11e-35	6.23e-32	0.64	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.844	rs6083851	ENSG00000125804.12	FAM182A	13.47	3.11e-35	6.24e-32	0.64	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26054655~26086917:+
LGG	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-13.47	3.18e-35	6.37e-32	-0.68	-0.53	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	13.46	3.19e-35	6.4e-32	0.65	0.53	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	13.46	3.19e-35	6.4e-32	0.65	0.53	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	13.46	3.19e-35	6.4e-32	0.65	0.53	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
LGG	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-13.46	3.2e-35	6.42e-32	-0.44	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	13.46	3.25e-35	6.52e-32	0.66	0.53	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	13.46	3.3e-35	6.62e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
LGG	cis	rs7267979	0.789	rs6083841	ENSG00000125804.12	FAM182A	13.46	3.42e-35	6.84e-32	0.62	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26054655~26086917:+
LGG	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	13.46	3.42e-35	6.85e-32	0.84	0.53	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
LGG	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	13.46	3.5e-35	7e-32	0.65	0.53	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	13.45	3.51e-35	7.03e-32	0.6	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-13.45	3.52e-35	7.04e-32	-0.64	-0.53	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
LGG	cis	rs6452524	0.935	rs1542539	ENSG00000248112.1	RP11-78C3.1	13.45	3.56e-35	7.12e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:82919376~82921119:-
LGG	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-13.45	3.58e-35	7.17e-32	-0.57	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
LGG	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	13.45	3.64e-35	7.28e-32	0.69	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
LGG	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-13.45	3.68e-35	7.36e-32	-0.66	-0.53	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
LGG	cis	rs4819052	0.851	rs914214	ENSG00000223768.1	LINC00205	-13.45	3.68e-35	7.36e-32	-0.59	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45293285~45297354:+
LGG	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	13.45	3.68e-35	7.36e-32	0.71	0.53	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
LGG	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-13.45	3.71e-35	7.42e-32	-0.61	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
LGG	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-13.45	3.71e-35	7.42e-32	-0.58	-0.53	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
LGG	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	13.45	3.74e-35	7.48e-32	0.85	0.53	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
LGG	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	13.45	3.76e-35	7.51e-32	0.59	0.53	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
LGG	cis	rs6452524	0.967	rs1564211	ENSG00000248112.1	RP11-78C3.1	13.45	3.79e-35	7.58e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	13.45	3.82e-35	7.64e-32	0.67	0.53	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
LGG	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-13.45	3.82e-35	7.64e-32	-0.62	-0.53	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
LGG	cis	rs4819052	0.851	rs8133045	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2877018	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2330012	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2877019	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2877020	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs10470245	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs10470258	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs4819038	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs4819039	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs4818768	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs4819042	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.8	rs4819045	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs13048789	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs13047598	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.724	rs9753962	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.724	rs9753987	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs9753963	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs9754134	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs34101026	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2838828	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs13049337	ENSG00000223768.1	LINC00205	-13.45	3.86e-35	7.7e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45293285~45297354:+
LGG	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-13.44	3.88e-35	7.73e-32	-0.63	-0.53	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
LGG	cis	rs8062405	1	rs4451951	ENSG00000271623.1	RP11-435I10.5	-13.44	3.97e-35	7.91e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs8061590	ENSG00000271623.1	RP11-435I10.5	-13.44	3.97e-35	7.92e-32	-0.62	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28364700~28365333:+
LGG	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	13.44	3.99e-35	7.96e-32	0.6	0.53	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
LGG	cis	rs651907	0.557	rs11924013	ENSG00000244119.1	PDCL3P4	13.44	4.03e-35	8.04e-32	0.4	0.53	Colorectal cancer;	chr3:101647854	chr3:101712472~101713191:+
LGG	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-13.44	4.04e-35	8.06e-32	-0.61	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
LGG	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-13.44	4.09e-35	8.16e-32	-0.78	-0.53	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
LGG	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-13.44	4.09e-35	8.16e-32	-0.78	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
LGG	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	13.44	4.1e-35	8.16e-32	0.94	0.53	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
LGG	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	-13.44	4.16e-35	8.28e-32	-0.55	-0.53	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
LGG	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-13.44	4.18e-35	8.32e-32	-0.68	-0.53	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
LGG	cis	rs6452524	0.534	rs10061690	ENSG00000248112.1	RP11-78C3.1	13.44	4.21e-35	8.38e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:82919376~82921119:-
LGG	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-13.43	4.28e-35	8.51e-32	-0.62	-0.53	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
LGG	cis	rs8062405	0.721	rs151181	ENSG00000271623.1	RP11-435I10.5	-13.43	4.3e-35	8.55e-32	-0.64	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.851	rs9974628	ENSG00000223768.1	LINC00205	-13.43	4.39e-35	8.72e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.885	rs28576202	ENSG00000223768.1	LINC00205	-13.43	4.39e-35	8.72e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs35871601	ENSG00000223768.1	LINC00205	-13.43	4.39e-35	8.72e-32	-0.58	-0.53	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45293285~45297354:+
LGG	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	13.43	4.4e-35	8.74e-32	0.59	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
LGG	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-13.43	4.4e-35	8.75e-32	-0.69	-0.53	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
LGG	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-13.43	4.42e-35	8.78e-32	-0.61	-0.53	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
LGG	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	13.43	4.44e-35	8.82e-32	0.6	0.53	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
LGG	cis	rs853679	0.666	rs200956	ENSG00000199851.2	U3	13.43	4.46e-35	8.86e-32	0.89	0.53	Depression;	chr6:27871968	chr6:28015568~28015777:+
LGG	cis	rs6452524	1	rs1382369	ENSG00000248112.1	RP11-78C3.1	13.43	4.49e-35	8.92e-32	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs62374374	ENSG00000248112.1	RP11-78C3.1	13.43	4.56e-35	9.06e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs1382372	ENSG00000248112.1	RP11-78C3.1	13.43	4.56e-35	9.06e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs1382371	ENSG00000248112.1	RP11-78C3.1	13.43	4.56e-35	9.06e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:82919376~82921119:-
LGG	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	13.43	4.61e-35	9.14e-32	0.83	0.52	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
LGG	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-13.43	4.64e-35	9.2e-32	-0.58	-0.52	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
LGG	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	13.43	4.65e-35	9.22e-32	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
LGG	cis	rs6452524	0.935	rs10076059	ENSG00000248112.1	RP11-78C3.1	13.43	4.66e-35	9.24e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs7736783	ENSG00000248112.1	RP11-78C3.1	13.43	4.66e-35	9.24e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs11951257	ENSG00000248112.1	RP11-78C3.1	13.43	4.66e-35	9.24e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs767771	ENSG00000248112.1	RP11-78C3.1	13.43	4.66e-35	9.24e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs1543847	ENSG00000248112.1	RP11-78C3.1	13.43	4.66e-35	9.24e-32	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:82919376~82921119:-
LGG	cis	rs4819052	0.851	rs13052312	ENSG00000223768.1	LINC00205	-13.43	4.67e-35	9.25e-32	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45293285~45297354:+
LGG	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-13.42	4.76e-35	9.43e-32	-0.62	-0.52	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
LGG	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	-13.42	4.76e-35	9.43e-32	-0.55	-0.52	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
LGG	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-13.42	4.79e-35	9.5e-32	-0.7	-0.52	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
LGG	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	13.42	4.87e-35	9.64e-32	0.76	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
LGG	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	13.42	4.87e-35	9.64e-32	0.76	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
LGG	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-13.42	4.88e-35	9.67e-32	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
LGG	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-13.42	4.9e-35	9.71e-32	-0.58	-0.52	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
LGG	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	13.42	4.93e-35	9.77e-32	0.59	0.52	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	13.42	5.01e-35	9.92e-32	0.59	0.52	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	13.42	5.01e-35	9.92e-32	0.59	0.52	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	13.42	5.01e-35	9.92e-32	0.59	0.52	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
LGG	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-13.42	5.01e-35	9.92e-32	-0.6	-0.52	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
LGG	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	13.42	5.09e-35	1.01e-31	0.65	0.52	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
LGG	cis	rs741668	0.795	rs1041167	ENSG00000235903.6	CPB2-AS1	13.42	5.17e-35	1.02e-31	0.56	0.52	Cerebrospinal fluid clusterin levels;	chr13:46046000	chr13:46052806~46113332:+
LGG	cis	rs4819052	0.851	rs35064782	ENSG00000223768.1	LINC00205	-13.42	5.17e-35	1.02e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45293285~45297354:+
LGG	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	13.42	5.17e-35	1.02e-31	0.68	0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
LGG	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-13.41	5.24e-35	1.04e-31	-0.89	-0.52	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
LGG	cis	rs8062405	0.755	rs17707300	ENSG00000271623.1	RP11-435I10.5	-13.41	5.27e-35	1.04e-31	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28364700~28365333:+
LGG	cis	rs6452524	1	rs6864479	ENSG00000248112.1	RP11-78C3.1	13.41	5.32e-35	1.05e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs13436667	ENSG00000248112.1	RP11-78C3.1	13.41	5.32e-35	1.05e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs7726564	ENSG00000248112.1	RP11-78C3.1	13.41	5.32e-35	1.05e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:82919376~82921119:-
LGG	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	13.41	5.34e-35	1.05e-31	0.54	0.52	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
LGG	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-13.41	5.36e-35	1.06e-31	-0.89	-0.52	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
LGG	cis	rs8062405	1	rs62036616	ENSG00000271623.1	RP11-435I10.5	-13.41	5.45e-35	1.08e-31	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	13.41	5.54e-35	1.09e-31	0.67	0.52	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
LGG	cis	rs6452524	0.905	rs1478482	ENSG00000248112.1	RP11-78C3.1	13.41	5.6e-35	1.1e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:82919376~82921119:-
LGG	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	13.41	5.6e-35	1.1e-31	0.59	0.52	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
LGG	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-13.41	5.64e-35	1.11e-31	-0.74	-0.52	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
LGG	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	13.41	5.65e-35	1.12e-31	0.65	0.52	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
LGG	cis	rs4819052	0.851	rs9979545	ENSG00000223768.1	LINC00205	-13.4	5.78e-35	1.14e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45293285~45297354:+
LGG	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-13.4	5.99e-35	1.18e-31	-0.69	-0.52	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
LGG	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	13.4	6.01e-35	1.18e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
LGG	cis	rs4819052	0.851	rs13047104	ENSG00000223768.1	LINC00205	-13.4	6.05e-35	1.19e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45293285~45297354:+
LGG	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	13.4	6.06e-35	1.19e-31	0.55	0.52	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
LGG	cis	rs4713118	0.699	rs573179	ENSG00000216901.1	AL022393.7	13.4	6.08e-35	1.2e-31	0.75	0.52	Parkinson's disease;	chr6:27881898	chr6:28176188~28176674:+
LGG	cis	rs7315956	0.865	rs7296613	ENSG00000257139.1	RP11-320P7.2	-13.4	6.09e-35	1.2e-31	-0.63	-0.52	Testicular germ cell tumor;	chr12:70155737	chr12:70180338~70202004:+
LGG	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-13.4	6.1e-35	1.2e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-13.4	6.1e-35	1.2e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-13.4	6.1e-35	1.2e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-13.4	6.1e-35	1.2e-31	-0.59	-0.52	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
LGG	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-13.4	6.14e-35	1.21e-31	-0.61	-0.52	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.816	rs390123	ENSG00000125804.12	FAM182A	-13.4	6.15e-35	1.21e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.816	rs404775	ENSG00000125804.12	FAM182A	-13.4	6.18e-35	1.22e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.816	rs374701	ENSG00000125804.12	FAM182A	-13.4	6.18e-35	1.22e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.816	rs405822	ENSG00000125804.12	FAM182A	-13.4	6.19e-35	1.22e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.816	rs6138593	ENSG00000125804.12	FAM182A	-13.4	6.19e-35	1.22e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.816	rs409853	ENSG00000125804.12	FAM182A	-13.4	6.19e-35	1.22e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	13.4	6.2e-35	1.22e-31	0.67	0.52	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
LGG	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	13.4	6.2e-35	1.22e-31	0.73	0.52	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
LGG	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-13.4	6.2e-35	1.22e-31	-0.63	-0.52	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
LGG	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-13.4	6.26e-35	1.23e-31	-0.58	-0.52	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
LGG	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-13.4	6.31e-35	1.24e-31	-0.57	-0.52	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
LGG	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	13.39	6.37e-35	1.25e-31	0.59	0.52	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
LGG	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	13.39	6.45e-35	1.27e-31	0.69	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
LGG	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	13.39	6.45e-35	1.27e-31	0.69	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
LGG	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	13.39	6.45e-35	1.27e-31	0.69	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
LGG	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	13.39	6.5e-35	1.28e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	13.39	6.5e-35	1.28e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	13.39	6.5e-35	1.28e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
LGG	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	13.39	6.51e-35	1.28e-31	0.84	0.52	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
LGG	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	13.39	6.51e-35	1.28e-31	0.84	0.52	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
LGG	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-13.39	6.61e-35	1.3e-31	-0.43	-0.52	Height;	chr11:118808920	chr11:118791254~118793137:+
LGG	cis	rs7267979	0.816	rs422148	ENSG00000125804.12	FAM182A	-13.39	6.65e-35	1.3e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.844	rs2424703	ENSG00000125804.12	FAM182A	-13.39	6.66e-35	1.31e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26054655~26086917:+
LGG	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-13.39	6.69e-35	1.31e-31	-0.61	-0.52	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
LGG	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	13.39	6.7e-35	1.31e-31	0.59	0.52	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	13.39	6.7e-35	1.31e-31	0.59	0.52	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	13.39	6.7e-35	1.31e-31	0.59	0.52	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	13.39	6.7e-35	1.31e-31	0.59	0.52	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
LGG	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	13.39	6.75e-35	1.32e-31	0.66	0.52	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
LGG	cis	rs4819052	0.765	rs2838854	ENSG00000223768.1	LINC00205	-13.39	6.78e-35	1.33e-31	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45293285~45297354:+
LGG	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	13.39	6.79e-35	1.33e-31	0.65	0.52	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
LGG	cis	rs7267979	0.844	rs35735333	ENSG00000125804.12	FAM182A	13.39	6.79e-35	1.33e-31	0.63	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26054655~26086917:+
LGG	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-13.39	6.83e-35	1.34e-31	-0.66	-0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
LGG	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-13.38	7.09e-35	1.39e-31	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
LGG	cis	rs7315956	1	rs983787	ENSG00000257139.1	RP11-320P7.2	-13.38	7.11e-35	1.39e-31	-0.64	-0.52	Testicular germ cell tumor;	chr12:70190275	chr12:70180338~70202004:+
LGG	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	13.38	7.12e-35	1.39e-31	0.61	0.52	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	13.38	7.16e-35	1.4e-31	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	13.38	7.18e-35	1.41e-31	0.66	0.52	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
LGG	cis	rs7315956	0.963	rs7954979	ENSG00000257139.1	RP11-320P7.2	-13.38	7.22e-35	1.41e-31	-0.64	-0.52	Testicular germ cell tumor;	chr12:70206116	chr12:70180338~70202004:+
LGG	cis	rs7315956	0.892	rs7978439	ENSG00000257139.1	RP11-320P7.2	-13.38	7.22e-35	1.41e-31	-0.64	-0.52	Testicular germ cell tumor;	chr12:70208668	chr12:70180338~70202004:+
LGG	cis	rs6500637	0.591	rs2075466	ENSG00000267077.1	RP11-127I20.5	13.38	7.25e-35	1.42e-31	0.58	0.52	Cancer;	chr16:4822969	chr16:4795265~4796532:-
LGG	cis	rs7267979	0.844	rs4815413	ENSG00000125804.12	FAM182A	13.38	7.29e-35	1.43e-31	0.63	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.844	rs6083824	ENSG00000125804.12	FAM182A	13.38	7.29e-35	1.43e-31	0.63	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26054655~26086917:+
LGG	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	13.38	7.32e-35	1.43e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
LGG	cis	rs6452524	0.935	rs10045744	ENSG00000248112.1	RP11-78C3.1	13.38	7.38e-35	1.44e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:82919376~82921119:-
LGG	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	13.38	7.42e-35	1.45e-31	0.59	0.52	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	13.38	7.42e-35	1.45e-31	0.59	0.52	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
LGG	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	13.38	7.43e-35	1.45e-31	0.94	0.52	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
LGG	cis	rs6452524	1	rs6452531	ENSG00000248112.1	RP11-78C3.1	13.38	7.46e-35	1.46e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:82919376~82921119:-
LGG	cis	rs916888	0.773	rs169201	ENSG00000232300.1	FAM215B	13.38	7.53e-35	1.47e-31	0.77	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46558830~46562795:-
LGG	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-13.38	7.54e-35	1.47e-31	-0.66	-0.52	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
LGG	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-13.38	7.54e-35	1.47e-31	-0.66	-0.52	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
LGG	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	13.37	7.68e-35	1.5e-31	0.65	0.52	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-13.37	7.75e-35	1.51e-31	-0.64	-0.52	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
LGG	cis	rs916888	0.773	rs538628	ENSG00000232300.1	FAM215B	13.37	7.83e-35	1.53e-31	0.77	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46558830~46562795:-
LGG	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	13.37	7.91e-35	1.54e-31	0.65	0.52	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-13.37	7.98e-35	1.56e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
LGG	cis	rs4713118	0.911	rs9461406	ENSG00000199851.2	U3	-13.37	8.01e-35	1.56e-31	-0.79	-0.52	Parkinson's disease;	chr6:27751985	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	13.37	8.07e-35	1.57e-31	0.65	0.52	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
LGG	cis	rs7315956	1	rs1036537	ENSG00000257139.1	RP11-320P7.2	-13.37	8.28e-35	1.61e-31	-0.63	-0.52	Testicular germ cell tumor;	chr12:70182167	chr12:70180338~70202004:+
LGG	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	13.37	8.3e-35	1.62e-31	0.58	0.52	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	13.36	8.49e-35	1.65e-31	0.65	0.52	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-13.36	8.49e-35	1.65e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-13.36	8.49e-35	1.65e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-13.36	8.49e-35	1.65e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
LGG	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-13.36	8.5e-35	1.66e-31	-0.45	-0.52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	13.36	8.62e-35	1.68e-31	0.65	0.52	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	13.36	8.65e-35	1.68e-31	0.65	0.52	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	13.36	8.65e-35	1.68e-31	0.65	0.52	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
LGG	cis	rs6452524	1	rs11740478	ENSG00000248112.1	RP11-78C3.1	13.36	8.71e-35	1.7e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:82919376~82921119:-
LGG	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	13.36	8.75e-35	1.7e-31	0.85	0.52	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
LGG	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-13.36	8.75e-35	1.7e-31	-0.9	-0.52	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
LGG	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-13.36	8.76e-35	1.7e-31	-0.69	-0.52	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
LGG	cis	rs6452524	1	rs1382368	ENSG00000248112.1	RP11-78C3.1	13.36	9e-35	1.75e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs1382366	ENSG00000248112.1	RP11-78C3.1	13.36	9e-35	1.75e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs13358361	ENSG00000248112.1	RP11-78C3.1	13.36	9e-35	1.75e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6452528	ENSG00000248112.1	RP11-78C3.1	13.36	9e-35	1.75e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:82919376~82921119:-
LGG	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	13.36	9.01e-35	1.75e-31	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	13.36	9.01e-35	1.75e-31	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	13.36	9.01e-35	1.75e-31	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	13.36	9.01e-35	1.75e-31	0.95	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
LGG	cis	rs6452524	0.534	rs72765386	ENSG00000248112.1	RP11-78C3.1	13.36	9.04e-35	1.76e-31	0.68	0.52	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:82919376~82921119:-
LGG	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	13.36	9.24e-35	1.79e-31	0.66	0.52	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
LGG	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	13.35	9.33e-35	1.81e-31	0.67	0.52	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	13.35	9.35e-35	1.81e-31	0.65	0.52	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
LGG	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-13.35	9.36e-35	1.82e-31	-0.43	-0.52	Height;	chr11:118742526	chr11:118791254~118793137:+
LGG	cis	rs4713118	0.699	rs200978	ENSG00000216901.1	AL022393.7	13.35	9.41e-35	1.83e-31	0.74	0.52	Parkinson's disease;	chr6:27885390	chr6:28176188~28176674:+
LGG	cis	rs7267979	0.753	rs400357	ENSG00000125804.12	FAM182A	-13.35	9.43e-35	1.83e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26054655~26086917:+
LGG	cis	rs6452524	0.967	rs965674	ENSG00000248112.1	RP11-78C3.1	13.35	9.44e-35	1.83e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2662242	ENSG00000248112.1	RP11-78C3.1	13.35	9.44e-35	1.83e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2731844	ENSG00000248112.1	RP11-78C3.1	13.35	9.44e-35	1.83e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.901	rs2940540	ENSG00000248112.1	RP11-78C3.1	13.35	9.44e-35	1.83e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	13.35	9.6e-35	1.86e-31	0.65	0.52	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
LGG	cis	rs6452524	1	rs2386240	ENSG00000248112.1	RP11-78C3.1	13.35	9.69e-35	1.88e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs9986131	ENSG00000248112.1	RP11-78C3.1	13.35	9.69e-35	1.88e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:82919376~82921119:-
LGG	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	13.35	9.8e-35	1.9e-31	0.59	0.52	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
LGG	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-13.35	9.81e-35	1.9e-31	-0.69	-0.52	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
LGG	cis	rs6452524	0.967	rs2974444	ENSG00000248112.1	RP11-78C3.1	13.35	9.86e-35	1.91e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2940542	ENSG00000248112.1	RP11-78C3.1	13.35	9.86e-35	1.91e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	13.35	9.87e-35	1.91e-31	0.72	0.52	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
LGG	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	13.35	1e-34	1.94e-31	0.65	0.52	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
LGG	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-13.35	1e-34	1.94e-31	-0.66	-0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
LGG	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	13.35	1e-34	1.94e-31	0.65	0.52	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
LGG	cis	rs7267979	0.74	rs2259961	ENSG00000125804.12	FAM182A	-13.34	1.03e-34	1.99e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.844	rs2474780	ENSG00000125804.12	FAM182A	-13.34	1.03e-34	1.99e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.789	rs4815400	ENSG00000125804.12	FAM182A	13.34	1.03e-34	2e-31	0.63	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.844	rs6076343	ENSG00000125804.12	FAM182A	13.34	1.04e-34	2.01e-31	0.63	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.844	rs6083845	ENSG00000125804.12	FAM182A	13.34	1.04e-34	2.01e-31	0.63	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26054655~26086917:+
LGG	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-13.34	1.04e-34	2.01e-31	-0.55	-0.52	Height;	chr3:52994359	chr3:53064283~53065091:-
LGG	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	13.34	1.04e-34	2.02e-31	0.61	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
LGG	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	13.34	1.05e-34	2.03e-31	0.62	0.52	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
LGG	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-13.34	1.08e-34	2.08e-31	-0.68	-0.52	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
LGG	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-13.34	1.08e-34	2.09e-31	-0.63	-0.52	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
LGG	cis	rs916888	0.773	rs199457	ENSG00000232300.1	FAM215B	13.34	1.1e-34	2.12e-31	0.76	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46558830~46562795:-
LGG	cis	rs916888	0.687	rs199456	ENSG00000232300.1	FAM215B	13.34	1.1e-34	2.12e-31	0.76	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46558830~46562795:-
LGG	cis	rs6452524	0.506	rs7891	ENSG00000248112.1	RP11-78C3.1	13.34	1.11e-34	2.15e-31	0.68	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:82919376~82921119:-
LGG	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-13.34	1.12e-34	2.17e-31	-0.66	-0.52	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
LGG	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	13.34	1.13e-34	2.18e-31	0.65	0.52	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
LGG	cis	rs6452524	0.967	rs2974448	ENSG00000248112.1	RP11-78C3.1	13.34	1.13e-34	2.18e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:82919376~82921119:-
LGG	cis	rs741668	0.759	rs73188488	ENSG00000235903.6	CPB2-AS1	13.34	1.13e-34	2.19e-31	0.55	0.52	Cerebrospinal fluid clusterin levels;	chr13:46050849	chr13:46052806~46113332:+
LGG	cis	rs6452524	1	rs4591730	ENSG00000248112.1	RP11-78C3.1	13.33	1.13e-34	2.19e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs1031902	ENSG00000248112.1	RP11-78C3.1	13.33	1.13e-34	2.19e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10474094	ENSG00000248112.1	RP11-78C3.1	13.33	1.13e-34	2.19e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:82919376~82921119:-
LGG	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-13.33	1.15e-34	2.22e-31	-0.58	-0.52	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
LGG	cis	rs6452524	1	rs10069402	ENSG00000248112.1	RP11-78C3.1	13.33	1.16e-34	2.23e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:82919376~82921119:-
LGG	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	13.33	1.16e-34	2.24e-31	0.6	0.52	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
LGG	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	13.33	1.17e-34	2.26e-31	0.58	0.52	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
LGG	cis	rs6452524	1	rs1382364	ENSG00000248112.1	RP11-78C3.1	13.33	1.17e-34	2.26e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs1382363	ENSG00000248112.1	RP11-78C3.1	13.33	1.17e-34	2.26e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs11741897	ENSG00000248112.1	RP11-78C3.1	13.33	1.17e-34	2.26e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10076000	ENSG00000248112.1	RP11-78C3.1	13.33	1.17e-34	2.26e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:82919376~82921119:-
LGG	cis	rs4682868	0.611	rs734969	ENSG00000273328.4	RP11-141M3.6	-13.33	1.18e-34	2.29e-31	-0.61	-0.52	Monocyte percentage of white cells;	chr3:42876414	chr3:42809414~42908105:+
LGG	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-13.33	1.19e-34	2.29e-31	-0.74	-0.52	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	13.33	1.21e-34	2.33e-31	0.64	0.52	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
LGG	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	13.33	1.21e-34	2.34e-31	0.59	0.52	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	13.33	1.21e-34	2.34e-31	0.59	0.52	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
LGG	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	13.33	1.22e-34	2.34e-31	0.64	0.52	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
LGG	cis	rs6500637	0.686	rs8048701	ENSG00000267077.1	RP11-127I20.5	13.33	1.22e-34	2.35e-31	0.6	0.52	Cancer;	chr16:4863536	chr16:4795265~4796532:-
LGG	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	13.33	1.23e-34	2.36e-31	0.66	0.52	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
LGG	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	13.33	1.24e-34	2.39e-31	0.69	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
LGG	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-13.33	1.24e-34	2.39e-31	-0.66	-0.52	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
LGG	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	13.33	1.25e-34	2.4e-31	0.63	0.52	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
LGG	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	13.32	1.25e-34	2.41e-31	0.62	0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
LGG	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	13.32	1.26e-34	2.43e-31	0.71	0.52	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
LGG	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-13.32	1.27e-34	2.44e-31	-0.66	-0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
LGG	cis	rs6452524	0.934	rs12153179	ENSG00000248112.1	RP11-78C3.1	13.32	1.28e-34	2.47e-31	0.68	0.52	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:82919376~82921119:-
LGG	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	-13.32	1.29e-34	2.48e-31	-0.54	-0.52	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
LGG	cis	rs6452524	1	rs10076271	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10076274	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10061521	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs7733151	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs7733330	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs7733354	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs4634330	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs2386238	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs2386239	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.934	rs7700253	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs10067439	ENSG00000248112.1	RP11-78C3.1	13.32	1.29e-34	2.48e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.934	rs2940543	ENSG00000248112.1	RP11-78C3.1	13.32	1.3e-34	2.5e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2974450	ENSG00000248112.1	RP11-78C3.1	13.32	1.3e-34	2.5e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2974449	ENSG00000248112.1	RP11-78C3.1	13.32	1.3e-34	2.5e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2662241	ENSG00000248112.1	RP11-78C3.1	13.32	1.3e-34	2.5e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs2940544	ENSG00000248112.1	RP11-78C3.1	13.32	1.3e-34	2.5e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2731865	ENSG00000248112.1	RP11-78C3.1	13.32	1.3e-34	2.5e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs11958314	ENSG00000248112.1	RP11-78C3.1	13.32	1.32e-34	2.53e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.686	rs6452517	ENSG00000248112.1	RP11-78C3.1	13.32	1.32e-34	2.53e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.686	rs6452518	ENSG00000248112.1	RP11-78C3.1	13.32	1.32e-34	2.53e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.563	rs10473863	ENSG00000248112.1	RP11-78C3.1	13.32	1.33e-34	2.55e-31	0.68	0.52	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs17284288	ENSG00000248112.1	RP11-78C3.1	13.32	1.33e-34	2.56e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.934	rs10473870	ENSG00000248112.1	RP11-78C3.1	13.32	1.33e-34	2.56e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:82919376~82921119:-
LGG	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-13.32	1.37e-34	2.62e-31	-0.77	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
LGG	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	13.32	1.38e-34	2.64e-31	0.58	0.52	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
LGG	cis	rs916888	0.773	rs199439	ENSG00000232300.1	FAM215B	13.31	1.39e-34	2.66e-31	0.76	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46558830~46562795:-
LGG	cis	rs651907	0.557	rs13077925	ENSG00000244119.1	PDCL3P4	13.31	1.39e-34	2.66e-31	0.4	0.52	Colorectal cancer;	chr3:101769337	chr3:101712472~101713191:+
LGG	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	13.31	1.39e-34	2.67e-31	0.86	0.52	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
LGG	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	13.31	1.39e-34	2.67e-31	0.63	0.52	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
LGG	cis	rs4819052	0.851	rs10470246	ENSG00000223768.1	LINC00205	-13.31	1.39e-34	2.67e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs10470247	ENSG00000223768.1	LINC00205	-13.31	1.39e-34	2.67e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs4819043	ENSG00000223768.1	LINC00205	-13.31	1.39e-34	2.67e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs4819044	ENSG00000223768.1	LINC00205	-13.31	1.39e-34	2.67e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45293285~45297354:+
LGG	cis	rs6452524	1	rs6452519	ENSG00000248112.1	RP11-78C3.1	13.31	1.42e-34	2.72e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:82919376~82921119:-
LGG	cis	rs916888	0.773	rs1378358	ENSG00000232300.1	FAM215B	13.31	1.45e-34	2.78e-31	0.77	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46558830~46562795:-
LGG	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	13.31	1.45e-34	2.79e-31	0.61	0.52	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
LGG	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	13.31	1.47e-34	2.81e-31	0.59	0.52	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
LGG	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-13.31	1.47e-34	2.82e-31	-0.66	-0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-13.31	1.47e-34	2.82e-31	-0.66	-0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
LGG	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-13.31	1.47e-34	2.82e-31	-0.66	-0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
LGG	cis	rs4819052	0.851	rs13050359	ENSG00000223768.1	LINC00205	-13.3	1.52e-34	2.92e-31	-0.58	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45293285~45297354:+
LGG	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-13.3	1.53e-34	2.92e-31	-0.59	-0.52	Height;	chr3:53052712	chr3:53064283~53065091:-
LGG	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-13.3	1.54e-34	2.95e-31	-0.59	-0.52	Height;	chr3:53047596	chr3:53064283~53065091:-
LGG	cis	rs741668	0.795	rs17600555	ENSG00000235903.6	CPB2-AS1	13.3	1.54e-34	2.95e-31	0.55	0.52	Cerebrospinal fluid clusterin levels;	chr13:46049527	chr13:46052806~46113332:+
LGG	cis	rs741668	0.795	rs7324938	ENSG00000235903.6	CPB2-AS1	13.3	1.54e-34	2.95e-31	0.55	0.52	Cerebrospinal fluid clusterin levels;	chr13:46049937	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	13.3	1.55e-34	2.96e-31	0.64	0.52	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	13.3	1.55e-34	2.96e-31	0.64	0.52	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	13.3	1.55e-34	2.96e-31	0.64	0.52	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	13.3	1.55e-34	2.96e-31	0.64	0.52	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	13.3	1.55e-34	2.96e-31	0.64	0.52	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	13.3	1.55e-34	2.96e-31	0.64	0.52	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	13.3	1.55e-34	2.96e-31	0.64	0.52	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-13.3	1.55e-34	2.96e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-13.3	1.55e-34	2.96e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-13.3	1.55e-34	2.96e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
LGG	cis	rs8064024	0.676	rs9926458	ENSG00000267077.1	RP11-127I20.5	13.3	1.55e-34	2.96e-31	0.51	0.52	Cancer;	chr16:4822627	chr16:4795265~4796532:-
LGG	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	13.3	1.56e-34	2.99e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
LGG	cis	rs7267979	0.789	rs62213729	ENSG00000125804.12	FAM182A	13.3	1.56e-34	2.99e-31	0.62	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	13.3	1.6e-34	3.06e-31	0.65	0.52	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	13.3	1.6e-34	3.06e-31	0.65	0.52	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
LGG	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-13.3	1.6e-34	3.06e-31	-0.69	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
LGG	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-13.3	1.6e-34	3.06e-31	-0.69	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
LGG	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-13.3	1.6e-34	3.06e-31	-0.69	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
LGG	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	13.3	1.63e-34	3.11e-31	0.64	0.52	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
LGG	cis	rs172166	0.543	rs1150691	ENSG00000199851.2	U3	13.3	1.64e-34	3.13e-31	0.7	0.52	Cardiac Troponin-T levels;	chr6:28200255	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	13.3	1.65e-34	3.15e-31	0.8	0.52	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
LGG	cis	rs6452524	0.967	rs11949474	ENSG00000248112.1	RP11-78C3.1	13.3	1.65e-34	3.15e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs9293330	ENSG00000248112.1	RP11-78C3.1	13.3	1.65e-34	3.16e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:82919376~82921119:-
LGG	cis	rs651907	0.557	rs11710533	ENSG00000244119.1	PDCL3P4	13.29	1.7e-34	3.24e-31	0.41	0.52	Colorectal cancer;	chr3:101632628	chr3:101712472~101713191:+
LGG	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	13.29	1.7e-34	3.24e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	13.29	1.71e-34	3.27e-31	0.66	0.52	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	13.29	1.75e-34	3.33e-31	0.64	0.52	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	13.29	1.75e-34	3.33e-31	0.64	0.52	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
LGG	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	13.29	1.8e-34	3.44e-31	0.67	0.52	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
LGG	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	13.29	1.83e-34	3.49e-31	0.66	0.52	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	13.28	1.85e-34	3.52e-31	0.59	0.52	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	13.28	1.85e-34	3.52e-31	0.59	0.52	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
LGG	cis	rs6452524	0.967	rs4290995	ENSG00000248112.1	RP11-78C3.1	13.28	1.89e-34	3.6e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:82919376~82921119:-
LGG	cis	rs172166	0.516	rs1225710	ENSG00000199851.2	U3	-13.28	1.93e-34	3.67e-31	-0.69	-0.52	Cardiac Troponin-T levels;	chr6:28132862	chr6:28015568~28015777:+
LGG	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-13.28	1.94e-34	3.69e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-13.28	1.94e-34	3.69e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-13.28	1.94e-34	3.69e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-13.28	1.94e-34	3.69e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-13.28	1.94e-34	3.69e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
LGG	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	13.28	1.94e-34	3.69e-31	0.64	0.52	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
LGG	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	13.28	1.94e-34	3.7e-31	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
LGG	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-13.28	1.97e-34	3.75e-31	-0.4	-0.52	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
LGG	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-13.28	1.98e-34	3.76e-31	-0.58	-0.52	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
LGG	cis	rs4819052	0.851	rs1999333	ENSG00000223768.1	LINC00205	-13.28	1.99e-34	3.78e-31	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45293285~45297354:+
LGG	cis	rs6452524	0.967	rs62374400	ENSG00000248112.1	RP11-78C3.1	13.28	1.99e-34	3.79e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs10040363	ENSG00000248112.1	RP11-78C3.1	13.28	1.99e-34	3.79e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs10051542	ENSG00000248112.1	RP11-78C3.1	13.28	1.99e-34	3.79e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs10051557	ENSG00000248112.1	RP11-78C3.1	13.28	1.99e-34	3.79e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:82919376~82921119:-
LGG	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-13.28	2.03e-34	3.86e-31	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
LGG	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-13.27	2.03e-34	3.87e-31	-0.78	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
LGG	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	-13.27	2.05e-34	3.9e-31	-0.54	-0.52	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	13.27	2.05e-34	3.9e-31	0.64	0.52	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
LGG	cis	rs8062405	1	rs62036622	ENSG00000271623.1	RP11-435I10.5	-13.27	2.07e-34	3.93e-31	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28364700~28365333:+
LGG	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-13.27	2.09e-34	3.96e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	-13.27	2.1e-34	4e-31	-0.54	-0.52	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
LGG	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-13.27	2.11e-34	4.01e-31	-0.63	-0.52	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
LGG	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-13.27	2.13e-34	4.04e-31	-0.58	-0.52	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
LGG	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	13.27	2.15e-34	4.07e-31	0.65	0.52	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
LGG	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-13.26	2.29e-34	4.35e-31	-0.61	-0.52	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
LGG	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	13.26	2.32e-34	4.39e-31	0.65	0.52	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
LGG	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-13.26	2.33e-34	4.42e-31	-0.55	-0.52	Height;	chr3:52998472	chr3:53064283~53065091:-
LGG	cis	rs7829975	0.593	rs2921061	ENSG00000173295.6	FAM86B3P	-13.26	2.34e-34	4.44e-31	-0.54	-0.52	Mood instability;	chr8:8460105	chr8:8228595~8244865:+
LGG	cis	rs741668	0.759	rs3736943	ENSG00000235903.6	CPB2-AS1	13.26	2.36e-34	4.46e-31	0.55	0.52	Cerebrospinal fluid clusterin levels;	chr13:46044936	chr13:46052806~46113332:+
LGG	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	13.26	2.36e-34	4.47e-31	0.59	0.52	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	13.26	2.36e-34	4.47e-31	0.59	0.52	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
LGG	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	13.26	2.37e-34	4.5e-31	0.76	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
LGG	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-13.26	2.41e-34	4.56e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.851	rs8127834	ENSG00000223768.1	LINC00205	-13.26	2.42e-34	4.58e-31	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45293285~45297354:+
LGG	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	13.26	2.42e-34	4.59e-31	0.56	0.52	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
LGG	cis	rs2980439	0.517	rs17594093	ENSG00000173295.6	FAM86B3P	13.26	2.43e-34	4.61e-31	0.59	0.52	Neuroticism;	chr8:8248884	chr8:8228595~8244865:+
LGG	cis	rs6452524	0.967	rs2974445	ENSG00000248112.1	RP11-78C3.1	-13.26	2.43e-34	4.61e-31	-0.66	-0.52	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:82919376~82921119:-
LGG	cis	rs7267979	0.844	rs2257649	ENSG00000125804.12	FAM182A	-13.26	2.45e-34	4.64e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26054655~26086917:+
LGG	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-13.26	2.47e-34	4.67e-31	-0.63	-0.52	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
LGG	cis	rs916888	0.531	rs183211	ENSG00000262500.1	RP11-259G18.2	13.25	2.47e-34	4.68e-31	0.69	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46243606~46245044:+
LGG	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-13.25	2.5e-34	4.72e-31	-0.54	-0.52	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-13.25	2.5e-34	4.72e-31	-0.54	-0.52	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
LGG	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-13.25	2.53e-34	4.79e-31	-0.64	-0.52	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
LGG	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-13.25	2.53e-34	4.79e-31	-0.64	-0.52	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
LGG	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-13.25	2.58e-34	4.88e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
LGG	cis	rs6452524	0.967	rs2974443	ENSG00000248112.1	RP11-78C3.1	13.25	2.58e-34	4.88e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2974441	ENSG00000248112.1	RP11-78C3.1	13.25	2.58e-34	4.88e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs2731861	ENSG00000248112.1	RP11-78C3.1	13.25	2.6e-34	4.92e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:82919376~82921119:-
LGG	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-13.25	2.61e-34	4.94e-31	-0.53	-0.52	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
LGG	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	13.25	2.63e-34	4.98e-31	0.65	0.52	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
LGG	cis	rs6452524	0.967	rs4616871	ENSG00000248112.1	RP11-78C3.1	13.25	2.63e-34	4.98e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:82919376~82921119:-
LGG	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-13.25	2.64e-34	4.99e-31	-0.69	-0.52	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
LGG	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-13.25	2.65e-34	5.02e-31	-0.89	-0.52	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
LGG	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	13.25	2.66e-34	5.03e-31	0.58	0.52	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	13.25	2.66e-34	5.03e-31	0.58	0.52	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	13.25	2.66e-34	5.03e-31	0.58	0.52	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	13.25	2.66e-34	5.03e-31	0.58	0.52	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
LGG	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	-13.25	2.68e-34	5.05e-31	-0.55	-0.52	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
LGG	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-13.25	2.69e-34	5.07e-31	-0.66	-0.52	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
LGG	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	13.24	2.72e-34	5.15e-31	0.58	0.52	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	13.24	2.8e-34	5.28e-31	0.64	0.52	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	13.24	2.81e-34	5.3e-31	0.58	0.52	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
LGG	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-13.24	2.88e-34	5.43e-31	-0.42	-0.52	Height;	chr11:118809363	chr11:118791254~118793137:+
LGG	cis	rs6452524	0.967	rs6897075	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs10065973	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs12153441	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs12152891	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs7717964	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.934	rs1120477	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.934	rs1120478	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs6452514	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs6884543	ENSG00000248112.1	RP11-78C3.1	13.24	2.99e-34	5.64e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:82919376~82921119:-
LGG	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	13.23	3.02e-34	5.68e-31	0.58	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
LGG	cis	rs6452524	0.934	rs6452512	ENSG00000248112.1	RP11-78C3.1	13.23	3.04e-34	5.73e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:82919376~82921119:-
LGG	cis	rs916888	0.61	rs199436	ENSG00000262500.1	RP11-259G18.2	-13.23	3.06e-34	5.77e-31	-0.68	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46243606~46245044:+
LGG	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	13.23	3.13e-34	5.9e-31	0.54	0.52	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
LGG	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-13.23	3.16e-34	5.95e-31	-0.6	-0.52	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-13.23	3.16e-34	5.95e-31	-0.6	-0.52	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
LGG	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	13.23	3.17e-34	5.96e-31	0.64	0.52	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
LGG	cis	rs916888	0.61	rs199530	ENSG00000261575.2	RP11-259G18.1	-13.23	3.25e-34	6.11e-31	-0.63	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46267037~46268694:+
LGG	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	13.23	3.26e-34	6.13e-31	0.64	0.52	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
LGG	cis	rs916888	0.61	rs199438	ENSG00000262500.1	RP11-259G18.2	13.23	3.28e-34	6.17e-31	0.68	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46243606~46245044:+
LGG	cis	rs4819052	0.851	rs28622522	ENSG00000223768.1	LINC00205	-13.22	3.32e-34	6.24e-31	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45293285~45297354:+
LGG	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	13.22	3.36e-34	6.32e-31	0.61	0.52	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
LGG	cis	rs6452524	1	rs6452520	ENSG00000248112.1	RP11-78C3.1	13.22	3.43e-34	6.45e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6452521	ENSG00000248112.1	RP11-78C3.1	13.22	3.43e-34	6.45e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs6452522	ENSG00000248112.1	RP11-78C3.1	13.22	3.43e-34	6.45e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs9293334	ENSG00000248112.1	RP11-78C3.1	13.22	3.45e-34	6.49e-31	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:82919376~82921119:-
LGG	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-13.22	3.51e-34	6.59e-31	-0.63	-0.52	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
LGG	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	13.22	3.58e-34	6.72e-31	0.61	0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
LGG	cis	rs853679	0.76	rs9468317	ENSG00000199851.2	U3	13.22	3.6e-34	6.76e-31	0.88	0.52	Depression;	chr6:28230678	chr6:28015568~28015777:+
LGG	cis	rs1061377	0.965	rs1137714	ENSG00000249685.1	RP11-360F5.3	13.22	3.61e-34	6.77e-31	0.6	0.52	Uric acid levels;	chr4:39143105	chr4:39133913~39135608:+
LGG	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	13.22	3.61e-34	6.78e-31	0.46	0.52	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
LGG	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	-13.22	3.62e-34	6.79e-31	-0.54	-0.52	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
LGG	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-13.22	3.63e-34	6.82e-31	-0.69	-0.52	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
LGG	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	13.22	3.64e-34	6.83e-31	0.65	0.52	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
LGG	cis	rs7927771	1	rs12419692	ENSG00000280615.1	Y_RNA	13.21	3.66e-34	6.88e-31	0.65	0.52	Subjective well-being;	chr11:47603162	chr11:47614898~47614994:-
LGG	cis	rs8062405	1	rs12443881	ENSG00000271623.1	RP11-435I10.5	-13.21	3.67e-34	6.88e-31	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.807	rs1075788	ENSG00000223768.1	LINC00205	-13.21	3.79e-34	7.11e-31	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45293285~45297354:+
LGG	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	13.21	3.83e-34	7.18e-31	0.72	0.52	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
LGG	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-13.21	3.85e-34	7.22e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
LGG	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-13.21	3.89e-34	7.31e-31	-0.68	-0.52	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
LGG	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	13.21	3.93e-34	7.37e-31	0.58	0.52	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
LGG	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-13.21	3.94e-34	7.38e-31	-0.64	-0.52	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
LGG	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-13.21	3.99e-34	7.47e-31	-0.68	-0.52	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	13.2	4.04e-34	7.58e-31	0.64	0.52	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
LGG	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-13.2	4.07e-34	7.62e-31	-0.65	-0.52	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
LGG	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-13.2	4.09e-34	7.67e-31	-0.64	-0.52	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	13.2	4.17e-34	7.82e-31	0.64	0.52	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
LGG	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	13.2	4.17e-34	7.82e-31	0.56	0.52	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
LGG	cis	rs7267979	0.844	rs6107027	ENSG00000125804.12	FAM182A	-13.2	4.21e-34	7.88e-31	-0.63	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26054655~26086917:+
LGG	cis	rs4819052	0.851	rs2838839	ENSG00000215447.6	BX322557.10	13.2	4.3e-34	8.05e-31	0.4	0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45288052~45291738:+
LGG	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-13.2	4.38e-34	8.19e-31	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-13.2	4.38e-34	8.19e-31	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	13.2	4.39e-34	8.22e-31	0.64	0.52	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
LGG	cis	rs4819052	0.851	rs2838834	ENSG00000215447.6	BX322557.10	-13.19	4.45e-34	8.33e-31	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45288052~45291738:+
LGG	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	13.19	4.46e-34	8.34e-31	0.64	0.52	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
LGG	cis	rs6452524	1	rs6887846	ENSG00000248112.1	RP11-78C3.1	-13.19	4.5e-34	8.41e-31	-0.67	-0.52	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	13.19	4.51e-34	8.44e-31	0.63	0.52	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	13.19	4.54e-34	8.5e-31	0.64	0.52	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	13.19	4.55e-34	8.52e-31	0.59	0.52	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
LGG	cis	rs4819052	0.851	rs4819049	ENSG00000223768.1	LINC00205	-13.19	4.63e-34	8.65e-31	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45293285~45297354:+
LGG	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-13.19	4.64e-34	8.66e-31	-0.68	-0.52	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
LGG	cis	rs4819052	0.851	rs28616694	ENSG00000223768.1	LINC00205	-13.19	4.65e-34	8.69e-31	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45293285~45297354:+
LGG	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-13.19	4.66e-34	8.71e-31	-0.6	-0.52	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
LGG	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-13.19	4.66e-34	8.72e-31	-0.52	-0.52	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
LGG	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	13.19	4.69e-34	8.75e-31	0.4	0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
LGG	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-13.19	4.76e-34	8.89e-31	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
LGG	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	13.18	4.88e-34	9.1e-31	0.75	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
LGG	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-13.18	5e-34	9.32e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-13.18	5e-34	9.32e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-13.18	5e-34	9.32e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-13.18	5e-34	9.32e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
LGG	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-13.18	5.1e-34	9.51e-31	-0.55	-0.52	Height;	chr3:52994045	chr3:53064283~53065091:-
LGG	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-13.18	5.1e-34	9.51e-31	-0.55	-0.52	Height;	chr3:52994990	chr3:53064283~53065091:-
LGG	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	13.18	5.1e-34	9.51e-31	0.65	0.52	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	13.18	5.11e-34	9.54e-31	0.63	0.52	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	13.18	5.11e-34	9.54e-31	0.63	0.52	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	13.18	5.11e-34	9.54e-31	0.64	0.52	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-13.18	5.13e-34	9.57e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-13.18	5.25e-34	9.79e-31	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-13.18	5.27e-34	9.83e-31	-0.65	-0.52	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-13.18	5.28e-34	9.83e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-13.18	5.28e-34	9.83e-31	-0.61	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
LGG	cis	rs4804815	1	rs4804815	ENSG00000268297.1	CLEC4GP1	13.18	5.29e-34	9.86e-31	0.56	0.52	Neutrophil count;	chr19:7777783	chr19:7787549~7790621:+
LGG	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-13.18	5.35e-34	9.96e-31	-0.6	-0.52	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
LGG	cis	rs7267979	0.844	rs869358	ENSG00000125804.12	FAM182A	13.18	5.35e-34	9.97e-31	0.63	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26054655~26086917:+
LGG	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	13.18	5.36e-34	9.97e-31	0.58	0.52	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	13.18	5.36e-34	9.97e-31	0.58	0.52	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	13.18	5.36e-34	9.97e-31	0.58	0.52	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	13.18	5.36e-34	9.97e-31	0.58	0.52	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	13.18	5.36e-34	9.97e-31	0.58	0.52	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	13.18	5.37e-34	9.99e-31	0.63	0.52	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	13.18	5.37e-34	9.99e-31	0.63	0.52	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	13.18	5.37e-34	9.99e-31	0.63	0.52	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	13.18	5.37e-34	9.99e-31	0.63	0.52	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	13.18	5.37e-34	9.99e-31	0.63	0.52	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	13.18	5.37e-34	9.99e-31	0.63	0.52	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
LGG	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-13.17	5.39e-34	1e-30	-0.6	-0.52	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
LGG	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	13.17	5.47e-34	1.02e-30	0.4	0.52	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
LGG	cis	rs9532669	0.963	rs9566607	ENSG00000176268.5	CYCSP34	-13.17	5.5e-34	1.02e-30	-0.66	-0.52	Cervical cancer;	chr13:40921788	chr13:40863599~40863902:-
LGG	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	13.17	5.53e-34	1.03e-30	0.64	0.52	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
LGG	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-13.17	5.53e-34	1.03e-30	-0.66	-0.52	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
LGG	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-13.17	5.53e-34	1.03e-30	-0.66	-0.52	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
LGG	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	13.17	5.55e-34	1.03e-30	0.68	0.52	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
LGG	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-13.17	5.59e-34	1.04e-30	-0.93	-0.52	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
LGG	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	13.17	5.67e-34	1.05e-30	0.59	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
LGG	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-13.17	5.8e-34	1.08e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.819	rs13046807	ENSG00000223768.1	LINC00205	-13.17	5.81e-34	1.08e-30	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45293285~45297354:+
LGG	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	13.17	5.83e-34	1.08e-30	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
LGG	cis	rs741668	0.759	rs12428399	ENSG00000235903.6	CPB2-AS1	13.17	5.85e-34	1.09e-30	0.56	0.52	Cerebrospinal fluid clusterin levels;	chr13:46060804	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	13.17	5.88e-34	1.09e-30	0.65	0.52	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	13.16	5.98e-34	1.11e-30	0.58	0.52	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	13.16	5.98e-34	1.11e-30	0.58	0.52	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	13.16	5.98e-34	1.11e-30	0.58	0.52	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	13.16	5.98e-34	1.11e-30	0.58	0.52	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
LGG	cis	rs4373814	0.857	rs12570727	ENSG00000226083.4	SLC39A12-AS1	13.16	6.01e-34	1.12e-30	0.54	0.52	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18136590	chr10:18001786~18010562:-
LGG	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-13.16	6.06e-34	1.12e-30	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	13.16	6.07e-34	1.13e-30	0.58	0.52	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
LGG	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-13.16	6.17e-34	1.14e-30	-0.65	-0.52	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-13.16	6.17e-34	1.14e-30	-0.65	-0.52	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-13.16	6.17e-34	1.14e-30	-0.65	-0.52	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
LGG	cis	rs6452524	1	rs10042854	ENSG00000248112.1	RP11-78C3.1	-13.16	6.19e-34	1.15e-30	-0.66	-0.52	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:82919376~82921119:-
LGG	cis	rs4819052	0.851	rs9977178	ENSG00000215447.6	BX322557.10	-13.16	6.2e-34	1.15e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45288052~45291738:+
LGG	cis	rs11098499	0.82	rs2389885	ENSG00000249244.1	RP11-548H18.2	13.16	6.23e-34	1.16e-30	0.59	0.52	Corneal astigmatism;	chr4:119612776	chr4:119391831~119395335:-
LGG	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-13.16	6.24e-34	1.16e-30	-0.63	-0.52	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
LGG	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	13.16	6.25e-34	1.16e-30	0.58	0.52	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
LGG	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	13.16	6.27e-34	1.16e-30	0.76	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
LGG	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	13.16	6.28e-34	1.16e-30	0.6	0.52	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
LGG	cis	rs6452524	0.967	rs6452507	ENSG00000248112.1	RP11-78C3.1	13.16	6.39e-34	1.18e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs6452508	ENSG00000248112.1	RP11-78C3.1	13.16	6.39e-34	1.18e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	13.15	6.57e-34	1.22e-30	0.71	0.52	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs10474081	ENSG00000248112.1	RP11-78C3.1	13.15	6.58e-34	1.22e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:82919376~82921119:-
LGG	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-13.15	6.61e-34	1.22e-30	-0.64	-0.52	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
LGG	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-13.15	6.81e-34	1.26e-30	-0.85	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
LGG	cis	rs6452524	0.967	rs4541638	ENSG00000248112.1	RP11-78C3.1	13.15	6.86e-34	1.27e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs28360104	ENSG00000248112.1	RP11-78C3.1	13.15	6.86e-34	1.27e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:82919376~82921119:-
LGG	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	13.15	7.07e-34	1.31e-30	0.6	0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	13.15	7.07e-34	1.31e-30	0.6	0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-13.15	7.07e-34	1.31e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-13.15	7.07e-34	1.31e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-13.15	7.07e-34	1.31e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-13.15	7.07e-34	1.31e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-13.15	7.07e-34	1.31e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-13.15	7.07e-34	1.31e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-13.15	7.07e-34	1.31e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
LGG	cis	rs6452524	0.534	rs7724935	ENSG00000248112.1	RP11-78C3.1	13.15	7.13e-34	1.32e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.506	rs7707143	ENSG00000248112.1	RP11-78C3.1	13.15	7.13e-34	1.32e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	13.14	7.19e-34	1.33e-30	0.71	0.52	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
LGG	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-13.14	7.21e-34	1.33e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
LGG	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	13.14	7.22e-34	1.33e-30	0.62	0.52	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	13.14	7.22e-34	1.33e-30	0.62	0.52	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
LGG	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-13.14	7.36e-34	1.36e-30	-0.54	-0.52	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	13.14	7.36e-34	1.36e-30	0.54	0.52	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
LGG	cis	rs651907	0.557	rs11917569	ENSG00000244119.1	PDCL3P4	13.14	7.46e-34	1.38e-30	0.41	0.52	Colorectal cancer;	chr3:101636219	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs11917682	ENSG00000244119.1	PDCL3P4	13.14	7.46e-34	1.38e-30	0.41	0.52	Colorectal cancer;	chr3:101636583	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs12629658	ENSG00000244119.1	PDCL3P4	13.14	7.46e-34	1.38e-30	0.41	0.52	Colorectal cancer;	chr3:101637691	chr3:101712472~101713191:+
LGG	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	13.14	7.5e-34	1.38e-30	0.62	0.52	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	13.14	7.5e-34	1.38e-30	0.62	0.52	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
LGG	cis	rs8062405	0.964	rs7187333	ENSG00000271623.1	RP11-435I10.5	-13.14	7.5e-34	1.38e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs12446589	ENSG00000271623.1	RP11-435I10.5	-13.14	7.5e-34	1.38e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.851	rs28501512	ENSG00000223768.1	LINC00205	-13.14	7.52e-34	1.39e-30	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45293285~45297354:+
LGG	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-13.14	7.54e-34	1.39e-30	-0.73	-0.52	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
LGG	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	13.14	7.57e-34	1.4e-30	0.53	0.52	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
LGG	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-13.14	7.58e-34	1.4e-30	-0.67	-0.52	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
LGG	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	13.14	7.72e-34	1.42e-30	0.58	0.52	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
LGG	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-13.14	7.76e-34	1.43e-30	-0.63	-0.52	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
LGG	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-13.14	7.8e-34	1.44e-30	-0.61	-0.52	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
LGG	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-13.14	7.84e-34	1.44e-30	-0.62	-0.52	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
LGG	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-13.14	7.87e-34	1.45e-30	-0.63	-0.52	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
LGG	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	13.13	7.93e-34	1.46e-30	0.65	0.52	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
LGG	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-13.13	8.11e-34	1.49e-30	-0.42	-0.52	Height;	chr11:118746590	chr11:118791254~118793137:+
LGG	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	13.13	8.17e-34	1.5e-30	0.57	0.52	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	13.13	8.24e-34	1.52e-30	0.65	0.52	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-13.13	8.24e-34	1.52e-30	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
LGG	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	13.13	8.29e-34	1.53e-30	0.71	0.52	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
LGG	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	13.13	8.32e-34	1.53e-30	0.66	0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
LGG	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	13.13	8.35e-34	1.54e-30	0.63	0.52	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
LGG	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-13.13	8.4e-34	1.54e-30	-0.63	-0.52	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
LGG	cis	rs6452524	0.905	rs10040244	ENSG00000248112.1	RP11-78C3.1	13.13	8.41e-34	1.55e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	13.13	8.44e-34	1.55e-30	0.71	0.52	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
LGG	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-13.13	8.52e-34	1.57e-30	-0.61	-0.52	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
LGG	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-13.13	8.65e-34	1.59e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
LGG	cis	rs6452524	0.534	rs9293328	ENSG00000248112.1	RP11-78C3.1	13.13	8.69e-34	1.6e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.534	rs11746747	ENSG00000248112.1	RP11-78C3.1	13.13	8.69e-34	1.6e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:82919376~82921119:-
LGG	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	13.13	8.69e-34	1.6e-30	0.55	0.52	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
LGG	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-13.12	8.75e-34	1.61e-30	-0.63	-0.52	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
LGG	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-13.12	8.82e-34	1.62e-30	-0.62	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.807	rs4819047	ENSG00000215447.6	BX322557.10	-13.12	8.87e-34	1.63e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45288052~45291738:+
LGG	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	13.12	8.9e-34	1.64e-30	0.63	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
LGG	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	13.12	8.9e-34	1.64e-30	0.63	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
LGG	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	13.12	8.9e-34	1.64e-30	0.63	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
LGG	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-13.12	8.9e-34	1.64e-30	-0.69	-0.52	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
LGG	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-13.12	9.03e-34	1.66e-30	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-13.12	9.03e-34	1.66e-30	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-13.12	9.03e-34	1.66e-30	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
LGG	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-13.12	9.03e-34	1.66e-30	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-13.12	9.03e-34	1.66e-30	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-13.12	9.03e-34	1.66e-30	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
LGG	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	13.12	9.11e-34	1.67e-30	0.62	0.52	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
LGG	cis	rs2282300	1	rs12799529	ENSG00000254532.1	RP11-624D11.2	13.12	9.26e-34	1.7e-30	0.76	0.52	Morning vs. evening chronotype;	chr11:30387005	chr11:30044058~30084343:-
LGG	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-13.12	9.27e-34	1.7e-30	-0.65	-0.52	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
LGG	cis	rs8062405	0.723	rs4788079	ENSG00000271623.1	RP11-435I10.5	-13.12	9.33e-34	1.71e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28364700~28365333:+
LGG	cis	rs12495178	0.599	rs12492459	ENSG00000239519.1	CADM2-AS1	13.12	9.53e-34	1.75e-30	0.59	0.52	Body mass index;	chr3:85972896	chr3:85992183~86028007:-
LGG	cis	rs12495178	0.599	rs12485709	ENSG00000239519.1	CADM2-AS1	13.12	9.53e-34	1.75e-30	0.59	0.52	Body mass index;	chr3:85976101	chr3:85992183~86028007:-
LGG	cis	rs651907	0.557	rs62284198	ENSG00000244119.1	PDCL3P4	13.11	9.65e-34	1.77e-30	0.4	0.52	Colorectal cancer;	chr3:101755855	chr3:101712472~101713191:+
LGG	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	13.11	9.65e-34	1.77e-30	0.4	0.52	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
LGG	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-13.11	9.84e-34	1.8e-30	-0.59	-0.52	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-13.11	9.84e-34	1.8e-30	-0.59	-0.52	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
LGG	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-13.11	9.94e-34	1.82e-30	-0.6	-0.52	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	13.11	9.94e-34	1.82e-30	0.57	0.52	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
LGG	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	13.11	1.01e-33	1.85e-30	0.59	0.52	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
LGG	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-13.11	1.01e-33	1.86e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-13.11	1.01e-33	1.86e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-13.11	1.01e-33	1.86e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-13.11	1.01e-33	1.86e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
LGG	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-13.11	1.02e-33	1.86e-30	-0.54	-0.52	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
LGG	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	13.11	1.03e-33	1.88e-30	0.63	0.52	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
LGG	cis	rs7267979	0.718	rs2983489	ENSG00000125804.12	FAM182A	-13.11	1.03e-33	1.89e-30	-0.62	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.727	rs2474765	ENSG00000125804.12	FAM182A	-13.11	1.03e-33	1.89e-30	-0.62	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26054655~26086917:+
LGG	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-13.11	1.04e-33	1.89e-30	-1.04	-0.52	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
LGG	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-13.11	1.04e-33	1.9e-30	-0.73	-0.52	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
LGG	cis	rs6452524	0.537	rs1583	ENSG00000248112.1	RP11-78C3.1	13.11	1.04e-33	1.91e-30	0.68	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	13.11	1.06e-33	1.93e-30	0.63	0.52	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	13.11	1.06e-33	1.93e-30	0.63	0.52	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
LGG	cis	rs8062405	0.755	rs62034350	ENSG00000271623.1	RP11-435I10.5	-13.1	1.07e-33	1.96e-30	-0.61	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.808	rs11909411	ENSG00000223768.1	LINC00205	-13.1	1.07e-33	1.96e-30	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs28676615	ENSG00000223768.1	LINC00205	-13.1	1.07e-33	1.96e-30	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45293285~45297354:+
LGG	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	13.1	1.08e-33	1.97e-30	0.55	0.52	Height;	chr3:53082835	chr3:53064283~53065091:-
LGG	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	13.1	1.09e-33	1.99e-30	0.54	0.52	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	13.1	1.09e-33	1.99e-30	0.54	0.52	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	13.1	1.09e-33	1.99e-30	0.54	0.52	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	13.1	1.09e-33	1.99e-30	0.54	0.52	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	13.1	1.09e-33	1.99e-30	0.54	0.52	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
LGG	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-13.1	1.09e-33	1.99e-30	-0.54	-0.52	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
LGG	cis	rs8062405	0.755	rs7193402	ENSG00000271623.1	RP11-435I10.5	-13.1	1.09e-33	1.99e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs12445823	ENSG00000271623.1	RP11-435I10.5	-13.1	1.09e-33	1.99e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.723	rs12445744	ENSG00000271623.1	RP11-435I10.5	-13.1	1.09e-33	1.99e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs4787455	ENSG00000271623.1	RP11-435I10.5	-13.1	1.09e-33	1.99e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	13.1	1.1e-33	2.01e-30	0.63	0.52	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
LGG	cis	rs8064024	0.676	rs2075467	ENSG00000267077.1	RP11-127I20.5	-13.1	1.1e-33	2.02e-30	-0.5	-0.52	Cancer;	chr16:4823241	chr16:4795265~4796532:-
LGG	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-13.1	1.1e-33	2.02e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
LGG	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	13.1	1.11e-33	2.02e-30	0.63	0.52	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
LGG	cis	rs6452524	1	rs2126990	ENSG00000248112.1	RP11-78C3.1	13.1	1.12e-33	2.04e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	13.1	1.13e-33	2.06e-30	0.64	0.52	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
LGG	cis	rs4713118	0.786	rs200502	ENSG00000199851.2	U3	13.1	1.14e-33	2.08e-30	0.77	0.52	Parkinson's disease;	chr6:27820284	chr6:28015568~28015777:+
LGG	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	13.1	1.14e-33	2.08e-30	0.54	0.52	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
LGG	cis	rs4819052	0.851	rs13052344	ENSG00000223768.1	LINC00205	-13.1	1.14e-33	2.09e-30	-0.57	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45293285~45297354:+
LGG	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-13.1	1.15e-33	2.11e-30	-0.63	-0.52	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
LGG	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	-13.1	1.16e-33	2.11e-30	-0.53	-0.52	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	13.1	1.16e-33	2.12e-30	0.63	0.52	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
LGG	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	13.09	1.17e-33	2.14e-30	0.67	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
LGG	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	-13.09	1.17e-33	2.14e-30	-0.53	-0.52	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
LGG	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	-13.09	1.17e-33	2.14e-30	-0.53	-0.52	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	13.09	1.18e-33	2.14e-30	0.64	0.52	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	13.09	1.18e-33	2.14e-30	0.64	0.52	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
LGG	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-13.09	1.18e-33	2.14e-30	-0.53	-0.52	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
LGG	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	13.09	1.18e-33	2.15e-30	0.64	0.52	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
LGG	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-13.09	1.18e-33	2.15e-30	-0.73	-0.52	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
LGG	cis	rs8062405	0.895	rs62036658	ENSG00000271623.1	RP11-435I10.5	-13.09	1.2e-33	2.18e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28364700~28365333:+
LGG	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-13.09	1.2e-33	2.19e-30	-0.6	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	13.09	1.23e-33	2.24e-30	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
LGG	cis	rs4819052	0.851	rs12626188	ENSG00000215447.6	BX322557.10	-13.09	1.25e-33	2.28e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45288052~45291738:+
LGG	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	13.09	1.27e-33	2.3e-30	0.63	0.52	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
LGG	cis	rs7315956	0.964	rs735309	ENSG00000257139.1	RP11-320P7.2	-13.09	1.27e-33	2.31e-30	-0.62	-0.52	Testicular germ cell tumor;	chr12:70178637	chr12:70180338~70202004:+
LGG	cis	rs6452524	0.534	rs10514246	ENSG00000248112.1	RP11-78C3.1	13.09	1.27e-33	2.31e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.534	rs10037377	ENSG00000248112.1	RP11-78C3.1	13.09	1.27e-33	2.31e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:82919376~82921119:-
LGG	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-13.09	1.28e-33	2.32e-30	-0.6	-0.52	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-13.08	1.29e-33	2.34e-30	-0.61	-0.52	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
LGG	cis	rs8062405	0.698	rs7188071	ENSG00000271623.1	RP11-435I10.5	13.08	1.29e-33	2.35e-30	0.63	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-13.08	1.31e-33	2.39e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-13.08	1.31e-33	2.39e-30	-0.4	-0.52	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
LGG	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-13.08	1.32e-33	2.4e-30	-0.61	-0.52	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
LGG	cis	rs6452524	0.967	rs11741420	ENSG00000248112.1	RP11-78C3.1	13.08	1.32e-33	2.41e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs4401555	ENSG00000248112.1	RP11-78C3.1	13.08	1.32e-33	2.41e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:82919376~82921119:-
LGG	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-13.08	1.33e-33	2.42e-30	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
LGG	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	13.08	1.34e-33	2.44e-30	0.64	0.51	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	13.08	1.35e-33	2.45e-30	0.63	0.51	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	13.08	1.36e-33	2.46e-30	0.63	0.51	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	13.08	1.36e-33	2.46e-30	0.63	0.51	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
LGG	cis	rs8062405	0.755	rs4788080	ENSG00000271623.1	RP11-435I10.5	-13.08	1.38e-33	2.51e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs4787456	ENSG00000271623.1	RP11-435I10.5	-13.08	1.38e-33	2.51e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs4788078	ENSG00000271623.1	RP11-435I10.5	-13.08	1.38e-33	2.51e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.69	rs7187604	ENSG00000271623.1	RP11-435I10.5	-13.08	1.38e-33	2.51e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28364700~28365333:+
LGG	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-13.08	1.39e-33	2.52e-30	-0.59	-0.51	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
LGG	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-13.08	1.4e-33	2.53e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
LGG	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	13.08	1.41e-33	2.55e-30	0.57	0.51	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
LGG	cis	rs8062405	0.755	rs56272201	ENSG00000271623.1	RP11-435I10.5	-13.08	1.41e-33	2.56e-30	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.755	rs62034355	ENSG00000271623.1	RP11-435I10.5	-13.08	1.41e-33	2.56e-30	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28364700~28365333:+
LGG	cis	rs6452524	0.71	rs7708124	ENSG00000248112.1	RP11-78C3.1	13.07	1.42e-33	2.57e-30	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:82919376~82921119:-
LGG	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	13.07	1.42e-33	2.58e-30	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
LGG	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	13.07	1.42e-33	2.58e-30	0.6	0.51	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
LGG	cis	rs916888	0.773	rs199447	ENSG00000232300.1	FAM215B	13.07	1.43e-33	2.6e-30	0.76	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46558830~46562795:-
LGG	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-13.07	1.44e-33	2.61e-30	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
LGG	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-13.07	1.47e-33	2.66e-30	-0.67	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
LGG	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-13.07	1.47e-33	2.66e-30	-0.63	-0.51	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
LGG	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-13.07	1.48e-33	2.68e-30	-0.73	-0.51	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
LGG	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-13.07	1.49e-33	2.7e-30	-0.62	-0.51	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
LGG	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-13.07	1.51e-33	2.73e-30	-0.62	-0.51	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
LGG	cis	rs1930961	1	rs6004657	ENSG00000272977.1	CTA-390C10.10	-13.07	1.51e-33	2.74e-30	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25476218~25479971:+
LGG	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-13.07	1.53e-33	2.77e-30	-0.65	-0.51	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
LGG	cis	rs8062405	0.755	rs4788074	ENSG00000271623.1	RP11-435I10.5	13.07	1.54e-33	2.78e-30	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28364700~28365333:+
LGG	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	13.07	1.56e-33	2.82e-30	0.6	0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.851	rs8134392	ENSG00000215447.6	BX322557.10	13.06	1.59e-33	2.87e-30	0.4	0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45288052~45291738:+
LGG	cis	rs8062405	0.755	rs4788076	ENSG00000271623.1	RP11-435I10.5	-13.06	1.6e-33	2.89e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28364700~28365333:+
LGG	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	13.06	1.6e-33	2.9e-30	0.4	0.51	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
LGG	cis	rs11148252	0.553	rs9536236	ENSG00000235660.1	LINC00345	-13.06	1.6e-33	2.9e-30	-0.64	-0.51	Lewy body disease;	chr13:52680877	chr13:52484161~52484680:-
LGG	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	13.06	1.6e-33	2.9e-30	0.63	0.51	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
LGG	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-13.06	1.62e-33	2.92e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
LGG	cis	rs172166	0.61	rs276369	ENSG00000199851.2	U3	13.06	1.63e-33	2.94e-30	0.69	0.51	Cardiac Troponin-T levels;	chr6:27951465	chr6:28015568~28015777:+
LGG	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-13.06	1.63e-33	2.94e-30	-0.62	-0.51	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
LGG	cis	rs8062405	0.755	rs62034358	ENSG00000271623.1	RP11-435I10.5	-13.06	1.64e-33	2.96e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28364700~28365333:+
LGG	cis	rs7216064	0.589	rs8072723	ENSG00000278219.1	AC145343.1	13.06	1.64e-33	2.97e-30	0.62	0.51	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68101538~68101639:+
LGG	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-13.06	1.65e-33	2.98e-30	-0.68	-0.51	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
LGG	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-13.06	1.65e-33	2.98e-30	-0.68	-0.51	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
LGG	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	13.06	1.66e-33	3e-30	0.39	0.51	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
LGG	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	13.06	1.67e-33	3.02e-30	0.58	0.51	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	13.06	1.67e-33	3.02e-30	0.58	0.51	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	13.06	1.67e-33	3.02e-30	0.87	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
LGG	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-13.06	1.68e-33	3.02e-30	-0.64	-0.51	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-13.06	1.68e-33	3.02e-30	-0.64	-0.51	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
LGG	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-13.06	1.68e-33	3.03e-30	-0.68	-0.51	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
LGG	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	13.06	1.68e-33	3.03e-30	0.94	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
LGG	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	13.06	1.69e-33	3.04e-30	0.84	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
LGG	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	13.06	1.69e-33	3.05e-30	0.54	0.51	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
LGG	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	13.06	1.69e-33	3.05e-30	0.63	0.51	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	13.06	1.69e-33	3.05e-30	0.63	0.51	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	13.06	1.69e-33	3.05e-30	0.63	0.51	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	13.06	1.69e-33	3.05e-30	0.63	0.51	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	13.06	1.69e-33	3.06e-30	0.64	0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-13.05	1.73e-33	3.12e-30	-0.62	-0.51	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	13.05	1.74e-33	3.14e-30	0.63	0.51	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	13.05	1.74e-33	3.14e-30	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
LGG	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	13.05	1.75e-33	3.16e-30	0.58	0.51	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
LGG	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	13.05	1.78e-33	3.21e-30	0.64	0.51	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
LGG	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-13.05	1.79e-33	3.22e-30	-0.64	-0.51	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
LGG	cis	rs4819052	0.851	rs2255766	ENSG00000223768.1	LINC00205	-13.05	1.84e-33	3.31e-30	-0.57	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45293285~45297354:+
LGG	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	13.05	1.84e-33	3.32e-30	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	13.05	1.84e-33	3.32e-30	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	13.05	1.84e-33	3.32e-30	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
LGG	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-13.05	1.85e-33	3.34e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
LGG	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-13.05	1.86e-33	3.34e-30	-0.58	-0.51	Height;	chr3:53034139	chr3:53064283~53065091:-
LGG	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	13.05	1.88e-33	3.39e-30	0.67	0.51	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
LGG	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	-13.04	1.9e-33	3.43e-30	-0.54	-0.51	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
LGG	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-13.04	1.91e-33	3.44e-30	-0.85	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
LGG	cis	rs4713118	0.786	rs200503	ENSG00000199851.2	U3	13.04	1.92e-33	3.45e-30	0.76	0.51	Parkinson's disease;	chr6:27818104	chr6:28015568~28015777:+
LGG	cis	rs8062405	0.723	rs4788077	ENSG00000271623.1	RP11-435I10.5	-13.04	1.92e-33	3.45e-30	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28364700~28365333:+
LGG	cis	rs7267979	0.764	rs2474767	ENSG00000125804.12	FAM182A	-13.04	1.92e-33	3.45e-30	-0.61	-0.51	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26054655~26086917:+
LGG	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-13.04	1.94e-33	3.48e-30	-0.61	-0.51	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
LGG	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	13.04	1.94e-33	3.5e-30	0.45	0.51	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
LGG	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-13.04	1.95e-33	3.51e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
LGG	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-13.04	1.95e-33	3.51e-30	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
LGG	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	13.04	1.95e-33	3.51e-30	0.71	0.51	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
LGG	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	13.04	1.96e-33	3.53e-30	0.58	0.51	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
LGG	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	13.04	1.96e-33	3.53e-30	0.68	0.51	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
LGG	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	13.04	1.98e-33	3.55e-30	0.63	0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
LGG	cis	rs6908034	0.607	rs73378506	ENSG00000228412.5	RP4-625H18.2	13.04	1.99e-33	3.58e-30	0.79	0.51	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819756	chr6:19802164~19804752:-
LGG	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-13.04	2e-33	3.59e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-13.04	2e-33	3.59e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
LGG	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	13.04	2.01e-33	3.6e-30	0.71	0.51	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
LGG	cis	rs4819052	0.851	rs2838858	ENSG00000223768.1	LINC00205	-13.04	2.02e-33	3.64e-30	-0.56	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45293285~45297354:+
LGG	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-13.04	2.04e-33	3.66e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
LGG	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	13.04	2.07e-33	3.72e-30	0.57	0.51	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	13.04	2.07e-33	3.72e-30	0.57	0.51	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
LGG	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	13.04	2.07e-33	3.72e-30	0.61	0.51	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
LGG	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-13.04	2.07e-33	3.72e-30	-0.62	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
LGG	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-13.03	2.08e-33	3.74e-30	-0.64	-0.51	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
LGG	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	13.03	2.11e-33	3.78e-30	0.59	0.51	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	13.03	2.12e-33	3.81e-30	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	13.03	2.12e-33	3.81e-30	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	13.03	2.13e-33	3.82e-30	0.63	0.51	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
LGG	cis	rs9532669	0.819	rs9532652	ENSG00000176268.5	CYCSP34	13.03	2.14e-33	3.83e-30	0.65	0.51	Cervical cancer;	chr13:40903300	chr13:40863599~40863902:-
LGG	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	13.03	2.16e-33	3.87e-30	0.6	0.51	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
LGG	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-13.03	2.18e-33	3.9e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
LGG	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-13.03	2.18e-33	3.92e-30	-1.04	-0.51	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
LGG	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	13.03	2.19e-33	3.93e-30	0.71	0.51	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
LGG	cis	rs8062405	1	rs72793811	ENSG00000271623.1	RP11-435I10.5	-13.03	2.2e-33	3.94e-30	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-13.03	2.2e-33	3.95e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-13.03	2.21e-33	3.96e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
LGG	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	13.03	2.25e-33	4.02e-30	0.56	0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
LGG	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	13.03	2.25e-33	4.04e-30	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
LGG	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	13.03	2.27e-33	4.07e-30	0.4	0.51	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
LGG	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-13.02	2.29e-33	4.1e-30	-0.54	-0.51	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
LGG	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	13.02	2.31e-33	4.13e-30	0.58	0.51	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	13.02	2.31e-33	4.13e-30	0.58	0.51	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	13.02	2.31e-33	4.13e-30	0.58	0.51	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	13.02	2.31e-33	4.13e-30	0.58	0.51	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	13.02	2.31e-33	4.13e-30	0.58	0.51	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
LGG	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-13.02	2.32e-33	4.14e-30	-0.73	-0.51	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
LGG	cis	rs8062405	0.69	rs62034351	ENSG00000271623.1	RP11-435I10.5	-13.02	2.32e-33	4.15e-30	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28364700~28365333:+
LGG	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	13.02	2.32e-33	4.16e-30	0.56	0.51	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
LGG	cis	rs8062405	1	rs7498555	ENSG00000271623.1	RP11-435I10.5	-13.02	2.34e-33	4.19e-30	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28364700~28365333:+
LGG	cis	rs9890032	0.509	rs11656986	ENSG00000266490.1	CTD-2349P21.9	13.02	2.35e-33	4.2e-30	0.47	0.51	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30792372~30792833:+
LGG	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	13.02	2.35e-33	4.2e-30	0.58	0.51	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	13.02	2.35e-33	4.2e-30	0.58	0.51	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
LGG	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-13.02	2.35e-33	4.2e-30	-0.64	-0.51	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
LGG	cis	rs651907	0.535	rs9830943	ENSG00000244119.1	PDCL3P4	13.02	2.39e-33	4.28e-30	0.4	0.51	Colorectal cancer;	chr3:101710055	chr3:101712472~101713191:+
LGG	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	13.02	2.41e-33	4.31e-30	0.63	0.51	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
LGG	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-13.02	2.47e-33	4.42e-30	-0.63	-0.51	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
LGG	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	13.02	2.49e-33	4.44e-30	0.53	0.51	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
LGG	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-13.02	2.5e-33	4.47e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2236444	ENSG00000223768.1	LINC00205	-13.02	2.51e-33	4.49e-30	-0.57	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45293285~45297354:+
LGG	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	13.01	2.55e-33	4.56e-30	0.39	0.51	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
LGG	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-13.01	2.58e-33	4.62e-30	-0.59	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	13.01	2.61e-33	4.67e-30	0.63	0.51	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	13.01	2.61e-33	4.67e-30	0.63	0.51	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	13.01	2.61e-33	4.67e-30	0.63	0.51	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
LGG	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-13.01	2.63e-33	4.7e-30	-0.64	-0.51	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
LGG	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-13.01	2.63e-33	4.7e-30	-0.64	-0.51	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
LGG	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	13.01	2.64e-33	4.71e-30	0.62	0.51	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
LGG	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-13.01	2.64e-33	4.72e-30	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
LGG	cis	rs2283792	0.566	rs1005579	ENSG00000228050.1	TOP3BP1	13.01	2.65e-33	4.73e-30	0.59	0.51	Multiple sclerosis;	chr22:21946569	chr22:22223187~22224566:-
LGG	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	13.01	2.7e-33	4.82e-30	0.63	0.51	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
LGG	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	13.01	2.71e-33	4.83e-30	0.67	0.51	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
LGG	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-13.01	2.72e-33	4.85e-30	-0.63	-0.51	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
LGG	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-13.01	2.72e-33	4.86e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
LGG	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-13.01	2.72e-33	4.86e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
LGG	cis	rs8062405	0.723	rs113208333	ENSG00000271623.1	RP11-435I10.5	-13.01	2.72e-33	4.86e-30	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28364700~28365333:+
LGG	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	13.01	2.75e-33	4.9e-30	0.58	0.51	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
LGG	cis	rs4713118	0.869	rs7776351	ENSG00000199851.2	U3	-13.01	2.77e-33	4.94e-30	-0.75	-0.51	Parkinson's disease;	chr6:27758952	chr6:28015568~28015777:+
LGG	cis	rs8062405	1	rs72793812	ENSG00000271623.1	RP11-435I10.5	-13	2.81e-33	5.01e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28364700~28365333:+
LGG	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-13	2.82e-33	5.02e-30	-0.53	-0.51	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
LGG	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	13	2.83e-33	5.04e-30	0.63	0.51	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
LGG	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	13	2.84e-33	5.05e-30	0.63	0.51	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
LGG	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-13	2.85e-33	5.08e-30	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
LGG	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-13	2.9e-33	5.17e-30	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
LGG	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-13	2.92e-33	5.19e-30	-0.65	-0.51	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
LGG	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-13	3.03e-33	5.39e-30	-0.64	-0.51	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
LGG	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	13	3.04e-33	5.41e-30	0.71	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
LGG	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	12.99	3.06e-33	5.45e-30	0.58	0.51	Height;	chr11:118809363	chr11:118688039~118690600:-
LGG	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-12.99	3.09e-33	5.49e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-12.99	3.09e-33	5.49e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-12.99	3.09e-33	5.49e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
LGG	cis	rs494459	0.733	rs556437	ENSG00000278376.1	RP11-158I9.8	-12.99	3.11e-33	5.53e-30	-0.43	-0.51	Height;	chr11:118835044	chr11:118791254~118793137:+
LGG	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-12.99	3.16e-33	5.62e-30	-0.64	-0.51	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-12.99	3.16e-33	5.62e-30	-0.64	-0.51	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-12.99	3.16e-33	5.62e-30	-0.64	-0.51	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-12.99	3.16e-33	5.62e-30	-0.64	-0.51	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-12.99	3.16e-33	5.62e-30	-0.64	-0.51	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
LGG	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	12.99	3.17e-33	5.63e-30	0.57	0.51	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
LGG	cis	rs6452524	0.507	rs28592576	ENSG00000248112.1	RP11-78C3.1	12.99	3.19e-33	5.66e-30	0.67	0.51	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.534	rs7727691	ENSG00000248112.1	RP11-78C3.1	12.99	3.19e-33	5.66e-30	0.67	0.51	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:82919376~82921119:-
LGG	cis	rs4819052	0.851	rs4819046	ENSG00000215447.6	BX322557.10	-12.99	3.21e-33	5.7e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838837	ENSG00000215447.6	BX322557.10	-12.99	3.22e-33	5.72e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838829	ENSG00000215447.6	BX322557.10	-12.99	3.22e-33	5.72e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.885	rs9980676	ENSG00000215447.6	BX322557.10	-12.99	3.22e-33	5.72e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838836	ENSG00000215447.6	BX322557.10	-12.99	3.22e-33	5.72e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-12.99	3.24e-33	5.75e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-12.99	3.24e-33	5.75e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
LGG	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	12.99	3.24e-33	5.76e-30	0.63	0.51	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	12.99	3.26e-33	5.79e-30	0.63	0.51	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
LGG	cis	rs8062405	1	rs12325113	ENSG00000271623.1	RP11-435I10.5	-12.99	3.27e-33	5.81e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28364700~28365333:+
LGG	cis	rs56163509	1	rs56163509	ENSG00000271623.1	RP11-435I10.5	-12.99	3.27e-33	5.81e-30	-0.61	-0.51	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28364700~28365333:+
LGG	cis	rs8062405	1	rs62037369	ENSG00000271623.1	RP11-435I10.5	-12.99	3.27e-33	5.81e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.965	rs7359397	ENSG00000271623.1	RP11-435I10.5	-12.99	3.27e-33	5.81e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28364700~28365333:+
LGG	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-12.99	3.29e-33	5.84e-30	-0.74	-0.51	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
LGG	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-12.99	3.34e-33	5.92e-30	-0.71	-0.51	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
LGG	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-12.99	3.34e-33	5.93e-30	-0.72	-0.51	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
LGG	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-12.99	3.35e-33	5.93e-30	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-12.99	3.35e-33	5.93e-30	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-12.98	3.49e-33	6.19e-30	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-12.98	3.49e-33	6.19e-30	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
LGG	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-12.98	3.51e-33	6.22e-30	-0.73	-0.51	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
LGG	cis	rs4819052	0.851	rs2838844	ENSG00000215447.6	BX322557.10	-12.98	3.51e-33	6.22e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45288052~45291738:+
LGG	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	12.98	3.53e-33	6.25e-30	0.86	0.51	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
LGG	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	12.98	3.53e-33	6.25e-30	0.86	0.51	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
LGG	cis	rs7315956	0.929	rs6581924	ENSG00000257139.1	RP11-320P7.2	-12.98	3.54e-33	6.27e-30	-0.61	-0.51	Testicular germ cell tumor;	chr12:70168208	chr12:70180338~70202004:+
LGG	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	12.98	3.56e-33	6.3e-30	0.45	0.51	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
LGG	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-12.98	3.56e-33	6.31e-30	-0.73	-0.51	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
LGG	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-12.98	3.6e-33	6.38e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
LGG	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	12.98	3.68e-33	6.52e-30	0.81	0.51	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
LGG	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-12.97	3.73e-33	6.6e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
LGG	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	12.97	3.73e-33	6.6e-30	0.52	0.51	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
LGG	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	12.97	3.75e-33	6.64e-30	0.45	0.51	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
LGG	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-12.97	3.78e-33	6.69e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-12.97	3.78e-33	6.69e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
LGG	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-12.97	3.79e-33	6.7e-30	-0.72	-0.51	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
LGG	cis	rs8062405	0.755	rs4787457	ENSG00000271623.1	RP11-435I10.5	-12.97	3.81e-33	6.73e-30	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-12.97	3.81e-33	6.74e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
LGG	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-12.97	3.85e-33	6.8e-30	-0.6	-0.51	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-12.97	3.85e-33	6.8e-30	-0.6	-0.51	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
LGG	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	12.97	3.86e-33	6.82e-30	1.09	0.51	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
LGG	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-12.97	3.86e-33	6.83e-30	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
LGG	cis	rs4819052	0.851	rs2838832	ENSG00000223768.1	LINC00205	12.97	3.87e-33	6.83e-30	0.56	0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45293285~45297354:+
LGG	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	12.97	3.87e-33	6.85e-30	0.66	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
LGG	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	12.97	3.94e-33	6.96e-30	0.72	0.51	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	12.97	3.94e-33	6.96e-30	0.72	0.51	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	12.97	3.94e-33	6.96e-30	0.72	0.51	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
LGG	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	12.97	4e-33	7.07e-30	0.61	0.51	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
LGG	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-12.97	4.01e-33	7.07e-30	-0.71	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
LGG	cis	rs1150668	0.799	rs1736891	ENSG00000199851.2	U3	12.97	4.06e-33	7.16e-30	0.69	0.51	Pubertal anthropometrics;	chr6:28219323	chr6:28015568~28015777:+
LGG	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	12.96	4.11e-33	7.25e-30	0.66	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
LGG	cis	rs2486288	0.586	rs12909883	ENSG00000259433.2	CTD-2651B20.4	12.96	4.12e-33	7.26e-30	0.56	0.51	Glomerular filtration rate;	chr15:45279856	chr15:45330209~45332634:-
LGG	cis	rs4819052	0.851	rs875621	ENSG00000223768.1	LINC00205	-12.96	4.15e-33	7.33e-30	-0.57	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45293285~45297354:+
LGG	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	12.96	4.16e-33	7.35e-30	0.7	0.51	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
LGG	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-12.96	4.16e-33	7.35e-30	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-12.96	4.16e-33	7.35e-30	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-12.96	4.16e-33	7.35e-30	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
LGG	cis	rs56262138	0.5	rs12486982	ENSG00000239519.1	CADM2-AS1	12.96	4.17e-33	7.35e-30	0.58	0.51	Educational attainment (years of education);	chr3:85988012	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs4688895	ENSG00000239519.1	CADM2-AS1	12.96	4.17e-33	7.36e-30	0.58	0.51	Educational attainment (years of education);	chr3:85985606	chr3:85992183~86028007:-
LGG	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-12.96	4.21e-33	7.42e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
LGG	cis	rs7315956	0.892	rs4761184	ENSG00000257139.1	RP11-320P7.2	12.96	4.23e-33	7.45e-30	0.62	0.51	Testicular germ cell tumor;	chr12:70213887	chr12:70180338~70202004:+
LGG	cis	rs4819052	0.851	rs2838855	ENSG00000223768.1	LINC00205	12.96	4.25e-33	7.5e-30	0.56	0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45293285~45297354:+
LGG	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-12.96	4.38e-33	7.72e-30	-0.57	-0.51	Height;	chr3:52949886	chr3:53064283~53065091:-
LGG	cis	rs9532669	0.89	rs2149570	ENSG00000176268.5	CYCSP34	12.96	4.4e-33	7.74e-30	0.61	0.51	Cervical cancer;	chr13:40858533	chr13:40863599~40863902:-
LGG	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-12.96	4.44e-33	7.82e-30	-0.65	-0.51	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
LGG	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	12.96	4.49e-33	7.9e-30	0.63	0.51	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	12.96	4.49e-33	7.9e-30	0.63	0.51	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
LGG	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-12.95	4.52e-33	7.96e-30	-0.57	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
LGG	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	12.95	4.55e-33	8.02e-30	0.53	0.51	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
LGG	cis	rs2980439	0.783	rs2948305	ENSG00000253893.2	FAM85B	-12.95	4.61e-33	8.11e-30	-0.63	-0.51	Neuroticism;	chr8:8241055	chr8:8167819~8226614:-
LGG	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	12.95	4.61e-33	8.11e-30	0.83	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
LGG	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	12.95	4.62e-33	8.13e-30	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
LGG	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	12.95	4.66e-33	8.19e-30	0.45	0.51	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
LGG	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	12.95	4.67e-33	8.21e-30	1.08	0.51	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
LGG	cis	rs7216064	1	rs4791212	ENSG00000278219.1	AC145343.1	-12.95	4.68e-33	8.23e-30	-0.61	-0.51	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67979269	chr17:68101538~68101639:+
LGG	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	12.95	4.72e-33	8.3e-30	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
LGG	cis	rs4819052	0.851	rs2838831	ENSG00000215447.6	BX322557.10	-12.95	4.76e-33	8.38e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45288052~45291738:+
LGG	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-12.95	4.79e-33	8.42e-30	-0.6	-0.51	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-12.95	4.79e-33	8.42e-30	-0.6	-0.51	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-12.95	4.79e-33	8.42e-30	-0.6	-0.51	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-12.95	4.79e-33	8.42e-30	-0.6	-0.51	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
LGG	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-12.95	4.82e-33	8.47e-30	-0.59	-0.51	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
LGG	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	12.95	4.84e-33	8.51e-30	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
LGG	cis	rs4713118	0.869	rs7773070	ENSG00000199851.2	U3	12.95	4.85e-33	8.52e-30	0.75	0.51	Parkinson's disease;	chr6:27761048	chr6:28015568~28015777:+
LGG	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-12.95	4.88e-33	8.57e-30	-0.67	-0.51	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
LGG	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	-12.95	4.89e-33	8.58e-30	-0.62	-0.51	Depression;	chr6:28167882	chr6:28161781~28169594:+
LGG	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	-12.95	4.89e-33	8.59e-30	-0.52	-0.51	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
LGG	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-12.95	4.9e-33	8.62e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
LGG	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-12.95	4.9e-33	8.62e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
LGG	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	12.94	4.98e-33	8.75e-30	0.4	0.51	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	12.94	4.98e-33	8.75e-30	0.4	0.51	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
LGG	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-12.94	5e-33	8.77e-30	-0.64	-0.51	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
LGG	cis	rs17772222	0.92	rs61975260	ENSG00000258983.2	RP11-507K2.2	12.94	5.03e-33	8.83e-30	0.64	0.51	Coronary artery calcification;	chr14:88429597	chr14:88499334~88515502:+
LGG	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-12.94	5.14e-33	9.01e-30	-0.67	-0.51	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
LGG	cis	rs8064024	0.68	rs3747613	ENSG00000267077.1	RP11-127I20.5	-12.94	5.17e-33	9.07e-30	-0.5	-0.51	Cancer;	chr16:4858503	chr16:4795265~4796532:-
LGG	cis	rs6452524	0.562	rs10474080	ENSG00000248112.1	RP11-78C3.1	12.94	5.2e-33	9.12e-30	0.67	0.51	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:82919376~82921119:-
LGG	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-12.94	5.22e-33	9.15e-30	-0.57	-0.51	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
LGG	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-12.94	5.23e-33	9.17e-30	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
LGG	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-12.94	5.27e-33	9.24e-30	-0.5	-0.51	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
LGG	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	12.94	5.28e-33	9.25e-30	0.61	0.51	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
LGG	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-12.94	5.28e-33	9.26e-30	-0.7	-0.51	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
LGG	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-12.94	5.32e-33	9.32e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
LGG	cis	rs11098499	0.863	rs6858592	ENSG00000249244.1	RP11-548H18.2	12.94	5.32e-33	9.32e-30	0.57	0.51	Corneal astigmatism;	chr4:119537537	chr4:119391831~119395335:-
LGG	cis	rs56262138	0.5	rs68058340	ENSG00000239519.1	CADM2-AS1	12.94	5.32e-33	9.32e-30	0.58	0.51	Educational attainment (years of education);	chr3:85980808	chr3:85992183~86028007:-
LGG	cis	rs11155671	0.53	rs9397398	ENSG00000216621.7	RP11-244K5.6	12.94	5.34e-33	9.36e-30	0.59	0.51	Testicular germ cell tumor;	chr6:149872467	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	12.93	5.5e-33	9.62e-30	0.62	0.51	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
LGG	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	12.93	5.52e-33	9.66e-30	0.63	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
LGG	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-12.93	5.57e-33	9.74e-30	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
LGG	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-12.93	5.6e-33	9.8e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
LGG	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	-12.93	5.64e-33	9.86e-30	-0.52	-0.51	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
LGG	cis	rs4819052	0.851	rs1999335	ENSG00000215447.6	BX322557.10	-12.93	5.68e-33	9.93e-30	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45288052~45291738:+
LGG	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-12.93	5.71e-33	9.98e-30	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
LGG	cis	rs4682868	0.583	rs10865925	ENSG00000273328.4	RP11-141M3.6	-12.93	5.82e-33	1.02e-29	-0.61	-0.51	Monocyte percentage of white cells;	chr3:42872118	chr3:42809414~42908105:+
LGG	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-12.93	5.88e-33	1.03e-29	-0.59	-0.51	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
LGG	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-12.93	5.9e-33	1.03e-29	-0.54	-0.51	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
LGG	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-12.93	5.98e-33	1.04e-29	-0.71	-0.51	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	12.92	6.06e-33	1.06e-29	0.62	0.51	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	12.92	6.06e-33	1.06e-29	0.62	0.51	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
LGG	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-12.92	6.07e-33	1.06e-29	-0.71	-0.51	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	12.92	6.09e-33	1.06e-29	0.62	0.51	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
LGG	cis	rs6452524	0.508	rs40214	ENSG00000248112.1	RP11-78C3.1	-12.92	6.13e-33	1.07e-29	-0.65	-0.51	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:82919376~82921119:-
LGG	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	12.92	6.19e-33	1.08e-29	0.45	0.51	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
LGG	cis	rs7216064	0.532	rs3890640	ENSG00000278219.1	AC145343.1	12.92	6.2e-33	1.08e-29	0.61	0.51	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68101538~68101639:+
LGG	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	12.92	6.23e-33	1.09e-29	0.56	0.51	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
LGG	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	12.92	6.24e-33	1.09e-29	0.66	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
LGG	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	12.92	6.25e-33	1.09e-29	0.63	0.51	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
LGG	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	12.92	6.27e-33	1.09e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
LGG	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	12.92	6.34e-33	1.11e-29	0.53	0.51	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
LGG	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	12.92	6.38e-33	1.11e-29	0.58	0.51	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
LGG	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	12.92	6.42e-33	1.12e-29	0.61	0.51	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
LGG	cis	rs8064024	0.676	rs56919624	ENSG00000267077.1	RP11-127I20.5	12.92	6.42e-33	1.12e-29	0.5	0.51	Cancer;	chr16:4827592	chr16:4795265~4796532:-
LGG	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	12.92	6.43e-33	1.12e-29	0.62	0.51	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	12.92	6.51e-33	1.14e-29	0.63	0.51	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	12.92	6.53e-33	1.14e-29	0.56	0.51	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
LGG	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-12.92	6.6e-33	1.15e-29	-0.6	-0.51	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
LGG	cis	rs12495178	0.626	rs12491363	ENSG00000239519.1	CADM2-AS1	-12.91	6.61e-33	1.15e-29	-0.58	-0.51	Body mass index;	chr3:85971319	chr3:85992183~86028007:-
LGG	cis	rs4682868	0.611	rs2888271	ENSG00000273328.4	RP11-141M3.6	-12.91	6.64e-33	1.16e-29	-0.6	-0.51	Monocyte percentage of white cells;	chr3:42873384	chr3:42809414~42908105:+
LGG	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	12.91	6.69e-33	1.16e-29	0.62	0.51	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
LGG	cis	rs2739330	0.857	rs9608229	ENSG00000099984.9	GSTT2	-12.91	6.72e-33	1.17e-29	-0.7	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23980123~23983911:+
LGG	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-12.91	6.74e-33	1.17e-29	-0.7	-0.51	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
LGG	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	12.91	6.78e-33	1.18e-29	0.82	0.51	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
LGG	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	12.91	6.81e-33	1.18e-29	0.58	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
LGG	cis	rs7315956	0.929	rs10879101	ENSG00000257139.1	RP11-320P7.2	-12.91	6.85e-33	1.19e-29	-0.61	-0.51	Testicular germ cell tumor;	chr12:70168344	chr12:70180338~70202004:+
LGG	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	12.91	6.88e-33	1.2e-29	0.65	0.51	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
LGG	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-12.91	7.01e-33	1.22e-29	-0.68	-0.51	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
LGG	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-12.91	7.01e-33	1.22e-29	-0.68	-0.51	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
LGG	cis	rs4819052	0.851	rs2838845	ENSG00000215447.6	BX322557.10	-12.91	7.04e-33	1.22e-29	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45288052~45291738:+
LGG	cis	rs6452524	1	rs7716962	ENSG00000248112.1	RP11-78C3.1	12.91	7.08e-33	1.23e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6882179	ENSG00000248112.1	RP11-78C3.1	12.91	7.08e-33	1.23e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6863300	ENSG00000248112.1	RP11-78C3.1	12.91	7.08e-33	1.23e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs7732092	ENSG00000248112.1	RP11-78C3.1	12.91	7.08e-33	1.23e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:82919376~82921119:-
LGG	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	12.91	7.16e-33	1.24e-29	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
LGG	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	12.91	7.21e-33	1.25e-29	0.7	0.51	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
LGG	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	12.91	7.25e-33	1.26e-29	0.66	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	12.91	7.25e-33	1.26e-29	0.66	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
LGG	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-12.91	7.28e-33	1.26e-29	-0.57	-0.51	Height;	chr3:52967831	chr3:53064283~53065091:-
LGG	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-12.9	7.31e-33	1.27e-29	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
LGG	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	12.9	7.36e-33	1.28e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
LGG	cis	rs56262138	0.5	rs56339824	ENSG00000239519.1	CADM2-AS1	12.9	7.44e-33	1.29e-29	0.58	0.51	Educational attainment (years of education);	chr3:85987159	chr3:85992183~86028007:-
LGG	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	12.9	7.48e-33	1.3e-29	0.71	0.51	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
LGG	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-12.9	7.55e-33	1.31e-29	-0.64	-0.51	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
LGG	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	12.9	7.63e-33	1.32e-29	0.65	0.51	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
LGG	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-12.9	7.68e-33	1.33e-29	-0.63	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
LGG	cis	rs4373814	0.963	rs12770520	ENSG00000226083.4	SLC39A12-AS1	12.9	7.8e-33	1.35e-29	0.53	0.51	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18136513	chr10:18001786~18010562:-
LGG	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	12.9	7.84e-33	1.36e-29	0.63	0.51	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
LGG	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-12.9	7.88e-33	1.36e-29	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
LGG	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	12.9	7.94e-33	1.37e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	12.9	7.94e-33	1.37e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	12.9	7.94e-33	1.37e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	12.9	7.94e-33	1.37e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	12.9	7.94e-33	1.37e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
LGG	cis	rs741668	0.641	rs4942472	ENSG00000235903.6	CPB2-AS1	-12.9	7.95e-33	1.38e-29	-0.51	-0.51	Cerebrospinal fluid clusterin levels;	chr13:46070980	chr13:46052806~46113332:+
LGG	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	12.9	7.95e-33	1.38e-29	0.6	0.51	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
LGG	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	12.9	7.96e-33	1.38e-29	0.63	0.51	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	12.89	8.11e-33	1.4e-29	0.56	0.51	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	12.89	8.13e-33	1.41e-29	0.56	0.51	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	12.89	8.13e-33	1.41e-29	0.56	0.51	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
LGG	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-12.89	8.15e-33	1.41e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
LGG	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	12.89	8.17e-33	1.41e-29	0.57	0.51	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	12.89	8.17e-33	1.41e-29	0.57	0.51	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	12.89	8.17e-33	1.41e-29	0.57	0.51	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	12.89	8.17e-33	1.41e-29	0.57	0.51	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
LGG	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-12.89	8.29e-33	1.43e-29	-0.71	-0.51	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
LGG	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	12.89	8.55e-33	1.48e-29	0.61	0.51	Depression;	chr6:28151096	chr6:28161781~28169594:+
LGG	cis	rs2980439	0.818	rs2948300	ENSG00000173295.6	FAM86B3P	-12.89	8.59e-33	1.48e-29	-0.52	-0.51	Neuroticism;	chr8:8248986	chr8:8228595~8244865:+
LGG	cis	rs2486288	0.656	rs7171312	ENSG00000259433.2	CTD-2651B20.4	12.89	8.59e-33	1.48e-29	0.56	0.51	Glomerular filtration rate;	chr15:45278027	chr15:45330209~45332634:-
LGG	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	12.89	8.66e-33	1.5e-29	0.61	0.51	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
LGG	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	12.89	8.66e-33	1.5e-29	0.61	0.51	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
LGG	cis	rs8062405	0.656	rs7189927	ENSG00000271623.1	RP11-435I10.5	12.89	8.79e-33	1.52e-29	0.63	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28364700~28365333:+
LGG	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	12.89	8.79e-33	1.52e-29	0.66	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
LGG	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-12.89	8.79e-33	1.52e-29	-0.62	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
LGG	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	12.88	8.83e-33	1.52e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
LGG	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	12.88	8.87e-33	1.53e-29	0.46	0.51	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
LGG	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-12.88	8.88e-33	1.53e-29	-0.53	-0.51	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
LGG	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	12.88	8.89e-33	1.53e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
LGG	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	12.88	8.92e-33	1.54e-29	0.62	0.51	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	12.88	8.92e-33	1.54e-29	0.62	0.51	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
LGG	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	12.88	9.24e-33	1.59e-29	0.6	0.51	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
LGG	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	12.88	9.37e-33	1.62e-29	0.63	0.51	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
LGG	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-12.88	9.43e-33	1.63e-29	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
LGG	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-12.88	9.59e-33	1.65e-29	-0.62	-0.51	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
LGG	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-12.88	9.68e-33	1.67e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-12.88	9.68e-33	1.67e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-12.88	9.68e-33	1.67e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-12.88	9.68e-33	1.67e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.851	rs2838865	ENSG00000215447.6	BX322557.10	-12.87	9.77e-33	1.68e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-12.87	9.78e-33	1.68e-29	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
LGG	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-12.87	9.78e-33	1.68e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-12.87	9.78e-33	1.68e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-12.87	9.78e-33	1.68e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-12.87	9.78e-33	1.68e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-12.87	9.78e-33	1.68e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-12.87	9.78e-33	1.68e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
LGG	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-12.87	9.8e-33	1.69e-29	-0.44	-0.51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
LGG	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	12.87	9.85e-33	1.7e-29	0.57	0.51	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	12.87	9.86e-33	1.7e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	12.87	9.86e-33	1.7e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	12.87	9.86e-33	1.7e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
LGG	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-12.87	1.02e-32	1.76e-29	-0.66	-0.51	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
LGG	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	12.87	1.03e-32	1.77e-29	0.65	0.51	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
LGG	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-12.87	1.05e-32	1.81e-29	-0.58	-0.51	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
LGG	cis	rs651907	0.535	rs34743741	ENSG00000244119.1	PDCL3P4	12.87	1.06e-32	1.82e-29	0.4	0.51	Colorectal cancer;	chr3:101813604	chr3:101712472~101713191:+
LGG	cis	rs1150668	0.799	rs7206	ENSG00000199851.2	U3	12.87	1.06e-32	1.82e-29	0.68	0.51	Pubertal anthropometrics;	chr6:28233360	chr6:28015568~28015777:+
LGG	cis	rs172166	0.61	rs156737	ENSG00000199851.2	U3	12.87	1.06e-32	1.83e-29	0.69	0.51	Cardiac Troponin-T levels;	chr6:27927435	chr6:28015568~28015777:+
LGG	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-12.86	1.07e-32	1.84e-29	-0.71	-0.51	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
LGG	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-12.86	1.07e-32	1.84e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
LGG	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-12.86	1.08e-32	1.85e-29	-0.71	-0.51	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
LGG	cis	rs4713118	0.869	rs4713121	ENSG00000199851.2	U3	12.86	1.08e-32	1.86e-29	0.76	0.51	Parkinson's disease;	chr6:27754285	chr6:28015568~28015777:+
LGG	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-12.86	1.08e-32	1.86e-29	-0.64	-0.51	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
LGG	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-12.86	1.08e-32	1.86e-29	-0.64	-0.51	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
LGG	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	12.86	1.09e-32	1.87e-29	0.63	0.51	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
LGG	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	12.86	1.1e-32	1.89e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
LGG	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	12.86	1.1e-32	1.89e-29	0.61	0.51	Depression;	chr6:28180209	chr6:28161781~28169594:+
LGG	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-12.86	1.1e-32	1.9e-29	-0.61	-0.51	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-12.86	1.1e-32	1.9e-29	-0.61	-0.51	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
LGG	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	12.86	1.11e-32	1.9e-29	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
LGG	cis	rs2486288	0.656	rs1719232	ENSG00000259433.2	CTD-2651B20.4	12.86	1.12e-32	1.93e-29	0.55	0.51	Glomerular filtration rate;	chr15:45279874	chr15:45330209~45332634:-
LGG	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-12.86	1.13e-32	1.93e-29	-0.53	-0.51	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
LGG	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-12.86	1.13e-32	1.93e-29	-0.67	-0.51	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
LGG	cis	rs4819052	0.851	rs13052312	ENSG00000215447.6	BX322557.10	-12.86	1.14e-32	1.95e-29	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45288052~45291738:+
LGG	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-12.86	1.14e-32	1.95e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-12.86	1.14e-32	1.95e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-12.86	1.14e-32	1.95e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-12.86	1.14e-32	1.95e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
LGG	cis	rs4819052	0.851	rs2838833	ENSG00000215447.6	BX322557.10	-12.86	1.15e-32	1.97e-29	-0.4	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45288052~45291738:+
LGG	cis	rs2486288	0.656	rs2461705	ENSG00000259433.2	CTD-2651B20.4	12.86	1.15e-32	1.97e-29	0.55	0.51	Glomerular filtration rate;	chr15:45278043	chr15:45330209~45332634:-
LGG	cis	rs143626010	1	rs143626010	ENSG00000271623.1	RP11-435I10.5	-12.86	1.17e-32	2e-29	-0.61	-0.51	Mosquito bite size;	chr16:28528081	chr16:28364700~28365333:+
LGG	cis	rs4819052	0.851	rs8133045	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2877018	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2330012	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2877019	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2877020	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs10470245	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs10470258	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs4819038	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs4819039	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs4818768	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs4819042	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.8	rs4819045	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs13048789	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs13047598	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.724	rs9753962	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.724	rs9753987	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs9753963	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs9754134	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs34101026	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-12.86	1.17e-32	2e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
LGG	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-12.85	1.18e-32	2.02e-29	-0.44	-0.51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
LGG	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.09e-29	0.4	0.51	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	12.85	1.23e-32	2.1e-29	0.4	0.51	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
LGG	cis	rs2486288	0.656	rs6493143	ENSG00000259433.2	CTD-2651B20.4	12.85	1.23e-32	2.11e-29	0.56	0.51	Glomerular filtration rate;	chr15:45278583	chr15:45330209~45332634:-
LGG	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-12.85	1.24e-32	2.12e-29	-0.62	-0.51	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
LGG	cis	rs2486288	0.656	rs7162022	ENSG00000259433.2	CTD-2651B20.4	12.85	1.25e-32	2.14e-29	0.56	0.51	Glomerular filtration rate;	chr15:45273055	chr15:45330209~45332634:-
LGG	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	12.85	1.25e-32	2.14e-29	0.61	0.51	Depression;	chr6:28143758	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	12.85	1.25e-32	2.14e-29	0.61	0.51	Depression;	chr6:28144784	chr6:28161781~28169594:+
LGG	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-12.85	1.26e-32	2.15e-29	-0.62	-0.51	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
LGG	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	12.85	1.26e-32	2.15e-29	0.6	0.51	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
LGG	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	12.85	1.26e-32	2.16e-29	0.63	0.51	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
LGG	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	12.85	1.29e-32	2.19e-29	0.7	0.51	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	12.85	1.29e-32	2.19e-29	0.7	0.51	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	12.85	1.29e-32	2.19e-29	0.7	0.51	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
LGG	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-12.84	1.3e-32	2.21e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
LGG	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-12.84	1.31e-32	2.24e-29	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
LGG	cis	rs853679	0.882	rs3757188	ENSG00000199851.2	U3	12.84	1.33e-32	2.27e-29	1.06	0.51	Depression;	chr6:28139579	chr6:28015568~28015777:+
LGG	cis	rs2712184	0.875	rs7586692	ENSG00000229352.1	AC007563.3	-12.84	1.34e-32	2.28e-29	-0.59	-0.51	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216809980	chr2:216799608~216805335:+
LGG	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	12.84	1.34e-32	2.28e-29	0.61	0.51	Depression;	chr6:28173770	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	12.84	1.34e-32	2.28e-29	0.61	0.51	Depression;	chr6:28174809	chr6:28161781~28169594:+
LGG	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	12.84	1.34e-32	2.28e-29	0.61	0.51	Depression;	chr6:28175233	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	12.84	1.34e-32	2.28e-29	0.61	0.51	Depression;	chr6:28176973	chr6:28161781~28169594:+
LGG	cis	rs2486288	0.586	rs12909625	ENSG00000259433.2	CTD-2651B20.4	12.84	1.34e-32	2.28e-29	0.56	0.51	Glomerular filtration rate;	chr15:45279855	chr15:45330209~45332634:-
LGG	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28145952	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28147378	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28147406	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28148143	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28149979	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28152885	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28153120	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28154567	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28156691	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28158424	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28159056	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28159666	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28161802	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28162053	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28162598	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28163375	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28163759	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28164580	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28164825	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28164948	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28165025	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28165528	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28168434	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28169019	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28169249	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28169676	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28169755	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28169791	chr6:28161781~28169594:+
LGG	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	12.84	1.36e-32	2.32e-29	0.61	0.51	Depression;	chr6:28170075	chr6:28161781~28169594:+
LGG	cis	rs916888	0.61	rs199454	ENSG00000261575.2	RP11-259G18.1	-12.84	1.39e-32	2.36e-29	-0.63	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46267037~46268694:+
LGG	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-12.84	1.39e-32	2.36e-29	-0.63	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
LGG	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-12.84	1.39e-32	2.36e-29	-0.63	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
LGG	cis	rs11155671	0.53	rs9371215	ENSG00000216621.7	RP11-244K5.6	12.84	1.39e-32	2.37e-29	0.59	0.51	Testicular germ cell tumor;	chr6:149873162	chr6:149934527~149936782:+
LGG	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	12.84	1.4e-32	2.37e-29	0.65	0.51	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
LGG	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	12.84	1.42e-32	2.4e-29	0.65	0.51	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
LGG	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-12.84	1.42e-32	2.41e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
LGG	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-12.83	1.44e-32	2.44e-29	-0.88	-0.51	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
LGG	cis	rs8062405	0.755	rs62034325	ENSG00000271623.1	RP11-435I10.5	-12.83	1.44e-32	2.45e-29	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28364700~28365333:+
LGG	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-12.83	1.45e-32	2.45e-29	-0.62	-0.51	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
LGG	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	-12.83	1.48e-32	2.51e-29	-0.61	-0.51	Depression;	chr6:28142370	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	12.83	1.49e-32	2.52e-29	0.62	0.51	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
LGG	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	12.83	1.51e-32	2.56e-29	0.39	0.51	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
LGG	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	12.83	1.52e-32	2.57e-29	0.57	0.51	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	12.83	1.52e-32	2.57e-29	0.57	0.51	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
LGG	cis	rs2486288	0.656	rs8024620	ENSG00000259433.2	CTD-2651B20.4	12.83	1.54e-32	2.61e-29	0.56	0.51	Glomerular filtration rate;	chr15:45282131	chr15:45330209~45332634:-
LGG	cis	rs1150668	0.799	rs1150707	ENSG00000199851.2	U3	12.83	1.55e-32	2.63e-29	0.68	0.51	Pubertal anthropometrics;	chr6:28229827	chr6:28015568~28015777:+
LGG	cis	rs1150668	0.768	rs1233713	ENSG00000199851.2	U3	12.83	1.55e-32	2.63e-29	0.68	0.51	Pubertal anthropometrics;	chr6:28230503	chr6:28015568~28015777:+
LGG	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	12.83	1.57e-32	2.65e-29	0.57	0.51	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
LGG	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-12.82	1.57e-32	2.66e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
LGG	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-12.82	1.57e-32	2.66e-29	-0.63	-0.51	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
LGG	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	12.82	1.57e-32	2.66e-29	0.64	0.51	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
LGG	cis	rs651907	0.557	rs34947019	ENSG00000244119.1	PDCL3P4	12.82	1.59e-32	2.7e-29	0.4	0.51	Colorectal cancer;	chr3:101813391	chr3:101712472~101713191:+
LGG	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	12.82	1.6e-32	2.71e-29	0.39	0.51	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
LGG	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	12.82	1.62e-32	2.74e-29	0.46	0.51	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
LGG	cis	rs6452524	1	rs4590162	ENSG00000248112.1	RP11-78C3.1	12.82	1.62e-32	2.74e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:82919376~82921119:-
LGG	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-12.82	1.63e-32	2.75e-29	-0.66	-0.51	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	12.82	1.64e-32	2.78e-29	0.61	0.51	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
LGG	cis	rs8062405	0.789	rs1968752	ENSG00000271623.1	RP11-435I10.5	-12.82	1.65e-32	2.79e-29	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28364700~28365333:+
LGG	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	12.82	1.66e-32	2.8e-29	0.76	0.51	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
LGG	cis	rs8062405	0.722	rs3785354	ENSG00000271623.1	RP11-435I10.5	-12.82	1.66e-32	2.8e-29	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28364700~28365333:+
LGG	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	12.82	1.66e-32	2.81e-29	0.56	0.51	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	12.82	1.66e-32	2.81e-29	0.56	0.51	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	12.82	1.66e-32	2.81e-29	0.56	0.51	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	12.82	1.66e-32	2.81e-29	0.56	0.51	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	12.82	1.67e-32	2.82e-29	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
LGG	cis	rs11155671	0.53	rs9968871	ENSG00000216621.7	RP11-244K5.6	12.82	1.67e-32	2.82e-29	0.58	0.51	Testicular germ cell tumor;	chr6:149888060	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs9969044	ENSG00000216621.7	RP11-244K5.6	12.82	1.67e-32	2.82e-29	0.58	0.51	Testicular germ cell tumor;	chr6:149888068	chr6:149934527~149936782:+
LGG	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.85e-29	0.57	0.51	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.85e-29	0.57	0.51	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.85e-29	0.57	0.51	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.85e-29	0.57	0.51	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.85e-29	0.57	0.51	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.86e-29	0.57	0.51	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.86e-29	0.57	0.51	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.86e-29	0.57	0.51	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	12.82	1.69e-32	2.86e-29	0.57	0.51	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
LGG	cis	rs2486288	0.656	rs12911861	ENSG00000259433.2	CTD-2651B20.4	12.82	1.71e-32	2.89e-29	0.56	0.51	Glomerular filtration rate;	chr15:45274520	chr15:45330209~45332634:-
LGG	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	12.81	1.74e-32	2.94e-29	0.63	0.51	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
LGG	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-12.81	1.74e-32	2.94e-29	-0.61	-0.51	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
LGG	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	12.81	1.75e-32	2.96e-29	0.39	0.51	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
LGG	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-12.81	1.76e-32	2.97e-29	-0.58	-0.51	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
LGG	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-12.81	1.78e-32	3e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-12.81	1.81e-32	3.06e-29	-0.82	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
LGG	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-12.81	1.82e-32	3.07e-29	-0.74	-0.51	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
LGG	cis	rs853679	1	rs735765	ENSG00000216901.1	AL022393.7	12.81	1.82e-32	3.07e-29	0.89	0.51	Depression;	chr6:28202519	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	12.81	1.83e-32	3.08e-29	0.62	0.51	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	12.81	1.83e-32	3.08e-29	0.62	0.51	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	12.81	1.83e-32	3.08e-29	0.62	0.51	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	12.81	1.83e-32	3.08e-29	0.62	0.51	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	12.81	1.83e-32	3.08e-29	0.62	0.51	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
LGG	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	12.8	1.92e-32	3.24e-29	0.6	0.51	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
LGG	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-12.8	1.94e-32	3.26e-29	-0.58	-0.51	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
LGG	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	12.8	1.94e-32	3.26e-29	0.66	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
LGG	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	12.8	1.95e-32	3.28e-29	0.61	0.51	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
LGG	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	12.8	1.96e-32	3.29e-29	0.61	0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
LGG	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	12.8	2.01e-32	3.37e-29	0.45	0.51	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	12.8	2.01e-32	3.37e-29	0.45	0.51	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
LGG	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-12.8	2.03e-32	3.4e-29	-0.53	-0.51	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
LGG	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	12.8	2.03e-32	3.42e-29	0.46	0.51	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
LGG	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-12.8	2.03e-32	3.42e-29	-0.63	-0.51	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
LGG	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	12.8	2.07e-32	3.48e-29	0.6	0.51	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
LGG	cis	rs6452524	0.534	rs17284134	ENSG00000248112.1	RP11-78C3.1	-12.8	2.07e-32	3.48e-29	-0.66	-0.51	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:82919376~82921119:-
LGG	cis	rs2486288	0.656	rs12910009	ENSG00000259433.2	CTD-2651B20.4	12.8	2.08e-32	3.49e-29	0.56	0.51	Glomerular filtration rate;	chr15:45280210	chr15:45330209~45332634:-
LGG	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	12.8	2.09e-32	3.51e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
LGG	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-12.8	2.09e-32	3.51e-29	-0.62	-0.51	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
LGG	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-12.79	2.09e-32	3.51e-29	-0.61	-0.51	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
LGG	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-12.79	2.09e-32	3.51e-29	-0.61	-0.51	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
LGG	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	12.79	2.1e-32	3.52e-29	0.46	0.51	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	12.79	2.1e-32	3.52e-29	0.46	0.51	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
LGG	cis	rs4682868	0.581	rs6774801	ENSG00000273328.4	RP11-141M3.6	12.79	2.12e-32	3.55e-29	0.59	0.51	Monocyte percentage of white cells;	chr3:42882284	chr3:42809414~42908105:+
LGG	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-12.79	2.12e-32	3.56e-29	-0.81	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-12.79	2.15e-32	3.6e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
LGG	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-12.79	2.15e-32	3.6e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
LGG	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-12.79	2.15e-32	3.61e-29	-0.61	-0.51	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
LGG	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-12.79	2.16e-32	3.62e-29	-0.58	-0.51	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-12.79	2.16e-32	3.62e-29	-0.58	-0.51	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-12.79	2.16e-32	3.62e-29	-0.59	-0.51	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
LGG	cis	rs12495178	0.599	rs2325006	ENSG00000239519.1	CADM2-AS1	12.79	2.16e-32	3.63e-29	0.58	0.51	Body mass index;	chr3:85970644	chr3:85992183~86028007:-
LGG	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-12.79	2.2e-32	3.68e-29	-0.62	-0.51	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
LGG	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-12.79	2.21e-32	3.7e-29	-0.7	-0.51	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
LGG	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-12.79	2.22e-32	3.73e-29	-0.59	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
LGG	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	12.79	2.23e-32	3.73e-29	0.4	0.51	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
LGG	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-12.79	2.23e-32	3.74e-29	-0.49	-0.51	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
LGG	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	12.79	2.24e-32	3.76e-29	0.57	0.51	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	12.79	2.24e-32	3.76e-29	0.57	0.51	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
LGG	cis	rs651907	0.535	rs13084113	ENSG00000244119.1	PDCL3P4	12.79	2.25e-32	3.77e-29	0.4	0.51	Colorectal cancer;	chr3:101815195	chr3:101712472~101713191:+
LGG	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	12.79	2.25e-32	3.78e-29	0.57	0.51	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
LGG	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-12.79	2.27e-32	3.8e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-12.79	2.27e-32	3.8e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-12.79	2.27e-32	3.8e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-12.79	2.27e-32	3.8e-29	-0.61	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000235689.1	AP000351.13	12.79	2.27e-32	3.81e-29	0.62	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:24006305~24008258:-
LGG	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	12.79	2.29e-32	3.83e-29	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	12.79	2.29e-32	3.83e-29	0.6	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
LGG	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-12.78	2.3e-32	3.85e-29	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-12.78	2.3e-32	3.85e-29	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-12.78	2.3e-32	3.85e-29	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-12.78	2.3e-32	3.85e-29	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-12.78	2.3e-32	3.85e-29	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-12.78	2.3e-32	3.85e-29	-0.6	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
LGG	cis	rs56262138	0.5	rs35259978	ENSG00000239519.1	CADM2-AS1	12.78	2.33e-32	3.89e-29	0.58	0.51	Educational attainment (years of education);	chr3:85988801	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs35012249	ENSG00000239519.1	CADM2-AS1	12.78	2.33e-32	3.89e-29	0.58	0.51	Educational attainment (years of education);	chr3:85989111	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs62261591	ENSG00000239519.1	CADM2-AS1	12.78	2.33e-32	3.89e-29	0.58	0.51	Educational attainment (years of education);	chr3:85989540	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs62261592	ENSG00000239519.1	CADM2-AS1	12.78	2.33e-32	3.89e-29	0.58	0.51	Educational attainment (years of education);	chr3:85989612	chr3:85992183~86028007:-
LGG	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	12.78	2.33e-32	3.9e-29	0.4	0.51	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
LGG	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	12.78	2.34e-32	3.92e-29	0.58	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
LGG	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-12.78	2.35e-32	3.92e-29	-0.7	-0.51	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
LGG	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	12.78	2.36e-32	3.94e-29	0.62	0.51	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	12.78	2.36e-32	3.94e-29	0.62	0.51	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
LGG	cis	rs6452524	1	rs67683443	ENSG00000248112.1	RP11-78C3.1	12.78	2.36e-32	3.94e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:82919376~82921119:-
LGG	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	12.78	2.36e-32	3.95e-29	0.61	0.51	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
LGG	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-12.78	2.39e-32	4e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
LGG	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	12.78	2.4e-32	4.01e-29	0.88	0.51	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
LGG	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	12.78	2.41e-32	4.03e-29	0.61	0.51	Depression;	chr6:28140454	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	12.78	2.41e-32	4.03e-29	0.61	0.51	Depression;	chr6:28141189	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	12.78	2.41e-32	4.03e-29	0.61	0.51	Depression;	chr6:28141484	chr6:28161781~28169594:+
LGG	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	-12.78	2.44e-32	4.08e-29	-0.52	-0.51	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
LGG	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	12.78	2.46e-32	4.11e-29	0.46	0.51	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
LGG	cis	rs4819052	0.851	rs2838864	ENSG00000223768.1	LINC00205	12.78	2.48e-32	4.14e-29	0.56	0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45293285~45297354:+
LGG	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	12.78	2.51e-32	4.2e-29	0.45	0.51	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
LGG	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	12.78	2.52e-32	4.2e-29	0.69	0.51	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
LGG	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	12.78	2.52e-32	4.21e-29	0.88	0.51	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
LGG	cis	rs2282300	1	rs12796693	ENSG00000254532.1	RP11-624D11.2	12.78	2.53e-32	4.22e-29	0.73	0.51	Morning vs. evening chronotype;	chr11:30408036	chr11:30044058~30084343:-
LGG	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	12.77	2.54e-32	4.24e-29	0.87	0.51	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
LGG	cis	rs6452524	0.967	rs62372752	ENSG00000248112.1	RP11-78C3.1	12.77	2.55e-32	4.26e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:82919376~82921119:-
LGG	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	12.77	2.56e-32	4.28e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	12.77	2.56e-32	4.28e-29	0.93	0.51	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
LGG	cis	rs4713118	0.955	rs9468206	ENSG00000199851.2	U3	12.77	2.57e-32	4.28e-29	0.75	0.51	Parkinson's disease;	chr6:27722674	chr6:28015568~28015777:+
LGG	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-12.77	2.58e-32	4.3e-29	-0.44	-0.51	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
LGG	cis	rs8062405	0.691	rs743590	ENSG00000271623.1	RP11-435I10.5	-12.77	2.58e-32	4.31e-29	-0.61	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28364700~28365333:+
LGG	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-12.77	2.59e-32	4.31e-29	-0.43	-0.51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
LGG	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	12.77	2.59e-32	4.32e-29	0.56	0.51	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	12.77	2.59e-32	4.32e-29	0.93	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
LGG	cis	rs2486288	0.656	rs62026703	ENSG00000259433.2	CTD-2651B20.4	12.77	2.62e-32	4.37e-29	0.55	0.51	Glomerular filtration rate;	chr15:45277731	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs7165039	ENSG00000259433.2	CTD-2651B20.4	12.77	2.62e-32	4.37e-29	0.55	0.51	Glomerular filtration rate;	chr15:45278215	chr15:45330209~45332634:-
LGG	cis	rs6452524	1	rs10080123	ENSG00000248112.1	RP11-78C3.1	-12.77	2.63e-32	4.39e-29	-0.65	-0.51	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:82919376~82921119:-
LGG	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	12.77	2.64e-32	4.4e-29	0.63	0.51	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
LGG	cis	rs651907	0.535	rs35810977	ENSG00000244119.1	PDCL3P4	12.77	2.64e-32	4.41e-29	0.39	0.51	Colorectal cancer;	chr3:101812536	chr3:101712472~101713191:+
LGG	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-12.77	2.66e-32	4.43e-29	-0.41	-0.51	Height;	chr11:118747911	chr11:118791254~118793137:+
LGG	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	12.77	2.68e-32	4.47e-29	0.53	0.51	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
LGG	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-12.77	2.69e-32	4.48e-29	-0.62	-0.51	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
LGG	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-12.77	2.69e-32	4.48e-29	-0.42	-0.51	Height;	chr11:118737916	chr11:118791254~118793137:+
LGG	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-12.77	2.7e-32	4.49e-29	-0.58	-0.51	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
LGG	cis	rs17345786	0.511	rs12639028	ENSG00000244119.1	PDCL3P4	12.77	2.71e-32	4.51e-29	0.41	0.51	Colonoscopy-negative controls vs population controls;	chr3:101627189	chr3:101712472~101713191:+
LGG	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	12.77	2.73e-32	4.54e-29	0.61	0.51	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
LGG	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-12.77	2.74e-32	4.57e-29	-0.57	-0.51	Height;	chr3:53029908	chr3:53064283~53065091:-
LGG	cis	rs4713118	0.869	rs9461405	ENSG00000199851.2	U3	12.77	2.76e-32	4.59e-29	0.73	0.51	Parkinson's disease;	chr6:27751596	chr6:28015568~28015777:+
LGG	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	12.77	2.76e-32	4.6e-29	0.61	0.51	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
LGG	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-12.77	2.78e-32	4.63e-29	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
LGG	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-12.76	2.79e-32	4.64e-29	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-12.76	2.79e-32	4.64e-29	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-12.76	2.79e-32	4.64e-29	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-12.76	2.79e-32	4.64e-29	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
LGG	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	12.76	2.8e-32	4.67e-29	0.72	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
LGG	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-12.76	2.81e-32	4.67e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
LGG	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-12.76	2.83e-32	4.71e-29	-0.58	-0.51	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-12.76	2.83e-32	4.71e-29	-0.58	-0.51	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
LGG	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	12.76	2.84e-32	4.73e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
LGG	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	12.76	2.85e-32	4.73e-29	0.56	0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
LGG	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	12.76	2.9e-32	4.83e-29	0.55	0.51	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
LGG	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-12.76	2.95e-32	4.9e-29	-0.61	-0.51	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
LGG	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	12.76	2.97e-32	4.93e-29	0.85	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
LGG	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	12.76	2.97e-32	4.93e-29	0.85	0.51	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
LGG	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	12.76	2.98e-32	4.95e-29	0.71	0.51	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
LGG	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-12.76	2.98e-32	4.95e-29	-0.41	-0.51	Height;	chr11:118737823	chr11:118791254~118793137:+
LGG	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-12.76	2.98e-32	4.95e-29	-0.62	-0.51	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
LGG	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-12.76	2.99e-32	4.96e-29	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
LGG	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-12.76	2.99e-32	4.96e-29	-0.65	-0.51	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
LGG	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-12.76	3.02e-32	5.02e-29	-0.56	-0.51	Height;	chr3:52975027	chr3:53064283~53065091:-
LGG	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	12.76	3.05e-32	5.07e-29	0.62	0.51	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
LGG	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-12.75	3.09e-32	5.13e-29	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-12.75	3.09e-32	5.13e-29	-0.63	-0.51	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
LGG	cis	rs2486288	0.656	rs12908818	ENSG00000259433.2	CTD-2651B20.4	12.75	3.1e-32	5.15e-29	0.55	0.51	Glomerular filtration rate;	chr15:45279470	chr15:45330209~45332634:-
LGG	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-12.75	3.1e-32	5.15e-29	-0.66	-0.51	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
LGG	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	12.75	3.13e-32	5.19e-29	0.61	0.51	Depression;	chr6:28159925	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	12.75	3.13e-32	5.19e-29	0.61	0.51	Depression;	chr6:28159932	chr6:28161781~28169594:+
LGG	cis	rs2486288	0.656	rs11639349	ENSG00000259433.2	CTD-2651B20.4	12.75	3.14e-32	5.21e-29	0.55	0.51	Glomerular filtration rate;	chr15:45276062	chr15:45330209~45332634:-
LGG	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	12.75	3.17e-32	5.26e-29	0.77	0.51	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
LGG	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-12.75	3.18e-32	5.28e-29	-0.39	-0.51	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
LGG	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-12.75	3.19e-32	5.29e-29	-0.61	-0.51	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
LGG	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-12.75	3.2e-32	5.31e-29	-0.61	-0.51	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
LGG	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-12.75	3.22e-32	5.34e-29	-0.61	-0.51	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
LGG	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	12.75	3.25e-32	5.4e-29	0.44	0.51	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
LGG	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	12.75	3.26e-32	5.41e-29	0.45	0.51	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
LGG	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-12.75	3.27e-32	5.43e-29	-0.8	-0.51	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
LGG	cis	rs1475911	0.656	rs9980065	ENSG00000184385.2	UMODL1-AS1	12.75	3.32e-32	5.51e-29	0.68	0.51	IgG glycosylation;	chr21:42107962	chr21:42102134~42108534:-
LGG	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-12.75	3.36e-32	5.58e-29	-0.61	-0.51	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
LGG	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	12.74	3.4e-32	5.64e-29	0.6	0.51	Depression;	chr6:28140307	chr6:28161781~28169594:+
LGG	cis	rs56262138	0.5	rs35772683	ENSG00000239519.1	CADM2-AS1	12.74	3.41e-32	5.66e-29	0.58	0.51	Educational attainment (years of education);	chr3:85996916	chr3:85992183~86028007:-
LGG	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-12.74	3.43e-32	5.69e-29	-0.56	-0.51	Height;	chr3:52972039	chr3:53064283~53065091:-
LGG	cis	rs8062405	0.691	rs11646653	ENSG00000271623.1	RP11-435I10.5	12.74	3.44e-32	5.71e-29	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28364700~28365333:+
LGG	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	12.74	3.51e-32	5.81e-29	0.68	0.51	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
LGG	cis	rs916888	0.61	rs199438	ENSG00000261575.2	RP11-259G18.1	12.74	3.53e-32	5.85e-29	0.62	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46267037~46268694:+
LGG	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	12.74	3.54e-32	5.87e-29	0.54	0.51	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
LGG	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-12.74	3.55e-32	5.88e-29	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
LGG	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-12.74	3.58e-32	5.93e-29	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
LGG	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	12.74	3.59e-32	5.94e-29	0.68	0.51	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
LGG	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	12.74	3.59e-32	5.95e-29	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
LGG	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	12.74	3.61e-32	5.97e-29	0.57	0.5	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	12.74	3.61e-32	5.97e-29	0.57	0.5	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
LGG	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-12.74	3.62e-32	5.99e-29	-0.7	-0.5	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
LGG	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-12.74	3.68e-32	6.08e-29	-0.58	-0.5	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
LGG	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-12.74	3.69e-32	6.11e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-12.74	3.69e-32	6.11e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-12.74	3.69e-32	6.11e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-12.74	3.69e-32	6.11e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
LGG	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	12.74	3.7e-32	6.12e-29	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
LGG	cis	rs2486288	0.656	rs7166580	ENSG00000259433.2	CTD-2651B20.4	12.73	3.74e-32	6.18e-29	0.55	0.5	Glomerular filtration rate;	chr15:45279011	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs2413768	ENSG00000259433.2	CTD-2651B20.4	12.73	3.75e-32	6.2e-29	0.56	0.5	Glomerular filtration rate;	chr15:45269786	chr15:45330209~45332634:-
LGG	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-12.73	3.75e-32	6.2e-29	-0.53	-0.5	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
LGG	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-12.73	3.77e-32	6.24e-29	-0.64	-0.5	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
LGG	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-12.73	3.8e-32	6.29e-29	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-12.73	3.81e-32	6.3e-29	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-12.73	3.85e-32	6.36e-29	-0.61	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
LGG	cis	rs7315956	1	rs7315956	ENSG00000257139.1	RP11-320P7.2	-12.73	3.86e-32	6.37e-29	-0.6	-0.5	Testicular germ cell tumor;	chr12:70170085	chr12:70180338~70202004:+
LGG	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-12.73	3.86e-32	6.38e-29	-0.53	-0.5	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
LGG	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-12.73	3.88e-32	6.41e-29	-0.71	-0.5	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
LGG	cis	rs11155671	0.53	rs7742993	ENSG00000216621.7	RP11-244K5.6	12.73	3.9e-32	6.44e-29	0.57	0.5	Testicular germ cell tumor;	chr6:149883959	chr6:149934527~149936782:+
LGG	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	12.73	3.93e-32	6.48e-29	0.65	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
LGG	cis	rs6452524	0.935	rs7718284	ENSG00000248112.1	RP11-78C3.1	-12.73	3.97e-32	6.54e-29	-0.66	-0.5	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:82919376~82921119:-
LGG	cis	rs8064024	0.719	rs17137286	ENSG00000267077.1	RP11-127I20.5	12.73	3.99e-32	6.58e-29	0.5	0.5	Cancer;	chr16:4802891	chr16:4795265~4796532:-
LGG	cis	rs8064024	0.764	rs3827528	ENSG00000267077.1	RP11-127I20.5	12.73	3.99e-32	6.58e-29	0.5	0.5	Cancer;	chr16:4803091	chr16:4795265~4796532:-
LGG	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	12.73	3.99e-32	6.58e-29	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
LGG	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-12.73	4.02e-32	6.63e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
LGG	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	12.73	4.05e-32	6.68e-29	0.66	0.5	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
LGG	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-12.73	4.06e-32	6.68e-29	-0.61	-0.5	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
LGG	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-12.72	4.08e-32	6.73e-29	-0.59	-0.5	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
LGG	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	12.72	4.14e-32	6.82e-29	0.61	0.5	Depression;	chr6:28071808	chr6:28161781~28169594:+
LGG	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-12.72	4.14e-32	6.82e-29	-0.57	-0.5	Height;	chr3:52936861	chr3:53064283~53065091:-
LGG	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-12.72	4.14e-32	6.82e-29	-0.57	-0.5	Height;	chr3:52938846	chr3:53064283~53065091:-
LGG	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-12.72	4.14e-32	6.82e-29	-0.57	-0.5	Height;	chr3:52941053	chr3:53064283~53065091:-
LGG	cis	rs56262138	0.5	rs34289000	ENSG00000239519.1	CADM2-AS1	12.72	4.16e-32	6.85e-29	0.58	0.5	Educational attainment (years of education);	chr3:85997905	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs35242846	ENSG00000239519.1	CADM2-AS1	12.72	4.16e-32	6.85e-29	0.58	0.5	Educational attainment (years of education);	chr3:85998085	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs12488773	ENSG00000239519.1	CADM2-AS1	12.72	4.16e-32	6.85e-29	0.58	0.5	Educational attainment (years of education);	chr3:85999097	chr3:85992183~86028007:-
LGG	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-12.72	4.19e-32	6.9e-29	-0.63	-0.5	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
LGG	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-12.72	4.22e-32	6.95e-29	-0.67	-0.5	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
LGG	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-12.72	4.23e-32	6.97e-29	-0.66	-0.5	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
LGG	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	12.72	4.26e-32	7.01e-29	0.75	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
LGG	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	12.72	4.26e-32	7.01e-29	0.75	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
LGG	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	12.72	4.29e-32	7.06e-29	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
LGG	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-12.72	4.31e-32	7.09e-29	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	12.72	4.33e-32	7.13e-29	0.57	0.5	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	12.72	4.4e-32	7.24e-29	0.84	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
LGG	cis	rs494459	0.733	rs556437	ENSG00000255239.1	AP002954.6	12.72	4.43e-32	7.28e-29	0.58	0.5	Height;	chr11:118835044	chr11:118688039~118690600:-
LGG	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-12.72	4.43e-32	7.28e-29	-0.74	-0.5	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
LGG	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	12.72	4.49e-32	7.38e-29	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
LGG	cis	rs8062405	0.755	rs2077031	ENSG00000271623.1	RP11-435I10.5	-12.71	4.49e-32	7.39e-29	-0.61	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28364700~28365333:+
LGG	cis	rs7216064	0.953	rs10445361	ENSG00000278219.1	AC145343.1	12.71	4.5e-32	7.39e-29	0.6	0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67966122	chr17:68101538~68101639:+
LGG	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-12.71	4.52e-32	7.42e-29	-0.62	-0.5	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
LGG	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	12.71	4.54e-32	7.46e-29	0.54	0.5	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
LGG	cis	rs6452524	0.508	rs256795	ENSG00000248112.1	RP11-78C3.1	-12.71	4.54e-32	7.46e-29	-0.63	-0.5	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:82919376~82921119:-
LGG	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	12.71	4.58e-32	7.52e-29	0.39	0.5	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
LGG	cis	rs2486288	0.656	rs6493145	ENSG00000259433.2	CTD-2651B20.4	12.71	4.63e-32	7.61e-29	0.55	0.5	Glomerular filtration rate;	chr15:45281664	chr15:45330209~45332634:-
LGG	cis	rs11155671	0.53	rs1334510	ENSG00000216621.7	RP11-244K5.6	12.71	4.65e-32	7.63e-29	0.57	0.5	Testicular germ cell tumor;	chr6:149880043	chr6:149934527~149936782:+
LGG	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-12.71	4.66e-32	7.65e-29	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
LGG	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-12.71	4.66e-32	7.66e-29	-0.59	-0.5	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
LGG	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	12.71	4.68e-32	7.69e-29	0.63	0.5	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
LGG	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-12.71	4.7e-32	7.72e-29	-0.53	-0.5	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
LGG	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-12.71	4.7e-32	7.72e-29	-0.53	-0.5	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
LGG	cis	rs2486288	0.656	rs12440356	ENSG00000259433.2	CTD-2651B20.4	-12.71	4.79e-32	7.85e-29	-0.55	-0.5	Glomerular filtration rate;	chr15:45275331	chr15:45330209~45332634:-
LGG	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	12.71	4.84e-32	7.93e-29	0.65	0.5	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
LGG	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	12.71	4.9e-32	8.02e-29	0.53	0.5	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
LGG	cis	rs6452524	0.934	rs12153440	ENSG00000248112.1	RP11-78C3.1	12.71	4.93e-32	8.07e-29	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:82919376~82921119:-
LGG	cis	rs916888	0.61	rs199529	ENSG00000232300.1	FAM215B	12.7	4.95e-32	8.1e-29	0.69	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46558830~46562795:-
LGG	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	12.7	5.01e-32	8.2e-29	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
LGG	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-12.7	5.13e-32	8.39e-29	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
LGG	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	12.7	5.15e-32	8.43e-29	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
LGG	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-12.7	5.18e-32	8.47e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
LGG	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	12.7	5.24e-32	8.57e-29	0.84	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	12.7	5.24e-32	8.57e-29	0.84	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	12.7	5.24e-32	8.57e-29	0.84	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
LGG	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	12.7	5.25e-32	8.59e-29	0.67	0.5	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
LGG	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-12.7	5.26e-32	8.6e-29	-0.58	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
LGG	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	12.7	5.27e-32	8.61e-29	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
LGG	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-12.7	5.28e-32	8.63e-29	-1.04	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
LGG	cis	rs8064024	0.599	rs2456779	ENSG00000267077.1	RP11-127I20.5	12.7	5.29e-32	8.64e-29	0.53	0.5	Cancer;	chr16:4875816	chr16:4795265~4796532:-
LGG	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	12.7	5.34e-32	8.72e-29	0.84	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
LGG	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-12.7	5.36e-32	8.75e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
LGG	cis	rs916888	0.61	rs142167	ENSG00000262500.1	RP11-259G18.2	-12.7	5.38e-32	8.79e-29	-0.66	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46243606~46245044:+
LGG	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	12.7	5.4e-32	8.82e-29	0.61	0.5	Depression;	chr6:28159843	chr6:28161781~28169594:+
LGG	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-12.7	5.4e-32	8.82e-29	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
LGG	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-12.7	5.42e-32	8.86e-29	-0.63	-0.5	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
LGG	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-12.69	5.43e-32	8.87e-29	-0.6	-0.5	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
LGG	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	12.69	5.44e-32	8.88e-29	0.56	0.5	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
LGG	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	12.69	5.52e-32	9.01e-29	0.5	0.5	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
LGG	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-12.69	5.55e-32	9.05e-29	-0.6	-0.5	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
LGG	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-12.69	5.57e-32	9.08e-29	-0.53	-0.5	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
LGG	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-12.69	5.57e-32	9.08e-29	-0.53	-0.5	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
LGG	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-12.69	5.58e-32	9.1e-29	-0.52	-0.5	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
LGG	cis	rs4713118	0.868	rs35069907	ENSG00000199851.2	U3	12.69	5.65e-32	9.21e-29	0.78	0.5	Parkinson's disease;	chr6:27778913	chr6:28015568~28015777:+
LGG	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-12.69	5.65e-32	9.22e-29	-0.67	-0.5	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
LGG	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	12.69	5.68e-32	9.27e-29	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
LGG	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-12.69	5.74e-32	9.36e-29	-0.66	-0.5	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
LGG	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-12.69	5.74e-32	9.36e-29	-0.66	-0.5	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
LGG	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-12.69	5.74e-32	9.36e-29	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
LGG	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-12.69	5.75e-32	9.38e-29	-0.7	-0.5	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
LGG	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-12.69	5.77e-32	9.4e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-12.69	5.77e-32	9.4e-29	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
LGG	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-12.69	5.81e-32	9.47e-29	-0.66	-0.5	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
LGG	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	12.69	5.81e-32	9.48e-29	0.49	0.5	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
LGG	cis	rs853679	0.824	rs34712084	ENSG00000199851.2	U3	12.69	5.84e-32	9.51e-29	1.05	0.5	Depression;	chr6:28076050	chr6:28015568~28015777:+
LGG	cis	rs853679	0.824	rs1321505	ENSG00000199851.2	U3	12.69	5.84e-32	9.51e-29	1.05	0.5	Depression;	chr6:28085045	chr6:28015568~28015777:+
LGG	cis	rs853679	0.882	rs9468287	ENSG00000199851.2	U3	12.69	5.84e-32	9.51e-29	1.05	0.5	Depression;	chr6:28111963	chr6:28015568~28015777:+
LGG	cis	rs853679	0.882	rs9461432	ENSG00000199851.2	U3	12.69	5.84e-32	9.51e-29	1.05	0.5	Depression;	chr6:28119105	chr6:28015568~28015777:+
LGG	cis	rs853679	0.882	rs4713139	ENSG00000199851.2	U3	12.69	5.84e-32	9.51e-29	1.05	0.5	Depression;	chr6:28124907	chr6:28015568~28015777:+
LGG	cis	rs2980439	0.557	rs2976876	ENSG00000173295.6	FAM86B3P	-12.68	6e-32	9.76e-29	-0.52	-0.5	Neuroticism;	chr8:8461340	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	12.68	6.14e-32	9.99e-29	0.63	0.5	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
LGG	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	12.68	6.17e-32	1e-28	0.62	0.5	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
LGG	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	12.68	6.2e-32	1.01e-28	0.62	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
LGG	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	12.68	6.29e-32	1.02e-28	0.62	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
LGG	cis	rs2486288	0.656	rs1706768	ENSG00000259433.2	CTD-2651B20.4	12.68	6.33e-32	1.03e-28	0.54	0.5	Glomerular filtration rate;	chr15:45277245	chr15:45330209~45332634:-
LGG	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-12.68	6.36e-32	1.03e-28	-0.59	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	12.68	6.37e-32	1.04e-28	0.63	0.5	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
LGG	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	12.68	6.42e-32	1.04e-28	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
LGG	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-12.68	6.42e-32	1.04e-28	-0.58	-0.5	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
LGG	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-12.68	6.47e-32	1.05e-28	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
LGG	cis	rs2486288	0.656	rs6493144	ENSG00000259433.2	CTD-2651B20.4	-12.68	6.51e-32	1.06e-28	-0.55	-0.5	Glomerular filtration rate;	chr15:45281291	chr15:45330209~45332634:-
LGG	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	12.68	6.51e-32	1.06e-28	0.6	0.5	Depression;	chr6:28139876	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	12.68	6.51e-32	1.06e-28	0.6	0.5	Depression;	chr6:28139998	chr6:28161781~28169594:+
LGG	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	12.68	6.54e-32	1.06e-28	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
LGG	cis	rs4819052	0.851	rs2838832	ENSG00000215447.6	BX322557.10	12.67	6.64e-32	1.08e-28	0.39	0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45288052~45291738:+
LGG	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	12.67	6.64e-32	1.08e-28	0.58	0.5	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
LGG	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-12.67	6.76e-32	1.1e-28	-0.68	-0.5	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
LGG	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-12.67	6.78e-32	1.1e-28	-0.58	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
LGG	cis	rs6452524	0.934	rs6452510	ENSG00000248112.1	RP11-78C3.1	12.67	6.8e-32	1.1e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs6452509	ENSG00000248112.1	RP11-78C3.1	12.67	7.1e-32	1.15e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:82919376~82921119:-
LGG	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-12.67	7.13e-32	1.16e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
LGG	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-12.67	7.21e-32	1.17e-28	-0.67	-0.5	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
LGG	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	12.66	7.26e-32	1.18e-28	0.93	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	12.66	7.26e-32	1.18e-28	0.93	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	12.66	7.26e-32	1.18e-28	0.93	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
LGG	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-12.66	7.28e-32	1.18e-28	-0.56	-0.5	Height;	chr3:52971094	chr3:53064283~53065091:-
LGG	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-12.66	7.39e-32	1.2e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
LGG	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	12.66	7.44e-32	1.21e-28	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
LGG	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	12.66	7.48e-32	1.21e-28	0.62	0.5	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
LGG	cis	rs7315956	0.826	rs6581921	ENSG00000257139.1	RP11-320P7.2	-12.66	7.49e-32	1.21e-28	-0.6	-0.5	Testicular germ cell tumor;	chr12:70145123	chr12:70180338~70202004:+
LGG	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-12.66	7.57e-32	1.23e-28	-0.41	-0.5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	12.66	7.68e-32	1.24e-28	0.62	0.5	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
LGG	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	-12.66	7.85e-32	1.27e-28	-0.6	-0.5	Depression;	chr6:28109824	chr6:28161781~28169594:+
LGG	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	-12.66	7.86e-32	1.27e-28	-0.52	-0.5	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
LGG	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	12.66	7.86e-32	1.27e-28	0.6	0.5	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
LGG	cis	rs2980439	0.557	rs2921056	ENSG00000173295.6	FAM86B3P	-12.65	7.95e-32	1.29e-28	-0.52	-0.5	Neuroticism;	chr8:8461672	chr8:8228595~8244865:+
LGG	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	12.65	8.02e-32	1.3e-28	0.62	0.5	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	12.65	8.02e-32	1.3e-28	0.62	0.5	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
LGG	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	12.65	8.14e-32	1.32e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
LGG	cis	rs741668	0.641	rs9534306	ENSG00000235903.6	CPB2-AS1	12.65	8.26e-32	1.33e-28	0.5	0.5	Cerebrospinal fluid clusterin levels;	chr13:46069100	chr13:46052806~46113332:+
LGG	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	12.65	8.31e-32	1.34e-28	0.55	0.5	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	12.65	8.34e-32	1.35e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
LGG	cis	rs7826238	0.524	rs2921055	ENSG00000173295.6	FAM86B3P	-12.65	8.37e-32	1.35e-28	-0.52	-0.5	Systolic blood pressure;	chr8:8461832	chr8:8228595~8244865:+
LGG	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	12.65	8.4e-32	1.36e-28	0.43	0.5	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
LGG	cis	rs6452524	0.967	rs62374399	ENSG00000248112.1	RP11-78C3.1	12.65	8.41e-32	1.36e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs62374401	ENSG00000248112.1	RP11-78C3.1	12.65	8.41e-32	1.36e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:82919376~82921119:-
LGG	cis	rs8062405	0.755	rs1074631	ENSG00000271623.1	RP11-435I10.5	12.65	8.45e-32	1.36e-28	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28364700~28365333:+
LGG	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-12.65	8.55e-32	1.38e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
LGG	cis	rs11098499	0.73	rs12505735	ENSG00000249244.1	RP11-548H18.2	12.65	8.57e-32	1.38e-28	0.56	0.5	Corneal astigmatism;	chr4:119611801	chr4:119391831~119395335:-
LGG	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-12.65	8.57e-32	1.38e-28	-0.66	-0.5	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
LGG	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-12.65	8.62e-32	1.39e-28	-0.56	-0.5	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
LGG	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-12.65	8.69e-32	1.4e-28	-0.41	-0.5	Height;	chr11:118781100	chr11:118791254~118793137:+
LGG	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-12.64	8.77e-32	1.42e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
LGG	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-12.64	8.79e-32	1.42e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
LGG	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-12.64	8.87e-32	1.43e-28	-0.69	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
LGG	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-12.64	8.88e-32	1.43e-28	-0.54	-0.5	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
LGG	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	12.64	8.89e-32	1.43e-28	0.59	0.5	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	12.64	9.04e-32	1.46e-28	0.61	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
LGG	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	12.64	9.11e-32	1.47e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	12.64	9.11e-32	1.47e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
LGG	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-12.64	9.17e-32	1.48e-28	-0.52	-0.5	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
LGG	cis	rs6452524	0.532	rs27363	ENSG00000248112.1	RP11-78C3.1	12.64	9.23e-32	1.49e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:82919376~82921119:-
LGG	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-12.64	9.24e-32	1.49e-28	-0.66	-0.5	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
LGG	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-12.64	9.31e-32	1.5e-28	-0.52	-0.5	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-12.64	9.31e-32	1.5e-28	-0.52	-0.5	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
LGG	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-12.64	9.57e-32	1.54e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
LGG	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-12.64	9.58e-32	1.54e-28	-0.58	-0.5	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
LGG	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	12.64	9.59e-32	1.54e-28	0.68	0.5	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	12.64	9.59e-32	1.54e-28	0.68	0.5	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	12.64	9.59e-32	1.54e-28	0.68	0.5	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	12.64	9.59e-32	1.54e-28	0.68	0.5	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	12.64	9.59e-32	1.54e-28	0.68	0.5	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
LGG	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-12.63	9.82e-32	1.58e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
LGG	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-12.63	9.82e-32	1.58e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
LGG	cis	rs853679	0.882	rs3757188	ENSG00000216901.1	AL022393.7	12.63	9.82e-32	1.58e-28	0.93	0.5	Depression;	chr6:28139579	chr6:28176188~28176674:+
LGG	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-12.63	9.85e-32	1.59e-28	-0.56	-0.5	Height;	chr3:52989619	chr3:53064283~53065091:-
LGG	cis	rs2486288	0.656	rs11637364	ENSG00000259433.2	CTD-2651B20.4	12.63	9.87e-32	1.59e-28	0.55	0.5	Glomerular filtration rate;	chr15:45287040	chr15:45330209~45332634:-
LGG	cis	rs11098499	0.866	rs7665125	ENSG00000249244.1	RP11-548H18.2	12.63	9.91e-32	1.59e-28	0.54	0.5	Corneal astigmatism;	chr4:119480924	chr4:119391831~119395335:-
LGG	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-12.63	9.95e-32	1.6e-28	-0.52	-0.5	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
LGG	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	12.63	1.01e-31	1.63e-28	0.56	0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
LGG	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28076559	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28076704	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28078391	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28080757	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28080760	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28082231	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28082261	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28082984	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28083994	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28084025	chr6:28161781~28169594:+
LGG	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	12.63	1.02e-31	1.64e-28	0.6	0.5	Depression;	chr6:28085319	chr6:28161781~28169594:+
LGG	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-12.63	1.03e-31	1.65e-28	-0.39	-0.5	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
LGG	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	12.63	1.03e-31	1.65e-28	0.6	0.5	Depression;	chr6:28071237	chr6:28161781~28169594:+
LGG	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-12.63	1.03e-31	1.66e-28	-0.53	-0.5	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
LGG	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-12.63	1.04e-31	1.68e-28	-0.56	-0.5	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
LGG	cis	rs12495178	0.55	rs28522091	ENSG00000239519.1	CADM2-AS1	-12.63	1.04e-31	1.68e-28	-0.58	-0.5	Body mass index;	chr3:85954797	chr3:85992183~86028007:-
LGG	cis	rs2282300	1	rs12575085	ENSG00000254532.1	RP11-624D11.2	12.63	1.05e-31	1.68e-28	0.72	0.5	Morning vs. evening chronotype;	chr11:30406715	chr11:30044058~30084343:-
LGG	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-12.63	1.05e-31	1.68e-28	-0.58	-0.5	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
LGG	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-12.63	1.06e-31	1.7e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
LGG	cis	rs172166	0.516	rs1225618	ENSG00000226314.6	ZNF192P1	12.62	1.06e-31	1.7e-28	0.49	0.5	Cardiac Troponin-T levels;	chr6:28161935	chr6:28161781~28169594:+
LGG	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	12.62	1.07e-31	1.71e-28	0.43	0.5	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
LGG	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28089816	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28090857	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28091439	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28091659	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28092227	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28093966	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28094014	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28096077	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28096855	chr6:28161781~28169594:+
LGG	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28099759	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28100648	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28104824	chr6:28161781~28169594:+
LGG	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28107222	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28108492	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28110254	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28111382	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28111650	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28112175	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28113851	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28114487	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28114933	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28115743	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28116411	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
LGG	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28123153	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28124529	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28127577	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28131566	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28133900	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28136698	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28136856	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28137418	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28138363	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28138981	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	12.62	1.07e-31	1.71e-28	0.6	0.5	Depression;	chr6:28139012	chr6:28161781~28169594:+
LGG	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-12.62	1.09e-31	1.74e-28	-0.59	-0.5	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
LGG	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-12.62	1.1e-31	1.76e-28	-0.68	-0.5	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
LGG	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	12.62	1.11e-31	1.77e-28	0.66	0.5	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
LGG	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-12.62	1.12e-31	1.79e-28	-0.44	-0.5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
LGG	cis	rs6452524	0.901	rs1842020	ENSG00000248112.1	RP11-78C3.1	12.62	1.12e-31	1.8e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.967	rs7718278	ENSG00000248112.1	RP11-78C3.1	12.62	1.12e-31	1.8e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.934	rs1120476	ENSG00000248112.1	RP11-78C3.1	12.62	1.12e-31	1.8e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:82919376~82921119:-
LGG	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-12.62	1.13e-31	1.81e-28	-0.54	-0.5	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
LGG	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-12.62	1.14e-31	1.83e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
LGG	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	-12.62	1.14e-31	1.83e-28	-0.52	-0.5	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
LGG	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	12.61	1.18e-31	1.88e-28	0.68	0.5	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	12.61	1.18e-31	1.88e-28	0.68	0.5	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	12.61	1.18e-31	1.88e-28	0.68	0.5	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	12.61	1.18e-31	1.88e-28	0.68	0.5	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	12.61	1.18e-31	1.88e-28	0.68	0.5	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	12.61	1.18e-31	1.88e-28	0.68	0.5	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
LGG	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	12.61	1.18e-31	1.88e-28	0.68	0.5	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
LGG	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	12.61	1.18e-31	1.89e-28	0.6	0.5	Depression;	chr6:28139049	chr6:28161781~28169594:+
LGG	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	12.61	1.19e-31	1.9e-28	0.6	0.5	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	12.61	1.19e-31	1.9e-28	0.6	0.5	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	12.61	1.19e-31	1.9e-28	0.6	0.5	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	12.61	1.19e-31	1.9e-28	0.6	0.5	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-12.61	1.2e-31	1.92e-28	-0.66	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
LGG	cis	rs9532669	0.926	rs4356344	ENSG00000176268.5	CYCSP34	12.61	1.21e-31	1.93e-28	0.63	0.5	Cervical cancer;	chr13:40874086	chr13:40863599~40863902:-
LGG	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	12.61	1.21e-31	1.94e-28	0.68	0.5	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.532	rs26263	ENSG00000248112.1	RP11-78C3.1	12.61	1.22e-31	1.95e-28	0.66	0.5	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:82919376~82921119:-
LGG	cis	rs8062405	0.723	rs62031562	ENSG00000271623.1	RP11-435I10.5	-12.61	1.22e-31	1.95e-28	-0.61	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	12.61	1.23e-31	1.97e-28	0.61	0.5	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
LGG	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-12.61	1.24e-31	1.98e-28	-1.04	-0.5	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
LGG	cis	rs56262138	0.5	rs35177461	ENSG00000239519.1	CADM2-AS1	12.61	1.24e-31	1.98e-28	0.58	0.5	Educational attainment (years of education);	chr3:86030768	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs13073604	ENSG00000239519.1	CADM2-AS1	12.61	1.24e-31	1.98e-28	0.58	0.5	Educational attainment (years of education);	chr3:86031021	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs62263322	ENSG00000239519.1	CADM2-AS1	12.61	1.24e-31	1.98e-28	0.58	0.5	Educational attainment (years of education);	chr3:86033155	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs13061174	ENSG00000239519.1	CADM2-AS1	12.61	1.24e-31	1.98e-28	0.58	0.5	Educational attainment (years of education);	chr3:86037722	chr3:85992183~86028007:-
LGG	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	12.61	1.24e-31	1.98e-28	0.88	0.5	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	12.61	1.24e-31	1.98e-28	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
LGG	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	12.61	1.24e-31	1.98e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
LGG	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	12.61	1.24e-31	1.99e-28	0.6	0.5	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
LGG	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-12.61	1.24e-31	1.99e-28	-0.44	-0.5	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
LGG	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-12.61	1.25e-31	1.99e-28	-0.44	-0.5	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
LGG	cis	rs11155671	0.53	rs4870080	ENSG00000216621.7	RP11-244K5.6	12.61	1.25e-31	2e-28	0.57	0.5	Testicular germ cell tumor;	chr6:149881508	chr6:149934527~149936782:+
LGG	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	12.61	1.26e-31	2.02e-28	0.54	0.5	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
LGG	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	12.61	1.27e-31	2.02e-28	0.67	0.5	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
LGG	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-12.6	1.29e-31	2.06e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
LGG	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-12.6	1.29e-31	2.06e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
LGG	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-12.6	1.29e-31	2.06e-28	-0.53	-0.5	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
LGG	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	-12.6	1.29e-31	2.06e-28	-0.52	-0.5	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
LGG	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	12.6	1.31e-31	2.09e-28	0.62	0.5	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
LGG	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	12.6	1.32e-31	2.1e-28	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
LGG	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	12.6	1.32e-31	2.11e-28	0.56	0.5	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	12.6	1.32e-31	2.11e-28	0.56	0.5	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	12.6	1.34e-31	2.13e-28	0.56	0.5	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
LGG	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-12.6	1.34e-31	2.13e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	12.6	1.34e-31	2.13e-28	0.62	0.5	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
LGG	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	12.6	1.34e-31	2.14e-28	0.6	0.5	Depression;	chr6:28079011	chr6:28161781~28169594:+
LGG	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	12.6	1.35e-31	2.15e-28	0.65	0.5	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
LGG	cis	rs853679	0.766	rs9368561	ENSG00000216901.1	AL022393.7	12.6	1.37e-31	2.18e-28	0.94	0.5	Depression;	chr6:28200565	chr6:28176188~28176674:+
LGG	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-12.6	1.37e-31	2.18e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
LGG	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-12.6	1.38e-31	2.19e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
LGG	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	12.6	1.38e-31	2.2e-28	0.88	0.5	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
LGG	cis	rs7216064	1	rs58551145	ENSG00000278219.1	AC145343.1	-12.6	1.38e-31	2.2e-28	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841119	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.906	rs78452260	ENSG00000278219.1	AC145343.1	-12.6	1.38e-31	2.2e-28	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852406	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs62084240	ENSG00000278219.1	AC145343.1	-12.6	1.38e-31	2.2e-28	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67863117	chr17:68101538~68101639:+
LGG	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-12.6	1.39e-31	2.21e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
LGG	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	12.6	1.39e-31	2.21e-28	0.55	0.5	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
LGG	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-12.6	1.39e-31	2.21e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
LGG	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	12.6	1.39e-31	2.22e-28	0.6	0.5	Depression;	chr6:28091242	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	12.6	1.39e-31	2.22e-28	0.6	0.5	Depression;	chr6:28126588	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	12.6	1.39e-31	2.22e-28	0.6	0.5	Depression;	chr6:28126953	chr6:28161781~28169594:+
LGG	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	12.59	1.44e-31	2.29e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	12.59	1.44e-31	2.29e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
LGG	cis	rs950027	0.572	rs12910764	ENSG00000259433.2	CTD-2651B20.4	12.59	1.44e-31	2.29e-28	0.55	0.5	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45330209~45332634:-
LGG	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	12.59	1.44e-31	2.29e-28	0.53	0.5	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
LGG	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	12.59	1.45e-31	2.3e-28	0.75	0.5	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
LGG	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	12.59	1.45e-31	2.31e-28	0.43	0.5	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
LGG	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-12.59	1.45e-31	2.31e-28	-0.56	-0.5	Height;	chr3:53007328	chr3:53064283~53065091:-
LGG	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-12.59	1.49e-31	2.36e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
LGG	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	12.59	1.49e-31	2.37e-28	0.65	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
LGG	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-12.59	1.49e-31	2.37e-28	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
LGG	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-12.59	1.5e-31	2.38e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
LGG	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-12.59	1.51e-31	2.4e-28	-0.61	-0.5	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
LGG	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	12.59	1.53e-31	2.43e-28	0.54	0.5	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
LGG	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	12.59	1.55e-31	2.45e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	12.59	1.55e-31	2.45e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
LGG	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-12.58	1.55e-31	2.46e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
LGG	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-12.58	1.55e-31	2.46e-28	-0.58	-0.5	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
LGG	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-12.58	1.56e-31	2.47e-28	-0.55	-0.5	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
LGG	cis	rs2739330	1	rs2739330	ENSG00000099984.9	GSTT2	-12.58	1.56e-31	2.48e-28	-0.66	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23980123~23983911:+
LGG	cis	rs7216064	0.953	rs62086044	ENSG00000278219.1	AC145343.1	-12.58	1.57e-31	2.49e-28	-0.6	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68101538~68101639:+
LGG	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	12.58	1.58e-31	2.5e-28	0.54	0.5	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
LGG	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-12.58	1.58e-31	2.51e-28	-0.66	-0.5	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
LGG	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	12.58	1.59e-31	2.51e-28	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
LGG	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	12.58	1.59e-31	2.52e-28	0.56	0.5	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	12.58	1.59e-31	2.52e-28	0.56	0.5	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
LGG	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-12.58	1.61e-31	2.54e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
LGG	cis	rs2486288	0.656	rs11632419	ENSG00000259433.2	CTD-2651B20.4	12.58	1.65e-31	2.61e-28	0.55	0.5	Glomerular filtration rate;	chr15:45265258	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs2271438	ENSG00000259433.2	CTD-2651B20.4	12.58	1.65e-31	2.61e-28	0.55	0.5	Glomerular filtration rate;	chr15:45265270	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11854365	ENSG00000259433.2	CTD-2651B20.4	12.58	1.65e-31	2.61e-28	0.55	0.5	Glomerular filtration rate;	chr15:45265885	chr15:45330209~45332634:-
LGG	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-12.58	1.66e-31	2.63e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
LGG	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	12.58	1.67e-31	2.64e-28	0.65	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
LGG	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	12.58	1.68e-31	2.65e-28	0.6	0.5	Depression;	chr6:28070115	chr6:28161781~28169594:+
LGG	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-12.58	1.68e-31	2.66e-28	-0.6	-0.5	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
LGG	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	12.58	1.68e-31	2.66e-28	0.68	0.5	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
LGG	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	12.58	1.68e-31	2.66e-28	0.68	0.5	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
LGG	cis	rs4713118	0.869	rs6914924	ENSG00000199851.2	U3	12.58	1.69e-31	2.67e-28	0.73	0.5	Parkinson's disease;	chr6:27743751	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs6930992	ENSG00000199851.2	U3	12.58	1.69e-31	2.67e-28	0.73	0.5	Parkinson's disease;	chr6:27744341	chr6:28015568~28015777:+
LGG	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-12.57	1.7e-31	2.7e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
LGG	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	-12.57	1.71e-31	2.7e-28	-0.59	-0.5	Depression;	chr6:28110525	chr6:28161781~28169594:+
LGG	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-12.57	1.71e-31	2.7e-28	-0.43	-0.5	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
LGG	cis	rs12495178	0.574	rs36080783	ENSG00000239519.1	CADM2-AS1	12.57	1.72e-31	2.71e-28	0.58	0.5	Body mass index;	chr3:85935680	chr3:85992183~86028007:-
LGG	cis	rs12495178	0.574	rs11127913	ENSG00000239519.1	CADM2-AS1	12.57	1.72e-31	2.71e-28	0.58	0.5	Body mass index;	chr3:85937958	chr3:85992183~86028007:-
LGG	cis	rs12495178	0.528	rs9879903	ENSG00000239519.1	CADM2-AS1	-12.57	1.72e-31	2.71e-28	-0.58	-0.5	Body mass index;	chr3:85948218	chr3:85992183~86028007:-
LGG	cis	rs1475911	0.507	rs11702347	ENSG00000184385.2	UMODL1-AS1	12.57	1.72e-31	2.72e-28	0.67	0.5	IgG glycosylation;	chr21:42106344	chr21:42102134~42108534:-
LGG	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	12.57	1.74e-31	2.76e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
LGG	cis	rs56262138	0.5	rs2324975	ENSG00000239519.1	CADM2-AS1	12.57	1.75e-31	2.77e-28	0.58	0.5	Educational attainment (years of education);	chr3:86009295	chr3:85992183~86028007:-
LGG	cis	rs56262138	0.5	rs12486099	ENSG00000239519.1	CADM2-AS1	12.57	1.75e-31	2.77e-28	0.58	0.5	Educational attainment (years of education);	chr3:86011185	chr3:85992183~86028007:-
LGG	cis	rs12495178	0.502	rs13065014	ENSG00000239519.1	CADM2-AS1	12.57	1.75e-31	2.77e-28	0.58	0.5	Body mass index;	chr3:86011753	chr3:85992183~86028007:-
LGG	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	12.57	1.76e-31	2.77e-28	0.61	0.5	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
LGG	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	12.57	1.76e-31	2.77e-28	0.61	0.5	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
LGG	cis	rs657075	0.697	rs3788987	ENSG00000233006.5	AC034220.3	-12.57	1.76e-31	2.78e-28	-0.77	-0.5	Rheumatoid arthritis;	chr5:132370597	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs13185655	ENSG00000233006.5	AC034220.3	-12.57	1.76e-31	2.78e-28	-0.77	-0.5	Rheumatoid arthritis;	chr5:132371055	chr5:132311285~132369916:-
LGG	cis	rs12495178	0.529	rs112998994	ENSG00000239519.1	CADM2-AS1	12.57	1.78e-31	2.81e-28	0.58	0.5	Body mass index;	chr3:85927841	chr3:85992183~86028007:-
LGG	cis	rs9532669	0.889	rs7320344	ENSG00000176268.5	CYCSP34	12.57	1.78e-31	2.81e-28	0.62	0.5	Cervical cancer;	chr13:40885502	chr13:40863599~40863902:-
LGG	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-12.57	1.79e-31	2.83e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
LGG	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-12.57	1.79e-31	2.83e-28	-0.65	-0.5	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
LGG	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	12.57	1.8e-31	2.84e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
LGG	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-12.57	1.8e-31	2.84e-28	-0.59	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
LGG	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	12.57	1.8e-31	2.85e-28	0.61	0.5	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
LGG	cis	rs2486288	0.554	rs1719235	ENSG00000259433.2	CTD-2651B20.4	12.57	1.84e-31	2.9e-28	0.55	0.5	Glomerular filtration rate;	chr15:45283910	chr15:45330209~45332634:-
LGG	cis	rs6452524	1	rs10068099	ENSG00000248112.1	RP11-78C3.1	12.57	1.85e-31	2.93e-28	0.65	0.5	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:82919376~82921119:-
LGG	cis	rs56262138	0.5	rs62263325	ENSG00000239519.1	CADM2-AS1	12.56	1.88e-31	2.96e-28	0.58	0.5	Educational attainment (years of education);	chr3:86073373	chr3:85992183~86028007:-
LGG	cis	rs651907	0.535	rs2290859	ENSG00000244119.1	PDCL3P4	12.56	1.88e-31	2.97e-28	0.39	0.5	Colorectal cancer;	chr3:101806781	chr3:101712472~101713191:+
LGG	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	12.56	1.88e-31	2.97e-28	1.07	0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
LGG	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-12.56	1.89e-31	2.98e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
LGG	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	12.56	1.9e-31	3e-28	0.65	0.5	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
LGG	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	12.56	1.91e-31	3.01e-28	0.65	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
LGG	cis	rs7927771	0.864	rs10838724	ENSG00000280615.1	Y_RNA	-12.56	1.91e-31	3.01e-28	-0.63	-0.5	Subjective well-being;	chr11:47505500	chr11:47614898~47614994:-
LGG	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	12.56	1.92e-31	3.02e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
LGG	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-12.56	1.93e-31	3.04e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
LGG	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	12.56	1.95e-31	3.08e-28	0.6	0.5	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
LGG	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-12.56	2.03e-31	3.2e-28	-0.42	-0.5	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
LGG	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	12.56	2.04e-31	3.21e-28	0.6	0.5	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
LGG	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-12.56	2.04e-31	3.21e-28	-0.6	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
LGG	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-12.56	2.04e-31	3.22e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
LGG	cis	rs2486288	0.656	rs8039153	ENSG00000259433.2	CTD-2651B20.4	12.56	2.05e-31	3.22e-28	0.55	0.5	Glomerular filtration rate;	chr15:45287615	chr15:45330209~45332634:-
LGG	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-12.55	2.07e-31	3.26e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
LGG	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	12.55	2.08e-31	3.28e-28	0.62	0.5	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
LGG	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-12.55	2.08e-31	3.28e-28	-0.6	-0.5	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
LGG	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	12.55	2.1e-31	3.3e-28	0.88	0.5	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
LGG	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	12.55	2.1e-31	3.3e-28	0.88	0.5	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
LGG	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	12.55	2.1e-31	3.31e-28	0.6	0.5	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
LGG	cis	rs8062405	0.723	rs35175818	ENSG00000271623.1	RP11-435I10.5	-12.55	2.11e-31	3.31e-28	-0.61	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28364700~28365333:+
LGG	cis	rs748404	0.518	rs2927085	ENSG00000249839.1	AC011330.5	-12.55	2.11e-31	3.33e-28	-0.65	-0.5	Lung cancer;	chr15:43697332	chr15:43663654~43684339:-
LGG	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-12.55	2.11e-31	3.33e-28	-0.55	-0.5	Height;	chr3:52991821	chr3:53064283~53065091:-
LGG	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-12.55	2.11e-31	3.33e-28	-0.55	-0.5	Height;	chr3:52992698	chr3:53064283~53065091:-
LGG	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	12.55	2.12e-31	3.33e-28	0.53	0.5	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
LGG	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	12.55	2.14e-31	3.36e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
LGG	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-12.55	2.19e-31	3.44e-28	-0.42	-0.5	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
LGG	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-12.55	2.19e-31	3.44e-28	-0.42	-0.5	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
LGG	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	12.55	2.2e-31	3.45e-28	0.62	0.5	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
LGG	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	12.55	2.21e-31	3.47e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
LGG	cis	rs7315956	0.929	rs10879100	ENSG00000257139.1	RP11-320P7.2	-12.55	2.24e-31	3.52e-28	-0.59	-0.5	Testicular germ cell tumor;	chr12:70167411	chr12:70180338~70202004:+
LGG	cis	rs4713118	0.955	rs9393848	ENSG00000199851.2	U3	12.54	2.28e-31	3.57e-28	0.74	0.5	Parkinson's disease;	chr6:27720590	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs6902689	ENSG00000199851.2	U3	12.54	2.34e-31	3.66e-28	0.73	0.5	Parkinson's disease;	chr6:27741662	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9468214	ENSG00000199851.2	U3	12.54	2.34e-31	3.66e-28	0.73	0.5	Parkinson's disease;	chr6:27745520	chr6:28015568~28015777:+
LGG	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-12.54	2.36e-31	3.69e-28	-0.56	-0.5	Height;	chr3:53009621	chr3:53064283~53065091:-
LGG	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	12.54	2.36e-31	3.7e-28	0.63	0.5	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
LGG	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	12.54	2.37e-31	3.7e-28	0.58	0.5	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
LGG	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	12.54	2.37e-31	3.71e-28	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
LGG	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	12.54	2.37e-31	3.71e-28	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
LGG	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-12.54	2.37e-31	3.71e-28	-0.58	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
LGG	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	12.54	2.44e-31	3.81e-28	0.54	0.5	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
LGG	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-12.54	2.44e-31	3.82e-28	-0.58	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-12.54	2.44e-31	3.82e-28	-0.58	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
LGG	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	12.54	2.47e-31	3.86e-28	0.59	0.5	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
LGG	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-12.54	2.47e-31	3.86e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-12.54	2.47e-31	3.86e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-12.54	2.47e-31	3.86e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-12.54	2.47e-31	3.86e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
LGG	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-12.53	2.51e-31	3.92e-28	-0.56	-0.5	Height;	chr3:52977358	chr3:53064283~53065091:-
LGG	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-12.53	2.51e-31	3.93e-28	-0.52	-0.5	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
LGG	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-12.53	2.51e-31	3.93e-28	-0.59	-0.5	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
LGG	cis	rs7216064	0.953	rs62086043	ENSG00000278219.1	AC145343.1	-12.53	2.55e-31	3.99e-28	-0.6	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971887	chr17:68101538~68101639:+
LGG	cis	rs4819052	0.807	rs1075788	ENSG00000215447.6	BX322557.10	-12.53	2.59e-31	4.05e-28	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45288052~45291738:+
LGG	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-12.53	2.66e-31	4.15e-28	-0.91	-0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
LGG	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	12.53	2.67e-31	4.17e-28	0.62	0.5	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	12.53	2.67e-31	4.17e-28	0.62	0.5	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	12.53	2.67e-31	4.17e-28	0.62	0.5	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	12.53	2.67e-31	4.17e-28	0.62	0.5	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
LGG	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-12.53	2.68e-31	4.18e-28	-0.6	-0.5	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
LGG	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-12.53	2.68e-31	4.19e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
LGG	cis	rs2486288	0.656	rs1706770	ENSG00000259433.2	CTD-2651B20.4	12.53	2.7e-31	4.22e-28	0.54	0.5	Glomerular filtration rate;	chr15:45282864	chr15:45330209~45332634:-
LGG	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	12.53	2.71e-31	4.23e-28	0.75	0.5	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
LGG	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	12.52	2.74e-31	4.29e-28	0.59	0.5	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
LGG	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	12.52	2.74e-31	4.29e-28	0.59	0.5	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
LGG	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	12.52	2.77e-31	4.33e-28	0.44	0.5	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
LGG	cis	rs4713118	0.955	rs9380010	ENSG00000199851.2	U3	12.52	2.81e-31	4.38e-28	0.74	0.5	Parkinson's disease;	chr6:27715793	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.955	rs9368528	ENSG00000199851.2	U3	12.52	2.81e-31	4.38e-28	0.74	0.5	Parkinson's disease;	chr6:27716019	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.955	rs9380011	ENSG00000199851.2	U3	12.52	2.81e-31	4.38e-28	0.74	0.5	Parkinson's disease;	chr6:27716145	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.955	rs9380012	ENSG00000199851.2	U3	12.52	2.81e-31	4.38e-28	0.74	0.5	Parkinson's disease;	chr6:27716875	chr6:28015568~28015777:+
LGG	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-12.52	2.81e-31	4.38e-28	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
LGG	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-12.52	2.81e-31	4.38e-28	-0.59	-0.5	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-12.52	2.81e-31	4.38e-28	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-12.52	2.81e-31	4.38e-28	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
LGG	cis	rs9322193	0.504	rs7771014	ENSG00000216621.7	RP11-244K5.6	12.52	2.83e-31	4.41e-28	0.56	0.5	Lung cancer;	chr6:149884310	chr6:149934527~149936782:+
LGG	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-12.52	2.83e-31	4.42e-28	-0.55	-0.5	Height;	chr3:52989412	chr3:53064283~53065091:-
LGG	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-12.52	2.84e-31	4.43e-28	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
LGG	cis	rs4713118	0.955	rs9368529	ENSG00000199851.2	U3	12.52	2.86e-31	4.47e-28	0.74	0.5	Parkinson's disease;	chr6:27716852	chr6:28015568~28015777:+
LGG	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-12.52	2.88e-31	4.49e-28	-0.97	-0.5	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
LGG	cis	rs853679	0.766	rs9368561	ENSG00000199851.2	U3	12.52	2.89e-31	4.51e-28	1.04	0.5	Depression;	chr6:28200565	chr6:28015568~28015777:+
LGG	cis	rs2486288	0.656	rs11639420	ENSG00000259433.2	CTD-2651B20.4	12.52	2.9e-31	4.51e-28	0.55	0.5	Glomerular filtration rate;	chr15:45267070	chr15:45330209~45332634:-
LGG	cis	rs4713118	0.869	rs9366700	ENSG00000199851.2	U3	12.52	2.96e-31	4.6e-28	0.73	0.5	Parkinson's disease;	chr6:27729172	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs6456802	ENSG00000199851.2	U3	12.52	2.96e-31	4.6e-28	0.73	0.5	Parkinson's disease;	chr6:27730576	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9393851	ENSG00000199851.2	U3	12.52	2.96e-31	4.6e-28	0.73	0.5	Parkinson's disease;	chr6:27731802	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9461400	ENSG00000199851.2	U3	12.52	2.96e-31	4.6e-28	0.73	0.5	Parkinson's disease;	chr6:27732780	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9295742	ENSG00000199851.2	U3	12.52	2.96e-31	4.6e-28	0.73	0.5	Parkinson's disease;	chr6:27735053	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9461401	ENSG00000199851.2	U3	12.52	2.96e-31	4.6e-28	0.73	0.5	Parkinson's disease;	chr6:27735512	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.857	rs9608229	ENSG00000231271.1	AP000350.8	12.52	2.96e-31	4.61e-28	0.67	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23949918~23954042:+
LGG	cis	rs853679	0.882	rs9393908	ENSG00000199851.2	U3	12.52	2.96e-31	4.61e-28	1.05	0.5	Depression;	chr6:28223052	chr6:28015568~28015777:+
LGG	cis	rs853679	0.882	rs9366717	ENSG00000199851.2	U3	12.52	2.96e-31	4.61e-28	1.05	0.5	Depression;	chr6:28223279	chr6:28015568~28015777:+
LGG	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-12.52	2.97e-31	4.62e-28	-0.43	-0.5	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-12.52	2.97e-31	4.62e-28	-0.66	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
LGG	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-12.52	2.97e-31	4.63e-28	-1.06	-0.5	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
LGG	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	12.52	2.97e-31	4.63e-28	0.56	0.5	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
LGG	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	12.52	2.99e-31	4.66e-28	0.85	0.5	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
LGG	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	12.52	2.99e-31	4.66e-28	0.85	0.5	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
LGG	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-12.52	3e-31	4.66e-28	-0.56	-0.5	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
LGG	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-12.51	3.05e-31	4.74e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
LGG	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	12.51	3.06e-31	4.76e-28	0.55	0.5	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
LGG	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-12.51	3.07e-31	4.78e-28	-0.69	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
LGG	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	12.51	3.07e-31	4.78e-28	0.55	0.5	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
LGG	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-12.51	3.08e-31	4.79e-28	-0.53	-0.5	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
LGG	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-12.51	3.1e-31	4.82e-28	-0.41	-0.5	Height;	chr11:118703185	chr11:118791254~118793137:+
LGG	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-12.51	3.1e-31	4.82e-28	-0.41	-0.5	Height;	chr11:118703207	chr11:118791254~118793137:+
LGG	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-12.51	3.1e-31	4.82e-28	-0.41	-0.5	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
LGG	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	12.51	3.11e-31	4.83e-28	0.63	0.5	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
LGG	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-12.51	3.11e-31	4.84e-28	-1.06	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-12.51	3.11e-31	4.84e-28	-1.06	-0.5	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
LGG	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	12.51	3.12e-31	4.84e-28	0.54	0.5	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
LGG	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	12.51	3.12e-31	4.85e-28	0.6	0.5	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
LGG	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	12.51	3.12e-31	4.85e-28	0.6	0.5	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
LGG	cis	rs4713118	0.587	rs61471148	ENSG00000226314.6	ZNF192P1	12.51	3.17e-31	4.92e-28	0.6	0.5	Parkinson's disease;	chr6:28069254	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.567	rs7747457	ENSG00000216621.7	RP11-244K5.6	12.51	3.21e-31	4.98e-28	0.57	0.5	Lung cancer;	chr6:149892366	chr6:149934527~149936782:+
LGG	cis	rs853679	0.882	rs9468300	ENSG00000216901.1	AL022393.7	12.51	3.22e-31	5e-28	0.93	0.5	Depression;	chr6:28159062	chr6:28176188~28176674:+
LGG	cis	rs853679	0.825	rs8180562	ENSG00000216901.1	AL022393.7	12.51	3.22e-31	5e-28	0.93	0.5	Depression;	chr6:28173682	chr6:28176188~28176674:+
LGG	cis	rs853679	0.882	rs9380064	ENSG00000216901.1	AL022393.7	12.51	3.22e-31	5e-28	0.93	0.5	Depression;	chr6:28175340	chr6:28176188~28176674:+
LGG	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	12.51	3.26e-31	5.06e-28	0.54	0.5	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
LGG	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-12.51	3.27e-31	5.08e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
LGG	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	12.5	3.33e-31	5.16e-28	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
LGG	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-12.5	3.33e-31	5.17e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
LGG	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-12.5	3.45e-31	5.35e-28	-0.71	-0.5	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
LGG	cis	rs12495178	0.599	rs4368495	ENSG00000239519.1	CADM2-AS1	12.5	3.49e-31	5.42e-28	0.58	0.5	Body mass index;	chr3:85964667	chr3:85992183~86028007:-
LGG	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	12.5	3.5e-31	5.42e-28	0.59	0.5	Depression;	chr6:28113616	chr6:28161781~28169594:+
LGG	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-12.5	3.51e-31	5.45e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
LGG	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-12.5	3.53e-31	5.47e-28	-0.58	-0.5	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
LGG	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-12.5	3.54e-31	5.48e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
LGG	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-12.5	3.57e-31	5.54e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-12.5	3.57e-31	5.54e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-12.5	3.57e-31	5.54e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
LGG	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-12.5	3.59e-31	5.56e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
LGG	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-12.49	3.63e-31	5.63e-28	-0.39	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
LGG	cis	rs11155671	0.53	rs7756850	ENSG00000216621.7	RP11-244K5.6	12.49	3.69e-31	5.71e-28	0.57	0.5	Testicular germ cell tumor;	chr6:149891460	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs9371223	ENSG00000216621.7	RP11-244K5.6	12.49	3.69e-31	5.71e-28	0.57	0.5	Testicular germ cell tumor;	chr6:149893670	chr6:149934527~149936782:+
LGG	cis	rs4713118	0.911	rs2394000	ENSG00000199851.2	U3	12.49	3.7e-31	5.73e-28	0.74	0.5	Parkinson's disease;	chr6:27719212	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.955	rs9393847	ENSG00000199851.2	U3	12.49	3.7e-31	5.73e-28	0.74	0.5	Parkinson's disease;	chr6:27720194	chr6:28015568~28015777:+
LGG	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-12.49	3.73e-31	5.78e-28	-0.61	-0.5	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
LGG	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	12.49	3.75e-31	5.8e-28	0.75	0.5	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
LGG	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-12.49	3.77e-31	5.83e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-12.49	3.77e-31	5.83e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
LGG	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	12.49	3.8e-31	5.87e-28	0.65	0.5	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
LGG	cis	rs950027	0.549	rs12909409	ENSG00000259433.2	CTD-2651B20.4	12.49	3.8e-31	5.87e-28	0.54	0.5	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45330209~45332634:-
LGG	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-12.49	3.83e-31	5.92e-28	-0.52	-0.5	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
LGG	cis	rs11155671	0.53	rs9397420	ENSG00000216621.7	RP11-244K5.6	-12.49	3.84e-31	5.93e-28	-0.56	-0.5	Testicular germ cell tumor;	chr6:149885645	chr6:149934527~149936782:+
LGG	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	12.49	3.89e-31	6.01e-28	0.55	0.5	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
LGG	cis	rs2486288	0.656	rs1060896	ENSG00000259433.2	CTD-2651B20.4	12.49	3.93e-31	6.07e-28	0.55	0.5	Glomerular filtration rate;	chr15:45262069	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-12.49	3.95e-31	6.11e-28	-0.71	-0.5	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
LGG	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	12.49	3.97e-31	6.13e-28	0.6	0.5	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
LGG	cis	rs4713118	0.955	rs9468201	ENSG00000199851.2	U3	12.49	3.97e-31	6.14e-28	0.74	0.5	Parkinson's disease;	chr6:27719256	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs6901520	ENSG00000199851.2	U3	12.49	3.98e-31	6.15e-28	0.73	0.5	Parkinson's disease;	chr6:27746796	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9283880	ENSG00000199851.2	U3	12.49	3.98e-31	6.15e-28	0.73	0.5	Parkinson's disease;	chr6:27747464	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9283881	ENSG00000199851.2	U3	12.49	3.98e-31	6.15e-28	0.73	0.5	Parkinson's disease;	chr6:27747476	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs9283882	ENSG00000199851.2	U3	12.49	3.98e-31	6.15e-28	0.73	0.5	Parkinson's disease;	chr6:27747479	chr6:28015568~28015777:+
LGG	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	12.48	4.02e-31	6.2e-28	0.85	0.5	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
LGG	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-12.48	4.03e-31	6.22e-28	-0.49	-0.5	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
LGG	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-12.48	4.04e-31	6.23e-28	-0.56	-0.5	Height;	chr3:53027969	chr3:53064283~53065091:-
LGG	cis	rs11155671	0.53	rs2342769	ENSG00000216621.7	RP11-244K5.6	12.48	4.13e-31	6.37e-28	0.57	0.5	Testicular germ cell tumor;	chr6:149895371	chr6:149934527~149936782:+
LGG	cis	rs853679	0.824	rs34712084	ENSG00000216901.1	AL022393.7	12.48	4.14e-31	6.39e-28	0.93	0.5	Depression;	chr6:28076050	chr6:28176188~28176674:+
LGG	cis	rs853679	0.824	rs1321505	ENSG00000216901.1	AL022393.7	12.48	4.14e-31	6.39e-28	0.93	0.5	Depression;	chr6:28085045	chr6:28176188~28176674:+
LGG	cis	rs853679	0.882	rs9468287	ENSG00000216901.1	AL022393.7	12.48	4.14e-31	6.39e-28	0.93	0.5	Depression;	chr6:28111963	chr6:28176188~28176674:+
LGG	cis	rs853679	0.882	rs9461432	ENSG00000216901.1	AL022393.7	12.48	4.14e-31	6.39e-28	0.93	0.5	Depression;	chr6:28119105	chr6:28176188~28176674:+
LGG	cis	rs853679	0.882	rs4713139	ENSG00000216901.1	AL022393.7	12.48	4.14e-31	6.39e-28	0.93	0.5	Depression;	chr6:28124907	chr6:28176188~28176674:+
LGG	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	12.48	4.26e-31	6.57e-28	0.62	0.5	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
LGG	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	12.48	4.29e-31	6.61e-28	0.59	0.5	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
LGG	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	12.48	4.33e-31	6.68e-28	0.54	0.5	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	12.48	4.33e-31	6.68e-28	0.54	0.5	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
LGG	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-12.48	4.34e-31	6.69e-28	-0.58	-0.5	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
LGG	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	12.47	4.39e-31	6.77e-28	0.61	0.5	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
LGG	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-12.47	4.44e-31	6.83e-28	-0.64	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
LGG	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-12.47	4.44e-31	6.83e-28	-0.64	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
LGG	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-12.47	4.44e-31	6.83e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
LGG	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	12.47	4.47e-31	6.88e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	12.47	4.48e-31	6.9e-28	0.72	0.5	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
LGG	cis	rs657075	0.697	rs4646304	ENSG00000233006.5	AC034220.3	-12.47	4.5e-31	6.92e-28	-0.77	-0.5	Rheumatoid arthritis;	chr5:132379086	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs4646305	ENSG00000233006.5	AC034220.3	-12.47	4.5e-31	6.92e-28	-0.77	-0.5	Rheumatoid arthritis;	chr5:132382847	chr5:132311285~132369916:-
LGG	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	12.47	4.54e-31	6.99e-28	0.57	0.5	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
LGG	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-12.47	4.57e-31	7.03e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
LGG	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	12.47	4.57e-31	7.04e-28	0.65	0.5	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
LGG	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-12.47	4.58e-31	7.05e-28	-0.48	-0.5	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
LGG	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	12.47	4.6e-31	7.08e-28	0.65	0.5	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	12.47	4.63e-31	7.12e-28	0.61	0.5	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
LGG	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	12.47	4.64e-31	7.15e-28	0.54	0.5	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
LGG	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-12.47	4.64e-31	7.15e-28	-0.62	-0.5	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
LGG	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-12.47	4.67e-31	7.19e-28	-0.47	-0.5	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
LGG	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-12.47	4.7e-31	7.22e-28	-0.57	-0.5	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
LGG	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	12.47	4.73e-31	7.27e-28	0.69	0.5	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	12.47	4.75e-31	7.31e-28	0.65	0.5	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
LGG	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	12.47	4.79e-31	7.35e-28	0.54	0.5	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
LGG	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-12.46	4.83e-31	7.43e-28	-0.52	-0.5	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
LGG	cis	rs2486288	0.656	rs2413771	ENSG00000259433.2	CTD-2651B20.4	12.46	4.87e-31	7.46e-28	0.55	0.5	Glomerular filtration rate;	chr15:45260942	chr15:45330209~45332634:-
LGG	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-12.46	4.91e-31	7.53e-28	-0.62	-0.5	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
LGG	cis	rs7829975	0.522	rs6601689	ENSG00000173295.6	FAM86B3P	-12.46	4.93e-31	7.56e-28	-0.53	-0.5	Mood instability;	chr8:8314761	chr8:8228595~8244865:+
LGG	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	12.46	4.99e-31	7.64e-28	0.77	0.5	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.955	rs9468204	ENSG00000199851.2	U3	12.46	5e-31	7.67e-28	0.73	0.5	Parkinson's disease;	chr6:27721030	chr6:28015568~28015777:+
LGG	cis	rs9637599	0.69	rs2869926	ENSG00000246375.2	RP11-10L7.1	12.46	5.11e-31	7.83e-28	0.6	0.5	Metabolite levels (small molecules and protein measures);	chr4:88280224	chr4:88284942~88331421:+
LGG	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-12.46	5.13e-31	7.85e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-12.46	5.13e-31	7.85e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
LGG	cis	rs2712184	0.875	rs2541382	ENSG00000229352.1	AC007563.3	-12.46	5.16e-31	7.9e-28	-0.58	-0.5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216815311	chr2:216799608~216805335:+
LGG	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	12.46	5.22e-31	7.98e-28	0.44	0.5	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	12.46	5.22e-31	7.98e-28	0.44	0.5	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
LGG	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	12.46	5.25e-31	8.03e-28	0.61	0.5	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
LGG	cis	rs853679	0.882	rs9468300	ENSG00000199851.2	U3	12.46	5.28e-31	8.07e-28	1.04	0.5	Depression;	chr6:28159062	chr6:28015568~28015777:+
LGG	cis	rs853679	0.825	rs8180562	ENSG00000199851.2	U3	12.46	5.28e-31	8.07e-28	1.04	0.5	Depression;	chr6:28173682	chr6:28015568~28015777:+
LGG	cis	rs853679	0.882	rs9380064	ENSG00000199851.2	U3	12.46	5.28e-31	8.07e-28	1.04	0.5	Depression;	chr6:28175340	chr6:28015568~28015777:+
LGG	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	12.46	5.29e-31	8.09e-28	0.54	0.5	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	12.46	5.29e-31	8.09e-28	0.54	0.5	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
LGG	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	12.46	5.29e-31	8.09e-28	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
LGG	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-12.45	5.31e-31	8.12e-28	-0.61	-0.5	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
LGG	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	12.45	5.33e-31	8.15e-28	0.54	0.5	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
LGG	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	12.45	5.33e-31	8.16e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	12.45	5.39e-31	8.25e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
LGG	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	12.45	5.48e-31	8.37e-28	0.6	0.5	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
LGG	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	12.45	5.48e-31	8.38e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
LGG	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	12.45	5.48e-31	8.38e-28	0.59	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
LGG	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	12.45	5.52e-31	8.43e-28	0.63	0.5	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
LGG	cis	rs4713118	0.869	rs9283883	ENSG00000199851.2	U3	12.45	5.53e-31	8.44e-28	0.73	0.5	Parkinson's disease;	chr6:27747691	chr6:28015568~28015777:+
LGG	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-12.45	5.57e-31	8.5e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
LGG	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-12.45	5.58e-31	8.52e-28	-0.58	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
LGG	cis	rs2712184	0.846	rs7598172	ENSG00000229352.1	AC007563.3	-12.45	5.6e-31	8.55e-28	-0.58	-0.5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216813276	chr2:216799608~216805335:+
LGG	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	12.45	5.76e-31	8.79e-28	0.85	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
LGG	cis	rs11155671	0.53	rs9383912	ENSG00000216621.7	RP11-244K5.6	12.45	5.79e-31	8.83e-28	0.56	0.5	Testicular germ cell tumor;	chr6:149885479	chr6:149934527~149936782:+
LGG	cis	rs12495178	0.549	rs4303861	ENSG00000239519.1	CADM2-AS1	12.45	5.81e-31	8.86e-28	0.56	0.5	Body mass index;	chr3:85975423	chr3:85992183~86028007:-
LGG	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-12.45	5.81e-31	8.87e-28	-0.45	-0.5	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
LGG	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-12.44	5.85e-31	8.93e-28	-0.64	-0.5	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
LGG	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-12.44	5.86e-31	8.94e-28	-0.62	-0.5	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
LGG	cis	rs11155671	0.53	rs9371542	ENSG00000216621.7	RP11-244K5.6	12.44	5.9e-31	8.99e-28	0.57	0.5	Testicular germ cell tumor;	chr6:149891949	chr6:149934527~149936782:+
LGG	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	12.44	5.96e-31	9.08e-28	0.51	0.5	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
LGG	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	12.44	5.98e-31	9.12e-28	0.45	0.5	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
LGG	cis	rs8062405	0.755	rs4149398	ENSG00000271623.1	RP11-435I10.5	-12.44	6.08e-31	9.27e-28	-0.6	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28364700~28365333:+
LGG	cis	rs657075	0.697	rs34590412	ENSG00000233006.5	AC034220.3	-12.44	6.11e-31	9.32e-28	-0.77	-0.5	Rheumatoid arthritis;	chr5:132374335	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs4646302	ENSG00000233006.5	AC034220.3	-12.44	6.11e-31	9.32e-28	-0.77	-0.5	Rheumatoid arthritis;	chr5:132376790	chr5:132311285~132369916:-
LGG	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-12.44	6.14e-31	9.35e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
LGG	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	12.44	6.17e-31	9.4e-28	0.54	0.5	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
LGG	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	12.44	6.19e-31	9.43e-28	0.62	0.5	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
LGG	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	12.44	6.24e-31	9.5e-28	0.65	0.5	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
LGG	cis	rs853679	0.55	rs1150692	ENSG00000226314.6	ZNF192P1	12.44	6.31e-31	9.6e-28	0.58	0.5	Depression;	chr6:28206179	chr6:28161781~28169594:+
LGG	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-12.43	6.39e-31	9.73e-28	-0.61	-0.5	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
LGG	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	12.43	6.41e-31	9.75e-28	0.65	0.5	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
LGG	cis	rs4713118	0.955	rs9468200	ENSG00000199851.2	U3	12.43	6.43e-31	9.78e-28	0.74	0.5	Parkinson's disease;	chr6:27715284	chr6:28015568~28015777:+
LGG	cis	rs950027	0.549	rs1719250	ENSG00000259433.2	CTD-2651B20.4	-12.43	6.48e-31	9.86e-28	-0.53	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45330209~45332634:-
LGG	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-12.43	6.48e-31	9.86e-28	-0.65	-0.5	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
LGG	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-12.43	6.55e-31	9.96e-28	-0.56	-0.5	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
LGG	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	12.43	6.57e-31	9.98e-28	0.54	0.5	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
LGG	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-12.43	6.59e-31	1e-27	-0.65	-0.5	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
LGG	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-12.43	6.62e-31	1.01e-27	-0.59	-0.5	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
LGG	cis	rs4713118	0.955	rs34752872	ENSG00000199851.2	U3	12.43	6.66e-31	1.01e-27	0.74	0.5	Parkinson's disease;	chr6:27715465	chr6:28015568~28015777:+
LGG	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	12.43	6.71e-31	1.02e-27	0.44	0.5	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
LGG	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-12.43	6.73e-31	1.02e-27	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
LGG	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	12.43	6.74e-31	1.02e-27	0.59	0.5	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
LGG	cis	rs4819052	0.851	rs1999333	ENSG00000215447.6	BX322557.10	-12.43	6.86e-31	1.04e-27	-0.38	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45288052~45291738:+
LGG	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-12.43	6.92e-31	1.05e-27	-0.69	-0.5	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
LGG	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-12.43	6.94e-31	1.05e-27	-1.06	-0.5	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-12.43	6.94e-31	1.05e-27	-1.06	-0.5	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
LGG	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-12.43	6.95e-31	1.05e-27	-0.54	-0.5	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
LGG	cis	rs7216064	0.953	rs11868959	ENSG00000278219.1	AC145343.1	-12.43	6.95e-31	1.06e-27	-0.6	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844694	chr17:68101538~68101639:+
LGG	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	12.42	7.2e-31	1.09e-27	0.63	0.5	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
LGG	cis	rs7216064	1	rs62084246	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871795	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs11869819	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872553	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs55939964	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873181	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs12602912	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873957	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs12450907	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67874528	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs4569324	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67876634	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs62084248	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878425	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs12451511	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878745	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs62084249	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878882	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs35243555	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880361	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs58122682	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880799	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs62084251	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882620	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs4318247	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67886056	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs75231441	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889369	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.954	rs8079291	ENSG00000278219.1	AC145343.1	-12.42	7.25e-31	1.1e-27	-0.61	-0.5	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891506	chr17:68101538~68101639:+
LGG	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-12.42	7.28e-31	1.1e-27	-0.64	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
LGG	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	12.42	7.42e-31	1.12e-27	0.44	0.5	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
LGG	cis	rs9322193	0.567	rs7742692	ENSG00000216621.7	RP11-244K5.6	12.42	7.44e-31	1.13e-27	0.56	0.5	Lung cancer;	chr6:149892363	chr6:149934527~149936782:+
LGG	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	12.42	7.47e-31	1.13e-27	0.54	0.5	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
LGG	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-12.42	7.49e-31	1.13e-27	-0.73	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
LGG	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-12.42	7.49e-31	1.13e-27	-0.57	-0.5	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
LGG	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-12.41	7.83e-31	1.19e-27	-0.52	-0.5	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
LGG	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-12.41	7.84e-31	1.19e-27	-0.71	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-12.41	7.85e-31	1.19e-27	-0.66	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
LGG	cis	rs8062405	0.723	rs762633	ENSG00000271623.1	RP11-435I10.5	-12.41	7.86e-31	1.19e-27	-0.6	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28364700~28365333:+
LGG	cis	rs2712184	0.756	rs2541388	ENSG00000229352.1	AC007563.3	12.41	7.95e-31	1.2e-27	0.57	0.5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216799561	chr2:216799608~216805335:+
LGG	cis	rs11155671	0.53	rs4458704	ENSG00000216621.7	RP11-244K5.6	12.41	7.95e-31	1.2e-27	0.57	0.5	Testicular germ cell tumor;	chr6:149911743	chr6:149934527~149936782:+
LGG	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-12.41	7.96e-31	1.2e-27	-0.5	-0.5	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
LGG	cis	rs2739330	1	rs2739330	ENSG00000231271.1	AP000350.8	12.41	7.96e-31	1.2e-27	0.64	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23949918~23954042:+
LGG	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-12.41	7.99e-31	1.21e-27	-0.58	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
LGG	cis	rs2486288	0.656	rs9921025	ENSG00000259433.2	CTD-2651B20.4	12.41	8.01e-31	1.21e-27	0.55	0.5	Glomerular filtration rate;	chr15:45254404	chr15:45330209~45332634:-
LGG	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-12.41	8.19e-31	1.24e-27	-0.58	-0.5	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-12.41	8.19e-31	1.24e-27	-0.58	-0.5	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
LGG	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	12.41	8.21e-31	1.24e-27	0.54	0.5	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
LGG	cis	rs11155671	0.53	rs9383577	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149886059	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs9383914	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149886098	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.517	rs9397058	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149886113	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs7768626	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149886826	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs7768665	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149886888	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs7758020	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149886975	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs9322228	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149888173	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs7774787	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149888296	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs2342767	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149888581	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs7764376	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149889208	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs6933882	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149889666	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs6939761	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149889858	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs3823021	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149889863	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs4869763	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149890548	chr6:149934527~149936782:+
LGG	cis	rs11155671	0.53	rs4869764	ENSG00000216621.7	RP11-244K5.6	12.41	8.22e-31	1.24e-27	0.56	0.5	Testicular germ cell tumor;	chr6:149890692	chr6:149934527~149936782:+
LGG	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-12.41	8.26e-31	1.25e-27	-0.65	-0.5	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
LGG	cis	rs2486288	0.656	rs11631021	ENSG00000259433.2	CTD-2651B20.4	12.41	8.4e-31	1.27e-27	0.54	0.5	Glomerular filtration rate;	chr15:45264631	chr15:45330209~45332634:-
LGG	cis	rs172166	0.516	rs1225715	ENSG00000199851.2	U3	-12.4	8.48e-31	1.28e-27	-0.73	-0.5	Cardiac Troponin-T levels;	chr6:28145595	chr6:28015568~28015777:+
LGG	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-12.4	8.49e-31	1.28e-27	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
LGG	cis	rs2486288	0.656	rs11854325	ENSG00000259433.2	CTD-2651B20.4	12.4	8.5e-31	1.28e-27	0.55	0.5	Glomerular filtration rate;	chr15:45256761	chr15:45330209~45332634:-
LGG	cis	rs4713118	0.869	rs10214440	ENSG00000199851.2	U3	12.4	8.52e-31	1.28e-27	0.72	0.5	Parkinson's disease;	chr6:27734661	chr6:28015568~28015777:+
LGG	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-12.4	8.55e-31	1.29e-27	-0.56	-0.5	Height;	chr3:53015087	chr3:53064283~53065091:-
LGG	cis	rs2486288	0.656	rs9921035	ENSG00000259433.2	CTD-2651B20.4	12.4	8.7e-31	1.31e-27	0.55	0.49	Glomerular filtration rate;	chr15:45254462	chr15:45330209~45332634:-
LGG	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	12.4	8.82e-31	1.33e-27	0.54	0.49	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
LGG	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-12.4	8.95e-31	1.35e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	12.4	9.01e-31	1.36e-27	0.56	0.49	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
LGG	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	12.4	9.31e-31	1.4e-27	0.39	0.49	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
LGG	cis	rs4819052	0.851	rs7279011	ENSG00000223768.1	LINC00205	-12.39	9.34e-31	1.4e-27	-0.54	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.765	rs2838827	ENSG00000223768.1	LINC00205	-12.39	9.34e-31	1.4e-27	-0.54	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45293285~45297354:+
LGG	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	12.39	9.4e-31	1.41e-27	0.62	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	12.39	9.47e-31	1.42e-27	0.63	0.49	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
LGG	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-12.39	9.65e-31	1.45e-27	-0.5	-0.49	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
LGG	cis	rs657075	0.697	rs3761659	ENSG00000233006.5	AC034220.3	-12.39	9.65e-31	1.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132322091	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3805672	ENSG00000233006.5	AC034220.3	-12.39	9.65e-31	1.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132323281	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3805673	ENSG00000233006.5	AC034220.3	-12.39	9.65e-31	1.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132323410	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583474	ENSG00000233006.5	AC034220.3	-12.39	9.65e-31	1.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132326117	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs77975982	ENSG00000233006.5	AC034220.3	-12.39	9.65e-31	1.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132326300	chr5:132311285~132369916:-
LGG	cis	rs657075	0.64	rs71583475	ENSG00000233006.5	AC034220.3	-12.39	9.65e-31	1.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132326814	chr5:132311285~132369916:-
LGG	cis	rs853679	0.882	rs4713140	ENSG00000199851.2	U3	12.39	9.7e-31	1.46e-27	0.99	0.49	Depression;	chr6:28129415	chr6:28015568~28015777:+
LGG	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	12.39	9.74e-31	1.46e-27	0.53	0.49	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	12.39	9.74e-31	1.46e-27	0.53	0.49	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	12.39	9.74e-31	1.46e-27	0.53	0.49	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	12.39	9.74e-31	1.46e-27	0.53	0.49	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
LGG	cis	rs172166	0.516	rs1225710	ENSG00000280107.1	AL022393.9	12.39	9.81e-31	1.47e-27	0.48	0.49	Cardiac Troponin-T levels;	chr6:28132862	chr6:28170845~28172521:+
LGG	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	12.39	9.87e-31	1.48e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
LGG	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-12.39	1e-30	1.5e-27	-0.53	-0.49	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
LGG	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	12.39	1.02e-30	1.53e-27	0.64	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
LGG	cis	rs4819052	0.851	rs2838855	ENSG00000215447.6	BX322557.10	12.38	1.06e-30	1.58e-27	0.38	0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45288052~45291738:+
LGG	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	12.38	1.07e-30	1.6e-27	0.62	0.49	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
LGG	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-12.38	1.08e-30	1.62e-27	-0.6	-0.49	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
LGG	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-12.38	1.11e-30	1.67e-27	-0.65	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
LGG	cis	rs11098499	0.954	rs6820115	ENSG00000249244.1	RP11-548H18.2	12.38	1.11e-30	1.67e-27	0.53	0.49	Corneal astigmatism;	chr4:119477027	chr4:119391831~119395335:-
LGG	cis	rs4819052	0.851	rs7279182	ENSG00000223768.1	LINC00205	-12.38	1.11e-30	1.67e-27	-0.54	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45293285~45297354:+
LGG	cis	rs8064024	0.676	rs9938805	ENSG00000267077.1	RP11-127I20.5	-12.38	1.12e-30	1.68e-27	-0.49	-0.49	Cancer;	chr16:4827552	chr16:4795265~4796532:-
LGG	cis	rs7216064	1	rs12451707	ENSG00000278219.1	AC145343.1	-12.38	1.12e-30	1.68e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875482	chr17:68101538~68101639:+
LGG	cis	rs651907	0.557	rs3094297	ENSG00000256628.3	ZBTB11-AS1	12.37	1.14e-30	1.7e-27	0.55	0.49	Colorectal cancer;	chr3:101680416	chr3:101676475~101679217:+
LGG	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-12.37	1.14e-30	1.71e-27	-0.53	-0.49	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-12.37	1.15e-30	1.72e-27	-0.7	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
LGG	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	12.37	1.15e-30	1.72e-27	0.59	0.49	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
LGG	cis	rs7216064	0.953	rs11871285	ENSG00000278219.1	AC145343.1	-12.37	1.18e-30	1.77e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844693	chr17:68101538~68101639:+
LGG	cis	rs9532669	0.889	rs9525397	ENSG00000176268.5	CYCSP34	12.37	1.2e-30	1.79e-27	0.63	0.49	Cervical cancer;	chr13:40851575	chr13:40863599~40863902:-
LGG	cis	rs1150668	0.835	rs203869	ENSG00000226314.6	ZNF192P1	12.37	1.21e-30	1.8e-27	0.48	0.49	Pubertal anthropometrics;	chr6:28073041	chr6:28161781~28169594:+
LGG	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-12.37	1.22e-30	1.83e-27	-0.65	-0.49	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
LGG	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-12.37	1.23e-30	1.83e-27	-0.57	-0.49	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-12.37	1.23e-30	1.83e-27	-0.57	-0.49	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
LGG	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	12.37	1.23e-30	1.84e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
LGG	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	12.37	1.23e-30	1.84e-27	0.82	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
LGG	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	12.36	1.24e-30	1.85e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	12.36	1.24e-30	1.85e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
LGG	cis	rs916888	0.821	rs70600	ENSG00000232300.1	FAM215B	12.36	1.24e-30	1.85e-27	0.73	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46558830~46562795:-
LGG	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-12.36	1.25e-30	1.87e-27	-0.62	-0.49	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
LGG	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	12.36	1.25e-30	1.87e-27	0.53	0.49	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
LGG	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	12.36	1.26e-30	1.88e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
LGG	cis	rs2712184	0.729	rs4674115	ENSG00000229352.1	AC007563.3	-12.36	1.27e-30	1.89e-27	-0.57	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216794905	chr2:216799608~216805335:+
LGG	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-12.36	1.27e-30	1.89e-27	-0.71	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
LGG	cis	rs7216064	0.953	rs2086744	ENSG00000278219.1	AC145343.1	-12.36	1.28e-30	1.91e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853159	chr17:68101538~68101639:+
LGG	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	12.36	1.28e-30	1.92e-27	0.62	0.49	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs9383940	ENSG00000216621.7	RP11-244K5.6	12.36	1.29e-30	1.92e-27	0.57	0.49	Testicular germ cell tumor;	chr6:149904923	chr6:149934527~149936782:+
LGG	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	12.36	1.29e-30	1.93e-27	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
LGG	cis	rs2486288	0.656	rs2413773	ENSG00000259433.2	CTD-2651B20.4	12.36	1.31e-30	1.95e-27	0.55	0.49	Glomerular filtration rate;	chr15:45257244	chr15:45330209~45332634:-
LGG	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-12.36	1.31e-30	1.95e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
LGG	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	12.36	1.31e-30	1.96e-27	0.67	0.49	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
LGG	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-12.36	1.33e-30	1.99e-27	-0.54	-0.49	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
LGG	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-12.36	1.34e-30	1.99e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
LGG	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	12.36	1.34e-30	2e-27	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
LGG	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	12.36	1.34e-30	2e-27	0.59	0.49	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
LGG	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-12.35	1.37e-30	2.04e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-12.35	1.37e-30	2.04e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-12.35	1.37e-30	2.04e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-12.35	1.37e-30	2.04e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-12.35	1.37e-30	2.04e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-12.35	1.37e-30	2.04e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-12.35	1.37e-30	2.04e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
LGG	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	12.35	1.38e-30	2.05e-27	0.59	0.49	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
LGG	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	12.35	1.38e-30	2.05e-27	0.52	0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
LGG	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	12.35	1.4e-30	2.08e-27	0.54	0.49	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	12.35	1.4e-30	2.08e-27	0.54	0.49	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	12.35	1.4e-30	2.08e-27	0.54	0.49	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
LGG	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-12.35	1.4e-30	2.09e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-12.35	1.41e-30	2.1e-27	-0.54	-0.49	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
LGG	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	12.35	1.41e-30	2.1e-27	0.43	0.49	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
LGG	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-12.35	1.42e-30	2.12e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
LGG	cis	rs8062405	0.698	rs8046545	ENSG00000271623.1	RP11-435I10.5	12.35	1.43e-30	2.12e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.698	rs10499	ENSG00000271623.1	RP11-435I10.5	12.35	1.43e-30	2.12e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28364700~28365333:+
LGG	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-12.35	1.43e-30	2.13e-27	-0.47	-0.49	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
LGG	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	12.35	1.43e-30	2.13e-27	0.63	0.49	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
LGG	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	12.35	1.44e-30	2.14e-27	0.54	0.49	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	12.35	1.44e-30	2.14e-27	0.54	0.49	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	12.35	1.44e-30	2.14e-27	0.54	0.49	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	12.35	1.44e-30	2.14e-27	0.54	0.49	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	12.35	1.44e-30	2.14e-27	0.54	0.49	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
LGG	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-12.35	1.45e-30	2.16e-27	-0.54	-0.49	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
LGG	cis	rs4713118	0.868	rs10484401	ENSG00000199851.2	U3	-12.35	1.47e-30	2.18e-27	-0.77	-0.49	Parkinson's disease;	chr6:27778811	chr6:28015568~28015777:+
LGG	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	12.35	1.47e-30	2.18e-27	0.54	0.49	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
LGG	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	12.35	1.47e-30	2.19e-27	0.45	0.49	Breast size;	chr12:9219433	chr12:9277235~9313241:+
LGG	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	12.35	1.47e-30	2.19e-27	0.45	0.49	Breast size;	chr12:9220132	chr12:9277235~9313241:+
LGG	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	12.35	1.49e-30	2.21e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
LGG	cis	rs2486288	0.656	rs2413774	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45257225	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11632724	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45258593	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11632651	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45258640	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11637920	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45258707	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11632777	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45258847	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11632778	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45258858	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11632752	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45258942	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs12911186	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45259225	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs12915314	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45259293	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs8039138	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45259394	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs8039354	ENSG00000259433.2	CTD-2651B20.4	-12.34	1.51e-30	2.24e-27	-0.54	-0.49	Glomerular filtration rate;	chr15:45259558	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs8039540	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45259644	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs8040185	ENSG00000259433.2	CTD-2651B20.4	12.34	1.51e-30	2.24e-27	0.54	0.49	Glomerular filtration rate;	chr15:45259883	chr15:45330209~45332634:-
LGG	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-12.34	1.51e-30	2.24e-27	-0.51	-0.49	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
LGG	cis	rs2712184	0.756	rs2712164	ENSG00000229352.1	AC007563.3	-12.34	1.53e-30	2.26e-27	-0.57	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216795193	chr2:216799608~216805335:+
LGG	cis	rs2712184	0.756	rs2712163	ENSG00000229352.1	AC007563.3	-12.34	1.53e-30	2.26e-27	-0.57	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216795623	chr2:216799608~216805335:+
LGG	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	12.34	1.53e-30	2.27e-27	0.55	0.49	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
LGG	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	12.34	1.53e-30	2.27e-27	0.59	0.49	Depression;	chr6:28074687	chr6:28161781~28169594:+
LGG	cis	rs7829975	0.51	rs2921073	ENSG00000173295.6	FAM86B3P	-12.34	1.53e-30	2.27e-27	-0.52	-0.49	Mood instability;	chr8:8450133	chr8:8228595~8244865:+
LGG	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	12.34	1.54e-30	2.29e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
LGG	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	12.34	1.54e-30	2.29e-27	0.62	0.49	Depression;	chr6:28096845	chr6:28161781~28169594:+
LGG	cis	rs7829975	0.51	rs2979160	ENSG00000173295.6	FAM86B3P	-12.34	1.54e-30	2.29e-27	-0.52	-0.49	Mood instability;	chr8:8450156	chr8:8228595~8244865:+
LGG	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-12.34	1.55e-30	2.29e-27	-0.52	-0.49	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
LGG	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	12.34	1.56e-30	2.31e-27	0.85	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
LGG	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-12.34	1.57e-30	2.32e-27	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
LGG	cis	rs8062405	0.69	rs762634	ENSG00000271623.1	RP11-435I10.5	-12.34	1.57e-30	2.33e-27	-0.6	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28364700~28365333:+
LGG	cis	rs4713118	0.869	rs9295743	ENSG00000199851.2	U3	12.34	1.58e-30	2.34e-27	0.72	0.49	Parkinson's disease;	chr6:27747323	chr6:28015568~28015777:+
LGG	cis	rs853679	0.55	rs1237875	ENSG00000226314.6	ZNF192P1	-12.34	1.62e-30	2.4e-27	-0.57	-0.49	Depression;	chr6:28205232	chr6:28161781~28169594:+
LGG	cis	rs1061377	0.965	rs7690465	ENSG00000249685.1	RP11-360F5.3	12.34	1.62e-30	2.4e-27	0.56	0.49	Uric acid levels;	chr4:39147015	chr4:39133913~39135608:+
LGG	cis	rs2980439	0.556	rs2921059	ENSG00000173295.6	FAM86B3P	-12.34	1.62e-30	2.41e-27	-0.52	-0.49	Neuroticism;	chr8:8460377	chr8:8228595~8244865:+
LGG	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	12.34	1.63e-30	2.41e-27	0.6	0.49	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
LGG	cis	rs853679	0.882	rs9393908	ENSG00000216901.1	AL022393.7	12.33	1.65e-30	2.44e-27	0.93	0.49	Depression;	chr6:28223052	chr6:28176188~28176674:+
LGG	cis	rs853679	0.882	rs9366717	ENSG00000216901.1	AL022393.7	12.33	1.65e-30	2.44e-27	0.93	0.49	Depression;	chr6:28223279	chr6:28176188~28176674:+
LGG	cis	rs9637599	0.69	rs881561	ENSG00000246375.2	RP11-10L7.1	12.33	1.68e-30	2.49e-27	0.59	0.49	Metabolite levels (small molecules and protein measures);	chr4:88281890	chr4:88284942~88331421:+
LGG	cis	rs2486288	0.656	rs11629807	ENSG00000259433.2	CTD-2651B20.4	12.33	1.71e-30	2.53e-27	0.55	0.49	Glomerular filtration rate;	chr15:45254839	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.587	rs12899942	ENSG00000259433.2	CTD-2651B20.4	12.33	1.71e-30	2.53e-27	0.55	0.49	Glomerular filtration rate;	chr15:45255082	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs12899058	ENSG00000259433.2	CTD-2651B20.4	12.33	1.71e-30	2.53e-27	0.55	0.49	Glomerular filtration rate;	chr15:45255126	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs12904150	ENSG00000259433.2	CTD-2651B20.4	12.33	1.71e-30	2.53e-27	0.55	0.49	Glomerular filtration rate;	chr15:45255407	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs9920290	ENSG00000259433.2	CTD-2651B20.4	12.33	1.71e-30	2.53e-27	0.55	0.49	Glomerular filtration rate;	chr15:45255837	chr15:45330209~45332634:-
LGG	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-12.33	1.72e-30	2.55e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-12.33	1.72e-30	2.55e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-12.33	1.72e-30	2.55e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-12.33	1.72e-30	2.55e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
LGG	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	12.33	1.72e-30	2.55e-27	0.54	0.49	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
LGG	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-12.33	1.74e-30	2.57e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-12.33	1.74e-30	2.57e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-12.33	1.74e-30	2.57e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-12.33	1.74e-30	2.57e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-12.33	1.74e-30	2.57e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
LGG	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	12.33	1.75e-30	2.59e-27	0.49	0.49	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
LGG	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	12.33	1.76e-30	2.6e-27	0.64	0.49	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
LGG	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-12.33	1.76e-30	2.61e-27	-0.64	-0.49	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-12.33	1.76e-30	2.61e-27	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
LGG	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	12.33	1.78e-30	2.63e-27	0.54	0.49	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
LGG	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-12.33	1.79e-30	2.65e-27	-0.51	-0.49	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
LGG	cis	rs1150668	0.835	rs1233696	ENSG00000226314.6	ZNF192P1	12.33	1.79e-30	2.65e-27	0.48	0.49	Pubertal anthropometrics;	chr6:28175232	chr6:28161781~28169594:+
LGG	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-12.32	1.84e-30	2.72e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
LGG	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	12.32	1.84e-30	2.72e-27	0.6	0.49	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
LGG	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	12.32	1.84e-30	2.72e-27	0.6	0.49	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
LGG	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	12.32	1.85e-30	2.73e-27	0.62	0.49	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs6557133	ENSG00000216621.7	RP11-244K5.6	12.32	1.87e-30	2.76e-27	0.56	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149934527~149936782:+
LGG	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	12.32	1.87e-30	2.76e-27	0.54	0.49	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	12.32	1.87e-30	2.76e-27	0.54	0.49	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	12.32	1.87e-30	2.76e-27	0.54	0.49	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
LGG	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-12.32	1.89e-30	2.79e-27	-0.62	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
LGG	cis	rs172166	0.516	rs1150670	ENSG00000226314.6	ZNF192P1	12.32	1.89e-30	2.79e-27	0.48	0.49	Cardiac Troponin-T levels;	chr6:28162781	chr6:28161781~28169594:+
LGG	cis	rs172166	0.516	rs2021826	ENSG00000226314.6	ZNF192P1	12.32	1.89e-30	2.79e-27	0.48	0.49	Cardiac Troponin-T levels;	chr6:28164978	chr6:28161781~28169594:+
LGG	cis	rs2486288	0.656	rs11632920	ENSG00000259433.2	CTD-2651B20.4	12.32	1.89e-30	2.79e-27	0.55	0.49	Glomerular filtration rate;	chr15:45259066	chr15:45330209~45332634:-
LGG	cis	rs853679	0.55	rs9295762	ENSG00000226314.6	ZNF192P1	-12.32	1.91e-30	2.81e-27	-0.57	-0.49	Depression;	chr6:28187640	chr6:28161781~28169594:+
LGG	cis	rs12495178	0.574	rs4600827	ENSG00000239519.1	CADM2-AS1	12.32	1.91e-30	2.81e-27	0.56	0.49	Body mass index;	chr3:85909234	chr3:85992183~86028007:-
LGG	cis	rs950027	0.549	rs9920634	ENSG00000259433.2	CTD-2651B20.4	12.32	1.93e-30	2.84e-27	0.54	0.49	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45330209~45332634:-
LGG	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	-12.32	1.94e-30	2.86e-27	-0.57	-0.49	Depression;	chr6:28200948	chr6:28161781~28169594:+
LGG	cis	rs7216064	1	rs8082512	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840943	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs8073510	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67843094	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs62084213	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845900	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs7224923	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846149	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs62084214	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67847209	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs2046323	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853811	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.773	rs74541577	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67857535	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs2128792	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861061	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs2365764	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861598	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs59950564	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864743	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs34872586	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867350	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs58141639	ENSG00000278219.1	AC145343.1	-12.32	1.95e-30	2.87e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67868786	chr17:68101538~68101639:+
LGG	cis	rs11155671	0.53	rs7757984	ENSG00000216621.7	RP11-244K5.6	12.32	1.95e-30	2.87e-27	0.56	0.49	Testicular germ cell tumor;	chr6:149887515	chr6:149934527~149936782:+
LGG	cis	rs4713118	0.955	rs9468203	ENSG00000199851.2	U3	12.32	1.95e-30	2.88e-27	0.72	0.49	Parkinson's disease;	chr6:27720888	chr6:28015568~28015777:+
LGG	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-12.32	1.96e-30	2.89e-27	-0.58	-0.49	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
LGG	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-12.32	1.96e-30	2.89e-27	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-12.32	1.97e-30	2.9e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
LGG	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-12.32	1.97e-30	2.9e-27	-0.54	-0.49	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
LGG	cis	rs11155671	0.53	rs6935829	ENSG00000216621.7	RP11-244K5.6	12.31	1.99e-30	2.93e-27	0.57	0.49	Testicular germ cell tumor;	chr6:149896675	chr6:149934527~149936782:+
LGG	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-12.31	2.03e-30	2.99e-27	-0.54	-0.49	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
LGG	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-12.31	2.03e-30	2.99e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
LGG	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	12.31	2.04e-30	3.01e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
LGG	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	12.31	2.05e-30	3.02e-27	0.65	0.49	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
LGG	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-12.31	2.08e-30	3.06e-27	-0.44	-0.49	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
LGG	cis	rs657075	0.697	rs2304081	ENSG00000233006.5	AC034220.3	12.31	2.08e-30	3.07e-27	0.76	0.49	Rheumatoid arthritis;	chr5:132331855	chr5:132311285~132369916:-
LGG	cis	rs8064024	0.649	rs11076849	ENSG00000267077.1	RP11-127I20.5	12.31	2.09e-30	3.08e-27	0.49	0.49	Cancer;	chr16:4838303	chr16:4795265~4796532:-
LGG	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-12.31	2.1e-30	3.09e-27	-0.66	-0.49	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
LGG	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-12.31	2.11e-30	3.1e-27	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
LGG	cis	rs2486288	0.656	rs11637838	ENSG00000259433.2	CTD-2651B20.4	12.31	2.11e-30	3.1e-27	0.54	0.49	Glomerular filtration rate;	chr15:45258459	chr15:45330209~45332634:-
LGG	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	12.31	2.11e-30	3.1e-27	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
LGG	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-12.31	2.12e-30	3.12e-27	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
LGG	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	12.31	2.13e-30	3.13e-27	0.64	0.49	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
LGG	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-12.31	2.14e-30	3.15e-27	-0.54	-0.49	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
LGG	cis	rs172166	0.516	rs2791333	ENSG00000226314.6	ZNF192P1	12.31	2.15e-30	3.15e-27	0.48	0.49	Cardiac Troponin-T levels;	chr6:28143336	chr6:28161781~28169594:+
LGG	cis	rs172166	0.516	rs2622322	ENSG00000226314.6	ZNF192P1	12.3	2.18e-30	3.2e-27	0.48	0.49	Cardiac Troponin-T levels;	chr6:28149665	chr6:28161781~28169594:+
LGG	cis	rs6452524	1	rs7349753	ENSG00000248112.1	RP11-78C3.1	12.3	2.21e-30	3.25e-27	0.64	0.49	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:82919376~82921119:-
LGG	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-12.3	2.24e-30	3.29e-27	-0.54	-0.49	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
LGG	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-12.3	2.25e-30	3.3e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-12.3	2.25e-30	3.3e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-12.3	2.25e-30	3.3e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
LGG	cis	rs7216064	0.817	rs28609796	ENSG00000278219.1	AC145343.1	-12.3	2.27e-30	3.33e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67858988	chr17:68101538~68101639:+
LGG	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-12.3	2.28e-30	3.35e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
LGG	cis	rs2486288	0.656	rs11629858	ENSG00000259433.2	CTD-2651B20.4	12.3	2.3e-30	3.37e-27	0.55	0.49	Glomerular filtration rate;	chr15:45254916	chr15:45330209~45332634:-
LGG	cis	rs2486288	0.656	rs11629859	ENSG00000259433.2	CTD-2651B20.4	12.3	2.3e-30	3.37e-27	0.55	0.49	Glomerular filtration rate;	chr15:45254923	chr15:45330209~45332634:-
LGG	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-12.3	2.31e-30	3.38e-27	-0.62	-0.49	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
LGG	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-12.3	2.32e-30	3.41e-27	-0.62	-0.49	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
LGG	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	12.3	2.34e-30	3.43e-27	0.59	0.49	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
LGG	cis	rs2712184	0.875	rs1015784	ENSG00000229352.1	AC007563.3	-12.3	2.35e-30	3.44e-27	-0.57	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216817110	chr2:216799608~216805335:+
LGG	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-12.3	2.37e-30	3.48e-27	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
LGG	cis	rs7216064	1	rs11079706	ENSG00000278219.1	AC145343.1	-12.3	2.38e-30	3.49e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839354	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs80135947	ENSG00000278219.1	AC145343.1	-12.3	2.38e-30	3.49e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839885	chr17:68101538~68101639:+
LGG	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-12.3	2.38e-30	3.49e-27	-0.53	-0.49	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
LGG	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	12.29	2.4e-30	3.51e-27	0.76	0.49	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
LGG	cis	rs916888	0.779	rs199498	ENSG00000262500.1	RP11-259G18.2	12.29	2.4e-30	3.51e-27	0.71	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46243606~46245044:+
LGG	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	12.29	2.4e-30	3.51e-27	0.67	0.49	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
LGG	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-12.29	2.41e-30	3.53e-27	-0.48	-0.49	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
LGG	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-12.29	2.41e-30	3.54e-27	-0.51	-0.49	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
LGG	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-12.29	2.45e-30	3.58e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
LGG	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-12.29	2.46e-30	3.61e-27	-0.75	-0.49	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
LGG	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	12.29	2.47e-30	3.62e-27	0.54	0.49	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
LGG	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-12.29	2.5e-30	3.65e-27	-0.55	-0.49	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
LGG	cis	rs741668	0.641	rs1022951	ENSG00000235903.6	CPB2-AS1	12.29	2.52e-30	3.69e-27	0.49	0.49	Cerebrospinal fluid clusterin levels;	chr13:46075319	chr13:46052806~46113332:+
LGG	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	12.29	2.56e-30	3.74e-27	0.43	0.49	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
LGG	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	12.29	2.58e-30	3.78e-27	0.65	0.49	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
LGG	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	12.28	2.65e-30	3.87e-27	0.6	0.49	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
LGG	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-12.28	2.71e-30	3.97e-27	-0.53	-0.49	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
LGG	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-12.28	2.72e-30	3.97e-27	-0.54	-0.49	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
LGG	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	12.28	2.73e-30	3.99e-27	0.57	0.49	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
LGG	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-12.28	2.73e-30	4e-27	-0.54	-0.49	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
LGG	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-12.28	2.76e-30	4.04e-27	-0.58	-0.49	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
LGG	cis	rs7216064	1	rs8079754	ENSG00000278219.1	AC145343.1	-12.28	2.77e-30	4.05e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891780	chr17:68101538~68101639:+
LGG	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-12.28	2.81e-30	4.1e-27	-0.65	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
LGG	cis	rs853679	0.55	rs6901017	ENSG00000226314.6	ZNF192P1	12.28	2.82e-30	4.12e-27	0.57	0.49	Depression;	chr6:28184805	chr6:28161781~28169594:+
LGG	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-12.28	2.85e-30	4.16e-27	-0.59	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
LGG	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	12.28	2.86e-30	4.18e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	12.28	2.86e-30	4.18e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	12.28	2.86e-30	4.18e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
LGG	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	12.28	2.86e-30	4.18e-27	0.64	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
LGG	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-12.28	2.86e-30	4.18e-27	-0.68	-0.49	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
LGG	cis	rs6500637	0.58	rs2660243	ENSG00000267077.1	RP11-127I20.5	-12.28	2.87e-30	4.19e-27	-0.56	-0.49	Cancer;	chr16:4891396	chr16:4795265~4796532:-
LGG	cis	rs950027	0.549	rs2899375	ENSG00000259433.2	CTD-2651B20.4	12.28	2.87e-30	4.19e-27	0.54	0.49	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45330209~45332634:-
LGG	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-12.27	2.91e-30	4.24e-27	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
LGG	cis	rs62034325	0.697	rs710410	ENSG00000271623.1	RP11-435I10.5	-12.27	2.92e-30	4.25e-27	-0.6	-0.49	Body mass index;	chr16:28592021	chr16:28364700~28365333:+
LGG	cis	rs950027	0.549	rs11070452	ENSG00000259433.2	CTD-2651B20.4	12.27	2.97e-30	4.33e-27	0.54	0.49	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45330209~45332634:-
LGG	cis	rs657075	0.697	rs4646301	ENSG00000233006.5	AC034220.3	-12.27	2.98e-30	4.35e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132375408	chr5:132311285~132369916:-
LGG	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-12.27	2.98e-30	4.35e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
LGG	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	12.27	3.02e-30	4.41e-27	0.8	0.49	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
LGG	cis	rs4819052	0.851	rs2330011	ENSG00000223768.1	LINC00205	-12.27	3.04e-30	4.43e-27	-0.54	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45293285~45297354:+
LGG	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	12.27	3.05e-30	4.44e-27	0.69	0.49	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
LGG	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-12.27	3.05e-30	4.44e-27	-0.65	-0.49	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
LGG	cis	rs9637599	0.69	rs34752329	ENSG00000246375.2	RP11-10L7.1	12.27	3.05e-30	4.45e-27	0.6	0.49	Metabolite levels (small molecules and protein measures);	chr4:88274388	chr4:88284942~88331421:+
LGG	cis	rs2486288	0.656	rs10519018	ENSG00000259433.2	CTD-2651B20.4	12.27	3.07e-30	4.47e-27	0.54	0.49	Glomerular filtration rate;	chr15:45257067	chr15:45330209~45332634:-
LGG	cis	rs11155671	0.53	rs9371544	ENSG00000216621.7	RP11-244K5.6	12.27	3.09e-30	4.5e-27	0.57	0.49	Testicular germ cell tumor;	chr6:149896224	chr6:149934527~149936782:+
LGG	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-12.27	3.09e-30	4.51e-27	-0.9	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
LGG	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	12.27	3.1e-30	4.52e-27	0.54	0.49	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	12.27	3.1e-30	4.52e-27	0.54	0.49	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
LGG	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	12.27	3.13e-30	4.56e-27	0.68	0.49	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	12.27	3.13e-30	4.56e-27	0.68	0.49	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
LGG	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-12.27	3.14e-30	4.57e-27	-0.59	-0.49	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
LGG	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-12.27	3.15e-30	4.58e-27	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
LGG	cis	rs8064024	0.557	rs2251666	ENSG00000267077.1	RP11-127I20.5	12.26	3.18e-30	4.63e-27	0.52	0.49	Cancer;	chr16:4873090	chr16:4795265~4796532:-
LGG	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-12.26	3.19e-30	4.65e-27	-0.65	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	12.26	3.25e-30	4.73e-27	0.63	0.49	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
LGG	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-12.26	3.31e-30	4.81e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
LGG	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-12.26	3.31e-30	4.82e-27	-0.66	-0.49	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
LGG	cis	rs8064024	0.62	rs8048709	ENSG00000267077.1	RP11-127I20.5	12.26	3.32e-30	4.82e-27	0.48	0.49	Cancer;	chr16:4863760	chr16:4795265~4796532:-
LGG	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	12.26	3.35e-30	4.87e-27	0.61	0.49	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	12.26	3.38e-30	4.91e-27	0.56	0.49	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	12.26	3.38e-30	4.91e-27	0.56	0.49	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	12.26	3.38e-30	4.91e-27	0.56	0.49	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	12.26	3.38e-30	4.91e-27	0.56	0.49	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	12.26	3.38e-30	4.91e-27	0.56	0.49	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	12.26	3.38e-30	4.91e-27	0.56	0.49	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	12.26	3.38e-30	4.91e-27	0.56	0.49	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
LGG	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-12.26	3.44e-30	4.99e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-12.26	3.44e-30	4.99e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-12.26	3.44e-30	4.99e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-12.26	3.44e-30	4.99e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-12.26	3.44e-30	4.99e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
LGG	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	12.26	3.47e-30	5.03e-27	0.61	0.49	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
LGG	cis	rs7829975	0.514	rs2920983	ENSG00000173295.6	FAM86B3P	-12.25	3.51e-30	5.09e-27	-0.51	-0.49	Mood instability;	chr8:8410553	chr8:8228595~8244865:+
LGG	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	12.25	3.55e-30	5.14e-27	0.6	0.49	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
LGG	cis	rs1150668	0.835	rs203869	ENSG00000280107.1	AL022393.9	-12.25	3.55e-30	5.15e-27	-0.48	-0.49	Pubertal anthropometrics;	chr6:28073041	chr6:28170845~28172521:+
LGG	cis	rs4713118	0.869	rs9348775	ENSG00000199851.2	U3	12.25	3.56e-30	5.17e-27	0.73	0.49	Parkinson's disease;	chr6:27727550	chr6:28015568~28015777:+
LGG	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	12.25	3.57e-30	5.17e-27	0.54	0.49	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	12.25	3.57e-30	5.17e-27	0.54	0.49	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
LGG	cis	rs7216064	0.953	rs11079705	ENSG00000278219.1	AC145343.1	-12.25	3.59e-30	5.2e-27	-0.59	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839336	chr17:68101538~68101639:+
LGG	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-12.25	3.6e-30	5.22e-27	-0.57	-0.49	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
LGG	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	12.25	3.69e-30	5.34e-27	0.45	0.49	Breast size;	chr12:9232939	chr12:9277235~9313241:+
LGG	cis	rs1150668	0.799	rs9301	ENSG00000199851.2	U3	12.25	3.71e-30	5.37e-27	0.66	0.49	Pubertal anthropometrics;	chr6:28324929	chr6:28015568~28015777:+
LGG	cis	rs1150668	0.799	rs853684	ENSG00000199851.2	U3	12.25	3.71e-30	5.37e-27	0.66	0.49	Pubertal anthropometrics;	chr6:28326773	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.869	rs2056925	ENSG00000199851.2	U3	12.25	3.75e-30	5.42e-27	0.72	0.49	Parkinson's disease;	chr6:27723126	chr6:28015568~28015777:+
LGG	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-12.24	3.84e-30	5.55e-27	-0.59	-0.49	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-12.24	3.84e-30	5.55e-27	-0.59	-0.49	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
LGG	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	12.24	3.85e-30	5.56e-27	0.41	0.49	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
LGG	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-12.24	3.9e-30	5.63e-27	-0.5	-0.49	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
LGG	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	12.24	3.95e-30	5.7e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
LGG	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-12.24	4e-30	5.78e-27	-0.63	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
LGG	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	12.24	4.15e-30	5.99e-27	0.5	0.49	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
LGG	cis	rs4819052	0.851	rs35560973	ENSG00000223768.1	LINC00205	-12.24	4.18e-30	6.03e-27	-0.54	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45293285~45297354:+
LGG	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	12.23	4.2e-30	6.06e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
LGG	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	12.23	4.21e-30	6.08e-27	0.63	0.49	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
LGG	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-12.23	4.23e-30	6.1e-27	-0.86	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
LGG	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-12.23	4.26e-30	6.14e-27	-0.53	-0.49	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
LGG	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-12.23	4.26e-30	6.15e-27	-0.69	-0.49	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
LGG	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	12.23	4.26e-30	6.15e-27	0.61	0.49	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
LGG	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	12.23	4.27e-30	6.16e-27	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	12.23	4.27e-30	6.16e-27	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
LGG	cis	rs950027	0.549	rs11636114	ENSG00000259433.2	CTD-2651B20.4	-12.23	4.36e-30	6.29e-27	-0.55	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45330209~45332634:-
LGG	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	12.23	4.36e-30	6.29e-27	0.55	0.49	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
LGG	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-12.23	4.41e-30	6.35e-27	-0.57	-0.49	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
LGG	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-12.23	4.42e-30	6.37e-27	-0.52	-0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
LGG	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-12.23	4.42e-30	6.37e-27	-0.52	-0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
LGG	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-12.23	4.42e-30	6.37e-27	-0.52	-0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
LGG	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-12.23	4.47e-30	6.44e-27	-0.71	-0.49	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
LGG	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	12.23	4.47e-30	6.44e-27	0.61	0.49	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	12.23	4.49e-30	6.46e-27	0.61	0.49	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
LGG	cis	rs11098499	0.866	rs10518329	ENSG00000249244.1	RP11-548H18.2	12.22	4.65e-30	6.69e-27	0.53	0.49	Corneal astigmatism;	chr4:119480680	chr4:119391831~119395335:-
LGG	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	12.22	4.65e-30	6.7e-27	0.53	0.49	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
LGG	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	12.22	4.66e-30	6.71e-27	0.85	0.49	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
LGG	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	12.22	4.67e-30	6.72e-27	0.54	0.49	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
LGG	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	12.22	4.67e-30	6.72e-27	0.54	0.49	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
LGG	cis	rs7216064	1	rs7214758	ENSG00000278219.1	AC145343.1	-12.22	4.72e-30	6.8e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67884422	chr17:68101538~68101639:+
LGG	cis	rs9637599	0.69	rs6819344	ENSG00000246375.2	RP11-10L7.1	12.22	4.86e-30	6.98e-27	0.6	0.49	Metabolite levels (small molecules and protein measures);	chr4:88276367	chr4:88284942~88331421:+
LGG	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	-12.22	4.9e-30	7.04e-27	-0.58	-0.49	Depression;	chr6:28086929	chr6:28161781~28169594:+
LGG	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	12.22	4.91e-30	7.05e-27	0.6	0.49	Depression;	chr6:28135913	chr6:28161781~28169594:+
LGG	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-12.22	4.91e-30	7.06e-27	-0.6	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
LGG	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	12.22	4.92e-30	7.06e-27	0.79	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
LGG	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	12.22	4.94e-30	7.1e-27	0.63	0.49	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
LGG	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	12.22	4.95e-30	7.11e-27	0.61	0.49	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
LGG	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	12.22	5.03e-30	7.22e-27	0.65	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
LGG	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-12.21	5.09e-30	7.31e-27	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
LGG	cis	rs2712184	0.875	rs35925637	ENSG00000229352.1	AC007563.3	12.21	5.09e-30	7.31e-27	0.57	0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216811905	chr2:216799608~216805335:+
LGG	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-12.21	5.1e-30	7.31e-27	-0.71	-0.49	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
LGG	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-12.21	5.11e-30	7.33e-27	-0.69	-0.49	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
LGG	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	-12.21	5.13e-30	7.35e-27	-0.51	-0.49	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
LGG	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	12.21	5.17e-30	7.42e-27	0.68	0.49	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
LGG	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-12.21	5.25e-30	7.53e-27	-0.49	-0.49	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
LGG	cis	rs657075	0.64	rs13167994	ENSG00000233006.5	AC034220.3	-12.21	5.28e-30	7.56e-27	-0.77	-0.49	Rheumatoid arthritis;	chr5:132371131	chr5:132311285~132369916:-
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	12.21	5.31e-30	7.61e-27	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
LGG	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-12.21	5.33e-30	7.64e-27	-0.68	-0.49	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
LGG	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-12.21	5.35e-30	7.67e-27	-0.41	-0.49	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
LGG	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	12.21	5.36e-30	7.68e-27	0.68	0.49	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	12.21	5.36e-30	7.68e-27	0.68	0.49	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	12.21	5.36e-30	7.68e-27	0.68	0.49	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
LGG	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-12.21	5.38e-30	7.71e-27	-0.66	-0.49	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
LGG	cis	rs7216064	1	rs62084238	ENSG00000278219.1	AC145343.1	-12.21	5.42e-30	7.77e-27	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67860457	chr17:68101538~68101639:+
LGG	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	12.21	5.49e-30	7.86e-27	0.64	0.49	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
LGG	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	12.21	5.49e-30	7.86e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	12.21	5.49e-30	7.86e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
LGG	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-12.21	5.51e-30	7.88e-27	-0.61	-0.49	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
LGG	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-12.2	5.56e-30	7.95e-27	-0.59	-0.49	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
LGG	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-12.2	5.57e-30	7.97e-27	-0.6	-0.49	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
LGG	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	12.2	5.6e-30	8.01e-27	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
LGG	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-12.2	5.66e-30	8.09e-27	-0.65	-0.49	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
LGG	cis	rs11098499	0.657	rs10434028	ENSG00000249244.1	RP11-548H18.2	12.2	5.66e-30	8.1e-27	0.54	0.49	Corneal astigmatism;	chr4:119373309	chr4:119391831~119395335:-
LGG	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-12.2	5.73e-30	8.19e-27	-0.62	-0.49	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
LGG	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-12.2	5.77e-30	8.25e-27	-0.57	-0.49	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
LGG	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	12.2	5.81e-30	8.31e-27	0.54	0.49	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
LGG	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	12.2	5.88e-30	8.4e-27	0.59	0.49	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-12.2	5.91e-30	8.44e-27	-0.63	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
LGG	cis	rs11155671	0.53	rs7758033	ENSG00000216621.7	RP11-244K5.6	12.2	5.91e-30	8.44e-27	0.55	0.49	Testicular germ cell tumor;	chr6:149886999	chr6:149934527~149936782:+
LGG	cis	rs657075	0.639	rs3792885	ENSG00000233006.5	AC034220.3	-12.2	5.91e-30	8.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132316555	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs34757387	ENSG00000233006.5	AC034220.3	-12.2	5.91e-30	8.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132316984	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs34604423	ENSG00000233006.5	AC034220.3	-12.2	5.91e-30	8.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132317818	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs57600888	ENSG00000233006.5	AC034220.3	-12.2	5.91e-30	8.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132318360	chr5:132311285~132369916:-
LGG	cis	rs657075	0.643	rs71583471	ENSG00000233006.5	AC034220.3	-12.2	5.91e-30	8.45e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132318474	chr5:132311285~132369916:-
LGG	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	12.2	5.92e-30	8.46e-27	0.59	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
LGG	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	12.2	5.98e-30	8.54e-27	0.71	0.49	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
LGG	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	12.2	6.01e-30	8.58e-27	0.61	0.49	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	12.2	6.01e-30	8.58e-27	0.61	0.49	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
LGG	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	12.2	6.04e-30	8.63e-27	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
LGG	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	12.2	6.07e-30	8.66e-27	0.53	0.49	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-12.2	6.08e-30	8.68e-27	-0.53	-0.49	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
LGG	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-12.2	6.08e-30	8.68e-27	-0.64	-0.49	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
LGG	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
LGG	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	12.19	6.09e-30	8.69e-27	0.55	0.49	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.868	rs760587	ENSG00000199851.2	U3	12.19	6.2e-30	8.84e-27	0.76	0.49	Parkinson's disease;	chr6:27772521	chr6:28015568~28015777:+
LGG	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-12.19	6.22e-30	8.87e-27	-0.62	-0.49	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
LGG	cis	rs2712184	0.756	rs2024489	ENSG00000229352.1	AC007563.3	-12.19	6.26e-30	8.92e-27	-0.57	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216796807	chr2:216799608~216805335:+
LGG	cis	rs2712184	0.756	rs2712161	ENSG00000229352.1	AC007563.3	-12.19	6.26e-30	8.92e-27	-0.57	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216797661	chr2:216799608~216805335:+
LGG	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	12.19	6.26e-30	8.93e-27	0.54	0.49	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
LGG	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	12.19	6.29e-30	8.96e-27	0.55	0.49	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	12.19	6.29e-30	8.96e-27	0.55	0.49	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	12.19	6.29e-30	8.96e-27	0.55	0.49	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	12.19	6.29e-30	8.97e-27	0.61	0.49	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
LGG	cis	rs12495178	0.574	rs56760958	ENSG00000239519.1	CADM2-AS1	12.19	6.33e-30	9.02e-27	0.57	0.49	Body mass index;	chr3:85933988	chr3:85992183~86028007:-
LGG	cis	rs657075	0.697	rs71583484	ENSG00000233006.5	AC034220.3	-12.19	6.35e-30	9.05e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132383438	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583485	ENSG00000233006.5	AC034220.3	-12.19	6.35e-30	9.05e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132383690	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583486	ENSG00000233006.5	AC034220.3	-12.19	6.35e-30	9.05e-27	-0.76	-0.49	Rheumatoid arthritis;	chr5:132383997	chr5:132311285~132369916:-
LGG	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-12.19	6.37e-30	9.08e-27	-0.55	-0.49	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
LGG	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	12.19	6.37e-30	9.08e-27	0.79	0.49	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
LGG	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
LGG	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-12.19	6.46e-30	9.2e-27	-0.61	-0.49	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
LGG	cis	rs172166	0.538	rs149956	ENSG00000226314.6	ZNF192P1	12.19	6.47e-30	9.21e-27	0.48	0.49	Cardiac Troponin-T levels;	chr6:28068473	chr6:28161781~28169594:+
LGG	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	12.19	6.5e-30	9.25e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	12.19	6.5e-30	9.25e-27	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	12.19	6.57e-30	9.34e-27	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
LGG	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-12.19	6.57e-30	9.35e-27	-0.53	-0.49	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
LGG	cis	rs7829975	0.5	rs7841082	ENSG00000173295.6	FAM86B3P	12.19	6.57e-30	9.35e-27	0.53	0.49	Mood instability;	chr8:8311465	chr8:8228595~8244865:+
LGG	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-12.19	6.62e-30	9.42e-27	-0.68	-0.49	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	12.19	6.64e-30	9.44e-27	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
LGG	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-12.18	6.73e-30	9.57e-27	-0.61	-0.49	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	12.18	6.78e-30	9.64e-27	0.68	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
LGG	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-12.18	6.84e-30	9.73e-27	-0.59	-0.49	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
LGG	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	12.18	6.87e-30	9.77e-27	0.43	0.49	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
LGG	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-12.18	6.9e-30	9.8e-27	-0.61	-0.49	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-12.18	6.9e-30	9.8e-27	-0.61	-0.49	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-12.18	6.9e-30	9.8e-27	-0.61	-0.49	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-12.18	6.9e-30	9.8e-27	-0.61	-0.49	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-12.18	6.9e-30	9.8e-27	-0.61	-0.49	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-12.18	6.9e-30	9.8e-27	-0.61	-0.49	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
LGG	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	12.18	6.92e-30	9.83e-27	0.67	0.49	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
LGG	cis	rs4713118	0.868	rs9468220	ENSG00000199851.2	U3	-12.18	7.02e-30	9.97e-27	-0.75	-0.49	Parkinson's disease;	chr6:27765197	chr6:28015568~28015777:+
LGG	cis	rs657075	0.697	rs34689843	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132349563	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583477	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132350347	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs35948329	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132350759	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs36108085	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132350786	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs34754328	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132352381	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs56996855	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132353945	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs34034297	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132355483	chr5:132311285~132369916:-
LGG	cis	rs657075	0.584	rs71583479	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132356459	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs35834048	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132359643	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs35809179	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132359713	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583480	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132360559	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583481	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132360859	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583482	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132362249	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs71583483	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132362327	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs34786243	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132369028	chr5:132311285~132369916:-
LGG	cis	rs657075	0.643	rs4646298	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132369527	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3788988	ENSG00000233006.5	AC034220.3	-12.18	7.06e-30	1e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132370679	chr5:132311285~132369916:-
LGG	cis	rs2486288	0.656	rs8041702	ENSG00000259433.2	CTD-2651B20.4	12.18	7.07e-30	1e-26	0.54	0.49	Glomerular filtration rate;	chr15:45254895	chr15:45330209~45332634:-
LGG	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	12.18	7.08e-30	1e-26	0.58	0.49	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
LGG	cis	rs4819052	0.851	rs2838864	ENSG00000215447.6	BX322557.10	12.18	7.08e-30	1e-26	0.38	0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45288052~45291738:+
LGG	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	12.18	7.14e-30	1.01e-26	0.61	0.49	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
LGG	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-12.18	7.16e-30	1.02e-26	-0.52	-0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
LGG	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-12.18	7.16e-30	1.02e-26	-0.52	-0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
LGG	cis	rs172166	0.694	rs9295760	ENSG00000226314.6	ZNF192P1	12.17	7.44e-30	1.05e-26	0.54	0.49	Cardiac Troponin-T levels;	chr6:28179607	chr6:28161781~28169594:+
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-12.17	7.44e-30	1.05e-26	-0.63	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
LGG	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-12.17	7.44e-30	1.05e-26	-0.57	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
LGG	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	12.17	7.5e-30	1.06e-26	0.53	0.49	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	12.17	7.5e-30	1.06e-26	0.53	0.49	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	12.17	7.5e-30	1.06e-26	0.53	0.49	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-12.17	7.5e-30	1.06e-26	-0.53	-0.49	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
LGG	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-12.17	7.53e-30	1.07e-26	-0.61	-0.49	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
LGG	cis	rs12495178	0.574	rs4464472	ENSG00000239519.1	CADM2-AS1	12.17	7.54e-30	1.07e-26	0.56	0.49	Body mass index;	chr3:85909398	chr3:85992183~86028007:-
LGG	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-12.17	7.57e-30	1.07e-26	-0.61	-0.49	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
LGG	cis	rs4713118	0.512	rs2622319	ENSG00000226314.6	ZNF192P1	12.17	7.57e-30	1.07e-26	0.54	0.49	Parkinson's disease;	chr6:28152623	chr6:28161781~28169594:+
LGG	cis	rs172166	0.694	rs1150666	ENSG00000226314.6	ZNF192P1	12.17	7.57e-30	1.07e-26	0.54	0.49	Cardiac Troponin-T levels;	chr6:28156150	chr6:28161781~28169594:+
LGG	cis	rs11155671	0.53	rs2342770	ENSG00000216621.7	RP11-244K5.6	12.17	7.61e-30	1.08e-26	0.56	0.49	Testicular germ cell tumor;	chr6:149895549	chr6:149934527~149936782:+
LGG	cis	rs7216064	1	rs12600941	ENSG00000278219.1	AC145343.1	-12.17	7.69e-30	1.09e-26	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67922691	chr17:68101538~68101639:+
LGG	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-12.17	7.83e-30	1.11e-26	-0.66	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
LGG	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-12.17	7.83e-30	1.11e-26	-0.54	-0.49	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
LGG	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-12.17	7.85e-30	1.11e-26	-0.85	-0.49	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
LGG	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-12.17	7.87e-30	1.11e-26	-0.6	-0.49	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
LGG	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-12.17	7.91e-30	1.12e-26	-0.82	-0.49	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
LGG	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	12.17	7.91e-30	1.12e-26	0.53	0.49	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
LGG	cis	rs172166	0.56	rs203878	ENSG00000280107.1	AL022393.9	-12.17	8e-30	1.13e-26	-0.47	-0.49	Cardiac Troponin-T levels;	chr6:28081218	chr6:28170845~28172521:+
LGG	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-12.17	8.02e-30	1.13e-26	-0.52	-0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
LGG	cis	rs2486288	0.656	rs2413772	ENSG00000259433.2	CTD-2651B20.4	12.17	8.04e-30	1.14e-26	0.54	0.49	Glomerular filtration rate;	chr15:45257664	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	12.16	8.16e-30	1.15e-26	0.64	0.49	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
LGG	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-12.16	8.16e-30	1.15e-26	-0.65	-0.49	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
LGG	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-12.16	8.17e-30	1.16e-26	-0.62	-0.49	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
LGG	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	12.16	8.26e-30	1.17e-26	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
LGG	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	12.16	8.26e-30	1.17e-26	0.51	0.49	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
LGG	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	12.16	8.32e-30	1.18e-26	0.68	0.49	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
LGG	cis	rs2712184	1	rs2712184	ENSG00000229352.1	AC007563.3	-12.16	8.33e-30	1.18e-26	-0.56	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216818056	chr2:216799608~216805335:+
LGG	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	12.16	8.54e-30	1.21e-26	0.45	0.49	Breast size;	chr12:9220266	chr12:9277235~9313241:+
LGG	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-12.16	8.54e-30	1.21e-26	-0.51	-0.49	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
LGG	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-12.16	8.54e-30	1.21e-26	-0.51	-0.49	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
LGG	cis	rs12495178	0.562	rs12489145	ENSG00000239519.1	CADM2-AS1	12.16	8.62e-30	1.22e-26	0.56	0.49	Body mass index;	chr3:85923462	chr3:85992183~86028007:-
LGG	cis	rs12495178	0.536	rs34420989	ENSG00000239519.1	CADM2-AS1	12.16	8.65e-30	1.22e-26	0.56	0.49	Body mass index;	chr3:85914328	chr3:85992183~86028007:-
LGG	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-12.16	8.7e-30	1.23e-26	-0.5	-0.49	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
LGG	cis	rs7216064	1	rs7210027	ENSG00000278219.1	AC145343.1	12.16	8.72e-30	1.23e-26	0.59	0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67980937	chr17:68101538~68101639:+
LGG	cis	rs916888	0.61	rs142167	ENSG00000261575.2	RP11-259G18.1	-12.16	8.81e-30	1.24e-26	-0.6	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46267037~46268694:+
LGG	cis	rs11098499	0.691	rs9996644	ENSG00000249244.1	RP11-548H18.2	12.15	8.88e-30	1.25e-26	0.52	0.49	Corneal astigmatism;	chr4:119317722	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.691	rs9996494	ENSG00000249244.1	RP11-548H18.2	12.15	8.88e-30	1.25e-26	0.52	0.49	Corneal astigmatism;	chr4:119317725	chr4:119391831~119395335:-
LGG	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-12.15	8.89e-30	1.25e-26	-0.51	-0.49	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
LGG	cis	rs7216064	1	rs62085992	ENSG00000278219.1	AC145343.1	-12.15	8.91e-30	1.26e-26	-0.59	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67926967	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs12451721	ENSG00000278219.1	AC145343.1	-12.15	8.91e-30	1.26e-26	-0.59	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942959	chr17:68101538~68101639:+
LGG	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	12.15	8.92e-30	1.26e-26	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
LGG	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	12.15	9.03e-30	1.27e-26	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
LGG	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	12.15	9.03e-30	1.27e-26	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
LGG	cis	rs172166	0.516	rs1225710	ENSG00000218016.2	ZNF192P2	12.15	9.22e-30	1.3e-26	0.57	0.49	Cardiac Troponin-T levels;	chr6:28132862	chr6:28188050~28189432:+
LGG	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	12.15	9.23e-30	1.3e-26	0.64	0.49	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
LGG	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-12.15	9.27e-30	1.31e-26	-0.58	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
LGG	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-12.15	9.28e-30	1.31e-26	-0.59	-0.49	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
LGG	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	12.15	9.29e-30	1.31e-26	0.64	0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
LGG	cis	rs8062405	0.755	rs62031607	ENSG00000271623.1	RP11-435I10.5	-12.15	9.3e-30	1.31e-26	-0.6	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	12.15	9.36e-30	1.32e-26	0.68	0.49	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
LGG	cis	rs4713118	0.715	rs200480	ENSG00000199851.2	U3	12.15	9.4e-30	1.32e-26	0.66	0.49	Parkinson's disease;	chr6:27805886	chr6:28015568~28015777:+
LGG	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-12.15	9.4e-30	1.32e-26	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
LGG	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	12.15	9.47e-30	1.33e-26	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
LGG	cis	rs11098499	0.663	rs9996501	ENSG00000249244.1	RP11-548H18.2	12.15	9.47e-30	1.33e-26	0.52	0.49	Corneal astigmatism;	chr4:119317763	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.697	rs28458294	ENSG00000249244.1	RP11-548H18.2	12.15	9.47e-30	1.33e-26	0.52	0.49	Corneal astigmatism;	chr4:119317769	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.663	rs28369503	ENSG00000249244.1	RP11-548H18.2	12.15	9.47e-30	1.33e-26	0.52	0.49	Corneal astigmatism;	chr4:119317770	chr4:119391831~119395335:-
LGG	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-12.15	9.52e-30	1.34e-26	-0.64	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
LGG	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	12.15	9.52e-30	1.34e-26	0.53	0.49	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
LGG	cis	rs9637599	0.69	rs893971	ENSG00000246375.2	RP11-10L7.1	-12.15	9.65e-30	1.36e-26	-0.6	-0.49	Metabolite levels (small molecules and protein measures);	chr4:88282518	chr4:88284942~88331421:+
LGG	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	-12.15	9.65e-30	1.36e-26	-0.51	-0.49	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
LGG	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-12.14	9.71e-30	1.37e-26	-0.61	-0.49	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
LGG	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-12.14	9.74e-30	1.37e-26	-0.58	-0.49	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	12.14	9.77e-30	1.37e-26	0.51	0.49	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
LGG	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-12.14	9.84e-30	1.38e-26	-0.41	-0.49	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
LGG	cis	rs2712184	0.868	rs1548946	ENSG00000229352.1	AC007563.3	-12.14	9.93e-30	1.4e-26	-0.56	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216800645	chr2:216799608~216805335:+
LGG	cis	rs2712184	0.935	rs2541387	ENSG00000229352.1	AC007563.3	-12.14	9.93e-30	1.4e-26	-0.56	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216801451	chr2:216799608~216805335:+
LGG	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-12.14	9.94e-30	1.4e-26	-0.59	-0.49	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
LGG	cis	rs853679	0.55	rs1225598	ENSG00000226314.6	ZNF192P1	12.14	9.94e-30	1.4e-26	0.56	0.49	Depression;	chr6:28193021	chr6:28161781~28169594:+
LGG	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	12.14	9.94e-30	1.4e-26	0.56	0.49	Depression;	chr6:28197321	chr6:28161781~28169594:+
LGG	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	12.14	9.94e-30	1.4e-26	0.56	0.49	Depression;	chr6:28197412	chr6:28161781~28169594:+
LGG	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	12.14	9.94e-30	1.4e-26	0.56	0.49	Depression;	chr6:28198669	chr6:28161781~28169594:+
LGG	cis	rs853679	0.55	rs1233707	ENSG00000226314.6	ZNF192P1	12.14	9.94e-30	1.4e-26	0.56	0.49	Depression;	chr6:28205175	chr6:28161781~28169594:+
LGG	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	12.14	9.99e-30	1.4e-26	0.54	0.49	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
LGG	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-12.14	1.02e-29	1.43e-26	-0.75	-0.49	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
LGG	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-12.14	1.03e-29	1.44e-26	-0.61	-0.49	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
LGG	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-12.14	1.03e-29	1.44e-26	-0.61	-0.49	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
LGG	cis	rs657075	0.757	rs3805665	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132309025	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3792879	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132309142	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3792882	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132309418	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs34695718	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132309839	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3805667	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132310823	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3805668	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132310895	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3805669	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132311069	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs4646194	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132313369	chr5:132311285~132369916:-
LGG	cis	rs657075	0.64	rs2073838	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132313529	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs2073839	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132314552	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3792883	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132315488	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3828673	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132315872	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs3805676	ENSG00000233006.5	AC034220.3	-12.14	1.04e-29	1.46e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132332774	chr5:132311285~132369916:-
LGG	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	12.14	1.05e-29	1.47e-26	0.65	0.49	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
LGG	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	12.14	1.05e-29	1.48e-26	0.67	0.49	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	12.14	1.05e-29	1.48e-26	0.67	0.49	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	12.14	1.05e-29	1.48e-26	0.67	0.49	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
LGG	cis	rs657075	0.697	rs3805666	ENSG00000233006.5	AC034220.3	-12.14	1.05e-29	1.48e-26	-0.75	-0.49	Rheumatoid arthritis;	chr5:132310782	chr5:132311285~132369916:-
LGG	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-12.14	1.06e-29	1.49e-26	-0.61	-0.49	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
LGG	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-12.13	1.08e-29	1.51e-26	-0.63	-0.49	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
LGG	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	12.13	1.09e-29	1.52e-26	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
LGG	cis	rs657075	0.527	rs13180169	ENSG00000233006.5	AC034220.3	-12.13	1.09e-29	1.53e-26	-0.76	-0.49	Rheumatoid arthritis;	chr5:132369834	chr5:132311285~132369916:-
LGG	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-12.13	1.1e-29	1.54e-26	-0.64	-0.49	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
LGG	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-12.13	1.1e-29	1.55e-26	-0.63	-0.49	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
LGG	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	12.13	1.12e-29	1.57e-26	0.55	0.49	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
LGG	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	12.13	1.12e-29	1.58e-26	0.68	0.49	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
LGG	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-12.13	1.13e-29	1.59e-26	-0.62	-0.49	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
LGG	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	12.13	1.14e-29	1.59e-26	0.58	0.49	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
LGG	cis	rs4804815	0.697	rs73008237	ENSG00000268297.1	CLEC4GP1	12.13	1.14e-29	1.6e-26	0.54	0.49	Neutrophil count;	chr19:7776302	chr19:7787549~7790621:+
LGG	cis	rs2712184	0.967	rs1014680	ENSG00000229352.1	AC007563.3	12.13	1.14e-29	1.6e-26	0.55	0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216808101	chr2:216799608~216805335:+
LGG	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-12.13	1.14e-29	1.6e-26	-0.61	-0.49	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
LGG	cis	rs7216064	1	rs12452511	ENSG00000278219.1	AC145343.1	-12.13	1.16e-29	1.62e-26	-0.59	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836460	chr17:68101538~68101639:+
LGG	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	12.12	1.17e-29	1.64e-26	0.59	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	12.12	1.17e-29	1.64e-26	0.59	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	12.12	1.17e-29	1.64e-26	0.59	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	12.12	1.17e-29	1.64e-26	0.59	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
LGG	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-12.12	1.19e-29	1.66e-26	-0.71	-0.49	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
LGG	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	12.12	1.19e-29	1.66e-26	0.58	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
LGG	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-12.12	1.19e-29	1.67e-26	-0.55	-0.49	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
LGG	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	12.12	1.2e-29	1.67e-26	0.53	0.49	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
LGG	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-12.12	1.22e-29	1.7e-26	-0.7	-0.49	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
LGG	cis	rs651907	0.557	rs17347644	ENSG00000244119.1	PDCL3P4	12.12	1.22e-29	1.71e-26	0.38	0.49	Colorectal cancer;	chr3:101828889	chr3:101712472~101713191:+
LGG	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	12.12	1.22e-29	1.71e-26	0.62	0.49	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	12.12	1.22e-29	1.71e-26	0.62	0.49	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	12.12	1.22e-29	1.71e-26	0.62	0.49	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
LGG	cis	rs7216064	0.906	rs1976052	ENSG00000278219.1	AC145343.1	-12.12	1.23e-29	1.71e-26	-0.6	-0.49	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834462	chr17:68101538~68101639:+
LGG	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	-12.12	1.23e-29	1.72e-26	-0.5	-0.49	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
LGG	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	12.12	1.24e-29	1.73e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
LGG	cis	rs8064024	0.68	rs2063101	ENSG00000267077.1	RP11-127I20.5	12.12	1.26e-29	1.76e-26	0.48	0.49	Cancer;	chr16:4866347	chr16:4795265~4796532:-
LGG	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	12.12	1.27e-29	1.77e-26	0.67	0.49	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
LGG	cis	rs2712184	0.967	rs11892032	ENSG00000229352.1	AC007563.3	-12.11	1.28e-29	1.79e-26	-0.56	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216804258	chr2:216799608~216805335:+
LGG	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	12.11	1.3e-29	1.81e-26	0.61	0.49	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
LGG	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	12.11	1.31e-29	1.83e-26	0.45	0.49	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
LGG	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	12.11	1.31e-29	1.83e-26	0.57	0.49	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
LGG	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	12.11	1.31e-29	1.83e-26	0.52	0.49	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
LGG	cis	rs5742933	0.857	rs1437891	ENSG00000273240.1	RP11-455J20.3	-12.11	1.32e-29	1.85e-26	-0.57	-0.49	Ferritin levels;	chr2:189697982	chr2:189763859~189764456:-
LGG	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-12.11	1.34e-29	1.86e-26	-0.63	-0.49	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
LGG	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	12.11	1.34e-29	1.87e-26	0.6	0.49	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	12.11	1.35e-29	1.88e-26	0.68	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
LGG	cis	rs172166	0.56	rs203878	ENSG00000218016.2	ZNF192P2	-12.11	1.35e-29	1.88e-26	-0.56	-0.49	Cardiac Troponin-T levels;	chr6:28081218	chr6:28188050~28189432:+
LGG	cis	rs6908034	0.607	rs73376650	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805275	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs112599867	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805301	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs73376651	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805328	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs73376655	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805433	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs73376657	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805729	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs74573060	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805801	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs113592672	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805832	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs113894708	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.91	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805835	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs62404179	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.9	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806041	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.546	rs73376662	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.9	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806109	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs12529148	ENSG00000228412.5	RP4-625H18.2	12.11	1.38e-29	1.92e-26	0.9	0.49	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806566	chr6:19802164~19804752:-
LGG	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.38e-29	1.93e-26	-0.69	-0.49	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.38e-29	1.93e-26	-0.69	-0.49	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
LGG	cis	rs853679	0.713	rs200991	ENSG00000199851.2	U3	-12.11	1.39e-29	1.94e-26	-0.85	-0.49	Depression;	chr6:27847716	chr6:28015568~28015777:+
LGG	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-12.11	1.39e-29	1.94e-26	-1.06	-0.49	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.857	rs9608229	ENSG00000250470.1	AP000351.3	12.11	1.4e-29	1.95e-26	0.7	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23976904~23977585:-
LGG	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-12.11	1.4e-29	1.95e-26	-0.5	-0.49	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
LGG	cis	rs657075	0.697	rs71583478	ENSG00000233006.5	AC034220.3	-12.11	1.41e-29	1.96e-26	-0.77	-0.49	Rheumatoid arthritis;	chr5:132353131	chr5:132311285~132369916:-
LGG	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-12.1	1.41e-29	1.96e-26	-0.59	-0.49	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
LGG	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-12.1	1.41e-29	1.96e-26	-0.63	-0.49	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-12.1	1.41e-29	1.96e-26	-0.63	-0.49	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
LGG	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	12.1	1.42e-29	1.97e-26	0.63	0.49	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
LGG	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	12.1	1.42e-29	1.97e-26	0.63	0.49	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
LGG	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-12.1	1.43e-29	1.99e-26	-0.62	-0.49	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
LGG	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-12.1	1.43e-29	1.99e-26	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
LGG	cis	rs8062405	0.688	rs3924376	ENSG00000271623.1	RP11-435I10.5	12.1	1.44e-29	2.01e-26	0.6	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	12.1	1.45e-29	2.02e-26	0.64	0.49	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
LGG	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-12.1	1.45e-29	2.02e-26	-0.62	-0.49	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
LGG	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	12.1	1.45e-29	2.02e-26	0.52	0.49	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
LGG	cis	rs2712184	0.756	rs715049	ENSG00000229352.1	AC007563.3	-12.1	1.46e-29	2.03e-26	-0.56	-0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216792379	chr2:216799608~216805335:+
LGG	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	12.1	1.47e-29	2.04e-26	0.63	0.49	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
LGG	cis	rs172166	0.585	rs149963	ENSG00000226314.6	ZNF192P1	12.1	1.49e-29	2.07e-26	0.48	0.49	Cardiac Troponin-T levels;	chr6:28049354	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	12.1	1.49e-29	2.08e-26	0.52	0.49	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	12.1	1.49e-29	2.08e-26	0.52	0.49	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
LGG	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-12.1	1.5e-29	2.08e-26	-0.59	-0.49	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
LGG	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	12.1	1.54e-29	2.13e-26	0.44	0.49	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
LGG	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	12.09	1.55e-29	2.15e-26	0.53	0.49	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
LGG	cis	rs1420956	0.562	rs16943845	ENSG00000264151.4	RP11-739N10.1	12.09	1.56e-29	2.16e-26	0.63	0.49	Obesity-related traits;	chr18:27611959	chr18:27336379~27595164:-
LGG	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-12.09	1.58e-29	2.19e-26	-0.83	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
LGG	cis	rs172166	0.561	rs149976	ENSG00000226314.6	ZNF192P1	-12.09	1.58e-29	2.2e-26	-0.48	-0.49	Cardiac Troponin-T levels;	chr6:28019998	chr6:28161781~28169594:+
LGG	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-12.09	1.59e-29	2.2e-26	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
LGG	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-12.09	1.59e-29	2.2e-26	-1.07	-0.49	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
LGG	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-12.09	1.59e-29	2.2e-26	-0.5	-0.49	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
LGG	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-12.09	1.6e-29	2.22e-26	-0.62	-0.49	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
LGG	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	12.09	1.61e-29	2.23e-26	0.53	0.49	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
LGG	cis	rs172166	0.561	rs149973	ENSG00000226314.6	ZNF192P1	12.09	1.62e-29	2.24e-26	0.48	0.49	Cardiac Troponin-T levels;	chr6:28015835	chr6:28161781~28169594:+
LGG	cis	rs172166	0.561	rs149974	ENSG00000226314.6	ZNF192P1	12.09	1.62e-29	2.24e-26	0.48	0.49	Cardiac Troponin-T levels;	chr6:28017318	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.868	rs7756968	ENSG00000199851.2	U3	12.09	1.64e-29	2.27e-26	0.74	0.49	Parkinson's disease;	chr6:27767175	chr6:28015568~28015777:+
LGG	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	12.09	1.66e-29	2.3e-26	0.45	0.49	Breast size;	chr12:9228263	chr12:9277235~9313241:+
LGG	cis	rs8064024	0.68	rs8056320	ENSG00000267077.1	RP11-127I20.5	12.09	1.66e-29	2.3e-26	0.48	0.49	Cancer;	chr16:4868016	chr16:4795265~4796532:-
LGG	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	12.09	1.67e-29	2.31e-26	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
LGG	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	12.09	1.69e-29	2.34e-26	0.53	0.49	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
LGG	cis	rs7829975	0.514	rs2979139	ENSG00000173295.6	FAM86B3P	-12.08	1.73e-29	2.39e-26	-0.51	-0.49	Mood instability;	chr8:8410803	chr8:8228595~8244865:+
LGG	cis	rs172166	0.694	rs1225716	ENSG00000226314.6	ZNF192P1	12.08	1.73e-29	2.39e-26	0.53	0.49	Cardiac Troponin-T levels;	chr6:28145968	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	12.08	1.74e-29	2.41e-26	0.52	0.49	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	12.08	1.74e-29	2.41e-26	0.52	0.49	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
LGG	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-12.08	1.75e-29	2.42e-26	-0.68	-0.49	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
LGG	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	12.08	1.75e-29	2.42e-26	0.61	0.49	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
LGG	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-12.08	1.8e-29	2.48e-26	-0.44	-0.49	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
LGG	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	12.08	1.81e-29	2.51e-26	0.52	0.49	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
LGG	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	12.08	1.82e-29	2.52e-26	0.53	0.49	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
LGG	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	12.08	1.85e-29	2.55e-26	0.57	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
LGG	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-12.08	1.85e-29	2.56e-26	-0.5	-0.49	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
LGG	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	12.08	1.86e-29	2.57e-26	0.52	0.49	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
LGG	cis	rs2712184	0.756	rs2024487	ENSG00000229352.1	AC007563.3	12.07	1.87e-29	2.58e-26	0.56	0.49	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216798548	chr2:216799608~216805335:+
LGG	cis	rs4819052	0.851	rs7279011	ENSG00000215447.6	BX322557.10	-12.07	1.91e-29	2.63e-26	-0.37	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.765	rs2838827	ENSG00000215447.6	BX322557.10	-12.07	1.91e-29	2.63e-26	-0.37	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45288052~45291738:+
LGG	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	12.07	1.91e-29	2.64e-26	0.71	0.48	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
LGG	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	12.07	1.91e-29	2.64e-26	0.71	0.48	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
LGG	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	12.07	1.92e-29	2.65e-26	0.66	0.48	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
LGG	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	12.07	1.93e-29	2.66e-26	0.5	0.48	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
LGG	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	12.07	1.93e-29	2.67e-26	0.55	0.48	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
LGG	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-12.07	1.94e-29	2.68e-26	-0.68	-0.48	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
LGG	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-12.07	1.95e-29	2.68e-26	-0.51	-0.48	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
LGG	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-12.07	1.95e-29	2.69e-26	-0.57	-0.48	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
LGG	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	12.07	1.95e-29	2.69e-26	0.58	0.48	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
LGG	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-12.07	1.95e-29	2.69e-26	-0.57	-0.48	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
LGG	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	-12.07	1.96e-29	2.7e-26	-0.5	-0.48	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
LGG	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	12.07	1.97e-29	2.71e-26	0.62	0.48	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
LGG	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	12.07	1.98e-29	2.73e-26	0.82	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
LGG	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-12.07	1.99e-29	2.74e-26	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
LGG	cis	rs172166	0.56	rs203878	ENSG00000226314.6	ZNF192P1	12.07	2e-29	2.75e-26	0.47	0.48	Cardiac Troponin-T levels;	chr6:28081218	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	12.07	2e-29	2.76e-26	0.53	0.48	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
LGG	cis	rs7216064	1	rs12602655	ENSG00000278219.1	AC145343.1	-12.07	2e-29	2.76e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67913326	chr17:68101538~68101639:+
LGG	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-12.07	2.01e-29	2.77e-26	-0.62	-0.48	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-12.07	2.01e-29	2.77e-26	-0.62	-0.48	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
LGG	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-12.07	2.02e-29	2.78e-26	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
LGG	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	12.07	2.02e-29	2.78e-26	0.68	0.48	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
LGG	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	12.07	2.03e-29	2.79e-26	0.5	0.48	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
LGG	cis	rs8062405	0.655	rs7184597	ENSG00000271623.1	RP11-435I10.5	12.07	2.03e-29	2.79e-26	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28364700~28365333:+
LGG	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-12.07	2.04e-29	2.81e-26	-0.65	-0.48	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
LGG	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	12.06	2.05e-29	2.82e-26	0.67	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
LGG	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-12.06	2.05e-29	2.83e-26	-0.53	-0.48	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
LGG	cis	rs1420956	0.562	rs2287295	ENSG00000264151.4	RP11-739N10.1	12.06	2.08e-29	2.86e-26	0.64	0.48	Obesity-related traits;	chr18:27595323	chr18:27336379~27595164:-
LGG	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-12.06	2.08e-29	2.87e-26	-0.56	-0.48	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
LGG	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	12.06	2.09e-29	2.88e-26	0.7	0.48	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
LGG	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-12.06	2.11e-29	2.91e-26	-0.62	-0.48	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
LGG	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	12.06	2.12e-29	2.91e-26	0.67	0.48	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	12.06	2.12e-29	2.91e-26	0.67	0.48	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	12.06	2.12e-29	2.91e-26	0.67	0.48	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
LGG	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	12.06	2.12e-29	2.92e-26	0.62	0.48	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
LGG	cis	rs853679	0.506	rs1150693	ENSG00000226314.6	ZNF192P1	12.06	2.12e-29	2.92e-26	0.57	0.48	Depression;	chr6:28206812	chr6:28161781~28169594:+
LGG	cis	rs3096299	0.967	rs3102383	ENSG00000274627.1	RP11-104N10.2	12.06	2.14e-29	2.94e-26	0.43	0.48	Multiple myeloma (IgH translocation);	chr16:89344887	chr16:89516797~89522217:+
LGG	cis	rs4713118	0.505	rs156740	ENSG00000226314.6	ZNF192P1	12.06	2.14e-29	2.94e-26	0.48	0.48	Parkinson's disease;	chr6:27992657	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.826	rs2893929	ENSG00000199851.2	U3	12.06	2.16e-29	2.97e-26	0.74	0.48	Parkinson's disease;	chr6:27770953	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.666	rs4140646	ENSG00000199851.2	U3	12.06	2.16e-29	2.97e-26	0.74	0.48	Parkinson's disease;	chr6:27771022	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.666	rs2893930	ENSG00000199851.2	U3	12.06	2.16e-29	2.97e-26	0.74	0.48	Parkinson's disease;	chr6:27771027	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.868	rs742047	ENSG00000199851.2	U3	12.06	2.16e-29	2.97e-26	0.74	0.48	Parkinson's disease;	chr6:27771601	chr6:28015568~28015777:+
LGG	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-12.06	2.16e-29	2.97e-26	-0.62	-0.48	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
LGG	cis	rs112374913	1	rs112374913	ENSG00000239519.1	CADM2-AS1	12.06	2.17e-29	2.98e-26	0.56	0.48	Educational attainment;	chr3:85897356	chr3:85992183~86028007:-
LGG	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	12.06	2.18e-29	2.99e-26	0.72	0.48	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
LGG	cis	rs11098499	0.566	rs7664440	ENSG00000249244.1	RP11-548H18.2	12.06	2.19e-29	3.01e-26	0.55	0.48	Corneal astigmatism;	chr4:119657385	chr4:119391831~119395335:-
LGG	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	12.06	2.2e-29	3.02e-26	0.43	0.48	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
LGG	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-12.06	2.21e-29	3.04e-26	-0.69	-0.48	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
LGG	cis	rs7216064	1	rs11079707	ENSG00000278219.1	AC145343.1	12.06	2.21e-29	3.04e-26	0.58	0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839501	chr17:68101538~68101639:+
LGG	cis	rs2013441	1	rs2526480	ENSG00000230528.6	NOS2P3	-12.06	2.22e-29	3.05e-26	-0.45	-0.48	Obesity-related traits;	chr17:20226761	chr17:20436337~20447249:+
LGG	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-12.06	2.22e-29	3.06e-26	-0.62	-0.48	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
LGG	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	12.06	2.23e-29	3.06e-26	0.53	0.48	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
LGG	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-12.06	2.23e-29	3.06e-26	-0.5	-0.48	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
LGG	cis	rs1150668	0.799	rs1736891	ENSG00000218016.2	ZNF192P2	-12.06	2.23e-29	3.07e-26	-0.57	-0.48	Pubertal anthropometrics;	chr6:28219323	chr6:28188050~28189432:+
LGG	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-12.06	2.24e-29	3.08e-26	-0.61	-0.48	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
LGG	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	12.06	2.24e-29	3.08e-26	0.55	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
LGG	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	12.05	2.25e-29	3.09e-26	0.53	0.48	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
LGG	cis	rs5742933	0.857	rs10931430	ENSG00000273240.1	RP11-455J20.3	12.05	2.26e-29	3.1e-26	0.57	0.48	Ferritin levels;	chr2:189677460	chr2:189763859~189764456:-
LGG	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-12.05	2.28e-29	3.13e-26	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-12.05	2.28e-29	3.13e-26	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
LGG	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	12.05	2.29e-29	3.14e-26	0.52	0.48	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	12.05	2.29e-29	3.14e-26	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
LGG	cis	rs4819052	0.851	rs7279182	ENSG00000215447.6	BX322557.10	-12.05	2.3e-29	3.15e-26	-0.37	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45288052~45291738:+
LGG	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-12.05	2.31e-29	3.17e-26	-0.54	-0.48	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
LGG	cis	rs2486288	0.656	rs8039352	ENSG00000259433.2	CTD-2651B20.4	12.05	2.32e-29	3.19e-26	0.53	0.48	Glomerular filtration rate;	chr15:45259592	chr15:45330209~45332634:-
LGG	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	12.05	2.34e-29	3.21e-26	0.51	0.48	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
LGG	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	12.05	2.34e-29	3.22e-26	0.42	0.48	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
LGG	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	12.05	2.39e-29	3.28e-26	0.83	0.48	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
LGG	cis	rs657075	0.697	rs34452667	ENSG00000233006.5	AC034220.3	-12.05	2.4e-29	3.29e-26	-0.76	-0.48	Rheumatoid arthritis;	chr5:132377863	chr5:132311285~132369916:-
LGG	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-12.05	2.4e-29	3.29e-26	-0.61	-0.48	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
LGG	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	12.05	2.43e-29	3.33e-26	0.53	0.48	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
LGG	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-12.05	2.44e-29	3.34e-26	-0.57	-0.48	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
LGG	cis	rs9637599	0.69	rs6821589	ENSG00000246375.2	RP11-10L7.1	12.05	2.45e-29	3.35e-26	0.59	0.48	Metabolite levels (small molecules and protein measures);	chr4:88271640	chr4:88284942~88331421:+
LGG	cis	rs9637599	0.69	rs17789147	ENSG00000246375.2	RP11-10L7.1	12.05	2.45e-29	3.35e-26	0.59	0.48	Metabolite levels (small molecules and protein measures);	chr4:88272488	chr4:88284942~88331421:+
LGG	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	12.05	2.45e-29	3.36e-26	0.66	0.48	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
LGG	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	-12.05	2.46e-29	3.37e-26	-0.51	-0.48	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
LGG	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-12.04	2.47e-29	3.38e-26	-0.62	-0.48	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-12.04	2.47e-29	3.38e-26	-0.62	-0.48	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-12.04	2.47e-29	3.38e-26	-0.62	-0.48	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
LGG	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-12.04	2.5e-29	3.42e-26	-0.5	-0.48	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
LGG	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-12.04	2.5e-29	3.42e-26	-0.5	-0.48	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
LGG	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-12.04	2.5e-29	3.42e-26	-0.5	-0.48	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
LGG	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-12.04	2.5e-29	3.42e-26	-0.5	-0.48	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
LGG	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-12.04	2.5e-29	3.42e-26	-0.5	-0.48	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
LGG	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-12.04	2.51e-29	3.43e-26	-0.61	-0.48	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	12.04	2.55e-29	3.48e-26	0.68	0.48	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
LGG	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	12.04	2.55e-29	3.49e-26	0.53	0.48	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
LGG	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	12.04	2.55e-29	3.49e-26	0.44	0.48	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
LGG	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	12.04	2.55e-29	3.49e-26	0.56	0.48	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	12.04	2.55e-29	3.49e-26	0.56	0.48	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
LGG	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	12.04	2.56e-29	3.5e-26	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
LGG	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	12.04	2.56e-29	3.51e-26	0.53	0.48	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
LGG	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	12.04	2.59e-29	3.54e-26	0.67	0.48	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
LGG	cis	rs172166	0.516	rs1150670	ENSG00000218016.2	ZNF192P2	-12.04	2.59e-29	3.54e-26	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28162781	chr6:28188050~28189432:+
LGG	cis	rs172166	0.516	rs2021826	ENSG00000218016.2	ZNF192P2	-12.04	2.59e-29	3.54e-26	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28164978	chr6:28188050~28189432:+
LGG	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	12.04	2.62e-29	3.58e-26	0.56	0.48	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	12.04	2.62e-29	3.58e-26	0.56	0.48	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
LGG	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	12.04	2.62e-29	3.59e-26	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
LGG	cis	rs8064024	0.65	rs12926178	ENSG00000267077.1	RP11-127I20.5	-12.04	2.63e-29	3.6e-26	-0.48	-0.48	Cancer;	chr16:4855914	chr16:4795265~4796532:-
LGG	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-12.04	2.64e-29	3.61e-26	-0.57	-0.48	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
LGG	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-12.04	2.64e-29	3.61e-26	-0.57	-0.48	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
LGG	cis	rs172166	0.516	rs2622322	ENSG00000218016.2	ZNF192P2	-12.04	2.65e-29	3.62e-26	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28149665	chr6:28188050~28189432:+
LGG	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-12.04	2.67e-29	3.65e-26	-0.59	-0.48	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
LGG	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	12.04	2.69e-29	3.67e-26	0.51	0.48	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
LGG	cis	rs853679	1	rs7740487	ENSG00000216901.1	AL022393.7	12.04	2.69e-29	3.67e-26	0.83	0.48	Depression;	chr6:28248708	chr6:28176188~28176674:+
LGG	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	12.04	2.69e-29	3.67e-26	0.5	0.48	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
LGG	cis	rs1420956	0.562	rs16943800	ENSG00000264151.4	RP11-739N10.1	12.03	2.7e-29	3.69e-26	0.64	0.48	Obesity-related traits;	chr18:27593566	chr18:27336379~27595164:-
LGG	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	12.03	2.72e-29	3.71e-26	0.51	0.48	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
LGG	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	12.03	2.73e-29	3.72e-26	0.53	0.48	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
LGG	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	12.03	2.74e-29	3.74e-26	0.61	0.48	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	12.03	2.74e-29	3.74e-26	0.61	0.48	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
LGG	cis	rs172166	0.561	rs149971	ENSG00000218016.2	ZNF192P2	-12.03	2.75e-29	3.75e-26	-0.57	-0.48	Cardiac Troponin-T levels;	chr6:28014374	chr6:28188050~28189432:+
LGG	cis	rs5742933	0.857	rs13021611	ENSG00000273240.1	RP11-455J20.3	12.03	2.76e-29	3.76e-26	0.58	0.48	Ferritin levels;	chr2:189700038	chr2:189763859~189764456:-
LGG	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-12.03	2.84e-29	3.87e-26	-0.52	-0.48	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
LGG	cis	rs7216064	0.553	rs62084690	ENSG00000278219.1	AC145343.1	12.03	2.88e-29	3.93e-26	0.53	0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68039295	chr17:68101538~68101639:+
LGG	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-12.03	2.9e-29	3.96e-26	-0.62	-0.48	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-12.03	2.9e-29	3.96e-26	-0.62	-0.48	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-12.03	2.9e-29	3.96e-26	-0.62	-0.48	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
LGG	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	12.03	2.9e-29	3.96e-26	0.52	0.48	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
LGG	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	12.03	2.94e-29	4.01e-26	0.62	0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
LGG	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-12.03	2.95e-29	4.02e-26	-0.59	-0.48	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
LGG	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	12.03	2.95e-29	4.02e-26	0.66	0.48	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
LGG	cis	rs172166	0.516	rs2791333	ENSG00000218016.2	ZNF192P2	-12.02	2.97e-29	4.05e-26	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28143336	chr6:28188050~28189432:+
LGG	cis	rs1150668	0.835	rs1233696	ENSG00000218016.2	ZNF192P2	-12.02	2.97e-29	4.05e-26	-0.56	-0.48	Pubertal anthropometrics;	chr6:28175232	chr6:28188050~28189432:+
LGG	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-12.02	2.98e-29	4.05e-26	-0.73	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
LGG	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-12.02	2.99e-29	4.07e-26	-0.5	-0.48	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
LGG	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	12.02	3e-29	4.08e-26	0.54	0.48	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
LGG	cis	rs6908034	0.607	rs112659166	ENSG00000228412.5	RP4-625H18.2	12.02	3.01e-29	4.1e-26	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807178	chr6:19802164~19804752:-
LGG	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	-12.02	3.02e-29	4.11e-26	-0.5	-0.48	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
LGG	cis	rs1420956	0.562	rs16943820	ENSG00000264151.4	RP11-739N10.1	12.02	3.02e-29	4.11e-26	0.64	0.48	Obesity-related traits;	chr18:27599849	chr18:27336379~27595164:-
LGG	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	12.02	3.04e-29	4.14e-26	0.53	0.48	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
LGG	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	12.02	3.04e-29	4.14e-26	0.6	0.48	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
LGG	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-12.02	3.06e-29	4.17e-26	-0.62	-0.48	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
LGG	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-12.02	3.08e-29	4.19e-26	-0.5	-0.48	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
LGG	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-12.02	3.09e-29	4.2e-26	-0.5	-0.48	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
LGG	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-12.02	3.09e-29	4.2e-26	-0.5	-0.48	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
LGG	cis	rs4819052	0.851	rs2838826	ENSG00000215447.6	BX322557.10	-12.02	3.09e-29	4.2e-26	-0.37	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45288052~45291738:+
LGG	cis	rs853679	1	rs68141011	ENSG00000216901.1	AL022393.7	12.02	3.1e-29	4.21e-26	0.82	0.48	Depression;	chr6:28250019	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs13200462	ENSG00000216901.1	AL022393.7	12.02	3.1e-29	4.21e-26	0.82	0.48	Depression;	chr6:28250421	chr6:28176188~28176674:+
LGG	cis	rs651907	0.557	rs3806654	ENSG00000256628.3	ZBTB11-AS1	12.02	3.1e-29	4.22e-26	0.55	0.48	Colorectal cancer;	chr3:101677685	chr3:101676475~101679217:+
LGG	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	12.02	3.11e-29	4.23e-26	0.5	0.48	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
LGG	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	12.02	3.14e-29	4.27e-26	0.57	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
LGG	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-12.02	3.15e-29	4.28e-26	-0.66	-0.48	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
LGG	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-12.02	3.16e-29	4.29e-26	-0.51	-0.48	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
LGG	cis	rs2013441	0.896	rs1812934	ENSG00000230528.6	NOS2P3	12.02	3.17e-29	4.31e-26	0.45	0.48	Obesity-related traits;	chr17:20127647	chr17:20436337~20447249:+
LGG	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-12.02	3.21e-29	4.36e-26	-0.54	-0.48	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
LGG	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-12.02	3.22e-29	4.37e-26	-0.55	-0.48	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
LGG	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-12.02	3.22e-29	4.38e-26	-0.67	-0.48	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-12.02	3.22e-29	4.38e-26	-0.67	-0.48	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
LGG	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-12.02	3.23e-29	4.39e-26	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
LGG	cis	rs853679	1	rs9986596	ENSG00000216901.1	AL022393.7	12.02	3.24e-29	4.4e-26	0.82	0.48	Depression;	chr6:28251883	chr6:28176188~28176674:+
LGG	cis	rs11098499	0.604	rs2389887	ENSG00000249244.1	RP11-548H18.2	12.02	3.25e-29	4.41e-26	0.54	0.48	Corneal astigmatism;	chr4:119649489	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.604	rs34278750	ENSG00000249244.1	RP11-548H18.2	12.02	3.25e-29	4.41e-26	0.54	0.48	Corneal astigmatism;	chr4:119649981	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.604	rs10022185	ENSG00000249244.1	RP11-548H18.2	12.02	3.25e-29	4.41e-26	0.54	0.48	Corneal astigmatism;	chr4:119650610	chr4:119391831~119395335:-
LGG	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-12.01	3.35e-29	4.55e-26	-0.62	-0.48	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
LGG	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-12.01	3.41e-29	4.62e-26	-0.57	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
LGG	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-12.01	3.42e-29	4.63e-26	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
LGG	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-12.01	3.44e-29	4.67e-26	-0.59	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
LGG	cis	rs916888	0.779	rs199498	ENSG00000261575.2	RP11-259G18.1	12.01	3.46e-29	4.68e-26	0.65	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46267037~46268694:+
LGG	cis	rs7216064	1	rs9915108	ENSG00000278219.1	AC145343.1	-12.01	3.46e-29	4.69e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878347	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs9913471	ENSG00000278219.1	AC145343.1	-12.01	3.46e-29	4.69e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878379	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.861	rs73352810	ENSG00000278219.1	AC145343.1	-12.01	3.46e-29	4.69e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879068	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.906	rs8074644	ENSG00000278219.1	AC145343.1	-12.01	3.46e-29	4.69e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882101	chr17:68101538~68101639:+
LGG	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-12.01	3.5e-29	4.73e-26	-0.61	-0.48	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
LGG	cis	rs1150668	0.768	rs1150716	ENSG00000199851.2	U3	12.01	3.53e-29	4.77e-26	0.65	0.48	Pubertal anthropometrics;	chr6:28294921	chr6:28015568~28015777:+
LGG	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	12.01	3.55e-29	4.8e-26	0.67	0.48	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
LGG	cis	rs2712184	0.729	rs2541390	ENSG00000229352.1	AC007563.3	-12	3.63e-29	4.92e-26	-0.56	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216799297	chr2:216799608~216805335:+
LGG	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-12	3.66e-29	4.96e-26	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
LGG	cis	rs11098499	0.731	rs6846966	ENSG00000249244.1	RP11-548H18.2	12	3.7e-29	5e-26	0.53	0.48	Corneal astigmatism;	chr4:119372053	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	12	3.7e-29	5e-26	0.53	0.48	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
LGG	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-12	3.71e-29	5.01e-26	-0.53	-0.48	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-12	3.71e-29	5.01e-26	-0.53	-0.48	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
LGG	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	12	3.72e-29	5.03e-26	0.44	0.48	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
LGG	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-12	3.74e-29	5.06e-26	-0.57	-0.48	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
LGG	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-12	3.74e-29	5.06e-26	-0.61	-0.48	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
LGG	cis	rs7216064	1	rs9912084	ENSG00000278219.1	AC145343.1	-12	3.76e-29	5.09e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871919	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs9912770	ENSG00000278219.1	AC145343.1	-12	3.76e-29	5.09e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872117	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs9890629	ENSG00000278219.1	AC145343.1	-12	3.76e-29	5.09e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875443	chr17:68101538~68101639:+
LGG	cis	rs1150668	0.799	rs1736891	ENSG00000280107.1	AL022393.9	-12	3.76e-29	5.09e-26	-0.48	-0.48	Pubertal anthropometrics;	chr6:28219323	chr6:28170845~28172521:+
LGG	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	12	3.77e-29	5.09e-26	0.52	0.48	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	12	3.77e-29	5.09e-26	0.52	0.48	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	12	3.77e-29	5.09e-26	0.52	0.48	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	12	3.77e-29	5.09e-26	0.52	0.48	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
LGG	cis	rs5742933	0.857	rs7571089	ENSG00000273240.1	RP11-455J20.3	12	3.77e-29	5.1e-26	0.57	0.48	Ferritin levels;	chr2:189697067	chr2:189763859~189764456:-
LGG	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-12	3.78e-29	5.1e-26	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
LGG	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-12	3.78e-29	5.11e-26	-0.5	-0.48	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
LGG	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-12	3.79e-29	5.13e-26	-0.63	-0.48	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
LGG	cis	rs7546	0.501	rs12102426	ENSG00000267077.1	RP11-127I20.5	12	3.81e-29	5.14e-26	0.49	0.48	Cancer;	chr16:4872449	chr16:4795265~4796532:-
LGG	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-12	3.81e-29	5.14e-26	-0.5	-0.48	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
LGG	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	12	3.82e-29	5.15e-26	0.67	0.48	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
LGG	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	12	3.83e-29	5.17e-26	0.67	0.48	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.923	rs2184370	ENSG00000223701.3	RAET1E-AS1	12	3.84e-29	5.18e-26	0.61	0.48	Lung cancer;	chr6:149843242	chr6:149884431~149919508:+
LGG	cis	rs11155671	0.53	rs7763849	ENSG00000216621.7	RP11-244K5.6	12	3.85e-29	5.19e-26	0.56	0.48	Testicular germ cell tumor;	chr6:149885244	chr6:149934527~149936782:+
LGG	cis	rs7216064	1	rs7221651	ENSG00000278219.1	AC145343.1	12	3.85e-29	5.19e-26	0.59	0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836274	chr17:68101538~68101639:+
LGG	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-12	3.85e-29	5.2e-26	-0.56	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
LGG	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-12	3.87e-29	5.22e-26	-0.52	-0.48	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
LGG	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	12	3.88e-29	5.23e-26	0.51	0.48	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
LGG	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	12	3.89e-29	5.25e-26	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
LGG	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-12	3.91e-29	5.27e-26	-0.59	-0.48	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
LGG	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-11.99	3.92e-29	5.28e-26	-0.61	-0.48	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
LGG	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	11.99	3.93e-29	5.3e-26	0.62	0.48	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
LGG	cis	rs657075	0.697	rs4646204	ENSG00000233006.5	AC034220.3	-11.99	4.01e-29	5.4e-26	-0.75	-0.48	Rheumatoid arthritis;	chr5:132344302	chr5:132311285~132369916:-
LGG	cis	rs9637599	0.755	rs6843634	ENSG00000246375.2	RP11-10L7.1	11.99	4.01e-29	5.41e-26	0.56	0.48	Metabolite levels (small molecules and protein measures);	chr4:88267841	chr4:88284942~88331421:+
LGG	cis	rs2013441	1	rs2703782	ENSG00000230528.6	NOS2P3	11.99	4.07e-29	5.48e-26	0.45	0.48	Obesity-related traits;	chr17:20241486	chr17:20436337~20447249:+
LGG	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	11.99	4.07e-29	5.49e-26	0.83	0.48	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
LGG	cis	rs496547	1	rs496547	ENSG00000255239.1	AP002954.6	11.99	4.09e-29	5.51e-26	0.61	0.48	Hip minimal joint space width;	chr11:118705754	chr11:118688039~118690600:-
LGG	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-11.99	4.09e-29	5.51e-26	-0.61	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
LGG	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-11.99	4.1e-29	5.53e-26	-0.5	-0.48	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
LGG	cis	rs1150668	0.835	rs1233696	ENSG00000280107.1	AL022393.9	-11.99	4.15e-29	5.59e-26	-0.47	-0.48	Pubertal anthropometrics;	chr6:28175232	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	11.99	4.15e-29	5.6e-26	0.68	0.48	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
LGG	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	11.99	4.16e-29	5.6e-26	0.66	0.48	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	11.99	4.16e-29	5.6e-26	0.66	0.48	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
LGG	cis	rs7216064	1	rs11870068	ENSG00000278219.1	AC145343.1	-11.99	4.16e-29	5.6e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67948399	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs7223813	ENSG00000278219.1	AC145343.1	-11.99	4.16e-29	5.6e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67949724	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.954	rs4790973	ENSG00000278219.1	AC145343.1	-11.99	4.16e-29	5.6e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67955017	chr17:68101538~68101639:+
LGG	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-11.99	4.23e-29	5.69e-26	-0.69	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
LGG	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
LGG	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
LGG	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
LGG	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-11.99	4.26e-29	5.73e-26	-0.67	-0.48	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
LGG	cis	rs7216064	1	rs8074078	ENSG00000278219.1	AC145343.1	-11.99	4.26e-29	5.73e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67842627	chr17:68101538~68101639:+
LGG	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	11.98	4.3e-29	5.78e-26	0.43	0.48	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
LGG	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-11.98	4.33e-29	5.81e-26	-0.59	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
LGG	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-11.98	4.33e-29	5.82e-26	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
LGG	cis	rs357618	1	rs357618	ENSG00000260581.1	CTB-113P19.4	11.98	4.34e-29	5.82e-26	0.5	0.48	Basophil percentage of white cells;	chr5:151467051	chr5:151652275~151655449:+
LGG	cis	rs11098499	0.697	rs35280960	ENSG00000249244.1	RP11-548H18.2	11.98	4.37e-29	5.87e-26	0.52	0.48	Corneal astigmatism;	chr4:119335904	chr4:119391831~119395335:-
LGG	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	11.98	4.41e-29	5.92e-26	0.6	0.48	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	11.98	4.41e-29	5.92e-26	0.6	0.48	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
LGG	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-11.98	4.43e-29	5.95e-26	-0.69	-0.48	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
LGG	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-11.98	4.44e-29	5.96e-26	-0.7	-0.48	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
LGG	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	11.98	4.45e-29	5.97e-26	0.85	0.48	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
LGG	cis	rs4819052	0.808	rs2838825	ENSG00000215447.6	BX322557.10	-11.98	4.45e-29	5.97e-26	-0.37	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45288052~45291738:+
LGG	cis	rs11098499	0.866	rs6847778	ENSG00000249244.1	RP11-548H18.2	11.98	4.52e-29	6.07e-26	0.53	0.48	Corneal astigmatism;	chr4:119372427	chr4:119391831~119395335:-
LGG	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	11.98	4.54e-29	6.1e-26	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
LGG	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	11.98	4.57e-29	6.13e-26	0.51	0.48	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
LGG	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-11.98	4.57e-29	6.13e-26	-0.61	-0.48	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
LGG	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	11.98	4.59e-29	6.15e-26	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
LGG	cis	rs172166	0.694	rs2791332	ENSG00000226314.6	ZNF192P1	11.98	4.63e-29	6.2e-26	0.53	0.48	Cardiac Troponin-T levels;	chr6:28141010	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	11.98	4.64e-29	6.21e-26	0.68	0.48	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	11.98	4.64e-29	6.21e-26	0.68	0.48	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
LGG	cis	rs2564921	0.513	rs12638195	ENSG00000242142.1	SERBP1P3	-11.98	4.69e-29	6.28e-26	-0.56	-0.48	Height;	chr3:52842623	chr3:53064283~53065091:-
LGG	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	11.98	4.71e-29	6.3e-26	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
LGG	cis	rs172166	0.561	rs149976	ENSG00000218016.2	ZNF192P2	11.97	4.71e-29	6.3e-26	0.57	0.48	Cardiac Troponin-T levels;	chr6:28019998	chr6:28188050~28189432:+
LGG	cis	rs657075	0.697	rs3792880	ENSG00000233006.5	AC034220.3	11.97	4.72e-29	6.31e-26	0.72	0.48	Rheumatoid arthritis;	chr5:132309272	chr5:132311285~132369916:-
LGG	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	11.97	4.73e-29	6.33e-26	0.53	0.48	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	11.97	4.73e-29	6.33e-26	0.53	0.48	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
LGG	cis	rs12495178	0.574	rs9860792	ENSG00000239519.1	CADM2-AS1	11.97	4.75e-29	6.35e-26	0.54	0.48	Body mass index;	chr3:85900539	chr3:85992183~86028007:-
LGG	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	11.97	4.76e-29	6.36e-26	0.57	0.48	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	11.97	4.79e-29	6.41e-26	0.56	0.48	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	11.97	4.79e-29	6.41e-26	0.56	0.48	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	11.97	4.79e-29	6.41e-26	0.56	0.48	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	11.97	4.79e-29	6.41e-26	0.56	0.48	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	11.97	4.79e-29	6.41e-26	0.56	0.48	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	11.97	4.79e-29	6.41e-26	0.56	0.48	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
LGG	cis	rs9481169	1	rs9481169	ENSG00000255389.1	C6orf3	-11.97	4.8e-29	6.41e-26	-0.87	-0.48	Inflammatory skin disease;	chr6:111608659	chr6:111599875~111602295:+
LGG	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	11.97	4.82e-29	6.44e-26	0.68	0.48	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
LGG	cis	rs11148252	0.532	rs9536262	ENSG00000235660.1	LINC00345	11.97	4.83e-29	6.45e-26	0.61	0.48	Lewy body disease;	chr13:52728939	chr13:52484161~52484680:-
LGG	cis	rs657075	0.697	rs13184379	ENSG00000233006.5	AC034220.3	-11.97	4.84e-29	6.47e-26	-0.76	-0.48	Rheumatoid arthritis;	chr5:132342452	chr5:132311285~132369916:-
LGG	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-11.97	4.85e-29	6.49e-26	-0.62	-0.48	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
LGG	cis	rs6908034	0.607	rs34109983	ENSG00000228412.5	RP4-625H18.2	11.97	4.92e-29	6.57e-26	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807811	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs73376680	ENSG00000228412.5	RP4-625H18.2	11.97	4.92e-29	6.57e-26	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807868	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs73376681	ENSG00000228412.5	RP4-625H18.2	11.97	4.92e-29	6.57e-26	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807944	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs80355837	ENSG00000228412.5	RP4-625H18.2	11.97	4.92e-29	6.57e-26	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808112	chr6:19802164~19804752:-
LGG	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-11.97	4.93e-29	6.59e-26	-0.54	-0.48	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
LGG	cis	rs172166	0.694	rs203893	ENSG00000226314.6	ZNF192P1	11.97	5.11e-29	6.82e-26	0.53	0.48	Cardiac Troponin-T levels;	chr6:28094288	chr6:28161781~28169594:+
LGG	cis	rs172166	0.652	rs476167	ENSG00000226314.6	ZNF192P1	11.97	5.11e-29	6.82e-26	0.53	0.48	Cardiac Troponin-T levels;	chr6:28098110	chr6:28161781~28169594:+
LGG	cis	rs172166	0.694	rs203892	ENSG00000226314.6	ZNF192P1	11.97	5.11e-29	6.82e-26	0.53	0.48	Cardiac Troponin-T levels;	chr6:28099418	chr6:28161781~28169594:+
LGG	cis	rs172166	0.611	rs203883	ENSG00000226314.6	ZNF192P1	11.97	5.11e-29	6.82e-26	0.53	0.48	Cardiac Troponin-T levels;	chr6:28110578	chr6:28161781~28169594:+
LGG	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-11.97	5.11e-29	6.83e-26	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
LGG	cis	rs172166	0.694	rs203876	ENSG00000226314.6	ZNF192P1	11.97	5.11e-29	6.83e-26	0.53	0.48	Cardiac Troponin-T levels;	chr6:28078895	chr6:28161781~28169594:+
LGG	cis	rs172166	0.694	rs203877	ENSG00000226314.6	ZNF192P1	11.97	5.11e-29	6.83e-26	0.53	0.48	Cardiac Troponin-T levels;	chr6:28080846	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.962	rs2275045	ENSG00000223701.3	RAET1E-AS1	11.97	5.15e-29	6.87e-26	0.61	0.48	Lung cancer;	chr6:149842775	chr6:149884431~149919508:+
LGG	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	11.96	5.17e-29	6.9e-26	0.6	0.48	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
LGG	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	11.96	5.17e-29	6.9e-26	0.53	0.48	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
LGG	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	11.96	5.18e-29	6.92e-26	0.62	0.48	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
LGG	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-11.96	5.19e-29	6.93e-26	-0.59	-0.48	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
LGG	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-11.96	5.21e-29	6.95e-26	-0.55	-0.48	Height;	chr3:53027361	chr3:53064283~53065091:-
LGG	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	11.96	5.25e-29	7.01e-26	0.53	0.48	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
LGG	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-11.96	5.31e-29	7.08e-26	-0.62	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
LGG	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-11.96	5.33e-29	7.11e-26	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
LGG	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-11.96	5.36e-29	7.14e-26	-0.7	-0.48	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-11.96	5.36e-29	7.14e-26	-0.7	-0.48	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	11.96	5.36e-29	7.14e-26	0.7	0.48	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
LGG	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	11.96	5.36e-29	7.15e-26	0.59	0.48	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
LGG	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-11.96	5.37e-29	7.16e-26	-0.62	-0.48	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
LGG	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	11.96	5.37e-29	7.16e-26	0.67	0.48	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
LGG	cis	rs2712184	0.873	rs1548945	ENSG00000229352.1	AC007563.3	-11.96	5.45e-29	7.26e-26	-0.55	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216801065	chr2:216799608~216805335:+
LGG	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-11.96	5.49e-29	7.31e-26	-0.54	-0.48	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
LGG	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-11.96	5.52e-29	7.36e-26	-0.5	-0.48	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
LGG	cis	rs12495178	0.55	rs12633520	ENSG00000239519.1	CADM2-AS1	11.96	5.61e-29	7.46e-26	0.55	0.48	Body mass index;	chr3:85900754	chr3:85992183~86028007:-
LGG	cis	rs12495178	0.551	rs34803122	ENSG00000239519.1	CADM2-AS1	11.96	5.61e-29	7.46e-26	0.55	0.48	Body mass index;	chr3:85902571	chr3:85992183~86028007:-
LGG	cis	rs4713118	0.869	rs6922574	ENSG00000199851.2	U3	11.96	5.61e-29	7.47e-26	0.71	0.48	Parkinson's disease;	chr6:27725224	chr6:28015568~28015777:+
LGG	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	11.96	5.61e-29	7.47e-26	0.66	0.48	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	11.96	5.61e-29	7.47e-26	0.66	0.48	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	11.96	5.61e-29	7.47e-26	0.66	0.48	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
LGG	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-11.96	5.64e-29	7.5e-26	-0.55	-0.48	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
LGG	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-11.96	5.65e-29	7.52e-26	-0.5	-0.48	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
LGG	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-11.96	5.65e-29	7.52e-26	-0.5	-0.48	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
LGG	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	11.96	5.66e-29	7.53e-26	0.49	0.48	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
LGG	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	11.96	5.66e-29	7.53e-26	0.51	0.48	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
LGG	cis	rs657075	0.64	rs13180186	ENSG00000233006.5	AC034220.3	-11.96	5.66e-29	7.53e-26	-0.75	-0.48	Rheumatoid arthritis;	chr5:132369866	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs13180295	ENSG00000233006.5	AC034220.3	-11.96	5.66e-29	7.53e-26	-0.75	-0.48	Rheumatoid arthritis;	chr5:132369896	chr5:132311285~132369916:-
LGG	cis	rs7216064	1	rs7208663	ENSG00000278219.1	AC145343.1	-11.95	5.71e-29	7.59e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889055	chr17:68101538~68101639:+
LGG	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
LGG	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	11.95	5.8e-29	7.7e-26	0.51	0.48	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
LGG	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-11.95	5.84e-29	7.75e-26	-0.68	-0.48	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
LGG	cis	rs11098499	0.604	rs12642411	ENSG00000249244.1	RP11-548H18.2	11.95	5.89e-29	7.82e-26	0.55	0.48	Corneal astigmatism;	chr4:119659370	chr4:119391831~119395335:-
LGG	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-11.95	5.92e-29	7.85e-26	-0.53	-0.48	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
LGG	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	11.95	5.93e-29	7.87e-26	0.51	0.48	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.604	rs2389886	ENSG00000249244.1	RP11-548H18.2	11.95	5.95e-29	7.9e-26	0.54	0.48	Corneal astigmatism;	chr4:119649267	chr4:119391831~119395335:-
LGG	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-11.95	5.98e-29	7.94e-26	-0.5	-0.48	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
LGG	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-11.95	5.98e-29	7.94e-26	-0.5	-0.48	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
LGG	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-11.95	5.99e-29	7.95e-26	-0.67	-0.48	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-11.95	5.99e-29	7.95e-26	-0.67	-0.48	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-11.95	5.99e-29	7.95e-26	-0.67	-0.48	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
LGG	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	11.95	6.1e-29	8.08e-26	0.66	0.48	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
LGG	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	11.95	6.11e-29	8.11e-26	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
LGG	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-11.95	6.12e-29	8.12e-26	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
LGG	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-11.95	6.13e-29	8.13e-26	-0.57	-0.48	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
LGG	cis	rs172166	0.516	rs1225618	ENSG00000280107.1	AL022393.9	-11.95	6.14e-29	8.14e-26	-0.47	-0.48	Cardiac Troponin-T levels;	chr6:28161935	chr6:28170845~28172521:+
LGG	cis	rs1150668	0.799	rs2142730	ENSG00000199851.2	U3	11.95	6.15e-29	8.15e-26	0.65	0.48	Pubertal anthropometrics;	chr6:28298372	chr6:28015568~28015777:+
LGG	cis	rs1150668	0.835	rs203869	ENSG00000218016.2	ZNF192P2	-11.95	6.15e-29	8.16e-26	-0.56	-0.48	Pubertal anthropometrics;	chr6:28073041	chr6:28188050~28189432:+
LGG	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	11.95	6.16e-29	8.16e-26	0.57	0.48	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
LGG	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	11.95	6.17e-29	8.18e-26	0.52	0.48	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
LGG	cis	rs7216064	0.953	rs1599859	ENSG00000278219.1	AC145343.1	-11.94	6.24e-29	8.27e-26	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841077	chr17:68101538~68101639:+
LGG	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-11.94	6.24e-29	8.27e-26	-0.53	-0.48	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
LGG	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	11.94	6.3e-29	8.35e-26	0.56	0.48	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
LGG	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-11.94	6.31e-29	8.36e-26	-0.54	-0.48	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
LGG	cis	rs916888	0.697	rs199516	ENSG00000232300.1	FAM215B	-11.94	6.32e-29	8.37e-26	-0.7	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46558830~46562795:-
LGG	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-11.94	6.32e-29	8.38e-26	-0.55	-0.48	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
LGG	cis	rs12495178	0.574	rs11708377	ENSG00000239519.1	CADM2-AS1	11.94	6.33e-29	8.38e-26	0.55	0.48	Body mass index;	chr3:85882768	chr3:85992183~86028007:-
LGG	cis	rs12495178	0.574	rs62261744	ENSG00000239519.1	CADM2-AS1	11.94	6.33e-29	8.38e-26	0.55	0.48	Body mass index;	chr3:85884979	chr3:85992183~86028007:-
LGG	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-11.94	6.35e-29	8.4e-26	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-11.94	6.35e-29	8.4e-26	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
LGG	cis	rs12946454	0.668	rs4792867	ENSG00000267288.2	RP13-890H12.2	-11.94	6.36e-29	8.42e-26	-0.6	-0.48	Systolic blood pressure;	chr17:45172077	chr17:45168800~45171584:-
LGG	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	11.94	6.37e-29	8.43e-26	0.42	0.48	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
LGG	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	11.94	6.37e-29	8.43e-26	0.55	0.48	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	11.94	6.37e-29	8.43e-26	0.55	0.48	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
LGG	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	11.94	6.37e-29	8.44e-26	0.69	0.48	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
LGG	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	11.94	6.57e-29	8.7e-26	0.51	0.48	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
LGG	cis	rs7216064	0.953	rs12601759	ENSG00000278219.1	AC145343.1	-11.94	6.57e-29	8.7e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67959168	chr17:68101538~68101639:+
LGG	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	11.94	6.6e-29	8.73e-26	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
LGG	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	11.94	6.6e-29	8.73e-26	0.53	0.48	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
LGG	cis	rs2712184	0.729	rs2541397	ENSG00000229352.1	AC007563.3	-11.94	6.61e-29	8.74e-26	-0.55	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216781970	chr2:216799608~216805335:+
LGG	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	11.94	6.62e-29	8.76e-26	0.52	0.48	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	11.94	6.62e-29	8.76e-26	0.52	0.48	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	11.94	6.62e-29	8.76e-26	0.52	0.48	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
LGG	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-11.94	6.64e-29	8.78e-26	-0.59	-0.48	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
LGG	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-11.94	6.65e-29	8.79e-26	-0.59	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	11.94	6.69e-29	8.84e-26	0.67	0.48	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
LGG	cis	rs7216064	1	rs6504549	ENSG00000278219.1	AC145343.1	-11.94	6.69e-29	8.84e-26	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67892668	chr17:68101538~68101639:+
LGG	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	11.94	6.7e-29	8.86e-26	0.67	0.48	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
LGG	cis	rs8064024	0.65	rs3813749	ENSG00000267077.1	RP11-127I20.5	11.94	6.71e-29	8.87e-26	0.48	0.48	Cancer;	chr16:4869126	chr16:4795265~4796532:-
LGG	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	11.94	6.71e-29	8.88e-26	0.56	0.48	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
LGG	cis	rs8064024	0.681	rs1395602	ENSG00000267077.1	RP11-127I20.5	11.94	6.75e-29	8.92e-26	0.48	0.48	Cancer;	chr16:4861238	chr16:4795265~4796532:-
LGG	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	11.93	6.86e-29	9.06e-26	0.55	0.48	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
LGG	cis	rs651907	0.557	rs7629753	ENSG00000256628.3	ZBTB11-AS1	-11.93	6.87e-29	9.08e-26	-0.54	-0.48	Colorectal cancer;	chr3:101653078	chr3:101676475~101679217:+
LGG	cis	rs2712184	0.967	rs2541385	ENSG00000229352.1	AC007563.3	-11.93	6.91e-29	9.13e-26	-0.55	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216804872	chr2:216799608~216805335:+
LGG	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-11.93	7.01e-29	9.25e-26	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-11.93	7.01e-29	9.25e-26	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
LGG	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	11.93	7.07e-29	9.34e-26	0.51	0.48	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
LGG	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	11.93	7.08e-29	9.34e-26	0.64	0.48	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
LGG	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-11.93	7.15e-29	9.43e-26	-0.67	-0.48	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
LGG	cis	rs4819052	0.851	rs7276103	ENSG00000223768.1	LINC00205	-11.93	7.15e-29	9.44e-26	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45293285~45297354:+
LGG	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	11.93	7.15e-29	9.44e-26	0.81	0.48	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
LGG	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	11.93	7.19e-29	9.49e-26	0.58	0.48	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
LGG	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-11.93	7.27e-29	9.59e-26	-0.69	-0.48	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
LGG	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-11.93	7.27e-29	9.59e-26	-0.55	-0.48	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
LGG	cis	rs651907	0.557	rs3864012	ENSG00000256628.3	ZBTB11-AS1	11.93	7.27e-29	9.59e-26	0.54	0.48	Colorectal cancer;	chr3:101678779	chr3:101676475~101679217:+
LGG	cis	rs2712184	0.655	rs1003622	ENSG00000229352.1	AC007563.3	-11.93	7.28e-29	9.61e-26	-0.55	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216788885	chr2:216799608~216805335:+
LGG	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-11.93	7.33e-29	9.67e-26	-0.67	-0.48	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
LGG	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-11.93	7.33e-29	9.67e-26	-0.67	-0.48	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-11.93	7.33e-29	9.67e-26	-0.67	-0.48	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-11.93	7.33e-29	9.67e-26	-0.67	-0.48	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
LGG	cis	rs11098499	0.754	rs12711071	ENSG00000249244.1	RP11-548H18.2	11.93	7.34e-29	9.67e-26	0.52	0.48	Corneal astigmatism;	chr4:119319779	chr4:119391831~119395335:-
LGG	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-11.93	7.34e-29	9.68e-26	-0.53	-0.48	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
LGG	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-11.93	7.36e-29	9.7e-26	-0.53	-0.48	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
LGG	cis	rs2712184	0.66	rs10164732	ENSG00000229352.1	AC007563.3	11.93	7.44e-29	9.8e-26	0.55	0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780946	chr2:216799608~216805335:+
LGG	cis	rs5742933	0.817	rs11679767	ENSG00000273240.1	RP11-455J20.3	11.93	7.45e-29	9.82e-26	0.57	0.48	Ferritin levels;	chr2:189681574	chr2:189763859~189764456:-
LGG	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	11.93	7.45e-29	9.82e-26	0.51	0.48	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
LGG	cis	rs2712184	0.687	rs62180470	ENSG00000229352.1	AC007563.3	11.92	7.51e-29	9.9e-26	0.55	0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780728	chr2:216799608~216805335:+
LGG	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	11.92	7.52e-29	9.91e-26	0.51	0.48	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.564	rs11098507	ENSG00000249244.1	RP11-548H18.2	11.92	7.55e-29	9.95e-26	0.52	0.48	Corneal astigmatism;	chr4:119367131	chr4:119391831~119395335:-
LGG	cis	rs4819052	0.851	rs4819040	ENSG00000223768.1	LINC00205	-11.92	7.59e-29	9.99e-26	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45293285~45297354:+
LGG	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-11.92	7.67e-29	1.01e-25	-0.58	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
LGG	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-11.92	7.78e-29	1.02e-25	-0.42	-0.48	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
LGG	cis	rs172166	0.694	rs203884	ENSG00000226314.6	ZNF192P1	11.92	7.83e-29	1.03e-25	0.53	0.48	Cardiac Troponin-T levels;	chr6:28109596	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	11.92	7.97e-29	1.05e-25	0.52	0.48	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
LGG	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	11.92	8e-29	1.05e-25	0.7	0.48	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
LGG	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-11.92	8.13e-29	1.07e-25	-0.67	-0.48	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
LGG	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-11.92	8.17e-29	1.07e-25	-0.63	-0.48	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
LGG	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-11.91	8.26e-29	1.09e-25	-0.53	-0.48	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
LGG	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-11.91	8.33e-29	1.09e-25	-0.67	-0.48	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-11.91	8.33e-29	1.09e-25	-0.67	-0.48	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-11.91	8.33e-29	1.09e-25	-0.67	-0.48	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-11.91	8.33e-29	1.09e-25	-0.67	-0.48	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
LGG	cis	rs2486288	0.656	rs8037583	ENSG00000259433.2	CTD-2651B20.4	11.91	8.38e-29	1.1e-25	0.54	0.48	Glomerular filtration rate;	chr15:45254180	chr15:45330209~45332634:-
LGG	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-11.91	8.38e-29	1.1e-25	-0.6	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	11.91	8.39e-29	1.1e-25	0.67	0.48	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
LGG	cis	rs12495178	0.55	rs35498642	ENSG00000239519.1	CADM2-AS1	11.91	8.41e-29	1.1e-25	0.55	0.48	Body mass index;	chr3:85879484	chr3:85992183~86028007:-
LGG	cis	rs1420956	0.562	rs9956311	ENSG00000264151.4	RP11-739N10.1	11.91	8.45e-29	1.11e-25	0.63	0.48	Obesity-related traits;	chr18:27582888	chr18:27336379~27595164:-
LGG	cis	rs172166	0.694	rs188105	ENSG00000226314.6	ZNF192P1	11.91	8.54e-29	1.12e-25	0.53	0.48	Cardiac Troponin-T levels;	chr6:28103615	chr6:28161781~28169594:+
LGG	cis	rs172166	0.611	rs203882	ENSG00000226314.6	ZNF192P1	11.91	8.54e-29	1.12e-25	0.53	0.48	Cardiac Troponin-T levels;	chr6:28110724	chr6:28161781~28169594:+
LGG	cis	rs172166	0.694	rs1770131	ENSG00000226314.6	ZNF192P1	11.91	8.54e-29	1.12e-25	0.53	0.48	Cardiac Troponin-T levels;	chr6:28118635	chr6:28161781~28169594:+
LGG	cis	rs172166	0.694	rs1631552	ENSG00000226314.6	ZNF192P1	11.91	8.54e-29	1.12e-25	0.53	0.48	Cardiac Troponin-T levels;	chr6:28121921	chr6:28161781~28169594:+
LGG	cis	rs6003958	1	rs6003958	ENSG00000225282.1	AP000350.6	-11.91	8.56e-29	1.12e-25	-0.73	-0.48	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23926900~23929574:+
LGG	cis	rs5760092	0.755	rs6003959	ENSG00000225282.1	AP000350.6	-11.91	8.56e-29	1.12e-25	-0.73	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23926900~23929574:+
LGG	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	11.91	8.57e-29	1.12e-25	0.52	0.48	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
LGG	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-11.91	8.58e-29	1.13e-25	-0.62	-0.48	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
LGG	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-11.91	8.6e-29	1.13e-25	-0.49	-0.48	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
LGG	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-11.91	8.6e-29	1.13e-25	-0.62	-0.48	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
LGG	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-11.91	8.61e-29	1.13e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
LGG	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	11.91	8.67e-29	1.14e-25	0.52	0.48	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
LGG	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	11.91	8.67e-29	1.14e-25	0.52	0.48	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
LGG	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	11.91	8.67e-29	1.14e-25	0.52	0.48	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
LGG	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	11.91	8.67e-29	1.14e-25	0.52	0.48	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
LGG	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-11.91	8.69e-29	1.14e-25	-0.53	-0.48	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
LGG	cis	rs172166	0.538	rs1150686	ENSG00000280107.1	AL022393.9	-11.91	8.72e-29	1.14e-25	-0.47	-0.48	Cardiac Troponin-T levels;	chr6:28193493	chr6:28170845~28172521:+
LGG	cis	rs1150688	1	rs1150688	ENSG00000280107.1	AL022393.9	-11.91	8.72e-29	1.14e-25	-0.47	-0.48	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28170845~28172521:+
LGG	cis	rs7216064	1	rs3935969	ENSG00000278219.1	AC145343.1	-11.91	8.79e-29	1.15e-25	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67885843	chr17:68101538~68101639:+
LGG	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	11.91	8.83e-29	1.16e-25	0.66	0.48	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-11.91	8.85e-29	1.16e-25	-0.63	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
LGG	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-11.91	8.99e-29	1.18e-25	-0.43	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
LGG	cis	rs17772222	0.793	rs7143853	ENSG00000258983.2	RP11-507K2.2	11.9	9.03e-29	1.18e-25	0.6	0.48	Coronary artery calcification;	chr14:88578477	chr14:88499334~88515502:+
LGG	cis	rs7216064	0.953	rs1966410	ENSG00000278219.1	AC145343.1	-11.9	9.04e-29	1.18e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841099	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs8067892	ENSG00000278219.1	AC145343.1	-11.9	9.04e-29	1.18e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841867	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs7223930	ENSG00000278219.1	AC145343.1	-11.9	9.04e-29	1.18e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846070	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs8081517	ENSG00000278219.1	AC145343.1	-11.9	9.04e-29	1.18e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67849581	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs4790908	ENSG00000278219.1	AC145343.1	-11.9	9.04e-29	1.18e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67856791	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs60432293	ENSG00000278219.1	AC145343.1	-11.9	9.04e-29	1.18e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864291	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs4790905	ENSG00000278219.1	AC145343.1	-11.9	9.04e-29	1.18e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867234	chr17:68101538~68101639:+
LGG	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-11.9	9.04e-29	1.18e-25	-0.62	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
LGG	cis	rs172166	0.516	rs2622322	ENSG00000280107.1	AL022393.9	-11.9	9.17e-29	1.2e-25	-0.47	-0.48	Cardiac Troponin-T levels;	chr6:28149665	chr6:28170845~28172521:+
LGG	cis	rs1150668	0.699	rs2394049	ENSG00000199851.2	U3	11.9	9.18e-29	1.2e-25	0.63	0.48	Pubertal anthropometrics;	chr6:28271903	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-11.9	9.21e-29	1.21e-25	-0.68	-0.48	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-11.9	9.21e-29	1.21e-25	-0.68	-0.48	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-11.9	9.21e-29	1.21e-25	-0.68	-0.48	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	11.9	9.34e-29	1.22e-25	0.67	0.48	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
LGG	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	11.9	9.36e-29	1.22e-25	0.51	0.48	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	11.9	9.36e-29	1.22e-25	0.51	0.48	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
LGG	cis	rs2013441	1	rs2386429	ENSG00000230528.6	NOS2P3	11.9	9.44e-29	1.23e-25	0.44	0.48	Obesity-related traits;	chr17:20307496	chr17:20436337~20447249:+
LGG	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	11.9	9.47e-29	1.24e-25	0.52	0.48	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
LGG	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-11.9	9.53e-29	1.25e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
LGG	cis	rs172166	0.516	rs2791333	ENSG00000280107.1	AL022393.9	-11.9	9.55e-29	1.25e-25	-0.47	-0.48	Cardiac Troponin-T levels;	chr6:28143336	chr6:28170845~28172521:+
LGG	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	11.9	9.59e-29	1.25e-25	0.66	0.48	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	11.9	9.61e-29	1.25e-25	0.68	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
LGG	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-11.9	9.66e-29	1.26e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-11.9	9.66e-29	1.26e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-11.9	9.66e-29	1.26e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-11.9	9.66e-29	1.26e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-11.9	9.66e-29	1.26e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
LGG	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-11.9	9.68e-29	1.26e-25	-0.61	-0.48	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
LGG	cis	rs2739330	1	rs2739330	ENSG00000250470.1	AP000351.3	11.9	9.69e-29	1.27e-25	0.67	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23976904~23977585:-
LGG	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	11.9	9.73e-29	1.27e-25	0.55	0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	11.9	9.73e-29	1.27e-25	0.55	0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
LGG	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-11.89	9.91e-29	1.29e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-11.89	9.95e-29	1.3e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-11.89	9.95e-29	1.3e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-11.89	9.95e-29	1.3e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-11.89	9.95e-29	1.3e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
LGG	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	11.89	9.99e-29	1.3e-25	0.59	0.48	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
LGG	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-11.89	1e-28	1.31e-25	-0.67	-0.48	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
LGG	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-11.89	1.01e-28	1.32e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-11.89	1.01e-28	1.32e-25	-0.56	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
LGG	cis	rs172166	0.516	rs1150670	ENSG00000280107.1	AL022393.9	-11.89	1.02e-28	1.33e-25	-0.47	-0.48	Cardiac Troponin-T levels;	chr6:28162781	chr6:28170845~28172521:+
LGG	cis	rs172166	0.516	rs2021826	ENSG00000280107.1	AL022393.9	-11.89	1.02e-28	1.33e-25	-0.47	-0.48	Cardiac Troponin-T levels;	chr6:28164978	chr6:28170845~28172521:+
LGG	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-11.89	1.02e-28	1.33e-25	-0.69	-0.48	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-11.89	1.02e-28	1.33e-25	-0.69	-0.48	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
LGG	cis	rs12495178	0.574	rs11127912	ENSG00000239519.1	CADM2-AS1	11.89	1.03e-28	1.34e-25	0.55	0.48	Body mass index;	chr3:85898333	chr3:85992183~86028007:-
LGG	cis	rs4819052	0.851	rs2838857	ENSG00000223768.1	LINC00205	-11.89	1.03e-28	1.34e-25	-0.51	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45293285~45297354:+
LGG	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-11.89	1.03e-28	1.34e-25	-0.72	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
LGG	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	11.89	1.04e-28	1.36e-25	0.52	0.48	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
LGG	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-11.89	1.05e-28	1.36e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
LGG	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-11.89	1.05e-28	1.36e-25	-0.73	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
LGG	cis	rs1420956	0.603	rs62080908	ENSG00000264151.4	RP11-739N10.1	11.89	1.05e-28	1.36e-25	0.63	0.48	Obesity-related traits;	chr18:27569224	chr18:27336379~27595164:-
LGG	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-11.89	1.05e-28	1.37e-25	-0.55	-0.48	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-11.89	1.05e-28	1.37e-25	-0.55	-0.48	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
LGG	cis	rs651907	0.557	rs59596156	ENSG00000256628.3	ZBTB11-AS1	11.89	1.08e-28	1.4e-25	0.54	0.48	Colorectal cancer;	chr3:101675373	chr3:101676475~101679217:+
LGG	cis	rs7216064	1	rs1976054	ENSG00000278219.1	AC145343.1	-11.89	1.08e-28	1.4e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67837108	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs6504542	ENSG00000278219.1	AC145343.1	-11.89	1.08e-28	1.4e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840526	chr17:68101538~68101639:+
LGG	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-11.88	1.09e-28	1.41e-25	-0.54	-0.48	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
LGG	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	11.88	1.09e-28	1.41e-25	0.41	0.48	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
LGG	cis	rs1420956	0.505	rs11083217	ENSG00000264151.4	RP11-739N10.1	11.88	1.09e-28	1.42e-25	0.63	0.48	Obesity-related traits;	chr18:27584396	chr18:27336379~27595164:-
LGG	cis	rs1420956	0.524	rs11083218	ENSG00000264151.4	RP11-739N10.1	11.88	1.09e-28	1.42e-25	0.63	0.48	Obesity-related traits;	chr18:27584397	chr18:27336379~27595164:-
LGG	cis	rs2013441	1	rs11871827	ENSG00000230528.6	NOS2P3	11.88	1.09e-28	1.42e-25	0.45	0.48	Obesity-related traits;	chr17:20312592	chr17:20436337~20447249:+
LGG	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-11.88	1.1e-28	1.42e-25	-0.5	-0.48	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
LGG	cis	rs657075	0.697	rs3805678	ENSG00000233006.5	AC034220.3	-11.88	1.1e-28	1.43e-25	-0.75	-0.48	Rheumatoid arthritis;	chr5:132339514	chr5:132311285~132369916:-
LGG	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-11.88	1.1e-28	1.43e-25	-0.62	-0.48	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
LGG	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-11.88	1.11e-28	1.44e-25	-0.62	-0.48	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
LGG	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-11.88	1.11e-28	1.44e-25	-0.67	-0.48	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-11.88	1.11e-28	1.44e-25	-0.67	-0.48	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-11.88	1.11e-28	1.44e-25	-0.67	-0.48	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-11.88	1.11e-28	1.44e-25	-0.67	-0.48	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-11.88	1.11e-28	1.44e-25	-0.67	-0.48	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-11.88	1.11e-28	1.44e-25	-0.67	-0.48	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
LGG	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-11.88	1.11e-28	1.44e-25	-0.7	-0.48	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
LGG	cis	rs172166	0.538	rs1150686	ENSG00000218016.2	ZNF192P2	-11.88	1.11e-28	1.44e-25	-0.55	-0.48	Cardiac Troponin-T levels;	chr6:28193493	chr6:28188050~28189432:+
LGG	cis	rs1150688	1	rs1150688	ENSG00000218016.2	ZNF192P2	-11.88	1.11e-28	1.44e-25	-0.55	-0.48	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28188050~28189432:+
LGG	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-11.88	1.12e-28	1.46e-25	-0.63	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
LGG	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-11.88	1.14e-28	1.48e-25	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
LGG	cis	rs12946454	0.621	rs11651809	ENSG00000267288.2	RP13-890H12.2	-11.88	1.15e-28	1.49e-25	-0.6	-0.48	Systolic blood pressure;	chr17:45178314	chr17:45168800~45171584:-
LGG	cis	rs67340775	0.541	rs200979	ENSG00000199851.2	U3	11.88	1.15e-28	1.49e-25	0.91	0.48	Lung cancer in ever smokers;	chr6:27884579	chr6:28015568~28015777:+
LGG	cis	rs67340775	0.541	rs200975	ENSG00000199851.2	U3	11.88	1.15e-28	1.49e-25	0.91	0.48	Lung cancer in ever smokers;	chr6:27887847	chr6:28015568~28015777:+
LGG	cis	rs67340775	0.541	rs200974	ENSG00000199851.2	U3	11.88	1.15e-28	1.49e-25	0.91	0.48	Lung cancer in ever smokers;	chr6:27888067	chr6:28015568~28015777:+
LGG	cis	rs172166	0.538	rs149956	ENSG00000218016.2	ZNF192P2	-11.88	1.15e-28	1.49e-25	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28068473	chr6:28188050~28189432:+
LGG	cis	rs172166	0.543	rs1150691	ENSG00000226314.6	ZNF192P1	11.88	1.15e-28	1.49e-25	0.47	0.48	Cardiac Troponin-T levels;	chr6:28200255	chr6:28161781~28169594:+
LGG	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	11.88	1.15e-28	1.5e-25	0.7	0.48	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
LGG	cis	rs853679	1	rs1679732	ENSG00000216901.1	AL022393.7	-11.88	1.15e-28	1.5e-25	-0.81	-0.48	Depression;	chr6:28253486	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs1679709	ENSG00000216901.1	AL022393.7	-11.88	1.15e-28	1.5e-25	-0.81	-0.48	Depression;	chr6:28260564	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs1778511	ENSG00000216901.1	AL022393.7	-11.88	1.15e-28	1.5e-25	-0.81	-0.48	Depression;	chr6:28261633	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs1778508	ENSG00000216901.1	AL022393.7	-11.88	1.15e-28	1.5e-25	-0.81	-0.48	Depression;	chr6:28262103	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs11965538	ENSG00000216901.1	AL022393.7	11.88	1.15e-28	1.5e-25	0.81	0.48	Depression;	chr6:28272137	chr6:28176188~28176674:+
LGG	cis	rs853679	0.882	rs2743555	ENSG00000216901.1	AL022393.7	11.88	1.15e-28	1.5e-25	0.81	0.48	Depression;	chr6:28273304	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs1419183	ENSG00000216901.1	AL022393.7	11.88	1.15e-28	1.5e-25	0.81	0.48	Depression;	chr6:28275017	chr6:28176188~28176674:+
LGG	cis	rs11098499	0.913	rs12186259	ENSG00000249244.1	RP11-548H18.2	11.88	1.17e-28	1.51e-25	0.53	0.48	Corneal astigmatism;	chr4:119230884	chr4:119391831~119395335:-
LGG	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-11.88	1.17e-28	1.52e-25	-0.61	-0.48	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
LGG	cis	rs4804815	0.78	rs62125168	ENSG00000268297.1	CLEC4GP1	11.88	1.17e-28	1.52e-25	0.52	0.48	Neutrophil count;	chr19:7775635	chr19:7787549~7790621:+
LGG	cis	rs4804815	0.78	rs75533704	ENSG00000268297.1	CLEC4GP1	11.88	1.17e-28	1.52e-25	0.52	0.48	Neutrophil count;	chr19:7775671	chr19:7787549~7790621:+
LGG	cis	rs12946454	0.696	rs4792819	ENSG00000267288.2	RP13-890H12.2	-11.88	1.17e-28	1.52e-25	-0.59	-0.48	Systolic blood pressure;	chr17:45170590	chr17:45168800~45171584:-
LGG	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-11.88	1.18e-28	1.52e-25	-0.6	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
LGG	cis	rs1150668	0.799	rs1150707	ENSG00000218016.2	ZNF192P2	-11.88	1.18e-28	1.53e-25	-0.56	-0.48	Pubertal anthropometrics;	chr6:28229827	chr6:28188050~28189432:+
LGG	cis	rs1150668	0.768	rs1233713	ENSG00000218016.2	ZNF192P2	-11.88	1.18e-28	1.53e-25	-0.56	-0.48	Pubertal anthropometrics;	chr6:28230503	chr6:28188050~28189432:+
LGG	cis	rs2013441	1	rs2703774	ENSG00000230528.6	NOS2P3	11.88	1.18e-28	1.53e-25	0.45	0.48	Obesity-related traits;	chr17:20230225	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.932	rs2526488	ENSG00000230528.6	NOS2P3	11.87	1.19e-28	1.54e-25	0.44	0.48	Obesity-related traits;	chr17:20195304	chr17:20436337~20447249:+
LGG	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-11.87	1.19e-28	1.55e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
LGG	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	11.87	1.21e-28	1.57e-25	0.62	0.48	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
LGG	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-11.87	1.22e-28	1.58e-25	-0.67	-0.48	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
LGG	cis	rs4819052	0.851	rs2838857	ENSG00000215447.6	BX322557.10	-11.87	1.22e-28	1.58e-25	-0.36	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45288052~45291738:+
LGG	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	11.87	1.22e-28	1.58e-25	0.53	0.48	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
LGG	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	11.87	1.22e-28	1.58e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	11.87	1.22e-28	1.58e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
LGG	cis	rs172166	0.637	rs1225592	ENSG00000226314.6	ZNF192P1	11.87	1.23e-28	1.59e-25	0.52	0.48	Cardiac Troponin-T levels;	chr6:28182464	chr6:28161781~28169594:+
LGG	cis	rs172166	0.637	rs1225595	ENSG00000226314.6	ZNF192P1	11.87	1.23e-28	1.59e-25	0.52	0.48	Cardiac Troponin-T levels;	chr6:28183562	chr6:28161781~28169594:+
LGG	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	11.87	1.23e-28	1.59e-25	0.44	0.48	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
LGG	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-11.87	1.23e-28	1.59e-25	-0.5	-0.48	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
LGG	cis	rs6908034	0.607	rs12525152	ENSG00000228412.5	RP4-625H18.2	11.87	1.23e-28	1.59e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19802164~19804752:-
LGG	cis	rs2013441	1	rs9900166	ENSG00000230528.6	NOS2P3	11.87	1.24e-28	1.6e-25	0.44	0.48	Obesity-related traits;	chr17:20289656	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.965	rs6587063	ENSG00000230528.6	NOS2P3	11.87	1.24e-28	1.6e-25	0.44	0.48	Obesity-related traits;	chr17:20290627	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs1561974	ENSG00000230528.6	NOS2P3	11.87	1.24e-28	1.6e-25	0.44	0.48	Obesity-related traits;	chr17:20292831	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2034109	ENSG00000230528.6	NOS2P3	11.87	1.24e-28	1.6e-25	0.44	0.48	Obesity-related traits;	chr17:20293320	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs9325894	ENSG00000230528.6	NOS2P3	11.87	1.24e-28	1.6e-25	0.44	0.48	Obesity-related traits;	chr17:20293788	chr17:20436337~20447249:+
LGG	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-11.87	1.24e-28	1.6e-25	-0.43	-0.48	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
LGG	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-11.87	1.25e-28	1.62e-25	-0.5	-0.48	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
LGG	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-11.87	1.25e-28	1.62e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
LGG	cis	rs853679	1	rs6901575	ENSG00000216901.1	AL022393.7	11.87	1.26e-28	1.63e-25	0.81	0.48	Depression;	chr6:28283207	chr6:28176188~28176674:+
LGG	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-11.87	1.27e-28	1.63e-25	-0.61	-0.48	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
LGG	cis	rs1150668	0.799	rs9301	ENSG00000226314.6	ZNF192P1	11.87	1.27e-28	1.64e-25	0.47	0.48	Pubertal anthropometrics;	chr6:28324929	chr6:28161781~28169594:+
LGG	cis	rs1150668	0.799	rs853684	ENSG00000226314.6	ZNF192P1	11.87	1.27e-28	1.64e-25	0.47	0.48	Pubertal anthropometrics;	chr6:28326773	chr6:28161781~28169594:+
LGG	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	11.87	1.27e-28	1.65e-25	0.63	0.48	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
LGG	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	11.87	1.27e-28	1.65e-25	0.63	0.48	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
LGG	cis	rs172166	0.585	rs149963	ENSG00000218016.2	ZNF192P2	-11.87	1.28e-28	1.66e-25	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28049354	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs149962	ENSG00000226314.6	ZNF192P1	11.87	1.29e-28	1.67e-25	0.53	0.48	Parkinson's disease;	chr6:28048140	chr6:28161781~28169594:+
LGG	cis	rs5821446	1	rs5821446	ENSG00000278219.1	AC145343.1	11.86	1.31e-28	1.69e-25	0.57	0.48	Eosinophil percentage of granulocytes;	chr17:67966422	chr17:68101538~68101639:+
LGG	cis	rs4819052	0.851	rs1006779	ENSG00000223768.1	LINC00205	-11.86	1.31e-28	1.7e-25	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45293285~45297354:+
LGG	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
LGG	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
LGG	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.32e-28	1.7e-25	-0.67	-0.48	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
LGG	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	11.86	1.32e-28	1.7e-25	0.55	0.48	Depression;	chr6:28201380	chr6:28161781~28169594:+
LGG	cis	rs7216064	1	rs7209675	ENSG00000278219.1	AC145343.1	-11.86	1.33e-28	1.72e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67835142	chr17:68101538~68101639:+
LGG	cis	rs7927771	0.698	rs34467936	ENSG00000280615.1	Y_RNA	-11.86	1.34e-28	1.73e-25	-0.61	-0.48	Subjective well-being;	chr11:47893747	chr11:47614898~47614994:-
LGG	cis	rs172166	0.694	rs536704	ENSG00000226314.6	ZNF192P1	11.86	1.35e-28	1.74e-25	0.52	0.48	Cardiac Troponin-T levels;	chr6:28124825	chr6:28161781~28169594:+
LGG	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-11.86	1.35e-28	1.74e-25	-0.5	-0.48	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-11.86	1.35e-28	1.74e-25	-0.5	-0.48	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
LGG	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-11.86	1.35e-28	1.74e-25	-0.54	-0.48	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
LGG	cis	rs2013441	0.931	rs4925089	ENSG00000230528.6	NOS2P3	-11.86	1.36e-28	1.75e-25	-0.44	-0.48	Obesity-related traits;	chr17:20161471	chr17:20436337~20447249:+
LGG	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	11.86	1.36e-28	1.75e-25	0.59	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	11.86	1.36e-28	1.75e-25	0.59	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
LGG	cis	rs172166	0.538	rs1150686	ENSG00000226314.6	ZNF192P1	11.86	1.38e-28	1.78e-25	0.46	0.48	Cardiac Troponin-T levels;	chr6:28193493	chr6:28161781~28169594:+
LGG	cis	rs1150688	1	rs1150688	ENSG00000226314.6	ZNF192P1	11.86	1.38e-28	1.78e-25	0.46	0.48	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	11.86	1.39e-28	1.79e-25	0.52	0.48	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
LGG	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	11.86	1.4e-28	1.8e-25	0.98	0.48	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
LGG	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-11.86	1.42e-28	1.83e-25	-0.57	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
LGG	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
LGG	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.42e-28	1.83e-25	-0.67	-0.48	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
LGG	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-11.85	1.43e-28	1.84e-25	-0.69	-0.48	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
LGG	cis	rs2013441	0.804	rs1811453	ENSG00000230528.6	NOS2P3	11.85	1.44e-28	1.85e-25	0.44	0.48	Obesity-related traits;	chr17:20328880	chr17:20436337~20447249:+
LGG	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-11.85	1.46e-28	1.88e-25	-0.42	-0.48	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
LGG	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-11.85	1.46e-28	1.88e-25	-0.42	-0.48	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
LGG	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-11.85	1.46e-28	1.88e-25	-0.5	-0.48	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
LGG	cis	rs2013441	0.931	rs12937827	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20129889	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs17686839	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20135858	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs4924809	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20141360	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs34712254	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20145995	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs34089239	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20154646	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs34644796	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20160815	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs4924810	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20168506	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703794	ENSG00000230528.6	NOS2P3	-11.85	1.49e-28	1.91e-25	-0.44	-0.48	Obesity-related traits;	chr17:20170025	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526464	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20171739	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2189710	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20175651	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703799	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20182455	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526460	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20183039	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2243732	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20185276	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526458	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20188887	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs8079701	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20313252	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2058971	ENSG00000230528.6	NOS2P3	11.85	1.49e-28	1.91e-25	0.44	0.48	Obesity-related traits;	chr17:20316195	chr17:20436337~20447249:+
LGG	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-11.85	1.51e-28	1.94e-25	-0.54	-0.48	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
LGG	cis	rs2013441	1	rs8074047	ENSG00000230528.6	NOS2P3	11.85	1.52e-28	1.95e-25	0.44	0.48	Obesity-related traits;	chr17:20273390	chr17:20436337~20447249:+
LGG	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	11.85	1.55e-28	1.99e-25	0.51	0.48	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
LGG	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-11.85	1.56e-28	1.99e-25	-0.61	-0.48	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-11.85	1.56e-28	1.99e-25	-0.61	-0.48	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-11.85	1.56e-28	1.99e-25	-0.61	-0.48	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
LGG	cis	rs4819052	0.851	rs28442024	ENSG00000223768.1	LINC00205	-11.85	1.56e-28	2e-25	-0.53	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45293285~45297354:+
LGG	cis	rs2013441	1	rs4588033	ENSG00000230528.6	NOS2P3	11.84	1.57e-28	2.01e-25	0.45	0.48	Obesity-related traits;	chr17:20126588	chr17:20436337~20447249:+
LGG	cis	rs4713118	0.513	rs149955	ENSG00000226314.6	ZNF192P1	11.84	1.57e-28	2.02e-25	0.52	0.48	Parkinson's disease;	chr6:28068447	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.868	rs2893928	ENSG00000199851.2	U3	11.84	1.58e-28	2.02e-25	0.75	0.48	Parkinson's disease;	chr6:27770651	chr6:28015568~28015777:+
LGG	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-11.84	1.58e-28	2.02e-25	-0.42	-0.48	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
LGG	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-11.84	1.58e-28	2.02e-25	-0.42	-0.48	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
LGG	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	11.84	1.58e-28	2.02e-25	0.51	0.48	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
LGG	cis	rs2013441	1	rs9897328	ENSG00000230528.6	NOS2P3	11.84	1.58e-28	2.02e-25	0.44	0.48	Obesity-related traits;	chr17:20271539	chr17:20436337~20447249:+
LGG	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	11.84	1.58e-28	2.03e-25	0.51	0.48	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
LGG	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-11.84	1.59e-28	2.03e-25	-0.43	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
LGG	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	11.84	1.59e-28	2.04e-25	0.59	0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
LGG	cis	rs2013441	1	rs2080673	ENSG00000230528.6	NOS2P3	-11.84	1.59e-28	2.04e-25	-0.44	-0.48	Obesity-related traits;	chr17:20159082	chr17:20436337~20447249:+
LGG	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-11.84	1.6e-28	2.05e-25	-0.62	-0.48	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
LGG	cis	rs2013441	0.965	rs2386485	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20191933	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526490	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20194213	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703801	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20197287	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703802	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20197726	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526484	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20200447	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703804	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20203882	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703806	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20204926	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526483	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20208903	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703810	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20210402	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.965	rs1544421	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20210904	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703816	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20215574	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703818	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20216663	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703821	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20218213	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.901	rs2526474	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20233821	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526472	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20234575	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703778	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20235587	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2158473	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20235777	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703780	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20240359	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703785	ENSG00000230528.6	NOS2P3	11.84	1.61e-28	2.05e-25	0.44	0.48	Obesity-related traits;	chr17:20249105	chr17:20436337~20447249:+
LGG	cis	rs6908034	0.607	rs79406203	ENSG00000228412.5	RP4-625H18.2	11.84	1.62e-28	2.07e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19815990	chr6:19802164~19804752:-
LGG	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-11.84	1.63e-28	2.08e-25	-0.67	-0.48	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
LGG	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-11.84	1.63e-28	2.09e-25	-0.58	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
LGG	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	11.84	1.64e-28	2.1e-25	0.51	0.48	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
LGG	cis	rs8064024	0.538	rs12446456	ENSG00000267077.1	RP11-127I20.5	11.84	1.64e-28	2.1e-25	0.48	0.48	Cancer;	chr16:4872200	chr16:4795265~4796532:-
LGG	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	11.84	1.65e-28	2.11e-25	0.59	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
LGG	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	11.84	1.65e-28	2.11e-25	0.56	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
LGG	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	11.84	1.66e-28	2.12e-25	0.52	0.48	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	11.84	1.66e-28	2.12e-25	0.52	0.48	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	11.84	1.66e-28	2.12e-25	0.52	0.48	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	11.84	1.66e-28	2.12e-25	0.52	0.48	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
LGG	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	11.84	1.67e-28	2.13e-25	0.53	0.48	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
LGG	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	11.84	1.67e-28	2.13e-25	0.74	0.48	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
LGG	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	11.84	1.67e-28	2.13e-25	0.54	0.48	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
LGG	cis	rs172166	0.637	rs1233691	ENSG00000226314.6	ZNF192P1	11.84	1.67e-28	2.13e-25	0.51	0.48	Cardiac Troponin-T levels;	chr6:28186119	chr6:28161781~28169594:+
LGG	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	11.84	1.67e-28	2.13e-25	0.59	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
LGG	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-11.84	1.68e-28	2.14e-25	-0.49	-0.48	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
LGG	cis	rs2013441	0.965	rs2703820	ENSG00000230528.6	NOS2P3	11.84	1.69e-28	2.15e-25	0.44	0.48	Obesity-related traits;	chr17:20218166	chr17:20436337~20447249:+
LGG	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-11.84	1.69e-28	2.16e-25	-0.66	-0.48	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
LGG	cis	rs853679	1	rs2799077	ENSG00000216901.1	AL022393.7	11.84	1.7e-28	2.16e-25	0.81	0.48	Depression;	chr6:28266819	chr6:28176188~28176674:+
LGG	cis	rs172166	0.561	rs149971	ENSG00000226314.6	ZNF192P1	11.84	1.7e-28	2.17e-25	0.47	0.48	Cardiac Troponin-T levels;	chr6:28014374	chr6:28161781~28169594:+
LGG	cis	rs2013441	1	rs1992562	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.2e-25	0.44	0.48	Obesity-related traits;	chr17:20315480	chr17:20436337~20447249:+
LGG	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	11.83	1.73e-28	2.21e-25	0.63	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
LGG	cis	rs2013441	1	rs2703817	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20216364	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703789	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20259610	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.965	rs2703790	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20259896	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703791	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20260216	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2526467	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20261741	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703792	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20263637	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2013576	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20264379	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.965	rs9896221	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20277024	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs9896709	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20277237	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs3850781	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20278626	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.932	rs3850782	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20278627	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs3850784	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20281717	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.932	rs3850785	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20281935	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs9905493	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20285268	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs1373147	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20303332	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs11871945	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20303570	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2120282	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20306161	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2165897	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20306408	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.965	rs8071665	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20306630	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.965	rs8068720	ENSG00000230528.6	NOS2P3	11.83	1.73e-28	2.21e-25	0.44	0.48	Obesity-related traits;	chr17:20310858	chr17:20436337~20447249:+
LGG	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-11.83	1.74e-28	2.22e-25	-0.53	-0.48	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
LGG	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-11.83	1.75e-28	2.23e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
LGG	cis	rs11098499	0.604	rs17051352	ENSG00000249244.1	RP11-548H18.2	11.83	1.75e-28	2.23e-25	0.55	0.48	Corneal astigmatism;	chr4:119660272	chr4:119391831~119395335:-
LGG	cis	rs6908034	0.66	rs12525506	ENSG00000228412.5	RP4-625H18.2	11.83	1.75e-28	2.24e-25	0.91	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19802164~19804752:-
LGG	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	11.83	1.77e-28	2.25e-25	0.52	0.48	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
LGG	cis	rs1150668	0.699	rs1531681	ENSG00000199851.2	U3	11.83	1.79e-28	2.27e-25	0.62	0.48	Pubertal anthropometrics;	chr6:28259100	chr6:28015568~28015777:+
LGG	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-11.83	1.83e-28	2.32e-25	-0.61	-0.48	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
LGG	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-11.83	1.84e-28	2.34e-25	-0.58	-0.48	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
LGG	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.84e-28	2.34e-25	-0.66	-0.48	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
LGG	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-11.83	1.85e-28	2.36e-25	-0.42	-0.48	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
LGG	cis	rs11098499	0.779	rs10857066	ENSG00000249244.1	RP11-548H18.2	11.83	1.86e-28	2.36e-25	0.52	0.48	Corneal astigmatism;	chr4:119365441	chr4:119391831~119395335:-
LGG	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-11.83	1.86e-28	2.36e-25	-0.58	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
LGG	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	11.83	1.86e-28	2.37e-25	0.69	0.48	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
LGG	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	11.83	1.86e-28	2.37e-25	0.51	0.48	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
LGG	cis	rs4819052	0.808	rs2838825	ENSG00000223768.1	LINC00205	-11.83	1.87e-28	2.38e-25	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45293285~45297354:+
LGG	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-11.82	1.89e-28	2.4e-25	-0.54	-0.48	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
LGG	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-11.82	1.89e-28	2.4e-25	-0.67	-0.48	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-11.82	1.89e-28	2.4e-25	-0.67	-0.48	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-11.82	1.89e-28	2.4e-25	-0.67	-0.48	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-11.82	1.89e-28	2.4e-25	-0.67	-0.48	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
LGG	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	11.82	1.9e-28	2.41e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
LGG	cis	rs2712184	0.756	rs2541393	ENSG00000229352.1	AC007563.3	-11.82	1.9e-28	2.41e-25	-0.55	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216786507	chr2:216799608~216805335:+
LGG	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-11.82	1.92e-28	2.44e-25	-0.67	-0.48	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
LGG	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-11.82	1.95e-28	2.48e-25	-0.5	-0.48	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
LGG	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	11.82	1.95e-28	2.48e-25	0.56	0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.866	rs11098506	ENSG00000249244.1	RP11-548H18.2	11.82	1.96e-28	2.49e-25	0.52	0.48	Corneal astigmatism;	chr4:119363816	chr4:119391831~119395335:-
LGG	cis	rs916888	0.738	rs199515	ENSG00000232300.1	FAM215B	-11.82	1.97e-28	2.5e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46558830~46562795:-
LGG	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-11.82	1.97e-28	2.5e-25	-0.81	-0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
LGG	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-11.82	1.97e-28	2.51e-25	-0.59	-0.48	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
LGG	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-11.82	1.98e-28	2.51e-25	-0.7	-0.48	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-11.82	1.98e-28	2.51e-25	-0.7	-0.48	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
LGG	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-11.82	1.98e-28	2.51e-25	-0.49	-0.48	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
LGG	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	11.82	1.99e-28	2.53e-25	0.74	0.48	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
LGG	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	11.82	2.01e-28	2.55e-25	0.63	0.48	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
LGG	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	11.82	2.01e-28	2.55e-25	0.57	0.48	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
LGG	cis	rs8064024	0.681	rs9925944	ENSG00000267077.1	RP11-127I20.5	11.82	2.01e-28	2.55e-25	0.47	0.48	Cancer;	chr16:4835228	chr16:4795265~4796532:-
LGG	cis	rs7216064	1	rs62084208	ENSG00000278219.1	AC145343.1	-11.82	2.01e-28	2.55e-25	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67831327	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs73352808	ENSG00000278219.1	AC145343.1	-11.82	2.03e-28	2.57e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879041	chr17:68101538~68101639:+
LGG	cis	rs1420956	0.543	rs12455678	ENSG00000264151.4	RP11-739N10.1	11.82	2.03e-28	2.58e-25	0.62	0.48	Obesity-related traits;	chr18:27611276	chr18:27336379~27595164:-
LGG	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-11.82	2.03e-28	2.58e-25	-0.54	-0.48	Height;	chr3:52819385	chr3:53064283~53065091:-
LGG	cis	rs11098499	0.738	rs28687057	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119359657	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.775	rs67281037	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119360002	chr4:119391831~119395335:-
LGG	cis	rs10028773	0.506	rs12374346	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Educational attainment;	chr4:119360550	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs12374244	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119360817	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs12374352	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119360822	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.775	rs10021601	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119361408	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs6857892	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119361541	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.909	rs28581362	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119362393	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.82	rs12503082	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119363162	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs12499602	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119363232	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.774	rs11098505	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119363472	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs13105020	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119364533	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs6824111	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119364813	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.775	rs10029303	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119365600	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs9995136	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119365690	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs13125526	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119366864	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs12513310	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119366884	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs12510451	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119367988	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.774	rs73842616	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119369528	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.645	rs72676059	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119369673	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.569	rs55845118	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119369758	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs7677068	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119370549	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs9991221	ENSG00000249244.1	RP11-548H18.2	11.82	2.06e-28	2.61e-25	0.52	0.48	Corneal astigmatism;	chr4:119370952	chr4:119391831~119395335:-
LGG	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-11.81	2.06e-28	2.61e-25	-0.69	-0.48	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
LGG	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-11.81	2.07e-28	2.62e-25	-0.5	-0.48	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
LGG	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-11.81	2.07e-28	2.62e-25	-0.66	-0.48	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
LGG	cis	rs172166	0.769	rs149965	ENSG00000226314.6	ZNF192P1	11.81	2.08e-28	2.63e-25	0.52	0.48	Cardiac Troponin-T levels;	chr6:28050911	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	11.81	2.08e-28	2.63e-25	0.52	0.48	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
LGG	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-11.81	2.08e-28	2.64e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
LGG	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-11.81	2.08e-28	2.64e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-11.81	2.08e-28	2.64e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
LGG	cis	rs12495178	0.574	rs13082138	ENSG00000239519.1	CADM2-AS1	11.81	2.09e-28	2.64e-25	0.54	0.48	Body mass index;	chr3:85905217	chr3:85992183~86028007:-
LGG	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	11.81	2.09e-28	2.64e-25	0.66	0.48	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
LGG	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-11.81	2.1e-28	2.65e-25	-0.67	-0.48	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
LGG	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	11.81	2.1e-28	2.66e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
LGG	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	11.81	2.11e-28	2.67e-25	0.61	0.48	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
LGG	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-11.81	2.12e-28	2.68e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
LGG	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-11.81	2.13e-28	2.69e-25	-0.69	-0.48	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	11.81	2.13e-28	2.69e-25	0.69	0.48	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
LGG	cis	rs657075	0.697	rs2073642	ENSG00000233006.5	AC034220.3	11.81	2.14e-28	2.71e-25	0.72	0.48	Rheumatoid arthritis;	chr5:132378082	chr5:132311285~132369916:-
LGG	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	11.81	2.15e-28	2.71e-25	0.52	0.48	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
LGG	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-11.81	2.15e-28	2.71e-25	-0.62	-0.48	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
LGG	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-11.81	2.16e-28	2.73e-25	-0.59	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
LGG	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-11.81	2.17e-28	2.75e-25	-0.53	-0.48	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-11.81	2.17e-28	2.75e-25	-0.53	-0.48	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-11.81	2.17e-28	2.75e-25	-0.53	-0.48	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-11.81	2.17e-28	2.75e-25	-0.53	-0.48	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-11.81	2.17e-28	2.75e-25	-0.53	-0.48	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
LGG	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-11.81	2.18e-28	2.75e-25	-0.54	-0.48	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
LGG	cis	rs4713118	0.513	rs149959	ENSG00000226314.6	ZNF192P1	11.81	2.23e-28	2.81e-25	0.52	0.48	Parkinson's disease;	chr6:28046076	chr6:28161781~28169594:+
LGG	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	11.81	2.23e-28	2.81e-25	0.7	0.48	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
LGG	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	11.81	2.23e-28	2.81e-25	0.7	0.48	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
LGG	cis	rs4819052	0.851	rs4819041	ENSG00000223768.1	LINC00205	-11.81	2.23e-28	2.81e-25	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45293285~45297354:+
LGG	cis	rs1150668	0.799	rs7206	ENSG00000218016.2	ZNF192P2	-11.81	2.25e-28	2.83e-25	-0.55	-0.48	Pubertal anthropometrics;	chr6:28233360	chr6:28188050~28189432:+
LGG	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-11.81	2.25e-28	2.84e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
LGG	cis	rs916888	0.821	rs199512	ENSG00000232300.1	FAM215B	-11.81	2.26e-28	2.84e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46558830~46562795:-
LGG	cis	rs916888	0.821	rs199509	ENSG00000232300.1	FAM215B	-11.81	2.26e-28	2.84e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46558830~46562795:-
LGG	cis	rs916888	0.821	rs199507	ENSG00000232300.1	FAM215B	-11.81	2.26e-28	2.84e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46558830~46562795:-
LGG	cis	rs916888	0.821	rs415430	ENSG00000232300.1	FAM215B	-11.81	2.26e-28	2.84e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46558830~46562795:-
LGG	cis	rs916888	0.779	rs430685	ENSG00000232300.1	FAM215B	-11.81	2.26e-28	2.84e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46558830~46562795:-
LGG	cis	rs916888	0.821	rs199505	ENSG00000232300.1	FAM215B	-11.81	2.26e-28	2.84e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46558830~46562795:-
LGG	cis	rs916888	0.821	rs70602	ENSG00000232300.1	FAM215B	-11.81	2.26e-28	2.84e-25	-0.69	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46558830~46562795:-
LGG	cis	rs7216064	0.954	rs12602556	ENSG00000278219.1	AC145343.1	-11.8	2.26e-28	2.85e-25	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67830745	chr17:68101538~68101639:+
LGG	cis	rs4713118	0.621	rs9295755	ENSG00000226314.6	ZNF192P1	-11.8	2.26e-28	2.85e-25	-0.58	-0.48	Parkinson's disease;	chr6:28065396	chr6:28161781~28169594:+
LGG	cis	rs7216064	1	rs62084210	ENSG00000278219.1	AC145343.1	-11.8	2.27e-28	2.86e-25	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67832594	chr17:68101538~68101639:+
LGG	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-11.8	2.27e-28	2.86e-25	-0.7	-0.48	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
LGG	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	11.8	2.28e-28	2.87e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
LGG	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-11.8	2.28e-28	2.88e-25	-0.53	-0.48	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
LGG	cis	rs2486288	0.656	rs7167146	ENSG00000259433.2	CTD-2651B20.4	-11.8	2.28e-28	2.88e-25	-0.53	-0.48	Glomerular filtration rate;	chr15:45279188	chr15:45330209~45332634:-
LGG	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-11.8	2.29e-28	2.89e-25	-0.61	-0.48	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
LGG	cis	rs2739330	0.857	rs9608229	ENSG00000235689.1	AP000351.13	11.8	2.3e-28	2.9e-25	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:24006305~24008258:-
LGG	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-11.8	2.3e-28	2.9e-25	-0.65	-0.48	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
LGG	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-11.8	2.31e-28	2.91e-25	-0.61	-0.48	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-11.8	2.31e-28	2.91e-25	-0.61	-0.48	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
LGG	cis	rs357618	1	rs357627	ENSG00000260581.1	CTB-113P19.4	11.8	2.32e-28	2.92e-25	0.5	0.48	Basophil percentage of white cells;	chr5:151470699	chr5:151652275~151655449:+
LGG	cis	rs357618	1	rs357628	ENSG00000260581.1	CTB-113P19.4	11.8	2.32e-28	2.92e-25	0.5	0.48	Basophil percentage of white cells;	chr5:151470791	chr5:151652275~151655449:+
LGG	cis	rs357618	1	rs165352	ENSG00000260581.1	CTB-113P19.4	11.8	2.32e-28	2.92e-25	0.5	0.48	Basophil percentage of white cells;	chr5:151476546	chr5:151652275~151655449:+
LGG	cis	rs357618	1	rs165353	ENSG00000260581.1	CTB-113P19.4	11.8	2.32e-28	2.92e-25	0.5	0.48	Basophil percentage of white cells;	chr5:151477196	chr5:151652275~151655449:+
LGG	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-11.8	2.32e-28	2.93e-25	-0.5	-0.48	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
LGG	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-11.8	2.33e-28	2.93e-25	-0.66	-0.48	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
LGG	cis	rs1420956	0.603	rs12456956	ENSG00000264151.4	RP11-739N10.1	11.8	2.33e-28	2.93e-25	0.62	0.48	Obesity-related traits;	chr18:27610887	chr18:27336379~27595164:-
LGG	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	11.8	2.33e-28	2.93e-25	0.59	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
LGG	cis	rs4713118	0.513	rs149958	ENSG00000226314.6	ZNF192P1	11.8	2.33e-28	2.94e-25	0.52	0.48	Parkinson's disease;	chr6:28045839	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.513	rs156738	ENSG00000226314.6	ZNF192P1	11.8	2.33e-28	2.94e-25	0.52	0.48	Parkinson's disease;	chr6:28046247	chr6:28161781~28169594:+
LGG	cis	rs6908034	0.607	rs76413455	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs76525593	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.546	rs74514942	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810289	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs78402429	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19811459	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs77791009	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812371	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs75060331	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812725	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs77753186	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812749	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs79162793	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812834	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs76245225	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812957	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs75110577	ENSG00000228412.5	RP4-625H18.2	11.8	2.34e-28	2.94e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814292	chr6:19802164~19804752:-
LGG	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-11.8	2.34e-28	2.95e-25	-0.58	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-11.8	2.34e-28	2.95e-25	-0.58	-0.48	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
LGG	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-11.8	2.36e-28	2.98e-25	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
LGG	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-11.8	2.37e-28	2.98e-25	-0.62	-0.48	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-11.8	2.37e-28	2.98e-25	-0.62	-0.48	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
LGG	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-11.8	2.37e-28	2.98e-25	-0.5	-0.48	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
LGG	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-11.8	2.38e-28	2.99e-25	-0.53	-0.48	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
LGG	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-11.8	2.38e-28	3e-25	-0.49	-0.48	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-11.8	2.38e-28	3e-25	-0.49	-0.48	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-11.8	2.38e-28	3e-25	-0.49	-0.48	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-11.8	2.38e-28	3e-25	-0.49	-0.48	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-11.8	2.38e-28	3e-25	-0.49	-0.48	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-11.8	2.38e-28	3e-25	-0.49	-0.48	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
LGG	cis	rs2712184	0.756	rs2712182	ENSG00000229352.1	AC007563.3	-11.8	2.43e-28	3.05e-25	-0.55	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216782802	chr2:216799608~216805335:+
LGG	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	11.8	2.43e-28	3.06e-25	0.59	0.48	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
LGG	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	11.8	2.45e-28	3.08e-25	0.72	0.48	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
LGG	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-11.8	2.45e-28	3.08e-25	-0.61	-0.48	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
LGG	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-11.8	2.46e-28	3.09e-25	-0.66	-0.48	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
LGG	cis	rs6908034	0.607	rs74559916	ENSG00000228412.5	RP4-625H18.2	11.8	2.47e-28	3.1e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818486	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.505	rs76391302	ENSG00000228412.5	RP4-625H18.2	11.8	2.47e-28	3.1e-25	0.89	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818885	chr6:19802164~19804752:-
LGG	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	11.79	2.48e-28	3.11e-25	0.72	0.48	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
LGG	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	11.79	2.48e-28	3.11e-25	0.72	0.48	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
LGG	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	11.79	2.48e-28	3.12e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
LGG	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-11.79	2.49e-28	3.12e-25	-0.69	-0.48	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-11.79	2.49e-28	3.12e-25	-0.69	-0.48	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
LGG	cis	rs4819052	0.724	rs1304487	ENSG00000223768.1	LINC00205	11.79	2.5e-28	3.14e-25	0.52	0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs7275468	ENSG00000223768.1	LINC00205	-11.79	2.5e-28	3.14e-25	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45293285~45297354:+
LGG	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-11.79	2.5e-28	3.14e-25	-0.5	-0.48	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
LGG	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	11.79	2.51e-28	3.15e-25	0.53	0.48	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
LGG	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-11.79	2.56e-28	3.21e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
LGG	cis	rs853679	0.55	rs1233704	ENSG00000226314.6	ZNF192P1	-11.79	2.56e-28	3.21e-25	-0.55	-0.48	Depression;	chr6:28199145	chr6:28161781~28169594:+
LGG	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	11.79	2.56e-28	3.21e-25	0.96	0.48	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
LGG	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	11.79	2.58e-28	3.24e-25	0.53	0.48	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	11.79	2.58e-28	3.24e-25	0.53	0.48	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
LGG	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-11.79	2.58e-28	3.24e-25	-0.51	-0.48	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
LGG	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-11.79	2.59e-28	3.25e-25	-0.8	-0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
LGG	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-11.79	2.59e-28	3.25e-25	-0.53	-0.48	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
LGG	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-11.79	2.62e-28	3.29e-25	-0.5	-0.48	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
LGG	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-11.79	2.64e-28	3.31e-25	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
LGG	cis	rs6908034	0.66	rs111509549	ENSG00000228412.5	RP4-625H18.2	11.79	2.64e-28	3.31e-25	0.9	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19798139	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.6	rs79733895	ENSG00000228412.5	RP4-625H18.2	11.79	2.64e-28	3.31e-25	0.9	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19799310	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.66	rs76322282	ENSG00000228412.5	RP4-625H18.2	11.79	2.64e-28	3.31e-25	0.9	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.66	rs111231540	ENSG00000228412.5	RP4-625H18.2	11.79	2.64e-28	3.31e-25	0.9	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801995	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs111533721	ENSG00000228412.5	RP4-625H18.2	11.79	2.64e-28	3.31e-25	0.9	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs112824001	ENSG00000228412.5	RP4-625H18.2	11.79	2.64e-28	3.31e-25	0.9	0.48	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804460	chr6:19802164~19804752:-
LGG	cis	rs4713118	0.824	rs2092075	ENSG00000199851.2	U3	11.79	2.65e-28	3.32e-25	0.7	0.48	Parkinson's disease;	chr6:27781551	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.824	rs13211701	ENSG00000199851.2	U3	11.79	2.65e-28	3.32e-25	0.7	0.48	Parkinson's disease;	chr6:27782300	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.824	rs9468229	ENSG00000199851.2	U3	11.79	2.65e-28	3.32e-25	0.7	0.48	Parkinson's disease;	chr6:27782307	chr6:28015568~28015777:+
LGG	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	11.79	2.67e-28	3.35e-25	0.57	0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
LGG	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	11.79	2.68e-28	3.35e-25	0.66	0.48	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
LGG	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-11.79	2.7e-28	3.38e-25	-0.61	-0.48	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
LGG	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-11.79	2.7e-28	3.38e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-11.79	2.7e-28	3.38e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-11.79	2.7e-28	3.38e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-11.79	2.7e-28	3.38e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
LGG	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	11.79	2.7e-28	3.39e-25	0.61	0.48	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
LGG	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	11.78	2.72e-28	3.4e-25	0.61	0.48	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
LGG	cis	rs2712184	0.875	rs2541381	ENSG00000229352.1	AC007563.3	-11.78	2.72e-28	3.41e-25	-0.56	-0.48	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216819113	chr2:216799608~216805335:+
LGG	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-11.78	2.73e-28	3.41e-25	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
LGG	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-11.78	2.75e-28	3.45e-25	-0.61	-0.48	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
LGG	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-11.78	2.76e-28	3.45e-25	-0.61	-0.48	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
LGG	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-11.78	2.77e-28	3.47e-25	-0.6	-0.48	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
LGG	cis	rs2013441	1	rs2263175	ENSG00000230528.6	NOS2P3	11.78	2.78e-28	3.47e-25	0.44	0.48	Obesity-related traits;	chr17:20224716	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.932	rs2526479	ENSG00000230528.6	NOS2P3	11.78	2.78e-28	3.47e-25	0.44	0.48	Obesity-related traits;	chr17:20226908	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703772	ENSG00000230528.6	NOS2P3	11.78	2.78e-28	3.47e-25	0.44	0.48	Obesity-related traits;	chr17:20228140	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2703787	ENSG00000230528.6	NOS2P3	11.78	2.78e-28	3.47e-25	0.44	0.48	Obesity-related traits;	chr17:20255352	chr17:20436337~20447249:+
LGG	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-11.78	2.78e-28	3.48e-25	-0.51	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
LGG	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	11.78	2.79e-28	3.49e-25	0.72	0.48	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
LGG	cis	rs4713118	0.621	rs9368548	ENSG00000226314.6	ZNF192P1	11.78	2.79e-28	3.49e-25	0.58	0.48	Parkinson's disease;	chr6:28066959	chr6:28161781~28169594:+
LGG	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-11.78	2.82e-28	3.52e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-11.78	2.82e-28	3.52e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
LGG	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-11.78	2.82e-28	3.52e-25	-0.62	-0.48	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
LGG	cis	rs357618	0.965	rs187180	ENSG00000260581.1	CTB-113P19.4	11.78	2.82e-28	3.53e-25	0.5	0.48	Basophil percentage of white cells;	chr5:151468434	chr5:151652275~151655449:+
LGG	cis	rs7216064	1	rs3206817	ENSG00000278219.1	AC145343.1	-11.78	2.84e-28	3.55e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896718	chr17:68101538~68101639:+
LGG	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	11.78	2.85e-28	3.56e-25	0.61	0.48	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.543	rs9371533	ENSG00000216621.7	RP11-244K5.6	11.78	2.86e-28	3.57e-25	0.54	0.48	Lung cancer;	chr6:149889545	chr6:149934527~149936782:+
LGG	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-11.78	2.86e-28	3.58e-25	-0.53	-0.48	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
LGG	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	11.78	2.86e-28	3.58e-25	0.59	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
LGG	cis	rs4819052	0.851	rs2330011	ENSG00000215447.6	BX322557.10	-11.78	2.88e-28	3.61e-25	-0.37	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45288052~45291738:+
LGG	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-11.78	2.9e-28	3.62e-25	-0.49	-0.48	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
LGG	cis	rs7216064	0.861	rs62084252	ENSG00000278219.1	AC145343.1	-11.78	2.9e-28	3.63e-25	-0.59	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883462	chr17:68101538~68101639:+
LGG	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-11.78	2.9e-28	3.63e-25	-0.7	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
LGG	cis	rs950027	0.787	rs2433616	ENSG00000259433.2	CTD-2651B20.4	-11.78	2.9e-28	3.63e-25	-0.52	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45330209~45332634:-
LGG	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-11.78	2.92e-28	3.64e-25	-0.69	-0.48	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-11.78	2.92e-28	3.64e-25	-0.69	-0.48	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-11.78	2.92e-28	3.64e-25	-0.69	-0.48	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
LGG	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	11.78	2.92e-28	3.64e-25	0.69	0.48	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	11.78	2.92e-28	3.64e-25	0.69	0.48	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	11.78	2.92e-28	3.64e-25	0.69	0.48	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
LGG	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-11.78	2.92e-28	3.65e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
LGG	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-11.78	2.93e-28	3.66e-25	-0.49	-0.48	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
LGG	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	11.78	2.95e-28	3.68e-25	0.54	0.48	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
LGG	cis	rs9326248	0.608	rs1076485	ENSG00000254851.1	RP11-109L13.1	11.78	2.97e-28	3.71e-25	0.88	0.48	Blood protein levels;	chr11:116901725	chr11:117135528~117138582:+
LGG	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	11.78	2.97e-28	3.71e-25	0.85	0.48	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	11.77	3e-28	3.75e-25	0.62	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
LGG	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	11.77	3.02e-28	3.77e-25	0.61	0.48	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
LGG	cis	rs7216064	1	rs6504548	ENSG00000278219.1	AC145343.1	-11.77	3.03e-28	3.78e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889932	chr17:68101538~68101639:+
LGG	cis	rs651907	0.557	rs7651406	ENSG00000256628.3	ZBTB11-AS1	11.77	3.05e-28	3.8e-25	0.54	0.48	Colorectal cancer;	chr3:101674452	chr3:101676475~101679217:+
LGG	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	11.77	3.05e-28	3.81e-25	0.61	0.48	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
LGG	cis	rs1150668	0.768	rs1150716	ENSG00000226314.6	ZNF192P1	11.77	3.06e-28	3.82e-25	0.47	0.48	Pubertal anthropometrics;	chr6:28294921	chr6:28161781~28169594:+
LGG	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	11.77	3.09e-28	3.85e-25	0.52	0.48	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
LGG	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	11.77	3.1e-28	3.87e-25	0.59	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
LGG	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	11.77	3.11e-28	3.88e-25	0.57	0.48	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
LGG	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-11.77	3.12e-28	3.89e-25	-0.54	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
LGG	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-11.77	3.16e-28	3.94e-25	-0.61	-0.48	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
LGG	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	11.77	3.18e-28	3.96e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	11.77	3.18e-28	3.96e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	11.77	3.18e-28	3.96e-25	0.66	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
LGG	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-11.77	3.18e-28	3.96e-25	-0.37	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
LGG	cis	rs2013441	0.965	rs2703808	ENSG00000230528.6	NOS2P3	11.77	3.19e-28	3.97e-25	0.44	0.48	Obesity-related traits;	chr17:20206352	chr17:20436337~20447249:+
LGG	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-11.77	3.25e-28	4.05e-25	-0.53	-0.48	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
LGG	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-11.77	3.26e-28	4.06e-25	-0.5	-0.48	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
LGG	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-11.76	3.26e-28	4.07e-25	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-11.76	3.26e-28	4.07e-25	-0.55	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
LGG	cis	rs1150668	0.796	rs1005125	ENSG00000199851.2	U3	11.76	3.26e-28	4.07e-25	0.62	0.48	Pubertal anthropometrics;	chr6:28399578	chr6:28015568~28015777:+
LGG	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-11.76	3.29e-28	4.09e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
LGG	cis	rs2013441	1	rs2107566	ENSG00000230528.6	NOS2P3	11.76	3.3e-28	4.11e-25	0.44	0.48	Obesity-related traits;	chr17:20199939	chr17:20436337~20447249:+
LGG	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	11.76	3.31e-28	4.12e-25	0.63	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	11.76	3.31e-28	4.12e-25	0.63	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
LGG	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-11.76	3.31e-28	4.12e-25	-0.42	-0.48	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
LGG	cis	rs950027	0.787	rs1547487	ENSG00000259433.2	CTD-2651B20.4	-11.76	3.32e-28	4.13e-25	-0.52	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45330209~45332634:-
LGG	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-11.76	3.35e-28	4.17e-25	-0.65	-0.48	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-11.76	3.35e-28	4.17e-25	-0.65	-0.48	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
LGG	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	11.76	3.38e-28	4.21e-25	0.52	0.48	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
LGG	cis	rs1420956	0.562	rs11083216	ENSG00000264151.4	RP11-739N10.1	11.76	3.38e-28	4.21e-25	0.62	0.48	Obesity-related traits;	chr18:27577684	chr18:27336379~27595164:-
LGG	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	11.76	3.38e-28	4.21e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	11.76	3.38e-28	4.21e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	11.76	3.38e-28	4.21e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
LGG	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-11.76	3.39e-28	4.22e-25	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
LGG	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	11.76	3.42e-28	4.25e-25	0.53	0.48	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
LGG	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-11.76	3.42e-28	4.25e-25	-0.61	-0.48	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-11.76	3.42e-28	4.25e-25	-0.61	-0.48	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
LGG	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	11.76	3.43e-28	4.27e-25	0.52	0.48	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
LGG	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	11.76	3.45e-28	4.28e-25	0.54	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
LGG	cis	rs7216064	1	rs2052187	ENSG00000278219.1	AC145343.1	-11.76	3.45e-28	4.29e-25	-0.58	-0.48	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67838621	chr17:68101538~68101639:+
LGG	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	11.76	3.46e-28	4.31e-25	0.5	0.48	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
LGG	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	11.76	3.46e-28	4.31e-25	0.5	0.48	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
LGG	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-11.76	3.48e-28	4.32e-25	-0.63	-0.48	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
LGG	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	11.76	3.5e-28	4.35e-25	0.53	0.48	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
LGG	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-11.76	3.52e-28	4.38e-25	-0.54	-0.48	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
LGG	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-11.76	3.56e-28	4.43e-25	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
LGG	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	11.76	3.56e-28	4.43e-25	0.53	0.48	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
LGG	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-11.76	3.57e-28	4.44e-25	-0.63	-0.48	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-11.76	3.57e-28	4.44e-25	-0.68	-0.48	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
LGG	cis	rs9637599	0.69	rs4423843	ENSG00000246375.2	RP11-10L7.1	11.76	3.57e-28	4.44e-25	0.58	0.48	Metabolite levels (small molecules and protein measures);	chr4:88285604	chr4:88284942~88331421:+
LGG	cis	rs4713118	0.513	rs156739	ENSG00000226314.6	ZNF192P1	11.75	3.61e-28	4.49e-25	0.52	0.48	Parkinson's disease;	chr6:28045632	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	11.75	3.63e-28	4.5e-25	0.52	0.48	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	11.75	3.63e-28	4.5e-25	0.52	0.48	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	11.75	3.63e-28	4.5e-25	0.52	0.48	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
LGG	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	11.75	3.63e-28	4.5e-25	0.52	0.48	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
LGG	cis	rs8064024	0.65	rs8056889	ENSG00000267077.1	RP11-127I20.5	11.75	3.66e-28	4.54e-25	0.47	0.48	Cancer;	chr16:4853242	chr16:4795265~4796532:-
LGG	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-11.75	3.66e-28	4.54e-25	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
LGG	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-11.75	3.66e-28	4.54e-25	-0.4	-0.48	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
LGG	cis	rs1150668	0.699	rs12214383	ENSG00000199851.2	U3	-11.75	3.67e-28	4.56e-25	-0.62	-0.48	Pubertal anthropometrics;	chr6:28255953	chr6:28015568~28015777:+
LGG	cis	rs11647589	0.678	rs7198521	ENSG00000260762.1	ACSM5P1	11.75	3.68e-28	4.57e-25	0.67	0.47	Blood metabolite levels;	chr16:20441382	chr16:20586550~20607107:-
LGG	cis	rs4713118	0.513	rs1225591	ENSG00000226314.6	ZNF192P1	11.75	3.71e-28	4.6e-25	0.53	0.47	Parkinson's disease;	chr6:28180974	chr6:28161781~28169594:+
LGG	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-11.75	3.74e-28	4.63e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
LGG	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-11.75	3.75e-28	4.65e-25	-0.67	-0.47	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
LGG	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-11.75	3.76e-28	4.66e-25	-0.69	-0.47	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
LGG	cis	rs2712184	0.756	rs2712181	ENSG00000229352.1	AC007563.3	11.75	3.79e-28	4.7e-25	0.55	0.47	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216790146	chr2:216799608~216805335:+
LGG	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-11.75	3.87e-28	4.8e-25	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-11.75	3.87e-28	4.8e-25	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
LGG	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-11.75	3.88e-28	4.8e-25	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-11.75	3.88e-28	4.8e-25	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
LGG	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	11.75	3.88e-28	4.8e-25	0.77	0.47	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
LGG	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	11.75	3.88e-28	4.8e-25	0.77	0.47	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
LGG	cis	rs7216064	0.953	rs4791046	ENSG00000278219.1	AC145343.1	-11.75	3.91e-28	4.84e-25	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67855857	chr17:68101538~68101639:+
LGG	cis	rs2013441	1	rs972966	ENSG00000230528.6	NOS2P3	-11.74	3.93e-28	4.86e-25	-0.44	-0.47	Obesity-related traits;	chr17:20127679	chr17:20436337~20447249:+
LGG	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	11.74	3.94e-28	4.87e-25	0.6	0.47	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
LGG	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-11.74	3.94e-28	4.87e-25	-0.61	-0.47	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
LGG	cis	rs1150668	0.699	rs13408	ENSG00000199851.2	U3	11.74	3.94e-28	4.88e-25	0.63	0.47	Pubertal anthropometrics;	chr6:28244970	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-11.74	3.95e-28	4.89e-25	-0.67	-0.47	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
LGG	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	11.74	3.96e-28	4.9e-25	0.53	0.47	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	11.74	3.96e-28	4.9e-25	0.53	0.47	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
LGG	cis	rs1150668	0.799	rs1150707	ENSG00000280107.1	AL022393.9	-11.74	3.98e-28	4.93e-25	-0.47	-0.47	Pubertal anthropometrics;	chr6:28229827	chr6:28170845~28172521:+
LGG	cis	rs1150668	0.768	rs1233713	ENSG00000280107.1	AL022393.9	-11.74	3.98e-28	4.93e-25	-0.47	-0.47	Pubertal anthropometrics;	chr6:28230503	chr6:28170845~28172521:+
LGG	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-11.74	4e-28	4.95e-25	-0.54	-0.47	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
LGG	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	11.74	4.01e-28	4.96e-25	0.63	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
LGG	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-11.74	4.01e-28	4.96e-25	-0.69	-0.47	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-11.74	4.01e-28	4.96e-25	-0.69	-0.47	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
LGG	cis	rs7216064	0.906	rs7223643	ENSG00000278219.1	AC145343.1	-11.74	4.02e-28	4.98e-25	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834166	chr17:68101538~68101639:+
LGG	cis	rs950027	0.787	rs1153845	ENSG00000259433.2	CTD-2651B20.4	11.74	4.04e-28	5e-25	0.52	0.47	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45330209~45332634:-
LGG	cis	rs7829975	0.514	rs2945873	ENSG00000173295.6	FAM86B3P	-11.74	4.08e-28	5.05e-25	-0.5	-0.47	Mood instability;	chr8:8402935	chr8:8228595~8244865:+
LGG	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	11.74	4.09e-28	5.06e-25	0.61	0.47	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
LGG	cis	rs357618	0.931	rs394736	ENSG00000260581.1	CTB-113P19.4	11.74	4.1e-28	5.07e-25	0.5	0.47	Basophil percentage of white cells;	chr5:151467948	chr5:151652275~151655449:+
LGG	cis	rs357618	0.965	rs357621	ENSG00000260581.1	CTB-113P19.4	11.74	4.1e-28	5.07e-25	0.5	0.47	Basophil percentage of white cells;	chr5:151467993	chr5:151652275~151655449:+
LGG	cis	rs357618	1	rs193299	ENSG00000260581.1	CTB-113P19.4	11.74	4.1e-28	5.07e-25	0.5	0.47	Basophil percentage of white cells;	chr5:151468094	chr5:151652275~151655449:+
LGG	cis	rs357618	1	rs357622	ENSG00000260581.1	CTB-113P19.4	11.74	4.1e-28	5.07e-25	0.5	0.47	Basophil percentage of white cells;	chr5:151468844	chr5:151652275~151655449:+
LGG	cis	rs357618	1	rs357623	ENSG00000260581.1	CTB-113P19.4	11.74	4.1e-28	5.07e-25	0.5	0.47	Basophil percentage of white cells;	chr5:151468939	chr5:151652275~151655449:+
LGG	cis	rs357618	1	rs357624	ENSG00000260581.1	CTB-113P19.4	11.74	4.1e-28	5.07e-25	0.5	0.47	Basophil percentage of white cells;	chr5:151469140	chr5:151652275~151655449:+
LGG	cis	rs2013441	1	rs3850783	ENSG00000230528.6	NOS2P3	-11.74	4.13e-28	5.1e-25	-0.44	-0.47	Obesity-related traits;	chr17:20281188	chr17:20436337~20447249:+
LGG	cis	rs2921073	0.51	rs2976945	ENSG00000173295.6	FAM86B3P	-11.74	4.13e-28	5.11e-25	-0.5	-0.47	Parkinson's disease;	chr8:8413361	chr8:8228595~8244865:+
LGG	cis	rs2712184	0.935	rs2712169	ENSG00000229352.1	AC007563.3	-11.74	4.16e-28	5.14e-25	-0.54	-0.47	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216806626	chr2:216799608~216805335:+
LGG	cis	rs8064024	0.681	rs7194890	ENSG00000267077.1	RP11-127I20.5	11.74	4.19e-28	5.17e-25	0.47	0.47	Cancer;	chr16:4833780	chr16:4795265~4796532:-
LGG	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-11.74	4.2e-28	5.19e-25	-0.7	-0.47	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
LGG	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-11.74	4.2e-28	5.19e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
LGG	cis	rs7216064	0.817	rs12603589	ENSG00000278219.1	AC145343.1	-11.74	4.21e-28	5.2e-25	-0.59	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829132	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.817	rs12601921	ENSG00000278219.1	AC145343.1	-11.74	4.21e-28	5.2e-25	-0.59	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829238	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.813	rs12601919	ENSG00000278219.1	AC145343.1	-11.74	4.21e-28	5.2e-25	-0.59	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829258	chr17:68101538~68101639:+
LGG	cis	rs357618	1	rs357625	ENSG00000260581.1	CTB-113P19.4	11.74	4.22e-28	5.21e-25	0.5	0.47	Basophil percentage of white cells;	chr5:151469313	chr5:151652275~151655449:+
LGG	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-11.74	4.22e-28	5.21e-25	-0.49	-0.47	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
LGG	cis	rs4713118	0.513	rs9368547	ENSG00000226314.6	ZNF192P1	11.74	4.22e-28	5.22e-25	0.52	0.47	Parkinson's disease;	chr6:28060289	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.513	rs183244	ENSG00000226314.6	ZNF192P1	11.74	4.22e-28	5.22e-25	0.52	0.47	Parkinson's disease;	chr6:28064060	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.513	rs149950	ENSG00000226314.6	ZNF192P1	11.74	4.22e-28	5.22e-25	0.52	0.47	Parkinson's disease;	chr6:28065261	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.513	rs149951	ENSG00000226314.6	ZNF192P1	11.74	4.22e-28	5.22e-25	0.52	0.47	Parkinson's disease;	chr6:28065309	chr6:28161781~28169594:+
LGG	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-11.74	4.23e-28	5.22e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
LGG	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-11.74	4.23e-28	5.23e-25	-0.5	-0.47	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
LGG	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-11.74	4.23e-28	5.23e-25	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
LGG	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-11.74	4.26e-28	5.25e-25	-0.49	-0.47	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
LGG	cis	rs357618	1	rs357629	ENSG00000260581.1	CTB-113P19.4	-11.74	4.26e-28	5.26e-25	-0.5	-0.47	Basophil percentage of white cells;	chr5:151471385	chr5:151652275~151655449:+
LGG	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-11.74	4.26e-28	5.26e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
LGG	cis	rs8062405	0.754	rs28410083	ENSG00000271623.1	RP11-435I10.5	11.73	4.29e-28	5.3e-25	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.789	rs1968751	ENSG00000271623.1	RP11-435I10.5	11.73	4.29e-28	5.3e-25	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28364700~28365333:+
LGG	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-11.73	4.31e-28	5.32e-25	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
LGG	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-11.73	4.32e-28	5.33e-25	-0.5	-0.47	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
LGG	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	11.73	4.34e-28	5.35e-25	0.63	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
LGG	cis	rs11098499	0.687	rs71610270	ENSG00000249244.1	RP11-548H18.2	11.73	4.35e-28	5.37e-25	0.52	0.47	Corneal astigmatism;	chr4:119366281	chr4:119391831~119395335:-
LGG	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-11.73	4.4e-28	5.43e-25	-0.63	-0.47	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
LGG	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	11.73	4.41e-28	5.44e-25	0.61	0.47	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
LGG	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-11.73	4.42e-28	5.45e-25	-0.7	-0.47	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
LGG	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-11.73	4.42e-28	5.45e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
LGG	cis	rs7216064	0.531	rs6504573	ENSG00000278219.1	AC145343.1	-11.73	4.46e-28	5.5e-25	-0.51	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68019847	chr17:68101538~68101639:+
LGG	cis	rs8064024	0.599	rs1876359	ENSG00000267077.1	RP11-127I20.5	11.73	4.47e-28	5.51e-25	0.5	0.47	Cancer;	chr16:4880099	chr16:4795265~4796532:-
LGG	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	11.73	4.5e-28	5.55e-25	0.52	0.47	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
LGG	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-11.73	4.5e-28	5.55e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
LGG	cis	rs7927771	0.697	rs11039307	ENSG00000280615.1	Y_RNA	-11.73	4.51e-28	5.56e-25	-0.58	-0.47	Subjective well-being;	chr11:47589600	chr11:47614898~47614994:-
LGG	cis	rs7216064	1	rs62085993	ENSG00000278219.1	AC145343.1	-11.73	4.52e-28	5.57e-25	-0.57	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67927036	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs56393562	ENSG00000278219.1	AC145343.1	-11.73	4.52e-28	5.57e-25	-0.57	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67937802	chr17:68101538~68101639:+
LGG	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-11.73	4.66e-28	5.74e-25	-0.6	-0.47	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
LGG	cis	rs1150668	0.796	rs213237	ENSG00000199851.2	U3	11.73	4.67e-28	5.75e-25	0.61	0.47	Pubertal anthropometrics;	chr6:28356161	chr6:28015568~28015777:+
LGG	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-11.73	4.67e-28	5.75e-25	-0.57	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
LGG	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-11.72	4.71e-28	5.8e-25	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-11.72	4.71e-28	5.8e-25	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-11.72	4.71e-28	5.8e-25	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
LGG	cis	rs1150668	0.699	rs1736895	ENSG00000199851.2	U3	11.72	4.72e-28	5.81e-25	0.62	0.47	Pubertal anthropometrics;	chr6:28252048	chr6:28015568~28015777:+
LGG	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	11.72	4.73e-28	5.82e-25	0.6	0.47	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
LGG	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-11.72	4.79e-28	5.89e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
LGG	cis	rs4713118	0.621	rs9295756	ENSG00000226314.6	ZNF192P1	11.72	4.81e-28	5.92e-25	0.58	0.47	Parkinson's disease;	chr6:28065618	chr6:28161781~28169594:+
LGG	cis	rs4804815	0.78	rs4804231	ENSG00000268297.1	CLEC4GP1	11.72	4.84e-28	5.95e-25	0.51	0.47	Neutrophil count;	chr19:7774917	chr19:7787549~7790621:+
LGG	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-11.72	4.88e-28	6e-25	-0.62	-0.47	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
LGG	cis	rs2013441	1	rs2703815	ENSG00000230528.6	NOS2P3	-11.72	4.88e-28	6e-25	-0.44	-0.47	Obesity-related traits;	chr17:20215186	chr17:20436337~20447249:+
LGG	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-11.72	4.88e-28	6e-25	-0.49	-0.47	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-11.72	4.88e-28	6e-25	-0.49	-0.47	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-11.72	4.88e-28	6e-25	-0.49	-0.47	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-11.72	4.88e-28	6e-25	-0.49	-0.47	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
LGG	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-11.72	4.9e-28	6.03e-25	-0.46	-0.47	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
LGG	cis	rs11098499	0.722	rs1814814	ENSG00000249244.1	RP11-548H18.2	11.72	4.9e-28	6.03e-25	0.49	0.47	Corneal astigmatism;	chr4:119336969	chr4:119391831~119395335:-
LGG	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	11.72	4.91e-28	6.03e-25	0.6	0.47	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
LGG	cis	rs172166	0.516	rs1225618	ENSG00000218016.2	ZNF192P2	-11.72	4.94e-28	6.07e-25	-0.55	-0.47	Cardiac Troponin-T levels;	chr6:28161935	chr6:28188050~28189432:+
LGG	cis	rs7216064	0.953	rs4790981	ENSG00000278219.1	AC145343.1	-11.72	4.98e-28	6.11e-25	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67925718	chr17:68101538~68101639:+
LGG	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	11.72	4.98e-28	6.12e-25	0.73	0.47	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
LGG	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-11.72	4.98e-28	6.12e-25	-0.49	-0.47	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-11.72	4.98e-28	6.12e-25	-0.49	-0.47	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
LGG	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-11.72	5.04e-28	6.19e-25	-0.4	-0.47	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
LGG	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	11.72	5.06e-28	6.21e-25	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	11.72	5.06e-28	6.21e-25	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	11.72	5.06e-28	6.21e-25	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
LGG	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	11.71	5.19e-28	6.37e-25	0.61	0.47	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
LGG	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	11.71	5.3e-28	6.5e-25	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
LGG	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-11.71	5.31e-28	6.51e-25	-0.7	-0.47	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
LGG	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-11.71	5.33e-28	6.53e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
LGG	cis	rs8064024	0.59	rs2219271	ENSG00000267077.1	RP11-127I20.5	11.71	5.36e-28	6.57e-25	0.47	0.47	Cancer;	chr16:4848119	chr16:4795265~4796532:-
LGG	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-11.71	5.41e-28	6.63e-25	-0.4	-0.47	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
LGG	cis	rs7927771	0.839	rs7124681	ENSG00000280615.1	Y_RNA	-11.71	5.41e-28	6.63e-25	-0.58	-0.47	Subjective well-being;	chr11:47508395	chr11:47614898~47614994:-
LGG	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	11.71	5.41e-28	6.63e-25	0.7	0.47	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
LGG	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-11.71	5.42e-28	6.64e-25	-0.5	-0.47	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
LGG	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-11.71	5.43e-28	6.65e-25	-0.67	-0.47	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
LGG	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-11.71	5.44e-28	6.66e-25	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
LGG	cis	rs7216064	0.911	rs12449442	ENSG00000278219.1	AC145343.1	-11.71	5.47e-28	6.7e-25	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67951524	chr17:68101538~68101639:+
LGG	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	11.71	5.49e-28	6.72e-25	0.69	0.47	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	11.71	5.49e-28	6.72e-25	0.69	0.47	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	11.71	5.49e-28	6.72e-25	0.69	0.47	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-11.71	5.49e-28	6.72e-25	-0.69	-0.47	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
LGG	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-11.71	5.51e-28	6.74e-25	-0.6	-0.47	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
LGG	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	11.71	5.52e-28	6.75e-25	0.77	0.47	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
LGG	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-11.71	5.56e-28	6.81e-25	-0.63	-0.47	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
LGG	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	11.71	5.59e-28	6.84e-25	0.52	0.47	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
LGG	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	11.71	5.6e-28	6.85e-25	0.69	0.47	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	11.71	5.6e-28	6.85e-25	0.69	0.47	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
LGG	cis	rs2013441	0.76	rs8080827	ENSG00000230528.6	NOS2P3	11.71	5.61e-28	6.86e-25	0.45	0.47	Obesity-related traits;	chr17:20270623	chr17:20436337~20447249:+
LGG	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-11.7	5.65e-28	6.91e-25	-0.5	-0.47	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
LGG	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-11.7	5.66e-28	6.92e-25	-0.61	-0.47	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-11.7	5.67e-28	6.93e-25	-0.61	-0.47	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
LGG	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-11.7	5.75e-28	7.03e-25	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
LGG	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-11.7	5.75e-28	7.03e-25	-0.57	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
LGG	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-11.7	5.75e-28	7.03e-25	-0.67	-0.47	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
LGG	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	11.7	5.76e-28	7.04e-25	0.49	0.47	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
LGG	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	11.7	5.76e-28	7.04e-25	0.61	0.47	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
LGG	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-11.7	5.77e-28	7.05e-25	-0.63	-0.47	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
LGG	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-11.7	5.78e-28	7.07e-25	-0.63	-0.47	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
LGG	cis	rs2013441	0.786	rs4003797	ENSG00000230528.6	NOS2P3	11.7	5.82e-28	7.12e-25	0.44	0.47	Obesity-related traits;	chr17:20385587	chr17:20436337~20447249:+
LGG	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	11.7	5.88e-28	7.18e-25	0.66	0.47	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
LGG	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-11.7	5.89e-28	7.19e-25	-0.58	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
LGG	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-11.7	5.96e-28	7.28e-25	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
LGG	cis	rs12495178	0.574	rs55971481	ENSG00000239519.1	CADM2-AS1	11.7	5.98e-28	7.31e-25	0.54	0.47	Body mass index;	chr3:85871507	chr3:85992183~86028007:-
LGG	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	11.7	6.04e-28	7.38e-25	0.6	0.47	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
LGG	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-11.7	6.05e-28	7.39e-25	-0.6	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
LGG	cis	rs4819052	0.851	rs2838866	ENSG00000223768.1	LINC00205	-11.7	6.08e-28	7.43e-25	-0.54	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45293285~45297354:+
LGG	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	11.7	6.08e-28	7.43e-25	0.51	0.47	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
LGG	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	11.7	6.12e-28	7.47e-25	0.6	0.47	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
LGG	cis	rs651907	0.557	rs11712748	ENSG00000256628.3	ZBTB11-AS1	11.7	6.15e-28	7.5e-25	0.53	0.47	Colorectal cancer;	chr3:101664718	chr3:101676475~101679217:+
LGG	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	11.7	6.15e-28	7.51e-25	0.53	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
LGG	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-11.7	6.17e-28	7.52e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
LGG	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-11.69	6.22e-28	7.59e-25	-0.4	-0.47	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
LGG	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-11.69	6.22e-28	7.59e-25	-0.4	-0.47	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
LGG	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-11.69	6.22e-28	7.59e-25	-0.4	-0.47	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
LGG	cis	rs1150668	0.799	rs2142730	ENSG00000226314.6	ZNF192P1	11.69	6.33e-28	7.72e-25	0.46	0.47	Pubertal anthropometrics;	chr6:28298372	chr6:28161781~28169594:+
LGG	cis	rs7216064	1	rs7216064	ENSG00000278219.1	AC145343.1	-11.69	6.35e-28	7.74e-25	-0.57	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67902693	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs4271626	ENSG00000278219.1	AC145343.1	-11.69	6.35e-28	7.74e-25	-0.57	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934017	chr17:68101538~68101639:+
LGG	cis	rs4819052	0.851	rs2236445	ENSG00000223768.1	LINC00205	-11.69	6.37e-28	7.77e-25	-0.52	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45293285~45297354:+
LGG	cis	rs7829975	1	rs7829975	ENSG00000173295.6	FAM86B3P	11.69	6.39e-28	7.79e-25	0.5	0.47	Mood instability;	chr8:8690607	chr8:8228595~8244865:+
LGG	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	11.69	6.5e-28	7.92e-25	0.6	0.47	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
LGG	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-11.69	6.55e-28	7.98e-25	-0.61	-0.47	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
LGG	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-11.69	6.63e-28	8.07e-25	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-11.69	6.63e-28	8.07e-25	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-11.69	6.63e-28	8.07e-25	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
LGG	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	11.69	6.66e-28	8.1e-25	0.53	0.47	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
LGG	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	11.69	6.77e-28	8.23e-25	0.72	0.47	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
LGG	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-11.68	6.78e-28	8.25e-25	-0.56	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
LGG	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	11.68	6.84e-28	8.31e-25	0.61	0.47	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
LGG	cis	rs172166	0.61	rs276369	ENSG00000226314.6	ZNF192P1	11.68	6.84e-28	8.31e-25	0.47	0.47	Cardiac Troponin-T levels;	chr6:27951465	chr6:28161781~28169594:+
LGG	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	11.68	6.86e-28	8.34e-25	0.67	0.47	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
LGG	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-11.68	6.9e-28	8.38e-25	-0.6	-0.47	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
LGG	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	11.68	6.9e-28	8.39e-25	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
LGG	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	11.68	6.94e-28	8.43e-25	0.61	0.47	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
LGG	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	11.68	6.98e-28	8.48e-25	0.59	0.47	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
LGG	cis	rs916888	0.821	rs199506	ENSG00000232300.1	FAM215B	-11.68	7.02e-28	8.53e-25	-0.69	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46558830~46562795:-
LGG	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-11.68	7.02e-28	8.53e-25	-0.49	-0.47	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
LGG	cis	rs7216064	1	rs6504543	ENSG00000278219.1	AC145343.1	-11.68	7.07e-28	8.58e-25	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841543	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs2365468	ENSG00000278219.1	AC145343.1	-11.68	7.07e-28	8.58e-25	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845202	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs9897982	ENSG00000278219.1	AC145343.1	-11.68	7.08e-28	8.6e-25	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883476	chr17:68101538~68101639:+
LGG	cis	rs4713118	0.866	rs2179094	ENSG00000199851.2	U3	11.68	7.1e-28	8.62e-25	0.7	0.47	Parkinson's disease;	chr6:27774046	chr6:28015568~28015777:+
LGG	cis	rs2013441	1	rs2526462	ENSG00000230528.6	NOS2P3	11.68	7.12e-28	8.64e-25	0.44	0.47	Obesity-related traits;	chr17:20176147	chr17:20436337~20447249:+
LGG	cis	rs1150668	0.83	rs213240	ENSG00000218016.2	ZNF192P2	-11.68	7.15e-28	8.69e-25	-0.55	-0.47	Pubertal anthropometrics;	chr6:28348098	chr6:28188050~28189432:+
LGG	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	11.68	7.22e-28	8.77e-25	0.6	0.47	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
LGG	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-11.68	7.24e-28	8.78e-25	-0.69	-0.47	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-11.68	7.24e-28	8.78e-25	-0.69	-0.47	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-11.68	7.24e-28	8.78e-25	-0.69	-0.47	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-11.68	7.24e-28	8.78e-25	-0.69	-0.47	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
LGG	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-11.68	7.26e-28	8.81e-25	-0.47	-0.47	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
LGG	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-11.68	7.29e-28	8.85e-25	-0.61	-0.47	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
LGG	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	11.68	7.37e-28	8.94e-25	0.63	0.47	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
LGG	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-11.68	7.39e-28	8.97e-25	-0.56	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
LGG	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-11.68	7.42e-28	9.01e-25	-0.6	-0.47	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
LGG	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-11.68	7.43e-28	9.01e-25	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
LGG	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	11.67	7.48e-28	9.07e-25	0.52	0.47	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
LGG	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-11.67	7.53e-28	9.14e-25	-0.53	-0.47	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
LGG	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-11.67	7.55e-28	9.15e-25	-0.63	-0.47	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
LGG	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	11.67	7.63e-28	9.26e-25	0.68	0.47	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
LGG	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	11.67	7.64e-28	9.26e-25	0.49	0.47	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
LGG	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-11.67	7.7e-28	9.34e-25	-0.6	-0.47	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
LGG	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-11.67	7.73e-28	9.37e-25	-0.64	-0.47	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
LGG	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-11.67	7.76e-28	9.4e-25	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
LGG	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-11.67	7.79e-28	9.45e-25	-0.55	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
LGG	cis	rs916888	0.821	rs199514	ENSG00000232300.1	FAM215B	-11.67	7.8e-28	9.46e-25	-0.69	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46558830~46562795:-
LGG	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-11.67	7.8e-28	9.46e-25	-0.5	-0.47	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
LGG	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-11.67	7.81e-28	9.47e-25	-0.68	-0.47	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
LGG	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	11.67	7.82e-28	9.47e-25	0.59	0.47	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	11.67	7.82e-28	9.47e-25	0.59	0.47	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
LGG	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	11.67	7.83e-28	9.49e-25	0.6	0.47	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
LGG	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-11.67	7.84e-28	9.49e-25	-0.65	-0.47	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-11.67	7.84e-28	9.49e-25	-0.65	-0.47	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
LGG	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	11.67	7.84e-28	9.49e-25	0.54	0.47	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
LGG	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	11.67	7.85e-28	9.51e-25	0.6	0.47	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
LGG	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	11.67	7.85e-28	9.51e-25	0.6	0.47	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
LGG	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-11.67	7.85e-28	9.51e-25	-0.63	-0.47	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
LGG	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	11.67	7.86e-28	9.52e-25	0.96	0.47	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
LGG	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	11.67	7.9e-28	9.57e-25	0.53	0.47	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
LGG	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	11.67	7.93e-28	9.6e-25	0.58	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
LGG	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-11.67	8.02e-28	9.71e-25	-0.5	-0.47	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
LGG	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	11.67	8.06e-28	9.76e-25	0.54	0.47	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
LGG	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	11.67	8.07e-28	9.76e-25	0.58	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
LGG	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	11.67	8.08e-28	9.78e-25	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
LGG	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	11.67	8.13e-28	9.83e-25	0.64	0.47	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
LGG	cis	rs916888	0.821	rs199504	ENSG00000232300.1	FAM215B	-11.66	8.23e-28	9.96e-25	-0.69	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46558830~46562795:-
LGG	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	11.66	8.29e-28	1e-24	0.98	0.47	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
LGG	cis	rs4819052	0.851	rs1056100	ENSG00000223768.1	LINC00205	-11.66	8.29e-28	1e-24	-0.51	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45293285~45297354:+
LGG	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-11.66	8.32e-28	1.01e-24	-0.49	-0.47	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
LGG	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	11.66	8.36e-28	1.01e-24	0.8	0.47	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
LGG	cis	rs4819052	0.851	rs2838826	ENSG00000223768.1	LINC00205	-11.66	8.41e-28	1.02e-24	-0.52	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45293285~45297354:+
LGG	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	11.66	8.41e-28	1.02e-24	0.53	0.47	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
LGG	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	11.66	8.41e-28	1.02e-24	0.49	0.47	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
LGG	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-11.66	8.45e-28	1.02e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-11.66	8.45e-28	1.02e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
LGG	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	11.66	8.5e-28	1.03e-24	0.59	0.47	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
LGG	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	11.66	8.53e-28	1.03e-24	0.32	0.47	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
LGG	cis	rs1150668	0.796	rs213236	ENSG00000199851.2	U3	11.66	8.6e-28	1.04e-24	0.61	0.47	Pubertal anthropometrics;	chr6:28356620	chr6:28015568~28015777:+
LGG	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-11.66	8.65e-28	1.05e-24	-0.49	-0.47	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-11.66	8.68e-28	1.05e-24	-0.49	-0.47	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
LGG	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-11.66	8.68e-28	1.05e-24	-0.49	-0.47	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
LGG	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	11.66	8.78e-28	1.06e-24	0.5	0.47	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
LGG	cis	rs6908034	0.556	rs113071446	ENSG00000228412.5	RP4-625H18.2	11.66	8.85e-28	1.07e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810604	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs77386860	ENSG00000228412.5	RP4-625H18.2	11.66	8.85e-28	1.07e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814524	chr6:19802164~19804752:-
LGG	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	11.65	8.95e-28	1.08e-24	0.76	0.47	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
LGG	cis	rs8064024	0.619	rs9935080	ENSG00000267077.1	RP11-127I20.5	11.65	8.97e-28	1.08e-24	0.47	0.47	Cancer;	chr16:4852206	chr16:4795265~4796532:-
LGG	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-11.65	8.98e-28	1.08e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
LGG	cis	rs8062405	0.69	rs6498089	ENSG00000271623.1	RP11-435I10.5	11.65	8.99e-28	1.08e-24	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28364700~28365333:+
LGG	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-11.65	9.04e-28	1.09e-24	-0.53	-0.47	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
LGG	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-11.65	9.05e-28	1.09e-24	-0.51	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
LGG	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	11.65	9.26e-28	1.12e-24	0.83	0.47	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
LGG	cis	rs853679	0.882	rs4713140	ENSG00000216901.1	AL022393.7	11.65	9.39e-28	1.13e-24	0.85	0.47	Depression;	chr6:28129415	chr6:28176188~28176674:+
LGG	cis	rs7216064	0.861	rs12449312	ENSG00000278219.1	AC145343.1	-11.65	9.43e-28	1.13e-24	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67833242	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.953	rs4791048	ENSG00000278219.1	AC145343.1	-11.65	9.43e-28	1.13e-24	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852878	chr17:68101538~68101639:+
LGG	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	11.65	9.44e-28	1.14e-24	0.69	0.47	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
LGG	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
LGG	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-11.65	9.46e-28	1.14e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
LGG	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-11.65	9.53e-28	1.14e-24	-0.49	-0.47	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
LGG	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-11.65	9.67e-28	1.16e-24	-0.52	-0.47	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
LGG	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-11.65	9.67e-28	1.16e-24	-0.52	-0.47	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
LGG	cis	rs7216064	1	rs1976053	ENSG00000278219.1	AC145343.1	-11.65	9.7e-28	1.16e-24	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836886	chr17:68101538~68101639:+
LGG	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	11.65	9.72e-28	1.17e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	11.65	9.72e-28	1.17e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
LGG	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-11.65	9.74e-28	1.17e-24	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
LGG	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-11.65	9.75e-28	1.17e-24	-0.49	-0.47	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
LGG	cis	rs7927771	0.864	rs11604680	ENSG00000280615.1	Y_RNA	-11.65	9.76e-28	1.17e-24	-0.6	-0.47	Subjective well-being;	chr11:47435988	chr11:47614898~47614994:-
LGG	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	11.64	9.77e-28	1.17e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
LGG	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	11.64	9.77e-28	1.17e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
LGG	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	11.64	9.78e-28	1.17e-24	0.69	0.47	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
LGG	cis	rs6908034	0.505	rs77880623	ENSG00000228412.5	RP4-625H18.2	11.64	9.8e-28	1.18e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819223	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs12526109	ENSG00000228412.5	RP4-625H18.2	11.64	9.8e-28	1.18e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819858	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs78774173	ENSG00000228412.5	RP4-625H18.2	11.64	9.8e-28	1.18e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19820455	chr6:19802164~19804752:-
LGG	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	11.64	9.83e-28	1.18e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	11.64	9.83e-28	1.18e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
LGG	cis	rs2712184	0.967	rs7587010	ENSG00000229352.1	AC007563.3	-11.64	9.84e-28	1.18e-24	-0.54	-0.47	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216810266	chr2:216799608~216805335:+
LGG	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	11.64	9.85e-28	1.18e-24	0.59	0.47	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	11.64	9.85e-28	1.18e-24	0.59	0.47	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
LGG	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-11.64	9.91e-28	1.19e-24	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
LGG	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-11.64	9.94e-28	1.19e-24	-0.64	-0.47	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
LGG	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-11.64	9.95e-28	1.19e-24	-0.53	-0.47	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
LGG	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-11.64	9.96e-28	1.19e-24	-0.51	-0.47	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
LGG	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-11.64	9.98e-28	1.2e-24	-0.53	-0.47	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
LGG	cis	rs4713118	0.739	rs2893931	ENSG00000199851.2	U3	11.64	1e-27	1.2e-24	0.69	0.47	Parkinson's disease;	chr6:27780231	chr6:28015568~28015777:+
LGG	cis	rs6908034	0.556	rs77486465	ENSG00000228412.5	RP4-625H18.2	11.64	1.01e-27	1.21e-24	0.9	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803631	chr6:19802164~19804752:-
LGG	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-11.64	1.01e-27	1.21e-24	-0.55	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
LGG	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-11.64	1.01e-27	1.21e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
LGG	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-11.64	1.01e-27	1.21e-24	-0.61	-0.47	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
LGG	cis	rs853679	0.882	rs9380069	ENSG00000216901.1	AL022393.7	11.64	1.01e-27	1.22e-24	0.83	0.47	Depression;	chr6:28235522	chr6:28176188~28176674:+
LGG	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	11.64	1.02e-27	1.22e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	11.64	1.02e-27	1.22e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
LGG	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	11.64	1.03e-27	1.23e-24	0.6	0.47	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
LGG	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	11.64	1.03e-27	1.23e-24	0.6	0.47	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
LGG	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	11.64	1.03e-27	1.23e-24	0.59	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
LGG	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	11.64	1.04e-27	1.24e-24	0.52	0.47	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
LGG	cis	rs9309711	0.621	rs11127428	ENSG00000225234.1	TRAPPC12-AS1	-11.64	1.04e-27	1.24e-24	-0.46	-0.47	Neurofibrillary tangles;	chr2:3467375	chr2:3481242~3482409:-
LGG	cis	rs4713118	0.621	rs10484403	ENSG00000226314.6	ZNF192P1	11.64	1.05e-27	1.26e-24	0.57	0.47	Parkinson's disease;	chr6:28065745	chr6:28161781~28169594:+
LGG	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	11.64	1.05e-27	1.26e-24	0.72	0.47	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
LGG	cis	rs4804815	0.784	rs2098701	ENSG00000268297.1	CLEC4GP1	11.64	1.06e-27	1.26e-24	0.51	0.47	Neutrophil count;	chr19:7775254	chr19:7787549~7790621:+
LGG	cis	rs4804815	0.78	rs2081100	ENSG00000268297.1	CLEC4GP1	11.64	1.06e-27	1.26e-24	0.51	0.47	Neutrophil count;	chr19:7775387	chr19:7787549~7790621:+
LGG	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-11.64	1.06e-27	1.26e-24	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
LGG	cis	rs11098499	0.73	rs78971550	ENSG00000249244.1	RP11-548H18.2	11.64	1.06e-27	1.27e-24	0.51	0.47	Corneal astigmatism;	chr4:119359886	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.645	rs78422072	ENSG00000249244.1	RP11-548H18.2	11.64	1.06e-27	1.27e-24	0.51	0.47	Corneal astigmatism;	chr4:119359887	chr4:119391831~119395335:-
LGG	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-11.64	1.06e-27	1.27e-24	-0.57	-0.47	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
LGG	cis	rs853679	0.882	rs9380069	ENSG00000199851.2	U3	11.64	1.06e-27	1.27e-24	0.93	0.47	Depression;	chr6:28235522	chr6:28015568~28015777:+
LGG	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	11.64	1.06e-27	1.27e-24	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
LGG	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	11.63	1.07e-27	1.28e-24	0.52	0.47	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
LGG	cis	rs2013441	1	rs2526475	ENSG00000230528.6	NOS2P3	11.63	1.07e-27	1.29e-24	0.44	0.47	Obesity-related traits;	chr17:20232903	chr17:20436337~20447249:+
LGG	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	11.63	1.08e-27	1.29e-24	0.72	0.47	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
LGG	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-11.63	1.09e-27	1.31e-24	-0.69	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
LGG	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-11.63	1.1e-27	1.31e-24	-0.65	-0.47	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
LGG	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-11.63	1.11e-27	1.32e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
LGG	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	11.63	1.11e-27	1.33e-24	0.72	0.47	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
LGG	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-11.63	1.11e-27	1.33e-24	-0.5	-0.47	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	11.63	1.12e-27	1.33e-24	0.54	0.47	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
LGG	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	11.63	1.12e-27	1.33e-24	0.6	0.47	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
LGG	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-11.63	1.12e-27	1.34e-24	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
LGG	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-11.63	1.13e-27	1.35e-24	-0.5	-0.47	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
LGG	cis	rs8064024	0.625	rs960006	ENSG00000267077.1	RP11-127I20.5	11.63	1.15e-27	1.37e-24	0.47	0.47	Cancer;	chr16:4861194	chr16:4795265~4796532:-
LGG	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-11.63	1.15e-27	1.37e-24	-0.7	-0.47	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
LGG	cis	rs7927771	0.801	rs12798028	ENSG00000280615.1	Y_RNA	-11.63	1.15e-27	1.38e-24	-0.57	-0.47	Subjective well-being;	chr11:47583087	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.839	rs11039308	ENSG00000280615.1	Y_RNA	-11.63	1.15e-27	1.38e-24	-0.57	-0.47	Subjective well-being;	chr11:47600860	chr11:47614898~47614994:-
LGG	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-11.63	1.17e-27	1.4e-24	-0.53	-0.47	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
LGG	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	11.62	1.17e-27	1.4e-24	0.53	0.47	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
LGG	cis	rs2919917	0.628	rs11776243	ENSG00000254352.1	RP11-578O24.2	11.62	1.19e-27	1.42e-24	0.66	0.47	Lymphocyte counts;	chr8:78648848	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.628	rs10110524	ENSG00000254352.1	RP11-578O24.2	11.62	1.19e-27	1.42e-24	0.66	0.47	Lymphocyte counts;	chr8:78648871	chr8:78723796~78724136:-
LGG	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-11.62	1.19e-27	1.42e-24	-0.52	-0.47	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
LGG	cis	rs12946454	0.521	rs4559944	ENSG00000267288.2	RP13-890H12.2	11.62	1.2e-27	1.43e-24	0.6	0.47	Systolic blood pressure;	chr17:45183513	chr17:45168800~45171584:-
LGG	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-11.62	1.21e-27	1.44e-24	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
LGG	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-11.62	1.21e-27	1.44e-24	-0.51	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
LGG	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	11.62	1.22e-27	1.45e-24	0.53	0.47	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
LGG	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-11.62	1.22e-27	1.45e-24	-0.65	-0.47	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
LGG	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	11.62	1.22e-27	1.45e-24	0.59	0.47	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	11.62	1.22e-27	1.45e-24	0.59	0.47	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	11.62	1.22e-27	1.45e-24	0.59	0.47	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
LGG	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-11.62	1.23e-27	1.46e-24	-0.61	-0.47	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-11.62	1.23e-27	1.46e-24	-0.61	-0.47	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-11.62	1.23e-27	1.46e-24	-0.61	-0.47	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-11.62	1.23e-27	1.46e-24	-0.61	-0.47	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	11.62	1.23e-27	1.46e-24	0.6	0.47	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
LGG	cis	rs7927771	0.931	rs12361256	ENSG00000280615.1	Y_RNA	-11.62	1.24e-27	1.47e-24	-0.59	-0.47	Subjective well-being;	chr11:47889271	chr11:47614898~47614994:-
LGG	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-11.62	1.24e-27	1.48e-24	-0.6	-0.47	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
LGG	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	11.62	1.26e-27	1.5e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
LGG	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-11.62	1.27e-27	1.51e-24	-0.59	-0.47	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
LGG	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-11.62	1.27e-27	1.51e-24	-0.61	-0.47	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
LGG	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	11.62	1.28e-27	1.52e-24	0.5	0.47	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
LGG	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	11.62	1.28e-27	1.52e-24	0.5	0.47	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
LGG	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	11.62	1.28e-27	1.52e-24	0.5	0.47	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
LGG	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	11.62	1.28e-27	1.52e-24	0.5	0.47	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
LGG	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-11.62	1.28e-27	1.52e-24	-0.6	-0.47	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
LGG	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	11.62	1.28e-27	1.52e-24	0.84	0.47	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	11.62	1.28e-27	1.52e-24	0.84	0.47	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	11.62	1.28e-27	1.52e-24	0.84	0.47	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
LGG	cis	rs2013441	1	rs17686798	ENSG00000230528.6	NOS2P3	11.62	1.28e-27	1.52e-24	0.43	0.47	Obesity-related traits;	chr17:20125857	chr17:20436337~20447249:+
LGG	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-11.61	1.29e-27	1.53e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
LGG	cis	rs8064024	0.619	rs4141486	ENSG00000267077.1	RP11-127I20.5	11.61	1.29e-27	1.54e-24	0.47	0.47	Cancer;	chr16:4846779	chr16:4795265~4796532:-
LGG	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-11.61	1.3e-27	1.55e-24	-0.53	-0.47	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
LGG	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-11.61	1.31e-27	1.55e-24	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
LGG	cis	rs2712184	0.652	rs13000985	ENSG00000229352.1	AC007563.3	11.61	1.31e-27	1.56e-24	0.54	0.47	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216779638	chr2:216799608~216805335:+
LGG	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-11.61	1.33e-27	1.58e-24	-0.6	-0.47	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-11.61	1.33e-27	1.58e-24	-0.6	-0.47	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-11.61	1.33e-27	1.58e-24	-0.6	-0.47	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-11.61	1.33e-27	1.58e-24	-0.61	-0.47	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-11.61	1.33e-27	1.58e-24	-0.61	-0.47	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
LGG	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-11.61	1.33e-27	1.58e-24	-0.68	-0.47	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
LGG	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	11.61	1.34e-27	1.59e-24	0.72	0.47	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
LGG	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-11.61	1.34e-27	1.6e-24	-0.49	-0.47	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
LGG	cis	rs8064024	0.679	rs2072595	ENSG00000267077.1	RP11-127I20.5	11.61	1.35e-27	1.6e-24	0.47	0.47	Cancer;	chr16:4847152	chr16:4795265~4796532:-
LGG	cis	rs8064024	0.68	rs1827983	ENSG00000267077.1	RP11-127I20.5	11.61	1.35e-27	1.6e-24	0.47	0.47	Cancer;	chr16:4848516	chr16:4795265~4796532:-
LGG	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-11.61	1.36e-27	1.61e-24	-0.57	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
LGG	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-11.61	1.36e-27	1.61e-24	-0.72	-0.47	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
LGG	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-11.61	1.36e-27	1.62e-24	-0.61	-0.47	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-11.61	1.36e-27	1.62e-24	-0.61	-0.47	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-11.61	1.36e-27	1.62e-24	-0.61	-0.47	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
LGG	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-11.61	1.37e-27	1.63e-24	-0.51	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
LGG	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-11.61	1.38e-27	1.64e-24	-0.5	-0.47	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
LGG	cis	rs4819052	0.851	rs1999334	ENSG00000223768.1	LINC00205	-11.61	1.38e-27	1.64e-24	-0.51	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45293285~45297354:+
LGG	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-11.61	1.4e-27	1.67e-24	-0.54	-0.47	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
LGG	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	11.6	1.41e-27	1.67e-24	0.59	0.47	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
LGG	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-11.6	1.43e-27	1.69e-24	-0.6	-0.47	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
LGG	cis	rs1150668	0.799	rs1150705	ENSG00000199851.2	U3	11.6	1.49e-27	1.77e-24	0.63	0.47	Pubertal anthropometrics;	chr6:28226008	chr6:28015568~28015777:+
LGG	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-11.6	1.5e-27	1.78e-24	-0.6	-0.47	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
LGG	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	11.6	1.5e-27	1.78e-24	0.54	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
LGG	cis	rs6908034	0.607	rs79842087	ENSG00000228412.5	RP4-625H18.2	11.6	1.51e-27	1.79e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821085	chr6:19802164~19804752:-
LGG	cis	rs6908034	0.607	rs12527834	ENSG00000228412.5	RP4-625H18.2	11.6	1.51e-27	1.79e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19821550	chr6:19802164~19804752:-
LGG	cis	rs11098499	0.78	rs10013652	ENSG00000249244.1	RP11-548H18.2	11.6	1.52e-27	1.8e-24	0.51	0.47	Corneal astigmatism;	chr4:119371101	chr4:119391831~119395335:-
LGG	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-11.6	1.52e-27	1.8e-24	-0.6	-0.47	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
LGG	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-11.6	1.52e-27	1.8e-24	-0.5	-0.47	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
LGG	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	11.6	1.52e-27	1.81e-24	0.54	0.47	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
LGG	cis	rs7216064	0.7	rs4791295	ENSG00000278219.1	AC145343.1	-11.6	1.52e-27	1.81e-24	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68101538~68101639:+
LGG	cis	rs1150668	0.799	rs7206	ENSG00000280107.1	AL022393.9	-11.6	1.52e-27	1.81e-24	-0.46	-0.47	Pubertal anthropometrics;	chr6:28233360	chr6:28170845~28172521:+
LGG	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	11.59	1.56e-27	1.85e-24	0.54	0.47	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
LGG	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-11.59	1.56e-27	1.85e-24	-0.69	-0.47	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
LGG	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	11.59	1.59e-27	1.88e-24	0.66	0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
LGG	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-11.59	1.6e-27	1.89e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
LGG	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	11.59	1.6e-27	1.9e-24	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
LGG	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-11.59	1.61e-27	1.9e-24	-0.49	-0.47	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
LGG	cis	rs2980439	0.525	rs2980508	ENSG00000173295.6	FAM86B3P	-11.59	1.61e-27	1.9e-24	-0.48	-0.47	Neuroticism;	chr8:8314210	chr8:8228595~8244865:+
LGG	cis	rs4713118	0.824	rs9468225	ENSG00000199851.2	U3	11.59	1.61e-27	1.91e-24	0.69	0.47	Parkinson's disease;	chr6:27777940	chr6:28015568~28015777:+
LGG	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	11.59	1.64e-27	1.94e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
LGG	cis	rs8064024	0.59	rs7186142	ENSG00000267077.1	RP11-127I20.5	11.59	1.65e-27	1.96e-24	0.47	0.47	Cancer;	chr16:4850986	chr16:4795265~4796532:-
LGG	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	11.59	1.66e-27	1.97e-24	0.83	0.47	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
LGG	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	11.59	1.68e-27	1.99e-24	0.55	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	11.59	1.68e-27	1.99e-24	0.55	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
LGG	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-11.58	1.69e-27	2e-24	-0.7	-0.47	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
LGG	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-11.58	1.69e-27	2e-24	-0.54	-0.47	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
LGG	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	11.58	1.7e-27	2.01e-24	0.54	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
LGG	cis	rs651907	0.557	rs11924013	ENSG00000256628.3	ZBTB11-AS1	11.58	1.7e-27	2.01e-24	0.53	0.47	Colorectal cancer;	chr3:101647854	chr3:101676475~101679217:+
LGG	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-11.58	1.7e-27	2.01e-24	-0.61	-0.47	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-11.58	1.7e-27	2.01e-24	-0.61	-0.47	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-11.58	1.7e-27	2.01e-24	-0.61	-0.47	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
LGG	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	11.58	1.71e-27	2.01e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	11.58	1.71e-27	2.01e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
LGG	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-11.58	1.71e-27	2.02e-24	-0.52	-0.47	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
LGG	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-11.58	1.72e-27	2.04e-24	-0.63	-0.47	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
LGG	cis	rs853679	1	rs6901575	ENSG00000199851.2	U3	11.58	1.74e-27	2.05e-24	0.89	0.47	Depression;	chr6:28283207	chr6:28015568~28015777:+
LGG	cis	rs4373814	0.671	rs2840320	ENSG00000226083.4	SLC39A12-AS1	11.58	1.74e-27	2.06e-24	0.47	0.47	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18145261	chr10:18001786~18010562:-
LGG	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-11.58	1.75e-27	2.07e-24	-0.49	-0.47	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
LGG	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	11.58	1.75e-27	2.07e-24	0.59	0.47	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
LGG	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	11.58	1.77e-27	2.08e-24	0.59	0.47	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
LGG	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	11.58	1.77e-27	2.08e-24	0.59	0.47	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
LGG	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	11.58	1.78e-27	2.1e-24	0.58	0.47	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
LGG	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	11.58	1.78e-27	2.1e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	11.58	1.78e-27	2.1e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	11.58	1.78e-27	2.1e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	11.58	1.78e-27	2.1e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
LGG	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-11.58	1.78e-27	2.1e-24	-0.55	-0.47	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
LGG	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-11.58	1.78e-27	2.1e-24	-0.49	-0.47	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
LGG	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-11.58	1.8e-27	2.12e-24	-0.59	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
LGG	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-11.58	1.8e-27	2.13e-24	-0.47	-0.47	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
LGG	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	11.58	1.8e-27	2.13e-24	0.84	0.47	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
LGG	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	11.58	1.82e-27	2.15e-24	0.59	0.47	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
LGG	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-11.58	1.82e-27	2.15e-24	-0.53	-0.47	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-11.58	1.82e-27	2.15e-24	-0.53	-0.47	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-11.58	1.82e-27	2.15e-24	-0.53	-0.47	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
LGG	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-11.58	1.83e-27	2.15e-24	-0.49	-0.47	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
LGG	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-11.58	1.83e-27	2.15e-24	-0.49	-0.47	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
LGG	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-11.58	1.84e-27	2.17e-24	-0.61	-0.47	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
LGG	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-11.57	1.86e-27	2.19e-24	-0.63	-0.47	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
LGG	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	11.57	1.9e-27	2.24e-24	0.52	0.47	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
LGG	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	11.57	1.91e-27	2.25e-24	0.5	0.47	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
LGG	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-11.57	1.92e-27	2.26e-24	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
LGG	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-11.57	1.92e-27	2.27e-24	-0.6	-0.47	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
LGG	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-11.57	1.94e-27	2.28e-24	-0.49	-0.47	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
LGG	cis	rs657075	0.697	rs4646200	ENSG00000233006.5	AC034220.3	-11.57	1.99e-27	2.34e-24	-0.74	-0.47	Rheumatoid arthritis;	chr5:132335443	chr5:132311285~132369916:-
LGG	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-11.57	2e-27	2.35e-24	-0.63	-0.47	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
LGG	cis	rs8064024	0.649	rs9934930	ENSG00000267077.1	RP11-127I20.5	11.57	2.02e-27	2.37e-24	0.47	0.47	Cancer;	chr16:4852037	chr16:4795265~4796532:-
LGG	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	11.56	2.03e-27	2.38e-24	0.72	0.47	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
LGG	cis	rs4713118	0.824	rs9468223	ENSG00000199851.2	U3	11.56	2.03e-27	2.38e-24	0.69	0.47	Parkinson's disease;	chr6:27772887	chr6:28015568~28015777:+
LGG	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	11.56	2.03e-27	2.39e-24	0.72	0.47	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
LGG	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	11.56	2.04e-27	2.4e-24	0.55	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
LGG	cis	rs2013441	1	rs17759923	ENSG00000230528.6	NOS2P3	-11.56	2.05e-27	2.42e-24	-0.43	-0.47	Obesity-related traits;	chr17:20118722	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs2013441	ENSG00000230528.6	NOS2P3	-11.56	2.05e-27	2.42e-24	-0.43	-0.47	Obesity-related traits;	chr17:20119786	chr17:20436337~20447249:+
LGG	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-11.56	2.06e-27	2.42e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
LGG	cis	rs651907	0.557	rs1056579	ENSG00000256628.3	ZBTB11-AS1	11.56	2.08e-27	2.45e-24	0.54	0.47	Colorectal cancer;	chr3:101679033	chr3:101676475~101679217:+
LGG	cis	rs17345786	0.511	rs1138818	ENSG00000256628.3	ZBTB11-AS1	11.56	2.08e-27	2.45e-24	0.54	0.47	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101676475~101679217:+
LGG	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-11.56	2.08e-27	2.45e-24	-0.6	-0.47	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-11.56	2.09e-27	2.46e-24	-0.61	-0.47	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
LGG	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-11.56	2.09e-27	2.46e-24	-0.54	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
LGG	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	11.56	2.09e-27	2.46e-24	0.62	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
LGG	cis	rs4713118	0.629	rs149899	ENSG00000226314.6	ZNF192P1	11.56	2.1e-27	2.47e-24	0.57	0.47	Parkinson's disease;	chr6:28052201	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.629	rs172165	ENSG00000226314.6	ZNF192P1	11.56	2.1e-27	2.47e-24	0.57	0.47	Parkinson's disease;	chr6:28053036	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.597	rs172166	ENSG00000226314.6	ZNF192P1	11.56	2.1e-27	2.47e-24	0.57	0.47	Parkinson's disease;	chr6:28053042	chr6:28161781~28169594:+
LGG	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-11.56	2.1e-27	2.47e-24	-0.49	-0.47	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
LGG	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-11.56	2.1e-27	2.47e-24	-0.61	-0.47	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
LGG	cis	rs6003958	1	rs6003958	ENSG00000218537.1	MIF-AS1	-11.56	2.1e-27	2.47e-24	-0.69	-0.47	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23894426~23898930:-
LGG	cis	rs5760092	0.755	rs6003959	ENSG00000218537.1	MIF-AS1	-11.56	2.1e-27	2.47e-24	-0.69	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23894426~23898930:-
LGG	cis	rs853679	1	rs2799077	ENSG00000199851.2	U3	11.56	2.13e-27	2.5e-24	0.89	0.47	Depression;	chr6:28266819	chr6:28015568~28015777:+
LGG	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-11.56	2.14e-27	2.51e-24	-0.69	-0.47	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-11.56	2.14e-27	2.51e-24	-0.69	-0.47	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-11.56	2.14e-27	2.51e-24	-0.69	-0.47	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
LGG	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-11.56	2.14e-27	2.51e-24	-0.69	-0.47	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-11.56	2.14e-27	2.51e-24	-0.69	-0.47	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-11.56	2.14e-27	2.51e-24	-0.69	-0.47	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
LGG	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-11.56	2.15e-27	2.52e-24	-0.41	-0.47	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
LGG	cis	rs1150668	0.768	rs1150716	ENSG00000218016.2	ZNF192P2	-11.56	2.15e-27	2.52e-24	-0.55	-0.47	Pubertal anthropometrics;	chr6:28294921	chr6:28188050~28189432:+
LGG	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-11.56	2.16e-27	2.53e-24	-0.63	-0.47	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
LGG	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-11.56	2.19e-27	2.56e-24	-0.6	-0.47	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
LGG	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	11.56	2.21e-27	2.59e-24	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	11.56	2.21e-27	2.59e-24	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
LGG	cis	rs4713118	0.662	rs149961	ENSG00000226314.6	ZNF192P1	11.56	2.21e-27	2.6e-24	0.57	0.47	Parkinson's disease;	chr6:28047791	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	11.55	2.23e-27	2.61e-24	0.58	0.47	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
LGG	cis	rs1150668	0.799	rs9301	ENSG00000218016.2	ZNF192P2	-11.55	2.24e-27	2.63e-24	-0.55	-0.47	Pubertal anthropometrics;	chr6:28324929	chr6:28188050~28189432:+
LGG	cis	rs1150668	0.799	rs853684	ENSG00000218016.2	ZNF192P2	-11.55	2.24e-27	2.63e-24	-0.55	-0.47	Pubertal anthropometrics;	chr6:28326773	chr6:28188050~28189432:+
LGG	cis	rs67340775	0.541	rs200965	ENSG00000199851.2	U3	11.55	2.26e-27	2.65e-24	0.88	0.47	Lung cancer in ever smokers;	chr6:27898606	chr6:28015568~28015777:+
LGG	cis	rs4819052	0.851	rs1006779	ENSG00000215447.6	BX322557.10	-11.55	2.26e-27	2.65e-24	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45288052~45291738:+
LGG	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	11.55	2.28e-27	2.68e-24	0.62	0.47	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
LGG	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-11.55	2.3e-27	2.7e-24	-0.7	-0.47	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
LGG	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-11.55	2.3e-27	2.7e-24	-0.54	-0.47	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-11.55	2.3e-27	2.7e-24	-0.54	-0.47	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-11.55	2.3e-27	2.7e-24	-0.54	-0.47	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
LGG	cis	rs5742933	0.711	rs12693551	ENSG00000273240.1	RP11-455J20.3	11.55	2.3e-27	2.7e-24	0.56	0.47	Ferritin levels;	chr2:189664505	chr2:189763859~189764456:-
LGG	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-11.55	2.32e-27	2.72e-24	-0.59	-0.47	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-11.55	2.32e-27	2.72e-24	-0.59	-0.47	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
LGG	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	11.55	2.33e-27	2.73e-24	0.53	0.47	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
LGG	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-11.55	2.33e-27	2.73e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
LGG	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-11.55	2.34e-27	2.74e-24	-0.53	-0.47	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
LGG	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	11.55	2.38e-27	2.78e-24	0.69	0.47	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
LGG	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-11.55	2.38e-27	2.79e-24	-0.49	-0.47	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
LGG	cis	rs4713118	0.621	rs4713132	ENSG00000226314.6	ZNF192P1	11.55	2.38e-27	2.79e-24	0.58	0.47	Parkinson's disease;	chr6:28066257	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.621	rs4713133	ENSG00000226314.6	ZNF192P1	11.55	2.38e-27	2.79e-24	0.58	0.47	Parkinson's disease;	chr6:28066263	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.621	rs4713134	ENSG00000226314.6	ZNF192P1	11.55	2.38e-27	2.79e-24	0.58	0.47	Parkinson's disease;	chr6:28066343	chr6:28161781~28169594:+
LGG	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-11.55	2.4e-27	2.81e-24	-0.54	-0.47	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-11.55	2.4e-27	2.81e-24	-0.54	-0.47	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
LGG	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	11.55	2.4e-27	2.81e-24	0.4	0.47	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
LGG	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-11.55	2.4e-27	2.81e-24	-0.4	-0.47	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
LGG	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-11.55	2.4e-27	2.81e-24	-0.4	-0.47	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
LGG	cis	rs7615952	0.546	rs2979350	ENSG00000242001.1	GS1-388B5.1	11.55	2.41e-27	2.82e-24	0.66	0.47	Blood pressure (smoking interaction);	chr3:125643371	chr3:125681305~125681453:+
LGG	cis	rs8064024	0.582	rs2660241	ENSG00000267077.1	RP11-127I20.5	11.55	2.43e-27	2.84e-24	0.51	0.47	Cancer;	chr16:4890022	chr16:4795265~4796532:-
LGG	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	11.54	2.45e-27	2.86e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	11.54	2.45e-27	2.87e-24	0.58	0.47	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	11.54	2.45e-27	2.87e-24	0.58	0.47	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	11.54	2.45e-27	2.87e-24	0.58	0.47	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
LGG	cis	rs11148252	0.595	rs4884522	ENSG00000235660.1	LINC00345	-11.54	2.45e-27	2.87e-24	-0.58	-0.47	Lewy body disease;	chr13:52479633	chr13:52484161~52484680:-
LGG	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-11.54	2.47e-27	2.89e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
LGG	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-11.54	2.48e-27	2.9e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
LGG	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-11.54	2.5e-27	2.92e-24	-0.6	-0.47	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
LGG	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-11.54	2.5e-27	2.92e-24	-0.4	-0.47	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
LGG	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
LGG	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
LGG	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
LGG	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-11.54	2.51e-27	2.94e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
LGG	cis	rs357618	1	rs165351	ENSG00000260581.1	CTB-113P19.4	11.54	2.53e-27	2.96e-24	0.49	0.47	Basophil percentage of white cells;	chr5:151475320	chr5:151652275~151655449:+
LGG	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-11.54	2.54e-27	2.97e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
LGG	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-11.54	2.56e-27	2.99e-24	-0.51	-0.47	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
LGG	cis	rs4713118	0.738	rs200465	ENSG00000199851.2	U3	11.54	2.56e-27	2.99e-24	0.7	0.47	Parkinson's disease;	chr6:27789875	chr6:28015568~28015777:+
LGG	cis	rs5742933	0.744	rs12693557	ENSG00000273240.1	RP11-455J20.3	11.54	2.58e-27	3.01e-24	0.55	0.47	Ferritin levels;	chr2:189726211	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.817	rs13035966	ENSG00000273240.1	RP11-455J20.3	11.54	2.58e-27	3.01e-24	0.55	0.47	Ferritin levels;	chr2:189726507	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.762	rs2033746	ENSG00000273240.1	RP11-455J20.3	11.54	2.58e-27	3.01e-24	0.55	0.47	Ferritin levels;	chr2:189734726	chr2:189763859~189764456:-
LGG	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	11.54	2.59e-27	3.03e-24	0.72	0.47	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
LGG	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	11.54	2.6e-27	3.03e-24	0.58	0.47	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
LGG	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	11.54	2.6e-27	3.04e-24	0.33	0.47	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
LGG	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-11.54	2.63e-27	3.07e-24	-0.62	-0.47	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
LGG	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	11.54	2.65e-27	3.1e-24	0.59	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	11.54	2.65e-27	3.1e-24	0.59	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
LGG	cis	rs1150668	0.83	rs213240	ENSG00000199851.2	U3	11.53	2.67e-27	3.11e-24	0.62	0.47	Pubertal anthropometrics;	chr6:28348098	chr6:28015568~28015777:+
LGG	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	11.53	2.7e-27	3.15e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-11.53	2.72e-27	3.17e-24	-0.35	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
LGG	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-11.53	2.74e-27	3.19e-24	-0.53	-0.47	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
LGG	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	11.53	2.74e-27	3.2e-24	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
LGG	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-11.53	2.74e-27	3.2e-24	-0.49	-0.47	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
LGG	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-11.53	2.76e-27	3.22e-24	-0.41	-0.47	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
LGG	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-11.53	2.78e-27	3.23e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
LGG	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-11.53	2.79e-27	3.25e-24	-0.68	-0.47	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
LGG	cis	rs8064024	0.681	rs7189135	ENSG00000267077.1	RP11-127I20.5	11.53	2.8e-27	3.26e-24	0.47	0.47	Cancer;	chr16:4834367	chr16:4795265~4796532:-
LGG	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-11.53	2.82e-27	3.28e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
LGG	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-11.53	2.82e-27	3.28e-24	-0.52	-0.47	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
LGG	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	11.53	2.84e-27	3.3e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
LGG	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	11.53	2.84e-27	3.31e-24	0.85	0.47	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
LGG	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	11.53	2.87e-27	3.34e-24	0.34	0.47	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
LGG	cis	rs7615952	0.546	rs4428131	ENSG00000242001.1	GS1-388B5.1	11.53	2.88e-27	3.35e-24	0.68	0.47	Blood pressure (smoking interaction);	chr3:125627635	chr3:125681305~125681453:+
LGG	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	11.53	2.9e-27	3.37e-24	0.33	0.47	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	11.53	2.9e-27	3.37e-24	0.33	0.47	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
LGG	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	11.53	2.9e-27	3.37e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
LGG	cis	rs853679	1	rs1679732	ENSG00000199851.2	U3	-11.52	2.92e-27	3.39e-24	-0.89	-0.47	Depression;	chr6:28253486	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs1679709	ENSG00000199851.2	U3	-11.52	2.92e-27	3.39e-24	-0.89	-0.47	Depression;	chr6:28260564	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs1778511	ENSG00000199851.2	U3	-11.52	2.92e-27	3.39e-24	-0.89	-0.47	Depression;	chr6:28261633	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs1778508	ENSG00000199851.2	U3	-11.52	2.92e-27	3.39e-24	-0.89	-0.47	Depression;	chr6:28262103	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs11965538	ENSG00000199851.2	U3	11.52	2.92e-27	3.39e-24	0.89	0.47	Depression;	chr6:28272137	chr6:28015568~28015777:+
LGG	cis	rs853679	0.882	rs2743555	ENSG00000199851.2	U3	11.52	2.92e-27	3.39e-24	0.89	0.47	Depression;	chr6:28273304	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs1419183	ENSG00000199851.2	U3	11.52	2.92e-27	3.39e-24	0.89	0.47	Depression;	chr6:28275017	chr6:28015568~28015777:+
LGG	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	11.52	2.93e-27	3.4e-24	0.96	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
LGG	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-11.52	2.95e-27	3.43e-24	-0.7	-0.47	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
LGG	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-11.52	2.97e-27	3.46e-24	-0.51	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
LGG	cis	rs651907	0.557	rs3094295	ENSG00000256628.3	ZBTB11-AS1	11.52	2.99e-27	3.47e-24	0.53	0.47	Colorectal cancer;	chr3:101683151	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs17411983	ENSG00000256628.3	ZBTB11-AS1	-11.52	2.99e-27	3.47e-24	-0.53	-0.47	Colorectal cancer;	chr3:101680282	chr3:101676475~101679217:+
LGG	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	11.52	2.99e-27	3.48e-24	0.55	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	11.52	2.99e-27	3.48e-24	0.55	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
LGG	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	11.52	3e-27	3.48e-24	0.53	0.47	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
LGG	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-11.52	3.01e-27	3.5e-24	-0.62	-0.47	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
LGG	cis	rs4713118	0.824	rs2179095	ENSG00000199851.2	U3	-11.52	3.01e-27	3.5e-24	-0.7	-0.47	Parkinson's disease;	chr6:27783079	chr6:28015568~28015777:+
LGG	cis	rs11992186	0.505	rs7845203	ENSG00000173295.6	FAM86B3P	-11.52	3.02e-27	3.51e-24	-0.5	-0.47	Neuroticism;	chr8:8287918	chr8:8228595~8244865:+
LGG	cis	rs8064024	0.62	rs9923349	ENSG00000267077.1	RP11-127I20.5	11.52	3.04e-27	3.53e-24	0.47	0.47	Cancer;	chr16:4855123	chr16:4795265~4796532:-
LGG	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-11.52	3.05e-27	3.54e-24	-0.51	-0.47	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
LGG	cis	rs6904897	0.563	rs9321479	ENSG00000232876.1	CTA-212D2.2	11.52	3.06e-27	3.56e-24	0.59	0.47	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134912771	chr6:135055033~135060550:+
LGG	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	11.52	3.08e-27	3.57e-24	0.58	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
LGG	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	11.52	3.11e-27	3.6e-24	0.52	0.47	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
LGG	cis	rs7615952	0.546	rs2979333	ENSG00000242001.1	GS1-388B5.1	11.52	3.11e-27	3.6e-24	0.66	0.47	Blood pressure (smoking interaction);	chr3:125641499	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.546	rs111812401	ENSG00000242001.1	GS1-388B5.1	11.52	3.11e-27	3.6e-24	0.66	0.47	Blood pressure (smoking interaction);	chr3:125642651	chr3:125681305~125681453:+
LGG	cis	rs7216064	1	rs9915591	ENSG00000278219.1	AC145343.1	-11.52	3.13e-27	3.64e-24	-0.58	-0.47	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67829974	chr17:68101538~68101639:+
LGG	cis	rs5742933	0.725	rs1132360	ENSG00000273240.1	RP11-455J20.3	11.52	3.13e-27	3.64e-24	0.56	0.47	Ferritin levels;	chr2:189661498	chr2:189763859~189764456:-
LGG	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	11.52	3.14e-27	3.64e-24	0.64	0.47	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
LGG	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-11.52	3.14e-27	3.65e-24	-0.55	-0.47	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
LGG	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-11.52	3.18e-27	3.69e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
LGG	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	11.51	3.19e-27	3.7e-24	0.52	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
LGG	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	11.51	3.2e-27	3.71e-24	0.53	0.47	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
LGG	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	11.51	3.2e-27	3.71e-24	0.56	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-11.51	3.2e-27	3.71e-24	-0.56	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
LGG	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	11.51	3.22e-27	3.73e-24	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
LGG	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-11.51	3.23e-27	3.74e-24	-0.51	-0.47	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
LGG	cis	rs4713118	0.513	rs202908	ENSG00000226314.6	ZNF192P1	11.51	3.23e-27	3.75e-24	0.51	0.47	Parkinson's disease;	chr6:28043773	chr6:28161781~28169594:+
LGG	cis	rs172166	0.61	rs156737	ENSG00000226314.6	ZNF192P1	11.51	3.24e-27	3.75e-24	0.46	0.47	Cardiac Troponin-T levels;	chr6:27927435	chr6:28161781~28169594:+
LGG	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-11.51	3.25e-27	3.77e-24	-0.59	-0.47	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
LGG	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	11.51	3.29e-27	3.81e-24	0.63	0.47	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
LGG	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-11.51	3.29e-27	3.81e-24	-0.49	-0.47	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
LGG	cis	rs357618	0.897	rs357630	ENSG00000260581.1	CTB-113P19.4	11.51	3.3e-27	3.82e-24	0.49	0.47	Basophil percentage of white cells;	chr5:151471697	chr5:151652275~151655449:+
LGG	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	11.51	3.32e-27	3.84e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
LGG	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-11.51	3.4e-27	3.93e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-11.51	3.4e-27	3.93e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
LGG	cis	rs7267979	0.565	rs6107060	ENSG00000125804.12	FAM182A	-11.51	3.41e-27	3.95e-24	-0.57	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26054655~26086917:+
LGG	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-11.51	3.43e-27	3.97e-24	-0.59	-0.47	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
LGG	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	11.51	3.44e-27	3.99e-24	0.63	0.47	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
LGG	cis	rs4713118	0.513	rs149897	ENSG00000226314.6	ZNF192P1	11.51	3.45e-27	3.99e-24	0.5	0.47	Parkinson's disease;	chr6:28038872	chr6:28161781~28169594:+
LGG	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-11.51	3.45e-27	3.99e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
LGG	cis	rs4713118	0.662	rs9380045	ENSG00000226314.6	ZNF192P1	11.51	3.47e-27	4.02e-24	0.56	0.47	Parkinson's disease;	chr6:28057501	chr6:28161781~28169594:+
LGG	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-11.51	3.48e-27	4.03e-24	-0.49	-0.47	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
LGG	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-11.5	3.49e-27	4.04e-24	-0.49	-0.47	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
LGG	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-11.5	3.49e-27	4.04e-24	-0.49	-0.47	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
LGG	cis	rs4819052	0.851	rs7276103	ENSG00000215447.6	BX322557.10	-11.5	3.5e-27	4.05e-24	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45288052~45291738:+
LGG	cis	rs6908034	0.505	rs76709285	ENSG00000228412.5	RP4-625H18.2	11.5	3.55e-27	4.11e-24	0.88	0.47	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19802164~19804752:-
LGG	cis	rs8064024	0.599	rs882235	ENSG00000267077.1	RP11-127I20.5	11.5	3.56e-27	4.12e-24	0.5	0.47	Cancer;	chr16:4881650	chr16:4795265~4796532:-
LGG	cis	rs4713118	0.696	rs2394002	ENSG00000199851.2	U3	11.5	3.56e-27	4.12e-24	0.69	0.47	Parkinson's disease;	chr6:27780236	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149954	ENSG00000226314.6	ZNF192P1	11.5	3.57e-27	4.13e-24	0.52	0.47	Parkinson's disease;	chr6:28067468	chr6:28161781~28169594:+
LGG	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-11.5	3.63e-27	4.19e-24	-0.66	-0.47	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
LGG	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	11.5	3.63e-27	4.2e-24	0.68	0.47	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
LGG	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	11.5	3.67e-27	4.24e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	11.5	3.68e-27	4.26e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
LGG	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	11.5	3.69e-27	4.26e-24	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
LGG	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-11.5	3.7e-27	4.27e-24	-0.59	-0.47	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
LGG	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-11.5	3.71e-27	4.29e-24	-0.68	-0.47	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
LGG	cis	rs7615952	0.546	rs2979340	ENSG00000242001.1	GS1-388B5.1	11.5	3.72e-27	4.29e-24	0.68	0.47	Blood pressure (smoking interaction);	chr3:125622540	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.546	rs2979338	ENSG00000242001.1	GS1-388B5.1	11.5	3.72e-27	4.29e-24	0.68	0.47	Blood pressure (smoking interaction);	chr3:125624282	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.546	rs2922171	ENSG00000242001.1	GS1-388B5.1	11.5	3.72e-27	4.29e-24	0.68	0.47	Blood pressure (smoking interaction);	chr3:125624349	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.546	rs112919177	ENSG00000242001.1	GS1-388B5.1	11.5	3.72e-27	4.29e-24	0.68	0.47	Blood pressure (smoking interaction);	chr3:125627226	chr3:125681305~125681453:+
LGG	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-11.5	3.73e-27	4.3e-24	-0.63	-0.47	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-11.5	3.73e-27	4.3e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
LGG	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-11.5	3.73e-27	4.3e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
LGG	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	11.5	3.73e-27	4.31e-24	0.5	0.47	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
LGG	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	11.5	3.73e-27	4.31e-24	0.59	0.47	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
LGG	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-11.5	3.77e-27	4.36e-24	-0.7	-0.47	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
LGG	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	11.5	3.78e-27	4.36e-24	0.52	0.47	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
LGG	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-11.5	3.8e-27	4.38e-24	-0.53	-0.47	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
LGG	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-11.5	3.8e-27	4.39e-24	-0.58	-0.47	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
LGG	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	11.5	3.8e-27	4.39e-24	0.51	0.47	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
LGG	cis	rs2013441	1	rs17759959	ENSG00000230528.6	NOS2P3	-11.5	3.81e-27	4.4e-24	-0.43	-0.47	Obesity-related traits;	chr17:20120782	chr17:20436337~20447249:+
LGG	cis	rs2013441	1	rs12451216	ENSG00000230528.6	NOS2P3	-11.5	3.81e-27	4.4e-24	-0.43	-0.47	Obesity-related traits;	chr17:20122527	chr17:20436337~20447249:+
LGG	cis	rs4713118	0.629	rs203887	ENSG00000216901.1	AL022393.7	11.49	3.83e-27	4.42e-24	0.76	0.47	Parkinson's disease;	chr6:28053491	chr6:28176188~28176674:+
LGG	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-11.49	3.84e-27	4.43e-24	-0.6	-0.47	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
LGG	cis	rs7240205	0.818	rs12964926	ENSG00000275805.1	RP11-349H17.2	11.49	3.84e-27	4.43e-24	0.53	0.47	Breast cancer;	chr18:26567363	chr18:26565723~26575626:-
LGG	cis	rs11647589	0.735	rs2221448	ENSG00000260762.1	ACSM5P1	11.49	3.85e-27	4.44e-24	0.65	0.47	Blood metabolite levels;	chr16:20473548	chr16:20586550~20607107:-
LGG	cis	rs5742933	0.857	rs12471217	ENSG00000273240.1	RP11-455J20.3	11.49	3.85e-27	4.45e-24	0.55	0.47	Ferritin levels;	chr2:189707337	chr2:189763859~189764456:-
LGG	cis	rs4713118	0.513	rs156734	ENSG00000226314.6	ZNF192P1	11.49	3.87e-27	4.46e-24	0.51	0.47	Parkinson's disease;	chr6:28039579	chr6:28161781~28169594:+
LGG	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-11.49	3.87e-27	4.47e-24	-0.74	-0.47	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
LGG	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-11.49	3.88e-27	4.47e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
LGG	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-11.49	3.88e-27	4.48e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
LGG	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-11.49	3.93e-27	4.53e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-11.49	3.94e-27	4.54e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
LGG	cis	rs4819052	0.851	rs1056101	ENSG00000223768.1	LINC00205	-11.49	3.94e-27	4.55e-24	-0.51	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45293285~45297354:+
LGG	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-11.49	4e-27	4.61e-24	-0.53	-0.47	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
LGG	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	11.49	4.02e-27	4.64e-24	0.6	0.47	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
LGG	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	11.49	4.03e-27	4.64e-24	0.53	0.47	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
LGG	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	11.49	4.05e-27	4.66e-24	0.51	0.47	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
LGG	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	11.49	4.05e-27	4.67e-24	0.61	0.47	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
LGG	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-11.49	4.06e-27	4.68e-24	-0.65	-0.47	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
LGG	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-11.49	4.06e-27	4.68e-24	-0.53	-0.47	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
LGG	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-11.49	4.07e-27	4.69e-24	-0.35	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs4819041	ENSG00000215447.6	BX322557.10	-11.49	4.07e-27	4.69e-24	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45288052~45291738:+
LGG	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	11.49	4.08e-27	4.7e-24	0.56	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
LGG	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-11.49	4.15e-27	4.78e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
LGG	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-11.48	4.21e-27	4.84e-24	-0.5	-0.47	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
LGG	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-11.48	4.21e-27	4.84e-24	-0.5	-0.47	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
LGG	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-11.48	4.21e-27	4.84e-24	-0.5	-0.47	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
LGG	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-11.48	4.23e-27	4.87e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-11.48	4.23e-27	4.87e-24	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
LGG	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-11.48	4.24e-27	4.87e-24	-0.53	-0.47	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
LGG	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-11.48	4.24e-27	4.87e-24	-0.81	-0.47	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
LGG	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	11.48	4.3e-27	4.94e-24	0.58	0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
LGG	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-11.48	4.32e-27	4.96e-24	-0.79	-0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
LGG	cis	rs7615952	0.546	rs11718647	ENSG00000242001.1	GS1-388B5.1	11.48	4.34e-27	4.99e-24	0.66	0.47	Blood pressure (smoking interaction);	chr3:125633178	chr3:125681305~125681453:+
LGG	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-11.48	4.34e-27	4.99e-24	-0.68	-0.47	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
LGG	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	11.48	4.38e-27	5.04e-24	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
LGG	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-11.48	4.39e-27	5.04e-24	-0.56	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
LGG	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-11.48	4.4e-27	5.05e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
LGG	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	11.48	4.41e-27	5.07e-24	0.81	0.47	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
LGG	cis	rs2712184	0.683	rs2541403	ENSG00000229352.1	AC007563.3	11.48	4.43e-27	5.08e-24	0.54	0.47	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216773162	chr2:216799608~216805335:+
LGG	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	11.48	4.44e-27	5.1e-24	0.59	0.47	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
LGG	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-11.48	4.47e-27	5.13e-24	-0.58	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
LGG	cis	rs7927771	0.839	rs3817334	ENSG00000280615.1	Y_RNA	-11.48	4.47e-27	5.14e-24	-0.57	-0.47	Subjective well-being;	chr11:47629441	chr11:47614898~47614994:-
LGG	cis	rs1150668	0.796	rs2531825	ENSG00000199851.2	U3	11.48	4.52e-27	5.19e-24	0.6	0.47	Pubertal anthropometrics;	chr6:28381487	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	11.48	4.57e-27	5.24e-24	0.58	0.47	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	11.47	4.59e-27	5.27e-24	0.66	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
LGG	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	11.47	4.62e-27	5.3e-24	0.33	0.47	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
LGG	cis	rs2013441	1	rs11870147	ENSG00000230528.6	NOS2P3	11.47	4.62e-27	5.3e-24	0.43	0.47	Obesity-related traits;	chr17:20312782	chr17:20436337~20447249:+
LGG	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-11.47	4.63e-27	5.31e-24	-0.52	-0.47	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
LGG	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	11.47	4.64e-27	5.33e-24	0.55	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
LGG	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-11.47	4.67e-27	5.35e-24	-0.59	-0.47	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-11.47	4.67e-27	5.35e-24	-0.59	-0.47	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
LGG	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-11.47	4.69e-27	5.38e-24	-0.62	-0.47	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
LGG	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-11.47	4.76e-27	5.46e-24	-0.7	-0.47	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
LGG	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	11.47	4.78e-27	5.48e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
LGG	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-11.47	4.79e-27	5.49e-24	-0.65	-0.47	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
LGG	cis	rs1150668	0.83	rs2023493	ENSG00000199851.2	U3	11.47	4.79e-27	5.49e-24	0.61	0.47	Pubertal anthropometrics;	chr6:28432385	chr6:28015568~28015777:+
LGG	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	11.47	4.79e-27	5.49e-24	0.53	0.47	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
LGG	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	11.47	4.81e-27	5.52e-24	0.57	0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
LGG	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	11.47	4.85e-27	5.56e-24	0.59	0.47	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
LGG	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-11.47	4.91e-27	5.63e-24	-0.52	-0.47	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-11.47	4.91e-27	5.63e-24	-0.52	-0.47	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
LGG	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	11.47	4.93e-27	5.65e-24	0.58	0.47	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
LGG	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-11.47	5e-27	5.72e-24	-0.6	-0.47	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
LGG	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-11.46	5.04e-27	5.77e-24	-0.35	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
LGG	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-11.46	5.1e-27	5.84e-24	-0.69	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
LGG	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	11.46	5.13e-27	5.87e-24	0.7	0.47	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	11.46	5.13e-27	5.87e-24	0.7	0.47	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	11.46	5.13e-27	5.87e-24	0.7	0.47	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	11.46	5.13e-27	5.87e-24	0.7	0.47	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	11.46	5.13e-27	5.87e-24	0.7	0.47	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	11.46	5.13e-27	5.87e-24	0.7	0.47	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
LGG	cis	rs1150668	0.83	rs2859365	ENSG00000199851.2	U3	-11.46	5.13e-27	5.87e-24	-0.6	-0.47	Pubertal anthropometrics;	chr6:28423688	chr6:28015568~28015777:+
LGG	cis	rs657075	0.639	rs2306772	ENSG00000233006.5	AC034220.3	-11.46	5.19e-27	5.93e-24	-0.75	-0.47	Rheumatoid arthritis;	chr5:132340288	chr5:132311285~132369916:-
LGG	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-11.46	5.19e-27	5.94e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
LGG	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	11.46	5.24e-27	5.99e-24	0.53	0.47	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	11.46	5.24e-27	5.99e-24	0.53	0.47	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
LGG	cis	rs1150668	0.799	rs1150705	ENSG00000280107.1	AL022393.9	-11.46	5.26e-27	6.02e-24	-0.46	-0.47	Pubertal anthropometrics;	chr6:28226008	chr6:28170845~28172521:+
LGG	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-11.46	5.3e-27	6.06e-24	-0.41	-0.47	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
LGG	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-11.46	5.3e-27	6.06e-24	-0.49	-0.47	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
LGG	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	11.46	5.32e-27	6.08e-24	0.52	0.47	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
LGG	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	11.46	5.36e-27	6.12e-24	0.52	0.47	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
LGG	cis	rs657075	0.697	rs35497612	ENSG00000233006.5	AC034220.3	-11.46	5.36e-27	6.12e-24	-0.73	-0.47	Rheumatoid arthritis;	chr5:132337413	chr5:132311285~132369916:-
LGG	cis	rs172166	0.637	rs1071893	ENSG00000226314.6	ZNF192P1	11.46	5.36e-27	6.13e-24	0.5	0.47	Cardiac Troponin-T levels;	chr6:28199857	chr6:28161781~28169594:+
LGG	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	11.46	5.41e-27	6.18e-24	0.82	0.47	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	11.46	5.41e-27	6.18e-24	0.82	0.47	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
LGG	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-11.46	5.43e-27	6.21e-24	-0.36	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
LGG	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-11.46	5.43e-27	6.21e-24	-0.85	-0.47	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
LGG	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-11.46	5.47e-27	6.25e-24	-0.49	-0.47	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
LGG	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	11.45	5.49e-27	6.27e-24	0.54	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	11.45	5.49e-27	6.27e-24	0.54	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	11.45	5.49e-27	6.27e-24	0.54	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	11.45	5.49e-27	6.27e-24	0.54	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
LGG	cis	rs1150668	0.764	rs9368565	ENSG00000199851.2	U3	-11.45	5.5e-27	6.28e-24	-0.61	-0.47	Pubertal anthropometrics;	chr6:28377433	chr6:28015568~28015777:+
LGG	cis	rs1150668	0.796	rs1052215	ENSG00000199851.2	U3	-11.45	5.5e-27	6.28e-24	-0.61	-0.47	Pubertal anthropometrics;	chr6:28380381	chr6:28015568~28015777:+
LGG	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	11.45	5.55e-27	6.33e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	11.45	5.55e-27	6.33e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	11.45	5.55e-27	6.33e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
LGG	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	11.45	5.62e-27	6.41e-24	0.5	0.47	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
LGG	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	11.45	5.7e-27	6.5e-24	0.59	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	11.45	5.7e-27	6.5e-24	0.59	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
LGG	cis	rs1150668	0.799	rs1736891	ENSG00000226314.6	ZNF192P1	11.45	5.72e-27	6.52e-24	0.46	0.47	Pubertal anthropometrics;	chr6:28219323	chr6:28161781~28169594:+
LGG	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-11.45	5.75e-27	6.55e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-11.45	5.75e-27	6.55e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-11.45	5.75e-27	6.55e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-11.45	5.75e-27	6.55e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-11.45	5.75e-27	6.55e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-11.45	5.75e-27	6.55e-24	-0.54	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-11.45	5.79e-27	6.6e-24	-0.55	-0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	11.45	5.79e-27	6.6e-24	0.58	0.47	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
LGG	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	11.45	5.88e-27	6.69e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
LGG	cis	rs1150668	0.796	rs728122	ENSG00000199851.2	U3	11.45	5.89e-27	6.7e-24	0.6	0.47	Pubertal anthropometrics;	chr6:28431347	chr6:28015568~28015777:+
LGG	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	11.45	5.89e-27	6.71e-24	0.32	0.47	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
LGG	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	11.45	5.92e-27	6.74e-24	0.57	0.47	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
LGG	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	11.45	5.93e-27	6.76e-24	0.59	0.47	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
LGG	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	11.45	5.93e-27	6.76e-24	0.59	0.47	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
LGG	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-11.45	5.98e-27	6.81e-24	-0.63	-0.47	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-11.45	6e-27	6.82e-24	-0.62	-0.47	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
LGG	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	11.45	6e-27	6.83e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	11.45	6e-27	6.83e-24	0.57	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
LGG	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-11.44	6.1e-27	6.93e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
LGG	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-11.44	6.1e-27	6.93e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
LGG	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	11.44	6.1e-27	6.94e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
LGG	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	11.44	6.1e-27	6.94e-24	0.53	0.47	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
LGG	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-11.44	6.1e-27	6.94e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
LGG	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-11.44	6.15e-27	6.99e-24	-0.62	-0.47	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
LGG	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-11.44	6.29e-27	7.15e-24	-0.7	-0.47	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
LGG	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	11.44	6.3e-27	7.16e-24	0.51	0.47	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
LGG	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	11.44	6.31e-27	7.17e-24	0.53	0.47	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
LGG	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	11.44	6.34e-27	7.2e-24	0.58	0.47	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
LGG	cis	rs172166	0.516	rs1225715	ENSG00000226314.6	ZNF192P1	-11.44	6.37e-27	7.23e-24	-0.5	-0.47	Cardiac Troponin-T levels;	chr6:28145595	chr6:28161781~28169594:+
LGG	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-11.44	6.44e-27	7.31e-24	-0.47	-0.47	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
LGG	cis	rs1475911	1	rs12482477	ENSG00000184385.2	UMODL1-AS1	11.44	6.46e-27	7.34e-24	0.61	0.47	IgG glycosylation;	chr21:42097123	chr21:42102134~42108534:-
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	11.44	6.48e-27	7.36e-24	0.64	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
LGG	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	11.44	6.5e-27	7.38e-24	0.67	0.47	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
LGG	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	11.44	6.51e-27	7.39e-24	0.5	0.47	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
LGG	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-11.44	6.51e-27	7.39e-24	-0.53	-0.47	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
LGG	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-11.43	6.62e-27	7.51e-24	-0.49	-0.46	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
LGG	cis	rs2013441	1	rs11654025	ENSG00000230528.6	NOS2P3	11.43	6.66e-27	7.56e-24	0.43	0.46	Obesity-related traits;	chr17:20294847	chr17:20436337~20447249:+
LGG	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-11.43	6.7e-27	7.61e-24	-0.49	-0.46	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
LGG	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	11.43	6.71e-27	7.61e-24	0.52	0.46	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
LGG	cis	rs11098499	0.566	rs17051356	ENSG00000249244.1	RP11-548H18.2	11.43	6.71e-27	7.62e-24	0.53	0.46	Corneal astigmatism;	chr4:119664153	chr4:119391831~119395335:-
LGG	cis	rs1150668	0.796	rs2247002	ENSG00000199851.2	U3	11.43	6.73e-27	7.64e-24	0.6	0.46	Pubertal anthropometrics;	chr6:28430174	chr6:28015568~28015777:+
LGG	cis	rs7267979	0.565	rs4815432	ENSG00000125804.12	FAM182A	11.43	6.75e-27	7.65e-24	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26054655~26086917:+
LGG	cis	rs12495178	0.599	rs7620825	ENSG00000239519.1	CADM2-AS1	11.43	6.8e-27	7.72e-24	0.52	0.46	Body mass index;	chr3:85868139	chr3:85992183~86028007:-
LGG	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	11.43	6.81e-27	7.72e-24	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
LGG	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-11.43	6.83e-27	7.75e-24	-0.63	-0.46	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-11.43	6.83e-27	7.75e-24	-0.63	-0.46	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-11.43	6.83e-27	7.75e-24	-0.63	-0.46	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-11.43	6.83e-27	7.75e-24	-0.63	-0.46	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
LGG	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-11.43	6.85e-27	7.76e-24	-0.48	-0.46	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
LGG	cis	rs4819052	0.851	rs1999334	ENSG00000215447.6	BX322557.10	-11.43	6.86e-27	7.77e-24	-0.36	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45288052~45291738:+
LGG	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-11.43	6.86e-27	7.78e-24	-0.51	-0.46	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
LGG	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-11.43	6.89e-27	7.81e-24	-0.6	-0.46	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
LGG	cis	rs172166	0.637	rs1225597	ENSG00000226314.6	ZNF192P1	11.43	6.93e-27	7.86e-24	0.5	0.46	Cardiac Troponin-T levels;	chr6:28194309	chr6:28161781~28169594:+
LGG	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	11.43	7.06e-27	8e-24	0.57	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
LGG	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-11.43	7.16e-27	8.11e-24	-0.48	-0.46	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
LGG	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	11.43	7.17e-27	8.12e-24	0.62	0.46	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
LGG	cis	rs1150668	0.796	rs1124132	ENSG00000199851.2	U3	11.43	7.17e-27	8.12e-24	0.61	0.46	Pubertal anthropometrics;	chr6:28412544	chr6:28015568~28015777:+
LGG	cis	rs1150668	0.796	rs2531832	ENSG00000199851.2	U3	11.43	7.17e-27	8.12e-24	0.61	0.46	Pubertal anthropometrics;	chr6:28421445	chr6:28015568~28015777:+
LGG	cis	rs1150668	0.799	rs2142730	ENSG00000218016.2	ZNF192P2	-11.42	7.21e-27	8.16e-24	-0.54	-0.46	Pubertal anthropometrics;	chr6:28298372	chr6:28188050~28189432:+
LGG	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	11.42	7.27e-27	8.23e-24	0.58	0.46	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
LGG	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-11.42	7.33e-27	8.3e-24	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
LGG	cis	rs357618	0.897	rs165362	ENSG00000260581.1	CTB-113P19.4	11.42	7.34e-27	8.31e-24	0.49	0.46	Basophil percentage of white cells;	chr5:151483526	chr5:151652275~151655449:+
LGG	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-11.42	7.35e-27	8.32e-24	-0.68	-0.46	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-11.42	7.35e-27	8.32e-24	-0.68	-0.46	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-11.42	7.35e-27	8.32e-24	-0.68	-0.46	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
LGG	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-11.42	7.39e-27	8.36e-24	-0.5	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-11.42	7.39e-27	8.36e-24	-0.5	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
LGG	cis	rs4713118	0.662	rs9357060	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28056708	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs9468271	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28056792	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs9468274	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28058299	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs9468275	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28058358	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs9468276	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28059910	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs9468277	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28060612	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs9468278	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28060704	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs13218430	ENSG00000226314.6	ZNF192P1	11.42	7.44e-27	8.42e-24	0.56	0.46	Parkinson's disease;	chr6:28062059	chr6:28161781~28169594:+
LGG	cis	rs2921073	0.51	rs2976944	ENSG00000173295.6	FAM86B3P	-11.42	7.45e-27	8.42e-24	-0.5	-0.46	Parkinson's disease;	chr8:8413404	chr8:8228595~8244865:+
LGG	cis	rs11647589	0.688	rs28556968	ENSG00000260762.1	ACSM5P1	11.42	7.46e-27	8.44e-24	0.64	0.46	Blood metabolite levels;	chr16:20469357	chr16:20586550~20607107:-
LGG	cis	rs5742933	0.762	rs12992061	ENSG00000273240.1	RP11-455J20.3	11.42	7.48e-27	8.46e-24	0.55	0.46	Ferritin levels;	chr2:189736026	chr2:189763859~189764456:-
LGG	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-11.42	7.48e-27	8.46e-24	-0.45	-0.46	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
LGG	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-11.42	7.51e-27	8.5e-24	-0.51	-0.46	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
LGG	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-11.42	7.54e-27	8.53e-24	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	11.42	7.55e-27	8.54e-24	0.58	0.46	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
LGG	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-11.42	7.58e-27	8.57e-24	-0.52	-0.46	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
LGG	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	11.42	7.67e-27	8.67e-24	0.49	0.46	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
LGG	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	11.42	7.71e-27	8.71e-24	0.7	0.46	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	11.42	7.71e-27	8.71e-24	0.7	0.46	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	11.42	7.71e-27	8.71e-24	0.7	0.46	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	11.42	7.71e-27	8.71e-24	0.7	0.46	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	11.42	7.71e-27	8.71e-24	0.7	0.46	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
LGG	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-11.42	7.8e-27	8.82e-24	-0.4	-0.46	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
LGG	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	11.42	7.81e-27	8.83e-24	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
LGG	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-11.42	7.84e-27	8.86e-24	-0.53	-0.46	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-11.42	7.84e-27	8.86e-24	-0.53	-0.46	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
LGG	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-11.42	7.86e-27	8.87e-24	-0.6	-0.46	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
LGG	cis	rs17345786	0.511	rs13061565	ENSG00000256628.3	ZBTB11-AS1	11.41	7.93e-27	8.95e-24	0.53	0.46	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs7651404	ENSG00000256628.3	ZBTB11-AS1	11.41	7.93e-27	8.95e-24	0.53	0.46	Colorectal cancer;	chr3:101674450	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs3806653	ENSG00000256628.3	ZBTB11-AS1	11.41	7.93e-27	8.95e-24	0.53	0.46	Colorectal cancer;	chr3:101678128	chr3:101676475~101679217:+
LGG	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-11.41	8.19e-27	9.24e-24	-0.59	-0.46	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-11.41	8.19e-27	9.24e-24	-0.59	-0.46	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
LGG	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	-11.41	8.2e-27	9.25e-24	-0.49	-0.46	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
LGG	cis	rs4713118	0.629	rs203888	ENSG00000226314.6	ZNF192P1	11.41	8.29e-27	9.35e-24	0.56	0.46	Parkinson's disease;	chr6:28053811	chr6:28161781~28169594:+
LGG	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	11.41	8.31e-27	9.37e-24	0.52	0.46	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
LGG	cis	rs5742933	0.779	rs1899025	ENSG00000273240.1	RP11-455J20.3	11.41	8.33e-27	9.4e-24	0.55	0.46	Ferritin levels;	chr2:189784856	chr2:189763859~189764456:-
LGG	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	11.41	8.39e-27	9.46e-24	0.52	0.46	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
LGG	cis	rs4713118	0.662	rs149900	ENSG00000226314.6	ZNF192P1	11.41	8.46e-27	9.53e-24	0.57	0.46	Parkinson's disease;	chr6:28046819	chr6:28161781~28169594:+
LGG	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	11.41	8.47e-27	9.54e-24	0.51	0.46	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
LGG	cis	rs7216064	1	rs8071463	ENSG00000278219.1	AC145343.1	11.41	8.51e-27	9.59e-24	0.57	0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942539	chr17:68101538~68101639:+
LGG	cis	rs853679	1	rs7740487	ENSG00000199851.2	U3	11.41	8.52e-27	9.59e-24	0.89	0.46	Depression;	chr6:28248708	chr6:28015568~28015777:+
LGG	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-11.41	8.52e-27	9.59e-24	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
LGG	cis	rs1150668	0.799	rs1150705	ENSG00000218016.2	ZNF192P2	-11.4	8.62e-27	9.71e-24	-0.54	-0.46	Pubertal anthropometrics;	chr6:28226008	chr6:28188050~28189432:+
LGG	cis	rs7927771	0.832	rs10838704	ENSG00000280615.1	Y_RNA	-11.4	8.63e-27	9.72e-24	-0.59	-0.46	Subjective well-being;	chr11:47403166	chr11:47614898~47614994:-
LGG	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	11.4	8.65e-27	9.74e-24	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
LGG	cis	rs1150668	0.745	rs213238	ENSG00000199851.2	U3	11.4	8.65e-27	9.74e-24	0.61	0.46	Pubertal anthropometrics;	chr6:28354216	chr6:28015568~28015777:+
LGG	cis	rs172166	0.561	rs149971	ENSG00000280107.1	AL022393.9	-11.4	8.67e-27	9.77e-24	-0.46	-0.46	Cardiac Troponin-T levels;	chr6:28014374	chr6:28170845~28172521:+
LGG	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-11.4	8.69e-27	9.78e-24	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	11.4	8.7e-27	9.79e-24	0.72	0.46	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
LGG	cis	rs11690935	0.879	rs13017585	ENSG00000228389.1	AC068039.4	11.4	8.74e-27	9.84e-24	0.52	0.46	Schizophrenia;	chr2:171865298	chr2:171773482~171775844:+
LGG	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	11.4	8.76e-27	9.86e-24	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
LGG	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	11.4	8.79e-27	9.89e-24	0.7	0.46	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
LGG	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-11.4	8.79e-27	9.89e-24	-0.53	-0.46	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-11.4	8.79e-27	9.89e-24	-0.53	-0.46	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-11.4	8.79e-27	9.89e-24	-0.53	-0.46	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-11.4	8.79e-27	9.89e-24	-0.53	-0.46	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-11.4	8.79e-27	9.89e-24	-0.53	-0.46	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
LGG	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-11.4	8.79e-27	9.9e-24	-0.5	-0.46	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
LGG	cis	rs9637599	0.513	rs9995984	ENSG00000246375.2	RP11-10L7.1	11.4	8.8e-27	9.9e-24	0.54	0.46	Metabolite levels (small molecules and protein measures);	chr4:88303936	chr4:88284942~88331421:+
LGG	cis	rs11098499	0.874	rs7661020	ENSG00000249244.1	RP11-548H18.2	11.4	8.9e-27	1e-23	0.51	0.46	Corneal astigmatism;	chr4:119185827	chr4:119391831~119395335:-
LGG	cis	rs4713118	0.662	rs9380046	ENSG00000226314.6	ZNF192P1	11.4	8.99e-27	1.01e-23	0.56	0.46	Parkinson's disease;	chr6:28062721	chr6:28161781~28169594:+
LGG	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-11.4	9.02e-27	1.01e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
LGG	cis	rs7829975	0.742	rs7832968	ENSG00000173295.6	FAM86B3P	-11.4	9.03e-27	1.02e-23	-0.49	-0.46	Mood instability;	chr8:8795379	chr8:8228595~8244865:+
LGG	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-11.4	9.1e-27	1.02e-23	-0.54	-0.46	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
LGG	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-11.4	9.12e-27	1.03e-23	-0.55	-0.46	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
LGG	cis	rs853679	1	rs2799079	ENSG00000216901.1	AL022393.7	11.4	9.18e-27	1.03e-23	0.77	0.46	Depression;	chr6:28267398	chr6:28176188~28176674:+
LGG	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	11.4	9.22e-27	1.04e-23	0.68	0.46	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	11.4	9.22e-27	1.04e-23	0.68	0.46	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	11.4	9.27e-27	1.04e-23	0.57	0.46	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
LGG	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-11.4	9.4e-27	1.06e-23	-0.7	-0.46	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
LGG	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	11.4	9.41e-27	1.06e-23	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
LGG	cis	rs8092443	0.935	rs4243321	ENSG00000278971.1	RP11-644A7.2	11.39	9.49e-27	1.07e-23	0.67	0.46	Response to antipsychotic treatment;	chr18:70493434	chr18:70489630~70491205:+
LGG	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	11.39	9.55e-27	1.07e-23	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
LGG	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	11.39	9.56e-27	1.07e-23	0.32	0.46	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	11.39	9.56e-27	1.07e-23	0.32	0.46	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
LGG	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-11.39	9.63e-27	1.08e-23	-0.38	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
LGG	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-11.39	9.68e-27	1.09e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
LGG	cis	rs8092443	1	rs4597426	ENSG00000278971.1	RP11-644A7.2	11.39	9.7e-27	1.09e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70490916	chr18:70489630~70491205:+
LGG	cis	rs8092443	1	rs12607188	ENSG00000278971.1	RP11-644A7.2	11.39	9.7e-27	1.09e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70492120	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.938	rs12604913	ENSG00000278971.1	RP11-644A7.2	11.39	9.7e-27	1.09e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70492236	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.938	rs10871669	ENSG00000278971.1	RP11-644A7.2	11.39	9.7e-27	1.09e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70492720	chr18:70489630~70491205:+
LGG	cis	rs8092443	1	rs11664660	ENSG00000278971.1	RP11-644A7.2	11.39	9.7e-27	1.09e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70492959	chr18:70489630~70491205:+
LGG	cis	rs8092443	1	rs4891859	ENSG00000278971.1	RP11-644A7.2	11.39	9.7e-27	1.09e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70493077	chr18:70489630~70491205:+
LGG	cis	rs172166	0.516	rs1225710	ENSG00000226314.6	ZNF192P1	-11.39	9.76e-27	1.1e-23	-0.45	-0.46	Cardiac Troponin-T levels;	chr6:28132862	chr6:28161781~28169594:+
LGG	cis	rs4819052	0.724	rs1304487	ENSG00000215447.6	BX322557.10	11.39	9.79e-27	1.1e-23	0.35	0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45288052~45291738:+
LGG	cis	rs1150668	0.83	rs213240	ENSG00000226314.6	ZNF192P1	11.39	9.87e-27	1.11e-23	0.45	0.46	Pubertal anthropometrics;	chr6:28348098	chr6:28161781~28169594:+
LGG	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	11.39	9.91e-27	1.11e-23	0.58	0.46	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
LGG	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-11.39	9.91e-27	1.11e-23	-0.38	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
LGG	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	11.39	9.96e-27	1.12e-23	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
LGG	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-11.39	9.96e-27	1.12e-23	-0.6	-0.46	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
LGG	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	11.39	9.96e-27	1.12e-23	0.51	0.46	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
LGG	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	11.39	9.96e-27	1.12e-23	0.57	0.46	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	11.39	9.96e-27	1.12e-23	0.57	0.46	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
LGG	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-11.39	1e-26	1.12e-23	-0.41	-0.46	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
LGG	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	11.39	1e-26	1.12e-23	0.59	0.46	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
LGG	cis	rs4713118	0.505	rs276371	ENSG00000199851.2	U3	11.39	1e-26	1.13e-23	0.63	0.46	Parkinson's disease;	chr6:27942930	chr6:28015568~28015777:+
LGG	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-11.39	1.01e-26	1.13e-23	-0.54	-0.46	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
LGG	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	11.39	1.01e-26	1.13e-23	0.7	0.46	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	11.39	1.01e-26	1.14e-23	0.7	0.46	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
LGG	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-11.39	1.02e-26	1.15e-23	-0.5	-0.46	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
LGG	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-11.39	1.02e-26	1.15e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
LGG	cis	rs2287838	0.686	rs2233679	ENSG00000267289.1	CTD-2623N2.11	-11.39	1.03e-26	1.15e-23	-0.52	-0.46	Sleep duration;	chr19:9834678	chr19:9834079~9835013:-
LGG	cis	rs5742933	0.681	rs4525728	ENSG00000273240.1	RP11-455J20.3	11.38	1.03e-26	1.16e-23	0.55	0.46	Ferritin levels;	chr2:189780324	chr2:189763859~189764456:-
LGG	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	11.38	1.04e-26	1.16e-23	0.57	0.46	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	11.38	1.04e-26	1.16e-23	0.57	0.46	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
LGG	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-11.38	1.04e-26	1.16e-23	-0.6	-0.46	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
LGG	cis	rs7267979	0.565	rs3752273	ENSG00000125804.12	FAM182A	11.38	1.04e-26	1.17e-23	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26054655~26086917:+
LGG	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-11.38	1.04e-26	1.17e-23	-0.54	-0.46	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-11.38	1.04e-26	1.17e-23	-0.54	-0.46	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
LGG	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	11.38	1.05e-26	1.18e-23	0.58	0.46	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
LGG	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	11.38	1.05e-26	1.18e-23	0.54	0.46	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
LGG	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	11.38	1.05e-26	1.18e-23	0.44	0.46	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
LGG	cis	rs4819052	0.851	rs7275468	ENSG00000215447.6	BX322557.10	-11.38	1.06e-26	1.18e-23	-0.35	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45288052~45291738:+
LGG	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	11.38	1.06e-26	1.18e-23	0.69	0.46	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	11.38	1.06e-26	1.18e-23	0.69	0.46	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
LGG	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	11.38	1.06e-26	1.18e-23	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
LGG	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-11.38	1.06e-26	1.18e-23	-0.6	-0.46	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
LGG	cis	rs2287838	0.686	rs730554	ENSG00000267289.1	CTD-2623N2.11	-11.38	1.07e-26	1.19e-23	-0.51	-0.46	Sleep duration;	chr19:9850870	chr19:9834079~9835013:-
LGG	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	11.38	1.07e-26	1.19e-23	0.55	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
LGG	cis	rs853679	1	rs68141011	ENSG00000199851.2	U3	11.38	1.07e-26	1.19e-23	0.89	0.46	Depression;	chr6:28250019	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs13200462	ENSG00000199851.2	U3	11.38	1.07e-26	1.19e-23	0.89	0.46	Depression;	chr6:28250421	chr6:28015568~28015777:+
LGG	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-11.38	1.08e-26	1.21e-23	-0.53	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
LGG	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-11.38	1.09e-26	1.22e-23	-0.55	-0.46	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
LGG	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	11.38	1.09e-26	1.22e-23	0.5	0.46	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
LGG	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	11.38	1.09e-26	1.22e-23	0.51	0.46	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
LGG	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-11.38	1.1e-26	1.22e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-11.38	1.1e-26	1.22e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
LGG	cis	rs172166	0.538	rs149956	ENSG00000280107.1	AL022393.9	-11.38	1.1e-26	1.23e-23	-0.46	-0.46	Cardiac Troponin-T levels;	chr6:28068473	chr6:28170845~28172521:+
LGG	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	11.38	1.1e-26	1.23e-23	0.69	0.46	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	11.38	1.1e-26	1.23e-23	0.69	0.46	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	11.38	1.1e-26	1.23e-23	0.69	0.46	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
LGG	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-11.38	1.11e-26	1.24e-23	-0.56	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
LGG	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	11.38	1.11e-26	1.24e-23	0.51	0.46	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
LGG	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	11.38	1.11e-26	1.24e-23	0.67	0.46	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
LGG	cis	rs7267979	0.565	rs6107059	ENSG00000125804.12	FAM182A	11.38	1.12e-26	1.25e-23	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26054655~26086917:+
LGG	cis	rs651907	0.557	rs7651721	ENSG00000256628.3	ZBTB11-AS1	11.37	1.13e-26	1.26e-23	0.53	0.46	Colorectal cancer;	chr3:101674739	chr3:101676475~101679217:+
LGG	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	11.37	1.14e-26	1.27e-23	0.57	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	11.37	1.14e-26	1.27e-23	0.57	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-11.37	1.15e-26	1.28e-23	-0.54	-0.46	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
LGG	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-11.37	1.15e-26	1.28e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
LGG	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-11.37	1.15e-26	1.28e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-11.37	1.15e-26	1.28e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
LGG	cis	rs5742933	0.857	rs893784	ENSG00000273240.1	RP11-455J20.3	-11.37	1.16e-26	1.3e-23	-0.55	-0.46	Ferritin levels;	chr2:189671557	chr2:189763859~189764456:-
LGG	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-11.37	1.17e-26	1.3e-23	-0.49	-0.46	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
LGG	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	11.37	1.17e-26	1.31e-23	0.41	0.46	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
LGG	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-11.37	1.17e-26	1.31e-23	-0.54	-0.46	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
LGG	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-11.37	1.19e-26	1.32e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
LGG	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	11.37	1.2e-26	1.33e-23	0.69	0.46	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.513	rs149989	ENSG00000226314.6	ZNF192P1	11.37	1.2e-26	1.33e-23	0.5	0.46	Parkinson's disease;	chr6:28030406	chr6:28161781~28169594:+
LGG	cis	rs7216064	1	rs8072225	ENSG00000278219.1	AC145343.1	-11.37	1.21e-26	1.34e-23	-0.57	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67916844	chr17:68101538~68101639:+
LGG	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	11.37	1.21e-26	1.35e-23	0.51	0.46	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
LGG	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-11.37	1.21e-26	1.35e-23	-0.54	-0.46	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-11.37	1.21e-26	1.35e-23	-0.54	-0.46	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
LGG	cis	rs657075	0.697	rs35373795	ENSG00000233006.5	AC034220.3	-11.37	1.23e-26	1.37e-23	-0.72	-0.46	Rheumatoid arthritis;	chr5:132418132	chr5:132311285~132369916:-
LGG	cis	rs8064024	0.501	rs28375268	ENSG00000267077.1	RP11-127I20.5	-11.36	1.25e-26	1.39e-23	-0.49	-0.46	Cancer;	chr16:4899527	chr16:4795265~4796532:-
LGG	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.26e-26	1.4e-23	-0.67	-0.46	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
LGG	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	11.36	1.26e-26	1.4e-23	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	11.36	1.26e-26	1.4e-23	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
LGG	cis	rs2013441	0.965	rs7207611	ENSG00000230528.6	NOS2P3	-11.36	1.26e-26	1.4e-23	-0.43	-0.46	Obesity-related traits;	chr17:20301203	chr17:20436337~20447249:+
LGG	cis	rs8064024	0.599	rs3185547	ENSG00000267077.1	RP11-127I20.5	11.36	1.26e-26	1.4e-23	0.49	0.46	Cancer;	chr16:4881099	chr16:4795265~4796532:-
LGG	cis	rs4713118	0.616	rs9348789	ENSG00000226314.6	ZNF192P1	11.36	1.27e-26	1.41e-23	0.56	0.46	Parkinson's disease;	chr6:28057708	chr6:28161781~28169594:+
LGG	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-11.36	1.28e-26	1.42e-23	-0.4	-0.46	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
LGG	cis	rs7208859	0.673	rs216411	ENSG00000263531.1	RP13-753N3.1	-11.36	1.28e-26	1.42e-23	-0.79	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30863921~30864940:-
LGG	cis	rs67340775	0.541	rs200968	ENSG00000199851.2	U3	11.36	1.28e-26	1.43e-23	0.87	0.46	Lung cancer in ever smokers;	chr6:27891790	chr6:28015568~28015777:+
LGG	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-11.36	1.29e-26	1.44e-23	-0.61	-0.46	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
LGG	cis	rs1150668	0.799	rs1150707	ENSG00000226314.6	ZNF192P1	11.36	1.3e-26	1.45e-23	0.45	0.46	Pubertal anthropometrics;	chr6:28229827	chr6:28161781~28169594:+
LGG	cis	rs1150668	0.768	rs1233713	ENSG00000226314.6	ZNF192P1	11.36	1.3e-26	1.45e-23	0.45	0.46	Pubertal anthropometrics;	chr6:28230503	chr6:28161781~28169594:+
LGG	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	11.36	1.3e-26	1.45e-23	0.49	0.46	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
LGG	cis	rs1150668	0.799	rs7206	ENSG00000226314.6	ZNF192P1	11.36	1.31e-26	1.46e-23	0.45	0.46	Pubertal anthropometrics;	chr6:28233360	chr6:28161781~28169594:+
LGG	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	11.36	1.32e-26	1.47e-23	0.82	0.46	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
LGG	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	11.36	1.32e-26	1.47e-23	0.56	0.46	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
LGG	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	11.36	1.33e-26	1.48e-23	0.57	0.46	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
LGG	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-11.36	1.33e-26	1.48e-23	-0.63	-0.46	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
LGG	cis	rs853679	1	rs10456362	ENSG00000216901.1	AL022393.7	-11.36	1.33e-26	1.48e-23	-0.77	-0.46	Depression;	chr6:28254038	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.629	rs203889	ENSG00000226314.6	ZNF192P1	11.36	1.34e-26	1.49e-23	0.56	0.46	Parkinson's disease;	chr6:28053997	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	11.36	1.35e-26	1.5e-23	0.57	0.46	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
LGG	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	11.36	1.35e-26	1.5e-23	0.58	0.46	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
LGG	cis	rs2013441	1	rs4924808	ENSG00000230528.6	NOS2P3	11.36	1.35e-26	1.5e-23	0.43	0.46	Obesity-related traits;	chr17:20123235	chr17:20436337~20447249:+
LGG	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	11.35	1.37e-26	1.52e-23	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
LGG	cis	rs853679	1	rs853694	ENSG00000216901.1	AL022393.7	11.35	1.38e-26	1.53e-23	0.76	0.46	Depression;	chr6:28311323	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs853685	ENSG00000216901.1	AL022393.7	11.35	1.38e-26	1.53e-23	0.77	0.46	Depression;	chr6:28321008	chr6:28176188~28176674:+
LGG	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-11.35	1.38e-26	1.54e-23	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
LGG	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-11.35	1.39e-26	1.54e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	11.35	1.4e-26	1.56e-23	0.54	0.46	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
LGG	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	11.35	1.4e-26	1.56e-23	0.53	0.46	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
LGG	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-11.35	1.42e-26	1.58e-23	-0.65	-0.46	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
LGG	cis	rs7240205	0.816	rs7233016	ENSG00000275805.1	RP11-349H17.2	-11.35	1.43e-26	1.58e-23	-0.52	-0.46	Breast cancer;	chr18:26541387	chr18:26565723~26575626:-
LGG	cis	rs7216064	0.648	rs61676547	ENSG00000278219.1	AC145343.1	-11.35	1.43e-26	1.59e-23	-0.57	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896391	chr17:68101538~68101639:+
LGG	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	11.35	1.43e-26	1.59e-23	0.52	0.46	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
LGG	cis	rs4804815	0.78	rs4804814	ENSG00000268297.1	CLEC4GP1	-11.35	1.44e-26	1.59e-23	-0.5	-0.46	Neutrophil count;	chr19:7775424	chr19:7787549~7790621:+
LGG	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-11.35	1.44e-26	1.59e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
LGG	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	-11.35	1.45e-26	1.61e-23	-0.48	-0.46	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
LGG	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-11.35	1.46e-26	1.62e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
LGG	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-11.35	1.47e-26	1.63e-23	-0.65	-0.46	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
LGG	cis	rs1150668	0.796	rs9468372	ENSG00000199851.2	U3	11.35	1.47e-26	1.63e-23	0.6	0.46	Pubertal anthropometrics;	chr6:28411584	chr6:28015568~28015777:+
LGG	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-11.35	1.47e-26	1.63e-23	-0.36	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
LGG	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-11.35	1.47e-26	1.63e-23	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-11.35	1.48e-26	1.63e-23	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
LGG	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-11.34	1.48e-26	1.64e-23	-0.49	-0.46	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
LGG	cis	rs4819052	1	rs2838847	ENSG00000223768.1	LINC00205	-11.34	1.49e-26	1.64e-23	-0.56	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.959	rs8130866	ENSG00000223768.1	LINC00205	-11.34	1.49e-26	1.64e-23	-0.56	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45293285~45297354:+
LGG	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	11.34	1.49e-26	1.65e-23	0.95	0.46	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
LGG	cis	rs12495178	0.639	rs13071488	ENSG00000239519.1	CADM2-AS1	11.34	1.49e-26	1.65e-23	0.52	0.46	Body mass index;	chr3:85866747	chr3:85992183~86028007:-
LGG	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	11.34	1.5e-26	1.66e-23	0.53	0.46	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
LGG	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	11.34	1.5e-26	1.66e-23	0.52	0.46	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
LGG	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-11.34	1.5e-26	1.66e-23	-0.59	-0.46	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
LGG	cis	rs651907	0.557	rs13081846	ENSG00000256628.3	ZBTB11-AS1	11.34	1.51e-26	1.67e-23	0.53	0.46	Colorectal cancer;	chr3:101664477	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs11711079	ENSG00000256628.3	ZBTB11-AS1	11.34	1.51e-26	1.67e-23	0.53	0.46	Colorectal cancer;	chr3:101668074	chr3:101676475~101679217:+
LGG	cis	rs7216064	0.953	rs4791300	ENSG00000278219.1	AC145343.1	-11.34	1.53e-26	1.7e-23	-0.56	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934656	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs4791299	ENSG00000278219.1	AC145343.1	-11.34	1.53e-26	1.7e-23	-0.56	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934821	chr17:68101538~68101639:+
LGG	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	11.34	1.54e-26	1.7e-23	0.51	0.46	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
LGG	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-11.34	1.55e-26	1.72e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
LGG	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-11.34	1.56e-26	1.73e-23	-0.41	-0.46	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	11.34	1.57e-26	1.73e-23	0.65	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
LGG	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	11.34	1.58e-26	1.75e-23	0.56	0.46	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
LGG	cis	rs17767294	0.612	rs9461424	ENSG00000199851.2	U3	11.34	1.59e-26	1.76e-23	1.05	0.46	Parkinson's disease;	chr6:27951623	chr6:28015568~28015777:+
LGG	cis	rs8064024	0.557	rs7193783	ENSG00000267077.1	RP11-127I20.5	-11.34	1.59e-26	1.76e-23	-0.49	-0.46	Cancer;	chr16:4899607	chr16:4795265~4796532:-
LGG	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	11.34	1.6e-26	1.77e-23	0.54	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
LGG	cis	rs7267979	0.528	rs6076366	ENSG00000125804.12	FAM182A	11.34	1.6e-26	1.77e-23	0.54	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.527	rs6083891	ENSG00000125804.12	FAM182A	11.34	1.6e-26	1.77e-23	0.54	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.527	rs6076369	ENSG00000125804.12	FAM182A	11.34	1.6e-26	1.77e-23	0.54	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	11.34	1.61e-26	1.77e-23	0.69	0.46	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
LGG	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-11.34	1.61e-26	1.78e-23	-0.6	-0.46	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
LGG	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-11.34	1.61e-26	1.78e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-11.34	1.61e-26	1.78e-23	-0.54	-0.46	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
LGG	cis	rs172166	0.561	rs149973	ENSG00000218016.2	ZNF192P2	-11.33	1.63e-26	1.8e-23	-0.55	-0.46	Cardiac Troponin-T levels;	chr6:28015835	chr6:28188050~28189432:+
LGG	cis	rs172166	0.561	rs149974	ENSG00000218016.2	ZNF192P2	-11.33	1.63e-26	1.8e-23	-0.55	-0.46	Cardiac Troponin-T levels;	chr6:28017318	chr6:28188050~28189432:+
LGG	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-11.33	1.63e-26	1.8e-23	-0.38	-0.46	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
LGG	cis	rs2486288	0.656	rs1719236	ENSG00000259433.2	CTD-2651B20.4	11.33	1.64e-26	1.81e-23	0.52	0.46	Glomerular filtration rate;	chr15:45285585	chr15:45330209~45332634:-
LGG	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.66e-26	1.83e-23	-0.49	-0.46	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
LGG	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	11.33	1.66e-26	1.83e-23	0.56	0.46	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
LGG	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	11.33	1.68e-26	1.85e-23	0.68	0.46	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	11.33	1.68e-26	1.86e-23	0.57	0.46	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
LGG	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	11.33	1.69e-26	1.86e-23	0.6	0.46	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
LGG	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-11.33	1.69e-26	1.86e-23	-0.53	-0.46	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-11.33	1.69e-26	1.86e-23	-0.53	-0.46	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-11.33	1.69e-26	1.86e-23	-0.53	-0.46	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
LGG	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	11.33	1.7e-26	1.87e-23	0.58	0.46	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	11.33	1.7e-26	1.87e-23	0.58	0.46	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
LGG	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	11.33	1.7e-26	1.87e-23	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
LGG	cis	rs853679	1	rs853679	ENSG00000216901.1	AL022393.7	11.33	1.7e-26	1.88e-23	0.76	0.46	Depression;	chr6:28329086	chr6:28176188~28176674:+
LGG	cis	rs853679	1	rs853678	ENSG00000216901.1	AL022393.7	11.33	1.7e-26	1.88e-23	0.76	0.46	Depression;	chr6:28329536	chr6:28176188~28176674:+
LGG	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	11.33	1.7e-26	1.88e-23	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	11.33	1.7e-26	1.88e-23	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
LGG	cis	rs357618	1	rs441652	ENSG00000260581.1	CTB-113P19.4	11.33	1.72e-26	1.89e-23	0.49	0.46	Basophil percentage of white cells;	chr5:151467944	chr5:151652275~151655449:+
LGG	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-11.33	1.72e-26	1.89e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
LGG	cis	rs4819052	1	rs2297285	ENSG00000223768.1	LINC00205	11.33	1.73e-26	1.91e-23	0.58	0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45293285~45297354:+
LGG	cis	rs7267979	0.565	rs958075	ENSG00000125804.12	FAM182A	11.33	1.74e-26	1.92e-23	0.54	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26054655~26086917:+
LGG	cis	rs7216064	0.954	rs9907491	ENSG00000278219.1	AC145343.1	11.33	1.75e-26	1.93e-23	0.56	0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67953877	chr17:68101538~68101639:+
LGG	cis	rs7216064	0.954	rs4790974	ENSG00000278219.1	AC145343.1	11.33	1.75e-26	1.93e-23	0.56	0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67954991	chr17:68101538~68101639:+
LGG	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	11.32	1.79e-26	1.97e-23	0.57	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
LGG	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-11.32	1.79e-26	1.98e-23	-0.54	-0.46	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-11.32	1.79e-26	1.98e-23	-0.54	-0.46	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-11.32	1.79e-26	1.98e-23	-0.54	-0.46	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-11.32	1.79e-26	1.98e-23	-0.54	-0.46	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-11.32	1.79e-26	1.98e-23	-0.54	-0.46	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
LGG	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	11.32	1.8e-26	1.99e-23	0.58	0.46	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
LGG	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	11.32	1.81e-26	2e-23	0.56	0.46	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	11.32	1.82e-26	2e-23	0.58	0.46	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
LGG	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-11.32	1.82e-26	2.01e-23	-0.35	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-11.32	1.82e-26	2.01e-23	-0.35	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
LGG	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-11.32	1.83e-26	2.01e-23	-0.49	-0.46	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
LGG	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-11.32	1.83e-26	2.02e-23	-0.54	-0.46	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
LGG	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	11.32	1.87e-26	2.06e-23	0.67	0.46	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
LGG	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-11.32	1.88e-26	2.07e-23	-0.41	-0.46	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
LGG	cis	rs853679	1	rs6905391	ENSG00000216901.1	AL022393.7	11.32	1.88e-26	2.07e-23	0.76	0.46	Depression;	chr6:28294909	chr6:28176188~28176674:+
LGG	cis	rs5742933	0.857	rs11685425	ENSG00000273240.1	RP11-455J20.3	11.32	1.88e-26	2.07e-23	0.56	0.46	Ferritin levels;	chr2:189747977	chr2:189763859~189764456:-
LGG	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-11.32	1.93e-26	2.12e-23	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
LGG	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-11.32	1.93e-26	2.13e-23	-0.52	-0.46	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
LGG	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-11.32	1.93e-26	2.13e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-11.32	1.93e-26	2.13e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
LGG	cis	rs7267979	0.899	rs6115213	ENSG00000125804.12	FAM182A	-11.31	1.94e-26	2.13e-23	-0.56	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:26054655~26086917:+
LGG	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-11.31	1.96e-26	2.15e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
LGG	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-11.31	1.97e-26	2.17e-23	-0.54	-0.46	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
LGG	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	11.31	1.97e-26	2.17e-23	0.56	0.46	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
LGG	cis	rs6500637	0.931	rs79338890	ENSG00000267077.1	RP11-127I20.5	11.31	1.97e-26	2.17e-23	0.49	0.46	Cancer;	chr16:4855126	chr16:4795265~4796532:-
LGG	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-11.31	1.98e-26	2.17e-23	-0.65	-0.46	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
LGG	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	11.31	1.98e-26	2.17e-23	0.53	0.46	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
LGG	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	11.31	2e-26	2.2e-23	0.41	0.46	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
LGG	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-11.31	2.02e-26	2.22e-23	-0.63	-0.46	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
LGG	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-11.31	2.03e-26	2.22e-23	-0.63	-0.46	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
LGG	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	11.31	2.05e-26	2.25e-23	0.62	0.46	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
LGG	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-11.31	2.05e-26	2.25e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
LGG	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-11.31	2.06e-26	2.26e-23	-0.49	-0.46	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
LGG	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	11.31	2.07e-26	2.27e-23	0.69	0.46	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
LGG	cis	rs7927771	0.839	rs59360790	ENSG00000280615.1	Y_RNA	-11.31	2.08e-26	2.29e-23	-0.57	-0.46	Subjective well-being;	chr11:47647623	chr11:47614898~47614994:-
LGG	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-11.31	2.09e-26	2.29e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
LGG	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	11.31	2.1e-26	2.3e-23	0.69	0.46	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
LGG	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	11.31	2.12e-26	2.32e-23	0.5	0.46	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
LGG	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	11.3	2.13e-26	2.34e-23	0.53	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
LGG	cis	rs8092443	1	rs4891860	ENSG00000278971.1	RP11-644A7.2	11.3	2.13e-26	2.34e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70493111	chr18:70489630~70491205:+
LGG	cis	rs8092443	1	rs4243320	ENSG00000278971.1	RP11-644A7.2	11.3	2.13e-26	2.34e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70493338	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.938	rs4243323	ENSG00000278971.1	RP11-644A7.2	11.3	2.13e-26	2.34e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70493562	chr18:70489630~70491205:+
LGG	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	11.3	2.14e-26	2.35e-23	0.51	0.46	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
LGG	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	11.3	2.15e-26	2.35e-23	0.7	0.46	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	11.3	2.15e-26	2.35e-23	0.7	0.46	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
LGG	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-11.3	2.16e-26	2.36e-23	-0.54	-0.46	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
LGG	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-11.3	2.17e-26	2.38e-23	-0.68	-0.46	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.824	rs7759217	ENSG00000199851.2	U3	11.3	2.18e-26	2.38e-23	0.68	0.46	Parkinson's disease;	chr6:27762684	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.784	rs9468219	ENSG00000199851.2	U3	11.3	2.18e-26	2.38e-23	0.68	0.46	Parkinson's disease;	chr6:27763976	chr6:28015568~28015777:+
LGG	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	11.3	2.18e-26	2.39e-23	0.41	0.46	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
LGG	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-11.3	2.18e-26	2.39e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
LGG	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-11.3	2.18e-26	2.39e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
LGG	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	11.3	2.19e-26	2.4e-23	0.5	0.46	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
LGG	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	11.3	2.19e-26	2.4e-23	0.53	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
LGG	cis	rs4713118	0.629	rs203890	ENSG00000226314.6	ZNF192P1	11.3	2.19e-26	2.4e-23	0.56	0.46	Parkinson's disease;	chr6:28054470	chr6:28161781~28169594:+
LGG	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	11.3	2.25e-26	2.47e-23	0.51	0.46	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
LGG	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	11.3	2.25e-26	2.47e-23	0.62	0.46	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
LGG	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-11.3	2.29e-26	2.5e-23	-0.52	-0.46	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
LGG	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	11.3	2.3e-26	2.51e-23	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
LGG	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-11.3	2.31e-26	2.53e-23	-0.49	-0.46	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
LGG	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-11.29	2.33e-26	2.55e-23	-0.53	-0.46	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
LGG	cis	rs7267979	0.528	rs34485039	ENSG00000125804.12	FAM182A	11.29	2.33e-26	2.55e-23	0.54	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.565	rs4815437	ENSG00000125804.12	FAM182A	11.29	2.33e-26	2.55e-23	0.54	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26054655~26086917:+
LGG	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-11.29	2.34e-26	2.56e-23	-0.5	-0.46	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
LGG	cis	rs7829975	0.714	rs11777085	ENSG00000173295.6	FAM86B3P	-11.29	2.38e-26	2.61e-23	-0.48	-0.46	Mood instability;	chr8:8814919	chr8:8228595~8244865:+
LGG	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-11.29	2.39e-26	2.61e-23	-0.59	-0.46	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
LGG	cis	rs1150668	0.745	rs213238	ENSG00000226314.6	ZNF192P1	11.29	2.39e-26	2.61e-23	0.44	0.46	Pubertal anthropometrics;	chr6:28354216	chr6:28161781~28169594:+
LGG	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-11.29	2.39e-26	2.61e-23	-0.68	-0.46	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
LGG	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-11.29	2.4e-26	2.62e-23	-0.49	-0.46	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
LGG	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	-11.29	2.41e-26	2.63e-23	-0.48	-0.46	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
LGG	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-11.29	2.41e-26	2.63e-23	-0.4	-0.46	Height;	chr11:118860890	chr11:118791254~118793137:+
LGG	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-11.29	2.41e-26	2.63e-23	-0.4	-0.46	Height;	chr11:118861053	chr11:118791254~118793137:+
LGG	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	11.29	2.45e-26	2.67e-23	0.82	0.46	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
LGG	cis	rs4713118	0.513	rs149944	ENSG00000226314.6	ZNF192P1	11.29	2.47e-26	2.69e-23	0.49	0.46	Parkinson's disease;	chr6:28035040	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.824	rs9366702	ENSG00000199851.2	U3	11.29	2.48e-26	2.71e-23	0.68	0.46	Parkinson's disease;	chr6:27766691	chr6:28015568~28015777:+
LGG	cis	rs12495178	0.599	rs13099482	ENSG00000239519.1	CADM2-AS1	11.29	2.48e-26	2.71e-23	0.52	0.46	Body mass index;	chr3:85867392	chr3:85992183~86028007:-
LGG	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-11.29	2.48e-26	2.71e-23	-0.56	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
LGG	cis	rs1150668	0.83	rs2531831	ENSG00000199851.2	U3	11.29	2.49e-26	2.72e-23	0.6	0.46	Pubertal anthropometrics;	chr6:28420988	chr6:28015568~28015777:+
LGG	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-11.29	2.49e-26	2.72e-23	-0.48	-0.46	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
LGG	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	11.29	2.51e-26	2.74e-23	0.8	0.46	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
LGG	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	11.29	2.51e-26	2.74e-23	0.56	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
LGG	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-11.29	2.52e-26	2.75e-23	-0.6	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
LGG	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-11.29	2.52e-26	2.75e-23	-0.47	-0.46	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
LGG	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	11.29	2.52e-26	2.75e-23	0.46	0.46	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
LGG	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-11.28	2.54e-26	2.77e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
LGG	cis	rs5742933	0.817	rs4667297	ENSG00000273240.1	RP11-455J20.3	11.28	2.55e-26	2.79e-23	0.55	0.46	Ferritin levels;	chr2:189664270	chr2:189763859~189764456:-
LGG	cis	rs853679	1	rs9986596	ENSG00000199851.2	U3	11.28	2.56e-26	2.79e-23	0.87	0.46	Depression;	chr6:28251883	chr6:28015568~28015777:+
LGG	cis	rs6908034	0.66	rs6918235	ENSG00000228412.5	RP4-625H18.2	11.28	2.56e-26	2.8e-23	0.89	0.46	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19788196	chr6:19802164~19804752:-
LGG	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-11.28	2.57e-26	2.8e-23	-0.54	-0.46	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	11.28	2.57e-26	2.8e-23	0.57	0.46	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
LGG	cis	rs5742933	0.817	rs1233265	ENSG00000273240.1	RP11-455J20.3	-11.28	2.58e-26	2.81e-23	-0.54	-0.46	Ferritin levels;	chr2:189796390	chr2:189763859~189764456:-
LGG	cis	rs1150668	0.764	rs9368565	ENSG00000218016.2	ZNF192P2	11.28	2.6e-26	2.84e-23	0.53	0.46	Pubertal anthropometrics;	chr6:28377433	chr6:28188050~28189432:+
LGG	cis	rs1150668	0.796	rs1052215	ENSG00000218016.2	ZNF192P2	11.28	2.6e-26	2.84e-23	0.53	0.46	Pubertal anthropometrics;	chr6:28380381	chr6:28188050~28189432:+
LGG	cis	rs853679	0.666	rs200956	ENSG00000216901.1	AL022393.7	11.28	2.61e-26	2.84e-23	0.69	0.46	Depression;	chr6:27871968	chr6:28176188~28176674:+
LGG	cis	rs7119038	0.629	rs73001429	ENSG00000255239.1	AP002954.6	-11.28	2.62e-26	2.85e-23	-0.62	-0.46	Sjögren's syndrome;	chr11:118732456	chr11:118688039~118690600:-
LGG	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	11.28	2.66e-26	2.9e-23	0.5	0.46	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
LGG	cis	rs8092443	1	rs11151592	ENSG00000278971.1	RP11-644A7.2	11.28	2.66e-26	2.9e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70492593	chr18:70489630~70491205:+
LGG	cis	rs172166	0.561	rs149976	ENSG00000280107.1	AL022393.9	11.28	2.7e-26	2.94e-23	0.45	0.46	Cardiac Troponin-T levels;	chr6:28019998	chr6:28170845~28172521:+
LGG	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	11.28	2.7e-26	2.94e-23	0.71	0.46	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	11.28	2.71e-26	2.95e-23	0.69	0.46	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
LGG	cis	rs916888	0.647	rs199449	ENSG00000232300.1	FAM215B	11.28	2.71e-26	2.95e-23	0.59	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46558830~46562795:-
LGG	cis	rs916888	0.61	rs199444	ENSG00000232300.1	FAM215B	11.28	2.71e-26	2.95e-23	0.59	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46558830~46562795:-
LGG	cis	rs916888	0.61	rs199442	ENSG00000232300.1	FAM215B	11.28	2.71e-26	2.95e-23	0.59	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46558830~46562795:-
LGG	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	11.28	2.72e-26	2.96e-23	0.57	0.46	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
LGG	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-11.28	2.72e-26	2.96e-23	-0.69	-0.46	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
LGG	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	11.28	2.73e-26	2.97e-23	0.49	0.46	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
LGG	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-11.28	2.75e-26	2.99e-23	-0.48	-0.46	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
LGG	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-11.28	2.76e-26	3e-23	-0.54	-0.46	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
LGG	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	11.28	2.77e-26	3.01e-23	0.95	0.46	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
LGG	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-11.27	2.77e-26	3.02e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
LGG	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-11.27	2.81e-26	3.06e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
LGG	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-11.27	2.84e-26	3.09e-23	-0.4	-0.46	Height;	chr11:118859432	chr11:118791254~118793137:+
LGG	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	11.27	2.84e-26	3.09e-23	0.57	0.46	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
LGG	cis	rs8092443	1	rs8094337	ENSG00000278971.1	RP11-644A7.2	11.27	2.84e-26	3.09e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70491518	chr18:70489630~70491205:+
LGG	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	11.27	2.85e-26	3.1e-23	0.67	0.46	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
LGG	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-11.27	2.86e-26	3.11e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
LGG	cis	rs4713118	0.513	rs149941	ENSG00000226314.6	ZNF192P1	11.27	2.86e-26	3.12e-23	0.49	0.46	Parkinson's disease;	chr6:28033255	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.513	rs149942	ENSG00000226314.6	ZNF192P1	11.27	2.86e-26	3.12e-23	0.49	0.46	Parkinson's disease;	chr6:28033832	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.513	rs149945	ENSG00000226314.6	ZNF192P1	11.27	2.86e-26	3.12e-23	0.49	0.46	Parkinson's disease;	chr6:28035075	chr6:28161781~28169594:+
LGG	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	11.27	2.88e-26	3.13e-23	0.63	0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
LGG	cis	rs7829975	0.711	rs12682352	ENSG00000173295.6	FAM86B3P	-11.27	2.89e-26	3.14e-23	-0.49	-0.46	Mood instability;	chr8:8788736	chr8:8228595~8244865:+
LGG	cis	rs916888	0.61	rs199453	ENSG00000232300.1	FAM215B	11.27	2.89e-26	3.15e-23	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46558830~46562795:-
LGG	cis	rs5742933	0.817	rs2033870	ENSG00000273240.1	RP11-455J20.3	-11.27	2.96e-26	3.22e-23	-0.55	-0.46	Ferritin levels;	chr2:189739104	chr2:189763859~189764456:-
LGG	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	11.27	2.96e-26	3.22e-23	0.58	0.46	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	11.27	2.96e-26	3.22e-23	0.58	0.46	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	11.27	2.96e-26	3.22e-23	0.58	0.46	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
LGG	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-11.27	2.96e-26	3.22e-23	-0.53	-0.46	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
LGG	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-11.27	2.97e-26	3.22e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
LGG	cis	rs7267979	0.528	rs2387976	ENSG00000125804.12	FAM182A	11.27	2.98e-26	3.23e-23	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-11.27	2.99e-26	3.25e-23	-0.57	-0.46	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
LGG	cis	rs9527	0.637	rs12219247	ENSG00000272912.1	RP11-724N1.1	-11.27	3.02e-26	3.27e-23	-0.53	-0.46	Arsenic metabolism;	chr10:102853604	chr10:102914585~102915404:+
LGG	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	11.27	3.02e-26	3.28e-23	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
LGG	cis	rs7216064	1	rs56404791	ENSG00000278219.1	AC145343.1	-11.26	3.06e-26	3.33e-23	-0.56	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896903	chr17:68101538~68101639:+
LGG	cis	rs7216064	1	rs55896768	ENSG00000278219.1	AC145343.1	-11.26	3.06e-26	3.33e-23	-0.56	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67917242	chr17:68101538~68101639:+
LGG	cis	rs7267979	0.565	rs13040726	ENSG00000125804.12	FAM182A	11.26	3.07e-26	3.33e-23	0.54	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26054655~26086917:+
LGG	cis	rs7829975	0.714	rs7823757	ENSG00000173295.6	FAM86B3P	-11.26	3.07e-26	3.33e-23	-0.48	-0.46	Mood instability;	chr8:8812667	chr8:8228595~8244865:+
LGG	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-11.26	3.11e-26	3.37e-23	-0.54	-0.46	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
LGG	cis	rs5742933	0.817	rs5742938	ENSG00000273240.1	RP11-455J20.3	11.26	3.12e-26	3.39e-23	0.54	0.46	Ferritin levels;	chr2:189785232	chr2:189763859~189764456:-
LGG	cis	rs916888	0.61	rs199436	ENSG00000232300.1	FAM215B	-11.26	3.14e-26	3.4e-23	-0.58	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46558830~46562795:-
LGG	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	11.26	3.21e-26	3.47e-23	0.57	0.46	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
LGG	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-11.26	3.23e-26	3.5e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
LGG	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	11.26	3.23e-26	3.51e-23	0.8	0.46	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
LGG	cis	rs5742933	0.948	rs7592066	ENSG00000273240.1	RP11-455J20.3	11.26	3.24e-26	3.51e-23	0.55	0.46	Ferritin levels;	chr2:189778792	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.779	rs7595020	ENSG00000273240.1	RP11-455J20.3	11.26	3.24e-26	3.51e-23	0.55	0.46	Ferritin levels;	chr2:189778950	chr2:189763859~189764456:-
LGG	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-11.26	3.25e-26	3.52e-23	-0.59	-0.46	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
LGG	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-11.26	3.26e-26	3.53e-23	-0.59	-0.46	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
LGG	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-11.26	3.26e-26	3.53e-23	-0.59	-0.46	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
LGG	cis	rs11098499	0.532	rs4833624	ENSG00000249244.1	RP11-548H18.2	11.26	3.28e-26	3.56e-23	0.51	0.46	Corneal astigmatism;	chr4:119664342	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.532	rs12512646	ENSG00000249244.1	RP11-548H18.2	11.26	3.28e-26	3.56e-23	0.51	0.46	Corneal astigmatism;	chr4:119664578	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.866	rs12501602	ENSG00000249244.1	RP11-548H18.2	11.26	3.29e-26	3.57e-23	0.5	0.46	Corneal astigmatism;	chr4:119366780	chr4:119391831~119395335:-
LGG	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	11.25	3.32e-26	3.59e-23	0.57	0.46	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
LGG	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	11.25	3.35e-26	3.62e-23	0.63	0.46	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
LGG	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-11.25	3.36e-26	3.64e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	11.25	3.36e-26	3.64e-23	0.57	0.46	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	11.25	3.37e-26	3.65e-23	0.58	0.46	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
LGG	cis	rs11098499	0.78	rs7692994	ENSG00000249244.1	RP11-548H18.2	11.25	3.38e-26	3.66e-23	0.49	0.46	Corneal astigmatism;	chr4:119506334	chr4:119391831~119395335:-
LGG	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	11.25	3.38e-26	3.66e-23	0.51	0.46	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
LGG	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	11.25	3.41e-26	3.69e-23	0.57	0.46	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
LGG	cis	rs5742933	0.744	rs13002216	ENSG00000273240.1	RP11-455J20.3	11.25	3.42e-26	3.7e-23	0.54	0.46	Ferritin levels;	chr2:189746358	chr2:189763859~189764456:-
LGG	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-11.25	3.42e-26	3.7e-23	-0.6	-0.46	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
LGG	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	11.25	3.42e-26	3.7e-23	0.56	0.46	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	11.25	3.42e-26	3.7e-23	0.56	0.46	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
LGG	cis	rs7829975	0.66	rs10093926	ENSG00000173295.6	FAM86B3P	11.25	3.42e-26	3.7e-23	0.49	0.46	Mood instability;	chr8:8691510	chr8:8228595~8244865:+
LGG	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	11.25	3.44e-26	3.72e-23	0.79	0.46	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	11.25	3.44e-26	3.72e-23	0.79	0.46	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	11.25	3.44e-26	3.72e-23	0.79	0.46	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	11.25	3.46e-26	3.74e-23	0.8	0.46	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	11.25	3.46e-26	3.74e-23	0.8	0.46	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
LGG	cis	rs7216064	1	rs56148300	ENSG00000278219.1	AC145343.1	-11.25	3.48e-26	3.76e-23	-0.56	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896636	chr17:68101538~68101639:+
LGG	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-11.25	3.52e-26	3.8e-23	-0.59	-0.46	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
LGG	cis	rs11098499	0.874	rs13123591	ENSG00000249244.1	RP11-548H18.2	11.25	3.55e-26	3.84e-23	0.5	0.46	Corneal astigmatism;	chr4:119184835	chr4:119391831~119395335:-
LGG	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	11.25	3.56e-26	3.84e-23	0.68	0.46	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
LGG	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-11.25	3.56e-26	3.85e-23	-0.41	-0.46	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
LGG	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-11.25	3.56e-26	3.85e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
LGG	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-11.25	3.57e-26	3.85e-23	-0.48	-0.46	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
LGG	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	11.25	3.57e-26	3.86e-23	0.57	0.46	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
LGG	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-11.25	3.58e-26	3.86e-23	-0.6	-0.46	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
LGG	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	11.25	3.59e-26	3.88e-23	0.51	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
LGG	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-11.25	3.59e-26	3.88e-23	-0.49	-0.46	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
LGG	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-11.25	3.59e-26	3.88e-23	-0.49	-0.46	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
LGG	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-11.25	3.59e-26	3.88e-23	-0.49	-0.46	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
LGG	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-11.25	3.59e-26	3.88e-23	-0.49	-0.46	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
LGG	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-11.25	3.59e-26	3.88e-23	-0.49	-0.46	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
LGG	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-11.25	3.59e-26	3.88e-23	-0.49	-0.46	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
LGG	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-11.25	3.62e-26	3.91e-23	-0.37	-0.46	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
LGG	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	11.25	3.62e-26	3.91e-23	0.68	0.46	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	11.24	3.67e-26	3.96e-23	0.69	0.46	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
LGG	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-11.24	3.67e-26	3.96e-23	-0.53	-0.46	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
LGG	cis	rs7829975	0.777	rs486781	ENSG00000173295.6	FAM86B3P	11.24	3.68e-26	3.97e-23	0.49	0.46	Mood instability;	chr8:8782230	chr8:8228595~8244865:+
LGG	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-11.24	3.7e-26	3.99e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
LGG	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-11.24	3.72e-26	4.01e-23	-0.59	-0.46	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	11.24	3.72e-26	4.02e-23	0.57	0.46	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
LGG	cis	rs12802244	1	rs12802244	ENSG00000280615.1	Y_RNA	-11.24	3.73e-26	4.03e-23	-0.58	-0.46	Neuroticism;	chr11:47911114	chr11:47614898~47614994:-
LGG	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-11.24	3.77e-26	4.06e-23	-0.54	-0.46	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-11.24	3.77e-26	4.06e-23	-0.54	-0.46	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
LGG	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-11.24	3.78e-26	4.07e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	11.24	3.79e-26	4.09e-23	0.57	0.46	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
LGG	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	11.24	3.79e-26	4.09e-23	0.63	0.46	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
LGG	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-11.24	3.81e-26	4.11e-23	-0.53	-0.46	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
LGG	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	11.24	3.81e-26	4.11e-23	0.8	0.46	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
LGG	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	11.24	3.81e-26	4.11e-23	0.57	0.46	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
LGG	cis	rs651907	0.557	rs13069443	ENSG00000256628.3	ZBTB11-AS1	11.24	3.82e-26	4.12e-23	0.52	0.46	Colorectal cancer;	chr3:101654461	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs11925001	ENSG00000256628.3	ZBTB11-AS1	11.24	3.82e-26	4.12e-23	0.52	0.46	Colorectal cancer;	chr3:101655122	chr3:101676475~101679217:+
LGG	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	11.24	3.82e-26	4.12e-23	0.39	0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	11.24	3.83e-26	4.13e-23	0.57	0.46	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	11.24	3.87e-26	4.17e-23	0.57	0.46	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	11.24	3.87e-26	4.17e-23	0.57	0.46	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
LGG	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	11.24	3.9e-26	4.2e-23	0.68	0.46	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
LGG	cis	rs8092443	1	rs4891861	ENSG00000278971.1	RP11-644A7.2	11.24	3.9e-26	4.2e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70493801	chr18:70489630~70491205:+
LGG	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	11.24	3.91e-26	4.21e-23	0.58	0.46	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
LGG	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-11.24	3.91e-26	4.21e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
LGG	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-11.24	3.91e-26	4.21e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
LGG	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	11.24	3.93e-26	4.23e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
LGG	cis	rs7829975	0.846	rs11779061	ENSG00000173295.6	FAM86B3P	11.24	3.93e-26	4.24e-23	0.49	0.46	Mood instability;	chr8:8691922	chr8:8228595~8244865:+
LGG	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-11.24	3.95e-26	4.26e-23	-0.63	-0.46	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
LGG	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-11.23	3.98e-26	4.28e-23	-0.65	-0.46	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-11.23	3.98e-26	4.28e-23	-0.65	-0.46	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
LGG	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-11.23	3.98e-26	4.29e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
LGG	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-11.23	3.99e-26	4.29e-23	-0.54	-0.46	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	11.23	3.99e-26	4.29e-23	0.57	0.46	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	11.23	3.99e-26	4.29e-23	0.57	0.46	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	11.23	3.99e-26	4.29e-23	0.57	0.46	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
LGG	cis	rs853679	0.628	rs9368560	ENSG00000226314.6	ZNF192P1	11.23	3.99e-26	4.29e-23	0.56	0.46	Depression;	chr6:28192182	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	11.23	4.06e-26	4.37e-23	0.57	0.46	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
LGG	cis	rs651907	0.557	rs34624546	ENSG00000256628.3	ZBTB11-AS1	11.23	4.07e-26	4.38e-23	0.52	0.46	Colorectal cancer;	chr3:101655382	chr3:101676475~101679217:+
LGG	cis	rs12495178	0.639	rs17879296	ENSG00000239519.1	CADM2-AS1	11.23	4.07e-26	4.38e-23	0.51	0.46	Body mass index;	chr3:85862400	chr3:85992183~86028007:-
LGG	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-11.23	4.11e-26	4.42e-23	-0.59	-0.46	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
LGG	cis	rs4713118	0.869	rs4713121	ENSG00000216901.1	AL022393.7	11.23	4.16e-26	4.47e-23	0.61	0.46	Parkinson's disease;	chr6:27754285	chr6:28176188~28176674:+
LGG	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-11.23	4.18e-26	4.49e-23	-0.47	-0.46	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
LGG	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	11.23	4.19e-26	4.5e-23	0.57	0.46	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	11.23	4.19e-26	4.5e-23	0.57	0.46	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	11.23	4.19e-26	4.5e-23	0.57	0.46	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
LGG	cis	rs853679	1	rs1936365	ENSG00000216901.1	AL022393.7	-11.23	4.2e-26	4.51e-23	-0.75	-0.46	Depression;	chr6:28300675	chr6:28176188~28176674:+
LGG	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-11.23	4.23e-26	4.55e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-11.23	4.23e-26	4.55e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-11.23	4.23e-26	4.55e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
LGG	cis	rs853679	1	rs853676	ENSG00000216901.1	AL022393.7	11.23	4.24e-26	4.55e-23	0.77	0.46	Depression;	chr6:28331910	chr6:28176188~28176674:+
LGG	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-11.23	4.25e-26	4.56e-23	-0.6	-0.46	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
LGG	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	11.23	4.28e-26	4.6e-23	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
LGG	cis	rs5742933	0.817	rs1233299	ENSG00000273240.1	RP11-455J20.3	-11.23	4.3e-26	4.62e-23	-0.54	-0.46	Ferritin levels;	chr2:189799912	chr2:189763859~189764456:-
LGG	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	11.23	4.31e-26	4.63e-23	0.68	0.46	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
LGG	cis	rs1475911	1	rs34421316	ENSG00000184385.2	UMODL1-AS1	11.23	4.32e-26	4.64e-23	0.59	0.46	IgG glycosylation;	chr21:42093879	chr21:42102134~42108534:-
LGG	cis	rs5742933	0.857	rs13021611	ENSG00000253559.1	OSGEPL1-AS1	11.22	4.36e-26	4.68e-23	0.55	0.46	Ferritin levels;	chr2:189700038	chr2:189762704~189765556:+
LGG	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	11.22	4.37e-26	4.69e-23	0.56	0.46	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	11.22	4.37e-26	4.69e-23	0.56	0.46	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
LGG	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-11.22	4.42e-26	4.74e-23	-0.49	-0.46	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
LGG	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-11.22	4.43e-26	4.75e-23	-0.4	-0.46	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
LGG	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-11.22	4.43e-26	4.75e-23	-0.4	-0.46	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
LGG	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-11.22	4.45e-26	4.77e-23	-0.59	-0.46	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-11.22	4.45e-26	4.77e-23	-0.59	-0.46	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-11.22	4.45e-26	4.77e-23	-0.59	-0.46	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
LGG	cis	rs4819052	0.84	rs914217	ENSG00000223768.1	LINC00205	-11.22	4.46e-26	4.79e-23	-0.56	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45293285~45297354:+
LGG	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	11.22	4.48e-26	4.8e-23	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
LGG	cis	rs4373814	0.698	rs10764325	ENSG00000226083.4	SLC39A12-AS1	-11.22	4.54e-26	4.87e-23	-0.46	-0.46	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18151804	chr10:18001786~18010562:-
LGG	cis	rs1475911	1	rs55645900	ENSG00000184385.2	UMODL1-AS1	11.22	4.58e-26	4.91e-23	0.59	0.46	IgG glycosylation;	chr21:42095618	chr21:42102134~42108534:-
LGG	cis	rs9388451	0.626	rs7748729	ENSG00000237742.5	RP11-624M8.1	-11.22	4.59e-26	4.92e-23	-0.4	-0.46	Brugada syndrome;	chr6:125756235	chr6:125578558~125749190:-
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	11.22	4.6e-26	4.93e-23	0.6	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
LGG	cis	rs453301	0.571	rs2929305	ENSG00000173295.6	FAM86B3P	11.22	4.63e-26	4.97e-23	0.47	0.46	Joint mobility (Beighton score);	chr8:9227707	chr8:8228595~8244865:+
LGG	cis	rs9595066	1	rs9595066	ENSG00000230731.2	RP11-478K15.6	11.22	4.66e-26	5e-23	0.72	0.46	Schizophrenia;	chr13:44132132	chr13:44234118~44243192:-
LGG	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-11.22	4.68e-26	5.01e-23	-0.59	-0.46	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
LGG	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	11.22	4.69e-26	5.02e-23	0.6	0.46	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
LGG	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-11.22	4.69e-26	5.03e-23	-0.53	-0.46	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
LGG	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	11.22	4.7e-26	5.04e-23	0.5	0.46	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
LGG	cis	rs7267979	0.565	rs6076364	ENSG00000125804.12	FAM182A	11.21	4.77e-26	5.11e-23	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26054655~26086917:+
LGG	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	11.21	4.77e-26	5.11e-23	0.55	0.46	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
LGG	cis	rs1150668	0.768	rs1150716	ENSG00000280107.1	AL022393.9	-11.21	4.83e-26	5.18e-23	-0.45	-0.46	Pubertal anthropometrics;	chr6:28294921	chr6:28170845~28172521:+
LGG	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-11.21	4.84e-26	5.18e-23	-0.5	-0.46	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
LGG	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-11.21	4.84e-26	5.18e-23	-0.53	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
LGG	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	11.21	4.84e-26	5.18e-23	0.54	0.46	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
LGG	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	11.21	4.86e-26	5.2e-23	0.51	0.46	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
LGG	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-11.21	4.91e-26	5.26e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-11.21	4.91e-26	5.26e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-11.21	4.91e-26	5.26e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-11.21	4.91e-26	5.26e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
LGG	cis	rs1150668	0.796	rs1124132	ENSG00000218016.2	ZNF192P2	-11.21	4.94e-26	5.28e-23	-0.52	-0.46	Pubertal anthropometrics;	chr6:28412544	chr6:28188050~28189432:+
LGG	cis	rs1150668	0.796	rs2531832	ENSG00000218016.2	ZNF192P2	-11.21	4.94e-26	5.28e-23	-0.52	-0.46	Pubertal anthropometrics;	chr6:28421445	chr6:28188050~28189432:+
LGG	cis	rs7615952	0.546	rs2979306	ENSG00000242001.1	GS1-388B5.1	11.21	4.94e-26	5.28e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125593286	chr3:125681305~125681453:+
LGG	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	11.21	4.95e-26	5.3e-23	0.56	0.46	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
LGG	cis	rs453301	0.507	rs2929306	ENSG00000173295.6	FAM86B3P	11.21	4.99e-26	5.34e-23	0.47	0.46	Joint mobility (Beighton score);	chr8:9227399	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	11.21	5.01e-26	5.36e-23	0.56	0.46	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	11.21	5.03e-26	5.38e-23	0.57	0.46	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	11.21	5.03e-26	5.38e-23	0.57	0.46	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
LGG	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-11.21	5.05e-26	5.4e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
LGG	cis	rs3742264	0.816	rs9534319	ENSG00000235903.6	CPB2-AS1	11.21	5.06e-26	5.41e-23	0.5	0.46	Blood protein levels;	chr13:46090309	chr13:46052806~46113332:+
LGG	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-11.21	5.09e-26	5.44e-23	-0.5	-0.46	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
LGG	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	11.21	5.13e-26	5.48e-23	0.58	0.46	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
LGG	cis	rs9637599	0.513	rs7678928	ENSG00000246375.2	RP11-10L7.1	-11.21	5.14e-26	5.5e-23	-0.54	-0.46	Metabolite levels (small molecules and protein measures);	chr4:88301675	chr4:88284942~88331421:+
LGG	cis	rs2287838	0.638	rs55975644	ENSG00000267289.1	CTD-2623N2.11	11.21	5.18e-26	5.53e-23	0.52	0.46	Sleep duration;	chr19:9850311	chr19:9834079~9835013:-
LGG	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-11.2	5.18e-26	5.54e-23	-0.64	-0.46	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
LGG	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	11.2	5.25e-26	5.6e-23	0.5	0.46	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
LGG	cis	rs7216064	1	rs7212293	ENSG00000278219.1	AC145343.1	-11.2	5.31e-26	5.67e-23	-0.55	-0.46	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67851209	chr17:68101538~68101639:+
LGG	cis	rs4373814	0.737	rs10740995	ENSG00000226083.4	SLC39A12-AS1	11.2	5.31e-26	5.67e-23	0.47	0.46	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18156159	chr10:18001786~18010562:-
LGG	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	11.2	5.36e-26	5.73e-23	0.57	0.46	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	11.2	5.36e-26	5.73e-23	0.57	0.46	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
LGG	cis	rs4819052	1	rs2838830	ENSG00000223768.1	LINC00205	-11.2	5.37e-26	5.73e-23	-0.55	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45293285~45297354:+
LGG	cis	rs651907	0.514	rs34301719	ENSG00000256628.3	ZBTB11-AS1	11.2	5.37e-26	5.74e-23	0.53	0.46	Colorectal cancer;	chr3:101699149	chr3:101676475~101679217:+
LGG	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-11.2	5.42e-26	5.79e-23	-0.57	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	11.2	5.47e-26	5.84e-23	0.56	0.46	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	11.2	5.48e-26	5.85e-23	0.56	0.46	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	11.2	5.48e-26	5.85e-23	0.56	0.46	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
LGG	cis	rs651907	0.557	rs56291106	ENSG00000256628.3	ZBTB11-AS1	11.2	5.5e-26	5.87e-23	0.52	0.46	Colorectal cancer;	chr3:101658630	chr3:101676475~101679217:+
LGG	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-11.2	5.54e-26	5.91e-23	-0.65	-0.46	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-11.2	5.54e-26	5.91e-23	-0.65	-0.46	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-11.2	5.54e-26	5.91e-23	-0.65	-0.46	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
LGG	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-11.2	5.58e-26	5.95e-23	-0.49	-0.46	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
LGG	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	11.2	5.65e-26	6.02e-23	0.79	0.46	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
LGG	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-11.19	5.68e-26	6.05e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	11.19	5.68e-26	6.06e-23	0.57	0.46	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
LGG	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-11.19	5.69e-26	6.07e-23	-0.58	-0.46	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
LGG	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-11.19	5.71e-26	6.09e-23	-0.47	-0.46	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
LGG	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	11.19	5.78e-26	6.16e-23	0.94	0.46	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
LGG	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-11.19	5.8e-26	6.18e-23	-0.53	-0.46	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
LGG	cis	rs67340775	0.541	rs169287	ENSG00000199851.2	U3	11.19	5.83e-26	6.21e-23	0.86	0.46	Lung cancer in ever smokers;	chr6:27886982	chr6:28015568~28015777:+
LGG	cis	rs4373814	0.633	rs10828277	ENSG00000226083.4	SLC39A12-AS1	11.19	5.87e-26	6.25e-23	0.47	0.46	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18154797	chr10:18001786~18010562:-
LGG	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-11.19	5.96e-26	6.34e-23	-0.35	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
LGG	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-11.19	6e-26	6.38e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-11.19	6e-26	6.39e-23	-0.52	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.644	rs10009566	ENSG00000249244.1	RP11-548H18.2	11.19	6.03e-26	6.42e-23	0.49	0.46	Corneal astigmatism;	chr4:119637453	chr4:119391831~119395335:-
LGG	cis	rs453301	0.571	rs2929456	ENSG00000173295.6	FAM86B3P	11.19	6.04e-26	6.43e-23	0.48	0.46	Joint mobility (Beighton score);	chr8:9225906	chr8:8228595~8244865:+
LGG	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-11.19	6.09e-26	6.48e-23	-0.52	-0.46	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
LGG	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	11.19	6.1e-26	6.49e-23	0.53	0.46	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
LGG	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	11.19	6.1e-26	6.49e-23	0.56	0.46	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	11.19	6.1e-26	6.49e-23	0.56	0.46	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	11.19	6.1e-26	6.49e-23	0.56	0.46	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-11.19	6.11e-26	6.5e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
LGG	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	11.19	6.12e-26	6.51e-23	0.47	0.46	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
LGG	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-11.19	6.17e-26	6.56e-23	-0.62	-0.46	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
LGG	cis	rs7267979	0.932	rs6115214	ENSG00000125804.12	FAM182A	11.18	6.22e-26	6.61e-23	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	11.18	6.39e-26	6.79e-23	0.64	0.46	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
LGG	cis	rs9388451	0.626	rs3799708	ENSG00000237742.5	RP11-624M8.1	-11.18	6.41e-26	6.81e-23	-0.4	-0.46	Brugada syndrome;	chr6:125757384	chr6:125578558~125749190:-
LGG	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-11.18	6.43e-26	6.83e-23	-0.53	-0.46	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
LGG	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-11.18	6.44e-26	6.84e-23	-0.53	-0.46	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	11.18	6.45e-26	6.86e-23	0.64	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
LGG	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-11.18	6.47e-26	6.87e-23	-0.53	-0.46	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
LGG	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
LGG	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	11.18	6.47e-26	6.87e-23	0.56	0.46	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
LGG	cis	rs4713118	0.662	rs149948	ENSG00000226314.6	ZNF192P1	11.18	6.48e-26	6.88e-23	0.52	0.46	Parkinson's disease;	chr6:28007039	chr6:28161781~28169594:+
LGG	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	11.18	6.56e-26	6.97e-23	0.48	0.46	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
LGG	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-11.18	6.57e-26	6.98e-23	-0.65	-0.46	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
LGG	cis	rs453301	0.571	rs2929452	ENSG00000173295.6	FAM86B3P	11.18	6.58e-26	6.98e-23	0.47	0.46	Joint mobility (Beighton score);	chr8:9226955	chr8:8228595~8244865:+
LGG	cis	rs11098499	0.754	rs1814813	ENSG00000249244.1	RP11-548H18.2	-11.18	6.59e-26	6.99e-23	-0.48	-0.46	Corneal astigmatism;	chr4:119337052	chr4:119391831~119395335:-
LGG	cis	rs4819052	1	rs2297286	ENSG00000223768.1	LINC00205	-11.18	6.61e-26	7.02e-23	-0.56	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.918	rs34886433	ENSG00000223768.1	LINC00205	-11.18	6.67e-26	7.08e-23	-0.57	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45293285~45297354:+
LGG	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-11.18	6.68e-26	7.09e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-11.18	6.68e-26	7.09e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
LGG	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	11.18	6.69e-26	7.1e-23	0.69	0.46	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
LGG	cis	rs1150668	0.799	rs2142730	ENSG00000280107.1	AL022393.9	-11.18	6.75e-26	7.16e-23	-0.45	-0.46	Pubertal anthropometrics;	chr6:28298372	chr6:28170845~28172521:+
LGG	cis	rs1150668	0.799	rs9301	ENSG00000280107.1	AL022393.9	-11.18	6.75e-26	7.16e-23	-0.45	-0.46	Pubertal anthropometrics;	chr6:28324929	chr6:28170845~28172521:+
LGG	cis	rs1150668	0.799	rs853684	ENSG00000280107.1	AL022393.9	-11.18	6.75e-26	7.16e-23	-0.45	-0.46	Pubertal anthropometrics;	chr6:28326773	chr6:28170845~28172521:+
LGG	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	11.18	6.76e-26	7.17e-23	0.6	0.46	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
LGG	cis	rs172166	0.585	rs149963	ENSG00000280107.1	AL022393.9	-11.17	6.78e-26	7.19e-23	-0.45	-0.46	Cardiac Troponin-T levels;	chr6:28049354	chr6:28170845~28172521:+
LGG	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-11.17	6.85e-26	7.26e-23	-0.47	-0.46	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
LGG	cis	rs453301	0.571	rs2929454	ENSG00000173295.6	FAM86B3P	11.17	6.88e-26	7.29e-23	0.47	0.46	Joint mobility (Beighton score);	chr8:9226344	chr8:8228595~8244865:+
LGG	cis	rs11098499	0.863	rs1010739	ENSG00000249244.1	RP11-548H18.2	11.17	6.9e-26	7.31e-23	0.53	0.46	Corneal astigmatism;	chr4:119542316	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	11.17	6.93e-26	7.35e-23	0.62	0.46	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
LGG	cis	rs5758511	0.596	rs55644935	ENSG00000227370.1	RP4-669P10.19	11.17	6.93e-26	7.35e-23	0.51	0.46	Birth weight;	chr22:42270063	chr22:42132543~42132998:+
LGG	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-11.17	7.04e-26	7.46e-23	-0.53	-0.46	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
LGG	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-11.17	7.05e-26	7.47e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-11.17	7.05e-26	7.47e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
LGG	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-11.17	7.05e-26	7.47e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-11.17	7.05e-26	7.47e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
LGG	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-11.17	7.05e-26	7.47e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
LGG	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-11.17	7.11e-26	7.54e-23	-0.59	-0.46	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
LGG	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-11.17	7.11e-26	7.54e-23	-0.59	-0.46	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
LGG	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	11.17	7.17e-26	7.59e-23	0.54	0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.874	rs9995277	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119187448	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs17839089	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119189914	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs6826823	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119190943	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	11.17	7.22e-26	7.65e-23	0.5	0.46	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
LGG	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-11.17	7.24e-26	7.66e-23	-0.54	-0.46	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	11.17	7.29e-26	7.72e-23	0.56	0.46	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	11.17	7.29e-26	7.72e-23	0.56	0.46	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	11.17	7.29e-26	7.72e-23	0.56	0.46	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-11.17	7.31e-26	7.73e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-11.17	7.31e-26	7.73e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-11.17	7.31e-26	7.73e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
LGG	cis	rs5742933	0.857	rs2289226	ENSG00000273240.1	RP11-455J20.3	-11.17	7.37e-26	7.79e-23	-0.55	-0.46	Ferritin levels;	chr2:189661479	chr2:189763859~189764456:-
LGG	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
LGG	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-11.17	7.37e-26	7.79e-23	-0.54	-0.46	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
LGG	cis	rs4713118	0.662	rs175954	ENSG00000226314.6	ZNF192P1	11.16	7.47e-26	7.89e-23	0.55	0.46	Parkinson's disease;	chr6:28043807	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	11.16	7.48e-26	7.91e-23	0.56	0.46	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
LGG	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-11.16	7.5e-26	7.92e-23	-0.52	-0.46	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
LGG	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	11.16	7.58e-26	8e-23	0.32	0.46	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	11.16	7.58e-26	8e-23	0.32	0.46	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
LGG	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	11.16	7.62e-26	8.05e-23	0.57	0.46	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
LGG	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	11.16	7.62e-26	8.05e-23	0.65	0.46	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
LGG	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-11.16	7.63e-26	8.05e-23	-0.54	-0.46	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
LGG	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	11.16	7.63e-26	8.05e-23	0.68	0.46	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-11.16	7.63e-26	8.06e-23	-0.64	-0.46	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	11.16	7.69e-26	8.12e-23	0.57	0.46	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
LGG	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	11.16	7.7e-26	8.13e-23	0.8	0.46	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
LGG	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	11.16	7.7e-26	8.13e-23	0.32	0.46	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
LGG	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	11.16	7.73e-26	8.16e-23	0.57	0.46	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
LGG	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-11.16	7.74e-26	8.17e-23	-0.59	-0.46	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
LGG	cis	rs5742933	0.803	rs1233262	ENSG00000273240.1	RP11-455J20.3	-11.16	7.85e-26	8.28e-23	-0.55	-0.46	Ferritin levels;	chr2:189793107	chr2:189763859~189764456:-
LGG	cis	rs7246657	0.722	rs2972437	ENSG00000267422.1	CTD-2554C21.1	-11.16	7.95e-26	8.39e-23	-0.58	-0.46	Coronary artery calcification;	chr19:37719610	chr19:37779686~37792865:+
LGG	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	11.16	8.01e-26	8.45e-23	0.52	0.46	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
LGG	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	11.15	8.18e-26	8.63e-23	0.52	0.46	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
LGG	cis	rs11098499	0.532	rs4504231	ENSG00000249244.1	RP11-548H18.2	11.15	8.21e-26	8.66e-23	0.5	0.46	Corneal astigmatism;	chr4:119665736	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-11.15	8.23e-26	8.68e-23	-0.52	-0.46	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
LGG	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	11.15	8.35e-26	8.8e-23	0.66	0.46	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	11.15	8.35e-26	8.8e-23	0.66	0.46	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	11.15	8.35e-26	8.8e-23	0.66	0.46	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	11.15	8.35e-26	8.8e-23	0.66	0.46	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
LGG	cis	rs7267979	0.866	rs6138609	ENSG00000125804.12	FAM182A	-11.15	8.36e-26	8.81e-23	-0.55	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:26054655~26086917:+
LGG	cis	rs9527	0.637	rs7085104	ENSG00000272912.1	RP11-724N1.1	-11.15	8.38e-26	8.83e-23	-0.53	-0.46	Arsenic metabolism;	chr10:102869116	chr10:102914585~102915404:+
LGG	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-11.15	8.43e-26	8.89e-23	-0.54	-0.46	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
LGG	cis	rs172166	0.561	rs149973	ENSG00000280107.1	AL022393.9	-11.15	8.44e-26	8.9e-23	-0.46	-0.46	Cardiac Troponin-T levels;	chr6:28015835	chr6:28170845~28172521:+
LGG	cis	rs172166	0.561	rs149974	ENSG00000280107.1	AL022393.9	-11.15	8.44e-26	8.9e-23	-0.46	-0.46	Cardiac Troponin-T levels;	chr6:28017318	chr6:28170845~28172521:+
LGG	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	11.15	8.47e-26	8.92e-23	0.66	0.46	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	11.15	8.47e-26	8.92e-23	0.66	0.46	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	11.15	8.47e-26	8.92e-23	0.66	0.46	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	11.15	8.47e-26	8.92e-23	0.66	0.46	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	11.15	8.47e-26	8.92e-23	0.66	0.46	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	11.15	8.47e-26	8.92e-23	0.66	0.46	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
LGG	cis	rs4713118	0.513	rs149972	ENSG00000226314.6	ZNF192P1	11.15	8.48e-26	8.94e-23	0.49	0.46	Parkinson's disease;	chr6:28015449	chr6:28161781~28169594:+
LGG	cis	rs172166	0.61	rs276369	ENSG00000218016.2	ZNF192P2	-11.15	8.53e-26	8.99e-23	-0.54	-0.46	Cardiac Troponin-T levels;	chr6:27951465	chr6:28188050~28189432:+
LGG	cis	rs3742264	0.816	rs1952187	ENSG00000235903.6	CPB2-AS1	-11.15	8.54e-26	9e-23	-0.5	-0.46	Blood protein levels;	chr13:46100774	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	11.15	8.64e-26	9.1e-23	0.57	0.46	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
LGG	cis	rs651907	0.557	rs2288272	ENSG00000256628.3	ZBTB11-AS1	11.15	8.69e-26	9.15e-23	0.52	0.46	Colorectal cancer;	chr3:101659632	chr3:101676475~101679217:+
LGG	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	11.15	8.73e-26	9.19e-23	0.56	0.46	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-11.15	8.74e-26	9.2e-23	-0.55	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	11.15	8.78e-26	9.25e-23	0.64	0.46	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
LGG	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	11.14	8.87e-26	9.33e-23	0.56	0.46	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
LGG	cis	rs11098499	0.604	rs2389882	ENSG00000249244.1	RP11-548H18.2	11.14	8.98e-26	9.45e-23	0.52	0.46	Corneal astigmatism;	chr4:119645578	chr4:119391831~119395335:-
LGG	cis	rs172166	0.637	rs1233708	ENSG00000226314.6	ZNF192P1	11.14	9.02e-26	9.49e-23	0.49	0.46	Cardiac Troponin-T levels;	chr6:28205441	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.505	rs156740	ENSG00000218016.2	ZNF192P2	-11.14	9.08e-26	9.55e-23	-0.54	-0.46	Parkinson's disease;	chr6:27992657	chr6:28188050~28189432:+
LGG	cis	rs9527	0.637	rs11191424	ENSG00000272912.1	RP11-724N1.1	-11.14	9.08e-26	9.56e-23	-0.53	-0.46	Arsenic metabolism;	chr10:102866129	chr10:102914585~102915404:+
LGG	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	11.14	9.19e-26	9.66e-23	0.56	0.46	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
LGG	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-11.14	9.22e-26	9.7e-23	-0.65	-0.46	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
LGG	cis	rs11098499	0.644	rs3806808	ENSG00000249244.1	RP11-548H18.2	11.14	9.33e-26	9.81e-23	0.48	0.46	Corneal astigmatism;	chr4:119629930	chr4:119391831~119395335:-
LGG	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-11.14	9.33e-26	9.81e-23	-0.52	-0.46	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
LGG	cis	rs1150668	0.796	rs213236	ENSG00000218016.2	ZNF192P2	-11.14	9.34e-26	9.82e-23	-0.51	-0.46	Pubertal anthropometrics;	chr6:28356620	chr6:28188050~28189432:+
LGG	cis	rs8092443	1	rs11875350	ENSG00000278971.1	RP11-644A7.2	11.14	9.38e-26	9.86e-23	0.66	0.46	Response to antipsychotic treatment;	chr18:70489629	chr18:70489630~70491205:+
LGG	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	11.14	9.4e-26	9.88e-23	0.67	0.46	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	11.14	9.4e-26	9.88e-23	0.67	0.46	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	11.14	9.4e-26	9.88e-23	0.67	0.46	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
LGG	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	11.14	9.43e-26	9.91e-23	0.41	0.46	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
LGG	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-11.14	9.46e-26	9.94e-23	-0.57	-0.46	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
LGG	cis	rs4713118	0.824	rs742046	ENSG00000199851.2	U3	11.14	9.51e-26	9.99e-23	0.66	0.46	Parkinson's disease;	chr6:27771475	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	11.14	9.53e-26	1e-22	0.56	0.46	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
LGG	cis	rs7240205	0.853	rs10454719	ENSG00000275805.1	RP11-349H17.2	-11.14	9.57e-26	1.01e-22	-0.52	-0.46	Breast cancer;	chr18:26559666	chr18:26565723~26575626:-
LGG	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-11.14	9.58e-26	1.01e-22	-0.64	-0.46	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
LGG	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	11.14	9.61e-26	1.01e-22	0.64	0.46	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
LGG	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	11.14	9.62e-26	1.01e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
LGG	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	11.13	9.69e-26	1.02e-22	0.57	0.46	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
LGG	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-11.13	9.71e-26	1.02e-22	-0.59	-0.46	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	11.13	9.71e-26	1.02e-22	0.56	0.46	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
LGG	cis	rs2013441	0.866	rs7207817	ENSG00000230528.6	NOS2P3	11.13	9.77e-26	1.03e-22	0.44	0.46	Obesity-related traits;	chr17:20318015	chr17:20436337~20447249:+
LGG	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	11.13	9.8e-26	1.03e-22	0.57	0.46	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
LGG	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-11.13	9.8e-26	1.03e-22	-0.64	-0.46	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
LGG	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	11.13	9.83e-26	1.03e-22	0.36	0.46	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
LGG	cis	rs4819052	1	rs9984901	ENSG00000223768.1	LINC00205	-11.13	9.88e-26	1.04e-22	-0.55	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45293285~45297354:+
LGG	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	11.13	9.95e-26	1.04e-22	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
LGG	cis	rs4713118	0.513	rs149975	ENSG00000226314.6	ZNF192P1	11.13	9.97e-26	1.05e-22	0.49	0.46	Parkinson's disease;	chr6:28018562	chr6:28161781~28169594:+
LGG	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-11.13	1e-25	1.05e-22	-0.55	-0.46	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
LGG	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	11.13	1.01e-25	1.06e-22	0.64	0.46	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	11.13	1.01e-25	1.06e-22	0.62	0.46	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
LGG	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-11.13	1.01e-25	1.06e-22	-0.48	-0.46	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
LGG	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	11.13	1.01e-25	1.06e-22	0.32	0.46	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
LGG	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-11.13	1.01e-25	1.06e-22	-0.48	-0.46	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
LGG	cis	rs1150668	0.83	rs213240	ENSG00000280107.1	AL022393.9	-11.13	1.02e-25	1.07e-22	-0.44	-0.46	Pubertal anthropometrics;	chr6:28348098	chr6:28170845~28172521:+
LGG	cis	rs11098499	0.644	rs2389880	ENSG00000249244.1	RP11-548H18.2	11.13	1.02e-25	1.07e-22	0.49	0.46	Corneal astigmatism;	chr4:119638715	chr4:119391831~119395335:-
LGG	cis	rs4819052	1	rs733739	ENSG00000223768.1	LINC00205	-11.13	1.03e-25	1.08e-22	-0.55	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45293285~45297354:+
LGG	cis	rs4819052	1	rs4818769	ENSG00000223768.1	LINC00205	-11.13	1.03e-25	1.08e-22	-0.55	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45293285~45297354:+
LGG	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-11.13	1.04e-25	1.09e-22	-0.58	-0.46	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
LGG	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	11.13	1.04e-25	1.09e-22	0.59	0.46	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
LGG	cis	rs1150668	0.699	rs1531681	ENSG00000218016.2	ZNF192P2	-11.13	1.04e-25	1.09e-22	-0.52	-0.46	Pubertal anthropometrics;	chr6:28259100	chr6:28188050~28189432:+
LGG	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	11.13	1.05e-25	1.1e-22	0.77	0.46	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
LGG	cis	rs4713118	0.662	rs149901	ENSG00000226314.6	ZNF192P1	11.13	1.05e-25	1.1e-22	0.52	0.46	Parkinson's disease;	chr6:27997725	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs464312	ENSG00000226314.6	ZNF192P1	11.13	1.05e-25	1.1e-22	0.52	0.46	Parkinson's disease;	chr6:27999813	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs469228	ENSG00000226314.6	ZNF192P1	11.13	1.05e-25	1.1e-22	0.52	0.46	Parkinson's disease;	chr6:28002926	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.54	rs469227	ENSG00000226314.6	ZNF192P1	11.13	1.05e-25	1.1e-22	0.52	0.46	Parkinson's disease;	chr6:28002927	chr6:28161781~28169594:+
LGG	cis	rs5758511	0.68	rs739146	ENSG00000227370.1	RP4-669P10.19	11.13	1.06e-25	1.11e-22	0.51	0.46	Birth weight;	chr22:42264408	chr22:42132543~42132998:+
LGG	cis	rs9388451	0.626	rs3799712	ENSG00000237742.5	RP11-624M8.1	-11.12	1.06e-25	1.11e-22	-0.4	-0.46	Brugada syndrome;	chr6:125753957	chr6:125578558~125749190:-
LGG	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-11.12	1.06e-25	1.11e-22	-0.53	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-11.12	1.06e-25	1.11e-22	-0.53	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-11.12	1.06e-25	1.11e-22	-0.53	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.714	rs4840362	ENSG00000173295.6	FAM86B3P	11.12	1.06e-25	1.11e-22	0.47	0.46	Mood instability;	chr8:8812572	chr8:8228595~8244865:+
LGG	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	11.12	1.06e-25	1.11e-22	0.56	0.46	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
LGG	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	11.12	1.06e-25	1.11e-22	0.56	0.46	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
LGG	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-11.12	1.06e-25	1.11e-22	-0.53	-0.45	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
LGG	cis	rs853679	0.513	rs13437444	ENSG00000226314.6	ZNF192P1	11.12	1.08e-25	1.14e-22	0.62	0.45	Depression;	chr6:28103220	chr6:28161781~28169594:+
LGG	cis	rs1150668	0.699	rs2394049	ENSG00000218016.2	ZNF192P2	-11.12	1.09e-25	1.14e-22	-0.52	-0.45	Pubertal anthropometrics;	chr6:28271903	chr6:28188050~28189432:+
LGG	cis	rs7119038	0.629	rs11216994	ENSG00000255239.1	AP002954.6	-11.12	1.09e-25	1.14e-22	-0.62	-0.45	Sjögren's syndrome;	chr11:118732811	chr11:118688039~118690600:-
LGG	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-11.12	1.1e-25	1.15e-22	-0.54	-0.45	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-11.12	1.1e-25	1.15e-22	-0.54	-0.45	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
LGG	cis	rs7615952	0.546	rs16836896	ENSG00000242001.1	GS1-388B5.1	11.12	1.1e-25	1.15e-22	0.64	0.45	Blood pressure (smoking interaction);	chr3:125592418	chr3:125681305~125681453:+
LGG	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	11.12	1.11e-25	1.16e-22	0.6	0.45	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
LGG	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	11.12	1.11e-25	1.16e-22	0.6	0.45	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
LGG	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	11.12	1.11e-25	1.16e-22	0.6	0.45	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
LGG	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	11.12	1.13e-25	1.18e-22	0.52	0.45	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
LGG	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-11.12	1.13e-25	1.19e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
LGG	cis	rs8092443	1	rs9949502	ENSG00000278971.1	RP11-644A7.2	-11.12	1.14e-25	1.19e-22	-0.69	-0.45	Response to antipsychotic treatment;	chr18:70492821	chr18:70489630~70491205:+
LGG	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-11.12	1.14e-25	1.19e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
LGG	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-11.12	1.14e-25	1.19e-22	-0.54	-0.45	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
LGG	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	11.12	1.14e-25	1.19e-22	0.51	0.45	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
LGG	cis	rs8092443	0.882	rs12956725	ENSG00000278971.1	RP11-644A7.2	-11.12	1.14e-25	1.2e-22	-0.66	-0.45	Response to antipsychotic treatment;	chr18:70494945	chr18:70489630~70491205:+
LGG	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-11.12	1.15e-25	1.21e-22	-0.37	-0.45	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
LGG	cis	rs453301	0.571	rs2929453	ENSG00000173295.6	FAM86B3P	11.11	1.16e-25	1.21e-22	0.47	0.45	Joint mobility (Beighton score);	chr8:9226831	chr8:8228595~8244865:+
LGG	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-11.11	1.16e-25	1.21e-22	-0.37	-0.45	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
LGG	cis	rs9595066	1	rs4942281	ENSG00000230731.2	RP11-478K15.6	11.11	1.16e-25	1.21e-22	0.76	0.45	Schizophrenia;	chr13:44133990	chr13:44234118~44243192:-
LGG	cis	rs9595066	1	rs4942282	ENSG00000230731.2	RP11-478K15.6	11.11	1.16e-25	1.21e-22	0.76	0.45	Schizophrenia;	chr13:44134280	chr13:44234118~44243192:-
LGG	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	11.11	1.16e-25	1.22e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	11.11	1.16e-25	1.22e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	11.11	1.16e-25	1.22e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	11.11	1.16e-25	1.22e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	11.11	1.16e-25	1.22e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	11.11	1.16e-25	1.22e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
LGG	cis	rs4819052	1	rs4819052	ENSG00000223768.1	LINC00205	-11.11	1.17e-25	1.22e-22	-0.56	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45293285~45297354:+
LGG	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	11.11	1.17e-25	1.22e-22	0.69	0.45	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
LGG	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-11.11	1.17e-25	1.22e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-11.11	1.17e-25	1.22e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
LGG	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	11.11	1.17e-25	1.22e-22	0.47	0.45	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
LGG	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-11.11	1.17e-25	1.22e-22	-0.53	-0.45	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
LGG	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-11.11	1.18e-25	1.23e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
LGG	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	11.11	1.18e-25	1.23e-22	0.66	0.45	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
LGG	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	11.11	1.18e-25	1.24e-22	0.78	0.45	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
LGG	cis	rs7119038	0.629	rs10892273	ENSG00000255239.1	AP002954.6	-11.11	1.19e-25	1.24e-22	-0.61	-0.45	Sjögren's syndrome;	chr11:118732100	chr11:118688039~118690600:-
LGG	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	11.11	1.19e-25	1.24e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.851	rs2838866	ENSG00000215447.6	BX322557.10	-11.11	1.2e-25	1.25e-22	-0.36	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45288052~45291738:+
LGG	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-11.11	1.2e-25	1.26e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
LGG	cis	rs6908034	0.556	rs79028848	ENSG00000228412.5	RP4-625H18.2	11.11	1.21e-25	1.26e-22	0.88	0.45	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782922	chr6:19802164~19804752:-
LGG	cis	rs7615952	0.546	rs2979307	ENSG00000242001.1	GS1-388B5.1	-11.11	1.21e-25	1.26e-22	-0.65	-0.45	Blood pressure (smoking interaction);	chr3:125590730	chr3:125681305~125681453:+
LGG	cis	rs1150668	0.699	rs13408	ENSG00000226314.6	ZNF192P1	11.11	1.21e-25	1.27e-22	0.44	0.45	Pubertal anthropometrics;	chr6:28244970	chr6:28161781~28169594:+
LGG	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	11.11	1.22e-25	1.27e-22	0.32	0.45	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
LGG	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-11.11	1.22e-25	1.27e-22	-0.53	-0.45	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-11.11	1.22e-25	1.27e-22	-0.53	-0.45	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
LGG	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	11.11	1.22e-25	1.28e-22	0.67	0.45	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	11.11	1.22e-25	1.28e-22	0.67	0.45	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
LGG	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	11.11	1.23e-25	1.28e-22	0.65	0.45	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	11.11	1.24e-25	1.29e-22	0.56	0.45	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
LGG	cis	rs1150668	0.83	rs2023493	ENSG00000218016.2	ZNF192P2	-11.11	1.25e-25	1.3e-22	-0.52	-0.45	Pubertal anthropometrics;	chr6:28432385	chr6:28188050~28189432:+
LGG	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-11.11	1.25e-25	1.3e-22	-0.53	-0.45	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
LGG	cis	rs916888	0.61	rs199454	ENSG00000232300.1	FAM215B	-11.1	1.26e-25	1.32e-22	-0.58	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46558830~46562795:-
LGG	cis	rs916888	0.61	rs199446	ENSG00000232300.1	FAM215B	-11.1	1.26e-25	1.32e-22	-0.58	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46558830~46562795:-
LGG	cis	rs916888	0.61	rs199536	ENSG00000232300.1	FAM215B	-11.1	1.26e-25	1.32e-22	-0.58	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46558830~46562795:-
LGG	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-11.1	1.27e-25	1.32e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
LGG	cis	rs8064024	0.538	rs12596053	ENSG00000267077.1	RP11-127I20.5	-11.1	1.28e-25	1.33e-22	-0.46	-0.45	Cancer;	chr16:4896793	chr16:4795265~4796532:-
LGG	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-11.1	1.29e-25	1.34e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-11.1	1.29e-25	1.34e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-11.1	1.29e-25	1.34e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-11.1	1.29e-25	1.34e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
LGG	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	11.1	1.29e-25	1.35e-22	0.57	0.45	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	11.1	1.29e-25	1.35e-22	0.57	0.45	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
LGG	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	11.1	1.29e-25	1.35e-22	0.57	0.45	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	11.1	1.29e-25	1.35e-22	0.57	0.45	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
LGG	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	11.1	1.29e-25	1.35e-22	0.78	0.45	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	11.1	1.29e-25	1.35e-22	0.78	0.45	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
LGG	cis	rs1150668	0.796	rs1005125	ENSG00000218016.2	ZNF192P2	-11.1	1.3e-25	1.35e-22	-0.52	-0.45	Pubertal anthropometrics;	chr6:28399578	chr6:28188050~28189432:+
LGG	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	11.1	1.3e-25	1.35e-22	0.51	0.45	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
LGG	cis	rs9527	0.571	rs12765337	ENSG00000272912.1	RP11-724N1.1	-11.1	1.3e-25	1.35e-22	-0.52	-0.45	Arsenic metabolism;	chr10:102875587	chr10:102914585~102915404:+
LGG	cis	rs9527	0.525	rs12770034	ENSG00000272912.1	RP11-724N1.1	-11.1	1.3e-25	1.35e-22	-0.52	-0.45	Arsenic metabolism;	chr10:102875838	chr10:102914585~102915404:+
LGG	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-11.1	1.31e-25	1.36e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-11.1	1.31e-25	1.36e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-11.1	1.31e-25	1.36e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-11.1	1.31e-25	1.36e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
LGG	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	11.1	1.32e-25	1.37e-22	0.67	0.45	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	11.1	1.32e-25	1.37e-22	0.67	0.45	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	11.1	1.32e-25	1.37e-22	0.67	0.45	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
LGG	cis	rs916888	0.61	rs199438	ENSG00000232300.1	FAM215B	11.1	1.32e-25	1.37e-22	0.58	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46558830~46562795:-
LGG	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	11.1	1.32e-25	1.37e-22	0.54	0.45	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
LGG	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-11.1	1.32e-25	1.38e-22	-0.58	-0.45	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
LGG	cis	rs7829975	0.591	rs12677543	ENSG00000173295.6	FAM86B3P	-11.1	1.33e-25	1.38e-22	-0.48	-0.45	Mood instability;	chr8:8786764	chr8:8228595~8244865:+
LGG	cis	rs11148252	0.512	rs9526950	ENSG00000273784.3	RP11-78J21.7	-11.1	1.33e-25	1.38e-22	-0.54	-0.45	Lewy body disease;	chr13:52600328	chr13:52600042~52642542:+
LGG	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-11.1	1.33e-25	1.39e-22	-0.58	-0.45	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
LGG	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	11.1	1.34e-25	1.39e-22	0.37	0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
LGG	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	11.1	1.34e-25	1.4e-22	0.68	0.45	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
LGG	cis	rs4713118	0.505	rs276371	ENSG00000226314.6	ZNF192P1	11.1	1.35e-25	1.4e-22	0.45	0.45	Parkinson's disease;	chr6:27942930	chr6:28161781~28169594:+
LGG	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-11.1	1.36e-25	1.41e-22	-0.61	-0.45	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
LGG	cis	rs916888	0.531	rs183211	ENSG00000232300.1	FAM215B	11.1	1.36e-25	1.41e-22	0.58	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46558830~46562795:-
LGG	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-11.1	1.37e-25	1.42e-22	-0.68	-0.45	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
LGG	cis	rs1150668	0.699	rs2394049	ENSG00000280107.1	AL022393.9	-11.1	1.37e-25	1.42e-22	-0.44	-0.45	Pubertal anthropometrics;	chr6:28271903	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	11.09	1.39e-25	1.45e-22	0.57	0.45	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
LGG	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	11.09	1.44e-25	1.49e-22	0.56	0.45	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
LGG	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	11.09	1.45e-25	1.5e-22	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
LGG	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	11.09	1.45e-25	1.5e-22	0.53	0.45	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
LGG	cis	rs11098499	0.644	rs10012252	ENSG00000249244.1	RP11-548H18.2	11.09	1.45e-25	1.51e-22	0.48	0.45	Corneal astigmatism;	chr4:119637984	chr4:119391831~119395335:-
LGG	cis	rs7240205	0.816	rs2019480	ENSG00000275805.1	RP11-349H17.2	11.09	1.46e-25	1.51e-22	0.52	0.45	Breast cancer;	chr18:26545720	chr18:26565723~26575626:-
LGG	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	11.09	1.46e-25	1.51e-22	0.78	0.45	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
LGG	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	11.09	1.47e-25	1.52e-22	0.56	0.45	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
LGG	cis	rs11098499	0.644	rs10050092	ENSG00000249244.1	RP11-548H18.2	11.09	1.47e-25	1.52e-22	0.48	0.45	Corneal astigmatism;	chr4:119610930	chr4:119391831~119395335:-
LGG	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	11.09	1.47e-25	1.53e-22	0.64	0.45	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
LGG	cis	rs9527	0.571	rs7904113	ENSG00000272912.1	RP11-724N1.1	-11.09	1.48e-25	1.54e-22	-0.51	-0.45	Arsenic metabolism;	chr10:102873357	chr10:102914585~102915404:+
LGG	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	11.09	1.48e-25	1.54e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-11.09	1.48e-25	1.54e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
LGG	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	11.09	1.49e-25	1.55e-22	0.63	0.45	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	11.09	1.5e-25	1.56e-22	0.56	0.45	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
LGG	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	-11.09	1.51e-25	1.56e-22	-0.48	-0.45	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
LGG	cis	rs4713118	0.513	rs149878	ENSG00000226314.6	ZNF192P1	11.08	1.51e-25	1.56e-22	0.48	0.45	Parkinson's disease;	chr6:27910960	chr6:28161781~28169594:+
LGG	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-11.08	1.53e-25	1.58e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-11.08	1.53e-25	1.58e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-11.08	1.53e-25	1.58e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
LGG	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-11.08	1.53e-25	1.58e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	11.08	1.54e-25	1.59e-22	0.57	0.45	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
LGG	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	11.08	1.55e-25	1.6e-22	0.66	0.45	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
LGG	cis	rs7267979	0.932	rs6132848	ENSG00000125804.12	FAM182A	-11.08	1.55e-25	1.6e-22	-0.55	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs6115215	ENSG00000125804.12	FAM182A	-11.08	1.55e-25	1.6e-22	-0.55	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-11.08	1.55e-25	1.6e-22	-0.57	-0.45	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
LGG	cis	rs741668	0.897	rs41284147	ENSG00000235903.6	CPB2-AS1	11.08	1.55e-25	1.6e-22	0.51	0.45	Cerebrospinal fluid clusterin levels;	chr13:45957558	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-11.08	1.57e-25	1.62e-22	-0.56	-0.45	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
LGG	cis	rs11647589	0.687	rs12598584	ENSG00000260762.1	ACSM5P1	-11.08	1.58e-25	1.63e-22	-0.63	-0.45	Blood metabolite levels;	chr16:20476785	chr16:20586550~20607107:-
LGG	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-11.08	1.59e-25	1.64e-22	-0.48	-0.45	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
LGG	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-11.08	1.59e-25	1.65e-22	-0.68	-0.45	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
LGG	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	11.08	1.6e-25	1.65e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
LGG	cis	rs11191419	1	rs11191419	ENSG00000272912.1	RP11-724N1.1	-11.08	1.61e-25	1.66e-22	-0.53	-0.45	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102914585~102915404:+
LGG	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	11.08	1.61e-25	1.66e-22	0.56	0.45	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
LGG	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	11.08	1.61e-25	1.66e-22	0.8	0.45	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
LGG	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	11.08	1.62e-25	1.67e-22	0.67	0.45	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	11.08	1.62e-25	1.67e-22	0.67	0.45	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	11.08	1.62e-25	1.67e-22	0.67	0.45	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	11.08	1.62e-25	1.67e-22	0.67	0.45	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	11.08	1.62e-25	1.67e-22	0.67	0.45	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	11.08	1.62e-25	1.68e-22	0.56	0.45	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
LGG	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-11.08	1.64e-25	1.69e-22	-0.37	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
LGG	cis	rs8092443	0.832	rs11662261	ENSG00000278971.1	RP11-644A7.2	11.08	1.64e-25	1.69e-22	0.66	0.45	Response to antipsychotic treatment;	chr18:70494268	chr18:70489630~70491205:+
LGG	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-11.08	1.64e-25	1.7e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-11.08	1.64e-25	1.7e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
LGG	cis	rs1475911	1	rs1475911	ENSG00000184385.2	UMODL1-AS1	11.07	1.65e-25	1.7e-22	0.58	0.45	IgG glycosylation;	chr21:42093370	chr21:42102134~42108534:-
LGG	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-11.07	1.66e-25	1.71e-22	-0.49	-0.45	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
LGG	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	11.07	1.66e-25	1.72e-22	0.67	0.45	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
LGG	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-11.07	1.66e-25	1.72e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
LGG	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-11.07	1.67e-25	1.73e-22	-0.54	-0.45	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
LGG	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-11.07	1.68e-25	1.73e-22	-0.54	-0.45	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
LGG	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-11.07	1.68e-25	1.74e-22	-0.64	-0.45	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-11.07	1.68e-25	1.74e-22	-0.65	-0.45	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
LGG	cis	rs916888	0.821	rs199513	ENSG00000232300.1	FAM215B	-11.07	1.71e-25	1.76e-22	-0.65	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46558830~46562795:-
LGG	cis	rs7927771	0.8	rs12146565	ENSG00000280615.1	Y_RNA	-11.07	1.73e-25	1.78e-22	-0.58	-0.45	Subjective well-being;	chr11:47377412	chr11:47614898~47614994:-
LGG	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	11.07	1.74e-25	1.79e-22	0.56	0.45	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
LGG	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-11.07	1.75e-25	1.81e-22	-0.39	-0.45	Height;	chr11:118855938	chr11:118791254~118793137:+
LGG	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	11.07	1.76e-25	1.81e-22	0.49	0.45	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	11.07	1.76e-25	1.81e-22	0.49	0.45	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
LGG	cis	rs1150668	0.745	rs213238	ENSG00000218016.2	ZNF192P2	-11.07	1.76e-25	1.82e-22	-0.52	-0.45	Pubertal anthropometrics;	chr6:28354216	chr6:28188050~28189432:+
LGG	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	11.07	1.77e-25	1.82e-22	0.57	0.45	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-11.07	1.77e-25	1.82e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
LGG	cis	rs7119038	0.629	rs10892272	ENSG00000255239.1	AP002954.6	-11.07	1.78e-25	1.83e-22	-0.61	-0.45	Sjögren's syndrome;	chr11:118731998	chr11:118688039~118690600:-
LGG	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-11.07	1.78e-25	1.83e-22	-0.54	-0.45	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
LGG	cis	rs1150668	0.699	rs12214383	ENSG00000280107.1	AL022393.9	11.07	1.78e-25	1.84e-22	0.44	0.45	Pubertal anthropometrics;	chr6:28255953	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	11.07	1.79e-25	1.84e-22	0.56	0.45	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	11.07	1.79e-25	1.84e-22	0.57	0.45	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	11.07	1.79e-25	1.85e-22	0.64	0.45	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
LGG	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-11.06	1.81e-25	1.86e-22	-0.48	-0.45	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
LGG	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-11.06	1.81e-25	1.86e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.774	rs11249893	ENSG00000173295.6	FAM86B3P	-11.06	1.82e-25	1.87e-22	-0.48	-0.45	Mood instability;	chr8:8843341	chr8:8228595~8244865:+
LGG	cis	rs453301	0.522	rs2929455	ENSG00000173295.6	FAM86B3P	11.06	1.83e-25	1.88e-22	0.47	0.45	Joint mobility (Beighton score);	chr8:9225923	chr8:8228595~8244865:+
LGG	cis	rs2712184	0.721	rs2541401	ENSG00000229352.1	AC007563.3	-11.06	1.84e-25	1.89e-22	-0.53	-0.45	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216776283	chr2:216799608~216805335:+
LGG	cis	rs741668	0.895	rs61953326	ENSG00000235903.6	CPB2-AS1	11.06	1.84e-25	1.89e-22	0.51	0.45	Cerebrospinal fluid clusterin levels;	chr13:45994147	chr13:46052806~46113332:+
LGG	cis	rs741668	0.931	rs7317990	ENSG00000235903.6	CPB2-AS1	11.06	1.84e-25	1.89e-22	0.51	0.45	Cerebrospinal fluid clusterin levels;	chr13:45994362	chr13:46052806~46113332:+
LGG	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	11.06	1.85e-25	1.9e-22	0.54	0.45	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
LGG	cis	rs7119038	0.629	rs11216995	ENSG00000255239.1	AP002954.6	-11.06	1.86e-25	1.91e-22	-0.62	-0.45	Sjögren's syndrome;	chr11:118732817	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	11.06	1.87e-25	1.92e-22	0.56	0.45	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	11.06	1.87e-25	1.92e-22	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
LGG	cis	rs7216064	1	rs6504555	ENSG00000278219.1	AC145343.1	11.06	1.88e-25	1.93e-22	0.56	0.45	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67944611	chr17:68101538~68101639:+
LGG	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-11.06	1.89e-25	1.94e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
LGG	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-11.06	1.89e-25	1.94e-22	-0.65	-0.45	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	11.06	1.9e-25	1.96e-22	0.57	0.45	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	11.06	1.91e-25	1.97e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
LGG	cis	rs5742933	0.817	rs6738042	ENSG00000273240.1	RP11-455J20.3	11.06	1.92e-25	1.98e-22	0.54	0.45	Ferritin levels;	chr2:189776958	chr2:189763859~189764456:-
LGG	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	-11.06	1.93e-25	1.99e-22	-0.47	-0.45	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
LGG	cis	rs1061377	0.748	rs12506723	ENSG00000249685.1	RP11-360F5.3	11.06	1.95e-25	2.01e-22	0.52	0.45	Uric acid levels;	chr4:39103152	chr4:39133913~39135608:+
LGG	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	11.05	1.97e-25	2.02e-22	0.55	0.45	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
LGG	cis	rs7829975	0.777	rs560544	ENSG00000173295.6	FAM86B3P	11.05	1.98e-25	2.04e-22	0.47	0.45	Mood instability;	chr8:8779919	chr8:8228595~8244865:+
LGG	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-11.05	1.99e-25	2.04e-22	-0.65	-0.45	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
LGG	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	11.05	2e-25	2.05e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
LGG	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	11.05	2e-25	2.05e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-11.05	2e-25	2.06e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-11.05	2e-25	2.06e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
LGG	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	11.05	2.02e-25	2.07e-22	0.57	0.45	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
LGG	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-11.05	2.02e-25	2.08e-22	-0.47	-0.45	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
LGG	cis	rs9527	0.637	rs7096169	ENSG00000272912.1	RP11-724N1.1	-11.05	2.03e-25	2.08e-22	-0.53	-0.45	Arsenic metabolism;	chr10:102858938	chr10:102914585~102915404:+
LGG	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-11.05	2.03e-25	2.08e-22	-0.53	-0.45	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
LGG	cis	rs453301	0.522	rs2929309	ENSG00000173295.6	FAM86B3P	11.05	2.03e-25	2.08e-22	0.47	0.45	Joint mobility (Beighton score);	chr8:9226261	chr8:8228595~8244865:+
LGG	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	11.05	2.06e-25	2.11e-22	0.62	0.45	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
LGG	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	11.05	2.06e-25	2.11e-22	0.62	0.45	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
LGG	cis	rs8062405	0.757	rs2411453	ENSG00000271623.1	RP11-435I10.5	11.05	2.07e-25	2.12e-22	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28364700~28365333:+
LGG	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-11.05	2.07e-25	2.12e-22	-0.51	-0.45	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
LGG	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-11.05	2.07e-25	2.12e-22	-0.51	-0.45	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
LGG	cis	rs651907	0.557	rs35850993	ENSG00000256628.3	ZBTB11-AS1	11.05	2.07e-25	2.13e-22	0.51	0.45	Colorectal cancer;	chr3:101718589	chr3:101676475~101679217:+
LGG	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-11.05	2.1e-25	2.15e-22	-0.68	-0.45	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
LGG	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-11.05	2.1e-25	2.15e-22	-0.46	-0.45	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
LGG	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-11.05	2.1e-25	2.16e-22	-0.53	-0.45	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
LGG	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	11.05	2.11e-25	2.16e-22	0.6	0.45	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
LGG	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	11.05	2.12e-25	2.17e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	11.05	2.12e-25	2.17e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
LGG	cis	rs11098499	0.644	rs7693919	ENSG00000249244.1	RP11-548H18.2	11.05	2.12e-25	2.17e-22	0.48	0.45	Corneal astigmatism;	chr4:119619416	chr4:119391831~119395335:-
LGG	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	11.05	2.13e-25	2.18e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
LGG	cis	rs2287838	0.638	rs2010457	ENSG00000267289.1	CTD-2623N2.11	11.05	2.13e-25	2.18e-22	0.52	0.45	Sleep duration;	chr19:9848202	chr19:9834079~9835013:-
LGG	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-11.05	2.13e-25	2.18e-22	-0.4	-0.45	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
LGG	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-11.05	2.13e-25	2.18e-22	-0.4	-0.45	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
LGG	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-11.05	2.13e-25	2.18e-22	-0.4	-0.45	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
LGG	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	11.05	2.14e-25	2.19e-22	0.7	0.45	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
LGG	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-11.05	2.14e-25	2.19e-22	-0.53	-0.45	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
LGG	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	11.04	2.17e-25	2.22e-22	0.56	0.45	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
LGG	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	11.04	2.18e-25	2.23e-22	0.52	0.45	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
LGG	cis	rs494459	0.536	rs7103067	ENSG00000278376.1	RP11-158I9.8	-11.04	2.18e-25	2.23e-22	-0.39	-0.45	Height;	chr11:118852670	chr11:118791254~118793137:+
LGG	cis	rs2013441	0.795	rs6587064	ENSG00000230528.6	NOS2P3	11.04	2.2e-25	2.25e-22	0.43	0.45	Obesity-related traits;	chr17:20304571	chr17:20436337~20447249:+
LGG	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-11.04	2.2e-25	2.25e-22	-0.41	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
LGG	cis	rs11118620	0.853	rs12037861	ENSG00000257551.1	HLX-AS1	11.04	2.21e-25	2.26e-22	0.59	0.45	Heart failure;	chr1:220864835	chr1:220832763~220880140:-
LGG	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	11.04	2.21e-25	2.26e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
LGG	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	11.04	2.22e-25	2.27e-22	0.49	0.45	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
LGG	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-11.04	2.23e-25	2.28e-22	-0.55	-0.45	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
LGG	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	11.04	2.25e-25	2.3e-22	0.56	0.45	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	11.04	2.25e-25	2.3e-22	0.56	0.45	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	11.04	2.25e-25	2.3e-22	0.56	0.45	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	11.04	2.25e-25	2.3e-22	0.56	0.45	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	11.04	2.25e-25	2.3e-22	0.56	0.45	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	11.04	2.25e-25	2.3e-22	0.56	0.45	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
LGG	cis	rs4718428	0.576	rs12698546	ENSG00000226824.5	RP4-756H11.3	-11.04	2.26e-25	2.31e-22	-0.69	-0.45	Corneal structure;	chr7:66801919	chr7:66654538~66669855:+
LGG	cis	rs1150668	0.699	rs2394049	ENSG00000226314.6	ZNF192P1	11.04	2.27e-25	2.32e-22	0.43	0.45	Pubertal anthropometrics;	chr6:28271903	chr6:28161781~28169594:+
LGG	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-11.04	2.27e-25	2.32e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
LGG	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-11.04	2.27e-25	2.32e-22	-0.94	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
LGG	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-11.04	2.27e-25	2.32e-22	-0.94	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-11.04	2.27e-25	2.32e-22	-0.94	-0.45	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-11.04	2.27e-25	2.32e-22	-0.94	-0.45	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-11.04	2.27e-25	2.32e-22	-0.94	-0.45	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
LGG	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-11.04	2.27e-25	2.32e-22	-0.94	-0.45	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
LGG	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	11.04	2.28e-25	2.33e-22	0.62	0.45	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
LGG	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-11.04	2.28e-25	2.33e-22	-0.55	-0.45	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
LGG	cis	rs9481169	0.85	rs4947129	ENSG00000255389.1	C6orf3	-11.04	2.29e-25	2.34e-22	-0.91	-0.45	Inflammatory skin disease;	chr6:111609703	chr6:111599875~111602295:+
LGG	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	11.04	2.3e-25	2.35e-22	0.56	0.45	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
LGG	cis	rs9388451	0.626	rs3734637	ENSG00000237742.5	RP11-624M8.1	-11.04	2.31e-25	2.36e-22	-0.4	-0.45	Brugada syndrome;	chr6:125760173	chr6:125578558~125749190:-
LGG	cis	rs11098499	0.913	rs56122576	ENSG00000249244.1	RP11-548H18.2	11.04	2.31e-25	2.36e-22	0.49	0.45	Corneal astigmatism;	chr4:119208181	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	11.04	2.32e-25	2.37e-22	0.56	0.45	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
LGG	cis	rs2283792	0.812	rs94194	ENSG00000228050.1	TOP3BP1	11.04	2.35e-25	2.4e-22	0.51	0.45	Multiple sclerosis;	chr22:21933937	chr22:22223187~22224566:-
LGG	cis	rs741668	0.897	rs12429980	ENSG00000235903.6	CPB2-AS1	11.03	2.36e-25	2.41e-22	0.51	0.45	Cerebrospinal fluid clusterin levels;	chr13:45976003	chr13:46052806~46113332:+
LGG	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	11.03	2.36e-25	2.41e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
LGG	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-11.03	2.37e-25	2.42e-22	-0.53	-0.45	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
LGG	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-11.03	2.37e-25	2.42e-22	-0.54	-0.45	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
LGG	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-11.03	2.37e-25	2.42e-22	-0.6	-0.45	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
LGG	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-11.03	2.37e-25	2.42e-22	-0.94	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
LGG	cis	rs4373814	0.737	rs10740993	ENSG00000226083.4	SLC39A12-AS1	11.03	2.37e-25	2.42e-22	0.46	0.45	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18153553	chr10:18001786~18010562:-
LGG	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	11.03	2.39e-25	2.44e-22	0.63	0.45	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
LGG	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-11.03	2.41e-25	2.46e-22	-0.52	-0.45	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-11.03	2.41e-25	2.46e-22	-0.52	-0.45	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-11.03	2.41e-25	2.46e-22	-0.52	-0.45	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-11.03	2.41e-25	2.46e-22	-0.52	-0.45	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-11.03	2.41e-25	2.46e-22	-0.52	-0.45	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-11.03	2.41e-25	2.46e-22	-0.52	-0.45	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
LGG	cis	rs4819052	1	rs13047688	ENSG00000223768.1	LINC00205	-11.03	2.41e-25	2.46e-22	-0.55	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45293285~45297354:+
LGG	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-11.03	2.43e-25	2.48e-22	-0.53	-0.45	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
LGG	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	11.03	2.43e-25	2.48e-22	0.52	0.45	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
LGG	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-11.03	2.45e-25	2.5e-22	-0.43	-0.45	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
LGG	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	11.03	2.45e-25	2.5e-22	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
LGG	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	11.03	2.46e-25	2.51e-22	0.5	0.45	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
LGG	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	11.03	2.48e-25	2.53e-22	0.53	0.45	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
LGG	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-11.03	2.5e-25	2.55e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
LGG	cis	rs494459	0.536	rs57719838	ENSG00000278376.1	RP11-158I9.8	-11.03	2.51e-25	2.56e-22	-0.39	-0.45	Height;	chr11:118854014	chr11:118791254~118793137:+
LGG	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-11.03	2.52e-25	2.57e-22	-0.39	-0.45	Height;	chr11:118856460	chr11:118791254~118793137:+
LGG	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-11.03	2.52e-25	2.57e-22	-0.39	-0.45	Height;	chr11:118856623	chr11:118791254~118793137:+
LGG	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-11.03	2.53e-25	2.57e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-11.03	2.53e-25	2.57e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
LGG	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-11.03	2.53e-25	2.58e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-11.03	2.53e-25	2.58e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
LGG	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-11.03	2.55e-25	2.6e-22	-0.68	-0.45	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
LGG	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-11.03	2.55e-25	2.6e-22	-0.68	-0.45	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	11.03	2.56e-25	2.61e-22	0.68	0.45	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
LGG	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	11.03	2.56e-25	2.61e-22	0.68	0.45	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
LGG	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	11.03	2.56e-25	2.61e-22	0.68	0.45	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
LGG	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-11.02	2.58e-25	2.62e-22	-0.4	-0.45	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
LGG	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	11.02	2.58e-25	2.63e-22	0.56	0.45	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
LGG	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-11.02	2.59e-25	2.64e-22	-0.52	-0.45	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
LGG	cis	rs6908034	0.66	rs74795718	ENSG00000228412.5	RP4-625H18.2	11.02	2.6e-25	2.65e-22	0.88	0.45	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782068	chr6:19802164~19804752:-
LGG	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	11.02	2.6e-25	2.65e-22	0.56	0.45	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
LGG	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-11.02	2.63e-25	2.68e-22	-0.36	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
LGG	cis	rs651907	0.557	rs62284198	ENSG00000256628.3	ZBTB11-AS1	11.02	2.64e-25	2.69e-22	0.51	0.45	Colorectal cancer;	chr3:101755855	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs2318090	ENSG00000256628.3	ZBTB11-AS1	11.02	2.64e-25	2.69e-22	0.51	0.45	Colorectal cancer;	chr3:101756089	chr3:101676475~101679217:+
LGG	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	11.02	2.64e-25	2.69e-22	0.56	0.45	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
LGG	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	11.02	2.64e-25	2.69e-22	0.48	0.45	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
LGG	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	11.02	2.65e-25	2.7e-22	0.4	0.45	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
LGG	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	11.02	2.68e-25	2.73e-22	0.59	0.45	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
LGG	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-11.02	2.71e-25	2.76e-22	-0.53	-0.45	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
LGG	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	11.02	2.72e-25	2.77e-22	0.55	0.45	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	11.02	2.72e-25	2.77e-22	0.55	0.45	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
LGG	cis	rs5742933	0.652	rs10210345	ENSG00000273240.1	RP11-455J20.3	11.02	2.73e-25	2.78e-22	0.54	0.45	Ferritin levels;	chr2:189754760	chr2:189763859~189764456:-
LGG	cis	rs5758511	0.68	rs5758686	ENSG00000227370.1	RP4-669P10.19	11.02	2.74e-25	2.78e-22	0.51	0.45	Birth weight;	chr22:42259371	chr22:42132543~42132998:+
LGG	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-11.02	2.75e-25	2.79e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
LGG	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-11.02	2.75e-25	2.79e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
LGG	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-11.02	2.75e-25	2.79e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-11.02	2.75e-25	2.79e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-11.02	2.75e-25	2.79e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
LGG	cis	rs17345786	1	rs17345786	ENSG00000244119.1	PDCL3P4	-11.02	2.76e-25	2.81e-22	-0.39	-0.45	Colonoscopy-negative controls vs population controls;	chr3:101599474	chr3:101712472~101713191:+
LGG	cis	rs17345786	1	rs58907984	ENSG00000244119.1	PDCL3P4	11.02	2.76e-25	2.81e-22	0.39	0.45	Colonoscopy-negative controls vs population controls;	chr3:101586326	chr3:101712472~101713191:+
LGG	cis	rs17345786	0.954	rs17508319	ENSG00000244119.1	PDCL3P4	11.02	2.76e-25	2.81e-22	0.39	0.45	Colonoscopy-negative controls vs population controls;	chr3:101600059	chr3:101712472~101713191:+
LGG	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	11.02	2.77e-25	2.82e-22	0.79	0.45	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
LGG	cis	rs5742933	0.744	rs13009889	ENSG00000273240.1	RP11-455J20.3	11.02	2.78e-25	2.82e-22	0.54	0.45	Ferritin levels;	chr2:189763842	chr2:189763859~189764456:-
LGG	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	-11.02	2.8e-25	2.84e-22	-0.47	-0.45	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
LGG	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-11.01	2.81e-25	2.85e-22	-0.65	-0.45	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
LGG	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-11.01	2.81e-25	2.85e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
LGG	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	11.01	2.83e-25	2.87e-22	0.56	0.45	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
LGG	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-11.01	2.86e-25	2.9e-22	-0.39	-0.45	Height;	chr11:118855233	chr11:118791254~118793137:+
LGG	cis	rs4819052	1	rs9306123	ENSG00000223768.1	LINC00205	-11.01	2.86e-25	2.9e-22	-0.55	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45293285~45297354:+
LGG	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	11.01	2.86e-25	2.91e-22	0.48	0.45	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
LGG	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	11.01	2.86e-25	2.91e-22	0.56	0.45	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
LGG	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-11.01	2.87e-25	2.91e-22	-0.39	-0.45	Height;	chr11:118857611	chr11:118791254~118793137:+
LGG	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-11.01	2.88e-25	2.92e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
LGG	cis	rs1061377	0.965	rs1137714	ENSG00000249207.1	RP11-360F5.1	-11.01	2.91e-25	2.95e-22	-0.48	-0.45	Uric acid levels;	chr4:39143105	chr4:39112677~39126818:-
LGG	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	11.01	2.91e-25	2.96e-22	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
LGG	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	11.01	2.92e-25	2.96e-22	0.48	0.45	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
LGG	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	11.01	2.95e-25	2.99e-22	0.56	0.45	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	11.01	2.95e-25	2.99e-22	0.56	0.45	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	11.01	2.95e-25	2.99e-22	0.56	0.45	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	11.01	2.95e-25	2.99e-22	0.56	0.45	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	11.01	2.95e-25	2.99e-22	0.56	0.45	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	11.01	2.95e-25	2.99e-22	0.56	0.45	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	11.01	2.95e-25	2.99e-22	0.56	0.45	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
LGG	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	11.01	2.95e-25	2.99e-22	0.5	0.45	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
LGG	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	11.01	2.96e-25	2.99e-22	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
LGG	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	-11.01	2.96e-25	3e-22	-0.47	-0.45	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
LGG	cis	rs5742933	0.817	rs3816196	ENSG00000273240.1	RP11-455J20.3	11.01	2.97e-25	3.01e-22	0.54	0.45	Ferritin levels;	chr2:189775749	chr2:189763859~189764456:-
LGG	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	11.01	2.98e-25	3.02e-22	0.56	0.45	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	11.01	2.99e-25	3.02e-22	0.56	0.45	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-11.01	2.99e-25	3.03e-22	-0.61	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
LGG	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	11.01	3e-25	3.03e-22	0.59	0.45	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
LGG	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	-11.01	3.02e-25	3.06e-22	-0.47	-0.45	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
LGG	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	11	3.08e-25	3.12e-22	0.54	0.45	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	11	3.09e-25	3.12e-22	0.57	0.45	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
LGG	cis	rs2287838	0.686	rs1862472	ENSG00000267289.1	CTD-2623N2.11	-11	3.1e-25	3.14e-22	-0.5	-0.45	Sleep duration;	chr19:9847181	chr19:9834079~9835013:-
LGG	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	11	3.12e-25	3.16e-22	0.53	0.45	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
LGG	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-11	3.13e-25	3.17e-22	-0.63	-0.45	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
LGG	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-11	3.14e-25	3.18e-22	-0.43	-0.45	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
LGG	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	11	3.17e-25	3.21e-22	0.65	0.45	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
LGG	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	11	3.18e-25	3.21e-22	0.48	0.45	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
LGG	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	11	3.2e-25	3.23e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
LGG	cis	rs5742933	0.817	rs1055091	ENSG00000273240.1	RP11-455J20.3	11	3.2e-25	3.23e-22	0.54	0.45	Ferritin levels;	chr2:189770417	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.817	rs6942	ENSG00000273240.1	RP11-455J20.3	11	3.2e-25	3.23e-22	0.54	0.45	Ferritin levels;	chr2:189771685	chr2:189763859~189764456:-
LGG	cis	rs916888	0.61	rs199452	ENSG00000232300.1	FAM215B	11	3.21e-25	3.24e-22	0.57	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46558830~46562795:-
LGG	cis	rs7267979	0.899	rs2179459	ENSG00000125804.12	FAM182A	-11	3.22e-25	3.25e-22	-0.55	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:26054655~26086917:+
LGG	cis	rs6452524	0.837	rs1479569	ENSG00000248112.1	RP11-78C3.1	11	3.23e-25	3.26e-22	0.6	0.45	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:82919376~82921119:-
LGG	cis	rs6908034	0.66	rs74457659	ENSG00000228412.5	RP4-625H18.2	11	3.23e-25	3.27e-22	0.9	0.45	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19760494	chr6:19802164~19804752:-
LGG	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-11	3.24e-25	3.27e-22	-0.33	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
LGG	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-11	3.24e-25	3.28e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-11	3.24e-25	3.28e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-11	3.25e-25	3.28e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
LGG	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	11	3.29e-25	3.32e-22	0.53	0.45	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
LGG	cis	rs916888	0.61	rs142167	ENSG00000232300.1	FAM215B	-11	3.29e-25	3.32e-22	-0.57	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46558830~46562795:-
LGG	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	11	3.31e-25	3.34e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
LGG	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-11	3.33e-25	3.37e-22	-0.6	-0.45	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
LGG	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-11	3.34e-25	3.37e-22	-0.34	-0.45	Breast cancer;	chr11:743813	chr11:781645~782105:+
LGG	cis	rs4373814	0.561	rs1331330	ENSG00000226083.4	SLC39A12-AS1	10.99	3.36e-25	3.4e-22	0.45	0.45	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18146087	chr10:18001786~18010562:-
LGG	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	10.99	3.38e-25	3.42e-22	0.56	0.45	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
LGG	cis	rs1150668	0.699	rs1531681	ENSG00000280107.1	AL022393.9	-10.99	3.39e-25	3.42e-22	-0.43	-0.45	Pubertal anthropometrics;	chr6:28259100	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	10.99	3.39e-25	3.42e-22	0.56	0.45	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	10.99	3.39e-25	3.42e-22	0.56	0.45	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
LGG	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	10.99	3.43e-25	3.46e-22	0.57	0.45	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
LGG	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	10.99	3.46e-25	3.5e-22	0.57	0.45	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
LGG	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-10.99	3.47e-25	3.5e-22	-0.49	-0.45	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
LGG	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-10.99	3.48e-25	3.51e-22	-0.68	-0.45	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
LGG	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-10.99	3.48e-25	3.52e-22	-0.65	-0.45	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
LGG	cis	rs7267979	0.932	rs4280527	ENSG00000125804.12	FAM182A	-10.99	3.48e-25	3.52e-22	-0.55	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:26054655~26086917:+
LGG	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-10.99	3.54e-25	3.57e-22	-0.53	-0.45	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
LGG	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	10.99	3.54e-25	3.57e-22	0.57	0.45	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
LGG	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-10.99	3.56e-25	3.59e-22	-0.39	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
LGG	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	10.99	3.58e-25	3.61e-22	0.64	0.45	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
LGG	cis	rs11098499	0.57	rs6832740	ENSG00000249244.1	RP11-548H18.2	10.99	3.61e-25	3.64e-22	0.48	0.45	Corneal astigmatism;	chr4:119624981	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.644	rs6855918	ENSG00000249244.1	RP11-548H18.2	10.99	3.61e-25	3.64e-22	0.48	0.45	Corneal astigmatism;	chr4:119625144	chr4:119391831~119395335:-
LGG	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-10.99	3.62e-25	3.65e-22	-0.54	-0.45	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
LGG	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-10.99	3.63e-25	3.66e-22	-0.68	-0.45	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
LGG	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	10.99	3.65e-25	3.68e-22	0.39	0.45	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
LGG	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	10.98	3.68e-25	3.71e-22	0.5	0.45	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
LGG	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	10.98	3.7e-25	3.72e-22	0.31	0.45	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
LGG	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	10.98	3.72e-25	3.74e-22	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
LGG	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-10.98	3.72e-25	3.75e-22	-0.66	-0.45	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
LGG	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	10.98	3.73e-25	3.76e-22	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
LGG	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-10.98	3.73e-25	3.76e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
LGG	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	10.98	3.74e-25	3.77e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	10.98	3.74e-25	3.77e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
LGG	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-10.98	3.74e-25	3.77e-22	-0.94	-0.45	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
LGG	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-10.98	3.75e-25	3.78e-22	-0.68	-0.45	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
LGG	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	10.98	3.76e-25	3.78e-22	0.58	0.45	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
LGG	cis	rs17345786	0.911	rs10936707	ENSG00000244119.1	PDCL3P4	10.98	3.81e-25	3.83e-22	0.38	0.45	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101712472~101713191:+
LGG	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-10.98	3.84e-25	3.86e-22	-0.53	-0.45	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-10.98	3.84e-25	3.86e-22	-0.53	-0.45	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
LGG	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-10.98	3.84e-25	3.86e-22	-0.6	-0.45	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
LGG	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	10.98	3.84e-25	3.87e-22	0.51	0.45	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
LGG	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-10.98	3.85e-25	3.87e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
LGG	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	10.98	3.87e-25	3.9e-22	0.55	0.45	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
LGG	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-10.98	3.89e-25	3.91e-22	-0.52	-0.45	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
LGG	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	10.98	3.91e-25	3.93e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
LGG	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	10.98	3.91e-25	3.93e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
LGG	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	10.98	3.94e-25	3.97e-22	0.78	0.45	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
LGG	cis	rs7615952	0.546	rs11717632	ENSG00000242001.1	GS1-388B5.1	10.98	3.97e-25	3.99e-22	0.65	0.45	Blood pressure (smoking interaction);	chr3:125602286	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.546	rs2922197	ENSG00000242001.1	GS1-388B5.1	10.98	3.97e-25	3.99e-22	0.65	0.45	Blood pressure (smoking interaction);	chr3:125603188	chr3:125681305~125681453:+
LGG	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	10.98	3.97e-25	3.99e-22	0.56	0.45	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	10.98	3.98e-25	4e-22	0.56	0.45	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
LGG	cis	rs1150668	0.796	rs2531825	ENSG00000218016.2	ZNF192P2	-10.97	4e-25	4.02e-22	-0.51	-0.45	Pubertal anthropometrics;	chr6:28381487	chr6:28188050~28189432:+
LGG	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	10.97	4e-25	4.02e-22	0.58	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
LGG	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	10.97	4.08e-25	4.1e-22	0.56	0.45	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	10.97	4.08e-25	4.1e-22	0.56	0.45	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-10.97	4.1e-25	4.12e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
LGG	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-10.97	4.1e-25	4.12e-22	-0.37	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	10.97	4.13e-25	4.15e-22	0.56	0.45	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
LGG	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	10.97	4.16e-25	4.17e-22	0.5	0.45	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	10.97	4.16e-25	4.17e-22	0.5	0.45	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
LGG	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	10.97	4.18e-25	4.2e-22	0.67	0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
LGG	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-10.97	4.19e-25	4.2e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-10.97	4.19e-25	4.2e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
LGG	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-10.97	4.19e-25	4.2e-22	-0.61	-0.45	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
LGG	cis	rs893971	0.508	rs1440581	ENSG00000246375.2	RP11-10L7.1	10.97	4.19e-25	4.21e-22	0.52	0.45	Conduct disorder (maternal expressed emotions interaction);	chr4:88305270	chr4:88284942~88331421:+
LGG	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	10.97	4.2e-25	4.21e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	10.97	4.2e-25	4.21e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	10.97	4.2e-25	4.21e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	10.97	4.2e-25	4.21e-22	0.57	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
LGG	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	10.97	4.2e-25	4.21e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
LGG	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	10.97	4.23e-25	4.24e-22	0.53	0.45	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
LGG	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	10.97	4.24e-25	4.26e-22	0.49	0.45	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
LGG	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-10.97	4.25e-25	4.26e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
LGG	cis	rs2712184	0.683	rs2541406	ENSG00000229352.1	AC007563.3	-10.97	4.25e-25	4.26e-22	-0.51	-0.45	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216771124	chr2:216799608~216805335:+
LGG	cis	rs7927771	0.864	rs4752999	ENSG00000280615.1	Y_RNA	-10.97	4.26e-25	4.27e-22	-0.56	-0.45	Subjective well-being;	chr11:47407014	chr11:47614898~47614994:-
LGG	cis	rs17345786	1	rs17345528	ENSG00000244119.1	PDCL3P4	-10.97	4.28e-25	4.29e-22	-0.39	-0.45	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101712472~101713191:+
LGG	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-10.97	4.28e-25	4.29e-22	-0.38	-0.45	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-10.97	4.28e-25	4.29e-22	-0.38	-0.45	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-10.97	4.28e-25	4.29e-22	-0.38	-0.45	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
LGG	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-10.97	4.29e-25	4.3e-22	-0.56	-0.45	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
LGG	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	10.97	4.34e-25	4.35e-22	0.56	0.45	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	10.97	4.34e-25	4.35e-22	0.56	0.45	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
LGG	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	10.97	4.35e-25	4.35e-22	0.64	0.45	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
LGG	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	10.97	4.36e-25	4.37e-22	0.53	0.45	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
LGG	cis	rs1150668	0.699	rs1736895	ENSG00000218016.2	ZNF192P2	-10.96	4.37e-25	4.38e-22	-0.51	-0.45	Pubertal anthropometrics;	chr6:28252048	chr6:28188050~28189432:+
LGG	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	10.96	4.38e-25	4.39e-22	0.51	0.45	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
LGG	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-10.96	4.38e-25	4.39e-22	-0.61	-0.45	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
LGG	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-10.96	4.39e-25	4.4e-22	-0.68	-0.45	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
LGG	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	10.96	4.41e-25	4.41e-22	0.58	0.45	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
LGG	cis	rs853679	1	rs2799079	ENSG00000199851.2	U3	10.96	4.47e-25	4.47e-22	0.84	0.45	Depression;	chr6:28267398	chr6:28015568~28015777:+
LGG	cis	rs651907	0.557	rs2303474	ENSG00000256628.3	ZBTB11-AS1	10.96	4.47e-25	4.48e-22	0.51	0.45	Colorectal cancer;	chr3:101653055	chr3:101676475~101679217:+
LGG	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	10.96	4.47e-25	4.48e-22	0.68	0.45	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
LGG	cis	rs17345786	1	rs3804778	ENSG00000244119.1	PDCL3P4	10.96	4.48e-25	4.48e-22	0.39	0.45	Colonoscopy-negative controls vs population controls;	chr3:101575728	chr3:101712472~101713191:+
LGG	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	10.96	4.49e-25	4.5e-22	0.56	0.45	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	10.96	4.49e-25	4.5e-22	0.56	0.45	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	10.96	4.49e-25	4.5e-22	0.56	0.45	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	10.96	4.49e-25	4.5e-22	0.68	0.45	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
LGG	cis	rs7267979	1	rs6138572	ENSG00000125804.12	FAM182A	-10.96	4.5e-25	4.5e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6138575	ENSG00000125804.12	FAM182A	-10.96	4.5e-25	4.5e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs11087521	ENSG00000125804.12	FAM182A	-10.96	4.5e-25	4.5e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs13038834	ENSG00000125804.12	FAM182A	-10.96	4.5e-25	4.5e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:26054655~26086917:+
LGG	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-10.96	4.51e-25	4.52e-22	-0.52	-0.45	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-10.96	4.51e-25	4.52e-22	-0.52	-0.45	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
LGG	cis	rs4373814	0.698	rs10734038	ENSG00000226083.4	SLC39A12-AS1	10.96	4.53e-25	4.53e-22	0.46	0.45	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18147586	chr10:18001786~18010562:-
LGG	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-10.96	4.53e-25	4.53e-22	-0.53	-0.45	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-10.96	4.53e-25	4.53e-22	-0.53	-0.45	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-10.96	4.53e-25	4.53e-22	-0.53	-0.45	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
LGG	cis	rs8092443	0.882	rs2366383	ENSG00000278971.1	RP11-644A7.2	10.96	4.57e-25	4.57e-22	0.65	0.45	Response to antipsychotic treatment;	chr18:70485064	chr18:70489630~70491205:+
LGG	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-10.96	4.58e-25	4.58e-22	-0.68	-0.45	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
LGG	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	10.96	4.59e-25	4.6e-22	0.76	0.45	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
LGG	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	10.96	4.61e-25	4.61e-22	0.64	0.45	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
LGG	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	10.96	4.61e-25	4.61e-22	0.64	0.45	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
LGG	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-10.96	4.61e-25	4.62e-22	-0.58	-0.45	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
LGG	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-10.96	4.62e-25	4.62e-22	-0.68	-0.45	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
LGG	cis	rs7267979	0.932	rs1541061	ENSG00000125804.12	FAM182A	-10.96	4.64e-25	4.64e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs6138600	ENSG00000125804.12	FAM182A	-10.96	4.64e-25	4.64e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.899	rs2104734	ENSG00000125804.12	FAM182A	-10.96	4.64e-25	4.64e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:26054655~26086917:+
LGG	cis	rs6683071	0.689	rs12063226	ENSG00000272750.1	RP11-378J18.8	-10.96	4.66e-25	4.66e-22	-0.54	-0.45	Cognitive performance;	chr1:222753913	chr1:222658867~222661512:-
LGG	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	10.96	4.67e-25	4.67e-22	0.53	0.45	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
LGG	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-10.96	4.68e-25	4.68e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-10.96	4.68e-25	4.68e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
LGG	cis	rs741668	0.931	rs17428874	ENSG00000235903.6	CPB2-AS1	10.96	4.7e-25	4.69e-22	0.51	0.45	Cerebrospinal fluid clusterin levels;	chr13:45955427	chr13:46052806~46113332:+
LGG	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-10.96	4.72e-25	4.71e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-10.96	4.72e-25	4.71e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-10.96	4.72e-25	4.71e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-10.96	4.72e-25	4.71e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-10.96	4.72e-25	4.71e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
LGG	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-10.96	4.72e-25	4.71e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
LGG	cis	rs741668	0.897	rs17429573	ENSG00000235903.6	CPB2-AS1	10.96	4.72e-25	4.72e-22	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:45995923	chr13:46052806~46113332:+
LGG	cis	rs4713118	0.615	rs57252182	ENSG00000199851.2	U3	10.96	4.73e-25	4.73e-22	0.62	0.45	Parkinson's disease;	chr6:27752470	chr6:28015568~28015777:+
LGG	cis	rs34034915	1	rs34034915	ENSG00000199851.2	U3	10.96	4.73e-25	4.73e-22	0.62	0.45	Hepatitis A;	chr6:27752924	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.527	rs36042294	ENSG00000199851.2	U3	10.96	4.73e-25	4.73e-22	0.62	0.45	Parkinson's disease;	chr6:27752933	chr6:28015568~28015777:+
LGG	cis	rs1150668	0.83	rs2531831	ENSG00000218016.2	ZNF192P2	-10.96	4.74e-25	4.74e-22	-0.51	-0.45	Pubertal anthropometrics;	chr6:28420988	chr6:28188050~28189432:+
LGG	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-10.95	4.76e-25	4.76e-22	-0.52	-0.45	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
LGG	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-10.95	4.77e-25	4.76e-22	-0.68	-0.45	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
LGG	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-10.95	4.77e-25	4.76e-22	-0.52	-0.45	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
LGG	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-10.95	4.78e-25	4.77e-22	-0.52	-0.45	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
LGG	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	10.95	4.79e-25	4.79e-22	0.78	0.45	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
LGG	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	10.95	4.83e-25	4.82e-22	0.55	0.45	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
LGG	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	10.95	4.83e-25	4.83e-22	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	10.95	4.83e-25	4.83e-22	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	10.95	4.83e-25	4.83e-22	0.52	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
LGG	cis	rs4819052	0.918	rs2330013	ENSG00000223768.1	LINC00205	-10.95	4.85e-25	4.84e-22	-0.55	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45293285~45297354:+
LGG	cis	rs4819052	1	rs28628220	ENSG00000223768.1	LINC00205	-10.95	4.85e-25	4.84e-22	-0.55	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45293285~45297354:+
LGG	cis	rs11098499	0.675	rs11098534	ENSG00000249244.1	RP11-548H18.2	10.95	4.86e-25	4.86e-22	0.48	0.45	Corneal astigmatism;	chr4:119635617	chr4:119391831~119395335:-
LGG	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	10.95	4.87e-25	4.86e-22	0.55	0.45	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
LGG	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	10.95	4.92e-25	4.91e-22	0.52	0.45	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	10.95	4.92e-25	4.91e-22	0.56	0.45	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
LGG	cis	rs1150668	0.699	rs12214383	ENSG00000218016.2	ZNF192P2	10.95	4.95e-25	4.94e-22	0.51	0.45	Pubertal anthropometrics;	chr6:28255953	chr6:28188050~28189432:+
LGG	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-10.95	4.96e-25	4.95e-22	-0.65	-0.45	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
LGG	cis	rs853679	0.506	rs1150711	ENSG00000280107.1	AL022393.9	-10.95	4.97e-25	4.96e-22	-0.47	-0.45	Depression;	chr6:28240757	chr6:28170845~28172521:+
LGG	cis	rs7267979	1	rs11087520	ENSG00000125804.12	FAM182A	-10.95	4.97e-25	4.96e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs397119	ENSG00000125804.12	FAM182A	-10.95	4.97e-25	4.96e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:26054655~26086917:+
LGG	cis	rs741668	0.894	rs2031633	ENSG00000235903.6	CPB2-AS1	10.95	5.02e-25	5.01e-22	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:46022005	chr13:46052806~46113332:+
LGG	cis	rs741668	0.931	rs61953335	ENSG00000235903.6	CPB2-AS1	10.95	5.02e-25	5.01e-22	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:46024681	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-10.95	5.02e-25	5.01e-22	-0.64	-0.45	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
LGG	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-10.95	5.02e-25	5.01e-22	-0.36	-0.45	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
LGG	cis	rs9527	0.571	rs12219246	ENSG00000272912.1	RP11-724N1.1	-10.95	5.04e-25	5.03e-22	-0.51	-0.45	Arsenic metabolism;	chr10:102853598	chr10:102914585~102915404:+
LGG	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	10.95	5.07e-25	5.05e-22	0.64	0.45	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
LGG	cis	rs7829975	0.774	rs35039922	ENSG00000173295.6	FAM86B3P	-10.95	5.1e-25	5.09e-22	-0.48	-0.45	Mood instability;	chr8:8817815	chr8:8228595~8244865:+
LGG	cis	rs7615952	0.546	rs11711150	ENSG00000242001.1	GS1-388B5.1	10.95	5.11e-25	5.1e-22	0.65	0.45	Blood pressure (smoking interaction);	chr3:125596819	chr3:125681305~125681453:+
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	10.95	5.14e-25	5.12e-22	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
LGG	cis	rs741668	0.931	rs4417456	ENSG00000235903.6	CPB2-AS1	10.95	5.17e-25	5.15e-22	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:46014273	chr13:46052806~46113332:+
LGG	cis	rs741668	0.931	rs61953330	ENSG00000235903.6	CPB2-AS1	10.95	5.17e-25	5.15e-22	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:46014741	chr13:46052806~46113332:+
LGG	cis	rs741668	0.931	rs61953331	ENSG00000235903.6	CPB2-AS1	10.95	5.17e-25	5.15e-22	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:46015336	chr13:46052806~46113332:+
LGG	cis	rs4819052	1	rs2297286	ENSG00000215447.6	BX322557.10	-10.95	5.19e-25	5.17e-22	-0.39	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45288052~45291738:+
LGG	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-10.95	5.19e-25	5.17e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
LGG	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	10.95	5.19e-25	5.17e-22	0.56	0.45	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
LGG	cis	rs1150668	0.699	rs1736895	ENSG00000226314.6	ZNF192P1	10.94	5.2e-25	5.18e-22	0.43	0.45	Pubertal anthropometrics;	chr6:28252048	chr6:28161781~28169594:+
LGG	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	10.94	5.21e-25	5.19e-22	0.5	0.45	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
LGG	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	10.94	5.22e-25	5.2e-22	0.62	0.45	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
LGG	cis	rs651907	0.557	rs7645391	ENSG00000256628.3	ZBTB11-AS1	10.94	5.22e-25	5.2e-22	0.51	0.45	Colorectal cancer;	chr3:101642662	chr3:101676475~101679217:+
LGG	cis	rs7829975	0.711	rs4481596	ENSG00000173295.6	FAM86B3P	-10.94	5.23e-25	5.21e-22	-0.47	-0.45	Mood instability;	chr8:8846820	chr8:8228595~8244865:+
LGG	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	10.94	5.23e-25	5.21e-22	0.54	0.45	Height;	chr11:118857611	chr11:118688039~118690600:-
LGG	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-10.94	5.24e-25	5.22e-22	-0.52	-0.45	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
LGG	cis	rs904251	0.523	rs9349039	ENSG00000204110.6	RP1-153P14.8	-10.94	5.28e-25	5.25e-22	-0.48	-0.45	Cognitive performance;	chr6:37512616	chr6:37507348~37535616:+
LGG	cis	rs904251	0.523	rs9366935	ENSG00000204110.6	RP1-153P14.8	-10.94	5.28e-25	5.25e-22	-0.48	-0.45	Cognitive performance;	chr6:37512628	chr6:37507348~37535616:+
LGG	cis	rs7829975	0.681	rs2271342	ENSG00000173295.6	FAM86B3P	-10.94	5.29e-25	5.27e-22	-0.47	-0.45	Mood instability;	chr8:8786428	chr8:8228595~8244865:+
LGG	cis	rs7267979	1	rs2258719	ENSG00000125804.12	FAM182A	-10.94	5.3e-25	5.28e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:26054655~26086917:+
LGG	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	10.94	5.31e-25	5.28e-22	0.51	0.45	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
LGG	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	10.94	5.31e-25	5.29e-22	0.56	0.45	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	10.94	5.31e-25	5.29e-22	0.56	0.45	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
LGG	cis	rs7267979	1	rs398036	ENSG00000125804.12	FAM182A	-10.94	5.37e-25	5.35e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:26054655~26086917:+
LGG	cis	rs17345786	1	rs997739	ENSG00000244119.1	PDCL3P4	10.94	5.4e-25	5.37e-22	0.38	0.45	Colonoscopy-negative controls vs population controls;	chr3:101595096	chr3:101712472~101713191:+
LGG	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-10.94	5.41e-25	5.38e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
LGG	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	10.94	5.41e-25	5.39e-22	0.47	0.45	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
LGG	cis	rs7267979	0.932	rs417130	ENSG00000125804.12	FAM182A	-10.94	5.45e-25	5.42e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs6037125	ENSG00000125804.12	FAM182A	-10.94	5.45e-25	5.42e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs372678	ENSG00000125804.12	FAM182A	-10.94	5.45e-25	5.42e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:26054655~26086917:+
LGG	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	10.94	5.47e-25	5.44e-22	0.54	0.45	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
LGG	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	10.94	5.48e-25	5.45e-22	0.36	0.45	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
LGG	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	10.94	5.51e-25	5.48e-22	0.67	0.45	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
LGG	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-10.94	5.52e-25	5.49e-22	-0.52	-0.45	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-10.94	5.52e-25	5.49e-22	-0.52	-0.45	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
LGG	cis	rs12495178	0.639	rs7627287	ENSG00000239519.1	CADM2-AS1	-10.94	5.57e-25	5.54e-22	-0.5	-0.45	Body mass index;	chr3:85863363	chr3:85992183~86028007:-
LGG	cis	rs4713118	0.662	rs149946	ENSG00000226314.6	ZNF192P1	-10.94	5.62e-25	5.59e-22	-0.53	-0.45	Parkinson's disease;	chr6:28002253	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	10.94	5.62e-25	5.59e-22	0.53	0.45	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	10.94	5.62e-25	5.59e-22	0.53	0.45	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
LGG	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-10.94	5.64e-25	5.6e-22	-0.51	-0.45	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
LGG	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-10.94	5.64e-25	5.6e-22	-0.52	-0.45	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-10.94	5.64e-25	5.6e-22	-0.52	-0.45	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-10.94	5.64e-25	5.6e-22	-0.52	-0.45	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-10.94	5.64e-25	5.6e-22	-0.52	-0.45	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
LGG	cis	rs7267979	1	rs2424713	ENSG00000125804.12	FAM182A	-10.94	5.68e-25	5.64e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2387885	ENSG00000125804.12	FAM182A	10.94	5.68e-25	5.64e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:26054655~26086917:+
LGG	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	10.93	5.68e-25	5.64e-22	0.6	0.45	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
LGG	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	10.93	5.73e-25	5.69e-22	0.79	0.45	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
LGG	cis	rs7267979	1	rs2482943	ENSG00000125804.12	FAM182A	10.93	5.73e-25	5.69e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:26054655~26086917:+
LGG	cis	rs5758511	0.68	rs5758699	ENSG00000227370.1	RP4-669P10.19	10.93	5.75e-25	5.71e-22	0.5	0.45	Birth weight;	chr22:42292028	chr22:42132543~42132998:+
LGG	cis	rs172166	0.61	rs156737	ENSG00000218016.2	ZNF192P2	-10.93	5.77e-25	5.73e-22	-0.53	-0.45	Cardiac Troponin-T levels;	chr6:27927435	chr6:28188050~28189432:+
LGG	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	10.93	5.8e-25	5.76e-22	0.79	0.45	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
LGG	cis	rs7927771	0.832	rs6485753	ENSG00000280615.1	Y_RNA	10.93	5.82e-25	5.78e-22	0.57	0.45	Subjective well-being;	chr11:47388649	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.832	rs4752993	ENSG00000280615.1	Y_RNA	10.93	5.82e-25	5.78e-22	0.57	0.45	Subjective well-being;	chr11:47389400	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.832	rs4752994	ENSG00000280615.1	Y_RNA	10.93	5.82e-25	5.78e-22	0.57	0.45	Subjective well-being;	chr11:47389514	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.832	rs10769262	ENSG00000280615.1	Y_RNA	10.93	5.82e-25	5.78e-22	0.57	0.45	Subjective well-being;	chr11:47390030	chr11:47614898~47614994:-
LGG	cis	rs651907	0.557	rs13099674	ENSG00000256628.3	ZBTB11-AS1	10.93	5.82e-25	5.78e-22	0.51	0.45	Colorectal cancer;	chr3:101770785	chr3:101676475~101679217:+
LGG	cis	rs17345786	1	rs11715368	ENSG00000244119.1	PDCL3P4	10.93	5.84e-25	5.8e-22	0.39	0.45	Colonoscopy-negative controls vs population controls;	chr3:101617536	chr3:101712472~101713191:+
LGG	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	10.93	5.86e-25	5.82e-22	0.53	0.45	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
LGG	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	10.93	5.89e-25	5.84e-22	0.55	0.45	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
LGG	cis	rs7267979	0.932	rs6115200	ENSG00000125804.12	FAM182A	-10.93	5.9e-25	5.86e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs6138588	ENSG00000125804.12	FAM182A	-10.93	5.9e-25	5.86e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	10.93	5.93e-25	5.89e-22	0.55	0.45	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
LGG	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	10.93	5.97e-25	5.93e-22	0.58	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
LGG	cis	rs1150668	0.699	rs1736895	ENSG00000280107.1	AL022393.9	-10.93	6.01e-25	5.96e-22	-0.43	-0.45	Pubertal anthropometrics;	chr6:28252048	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	10.93	6.07e-25	6.02e-22	0.63	0.45	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
LGG	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	10.93	6.09e-25	6.04e-22	0.91	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
LGG	cis	rs9388451	0.626	rs9385383	ENSG00000237742.5	RP11-624M8.1	-10.93	6.09e-25	6.04e-22	-0.4	-0.45	Brugada syndrome;	chr6:125765144	chr6:125578558~125749190:-
LGG	cis	rs4819052	1	rs2297284	ENSG00000223768.1	LINC00205	-10.93	6.12e-25	6.07e-22	-0.55	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45293285~45297354:+
LGG	cis	rs11148252	0.532	rs9536185	ENSG00000273784.3	RP11-78J21.7	-10.93	6.14e-25	6.09e-22	-0.53	-0.45	Lewy body disease;	chr13:52605666	chr13:52600042~52642542:+
LGG	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	10.93	6.15e-25	6.09e-22	0.58	0.45	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
LGG	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	10.93	6.17e-25	6.12e-22	0.55	0.45	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
LGG	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-10.93	6.18e-25	6.13e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-10.93	6.18e-25	6.13e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-10.93	6.18e-25	6.13e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-10.93	6.18e-25	6.13e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-10.93	6.18e-25	6.13e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
LGG	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-10.92	6.23e-25	6.17e-22	-0.52	-0.45	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-10.92	6.23e-25	6.17e-22	-0.52	-0.45	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
LGG	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	10.92	6.26e-25	6.2e-22	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
LGG	cis	rs5758511	0.68	rs5758687	ENSG00000227370.1	RP4-669P10.19	10.92	6.27e-25	6.21e-22	0.51	0.45	Birth weight;	chr22:42260582	chr22:42132543~42132998:+
LGG	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	-10.92	6.27e-25	6.21e-22	-0.46	-0.45	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	10.92	6.31e-25	6.25e-22	0.55	0.45	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
LGG	cis	rs1150668	0.699	rs12214383	ENSG00000226314.6	ZNF192P1	-10.92	6.32e-25	6.25e-22	-0.43	-0.45	Pubertal anthropometrics;	chr6:28255953	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.874	rs28452522	ENSG00000249244.1	RP11-548H18.2	10.92	6.33e-25	6.27e-22	0.49	0.45	Corneal astigmatism;	chr4:119189629	chr4:119391831~119395335:-
LGG	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-10.92	6.35e-25	6.28e-22	-0.6	-0.45	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
LGG	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	10.92	6.36e-25	6.29e-22	0.59	0.45	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
LGG	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	10.92	6.36e-25	6.29e-22	0.78	0.45	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	10.92	6.36e-25	6.3e-22	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
LGG	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	10.92	6.36e-25	6.3e-22	0.59	0.45	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
LGG	cis	rs1150668	0.699	rs1531681	ENSG00000226314.6	ZNF192P1	10.92	6.37e-25	6.31e-22	0.43	0.45	Pubertal anthropometrics;	chr6:28259100	chr6:28161781~28169594:+
LGG	cis	rs67340775	0.541	rs200965	ENSG00000216901.1	AL022393.7	10.92	6.39e-25	6.32e-22	0.75	0.45	Lung cancer in ever smokers;	chr6:27898606	chr6:28176188~28176674:+
LGG	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-10.92	6.4e-25	6.33e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
LGG	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-10.92	6.4e-25	6.34e-22	-0.55	-0.45	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
LGG	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	10.92	6.4e-25	6.34e-22	0.59	0.45	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	10.92	6.4e-25	6.34e-22	0.59	0.45	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
LGG	cis	rs5758511	0.68	rs1001586	ENSG00000227370.1	RP4-669P10.19	10.92	6.45e-25	6.38e-22	0.5	0.45	Birth weight;	chr22:42274287	chr22:42132543~42132998:+
LGG	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	10.92	6.47e-25	6.41e-22	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
LGG	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	10.92	6.49e-25	6.42e-22	0.57	0.45	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
LGG	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	10.92	6.5e-25	6.43e-22	0.58	0.45	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
LGG	cis	rs7927771	0.826	rs2293578	ENSG00000280615.1	Y_RNA	-10.92	6.53e-25	6.46e-22	-0.57	-0.45	Subjective well-being;	chr11:47415852	chr11:47614898~47614994:-
LGG	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-10.92	6.55e-25	6.47e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
LGG	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	10.92	6.55e-25	6.48e-22	0.7	0.45	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
LGG	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	10.92	6.57e-25	6.5e-22	0.63	0.45	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	10.92	6.6e-25	6.52e-22	0.56	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
LGG	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	10.92	6.69e-25	6.61e-22	0.58	0.45	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	10.92	6.69e-25	6.61e-22	0.58	0.45	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	10.92	6.69e-25	6.61e-22	0.58	0.45	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	10.92	6.69e-25	6.61e-22	0.58	0.45	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	10.92	6.69e-25	6.61e-22	0.58	0.45	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	10.92	6.69e-25	6.61e-22	0.58	0.45	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	10.92	6.71e-25	6.63e-22	0.56	0.45	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
LGG	cis	rs7267979	1	rs8125868	ENSG00000125804.12	FAM182A	10.92	6.74e-25	6.66e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:26054655~26086917:+
LGG	cis	rs5742933	0.817	rs2033870	ENSG00000253559.1	OSGEPL1-AS1	-10.92	6.75e-25	6.67e-22	-0.54	-0.45	Ferritin levels;	chr2:189739104	chr2:189762704~189765556:+
LGG	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-10.91	6.81e-25	6.73e-22	-0.37	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
LGG	cis	rs9527	0.571	rs3740400	ENSG00000272912.1	RP11-724N1.1	-10.91	6.81e-25	6.73e-22	-0.51	-0.45	Arsenic metabolism;	chr10:102869708	chr10:102914585~102915404:+
LGG	cis	rs7829975	0.714	rs4841040	ENSG00000173295.6	FAM86B3P	-10.91	6.82e-25	6.73e-22	-0.47	-0.45	Mood instability;	chr8:8797017	chr8:8228595~8244865:+
LGG	cis	rs11098499	0.644	rs28787668	ENSG00000249244.1	RP11-548H18.2	10.91	6.82e-25	6.74e-22	0.48	0.45	Corneal astigmatism;	chr4:119633532	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	10.91	6.85e-25	6.77e-22	0.55	0.45	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	10.91	6.86e-25	6.77e-22	0.56	0.45	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	10.91	6.86e-25	6.77e-22	0.56	0.45	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	10.91	6.86e-25	6.77e-22	0.56	0.45	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
LGG	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-10.91	6.86e-25	6.77e-22	-0.47	-0.45	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
LGG	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-10.91	6.89e-25	6.8e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
LGG	cis	rs5742933	0.803	rs1233302	ENSG00000273240.1	RP11-455J20.3	-10.91	6.92e-25	6.83e-22	-0.52	-0.45	Ferritin levels;	chr2:189804154	chr2:189763859~189764456:-
LGG	cis	rs8092443	0.938	rs8093268	ENSG00000278971.1	RP11-644A7.2	10.91	6.96e-25	6.87e-22	0.65	0.45	Response to antipsychotic treatment;	chr18:70491547	chr18:70489630~70491205:+
LGG	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-10.91	6.98e-25	6.89e-22	-0.47	-0.45	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
LGG	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	10.91	6.99e-25	6.9e-22	0.54	0.45	Height;	chr11:118856460	chr11:118688039~118690600:-
LGG	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	10.91	6.99e-25	6.9e-22	0.54	0.45	Height;	chr11:118856623	chr11:118688039~118690600:-
LGG	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	10.91	7.05e-25	6.96e-22	0.57	0.45	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
LGG	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-10.91	7.06e-25	6.97e-22	-0.68	-0.45	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
LGG	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-10.91	7.06e-25	6.97e-22	-0.68	-0.45	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
LGG	cis	rs11098499	0.644	rs7676296	ENSG00000249244.1	RP11-548H18.2	10.91	7.1e-25	7e-22	0.48	0.45	Corneal astigmatism;	chr4:119634532	chr4:119391831~119395335:-
LGG	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	10.91	7.14e-25	7.04e-22	0.56	0.45	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
LGG	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	10.91	7.17e-25	7.07e-22	0.47	0.45	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
LGG	cis	rs1061377	0.748	rs1964345	ENSG00000249685.1	RP11-360F5.3	10.91	7.19e-25	7.09e-22	0.52	0.45	Uric acid levels;	chr4:39104793	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.748	rs1964347	ENSG00000249685.1	RP11-360F5.3	10.91	7.19e-25	7.09e-22	0.52	0.45	Uric acid levels;	chr4:39104956	chr4:39133913~39135608:+
LGG	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	10.91	7.19e-25	7.09e-22	0.67	0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
LGG	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-10.91	7.22e-25	7.12e-22	-0.65	-0.45	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
LGG	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-10.91	7.22e-25	7.12e-22	-0.57	-0.45	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	10.91	7.29e-25	7.18e-22	0.55	0.45	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
LGG	cis	rs4373814	0.581	rs61084330	ENSG00000226083.4	SLC39A12-AS1	10.91	7.3e-25	7.19e-22	0.53	0.45	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18133719	chr10:18001786~18010562:-
LGG	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	10.91	7.34e-25	7.23e-22	0.55	0.45	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
LGG	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	10.91	7.37e-25	7.26e-22	0.58	0.45	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	10.91	7.37e-25	7.26e-22	0.58	0.45	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
LGG	cis	rs17345786	1	rs3762729	ENSG00000244119.1	PDCL3P4	10.91	7.38e-25	7.26e-22	0.38	0.45	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101712472~101713191:+
LGG	cis	rs17345786	1	rs73863360	ENSG00000244119.1	PDCL3P4	10.91	7.38e-25	7.26e-22	0.38	0.45	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101712472~101713191:+
LGG	cis	rs2739330	1	rs2739330	ENSG00000235689.1	AP000351.13	10.91	7.38e-25	7.27e-22	0.53	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:24006305~24008258:-
LGG	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	10.9	7.39e-25	7.28e-22	0.55	0.45	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	10.9	7.43e-25	7.32e-22	0.55	0.45	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	10.9	7.44e-25	7.33e-22	0.55	0.45	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	10.9	7.44e-25	7.33e-22	0.55	0.45	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
LGG	cis	rs4819052	1	rs13053002	ENSG00000223768.1	LINC00205	-10.9	7.48e-25	7.36e-22	-0.54	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45293285~45297354:+
LGG	cis	rs8064024	1	rs8064024	ENSG00000267077.1	RP11-127I20.5	-10.9	7.52e-25	7.4e-22	-0.43	-0.45	Cancer;	chr16:4805278	chr16:4795265~4796532:-
LGG	cis	rs4819052	1	rs4819052	ENSG00000215447.6	BX322557.10	-10.9	7.54e-25	7.42e-22	-0.39	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45288052~45291738:+
LGG	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
LGG	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-10.9	7.54e-25	7.42e-22	-0.36	-0.45	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
LGG	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-10.9	7.57e-25	7.44e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
LGG	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	10.9	7.61e-25	7.48e-22	0.55	0.45	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
LGG	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-10.9	7.64e-25	7.5e-22	-0.53	-0.45	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
LGG	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-10.9	7.64e-25	7.5e-22	-0.68	-0.45	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
LGG	cis	rs7267979	0.966	rs7270835	ENSG00000125804.12	FAM182A	-10.9	7.65e-25	7.52e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6115191	ENSG00000125804.12	FAM182A	-10.9	7.65e-25	7.52e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6107046	ENSG00000125804.12	FAM182A	-10.9	7.65e-25	7.52e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6107047	ENSG00000125804.12	FAM182A	-10.9	7.65e-25	7.52e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:26054655~26086917:+
LGG	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	10.9	7.67e-25	7.54e-22	0.63	0.45	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
LGG	cis	rs10759883	0.651	rs689860	ENSG00000175611.10	LINC00476	10.9	7.69e-25	7.56e-22	0.57	0.45	Nicotine dependence;	chr9:95886950	chr9:95759231~95875977:-
LGG	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-10.9	7.7e-25	7.56e-22	-0.51	-0.45	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
LGG	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-10.9	7.7e-25	7.56e-22	-0.5	-0.45	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
LGG	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	10.9	7.73e-25	7.59e-22	0.64	0.45	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	10.9	7.73e-25	7.59e-22	0.64	0.45	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	10.9	7.73e-25	7.59e-22	0.64	0.45	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	10.9	7.73e-25	7.59e-22	0.64	0.45	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
LGG	cis	rs7267979	1	rs2500443	ENSG00000125804.12	FAM182A	10.9	7.83e-25	7.69e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482928	ENSG00000125804.12	FAM182A	10.9	7.83e-25	7.69e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:26054655~26086917:+
LGG	cis	rs11148252	0.532	rs9536190	ENSG00000273784.3	RP11-78J21.7	-10.9	7.84e-25	7.7e-22	-0.53	-0.45	Lewy body disease;	chr13:52606909	chr13:52600042~52642542:+
LGG	cis	rs7267979	1	rs6515651	ENSG00000125804.12	FAM182A	10.9	7.87e-25	7.72e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2151144	ENSG00000125804.12	FAM182A	10.9	7.87e-25	7.72e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2424716	ENSG00000125804.12	FAM182A	-10.9	7.87e-25	7.72e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs761025	ENSG00000125804.12	FAM182A	-10.9	7.87e-25	7.72e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050631	ENSG00000125804.12	FAM182A	-10.9	7.87e-25	7.72e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:26054655~26086917:+
LGG	cis	rs7119038	0.629	rs10892271	ENSG00000255239.1	AP002954.6	-10.9	7.89e-25	7.74e-22	-0.61	-0.45	Sjögren's syndrome;	chr11:118727835	chr11:118688039~118690600:-
LGG	cis	rs7267979	0.932	rs6107052	ENSG00000125804.12	FAM182A	-10.9	7.91e-25	7.76e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:26054655~26086917:+
LGG	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	10.9	7.92e-25	7.77e-22	0.63	0.45	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
LGG	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	10.9	7.92e-25	7.77e-22	0.56	0.45	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	10.9	7.93e-25	7.78e-22	0.55	0.45	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-10.9	7.93e-25	7.79e-22	-0.55	-0.45	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
LGG	cis	rs7927771	0.832	rs7924485	ENSG00000280615.1	Y_RNA	10.9	7.99e-25	7.83e-22	0.56	0.45	Subjective well-being;	chr11:47397578	chr11:47614898~47614994:-
LGG	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	10.9	8.01e-25	7.85e-22	0.55	0.45	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
LGG	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-10.9	8.01e-25	7.86e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-10.9	8.01e-25	7.86e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	10.9	8.05e-25	7.89e-22	0.56	0.45	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
LGG	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-10.9	8.06e-25	7.9e-22	-0.62	-0.45	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
LGG	cis	rs5758511	0.68	rs1107554	ENSG00000227370.1	RP4-669P10.19	10.9	8.06e-25	7.9e-22	0.5	0.45	Birth weight;	chr22:42271588	chr22:42132543~42132998:+
LGG	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	10.89	8.1e-25	7.94e-22	0.64	0.45	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
LGG	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	10.89	8.12e-25	7.96e-22	0.59	0.45	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
LGG	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	10.89	8.12e-25	7.96e-22	0.53	0.45	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
LGG	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-10.89	8.14e-25	7.98e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
LGG	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	10.89	8.15e-25	7.99e-22	0.55	0.45	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
LGG	cis	rs1061377	0.748	rs1036033	ENSG00000249685.1	RP11-360F5.3	10.89	8.16e-25	8e-22	0.52	0.45	Uric acid levels;	chr4:39105295	chr4:39133913~39135608:+
LGG	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	10.89	8.17e-25	8e-22	0.64	0.45	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
LGG	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	10.89	8.17e-25	8.01e-22	0.52	0.45	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
LGG	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-10.89	8.18e-25	8.01e-22	-0.37	-0.45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
LGG	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	10.89	8.21e-25	8.04e-22	0.57	0.45	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
LGG	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
LGG	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	10.89	8.37e-25	8.19e-22	0.58	0.45	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
LGG	cis	rs1062177	0.502	rs10463321	ENSG00000253921.1	CTB-113P19.3	-10.89	8.38e-25	8.2e-22	-0.6	-0.45	Preschool internalizing problems;	chr5:151944344	chr5:151753992~151767247:+
LGG	cis	rs7829975	0.807	rs519019	ENSG00000173295.6	FAM86B3P	10.89	8.38e-25	8.2e-22	0.47	0.45	Mood instability;	chr8:8737594	chr8:8228595~8244865:+
LGG	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	10.89	8.39e-25	8.21e-22	0.32	0.45	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
LGG	cis	rs7829975	0.742	rs882462	ENSG00000173295.6	FAM86B3P	-10.89	8.39e-25	8.21e-22	-0.47	-0.45	Mood instability;	chr8:8821020	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	10.89	8.44e-25	8.25e-22	0.55	0.45	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	10.89	8.46e-25	8.27e-22	0.55	0.45	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	10.89	8.46e-25	8.27e-22	0.55	0.45	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	10.89	8.46e-25	8.27e-22	0.55	0.45	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	10.89	8.46e-25	8.27e-22	0.55	0.45	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
LGG	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	10.89	8.47e-25	8.28e-22	0.59	0.45	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
LGG	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	10.89	8.52e-25	8.33e-22	0.52	0.45	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
LGG	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	10.89	8.56e-25	8.37e-22	0.56	0.45	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
LGG	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-10.89	8.59e-25	8.39e-22	-0.32	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
LGG	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	10.89	8.62e-25	8.42e-22	0.49	0.45	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
LGG	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-10.89	8.63e-25	8.43e-22	-0.36	-0.45	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
LGG	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	10.89	8.65e-25	8.45e-22	0.58	0.45	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	10.89	8.65e-25	8.45e-22	0.58	0.45	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
LGG	cis	rs7267979	0.932	rs2387891	ENSG00000125804.12	FAM182A	-10.89	8.66e-25	8.45e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:26054655~26086917:+
LGG	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	10.89	8.66e-25	8.46e-22	0.57	0.45	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
LGG	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	10.89	8.71e-25	8.5e-22	0.51	0.45	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
LGG	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-10.89	8.71e-25	8.51e-22	-0.68	-0.45	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
LGG	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	10.89	8.74e-25	8.53e-22	0.53	0.45	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
LGG	cis	rs7267979	1	rs6083856	ENSG00000125804.12	FAM182A	10.89	8.74e-25	8.53e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482927	ENSG00000125804.12	FAM182A	10.89	8.76e-25	8.55e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6050611	ENSG00000125804.12	FAM182A	-10.88	8.82e-25	8.61e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:26054655~26086917:+
LGG	cis	rs5758511	0.633	rs5751258	ENSG00000227370.1	RP4-669P10.19	10.88	8.83e-25	8.61e-22	0.5	0.45	Birth weight;	chr22:42267865	chr22:42132543~42132998:+
LGG	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-10.88	8.85e-25	8.64e-22	-0.61	-0.45	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
LGG	cis	rs2581828	0.618	rs6777975	ENSG00000242142.1	SERBP1P3	-10.88	8.86e-25	8.64e-22	-0.51	-0.45	Crohn's disease;	chr3:53132119	chr3:53064283~53065091:-
LGG	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-10.88	8.86e-25	8.64e-22	-0.52	-0.45	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
LGG	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	10.88	8.86e-25	8.65e-22	0.39	0.45	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
LGG	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	10.88	8.89e-25	8.68e-22	0.52	0.45	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
LGG	cis	rs2274273	0.935	rs3818451	ENSG00000258413.1	RP11-665C16.6	-10.88	8.92e-25	8.7e-22	-0.57	-0.45	Protein biomarker;	chr14:55154398	chr14:55262767~55272075:-
LGG	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-10.88	8.96e-25	8.74e-22	-0.32	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-10.88	8.96e-25	8.74e-22	-0.32	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
LGG	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	10.88	8.98e-25	8.76e-22	0.57	0.45	QT interval;	chr16:28860645	chr16:28700294~28701540:-
LGG	cis	rs7267979	1	rs453329	ENSG00000125804.12	FAM182A	-10.88	8.98e-25	8.76e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:26054655~26086917:+
LGG	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-10.88	9e-25	8.77e-22	-0.51	-0.45	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
LGG	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-10.88	9e-25	8.78e-22	-0.68	-0.45	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
LGG	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-10.88	9.01e-25	8.78e-22	-0.75	-0.45	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
LGG	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-10.88	9.04e-25	8.81e-22	-0.64	-0.45	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
LGG	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-10.88	9.07e-25	8.84e-22	-0.54	-0.45	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
LGG	cis	rs9527	0.614	rs4919691	ENSG00000272912.1	RP11-724N1.1	-10.88	9.11e-25	8.88e-22	-0.51	-0.45	Arsenic metabolism;	chr10:102864718	chr10:102914585~102915404:+
LGG	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	10.88	9.11e-25	8.88e-22	0.64	0.45	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
LGG	cis	rs7267979	1	rs2500448	ENSG00000125804.12	FAM182A	10.88	9.14e-25	8.91e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:26054655~26086917:+
LGG	cis	rs6452524	0.868	rs1564379	ENSG00000248112.1	RP11-78C3.1	10.88	9.15e-25	8.92e-22	0.59	0.45	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	10.88	9.18e-25	8.94e-22	0.55	0.45	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
LGG	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	10.88	9.25e-25	9.01e-22	0.32	0.45	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	10.88	9.25e-25	9.01e-22	0.32	0.45	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-10.88	9.25e-25	9.01e-22	-0.32	-0.45	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-10.88	9.25e-25	9.01e-22	-0.32	-0.45	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-10.88	9.25e-25	9.01e-22	-0.32	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-10.88	9.25e-25	9.01e-22	-0.32	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
LGG	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-10.88	9.26e-25	9.01e-22	-0.52	-0.45	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
LGG	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-10.88	9.26e-25	9.02e-22	-0.56	-0.45	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
LGG	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	10.88	9.28e-25	9.04e-22	0.52	0.45	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
LGG	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	10.88	9.29e-25	9.05e-22	0.64	0.45	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
LGG	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-10.88	9.29e-25	9.05e-22	-0.53	-0.45	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
LGG	cis	rs7267979	1	rs1888999	ENSG00000125804.12	FAM182A	-10.88	9.33e-25	9.09e-22	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:26054655~26086917:+
LGG	cis	rs4819052	0.84	rs914217	ENSG00000215447.6	BX322557.10	-10.88	9.36e-25	9.12e-22	-0.38	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45288052~45291738:+
LGG	cis	rs741668	0.897	rs2274381	ENSG00000235903.6	CPB2-AS1	10.88	9.37e-25	9.12e-22	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:46052326	chr13:46052806~46113332:+
LGG	cis	rs7267979	1	rs2500436	ENSG00000125804.12	FAM182A	10.88	9.38e-25	9.13e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:26054655~26086917:+
LGG	cis	rs7829975	0.744	rs2409092	ENSG00000173295.6	FAM86B3P	-10.88	9.41e-25	9.16e-22	-0.47	-0.45	Mood instability;	chr8:8824682	chr8:8228595~8244865:+
LGG	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	10.88	9.54e-25	9.28e-22	0.52	0.45	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	10.88	9.54e-25	9.28e-22	0.52	0.45	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
LGG	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-10.88	9.57e-25	9.31e-22	-0.51	-0.45	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
LGG	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	10.88	9.59e-25	9.33e-22	0.46	0.45	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.644	rs34835603	ENSG00000249244.1	RP11-548H18.2	10.88	9.61e-25	9.35e-22	0.47	0.45	Corneal astigmatism;	chr4:119632273	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.615	rs28850368	ENSG00000249244.1	RP11-548H18.2	10.88	9.61e-25	9.35e-22	0.47	0.45	Corneal astigmatism;	chr4:119633158	chr4:119391831~119395335:-
LGG	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-10.87	9.65e-25	9.39e-22	-0.47	-0.45	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
LGG	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-10.87	9.65e-25	9.39e-22	-0.54	-0.45	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
LGG	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	10.87	9.68e-25	9.41e-22	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
LGG	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-10.87	9.69e-25	9.42e-22	-0.68	-0.45	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
LGG	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-10.87	9.69e-25	9.42e-22	-0.52	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
LGG	cis	rs30380	0.69	rs2042381	ENSG00000248734.2	CTD-2260A17.1	10.87	9.76e-25	9.49e-22	0.49	0.45	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96784777~96785999:+
LGG	cis	rs4819052	1	rs2838847	ENSG00000215447.6	BX322557.10	-10.87	9.76e-25	9.49e-22	-0.38	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.959	rs8130866	ENSG00000215447.6	BX322557.10	-10.87	9.76e-25	9.49e-22	-0.38	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45288052~45291738:+
LGG	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	10.87	9.87e-25	9.6e-22	0.62	0.45	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-10.87	9.88e-25	9.6e-22	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	10.87	9.89e-25	9.61e-22	0.55	0.45	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
LGG	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-10.87	9.94e-25	9.66e-22	-0.53	-0.45	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
LGG	cis	rs853679	0.527	rs9461443	ENSG00000226314.6	ZNF192P1	10.87	9.95e-25	9.66e-22	0.52	0.45	Depression;	chr6:28226851	chr6:28161781~28169594:+
LGG	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	10.87	1.01e-24	9.79e-22	0.66	0.45	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
LGG	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-10.87	1.01e-24	9.79e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
LGG	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	10.87	1.01e-24	9.79e-22	0.53	0.45	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
LGG	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-10.87	1.01e-24	9.8e-22	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
LGG	cis	rs2283792	0.812	rs5995269	ENSG00000228050.1	TOP3BP1	10.87	1.01e-24	9.81e-22	0.51	0.45	Multiple sclerosis;	chr22:21935025	chr22:22223187~22224566:-
LGG	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-10.87	1.01e-24	9.83e-22	-0.52	-0.45	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-10.87	1.01e-24	9.83e-22	-0.52	-0.45	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	10.87	1.02e-24	9.91e-22	0.55	0.45	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	10.87	1.02e-24	9.91e-22	0.55	0.45	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
LGG	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	10.87	1.03e-24	9.95e-22	0.59	0.45	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
LGG	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	10.87	1.03e-24	9.95e-22	0.55	0.45	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
LGG	cis	rs7267979	0.873	rs6083853	ENSG00000125804.12	FAM182A	10.87	1.03e-24	9.98e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.934	rs2482913	ENSG00000125804.12	FAM182A	10.87	1.03e-24	9.98e-22	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:26054655~26086917:+
LGG	cis	rs2287838	0.624	rs62105748	ENSG00000267289.1	CTD-2623N2.11	10.87	1.03e-24	1e-21	0.51	0.45	Sleep duration;	chr19:9840494	chr19:9834079~9835013:-
LGG	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	10.87	1.04e-24	1e-21	0.52	0.45	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
LGG	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	10.87	1.04e-24	1.01e-21	0.64	0.45	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	10.87	1.04e-24	1.01e-21	0.64	0.45	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	10.87	1.04e-24	1.01e-21	0.64	0.45	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
LGG	cis	rs9527	0.571	rs7096249	ENSG00000272912.1	RP11-724N1.1	-10.87	1.04e-24	1.01e-21	-0.51	-0.45	Arsenic metabolism;	chr10:102858767	chr10:102914585~102915404:+
LGG	cis	rs9527	0.571	rs10786715	ENSG00000272912.1	RP11-724N1.1	-10.87	1.04e-24	1.01e-21	-0.51	-0.45	Arsenic metabolism;	chr10:102860978	chr10:102914585~102915404:+
LGG	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-10.87	1.04e-24	1.01e-21	-0.51	-0.45	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.966	rs2482918	ENSG00000125804.12	FAM182A	10.87	1.04e-24	1.01e-21	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	10.87	1.05e-24	1.02e-21	0.55	0.45	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
LGG	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	10.87	1.05e-24	1.02e-21	0.33	0.45	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
LGG	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	10.87	1.05e-24	1.02e-21	0.58	0.45	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
LGG	cis	rs7267979	0.932	rs1985737	ENSG00000125804.12	FAM182A	-10.86	1.05e-24	1.02e-21	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:26054655~26086917:+
LGG	cis	rs5742933	0.75	rs10197331	ENSG00000273240.1	RP11-455J20.3	10.86	1.05e-24	1.02e-21	0.53	0.45	Ferritin levels;	chr2:189768112	chr2:189763859~189764456:-
LGG	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	10.86	1.05e-24	1.02e-21	0.52	0.45	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
LGG	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	10.86	1.06e-24	1.02e-21	0.58	0.45	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-10.86	1.06e-24	1.03e-21	-0.55	-0.45	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
LGG	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	10.86	1.06e-24	1.03e-21	0.58	0.45	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
LGG	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	10.86	1.07e-24	1.03e-21	0.32	0.45	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	10.86	1.07e-24	1.03e-21	0.32	0.45	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
LGG	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-10.86	1.07e-24	1.03e-21	-0.53	-0.45	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
LGG	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	10.86	1.07e-24	1.04e-21	0.58	0.45	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
LGG	cis	rs17345786	0.953	rs78645744	ENSG00000244119.1	PDCL3P4	10.86	1.08e-24	1.04e-21	0.38	0.45	Colonoscopy-negative controls vs population controls;	chr3:101608945	chr3:101712472~101713191:+
LGG	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	10.86	1.08e-24	1.04e-21	0.52	0.45	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
LGG	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-10.86	1.08e-24	1.04e-21	-0.56	-0.45	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
LGG	cis	rs7267979	1	rs6050559	ENSG00000125804.12	FAM182A	-10.86	1.08e-24	1.04e-21	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:26054655~26086917:+
LGG	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	10.86	1.08e-24	1.04e-21	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	10.86	1.08e-24	1.04e-21	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
LGG	cis	rs741668	0.931	rs17350833	ENSG00000235903.6	CPB2-AS1	10.86	1.09e-24	1.05e-21	0.5	0.45	Cerebrospinal fluid clusterin levels;	chr13:45963622	chr13:46052806~46113332:+
LGG	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-10.86	1.09e-24	1.05e-21	-0.68	-0.45	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
LGG	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	10.86	1.09e-24	1.06e-21	0.64	0.45	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-10.86	1.09e-24	1.06e-21	-0.67	-0.45	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
LGG	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-10.86	1.09e-24	1.06e-21	-0.49	-0.45	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
LGG	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	10.86	1.1e-24	1.06e-21	0.55	0.45	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	10.86	1.1e-24	1.06e-21	0.55	0.45	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
LGG	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-10.86	1.1e-24	1.07e-21	-0.64	-0.45	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
LGG	cis	rs5758511	0.634	rs1001587	ENSG00000227370.1	RP4-669P10.19	10.86	1.1e-24	1.07e-21	0.5	0.45	Birth weight;	chr22:42274105	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.68	rs5758688	ENSG00000227370.1	RP4-669P10.19	10.86	1.1e-24	1.07e-21	0.5	0.45	Birth weight;	chr22:42266495	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.689	rs5758691	ENSG00000227370.1	RP4-669P10.19	10.86	1.1e-24	1.07e-21	0.5	0.45	Birth weight;	chr22:42272498	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.68	rs739147	ENSG00000227370.1	RP4-669P10.19	10.86	1.1e-24	1.07e-21	0.5	0.45	Birth weight;	chr22:42275060	chr22:42132543~42132998:+
LGG	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-10.86	1.1e-24	1.07e-21	-0.53	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
LGG	cis	rs5742933	0.857	rs1233282	ENSG00000273240.1	RP11-455J20.3	-10.86	1.11e-24	1.07e-21	-0.52	-0.45	Ferritin levels;	chr2:189823518	chr2:189763859~189764456:-
LGG	cis	rs11233250	0.697	rs60491498	ENSG00000245832.5	RP11-179A16.1	10.86	1.11e-24	1.07e-21	0.68	0.45	Glioblastoma;Glioma;	chr11:82722728	chr11:81879851~82718082:-
LGG	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-10.86	1.11e-24	1.07e-21	-0.52	-0.45	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-10.86	1.13e-24	1.09e-21	-0.52	-0.45	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
LGG	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	10.86	1.13e-24	1.09e-21	0.36	0.45	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
LGG	cis	rs1150668	0.764	rs9368565	ENSG00000280107.1	AL022393.9	10.86	1.13e-24	1.09e-21	0.43	0.45	Pubertal anthropometrics;	chr6:28377433	chr6:28170845~28172521:+
LGG	cis	rs1150668	0.796	rs1052215	ENSG00000280107.1	AL022393.9	10.86	1.13e-24	1.09e-21	0.43	0.45	Pubertal anthropometrics;	chr6:28380381	chr6:28170845~28172521:+
LGG	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	10.86	1.13e-24	1.09e-21	0.39	0.45	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
LGG	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	10.86	1.13e-24	1.09e-21	0.32	0.45	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	10.86	1.13e-24	1.09e-21	0.32	0.45	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	10.86	1.13e-24	1.09e-21	0.32	0.45	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
LGG	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-10.86	1.14e-24	1.1e-21	-0.53	-0.45	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
LGG	cis	rs7267979	0.932	rs928121	ENSG00000125804.12	FAM182A	-10.86	1.14e-24	1.1e-21	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:26054655~26086917:+
LGG	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-10.85	1.15e-24	1.11e-21	-0.52	-0.45	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
LGG	cis	rs2013441	0.866	rs12947950	ENSG00000230528.6	NOS2P3	-10.85	1.16e-24	1.12e-21	-0.43	-0.45	Obesity-related traits;	chr17:20141863	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs10438824	ENSG00000230528.6	NOS2P3	-10.85	1.16e-24	1.12e-21	-0.43	-0.45	Obesity-related traits;	chr17:20155197	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs1009082	ENSG00000230528.6	NOS2P3	-10.85	1.16e-24	1.12e-21	-0.43	-0.45	Obesity-related traits;	chr17:20159646	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs2703797	ENSG00000230528.6	NOS2P3	10.85	1.16e-24	1.12e-21	0.43	0.45	Obesity-related traits;	chr17:20176988	chr17:20436337~20447249:+
LGG	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	10.85	1.16e-24	1.12e-21	0.79	0.45	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
LGG	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-10.85	1.16e-24	1.12e-21	-0.51	-0.45	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
LGG	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	10.85	1.17e-24	1.13e-21	0.56	0.45	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
LGG	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-10.85	1.17e-24	1.13e-21	-0.54	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
LGG	cis	rs8092443	0.938	rs11663206	ENSG00000278971.1	RP11-644A7.2	10.85	1.17e-24	1.13e-21	0.64	0.45	Response to antipsychotic treatment;	chr18:70486384	chr18:70489630~70491205:+
LGG	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	10.85	1.18e-24	1.13e-21	0.63	0.45	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
LGG	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-10.85	1.18e-24	1.14e-21	-0.76	-0.45	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
LGG	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-10.85	1.18e-24	1.14e-21	-0.51	-0.45	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
LGG	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-10.85	1.18e-24	1.14e-21	-0.52	-0.45	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
LGG	cis	rs7829975	0.774	rs1703982	ENSG00000173295.6	FAM86B3P	10.85	1.18e-24	1.14e-21	0.46	0.45	Mood instability;	chr8:8740878	chr8:8228595~8244865:+
LGG	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-10.85	1.19e-24	1.15e-21	-0.52	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-10.85	1.19e-24	1.15e-21	-0.52	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
LGG	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-10.85	1.19e-24	1.15e-21	-0.62	-0.45	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-10.85	1.19e-24	1.15e-21	-0.62	-0.45	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-10.85	1.19e-24	1.15e-21	-0.62	-0.45	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-10.85	1.19e-24	1.15e-21	-0.62	-0.45	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-10.85	1.19e-24	1.15e-21	-0.62	-0.45	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-10.85	1.19e-24	1.15e-21	-0.62	-0.45	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
LGG	cis	rs6421571	0.564	rs11216972	ENSG00000255239.1	AP002954.6	-10.85	1.19e-24	1.15e-21	-0.6	-0.45	Primary biliary cholangitis;	chr11:118715117	chr11:118688039~118690600:-
LGG	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-10.85	1.2e-24	1.16e-21	-0.54	-0.45	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
LGG	cis	rs4819052	1	rs9984901	ENSG00000215447.6	BX322557.10	-10.85	1.21e-24	1.17e-21	-0.38	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45288052~45291738:+
LGG	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-10.85	1.22e-24	1.17e-21	-0.52	-0.45	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-10.85	1.22e-24	1.18e-21	-0.52	-0.45	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-10.85	1.22e-24	1.18e-21	-0.52	-0.45	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-10.85	1.22e-24	1.18e-21	-0.52	-0.45	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
LGG	cis	rs7829975	0.774	rs11775523	ENSG00000173295.6	FAM86B3P	-10.85	1.22e-24	1.18e-21	-0.47	-0.45	Mood instability;	chr8:8821666	chr8:8228595~8244865:+
LGG	cis	rs1150668	0.796	rs9468372	ENSG00000218016.2	ZNF192P2	-10.85	1.23e-24	1.18e-21	-0.5	-0.45	Pubertal anthropometrics;	chr6:28411584	chr6:28188050~28189432:+
LGG	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-10.85	1.23e-24	1.18e-21	-0.52	-0.45	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
LGG	cis	rs2013441	0.835	rs2526491	ENSG00000230528.6	NOS2P3	10.85	1.23e-24	1.18e-21	0.43	0.45	Obesity-related traits;	chr17:20194149	chr17:20436337~20447249:+
LGG	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	10.85	1.23e-24	1.19e-21	0.55	0.45	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
LGG	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	10.85	1.24e-24	1.2e-21	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
LGG	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	10.84	1.26e-24	1.21e-21	0.56	0.45	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
LGG	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-10.84	1.26e-24	1.21e-21	-0.36	-0.45	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
LGG	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-10.84	1.26e-24	1.21e-21	-0.36	-0.45	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
LGG	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-10.84	1.26e-24	1.21e-21	-0.36	-0.45	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
LGG	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-10.84	1.27e-24	1.22e-21	-0.46	-0.45	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
LGG	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	10.84	1.28e-24	1.23e-21	0.58	0.45	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	10.84	1.28e-24	1.23e-21	0.58	0.45	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	10.84	1.28e-24	1.23e-21	0.58	0.45	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	10.84	1.28e-24	1.23e-21	0.58	0.45	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	10.84	1.28e-24	1.23e-21	0.58	0.45	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	10.84	1.28e-24	1.23e-21	0.58	0.45	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	10.84	1.28e-24	1.23e-21	0.58	0.45	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
LGG	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-10.84	1.28e-24	1.23e-21	-0.52	-0.45	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
LGG	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	10.84	1.29e-24	1.24e-21	0.54	0.45	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
LGG	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	10.84	1.29e-24	1.24e-21	0.54	0.45	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
LGG	cis	rs651907	0.557	rs13066768	ENSG00000256628.3	ZBTB11-AS1	-10.84	1.3e-24	1.25e-21	-0.51	-0.45	Colorectal cancer;	chr3:101768076	chr3:101676475~101679217:+
LGG	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	10.84	1.3e-24	1.25e-21	0.59	0.45	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
LGG	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	10.84	1.3e-24	1.25e-21	0.59	0.45	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
LGG	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	10.84	1.31e-24	1.25e-21	0.32	0.45	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
LGG	cis	rs7119038	0.629	rs11216993	ENSG00000255239.1	AP002954.6	-10.84	1.31e-24	1.25e-21	-0.62	-0.45	Sjögren's syndrome;	chr11:118732786	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	10.84	1.31e-24	1.26e-21	0.55	0.45	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	10.84	1.31e-24	1.26e-21	0.55	0.45	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
LGG	cis	rs7927771	0.826	rs7925389	ENSG00000280615.1	Y_RNA	-10.84	1.31e-24	1.26e-21	-0.56	-0.45	Subjective well-being;	chr11:47445238	chr11:47614898~47614994:-
LGG	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	10.84	1.32e-24	1.27e-21	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
LGG	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	10.84	1.32e-24	1.27e-21	0.54	0.45	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
LGG	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	10.84	1.32e-24	1.27e-21	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	10.84	1.32e-24	1.27e-21	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
LGG	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-10.84	1.33e-24	1.27e-21	-0.36	-0.45	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
LGG	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-10.84	1.33e-24	1.28e-21	-0.51	-0.45	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
LGG	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	10.84	1.33e-24	1.28e-21	0.32	0.45	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
LGG	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	10.84	1.34e-24	1.29e-21	0.55	0.45	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	10.84	1.34e-24	1.29e-21	0.55	0.45	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
LGG	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-10.84	1.35e-24	1.3e-21	-0.52	-0.45	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-10.84	1.35e-24	1.3e-21	-0.52	-0.45	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
LGG	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	10.84	1.35e-24	1.3e-21	0.63	0.45	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
LGG	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	10.84	1.35e-24	1.3e-21	0.6	0.45	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
LGG	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-10.84	1.36e-24	1.3e-21	-0.52	-0.45	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
LGG	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.3e-21	-0.52	-0.45	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
LGG	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	10.84	1.36e-24	1.3e-21	0.63	0.45	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
LGG	cis	rs7240205	0.593	rs113592062	ENSG00000275805.1	RP11-349H17.2	-10.84	1.36e-24	1.31e-21	-0.56	-0.45	Breast cancer;	chr18:26566829	chr18:26565723~26575626:-
LGG	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-10.84	1.36e-24	1.31e-21	-0.51	-0.45	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
LGG	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	10.83	1.37e-24	1.31e-21	0.61	0.45	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
LGG	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-10.83	1.37e-24	1.31e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-10.83	1.37e-24	1.31e-21	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
LGG	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	10.83	1.37e-24	1.31e-21	0.81	0.45	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
LGG	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-10.83	1.38e-24	1.32e-21	-0.54	-0.45	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
LGG	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	10.83	1.38e-24	1.32e-21	0.55	0.45	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
LGG	cis	rs7267979	1	rs7267979	ENSG00000125804.12	FAM182A	-10.83	1.38e-24	1.33e-21	-0.53	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:26054655~26086917:+
LGG	cis	rs2013441	0.866	rs2703813	ENSG00000230528.6	NOS2P3	10.83	1.39e-24	1.33e-21	0.43	0.45	Obesity-related traits;	chr17:20212002	chr17:20436337~20447249:+
LGG	cis	rs4713118	0.869	rs7773070	ENSG00000216901.1	AL022393.7	10.83	1.39e-24	1.33e-21	0.58	0.45	Parkinson's disease;	chr6:27761048	chr6:28176188~28176674:+
LGG	cis	rs7267979	1	rs4815404	ENSG00000125804.12	FAM182A	10.83	1.4e-24	1.34e-21	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6083805	ENSG00000125804.12	FAM182A	10.83	1.4e-24	1.34e-21	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050544	ENSG00000125804.12	FAM182A	10.83	1.4e-24	1.34e-21	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6037095	ENSG00000125804.12	FAM182A	10.83	1.4e-24	1.34e-21	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050562	ENSG00000125804.12	FAM182A	10.83	1.4e-24	1.34e-21	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:26054655~26086917:+
LGG	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	10.83	1.4e-24	1.34e-21	0.58	0.45	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
LGG	cis	rs853679	1	rs10456362	ENSG00000199851.2	U3	-10.83	1.4e-24	1.34e-21	-0.83	-0.45	Depression;	chr6:28254038	chr6:28015568~28015777:+
LGG	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	10.83	1.41e-24	1.35e-21	0.36	0.45	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
LGG	cis	rs7267979	0.966	rs4813557	ENSG00000125804.12	FAM182A	10.83	1.41e-24	1.35e-21	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	10.83	1.42e-24	1.36e-21	0.55	0.45	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
LGG	cis	rs7829975	0.774	rs57312668	ENSG00000173295.6	FAM86B3P	-10.83	1.44e-24	1.38e-21	-0.47	-0.45	Mood instability;	chr8:8822967	chr8:8228595~8244865:+
LGG	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-10.83	1.44e-24	1.38e-21	-0.61	-0.45	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
LGG	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	10.83	1.45e-24	1.38e-21	0.52	0.45	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
LGG	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	10.83	1.45e-24	1.39e-21	0.76	0.45	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
LGG	cis	rs8064024	0.783	rs2341986	ENSG00000267077.1	RP11-127I20.5	10.83	1.46e-24	1.39e-21	0.45	0.45	Cancer;	chr16:4769495	chr16:4795265~4796532:-
LGG	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-10.83	1.46e-24	1.4e-21	-0.52	-0.45	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	10.83	1.46e-24	1.4e-21	0.55	0.45	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
LGG	cis	rs7829975	0.774	rs1039915	ENSG00000173295.6	FAM86B3P	-10.83	1.47e-24	1.4e-21	-0.47	-0.45	Mood instability;	chr8:8822104	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	10.83	1.48e-24	1.42e-21	0.55	0.45	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
LGG	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	10.82	1.5e-24	1.43e-21	0.51	0.45	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
LGG	cis	rs4819052	1	rs3746980	ENSG00000223768.1	LINC00205	-10.82	1.5e-24	1.44e-21	-0.55	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45293285~45297354:+
LGG	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	10.82	1.51e-24	1.44e-21	0.81	0.45	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
LGG	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	10.82	1.51e-24	1.44e-21	0.31	0.45	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	10.82	1.51e-24	1.44e-21	0.31	0.45	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
LGG	cis	rs6519955	0.765	rs7292527	ENSG00000231711.2	LINC00899	-10.82	1.51e-24	1.44e-21	-0.56	-0.45	Dupuytren's disease;	chr22:46027245	chr22:46039907~46044853:-
LGG	cis	rs2013441	0.866	rs2526492	ENSG00000230528.6	NOS2P3	10.82	1.51e-24	1.44e-21	0.43	0.45	Obesity-related traits;	chr17:20192302	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs2703811	ENSG00000230528.6	NOS2P3	10.82	1.51e-24	1.44e-21	0.43	0.45	Obesity-related traits;	chr17:20210662	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs2526473	ENSG00000230528.6	NOS2P3	10.82	1.51e-24	1.44e-21	0.43	0.45	Obesity-related traits;	chr17:20234165	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs2703784	ENSG00000230528.6	NOS2P3	10.82	1.51e-24	1.44e-21	0.43	0.45	Obesity-related traits;	chr17:20248007	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs2526471	ENSG00000230528.6	NOS2P3	10.82	1.51e-24	1.44e-21	0.43	0.45	Obesity-related traits;	chr17:20248360	chr17:20436337~20447249:+
LGG	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-10.82	1.52e-24	1.45e-21	-0.52	-0.45	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
LGG	cis	rs1150668	0.796	rs2247002	ENSG00000218016.2	ZNF192P2	-10.82	1.52e-24	1.45e-21	-0.5	-0.45	Pubertal anthropometrics;	chr6:28430174	chr6:28188050~28189432:+
LGG	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	10.82	1.53e-24	1.46e-21	0.54	0.45	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	10.82	1.54e-24	1.47e-21	0.53	0.45	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
LGG	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	10.82	1.54e-24	1.47e-21	0.33	0.45	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
LGG	cis	rs7119038	0.509	rs10790261	ENSG00000255239.1	AP002954.6	10.82	1.55e-24	1.48e-21	0.61	0.45	Sjögren's syndrome;	chr11:118709038	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	10.82	1.55e-24	1.48e-21	0.55	0.45	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
LGG	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	10.82	1.55e-24	1.48e-21	0.36	0.45	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
LGG	cis	rs2013441	0.866	rs8070401	ENSG00000230528.6	NOS2P3	10.82	1.55e-24	1.48e-21	0.43	0.45	Obesity-related traits;	chr17:20311179	chr17:20436337~20447249:+
LGG	cis	rs651907	0.557	rs34181125	ENSG00000256628.3	ZBTB11-AS1	10.82	1.55e-24	1.48e-21	0.5	0.45	Colorectal cancer;	chr3:101771434	chr3:101676475~101679217:+
LGG	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-10.82	1.55e-24	1.48e-21	-0.67	-0.45	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
LGG	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-10.82	1.55e-24	1.48e-21	-0.53	-0.45	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
LGG	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	10.82	1.56e-24	1.49e-21	0.58	0.45	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	10.82	1.56e-24	1.49e-21	0.58	0.45	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
LGG	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	10.82	1.56e-24	1.49e-21	0.62	0.45	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
LGG	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	10.82	1.56e-24	1.49e-21	0.66	0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
LGG	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-10.82	1.56e-24	1.49e-21	-0.53	-0.45	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
LGG	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	10.82	1.57e-24	1.49e-21	0.32	0.45	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
LGG	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	10.82	1.57e-24	1.5e-21	0.63	0.45	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	10.82	1.57e-24	1.5e-21	0.63	0.45	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	10.82	1.57e-24	1.5e-21	0.63	0.45	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	10.82	1.57e-24	1.5e-21	0.63	0.45	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	10.82	1.57e-24	1.5e-21	0.63	0.45	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	10.82	1.57e-24	1.5e-21	0.63	0.45	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
LGG	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	10.82	1.58e-24	1.51e-21	0.61	0.44	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
LGG	cis	rs7927771	0.832	rs56030824	ENSG00000280615.1	Y_RNA	-10.82	1.59e-24	1.52e-21	-0.57	-0.44	Subjective well-being;	chr11:47375802	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.864	rs112060627	ENSG00000280615.1	Y_RNA	-10.82	1.6e-24	1.52e-21	-0.56	-0.44	Subjective well-being;	chr11:47405405	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.864	rs7107726	ENSG00000280615.1	Y_RNA	-10.82	1.6e-24	1.52e-21	-0.56	-0.44	Subjective well-being;	chr11:47407694	chr11:47614898~47614994:-
LGG	cis	rs11233250	0.697	rs59068249	ENSG00000245832.5	RP11-179A16.1	10.82	1.6e-24	1.52e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82707867	chr11:81879851~82718082:-
LGG	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-10.82	1.6e-24	1.52e-21	-0.61	-0.44	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
LGG	cis	rs7267979	1	rs1888997	ENSG00000125804.12	FAM182A	10.82	1.6e-24	1.53e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs3002698	ENSG00000125804.12	FAM182A	10.82	1.6e-24	1.53e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482930	ENSG00000125804.12	FAM182A	10.82	1.6e-24	1.53e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2500446	ENSG00000125804.12	FAM182A	10.82	1.6e-24	1.53e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:26054655~26086917:+
LGG	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-10.82	1.61e-24	1.53e-21	-0.52	-0.44	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
LGG	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-10.82	1.61e-24	1.53e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-10.82	1.61e-24	1.53e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	10.82	1.61e-24	1.53e-21	0.52	0.44	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
LGG	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-10.82	1.62e-24	1.54e-21	-0.6	-0.44	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
LGG	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	10.82	1.62e-24	1.54e-21	0.56	0.44	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
LGG	cis	rs11233250	0.697	rs55862501	ENSG00000245832.5	RP11-179A16.1	10.82	1.62e-24	1.54e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82720554	chr11:81879851~82718082:-
LGG	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-10.82	1.62e-24	1.55e-21	-0.51	-0.44	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	10.81	1.64e-24	1.56e-21	0.63	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
LGG	cis	rs4819052	1	rs13052356	ENSG00000223768.1	LINC00205	-10.81	1.64e-24	1.56e-21	-0.54	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45293285~45297354:+
LGG	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	10.81	1.64e-24	1.56e-21	0.63	0.44	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	10.81	1.64e-24	1.56e-21	0.63	0.44	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
LGG	cis	rs7119038	0.615	rs10892274	ENSG00000255239.1	AP002954.6	-10.81	1.65e-24	1.57e-21	-0.6	-0.44	Sjögren's syndrome;	chr11:118734754	chr11:118688039~118690600:-
LGG	cis	rs5742933	0.744	rs12693557	ENSG00000253559.1	OSGEPL1-AS1	10.81	1.65e-24	1.57e-21	0.53	0.44	Ferritin levels;	chr2:189726211	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.817	rs13035966	ENSG00000253559.1	OSGEPL1-AS1	10.81	1.65e-24	1.57e-21	0.53	0.44	Ferritin levels;	chr2:189726507	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	10.81	1.65e-24	1.57e-21	0.53	0.44	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
LGG	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.57e-21	-0.52	-0.44	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
LGG	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-10.81	1.66e-24	1.57e-21	-0.5	-0.44	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
LGG	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.58e-21	-0.52	-0.44	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-10.81	1.66e-24	1.58e-21	-0.52	-0.44	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
LGG	cis	rs1150668	0.796	rs728122	ENSG00000218016.2	ZNF192P2	-10.81	1.66e-24	1.58e-21	-0.5	-0.44	Pubertal anthropometrics;	chr6:28431347	chr6:28188050~28189432:+
LGG	cis	rs7246657	0.606	rs2972439	ENSG00000267422.1	CTD-2554C21.1	10.81	1.66e-24	1.58e-21	0.55	0.44	Coronary artery calcification;	chr19:37721680	chr19:37779686~37792865:+
LGG	cis	rs7246657	0.722	rs2909100	ENSG00000267422.1	CTD-2554C21.1	10.81	1.66e-24	1.58e-21	0.55	0.44	Coronary artery calcification;	chr19:37721779	chr19:37779686~37792865:+
LGG	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	10.81	1.66e-24	1.58e-21	0.5	0.44	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
LGG	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	10.81	1.67e-24	1.58e-21	0.64	0.44	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
LGG	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	10.81	1.67e-24	1.59e-21	0.32	0.44	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
LGG	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-10.81	1.67e-24	1.59e-21	-0.31	-0.44	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
LGG	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-10.81	1.68e-24	1.6e-21	-0.52	-0.44	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
LGG	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-10.81	1.69e-24	1.6e-21	-0.55	-0.44	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
LGG	cis	rs6519955	0.796	rs4072455	ENSG00000231711.2	LINC00899	10.81	1.7e-24	1.61e-21	0.55	0.44	Dupuytren's disease;	chr22:46027058	chr22:46039907~46044853:-
LGG	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-10.81	1.72e-24	1.63e-21	-0.46	-0.44	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
LGG	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	10.81	1.72e-24	1.63e-21	0.53	0.44	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
LGG	cis	rs7615952	0.546	rs2922194	ENSG00000242001.1	GS1-388B5.1	10.81	1.72e-24	1.63e-21	0.64	0.44	Blood pressure (smoking interaction);	chr3:125613419	chr3:125681305~125681453:+
LGG	cis	rs4819052	1	rs733739	ENSG00000215447.6	BX322557.10	-10.81	1.73e-24	1.64e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45288052~45291738:+
LGG	cis	rs4819052	1	rs4818769	ENSG00000215447.6	BX322557.10	-10.81	1.73e-24	1.64e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45288052~45291738:+
LGG	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	10.81	1.73e-24	1.64e-21	0.31	0.44	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
LGG	cis	rs2013441	0.761	rs2526468	ENSG00000230528.6	NOS2P3	10.81	1.73e-24	1.64e-21	0.43	0.44	Obesity-related traits;	chr17:20259759	chr17:20436337~20447249:+
LGG	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-10.81	1.74e-24	1.65e-21	-0.76	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
LGG	cis	rs7267979	1	rs7018	ENSG00000125804.12	FAM182A	-10.81	1.74e-24	1.65e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4815408	ENSG00000125804.12	FAM182A	10.81	1.74e-24	1.65e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050566	ENSG00000125804.12	FAM182A	10.81	1.74e-24	1.65e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4813563	ENSG00000125804.12	FAM182A	10.81	1.74e-24	1.65e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6037103	ENSG00000125804.12	FAM182A	10.81	1.74e-24	1.65e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4815424	ENSG00000125804.12	FAM182A	10.81	1.74e-24	1.65e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:26054655~26086917:+
LGG	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-10.81	1.74e-24	1.65e-21	-0.36	-0.44	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
LGG	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-10.81	1.74e-24	1.65e-21	-0.36	-0.44	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
LGG	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-10.81	1.74e-24	1.65e-21	-0.36	-0.44	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-10.81	1.74e-24	1.65e-21	-0.36	-0.44	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
LGG	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-10.81	1.74e-24	1.65e-21	-0.46	-0.44	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
LGG	cis	rs7914558	0.966	rs3902934	ENSG00000272912.1	RP11-724N1.1	-10.81	1.74e-24	1.65e-21	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102914585~102915404:+
LGG	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-10.81	1.75e-24	1.65e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-10.81	1.75e-24	1.65e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-10.81	1.75e-24	1.65e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-10.81	1.75e-24	1.65e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
LGG	cis	rs2287838	0.638	rs62105751	ENSG00000267289.1	CTD-2623N2.11	10.81	1.75e-24	1.66e-21	0.51	0.44	Sleep duration;	chr19:9847213	chr19:9834079~9835013:-
LGG	cis	rs7829975	0.84	rs555617	ENSG00000173295.6	FAM86B3P	10.81	1.75e-24	1.66e-21	0.46	0.44	Mood instability;	chr8:8735335	chr8:8228595~8244865:+
LGG	cis	rs651907	0.557	rs11710533	ENSG00000256628.3	ZBTB11-AS1	10.81	1.75e-24	1.66e-21	0.52	0.44	Colorectal cancer;	chr3:101632628	chr3:101676475~101679217:+
LGG	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-10.81	1.75e-24	1.66e-21	-0.51	-0.44	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-10.81	1.76e-24	1.66e-21	-0.52	-0.44	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
LGG	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	10.81	1.77e-24	1.68e-21	0.5	0.44	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
LGG	cis	rs7267979	0.966	rs2500433	ENSG00000125804.12	FAM182A	10.8	1.78e-24	1.68e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2482948	ENSG00000125804.12	FAM182A	10.8	1.78e-24	1.68e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:26054655~26086917:+
LGG	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-10.8	1.78e-24	1.69e-21	-0.52	-0.44	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-10.8	1.78e-24	1.69e-21	-0.52	-0.44	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
LGG	cis	rs8064024	0.56	rs741769	ENSG00000267077.1	RP11-127I20.5	10.8	1.78e-24	1.69e-21	0.47	0.44	Cancer;	chr16:4886204	chr16:4795265~4796532:-
LGG	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-10.8	1.79e-24	1.69e-21	-0.58	-0.44	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
LGG	cis	rs7267979	1	rs2482919	ENSG00000125804.12	FAM182A	10.8	1.79e-24	1.69e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6037086	ENSG00000125804.12	FAM182A	10.8	1.79e-24	1.69e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482931	ENSG00000125804.12	FAM182A	10.8	1.79e-24	1.69e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:26054655~26086917:+
LGG	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-10.8	1.79e-24	1.69e-21	-0.52	-0.44	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
LGG	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-10.8	1.8e-24	1.7e-21	-0.36	-0.44	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	10.8	1.8e-24	1.7e-21	0.36	0.44	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
LGG	cis	rs172166	0.61	rs156737	ENSG00000280107.1	AL022393.9	-10.8	1.81e-24	1.71e-21	-0.44	-0.44	Cardiac Troponin-T levels;	chr6:27927435	chr6:28170845~28172521:+
LGG	cis	rs7267979	1	rs4815407	ENSG00000125804.12	FAM182A	10.8	1.81e-24	1.71e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:26054655~26086917:+
LGG	cis	rs5758511	0.68	rs56111723	ENSG00000227370.1	RP4-669P10.19	10.8	1.82e-24	1.73e-21	0.49	0.44	Birth weight;	chr22:42268877	chr22:42132543~42132998:+
LGG	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-10.8	1.83e-24	1.73e-21	-0.56	-0.44	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
LGG	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	10.8	1.85e-24	1.75e-21	0.78	0.44	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
LGG	cis	rs657075	0.697	rs78003854	ENSG00000233006.5	AC034220.3	-10.8	1.86e-24	1.76e-21	-0.7	-0.44	Rheumatoid arthritis;	chr5:132424697	chr5:132311285~132369916:-
LGG	cis	rs657075	0.697	rs34362950	ENSG00000233006.5	AC034220.3	-10.8	1.86e-24	1.76e-21	-0.7	-0.44	Rheumatoid arthritis;	chr5:132430811	chr5:132311285~132369916:-
LGG	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-10.8	1.86e-24	1.76e-21	-0.35	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	10.8	1.87e-24	1.76e-21	0.54	0.44	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	10.8	1.87e-24	1.76e-21	0.54	0.44	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	10.8	1.87e-24	1.76e-21	0.55	0.44	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
LGG	cis	rs7267979	1	rs6107045	ENSG00000125804.12	FAM182A	-10.8	1.87e-24	1.77e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:26054655~26086917:+
LGG	cis	rs5742933	0.857	rs1233284	ENSG00000273240.1	RP11-455J20.3	-10.8	1.87e-24	1.77e-21	-0.52	-0.44	Ferritin levels;	chr2:189825045	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.817	rs1233288	ENSG00000273240.1	RP11-455J20.3	-10.8	1.87e-24	1.77e-21	-0.52	-0.44	Ferritin levels;	chr2:189825999	chr2:189763859~189764456:-
LGG	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	10.8	1.88e-24	1.77e-21	0.32	0.44	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
LGG	cis	rs7267979	0.966	rs2482923	ENSG00000125804.12	FAM182A	10.8	1.88e-24	1.78e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2500424	ENSG00000125804.12	FAM182A	10.8	1.89e-24	1.78e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:26054655~26086917:+
LGG	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	10.8	1.89e-24	1.78e-21	0.62	0.44	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
LGG	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-10.8	1.9e-24	1.79e-21	-0.58	-0.44	QT interval;	chr16:28877088	chr16:28700294~28701540:-
LGG	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	10.8	1.9e-24	1.8e-21	0.52	0.44	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
LGG	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	10.8	1.91e-24	1.81e-21	0.67	0.44	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	10.8	1.91e-24	1.81e-21	0.67	0.44	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
LGG	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	10.8	1.92e-24	1.81e-21	0.52	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
LGG	cis	rs7267979	1	rs2424710	ENSG00000125804.12	FAM182A	-10.8	1.92e-24	1.81e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6115140	ENSG00000125804.12	FAM182A	-10.8	1.92e-24	1.81e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482937	ENSG00000125804.12	FAM182A	10.8	1.92e-24	1.81e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2263204	ENSG00000125804.12	FAM182A	10.8	1.92e-24	1.81e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2500417	ENSG00000125804.12	FAM182A	10.8	1.92e-24	1.81e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482911	ENSG00000125804.12	FAM182A	10.8	1.92e-24	1.81e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:26054655~26086917:+
LGG	cis	rs5742933	0.857	rs12471217	ENSG00000253559.1	OSGEPL1-AS1	10.8	1.92e-24	1.81e-21	0.53	0.44	Ferritin levels;	chr2:189707337	chr2:189762704~189765556:+
LGG	cis	rs4683346	0.702	rs4682863	ENSG00000273328.4	RP11-141M3.6	-10.8	1.93e-24	1.82e-21	-0.5	-0.44	Granulocyte percentage of myeloid white cells;	chr3:42836219	chr3:42809414~42908105:+
LGG	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-10.8	1.93e-24	1.83e-21	-0.53	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-10.8	1.93e-24	1.83e-21	-0.53	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
LGG	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	10.79	1.94e-24	1.83e-21	0.36	0.44	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	10.79	1.94e-24	1.83e-21	0.36	0.44	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	10.79	1.94e-24	1.83e-21	0.36	0.44	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	10.79	1.94e-24	1.83e-21	0.36	0.44	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
LGG	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	10.79	1.94e-24	1.83e-21	0.36	0.44	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
LGG	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
LGG	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-10.79	1.94e-24	1.83e-21	-0.36	-0.44	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
LGG	cis	rs741668	0.931	rs12431359	ENSG00000235903.6	CPB2-AS1	10.79	1.95e-24	1.84e-21	0.51	0.44	Cerebrospinal fluid clusterin levels;	chr13:45972048	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	10.79	1.97e-24	1.86e-21	0.67	0.44	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
LGG	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-10.79	1.97e-24	1.86e-21	-0.66	-0.44	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
LGG	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	10.79	1.97e-24	1.86e-21	0.62	0.44	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
LGG	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	10.79	1.98e-24	1.87e-21	0.58	0.44	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	10.79	1.98e-24	1.87e-21	0.67	0.44	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
LGG	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-10.79	1.98e-24	1.87e-21	-0.58	-0.44	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
LGG	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	10.79	1.99e-24	1.88e-21	0.58	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
LGG	cis	rs7267979	0.934	rs2500399	ENSG00000125804.12	FAM182A	10.79	1.99e-24	1.88e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:26054655~26086917:+
LGG	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-10.79	1.99e-24	1.88e-21	-0.51	-0.44	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
LGG	cis	rs8092443	0.687	rs2366385	ENSG00000278971.1	RP11-644A7.2	10.79	2.01e-24	1.9e-21	0.64	0.44	Response to antipsychotic treatment;	chr18:70487988	chr18:70489630~70491205:+
LGG	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-10.79	2.02e-24	1.9e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-10.79	2.02e-24	1.9e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
LGG	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-10.79	2.02e-24	1.91e-21	-0.51	-0.44	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
LGG	cis	rs1150668	0.796	rs213237	ENSG00000218016.2	ZNF192P2	-10.79	2.03e-24	1.91e-21	-0.5	-0.44	Pubertal anthropometrics;	chr6:28356161	chr6:28188050~28189432:+
LGG	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-10.79	2.05e-24	1.93e-21	-0.52	-0.44	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
LGG	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-10.79	2.06e-24	1.94e-21	-0.59	-0.44	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
LGG	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	10.79	2.06e-24	1.94e-21	0.64	0.44	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
LGG	cis	rs1150668	0.796	rs1005125	ENSG00000226314.6	ZNF192P1	10.79	2.06e-24	1.94e-21	0.42	0.44	Pubertal anthropometrics;	chr6:28399578	chr6:28161781~28169594:+
LGG	cis	rs17345786	0.817	rs11720560	ENSG00000244119.1	PDCL3P4	10.79	2.08e-24	1.96e-21	0.38	0.44	Colonoscopy-negative controls vs population controls;	chr3:101609640	chr3:101712472~101713191:+
LGG	cis	rs2013441	0.866	rs9898295	ENSG00000230528.6	NOS2P3	10.79	2.09e-24	1.96e-21	0.43	0.44	Obesity-related traits;	chr17:20217281	chr17:20436337~20447249:+
LGG	cis	rs482329	1	rs482329	ENSG00000228044.2	RP4-781K5.4	10.79	2.09e-24	1.96e-21	0.51	0.44	Life threatening arrhythmia;	chr1:234680808	chr1:234646289~234683176:+
LGG	cis	rs7267979	1	rs884613	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs1888998	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482940	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2027003	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2027004	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2500404	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2500405	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2482941	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.903	rs2500423	ENSG00000125804.12	FAM182A	10.79	2.1e-24	1.97e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.933	rs2424708	ENSG00000125804.12	FAM182A	-10.79	2.1e-24	1.97e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:26054655~26086917:+
LGG	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-10.79	2.1e-24	1.97e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
LGG	cis	rs7546	0.504	rs2075637	ENSG00000267077.1	RP11-127I20.5	-10.79	2.11e-24	1.98e-21	-0.45	-0.44	Cancer;	chr16:4888279	chr16:4795265~4796532:-
LGG	cis	rs7546	0.504	rs2075636	ENSG00000267077.1	RP11-127I20.5	-10.79	2.11e-24	1.98e-21	-0.45	-0.44	Cancer;	chr16:4888320	chr16:4795265~4796532:-
LGG	cis	rs6496932	0.663	rs4843051	ENSG00000218052.5	ADAMTS7P4	-10.79	2.11e-24	1.98e-21	-0.62	-0.44	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85255369~85330334:-
LGG	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-10.79	2.11e-24	1.99e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
LGG	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	10.78	2.12e-24	1.99e-21	0.31	0.44	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	10.78	2.12e-24	1.99e-21	0.31	0.44	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	10.78	2.12e-24	1.99e-21	0.31	0.44	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	10.78	2.12e-24	1.99e-21	0.31	0.44	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	10.78	2.12e-24	1.99e-21	0.31	0.44	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
LGG	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-10.78	2.12e-24	1.99e-21	-0.36	-0.44	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
LGG	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	10.78	2.14e-24	2.01e-21	0.52	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
LGG	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-10.78	2.14e-24	2.01e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
LGG	cis	rs5742933	0.857	rs11685425	ENSG00000253559.1	OSGEPL1-AS1	10.78	2.15e-24	2.02e-21	0.54	0.44	Ferritin levels;	chr2:189747977	chr2:189762704~189765556:+
LGG	cis	rs5758511	0.633	rs5758690	ENSG00000227370.1	RP4-669P10.19	10.78	2.15e-24	2.02e-21	0.5	0.44	Birth weight;	chr22:42272289	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.633	rs5758689	ENSG00000227370.1	RP4-669P10.19	10.78	2.15e-24	2.02e-21	0.5	0.44	Birth weight;	chr22:42268966	chr22:42132543~42132998:+
LGG	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-10.78	2.16e-24	2.03e-21	-0.51	-0.44	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
LGG	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-10.78	2.16e-24	2.03e-21	-0.46	-0.44	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
LGG	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	10.78	2.17e-24	2.03e-21	0.46	0.44	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	10.78	2.17e-24	2.04e-21	0.57	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
LGG	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	10.78	2.18e-24	2.04e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
LGG	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	10.78	2.18e-24	2.04e-21	0.76	0.44	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
LGG	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-10.78	2.18e-24	2.05e-21	-0.57	-0.44	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
LGG	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-10.78	2.19e-24	2.05e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
LGG	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	10.78	2.21e-24	2.07e-21	0.63	0.44	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
LGG	cis	rs5758511	0.68	rs5758692	ENSG00000227370.1	RP4-669P10.19	10.78	2.21e-24	2.07e-21	0.5	0.44	Birth weight;	chr22:42273023	chr22:42132543~42132998:+
LGG	cis	rs67340775	0.541	rs200968	ENSG00000216901.1	AL022393.7	10.78	2.21e-24	2.08e-21	0.74	0.44	Lung cancer in ever smokers;	chr6:27891790	chr6:28176188~28176674:+
LGG	cis	rs950027	0.967	rs2486280	ENSG00000259520.4	CTD-2651B20.3	-10.78	2.22e-24	2.08e-21	-0.57	-0.44	Response to fenofibrate (adiponectin levels);	chr15:45459691	chr15:45251580~45279251:-
LGG	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-10.78	2.23e-24	2.09e-21	-0.52	-0.44	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-10.78	2.23e-24	2.09e-21	-0.52	-0.44	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-10.78	2.23e-24	2.09e-21	-0.52	-0.44	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
LGG	cis	rs2287838	0.638	rs55832059	ENSG00000267289.1	CTD-2623N2.11	10.78	2.23e-24	2.09e-21	0.51	0.44	Sleep duration;	chr19:9845000	chr19:9834079~9835013:-
LGG	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	10.78	2.24e-24	2.1e-21	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
LGG	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	10.78	2.27e-24	2.13e-21	0.54	0.44	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
LGG	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	-10.78	2.27e-24	2.13e-21	-0.47	-0.44	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
LGG	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-10.78	2.3e-24	2.16e-21	-0.61	-0.44	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
LGG	cis	rs4819052	1	rs2838830	ENSG00000215447.6	BX322557.10	-10.77	2.31e-24	2.17e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45288052~45291738:+
LGG	cis	rs741668	0.897	rs56223000	ENSG00000235903.6	CPB2-AS1	10.77	2.32e-24	2.17e-21	0.5	0.44	Cerebrospinal fluid clusterin levels;	chr13:46028500	chr13:46052806~46113332:+
LGG	cis	rs4713118	0.591	rs2056924	ENSG00000199851.2	U3	10.77	2.32e-24	2.17e-21	0.61	0.44	Parkinson's disease;	chr6:27722395	chr6:28015568~28015777:+
LGG	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-10.77	2.32e-24	2.18e-21	-0.59	-0.44	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
LGG	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-10.77	2.33e-24	2.18e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
LGG	cis	rs7927771	0.864	rs4752838	ENSG00000280615.1	Y_RNA	-10.77	2.33e-24	2.18e-21	-0.56	-0.44	Subjective well-being;	chr11:47444454	chr11:47614898~47614994:-
LGG	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	-10.77	2.36e-24	2.21e-21	-0.47	-0.44	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	10.77	2.39e-24	2.23e-21	0.54	0.44	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
LGG	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	10.77	2.4e-24	2.25e-21	0.55	0.44	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
LGG	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	10.77	2.4e-24	2.25e-21	0.55	0.44	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
LGG	cis	rs4819052	1	rs2297285	ENSG00000215447.6	BX322557.10	10.77	2.41e-24	2.25e-21	0.39	0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45288052~45291738:+
LGG	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	10.77	2.42e-24	2.26e-21	0.63	0.44	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
LGG	cis	rs7927771	0.8	rs11039200	ENSG00000280615.1	Y_RNA	-10.77	2.42e-24	2.26e-21	-0.57	-0.44	Subjective well-being;	chr11:47358095	chr11:47614898~47614994:-
LGG	cis	rs916888	0.61	rs199530	ENSG00000232300.1	FAM215B	-10.77	2.42e-24	2.27e-21	-0.56	-0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46558830~46562795:-
LGG	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-10.77	2.43e-24	2.27e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-10.77	2.43e-24	2.27e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-10.77	2.43e-24	2.27e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-10.77	2.43e-24	2.27e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-10.77	2.43e-24	2.27e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
LGG	cis	rs651907	0.535	rs36060163	ENSG00000256628.3	ZBTB11-AS1	10.77	2.43e-24	2.27e-21	0.51	0.44	Colorectal cancer;	chr3:101642119	chr3:101676475~101679217:+
LGG	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-10.77	2.44e-24	2.28e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
LGG	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-10.77	2.44e-24	2.28e-21	-0.35	-0.44	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-10.77	2.44e-24	2.28e-21	-0.35	-0.44	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-10.77	2.44e-24	2.28e-21	-0.35	-0.44	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-10.77	2.44e-24	2.28e-21	-0.35	-0.44	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
LGG	cis	rs4683346	0.656	rs11129979	ENSG00000273328.4	RP11-141M3.6	-10.77	2.45e-24	2.29e-21	-0.5	-0.44	Granulocyte percentage of myeloid white cells;	chr3:42849239	chr3:42809414~42908105:+
LGG	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-10.77	2.46e-24	2.29e-21	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
LGG	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-10.77	2.46e-24	2.3e-21	-0.51	-0.44	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	10.77	2.46e-24	2.3e-21	0.68	0.44	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
LGG	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-10.77	2.47e-24	2.31e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
LGG	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-10.77	2.47e-24	2.31e-21	-0.52	-0.44	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
LGG	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	10.77	2.47e-24	2.31e-21	0.52	0.44	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
LGG	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-10.77	2.49e-24	2.32e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
LGG	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	10.77	2.49e-24	2.32e-21	0.53	0.44	Height;	chr11:118854014	chr11:118688039~118690600:-
LGG	cis	rs7927771	0.832	rs4992357	ENSG00000280615.1	Y_RNA	-10.77	2.49e-24	2.32e-21	-0.55	-0.44	Subjective well-being;	chr11:47372087	chr11:47614898~47614994:-
LGG	cis	rs1150668	0.796	rs1124132	ENSG00000280107.1	AL022393.9	-10.77	2.5e-24	2.33e-21	-0.43	-0.44	Pubertal anthropometrics;	chr6:28412544	chr6:28170845~28172521:+
LGG	cis	rs1150668	0.796	rs2531832	ENSG00000280107.1	AL022393.9	-10.77	2.5e-24	2.33e-21	-0.43	-0.44	Pubertal anthropometrics;	chr6:28421445	chr6:28170845~28172521:+
LGG	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	10.77	2.51e-24	2.34e-21	0.53	0.44	Height;	chr11:118855233	chr11:118688039~118690600:-
LGG	cis	rs7267979	1	rs2500418	ENSG00000125804.12	FAM182A	10.76	2.52e-24	2.35e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:26054655~26086917:+
LGG	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-10.76	2.53e-24	2.35e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
LGG	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-10.76	2.53e-24	2.36e-21	-0.52	-0.44	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
LGG	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	10.76	2.54e-24	2.36e-21	0.52	0.44	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
LGG	cis	rs7914558	1	rs1890184	ENSG00000272912.1	RP11-724N1.1	-10.76	2.57e-24	2.39e-21	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102914585~102915404:+
LGG	cis	rs651907	0.535	rs11919389	ENSG00000256628.3	ZBTB11-AS1	10.76	2.57e-24	2.39e-21	0.5	0.44	Colorectal cancer;	chr3:101705614	chr3:101676475~101679217:+
LGG	cis	rs1150668	0.83	rs2023493	ENSG00000280107.1	AL022393.9	-10.76	2.57e-24	2.39e-21	-0.42	-0.44	Pubertal anthropometrics;	chr6:28432385	chr6:28170845~28172521:+
LGG	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	10.76	2.57e-24	2.39e-21	0.53	0.44	Height;	chr11:118855938	chr11:118688039~118690600:-
LGG	cis	rs2013441	0.866	rs2703773	ENSG00000230528.6	NOS2P3	10.76	2.57e-24	2.4e-21	0.43	0.44	Obesity-related traits;	chr17:20228501	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs2526470	ENSG00000230528.6	NOS2P3	10.76	2.57e-24	2.4e-21	0.43	0.44	Obesity-related traits;	chr17:20256957	chr17:20436337~20447249:+
LGG	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-10.76	2.58e-24	2.4e-21	-0.48	-0.44	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
LGG	cis	rs5742933	0.857	rs1233291	ENSG00000273240.1	RP11-455J20.3	-10.76	2.58e-24	2.4e-21	-0.52	-0.44	Ferritin levels;	chr2:189826225	chr2:189763859~189764456:-
LGG	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	10.76	2.59e-24	2.41e-21	0.62	0.44	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
LGG	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-10.76	2.59e-24	2.41e-21	-0.52	-0.44	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
LGG	cis	rs4373814	0.737	rs10828269	ENSG00000226083.4	SLC39A12-AS1	10.76	2.59e-24	2.41e-21	0.45	0.44	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18149643	chr10:18001786~18010562:-
LGG	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-10.76	2.59e-24	2.41e-21	-0.52	-0.44	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
LGG	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-10.76	2.6e-24	2.42e-21	-0.46	-0.44	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-10.76	2.6e-24	2.42e-21	-0.46	-0.44	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
LGG	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-10.76	2.6e-24	2.42e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
LGG	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-10.76	2.62e-24	2.43e-21	-0.56	-0.44	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
LGG	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-10.76	2.62e-24	2.44e-21	-0.52	-0.44	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-10.76	2.62e-24	2.44e-21	-0.52	-0.44	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-10.76	2.62e-24	2.44e-21	-0.52	-0.44	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
LGG	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-10.76	2.64e-24	2.45e-21	-0.52	-0.44	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
LGG	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-10.76	2.67e-24	2.48e-21	-0.51	-0.44	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
LGG	cis	rs4819052	1	rs9306123	ENSG00000215447.6	BX322557.10	-10.76	2.67e-24	2.48e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45288052~45291738:+
LGG	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	10.76	2.67e-24	2.48e-21	0.63	0.44	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
LGG	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
LGG	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-10.76	2.68e-24	2.49e-21	-0.36	-0.44	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
LGG	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	10.76	2.68e-24	2.49e-21	0.36	0.44	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	10.76	2.68e-24	2.49e-21	0.36	0.44	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	10.76	2.68e-24	2.49e-21	0.36	0.44	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
LGG	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-10.76	2.7e-24	2.51e-21	-0.62	-0.44	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
LGG	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-10.76	2.7e-24	2.51e-21	-0.97	-0.44	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
LGG	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-10.76	2.72e-24	2.53e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
LGG	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-10.76	2.74e-24	2.54e-21	-0.46	-0.44	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
LGG	cis	rs8062405	0.789	rs240704	ENSG00000251417.2	RP11-1348G14.4	-10.76	2.74e-24	2.54e-21	-0.51	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28802743~28817828:+
LGG	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	10.75	2.75e-24	2.56e-21	0.36	0.44	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
LGG	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-10.75	2.75e-24	2.56e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-10.75	2.75e-24	2.56e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
LGG	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	10.75	2.76e-24	2.56e-21	0.54	0.44	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
LGG	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-10.75	2.77e-24	2.57e-21	-0.48	-0.44	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
LGG	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	10.75	2.77e-24	2.57e-21	0.52	0.44	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
LGG	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-10.75	2.79e-24	2.59e-21	-0.62	-0.44	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
LGG	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-10.75	2.79e-24	2.59e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
LGG	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	10.75	2.79e-24	2.59e-21	0.46	0.44	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
LGG	cis	rs950027	0.815	rs1153835	ENSG00000259520.4	CTD-2651B20.3	-10.75	2.8e-24	2.6e-21	-0.58	-0.44	Response to fenofibrate (adiponectin levels);	chr15:45456409	chr15:45251580~45279251:-
LGG	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	10.75	2.82e-24	2.61e-21	0.32	0.44	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
LGG	cis	rs17345786	1	rs55641278	ENSG00000244119.1	PDCL3P4	10.75	2.83e-24	2.62e-21	0.38	0.44	Colonoscopy-negative controls vs population controls;	chr3:101571733	chr3:101712472~101713191:+
LGG	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-10.75	2.84e-24	2.63e-21	-0.52	-0.44	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
LGG	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-10.75	2.84e-24	2.63e-21	-0.46	-0.44	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
LGG	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-10.75	2.85e-24	2.64e-21	-0.46	-0.44	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
LGG	cis	rs11233250	0.697	rs2888789	ENSG00000245832.5	RP11-179A16.1	10.75	2.86e-24	2.65e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82719127	chr11:81879851~82718082:-
LGG	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	10.75	2.87e-24	2.66e-21	0.52	0.44	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
LGG	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	10.75	2.88e-24	2.66e-21	0.67	0.44	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
LGG	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-10.75	2.89e-24	2.67e-21	-0.6	-0.44	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
LGG	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
LGG	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-10.75	2.89e-24	2.67e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-10.75	2.9e-24	2.68e-21	-0.62	-0.44	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
LGG	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	10.75	2.9e-24	2.69e-21	0.57	0.44	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
LGG	cis	rs11233250	0.697	rs1390978	ENSG00000245832.5	RP11-179A16.1	10.75	2.9e-24	2.69e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82713330	chr11:81879851~82718082:-
LGG	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-10.75	2.91e-24	2.69e-21	-0.57	-0.44	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
LGG	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-10.75	2.92e-24	2.7e-21	-0.36	-0.44	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
LGG	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-10.75	2.93e-24	2.71e-21	-0.47	-0.44	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
LGG	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	10.75	2.93e-24	2.71e-21	0.67	0.44	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
LGG	cis	rs7267979	1	rs7019	ENSG00000125804.12	FAM182A	-10.75	2.93e-24	2.71e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:26054655~26086917:+
LGG	cis	rs4683346	0.656	rs4682862	ENSG00000273328.4	RP11-141M3.6	-10.75	2.93e-24	2.71e-21	-0.5	-0.44	Granulocyte percentage of myeloid white cells;	chr3:42835921	chr3:42809414~42908105:+
LGG	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	10.75	2.94e-24	2.72e-21	0.58	0.44	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
LGG	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-10.75	2.94e-24	2.72e-21	-0.46	-0.44	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
LGG	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-10.75	2.95e-24	2.73e-21	-0.48	-0.44	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
LGG	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	10.75	2.97e-24	2.74e-21	0.55	0.44	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	10.75	2.97e-24	2.74e-21	0.55	0.44	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
LGG	cis	rs7927771	0.864	rs3781627	ENSG00000280615.1	Y_RNA	10.75	2.98e-24	2.76e-21	0.57	0.44	Subjective well-being;	chr11:47419921	chr11:47614898~47614994:-
LGG	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	10.75	2.99e-24	2.77e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
LGG	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	10.75	3e-24	2.77e-21	0.52	0.44	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
LGG	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-10.74	3e-24	2.77e-21	-0.76	-0.44	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
LGG	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	10.74	3.01e-24	2.78e-21	0.52	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
LGG	cis	rs67340775	0.541	rs200979	ENSG00000216901.1	AL022393.7	10.74	3.02e-24	2.79e-21	0.75	0.44	Lung cancer in ever smokers;	chr6:27884579	chr6:28176188~28176674:+
LGG	cis	rs67340775	0.541	rs200975	ENSG00000216901.1	AL022393.7	10.74	3.02e-24	2.79e-21	0.75	0.44	Lung cancer in ever smokers;	chr6:27887847	chr6:28176188~28176674:+
LGG	cis	rs67340775	0.541	rs200974	ENSG00000216901.1	AL022393.7	10.74	3.02e-24	2.79e-21	0.75	0.44	Lung cancer in ever smokers;	chr6:27888067	chr6:28176188~28176674:+
LGG	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	10.74	3.03e-24	2.8e-21	0.35	0.44	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
LGG	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	10.74	3.07e-24	2.83e-21	0.31	0.44	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
LGG	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	10.74	3.07e-24	2.84e-21	0.57	0.44	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
LGG	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-10.74	3.08e-24	2.85e-21	-0.53	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
LGG	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-10.74	3.08e-24	2.85e-21	-0.5	-0.44	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
LGG	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	10.74	3.09e-24	2.86e-21	0.7	0.44	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
LGG	cis	rs482329	0.93	rs619469	ENSG00000228044.2	RP4-781K5.4	10.74	3.1e-24	2.86e-21	0.51	0.44	Life threatening arrhythmia;	chr1:234682927	chr1:234646289~234683176:+
LGG	cis	rs7267979	0.934	rs4815423	ENSG00000125804.12	FAM182A	10.74	3.13e-24	2.89e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:26054655~26086917:+
LGG	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-10.74	3.15e-24	2.9e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
LGG	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-10.74	3.16e-24	2.91e-21	-0.76	-0.44	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
LGG	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-10.74	3.16e-24	2.92e-21	-0.53	-0.44	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
LGG	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-10.74	3.17e-24	2.92e-21	-0.55	-0.44	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
LGG	cis	rs9595066	0.564	rs12869383	ENSG00000230731.2	RP11-478K15.6	-10.74	3.17e-24	2.92e-21	-0.59	-0.44	Schizophrenia;	chr13:44131305	chr13:44234118~44243192:-
LGG	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-10.74	3.18e-24	2.94e-21	-0.53	-0.44	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
LGG	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	10.74	3.18e-24	2.94e-21	0.63	0.44	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
LGG	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-10.74	3.19e-24	2.94e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
LGG	cis	rs17767294	0.612	rs9461425	ENSG00000199851.2	U3	10.74	3.2e-24	2.95e-21	0.99	0.44	Parkinson's disease;	chr6:27951910	chr6:28015568~28015777:+
LGG	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
LGG	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-10.74	3.21e-24	2.96e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
LGG	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-10.74	3.22e-24	2.97e-21	-0.51	-0.44	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
LGG	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	10.74	3.23e-24	2.98e-21	0.52	0.44	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
LGG	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-10.74	3.26e-24	3e-21	-0.57	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-10.74	3.26e-24	3e-21	-0.57	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
LGG	cis	rs950027	0.815	rs1153835	ENSG00000259433.2	CTD-2651B20.4	-10.74	3.26e-24	3.01e-21	-0.48	-0.44	Response to fenofibrate (adiponectin levels);	chr15:45456409	chr15:45330209~45332634:-
LGG	cis	rs11233250	0.697	rs78000356	ENSG00000245832.5	RP11-179A16.1	10.74	3.27e-24	3.01e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82717577	chr11:81879851~82718082:-
LGG	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-10.74	3.27e-24	3.01e-21	-0.62	-0.44	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
LGG	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-10.74	3.27e-24	3.01e-21	-0.62	-0.44	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
LGG	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-10.73	3.28e-24	3.02e-21	-0.62	-0.44	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
LGG	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	10.73	3.29e-24	3.03e-21	0.55	0.44	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
LGG	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-10.73	3.29e-24	3.03e-21	-0.53	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
LGG	cis	rs2013441	0.866	rs17686622	ENSG00000230528.6	NOS2P3	10.73	3.32e-24	3.06e-21	0.43	0.44	Obesity-related traits;	chr17:20117051	chr17:20436337~20447249:+
LGG	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-10.73	3.36e-24	3.09e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
LGG	cis	rs1150668	0.796	rs213237	ENSG00000226314.6	ZNF192P1	10.73	3.36e-24	3.1e-21	0.41	0.44	Pubertal anthropometrics;	chr6:28356161	chr6:28161781~28169594:+
LGG	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	10.73	3.37e-24	3.11e-21	0.67	0.44	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
LGG	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-10.73	3.38e-24	3.12e-21	-0.9	-0.44	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
LGG	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	10.73	3.39e-24	3.12e-21	0.61	0.44	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
LGG	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-10.73	3.39e-24	3.12e-21	-0.53	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
LGG	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-10.73	3.43e-24	3.16e-21	-0.35	-0.44	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
LGG	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-10.73	3.44e-24	3.16e-21	-0.63	-0.44	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
LGG	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-10.73	3.44e-24	3.17e-21	-0.32	-0.44	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
LGG	cis	rs12495178	0.608	rs9863150	ENSG00000239519.1	CADM2-AS1	10.73	3.45e-24	3.17e-21	0.49	0.44	Body mass index;	chr3:85865885	chr3:85992183~86028007:-
LGG	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	10.73	3.46e-24	3.18e-21	0.78	0.44	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
LGG	cis	rs4713118	0.615	rs9295747	ENSG00000199851.2	U3	-10.73	3.48e-24	3.21e-21	-0.6	-0.44	Parkinson's disease;	chr6:27769214	chr6:28015568~28015777:+
LGG	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-10.73	3.51e-24	3.23e-21	-0.46	-0.44	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
LGG	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-10.73	3.53e-24	3.24e-21	-0.52	-0.44	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
LGG	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-10.73	3.53e-24	3.24e-21	-0.36	-0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
LGG	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-10.73	3.53e-24	3.24e-21	-0.46	-0.44	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
LGG	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	10.73	3.55e-24	3.26e-21	0.59	0.44	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
LGG	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	10.73	3.56e-24	3.27e-21	0.58	0.44	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
LGG	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	10.73	3.56e-24	3.27e-21	0.57	0.44	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	10.73	3.56e-24	3.27e-21	0.57	0.44	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
LGG	cis	rs11168351	0.927	rs7971880	ENSG00000258273.1	RP11-370I10.4	-10.72	3.58e-24	3.29e-21	-0.55	-0.44	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48333755~48333901:-
LGG	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-10.72	3.58e-24	3.29e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
LGG	cis	rs7267979	0.966	rs2261747	ENSG00000125804.12	FAM182A	-10.72	3.59e-24	3.3e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:26054655~26086917:+
LGG	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	10.72	3.62e-24	3.32e-21	0.42	0.44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
LGG	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	10.72	3.63e-24	3.33e-21	0.58	0.44	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
LGG	cis	rs4819052	1	rs13047688	ENSG00000215447.6	BX322557.10	-10.72	3.63e-24	3.33e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45288052~45291738:+
LGG	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	10.72	3.63e-24	3.33e-21	0.54	0.44	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
LGG	cis	rs9595066	0.941	rs9533777	ENSG00000230731.2	RP11-478K15.6	-10.72	3.65e-24	3.35e-21	-0.67	-0.44	Schizophrenia;	chr13:44134584	chr13:44234118~44243192:-
LGG	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	10.72	3.65e-24	3.35e-21	0.5	0.44	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
LGG	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	-10.72	3.7e-24	3.4e-21	-0.45	-0.44	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
LGG	cis	rs67340775	0.541	rs200966	ENSG00000199851.2	U3	10.72	3.71e-24	3.4e-21	0.82	0.44	Lung cancer in ever smokers;	chr6:27894374	chr6:28015568~28015777:+
LGG	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	10.72	3.71e-24	3.41e-21	0.67	0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
LGG	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-10.72	3.72e-24	3.42e-21	-0.51	-0.44	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
LGG	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	10.72	3.72e-24	3.42e-21	0.48	0.44	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
LGG	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-10.72	3.72e-24	3.42e-21	-0.95	-0.44	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
LGG	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-10.72	3.73e-24	3.42e-21	-0.36	-0.44	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-10.72	3.73e-24	3.42e-21	-0.36	-0.44	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-10.72	3.73e-24	3.42e-21	-0.36	-0.44	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-10.72	3.73e-24	3.42e-21	-0.36	-0.44	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-10.72	3.73e-24	3.42e-21	-0.36	-0.44	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	10.72	3.73e-24	3.42e-21	0.54	0.44	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
LGG	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-10.72	3.74e-24	3.44e-21	-0.51	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
LGG	cis	rs9322193	0.923	rs9371207	ENSG00000216621.7	RP11-244K5.6	10.72	3.75e-24	3.44e-21	0.54	0.44	Lung cancer;	chr6:149858087	chr6:149934527~149936782:+
LGG	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	10.72	3.75e-24	3.44e-21	0.46	0.44	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
LGG	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-10.72	3.76e-24	3.45e-21	-0.48	-0.44	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
LGG	cis	rs1150668	0.83	rs2859365	ENSG00000218016.2	ZNF192P2	10.72	3.77e-24	3.46e-21	0.49	0.44	Pubertal anthropometrics;	chr6:28423688	chr6:28188050~28189432:+
LGG	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	10.72	3.79e-24	3.47e-21	0.58	0.44	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
LGG	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	10.72	3.79e-24	3.48e-21	0.64	0.44	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
LGG	cis	rs741668	0.894	rs6561282	ENSG00000235903.6	CPB2-AS1	10.72	3.81e-24	3.49e-21	0.5	0.44	Cerebrospinal fluid clusterin levels;	chr13:46022607	chr13:46052806~46113332:+
LGG	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-10.72	3.82e-24	3.5e-21	-0.45	-0.44	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
LGG	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	10.72	3.86e-24	3.54e-21	0.54	0.44	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	10.72	3.86e-24	3.54e-21	0.54	0.44	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
LGG	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	10.72	3.87e-24	3.54e-21	0.35	0.44	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
LGG	cis	rs7927771	0.832	rs1317164	ENSG00000280615.1	Y_RNA	-10.72	3.87e-24	3.55e-21	-0.56	-0.44	Subjective well-being;	chr11:47398206	chr11:47614898~47614994:-
LGG	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-10.72	3.87e-24	3.55e-21	-0.51	-0.44	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
LGG	cis	rs1150668	0.796	rs213236	ENSG00000226314.6	ZNF192P1	10.72	3.88e-24	3.55e-21	0.42	0.44	Pubertal anthropometrics;	chr6:28356620	chr6:28161781~28169594:+
LGG	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-10.72	3.88e-24	3.56e-21	-0.51	-0.44	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-10.72	3.88e-24	3.56e-21	-0.51	-0.44	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-10.72	3.88e-24	3.56e-21	-0.51	-0.44	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
LGG	cis	rs3742264	1	rs9316180	ENSG00000235903.6	CPB2-AS1	10.71	3.89e-24	3.57e-21	0.47	0.44	Blood protein levels;	chr13:46067550	chr13:46052806~46113332:+
LGG	cis	rs8092443	1	rs8089292	ENSG00000278971.1	RP11-644A7.2	10.71	3.9e-24	3.58e-21	0.65	0.44	Response to antipsychotic treatment;	chr18:70483865	chr18:70489630~70491205:+
LGG	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-10.71	3.91e-24	3.58e-21	-0.36	-0.44	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
LGG	cis	rs741668	0.931	rs61953332	ENSG00000235903.6	CPB2-AS1	10.71	3.93e-24	3.59e-21	0.5	0.44	Cerebrospinal fluid clusterin levels;	chr13:46016139	chr13:46052806~46113332:+
LGG	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	10.71	3.96e-24	3.62e-21	0.5	0.44	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
LGG	cis	rs7267979	0.932	rs13040655	ENSG00000125804.12	FAM182A	-10.71	3.99e-24	3.65e-21	-0.54	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:26054655~26086917:+
LGG	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	10.71	4e-24	3.66e-21	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
LGG	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-10.71	4.01e-24	3.67e-21	-0.36	-0.44	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-10.71	4.01e-24	3.67e-21	-0.36	-0.44	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
LGG	cis	rs67340775	0.541	rs200964	ENSG00000199851.2	U3	10.71	4.01e-24	3.67e-21	0.82	0.44	Lung cancer in ever smokers;	chr6:27899165	chr6:28015568~28015777:+
LGG	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	10.71	4.02e-24	3.67e-21	0.57	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
LGG	cis	rs5758511	0.68	rs34107327	ENSG00000227370.1	RP4-669P10.19	10.71	4.03e-24	3.68e-21	0.5	0.44	Birth weight;	chr22:42252347	chr22:42132543~42132998:+
LGG	cis	rs1475911	1	rs2839467	ENSG00000184385.2	UMODL1-AS1	-10.71	4.03e-24	3.69e-21	-0.57	-0.44	IgG glycosylation;	chr21:42093090	chr21:42102134~42108534:-
LGG	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	10.71	4.05e-24	3.7e-21	0.54	0.44	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
LGG	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	10.71	4.05e-24	3.7e-21	0.67	0.44	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
LGG	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-10.71	4.08e-24	3.73e-21	-0.97	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
LGG	cis	rs7267979	0.934	rs2261115	ENSG00000125804.12	FAM182A	-10.71	4.09e-24	3.74e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:26054655~26086917:+
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	10.71	4.11e-24	3.76e-21	0.61	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
LGG	cis	rs11118620	0.81	rs1603047	ENSG00000257551.1	HLX-AS1	10.71	4.12e-24	3.76e-21	0.58	0.44	Heart failure;	chr1:220849953	chr1:220832763~220880140:-
LGG	cis	rs11233250	0.697	rs12421066	ENSG00000245832.5	RP11-179A16.1	10.71	4.14e-24	3.78e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82703938	chr11:81879851~82718082:-
LGG	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	10.71	4.17e-24	3.81e-21	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
LGG	cis	rs4713118	0.662	rs9393881	ENSG00000226314.6	ZNF192P1	10.71	4.18e-24	3.81e-21	0.54	0.44	Parkinson's disease;	chr6:28055973	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	10.71	4.18e-24	3.81e-21	0.55	0.44	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
LGG	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	10.71	4.21e-24	3.85e-21	0.57	0.44	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
LGG	cis	rs11098499	0.644	rs3986377	ENSG00000249244.1	RP11-548H18.2	10.71	4.23e-24	3.86e-21	0.46	0.44	Corneal astigmatism;	chr4:119339115	chr4:119391831~119395335:-
LGG	cis	rs10028773	0.556	rs4473640	ENSG00000249244.1	RP11-548H18.2	10.71	4.23e-24	3.86e-21	0.46	0.44	Educational attainment;	chr4:119339282	chr4:119391831~119395335:-
LGG	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	10.7	4.26e-24	3.89e-21	0.47	0.44	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
LGG	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-10.7	4.26e-24	3.89e-21	-0.51	-0.44	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
LGG	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-10.7	4.27e-24	3.89e-21	-0.68	-0.44	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
LGG	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-10.7	4.34e-24	3.96e-21	-0.56	-0.44	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
LGG	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	10.7	4.37e-24	3.98e-21	0.52	0.44	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
LGG	cis	rs893971	0.527	rs10018448	ENSG00000246375.2	RP11-10L7.1	10.7	4.39e-24	4e-21	0.52	0.44	Conduct disorder (maternal expressed emotions interaction);	chr4:88304019	chr4:88284942~88331421:+
LGG	cis	rs5758511	0.68	rs5758682	ENSG00000227370.1	RP4-669P10.19	10.7	4.41e-24	4.02e-21	0.5	0.44	Birth weight;	chr22:42249196	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.68	rs5758684	ENSG00000227370.1	RP4-669P10.19	10.7	4.41e-24	4.02e-21	0.5	0.44	Birth weight;	chr22:42253503	chr22:42132543~42132998:+
LGG	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	10.7	4.41e-24	4.02e-21	0.54	0.44	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
LGG	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-10.7	4.41e-24	4.02e-21	-0.5	-0.44	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
LGG	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-10.7	4.43e-24	4.04e-21	-0.55	-0.44	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
LGG	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-10.7	4.43e-24	4.04e-21	-0.55	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
LGG	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-10.7	4.44e-24	4.04e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
LGG	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-10.7	4.44e-24	4.04e-21	-0.54	-0.44	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
LGG	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-10.7	4.49e-24	4.09e-21	-0.61	-0.44	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
LGG	cis	rs7267979	1	rs6083828	ENSG00000125804.12	FAM182A	10.7	4.52e-24	4.11e-21	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:26054655~26086917:+
LGG	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-10.7	4.52e-24	4.11e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-10.7	4.52e-24	4.11e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-10.7	4.52e-24	4.11e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
LGG	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-10.7	4.54e-24	4.13e-21	-0.51	-0.44	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
LGG	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-10.7	4.54e-24	4.14e-21	-0.36	-0.44	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-10.7	4.54e-24	4.14e-21	-0.36	-0.44	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
LGG	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-10.7	4.55e-24	4.15e-21	-0.52	-0.44	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
LGG	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-10.7	4.58e-24	4.17e-21	-0.51	-0.44	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	10.7	4.59e-24	4.18e-21	0.54	0.44	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
LGG	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-10.7	4.62e-24	4.2e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-10.7	4.62e-24	4.2e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
LGG	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-10.7	4.63e-24	4.21e-21	-0.55	-0.44	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
LGG	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-10.69	4.65e-24	4.23e-21	-0.57	-0.44	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
LGG	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-10.69	4.65e-24	4.23e-21	-0.57	-0.44	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
LGG	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-10.69	4.65e-24	4.23e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
LGG	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-10.69	4.69e-24	4.26e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-10.69	4.69e-24	4.26e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-10.69	4.69e-24	4.26e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-10.69	4.69e-24	4.26e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-10.69	4.69e-24	4.26e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-10.69	4.69e-24	4.26e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-10.69	4.69e-24	4.26e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
LGG	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-10.69	4.7e-24	4.27e-21	-0.45	-0.44	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
LGG	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	10.69	4.7e-24	4.27e-21	0.35	0.44	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
LGG	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	10.69	4.7e-24	4.27e-21	0.35	0.44	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
LGG	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-10.69	4.74e-24	4.31e-21	-0.52	-0.44	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
LGG	cis	rs5758511	0.68	rs5758657	ENSG00000227370.1	RP4-669P10.19	10.69	4.78e-24	4.34e-21	0.5	0.44	Birth weight;	chr22:42222663	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.68	rs1033459	ENSG00000227370.1	RP4-669P10.19	10.69	4.78e-24	4.34e-21	0.5	0.44	Birth weight;	chr22:42223061	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.68	rs1033460	ENSG00000227370.1	RP4-669P10.19	10.69	4.78e-24	4.34e-21	0.5	0.44	Birth weight;	chr22:42223302	chr22:42132543~42132998:+
LGG	cis	rs11098499	0.722	rs17595727	ENSG00000249244.1	RP11-548H18.2	-10.69	4.79e-24	4.35e-21	-0.46	-0.44	Corneal astigmatism;	chr4:119340919	chr4:119391831~119395335:-
LGG	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-10.69	4.79e-24	4.35e-21	-0.51	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
LGG	cis	rs11233250	0.697	rs57630229	ENSG00000245832.5	RP11-179A16.1	10.69	4.79e-24	4.36e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82698589	chr11:81879851~82718082:-
LGG	cis	rs11233250	0.697	rs72942432	ENSG00000245832.5	RP11-179A16.1	10.69	4.79e-24	4.36e-21	0.68	0.44	Glioblastoma;Glioma;	chr11:82699873	chr11:81879851~82718082:-
LGG	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	10.69	4.8e-24	4.36e-21	0.55	0.44	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
LGG	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-10.69	4.8e-24	4.36e-21	-0.36	-0.44	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
LGG	cis	rs6500637	0.558	rs11076856	ENSG00000267077.1	RP11-127I20.5	-10.69	4.8e-24	4.36e-21	-0.44	-0.44	Cancer;	chr16:4899814	chr16:4795265~4796532:-
LGG	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-10.69	4.83e-24	4.39e-21	-0.47	-0.44	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
LGG	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-10.69	4.89e-24	4.44e-21	-0.52	-0.44	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
LGG	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-10.69	4.89e-24	4.44e-21	-0.51	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
LGG	cis	rs2283792	0.687	rs381849	ENSG00000228050.1	TOP3BP1	10.69	4.9e-24	4.45e-21	0.5	0.44	Multiple sclerosis;	chr22:21951341	chr22:22223187~22224566:-
LGG	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-10.69	4.9e-24	4.45e-21	-0.57	-0.44	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
LGG	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-10.69	4.91e-24	4.46e-21	-0.51	-0.44	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-10.69	4.91e-24	4.46e-21	-0.51	-0.44	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-10.69	4.91e-24	4.46e-21	-0.51	-0.44	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
LGG	cis	rs7927771	0.832	rs55677087	ENSG00000280615.1	Y_RNA	-10.69	4.96e-24	4.51e-21	-0.56	-0.44	Subjective well-being;	chr11:47376163	chr11:47614898~47614994:-
LGG	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-10.69	4.96e-24	4.51e-21	-0.49	-0.44	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
LGG	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-10.69	5.02e-24	4.56e-21	-0.5	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
LGG	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-10.69	5.05e-24	4.58e-21	-0.51	-0.44	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-10.69	5.05e-24	4.58e-21	-0.51	-0.44	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
LGG	cis	rs172166	0.61	rs276369	ENSG00000280107.1	AL022393.9	-10.68	5.06e-24	4.59e-21	-0.44	-0.44	Cardiac Troponin-T levels;	chr6:27951465	chr6:28170845~28172521:+
LGG	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-10.68	5.06e-24	4.59e-21	-0.52	-0.44	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
LGG	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	10.68	5.07e-24	4.6e-21	0.51	0.44	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
LGG	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-10.68	5.07e-24	4.6e-21	-0.45	-0.44	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
LGG	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	10.68	5.08e-24	4.61e-21	0.63	0.44	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
LGG	cis	rs2013441	0.866	rs12949485	ENSG00000230528.6	NOS2P3	-10.68	5.12e-24	4.64e-21	-0.43	-0.44	Obesity-related traits;	chr17:20118348	chr17:20436337~20447249:+
LGG	cis	rs2013441	0.866	rs62067558	ENSG00000230528.6	NOS2P3	-10.68	5.12e-24	4.64e-21	-0.43	-0.44	Obesity-related traits;	chr17:20122393	chr17:20436337~20447249:+
LGG	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	10.68	5.12e-24	4.64e-21	0.66	0.44	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
LGG	cis	rs651907	0.557	rs12629954	ENSG00000256628.3	ZBTB11-AS1	10.68	5.13e-24	4.65e-21	0.51	0.44	Colorectal cancer;	chr3:101641779	chr3:101676475~101679217:+
LGG	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-10.68	5.15e-24	4.66e-21	-0.57	-0.44	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
LGG	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-10.68	5.15e-24	4.66e-21	-0.57	-0.44	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
LGG	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-10.68	5.15e-24	4.66e-21	-0.57	-0.44	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
LGG	cis	rs5758511	0.68	rs1107553	ENSG00000227370.1	RP4-669P10.19	10.68	5.18e-24	4.69e-21	0.49	0.44	Birth weight;	chr22:42271467	chr22:42132543~42132998:+
LGG	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-10.68	5.18e-24	4.69e-21	-0.56	-0.44	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-10.68	5.18e-24	4.69e-21	-0.56	-0.44	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
LGG	cis	rs5758511	0.679	rs55867855	ENSG00000227370.1	RP4-669P10.19	10.68	5.21e-24	4.72e-21	0.5	0.44	Birth weight;	chr22:42227252	chr22:42132543~42132998:+
LGG	cis	rs9388451	0.874	rs1159974	ENSG00000237742.5	RP11-624M8.1	10.68	5.23e-24	4.73e-21	0.38	0.44	Brugada syndrome;	chr6:125769131	chr6:125578558~125749190:-
LGG	cis	rs2013441	0.83	rs2526469	ENSG00000230528.6	NOS2P3	10.68	5.26e-24	4.76e-21	0.42	0.44	Obesity-related traits;	chr17:20259435	chr17:20436337~20447249:+
LGG	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-10.68	5.28e-24	4.77e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-10.68	5.28e-24	4.77e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-10.68	5.28e-24	4.77e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-10.68	5.28e-24	4.77e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-10.68	5.28e-24	4.77e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
LGG	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-10.68	5.31e-24	4.81e-21	-0.51	-0.44	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-10.68	5.31e-24	4.81e-21	-0.51	-0.44	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
LGG	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-10.68	5.34e-24	4.83e-21	-0.59	-0.44	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
LGG	cis	rs4819052	0.918	rs2330013	ENSG00000215447.6	BX322557.10	-10.68	5.36e-24	4.85e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45288052~45291738:+
LGG	cis	rs4819052	1	rs28628220	ENSG00000215447.6	BX322557.10	-10.68	5.36e-24	4.85e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45288052~45291738:+
LGG	cis	rs8062405	0.656	rs7189927	ENSG00000251417.2	RP11-1348G14.4	10.68	5.38e-24	4.86e-21	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28802743~28817828:+
LGG	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-10.68	5.39e-24	4.87e-21	-0.51	-0.44	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
LGG	cis	rs9595066	1	rs7981575	ENSG00000230731.2	RP11-478K15.6	10.68	5.39e-24	4.88e-21	0.73	0.44	Schizophrenia;	chr13:44136811	chr13:44234118~44243192:-
LGG	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-10.68	5.41e-24	4.9e-21	-0.51	-0.44	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-10.68	5.41e-24	4.9e-21	-0.51	-0.44	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-10.68	5.41e-24	4.9e-21	-0.51	-0.44	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-10.68	5.41e-24	4.9e-21	-0.51	-0.44	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-10.68	5.41e-24	4.9e-21	-0.51	-0.44	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.923	rs2880436	ENSG00000216621.7	RP11-244K5.6	10.68	5.47e-24	4.94e-21	0.54	0.44	Lung cancer;	chr6:149859123	chr6:149934527~149936782:+
LGG	cis	rs7849270	1	rs3124498	ENSG00000268707.1	RP11-247A12.7	10.68	5.5e-24	4.97e-21	0.53	0.44	Blood metabolite ratios;	chr9:129103214	chr9:129170434~129170940:+
LGG	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-10.68	5.5e-24	4.97e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-10.67	5.52e-24	4.99e-21	-0.53	-0.44	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
LGG	cis	rs4819052	0.918	rs34886433	ENSG00000215447.6	BX322557.10	-10.67	5.59e-24	5.05e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45288052~45291738:+
LGG	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-10.67	5.61e-24	5.07e-21	-0.5	-0.44	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
LGG	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-10.67	5.64e-24	5.09e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
LGG	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	10.67	5.65e-24	5.1e-21	0.51	0.44	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
LGG	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	10.67	5.66e-24	5.11e-21	0.53	0.44	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
LGG	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-10.67	5.68e-24	5.13e-21	-0.52	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
LGG	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	10.67	5.72e-24	5.16e-21	0.57	0.44	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	10.67	5.72e-24	5.16e-21	0.57	0.44	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	10.67	5.72e-24	5.16e-21	0.57	0.44	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
LGG	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	10.67	5.74e-24	5.19e-21	0.48	0.44	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
LGG	cis	rs7927771	0.832	rs4752990	ENSG00000280615.1	Y_RNA	-10.67	5.81e-24	5.25e-21	-0.55	-0.44	Subjective well-being;	chr11:47388842	chr11:47614898~47614994:-
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	10.67	5.86e-24	5.29e-21	0.57	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
LGG	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	10.67	5.87e-24	5.3e-21	0.51	0.44	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
LGG	cis	rs11118620	0.81	rs4587570	ENSG00000257551.1	HLX-AS1	10.67	5.88e-24	5.31e-21	0.58	0.44	Heart failure;	chr1:220860693	chr1:220832763~220880140:-
LGG	cis	rs7267979	0.808	rs84816	ENSG00000125804.12	FAM182A	-10.67	5.89e-24	5.31e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	10.67	5.89e-24	5.32e-21	0.55	0.44	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
LGG	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-10.67	5.94e-24	5.35e-21	-0.57	-0.44	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
LGG	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	10.67	5.94e-24	5.36e-21	0.6	0.44	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
LGG	cis	rs4713118	0.505	rs156740	ENSG00000280107.1	AL022393.9	-10.67	5.95e-24	5.36e-21	-0.44	-0.44	Parkinson's disease;	chr6:27992657	chr6:28170845~28172521:+
LGG	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-10.67	5.96e-24	5.37e-21	-0.47	-0.44	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
LGG	cis	rs1150668	0.796	rs213236	ENSG00000280107.1	AL022393.9	-10.67	5.97e-24	5.38e-21	-0.42	-0.44	Pubertal anthropometrics;	chr6:28356620	chr6:28170845~28172521:+
LGG	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-10.67	5.97e-24	5.39e-21	-0.51	-0.44	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
LGG	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	10.67	5.99e-24	5.4e-21	0.32	0.44	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
LGG	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-10.67	5.99e-24	5.41e-21	-0.5	-0.44	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
LGG	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-10.67	6e-24	5.41e-21	-0.57	-0.44	QT interval;	chr16:28857143	chr16:28700294~28701540:-
LGG	cis	rs7829975	0.711	rs1039916	ENSG00000173295.6	FAM86B3P	-10.66	6.02e-24	5.43e-21	-0.46	-0.44	Mood instability;	chr8:8828344	chr8:8228595~8244865:+
LGG	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	10.66	6.03e-24	5.43e-21	0.5	0.44	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
LGG	cis	rs7267979	1	rs7020	ENSG00000125804.12	FAM182A	-10.66	6.04e-24	5.44e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:26054655~26086917:+
LGG	cis	rs7914558	0.899	rs7913682	ENSG00000272912.1	RP11-724N1.1	-10.66	6.05e-24	5.46e-21	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102914585~102915404:+
LGG	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-10.66	6.08e-24	5.48e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
LGG	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-10.66	6.09e-24	5.49e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-10.66	6.09e-24	5.49e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-10.66	6.09e-24	5.49e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
LGG	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-10.66	6.1e-24	5.49e-21	-0.45	-0.44	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
LGG	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	10.66	6.1e-24	5.49e-21	0.57	0.44	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
LGG	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	10.66	6.1e-24	5.49e-21	0.51	0.44	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
LGG	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	10.66	6.1e-24	5.49e-21	0.51	0.44	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
LGG	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-10.66	6.11e-24	5.5e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
LGG	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	10.66	6.11e-24	5.5e-21	0.49	0.44	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	10.66	6.11e-24	5.5e-21	0.49	0.44	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
LGG	cis	rs7914558	0.966	rs7096269	ENSG00000272912.1	RP11-724N1.1	-10.66	6.14e-24	5.53e-21	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102914585~102915404:+
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-10.66	6.14e-24	5.53e-21	-0.59	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
LGG	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-10.66	6.16e-24	5.54e-21	-0.59	-0.44	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
LGG	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-10.66	6.16e-24	5.54e-21	-0.59	-0.44	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
LGG	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-10.66	6.19e-24	5.57e-21	-0.5	-0.44	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
LGG	cis	rs651907	0.557	rs36002990	ENSG00000256628.3	ZBTB11-AS1	10.66	6.2e-24	5.58e-21	0.5	0.44	Colorectal cancer;	chr3:101719018	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs11720745	ENSG00000256628.3	ZBTB11-AS1	10.66	6.2e-24	5.58e-21	0.5	0.44	Colorectal cancer;	chr3:101722846	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs35117343	ENSG00000256628.3	ZBTB11-AS1	10.66	6.2e-24	5.58e-21	0.5	0.44	Colorectal cancer;	chr3:101726282	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs11914318	ENSG00000256628.3	ZBTB11-AS1	10.66	6.2e-24	5.58e-21	0.5	0.44	Colorectal cancer;	chr3:101735014	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs1031710	ENSG00000256628.3	ZBTB11-AS1	10.66	6.2e-24	5.58e-21	0.5	0.44	Colorectal cancer;	chr3:101745051	chr3:101676475~101679217:+
LGG	cis	rs2283792	0.718	rs239918	ENSG00000228050.1	TOP3BP1	10.66	6.21e-24	5.58e-21	0.5	0.44	Multiple sclerosis;	chr22:21959457	chr22:22223187~22224566:-
LGG	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	10.66	6.25e-24	5.62e-21	0.3	0.44	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
LGG	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-10.66	6.25e-24	5.63e-21	-0.5	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-10.66	6.25e-24	5.63e-21	-0.5	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
LGG	cis	rs11118620	1	rs11118620	ENSG00000257551.1	HLX-AS1	10.66	6.26e-24	5.63e-21	0.58	0.44	Heart failure;	chr1:220855166	chr1:220832763~220880140:-
LGG	cis	rs5758511	0.68	rs17002902	ENSG00000227370.1	RP4-669P10.19	10.66	6.26e-24	5.63e-21	0.5	0.44	Birth weight;	chr22:42229503	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.68	rs5758662	ENSG00000227370.1	RP4-669P10.19	10.66	6.26e-24	5.63e-21	0.5	0.44	Birth weight;	chr22:42232082	chr22:42132543~42132998:+
LGG	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-10.66	6.28e-24	5.65e-21	-0.51	-0.44	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-10.66	6.28e-24	5.65e-21	-0.51	-0.44	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-10.66	6.28e-24	5.65e-21	-0.51	-0.44	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-10.66	6.28e-24	5.65e-21	-0.51	-0.44	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-10.66	6.28e-24	5.65e-21	-0.51	-0.44	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-10.66	6.28e-24	5.65e-21	-0.51	-0.44	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
LGG	cis	rs11233250	0.697	rs72942468	ENSG00000245832.5	RP11-179A16.1	10.66	6.31e-24	5.68e-21	0.67	0.44	Glioblastoma;Glioma;	chr11:82715694	chr11:81879851~82718082:-
LGG	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-10.66	6.32e-24	5.68e-21	-0.51	-0.44	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
LGG	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	10.66	6.33e-24	5.7e-21	0.32	0.44	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
LGG	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-10.66	6.37e-24	5.73e-21	-0.5	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
LGG	cis	rs5758511	0.68	rs58654759	ENSG00000227370.1	RP4-669P10.19	10.66	6.4e-24	5.75e-21	0.5	0.44	Birth weight;	chr22:42246570	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.68	rs5758652	ENSG00000227370.1	RP4-669P10.19	10.66	6.41e-24	5.76e-21	0.5	0.44	Birth weight;	chr22:42216402	chr22:42132543~42132998:+
LGG	cis	rs5742933	0.779	rs1899025	ENSG00000253559.1	OSGEPL1-AS1	10.66	6.44e-24	5.79e-21	0.53	0.44	Ferritin levels;	chr2:189784856	chr2:189762704~189765556:+
LGG	cis	rs4819052	1	rs2297284	ENSG00000215447.6	BX322557.10	-10.66	6.47e-24	5.82e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45288052~45291738:+
LGG	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-10.66	6.48e-24	5.82e-21	-0.5	-0.44	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
LGG	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-10.66	6.48e-24	5.83e-21	-0.51	-0.44	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
LGG	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	10.66	6.5e-24	5.84e-21	0.55	0.44	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
LGG	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	10.66	6.5e-24	5.84e-21	0.79	0.44	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
LGG	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-10.66	6.53e-24	5.87e-21	-0.51	-0.44	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-10.66	6.53e-24	5.87e-21	-0.51	-0.44	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-10.66	6.53e-24	5.87e-21	-0.51	-0.44	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
LGG	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-10.66	6.54e-24	5.87e-21	-0.56	-0.44	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
LGG	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	10.65	6.56e-24	5.89e-21	0.35	0.44	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
LGG	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	10.65	6.57e-24	5.9e-21	0.57	0.44	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
LGG	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	10.65	6.58e-24	5.91e-21	0.55	0.44	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
LGG	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-10.65	6.65e-24	5.97e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-10.65	6.65e-24	5.97e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-10.65	6.65e-24	5.97e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-10.65	6.65e-24	5.97e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
LGG	cis	rs7615952	0.866	rs6438949	ENSG00000171084.14	FAM86JP	10.65	6.68e-24	6e-21	0.75	0.44	Blood pressure (smoking interaction);	chr3:125931221	chr3:125916620~125930024:+
LGG	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	10.65	6.7e-24	6.01e-21	0.57	0.44	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
LGG	cis	rs7914558	0.966	rs1971589	ENSG00000272912.1	RP11-724N1.1	-10.65	6.71e-24	6.02e-21	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102914585~102915404:+
LGG	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	10.65	6.72e-24	6.03e-21	0.61	0.44	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
LGG	cis	rs7914558	0.933	rs10883814	ENSG00000272912.1	RP11-724N1.1	-10.65	6.72e-24	6.03e-21	-0.49	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102914585~102915404:+
LGG	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	10.65	6.73e-24	6.04e-21	0.64	0.44	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
LGG	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-10.65	6.73e-24	6.04e-21	-0.46	-0.44	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
LGG	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	10.65	6.81e-24	6.1e-21	0.56	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
LGG	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-10.65	6.83e-24	6.12e-21	-0.7	-0.44	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
LGG	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-10.65	6.83e-24	6.13e-21	-0.51	-0.44	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
LGG	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-10.65	6.84e-24	6.13e-21	-0.52	-0.44	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
LGG	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	10.65	6.91e-24	6.19e-21	0.77	0.44	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
LGG	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	10.65	6.92e-24	6.2e-21	0.47	0.44	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
LGG	cis	rs8064024	0.901	rs930855	ENSG00000267077.1	RP11-127I20.5	10.65	6.94e-24	6.22e-21	0.42	0.44	Cancer;	chr16:4814178	chr16:4795265~4796532:-
LGG	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-10.65	6.96e-24	6.24e-21	-0.51	-0.44	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
LGG	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	10.65	6.98e-24	6.25e-21	0.57	0.44	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
LGG	cis	rs12168402	0.51	rs1076116	ENSG00000235209.1	CTA-150C2.13	10.65	7.04e-24	6.3e-21	0.56	0.44	Subjective well-being;	chr22:38841832	chr22:38921227~38924708:+
LGG	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-10.65	7.04e-24	6.3e-21	-0.54	-0.44	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
LGG	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-10.65	7.04e-24	6.3e-21	-0.54	-0.44	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
LGG	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	10.65	7.04e-24	6.3e-21	0.54	0.44	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
LGG	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-10.65	7.05e-24	6.31e-21	-0.35	-0.44	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
LGG	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-10.65	7.06e-24	6.31e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
LGG	cis	rs2581828	0.58	rs4687570	ENSG00000242142.1	SERBP1P3	10.65	7.07e-24	6.33e-21	0.5	0.44	Crohn's disease;	chr3:53136484	chr3:53064283~53065091:-
LGG	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-10.65	7.09e-24	6.34e-21	-0.55	-0.44	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
LGG	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-10.65	7.1e-24	6.35e-21	-0.51	-0.44	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
LGG	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-10.65	7.12e-24	6.37e-21	-0.57	-0.44	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
LGG	cis	rs7849270	0.918	rs746873	ENSG00000268707.1	RP11-247A12.7	10.65	7.12e-24	6.37e-21	0.52	0.44	Blood metabolite ratios;	chr9:129102671	chr9:129170434~129170940:+
LGG	cis	rs7849270	0.959	rs746872	ENSG00000268707.1	RP11-247A12.7	10.65	7.12e-24	6.37e-21	0.52	0.44	Blood metabolite ratios;	chr9:129102748	chr9:129170434~129170940:+
LGG	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-10.65	7.14e-24	6.39e-21	-0.35	-0.44	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-10.65	7.14e-24	6.39e-21	-0.35	-0.44	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-10.65	7.14e-24	6.39e-21	-0.35	-0.44	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-10.65	7.14e-24	6.39e-21	-0.35	-0.44	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
LGG	cis	rs6452524	0.836	rs10041617	ENSG00000248112.1	RP11-78C3.1	10.65	7.15e-24	6.39e-21	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:82919376~82921119:-
LGG	cis	rs7267979	0.903	rs6107015	ENSG00000125804.12	FAM182A	-10.65	7.15e-24	6.39e-21	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.868	rs6138553	ENSG00000125804.12	FAM182A	-10.64	7.21e-24	6.44e-21	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:26054655~26086917:+
LGG	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-10.64	7.26e-24	6.49e-21	-0.51	-0.44	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
LGG	cis	rs2408955	0.522	rs4760612	ENSG00000258273.1	RP11-370I10.4	10.64	7.27e-24	6.5e-21	0.55	0.44	Glycated hemoglobin levels;	chr12:48028073	chr12:48333755~48333901:-
LGG	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	10.64	7.31e-24	6.53e-21	0.33	0.44	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
LGG	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	10.64	7.32e-24	6.54e-21	0.47	0.44	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
LGG	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	10.64	7.33e-24	6.55e-21	0.35	0.44	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	10.64	7.33e-24	6.55e-21	0.35	0.44	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	10.64	7.33e-24	6.55e-21	0.35	0.44	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
LGG	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-10.64	7.35e-24	6.57e-21	-0.75	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
LGG	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-10.64	7.37e-24	6.58e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
LGG	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-10.64	7.4e-24	6.61e-21	-0.49	-0.44	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
LGG	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	10.64	7.47e-24	6.67e-21	0.56	0.44	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
LGG	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-10.64	7.47e-24	6.67e-21	-0.35	-0.44	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
LGG	cis	rs7119038	0.509	rs11216961	ENSG00000255239.1	AP002954.6	-10.64	7.48e-24	6.67e-21	-0.59	-0.44	Sjögren's syndrome;	chr11:118709629	chr11:118688039~118690600:-
LGG	cis	rs496547	0.52	rs11216963	ENSG00000255239.1	AP002954.6	-10.64	7.48e-24	6.67e-21	-0.59	-0.44	Hip minimal joint space width;	chr11:118710105	chr11:118688039~118690600:-
LGG	cis	rs7927771	0.864	rs755555	ENSG00000280615.1	Y_RNA	-10.64	7.48e-24	6.67e-21	-0.56	-0.44	Subjective well-being;	chr11:47410415	chr11:47614898~47614994:-
LGG	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-10.64	7.52e-24	6.71e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
LGG	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-10.64	7.53e-24	6.72e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-10.64	7.53e-24	6.72e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
LGG	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-10.64	7.55e-24	6.73e-21	-0.57	-0.44	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
LGG	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-10.64	7.55e-24	6.73e-21	-0.57	-0.44	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
LGG	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-10.64	7.55e-24	6.73e-21	-0.57	-0.44	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
LGG	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-10.64	7.55e-24	6.73e-21	-0.57	-0.44	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
LGG	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-10.64	7.55e-24	6.74e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
LGG	cis	rs11148252	0.574	rs3742297	ENSG00000273784.3	RP11-78J21.7	-10.64	7.61e-24	6.78e-21	-0.49	-0.44	Lewy body disease;	chr13:52703932	chr13:52600042~52642542:+
LGG	cis	rs11148252	0.574	rs9536247	ENSG00000273784.3	RP11-78J21.7	-10.64	7.61e-24	6.78e-21	-0.49	-0.44	Lewy body disease;	chr13:52705407	chr13:52600042~52642542:+
LGG	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	10.64	7.63e-24	6.8e-21	0.51	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
LGG	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	10.64	7.68e-24	6.84e-21	0.35	0.44	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
LGG	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-10.64	7.69e-24	6.85e-21	-0.51	-0.44	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
LGG	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-10.64	7.74e-24	6.89e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-10.64	7.74e-24	6.89e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-10.64	7.74e-24	6.89e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-10.64	7.74e-24	6.89e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-10.64	7.77e-24	6.92e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
LGG	cis	rs1150668	0.799	rs1150705	ENSG00000226314.6	ZNF192P1	10.63	7.81e-24	6.95e-21	0.43	0.44	Pubertal anthropometrics;	chr6:28226008	chr6:28161781~28169594:+
LGG	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-10.63	7.83e-24	6.97e-21	-0.5	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
LGG	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-10.63	7.85e-24	6.99e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
LGG	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-10.63	7.86e-24	7e-21	-0.5	-0.44	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-10.63	7.86e-24	7e-21	-0.5	-0.44	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
LGG	cis	rs8092443	0.832	rs2366382	ENSG00000278971.1	RP11-644A7.2	10.63	7.87e-24	7.01e-21	0.64	0.44	Response to antipsychotic treatment;	chr18:70481689	chr18:70489630~70491205:+
LGG	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-10.63	7.89e-24	7.03e-21	-0.57	-0.44	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
LGG	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-10.63	7.89e-24	7.03e-21	-0.57	-0.44	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
LGG	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-10.63	7.89e-24	7.03e-21	-0.57	-0.44	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
LGG	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-10.63	7.9e-24	7.03e-21	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
LGG	cis	rs6452524	0.935	rs3901654	ENSG00000248112.1	RP11-78C3.1	10.63	7.95e-24	7.07e-21	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs1478480	ENSG00000248112.1	RP11-78C3.1	10.63	7.95e-24	7.07e-21	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:82919376~82921119:-
LGG	cis	rs7267979	0.933	rs1130694	ENSG00000125804.12	FAM182A	-10.63	7.95e-24	7.07e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:26054655~26086917:+
LGG	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
LGG	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	10.63	7.96e-24	7.08e-21	0.35	0.44	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
LGG	cis	rs2013441	0.866	rs12941200	ENSG00000230528.6	NOS2P3	-10.63	7.97e-24	7.09e-21	-0.43	-0.44	Obesity-related traits;	chr17:20108248	chr17:20436337~20447249:+
LGG	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-10.63	7.97e-24	7.09e-21	-0.56	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
LGG	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-10.63	7.98e-24	7.1e-21	-0.97	-0.44	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
LGG	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-10.63	7.99e-24	7.1e-21	-0.55	-0.44	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
LGG	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-10.63	7.99e-24	7.1e-21	-0.61	-0.44	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
LGG	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-10.63	7.99e-24	7.1e-21	-0.61	-0.44	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
LGG	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-10.63	7.99e-24	7.1e-21	-0.61	-0.44	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
LGG	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-10.63	8.02e-24	7.12e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-10.63	8.02e-24	7.12e-21	-0.32	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
LGG	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	10.63	8.02e-24	7.13e-21	0.64	0.44	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
LGG	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	10.63	8.03e-24	7.14e-21	0.46	0.44	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
LGG	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-10.63	8.05e-24	7.15e-21	-0.48	-0.44	Depression;	chr6:28159843	chr6:28115628~28116551:+
LGG	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-10.63	8.05e-24	7.16e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-10.63	8.05e-24	7.16e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
LGG	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	10.63	8.07e-24	7.17e-21	0.8	0.44	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	10.63	8.1e-24	7.19e-21	0.59	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
LGG	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-10.63	8.11e-24	7.21e-21	-0.35	-0.44	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
LGG	cis	rs657075	0.595	rs57750646	ENSG00000233006.5	AC034220.3	-10.63	8.16e-24	7.25e-21	-0.67	-0.44	Rheumatoid arthritis;	chr5:132344571	chr5:132311285~132369916:-
LGG	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-10.63	8.17e-24	7.26e-21	-0.37	-0.44	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
LGG	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-10.63	8.18e-24	7.26e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-10.63	8.18e-24	7.26e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-10.63	8.18e-24	7.26e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-10.63	8.18e-24	7.26e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-10.63	8.18e-24	7.26e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-10.63	8.18e-24	7.26e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-10.63	8.18e-24	7.26e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
LGG	cis	rs172166	0.543	rs1150691	ENSG00000280107.1	AL022393.9	-10.63	8.21e-24	7.29e-21	-0.44	-0.44	Cardiac Troponin-T levels;	chr6:28200255	chr6:28170845~28172521:+
LGG	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	10.63	8.22e-24	7.3e-21	0.35	0.44	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
LGG	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-10.63	8.23e-24	7.31e-21	-0.51	-0.44	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
LGG	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	10.63	8.38e-24	7.43e-21	0.79	0.44	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
LGG	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	10.63	8.38e-24	7.43e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
LGG	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-10.63	8.38e-24	7.43e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
LGG	cis	rs4713118	0.662	rs149969	ENSG00000226314.6	ZNF192P1	10.63	8.45e-24	7.5e-21	0.52	0.44	Parkinson's disease;	chr6:28009959	chr6:28161781~28169594:+
LGG	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-10.63	8.49e-24	7.53e-21	-0.57	-0.44	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
LGG	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	10.62	8.5e-24	7.54e-21	0.51	0.44	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
LGG	cis	rs6500637	0.631	rs12921187	ENSG00000267077.1	RP11-127I20.5	-10.62	8.54e-24	7.57e-21	-0.45	-0.44	Cancer;	chr16:4893018	chr16:4795265~4796532:-
LGG	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-10.62	8.57e-24	7.6e-21	-0.59	-0.44	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
LGG	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-10.62	8.57e-24	7.6e-21	-0.59	-0.44	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-10.62	8.57e-24	7.6e-21	-0.59	-0.44	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
LGG	cis	rs7267979	0.903	rs6115109	ENSG00000125804.12	FAM182A	-10.62	8.57e-24	7.6e-21	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.833	rs4619688	ENSG00000125804.12	FAM182A	-10.62	8.57e-24	7.6e-21	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.903	rs6115118	ENSG00000125804.12	FAM182A	-10.62	8.57e-24	7.6e-21	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.903	rs1118963	ENSG00000125804.12	FAM182A	-10.62	8.57e-24	7.6e-21	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:26054655~26086917:+
LGG	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-10.62	8.58e-24	7.6e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-10.62	8.66e-24	7.67e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
LGG	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-10.62	8.67e-24	7.68e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-10.62	8.67e-24	7.68e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
LGG	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-10.62	8.67e-24	7.69e-21	-0.51	-0.44	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
LGG	cis	rs1150668	0.796	rs2531825	ENSG00000280107.1	AL022393.9	-10.62	8.7e-24	7.71e-21	-0.42	-0.44	Pubertal anthropometrics;	chr6:28381487	chr6:28170845~28172521:+
LGG	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	10.62	8.74e-24	7.75e-21	0.54	0.44	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
LGG	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-10.62	8.77e-24	7.76e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-10.62	8.77e-24	7.76e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-10.62	8.77e-24	7.76e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
LGG	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	10.62	8.77e-24	7.76e-21	0.35	0.44	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	10.62	8.77e-24	7.76e-21	0.35	0.44	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
LGG	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	10.62	8.77e-24	7.76e-21	0.35	0.44	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	10.62	8.77e-24	7.76e-21	0.35	0.44	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
LGG	cis	rs11098499	0.691	rs10010355	ENSG00000249244.1	RP11-548H18.2	10.62	8.77e-24	7.77e-21	0.45	0.44	Corneal astigmatism;	chr4:119339888	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.691	rs9307471	ENSG00000249244.1	RP11-548H18.2	10.62	8.77e-24	7.77e-21	0.45	0.44	Corneal astigmatism;	chr4:119340107	chr4:119391831~119395335:-
LGG	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-10.62	8.92e-24	7.89e-21	-0.51	-0.44	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
LGG	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-10.62	8.94e-24	7.91e-21	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
LGG	cis	rs7829975	0.846	rs7005216	ENSG00000173295.6	FAM86B3P	10.62	8.95e-24	7.93e-21	0.46	0.44	Mood instability;	chr8:8689600	chr8:8228595~8244865:+
LGG	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-10.62	8.97e-24	7.94e-21	-0.5	-0.44	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
LGG	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-10.62	8.97e-24	7.95e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
LGG	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-10.62	8.98e-24	7.95e-21	-0.51	-0.44	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
LGG	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	10.62	8.98e-24	7.95e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
LGG	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	10.62	9.02e-24	7.98e-21	0.47	0.44	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
LGG	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-10.62	9.04e-24	8e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
LGG	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-10.62	9.04e-24	8e-21	-0.5	-0.44	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-10.62	9.04e-24	8e-21	-0.5	-0.44	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	10.62	9.07e-24	8.02e-21	0.55	0.44	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
LGG	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	10.62	9.08e-24	8.03e-21	0.32	0.44	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
LGG	cis	rs7267979	0.966	rs910996	ENSG00000125804.12	FAM182A	-10.62	9.12e-24	8.06e-21	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:26054655~26086917:+
LGG	cis	rs7119038	0.509	rs11216960	ENSG00000255239.1	AP002954.6	-10.62	9.12e-24	8.07e-21	-0.59	-0.44	Sjögren's syndrome;	chr11:118707164	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.509	rs10892256	ENSG00000255239.1	AP002954.6	-10.62	9.12e-24	8.07e-21	-0.59	-0.44	Sjögren's syndrome;	chr11:118707996	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.509	rs10892257	ENSG00000255239.1	AP002954.6	-10.62	9.12e-24	8.07e-21	-0.59	-0.44	Sjögren's syndrome;	chr11:118708618	chr11:118688039~118690600:-
LGG	cis	rs651907	0.535	rs13065944	ENSG00000256628.3	ZBTB11-AS1	10.62	9.13e-24	8.08e-21	0.5	0.44	Colorectal cancer;	chr3:101754244	chr3:101676475~101679217:+
LGG	cis	rs3002131	0.522	rs2378583	ENSG00000225265.1	TAF1A-AS1	-10.62	9.17e-24	8.11e-21	-0.63	-0.44	Interleukin-10 levels;	chr1:222565958	chr1:222589825~222593032:+
LGG	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	10.62	9.19e-24	8.12e-21	0.57	0.44	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
LGG	cis	rs7914558	1	rs67908413	ENSG00000272912.1	RP11-724N1.1	-10.62	9.25e-24	8.18e-21	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102914585~102915404:+
LGG	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-10.62	9.25e-24	8.18e-21	-0.54	-0.44	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
LGG	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	10.61	9.34e-24	8.26e-21	0.35	0.44	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
LGG	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-10.61	9.36e-24	8.27e-21	-0.57	-0.44	QT interval;	chr16:28824579	chr16:28700294~28701540:-
LGG	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	10.61	9.46e-24	8.36e-21	0.49	0.44	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
LGG	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-10.61	9.47e-24	8.37e-21	-0.38	-0.44	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
LGG	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	10.61	9.49e-24	8.39e-21	0.66	0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-10.61	9.54e-24	8.42e-21	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
LGG	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-10.61	9.56e-24	8.45e-21	-0.51	-0.44	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
LGG	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-10.61	9.57e-24	8.45e-21	-0.93	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
LGG	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-10.61	9.58e-24	8.46e-21	-0.56	-0.44	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
LGG	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	10.61	9.61e-24	8.48e-21	0.5	0.44	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
LGG	cis	rs651907	0.557	rs11917569	ENSG00000256628.3	ZBTB11-AS1	10.61	9.63e-24	8.51e-21	0.51	0.44	Colorectal cancer;	chr3:101636219	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs11917682	ENSG00000256628.3	ZBTB11-AS1	10.61	9.63e-24	8.51e-21	0.51	0.44	Colorectal cancer;	chr3:101636583	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs12629658	ENSG00000256628.3	ZBTB11-AS1	10.61	9.63e-24	8.51e-21	0.51	0.44	Colorectal cancer;	chr3:101637691	chr3:101676475~101679217:+
LGG	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-10.61	9.68e-24	8.55e-21	-0.59	-0.44	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
LGG	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-10.61	9.68e-24	8.55e-21	-0.59	-0.44	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
LGG	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-10.61	9.68e-24	8.55e-21	-0.59	-0.44	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
LGG	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-10.61	9.68e-24	8.55e-21	-0.59	-0.44	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
LGG	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-10.61	9.7e-24	8.56e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
LGG	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-10.61	9.7e-24	8.56e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
LGG	cis	rs1420956	0.624	rs62080907	ENSG00000264151.4	RP11-739N10.1	10.61	9.72e-24	8.58e-21	0.55	0.44	Obesity-related traits;	chr18:27569221	chr18:27336379~27595164:-
LGG	cis	rs1420956	0.603	rs62080909	ENSG00000264151.4	RP11-739N10.1	10.61	9.72e-24	8.58e-21	0.55	0.44	Obesity-related traits;	chr18:27569247	chr18:27336379~27595164:-
LGG	cis	rs1420956	0.624	rs62080910	ENSG00000264151.4	RP11-739N10.1	10.61	9.72e-24	8.58e-21	0.55	0.44	Obesity-related traits;	chr18:27569294	chr18:27336379~27595164:-
LGG	cis	rs7914558	0.966	rs1890185	ENSG00000272912.1	RP11-724N1.1	-10.61	9.74e-24	8.6e-21	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102914585~102915404:+
LGG	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	10.61	9.81e-24	8.66e-21	0.54	0.44	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
LGG	cis	rs5742933	0.948	rs7592066	ENSG00000253559.1	OSGEPL1-AS1	10.61	9.82e-24	8.66e-21	0.53	0.44	Ferritin levels;	chr2:189778792	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.779	rs7595020	ENSG00000253559.1	OSGEPL1-AS1	10.61	9.82e-24	8.66e-21	0.53	0.44	Ferritin levels;	chr2:189778950	chr2:189762704~189765556:+
LGG	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	-10.61	9.82e-24	8.66e-21	-0.46	-0.44	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
LGG	cis	rs8064024	0.87	rs930854	ENSG00000267077.1	RP11-127I20.5	10.61	9.92e-24	8.75e-21	0.42	0.44	Cancer;	chr16:4814100	chr16:4795265~4796532:-
LGG	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-10.61	9.92e-24	8.75e-21	-0.47	-0.44	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
LGG	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-10.61	9.94e-24	8.77e-21	-0.48	-0.44	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
LGG	cis	rs4819052	1	rs3746980	ENSG00000215447.6	BX322557.10	-10.61	1e-23	8.83e-21	-0.38	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45288052~45291738:+
LGG	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-10.61	1.01e-23	8.86e-21	-0.56	-0.44	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
LGG	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-10.61	1.01e-23	8.86e-21	-0.56	-0.44	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
LGG	cis	rs7267979	1	rs2500432	ENSG00000125804.12	FAM182A	-10.61	1.01e-23	8.9e-21	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:26054655~26086917:+
LGG	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-10.6	1.01e-23	8.93e-21	-0.51	-0.44	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
LGG	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	10.6	1.02e-23	8.97e-21	0.68	0.44	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
LGG	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	10.6	1.03e-23	9.05e-21	0.31	0.44	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
LGG	cis	rs11233250	0.697	rs1472401	ENSG00000245832.5	RP11-179A16.1	10.6	1.03e-23	9.07e-21	0.67	0.44	Glioblastoma;Glioma;	chr11:82711904	chr11:81879851~82718082:-
LGG	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-10.6	1.04e-23	9.12e-21	-0.48	-0.44	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
LGG	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-10.6	1.04e-23	9.19e-21	-0.51	-0.44	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
LGG	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-10.6	1.05e-23	9.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	10.6	1.05e-23	9.22e-21	0.53	0.44	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
LGG	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	10.6	1.05e-23	9.26e-21	0.57	0.44	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
LGG	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	10.6	1.06e-23	9.3e-21	0.57	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
LGG	cis	rs12935418	0.583	rs2911150	ENSG00000260213.4	RP11-303E16.3	-10.6	1.06e-23	9.32e-21	-0.53	-0.44	Mean corpuscular volume;	chr16:80995194	chr16:81016792~81035759:-
LGG	cis	rs17345786	1	rs3804775	ENSG00000244119.1	PDCL3P4	10.6	1.06e-23	9.36e-21	0.37	0.44	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101712472~101713191:+
LGG	cis	rs67340775	0.541	rs200964	ENSG00000216901.1	AL022393.7	10.6	1.06e-23	9.36e-21	0.72	0.44	Lung cancer in ever smokers;	chr6:27899165	chr6:28176188~28176674:+
LGG	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	10.6	1.07e-23	9.37e-21	0.56	0.44	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
LGG	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	10.6	1.07e-23	9.37e-21	0.49	0.44	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
LGG	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-10.6	1.07e-23	9.38e-21	-0.46	-0.44	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
LGG	cis	rs7119038	0.509	rs10892259	ENSG00000255239.1	AP002954.6	-10.6	1.07e-23	9.43e-21	-0.59	-0.44	Sjögren's syndrome;	chr11:118712293	chr11:118688039~118690600:-
LGG	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	10.6	1.07e-23	9.43e-21	0.31	0.44	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	10.6	1.07e-23	9.43e-21	0.31	0.44	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	10.6	1.07e-23	9.43e-21	0.31	0.44	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
LGG	cis	rs657075	0.697	rs13179900	ENSG00000233006.5	AC034220.3	10.6	1.07e-23	9.44e-21	0.67	0.44	Rheumatoid arthritis;	chr5:132311897	chr5:132311285~132369916:-
LGG	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	10.6	1.09e-23	9.6e-21	0.5	0.44	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
LGG	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-10.6	1.09e-23	9.61e-21	-0.57	-0.44	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
LGG	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-10.6	1.1e-23	9.63e-21	-0.5	-0.44	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-10.6	1.1e-23	9.63e-21	-0.5	-0.44	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
LGG	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	10.59	1.11e-23	9.72e-21	0.53	0.44	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
LGG	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-10.59	1.11e-23	9.72e-21	-0.51	-0.44	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-10.59	1.11e-23	9.72e-21	-0.51	-0.44	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-10.59	1.11e-23	9.72e-21	-0.51	-0.44	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
LGG	cis	rs7829975	0.871	rs7829826	ENSG00000173295.6	FAM86B3P	10.59	1.11e-23	9.73e-21	0.47	0.44	Mood instability;	chr8:8720610	chr8:8228595~8244865:+
LGG	cis	rs1150668	0.83	rs2859365	ENSG00000226314.6	ZNF192P1	-10.59	1.11e-23	9.74e-21	-0.41	-0.44	Pubertal anthropometrics;	chr6:28423688	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	10.59	1.11e-23	9.74e-21	0.66	0.44	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
LGG	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-10.59	1.11e-23	9.76e-21	-0.51	-0.44	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
LGG	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	10.59	1.11e-23	9.76e-21	0.54	0.44	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
LGG	cis	rs9527	0.551	rs28606370	ENSG00000272912.1	RP11-724N1.1	-10.59	1.11e-23	9.77e-21	-0.5	-0.44	Arsenic metabolism;	chr10:102911075	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs10450373	ENSG00000272912.1	RP11-724N1.1	-10.59	1.12e-23	9.84e-21	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs2065977	ENSG00000272912.1	RP11-724N1.1	-10.59	1.12e-23	9.84e-21	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs12569617	ENSG00000272912.1	RP11-724N1.1	-10.59	1.12e-23	9.84e-21	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.933	rs1538204	ENSG00000272912.1	RP11-724N1.1	-10.59	1.12e-23	9.84e-21	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102914585~102915404:+
LGG	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	10.59	1.12e-23	9.86e-21	0.51	0.44	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-10.59	1.12e-23	9.86e-21	-0.51	-0.44	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-10.59	1.12e-23	9.86e-21	-0.51	-0.44	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-10.59	1.12e-23	9.86e-21	-0.51	-0.44	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
LGG	cis	rs7267979	0.903	rs2474769	ENSG00000125804.12	FAM182A	-10.59	1.13e-23	9.91e-21	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:26054655~26086917:+
LGG	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-10.59	1.13e-23	9.91e-21	-0.49	-0.44	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
LGG	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-10.59	1.13e-23	9.92e-21	-0.56	-0.44	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
LGG	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-10.59	1.13e-23	9.92e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
LGG	cis	rs6940116	1	rs6940116	ENSG00000199851.2	U3	10.59	1.13e-23	9.92e-21	0.75	0.44	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28015568~28015777:+
LGG	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	-10.59	1.13e-23	9.94e-21	-0.46	-0.44	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
LGG	cis	rs17345786	1	rs7641261	ENSG00000244119.1	PDCL3P4	10.59	1.14e-23	9.97e-21	0.37	0.44	Colonoscopy-negative controls vs population controls;	chr3:101560162	chr3:101712472~101713191:+
LGG	cis	rs9322193	0.961	rs9285521	ENSG00000223701.3	RAET1E-AS1	10.59	1.14e-23	1e-20	0.56	0.44	Lung cancer;	chr6:149585576	chr6:149884431~149919508:+
LGG	cis	rs5758511	0.68	rs5758667	ENSG00000227370.1	RP4-669P10.19	10.59	1.15e-23	1.01e-20	0.5	0.44	Birth weight;	chr22:42237198	chr22:42132543~42132998:+
LGG	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-10.59	1.15e-23	1.01e-20	-0.67	-0.44	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
LGG	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	10.59	1.15e-23	1.01e-20	0.53	0.44	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
LGG	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-10.59	1.15e-23	1.01e-20	-0.54	-0.44	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
LGG	cis	rs7927771	0.864	rs2053979	ENSG00000280615.1	Y_RNA	-10.59	1.15e-23	1.01e-20	-0.55	-0.44	Subjective well-being;	chr11:47417893	chr11:47614898~47614994:-
LGG	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	10.59	1.16e-23	1.02e-20	0.31	0.44	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	10.59	1.16e-23	1.02e-20	0.31	0.44	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	10.59	1.16e-23	1.02e-20	0.31	0.44	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
LGG	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	10.59	1.16e-23	1.02e-20	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
LGG	cis	rs1150668	0.83	rs2531831	ENSG00000226314.6	ZNF192P1	10.59	1.16e-23	1.02e-20	0.42	0.44	Pubertal anthropometrics;	chr6:28420988	chr6:28161781~28169594:+
LGG	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-10.59	1.17e-23	1.02e-20	-0.5	-0.44	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
LGG	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	10.59	1.17e-23	1.03e-20	0.53	0.44	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
LGG	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	10.59	1.17e-23	1.03e-20	0.32	0.44	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
LGG	cis	rs11098499	0.644	rs17517414	ENSG00000249244.1	RP11-548H18.2	10.59	1.17e-23	1.03e-20	0.45	0.44	Corneal astigmatism;	chr4:119340946	chr4:119391831~119395335:-
LGG	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-10.59	1.18e-23	1.03e-20	-0.92	-0.44	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
LGG	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-10.59	1.19e-23	1.04e-20	-0.49	-0.44	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
LGG	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-10.59	1.19e-23	1.04e-20	-0.48	-0.44	Depression;	chr6:28139049	chr6:28115628~28116551:+
LGG	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	10.59	1.19e-23	1.04e-20	0.96	0.44	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
LGG	cis	rs2283792	0.765	rs9607241	ENSG00000224086.5	LL22NC03-86G7.1	-10.59	1.2e-23	1.05e-20	-0.48	-0.44	Multiple sclerosis;	chr22:21750584	chr22:21938293~21977632:+
LGG	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	10.58	1.2e-23	1.05e-20	0.66	0.44	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
LGG	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-10.58	1.21e-23	1.06e-20	-0.51	-0.44	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
LGG	cis	rs7119038	0.509	rs11216964	ENSG00000255239.1	AP002954.6	-10.58	1.21e-23	1.06e-20	-0.59	-0.44	Sjögren's syndrome;	chr11:118711186	chr11:118688039~118690600:-
LGG	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-10.58	1.21e-23	1.06e-20	-0.51	-0.44	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
LGG	cis	rs7927771	0.864	rs2868459	ENSG00000280615.1	Y_RNA	-10.58	1.21e-23	1.06e-20	-0.55	-0.44	Subjective well-being;	chr11:47433421	chr11:47614898~47614994:-
LGG	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-10.58	1.22e-23	1.07e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-10.58	1.22e-23	1.07e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-10.58	1.22e-23	1.07e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-10.58	1.22e-23	1.07e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-10.58	1.22e-23	1.07e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
LGG	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	10.58	1.22e-23	1.07e-20	0.54	0.44	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
LGG	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	10.58	1.23e-23	1.07e-20	0.54	0.44	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
LGG	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	10.58	1.23e-23	1.07e-20	0.54	0.44	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
LGG	cis	rs7115242	0.699	rs12285074	ENSG00000254851.1	RP11-109L13.1	10.58	1.23e-23	1.08e-20	0.95	0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891312	chr11:117135528~117138582:+
LGG	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28076559	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28076704	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28078391	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28080757	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28080760	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28082231	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28082261	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28082984	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28083994	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28084025	chr6:28115628~28116551:+
LGG	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Depression;	chr6:28085319	chr6:28115628~28116551:+
LGG	cis	rs11098499	0.874	rs13139045	ENSG00000249244.1	RP11-548H18.2	10.58	1.23e-23	1.08e-20	0.47	0.44	Corneal astigmatism;	chr4:119247433	chr4:119391831~119395335:-
LGG	cis	rs6421571	0.565	rs10892263	ENSG00000255239.1	AP002954.6	-10.58	1.23e-23	1.08e-20	-0.6	-0.44	Primary biliary cholangitis;	chr11:118716610	chr11:118688039~118690600:-
LGG	cis	rs7914558	1	rs7911789	ENSG00000272912.1	RP11-724N1.1	-10.58	1.23e-23	1.08e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102914585~102915404:+
LGG	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-10.58	1.24e-23	1.08e-20	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
LGG	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	10.58	1.24e-23	1.08e-20	0.34	0.44	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
LGG	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	10.58	1.24e-23	1.09e-20	0.54	0.44	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
LGG	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	10.58	1.24e-23	1.09e-20	0.54	0.44	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
LGG	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	10.58	1.24e-23	1.09e-20	0.67	0.44	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
LGG	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	10.58	1.25e-23	1.09e-20	0.48	0.44	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
LGG	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-10.58	1.25e-23	1.09e-20	-0.48	-0.44	Depression;	chr6:28070115	chr6:28115628~28116551:+
LGG	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-10.58	1.25e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
LGG	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-10.58	1.26e-23	1.1e-20	-0.57	-0.44	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
LGG	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-10.58	1.26e-23	1.1e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
LGG	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-10.58	1.26e-23	1.1e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
LGG	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	10.58	1.27e-23	1.11e-20	0.55	0.44	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
LGG	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-10.58	1.27e-23	1.11e-20	-0.48	-0.44	Depression;	chr6:28140454	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-10.58	1.27e-23	1.11e-20	-0.48	-0.44	Depression;	chr6:28141189	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-10.58	1.27e-23	1.11e-20	-0.48	-0.44	Depression;	chr6:28141484	chr6:28115628~28116551:+
LGG	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-10.58	1.27e-23	1.11e-20	-0.49	-0.44	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-10.58	1.27e-23	1.11e-20	-0.49	-0.44	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-10.58	1.27e-23	1.11e-20	-0.49	-0.44	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
LGG	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	10.58	1.28e-23	1.11e-20	0.51	0.44	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
LGG	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-10.58	1.28e-23	1.11e-20	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
LGG	cis	rs7267979	0.903	rs6115101	ENSG00000125804.12	FAM182A	-10.58	1.28e-23	1.11e-20	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.868	rs6107019	ENSG00000125804.12	FAM182A	-10.58	1.28e-23	1.11e-20	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:26054655~26086917:+
LGG	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	10.58	1.29e-23	1.13e-20	0.6	0.44	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
LGG	cis	rs4713118	0.615	rs57252182	ENSG00000216901.1	AL022393.7	10.58	1.3e-23	1.14e-20	0.53	0.44	Parkinson's disease;	chr6:27752470	chr6:28176188~28176674:+
LGG	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	10.58	1.3e-23	1.14e-20	0.53	0.44	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	10.58	1.3e-23	1.14e-20	0.53	0.44	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
LGG	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	10.58	1.31e-23	1.14e-20	0.54	0.44	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
LGG	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-10.57	1.31e-23	1.14e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
LGG	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-10.57	1.31e-23	1.15e-20	-0.49	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
LGG	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-10.57	1.31e-23	1.15e-20	-0.6	-0.44	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
LGG	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-10.57	1.31e-23	1.15e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-10.57	1.31e-23	1.15e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-10.57	1.31e-23	1.15e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-10.57	1.31e-23	1.15e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-10.57	1.32e-23	1.15e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-10.57	1.32e-23	1.15e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-10.57	1.32e-23	1.15e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
LGG	cis	rs4819052	1	rs13052356	ENSG00000215447.6	BX322557.10	-10.57	1.33e-23	1.16e-20	-0.37	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45288052~45291738:+
LGG	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	10.57	1.34e-23	1.17e-20	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
LGG	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-10.57	1.34e-23	1.17e-20	-0.54	-0.44	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
LGG	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	10.57	1.35e-23	1.18e-20	0.52	0.44	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
LGG	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	10.57	1.35e-23	1.18e-20	0.52	0.44	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
LGG	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-10.57	1.35e-23	1.18e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
LGG	cis	rs7927771	0.793	rs12803525	ENSG00000280615.1	Y_RNA	-10.57	1.35e-23	1.18e-20	-0.55	-0.44	Subjective well-being;	chr11:47391924	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.8	rs55876153	ENSG00000280615.1	Y_RNA	-10.57	1.35e-23	1.18e-20	-0.55	-0.44	Subjective well-being;	chr11:47395085	chr11:47614898~47614994:-
LGG	cis	rs5742933	0.681	rs4525728	ENSG00000253559.1	OSGEPL1-AS1	10.57	1.35e-23	1.18e-20	0.53	0.44	Ferritin levels;	chr2:189780324	chr2:189762704~189765556:+
LGG	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28089816	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28090857	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28091439	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28091659	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28092227	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28093966	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28094014	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28096077	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28096855	chr6:28115628~28116551:+
LGG	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28099759	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28100648	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28104824	chr6:28115628~28116551:+
LGG	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28107222	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28108492	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28110254	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28111382	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28111650	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28112175	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28113851	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28114487	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28114933	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28115743	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28116411	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
LGG	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28123153	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28124529	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28127577	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28131566	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28133900	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28136698	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28136856	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28137418	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28138363	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28138981	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-10.57	1.35e-23	1.18e-20	-0.48	-0.44	Depression;	chr6:28139012	chr6:28115628~28116551:+
LGG	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-10.57	1.35e-23	1.18e-20	-0.51	-0.44	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
LGG	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-10.57	1.35e-23	1.18e-20	-0.57	-0.44	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
LGG	cis	rs4819052	1	rs13053002	ENSG00000215447.6	BX322557.10	-10.57	1.37e-23	1.19e-20	-0.37	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45288052~45291738:+
LGG	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-10.57	1.37e-23	1.2e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
LGG	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-10.57	1.38e-23	1.2e-20	-0.49	-0.44	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
LGG	cis	rs651907	0.557	rs13077925	ENSG00000256628.3	ZBTB11-AS1	10.57	1.38e-23	1.2e-20	0.5	0.44	Colorectal cancer;	chr3:101769337	chr3:101676475~101679217:+
LGG	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-10.57	1.38e-23	1.2e-20	-0.67	-0.44	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-10.57	1.38e-23	1.2e-20	-0.67	-0.44	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
LGG	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-10.57	1.38e-23	1.2e-20	-0.67	-0.44	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
LGG	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-10.57	1.38e-23	1.2e-20	-0.51	-0.44	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
LGG	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	10.57	1.38e-23	1.2e-20	0.54	0.44	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
LGG	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	10.57	1.38e-23	1.2e-20	0.58	0.44	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	10.57	1.38e-23	1.2e-20	0.58	0.44	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
LGG	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	10.57	1.39e-23	1.21e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
LGG	cis	rs4938573	0.526	rs11216973	ENSG00000255239.1	AP002954.6	-10.57	1.4e-23	1.21e-20	-0.6	-0.44	Follicular lymphoma;	chr11:118716292	chr11:118688039~118690600:-
LGG	cis	rs9527	0.501	rs12244388	ENSG00000272912.1	RP11-724N1.1	-10.57	1.4e-23	1.22e-20	-0.5	-0.44	Arsenic metabolism;	chr10:102880295	chr10:102914585~102915404:+
LGG	cis	rs1475911	0.744	rs12481958	ENSG00000184385.2	UMODL1-AS1	10.57	1.4e-23	1.22e-20	0.53	0.44	IgG glycosylation;	chr21:42097159	chr21:42102134~42108534:-
LGG	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	10.57	1.4e-23	1.22e-20	0.49	0.44	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	10.57	1.4e-23	1.22e-20	0.49	0.44	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	10.57	1.4e-23	1.22e-20	0.49	0.44	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	10.57	1.4e-23	1.22e-20	0.49	0.44	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	10.57	1.41e-23	1.23e-20	0.49	0.44	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	10.57	1.41e-23	1.23e-20	0.49	0.44	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
LGG	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	10.57	1.41e-23	1.23e-20	0.61	0.44	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
LGG	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-10.57	1.41e-23	1.23e-20	-0.59	-0.44	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-10.57	1.41e-23	1.23e-20	-0.59	-0.44	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
LGG	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	10.57	1.42e-23	1.23e-20	0.35	0.44	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
LGG	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-10.57	1.42e-23	1.24e-20	-0.56	-0.44	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
LGG	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-10.57	1.43e-23	1.24e-20	-0.48	-0.44	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
LGG	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	10.56	1.43e-23	1.24e-20	0.45	0.44	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
LGG	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	10.56	1.43e-23	1.25e-20	0.35	0.44	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-10.56	1.43e-23	1.25e-20	-0.35	-0.44	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
LGG	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	10.56	1.44e-23	1.25e-20	0.52	0.44	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
LGG	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	10.56	1.44e-23	1.25e-20	0.57	0.44	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
LGG	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-10.56	1.44e-23	1.25e-20	-0.56	-0.44	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
LGG	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-10.56	1.46e-23	1.27e-20	-0.47	-0.44	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-10.56	1.46e-23	1.27e-20	-0.47	-0.44	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-10.56	1.46e-23	1.27e-20	-0.47	-0.44	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
LGG	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	10.56	1.46e-23	1.27e-20	0.53	0.44	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
LGG	cis	rs1150668	0.796	rs1005125	ENSG00000280107.1	AL022393.9	-10.56	1.46e-23	1.27e-20	-0.42	-0.44	Pubertal anthropometrics;	chr6:28399578	chr6:28170845~28172521:+
LGG	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-10.56	1.46e-23	1.27e-20	-0.56	-0.44	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
LGG	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-10.56	1.46e-23	1.27e-20	-0.59	-0.44	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
LGG	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-10.56	1.47e-23	1.28e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-10.56	1.47e-23	1.28e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
LGG	cis	rs3812049	0.784	rs3749748	ENSG00000245937.6	LINC01184	-10.56	1.48e-23	1.28e-20	-0.51	-0.44	Lymphocyte counts;Red cell distribution width;	chr5:128014857	chr5:127940426~128083172:-
LGG	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-10.56	1.49e-23	1.29e-20	-0.48	-0.44	Depression;	chr6:28071237	chr6:28115628~28116551:+
LGG	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-10.56	1.49e-23	1.29e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
LGG	cis	rs11148252	0.574	rs73186430	ENSG00000273784.3	RP11-78J21.7	-10.56	1.5e-23	1.3e-20	-0.48	-0.44	Lewy body disease;	chr13:52658756	chr13:52600042~52642542:+
LGG	cis	rs5742933	0.817	rs5742938	ENSG00000253559.1	OSGEPL1-AS1	10.56	1.5e-23	1.3e-20	0.52	0.44	Ferritin levels;	chr2:189785232	chr2:189762704~189765556:+
LGG	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	10.56	1.5e-23	1.3e-20	0.6	0.44	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
LGG	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-10.56	1.51e-23	1.31e-20	-0.67	-0.44	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
LGG	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	10.56	1.51e-23	1.31e-20	0.48	0.44	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
LGG	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-10.56	1.52e-23	1.32e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-10.56	1.52e-23	1.32e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.961	rs4870144	ENSG00000223701.3	RAET1E-AS1	10.56	1.53e-23	1.32e-20	0.55	0.44	Lung cancer;	chr6:149575540	chr6:149884431~149919508:+
LGG	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	10.56	1.54e-23	1.33e-20	0.61	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
LGG	cis	rs7267979	0.868	rs6138546	ENSG00000125804.12	FAM182A	-10.56	1.54e-23	1.34e-20	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:26054655~26086917:+
LGG	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	10.56	1.55e-23	1.34e-20	0.54	0.44	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
LGG	cis	rs11168351	0.927	rs10875716	ENSG00000258273.1	RP11-370I10.4	-10.56	1.55e-23	1.34e-20	-0.54	-0.44	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48333755~48333901:-
LGG	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	10.56	1.55e-23	1.34e-20	0.31	0.44	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
LGG	cis	rs7615952	0.8	rs11914298	ENSG00000171084.14	FAM86JP	10.55	1.56e-23	1.35e-20	0.77	0.44	Blood pressure (smoking interaction);	chr3:125924929	chr3:125916620~125930024:+
LGG	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-10.55	1.56e-23	1.35e-20	-0.62	-0.44	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
LGG	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-10.55	1.56e-23	1.35e-20	-0.94	-0.44	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
LGG	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-10.55	1.56e-23	1.35e-20	-0.94	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
LGG	cis	rs4373814	0.595	rs1891393	ENSG00000226083.4	SLC39A12-AS1	10.55	1.57e-23	1.36e-20	0.47	0.44	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18138501	chr10:18001786~18010562:-
LGG	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	10.55	1.57e-23	1.36e-20	0.52	0.44	Height;	chr11:118852670	chr11:118688039~118690600:-
LGG	cis	rs6452524	0.868	rs1011981	ENSG00000248112.1	RP11-78C3.1	10.55	1.57e-23	1.36e-20	0.58	0.44	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.868	rs17284218	ENSG00000248112.1	RP11-78C3.1	10.55	1.57e-23	1.36e-20	0.58	0.44	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:82919376~82921119:-
LGG	cis	rs1420956	0.624	rs16943751	ENSG00000264151.4	RP11-739N10.1	10.55	1.57e-23	1.36e-20	0.55	0.44	Obesity-related traits;	chr18:27568961	chr18:27336379~27595164:-
LGG	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	10.55	1.58e-23	1.37e-20	0.51	0.44	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
LGG	cis	rs7267979	0.833	rs6138556	ENSG00000125804.12	FAM182A	-10.55	1.58e-23	1.37e-20	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:26054655~26086917:+
LGG	cis	rs1799949	0.832	rs2070835	ENSG00000267681.1	CTD-3199J23.6	-10.55	1.59e-23	1.37e-20	-0.5	-0.44	Menopause (age at onset);	chr17:43022008	chr17:43144956~43145255:+
LGG	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	10.55	1.59e-23	1.38e-20	0.55	0.44	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
LGG	cis	rs7927771	0.756	rs10742803	ENSG00000280615.1	Y_RNA	10.55	1.59e-23	1.38e-20	0.55	0.44	Subjective well-being;	chr11:47418387	chr11:47614898~47614994:-
LGG	cis	rs7914558	0.966	rs11191471	ENSG00000272912.1	RP11-724N1.1	-10.55	1.6e-23	1.39e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102914585~102915404:+
LGG	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-10.55	1.6e-23	1.39e-20	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
LGG	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-10.55	1.6e-23	1.39e-20	-0.47	-0.44	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
LGG	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	10.55	1.61e-23	1.39e-20	0.63	0.44	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
LGG	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-10.55	1.61e-23	1.39e-20	-0.35	-0.44	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
LGG	cis	rs8092443	1	rs8092443	ENSG00000278971.1	RP11-644A7.2	10.55	1.62e-23	1.4e-20	0.63	0.44	Response to antipsychotic treatment;	chr18:70475178	chr18:70489630~70491205:+
LGG	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-10.55	1.62e-23	1.4e-20	-0.51	-0.44	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-10.55	1.62e-23	1.4e-20	-0.51	-0.44	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
LGG	cis	rs7267979	1	rs2856	ENSG00000125804.12	FAM182A	-10.55	1.63e-23	1.41e-20	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:26054655~26086917:+
LGG	cis	rs1420956	0.624	rs62080906	ENSG00000264151.4	RP11-739N10.1	10.55	1.65e-23	1.43e-20	0.54	0.44	Obesity-related traits;	chr18:27569099	chr18:27336379~27595164:-
LGG	cis	rs7119038	0.509	rs10892260	ENSG00000255239.1	AP002954.6	-10.55	1.66e-23	1.43e-20	-0.59	-0.44	Sjögren's syndrome;	chr11:118712816	chr11:118688039~118690600:-
LGG	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-10.55	1.66e-23	1.43e-20	-0.35	-0.44	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
LGG	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-10.55	1.66e-23	1.44e-20	-0.47	-0.44	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-10.55	1.66e-23	1.44e-20	-0.47	-0.44	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
LGG	cis	rs1420956	0.603	rs8092173	ENSG00000264151.4	RP11-739N10.1	10.55	1.67e-23	1.44e-20	0.54	0.44	Obesity-related traits;	chr18:27569506	chr18:27336379~27595164:-
LGG	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-10.55	1.67e-23	1.45e-20	-0.48	-0.44	Depression;	chr6:28151096	chr6:28115628~28116551:+
LGG	cis	rs8092443	1	rs73459349	ENSG00000278971.1	RP11-644A7.2	-10.55	1.68e-23	1.45e-20	-0.63	-0.44	Response to antipsychotic treatment;	chr18:70477271	chr18:70489630~70491205:+
LGG	cis	rs8092443	1	rs73459351	ENSG00000278971.1	RP11-644A7.2	-10.55	1.68e-23	1.45e-20	-0.63	-0.44	Response to antipsychotic treatment;	chr18:70477392	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.872	rs7234487	ENSG00000278971.1	RP11-644A7.2	-10.55	1.68e-23	1.45e-20	-0.63	-0.44	Response to antipsychotic treatment;	chr18:70478289	chr18:70489630~70491205:+
LGG	cis	rs1150668	0.796	rs728122	ENSG00000280107.1	AL022393.9	-10.55	1.68e-23	1.45e-20	-0.41	-0.44	Pubertal anthropometrics;	chr6:28431347	chr6:28170845~28172521:+
LGG	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	10.55	1.69e-23	1.46e-20	0.46	0.44	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
LGG	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-10.55	1.69e-23	1.46e-20	-0.58	-0.44	QT interval;	chr16:28884339	chr16:28700294~28701540:-
LGG	cis	rs67340775	0.541	rs200973	ENSG00000199851.2	U3	10.54	1.7e-23	1.47e-20	0.8	0.44	Lung cancer in ever smokers;	chr6:27890643	chr6:28015568~28015777:+
LGG	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-10.54	1.7e-23	1.47e-20	-0.45	-0.44	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
LGG	cis	rs7119038	0.509	rs11216956	ENSG00000255239.1	AP002954.6	-10.54	1.71e-23	1.47e-20	-0.6	-0.44	Sjögren's syndrome;	chr11:118704617	chr11:118688039~118690600:-
LGG	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-10.54	1.71e-23	1.48e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
LGG	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-10.54	1.71e-23	1.48e-20	-0.35	-0.44	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
LGG	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-10.54	1.71e-23	1.48e-20	-0.48	-0.44	Depression;	chr6:28139876	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-10.54	1.71e-23	1.48e-20	-0.48	-0.44	Depression;	chr6:28139998	chr6:28115628~28116551:+
LGG	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	10.54	1.72e-23	1.48e-20	0.49	0.44	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
LGG	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-10.54	1.72e-23	1.49e-20	-0.49	-0.44	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
LGG	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-10.54	1.73e-23	1.49e-20	-0.96	-0.44	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
LGG	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-10.54	1.73e-23	1.5e-20	-0.48	-0.44	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
LGG	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-10.54	1.74e-23	1.5e-20	-0.36	-0.44	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
LGG	cis	rs651907	0.514	rs55654108	ENSG00000256628.3	ZBTB11-AS1	10.54	1.74e-23	1.5e-20	0.5	0.44	Colorectal cancer;	chr3:101706859	chr3:101676475~101679217:+
LGG	cis	rs651907	0.514	rs10936744	ENSG00000256628.3	ZBTB11-AS1	10.54	1.74e-23	1.5e-20	0.5	0.44	Colorectal cancer;	chr3:101714596	chr3:101676475~101679217:+
LGG	cis	rs651907	0.514	rs12636047	ENSG00000256628.3	ZBTB11-AS1	10.54	1.74e-23	1.5e-20	0.5	0.44	Colorectal cancer;	chr3:101715605	chr3:101676475~101679217:+
LGG	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	10.54	1.74e-23	1.5e-20	0.35	0.44	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
LGG	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-10.54	1.74e-23	1.51e-20	-0.51	-0.44	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
LGG	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
LGG	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
LGG	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
LGG	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-10.54	1.75e-23	1.51e-20	-0.35	-0.44	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
LGG	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-10.54	1.75e-23	1.51e-20	-0.52	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
LGG	cis	rs2013441	1	rs9904928	ENSG00000230528.6	NOS2P3	-10.54	1.76e-23	1.51e-20	-0.42	-0.44	Obesity-related traits;	chr17:20277223	chr17:20436337~20447249:+
LGG	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-10.54	1.76e-23	1.52e-20	-0.85	-0.44	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
LGG	cis	rs7829975	0.811	rs7011229	ENSG00000173295.6	FAM86B3P	10.54	1.77e-23	1.52e-20	0.46	0.44	Mood instability;	chr8:8685814	chr8:8228595~8244865:+
LGG	cis	rs11233250	0.697	rs12419612	ENSG00000245832.5	RP11-179A16.1	10.54	1.77e-23	1.53e-20	0.67	0.44	Glioblastoma;Glioma;	chr11:82695034	chr11:81879851~82718082:-
LGG	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-10.54	1.77e-23	1.53e-20	-0.49	-0.44	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
LGG	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	10.54	1.78e-23	1.54e-20	0.6	0.44	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
LGG	cis	rs1150668	0.796	rs2247002	ENSG00000280107.1	AL022393.9	-10.54	1.78e-23	1.54e-20	-0.41	-0.44	Pubertal anthropometrics;	chr6:28430174	chr6:28170845~28172521:+
LGG	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	10.54	1.78e-23	1.54e-20	0.6	0.44	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
LGG	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-10.54	1.79e-23	1.54e-20	-0.66	-0.44	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
LGG	cis	rs17767294	0.612	rs12332927	ENSG00000199851.2	U3	10.54	1.79e-23	1.54e-20	0.94	0.44	Parkinson's disease;	chr6:27987337	chr6:28015568~28015777:+
LGG	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-10.54	1.79e-23	1.54e-20	-0.55	-0.44	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
LGG	cis	rs4713118	0.629	rs203887	ENSG00000226314.6	ZNF192P1	10.54	1.8e-23	1.55e-20	0.58	0.44	Parkinson's disease;	chr6:28053491	chr6:28161781~28169594:+
LGG	cis	rs7914558	0.966	rs10883805	ENSG00000272912.1	RP11-724N1.1	-10.54	1.8e-23	1.55e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102914585~102915404:+
LGG	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	10.54	1.8e-23	1.55e-20	0.5	0.44	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
LGG	cis	rs4819052	1	rs733738	ENSG00000223768.1	LINC00205	10.54	1.8e-23	1.55e-20	0.53	0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45293285~45297354:+
LGG	cis	rs7914558	1	rs12780843	ENSG00000272912.1	RP11-724N1.1	-10.54	1.8e-23	1.56e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs10748836	ENSG00000272912.1	RP11-724N1.1	-10.54	1.81e-23	1.56e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs10786727	ENSG00000272912.1	RP11-724N1.1	-10.54	1.81e-23	1.56e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.933	rs10786729	ENSG00000272912.1	RP11-724N1.1	-10.54	1.81e-23	1.56e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102914585~102915404:+
LGG	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	10.54	1.82e-23	1.57e-20	0.56	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
LGG	cis	rs4713118	0.568	rs9468213	ENSG00000199851.2	U3	10.54	1.82e-23	1.57e-20	0.59	0.44	Parkinson's disease;	chr6:27738401	chr6:28015568~28015777:+
LGG	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-10.54	1.82e-23	1.57e-20	-0.48	-0.44	Depression;	chr6:28071808	chr6:28115628~28116551:+
LGG	cis	rs11233250	0.697	rs1945794	ENSG00000245832.5	RP11-179A16.1	10.54	1.82e-23	1.57e-20	0.67	0.44	Glioblastoma;Glioma;	chr11:82697229	chr11:81879851~82718082:-
LGG	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	10.54	1.84e-23	1.59e-20	0.54	0.44	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
LGG	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-10.53	1.85e-23	1.59e-20	-0.51	-0.44	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
LGG	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	10.53	1.85e-23	1.59e-20	0.52	0.44	Height;	chr11:118859432	chr11:118688039~118690600:-
LGG	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-10.53	1.88e-23	1.61e-20	-0.52	-0.44	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	10.53	1.88e-23	1.62e-20	0.5	0.44	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
LGG	cis	rs7849270	0.84	rs12346996	ENSG00000268707.1	RP11-247A12.7	-10.53	1.88e-23	1.62e-20	-0.52	-0.44	Blood metabolite ratios;	chr9:129078577	chr9:129170434~129170940:+
LGG	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	10.53	1.88e-23	1.62e-20	0.54	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
LGG	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	10.53	1.89e-23	1.62e-20	0.54	0.44	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
LGG	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	10.53	1.89e-23	1.62e-20	0.52	0.44	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	10.53	1.89e-23	1.62e-20	0.52	0.44	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
LGG	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	10.53	1.89e-23	1.62e-20	0.54	0.44	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
LGG	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	10.53	1.89e-23	1.63e-20	0.51	0.44	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
LGG	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-10.53	1.89e-23	1.63e-20	-0.66	-0.44	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
LGG	cis	rs11098499	0.569	rs10023641	ENSG00000249244.1	RP11-548H18.2	10.53	1.9e-23	1.63e-20	0.45	0.44	Corneal astigmatism;	chr4:119337255	chr4:119391831~119395335:-
LGG	cis	rs651907	0.535	rs13059470	ENSG00000256628.3	ZBTB11-AS1	-10.53	1.9e-23	1.64e-20	-0.5	-0.44	Colorectal cancer;	chr3:101705956	chr3:101676475~101679217:+
LGG	cis	rs11675119	0.501	rs13003003	ENSG00000225234.1	TRAPPC12-AS1	-10.53	1.91e-23	1.64e-20	-0.44	-0.44	Neurofibrillary tangles;	chr2:3489789	chr2:3481242~3482409:-
LGG	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	10.53	1.92e-23	1.65e-20	0.53	0.44	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.887	rs4870139	ENSG00000223701.3	RAET1E-AS1	10.53	1.92e-23	1.65e-20	0.56	0.44	Lung cancer;	chr6:149575182	chr6:149884431~149919508:+
LGG	cis	rs8064024	0.87	rs6500635	ENSG00000267077.1	RP11-127I20.5	10.53	1.92e-23	1.65e-20	0.42	0.44	Cancer;	chr16:4817564	chr16:4795265~4796532:-
LGG	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	10.53	1.93e-23	1.66e-20	0.47	0.44	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
LGG	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	10.53	1.94e-23	1.66e-20	0.49	0.44	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	10.53	1.94e-23	1.66e-20	0.49	0.44	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
LGG	cis	rs853679	1	rs6905391	ENSG00000199851.2	U3	10.53	1.95e-23	1.67e-20	0.81	0.44	Depression;	chr6:28294909	chr6:28015568~28015777:+
LGG	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-10.53	1.95e-23	1.67e-20	-0.58	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
LGG	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-10.53	1.95e-23	1.68e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
LGG	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	10.53	1.96e-23	1.68e-20	0.54	0.44	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
LGG	cis	rs7267979	0.932	rs367666	ENSG00000125804.12	FAM182A	-10.53	1.96e-23	1.69e-20	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	10.53	1.97e-23	1.69e-20	0.66	0.44	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
LGG	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-10.53	1.97e-23	1.7e-20	-0.56	-0.44	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
LGG	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	10.53	1.98e-23	1.7e-20	0.54	0.44	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
LGG	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	10.53	1.98e-23	1.7e-20	0.46	0.44	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
LGG	cis	rs17772222	0.839	rs2274735	ENSG00000258983.2	RP11-507K2.2	10.53	1.98e-23	1.7e-20	0.48	0.44	Coronary artery calcification;	chr14:88505414	chr14:88499334~88515502:+
LGG	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-10.53	1.98e-23	1.7e-20	-0.45	-0.44	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
LGG	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	10.53	1.99e-23	1.71e-20	0.55	0.44	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
LGG	cis	rs7246657	0.722	rs2909093	ENSG00000267422.1	CTD-2554C21.1	10.53	1.99e-23	1.71e-20	0.53	0.44	Coronary artery calcification;	chr19:37708561	chr19:37779686~37792865:+
LGG	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-10.53	1.99e-23	1.71e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
LGG	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-10.53	2e-23	1.72e-20	-0.51	-0.44	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
LGG	cis	rs7267979	0.903	rs2474766	ENSG00000125804.12	FAM182A	-10.53	2e-23	1.72e-20	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:26054655~26086917:+
LGG	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	10.53	2.01e-23	1.73e-20	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
LGG	cis	rs7927771	0.864	rs2293577	ENSG00000280615.1	Y_RNA	10.53	2.01e-23	1.73e-20	0.55	0.44	Subjective well-being;	chr11:47415651	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.864	rs3781626	ENSG00000280615.1	Y_RNA	-10.52	2.02e-23	1.73e-20	-0.55	-0.44	Subjective well-being;	chr11:47421342	chr11:47614898~47614994:-
LGG	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-10.52	2.02e-23	1.73e-20	-0.55	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
LGG	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-10.52	2.02e-23	1.73e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
LGG	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	10.52	2.02e-23	1.74e-20	0.35	0.44	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	10.52	2.02e-23	1.74e-20	0.35	0.44	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	10.52	2.02e-23	1.74e-20	0.35	0.44	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
LGG	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	10.52	2.02e-23	1.74e-20	0.35	0.44	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	10.52	2.02e-23	1.74e-20	0.35	0.44	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
LGG	cis	rs5758511	0.68	rs5758651	ENSG00000227370.1	RP4-669P10.19	10.52	2.02e-23	1.74e-20	0.5	0.44	Birth weight;	chr22:42213142	chr22:42132543~42132998:+
LGG	cis	rs7914558	1	rs10509757	ENSG00000272912.1	RP11-724N1.1	-10.52	2.03e-23	1.74e-20	-0.48	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102914585~102915404:+
LGG	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	10.52	2.04e-23	1.75e-20	0.55	0.44	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	10.52	2.04e-23	1.75e-20	0.53	0.44	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
LGG	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	10.52	2.05e-23	1.75e-20	0.95	0.44	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
LGG	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	10.52	2.06e-23	1.77e-20	0.49	0.44	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	10.52	2.06e-23	1.77e-20	0.49	0.44	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
LGG	cis	rs5758511	0.514	rs5751221	ENSG00000227370.1	RP4-669P10.19	10.52	2.06e-23	1.77e-20	0.49	0.44	Birth weight;	chr22:42120362	chr22:42132543~42132998:+
LGG	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
LGG	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
LGG	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
LGG	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
LGG	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-10.52	2.07e-23	1.77e-20	-0.58	-0.44	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.886	rs4039600	ENSG00000223701.3	RAET1E-AS1	10.52	2.07e-23	1.77e-20	0.54	0.44	Lung cancer;	chr6:149576319	chr6:149884431~149919508:+
LGG	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-10.52	2.07e-23	1.78e-20	-0.94	-0.44	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-10.52	2.07e-23	1.78e-20	-0.94	-0.44	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-10.52	2.07e-23	1.78e-20	-0.94	-0.44	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
LGG	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	10.52	2.07e-23	1.78e-20	0.54	0.44	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
LGG	cis	rs11098499	0.698	rs4422403	ENSG00000249244.1	RP11-548H18.2	10.52	2.1e-23	1.8e-20	0.45	0.44	Corneal astigmatism;	chr4:119337039	chr4:119391831~119395335:-
LGG	cis	rs1150668	0.796	rs2531825	ENSG00000226314.6	ZNF192P1	10.52	2.1e-23	1.8e-20	0.41	0.44	Pubertal anthropometrics;	chr6:28381487	chr6:28161781~28169594:+
LGG	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	10.52	2.11e-23	1.81e-20	0.3	0.44	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	10.52	2.11e-23	1.81e-20	0.3	0.44	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	10.52	2.11e-23	1.81e-20	0.3	0.44	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	10.52	2.11e-23	1.81e-20	0.3	0.44	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	10.52	2.11e-23	1.81e-20	0.3	0.44	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	10.52	2.11e-23	1.81e-20	0.3	0.44	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
LGG	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-10.52	2.12e-23	1.81e-20	-0.74	-0.44	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
LGG	cis	rs7246657	0.722	rs968073	ENSG00000267422.1	CTD-2554C21.1	10.52	2.12e-23	1.81e-20	0.52	0.44	Coronary artery calcification;	chr19:37701120	chr19:37779686~37792865:+
LGG	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-10.52	2.12e-23	1.82e-20	-0.35	-0.44	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
LGG	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	10.52	2.13e-23	1.83e-20	0.6	0.44	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
LGG	cis	rs853679	1	rs853694	ENSG00000199851.2	U3	10.52	2.13e-23	1.83e-20	0.81	0.44	Depression;	chr6:28311323	chr6:28015568~28015777:+
LGG	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-10.52	2.14e-23	1.83e-20	-0.37	-0.44	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
LGG	cis	rs9595066	1	rs66786230	ENSG00000230731.2	RP11-478K15.6	10.52	2.14e-23	1.83e-20	0.74	0.44	Schizophrenia;	chr13:44137489	chr13:44234118~44243192:-
LGG	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-10.52	2.15e-23	1.84e-20	-0.48	-0.43	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
LGG	cis	rs853679	0.55	rs34477097	ENSG00000226314.6	ZNF192P1	10.52	2.16e-23	1.85e-20	0.5	0.43	Depression;	chr6:28229408	chr6:28161781~28169594:+
LGG	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	10.52	2.16e-23	1.85e-20	0.62	0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
LGG	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-10.52	2.16e-23	1.85e-20	-0.35	-0.43	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-10.52	2.16e-23	1.85e-20	-0.35	-0.43	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
LGG	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-10.52	2.17e-23	1.85e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
LGG	cis	rs4713118	0.505	rs276371	ENSG00000218016.2	ZNF192P2	-10.52	2.17e-23	1.85e-20	-0.51	-0.43	Parkinson's disease;	chr6:27942930	chr6:28188050~28189432:+
LGG	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-10.52	2.17e-23	1.86e-20	-0.45	-0.43	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
LGG	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	10.52	2.19e-23	1.87e-20	0.49	0.43	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
LGG	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-10.51	2.21e-23	1.89e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
LGG	cis	rs7267979	0.868	rs6138550	ENSG00000125804.12	FAM182A	-10.51	2.22e-23	1.9e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.903	rs6050481	ENSG00000125804.12	FAM182A	-10.51	2.22e-23	1.9e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.834	rs6115100	ENSG00000125804.12	FAM182A	-10.51	2.22e-23	1.9e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:26054655~26086917:+
LGG	cis	rs67340775	0.541	rs200966	ENSG00000216901.1	AL022393.7	10.51	2.23e-23	1.9e-20	0.72	0.43	Lung cancer in ever smokers;	chr6:27894374	chr6:28176188~28176674:+
LGG	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-10.51	2.24e-23	1.91e-20	-0.55	-0.43	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
LGG	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-10.51	2.24e-23	1.91e-20	-0.32	-0.43	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
LGG	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-10.51	2.24e-23	1.91e-20	-0.32	-0.43	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.573	rs133381	ENSG00000205702.9	CYP2D7	10.51	2.24e-23	1.91e-20	0.32	0.43	Schizophrenia;	chr22:42074604	chr22:42140203~42144577:-
LGG	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
LGG	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-10.51	2.25e-23	1.92e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
LGG	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-10.51	2.25e-23	1.92e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-10.51	2.25e-23	1.92e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
LGG	cis	rs651907	0.514	rs12636046	ENSG00000256628.3	ZBTB11-AS1	10.51	2.26e-23	1.93e-20	0.49	0.43	Colorectal cancer;	chr3:101715604	chr3:101676475~101679217:+
LGG	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-10.51	2.26e-23	1.93e-20	-0.58	-0.43	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
LGG	cis	rs7119038	0.818	rs76704408	ENSG00000255239.1	AP002954.6	-10.51	2.27e-23	1.93e-20	-0.6	-0.43	Sjögren's syndrome;	chr11:118812618	chr11:118688039~118690600:-
LGG	cis	rs1150668	0.699	rs13408	ENSG00000218016.2	ZNF192P2	-10.51	2.28e-23	1.94e-20	-0.5	-0.43	Pubertal anthropometrics;	chr6:28244970	chr6:28188050~28189432:+
LGG	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-10.51	2.28e-23	1.94e-20	-0.35	-0.43	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
LGG	cis	rs7914558	0.966	rs10786719	ENSG00000272912.1	RP11-724N1.1	10.51	2.29e-23	1.96e-20	0.48	0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102914585~102915404:+
LGG	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-10.51	2.3e-23	1.96e-20	-0.42	-0.43	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
LGG	cis	rs1150668	0.796	rs2247002	ENSG00000226314.6	ZNF192P1	10.51	2.3e-23	1.96e-20	0.41	0.43	Pubertal anthropometrics;	chr6:28430174	chr6:28161781~28169594:+
LGG	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-10.51	2.32e-23	1.98e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
LGG	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-10.51	2.33e-23	1.99e-20	-0.35	-0.43	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
LGG	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	10.51	2.33e-23	1.99e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	10.51	2.33e-23	1.99e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	10.51	2.33e-23	1.99e-20	0.54	0.43	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
LGG	cis	rs1150668	0.699	rs13408	ENSG00000280107.1	AL022393.9	-10.51	2.34e-23	1.99e-20	-0.42	-0.43	Pubertal anthropometrics;	chr6:28244970	chr6:28170845~28172521:+
LGG	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-10.51	2.35e-23	2e-20	-0.48	-0.43	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
LGG	cis	rs7267979	0.866	rs2424698	ENSG00000125804.12	FAM182A	-10.51	2.35e-23	2e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:26054655~26086917:+
LGG	cis	rs5742933	0.857	rs1233282	ENSG00000253559.1	OSGEPL1-AS1	-10.51	2.36e-23	2.01e-20	-0.51	-0.43	Ferritin levels;	chr2:189823518	chr2:189762704~189765556:+
LGG	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	10.51	2.36e-23	2.01e-20	0.31	0.43	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
LGG	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	10.51	2.36e-23	2.01e-20	0.48	0.43	Depression;	chr6:28142370	chr6:28115628~28116551:+
LGG	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	10.51	2.38e-23	2.03e-20	0.57	0.43	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	10.51	2.38e-23	2.03e-20	0.57	0.43	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
LGG	cis	rs9527	0.571	rs4917985	ENSG00000272912.1	RP11-724N1.1	-10.51	2.38e-23	2.03e-20	-0.49	-0.43	Arsenic metabolism;	chr10:102864315	chr10:102914585~102915404:+
LGG	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	10.51	2.39e-23	2.03e-20	0.54	0.43	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
LGG	cis	rs6496932	0.663	rs12915663	ENSG00000218052.5	ADAMTS7P4	-10.51	2.39e-23	2.03e-20	-0.6	-0.43	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85255369~85330334:-
LGG	cis	rs5742933	0.817	rs1233265	ENSG00000253559.1	OSGEPL1-AS1	-10.5	2.4e-23	2.04e-20	-0.52	-0.43	Ferritin levels;	chr2:189796390	chr2:189762704~189765556:+
LGG	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	10.5	2.4e-23	2.04e-20	0.31	0.43	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
LGG	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	10.5	2.4e-23	2.04e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
LGG	cis	rs1150668	0.796	rs728122	ENSG00000226314.6	ZNF192P1	10.5	2.42e-23	2.06e-20	0.41	0.43	Pubertal anthropometrics;	chr6:28431347	chr6:28161781~28169594:+
LGG	cis	rs7914558	0.966	rs4532960	ENSG00000272912.1	RP11-724N1.1	-10.5	2.43e-23	2.06e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs10786724	ENSG00000272912.1	RP11-724N1.1	-10.5	2.43e-23	2.06e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs2297786	ENSG00000272912.1	RP11-724N1.1	-10.5	2.43e-23	2.06e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs10786725	ENSG00000272912.1	RP11-724N1.1	-10.5	2.43e-23	2.06e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102914585~102915404:+
LGG	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	10.5	2.43e-23	2.06e-20	0.52	0.43	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
LGG	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-10.5	2.43e-23	2.06e-20	-0.6	-0.43	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
LGG	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-10.5	2.43e-23	2.07e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
LGG	cis	rs8092443	0.81	rs55958727	ENSG00000278971.1	RP11-644A7.2	-10.5	2.43e-23	2.07e-20	-0.69	-0.43	Response to antipsychotic treatment;	chr18:70474314	chr18:70489630~70491205:+
LGG	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-10.5	2.44e-23	2.07e-20	-0.49	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
LGG	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-10.5	2.44e-23	2.08e-20	-0.35	-0.43	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
LGG	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-10.5	2.44e-23	2.08e-20	-0.35	-0.43	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-10.5	2.44e-23	2.08e-20	-0.35	-0.43	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-10.5	2.44e-23	2.08e-20	-0.35	-0.43	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
LGG	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-10.5	2.47e-23	2.09e-20	-0.56	-0.43	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	10.5	2.47e-23	2.1e-20	0.5	0.43	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
LGG	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-10.5	2.47e-23	2.1e-20	-0.48	-0.43	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
LGG	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-10.5	2.48e-23	2.11e-20	-0.51	-0.43	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
LGG	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-10.5	2.5e-23	2.12e-20	-0.47	-0.43	Depression;	chr6:28079011	chr6:28115628~28116551:+
LGG	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	10.5	2.5e-23	2.12e-20	0.66	0.43	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
LGG	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-10.5	2.51e-23	2.13e-20	-0.49	-0.43	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
LGG	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-10.5	2.52e-23	2.14e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	10.5	2.52e-23	2.14e-20	0.53	0.43	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	10.5	2.52e-23	2.14e-20	0.53	0.43	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
LGG	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-10.5	2.52e-23	2.14e-20	-0.47	-0.43	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
LGG	cis	rs2408955	0.522	rs2051851	ENSG00000258273.1	RP11-370I10.4	10.5	2.53e-23	2.15e-20	0.54	0.43	Glycated hemoglobin levels;	chr12:48092157	chr12:48333755~48333901:-
LGG	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-10.5	2.54e-23	2.16e-20	-0.57	-0.43	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
LGG	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-10.5	2.55e-23	2.16e-20	-0.48	-0.43	Depression;	chr6:28074687	chr6:28115628~28116551:+
LGG	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-10.5	2.56e-23	2.17e-20	-0.47	-0.43	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
LGG	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-10.5	2.57e-23	2.18e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
LGG	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	10.5	2.57e-23	2.18e-20	0.54	0.43	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
LGG	cis	rs2408955	0.561	rs9971924	ENSG00000258273.1	RP11-370I10.4	10.5	2.57e-23	2.18e-20	0.54	0.43	Glycated hemoglobin levels;	chr12:48086049	chr12:48333755~48333901:-
LGG	cis	rs2408955	0.522	rs7139330	ENSG00000258273.1	RP11-370I10.4	10.5	2.57e-23	2.18e-20	0.54	0.43	Glycated hemoglobin levels;	chr12:48089701	chr12:48333755~48333901:-
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-10.5	2.59e-23	2.2e-20	-0.61	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	10.5	2.59e-23	2.2e-20	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
LGG	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	10.5	2.59e-23	2.2e-20	0.53	0.43	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	10.5	2.59e-23	2.2e-20	0.53	0.43	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	10.5	2.59e-23	2.2e-20	0.53	0.43	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	10.5	2.59e-23	2.2e-20	0.53	0.43	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	10.5	2.59e-23	2.2e-20	0.53	0.43	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
LGG	cis	rs7267979	0.932	rs446649	ENSG00000125804.12	FAM182A	-10.5	2.6e-23	2.21e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:26054655~26086917:+
LGG	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-10.49	2.61e-23	2.21e-20	-0.44	-0.43	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
LGG	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	10.49	2.61e-23	2.22e-20	0.6	0.43	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
LGG	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	10.49	2.61e-23	2.22e-20	0.6	0.43	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
LGG	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	10.49	2.62e-23	2.22e-20	0.35	0.43	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
LGG	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	10.49	2.62e-23	2.22e-20	0.54	0.43	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
LGG	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	10.49	2.62e-23	2.22e-20	0.54	0.43	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
LGG	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-10.49	2.63e-23	2.23e-20	-0.56	-0.43	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
LGG	cis	rs7267979	0.966	rs454723	ENSG00000125804.12	FAM182A	-10.49	2.63e-23	2.23e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:26054655~26086917:+
LGG	cis	rs7246657	0.639	rs3112434	ENSG00000267422.1	CTD-2554C21.1	10.49	2.65e-23	2.25e-20	0.53	0.43	Coronary artery calcification;	chr19:37707247	chr19:37779686~37792865:+
LGG	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-10.49	2.65e-23	2.25e-20	-0.48	-0.43	Depression;	chr6:28143758	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-10.49	2.65e-23	2.25e-20	-0.48	-0.43	Depression;	chr6:28144784	chr6:28115628~28116551:+
LGG	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-10.49	2.66e-23	2.25e-20	-0.93	-0.43	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
LGG	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-10.49	2.66e-23	2.25e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
LGG	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-10.49	2.66e-23	2.26e-20	-0.48	-0.43	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
LGG	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	10.49	2.68e-23	2.27e-20	0.47	0.43	Depression;	chr6:28110525	chr6:28115628~28116551:+
LGG	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	10.49	2.69e-23	2.27e-20	0.35	0.43	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
LGG	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-10.49	2.69e-23	2.28e-20	-0.47	-0.43	Depression;	chr6:28140307	chr6:28115628~28116551:+
LGG	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-10.49	2.7e-23	2.28e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
LGG	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-10.49	2.7e-23	2.29e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
LGG	cis	rs4373814	0.607	rs7080195	ENSG00000226083.4	SLC39A12-AS1	10.49	2.7e-23	2.29e-20	0.45	0.43	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18170218	chr10:18001786~18010562:-
LGG	cis	rs853679	1	rs853685	ENSG00000199851.2	U3	10.49	2.7e-23	2.29e-20	0.81	0.43	Depression;	chr6:28321008	chr6:28015568~28015777:+
LGG	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-10.49	2.7e-23	2.29e-20	-0.5	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
LGG	cis	rs7267979	0.903	rs6115101	ENSG00000276952.1	RP5-965G21.6	10.49	2.71e-23	2.29e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.868	rs6107019	ENSG00000276952.1	RP5-965G21.6	10.49	2.71e-23	2.29e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25284915~25285588:-
LGG	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-10.49	2.71e-23	2.3e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-10.49	2.71e-23	2.3e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
LGG	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	10.49	2.72e-23	2.3e-20	0.52	0.43	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
LGG	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-10.49	2.72e-23	2.3e-20	-0.47	-0.43	Depression;	chr6:28091242	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-10.49	2.72e-23	2.3e-20	-0.47	-0.43	Depression;	chr6:28126588	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-10.49	2.72e-23	2.3e-20	-0.47	-0.43	Depression;	chr6:28126953	chr6:28115628~28116551:+
LGG	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-10.49	2.73e-23	2.31e-20	-0.47	-0.43	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
LGG	cis	rs5742933	0.842	rs1225101	ENSG00000273240.1	RP11-455J20.3	-10.49	2.74e-23	2.32e-20	-0.55	-0.43	Ferritin levels;	chr2:189740695	chr2:189763859~189764456:-
LGG	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-10.49	2.74e-23	2.32e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-10.49	2.74e-23	2.32e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
LGG	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-10.49	2.75e-23	2.32e-20	-0.48	-0.43	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
LGG	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	10.49	2.76e-23	2.34e-20	0.52	0.43	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
LGG	cis	rs651907	0.535	rs13085776	ENSG00000244119.1	PDCL3P4	10.49	2.77e-23	2.34e-20	0.37	0.43	Colorectal cancer;	chr3:101786663	chr3:101712472~101713191:+
LGG	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-10.49	2.77e-23	2.34e-20	-0.57	-0.43	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
LGG	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	10.49	2.78e-23	2.35e-20	0.6	0.43	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
LGG	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-10.49	2.78e-23	2.35e-20	-0.5	-0.43	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-10.49	2.78e-23	2.35e-20	-0.5	-0.43	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-10.49	2.78e-23	2.35e-20	-0.5	-0.43	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-10.49	2.78e-23	2.35e-20	-0.5	-0.43	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-10.49	2.78e-23	2.35e-20	-0.5	-0.43	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-10.49	2.78e-23	2.35e-20	-0.5	-0.43	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
LGG	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-10.49	2.78e-23	2.35e-20	-0.5	-0.43	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
LGG	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-10.49	2.78e-23	2.35e-20	-0.55	-0.43	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
LGG	cis	rs5758511	0.524	rs738257	ENSG00000227370.1	RP4-669P10.19	10.49	2.81e-23	2.38e-20	0.5	0.43	Birth weight;	chr22:42173292	chr22:42132543~42132998:+
LGG	cis	rs11098499	0.821	rs56155624	ENSG00000249244.1	RP11-548H18.2	10.49	2.81e-23	2.38e-20	0.5	0.43	Corneal astigmatism;	chr4:119369871	chr4:119391831~119395335:-
LGG	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	10.49	2.81e-23	2.38e-20	0.32	0.43	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
LGG	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	10.49	2.82e-23	2.38e-20	0.35	0.43	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
LGG	cis	rs12935418	0.616	rs2602453	ENSG00000260213.4	RP11-303E16.3	10.49	2.83e-23	2.39e-20	0.52	0.43	Mean corpuscular volume;	chr16:80994358	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2970086	ENSG00000260213.4	RP11-303E16.3	10.49	2.83e-23	2.39e-20	0.52	0.43	Mean corpuscular volume;	chr16:80994835	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2970085	ENSG00000260213.4	RP11-303E16.3	10.49	2.83e-23	2.39e-20	0.52	0.43	Mean corpuscular volume;	chr16:80994842	chr16:81016792~81035759:-
LGG	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	10.49	2.84e-23	2.4e-20	0.5	0.43	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
LGG	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-10.48	2.85e-23	2.4e-20	-0.47	-0.43	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
LGG	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-10.48	2.86e-23	2.42e-20	-0.48	-0.43	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
LGG	cis	rs496547	1	rs496547	ENSG00000278376.1	RP11-158I9.8	-10.48	2.86e-23	2.42e-20	-0.4	-0.43	Hip minimal joint space width;	chr11:118705754	chr11:118791254~118793137:+
LGG	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-10.48	2.88e-23	2.43e-20	-0.6	-0.43	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
LGG	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-10.48	2.88e-23	2.44e-20	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
LGG	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-10.48	2.89e-23	2.44e-20	-0.6	-0.43	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
LGG	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-10.48	2.9e-23	2.45e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-10.48	2.92e-23	2.47e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-10.48	2.92e-23	2.47e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-10.48	2.92e-23	2.47e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-10.48	2.92e-23	2.47e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
LGG	cis	rs853679	0.527	rs1997660	ENSG00000280107.1	AL022393.9	-10.48	2.92e-23	2.47e-20	-0.45	-0.43	Depression;	chr6:28301886	chr6:28170845~28172521:+
LGG	cis	rs5758511	0.514	rs5758580	ENSG00000227370.1	RP4-669P10.19	10.48	2.93e-23	2.47e-20	0.49	0.43	Birth weight;	chr22:42097871	chr22:42132543~42132998:+
LGG	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	10.48	2.93e-23	2.47e-20	0.48	0.43	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
LGG	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	10.48	2.93e-23	2.47e-20	0.56	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	10.48	2.94e-23	2.48e-20	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
LGG	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	10.48	2.97e-23	2.5e-20	0.56	0.43	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
LGG	cis	rs4683346	0.576	rs4683339	ENSG00000273328.4	RP11-141M3.6	-10.48	2.97e-23	2.51e-20	-0.5	-0.43	Granulocyte percentage of myeloid white cells;	chr3:42835249	chr3:42809414~42908105:+
LGG	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	10.48	2.98e-23	2.51e-20	0.54	0.43	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
LGG	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	10.48	3e-23	2.53e-20	0.6	0.43	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
LGG	cis	rs5742933	0.857	rs1233291	ENSG00000253559.1	OSGEPL1-AS1	-10.48	3e-23	2.53e-20	-0.51	-0.43	Ferritin levels;	chr2:189826225	chr2:189762704~189765556:+
LGG	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-10.48	3.05e-23	2.57e-20	-0.47	-0.43	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	10.48	3.05e-23	2.57e-20	0.57	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
LGG	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	10.48	3.06e-23	2.58e-20	0.54	0.43	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
LGG	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-10.48	3.07e-23	2.58e-20	-0.6	-0.43	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
LGG	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-10.48	3.07e-23	2.58e-20	-0.6	-0.43	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
LGG	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-10.48	3.07e-23	2.59e-20	-0.47	-0.43	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
LGG	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	10.48	3.08e-23	2.6e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
LGG	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-10.47	3.1e-23	2.61e-20	-0.51	-0.43	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
LGG	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	10.47	3.11e-23	2.62e-20	0.46	0.43	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
LGG	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-10.47	3.12e-23	2.62e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
LGG	cis	rs5742933	0.817	rs7591929	ENSG00000273240.1	RP11-455J20.3	10.47	3.12e-23	2.62e-20	0.52	0.43	Ferritin levels;	chr2:189778531	chr2:189763859~189764456:-
LGG	cis	rs7267979	0.966	rs2482923	ENSG00000276952.1	RP5-965G21.6	-10.47	3.13e-23	2.63e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25284915~25285588:-
LGG	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-10.47	3.14e-23	2.65e-20	-0.48	-0.43	Depression;	chr6:28180209	chr6:28115628~28116551:+
LGG	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-10.47	3.19e-23	2.69e-20	-0.57	-0.43	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
LGG	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28173770	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28174809	chr6:28115628~28116551:+
LGG	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28175233	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28176973	chr6:28115628~28116551:+
LGG	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-10.47	3.22e-23	2.71e-20	-0.93	-0.43	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
LGG	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-10.47	3.22e-23	2.71e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
LGG	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28145952	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28147378	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28147406	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28148143	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28149979	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28152885	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28153120	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28154567	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28156691	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28158424	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28159056	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28159666	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28161802	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28162053	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28162598	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28163375	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28163759	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28164580	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28164825	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28164948	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28165025	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28165528	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28168434	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28169019	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28169249	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28169676	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28169755	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28169791	chr6:28115628~28116551:+
LGG	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-10.47	3.22e-23	2.71e-20	-0.48	-0.43	Depression;	chr6:28170075	chr6:28115628~28116551:+
LGG	cis	rs5758511	0.68	rs5751243	ENSG00000227370.1	RP4-669P10.19	10.47	3.24e-23	2.72e-20	0.5	0.43	Birth weight;	chr22:42221171	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.637	rs5751244	ENSG00000227370.1	RP4-669P10.19	10.47	3.24e-23	2.72e-20	0.5	0.43	Birth weight;	chr22:42221405	chr22:42132543~42132998:+
LGG	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	10.47	3.24e-23	2.72e-20	0.34	0.43	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
LGG	cis	rs7945705	0.967	rs10840147	ENSG00000254860.4	TMEM9B-AS1	-10.47	3.24e-23	2.72e-20	-0.49	-0.43	Hemoglobin concentration;	chr11:8899157	chr11:8964675~8977527:+
LGG	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-10.47	3.24e-23	2.73e-20	-0.93	-0.43	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
LGG	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-10.47	3.24e-23	2.73e-20	-0.93	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-10.47	3.24e-23	2.73e-20	-0.93	-0.43	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-10.47	3.24e-23	2.73e-20	-0.93	-0.43	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-10.47	3.24e-23	2.73e-20	-0.93	-0.43	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-10.47	3.24e-23	2.73e-20	-0.93	-0.43	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
LGG	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-10.47	3.24e-23	2.73e-20	-0.93	-0.43	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
LGG	cis	rs12935418	0.616	rs2549863	ENSG00000260213.4	RP11-303E16.3	10.47	3.24e-23	2.73e-20	0.52	0.43	Mean corpuscular volume;	chr16:80995762	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.616	rs1469123	ENSG00000260213.4	RP11-303E16.3	10.47	3.24e-23	2.73e-20	0.52	0.43	Mean corpuscular volume;	chr16:80995944	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs1469124	ENSG00000260213.4	RP11-303E16.3	10.47	3.24e-23	2.73e-20	0.52	0.43	Mean corpuscular volume;	chr16:80996049	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs1469125	ENSG00000260213.4	RP11-303E16.3	10.47	3.24e-23	2.73e-20	0.52	0.43	Mean corpuscular volume;	chr16:80996163	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.523	rs1469126	ENSG00000260213.4	RP11-303E16.3	10.47	3.24e-23	2.73e-20	0.52	0.43	Mean corpuscular volume;	chr16:80996284	chr16:81016792~81035759:-
LGG	cis	rs8092443	0.688	rs2366386	ENSG00000278971.1	RP11-644A7.2	-10.47	3.28e-23	2.75e-20	-0.68	-0.43	Response to antipsychotic treatment;	chr18:70494233	chr18:70489630~70491205:+
LGG	cis	rs7267979	1	rs1888999	ENSG00000276952.1	RP5-965G21.6	10.47	3.28e-23	2.76e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25284915~25285588:-
LGG	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-10.47	3.28e-23	2.76e-20	-0.52	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
LGG	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-10.47	3.29e-23	2.76e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
LGG	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	10.47	3.3e-23	2.77e-20	0.59	0.43	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
LGG	cis	rs7927771	0.69	rs35496532	ENSG00000280615.1	Y_RNA	-10.47	3.31e-23	2.78e-20	-0.54	-0.43	Subjective well-being;	chr11:47428787	chr11:47614898~47614994:-
LGG	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	10.47	3.31e-23	2.78e-20	0.35	0.43	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
LGG	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-10.47	3.31e-23	2.78e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-10.47	3.31e-23	2.78e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-10.47	3.31e-23	2.78e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-10.47	3.31e-23	2.78e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
LGG	cis	rs1420956	0.692	rs1024877	ENSG00000264151.4	RP11-739N10.1	10.47	3.32e-23	2.78e-20	0.55	0.43	Obesity-related traits;	chr18:27594556	chr18:27336379~27595164:-
LGG	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	10.47	3.32e-23	2.79e-20	0.63	0.43	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
LGG	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	10.47	3.32e-23	2.79e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
LGG	cis	rs67340775	0.541	rs169287	ENSG00000216901.1	AL022393.7	10.47	3.32e-23	2.79e-20	0.73	0.43	Lung cancer in ever smokers;	chr6:27886982	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-10.47	3.34e-23	2.8e-20	-0.64	-0.43	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
LGG	cis	rs7914558	1	rs10883824	ENSG00000272912.1	RP11-724N1.1	-10.47	3.35e-23	2.81e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs11191542	ENSG00000272912.1	RP11-724N1.1	-10.47	3.35e-23	2.81e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:102914585~102915404:+
LGG	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	10.47	3.36e-23	2.82e-20	0.53	0.43	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
LGG	cis	rs4713118	0.869	rs10214440	ENSG00000216901.1	AL022393.7	10.47	3.37e-23	2.82e-20	0.56	0.43	Parkinson's disease;	chr6:27734661	chr6:28176188~28176674:+
LGG	cis	rs5742933	0.817	rs3816196	ENSG00000253559.1	OSGEPL1-AS1	10.46	3.38e-23	2.83e-20	0.52	0.43	Ferritin levels;	chr2:189775749	chr2:189762704~189765556:+
LGG	cis	rs7927771	0.864	rs60075622	ENSG00000280615.1	Y_RNA	-10.46	3.39e-23	2.84e-20	-0.54	-0.43	Subjective well-being;	chr11:47427550	chr11:47614898~47614994:-
LGG	cis	rs8092443	0.81	rs73459372	ENSG00000278971.1	RP11-644A7.2	-10.46	3.39e-23	2.84e-20	-0.68	-0.43	Response to antipsychotic treatment;	chr18:70484050	chr18:70489630~70491205:+
LGG	cis	rs651907	0.557	rs7612283	ENSG00000256628.3	ZBTB11-AS1	10.46	3.39e-23	2.84e-20	0.49	0.43	Colorectal cancer;	chr3:101716075	chr3:101676475~101679217:+
LGG	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-10.46	3.41e-23	2.85e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
LGG	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-10.46	3.41e-23	2.85e-20	-0.44	-0.43	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
LGG	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	10.46	3.41e-23	2.85e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
LGG	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-10.46	3.42e-23	2.85e-20	-0.55	-0.43	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
LGG	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-10.46	3.42e-23	2.86e-20	-0.5	-0.43	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
LGG	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-10.46	3.43e-23	2.86e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
LGG	cis	rs5742933	0.817	rs1233297	ENSG00000273240.1	RP11-455J20.3	-10.46	3.45e-23	2.88e-20	-0.51	-0.43	Ferritin levels;	chr2:189829449	chr2:189763859~189764456:-
LGG	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-10.46	3.45e-23	2.88e-20	-0.57	-0.43	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
LGG	cis	rs111326718	1	rs111326718	ENSG00000272912.1	RP11-724N1.1	-10.46	3.45e-23	2.88e-20	-0.48	-0.43	Reticulocyte count;	chr10:103011454	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs7071373	ENSG00000272912.1	RP11-724N1.1	-10.46	3.45e-23	2.88e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs4917380	ENSG00000272912.1	RP11-724N1.1	-10.46	3.45e-23	2.88e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs7914558	ENSG00000272912.1	RP11-724N1.1	-10.46	3.45e-23	2.88e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102914585~102915404:+
LGG	cis	rs7267979	1	rs2297497	ENSG00000125804.12	FAM182A	10.46	3.46e-23	2.89e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:26054655~26086917:+
LGG	cis	rs7829975	0.871	rs777709	ENSG00000173295.6	FAM86B3P	10.46	3.48e-23	2.91e-20	0.45	0.43	Mood instability;	chr8:8726362	chr8:8228595~8244865:+
LGG	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	10.46	3.49e-23	2.91e-20	0.57	0.43	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	10.46	3.49e-23	2.91e-20	0.57	0.43	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
LGG	cis	rs7927771	0.864	rs11600581	ENSG00000280615.1	Y_RNA	-10.46	3.49e-23	2.91e-20	-0.54	-0.43	Subjective well-being;	chr11:47426946	chr11:47614898~47614994:-
LGG	cis	rs853679	0.599	rs202906	ENSG00000199851.2	U3	-10.46	3.5e-23	2.92e-20	-0.89	-0.43	Depression;	chr6:28043874	chr6:28015568~28015777:+
LGG	cis	rs7927771	0.864	rs7937331	ENSG00000280615.1	Y_RNA	10.46	3.5e-23	2.92e-20	0.54	0.43	Subjective well-being;	chr11:47408907	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.864	rs755553	ENSG00000280615.1	Y_RNA	10.46	3.5e-23	2.92e-20	0.54	0.43	Subjective well-being;	chr11:47410752	chr11:47614898~47614994:-
LGG	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-10.46	3.54e-23	2.95e-20	-0.61	-0.43	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
LGG	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-10.46	3.54e-23	2.95e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
LGG	cis	rs7267979	0.966	rs2500433	ENSG00000276952.1	RP5-965G21.6	-10.46	3.55e-23	2.96e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2482948	ENSG00000276952.1	RP5-965G21.6	-10.46	3.55e-23	2.96e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25284915~25285588:-
LGG	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	10.46	3.55e-23	2.96e-20	0.32	0.43	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
LGG	cis	rs7267979	0.903	rs6132819	ENSG00000125804.12	FAM182A	-10.46	3.55e-23	2.96e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	10.46	3.56e-23	2.97e-20	0.55	0.43	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
LGG	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-10.46	3.59e-23	2.99e-20	-0.55	-0.43	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-10.46	3.59e-23	2.99e-20	-0.55	-0.43	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-10.46	3.59e-23	2.99e-20	-0.55	-0.43	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-10.46	3.59e-23	2.99e-20	-0.55	-0.43	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	10.46	3.6e-23	3e-20	0.5	0.43	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	10.46	3.6e-23	3e-20	0.5	0.43	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
LGG	cis	rs5742933	0.744	rs13009889	ENSG00000253559.1	OSGEPL1-AS1	10.46	3.61e-23	3.01e-20	0.53	0.43	Ferritin levels;	chr2:189763842	chr2:189762704~189765556:+
LGG	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-10.46	3.64e-23	3.03e-20	-0.49	-0.43	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
LGG	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-10.46	3.64e-23	3.04e-20	-0.55	-0.43	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-10.46	3.64e-23	3.04e-20	-0.55	-0.43	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
LGG	cis	rs4713118	0.581	rs200504	ENSG00000199851.2	U3	10.46	3.65e-23	3.04e-20	0.69	0.43	Parkinson's disease;	chr6:27818042	chr6:28015568~28015777:+
LGG	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	10.46	3.65e-23	3.04e-20	0.5	0.43	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
LGG	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-10.46	3.65e-23	3.04e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
LGG	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-10.46	3.65e-23	3.04e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
LGG	cis	rs7267979	0.933	rs2424708	ENSG00000276952.1	RP5-965G21.6	10.46	3.65e-23	3.04e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs884613	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs1888998	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482940	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2027003	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2027004	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2500404	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2500405	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482941	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.903	rs2500423	ENSG00000276952.1	RP5-965G21.6	-10.46	3.65e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482919	ENSG00000276952.1	RP5-965G21.6	-10.46	3.66e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6037086	ENSG00000276952.1	RP5-965G21.6	-10.46	3.66e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482931	ENSG00000276952.1	RP5-965G21.6	-10.46	3.66e-23	3.04e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25284915~25285588:-
LGG	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	10.45	3.68e-23	3.07e-20	0.53	0.43	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
LGG	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-10.45	3.7e-23	3.08e-20	-0.84	-0.43	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
LGG	cis	rs8064024	0.538	rs11076854	ENSG00000267077.1	RP11-127I20.5	-10.45	3.71e-23	3.08e-20	-0.44	-0.43	Cancer;	chr16:4879268	chr16:4795265~4796532:-
LGG	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	10.45	3.75e-23	3.12e-20	0.34	0.43	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	10.45	3.75e-23	3.12e-20	0.34	0.43	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
LGG	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	10.45	3.75e-23	3.12e-20	0.34	0.43	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-10.45	3.77e-23	3.13e-20	-0.35	-0.43	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-10.45	3.77e-23	3.13e-20	-0.35	-0.43	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-10.45	3.77e-23	3.13e-20	-0.35	-0.43	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
LGG	cis	rs7829975	0.559	rs4841025	ENSG00000173295.6	FAM86B3P	10.45	3.77e-23	3.13e-20	0.46	0.43	Mood instability;	chr8:8745650	chr8:8228595~8244865:+
LGG	cis	rs7829975	0.6	rs1719381	ENSG00000173295.6	FAM86B3P	10.45	3.77e-23	3.13e-20	0.46	0.43	Mood instability;	chr8:8744834	chr8:8228595~8244865:+
LGG	cis	rs7267979	1	rs2500424	ENSG00000276952.1	RP5-965G21.6	-10.45	3.8e-23	3.16e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25284915~25285588:-
LGG	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-10.45	3.81e-23	3.17e-20	-0.57	-0.43	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
LGG	cis	rs8092443	0.81	rs17819660	ENSG00000278971.1	RP11-644A7.2	-10.45	3.81e-23	3.17e-20	-0.68	-0.43	Response to antipsychotic treatment;	chr18:70493937	chr18:70489630~70491205:+
LGG	cis	rs5742933	0.817	rs6738042	ENSG00000253559.1	OSGEPL1-AS1	10.45	3.82e-23	3.17e-20	0.52	0.43	Ferritin levels;	chr2:189776958	chr2:189762704~189765556:+
LGG	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	10.45	3.83e-23	3.18e-20	0.57	0.43	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	10.45	3.83e-23	3.18e-20	0.57	0.43	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
LGG	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	10.45	3.87e-23	3.21e-20	0.53	0.43	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
LGG	cis	rs5758511	0.514	rs5751211	ENSG00000227370.1	RP4-669P10.19	10.45	3.87e-23	3.22e-20	0.48	0.43	Birth weight;	chr22:42090052	chr22:42132543~42132998:+
LGG	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	10.45	3.89e-23	3.23e-20	0.51	0.43	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
LGG	cis	rs7927771	0.832	rs7940536	ENSG00000280615.1	Y_RNA	10.45	3.9e-23	3.24e-20	0.54	0.43	Subjective well-being;	chr11:47373689	chr11:47614898~47614994:-
LGG	cis	rs8092443	0.654	rs8083222	ENSG00000278971.1	RP11-644A7.2	10.45	3.91e-23	3.24e-20	0.67	0.43	Response to antipsychotic treatment;	chr18:70480128	chr18:70489630~70491205:+
LGG	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-10.45	3.91e-23	3.25e-20	-0.35	-0.43	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-10.45	3.91e-23	3.25e-20	-0.35	-0.43	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
LGG	cis	rs7119038	0.629	rs11217000	ENSG00000255239.1	AP002954.6	-10.45	3.92e-23	3.26e-20	-0.61	-0.43	Sjögren's syndrome;	chr11:118734275	chr11:118688039~118690600:-
LGG	cis	rs1560104	0.709	rs2217271	ENSG00000274834.1	CTD-3037G24.5	-10.45	3.93e-23	3.26e-20	-0.55	-0.43	Obesity-related traits;	chr16:12610623	chr16:12614451~12614852:+
LGG	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	10.45	3.95e-23	3.28e-20	0.59	0.43	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
LGG	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	10.45	3.96e-23	3.29e-20	0.31	0.43	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
LGG	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-10.45	3.97e-23	3.29e-20	-0.47	-0.43	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-10.45	3.97e-23	3.29e-20	-0.47	-0.43	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
LGG	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-10.44	4.01e-23	3.33e-20	-0.49	-0.43	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
LGG	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-10.44	4.02e-23	3.34e-20	-0.55	-0.43	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-10.44	4.02e-23	3.34e-20	-0.55	-0.43	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
LGG	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-10.44	4.03e-23	3.34e-20	-0.51	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
LGG	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-10.44	4.04e-23	3.36e-20	-0.38	-0.43	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
LGG	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-10.44	4.05e-23	3.36e-20	-0.48	-0.43	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
LGG	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-10.44	4.05e-23	3.36e-20	-0.56	-0.43	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	10.44	4.11e-23	3.41e-20	0.54	0.43	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
LGG	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-10.44	4.11e-23	3.41e-20	-0.35	-0.43	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
LGG	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-10.44	4.13e-23	3.43e-20	-0.56	-0.43	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
LGG	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-10.44	4.15e-23	3.44e-20	-0.56	-0.43	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-10.44	4.15e-23	3.44e-20	-0.56	-0.43	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
LGG	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-10.44	4.16e-23	3.45e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
LGG	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-10.44	4.17e-23	3.46e-20	-0.57	-0.43	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
LGG	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	10.44	4.17e-23	3.46e-20	0.52	0.43	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
LGG	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-10.44	4.18e-23	3.47e-20	-0.57	-0.43	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
LGG	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-10.44	4.19e-23	3.47e-20	-0.93	-0.43	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
LGG	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	10.44	4.19e-23	3.48e-20	0.44	0.43	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
LGG	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-10.44	4.2e-23	3.48e-20	-0.55	-0.43	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
LGG	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-10.44	4.22e-23	3.49e-20	-0.93	-0.43	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
LGG	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	10.44	4.23e-23	3.5e-20	0.49	0.43	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
LGG	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-10.44	4.25e-23	3.52e-20	-0.51	-0.43	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
LGG	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-10.44	4.26e-23	3.53e-20	-0.52	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
LGG	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-10.44	4.26e-23	3.53e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-10.44	4.26e-23	3.53e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-10.44	4.26e-23	3.53e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-10.44	4.26e-23	3.53e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-10.44	4.26e-23	3.53e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-10.44	4.26e-23	3.53e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
LGG	cis	rs5742933	0.817	rs1055091	ENSG00000253559.1	OSGEPL1-AS1	10.44	4.28e-23	3.54e-20	0.52	0.43	Ferritin levels;	chr2:189770417	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.817	rs6942	ENSG00000253559.1	OSGEPL1-AS1	10.44	4.28e-23	3.54e-20	0.52	0.43	Ferritin levels;	chr2:189771685	chr2:189762704~189765556:+
LGG	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-10.44	4.31e-23	3.57e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-10.44	4.31e-23	3.57e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
LGG	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	10.44	4.31e-23	3.57e-20	0.49	0.43	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
LGG	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-10.44	4.32e-23	3.58e-20	-0.61	-0.43	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
LGG	cis	rs5758511	0.514	rs3985938	ENSG00000227370.1	RP4-669P10.19	10.44	4.33e-23	3.59e-20	0.48	0.43	Birth weight;	chr22:42115723	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.514	rs5758586	ENSG00000227370.1	RP4-669P10.19	10.44	4.33e-23	3.59e-20	0.48	0.43	Birth weight;	chr22:42121467	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.514	rs5751222	ENSG00000227370.1	RP4-669P10.19	10.44	4.33e-23	3.59e-20	0.48	0.43	Birth weight;	chr22:42121918	chr22:42132543~42132998:+
LGG	cis	rs7267979	0.966	rs6037083	ENSG00000125804.12	FAM182A	10.44	4.34e-23	3.59e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:26054655~26086917:+
LGG	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	10.44	4.36e-23	3.61e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
LGG	cis	rs893971	0.508	rs1899132	ENSG00000246375.2	RP11-10L7.1	10.43	4.38e-23	3.62e-20	0.51	0.43	Conduct disorder (maternal expressed emotions interaction);	chr4:88308185	chr4:88284942~88331421:+
LGG	cis	rs17767294	1	rs17767294	ENSG00000199851.2	U3	10.43	4.39e-23	3.64e-20	1.14	0.43	Parkinson's disease;	chr6:28086420	chr6:28015568~28015777:+
LGG	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-10.43	4.4e-23	3.64e-20	-0.55	-0.43	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
LGG	cis	rs7267979	1	rs2387881	ENSG00000125804.12	FAM182A	10.43	4.4e-23	3.64e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:26054655~26086917:+
LGG	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-10.43	4.41e-23	3.64e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
LGG	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-10.43	4.42e-23	3.65e-20	-0.55	-0.43	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
LGG	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-10.43	4.42e-23	3.65e-20	-0.56	-0.43	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
LGG	cis	rs7119038	0.818	rs11217042	ENSG00000255239.1	AP002954.6	-10.43	4.42e-23	3.66e-20	-0.59	-0.43	Sjögren's syndrome;	chr11:118811819	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.818	rs17122453	ENSG00000255239.1	AP002954.6	-10.43	4.42e-23	3.66e-20	-0.59	-0.43	Sjögren's syndrome;	chr11:118812855	chr11:118688039~118690600:-
LGG	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-10.43	4.46e-23	3.69e-20	-0.45	-0.43	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
LGG	cis	rs7267979	0.934	rs2500399	ENSG00000276952.1	RP5-965G21.6	-10.43	4.46e-23	3.69e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25284915~25285588:-
LGG	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	10.43	4.48e-23	3.7e-20	0.51	0.43	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
LGG	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	10.43	4.48e-23	3.7e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
LGG	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	10.43	4.49e-23	3.71e-20	0.46	0.43	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
LGG	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	10.43	4.5e-23	3.72e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	10.43	4.5e-23	3.72e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	10.43	4.5e-23	3.72e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
LGG	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-10.43	4.5e-23	3.72e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-10.43	4.5e-23	3.72e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
LGG	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	10.43	4.51e-23	3.72e-20	0.5	0.43	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
LGG	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-10.43	4.51e-23	3.73e-20	-0.46	-0.43	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
LGG	cis	rs4713118	0.869	rs6914924	ENSG00000216901.1	AL022393.7	10.43	4.51e-23	3.73e-20	0.56	0.43	Parkinson's disease;	chr6:27743751	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs6930992	ENSG00000216901.1	AL022393.7	10.43	4.51e-23	3.73e-20	0.56	0.43	Parkinson's disease;	chr6:27744341	chr6:28176188~28176674:+
LGG	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	10.43	4.52e-23	3.73e-20	0.33	0.43	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
LGG	cis	rs6452524	0.967	rs2662243	ENSG00000248112.1	RP11-78C3.1	10.43	4.53e-23	3.74e-20	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:82919376~82921119:-
LGG	cis	rs7119038	0.509	rs10892258	ENSG00000255239.1	AP002954.6	10.43	4.53e-23	3.74e-20	0.58	0.43	Sjögren's syndrome;	chr11:118709156	chr11:118688039~118690600:-
LGG	cis	rs1150668	0.796	rs213237	ENSG00000280107.1	AL022393.9	-10.43	4.54e-23	3.75e-20	-0.41	-0.43	Pubertal anthropometrics;	chr6:28356161	chr6:28170845~28172521:+
LGG	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	10.43	4.54e-23	3.75e-20	0.47	0.43	Depression;	chr6:28109824	chr6:28115628~28116551:+
LGG	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-10.43	4.59e-23	3.78e-20	-0.49	-0.43	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
LGG	cis	rs7914558	1	rs12255047	ENSG00000272912.1	RP11-724N1.1	-10.43	4.6e-23	3.79e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102914585~102915404:+
LGG	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	-10.43	4.61e-23	3.8e-20	-0.45	-0.43	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
LGG	cis	rs7267979	1	rs2424712	ENSG00000125804.12	FAM182A	-10.43	4.61e-23	3.81e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:26054655~26086917:+
LGG	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-10.43	4.65e-23	3.83e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
LGG	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-10.43	4.67e-23	3.85e-20	-0.46	-0.43	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
LGG	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	-10.43	4.67e-23	3.85e-20	-0.45	-0.43	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
LGG	cis	rs7267979	0.833	rs6138556	ENSG00000276952.1	RP5-965G21.6	10.43	4.68e-23	3.86e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25284915~25285588:-
LGG	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-10.43	4.68e-23	3.86e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
LGG	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-10.43	4.7e-23	3.87e-20	-0.55	-0.43	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
LGG	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-10.43	4.7e-23	3.88e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-10.43	4.7e-23	3.88e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
LGG	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-10.43	4.7e-23	3.88e-20	-0.47	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
LGG	cis	rs1420956	0.562	rs8088837	ENSG00000264151.4	RP11-739N10.1	10.43	4.72e-23	3.89e-20	0.54	0.43	Obesity-related traits;	chr18:27569676	chr18:27336379~27595164:-
LGG	cis	rs7829975	0.686	rs907180	ENSG00000173295.6	FAM86B3P	-10.43	4.73e-23	3.9e-20	-0.46	-0.43	Mood instability;	chr8:8845317	chr8:8228595~8244865:+
LGG	cis	rs1023500	0.506	rs6002625	ENSG00000205702.9	CYP2D7	-10.43	4.73e-23	3.9e-20	-0.32	-0.43	Schizophrenia;	chr22:42121685	chr22:42140203~42144577:-
LGG	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-10.43	4.74e-23	3.91e-20	-0.47	-0.43	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
LGG	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-10.43	4.75e-23	3.91e-20	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
LGG	cis	rs7115242	0.699	rs17174502	ENSG00000254851.1	RP11-109L13.1	10.43	4.75e-23	3.91e-20	0.94	0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116888939	chr11:117135528~117138582:+
LGG	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	10.42	4.75e-23	3.92e-20	0.56	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
LGG	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-10.42	4.76e-23	3.92e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-10.42	4.76e-23	3.92e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
LGG	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-10.42	4.77e-23	3.93e-20	-0.57	-0.43	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
LGG	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-10.42	4.79e-23	3.94e-20	-0.46	-0.43	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
LGG	cis	rs7927771	0.832	rs896816	ENSG00000280615.1	Y_RNA	10.42	4.83e-23	3.98e-20	0.54	0.43	Subjective well-being;	chr11:47372787	chr11:47614898~47614994:-
LGG	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	10.42	4.84e-23	3.98e-20	0.49	0.43	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
LGG	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-10.42	4.86e-23	4e-20	-0.47	-0.43	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
LGG	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-10.42	4.87e-23	4.01e-20	-0.58	-0.43	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
LGG	cis	rs4713118	0.869	rs6902689	ENSG00000216901.1	AL022393.7	10.42	4.87e-23	4.01e-20	0.56	0.43	Parkinson's disease;	chr6:27741662	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9468214	ENSG00000216901.1	AL022393.7	10.42	4.87e-23	4.01e-20	0.56	0.43	Parkinson's disease;	chr6:27745520	chr6:28176188~28176674:+
LGG	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-10.42	4.88e-23	4.02e-20	-0.57	-0.43	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
LGG	cis	rs8092443	1	rs8092963	ENSG00000278971.1	RP11-644A7.2	10.42	4.9e-23	4.03e-20	0.63	0.43	Response to antipsychotic treatment;	chr18:70475685	chr18:70489630~70491205:+
LGG	cis	rs7927771	0.864	rs55927797	ENSG00000280615.1	Y_RNA	-10.42	4.9e-23	4.03e-20	-0.54	-0.43	Subjective well-being;	chr11:47424741	chr11:47614898~47614994:-
LGG	cis	rs2013441	0.711	rs1682297	ENSG00000230528.6	NOS2P3	-10.42	4.91e-23	4.04e-20	-0.41	-0.43	Obesity-related traits;	chr17:20481607	chr17:20436337~20447249:+
LGG	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	10.42	4.91e-23	4.04e-20	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
LGG	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-10.42	4.92e-23	4.05e-20	-0.55	-0.43	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-10.42	4.92e-23	4.05e-20	-0.55	-0.43	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-10.42	4.92e-23	4.05e-20	-0.55	-0.43	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
LGG	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-10.42	4.93e-23	4.06e-20	-0.52	-0.43	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
LGG	cis	rs4373814	0.571	rs2183719	ENSG00000226083.4	SLC39A12-AS1	10.42	4.94e-23	4.06e-20	0.45	0.43	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18165113	chr10:18001786~18010562:-
LGG	cis	rs4373814	0.571	rs2183718	ENSG00000226083.4	SLC39A12-AS1	10.42	4.94e-23	4.06e-20	0.45	0.43	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18165543	chr10:18001786~18010562:-
LGG	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-10.42	4.94e-23	4.07e-20	-0.48	-0.43	Depression;	chr6:28159925	chr6:28115628~28116551:+
LGG	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-10.42	4.94e-23	4.07e-20	-0.48	-0.43	Depression;	chr6:28159932	chr6:28115628~28116551:+
LGG	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-10.42	4.95e-23	4.07e-20	-0.5	-0.43	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
LGG	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	10.42	4.95e-23	4.08e-20	0.54	0.43	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	10.42	4.95e-23	4.08e-20	0.54	0.43	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
LGG	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	10.42	5e-23	4.11e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
LGG	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	10.42	5.01e-23	4.12e-20	0.51	0.43	Height;	chr11:118860890	chr11:118688039~118690600:-
LGG	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	10.42	5.01e-23	4.12e-20	0.51	0.43	Height;	chr11:118861053	chr11:118688039~118690600:-
LGG	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	10.42	5.1e-23	4.2e-20	0.35	0.43	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
LGG	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-10.42	5.13e-23	4.21e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-10.42	5.13e-23	4.21e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-10.42	5.13e-23	4.21e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-10.42	5.13e-23	4.21e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-10.42	5.13e-23	4.21e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-10.42	5.13e-23	4.21e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
LGG	cis	rs7267979	0.899	rs6115213	ENSG00000276952.1	RP5-965G21.6	10.42	5.14e-23	4.23e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25284915~25285588:-
LGG	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	10.42	5.16e-23	4.24e-20	0.57	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
LGG	cis	rs4373814	0.624	rs10764332	ENSG00000226083.4	SLC39A12-AS1	10.42	5.16e-23	4.24e-20	0.44	0.43	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18163040	chr10:18001786~18010562:-
LGG	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-10.42	5.16e-23	4.24e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
LGG	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	10.42	5.17e-23	4.25e-20	0.49	0.43	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
LGG	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	10.41	5.21e-23	4.28e-20	0.52	0.43	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
LGG	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	10.41	5.21e-23	4.28e-20	0.52	0.43	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
LGG	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	10.41	5.21e-23	4.28e-20	0.52	0.43	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
LGG	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	10.41	5.21e-23	4.28e-20	0.52	0.43	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	10.41	5.21e-23	4.28e-20	0.52	0.43	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
LGG	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	10.41	5.21e-23	4.28e-20	0.52	0.43	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
LGG	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-10.41	5.22e-23	4.29e-20	-0.65	-0.43	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
LGG	cis	rs1065852	0.906	rs9611734	ENSG00000227370.1	RP4-669P10.19	10.41	5.23e-23	4.29e-20	0.48	0.43	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42106066	chr22:42132543~42132998:+
LGG	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	10.41	5.24e-23	4.3e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	10.41	5.24e-23	4.3e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	10.41	5.24e-23	4.3e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	10.41	5.24e-23	4.3e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
LGG	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.28e-23	4.33e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.28e-23	4.33e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.28e-23	4.33e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.28e-23	4.33e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.28e-23	4.33e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.28e-23	4.33e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.28e-23	4.33e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
LGG	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	10.41	5.28e-23	4.33e-20	0.3	0.43	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
LGG	cis	rs9388451	0.559	rs1777210	ENSG00000237742.5	RP11-624M8.1	-10.41	5.34e-23	4.38e-20	-0.39	-0.43	Brugada syndrome;	chr6:125777770	chr6:125578558~125749190:-
LGG	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	10.41	5.35e-23	4.39e-20	0.85	0.43	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
LGG	cis	rs853679	0.713	rs200991	ENSG00000216901.1	AL022393.7	-10.41	5.35e-23	4.39e-20	-0.67	-0.43	Depression;	chr6:27847716	chr6:28176188~28176674:+
LGG	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	10.41	5.37e-23	4.4e-20	0.53	0.43	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
LGG	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	10.41	5.37e-23	4.4e-20	0.3	0.43	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
LGG	cis	rs7267979	1	rs3761117	ENSG00000125804.12	FAM182A	10.41	5.37e-23	4.41e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:26054655~26086917:+
LGG	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-10.41	5.38e-23	4.41e-20	-0.53	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
LGG	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.43e-23	4.45e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.43e-23	4.45e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-10.41	5.43e-23	4.45e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
LGG	cis	rs4713118	0.869	rs7776351	ENSG00000216901.1	AL022393.7	-10.41	5.43e-23	4.45e-20	-0.56	-0.43	Parkinson's disease;	chr6:27758952	chr6:28176188~28176674:+
LGG	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-10.41	5.44e-23	4.46e-20	-0.35	-0.43	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
LGG	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-10.41	5.46e-23	4.47e-20	-0.57	-0.43	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
LGG	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-10.41	5.46e-23	4.47e-20	-0.57	-0.43	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
LGG	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-10.41	5.46e-23	4.47e-20	-0.57	-0.43	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
LGG	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	10.41	5.47e-23	4.48e-20	0.57	0.43	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
LGG	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	10.41	5.47e-23	4.48e-20	0.52	0.43	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
LGG	cis	rs9388451	0.626	rs1739384	ENSG00000237742.5	RP11-624M8.1	-10.41	5.48e-23	4.49e-20	-0.39	-0.43	Brugada syndrome;	chr6:125778100	chr6:125578558~125749190:-
LGG	cis	rs9388451	0.587	rs1739385	ENSG00000237742.5	RP11-624M8.1	-10.41	5.48e-23	4.49e-20	-0.39	-0.43	Brugada syndrome;	chr6:125778793	chr6:125578558~125749190:-
LGG	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	10.41	5.5e-23	4.51e-20	0.64	0.43	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
LGG	cis	rs8092443	0.81	rs73459320	ENSG00000278971.1	RP11-644A7.2	-10.41	5.51e-23	4.51e-20	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70471165	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.748	rs111352946	ENSG00000278971.1	RP11-644A7.2	-10.41	5.51e-23	4.51e-20	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70471238	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs28459797	ENSG00000278971.1	RP11-644A7.2	-10.41	5.51e-23	4.51e-20	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70471721	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs28759291	ENSG00000278971.1	RP11-644A7.2	-10.41	5.51e-23	4.51e-20	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70471844	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs9953912	ENSG00000278971.1	RP11-644A7.2	-10.41	5.51e-23	4.51e-20	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70472708	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs9964993	ENSG00000278971.1	RP11-644A7.2	-10.41	5.51e-23	4.51e-20	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70472757	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs58830422	ENSG00000278971.1	RP11-644A7.2	-10.41	5.51e-23	4.51e-20	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70473290	chr18:70489630~70491205:+
LGG	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	10.41	5.51e-23	4.51e-20	0.45	0.43	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
LGG	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-10.41	5.51e-23	4.51e-20	-0.56	-0.43	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
LGG	cis	rs1420956	0.646	rs7231167	ENSG00000264151.4	RP11-739N10.1	10.41	5.57e-23	4.56e-20	0.54	0.43	Obesity-related traits;	chr18:27568257	chr18:27336379~27595164:-
LGG	cis	rs2408955	0.522	rs4760679	ENSG00000258273.1	RP11-370I10.4	10.41	5.58e-23	4.57e-20	0.54	0.43	Glycated hemoglobin levels;	chr12:48067852	chr12:48333755~48333901:-
LGG	cis	rs1150668	0.796	rs9468372	ENSG00000280107.1	AL022393.9	-10.41	5.59e-23	4.58e-20	-0.41	-0.43	Pubertal anthropometrics;	chr6:28411584	chr6:28170845~28172521:+
LGG	cis	rs8092443	0.81	rs10469108	ENSG00000278971.1	RP11-644A7.2	10.41	5.6e-23	4.59e-20	0.63	0.43	Response to antipsychotic treatment;	chr18:70487178	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs2886659	ENSG00000278971.1	RP11-644A7.2	10.41	5.6e-23	4.59e-20	0.63	0.43	Response to antipsychotic treatment;	chr18:70487706	chr18:70489630~70491205:+
LGG	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-10.41	5.62e-23	4.6e-20	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
LGG	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	10.4	5.65e-23	4.62e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	10.4	5.65e-23	4.62e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
LGG	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	10.4	5.65e-23	4.63e-20	0.3	0.43	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
LGG	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-10.4	5.67e-23	4.64e-20	-0.56	-0.43	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
LGG	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-10.4	5.67e-23	4.64e-20	-0.56	-0.43	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-10.4	5.67e-23	4.64e-20	-0.56	-0.43	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
LGG	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	10.4	5.68e-23	4.65e-20	0.3	0.43	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
LGG	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-10.4	5.7e-23	4.66e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
LGG	cis	rs7267979	1	rs6115182	ENSG00000125804.12	FAM182A	10.4	5.75e-23	4.7e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:26054655~26086917:+
LGG	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-10.4	5.75e-23	4.7e-20	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
LGG	cis	rs482329	0.965	rs556186	ENSG00000228044.2	RP4-781K5.4	10.4	5.78e-23	4.72e-20	0.49	0.43	Life threatening arrhythmia;	chr1:234679138	chr1:234646289~234683176:+
LGG	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	10.4	5.79e-23	4.73e-20	0.44	0.43	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
LGG	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	10.4	5.79e-23	4.73e-20	0.44	0.43	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
LGG	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	10.4	5.79e-23	4.73e-20	0.44	0.43	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
LGG	cis	rs1075265	0.868	rs4671872	ENSG00000233266.1	HMGB1P31	10.4	5.8e-23	4.74e-20	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54134035	chr2:54051334~54051760:+
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	10.4	5.85e-23	4.78e-20	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
LGG	cis	rs7927771	0.864	rs3781625	ENSG00000280615.1	Y_RNA	-10.4	5.88e-23	4.8e-20	-0.54	-0.43	Subjective well-being;	chr11:47421529	chr11:47614898~47614994:-
LGG	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-10.4	5.88e-23	4.8e-20	-0.93	-0.43	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
LGG	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-10.4	5.88e-23	4.8e-20	-0.93	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
LGG	cis	rs7267979	0.844	rs6050477	ENSG00000125804.12	FAM182A	10.4	5.93e-23	4.85e-20	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26054655~26086917:+
LGG	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-10.4	5.94e-23	4.85e-20	-0.46	-0.43	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
LGG	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-10.4	5.94e-23	4.85e-20	-0.46	-0.43	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
LGG	cis	rs7267979	0.868	rs6138553	ENSG00000276952.1	RP5-965G21.6	10.4	5.95e-23	4.86e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25284915~25285588:-
LGG	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	10.4	5.96e-23	4.87e-20	0.54	0.43	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	10.4	5.96e-23	4.87e-20	0.54	0.43	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	10.4	5.96e-23	4.87e-20	0.54	0.43	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	10.4	5.96e-23	4.87e-20	0.54	0.43	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	10.4	5.96e-23	4.87e-20	0.54	0.43	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
LGG	cis	rs9322193	0.884	rs1108889	ENSG00000216621.7	RP11-244K5.6	10.4	5.96e-23	4.87e-20	0.52	0.43	Lung cancer;	chr6:149845433	chr6:149934527~149936782:+
LGG	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	10.4	5.98e-23	4.89e-20	0.56	0.43	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
LGG	cis	rs5742933	0.652	rs10210345	ENSG00000253559.1	OSGEPL1-AS1	10.4	6.03e-23	4.92e-20	0.52	0.43	Ferritin levels;	chr2:189754760	chr2:189762704~189765556:+
LGG	cis	rs1150668	0.83	rs2023493	ENSG00000226314.6	ZNF192P1	10.4	6.06e-23	4.95e-20	0.41	0.43	Pubertal anthropometrics;	chr6:28432385	chr6:28161781~28169594:+
LGG	cis	rs1150668	0.796	rs9468372	ENSG00000226314.6	ZNF192P1	10.4	6.07e-23	4.96e-20	0.41	0.43	Pubertal anthropometrics;	chr6:28411584	chr6:28161781~28169594:+
LGG	cis	rs7267979	1	rs6050609	ENSG00000125804.12	FAM182A	10.4	6.08e-23	4.96e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2424714	ENSG00000125804.12	FAM182A	-10.4	6.08e-23	4.96e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2424715	ENSG00000125804.12	FAM182A	-10.4	6.08e-23	4.96e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:26054655~26086917:+
LGG	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	10.4	6.09e-23	4.97e-20	0.6	0.43	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
LGG	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-10.4	6.09e-23	4.97e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
LGG	cis	rs6452524	0.967	rs1031901	ENSG00000248112.1	RP11-78C3.1	10.4	6.09e-23	4.98e-20	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:82919376~82921119:-
LGG	cis	rs5742933	0.857	rs1233272	ENSG00000273240.1	RP11-455J20.3	-10.4	6.11e-23	4.99e-20	-0.5	-0.43	Ferritin levels;	chr2:189814968	chr2:189763859~189764456:-
LGG	cis	rs7914558	0.966	rs11191438	ENSG00000272912.1	RP11-724N1.1	-10.4	6.13e-23	5e-20	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102914585~102915404:+
LGG	cis	rs7267979	0.932	rs424487	ENSG00000125804.12	FAM182A	-10.39	6.16e-23	5.03e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:26054655~26086917:+
LGG	cis	rs7927771	0.864	rs2293580	ENSG00000280615.1	Y_RNA	10.39	6.17e-23	5.04e-20	0.54	0.43	Subjective well-being;	chr11:47418732	chr11:47614898~47614994:-
LGG	cis	rs7267979	1	rs6050617	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.933	rs2387887	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050626	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6037121	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs1047171	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050629	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050630	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050632	ENSG00000125804.12	FAM182A	-10.39	6.19e-23	5.05e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:26054655~26086917:+
LGG	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-10.39	6.19e-23	5.05e-20	-0.41	-0.43	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
LGG	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	10.39	6.2e-23	5.06e-20	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
LGG	cis	rs7267979	1	rs2257991	ENSG00000125804.12	FAM182A	10.39	6.2e-23	5.06e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:26054655~26086917:+
LGG	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-10.39	6.22e-23	5.08e-20	-0.35	-0.43	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
LGG	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-10.39	6.23e-23	5.08e-20	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-10.39	6.23e-23	5.08e-20	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-10.39	6.23e-23	5.08e-20	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
LGG	cis	rs7267979	0.966	rs6083855	ENSG00000125804.12	FAM182A	10.39	6.23e-23	5.08e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4815426	ENSG00000125804.12	FAM182A	10.39	6.23e-23	5.08e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2257420	ENSG00000125804.12	FAM182A	-10.39	6.26e-23	5.1e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:26054655~26086917:+
LGG	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	10.39	6.26e-23	5.11e-20	0.85	0.43	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	10.39	6.26e-23	5.11e-20	0.85	0.43	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
LGG	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-10.39	6.28e-23	5.12e-20	-0.35	-0.43	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
LGG	cis	rs4713118	0.869	rs9366700	ENSG00000216901.1	AL022393.7	10.39	6.36e-23	5.19e-20	0.56	0.43	Parkinson's disease;	chr6:27729172	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs6456802	ENSG00000216901.1	AL022393.7	10.39	6.36e-23	5.19e-20	0.56	0.43	Parkinson's disease;	chr6:27730576	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9393851	ENSG00000216901.1	AL022393.7	10.39	6.36e-23	5.19e-20	0.56	0.43	Parkinson's disease;	chr6:27731802	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9461400	ENSG00000216901.1	AL022393.7	10.39	6.36e-23	5.19e-20	0.56	0.43	Parkinson's disease;	chr6:27732780	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9295742	ENSG00000216901.1	AL022393.7	10.39	6.36e-23	5.19e-20	0.56	0.43	Parkinson's disease;	chr6:27735053	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9461401	ENSG00000216901.1	AL022393.7	10.39	6.36e-23	5.19e-20	0.56	0.43	Parkinson's disease;	chr6:27735512	chr6:28176188~28176674:+
LGG	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	10.39	6.39e-23	5.2e-20	0.54	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
LGG	cis	rs7267979	0.903	rs2500400	ENSG00000125804.12	FAM182A	10.39	6.39e-23	5.21e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:26054655~26086917:+
LGG	cis	rs5758511	0.514	rs5751240	ENSG00000227370.1	RP4-669P10.19	10.39	6.43e-23	5.24e-20	0.5	0.43	Birth weight;	chr22:42199252	chr22:42132543~42132998:+
LGG	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	10.39	6.43e-23	5.24e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
LGG	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-10.39	6.44e-23	5.25e-20	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
LGG	cis	rs482329	0.93	rs572408	ENSG00000228044.2	RP4-781K5.4	-10.39	6.44e-23	5.25e-20	-0.49	-0.43	Life threatening arrhythmia;	chr1:234666347	chr1:234646289~234683176:+
LGG	cis	rs17345786	0.511	rs12639028	ENSG00000256628.3	ZBTB11-AS1	10.39	6.45e-23	5.26e-20	0.51	0.43	Colonoscopy-negative controls vs population controls;	chr3:101627189	chr3:101676475~101679217:+
LGG	cis	rs7267979	1	rs2424704	ENSG00000125804.12	FAM182A	-10.39	6.45e-23	5.26e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:26054655~26086917:+
LGG	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	10.39	6.46e-23	5.26e-20	0.53	0.43	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
LGG	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-10.39	6.47e-23	5.27e-20	-0.57	-0.43	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
LGG	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	10.39	6.48e-23	5.28e-20	0.44	0.43	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
LGG	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	10.39	6.48e-23	5.28e-20	0.44	0.43	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
LGG	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	10.39	6.48e-23	5.28e-20	0.44	0.43	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
LGG	cis	rs1150668	0.764	rs9368565	ENSG00000226314.6	ZNF192P1	-10.39	6.49e-23	5.28e-20	-0.41	-0.43	Pubertal anthropometrics;	chr6:28377433	chr6:28161781~28169594:+
LGG	cis	rs1150668	0.796	rs1052215	ENSG00000226314.6	ZNF192P1	-10.39	6.49e-23	5.28e-20	-0.41	-0.43	Pubertal anthropometrics;	chr6:28380381	chr6:28161781~28169594:+
LGG	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	10.39	6.52e-23	5.31e-20	0.85	0.43	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
LGG	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	10.39	6.52e-23	5.31e-20	0.57	0.43	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
LGG	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	10.39	6.52e-23	5.31e-20	0.78	0.43	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
LGG	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	10.39	6.52e-23	5.31e-20	0.56	0.43	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
LGG	cis	rs4927850	1	rs6799572	ENSG00000231464.1	AC024937.4	10.39	6.56e-23	5.34e-20	0.58	0.43	Pancreatic cancer;	chr3:196013537	chr3:195996738~195998233:+
LGG	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	10.39	6.57e-23	5.35e-20	0.47	0.43	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
LGG	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-10.39	6.58e-23	5.36e-20	-0.57	-0.43	QT interval;	chr16:28845498	chr16:28700294~28701540:-
LGG	cis	rs7267979	0.966	rs4815425	ENSG00000125804.12	FAM182A	10.39	6.6e-23	5.37e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050599	ENSG00000125804.12	FAM182A	10.39	6.6e-23	5.37e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050602	ENSG00000125804.12	FAM182A	10.39	6.6e-23	5.37e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:26054655~26086917:+
LGG	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	10.39	6.62e-23	5.39e-20	0.39	0.43	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
LGG	cis	rs67340775	0.541	rs200973	ENSG00000216901.1	AL022393.7	10.39	6.63e-23	5.4e-20	0.7	0.43	Lung cancer in ever smokers;	chr6:27890643	chr6:28176188~28176674:+
LGG	cis	rs453301	0.682	rs2929308	ENSG00000173295.6	FAM86B3P	10.39	6.64e-23	5.4e-20	0.44	0.43	Joint mobility (Beighton score);	chr8:9226611	chr8:8228595~8244865:+
LGG	cis	rs7914558	0.966	rs10748835	ENSG00000272912.1	RP11-724N1.1	-10.39	6.65e-23	5.41e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900499	chr10:102914585~102915404:+
LGG	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-10.39	6.66e-23	5.42e-20	-0.57	-0.43	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
LGG	cis	rs7119038	0.774	rs73005426	ENSG00000255239.1	AP002954.6	-10.39	6.69e-23	5.44e-20	-0.59	-0.43	Sjögren's syndrome;	chr11:118810374	chr11:118688039~118690600:-
LGG	cis	rs651907	0.557	rs34457525	ENSG00000256628.3	ZBTB11-AS1	10.38	6.71e-23	5.46e-20	0.49	0.43	Colorectal cancer;	chr3:101716381	chr3:101676475~101679217:+
LGG	cis	rs7119038	0.818	rs10892294	ENSG00000255239.1	AP002954.6	10.38	6.72e-23	5.46e-20	0.59	0.43	Sjögren's syndrome;	chr11:118796648	chr11:118688039~118690600:-
LGG	cis	rs7267979	0.903	rs6115109	ENSG00000276952.1	RP5-965G21.6	10.38	6.73e-23	5.47e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.833	rs4619688	ENSG00000276952.1	RP5-965G21.6	10.38	6.73e-23	5.47e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.903	rs6115118	ENSG00000276952.1	RP5-965G21.6	10.38	6.73e-23	5.47e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.903	rs1118963	ENSG00000276952.1	RP5-965G21.6	10.38	6.73e-23	5.47e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2387885	ENSG00000276952.1	RP5-965G21.6	-10.38	6.73e-23	5.47e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2424713	ENSG00000276952.1	RP5-965G21.6	10.38	6.73e-23	5.47e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25284915~25285588:-
LGG	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	10.38	6.73e-23	5.47e-20	0.85	0.43	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
LGG	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	10.38	6.75e-23	5.49e-20	0.54	0.43	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	10.38	6.75e-23	5.49e-20	0.54	0.43	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	10.38	6.75e-23	5.49e-20	0.54	0.43	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	10.38	6.75e-23	5.49e-20	0.54	0.43	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
LGG	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	10.38	6.75e-23	5.49e-20	0.54	0.43	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
LGG	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	10.38	6.77e-23	5.5e-20	0.51	0.43	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
LGG	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	10.38	6.77e-23	5.5e-20	0.51	0.43	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
LGG	cis	rs11148252	0.553	rs7999849	ENSG00000273784.3	RP11-78J21.7	-10.38	6.82e-23	5.54e-20	-0.48	-0.43	Lewy body disease;	chr13:52675279	chr13:52600042~52642542:+
LGG	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-10.38	6.84e-23	5.56e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-10.38	6.84e-23	5.56e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
LGG	cis	rs7267979	0.932	rs449370	ENSG00000125804.12	FAM182A	10.38	6.88e-23	5.59e-20	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:26054655~26086917:+
LGG	cis	rs853679	0.599	rs149949	ENSG00000199851.2	U3	10.38	6.9e-23	5.61e-20	0.91	0.43	Depression;	chr6:28043738	chr6:28015568~28015777:+
LGG	cis	rs9388451	0.839	rs3799709	ENSG00000237742.5	RP11-624M8.1	-10.38	6.93e-23	5.63e-20	-0.37	-0.43	Brugada syndrome;	chr6:125757215	chr6:125578558~125749190:-
LGG	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	10.38	6.97e-23	5.66e-20	0.92	0.43	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
LGG	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	10.38	6.98e-23	5.67e-20	0.59	0.43	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
LGG	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	10.38	6.98e-23	5.67e-20	0.59	0.43	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
LGG	cis	rs4713118	0.866	rs9468217	ENSG00000216901.1	AL022393.7	10.38	6.99e-23	5.67e-20	0.58	0.43	Parkinson's disease;	chr6:27758688	chr6:28176188~28176674:+
LGG	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-10.38	6.99e-23	5.68e-20	-0.49	-0.43	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
LGG	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-10.38	7.02e-23	5.7e-20	-0.47	-0.43	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
LGG	cis	rs7267979	1	rs6115153	ENSG00000125804.12	FAM182A	10.38	7.05e-23	5.72e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs7268053	ENSG00000125804.12	FAM182A	10.38	7.05e-23	5.72e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6083809	ENSG00000125804.12	FAM182A	10.38	7.05e-23	5.72e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:26054655~26086917:+
LGG	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	10.38	7.07e-23	5.74e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
LGG	cis	rs8092443	0.748	rs73459338	ENSG00000278971.1	RP11-644A7.2	-10.38	7.1e-23	5.76e-20	-0.68	-0.43	Response to antipsychotic treatment;	chr18:70476033	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.748	rs78547780	ENSG00000278971.1	RP11-644A7.2	-10.38	7.1e-23	5.76e-20	-0.68	-0.43	Response to antipsychotic treatment;	chr18:70476221	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs112956841	ENSG00000278971.1	RP11-644A7.2	-10.38	7.1e-23	5.76e-20	-0.68	-0.43	Response to antipsychotic treatment;	chr18:70477118	chr18:70489630~70491205:+
LGG	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	10.38	7.12e-23	5.77e-20	0.46	0.43	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
LGG	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	10.38	7.13e-23	5.78e-20	0.3	0.43	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
LGG	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-10.38	7.16e-23	5.81e-20	-0.35	-0.43	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-10.38	7.16e-23	5.81e-20	-0.35	-0.43	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
LGG	cis	rs7267979	0.932	rs431579	ENSG00000125804.12	FAM182A	-10.38	7.18e-23	5.82e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:26054655~26086917:+
LGG	cis	rs9527	1	rs12416687	ENSG00000272912.1	RP11-724N1.1	-10.38	7.19e-23	5.83e-20	-0.53	-0.43	Arsenic metabolism;	chr10:102869254	chr10:102914585~102915404:+
LGG	cis	rs111649495	1	rs111649495	ENSG00000250678.1	CTB-161M19.1	-10.38	7.21e-23	5.85e-20	-0.78	-0.43	Response to amphetamines;	chr5:119020720	chr5:119010060~119010542:+
LGG	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	10.38	7.22e-23	5.86e-20	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
LGG	cis	rs5742933	1	rs1966729	ENSG00000273240.1	RP11-455J20.3	-10.38	7.22e-23	5.86e-20	-0.54	-0.43	Ferritin levels;	chr2:189721105	chr2:189763859~189764456:-
LGG	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	10.38	7.23e-23	5.86e-20	0.57	0.43	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	10.38	7.23e-23	5.86e-20	0.57	0.43	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	10.38	7.23e-23	5.86e-20	0.57	0.43	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
LGG	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	10.38	7.25e-23	5.88e-20	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
LGG	cis	rs1150668	0.83	rs2531831	ENSG00000280107.1	AL022393.9	-10.38	7.26e-23	5.89e-20	-0.41	-0.43	Pubertal anthropometrics;	chr6:28420988	chr6:28170845~28172521:+
LGG	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	10.38	7.26e-23	5.89e-20	0.56	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
LGG	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-10.38	7.27e-23	5.89e-20	-0.49	-0.43	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
LGG	cis	rs5742933	0.803	rs1233262	ENSG00000253559.1	OSGEPL1-AS1	-10.37	7.3e-23	5.92e-20	-0.52	-0.43	Ferritin levels;	chr2:189793107	chr2:189762704~189765556:+
LGG	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-10.37	7.34e-23	5.95e-20	-0.49	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
LGG	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	10.37	7.34e-23	5.95e-20	0.32	0.43	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
LGG	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	10.37	7.37e-23	5.97e-20	0.53	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
LGG	cis	rs7267979	0.866	rs437635	ENSG00000125804.12	FAM182A	-10.37	7.38e-23	5.98e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.899	rs442834	ENSG00000125804.12	FAM182A	-10.37	7.38e-23	5.98e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs417110	ENSG00000125804.12	FAM182A	-10.37	7.38e-23	5.98e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs449703	ENSG00000125804.12	FAM182A	-10.37	7.38e-23	5.98e-20	-0.52	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:26054655~26086917:+
LGG	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	10.37	7.39e-23	5.99e-20	0.44	0.43	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
LGG	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-10.37	7.41e-23	6e-20	-0.49	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-10.37	7.41e-23	6e-20	-0.49	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
LGG	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-10.37	7.44e-23	6.03e-20	-0.49	-0.43	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
LGG	cis	rs8092443	0.81	rs17082653	ENSG00000278971.1	RP11-644A7.2	-10.37	7.46e-23	6.04e-20	-0.66	-0.43	Response to antipsychotic treatment;	chr18:70471997	chr18:70489630~70491205:+
LGG	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-10.37	7.47e-23	6.05e-20	-0.55	-0.43	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
LGG	cis	rs7267979	1	rs6132835	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.933	rs11699203	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.933	rs6138571	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs416745	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs448396	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs447722	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs422424	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs422844	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs401166	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs404394	ENSG00000125804.12	FAM182A	-10.37	7.49e-23	6.07e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:26054655~26086917:+
LGG	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	10.37	7.51e-23	6.08e-20	0.42	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
LGG	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-10.37	7.51e-23	6.08e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-10.37	7.51e-23	6.08e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
LGG	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	10.37	7.51e-23	6.08e-20	0.58	0.43	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
LGG	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	10.37	7.58e-23	6.13e-20	0.32	0.43	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
LGG	cis	rs7267979	0.932	rs2260997	ENSG00000125804.12	FAM182A	10.37	7.61e-23	6.16e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:26054655~26086917:+
LGG	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-10.37	7.65e-23	6.19e-20	-0.93	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
LGG	cis	rs7267979	1	rs2500448	ENSG00000276952.1	RP5-965G21.6	-10.37	7.69e-23	6.22e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.911	rs9295746	ENSG00000216901.1	AL022393.7	10.37	7.7e-23	6.23e-20	0.59	0.43	Parkinson's disease;	chr6:27762285	chr6:28176188~28176674:+
LGG	cis	rs7927771	0.832	rs10769258	ENSG00000280615.1	Y_RNA	10.37	7.81e-23	6.31e-20	0.54	0.43	Subjective well-being;	chr11:47369488	chr11:47614898~47614994:-
LGG	cis	rs5742933	0.817	rs1233297	ENSG00000253559.1	OSGEPL1-AS1	-10.37	7.82e-23	6.32e-20	-0.51	-0.43	Ferritin levels;	chr2:189829449	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.817	rs1233299	ENSG00000253559.1	OSGEPL1-AS1	-10.37	7.87e-23	6.36e-20	-0.51	-0.43	Ferritin levels;	chr2:189799912	chr2:189762704~189765556:+
LGG	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	10.37	7.87e-23	6.36e-20	0.59	0.43	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
LGG	cis	rs9388451	0.537	rs1739383	ENSG00000237742.5	RP11-624M8.1	-10.37	7.9e-23	6.38e-20	-0.39	-0.43	Brugada syndrome;	chr6:125777769	chr6:125578558~125749190:-
LGG	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-10.37	7.91e-23	6.39e-20	-0.49	-0.43	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
LGG	cis	rs6903823	0.527	rs4713158	ENSG00000199851.2	U3	10.37	7.92e-23	6.4e-20	0.6	0.43	Pulmonary function;	chr6:28309994	chr6:28015568~28015777:+
LGG	cis	rs5758511	0.68	rs5758698	ENSG00000227370.1	RP4-669P10.19	10.37	7.94e-23	6.41e-20	0.48	0.43	Birth weight;	chr22:42288812	chr22:42132543~42132998:+
LGG	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	10.36	7.99e-23	6.45e-20	0.58	0.43	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
LGG	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	10.36	8e-23	6.46e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
LGG	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	10.36	8.03e-23	6.48e-20	0.3	0.43	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
LGG	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	10.36	8.06e-23	6.51e-20	0.84	0.43	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
LGG	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	-10.36	8.08e-23	6.52e-20	-0.47	-0.43	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
LGG	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-10.36	8.1e-23	6.54e-20	-0.93	-0.43	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
LGG	cis	rs482329	0.93	rs617029	ENSG00000228044.2	RP4-781K5.4	10.36	8.11e-23	6.55e-20	0.49	0.43	Life threatening arrhythmia;	chr1:234672580	chr1:234646289~234683176:+
LGG	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	-10.36	8.11e-23	6.55e-20	-0.45	-0.43	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
LGG	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	-10.36	8.11e-23	6.55e-20	-0.45	-0.43	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
LGG	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	10.36	8.12e-23	6.55e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
LGG	cis	rs7267979	0.903	rs6132819	ENSG00000276952.1	RP5-965G21.6	10.36	8.13e-23	6.56e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25284915~25285588:-
LGG	cis	rs7119038	0.686	rs55894437	ENSG00000255239.1	AP002954.6	-10.36	8.18e-23	6.61e-20	-0.58	-0.43	Sjögren's syndrome;	chr11:118736708	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	10.36	8.19e-23	6.61e-20	0.55	0.43	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
LGG	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	10.36	8.19e-23	6.61e-20	0.38	0.43	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-10.36	8.19e-23	6.61e-20	-0.35	-0.43	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
LGG	cis	rs6496932	0.663	rs7183764	ENSG00000218052.5	ADAMTS7P4	-10.36	8.19e-23	6.61e-20	-0.59	-0.43	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85255369~85330334:-
LGG	cis	rs6496932	0.663	rs4842878	ENSG00000218052.5	ADAMTS7P4	-10.36	8.19e-23	6.61e-20	-0.59	-0.43	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85255369~85330334:-
LGG	cis	rs6496932	0.663	rs8040940	ENSG00000218052.5	ADAMTS7P4	-10.36	8.19e-23	6.61e-20	-0.59	-0.43	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85255369~85330334:-
LGG	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-10.36	8.22e-23	6.63e-20	-0.35	-0.43	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-10.36	8.22e-23	6.63e-20	-0.35	-0.43	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
LGG	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-10.36	8.22e-23	6.63e-20	-0.35	-0.43	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
LGG	cis	rs11233250	0.697	rs17144197	ENSG00000245832.5	RP11-179A16.1	10.36	8.24e-23	6.65e-20	0.63	0.43	Glioblastoma;Glioma;	chr11:82721092	chr11:81879851~82718082:-
LGG	cis	rs7267979	0.873	rs6083853	ENSG00000276952.1	RP5-965G21.6	-10.36	8.3e-23	6.69e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.934	rs2482913	ENSG00000276952.1	RP5-965G21.6	-10.36	8.3e-23	6.69e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25284915~25285588:-
LGG	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.31e-23	6.7e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
LGG	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	10.36	8.31e-23	6.7e-20	0.51	0.43	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
LGG	cis	rs11675119	0.517	rs12619851	ENSG00000225234.1	TRAPPC12-AS1	-10.36	8.32e-23	6.71e-20	-0.42	-0.43	Neurofibrillary tangles;	chr2:3488976	chr2:3481242~3482409:-
LGG	cis	rs7267979	1	rs2482927	ENSG00000276952.1	RP5-965G21.6	-10.36	8.35e-23	6.73e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25284915~25285588:-
LGG	cis	rs11148252	0.574	rs2038826	ENSG00000273784.3	RP11-78J21.7	-10.36	8.42e-23	6.79e-20	-0.48	-0.43	Lewy body disease;	chr13:52705878	chr13:52600042~52642542:+
LGG	cis	rs482329	0.93	rs636705	ENSG00000228044.2	RP4-781K5.4	10.36	8.42e-23	6.79e-20	0.49	0.43	Life threatening arrhythmia;	chr1:234667873	chr1:234646289~234683176:+
LGG	cis	rs9388451	0.626	rs1268074	ENSG00000237742.5	RP11-624M8.1	-10.36	8.43e-23	6.8e-20	-0.39	-0.43	Brugada syndrome;	chr6:125786645	chr6:125578558~125749190:-
LGG	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	10.36	8.47e-23	6.83e-20	0.41	0.43	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
LGG	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	10.36	8.48e-23	6.84e-20	0.48	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
LGG	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	10.36	8.53e-23	6.88e-20	0.46	0.43	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
LGG	cis	rs7267979	1	rs2258719	ENSG00000276952.1	RP5-965G21.6	10.36	8.54e-23	6.88e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25284915~25285588:-
LGG	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-10.36	8.56e-23	6.9e-20	-0.53	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
LGG	cis	rs5742933	0.948	rs10195109	ENSG00000273240.1	RP11-455J20.3	10.36	8.58e-23	6.92e-20	0.55	0.43	Ferritin levels;	chr2:189704465	chr2:189763859~189764456:-
LGG	cis	rs1150668	0.796	rs1124132	ENSG00000226314.6	ZNF192P1	10.36	8.6e-23	6.93e-20	0.41	0.43	Pubertal anthropometrics;	chr6:28412544	chr6:28161781~28169594:+
LGG	cis	rs1150668	0.796	rs2531832	ENSG00000226314.6	ZNF192P1	10.36	8.6e-23	6.93e-20	0.41	0.43	Pubertal anthropometrics;	chr6:28421445	chr6:28161781~28169594:+
LGG	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	10.36	8.61e-23	6.94e-20	0.52	0.43	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	10.36	8.61e-23	6.94e-20	0.52	0.43	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
LGG	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-10.35	8.67e-23	6.98e-20	-0.46	-0.43	Depression;	chr6:28206812	chr6:28115628~28116551:+
LGG	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-10.35	8.73e-23	7.04e-20	-0.58	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
LGG	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-10.35	8.73e-23	7.04e-20	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
LGG	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	10.35	8.78e-23	7.07e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
LGG	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-10.35	8.79e-23	7.08e-20	-0.67	-0.43	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
LGG	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-10.35	8.79e-23	7.08e-20	-0.67	-0.43	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
LGG	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-10.35	8.79e-23	7.08e-20	-0.67	-0.43	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
LGG	cis	rs357618	0.531	rs152389	ENSG00000260581.1	CTB-113P19.4	10.35	8.8e-23	7.08e-20	0.51	0.43	Basophil percentage of white cells;	chr5:151482619	chr5:151652275~151655449:+
LGG	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	10.35	8.81e-23	7.09e-20	0.66	0.43	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
LGG	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-10.35	8.92e-23	7.18e-20	-0.55	-0.43	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
LGG	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	10.35	8.95e-23	7.2e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	10.35	8.95e-23	7.2e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	10.35	8.95e-23	7.2e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	10.35	8.95e-23	7.2e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	10.35	8.95e-23	7.2e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	10.35	8.95e-23	7.2e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	10.35	8.95e-23	7.2e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
LGG	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-10.35	9.02e-23	7.25e-20	-0.63	-0.43	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	10.35	9.05e-23	7.28e-20	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
LGG	cis	rs10028773	0.666	rs12498657	ENSG00000249244.1	RP11-548H18.2	10.35	9.08e-23	7.3e-20	0.45	0.43	Educational attainment;	chr4:119341711	chr4:119391831~119395335:-
LGG	cis	rs7267979	1	rs2500418	ENSG00000276952.1	RP5-965G21.6	-10.35	9.1e-23	7.32e-20	-0.43	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.619	rs200486	ENSG00000199851.2	U3	10.35	9.13e-23	7.34e-20	0.69	0.43	Parkinson's disease;	chr6:27811728	chr6:28015568~28015777:+
LGG	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	10.35	9.15e-23	7.36e-20	0.59	0.43	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
LGG	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-10.35	9.16e-23	7.37e-20	-0.59	-0.43	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
LGG	cis	rs11148252	0.595	rs9526968	ENSG00000273784.3	RP11-78J21.7	-10.35	9.17e-23	7.37e-20	-0.48	-0.43	Lewy body disease;	chr13:52666048	chr13:52600042~52642542:+
LGG	cis	rs9875589	0.957	rs1108341	ENSG00000233121.1	VN1R20P	10.35	9.18e-23	7.38e-20	0.44	0.43	Ovarian reserve;	chr3:13895831	chr3:13926813~13927778:+
LGG	cis	rs9875589	0.957	rs35485647	ENSG00000233121.1	VN1R20P	10.35	9.18e-23	7.38e-20	0.44	0.43	Ovarian reserve;	chr3:13896440	chr3:13926813~13927778:+
LGG	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-10.35	9.2e-23	7.4e-20	-0.51	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
LGG	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	10.35	9.21e-23	7.41e-20	0.64	0.43	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
LGG	cis	rs6452524	0.87	rs2174976	ENSG00000248112.1	RP11-78C3.1	10.35	9.27e-23	7.45e-20	0.57	0.43	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:82919376~82921119:-
LGG	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-10.34	9.42e-23	7.57e-20	-0.56	-0.43	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
LGG	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-10.34	9.46e-23	7.6e-20	-0.46	-0.43	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
LGG	cis	rs482329	0.93	rs533048	ENSG00000228044.2	RP4-781K5.4	10.34	9.52e-23	7.65e-20	0.49	0.43	Life threatening arrhythmia;	chr1:234672272	chr1:234646289~234683176:+
LGG	cis	rs12935418	0.672	rs2602424	ENSG00000260213.4	RP11-303E16.3	10.34	9.66e-23	7.75e-20	0.52	0.43	Mean corpuscular volume;	chr16:81009600	chr16:81016792~81035759:-
LGG	cis	rs5742933	0.948	rs2264018	ENSG00000273240.1	RP11-455J20.3	-10.34	9.68e-23	7.77e-20	-0.54	-0.43	Ferritin levels;	chr2:189712052	chr2:189763859~189764456:-
LGG	cis	rs7267979	1	rs4815412	ENSG00000125804.12	FAM182A	-10.34	9.69e-23	7.78e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:26054655~26086917:+
LGG	cis	rs7615952	0.512	rs2979351	ENSG00000242001.1	GS1-388B5.1	10.34	9.73e-23	7.81e-20	0.57	0.43	Blood pressure (smoking interaction);	chr3:125644755	chr3:125681305~125681453:+
LGG	cis	rs11098499	0.722	rs10006192	ENSG00000249244.1	RP11-548H18.2	10.34	9.74e-23	7.82e-20	0.44	0.43	Corneal astigmatism;	chr4:119341867	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.615	rs28551750	ENSG00000249244.1	RP11-548H18.2	10.34	9.74e-23	7.82e-20	0.44	0.43	Corneal astigmatism;	chr4:119343746	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.691	rs9995716	ENSG00000249244.1	RP11-548H18.2	10.34	9.74e-23	7.82e-20	0.44	0.43	Corneal astigmatism;	chr4:119343841	chr4:119391831~119395335:-
LGG	cis	rs4713118	0.869	rs6901520	ENSG00000216901.1	AL022393.7	10.34	9.75e-23	7.82e-20	0.56	0.43	Parkinson's disease;	chr6:27746796	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9283880	ENSG00000216901.1	AL022393.7	10.34	9.75e-23	7.82e-20	0.56	0.43	Parkinson's disease;	chr6:27747464	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9283881	ENSG00000216901.1	AL022393.7	10.34	9.75e-23	7.82e-20	0.56	0.43	Parkinson's disease;	chr6:27747476	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.869	rs9283882	ENSG00000216901.1	AL022393.7	10.34	9.75e-23	7.82e-20	0.56	0.43	Parkinson's disease;	chr6:27747479	chr6:28176188~28176674:+
LGG	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	10.34	9.77e-23	7.84e-20	0.56	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
LGG	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-10.34	9.78e-23	7.85e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
LGG	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-10.34	9.8e-23	7.87e-20	-0.51	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
LGG	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	10.34	9.83e-23	7.88e-20	0.9	0.43	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
LGG	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-10.34	9.86e-23	7.91e-20	-0.57	-0.43	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
LGG	cis	rs7267979	1	rs4815411	ENSG00000125804.12	FAM182A	10.34	9.87e-23	7.92e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:26054655~26086917:+
LGG	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	10.34	9.88e-23	7.93e-20	0.31	0.43	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
LGG	cis	rs7267979	1	rs6050547	ENSG00000125804.12	FAM182A	10.34	9.9e-23	7.94e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.903	rs6107015	ENSG00000276952.1	RP5-965G21.6	10.34	9.93e-23	7.96e-20	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25284915~25285588:-
LGG	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	10.34	9.95e-23	7.98e-20	0.45	0.43	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
LGG	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	10.34	9.95e-23	7.98e-20	0.5	0.43	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
LGG	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-10.34	9.95e-23	7.98e-20	-0.47	-0.43	Depression;	chr6:28113616	chr6:28115628~28116551:+
LGG	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	10.34	9.99e-23	8e-20	0.47	0.43	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
LGG	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
LGG	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
LGG	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
LGG	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
LGG	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
LGG	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
LGG	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
LGG	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
LGG	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-10.34	9.99e-23	8e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
LGG	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	10.34	1e-22	8.03e-20	0.5	0.43	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	10.34	1e-22	8.03e-20	0.5	0.43	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	10.34	1e-22	8.03e-20	0.5	0.43	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
LGG	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	10.34	1e-22	8.05e-20	0.3	0.43	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	10.34	1e-22	8.05e-20	0.3	0.43	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	10.34	1e-22	8.05e-20	0.3	0.43	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	10.34	1e-22	8.05e-20	0.3	0.43	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
LGG	cis	rs7927771	0.832	rs10838698	ENSG00000280615.1	Y_RNA	10.34	1.01e-22	8.05e-20	0.54	0.43	Subjective well-being;	chr11:47364372	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.832	rs10838699	ENSG00000280615.1	Y_RNA	10.34	1.01e-22	8.05e-20	0.54	0.43	Subjective well-being;	chr11:47364522	chr11:47614898~47614994:-
LGG	cis	rs1799949	1	rs4793236	ENSG00000267681.1	CTD-3199J23.6	-10.34	1.01e-22	8.08e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43359072	chr17:43144956~43145255:+
LGG	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	10.34	1.01e-22	8.08e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
LGG	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-10.34	1.01e-22	8.1e-20	-0.47	-0.43	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-10.34	1.01e-22	8.1e-20	-0.47	-0.43	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
LGG	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-10.34	1.01e-22	8.1e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
LGG	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-10.34	1.01e-22	8.1e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
LGG	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-10.34	1.01e-22	8.1e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
LGG	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-10.34	1.01e-22	8.1e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
LGG	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-10.34	1.01e-22	8.11e-20	-0.49	-0.43	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
LGG	cis	rs6452524	1	rs7738033	ENSG00000248112.1	RP11-78C3.1	10.34	1.01e-22	8.11e-20	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:82919376~82921119:-
LGG	cis	rs6452524	1	rs6860239	ENSG00000248112.1	RP11-78C3.1	10.34	1.01e-22	8.11e-20	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:82919376~82921119:-
LGG	cis	rs4713118	0.869	rs9295743	ENSG00000216901.1	AL022393.7	10.34	1.02e-22	8.16e-20	0.56	0.43	Parkinson's disease;	chr6:27747323	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	10.34	1.02e-22	8.18e-20	0.52	0.43	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
LGG	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	10.34	1.02e-22	8.18e-20	0.32	0.43	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
LGG	cis	rs482329	0.93	rs621167	ENSG00000228044.2	RP4-781K5.4	10.33	1.03e-22	8.22e-20	0.49	0.43	Life threatening arrhythmia;	chr1:234671712	chr1:234646289~234683176:+
LGG	cis	rs8092443	0.81	rs4265918	ENSG00000278971.1	RP11-644A7.2	-10.33	1.03e-22	8.25e-20	-0.68	-0.43	Response to antipsychotic treatment;	chr18:70487286	chr18:70489630~70491205:+
LGG	cis	rs6500637	0.86	rs11644917	ENSG00000267077.1	RP11-127I20.5	-10.33	1.04e-22	8.29e-20	-0.45	-0.43	Cancer;	chr16:4890386	chr16:4795265~4796532:-
LGG	cis	rs853679	1	rs1936365	ENSG00000199851.2	U3	-10.33	1.05e-22	8.37e-20	-0.78	-0.43	Depression;	chr6:28300675	chr6:28015568~28015777:+
LGG	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	10.33	1.05e-22	8.37e-20	0.55	0.43	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
LGG	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	10.33	1.05e-22	8.37e-20	0.55	0.43	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
LGG	cis	rs4683346	0.503	rs9840276	ENSG00000273328.4	RP11-141M3.6	-10.33	1.05e-22	8.42e-20	-0.49	-0.43	Granulocyte percentage of myeloid white cells;	chr3:42835238	chr3:42809414~42908105:+
LGG	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	10.33	1.05e-22	8.42e-20	0.31	0.43	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
LGG	cis	rs7914558	1	rs10883826	ENSG00000272912.1	RP11-724N1.1	-10.33	1.05e-22	8.43e-20	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102914585~102915404:+
LGG	cis	rs4713118	0.869	rs9283883	ENSG00000216901.1	AL022393.7	10.33	1.05e-22	8.43e-20	0.56	0.43	Parkinson's disease;	chr6:27747691	chr6:28176188~28176674:+
LGG	cis	rs7267979	0.932	rs1541061	ENSG00000276952.1	RP5-965G21.6	10.33	1.05e-22	8.43e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.932	rs6138600	ENSG00000276952.1	RP5-965G21.6	10.33	1.05e-22	8.43e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.899	rs2104734	ENSG00000276952.1	RP5-965G21.6	10.33	1.05e-22	8.43e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25284915~25285588:-
LGG	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-10.33	1.06e-22	8.44e-20	-0.48	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
LGG	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	10.33	1.06e-22	8.44e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
LGG	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-10.33	1.06e-22	8.47e-20	-0.54	-0.43	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
LGG	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-10.33	1.06e-22	8.5e-20	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
LGG	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-10.33	1.07e-22	8.52e-20	-0.45	-0.43	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
LGG	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-10.33	1.07e-22	8.56e-20	-0.48	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
LGG	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-10.33	1.07e-22	8.56e-20	-0.48	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
LGG	cis	rs7267979	1	rs4815418	ENSG00000125804.12	FAM182A	10.33	1.08e-22	8.6e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:26054655~26086917:+
LGG	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-10.33	1.08e-22	8.6e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
LGG	cis	rs7267979	0.706	rs6138542	ENSG00000125804.12	FAM182A	-10.33	1.08e-22	8.64e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:26054655~26086917:+
LGG	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	10.33	1.08e-22	8.65e-20	0.56	0.43	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
LGG	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	10.33	1.08e-22	8.65e-20	0.56	0.43	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
LGG	cis	rs6539247	0.509	rs4275717	ENSG00000257890.1	RP11-114F10.2	-10.33	1.09e-22	8.71e-20	-0.52	-0.43	Attention function in attention deficit hyperactive disorder;	chr12:106052074	chr12:106050961~106058254:-
LGG	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-10.33	1.1e-22	8.76e-20	-0.38	-0.43	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
LGG	cis	rs11148252	0.557	rs9536223	ENSG00000273784.3	RP11-78J21.7	-10.33	1.1e-22	8.81e-20	-0.48	-0.43	Lewy body disease;	chr13:52659059	chr13:52600042~52642542:+
LGG	cis	rs4819052	0.765	rs2838868	ENSG00000223768.1	LINC00205	10.33	1.1e-22	8.82e-20	0.49	0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45293285~45297354:+
LGG	cis	rs9388451	0.868	rs1268083	ENSG00000237742.5	RP11-624M8.1	10.33	1.11e-22	8.85e-20	0.38	0.43	Brugada syndrome;	chr6:125727894	chr6:125578558~125749190:-
LGG	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	10.33	1.11e-22	8.89e-20	0.59	0.43	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
LGG	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-10.32	1.12e-22	8.96e-20	-0.57	-0.43	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
LGG	cis	rs853679	0.527	rs9468333	ENSG00000199851.2	U3	10.32	1.12e-22	8.96e-20	0.6	0.43	Depression;	chr6:28303421	chr6:28015568~28015777:+
LGG	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-10.32	1.12e-22	8.97e-20	-0.63	-0.43	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
LGG	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-10.32	1.14e-22	9.07e-20	-0.51	-0.43	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
LGG	cis	rs8092443	1	rs9944770	ENSG00000278971.1	RP11-644A7.2	-10.32	1.15e-22	9.16e-20	-0.62	-0.43	Response to antipsychotic treatment;	chr18:70473593	chr18:70489630~70491205:+
LGG	cis	rs7267979	0.873	rs6115093	ENSG00000125804.12	FAM182A	-10.32	1.15e-22	9.18e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:26054655~26086917:+
LGG	cis	rs357618	0.581	rs165359	ENSG00000260581.1	CTB-113P19.4	10.32	1.16e-22	9.27e-20	0.5	0.43	Basophil percentage of white cells;	chr5:151481475	chr5:151652275~151655449:+
LGG	cis	rs6496932	0.635	rs12900455	ENSG00000218052.5	ADAMTS7P4	-10.32	1.16e-22	9.28e-20	-0.59	-0.43	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85255369~85330334:-
LGG	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-10.32	1.16e-22	9.29e-20	-0.56	-0.43	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
LGG	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	10.32	1.16e-22	9.29e-20	0.46	0.43	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
LGG	cis	rs7914558	0.966	rs10883817	ENSG00000272912.1	RP11-724N1.1	-10.32	1.17e-22	9.3e-20	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102914585~102915404:+
LGG	cis	rs7267979	1	rs1077889	ENSG00000125804.12	FAM182A	-10.32	1.17e-22	9.35e-20	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:26054655~26086917:+
LGG	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	-10.32	1.17e-22	9.36e-20	-0.45	-0.43	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
LGG	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-10.32	1.18e-22	9.37e-20	-0.57	-0.43	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
LGG	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-10.32	1.18e-22	9.37e-20	-0.57	-0.43	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
LGG	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-10.32	1.18e-22	9.37e-20	-0.57	-0.43	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
LGG	cis	rs357618	0.581	rs165363	ENSG00000260581.1	CTB-113P19.4	10.32	1.18e-22	9.4e-20	0.5	0.43	Basophil percentage of white cells;	chr5:151486257	chr5:151652275~151655449:+
LGG	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	10.32	1.18e-22	9.4e-20	0.53	0.43	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	10.32	1.18e-22	9.4e-20	0.53	0.43	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
LGG	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-10.32	1.18e-22	9.43e-20	-0.58	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
LGG	cis	rs6496932	0.635	rs11632761	ENSG00000218052.5	ADAMTS7P4	-10.32	1.18e-22	9.43e-20	-0.62	-0.43	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85255369~85330334:-
LGG	cis	rs6496932	0.635	rs67659163	ENSG00000218052.5	ADAMTS7P4	-10.32	1.18e-22	9.43e-20	-0.62	-0.43	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85255369~85330334:-
LGG	cis	rs7546	0.505	rs760118	ENSG00000267077.1	RP11-127I20.5	-10.32	1.19e-22	9.47e-20	-0.44	-0.43	Cancer;	chr16:4890993	chr16:4795265~4796532:-
LGG	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-10.32	1.21e-22	9.63e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
LGG	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-10.32	1.21e-22	9.63e-20	-0.38	-0.43	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
LGG	cis	rs7267979	0.966	rs8123949	ENSG00000125804.12	FAM182A	10.32	1.21e-22	9.67e-20	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:26054655~26086917:+
LGG	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	10.32	1.21e-22	9.67e-20	0.44	0.43	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
LGG	cis	rs7267979	0.966	rs6050611	ENSG00000276952.1	RP5-965G21.6	10.31	1.21e-22	9.68e-20	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25284915~25285588:-
LGG	cis	rs11233250	0.697	rs17144112	ENSG00000245832.5	RP11-179A16.1	10.31	1.22e-22	9.71e-20	0.65	0.43	Glioblastoma;Glioma;	chr11:82692788	chr11:81879851~82718082:-
LGG	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-10.31	1.22e-22	9.75e-20	-0.51	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-10.31	1.22e-22	9.75e-20	-0.51	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
LGG	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-10.31	1.23e-22	9.77e-20	-0.48	-0.43	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
LGG	cis	rs8092443	0.81	rs2886660	ENSG00000278971.1	RP11-644A7.2	10.31	1.23e-22	9.82e-20	0.63	0.43	Response to antipsychotic treatment;	chr18:70489246	chr18:70489630~70491205:+
LGG	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-10.31	1.24e-22	9.84e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-10.31	1.24e-22	9.84e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-10.31	1.24e-22	9.84e-20	-0.48	-0.43	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
LGG	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	10.31	1.24e-22	9.87e-20	0.57	0.43	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
LGG	cis	rs1153858	1	rs4775911	ENSG00000259433.2	CTD-2651B20.4	10.31	1.24e-22	9.87e-20	0.49	0.43	Homoarginine levels;	chr15:45357589	chr15:45330209~45332634:-
LGG	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	10.31	1.24e-22	9.9e-20	0.57	0.43	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
LGG	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	10.31	1.25e-22	9.97e-20	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
LGG	cis	rs879620	1	rs879620	ENSG00000262888.1	RP11-462G12.2	10.31	1.26e-22	9.98e-20	0.58	0.43	Hip circumference;Body mass index;	chr16:3965728	chr16:3931217~3946305:-
LGG	cis	rs7914558	1	rs4917994	ENSG00000272912.1	RP11-724N1.1	-10.31	1.26e-22	1e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs2275271	ENSG00000272912.1	RP11-724N1.1	-10.31	1.26e-22	1e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs11191539	ENSG00000272912.1	RP11-724N1.1	-10.31	1.26e-22	1e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs11191541	ENSG00000272912.1	RP11-724N1.1	-10.31	1.26e-22	1e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs943038	ENSG00000272912.1	RP11-724N1.1	-10.31	1.26e-22	1e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102914585~102915404:+
LGG	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	10.31	1.26e-22	1e-19	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
LGG	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-10.31	1.27e-22	1.01e-19	-0.47	-0.43	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
LGG	cis	rs7267979	1	rs4815406	ENSG00000125804.12	FAM182A	10.31	1.27e-22	1.01e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:26054655~26086917:+
LGG	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	10.31	1.28e-22	1.02e-19	0.56	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
LGG	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-10.31	1.28e-22	1.02e-19	-0.34	-0.43	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
LGG	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-10.31	1.29e-22	1.02e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
LGG	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	10.31	1.31e-22	1.04e-19	0.46	0.43	Depression;	chr6:28187640	chr6:28115628~28116551:+
LGG	cis	rs6496932	0.635	rs4356428	ENSG00000218052.5	ADAMTS7P4	-10.31	1.31e-22	1.04e-19	-0.62	-0.43	Central corneal thickness;Corneal structure;	chr15:85386349	chr15:85255369~85330334:-
LGG	cis	rs7267979	1	rs10966	ENSG00000125804.12	FAM182A	-10.31	1.31e-22	1.04e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6037097	ENSG00000125804.12	FAM182A	-10.31	1.31e-22	1.04e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050598	ENSG00000125804.12	FAM182A	-10.31	1.31e-22	1.04e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6083817	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050564	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6083818	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4815409	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050565	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6107031	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6115159	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4813562	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6050567	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6037099	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs4815414	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6083825	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs34645895	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs3827014	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6115168	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6037105	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2387880	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2387882	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2387884	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6076345	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050590	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4813566	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4815421	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2184000	ENSG00000125804.12	FAM182A	10.31	1.31e-22	1.04e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:26054655~26086917:+
LGG	cis	rs6903823	0.527	rs4713158	ENSG00000280107.1	AL022393.9	-10.31	1.31e-22	1.04e-19	-0.44	-0.43	Pulmonary function;	chr6:28309994	chr6:28170845~28172521:+
LGG	cis	rs3742264	1	rs9316181	ENSG00000235903.6	CPB2-AS1	-10.31	1.32e-22	1.04e-19	-0.47	-0.43	Blood protein levels;	chr13:46071605	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.961	rs9534308	ENSG00000235903.6	CPB2-AS1	-10.31	1.32e-22	1.04e-19	-0.47	-0.43	Blood protein levels;	chr13:46071726	chr13:46052806~46113332:+
LGG	cis	rs7267979	1	rs6076339	ENSG00000125804.12	FAM182A	10.31	1.32e-22	1.05e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6107033	ENSG00000125804.12	FAM182A	10.31	1.32e-22	1.05e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:26054655~26086917:+
LGG	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	10.31	1.32e-22	1.05e-19	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
LGG	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-10.3	1.33e-22	1.05e-19	-0.58	-0.43	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
LGG	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-10.3	1.34e-22	1.06e-19	-0.46	-0.43	Depression;	chr6:28206179	chr6:28115628~28116551:+
LGG	cis	rs12935418	0.672	rs2549879	ENSG00000260213.4	RP11-303E16.3	10.3	1.35e-22	1.07e-19	0.53	0.43	Mean corpuscular volume;	chr16:81012496	chr16:81016792~81035759:-
LGG	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	10.3	1.35e-22	1.07e-19	0.49	0.43	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
LGG	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-10.3	1.35e-22	1.07e-19	-0.51	-0.43	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
LGG	cis	rs7927771	0.864	rs755554	ENSG00000280615.1	Y_RNA	10.3	1.36e-22	1.08e-19	0.54	0.43	Subjective well-being;	chr11:47410483	chr11:47614898~47614994:-
LGG	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	10.3	1.36e-22	1.08e-19	0.33	0.43	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
LGG	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-10.3	1.37e-22	1.08e-19	-0.38	-0.43	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
LGG	cis	rs9527	1	rs9527	ENSG00000272912.1	RP11-724N1.1	-10.3	1.37e-22	1.09e-19	-0.54	-0.43	Arsenic metabolism;	chr10:102863821	chr10:102914585~102915404:+
LGG	cis	rs7267979	1	rs6050561	ENSG00000125804.12	FAM182A	10.3	1.4e-22	1.1e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6083813	ENSG00000125804.12	FAM182A	10.3	1.4e-22	1.1e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:26054655~26086917:+
LGG	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-10.3	1.4e-22	1.11e-19	-0.43	-0.43	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
LGG	cis	rs357618	0.581	rs165365	ENSG00000260581.1	CTB-113P19.4	-10.3	1.4e-22	1.11e-19	-0.51	-0.43	Basophil percentage of white cells;	chr5:151486884	chr5:151652275~151655449:+
LGG	cis	rs4713118	0.869	rs2056925	ENSG00000216901.1	AL022393.7	10.3	1.4e-22	1.11e-19	0.56	0.43	Parkinson's disease;	chr6:27723126	chr6:28176188~28176674:+
LGG	cis	rs6496932	0.635	rs2200214	ENSG00000218052.5	ADAMTS7P4	-10.3	1.4e-22	1.11e-19	-0.62	-0.43	Central corneal thickness;Corneal structure;	chr15:85383745	chr15:85255369~85330334:-
LGG	cis	rs7267979	1	rs6107045	ENSG00000276952.1	RP5-965G21.6	10.3	1.41e-22	1.11e-19	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25284915~25285588:-
LGG	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-10.3	1.41e-22	1.12e-19	-0.45	-0.43	Depression;	chr6:28184805	chr6:28115628~28116551:+
LGG	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-10.3	1.42e-22	1.12e-19	-0.47	-0.43	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
LGG	cis	rs11098499	1	rs1011054	ENSG00000249244.1	RP11-548H18.2	-10.3	1.42e-22	1.12e-19	-0.48	-0.43	Corneal astigmatism;	chr4:119281232	chr4:119391831~119395335:-
LGG	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-10.3	1.43e-22	1.13e-19	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
LGG	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-10.3	1.43e-22	1.13e-19	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
LGG	cis	rs357618	0.581	rs165366	ENSG00000260581.1	CTB-113P19.4	10.3	1.44e-22	1.14e-19	0.5	0.43	Basophil percentage of white cells;	chr5:151487347	chr5:151652275~151655449:+
LGG	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-10.29	1.44e-22	1.14e-19	-0.58	-0.43	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
LGG	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-10.29	1.45e-22	1.15e-19	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
LGG	cis	rs7267979	1	rs2258135	ENSG00000125804.12	FAM182A	-10.29	1.45e-22	1.15e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.932	rs433352	ENSG00000125804.12	FAM182A	10.29	1.45e-22	1.15e-19	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:26054655~26086917:+
LGG	cis	rs482329	0.894	rs474100	ENSG00000228044.2	RP4-781K5.4	10.29	1.46e-22	1.15e-19	0.49	0.43	Life threatening arrhythmia;	chr1:234670470	chr1:234646289~234683176:+
LGG	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	10.29	1.47e-22	1.16e-19	0.3	0.43	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
LGG	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-10.29	1.47e-22	1.16e-19	-0.34	-0.43	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-10.29	1.47e-22	1.16e-19	-0.34	-0.43	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-10.29	1.47e-22	1.16e-19	-0.34	-0.43	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
LGG	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-10.29	1.47e-22	1.16e-19	-0.55	-0.43	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
LGG	cis	rs56114371	0.53	rs2056923	ENSG00000199851.2	U3	10.29	1.47e-22	1.16e-19	0.74	0.43	Breast cancer;	chr6:27722160	chr6:28015568~28015777:+
LGG	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-10.29	1.49e-22	1.18e-19	-0.66	-0.43	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
LGG	cis	rs7267979	1	rs2257808	ENSG00000125804.12	FAM182A	-10.29	1.49e-22	1.18e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2257809	ENSG00000125804.12	FAM182A	-10.29	1.49e-22	1.18e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2424700	ENSG00000125804.12	FAM182A	-10.29	1.49e-22	1.18e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:26054655~26086917:+
LGG	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-10.29	1.5e-22	1.18e-19	-0.48	-0.43	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
LGG	cis	rs9388451	0.839	rs3799711	ENSG00000237742.5	RP11-624M8.1	10.29	1.5e-22	1.19e-19	0.38	0.43	Brugada syndrome;	chr6:125754167	chr6:125578558~125749190:-
LGG	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-10.29	1.51e-22	1.19e-19	-0.53	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
LGG	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-10.29	1.52e-22	1.2e-19	-0.94	-0.43	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
LGG	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	10.29	1.52e-22	1.2e-19	0.46	0.43	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
LGG	cis	rs853679	0.527	rs9468333	ENSG00000280107.1	AL022393.9	-10.29	1.52e-22	1.2e-19	-0.44	-0.43	Depression;	chr6:28303421	chr6:28170845~28172521:+
LGG	cis	rs8092443	0.81	rs9956900	ENSG00000278971.1	RP11-644A7.2	-10.29	1.52e-22	1.2e-19	-0.66	-0.43	Response to antipsychotic treatment;	chr18:70473428	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs7232674	ENSG00000278971.1	RP11-644A7.2	-10.29	1.52e-22	1.2e-19	-0.66	-0.43	Response to antipsychotic treatment;	chr18:70474677	chr18:70489630~70491205:+
LGG	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-10.29	1.52e-22	1.2e-19	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
LGG	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	10.29	1.52e-22	1.2e-19	0.44	0.43	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
LGG	cis	rs482329	0.93	rs638454	ENSG00000228044.2	RP4-781K5.4	10.29	1.53e-22	1.2e-19	0.48	0.43	Life threatening arrhythmia;	chr1:234668219	chr1:234646289~234683176:+
LGG	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-10.29	1.54e-22	1.22e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
LGG	cis	rs8092443	0.81	rs28505079	ENSG00000278971.1	RP11-644A7.2	-10.29	1.55e-22	1.22e-19	-0.67	-0.43	Response to antipsychotic treatment;	chr18:70469288	chr18:70489630~70491205:+
LGG	cis	rs7267979	0.932	rs1985737	ENSG00000276952.1	RP5-965G21.6	10.29	1.55e-22	1.22e-19	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.899	rs2179459	ENSG00000276952.1	RP5-965G21.6	10.29	1.57e-22	1.24e-19	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25284915~25285588:-
LGG	cis	rs507080	0.845	rs667982	ENSG00000278376.1	RP11-158I9.8	-10.28	1.57e-22	1.24e-19	-0.38	-0.43	Serum metabolite levels;	chr11:118692058	chr11:118791254~118793137:+
LGG	cis	rs4683346	0.576	rs9840290	ENSG00000273328.4	RP11-141M3.6	-10.28	1.57e-22	1.24e-19	-0.49	-0.43	Granulocyte percentage of myeloid white cells;	chr3:42835272	chr3:42809414~42908105:+
LGG	cis	rs9388451	0.839	rs9321054	ENSG00000237742.5	RP11-624M8.1	10.28	1.58e-22	1.24e-19	0.37	0.43	Brugada syndrome;	chr6:125758822	chr6:125578558~125749190:-
LGG	cis	rs4713118	0.505	rs276371	ENSG00000280107.1	AL022393.9	-10.28	1.58e-22	1.25e-19	-0.42	-0.43	Parkinson's disease;	chr6:27942930	chr6:28170845~28172521:+
LGG	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-10.28	1.59e-22	1.26e-19	-0.51	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
LGG	cis	rs11098499	0.554	rs2175381	ENSG00000249244.1	RP11-548H18.2	10.28	1.6e-22	1.26e-19	0.44	0.43	Corneal astigmatism;	chr4:119344812	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.599	rs3864142	ENSG00000249244.1	RP11-548H18.2	10.28	1.6e-22	1.26e-19	0.44	0.43	Corneal astigmatism;	chr4:119345036	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.605	rs6833140	ENSG00000249244.1	RP11-548H18.2	10.28	1.6e-22	1.26e-19	0.44	0.43	Corneal astigmatism;	chr4:119345667	chr4:119391831~119395335:-
LGG	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	10.28	1.6e-22	1.26e-19	0.63	0.43	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
LGG	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	10.28	1.6e-22	1.26e-19	0.51	0.43	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
LGG	cis	rs7267979	1	rs910997	ENSG00000125804.12	FAM182A	-10.28	1.61e-22	1.27e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs3002702	ENSG00000125804.12	FAM182A	-10.28	1.61e-22	1.27e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2257985	ENSG00000125804.12	FAM182A	-10.28	1.61e-22	1.27e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2257988	ENSG00000125804.12	FAM182A	-10.28	1.61e-22	1.27e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2257432	ENSG00000125804.12	FAM182A	-10.28	1.61e-22	1.27e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2258066	ENSG00000125804.12	FAM182A	-10.28	1.61e-22	1.27e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2257982	ENSG00000125804.12	FAM182A	-10.28	1.61e-22	1.27e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:26054655~26086917:+
LGG	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-10.28	1.61e-22	1.27e-19	-0.91	-0.43	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
LGG	cis	rs4713118	0.513	rs149878	ENSG00000219392.1	RP1-265C24.5	-10.28	1.62e-22	1.27e-19	-0.41	-0.43	Parkinson's disease;	chr6:27910960	chr6:28115628~28116551:+
LGG	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	10.28	1.62e-22	1.27e-19	0.33	0.43	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
LGG	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	10.28	1.62e-22	1.27e-19	0.33	0.43	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
LGG	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	10.28	1.62e-22	1.28e-19	0.56	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
LGG	cis	rs11148252	0.574	rs7139495	ENSG00000273784.3	RP11-78J21.7	-10.28	1.64e-22	1.29e-19	-0.48	-0.43	Lewy body disease;	chr13:52709183	chr13:52600042~52642542:+
LGG	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	10.28	1.66e-22	1.3e-19	0.45	0.43	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	10.28	1.66e-22	1.3e-19	0.45	0.43	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
LGG	cis	rs7914558	1	rs10786733	ENSG00000272912.1	RP11-724N1.1	-10.28	1.66e-22	1.31e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103035190	chr10:102914585~102915404:+
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-10.28	1.67e-22	1.31e-19	-0.56	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
LGG	cis	rs7267979	0.932	rs6115200	ENSG00000276952.1	RP5-965G21.6	10.28	1.67e-22	1.32e-19	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.932	rs6138588	ENSG00000276952.1	RP5-965G21.6	10.28	1.67e-22	1.32e-19	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25284915~25285588:-
LGG	cis	rs7914558	1	rs7094843	ENSG00000272912.1	RP11-724N1.1	-10.28	1.68e-22	1.32e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102914585~102915404:+
LGG	cis	rs482329	0.93	rs652023	ENSG00000228044.2	RP4-781K5.4	10.28	1.68e-22	1.32e-19	0.48	0.43	Life threatening arrhythmia;	chr1:234668929	chr1:234646289~234683176:+
LGG	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-10.28	1.68e-22	1.32e-19	-0.56	-0.43	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
LGG	cis	rs4713118	0.55	rs9368527	ENSG00000216901.1	AL022393.7	10.28	1.69e-22	1.33e-19	0.52	0.43	Parkinson's disease;	chr6:27711666	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.628	rs9295740	ENSG00000199851.2	U3	10.28	1.71e-22	1.34e-19	0.68	0.43	Parkinson's disease;	chr6:27721723	chr6:28015568~28015777:+
LGG	cis	rs7826238	0.72	rs12546760	ENSG00000173295.6	FAM86B3P	10.27	1.71e-22	1.34e-19	0.44	0.43	Systolic blood pressure;	chr8:8517326	chr8:8228595~8244865:+
LGG	cis	rs3742264	1	rs17844080	ENSG00000235903.6	CPB2-AS1	-10.27	1.71e-22	1.34e-19	-0.47	-0.43	Blood protein levels;	chr13:46070270	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs2404964	ENSG00000235903.6	CPB2-AS1	-10.27	1.71e-22	1.34e-19	-0.47	-0.43	Blood protein levels;	chr13:46070739	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	10.27	1.72e-22	1.36e-19	0.49	0.43	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
LGG	cis	rs7829975	0.51	rs2921073	ENSG00000253893.2	FAM85B	-10.27	1.76e-22	1.38e-19	-0.52	-0.43	Mood instability;	chr8:8450133	chr8:8167819~8226614:-
LGG	cis	rs2921073	0.604	rs2979140	ENSG00000173295.6	FAM86B3P	-10.27	1.76e-22	1.38e-19	-0.45	-0.43	Parkinson's disease;	chr8:8409692	chr8:8228595~8244865:+
LGG	cis	rs6452524	0.967	rs12186460	ENSG00000248112.1	RP11-78C3.1	10.27	1.77e-22	1.39e-19	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:82919376~82921119:-
LGG	cis	rs3742264	1	rs9526137	ENSG00000235903.6	CPB2-AS1	-10.27	1.78e-22	1.4e-19	-0.47	-0.43	Blood protein levels;	chr13:46067114	chr13:46052806~46113332:+
LGG	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-10.27	1.78e-22	1.4e-19	-0.34	-0.43	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
LGG	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	10.27	1.79e-22	1.4e-19	0.41	0.43	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
LGG	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.79e-22	1.4e-19	-0.57	-0.43	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
LGG	cis	rs853679	0.527	rs853690	ENSG00000280107.1	AL022393.9	-10.27	1.79e-22	1.4e-19	-0.44	-0.43	Depression;	chr6:28317705	chr6:28170845~28172521:+
LGG	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-10.27	1.79e-22	1.41e-19	-0.59	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
LGG	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	10.27	1.79e-22	1.41e-19	0.43	0.43	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
LGG	cis	rs4713118	0.738	rs200465	ENSG00000216901.1	AL022393.7	10.27	1.8e-22	1.41e-19	0.56	0.43	Parkinson's disease;	chr6:27789875	chr6:28176188~28176674:+
LGG	cis	rs7267979	0.932	rs6132848	ENSG00000276952.1	RP5-965G21.6	10.27	1.8e-22	1.41e-19	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.932	rs6115215	ENSG00000276952.1	RP5-965G21.6	10.27	1.8e-22	1.41e-19	0.43	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25284915~25285588:-
LGG	cis	rs482329	0.894	rs639538	ENSG00000228044.2	RP4-781K5.4	10.27	1.8e-22	1.42e-19	0.48	0.43	Life threatening arrhythmia;	chr1:234668508	chr1:234646289~234683176:+
LGG	cis	rs1420956	0.766	rs8086623	ENSG00000264151.4	RP11-739N10.1	10.27	1.81e-22	1.42e-19	0.54	0.43	Obesity-related traits;	chr18:27590232	chr18:27336379~27595164:-
LGG	cis	rs482329	0.93	rs592197	ENSG00000228044.2	RP4-781K5.4	10.27	1.81e-22	1.42e-19	0.49	0.43	Life threatening arrhythmia;	chr1:234681537	chr1:234646289~234683176:+
LGG	cis	rs6539247	0.509	rs2374584	ENSG00000257890.1	RP11-114F10.2	-10.27	1.81e-22	1.42e-19	-0.52	-0.43	Attention function in attention deficit hyperactive disorder;	chr12:106052210	chr12:106050961~106058254:-
LGG	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	10.27	1.82e-22	1.42e-19	0.48	0.43	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
LGG	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	10.27	1.82e-22	1.43e-19	0.54	0.43	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
LGG	cis	rs1075265	0.722	rs13414216	ENSG00000233266.1	HMGB1P31	10.27	1.82e-22	1.43e-19	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53699166	chr2:54051334~54051760:+
LGG	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-10.27	1.82e-22	1.43e-19	-0.51	-0.43	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.51	rs2979160	ENSG00000253893.2	FAM85B	-10.27	1.83e-22	1.43e-19	-0.52	-0.43	Mood instability;	chr8:8450156	chr8:8167819~8226614:-
LGG	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-10.27	1.85e-22	1.45e-19	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
LGG	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	10.27	1.86e-22	1.46e-19	0.3	0.43	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
LGG	cis	rs4373814	0.537	rs10764319	ENSG00000226083.4	SLC39A12-AS1	10.26	1.86e-22	1.46e-19	0.48	0.43	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18139486	chr10:18001786~18010562:-
LGG	cis	rs7267979	1	rs2258563	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2258617	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2258769	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2258879	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2257496	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2258884	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2259837	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2259873	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs11100	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs1046073	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2259926	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2259928	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2259956	ENSG00000125804.12	FAM182A	-10.26	1.87e-22	1.47e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2261784	ENSG00000125804.12	FAM182A	-10.26	1.89e-22	1.48e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2261785	ENSG00000125804.12	FAM182A	-10.26	1.89e-22	1.48e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:26054655~26086917:+
LGG	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	10.26	1.9e-22	1.49e-19	0.33	0.43	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
LGG	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	10.26	1.9e-22	1.49e-19	0.33	0.43	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
LGG	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-10.26	1.91e-22	1.5e-19	-0.52	-0.43	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
LGG	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	10.26	1.92e-22	1.5e-19	0.64	0.43	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
LGG	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	10.26	1.92e-22	1.5e-19	0.6	0.43	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
LGG	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-10.26	1.92e-22	1.51e-19	-0.53	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
LGG	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-10.26	1.93e-22	1.51e-19	-0.6	-0.43	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
LGG	cis	rs1150668	0.83	rs2859365	ENSG00000280107.1	AL022393.9	10.26	1.93e-22	1.51e-19	0.4	0.43	Pubertal anthropometrics;	chr6:28423688	chr6:28170845~28172521:+
LGG	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	10.26	1.94e-22	1.52e-19	0.3	0.43	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
LGG	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	10.26	1.94e-22	1.52e-19	0.3	0.43	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
LGG	cis	rs7267979	1	rs2258201	ENSG00000125804.12	FAM182A	-10.26	1.94e-22	1.52e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs2297496	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs7343481	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6115146	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.934	rs6037085	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs6050532	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6083804	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs4815405	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6050542	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:26054655~26086917:+
LGG	cis	rs7267979	1	rs6076336	ENSG00000125804.12	FAM182A	10.26	1.94e-22	1.52e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:26054655~26086917:+
LGG	cis	rs7829975	0.658	rs907181	ENSG00000173295.6	FAM86B3P	-10.26	1.95e-22	1.52e-19	-0.45	-0.43	Mood instability;	chr8:8845365	chr8:8228595~8244865:+
LGG	cis	rs853679	0.527	rs853690	ENSG00000199851.2	U3	10.26	1.96e-22	1.53e-19	0.6	0.43	Depression;	chr6:28317705	chr6:28015568~28015777:+
LGG	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-10.26	1.97e-22	1.54e-19	-0.45	-0.43	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-10.26	1.97e-22	1.54e-19	-0.45	-0.43	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
LGG	cis	rs8092443	0.81	rs28580582	ENSG00000278971.1	RP11-644A7.2	-10.26	1.97e-22	1.54e-19	-0.66	-0.43	Response to antipsychotic treatment;	chr18:70469178	chr18:70489630~70491205:+
LGG	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	10.26	1.97e-22	1.54e-19	0.5	0.43	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
LGG	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	10.26	1.98e-22	1.55e-19	0.5	0.43	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
LGG	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	10.26	1.98e-22	1.55e-19	0.5	0.43	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
LGG	cis	rs7914558	0.752	rs7896519	ENSG00000272912.1	RP11-724N1.1	-10.26	2e-22	1.56e-19	-0.48	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102914585~102915404:+
LGG	cis	rs8092443	0.81	rs60088432	ENSG00000278971.1	RP11-644A7.2	-10.26	2e-22	1.57e-19	-0.65	-0.43	Response to antipsychotic treatment;	chr18:70477745	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs7233902	ENSG00000278971.1	RP11-644A7.2	-10.26	2e-22	1.57e-19	-0.65	-0.43	Response to antipsychotic treatment;	chr18:70478074	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs7234494	ENSG00000278971.1	RP11-644A7.2	-10.26	2e-22	1.57e-19	-0.65	-0.43	Response to antipsychotic treatment;	chr18:70478307	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs7234834	ENSG00000278971.1	RP11-644A7.2	-10.26	2e-22	1.57e-19	-0.65	-0.43	Response to antipsychotic treatment;	chr18:70478459	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.688	rs7240698	ENSG00000278971.1	RP11-644A7.2	-10.26	2e-22	1.57e-19	-0.65	-0.43	Response to antipsychotic treatment;	chr18:70479803	chr18:70489630~70491205:+
LGG	cis	rs12935418	0.523	rs2549845	ENSG00000260213.4	RP11-303E16.3	10.26	2.01e-22	1.57e-19	0.52	0.43	Mean corpuscular volume;	chr16:80990520	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.523	rs2549846	ENSG00000260213.4	RP11-303E16.3	10.26	2.01e-22	1.57e-19	0.52	0.43	Mean corpuscular volume;	chr16:80990522	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2098726	ENSG00000260213.4	RP11-303E16.3	10.26	2.01e-22	1.57e-19	0.52	0.43	Mean corpuscular volume;	chr16:80991670	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2113197	ENSG00000260213.4	RP11-303E16.3	10.26	2.01e-22	1.57e-19	0.52	0.43	Mean corpuscular volume;	chr16:80991901	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2549852	ENSG00000260213.4	RP11-303E16.3	10.26	2.01e-22	1.57e-19	0.52	0.43	Mean corpuscular volume;	chr16:80992410	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.616	rs2549859	ENSG00000260213.4	RP11-303E16.3	10.26	2.02e-22	1.58e-19	0.52	0.43	Mean corpuscular volume;	chr16:80993398	chr16:81016792~81035759:-
LGG	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-10.25	2.04e-22	1.6e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
LGG	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-10.25	2.04e-22	1.6e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
LGG	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-10.25	2.04e-22	1.6e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
LGG	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-10.25	2.04e-22	1.6e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
LGG	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	10.25	2.05e-22	1.6e-19	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
LGG	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-10.25	2.06e-22	1.61e-19	-0.43	-0.43	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
LGG	cis	rs8092443	0.81	rs56756677	ENSG00000278971.1	RP11-644A7.2	-10.25	2.06e-22	1.61e-19	-0.66	-0.43	Response to antipsychotic treatment;	chr18:70470013	chr18:70489630~70491205:+
LGG	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	10.25	2.07e-22	1.62e-19	0.35	0.43	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
LGG	cis	rs1475911	1	rs17114359	ENSG00000184385.2	UMODL1-AS1	10.25	2.07e-22	1.62e-19	0.55	0.43	IgG glycosylation;	chr21:42090327	chr21:42102134~42108534:-
LGG	cis	rs12935418	0.672	rs2602423	ENSG00000260213.4	RP11-303E16.3	10.25	2.08e-22	1.62e-19	0.52	0.43	Mean corpuscular volume;	chr16:81008423	chr16:81016792~81035759:-
LGG	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-10.25	2.08e-22	1.62e-19	-0.45	-0.43	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
LGG	cis	rs7267979	1	rs1888997	ENSG00000276952.1	RP5-965G21.6	-10.25	2.1e-22	1.64e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs3002698	ENSG00000276952.1	RP5-965G21.6	-10.25	2.1e-22	1.64e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482930	ENSG00000276952.1	RP5-965G21.6	-10.25	2.1e-22	1.64e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2500446	ENSG00000276952.1	RP5-965G21.6	-10.25	2.1e-22	1.64e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25284915~25285588:-
LGG	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	10.25	2.1e-22	1.64e-19	0.62	0.43	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
LGG	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-10.25	2.1e-22	1.64e-19	-0.51	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
LGG	cis	rs4713118	0.869	rs9461405	ENSG00000216901.1	AL022393.7	10.25	2.11e-22	1.64e-19	0.55	0.43	Parkinson's disease;	chr6:27751596	chr6:28176188~28176674:+
LGG	cis	rs12935418	0.583	rs2549861	ENSG00000260213.4	RP11-303E16.3	10.25	2.11e-22	1.65e-19	0.52	0.43	Mean corpuscular volume;	chr16:80994699	chr16:81016792~81035759:-
LGG	cis	rs1560104	0.675	rs9927256	ENSG00000274834.1	CTD-3037G24.5	-10.25	2.12e-22	1.66e-19	-0.54	-0.43	Obesity-related traits;	chr16:12611158	chr16:12614451~12614852:+
LGG	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	10.25	2.13e-22	1.66e-19	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
LGG	cis	rs7267979	1	rs2424710	ENSG00000276952.1	RP5-965G21.6	10.25	2.13e-22	1.67e-19	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6115140	ENSG00000276952.1	RP5-965G21.6	10.25	2.13e-22	1.67e-19	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482937	ENSG00000276952.1	RP5-965G21.6	-10.25	2.13e-22	1.67e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2263204	ENSG00000276952.1	RP5-965G21.6	-10.25	2.13e-22	1.67e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2500417	ENSG00000276952.1	RP5-965G21.6	-10.25	2.13e-22	1.67e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482911	ENSG00000276952.1	RP5-965G21.6	-10.25	2.13e-22	1.67e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25284915~25285588:-
LGG	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-10.25	2.14e-22	1.67e-19	-0.51	-0.43	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
LGG	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-10.25	2.14e-22	1.67e-19	-0.51	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
LGG	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-10.25	2.14e-22	1.67e-19	-0.51	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
LGG	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	10.25	2.14e-22	1.67e-19	0.3	0.43	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
LGG	cis	rs8092443	0.81	rs75918099	ENSG00000278971.1	RP11-644A7.2	-10.25	2.15e-22	1.68e-19	-0.7	-0.43	Response to antipsychotic treatment;	chr18:70468019	chr18:70489630~70491205:+
LGG	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	10.25	2.15e-22	1.68e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
LGG	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-10.25	2.15e-22	1.68e-19	-0.56	-0.43	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
LGG	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-10.25	2.16e-22	1.68e-19	-0.49	-0.43	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
LGG	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	10.25	2.16e-22	1.68e-19	0.5	0.43	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	10.25	2.16e-22	1.68e-19	0.52	0.43	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
LGG	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	10.25	2.16e-22	1.69e-19	0.56	0.43	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
LGG	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-10.25	2.17e-22	1.69e-19	-0.52	-0.43	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
LGG	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	10.25	2.17e-22	1.69e-19	0.6	0.43	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
LGG	cis	rs8092443	0.872	rs12607642	ENSG00000278971.1	RP11-644A7.2	10.25	2.18e-22	1.7e-19	0.62	0.43	Response to antipsychotic treatment;	chr18:70484545	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs12607670	ENSG00000278971.1	RP11-644A7.2	10.25	2.18e-22	1.7e-19	0.62	0.43	Response to antipsychotic treatment;	chr18:70484695	chr18:70489630~70491205:+
LGG	cis	rs7914558	1	rs943036	ENSG00000272912.1	RP11-724N1.1	-10.25	2.19e-22	1.71e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103076290	chr10:102914585~102915404:+
LGG	cis	rs9322193	0.887	rs3734295	ENSG00000223701.3	RAET1E-AS1	10.24	2.2e-22	1.72e-19	0.54	0.43	Lung cancer;	chr6:149593917	chr6:149884431~149919508:+
LGG	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-10.24	2.21e-22	1.72e-19	-0.56	-0.43	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
LGG	cis	rs4819052	0.851	rs2256000	ENSG00000223768.1	LINC00205	-10.24	2.21e-22	1.72e-19	-0.46	-0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45293285~45297354:+
LGG	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	10.24	2.21e-22	1.72e-19	0.51	0.43	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	10.24	2.21e-22	1.72e-19	0.49	0.43	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
LGG	cis	rs12935418	0.616	rs2549855	ENSG00000260213.4	RP11-303E16.3	-10.24	2.22e-22	1.73e-19	-0.51	-0.43	Mean corpuscular volume;	chr16:80993247	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.616	rs2549857	ENSG00000260213.4	RP11-303E16.3	-10.24	2.22e-22	1.73e-19	-0.51	-0.43	Mean corpuscular volume;	chr16:80993353	chr16:81016792~81035759:-
LGG	cis	rs7267979	1	rs12428	ENSG00000125804.12	FAM182A	10.24	2.23e-22	1.74e-19	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:26054655~26086917:+
LGG	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-10.24	2.23e-22	1.74e-19	-0.44	-0.43	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
LGG	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-10.24	2.25e-22	1.75e-19	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
LGG	cis	rs17772222	0.682	rs7142053	ENSG00000258983.2	RP11-507K2.2	10.24	2.25e-22	1.75e-19	0.49	0.43	Coronary artery calcification;	chr14:88511594	chr14:88499334~88515502:+
LGG	cis	rs4713118	0.911	rs9461406	ENSG00000216901.1	AL022393.7	-10.24	2.26e-22	1.76e-19	-0.58	-0.43	Parkinson's disease;	chr6:27751985	chr6:28176188~28176674:+
LGG	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-10.24	2.26e-22	1.76e-19	-0.59	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
LGG	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-10.24	2.26e-22	1.76e-19	-0.59	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
LGG	cis	rs7927771	0.832	rs7105851	ENSG00000280615.1	Y_RNA	10.24	2.26e-22	1.76e-19	0.53	0.43	Subjective well-being;	chr11:47361724	chr11:47614898~47614994:-
LGG	cis	rs879620	0.929	rs2238435	ENSG00000262888.1	RP11-462G12.2	-10.24	2.27e-22	1.77e-19	-0.57	-0.43	Hip circumference;Body mass index;	chr16:3964281	chr16:3931217~3946305:-
LGG	cis	rs7267979	1	rs7018	ENSG00000276952.1	RP5-965G21.6	10.24	2.28e-22	1.77e-19	0.42	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4815408	ENSG00000276952.1	RP5-965G21.6	-10.24	2.28e-22	1.77e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050566	ENSG00000276952.1	RP5-965G21.6	-10.24	2.28e-22	1.77e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4813563	ENSG00000276952.1	RP5-965G21.6	-10.24	2.28e-22	1.77e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs6037103	ENSG00000276952.1	RP5-965G21.6	-10.24	2.28e-22	1.77e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4815424	ENSG00000276952.1	RP5-965G21.6	-10.24	2.28e-22	1.77e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	10.24	2.3e-22	1.79e-19	0.54	0.43	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
LGG	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-10.24	2.31e-22	1.8e-19	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
LGG	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	10.24	2.32e-22	1.8e-19	0.59	0.43	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
LGG	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	10.24	2.32e-22	1.8e-19	0.59	0.43	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
LGG	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	10.24	2.32e-22	1.8e-19	0.59	0.43	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
LGG	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	10.24	2.32e-22	1.8e-19	0.59	0.43	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
LGG	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	10.24	2.32e-22	1.8e-19	0.59	0.43	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
LGG	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	10.24	2.32e-22	1.8e-19	0.83	0.43	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
LGG	cis	rs5742933	0.75	rs10197331	ENSG00000253559.1	OSGEPL1-AS1	10.24	2.32e-22	1.81e-19	0.52	0.43	Ferritin levels;	chr2:189768112	chr2:189762704~189765556:+
LGG	cis	rs11168351	0.889	rs12817104	ENSG00000258273.1	RP11-370I10.4	-10.24	2.32e-22	1.81e-19	-0.54	-0.43	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48333755~48333901:-
LGG	cis	rs11118620	0.622	rs11118618	ENSG00000257551.1	HLX-AS1	10.24	2.33e-22	1.82e-19	0.62	0.43	Heart failure;	chr1:220838204	chr1:220832763~220880140:-
LGG	cis	rs12935418	0.616	rs2549853	ENSG00000260213.4	RP11-303E16.3	10.24	2.33e-22	1.82e-19	0.52	0.43	Mean corpuscular volume;	chr16:80992850	chr16:81016792~81035759:-
LGG	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	10.24	2.34e-22	1.82e-19	0.53	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
LGG	cis	rs3002131	0.604	rs3008641	ENSG00000225265.1	TAF1A-AS1	-10.24	2.34e-22	1.82e-19	-0.6	-0.43	Interleukin-10 levels;	chr1:222566947	chr1:222589825~222593032:+
LGG	cis	rs4713118	0.824	rs2092075	ENSG00000216901.1	AL022393.7	10.24	2.34e-22	1.82e-19	0.56	0.43	Parkinson's disease;	chr6:27781551	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.824	rs13211701	ENSG00000216901.1	AL022393.7	10.24	2.34e-22	1.82e-19	0.56	0.43	Parkinson's disease;	chr6:27782300	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.824	rs9468229	ENSG00000216901.1	AL022393.7	10.24	2.34e-22	1.82e-19	0.56	0.43	Parkinson's disease;	chr6:27782307	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs4870052	ENSG00000216621.7	RP11-244K5.6	10.24	2.34e-22	1.82e-19	0.53	0.43	Lung cancer;	chr6:149839978	chr6:149934527~149936782:+
LGG	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-10.24	2.35e-22	1.83e-19	-0.59	-0.43	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
LGG	cis	rs9388451	0.874	rs9398787	ENSG00000237742.5	RP11-624M8.1	-10.24	2.36e-22	1.84e-19	-0.37	-0.43	Brugada syndrome;	chr6:125769462	chr6:125578558~125749190:-
LGG	cis	rs9388451	0.807	rs1269175	ENSG00000237742.5	RP11-624M8.1	10.24	2.37e-22	1.85e-19	0.38	0.43	Brugada syndrome;	chr6:125719289	chr6:125578558~125749190:-
LGG	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-10.24	2.37e-22	1.85e-19	-0.5	-0.43	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
LGG	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	10.24	2.38e-22	1.85e-19	0.59	0.43	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
LGG	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	10.24	2.38e-22	1.85e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
LGG	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	10.24	2.38e-22	1.85e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
LGG	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	10.24	2.38e-22	1.85e-19	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
LGG	cis	rs8092443	0.81	rs8092458	ENSG00000278971.1	RP11-644A7.2	-10.24	2.38e-22	1.85e-19	-0.65	-0.43	Response to antipsychotic treatment;	chr18:70475211	chr18:70489630~70491205:+
LGG	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-10.24	2.39e-22	1.86e-19	-0.38	-0.43	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
LGG	cis	rs1707322	0.686	rs2991977	ENSG00000281133.1	AL355480.3	10.23	2.4e-22	1.86e-19	0.52	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.656	rs2991981	ENSG00000281133.1	AL355480.3	10.23	2.4e-22	1.86e-19	0.52	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45580892~45580996:-
LGG	cis	rs853679	0.527	rs853683	ENSG00000199851.2	U3	10.23	2.4e-22	1.86e-19	0.6	0.43	Depression;	chr6:28327262	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.615	rs9348772	ENSG00000199851.2	U3	10.23	2.43e-22	1.89e-19	0.59	0.43	Parkinson's disease;	chr6:27688311	chr6:28015568~28015777:+
LGG	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-10.23	2.43e-22	1.89e-19	-0.53	-0.43	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
LGG	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-10.23	2.43e-22	1.89e-19	-0.53	-0.43	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
LGG	cis	rs1560104	0.718	rs36003824	ENSG00000274834.1	CTD-3037G24.5	-10.23	2.43e-22	1.89e-19	-0.55	-0.43	Obesity-related traits;	chr16:12611781	chr16:12614451~12614852:+
LGG	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-10.23	2.44e-22	1.89e-19	-0.51	-0.43	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
LGG	cis	rs7267979	1	rs2482943	ENSG00000276952.1	RP5-965G21.6	-10.23	2.46e-22	1.91e-19	-0.42	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25284915~25285588:-
LGG	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-10.23	2.46e-22	1.91e-19	-0.5	-0.43	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
LGG	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	10.23	2.47e-22	1.92e-19	0.3	0.43	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
LGG	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	10.23	2.47e-22	1.92e-19	0.53	0.43	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
LGG	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-10.23	2.48e-22	1.93e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
LGG	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-10.23	2.48e-22	1.93e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
LGG	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	10.23	2.49e-22	1.94e-19	0.83	0.43	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
LGG	cis	rs5742933	0.597	rs6756913	ENSG00000253559.1	OSGEPL1-AS1	10.23	2.5e-22	1.94e-19	0.54	0.43	Ferritin levels;	chr2:189641040	chr2:189762704~189765556:+
LGG	cis	rs2408955	0.522	rs6580650	ENSG00000258273.1	RP11-370I10.4	10.23	2.51e-22	1.95e-19	0.54	0.43	Glycated hemoglobin levels;	chr12:48024773	chr12:48333755~48333901:-
LGG	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	10.23	2.51e-22	1.95e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
LGG	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	10.23	2.54e-22	1.97e-19	0.37	0.43	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
LGG	cis	rs7267979	1	rs6050555	ENSG00000125804.12	FAM182A	10.23	2.57e-22	1.99e-19	0.51	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:26054655~26086917:+
LGG	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	10.23	2.57e-22	1.99e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
LGG	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	10.23	2.57e-22	1.99e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
LGG	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	10.23	2.57e-22	1.99e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
LGG	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-10.23	2.58e-22	2e-19	-0.58	-0.43	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
LGG	cis	rs7267979	1	rs6050573	ENSG00000125804.12	FAM182A	-10.23	2.59e-22	2.01e-19	-0.51	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:26054655~26086917:+
LGG	cis	rs5742933	0.597	rs7568449	ENSG00000253559.1	OSGEPL1-AS1	10.23	2.59e-22	2.01e-19	0.55	0.43	Ferritin levels;	chr2:189656328	chr2:189762704~189765556:+
LGG	cis	rs507080	0.845	rs481903	ENSG00000278376.1	RP11-158I9.8	-10.23	2.6e-22	2.01e-19	-0.38	-0.43	Serum metabolite levels;	chr11:118697024	chr11:118791254~118793137:+
LGG	cis	rs7914558	0.966	rs7908280	ENSG00000272912.1	RP11-724N1.1	-10.23	2.6e-22	2.01e-19	-0.47	-0.43	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102914585~102915404:+
LGG	cis	rs11148252	0.532	rs9526975	ENSG00000273784.3	RP11-78J21.7	-10.22	2.62e-22	2.03e-19	-0.48	-0.43	Lewy body disease;	chr13:52681669	chr13:52600042~52642542:+
LGG	cis	rs853679	0.527	rs707907	ENSG00000280107.1	AL022393.9	-10.22	2.62e-22	2.03e-19	-0.44	-0.43	Depression;	chr6:28323463	chr6:28170845~28172521:+
LGG	cis	rs3742264	1	rs9534302	ENSG00000235903.6	CPB2-AS1	-10.22	2.63e-22	2.04e-19	-0.46	-0.43	Blood protein levels;	chr13:46065920	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs9534303	ENSG00000235903.6	CPB2-AS1	-10.22	2.63e-22	2.04e-19	-0.46	-0.43	Blood protein levels;	chr13:46066007	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.961	rs9534304	ENSG00000235903.6	CPB2-AS1	-10.22	2.63e-22	2.04e-19	-0.46	-0.43	Blood protein levels;	chr13:46066467	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.922	rs7336360	ENSG00000235903.6	CPB2-AS1	-10.22	2.63e-22	2.04e-19	-0.46	-0.43	Blood protein levels;	chr13:46066946	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs9526136	ENSG00000235903.6	CPB2-AS1	-10.22	2.63e-22	2.04e-19	-0.46	-0.43	Blood protein levels;	chr13:46067012	chr13:46052806~46113332:+
LGG	cis	rs853679	1	rs735765	ENSG00000199851.2	U3	10.22	2.64e-22	2.04e-19	0.83	0.43	Depression;	chr6:28202519	chr6:28015568~28015777:+
LGG	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	10.22	2.64e-22	2.04e-19	0.59	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
LGG	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-10.22	2.65e-22	2.05e-19	-0.58	-0.43	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
LGG	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-10.22	2.66e-22	2.06e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
LGG	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-10.22	2.66e-22	2.06e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
LGG	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-10.22	2.66e-22	2.06e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
LGG	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-10.22	2.66e-22	2.06e-19	-0.43	-0.43	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
LGG	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	10.22	2.66e-22	2.06e-19	0.56	0.43	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
LGG	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	10.22	2.67e-22	2.07e-19	0.48	0.43	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
LGG	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-10.22	2.68e-22	2.07e-19	-0.51	-0.42	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
LGG	cis	rs9322193	0.884	rs880245	ENSG00000216621.7	RP11-244K5.6	-10.22	2.68e-22	2.07e-19	-0.51	-0.42	Lung cancer;	chr6:149846262	chr6:149934527~149936782:+
LGG	cis	rs7267979	0.934	rs4815423	ENSG00000276952.1	RP5-965G21.6	-10.22	2.73e-22	2.11e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25284915~25285588:-
LGG	cis	rs7615952	0.512	rs2979336	ENSG00000242001.1	GS1-388B5.1	10.22	2.73e-22	2.11e-19	0.56	0.42	Blood pressure (smoking interaction);	chr3:125638626	chr3:125681305~125681453:+
LGG	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	10.22	2.74e-22	2.12e-19	0.3	0.42	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
LGG	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	10.22	2.74e-22	2.12e-19	0.52	0.42	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
LGG	cis	rs3742264	1	rs4942471	ENSG00000235903.6	CPB2-AS1	-10.22	2.75e-22	2.13e-19	-0.47	-0.42	Blood protein levels;	chr13:46070358	chr13:46052806~46113332:+
LGG	cis	rs7615952	0.512	rs4679430	ENSG00000242001.1	GS1-388B5.1	10.22	2.76e-22	2.13e-19	0.56	0.42	Blood pressure (smoking interaction);	chr3:125639049	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.512	rs34651730	ENSG00000242001.1	GS1-388B5.1	10.22	2.76e-22	2.13e-19	0.56	0.42	Blood pressure (smoking interaction);	chr3:125639796	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.512	rs2979334	ENSG00000242001.1	GS1-388B5.1	10.22	2.76e-22	2.13e-19	0.56	0.42	Blood pressure (smoking interaction);	chr3:125639980	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.512	rs11929125	ENSG00000242001.1	GS1-388B5.1	10.22	2.76e-22	2.13e-19	0.56	0.42	Blood pressure (smoking interaction);	chr3:125640599	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.512	rs11921452	ENSG00000242001.1	GS1-388B5.1	10.22	2.76e-22	2.13e-19	0.56	0.42	Blood pressure (smoking interaction);	chr3:125640906	chr3:125681305~125681453:+
LGG	cis	rs7615952	0.512	rs2922175	ENSG00000242001.1	GS1-388B5.1	10.22	2.76e-22	2.13e-19	0.56	0.42	Blood pressure (smoking interaction);	chr3:125642516	chr3:125681305~125681453:+
LGG	cis	rs12935418	0.672	rs1453327	ENSG00000260213.4	RP11-303E16.3	10.22	2.76e-22	2.13e-19	0.52	0.42	Mean corpuscular volume;	chr16:81014959	chr16:81016792~81035759:-
LGG	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-10.22	2.78e-22	2.15e-19	-0.58	-0.42	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
LGG	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-10.22	2.78e-22	2.15e-19	-0.58	-0.42	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
LGG	cis	rs4373814	0.698	rs10764326	ENSG00000226083.4	SLC39A12-AS1	10.22	2.8e-22	2.16e-19	0.44	0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18159133	chr10:18001786~18010562:-
LGG	cis	rs4373814	0.698	rs10740996	ENSG00000226083.4	SLC39A12-AS1	10.22	2.8e-22	2.16e-19	0.44	0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18159180	chr10:18001786~18010562:-
LGG	cis	rs4713118	0.786	rs200503	ENSG00000216901.1	AL022393.7	10.22	2.83e-22	2.19e-19	0.56	0.42	Parkinson's disease;	chr6:27818104	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-10.22	2.83e-22	2.19e-19	-0.59	-0.42	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
LGG	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-10.21	2.85e-22	2.2e-19	-0.62	-0.42	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
LGG	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-10.21	2.85e-22	2.2e-19	-0.46	-0.42	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-10.21	2.85e-22	2.2e-19	-0.46	-0.42	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
LGG	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	10.21	2.88e-22	2.23e-19	0.59	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
LGG	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	10.21	2.88e-22	2.23e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000235689.1	AP000351.13	10.21	2.91e-22	2.24e-19	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:24006305~24008258:-
LGG	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	10.21	2.92e-22	2.25e-19	0.49	0.42	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
LGG	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	10.21	2.92e-22	2.26e-19	0.54	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
LGG	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	10.21	2.93e-22	2.26e-19	0.82	0.42	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
LGG	cis	rs7181230	0.885	rs35781999	ENSG00000275636.1	RP11-521C20.5	10.21	2.93e-22	2.27e-19	0.49	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40078892~40079347:+
LGG	cis	rs7181230	0.885	rs28444847	ENSG00000275636.1	RP11-521C20.5	10.21	2.93e-22	2.27e-19	0.49	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40078892~40079347:+
LGG	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	10.21	2.94e-22	2.27e-19	0.32	0.42	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
LGG	cis	rs1167827	0.68	rs1167800	ENSG00000127957.15	PMS2P3	-10.21	2.97e-22	2.29e-19	-0.34	-0.42	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75502930~75528148:-
LGG	cis	rs11233250	0.619	rs1497119	ENSG00000245832.5	RP11-179A16.1	10.21	2.99e-22	2.31e-19	0.65	0.42	Glioblastoma;Glioma;	chr11:82691866	chr11:81879851~82718082:-
LGG	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-10.21	2.99e-22	2.31e-19	-0.57	-0.42	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-10.21	2.99e-22	2.31e-19	-0.57	-0.42	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
LGG	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	10.21	2.99e-22	2.31e-19	0.5	0.42	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
LGG	cis	rs4373814	0.698	rs10764327	ENSG00000226083.4	SLC39A12-AS1	10.21	2.99e-22	2.31e-19	0.44	0.42	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18159919	chr10:18001786~18010562:-
LGG	cis	rs7267979	0.966	rs2261795	ENSG00000125804.12	FAM182A	-10.21	3.01e-22	2.32e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:26054655~26086917:+
LGG	cis	rs853679	0.585	rs201004	ENSG00000199851.2	U3	10.21	3.02e-22	2.33e-19	0.68	0.42	Depression;	chr6:27837156	chr6:28015568~28015777:+
LGG	cis	rs853679	0.585	rs201001	ENSG00000199851.2	U3	10.21	3.02e-22	2.33e-19	0.68	0.42	Depression;	chr6:27841121	chr6:28015568~28015777:+
LGG	cis	rs853679	0.585	rs201000	ENSG00000199851.2	U3	10.21	3.02e-22	2.33e-19	0.68	0.42	Depression;	chr6:27841381	chr6:28015568~28015777:+
LGG	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	10.21	3.03e-22	2.33e-19	0.54	0.42	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
LGG	cis	rs12935418	0.583	rs2244452	ENSG00000260213.4	RP11-303E16.3	10.21	3.03e-22	2.34e-19	0.51	0.42	Mean corpuscular volume;	chr16:80991767	chr16:81016792~81035759:-
LGG	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-10.21	3.03e-22	2.34e-19	-0.5	-0.42	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
LGG	cis	rs950027	0.967	rs3120975	ENSG00000259520.4	CTD-2651B20.3	-10.21	3.03e-22	2.34e-19	-0.54	-0.42	Response to fenofibrate (adiponectin levels);	chr15:45452927	chr15:45251580~45279251:-
LGG	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	10.21	3.04e-22	2.34e-19	0.59	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
LGG	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	10.21	3.04e-22	2.35e-19	0.5	0.42	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
LGG	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	10.21	3.05e-22	2.35e-19	0.45	0.42	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
LGG	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	10.21	3.05e-22	2.35e-19	0.48	0.42	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
LGG	cis	rs7914558	1	rs8139	ENSG00000272912.1	RP11-724N1.1	-10.21	3.06e-22	2.36e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102914585~102915404:+
LGG	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-10.21	3.07e-22	2.37e-19	-0.43	-0.42	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
LGG	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	10.2	3.09e-22	2.39e-19	0.72	0.42	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
LGG	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-10.2	3.11e-22	2.4e-19	-0.4	-0.42	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
LGG	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	10.2	3.13e-22	2.41e-19	0.54	0.42	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
LGG	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	10.2	3.14e-22	2.42e-19	0.37	0.42	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
LGG	cis	rs6500637	0.57	rs1049205	ENSG00000267077.1	RP11-127I20.5	-10.2	3.17e-22	2.44e-19	-0.44	-0.42	Cancer;	chr16:4892098	chr16:4795265~4796532:-
LGG	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	10.2	3.17e-22	2.44e-19	0.48	0.42	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
LGG	cis	rs879620	1	rs2531995	ENSG00000262888.1	RP11-462G12.2	-10.2	3.19e-22	2.45e-19	-0.56	-0.42	Hip circumference;Body mass index;	chr16:3963466	chr16:3931217~3946305:-
LGG	cis	rs7267979	0.932	rs6115214	ENSG00000276952.1	RP5-965G21.6	-10.2	3.21e-22	2.47e-19	-0.43	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25284915~25285588:-
LGG	cis	rs12935418	0.583	rs2167889	ENSG00000260213.4	RP11-303E16.3	10.2	3.23e-22	2.49e-19	0.51	0.42	Mean corpuscular volume;	chr16:80987867	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.552	rs2549833	ENSG00000260213.4	RP11-303E16.3	10.2	3.23e-22	2.49e-19	0.51	0.42	Mean corpuscular volume;	chr16:80988627	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.552	rs2602448	ENSG00000260213.4	RP11-303E16.3	10.2	3.23e-22	2.49e-19	0.51	0.42	Mean corpuscular volume;	chr16:80989067	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2549836	ENSG00000260213.4	RP11-303E16.3	10.2	3.23e-22	2.49e-19	0.51	0.42	Mean corpuscular volume;	chr16:80989476	chr16:81016792~81035759:-
LGG	cis	rs482329	0.93	rs610329	ENSG00000228044.2	RP4-781K5.4	10.2	3.23e-22	2.49e-19	0.48	0.42	Life threatening arrhythmia;	chr1:234666521	chr1:234646289~234683176:+
LGG	cis	rs4713118	0.786	rs200502	ENSG00000216901.1	AL022393.7	10.2	3.24e-22	2.5e-19	0.56	0.42	Parkinson's disease;	chr6:27820284	chr6:28176188~28176674:+
LGG	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-10.2	3.24e-22	2.5e-19	-0.45	-0.42	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
LGG	cis	rs4713118	0.662	rs149970	ENSG00000226314.6	ZNF192P1	10.2	3.24e-22	2.5e-19	0.47	0.42	Parkinson's disease;	chr6:28012442	chr6:28161781~28169594:+
LGG	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-10.2	3.27e-22	2.52e-19	-0.48	-0.42	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
LGG	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	10.2	3.27e-22	2.52e-19	0.49	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
LGG	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-10.2	3.28e-22	2.52e-19	-0.57	-0.42	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
LGG	cis	rs8092443	0.81	rs9952001	ENSG00000278971.1	RP11-644A7.2	-10.2	3.29e-22	2.53e-19	-0.67	-0.42	Response to antipsychotic treatment;	chr18:70483926	chr18:70489630~70491205:+
LGG	cis	rs10028773	0.6	rs4001390	ENSG00000249244.1	RP11-548H18.2	10.2	3.29e-22	2.54e-19	0.44	0.42	Educational attainment;	chr4:119344628	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.691	rs2136911	ENSG00000249244.1	RP11-548H18.2	10.2	3.29e-22	2.54e-19	0.44	0.42	Corneal astigmatism;	chr4:119344704	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.779	rs6815934	ENSG00000249244.1	RP11-548H18.2	10.2	3.29e-22	2.54e-19	0.44	0.42	Corneal astigmatism;	chr4:119346155	chr4:119391831~119395335:-
LGG	cis	rs10028773	0.568	rs6838457	ENSG00000249244.1	RP11-548H18.2	10.2	3.29e-22	2.54e-19	0.44	0.42	Educational attainment;	chr4:119346212	chr4:119391831~119395335:-
LGG	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-10.2	3.3e-22	2.54e-19	-0.47	-0.42	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
LGG	cis	rs7914558	0.966	rs1591915	ENSG00000272912.1	RP11-724N1.1	-10.2	3.34e-22	2.57e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs56946876	ENSG00000272912.1	RP11-724N1.1	-10.2	3.34e-22	2.57e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.933	rs12763665	ENSG00000272912.1	RP11-724N1.1	-10.2	3.34e-22	2.57e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs10786721	ENSG00000272912.1	RP11-724N1.1	-10.2	3.34e-22	2.57e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102914585~102915404:+
LGG	cis	rs5758511	0.508	rs58099562	ENSG00000227370.1	RP4-669P10.19	10.2	3.34e-22	2.57e-19	0.5	0.42	Birth weight;	chr22:42057768	chr22:42132543~42132998:+
LGG	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-10.2	3.36e-22	2.58e-19	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
LGG	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-10.19	3.36e-22	2.58e-19	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
LGG	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-10.19	3.38e-22	2.6e-19	-0.96	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
LGG	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	10.19	3.38e-22	2.6e-19	0.55	0.42	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
LGG	cis	rs853679	0.599	rs188015	ENSG00000199851.2	U3	10.19	3.41e-22	2.63e-19	0.9	0.42	Depression;	chr6:27909668	chr6:28015568~28015777:+
LGG	cis	rs4819052	1	rs733738	ENSG00000215447.6	BX322557.10	10.19	3.42e-22	2.63e-19	0.36	0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45288052~45291738:+
LGG	cis	rs7826238	0.653	rs2979202	ENSG00000173295.6	FAM86B3P	-10.19	3.42e-22	2.63e-19	-0.44	-0.42	Systolic blood pressure;	chr8:8486617	chr8:8228595~8244865:+
LGG	cis	rs2799081	1	rs2799081	ENSG00000280107.1	AL022393.9	-10.19	3.42e-22	2.63e-19	-0.45	-0.42	Myopia;	chr6:28302807	chr6:28170845~28172521:+
LGG	cis	rs27524	0.734	rs27037	ENSG00000248734.2	CTD-2260A17.1	10.19	3.42e-22	2.63e-19	0.45	0.42	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96784777~96785999:+
LGG	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-10.19	3.42e-22	2.63e-19	-0.45	-0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
LGG	cis	rs3002131	0.604	rs2133185	ENSG00000225265.1	TAF1A-AS1	-10.19	3.44e-22	2.64e-19	-0.59	-0.42	Interleukin-10 levels;	chr1:222565628	chr1:222589825~222593032:+
LGG	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	10.19	3.45e-22	2.65e-19	0.49	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
LGG	cis	rs7267979	1	rs4815417	ENSG00000125804.12	FAM182A	10.19	3.45e-22	2.65e-19	0.5	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:26054655~26086917:+
LGG	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	10.19	3.46e-22	2.66e-19	0.46	0.42	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
LGG	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	10.19	3.48e-22	2.67e-19	0.37	0.42	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	10.19	3.48e-22	2.67e-19	0.37	0.42	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
LGG	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-10.19	3.5e-22	2.69e-19	-0.48	-0.42	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
LGG	cis	rs7829975	0.682	rs7013471	ENSG00000173295.6	FAM86B3P	10.19	3.5e-22	2.69e-19	0.45	0.42	Mood instability;	chr8:8829815	chr8:8228595~8244865:+
LGG	cis	rs12935418	0.552	rs2549847	ENSG00000260213.4	RP11-303E16.3	10.19	3.56e-22	2.73e-19	0.51	0.42	Mean corpuscular volume;	chr16:80990617	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2602449	ENSG00000260213.4	RP11-303E16.3	10.19	3.56e-22	2.73e-19	0.51	0.42	Mean corpuscular volume;	chr16:80990668	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2549848	ENSG00000260213.4	RP11-303E16.3	10.19	3.56e-22	2.73e-19	0.51	0.42	Mean corpuscular volume;	chr16:80990693	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2316923	ENSG00000260213.4	RP11-303E16.3	10.19	3.56e-22	2.73e-19	0.51	0.42	Mean corpuscular volume;	chr16:80991216	chr16:81016792~81035759:-
LGG	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-10.19	3.56e-22	2.73e-19	-0.41	-0.42	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
LGG	cis	rs853679	1	rs853679	ENSG00000199851.2	U3	10.19	3.57e-22	2.74e-19	0.78	0.42	Depression;	chr6:28329086	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs853678	ENSG00000199851.2	U3	10.19	3.57e-22	2.74e-19	0.78	0.42	Depression;	chr6:28329536	chr6:28015568~28015777:+
LGG	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	10.19	3.57e-22	2.74e-19	0.51	0.42	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
LGG	cis	rs651907	0.513	rs34963630	ENSG00000256628.3	ZBTB11-AS1	10.19	3.61e-22	2.77e-19	0.49	0.42	Colorectal cancer;	chr3:101785973	chr3:101676475~101679217:+
LGG	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	10.19	3.61e-22	2.77e-19	0.81	0.42	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
LGG	cis	rs1560104	0.709	rs9806858	ENSG00000274834.1	CTD-3037G24.5	-10.19	3.62e-22	2.78e-19	-0.54	-0.42	Obesity-related traits;	chr16:12610564	chr16:12614451~12614852:+
LGG	cis	rs7267979	1	rs7019	ENSG00000276952.1	RP5-965G21.6	10.19	3.63e-22	2.78e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25284915~25285588:-
LGG	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-10.19	3.65e-22	2.8e-19	-0.48	-0.42	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
LGG	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	10.18	3.65e-22	2.8e-19	0.3	0.42	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
LGG	cis	rs5742933	0.857	rs1233284	ENSG00000253559.1	OSGEPL1-AS1	-10.18	3.67e-22	2.81e-19	-0.5	-0.42	Ferritin levels;	chr2:189825045	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.817	rs1233288	ENSG00000253559.1	OSGEPL1-AS1	-10.18	3.67e-22	2.81e-19	-0.5	-0.42	Ferritin levels;	chr2:189825999	chr2:189762704~189765556:+
LGG	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-10.18	3.68e-22	2.83e-19	-0.56	-0.42	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
LGG	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	10.18	3.68e-22	2.83e-19	0.56	0.42	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
LGG	cis	rs853679	0.527	rs9468333	ENSG00000226314.6	ZNF192P1	10.18	3.69e-22	2.83e-19	0.44	0.42	Depression;	chr6:28303421	chr6:28161781~28169594:+
LGG	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-10.18	3.71e-22	2.85e-19	-0.57	-0.42	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
LGG	cis	rs12935418	0.552	rs2113196	ENSG00000260213.4	RP11-303E16.3	10.18	3.72e-22	2.85e-19	0.52	0.42	Mean corpuscular volume;	chr16:80991885	chr16:81016792~81035759:-
LGG	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	10.18	3.72e-22	2.85e-19	0.38	0.42	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
LGG	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-10.18	3.72e-22	2.85e-19	-0.47	-0.42	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
LGG	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	10.18	3.73e-22	2.86e-19	0.44	0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
LGG	cis	rs5742933	0.803	rs1233302	ENSG00000253559.1	OSGEPL1-AS1	-10.18	3.73e-22	2.86e-19	-0.5	-0.42	Ferritin levels;	chr2:189804154	chr2:189762704~189765556:+
LGG	cis	rs482329	0.93	rs622239	ENSG00000228044.2	RP4-781K5.4	10.18	3.74e-22	2.87e-19	0.48	0.42	Life threatening arrhythmia;	chr1:234666895	chr1:234646289~234683176:+
LGG	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	10.18	3.77e-22	2.89e-19	0.3	0.42	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
LGG	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	10.18	3.77e-22	2.89e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
LGG	cis	rs6496932	0.635	rs11074191	ENSG00000218052.5	ADAMTS7P4	-10.18	3.77e-22	2.89e-19	-0.61	-0.42	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85255369~85330334:-
LGG	cis	rs7546	0.504	rs2015319	ENSG00000267077.1	RP11-127I20.5	-10.18	3.79e-22	2.9e-19	-0.44	-0.42	Cancer;	chr16:4886279	chr16:4795265~4796532:-
LGG	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-10.18	3.81e-22	2.92e-19	-0.52	-0.42	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
LGG	cis	rs7246657	0.678	rs2927740	ENSG00000267422.1	CTD-2554C21.1	10.18	3.82e-22	2.93e-19	0.53	0.42	Coronary artery calcification;	chr19:37650065	chr19:37779686~37792865:+
LGG	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-10.18	3.83e-22	2.94e-19	-0.71	-0.42	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
LGG	cis	rs507080	1	rs507080	ENSG00000278376.1	RP11-158I9.8	-10.18	3.84e-22	2.94e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118678873	chr11:118791254~118793137:+
LGG	cis	rs853679	0.527	rs853690	ENSG00000226314.6	ZNF192P1	10.18	3.86e-22	2.96e-19	0.44	0.42	Depression;	chr6:28317705	chr6:28161781~28169594:+
LGG	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	10.18	3.86e-22	2.96e-19	0.64	0.42	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
LGG	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-10.18	3.87e-22	2.96e-19	-0.48	-0.42	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
LGG	cis	rs7267979	0.933	rs2261109	ENSG00000125804.12	FAM182A	-10.18	3.89e-22	2.98e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2261698	ENSG00000125804.12	FAM182A	-10.18	3.89e-22	2.98e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2261720	ENSG00000125804.12	FAM182A	-10.18	3.89e-22	2.98e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2227890	ENSG00000125804.12	FAM182A	-10.18	3.89e-22	2.98e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:26054655~26086917:+
LGG	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	10.18	3.89e-22	2.98e-19	0.54	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
LGG	cis	rs3002131	0.604	rs1319392	ENSG00000225265.1	TAF1A-AS1	-10.18	3.9e-22	2.98e-19	-0.59	-0.42	Interleukin-10 levels;	chr1:222567271	chr1:222589825~222593032:+
LGG	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	10.18	3.94e-22	3.02e-19	0.56	0.42	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
LGG	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-10.18	3.94e-22	3.02e-19	-0.51	-0.42	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
LGG	cis	rs7119038	0.58	rs7123726	ENSG00000255239.1	AP002954.6	-10.18	3.94e-22	3.02e-19	-0.59	-0.42	Sjögren's syndrome;	chr11:118823838	chr11:118688039~118690600:-
LGG	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	10.18	3.94e-22	3.02e-19	0.42	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
LGG	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-10.18	3.96e-22	3.03e-19	-0.4	-0.42	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
LGG	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-10.17	3.98e-22	3.05e-19	-0.42	-0.42	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
LGG	cis	rs853679	0.527	rs853683	ENSG00000280107.1	AL022393.9	-10.17	4.02e-22	3.08e-19	-0.44	-0.42	Depression;	chr6:28327262	chr6:28170845~28172521:+
LGG	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	10.17	4.03e-22	3.08e-19	0.31	0.42	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
LGG	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	10.17	4.04e-22	3.09e-19	0.81	0.42	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
LGG	cis	rs7927771	0.832	rs935914	ENSG00000280615.1	Y_RNA	10.17	4.05e-22	3.1e-19	0.53	0.42	Subjective well-being;	chr11:47366048	chr11:47614898~47614994:-
LGG	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-10.17	4.07e-22	3.11e-19	-0.57	-0.42	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
LGG	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-10.17	4.07e-22	3.11e-19	-0.49	-0.42	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
LGG	cis	rs853679	0.599	rs149990	ENSG00000199851.2	U3	10.17	4.11e-22	3.14e-19	0.89	0.42	Depression;	chr6:28030480	chr6:28015568~28015777:+
LGG	cis	rs7914558	0.966	rs943035	ENSG00000272912.1	RP11-724N1.1	-10.17	4.11e-22	3.14e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs7921574	ENSG00000272912.1	RP11-724N1.1	-10.17	4.11e-22	3.14e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:102914585~102915404:+
LGG	cis	rs7267979	0.934	rs2261753	ENSG00000125804.12	FAM182A	-10.17	4.11e-22	3.14e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:26054655~26086917:+
LGG	cis	rs1475911	0.947	rs67055914	ENSG00000184385.2	UMODL1-AS1	10.17	4.13e-22	3.15e-19	0.53	0.42	IgG glycosylation;	chr21:42090317	chr21:42102134~42108534:-
LGG	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-10.17	4.16e-22	3.18e-19	-0.47	-0.42	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
LGG	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	10.17	4.16e-22	3.18e-19	0.37	0.42	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-10.17	4.19e-22	3.2e-19	-0.35	-0.42	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-10.17	4.19e-22	3.2e-19	-0.35	-0.42	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-10.17	4.19e-22	3.2e-19	-0.35	-0.42	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
LGG	cis	rs7267979	1	rs2424704	ENSG00000276952.1	RP5-965G21.6	10.17	4.2e-22	3.2e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25284915~25285588:-
LGG	cis	rs571497	0.583	rs62128261	ENSG00000268297.1	CLEC4GP1	10.17	4.2e-22	3.21e-19	0.6	0.42	Monocyte count;	chr19:7773103	chr19:7787549~7790621:+
LGG	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	10.17	4.22e-22	3.22e-19	0.54	0.42	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
LGG	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-10.17	4.28e-22	3.27e-19	-0.55	-0.42	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
LGG	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	10.17	4.31e-22	3.29e-19	0.45	0.42	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
LGG	cis	rs8092443	0.81	rs73459346	ENSG00000278971.1	RP11-644A7.2	-10.17	4.31e-22	3.29e-19	-0.66	-0.42	Response to antipsychotic treatment;	chr18:70477175	chr18:70489630~70491205:+
LGG	cis	rs9322193	0.884	rs7743823	ENSG00000216621.7	RP11-244K5.6	10.17	4.32e-22	3.29e-19	0.5	0.42	Lung cancer;	chr6:149849744	chr6:149934527~149936782:+
LGG	cis	rs7115242	0.699	rs72645459	ENSG00000254851.1	RP11-109L13.1	10.17	4.32e-22	3.3e-19	0.94	0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891441	chr11:117135528~117138582:+
LGG	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	10.16	4.33e-22	3.3e-19	0.54	0.42	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	10.16	4.33e-22	3.3e-19	0.54	0.42	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	10.16	4.33e-22	3.3e-19	0.54	0.42	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	10.16	4.33e-22	3.3e-19	0.54	0.42	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
LGG	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-10.16	4.33e-22	3.3e-19	-0.59	-0.42	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
LGG	cis	rs7119038	0.774	rs7945144	ENSG00000255239.1	AP002954.6	-10.16	4.34e-22	3.31e-19	-0.57	-0.42	Sjögren's syndrome;	chr11:118738007	chr11:118688039~118690600:-
LGG	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-10.16	4.36e-22	3.33e-19	-0.52	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
LGG	cis	rs172166	0.516	rs1225715	ENSG00000280107.1	AL022393.9	10.16	4.37e-22	3.33e-19	0.46	0.42	Cardiac Troponin-T levels;	chr6:28145595	chr6:28170845~28172521:+
LGG	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-10.16	4.37e-22	3.34e-19	-0.48	-0.42	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
LGG	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-10.16	4.39e-22	3.35e-19	-0.57	-0.42	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
LGG	cis	rs7247513	0.964	rs12104149	ENSG00000213290.4	PGK1P2	-10.16	4.41e-22	3.36e-19	-0.46	-0.42	Bipolar disorder;	chr19:12610274	chr19:12559571~12561105:+
LGG	cis	rs7267979	0.866	rs6138609	ENSG00000276952.1	RP5-965G21.6	10.16	4.42e-22	3.37e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25284915~25285588:-
LGG	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-10.16	4.43e-22	3.38e-19	-0.46	-0.42	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
LGG	cis	rs893971	0.647	rs1440580	ENSG00000246375.2	RP11-10L7.1	10.16	4.46e-22	3.4e-19	0.49	0.42	Conduct disorder (maternal expressed emotions interaction);	chr4:88305595	chr4:88284942~88331421:+
LGG	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	10.16	4.47e-22	3.41e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
LGG	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-10.16	4.48e-22	3.41e-19	-0.35	-0.42	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
LGG	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	10.16	4.49e-22	3.42e-19	0.49	0.42	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
LGG	cis	rs6921919	0.515	rs1339898	ENSG00000280107.1	AL022393.9	-10.16	4.5e-22	3.43e-19	-0.42	-0.42	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28170845~28172521:+
LGG	cis	rs7267979	0.668	rs4815398	ENSG00000125804.12	FAM182A	10.16	4.51e-22	3.43e-19	0.51	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26054655~26086917:+
LGG	cis	rs1065852	0.906	rs5751230	ENSG00000227370.1	RP4-669P10.19	10.16	4.51e-22	3.44e-19	0.47	0.42	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42157347	chr22:42132543~42132998:+
LGG	cis	rs7267979	0.966	rs2261790	ENSG00000125804.12	FAM182A	-10.16	4.54e-22	3.46e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2261794	ENSG00000125804.12	FAM182A	-10.16	4.54e-22	3.46e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2145126	ENSG00000125804.12	FAM182A	-10.16	4.54e-22	3.46e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2257705	ENSG00000125804.12	FAM182A	-10.16	4.54e-22	3.46e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2227892	ENSG00000125804.12	FAM182A	-10.16	4.54e-22	3.46e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2257712	ENSG00000125804.12	FAM182A	-10.16	4.54e-22	3.46e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.966	rs2257461	ENSG00000125804.12	FAM182A	-10.16	4.54e-22	3.46e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:26054655~26086917:+
LGG	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	10.16	4.57e-22	3.48e-19	0.48	0.42	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	10.16	4.57e-22	3.48e-19	0.48	0.42	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	10.16	4.57e-22	3.48e-19	0.48	0.42	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
LGG	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	10.16	4.58e-22	3.49e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
LGG	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	10.16	4.58e-22	3.49e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
LGG	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	10.16	4.58e-22	3.49e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
LGG	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	10.16	4.61e-22	3.51e-19	0.32	0.42	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
LGG	cis	rs7267979	0.966	rs7270835	ENSG00000276952.1	RP5-965G21.6	10.16	4.63e-22	3.53e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6115191	ENSG00000276952.1	RP5-965G21.6	10.16	4.63e-22	3.53e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6107046	ENSG00000276952.1	RP5-965G21.6	10.16	4.63e-22	3.53e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6107047	ENSG00000276952.1	RP5-965G21.6	10.16	4.63e-22	3.53e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25284915~25285588:-
LGG	cis	rs7927771	0.832	rs11039212	ENSG00000280615.1	Y_RNA	10.16	4.68e-22	3.56e-19	0.53	0.42	Subjective well-being;	chr11:47371752	chr11:47614898~47614994:-
LGG	cis	rs5758511	0.508	rs2413667	ENSG00000227370.1	RP4-669P10.19	10.16	4.7e-22	3.58e-19	0.5	0.42	Birth weight;	chr22:42076233	chr22:42132543~42132998:+
LGG	cis	rs7267979	1	rs2500443	ENSG00000276952.1	RP5-965G21.6	-10.15	4.73e-22	3.6e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2482928	ENSG00000276952.1	RP5-965G21.6	-10.15	4.73e-22	3.6e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25284915~25285588:-
LGG	cis	rs8092443	0.688	rs2366387	ENSG00000278971.1	RP11-644A7.2	-10.15	4.73e-22	3.6e-19	-0.67	-0.42	Response to antipsychotic treatment;	chr18:70494429	chr18:70489630~70491205:+
LGG	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	10.15	4.76e-22	3.62e-19	0.49	0.42	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	10.15	4.76e-22	3.62e-19	0.49	0.42	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
LGG	cis	rs9388451	0.874	rs13209968	ENSG00000237742.5	RP11-624M8.1	-10.15	4.76e-22	3.62e-19	-0.37	-0.42	Brugada syndrome;	chr6:125768139	chr6:125578558~125749190:-
LGG	cis	rs6903823	0.527	rs4713158	ENSG00000226314.6	ZNF192P1	10.15	4.77e-22	3.63e-19	0.43	0.42	Pulmonary function;	chr6:28309994	chr6:28161781~28169594:+
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-10.15	4.77e-22	3.63e-19	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
LGG	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-10.15	4.77e-22	3.63e-19	-0.35	-0.42	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
LGG	cis	rs7267979	1	rs2500436	ENSG00000276952.1	RP5-965G21.6	-10.15	4.78e-22	3.64e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.903	rs6050482	ENSG00000125804.12	FAM182A	-10.15	4.79e-22	3.65e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.706	rs6037069	ENSG00000125804.12	FAM182A	-10.15	4.79e-22	3.65e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:26054655~26086917:+
LGG	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-10.15	4.84e-22	3.68e-19	-0.42	-0.42	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
LGG	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	10.15	4.85e-22	3.68e-19	0.79	0.42	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
LGG	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-10.15	4.85e-22	3.69e-19	-0.51	-0.42	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
LGG	cis	rs7829975	0.684	rs488904	ENSG00000173295.6	FAM86B3P	10.15	4.87e-22	3.7e-19	0.45	0.42	Mood instability;	chr8:8730061	chr8:8228595~8244865:+
LGG	cis	rs7302981	1	rs7308356	ENSG00000272368.2	RP4-605O3.4	-10.15	4.87e-22	3.7e-19	-0.42	-0.42	Systolic blood pressure;	chr12:50145828	chr12:50112197~50165618:+
LGG	cis	rs7302981	0.934	rs7301649	ENSG00000272368.2	RP4-605O3.4	-10.15	4.87e-22	3.7e-19	-0.42	-0.42	Systolic blood pressure;	chr12:50147087	chr12:50112197~50165618:+
LGG	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-10.15	4.89e-22	3.71e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-10.15	4.89e-22	3.71e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
LGG	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-10.15	4.89e-22	3.71e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
LGG	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	10.15	4.93e-22	3.74e-19	0.56	0.42	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
LGG	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-10.15	4.94e-22	3.75e-19	-0.29	-0.42	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
LGG	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-10.15	4.98e-22	3.78e-19	-0.44	-0.42	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
LGG	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-10.15	4.98e-22	3.78e-19	-0.52	-0.42	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
LGG	cis	rs6500637	0.58	rs5013674	ENSG00000267077.1	RP11-127I20.5	-10.15	4.98e-22	3.79e-19	-0.44	-0.42	Cancer;	chr16:4882469	chr16:4795265~4796532:-
LGG	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	10.15	5.03e-22	3.82e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
LGG	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-10.15	5.03e-22	3.82e-19	-0.48	-0.42	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
LGG	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	10.15	5.05e-22	3.83e-19	0.49	0.42	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
LGG	cis	rs9875589	0.957	rs13077668	ENSG00000233121.1	VN1R20P	-10.15	5.08e-22	3.86e-19	-0.43	-0.42	Ovarian reserve;	chr3:13888259	chr3:13926813~13927778:+
LGG	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-10.15	5.09e-22	3.86e-19	-0.49	-0.42	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
LGG	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	10.15	5.09e-22	3.86e-19	0.54	0.42	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
LGG	cis	rs7267979	0.966	rs4813557	ENSG00000276952.1	RP5-965G21.6	-10.15	5.11e-22	3.88e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25284915~25285588:-
LGG	cis	rs8092443	0.81	rs11872986	ENSG00000278971.1	RP11-644A7.2	-10.14	5.14e-22	3.9e-19	-0.68	-0.42	Response to antipsychotic treatment;	chr18:70481612	chr18:70489630~70491205:+
LGG	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-10.14	5.15e-22	3.91e-19	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
LGG	cis	rs7267979	1	rs4815404	ENSG00000276952.1	RP5-965G21.6	-10.14	5.18e-22	3.93e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6083805	ENSG00000276952.1	RP5-965G21.6	-10.14	5.18e-22	3.93e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050544	ENSG00000276952.1	RP5-965G21.6	-10.14	5.18e-22	3.93e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6037095	ENSG00000276952.1	RP5-965G21.6	-10.14	5.18e-22	3.93e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050562	ENSG00000276952.1	RP5-965G21.6	-10.14	5.18e-22	3.93e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25284915~25285588:-
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	10.14	5.18e-22	3.93e-19	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
LGG	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-10.14	5.27e-22	4e-19	-0.5	-0.42	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
LGG	cis	rs6452524	0.804	rs1478481	ENSG00000248112.1	RP11-78C3.1	10.14	5.32e-22	4.04e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:82919376~82921119:-
LGG	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	10.14	5.33e-22	4.04e-19	0.37	0.42	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
LGG	cis	rs7267979	0.866	rs2424698	ENSG00000276952.1	RP5-965G21.6	10.14	5.35e-22	4.06e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25284915~25285588:-
LGG	cis	rs6539247	0.527	rs10778456	ENSG00000257890.1	RP11-114F10.2	-10.14	5.35e-22	4.06e-19	-0.51	-0.42	Attention function in attention deficit hyperactive disorder;	chr12:106054524	chr12:106050961~106058254:-
LGG	cis	rs7914558	0.966	rs11191518	ENSG00000272912.1	RP11-724N1.1	-10.14	5.38e-22	4.08e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102914585~102915404:+
LGG	cis	rs7240205	0.724	rs6508447	ENSG00000275805.1	RP11-349H17.2	10.14	5.39e-22	4.09e-19	0.48	0.42	Breast cancer;	chr18:26552657	chr18:26565723~26575626:-
LGG	cis	rs8064024	0.508	rs2037912	ENSG00000267077.1	RP11-127I20.5	-10.14	5.42e-22	4.11e-19	-0.43	-0.42	Cancer;	chr16:4883938	chr16:4795265~4796532:-
LGG	cis	rs8092443	0.745	rs2366384	ENSG00000278971.1	RP11-644A7.2	10.14	5.42e-22	4.11e-19	0.62	0.42	Response to antipsychotic treatment;	chr18:70485727	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.81	rs11659771	ENSG00000278971.1	RP11-644A7.2	10.14	5.42e-22	4.11e-19	0.62	0.42	Response to antipsychotic treatment;	chr18:70486462	chr18:70489630~70491205:+
LGG	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-10.14	5.44e-22	4.12e-19	-0.46	-0.42	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
LGG	cis	rs482329	0.86	rs611634	ENSG00000228044.2	RP4-781K5.4	-10.14	5.47e-22	4.14e-19	-0.48	-0.42	Life threatening arrhythmia;	chr1:234660117	chr1:234646289~234683176:+
LGG	cis	rs7119038	0.865	rs11217044	ENSG00000255239.1	AP002954.6	-10.14	5.48e-22	4.15e-19	-0.59	-0.42	Sjögren's syndrome;	chr11:118825313	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-10.14	5.49e-22	4.16e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
LGG	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-10.14	5.49e-22	4.16e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
LGG	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-10.14	5.49e-22	4.16e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
LGG	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	10.14	5.53e-22	4.19e-19	0.55	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
LGG	cis	rs7267979	1	rs6083856	ENSG00000276952.1	RP5-965G21.6	-10.14	5.53e-22	4.19e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.847	rs880246	ENSG00000216621.7	RP11-244K5.6	10.14	5.55e-22	4.2e-19	0.5	0.42	Lung cancer;	chr6:149845972	chr6:149934527~149936782:+
LGG	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	10.14	5.56e-22	4.21e-19	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
LGG	cis	rs853679	0.599	rs188015	ENSG00000216901.1	AL022393.7	10.13	5.6e-22	4.24e-19	0.8	0.42	Depression;	chr6:27909668	chr6:28176188~28176674:+
LGG	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-10.13	5.62e-22	4.26e-19	-0.5	-0.42	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
LGG	cis	rs7302981	0.934	rs7294548	ENSG00000272368.2	RP4-605O3.4	-10.13	5.63e-22	4.26e-19	-0.42	-0.42	Systolic blood pressure;	chr12:50149418	chr12:50112197~50165618:+
LGG	cis	rs7267979	1	rs4815407	ENSG00000276952.1	RP5-965G21.6	-10.13	5.64e-22	4.27e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25284915~25285588:-
LGG	cis	rs853679	0.769	rs17720293	ENSG00000216901.1	AL022393.7	10.13	5.64e-22	4.27e-19	0.84	0.42	Depression;	chr6:28246920	chr6:28176188~28176674:+
LGG	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-10.13	5.66e-22	4.28e-19	-0.54	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
LGG	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-10.13	5.66e-22	4.29e-19	-0.52	-0.42	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
LGG	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	10.13	5.68e-22	4.3e-19	0.53	0.42	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
LGG	cis	rs12935418	0.552	rs2911148	ENSG00000260213.4	RP11-303E16.3	10.13	5.71e-22	4.32e-19	0.51	0.42	Mean corpuscular volume;	chr16:80988289	chr16:81016792~81035759:-
LGG	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	10.13	5.76e-22	4.36e-19	0.71	0.42	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
LGG	cis	rs9810089	0.903	rs7432375	ENSG00000261758.1	RP11-102M11.2	10.13	5.76e-22	4.36e-19	0.44	0.42	Gestational age at birth (child effect);	chr3:136569563	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.903	rs10935185	ENSG00000261758.1	RP11-102M11.2	10.13	5.76e-22	4.36e-19	0.44	0.42	Gestational age at birth (child effect);	chr3:136571687	chr3:136752630~136755780:+
LGG	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-10.13	5.79e-22	4.38e-19	-0.4	-0.42	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
LGG	cis	rs9876781	1	rs2242150	ENSG00000244380.1	RP11-24C3.2	-10.13	5.81e-22	4.39e-19	-0.52	-0.42	Longevity;	chr3:48464565	chr3:48440352~48446656:-
LGG	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	10.13	5.81e-22	4.4e-19	0.3	0.42	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
LGG	cis	rs6452524	0.868	rs10079372	ENSG00000248112.1	RP11-78C3.1	10.13	5.82e-22	4.4e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:82919376~82921119:-
LGG	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	10.13	5.82e-22	4.4e-19	0.56	0.42	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
LGG	cis	rs9875589	0.957	rs60060718	ENSG00000233121.1	VN1R20P	10.13	5.83e-22	4.41e-19	0.43	0.42	Ovarian reserve;	chr3:13908836	chr3:13926813~13927778:+
LGG	cis	rs9875589	0.957	rs4407395	ENSG00000233121.1	VN1R20P	10.13	5.83e-22	4.41e-19	0.43	0.42	Ovarian reserve;	chr3:13910176	chr3:13926813~13927778:+
LGG	cis	rs9810089	0.903	rs7427564	ENSG00000261758.1	RP11-102M11.2	10.13	5.85e-22	4.42e-19	0.44	0.42	Gestational age at birth (child effect);	chr3:136555593	chr3:136752630~136755780:+
LGG	cis	rs6496932	0.635	rs28559998	ENSG00000218052.5	ADAMTS7P4	-10.13	5.86e-22	4.43e-19	-0.56	-0.42	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85255369~85330334:-
LGG	cis	rs6496932	0.635	rs8023859	ENSG00000218052.5	ADAMTS7P4	-10.13	5.86e-22	4.43e-19	-0.56	-0.42	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85255369~85330334:-
LGG	cis	rs7432375	1	rs10935186	ENSG00000261758.1	RP11-102M11.2	10.13	5.88e-22	4.44e-19	0.44	0.42	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136627364	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.966	rs6808312	ENSG00000261758.1	RP11-102M11.2	-10.13	5.88e-22	4.44e-19	-0.44	-0.42	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652662	chr3:136752630~136755780:+
LGG	cis	rs7432375	1	rs6439649	ENSG00000261758.1	RP11-102M11.2	-10.13	5.88e-22	4.44e-19	-0.44	-0.42	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136652849	chr3:136752630~136755780:+
LGG	cis	rs7634476	1	rs7634476	ENSG00000261758.1	RP11-102M11.2	-10.13	5.88e-22	4.44e-19	-0.44	-0.42	Neuroticism;	chr3:136679545	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.966	rs7618871	ENSG00000261758.1	RP11-102M11.2	-10.13	5.88e-22	4.44e-19	-0.44	-0.42	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136681578	chr3:136752630~136755780:+
LGG	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-10.13	5.92e-22	4.47e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
LGG	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-10.13	5.94e-22	4.49e-19	-0.58	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
LGG	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-10.13	5.94e-22	4.49e-19	-0.58	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
LGG	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	10.13	5.97e-22	4.51e-19	0.49	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
LGG	cis	rs7267979	1	rs2424716	ENSG00000276952.1	RP5-965G21.6	10.13	5.98e-22	4.52e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs761025	ENSG00000276952.1	RP5-965G21.6	10.13	5.98e-22	4.52e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050631	ENSG00000276952.1	RP5-965G21.6	10.13	5.98e-22	4.52e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6515651	ENSG00000276952.1	RP5-965G21.6	-10.13	5.98e-22	4.52e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2151144	ENSG00000276952.1	RP5-965G21.6	-10.13	5.98e-22	4.52e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25284915~25285588:-
LGG	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	10.13	5.98e-22	4.52e-19	0.47	0.42	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	10.13	5.98e-22	4.52e-19	0.47	0.42	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	10.13	5.98e-22	4.52e-19	0.47	0.42	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	10.13	5.98e-22	4.52e-19	0.47	0.42	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
LGG	cis	rs41157	0.528	rs15888	ENSG00000279159.1	RP3-394A18.1	10.13	5.99e-22	4.52e-19	0.42	0.42	Cerebrospinal P-tau181p levels;	chr22:30030346	chr22:29978950~30028236:-
LGG	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	10.13	6e-22	4.53e-19	0.52	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
LGG	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	10.13	6.01e-22	4.54e-19	0.3	0.42	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
LGG	cis	rs853679	0.527	rs707907	ENSG00000199851.2	U3	10.13	6.02e-22	4.54e-19	0.59	0.42	Depression;	chr6:28323463	chr6:28015568~28015777:+
LGG	cis	rs853679	0.527	rs1997660	ENSG00000199851.2	U3	10.12	6.07e-22	4.58e-19	0.59	0.42	Depression;	chr6:28301886	chr6:28015568~28015777:+
LGG	cis	rs6903823	0.508	rs1150726	ENSG00000280107.1	AL022393.9	-10.12	6.08e-22	4.59e-19	-0.43	-0.42	Pulmonary function;	chr6:28275265	chr6:28170845~28172521:+
LGG	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	10.12	6.08e-22	4.59e-19	0.42	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
LGG	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-10.12	6.09e-22	4.59e-19	-0.3	-0.42	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
LGG	cis	rs7267979	0.966	rs2482918	ENSG00000276952.1	RP5-965G21.6	-10.12	6.09e-22	4.59e-19	-0.42	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25284915~25285588:-
LGG	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	10.12	6.09e-22	4.6e-19	0.53	0.42	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
LGG	cis	rs10759883	0.539	rs609296	ENSG00000175611.10	LINC00476	10.12	6.14e-22	4.63e-19	0.55	0.42	Nicotine dependence;	chr9:95973604	chr9:95759231~95875977:-
LGG	cis	rs7267979	1	rs6083844	ENSG00000125804.12	FAM182A	10.12	6.16e-22	4.64e-19	0.5	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:26054655~26086917:+
LGG	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-10.12	6.18e-22	4.66e-19	-0.42	-0.42	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
LGG	cis	rs3742264	1	rs9526139	ENSG00000235903.6	CPB2-AS1	-10.12	6.2e-22	4.68e-19	-0.46	-0.42	Blood protein levels;	chr13:46069921	chr13:46052806~46113332:+
LGG	cis	rs7246657	0.722	rs2972458	ENSG00000267422.1	CTD-2554C21.1	10.12	6.22e-22	4.69e-19	0.51	0.42	Coronary artery calcification;	chr19:37644502	chr19:37779686~37792865:+
LGG	cis	rs5758511	0.689	rs56906457	ENSG00000227370.1	RP4-669P10.19	10.12	6.27e-22	4.73e-19	0.5	0.42	Birth weight;	chr22:42232329	chr22:42132543~42132998:+
LGG	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	10.12	6.27e-22	4.73e-19	0.51	0.42	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
LGG	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-10.12	6.3e-22	4.75e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
LGG	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-10.12	6.31e-22	4.75e-19	-0.71	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
LGG	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-10.12	6.33e-22	4.77e-19	-0.58	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
LGG	cis	rs507080	0.922	rs502601	ENSG00000278376.1	RP11-158I9.8	-10.12	6.42e-22	4.84e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118694970	chr11:118791254~118793137:+
LGG	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-10.12	6.45e-22	4.86e-19	-0.34	-0.42	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
LGG	cis	rs12935418	0.583	rs2549837	ENSG00000260213.4	RP11-303E16.3	10.12	6.46e-22	4.87e-19	0.51	0.42	Mean corpuscular volume;	chr16:80989510	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.552	rs2549838	ENSG00000260213.4	RP11-303E16.3	10.12	6.48e-22	4.88e-19	0.51	0.42	Mean corpuscular volume;	chr16:80989605	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2549839	ENSG00000260213.4	RP11-303E16.3	10.12	6.48e-22	4.88e-19	0.51	0.42	Mean corpuscular volume;	chr16:80989630	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.583	rs2549843	ENSG00000260213.4	RP11-303E16.3	10.12	6.48e-22	4.88e-19	0.51	0.42	Mean corpuscular volume;	chr16:80990140	chr16:81016792~81035759:-
LGG	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	10.12	6.48e-22	4.88e-19	0.45	0.42	Depression;	chr6:28200948	chr6:28115628~28116551:+
LGG	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	10.12	6.48e-22	4.88e-19	0.53	0.42	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
LGG	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	10.12	6.49e-22	4.88e-19	0.54	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
LGG	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	10.12	6.49e-22	4.88e-19	0.74	0.42	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
LGG	cis	rs4713118	1	rs4713118	ENSG00000199851.2	U3	10.12	6.5e-22	4.9e-19	0.61	0.42	Parkinson's disease;	chr6:27709015	chr6:28015568~28015777:+
LGG	cis	rs4713118	1	rs13215072	ENSG00000199851.2	U3	10.12	6.5e-22	4.9e-19	0.61	0.42	Parkinson's disease;	chr6:27709949	chr6:28015568~28015777:+
LGG	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-10.12	6.53e-22	4.91e-19	-0.45	-0.42	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
LGG	cis	rs853679	0.527	rs213228	ENSG00000280107.1	AL022393.9	-10.12	6.54e-22	4.92e-19	-0.42	-0.42	Depression;	chr6:28363475	chr6:28170845~28172521:+
LGG	cis	rs6496932	0.663	rs7182814	ENSG00000218052.5	ADAMTS7P4	-10.12	6.57e-22	4.95e-19	-0.55	-0.42	Central corneal thickness;Corneal structure;	chr15:85362840	chr15:85255369~85330334:-
LGG	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	10.12	6.58e-22	4.95e-19	0.52	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
LGG	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	10.11	6.63e-22	4.99e-19	0.45	0.42	Depression;	chr6:28205232	chr6:28115628~28116551:+
LGG	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-10.11	6.65e-22	5e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
LGG	cis	rs5742933	1	rs1898560	ENSG00000273240.1	RP11-455J20.3	-10.11	6.72e-22	5.05e-19	-0.53	-0.42	Ferritin levels;	chr2:189747601	chr2:189763859~189764456:-
LGG	cis	rs7267979	0.934	rs2261115	ENSG00000276952.1	RP5-965G21.6	10.11	6.74e-22	5.07e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25284915~25285588:-
LGG	cis	rs56114371	0.53	rs9348774	ENSG00000199851.2	U3	10.11	6.75e-22	5.07e-19	0.67	0.42	Breast cancer;	chr6:27721151	chr6:28015568~28015777:+
LGG	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-10.11	6.77e-22	5.09e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
LGG	cis	rs5742933	0.512	rs80277863	ENSG00000273240.1	RP11-455J20.3	-10.11	6.78e-22	5.1e-19	-0.52	-0.42	Ferritin levels;	chr2:189766733	chr2:189763859~189764456:-
LGG	cis	rs9810089	0.934	rs66691851	ENSG00000261758.1	RP11-102M11.2	10.11	6.81e-22	5.12e-19	0.44	0.42	Gestational age at birth (child effect);	chr3:136435986	chr3:136752630~136755780:+
LGG	cis	rs642803	1	rs557675	ENSG00000255120.4	OVOL1-AS1	-10.11	6.85e-22	5.15e-19	-0.5	-0.42	Urate levels;	chr11:65799248	chr11:65789051~65790868:-
LGG	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	10.11	6.9e-22	5.18e-19	0.48	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000235689.1	AP000351.13	10.11	6.91e-22	5.19e-19	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:24006305~24008258:-
LGG	cis	rs1065852	0.906	rs5751232	ENSG00000227370.1	RP4-669P10.19	10.11	6.92e-22	5.2e-19	0.49	0.42	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42132543~42132998:+
LGG	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	10.11	6.92e-22	5.2e-19	0.37	0.42	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
LGG	cis	rs507080	0.883	rs656575	ENSG00000278376.1	RP11-158I9.8	-10.11	6.93e-22	5.2e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118679199	chr11:118791254~118793137:+
LGG	cis	rs507080	0.961	rs656505	ENSG00000278376.1	RP11-158I9.8	-10.11	6.93e-22	5.2e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118679245	chr11:118791254~118793137:+
LGG	cis	rs507080	0.961	rs660489	ENSG00000278376.1	RP11-158I9.8	-10.11	6.93e-22	5.2e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118679255	chr11:118791254~118793137:+
LGG	cis	rs507080	0.961	rs543327	ENSG00000278376.1	RP11-158I9.8	-10.11	6.93e-22	5.2e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118679276	chr11:118791254~118793137:+
LGG	cis	rs507080	0.961	rs543413	ENSG00000278376.1	RP11-158I9.8	-10.11	6.93e-22	5.2e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118679308	chr11:118791254~118793137:+
LGG	cis	rs7811142	0.945	rs6974282	ENSG00000242294.5	STAG3L5P	10.11	6.93e-22	5.2e-19	0.3	0.42	Platelet count;	chr7:100500672	chr7:100336079~100351900:+
LGG	cis	rs853679	0.527	rs853693	ENSG00000280107.1	AL022393.9	-10.11	6.96e-22	5.22e-19	-0.44	-0.42	Depression;	chr6:28314871	chr6:28170845~28172521:+
LGG	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	10.11	6.99e-22	5.25e-19	0.3	0.42	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
LGG	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-10.11	7e-22	5.26e-19	-0.73	-0.42	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
LGG	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-10.11	7e-22	5.26e-19	-0.42	-0.42	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
LGG	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-10.11	7.03e-22	5.28e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
LGG	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	10.11	7.03e-22	5.28e-19	0.64	0.42	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
LGG	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	10.11	7.04e-22	5.28e-19	0.46	0.42	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	10.11	7.04e-22	5.28e-19	0.46	0.42	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	10.11	7.04e-22	5.28e-19	0.46	0.42	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	10.11	7.04e-22	5.28e-19	0.46	0.42	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
LGG	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	10.11	7.06e-22	5.3e-19	0.52	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
LGG	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-10.11	7.06e-22	5.3e-19	-0.58	-0.42	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
LGG	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	10.11	7.09e-22	5.32e-19	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
LGG	cis	rs6452524	0.868	rs10057303	ENSG00000248112.1	RP11-78C3.1	10.11	7.11e-22	5.34e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.868	rs2386235	ENSG00000248112.1	RP11-78C3.1	10.11	7.11e-22	5.34e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:82919376~82921119:-
LGG	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-10.1	7.19e-22	5.39e-19	-0.49	-0.42	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
LGG	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-10.1	7.19e-22	5.39e-19	-0.51	-0.42	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	10.1	7.34e-22	5.5e-19	0.5	0.42	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
LGG	cis	rs11838725	1	rs11838725	ENSG00000176268.5	CYCSP34	10.1	7.37e-22	5.52e-19	0.5	0.42	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40863599~40863902:-
LGG	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	10.1	7.45e-22	5.58e-19	0.48	0.42	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
LGG	cis	rs950776	0.518	rs28438420	ENSG00000261762.1	RP11-650L12.2	-10.1	7.48e-22	5.6e-19	-0.51	-0.42	Sudden cardiac arrest;	chr15:78543946	chr15:78589123~78591276:-
LGG	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	10.1	7.5e-22	5.62e-19	0.57	0.42	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
LGG	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	-10.1	7.52e-22	5.63e-19	-0.46	-0.42	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
LGG	cis	rs853679	0.527	rs707907	ENSG00000226314.6	ZNF192P1	10.1	7.57e-22	5.67e-19	0.43	0.42	Depression;	chr6:28323463	chr6:28161781~28169594:+
LGG	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-10.1	7.62e-22	5.7e-19	-0.44	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
LGG	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	10.1	7.62e-22	5.71e-19	0.46	0.42	Depression;	chr6:28086929	chr6:28115628~28116551:+
LGG	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	10.1	7.64e-22	5.72e-19	0.37	0.42	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
LGG	cis	rs7914558	1	rs7081075	ENSG00000272912.1	RP11-724N1.1	-10.1	7.65e-22	5.72e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs10786740	ENSG00000272912.1	RP11-724N1.1	-10.1	7.65e-22	5.72e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:102914585~102915404:+
LGG	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	10.1	7.68e-22	5.75e-19	0.5	0.42	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
LGG	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	10.1	7.68e-22	5.75e-19	0.5	0.42	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
LGG	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	10.1	7.68e-22	5.75e-19	0.5	0.42	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
LGG	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	10.1	7.7e-22	5.76e-19	0.45	0.42	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
LGG	cis	rs7914558	1	rs4917996	ENSG00000272912.1	RP11-724N1.1	-10.1	7.7e-22	5.76e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs6584540	ENSG00000272912.1	RP11-724N1.1	-10.1	7.7e-22	5.76e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:102914585~102915404:+
LGG	cis	rs6452524	0.868	rs62372714	ENSG00000248112.1	RP11-78C3.1	10.1	7.7e-22	5.76e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.868	rs17205699	ENSG00000248112.1	RP11-78C3.1	10.1	7.7e-22	5.76e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:82919376~82921119:-
LGG	cis	rs3742264	1	rs9534305	ENSG00000235903.6	CPB2-AS1	-10.09	7.8e-22	5.83e-19	-0.46	-0.42	Blood protein levels;	chr13:46068021	chr13:46052806~46113332:+
LGG	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
LGG	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-10.09	7.82e-22	5.84e-19	-0.58	-0.42	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	10.09	7.82e-22	5.84e-19	0.58	0.42	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
LGG	cis	rs6452524	0.806	rs10078084	ENSG00000248112.1	RP11-78C3.1	10.09	7.83e-22	5.85e-19	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.868	rs11750836	ENSG00000248112.1	RP11-78C3.1	10.09	7.83e-22	5.85e-19	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:82919376~82921119:-
LGG	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	10.09	7.91e-22	5.9e-19	0.53	0.42	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
LGG	cis	rs853679	0.599	rs149949	ENSG00000216901.1	AL022393.7	10.09	7.91e-22	5.91e-19	0.79	0.42	Depression;	chr6:28043738	chr6:28176188~28176674:+
LGG	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	10.09	7.95e-22	5.94e-19	0.49	0.42	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
LGG	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	10.09	7.96e-22	5.94e-19	0.47	0.42	Depression;	chr6:28167882	chr6:28115628~28116551:+
LGG	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-10.09	7.98e-22	5.96e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
LGG	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-10.09	8.06e-22	6.02e-19	-0.41	-0.42	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-10.09	8.06e-22	6.02e-19	-0.41	-0.42	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-10.09	8.06e-22	6.02e-19	-0.41	-0.42	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
LGG	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	10.09	8.09e-22	6.04e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
LGG	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-10.09	8.09e-22	6.04e-19	-0.4	-0.42	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
LGG	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-10.09	8.12e-22	6.06e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
LGG	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	10.09	8.12e-22	6.06e-19	0.49	0.42	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
LGG	cis	rs9322193	0.884	rs7769115	ENSG00000216621.7	RP11-244K5.6	10.09	8.17e-22	6.1e-19	0.5	0.42	Lung cancer;	chr6:149848796	chr6:149934527~149936782:+
LGG	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	10.09	8.17e-22	6.1e-19	0.3	0.42	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
LGG	cis	rs7085104	0.591	rs4919683	ENSG00000272912.1	RP11-724N1.1	-10.09	8.18e-22	6.11e-19	-0.46	-0.42	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102914585~102915404:+
LGG	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-10.09	8.18e-22	6.11e-19	-0.42	-0.42	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
LGG	cis	rs7119038	0.818	rs715412	ENSG00000255239.1	AP002954.6	-10.09	8.19e-22	6.11e-19	-0.59	-0.42	Sjögren's syndrome;	chr11:118813901	chr11:118688039~118690600:-
LGG	cis	rs7267979	0.933	rs2258728	ENSG00000125804.12	FAM182A	-10.09	8.22e-22	6.13e-19	-0.51	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:26054655~26086917:+
LGG	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-10.09	8.22e-22	6.13e-19	-0.44	-0.42	Depression;	chr6:28193021	chr6:28115628~28116551:+
LGG	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-10.09	8.22e-22	6.13e-19	-0.44	-0.42	Depression;	chr6:28197321	chr6:28115628~28116551:+
LGG	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-10.09	8.22e-22	6.13e-19	-0.44	-0.42	Depression;	chr6:28197412	chr6:28115628~28116551:+
LGG	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-10.09	8.22e-22	6.13e-19	-0.44	-0.42	Depression;	chr6:28198669	chr6:28115628~28116551:+
LGG	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-10.09	8.22e-22	6.13e-19	-0.44	-0.42	Depression;	chr6:28205175	chr6:28115628~28116551:+
LGG	cis	rs9322193	0.884	rs9397036	ENSG00000216621.7	RP11-244K5.6	10.09	8.23e-22	6.14e-19	0.5	0.42	Lung cancer;	chr6:149851787	chr6:149934527~149936782:+
LGG	cis	rs507080	0.922	rs642662	ENSG00000278376.1	RP11-158I9.8	-10.09	8.25e-22	6.15e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118696311	chr11:118791254~118793137:+
LGG	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-10.09	8.27e-22	6.17e-19	-0.55	-0.42	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
LGG	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-10.09	8.28e-22	6.17e-19	-0.39	-0.42	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
LGG	cis	rs56114371	0.53	rs9357045	ENSG00000199851.2	U3	10.09	8.36e-22	6.24e-19	0.67	0.42	Breast cancer;	chr6:27721148	chr6:28015568~28015777:+
LGG	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-10.09	8.37e-22	6.24e-19	-0.43	-0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
LGG	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-10.09	8.38e-22	6.24e-19	-0.57	-0.42	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-10.09	8.38e-22	6.24e-19	-0.57	-0.42	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
LGG	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-10.09	8.38e-22	6.25e-19	-0.42	-0.42	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-10.09	8.38e-22	6.25e-19	-0.42	-0.42	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-10.09	8.38e-22	6.25e-19	-0.42	-0.42	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-10.09	8.38e-22	6.25e-19	-0.42	-0.42	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
LGG	cis	rs12935418	0.616	rs1127390	ENSG00000260213.4	RP11-303E16.3	-10.09	8.39e-22	6.25e-19	-0.51	-0.42	Mean corpuscular volume;	chr16:80976176	chr16:81016792~81035759:-
LGG	cis	rs7119038	0.818	rs11217032	ENSG00000255239.1	AP002954.6	-10.09	8.39e-22	6.25e-19	-0.58	-0.42	Sjögren's syndrome;	chr11:118798896	chr11:118688039~118690600:-
LGG	cis	rs7829975	0.626	rs332040	ENSG00000173295.6	FAM86B3P	-10.09	8.43e-22	6.28e-19	-0.45	-0.42	Mood instability;	chr8:8872978	chr8:8228595~8244865:+
LGG	cis	rs507080	0.961	rs600969	ENSG00000278376.1	RP11-158I9.8	-10.08	8.47e-22	6.31e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118675087	chr11:118791254~118793137:+
LGG	cis	rs507080	0.961	rs673770	ENSG00000278376.1	RP11-158I9.8	-10.08	8.47e-22	6.31e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118679892	chr11:118791254~118793137:+
LGG	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	10.08	8.48e-22	6.32e-19	0.49	0.42	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
LGG	cis	rs12935418	0.523	rs2549840	ENSG00000260213.4	RP11-303E16.3	10.08	8.53e-22	6.35e-19	0.51	0.42	Mean corpuscular volume;	chr16:80989817	chr16:81016792~81035759:-
LGG	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-10.08	8.53e-22	6.36e-19	-0.47	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
LGG	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-10.08	8.54e-22	6.37e-19	-0.53	-0.42	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
LGG	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	10.08	8.61e-22	6.41e-19	0.53	0.42	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
LGG	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-10.08	8.63e-22	6.43e-19	-0.45	-0.42	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
LGG	cis	rs8064024	0.604	rs1049212	ENSG00000267077.1	RP11-127I20.5	-10.08	8.73e-22	6.5e-19	-0.43	-0.42	Cancer;	chr16:4882928	chr16:4795265~4796532:-
LGG	cis	rs172166	0.543	rs1150691	ENSG00000218016.2	ZNF192P2	-10.08	8.73e-22	6.5e-19	-0.5	-0.42	Cardiac Troponin-T levels;	chr6:28200255	chr6:28188050~28189432:+
LGG	cis	rs5742933	0.597	rs12471663	ENSG00000253559.1	OSGEPL1-AS1	10.08	8.74e-22	6.5e-19	0.53	0.42	Ferritin levels;	chr2:189642372	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.597	rs6761923	ENSG00000253559.1	OSGEPL1-AS1	10.08	8.74e-22	6.5e-19	0.53	0.42	Ferritin levels;	chr2:189642873	chr2:189762704~189765556:+
LGG	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-10.08	8.74e-22	6.51e-19	-0.57	-0.42	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
LGG	cis	rs7267979	0.966	rs2261747	ENSG00000276952.1	RP5-965G21.6	10.08	8.75e-22	6.51e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25284915~25285588:-
LGG	cis	rs741668	0.931	rs2806926	ENSG00000235903.6	CPB2-AS1	10.08	8.76e-22	6.52e-19	0.46	0.42	Cerebrospinal fluid clusterin levels;	chr13:45947532	chr13:46052806~46113332:+
LGG	cis	rs7267979	0.714	rs6132825	ENSG00000125804.12	FAM182A	-10.08	8.76e-22	6.52e-19	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:26054655~26086917:+
LGG	cis	rs7181230	0.885	rs8026641	ENSG00000275636.1	RP11-521C20.5	-10.08	8.94e-22	6.65e-19	-0.47	-0.42	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40078892~40079347:+
LGG	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-10.08	8.96e-22	6.66e-19	-0.71	-0.42	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
LGG	cis	rs7927771	0.8	rs35996350	ENSG00000280615.1	Y_RNA	-10.08	8.98e-22	6.68e-19	-0.52	-0.42	Subjective well-being;	chr11:47367672	chr11:47614898~47614994:-
LGG	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-10.08	9.08e-22	6.75e-19	-0.59	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
LGG	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-10.08	9.11e-22	6.77e-19	-0.56	-0.42	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
LGG	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-10.08	9.11e-22	6.78e-19	-0.53	-0.42	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
LGG	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-10.08	9.16e-22	6.81e-19	-0.58	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
LGG	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	10.08	9.17e-22	6.82e-19	0.49	0.42	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	10.08	9.17e-22	6.82e-19	0.49	0.42	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	10.08	9.17e-22	6.82e-19	0.49	0.42	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.932	rs6107052	ENSG00000276952.1	RP5-965G21.6	10.08	9.2e-22	6.84e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25284915~25285588:-
LGG	cis	rs571497	0.697	rs62128260	ENSG00000268297.1	CLEC4GP1	10.07	9.23e-22	6.86e-19	0.6	0.42	Monocyte count;	chr19:7768990	chr19:7787549~7790621:+
LGG	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-10.07	9.31e-22	6.92e-19	-0.37	-0.42	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-10.07	9.31e-22	6.92e-19	-0.37	-0.42	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
LGG	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	10.07	9.31e-22	6.92e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
LGG	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-10.07	9.32e-22	6.93e-19	-0.52	-0.42	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
LGG	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-10.07	9.32e-22	6.93e-19	-0.52	-0.42	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
LGG	cis	rs7914558	1	rs3740387	ENSG00000272912.1	RP11-724N1.1	-10.07	9.35e-22	6.95e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102914585~102915404:+
LGG	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-10.07	9.45e-22	7.02e-19	-0.58	-0.42	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
LGG	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-10.07	9.45e-22	7.02e-19	-0.58	-0.42	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
LGG	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-10.07	9.48e-22	7.04e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
LGG	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	10.07	9.53e-22	7.08e-19	0.56	0.42	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
LGG	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-10.07	9.56e-22	7.1e-19	-0.47	-0.42	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
LGG	cis	rs7246657	0.722	rs2972438	ENSG00000267422.1	CTD-2554C21.1	-10.07	9.57e-22	7.11e-19	-0.53	-0.42	Coronary artery calcification;	chr19:37719946	chr19:37779686~37792865:+
LGG	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-10.07	9.58e-22	7.11e-19	-0.42	-0.42	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
LGG	cis	rs7267979	1	rs4815420	ENSG00000125804.12	FAM182A	10.07	9.58e-22	7.11e-19	0.5	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:26054655~26086917:+
LGG	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	10.07	9.6e-22	7.12e-19	0.37	0.42	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	10.07	9.6e-22	7.12e-19	0.37	0.42	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
LGG	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-10.07	9.66e-22	7.17e-19	-0.48	-0.42	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
LGG	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-10.07	9.68e-22	7.18e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
LGG	cis	rs7267979	0.868	rs6138550	ENSG00000276952.1	RP5-965G21.6	10.07	9.68e-22	7.18e-19	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.903	rs6050481	ENSG00000276952.1	RP5-965G21.6	10.07	9.68e-22	7.18e-19	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.834	rs6115100	ENSG00000276952.1	RP5-965G21.6	10.07	9.68e-22	7.18e-19	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25284915~25285588:-
LGG	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	10.07	9.72e-22	7.21e-19	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
LGG	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-10.07	9.73e-22	7.22e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
LGG	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	10.07	9.85e-22	7.31e-19	0.46	0.42	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
LGG	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-10.07	9.86e-22	7.31e-19	-0.5	-0.42	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
LGG	cis	rs11148252	0.553	rs9536219	ENSG00000273784.3	RP11-78J21.7	-10.07	9.88e-22	7.33e-19	-0.47	-0.42	Lewy body disease;	chr13:52653166	chr13:52600042~52642542:+
LGG	cis	rs12935418	0.616	rs874053	ENSG00000260213.4	RP11-303E16.3	-10.07	9.91e-22	7.35e-19	-0.51	-0.42	Mean corpuscular volume;	chr16:80972210	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.616	rs874054	ENSG00000260213.4	RP11-303E16.3	-10.07	9.91e-22	7.35e-19	-0.51	-0.42	Mean corpuscular volume;	chr16:80972245	chr16:81016792~81035759:-
LGG	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	10.07	9.92e-22	7.36e-19	0.37	0.42	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
LGG	cis	rs17772222	0.958	rs2297128	ENSG00000222990.1	RNU4-22P	10.07	9.97e-22	7.39e-19	0.54	0.42	Coronary artery calcification;	chr14:88469910	chr14:88513498~88513663:+
LGG	cis	rs7267979	0.903	rs6050482	ENSG00000276952.1	RP5-965G21.6	10.07	9.97e-22	7.39e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.706	rs6037069	ENSG00000276952.1	RP5-965G21.6	10.07	9.97e-22	7.39e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25284915~25285588:-
LGG	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-10.07	9.99e-22	7.41e-19	-0.4	-0.42	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
LGG	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	10.07	1e-21	7.41e-19	0.49	0.42	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
LGG	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	10.06	1e-21	7.44e-19	0.52	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
LGG	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-10.06	1e-21	7.44e-19	-0.52	-0.42	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
LGG	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-10.06	1.01e-21	7.47e-19	-0.37	-0.42	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-10.06	1.01e-21	7.47e-19	-0.37	-0.42	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-10.06	1.01e-21	7.47e-19	-0.37	-0.42	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	10.06	1.01e-21	7.47e-19	0.37	0.42	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
LGG	cis	rs3812049	1	rs3812049	ENSG00000245937.6	LINC01184	10.06	1.01e-21	7.47e-19	0.49	0.42	Lymphocyte counts;Red cell distribution width;	chr5:128083158	chr5:127940426~128083172:-
LGG	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	10.06	1.01e-21	7.51e-19	0.42	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
LGG	cis	rs5758511	0.514	rs5758626	ENSG00000227370.1	RP4-669P10.19	10.06	1.02e-21	7.52e-19	0.48	0.42	Birth weight;	chr22:42176357	chr22:42132543~42132998:+
LGG	cis	rs1065852	0.861	rs5758627	ENSG00000227370.1	RP4-669P10.19	10.06	1.02e-21	7.52e-19	0.48	0.42	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42132543~42132998:+
LGG	cis	rs8064024	0.513	rs1049207	ENSG00000267077.1	RP11-127I20.5	-10.06	1.02e-21	7.54e-19	-0.43	-0.42	Cancer;	chr16:4884563	chr16:4795265~4796532:-
LGG	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-10.06	1.02e-21	7.54e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
LGG	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	10.06	1.02e-21	7.55e-19	0.37	0.42	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	10.06	1.02e-21	7.55e-19	0.37	0.42	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	10.06	1.02e-21	7.55e-19	0.37	0.42	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	10.06	1.02e-21	7.55e-19	0.37	0.42	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
LGG	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-10.06	1.02e-21	7.56e-19	-0.58	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
LGG	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-10.06	1.02e-21	7.56e-19	-0.58	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
LGG	cis	rs7811142	0.945	rs6978739	ENSG00000242294.5	STAG3L5P	10.06	1.03e-21	7.63e-19	0.3	0.42	Platelet count;	chr7:100501057	chr7:100336079~100351900:+
LGG	cis	rs7615952	0.543	rs4645102	ENSG00000242001.1	GS1-388B5.1	10.06	1.04e-21	7.66e-19	0.55	0.42	Blood pressure (smoking interaction);	chr3:125705597	chr3:125681305~125681453:+
LGG	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-10.06	1.04e-21	7.66e-19	-0.53	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
LGG	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	10.06	1.04e-21	7.67e-19	0.52	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
LGG	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-10.06	1.05e-21	7.76e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
LGG	cis	rs12946454	0.521	rs66827053	ENSG00000267288.2	RP13-890H12.2	-10.06	1.05e-21	7.78e-19	-0.57	-0.42	Systolic blood pressure;	chr17:45173286	chr17:45168800~45171584:-
LGG	cis	rs7267979	1	rs453329	ENSG00000276952.1	RP5-965G21.6	10.06	1.05e-21	7.8e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs910996	ENSG00000276952.1	RP5-965G21.6	10.06	1.05e-21	7.8e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25284915~25285588:-
LGG	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-10.06	1.05e-21	7.8e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
LGG	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-10.06	1.05e-21	7.8e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
LGG	cis	rs7267979	1	rs6083828	ENSG00000276952.1	RP5-965G21.6	-10.06	1.06e-21	7.83e-19	-0.41	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25284915~25285588:-
LGG	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	10.06	1.06e-21	7.87e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
LGG	cis	rs7432375	1	rs940174	ENSG00000261758.1	RP11-102M11.2	10.06	1.07e-21	7.88e-19	0.44	0.42	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136590868	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.903	rs711975	ENSG00000261758.1	RP11-102M11.2	10.06	1.07e-21	7.91e-19	0.44	0.42	Gestational age at birth (child effect);	chr3:136517066	chr3:136752630~136755780:+
LGG	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-10.06	1.07e-21	7.92e-19	-0.52	-0.42	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
LGG	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-10.06	1.07e-21	7.94e-19	-0.37	-0.42	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
LGG	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	10.06	1.08e-21	7.98e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
LGG	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-10.06	1.08e-21	8.01e-19	-0.49	-0.42	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
LGG	cis	rs879620	0.89	rs2601781	ENSG00000262888.1	RP11-462G12.2	-10.05	1.09e-21	8.08e-19	-0.57	-0.42	Hip circumference;Body mass index;	chr16:3967391	chr16:3931217~3946305:-
LGG	cis	rs6903823	0.508	rs1778484	ENSG00000280107.1	AL022393.9	-10.05	1.1e-21	8.11e-19	-0.43	-0.42	Pulmonary function;	chr6:28273021	chr6:28170845~28172521:+
LGG	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	10.05	1.1e-21	8.11e-19	0.46	0.42	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
LGG	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-10.05	1.1e-21	8.12e-19	-0.42	-0.42	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-10.05	1.1e-21	8.12e-19	-0.42	-0.42	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
LGG	cis	rs7267979	1	rs7020	ENSG00000276952.1	RP5-965G21.6	10.05	1.1e-21	8.12e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25284915~25285588:-
LGG	cis	rs6452524	0.868	rs11746977	ENSG00000248112.1	RP11-78C3.1	10.05	1.1e-21	8.13e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:82919376~82921119:-
LGG	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	-10.05	1.1e-21	8.13e-19	-0.46	-0.42	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
LGG	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-10.05	1.1e-21	8.15e-19	-0.34	-0.42	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
LGG	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	10.05	1.12e-21	8.24e-19	0.43	0.42	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
LGG	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-10.05	1.13e-21	8.37e-19	-0.37	-0.42	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
LGG	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	10.05	1.13e-21	8.38e-19	0.52	0.42	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
LGG	cis	rs9876781	1	rs9876781	ENSG00000244380.1	RP11-24C3.2	10.05	1.14e-21	8.4e-19	0.51	0.42	Longevity;	chr3:48445934	chr3:48440352~48446656:-
LGG	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-10.05	1.14e-21	8.43e-19	-0.41	-0.42	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
LGG	cis	rs12935418	0.616	rs2549828	ENSG00000260213.4	RP11-303E16.3	10.05	1.14e-21	8.44e-19	0.51	0.42	Mean corpuscular volume;	chr16:80985378	chr16:81016792~81035759:-
LGG	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	10.05	1.15e-21	8.48e-19	0.44	0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
LGG	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	10.05	1.15e-21	8.5e-19	0.49	0.42	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
LGG	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-10.05	1.15e-21	8.5e-19	-0.78	-0.42	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
LGG	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-10.05	1.15e-21	8.51e-19	-0.53	-0.42	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
LGG	cis	rs17772222	0.727	rs3179969	ENSG00000258983.2	RP11-507K2.2	10.05	1.16e-21	8.53e-19	0.47	0.42	Coronary artery calcification;	chr14:88396185	chr14:88499334~88515502:+
LGG	cis	rs7188445	0.736	rs4889012	ENSG00000261390.4	RP11-345M22.2	10.05	1.16e-21	8.53e-19	0.45	0.42	Urate levels;	chr16:79667485	chr16:79715232~79770563:-
LGG	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-10.05	1.16e-21	8.57e-19	-0.33	-0.42	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
LGG	cis	rs3742264	0.961	rs11620307	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46075586	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.961	rs11620308	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46075588	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs9534311	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46075986	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs9534313	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46076411	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs17844052	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46076653	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.848	rs9567615	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46076945	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.848	rs9567616	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46076956	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.848	rs9567617	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46076973	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.922	rs4942473	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46077173	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.961	rs4942474	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46077209	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.922	rs4942475	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46077386	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.922	rs4942477	ENSG00000235903.6	CPB2-AS1	-10.05	1.17e-21	8.61e-19	-0.46	-0.42	Blood protein levels;	chr13:46077628	chr13:46052806~46113332:+
LGG	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	10.05	1.17e-21	8.61e-19	0.51	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
LGG	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	10.05	1.17e-21	8.62e-19	0.86	0.42	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
LGG	cis	rs7267979	1	rs8125868	ENSG00000276952.1	RP5-965G21.6	-10.05	1.17e-21	8.65e-19	-0.41	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs7267979	ENSG00000276952.1	RP5-965G21.6	10.05	1.18e-21	8.7e-19	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25284915~25285588:-
LGG	cis	rs507080	0.883	rs558593	ENSG00000278376.1	RP11-158I9.8	-10.05	1.18e-21	8.73e-19	-0.37	-0.42	Serum metabolite levels;	chr11:118691811	chr11:118791254~118793137:+
LGG	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-10.04	1.19e-21	8.74e-19	-0.55	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
LGG	cis	rs9322193	0.887	rs11155662	ENSG00000223701.3	RAET1E-AS1	10.04	1.19e-21	8.77e-19	0.53	0.42	Lung cancer;	chr6:149592731	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs9383864	ENSG00000216621.7	RP11-244K5.6	10.04	1.19e-21	8.77e-19	0.5	0.42	Lung cancer;	chr6:149851969	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.884	rs9383865	ENSG00000216621.7	RP11-244K5.6	10.04	1.19e-21	8.77e-19	0.5	0.42	Lung cancer;	chr6:149852043	chr6:149934527~149936782:+
LGG	cis	rs6452524	0.836	rs62372713	ENSG00000248112.1	RP11-78C3.1	10.04	1.19e-21	8.78e-19	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:82919376~82921119:-
LGG	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-10.04	1.2e-21	8.83e-19	-0.54	-0.42	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
LGG	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	10.04	1.2e-21	8.87e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
LGG	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-10.04	1.21e-21	8.91e-19	-0.56	-0.42	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
LGG	cis	rs7267979	1	rs11087520	ENSG00000276952.1	RP5-965G21.6	10.04	1.21e-21	8.92e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs397119	ENSG00000276952.1	RP5-965G21.6	10.04	1.21e-21	8.92e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-10.04	1.21e-21	8.95e-19	-0.42	-0.42	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
LGG	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	10.04	1.22e-21	8.96e-19	0.37	0.42	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
LGG	cis	rs7267979	0.932	rs2387891	ENSG00000276952.1	RP5-965G21.6	10.04	1.22e-21	8.99e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25284915~25285588:-
LGG	cis	rs651907	0.557	rs62284199	ENSG00000256628.3	ZBTB11-AS1	10.04	1.22e-21	9e-19	0.48	0.42	Colorectal cancer;	chr3:101759687	chr3:101676475~101679217:+
LGG	cis	rs651907	0.557	rs34376498	ENSG00000256628.3	ZBTB11-AS1	10.04	1.22e-21	9e-19	0.48	0.42	Colorectal cancer;	chr3:101761312	chr3:101676475~101679217:+
LGG	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-10.04	1.22e-21	9e-19	-0.47	-0.42	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
LGG	cis	rs7267979	1	rs398036	ENSG00000276952.1	RP5-965G21.6	10.04	1.22e-21	9.02e-19	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25284915~25285588:-
LGG	cis	rs11168351	0.927	rs11168342	ENSG00000258273.1	RP11-370I10.4	-10.04	1.23e-21	9.06e-19	-0.52	-0.42	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48333755~48333901:-
LGG	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-10.04	1.23e-21	9.06e-19	-0.49	-0.42	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
LGG	cis	rs12935418	0.616	rs2549858	ENSG00000260213.4	RP11-303E16.3	10.04	1.24e-21	9.15e-19	0.51	0.42	Mean corpuscular volume;	chr16:80993389	chr16:81016792~81035759:-
LGG	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-10.04	1.24e-21	9.15e-19	-0.51	-0.42	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
LGG	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-10.04	1.24e-21	9.15e-19	-0.51	-0.42	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
LGG	cis	rs12935418	0.579	rs1477381	ENSG00000260213.4	RP11-303E16.3	10.04	1.25e-21	9.19e-19	0.51	0.42	Mean corpuscular volume;	chr16:80981095	chr16:81016792~81035759:-
LGG	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	10.04	1.25e-21	9.21e-19	0.44	0.42	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
LGG	cis	rs7119038	0.818	rs11217040	ENSG00000255239.1	AP002954.6	-10.04	1.26e-21	9.29e-19	-0.58	-0.42	Sjögren's syndrome;	chr11:118809939	chr11:118688039~118690600:-
LGG	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-10.04	1.26e-21	9.29e-19	-0.47	-0.42	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
LGG	cis	rs7119038	0.774	rs73005423	ENSG00000255239.1	AP002954.6	-10.04	1.27e-21	9.32e-19	-0.59	-0.42	Sjögren's syndrome;	chr11:118810370	chr11:118688039~118690600:-
LGG	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-10.04	1.27e-21	9.33e-19	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
LGG	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-10.04	1.27e-21	9.34e-19	-0.47	-0.42	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
LGG	cis	rs4713118	0.869	rs6922574	ENSG00000216901.1	AL022393.7	10.04	1.28e-21	9.41e-19	0.55	0.42	Parkinson's disease;	chr6:27725224	chr6:28176188~28176674:+
LGG	cis	rs853679	0.599	rs149943	ENSG00000199851.2	U3	10.04	1.28e-21	9.41e-19	0.88	0.42	Depression;	chr6:28034610	chr6:28015568~28015777:+
LGG	cis	rs7914558	0.901	rs35525740	ENSG00000272912.1	RP11-724N1.1	-10.04	1.28e-21	9.41e-19	-0.47	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:102914585~102915404:+
LGG	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-10.04	1.28e-21	9.43e-19	-0.71	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
LGG	cis	rs7927771	0.832	rs11605672	ENSG00000280615.1	Y_RNA	-10.04	1.28e-21	9.43e-19	-0.53	-0.42	Subjective well-being;	chr11:47392182	chr11:47614898~47614994:-
LGG	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-10.04	1.28e-21	9.45e-19	-0.58	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
LGG	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-10.03	1.29e-21	9.48e-19	-0.48	-0.42	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
LGG	cis	rs507080	0.733	rs497678	ENSG00000278376.1	RP11-158I9.8	-10.03	1.29e-21	9.49e-19	-0.38	-0.42	Serum metabolite levels;	chr11:118697172	chr11:118791254~118793137:+
LGG	cis	rs12935418	0.583	rs2549856	ENSG00000260213.4	RP11-303E16.3	10.03	1.29e-21	9.49e-19	0.51	0.42	Mean corpuscular volume;	chr16:80993322	chr16:81016792~81035759:-
LGG	cis	rs17772222	0.655	rs7160717	ENSG00000258983.2	RP11-507K2.2	10.03	1.29e-21	9.5e-19	0.47	0.42	Coronary artery calcification;	chr14:88498232	chr14:88499334~88515502:+
LGG	cis	rs11148252	0.595	rs4885117	ENSG00000273784.3	RP11-78J21.7	-10.03	1.29e-21	9.52e-19	-0.47	-0.42	Lewy body disease;	chr13:52578892	chr13:52600042~52642542:+
LGG	cis	rs7267979	0.903	rs2474766	ENSG00000276952.1	RP5-965G21.6	10.03	1.29e-21	9.52e-19	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25284915~25285588:-
LGG	cis	rs3742264	1	rs9534307	ENSG00000235903.6	CPB2-AS1	-10.03	1.3e-21	9.55e-19	-0.46	-0.42	Blood protein levels;	chr13:46069995	chr13:46052806~46113332:+
LGG	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	10.03	1.3e-21	9.59e-19	0.39	0.42	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
LGG	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	10.03	1.3e-21	9.59e-19	0.39	0.42	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
LGG	cis	rs853679	1	rs853676	ENSG00000199851.2	U3	10.03	1.32e-21	9.69e-19	0.79	0.42	Depression;	chr6:28331910	chr6:28015568~28015777:+
LGG	cis	rs5758511	0.514	rs5758622	ENSG00000227370.1	RP4-669P10.19	10.03	1.33e-21	9.79e-19	0.48	0.42	Birth weight;	chr22:42167927	chr22:42132543~42132998:+
LGG	cis	rs5758511	0.514	rs9607882	ENSG00000227370.1	RP4-669P10.19	10.03	1.33e-21	9.79e-19	0.48	0.42	Birth weight;	chr22:42171445	chr22:42132543~42132998:+
LGG	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-10.03	1.33e-21	9.8e-19	-0.55	-0.42	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
LGG	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-10.03	1.33e-21	9.8e-19	-0.55	-0.42	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
LGG	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	10.03	1.34e-21	9.88e-19	0.48	0.42	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
LGG	cis	rs1153858	1	rs11852800	ENSG00000259433.2	CTD-2651B20.4	10.03	1.35e-21	9.91e-19	0.48	0.42	Homoarginine levels;	chr15:45346933	chr15:45330209~45332634:-
LGG	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	10.03	1.36e-21	9.98e-19	0.5	0.42	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
LGG	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	10.03	1.36e-21	1e-18	0.55	0.42	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
LGG	cis	rs4713118	0.869	rs9348775	ENSG00000216901.1	AL022393.7	10.03	1.36e-21	1e-18	0.55	0.42	Parkinson's disease;	chr6:27727550	chr6:28176188~28176674:+
LGG	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	10.03	1.37e-21	1e-18	0.47	0.42	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	10.03	1.37e-21	1.01e-18	0.47	0.42	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
LGG	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-10.03	1.37e-21	1.01e-18	-0.56	-0.42	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
LGG	cis	rs4713118	1	rs1139226	ENSG00000199851.2	U3	10.03	1.38e-21	1.01e-18	0.61	0.42	Parkinson's disease;	chr6:27707511	chr6:28015568~28015777:+
LGG	cis	rs4713118	1	rs9468195	ENSG00000199851.2	U3	10.03	1.38e-21	1.01e-18	0.61	0.42	Parkinson's disease;	chr6:27708530	chr6:28015568~28015777:+
LGG	cis	rs11148252	0.574	rs61958118	ENSG00000273784.3	RP11-78J21.7	-10.03	1.38e-21	1.01e-18	-0.47	-0.42	Lewy body disease;	chr13:52596091	chr13:52600042~52642542:+
LGG	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-10.03	1.38e-21	1.01e-18	-0.42	-0.42	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-10.03	1.38e-21	1.01e-18	-0.42	-0.42	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
LGG	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-10.03	1.38e-21	1.01e-18	-0.42	-0.42	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
LGG	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-10.03	1.39e-21	1.02e-18	-0.41	-0.42	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
LGG	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-10.03	1.39e-21	1.02e-18	-0.41	-0.42	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
LGG	cis	rs357618	0.581	rs14160	ENSG00000260581.1	CTB-113P19.4	10.03	1.39e-21	1.02e-18	0.5	0.42	Basophil percentage of white cells;	chr5:151491719	chr5:151652275~151655449:+
LGG	cis	rs357618	0.581	rs165328	ENSG00000260581.1	CTB-113P19.4	10.03	1.39e-21	1.02e-18	0.5	0.42	Basophil percentage of white cells;	chr5:151494210	chr5:151652275~151655449:+
LGG	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-10.03	1.4e-21	1.02e-18	-0.38	-0.42	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-10.03	1.4e-21	1.02e-18	-0.38	-0.42	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
LGG	cis	rs2980439	0.517	rs17594093	ENSG00000253893.2	FAM85B	10.03	1.4e-21	1.02e-18	0.55	0.42	Neuroticism;	chr8:8248884	chr8:8167819~8226614:-
LGG	cis	rs7267979	1	rs6076339	ENSG00000276952.1	RP5-965G21.6	-10.03	1.4e-21	1.03e-18	-0.41	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6107033	ENSG00000276952.1	RP5-965G21.6	-10.03	1.4e-21	1.03e-18	-0.41	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25284915~25285588:-
LGG	cis	rs4819052	0.851	rs2256000	ENSG00000215447.6	BX322557.10	-10.02	1.41e-21	1.04e-18	-0.32	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45288052~45291738:+
LGG	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-10.02	1.41e-21	1.04e-18	-0.56	-0.42	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
LGG	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	10.02	1.42e-21	1.04e-18	0.37	0.42	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
LGG	cis	rs9388451	0.839	rs3757217	ENSG00000237742.5	RP11-624M8.1	-10.02	1.42e-21	1.04e-18	-0.37	-0.42	Brugada syndrome;	chr6:125748490	chr6:125578558~125749190:-
LGG	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	10.02	1.43e-21	1.05e-18	0.85	0.42	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
LGG	cis	rs1560104	0.665	rs4381587	ENSG00000274834.1	CTD-3037G24.5	-10.02	1.44e-21	1.06e-18	-0.53	-0.42	Obesity-related traits;	chr16:12609047	chr16:12614451~12614852:+
LGG	cis	rs2283792	0.567	rs2027789	ENSG00000228050.1	TOP3BP1	10.02	1.44e-21	1.06e-18	0.49	0.42	Multiple sclerosis;	chr22:21933490	chr22:22223187~22224566:-
LGG	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	10.02	1.44e-21	1.06e-18	0.41	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
LGG	cis	rs7927771	0.832	rs11601173	ENSG00000280615.1	Y_RNA	-10.02	1.44e-21	1.06e-18	-0.53	-0.42	Subjective well-being;	chr11:47379507	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.832	rs11607981	ENSG00000280615.1	Y_RNA	-10.02	1.44e-21	1.06e-18	-0.53	-0.42	Subjective well-being;	chr11:47379509	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.832	rs11601603	ENSG00000280615.1	Y_RNA	-10.02	1.44e-21	1.06e-18	-0.53	-0.42	Subjective well-being;	chr11:47379620	chr11:47614898~47614994:-
LGG	cis	rs7302981	0.967	rs7297421	ENSG00000272368.2	RP4-605O3.4	-10.02	1.45e-21	1.06e-18	-0.41	-0.42	Systolic blood pressure;	chr12:50125143	chr12:50112197~50165618:+
LGG	cis	rs12935418	0.583	rs2549841	ENSG00000260213.4	RP11-303E16.3	10.02	1.45e-21	1.06e-18	0.5	0.42	Mean corpuscular volume;	chr16:80989967	chr16:81016792~81035759:-
LGG	cis	rs7829975	0.684	rs474892	ENSG00000173295.6	FAM86B3P	10.02	1.45e-21	1.06e-18	0.44	0.42	Mood instability;	chr8:8739221	chr8:8228595~8244865:+
LGG	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	10.02	1.45e-21	1.06e-18	0.49	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
LGG	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-10.02	1.45e-21	1.06e-18	-0.48	-0.42	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
LGG	cis	rs7927771	0.689	rs10734557	ENSG00000280615.1	Y_RNA	10.02	1.45e-21	1.06e-18	0.53	0.42	Subjective well-being;	chr11:47358510	chr11:47614898~47614994:-
LGG	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	10.02	1.46e-21	1.07e-18	0.48	0.42	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
LGG	cis	rs7302981	0.934	rs7279	ENSG00000272368.2	RP4-605O3.4	-10.02	1.47e-21	1.07e-18	-0.41	-0.42	Systolic blood pressure;	chr12:50130164	chr12:50112197~50165618:+
LGG	cis	rs7302981	0.934	rs7532	ENSG00000272368.2	RP4-605O3.4	-10.02	1.47e-21	1.07e-18	-0.41	-0.42	Systolic blood pressure;	chr12:50130181	chr12:50112197~50165618:+
LGG	cis	rs3742264	1	rs9567614	ENSG00000235903.6	CPB2-AS1	-10.02	1.47e-21	1.08e-18	-0.46	-0.42	Blood protein levels;	chr13:46075318	chr13:46052806~46113332:+
LGG	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-10.02	1.47e-21	1.08e-18	-0.51	-0.42	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
LGG	cis	rs7267979	0.903	rs2474769	ENSG00000276952.1	RP5-965G21.6	10.02	1.47e-21	1.08e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25284915~25285588:-
LGG	cis	rs7432375	0.933	rs55970317	ENSG00000261758.1	RP11-102M11.2	10.02	1.48e-21	1.08e-18	0.44	0.42	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136634351	chr3:136752630~136755780:+
LGG	cis	rs7914558	1	rs7067970	ENSG00000272912.1	RP11-724N1.1	-10.02	1.48e-21	1.08e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102914585~102915404:+
LGG	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-10.02	1.49e-21	1.09e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
LGG	cis	rs7914558	1	rs1926030	ENSG00000272912.1	RP11-724N1.1	-10.02	1.49e-21	1.09e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102914585~102915404:+
LGG	cis	rs7267979	0.932	rs928121	ENSG00000276952.1	RP5-965G21.6	10.02	1.49e-21	1.09e-18	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2387881	ENSG00000276952.1	RP5-965G21.6	-10.02	1.5e-21	1.09e-18	-0.41	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25284915~25285588:-
LGG	cis	rs5742933	0.557	rs6756571	ENSG00000253559.1	OSGEPL1-AS1	10.02	1.5e-21	1.09e-18	0.53	0.42	Ferritin levels;	chr2:189640971	chr2:189762704~189765556:+
LGG	cis	rs9527	0.615	rs12248123	ENSG00000272912.1	RP11-724N1.1	-10.02	1.5e-21	1.09e-18	-0.47	-0.42	Arsenic metabolism;	chr10:102975609	chr10:102914585~102915404:+
LGG	cis	rs7119038	0.731	rs28409215	ENSG00000255239.1	AP002954.6	-10.02	1.5e-21	1.1e-18	-0.58	-0.42	Sjögren's syndrome;	chr11:118808595	chr11:118688039~118690600:-
LGG	cis	rs507080	0.961	rs34413584	ENSG00000278376.1	RP11-158I9.8	-10.02	1.5e-21	1.1e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118675072	chr11:118791254~118793137:+
LGG	cis	rs6452524	0.935	rs2731846	ENSG00000248112.1	RP11-78C3.1	10.02	1.5e-21	1.1e-18	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:82919376~82921119:-
LGG	cis	rs3742264	0.885	rs4942476	ENSG00000235903.6	CPB2-AS1	-10.02	1.5e-21	1.1e-18	-0.47	-0.42	Blood protein levels;	chr13:46077491	chr13:46052806~46113332:+
LGG	cis	rs651907	0.535	rs11717638	ENSG00000256628.3	ZBTB11-AS1	10.02	1.5e-21	1.1e-18	0.48	0.42	Colorectal cancer;	chr3:101786624	chr3:101676475~101679217:+
LGG	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-10.02	1.51e-21	1.1e-18	-0.44	-0.42	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
LGG	cis	rs7267979	1	rs6050559	ENSG00000276952.1	RP5-965G21.6	10.02	1.51e-21	1.11e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25284915~25285588:-
LGG	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	10.02	1.52e-21	1.11e-18	0.44	0.42	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
LGG	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	10.01	1.52e-21	1.11e-18	0.54	0.42	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
LGG	cis	rs12935418	0.616	rs9931292	ENSG00000260213.4	RP11-303E16.3	-10.01	1.53e-21	1.12e-18	-0.51	-0.42	Mean corpuscular volume;	chr16:80975671	chr16:81016792~81035759:-
LGG	cis	rs1560104	0.709	rs6498334	ENSG00000274834.1	CTD-3037G24.5	-10.01	1.53e-21	1.12e-18	-0.53	-0.42	Obesity-related traits;	chr16:12602789	chr16:12614451~12614852:+
LGG	cis	rs7181230	0.885	rs4497657	ENSG00000275636.1	RP11-521C20.5	10.01	1.54e-21	1.13e-18	0.48	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40078892~40079347:+
LGG	cis	rs5742933	1	rs5742933	ENSG00000273240.1	RP11-455J20.3	-10.01	1.55e-21	1.13e-18	-0.53	-0.42	Ferritin levels;	chr2:189784590	chr2:189763859~189764456:-
LGG	cis	rs1153858	1	rs1554521	ENSG00000259433.2	CTD-2651B20.4	10.01	1.56e-21	1.14e-18	0.48	0.42	Homoarginine levels;	chr15:45371991	chr15:45330209~45332634:-
LGG	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-10.01	1.56e-21	1.14e-18	-0.44	-0.42	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
LGG	cis	rs1475911	1	rs2839465	ENSG00000184385.2	UMODL1-AS1	10.01	1.56e-21	1.14e-18	0.52	0.42	IgG glycosylation;	chr21:42091122	chr21:42102134~42108534:-
LGG	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-10.01	1.56e-21	1.14e-18	-0.49	-0.42	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
LGG	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	10.01	1.57e-21	1.15e-18	0.51	0.42	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
LGG	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	10.01	1.58e-21	1.15e-18	0.44	0.42	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
LGG	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	10.01	1.58e-21	1.15e-18	0.44	0.42	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
LGG	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-10.01	1.58e-21	1.15e-18	-0.56	-0.42	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
LGG	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-10.01	1.58e-21	1.15e-18	-0.56	-0.42	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-10.01	1.58e-21	1.15e-18	-0.56	-0.42	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
LGG	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-10.01	1.58e-21	1.16e-18	-0.55	-0.42	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
LGG	cis	rs17772222	0.597	rs17700296	ENSG00000258983.2	RP11-507K2.2	10.01	1.59e-21	1.16e-18	0.52	0.42	Coronary artery calcification;	chr14:88840976	chr14:88499334~88515502:+
LGG	cis	rs9810089	0.868	rs4630889	ENSG00000261758.1	RP11-102M11.2	10.01	1.59e-21	1.16e-18	0.44	0.42	Gestational age at birth (child effect);	chr3:136559409	chr3:136752630~136755780:+
LGG	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-10.01	1.6e-21	1.17e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
LGG	cis	rs7914558	0.932	rs4307650	ENSG00000272912.1	RP11-724N1.1	-10.01	1.6e-21	1.17e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102914585~102915404:+
LGG	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	10.01	1.6e-21	1.17e-18	0.5	0.42	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
LGG	cis	rs853679	0.527	rs853683	ENSG00000226314.6	ZNF192P1	10.01	1.6e-21	1.17e-18	0.43	0.42	Depression;	chr6:28327262	chr6:28161781~28169594:+
LGG	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-10.01	1.61e-21	1.17e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
LGG	cis	rs507080	0.922	rs518028	ENSG00000278376.1	RP11-158I9.8	-10.01	1.61e-21	1.17e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118694273	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs519982	ENSG00000278376.1	RP11-158I9.8	-10.01	1.61e-21	1.17e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118694522	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs478371	ENSG00000278376.1	RP11-158I9.8	-10.01	1.61e-21	1.17e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118694627	chr11:118791254~118793137:+
LGG	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-10.01	1.61e-21	1.17e-18	-0.5	-0.42	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
LGG	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-10.01	1.61e-21	1.18e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-10.01	1.61e-21	1.18e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
LGG	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	10.01	1.61e-21	1.18e-18	0.52	0.42	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
LGG	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	10.01	1.61e-21	1.18e-18	0.51	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
LGG	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-10.01	1.62e-21	1.18e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
LGG	cis	rs5742933	0.948	rs6434363	ENSG00000273240.1	RP11-455J20.3	-10.01	1.63e-21	1.19e-18	-0.53	-0.42	Ferritin levels;	chr2:189707565	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs16831939	ENSG00000273240.1	RP11-455J20.3	-10.01	1.63e-21	1.19e-18	-0.53	-0.42	Ferritin levels;	chr2:189739282	chr2:189763859~189764456:-
LGG	cis	rs17772222	0.917	rs61977053	ENSG00000222990.1	RNU4-22P	10.01	1.63e-21	1.19e-18	0.52	0.42	Coronary artery calcification;	chr14:88380876	chr14:88513498~88513663:+
LGG	cis	rs7119038	0.818	rs7942535	ENSG00000255239.1	AP002954.6	10.01	1.63e-21	1.19e-18	0.57	0.42	Sjögren's syndrome;	chr11:118810755	chr11:118688039~118690600:-
LGG	cis	rs9875589	0.915	rs13097822	ENSG00000233121.1	VN1R20P	10.01	1.63e-21	1.19e-18	0.43	0.42	Ovarian reserve;	chr3:13927899	chr3:13926813~13927778:+
LGG	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	10.01	1.64e-21	1.19e-18	0.53	0.42	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	10.01	1.64e-21	1.19e-18	0.53	0.42	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
LGG	cis	rs5758511	0.508	rs28715885	ENSG00000227370.1	RP4-669P10.19	10.01	1.64e-21	1.19e-18	0.49	0.42	Birth weight;	chr22:42045087	chr22:42132543~42132998:+
LGG	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-10.01	1.65e-21	1.2e-18	-0.42	-0.42	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
LGG	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	10.01	1.65e-21	1.2e-18	0.49	0.42	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
LGG	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-10.01	1.65e-21	1.2e-18	-0.44	-0.42	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
LGG	cis	rs853679	0.545	rs35949109	ENSG00000199851.2	U3	10.01	1.65e-21	1.2e-18	0.89	0.42	Depression;	chr6:28058148	chr6:28015568~28015777:+
LGG	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-10	1.66e-21	1.21e-18	-0.5	-0.42	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
LGG	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-10	1.66e-21	1.21e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
LGG	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-10	1.67e-21	1.21e-18	-0.38	-0.42	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
LGG	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-10	1.67e-21	1.22e-18	-0.49	-0.42	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
LGG	cis	rs9527	0.615	rs7096452	ENSG00000272912.1	RP11-724N1.1	-10	1.68e-21	1.22e-18	-0.47	-0.42	Arsenic metabolism;	chr10:102976806	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs7080462	ENSG00000272912.1	RP11-724N1.1	-10	1.68e-21	1.22e-18	-0.47	-0.42	Arsenic metabolism;	chr10:102976942	chr10:102914585~102915404:+
LGG	cis	rs4986172	0.69	rs11657325	ENSG00000267288.2	RP13-890H12.2	-10	1.68e-21	1.22e-18	-0.55	-0.42	Height;	chr17:45165327	chr17:45168800~45171584:-
LGG	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-10	1.69e-21	1.23e-18	-0.44	-0.42	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-10	1.69e-21	1.23e-18	-0.44	-0.42	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
LGG	cis	rs7914558	0.869	rs10883842	ENSG00000272912.1	RP11-724N1.1	-10	1.7e-21	1.23e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:102914585~102915404:+
LGG	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	10	1.7e-21	1.24e-18	0.55	0.42	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
LGG	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	10	1.71e-21	1.25e-18	0.49	0.42	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
LGG	cis	rs17772222	0.958	rs60213984	ENSG00000222990.1	RNU4-22P	10	1.72e-21	1.25e-18	0.53	0.42	Coronary artery calcification;	chr14:88401473	chr14:88513498~88513663:+
LGG	cis	rs4713118	0.696	rs2394002	ENSG00000216901.1	AL022393.7	10	1.72e-21	1.25e-18	0.55	0.42	Parkinson's disease;	chr6:27780236	chr6:28176188~28176674:+
LGG	cis	rs12935418	0.579	rs2123627	ENSG00000260213.4	RP11-303E16.3	10	1.72e-21	1.25e-18	0.51	0.42	Mean corpuscular volume;	chr16:80988211	chr16:81016792~81035759:-
LGG	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-10	1.73e-21	1.26e-18	-0.57	-0.42	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
LGG	cis	rs507080	0.922	rs558781	ENSG00000278376.1	RP11-158I9.8	-10	1.73e-21	1.26e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118693688	chr11:118791254~118793137:+
LGG	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-10	1.73e-21	1.26e-18	-0.46	-0.42	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
LGG	cis	rs507080	0.922	rs582630	ENSG00000278376.1	RP11-158I9.8	-10	1.73e-21	1.26e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118692090	chr11:118791254~118793137:+
LGG	cis	rs507080	0.883	rs527475	ENSG00000278376.1	RP11-158I9.8	-10	1.73e-21	1.26e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118692530	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs585039	ENSG00000278376.1	RP11-158I9.8	-10	1.73e-21	1.26e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118692672	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs508640	ENSG00000278376.1	RP11-158I9.8	-10	1.73e-21	1.26e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118693704	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs471227	ENSG00000278376.1	RP11-158I9.8	-10	1.73e-21	1.26e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118693892	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs516153	ENSG00000278376.1	RP11-158I9.8	-10	1.73e-21	1.26e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118694053	chr11:118791254~118793137:+
LGG	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	10	1.73e-21	1.26e-18	0.32	0.42	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
LGG	cis	rs853679	0.527	rs1997660	ENSG00000226314.6	ZNF192P1	10	1.74e-21	1.27e-18	0.43	0.42	Depression;	chr6:28301886	chr6:28161781~28169594:+
LGG	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-10	1.75e-21	1.27e-18	-0.41	-0.42	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
LGG	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	10	1.75e-21	1.27e-18	0.49	0.42	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
LGG	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	10	1.75e-21	1.27e-18	0.43	0.42	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
LGG	cis	rs950776	0.518	rs2869055	ENSG00000261762.1	RP11-650L12.2	-10	1.75e-21	1.27e-18	-0.5	-0.42	Sudden cardiac arrest;	chr15:78530046	chr15:78589123~78591276:-
LGG	cis	rs5758511	0.514	rs2899354	ENSG00000227370.1	RP4-669P10.19	10	1.76e-21	1.28e-18	0.48	0.42	Birth weight;	chr22:42158403	chr22:42132543~42132998:+
LGG	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	10	1.76e-21	1.28e-18	0.47	0.42	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
LGG	cis	rs5758511	0.514	rs5758629	ENSG00000227370.1	RP4-669P10.19	10	1.77e-21	1.28e-18	0.48	0.42	Birth weight;	chr22:42178549	chr22:42132543~42132998:+
LGG	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-10	1.78e-21	1.29e-18	-0.81	-0.42	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
LGG	cis	rs5742933	0.817	rs7591929	ENSG00000253559.1	OSGEPL1-AS1	10	1.79e-21	1.3e-18	0.5	0.42	Ferritin levels;	chr2:189778531	chr2:189762704~189765556:+
LGG	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-10	1.79e-21	1.3e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
LGG	cis	rs7914558	0.966	rs10786745	ENSG00000272912.1	RP11-724N1.1	-10	1.8e-21	1.31e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102914585~102915404:+
LGG	cis	rs651907	0.535	rs17412601	ENSG00000256628.3	ZBTB11-AS1	9.99	1.81e-21	1.31e-18	0.48	0.42	Colorectal cancer;	chr3:101780431	chr3:101676475~101679217:+
LGG	cis	rs7914558	0.966	rs10748839	ENSG00000272912.1	RP11-724N1.1	-9.99	1.81e-21	1.31e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102914585~102915404:+
LGG	cis	rs11148252	0.532	rs9536185	ENSG00000198384.8	TPTE2P3	-9.99	1.81e-21	1.31e-18	-0.39	-0.42	Lewy body disease;	chr13:52605666	chr13:52522632~52586906:+
LGG	cis	rs8092443	0.81	rs8093705	ENSG00000278971.1	RP11-644A7.2	-9.99	1.81e-21	1.32e-18	-0.64	-0.42	Response to antipsychotic treatment;	chr18:70475478	chr18:70489630~70491205:+
LGG	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-9.99	1.82e-21	1.32e-18	-0.54	-0.42	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
LGG	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-9.99	1.82e-21	1.32e-18	-0.56	-0.42	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
LGG	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-9.99	1.82e-21	1.32e-18	-0.56	-0.42	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
LGG	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-9.99	1.82e-21	1.32e-18	-0.42	-0.42	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
LGG	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-9.99	1.84e-21	1.33e-18	-0.4	-0.42	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
LGG	cis	rs8092443	0.81	rs12607666	ENSG00000278971.1	RP11-644A7.2	-9.99	1.85e-21	1.34e-18	-0.61	-0.42	Response to antipsychotic treatment;	chr18:70484561	chr18:70489630~70491205:+
LGG	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	9.99	1.85e-21	1.34e-18	0.59	0.42	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
LGG	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	9.99	1.85e-21	1.34e-18	0.36	0.42	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	9.99	1.85e-21	1.34e-18	0.36	0.42	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
LGG	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-9.99	1.85e-21	1.34e-18	-0.57	-0.42	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
LGG	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-9.99	1.85e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
LGG	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
LGG	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
LGG	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
LGG	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
LGG	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
LGG	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
LGG	cis	rs507080	0.883	rs12798453	ENSG00000278376.1	RP11-158I9.8	-9.99	1.86e-21	1.35e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118690701	chr11:118791254~118793137:+
LGG	cis	rs7302981	0.967	rs11831413	ENSG00000272368.2	RP4-605O3.4	9.99	1.86e-21	1.35e-18	0.41	0.42	Systolic blood pressure;	chr12:50156600	chr12:50112197~50165618:+
LGG	cis	rs7302981	0.967	rs2178173	ENSG00000272368.2	RP4-605O3.4	-9.99	1.87e-21	1.35e-18	-0.41	-0.42	Systolic blood pressure;	chr12:50124146	chr12:50112197~50165618:+
LGG	cis	rs12935418	0.616	rs9921448	ENSG00000260213.4	RP11-303E16.3	-9.99	1.89e-21	1.37e-18	-0.5	-0.42	Mean corpuscular volume;	chr16:80975593	chr16:81016792~81035759:-
LGG	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	9.99	1.9e-21	1.38e-18	0.52	0.42	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
LGG	cis	rs1420956	0.646	rs7243150	ENSG00000264151.4	RP11-739N10.1	9.99	1.9e-21	1.38e-18	0.52	0.42	Obesity-related traits;	chr18:27617983	chr18:27336379~27595164:-
LGG	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-9.99	1.9e-21	1.38e-18	-0.54	-0.42	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
LGG	cis	rs7302981	0.967	rs35549836	ENSG00000272368.2	RP4-605O3.4	9.99	1.9e-21	1.38e-18	0.41	0.42	Systolic blood pressure;	chr12:50159419	chr12:50112197~50165618:+
LGG	cis	rs7302981	0.967	rs35998534	ENSG00000272368.2	RP4-605O3.4	9.99	1.9e-21	1.38e-18	0.41	0.42	Systolic blood pressure;	chr12:50162999	chr12:50112197~50165618:+
LGG	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	9.99	1.91e-21	1.39e-18	0.36	0.42	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	9.99	1.91e-21	1.39e-18	0.36	0.42	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	9.99	1.91e-21	1.39e-18	0.36	0.42	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
LGG	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-9.99	1.91e-21	1.39e-18	-0.36	-0.42	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-9.99	1.91e-21	1.39e-18	-0.36	-0.42	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-9.99	1.91e-21	1.39e-18	-0.36	-0.42	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
LGG	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	9.99	1.91e-21	1.39e-18	0.48	0.42	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
LGG	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	9.99	1.92e-21	1.39e-18	0.36	0.42	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	9.99	1.92e-21	1.39e-18	0.36	0.42	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-9.99	1.92e-21	1.39e-18	-0.36	-0.42	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	9.99	1.92e-21	1.39e-18	0.48	0.42	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
LGG	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	9.99	1.93e-21	1.4e-18	0.58	0.42	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
LGG	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	9.99	1.93e-21	1.4e-18	0.94	0.42	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
LGG	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-9.99	1.94e-21	1.4e-18	-0.42	-0.42	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
LGG	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-9.99	1.94e-21	1.41e-18	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
LGG	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-9.99	1.95e-21	1.41e-18	-0.5	-0.42	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
LGG	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-9.99	1.95e-21	1.41e-18	-0.49	-0.42	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
LGG	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-9.98	1.95e-21	1.42e-18	-0.49	-0.42	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
LGG	cis	rs8092443	0.654	rs8090108	ENSG00000278971.1	RP11-644A7.2	9.98	1.96e-21	1.42e-18	0.62	0.42	Response to antipsychotic treatment;	chr18:70483775	chr18:70489630~70491205:+
LGG	cis	rs1153858	0.945	rs2467854	ENSG00000259433.2	CTD-2651B20.4	-9.98	1.96e-21	1.42e-18	-0.49	-0.42	Homoarginine levels;	chr15:45409399	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs2461701	ENSG00000259433.2	CTD-2651B20.4	-9.98	1.96e-21	1.42e-18	-0.49	-0.42	Homoarginine levels;	chr15:45411193	chr15:45330209~45332634:-
LGG	cis	rs507080	0.922	rs644867	ENSG00000278376.1	RP11-158I9.8	-9.98	1.97e-21	1.42e-18	-0.38	-0.42	Serum metabolite levels;	chr11:118696836	chr11:118791254~118793137:+
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000272787.1	KB-226F1.2	9.98	1.97e-21	1.43e-18	0.44	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23969211~23969873:+
LGG	cis	rs7914558	1	rs7077097	ENSG00000272912.1	RP11-724N1.1	-9.98	1.97e-21	1.43e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs7077291	ENSG00000272912.1	RP11-724N1.1	-9.98	1.97e-21	1.43e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:102914585~102915404:+
LGG	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	9.98	1.98e-21	1.43e-18	0.37	0.42	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-9.98	1.98e-21	1.43e-18	-0.37	-0.42	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-9.98	1.98e-21	1.43e-18	-0.37	-0.42	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-9.98	1.98e-21	1.43e-18	-0.37	-0.42	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-9.98	1.98e-21	1.43e-18	-0.37	-0.42	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
LGG	cis	rs7927771	0.77	rs11039203	ENSG00000280615.1	Y_RNA	-9.98	1.98e-21	1.43e-18	-0.52	-0.42	Subjective well-being;	chr11:47363046	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.832	rs67116452	ENSG00000280615.1	Y_RNA	-9.98	1.98e-21	1.43e-18	-0.52	-0.42	Subjective well-being;	chr11:47363643	chr11:47614898~47614994:-
LGG	cis	rs3742264	1	rs9562633	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46068624	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs9567610	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46068632	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs9562636	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46068889	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs7990092	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46069154	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs7988836	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46069238	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs7993537	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46069426	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs7993567	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46069471	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs7995615	ENSG00000235903.6	CPB2-AS1	-9.98	1.98e-21	1.44e-18	-0.45	-0.42	Blood protein levels;	chr13:46069673	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.961	rs9534309	ENSG00000235903.6	CPB2-AS1	-9.98	1.99e-21	1.44e-18	-0.46	-0.42	Blood protein levels;	chr13:46073402	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs3742264	ENSG00000235903.6	CPB2-AS1	-9.98	1.99e-21	1.44e-18	-0.46	-0.42	Blood protein levels;	chr13:46073959	chr13:46052806~46113332:+
LGG	cis	rs3742264	0.961	rs1326400	ENSG00000235903.6	CPB2-AS1	-9.98	1.99e-21	1.44e-18	-0.46	-0.42	Blood protein levels;	chr13:46074388	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs1326399	ENSG00000235903.6	CPB2-AS1	-9.98	1.99e-21	1.44e-18	-0.46	-0.42	Blood protein levels;	chr13:46074472	chr13:46052806~46113332:+
LGG	cis	rs3742264	1	rs9534310	ENSG00000235903.6	CPB2-AS1	-9.98	1.99e-21	1.44e-18	-0.46	-0.42	Blood protein levels;	chr13:46074840	chr13:46052806~46113332:+
LGG	cis	rs7914558	1	rs10748838	ENSG00000272912.1	RP11-724N1.1	-9.98	2.01e-21	1.45e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs3758543	ENSG00000272912.1	RP11-724N1.1	-9.98	2.01e-21	1.45e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs4917997	ENSG00000272912.1	RP11-724N1.1	-9.98	2.01e-21	1.45e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:102914585~102915404:+
LGG	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	9.98	2.01e-21	1.45e-18	0.47	0.42	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
LGG	cis	rs7302981	0.967	rs12815871	ENSG00000272368.2	RP4-605O3.4	9.98	2.01e-21	1.45e-18	0.41	0.42	Systolic blood pressure;	chr12:50157165	chr12:50112197~50165618:+
LGG	cis	rs7267979	0.933	rs1130694	ENSG00000276952.1	RP5-965G21.6	9.98	2.01e-21	1.45e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25284915~25285588:-
LGG	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	9.98	2.02e-21	1.46e-18	0.97	0.42	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
LGG	cis	rs1153858	1	rs56850226	ENSG00000259433.2	CTD-2651B20.4	-9.98	2.02e-21	1.46e-18	-0.48	-0.42	Homoarginine levels;	chr15:45340920	chr15:45330209~45332634:-
LGG	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	9.98	2.03e-21	1.47e-18	0.48	0.42	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
LGG	cis	rs3742264	1	rs1409434	ENSG00000235903.6	CPB2-AS1	-9.98	2.03e-21	1.47e-18	-0.46	-0.42	Blood protein levels;	chr13:46072309	chr13:46052806~46113332:+
LGG	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	9.98	2.03e-21	1.47e-18	0.49	0.42	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	9.98	2.03e-21	1.47e-18	0.49	0.42	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
LGG	cis	rs673078	0.562	rs61944672	ENSG00000275759.1	RP11-131L12.3	-9.98	2.03e-21	1.47e-18	-0.58	-0.42	Glucose homeostasis traits;	chr12:118450123	chr12:118428281~118428870:+
LGG	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	9.98	2.04e-21	1.47e-18	0.59	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
LGG	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-9.98	2.04e-21	1.47e-18	-0.45	-0.42	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
LGG	cis	rs7927771	0.832	rs1542321	ENSG00000280615.1	Y_RNA	9.98	2.04e-21	1.47e-18	0.53	0.42	Subjective well-being;	chr11:47358064	chr11:47614898~47614994:-
LGG	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	9.98	2.04e-21	1.47e-18	0.3	0.42	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
LGG	cis	rs5742933	0.597	rs7568449	ENSG00000273240.1	RP11-455J20.3	9.98	2.04e-21	1.48e-18	0.53	0.42	Ferritin levels;	chr2:189656328	chr2:189763859~189764456:-
LGG	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	9.98	2.04e-21	1.48e-18	0.48	0.42	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
LGG	cis	rs651907	0.535	rs35810977	ENSG00000256628.3	ZBTB11-AS1	9.98	2.05e-21	1.48e-18	0.48	0.42	Colorectal cancer;	chr3:101812536	chr3:101676475~101679217:+
LGG	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	9.98	2.05e-21	1.48e-18	0.46	0.42	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
LGG	cis	rs11098499	0.71	rs4145952	ENSG00000249244.1	RP11-548H18.2	9.98	2.07e-21	1.5e-18	0.43	0.42	Corneal astigmatism;	chr4:119234651	chr4:119391831~119395335:-
LGG	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	9.98	2.07e-21	1.5e-18	0.31	0.42	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
LGG	cis	rs651907	0.535	rs34263427	ENSG00000256628.3	ZBTB11-AS1	9.98	2.08e-21	1.5e-18	0.48	0.42	Colorectal cancer;	chr3:101788961	chr3:101676475~101679217:+
LGG	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	9.98	2.08e-21	1.5e-18	0.41	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
LGG	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-9.98	2.1e-21	1.52e-18	-0.45	-0.42	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
LGG	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	9.98	2.1e-21	1.52e-18	0.54	0.42	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
LGG	cis	rs9388451	0.874	rs7739566	ENSG00000237742.5	RP11-624M8.1	-9.98	2.1e-21	1.52e-18	-0.37	-0.42	Brugada syndrome;	chr6:125773611	chr6:125578558~125749190:-
LGG	cis	rs9388451	0.839	rs4897155	ENSG00000237742.5	RP11-624M8.1	-9.98	2.1e-21	1.52e-18	-0.37	-0.42	Brugada syndrome;	chr6:125773998	chr6:125578558~125749190:-
LGG	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	-9.98	2.1e-21	1.52e-18	-0.46	-0.42	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	9.98	2.12e-21	1.53e-18	0.56	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
LGG	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-9.98	2.12e-21	1.53e-18	-0.47	-0.42	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-9.98	2.12e-21	1.53e-18	-0.47	-0.42	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
LGG	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	9.97	2.15e-21	1.55e-18	0.35	0.42	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
LGG	cis	rs7267979	1	rs2257420	ENSG00000276952.1	RP5-965G21.6	9.97	2.15e-21	1.55e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25284915~25285588:-
LGG	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-9.97	2.15e-21	1.55e-18	-0.54	-0.42	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
LGG	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	9.97	2.17e-21	1.57e-18	0.45	0.42	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
LGG	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	9.97	2.18e-21	1.57e-18	0.53	0.42	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
LGG	cis	rs9527	0.622	rs12779263	ENSG00000272912.1	RP11-724N1.1	-9.97	2.18e-21	1.58e-18	-0.48	-0.42	Arsenic metabolism;	chr10:103126776	chr10:102914585~102915404:+
LGG	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-9.97	2.19e-21	1.58e-18	-0.55	-0.42	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
LGG	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	9.97	2.19e-21	1.58e-18	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
LGG	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	9.97	2.2e-21	1.59e-18	0.47	0.42	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
LGG	cis	rs11148252	0.553	rs9536236	ENSG00000273784.3	RP11-78J21.7	-9.97	2.2e-21	1.59e-18	-0.48	-0.42	Lewy body disease;	chr13:52680877	chr13:52600042~52642542:+
LGG	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	9.97	2.21e-21	1.59e-18	0.52	0.42	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	9.97	2.21e-21	1.59e-18	0.52	0.42	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	9.97	2.21e-21	1.59e-18	0.52	0.42	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
LGG	cis	rs17772222	0.916	rs77306894	ENSG00000222990.1	RNU4-22P	9.97	2.22e-21	1.6e-18	0.54	0.42	Coronary artery calcification;	chr14:88494507	chr14:88513498~88513663:+
LGG	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-9.97	2.25e-21	1.62e-18	-0.46	-0.42	Depression;	chr6:28192182	chr6:28115628~28116551:+
LGG	cis	rs7267979	0.932	rs417130	ENSG00000276952.1	RP5-965G21.6	9.97	2.26e-21	1.63e-18	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.932	rs6037125	ENSG00000276952.1	RP5-965G21.6	9.97	2.26e-21	1.63e-18	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.932	rs372678	ENSG00000276952.1	RP5-965G21.6	9.97	2.26e-21	1.63e-18	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25284915~25285588:-
LGG	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	9.97	2.27e-21	1.64e-18	0.55	0.42	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
LGG	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-9.97	2.28e-21	1.64e-18	-0.46	-0.42	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
LGG	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-9.97	2.28e-21	1.64e-18	-0.48	-0.42	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
LGG	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	9.97	2.28e-21	1.64e-18	0.56	0.42	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
LGG	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	9.97	2.29e-21	1.65e-18	0.48	0.42	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
LGG	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-9.97	2.3e-21	1.65e-18	-0.4	-0.42	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
LGG	cis	rs1153858	1	rs2467858	ENSG00000259433.2	CTD-2651B20.4	-9.97	2.3e-21	1.66e-18	-0.49	-0.42	Homoarginine levels;	chr15:45419294	chr15:45330209~45332634:-
LGG	cis	rs507080	0.922	rs7114458	ENSG00000278376.1	RP11-158I9.8	-9.96	2.31e-21	1.66e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118695466	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs7114216	ENSG00000278376.1	RP11-158I9.8	-9.96	2.31e-21	1.66e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118695525	chr11:118791254~118793137:+
LGG	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	9.96	2.32e-21	1.67e-18	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
LGG	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	9.96	2.32e-21	1.67e-18	0.47	0.42	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
LGG	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	9.96	2.32e-21	1.67e-18	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
LGG	cis	rs8092443	0.745	rs11151588	ENSG00000278971.1	RP11-644A7.2	9.96	2.33e-21	1.68e-18	0.62	0.42	Response to antipsychotic treatment;	chr18:70483459	chr18:70489630~70491205:+
LGG	cis	rs7267979	0.903	rs2500400	ENSG00000276952.1	RP5-965G21.6	-9.96	2.34e-21	1.69e-18	-0.41	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.739	rs2893931	ENSG00000216901.1	AL022393.7	9.96	2.36e-21	1.7e-18	0.55	0.42	Parkinson's disease;	chr6:27780231	chr6:28176188~28176674:+
LGG	cis	rs11148252	0.595	rs4885325	ENSG00000273784.3	RP11-78J21.7	-9.96	2.37e-21	1.7e-18	-0.47	-0.42	Lewy body disease;	chr13:52597182	chr13:52600042~52642542:+
LGG	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-9.96	2.37e-21	1.71e-18	-0.45	-0.42	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-9.96	2.37e-21	1.71e-18	-0.45	-0.42	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
LGG	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	9.96	2.37e-21	1.71e-18	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
LGG	cis	rs642803	0.933	rs644740	ENSG00000255120.4	OVOL1-AS1	9.96	2.38e-21	1.71e-18	0.51	0.42	Urate levels;	chr11:65793997	chr11:65789051~65790868:-
LGG	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	9.96	2.38e-21	1.71e-18	0.47	0.42	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
LGG	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	9.96	2.4e-21	1.73e-18	0.36	0.42	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
LGG	cis	rs3742264	1	rs9526140	ENSG00000235903.6	CPB2-AS1	-9.96	2.4e-21	1.73e-18	-0.45	-0.42	Blood protein levels;	chr13:46070017	chr13:46052806~46113332:+
LGG	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	9.96	2.41e-21	1.73e-18	0.53	0.42	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	9.96	2.41e-21	1.73e-18	0.53	0.42	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	9.96	2.41e-21	1.73e-18	0.53	0.42	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
LGG	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-9.96	2.41e-21	1.73e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
LGG	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-9.96	2.41e-21	1.73e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
LGG	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-9.96	2.41e-21	1.73e-18	-0.54	-0.42	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
LGG	cis	rs7615952	0.558	rs7641353	ENSG00000242001.1	GS1-388B5.1	9.96	2.42e-21	1.74e-18	0.55	0.42	Blood pressure (smoking interaction);	chr3:125621035	chr3:125681305~125681453:+
LGG	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	9.96	2.42e-21	1.74e-18	0.48	0.42	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.932	rs13040655	ENSG00000276952.1	RP5-965G21.6	9.96	2.43e-21	1.74e-18	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:25284915~25285588:-
LGG	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	9.96	2.44e-21	1.75e-18	0.53	0.42	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
LGG	cis	rs9527	0.615	rs11191489	ENSG00000272912.1	RP11-724N1.1	-9.96	2.44e-21	1.75e-18	-0.47	-0.42	Arsenic metabolism;	chr10:102980811	chr10:102914585~102915404:+
LGG	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	9.96	2.46e-21	1.77e-18	0.48	0.42	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
LGG	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-9.96	2.46e-21	1.77e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
LGG	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	9.96	2.47e-21	1.78e-18	0.41	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
LGG	cis	rs4713118	0.824	rs9468225	ENSG00000216901.1	AL022393.7	9.96	2.48e-21	1.78e-18	0.55	0.42	Parkinson's disease;	chr6:27777940	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.515	rs1558205	ENSG00000280107.1	AL022393.9	9.96	2.48e-21	1.78e-18	0.41	0.42	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28170845~28172521:+
LGG	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	9.96	2.48e-21	1.78e-18	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
LGG	cis	rs9527	0.544	rs1572578	ENSG00000272912.1	RP11-724N1.1	-9.96	2.49e-21	1.79e-18	-0.47	-0.42	Arsenic metabolism;	chr10:103062674	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs11191540	ENSG00000272912.1	RP11-724N1.1	-9.96	2.49e-21	1.79e-18	-0.47	-0.42	Arsenic metabolism;	chr10:103063052	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs7092029	ENSG00000272912.1	RP11-724N1.1	-9.96	2.49e-21	1.79e-18	-0.47	-0.42	Arsenic metabolism;	chr10:103064152	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs943039	ENSG00000272912.1	RP11-724N1.1	-9.96	2.49e-21	1.79e-18	-0.47	-0.42	Arsenic metabolism;	chr10:103065375	chr10:102914585~102915404:+
LGG	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	-9.96	2.49e-21	1.79e-18	-0.46	-0.42	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
LGG	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-9.96	2.49e-21	1.79e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
LGG	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	9.96	2.49e-21	1.79e-18	0.53	0.42	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
LGG	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-9.96	2.49e-21	1.79e-18	-0.5	-0.42	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
LGG	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	9.96	2.49e-21	1.79e-18	0.36	0.42	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	9.96	2.49e-21	1.79e-18	0.36	0.42	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
LGG	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-9.96	2.49e-21	1.79e-18	-0.59	-0.42	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
LGG	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	9.95	2.51e-21	1.8e-18	0.49	0.42	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
LGG	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	9.95	2.51e-21	1.8e-18	0.49	0.42	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
LGG	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	9.95	2.51e-21	1.8e-18	0.49	0.42	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
LGG	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-9.95	2.53e-21	1.81e-18	-0.5	-0.42	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
LGG	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	9.95	2.54e-21	1.82e-18	0.46	0.42	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
LGG	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-9.95	2.55e-21	1.83e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
LGG	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	9.95	2.56e-21	1.84e-18	0.51	0.42	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
LGG	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	9.95	2.56e-21	1.84e-18	0.51	0.42	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
LGG	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-9.95	2.56e-21	1.84e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
LGG	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	9.95	2.57e-21	1.84e-18	0.63	0.42	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
LGG	cis	rs11148252	0.532	rs9536190	ENSG00000198384.8	TPTE2P3	-9.95	2.58e-21	1.85e-18	-0.39	-0.42	Lewy body disease;	chr13:52606909	chr13:52522632~52586906:+
LGG	cis	rs7267979	1	rs2500432	ENSG00000276952.1	RP5-965G21.6	9.95	2.59e-21	1.86e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25284915~25285588:-
LGG	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	9.95	2.59e-21	1.86e-18	0.49	0.42	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
LGG	cis	rs7914558	1	rs10883837	ENSG00000272912.1	RP11-724N1.1	-9.95	2.59e-21	1.86e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs746293	ENSG00000272912.1	RP11-724N1.1	-9.95	2.59e-21	1.86e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102914585~102915404:+
LGG	cis	rs7914558	1	rs11191577	ENSG00000272912.1	RP11-724N1.1	-9.95	2.59e-21	1.86e-18	-0.46	-0.42	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102914585~102915404:+
LGG	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	9.95	2.6e-21	1.86e-18	0.36	0.42	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-9.95	2.6e-21	1.86e-18	-0.36	-0.42	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
LGG	cis	rs507080	0.922	rs533646	ENSG00000278376.1	RP11-158I9.8	-9.95	2.6e-21	1.87e-18	-0.37	-0.42	Serum metabolite levels;	chr11:118696037	chr11:118791254~118793137:+
LGG	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	9.95	2.61e-21	1.87e-18	0.43	0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
LGG	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-9.95	2.61e-21	1.87e-18	-0.56	-0.42	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
LGG	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	9.95	2.62e-21	1.88e-18	0.53	0.42	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	9.95	2.62e-21	1.88e-18	0.53	0.42	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	9.95	2.62e-21	1.88e-18	0.53	0.42	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	9.95	2.62e-21	1.88e-18	0.53	0.42	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	9.95	2.62e-21	1.88e-18	0.53	0.42	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	9.95	2.62e-21	1.88e-18	0.53	0.42	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
LGG	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	9.95	2.62e-21	1.88e-18	0.3	0.42	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
LGG	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	9.95	2.63e-21	1.88e-18	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	9.95	2.63e-21	1.88e-18	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
LGG	cis	rs651907	0.514	rs11706494	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101790631	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs34063583	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101791104	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs34161138	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101791544	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs11714444	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101794838	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs12631513	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101798632	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs13094911	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101800177	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs11712309	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101800253	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs35799195	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101803083	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs13094753	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101806238	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs11716558	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101809637	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs12633089	ENSG00000256628.3	ZBTB11-AS1	9.95	2.64e-21	1.89e-18	0.48	0.42	Colorectal cancer;	chr3:101809919	chr3:101676475~101679217:+
LGG	cis	rs17772222	0.958	rs61579615	ENSG00000222990.1	RNU4-22P	9.95	2.64e-21	1.89e-18	0.52	0.42	Coronary artery calcification;	chr14:88400054	chr14:88513498~88513663:+
LGG	cis	rs17772222	1	rs61977058	ENSG00000222990.1	RNU4-22P	9.95	2.64e-21	1.89e-18	0.52	0.42	Coronary artery calcification;	chr14:88415571	chr14:88513498~88513663:+
LGG	cis	rs651907	0.557	rs34947019	ENSG00000256628.3	ZBTB11-AS1	9.95	2.65e-21	1.9e-18	0.48	0.42	Colorectal cancer;	chr3:101813391	chr3:101676475~101679217:+
LGG	cis	rs7267979	0.932	rs4280527	ENSG00000276952.1	RP5-965G21.6	9.95	2.66e-21	1.91e-18	0.42	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25284915~25285588:-
LGG	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-9.95	2.66e-21	1.91e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-9.95	2.66e-21	1.91e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-9.95	2.66e-21	1.91e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-9.95	2.66e-21	1.91e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-9.95	2.66e-21	1.91e-18	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
LGG	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-9.95	2.67e-21	1.91e-18	-0.57	-0.42	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-9.95	2.67e-21	1.91e-18	-0.57	-0.42	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
LGG	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	9.95	2.7e-21	1.93e-18	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
LGG	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	9.95	2.7e-21	1.94e-18	0.55	0.42	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
LGG	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	9.95	2.71e-21	1.94e-18	0.49	0.42	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
LGG	cis	rs9527	0.615	rs10883810	ENSG00000272912.1	RP11-724N1.1	-9.95	2.71e-21	1.94e-18	-0.47	-0.42	Arsenic metabolism;	chr10:102967467	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs10883811	ENSG00000272912.1	RP11-724N1.1	-9.95	2.71e-21	1.94e-18	-0.47	-0.42	Arsenic metabolism;	chr10:102967522	chr10:102914585~102915404:+
LGG	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-9.95	2.71e-21	1.94e-18	-0.57	-0.42	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	9.95	2.71e-21	1.94e-18	0.57	0.42	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-9.95	2.71e-21	1.94e-18	-0.57	-0.42	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
LGG	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	9.94	2.73e-21	1.95e-18	0.58	0.42	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
LGG	cis	rs5742933	1	rs5742998	ENSG00000273240.1	RP11-455J20.3	-9.94	2.73e-21	1.96e-18	-0.53	-0.42	Ferritin levels;	chr2:189799626	chr2:189763859~189764456:-
LGG	cis	rs4819052	0.959	rs9976074	ENSG00000215447.6	BX322557.10	-9.94	2.75e-21	1.97e-18	-0.35	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45288052~45291738:+
LGG	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	9.94	2.75e-21	1.97e-18	0.46	0.42	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
LGG	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	9.94	2.75e-21	1.97e-18	0.46	0.42	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
LGG	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-9.94	2.76e-21	1.97e-18	-0.58	-0.42	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
LGG	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	9.94	2.76e-21	1.98e-18	0.55	0.42	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
LGG	cis	rs9527	0.83	rs11191442	ENSG00000272912.1	RP11-724N1.1	-9.94	2.76e-21	1.98e-18	-0.5	-0.42	Arsenic metabolism;	chr10:102883839	chr10:102914585~102915404:+
LGG	cis	rs9527	0.83	rs12249194	ENSG00000272912.1	RP11-724N1.1	-9.94	2.76e-21	1.98e-18	-0.5	-0.42	Arsenic metabolism;	chr10:102883941	chr10:102914585~102915404:+
LGG	cis	rs357618	0.531	rs165333	ENSG00000260581.1	CTB-113P19.4	9.94	2.77e-21	1.98e-18	0.5	0.42	Basophil percentage of white cells;	chr5:151497586	chr5:151652275~151655449:+
LGG	cis	rs357618	0.581	rs165335	ENSG00000260581.1	CTB-113P19.4	9.94	2.77e-21	1.98e-18	0.5	0.42	Basophil percentage of white cells;	chr5:151498616	chr5:151652275~151655449:+
LGG	cis	rs507080	0.769	rs527290	ENSG00000278376.1	RP11-158I9.8	-9.94	2.78e-21	1.99e-18	-0.38	-0.42	Serum metabolite levels;	chr11:118644898	chr11:118791254~118793137:+
LGG	cis	rs9527	0.59	rs11191544	ENSG00000272912.1	RP11-724N1.1	-9.94	2.79e-21	1.99e-18	-0.47	-0.42	Arsenic metabolism;	chr10:103067441	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs11191547	ENSG00000272912.1	RP11-724N1.1	-9.94	2.79e-21	1.99e-18	-0.47	-0.42	Arsenic metabolism;	chr10:103083391	chr10:102914585~102915404:+
LGG	cis	rs7267979	1	rs2258563	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2258617	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2258769	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2258879	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2257496	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2258884	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2259837	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2259873	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs11100	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs1046073	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2259926	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2259928	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2259956	ENSG00000276952.1	RP5-965G21.6	9.94	2.79e-21	1.99e-18	0.41	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.866	rs2179094	ENSG00000216901.1	AL022393.7	9.94	2.8e-21	2e-18	0.54	0.42	Parkinson's disease;	chr6:27774046	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	9.94	2.8e-21	2e-18	0.45	0.42	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-9.94	2.8e-21	2e-18	-0.45	-0.42	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-9.94	2.8e-21	2e-18	-0.45	-0.42	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
LGG	cis	rs4819052	0.851	rs11558445	ENSG00000223768.1	LINC00205	-9.94	2.82e-21	2.02e-18	-0.45	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45293285~45297354:+
LGG	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	9.94	2.82e-21	2.02e-18	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000272787.1	KB-226F1.2	9.94	2.83e-21	2.02e-18	0.44	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23969211~23969873:+
LGG	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	9.94	2.83e-21	2.02e-18	0.53	0.42	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
LGG	cis	rs507080	0.769	rs570836	ENSG00000278376.1	RP11-158I9.8	-9.94	2.84e-21	2.03e-18	-0.38	-0.42	Serum metabolite levels;	chr11:118641444	chr11:118791254~118793137:+
LGG	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-9.94	2.84e-21	2.03e-18	-0.51	-0.42	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
LGG	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	9.94	2.84e-21	2.03e-18	0.55	0.42	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
LGG	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	9.94	2.84e-21	2.03e-18	0.48	0.42	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
LGG	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	9.94	2.86e-21	2.04e-18	0.33	0.42	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
LGG	cis	rs5742933	1	rs6717922	ENSG00000273240.1	RP11-455J20.3	-9.94	2.86e-21	2.05e-18	-0.53	-0.42	Ferritin levels;	chr2:189721497	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs4667306	ENSG00000273240.1	RP11-455J20.3	-9.94	2.86e-21	2.05e-18	-0.53	-0.42	Ferritin levels;	chr2:189725630	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs16831925	ENSG00000273240.1	RP11-455J20.3	-9.94	2.86e-21	2.05e-18	-0.53	-0.42	Ferritin levels;	chr2:189731178	chr2:189763859~189764456:-
LGG	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-9.94	2.87e-21	2.05e-18	-0.56	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
LGG	cis	rs5742933	1	rs7557519	ENSG00000273240.1	RP11-455J20.3	-9.94	2.87e-21	2.05e-18	-0.53	-0.42	Ferritin levels;	chr2:189718461	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs12052909	ENSG00000273240.1	RP11-455J20.3	-9.94	2.87e-21	2.05e-18	-0.53	-0.42	Ferritin levels;	chr2:189742484	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs16831955	ENSG00000273240.1	RP11-455J20.3	-9.94	2.87e-21	2.05e-18	-0.53	-0.42	Ferritin levels;	chr2:189745811	chr2:189763859~189764456:-
LGG	cis	rs651907	0.535	rs9830943	ENSG00000256628.3	ZBTB11-AS1	9.94	2.88e-21	2.05e-18	0.48	0.42	Colorectal cancer;	chr3:101710055	chr3:101676475~101679217:+
LGG	cis	rs9527	0.59	rs7910900	ENSG00000272912.1	RP11-724N1.1	-9.94	2.88e-21	2.05e-18	-0.47	-0.42	Arsenic metabolism;	chr10:103070141	chr10:102914585~102915404:+
LGG	cis	rs17345786	0.628	rs11718446	ENSG00000244119.1	PDCL3P4	9.94	2.89e-21	2.06e-18	0.34	0.42	Colonoscopy-negative controls vs population controls;	chr3:101833709	chr3:101712472~101713191:+
LGG	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-9.94	2.9e-21	2.07e-18	-0.63	-0.42	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
LGG	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-9.94	2.9e-21	2.07e-18	-0.48	-0.42	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
LGG	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-9.94	2.9e-21	2.07e-18	-0.49	-0.42	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
LGG	cis	rs17772222	0.636	rs3850390	ENSG00000258983.2	RP11-507K2.2	9.94	2.92e-21	2.08e-18	0.51	0.42	Coronary artery calcification;	chr14:88829185	chr14:88499334~88515502:+
LGG	cis	rs6452524	0.78	rs2386237	ENSG00000248112.1	RP11-78C3.1	9.94	2.94e-21	2.1e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:82919376~82921119:-
LGG	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-9.94	2.95e-21	2.1e-18	-0.48	-0.42	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-9.94	2.95e-21	2.1e-18	-0.48	-0.42	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-9.94	2.95e-21	2.1e-18	-0.48	-0.42	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
LGG	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	9.94	2.95e-21	2.11e-18	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
LGG	cis	rs9527	1	rs4919690	ENSG00000272912.1	RP11-724N1.1	9.94	2.95e-21	2.11e-18	0.52	0.42	Arsenic metabolism;	chr10:102856743	chr10:102914585~102915404:+
LGG	cis	rs17772222	0.876	rs12587528	ENSG00000222990.1	RNU4-22P	9.94	2.96e-21	2.11e-18	0.54	0.42	Coronary artery calcification;	chr14:88487652	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.837	rs1864748	ENSG00000222990.1	RNU4-22P	9.94	2.96e-21	2.11e-18	0.54	0.42	Coronary artery calcification;	chr14:88488847	chr14:88513498~88513663:+
LGG	cis	rs7119038	0.818	rs11826521	ENSG00000255239.1	AP002954.6	-9.93	2.97e-21	2.12e-18	-0.58	-0.42	Sjögren's syndrome;	chr11:118739840	chr11:118688039~118690600:-
LGG	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-9.93	2.97e-21	2.12e-18	-0.47	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-9.93	2.97e-21	2.12e-18	-0.47	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-9.93	2.97e-21	2.12e-18	-0.47	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
LGG	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-9.93	2.98e-21	2.13e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-9.93	2.98e-21	2.13e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
LGG	cis	rs2274273	1	rs10140857	ENSG00000258413.1	RP11-665C16.6	-9.93	2.99e-21	2.13e-18	-0.53	-0.42	Protein biomarker;	chr14:55152893	chr14:55262767~55272075:-
LGG	cis	rs2274273	1	rs74617736	ENSG00000258413.1	RP11-665C16.6	-9.93	2.99e-21	2.13e-18	-0.53	-0.42	Protein biomarker;	chr14:55154201	chr14:55262767~55272075:-
LGG	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-9.93	2.99e-21	2.13e-18	-0.47	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
LGG	cis	rs3742264	1	rs9562635	ENSG00000235903.6	CPB2-AS1	-9.93	2.99e-21	2.13e-18	-0.45	-0.42	Blood protein levels;	chr13:46068857	chr13:46052806~46113332:+
LGG	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	9.93	2.99e-21	2.13e-18	0.47	0.42	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
LGG	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-9.93	3e-21	2.14e-18	-0.56	-0.42	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
LGG	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	9.93	3.02e-21	2.15e-18	0.64	0.42	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
LGG	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	9.93	3.03e-21	2.16e-18	0.4	0.42	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
LGG	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-9.93	3.03e-21	2.16e-18	-0.49	-0.42	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
LGG	cis	rs1799949	0.931	rs9891977	ENSG00000267681.1	CTD-3199J23.6	-9.93	3.03e-21	2.16e-18	-0.46	-0.42	Menopause (age at onset);	chr17:43360030	chr17:43144956~43145255:+
LGG	cis	rs7267979	0.934	rs2257464	ENSG00000125804.12	FAM182A	-9.93	3.03e-21	2.16e-18	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:26054655~26086917:+
LGG	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-9.93	3.06e-21	2.18e-18	-0.57	-0.42	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
LGG	cis	rs12935418	0.616	rs2602446	ENSG00000260213.4	RP11-303E16.3	9.93	3.06e-21	2.18e-18	0.5	0.42	Mean corpuscular volume;	chr16:80984310	chr16:81016792~81035759:-
LGG	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	9.93	3.07e-21	2.19e-18	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
LGG	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-9.93	3.07e-21	2.19e-18	-0.44	-0.41	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
LGG	cis	rs5742933	1	rs62184283	ENSG00000273240.1	RP11-455J20.3	-9.93	3.08e-21	2.19e-18	-0.53	-0.41	Ferritin levels;	chr2:189801179	chr2:189763859~189764456:-
LGG	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	9.93	3.08e-21	2.19e-18	0.47	0.41	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
LGG	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-9.93	3.08e-21	2.2e-18	-0.47	-0.41	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
LGG	cis	rs4713118	1	rs1139226	ENSG00000216901.1	AL022393.7	9.93	3.08e-21	2.2e-18	0.54	0.41	Parkinson's disease;	chr6:27707511	chr6:28176188~28176674:+
LGG	cis	rs4713118	1	rs9468195	ENSG00000216901.1	AL022393.7	9.93	3.08e-21	2.2e-18	0.54	0.41	Parkinson's disease;	chr6:27708530	chr6:28176188~28176674:+
LGG	cis	rs507080	0.922	rs12577485	ENSG00000278376.1	RP11-158I9.8	-9.93	3.09e-21	2.2e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118676793	chr11:118791254~118793137:+
LGG	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-9.93	3.1e-21	2.21e-18	-0.55	-0.41	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
LGG	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-9.93	3.1e-21	2.21e-18	-0.44	-0.41	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
LGG	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-9.93	3.11e-21	2.21e-18	-0.47	-0.41	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-9.93	3.11e-21	2.21e-18	-0.47	-0.41	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-9.93	3.11e-21	2.21e-18	-0.47	-0.41	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
LGG	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	9.93	3.13e-21	2.23e-18	0.6	0.41	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
LGG	cis	rs7267979	1	rs6083862	ENSG00000276952.1	RP5-965G21.6	-9.93	3.14e-21	2.23e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25284915~25285588:-
LGG	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-9.93	3.14e-21	2.24e-18	-0.54	-0.41	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
LGG	cis	rs5742933	1	rs12619808	ENSG00000273240.1	RP11-455J20.3	-9.93	3.16e-21	2.25e-18	-0.54	-0.41	Ferritin levels;	chr2:189776458	chr2:189763859~189764456:-
LGG	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	9.93	3.17e-21	2.26e-18	0.52	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	9.93	3.17e-21	2.26e-18	0.52	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	9.93	3.17e-21	2.26e-18	0.52	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	9.93	3.17e-21	2.26e-18	0.52	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
LGG	cis	rs7615952	0.546	rs2976733	ENSG00000242001.1	GS1-388B5.1	9.93	3.17e-21	2.26e-18	0.54	0.41	Blood pressure (smoking interaction);	chr3:125695294	chr3:125681305~125681453:+
LGG	cis	rs9527	0.569	rs10786730	ENSG00000272912.1	RP11-724N1.1	-9.93	3.18e-21	2.26e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102964443	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs1556960	ENSG00000272912.1	RP11-724N1.1	-9.93	3.18e-21	2.26e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102966916	chr10:102914585~102915404:+
LGG	cis	rs9532669	0.927	rs9532670	ENSG00000168852.11	TPTE2P5	-9.93	3.19e-21	2.27e-18	-0.41	-0.41	Cervical cancer;	chr13:40927691	chr13:40822296~40921749:-
LGG	cis	rs853679	0.545	rs35949109	ENSG00000216901.1	AL022393.7	9.93	3.19e-21	2.27e-18	0.79	0.41	Depression;	chr6:28058148	chr6:28176188~28176674:+
LGG	cis	rs17772222	0.958	rs74074098	ENSG00000222990.1	RNU4-22P	9.93	3.2e-21	2.28e-18	0.54	0.41	Coronary artery calcification;	chr14:88484213	chr14:88513498~88513663:+
LGG	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-9.93	3.22e-21	2.29e-18	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
LGG	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-9.93	3.22e-21	2.29e-18	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
LGG	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	9.92	3.22e-21	2.29e-18	0.3	0.41	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
LGG	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-9.92	3.23e-21	2.29e-18	-0.57	-0.41	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
LGG	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-9.92	3.23e-21	2.3e-18	-0.44	-0.41	Depression;	chr6:28201380	chr6:28115628~28116551:+
LGG	cis	rs7302981	0.967	rs6580729	ENSG00000272368.2	RP4-605O3.4	9.92	3.23e-21	2.3e-18	0.41	0.41	Systolic blood pressure;	chr12:50153255	chr12:50112197~50165618:+
LGG	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-9.92	3.25e-21	2.31e-18	-0.46	-0.41	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
LGG	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-9.92	3.26e-21	2.32e-18	-0.46	-0.41	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
LGG	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-9.92	3.26e-21	2.32e-18	-0.46	-0.41	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
LGG	cis	rs11675119	0.501	rs9309716	ENSG00000225234.1	TRAPPC12-AS1	-9.92	3.26e-21	2.32e-18	-0.41	-0.41	Neurofibrillary tangles;	chr2:3489584	chr2:3481242~3482409:-
LGG	cis	rs17772222	1	rs11159856	ENSG00000222990.1	RNU4-22P	9.92	3.26e-21	2.32e-18	0.52	0.41	Coronary artery calcification;	chr14:88417585	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs17124652	ENSG00000222990.1	RNU4-22P	9.92	3.26e-21	2.32e-18	0.52	0.41	Coronary artery calcification;	chr14:88424384	chr14:88513498~88513663:+
LGG	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	9.92	3.28e-21	2.33e-18	0.49	0.41	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
LGG	cis	rs7432375	0.933	rs6791142	ENSG00000261758.1	RP11-102M11.2	9.92	3.28e-21	2.33e-18	0.43	0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136658535	chr3:136752630~136755780:+
LGG	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	9.92	3.29e-21	2.34e-18	0.43	0.41	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
LGG	cis	rs8064024	0.513	rs1049208	ENSG00000267077.1	RP11-127I20.5	-9.92	3.3e-21	2.34e-18	-0.43	-0.41	Cancer;	chr16:4884548	chr16:4795265~4796532:-
LGG	cis	rs17772222	0.674	rs112788894	ENSG00000222990.1	RNU4-22P	9.92	3.3e-21	2.34e-18	0.52	0.41	Coronary artery calcification;	chr14:88442850	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.876	rs4375590	ENSG00000222990.1	RNU4-22P	9.92	3.3e-21	2.34e-18	0.52	0.41	Coronary artery calcification;	chr14:88451334	chr14:88513498~88513663:+
LGG	cis	rs1153858	1	rs4775906	ENSG00000259433.2	CTD-2651B20.4	-9.92	3.31e-21	2.35e-18	-0.48	-0.41	Homoarginine levels;	chr15:45346096	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs7179743	ENSG00000259433.2	CTD-2651B20.4	-9.92	3.31e-21	2.35e-18	-0.48	-0.41	Homoarginine levels;	chr15:45346133	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs4775907	ENSG00000259433.2	CTD-2651B20.4	-9.92	3.31e-21	2.35e-18	-0.48	-0.41	Homoarginine levels;	chr15:45346449	chr15:45330209~45332634:-
LGG	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	9.92	3.31e-21	2.35e-18	0.52	0.41	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
LGG	cis	rs200972	1	rs200972	ENSG00000226314.6	ZNF192P1	9.92	3.35e-21	2.38e-18	0.42	0.41	Urinary tract infection frequency;	chr6:27891059	chr6:28161781~28169594:+
LGG	cis	rs9527	0.615	rs11191485	ENSG00000272912.1	RP11-724N1.1	-9.92	3.35e-21	2.38e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102970059	chr10:102914585~102915404:+
LGG	cis	rs7267979	0.808	rs84816	ENSG00000276952.1	RP5-965G21.6	9.92	3.35e-21	2.38e-18	0.42	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25284915~25285588:-
LGG	cis	rs9527	0.59	rs7089680	ENSG00000272912.1	RP11-724N1.1	9.92	3.37e-21	2.39e-18	0.46	0.41	Arsenic metabolism;	chr10:103042314	chr10:102914585~102915404:+
LGG	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	9.92	3.37e-21	2.39e-18	0.52	0.41	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
LGG	cis	rs12935418	0.672	rs11150334	ENSG00000260213.4	RP11-303E16.3	-9.92	3.38e-21	2.4e-18	-0.51	-0.41	Mean corpuscular volume;	chr16:81008937	chr16:81016792~81035759:-
LGG	cis	rs4713118	0.824	rs9366702	ENSG00000216901.1	AL022393.7	9.92	3.41e-21	2.42e-18	0.54	0.41	Parkinson's disease;	chr6:27766691	chr6:28176188~28176674:+
LGG	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-9.92	3.42e-21	2.42e-18	-0.45	-0.41	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-9.92	3.42e-21	2.42e-18	-0.45	-0.41	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
LGG	cis	rs1075265	0.73	rs6713088	ENSG00000233266.1	HMGB1P31	9.92	3.44e-21	2.44e-18	0.55	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54051334~54051760:+
LGG	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-9.92	3.47e-21	2.46e-18	-0.54	-0.41	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
LGG	cis	rs12935418	0.672	rs2549883	ENSG00000260213.4	RP11-303E16.3	9.92	3.47e-21	2.46e-18	0.51	0.41	Mean corpuscular volume;	chr16:81022273	chr16:81016792~81035759:-
LGG	cis	rs1150668	0.745	rs213238	ENSG00000280107.1	AL022393.9	-9.92	3.48e-21	2.47e-18	-0.4	-0.41	Pubertal anthropometrics;	chr6:28354216	chr6:28170845~28172521:+
LGG	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	9.92	3.49e-21	2.48e-18	0.46	0.41	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
LGG	cis	rs1153858	1	rs10519022	ENSG00000259433.2	CTD-2651B20.4	9.91	3.5e-21	2.48e-18	0.48	0.41	Homoarginine levels;	chr15:45371486	chr15:45330209~45332634:-
LGG	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-9.91	3.51e-21	2.49e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
LGG	cis	rs571497	0.583	rs4804809	ENSG00000268297.1	CLEC4GP1	9.91	3.51e-21	2.49e-18	0.58	0.41	Monocyte count;	chr19:7771091	chr19:7787549~7790621:+
LGG	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-9.91	3.53e-21	2.51e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
LGG	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-9.91	3.53e-21	2.51e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
LGG	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-9.91	3.53e-21	2.51e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
LGG	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-9.91	3.53e-21	2.51e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
LGG	cis	rs7267979	0.966	rs6037083	ENSG00000276952.1	RP5-965G21.6	-9.91	3.56e-21	2.53e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25284915~25285588:-
LGG	cis	rs7432375	0.901	rs4408829	ENSG00000261758.1	RP11-102M11.2	-9.91	3.57e-21	2.53e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136685841	chr3:136752630~136755780:+
LGG	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	9.91	3.57e-21	2.53e-18	0.48	0.41	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
LGG	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-9.91	3.59e-21	2.55e-18	-0.44	-0.41	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
LGG	cis	rs651907	0.557	rs3094296	ENSG00000256628.3	ZBTB11-AS1	9.91	3.6e-21	2.55e-18	0.48	0.41	Colorectal cancer;	chr3:101681323	chr3:101676475~101679217:+
LGG	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-9.91	3.62e-21	2.56e-18	-0.44	-0.41	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
LGG	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	9.91	3.63e-21	2.57e-18	0.36	0.41	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
LGG	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	9.91	3.63e-21	2.57e-18	0.33	0.41	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
LGG	cis	rs7267979	0.868	rs6138546	ENSG00000276952.1	RP5-965G21.6	9.91	3.64e-21	2.58e-18	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25284915~25285588:-
LGG	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	9.91	3.65e-21	2.58e-18	0.54	0.41	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
LGG	cis	rs7829975	0.755	rs3789849	ENSG00000173295.6	FAM86B3P	-9.91	3.65e-21	2.58e-18	-0.44	-0.41	Mood instability;	chr8:8829544	chr8:8228595~8244865:+
LGG	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	9.91	3.66e-21	2.59e-18	0.53	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
LGG	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-9.91	3.69e-21	2.61e-18	-0.57	-0.41	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
LGG	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	9.91	3.71e-21	2.63e-18	0.52	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	9.91	3.71e-21	2.63e-18	0.52	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	9.91	3.71e-21	2.63e-18	0.52	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
LGG	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-9.91	3.72e-21	2.63e-18	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
LGG	cis	rs7247513	0.856	rs2162863	ENSG00000213290.4	PGK1P2	-9.91	3.73e-21	2.64e-18	-0.45	-0.41	Bipolar disorder;	chr19:12588963	chr19:12559571~12561105:+
LGG	cis	rs7247513	1	rs8104385	ENSG00000213290.4	PGK1P2	-9.91	3.73e-21	2.64e-18	-0.45	-0.41	Bipolar disorder;	chr19:12589470	chr19:12559571~12561105:+
LGG	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	9.91	3.73e-21	2.64e-18	0.55	0.41	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
LGG	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	9.91	3.73e-21	2.64e-18	0.44	0.41	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
LGG	cis	rs853679	0.599	rs156743	ENSG00000199851.2	U3	9.91	3.74e-21	2.65e-18	0.86	0.41	Depression;	chr6:27999311	chr6:28015568~28015777:+
LGG	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-9.91	3.74e-21	2.65e-18	-0.36	-0.41	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
LGG	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	9.91	3.79e-21	2.68e-18	0.48	0.41	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
LGG	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	9.91	3.79e-21	2.68e-18	0.49	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	9.91	3.79e-21	2.68e-18	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
LGG	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-9.9	3.8e-21	2.69e-18	-0.55	-0.41	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
LGG	cis	rs8092443	0.81	rs8084120	ENSG00000278971.1	RP11-644A7.2	9.9	3.8e-21	2.69e-18	0.62	0.41	Response to antipsychotic treatment;	chr18:70480746	chr18:70489630~70491205:+
LGG	cis	rs8092443	0.745	rs4629075	ENSG00000278971.1	RP11-644A7.2	9.9	3.8e-21	2.69e-18	0.62	0.41	Response to antipsychotic treatment;	chr18:70481613	chr18:70489630~70491205:+
LGG	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	9.9	3.81e-21	2.69e-18	0.37	0.41	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
LGG	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	9.9	3.81e-21	2.69e-18	0.49	0.41	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
LGG	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-9.9	3.81e-21	2.7e-18	-0.46	-0.41	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-9.9	3.82e-21	2.7e-18	-0.46	-0.41	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
LGG	cis	rs11098499	0.691	rs17009144	ENSG00000249244.1	RP11-548H18.2	-9.9	3.82e-21	2.7e-18	-0.43	-0.41	Corneal astigmatism;	chr4:119349640	chr4:119391831~119395335:-
LGG	cis	rs1153858	0.943	rs12439575	ENSG00000259433.2	CTD-2651B20.4	-9.9	3.83e-21	2.71e-18	-0.48	-0.41	Homoarginine levels;	chr15:45392618	chr15:45330209~45332634:-
LGG	cis	rs4986172	0.726	rs12051846	ENSG00000267288.2	RP13-890H12.2	-9.9	3.87e-21	2.73e-18	-0.55	-0.41	Height;	chr17:45149520	chr17:45168800~45171584:-
LGG	cis	rs977987	0.669	rs1001861	ENSG00000261783.1	RP11-252K23.2	-9.9	3.87e-21	2.74e-18	-0.57	-0.41	Dupuytren's disease;	chr16:75272557	chr16:75379818~75381260:-
LGG	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-9.9	3.89e-21	2.75e-18	-0.41	-0.41	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
LGG	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-9.9	3.9e-21	2.76e-18	-0.44	-0.41	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
LGG	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-9.9	3.93e-21	2.77e-18	-0.46	-0.41	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
LGG	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-9.9	3.96e-21	2.79e-18	-0.49	-0.41	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
LGG	cis	rs9388451	0.839	rs9401845	ENSG00000237742.5	RP11-624M8.1	-9.9	3.97e-21	2.8e-18	-0.37	-0.41	Brugada syndrome;	chr6:125782972	chr6:125578558~125749190:-
LGG	cis	rs9388451	0.805	rs1028481	ENSG00000237742.5	RP11-624M8.1	-9.9	3.97e-21	2.8e-18	-0.37	-0.41	Brugada syndrome;	chr6:125785427	chr6:125578558~125749190:-
LGG	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-9.9	3.98e-21	2.81e-18	-0.43	-0.41	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
LGG	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-9.9	3.98e-21	2.81e-18	-0.44	-0.41	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
LGG	cis	rs9388451	0.869	rs7764016	ENSG00000237742.5	RP11-624M8.1	-9.9	4e-21	2.82e-18	-0.36	-0.41	Brugada syndrome;	chr6:125749643	chr6:125578558~125749190:-
LGG	cis	rs9388451	0.839	rs1811852	ENSG00000237742.5	RP11-624M8.1	-9.9	4e-21	2.83e-18	-0.36	-0.41	Brugada syndrome;	chr6:125750429	chr6:125578558~125749190:-
LGG	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	9.9	4.01e-21	2.83e-18	0.3	0.41	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
LGG	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	9.9	4.01e-21	2.83e-18	0.3	0.41	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
LGG	cis	rs11148252	0.595	rs9526974	ENSG00000273784.3	RP11-78J21.7	-9.9	4.01e-21	2.83e-18	-0.46	-0.41	Lewy body disease;	chr13:52676905	chr13:52600042~52642542:+
LGG	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-9.9	4.02e-21	2.84e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
LGG	cis	rs1075265	0.901	rs9808326	ENSG00000233266.1	HMGB1P31	9.9	4.03e-21	2.85e-18	0.53	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54115971	chr2:54051334~54051760:+
LGG	cis	rs507080	0.769	rs2077173	ENSG00000278376.1	RP11-158I9.8	-9.9	4.04e-21	2.85e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118621876	chr11:118791254~118793137:+
LGG	cis	rs7119038	0.818	rs6589685	ENSG00000255239.1	AP002954.6	-9.9	4.08e-21	2.88e-18	-0.56	-0.41	Sjögren's syndrome;	chr11:118741488	chr11:118688039~118690600:-
LGG	cis	rs4373814	0.698	rs10828280	ENSG00000226083.4	SLC39A12-AS1	9.9	4.08e-21	2.88e-18	0.43	0.41	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18160426	chr10:18001786~18010562:-
LGG	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-9.9	4.09e-21	2.88e-18	-0.46	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
LGG	cis	rs4713118	0.824	rs7759217	ENSG00000216901.1	AL022393.7	9.9	4.1e-21	2.89e-18	0.54	0.41	Parkinson's disease;	chr6:27762684	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.784	rs9468219	ENSG00000216901.1	AL022393.7	9.9	4.1e-21	2.89e-18	0.54	0.41	Parkinson's disease;	chr6:27763976	chr6:28176188~28176674:+
LGG	cis	rs2013441	1	rs9915059	ENSG00000230528.6	NOS2P3	9.89	4.13e-21	2.91e-18	0.41	0.41	Obesity-related traits;	chr17:20273791	chr17:20436337~20447249:+
LGG	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	9.89	4.14e-21	2.92e-18	0.48	0.41	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
LGG	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	9.89	4.15e-21	2.93e-18	0.48	0.41	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
LGG	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-9.89	4.21e-21	2.97e-18	-0.57	-0.41	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
LGG	cis	rs17772222	1	rs17772222	ENSG00000222990.1	RNU4-22P	-9.89	4.21e-21	2.97e-18	-0.52	-0.41	Coronary artery calcification;	chr14:88360138	chr14:88513498~88513663:+
LGG	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	9.89	4.29e-21	3.02e-18	0.49	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
LGG	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-9.89	4.29e-21	3.02e-18	-0.49	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
LGG	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-9.89	4.33e-21	3.05e-18	-0.58	-0.41	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
LGG	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-9.89	4.33e-21	3.05e-18	-0.58	-0.41	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
LGG	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	9.89	4.35e-21	3.06e-18	0.53	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
LGG	cis	rs9875589	0.957	rs62234598	ENSG00000233121.1	VN1R20P	9.89	4.35e-21	3.07e-18	0.42	0.41	Ovarian reserve;	chr3:13923113	chr3:13926813~13927778:+
LGG	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	9.89	4.36e-21	3.07e-18	0.49	0.41	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
LGG	cis	rs6558530	0.932	rs9022	ENSG00000253982.1	CTD-2336O2.1	9.89	4.37e-21	3.08e-18	0.42	0.41	Systolic blood pressure;	chr8:1762811	chr8:1761990~1764502:-
LGG	cis	rs6452524	0.868	rs10045104	ENSG00000248112.1	RP11-78C3.1	9.89	4.39e-21	3.09e-18	0.55	0.41	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:82919376~82921119:-
LGG	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	9.89	4.4e-21	3.1e-18	0.79	0.41	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
LGG	cis	rs9527	0.59	rs11191513	ENSG00000272912.1	RP11-724N1.1	-9.89	4.42e-21	3.11e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103013227	chr10:102914585~102915404:+
LGG	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-9.89	4.43e-21	3.12e-18	-0.44	-0.41	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
LGG	cis	rs357618	0.581	rs165331	ENSG00000260581.1	CTB-113P19.4	-9.89	4.43e-21	3.12e-18	-0.49	-0.41	Basophil percentage of white cells;	chr5:151496406	chr5:151652275~151655449:+
LGG	cis	rs9527	0.59	rs10883829	ENSG00000272912.1	RP11-724N1.1	-9.89	4.43e-21	3.12e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103080878	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs763914	ENSG00000272912.1	RP11-724N1.1	-9.89	4.43e-21	3.12e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103081830	chr10:102914585~102915404:+
LGG	cis	rs507080	0.961	rs642530	ENSG00000278376.1	RP11-158I9.8	-9.89	4.43e-21	3.12e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118680047	chr11:118791254~118793137:+
LGG	cis	rs741668	0.931	rs17428825	ENSG00000235903.6	CPB2-AS1	9.89	4.44e-21	3.12e-18	0.45	0.41	Cerebrospinal fluid clusterin levels;	chr13:45948541	chr13:46052806~46113332:+
LGG	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	9.89	4.44e-21	3.12e-18	0.45	0.41	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-9.89	4.44e-21	3.12e-18	-0.45	-0.41	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
LGG	cis	rs7914558	1	rs7920251	ENSG00000272912.1	RP11-724N1.1	-9.89	4.45e-21	3.13e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs4917992	ENSG00000272912.1	RP11-724N1.1	-9.89	4.45e-21	3.13e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103026556	chr10:102914585~102915404:+
LGG	cis	rs9322193	0.923	rs7769101	ENSG00000216621.7	RP11-244K5.6	9.89	4.45e-21	3.13e-18	0.49	0.41	Lung cancer;	chr6:149848768	chr6:149934527~149936782:+
LGG	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-9.89	4.45e-21	3.13e-18	-0.47	-0.41	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
LGG	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-9.89	4.46e-21	3.14e-18	-0.56	-0.41	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
LGG	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-9.88	4.49e-21	3.16e-18	-0.41	-0.41	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
LGG	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-9.88	4.51e-21	3.17e-18	-0.45	-0.41	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-9.88	4.51e-21	3.17e-18	-0.45	-0.41	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.602	rs8176199	ENSG00000267681.1	CTD-3199J23.6	-9.88	4.53e-21	3.18e-18	-0.53	-0.41	Menopause (age at onset);	chr17:43078507	chr17:43144956~43145255:+
LGG	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-9.88	4.54e-21	3.19e-18	-0.44	-0.41	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
LGG	cis	rs1153858	0.945	rs7182300	ENSG00000259433.2	CTD-2651B20.4	-9.88	4.54e-21	3.19e-18	-0.48	-0.41	Homoarginine levels;	chr15:45342730	chr15:45330209~45332634:-
LGG	cis	rs1153858	0.887	rs7171163	ENSG00000259433.2	CTD-2651B20.4	-9.88	4.54e-21	3.19e-18	-0.48	-0.41	Homoarginine levels;	chr15:45344197	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs56669689	ENSG00000259433.2	CTD-2651B20.4	-9.88	4.54e-21	3.19e-18	-0.48	-0.41	Homoarginine levels;	chr15:45345531	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs56806728	ENSG00000259433.2	CTD-2651B20.4	-9.88	4.54e-21	3.19e-18	-0.48	-0.41	Homoarginine levels;	chr15:45345616	chr15:45330209~45332634:-
LGG	cis	rs9527	0.615	rs7899622	ENSG00000272912.1	RP11-724N1.1	-9.88	4.55e-21	3.2e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102967576	chr10:102914585~102915404:+
LGG	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	9.88	4.56e-21	3.21e-18	0.52	0.41	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
LGG	cis	rs7119038	0.818	rs11217033	ENSG00000255239.1	AP002954.6	-9.88	4.62e-21	3.25e-18	-0.58	-0.41	Sjögren's syndrome;	chr11:118802997	chr11:118688039~118690600:-
LGG	cis	rs11217036	1	rs11217036	ENSG00000255239.1	AP002954.6	-9.88	4.62e-21	3.25e-18	-0.58	-0.41	Allergy;	chr11:118805063	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.774	rs11217038	ENSG00000255239.1	AP002954.6	-9.88	4.62e-21	3.25e-18	-0.58	-0.41	Sjögren's syndrome;	chr11:118806646	chr11:118688039~118690600:-
LGG	cis	rs2799081	1	rs2799081	ENSG00000218016.2	ZNF192P2	-9.88	4.62e-21	3.25e-18	-0.52	-0.41	Myopia;	chr6:28302807	chr6:28188050~28189432:+
LGG	cis	rs9527	0.59	rs10786744	ENSG00000272912.1	RP11-724N1.1	9.88	4.63e-21	3.25e-18	0.46	0.41	Arsenic metabolism;	chr10:103185271	chr10:102914585~102915404:+
LGG	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	9.88	4.64e-21	3.26e-18	0.49	0.41	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
LGG	cis	rs10759883	0.612	rs2943532	ENSG00000175611.10	LINC00476	9.88	4.64e-21	3.26e-18	0.54	0.41	Nicotine dependence;	chr9:96024975	chr9:95759231~95875977:-
LGG	cis	rs7085104	0.7	rs10786712	ENSG00000272912.1	RP11-724N1.1	9.88	4.66e-21	3.27e-18	0.45	0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102914585~102915404:+
LGG	cis	rs8092443	0.81	rs2886658	ENSG00000278971.1	RP11-644A7.2	9.88	4.68e-21	3.28e-18	0.62	0.41	Response to antipsychotic treatment;	chr18:70483119	chr18:70489630~70491205:+
LGG	cis	rs17772222	0.958	rs2274737	ENSG00000222990.1	RNU4-22P	9.88	4.68e-21	3.28e-18	0.53	0.41	Coronary artery calcification;	chr14:88469307	chr14:88513498~88513663:+
LGG	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-9.88	4.72e-21	3.32e-18	-0.46	-0.41	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
LGG	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-9.88	4.74e-21	3.33e-18	-0.55	-0.41	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
LGG	cis	rs5742933	1	rs12622902	ENSG00000273240.1	RP11-455J20.3	-9.88	4.74e-21	3.33e-18	-0.53	-0.41	Ferritin levels;	chr2:189776263	chr2:189763859~189764456:-
LGG	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	9.88	4.75e-21	3.33e-18	0.62	0.41	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
LGG	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-9.88	4.76e-21	3.34e-18	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
LGG	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-9.88	4.76e-21	3.34e-18	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
LGG	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	9.88	4.78e-21	3.35e-18	0.49	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
LGG	cis	rs4713118	1	rs4713118	ENSG00000216901.1	AL022393.7	9.88	4.78e-21	3.36e-18	0.54	0.41	Parkinson's disease;	chr6:27709015	chr6:28176188~28176674:+
LGG	cis	rs4713118	1	rs13215072	ENSG00000216901.1	AL022393.7	9.88	4.78e-21	3.36e-18	0.54	0.41	Parkinson's disease;	chr6:27709949	chr6:28176188~28176674:+
LGG	cis	rs12935418	0.552	rs2123626	ENSG00000260213.4	RP11-303E16.3	9.88	4.79e-21	3.36e-18	0.5	0.41	Mean corpuscular volume;	chr16:80988205	chr16:81016792~81035759:-
LGG	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-9.88	4.79e-21	3.36e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-9.88	4.79e-21	3.36e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-9.88	4.79e-21	3.36e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-9.88	4.79e-21	3.36e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	9.88	4.79e-21	3.36e-18	0.48	0.41	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	9.88	4.79e-21	3.36e-18	0.48	0.41	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
LGG	cis	rs1153858	1	rs1719247	ENSG00000259433.2	CTD-2651B20.4	-9.88	4.8e-21	3.37e-18	-0.48	-0.41	Homoarginine levels;	chr15:45328787	chr15:45330209~45332634:-
LGG	cis	rs9527	0.59	rs10509764	ENSG00000272912.1	RP11-724N1.1	-9.88	4.81e-21	3.37e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103016718	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs6584537	ENSG00000272912.1	RP11-724N1.1	-9.88	4.81e-21	3.37e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103018510	chr10:102914585~102915404:+
LGG	cis	rs9527	0.569	rs78193706	ENSG00000272912.1	RP11-724N1.1	-9.88	4.81e-21	3.37e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103020807	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs7906754	ENSG00000272912.1	RP11-724N1.1	-9.88	4.81e-21	3.37e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103022800	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs4917991	ENSG00000272912.1	RP11-724N1.1	-9.88	4.81e-21	3.37e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103024076	chr10:102914585~102915404:+
LGG	cis	rs6452524	0.775	rs10071579	ENSG00000248112.1	RP11-78C3.1	9.88	4.82e-21	3.38e-18	0.55	0.41	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:82919376~82921119:-
LGG	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-9.88	4.83e-21	3.38e-18	-0.44	-0.41	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
LGG	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-9.88	4.83e-21	3.38e-18	-0.55	-0.41	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
LGG	cis	rs7247513	0.93	rs28368916	ENSG00000213290.4	PGK1P2	-9.88	4.83e-21	3.39e-18	-0.45	-0.41	Bipolar disorder;	chr19:12590763	chr19:12559571~12561105:+
LGG	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-9.88	4.84e-21	3.4e-18	-0.46	-0.41	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
LGG	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	9.88	4.87e-21	3.41e-18	0.53	0.41	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	9.88	4.87e-21	3.41e-18	0.53	0.41	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	9.88	4.87e-21	3.41e-18	0.53	0.41	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	9.88	4.87e-21	3.41e-18	0.53	0.41	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	9.88	4.87e-21	3.41e-18	0.53	0.41	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	9.88	4.87e-21	3.41e-18	0.53	0.41	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
LGG	cis	rs651907	0.535	rs2290859	ENSG00000256628.3	ZBTB11-AS1	9.87	4.88e-21	3.42e-18	0.48	0.41	Colorectal cancer;	chr3:101806781	chr3:101676475~101679217:+
LGG	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	9.87	4.89e-21	3.43e-18	0.33	0.41	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
LGG	cis	rs9322193	0.886	rs4870049	ENSG00000216621.7	RP11-244K5.6	9.87	4.95e-21	3.47e-18	0.51	0.41	Lung cancer;	chr6:149837058	chr6:149934527~149936782:+
LGG	cis	rs2408955	0.522	rs10875721	ENSG00000258273.1	RP11-370I10.4	9.87	4.98e-21	3.49e-18	0.52	0.41	Glycated hemoglobin levels;	chr12:48019810	chr12:48333755~48333901:-
LGG	cis	rs9388451	0.839	rs3966775	ENSG00000237742.5	RP11-624M8.1	-9.87	4.99e-21	3.5e-18	-0.36	-0.41	Brugada syndrome;	chr6:125746509	chr6:125578558~125749190:-
LGG	cis	rs9527	0.59	rs10883830	ENSG00000272912.1	RP11-724N1.1	-9.87	5e-21	3.5e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103091528	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs11191553	ENSG00000272912.1	RP11-724N1.1	-9.87	5e-21	3.5e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103091639	chr10:102914585~102915404:+
LGG	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	9.87	5e-21	3.5e-18	0.49	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
LGG	cis	rs1153858	1	rs4395020	ENSG00000259433.2	CTD-2651B20.4	-9.87	5.03e-21	3.52e-18	-0.47	-0.41	Homoarginine levels;	chr15:45360691	chr15:45330209~45332634:-
LGG	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-9.87	5.03e-21	3.52e-18	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-9.87	5.03e-21	3.52e-18	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-9.87	5.03e-21	3.52e-18	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-9.87	5.03e-21	3.52e-18	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-9.87	5.03e-21	3.52e-18	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-9.87	5.03e-21	3.52e-18	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
LGG	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-9.87	5.03e-21	3.53e-18	-0.51	-0.41	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
LGG	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-9.87	5.06e-21	3.54e-18	-0.54	-0.41	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
LGG	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	-9.87	5.09e-21	3.56e-18	-0.43	-0.41	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
LGG	cis	rs17772222	1	rs12589480	ENSG00000222990.1	RNU4-22P	9.87	5.1e-21	3.57e-18	0.52	0.41	Coronary artery calcification;	chr14:88414926	chr14:88513498~88513663:+
LGG	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	9.87	5.13e-21	3.59e-18	0.46	0.41	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-9.87	5.16e-21	3.61e-18	-0.46	-0.41	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
LGG	cis	rs507080	0.922	rs478296	ENSG00000278376.1	RP11-158I9.8	-9.87	5.18e-21	3.63e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118696666	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs493834	ENSG00000278376.1	RP11-158I9.8	-9.87	5.18e-21	3.63e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118696735	chr11:118791254~118793137:+
LGG	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-9.87	5.24e-21	3.67e-18	-0.47	-0.41	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
LGG	cis	rs12935418	0.616	rs9937731	ENSG00000260213.4	RP11-303E16.3	-9.87	5.25e-21	3.68e-18	-0.51	-0.41	Mean corpuscular volume;	chr16:80978406	chr16:81016792~81035759:-
LGG	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-9.87	5.25e-21	3.68e-18	-0.46	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
LGG	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-9.87	5.25e-21	3.68e-18	-0.46	-0.41	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-9.87	5.25e-21	3.68e-18	-0.46	-0.41	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-9.87	5.25e-21	3.68e-18	-0.46	-0.41	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
LGG	cis	rs2921073	0.605	rs2976933	ENSG00000173295.6	FAM86B3P	-9.87	5.26e-21	3.68e-18	-0.43	-0.41	Parkinson's disease;	chr8:8397365	chr8:8228595~8244865:+
LGG	cis	rs507080	0.769	rs483283	ENSG00000278376.1	RP11-158I9.8	-9.87	5.26e-21	3.68e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118635684	chr11:118791254~118793137:+
LGG	cis	rs9527	0.544	rs11191549	ENSG00000272912.1	RP11-724N1.1	-9.87	5.27e-21	3.69e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103087040	chr10:102914585~102915404:+
LGG	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-9.87	5.28e-21	3.69e-18	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
LGG	cis	rs7432375	0.901	rs9836231	ENSG00000261758.1	RP11-102M11.2	-9.86	5.29e-21	3.7e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136695479	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.804	rs6764567	ENSG00000261758.1	RP11-102M11.2	-9.86	5.29e-21	3.7e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136706672	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.901	rs7616204	ENSG00000261758.1	RP11-102M11.2	-9.86	5.29e-21	3.7e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136725747	chr3:136752630~136755780:+
LGG	cis	rs9388451	0.839	rs10457469	ENSG00000237742.5	RP11-624M8.1	-9.86	5.32e-21	3.72e-18	-0.36	-0.41	Brugada syndrome;	chr6:125762512	chr6:125578558~125749190:-
LGG	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	9.86	5.32e-21	3.72e-18	0.48	0.41	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
LGG	cis	rs5742933	1	rs1317751	ENSG00000273240.1	RP11-455J20.3	-9.86	5.32e-21	3.72e-18	-0.53	-0.41	Ferritin levels;	chr2:189807898	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs3791770	ENSG00000273240.1	RP11-455J20.3	-9.86	5.32e-21	3.72e-18	-0.53	-0.41	Ferritin levels;	chr2:189809109	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.948	rs62184286	ENSG00000273240.1	RP11-455J20.3	-9.86	5.32e-21	3.72e-18	-0.53	-0.41	Ferritin levels;	chr2:189812147	chr2:189763859~189764456:-
LGG	cis	rs17772222	0.71	rs1028455	ENSG00000258983.2	RP11-507K2.2	9.86	5.33e-21	3.73e-18	0.46	0.41	Coronary artery calcification;	chr14:88363631	chr14:88499334~88515502:+
LGG	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-9.86	5.34e-21	3.73e-18	-0.46	-0.41	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-9.86	5.34e-21	3.73e-18	-0.46	-0.41	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
LGG	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	9.86	5.36e-21	3.74e-18	0.49	0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
LGG	cis	rs4986172	0.655	rs1044977	ENSG00000267288.2	RP13-890H12.2	-9.86	5.36e-21	3.74e-18	-0.55	-0.41	Height;	chr17:45149847	chr17:45168800~45171584:-
LGG	cis	rs7247513	1	rs2042947	ENSG00000213290.4	PGK1P2	-9.86	5.38e-21	3.76e-18	-0.45	-0.41	Bipolar disorder;	chr19:12582289	chr19:12559571~12561105:+
LGG	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-9.86	5.39e-21	3.76e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
LGG	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-9.86	5.45e-21	3.81e-18	-0.44	-0.41	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-9.86	5.45e-21	3.81e-18	-0.44	-0.41	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
LGG	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	9.86	5.51e-21	3.85e-18	0.63	0.41	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
LGG	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	9.86	5.52e-21	3.86e-18	0.52	0.41	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	9.86	5.52e-21	3.86e-18	0.52	0.41	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
LGG	cis	rs12935418	0.672	rs3784814	ENSG00000260213.4	RP11-303E16.3	-9.86	5.53e-21	3.86e-18	-0.51	-0.41	Mean corpuscular volume;	chr16:81007652	chr16:81016792~81035759:-
LGG	cis	rs853679	0.599	rs149990	ENSG00000216901.1	AL022393.7	9.86	5.54e-21	3.87e-18	0.77	0.41	Depression;	chr6:28030480	chr6:28176188~28176674:+
LGG	cis	rs1153858	1	rs7163720	ENSG00000259433.2	CTD-2651B20.4	-9.86	5.55e-21	3.88e-18	-0.47	-0.41	Homoarginine levels;	chr15:45347176	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs7167900	ENSG00000259433.2	CTD-2651B20.4	-9.86	5.55e-21	3.88e-18	-0.47	-0.41	Homoarginine levels;	chr15:45347273	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12591058	ENSG00000259433.2	CTD-2651B20.4	-9.86	5.55e-21	3.88e-18	-0.47	-0.41	Homoarginine levels;	chr15:45347974	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs7169587	ENSG00000259433.2	CTD-2651B20.4	-9.86	5.55e-21	3.88e-18	-0.47	-0.41	Homoarginine levels;	chr15:45348181	chr15:45330209~45332634:-
LGG	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-9.86	5.56e-21	3.88e-18	-0.41	-0.41	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
LGG	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	9.86	5.57e-21	3.89e-18	0.52	0.41	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
LGG	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-9.86	5.57e-21	3.89e-18	-0.45	-0.41	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
LGG	cis	rs5742933	0.948	rs6434365	ENSG00000273240.1	RP11-455J20.3	-9.86	5.58e-21	3.9e-18	-0.53	-0.41	Ferritin levels;	chr2:189707695	chr2:189763859~189764456:-
LGG	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-9.86	5.59e-21	3.9e-18	-0.55	-0.41	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
LGG	cis	rs5742933	1	rs55792400	ENSG00000273240.1	RP11-455J20.3	-9.86	5.61e-21	3.92e-18	-0.53	-0.41	Ferritin levels;	chr2:189686708	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.947	rs62185871	ENSG00000273240.1	RP11-455J20.3	-9.86	5.61e-21	3.92e-18	-0.53	-0.41	Ferritin levels;	chr2:189686980	chr2:189763859~189764456:-
LGG	cis	rs11148252	0.512	rs9526950	ENSG00000198384.8	TPTE2P3	-9.86	5.62e-21	3.93e-18	-0.39	-0.41	Lewy body disease;	chr13:52600328	chr13:52522632~52586906:+
LGG	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	9.86	5.63e-21	3.93e-18	0.46	0.41	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
LGG	cis	rs7914558	0.966	rs10748837	ENSG00000272912.1	RP11-724N1.1	-9.86	5.66e-21	3.95e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs12571568	ENSG00000272912.1	RP11-724N1.1	-9.86	5.66e-21	3.95e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.966	rs12766205	ENSG00000272912.1	RP11-724N1.1	-9.86	5.66e-21	3.95e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102914585~102915404:+
LGG	cis	rs651907	0.535	rs17347156	ENSG00000256628.3	ZBTB11-AS1	9.86	5.67e-21	3.96e-18	0.48	0.41	Colorectal cancer;	chr3:101785830	chr3:101676475~101679217:+
LGG	cis	rs7216064	0.765	rs6504550	ENSG00000278219.1	AC145343.1	-9.86	5.69e-21	3.97e-18	-0.47	-0.41	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67898426	chr17:68101538~68101639:+
LGG	cis	rs5742933	1	rs5743052	ENSG00000273240.1	RP11-455J20.3	-9.86	5.69e-21	3.97e-18	-0.52	-0.41	Ferritin levels;	chr2:189824558	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs5743032	ENSG00000273240.1	RP11-455J20.3	-9.86	5.69e-21	3.97e-18	-0.53	-0.41	Ferritin levels;	chr2:189814077	chr2:189763859~189764456:-
LGG	cis	rs9527	0.83	rs3740392	ENSG00000272912.1	RP11-724N1.1	-9.86	5.69e-21	3.97e-18	-0.5	-0.41	Arsenic metabolism;	chr10:102877098	chr10:102914585~102915404:+
LGG	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-9.86	5.73e-21	4e-18	-0.67	-0.41	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
LGG	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	9.86	5.74e-21	4.01e-18	0.48	0.41	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
LGG	cis	rs4986172	0.7	rs71373536	ENSG00000267288.2	RP13-890H12.2	-9.85	5.74e-21	4.01e-18	-0.55	-0.41	Height;	chr17:45144441	chr17:45168800~45171584:-
LGG	cis	rs1475911	1	rs2839466	ENSG00000184385.2	UMODL1-AS1	-9.85	5.81e-21	4.05e-18	-0.51	-0.41	IgG glycosylation;	chr21:42092214	chr21:42102134~42108534:-
LGG	cis	rs7085104	0.7	rs743572	ENSG00000272912.1	RP11-724N1.1	-9.85	5.85e-21	4.08e-18	-0.46	-0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102914585~102915404:+
LGG	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	9.85	5.88e-21	4.1e-18	0.48	0.41	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
LGG	cis	rs7302981	1	rs7302981	ENSG00000272368.2	RP4-605O3.4	-9.85	5.91e-21	4.12e-18	-0.41	-0.41	Systolic blood pressure;	chr12:50144032	chr12:50112197~50165618:+
LGG	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-9.85	5.93e-21	4.13e-18	-0.39	-0.41	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
LGG	cis	rs9322193	0.772	rs7738696	ENSG00000216621.7	RP11-244K5.6	9.85	5.95e-21	4.15e-18	0.49	0.41	Lung cancer;	chr6:149848985	chr6:149934527~149936782:+
LGG	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	9.85	6e-21	4.19e-18	0.48	0.41	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-9.85	6.01e-21	4.19e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.966	rs2257233	ENSG00000125804.12	FAM182A	9.85	6.02e-21	4.19e-18	0.5	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:26054655~26086917:+
LGG	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	9.85	6.02e-21	4.2e-18	0.36	0.41	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
LGG	cis	rs7085104	0.66	rs7902804	ENSG00000272912.1	RP11-724N1.1	-9.85	6.03e-21	4.21e-18	-0.45	-0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102914585~102915404:+
LGG	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	9.85	6.05e-21	4.22e-18	0.46	0.41	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
LGG	cis	rs11148252	0.553	rs2147692	ENSG00000273784.3	RP11-78J21.7	-9.85	6.06e-21	4.23e-18	-0.46	-0.41	Lewy body disease;	chr13:52712888	chr13:52600042~52642542:+
LGG	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	9.85	6.07e-21	4.23e-18	0.53	0.41	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
LGG	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-9.85	6.12e-21	4.26e-18	-0.49	-0.41	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
LGG	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-9.85	6.13e-21	4.27e-18	-0.53	-0.41	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
LGG	cis	rs9527	0.59	rs7087040	ENSG00000272912.1	RP11-724N1.1	-9.85	6.13e-21	4.27e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103039911	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs12785223	ENSG00000272912.1	RP11-724N1.1	9.85	6.17e-21	4.3e-18	0.46	0.41	Arsenic metabolism;	chr10:103084254	chr10:102914585~102915404:+
LGG	cis	rs3812049	0.784	rs2250127	ENSG00000245937.6	LINC01184	-9.85	6.17e-21	4.3e-18	-0.49	-0.41	Lymphocyte counts;Red cell distribution width;	chr5:128053152	chr5:127940426~128083172:-
LGG	cis	rs7914558	1	rs7896547	ENSG00000272912.1	RP11-724N1.1	-9.85	6.18e-21	4.31e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102914585~102915404:+
LGG	cis	rs7914558	0.933	rs2066323	ENSG00000272912.1	RP11-724N1.1	-9.85	6.18e-21	4.31e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102914585~102915404:+
LGG	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-9.85	6.22e-21	4.33e-18	-0.31	-0.41	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
LGG	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-9.85	6.22e-21	4.34e-18	-0.46	-0.41	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
LGG	cis	rs9322193	0.923	rs9688350	ENSG00000216621.7	RP11-244K5.6	9.85	6.23e-21	4.34e-18	0.49	0.41	Lung cancer;	chr6:149730977	chr6:149934527~149936782:+
LGG	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-9.84	6.24e-21	4.35e-18	-0.52	-0.41	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
LGG	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-9.84	6.27e-21	4.37e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
LGG	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-9.84	6.28e-21	4.38e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
LGG	cis	rs507080	0.697	rs653008	ENSG00000278376.1	RP11-158I9.8	-9.84	6.29e-21	4.38e-18	-0.38	-0.41	Serum metabolite levels;	chr11:118649775	chr11:118791254~118793137:+
LGG	cis	rs17772222	0.636	rs77528165	ENSG00000258983.2	RP11-507K2.2	9.84	6.32e-21	4.4e-18	0.52	0.41	Coronary artery calcification;	chr14:88794249	chr14:88499334~88515502:+
LGG	cis	rs7432375	0.901	rs4521165	ENSG00000261758.1	RP11-102M11.2	-9.84	6.34e-21	4.41e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136650868	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.901	rs7618518	ENSG00000261758.1	RP11-102M11.2	-9.84	6.34e-21	4.41e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136651250	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.901	rs4038587	ENSG00000261758.1	RP11-102M11.2	-9.84	6.34e-21	4.41e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136662526	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.901	rs11919030	ENSG00000261758.1	RP11-102M11.2	9.84	6.34e-21	4.41e-18	0.43	0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136629757	chr3:136752630~136755780:+
LGG	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	9.84	6.35e-21	4.42e-18	0.46	0.41	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
LGG	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-9.84	6.37e-21	4.43e-18	-0.49	-0.41	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
LGG	cis	rs7085104	0.66	rs3781286	ENSG00000272912.1	RP11-724N1.1	-9.84	6.37e-21	4.44e-18	-0.46	-0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102914585~102915404:+
LGG	cis	rs7119038	0.818	rs77209083	ENSG00000255239.1	AP002954.6	-9.84	6.38e-21	4.44e-18	-0.58	-0.41	Sjögren's syndrome;	chr11:118736860	chr11:118688039~118690600:-
LGG	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	9.84	6.38e-21	4.44e-18	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
LGG	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	9.84	6.38e-21	4.44e-18	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
LGG	cis	rs1555322	0.53	rs2425049	ENSG00000279253.1	RP4-614O4.13	-9.84	6.39e-21	4.45e-18	-0.46	-0.41	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35262727~35264187:-
LGG	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	9.84	6.39e-21	4.45e-18	0.45	0.41	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
LGG	cis	rs9810089	0.814	rs2688600	ENSG00000261758.1	RP11-102M11.2	9.84	6.45e-21	4.49e-18	0.43	0.41	Gestational age at birth (child effect);	chr3:136533754	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.777	rs2688601	ENSG00000261758.1	RP11-102M11.2	9.84	6.45e-21	4.49e-18	0.43	0.41	Gestational age at birth (child effect);	chr3:136533759	chr3:136752630~136755780:+
LGG	cis	rs9527	0.59	rs1046411	ENSG00000272912.1	RP11-724N1.1	-9.84	6.46e-21	4.49e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103078059	chr10:102914585~102915404:+
LGG	cis	rs1153858	1	rs7181167	ENSG00000259433.2	CTD-2651B20.4	-9.84	6.49e-21	4.52e-18	-0.48	-0.41	Homoarginine levels;	chr15:45394038	chr15:45330209~45332634:-
LGG	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-9.84	6.52e-21	4.53e-18	-0.49	-0.41	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
LGG	cis	rs7914558	0.966	rs3977751	ENSG00000272912.1	RP11-724N1.1	-9.84	6.52e-21	4.54e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102914585~102915404:+
LGG	cis	rs9388451	0.839	rs980014	ENSG00000237742.5	RP11-624M8.1	-9.84	6.54e-21	4.55e-18	-0.36	-0.41	Brugada syndrome;	chr6:125746855	chr6:125578558~125749190:-
LGG	cis	rs7267979	1	rs4815411	ENSG00000276952.1	RP5-965G21.6	-9.84	6.55e-21	4.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25284915~25285588:-
LGG	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-9.84	6.63e-21	4.61e-18	-0.46	-0.41	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
LGG	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-9.84	6.63e-21	4.61e-18	-0.54	-0.41	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
LGG	cis	rs9527	0.59	rs10883818	ENSG00000272912.1	RP11-724N1.1	-9.84	6.66e-21	4.63e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102999829	chr10:102914585~102915404:+
LGG	cis	rs9527	0.641	rs10786732	ENSG00000272912.1	RP11-724N1.1	-9.84	6.66e-21	4.63e-18	-0.47	-0.41	Arsenic metabolism;	chr10:103002778	chr10:102914585~102915404:+
LGG	cis	rs17772222	1	rs17124700	ENSG00000222990.1	RNU4-22P	9.84	6.67e-21	4.64e-18	0.52	0.41	Coronary artery calcification;	chr14:88439285	chr14:88513498~88513663:+
LGG	cis	rs1577917	0.687	rs13197828	ENSG00000203875.9	SNHG5	-9.84	6.68e-21	4.64e-18	-0.49	-0.41	Response to antipsychotic treatment;	chr6:86095912	chr6:85660950~85678736:-
LGG	cis	rs7302981	0.967	rs7136570	ENSG00000272368.2	RP4-605O3.4	-9.84	6.69e-21	4.65e-18	-0.4	-0.41	Systolic blood pressure;	chr12:50136153	chr12:50112197~50165618:+
LGG	cis	rs7085104	0.7	rs6163	ENSG00000272912.1	RP11-724N1.1	-9.84	6.73e-21	4.68e-18	-0.46	-0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102914585~102915404:+
LGG	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-9.84	6.74e-21	4.69e-18	-0.56	-0.41	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-9.84	6.74e-21	4.69e-18	-0.56	-0.41	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
LGG	cis	rs71403859	0.57	rs77809998	ENSG00000260886.1	TAT-AS1	9.83	6.79e-21	4.72e-18	0.82	0.41	Post bronchodilator FEV1;	chr16:71396784	chr16:71565789~71578187:+
LGG	cis	rs7267979	1	rs2258201	ENSG00000276952.1	RP5-965G21.6	9.83	6.79e-21	4.72e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2297496	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs7343481	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6115146	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.934	rs6037085	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs6050532	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6083804	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4815405	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050542	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6076336	ENSG00000276952.1	RP5-965G21.6	-9.83	6.79e-21	4.72e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25284915~25285588:-
LGG	cis	rs1153858	1	rs16942000	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.82e-21	4.74e-18	-0.48	-0.41	Homoarginine levels;	chr15:45340805	chr15:45330209~45332634:-
LGG	cis	rs9527	0.59	rs7074395	ENSG00000272912.1	RP11-724N1.1	9.83	6.86e-21	4.76e-18	0.46	0.41	Arsenic metabolism;	chr10:103085171	chr10:102914585~102915404:+
LGG	cis	rs9810089	0.786	rs10935183	ENSG00000261758.1	RP11-102M11.2	9.83	6.87e-21	4.77e-18	0.43	0.41	Gestational age at birth (child effect);	chr3:136430297	chr3:136752630~136755780:+
LGG	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-9.83	6.88e-21	4.78e-18	-0.46	-0.41	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-9.83	6.88e-21	4.78e-18	-0.46	-0.41	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-9.83	6.88e-21	4.78e-18	-0.46	-0.41	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-9.83	6.88e-21	4.78e-18	-0.46	-0.41	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
LGG	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-9.83	6.9e-21	4.79e-18	-0.8	-0.41	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
LGG	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-9.83	6.9e-21	4.79e-18	-0.8	-0.41	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
LGG	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-9.83	6.9e-21	4.79e-18	-0.52	-0.41	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
LGG	cis	rs17345786	0.906	rs11708616	ENSG00000244119.1	PDCL3P4	9.83	6.92e-21	4.8e-18	0.35	0.41	Colonoscopy-negative controls vs population controls;	chr3:101512887	chr3:101712472~101713191:+
LGG	cis	rs1153858	1	rs66528868	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45376349	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs7494956	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45376367	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12437840	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45376857	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12437887	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45376896	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs2114501	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45378118	chr15:45330209~45332634:-
LGG	cis	rs1153858	0.887	rs7164139	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45378653	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs67461176	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45384621	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs66939267	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45384704	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs4775937	ENSG00000259433.2	CTD-2651B20.4	-9.83	6.93e-21	4.81e-18	-0.48	-0.41	Homoarginine levels;	chr15:45386416	chr15:45330209~45332634:-
LGG	cis	rs7432375	0.901	rs1017882	ENSG00000261758.1	RP11-102M11.2	9.83	6.95e-21	4.82e-18	0.43	0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136638863	chr3:136752630~136755780:+
LGG	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	9.83	6.95e-21	4.82e-18	0.47	0.41	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
LGG	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	9.83	6.97e-21	4.84e-18	0.52	0.41	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	9.83	6.97e-21	4.84e-18	0.52	0.41	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
LGG	cis	rs7267979	1	rs4815406	ENSG00000276952.1	RP5-965G21.6	-9.83	7e-21	4.85e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25284915~25285588:-
LGG	cis	rs7119038	0.774	rs11217001	ENSG00000255239.1	AP002954.6	-9.83	7e-21	4.86e-18	-0.58	-0.41	Sjögren's syndrome;	chr11:118736337	chr11:118688039~118690600:-
LGG	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	9.83	7.02e-21	4.87e-18	0.53	0.41	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
LGG	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-9.83	7.05e-21	4.89e-18	-0.46	-0.41	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-9.83	7.05e-21	4.89e-18	-0.46	-0.41	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
LGG	cis	rs7432375	0.901	rs35874192	ENSG00000261758.1	RP11-102M11.2	-9.83	7.05e-21	4.89e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136751162	chr3:136752630~136755780:+
LGG	cis	rs7432375	0.901	rs900818	ENSG00000261758.1	RP11-102M11.2	-9.83	7.05e-21	4.89e-18	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136752973	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.814	rs10804640	ENSG00000261758.1	RP11-102M11.2	9.83	7.07e-21	4.91e-18	0.43	0.41	Gestational age at birth (child effect);	chr3:136446853	chr3:136752630~136755780:+
LGG	cis	rs853679	0.599	rs202906	ENSG00000216901.1	AL022393.7	-9.83	7.1e-21	4.92e-18	-0.76	-0.41	Depression;	chr6:28043874	chr6:28176188~28176674:+
LGG	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-9.83	7.1e-21	4.92e-18	-0.46	-0.41	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
LGG	cis	rs9309711	0.813	rs11690865	ENSG00000225234.1	TRAPPC12-AS1	-9.83	7.11e-21	4.93e-18	-0.45	-0.41	Neurofibrillary tangles;	chr2:3468179	chr2:3481242~3482409:-
LGG	cis	rs507080	0.769	rs11603616	ENSG00000278376.1	RP11-158I9.8	-9.83	7.11e-21	4.93e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118625350	chr11:118791254~118793137:+
LGG	cis	rs507080	0.769	rs570952	ENSG00000278376.1	RP11-158I9.8	-9.83	7.11e-21	4.93e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118629477	chr11:118791254~118793137:+
LGG	cis	rs7615952	0.512	rs4234285	ENSG00000242001.1	GS1-388B5.1	9.83	7.18e-21	4.97e-18	0.54	0.41	Blood pressure (smoking interaction);	chr3:125685633	chr3:125681305~125681453:+
LGG	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	9.83	7.18e-21	4.98e-18	0.5	0.41	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
LGG	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-9.83	7.19e-21	4.98e-18	-0.39	-0.41	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-9.83	7.19e-21	4.98e-18	-0.39	-0.41	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
LGG	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	9.83	7.23e-21	5.01e-18	0.63	0.41	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
LGG	cis	rs7914558	1	rs7899084	ENSG00000272912.1	RP11-724N1.1	-9.83	7.23e-21	5.01e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102914585~102915404:+
LGG	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-9.83	7.29e-21	5.05e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
LGG	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-9.83	7.29e-21	5.05e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
LGG	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-9.83	7.29e-21	5.05e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
LGG	cis	rs741668	0.931	rs2806924	ENSG00000235903.6	CPB2-AS1	-9.83	7.31e-21	5.06e-18	-0.45	-0.41	Cerebrospinal fluid clusterin levels;	chr13:45944831	chr13:46052806~46113332:+
LGG	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	9.83	7.31e-21	5.07e-18	0.48	0.41	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
LGG	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-9.83	7.32e-21	5.07e-18	-0.52	-0.41	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
LGG	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	9.83	7.34e-21	5.09e-18	0.48	0.41	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
LGG	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-9.83	7.35e-21	5.09e-18	-0.39	-0.41	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
LGG	cis	rs6903823	0.508	rs1150721	ENSG00000280107.1	AL022393.9	-9.82	7.36e-21	5.1e-18	-0.42	-0.41	Pulmonary function;	chr6:28287263	chr6:28170845~28172521:+
LGG	cis	rs30380	0.688	rs27524	ENSG00000248734.2	CTD-2260A17.1	9.82	7.36e-21	5.1e-18	0.43	0.41	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96784777~96785999:+
LGG	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-9.82	7.39e-21	5.12e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-9.82	7.39e-21	5.12e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
LGG	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	9.82	7.39e-21	5.12e-18	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
LGG	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-9.82	7.39e-21	5.12e-18	-0.44	-0.41	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
LGG	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	9.82	7.41e-21	5.13e-18	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
LGG	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	9.82	7.43e-21	5.15e-18	0.49	0.41	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
LGG	cis	rs9527	0.83	rs10883790	ENSG00000272912.1	RP11-724N1.1	-9.82	7.44e-21	5.15e-18	-0.49	-0.41	Arsenic metabolism;	chr10:102881198	chr10:102914585~102915404:+
LGG	cis	rs9527	0.83	rs11191440	ENSG00000272912.1	RP11-724N1.1	-9.82	7.44e-21	5.15e-18	-0.49	-0.41	Arsenic metabolism;	chr10:102881754	chr10:102914585~102915404:+
LGG	cis	rs6558530	0.965	rs6558535	ENSG00000253982.1	CTD-2336O2.1	9.82	7.46e-21	5.16e-18	0.42	0.41	Systolic blood pressure;	chr8:1762466	chr8:1761990~1764502:-
LGG	cis	rs3096299	0.596	rs889573	ENSG00000274627.1	RP11-104N10.2	9.82	7.48e-21	5.17e-18	0.37	0.41	Multiple myeloma (IgH translocation);	chr16:89371152	chr16:89516797~89522217:+
LGG	cis	rs1153858	1	rs11070456	ENSG00000259433.2	CTD-2651B20.4	-9.82	7.49e-21	5.18e-18	-0.47	-0.41	Homoarginine levels;	chr15:45394637	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs11070457	ENSG00000259433.2	CTD-2651B20.4	-9.82	7.49e-21	5.18e-18	-0.47	-0.41	Homoarginine levels;	chr15:45394745	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs3809472	ENSG00000259433.2	CTD-2651B20.4	-9.82	7.49e-21	5.18e-18	-0.47	-0.41	Homoarginine levels;	chr15:45402120	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1820518	ENSG00000259433.2	CTD-2651B20.4	-9.82	7.49e-21	5.18e-18	-0.47	-0.41	Homoarginine levels;	chr15:45402381	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1365610	ENSG00000259433.2	CTD-2651B20.4	-9.82	7.49e-21	5.18e-18	-0.47	-0.41	Homoarginine levels;	chr15:45402412	chr15:45330209~45332634:-
LGG	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-9.82	7.49e-21	5.18e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
LGG	cis	rs5742933	1	rs3791767	ENSG00000273240.1	RP11-455J20.3	9.82	7.49e-21	5.19e-18	0.52	0.41	Ferritin levels;	chr2:189775189	chr2:189763859~189764456:-
LGG	cis	rs9810089	0.758	rs12492510	ENSG00000261758.1	RP11-102M11.2	9.82	7.5e-21	5.19e-18	0.43	0.41	Gestational age at birth (child effect);	chr3:136432789	chr3:136752630~136755780:+
LGG	cis	rs7247513	1	rs12459123	ENSG00000213290.4	PGK1P2	-9.82	7.52e-21	5.21e-18	-0.46	-0.41	Bipolar disorder;	chr19:12578927	chr19:12559571~12561105:+
LGG	cis	rs9527	0.59	rs2274339	ENSG00000272912.1	RP11-724N1.1	-9.82	7.53e-21	5.21e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103100296	chr10:102914585~102915404:+
LGG	cis	rs6903823	0.508	rs1150724	ENSG00000280107.1	AL022393.9	-9.82	7.53e-21	5.21e-18	-0.42	-0.41	Pulmonary function;	chr6:28282459	chr6:28170845~28172521:+
LGG	cis	rs17345786	0.906	rs58835747	ENSG00000244119.1	PDCL3P4	9.82	7.59e-21	5.25e-18	0.36	0.41	Colonoscopy-negative controls vs population controls;	chr3:101524790	chr3:101712472~101713191:+
LGG	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	9.82	7.6e-21	5.25e-18	0.37	0.41	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	9.82	7.6e-21	5.25e-18	0.37	0.41	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	9.82	7.6e-21	5.25e-18	0.37	0.41	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
LGG	cis	rs7119038	0.818	rs73003215	ENSG00000255239.1	AP002954.6	-9.82	7.62e-21	5.27e-18	-0.55	-0.41	Sjögren's syndrome;	chr11:118778803	chr11:118688039~118690600:-
LGG	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-9.82	7.63e-21	5.27e-18	-0.42	-0.41	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
LGG	cis	rs5742933	1	rs3791773	ENSG00000273240.1	RP11-455J20.3	-9.82	7.63e-21	5.28e-18	-0.52	-0.41	Ferritin levels;	chr2:189817906	chr2:189763859~189764456:-
LGG	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-9.82	7.64e-21	5.28e-18	-0.45	-0.41	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
LGG	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	9.82	7.64e-21	5.28e-18	0.83	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
LGG	cis	rs7826238	0.543	rs2976908	ENSG00000173295.6	FAM86B3P	-9.82	7.68e-21	5.31e-18	-0.44	-0.41	Systolic blood pressure;	chr8:8488264	chr8:8228595~8244865:+
LGG	cis	rs2278702	1	rs2278702	ENSG00000259495.2	RP11-210M15.2	-9.82	7.69e-21	5.32e-18	-0.48	-0.41	Bipolar disorder;	chr15:80402580	chr15:80344853~80403575:-
LGG	cis	rs5742933	1	rs2289404	ENSG00000273240.1	RP11-455J20.3	-9.82	7.7e-21	5.32e-18	-0.53	-0.41	Ferritin levels;	chr2:189771288	chr2:189763859~189764456:-
LGG	cis	rs7829975	0.6	rs1719381	ENSG00000253893.2	FAM85B	9.82	7.73e-21	5.34e-18	0.5	0.41	Mood instability;	chr8:8744834	chr8:8167819~8226614:-
LGG	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	9.82	7.76e-21	5.36e-18	0.46	0.41	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
LGG	cis	rs507080	0.769	rs645637	ENSG00000278376.1	RP11-158I9.8	-9.82	7.76e-21	5.37e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118634373	chr11:118791254~118793137:+
LGG	cis	rs7829975	0.684	rs546603	ENSG00000173295.6	FAM86B3P	9.82	7.77e-21	5.37e-18	0.43	0.41	Mood instability;	chr8:8738328	chr8:8228595~8244865:+
LGG	cis	rs12935418	0.672	rs6564814	ENSG00000260213.4	RP11-303E16.3	-9.82	7.77e-21	5.37e-18	-0.51	-0.41	Mean corpuscular volume;	chr16:81016567	chr16:81016792~81035759:-
LGG	cis	rs4713118	0.824	rs9468223	ENSG00000216901.1	AL022393.7	9.82	7.77e-21	5.37e-18	0.54	0.41	Parkinson's disease;	chr6:27772887	chr6:28176188~28176674:+
LGG	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-9.82	7.79e-21	5.38e-18	-0.41	-0.41	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
LGG	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	9.82	7.81e-21	5.4e-18	0.3	0.41	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
LGG	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	9.82	7.82e-21	5.4e-18	0.56	0.41	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
LGG	cis	rs7914558	0.901	rs1926034	ENSG00000272912.1	RP11-724N1.1	-9.82	7.87e-21	5.44e-18	-0.46	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103069345	chr10:102914585~102915404:+
LGG	cis	rs7829975	0.559	rs4841025	ENSG00000253893.2	FAM85B	9.82	7.88e-21	5.44e-18	0.5	0.41	Mood instability;	chr8:8745650	chr8:8167819~8226614:-
LGG	cis	rs11098499	0.562	rs58583086	ENSG00000249244.1	RP11-548H18.2	-9.82	7.89e-21	5.45e-18	-0.42	-0.41	Corneal astigmatism;	chr4:119635207	chr4:119391831~119395335:-
LGG	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	9.82	7.9e-21	5.46e-18	0.34	0.41	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
LGG	cis	rs7267979	1	rs2258135	ENSG00000276952.1	RP5-965G21.6	9.82	7.96e-21	5.5e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25284915~25285588:-
LGG	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	9.82	7.98e-21	5.51e-18	0.59	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
LGG	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-9.81	8e-21	5.52e-18	-0.46	-0.41	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
LGG	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-9.81	8.03e-21	5.55e-18	-0.49	-0.41	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
LGG	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-9.81	8.04e-21	5.55e-18	-0.45	-0.41	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
LGG	cis	rs7267979	1	rs10966	ENSG00000276952.1	RP5-965G21.6	9.81	8.05e-21	5.56e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs6083817	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050564	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs6083818	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4815409	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs6037097	ENSG00000276952.1	RP5-965G21.6	9.81	8.05e-21	5.56e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050565	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs6107031	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6115159	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4813562	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs6050567	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6037099	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs4815414	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6083825	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs34645895	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs3827014	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6115168	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6037105	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2387880	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2387882	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2387884	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6076345	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050590	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4813566	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4815421	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2184000	ENSG00000276952.1	RP5-965G21.6	-9.81	8.05e-21	5.56e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050598	ENSG00000276952.1	RP5-965G21.6	9.81	8.05e-21	5.56e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25284915~25285588:-
LGG	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-9.81	8.06e-21	5.56e-18	-0.46	-0.41	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
LGG	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-9.81	8.07e-21	5.57e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
LGG	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-9.81	8.08e-21	5.58e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
LGG	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	9.81	8.11e-21	5.6e-18	0.49	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	9.81	8.11e-21	5.6e-18	0.49	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	9.81	8.11e-21	5.6e-18	0.49	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
LGG	cis	rs651907	0.535	rs58658478	ENSG00000256628.3	ZBTB11-AS1	9.81	8.15e-21	5.62e-18	0.47	0.41	Colorectal cancer;	chr3:101792823	chr3:101676475~101679217:+
LGG	cis	rs7119038	0.818	rs2155433	ENSG00000255239.1	AP002954.6	-9.81	8.17e-21	5.63e-18	-0.55	-0.41	Sjögren's syndrome;	chr11:118742212	chr11:118688039~118690600:-
LGG	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	9.81	8.18e-21	5.64e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
LGG	cis	rs9527	0.545	rs11191602	ENSG00000272912.1	RP11-724N1.1	-9.81	8.23e-21	5.67e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103194462	chr10:102914585~102915404:+
LGG	cis	rs9527	0.545	rs7095304	ENSG00000272912.1	RP11-724N1.1	-9.81	8.23e-21	5.67e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103195038	chr10:102914585~102915404:+
LGG	cis	rs9527	0.545	rs7100369	ENSG00000272912.1	RP11-724N1.1	-9.81	8.23e-21	5.67e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103196461	chr10:102914585~102915404:+
LGG	cis	rs9527	0.545	rs12784384	ENSG00000272912.1	RP11-724N1.1	-9.81	8.23e-21	5.67e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103197837	chr10:102914585~102915404:+
LGG	cis	rs9527	0.545	rs10883847	ENSG00000272912.1	RP11-724N1.1	-9.81	8.23e-21	5.67e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103198527	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs2152915	ENSG00000272912.1	RP11-724N1.1	-9.81	8.25e-21	5.68e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102931975	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs3897401	ENSG00000272912.1	RP11-724N1.1	-9.81	8.25e-21	5.68e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102936622	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs36045108	ENSG00000272912.1	RP11-724N1.1	-9.81	8.25e-21	5.68e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102938172	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs10883804	ENSG00000272912.1	RP11-724N1.1	-9.81	8.25e-21	5.68e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102946763	chr10:102914585~102915404:+
LGG	cis	rs9527	0.64	rs7089061	ENSG00000272912.1	RP11-724N1.1	-9.81	8.25e-21	5.68e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102963258	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs7089065	ENSG00000272912.1	RP11-724N1.1	-9.81	8.25e-21	5.68e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102963265	chr10:102914585~102915404:+
LGG	cis	rs8062405	0.54	rs151226	ENSG00000271623.1	RP11-435I10.5	-9.81	8.26e-21	5.69e-18	-0.46	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28364700~28365333:+
LGG	cis	rs4373814	0.661	rs10764329	ENSG00000226083.4	SLC39A12-AS1	9.81	8.26e-21	5.69e-18	0.42	0.41	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18161652	chr10:18001786~18010562:-
LGG	cis	rs11647589	0.553	rs6497484	ENSG00000260762.1	ACSM5P1	9.81	8.27e-21	5.7e-18	0.5	0.41	Blood metabolite levels;	chr16:20428396	chr16:20586550~20607107:-
LGG	cis	rs7267979	0.966	rs8123949	ENSG00000276952.1	RP5-965G21.6	-9.81	8.27e-21	5.7e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25284915~25285588:-
LGG	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	9.81	8.28e-21	5.71e-18	0.36	0.41	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
LGG	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-9.81	8.36e-21	5.76e-18	-0.38	-0.41	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
LGG	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	9.81	8.43e-21	5.81e-18	0.59	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
LGG	cis	rs7927771	0.832	rs10838697	ENSG00000280615.1	Y_RNA	-9.81	8.43e-21	5.81e-18	-0.52	-0.41	Subjective well-being;	chr11:47362933	chr11:47614898~47614994:-
LGG	cis	rs1153858	1	rs12594857	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45374980	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs7164602	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45379127	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12441971	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45379759	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1346268	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45380831	chr15:45330209~45332634:-
LGG	cis	rs1153858	0.943	rs67045941	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45384813	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs67744121	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45385039	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs16942568	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45385192	chr15:45330209~45332634:-
LGG	cis	rs1153858	0.943	rs11070454	ENSG00000259433.2	CTD-2651B20.4	-9.81	8.45e-21	5.82e-18	-0.47	-0.41	Homoarginine levels;	chr15:45388054	chr15:45330209~45332634:-
LGG	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-9.81	8.47e-21	5.83e-18	-0.54	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
LGG	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-9.81	8.49e-21	5.85e-18	-0.45	-0.41	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
LGG	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-9.81	8.52e-21	5.87e-18	-0.54	-0.41	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
LGG	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-9.81	8.52e-21	5.87e-18	-0.54	-0.41	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
LGG	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-9.81	8.52e-21	5.87e-18	-0.54	-0.41	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
LGG	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-9.81	8.52e-21	5.87e-18	-0.54	-0.41	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
LGG	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-9.81	8.53e-21	5.87e-18	-0.41	-0.41	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
LGG	cis	rs4683346	0.752	rs4683341	ENSG00000273328.4	RP11-141M3.6	-9.81	8.53e-21	5.87e-18	-0.47	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42835902	chr3:42809414~42908105:+
LGG	cis	rs9527	0.59	rs7901197	ENSG00000272912.1	RP11-724N1.1	-9.81	8.54e-21	5.88e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103080676	chr10:102914585~102915404:+
LGG	cis	rs9388451	0.868	rs10457467	ENSG00000237742.5	RP11-624M8.1	-9.81	8.56e-21	5.89e-18	-0.37	-0.41	Brugada syndrome;	chr6:125724002	chr6:125578558~125749190:-
LGG	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	9.81	8.64e-21	5.95e-18	0.46	0.41	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
LGG	cis	rs7267979	0.873	rs6115093	ENSG00000276952.1	RP5-965G21.6	9.81	8.65e-21	5.95e-18	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25284915~25285588:-
LGG	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-9.8	8.69e-21	5.98e-18	-0.45	-0.41	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
LGG	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	9.8	8.7e-21	5.99e-18	0.36	0.41	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
LGG	cis	rs9527	0.615	rs7917295	ENSG00000272912.1	RP11-724N1.1	-9.8	8.72e-21	6e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102941430	chr10:102914585~102915404:+
LGG	cis	rs7267979	1	rs6050561	ENSG00000276952.1	RP5-965G21.6	-9.8	8.76e-21	6.03e-18	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6083813	ENSG00000276952.1	RP5-965G21.6	-9.8	8.76e-21	6.03e-18	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.523	rs2179096	ENSG00000199851.2	U3	9.8	8.79e-21	6.05e-18	0.57	0.41	Parkinson's disease;	chr6:27698141	chr6:28015568~28015777:+
LGG	cis	rs3742264	1	rs8181800	ENSG00000235903.6	CPB2-AS1	-9.8	8.81e-21	6.06e-18	-0.46	-0.41	Blood protein levels;	chr13:46076559	chr13:46052806~46113332:+
LGG	cis	rs9465539	0.544	rs6910773	ENSG00000228412.5	RP4-625H18.2	-9.8	8.87e-21	6.11e-18	-0.53	-0.41	Neuroticism;	chr6:19820427	chr6:19802164~19804752:-
LGG	cis	rs7267979	0.706	rs6138542	ENSG00000276952.1	RP5-965G21.6	9.8	8.9e-21	6.12e-18	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25284915~25285588:-
LGG	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-9.8	8.91e-21	6.13e-18	-0.48	-0.41	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
LGG	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-9.8	8.92e-21	6.14e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
LGG	cis	rs5758511	0.689	rs17478227	ENSG00000227370.1	RP4-669P10.19	-9.8	8.94e-21	6.15e-18	-0.52	-0.41	Birth weight;	chr22:42258321	chr22:42132543~42132998:+
LGG	cis	rs12935418	0.616	rs13332902	ENSG00000260213.4	RP11-303E16.3	-9.8	8.95e-21	6.16e-18	-0.49	-0.41	Mean corpuscular volume;	chr16:80971903	chr16:81016792~81035759:-
LGG	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-9.8	8.96e-21	6.16e-18	-0.47	-0.41	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
LGG	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-9.8	9.01e-21	6.19e-18	-0.39	-0.41	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
LGG	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-9.8	9.05e-21	6.22e-18	-0.54	-0.41	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
LGG	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-9.8	9.05e-21	6.22e-18	-0.45	-0.41	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
LGG	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-9.8	9.06e-21	6.23e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
LGG	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-9.8	9.06e-21	6.23e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
LGG	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-9.8	9.06e-21	6.23e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
LGG	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-9.8	9.06e-21	6.23e-18	-0.53	-0.41	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
LGG	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-9.8	9.07e-21	6.23e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
LGG	cis	rs748404	0.534	rs489509	ENSG00000249839.1	AC011330.5	-9.8	9.21e-21	6.33e-18	-0.55	-0.41	Lung cancer;	chr15:43294709	chr15:43663654~43684339:-
LGG	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	9.8	9.21e-21	6.33e-18	0.93	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
LGG	cis	rs657075	0.595	rs35724182	ENSG00000233006.5	AC034220.3	-9.8	9.23e-21	6.34e-18	-0.57	-0.41	Rheumatoid arthritis;	chr5:132244608	chr5:132311285~132369916:-
LGG	cis	rs657075	0.595	rs35719560	ENSG00000233006.5	AC034220.3	-9.8	9.23e-21	6.34e-18	-0.57	-0.41	Rheumatoid arthritis;	chr5:132248702	chr5:132311285~132369916:-
LGG	cis	rs651907	0.535	rs34743741	ENSG00000256628.3	ZBTB11-AS1	9.8	9.25e-21	6.36e-18	0.47	0.41	Colorectal cancer;	chr3:101813604	chr3:101676475~101679217:+
LGG	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	9.8	9.27e-21	6.37e-18	0.52	0.41	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
LGG	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	9.8	9.29e-21	6.38e-18	0.49	0.41	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
LGG	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-9.8	9.37e-21	6.44e-18	-0.49	-0.41	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
LGG	cis	rs7615952	0.605	rs11708269	ENSG00000242001.1	GS1-388B5.1	9.8	9.37e-21	6.44e-18	0.67	0.41	Blood pressure (smoking interaction);	chr3:125613306	chr3:125681305~125681453:+
LGG	cis	rs7247513	1	rs7247513	ENSG00000213290.4	PGK1P2	-9.8	9.39e-21	6.45e-18	-0.45	-0.41	Bipolar disorder;	chr19:12580371	chr19:12559571~12561105:+
LGG	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-9.79	9.44e-21	6.49e-18	-0.39	-0.41	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
LGG	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-9.79	9.44e-21	6.49e-18	-0.39	-0.41	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
LGG	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-9.79	9.44e-21	6.49e-18	-0.39	-0.41	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
LGG	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-9.79	9.44e-21	6.49e-18	-0.39	-0.41	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
LGG	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	9.79	9.48e-21	6.51e-18	0.48	0.41	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
LGG	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-9.79	9.48e-21	6.51e-18	-0.46	-0.41	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
LGG	cis	rs758324	0.58	rs35566767	ENSG00000233006.5	AC034220.3	-9.79	9.54e-21	6.55e-18	-0.62	-0.41	Alzheimer's disease in APOE e4- carriers;	chr5:132270356	chr5:132311285~132369916:-
LGG	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-9.79	9.55e-21	6.56e-18	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
LGG	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	9.79	9.55e-21	6.56e-18	0.52	0.41	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	9.79	9.55e-21	6.56e-18	0.52	0.41	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	9.79	9.55e-21	6.56e-18	0.52	0.41	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	9.79	9.55e-21	6.56e-18	0.52	0.41	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
LGG	cis	rs7914558	0.902	rs7092200	ENSG00000272912.1	RP11-724N1.1	-9.79	9.56e-21	6.56e-18	-0.45	-0.41	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103085115	chr10:102914585~102915404:+
LGG	cis	rs11148252	0.595	rs4884522	ENSG00000273784.3	RP11-78J21.7	-9.79	9.61e-21	6.6e-18	-0.47	-0.41	Lewy body disease;	chr13:52479633	chr13:52600042~52642542:+
LGG	cis	rs1153858	1	rs9783731	ENSG00000259433.2	CTD-2651B20.4	9.79	9.63e-21	6.61e-18	0.47	0.41	Homoarginine levels;	chr15:45350686	chr15:45330209~45332634:-
LGG	cis	rs7267979	1	rs4815420	ENSG00000276952.1	RP5-965G21.6	-9.79	9.67e-21	6.64e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25284915~25285588:-
LGG	cis	rs651907	0.535	rs1460097	ENSG00000256628.3	ZBTB11-AS1	9.79	9.69e-21	6.65e-18	0.47	0.41	Colorectal cancer;	chr3:101778725	chr3:101676475~101679217:+
LGG	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-9.79	9.69e-21	6.65e-18	-0.5	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
LGG	cis	rs2921073	0.51	rs2976944	ENSG00000253893.2	FAM85B	-9.79	9.73e-21	6.67e-18	-0.5	-0.41	Parkinson's disease;	chr8:8413404	chr8:8167819~8226614:-
LGG	cis	rs507080	0.922	rs644498	ENSG00000278376.1	RP11-158I9.8	-9.79	9.75e-21	6.69e-18	-0.37	-0.41	Serum metabolite levels;	chr11:118696777	chr11:118791254~118793137:+
LGG	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-9.79	9.8e-21	6.72e-18	-0.51	-0.41	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
LGG	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-9.79	9.83e-21	6.74e-18	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
LGG	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	9.79	9.84e-21	6.75e-18	0.36	0.41	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
LGG	cis	rs7267979	1	rs4815412	ENSG00000276952.1	RP5-965G21.6	9.79	9.89e-21	6.79e-18	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25284915~25285588:-
LGG	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-9.79	9.92e-21	6.8e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-9.79	9.92e-21	6.8e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
LGG	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-9.79	9.92e-21	6.8e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
LGG	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-9.79	9.92e-21	6.8e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
LGG	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	9.79	9.94e-21	6.81e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	9.79	9.94e-21	6.81e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
LGG	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-9.79	9.95e-21	6.82e-18	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
LGG	cis	rs6600671	0.719	rs9728991	ENSG00000223345.3	HIST2H2BA	9.79	1e-20	6.87e-18	0.43	0.41	Hip geometry;	chr1:121522281	chr1:121108210~121117257:-
LGG	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	9.79	1e-20	6.87e-18	0.62	0.41	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
LGG	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-9.79	1.01e-20	6.94e-18	-0.54	-0.41	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
LGG	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-9.79	1.02e-20	6.96e-18	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
LGG	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	9.79	1.02e-20	6.97e-18	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
LGG	cis	rs651907	0.535	rs11711903	ENSG00000256628.3	ZBTB11-AS1	9.79	1.02e-20	6.98e-18	0.47	0.41	Colorectal cancer;	chr3:101781904	chr3:101676475~101679217:+
LGG	cis	rs9527	0.545	rs10218853	ENSG00000272912.1	RP11-724N1.1	-9.78	1.03e-20	7.06e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103037030	chr10:102914585~102915404:+
LGG	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-9.78	1.03e-20	7.08e-18	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
LGG	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	9.78	1.04e-20	7.09e-18	0.63	0.41	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
LGG	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-9.78	1.04e-20	7.09e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
LGG	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	9.78	1.04e-20	7.12e-18	0.47	0.41	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-9.78	1.04e-20	7.15e-18	-0.46	-0.41	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-9.78	1.04e-20	7.15e-18	-0.46	-0.41	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-9.78	1.04e-20	7.15e-18	-0.46	-0.41	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
LGG	cis	rs9527	0.59	rs7920868	ENSG00000272912.1	RP11-724N1.1	-9.78	1.05e-20	7.16e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103035652	chr10:102914585~102915404:+
LGG	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	9.78	1.05e-20	7.16e-18	0.35	0.41	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
LGG	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-9.78	1.05e-20	7.21e-18	-0.46	-0.41	Depression;	chr6:28135913	chr6:28115628~28116551:+
LGG	cis	rs9527	0.59	rs12415388	ENSG00000272912.1	RP11-724N1.1	-9.78	1.06e-20	7.22e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103036588	chr10:102914585~102915404:+
LGG	cis	rs12935418	0.672	rs3826048	ENSG00000260213.4	RP11-303E16.3	-9.78	1.06e-20	7.27e-18	-0.51	-0.41	Mean corpuscular volume;	chr16:81023230	chr16:81016792~81035759:-
LGG	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-9.78	1.06e-20	7.27e-18	-0.43	-0.41	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
LGG	cis	rs7267979	0.933	rs2261109	ENSG00000276952.1	RP5-965G21.6	9.78	1.07e-20	7.32e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2261698	ENSG00000276952.1	RP5-965G21.6	9.78	1.07e-20	7.32e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2261720	ENSG00000276952.1	RP5-965G21.6	9.78	1.07e-20	7.32e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2227890	ENSG00000276952.1	RP5-965G21.6	9.78	1.07e-20	7.32e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25284915~25285588:-
LGG	cis	rs2195224	1	rs2195224	ENSG00000273328.4	RP11-141M3.6	-9.78	1.07e-20	7.34e-18	-0.47	-0.41	Monocyte count;	chr3:42859508	chr3:42809414~42908105:+
LGG	cis	rs7267979	1	rs3761117	ENSG00000276952.1	RP5-965G21.6	-9.78	1.08e-20	7.37e-18	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25284915~25285588:-
LGG	cis	rs9872440	1	rs9872440	ENSG00000273328.4	RP11-141M3.6	-9.78	1.08e-20	7.37e-18	-0.47	-0.41	Granulocyte count;Myeloid white cell count;	chr3:42854959	chr3:42809414~42908105:+
LGG	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	9.78	1.08e-20	7.39e-18	0.48	0.41	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
LGG	cis	rs6452524	0.901	rs72767146	ENSG00000248112.1	RP11-78C3.1	9.78	1.08e-20	7.39e-18	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:82919376~82921119:-
LGG	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-9.78	1.08e-20	7.4e-18	-0.45	-0.41	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
LGG	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	9.78	1.08e-20	7.4e-18	0.66	0.41	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
LGG	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-9.78	1.09e-20	7.42e-18	-0.55	-0.41	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-9.78	1.09e-20	7.42e-18	-0.55	-0.41	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
LGG	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-9.78	1.09e-20	7.43e-18	-0.59	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
LGG	cis	rs17345786	1	rs17345528	ENSG00000256628.3	ZBTB11-AS1	-9.78	1.09e-20	7.44e-18	-0.53	-0.41	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101676475~101679217:+
LGG	cis	rs3002131	0.604	rs17163214	ENSG00000225265.1	TAF1A-AS1	-9.78	1.09e-20	7.45e-18	-0.59	-0.41	Interleukin-10 levels;	chr1:222559675	chr1:222589825~222593032:+
LGG	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	9.78	1.09e-20	7.46e-18	0.32	0.41	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
LGG	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-9.78	1.1e-20	7.51e-18	-0.66	-0.41	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-9.78	1.1e-20	7.51e-18	-0.66	-0.41	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-9.78	1.1e-20	7.51e-18	-0.66	-0.41	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-9.78	1.1e-20	7.51e-18	-0.66	-0.41	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
LGG	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-9.78	1.1e-20	7.54e-18	-0.41	-0.41	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
LGG	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-9.78	1.1e-20	7.54e-18	-0.54	-0.41	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
LGG	cis	rs7247513	0.93	rs35275129	ENSG00000213290.4	PGK1P2	-9.78	1.1e-20	7.54e-18	-0.44	-0.41	Bipolar disorder;	chr19:12605679	chr19:12559571~12561105:+
LGG	cis	rs7247513	0.897	rs12979146	ENSG00000213290.4	PGK1P2	-9.78	1.1e-20	7.54e-18	-0.44	-0.41	Bipolar disorder;	chr19:12607090	chr19:12559571~12561105:+
LGG	cis	rs12935418	0.616	rs55776427	ENSG00000260213.4	RP11-303E16.3	-9.78	1.11e-20	7.56e-18	-0.49	-0.41	Mean corpuscular volume;	chr16:80971999	chr16:81016792~81035759:-
LGG	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-9.78	1.11e-20	7.57e-18	-0.48	-0.41	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.934	rs2261753	ENSG00000276952.1	RP5-965G21.6	9.77	1.11e-20	7.59e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25284915~25285588:-
LGG	cis	rs1153858	0.943	rs7402632	ENSG00000259433.2	CTD-2651B20.4	-9.77	1.11e-20	7.6e-18	-0.48	-0.41	Homoarginine levels;	chr15:45409715	chr15:45330209~45332634:-
LGG	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	9.77	1.11e-20	7.6e-18	0.53	0.41	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
LGG	cis	rs6903823	0.508	rs1150718	ENSG00000280107.1	AL022393.9	-9.77	1.11e-20	7.6e-18	-0.42	-0.41	Pulmonary function;	chr6:28289170	chr6:28170845~28172521:+
LGG	cis	rs6903823	0.508	rs1233660	ENSG00000280107.1	AL022393.9	-9.77	1.11e-20	7.6e-18	-0.42	-0.41	Pulmonary function;	chr6:28292472	chr6:28170845~28172521:+
LGG	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-9.77	1.11e-20	7.61e-18	-0.52	-0.41	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
LGG	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	9.77	1.12e-20	7.63e-18	0.43	0.41	Depression;	chr6:28199145	chr6:28115628~28116551:+
LGG	cis	rs853679	0.769	rs17720293	ENSG00000199851.2	U3	9.77	1.12e-20	7.63e-18	0.91	0.41	Depression;	chr6:28246920	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	9.77	1.13e-20	7.69e-18	0.54	0.41	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
LGG	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-9.77	1.13e-20	7.7e-18	-0.42	-0.41	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
LGG	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-9.77	1.13e-20	7.7e-18	-0.45	-0.41	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
LGG	cis	rs9322193	0.923	rs4870050	ENSG00000216621.7	RP11-244K5.6	9.77	1.13e-20	7.71e-18	0.5	0.41	Lung cancer;	chr6:149838917	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs7752089	ENSG00000216621.7	RP11-244K5.6	9.77	1.13e-20	7.71e-18	0.5	0.41	Lung cancer;	chr6:149839298	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs4242279	ENSG00000216621.7	RP11-244K5.6	9.77	1.13e-20	7.71e-18	0.5	0.41	Lung cancer;	chr6:149839815	chr6:149934527~149936782:+
LGG	cis	rs12935418	0.616	rs13336292	ENSG00000260213.4	RP11-303E16.3	-9.77	1.13e-20	7.71e-18	-0.49	-0.41	Mean corpuscular volume;	chr16:80971795	chr16:81016792~81035759:-
LGG	cis	rs1153858	1	rs7402650	ENSG00000259433.2	CTD-2651B20.4	-9.77	1.13e-20	7.71e-18	-0.47	-0.41	Homoarginine levels;	chr15:45409697	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs8042786	ENSG00000259433.2	CTD-2651B20.4	-9.77	1.13e-20	7.71e-18	-0.47	-0.41	Homoarginine levels;	chr15:45411341	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12440038	ENSG00000259433.2	CTD-2651B20.4	-9.77	1.13e-20	7.71e-18	-0.47	-0.41	Homoarginine levels;	chr15:45414541	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs60476496	ENSG00000259433.2	CTD-2651B20.4	-9.77	1.13e-20	7.71e-18	-0.47	-0.41	Homoarginine levels;	chr15:45421603	chr15:45330209~45332634:-
LGG	cis	rs5758511	0.689	rs45441993	ENSG00000227370.1	RP4-669P10.19	9.77	1.13e-20	7.72e-18	0.51	0.41	Birth weight;	chr22:42075734	chr22:42132543~42132998:+
LGG	cis	rs7267979	1	rs6083844	ENSG00000276952.1	RP5-965G21.6	-9.77	1.14e-20	7.78e-18	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2261790	ENSG00000276952.1	RP5-965G21.6	9.77	1.14e-20	7.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2261794	ENSG00000276952.1	RP5-965G21.6	9.77	1.14e-20	7.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2145126	ENSG00000276952.1	RP5-965G21.6	9.77	1.14e-20	7.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2257705	ENSG00000276952.1	RP5-965G21.6	9.77	1.14e-20	7.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2227892	ENSG00000276952.1	RP5-965G21.6	9.77	1.14e-20	7.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2257712	ENSG00000276952.1	RP5-965G21.6	9.77	1.14e-20	7.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2257461	ENSG00000276952.1	RP5-965G21.6	9.77	1.14e-20	7.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.923	rs2184370	ENSG00000216621.7	RP11-244K5.6	9.77	1.15e-20	7.83e-18	0.5	0.41	Lung cancer;	chr6:149843242	chr6:149934527~149936782:+
LGG	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-9.77	1.15e-20	7.86e-18	-0.43	-0.41	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-9.77	1.15e-20	7.86e-18	-0.43	-0.41	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-9.77	1.15e-20	7.86e-18	-0.43	-0.41	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
LGG	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-9.77	1.15e-20	7.86e-18	-0.43	-0.41	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
LGG	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-9.77	1.16e-20	7.89e-18	-0.79	-0.41	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
LGG	cis	rs17345786	0.906	rs12638137	ENSG00000244119.1	PDCL3P4	9.77	1.16e-20	7.89e-18	0.36	0.41	Colonoscopy-negative controls vs population controls;	chr3:101432120	chr3:101712472~101713191:+
LGG	cis	rs17345786	0.861	rs79181492	ENSG00000244119.1	PDCL3P4	9.77	1.16e-20	7.89e-18	0.36	0.41	Colonoscopy-negative controls vs population controls;	chr3:101497177	chr3:101712472~101713191:+
LGG	cis	rs7302981	0.899	rs1862043	ENSG00000272368.2	RP4-605O3.4	-9.77	1.16e-20	7.91e-18	-0.41	-0.41	Systolic blood pressure;	chr12:50182533	chr12:50112197~50165618:+
LGG	cis	rs4683346	0.752	rs7612912	ENSG00000273328.4	RP11-141M3.6	-9.77	1.16e-20	7.92e-18	-0.47	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42869129	chr3:42809414~42908105:+
LGG	cis	rs9527	0.59	rs7087459	ENSG00000272912.1	RP11-724N1.1	-9.77	1.16e-20	7.93e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103031242	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs7088200	ENSG00000272912.1	RP11-724N1.1	-9.77	1.16e-20	7.93e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103033478	chr10:102914585~102915404:+
LGG	cis	rs7267979	0.966	rs2261795	ENSG00000276952.1	RP5-965G21.6	9.77	1.17e-20	7.95e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25284915~25285588:-
LGG	cis	rs1153858	1	rs8032904	ENSG00000259433.2	CTD-2651B20.4	-9.77	1.17e-20	7.97e-18	-0.47	-0.41	Homoarginine levels;	chr15:45359111	chr15:45330209~45332634:-
LGG	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-9.77	1.17e-20	7.97e-18	-0.39	-0.41	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
LGG	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-9.77	1.18e-20	8.01e-18	-0.4	-0.41	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
LGG	cis	rs17772222	0.958	rs1123421	ENSG00000222990.1	RNU4-22P	9.77	1.18e-20	8.06e-18	0.54	0.41	Coronary artery calcification;	chr14:88524651	chr14:88513498~88513663:+
LGG	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-9.77	1.19e-20	8.09e-18	-0.45	-0.41	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
LGG	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-9.77	1.19e-20	8.1e-18	-0.48	-0.41	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
LGG	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-9.77	1.19e-20	8.1e-18	-0.48	-0.41	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
LGG	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-9.77	1.19e-20	8.12e-18	-0.49	-0.41	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
LGG	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	9.77	1.2e-20	8.15e-18	0.37	0.41	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
LGG	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-9.77	1.2e-20	8.15e-18	-0.44	-0.41	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
LGG	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-9.77	1.2e-20	8.15e-18	-0.44	-0.41	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
LGG	cis	rs9527	0.615	rs9733635	ENSG00000272912.1	RP11-724N1.1	-9.76	1.21e-20	8.24e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102952183	chr10:102914585~102915404:+
LGG	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	9.76	1.21e-20	8.25e-18	0.52	0.41	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
LGG	cis	rs9322193	0.923	rs9767652	ENSG00000216621.7	RP11-244K5.6	9.76	1.22e-20	8.31e-18	0.49	0.41	Lung cancer;	chr6:149734502	chr6:149934527~149936782:+
LGG	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	9.76	1.22e-20	8.31e-18	0.62	0.41	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
LGG	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	9.76	1.22e-20	8.32e-18	0.46	0.41	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
LGG	cis	rs7119038	0.774	rs11217037	ENSG00000255239.1	AP002954.6	-9.76	1.23e-20	8.34e-18	-0.57	-0.41	Sjögren's syndrome;	chr11:118806377	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-9.76	1.23e-20	8.34e-18	-0.57	-0.41	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
LGG	cis	rs853679	0.599	rs149943	ENSG00000216901.1	AL022393.7	9.76	1.23e-20	8.34e-18	0.77	0.41	Depression;	chr6:28034610	chr6:28176188~28176674:+
LGG	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-9.76	1.23e-20	8.35e-18	-0.41	-0.41	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
LGG	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-9.76	1.23e-20	8.35e-18	-0.41	-0.41	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
LGG	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	9.76	1.23e-20	8.35e-18	0.48	0.41	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
LGG	cis	rs4819052	0.959	rs9976074	ENSG00000223768.1	LINC00205	-9.76	1.23e-20	8.38e-18	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45293285~45297354:+
LGG	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-9.76	1.23e-20	8.4e-18	-0.31	-0.41	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
LGG	cis	rs17772222	1	rs3814855	ENSG00000222990.1	RNU4-22P	9.76	1.23e-20	8.4e-18	0.51	0.41	Coronary artery calcification;	chr14:88467016	chr14:88513498~88513663:+
LGG	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-9.76	1.24e-20	8.43e-18	-0.51	-0.41	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
LGG	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	9.76	1.24e-20	8.43e-18	0.53	0.41	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
LGG	cis	rs1707322	0.721	rs10789468	ENSG00000281133.1	AL355480.3	-9.76	1.24e-20	8.46e-18	-0.48	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs6429574	ENSG00000281133.1	AL355480.3	-9.76	1.24e-20	8.46e-18	-0.48	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45580892~45580996:-
LGG	cis	rs853679	0.527	rs1997660	ENSG00000218016.2	ZNF192P2	-9.76	1.25e-20	8.51e-18	-0.5	-0.41	Depression;	chr6:28301886	chr6:28188050~28189432:+
LGG	cis	rs9388451	0.839	rs11154331	ENSG00000237742.5	RP11-624M8.1	-9.76	1.25e-20	8.51e-18	-0.36	-0.41	Brugada syndrome;	chr6:125790283	chr6:125578558~125749190:-
LGG	cis	rs7119038	0.818	rs10892279	ENSG00000255239.1	AP002954.6	-9.76	1.25e-20	8.53e-18	-0.56	-0.41	Sjögren's syndrome;	chr11:118741072	chr11:118688039~118690600:-
LGG	cis	rs1153858	1	rs4774577	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45352487	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs11070453	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45352956	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs4774578	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45353853	chr15:45330209~45332634:-
LGG	cis	rs61524473	1	rs61524473	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12593230	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45354770	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs10444821	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45355038	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs72623915	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45355235	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs66714503	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45355840	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs2066090	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45357820	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs61365925	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45358113	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs16952714	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45358160	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12101539	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45358468	chr15:45330209~45332634:-
LGG	cis	rs1153858	0.943	rs8038342	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45359339	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs4774579	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45359605	chr15:45330209~45332634:-
LGG	cis	rs1153858	0.943	rs4774580	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45359888	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs4625670	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45360728	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs4534782	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45360735	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1049503	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45361509	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs12595087	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45363034	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs3759899	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45363705	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1890565	ENSG00000259433.2	CTD-2651B20.4	-9.76	1.26e-20	8.53e-18	-0.47	-0.41	Homoarginine levels;	chr15:45371101	chr15:45330209~45332634:-
LGG	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-9.76	1.26e-20	8.54e-18	-0.43	-0.41	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
LGG	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-9.76	1.26e-20	8.55e-18	-0.52	-0.41	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
LGG	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-9.76	1.26e-20	8.56e-18	-0.62	-0.41	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
LGG	cis	rs17772222	1	rs2295135	ENSG00000222990.1	RNU4-22P	9.76	1.26e-20	8.56e-18	0.52	0.41	Coronary artery calcification;	chr14:88427866	chr14:88513498~88513663:+
LGG	cis	rs7188445	0.712	rs6564688	ENSG00000261390.4	RP11-345M22.2	9.76	1.26e-20	8.59e-18	0.45	0.41	Urate levels;	chr16:79680061	chr16:79715232~79770563:-
LGG	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	9.76	1.27e-20	8.6e-18	0.47	0.41	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
LGG	cis	rs7181230	0.848	rs1010879	ENSG00000275636.1	RP11-521C20.5	9.76	1.27e-20	8.6e-18	0.48	0.41	Dehydroepiandrosterone sulphate levels;	chr15:40041714	chr15:40078892~40079347:+
LGG	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	9.76	1.27e-20	8.62e-18	0.53	0.41	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
LGG	cis	rs1560104	0.709	rs7194367	ENSG00000274834.1	CTD-3037G24.5	-9.76	1.28e-20	8.66e-18	-0.52	-0.41	Obesity-related traits;	chr16:12604376	chr16:12614451~12614852:+
LGG	cis	rs12935418	0.579	rs7197606	ENSG00000260213.4	RP11-303E16.3	-9.76	1.28e-20	8.68e-18	-0.51	-0.41	Mean corpuscular volume;	chr16:81019914	chr16:81016792~81035759:-
LGG	cis	rs12935418	0.672	rs9921914	ENSG00000260213.4	RP11-303E16.3	-9.76	1.28e-20	8.68e-18	-0.51	-0.41	Mean corpuscular volume;	chr16:81022506	chr16:81016792~81035759:-
LGG	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	9.76	1.28e-20	8.7e-18	0.49	0.41	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
LGG	cis	rs2278702	0.943	rs3743408	ENSG00000259495.2	RP11-210M15.2	9.76	1.28e-20	8.7e-18	0.48	0.41	Bipolar disorder;	chr15:80397993	chr15:80344853~80403575:-
LGG	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	9.76	1.28e-20	8.71e-18	0.47	0.41	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
LGG	cis	rs9810089	0.934	rs10935184	ENSG00000261758.1	RP11-102M11.2	9.76	1.29e-20	8.74e-18	0.44	0.41	Gestational age at birth (child effect);	chr3:136434626	chr3:136752630~136755780:+
LGG	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-9.76	1.29e-20	8.75e-18	-0.45	-0.41	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
LGG	cis	rs1153858	1	rs1153858	ENSG00000259433.2	CTD-2651B20.4	9.76	1.29e-20	8.76e-18	0.47	0.41	Homoarginine levels;	chr15:45360505	chr15:45330209~45332634:-
LGG	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.79e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
LGG	cis	rs9527	0.615	rs10883800	ENSG00000272912.1	RP11-724N1.1	-9.76	1.3e-20	8.79e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102911455	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs7073295	ENSG00000272912.1	RP11-724N1.1	-9.76	1.3e-20	8.79e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102912476	chr10:102914585~102915404:+
LGG	cis	rs9527	0.569	rs10883801	ENSG00000272912.1	RP11-724N1.1	-9.76	1.3e-20	8.79e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102918130	chr10:102914585~102915404:+
LGG	cis	rs9527	0.615	rs17725614	ENSG00000272912.1	RP11-724N1.1	-9.76	1.3e-20	8.79e-18	-0.47	-0.41	Arsenic metabolism;	chr10:102925736	chr10:102914585~102915404:+
LGG	cis	rs7267979	0.966	rs454723	ENSG00000276952.1	RP5-965G21.6	9.76	1.3e-20	8.81e-18	0.41	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25284915~25285588:-
LGG	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	9.76	1.3e-20	8.83e-18	0.44	0.41	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
LGG	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-9.76	1.3e-20	8.83e-18	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-9.76	1.3e-20	8.83e-18	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-9.76	1.3e-20	8.83e-18	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	9.76	1.3e-20	8.83e-18	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-9.76	1.3e-20	8.84e-18	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
LGG	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	9.76	1.3e-20	8.84e-18	0.62	0.41	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
LGG	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	9.76	1.31e-20	8.86e-18	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
LGG	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	9.76	1.31e-20	8.86e-18	0.63	0.41	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
LGG	cis	rs1153858	1	rs7169818	ENSG00000259433.2	CTD-2651B20.4	-9.75	1.32e-20	8.94e-18	-0.47	-0.41	Homoarginine levels;	chr15:45347993	chr15:45330209~45332634:-
LGG	cis	rs4683346	0.752	rs1007638	ENSG00000273328.4	RP11-141M3.6	-9.75	1.32e-20	8.95e-18	-0.46	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42839573	chr3:42809414~42908105:+
LGG	cis	rs6496932	0.77	rs4843040	ENSG00000218052.5	ADAMTS7P4	9.75	1.32e-20	8.95e-18	0.54	0.41	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85255369~85330334:-
LGG	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	9.75	1.33e-20	9.01e-18	0.53	0.41	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
LGG	cis	rs357618	0.581	rs385255	ENSG00000260581.1	CTB-113P19.4	9.75	1.34e-20	9.05e-18	0.49	0.41	Basophil percentage of white cells;	chr5:151499453	chr5:151652275~151655449:+
LGG	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-9.75	1.34e-20	9.07e-18	-0.45	-0.41	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
LGG	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-9.75	1.34e-20	9.08e-18	-0.36	-0.41	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
LGG	cis	rs7188445	0.651	rs4889014	ENSG00000261390.4	RP11-345M22.2	9.75	1.35e-20	9.12e-18	0.44	0.41	Urate levels;	chr16:79684556	chr16:79715232~79770563:-
LGG	cis	rs7188445	0.688	rs4889015	ENSG00000261390.4	RP11-345M22.2	9.75	1.35e-20	9.12e-18	0.44	0.41	Urate levels;	chr16:79684833	chr16:79715232~79770563:-
LGG	cis	rs9527	0.59	rs10786741	ENSG00000272912.1	RP11-724N1.1	-9.75	1.35e-20	9.13e-18	-0.46	-0.41	Arsenic metabolism;	chr10:103179425	chr10:102914585~102915404:+
LGG	cis	rs1153858	1	rs2056493	ENSG00000259433.2	CTD-2651B20.4	-9.75	1.35e-20	9.14e-18	-0.47	-0.41	Homoarginine levels;	chr15:45356074	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.962	rs2275045	ENSG00000216621.7	RP11-244K5.6	9.75	1.36e-20	9.18e-18	0.5	0.41	Lung cancer;	chr6:149842775	chr6:149934527~149936782:+
LGG	cis	rs1153858	1	rs7171577	ENSG00000259433.2	CTD-2651B20.4	-9.75	1.36e-20	9.19e-18	-0.48	-0.41	Homoarginine levels;	chr15:45335781	chr15:45330209~45332634:-
LGG	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	9.75	1.36e-20	9.19e-18	0.47	0.41	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
LGG	cis	rs482329	0.56	rs588965	ENSG00000228044.2	RP4-781K5.4	9.75	1.36e-20	9.21e-18	0.45	0.41	Life threatening arrhythmia;	chr1:234685081	chr1:234646289~234683176:+
LGG	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-9.75	1.37e-20	9.27e-18	-0.47	-0.41	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
LGG	cis	rs7267979	0.78	rs2500413	ENSG00000125804.12	FAM182A	-9.75	1.37e-20	9.29e-18	-0.49	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.714	rs2474763	ENSG00000125804.12	FAM182A	-9.75	1.37e-20	9.29e-18	-0.49	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:26054655~26086917:+
LGG	cis	rs8092443	0.748	rs28373933	ENSG00000278971.1	RP11-644A7.2	-9.75	1.37e-20	9.29e-18	-0.61	-0.41	Response to antipsychotic treatment;	chr18:70469147	chr18:70489630~70491205:+
LGG	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-9.75	1.37e-20	9.3e-18	-0.49	-0.41	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
LGG	cis	rs893971	0.698	rs17732955	ENSG00000246375.2	RP11-10L7.1	9.75	1.37e-20	9.3e-18	0.54	0.41	Conduct disorder (maternal expressed emotions interaction);	chr4:88282941	chr4:88284942~88331421:+
LGG	cis	rs853679	0.607	rs67998226	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28270281	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34878803	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28282402	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34396849	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28283178	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13211507	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28289600	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34691223	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28290431	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34950484	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28310911	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34661125	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28314117	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13190888	ENSG00000216901.1	AL022393.7	9.75	1.38e-20	9.35e-18	0.89	0.41	Depression;	chr6:28318208	chr6:28176188~28176674:+
LGG	cis	rs1153858	0.943	rs28605551	ENSG00000259433.2	CTD-2651B20.4	-9.75	1.39e-20	9.38e-18	-0.47	-0.41	Homoarginine levels;	chr15:45349522	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-9.75	1.41e-20	9.51e-18	-0.62	-0.41	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
LGG	cis	rs7267979	1	rs4815418	ENSG00000276952.1	RP5-965G21.6	-9.75	1.41e-20	9.56e-18	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25284915~25285588:-
LGG	cis	rs651907	0.535	rs13084113	ENSG00000256628.3	ZBTB11-AS1	9.75	1.42e-20	9.59e-18	0.47	0.41	Colorectal cancer;	chr3:101815195	chr3:101676475~101679217:+
LGG	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-9.74	1.42e-20	9.62e-18	-0.54	-0.41	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-9.74	1.42e-20	9.62e-18	-0.54	-0.41	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-9.74	1.42e-20	9.62e-18	-0.54	-0.41	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
LGG	cis	rs12935418	0.552	rs2549835	ENSG00000260213.4	RP11-303E16.3	9.74	1.42e-20	9.62e-18	0.5	0.41	Mean corpuscular volume;	chr16:80989005	chr16:81016792~81035759:-
LGG	cis	rs7267979	0.873	rs6037062	ENSG00000125804.12	FAM182A	-9.74	1.43e-20	9.64e-18	-0.49	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:26054655~26086917:+
LGG	cis	rs9876781	1	rs2045554	ENSG00000244380.1	RP11-24C3.2	-9.74	1.44e-20	9.7e-18	-0.51	-0.41	Longevity;	chr3:48453142	chr3:48440352~48446656:-
LGG	cis	rs657075	0.697	rs3788987	ENSG00000263597.1	MIR3936	-9.74	1.44e-20	9.7e-18	-0.69	-0.41	Rheumatoid arthritis;	chr5:132370597	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs13185655	ENSG00000263597.1	MIR3936	-9.74	1.44e-20	9.7e-18	-0.69	-0.41	Rheumatoid arthritis;	chr5:132371055	chr5:132365490~132365599:-
LGG	cis	rs9876781	1	rs922075	ENSG00000244380.1	RP11-24C3.2	-9.74	1.44e-20	9.73e-18	-0.51	-0.41	Longevity;	chr3:48447994	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs9838618	ENSG00000244380.1	RP11-24C3.2	9.74	1.44e-20	9.73e-18	0.5	0.41	Longevity;	chr3:48445949	chr3:48440352~48446656:-
LGG	cis	rs2486288	0.656	rs1706767	ENSG00000259433.2	CTD-2651B20.4	9.74	1.44e-20	9.76e-18	0.42	0.41	Glomerular filtration rate;	chr15:45276901	chr15:45330209~45332634:-
LGG	cis	rs8092443	0.575	rs9952358	ENSG00000278971.1	RP11-644A7.2	-9.74	1.45e-20	9.77e-18	-0.66	-0.41	Response to antipsychotic treatment;	chr18:70463331	chr18:70489630~70491205:+
LGG	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-9.74	1.45e-20	9.79e-18	-0.45	-0.41	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-9.74	1.45e-20	9.79e-18	-0.45	-0.41	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-9.74	1.45e-20	9.79e-18	-0.45	-0.41	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-9.74	1.45e-20	9.79e-18	-0.45	-0.41	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
LGG	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	9.74	1.46e-20	9.83e-18	0.53	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
LGG	cis	rs7085104	0.7	rs10883785	ENSG00000272912.1	RP11-724N1.1	-9.74	1.46e-20	9.83e-18	-0.45	-0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102914585~102915404:+
LGG	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-9.74	1.46e-20	9.85e-18	-0.34	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
LGG	cis	rs7119038	0.818	rs10892288	ENSG00000255239.1	AP002954.6	-9.74	1.48e-20	1e-17	-0.57	-0.41	Sjögren's syndrome;	chr11:118773985	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.818	rs10892289	ENSG00000255239.1	AP002954.6	-9.74	1.48e-20	1e-17	-0.57	-0.41	Sjögren's syndrome;	chr11:118775294	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.818	rs56043232	ENSG00000255239.1	AP002954.6	-9.74	1.48e-20	1e-17	-0.57	-0.41	Sjögren's syndrome;	chr11:118777664	chr11:118688039~118690600:-
LGG	cis	rs651907	0.535	rs61396602	ENSG00000256628.3	ZBTB11-AS1	9.74	1.49e-20	1e-17	0.47	0.41	Colorectal cancer;	chr3:101790202	chr3:101676475~101679217:+
LGG	cis	rs651907	0.535	rs34648996	ENSG00000256628.3	ZBTB11-AS1	9.74	1.49e-20	1e-17	0.47	0.41	Colorectal cancer;	chr3:101792358	chr3:101676475~101679217:+
LGG	cis	rs7811142	1	rs6953107	ENSG00000242294.5	STAG3L5P	9.74	1.49e-20	1.01e-17	0.29	0.41	Platelet count;	chr7:100498041	chr7:100336079~100351900:+
LGG	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	9.74	1.5e-20	1.01e-17	0.52	0.41	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
LGG	cis	rs7119038	0.731	rs10892283	ENSG00000255239.1	AP002954.6	-9.74	1.5e-20	1.01e-17	-0.57	-0.41	Sjögren's syndrome;	chr11:118766272	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.774	rs11217020	ENSG00000255239.1	AP002954.6	-9.74	1.5e-20	1.01e-17	-0.57	-0.41	Sjögren's syndrome;	chr11:118768644	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.818	rs10892286	ENSG00000255239.1	AP002954.6	-9.74	1.5e-20	1.01e-17	-0.57	-0.41	Sjögren's syndrome;	chr11:118771376	chr11:118688039~118690600:-
LGG	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	9.74	1.5e-20	1.01e-17	0.54	0.41	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
LGG	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	9.74	1.51e-20	1.02e-17	0.5	0.41	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
LGG	cis	rs9388451	0.872	rs2008027	ENSG00000237742.5	RP11-624M8.1	-9.74	1.51e-20	1.02e-17	-0.36	-0.41	Brugada syndrome;	chr6:125731213	chr6:125578558~125749190:-
LGG	cis	rs9876781	1	rs9881491	ENSG00000244380.1	RP11-24C3.2	9.74	1.51e-20	1.02e-17	0.5	0.41	Longevity;	chr3:48446507	chr3:48440352~48446656:-
LGG	cis	rs9527	0.64	rs6584541	ENSG00000272912.1	RP11-724N1.1	-9.74	1.51e-20	1.02e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103169367	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs7917650	ENSG00000272912.1	RP11-724N1.1	-9.74	1.51e-20	1.02e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103177343	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs12355120	ENSG00000272912.1	RP11-724N1.1	-9.74	1.52e-20	1.02e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103092409	chr10:102914585~102915404:+
LGG	cis	rs9532669	0.926	rs7331435	ENSG00000168852.11	TPTE2P5	-9.74	1.52e-20	1.02e-17	-0.41	-0.41	Cervical cancer;	chr13:40862396	chr13:40822296~40921749:-
LGG	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	9.74	1.52e-20	1.02e-17	0.67	0.41	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
LGG	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-9.74	1.52e-20	1.03e-17	-0.43	-0.41	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
LGG	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-9.74	1.52e-20	1.03e-17	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
LGG	cis	rs6452524	0.87	rs12152892	ENSG00000248112.1	RP11-78C3.1	9.74	1.53e-20	1.03e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:82919376~82921119:-
LGG	cis	rs17345786	0.906	rs11710016	ENSG00000244119.1	PDCL3P4	-9.74	1.53e-20	1.03e-17	-0.35	-0.41	Colonoscopy-negative controls vs population controls;	chr3:101401186	chr3:101712472~101713191:+
LGG	cis	rs7267979	1	rs6050547	ENSG00000276952.1	RP5-965G21.6	-9.74	1.53e-20	1.03e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25284915~25285588:-
LGG	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-9.74	1.53e-20	1.03e-17	-0.45	-0.41	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
LGG	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	9.74	1.53e-20	1.03e-17	0.51	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
LGG	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	9.74	1.54e-20	1.04e-17	0.29	0.41	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
LGG	cis	rs2412819	0.571	rs8038068	ENSG00000249839.1	AC011330.5	-9.73	1.55e-20	1.04e-17	-0.66	-0.41	Lung cancer;	chr15:43622175	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs56246169	ENSG00000249839.1	AC011330.5	-9.73	1.55e-20	1.04e-17	-0.66	-0.41	Lung cancer;	chr15:43628358	chr15:43663654~43684339:-
LGG	cis	rs17772222	0.958	rs59136503	ENSG00000222990.1	RNU4-22P	9.73	1.55e-20	1.05e-17	0.53	0.41	Coronary artery calcification;	chr14:88501921	chr14:88513498~88513663:+
LGG	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-9.73	1.55e-20	1.05e-17	-0.31	-0.41	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
LGG	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	9.73	1.57e-20	1.06e-17	0.49	0.41	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
LGG	cis	rs853679	0.527	rs9468333	ENSG00000218016.2	ZNF192P2	-9.73	1.57e-20	1.06e-17	-0.5	-0.41	Depression;	chr6:28303421	chr6:28188050~28189432:+
LGG	cis	rs1153858	1	rs4271549	ENSG00000259433.2	CTD-2651B20.4	-9.73	1.57e-20	1.06e-17	-0.47	-0.41	Homoarginine levels;	chr15:45360532	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs4627277	ENSG00000259433.2	CTD-2651B20.4	-9.73	1.57e-20	1.06e-17	-0.47	-0.41	Homoarginine levels;	chr15:45360570	chr15:45330209~45332634:-
LGG	cis	rs17345786	0.906	rs59359251	ENSG00000244119.1	PDCL3P4	9.73	1.58e-20	1.06e-17	0.35	0.41	Colonoscopy-negative controls vs population controls;	chr3:101427518	chr3:101712472~101713191:+
LGG	cis	rs17345786	0.906	rs55710435	ENSG00000244119.1	PDCL3P4	9.73	1.58e-20	1.06e-17	0.35	0.41	Colonoscopy-negative controls vs population controls;	chr3:101461486	chr3:101712472~101713191:+
LGG	cis	rs17345786	0.906	rs72944107	ENSG00000244119.1	PDCL3P4	9.73	1.58e-20	1.06e-17	0.35	0.41	Colonoscopy-negative controls vs population controls;	chr3:101478346	chr3:101712472~101713191:+
LGG	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	9.73	1.58e-20	1.06e-17	0.49	0.41	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
LGG	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-9.73	1.58e-20	1.06e-17	-0.5	-0.41	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
LGG	cis	rs7267979	1	rs6132835	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.933	rs11699203	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.933	rs6138571	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs416745	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs448396	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs447722	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs422424	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs422844	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs401166	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs404394	ENSG00000276952.1	RP5-965G21.6	9.73	1.58e-20	1.07e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25284915~25285588:-
LGG	cis	rs9876781	1	rs6776700	ENSG00000244380.1	RP11-24C3.2	9.73	1.58e-20	1.07e-17	0.51	0.41	Longevity;	chr3:48455358	chr3:48440352~48446656:-
LGG	cis	rs507080	0.769	rs571001	ENSG00000278376.1	RP11-158I9.8	-9.73	1.59e-20	1.07e-17	-0.37	-0.41	Serum metabolite levels;	chr11:118629457	chr11:118791254~118793137:+
LGG	cis	rs482329	0.523	rs490559	ENSG00000228044.2	RP4-781K5.4	9.73	1.59e-20	1.07e-17	0.44	0.41	Life threatening arrhythmia;	chr1:234684585	chr1:234646289~234683176:+
LGG	cis	rs482329	0.523	rs491427	ENSG00000228044.2	RP4-781K5.4	9.73	1.59e-20	1.07e-17	0.44	0.41	Life threatening arrhythmia;	chr1:234684673	chr1:234646289~234683176:+
LGG	cis	rs9527	0.59	rs7898770	ENSG00000272912.1	RP11-724N1.1	9.73	1.59e-20	1.07e-17	0.46	0.41	Arsenic metabolism;	chr10:102996879	chr10:102914585~102915404:+
LGG	cis	rs10935480	0.577	rs10804683	ENSG00000239445.4	ST3GAL6-AS1	-9.73	1.59e-20	1.07e-17	-0.5	-0.41	Blood protein levels;	chr3:98661882	chr3:98714330~98732651:-
LGG	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	9.73	1.6e-20	1.08e-17	0.46	0.41	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
LGG	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	-9.73	1.6e-20	1.08e-17	-0.44	-0.41	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
LGG	cis	rs507080	0.733	rs601318	ENSG00000278376.1	RP11-158I9.8	-9.73	1.6e-20	1.08e-17	-0.37	-0.41	Serum metabolite levels;	chr11:118648845	chr11:118791254~118793137:+
LGG	cis	rs9876781	0.967	rs7618883	ENSG00000244380.1	RP11-24C3.2	9.73	1.6e-20	1.08e-17	0.51	0.41	Longevity;	chr3:48457056	chr3:48440352~48446656:-
LGG	cis	rs9810089	0.802	rs833861	ENSG00000261758.1	RP11-102M11.2	9.73	1.6e-20	1.08e-17	0.43	0.41	Gestational age at birth (child effect);	chr3:136512225	chr3:136752630~136755780:+
LGG	cis	rs3742264	1	rs11618062	ENSG00000235903.6	CPB2-AS1	9.73	1.61e-20	1.08e-17	0.45	0.41	Blood protein levels;	chr13:46075433	chr13:46052806~46113332:+
LGG	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-9.73	1.61e-20	1.08e-17	-0.47	-0.41	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
LGG	cis	rs4683346	0.752	rs2114883	ENSG00000273328.4	RP11-141M3.6	-9.73	1.61e-20	1.09e-17	-0.46	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42841176	chr3:42809414~42908105:+
LGG	cis	rs642803	1	rs642803	ENSG00000255120.4	OVOL1-AS1	9.73	1.61e-20	1.09e-17	0.5	0.41	Urate levels;	chr11:65793149	chr11:65789051~65790868:-
LGG	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-9.73	1.61e-20	1.09e-17	-0.53	-0.41	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
LGG	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-9.73	1.61e-20	1.09e-17	-0.53	-0.41	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
LGG	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	9.73	1.61e-20	1.09e-17	0.51	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
LGG	cis	rs4683346	0.752	rs11919717	ENSG00000273328.4	RP11-141M3.6	-9.73	1.62e-20	1.09e-17	-0.46	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42841510	chr3:42809414~42908105:+
LGG	cis	rs7267979	1	rs2257432	ENSG00000276952.1	RP5-965G21.6	9.73	1.63e-20	1.09e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2258066	ENSG00000276952.1	RP5-965G21.6	9.73	1.63e-20	1.09e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25284915~25285588:-
LGG	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	9.73	1.63e-20	1.09e-17	0.45	0.41	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
LGG	cis	rs7267979	0.932	rs449370	ENSG00000276952.1	RP5-965G21.6	-9.73	1.63e-20	1.09e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25284915~25285588:-
LGG	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-9.73	1.65e-20	1.11e-17	-0.41	-0.41	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
LGG	cis	rs853679	0.527	rs213228	ENSG00000218016.2	ZNF192P2	-9.73	1.66e-20	1.11e-17	-0.48	-0.41	Depression;	chr6:28363475	chr6:28188050~28189432:+
LGG	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-9.73	1.66e-20	1.12e-17	-0.5	-0.41	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
LGG	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	9.73	1.67e-20	1.12e-17	0.47	0.41	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
LGG	cis	rs9388451	0.903	rs9388446	ENSG00000237742.5	RP11-624M8.1	-9.72	1.68e-20	1.13e-17	-0.36	-0.41	Brugada syndrome;	chr6:125743774	chr6:125578558~125749190:-
LGG	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	9.72	1.69e-20	1.13e-17	0.62	0.41	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	9.72	1.69e-20	1.13e-17	0.62	0.41	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
LGG	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	9.72	1.69e-20	1.14e-17	0.44	0.41	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
LGG	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	9.72	1.7e-20	1.14e-17	0.49	0.41	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
LGG	cis	rs2283792	0.812	rs240066	ENSG00000228050.1	TOP3BP1	-9.72	1.74e-20	1.17e-17	-0.48	-0.41	Multiple sclerosis;	chr22:21938623	chr22:22223187~22224566:-
LGG	cis	rs3742264	1	rs9316179	ENSG00000235903.6	CPB2-AS1	9.72	1.74e-20	1.17e-17	0.46	0.41	Blood protein levels;	chr13:46067331	chr13:46052806~46113332:+
LGG	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	9.72	1.74e-20	1.17e-17	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
LGG	cis	rs7267979	0.966	rs6083855	ENSG00000276952.1	RP5-965G21.6	-9.72	1.74e-20	1.17e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs4815426	ENSG00000276952.1	RP5-965G21.6	-9.72	1.74e-20	1.17e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25284915~25285588:-
LGG	cis	rs5742933	0.857	rs1233272	ENSG00000253559.1	OSGEPL1-AS1	-9.72	1.74e-20	1.17e-17	-0.48	-0.41	Ferritin levels;	chr2:189814968	chr2:189762704~189765556:+
LGG	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	9.72	1.75e-20	1.18e-17	0.54	0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
LGG	cis	rs7849270	0.679	rs10988217	ENSG00000268707.1	RP11-247A12.7	-9.72	1.76e-20	1.18e-17	-0.42	-0.41	Blood metabolite ratios;	chr9:129125837	chr9:129170434~129170940:+
LGG	cis	rs7267979	1	rs2257808	ENSG00000276952.1	RP5-965G21.6	9.72	1.76e-20	1.18e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2257809	ENSG00000276952.1	RP5-965G21.6	9.72	1.76e-20	1.18e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2424700	ENSG00000276952.1	RP5-965G21.6	9.72	1.76e-20	1.18e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25284915~25285588:-
LGG	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	9.72	1.77e-20	1.19e-17	0.56	0.41	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
LGG	cis	rs9876781	1	rs13091785	ENSG00000244380.1	RP11-24C3.2	9.72	1.78e-20	1.19e-17	0.5	0.41	Longevity;	chr3:48452692	chr3:48440352~48446656:-
LGG	cis	rs1799949	0.587	rs1824890	ENSG00000267681.1	CTD-3199J23.6	-9.72	1.78e-20	1.19e-17	-0.52	-0.41	Menopause (age at onset);	chr17:43344536	chr17:43144956~43145255:+
LGG	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-9.72	1.79e-20	1.2e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
LGG	cis	rs7119038	0.774	rs10892290	ENSG00000255239.1	AP002954.6	-9.72	1.79e-20	1.2e-17	-0.58	-0.41	Sjögren's syndrome;	chr11:118782794	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.774	rs874621	ENSG00000255239.1	AP002954.6	-9.72	1.79e-20	1.2e-17	-0.58	-0.41	Sjögren's syndrome;	chr11:118784936	chr11:118688039~118690600:-
LGG	cis	rs9527	0.545	rs12247514	ENSG00000272912.1	RP11-724N1.1	-9.72	1.79e-20	1.2e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103198309	chr10:102914585~102915404:+
LGG	cis	rs17345786	0.906	rs72940399	ENSG00000244119.1	PDCL3P4	9.72	1.79e-20	1.2e-17	0.35	0.41	Colonoscopy-negative controls vs population controls;	chr3:101403731	chr3:101712472~101713191:+
LGG	cis	rs6452524	0.87	rs6452511	ENSG00000248112.1	RP11-78C3.1	9.72	1.8e-20	1.2e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:82919376~82921119:-
LGG	cis	rs17345786	0.906	rs72946021	ENSG00000244119.1	PDCL3P4	9.72	1.8e-20	1.21e-17	0.35	0.41	Colonoscopy-negative controls vs population controls;	chr3:101531164	chr3:101712472~101713191:+
LGG	cis	rs7267979	0.966	rs4815425	ENSG00000276952.1	RP5-965G21.6	-9.72	1.81e-20	1.21e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050599	ENSG00000276952.1	RP5-965G21.6	-9.72	1.81e-20	1.21e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050602	ENSG00000276952.1	RP5-965G21.6	-9.72	1.81e-20	1.21e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25284915~25285588:-
LGG	cis	rs7211079	0.917	rs8067991	ENSG00000279259.1	RP11-334C17.3	9.72	1.81e-20	1.21e-17	0.45	0.41	Myocardial infarction;	chr17:80145503	chr17:80147250~80148596:+
LGG	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-9.72	1.81e-20	1.22e-17	-0.43	-0.41	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
LGG	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	9.72	1.81e-20	1.22e-17	0.82	0.41	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
LGG	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-9.72	1.82e-20	1.22e-17	-0.46	-0.41	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	9.71	1.82e-20	1.22e-17	0.46	0.41	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
LGG	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	9.71	1.82e-20	1.22e-17	0.56	0.41	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
LGG	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-9.71	1.82e-20	1.22e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
LGG	cis	rs9322193	0.884	rs7744105	ENSG00000216621.7	RP11-244K5.6	9.71	1.83e-20	1.23e-17	0.48	0.41	Lung cancer;	chr6:149849308	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9479094	ENSG00000216621.7	RP11-244K5.6	9.71	1.85e-20	1.24e-17	0.49	0.41	Lung cancer;	chr6:149725083	chr6:149934527~149936782:+
LGG	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-9.71	1.85e-20	1.24e-17	-0.55	-0.41	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
LGG	cis	rs9527	0.668	rs7092815	ENSG00000272912.1	RP11-724N1.1	-9.71	1.86e-20	1.24e-17	-0.47	-0.41	Arsenic metabolism;	chr10:102976588	chr10:102914585~102915404:+
LGG	cis	rs7302981	0.899	rs4883481	ENSG00000272368.2	RP4-605O3.4	-9.71	1.86e-20	1.25e-17	-0.41	-0.41	Systolic blood pressure;	chr12:50180528	chr12:50112197~50165618:+
LGG	cis	rs6600671	0.691	rs6600662	ENSG00000223345.3	HIST2H2BA	9.71	1.86e-20	1.25e-17	0.43	0.41	Hip geometry;	chr1:121488992	chr1:121108210~121117257:-
LGG	cis	rs4819052	0.851	rs11558445	ENSG00000215447.6	BX322557.10	-9.71	1.86e-20	1.25e-17	-0.31	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45288052~45291738:+
LGG	cis	rs7267979	1	rs2856	ENSG00000276952.1	RP5-965G21.6	9.71	1.87e-20	1.25e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25284915~25285588:-
LGG	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	9.71	1.88e-20	1.26e-17	0.3	0.41	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
LGG	cis	rs7267979	1	rs2257982	ENSG00000276952.1	RP5-965G21.6	9.71	1.88e-20	1.26e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25284915~25285588:-
LGG	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-9.71	1.88e-20	1.26e-17	-0.45	-0.41	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
LGG	cis	rs12935418	0.673	rs2549887	ENSG00000260213.4	RP11-303E16.3	9.71	1.89e-20	1.26e-17	0.51	0.41	Mean corpuscular volume;	chr16:81028222	chr16:81016792~81035759:-
LGG	cis	rs1153858	1	rs4775909	ENSG00000259433.2	CTD-2651B20.4	-9.71	1.9e-20	1.27e-17	-0.47	-0.41	Homoarginine levels;	chr15:45350844	chr15:45330209~45332634:-
LGG	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-9.71	1.9e-20	1.27e-17	-0.46	-0.41	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
LGG	cis	rs889122	0.55	rs8108431	ENSG00000267289.1	CTD-2623N2.11	9.71	1.91e-20	1.28e-17	0.43	0.41	Menarche (age at onset);	chr19:9886011	chr19:9834079~9835013:-
LGG	cis	rs11098499	0.661	rs10015965	ENSG00000249244.1	RP11-548H18.2	9.71	1.92e-20	1.28e-17	0.42	0.41	Corneal astigmatism;	chr4:119347082	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.535	rs10005542	ENSG00000249244.1	RP11-548H18.2	9.71	1.92e-20	1.28e-17	0.42	0.41	Corneal astigmatism;	chr4:119347147	chr4:119391831~119395335:-
LGG	cis	rs1153858	1	rs67831559	ENSG00000259433.2	CTD-2651B20.4	-9.71	1.92e-20	1.28e-17	-0.47	-0.41	Homoarginine levels;	chr15:45357109	chr15:45330209~45332634:-
LGG	cis	rs6903823	0.527	rs4713158	ENSG00000218016.2	ZNF192P2	-9.71	1.92e-20	1.29e-17	-0.5	-0.41	Pulmonary function;	chr6:28309994	chr6:28188050~28189432:+
LGG	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-9.71	1.93e-20	1.29e-17	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
LGG	cis	rs651907	0.557	rs17347644	ENSG00000256628.3	ZBTB11-AS1	9.71	1.93e-20	1.29e-17	0.47	0.41	Colorectal cancer;	chr3:101828889	chr3:101676475~101679217:+
LGG	cis	rs11098499	0.588	rs6534149	ENSG00000249244.1	RP11-548H18.2	-9.71	1.95e-20	1.3e-17	-0.42	-0.41	Corneal astigmatism;	chr4:119638137	chr4:119391831~119395335:-
LGG	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-9.71	1.95e-20	1.3e-17	-0.66	-0.41	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-9.71	1.95e-20	1.3e-17	-0.66	-0.41	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
LGG	cis	rs7267979	1	rs910997	ENSG00000276952.1	RP5-965G21.6	9.71	1.95e-20	1.3e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs3002702	ENSG00000276952.1	RP5-965G21.6	9.71	1.95e-20	1.3e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2257985	ENSG00000276952.1	RP5-965G21.6	9.71	1.95e-20	1.3e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs2257988	ENSG00000276952.1	RP5-965G21.6	9.71	1.95e-20	1.3e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25284915~25285588:-
LGG	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-9.71	1.95e-20	1.31e-17	-0.53	-0.41	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
LGG	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	9.71	1.96e-20	1.31e-17	0.51	0.41	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
LGG	cis	rs1153858	1	rs2467864	ENSG00000259433.2	CTD-2651B20.4	9.71	1.96e-20	1.31e-17	0.47	0.41	Homoarginine levels;	chr15:45348900	chr15:45330209~45332634:-
LGG	cis	rs5742933	0.597	rs12471663	ENSG00000273240.1	RP11-455J20.3	9.71	1.96e-20	1.31e-17	0.51	0.41	Ferritin levels;	chr2:189642372	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.597	rs6761923	ENSG00000273240.1	RP11-455J20.3	9.71	1.96e-20	1.31e-17	0.51	0.41	Ferritin levels;	chr2:189642873	chr2:189763859~189764456:-
LGG	cis	rs12935418	0.616	rs13336629	ENSG00000260213.4	RP11-303E16.3	-9.71	1.97e-20	1.32e-17	-0.49	-0.41	Mean corpuscular volume;	chr16:80971909	chr16:81016792~81035759:-
LGG	cis	rs4683346	0.712	rs4683345	ENSG00000273328.4	RP11-141M3.6	-9.7	1.97e-20	1.32e-17	-0.46	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42845150	chr3:42809414~42908105:+
LGG	cis	rs7267979	1	rs6115153	ENSG00000276952.1	RP5-965G21.6	-9.7	1.97e-20	1.32e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs7268053	ENSG00000276952.1	RP5-965G21.6	-9.7	1.97e-20	1.32e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6083809	ENSG00000276952.1	RP5-965G21.6	-9.7	1.97e-20	1.32e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25284915~25285588:-
LGG	cis	rs4683346	0.752	rs7647523	ENSG00000273328.4	RP11-141M3.6	-9.7	1.97e-20	1.32e-17	-0.46	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42845563	chr3:42809414~42908105:+
LGG	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	9.7	1.98e-20	1.32e-17	0.45	0.41	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
LGG	cis	rs7267979	1	rs6115182	ENSG00000276952.1	RP5-965G21.6	-9.7	1.99e-20	1.33e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25284915~25285588:-
LGG	cis	rs9810089	0.802	rs10935182	ENSG00000261758.1	RP11-102M11.2	9.7	2e-20	1.34e-17	0.43	0.41	Gestational age at birth (child effect);	chr3:136418580	chr3:136752630~136755780:+
LGG	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	9.7	2.01e-20	1.34e-17	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
LGG	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-9.7	2.01e-20	1.34e-17	-0.55	-0.41	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
LGG	cis	rs7216064	0.911	rs6504551	ENSG00000278219.1	AC145343.1	-9.7	2.02e-20	1.35e-17	-0.47	-0.41	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67907210	chr17:68101538~68101639:+
LGG	cis	rs7119038	0.818	rs6589684	ENSG00000255239.1	AP002954.6	9.7	2.03e-20	1.35e-17	0.55	0.41	Sjögren's syndrome;	chr11:118740248	chr11:118688039~118690600:-
LGG	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-9.7	2.03e-20	1.36e-17	-0.48	-0.41	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
LGG	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-9.7	2.03e-20	1.36e-17	-0.55	-0.41	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-9.7	2.03e-20	1.36e-17	-0.55	-0.41	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
LGG	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	9.7	2.04e-20	1.36e-17	0.79	0.41	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
LGG	cis	rs7267979	1	rs6050617	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.933	rs2387887	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050626	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6037121	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs1047171	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050629	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050630	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050632	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25284915~25285588:-
LGG	cis	rs7267979	1	rs6050609	ENSG00000276952.1	RP5-965G21.6	-9.7	2.06e-20	1.38e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2424714	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2424715	ENSG00000276952.1	RP5-965G21.6	9.7	2.06e-20	1.38e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25284915~25285588:-
LGG	cis	rs9527	0.59	rs726010	ENSG00000272912.1	RP11-724N1.1	-9.7	2.09e-20	1.39e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103082220	chr10:102914585~102915404:+
LGG	cis	rs6903823	0.508	rs1778484	ENSG00000199851.2	U3	9.7	2.09e-20	1.39e-17	0.56	0.41	Pulmonary function;	chr6:28273021	chr6:28015568~28015777:+
LGG	cis	rs9527	0.59	rs1935323	ENSG00000272912.1	RP11-724N1.1	-9.7	2.11e-20	1.41e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103117278	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs7912517	ENSG00000272912.1	RP11-724N1.1	-9.7	2.11e-20	1.41e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103145772	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs2066322	ENSG00000272912.1	RP11-724N1.1	-9.7	2.11e-20	1.41e-17	-0.46	-0.41	Arsenic metabolism;	chr10:103149582	chr10:102914585~102915404:+
LGG	cis	rs1153858	1	rs10519021	ENSG00000259433.2	CTD-2651B20.4	-9.7	2.11e-20	1.41e-17	-0.48	-0.41	Homoarginine levels;	chr15:45339597	chr15:45330209~45332634:-
LGG	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-9.7	2.12e-20	1.41e-17	-0.4	-0.41	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
LGG	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	9.7	2.12e-20	1.41e-17	0.48	0.41	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
LGG	cis	rs1153858	1	rs9788780	ENSG00000259433.2	CTD-2651B20.4	-9.7	2.12e-20	1.41e-17	-0.47	-0.41	Homoarginine levels;	chr15:45393289	chr15:45330209~45332634:-
LGG	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	9.7	2.12e-20	1.41e-17	0.93	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	9.7	2.12e-20	1.41e-17	0.93	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	9.7	2.12e-20	1.41e-17	0.93	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	9.7	2.12e-20	1.41e-17	0.93	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
LGG	cis	rs4713118	0.824	rs2179095	ENSG00000216901.1	AL022393.7	-9.7	2.12e-20	1.42e-17	-0.54	-0.41	Parkinson's disease;	chr6:27783079	chr6:28176188~28176674:+
LGG	cis	rs7267979	1	rs2424712	ENSG00000276952.1	RP5-965G21.6	9.7	2.12e-20	1.42e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25284915~25285588:-
LGG	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	9.7	2.12e-20	1.42e-17	0.47	0.41	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
LGG	cis	rs1153858	1	rs12439274	ENSG00000259433.2	CTD-2651B20.4	-9.7	2.13e-20	1.42e-17	-0.47	-0.41	Homoarginine levels;	chr15:45344469	chr15:45330209~45332634:-
LGG	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-9.69	2.14e-20	1.43e-17	-0.58	-0.41	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
LGG	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	9.69	2.15e-20	1.43e-17	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
LGG	cis	rs9527	0.59	rs10883820	ENSG00000272912.1	RP11-724N1.1	9.69	2.15e-20	1.43e-17	0.46	0.41	Arsenic metabolism;	chr10:103004904	chr10:102914585~102915404:+
LGG	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-9.69	2.15e-20	1.44e-17	-0.46	-0.41	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
LGG	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	9.69	2.17e-20	1.44e-17	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
LGG	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-9.69	2.17e-20	1.45e-17	-0.55	-0.41	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
LGG	cis	rs853679	0.599	rs156743	ENSG00000216901.1	AL022393.7	9.69	2.19e-20	1.46e-17	0.76	0.41	Depression;	chr6:27999311	chr6:28176188~28176674:+
LGG	cis	rs5742933	1	rs1550388	ENSG00000273240.1	RP11-455J20.3	9.69	2.2e-20	1.47e-17	0.52	0.41	Ferritin levels;	chr2:189739054	chr2:189763859~189764456:-
LGG	cis	rs7181230	0.848	rs62004114	ENSG00000275636.1	RP11-521C20.5	9.69	2.21e-20	1.47e-17	0.47	0.41	Dehydroepiandrosterone sulphate levels;	chr15:40041154	chr15:40078892~40079347:+
LGG	cis	rs7181230	0.848	rs75509561	ENSG00000275636.1	RP11-521C20.5	9.69	2.21e-20	1.47e-17	0.47	0.41	Dehydroepiandrosterone sulphate levels;	chr15:40041268	chr15:40078892~40079347:+
LGG	cis	rs7181230	0.848	rs7497289	ENSG00000275636.1	RP11-521C20.5	9.69	2.21e-20	1.47e-17	0.47	0.41	Dehydroepiandrosterone sulphate levels;	chr15:40041456	chr15:40078892~40079347:+
LGG	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-9.69	2.21e-20	1.47e-17	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-9.69	2.21e-20	1.47e-17	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-9.69	2.21e-20	1.47e-17	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
LGG	cis	rs9527	0.568	rs12772775	ENSG00000272912.1	RP11-724N1.1	-9.69	2.23e-20	1.48e-17	-0.46	-0.41	Arsenic metabolism;	chr10:102943242	chr10:102914585~102915404:+
LGG	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	9.69	2.23e-20	1.48e-17	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
LGG	cis	rs17772222	0.917	rs1998670	ENSG00000222990.1	RNU4-22P	9.69	2.24e-20	1.49e-17	0.52	0.41	Coronary artery calcification;	chr14:88504581	chr14:88513498~88513663:+
LGG	cis	rs977987	0.732	rs999675	ENSG00000261783.1	RP11-252K23.2	-9.69	2.24e-20	1.49e-17	-0.56	-0.41	Dupuytren's disease;	chr16:75272504	chr16:75379818~75381260:-
LGG	cis	rs4713118	0.513	rs200971	ENSG00000226314.6	ZNF192P1	9.69	2.25e-20	1.5e-17	0.43	0.41	Parkinson's disease;	chr6:27891126	chr6:28161781~28169594:+
LGG	cis	rs7267979	0.933	rs2258728	ENSG00000276952.1	RP5-965G21.6	9.69	2.26e-20	1.5e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25284915~25285588:-
LGG	cis	rs172166	0.516	rs1225715	ENSG00000218016.2	ZNF192P2	9.69	2.27e-20	1.51e-17	0.53	0.41	Cardiac Troponin-T levels;	chr6:28145595	chr6:28188050~28189432:+
LGG	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	9.69	2.27e-20	1.51e-17	0.53	0.41	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
LGG	cis	rs9322193	0.884	rs9688699	ENSG00000216621.7	RP11-244K5.6	9.69	2.3e-20	1.53e-17	0.49	0.41	Lung cancer;	chr6:149733680	chr6:149934527~149936782:+
LGG	cis	rs657075	0.697	rs3792880	ENSG00000263597.1	MIR3936	9.69	2.3e-20	1.53e-17	0.66	0.41	Rheumatoid arthritis;	chr5:132309272	chr5:132365490~132365599:-
LGG	cis	rs1560104	0.709	rs2903042	ENSG00000274834.1	CTD-3037G24.5	-9.69	2.31e-20	1.53e-17	-0.52	-0.41	Obesity-related traits;	chr16:12604249	chr16:12614451~12614852:+
LGG	cis	rs6452524	0.901	rs12188673	ENSG00000248112.1	RP11-78C3.1	9.69	2.31e-20	1.53e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:82919376~82921119:-
LGG	cis	rs9388451	0.903	rs7758115	ENSG00000237742.5	RP11-624M8.1	-9.69	2.31e-20	1.54e-17	-0.36	-0.41	Brugada syndrome;	chr6:125740356	chr6:125578558~125749190:-
LGG	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-9.68	2.33e-20	1.55e-17	-0.46	-0.41	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
LGG	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-9.68	2.33e-20	1.55e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
LGG	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-9.68	2.35e-20	1.56e-17	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-9.68	2.35e-20	1.56e-17	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
LGG	cis	rs7211079	0.912	rs4889831	ENSG00000279259.1	RP11-334C17.3	9.68	2.36e-20	1.57e-17	0.45	0.41	Myocardial infarction;	chr17:80140854	chr17:80147250~80148596:+
LGG	cis	rs11148252	0.846	rs7333451	ENSG00000278238.1	RP11-245D16.4	-9.68	2.37e-20	1.58e-17	-0.39	-0.41	Lewy body disease;	chr13:52473574	chr13:52454775~52455331:-
LGG	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-9.68	2.38e-20	1.58e-17	-0.55	-0.41	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
LGG	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	9.68	2.4e-20	1.59e-17	0.43	0.41	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
LGG	cis	rs17772222	1	rs55722539	ENSG00000222990.1	RNU4-22P	9.68	2.4e-20	1.59e-17	0.51	0.41	Coronary artery calcification;	chr14:88411691	chr14:88513498~88513663:+
LGG	cis	rs7267979	0.932	rs431579	ENSG00000276952.1	RP5-965G21.6	9.68	2.41e-20	1.6e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25284915~25285588:-
LGG	cis	rs2412819	0.571	rs66903736	ENSG00000249839.1	AC011330.5	-9.68	2.41e-20	1.6e-17	-0.66	-0.41	Lung cancer;	chr15:43619435	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs66749753	ENSG00000249839.1	AC011330.5	-9.68	2.41e-20	1.6e-17	-0.66	-0.41	Lung cancer;	chr15:43619601	chr15:43663654~43684339:-
LGG	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	9.68	2.41e-20	1.6e-17	0.52	0.41	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
LGG	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-9.68	2.41e-20	1.6e-17	-0.5	-0.41	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
LGG	cis	rs7267979	0.866	rs2424699	ENSG00000125804.12	FAM182A	-9.68	2.42e-20	1.6e-17	-0.5	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:26054655~26086917:+
LGG	cis	rs7085104	0.684	rs7092690	ENSG00000272912.1	RP11-724N1.1	-9.68	2.42e-20	1.61e-17	-0.45	-0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102914585~102915404:+
LGG	cis	rs7267979	0.714	rs6115107	ENSG00000125804.12	FAM182A	-9.68	2.42e-20	1.61e-17	-0.49	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:26054655~26086917:+
LGG	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	9.68	2.42e-20	1.61e-17	0.56	0.41	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
LGG	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-9.68	2.42e-20	1.61e-17	-0.45	-0.41	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
LGG	cis	rs8062405	0.558	rs231976	ENSG00000271623.1	RP11-435I10.5	-9.68	2.42e-20	1.61e-17	-0.45	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28364700~28365333:+
LGG	cis	rs17772222	0.958	rs1816372	ENSG00000222990.1	RNU4-22P	9.68	2.47e-20	1.64e-17	0.51	0.41	Coronary artery calcification;	chr14:88507033	chr14:88513498~88513663:+
LGG	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	9.68	2.48e-20	1.64e-17	0.49	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
LGG	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	9.68	2.48e-20	1.64e-17	0.49	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
LGG	cis	rs507080	0.769	rs12290522	ENSG00000278376.1	RP11-158I9.8	-9.68	2.48e-20	1.64e-17	-0.37	-0.41	Serum metabolite levels;	chr11:118615610	chr11:118791254~118793137:+
LGG	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-9.68	2.48e-20	1.65e-17	-0.52	-0.41	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
LGG	cis	rs4713118	0.539	rs510987	ENSG00000226314.6	ZNF192P1	9.68	2.49e-20	1.65e-17	0.43	0.41	Parkinson's disease;	chr6:27879739	chr6:28161781~28169594:+
LGG	cis	rs17772222	0.917	rs2004329	ENSG00000222990.1	RNU4-22P	9.68	2.5e-20	1.66e-17	0.53	0.41	Coronary artery calcification;	chr14:88532965	chr14:88513498~88513663:+
LGG	cis	rs12935418	0.672	rs1453328	ENSG00000260213.4	RP11-303E16.3	-9.68	2.51e-20	1.67e-17	-0.51	-0.41	Mean corpuscular volume;	chr16:81019240	chr16:81016792~81035759:-
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-9.68	2.52e-20	1.67e-17	-0.53	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
LGG	cis	rs6452524	0.839	rs28745307	ENSG00000248112.1	RP11-78C3.1	9.67	2.54e-20	1.69e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:82919376~82921119:-
LGG	cis	rs7216064	0.734	rs12942774	ENSG00000278219.1	AC145343.1	9.67	2.56e-20	1.7e-17	0.45	0.41	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971446	chr17:68101538~68101639:+
LGG	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	9.67	2.56e-20	1.7e-17	0.46	0.41	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
LGG	cis	rs7267979	0.866	rs437635	ENSG00000276952.1	RP5-965G21.6	9.67	2.57e-20	1.7e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.899	rs442834	ENSG00000276952.1	RP5-965G21.6	9.67	2.57e-20	1.7e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.932	rs417110	ENSG00000276952.1	RP5-965G21.6	9.67	2.57e-20	1.7e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.932	rs449703	ENSG00000276952.1	RP5-965G21.6	9.67	2.57e-20	1.7e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.824	rs742046	ENSG00000216901.1	AL022393.7	9.67	2.58e-20	1.71e-17	0.52	0.41	Parkinson's disease;	chr6:27771475	chr6:28176188~28176674:+
LGG	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-9.67	2.58e-20	1.71e-17	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
LGG	cis	rs1153858	1	rs2467863	ENSG00000259433.2	CTD-2651B20.4	-9.67	2.59e-20	1.71e-17	-0.47	-0.41	Homoarginine levels;	chr15:45349682	chr15:45330209~45332634:-
LGG	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	9.67	2.59e-20	1.72e-17	0.34	0.41	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
LGG	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	9.67	2.59e-20	1.72e-17	0.4	0.41	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
LGG	cis	rs2797160	0.651	rs1268093	ENSG00000237742.5	RP11-624M8.1	9.67	2.6e-20	1.72e-17	0.36	0.41	Endometrial cancer;	chr6:125708089	chr6:125578558~125749190:-
LGG	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	9.67	2.62e-20	1.73e-17	0.92	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
LGG	cis	rs7267979	1	rs6050555	ENSG00000276952.1	RP5-965G21.6	-9.67	2.63e-20	1.74e-17	-0.41	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25284915~25285588:-
LGG	cis	rs11098499	0.615	rs59867181	ENSG00000249244.1	RP11-548H18.2	-9.67	2.63e-20	1.74e-17	-0.42	-0.41	Corneal astigmatism;	chr4:119635312	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	9.67	2.64e-20	1.75e-17	0.53	0.41	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
LGG	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-9.67	2.64e-20	1.75e-17	-0.57	-0.41	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-9.67	2.64e-20	1.75e-17	-0.57	-0.41	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
LGG	cis	rs11148252	0.846	rs9379	ENSG00000278238.1	RP11-245D16.4	-9.67	2.65e-20	1.75e-17	-0.39	-0.41	Lewy body disease;	chr13:52476344	chr13:52454775~52455331:-
LGG	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	9.67	2.66e-20	1.76e-17	0.52	0.41	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
LGG	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-9.67	2.67e-20	1.77e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
LGG	cis	rs1023500	0.505	rs134888	ENSG00000205702.9	CYP2D7	9.67	2.68e-20	1.77e-17	0.29	0.41	Schizophrenia;	chr22:42278275	chr22:42140203~42144577:-
LGG	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	9.67	2.68e-20	1.77e-17	0.36	0.41	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
LGG	cis	rs6903823	0.508	rs1150726	ENSG00000199851.2	U3	9.67	2.7e-20	1.79e-17	0.56	0.41	Pulmonary function;	chr6:28275265	chr6:28015568~28015777:+
LGG	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	-9.67	2.71e-20	1.79e-17	-0.44	-0.41	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
LGG	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-9.67	2.72e-20	1.8e-17	-0.54	-0.41	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
LGG	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	-9.67	2.73e-20	1.81e-17	-0.43	-0.41	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
LGG	cis	rs7432375	0.901	rs6802702	ENSG00000261758.1	RP11-102M11.2	-9.67	2.73e-20	1.81e-17	-0.43	-0.41	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136770721	chr3:136752630~136755780:+
LGG	cis	rs657075	0.697	rs4646304	ENSG00000263597.1	MIR3936	-9.67	2.73e-20	1.81e-17	-0.68	-0.41	Rheumatoid arthritis;	chr5:132379086	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs4646305	ENSG00000263597.1	MIR3936	-9.67	2.73e-20	1.81e-17	-0.68	-0.41	Rheumatoid arthritis;	chr5:132382847	chr5:132365490~132365599:-
LGG	cis	rs17772222	0.92	rs61975260	ENSG00000222990.1	RNU4-22P	9.66	2.76e-20	1.82e-17	0.53	0.41	Coronary artery calcification;	chr14:88429597	chr14:88513498~88513663:+
LGG	cis	rs1153858	1	rs2668747	ENSG00000259433.2	CTD-2651B20.4	-9.66	2.76e-20	1.82e-17	-0.47	-0.41	Homoarginine levels;	chr15:45325018	chr15:45330209~45332634:-
LGG	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	9.66	2.76e-20	1.83e-17	0.3	0.41	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
LGG	cis	rs853679	0.527	rs853690	ENSG00000218016.2	ZNF192P2	-9.66	2.77e-20	1.83e-17	-0.5	-0.41	Depression;	chr6:28317705	chr6:28188050~28189432:+
LGG	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	9.66	2.79e-20	1.84e-17	0.48	0.41	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
LGG	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	9.66	2.79e-20	1.85e-17	0.52	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
LGG	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	9.66	2.8e-20	1.85e-17	0.47	0.41	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
LGG	cis	rs7085104	0.7	rs7096183	ENSG00000272912.1	RP11-724N1.1	-9.66	2.8e-20	1.85e-17	-0.45	-0.41	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102914585~102915404:+
LGG	cis	rs9532669	0.926	rs9532657	ENSG00000168852.11	TPTE2P5	-9.66	2.82e-20	1.86e-17	-0.41	-0.41	Cervical cancer;	chr13:40918208	chr13:40822296~40921749:-
LGG	cis	rs7247513	0.866	rs2861405	ENSG00000213290.4	PGK1P2	-9.66	2.82e-20	1.86e-17	-0.44	-0.41	Bipolar disorder;	chr19:12611518	chr19:12559571~12561105:+
LGG	cis	rs2797160	0.651	rs6939969	ENSG00000237742.5	RP11-624M8.1	9.66	2.83e-20	1.87e-17	0.36	0.41	Endometrial cancer;	chr6:125713417	chr6:125578558~125749190:-
LGG	cis	rs7211079	0.957	rs935117	ENSG00000279259.1	RP11-334C17.3	9.66	2.83e-20	1.87e-17	0.44	0.41	Myocardial infarction;	chr17:80141685	chr17:80147250~80148596:+
LGG	cis	rs7211079	0.957	rs58120535	ENSG00000279259.1	RP11-334C17.3	9.66	2.83e-20	1.87e-17	0.44	0.41	Myocardial infarction;	chr17:80142225	chr17:80147250~80148596:+
LGG	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-9.66	2.84e-20	1.87e-17	-0.48	-0.41	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
LGG	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-9.66	2.84e-20	1.87e-17	-0.48	-0.41	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
LGG	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-9.66	2.84e-20	1.87e-17	-0.48	-0.41	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
LGG	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-9.66	2.84e-20	1.87e-17	-0.48	-0.41	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
LGG	cis	rs1707322	0.721	rs11211149	ENSG00000281133.1	AL355480.3	-9.66	2.87e-20	1.89e-17	-0.48	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs11211152	ENSG00000281133.1	AL355480.3	-9.66	2.87e-20	1.89e-17	-0.48	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45580892~45580996:-
LGG	cis	rs6452524	0.746	rs28745311	ENSG00000248112.1	RP11-78C3.1	9.66	2.87e-20	1.9e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:82919376~82921119:-
LGG	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-9.66	2.87e-20	1.9e-17	-0.48	-0.41	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
LGG	cis	rs2325036	0.783	rs10511067	ENSG00000239519.1	CADM2-AS1	9.66	2.87e-20	1.9e-17	0.46	0.41	Waist circumference;	chr3:85827649	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs12631564	ENSG00000239519.1	CADM2-AS1	9.66	2.87e-20	1.9e-17	0.46	0.41	Waist circumference;	chr3:85827898	chr3:85992183~86028007:-
LGG	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-9.66	2.88e-20	1.9e-17	-0.43	-0.41	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
LGG	cis	rs2412819	0.571	rs8030536	ENSG00000249839.1	AC011330.5	-9.66	2.88e-20	1.9e-17	-0.66	-0.41	Lung cancer;	chr15:43627365	chr15:43663654~43684339:-
LGG	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	9.66	2.89e-20	1.91e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
LGG	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	9.66	2.89e-20	1.91e-17	0.71	0.41	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
LGG	cis	rs11098499	0.562	rs2389879	ENSG00000249244.1	RP11-548H18.2	-9.66	2.9e-20	1.92e-17	-0.42	-0.41	Corneal astigmatism;	chr4:119636529	chr4:119391831~119395335:-
LGG	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-9.66	2.9e-20	1.92e-17	-0.52	-0.41	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
LGG	cis	rs7119038	0.779	rs11217045	ENSG00000255239.1	AP002954.6	-9.66	2.92e-20	1.93e-17	-0.58	-0.41	Sjögren's syndrome;	chr11:118827156	chr11:118688039~118690600:-
LGG	cis	rs651907	0.535	rs4342086	ENSG00000256628.3	ZBTB11-AS1	9.66	2.95e-20	1.95e-17	0.47	0.41	Colorectal cancer;	chr3:101784921	chr3:101676475~101679217:+
LGG	cis	rs657075	0.595	rs3749753	ENSG00000233006.5	AC034220.3	-9.65	2.99e-20	1.97e-17	-0.57	-0.41	Rheumatoid arthritis;	chr5:132251438	chr5:132311285~132369916:-
LGG	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-9.65	3e-20	1.98e-17	-0.49	-0.41	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
LGG	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	9.65	3.01e-20	1.98e-17	0.48	0.41	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
LGG	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	9.65	3.01e-20	1.99e-17	0.47	0.41	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-9.65	3.01e-20	1.99e-17	-0.47	-0.41	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-9.65	3.01e-20	1.99e-17	-0.47	-0.41	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
LGG	cis	rs1153858	1	rs1980288	ENSG00000259433.2	CTD-2651B20.4	-9.65	3.02e-20	1.99e-17	-0.47	-0.41	Homoarginine levels;	chr15:45328414	chr15:45330209~45332634:-
LGG	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-9.65	3.03e-20	2e-17	-0.49	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
LGG	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.03e-20	2e-17	-0.44	-0.41	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
LGG	cis	rs7267979	0.932	rs424487	ENSG00000276952.1	RP5-965G21.6	9.65	3.05e-20	2.01e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25284915~25285588:-
LGG	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-9.65	3.05e-20	2.01e-17	-0.43	-0.41	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
LGG	cis	rs8062405	0.558	rs151228	ENSG00000271623.1	RP11-435I10.5	-9.65	3.05e-20	2.01e-17	-0.46	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28364700~28365333:+
LGG	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-9.65	3.06e-20	2.02e-17	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
LGG	cis	rs17345786	0.906	rs56171035	ENSG00000244119.1	PDCL3P4	9.65	3.07e-20	2.02e-17	0.35	0.41	Colonoscopy-negative controls vs population controls;	chr3:101392264	chr3:101712472~101713191:+
LGG	cis	rs8062405	0.54	rs480400	ENSG00000271623.1	RP11-435I10.5	-9.65	3.09e-20	2.03e-17	-0.46	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28364700~28365333:+
LGG	cis	rs6903823	0.508	rs1150724	ENSG00000199851.2	U3	9.65	3.11e-20	2.05e-17	0.56	0.41	Pulmonary function;	chr6:28282459	chr6:28015568~28015777:+
LGG	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-9.65	3.11e-20	2.05e-17	-0.37	-0.41	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
LGG	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	9.65	3.12e-20	2.05e-17	0.78	0.41	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
LGG	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	-9.65	3.13e-20	2.06e-17	-0.41	-0.41	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
LGG	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	9.65	3.13e-20	2.06e-17	0.37	0.41	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
LGG	cis	rs1153858	1	rs12909158	ENSG00000259433.2	CTD-2651B20.4	-9.65	3.13e-20	2.06e-17	-0.47	-0.41	Homoarginine levels;	chr15:45328976	chr15:45330209~45332634:-
LGG	cis	rs7119038	0.865	rs11217046	ENSG00000255239.1	AP002954.6	-9.65	3.13e-20	2.06e-17	-0.58	-0.41	Sjögren's syndrome;	chr11:118828198	chr11:118688039~118690600:-
LGG	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	9.65	3.13e-20	2.06e-17	0.44	0.41	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
LGG	cis	rs4683346	0.691	rs12488474	ENSG00000273328.4	RP11-141M3.6	-9.65	3.13e-20	2.06e-17	-0.53	-0.41	Granulocyte percentage of myeloid white cells;	chr3:42896185	chr3:42809414~42908105:+
LGG	cis	rs7267979	1	rs4815417	ENSG00000276952.1	RP5-965G21.6	-9.65	3.13e-20	2.06e-17	-0.4	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25284915~25285588:-
LGG	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-9.65	3.14e-20	2.07e-17	-0.46	-0.41	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
LGG	cis	rs9810089	0.814	rs73226190	ENSG00000261758.1	RP11-102M11.2	9.65	3.14e-20	2.07e-17	0.43	0.41	Gestational age at birth (child effect);	chr3:136494468	chr3:136752630~136755780:+
LGG	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	9.65	3.16e-20	2.08e-17	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
LGG	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	9.65	3.16e-20	2.08e-17	0.47	0.41	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
LGG	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-9.65	3.18e-20	2.09e-17	-0.36	-0.41	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
LGG	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.18e-20	2.1e-17	-0.44	-0.41	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.18e-20	2.1e-17	-0.44	-0.41	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.18e-20	2.1e-17	-0.44	-0.41	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
LGG	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-9.65	3.19e-20	2.1e-17	-0.31	-0.41	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
LGG	cis	rs7267979	0.932	rs367666	ENSG00000276952.1	RP5-965G21.6	9.65	3.19e-20	2.1e-17	0.4	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25284915~25285588:-
LGG	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-9.65	3.21e-20	2.11e-17	-0.55	-0.41	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
LGG	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-9.64	3.22e-20	2.12e-17	-0.55	-0.41	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
LGG	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	9.64	3.23e-20	2.12e-17	0.52	0.41	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
LGG	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-9.64	3.23e-20	2.12e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	9.64	3.23e-20	2.12e-17	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-9.64	3.23e-20	2.12e-17	-0.36	-0.41	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
LGG	cis	rs7119038	0.818	rs57494551	ENSG00000255239.1	AP002954.6	-9.64	3.23e-20	2.13e-17	-0.57	-0.41	Sjögren's syndrome;	chr11:118790689	chr11:118688039~118690600:-
LGG	cis	rs9322193	0.923	rs56397000	ENSG00000216621.7	RP11-244K5.6	9.64	3.25e-20	2.14e-17	0.48	0.41	Lung cancer;	chr6:149739347	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.884	rs9689702	ENSG00000216621.7	RP11-244K5.6	9.64	3.25e-20	2.14e-17	0.48	0.41	Lung cancer;	chr6:149740720	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs10782315	ENSG00000216621.7	RP11-244K5.6	9.64	3.25e-20	2.14e-17	0.48	0.41	Lung cancer;	chr6:149743093	chr6:149934527~149936782:+
LGG	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-9.64	3.25e-20	2.14e-17	-0.8	-0.4	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-9.64	3.25e-20	2.14e-17	-0.54	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
LGG	cis	rs1560104	0.675	rs8063669	ENSG00000274834.1	CTD-3037G24.5	-9.64	3.26e-20	2.14e-17	-0.52	-0.4	Obesity-related traits;	chr16:12603379	chr16:12614451~12614852:+
LGG	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	9.64	3.3e-20	2.17e-17	0.62	0.4	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
LGG	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-9.64	3.3e-20	2.17e-17	-0.64	-0.4	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
LGG	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-9.64	3.31e-20	2.18e-17	-0.49	-0.4	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
LGG	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-9.64	3.32e-20	2.18e-17	-0.45	-0.4	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
LGG	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	9.64	3.32e-20	2.19e-17	0.31	0.4	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
LGG	cis	rs9388451	1	rs9388451	ENSG00000237742.5	RP11-624M8.1	-9.64	3.33e-20	2.19e-17	-0.36	-0.4	Brugada syndrome;	chr6:125769231	chr6:125578558~125749190:-
LGG	cis	rs6903823	0.508	rs1150718	ENSG00000199851.2	U3	9.64	3.34e-20	2.2e-17	0.56	0.4	Pulmonary function;	chr6:28289170	chr6:28015568~28015777:+
LGG	cis	rs6903823	0.508	rs1233660	ENSG00000199851.2	U3	9.64	3.34e-20	2.2e-17	0.56	0.4	Pulmonary function;	chr6:28292472	chr6:28015568~28015777:+
LGG	cis	rs507080	0.807	rs7926944	ENSG00000278376.1	RP11-158I9.8	-9.64	3.34e-20	2.2e-17	-0.36	-0.4	Serum metabolite levels;	chr11:118689119	chr11:118791254~118793137:+
LGG	cis	rs12935418	0.616	rs2549854	ENSG00000260213.4	RP11-303E16.3	-9.64	3.35e-20	2.2e-17	-0.51	-0.4	Mean corpuscular volume;	chr16:80993034	chr16:81016792~81035759:-
LGG	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	9.64	3.36e-20	2.21e-17	0.5	0.4	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
LGG	cis	rs4683346	0.752	rs4682868	ENSG00000273328.4	RP11-141M3.6	-9.64	3.37e-20	2.21e-17	-0.47	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42864023	chr3:42809414~42908105:+
LGG	cis	rs5742933	1	rs3762545	ENSG00000273240.1	RP11-455J20.3	-9.64	3.37e-20	2.21e-17	-0.52	-0.4	Ferritin levels;	chr2:189790835	chr2:189763859~189764456:-
LGG	cis	rs657075	0.697	rs34590412	ENSG00000263597.1	MIR3936	-9.64	3.4e-20	2.23e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132374335	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs4646302	ENSG00000263597.1	MIR3936	-9.64	3.4e-20	2.23e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132376790	chr5:132365490~132365599:-
LGG	cis	rs4950322	0.57	rs4950315	ENSG00000278811.3	LINC00624	-9.64	3.41e-20	2.24e-17	-0.4	-0.4	Protein quantitative trait loci;	chr1:147264433	chr1:147258885~147517875:-
LGG	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	9.64	3.42e-20	2.24e-17	0.49	0.4	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
LGG	cis	rs1153858	1	rs1153849	ENSG00000259433.2	CTD-2651B20.4	-9.64	3.43e-20	2.25e-17	-0.47	-0.4	Homoarginine levels;	chr15:45403497	chr15:45330209~45332634:-
LGG	cis	rs7267979	0.873	rs7453	ENSG00000125804.12	FAM182A	-9.64	3.43e-20	2.25e-17	-0.48	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:26054655~26086917:+
LGG	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	9.64	3.44e-20	2.26e-17	0.51	0.4	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
LGG	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-9.64	3.45e-20	2.26e-17	-0.55	-0.4	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
LGG	cis	rs17772222	1	rs1955599	ENSG00000222990.1	RNU4-22P	9.64	3.47e-20	2.27e-17	0.51	0.4	Coronary artery calcification;	chr14:88358788	chr14:88513498~88513663:+
LGG	cis	rs17772222	1	rs1955600	ENSG00000222990.1	RNU4-22P	9.64	3.47e-20	2.27e-17	0.51	0.4	Coronary artery calcification;	chr14:88359040	chr14:88513498~88513663:+
LGG	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-9.64	3.48e-20	2.28e-17	-0.43	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
LGG	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	9.63	3.5e-20	2.29e-17	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
LGG	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	9.63	3.54e-20	2.32e-17	0.55	0.4	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
LGG	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	9.63	3.55e-20	2.32e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
LGG	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	9.63	3.56e-20	2.33e-17	0.48	0.4	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
LGG	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-9.63	3.58e-20	2.34e-17	-0.4	-0.4	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
LGG	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	9.63	3.58e-20	2.35e-17	0.48	0.4	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
LGG	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-9.63	3.58e-20	2.35e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
LGG	cis	rs7119038	0.818	rs10892280	ENSG00000255239.1	AP002954.6	-9.63	3.63e-20	2.38e-17	-0.57	-0.4	Sjögren's syndrome;	chr11:118741108	chr11:118688039~118690600:-
LGG	cis	rs9388451	0.807	rs1268070	ENSG00000237742.5	RP11-624M8.1	-9.63	3.65e-20	2.39e-17	-0.36	-0.4	Brugada syndrome;	chr6:125720018	chr6:125578558~125749190:-
LGG	cis	rs1153858	0.895	rs12593402	ENSG00000259433.2	CTD-2651B20.4	-9.63	3.65e-20	2.39e-17	-0.48	-0.4	Homoarginine levels;	chr15:45325194	chr15:45330209~45332634:-
LGG	cis	rs12922040	0.607	rs11641649	ENSG00000263335.1	AF001548.5	-9.63	3.65e-20	2.39e-17	-0.41	-0.4	Serum uric acid levels in response to allopurinol in gout;	chr16:15773707	chr16:15726674~15732993:+
LGG	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-9.63	3.67e-20	2.4e-17	-0.34	-0.4	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
LGG	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-9.63	3.67e-20	2.41e-17	-0.52	-0.4	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
LGG	cis	rs17772222	0.917	rs10143767	ENSG00000222990.1	RNU4-22P	9.63	3.67e-20	2.41e-17	0.53	0.4	Coronary artery calcification;	chr14:88514867	chr14:88513498~88513663:+
LGG	cis	rs9810089	0.814	rs696518	ENSG00000261758.1	RP11-102M11.2	9.63	3.69e-20	2.42e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136401458	chr3:136752630~136755780:+
LGG	cis	rs7267979	0.714	rs3787082	ENSG00000125804.12	FAM182A	-9.63	3.7e-20	2.42e-17	-0.49	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:26054655~26086917:+
LGG	cis	rs1153858	0.832	rs1145078	ENSG00000259433.2	CTD-2651B20.4	-9.63	3.7e-20	2.42e-17	-0.47	-0.4	Homoarginine levels;	chr15:45390079	chr15:45330209~45332634:-
LGG	cis	rs7119038	0.818	rs1048024	ENSG00000255239.1	AP002954.6	-9.63	3.71e-20	2.43e-17	-0.57	-0.4	Sjögren's syndrome;	chr11:118748067	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.774	rs2004781	ENSG00000255239.1	AP002954.6	-9.63	3.71e-20	2.43e-17	-0.57	-0.4	Sjögren's syndrome;	chr11:118748544	chr11:118688039~118690600:-
LGG	cis	rs7119038	0.818	rs3889239	ENSG00000255239.1	AP002954.6	-9.63	3.71e-20	2.43e-17	-0.57	-0.4	Sjögren's syndrome;	chr11:118749251	chr11:118688039~118690600:-
LGG	cis	rs4819052	0.765	rs2838868	ENSG00000215447.6	BX322557.10	9.63	3.72e-20	2.43e-17	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45288052~45291738:+
LGG	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	9.63	3.74e-20	2.45e-17	0.52	0.4	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
LGG	cis	rs4683346	0.591	rs2559650	ENSG00000273328.4	RP11-141M3.6	-9.63	3.75e-20	2.45e-17	-0.51	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42953724	chr3:42809414~42908105:+
LGG	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-9.63	3.76e-20	2.46e-17	-0.43	-0.4	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
LGG	cis	rs9876781	0.967	rs1459249	ENSG00000244380.1	RP11-24C3.2	9.63	3.78e-20	2.47e-17	0.5	0.4	Longevity;	chr3:48438208	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs725309	ENSG00000244380.1	RP11-24C3.2	-9.62	3.79e-20	2.48e-17	-0.5	-0.4	Longevity;	chr3:48377218	chr3:48440352~48446656:-
LGG	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	9.62	3.79e-20	2.48e-17	0.42	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
LGG	cis	rs7302981	0.967	rs7972842	ENSG00000272368.2	RP4-605O3.4	-9.62	3.8e-20	2.49e-17	-0.4	-0.4	Systolic blood pressure;	chr12:50122540	chr12:50112197~50165618:+
LGG	cis	rs9876781	1	rs2362450	ENSG00000244380.1	RP11-24C3.2	9.62	3.82e-20	2.49e-17	0.5	0.4	Longevity;	chr3:48419904	chr3:48440352~48446656:-
LGG	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	9.62	3.85e-20	2.52e-17	0.5	0.4	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
LGG	cis	rs2797160	0.651	rs1268067	ENSG00000237742.5	RP11-624M8.1	9.62	3.86e-20	2.52e-17	0.36	0.4	Endometrial cancer;	chr6:125715475	chr6:125578558~125749190:-
LGG	cis	rs5758511	0.689	rs55906806	ENSG00000227370.1	RP4-669P10.19	9.62	3.86e-20	2.52e-17	0.5	0.4	Birth weight;	chr22:42248465	chr22:42132543~42132998:+
LGG	cis	rs1707322	0.691	rs11211175	ENSG00000281133.1	AL355480.3	-9.62	3.87e-20	2.53e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45580892~45580996:-
LGG	cis	rs9876781	0.9	rs1037773	ENSG00000244380.1	RP11-24C3.2	9.62	3.88e-20	2.53e-17	0.5	0.4	Longevity;	chr3:48426493	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs2279077	ENSG00000244380.1	RP11-24C3.2	9.62	3.88e-20	2.53e-17	0.5	0.4	Longevity;	chr3:48432839	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs1109227	ENSG00000244380.1	RP11-24C3.2	9.62	3.88e-20	2.53e-17	0.5	0.4	Longevity;	chr3:48437797	chr3:48440352~48446656:-
LGG	cis	rs7520050	0.645	rs1768809	ENSG00000280836.1	AL355480.1	9.62	3.9e-20	2.55e-17	0.43	0.4	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45581219~45581321:-
LGG	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-9.62	3.91e-20	2.55e-17	-0.47	-0.4	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
LGG	cis	rs11098499	0.722	rs10025925	ENSG00000249244.1	RP11-548H18.2	9.62	3.91e-20	2.55e-17	0.42	0.4	Corneal astigmatism;	chr4:119350589	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.731	rs10015579	ENSG00000249244.1	RP11-548H18.2	9.62	3.91e-20	2.55e-17	0.42	0.4	Corneal astigmatism;	chr4:119350647	chr4:119391831~119395335:-
LGG	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	9.62	3.91e-20	2.55e-17	0.48	0.4	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
LGG	cis	rs7474896	0.806	rs1779150	ENSG00000226578.1	RP11-258F22.1	-9.62	3.91e-20	2.55e-17	-0.84	-0.4	Obesity (extreme);	chr10:37749759	chr10:37775371~37784131:-
LGG	cis	rs7119038	0.818	rs56758835	ENSG00000255239.1	AP002954.6	-9.62	3.92e-20	2.56e-17	-0.57	-0.4	Sjögren's syndrome;	chr11:118744631	chr11:118688039~118690600:-
LGG	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-9.62	3.93e-20	2.56e-17	-0.45	-0.4	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
LGG	cis	rs6600671	0.693	rs1853731	ENSG00000223345.3	HIST2H2BA	9.62	3.94e-20	2.57e-17	0.43	0.4	Hip geometry;	chr1:121510262	chr1:121108210~121117257:-
LGG	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-9.62	3.95e-20	2.58e-17	-0.44	-0.4	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
LGG	cis	rs9810089	0.814	rs834305	ENSG00000261758.1	RP11-102M11.2	9.62	3.96e-20	2.58e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136400512	chr3:136752630~136755780:+
LGG	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-9.62	3.97e-20	2.59e-17	-0.64	-0.4	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
LGG	cis	rs9876781	1	rs9883759	ENSG00000244380.1	RP11-24C3.2	9.62	3.99e-20	2.6e-17	0.5	0.4	Longevity;	chr3:48422209	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs6442120	ENSG00000244380.1	RP11-24C3.2	9.62	3.99e-20	2.6e-17	0.5	0.4	Longevity;	chr3:48423094	chr3:48440352~48446656:-
LGG	cis	rs17345786	0.861	rs11707689	ENSG00000244119.1	PDCL3P4	9.62	3.99e-20	2.6e-17	0.35	0.4	Colonoscopy-negative controls vs population controls;	chr3:101367631	chr3:101712472~101713191:+
LGG	cis	rs4683346	0.752	rs1366045	ENSG00000273328.4	RP11-141M3.6	-9.62	4.01e-20	2.61e-17	-0.47	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42867558	chr3:42809414~42908105:+
LGG	cis	rs4683346	0.752	rs3919627	ENSG00000273328.4	RP11-141M3.6	-9.62	4.01e-20	2.61e-17	-0.47	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42867668	chr3:42809414~42908105:+
LGG	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-9.62	4.02e-20	2.62e-17	-0.51	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
LGG	cis	rs9876781	1	rs3774808	ENSG00000244380.1	RP11-24C3.2	9.62	4.03e-20	2.63e-17	0.5	0.4	Longevity;	chr3:48440237	chr3:48440352~48446656:-
LGG	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	9.62	4.04e-20	2.63e-17	0.53	0.4	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
LGG	cis	rs357618	0.531	rs7723079	ENSG00000260581.1	CTB-113P19.4	-9.62	4.05e-20	2.64e-17	-0.5	-0.4	Basophil percentage of white cells;	chr5:151507055	chr5:151652275~151655449:+
LGG	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	9.62	4.07e-20	2.65e-17	0.52	0.4	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	9.62	4.07e-20	2.65e-17	0.52	0.4	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	9.62	4.07e-20	2.65e-17	0.52	0.4	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
LGG	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-9.62	4.1e-20	2.67e-17	-0.53	-0.4	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
LGG	cis	rs9527	0.59	rs3781282	ENSG00000272912.1	RP11-724N1.1	9.61	4.11e-20	2.67e-17	0.45	0.4	Arsenic metabolism;	chr10:103092662	chr10:102914585~102915404:+
LGG	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	9.61	4.11e-20	2.68e-17	0.47	0.4	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
LGG	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-9.61	4.15e-20	2.7e-17	-0.54	-0.4	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-9.61	4.15e-20	2.7e-17	-0.54	-0.4	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
LGG	cis	rs1420956	0.875	rs9958092	ENSG00000264151.4	RP11-739N10.1	9.61	4.18e-20	2.72e-17	0.51	0.4	Obesity-related traits;	chr18:27586816	chr18:27336379~27595164:-
LGG	cis	rs7315956	0.859	rs7958266	ENSG00000257139.1	RP11-320P7.2	-9.61	4.19e-20	2.72e-17	-0.55	-0.4	Testicular germ cell tumor;	chr12:70240837	chr12:70180338~70202004:+
LGG	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-9.61	4.19e-20	2.72e-17	-0.44	-0.4	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
LGG	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-9.61	4.19e-20	2.73e-17	-0.47	-0.4	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
LGG	cis	rs8062405	0.54	rs193628	ENSG00000271623.1	RP11-435I10.5	9.61	4.2e-20	2.73e-17	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28570821	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.923	rs1572229	ENSG00000216621.7	RP11-244K5.6	9.61	4.25e-20	2.77e-17	0.48	0.4	Lung cancer;	chr6:149743841	chr6:149934527~149936782:+
LGG	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-9.61	4.26e-20	2.77e-17	-0.47	-0.4	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-9.61	4.26e-20	2.77e-17	-0.47	-0.4	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
LGG	cis	rs9810089	0.934	rs1279949	ENSG00000261758.1	RP11-102M11.2	9.61	4.28e-20	2.78e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136278028	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.934	rs570621	ENSG00000261758.1	RP11-102M11.2	9.61	4.28e-20	2.78e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136281901	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.872	rs527888	ENSG00000261758.1	RP11-102M11.2	9.61	4.28e-20	2.78e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136312516	chr3:136752630~136755780:+
LGG	cis	rs9876781	0.967	rs1870444	ENSG00000244380.1	RP11-24C3.2	9.61	4.29e-20	2.79e-17	0.5	0.4	Longevity;	chr3:48445369	chr3:48440352~48446656:-
LGG	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	9.61	4.29e-20	2.79e-17	0.62	0.4	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
LGG	cis	rs2613964	0.504	rs2399465	ENSG00000240057.4	RP11-572M11.4	-9.61	4.32e-20	2.81e-17	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129145	chr3:113019532~113183301:+
LGG	cis	rs2613964	0.504	rs2399466	ENSG00000240057.4	RP11-572M11.4	-9.61	4.32e-20	2.81e-17	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129190	chr3:113019532~113183301:+
LGG	cis	rs2613964	0.504	rs7617193	ENSG00000240057.4	RP11-572M11.4	-9.61	4.32e-20	2.81e-17	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130004	chr3:113019532~113183301:+
LGG	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	9.61	4.32e-20	2.81e-17	0.46	0.4	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
LGG	cis	rs6903823	0.508	rs1150721	ENSG00000199851.2	U3	9.61	4.33e-20	2.81e-17	0.56	0.4	Pulmonary function;	chr6:28287263	chr6:28015568~28015777:+
LGG	cis	rs1153858	1	rs4775895	ENSG00000259433.2	CTD-2651B20.4	-9.61	4.33e-20	2.82e-17	-0.47	-0.4	Homoarginine levels;	chr15:45325759	chr15:45330209~45332634:-
LGG	cis	rs12554020	0.892	rs59483310	ENSG00000237385.1	RP11-165J3.5	9.61	4.34e-20	2.82e-17	0.68	0.4	Schizophrenia;	chr9:93503318	chr9:93430342~93431299:-
LGG	cis	rs9810089	0.814	rs866758	ENSG00000261758.1	RP11-102M11.2	9.61	4.38e-20	2.85e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136399028	chr3:136752630~136755780:+
LGG	cis	rs9527	0.544	rs3781280	ENSG00000272912.1	RP11-724N1.1	-9.61	4.38e-20	2.85e-17	-0.46	-0.4	Arsenic metabolism;	chr10:103104086	chr10:102914585~102915404:+
LGG	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	9.61	4.39e-20	2.85e-17	0.44	0.4	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
LGG	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	9.61	4.4e-20	2.86e-17	0.55	0.4	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
LGG	cis	rs1153858	1	rs12593370	ENSG00000259433.2	CTD-2651B20.4	-9.61	4.41e-20	2.86e-17	-0.48	-0.4	Homoarginine levels;	chr15:45325219	chr15:45330209~45332634:-
LGG	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-9.61	4.41e-20	2.87e-17	-0.44	-0.4	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
LGG	cis	rs9322193	0.962	rs2342764	ENSG00000216621.7	RP11-244K5.6	9.61	4.42e-20	2.87e-17	0.49	0.4	Lung cancer;	chr6:149835068	chr6:149934527~149936782:+
LGG	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-9.61	4.44e-20	2.88e-17	-0.49	-0.4	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
LGG	cis	rs11098499	0.562	rs13101722	ENSG00000249244.1	RP11-548H18.2	-9.61	4.44e-20	2.89e-17	-0.41	-0.4	Corneal astigmatism;	chr4:119634820	chr4:119391831~119395335:-
LGG	cis	rs9527	0.59	rs10883843	ENSG00000272912.1	RP11-724N1.1	-9.61	4.45e-20	2.89e-17	-0.46	-0.4	Arsenic metabolism;	chr10:103187736	chr10:102914585~102915404:+
LGG	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-9.6	4.45e-20	2.89e-17	-0.4	-0.4	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
LGG	cis	rs11098499	0.629	rs28369518	ENSG00000249244.1	RP11-548H18.2	9.6	4.46e-20	2.89e-17	0.42	0.4	Corneal astigmatism;	chr4:119350475	chr4:119391831~119395335:-
LGG	cis	rs9876781	1	rs6784322	ENSG00000244380.1	RP11-24C3.2	9.6	4.5e-20	2.92e-17	0.5	0.4	Longevity;	chr3:48380745	chr3:48440352~48446656:-
LGG	cis	rs17772222	0.597	rs17700521	ENSG00000258983.2	RP11-507K2.2	9.6	4.51e-20	2.93e-17	0.5	0.4	Coronary artery calcification;	chr14:88849531	chr14:88499334~88515502:+
LGG	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	9.6	4.52e-20	2.94e-17	0.54	0.4	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
LGG	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-9.6	4.55e-20	2.95e-17	-0.45	-0.4	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
LGG	cis	rs12819124	0.502	rs10875718	ENSG00000258273.1	RP11-370I10.4	-9.6	4.56e-20	2.96e-17	-0.5	-0.4	Glycated hemoglobin levels;	chr12:48017319	chr12:48333755~48333901:-
LGG	cis	rs4713118	0.826	rs2893929	ENSG00000216901.1	AL022393.7	9.6	4.56e-20	2.96e-17	0.55	0.4	Parkinson's disease;	chr6:27770953	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.666	rs4140646	ENSG00000216901.1	AL022393.7	9.6	4.56e-20	2.96e-17	0.55	0.4	Parkinson's disease;	chr6:27771022	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.666	rs2893930	ENSG00000216901.1	AL022393.7	9.6	4.56e-20	2.96e-17	0.55	0.4	Parkinson's disease;	chr6:27771027	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.868	rs742047	ENSG00000216901.1	AL022393.7	9.6	4.56e-20	2.96e-17	0.55	0.4	Parkinson's disease;	chr6:27771601	chr6:28176188~28176674:+
LGG	cis	rs4683346	0.691	rs2081811	ENSG00000273328.4	RP11-141M3.6	-9.6	4.57e-20	2.96e-17	-0.53	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42892015	chr3:42809414~42908105:+
LGG	cis	rs1799949	0.965	rs4793237	ENSG00000267681.1	CTD-3199J23.6	-9.6	4.57e-20	2.97e-17	-0.44	-0.4	Menopause (age at onset);	chr17:43359227	chr17:43144956~43145255:+
LGG	cis	rs6452524	0.78	rs10078661	ENSG00000248112.1	RP11-78C3.1	9.6	4.61e-20	2.99e-17	0.54	0.4	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:82919376~82921119:-
LGG	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-9.6	4.62e-20	3e-17	-0.48	-0.4	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
LGG	cis	rs1707322	0.681	rs12048866	ENSG00000281133.1	AL355480.3	-9.6	4.62e-20	3e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs12024590	ENSG00000281133.1	AL355480.3	-9.6	4.62e-20	3e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs12027622	ENSG00000281133.1	AL355480.3	-9.6	4.62e-20	3e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.716	rs6699444	ENSG00000281133.1	AL355480.3	-9.6	4.62e-20	3e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45580892~45580996:-
LGG	cis	rs9876781	1	rs6442117	ENSG00000244380.1	RP11-24C3.2	-9.6	4.65e-20	3.01e-17	-0.5	-0.4	Longevity;	chr3:48378407	chr3:48440352~48446656:-
LGG	cis	rs4713118	0.868	rs7756968	ENSG00000216901.1	AL022393.7	9.6	4.66e-20	3.02e-17	0.55	0.4	Parkinson's disease;	chr6:27767175	chr6:28176188~28176674:+
LGG	cis	rs1420956	0.846	rs1420959	ENSG00000264151.4	RP11-739N10.1	9.6	4.66e-20	3.02e-17	0.51	0.4	Obesity-related traits;	chr18:27583540	chr18:27336379~27595164:-
LGG	cis	rs1707322	0.721	rs6699418	ENSG00000281133.1	AL355480.3	-9.6	4.66e-20	3.02e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs4431884	ENSG00000281133.1	AL355480.3	-9.6	4.66e-20	3.02e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.65	rs4660879	ENSG00000281133.1	AL355480.3	-9.6	4.66e-20	3.02e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45580892~45580996:-
LGG	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	9.6	4.68e-20	3.03e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
LGG	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	9.6	4.68e-20	3.03e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
LGG	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	9.6	4.68e-20	3.03e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
LGG	cis	rs3743772	0.5	rs9924562	ENSG00000279722.1	RP11-44F14.6	9.6	4.68e-20	3.03e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53487607~53489943:-
LGG	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	9.6	4.68e-20	3.03e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
LGG	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	9.6	4.68e-20	3.03e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
LGG	cis	rs7829975	0.684	rs546603	ENSG00000253893.2	FAM85B	9.6	4.69e-20	3.04e-17	0.49	0.4	Mood instability;	chr8:8738328	chr8:8167819~8226614:-
LGG	cis	rs1153858	1	rs1346266	ENSG00000259433.2	CTD-2651B20.4	-9.6	4.7e-20	3.04e-17	-0.47	-0.4	Homoarginine levels;	chr15:45402318	chr15:45330209~45332634:-
LGG	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-9.6	4.7e-20	3.04e-17	-0.55	-0.4	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
LGG	cis	rs12935418	0.672	rs7197370	ENSG00000260213.4	RP11-303E16.3	-9.6	4.7e-20	3.04e-17	-0.51	-0.4	Mean corpuscular volume;	chr16:81017520	chr16:81016792~81035759:-
LGG	cis	rs9810089	0.934	rs684195	ENSG00000261758.1	RP11-102M11.2	9.6	4.71e-20	3.05e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136274757	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.814	rs1279424	ENSG00000261758.1	RP11-102M11.2	9.6	4.71e-20	3.05e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136288491	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.843	rs556788	ENSG00000261758.1	RP11-102M11.2	9.6	4.71e-20	3.05e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136308707	chr3:136752630~136755780:+
LGG	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	9.6	4.72e-20	3.05e-17	0.36	0.4	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
LGG	cis	rs7085104	0.632	rs6162	ENSG00000272912.1	RP11-724N1.1	-9.6	4.73e-20	3.06e-17	-0.44	-0.4	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102914585~102915404:+
LGG	cis	rs9876781	1	rs7653691	ENSG00000244380.1	RP11-24C3.2	-9.6	4.74e-20	3.07e-17	-0.5	-0.4	Longevity;	chr3:48378199	chr3:48440352~48446656:-
LGG	cis	rs9322193	0.847	rs4870054	ENSG00000216621.7	RP11-244K5.6	9.6	4.77e-20	3.09e-17	0.51	0.4	Lung cancer;	chr6:149848402	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.847	rs868375	ENSG00000216621.7	RP11-244K5.6	9.6	4.77e-20	3.09e-17	0.48	0.4	Lung cancer;	chr6:149844905	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs10782314	ENSG00000216621.7	RP11-244K5.6	9.6	4.77e-20	3.09e-17	0.48	0.4	Lung cancer;	chr6:149735527	chr6:149934527~149936782:+
LGG	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-9.6	4.78e-20	3.09e-17	-0.46	-0.4	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-9.6	4.78e-20	3.09e-17	-0.46	-0.4	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
LGG	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	9.6	4.79e-20	3.1e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	9.6	4.79e-20	3.1e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	9.6	4.79e-20	3.1e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
LGG	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-9.6	4.79e-20	3.1e-17	-0.36	-0.4	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
LGG	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	9.59	4.84e-20	3.13e-17	0.52	0.4	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	9.59	4.84e-20	3.13e-17	0.52	0.4	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	9.59	4.84e-20	3.13e-17	0.52	0.4	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
LGG	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	9.59	4.85e-20	3.13e-17	0.52	0.4	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
LGG	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	9.59	4.85e-20	3.14e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
LGG	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	9.59	4.85e-20	3.14e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
LGG	cis	rs1560104	0.709	rs8063664	ENSG00000274834.1	CTD-3037G24.5	-9.59	4.87e-20	3.15e-17	-0.51	-0.4	Obesity-related traits;	chr16:12603354	chr16:12614451~12614852:+
LGG	cis	rs7267979	0.932	rs2260997	ENSG00000276952.1	RP5-965G21.6	-9.59	4.89e-20	3.16e-17	-0.4	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25284915~25285588:-
LGG	cis	rs1153858	0.725	rs74572151	ENSG00000259433.2	CTD-2651B20.4	-9.59	4.94e-20	3.19e-17	-0.47	-0.4	Homoarginine levels;	chr15:45355328	chr15:45330209~45332634:-
LGG	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-9.59	4.95e-20	3.2e-17	-0.41	-0.4	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
LGG	cis	rs7267979	1	rs1077889	ENSG00000276952.1	RP5-965G21.6	9.59	4.99e-20	3.23e-17	0.4	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25284915~25285588:-
LGG	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-9.59	5.01e-20	3.23e-17	-0.49	-0.4	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
LGG	cis	rs9527	0.64	rs35195396	ENSG00000272912.1	RP11-724N1.1	-9.59	5.01e-20	3.24e-17	-0.46	-0.4	Arsenic metabolism;	chr10:103169013	chr10:102914585~102915404:+
LGG	cis	rs9527	0.614	rs11191589	ENSG00000272912.1	RP11-724N1.1	-9.59	5.01e-20	3.24e-17	-0.46	-0.4	Arsenic metabolism;	chr10:103170625	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs3740386	ENSG00000272912.1	RP11-724N1.1	-9.59	5.01e-20	3.24e-17	-0.46	-0.4	Arsenic metabolism;	chr10:103171294	chr10:102914585~102915404:+
LGG	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-9.59	5.03e-20	3.25e-17	-0.49	-0.4	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
LGG	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-9.59	5.03e-20	3.25e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-9.59	5.03e-20	3.25e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
LGG	cis	rs12935418	0.673	rs2602426	ENSG00000260213.4	RP11-303E16.3	9.59	5.05e-20	3.26e-17	0.51	0.4	Mean corpuscular volume;	chr16:81027632	chr16:81016792~81035759:-
LGG	cis	rs9527	0.59	rs10509766	ENSG00000272912.1	RP11-724N1.1	-9.59	5.06e-20	3.27e-17	-0.46	-0.4	Arsenic metabolism;	chr10:103166577	chr10:102914585~102915404:+
LGG	cis	rs9532669	0.926	rs2039119	ENSG00000168852.11	TPTE2P5	-9.59	5.08e-20	3.28e-17	-0.4	-0.4	Cervical cancer;	chr13:40872432	chr13:40822296~40921749:-
LGG	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-9.59	5.09e-20	3.29e-17	-0.48	-0.4	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-9.59	5.09e-20	3.29e-17	-0.48	-0.4	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-9.59	5.09e-20	3.29e-17	-0.48	-0.4	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-9.59	5.09e-20	3.29e-17	-0.48	-0.4	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-9.59	5.09e-20	3.29e-17	-0.48	-0.4	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
LGG	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-9.59	5.09e-20	3.29e-17	-0.45	-0.4	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
LGG	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-9.59	5.1e-20	3.29e-17	-0.54	-0.4	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-9.59	5.1e-20	3.29e-17	-0.54	-0.4	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
LGG	cis	rs9322193	0.923	rs12526675	ENSG00000216621.7	RP11-244K5.6	-9.59	5.13e-20	3.31e-17	-0.49	-0.4	Lung cancer;	chr6:149729540	chr6:149934527~149936782:+
LGG	cis	rs2325036	0.783	rs11914525	ENSG00000239519.1	CADM2-AS1	9.59	5.16e-20	3.33e-17	0.46	0.4	Waist circumference;	chr3:85831618	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs11926422	ENSG00000239519.1	CADM2-AS1	9.59	5.16e-20	3.33e-17	0.46	0.4	Waist circumference;	chr3:85831676	chr3:85992183~86028007:-
LGG	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	9.59	5.18e-20	3.34e-17	0.52	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
LGG	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-9.59	5.19e-20	3.35e-17	-0.44	-0.4	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
LGG	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-9.58	5.24e-20	3.38e-17	-0.48	-0.4	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-9.58	5.24e-20	3.38e-17	-0.48	-0.4	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
LGG	cis	rs7267979	1	rs2297497	ENSG00000276952.1	RP5-965G21.6	-9.58	5.26e-20	3.39e-17	-0.4	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25284915~25285588:-
LGG	cis	rs4683346	0.712	rs1582882	ENSG00000273328.4	RP11-141M3.6	-9.58	5.27e-20	3.4e-17	-0.46	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42833442	chr3:42809414~42908105:+
LGG	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	9.58	5.28e-20	3.4e-17	0.61	0.4	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
LGG	cis	rs9810089	0.814	rs864437	ENSG00000261758.1	RP11-102M11.2	9.58	5.28e-20	3.4e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136401067	chr3:136752630~136755780:+
LGG	cis	rs9532669	0.963	rs2324739	ENSG00000168852.11	TPTE2P5	9.58	5.28e-20	3.4e-17	0.41	0.4	Cervical cancer;	chr13:40925479	chr13:40822296~40921749:-
LGG	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	9.58	5.28e-20	3.41e-17	0.31	0.4	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
LGG	cis	rs4713118	0.539	rs200951	ENSG00000226314.6	ZNF192P1	9.58	5.29e-20	3.41e-17	0.43	0.4	Parkinson's disease;	chr6:27868152	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.691	rs28396837	ENSG00000249244.1	RP11-548H18.2	9.58	5.31e-20	3.42e-17	0.42	0.4	Corneal astigmatism;	chr4:119350386	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.884	rs62439837	ENSG00000216621.7	RP11-244K5.6	9.58	5.31e-20	3.42e-17	0.49	0.4	Lung cancer;	chr6:149670380	chr6:149934527~149936782:+
LGG	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-9.58	5.34e-20	3.44e-17	-0.46	-0.4	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
LGG	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-9.58	5.34e-20	3.44e-17	-0.56	-0.4	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-9.58	5.34e-20	3.44e-17	-0.56	-0.4	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-9.58	5.34e-20	3.44e-17	-0.56	-0.4	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-9.58	5.34e-20	3.44e-17	-0.56	-0.4	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-9.58	5.34e-20	3.44e-17	-0.56	-0.4	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
LGG	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-9.58	5.36e-20	3.45e-17	-0.48	-0.4	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
LGG	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-9.58	5.39e-20	3.47e-17	-0.51	-0.4	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
LGG	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-9.58	5.39e-20	3.48e-17	-0.45	-0.4	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
LGG	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	9.58	5.41e-20	3.48e-17	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
LGG	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-9.58	5.41e-20	3.49e-17	-0.46	-0.4	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
LGG	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-9.58	5.41e-20	3.49e-17	-0.46	-0.4	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
LGG	cis	rs5758511	0.508	rs2854827	ENSG00000227370.1	RP4-669P10.19	9.58	5.42e-20	3.49e-17	0.46	0.4	Birth weight;	chr22:42065914	chr22:42132543~42132998:+
LGG	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	9.58	5.46e-20	3.51e-17	0.47	0.4	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
LGG	cis	rs7085104	0.632	rs3781287	ENSG00000272912.1	RP11-724N1.1	-9.58	5.46e-20	3.52e-17	-0.45	-0.4	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102914585~102915404:+
LGG	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	9.58	5.47e-20	3.52e-17	0.43	0.4	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
LGG	cis	rs6558530	0.965	rs7460287	ENSG00000253982.1	CTD-2336O2.1	9.58	5.48e-20	3.53e-17	0.4	0.4	Systolic blood pressure;	chr8:1760108	chr8:1761990~1764502:-
LGG	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	9.58	5.51e-20	3.55e-17	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
LGG	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	9.58	5.51e-20	3.55e-17	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
LGG	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	9.58	5.52e-20	3.55e-17	0.53	0.4	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
LGG	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-9.58	5.54e-20	3.57e-17	-0.48	-0.4	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
LGG	cis	rs657075	0.64	rs13167994	ENSG00000263597.1	MIR3936	-9.58	5.57e-20	3.58e-17	-0.69	-0.4	Rheumatoid arthritis;	chr5:132371131	chr5:132365490~132365599:-
LGG	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	9.58	5.58e-20	3.59e-17	0.36	0.4	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
LGG	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	9.58	5.59e-20	3.6e-17	0.53	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
LGG	cis	rs5758511	0.689	rs17002947	ENSG00000227370.1	RP4-669P10.19	-9.58	5.59e-20	3.6e-17	-0.46	-0.4	Birth weight;	chr22:42292526	chr22:42132543~42132998:+
LGG	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	9.58	5.61e-20	3.61e-17	0.52	0.4	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
LGG	cis	rs17772222	1	rs7145588	ENSG00000222990.1	RNU4-22P	9.58	5.66e-20	3.64e-17	0.51	0.4	Coronary artery calcification;	chr14:88360452	chr14:88513498~88513663:+
LGG	cis	rs17772222	1	rs61977049	ENSG00000222990.1	RNU4-22P	9.58	5.66e-20	3.64e-17	0.51	0.4	Coronary artery calcification;	chr14:88360656	chr14:88513498~88513663:+
LGG	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	9.58	5.67e-20	3.65e-17	0.36	0.4	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
LGG	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-9.58	5.67e-20	3.65e-17	-0.46	-0.4	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
LGG	cis	rs1153858	1	rs1145081	ENSG00000259433.2	CTD-2651B20.4	-9.58	5.68e-20	3.65e-17	-0.47	-0.4	Homoarginine levels;	chr15:45387469	chr15:45330209~45332634:-
LGG	cis	rs1153858	0.943	rs1145079	ENSG00000259433.2	CTD-2651B20.4	-9.58	5.68e-20	3.65e-17	-0.47	-0.4	Homoarginine levels;	chr15:45389563	chr15:45330209~45332634:-
LGG	cis	rs9527	0.545	rs7894588	ENSG00000272912.1	RP11-724N1.1	-9.57	5.69e-20	3.66e-17	-0.46	-0.4	Arsenic metabolism;	chr10:102996273	chr10:102914585~102915404:+
LGG	cis	rs1061377	0.608	rs35168672	ENSG00000249685.1	RP11-360F5.3	9.57	5.71e-20	3.67e-17	0.48	0.4	Uric acid levels;	chr4:39078902	chr4:39133913~39135608:+
LGG	cis	rs3742264	1	rs9534312	ENSG00000235903.6	CPB2-AS1	-9.57	5.72e-20	3.68e-17	-0.44	-0.4	Blood protein levels;	chr13:46076084	chr13:46052806~46113332:+
LGG	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-9.57	5.72e-20	3.68e-17	-0.43	-0.4	Height;	chr2:231516587	chr2:231508426~231514339:-
LGG	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-9.57	5.72e-20	3.68e-17	-0.47	-0.4	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
LGG	cis	rs7267979	1	rs2257991	ENSG00000276952.1	RP5-965G21.6	-9.57	5.73e-20	3.68e-17	-0.4	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25284915~25285588:-
LGG	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-9.57	5.75e-20	3.69e-17	-0.4	-0.4	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
LGG	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	9.57	5.76e-20	3.7e-17	0.92	0.4	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
LGG	cis	rs7085104	0.7	rs3740397	ENSG00000272912.1	RP11-724N1.1	-9.57	5.8e-20	3.73e-17	-0.45	-0.4	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102914585~102915404:+
LGG	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	9.57	5.81e-20	3.73e-17	0.74	0.4	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
LGG	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	9.57	5.82e-20	3.74e-17	0.48	0.4	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-9.57	5.82e-20	3.74e-17	-0.48	-0.4	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
LGG	cis	rs9876781	1	rs9311423	ENSG00000244380.1	RP11-24C3.2	9.57	5.86e-20	3.77e-17	0.49	0.4	Longevity;	chr3:48378818	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs7634377	ENSG00000244380.1	RP11-24C3.2	9.57	5.86e-20	3.77e-17	0.49	0.4	Longevity;	chr3:48379768	chr3:48440352~48446656:-
LGG	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	9.57	5.89e-20	3.78e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
LGG	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-9.57	5.9e-20	3.79e-17	-0.44	-0.4	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
LGG	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-9.57	5.91e-20	3.8e-17	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
LGG	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-9.57	5.91e-20	3.8e-17	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
LGG	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-9.57	5.91e-20	3.8e-17	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
LGG	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	9.57	5.95e-20	3.82e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
LGG	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	9.57	5.96e-20	3.82e-17	0.43	0.4	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
LGG	cis	rs1153858	1	rs59889118	ENSG00000259433.2	CTD-2651B20.4	-9.57	5.96e-20	3.83e-17	-0.47	-0.4	Homoarginine levels;	chr15:45326532	chr15:45330209~45332634:-
LGG	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	9.57	5.97e-20	3.83e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	9.57	5.97e-20	3.83e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	9.57	5.97e-20	3.83e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
LGG	cis	rs7216064	0.734	rs11653507	ENSG00000278219.1	AC145343.1	-9.57	5.97e-20	3.83e-17	-0.44	-0.4	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67895948	chr17:68101538~68101639:+
LGG	cis	rs1707322	0.627	rs3014213	ENSG00000281133.1	AL355480.3	9.57	5.97e-20	3.83e-17	0.49	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.686	rs2152078	ENSG00000281133.1	AL355480.3	9.57	5.97e-20	3.83e-17	0.49	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.686	rs2991979	ENSG00000281133.1	AL355480.3	9.57	5.97e-20	3.83e-17	0.49	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45580892~45580996:-
LGG	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	9.57	6.01e-20	3.86e-17	0.49	0.4	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
LGG	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	9.57	6.02e-20	3.86e-17	0.75	0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
LGG	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-9.57	6.04e-20	3.87e-17	-0.54	-0.4	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
LGG	cis	rs2325036	0.783	rs7431895	ENSG00000239519.1	CADM2-AS1	9.57	6.07e-20	3.9e-17	0.46	0.4	Waist circumference;	chr3:85821351	chr3:85992183~86028007:-
LGG	cis	rs9876781	1	rs7630741	ENSG00000244380.1	RP11-24C3.2	9.57	6.08e-20	3.9e-17	0.49	0.4	Longevity;	chr3:48378233	chr3:48440352~48446656:-
LGG	cis	rs200986	1	rs200986	ENSG00000226314.6	ZNF192P1	9.57	6.09e-20	3.91e-17	0.43	0.4	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28161781~28169594:+
LGG	cis	rs12168402	0.524	rs6001251	ENSG00000235209.1	CTA-150C2.13	9.57	6.1e-20	3.91e-17	0.52	0.4	Subjective well-being;	chr22:38836758	chr22:38921227~38924708:+
LGG	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	9.57	6.14e-20	3.94e-17	0.36	0.4	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	9.57	6.14e-20	3.94e-17	0.36	0.4	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.923	rs10872644	ENSG00000216621.7	RP11-244K5.6	9.57	6.15e-20	3.95e-17	0.48	0.4	Lung cancer;	chr6:149741819	chr6:149934527~149936782:+
LGG	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-9.56	6.17e-20	3.96e-17	-0.45	-0.4	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
LGG	cis	rs1560104	0.709	rs2217272	ENSG00000274834.1	CTD-3037G24.5	-9.56	6.17e-20	3.96e-17	-0.52	-0.4	Obesity-related traits;	chr16:12610654	chr16:12614451~12614852:+
LGG	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	9.56	6.2e-20	3.97e-17	0.5	0.4	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
LGG	cis	rs9532669	0.926	rs11147823	ENSG00000168852.11	TPTE2P5	-9.56	6.2e-20	3.98e-17	-0.4	-0.4	Cervical cancer;	chr13:40878138	chr13:40822296~40921749:-
LGG	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-9.56	6.21e-20	3.98e-17	-0.51	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
LGG	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-9.56	6.22e-20	3.99e-17	-0.55	-0.4	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
LGG	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	9.56	6.28e-20	4.03e-17	0.36	0.4	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
LGG	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-9.56	6.29e-20	4.03e-17	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
LGG	cis	rs7267979	1	rs6050573	ENSG00000276952.1	RP5-965G21.6	9.56	6.3e-20	4.04e-17	0.4	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25284915~25285588:-
LGG	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	9.56	6.32e-20	4.05e-17	0.43	0.4	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	9.56	6.32e-20	4.05e-17	0.43	0.4	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	9.56	6.32e-20	4.05e-17	0.43	0.4	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	9.56	6.32e-20	4.05e-17	0.43	0.4	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
LGG	cis	rs10028773	0.515	rs9994488	ENSG00000249244.1	RP11-548H18.2	9.56	6.33e-20	4.05e-17	0.45	0.4	Educational attainment;	chr4:119666626	chr4:119391831~119395335:-
LGG	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-9.56	6.34e-20	4.06e-17	-0.77	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
LGG	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-9.56	6.41e-20	4.11e-17	-0.53	-0.4	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
LGG	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-9.56	6.42e-20	4.12e-17	-0.4	-0.4	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
LGG	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	9.56	6.43e-20	4.12e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
LGG	cis	rs3743772	0.5	rs11859135	ENSG00000279722.1	RP11-44F14.6	9.56	6.43e-20	4.12e-17	0.52	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53487607~53489943:-
LGG	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	9.56	6.47e-20	4.15e-17	0.49	0.4	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
LGG	cis	rs853679	0.506	rs1150711	ENSG00000218016.2	ZNF192P2	-9.56	6.48e-20	4.15e-17	-0.49	-0.4	Depression;	chr6:28240757	chr6:28188050~28189432:+
LGG	cis	rs1707322	0.721	rs10890336	ENSG00000281133.1	AL355480.3	-9.56	6.51e-20	4.17e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs11211151	ENSG00000281133.1	AL355480.3	-9.56	6.51e-20	4.17e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs12045096	ENSG00000281133.1	AL355480.3	-9.56	6.51e-20	4.17e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45580892~45580996:-
LGG	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-9.56	6.51e-20	4.17e-17	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
LGG	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	9.56	6.51e-20	4.17e-17	0.44	0.4	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
LGG	cis	rs12935418	0.673	rs2549888	ENSG00000260213.4	RP11-303E16.3	9.56	6.51e-20	4.17e-17	0.51	0.4	Mean corpuscular volume;	chr16:81028425	chr16:81016792~81035759:-
LGG	cis	rs7811142	0.945	rs34989573	ENSG00000242294.5	STAG3L5P	9.56	6.54e-20	4.19e-17	0.28	0.4	Platelet count;	chr7:100500272	chr7:100336079~100351900:+
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000235689.1	AP000351.13	9.56	6.54e-20	4.19e-17	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:24006305~24008258:-
LGG	cis	rs7267979	0.966	rs2261784	ENSG00000276952.1	RP5-965G21.6	9.56	6.56e-20	4.2e-17	0.4	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.966	rs2261785	ENSG00000276952.1	RP5-965G21.6	9.56	6.56e-20	4.2e-17	0.4	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25284915~25285588:-
LGG	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-9.56	6.59e-20	4.22e-17	-0.48	-0.4	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
LGG	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	9.56	6.59e-20	4.22e-17	0.48	0.4	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
LGG	cis	rs1185460	0.508	rs7942757	ENSG00000271751.1	RP11-110I1.14	9.56	6.64e-20	4.25e-17	0.48	0.4	Coronary artery disease;	chr11:119032941	chr11:119065263~119065677:-
LGG	cis	rs10411262	0.935	rs314661	ENSG00000245598.5	DACT3-AS1	-9.56	6.64e-20	4.25e-17	-0.39	-0.4	Tonsillectomy;	chr19:46669216	chr19:46660364~46677447:+
LGG	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	9.56	6.66e-20	4.27e-17	0.36	0.4	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
LGG	cis	rs2325036	0.783	rs11714569	ENSG00000239519.1	CADM2-AS1	9.56	6.68e-20	4.27e-17	0.46	0.4	Waist circumference;	chr3:85828591	chr3:85992183~86028007:-
LGG	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-9.55	6.69e-20	4.28e-17	-0.46	-0.4	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-9.55	6.69e-20	4.28e-17	-0.46	-0.4	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
LGG	cis	rs9876781	1	rs13069724	ENSG00000244380.1	RP11-24C3.2	9.55	6.7e-20	4.29e-17	0.49	0.4	Longevity;	chr3:48436629	chr3:48440352~48446656:-
LGG	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-9.55	6.73e-20	4.31e-17	-0.48	-0.4	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
LGG	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	9.55	6.75e-20	4.32e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
LGG	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-9.55	6.79e-20	4.34e-17	-0.46	-0.4	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-9.55	6.81e-20	4.35e-17	-0.52	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
LGG	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	9.55	6.81e-20	4.36e-17	0.36	0.4	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
LGG	cis	rs11148252	0.716	rs3803262	ENSG00000278238.1	RP11-245D16.4	-9.55	6.81e-20	4.36e-17	-0.39	-0.4	Lewy body disease;	chr13:52462263	chr13:52454775~52455331:-
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000272787.1	KB-226F1.2	9.55	6.83e-20	4.37e-17	0.42	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23969211~23969873:+
LGG	cis	rs2325036	0.783	rs12495178	ENSG00000239519.1	CADM2-AS1	9.55	6.84e-20	4.37e-17	0.46	0.4	Waist circumference;	chr3:85836927	chr3:85992183~86028007:-
LGG	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	9.55	6.85e-20	4.38e-17	0.4	0.4	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
LGG	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	9.55	6.86e-20	4.39e-17	0.61	0.4	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
LGG	cis	rs17772222	0.958	rs76559451	ENSG00000222990.1	RNU4-22P	9.55	6.9e-20	4.41e-17	0.53	0.4	Coronary artery calcification;	chr14:88523193	chr14:88513498~88513663:+
LGG	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-9.55	6.91e-20	4.42e-17	-0.43	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-9.55	6.91e-20	4.42e-17	-0.43	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-9.55	6.91e-20	4.42e-17	-0.43	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-9.55	6.92e-20	4.42e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-9.55	6.92e-20	4.42e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
LGG	cis	rs657075	0.697	rs34689843	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132349563	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583477	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132350347	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs35948329	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132350759	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs36108085	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132350786	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs34754328	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132352381	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs56996855	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132353945	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs34034297	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132355483	chr5:132365490~132365599:-
LGG	cis	rs657075	0.584	rs71583479	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132356459	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs35834048	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132359643	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs35809179	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132359713	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583480	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132360559	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583481	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132360859	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583482	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132362249	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583483	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132362327	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs34786243	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132369028	chr5:132365490~132365599:-
LGG	cis	rs657075	0.643	rs4646298	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132369527	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3788988	ENSG00000263597.1	MIR3936	-9.55	6.92e-20	4.42e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132370679	chr5:132365490~132365599:-
LGG	cis	rs17345786	0.861	rs74768235	ENSG00000244119.1	PDCL3P4	9.55	6.92e-20	4.42e-17	0.35	0.4	Colonoscopy-negative controls vs population controls;	chr3:101423977	chr3:101712472~101713191:+
LGG	cis	rs2282300	0.637	rs1765131	ENSG00000254532.1	RP11-624D11.2	9.55	6.92e-20	4.42e-17	0.51	0.4	Morning vs. evening chronotype;	chr11:30382991	chr11:30044058~30084343:-
LGG	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-9.55	6.93e-20	4.43e-17	-0.56	-0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
LGG	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-9.55	6.93e-20	4.43e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
LGG	cis	rs9322193	0.809	rs9479808	ENSG00000216621.7	RP11-244K5.6	9.55	6.98e-20	4.46e-17	0.48	0.4	Lung cancer;	chr6:149751328	chr6:149934527~149936782:+
LGG	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-9.55	6.99e-20	4.47e-17	-0.53	-0.4	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
LGG	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-9.55	6.99e-20	4.47e-17	-0.53	-0.4	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
LGG	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-9.55	7e-20	4.47e-17	-0.48	-0.4	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-9.55	7e-20	4.47e-17	-0.48	-0.4	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
LGG	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-9.55	7.02e-20	4.49e-17	-0.54	-0.4	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
LGG	cis	rs1707322	0.752	rs4607935	ENSG00000281133.1	AL355480.3	-9.55	7.04e-20	4.49e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs3811436	ENSG00000281133.1	AL355480.3	-9.55	7.04e-20	4.49e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs4415615	ENSG00000281133.1	AL355480.3	-9.55	7.04e-20	4.49e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs7529699	ENSG00000281133.1	AL355480.3	-9.55	7.04e-20	4.49e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs10430105	ENSG00000281133.1	AL355480.3	-9.55	7.04e-20	4.49e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45580892~45580996:-
LGG	cis	rs9876781	1	rs2885510	ENSG00000244380.1	RP11-24C3.2	-9.55	7.05e-20	4.5e-17	-0.49	-0.4	Longevity;	chr3:48376736	chr3:48440352~48446656:-
LGG	cis	rs1707322	0.721	rs61784800	ENSG00000281133.1	AL355480.3	9.55	7.07e-20	4.51e-17	0.47	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.682	rs28508523	ENSG00000281133.1	AL355480.3	-9.55	7.07e-20	4.51e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45580892~45580996:-
LGG	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
LGG	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-9.55	7.08e-20	4.52e-17	-0.48	-0.4	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
LGG	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-9.55	7.14e-20	4.55e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-9.55	7.14e-20	4.55e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
LGG	cis	rs7432375	0.901	rs1729951	ENSG00000261758.1	RP11-102M11.2	-9.55	7.16e-20	4.57e-17	-0.43	-0.4	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136781891	chr3:136752630~136755780:+
LGG	cis	rs853679	0.527	rs707907	ENSG00000218016.2	ZNF192P2	-9.55	7.22e-20	4.61e-17	-0.49	-0.4	Depression;	chr6:28323463	chr6:28188050~28189432:+
LGG	cis	rs657075	0.697	rs3761659	ENSG00000263597.1	MIR3936	-9.55	7.23e-20	4.62e-17	-0.67	-0.4	Rheumatoid arthritis;	chr5:132322091	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3805672	ENSG00000263597.1	MIR3936	-9.55	7.23e-20	4.62e-17	-0.67	-0.4	Rheumatoid arthritis;	chr5:132323281	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3805673	ENSG00000263597.1	MIR3936	-9.55	7.23e-20	4.62e-17	-0.67	-0.4	Rheumatoid arthritis;	chr5:132323410	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583474	ENSG00000263597.1	MIR3936	-9.55	7.23e-20	4.62e-17	-0.67	-0.4	Rheumatoid arthritis;	chr5:132326117	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs77975982	ENSG00000263597.1	MIR3936	-9.55	7.23e-20	4.62e-17	-0.67	-0.4	Rheumatoid arthritis;	chr5:132326300	chr5:132365490~132365599:-
LGG	cis	rs657075	0.64	rs71583475	ENSG00000263597.1	MIR3936	-9.55	7.23e-20	4.62e-17	-0.67	-0.4	Rheumatoid arthritis;	chr5:132326814	chr5:132365490~132365599:-
LGG	cis	rs9876781	0.967	rs2885509	ENSG00000244380.1	RP11-24C3.2	-9.54	7.3e-20	4.66e-17	-0.49	-0.4	Longevity;	chr3:48376729	chr3:48440352~48446656:-
LGG	cis	rs4950322	0.57	rs72691032	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147261120	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691033	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147261267	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs111370771	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147261420	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4301678	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147261907	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs17356184	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147262943	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs80270233	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147263320	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950392	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147264889	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs17356219	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147265684	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691041	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147267084	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs17356233	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147268843	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs17356240	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147269877	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs1999820	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147270329	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs3737855	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147271257	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950316	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147273712	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs2354428	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147277512	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691054	ENSG00000278811.3	LINC00624	9.54	7.31e-20	4.66e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147277942	chr1:147258885~147517875:-
LGG	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-9.54	7.33e-20	4.67e-17	-0.38	-0.4	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
LGG	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-9.54	7.34e-20	4.68e-17	-0.44	-0.4	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
LGG	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	9.54	7.37e-20	4.7e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
LGG	cis	rs2325036	0.783	rs55782528	ENSG00000239519.1	CADM2-AS1	9.54	7.39e-20	4.71e-17	0.46	0.4	Waist circumference;	chr3:85844675	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs6787851	ENSG00000239519.1	CADM2-AS1	9.54	7.39e-20	4.71e-17	0.46	0.4	Waist circumference;	chr3:85847884	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs55776605	ENSG00000239519.1	CADM2-AS1	9.54	7.39e-20	4.71e-17	0.46	0.4	Waist circumference;	chr3:85848977	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs62261721	ENSG00000239519.1	CADM2-AS1	9.54	7.41e-20	4.72e-17	0.46	0.4	Waist circumference;	chr3:85833739	chr3:85992183~86028007:-
LGG	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-9.54	7.41e-20	4.72e-17	-0.47	-0.4	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
LGG	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	9.54	7.45e-20	4.75e-17	0.37	0.4	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
LGG	cis	rs7432375	0.901	rs7648531	ENSG00000261758.1	RP11-102M11.2	-9.54	7.49e-20	4.77e-17	-0.42	-0.4	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136743381	chr3:136752630~136755780:+
LGG	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	9.54	7.5e-20	4.78e-17	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
LGG	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	9.54	7.52e-20	4.79e-17	0.5	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
LGG	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-9.54	7.57e-20	4.82e-17	-0.47	-0.4	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
LGG	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-9.54	7.57e-20	4.82e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
LGG	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	9.54	7.62e-20	4.85e-17	0.36	0.4	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	9.54	7.62e-20	4.85e-17	0.36	0.4	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	9.54	7.62e-20	4.85e-17	0.36	0.4	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
LGG	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	9.54	7.62e-20	4.85e-17	0.36	0.4	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	9.54	7.62e-20	4.85e-17	0.36	0.4	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	9.54	7.62e-20	4.85e-17	0.36	0.4	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
LGG	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	9.54	7.65e-20	4.87e-17	0.48	0.4	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
LGG	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	9.54	7.66e-20	4.87e-17	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	9.54	7.66e-20	4.87e-17	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
LGG	cis	rs858239	0.601	rs11984129	ENSG00000230042.1	AK3P3	-9.54	7.69e-20	4.9e-17	-0.41	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23129178~23129841:+
LGG	cis	rs950776	0.714	rs17408276	ENSG00000261762.1	RP11-650L12.2	9.54	7.75e-20	4.93e-17	0.51	0.4	Sudden cardiac arrest;	chr15:78589276	chr15:78589123~78591276:-
LGG	cis	rs7208859	0.623	rs8082537	ENSG00000266490.1	CTD-2349P21.9	9.54	7.76e-20	4.93e-17	0.49	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30792372~30792833:+
LGG	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	9.54	7.83e-20	4.98e-17	0.36	0.4	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
LGG	cis	rs5742933	0.597	rs6756913	ENSG00000273240.1	RP11-455J20.3	9.54	7.83e-20	4.98e-17	0.5	0.4	Ferritin levels;	chr2:189641040	chr2:189763859~189764456:-
LGG	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-9.54	7.83e-20	4.98e-17	-0.54	-0.4	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
LGG	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-9.53	7.88e-20	5.01e-17	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
LGG	cis	rs950027	0.967	rs2486280	ENSG00000259433.2	CTD-2651B20.4	-9.53	7.89e-20	5.02e-17	-0.43	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45459691	chr15:45330209~45332634:-
LGG	cis	rs17772222	1	rs17772288	ENSG00000222990.1	RNU4-22P	9.53	7.89e-20	5.02e-17	0.5	0.4	Coronary artery calcification;	chr14:88361022	chr14:88513498~88513663:+
LGG	cis	rs4713118	0.868	rs35069907	ENSG00000216901.1	AL022393.7	9.53	7.92e-20	5.04e-17	0.55	0.4	Parkinson's disease;	chr6:27778913	chr6:28176188~28176674:+
LGG	cis	rs9876781	1	rs11130170	ENSG00000244380.1	RP11-24C3.2	9.53	7.93e-20	5.04e-17	0.49	0.4	Longevity;	chr3:48408490	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs10470686	ENSG00000244380.1	RP11-24C3.2	9.53	7.93e-20	5.04e-17	0.49	0.4	Longevity;	chr3:48408549	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs3214041	ENSG00000244380.1	RP11-24C3.2	9.53	7.93e-20	5.04e-17	0.49	0.4	Longevity;	chr3:48413059	chr3:48440352~48446656:-
LGG	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-9.53	7.95e-20	5.05e-17	-0.42	-0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
LGG	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-9.53	7.97e-20	5.06e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
LGG	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-9.53	7.97e-20	5.06e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-9.53	7.97e-20	5.06e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-9.53	7.97e-20	5.06e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
LGG	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	9.53	7.98e-20	5.07e-17	0.52	0.4	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
LGG	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-9.53	8.02e-20	5.09e-17	-0.52	-0.4	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
LGG	cis	rs4683346	0.653	rs704891	ENSG00000273328.4	RP11-141M3.6	-9.53	8.03e-20	5.1e-17	-0.51	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42945522	chr3:42809414~42908105:+
LGG	cis	rs4683346	0.653	rs704893	ENSG00000273328.4	RP11-141M3.6	-9.53	8.03e-20	5.1e-17	-0.51	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42950021	chr3:42809414~42908105:+
LGG	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-9.53	8.03e-20	5.1e-17	-0.38	-0.4	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
LGG	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-9.53	8.04e-20	5.11e-17	-0.42	-0.4	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-9.53	8.04e-20	5.11e-17	-0.42	-0.4	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
LGG	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	9.53	8.06e-20	5.12e-17	0.54	0.4	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
LGG	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-9.53	8.06e-20	5.12e-17	-0.46	-0.4	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
LGG	cis	rs9876781	1	rs898225	ENSG00000244380.1	RP11-24C3.2	-9.53	8.07e-20	5.13e-17	-0.5	-0.4	Longevity;	chr3:48371689	chr3:48440352~48446656:-
LGG	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-9.53	8.08e-20	5.13e-17	-0.77	-0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
LGG	cis	rs4713118	0.539	rs200967	ENSG00000226314.6	ZNF192P1	9.53	8.12e-20	5.16e-17	0.43	0.4	Parkinson's disease;	chr6:27894349	chr6:28161781~28169594:+
LGG	cis	rs17772222	0.958	rs60878614	ENSG00000222990.1	RNU4-22P	9.53	8.12e-20	5.16e-17	0.52	0.4	Coronary artery calcification;	chr14:88513871	chr14:88513498~88513663:+
LGG	cis	rs9876781	1	rs6442123	ENSG00000244380.1	RP11-24C3.2	9.53	8.14e-20	5.17e-17	0.5	0.4	Longevity;	chr3:48458887	chr3:48440352~48446656:-
LGG	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	9.53	8.14e-20	5.17e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
LGG	cis	rs9876781	1	rs7651407	ENSG00000244380.1	RP11-24C3.2	9.53	8.2e-20	5.21e-17	0.49	0.4	Longevity;	chr3:48402409	chr3:48440352~48446656:-
LGG	cis	rs9388451	0.839	rs4897157	ENSG00000237742.5	RP11-624M8.1	-9.53	8.21e-20	5.22e-17	-0.35	-0.4	Brugada syndrome;	chr6:125781835	chr6:125578558~125749190:-
LGG	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-9.53	8.23e-20	5.22e-17	-0.48	-0.4	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
LGG	cis	rs3096299	0.583	rs889574	ENSG00000274627.1	RP11-104N10.2	9.53	8.23e-20	5.23e-17	0.37	0.4	Multiple myeloma (IgH translocation);	chr16:89320400	chr16:89516797~89522217:+
LGG	cis	rs950027	1	rs950027	ENSG00000259433.2	CTD-2651B20.4	9.53	8.24e-20	5.23e-17	0.42	0.4	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45330209~45332634:-
LGG	cis	rs657075	0.697	rs4646301	ENSG00000263597.1	MIR3936	-9.53	8.24e-20	5.23e-17	-0.67	-0.4	Rheumatoid arthritis;	chr5:132375408	chr5:132365490~132365599:-
LGG	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	9.53	8.25e-20	5.24e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	9.53	8.25e-20	5.24e-17	0.47	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
LGG	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-9.53	8.28e-20	5.26e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
LGG	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	9.53	8.33e-20	5.29e-17	0.44	0.4	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
LGG	cis	rs17345786	0.861	rs11711808	ENSG00000244119.1	PDCL3P4	9.53	8.35e-20	5.3e-17	0.35	0.4	Colonoscopy-negative controls vs population controls;	chr3:101516257	chr3:101712472~101713191:+
LGG	cis	rs1707322	0.721	rs10890341	ENSG00000281133.1	AL355480.3	-9.53	8.35e-20	5.3e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45580892~45580996:-
LGG	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	9.53	8.37e-20	5.31e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
LGG	cis	rs4683346	0.653	rs834580	ENSG00000273328.4	RP11-141M3.6	-9.53	8.39e-20	5.32e-17	-0.51	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42928100	chr3:42809414~42908105:+
LGG	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	9.53	8.41e-20	5.33e-17	0.46	0.4	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
LGG	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-9.53	8.46e-20	5.36e-17	-0.8	-0.4	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
LGG	cis	rs1153858	1	rs1613559	ENSG00000259433.2	CTD-2651B20.4	-9.53	8.5e-20	5.39e-17	-0.47	-0.4	Homoarginine levels;	chr15:45329918	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1618874	ENSG00000259433.2	CTD-2651B20.4	-9.53	8.5e-20	5.39e-17	-0.47	-0.4	Homoarginine levels;	chr15:45330588	chr15:45330209~45332634:-
LGG	cis	rs7829975	0.777	rs486781	ENSG00000253893.2	FAM85B	9.53	8.5e-20	5.39e-17	0.49	0.4	Mood instability;	chr8:8782230	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	9.53	8.5e-20	5.39e-17	0.48	0.4	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	9.53	8.51e-20	5.4e-17	0.53	0.4	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
LGG	cis	rs11051970	0.559	rs7963887	ENSG00000274964.1	RP11-817I4.1	-9.52	8.53e-20	5.41e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32323073	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs10844184	ENSG00000274964.1	RP11-817I4.1	-9.52	8.53e-20	5.41e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32323918	chr12:32339368~32340724:+
LGG	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-9.52	8.55e-20	5.42e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-9.52	8.55e-20	5.42e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-9.52	8.55e-20	5.42e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-9.52	8.55e-20	5.42e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
LGG	cis	rs657075	0.527	rs13180169	ENSG00000263597.1	MIR3936	-9.52	8.57e-20	5.43e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132369834	chr5:132365490~132365599:-
LGG	cis	rs1153858	1	rs2453541	ENSG00000259433.2	CTD-2651B20.4	-9.52	8.62e-20	5.46e-17	-0.46	-0.4	Homoarginine levels;	chr15:45353180	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs2461702	ENSG00000259433.2	CTD-2651B20.4	-9.52	8.62e-20	5.46e-17	-0.46	-0.4	Homoarginine levels;	chr15:45355229	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1145091	ENSG00000259433.2	CTD-2651B20.4	-9.52	8.62e-20	5.46e-17	-0.46	-0.4	Homoarginine levels;	chr15:45357798	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1049508	ENSG00000259433.2	CTD-2651B20.4	-9.52	8.62e-20	5.46e-17	-0.46	-0.4	Homoarginine levels;	chr15:45361394	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1145085	ENSG00000259433.2	CTD-2651B20.4	-9.52	8.62e-20	5.46e-17	-0.46	-0.4	Homoarginine levels;	chr15:45365606	chr15:45330209~45332634:-
LGG	cis	rs1153858	1	rs1288775	ENSG00000259433.2	CTD-2651B20.4	-9.52	8.62e-20	5.46e-17	-0.46	-0.4	Homoarginine levels;	chr15:45369480	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.923	rs62441284	ENSG00000216621.7	RP11-244K5.6	9.52	8.63e-20	5.47e-17	0.48	0.4	Lung cancer;	chr6:149751542	chr6:149934527~149936782:+
LGG	cis	rs7119038	0.818	rs2077579	ENSG00000255239.1	AP002954.6	-9.52	8.68e-20	5.5e-17	-0.56	-0.4	Sjögren's syndrome;	chr11:118748338	chr11:118688039~118690600:-
LGG	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	9.52	8.68e-20	5.5e-17	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
LGG	cis	rs7267979	0.714	rs1555329	ENSG00000125804.12	FAM182A	-9.52	8.7e-20	5.51e-17	-0.48	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:26054655~26086917:+
LGG	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	9.52	8.75e-20	5.54e-17	0.53	0.4	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
LGG	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-9.52	8.76e-20	5.55e-17	-0.44	-0.4	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
LGG	cis	rs11098499	0.691	rs12510133	ENSG00000249244.1	RP11-548H18.2	9.52	8.76e-20	5.55e-17	0.42	0.4	Corneal astigmatism;	chr4:119350189	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.754	rs12506487	ENSG00000249244.1	RP11-548H18.2	9.52	8.76e-20	5.55e-17	0.42	0.4	Corneal astigmatism;	chr4:119350206	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.691	rs12502524	ENSG00000249244.1	RP11-548H18.2	9.52	8.76e-20	5.55e-17	0.42	0.4	Corneal astigmatism;	chr4:119350259	chr4:119391831~119395335:-
LGG	cis	rs11168351	0.926	rs10875719	ENSG00000258273.1	RP11-370I10.4	-9.52	8.76e-20	5.55e-17	-0.49	-0.4	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48333755~48333901:-
LGG	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	9.52	8.78e-20	5.56e-17	0.92	0.4	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
LGG	cis	rs9388451	0.874	rs3734634	ENSG00000237742.5	RP11-624M8.1	-9.52	8.85e-20	5.61e-17	-0.36	-0.4	Brugada syndrome;	chr6:125790654	chr6:125578558~125749190:-
LGG	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-9.52	8.86e-20	5.61e-17	-0.48	-0.4	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
LGG	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-9.52	8.86e-20	5.61e-17	-0.4	-0.4	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
LGG	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	9.52	8.88e-20	5.62e-17	0.89	0.4	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
LGG	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-9.52	8.89e-20	5.63e-17	-0.72	-0.4	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
LGG	cis	rs17772222	1	rs12587386	ENSG00000222990.1	RNU4-22P	9.52	8.94e-20	5.66e-17	0.5	0.4	Coronary artery calcification;	chr14:88361420	chr14:88513498~88513663:+
LGG	cis	rs9532669	0.926	rs6560963	ENSG00000168852.11	TPTE2P5	9.52	8.95e-20	5.67e-17	0.41	0.4	Cervical cancer;	chr13:40871126	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.963	rs9562238	ENSG00000168852.11	TPTE2P5	9.52	8.96e-20	5.68e-17	0.41	0.4	Cervical cancer;	chr13:40924785	chr13:40822296~40921749:-
LGG	cis	rs2325036	0.715	rs62261725	ENSG00000239519.1	CADM2-AS1	9.52	9.06e-20	5.73e-17	0.49	0.4	Waist circumference;	chr3:85849476	chr3:85992183~86028007:-
LGG	cis	rs9322193	0.923	rs2342765	ENSG00000216621.7	RP11-244K5.6	9.52	9.06e-20	5.73e-17	0.47	0.4	Lung cancer;	chr6:149858873	chr6:149934527~149936782:+
LGG	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	9.52	9.08e-20	5.75e-17	0.48	0.4	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	9.52	9.08e-20	5.75e-17	0.48	0.4	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	9.52	9.08e-20	5.75e-17	0.48	0.4	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
LGG	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	9.52	9.11e-20	5.76e-17	0.4	0.4	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
LGG	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	9.52	9.11e-20	5.76e-17	0.4	0.4	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
LGG	cis	rs9322193	0.923	rs55993747	ENSG00000216621.7	RP11-244K5.6	9.52	9.21e-20	5.82e-17	0.48	0.4	Lung cancer;	chr6:149622016	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs12660304	ENSG00000216621.7	RP11-244K5.6	9.52	9.22e-20	5.83e-17	0.49	0.4	Lung cancer;	chr6:149739647	chr6:149934527~149936782:+
LGG	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-9.51	9.25e-20	5.85e-17	-0.44	-0.4	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
LGG	cis	rs8064024	0.564	rs7214	ENSG00000267077.1	RP11-127I20.5	9.51	9.28e-20	5.87e-17	0.41	0.4	Cancer;	chr16:4882559	chr16:4795265~4796532:-
LGG	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
LGG	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-9.51	9.32e-20	5.89e-17	-0.48	-0.4	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
LGG	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	9.51	9.32e-20	5.89e-17	0.48	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
LGG	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	9.51	9.33e-20	5.9e-17	0.54	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
LGG	cis	rs4683346	0.653	rs704901	ENSG00000273328.4	RP11-141M3.6	-9.51	9.33e-20	5.9e-17	-0.51	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42926105	chr3:42809414~42908105:+
LGG	cis	rs9527	0.59	rs1926037	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103118253	chr10:102914585~102915404:+
LGG	cis	rs9527	0.567	rs6584539	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103119645	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs2148200	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103120090	chr10:102914585~102915404:+
LGG	cis	rs9527	0.614	rs2153774	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103121278	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs10883834	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103121645	chr10:102914585~102915404:+
LGG	cis	rs9527	0.545	rs7915816	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103121993	chr10:102914585~102915404:+
LGG	cis	rs9527	0.568	rs1926036	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103124055	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs1541213	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103125573	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs10883836	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103131441	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs11191572	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103133380	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs12415199	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103135779	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs34104646	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103136321	chr10:102914585~102915404:+
LGG	cis	rs9527	0.567	rs11191573	ENSG00000272912.1	RP11-724N1.1	-9.51	9.38e-20	5.93e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103137059	chr10:102914585~102915404:+
LGG	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	9.51	9.41e-20	5.94e-17	0.43	0.4	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
LGG	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	9.51	9.46e-20	5.97e-17	0.48	0.4	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
LGG	cis	rs7829975	0.774	rs11249893	ENSG00000253893.2	FAM85B	-9.51	9.55e-20	6.03e-17	-0.48	-0.4	Mood instability;	chr8:8843341	chr8:8167819~8226614:-
LGG	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	9.51	9.58e-20	6.05e-17	0.43	0.4	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
LGG	cis	rs853679	0.723	rs1736904	ENSG00000226314.6	ZNF192P1	9.51	9.63e-20	6.08e-17	0.48	0.4	Depression;	chr6:28251492	chr6:28161781~28169594:+
LGG	cis	rs17345786	0.861	rs17402964	ENSG00000244119.1	PDCL3P4	9.51	9.65e-20	6.09e-17	0.34	0.4	Colonoscopy-negative controls vs population controls;	chr3:101349101	chr3:101712472~101713191:+
LGG	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	9.51	9.65e-20	6.09e-17	0.31	0.4	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
LGG	cis	rs9527	0.59	rs3861984	ENSG00000272912.1	RP11-724N1.1	-9.51	9.66e-20	6.1e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103157223	chr10:102914585~102915404:+
LGG	cis	rs9322193	0.923	rs66516768	ENSG00000216621.7	RP11-244K5.6	9.51	9.67e-20	6.1e-17	0.48	0.4	Lung cancer;	chr6:149671999	chr6:149934527~149936782:+
LGG	cis	rs6452524	0.904	rs10473867	ENSG00000248112.1	RP11-78C3.1	9.51	9.67e-20	6.1e-17	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:82919376~82921119:-
LGG	cis	rs587080	0.624	rs674485	ENSG00000245532.5	NEAT1	-9.51	9.69e-20	6.11e-17	-0.29	-0.4	Plateletcrit;	chr11:65429922	chr11:65422774~65445540:+
LGG	cis	rs227275	0.525	rs4698874	ENSG00000230069.3	LRRC37A15P	-9.51	9.71e-20	6.13e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102727274~102730721:-
LGG	cis	rs2282300	0.589	rs1717776	ENSG00000254532.1	RP11-624D11.2	9.51	9.77e-20	6.16e-17	0.49	0.4	Morning vs. evening chronotype;	chr11:30394229	chr11:30044058~30084343:-
LGG	cis	rs9532669	1	rs9532669	ENSG00000168852.11	TPTE2P5	9.51	9.77e-20	6.16e-17	0.4	0.4	Cervical cancer;	chr13:40927414	chr13:40822296~40921749:-
LGG	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	9.51	9.79e-20	6.18e-17	0.44	0.4	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
LGG	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-9.51	9.82e-20	6.2e-17	-0.51	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
LGG	cis	rs4683346	0.691	rs66915117	ENSG00000273328.4	RP11-141M3.6	-9.51	9.86e-20	6.22e-17	-0.52	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42895374	chr3:42809414~42908105:+
LGG	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-9.51	9.87e-20	6.22e-17	-0.48	-0.4	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
LGG	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-9.51	9.87e-20	6.22e-17	-0.48	-0.4	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
LGG	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	9.51	9.88e-20	6.23e-17	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
LGG	cis	rs7119038	0.818	rs10892293	ENSG00000255239.1	AP002954.6	-9.51	9.91e-20	6.25e-17	-0.58	-0.4	Sjögren's syndrome;	chr11:118794866	chr11:118688039~118690600:-
LGG	cis	rs9527	0.59	rs11191578	ENSG00000272912.1	RP11-724N1.1	-9.51	9.94e-20	6.27e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103142580	chr10:102914585~102915404:+
LGG	cis	rs9527	0.641	rs34130454	ENSG00000272912.1	RP11-724N1.1	-9.51	9.94e-20	6.27e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103143881	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs7897663	ENSG00000272912.1	RP11-724N1.1	-9.51	9.94e-20	6.27e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103145847	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs12775302	ENSG00000272912.1	RP11-724N1.1	-9.51	9.94e-20	6.27e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103151599	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs12414232	ENSG00000272912.1	RP11-724N1.1	-9.51	9.94e-20	6.27e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103154734	chr10:102914585~102915404:+
LGG	cis	rs11051970	0.559	rs2291420	ENSG00000274964.1	RP11-817I4.1	-9.51	9.94e-20	6.27e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32334816	chr12:32339368~32340724:+
LGG	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-9.5	1e-19	6.33e-17	-0.54	-0.4	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
LGG	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	9.5	1.01e-19	6.34e-17	0.48	0.4	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	9.5	1.01e-19	6.34e-17	0.48	0.4	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
LGG	cis	rs1707322	0.721	rs6665808	ENSG00000281133.1	AL355480.3	-9.5	1.01e-19	6.35e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45580892~45580996:-
LGG	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	9.5	1.01e-19	6.36e-17	0.44	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
LGG	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	9.5	1.01e-19	6.36e-17	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
LGG	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	9.5	1.02e-19	6.4e-17	0.44	0.4	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
LGG	cis	rs1707322	0.717	rs3014249	ENSG00000281133.1	AL355480.3	9.5	1.03e-19	6.46e-17	0.48	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45580892~45580996:-
LGG	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-9.5	1.03e-19	6.47e-17	-0.36	-0.4	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
LGG	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	9.5	1.03e-19	6.48e-17	0.51	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
LGG	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	9.5	1.04e-19	6.54e-17	0.54	0.4	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
LGG	cis	rs1707322	0.721	rs4609469	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs12049027	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs10789467	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs10890337	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs3811435	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs9793568	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs11211157	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs11211158	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs6429575	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.685	rs6690926	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs8179402	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs8179296	ENSG00000281133.1	AL355480.3	-9.5	1.04e-19	6.54e-17	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45580892~45580996:-
LGG	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-9.5	1.04e-19	6.56e-17	-0.48	-0.4	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
LGG	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	9.5	1.04e-19	6.57e-17	0.61	0.4	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
LGG	cis	rs9322193	0.923	rs9688517	ENSG00000216621.7	RP11-244K5.6	9.5	1.04e-19	6.57e-17	0.47	0.4	Lung cancer;	chr6:149740655	chr6:149934527~149936782:+
LGG	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-9.5	1.05e-19	6.58e-17	-0.78	-0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
LGG	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	9.5	1.05e-19	6.59e-17	0.67	0.4	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
LGG	cis	rs17772222	0.63	rs61977024	ENSG00000258983.2	RP11-507K2.2	9.5	1.05e-19	6.6e-17	0.46	0.4	Coronary artery calcification;	chr14:88335961	chr14:88499334~88515502:+
LGG	cis	rs9876781	0.967	rs9876891	ENSG00000244380.1	RP11-24C3.2	9.5	1.05e-19	6.61e-17	0.49	0.4	Longevity;	chr3:48440024	chr3:48440352~48446656:-
LGG	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	9.5	1.06e-19	6.65e-17	0.43	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
LGG	cis	rs1707322	0.686	rs3014251	ENSG00000281133.1	AL355480.3	9.5	1.06e-19	6.66e-17	0.49	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45580892~45580996:-
LGG	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	9.5	1.07e-19	6.74e-17	0.48	0.4	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	9.5	1.07e-19	6.74e-17	0.48	0.4	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
LGG	cis	rs9875589	0.957	rs1579551	ENSG00000233121.1	VN1R20P	-9.5	1.07e-19	6.75e-17	-0.4	-0.4	Ovarian reserve;	chr3:13904074	chr3:13926813~13927778:+
LGG	cis	rs9322193	0.847	rs12191643	ENSG00000216621.7	RP11-244K5.6	9.5	1.08e-19	6.77e-17	0.48	0.4	Lung cancer;	chr6:149628912	chr6:149934527~149936782:+
LGG	cis	rs10411262	0.935	rs2312289	ENSG00000245598.5	DACT3-AS1	-9.5	1.08e-19	6.78e-17	-0.39	-0.4	Tonsillectomy;	chr19:46672358	chr19:46660364~46677447:+
LGG	cis	rs7247513	0.964	rs8105902	ENSG00000213290.4	PGK1P2	-9.5	1.08e-19	6.8e-17	-0.43	-0.4	Bipolar disorder;	chr19:12607537	chr19:12559571~12561105:+
LGG	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	9.5	1.08e-19	6.81e-17	0.51	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000235689.1	AP000351.13	9.5	1.08e-19	6.81e-17	0.46	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:24006305~24008258:-
LGG	cis	rs1275468	0.798	rs2366987	ENSG00000257497.2	RP11-585P4.5	-9.49	1.09e-19	6.85e-17	-0.5	-0.4	Polycystic ovary syndrome;	chr12:75536346	chr12:75483454~75489820:-
LGG	cis	rs9322193	0.884	rs9322210	ENSG00000216621.7	RP11-244K5.6	9.49	1.09e-19	6.85e-17	0.48	0.4	Lung cancer;	chr6:149695440	chr6:149934527~149936782:+
LGG	cis	rs9527	0.59	rs1926029	ENSG00000272912.1	RP11-724N1.1	-9.49	1.09e-19	6.86e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103095913	chr10:102914585~102915404:+
LGG	cis	rs657075	0.697	rs2304081	ENSG00000263597.1	MIR3936	9.49	1.09e-19	6.87e-17	0.67	0.4	Rheumatoid arthritis;	chr5:132331855	chr5:132365490~132365599:-
LGG	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	9.49	1.09e-19	6.88e-17	0.55	0.4	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
LGG	cis	rs4950322	0.517	rs114823926	ENSG00000278811.3	LINC00624	9.49	1.1e-19	6.91e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147281805	chr1:147258885~147517875:-
LGG	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-9.49	1.11e-19	6.94e-17	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
LGG	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	9.49	1.11e-19	6.94e-17	0.55	0.4	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
LGG	cis	rs1707322	0.721	rs10157795	ENSG00000281133.1	AL355480.3	-9.49	1.12e-19	7.01e-17	-0.49	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45580892~45580996:-
LGG	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	9.49	1.12e-19	7.02e-17	0.36	0.4	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
LGG	cis	rs11051970	0.559	rs11051928	ENSG00000274964.1	RP11-817I4.1	-9.49	1.12e-19	7.02e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32319580	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs11051929	ENSG00000274964.1	RP11-817I4.1	-9.49	1.12e-19	7.02e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32319617	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.592	rs58926489	ENSG00000274964.1	RP11-817I4.1	-9.49	1.12e-19	7.02e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32319949	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.592	rs58236386	ENSG00000274964.1	RP11-817I4.1	-9.49	1.12e-19	7.02e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32320143	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs11051932	ENSG00000274964.1	RP11-817I4.1	-9.49	1.12e-19	7.02e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32320701	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.527	rs7977938	ENSG00000274964.1	RP11-817I4.1	-9.49	1.12e-19	7.02e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32322406	chr12:32339368~32340724:+
LGG	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	9.49	1.12e-19	7.02e-17	0.4	0.4	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
LGG	cis	rs9532669	0.963	rs3764056	ENSG00000168852.11	TPTE2P5	9.49	1.12e-19	7.04e-17	0.41	0.4	Cervical cancer;	chr13:40943849	chr13:40822296~40921749:-
LGG	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-9.49	1.12e-19	7.05e-17	-0.47	-0.4	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
LGG	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-9.49	1.12e-19	7.05e-17	-0.56	-0.4	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
LGG	cis	rs9532669	0.926	rs9532671	ENSG00000168852.11	TPTE2P5	9.49	1.12e-19	7.05e-17	0.4	0.4	Cervical cancer;	chr13:40927761	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.833	rs9532672	ENSG00000168852.11	TPTE2P5	9.49	1.12e-19	7.05e-17	0.4	0.4	Cervical cancer;	chr13:40928285	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.963	rs7324625	ENSG00000168852.11	TPTE2P5	9.49	1.12e-19	7.05e-17	0.4	0.4	Cervical cancer;	chr13:40928606	chr13:40822296~40921749:-
LGG	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-9.49	1.13e-19	7.06e-17	-0.42	-0.4	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
LGG	cis	rs7085104	0.552	rs11191414	ENSG00000272912.1	RP11-724N1.1	-9.49	1.13e-19	7.07e-17	-0.44	-0.4	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102914585~102915404:+
LGG	cis	rs853679	0.657	rs1778483	ENSG00000280107.1	AL022393.9	-9.49	1.13e-19	7.08e-17	-0.41	-0.4	Depression;	chr6:28273214	chr6:28170845~28172521:+
LGG	cis	rs853679	0.657	rs1778482	ENSG00000280107.1	AL022393.9	-9.49	1.13e-19	7.08e-17	-0.41	-0.4	Depression;	chr6:28273215	chr6:28170845~28172521:+
LGG	cis	rs4950322	0.57	rs17360443	ENSG00000278811.3	LINC00624	9.49	1.13e-19	7.1e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147279737	chr1:147258885~147517875:-
LGG	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-9.49	1.14e-19	7.12e-17	-0.51	-0.4	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
LGG	cis	rs9532669	0.926	rs9532659	ENSG00000168852.11	TPTE2P5	9.49	1.14e-19	7.12e-17	0.41	0.4	Cervical cancer;	chr13:40920380	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs9594457	ENSG00000168852.11	TPTE2P5	9.49	1.14e-19	7.12e-17	0.41	0.4	Cervical cancer;	chr13:40920439	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9594458	ENSG00000168852.11	TPTE2P5	9.49	1.14e-19	7.12e-17	0.41	0.4	Cervical cancer;	chr13:40920448	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9590562	ENSG00000168852.11	TPTE2P5	9.49	1.14e-19	7.12e-17	0.41	0.4	Cervical cancer;	chr13:40920503	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.963	rs12857052	ENSG00000168852.11	TPTE2P5	9.49	1.14e-19	7.12e-17	0.41	0.4	Cervical cancer;	chr13:40920831	chr13:40822296~40921749:-
LGG	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	9.49	1.14e-19	7.13e-17	0.51	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
LGG	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	9.49	1.14e-19	7.17e-17	0.46	0.4	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
LGG	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	9.49	1.15e-19	7.23e-17	0.39	0.4	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
LGG	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	9.49	1.16e-19	7.24e-17	0.43	0.4	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	9.49	1.16e-19	7.24e-17	0.43	0.4	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	9.49	1.16e-19	7.24e-17	0.43	0.4	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	9.49	1.16e-19	7.24e-17	0.43	0.4	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	9.49	1.16e-19	7.24e-17	0.43	0.4	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
LGG	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	9.49	1.16e-19	7.28e-17	0.52	0.4	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
LGG	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	9.49	1.16e-19	7.28e-17	0.52	0.4	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
LGG	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-9.49	1.16e-19	7.28e-17	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
LGG	cis	rs6452524	0.904	rs10474095	ENSG00000248112.1	RP11-78C3.1	9.49	1.16e-19	7.29e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:82919376~82921119:-
LGG	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-9.49	1.16e-19	7.29e-17	-0.46	-0.4	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
LGG	cis	rs4683346	0.621	rs704898	ENSG00000273328.4	RP11-141M3.6	-9.49	1.17e-19	7.32e-17	-0.51	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42976202	chr3:42809414~42908105:+
LGG	cis	rs9322193	0.884	rs7450246	ENSG00000216621.7	RP11-244K5.6	9.49	1.17e-19	7.32e-17	0.48	0.4	Lung cancer;	chr6:149702517	chr6:149934527~149936782:+
LGG	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-9.49	1.17e-19	7.35e-17	-0.55	-0.4	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
LGG	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	9.48	1.18e-19	7.37e-17	0.48	0.4	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
LGG	cis	rs7219021	0.518	rs6504584	ENSG00000248278.1	SUMO2P17	-9.48	1.18e-19	7.4e-17	-0.47	-0.4	Schizophrenia or bipolar disorder;	chr17:48864057	chr17:48874860~48908983:-
LGG	cis	rs7267979	0.966	rs2257233	ENSG00000276952.1	RP5-965G21.6	-9.48	1.18e-19	7.4e-17	-0.4	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25284915~25285588:-
LGG	cis	rs2325036	0.82	rs1448614	ENSG00000239519.1	CADM2-AS1	9.48	1.19e-19	7.42e-17	0.45	0.4	Waist circumference;	chr3:85825791	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.713	rs1448613	ENSG00000239519.1	CADM2-AS1	9.48	1.19e-19	7.42e-17	0.45	0.4	Waist circumference;	chr3:85826115	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs17023377	ENSG00000239519.1	CADM2-AS1	9.48	1.19e-19	7.42e-17	0.45	0.4	Waist circumference;	chr3:85826509	chr3:85992183~86028007:-
LGG	cis	rs11051970	0.559	rs3748275	ENSG00000274964.1	RP11-817I4.1	-9.48	1.19e-19	7.44e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32328159	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs3748276	ENSG00000274964.1	RP11-817I4.1	-9.48	1.19e-19	7.44e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32328643	chr12:32339368~32340724:+
LGG	cis	rs11098499	0.691	rs10028773	ENSG00000249244.1	RP11-548H18.2	-9.48	1.19e-19	7.44e-17	-0.42	-0.4	Corneal astigmatism;	chr4:119344104	chr4:119391831~119395335:-
LGG	cis	rs12488721	1	rs12488721	ENSG00000261758.1	RP11-102M11.2	9.48	1.19e-19	7.44e-17	0.43	0.4	Neuroticism;	chr3:136273803	chr3:136752630~136755780:+
LGG	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	9.48	1.19e-19	7.46e-17	0.4	0.4	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
LGG	cis	rs2613964	0.504	rs3995917	ENSG00000240057.4	RP11-572M11.4	9.48	1.2e-19	7.48e-17	0.43	0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133767	chr3:113019532~113183301:+
LGG	cis	rs9876781	1	rs725310	ENSG00000244380.1	RP11-24C3.2	-9.48	1.2e-19	7.49e-17	-0.49	-0.4	Longevity;	chr3:48377081	chr3:48440352~48446656:-
LGG	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	9.48	1.2e-19	7.51e-17	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
LGG	cis	rs9527	0.59	rs2281877	ENSG00000272912.1	RP11-724N1.1	-9.48	1.2e-19	7.51e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103106305	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs10786738	ENSG00000272912.1	RP11-724N1.1	-9.48	1.2e-19	7.51e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103109694	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs1807298	ENSG00000272912.1	RP11-724N1.1	-9.48	1.2e-19	7.51e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103110461	chr10:102914585~102915404:+
LGG	cis	rs9527	0.59	rs2182348	ENSG00000272912.1	RP11-724N1.1	-9.48	1.2e-19	7.51e-17	-0.45	-0.4	Arsenic metabolism;	chr10:103112927	chr10:102914585~102915404:+
LGG	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	9.48	1.21e-19	7.54e-17	0.52	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
LGG	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	9.48	1.21e-19	7.55e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
LGG	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	9.48	1.21e-19	7.55e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
LGG	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	9.48	1.21e-19	7.55e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
LGG	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	9.48	1.21e-19	7.55e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
LGG	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	9.48	1.21e-19	7.55e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
LGG	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-9.48	1.21e-19	7.55e-17	-0.54	-0.4	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
LGG	cis	rs357618	0.513	rs7722485	ENSG00000260581.1	CTB-113P19.4	-9.48	1.21e-19	7.57e-17	-0.48	-0.4	Basophil percentage of white cells;	chr5:151506958	chr5:151652275~151655449:+
LGG	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-9.48	1.21e-19	7.59e-17	-0.49	-0.4	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
LGG	cis	rs6452524	0.935	rs72767160	ENSG00000248112.1	RP11-78C3.1	9.48	1.22e-19	7.6e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs5000997	ENSG00000248112.1	RP11-78C3.1	9.48	1.22e-19	7.6e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs6887915	ENSG00000248112.1	RP11-78C3.1	9.48	1.22e-19	7.6e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:82919376~82921119:-
LGG	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	9.48	1.22e-19	7.64e-17	0.43	0.4	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
LGG	cis	rs1707322	0.686	rs1547924	ENSG00000281133.1	AL355480.3	-9.48	1.24e-19	7.71e-17	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45580892~45580996:-
LGG	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-9.48	1.24e-19	7.72e-17	-0.48	-0.4	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
LGG	cis	rs17772222	1	rs74071851	ENSG00000222990.1	RNU4-22P	9.48	1.24e-19	7.72e-17	0.52	0.4	Coronary artery calcification;	chr14:88415858	chr14:88513498~88513663:+
LGG	cis	rs9532669	0.853	rs9315795	ENSG00000168852.11	TPTE2P5	9.48	1.24e-19	7.72e-17	0.41	0.4	Cervical cancer;	chr13:40943382	chr13:40822296~40921749:-
LGG	cis	rs11051970	0.559	rs11051944	ENSG00000274964.1	RP11-817I4.1	-9.48	1.24e-19	7.73e-17	-0.42	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32332984	chr12:32339368~32340724:+
LGG	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	9.48	1.24e-19	7.74e-17	0.52	0.4	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
LGG	cis	rs227275	0.525	rs11097796	ENSG00000230069.3	LRRC37A15P	-9.48	1.24e-19	7.75e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs11097797	ENSG00000230069.3	LRRC37A15P	-9.48	1.24e-19	7.75e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs13117110	ENSG00000230069.3	LRRC37A15P	-9.48	1.24e-19	7.75e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs13144033	ENSG00000230069.3	LRRC37A15P	-9.48	1.24e-19	7.75e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs10029073	ENSG00000230069.3	LRRC37A15P	-9.48	1.24e-19	7.75e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs724446	ENSG00000230069.3	LRRC37A15P	-9.48	1.24e-19	7.75e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102727274~102730721:-
LGG	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-9.48	1.24e-19	7.76e-17	-0.47	-0.4	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
LGG	cis	rs482329	0.523	rs554381	ENSG00000228044.2	RP4-781K5.4	9.48	1.25e-19	7.77e-17	0.44	0.4	Life threatening arrhythmia;	chr1:234685520	chr1:234646289~234683176:+
LGG	cis	rs482329	0.523	rs681075	ENSG00000228044.2	RP4-781K5.4	9.48	1.25e-19	7.77e-17	0.44	0.4	Life threatening arrhythmia;	chr1:234686322	chr1:234646289~234683176:+
LGG	cis	rs482329	0.56	rs501107	ENSG00000228044.2	RP4-781K5.4	9.48	1.25e-19	7.77e-17	0.44	0.4	Life threatening arrhythmia;	chr1:234687167	chr1:234646289~234683176:+
LGG	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	9.48	1.25e-19	7.77e-17	0.51	0.4	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
LGG	cis	rs1560104	0.709	rs62027318	ENSG00000274834.1	CTD-3037G24.5	-9.48	1.25e-19	7.78e-17	-0.51	-0.4	Obesity-related traits;	chr16:12610040	chr16:12614451~12614852:+
LGG	cis	rs5742933	0.842	rs1225101	ENSG00000253559.1	OSGEPL1-AS1	-9.48	1.25e-19	7.79e-17	-0.51	-0.4	Ferritin levels;	chr2:189740695	chr2:189762704~189765556:+
LGG	cis	rs11051970	0.559	rs11051925	ENSG00000274964.1	RP11-817I4.1	-9.48	1.25e-19	7.79e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32314860	chr12:32339368~32340724:+
LGG	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	9.48	1.25e-19	7.82e-17	0.48	0.4	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
LGG	cis	rs1707322	0.506	rs2991983	ENSG00000281133.1	AL355480.3	9.48	1.26e-19	7.84e-17	0.48	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45580892~45580996:-
LGG	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	9.48	1.26e-19	7.85e-17	0.51	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
LGG	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-9.48	1.26e-19	7.86e-17	-0.54	-0.4	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
LGG	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	9.48	1.26e-19	7.87e-17	0.36	0.4	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
LGG	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-9.48	1.26e-19	7.88e-17	-0.49	-0.4	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
LGG	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-9.48	1.26e-19	7.88e-17	-0.49	-0.4	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
LGG	cis	rs9388451	0.807	rs1268065	ENSG00000237742.5	RP11-624M8.1	9.48	1.27e-19	7.9e-17	0.36	0.4	Brugada syndrome;	chr6:125721637	chr6:125578558~125749190:-
LGG	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-9.48	1.27e-19	7.92e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
LGG	cis	rs17826219	0.561	rs11655876	ENSG00000266490.1	CTD-2349P21.9	9.48	1.27e-19	7.93e-17	0.49	0.4	Body mass index;	chr17:30690132	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9907197	ENSG00000266490.1	CTD-2349P21.9	9.48	1.27e-19	7.93e-17	0.49	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30792372~30792833:+
LGG	cis	rs6452524	0.901	rs4571449	ENSG00000248112.1	RP11-78C3.1	9.48	1.27e-19	7.93e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:82919376~82921119:-
LGG	cis	rs9322193	0.923	rs9800736	ENSG00000216621.7	RP11-244K5.6	9.47	1.28e-19	7.96e-17	0.48	0.4	Lung cancer;	chr6:149661281	chr6:149934527~149936782:+
LGG	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	9.47	1.28e-19	7.99e-17	0.59	0.4	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
LGG	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-9.47	1.29e-19	8.01e-17	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
LGG	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
LGG	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
LGG	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-9.47	1.29e-19	8.03e-17	-0.48	-0.4	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
LGG	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-9.47	1.29e-19	8.04e-17	-0.43	-0.4	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
LGG	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-9.47	1.3e-19	8.1e-17	-0.46	-0.4	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-9.47	1.3e-19	8.12e-17	-0.46	-0.4	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
LGG	cis	rs482329	0.523	rs627279	ENSG00000228044.2	RP4-781K5.4	9.47	1.31e-19	8.14e-17	0.44	0.4	Life threatening arrhythmia;	chr1:234695735	chr1:234646289~234683176:+
LGG	cis	rs651907	0.535	rs11707250	ENSG00000256628.3	ZBTB11-AS1	-9.47	1.31e-19	8.15e-17	-0.46	-0.4	Colorectal cancer;	chr3:101790527	chr3:101676475~101679217:+
LGG	cis	rs9322193	0.923	rs9479494	ENSG00000216621.7	RP11-244K5.6	9.47	1.32e-19	8.22e-17	0.47	0.4	Lung cancer;	chr6:149739108	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9800806	ENSG00000216621.7	RP11-244K5.6	9.47	1.32e-19	8.22e-17	0.47	0.4	Lung cancer;	chr6:149740350	chr6:149934527~149936782:+
LGG	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-9.47	1.33e-19	8.28e-17	-0.44	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
LGG	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-9.47	1.33e-19	8.31e-17	-0.48	-0.4	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
LGG	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	9.47	1.34e-19	8.32e-17	0.5	0.4	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	9.47	1.34e-19	8.32e-17	0.5	0.4	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	9.47	1.34e-19	8.32e-17	0.5	0.4	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	9.47	1.34e-19	8.32e-17	0.5	0.4	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
LGG	cis	rs2283792	0.846	rs240053	ENSG00000228050.1	TOP3BP1	9.47	1.34e-19	8.33e-17	0.46	0.4	Multiple sclerosis;	chr22:21911000	chr22:22223187~22224566:-
LGG	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-9.47	1.34e-19	8.35e-17	-0.51	-0.4	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
LGG	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-9.47	1.34e-19	8.36e-17	-0.48	-0.4	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
LGG	cis	rs9532669	0.926	rs2183144	ENSG00000168852.11	TPTE2P5	-9.47	1.35e-19	8.37e-17	-0.39	-0.4	Cervical cancer;	chr13:40862129	chr13:40822296~40921749:-
LGG	cis	rs11051970	0.559	rs11051938	ENSG00000274964.1	RP11-817I4.1	-9.47	1.35e-19	8.4e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32329882	chr12:32339368~32340724:+
LGG	cis	rs853679	0.769	rs7752608	ENSG00000216901.1	AL022393.7	9.47	1.35e-19	8.4e-17	0.78	0.4	Depression;	chr6:28333418	chr6:28176188~28176674:+
LGG	cis	rs227275	0.525	rs4699046	ENSG00000230069.3	LRRC37A15P	-9.47	1.35e-19	8.41e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs4699047	ENSG00000230069.3	LRRC37A15P	-9.47	1.35e-19	8.41e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs28778380	ENSG00000230069.3	LRRC37A15P	-9.47	1.35e-19	8.41e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102727274~102730721:-
LGG	cis	rs587080	0.654	rs595366	ENSG00000245532.5	NEAT1	-9.47	1.35e-19	8.41e-17	-0.29	-0.4	Plateletcrit;	chr11:65429460	chr11:65422774~65445540:+
LGG	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-9.47	1.35e-19	8.42e-17	-0.48	-0.4	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
LGG	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
LGG	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
LGG	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-9.47	1.37e-19	8.49e-17	-0.47	-0.4	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
LGG	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-9.47	1.37e-19	8.49e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
LGG	cis	rs11233250	0.688	rs76081377	ENSG00000245832.5	RP11-179A16.1	9.47	1.37e-19	8.52e-17	0.62	0.4	Glioblastoma;Glioma;	chr11:82689948	chr11:81879851~82718082:-
LGG	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	9.47	1.37e-19	8.52e-17	0.39	0.4	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
LGG	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	9.47	1.37e-19	8.54e-17	0.46	0.4	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
LGG	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	9.46	1.39e-19	8.63e-17	0.6	0.4	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
LGG	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	9.46	1.39e-19	8.65e-17	0.48	0.4	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
LGG	cis	rs11051970	0.559	rs10431283	ENSG00000274964.1	RP11-817I4.1	-9.46	1.39e-19	8.66e-17	-0.42	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32315070	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs10431225	ENSG00000274964.1	RP11-817I4.1	-9.46	1.39e-19	8.66e-17	-0.42	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32315177	chr12:32339368~32340724:+
LGG	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-9.46	1.4e-19	8.67e-17	-0.47	-0.4	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
LGG	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-9.46	1.4e-19	8.67e-17	-0.49	-0.4	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
LGG	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-9.46	1.4e-19	8.68e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-9.46	1.4e-19	8.68e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-9.46	1.4e-19	8.68e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
LGG	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-9.46	1.4e-19	8.68e-17	-0.42	-0.4	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-9.46	1.4e-19	8.68e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
LGG	cis	rs4683346	0.752	rs2228468	ENSG00000273328.4	RP11-141M3.6	-9.46	1.4e-19	8.7e-17	-0.46	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42865620	chr3:42809414~42908105:+
LGG	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-9.46	1.4e-19	8.72e-17	-0.41	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-9.46	1.4e-19	8.72e-17	-0.41	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
LGG	cis	rs7247513	0.964	rs1007352	ENSG00000213290.4	PGK1P2	-9.46	1.41e-19	8.73e-17	-0.43	-0.4	Bipolar disorder;	chr19:12611731	chr19:12559571~12561105:+
LGG	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	9.46	1.41e-19	8.76e-17	0.48	0.4	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
LGG	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-9.46	1.42e-19	8.81e-17	-0.54	-0.4	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
LGG	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-9.46	1.42e-19	8.81e-17	-0.51	-0.4	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
LGG	cis	rs657075	0.697	rs71583484	ENSG00000263597.1	MIR3936	-9.46	1.42e-19	8.83e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132383438	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583485	ENSG00000263597.1	MIR3936	-9.46	1.42e-19	8.83e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132383690	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs71583486	ENSG00000263597.1	MIR3936	-9.46	1.42e-19	8.83e-17	-0.68	-0.4	Rheumatoid arthritis;	chr5:132383997	chr5:132365490~132365599:-
LGG	cis	rs11051970	0.559	rs11536026	ENSG00000274964.1	RP11-817I4.1	-9.46	1.43e-19	8.87e-17	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32316593	chr12:32339368~32340724:+
LGG	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	9.46	1.43e-19	8.87e-17	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
LGG	cis	rs9532669	0.963	rs4600338	ENSG00000168852.11	TPTE2P5	9.46	1.44e-19	8.92e-17	0.4	0.4	Cervical cancer;	chr13:40925175	chr13:40822296~40921749:-
LGG	cis	rs1420956	0.935	rs8096529	ENSG00000264151.4	RP11-739N10.1	9.46	1.44e-19	8.94e-17	0.5	0.4	Obesity-related traits;	chr18:27585772	chr18:27336379~27595164:-
LGG	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	9.46	1.45e-19	9.01e-17	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
LGG	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	9.46	1.45e-19	9.01e-17	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
LGG	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	9.46	1.45e-19	9.01e-17	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
LGG	cis	rs1420956	0.967	rs7238941	ENSG00000264151.4	RP11-739N10.1	9.46	1.45e-19	9.02e-17	0.5	0.4	Obesity-related traits;	chr18:27579412	chr18:27336379~27595164:-
LGG	cis	rs4950322	0.57	rs6703892	ENSG00000278811.3	LINC00624	9.46	1.46e-19	9.03e-17	0.4	0.4	Protein quantitative trait loci;	chr1:147287627	chr1:147258885~147517875:-
LGG	cis	rs9322193	0.923	rs62441279	ENSG00000216621.7	RP11-244K5.6	9.46	1.46e-19	9.04e-17	0.47	0.4	Lung cancer;	chr6:149721194	chr6:149934527~149936782:+
LGG	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-9.46	1.46e-19	9.06e-17	-0.46	-0.4	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
LGG	cis	rs9532669	0.926	rs7328139	ENSG00000168852.11	TPTE2P5	9.46	1.47e-19	9.09e-17	0.4	0.4	Cervical cancer;	chr13:40862295	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7328145	ENSG00000168852.11	TPTE2P5	9.46	1.47e-19	9.09e-17	0.4	0.4	Cervical cancer;	chr13:40862307	chr13:40822296~40921749:-
LGG	cis	rs4713118	0.868	rs760587	ENSG00000216901.1	AL022393.7	9.46	1.47e-19	9.1e-17	0.55	0.4	Parkinson's disease;	chr6:27772521	chr6:28176188~28176674:+
LGG	cis	rs12935418	0.672	rs12446810	ENSG00000260213.4	RP11-303E16.3	-9.46	1.47e-19	9.1e-17	-0.51	-0.4	Mean corpuscular volume;	chr16:81009369	chr16:81016792~81035759:-
LGG	cis	rs4713118	0.699	rs200969	ENSG00000226314.6	ZNF192P1	9.46	1.47e-19	9.11e-17	0.46	0.4	Parkinson's disease;	chr6:27891675	chr6:28161781~28169594:+
LGG	cis	rs4373814	0.624	rs10764331	ENSG00000226083.4	SLC39A12-AS1	-9.46	1.48e-19	9.16e-17	-0.41	-0.4	Diastolic blood pressure;Systolic blood pressure;Hypertension;	chr10:18162907	chr10:18001786~18010562:-
LGG	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	9.46	1.48e-19	9.16e-17	0.43	0.4	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
LGG	cis	rs853679	0.527	rs853683	ENSG00000218016.2	ZNF192P2	-9.46	1.48e-19	9.18e-17	-0.49	-0.4	Depression;	chr6:28327262	chr6:28188050~28189432:+
LGG	cis	rs4819052	0.679	rs28623526	ENSG00000215447.6	BX322557.10	-9.46	1.48e-19	9.18e-17	-0.3	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45288052~45291738:+
LGG	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-9.46	1.48e-19	9.19e-17	-0.5	-0.4	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
LGG	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-9.46	1.48e-19	9.19e-17	-0.5	-0.4	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
LGG	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-9.46	1.49e-19	9.21e-17	-0.45	-0.4	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
LGG	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-9.46	1.49e-19	9.22e-17	-0.5	-0.4	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
LGG	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-9.46	1.49e-19	9.22e-17	-0.5	-0.4	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
LGG	cis	rs853679	0.607	rs67998226	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28270281	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34878803	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28282402	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34396849	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28283178	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13211507	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28289600	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34691223	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28290431	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34950484	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28310911	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34661125	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28314117	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13190888	ENSG00000199851.2	U3	9.46	1.49e-19	9.22e-17	0.97	0.4	Depression;	chr6:28318208	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000235689.1	AP000351.13	9.46	1.49e-19	9.25e-17	0.46	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:24006305~24008258:-
LGG	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-9.45	1.5e-19	9.28e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
LGG	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	9.45	1.5e-19	9.3e-17	0.43	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
LGG	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	9.45	1.51e-19	9.32e-17	0.5	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
LGG	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-9.45	1.51e-19	9.33e-17	-0.41	-0.4	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
LGG	cis	rs7267979	0.934	rs2257464	ENSG00000276952.1	RP5-965G21.6	9.45	1.52e-19	9.39e-17	0.4	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25284915~25285588:-
LGG	cis	rs7302981	0.809	rs66768395	ENSG00000272368.2	RP4-605O3.4	9.45	1.52e-19	9.4e-17	0.39	0.4	Systolic blood pressure;	chr12:50174482	chr12:50112197~50165618:+
LGG	cis	rs7302981	0.809	rs1044370	ENSG00000272368.2	RP4-605O3.4	9.45	1.52e-19	9.4e-17	0.39	0.4	Systolic blood pressure;	chr12:50176827	chr12:50112197~50165618:+
LGG	cis	rs9876781	1	rs13314659	ENSG00000244380.1	RP11-24C3.2	-9.45	1.52e-19	9.41e-17	-0.49	-0.4	Longevity;	chr3:48407742	chr3:48440352~48446656:-
LGG	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-9.45	1.53e-19	9.44e-17	-0.56	-0.4	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
LGG	cis	rs10276381	1	rs10276381	ENSG00000234336.5	JAZF1-AS1	9.45	1.53e-19	9.45e-17	0.49	0.4	Crohn's disease;	chr7:28150502	chr7:28180322~28243917:+
LGG	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	9.45	1.53e-19	9.48e-17	0.92	0.4	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
LGG	cis	rs7211079	1	rs73438122	ENSG00000279259.1	RP11-334C17.3	9.45	1.53e-19	9.49e-17	0.45	0.4	Myocardial infarction;	chr17:80133078	chr17:80147250~80148596:+
LGG	cis	rs9322193	0.923	rs12174349	ENSG00000216621.7	RP11-244K5.6	9.45	1.54e-19	9.54e-17	0.47	0.4	Lung cancer;	chr6:149718012	chr6:149934527~149936782:+
LGG	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	9.45	1.55e-19	9.58e-17	0.4	0.4	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
LGG	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	9.45	1.55e-19	9.58e-17	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
LGG	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-9.45	1.56e-19	9.66e-17	-0.49	-0.4	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
LGG	cis	rs858239	0.509	rs57611130	ENSG00000230042.1	AK3P3	-9.45	1.56e-19	9.66e-17	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23129178~23129841:+
LGG	cis	rs1153858	1	rs1145074	ENSG00000259433.2	CTD-2651B20.4	-9.45	1.57e-19	9.69e-17	-0.47	-0.4	Homoarginine levels;	chr15:45411626	chr15:45330209~45332634:-
LGG	cis	rs2325036	0.783	rs61439785	ENSG00000239519.1	CADM2-AS1	9.45	1.58e-19	9.75e-17	0.45	0.4	Waist circumference;	chr3:85819695	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs58382609	ENSG00000239519.1	CADM2-AS1	9.45	1.58e-19	9.75e-17	0.45	0.4	Waist circumference;	chr3:85819707	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.783	rs11127908	ENSG00000239519.1	CADM2-AS1	9.45	1.58e-19	9.75e-17	0.45	0.4	Waist circumference;	chr3:85820135	chr3:85992183~86028007:-
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	9.45	1.58e-19	9.78e-17	0.54	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
LGG	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-9.45	1.59e-19	9.82e-17	-0.45	-0.4	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
LGG	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-9.45	1.59e-19	9.82e-17	-0.45	-0.4	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
LGG	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-9.45	1.59e-19	9.82e-17	-0.45	-0.4	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
LGG	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-9.45	1.59e-19	9.82e-17	-0.45	-0.4	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
LGG	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-9.45	1.59e-19	9.83e-17	-0.45	-0.4	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
LGG	cis	rs1420956	0.902	rs8099487	ENSG00000264151.4	RP11-739N10.1	9.45	1.59e-19	9.85e-17	0.5	0.4	Obesity-related traits;	chr18:27581780	chr18:27336379~27595164:-
LGG	cis	rs227275	0.525	rs4623004	ENSG00000230069.3	LRRC37A15P	-9.45	1.6e-19	9.86e-17	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102727274~102730721:-
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-9.45	1.6e-19	9.86e-17	-0.53	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
LGG	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-9.45	1.6e-19	9.86e-17	-0.45	-0.4	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
LGG	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	9.45	1.6e-19	9.9e-17	0.6	0.4	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.923	rs9478291	ENSG00000216621.7	RP11-244K5.6	9.45	1.6e-19	9.9e-17	0.47	0.4	Lung cancer;	chr6:149729434	chr6:149934527~149936782:+
LGG	cis	rs1707322	0.686	rs2230658	ENSG00000281133.1	AL355480.3	9.45	1.61e-19	9.95e-17	0.48	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.686	rs2230659	ENSG00000281133.1	AL355480.3	9.45	1.61e-19	9.95e-17	0.48	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45580892~45580996:-
LGG	cis	rs9810089	0.934	rs1153877	ENSG00000261758.1	RP11-102M11.2	9.45	1.61e-19	9.96e-17	0.43	0.4	Gestational age at birth (child effect);	chr3:136286083	chr3:136752630~136755780:+
LGG	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-9.45	1.62e-19	9.99e-17	-0.46	-0.4	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-9.45	1.62e-19	9.99e-17	-0.46	-0.4	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-9.45	1.62e-19	9.99e-17	-0.46	-0.4	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-9.45	1.62e-19	9.99e-17	-0.46	-0.4	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.926	rs7338617	ENSG00000168852.11	TPTE2P5	9.44	1.63e-19	1.01e-16	0.4	0.4	Cervical cancer;	chr13:40870787	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.857	rs6560961	ENSG00000168852.11	TPTE2P5	9.44	1.63e-19	1.01e-16	0.4	0.4	Cervical cancer;	chr13:40870878	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs6560962	ENSG00000168852.11	TPTE2P5	9.44	1.63e-19	1.01e-16	0.4	0.4	Cervical cancer;	chr13:40870948	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs1055588	ENSG00000168852.11	TPTE2P5	9.44	1.63e-19	1.01e-16	0.4	0.4	Cervical cancer;	chr13:40871306	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs3610	ENSG00000168852.11	TPTE2P5	9.44	1.63e-19	1.01e-16	0.4	0.4	Cervical cancer;	chr13:40871334	chr13:40822296~40921749:-
LGG	cis	rs657075	0.697	rs34452667	ENSG00000263597.1	MIR3936	-9.44	1.63e-19	1.01e-16	-0.68	-0.4	Rheumatoid arthritis;	chr5:132377863	chr5:132365490~132365599:-
LGG	cis	rs9532669	0.857	rs9525427	ENSG00000168852.11	TPTE2P5	9.44	1.63e-19	1.01e-16	0.4	0.4	Cervical cancer;	chr13:40918029	chr13:40822296~40921749:-
LGG	cis	rs11051970	0.559	rs7956708	ENSG00000274964.1	RP11-817I4.1	-9.44	1.63e-19	1.01e-16	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32315908	chr12:32339368~32340724:+
LGG	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
LGG	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
LGG	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
LGG	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
LGG	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
LGG	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
LGG	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-9.44	1.64e-19	1.01e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
LGG	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-9.44	1.65e-19	1.02e-16	-0.35	-0.4	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
LGG	cis	rs9532669	0.926	rs4942005	ENSG00000168852.11	TPTE2P5	9.44	1.66e-19	1.02e-16	0.4	0.4	Cervical cancer;	chr13:40871636	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4942006	ENSG00000168852.11	TPTE2P5	9.44	1.66e-19	1.02e-16	0.4	0.4	Cervical cancer;	chr13:40871862	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4942008	ENSG00000168852.11	TPTE2P5	9.44	1.66e-19	1.02e-16	0.4	0.4	Cervical cancer;	chr13:40871989	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs2039118	ENSG00000168852.11	TPTE2P5	9.44	1.66e-19	1.02e-16	0.4	0.4	Cervical cancer;	chr13:40872260	chr13:40822296~40921749:-
LGG	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-9.44	1.66e-19	1.02e-16	-0.42	-0.4	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
LGG	cis	rs9322193	0.923	rs9383812	ENSG00000216621.7	RP11-244K5.6	9.44	1.66e-19	1.02e-16	0.48	0.4	Lung cancer;	chr6:149712355	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.847	rs9383844	ENSG00000216621.7	RP11-244K5.6	9.44	1.66e-19	1.02e-16	0.48	0.4	Lung cancer;	chr6:149716268	chr6:149934527~149936782:+
LGG	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-9.44	1.66e-19	1.03e-16	-0.57	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
LGG	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	9.44	1.67e-19	1.03e-16	0.55	0.4	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
LGG	cis	rs10276381	1	rs10260837	ENSG00000234336.5	JAZF1-AS1	-9.44	1.67e-19	1.03e-16	-0.5	-0.4	Crohn's disease;	chr7:28141510	chr7:28180322~28243917:+
LGG	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	9.44	1.68e-19	1.03e-16	0.43	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
LGG	cis	rs7247513	0.897	rs12972944	ENSG00000213290.4	PGK1P2	-9.44	1.69e-19	1.04e-16	-0.43	-0.4	Bipolar disorder;	chr19:12602994	chr19:12559571~12561105:+
LGG	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-9.44	1.69e-19	1.04e-16	-0.4	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
LGG	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-9.44	1.69e-19	1.04e-16	-0.38	-0.4	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
LGG	cis	rs1420956	0.935	rs4146246	ENSG00000264151.4	RP11-739N10.1	9.44	1.7e-19	1.05e-16	0.5	0.4	Obesity-related traits;	chr18:27589869	chr18:27336379~27595164:-
LGG	cis	rs1420956	0.935	rs8090669	ENSG00000264151.4	RP11-739N10.1	9.44	1.7e-19	1.05e-16	0.5	0.4	Obesity-related traits;	chr18:27590132	chr18:27336379~27595164:-
LGG	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	9.44	1.7e-19	1.05e-16	0.51	0.4	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
LGG	cis	rs9322193	0.923	rs17745062	ENSG00000216621.7	RP11-244K5.6	9.44	1.7e-19	1.05e-16	0.47	0.4	Lung cancer;	chr6:149721079	chr6:149934527~149936782:+
LGG	cis	rs7267979	0.932	rs446649	ENSG00000276952.1	RP5-965G21.6	9.44	1.71e-19	1.05e-16	0.39	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25284915~25285588:-
LGG	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-9.44	1.71e-19	1.05e-16	-0.48	-0.4	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-9.44	1.71e-19	1.05e-16	-0.48	-0.4	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
LGG	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-9.44	1.71e-19	1.05e-16	-0.48	-0.4	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
LGG	cis	rs2325036	0.748	rs1375217	ENSG00000239519.1	CADM2-AS1	9.44	1.73e-19	1.06e-16	0.45	0.4	Waist circumference;	chr3:85824748	chr3:85992183~86028007:-
LGG	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	9.44	1.73e-19	1.07e-16	0.43	0.4	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
LGG	cis	rs2739330	0.929	rs5751775	ENSG00000235689.1	AP000351.13	9.44	1.74e-19	1.07e-16	0.46	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:24006305~24008258:-
LGG	cis	rs10276381	1	rs10280937	ENSG00000234336.5	JAZF1-AS1	-9.44	1.74e-19	1.07e-16	-0.5	-0.4	Crohn's disease;	chr7:28142687	chr7:28180322~28243917:+
LGG	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-9.44	1.74e-19	1.07e-16	-0.73	-0.4	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
LGG	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-9.44	1.74e-19	1.07e-16	-0.73	-0.4	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-9.44	1.74e-19	1.07e-16	-0.73	-0.4	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
LGG	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	9.44	1.75e-19	1.07e-16	0.46	0.4	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
LGG	cis	rs7267979	1	rs12428	ENSG00000276952.1	RP5-965G21.6	-9.44	1.75e-19	1.08e-16	-0.4	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25284915~25285588:-
LGG	cis	rs6519955	0.897	rs4073601	ENSG00000231711.2	LINC00899	9.44	1.75e-19	1.08e-16	0.47	0.4	Dupuytren's disease;	chr22:46038806	chr22:46039907~46044853:-
LGG	cis	rs657075	0.639	rs3792885	ENSG00000263597.1	MIR3936	-9.44	1.75e-19	1.08e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132316555	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs34757387	ENSG00000263597.1	MIR3936	-9.44	1.75e-19	1.08e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132316984	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs34604423	ENSG00000263597.1	MIR3936	-9.44	1.75e-19	1.08e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132317818	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs57600888	ENSG00000263597.1	MIR3936	-9.44	1.75e-19	1.08e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132318360	chr5:132365490~132365599:-
LGG	cis	rs657075	0.643	rs71583471	ENSG00000263597.1	MIR3936	-9.44	1.75e-19	1.08e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132318474	chr5:132365490~132365599:-
LGG	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	9.43	1.76e-19	1.08e-16	0.61	0.4	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.886	rs4870055	ENSG00000216621.7	RP11-244K5.6	9.43	1.76e-19	1.08e-16	0.47	0.4	Lung cancer;	chr6:149848433	chr6:149934527~149936782:+
LGG	cis	rs6903823	0.508	rs1150718	ENSG00000226314.6	ZNF192P1	9.43	1.76e-19	1.09e-16	0.4	0.4	Pulmonary function;	chr6:28289170	chr6:28161781~28169594:+
LGG	cis	rs6903823	0.508	rs1233660	ENSG00000226314.6	ZNF192P1	9.43	1.76e-19	1.09e-16	0.4	0.4	Pulmonary function;	chr6:28292472	chr6:28161781~28169594:+
LGG	cis	rs9527	0.59	rs7067663	ENSG00000272912.1	RP11-724N1.1	-9.43	1.76e-19	1.09e-16	-0.45	-0.4	Arsenic metabolism;	chr10:103123893	chr10:102914585~102915404:+
LGG	cis	rs657075	0.64	rs13180186	ENSG00000263597.1	MIR3936	-9.43	1.77e-19	1.09e-16	-0.68	-0.4	Rheumatoid arthritis;	chr5:132369866	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs13180295	ENSG00000263597.1	MIR3936	-9.43	1.77e-19	1.09e-16	-0.68	-0.4	Rheumatoid arthritis;	chr5:132369896	chr5:132365490~132365599:-
LGG	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	9.43	1.77e-19	1.09e-16	0.5	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
LGG	cis	rs1275468	1	rs3847669	ENSG00000257497.2	RP11-585P4.5	-9.43	1.77e-19	1.09e-16	-0.52	-0.4	Polycystic ovary syndrome;	chr12:75555378	chr12:75483454~75489820:-
LGG	cis	rs11098499	0.739	rs9884728	ENSG00000249244.1	RP11-548H18.2	-9.43	1.77e-19	1.09e-16	-0.42	-0.4	Corneal astigmatism;	chr4:119205924	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.739	rs7441137	ENSG00000249244.1	RP11-548H18.2	-9.43	1.77e-19	1.09e-16	-0.42	-0.4	Corneal astigmatism;	chr4:119212066	chr4:119391831~119395335:-
LGG	cis	rs10276381	1	rs10281214	ENSG00000234336.5	JAZF1-AS1	-9.43	1.77e-19	1.09e-16	-0.5	-0.4	Crohn's disease;	chr7:28145925	chr7:28180322~28243917:+
LGG	cis	rs10276381	1	rs7796417	ENSG00000234336.5	JAZF1-AS1	-9.43	1.77e-19	1.09e-16	-0.5	-0.4	Crohn's disease;	chr7:28146500	chr7:28180322~28243917:+
LGG	cis	rs10276381	0.786	rs73089302	ENSG00000234336.5	JAZF1-AS1	-9.43	1.77e-19	1.09e-16	-0.5	-0.4	Crohn's disease;	chr7:28147515	chr7:28180322~28243917:+
LGG	cis	rs10276381	1	rs10263857	ENSG00000234336.5	JAZF1-AS1	-9.43	1.77e-19	1.09e-16	-0.5	-0.4	Crohn's disease;	chr7:28147665	chr7:28180322~28243917:+
LGG	cis	rs9532669	0.926	rs2875421	ENSG00000168852.11	TPTE2P5	9.43	1.78e-19	1.1e-16	0.4	0.4	Cervical cancer;	chr13:40936536	chr13:40822296~40921749:-
LGG	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	9.43	1.79e-19	1.1e-16	0.49	0.4	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
LGG	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	9.43	1.79e-19	1.1e-16	0.37	0.4	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
LGG	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-9.43	1.79e-19	1.1e-16	-0.38	-0.4	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
LGG	cis	rs5758511	0.514	rs9607885	ENSG00000227370.1	RP4-669P10.19	9.43	1.8e-19	1.11e-16	0.45	0.4	Birth weight;	chr22:42182590	chr22:42132543~42132998:+
LGG	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-9.43	1.8e-19	1.11e-16	-0.55	-0.4	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
LGG	cis	rs7119038	0.779	rs73005502	ENSG00000255239.1	AP002954.6	-9.43	1.81e-19	1.11e-16	-0.58	-0.4	Sjögren's syndrome;	chr11:118827197	chr11:118688039~118690600:-
LGG	cis	rs9876781	1	rs6794875	ENSG00000244380.1	RP11-24C3.2	9.43	1.81e-19	1.11e-16	0.49	0.4	Longevity;	chr3:48414217	chr3:48440352~48446656:-
LGG	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-9.43	1.82e-19	1.12e-16	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
LGG	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-9.43	1.82e-19	1.12e-16	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
LGG	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-9.43	1.82e-19	1.12e-16	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-9.43	1.83e-19	1.13e-16	-0.53	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
LGG	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	9.43	1.83e-19	1.13e-16	0.47	0.4	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
LGG	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	9.43	1.83e-19	1.13e-16	0.47	0.4	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	9.43	1.83e-19	1.13e-16	0.47	0.4	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	9.43	1.83e-19	1.13e-16	0.47	0.4	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
LGG	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-9.43	1.84e-19	1.13e-16	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
LGG	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	9.43	1.85e-19	1.14e-16	0.46	0.4	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
LGG	cis	rs11098499	0.71	rs6851130	ENSG00000249244.1	RP11-548H18.2	-9.43	1.86e-19	1.15e-16	-0.42	-0.4	Corneal astigmatism;	chr4:119212557	chr4:119391831~119395335:-
LGG	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-9.43	1.86e-19	1.15e-16	-0.47	-0.4	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
LGG	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-9.43	1.86e-19	1.15e-16	-0.47	-0.4	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
LGG	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	9.43	1.87e-19	1.15e-16	0.92	0.4	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
LGG	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	9.43	1.87e-19	1.15e-16	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	9.43	1.87e-19	1.15e-16	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
LGG	cis	rs2613964	0.504	rs9288972	ENSG00000240057.4	RP11-572M11.4	-9.43	1.87e-19	1.15e-16	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131422	chr3:113019532~113183301:+
LGG	cis	rs2613964	0.504	rs9838215	ENSG00000240057.4	RP11-572M11.4	-9.43	1.87e-19	1.15e-16	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131616	chr3:113019532~113183301:+
LGG	cis	rs2613964	0.504	rs9838253	ENSG00000240057.4	RP11-572M11.4	-9.43	1.87e-19	1.15e-16	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131678	chr3:113019532~113183301:+
LGG	cis	rs2613964	0.504	rs17317945	ENSG00000240057.4	RP11-572M11.4	-9.43	1.87e-19	1.15e-16	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131934	chr3:113019532~113183301:+
LGG	cis	rs2613964	0.504	rs12695288	ENSG00000240057.4	RP11-572M11.4	-9.43	1.87e-19	1.15e-16	-0.43	-0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113132668	chr3:113019532~113183301:+
LGG	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	9.43	1.88e-19	1.15e-16	0.61	0.4	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
LGG	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-9.43	1.88e-19	1.15e-16	-0.41	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
LGG	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-9.43	1.88e-19	1.15e-16	-0.46	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
LGG	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	9.43	1.88e-19	1.15e-16	0.52	0.4	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
LGG	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	9.43	1.89e-19	1.16e-16	0.48	0.4	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
LGG	cis	rs9876781	1	rs6804774	ENSG00000244380.1	RP11-24C3.2	9.43	1.89e-19	1.16e-16	0.49	0.4	Longevity;	chr3:48389129	chr3:48440352~48446656:-
LGG	cis	rs2843012	0.529	rs2843003	ENSG00000229921.5	KIF25-AS1	-9.43	1.9e-19	1.16e-16	-0.55	-0.4	Metabolite levels (5-HIAA);	chr6:168010042	chr6:167992822~167997077:-
LGG	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	9.43	1.9e-19	1.17e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	9.43	1.9e-19	1.17e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	9.43	1.9e-19	1.17e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
LGG	cis	rs10208649	0.611	rs12616263	ENSG00000272156.1	RP11-477N3.1	9.43	1.9e-19	1.17e-16	0.64	0.4	Body mass index;	chr2:54039235	chr2:54082554~54085066:+
LGG	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-9.42	1.91e-19	1.17e-16	-0.46	-0.4	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
LGG	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-9.42	1.91e-19	1.17e-16	-0.47	-0.4	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-9.42	1.91e-19	1.17e-16	-0.47	-0.4	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
LGG	cis	rs2613964	0.504	rs4682466	ENSG00000240057.4	RP11-572M11.4	9.42	1.91e-19	1.17e-16	0.43	0.4	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130841	chr3:113019532~113183301:+
LGG	cis	rs9876781	1	rs28824259	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48384185	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs12487542	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48384586	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs9864371	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48385276	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs73074358	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48385757	chr3:48440352~48446656:-
LGG	cis	rs9876781	0.967	rs34761139	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48386489	chr3:48440352~48446656:-
LGG	cis	rs9876781	0.868	rs9875280	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48387420	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs6796491	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48388977	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs9826195	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48392157	chr3:48440352~48446656:-
LGG	cis	rs9876781	0.967	rs9864815	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48392588	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs9809843	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48392923	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs1563736	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48395329	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs13071337	ENSG00000244380.1	RP11-24C3.2	9.42	1.91e-19	1.17e-16	0.49	0.4	Longevity;	chr3:48396724	chr3:48440352~48446656:-
LGG	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
LGG	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
LGG	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
LGG	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
LGG	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
LGG	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
LGG	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
LGG	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
LGG	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-9.42	1.92e-19	1.18e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
LGG	cis	rs7746199	0.736	rs17693963	ENSG00000216901.1	AL022393.7	9.42	1.92e-19	1.18e-16	0.85	0.4	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	9.42	1.92e-19	1.18e-16	0.46	0.4	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
LGG	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-9.42	1.92e-19	1.18e-16	-0.44	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
LGG	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	9.42	1.92e-19	1.18e-16	0.54	0.4	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
LGG	cis	rs4713118	0.868	rs9468220	ENSG00000216901.1	AL022393.7	-9.42	1.93e-19	1.18e-16	-0.54	-0.4	Parkinson's disease;	chr6:27765197	chr6:28176188~28176674:+
LGG	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-9.42	1.94e-19	1.19e-16	-0.54	-0.4	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
LGG	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-9.42	1.94e-19	1.19e-16	-0.58	-0.4	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
LGG	cis	rs1707322	0.686	rs11211179	ENSG00000281133.1	AL355480.3	-9.42	1.94e-19	1.19e-16	-0.49	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45580892~45580996:-
LGG	cis	rs9876781	1	rs11712561	ENSG00000244380.1	RP11-24C3.2	9.42	1.94e-19	1.19e-16	0.49	0.4	Longevity;	chr3:48393807	chr3:48440352~48446656:-
LGG	cis	rs7267979	0.932	rs433352	ENSG00000276952.1	RP5-965G21.6	-9.42	1.95e-19	1.19e-16	-0.4	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25284915~25285588:-
LGG	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	9.42	1.95e-19	1.19e-16	0.34	0.4	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
LGG	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	9.42	1.96e-19	1.2e-16	0.35	0.4	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	9.42	1.96e-19	1.2e-16	0.48	0.4	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	9.42	1.96e-19	1.2e-16	0.48	0.4	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	9.42	1.96e-19	1.2e-16	0.48	0.4	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
LGG	cis	rs4281086	0.93	rs4240647	ENSG00000253678.1	RP11-981G7.3	9.42	1.97e-19	1.2e-16	0.43	0.4	Obesity-related traits;	chr8:10497051	chr8:10477491~10479375:-
LGG	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	9.42	1.98e-19	1.21e-16	0.48	0.4	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
LGG	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	9.42	1.98e-19	1.21e-16	0.48	0.4	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
LGG	cis	rs7267979	0.773	rs6132821	ENSG00000276952.1	RP5-965G21.6	9.42	1.98e-19	1.21e-16	0.39	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25284915~25285588:-
LGG	cis	rs8037818	1	rs4544214	ENSG00000261064.1	RP11-1000B6.3	9.42	1.98e-19	1.22e-16	0.5	0.4	Obesity-related traits;	chr15:32639703	chr15:32536047~32587613:+
LGG	cis	rs7211079	0.917	rs4243251	ENSG00000279259.1	RP11-334C17.3	9.42	1.99e-19	1.22e-16	0.43	0.4	Myocardial infarction;	chr17:80138811	chr17:80147250~80148596:+
LGG	cis	rs9532669	0.926	rs4555012	ENSG00000168852.11	TPTE2P5	9.42	2e-19	1.22e-16	0.4	0.4	Cervical cancer;	chr13:40879997	chr13:40822296~40921749:-
LGG	cis	rs1061377	0.621	rs11096974	ENSG00000249685.1	RP11-360F5.3	9.42	2e-19	1.22e-16	0.47	0.4	Uric acid levels;	chr4:39062039	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.585	rs1367296	ENSG00000249685.1	RP11-360F5.3	9.42	2e-19	1.22e-16	0.47	0.4	Uric acid levels;	chr4:39066895	chr4:39133913~39135608:+
LGG	cis	rs6921919	0.609	rs9461455	ENSG00000218016.2	ZNF192P2	-9.42	2e-19	1.22e-16	-0.48	-0.4	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28188050~28189432:+
LGG	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-9.42	2.01e-19	1.23e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
LGG	cis	rs5758511	0.689	rs62240864	ENSG00000227370.1	RP4-669P10.19	9.42	2.01e-19	1.23e-16	0.49	0.4	Birth weight;	chr22:42167883	chr22:42132543~42132998:+
LGG	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-9.42	2.02e-19	1.24e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
LGG	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-9.42	2.02e-19	1.24e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-9.42	2.02e-19	1.24e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-9.42	2.02e-19	1.24e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-9.42	2.02e-19	1.24e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-9.42	2.02e-19	1.24e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
LGG	cis	rs9810089	0.934	rs696520	ENSG00000261758.1	RP11-102M11.2	9.42	2.02e-19	1.24e-16	0.43	0.4	Gestational age at birth (child effect);	chr3:136338019	chr3:136752630~136755780:+
LGG	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	9.42	2.03e-19	1.24e-16	0.48	0.4	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
LGG	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	9.42	2.03e-19	1.24e-16	0.48	0.4	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
LGG	cis	rs9532669	0.926	rs4356347	ENSG00000168852.11	TPTE2P5	9.42	2.03e-19	1.24e-16	0.4	0.4	Cervical cancer;	chr13:40872516	chr13:40822296~40921749:-
LGG	cis	rs657075	0.697	rs3805666	ENSG00000263597.1	MIR3936	-9.42	2.03e-19	1.24e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132310782	chr5:132365490~132365599:-
LGG	cis	rs4713118	0.955	rs9468206	ENSG00000216901.1	AL022393.7	9.42	2.03e-19	1.24e-16	0.52	0.4	Parkinson's disease;	chr6:27722674	chr6:28176188~28176674:+
LGG	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-9.42	2.04e-19	1.25e-16	-0.35	-0.4	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
LGG	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-9.42	2.04e-19	1.25e-16	-0.48	-0.4	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-9.42	2.04e-19	1.25e-16	-0.48	-0.4	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-9.42	2.04e-19	1.25e-16	-0.48	-0.4	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
LGG	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	9.41	2.07e-19	1.26e-16	0.51	0.4	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
LGG	cis	rs9532669	0.926	rs2324742	ENSG00000168852.11	TPTE2P5	9.41	2.07e-19	1.27e-16	0.41	0.4	Cervical cancer;	chr13:40919059	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.857	rs9594455	ENSG00000168852.11	TPTE2P5	9.41	2.07e-19	1.27e-16	0.41	0.4	Cervical cancer;	chr13:40919452	chr13:40822296~40921749:-
LGG	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	9.41	2.08e-19	1.27e-16	0.47	0.4	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
LGG	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	9.41	2.08e-19	1.27e-16	0.51	0.4	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
LGG	cis	rs1061377	0.585	rs3733271	ENSG00000249685.1	RP11-360F5.3	9.41	2.08e-19	1.27e-16	0.47	0.4	Uric acid levels;	chr4:39047948	chr4:39133913~39135608:+
LGG	cis	rs1061377	0.585	rs12648581	ENSG00000249685.1	RP11-360F5.3	9.41	2.08e-19	1.27e-16	0.47	0.4	Uric acid levels;	chr4:39054024	chr4:39133913~39135608:+
LGG	cis	rs7267979	1	rs2474777	ENSG00000276952.1	RP5-965G21.6	9.41	2.1e-19	1.28e-16	0.4	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25284915~25285588:-
LGG	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	9.41	2.11e-19	1.29e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	9.41	2.11e-19	1.29e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	9.41	2.11e-19	1.29e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	9.41	2.11e-19	1.29e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	9.41	2.11e-19	1.29e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
LGG	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	9.41	2.11e-19	1.29e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
LGG	cis	rs11098499	0.588	rs2389874	ENSG00000249244.1	RP11-548H18.2	-9.41	2.11e-19	1.29e-16	-0.41	-0.4	Corneal astigmatism;	chr4:119633836	chr4:119391831~119395335:-
LGG	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	9.41	2.12e-19	1.3e-16	0.6	0.4	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
LGG	cis	rs853679	0.546	rs13214023	ENSG00000216901.1	AL022393.7	-9.41	2.12e-19	1.3e-16	-0.79	-0.4	Depression;	chr6:28364364	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.884	rs10872646	ENSG00000216621.7	RP11-244K5.6	9.41	2.13e-19	1.3e-16	0.47	0.4	Lung cancer;	chr6:149746539	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.884	rs12528279	ENSG00000216621.7	RP11-244K5.6	9.41	2.13e-19	1.3e-16	0.47	0.4	Lung cancer;	chr6:149750892	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs10782316	ENSG00000216621.7	RP11-244K5.6	9.41	2.13e-19	1.3e-16	0.47	0.4	Lung cancer;	chr6:149752755	chr6:149934527~149936782:+
LGG	cis	rs853679	0.546	rs200949	ENSG00000199851.2	U3	9.41	2.14e-19	1.31e-16	0.8	0.4	Depression;	chr6:27867657	chr6:28015568~28015777:+
LGG	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-9.41	2.14e-19	1.31e-16	-0.53	-0.4	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
LGG	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-9.41	2.15e-19	1.31e-16	-0.48	-0.4	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
LGG	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-9.41	2.16e-19	1.32e-16	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
LGG	cis	rs4683346	0.752	rs9815043	ENSG00000273328.4	RP11-141M3.6	-9.41	2.16e-19	1.32e-16	-0.46	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42855147	chr3:42809414~42908105:+
LGG	cis	rs9322193	0.923	rs10747276	ENSG00000216621.7	RP11-244K5.6	9.41	2.16e-19	1.32e-16	0.48	0.4	Lung cancer;	chr6:149758739	chr6:149934527~149936782:+
LGG	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	9.41	2.18e-19	1.33e-16	0.44	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
LGG	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	9.41	2.18e-19	1.33e-16	0.59	0.4	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
LGG	cis	rs227275	0.525	rs2086499	ENSG00000230069.3	LRRC37A15P	-9.41	2.18e-19	1.33e-16	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102727274~102730721:-
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	9.41	2.18e-19	1.33e-16	0.54	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
LGG	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-9.41	2.18e-19	1.33e-16	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
LGG	cis	rs9532669	0.926	rs8002809	ENSG00000168852.11	TPTE2P5	9.41	2.18e-19	1.33e-16	0.4	0.4	Cervical cancer;	chr13:40872769	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.929	rs7982421	ENSG00000168852.11	TPTE2P5	9.41	2.18e-19	1.33e-16	0.4	0.4	Cervical cancer;	chr13:40872776	chr13:40822296~40921749:-
LGG	cis	rs4683346	0.752	rs1366046	ENSG00000273328.4	RP11-141M3.6	-9.41	2.18e-19	1.33e-16	-0.46	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42867283	chr3:42809414~42908105:+
LGG	cis	rs7432375	0.901	rs1681817	ENSG00000261758.1	RP11-102M11.2	-9.41	2.18e-19	1.33e-16	-0.41	-0.4	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136754886	chr3:136752630~136755780:+
LGG	cis	rs4683346	0.653	rs1071276	ENSG00000273328.4	RP11-141M3.6	-9.41	2.19e-19	1.33e-16	-0.5	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42965041	chr3:42809414~42908105:+
LGG	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-9.41	2.19e-19	1.34e-16	-0.46	-0.4	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
LGG	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	9.41	2.19e-19	1.34e-16	0.48	0.4	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
LGG	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-9.41	2.19e-19	1.34e-16	-0.38	-0.4	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
LGG	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-9.41	2.2e-19	1.34e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-9.41	2.2e-19	1.34e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
LGG	cis	rs9532669	0.684	rs7139788	ENSG00000168852.11	TPTE2P5	9.41	2.2e-19	1.34e-16	0.4	0.4	Cervical cancer;	chr13:40864264	chr13:40822296~40921749:-
LGG	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	9.41	2.2e-19	1.34e-16	0.48	0.4	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
LGG	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	9.41	2.2e-19	1.34e-16	0.34	0.4	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
LGG	cis	rs2325036	0.715	rs57533494	ENSG00000239519.1	CADM2-AS1	9.41	2.21e-19	1.35e-16	0.47	0.4	Waist circumference;	chr3:85853318	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.679	rs57153235	ENSG00000239519.1	CADM2-AS1	9.41	2.21e-19	1.35e-16	0.47	0.4	Waist circumference;	chr3:85853386	chr3:85992183~86028007:-
LGG	cis	rs9872570	1	rs9872570	ENSG00000273328.4	RP11-141M3.6	-9.41	2.21e-19	1.35e-16	-0.46	-0.4	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;	chr3:42855023	chr3:42809414~42908105:+
LGG	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-9.41	2.22e-19	1.35e-16	-0.46	-0.4	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
LGG	cis	rs1560104	0.709	rs7200211	ENSG00000274834.1	CTD-3037G24.5	-9.41	2.23e-19	1.36e-16	-0.51	-0.4	Obesity-related traits;	chr16:12605083	chr16:12614451~12614852:+
LGG	cis	rs1707322	0.752	rs6662164	ENSG00000281133.1	AL355480.3	-9.4	2.24e-19	1.36e-16	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45580892~45580996:-
LGG	cis	rs17772222	0.63	rs816069	ENSG00000258983.2	RP11-507K2.2	-9.4	2.24e-19	1.37e-16	-0.44	-0.4	Coronary artery calcification;	chr14:88500992	chr14:88499334~88515502:+
LGG	cis	rs9875589	0.957	rs6778297	ENSG00000233121.1	VN1R20P	9.4	2.24e-19	1.37e-16	0.4	0.4	Ovarian reserve;	chr3:13890646	chr3:13926813~13927778:+
LGG	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	9.4	2.25e-19	1.37e-16	0.47	0.4	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	9.4	2.25e-19	1.37e-16	0.47	0.4	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	9.4	2.25e-19	1.37e-16	0.47	0.4	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
LGG	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	9.4	2.25e-19	1.37e-16	0.47	0.4	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
LGG	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	9.4	2.25e-19	1.37e-16	0.47	0.4	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
LGG	cis	rs9322193	0.923	rs3798761	ENSG00000216621.7	RP11-244K5.6	9.4	2.25e-19	1.37e-16	0.47	0.4	Lung cancer;	chr6:149683643	chr6:149934527~149936782:+
LGG	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-9.4	2.25e-19	1.37e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-9.4	2.25e-19	1.37e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-9.4	2.25e-19	1.37e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
LGG	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	9.4	2.26e-19	1.38e-16	0.64	0.4	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
LGG	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-9.4	2.26e-19	1.38e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
LGG	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	9.4	2.27e-19	1.39e-16	0.48	0.4	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
LGG	cis	rs1153858	1	rs28679834	ENSG00000259433.2	CTD-2651B20.4	-9.4	2.28e-19	1.39e-16	-0.47	-0.4	Homoarginine levels;	chr15:45324008	chr15:45330209~45332634:-
LGG	cis	rs11051970	0.559	rs10844188	ENSG00000274964.1	RP11-817I4.1	-9.4	2.28e-19	1.39e-16	-0.42	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32334710	chr12:32339368~32340724:+
LGG	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-9.4	2.28e-19	1.39e-16	-0.47	-0.4	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
LGG	cis	rs9876781	1	rs1459242	ENSG00000244380.1	RP11-24C3.2	-9.4	2.29e-19	1.4e-16	-0.49	-0.4	Longevity;	chr3:48372047	chr3:48440352~48446656:-
LGG	cis	rs9532669	0.963	rs1056824	ENSG00000168852.11	TPTE2P5	9.4	2.3e-19	1.4e-16	0.4	0.4	Cervical cancer;	chr13:40932748	chr13:40822296~40921749:-
LGG	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-9.4	2.3e-19	1.4e-16	-0.54	-0.4	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
LGG	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-9.4	2.31e-19	1.41e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-9.4	2.31e-19	1.41e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
LGG	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-9.4	2.31e-19	1.41e-16	-0.38	-0.4	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-9.4	2.31e-19	1.41e-16	-0.38	-0.4	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-9.4	2.31e-19	1.41e-16	-0.38	-0.4	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-9.4	2.31e-19	1.41e-16	-0.38	-0.4	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-9.4	2.31e-19	1.41e-16	-0.38	-0.4	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-9.4	2.31e-19	1.41e-16	-0.38	-0.4	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-9.4	2.31e-19	1.41e-16	-0.38	-0.4	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
LGG	cis	rs9322193	0.923	rs62439840	ENSG00000216621.7	RP11-244K5.6	9.4	2.31e-19	1.41e-16	0.48	0.4	Lung cancer;	chr6:149674639	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9393175	ENSG00000216621.7	RP11-244K5.6	9.4	2.31e-19	1.41e-16	0.48	0.4	Lung cancer;	chr6:149677587	chr6:149934527~149936782:+
LGG	cis	rs6700559	0.74	rs6663322	ENSG00000260088.1	RP11-92G12.3	9.4	2.32e-19	1.41e-16	0.41	0.4	Coronary artery disease;	chr1:200680741	chr1:200669507~200694250:+
LGG	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-9.4	2.32e-19	1.41e-16	-0.36	-0.4	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
LGG	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	9.4	2.32e-19	1.42e-16	0.6	0.4	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
LGG	cis	rs657075	0.757	rs3805665	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132309025	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3792879	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132309142	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3792882	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132309418	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs34695718	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132309839	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3805667	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132310823	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3805668	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132310895	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3805669	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132311069	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs4646194	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132313369	chr5:132365490~132365599:-
LGG	cis	rs657075	0.64	rs2073838	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132313529	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs2073839	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132314552	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3792883	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132315488	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3828673	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132315872	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs3805676	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132332774	chr5:132365490~132365599:-
LGG	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-9.4	2.35e-19	1.43e-16	-0.5	-0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
LGG	cis	rs11051970	0.559	rs16919727	ENSG00000274964.1	RP11-817I4.1	-9.4	2.35e-19	1.43e-16	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32329976	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs11051940	ENSG00000274964.1	RP11-817I4.1	-9.4	2.35e-19	1.43e-16	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32330187	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs11051941	ENSG00000274964.1	RP11-817I4.1	-9.4	2.35e-19	1.43e-16	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32330338	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs11051942	ENSG00000274964.1	RP11-817I4.1	-9.4	2.35e-19	1.43e-16	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32330344	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs4316592	ENSG00000274964.1	RP11-817I4.1	-9.4	2.35e-19	1.43e-16	-0.43	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32331076	chr12:32339368~32340724:+
LGG	cis	rs657075	0.697	rs71583478	ENSG00000263597.1	MIR3936	-9.4	2.35e-19	1.43e-16	-0.68	-0.4	Rheumatoid arthritis;	chr5:132353131	chr5:132365490~132365599:-
LGG	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-9.4	2.37e-19	1.44e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
LGG	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-9.4	2.39e-19	1.45e-16	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
LGG	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	9.4	2.39e-19	1.46e-16	0.5	0.4	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
LGG	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	9.4	2.39e-19	1.46e-16	0.67	0.4	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
LGG	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	9.4	2.4e-19	1.46e-16	0.48	0.4	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
LGG	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-9.4	2.4e-19	1.46e-16	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
LGG	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-9.4	2.4e-19	1.46e-16	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
LGG	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-9.4	2.4e-19	1.46e-16	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
LGG	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-9.4	2.42e-19	1.47e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
LGG	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	9.4	2.42e-19	1.47e-16	0.47	0.4	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
LGG	cis	rs11051970	0.559	rs10844179	ENSG00000274964.1	RP11-817I4.1	9.39	2.43e-19	1.48e-16	0.42	0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32316667	chr12:32339368~32340724:+
LGG	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-9.39	2.43e-19	1.48e-16	-0.39	-0.4	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
LGG	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-9.39	2.43e-19	1.48e-16	-0.48	-0.4	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
LGG	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	9.39	2.43e-19	1.48e-16	0.6	0.4	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
LGG	cis	rs2325036	0.715	rs4856605	ENSG00000239519.1	CADM2-AS1	9.39	2.45e-19	1.49e-16	0.48	0.4	Waist circumference;	chr3:85858431	chr3:85992183~86028007:-
LGG	cis	rs9532669	0.89	rs12865032	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40873801	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs34123829	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40873808	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4488324	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40873864	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4288867	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40873880	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4415896	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40874001	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs4415897	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40874035	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4389021	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40874209	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.824	rs4628828	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40874369	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.737	rs34354179	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40874424	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9594445	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40874859	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9594446	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40874863	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4402423	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40875010	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.963	rs9532628	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40875172	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532629	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40875193	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7491149	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40875216	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532630	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40875472	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs4306385	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40875641	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4406939	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40876108	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4628824	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40876217	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532632	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40876309	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532633	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40876332	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532634	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40876369	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532635	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40876397	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs12428959	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40876638	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.895	rs4942009	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40877243	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4334153	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40877737	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4309270	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40877827	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4454835	ENSG00000168852.11	TPTE2P5	9.39	2.46e-19	1.5e-16	0.4	0.4	Cervical cancer;	chr13:40928978	chr13:40822296~40921749:-
LGG	cis	rs657075	0.697	rs35373795	ENSG00000263597.1	MIR3936	-9.39	2.46e-19	1.5e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132418132	chr5:132365490~132365599:-
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000272787.1	KB-226F1.2	9.39	2.47e-19	1.5e-16	0.42	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23969211~23969873:+
LGG	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-9.39	2.47e-19	1.5e-16	-0.48	-0.4	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
LGG	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-9.39	2.47e-19	1.5e-16	-0.48	-0.4	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
LGG	cis	rs853679	0.607	rs33932084	ENSG00000216901.1	AL022393.7	9.39	2.48e-19	1.51e-16	0.86	0.4	Depression;	chr6:28301047	chr6:28176188~28176674:+
LGG	cis	rs9388451	0.513	rs1268069	ENSG00000237742.5	RP11-624M8.1	-9.39	2.49e-19	1.51e-16	-0.36	-0.4	Brugada syndrome;	chr6:125718848	chr6:125578558~125749190:-
LGG	cis	rs7829975	0.667	rs1877119	ENSG00000173295.6	FAM86B3P	-9.39	2.49e-19	1.51e-16	-0.43	-0.4	Mood instability;	chr8:8849687	chr8:8228595~8244865:+
LGG	cis	rs12935418	0.672	rs9938541	ENSG00000260213.4	RP11-303E16.3	-9.39	2.5e-19	1.51e-16	-0.5	-0.4	Mean corpuscular volume;	chr16:81011623	chr16:81016792~81035759:-
LGG	cis	rs657075	0.697	rs13184379	ENSG00000263597.1	MIR3936	-9.39	2.5e-19	1.52e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132342452	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs4646204	ENSG00000263597.1	MIR3936	-9.39	2.51e-19	1.52e-16	-0.67	-0.4	Rheumatoid arthritis;	chr5:132344302	chr5:132365490~132365599:-
LGG	cis	rs853679	0.556	rs13200214	ENSG00000216901.1	AL022393.7	9.39	2.51e-19	1.52e-16	0.87	0.4	Depression;	chr6:28049472	chr6:28176188~28176674:+
LGG	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	9.39	2.52e-19	1.53e-16	0.47	0.4	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
LGG	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	9.39	2.53e-19	1.54e-16	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
LGG	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-9.39	2.54e-19	1.54e-16	-0.47	-0.4	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-9.39	2.54e-19	1.54e-16	-0.47	-0.4	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-9.39	2.54e-19	1.54e-16	-0.47	-0.4	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-9.39	2.54e-19	1.54e-16	-0.47	-0.4	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-9.39	2.54e-19	1.54e-16	-0.47	-0.4	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-9.39	2.54e-19	1.54e-16	-0.47	-0.4	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-9.39	2.54e-19	1.54e-16	-0.47	-0.4	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
LGG	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-9.39	2.55e-19	1.54e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
LGG	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-9.39	2.55e-19	1.54e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
LGG	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-9.39	2.56e-19	1.55e-16	-0.5	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
LGG	cis	rs9388451	0.772	rs1268064	ENSG00000237742.5	RP11-624M8.1	9.39	2.56e-19	1.55e-16	0.35	0.4	Brugada syndrome;	chr6:125721432	chr6:125578558~125749190:-
LGG	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-9.39	2.57e-19	1.56e-16	-0.46	-0.4	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
LGG	cis	rs6921919	0.609	rs9461455	ENSG00000280107.1	AL022393.9	-9.39	2.57e-19	1.56e-16	-0.4	-0.4	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28170845~28172521:+
LGG	cis	rs9532669	0.89	rs7333274	ENSG00000168852.11	TPTE2P5	9.39	2.57e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40862531	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4270044	ENSG00000168852.11	TPTE2P5	9.39	2.58e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40877923	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs11147824	ENSG00000168852.11	TPTE2P5	9.39	2.58e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40878183	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs9525417	ENSG00000168852.11	TPTE2P5	9.39	2.58e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40878431	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs9532638	ENSG00000168852.11	TPTE2P5	9.39	2.58e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40878471	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7997536	ENSG00000168852.11	TPTE2P5	9.39	2.58e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40878685	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7997560	ENSG00000168852.11	TPTE2P5	9.39	2.58e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40878723	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4600337	ENSG00000168852.11	TPTE2P5	9.39	2.58e-19	1.56e-16	0.4	0.4	Cervical cancer;	chr13:40879564	chr13:40822296~40921749:-
LGG	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-9.39	2.59e-19	1.57e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
LGG	cis	rs9532669	0.926	rs7982346	ENSG00000168852.11	TPTE2P5	9.39	2.62e-19	1.59e-16	0.4	0.4	Cervical cancer;	chr13:40873273	chr13:40822296~40921749:-
LGG	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-9.39	2.62e-19	1.59e-16	-0.48	-0.4	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
LGG	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-9.39	2.62e-19	1.59e-16	-0.34	-0.4	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
LGG	cis	rs12935418	0.672	rs12446304	ENSG00000260213.4	RP11-303E16.3	-9.38	2.64e-19	1.6e-16	-0.51	-0.4	Mean corpuscular volume;	chr16:81012730	chr16:81016792~81035759:-
LGG	cis	rs9876781	1	rs9815103	ENSG00000244380.1	RP11-24C3.2	9.38	2.65e-19	1.6e-16	0.49	0.4	Longevity;	chr3:48372725	chr3:48440352~48446656:-
LGG	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-9.38	2.65e-19	1.6e-16	-0.29	-0.4	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
LGG	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	9.38	2.65e-19	1.6e-16	0.5	0.4	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
LGG	cis	rs7829975	0.564	rs2921060	ENSG00000253981.4	ALG1L13P	9.38	2.65e-19	1.61e-16	0.4	0.4	Mood instability;	chr8:8460307	chr8:8236003~8244667:-
LGG	cis	rs9322193	0.923	rs35830138	ENSG00000216621.7	RP11-244K5.6	9.38	2.67e-19	1.62e-16	0.47	0.4	Lung cancer;	chr6:149668635	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	9.38	2.67e-19	1.62e-16	0.47	0.4	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
LGG	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-9.38	2.68e-19	1.62e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
LGG	cis	rs9532669	0.89	rs9315791	ENSG00000168852.11	TPTE2P5	9.38	2.69e-19	1.63e-16	0.4	0.4	Cervical cancer;	chr13:40863931	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.824	rs9315792	ENSG00000168852.11	TPTE2P5	9.38	2.69e-19	1.63e-16	0.4	0.4	Cervical cancer;	chr13:40863951	chr13:40822296~40921749:-
LGG	cis	rs227275	0.526	rs223497	ENSG00000230069.3	LRRC37A15P	-9.38	2.69e-19	1.63e-16	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102727274~102730721:-
LGG	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-9.38	2.72e-19	1.64e-16	-0.55	-0.4	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-9.38	2.72e-19	1.64e-16	-0.55	-0.4	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-9.38	2.72e-19	1.64e-16	-0.55	-0.4	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-9.38	2.72e-19	1.64e-16	-0.55	-0.4	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-9.38	2.72e-19	1.64e-16	-0.55	-0.4	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
LGG	cis	rs571497	0.697	rs657855	ENSG00000268297.1	CLEC4GP1	9.38	2.72e-19	1.64e-16	0.54	0.4	Monocyte count;	chr19:7768522	chr19:7787549~7790621:+
LGG	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	9.38	2.72e-19	1.65e-16	0.48	0.4	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
LGG	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	9.38	2.74e-19	1.66e-16	0.52	0.4	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
LGG	cis	rs11051970	0.559	rs4931012	ENSG00000274964.1	RP11-817I4.1	-9.38	2.75e-19	1.66e-16	-0.42	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32328970	chr12:32339368~32340724:+
LGG	cis	rs2797160	0.651	rs1268066	ENSG00000237742.5	RP11-624M8.1	9.38	2.75e-19	1.66e-16	0.36	0.4	Endometrial cancer;	chr6:125713895	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.651	rs1343121	ENSG00000237742.5	RP11-624M8.1	9.38	2.75e-19	1.66e-16	0.36	0.4	Endometrial cancer;	chr6:125715038	chr6:125578558~125749190:-
LGG	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	9.38	2.75e-19	1.67e-16	0.49	0.4	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
LGG	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-9.38	2.76e-19	1.67e-16	-0.4	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-9.38	2.76e-19	1.67e-16	-0.4	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-9.38	2.76e-19	1.67e-16	-0.4	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
LGG	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-9.38	2.77e-19	1.68e-16	-0.37	-0.4	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
LGG	cis	rs9527	0.521	rs12259163	ENSG00000272912.1	RP11-724N1.1	-9.38	2.78e-19	1.68e-16	-0.46	-0.4	Arsenic metabolism;	chr10:103201720	chr10:102914585~102915404:+
LGG	cis	rs4683346	0.636	rs4682867	ENSG00000273328.4	RP11-141M3.6	-9.38	2.81e-19	1.7e-16	-0.46	-0.4	Granulocyte percentage of myeloid white cells;	chr3:42863973	chr3:42809414~42908105:+
LGG	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	9.38	2.82e-19	1.7e-16	0.56	0.4	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
LGG	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-9.38	2.82e-19	1.7e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
LGG	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-9.38	2.82e-19	1.71e-16	-0.38	-0.4	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-9.38	2.82e-19	1.71e-16	-0.38	-0.4	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-9.38	2.82e-19	1.71e-16	-0.38	-0.4	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
LGG	cis	rs4713118	0.699	rs200978	ENSG00000226314.6	ZNF192P1	9.38	2.84e-19	1.72e-16	0.46	0.4	Parkinson's disease;	chr6:27885390	chr6:28161781~28169594:+
LGG	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-9.37	2.85e-19	1.72e-16	-0.35	-0.4	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
LGG	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-9.37	2.85e-19	1.72e-16	-0.35	-0.4	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
LGG	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-9.37	2.86e-19	1.72e-16	-0.4	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
LGG	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	9.37	2.93e-19	1.77e-16	0.47	0.4	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
LGG	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	9.37	2.94e-19	1.78e-16	0.67	0.4	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
LGG	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	9.37	2.94e-19	1.78e-16	0.67	0.4	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
LGG	cis	rs9532669	0.963	rs1056835	ENSG00000168852.11	TPTE2P5	9.37	2.95e-19	1.78e-16	0.41	0.4	Cervical cancer;	chr13:40932585	chr13:40822296~40921749:-
LGG	cis	rs17772222	0.958	rs12436326	ENSG00000222990.1	RNU4-22P	9.37	2.96e-19	1.78e-16	0.52	0.4	Coronary artery calcification;	chr14:88533632	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.958	rs17203789	ENSG00000222990.1	RNU4-22P	9.37	2.96e-19	1.78e-16	0.52	0.4	Coronary artery calcification;	chr14:88541362	chr14:88513498~88513663:+
LGG	cis	rs1420956	0.875	rs1008854	ENSG00000264151.4	RP11-739N10.1	9.37	2.96e-19	1.79e-16	0.5	0.4	Obesity-related traits;	chr18:27582236	chr18:27336379~27595164:-
LGG	cis	rs1707322	0.721	rs7520123	ENSG00000281133.1	AL355480.3	-9.37	2.96e-19	1.79e-16	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45580892~45580996:-
LGG	cis	rs9810089	0.9	rs11915629	ENSG00000261758.1	RP11-102M11.2	9.37	2.96e-19	1.79e-16	0.43	0.4	Gestational age at birth (child effect);	chr3:136420888	chr3:136752630~136755780:+
LGG	cis	rs1560104	0.709	rs8062074	ENSG00000274834.1	CTD-3037G24.5	-9.37	2.96e-19	1.79e-16	-0.51	-0.4	Obesity-related traits;	chr16:12609691	chr16:12614451~12614852:+
LGG	cis	rs1560104	0.709	rs62027316	ENSG00000274834.1	CTD-3037G24.5	-9.37	2.96e-19	1.79e-16	-0.51	-0.4	Obesity-related traits;	chr16:12609991	chr16:12614451~12614852:+
LGG	cis	rs1560104	0.709	rs35456341	ENSG00000274834.1	CTD-3037G24.5	-9.37	2.96e-19	1.79e-16	-0.51	-0.4	Obesity-related traits;	chr16:12610010	chr16:12614451~12614852:+
LGG	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-9.37	2.98e-19	1.8e-16	-0.47	-0.4	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-9.37	2.98e-19	1.8e-16	-0.47	-0.4	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
LGG	cis	rs228614	0.51	rs223438	ENSG00000230069.3	LRRC37A15P	9.37	2.99e-19	1.8e-16	0.38	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102727274~102730721:-
LGG	cis	rs1707322	0.721	rs56255771	ENSG00000281133.1	AL355480.3	-9.37	3e-19	1.81e-16	-0.48	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45580892~45580996:-
LGG	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-9.37	3.02e-19	1.82e-16	-0.73	-0.4	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
LGG	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-9.37	3.02e-19	1.82e-16	-0.73	-0.4	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
LGG	cis	rs4713118	0.699	rs573179	ENSG00000226314.6	ZNF192P1	9.37	3.04e-19	1.83e-16	0.46	0.4	Parkinson's disease;	chr6:27881898	chr6:28161781~28169594:+
LGG	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-9.37	3.04e-19	1.83e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
LGG	cis	rs7267979	0.745	rs6132845	ENSG00000276952.1	RP5-965G21.6	9.37	3.05e-19	1.84e-16	0.39	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25284915~25285588:-
LGG	cis	rs11098499	0.739	rs6534130	ENSG00000249244.1	RP11-548H18.2	-9.37	3.05e-19	1.84e-16	-0.42	-0.4	Corneal astigmatism;	chr4:119210184	chr4:119391831~119395335:-
LGG	cis	rs9532669	0.926	rs12871420	ENSG00000168852.11	TPTE2P5	9.37	3.05e-19	1.84e-16	0.4	0.4	Cervical cancer;	chr13:40880034	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs12871735	ENSG00000168852.11	TPTE2P5	9.37	3.05e-19	1.84e-16	0.4	0.4	Cervical cancer;	chr13:40880169	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs12871895	ENSG00000168852.11	TPTE2P5	9.37	3.05e-19	1.84e-16	0.4	0.4	Cervical cancer;	chr13:40880189	chr13:40822296~40921749:-
LGG	cis	rs7914558	0.902	rs3736922	ENSG00000272912.1	RP11-724N1.1	9.37	3.06e-19	1.84e-16	0.44	0.4	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102914585~102915404:+
LGG	cis	rs12935418	0.672	rs9923948	ENSG00000260213.4	RP11-303E16.3	-9.37	3.06e-19	1.84e-16	-0.51	-0.4	Mean corpuscular volume;	chr16:81013814	chr16:81016792~81035759:-
LGG	cis	rs9532669	0.963	rs4343141	ENSG00000168852.11	TPTE2P5	9.37	3.07e-19	1.85e-16	0.4	0.4	Cervical cancer;	chr13:40940497	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.963	rs3887418	ENSG00000168852.11	TPTE2P5	9.37	3.07e-19	1.85e-16	0.4	0.4	Cervical cancer;	chr13:40940560	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs1056820	ENSG00000168852.11	TPTE2P5	9.37	3.07e-19	1.85e-16	0.4	0.4	Cervical cancer;	chr13:40941150	chr13:40822296~40921749:-
LGG	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	9.36	3.08e-19	1.86e-16	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
LGG	cis	rs4713118	0.868	rs10484401	ENSG00000216901.1	AL022393.7	-9.36	3.08e-19	1.86e-16	-0.55	-0.4	Parkinson's disease;	chr6:27778811	chr6:28176188~28176674:+
LGG	cis	rs1707322	0.691	rs12031182	ENSG00000281133.1	AL355480.3	-9.36	3.09e-19	1.86e-16	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs10430123	ENSG00000281133.1	AL355480.3	-9.36	3.09e-19	1.86e-16	-0.47	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45580892~45580996:-
LGG	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-9.36	3.1e-19	1.87e-16	-0.5	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
LGG	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	9.36	3.11e-19	1.87e-16	0.5	0.4	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
LGG	cis	rs2283792	0.846	rs240051	ENSG00000228050.1	TOP3BP1	9.36	3.12e-19	1.88e-16	0.46	0.4	Multiple sclerosis;	chr22:21909763	chr22:22223187~22224566:-
LGG	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	9.36	3.12e-19	1.88e-16	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
LGG	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-9.36	3.13e-19	1.89e-16	-0.54	-0.4	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
LGG	cis	rs6452524	0.869	rs10051155	ENSG00000248112.1	RP11-78C3.1	9.36	3.14e-19	1.89e-16	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:82919376~82921119:-
LGG	cis	rs6452524	0.935	rs10043698	ENSG00000248112.1	RP11-78C3.1	9.36	3.14e-19	1.89e-16	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:82919376~82921119:-
LGG	cis	rs227275	0.525	rs6533052	ENSG00000230069.3	LRRC37A15P	-9.36	3.15e-19	1.9e-16	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs3974485	ENSG00000230069.3	LRRC37A15P	-9.36	3.15e-19	1.9e-16	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs7688940	ENSG00000230069.3	LRRC37A15P	-9.36	3.15e-19	1.9e-16	-0.38	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102727274~102730721:-
LGG	cis	rs2325036	0.783	rs60732670	ENSG00000239519.1	CADM2-AS1	9.36	3.15e-19	1.9e-16	0.45	0.4	Waist circumference;	chr3:85827090	chr3:85992183~86028007:-
LGG	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	9.36	3.16e-19	1.9e-16	0.42	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
LGG	cis	rs7267979	0.816	rs6076358	ENSG00000276952.1	RP5-965G21.6	-9.36	3.16e-19	1.9e-16	-0.39	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25284915~25285588:-
LGG	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	9.36	3.16e-19	1.9e-16	0.67	0.4	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
LGG	cis	rs9322193	0.923	rs2185352	ENSG00000216621.7	RP11-244K5.6	9.36	3.18e-19	1.91e-16	0.47	0.39	Lung cancer;	chr6:149714640	chr6:149934527~149936782:+
LGG	cis	rs9532669	0.963	rs1571116	ENSG00000168852.11	TPTE2P5	9.36	3.19e-19	1.92e-16	0.4	0.39	Cervical cancer;	chr13:40929765	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.963	rs9532673	ENSG00000168852.11	TPTE2P5	9.36	3.19e-19	1.92e-16	0.4	0.39	Cervical cancer;	chr13:40930412	chr13:40822296~40921749:-
LGG	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-9.36	3.22e-19	1.93e-16	-0.55	-0.39	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-9.36	3.22e-19	1.93e-16	-0.55	-0.39	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
LGG	cis	rs12935418	0.616	rs13332890	ENSG00000260213.4	RP11-303E16.3	-9.36	3.24e-19	1.95e-16	-0.49	-0.39	Mean corpuscular volume;	chr16:80971836	chr16:81016792~81035759:-
LGG	cis	rs5742933	0.948	rs2264018	ENSG00000253559.1	OSGEPL1-AS1	-9.36	3.26e-19	1.96e-16	-0.51	-0.39	Ferritin levels;	chr2:189712052	chr2:189762704~189765556:+
LGG	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-9.36	3.27e-19	1.97e-16	-0.48	-0.39	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
LGG	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-9.36	3.3e-19	1.98e-16	-0.45	-0.39	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
LGG	cis	rs13201294	1	rs13201294	ENSG00000216901.1	AL022393.7	9.36	3.31e-19	1.99e-16	0.77	0.39	Squamous cell lung carcinoma;	chr6:27588362	chr6:28176188~28176674:+
LGG	cis	rs950776	0.714	rs615470	ENSG00000261762.1	RP11-650L12.2	-9.36	3.31e-19	1.99e-16	-0.5	-0.39	Sudden cardiac arrest;	chr15:78593646	chr15:78589123~78591276:-
LGG	cis	rs11051970	0.559	rs11051939	ENSG00000274964.1	RP11-817I4.1	9.36	3.32e-19	2e-16	0.42	0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330107	chr12:32339368~32340724:+
LGG	cis	rs9532669	0.926	rs2324737	ENSG00000168852.11	TPTE2P5	9.35	3.34e-19	2.01e-16	0.4	0.39	Cervical cancer;	chr13:40862808	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs35396630	ENSG00000168852.11	TPTE2P5	9.35	3.34e-19	2.01e-16	0.4	0.39	Cervical cancer;	chr13:40863135	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4942001	ENSG00000168852.11	TPTE2P5	9.35	3.34e-19	2.01e-16	0.4	0.39	Cervical cancer;	chr13:40863176	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4942003	ENSG00000168852.11	TPTE2P5	9.35	3.34e-19	2.01e-16	0.4	0.39	Cervical cancer;	chr13:40863270	chr13:40822296~40921749:-
LGG	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	9.35	3.34e-19	2.01e-16	0.6	0.39	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
LGG	cis	rs17345786	0.911	rs10936707	ENSG00000256628.3	ZBTB11-AS1	9.35	3.35e-19	2.01e-16	0.5	0.39	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101676475~101679217:+
LGG	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-9.35	3.35e-19	2.01e-16	-0.39	-0.39	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
LGG	cis	rs6921919	0.551	rs13201753	ENSG00000218016.2	ZNF192P2	-9.35	3.35e-19	2.01e-16	-0.48	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28188050~28189432:+
LGG	cis	rs853679	0.607	rs67340775	ENSG00000216901.1	AL022393.7	9.35	3.36e-19	2.02e-16	0.88	0.39	Depression;	chr6:28336607	chr6:28176188~28176674:+
LGG	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-9.35	3.36e-19	2.02e-16	-0.48	-0.39	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
LGG	cis	rs5742933	0.557	rs6756571	ENSG00000273240.1	RP11-455J20.3	9.35	3.36e-19	2.02e-16	0.49	0.39	Ferritin levels;	chr2:189640971	chr2:189763859~189764456:-
LGG	cis	rs9876781	1	rs9849509	ENSG00000244380.1	RP11-24C3.2	9.35	3.37e-19	2.02e-16	0.48	0.39	Longevity;	chr3:48442021	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs60512868	ENSG00000244380.1	RP11-24C3.2	9.35	3.37e-19	2.02e-16	0.48	0.39	Longevity;	chr3:48442035	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs7636044	ENSG00000244380.1	RP11-24C3.2	9.35	3.37e-19	2.02e-16	0.48	0.39	Longevity;	chr3:48443151	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs4490383	ENSG00000244380.1	RP11-24C3.2	9.35	3.37e-19	2.02e-16	0.48	0.39	Longevity;	chr3:48443275	chr3:48440352~48446656:-
LGG	cis	rs9810089	0.843	rs834304	ENSG00000261758.1	RP11-102M11.2	9.35	3.37e-19	2.02e-16	0.42	0.39	Gestational age at birth (child effect);	chr3:136392816	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.843	rs11717954	ENSG00000261758.1	RP11-102M11.2	9.35	3.37e-19	2.02e-16	0.42	0.39	Gestational age at birth (child effect);	chr3:136393267	chr3:136752630~136755780:+
LGG	cis	rs9532669	0.963	rs4941391	ENSG00000168852.11	TPTE2P5	9.35	3.37e-19	2.03e-16	0.4	0.39	Cervical cancer;	chr13:40939787	chr13:40822296~40921749:-
LGG	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-9.35	3.37e-19	2.03e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
LGG	cis	rs9532669	0.926	rs9532647	ENSG00000168852.11	TPTE2P5	9.35	3.38e-19	2.03e-16	0.4	0.39	Cervical cancer;	chr13:40881799	chr13:40822296~40921749:-
LGG	cis	rs9322193	0.923	rs35961297	ENSG00000216621.7	RP11-244K5.6	9.35	3.39e-19	2.04e-16	0.47	0.39	Lung cancer;	chr6:149667929	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs62439842	ENSG00000216621.7	RP11-244K5.6	9.35	3.39e-19	2.04e-16	0.47	0.39	Lung cancer;	chr6:149675847	chr6:149934527~149936782:+
LGG	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-9.35	3.4e-19	2.04e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
LGG	cis	rs9532669	0.926	rs9532678	ENSG00000168852.11	TPTE2P5	9.35	3.42e-19	2.05e-16	0.4	0.39	Cervical cancer;	chr13:40941862	chr13:40822296~40921749:-
LGG	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	9.35	3.43e-19	2.06e-16	0.5	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
LGG	cis	rs227275	0.525	rs7685399	ENSG00000230069.3	LRRC37A15P	-9.35	3.44e-19	2.06e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs1383733	ENSG00000230069.3	LRRC37A15P	-9.35	3.44e-19	2.06e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs2866417	ENSG00000230069.3	LRRC37A15P	-9.35	3.44e-19	2.06e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102727274~102730721:-
LGG	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-9.35	3.44e-19	2.06e-16	-0.51	-0.39	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
LGG	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	9.35	3.44e-19	2.07e-16	0.61	0.39	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	9.35	3.44e-19	2.07e-16	0.61	0.39	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
LGG	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	9.35	3.44e-19	2.07e-16	0.61	0.39	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
LGG	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-9.35	3.45e-19	2.07e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
LGG	cis	rs853679	0.607	rs71559070	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28071151	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs35902873	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28091171	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13197574	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28092461	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34166054	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28098023	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34662244	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28106103	chr6:28176188~28176674:+
LGG	cis	rs35952432	1	rs35952432	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Lung cancer;	chr6:28107123	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13203816	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28111820	chr6:28176188~28176674:+
LGG	cis	rs853679	0.556	rs34588114	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28112850	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs34371502	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28113980	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs66886492	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28121953	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs35345226	ENSG00000216901.1	AL022393.7	9.35	3.47e-19	2.08e-16	0.87	0.39	Depression;	chr6:28123802	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs35967444	ENSG00000216621.7	RP11-244K5.6	9.35	3.47e-19	2.08e-16	0.47	0.39	Lung cancer;	chr6:149675588	chr6:149934527~149936782:+
LGG	cis	rs2325036	0.783	rs10865612	ENSG00000239519.1	CADM2-AS1	9.35	3.48e-19	2.09e-16	0.45	0.39	Waist circumference;	chr3:85819379	chr3:85992183~86028007:-
LGG	cis	rs9322193	0.923	rs11155670	ENSG00000216621.7	RP11-244K5.6	9.35	3.48e-19	2.09e-16	0.48	0.39	Lung cancer;	chr6:149644992	chr6:149934527~149936782:+
LGG	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	9.35	3.5e-19	2.1e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs216439	ENSG00000266490.1	CTD-2349P21.9	9.35	3.5e-19	2.1e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs216442	ENSG00000266490.1	CTD-2349P21.9	9.35	3.5e-19	2.1e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	9.35	3.5e-19	2.1e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	9.35	3.5e-19	2.1e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
LGG	cis	rs858239	0.601	rs10224327	ENSG00000230042.1	AK3P3	-9.35	3.5e-19	2.1e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23129178~23129841:+
LGG	cis	rs9532669	0.89	rs4942004	ENSG00000168852.11	TPTE2P5	9.35	3.5e-19	2.1e-16	0.4	0.39	Cervical cancer;	chr13:40863598	chr13:40822296~40921749:-
LGG	cis	rs2325036	0.783	rs10511068	ENSG00000239519.1	CADM2-AS1	-9.35	3.5e-19	2.1e-16	-0.45	-0.39	Waist circumference;	chr3:85823318	chr3:85992183~86028007:-
LGG	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-9.35	3.51e-19	2.1e-16	-0.5	-0.39	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
LGG	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-9.35	3.52e-19	2.11e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-9.35	3.52e-19	2.11e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-9.35	3.52e-19	2.11e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	9.35	3.52e-19	2.11e-16	0.4	0.39	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
LGG	cis	rs9322193	0.923	rs10782317	ENSG00000216621.7	RP11-244K5.6	-9.35	3.52e-19	2.11e-16	-0.47	-0.39	Lung cancer;	chr6:149753911	chr6:149934527~149936782:+
LGG	cis	rs9532669	0.963	rs9532681	ENSG00000168852.11	TPTE2P5	9.35	3.52e-19	2.11e-16	0.41	0.39	Cervical cancer;	chr13:40951633	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4516083	ENSG00000168852.11	TPTE2P5	9.35	3.52e-19	2.11e-16	0.41	0.39	Cervical cancer;	chr13:40951783	chr13:40822296~40921749:-
LGG	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	9.35	3.52e-19	2.11e-16	0.48	0.39	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	9.35	3.52e-19	2.11e-16	0.48	0.39	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
LGG	cis	rs11051970	0.559	rs12578899	ENSG00000274964.1	RP11-817I4.1	-9.35	3.53e-19	2.11e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32332017	chr12:32339368~32340724:+
LGG	cis	rs7267979	0.753	rs400357	ENSG00000276952.1	RP5-965G21.6	9.35	3.55e-19	2.12e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25284915~25285588:-
LGG	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	9.35	3.55e-19	2.12e-16	0.48	0.39	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
LGG	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-9.35	3.55e-19	2.12e-16	-0.55	-0.39	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
LGG	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	9.35	3.55e-19	2.13e-16	0.61	0.39	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
LGG	cis	rs7085104	0.632	rs7097872	ENSG00000272912.1	RP11-724N1.1	-9.35	3.55e-19	2.13e-16	-0.44	-0.39	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102914585~102915404:+
LGG	cis	rs6921919	0.583	rs1054372	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs9468354	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs7773051	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs12697938	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs13437294	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.609	rs9468357	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs34513104	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs9461456	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.525	rs9468360	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs16894021	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs11751693	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs7749736	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.525	rs9468361	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs7775132	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs3734563	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs1591913	ENSG00000280107.1	AL022393.9	-9.35	3.56e-19	2.13e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28170845~28172521:+
LGG	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-9.35	3.58e-19	2.14e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
LGG	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-9.35	3.58e-19	2.14e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
LGG	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-9.35	3.58e-19	2.14e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
LGG	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-9.35	3.58e-19	2.14e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
LGG	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-9.34	3.61e-19	2.16e-16	-0.54	-0.39	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-9.34	3.61e-19	2.16e-16	-0.54	-0.39	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
LGG	cis	rs9876781	1	rs6442118	ENSG00000244380.1	RP11-24C3.2	9.34	3.62e-19	2.16e-16	0.49	0.39	Longevity;	chr3:48398582	chr3:48440352~48446656:-
LGG	cis	rs17345786	1	rs58907984	ENSG00000256628.3	ZBTB11-AS1	9.34	3.63e-19	2.17e-16	0.5	0.39	Colonoscopy-negative controls vs population controls;	chr3:101586326	chr3:101676475~101679217:+
LGG	cis	rs17345786	1	rs17345786	ENSG00000256628.3	ZBTB11-AS1	-9.34	3.63e-19	2.17e-16	-0.5	-0.39	Colonoscopy-negative controls vs population controls;	chr3:101599474	chr3:101676475~101679217:+
LGG	cis	rs17345786	0.954	rs17508319	ENSG00000256628.3	ZBTB11-AS1	9.34	3.63e-19	2.17e-16	0.5	0.39	Colonoscopy-negative controls vs population controls;	chr3:101600059	chr3:101676475~101679217:+
LGG	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-9.34	3.63e-19	2.17e-16	-0.38	-0.39	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
LGG	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-9.34	3.67e-19	2.19e-16	-0.45	-0.39	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
LGG	cis	rs227275	0.554	rs6810668	ENSG00000230069.3	LRRC37A15P	-9.34	3.68e-19	2.2e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102727274~102730721:-
LGG	cis	rs10803016	0.564	rs2053191	ENSG00000272865.1	RP11-561I11.4	9.34	3.68e-19	2.2e-16	0.47	0.39	Coronary artery calcification;	chr1:242107071	chr1:242147514~242209129:+
LGG	cis	rs9322193	0.923	rs7767622	ENSG00000216621.7	RP11-244K5.6	9.34	3.68e-19	2.2e-16	0.47	0.39	Lung cancer;	chr6:149681766	chr6:149934527~149936782:+
LGG	cis	rs950027	0.967	rs3120975	ENSG00000259433.2	CTD-2651B20.4	-9.34	3.69e-19	2.21e-16	-0.42	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45452927	chr15:45330209~45332634:-
LGG	cis	rs853679	0.607	rs35030260	ENSG00000216901.1	AL022393.7	9.34	3.69e-19	2.21e-16	0.87	0.39	Depression;	chr6:28337731	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13217619	ENSG00000216901.1	AL022393.7	9.34	3.69e-19	2.21e-16	0.87	0.39	Depression;	chr6:28338894	chr6:28176188~28176674:+
LGG	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-9.34	3.71e-19	2.22e-16	-0.5	-0.39	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	9.34	3.74e-19	2.23e-16	0.54	0.39	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
LGG	cis	rs4950322	0.57	rs11800580	ENSG00000278811.3	LINC00624	-9.34	3.74e-19	2.24e-16	-0.39	-0.39	Protein quantitative trait loci;	chr1:147261053	chr1:147258885~147517875:-
LGG	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	9.34	3.76e-19	2.24e-16	0.46	0.39	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
LGG	cis	rs2739330	0.892	rs4822455	ENSG00000235689.1	AP000351.13	9.34	3.77e-19	2.25e-16	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:24006305~24008258:-
LGG	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-9.34	3.77e-19	2.25e-16	-0.39	-0.39	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
LGG	cis	rs9532669	0.89	rs2324738	ENSG00000168852.11	TPTE2P5	9.34	3.78e-19	2.25e-16	0.4	0.39	Cervical cancer;	chr13:40925242	chr13:40822296~40921749:-
LGG	cis	rs17345786	1	rs3762729	ENSG00000256628.3	ZBTB11-AS1	9.34	3.78e-19	2.26e-16	0.5	0.39	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101676475~101679217:+
LGG	cis	rs17345786	1	rs73863360	ENSG00000256628.3	ZBTB11-AS1	9.34	3.78e-19	2.26e-16	0.5	0.39	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101676475~101679217:+
LGG	cis	rs4950322	0.57	rs72692979	ENSG00000278811.3	LINC00624	9.34	3.79e-19	2.26e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147336094	chr1:147258885~147517875:-
LGG	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.81e-19	2.27e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
LGG	cis	rs9322193	0.923	rs9404048	ENSG00000216621.7	RP11-244K5.6	9.34	3.81e-19	2.28e-16	0.47	0.39	Lung cancer;	chr6:149616188	chr6:149934527~149936782:+
LGG	cis	rs9532669	0.89	rs9525420	ENSG00000168852.11	TPTE2P5	9.34	3.82e-19	2.28e-16	0.4	0.39	Cervical cancer;	chr13:40882628	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7324383	ENSG00000168852.11	TPTE2P5	9.34	3.82e-19	2.28e-16	0.4	0.39	Cervical cancer;	chr13:40882754	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532648	ENSG00000168852.11	TPTE2P5	9.34	3.82e-19	2.28e-16	0.4	0.39	Cervical cancer;	chr13:40882795	chr13:40822296~40921749:-
LGG	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-9.34	3.83e-19	2.28e-16	-0.47	-0.39	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
LGG	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-9.34	3.84e-19	2.29e-16	-0.38	-0.39	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
LGG	cis	rs9322193	0.923	rs12529698	ENSG00000216621.7	RP11-244K5.6	9.34	3.84e-19	2.29e-16	0.48	0.39	Lung cancer;	chr6:149650951	chr6:149934527~149936782:+
LGG	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	9.34	3.85e-19	2.3e-16	0.51	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
LGG	cis	rs2739330	0.731	rs4822450	ENSG00000272787.1	KB-226F1.2	9.34	3.85e-19	2.3e-16	0.42	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23969211~23969873:+
LGG	cis	rs9532669	0.89	rs9532676	ENSG00000168852.11	TPTE2P5	9.34	3.85e-19	2.3e-16	0.4	0.39	Cervical cancer;	chr13:40935626	chr13:40822296~40921749:-
LGG	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	9.34	3.86e-19	2.3e-16	0.52	0.39	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
LGG	cis	rs5742933	1	rs1966729	ENSG00000253559.1	OSGEPL1-AS1	-9.34	3.86e-19	2.31e-16	-0.5	-0.39	Ferritin levels;	chr2:189721105	chr2:189762704~189765556:+
LGG	cis	rs227275	0.556	rs11731885	ENSG00000230069.3	LRRC37A15P	-9.34	3.87e-19	2.31e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102727274~102730721:-
LGG	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-9.34	3.88e-19	2.31e-16	-0.35	-0.39	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
LGG	cis	rs7267979	0.873	rs6132822	ENSG00000276952.1	RP5-965G21.6	9.34	3.88e-19	2.32e-16	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs1555330	ENSG00000276952.1	RP5-965G21.6	9.34	3.88e-19	2.32e-16	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs6107017	ENSG00000276952.1	RP5-965G21.6	9.34	3.88e-19	2.32e-16	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs6132824	ENSG00000276952.1	RP5-965G21.6	9.34	3.88e-19	2.32e-16	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25284915~25285588:-
LGG	cis	rs7829975	0.51	rs332037	ENSG00000173295.6	FAM86B3P	-9.34	3.9e-19	2.32e-16	-0.42	-0.39	Mood instability;	chr8:8865165	chr8:8228595~8244865:+
LGG	cis	rs9876781	1	rs7635522	ENSG00000244380.1	RP11-24C3.2	9.34	3.9e-19	2.33e-16	0.49	0.39	Longevity;	chr3:48382166	chr3:48440352~48446656:-
LGG	cis	rs1560104	0.709	rs3919630	ENSG00000274834.1	CTD-3037G24.5	-9.34	3.91e-19	2.33e-16	-0.5	-0.39	Obesity-related traits;	chr16:12607086	chr16:12614451~12614852:+
LGG	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-9.33	3.93e-19	2.34e-16	-0.44	-0.39	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
LGG	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-9.33	3.93e-19	2.34e-16	-0.44	-0.39	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
LGG	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	9.33	3.94e-19	2.35e-16	0.35	0.39	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
LGG	cis	rs2739330	0.587	rs4820571	ENSG00000272787.1	KB-226F1.2	9.33	3.96e-19	2.36e-16	0.43	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23969211~23969873:+
LGG	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-9.33	4e-19	2.38e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
LGG	cis	rs657075	0.697	rs3805678	ENSG00000263597.1	MIR3936	-9.33	4.03e-19	2.4e-16	-0.67	-0.39	Rheumatoid arthritis;	chr5:132339514	chr5:132365490~132365599:-
LGG	cis	rs853679	0.607	rs13208096	ENSG00000216901.1	AL022393.7	9.33	4.05e-19	2.41e-16	0.87	0.39	Depression;	chr6:28257533	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13207345	ENSG00000216901.1	AL022393.7	9.33	4.05e-19	2.41e-16	0.87	0.39	Depression;	chr6:28297795	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs72854513	ENSG00000216901.1	AL022393.7	9.33	4.05e-19	2.41e-16	0.87	0.39	Depression;	chr6:28298177	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs56189111	ENSG00000216901.1	AL022393.7	9.33	4.05e-19	2.41e-16	0.87	0.39	Depression;	chr6:28304196	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs35072899	ENSG00000216901.1	AL022393.7	9.33	4.05e-19	2.41e-16	0.87	0.39	Depression;	chr6:28313764	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs56075693	ENSG00000216901.1	AL022393.7	9.33	4.05e-19	2.41e-16	0.87	0.39	Depression;	chr6:28322551	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34218844	ENSG00000216901.1	AL022393.7	9.33	4.05e-19	2.41e-16	0.87	0.39	Depression;	chr6:28322870	chr6:28176188~28176674:+
LGG	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-9.33	4.05e-19	2.41e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.662	rs4713120	ENSG00000199851.2	U3	9.33	4.06e-19	2.42e-16	0.53	0.39	Parkinson's disease;	chr6:27754056	chr6:28015568~28015777:+
LGG	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	9.33	4.06e-19	2.42e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.51	rs216402	ENSG00000266490.1	CTD-2349P21.9	9.33	4.06e-19	2.42e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	9.33	4.06e-19	2.42e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
LGG	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	9.33	4.07e-19	2.42e-16	0.4	0.39	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
LGG	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-9.33	4.08e-19	2.43e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
LGG	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-9.33	4.09e-19	2.43e-16	-0.47	-0.39	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-9.33	4.09e-19	2.43e-16	-0.47	-0.39	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-9.33	4.09e-19	2.43e-16	-0.47	-0.39	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
LGG	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-9.33	4.1e-19	2.44e-16	-0.54	-0.39	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
LGG	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-9.33	4.12e-19	2.45e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
LGG	cis	rs17345786	1	rs997739	ENSG00000256628.3	ZBTB11-AS1	9.33	4.12e-19	2.45e-16	0.5	0.39	Colonoscopy-negative controls vs population controls;	chr3:101595096	chr3:101676475~101679217:+
LGG	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	9.33	4.12e-19	2.45e-16	0.47	0.39	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
LGG	cis	rs11098499	0.739	rs4833612	ENSG00000249244.1	RP11-548H18.2	-9.33	4.13e-19	2.46e-16	-0.42	-0.39	Corneal astigmatism;	chr4:119226441	chr4:119391831~119395335:-
LGG	cis	rs11098499	0.739	rs10013032	ENSG00000249244.1	RP11-548H18.2	-9.33	4.13e-19	2.46e-16	-0.42	-0.39	Corneal astigmatism;	chr4:119228264	chr4:119391831~119395335:-
LGG	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-9.33	4.15e-19	2.47e-16	-0.72	-0.39	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
LGG	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-9.33	4.15e-19	2.47e-16	-0.33	-0.39	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
LGG	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-9.33	4.16e-19	2.47e-16	-0.5	-0.39	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
LGG	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-9.33	4.16e-19	2.47e-16	-0.5	-0.39	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
LGG	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-9.33	4.16e-19	2.47e-16	-0.5	-0.39	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
LGG	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-9.33	4.17e-19	2.48e-16	-0.47	-0.39	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-9.33	4.17e-19	2.48e-16	-0.47	-0.39	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
LGG	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-9.33	4.17e-19	2.48e-16	-0.47	-0.39	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
LGG	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	9.33	4.18e-19	2.49e-16	0.56	0.39	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
LGG	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-9.33	4.2e-19	2.49e-16	-0.49	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
LGG	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	9.33	4.2e-19	2.5e-16	0.48	0.39	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
LGG	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	9.33	4.2e-19	2.5e-16	0.46	0.39	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
LGG	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-9.33	4.21e-19	2.5e-16	-0.52	-0.39	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
LGG	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-9.32	4.26e-19	2.53e-16	-0.45	-0.39	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
LGG	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-9.32	4.26e-19	2.53e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
LGG	cis	rs7267979	0.549	rs11698185	ENSG00000276952.1	RP5-965G21.6	9.32	4.3e-19	2.55e-16	0.4	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:25284915~25285588:-
LGG	cis	rs1707322	0.752	rs11211146	ENSG00000281133.1	AL355480.3	-9.32	4.3e-19	2.56e-16	-0.48	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs11211147	ENSG00000281133.1	AL355480.3	-9.32	4.3e-19	2.56e-16	-0.48	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45580892~45580996:-
LGG	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-9.32	4.31e-19	2.56e-16	-0.44	-0.39	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
LGG	cis	rs6921919	0.551	rs13201753	ENSG00000280107.1	AL022393.9	-9.32	4.33e-19	2.57e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28170845~28172521:+
LGG	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-9.32	4.35e-19	2.58e-16	-0.38	-0.39	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
LGG	cis	rs1275468	0.678	rs2620687	ENSG00000257497.2	RP11-585P4.5	-9.32	4.36e-19	2.59e-16	-0.56	-0.39	Polycystic ovary syndrome;	chr12:75560395	chr12:75483454~75489820:-
LGG	cis	rs4713118	0.539	rs200988	ENSG00000226314.6	ZNF192P1	9.32	4.37e-19	2.59e-16	0.41	0.39	Parkinson's disease;	chr6:27851575	chr6:28161781~28169594:+
LGG	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-9.32	4.37e-19	2.59e-16	-0.45	-0.39	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
LGG	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-9.32	4.37e-19	2.59e-16	-0.45	-0.39	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
LGG	cis	rs17772222	1	rs56987357	ENSG00000222990.1	RNU4-22P	9.32	4.39e-19	2.61e-16	0.5	0.39	Coronary artery calcification;	chr14:88358019	chr14:88513498~88513663:+
LGG	cis	rs9532669	0.926	rs9532643	ENSG00000168852.11	TPTE2P5	9.32	4.39e-19	2.61e-16	0.39	0.39	Cervical cancer;	chr13:40880800	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.963	rs9532644	ENSG00000168852.11	TPTE2P5	9.32	4.39e-19	2.61e-16	0.39	0.39	Cervical cancer;	chr13:40880860	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532645	ENSG00000168852.11	TPTE2P5	9.32	4.39e-19	2.61e-16	0.39	0.39	Cervical cancer;	chr13:40880898	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9532646	ENSG00000168852.11	TPTE2P5	9.32	4.39e-19	2.61e-16	0.39	0.39	Cervical cancer;	chr13:40880989	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9525419	ENSG00000168852.11	TPTE2P5	9.32	4.39e-19	2.61e-16	0.39	0.39	Cervical cancer;	chr13:40881047	chr13:40822296~40921749:-
LGG	cis	rs11051970	0.513	rs7972023	ENSG00000274964.1	RP11-817I4.1	-9.32	4.4e-19	2.61e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32312174	chr12:32339368~32340724:+
LGG	cis	rs2282300	0.637	rs7941828	ENSG00000254532.1	RP11-624D11.2	9.32	4.41e-19	2.62e-16	0.48	0.39	Morning vs. evening chronotype;	chr11:30408784	chr11:30044058~30084343:-
LGG	cis	rs498872	0.507	rs10892247	ENSG00000255239.1	AP002954.6	-9.32	4.41e-19	2.62e-16	-0.54	-0.39	Glioma;	chr11:118619361	chr11:118688039~118690600:-
LGG	cis	rs1707322	0.721	rs6697821	ENSG00000281133.1	AL355480.3	-9.32	4.43e-19	2.63e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45580892~45580996:-
LGG	cis	rs1420956	0.967	rs1030095	ENSG00000264151.4	RP11-739N10.1	9.32	4.44e-19	2.64e-16	0.49	0.39	Obesity-related traits;	chr18:27579226	chr18:27336379~27595164:-
LGG	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	9.32	4.45e-19	2.64e-16	0.6	0.39	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
LGG	cis	rs227275	0.554	rs223367	ENSG00000230069.3	LRRC37A15P	-9.32	4.46e-19	2.65e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102727274~102730721:-
LGG	cis	rs9532669	0.926	rs12872288	ENSG00000168852.11	TPTE2P5	9.32	4.47e-19	2.65e-16	0.39	0.39	Cervical cancer;	chr13:40880268	chr13:40822296~40921749:-
LGG	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-9.32	4.48e-19	2.66e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
LGG	cis	rs1153858	0.668	rs63603561	ENSG00000259433.2	CTD-2651B20.4	9.32	4.48e-19	2.66e-16	0.47	0.39	Homoarginine levels;	chr15:45301125	chr15:45330209~45332634:-
LGG	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-9.32	4.49e-19	2.66e-16	-0.36	-0.39	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
LGG	cis	rs9876781	1	rs9817615	ENSG00000244380.1	RP11-24C3.2	9.32	4.51e-19	2.68e-16	0.48	0.39	Longevity;	chr3:48429347	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs2290822	ENSG00000244380.1	RP11-24C3.2	9.32	4.51e-19	2.68e-16	0.48	0.39	Longevity;	chr3:48431794	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs13076076	ENSG00000244380.1	RP11-24C3.2	9.32	4.51e-19	2.68e-16	0.48	0.39	Longevity;	chr3:48437629	chr3:48440352~48446656:-
LGG	cis	rs1707322	0.691	rs11211174	ENSG00000281133.1	AL355480.3	-9.32	4.52e-19	2.68e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45580892~45580996:-
LGG	cis	rs1153858	0.945	rs1974981	ENSG00000259433.2	CTD-2651B20.4	9.32	4.54e-19	2.69e-16	0.47	0.39	Homoarginine levels;	chr15:45436925	chr15:45330209~45332634:-
LGG	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-9.32	4.55e-19	2.7e-16	-0.35	-0.39	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	9.32	4.57e-19	2.71e-16	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
LGG	cis	rs9393777	0.92	rs13207689	ENSG00000199851.2	U3	9.32	4.58e-19	2.71e-16	0.99	0.39	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs13196692	ENSG00000199851.2	U3	9.32	4.58e-19	2.71e-16	0.99	0.39	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs34150729	ENSG00000199851.2	U3	9.32	4.58e-19	2.71e-16	0.99	0.39	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs13191227	ENSG00000199851.2	U3	9.32	4.58e-19	2.71e-16	0.99	0.39	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.955	rs9468203	ENSG00000216901.1	AL022393.7	9.32	4.58e-19	2.71e-16	0.51	0.39	Parkinson's disease;	chr6:27720888	chr6:28176188~28176674:+
LGG	cis	rs9876781	1	rs11130171	ENSG00000244380.1	RP11-24C3.2	9.31	4.6e-19	2.72e-16	0.48	0.39	Longevity;	chr3:48421052	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs9883927	ENSG00000244380.1	RP11-24C3.2	9.31	4.6e-19	2.72e-16	0.48	0.39	Longevity;	chr3:48422302	chr3:48440352~48446656:-
LGG	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-9.31	4.6e-19	2.72e-16	-0.38	-0.39	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
LGG	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	9.31	4.6e-19	2.73e-16	0.39	0.39	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
LGG	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-9.31	4.63e-19	2.74e-16	-0.5	-0.39	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
LGG	cis	rs7674212	0.556	rs34475639	ENSG00000230069.3	LRRC37A15P	-9.31	4.67e-19	2.76e-16	-0.39	-0.39	Type 2 diabetes;	chr4:103033694	chr4:102727274~102730721:-
LGG	cis	rs9532669	0.889	rs6560964	ENSG00000168852.11	TPTE2P5	9.31	4.67e-19	2.77e-16	0.4	0.39	Cervical cancer;	chr13:40871132	chr13:40822296~40921749:-
LGG	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-9.31	4.7e-19	2.78e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
LGG	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-9.31	4.71e-19	2.79e-16	-0.45	-0.39	Depression;	chr6:28096845	chr6:28115628~28116551:+
LGG	cis	rs227275	0.525	rs28445579	ENSG00000230069.3	LRRC37A15P	-9.31	4.72e-19	2.8e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs13150426	ENSG00000230069.3	LRRC37A15P	-9.31	4.73e-19	2.8e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102727274~102730721:-
LGG	cis	rs9532669	0.926	rs9532647	ENSG00000239827.7	SUGT1P3	-9.31	4.74e-19	2.81e-16	-0.41	-0.39	Cervical cancer;	chr13:40881799	chr13:40908159~40921774:-
LGG	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	9.31	4.75e-19	2.81e-16	0.39	0.39	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
LGG	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	9.31	4.76e-19	2.82e-16	0.52	0.39	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
LGG	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-9.31	4.77e-19	2.82e-16	-0.53	-0.39	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
LGG	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-9.31	4.78e-19	2.83e-16	-0.5	-0.39	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
LGG	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-9.31	4.8e-19	2.84e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
LGG	cis	rs9532669	0.926	rs9532640	ENSG00000168852.11	TPTE2P5	9.31	4.82e-19	2.85e-16	0.39	0.39	Cervical cancer;	chr13:40880628	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs9532641	ENSG00000168852.11	TPTE2P5	9.31	4.82e-19	2.85e-16	0.39	0.39	Cervical cancer;	chr13:40880648	chr13:40822296~40921749:-
LGG	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	9.31	4.82e-19	2.86e-16	0.63	0.39	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	9.31	4.82e-19	2.86e-16	0.63	0.39	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
LGG	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	9.31	4.82e-19	2.86e-16	0.63	0.39	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
LGG	cis	rs7615952	0.605	rs34865555	ENSG00000242001.1	GS1-388B5.1	9.31	4.83e-19	2.86e-16	0.64	0.39	Blood pressure (smoking interaction);	chr3:125585290	chr3:125681305~125681453:+
LGG	cis	rs9875589	0.957	rs66716710	ENSG00000233121.1	VN1R20P	9.31	4.87e-19	2.88e-16	0.39	0.39	Ovarian reserve;	chr3:13897231	chr3:13926813~13927778:+
LGG	cis	rs2325036	0.715	rs3911063	ENSG00000239519.1	CADM2-AS1	9.31	4.87e-19	2.88e-16	0.47	0.39	Waist circumference;	chr3:85857778	chr3:85992183~86028007:-
LGG	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	9.31	4.88e-19	2.89e-16	0.39	0.39	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
LGG	cis	rs11051970	0.559	rs4931621	ENSG00000274964.1	RP11-817I4.1	-9.31	4.9e-19	2.9e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32333569	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs3816819	ENSG00000274964.1	RP11-817I4.1	-9.31	4.9e-19	2.9e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32334123	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs2291421	ENSG00000274964.1	RP11-817I4.1	-9.31	4.9e-19	2.9e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32334173	chr12:32339368~32340724:+
LGG	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-9.31	4.9e-19	2.9e-16	-0.6	-0.39	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
LGG	cis	rs853679	0.599	rs13193295	ENSG00000199851.2	U3	9.31	4.91e-19	2.9e-16	0.96	0.39	Depression;	chr6:28035450	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs71559070	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28071151	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs35902873	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28091171	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13197574	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28092461	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34166054	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28098023	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34662244	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28106103	chr6:28015568~28015777:+
LGG	cis	rs35952432	1	rs35952432	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Lung cancer;	chr6:28107123	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13203816	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28111820	chr6:28015568~28015777:+
LGG	cis	rs853679	0.556	rs34588114	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28112850	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs34371502	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28113980	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs66886492	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28121953	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs35345226	ENSG00000199851.2	U3	9.31	4.92e-19	2.91e-16	0.97	0.39	Depression;	chr6:28123802	chr6:28015568~28015777:+
LGG	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-9.31	4.94e-19	2.92e-16	-0.53	-0.39	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
LGG	cis	rs227275	0.554	rs223363	ENSG00000230069.3	LRRC37A15P	-9.31	4.95e-19	2.93e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102727274~102730721:-
LGG	cis	rs853679	0.546	rs35016036	ENSG00000216901.1	AL022393.7	9.31	4.96e-19	2.93e-16	0.87	0.39	Depression;	chr6:28347103	chr6:28176188~28176674:+
LGG	cis	rs4683346	0.731	rs760193	ENSG00000273328.4	RP11-141M3.6	9.31	4.96e-19	2.93e-16	0.5	0.39	Granulocyte percentage of myeloid white cells;	chr3:42876805	chr3:42809414~42908105:+
LGG	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-9.31	4.96e-19	2.93e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
LGG	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-9.31	4.96e-19	2.93e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
LGG	cis	rs10208649	0.611	rs75340524	ENSG00000272156.1	RP11-477N3.1	9.3	4.99e-19	2.95e-16	0.65	0.39	Body mass index;	chr2:54068793	chr2:54082554~54085066:+
LGG	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-9.3	5e-19	2.95e-16	-0.49	-0.39	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
LGG	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-9.3	5e-19	2.96e-16	-0.52	-0.39	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
LGG	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	9.3	5.01e-19	2.96e-16	0.45	0.39	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
LGG	cis	rs227275	0.525	rs7698608	ENSG00000230069.3	LRRC37A15P	-9.3	5.03e-19	2.98e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102727274~102730721:-
LGG	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	9.3	5.03e-19	2.98e-16	0.31	0.39	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
LGG	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-9.3	5.06e-19	2.99e-16	-0.5	-0.39	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
LGG	cis	rs9322193	0.961	rs9285521	ENSG00000216621.7	RP11-244K5.6	9.3	5.07e-19	3e-16	0.48	0.39	Lung cancer;	chr6:149585576	chr6:149934527~149936782:+
LGG	cis	rs1153858	0.723	rs1719238	ENSG00000259433.2	CTD-2651B20.4	9.3	5.08e-19	3e-16	0.47	0.39	Homoarginine levels;	chr15:45302568	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	9.3	5.09e-19	3.01e-16	0.46	0.39	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
LGG	cis	rs7247513	0.964	rs8100964	ENSG00000213290.4	PGK1P2	-9.3	5.1e-19	3.01e-16	-0.43	-0.39	Bipolar disorder;	chr19:12609817	chr19:12559571~12561105:+
LGG	cis	rs4683346	0.731	rs11129983	ENSG00000273328.4	RP11-141M3.6	-9.3	5.1e-19	3.02e-16	-0.51	-0.39	Granulocyte percentage of myeloid white cells;	chr3:42883191	chr3:42809414~42908105:+
LGG	cis	rs1560104	0.709	rs9806831	ENSG00000274834.1	CTD-3037G24.5	-9.3	5.1e-19	3.02e-16	-0.5	-0.39	Obesity-related traits;	chr16:12610538	chr16:12614451~12614852:+
LGG	cis	rs858239	0.509	rs6962213	ENSG00000230042.1	AK3P3	-9.3	5.1e-19	3.02e-16	-0.41	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23129178~23129841:+
LGG	cis	rs227275	0.556	rs6842179	ENSG00000230069.3	LRRC37A15P	-9.3	5.11e-19	3.02e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102727274~102730721:-
LGG	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-9.3	5.11e-19	3.02e-16	-0.39	-0.39	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
LGG	cis	rs10028773	0.515	rs9994651	ENSG00000249244.1	RP11-548H18.2	9.3	5.11e-19	3.02e-16	0.44	0.39	Educational attainment;	chr4:119666648	chr4:119391831~119395335:-
LGG	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	9.3	5.12e-19	3.03e-16	0.37	0.39	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
LGG	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-9.3	5.14e-19	3.04e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
LGG	cis	rs1707322	0.691	rs61784803	ENSG00000281133.1	AL355480.3	9.3	5.16e-19	3.05e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.663	rs3935296	ENSG00000281133.1	AL355480.3	9.3	5.16e-19	3.05e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs28817701	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.691	rs28495425	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.685	rs28617418	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.682	rs28490344	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs28501477	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs28641748	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs4330955	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45580892~45580996:-
LGG	cis	rs6903823	0.508	rs1150724	ENSG00000226314.6	ZNF192P1	9.3	5.16e-19	3.05e-16	0.4	0.39	Pulmonary function;	chr6:28282459	chr6:28161781~28169594:+
LGG	cis	rs7119038	0.818	rs10892287	ENSG00000255239.1	AP002954.6	9.3	5.16e-19	3.05e-16	0.55	0.39	Sjögren's syndrome;	chr11:118772290	chr11:118688039~118690600:-
LGG	cis	rs1707322	0.752	rs11211173	ENSG00000281133.1	AL355480.3	-9.3	5.16e-19	3.05e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs2297932	ENSG00000216621.7	RP11-244K5.6	9.3	5.17e-19	3.05e-16	0.47	0.39	Lung cancer;	chr6:149718225	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs2297930	ENSG00000216621.7	RP11-244K5.6	9.3	5.17e-19	3.05e-16	0.47	0.39	Lung cancer;	chr6:149718360	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs2297928	ENSG00000216621.7	RP11-244K5.6	9.3	5.17e-19	3.05e-16	0.47	0.39	Lung cancer;	chr6:149718584	chr6:149934527~149936782:+
LGG	cis	rs9532669	0.89	rs9525420	ENSG00000239827.7	SUGT1P3	-9.3	5.17e-19	3.06e-16	-0.41	-0.39	Cervical cancer;	chr13:40882628	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7324383	ENSG00000239827.7	SUGT1P3	-9.3	5.17e-19	3.06e-16	-0.41	-0.39	Cervical cancer;	chr13:40882754	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532648	ENSG00000239827.7	SUGT1P3	-9.3	5.17e-19	3.06e-16	-0.41	-0.39	Cervical cancer;	chr13:40882795	chr13:40908159~40921774:-
LGG	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	9.3	5.18e-19	3.06e-16	0.5	0.39	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
LGG	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-9.3	5.2e-19	3.07e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
LGG	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	9.3	5.2e-19	3.07e-16	0.36	0.39	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
LGG	cis	rs9532669	0.963	rs7989303	ENSG00000168852.11	TPTE2P5	9.3	5.25e-19	3.1e-16	0.4	0.39	Cervical cancer;	chr13:40950087	chr13:40822296~40921749:-
LGG	cis	rs4819052	0.679	rs2255761	ENSG00000215447.6	BX322557.10	-9.3	5.26e-19	3.1e-16	-0.29	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45288052~45291738:+
LGG	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-9.3	5.27e-19	3.11e-16	-0.36	-0.39	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
LGG	cis	rs1560104	0.675	rs9937086	ENSG00000274834.1	CTD-3037G24.5	-9.3	5.27e-19	3.11e-16	-0.5	-0.39	Obesity-related traits;	chr16:12611090	chr16:12614451~12614852:+
LGG	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	9.3	5.28e-19	3.12e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
LGG	cis	rs2282300	0.956	rs654710	ENSG00000242353.1	RP4-710M3.1	9.3	5.29e-19	3.12e-16	0.55	0.39	Morning vs. evening chronotype;	chr11:30372756	chr11:30368148~30368646:+
LGG	cis	rs9322193	1	rs9399693	ENSG00000216621.7	RP11-244K5.6	9.3	5.32e-19	3.14e-16	0.48	0.39	Lung cancer;	chr6:149612718	chr6:149934527~149936782:+
LGG	cis	rs227275	0.525	rs11737544	ENSG00000230069.3	LRRC37A15P	-9.3	5.34e-19	3.15e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102727274~102730721:-
LGG	cis	rs9527	0.615	rs4919685	ENSG00000272912.1	RP11-724N1.1	-9.3	5.34e-19	3.15e-16	-0.45	-0.39	Arsenic metabolism;	chr10:102827605	chr10:102914585~102915404:+
LGG	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-9.3	5.36e-19	3.16e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
LGG	cis	rs9532669	0.963	rs3736953	ENSG00000168852.11	TPTE2P5	9.3	5.36e-19	3.16e-16	0.4	0.39	Cervical cancer;	chr13:40951450	chr13:40822296~40921749:-
LGG	cis	rs7267979	1	rs6083862	ENSG00000125804.12	FAM182A	9.29	5.43e-19	3.2e-16	0.47	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:26054655~26086917:+
LGG	cis	rs4266144	0.821	rs4325879	ENSG00000244515.1	KRT18P34	-9.29	5.46e-19	3.22e-16	-0.48	-0.39	Coronary artery disease;	chr3:157134195	chr3:157162663~157163932:-
LGG	cis	rs7674212	0.581	rs13150953	ENSG00000230069.3	LRRC37A15P	-9.29	5.48e-19	3.23e-16	-0.39	-0.39	Type 2 diabetes;	chr4:103021341	chr4:102727274~102730721:-
LGG	cis	rs7674212	0.556	rs13151569	ENSG00000230069.3	LRRC37A15P	-9.29	5.48e-19	3.23e-16	-0.39	-0.39	Type 2 diabetes;	chr4:103021633	chr4:102727274~102730721:-
LGG	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	9.29	5.49e-19	3.24e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
LGG	cis	rs11051970	0.559	rs3789975	ENSG00000274964.1	RP11-817I4.1	-9.29	5.5e-19	3.24e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32331469	chr12:32339368~32340724:+
LGG	cis	rs17772222	0.837	rs57118463	ENSG00000222990.1	RNU4-22P	9.29	5.51e-19	3.25e-16	0.52	0.39	Coronary artery calcification;	chr14:88665822	chr14:88513498~88513663:+
LGG	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-9.29	5.52e-19	3.25e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
LGG	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	9.29	5.52e-19	3.26e-16	0.42	0.39	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
LGG	cis	rs12935418	0.672	rs12448656	ENSG00000260213.4	RP11-303E16.3	-9.29	5.53e-19	3.26e-16	-0.5	-0.39	Mean corpuscular volume;	chr16:81008876	chr16:81016792~81035759:-
LGG	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-9.29	5.53e-19	3.26e-16	-0.45	-0.39	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
LGG	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	9.29	5.53e-19	3.26e-16	0.39	0.39	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
LGG	cis	rs9322193	0.923	rs10782318	ENSG00000216621.7	RP11-244K5.6	9.29	5.53e-19	3.26e-16	0.47	0.39	Lung cancer;	chr6:149754137	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs11155674	ENSG00000216621.7	RP11-244K5.6	9.29	5.56e-19	3.28e-16	0.47	0.39	Lung cancer;	chr6:149711111	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs3924871	ENSG00000216621.7	RP11-244K5.6	9.29	5.62e-19	3.31e-16	0.47	0.39	Lung cancer;	chr6:149662080	chr6:149934527~149936782:+
LGG	cis	rs9532669	0.926	rs9532654	ENSG00000168852.11	TPTE2P5	9.29	5.62e-19	3.31e-16	0.39	0.39	Cervical cancer;	chr13:40909812	chr13:40822296~40921749:-
LGG	cis	rs4950322	0.634	rs7542951	ENSG00000278811.3	LINC00624	9.29	5.64e-19	3.32e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147340308	chr1:147258885~147517875:-
LGG	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-9.29	5.65e-19	3.33e-16	-0.38	-0.39	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
LGG	cis	rs17772222	0.874	rs61984746	ENSG00000222990.1	RNU4-22P	9.29	5.67e-19	3.34e-16	0.52	0.39	Coronary artery calcification;	chr14:88668136	chr14:88513498~88513663:+
LGG	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-9.29	5.67e-19	3.34e-16	-0.49	-0.39	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-9.29	5.67e-19	3.34e-16	-0.49	-0.39	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-9.29	5.67e-19	3.34e-16	-0.49	-0.39	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-9.29	5.67e-19	3.34e-16	-0.49	-0.39	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
LGG	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-9.29	5.67e-19	3.34e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
LGG	cis	rs9322193	0.923	rs9322209	ENSG00000216621.7	RP11-244K5.6	9.29	5.68e-19	3.35e-16	0.47	0.39	Lung cancer;	chr6:149691226	chr6:149934527~149936782:+
LGG	cis	rs11098499	0.739	rs951570	ENSG00000249244.1	RP11-548H18.2	-9.29	5.72e-19	3.37e-16	-0.42	-0.39	Corneal astigmatism;	chr4:119229312	chr4:119391831~119395335:-
LGG	cis	rs9322193	0.884	rs62439836	ENSG00000216621.7	RP11-244K5.6	9.29	5.73e-19	3.37e-16	0.47	0.39	Lung cancer;	chr6:149669173	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs4869812	ENSG00000216621.7	RP11-244K5.6	9.29	5.73e-19	3.37e-16	0.47	0.39	Lung cancer;	chr6:149669447	chr6:149934527~149936782:+
LGG	cis	rs1707322	0.752	rs4660313	ENSG00000281133.1	AL355480.3	9.29	5.73e-19	3.38e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45580892~45580996:-
LGG	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	9.29	5.74e-19	3.38e-16	0.39	0.39	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
LGG	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-9.29	5.79e-19	3.41e-16	-0.39	-0.39	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
LGG	cis	rs7267979	0.789	rs9927	ENSG00000276952.1	RP5-965G21.6	9.29	5.79e-19	3.41e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25284915~25285588:-
LGG	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-9.29	5.81e-19	3.42e-16	-0.51	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
LGG	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	9.29	5.81e-19	3.42e-16	0.46	0.39	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
LGG	cis	rs4713118	0.955	rs34752872	ENSG00000216901.1	AL022393.7	9.28	5.83e-19	3.43e-16	0.52	0.39	Parkinson's disease;	chr6:27715465	chr6:28176188~28176674:+
LGG	cis	rs1560104	0.584	rs12921820	ENSG00000274834.1	CTD-3037G24.5	-9.28	5.83e-19	3.43e-16	-0.5	-0.39	Obesity-related traits;	chr16:12606775	chr16:12614451~12614852:+
LGG	cis	rs9322193	0.923	rs4421206	ENSG00000216621.7	RP11-244K5.6	9.28	5.83e-19	3.43e-16	0.47	0.39	Lung cancer;	chr6:149682891	chr6:149934527~149936782:+
LGG	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	9.28	5.84e-19	3.44e-16	0.43	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
LGG	cis	rs2282300	0.637	rs7942037	ENSG00000254532.1	RP11-624D11.2	9.28	5.87e-19	3.45e-16	0.48	0.39	Morning vs. evening chronotype;	chr11:30408785	chr11:30044058~30084343:-
LGG	cis	rs7247513	0.964	rs4804202	ENSG00000213290.4	PGK1P2	-9.28	5.88e-19	3.46e-16	-0.42	-0.39	Bipolar disorder;	chr19:12607805	chr19:12559571~12561105:+
LGG	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-9.28	5.9e-19	3.47e-16	-0.78	-0.39	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
LGG	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-9.28	5.91e-19	3.48e-16	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	9.28	5.92e-19	3.48e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	9.28	5.92e-19	3.48e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	9.28	5.92e-19	3.48e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	9.28	5.92e-19	3.48e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
LGG	cis	rs9532669	0.963	rs9315794	ENSG00000168852.11	TPTE2P5	9.28	5.97e-19	3.51e-16	0.39	0.39	Cervical cancer;	chr13:40939489	chr13:40822296~40921749:-
LGG	cis	rs7302981	0.9	rs836179	ENSG00000272368.2	RP4-605O3.4	9.28	5.98e-19	3.51e-16	0.38	0.39	Systolic blood pressure;	chr12:50109299	chr12:50112197~50165618:+
LGG	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	9.28	5.98e-19	3.52e-16	0.38	0.39	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	9.28	5.98e-19	3.52e-16	0.38	0.39	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-9.28	5.98e-19	3.52e-16	-0.38	-0.39	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-9.28	5.98e-19	3.52e-16	-0.38	-0.39	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-9.28	5.98e-19	3.52e-16	-0.38	-0.39	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-9.28	5.98e-19	3.52e-16	-0.38	-0.39	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
LGG	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	9.28	5.98e-19	3.52e-16	0.47	0.39	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
LGG	cis	rs6903823	0.508	rs1150721	ENSG00000226314.6	ZNF192P1	9.28	5.99e-19	3.52e-16	0.4	0.39	Pulmonary function;	chr6:28287263	chr6:28161781~28169594:+
LGG	cis	rs9810089	0.835	rs6791611	ENSG00000261758.1	RP11-102M11.2	-9.28	6e-19	3.53e-16	-0.43	-0.39	Gestational age at birth (child effect);	chr3:136441748	chr3:136752630~136755780:+
LGG	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-9.28	6.02e-19	3.54e-16	-0.53	-0.39	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
LGG	cis	rs9322193	0.923	rs10872651	ENSG00000216621.7	RP11-244K5.6	9.28	6.03e-19	3.54e-16	0.47	0.39	Lung cancer;	chr6:149768273	chr6:149934527~149936782:+
LGG	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	9.28	6.07e-19	3.56e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	9.28	6.07e-19	3.56e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	9.28	6.07e-19	3.56e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	9.28	6.07e-19	3.56e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
LGG	cis	rs9532669	0.926	rs4555012	ENSG00000239827.7	SUGT1P3	-9.28	6.08e-19	3.57e-16	-0.41	-0.39	Cervical cancer;	chr13:40879997	chr13:40908159~40921774:-
LGG	cis	rs482329	0.523	rs624203	ENSG00000228044.2	RP4-781K5.4	9.28	6.09e-19	3.58e-16	0.43	0.39	Life threatening arrhythmia;	chr1:234696452	chr1:234646289~234683176:+
LGG	cis	rs916888	0.779	rs199498	ENSG00000232300.1	FAM215B	9.28	6.09e-19	3.58e-16	0.55	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46558830~46562795:-
LGG	cis	rs6700559	0.643	rs1540682	ENSG00000260088.1	RP11-92G12.3	9.28	6.11e-19	3.59e-16	0.41	0.39	Coronary artery disease;	chr1:200693231	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.643	rs4556395	ENSG00000260088.1	RP11-92G12.3	9.28	6.11e-19	3.59e-16	0.41	0.39	Coronary artery disease;	chr1:200693813	chr1:200669507~200694250:+
LGG	cis	rs4683346	0.731	rs11923822	ENSG00000273328.4	RP11-141M3.6	-9.28	6.13e-19	3.6e-16	-0.5	-0.39	Granulocyte percentage of myeloid white cells;	chr3:42880685	chr3:42809414~42908105:+
LGG	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-9.28	6.13e-19	3.6e-16	-0.35	-0.39	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
LGG	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-9.28	6.13e-19	3.6e-16	-0.35	-0.39	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
LGG	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-9.28	6.13e-19	3.6e-16	-0.35	-0.39	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
LGG	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	9.28	6.14e-19	3.61e-16	0.39	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
LGG	cis	rs1707322	0.662	rs11211160	ENSG00000281133.1	AL355480.3	-9.28	6.15e-19	3.61e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45580892~45580996:-
LGG	cis	rs9532669	0.926	rs9532643	ENSG00000239827.7	SUGT1P3	-9.28	6.2e-19	3.64e-16	-0.41	-0.39	Cervical cancer;	chr13:40880800	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.963	rs9532644	ENSG00000239827.7	SUGT1P3	-9.28	6.2e-19	3.64e-16	-0.41	-0.39	Cervical cancer;	chr13:40880860	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532645	ENSG00000239827.7	SUGT1P3	-9.28	6.2e-19	3.64e-16	-0.41	-0.39	Cervical cancer;	chr13:40880898	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532646	ENSG00000239827.7	SUGT1P3	-9.28	6.2e-19	3.64e-16	-0.41	-0.39	Cervical cancer;	chr13:40880989	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9525419	ENSG00000239827.7	SUGT1P3	-9.28	6.2e-19	3.64e-16	-0.41	-0.39	Cervical cancer;	chr13:40881047	chr13:40908159~40921774:-
LGG	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-9.28	6.2e-19	3.64e-16	-0.34	-0.39	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
LGG	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	9.28	6.2e-19	3.64e-16	0.56	0.39	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
LGG	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-9.28	6.21e-19	3.65e-16	-0.53	-0.39	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
LGG	cis	rs853679	0.556	rs13197633	ENSG00000199851.2	U3	9.28	6.23e-19	3.66e-16	0.97	0.39	Depression;	chr6:28206979	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000235689.1	AP000351.13	9.28	6.27e-19	3.68e-16	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:24006305~24008258:-
LGG	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-9.28	6.29e-19	3.69e-16	-0.43	-0.39	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
LGG	cis	rs853679	0.607	rs35749575	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28147040	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs72846780	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28151277	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13205911	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28156336	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13197176	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28161454	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13201308	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28162311	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34765154	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28162672	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34505829	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28165461	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs35098436	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28166443	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs72846794	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28169721	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13217984	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28171932	chr6:28015568~28015777:+
LGG	cis	rs853679	0.556	rs67297533	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28173475	chr6:28015568~28015777:+
LGG	cis	rs853679	0.505	rs35781323	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28177054	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs13195291	ENSG00000199851.2	U3	9.28	6.29e-19	3.69e-16	0.97	0.39	Depression;	chr6:28201463	chr6:28015568~28015777:+
LGG	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	9.28	6.3e-19	3.7e-16	0.45	0.39	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
LGG	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	9.27	6.31e-19	3.7e-16	0.43	0.39	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
LGG	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	9.27	6.37e-19	3.74e-16	0.58	0.39	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
LGG	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-9.27	6.39e-19	3.75e-16	-0.47	-0.39	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
LGG	cis	rs9810089	0.835	rs655836	ENSG00000261758.1	RP11-102M11.2	9.27	6.39e-19	3.75e-16	0.43	0.39	Gestational age at birth (child effect);	chr3:136378734	chr3:136752630~136755780:+
LGG	cis	rs34375054	0.672	rs2291247	ENSG00000279233.1	RP11-158L12.4	9.27	6.41e-19	3.76e-16	0.38	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125134407	chr12:125138245~125141711:+
LGG	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	9.27	6.41e-19	3.76e-16	0.5	0.39	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
LGG	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	9.27	6.41e-19	3.76e-16	0.5	0.39	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
LGG	cis	rs4950322	0.57	rs17356492	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147296089	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691093	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147297977	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs76236344	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147297989	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691095	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147298305	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691097	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147299711	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691098	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147300142	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72691102	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147301189	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692904	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147301437	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692905	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147301560	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692907	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147301921	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692914	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147302946	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692917	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147304389	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs66580541	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147308828	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs945742	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147313437	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.543	rs4950318	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147316240	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.543	rs4950319	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147316250	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.543	rs4453096	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147316574	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950401	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147319571	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950402	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147319684	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950404	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147319834	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692953	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147321416	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950409	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147335879	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692980	ENSG00000278811.3	LINC00624	9.27	6.41e-19	3.76e-16	0.39	0.39	Protein quantitative trait loci;	chr1:147337830	chr1:147258885~147517875:-
LGG	cis	rs1153858	0.723	rs4580098	ENSG00000259433.2	CTD-2651B20.4	-9.27	6.41e-19	3.76e-16	-0.46	-0.39	Homoarginine levels;	chr15:45304711	chr15:45330209~45332634:-
LGG	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	9.27	6.42e-19	3.76e-16	0.57	0.39	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
LGG	cis	rs853679	0.506	rs1150711	ENSG00000199851.2	U3	9.27	6.44e-19	3.77e-16	0.55	0.39	Depression;	chr6:28240757	chr6:28015568~28015777:+
LGG	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	9.27	6.5e-19	3.81e-16	0.57	0.39	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
LGG	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	9.27	6.51e-19	3.81e-16	0.46	0.39	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
LGG	cis	rs2287838	1	rs2303100	ENSG00000267289.1	CTD-2623N2.11	-9.27	6.54e-19	3.83e-16	-0.43	-0.39	Sleep duration;	chr19:9857758	chr19:9834079~9835013:-
LGG	cis	rs10411262	0.935	rs2871987	ENSG00000245598.5	DACT3-AS1	-9.27	6.54e-19	3.83e-16	-0.38	-0.39	Tonsillectomy;	chr19:46672271	chr19:46660364~46677447:+
LGG	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	9.27	6.58e-19	3.86e-16	0.48	0.39	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
LGG	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	9.27	6.63e-19	3.88e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
LGG	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-9.27	6.64e-19	3.89e-16	-0.42	-0.39	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
LGG	cis	rs9532669	0.926	rs4270044	ENSG00000239827.7	SUGT1P3	-9.27	6.64e-19	3.89e-16	-0.41	-0.39	Cervical cancer;	chr13:40877923	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs11147824	ENSG00000239827.7	SUGT1P3	-9.27	6.64e-19	3.89e-16	-0.41	-0.39	Cervical cancer;	chr13:40878183	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs9525417	ENSG00000239827.7	SUGT1P3	-9.27	6.64e-19	3.89e-16	-0.41	-0.39	Cervical cancer;	chr13:40878431	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs9532638	ENSG00000239827.7	SUGT1P3	-9.27	6.64e-19	3.89e-16	-0.41	-0.39	Cervical cancer;	chr13:40878471	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7997536	ENSG00000239827.7	SUGT1P3	-9.27	6.64e-19	3.89e-16	-0.41	-0.39	Cervical cancer;	chr13:40878685	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7997560	ENSG00000239827.7	SUGT1P3	-9.27	6.64e-19	3.89e-16	-0.41	-0.39	Cervical cancer;	chr13:40878723	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4600337	ENSG00000239827.7	SUGT1P3	-9.27	6.64e-19	3.89e-16	-0.41	-0.39	Cervical cancer;	chr13:40879564	chr13:40908159~40921774:-
LGG	cis	rs9322193	0.923	rs9800686	ENSG00000216621.7	RP11-244K5.6	9.27	6.64e-19	3.89e-16	0.47	0.39	Lung cancer;	chr6:149634464	chr6:149934527~149936782:+
LGG	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	9.27	6.69e-19	3.92e-16	0.44	0.39	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
LGG	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	9.27	6.7e-19	3.92e-16	0.44	0.39	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
LGG	cis	rs227275	0.525	rs7672319	ENSG00000230069.3	LRRC37A15P	-9.27	6.7e-19	3.92e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs6533051	ENSG00000230069.3	LRRC37A15P	-9.27	6.7e-19	3.92e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102727274~102730721:-
LGG	cis	rs17345786	1	rs3804775	ENSG00000256628.3	ZBTB11-AS1	9.27	6.76e-19	3.96e-16	0.49	0.39	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101676475~101679217:+
LGG	cis	rs9810089	0.802	rs73222302	ENSG00000261758.1	RP11-102M11.2	9.27	6.78e-19	3.97e-16	0.42	0.39	Gestational age at birth (child effect);	chr3:136379243	chr3:136752630~136755780:+
LGG	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-9.27	6.78e-19	3.97e-16	-0.48	-0.39	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
LGG	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-9.26	6.83e-19	4e-16	-0.47	-0.39	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
LGG	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-9.26	6.83e-19	4e-16	-0.45	-0.39	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
LGG	cis	rs853679	0.607	rs68188794	ENSG00000199851.2	U3	9.26	6.84e-19	4e-16	0.97	0.39	Depression;	chr6:28112999	chr6:28015568~28015777:+
LGG	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	9.26	6.84e-19	4e-16	0.58	0.39	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
LGG	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-9.26	6.87e-19	4.02e-16	-0.39	-0.39	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
LGG	cis	rs9481169	0.557	rs34896684	ENSG00000255389.1	C6orf3	-9.26	6.91e-19	4.04e-16	-0.79	-0.39	Inflammatory skin disease;	chr6:111572034	chr6:111599875~111602295:+
LGG	cis	rs11051970	0.559	rs2036304	ENSG00000274964.1	RP11-817I4.1	-9.26	6.94e-19	4.06e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32325441	chr12:32339368~32340724:+
LGG	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	9.26	6.96e-19	4.07e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
LGG	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-9.26	6.96e-19	4.07e-16	-0.47	-0.39	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
LGG	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	9.26	6.98e-19	4.08e-16	0.42	0.39	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
LGG	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-9.26	6.98e-19	4.08e-16	-0.83	-0.39	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
LGG	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-9.26	6.99e-19	4.09e-16	-0.47	-0.39	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.962	rs3805749	ENSG00000216621.7	RP11-244K5.6	9.26	7.01e-19	4.1e-16	0.47	0.39	Lung cancer;	chr6:149772546	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.847	rs9505972	ENSG00000216621.7	RP11-244K5.6	9.26	7.01e-19	4.1e-16	0.47	0.39	Lung cancer;	chr6:149775255	chr6:149934527~149936782:+
LGG	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-9.26	7.02e-19	4.1e-16	-0.38	-0.39	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
LGG	cis	rs9876781	1	rs6442119	ENSG00000244380.1	RP11-24C3.2	9.26	7.02e-19	4.1e-16	0.48	0.39	Longevity;	chr3:48398713	chr3:48440352~48446656:-
LGG	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	9.26	7.03e-19	4.11e-16	0.47	0.39	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	9.26	7.03e-19	4.11e-16	0.47	0.39	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	9.26	7.03e-19	4.11e-16	0.47	0.39	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
LGG	cis	rs853679	0.607	rs13194781	ENSG00000216901.1	AL022393.7	9.26	7.03e-19	4.11e-16	0.88	0.39	Depression;	chr6:27847861	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs36116761	ENSG00000216901.1	AL022393.7	9.26	7.03e-19	4.11e-16	0.88	0.39	Depression;	chr6:27850704	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs34194357	ENSG00000216901.1	AL022393.7	9.26	7.03e-19	4.11e-16	0.88	0.39	Depression;	chr6:27850757	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs12205092	ENSG00000216621.7	RP11-244K5.6	9.26	7.04e-19	4.11e-16	0.47	0.39	Lung cancer;	chr6:149761375	chr6:149934527~149936782:+
LGG	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-9.26	7.05e-19	4.12e-16	-0.46	-0.39	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
LGG	cis	rs1707322	0.721	rs10890333	ENSG00000281133.1	AL355480.3	-9.26	7.09e-19	4.14e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs12043945	ENSG00000281133.1	AL355480.3	-9.26	7.09e-19	4.14e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs12091503	ENSG00000281133.1	AL355480.3	-9.26	7.09e-19	4.14e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45580892~45580996:-
LGG	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-9.26	7.09e-19	4.14e-16	-0.43	-0.39	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
LGG	cis	rs7246657	0.722	rs958305	ENSG00000267422.1	CTD-2554C21.1	9.26	7.11e-19	4.15e-16	0.46	0.39	Coronary artery calcification;	chr19:37698539	chr19:37779686~37792865:+
LGG	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-9.26	7.12e-19	4.16e-16	-0.38	-0.39	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
LGG	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	9.26	7.12e-19	4.16e-16	0.54	0.39	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
LGG	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	9.26	7.13e-19	4.16e-16	0.39	0.39	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
LGG	cis	rs9322193	0.962	rs4380763	ENSG00000216621.7	RP11-244K5.6	9.26	7.14e-19	4.17e-16	0.47	0.39	Lung cancer;	chr6:149678086	chr6:149934527~149936782:+
LGG	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-9.26	7.16e-19	4.18e-16	-0.48	-0.39	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
LGG	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	9.26	7.16e-19	4.18e-16	0.71	0.39	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
LGG	cis	rs1560104	0.675	rs9936549	ENSG00000274834.1	CTD-3037G24.5	-9.26	7.19e-19	4.2e-16	-0.5	-0.39	Obesity-related traits;	chr16:12611147	chr16:12614451~12614852:+
LGG	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	9.26	7.23e-19	4.22e-16	0.46	0.39	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs7740784	ENSG00000216621.7	RP11-244K5.6	9.26	7.23e-19	4.22e-16	0.47	0.39	Lung cancer;	chr6:149833364	chr6:149934527~149936782:+
LGG	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	9.26	7.23e-19	4.22e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
LGG	cis	rs17772222	0.917	rs12434935	ENSG00000222990.1	RNU4-22P	9.26	7.29e-19	4.25e-16	0.52	0.39	Coronary artery calcification;	chr14:88645449	chr14:88513498~88513663:+
LGG	cis	rs6921919	0.525	rs11760133	ENSG00000280107.1	AL022393.9	-9.26	7.31e-19	4.26e-16	-0.4	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28170845~28172521:+
LGG	cis	rs2613964	0.504	rs1903431	ENSG00000240057.4	RP11-572M11.4	-9.26	7.34e-19	4.28e-16	-0.42	-0.39	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133810	chr3:113019532~113183301:+
LGG	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	9.26	7.35e-19	4.29e-16	0.38	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
LGG	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	9.26	7.36e-19	4.29e-16	0.56	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
LGG	cis	rs657075	0.697	rs2073642	ENSG00000263597.1	MIR3936	9.25	7.4e-19	4.31e-16	0.64	0.39	Rheumatoid arthritis;	chr5:132378082	chr5:132365490~132365599:-
LGG	cis	rs9322193	0.923	rs1934534	ENSG00000216621.7	RP11-244K5.6	9.25	7.4e-19	4.32e-16	0.46	0.39	Lung cancer;	chr6:149711896	chr6:149934527~149936782:+
LGG	cis	rs1707322	0.721	rs11211163	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs12037803	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs10789470	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs61784796	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs10749856	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs10890344	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs4564187	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs28438704	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs28442079	ENSG00000281133.1	AL355480.3	-9.25	7.41e-19	4.32e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45580892~45580996:-
LGG	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-9.25	7.44e-19	4.33e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-9.25	7.44e-19	4.33e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-9.25	7.44e-19	4.33e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
LGG	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	9.25	7.44e-19	4.34e-16	0.37	0.39	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
LGG	cis	rs7302981	0.9	rs836180	ENSG00000272368.2	RP4-605O3.4	9.25	7.45e-19	4.34e-16	0.38	0.39	Systolic blood pressure;	chr12:50109486	chr12:50112197~50165618:+
LGG	cis	rs227275	0.554	rs223359	ENSG00000230069.3	LRRC37A15P	-9.25	7.48e-19	4.36e-16	-0.38	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102727274~102730721:-
LGG	cis	rs17772222	0.876	rs12586348	ENSG00000222990.1	RNU4-22P	9.25	7.49e-19	4.36e-16	0.52	0.39	Coronary artery calcification;	chr14:88643523	chr14:88513498~88513663:+
LGG	cis	rs1707322	0.717	rs1135850	ENSG00000281133.1	AL355480.3	-9.25	7.49e-19	4.36e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.656	rs9429172	ENSG00000281133.1	AL355480.3	9.25	7.49e-19	4.36e-16	0.47	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45580892~45580996:-
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	9.25	7.53e-19	4.39e-16	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
LGG	cis	rs2282300	0.637	rs10767841	ENSG00000254532.1	RP11-624D11.2	9.25	7.54e-19	4.39e-16	0.48	0.39	Morning vs. evening chronotype;	chr11:30406728	chr11:30044058~30084343:-
LGG	cis	rs2282300	0.637	rs13642	ENSG00000254532.1	RP11-624D11.2	9.25	7.54e-19	4.39e-16	0.48	0.39	Morning vs. evening chronotype;	chr11:30410673	chr11:30044058~30084343:-
LGG	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	9.25	7.55e-19	4.4e-16	0.31	0.39	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
LGG	cis	rs11098499	0.954	rs11098524	ENSG00000249244.1	RP11-548H18.2	9.25	7.59e-19	4.42e-16	0.39	0.39	Corneal astigmatism;	chr4:119468877	chr4:119391831~119395335:-
LGG	cis	rs1707322	0.682	rs12041197	ENSG00000281133.1	AL355480.3	-9.25	7.61e-19	4.43e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45580892~45580996:-
LGG	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-9.25	7.64e-19	4.44e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
LGG	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	9.25	7.65e-19	4.45e-16	0.56	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
LGG	cis	rs6700559	0.643	rs4915451	ENSG00000260088.1	RP11-92G12.3	9.25	7.66e-19	4.46e-16	0.4	0.39	Coronary artery disease;	chr1:200690726	chr1:200669507~200694250:+
LGG	cis	rs6700559	0.643	rs6427844	ENSG00000260088.1	RP11-92G12.3	9.25	7.66e-19	4.46e-16	0.4	0.39	Coronary artery disease;	chr1:200692216	chr1:200669507~200694250:+
LGG	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	9.25	7.66e-19	4.46e-16	0.5	0.39	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
LGG	cis	rs11722779	0.869	rs223350	ENSG00000230069.3	LRRC37A15P	-9.25	7.68e-19	4.47e-16	-0.38	-0.39	Schizophrenia;	chr4:102856899	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	9.25	7.68e-19	4.47e-16	0.52	0.39	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	9.25	7.68e-19	4.47e-16	0.45	0.39	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
LGG	cis	rs10932679	0.532	rs2712162	ENSG00000229352.1	AC007563.3	-9.25	7.69e-19	4.48e-16	-0.5	-0.39	Pulse pressure;	chr2:216797065	chr2:216799608~216805335:+
LGG	cis	rs11671005	0.61	rs2305122	ENSG00000269600.1	AC016629.3	-9.25	7.7e-19	4.48e-16	-0.62	-0.39	Mean platelet volume;	chr19:58545385	chr19:58593896~58599355:-
LGG	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	9.25	7.73e-19	4.5e-16	0.46	0.39	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
LGG	cis	rs11051970	0.513	rs2892655	ENSG00000274964.1	RP11-817I4.1	-9.25	7.74e-19	4.5e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32337295	chr12:32339368~32340724:+
LGG	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-9.25	7.76e-19	4.51e-16	-0.45	-0.39	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
LGG	cis	rs2739330	0.828	rs4822454	ENSG00000235689.1	AP000351.13	9.25	7.78e-19	4.52e-16	0.45	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:24006305~24008258:-
LGG	cis	rs9876781	1	rs7636782	ENSG00000244380.1	RP11-24C3.2	9.25	7.78e-19	4.52e-16	0.48	0.39	Longevity;	chr3:48379897	chr3:48440352~48446656:-
LGG	cis	rs3096299	0.506	rs3114863	ENSG00000274627.1	RP11-104N10.2	9.25	7.81e-19	4.54e-16	0.36	0.39	Multiple myeloma (IgH translocation);	chr16:89372259	chr16:89516797~89522217:+
LGG	cis	rs853679	0.556	rs34706883	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Depression;	chr6:27837477	chr6:28176188~28176674:+
LGG	cis	rs67340775	0.748	rs13212651	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Lung cancer in ever smokers;	chr6:27839207	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs35819751	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Depression;	chr6:27842791	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13199772	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Depression;	chr6:27866307	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13199906	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Depression;	chr6:27866361	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs17763089	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Depression;	chr6:27867440	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs17695758	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Depression;	chr6:27869405	chr6:28176188~28176674:+
LGG	cis	rs853679	0.556	rs45509595	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.88	0.39	Depression;	chr6:27873148	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs68188794	ENSG00000216901.1	AL022393.7	9.25	7.82e-19	4.55e-16	0.86	0.39	Depression;	chr6:28112999	chr6:28176188~28176674:+
LGG	cis	rs2797160	0.651	rs9491503	ENSG00000237742.5	RP11-624M8.1	9.25	7.83e-19	4.56e-16	0.35	0.39	Endometrial cancer;	chr6:125710536	chr6:125578558~125749190:-
LGG	cis	rs67340775	0.834	rs13218875	ENSG00000216901.1	AL022393.7	9.25	7.85e-19	4.56e-16	0.86	0.39	Lung cancer in ever smokers;	chr6:27916234	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs67040724	ENSG00000216901.1	AL022393.7	9.25	7.85e-19	4.56e-16	0.86	0.39	Depression;	chr6:27937731	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs67662114	ENSG00000216901.1	AL022393.7	9.25	7.85e-19	4.56e-16	0.86	0.39	Depression;	chr6:27964523	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13216117	ENSG00000216901.1	AL022393.7	9.25	7.85e-19	4.56e-16	0.86	0.39	Depression;	chr6:27970706	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs36101351	ENSG00000216901.1	AL022393.7	9.25	7.85e-19	4.56e-16	0.86	0.39	Depression;	chr6:27975591	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs28360499	ENSG00000216901.1	AL022393.7	9.25	7.85e-19	4.56e-16	0.86	0.39	Depression;	chr6:27977618	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs71537572	ENSG00000216901.1	AL022393.7	9.25	7.85e-19	4.56e-16	0.86	0.39	Depression;	chr6:28002937	chr6:28176188~28176674:+
LGG	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-9.25	7.89e-19	4.59e-16	-0.28	-0.39	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
LGG	cis	rs7267979	0.727	rs4815431	ENSG00000276952.1	RP5-965G21.6	-9.25	7.92e-19	4.6e-16	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25284915~25285588:-
LGG	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-9.25	7.99e-19	4.64e-16	-0.4	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
LGG	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-9.24	8.03e-19	4.66e-16	-0.46	-0.39	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
LGG	cis	rs6921919	0.515	rs1339898	ENSG00000218016.2	ZNF192P2	-9.24	8.05e-19	4.68e-16	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28188050~28189432:+
LGG	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	9.24	8.07e-19	4.69e-16	0.46	0.39	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
LGG	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-9.24	8.07e-19	4.69e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
LGG	cis	rs9322193	0.923	rs4354168	ENSG00000216621.7	RP11-244K5.6	9.24	8.07e-19	4.69e-16	0.46	0.39	Lung cancer;	chr6:149696642	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs4455682	ENSG00000216621.7	RP11-244K5.6	9.24	8.07e-19	4.69e-16	0.46	0.39	Lung cancer;	chr6:149700161	chr6:149934527~149936782:+
LGG	cis	rs2797160	0.651	rs6569437	ENSG00000237742.5	RP11-624M8.1	9.24	8.08e-19	4.7e-16	0.35	0.39	Endometrial cancer;	chr6:125713394	chr6:125578558~125749190:-
LGG	cis	rs1707322	0.686	rs1541131	ENSG00000281133.1	AL355480.3	9.24	8.11e-19	4.71e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45580892~45580996:-
LGG	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	9.24	8.14e-19	4.73e-16	0.49	0.39	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
LGG	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	9.24	8.18e-19	4.75e-16	0.52	0.39	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
LGG	cis	rs228614	0.51	rs170565	ENSG00000230069.3	LRRC37A15P	-9.24	8.2e-19	4.76e-16	-0.39	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	9.24	8.28e-19	4.81e-16	0.45	0.39	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
LGG	cis	rs10932679	0.532	rs2024488	ENSG00000229352.1	AC007563.3	-9.24	8.29e-19	4.81e-16	-0.5	-0.39	Pulse pressure;	chr2:216798245	chr2:216799608~216805335:+
LGG	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	9.24	8.29e-19	4.81e-16	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
LGG	cis	rs9532669	0.926	rs9532640	ENSG00000239827.7	SUGT1P3	-9.24	8.3e-19	4.82e-16	-0.41	-0.39	Cervical cancer;	chr13:40880628	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs9532641	ENSG00000239827.7	SUGT1P3	-9.24	8.3e-19	4.82e-16	-0.41	-0.39	Cervical cancer;	chr13:40880648	chr13:40908159~40921774:-
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	9.24	8.34e-19	4.84e-16	0.51	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
LGG	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	9.24	8.35e-19	4.84e-16	0.45	0.39	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
LGG	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	9.24	8.37e-19	4.85e-16	0.5	0.39	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
LGG	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	9.24	8.43e-19	4.89e-16	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
LGG	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	9.24	8.45e-19	4.9e-16	0.36	0.39	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
LGG	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	9.24	8.45e-19	4.9e-16	0.45	0.39	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
LGG	cis	rs482329	0.523	rs685557	ENSG00000228044.2	RP4-781K5.4	9.24	8.46e-19	4.91e-16	0.43	0.39	Life threatening arrhythmia;	chr1:234691930	chr1:234646289~234683176:+
LGG	cis	rs482329	0.523	rs682791	ENSG00000228044.2	RP4-781K5.4	9.24	8.46e-19	4.91e-16	0.43	0.39	Life threatening arrhythmia;	chr1:234692553	chr1:234646289~234683176:+
LGG	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-9.24	8.48e-19	4.92e-16	-0.5	-0.39	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
LGG	cis	rs1420956	0.875	rs9960073	ENSG00000264151.4	RP11-739N10.1	9.24	8.5e-19	4.93e-16	0.49	0.39	Obesity-related traits;	chr18:27586261	chr18:27336379~27595164:-
LGG	cis	rs9322193	0.962	rs3805752	ENSG00000216621.7	RP11-244K5.6	9.24	8.51e-19	4.94e-16	0.47	0.39	Lung cancer;	chr6:149795490	chr6:149934527~149936782:+
LGG	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-9.24	8.54e-19	4.95e-16	-0.76	-0.39	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
LGG	cis	rs9322193	0.923	rs10872650	ENSG00000216621.7	RP11-244K5.6	9.24	8.55e-19	4.96e-16	0.47	0.39	Lung cancer;	chr6:149760959	chr6:149934527~149936782:+
LGG	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	9.24	8.57e-19	4.97e-16	0.54	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
LGG	cis	rs9532669	0.926	rs12872288	ENSG00000239827.7	SUGT1P3	-9.24	8.6e-19	4.99e-16	-0.41	-0.39	Cervical cancer;	chr13:40880268	chr13:40908159~40921774:-
LGG	cis	rs10276381	0.786	rs10255700	ENSG00000234336.5	JAZF1-AS1	-9.24	8.61e-19	4.99e-16	-0.49	-0.39	Crohn's disease;	chr7:28180609	chr7:28180322~28243917:+
LGG	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	9.24	8.63e-19	5e-16	0.5	0.39	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
LGG	cis	rs17772222	1	rs12589467	ENSG00000222990.1	RNU4-22P	9.24	8.66e-19	5.02e-16	0.49	0.39	Coronary artery calcification;	chr14:88357239	chr14:88513498~88513663:+
LGG	cis	rs2274273	0.662	rs4525413	ENSG00000258413.1	RP11-665C16.6	-9.24	8.66e-19	5.02e-16	-0.53	-0.39	Protein biomarker;	chr14:55194420	chr14:55262767~55272075:-
LGG	cis	rs7267979	0.549	rs6138536	ENSG00000276952.1	RP5-965G21.6	9.23	8.68e-19	5.03e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:25284915~25285588:-
LGG	cis	rs12935418	0.552	rs2549842	ENSG00000260213.4	RP11-303E16.3	-9.23	8.71e-19	5.05e-16	-0.49	-0.39	Mean corpuscular volume;	chr16:80990054	chr16:81016792~81035759:-
LGG	cis	rs853679	0.607	rs67101035	ENSG00000216901.1	AL022393.7	9.23	8.71e-19	5.05e-16	0.87	0.39	Depression;	chr6:27831109	chr6:28176188~28176674:+
LGG	cis	rs858239	0.601	rs6969733	ENSG00000230042.1	AK3P3	-9.23	8.73e-19	5.06e-16	-0.41	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23129178~23129841:+
LGG	cis	rs858239	0.601	rs4440529	ENSG00000230042.1	AK3P3	-9.23	8.73e-19	5.06e-16	-0.41	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23129178~23129841:+
LGG	cis	rs1153858	0.621	rs2687512	ENSG00000259433.2	CTD-2651B20.4	9.23	8.77e-19	5.08e-16	0.46	0.39	Homoarginine levels;	chr15:45289297	chr15:45330209~45332634:-
LGG	cis	rs4713118	0.955	rs9380010	ENSG00000216901.1	AL022393.7	9.23	8.78e-19	5.09e-16	0.52	0.39	Parkinson's disease;	chr6:27715793	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.955	rs9368528	ENSG00000216901.1	AL022393.7	9.23	8.78e-19	5.09e-16	0.52	0.39	Parkinson's disease;	chr6:27716019	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.955	rs9380011	ENSG00000216901.1	AL022393.7	9.23	8.78e-19	5.09e-16	0.52	0.39	Parkinson's disease;	chr6:27716145	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.955	rs9380012	ENSG00000216901.1	AL022393.7	9.23	8.78e-19	5.09e-16	0.52	0.39	Parkinson's disease;	chr6:27716875	chr6:28176188~28176674:+
LGG	cis	rs7085104	0.632	rs4290163	ENSG00000272912.1	RP11-724N1.1	-9.23	8.8e-19	5.1e-16	-0.43	-0.39	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102914585~102915404:+
LGG	cis	rs1707322	0.752	rs28890893	ENSG00000281133.1	AL355480.3	-9.23	8.8e-19	5.1e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs28719889	ENSG00000281133.1	AL355480.3	-9.23	8.8e-19	5.1e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs28812624	ENSG00000281133.1	AL355480.3	-9.23	8.8e-19	5.1e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs28568986	ENSG00000281133.1	AL355480.3	-9.23	8.8e-19	5.1e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.717	rs10890345	ENSG00000281133.1	AL355480.3	-9.23	8.8e-19	5.1e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs10789471	ENSG00000281133.1	AL355480.3	-9.23	8.8e-19	5.1e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45580892~45580996:-
LGG	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-9.23	8.81e-19	5.1e-16	-0.47	-0.39	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.923	rs4870509	ENSG00000216621.7	RP11-244K5.6	9.23	8.86e-19	5.13e-16	0.47	0.39	Lung cancer;	chr6:149702212	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9322214	ENSG00000216621.7	RP11-244K5.6	9.23	8.86e-19	5.13e-16	0.47	0.39	Lung cancer;	chr6:149703986	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	9.23	8.93e-19	5.17e-16	0.45	0.39	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-9.23	8.94e-19	5.18e-16	-0.45	-0.39	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
LGG	cis	rs7267979	0.718	rs2983489	ENSG00000276952.1	RP5-965G21.6	9.23	8.95e-19	5.18e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.727	rs2474765	ENSG00000276952.1	RP5-965G21.6	9.23	8.95e-19	5.18e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	9.23	8.97e-19	5.19e-16	0.45	0.39	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
LGG	cis	rs9532669	0.963	rs4942012	ENSG00000168852.11	TPTE2P5	9.23	8.98e-19	5.2e-16	0.4	0.39	Cervical cancer;	chr13:40939112	chr13:40822296~40921749:-
LGG	cis	rs1153858	0.887	rs28569043	ENSG00000259433.2	CTD-2651B20.4	-9.23	9e-19	5.21e-16	-0.46	-0.39	Homoarginine levels;	chr15:45438728	chr15:45330209~45332634:-
LGG	cis	rs853679	0.766	rs9368561	ENSG00000226314.6	ZNF192P1	9.23	9e-19	5.21e-16	0.6	0.39	Depression;	chr6:28200565	chr6:28161781~28169594:+
LGG	cis	rs11051970	0.559	rs11051945	ENSG00000274964.1	RP11-817I4.1	-9.23	9.02e-19	5.22e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32336191	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs11051946	ENSG00000274964.1	RP11-817I4.1	-9.23	9.02e-19	5.22e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32336335	chr12:32339368~32340724:+
LGG	cis	rs4819052	0.632	rs4819050	ENSG00000223768.1	LINC00205	-9.23	9.03e-19	5.23e-16	-0.41	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45293285~45297354:+
LGG	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	9.23	9.04e-19	5.23e-16	0.39	0.39	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
LGG	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	9.23	9.04e-19	5.23e-16	0.39	0.39	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
LGG	cis	rs9322193	0.923	rs57938011	ENSG00000216621.7	RP11-244K5.6	9.23	9.04e-19	5.23e-16	0.47	0.39	Lung cancer;	chr6:149642969	chr6:149934527~149936782:+
LGG	cis	rs2945232	1	rs2945232	ENSG00000253981.4	ALG1L13P	-9.23	9.04e-19	5.23e-16	-0.4	-0.39	Schizophrenia;	chr8:8240516	chr8:8236003~8244667:-
LGG	cis	rs227275	0.554	rs223333	ENSG00000230069.3	LRRC37A15P	-9.23	9.05e-19	5.24e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102727274~102730721:-
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-9.23	9.08e-19	5.25e-16	-0.52	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
LGG	cis	rs227275	0.554	rs223339	ENSG00000230069.3	LRRC37A15P	-9.23	9.09e-19	5.26e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102727274~102730721:-
LGG	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-9.23	9.1e-19	5.27e-16	-0.5	-0.39	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
LGG	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	9.23	9.12e-19	5.27e-16	0.42	0.39	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
LGG	cis	rs17772222	0.917	rs61984737	ENSG00000222990.1	RNU4-22P	9.23	9.12e-19	5.28e-16	0.51	0.39	Coronary artery calcification;	chr14:88637028	chr14:88513498~88513663:+
LGG	cis	rs6921919	0.583	rs7759191	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs7764737	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs9461458	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.609	rs9468365	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs1361385	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs1416918	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs9468367	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs9461459	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs28360638	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs9468368	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs2041230	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.609	rs1005127	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28170845~28172521:+
LGG	cis	rs853679	0.515	rs4580862	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Depression;	chr6:28399886	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs4357130	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs11755942	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs6907950	ENSG00000280107.1	AL022393.9	-9.23	9.14e-19	5.28e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28170845~28172521:+
LGG	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-9.23	9.15e-19	5.29e-16	-0.34	-0.39	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
LGG	cis	rs7267979	0.739	rs6138555	ENSG00000276952.1	RP5-965G21.6	9.23	9.16e-19	5.3e-16	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25284915~25285588:-
LGG	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-9.23	9.17e-19	5.3e-16	-0.47	-0.39	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
LGG	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-9.23	9.18e-19	5.31e-16	-0.54	-0.39	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
LGG	cis	rs11051970	0.527	rs2388989	ENSG00000274964.1	RP11-817I4.1	-9.23	9.21e-19	5.33e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32337341	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs2388988	ENSG00000274964.1	RP11-817I4.1	-9.23	9.21e-19	5.33e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32337414	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs4604975	ENSG00000274964.1	RP11-817I4.1	-9.23	9.21e-19	5.33e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32337441	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.527	rs7309590	ENSG00000274964.1	RP11-817I4.1	-9.23	9.21e-19	5.33e-16	-0.42	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:32339368~32340724:+
LGG	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-9.23	9.22e-19	5.33e-16	-0.47	-0.39	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
LGG	cis	rs7208859	0.623	rs79607958	ENSG00000266490.1	CTD-2349P21.9	9.23	9.25e-19	5.34e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs75136574	ENSG00000266490.1	CTD-2349P21.9	9.23	9.25e-19	5.34e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs77544470	ENSG00000266490.1	CTD-2349P21.9	9.23	9.25e-19	5.34e-16	0.5	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30792372~30792833:+
LGG	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	9.23	9.27e-19	5.36e-16	0.45	0.39	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	9.23	9.27e-19	5.36e-16	0.45	0.39	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
LGG	cis	rs853679	0.556	rs13197633	ENSG00000216901.1	AL022393.7	9.23	9.34e-19	5.4e-16	0.86	0.39	Depression;	chr6:28206979	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.911	rs2394000	ENSG00000216901.1	AL022393.7	9.23	9.37e-19	5.41e-16	0.52	0.39	Parkinson's disease;	chr6:27719212	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.955	rs9393847	ENSG00000216901.1	AL022393.7	9.23	9.37e-19	5.41e-16	0.52	0.39	Parkinson's disease;	chr6:27720194	chr6:28176188~28176674:+
LGG	cis	rs12935418	0.616	rs9936366	ENSG00000260213.4	RP11-303E16.3	-9.22	9.38e-19	5.42e-16	-0.5	-0.39	Mean corpuscular volume;	chr16:81011657	chr16:81016792~81035759:-
LGG	cis	rs9322193	0.923	rs9505982	ENSG00000216621.7	RP11-244K5.6	9.22	9.39e-19	5.42e-16	0.47	0.39	Lung cancer;	chr6:149618465	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9322196	ENSG00000216621.7	RP11-244K5.6	9.22	9.39e-19	5.42e-16	0.47	0.39	Lung cancer;	chr6:149619645	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs10747275	ENSG00000216621.7	RP11-244K5.6	9.22	9.39e-19	5.42e-16	0.47	0.39	Lung cancer;	chr6:149622782	chr6:149934527~149936782:+
LGG	cis	rs6452524	0.935	rs2386241	ENSG00000248112.1	RP11-78C3.1	-9.22	9.39e-19	5.42e-16	-0.52	-0.39	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:82919376~82921119:-
LGG	cis	rs4713118	0.955	rs9468200	ENSG00000216901.1	AL022393.7	9.22	9.53e-19	5.5e-16	0.52	0.39	Parkinson's disease;	chr6:27715284	chr6:28176188~28176674:+
LGG	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	9.22	9.6e-19	5.54e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
LGG	cis	rs9532669	0.926	rs12871420	ENSG00000239827.7	SUGT1P3	-9.22	9.65e-19	5.57e-16	-0.4	-0.39	Cervical cancer;	chr13:40880034	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs12871735	ENSG00000239827.7	SUGT1P3	-9.22	9.65e-19	5.57e-16	-0.4	-0.39	Cervical cancer;	chr13:40880169	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs12871895	ENSG00000239827.7	SUGT1P3	-9.22	9.65e-19	5.57e-16	-0.4	-0.39	Cervical cancer;	chr13:40880189	chr13:40908159~40921774:-
LGG	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	9.22	9.65e-19	5.57e-16	0.61	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
LGG	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-9.22	9.66e-19	5.57e-16	-0.41	-0.39	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	9.22	9.76e-19	5.63e-16	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
LGG	cis	rs1707322	0.963	rs34907901	ENSG00000281133.1	AL355480.3	-9.22	9.77e-19	5.64e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45580892~45580996:-
LGG	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-9.22	9.79e-19	5.65e-16	-0.32	-0.39	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
LGG	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	9.22	9.8e-19	5.65e-16	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
LGG	cis	rs9987353	0.566	rs34389718	ENSG00000173295.6	FAM86B3P	9.22	9.84e-19	5.67e-16	0.43	0.39	Recombination measurement;	chr8:9208015	chr8:8228595~8244865:+
LGG	cis	rs9810089	0.9	rs480162	ENSG00000261758.1	RP11-102M11.2	9.22	9.84e-19	5.68e-16	0.42	0.39	Gestational age at birth (child effect);	chr3:136349853	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.835	rs654237	ENSG00000261758.1	RP11-102M11.2	9.22	9.84e-19	5.68e-16	0.42	0.39	Gestational age at birth (child effect);	chr3:136349857	chr3:136752630~136755780:+
LGG	cis	rs6921919	0.583	rs1054372	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs9468354	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs7773051	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs12697938	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs13437294	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.609	rs9468357	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs34513104	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs9461456	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.525	rs9468360	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs16894021	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs11751693	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs7749736	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.525	rs9468361	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs7775132	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs3734563	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs1591913	ENSG00000218016.2	ZNF192P2	-9.22	9.85e-19	5.68e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28188050~28189432:+
LGG	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-9.22	9.85e-19	5.68e-16	-0.55	-0.39	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
LGG	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-9.22	9.85e-19	5.68e-16	-0.55	-0.39	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
LGG	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-9.22	9.86e-19	5.69e-16	-0.45	-0.39	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
LGG	cis	rs7119038	0.818	rs6589686	ENSG00000255239.1	AP002954.6	-9.22	9.87e-19	5.69e-16	-0.55	-0.39	Sjögren's syndrome;	chr11:118741856	chr11:118688039~118690600:-
LGG	cis	rs1275468	0.68	rs1697753	ENSG00000257497.2	RP11-585P4.5	-9.22	9.89e-19	5.7e-16	-0.55	-0.39	Polycystic ovary syndrome;	chr12:75562074	chr12:75483454~75489820:-
LGG	cis	rs10208649	0.706	rs75833613	ENSG00000272156.1	RP11-477N3.1	9.22	9.91e-19	5.71e-16	0.66	0.39	Body mass index;	chr2:54065224	chr2:54082554~54085066:+
LGG	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	9.22	9.92e-19	5.72e-16	0.63	0.39	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	9.22	9.92e-19	5.72e-16	0.63	0.39	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	9.22	9.92e-19	5.72e-16	0.63	0.39	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
LGG	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	9.22	9.93e-19	5.72e-16	0.45	0.39	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	9.22	9.93e-19	5.72e-16	0.45	0.39	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	9.22	9.93e-19	5.72e-16	0.45	0.39	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
LGG	cis	rs7247513	0.964	rs12979795	ENSG00000213290.4	PGK1P2	9.22	9.93e-19	5.72e-16	0.42	0.39	Bipolar disorder;	chr19:12607033	chr19:12559571~12561105:+
LGG	cis	rs9322193	0.887	rs4870139	ENSG00000216621.7	RP11-244K5.6	9.22	9.93e-19	5.72e-16	0.48	0.39	Lung cancer;	chr6:149575182	chr6:149934527~149936782:+
LGG	cis	rs11168351	1	rs11168351	ENSG00000258273.1	RP11-370I10.4	-9.22	9.95e-19	5.73e-16	-0.48	-0.39	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48333755~48333901:-
LGG	cis	rs1555322	0.872	rs2425046	ENSG00000126005.14	MMP24-AS1	-9.22	9.96e-19	5.74e-16	-0.62	-0.39	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35216462~35278131:-
LGG	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	9.22	9.99e-19	5.76e-16	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
LGG	cis	rs1707322	0.691	rs61784799	ENSG00000281133.1	AL355480.3	9.22	1e-18	5.76e-16	0.47	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45580892~45580996:-
LGG	cis	rs2739330	0.76	rs5751760	ENSG00000272787.1	KB-226F1.2	9.22	1e-18	5.77e-16	0.42	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23969211~23969873:+
LGG	cis	rs9322193	0.923	rs11155677	ENSG00000216621.7	RP11-244K5.6	9.22	1e-18	5.79e-16	0.47	0.39	Lung cancer;	chr6:149756953	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	9.22	1.01e-18	5.79e-16	0.45	0.39	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
LGG	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	9.22	1.01e-18	5.8e-16	0.31	0.39	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
LGG	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-9.22	1.01e-18	5.8e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
LGG	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-9.22	1.01e-18	5.82e-16	-0.43	-0.39	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
LGG	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	9.22	1.01e-18	5.83e-16	0.39	0.39	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
LGG	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-9.21	1.01e-18	5.85e-16	-0.47	-0.39	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
LGG	cis	rs45509595	0.841	rs17751184	ENSG00000216901.1	AL022393.7	9.21	1.02e-18	5.87e-16	0.87	0.39	Breast cancer;	chr6:27807250	chr6:28176188~28176674:+
LGG	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-9.21	1.02e-18	5.88e-16	-0.51	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
LGG	cis	rs9876781	1	rs2362452	ENSG00000244380.1	RP11-24C3.2	-9.21	1.02e-18	5.89e-16	-0.48	-0.39	Longevity;	chr3:48376724	chr3:48440352~48446656:-
LGG	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-9.21	1.03e-18	5.93e-16	-0.55	-0.39	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
LGG	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-9.21	1.03e-18	5.93e-16	-0.37	-0.39	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
LGG	cis	rs1275468	0.731	rs1795380	ENSG00000257497.2	RP11-585P4.5	-9.21	1.03e-18	5.93e-16	-0.56	-0.39	Polycystic ovary syndrome;	chr12:75559432	chr12:75483454~75489820:-
LGG	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-9.21	1.03e-18	5.93e-16	-0.6	-0.39	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
LGG	cis	rs17772222	0.917	rs12431548	ENSG00000222990.1	RNU4-22P	9.21	1.03e-18	5.93e-16	0.51	0.39	Coronary artery calcification;	chr14:88635826	chr14:88513498~88513663:+
LGG	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-9.21	1.03e-18	5.95e-16	-0.33	-0.39	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
LGG	cis	rs11722779	0.935	rs7676736	ENSG00000230069.3	LRRC37A15P	-9.21	1.04e-18	5.96e-16	-0.37	-0.39	Schizophrenia;	chr4:103016729	chr4:102727274~102730721:-
LGG	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-9.21	1.04e-18	5.98e-16	-0.47	-0.39	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
LGG	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-9.21	1.04e-18	5.98e-16	-0.35	-0.39	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
LGG	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-9.21	1.04e-18	5.98e-16	-0.35	-0.39	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
LGG	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	9.21	1.04e-18	5.98e-16	0.45	0.39	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
LGG	cis	rs5742933	0.948	rs10195109	ENSG00000253559.1	OSGEPL1-AS1	9.21	1.04e-18	5.98e-16	0.5	0.39	Ferritin levels;	chr2:189704465	chr2:189762704~189765556:+
LGG	cis	rs7267979	0.586	rs1007707	ENSG00000276952.1	RP5-965G21.6	9.21	1.04e-18	5.98e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	9.21	1.05e-18	6.02e-16	0.46	0.39	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	9.21	1.05e-18	6.02e-16	0.46	0.39	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	9.21	1.05e-18	6.02e-16	0.46	0.39	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
LGG	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	9.21	1.05e-18	6.03e-16	0.47	0.39	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
LGG	cis	rs9527	0.615	rs10883781	ENSG00000272912.1	RP11-724N1.1	-9.21	1.05e-18	6.04e-16	-0.45	-0.39	Arsenic metabolism;	chr10:102821373	chr10:102914585~102915404:+
LGG	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-9.21	1.05e-18	6.04e-16	-0.5	-0.39	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
LGG	cis	rs6903823	0.508	rs1778484	ENSG00000226314.6	ZNF192P1	9.21	1.05e-18	6.07e-16	0.39	0.39	Pulmonary function;	chr6:28273021	chr6:28161781~28169594:+
LGG	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-9.21	1.06e-18	6.1e-16	-0.31	-0.39	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
LGG	cis	rs853679	0.607	rs35749575	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28147040	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs72846780	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28151277	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13205911	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28156336	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13197176	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28161454	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13201308	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28162311	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34765154	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28162672	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs34505829	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28165461	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs35098436	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28166443	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs72846794	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28169721	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13217984	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28171932	chr6:28176188~28176674:+
LGG	cis	rs853679	0.556	rs67297533	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28173475	chr6:28176188~28176674:+
LGG	cis	rs853679	0.505	rs35781323	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28177054	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs13195291	ENSG00000216901.1	AL022393.7	9.21	1.07e-18	6.15e-16	0.86	0.39	Depression;	chr6:28201463	chr6:28176188~28176674:+
LGG	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	9.21	1.07e-18	6.16e-16	0.46	0.39	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	9.21	1.07e-18	6.16e-16	0.46	0.39	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
LGG	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	9.21	1.07e-18	6.16e-16	0.46	0.39	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
LGG	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	9.21	1.07e-18	6.16e-16	0.65	0.39	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
LGG	cis	rs7247513	0.759	rs8110545	ENSG00000213290.4	PGK1P2	-9.21	1.07e-18	6.17e-16	-0.43	-0.39	Bipolar disorder;	chr19:12644084	chr19:12559571~12561105:+
LGG	cis	rs4683346	0.731	rs35807837	ENSG00000273328.4	RP11-141M3.6	-9.21	1.07e-18	6.18e-16	-0.5	-0.39	Granulocyte percentage of myeloid white cells;	chr3:42878743	chr3:42809414~42908105:+
LGG	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-9.21	1.07e-18	6.18e-16	-0.52	-0.39	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
LGG	cis	rs228614	0.51	rs223349	ENSG00000230069.3	LRRC37A15P	-9.21	1.08e-18	6.23e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102727274~102730721:-
LGG	cis	rs853679	0.599	rs13193295	ENSG00000216901.1	AL022393.7	9.21	1.08e-18	6.24e-16	0.85	0.39	Depression;	chr6:28035450	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	9.21	1.09e-18	6.26e-16	0.46	0.39	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
LGG	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-9.21	1.09e-18	6.28e-16	-0.6	-0.39	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
LGG	cis	rs11098499	0.739	rs9996382	ENSG00000249244.1	RP11-548H18.2	9.21	1.09e-18	6.29e-16	0.41	0.39	Corneal astigmatism;	chr4:119229857	chr4:119391831~119395335:-
LGG	cis	rs9987353	0.566	rs13260067	ENSG00000173295.6	FAM86B3P	9.21	1.09e-18	6.29e-16	0.42	0.39	Recombination measurement;	chr8:9213523	chr8:8228595~8244865:+
LGG	cis	rs7746199	0.736	rs35037868	ENSG00000216901.1	AL022393.7	9.2	1.1e-18	6.32e-16	0.87	0.39	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28176188~28176674:+
LGG	cis	rs227275	0.524	rs223337	ENSG00000230069.3	LRRC37A15P	-9.2	1.1e-18	6.33e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	9.2	1.1e-18	6.34e-16	0.46	0.39	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	9.2	1.1e-18	6.34e-16	0.46	0.39	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
LGG	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	9.2	1.11e-18	6.37e-16	0.46	0.39	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
LGG	cis	rs4713118	0.955	rs9368529	ENSG00000216901.1	AL022393.7	9.2	1.11e-18	6.38e-16	0.52	0.39	Parkinson's disease;	chr6:27716852	chr6:28176188~28176674:+
LGG	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	9.2	1.11e-18	6.38e-16	0.45	0.39	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
LGG	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-9.2	1.11e-18	6.39e-16	-0.49	-0.39	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
LGG	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-9.2	1.11e-18	6.4e-16	-0.53	-0.39	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
LGG	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-9.2	1.12e-18	6.42e-16	-0.37	-0.39	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
LGG	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	9.2	1.12e-18	6.42e-16	0.4	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
LGG	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-9.2	1.12e-18	6.42e-16	-0.44	-0.39	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
LGG	cis	rs4713118	0.955	rs9468201	ENSG00000216901.1	AL022393.7	9.2	1.12e-18	6.44e-16	0.52	0.39	Parkinson's disease;	chr6:27719256	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs10872649	ENSG00000216621.7	RP11-244K5.6	9.2	1.13e-18	6.47e-16	0.47	0.39	Lung cancer;	chr6:149759454	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs4870529	ENSG00000216621.7	RP11-244K5.6	9.2	1.13e-18	6.48e-16	0.46	0.39	Lung cancer;	chr6:149716436	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9767309	ENSG00000216621.7	RP11-244K5.6	9.2	1.13e-18	6.48e-16	0.46	0.39	Lung cancer;	chr6:149716807	chr6:149934527~149936782:+
LGG	cis	rs11148252	0.532	rs9526975	ENSG00000198384.8	TPTE2P3	-9.2	1.13e-18	6.48e-16	-0.35	-0.39	Lewy body disease;	chr13:52681669	chr13:52522632~52586906:+
LGG	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	9.2	1.13e-18	6.48e-16	0.52	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
LGG	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	9.2	1.14e-18	6.53e-16	0.47	0.39	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
LGG	cis	rs2251666	0.539	rs17703146	ENSG00000267077.1	RP11-127I20.5	9.2	1.14e-18	6.53e-16	0.52	0.39	Cancer;	chr16:4810104	chr16:4795265~4796532:-
LGG	cis	rs9322193	0.923	rs9767123	ENSG00000216621.7	RP11-244K5.6	9.2	1.14e-18	6.54e-16	0.46	0.39	Lung cancer;	chr6:149660323	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs4870267	ENSG00000216621.7	RP11-244K5.6	9.2	1.14e-18	6.54e-16	0.46	0.39	Lung cancer;	chr6:149671572	chr6:149934527~149936782:+
LGG	cis	rs7267979	0.844	rs6107027	ENSG00000276952.1	RP5-965G21.6	9.2	1.14e-18	6.54e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25284915~25285588:-
LGG	cis	rs4683346	0.731	rs7623543	ENSG00000273328.4	RP11-141M3.6	-9.2	1.14e-18	6.54e-16	-0.5	-0.39	Granulocyte percentage of myeloid white cells;	chr3:42880135	chr3:42809414~42908105:+
LGG	cis	rs7746199	0.736	rs17693963	ENSG00000199851.2	U3	9.2	1.14e-18	6.55e-16	0.93	0.39	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28015568~28015777:+
LGG	cis	rs10208649	0.611	rs61740458	ENSG00000272156.1	RP11-477N3.1	9.2	1.15e-18	6.57e-16	0.65	0.39	Body mass index;	chr2:54065503	chr2:54082554~54085066:+
LGG	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-9.2	1.15e-18	6.58e-16	-0.53	-0.39	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
LGG	cis	rs9532669	0.926	rs12428966	ENSG00000168852.11	TPTE2P5	9.2	1.15e-18	6.58e-16	0.39	0.39	Cervical cancer;	chr13:40876552	chr13:40822296~40921749:-
LGG	cis	rs1707322	0.686	rs3014236	ENSG00000281133.1	AL355480.3	9.2	1.15e-18	6.59e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45580892~45580996:-
LGG	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	9.2	1.15e-18	6.61e-16	0.47	0.39	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
LGG	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-9.2	1.15e-18	6.62e-16	-0.5	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
LGG	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	9.2	1.16e-18	6.63e-16	0.31	0.39	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
LGG	cis	rs858239	0.537	rs6942981	ENSG00000230042.1	AK3P3	-9.2	1.16e-18	6.64e-16	-0.41	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23129178~23129841:+
LGG	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	9.2	1.16e-18	6.64e-16	0.53	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
LGG	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-9.2	1.16e-18	6.65e-16	-0.53	-0.39	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
LGG	cis	rs1707322	0.686	rs3014235	ENSG00000281133.1	AL355480.3	9.2	1.16e-18	6.66e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45580892~45580996:-
LGG	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-9.2	1.16e-18	6.67e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
LGG	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-9.2	1.16e-18	6.67e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
LGG	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-9.2	1.17e-18	6.69e-16	-0.33	-0.39	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
LGG	cis	rs2278702	0.943	rs77271632	ENSG00000259495.2	RP11-210M15.2	-9.2	1.17e-18	6.7e-16	-0.47	-0.39	Bipolar disorder;	chr15:80396735	chr15:80344853~80403575:-
LGG	cis	rs227275	0.554	rs223319	ENSG00000230069.3	LRRC37A15P	-9.2	1.17e-18	6.71e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102727274~102730721:-
LGG	cis	rs228614	0.509	rs223318	ENSG00000230069.3	LRRC37A15P	-9.2	1.17e-18	6.71e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223315	ENSG00000230069.3	LRRC37A15P	-9.2	1.17e-18	6.71e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102727274~102730721:-
LGG	cis	rs7208859	0.673	rs9915963	ENSG00000266490.1	CTD-2349P21.9	9.2	1.17e-18	6.71e-16	0.47	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30792372~30792833:+
LGG	cis	rs1707322	0.682	rs10890334	ENSG00000281133.1	AL355480.3	-9.2	1.17e-18	6.71e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.682	rs10890335	ENSG00000281133.1	AL355480.3	-9.2	1.17e-18	6.71e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.716	rs6694889	ENSG00000281133.1	AL355480.3	-9.2	1.17e-18	6.71e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45580892~45580996:-
LGG	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	9.2	1.18e-18	6.74e-16	0.93	0.39	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	9.2	1.18e-18	6.74e-16	0.47	0.39	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
LGG	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	9.2	1.18e-18	6.75e-16	0.28	0.39	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
LGG	cis	rs7267979	0.764	rs2474767	ENSG00000276952.1	RP5-965G21.6	9.2	1.18e-18	6.76e-16	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25284915~25285588:-
LGG	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-9.2	1.18e-18	6.77e-16	-0.37	-0.39	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
LGG	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	9.2	1.18e-18	6.77e-16	0.5	0.39	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
LGG	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-9.2	1.19e-18	6.8e-16	-0.49	-0.39	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
LGG	cis	rs1707322	0.721	rs4559551	ENSG00000281133.1	AL355480.3	-9.2	1.19e-18	6.8e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	9.2	1.19e-18	6.81e-16	0.45	0.39	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	9.2	1.19e-18	6.81e-16	0.45	0.39	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	9.2	1.19e-18	6.81e-16	0.45	0.39	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
LGG	cis	rs1560104	0.833	rs4381588	ENSG00000274834.1	CTD-3037G24.5	-9.19	1.19e-18	6.82e-16	-0.49	-0.39	Obesity-related traits;	chr16:12623414	chr16:12614451~12614852:+
LGG	cis	rs1560104	0.879	rs2865578	ENSG00000274834.1	CTD-3037G24.5	-9.19	1.19e-18	6.82e-16	-0.49	-0.39	Obesity-related traits;	chr16:12623457	chr16:12614451~12614852:+
LGG	cis	rs9322193	0.886	rs2065663	ENSG00000216621.7	RP11-244K5.6	9.19	1.19e-18	6.82e-16	0.47	0.39	Lung cancer;	chr6:149760331	chr6:149934527~149936782:+
LGG	cis	rs227275	0.554	rs223466	ENSG00000230069.3	LRRC37A15P	-9.19	1.21e-18	6.9e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102727274~102730721:-
LGG	cis	rs853679	0.546	rs35016036	ENSG00000199851.2	U3	9.19	1.21e-18	6.91e-16	0.97	0.39	Depression;	chr6:28347103	chr6:28015568~28015777:+
LGG	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	9.19	1.21e-18	6.91e-16	0.41	0.39	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
LGG	cis	rs1707322	1	rs6657720	ENSG00000281133.1	AL355480.3	-9.19	1.21e-18	6.93e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs7519181	ENSG00000281133.1	AL355480.3	-9.19	1.21e-18	6.93e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45580892~45580996:-
LGG	cis	rs2739330	0.76	rs5760095	ENSG00000272787.1	KB-226F1.2	9.19	1.21e-18	6.95e-16	0.41	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23969211~23969873:+
LGG	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-9.19	1.22e-18	6.96e-16	-0.45	-0.39	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
LGG	cis	rs9527	0.59	rs10883839	ENSG00000272912.1	RP11-724N1.1	-9.19	1.22e-18	6.96e-16	-0.46	-0.39	Arsenic metabolism;	chr10:103160584	chr10:102914585~102915404:+
LGG	cis	rs62184315	0.629	rs5743072	ENSG00000273240.1	RP11-455J20.3	-9.19	1.23e-18	7.02e-16	-0.52	-0.39	Alcohol dependence (age at onset);	chr2:189832198	chr2:189763859~189764456:-
LGG	cis	rs228614	0.536	rs150898	ENSG00000230069.3	LRRC37A15P	-9.19	1.23e-18	7.03e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102727274~102730721:-
LGG	cis	rs2282300	0.637	rs2065418	ENSG00000254532.1	RP11-624D11.2	9.19	1.23e-18	7.03e-16	0.47	0.39	Morning vs. evening chronotype;	chr11:30400521	chr11:30044058~30084343:-
LGG	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-9.19	1.23e-18	7.03e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
LGG	cis	rs228614	0.536	rs223478	ENSG00000230069.3	LRRC37A15P	-9.19	1.23e-18	7.03e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102727274~102730721:-
LGG	cis	rs228614	0.509	rs223476	ENSG00000230069.3	LRRC37A15P	-9.19	1.23e-18	7.04e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102727274~102730721:-
LGG	cis	rs228614	0.509	rs150896	ENSG00000230069.3	LRRC37A15P	-9.19	1.23e-18	7.04e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102727274~102730721:-
LGG	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	9.19	1.24e-18	7.08e-16	0.31	0.39	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
LGG	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	9.19	1.24e-18	7.08e-16	0.31	0.39	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
LGG	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	9.19	1.24e-18	7.09e-16	0.57	0.39	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
LGG	cis	rs7267979	0.789	rs4815429	ENSG00000276952.1	RP5-965G21.6	-9.19	1.24e-18	7.1e-16	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25284915~25285588:-
LGG	cis	rs657075	0.697	rs4646200	ENSG00000263597.1	MIR3936	-9.19	1.25e-18	7.12e-16	-0.66	-0.39	Rheumatoid arthritis;	chr5:132335443	chr5:132365490~132365599:-
LGG	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	9.19	1.25e-18	7.12e-16	0.46	0.39	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
LGG	cis	rs9322193	0.884	rs9688794	ENSG00000216621.7	RP11-244K5.6	9.19	1.25e-18	7.14e-16	0.47	0.39	Lung cancer;	chr6:149632121	chr6:149934527~149936782:+
LGG	cis	rs853679	0.607	rs34243448	ENSG00000216901.1	AL022393.7	9.19	1.25e-18	7.14e-16	0.86	0.39	Depression;	chr6:28225324	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13204012	ENSG00000216901.1	AL022393.7	9.19	1.25e-18	7.14e-16	0.86	0.39	Depression;	chr6:28233753	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs13205211	ENSG00000216901.1	AL022393.7	9.19	1.25e-18	7.14e-16	0.86	0.39	Depression;	chr6:28235278	chr6:28176188~28176674:+
LGG	cis	rs11722779	0.935	rs3857200	ENSG00000230069.3	LRRC37A15P	-9.19	1.25e-18	7.17e-16	-0.37	-0.39	Schizophrenia;	chr4:103001864	chr4:102727274~102730721:-
LGG	cis	rs3020264	0.579	rs2454517	ENSG00000271743.1	CTD-2541M15.3	-9.19	1.25e-18	7.17e-16	-0.45	-0.39	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6616237	chr8:6615604~6617198:-
LGG	cis	rs6921919	0.583	rs16894060	ENSG00000218016.2	ZNF192P2	-9.19	1.26e-18	7.18e-16	-0.47	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.515	rs1558205	ENSG00000218016.2	ZNF192P2	9.19	1.26e-18	7.19e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28188050~28189432:+
LGG	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	9.19	1.26e-18	7.21e-16	0.31	0.39	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
LGG	cis	rs7302981	0.845	rs56709084	ENSG00000272368.2	RP4-605O3.4	9.19	1.26e-18	7.23e-16	0.38	0.39	Systolic blood pressure;	chr12:50170107	chr12:50112197~50165618:+
LGG	cis	rs11098499	0.739	rs2203039	ENSG00000249244.1	RP11-548H18.2	-9.19	1.28e-18	7.32e-16	-0.42	-0.39	Corneal astigmatism;	chr4:119211192	chr4:119391831~119395335:-
LGG	cis	rs35491132	1	rs35491132	ENSG00000199851.2	U3	9.19	1.29e-18	7.35e-16	0.96	0.39	Urinary tract infection frequency;	chr6:27559449	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	9.18	1.3e-18	7.43e-16	0.44	0.39	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.686	rs2991987	ENSG00000281133.1	AL355480.3	9.18	1.3e-18	7.43e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45580892~45580996:-
LGG	cis	rs853679	0.546	rs35744819	ENSG00000216901.1	AL022393.7	9.18	1.31e-18	7.47e-16	0.87	0.39	Depression;	chr6:28350554	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.703	rs5760112	ENSG00000272787.1	KB-226F1.2	9.18	1.31e-18	7.47e-16	0.41	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23969211~23969873:+
LGG	cis	rs4281086	0.896	rs13280729	ENSG00000253678.1	RP11-981G7.3	-9.18	1.31e-18	7.48e-16	-0.43	-0.39	Obesity-related traits;	chr8:10508910	chr8:10477491~10479375:-
LGG	cis	rs853679	0.882	rs9468300	ENSG00000226314.6	ZNF192P1	9.18	1.31e-18	7.48e-16	0.59	0.39	Depression;	chr6:28159062	chr6:28161781~28169594:+
LGG	cis	rs853679	0.825	rs8180562	ENSG00000226314.6	ZNF192P1	9.18	1.31e-18	7.48e-16	0.59	0.39	Depression;	chr6:28173682	chr6:28161781~28169594:+
LGG	cis	rs853679	0.882	rs9380064	ENSG00000226314.6	ZNF192P1	9.18	1.31e-18	7.48e-16	0.59	0.39	Depression;	chr6:28175340	chr6:28161781~28169594:+
LGG	cis	rs853679	0.546	rs35744819	ENSG00000199851.2	U3	9.18	1.31e-18	7.5e-16	0.97	0.39	Depression;	chr6:28350554	chr6:28015568~28015777:+
LGG	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-9.18	1.31e-18	7.51e-16	-0.43	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
LGG	cis	rs227275	0.554	rs223467	ENSG00000230069.3	LRRC37A15P	-9.18	1.32e-18	7.51e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102727274~102730721:-
LGG	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-9.18	1.32e-18	7.52e-16	-0.34	-0.39	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
LGG	cis	rs1707322	0.717	rs1547925	ENSG00000281133.1	AL355480.3	9.18	1.32e-18	7.55e-16	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	9.18	1.33e-18	7.57e-16	0.45	0.39	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
LGG	cis	rs944990	0.576	rs10821135	ENSG00000227603.1	RP11-165J3.6	9.18	1.34e-18	7.64e-16	0.39	0.39	Body mass index;	chr9:93476296	chr9:93435332~93437121:-
LGG	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-9.18	1.34e-18	7.65e-16	-0.5	-0.39	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
LGG	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-9.18	1.34e-18	7.65e-16	-0.5	-0.39	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
LGG	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	9.18	1.34e-18	7.66e-16	0.45	0.39	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
LGG	cis	rs9481169	0.717	rs13191781	ENSG00000255389.1	C6orf3	-9.18	1.34e-18	7.67e-16	-0.8	-0.39	Inflammatory skin disease;	chr6:111620083	chr6:111599875~111602295:+
LGG	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	9.18	1.34e-18	7.67e-16	0.69	0.39	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
LGG	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-9.18	1.34e-18	7.67e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
LGG	cis	rs9322193	0.923	rs4869750	ENSG00000216621.7	RP11-244K5.6	9.18	1.35e-18	7.7e-16	0.46	0.39	Lung cancer;	chr6:149855996	chr6:149934527~149936782:+
LGG	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-9.18	1.36e-18	7.77e-16	-0.53	-0.39	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
LGG	cis	rs6921919	0.583	rs7764722	ENSG00000280107.1	AL022393.9	-9.18	1.36e-18	7.77e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28170845~28172521:+
LGG	cis	rs12922040	0.607	rs8059739	ENSG00000263335.1	AF001548.5	-9.18	1.36e-18	7.77e-16	-0.4	-0.39	Serum uric acid levels in response to allopurinol in gout;	chr16:15772869	chr16:15726674~15732993:+
LGG	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-9.18	1.36e-18	7.78e-16	-0.45	-0.39	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	9.18	1.36e-18	7.78e-16	0.45	0.39	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
LGG	cis	rs9532669	0.89	rs11619117	ENSG00000168852.11	TPTE2P5	9.18	1.37e-18	7.8e-16	0.39	0.39	Cervical cancer;	chr13:40880020	chr13:40822296~40921749:-
LGG	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-9.18	1.37e-18	7.82e-16	-0.46	-0.39	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
LGG	cis	rs228614	0.51	rs223397	ENSG00000230069.3	LRRC37A15P	-9.18	1.37e-18	7.83e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102727274~102730721:-
LGG	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-9.18	1.37e-18	7.84e-16	-0.52	-0.39	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
LGG	cis	rs853679	0.607	rs67101035	ENSG00000199851.2	U3	9.18	1.38e-18	7.84e-16	0.98	0.39	Depression;	chr6:27831109	chr6:28015568~28015777:+
LGG	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-9.18	1.38e-18	7.85e-16	-0.59	-0.39	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
LGG	cis	rs1707322	0.752	rs28550303	ENSG00000281133.1	AL355480.3	-9.18	1.38e-18	7.85e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.716	rs28375469	ENSG00000281133.1	AL355480.3	-9.18	1.38e-18	7.85e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs28545085	ENSG00000281133.1	AL355480.3	-9.18	1.38e-18	7.85e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs28507722	ENSG00000281133.1	AL355480.3	-9.18	1.38e-18	7.85e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.717	rs28396194	ENSG00000281133.1	AL355480.3	-9.18	1.38e-18	7.85e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.717	rs28752166	ENSG00000281133.1	AL355480.3	-9.18	1.38e-18	7.85e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45580892~45580996:-
LGG	cis	rs12935418	0.672	rs11866803	ENSG00000260213.4	RP11-303E16.3	-9.18	1.38e-18	7.87e-16	-0.5	-0.39	Mean corpuscular volume;	chr16:81017598	chr16:81016792~81035759:-
LGG	cis	rs9527	0.641	rs4919684	ENSG00000272912.1	RP11-724N1.1	-9.18	1.38e-18	7.88e-16	-0.44	-0.39	Arsenic metabolism;	chr10:102827267	chr10:102914585~102915404:+
LGG	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-9.18	1.39e-18	7.92e-16	-0.53	-0.39	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-9.18	1.39e-18	7.92e-16	-0.53	-0.39	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
LGG	cis	rs7267979	0.816	rs405822	ENSG00000276952.1	RP5-965G21.6	9.17	1.39e-18	7.95e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.816	rs6138593	ENSG00000276952.1	RP5-965G21.6	9.17	1.39e-18	7.95e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.816	rs409853	ENSG00000276952.1	RP5-965G21.6	9.17	1.39e-18	7.95e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.816	rs390123	ENSG00000276952.1	RP5-965G21.6	9.17	1.4e-18	7.95e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-9.17	1.4e-18	7.97e-16	-0.51	-0.39	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
LGG	cis	rs7267979	0.816	rs404775	ENSG00000276952.1	RP5-965G21.6	9.17	1.4e-18	7.97e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.816	rs374701	ENSG00000276952.1	RP5-965G21.6	9.17	1.4e-18	7.97e-16	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25284915~25285588:-
LGG	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-9.17	1.4e-18	7.98e-16	-0.3	-0.39	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
LGG	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-9.17	1.4e-18	7.98e-16	-0.3	-0.39	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
LGG	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-9.17	1.4e-18	7.98e-16	-0.3	-0.39	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
LGG	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-9.17	1.4e-18	7.98e-16	-0.44	-0.39	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
LGG	cis	rs4713118	0.955	rs9468204	ENSG00000216901.1	AL022393.7	9.17	1.41e-18	8.02e-16	0.51	0.39	Parkinson's disease;	chr6:27721030	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	9.17	1.41e-18	8.03e-16	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
LGG	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	-9.17	1.41e-18	8.03e-16	-0.4	-0.39	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
LGG	cis	rs227275	0.556	rs724447	ENSG00000230069.3	LRRC37A15P	9.17	1.42e-18	8.08e-16	0.37	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102727274~102730721:-
LGG	cis	rs7267979	0.844	rs4815413	ENSG00000276952.1	RP5-965G21.6	-9.17	1.42e-18	8.09e-16	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs6083824	ENSG00000276952.1	RP5-965G21.6	-9.17	1.42e-18	8.09e-16	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25284915~25285588:-
LGG	cis	rs4986172	0.726	rs12946454	ENSG00000267288.2	RP13-890H12.2	-9.17	1.42e-18	8.09e-16	-0.52	-0.39	Height;	chr17:45130754	chr17:45168800~45171584:-
LGG	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-9.17	1.42e-18	8.09e-16	-0.3	-0.39	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
LGG	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-9.17	1.42e-18	8.09e-16	-0.3	-0.39	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
LGG	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	9.17	1.42e-18	8.09e-16	0.56	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
LGG	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	-9.17	1.43e-18	8.12e-16	-0.4	-0.39	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
LGG	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-9.17	1.43e-18	8.12e-16	-0.3	-0.39	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
LGG	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-9.17	1.43e-18	8.12e-16	-0.3	-0.39	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
LGG	cis	rs10208649	0.611	rs3929001	ENSG00000272156.1	RP11-477N3.1	-9.17	1.43e-18	8.14e-16	-0.65	-0.39	Body mass index;	chr2:54055750	chr2:54082554~54085066:+
LGG	cis	rs9322193	0.923	rs55849538	ENSG00000216621.7	RP11-244K5.6	9.17	1.43e-18	8.17e-16	0.47	0.39	Lung cancer;	chr6:149635330	chr6:149934527~149936782:+
LGG	cis	rs7829975	0.511	rs1401390	ENSG00000253981.4	ALG1L13P	-9.17	1.44e-18	8.19e-16	-0.41	-0.39	Mood instability;	chr8:8278888	chr8:8236003~8244667:-
LGG	cis	rs2412819	0.571	rs4923965	ENSG00000249839.1	AC011330.5	9.17	1.44e-18	8.2e-16	0.63	0.39	Lung cancer;	chr15:43790232	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs4644832	ENSG00000249839.1	AC011330.5	9.17	1.44e-18	8.2e-16	0.63	0.39	Lung cancer;	chr15:43792507	chr15:43663654~43684339:-
LGG	cis	rs9810089	0.711	rs711972	ENSG00000261758.1	RP11-102M11.2	9.17	1.44e-18	8.21e-16	0.42	0.39	Gestational age at birth (child effect);	chr3:136391176	chr3:136752630~136755780:+
LGG	cis	rs1707322	0.717	rs12023439	ENSG00000281133.1	AL355480.3	-9.17	1.44e-18	8.21e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45580892~45580996:-
LGG	cis	rs9532669	0.89	rs9532593	ENSG00000239827.7	SUGT1P3	-9.17	1.44e-18	8.22e-16	-0.41	-0.39	Cervical cancer;	chr13:40847717	chr13:40908159~40921774:-
LGG	cis	rs9322193	0.847	rs62439808	ENSG00000216621.7	RP11-244K5.6	9.17	1.45e-18	8.23e-16	0.46	0.39	Lung cancer;	chr6:149629690	chr6:149934527~149936782:+
LGG	cis	rs17345786	0.953	rs78645744	ENSG00000256628.3	ZBTB11-AS1	9.17	1.45e-18	8.23e-16	0.49	0.39	Colonoscopy-negative controls vs population controls;	chr3:101608945	chr3:101676475~101679217:+
LGG	cis	rs228614	0.51	rs223328	ENSG00000230069.3	LRRC37A15P	-9.17	1.45e-18	8.28e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102727274~102730721:-
LGG	cis	rs228614	0.536	rs223325	ENSG00000230069.3	LRRC37A15P	-9.17	1.45e-18	8.28e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102727274~102730721:-
LGG	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-9.17	1.46e-18	8.28e-16	-0.5	-0.39	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
LGG	cis	rs7432375	0.899	rs6439655	ENSG00000261758.1	RP11-102M11.2	-9.17	1.46e-18	8.29e-16	-0.4	-0.39	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136747757	chr3:136752630~136755780:+
LGG	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	9.17	1.46e-18	8.31e-16	0.4	0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
LGG	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-9.17	1.46e-18	8.31e-16	-0.53	-0.39	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
LGG	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	9.17	1.46e-18	8.31e-16	0.39	0.39	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
LGG	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-9.17	1.46e-18	8.32e-16	-0.49	-0.39	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
LGG	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	9.17	1.46e-18	8.32e-16	0.45	0.39	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
LGG	cis	rs6921919	0.583	rs6908137	ENSG00000280107.1	AL022393.9	-9.17	1.46e-18	8.33e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28170845~28172521:+
LGG	cis	rs1707322	0.752	rs11211168	ENSG00000281133.1	AL355480.3	-9.17	1.47e-18	8.35e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs11211171	ENSG00000281133.1	AL355480.3	-9.17	1.47e-18	8.35e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs28623463	ENSG00000281133.1	AL355480.3	-9.17	1.47e-18	8.35e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.716	rs28370457	ENSG00000281133.1	AL355480.3	-9.17	1.47e-18	8.35e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	9.17	1.47e-18	8.37e-16	0.45	0.39	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.721	rs11211165	ENSG00000281133.1	AL355480.3	-9.17	1.47e-18	8.38e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs11211166	ENSG00000281133.1	AL355480.3	-9.17	1.47e-18	8.38e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.647	rs6686944	ENSG00000281133.1	AL355480.3	-9.17	1.48e-18	8.42e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
LGG	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.49e-16	0.45	0.39	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	9.17	1.5e-18	8.5e-16	0.45	0.39	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
LGG	cis	rs1707322	1	rs7517560	ENSG00000281133.1	AL355480.3	-9.17	1.5e-18	8.52e-16	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45580892~45580996:-
LGG	cis	rs893971	0.672	rs10024717	ENSG00000246375.2	RP11-10L7.1	9.17	1.5e-18	8.53e-16	0.47	0.39	Conduct disorder (maternal expressed emotions interaction);	chr4:88298493	chr4:88284942~88331421:+
LGG	cis	rs853679	0.607	rs13194781	ENSG00000199851.2	U3	9.16	1.51e-18	8.56e-16	0.98	0.39	Depression;	chr6:27847861	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs36116761	ENSG00000199851.2	U3	9.16	1.51e-18	8.56e-16	0.98	0.39	Depression;	chr6:27850704	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs34194357	ENSG00000199851.2	U3	9.16	1.51e-18	8.56e-16	0.98	0.39	Depression;	chr6:27850757	chr6:28015568~28015777:+
LGG	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	9.16	1.51e-18	8.59e-16	0.49	0.39	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
LGG	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-9.16	1.52e-18	8.6e-16	-0.49	-0.39	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
LGG	cis	rs9810089	0.708	rs711977	ENSG00000261758.1	RP11-102M11.2	9.16	1.52e-18	8.63e-16	0.41	0.39	Gestational age at birth (child effect);	chr3:136508545	chr3:136752630~136755780:+
LGG	cis	rs7267979	0.844	rs35735333	ENSG00000276952.1	RP5-965G21.6	-9.16	1.52e-18	8.64e-16	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25284915~25285588:-
LGG	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-9.16	1.52e-18	8.65e-16	-0.48	-0.39	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-9.16	1.52e-18	8.65e-16	-0.48	-0.39	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.923	rs6913486	ENSG00000216621.7	RP11-244K5.6	-9.16	1.53e-18	8.66e-16	-0.47	-0.39	Lung cancer;	chr6:149705060	chr6:149934527~149936782:+
LGG	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-9.16	1.53e-18	8.7e-16	-0.53	-0.39	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	9.16	1.53e-18	8.7e-16	0.45	0.39	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	9.16	1.53e-18	8.7e-16	0.45	0.39	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	9.16	1.53e-18	8.7e-16	0.45	0.39	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs10782310	ENSG00000216621.7	RP11-244K5.6	9.16	1.54e-18	8.71e-16	0.46	0.39	Lung cancer;	chr6:149622458	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs10782311	ENSG00000216621.7	RP11-244K5.6	9.16	1.54e-18	8.71e-16	0.46	0.39	Lung cancer;	chr6:149622592	chr6:149934527~149936782:+
LGG	cis	rs2739330	0.828	rs2186366	ENSG00000235689.1	AP000351.13	-9.16	1.54e-18	8.73e-16	-0.45	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:24006305~24008258:-
LGG	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-9.16	1.54e-18	8.76e-16	-0.39	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-9.16	1.54e-18	8.76e-16	-0.39	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
LGG	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	9.16	1.54e-18	8.76e-16	0.27	0.39	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
LGG	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-9.16	1.55e-18	8.78e-16	-0.31	-0.39	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
LGG	cis	rs9527	0.59	rs7894959	ENSG00000272912.1	RP11-724N1.1	-9.16	1.56e-18	8.85e-16	-0.45	-0.39	Arsenic metabolism;	chr10:102996425	chr10:102914585~102915404:+
LGG	cis	rs12935418	0.672	rs9889194	ENSG00000260213.4	RP11-303E16.3	-9.16	1.56e-18	8.86e-16	-0.49	-0.39	Mean corpuscular volume;	chr16:81017212	chr16:81016792~81035759:-
LGG	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	9.16	1.56e-18	8.87e-16	0.51	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
LGG	cis	rs7746199	0.736	rs35037868	ENSG00000199851.2	U3	9.16	1.57e-18	8.88e-16	0.97	0.39	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28015568~28015777:+
LGG	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	9.16	1.57e-18	8.92e-16	0.38	0.39	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
LGG	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-9.16	1.58e-18	8.94e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
LGG	cis	rs893363	0.61	rs920252	ENSG00000271916.1	RP11-884K10.6	-9.16	1.58e-18	8.97e-16	-0.49	-0.39	Axial length;	chr3:53814645	chr3:53797764~53798019:-
LGG	cis	rs45509595	0.841	rs17751184	ENSG00000199851.2	U3	9.16	1.58e-18	8.98e-16	0.97	0.39	Breast cancer;	chr6:27807250	chr6:28015568~28015777:+
LGG	cis	rs227275	0.554	rs223382	ENSG00000230069.3	LRRC37A15P	-9.16	1.59e-18	8.99e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223377	ENSG00000230069.3	LRRC37A15P	-9.16	1.59e-18	8.99e-16	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102727274~102730721:-
LGG	cis	rs2278702	0.943	rs57384130	ENSG00000259495.2	RP11-210M15.2	-9.16	1.59e-18	9e-16	-0.47	-0.39	Bipolar disorder;	chr15:80392604	chr15:80344853~80403575:-
LGG	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	9.16	1.59e-18	9.03e-16	0.47	0.39	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
LGG	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-9.16	1.6e-18	9.06e-16	-0.59	-0.39	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
LGG	cis	rs227275	0.554	rs223357	ENSG00000230069.3	LRRC37A15P	-9.16	1.6e-18	9.08e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102727274~102730721:-
LGG	cis	rs853679	0.607	rs35001169	ENSG00000199851.2	U3	9.16	1.6e-18	9.09e-16	0.97	0.39	Depression;	chr6:28219854	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs35656932	ENSG00000199851.2	U3	9.16	1.6e-18	9.09e-16	0.97	0.39	Depression;	chr6:28223510	chr6:28015568~28015777:+
LGG	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-9.16	1.6e-18	9.09e-16	-0.39	-0.39	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
LGG	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-9.16	1.61e-18	9.1e-16	-0.52	-0.39	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
LGG	cis	rs950776	0.518	rs4887063	ENSG00000261762.1	RP11-650L12.2	-9.16	1.61e-18	9.11e-16	-0.49	-0.39	Sudden cardiac arrest;	chr15:78547373	chr15:78589123~78591276:-
LGG	cis	rs853679	0.607	rs35001169	ENSG00000216901.1	AL022393.7	9.16	1.61e-18	9.11e-16	0.86	0.39	Depression;	chr6:28219854	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs35656932	ENSG00000216901.1	AL022393.7	9.16	1.61e-18	9.11e-16	0.86	0.39	Depression;	chr6:28223510	chr6:28176188~28176674:+
LGG	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-9.16	1.61e-18	9.15e-16	-0.3	-0.39	Breast cancer;	chr11:825777	chr11:781645~782105:+
LGG	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	9.16	1.62e-18	9.2e-16	0.45	0.39	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.752	rs12062535	ENSG00000281133.1	AL355480.3	-9.16	1.62e-18	9.2e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45580892~45580996:-
LGG	cis	rs9532669	0.926	rs4941995	ENSG00000239827.7	SUGT1P3	-9.16	1.63e-18	9.21e-16	-0.41	-0.39	Cervical cancer;	chr13:40850117	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9315789	ENSG00000239827.7	SUGT1P3	-9.16	1.63e-18	9.21e-16	-0.41	-0.39	Cervical cancer;	chr13:40852898	chr13:40908159~40921774:-
LGG	cis	rs17772222	0.582	rs1288122	ENSG00000258983.2	RP11-507K2.2	-9.16	1.63e-18	9.22e-16	-0.44	-0.39	Coronary artery calcification;	chr14:88472736	chr14:88499334~88515502:+
LGG	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	9.15	1.64e-18	9.26e-16	0.51	0.39	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
LGG	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-9.15	1.64e-18	9.28e-16	-0.31	-0.39	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
LGG	cis	rs17345786	0.817	rs11720560	ENSG00000256628.3	ZBTB11-AS1	9.15	1.64e-18	9.31e-16	0.49	0.39	Colonoscopy-negative controls vs population controls;	chr3:101609640	chr3:101676475~101679217:+
LGG	cis	rs4713118	0.868	rs2893928	ENSG00000216901.1	AL022393.7	9.15	1.65e-18	9.33e-16	0.54	0.39	Parkinson's disease;	chr6:27770651	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	9.15	1.65e-18	9.33e-16	0.45	0.39	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
LGG	cis	rs2282300	0.956	rs1222212	ENSG00000242353.1	RP4-710M3.1	-9.15	1.65e-18	9.35e-16	-0.55	-0.39	Morning vs. evening chronotype;	chr11:30353096	chr11:30368148~30368646:+
LGG	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-9.15	1.65e-18	9.35e-16	-0.42	-0.39	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
LGG	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	9.15	1.66e-18	9.38e-16	0.45	0.39	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	9.15	1.66e-18	9.39e-16	0.45	0.39	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.721	rs10430124	ENSG00000281133.1	AL355480.3	-9.15	1.66e-18	9.41e-16	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45580892~45580996:-
LGG	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	9.15	1.67e-18	9.43e-16	0.56	0.39	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
LGG	cis	rs853679	0.556	rs34706883	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Depression;	chr6:27837477	chr6:28015568~28015777:+
LGG	cis	rs67340775	0.748	rs13212651	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Lung cancer in ever smokers;	chr6:27839207	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs35819751	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Depression;	chr6:27842791	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13199772	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Depression;	chr6:27866307	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13199906	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Depression;	chr6:27866361	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs17763089	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Depression;	chr6:27867440	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs17695758	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Depression;	chr6:27869405	chr6:28015568~28015777:+
LGG	cis	rs853679	0.556	rs45509595	ENSG00000199851.2	U3	9.15	1.67e-18	9.46e-16	0.98	0.39	Depression;	chr6:27873148	chr6:28015568~28015777:+
LGG	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	9.15	1.68e-18	9.5e-16	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
LGG	cis	rs6921919	0.583	rs2071965	ENSG00000280107.1	AL022393.9	-9.15	1.68e-18	9.53e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28170845~28172521:+
LGG	cis	rs453301	0.574	rs10081437	ENSG00000253893.2	FAM85B	9.15	1.69e-18	9.55e-16	0.48	0.39	Joint mobility (Beighton score);	chr8:9091469	chr8:8167819~8226614:-
LGG	cis	rs6903823	0.508	rs1150726	ENSG00000226314.6	ZNF192P1	9.15	1.69e-18	9.56e-16	0.39	0.39	Pulmonary function;	chr6:28275265	chr6:28161781~28169594:+
LGG	cis	rs9532669	0.926	rs7322399	ENSG00000168852.11	TPTE2P5	9.15	1.69e-18	9.57e-16	0.4	0.39	Cervical cancer;	chr13:40952511	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7322097	ENSG00000168852.11	TPTE2P5	9.15	1.69e-18	9.57e-16	0.4	0.39	Cervical cancer;	chr13:40952513	chr13:40822296~40921749:-
LGG	cis	rs1555322	0.872	rs2425048	ENSG00000126005.14	MMP24-AS1	-9.15	1.69e-18	9.57e-16	-0.62	-0.39	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35216462~35278131:-
LGG	cis	rs5742933	1	rs1898560	ENSG00000253559.1	OSGEPL1-AS1	-9.15	1.7e-18	9.6e-16	-0.5	-0.39	Ferritin levels;	chr2:189747601	chr2:189762704~189765556:+
LGG	cis	rs571497	0.877	rs868878	ENSG00000268297.1	CLEC4GP1	-9.15	1.71e-18	9.65e-16	-0.52	-0.39	Monocyte count;	chr19:7766161	chr19:7787549~7790621:+
LGG	cis	rs227275	0.554	rs9307281	ENSG00000230069.3	LRRC37A15P	-9.15	1.71e-18	9.67e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.903	rs6533037	ENSG00000230069.3	LRRC37A15P	-9.15	1.71e-18	9.67e-16	-0.37	-0.39	Schizophrenia;	chr4:102935865	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.903	rs4530634	ENSG00000230069.3	LRRC37A15P	-9.15	1.71e-18	9.67e-16	-0.37	-0.39	Schizophrenia;	chr4:102937924	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs7676943	ENSG00000230069.3	LRRC37A15P	-9.15	1.71e-18	9.67e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs6419160	ENSG00000230069.3	LRRC37A15P	-9.15	1.71e-18	9.67e-16	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.838	rs3974494	ENSG00000230069.3	LRRC37A15P	-9.15	1.71e-18	9.67e-16	-0.37	-0.39	Schizophrenia;	chr4:102945323	chr4:102727274~102730721:-
LGG	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-9.15	1.71e-18	9.68e-16	-0.52	-0.39	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
LGG	cis	rs4819052	0.632	rs4819050	ENSG00000215447.6	BX322557.10	-9.15	1.71e-18	9.68e-16	-0.29	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45288052~45291738:+
LGG	cis	rs1420956	0.74	rs28550271	ENSG00000264151.4	RP11-739N10.1	9.15	1.71e-18	9.69e-16	0.48	0.39	Obesity-related traits;	chr18:27578610	chr18:27336379~27595164:-
LGG	cis	rs453301	0.538	rs7830804	ENSG00000253893.2	FAM85B	9.15	1.72e-18	9.73e-16	0.48	0.39	Joint mobility (Beighton score);	chr8:9113252	chr8:8167819~8226614:-
LGG	cis	rs6921919	0.583	rs7740351	ENSG00000280107.1	AL022393.9	-9.15	1.72e-18	9.74e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs16894108	ENSG00000280107.1	AL022393.9	-9.15	1.72e-18	9.74e-16	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	9.15	1.73e-18	9.77e-16	0.46	0.39	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	9.15	1.73e-18	9.77e-16	0.46	0.39	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	9.15	1.73e-18	9.77e-16	0.46	0.39	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
LGG	cis	rs6921919	0.609	rs9461455	ENSG00000199851.2	U3	9.15	1.74e-18	9.81e-16	0.54	0.39	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.777	rs35984974	ENSG00000199851.2	U3	9.15	1.74e-18	9.81e-16	0.85	0.39	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28015568~28015777:+
LGG	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-9.15	1.74e-18	9.81e-16	-0.43	-0.39	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	9.15	1.74e-18	9.82e-16	0.5	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
LGG	cis	rs7267979	0.78	rs6050679	ENSG00000276952.1	RP5-965G21.6	9.15	1.74e-18	9.83e-16	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25284915~25285588:-
LGG	cis	rs228614	0.51	rs150893	ENSG00000230069.3	LRRC37A15P	9.15	1.75e-18	9.87e-16	0.38	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	9.15	1.75e-18	9.88e-16	0.45	0.39	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	9.15	1.75e-18	9.88e-16	0.45	0.39	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	9.15	1.75e-18	9.88e-16	0.45	0.39	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	9.15	1.75e-18	9.88e-16	0.45	0.39	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	9.15	1.75e-18	9.88e-16	0.45	0.39	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	9.15	1.75e-18	9.88e-16	0.45	0.39	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
LGG	cis	rs1555322	0.872	rs6579227	ENSG00000126005.14	MMP24-AS1	-9.15	1.75e-18	9.88e-16	-0.62	-0.39	Attention deficit hyperactivity disorder;	chr20:35291403	chr20:35216462~35278131:-
LGG	cis	rs9322193	0.887	rs9767113	ENSG00000216621.7	RP11-244K5.6	9.15	1.75e-18	9.89e-16	0.46	0.39	Lung cancer;	chr6:149718157	chr6:149934527~149936782:+
LGG	cis	rs571497	0.756	rs557094	ENSG00000268297.1	CLEC4GP1	-9.15	1.76e-18	9.92e-16	-0.51	-0.39	Monocyte count;	chr19:7767400	chr19:7787549~7790621:+
LGG	cis	rs7267979	0.789	rs4815400	ENSG00000276952.1	RP5-965G21.6	-9.14	1.77e-18	1e-15	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25284915~25285588:-
LGG	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-9.14	1.78e-18	1e-15	-0.52	-0.39	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-9.14	1.78e-18	1e-15	-0.52	-0.39	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-9.14	1.78e-18	1e-15	-0.52	-0.39	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
LGG	cis	rs149866169	1	rs149866169	ENSG00000199851.2	U3	9.14	1.78e-18	1e-15	0.92	0.39	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.668	rs7749305	ENSG00000199851.2	U3	9.14	1.78e-18	1e-15	0.92	0.39	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.668	rs34864796	ENSG00000199851.2	U3	9.14	1.78e-18	1e-15	0.92	0.39	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs67859638	ENSG00000199851.2	U3	9.14	1.78e-18	1.01e-15	0.99	0.39	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs58616630	ENSG00000199851.2	U3	9.14	1.78e-18	1.01e-15	0.99	0.39	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs34573979	ENSG00000199851.2	U3	9.14	1.78e-18	1.01e-15	0.99	0.39	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs12176034	ENSG00000216621.7	RP11-244K5.6	9.14	1.78e-18	1.01e-15	0.48	0.39	Lung cancer;	chr6:149800557	chr6:149934527~149936782:+
LGG	cis	rs7267979	0.74	rs2259961	ENSG00000276952.1	RP5-965G21.6	9.14	1.78e-18	1.01e-15	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs2474780	ENSG00000276952.1	RP5-965G21.6	9.14	1.78e-18	1.01e-15	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs6076343	ENSG00000276952.1	RP5-965G21.6	-9.14	1.79e-18	1.01e-15	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs6083845	ENSG00000276952.1	RP5-965G21.6	-9.14	1.79e-18	1.01e-15	-0.39	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.884	rs9480009	ENSG00000216621.7	RP11-244K5.6	9.14	1.79e-18	1.01e-15	0.46	0.39	Lung cancer;	chr6:149758502	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9480031	ENSG00000216621.7	RP11-244K5.6	9.14	1.79e-18	1.01e-15	0.46	0.39	Lung cancer;	chr6:149758875	chr6:149934527~149936782:+
LGG	cis	rs9532669	0.75	rs9532598	ENSG00000239827.7	SUGT1P3	-9.14	1.8e-18	1.01e-15	-0.41	-0.39	Cervical cancer;	chr13:40860627	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.611	rs9532599	ENSG00000239827.7	SUGT1P3	-9.14	1.8e-18	1.01e-15	-0.41	-0.39	Cervical cancer;	chr13:40860633	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.571	rs9525405	ENSG00000239827.7	SUGT1P3	-9.14	1.8e-18	1.01e-15	-0.41	-0.39	Cervical cancer;	chr13:40860638	chr13:40908159~40921774:-
LGG	cis	rs8031584	0.56	rs7171208	ENSG00000270015.1	RP11-540B6.6	9.14	1.8e-18	1.02e-15	0.28	0.39	Huntington's disease progression;	chr15:30906726	chr15:30926514~30928407:+
LGG	cis	rs4713118	0.513	rs200971	ENSG00000219392.1	RP1-265C24.5	-9.14	1.8e-18	1.02e-15	-0.37	-0.39	Parkinson's disease;	chr6:27891126	chr6:28115628~28116551:+
LGG	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	9.14	1.81e-18	1.02e-15	0.74	0.39	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
LGG	cis	rs2278702	0.848	rs77593396	ENSG00000259495.2	RP11-210M15.2	-9.14	1.81e-18	1.02e-15	-0.47	-0.39	Bipolar disorder;	chr15:80387970	chr15:80344853~80403575:-
LGG	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	9.14	1.81e-18	1.02e-15	0.45	0.39	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
LGG	cis	rs2278702	0.943	rs78815690	ENSG00000259495.2	RP11-210M15.2	-9.14	1.81e-18	1.02e-15	-0.46	-0.39	Bipolar disorder;	chr15:80391946	chr15:80344853~80403575:-
LGG	cis	rs2278702	0.943	rs57525871	ENSG00000259495.2	RP11-210M15.2	-9.14	1.81e-18	1.02e-15	-0.46	-0.39	Bipolar disorder;	chr15:80392605	chr15:80344853~80403575:-
LGG	cis	rs2278702	0.943	rs78285258	ENSG00000259495.2	RP11-210M15.2	-9.14	1.81e-18	1.02e-15	-0.46	-0.39	Bipolar disorder;	chr15:80392771	chr15:80344853~80403575:-
LGG	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-9.14	1.82e-18	1.03e-15	-0.44	-0.39	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
LGG	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	9.14	1.83e-18	1.03e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
LGG	cis	rs1707322	1	rs7526369	ENSG00000281133.1	AL355480.3	-9.14	1.83e-18	1.03e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs10890371	ENSG00000281133.1	AL355480.3	-9.14	1.83e-18	1.03e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs10890372	ENSG00000281133.1	AL355480.3	-9.14	1.83e-18	1.03e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45580892~45580996:-
LGG	cis	rs893363	1	rs893363	ENSG00000271916.1	RP11-884K10.6	-9.14	1.84e-18	1.04e-15	-0.46	-0.39	Axial length;	chr3:53813035	chr3:53797764~53798019:-
LGG	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	9.14	1.84e-18	1.04e-15	0.61	0.39	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
LGG	cis	rs853679	0.882	rs3757188	ENSG00000226314.6	ZNF192P1	9.14	1.85e-18	1.04e-15	0.59	0.39	Depression;	chr6:28139579	chr6:28161781~28169594:+
LGG	cis	rs1707322	0.686	rs3014239	ENSG00000281133.1	AL355480.3	9.14	1.85e-18	1.04e-15	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45580892~45580996:-
LGG	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-9.14	1.85e-18	1.04e-15	-0.46	-0.39	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
LGG	cis	rs1707322	0.655	rs3014240	ENSG00000281133.1	AL355480.3	9.14	1.86e-18	1.05e-15	0.46	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs9767105	ENSG00000216621.7	RP11-244K5.6	9.14	1.86e-18	1.05e-15	0.47	0.39	Lung cancer;	chr6:149659591	chr6:149934527~149936782:+
LGG	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	9.14	1.86e-18	1.05e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
LGG	cis	rs12449964	0.515	rs9899364	ENSG00000223979.2	SMCR2	9.14	1.86e-18	1.05e-15	0.38	0.39	Coronary artery disease or ischemic stroke;	chr17:17663798	chr17:17674026~17677688:-
LGG	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	9.14	1.86e-18	1.05e-15	0.45	0.39	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	9.14	1.86e-18	1.05e-15	0.45	0.39	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
LGG	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	9.14	1.87e-18	1.05e-15	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
LGG	cis	rs9322193	0.923	rs2184370	ENSG00000216906.2	RP11-350J20.9	9.14	1.87e-18	1.05e-15	0.46	0.39	Lung cancer;	chr6:149843242	chr6:149904243~149906418:+
LGG	cis	rs11722779	0.901	rs28674656	ENSG00000230069.3	LRRC37A15P	-9.14	1.87e-18	1.05e-15	-0.37	-0.39	Schizophrenia;	chr4:102944396	chr4:102727274~102730721:-
LGG	cis	rs7267979	0.816	rs376742	ENSG00000276952.1	RP5-965G21.6	9.14	1.88e-18	1.06e-15	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.847	rs56103941	ENSG00000216621.7	RP11-244K5.6	9.14	1.9e-18	1.07e-15	0.47	0.39	Lung cancer;	chr6:149816095	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.847	rs12210605	ENSG00000216621.7	RP11-244K5.6	9.14	1.9e-18	1.07e-15	0.47	0.39	Lung cancer;	chr6:149817267	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9371199	ENSG00000216621.7	RP11-244K5.6	9.14	1.9e-18	1.07e-15	0.47	0.39	Lung cancer;	chr6:149817526	chr6:149934527~149936782:+
LGG	cis	rs6921919	0.583	rs6928771	ENSG00000280107.1	AL022393.9	-9.13	1.91e-18	1.07e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs6928773	ENSG00000280107.1	AL022393.9	-9.13	1.91e-18	1.07e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	9.13	1.91e-18	1.08e-15	0.44	0.39	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9322200	ENSG00000216621.7	RP11-244K5.6	9.13	1.92e-18	1.08e-15	0.46	0.39	Lung cancer;	chr6:149630078	chr6:149934527~149936782:+
LGG	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	9.13	1.92e-18	1.08e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
LGG	cis	rs6921919	0.583	rs3800328	ENSG00000280107.1	AL022393.9	-9.13	1.92e-18	1.08e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.609	rs67211468	ENSG00000280107.1	AL022393.9	-9.13	1.92e-18	1.08e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs35560946	ENSG00000280107.1	AL022393.9	-9.13	1.92e-18	1.08e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs740622	ENSG00000280107.1	AL022393.9	-9.13	1.92e-18	1.08e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28170845~28172521:+
LGG	cis	rs17772222	0.917	rs12587200	ENSG00000222990.1	RNU4-22P	9.13	1.93e-18	1.09e-15	0.51	0.39	Coronary artery calcification;	chr14:88632060	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs8006652	ENSG00000222990.1	RNU4-22P	9.13	1.93e-18	1.09e-15	0.51	0.39	Coronary artery calcification;	chr14:88631290	chr14:88513498~88513663:+
LGG	cis	rs2278702	0.848	rs1446334	ENSG00000259495.2	RP11-210M15.2	-9.13	1.93e-18	1.09e-15	-0.48	-0.39	Bipolar disorder;	chr15:80407371	chr15:80344853~80403575:-
LGG	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	9.13	1.93e-18	1.09e-15	0.45	0.39	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
LGG	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	9.13	1.95e-18	1.1e-15	0.45	0.39	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	9.13	1.95e-18	1.1e-15	0.45	0.39	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
LGG	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-9.13	1.96e-18	1.1e-15	-0.53	-0.39	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-9.13	1.96e-18	1.1e-15	-0.53	-0.39	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
LGG	cis	rs4713118	0.539	rs510987	ENSG00000219392.1	RP1-265C24.5	-9.13	1.96e-18	1.1e-15	-0.38	-0.39	Parkinson's disease;	chr6:27879739	chr6:28115628~28116551:+
LGG	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-9.13	1.96e-18	1.1e-15	-0.42	-0.39	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
LGG	cis	rs7267979	0.604	rs242130	ENSG00000125804.12	FAM182A	9.13	1.97e-18	1.11e-15	0.45	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:26054655~26086917:+
LGG	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	9.13	1.97e-18	1.11e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
LGG	cis	rs4281086	1	rs4535706	ENSG00000253678.1	RP11-981G7.3	-9.13	1.97e-18	1.11e-15	-0.42	-0.39	Obesity-related traits;	chr8:10494684	chr8:10477491~10479375:-
LGG	cis	rs6921919	0.583	rs4254981	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.525	rs6929825	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs35599905	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs1124131	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs6899389	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs6922374	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs6899603	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs6922429	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs6922169	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.559	rs13210866	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.609	rs36018474	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs13201726	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs2027361	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs4642462	ENSG00000280107.1	AL022393.9	-9.13	1.99e-18	1.12e-15	-0.39	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	9.13	1.99e-18	1.12e-15	0.45	0.39	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	9.13	1.99e-18	1.12e-15	0.45	0.39	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
LGG	cis	rs9987353	0.566	rs34491841	ENSG00000173295.6	FAM86B3P	9.13	1.99e-18	1.12e-15	0.42	0.39	Recombination measurement;	chr8:9208000	chr8:8228595~8244865:+
LGG	cis	rs657075	0.697	rs35497612	ENSG00000263597.1	MIR3936	-9.13	1.99e-18	1.12e-15	-0.66	-0.39	Rheumatoid arthritis;	chr5:132337413	chr5:132365490~132365599:-
LGG	cis	rs217727	0.818	rs2525883	ENSG00000226416.1	MRPL23-AS1	9.13	2e-18	1.12e-15	0.51	0.39	Breast cancer;	chr11:2000750	chr11:1983237~1989920:-
LGG	cis	rs9532669	0.926	rs4942000	ENSG00000239827.7	SUGT1P3	-9.13	2.02e-18	1.13e-15	-0.41	-0.39	Cervical cancer;	chr13:40859979	chr13:40908159~40921774:-
LGG	cis	rs12935418	0.561	rs2287991	ENSG00000260213.4	RP11-303E16.3	-9.13	2.02e-18	1.14e-15	-0.49	-0.39	Mean corpuscular volume;	chr16:81006950	chr16:81016792~81035759:-
LGG	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-9.13	2.03e-18	1.14e-15	-0.53	-0.39	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-9.13	2.03e-18	1.14e-15	-0.53	-0.39	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-9.13	2.03e-18	1.14e-15	-0.53	-0.39	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-9.13	2.03e-18	1.14e-15	-0.53	-0.39	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	9.13	2.03e-18	1.14e-15	0.45	0.39	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
LGG	cis	rs6997458	0.742	rs6988475	ENSG00000253549.4	RP11-317J10.2	9.13	2.04e-18	1.14e-15	0.31	0.39	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85471039	chr8:85441851~85464915:-
LGG	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	9.13	2.05e-18	1.15e-15	0.55	0.39	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
LGG	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	9.13	2.05e-18	1.15e-15	0.51	0.39	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
LGG	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-9.13	2.05e-18	1.15e-15	-0.54	-0.39	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
LGG	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-9.12	2.07e-18	1.16e-15	-0.53	-0.39	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-9.12	2.07e-18	1.16e-15	-0.53	-0.39	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
LGG	cis	rs853679	0.607	rs13208096	ENSG00000199851.2	U3	9.12	2.07e-18	1.16e-15	0.96	0.39	Depression;	chr6:28257533	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13207345	ENSG00000199851.2	U3	9.12	2.07e-18	1.16e-15	0.96	0.39	Depression;	chr6:28297795	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs72854513	ENSG00000199851.2	U3	9.12	2.07e-18	1.16e-15	0.96	0.39	Depression;	chr6:28298177	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs56189111	ENSG00000199851.2	U3	9.12	2.07e-18	1.16e-15	0.96	0.39	Depression;	chr6:28304196	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs35072899	ENSG00000199851.2	U3	9.12	2.07e-18	1.16e-15	0.96	0.39	Depression;	chr6:28313764	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs56075693	ENSG00000199851.2	U3	9.12	2.07e-18	1.16e-15	0.96	0.39	Depression;	chr6:28322551	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34218844	ENSG00000199851.2	U3	9.12	2.07e-18	1.16e-15	0.96	0.39	Depression;	chr6:28322870	chr6:28015568~28015777:+
LGG	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	9.12	2.07e-18	1.16e-15	0.36	0.39	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
LGG	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-9.12	2.07e-18	1.16e-15	-0.45	-0.39	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
LGG	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-9.12	2.07e-18	1.16e-15	-0.3	-0.39	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
LGG	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	9.12	2.07e-18	1.16e-15	0.7	0.39	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
LGG	cis	rs227275	0.525	rs223462	ENSG00000230069.3	LRRC37A15P	-9.12	2.08e-18	1.16e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102727274~102730721:-
LGG	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	9.12	2.08e-18	1.16e-15	0.49	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	9.12	2.08e-18	1.16e-15	0.49	0.39	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
LGG	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-9.12	2.08e-18	1.17e-15	-0.48	-0.39	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
LGG	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	9.12	2.09e-18	1.17e-15	0.46	0.39	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
LGG	cis	rs9532669	0.7	rs9525406	ENSG00000239827.7	SUGT1P3	-9.12	2.09e-18	1.17e-15	-0.41	-0.39	Cervical cancer;	chr13:40860812	chr13:40908159~40921774:-
LGG	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	9.12	2.09e-18	1.17e-15	0.3	0.39	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
LGG	cis	rs6921919	0.583	rs7759191	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs7764737	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs9461458	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.609	rs9468365	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs1361385	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs1416918	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs9468367	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs9461459	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs28360638	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs9468368	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs2041230	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.609	rs1005127	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28188050~28189432:+
LGG	cis	rs853679	0.515	rs4580862	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Depression;	chr6:28399886	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs4357130	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs11755942	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs6907950	ENSG00000218016.2	ZNF192P2	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28188050~28189432:+
LGG	cis	rs9875589	0.915	rs62234597	ENSG00000233121.1	VN1R20P	9.12	2.11e-18	1.18e-15	0.39	0.39	Ovarian reserve;	chr3:13922283	chr3:13926813~13927778:+
LGG	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
LGG	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-9.12	2.11e-18	1.18e-15	-0.46	-0.39	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
LGG	cis	rs9527	0.59	rs3781281	ENSG00000272912.1	RP11-724N1.1	9.12	2.11e-18	1.18e-15	0.44	0.39	Arsenic metabolism;	chr10:103092891	chr10:102914585~102915404:+
LGG	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	-9.12	2.13e-18	1.19e-15	-0.39	-0.39	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
LGG	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	9.12	2.13e-18	1.19e-15	0.45	0.39	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
LGG	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	9.12	2.13e-18	1.19e-15	0.42	0.39	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
LGG	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	9.12	2.14e-18	1.2e-15	0.47	0.39	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
LGG	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	9.12	2.14e-18	1.2e-15	0.49	0.39	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
LGG	cis	rs7267979	0.816	rs422148	ENSG00000276952.1	RP5-965G21.6	9.12	2.15e-18	1.2e-15	0.38	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.844	rs8184820	ENSG00000276952.1	RP5-965G21.6	-9.12	2.15e-18	1.21e-15	-0.38	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25284915~25285588:-
LGG	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	9.12	2.16e-18	1.21e-15	0.49	0.39	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
LGG	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-9.12	2.17e-18	1.22e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
LGG	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-9.12	2.17e-18	1.22e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
LGG	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-9.12	2.17e-18	1.22e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
LGG	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-9.12	2.17e-18	1.22e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
LGG	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-9.12	2.17e-18	1.22e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
LGG	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-9.12	2.17e-18	1.22e-15	-0.3	-0.39	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
LGG	cis	rs904251	0.704	rs2776873	ENSG00000204110.6	RP1-153P14.8	-9.12	2.18e-18	1.22e-15	-0.42	-0.39	Cognitive performance;	chr6:37515366	chr6:37507348~37535616:+
LGG	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	9.12	2.18e-18	1.22e-15	0.38	0.39	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
LGG	cis	rs12935418	0.672	rs9888895	ENSG00000260213.4	RP11-303E16.3	-9.12	2.18e-18	1.22e-15	-0.49	-0.39	Mean corpuscular volume;	chr16:81017496	chr16:81016792~81035759:-
LGG	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	9.12	2.18e-18	1.22e-15	0.46	0.39	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
LGG	cis	rs9532669	0.857	rs7327018	ENSG00000239827.7	SUGT1P3	-9.12	2.19e-18	1.22e-15	-0.41	-0.39	Cervical cancer;	chr13:40856376	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7327315	ENSG00000239827.7	SUGT1P3	-9.12	2.19e-18	1.22e-15	-0.41	-0.39	Cervical cancer;	chr13:40856383	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7327059	ENSG00000239827.7	SUGT1P3	-9.12	2.19e-18	1.22e-15	-0.41	-0.39	Cervical cancer;	chr13:40856458	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9594433	ENSG00000239827.7	SUGT1P3	-9.12	2.19e-18	1.22e-15	-0.41	-0.39	Cervical cancer;	chr13:40856935	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9525403	ENSG00000239827.7	SUGT1P3	-9.12	2.19e-18	1.22e-15	-0.41	-0.39	Cervical cancer;	chr13:40858292	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7318768	ENSG00000239827.7	SUGT1P3	-9.12	2.19e-18	1.22e-15	-0.41	-0.39	Cervical cancer;	chr13:40859140	chr13:40908159~40921774:-
LGG	cis	rs853679	0.607	rs35030260	ENSG00000199851.2	U3	9.12	2.19e-18	1.22e-15	0.95	0.39	Depression;	chr6:28337731	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13217619	ENSG00000199851.2	U3	9.12	2.19e-18	1.22e-15	0.95	0.39	Depression;	chr6:28338894	chr6:28015568~28015777:+
LGG	cis	rs1707322	0.686	rs1084086	ENSG00000281133.1	AL355480.3	9.12	2.19e-18	1.23e-15	0.49	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	9.12	2.19e-18	1.23e-15	0.44	0.39	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
LGG	cis	rs227275	0.527	rs223308	ENSG00000230069.3	LRRC37A15P	-9.12	2.2e-18	1.23e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102727274~102730721:-
LGG	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-9.12	2.2e-18	1.23e-15	-0.4	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
LGG	cis	rs1153858	0.723	rs11855527	ENSG00000259433.2	CTD-2651B20.4	9.12	2.21e-18	1.23e-15	0.46	0.39	Homoarginine levels;	chr15:45314487	chr15:45330209~45332634:-
LGG	cis	rs4281086	0.898	rs13254676	ENSG00000253678.1	RP11-981G7.3	-9.12	2.21e-18	1.24e-15	-0.43	-0.39	Obesity-related traits;	chr8:10509583	chr8:10477491~10479375:-
LGG	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-9.12	2.21e-18	1.24e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
LGG	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-9.12	2.21e-18	1.24e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
LGG	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-9.12	2.21e-18	1.24e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
LGG	cis	rs227275	0.554	rs223439	ENSG00000230069.3	LRRC37A15P	-9.12	2.21e-18	1.24e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223436	ENSG00000230069.3	LRRC37A15P	-9.12	2.21e-18	1.24e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102727274~102730721:-
LGG	cis	rs1153858	0.945	rs16943246	ENSG00000259433.2	CTD-2651B20.4	-9.12	2.22e-18	1.24e-15	-0.46	-0.39	Homoarginine levels;	chr15:45428399	chr15:45330209~45332634:-
LGG	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	9.12	2.22e-18	1.24e-15	0.3	0.39	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
LGG	cis	rs227275	0.554	rs150895	ENSG00000230069.3	LRRC37A15P	-9.12	2.22e-18	1.24e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102727274~102730721:-
LGG	cis	rs227275	0.586	rs223448	ENSG00000230069.3	LRRC37A15P	-9.12	2.22e-18	1.24e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223442	ENSG00000230069.3	LRRC37A15P	-9.12	2.22e-18	1.24e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223441	ENSG00000230069.3	LRRC37A15P	-9.12	2.22e-18	1.24e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102727274~102730721:-
LGG	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-9.12	2.23e-18	1.24e-15	-0.3	-0.39	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
LGG	cis	rs9876781	1	rs6810060	ENSG00000244380.1	RP11-24C3.2	9.12	2.23e-18	1.25e-15	0.48	0.39	Longevity;	chr3:48393284	chr3:48440352~48446656:-
LGG	cis	rs9876781	1	rs6770470	ENSG00000244380.1	RP11-24C3.2	9.12	2.23e-18	1.25e-15	0.48	0.39	Longevity;	chr3:48393659	chr3:48440352~48446656:-
LGG	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	9.11	2.23e-18	1.25e-15	0.31	0.39	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	9.11	2.23e-18	1.25e-15	0.31	0.39	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	9.11	2.23e-18	1.25e-15	0.31	0.39	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	9.11	2.23e-18	1.25e-15	0.31	0.39	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	9.11	2.23e-18	1.25e-15	0.31	0.39	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
LGG	cis	rs7267979	0.866	rs2424699	ENSG00000276952.1	RP5-965G21.6	9.11	2.24e-18	1.25e-15	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	9.11	2.25e-18	1.26e-15	0.44	0.39	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
LGG	cis	rs12444795	0.855	rs12445265	ENSG00000267077.1	RP11-127I20.5	9.11	2.26e-18	1.26e-15	0.57	0.39	Cancer;	chr16:4874159	chr16:4795265~4796532:-
LGG	cis	rs228614	0.51	rs223470	ENSG00000230069.3	LRRC37A15P	-9.11	2.26e-18	1.26e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223468	ENSG00000230069.3	LRRC37A15P	-9.11	2.26e-18	1.26e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223465	ENSG00000230069.3	LRRC37A15P	-9.11	2.26e-18	1.26e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223464	ENSG00000230069.3	LRRC37A15P	-9.11	2.26e-18	1.26e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	9.11	2.26e-18	1.26e-15	0.44	0.39	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
LGG	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-9.11	2.28e-18	1.27e-15	-0.46	-0.39	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
LGG	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	9.11	2.29e-18	1.28e-15	0.42	0.39	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
LGG	cis	rs1707322	0.716	rs10890342	ENSG00000281133.1	AL355480.3	-9.11	2.3e-18	1.28e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs6658700	ENSG00000281133.1	AL355480.3	-9.11	2.3e-18	1.28e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs12047629	ENSG00000281133.1	AL355480.3	-9.11	2.3e-18	1.28e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.752	rs11211169	ENSG00000281133.1	AL355480.3	-9.11	2.3e-18	1.28e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	9.11	2.3e-18	1.28e-15	0.45	0.39	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	9.11	2.31e-18	1.29e-15	0.45	0.39	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
LGG	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-9.11	2.32e-18	1.29e-15	-0.46	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
LGG	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	9.11	2.32e-18	1.29e-15	0.54	0.39	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	9.11	2.32e-18	1.29e-15	0.47	0.39	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
LGG	cis	rs1707322	1	rs6695421	ENSG00000281133.1	AL355480.3	-9.11	2.32e-18	1.29e-15	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45580892~45580996:-
LGG	cis	rs2251666	0.514	rs12444761	ENSG00000267077.1	RP11-127I20.5	9.11	2.34e-18	1.31e-15	0.56	0.39	Cancer;	chr16:4877284	chr16:4795265~4796532:-
LGG	cis	rs9532669	0.926	rs9525418	ENSG00000168852.11	TPTE2P5	-9.11	2.35e-18	1.31e-15	-0.4	-0.39	Cervical cancer;	chr13:40879081	chr13:40822296~40921749:-
LGG	cis	rs853679	0.546	rs35353359	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28356601	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs35017208	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28377505	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs13213152	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28381921	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs36092177	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28390030	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs13213986	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28390232	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs2232429	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28391855	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs2232426	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28392882	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs34546986	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28394532	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs34871267	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28396455	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs2232423	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28398374	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs35883476	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28400731	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.673	rs13201681	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28176188~28176674:+
LGG	cis	rs6921919	0.778	rs67381177	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28176188~28176674:+
LGG	cis	rs138024639	1	rs138024639	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Breast cancer;	chr6:28468244	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs55690788	ENSG00000216901.1	AL022393.7	9.11	2.35e-18	1.31e-15	0.86	0.39	Depression;	chr6:28468368	chr6:28176188~28176674:+
LGG	cis	rs2325036	0.516	rs62261746	ENSG00000239519.1	CADM2-AS1	9.11	2.35e-18	1.31e-15	0.49	0.39	Waist circumference;	chr3:85909804	chr3:85992183~86028007:-
LGG	cis	rs17772222	0.958	rs17798341	ENSG00000222990.1	RNU4-22P	9.11	2.36e-18	1.31e-15	0.51	0.39	Coronary artery calcification;	chr14:88548201	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.958	rs10134008	ENSG00000222990.1	RNU4-22P	9.11	2.36e-18	1.31e-15	0.51	0.39	Coronary artery calcification;	chr14:88549183	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.958	rs891750	ENSG00000222990.1	RNU4-22P	9.11	2.36e-18	1.31e-15	0.51	0.39	Coronary artery calcification;	chr14:88550856	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.958	rs891749	ENSG00000222990.1	RNU4-22P	9.11	2.36e-18	1.31e-15	0.51	0.39	Coronary artery calcification;	chr14:88550893	chr14:88513498~88513663:+
LGG	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-9.11	2.36e-18	1.32e-15	-0.33	-0.39	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
LGG	cis	rs6496932	1	rs2002642	ENSG00000218052.5	ADAMTS7P4	9.11	2.36e-18	1.32e-15	0.57	0.39	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85255369~85330334:-
LGG	cis	rs6496932	1	rs4842872	ENSG00000218052.5	ADAMTS7P4	9.11	2.36e-18	1.32e-15	0.57	0.39	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85255369~85330334:-
LGG	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	9.11	2.37e-18	1.32e-15	0.45	0.39	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	9.11	2.37e-18	1.32e-15	0.46	0.39	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
LGG	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-9.11	2.38e-18	1.32e-15	-0.31	-0.39	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
LGG	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-9.11	2.38e-18	1.32e-15	-0.31	-0.39	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-9.11	2.38e-18	1.32e-15	-0.31	-0.39	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-9.11	2.38e-18	1.32e-15	-0.31	-0.39	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
LGG	cis	rs17772222	0.917	rs17260380	ENSG00000222990.1	RNU4-22P	9.11	2.38e-18	1.33e-15	0.51	0.39	Coronary artery calcification;	chr14:88682142	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.876	rs12436982	ENSG00000222990.1	RNU4-22P	9.11	2.38e-18	1.33e-15	0.51	0.39	Coronary artery calcification;	chr14:88689862	chr14:88513498~88513663:+
LGG	cis	rs1707322	1	rs7527079	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.45	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs34446427	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.45	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs4660900	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.45	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4454479	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.45	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs12077546	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.45	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs12124291	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.45	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211228	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs11211229	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs9803784	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs12022335	ENSG00000281133.1	AL355480.3	-9.11	2.38e-18	1.33e-15	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45580892~45580996:-
LGG	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-9.11	2.39e-18	1.33e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
LGG	cis	rs4281086	0.897	rs4457299	ENSG00000253678.1	RP11-981G7.3	9.11	2.4e-18	1.34e-15	0.41	0.39	Obesity-related traits;	chr8:10487482	chr8:10477491~10479375:-
LGG	cis	rs227275	0.555	rs223403	ENSG00000230069.3	LRRC37A15P	-9.11	2.4e-18	1.34e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs9999303	ENSG00000230069.3	LRRC37A15P	-9.11	2.41e-18	1.34e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs6853193	ENSG00000230069.3	LRRC37A15P	-9.11	2.41e-18	1.34e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-9.11	2.41e-18	1.34e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
LGG	cis	rs56114371	0.568	rs200468	ENSG00000199851.2	U3	9.11	2.41e-18	1.34e-15	0.61	0.39	Breast cancer;	chr6:27790076	chr6:28015568~28015777:+
LGG	cis	rs17772222	1	rs17772064	ENSG00000222990.1	RNU4-22P	9.1	2.42e-18	1.35e-15	0.48	0.39	Coronary artery calcification;	chr14:88356527	chr14:88513498~88513663:+
LGG	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-9.1	2.43e-18	1.35e-15	-0.52	-0.39	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
LGG	cis	rs5760092	0.627	rs6519489	ENSG00000231271.1	AP000350.8	-9.1	2.43e-18	1.35e-15	-0.59	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23949918~23954042:+
LGG	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	9.1	2.44e-18	1.36e-15	0.45	0.39	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
LGG	cis	rs7267979	0.844	rs2257649	ENSG00000276952.1	RP5-965G21.6	9.1	2.46e-18	1.37e-15	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25284915~25285588:-
LGG	cis	rs17772222	1	rs12433464	ENSG00000222990.1	RNU4-22P	9.1	2.46e-18	1.37e-15	0.48	0.39	Coronary artery calcification;	chr14:88357671	chr14:88513498~88513663:+
LGG	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-9.1	2.46e-18	1.37e-15	-0.51	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
LGG	cis	rs7267979	0.586	rs11087505	ENSG00000276952.1	RP5-965G21.6	9.1	2.46e-18	1.37e-15	0.39	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25284915~25285588:-
LGG	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-9.1	2.47e-18	1.37e-15	-0.31	-0.39	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
LGG	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-9.1	2.47e-18	1.37e-15	-0.42	-0.39	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
LGG	cis	rs6921919	0.562	rs13198809	ENSG00000216901.1	AL022393.7	9.1	2.47e-18	1.38e-15	0.87	0.39	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28176188~28176674:+
LGG	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-9.1	2.49e-18	1.39e-15	-0.52	-0.39	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
LGG	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
LGG	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	9.1	2.49e-18	1.39e-15	0.31	0.39	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-9.1	2.49e-18	1.39e-15	-0.52	-0.39	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-9.1	2.49e-18	1.39e-15	-0.52	-0.39	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-9.1	2.49e-18	1.39e-15	-0.52	-0.39	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	9.1	2.51e-18	1.4e-15	0.44	0.39	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
LGG	cis	rs1707322	1	rs6687301	ENSG00000281133.1	AL355480.3	-9.1	2.51e-18	1.4e-15	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45580892~45580996:-
LGG	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-9.1	2.52e-18	1.4e-15	-0.33	-0.39	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
LGG	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	9.1	2.53e-18	1.41e-15	0.37	0.39	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
LGG	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-9.1	2.53e-18	1.41e-15	-0.52	-0.39	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
LGG	cis	rs6921919	0.551	rs13201753	ENSG00000199851.2	U3	9.1	2.54e-18	1.41e-15	0.53	0.39	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28015568~28015777:+
LGG	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-9.1	2.54e-18	1.41e-15	-0.88	-0.39	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
LGG	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-9.1	2.55e-18	1.42e-15	-0.42	-0.39	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
LGG	cis	rs1075265	0.537	rs2160929	ENSG00000233266.1	HMGB1P31	9.1	2.55e-18	1.42e-15	0.51	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53654735	chr2:54051334~54051760:+
LGG	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-9.1	2.56e-18	1.42e-15	-0.42	-0.39	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
LGG	cis	rs1707322	0.717	rs11211161	ENSG00000281133.1	AL355480.3	-9.1	2.57e-18	1.43e-15	-0.47	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45580892~45580996:-
LGG	cis	rs9876781	1	rs9812647	ENSG00000244380.1	RP11-24C3.2	-9.1	2.57e-18	1.43e-15	-0.48	-0.39	Longevity;	chr3:48407507	chr3:48440352~48446656:-
LGG	cis	rs853679	0.527	rs213228	ENSG00000199851.2	U3	9.1	2.57e-18	1.43e-15	0.52	0.39	Depression;	chr6:28363475	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs9767554	ENSG00000216621.7	RP11-244K5.6	9.1	2.58e-18	1.43e-15	0.46	0.39	Lung cancer;	chr6:149616860	chr6:149934527~149936782:+
LGG	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	9.1	2.58e-18	1.43e-15	0.46	0.39	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
LGG	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-9.1	2.59e-18	1.44e-15	-0.52	-0.39	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	9.1	2.59e-18	1.44e-15	0.44	0.39	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.928	rs6681068	ENSG00000281133.1	AL355480.3	-9.1	2.59e-18	1.44e-15	-0.46	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45580892~45580996:-
LGG	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	9.1	2.6e-18	1.44e-15	0.31	0.39	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
LGG	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	9.1	2.6e-18	1.44e-15	0.37	0.39	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
LGG	cis	rs227275	0.554	rs223404	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223399	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223395	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223388	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223386	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223385	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.873	rs223384	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Schizophrenia;	chr4:102829976	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223383	ENSG00000230069.3	LRRC37A15P	-9.1	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102727274~102730721:-
LGG	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-9.1	2.61e-18	1.45e-15	-0.48	-0.39	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
LGG	cis	rs227275	0.554	rs223424	ENSG00000230069.3	LRRC37A15P	-9.09	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102727274~102730721:-
LGG	cis	rs227275	0.524	rs223423	ENSG00000230069.3	LRRC37A15P	-9.09	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223422	ENSG00000230069.3	LRRC37A15P	-9.09	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102727274~102730721:-
LGG	cis	rs227275	0.524	rs150894	ENSG00000230069.3	LRRC37A15P	-9.09	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223409	ENSG00000230069.3	LRRC37A15P	-9.09	2.61e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.692	rs223414	ENSG00000230069.3	LRRC37A15P	-9.09	2.61e-18	1.45e-15	-0.37	-0.39	Schizophrenia;	chr4:102811688	chr4:102727274~102730721:-
LGG	cis	rs1420956	0.935	rs7236882	ENSG00000264151.4	RP11-739N10.1	9.09	2.62e-18	1.45e-15	0.48	0.39	Obesity-related traits;	chr18:27584093	chr18:27336379~27595164:-
LGG	cis	rs227275	0.554	rs149576	ENSG00000230069.3	LRRC37A15P	-9.09	2.62e-18	1.45e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102727274~102730721:-
LGG	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	9.09	2.62e-18	1.45e-15	0.31	0.39	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
LGG	cis	rs1420956	0.905	rs1420957	ENSG00000264151.4	RP11-739N10.1	9.09	2.62e-18	1.46e-15	0.48	0.39	Obesity-related traits;	chr18:27585037	chr18:27336379~27595164:-
LGG	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-9.09	2.63e-18	1.46e-15	-0.31	-0.39	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
LGG	cis	rs4281086	0.931	rs4496927	ENSG00000253678.1	RP11-981G7.3	9.09	2.63e-18	1.46e-15	0.43	0.39	Obesity-related traits;	chr8:10507063	chr8:10477491~10479375:-
LGG	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	9.09	2.63e-18	1.46e-15	0.39	0.39	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
LGG	cis	rs2278702	0.943	rs17315116	ENSG00000259495.2	RP11-210M15.2	-9.09	2.65e-18	1.47e-15	-0.46	-0.39	Bipolar disorder;	chr15:80396263	chr15:80344853~80403575:-
LGG	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-9.09	2.65e-18	1.47e-15	-0.45	-0.39	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.926	rs7328139	ENSG00000239827.7	SUGT1P3	-9.09	2.65e-18	1.47e-15	-0.4	-0.39	Cervical cancer;	chr13:40862295	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7328145	ENSG00000239827.7	SUGT1P3	-9.09	2.65e-18	1.47e-15	-0.4	-0.39	Cervical cancer;	chr13:40862307	chr13:40908159~40921774:-
LGG	cis	rs853679	0.607	rs34243448	ENSG00000199851.2	U3	9.09	2.65e-18	1.47e-15	0.96	0.39	Depression;	chr6:28225324	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13204012	ENSG00000199851.2	U3	9.09	2.65e-18	1.47e-15	0.96	0.39	Depression;	chr6:28233753	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13205211	ENSG00000199851.2	U3	9.09	2.65e-18	1.47e-15	0.96	0.39	Depression;	chr6:28235278	chr6:28015568~28015777:+
LGG	cis	rs10022462	0.933	rs10516806	ENSG00000246375.2	RP11-10L7.1	9.09	2.66e-18	1.47e-15	0.45	0.39	Breast cancer;Blood metabolite levels;	chr4:88325062	chr4:88284942~88331421:+
LGG	cis	rs2278702	0.943	rs77597614	ENSG00000259495.2	RP11-210M15.2	-9.09	2.66e-18	1.48e-15	-0.46	-0.39	Bipolar disorder;	chr15:80394618	chr15:80344853~80403575:-
LGG	cis	rs853679	0.556	rs13200214	ENSG00000199851.2	U3	9.09	2.68e-18	1.49e-15	0.95	0.39	Depression;	chr6:28049472	chr6:28015568~28015777:+
LGG	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-9.09	2.69e-18	1.49e-15	-0.53	-0.39	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
LGG	cis	rs9810089	0.676	rs526574	ENSG00000261758.1	RP11-102M11.2	9.09	2.69e-18	1.49e-15	0.41	0.39	Gestational age at birth (child effect);	chr3:136384507	chr3:136752630~136755780:+
LGG	cis	rs4950322	0.57	rs72692920	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147308501	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.571	rs4373796	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147316747	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.543	rs4568882	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147316885	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.543	rs2883323	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147316995	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.543	rs2883324	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147317157	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.542	rs72692942	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147318467	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950399	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147319302	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs4950403	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147319723	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692946	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147319966	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692948	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147320298	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692951	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147320551	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs77118461	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147320718	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.517	rs116479391	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147320940	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs78681047	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147321013	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs80070044	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147330238	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692963	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147331090	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.518	rs72692965	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147332085	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.518	rs72692968	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147332884	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.518	rs72692970	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147332887	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692971	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147333088	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692973	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147333281	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.57	rs72692975	ENSG00000278811.3	LINC00624	9.09	2.69e-18	1.49e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147333506	chr1:147258885~147517875:-
LGG	cis	rs227275	0.554	rs223457	ENSG00000230069.3	LRRC37A15P	-9.09	2.69e-18	1.49e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102727274~102730721:-
LGG	cis	rs853679	0.607	rs67340775	ENSG00000199851.2	U3	9.09	2.69e-18	1.49e-15	0.96	0.39	Depression;	chr6:28336607	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	9.09	2.7e-18	1.5e-15	0.45	0.39	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
LGG	cis	rs34119086	1	rs34119086	ENSG00000216901.1	AL022393.7	9.09	2.7e-18	1.5e-15	0.87	0.39	Breast cancer;	chr6:28594471	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.828	rs5760107	ENSG00000235689.1	AP000351.13	9.09	2.72e-18	1.51e-15	0.45	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:24006305~24008258:-
LGG	cis	rs2739330	0.789	rs5760109	ENSG00000235689.1	AP000351.13	9.09	2.72e-18	1.51e-15	0.45	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:24006305~24008258:-
LGG	cis	rs4281086	0.897	rs28485845	ENSG00000253678.1	RP11-981G7.3	9.09	2.72e-18	1.51e-15	0.42	0.39	Obesity-related traits;	chr8:10488759	chr8:10477491~10479375:-
LGG	cis	rs4950322	0.57	rs7554833	ENSG00000278811.3	LINC00624	-9.09	2.72e-18	1.51e-15	-0.38	-0.39	Protein quantitative trait loci;	chr1:147289362	chr1:147258885~147517875:-
LGG	cis	rs4281086	0.965	rs35483889	ENSG00000253678.1	RP11-981G7.3	-9.09	2.73e-18	1.51e-15	-0.42	-0.39	Obesity-related traits;	chr8:10520746	chr8:10477491~10479375:-
LGG	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-9.09	2.73e-18	1.51e-15	-0.5	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
LGG	cis	rs12554020	0.892	rs6479483	ENSG00000237385.1	RP11-165J3.5	9.09	2.74e-18	1.52e-15	0.65	0.39	Schizophrenia;	chr9:93441746	chr9:93430342~93431299:-
LGG	cis	rs8037818	1	rs4643284	ENSG00000261064.1	RP11-1000B6.3	-9.09	2.74e-18	1.52e-15	-0.46	-0.39	Obesity-related traits;	chr15:32639897	chr15:32536047~32587613:+
LGG	cis	rs7302981	0.719	rs844347	ENSG00000272368.2	RP4-605O3.4	9.09	2.74e-18	1.52e-15	0.37	0.39	Systolic blood pressure;	chr12:50067893	chr12:50112197~50165618:+
LGG	cis	rs11722779	0.935	rs3857199	ENSG00000230069.3	LRRC37A15P	-9.09	2.74e-18	1.52e-15	-0.37	-0.39	Schizophrenia;	chr4:102957991	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs5028609	ENSG00000230069.3	LRRC37A15P	-9.09	2.74e-18	1.52e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs6815540	ENSG00000230069.3	LRRC37A15P	-9.09	2.74e-18	1.52e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs7663876	ENSG00000230069.3	LRRC37A15P	-9.09	2.74e-18	1.52e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.873	rs6533041	ENSG00000230069.3	LRRC37A15P	-9.09	2.74e-18	1.52e-15	-0.37	-0.39	Schizophrenia;	chr4:102951615	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs4698867	ENSG00000230069.3	LRRC37A15P	-9.09	2.74e-18	1.52e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	9.09	2.75e-18	1.52e-15	0.45	0.39	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
LGG	cis	rs227275	0.554	rs223314	ENSG00000230069.3	LRRC37A15P	-9.09	2.75e-18	1.52e-15	-0.37	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs7254	ENSG00000230069.3	LRRC37A15P	-9.09	2.75e-18	1.52e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.566	rs6822658	ENSG00000230069.3	LRRC37A15P	-9.09	2.75e-18	1.52e-15	-0.37	-0.39	Schizophrenia;	chr4:102891964	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs6823625	ENSG00000230069.3	LRRC37A15P	-9.09	2.75e-18	1.52e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs6846762	ENSG00000230069.3	LRRC37A15P	-9.09	2.75e-18	1.52e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs4699032	ENSG00000230069.3	LRRC37A15P	-9.09	2.75e-18	1.52e-15	-0.37	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102727274~102730721:-
LGG	cis	rs507080	0.733	rs497678	ENSG00000255422.1	AP002954.4	-9.09	2.75e-18	1.53e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118697172	chr11:118704607~118750263:+
LGG	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-9.09	2.76e-18	1.53e-15	-0.43	-0.39	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
LGG	cis	rs4950322	0.57	rs113498894	ENSG00000278811.3	LINC00624	9.09	2.77e-18	1.53e-15	0.38	0.39	Protein quantitative trait loci;	chr1:147318880	chr1:147258885~147517875:-
LGG	cis	rs4281086	0.897	rs7357473	ENSG00000253678.1	RP11-981G7.3	-9.09	2.77e-18	1.53e-15	-0.42	-0.39	Obesity-related traits;	chr8:10495785	chr8:10477491~10479375:-
LGG	cis	rs9322193	0.923	rs9322208	ENSG00000216621.7	RP11-244K5.6	9.09	2.78e-18	1.54e-15	0.46	0.39	Lung cancer;	chr6:149658547	chr6:149934527~149936782:+
LGG	cis	rs2287838	1	rs11667192	ENSG00000267289.1	CTD-2623N2.11	-9.09	2.79e-18	1.54e-15	-0.42	-0.39	Sleep duration;	chr19:9865294	chr19:9834079~9835013:-
LGG	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-9.09	2.79e-18	1.54e-15	-0.46	-0.39	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
LGG	cis	rs7208859	0.623	rs426434	ENSG00000266490.1	CTD-2349P21.9	9.09	2.79e-18	1.55e-15	0.48	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30792372~30792833:+
LGG	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	9.09	2.8e-18	1.55e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
LGG	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	9.09	2.81e-18	1.55e-15	0.4	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
LGG	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	-9.08	2.83e-18	1.56e-15	-0.43	-0.39	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
LGG	cis	rs4281086	0.897	rs34037334	ENSG00000253678.1	RP11-981G7.3	9.08	2.83e-18	1.57e-15	0.42	0.39	Obesity-related traits;	chr8:10487623	chr8:10477491~10479375:-
LGG	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-9.08	2.84e-18	1.57e-15	-0.53	-0.39	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
LGG	cis	rs6921919	0.583	rs6908137	ENSG00000218016.2	ZNF192P2	-9.08	2.85e-18	1.57e-15	-0.46	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28188050~28189432:+
LGG	cis	rs2287838	0.901	rs5004102	ENSG00000267289.1	CTD-2623N2.11	-9.08	2.85e-18	1.58e-15	-0.42	-0.39	Sleep duration;	chr19:9871658	chr19:9834079~9835013:-
LGG	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	9.08	2.85e-18	1.58e-15	0.46	0.39	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	9.08	2.85e-18	1.58e-15	0.46	0.39	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	9.08	2.85e-18	1.58e-15	0.46	0.39	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
LGG	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	-9.08	2.85e-18	1.58e-15	-0.4	-0.39	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
LGG	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	9.08	2.85e-18	1.58e-15	0.45	0.39	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
LGG	cis	rs9527	0.662	rs743575	ENSG00000272912.1	RP11-724N1.1	-9.08	2.88e-18	1.59e-15	-0.45	-0.39	Arsenic metabolism;	chr10:102835149	chr10:102914585~102915404:+
LGG	cis	rs9532669	0.824	rs4941998	ENSG00000168852.11	TPTE2P5	9.08	2.89e-18	1.6e-15	0.39	0.38	Cervical cancer;	chr13:40859901	chr13:40822296~40921749:-
LGG	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-9.08	2.9e-18	1.6e-15	-0.46	-0.38	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
LGG	cis	rs9532669	0.89	rs12865032	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40873801	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs34123829	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40873808	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4488324	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40873864	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4288867	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40873880	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4415896	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40874001	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs4415897	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40874035	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4389021	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40874209	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.824	rs4628828	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40874369	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.737	rs34354179	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40874424	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9594445	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40874859	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9594446	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40874863	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4402423	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40875010	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.963	rs9532628	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40875172	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532629	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40875193	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7491149	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40875216	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532630	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40875472	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs4306385	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40875641	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4406939	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40876108	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4628824	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40876217	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532632	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40876309	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532633	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40876332	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532634	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40876369	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532635	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40876397	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs12428959	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40876638	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.895	rs4942009	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40877243	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4334153	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40877737	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4309270	ENSG00000239827.7	SUGT1P3	-9.08	2.91e-18	1.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40877827	chr13:40908159~40921774:-
LGG	cis	rs5742933	1	rs4666783	ENSG00000273240.1	RP11-455J20.3	-9.08	2.91e-18	1.61e-15	-0.47	-0.38	Ferritin levels;	chr2:189748254	chr2:189763859~189764456:-
LGG	cis	rs6921919	0.583	rs7764722	ENSG00000218016.2	ZNF192P2	-9.08	2.92e-18	1.61e-15	-0.46	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28188050~28189432:+
LGG	cis	rs482329	0.543	rs615086	ENSG00000228044.2	RP4-781K5.4	-9.08	2.92e-18	1.61e-15	-0.42	-0.38	Life threatening arrhythmia;	chr1:234702754	chr1:234646289~234683176:+
LGG	cis	rs4713118	0.539	rs200967	ENSG00000219392.1	RP1-265C24.5	-9.08	2.93e-18	1.62e-15	-0.37	-0.38	Parkinson's disease;	chr6:27894349	chr6:28115628~28116551:+
LGG	cis	rs7216064	0.651	rs12947658	ENSG00000278219.1	AC145343.1	9.08	2.94e-18	1.62e-15	0.42	0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67906890	chr17:68101538~68101639:+
LGG	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	9.08	2.95e-18	1.63e-15	0.44	0.38	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
LGG	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	-9.08	2.96e-18	1.64e-15	-0.4	-0.38	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
LGG	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-9.08	2.97e-18	1.64e-15	-0.48	-0.38	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
LGG	cis	rs7267979	0.586	rs6050439	ENSG00000276952.1	RP5-965G21.6	9.08	2.97e-18	1.64e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25284915~25285588:-
LGG	cis	rs9322193	0.961	rs4870144	ENSG00000216621.7	RP11-244K5.6	9.08	2.98e-18	1.64e-15	0.47	0.38	Lung cancer;	chr6:149575540	chr6:149934527~149936782:+
LGG	cis	rs9393777	0.844	rs72839477	ENSG00000199851.2	U3	9.08	2.98e-18	1.65e-15	0.99	0.38	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28015568~28015777:+
LGG	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	9.08	2.99e-18	1.65e-15	0.4	0.38	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
LGG	cis	rs6921919	0.583	rs9468370	ENSG00000280107.1	AL022393.9	-9.08	3e-18	1.66e-15	-0.39	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28170845~28172521:+
LGG	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	9.08	3.01e-18	1.66e-15	0.45	0.38	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.752	rs6703748	ENSG00000281133.1	AL355480.3	-9.08	3.01e-18	1.66e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45580892~45580996:-
LGG	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	9.08	3.02e-18	1.67e-15	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
LGG	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	9.08	3.02e-18	1.67e-15	0.46	0.38	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
LGG	cis	rs12554020	1	rs4552973	ENSG00000237385.1	RP11-165J3.5	9.08	3.03e-18	1.67e-15	0.6	0.38	Schizophrenia;	chr9:93539437	chr9:93430342~93431299:-
LGG	cis	rs9322193	0.81	rs62439811	ENSG00000216621.7	RP11-244K5.6	9.08	3.03e-18	1.67e-15	0.47	0.38	Lung cancer;	chr6:149640416	chr6:149934527~149936782:+
LGG	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-9.08	3.03e-18	1.67e-15	-0.6	-0.38	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
LGG	cis	rs227275	0.525	rs4699037	ENSG00000230069.3	LRRC37A15P	-9.08	3.03e-18	1.67e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs3857198	ENSG00000230069.3	LRRC37A15P	-9.08	3.03e-18	1.67e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs4699039	ENSG00000230069.3	LRRC37A15P	-9.08	3.03e-18	1.67e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs6821173	ENSG00000230069.3	LRRC37A15P	-9.08	3.03e-18	1.67e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102727274~102730721:-
LGG	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	9.08	3.04e-18	1.67e-15	0.4	0.38	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
LGG	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	9.08	3.04e-18	1.68e-15	0.56	0.38	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-9.08	3.04e-18	1.68e-15	-0.56	-0.38	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
LGG	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	9.08	3.04e-18	1.68e-15	0.45	0.38	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
LGG	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	9.08	3.04e-18	1.68e-15	0.46	0.38	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	9.08	3.04e-18	1.68e-15	0.46	0.38	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
LGG	cis	rs1707322	0.648	rs4439382	ENSG00000281133.1	AL355480.3	-9.08	3.04e-18	1.68e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	9.08	3.04e-18	1.68e-15	0.45	0.38	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
LGG	cis	rs17772222	0.917	rs61984683	ENSG00000222990.1	RNU4-22P	9.08	3.05e-18	1.68e-15	0.51	0.38	Coronary artery calcification;	chr14:88553162	chr14:88513498~88513663:+
LGG	cis	rs7267979	0.586	rs6037057	ENSG00000276952.1	RP5-965G21.6	9.08	3.05e-18	1.68e-15	0.39	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.955	rs9393848	ENSG00000216901.1	AL022393.7	9.08	3.05e-18	1.68e-15	0.51	0.38	Parkinson's disease;	chr6:27720590	chr6:28176188~28176674:+
LGG	cis	rs34787248	1	rs34787248	ENSG00000226314.6	ZNF192P1	9.07	3.05e-18	1.68e-15	0.49	0.38	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	9.07	3.06e-18	1.68e-15	0.45	0.38	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
LGG	cis	rs2287838	1	rs12609594	ENSG00000267289.1	CTD-2623N2.11	9.07	3.06e-18	1.69e-15	0.42	0.38	Sleep duration;	chr19:9861741	chr19:9834079~9835013:-
LGG	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-9.07	3.07e-18	1.69e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-9.07	3.07e-18	1.69e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-9.07	3.07e-18	1.69e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-9.07	3.07e-18	1.69e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
LGG	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-9.07	3.07e-18	1.69e-15	-0.5	-0.38	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
LGG	cis	rs227275	0.525	rs6533050	ENSG00000230069.3	LRRC37A15P	-9.07	3.08e-18	1.7e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs10032234	ENSG00000230069.3	LRRC37A15P	-9.07	3.08e-18	1.7e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs28845922	ENSG00000230069.3	LRRC37A15P	-9.07	3.08e-18	1.7e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102727274~102730721:-
LGG	cis	rs228614	0.517	rs3886722	ENSG00000230069.3	LRRC37A15P	-9.07	3.08e-18	1.7e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102727274~102730721:-
LGG	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-9.07	3.08e-18	1.7e-15	-0.4	-0.38	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
LGG	cis	rs227275	0.556	rs10015289	ENSG00000230069.3	LRRC37A15P	-9.07	3.09e-18	1.7e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs6852141	ENSG00000230069.3	LRRC37A15P	-9.07	3.09e-18	1.7e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102727274~102730721:-
LGG	cis	rs228614	0.509	rs4455415	ENSG00000230069.3	LRRC37A15P	-9.07	3.09e-18	1.7e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	9.07	3.09e-18	1.7e-15	0.45	0.38	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.717	rs2275086	ENSG00000281133.1	AL355480.3	9.07	3.09e-18	1.7e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45580892~45580996:-
LGG	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	9.07	3.09e-18	1.71e-15	0.46	0.38	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
LGG	cis	rs1707322	1	rs10890378	ENSG00000281133.1	AL355480.3	9.07	3.1e-18	1.71e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45580892~45580996:-
LGG	cis	rs228614	0.51	rs223378	ENSG00000230069.3	LRRC37A15P	-9.07	3.1e-18	1.71e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102727274~102730721:-
LGG	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-9.07	3.11e-18	1.71e-15	-0.39	-0.38	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
LGG	cis	rs5760092	0.755	rs11090298	ENSG00000231271.1	AP000350.8	-9.07	3.11e-18	1.71e-15	-0.59	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23949918~23954042:+
LGG	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-9.07	3.11e-18	1.72e-15	-0.46	-0.38	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	9.07	3.13e-18	1.72e-15	0.31	0.38	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
LGG	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	9.07	3.14e-18	1.73e-15	0.46	0.38	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
LGG	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	9.07	3.14e-18	1.73e-15	0.31	0.38	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
LGG	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	9.07	3.14e-18	1.73e-15	0.31	0.38	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
LGG	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-9.07	3.15e-18	1.74e-15	-0.5	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
LGG	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	9.07	3.16e-18	1.74e-15	0.44	0.38	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
LGG	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-9.07	3.16e-18	1.74e-15	-0.51	-0.38	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
LGG	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	9.07	3.18e-18	1.75e-15	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
LGG	cis	rs228614	0.51	rs223362	ENSG00000230069.3	LRRC37A15P	-9.07	3.19e-18	1.75e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102727274~102730721:-
LGG	cis	rs2797160	0.651	rs1269176	ENSG00000237742.5	RP11-624M8.1	-9.07	3.19e-18	1.75e-15	-0.34	-0.38	Endometrial cancer;	chr6:125708536	chr6:125578558~125749190:-
LGG	cis	rs4950322	0.57	rs72691090	ENSG00000278811.3	LINC00624	9.07	3.22e-18	1.77e-15	0.39	0.38	Protein quantitative trait loci;	chr1:147297884	chr1:147258885~147517875:-
LGG	cis	rs9532669	0.929	rs9532601	ENSG00000239827.7	SUGT1P3	-9.07	3.22e-18	1.77e-15	-0.41	-0.38	Cervical cancer;	chr13:40861086	chr13:40908159~40921774:-
LGG	cis	rs2278702	0.79	rs11858943	ENSG00000259495.2	RP11-210M15.2	-9.07	3.23e-18	1.78e-15	-0.45	-0.38	Bipolar disorder;	chr15:80388289	chr15:80344853~80403575:-
LGG	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-9.07	3.23e-18	1.78e-15	-0.46	-0.38	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
LGG	cis	rs227275	0.554	rs223371	ENSG00000230069.3	LRRC37A15P	-9.07	3.24e-18	1.78e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102727274~102730721:-
LGG	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-9.07	3.25e-18	1.79e-15	-0.44	-0.38	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	9.07	3.28e-18	1.8e-15	0.45	0.38	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
LGG	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-9.07	3.28e-18	1.8e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
LGG	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-9.07	3.28e-18	1.8e-15	-0.31	-0.38	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
LGG	cis	rs6921919	0.583	rs9468370	ENSG00000199851.2	U3	9.07	3.28e-18	1.8e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-9.07	3.3e-18	1.81e-15	-0.51	-0.38	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
LGG	cis	rs17772222	1	rs60310240	ENSG00000222990.1	RNU4-22P	9.06	3.3e-18	1.82e-15	0.48	0.38	Coronary artery calcification;	chr14:88356365	chr14:88513498~88513663:+
LGG	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-9.06	3.31e-18	1.82e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-9.06	3.31e-18	1.82e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-9.06	3.31e-18	1.82e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-9.06	3.31e-18	1.82e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
LGG	cis	rs7829975	0.582	rs11783950	ENSG00000173295.6	FAM86B3P	9.06	3.34e-18	1.83e-15	0.41	0.38	Mood instability;	chr8:8740321	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	9.06	3.37e-18	1.85e-15	0.45	0.38	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	9.06	3.37e-18	1.85e-15	0.45	0.38	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
LGG	cis	rs227275	0.556	rs3886723	ENSG00000230069.3	LRRC37A15P	-9.06	3.37e-18	1.85e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102727274~102730721:-
LGG	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-9.06	3.37e-18	1.85e-15	-0.33	-0.38	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
LGG	cis	rs228614	0.536	rs223477	ENSG00000230069.3	LRRC37A15P	-9.06	3.39e-18	1.86e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102727274~102730721:-
LGG	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	9.06	3.39e-18	1.86e-15	0.47	0.38	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
LGG	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	9.06	3.4e-18	1.86e-15	0.44	0.38	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
LGG	cis	rs2278702	1	rs75809369	ENSG00000259495.2	RP11-210M15.2	-9.06	3.42e-18	1.88e-15	-0.47	-0.38	Bipolar disorder;	chr15:80406225	chr15:80344853~80403575:-
LGG	cis	rs227275	0.554	rs223421	ENSG00000230069.3	LRRC37A15P	-9.06	3.42e-18	1.88e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102727274~102730721:-
LGG	cis	rs6997458	0.742	rs3758076	ENSG00000253549.4	RP11-317J10.2	9.06	3.42e-18	1.88e-15	0.31	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463306	chr8:85441851~85464915:-
LGG	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-9.06	3.42e-18	1.88e-15	-0.41	-0.38	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
LGG	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	9.06	3.43e-18	1.88e-15	0.45	0.38	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.857	rs7327018	ENSG00000168852.11	TPTE2P5	9.06	3.44e-18	1.89e-15	0.39	0.38	Cervical cancer;	chr13:40856376	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7327315	ENSG00000168852.11	TPTE2P5	9.06	3.44e-18	1.89e-15	0.39	0.38	Cervical cancer;	chr13:40856383	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7327059	ENSG00000168852.11	TPTE2P5	9.06	3.44e-18	1.89e-15	0.39	0.38	Cervical cancer;	chr13:40856458	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9594433	ENSG00000168852.11	TPTE2P5	9.06	3.44e-18	1.89e-15	0.39	0.38	Cervical cancer;	chr13:40856935	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9525403	ENSG00000168852.11	TPTE2P5	9.06	3.44e-18	1.89e-15	0.39	0.38	Cervical cancer;	chr13:40858292	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7318768	ENSG00000168852.11	TPTE2P5	9.06	3.44e-18	1.89e-15	0.39	0.38	Cervical cancer;	chr13:40859140	chr13:40822296~40921749:-
LGG	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	9.06	3.44e-18	1.89e-15	0.31	0.38	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
LGG	cis	rs217727	0.524	rs7483477	ENSG00000226416.1	MRPL23-AS1	-9.06	3.45e-18	1.89e-15	-0.42	-0.38	Breast cancer;	chr11:1899025	chr11:1983237~1989920:-
LGG	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	9.06	3.45e-18	1.89e-15	0.38	0.38	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
LGG	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	9.06	3.45e-18	1.89e-15	0.38	0.38	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
LGG	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	9.06	3.45e-18	1.89e-15	0.38	0.38	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
LGG	cis	rs2843012	0.529	rs2516815	ENSG00000229921.5	KIF25-AS1	-9.06	3.46e-18	1.89e-15	-0.53	-0.38	Metabolite levels (5-HIAA);	chr6:168010510	chr6:167992822~167997077:-
LGG	cis	rs2843012	0.529	rs2636358	ENSG00000229921.5	KIF25-AS1	-9.06	3.46e-18	1.89e-15	-0.53	-0.38	Metabolite levels (5-HIAA);	chr6:168010515	chr6:167992822~167997077:-
LGG	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	9.06	3.46e-18	1.9e-15	0.5	0.38	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
LGG	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	9.06	3.46e-18	1.9e-15	0.45	0.38	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
LGG	cis	rs228614	0.543	rs223330	ENSG00000230069.3	LRRC37A15P	-9.06	3.46e-18	1.9e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223329	ENSG00000230069.3	LRRC37A15P	-9.06	3.46e-18	1.9e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223324	ENSG00000230069.3	LRRC37A15P	-9.06	3.46e-18	1.9e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102727274~102730721:-
LGG	cis	rs17772222	0.917	rs7157149	ENSG00000222990.1	RNU4-22P	9.06	3.47e-18	1.9e-15	0.5	0.38	Coronary artery calcification;	chr14:88765501	chr14:88513498~88513663:+
LGG	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	9.06	3.49e-18	1.91e-15	0.63	0.38	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
LGG	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-9.06	3.5e-18	1.92e-15	-0.77	-0.38	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
LGG	cis	rs1707322	0.752	rs4586014	ENSG00000281133.1	AL355480.3	-9.06	3.5e-18	1.92e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45580892~45580996:-
LGG	cis	rs1153858	0.621	rs12913645	ENSG00000259433.2	CTD-2651B20.4	9.06	3.51e-18	1.92e-15	0.45	0.38	Homoarginine levels;	chr15:45262868	chr15:45330209~45332634:-
LGG	cis	rs9595066	0.627	rs4941486	ENSG00000230731.2	RP11-478K15.6	9.06	3.51e-18	1.92e-15	0.6	0.38	Schizophrenia;	chr13:44175021	chr13:44234118~44243192:-
LGG	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-9.06	3.52e-18	1.93e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
LGG	cis	rs66887589	0.592	rs62320740	ENSG00000249244.1	RP11-548H18.2	9.06	3.53e-18	1.93e-15	0.39	0.38	Diastolic blood pressure;	chr4:119358331	chr4:119391831~119395335:-
LGG	cis	rs227275	0.525	rs223461	ENSG00000230069.3	LRRC37A15P	-9.06	3.56e-18	1.95e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102727274~102730721:-
LGG	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	9.06	3.56e-18	1.95e-15	0.46	0.38	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
LGG	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	9.06	3.56e-18	1.95e-15	0.46	0.38	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
LGG	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	9.06	3.56e-18	1.95e-15	0.46	0.38	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	9.06	3.56e-18	1.95e-15	0.46	0.38	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
LGG	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-9.06	3.56e-18	1.95e-15	-0.5	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
LGG	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	9.06	3.57e-18	1.95e-15	0.44	0.38	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
LGG	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	9.05	3.58e-18	1.96e-15	0.46	0.38	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	9.05	3.58e-18	1.96e-15	0.46	0.38	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	9.05	3.58e-18	1.96e-15	0.46	0.38	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
LGG	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	9.05	3.59e-18	1.96e-15	0.31	0.38	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
LGG	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	9.05	3.59e-18	1.96e-15	0.31	0.38	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	9.05	3.6e-18	1.97e-15	0.44	0.38	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	9.05	3.6e-18	1.97e-15	0.44	0.38	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	9.05	3.6e-18	1.97e-15	0.44	0.38	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	9.05	3.6e-18	1.97e-15	0.44	0.38	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
LGG	cis	rs9346353	1	rs7741758	ENSG00000219881.1	GAPDHP42	9.05	3.61e-18	1.97e-15	0.36	0.38	Sleep duration;	chr6:69702488	chr6:69745871~69746851:+
LGG	cis	rs6921919	0.525	rs16894095	ENSG00000280107.1	AL022393.9	-9.05	3.61e-18	1.97e-15	-0.39	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28170845~28172521:+
LGG	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-9.05	3.61e-18	1.98e-15	-0.54	-0.38	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
LGG	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-9.05	3.61e-18	1.98e-15	-0.54	-0.38	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
LGG	cis	rs9532669	0.926	rs7338617	ENSG00000239827.7	SUGT1P3	-9.05	3.62e-18	1.98e-15	-0.4	-0.38	Cervical cancer;	chr13:40870787	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.857	rs6560961	ENSG00000239827.7	SUGT1P3	-9.05	3.62e-18	1.98e-15	-0.4	-0.38	Cervical cancer;	chr13:40870878	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs6560962	ENSG00000239827.7	SUGT1P3	-9.05	3.62e-18	1.98e-15	-0.4	-0.38	Cervical cancer;	chr13:40870948	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs1055588	ENSG00000239827.7	SUGT1P3	-9.05	3.62e-18	1.98e-15	-0.4	-0.38	Cervical cancer;	chr13:40871306	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs3610	ENSG00000239827.7	SUGT1P3	-9.05	3.62e-18	1.98e-15	-0.4	-0.38	Cervical cancer;	chr13:40871334	chr13:40908159~40921774:-
LGG	cis	rs12682352	0.652	rs3789843	ENSG00000173295.6	FAM86B3P	-9.05	3.63e-18	1.98e-15	-0.4	-0.38	Neuroticism;	chr8:8866747	chr8:8228595~8244865:+
LGG	cis	rs12682352	0.652	rs3827806	ENSG00000173295.6	FAM86B3P	-9.05	3.63e-18	1.98e-15	-0.4	-0.38	Neuroticism;	chr8:8866766	chr8:8228595~8244865:+
LGG	cis	rs6921919	0.583	rs9468355	ENSG00000218016.2	ZNF192P2	-9.05	3.64e-18	1.99e-15	-0.47	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28188050~28189432:+
LGG	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	9.05	3.65e-18	1.99e-15	0.5	0.38	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
LGG	cis	rs9532669	0.926	rs7982346	ENSG00000239827.7	SUGT1P3	-9.05	3.65e-18	1.99e-15	-0.4	-0.38	Cervical cancer;	chr13:40873273	chr13:40908159~40921774:-
LGG	cis	rs1707322	0.721	rs10890346	ENSG00000281133.1	AL355480.3	9.05	3.65e-18	2e-15	0.46	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45580892~45580996:-
LGG	cis	rs1560104	0.675	rs9927247	ENSG00000274834.1	CTD-3037G24.5	-9.05	3.65e-18	2e-15	-0.49	-0.38	Obesity-related traits;	chr16:12611124	chr16:12614451~12614852:+
LGG	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	9.05	3.65e-18	2e-15	0.67	0.38	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
LGG	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	9.05	3.66e-18	2e-15	0.31	0.38	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
LGG	cis	rs17345786	1	rs11715368	ENSG00000256628.3	ZBTB11-AS1	9.05	3.67e-18	2.01e-15	0.49	0.38	Colonoscopy-negative controls vs population controls;	chr3:101617536	chr3:101676475~101679217:+
LGG	cis	rs2282300	0.956	rs1717779	ENSG00000242353.1	RP4-710M3.1	-9.05	3.68e-18	2.01e-15	-0.55	-0.38	Morning vs. evening chronotype;	chr11:30355151	chr11:30368148~30368646:+
LGG	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-9.05	3.72e-18	2.03e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
LGG	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	9.05	3.72e-18	2.03e-15	0.31	0.38	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
LGG	cis	rs4819052	0.679	rs4819053	ENSG00000215447.6	BX322557.10	9.05	3.72e-18	2.03e-15	0.28	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45288052~45291738:+
LGG	cis	rs7267979	0.816	rs443009	ENSG00000276952.1	RP5-965G21.6	-9.05	3.73e-18	2.04e-15	-0.38	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25284915~25285588:-
LGG	cis	rs9981595	1	rs9981595	ENSG00000255568.3	BRWD1-AS2	9.05	3.73e-18	2.04e-15	0.47	0.38	Venous thromboembolism (SNP x SNP interaction);	chr21:39188752	chr21:39313935~39314962:+
LGG	cis	rs1707322	0.717	rs3014246	ENSG00000281133.1	AL355480.3	9.05	3.74e-18	2.04e-15	0.46	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45580892~45580996:-
LGG	cis	rs7665090	0.51	rs223498	ENSG00000230069.3	LRRC37A15P	9.05	3.74e-18	2.04e-15	0.37	0.38	Primary biliary cholangitis;	chr4:102730805	chr4:102727274~102730721:-
LGG	cis	rs7267979	0.844	rs6115188	ENSG00000276952.1	RP5-965G21.6	9.05	3.76e-18	2.05e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25284915~25285588:-
LGG	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-9.05	3.77e-18	2.06e-15	-0.46	-0.38	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
LGG	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-9.05	3.78e-18	2.06e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
LGG	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-9.05	3.79e-18	2.07e-15	-0.46	-0.38	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-9.05	3.79e-18	2.07e-15	-0.46	-0.38	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
LGG	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-9.05	3.79e-18	2.07e-15	-0.46	-0.38	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-9.05	3.79e-18	2.07e-15	-0.46	-0.38	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-9.05	3.8e-18	2.08e-15	-0.46	-0.38	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
LGG	cis	rs228614	0.51	rs223353	ENSG00000230069.3	LRRC37A15P	-9.05	3.8e-18	2.08e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223352	ENSG00000230069.3	LRRC37A15P	-9.05	3.8e-18	2.08e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102727274~102730721:-
LGG	cis	rs1153858	0.621	rs2413769	ENSG00000259433.2	CTD-2651B20.4	-9.05	3.82e-18	2.09e-15	-0.45	-0.38	Homoarginine levels;	chr15:45269670	chr15:45330209~45332634:-
LGG	cis	rs944990	0.597	rs11789176	ENSG00000227603.1	RP11-165J3.6	9.05	3.83e-18	2.09e-15	0.39	0.38	Body mass index;	chr9:93433884	chr9:93435332~93437121:-
LGG	cis	rs2739330	0.753	rs4822452	ENSG00000235689.1	AP000351.13	9.05	3.83e-18	2.09e-15	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:24006305~24008258:-
LGG	cis	rs9532669	0.926	rs4942005	ENSG00000239827.7	SUGT1P3	-9.05	3.83e-18	2.09e-15	-0.4	-0.38	Cervical cancer;	chr13:40871636	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4942006	ENSG00000239827.7	SUGT1P3	-9.05	3.83e-18	2.09e-15	-0.4	-0.38	Cervical cancer;	chr13:40871862	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4942008	ENSG00000239827.7	SUGT1P3	-9.05	3.83e-18	2.09e-15	-0.4	-0.38	Cervical cancer;	chr13:40871989	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs2039118	ENSG00000239827.7	SUGT1P3	-9.05	3.83e-18	2.09e-15	-0.4	-0.38	Cervical cancer;	chr13:40872260	chr13:40908159~40921774:-
LGG	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	9.05	3.83e-18	2.09e-15	0.45	0.38	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	9.05	3.83e-18	2.09e-15	0.45	0.38	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
LGG	cis	rs62263923	0.545	rs2325036	ENSG00000239519.1	CADM2-AS1	9.05	3.83e-18	2.09e-15	0.43	0.38	Educational attainment (years of education);	chr3:85770262	chr3:85992183~86028007:-
LGG	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-9.05	3.84e-18	2.09e-15	-0.36	-0.38	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
LGG	cis	rs853679	0.824	rs34712084	ENSG00000226314.6	ZNF192P1	9.05	3.84e-18	2.1e-15	0.59	0.38	Depression;	chr6:28076050	chr6:28161781~28169594:+
LGG	cis	rs853679	0.824	rs1321505	ENSG00000226314.6	ZNF192P1	9.05	3.84e-18	2.1e-15	0.59	0.38	Depression;	chr6:28085045	chr6:28161781~28169594:+
LGG	cis	rs853679	0.882	rs9468287	ENSG00000226314.6	ZNF192P1	9.05	3.84e-18	2.1e-15	0.59	0.38	Depression;	chr6:28111963	chr6:28161781~28169594:+
LGG	cis	rs853679	0.882	rs9461432	ENSG00000226314.6	ZNF192P1	9.05	3.84e-18	2.1e-15	0.59	0.38	Depression;	chr6:28119105	chr6:28161781~28169594:+
LGG	cis	rs853679	0.882	rs4713139	ENSG00000226314.6	ZNF192P1	9.05	3.84e-18	2.1e-15	0.59	0.38	Depression;	chr6:28124907	chr6:28161781~28169594:+
LGG	cis	rs17772222	0.917	rs58984912	ENSG00000222990.1	RNU4-22P	9.05	3.84e-18	2.1e-15	0.5	0.38	Coronary artery calcification;	chr14:88698172	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs17188207	ENSG00000222990.1	RNU4-22P	9.05	3.84e-18	2.1e-15	0.5	0.38	Coronary artery calcification;	chr14:88699579	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs4635267	ENSG00000222990.1	RNU4-22P	9.05	3.86e-18	2.1e-15	0.51	0.38	Coronary artery calcification;	chr14:88621922	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.876	rs56144430	ENSG00000222990.1	RNU4-22P	9.05	3.86e-18	2.1e-15	0.51	0.38	Coronary artery calcification;	chr14:88622013	chr14:88513498~88513663:+
LGG	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-9.04	3.86e-18	2.11e-15	-0.53	-0.38	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
LGG	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	9.04	3.86e-18	2.11e-15	0.67	0.38	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
LGG	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	9.04	3.86e-18	2.11e-15	0.45	0.38	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
LGG	cis	rs2251666	0.514	rs56159834	ENSG00000267077.1	RP11-127I20.5	9.04	3.86e-18	2.11e-15	0.54	0.38	Cancer;	chr16:4868731	chr16:4795265~4796532:-
LGG	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	9.04	3.86e-18	2.11e-15	0.45	0.38	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
LGG	cis	rs228614	0.51	rs50034	ENSG00000230069.3	LRRC37A15P	-9.04	3.89e-18	2.12e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs223380	ENSG00000230069.3	LRRC37A15P	-9.04	3.89e-18	2.12e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs223379	ENSG00000230069.3	LRRC37A15P	-9.04	3.89e-18	2.12e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102727274~102730721:-
LGG	cis	rs228614	0.536	rs223375	ENSG00000230069.3	LRRC37A15P	-9.04	3.89e-18	2.12e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102727274~102730721:-
LGG	cis	rs9527	0.662	rs10883783	ENSG00000272912.1	RP11-724N1.1	-9.04	3.9e-18	2.13e-15	-0.44	-0.38	Arsenic metabolism;	chr10:102831395	chr10:102914585~102915404:+
LGG	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	9.04	3.9e-18	2.13e-15	0.45	0.38	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
LGG	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-9.04	3.92e-18	2.14e-15	-0.42	-0.38	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
LGG	cis	rs9876781	0.933	rs6442124	ENSG00000244380.1	RP11-24C3.2	9.04	3.93e-18	2.14e-15	0.48	0.38	Longevity;	chr3:48463903	chr3:48440352~48446656:-
LGG	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	9.04	3.95e-18	2.15e-15	0.5	0.38	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
LGG	cis	rs9532669	0.824	rs4941998	ENSG00000239827.7	SUGT1P3	-9.04	3.99e-18	2.17e-15	-0.41	-0.38	Cervical cancer;	chr13:40859901	chr13:40908159~40921774:-
LGG	cis	rs893971	0.672	rs28375859	ENSG00000246375.2	RP11-10L7.1	9.04	3.99e-18	2.18e-15	0.46	0.38	Conduct disorder (maternal expressed emotions interaction);	chr4:88303033	chr4:88284942~88331421:+
LGG	cis	rs4281086	0.861	rs4339601	ENSG00000253678.1	RP11-981G7.3	9.04	3.99e-18	2.18e-15	0.42	0.38	Obesity-related traits;	chr8:10502027	chr8:10477491~10479375:-
LGG	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-9.04	3.99e-18	2.18e-15	-0.46	-0.38	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
LGG	cis	rs1707322	0.717	rs2253862	ENSG00000281133.1	AL355480.3	9.04	4e-18	2.18e-15	0.46	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.717	rs2991988	ENSG00000281133.1	AL355480.3	9.04	4e-18	2.18e-15	0.46	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.717	rs2991989	ENSG00000281133.1	AL355480.3	9.04	4e-18	2.18e-15	0.46	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	9.04	4e-18	2.18e-15	0.49	0.38	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
LGG	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
LGG	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
LGG	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
LGG	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	9.04	4.01e-18	2.18e-15	0.31	0.38	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	9.04	4.01e-18	2.18e-15	0.45	0.38	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	9.04	4.01e-18	2.18e-15	0.45	0.38	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
LGG	cis	rs453301	0.574	rs10081437	ENSG00000173295.6	FAM86B3P	9.04	4.02e-18	2.19e-15	0.42	0.38	Joint mobility (Beighton score);	chr8:9091469	chr8:8228595~8244865:+
LGG	cis	rs1153858	0.621	rs1719237	ENSG00000259433.2	CTD-2651B20.4	-9.04	4.03e-18	2.19e-15	-0.45	-0.38	Homoarginine levels;	chr15:45287624	chr15:45330209~45332634:-
LGG	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	9.04	4.05e-18	2.21e-15	0.47	0.38	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
LGG	cis	rs9595066	0.712	rs4391951	ENSG00000230731.2	RP11-478K15.6	-9.04	4.07e-18	2.22e-15	-0.59	-0.38	Schizophrenia;	chr13:44180935	chr13:44234118~44243192:-
LGG	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-9.04	4.07e-18	2.22e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-9.04	4.07e-18	2.22e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-9.04	4.07e-18	2.22e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
LGG	cis	rs7267979	0.844	rs4423675	ENSG00000276952.1	RP5-965G21.6	-9.04	4.07e-18	2.22e-15	-0.38	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25284915~25285588:-
LGG	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-9.04	4.07e-18	2.22e-15	-0.52	-0.38	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
LGG	cis	rs7267979	0.844	rs6083851	ENSG00000276952.1	RP5-965G21.6	-9.04	4.07e-18	2.22e-15	-0.38	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25284915~25285588:-
LGG	cis	rs2739330	0.685	rs4822453	ENSG00000272787.1	KB-226F1.2	9.04	4.09e-18	2.23e-15	0.4	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23969211~23969873:+
LGG	cis	rs7829975	0.539	rs940031	ENSG00000173295.6	FAM86B3P	9.04	4.11e-18	2.24e-15	0.42	0.38	Mood instability;	chr8:8689338	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	9.04	4.11e-18	2.24e-15	0.45	0.38	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	9.04	4.12e-18	2.24e-15	0.44	0.38	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	9.04	4.16e-18	2.26e-15	0.44	0.38	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
LGG	cis	rs858239	0.601	rs6461702	ENSG00000230042.1	AK3P3	-9.04	4.16e-18	2.27e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23129178~23129841:+
LGG	cis	rs12682352	0.715	rs332039	ENSG00000173295.6	FAM86B3P	-9.03	4.17e-18	2.27e-15	-0.41	-0.38	Neuroticism;	chr8:8866141	chr8:8228595~8244865:+
LGG	cis	rs9532669	0.89	rs9532593	ENSG00000168852.11	TPTE2P5	9.03	4.19e-18	2.28e-15	0.39	0.38	Cervical cancer;	chr13:40847717	chr13:40822296~40921749:-
LGG	cis	rs227275	0.525	rs4596243	ENSG00000230069.3	LRRC37A15P	-9.03	4.19e-18	2.28e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102727274~102730721:-
LGG	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-9.03	4.22e-18	2.3e-15	-0.45	-0.38	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
LGG	cis	rs4713118	0.614	rs9468209	ENSG00000199851.2	U3	9.03	4.23e-18	2.3e-15	0.51	0.38	Parkinson's disease;	chr6:27726642	chr6:28015568~28015777:+
LGG	cis	rs11722779	0.838	rs4533776	ENSG00000230069.3	LRRC37A15P	-9.03	4.23e-18	2.3e-15	-0.36	-0.38	Schizophrenia;	chr4:102912732	chr4:102727274~102730721:-
LGG	cis	rs228614	0.514	rs59550147	ENSG00000230069.3	LRRC37A15P	-9.03	4.23e-18	2.3e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs3974608	ENSG00000230069.3	LRRC37A15P	-9.03	4.23e-18	2.3e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102727274~102730721:-
LGG	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	9.03	4.23e-18	2.3e-15	0.46	0.38	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
LGG	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	9.03	4.24e-18	2.31e-15	0.51	0.38	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	9.03	4.24e-18	2.31e-15	0.51	0.38	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
LGG	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-9.03	4.25e-18	2.31e-15	-0.48	-0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
LGG	cis	rs7267979	0.789	rs9927	ENSG00000125804.12	FAM182A	-9.03	4.25e-18	2.31e-15	-0.46	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:26054655~26086917:+
LGG	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	9.03	4.25e-18	2.31e-15	0.31	0.38	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
LGG	cis	rs853679	0.546	rs200949	ENSG00000216901.1	AL022393.7	9.03	4.27e-18	2.32e-15	0.69	0.38	Depression;	chr6:27867657	chr6:28176188~28176674:+
LGG	cis	rs35491132	1	rs35491132	ENSG00000216901.1	AL022393.7	9.03	4.28e-18	2.33e-15	0.85	0.38	Urinary tract infection frequency;	chr6:27559449	chr6:28176188~28176674:+
LGG	cis	rs12935418	0.672	rs9925780	ENSG00000260213.4	RP11-303E16.3	-9.03	4.29e-18	2.33e-15	-0.49	-0.38	Mean corpuscular volume;	chr16:81011571	chr16:81016792~81035759:-
LGG	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	-9.03	4.3e-18	2.34e-15	-0.41	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
LGG	cis	rs7267979	0.586	rs1007708	ENSG00000276952.1	RP5-965G21.6	9.03	4.3e-18	2.34e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25284915~25285588:-
LGG	cis	rs227275	0.554	rs223381	ENSG00000230069.3	LRRC37A15P	-9.03	4.3e-18	2.34e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102727274~102730721:-
LGG	cis	rs17772222	0.701	rs1627444	ENSG00000258983.2	RP11-507K2.2	-9.03	4.31e-18	2.34e-15	-0.43	-0.38	Coronary artery calcification;	chr14:88413784	chr14:88499334~88515502:+
LGG	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-9.03	4.31e-18	2.34e-15	-0.38	-0.38	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
LGG	cis	rs6921919	0.583	rs740621	ENSG00000280107.1	AL022393.9	-9.03	4.31e-18	2.34e-15	-0.39	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28170845~28172521:+
LGG	cis	rs9532669	0.926	rs4941995	ENSG00000168852.11	TPTE2P5	9.03	4.32e-18	2.35e-15	0.39	0.38	Cervical cancer;	chr13:40850117	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9315789	ENSG00000168852.11	TPTE2P5	9.03	4.32e-18	2.35e-15	0.39	0.38	Cervical cancer;	chr13:40852898	chr13:40822296~40921749:-
LGG	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-9.03	4.32e-18	2.35e-15	-0.36	-0.38	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
LGG	cis	rs17772222	0.545	rs1758846	ENSG00000258983.2	RP11-507K2.2	-9.03	4.32e-18	2.35e-15	-0.43	-0.38	Coronary artery calcification;	chr14:88449288	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.675	rs845769	ENSG00000258983.2	RP11-507K2.2	-9.03	4.32e-18	2.35e-15	-0.43	-0.38	Coronary artery calcification;	chr14:88461455	chr14:88499334~88515502:+
LGG	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	9.03	4.32e-18	2.35e-15	0.45	0.38	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
LGG	cis	rs17482078	0.885	rs10045403	ENSG00000248734.2	CTD-2260A17.1	9.03	4.34e-18	2.36e-15	0.47	0.38	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96784777~96785999:+
LGG	cis	rs7267979	0.844	rs2424703	ENSG00000276952.1	RP5-965G21.6	9.03	4.34e-18	2.36e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25284915~25285588:-
LGG	cis	rs9532669	0.926	rs4942000	ENSG00000168852.11	TPTE2P5	9.03	4.39e-18	2.38e-15	0.39	0.38	Cervical cancer;	chr13:40859979	chr13:40822296~40921749:-
LGG	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-9.03	4.39e-18	2.38e-15	-0.41	-0.38	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
LGG	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-9.03	4.41e-18	2.39e-15	-0.46	-0.38	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
LGG	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	9.03	4.41e-18	2.39e-15	0.41	0.38	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
LGG	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	9.03	4.41e-18	2.39e-15	0.41	0.38	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
LGG	cis	rs227275	0.556	rs12508069	ENSG00000230069.3	LRRC37A15P	-9.03	4.42e-18	2.4e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102727274~102730721:-
LGG	cis	rs227275	0.527	rs12500379	ENSG00000230069.3	LRRC37A15P	-9.03	4.42e-18	2.4e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102727274~102730721:-
LGG	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	9.03	4.42e-18	2.4e-15	0.46	0.38	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
LGG	cis	rs228614	0.51	rs4699033	ENSG00000230069.3	LRRC37A15P	-9.03	4.43e-18	2.41e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102727274~102730721:-
LGG	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	9.03	4.44e-18	2.41e-15	0.46	0.38	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
LGG	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	9.03	4.46e-18	2.42e-15	0.46	0.38	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	9.03	4.46e-18	2.42e-15	0.46	0.38	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	9.03	4.46e-18	2.42e-15	0.46	0.38	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	9.03	4.46e-18	2.42e-15	0.46	0.38	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
LGG	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	9.03	4.47e-18	2.42e-15	0.31	0.38	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
LGG	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-9.03	4.47e-18	2.42e-15	-0.48	-0.38	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
LGG	cis	rs227275	0.556	rs6815526	ENSG00000230069.3	LRRC37A15P	-9.03	4.47e-18	2.42e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs6824070	ENSG00000230069.3	LRRC37A15P	-9.03	4.47e-18	2.42e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.935	rs6856176	ENSG00000230069.3	LRRC37A15P	-9.03	4.47e-18	2.42e-15	-0.36	-0.38	Schizophrenia;	chr4:102902574	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs11722779	ENSG00000230069.3	LRRC37A15P	-9.03	4.47e-18	2.42e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102727274~102730721:-
LGG	cis	rs6921919	0.583	rs9468370	ENSG00000218016.2	ZNF192P2	-9.03	4.47e-18	2.43e-15	-0.46	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28188050~28189432:+
LGG	cis	rs4281086	1	rs62490637	ENSG00000253678.1	RP11-981G7.3	-9.03	4.48e-18	2.43e-15	-0.41	-0.38	Obesity-related traits;	chr8:10490707	chr8:10477491~10479375:-
LGG	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-9.03	4.49e-18	2.43e-15	-0.75	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
LGG	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-9.02	4.52e-18	2.45e-15	-0.46	-0.38	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
LGG	cis	rs858239	0.6	rs59073109	ENSG00000230042.1	AK3P3	-9.02	4.53e-18	2.45e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs7788821	ENSG00000230042.1	AK3P3	-9.02	4.53e-18	2.45e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs6956595	ENSG00000230042.1	AK3P3	-9.02	4.53e-18	2.45e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23129178~23129841:+
LGG	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	9.02	4.53e-18	2.46e-15	0.62	0.38	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
LGG	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	9.02	4.55e-18	2.47e-15	0.42	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	9.02	4.55e-18	2.47e-15	0.44	0.38	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	9.02	4.55e-18	2.47e-15	0.44	0.38	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	9.02	4.55e-18	2.47e-15	0.44	0.38	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	9.02	4.55e-18	2.47e-15	0.44	0.38	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	9.02	4.55e-18	2.47e-15	0.44	0.38	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.65	rs4553239	ENSG00000281133.1	AL355480.3	-9.02	4.57e-18	2.48e-15	-0.46	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.717	rs1135812	ENSG00000281133.1	AL355480.3	-9.02	4.58e-18	2.48e-15	-0.46	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45580892~45580996:-
LGG	cis	rs6997458	0.742	rs10095352	ENSG00000253549.4	RP11-317J10.2	9.02	4.59e-18	2.49e-15	0.31	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85460203	chr8:85441851~85464915:-
LGG	cis	rs6997458	0.742	rs3758077	ENSG00000253549.4	RP11-317J10.2	9.02	4.59e-18	2.49e-15	0.31	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463274	chr8:85441851~85464915:-
LGG	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-9.02	4.59e-18	2.49e-15	-0.36	-0.38	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
LGG	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	9.02	4.61e-18	2.5e-15	0.48	0.38	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
LGG	cis	rs11722779	0.838	rs6821247	ENSG00000230069.3	LRRC37A15P	-9.02	4.61e-18	2.5e-15	-0.36	-0.38	Schizophrenia;	chr4:102913483	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs9917919	ENSG00000230069.3	LRRC37A15P	-9.02	4.61e-18	2.5e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102727274~102730721:-
LGG	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	9.02	4.62e-18	2.5e-15	0.39	0.38	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
LGG	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	9.02	4.62e-18	2.5e-15	0.44	0.38	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	9.02	4.62e-18	2.5e-15	0.44	0.38	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
LGG	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-9.02	4.63e-18	2.51e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
LGG	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	9.02	4.63e-18	2.51e-15	0.44	0.38	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
LGG	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-9.02	4.64e-18	2.51e-15	-0.45	-0.38	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
LGG	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-9.02	4.64e-18	2.51e-15	-0.45	-0.38	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
LGG	cis	rs9322193	0.961	rs2064520	ENSG00000216621.7	RP11-244K5.6	9.02	4.64e-18	2.51e-15	0.46	0.38	Lung cancer;	chr6:149603650	chr6:149934527~149936782:+
LGG	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-9.02	4.65e-18	2.52e-15	-0.48	-0.38	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
LGG	cis	rs9719620	0.606	rs7807337	ENSG00000236753.4	MKLN1-AS	-9.02	4.65e-18	2.52e-15	-0.39	-0.38	Male-pattern baldness;	chr7:131299059	chr7:131309744~131328222:-
LGG	cis	rs2075466	0.514	rs75804753	ENSG00000267077.1	RP11-127I20.5	9.02	4.65e-18	2.52e-15	0.55	0.38	Colonoscopy-negative controls vs population controls;	chr16:4893032	chr16:4795265~4796532:-
LGG	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	9.02	4.66e-18	2.52e-15	0.44	0.38	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	9.02	4.66e-18	2.52e-15	0.44	0.38	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.717	rs1972410	ENSG00000281133.1	AL355480.3	-9.02	4.68e-18	2.53e-15	-0.44	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45580892~45580996:-
LGG	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	9.02	4.7e-18	2.55e-15	0.5	0.38	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
LGG	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-9.02	4.73e-18	2.56e-15	-0.49	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
LGG	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	9.02	4.74e-18	2.57e-15	0.56	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
LGG	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	9.02	4.74e-18	2.57e-15	0.53	0.38	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
LGG	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	9.02	4.74e-18	2.57e-15	0.53	0.38	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
LGG	cis	rs7208859	0.673	rs1347360	ENSG00000266490.1	CTD-2349P21.9	9.02	4.75e-18	2.57e-15	0.47	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30792372~30792833:+
LGG	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	9.02	4.75e-18	2.57e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
LGG	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	9.02	4.75e-18	2.57e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
LGG	cis	rs9532669	0.926	rs4356347	ENSG00000239827.7	SUGT1P3	-9.02	4.76e-18	2.58e-15	-0.4	-0.38	Cervical cancer;	chr13:40872516	chr13:40908159~40921774:-
LGG	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	9.02	4.77e-18	2.58e-15	0.41	0.38	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
LGG	cis	rs6496932	0.503	rs4564526	ENSG00000218052.5	ADAMTS7P4	-9.02	4.77e-18	2.58e-15	-0.55	-0.38	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85255369~85330334:-
LGG	cis	rs858239	0.6	rs61292332	ENSG00000230042.1	AK3P3	-9.02	4.77e-18	2.58e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23129178~23129841:+
LGG	cis	rs853679	0.546	rs200977	ENSG00000199851.2	U3	9.02	4.78e-18	2.59e-15	0.84	0.38	Depression;	chr6:27886523	chr6:28015568~28015777:+
LGG	cis	rs8037818	1	rs11071856	ENSG00000261064.1	RP11-1000B6.3	-9.02	4.79e-18	2.59e-15	-0.5	-0.38	Obesity-related traits;	chr15:32633591	chr15:32536047~32587613:+
LGG	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	9.02	4.79e-18	2.59e-15	0.46	0.38	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
LGG	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	9.02	4.79e-18	2.59e-15	0.46	0.38	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	9.02	4.79e-18	2.59e-15	0.46	0.38	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	9.02	4.79e-18	2.59e-15	0.46	0.38	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
LGG	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-9.02	4.8e-18	2.6e-15	-0.59	-0.38	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
LGG	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-9.02	4.82e-18	2.61e-15	-0.33	-0.38	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
LGG	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-9.02	4.82e-18	2.61e-15	-0.33	-0.38	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
LGG	cis	rs9322193	0.923	rs9322204	ENSG00000216621.7	RP11-244K5.6	9.02	4.82e-18	2.61e-15	0.46	0.38	Lung cancer;	chr6:149636047	chr6:149934527~149936782:+
LGG	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-9.02	4.83e-18	2.61e-15	-0.28	-0.38	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
LGG	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	9.02	4.86e-18	2.63e-15	0.48	0.38	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
LGG	cis	rs1707322	0.721	rs12069121	ENSG00000281133.1	AL355480.3	-9.02	4.87e-18	2.64e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45580892~45580996:-
LGG	cis	rs5742933	0.948	rs6434363	ENSG00000253559.1	OSGEPL1-AS1	-9.01	4.88e-18	2.64e-15	-0.49	-0.38	Ferritin levels;	chr2:189707565	chr2:189762704~189765556:+
LGG	cis	rs5742933	1	rs16831939	ENSG00000253559.1	OSGEPL1-AS1	-9.01	4.88e-18	2.64e-15	-0.49	-0.38	Ferritin levels;	chr2:189739282	chr2:189762704~189765556:+
LGG	cis	rs1707322	0.682	rs3014241	ENSG00000281133.1	AL355480.3	9.01	4.88e-18	2.64e-15	0.46	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45580892~45580996:-
LGG	cis	rs11722779	0.935	rs3974481	ENSG00000230069.3	LRRC37A15P	-9.01	4.89e-18	2.64e-15	-0.37	-0.38	Schizophrenia;	chr4:102956834	chr4:102727274~102730721:-
LGG	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-9.01	4.89e-18	2.64e-15	-0.46	-0.38	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
LGG	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-9.01	4.89e-18	2.64e-15	-0.48	-0.38	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
LGG	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-9.01	4.89e-18	2.64e-15	-0.48	-0.38	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
LGG	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	9.01	4.89e-18	2.65e-15	0.44	0.38	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
LGG	cis	rs7826238	0.594	rs2948285	ENSG00000253981.4	ALG1L13P	-9.01	4.91e-18	2.65e-15	-0.4	-0.38	Systolic blood pressure;	chr8:8273016	chr8:8236003~8244667:-
LGG	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	9.01	4.91e-18	2.65e-15	0.44	0.38	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
LGG	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-9.01	4.91e-18	2.65e-15	-0.5	-0.38	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
LGG	cis	rs7267979	0.586	rs6050445	ENSG00000276952.1	RP5-965G21.6	9.01	4.94e-18	2.67e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25284915~25285588:-
LGG	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-9.01	4.98e-18	2.69e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
LGG	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-9.01	4.99e-18	2.69e-15	-0.43	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
LGG	cis	rs9527	0.59	rs2148198	ENSG00000272912.1	RP11-724N1.1	9.01	4.99e-18	2.7e-15	0.44	0.38	Arsenic metabolism;	chr10:103155553	chr10:102914585~102915404:+
LGG	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	9.01	4.99e-18	2.7e-15	0.49	0.38	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	9.01	4.99e-18	2.7e-15	0.49	0.38	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	9.01	4.99e-18	2.7e-15	0.49	0.38	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
LGG	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	-9.01	5e-18	2.7e-15	-0.39	-0.38	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
LGG	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	9.01	5e-18	2.7e-15	0.46	0.38	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
LGG	cis	rs9322193	0.923	rs9766886	ENSG00000216621.7	RP11-244K5.6	9.01	5.01e-18	2.71e-15	0.46	0.38	Lung cancer;	chr6:149637048	chr6:149934527~149936782:+
LGG	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	9.01	5.03e-18	2.72e-15	0.45	0.38	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
LGG	cis	rs3096299	0.838	rs2035481	ENSG00000274627.1	RP11-104N10.2	9.01	5.03e-18	2.72e-15	0.34	0.38	Multiple myeloma (IgH translocation);	chr16:89353948	chr16:89516797~89522217:+
LGG	cis	rs950027	0.967	rs2643718	ENSG00000259433.2	CTD-2651B20.4	-9.01	5.05e-18	2.73e-15	-0.4	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45330209~45332634:-
LGG	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	9.01	5.05e-18	2.73e-15	0.44	0.38	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	9.01	5.05e-18	2.73e-15	0.44	0.38	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
LGG	cis	rs7746199	0.736	rs13212093	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs34038546	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28176188~28176674:+
LGG	cis	rs141342723	1	rs141342723	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs34543938	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs56405707	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13210634	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13215275	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs17749927	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13192965	ENSG00000216901.1	AL022393.7	9.01	5.05e-18	2.73e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28176188~28176674:+
LGG	cis	rs71537559	1	rs71537559	ENSG00000216901.1	AL022393.7	9.01	5.08e-18	2.74e-15	0.84	0.38	Squamous cell lung carcinoma;	chr6:27342000	chr6:28176188~28176674:+
LGG	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	9.01	5.08e-18	2.75e-15	0.44	0.38	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
LGG	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-9.01	5.09e-18	2.75e-15	-0.48	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-9.01	5.09e-18	2.75e-15	-0.48	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
LGG	cis	rs4281086	0.729	rs7008169	ENSG00000253678.1	RP11-981G7.3	-9.01	5.09e-18	2.75e-15	-0.42	-0.38	Obesity-related traits;	chr8:10488667	chr8:10477491~10479375:-
LGG	cis	rs9527	0.662	rs4919687	ENSG00000272912.1	RP11-724N1.1	-9.01	5.1e-18	2.75e-15	-0.44	-0.38	Arsenic metabolism;	chr10:102835491	chr10:102914585~102915404:+
LGG	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	9.01	5.11e-18	2.76e-15	0.49	0.38	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
LGG	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-9.01	5.12e-18	2.76e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
LGG	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	9.01	5.13e-18	2.77e-15	0.46	0.38	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	9.01	5.13e-18	2.77e-15	0.46	0.38	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
LGG	cis	rs853679	0.607	rs13199649	ENSG00000199851.2	U3	9.01	5.14e-18	2.77e-15	0.98	0.38	Depression;	chr6:27901014	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	9.01	5.14e-18	2.77e-15	0.45	0.38	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
LGG	cis	rs858239	0.537	rs2286272	ENSG00000230042.1	AK3P3	-9.01	5.14e-18	2.78e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23129178~23129841:+
LGG	cis	rs858239	0.537	rs6955115	ENSG00000230042.1	AK3P3	-9.01	5.14e-18	2.78e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23129178~23129841:+
LGG	cis	rs228614	0.536	rs223437	ENSG00000230069.3	LRRC37A15P	-9.01	5.15e-18	2.78e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223313	ENSG00000230069.3	LRRC37A15P	-9.01	5.15e-18	2.78e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102727274~102730721:-
LGG	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	9.01	5.17e-18	2.79e-15	0.66	0.38	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
LGG	cis	rs9322193	0.886	rs9485408	ENSG00000216621.7	RP11-244K5.6	9.01	5.17e-18	2.79e-15	0.46	0.38	Lung cancer;	chr6:149618888	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.886	rs9322198	ENSG00000216621.7	RP11-244K5.6	9.01	5.17e-18	2.79e-15	0.46	0.38	Lung cancer;	chr6:149623772	chr6:149934527~149936782:+
LGG	cis	rs7746199	0.736	rs13195636	ENSG00000199851.2	U3	9.01	5.18e-18	2.79e-15	0.98	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs34788973	ENSG00000216901.1	AL022393.7	9.01	5.18e-18	2.8e-15	0.83	0.38	Depression;	chr6:27911422	chr6:28176188~28176674:+
LGG	cis	rs853679	0.607	rs61742093	ENSG00000216901.1	AL022393.7	9.01	5.18e-18	2.8e-15	0.83	0.38	Depression;	chr6:27912204	chr6:28176188~28176674:+
LGG	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-9.01	5.2e-18	2.8e-15	-0.52	-0.38	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
LGG	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-9.01	5.21e-18	2.81e-15	-0.54	-0.38	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
LGG	cis	rs853679	0.607	rs13199649	ENSG00000216901.1	AL022393.7	9.01	5.21e-18	2.81e-15	0.87	0.38	Depression;	chr6:27901014	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-9.01	5.23e-18	2.82e-15	-0.4	-0.38	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
LGG	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-9.01	5.23e-18	2.82e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
LGG	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-9.01	5.24e-18	2.83e-15	-0.41	-0.38	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
LGG	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	9.01	5.26e-18	2.83e-15	0.6	0.38	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
LGG	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	9	5.28e-18	2.84e-15	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
LGG	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-9	5.3e-18	2.86e-15	-0.43	-0.38	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
LGG	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	9	5.3e-18	2.86e-15	0.36	0.38	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
LGG	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-9	5.31e-18	2.86e-15	-0.52	-0.38	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-9	5.31e-18	2.86e-15	-0.52	-0.38	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-9	5.31e-18	2.86e-15	-0.52	-0.38	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
LGG	cis	rs1707322	0.752	rs61784793	ENSG00000281133.1	AL355480.3	-9	5.31e-18	2.86e-15	-0.46	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	9	5.31e-18	2.86e-15	0.44	0.38	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	9	5.31e-18	2.86e-15	0.44	0.38	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
LGG	cis	rs228614	0.51	rs223445	ENSG00000230069.3	LRRC37A15P	-9	5.32e-18	2.87e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223443	ENSG00000230069.3	LRRC37A15P	-9	5.32e-18	2.87e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102727274~102730721:-
LGG	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-9	5.35e-18	2.88e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
LGG	cis	rs12935418	0.672	rs9934957	ENSG00000260213.4	RP11-303E16.3	9	5.35e-18	2.88e-15	0.48	0.38	Mean corpuscular volume;	chr16:81016078	chr16:81016792~81035759:-
LGG	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-9	5.37e-18	2.89e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
LGG	cis	rs10276381	0.786	rs73300665	ENSG00000234336.5	JAZF1-AS1	-9	5.37e-18	2.89e-15	-0.49	-0.38	Crohn's disease;	chr7:28187405	chr7:28180322~28243917:+
LGG	cis	rs9322193	0.923	rs9800614	ENSG00000216621.7	RP11-244K5.6	9	5.37e-18	2.89e-15	0.46	0.38	Lung cancer;	chr6:149644604	chr6:149934527~149936782:+
LGG	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-9	5.39e-18	2.9e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
LGG	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-9	5.4e-18	2.91e-15	-0.53	-0.38	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
LGG	cis	rs17772222	0.565	rs845759	ENSG00000258983.2	RP11-507K2.2	-9	5.4e-18	2.91e-15	-0.42	-0.38	Coronary artery calcification;	chr14:88415538	chr14:88499334~88515502:+
LGG	cis	rs853679	0.769	rs7752448	ENSG00000216901.1	AL022393.7	9	5.4e-18	2.91e-15	0.7	0.38	Depression;	chr6:28333322	chr6:28176188~28176674:+
LGG	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	9	5.41e-18	2.91e-15	0.51	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
LGG	cis	rs17772222	0.701	rs845757	ENSG00000258983.2	RP11-507K2.2	-9	5.41e-18	2.92e-15	-0.42	-0.38	Coronary artery calcification;	chr14:88455372	chr14:88499334~88515502:+
LGG	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	9	5.42e-18	2.92e-15	0.43	0.38	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
LGG	cis	rs5760092	0.618	rs4461358	ENSG00000231271.1	AP000350.8	-9	5.42e-18	2.92e-15	-0.55	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23949918~23954042:+
LGG	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	9	5.46e-18	2.94e-15	0.45	0.38	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
LGG	cis	rs6496932	1	rs12917495	ENSG00000218052.5	ADAMTS7P4	9	5.46e-18	2.94e-15	0.56	0.38	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85255369~85330334:-
LGG	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-9	5.47e-18	2.95e-15	-0.36	-0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
LGG	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-9	5.47e-18	2.95e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
LGG	cis	rs12449964	0.515	rs7225141	ENSG00000223979.2	SMCR2	9	5.47e-18	2.95e-15	0.38	0.38	Coronary artery disease or ischemic stroke;	chr17:17667513	chr17:17674026~17677688:-
LGG	cis	rs12935418	0.634	rs9934940	ENSG00000260213.4	RP11-303E16.3	-9	5.49e-18	2.95e-15	-0.48	-0.38	Mean corpuscular volume;	chr16:81016021	chr16:81016792~81035759:-
LGG	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-9	5.49e-18	2.96e-15	-0.37	-0.38	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
LGG	cis	rs7829975	0.533	rs35900578	ENSG00000173295.6	FAM86B3P	-9	5.5e-18	2.96e-15	-0.42	-0.38	Mood instability;	chr8:8862003	chr8:8228595~8244865:+
LGG	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-9	5.5e-18	2.96e-15	-0.51	-0.38	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
LGG	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-9	5.52e-18	2.97e-15	-0.46	-0.38	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
LGG	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	9	5.53e-18	2.98e-15	0.31	0.38	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
LGG	cis	rs11722779	0.935	rs6533046	ENSG00000230069.3	LRRC37A15P	-9	5.53e-18	2.98e-15	-0.36	-0.38	Schizophrenia;	chr4:102965917	chr4:102727274~102730721:-
LGG	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-9	5.55e-18	2.99e-15	-0.36	-0.38	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
LGG	cis	rs17772222	0.917	rs61984708	ENSG00000222990.1	RNU4-22P	9	5.56e-18	2.99e-15	0.51	0.38	Coronary artery calcification;	chr14:88565523	chr14:88513498~88513663:+
LGG	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	9	5.56e-18	2.99e-15	0.59	0.38	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
LGG	cis	rs4281086	0.862	rs13255425	ENSG00000253678.1	RP11-981G7.3	-9	5.57e-18	3e-15	-0.42	-0.38	Obesity-related traits;	chr8:10511083	chr8:10477491~10479375:-
LGG	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	9	5.57e-18	3e-15	0.37	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
LGG	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	9	5.57e-18	3e-15	0.37	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
LGG	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	9	5.57e-18	3e-15	0.34	0.38	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
LGG	cis	rs9532669	0.926	rs2324737	ENSG00000239827.7	SUGT1P3	-9	5.57e-18	3e-15	-0.4	-0.38	Cervical cancer;	chr13:40862808	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs35396630	ENSG00000239827.7	SUGT1P3	-9	5.57e-18	3e-15	-0.4	-0.38	Cervical cancer;	chr13:40863135	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4942001	ENSG00000239827.7	SUGT1P3	-9	5.57e-18	3e-15	-0.4	-0.38	Cervical cancer;	chr13:40863176	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4942003	ENSG00000239827.7	SUGT1P3	-9	5.57e-18	3e-15	-0.4	-0.38	Cervical cancer;	chr13:40863270	chr13:40908159~40921774:-
LGG	cis	rs9322193	0.923	rs1080670	ENSG00000216621.7	RP11-244K5.6	9	5.59e-18	3.01e-15	0.46	0.38	Lung cancer;	chr6:149620161	chr6:149934527~149936782:+
LGG	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-9	5.61e-18	3.02e-15	-0.49	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
LGG	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-9	5.62e-18	3.02e-15	-0.36	-0.38	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
LGG	cis	rs77204473	0.744	rs76567973	ENSG00000254851.1	RP11-109L13.1	9	5.64e-18	3.03e-15	0.89	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100045	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs78135964	ENSG00000254851.1	RP11-109L13.1	9	5.64e-18	3.03e-15	0.89	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100961	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	9	5.64e-18	3.03e-15	0.89	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
LGG	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	9	5.67e-18	3.05e-15	0.46	0.38	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
LGG	cis	rs7267979	0.586	rs6083776	ENSG00000276952.1	RP5-965G21.6	9	5.67e-18	3.05e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.586	rs1473695	ENSG00000276952.1	RP5-965G21.6	9	5.67e-18	3.05e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25284915~25285588:-
LGG	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	9	5.67e-18	3.05e-15	0.46	0.38	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
LGG	cis	rs228614	0.51	rs6830407	ENSG00000230069.3	LRRC37A15P	-9	5.69e-18	3.06e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102727274~102730721:-
LGG	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	9	5.69e-18	3.06e-15	0.31	0.38	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
LGG	cis	rs9532669	0.684	rs7139788	ENSG00000239827.7	SUGT1P3	-9	5.69e-18	3.06e-15	-0.4	-0.38	Cervical cancer;	chr13:40864264	chr13:40908159~40921774:-
LGG	cis	rs889122	0.531	rs8113425	ENSG00000267289.1	CTD-2623N2.11	-8.99	5.69e-18	3.06e-15	-0.4	-0.38	Menarche (age at onset);	chr19:9889630	chr19:9834079~9835013:-
LGG	cis	rs7267979	0.586	rs6050429	ENSG00000276952.1	RP5-965G21.6	8.99	5.72e-18	3.07e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.586	rs6050431	ENSG00000276952.1	RP5-965G21.6	8.99	5.72e-18	3.07e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.586	rs6050432	ENSG00000276952.1	RP5-965G21.6	8.99	5.72e-18	3.07e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25284915~25285588:-
LGG	cis	rs4281086	0.965	rs4437611	ENSG00000253678.1	RP11-981G7.3	8.99	5.72e-18	3.07e-15	0.42	0.38	Obesity-related traits;	chr8:10524679	chr8:10477491~10479375:-
LGG	cis	rs7746199	0.736	rs13209332	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs35848276	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs34965299	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs10484399	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs34105070	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.673	rs72845046	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs67652222	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28015568~28015777:+
LGG	cis	rs45509595	0.556	rs34409918	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Breast cancer;	chr6:27717569	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs34064842	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13212318	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13202295	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13202291	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs17750424	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13193542	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13193480	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.673	rs72847313	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.611	rs17750747	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.673	rs35501037	ENSG00000199851.2	U3	8.99	5.72e-18	3.07e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28015568~28015777:+
LGG	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	8.99	5.75e-18	3.09e-15	0.38	0.38	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
LGG	cis	rs853679	0.607	rs66868086	ENSG00000199851.2	U3	8.99	5.75e-18	3.09e-15	0.98	0.38	Depression;	chr6:27898124	chr6:28015568~28015777:+
LGG	cis	rs11051970	0.527	rs7962680	ENSG00000274964.1	RP11-817I4.1	-8.99	5.82e-18	3.12e-15	-0.42	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32322377	chr12:32339368~32340724:+
LGG	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	8.99	5.82e-18	3.13e-15	0.36	0.38	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
LGG	cis	rs2412819	0.571	rs6493090	ENSG00000249839.1	AC011330.5	8.99	5.82e-18	3.13e-15	0.63	0.38	Lung cancer;	chr15:43792084	chr15:43663654~43684339:-
LGG	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-8.99	5.84e-18	3.14e-15	-0.37	-0.38	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
LGG	cis	rs9322193	0.923	rs9505823	ENSG00000216621.7	RP11-244K5.6	8.99	5.85e-18	3.14e-15	0.46	0.38	Lung cancer;	chr6:149628899	chr6:149934527~149936782:+
LGG	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	8.99	5.87e-18	3.15e-15	0.61	0.38	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
LGG	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-8.99	5.88e-18	3.16e-15	-0.46	-0.38	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
LGG	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-8.99	5.89e-18	3.16e-15	-0.43	-0.38	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
LGG	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-8.99	5.91e-18	3.17e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
LGG	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	8.99	5.92e-18	3.18e-15	0.46	0.38	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	8.99	5.92e-18	3.18e-15	0.46	0.38	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
LGG	cis	rs12554020	0.786	rs78619366	ENSG00000227603.1	RP11-165J3.6	8.99	5.93e-18	3.18e-15	0.72	0.38	Schizophrenia;	chr9:93590541	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.579	rs78814851	ENSG00000227603.1	RP11-165J3.6	8.99	5.93e-18	3.18e-15	0.72	0.38	Schizophrenia;	chr9:93590652	chr9:93435332~93437121:-
LGG	cis	rs858239	0.6	rs6967475	ENSG00000230042.1	AK3P3	-8.99	5.93e-18	3.18e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23129178~23129841:+
LGG	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	8.99	5.98e-18	3.21e-15	0.45	0.38	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
LGG	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-8.99	6.02e-18	3.23e-15	-0.54	-0.38	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
LGG	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	8.99	6.02e-18	3.23e-15	0.28	0.38	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
LGG	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	8.99	6.03e-18	3.23e-15	0.44	0.38	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
LGG	cis	rs11148252	0.5	rs342768	ENSG00000278238.1	RP11-245D16.4	-8.99	6.03e-18	3.23e-15	-0.35	-0.38	Lewy body disease;	chr13:52634747	chr13:52454775~52455331:-
LGG	cis	rs227275	0.555	rs223402	ENSG00000230069.3	LRRC37A15P	-8.99	6.03e-18	3.23e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223392	ENSG00000230069.3	LRRC37A15P	-8.99	6.03e-18	3.23e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223390	ENSG00000230069.3	LRRC37A15P	-8.99	6.03e-18	3.23e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223435	ENSG00000230069.3	LRRC37A15P	-8.99	6.06e-18	3.25e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223434	ENSG00000230069.3	LRRC37A15P	-8.99	6.06e-18	3.25e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs223426	ENSG00000230069.3	LRRC37A15P	-8.99	6.06e-18	3.25e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102727274~102730721:-
LGG	cis	rs227275	0.554	rs223425	ENSG00000230069.3	LRRC37A15P	-8.99	6.06e-18	3.25e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102727274~102730721:-
LGG	cis	rs228614	0.536	rs223418	ENSG00000230069.3	LRRC37A15P	-8.99	6.06e-18	3.25e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223415	ENSG00000230069.3	LRRC37A15P	-8.99	6.06e-18	3.25e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102727274~102730721:-
LGG	cis	rs12554020	1	rs12554020	ENSG00000237385.1	RP11-165J3.5	8.99	6.06e-18	3.25e-15	0.59	0.38	Schizophrenia;	chr9:93507955	chr9:93430342~93431299:-
LGG	cis	rs7746199	0.736	rs13212093	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs34038546	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28015568~28015777:+
LGG	cis	rs141342723	1	rs141342723	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs34543938	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs56405707	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13210634	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13215275	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs17749927	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28015568~28015777:+
LGG	cis	rs7746199	0.736	rs13192965	ENSG00000199851.2	U3	8.99	6.07e-18	3.25e-15	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28015568~28015777:+
LGG	cis	rs228614	0.536	rs223475	ENSG00000230069.3	LRRC37A15P	-8.99	6.07e-18	3.25e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102727274~102730721:-
LGG	cis	rs228614	0.536	rs223474	ENSG00000230069.3	LRRC37A15P	-8.99	6.07e-18	3.25e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102727274~102730721:-
LGG	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-8.99	6.07e-18	3.26e-15	-0.46	-0.38	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
LGG	cis	rs5742933	0.948	rs5743063	ENSG00000273240.1	RP11-455J20.3	8.99	6.08e-18	3.26e-15	0.45	0.38	Ferritin levels;	chr2:189829723	chr2:189763859~189764456:-
LGG	cis	rs228614	0.536	rs150897	ENSG00000230069.3	LRRC37A15P	-8.99	6.08e-18	3.26e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102727274~102730721:-
LGG	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	8.99	6.09e-18	3.26e-15	0.48	0.38	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
LGG	cis	rs7829975	0.502	rs7820738	ENSG00000173295.6	FAM86B3P	8.99	6.09e-18	3.26e-15	0.4	0.38	Mood instability;	chr8:8845097	chr8:8228595~8244865:+
LGG	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-8.99	6.09e-18	3.26e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
LGG	cis	rs7267979	0.816	rs6037158	ENSG00000276952.1	RP5-965G21.6	8.99	6.11e-18	3.28e-15	0.38	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25284915~25285588:-
LGG	cis	rs375066	0.935	rs430308	ENSG00000267191.1	RP11-15A1.2	-8.99	6.12e-18	3.28e-15	-0.4	-0.38	Breast cancer;	chr19:43896223	chr19:43902001~43926545:+
LGG	cis	rs733592	0.524	rs10875726	ENSG00000258273.1	RP11-370I10.4	8.99	6.12e-18	3.28e-15	0.46	0.38	Plateletcrit;	chr12:48032209	chr12:48333755~48333901:-
LGG	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	8.99	6.14e-18	3.29e-15	0.31	0.38	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
LGG	cis	rs11722779	0.935	rs7681629	ENSG00000230069.3	LRRC37A15P	-8.99	6.14e-18	3.29e-15	-0.36	-0.38	Schizophrenia;	chr4:102974407	chr4:102727274~102730721:-
LGG	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-8.99	6.15e-18	3.29e-15	-0.46	-0.38	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
LGG	cis	rs13191038	1	rs13191038	ENSG00000216901.1	AL022393.7	8.99	6.15e-18	3.3e-15	0.86	0.38	Urinary tract infection frequency;	chr6:28515140	chr6:28176188~28176674:+
LGG	cis	rs11722779	0.844	rs17033381	ENSG00000230069.3	LRRC37A15P	-8.98	6.17e-18	3.31e-15	-0.36	-0.38	Schizophrenia;	chr4:102974952	chr4:102727274~102730721:-
LGG	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-8.98	6.18e-18	3.31e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
LGG	cis	rs748404	0.697	rs546722	ENSG00000249839.1	AC011330.5	-8.98	6.18e-18	3.31e-15	-0.49	-0.38	Lung cancer;	chr15:43288621	chr15:43663654~43684339:-
LGG	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	8.98	6.18e-18	3.31e-15	0.45	0.38	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
LGG	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	8.98	6.2e-18	3.32e-15	0.42	0.38	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
LGG	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-8.98	6.2e-18	3.32e-15	-0.56	-0.38	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
LGG	cis	rs227275	0.556	rs4699044	ENSG00000230069.3	LRRC37A15P	-8.98	6.21e-18	3.33e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs4699045	ENSG00000230069.3	LRRC37A15P	-8.98	6.21e-18	3.33e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102727274~102730721:-
LGG	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-8.98	6.24e-18	3.34e-15	-0.31	-0.38	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-8.98	6.24e-18	3.34e-15	-0.31	-0.38	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-8.98	6.24e-18	3.34e-15	-0.31	-0.38	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
LGG	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-8.98	6.24e-18	3.34e-15	-0.31	-0.38	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-8.98	6.24e-18	3.34e-15	-0.31	-0.38	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
LGG	cis	rs6921919	0.583	rs16894060	ENSG00000199851.2	U3	8.98	6.25e-18	3.35e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28015568~28015777:+
LGG	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	8.98	6.26e-18	3.35e-15	0.31	0.38	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
LGG	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	8.98	6.28e-18	3.36e-15	0.46	0.38	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
LGG	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-8.98	6.28e-18	3.36e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-8.98	6.28e-18	3.36e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
LGG	cis	rs116927879	1	rs116927879	ENSG00000272556.1	RP11-638I8.1	-8.98	6.29e-18	3.37e-15	-0.43	-0.38	Subjective response to lithium treatment in bipolar disorder;	chr7:45825128	chr7:45814602~45815263:+
LGG	cis	rs9346353	0.966	rs8180582	ENSG00000219881.1	GAPDHP42	8.98	6.3e-18	3.37e-15	0.36	0.38	Sleep duration;	chr6:69670563	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs1542412	ENSG00000219881.1	GAPDHP42	8.98	6.3e-18	3.37e-15	0.36	0.38	Sleep duration;	chr6:69674234	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs1026441	ENSG00000219881.1	GAPDHP42	8.98	6.3e-18	3.37e-15	0.36	0.38	Sleep duration;	chr6:69675331	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs3823079	ENSG00000219881.1	GAPDHP42	8.98	6.3e-18	3.37e-15	0.36	0.38	Sleep duration;	chr6:69678918	chr6:69745871~69746851:+
LGG	cis	rs17772222	0.655	rs1152376	ENSG00000258983.2	RP11-507K2.2	-8.98	6.31e-18	3.38e-15	-0.43	-0.38	Coronary artery calcification;	chr14:88495121	chr14:88499334~88515502:+
LGG	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	8.98	6.33e-18	3.39e-15	0.42	0.38	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
LGG	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-8.98	6.33e-18	3.39e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
LGG	cis	rs5742933	1	rs7557519	ENSG00000253559.1	OSGEPL1-AS1	-8.98	6.34e-18	3.39e-15	-0.49	-0.38	Ferritin levels;	chr2:189718461	chr2:189762704~189765556:+
LGG	cis	rs5742933	1	rs12052909	ENSG00000253559.1	OSGEPL1-AS1	-8.98	6.34e-18	3.39e-15	-0.49	-0.38	Ferritin levels;	chr2:189742484	chr2:189762704~189765556:+
LGG	cis	rs5742933	1	rs16831955	ENSG00000253559.1	OSGEPL1-AS1	-8.98	6.34e-18	3.39e-15	-0.49	-0.38	Ferritin levels;	chr2:189745811	chr2:189762704~189765556:+
LGG	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-8.98	6.37e-18	3.41e-15	-0.54	-0.38	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
LGG	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-8.98	6.37e-18	3.41e-15	-0.52	-0.38	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	8.98	6.39e-18	3.42e-15	0.44	0.38	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	8.98	6.39e-18	3.42e-15	0.44	0.38	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
LGG	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-8.98	6.39e-18	3.42e-15	-0.5	-0.38	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
LGG	cis	rs1707322	0.686	rs1250	ENSG00000281133.1	AL355480.3	-8.98	6.39e-18	3.42e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45580892~45580996:-
LGG	cis	rs853679	0.607	rs66868086	ENSG00000216901.1	AL022393.7	8.98	6.4e-18	3.42e-15	0.87	0.38	Depression;	chr6:27898124	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.847	rs12234128	ENSG00000216621.7	RP11-244K5.6	8.98	6.4e-18	3.42e-15	0.45	0.38	Lung cancer;	chr6:149627553	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs57012784	ENSG00000216621.7	RP11-244K5.6	8.98	6.4e-18	3.42e-15	0.45	0.38	Lung cancer;	chr6:149627691	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9689599	ENSG00000216621.7	RP11-244K5.6	8.98	6.4e-18	3.42e-15	0.45	0.38	Lung cancer;	chr6:149631973	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9800580	ENSG00000216621.7	RP11-244K5.6	8.98	6.4e-18	3.42e-15	0.45	0.38	Lung cancer;	chr6:149632845	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.884	rs11155669	ENSG00000216621.7	RP11-244K5.6	8.98	6.4e-18	3.42e-15	0.45	0.38	Lung cancer;	chr6:149633501	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.887	rs9505824	ENSG00000216621.7	RP11-244K5.6	8.98	6.4e-18	3.42e-15	0.45	0.38	Lung cancer;	chr6:149633663	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9505826	ENSG00000216621.7	RP11-244K5.6	8.98	6.4e-18	3.42e-15	0.45	0.38	Lung cancer;	chr6:149633912	chr6:149934527~149936782:+
LGG	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	8.98	6.4e-18	3.42e-15	0.46	0.38	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
LGG	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-8.98	6.43e-18	3.44e-15	-0.45	-0.38	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	8.98	6.44e-18	3.44e-15	0.46	0.38	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
LGG	cis	rs1707322	0.721	rs11211178	ENSG00000281133.1	AL355480.3	-8.98	6.45e-18	3.45e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45580892~45580996:-
LGG	cis	rs228614	0.51	rs223459	ENSG00000230069.3	LRRC37A15P	-8.98	6.45e-18	3.45e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	8.98	6.47e-18	3.46e-15	0.44	0.38	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
LGG	cis	rs227275	0.588	rs223458	ENSG00000230069.3	LRRC37A15P	-8.98	6.47e-18	3.46e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102727274~102730721:-
LGG	cis	rs1707322	0.752	rs4660880	ENSG00000281133.1	AL355480.3	-8.98	6.48e-18	3.47e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45580892~45580996:-
LGG	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	8.98	6.49e-18	3.47e-15	0.46	0.38	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	8.98	6.49e-18	3.47e-15	0.46	0.38	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
LGG	cis	rs9322193	0.884	rs10782312	ENSG00000216621.7	RP11-244K5.6	8.98	6.52e-18	3.49e-15	0.45	0.38	Lung cancer;	chr6:149622669	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	8.98	6.53e-18	3.49e-15	0.44	0.38	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	8.98	6.53e-18	3.49e-15	0.44	0.38	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
LGG	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	8.98	6.53e-18	3.49e-15	0.63	0.38	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
LGG	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-8.98	6.54e-18	3.49e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
LGG	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-8.98	6.54e-18	3.5e-15	-0.4	-0.38	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
LGG	cis	rs6921919	0.583	rs1054372	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs9468354	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs7773051	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs12697938	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs13437294	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.609	rs9468357	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs34513104	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs9461456	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.525	rs9468360	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs16894021	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs11751693	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs7749736	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.525	rs9468361	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs7775132	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs3734563	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs1591913	ENSG00000199851.2	U3	8.98	6.54e-18	3.5e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28015568~28015777:+
LGG	cis	rs7829975	0.577	rs7816329	ENSG00000173295.6	FAM86B3P	8.98	6.57e-18	3.51e-15	0.42	0.38	Mood instability;	chr8:8686333	chr8:8228595~8244865:+
LGG	cis	rs227275	0.525	rs3974604	ENSG00000230069.3	LRRC37A15P	-8.98	6.59e-18	3.52e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102727274~102730721:-
LGG	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-8.98	6.6e-18	3.52e-15	-0.34	-0.38	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
LGG	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
LGG	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-8.98	6.6e-18	3.52e-15	-0.46	-0.38	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
LGG	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-8.98	6.61e-18	3.53e-15	-0.49	-0.38	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
LGG	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	8.98	6.61e-18	3.53e-15	0.46	0.38	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
LGG	cis	rs2281558	0.876	rs2281562	ENSG00000125804.12	FAM182A	-8.98	6.61e-18	3.53e-15	-0.51	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25292726	chr20:26054655~26086917:+
LGG	cis	rs4950322	0.57	rs4950400	ENSG00000278811.3	LINC00624	-8.98	6.62e-18	3.53e-15	-0.38	-0.38	Protein quantitative trait loci;	chr1:147319383	chr1:147258885~147517875:-
LGG	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	8.98	6.62e-18	3.53e-15	0.44	0.38	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	8.98	6.62e-18	3.53e-15	0.44	0.38	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	8.98	6.62e-18	3.53e-15	0.44	0.38	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	8.98	6.62e-18	3.53e-15	0.44	0.38	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	8.98	6.62e-18	3.53e-15	0.44	0.38	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
LGG	cis	rs227275	0.527	rs223338	ENSG00000230069.3	LRRC37A15P	-8.98	6.65e-18	3.55e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102727274~102730721:-
LGG	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-8.97	6.66e-18	3.55e-15	-0.52	-0.38	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.923	rs9688452	ENSG00000216621.7	RP11-244K5.6	8.97	6.69e-18	3.57e-15	0.46	0.38	Lung cancer;	chr6:149658764	chr6:149934527~149936782:+
LGG	cis	rs1707322	0.682	rs12037459	ENSG00000281133.1	AL355480.3	-8.97	6.69e-18	3.57e-15	-0.46	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs12174716	ENSG00000216621.7	RP11-244K5.6	8.97	6.7e-18	3.57e-15	0.46	0.38	Lung cancer;	chr6:149644487	chr6:149934527~149936782:+
LGG	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-8.97	6.7e-18	3.58e-15	-0.46	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
LGG	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-8.97	6.73e-18	3.59e-15	-0.46	-0.38	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
LGG	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	8.97	6.76e-18	3.61e-15	0.32	0.38	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
LGG	cis	rs9532669	0.89	rs4942004	ENSG00000239827.7	SUGT1P3	-8.97	6.76e-18	3.61e-15	-0.4	-0.38	Cervical cancer;	chr13:40863598	chr13:40908159~40921774:-
LGG	cis	rs7829975	0.564	rs2921057	ENSG00000253981.4	ALG1L13P	-8.97	6.78e-18	3.62e-15	-0.39	-0.38	Mood instability;	chr8:8461157	chr8:8236003~8244667:-
LGG	cis	rs9876781	1	rs4858817	ENSG00000244380.1	RP11-24C3.2	-8.97	6.78e-18	3.62e-15	-0.47	-0.38	Longevity;	chr3:48375266	chr3:48440352~48446656:-
LGG	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	8.97	6.78e-18	3.62e-15	0.9	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
LGG	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	8.97	6.79e-18	3.62e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
LGG	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	8.97	6.79e-18	3.62e-15	0.38	0.38	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
LGG	cis	rs853679	0.607	rs33932084	ENSG00000199851.2	U3	8.97	6.8e-18	3.63e-15	0.93	0.38	Depression;	chr6:28301047	chr6:28015568~28015777:+
LGG	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	8.97	6.8e-18	3.63e-15	0.5	0.38	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
LGG	cis	rs6997458	0.742	rs4566	ENSG00000253549.4	RP11-317J10.2	8.97	6.82e-18	3.64e-15	0.31	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85448853	chr8:85441851~85464915:-
LGG	cis	rs6997458	0.749	rs13270041	ENSG00000253549.4	RP11-317J10.2	8.97	6.82e-18	3.64e-15	0.31	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85450734	chr8:85441851~85464915:-
LGG	cis	rs6997458	0.742	rs9969643	ENSG00000253549.4	RP11-317J10.2	8.97	6.82e-18	3.64e-15	0.31	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85453758	chr8:85441851~85464915:-
LGG	cis	rs9532669	0.926	rs8002809	ENSG00000239827.7	SUGT1P3	-8.97	6.82e-18	3.64e-15	-0.4	-0.38	Cervical cancer;	chr13:40872769	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.929	rs7982421	ENSG00000239827.7	SUGT1P3	-8.97	6.82e-18	3.64e-15	-0.4	-0.38	Cervical cancer;	chr13:40872776	chr13:40908159~40921774:-
LGG	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-8.97	6.84e-18	3.65e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
LGG	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-8.97	6.84e-18	3.65e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
LGG	cis	rs7247513	0.639	rs12984441	ENSG00000213290.4	PGK1P2	-8.97	6.86e-18	3.66e-15	-0.41	-0.38	Bipolar disorder;	chr19:12649473	chr19:12559571~12561105:+
LGG	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-8.97	6.87e-18	3.66e-15	-0.41	-0.38	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
LGG	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-8.97	6.9e-18	3.68e-15	-0.5	-0.38	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
LGG	cis	rs228614	0.534	rs223387	ENSG00000230069.3	LRRC37A15P	-8.97	6.91e-18	3.68e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102727274~102730721:-
LGG	cis	rs733592	0.524	rs10875727	ENSG00000258273.1	RP11-370I10.4	8.97	6.91e-18	3.68e-15	0.46	0.38	Plateletcrit;	chr12:48032360	chr12:48333755~48333901:-
LGG	cis	rs11722779	0.658	rs6533044	ENSG00000230069.3	LRRC37A15P	-8.97	6.91e-18	3.69e-15	-0.36	-0.38	Schizophrenia;	chr4:102965261	chr4:102727274~102730721:-
LGG	cis	rs228614	0.509	rs223480	ENSG00000230069.3	LRRC37A15P	-8.97	6.92e-18	3.69e-15	-0.37	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102727274~102730721:-
LGG	cis	rs17807185	0.653	rs7802732	ENSG00000214293.7	APTR	8.97	6.92e-18	3.69e-15	0.37	0.38	Height;	chr7:77658613	chr7:77657660~77696265:-
LGG	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	8.97	6.93e-18	3.69e-15	0.56	0.38	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	8.97	6.93e-18	3.69e-15	0.56	0.38	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	8.97	6.93e-18	3.69e-15	0.56	0.38	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
LGG	cis	rs228614	0.51	rs65671	ENSG00000230069.3	LRRC37A15P	-8.97	6.93e-18	3.69e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223412	ENSG00000230069.3	LRRC37A15P	-8.97	6.93e-18	3.69e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102727274~102730721:-
LGG	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-8.97	6.94e-18	3.7e-15	-0.36	-0.38	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.923	rs11155671	ENSG00000216621.7	RP11-244K5.6	8.97	6.95e-18	3.7e-15	0.46	0.38	Lung cancer;	chr6:149650996	chr6:149934527~149936782:+
LGG	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-8.97	7e-18	3.73e-15	-0.52	-0.38	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
LGG	cis	rs11722779	0.903	rs6830193	ENSG00000230069.3	LRRC37A15P	-8.97	7e-18	3.73e-15	-0.36	-0.38	Schizophrenia;	chr4:102955457	chr4:102727274~102730721:-
LGG	cis	rs7302981	0.746	rs706793	ENSG00000272368.2	RP4-605O3.4	8.97	7.01e-18	3.73e-15	0.37	0.38	Systolic blood pressure;	chr12:50073986	chr12:50112197~50165618:+
LGG	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	8.97	7.01e-18	3.73e-15	0.45	0.38	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
LGG	cis	rs6921919	0.525	rs11760133	ENSG00000199851.2	U3	8.97	7.01e-18	3.73e-15	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28015568~28015777:+
LGG	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	8.97	7.01e-18	3.73e-15	0.56	0.38	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	8.97	7.03e-18	3.74e-15	0.57	0.38	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
LGG	cis	rs11722779	0.869	rs223323	ENSG00000230069.3	LRRC37A15P	-8.97	7.03e-18	3.74e-15	-0.36	-0.38	Schizophrenia;	chr4:102878412	chr4:102727274~102730721:-
LGG	cis	rs227275	0.531	rs223460	ENSG00000230069.3	LRRC37A15P	-8.97	7.03e-18	3.74e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102727274~102730721:-
LGG	cis	rs9532669	0.89	rs9315791	ENSG00000239827.7	SUGT1P3	-8.97	7.05e-18	3.75e-15	-0.4	-0.38	Cervical cancer;	chr13:40863931	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.824	rs9315792	ENSG00000239827.7	SUGT1P3	-8.97	7.05e-18	3.75e-15	-0.4	-0.38	Cervical cancer;	chr13:40863951	chr13:40908159~40921774:-
LGG	cis	rs4683346	0.653	rs1070283	ENSG00000273328.4	RP11-141M3.6	-8.97	7.05e-18	3.76e-15	-0.49	-0.38	Granulocyte percentage of myeloid white cells;	chr3:42920467	chr3:42809414~42908105:+
LGG	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-8.97	7.06e-18	3.76e-15	-0.59	-0.38	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
LGG	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-8.97	7.06e-18	3.76e-15	-0.59	-0.38	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
LGG	cis	rs17345786	0.798	rs4257518	ENSG00000256628.3	ZBTB11-AS1	-8.97	7.07e-18	3.77e-15	-0.45	-0.38	Colonoscopy-negative controls vs population controls;	chr3:101562865	chr3:101676475~101679217:+
LGG	cis	rs1153858	0.621	rs1706824	ENSG00000259433.2	CTD-2651B20.4	-8.97	7.1e-18	3.78e-15	-0.45	-0.38	Homoarginine levels;	chr15:45287750	chr15:45330209~45332634:-
LGG	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	8.97	7.12e-18	3.79e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
LGG	cis	rs9322193	0.851	rs9322194	ENSG00000216621.7	RP11-244K5.6	8.97	7.12e-18	3.79e-15	0.47	0.38	Lung cancer;	chr6:149599113	chr6:149934527~149936782:+
LGG	cis	rs34864796	0.547	rs200476	ENSG00000199851.2	U3	8.97	7.14e-18	3.8e-15	0.6	0.38	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28015568~28015777:+
LGG	cis	rs56114371	0.53	rs169262	ENSG00000199851.2	U3	8.97	7.14e-18	3.8e-15	0.6	0.38	Breast cancer;	chr6:27803112	chr6:28015568~28015777:+
LGG	cis	rs1707322	0.686	rs2275085	ENSG00000281133.1	AL355480.3	8.97	7.15e-18	3.81e-15	0.46	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45580892~45580996:-
LGG	cis	rs4819052	0.679	rs2838860	ENSG00000215447.6	BX322557.10	-8.97	7.16e-18	3.81e-15	-0.28	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45288052~45291738:+
LGG	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-8.97	7.18e-18	3.82e-15	-0.46	-0.38	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	8.97	7.18e-18	3.82e-15	0.45	0.38	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
LGG	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-8.97	7.18e-18	3.82e-15	-0.31	-0.38	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
LGG	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	8.97	7.19e-18	3.82e-15	0.63	0.38	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
LGG	cis	rs228614	0.51	rs223453	ENSG00000230069.3	LRRC37A15P	-8.96	7.2e-18	3.83e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102727274~102730721:-
LGG	cis	rs17772222	0.655	rs816072	ENSG00000258983.2	RP11-507K2.2	-8.96	7.23e-18	3.85e-15	-0.43	-0.38	Coronary artery calcification;	chr14:88484335	chr14:88499334~88515502:+
LGG	cis	rs1707322	0.752	rs7541962	ENSG00000281133.1	AL355480.3	-8.96	7.23e-18	3.85e-15	-0.48	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45580892~45580996:-
LGG	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	8.96	7.27e-18	3.87e-15	0.44	0.38	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
LGG	cis	rs1275468	1	rs3858534	ENSG00000257497.2	RP11-585P4.5	-8.96	7.3e-18	3.88e-15	-0.49	-0.38	Polycystic ovary syndrome;	chr12:75553304	chr12:75483454~75489820:-
LGG	cis	rs12682352	0.652	rs1567398	ENSG00000173295.6	FAM86B3P	8.96	7.31e-18	3.89e-15	0.41	0.38	Neuroticism;	chr8:8869294	chr8:8228595~8244865:+
LGG	cis	rs228614	0.51	rs223463	ENSG00000230069.3	LRRC37A15P	-8.96	7.33e-18	3.9e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102727274~102730721:-
LGG	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	8.96	7.34e-18	3.9e-15	0.61	0.38	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
LGG	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	8.96	7.34e-18	3.9e-15	0.45	0.38	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	8.96	7.34e-18	3.9e-15	0.45	0.38	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	8.96	7.34e-18	3.9e-15	0.45	0.38	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	8.96	7.34e-18	3.9e-15	0.45	0.38	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
LGG	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-8.96	7.35e-18	3.91e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
LGG	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-8.96	7.35e-18	3.91e-15	-0.5	-0.38	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
LGG	cis	rs227275	0.525	rs10028116	ENSG00000230069.3	LRRC37A15P	-8.96	7.35e-18	3.91e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102727274~102730721:-
LGG	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	8.96	7.35e-18	3.91e-15	0.37	0.38	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
LGG	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-8.96	7.36e-18	3.91e-15	-0.58	-0.38	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
LGG	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-8.96	7.38e-18	3.92e-15	-0.41	-0.38	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
LGG	cis	rs7267979	0.873	rs7453	ENSG00000276952.1	RP5-965G21.6	8.96	7.39e-18	3.93e-15	0.37	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25284915~25285588:-
LGG	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-8.96	7.41e-18	3.94e-15	-0.52	-0.38	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
LGG	cis	rs7746199	0.736	rs13209332	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs35848276	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs34965299	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs10484399	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs34105070	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.673	rs72845046	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs67652222	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28176188~28176674:+
LGG	cis	rs45509595	0.556	rs34409918	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Breast cancer;	chr6:27717569	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs34064842	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13212318	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13202295	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13202291	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs17750424	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13193542	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs13193480	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.673	rs72847313	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.611	rs17750747	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.673	rs35501037	ENSG00000216901.1	AL022393.7	8.96	7.41e-18	3.94e-15	0.85	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28176188~28176674:+
LGG	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-8.96	7.44e-18	3.95e-15	-0.36	-0.38	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
LGG	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	8.96	7.45e-18	3.96e-15	0.44	0.38	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9689716	ENSG00000216621.7	RP11-244K5.6	8.96	7.46e-18	3.97e-15	0.46	0.38	Lung cancer;	chr6:149655662	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9322207	ENSG00000216621.7	RP11-244K5.6	8.96	7.46e-18	3.97e-15	0.46	0.38	Lung cancer;	chr6:149657185	chr6:149934527~149936782:+
LGG	cis	rs1707322	0.685	rs11211177	ENSG00000281133.1	AL355480.3	-8.96	7.5e-18	3.98e-15	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45580892~45580996:-
LGG	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	8.96	7.52e-18	3.99e-15	0.31	0.38	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
LGG	cis	rs62184315	0.536	rs16831873	ENSG00000273240.1	RP11-455J20.3	-8.96	7.52e-18	3.99e-15	-0.57	-0.38	Alcohol dependence (age at onset);	chr2:189692172	chr2:189763859~189764456:-
LGG	cis	rs4950322	0.748	rs56392137	ENSG00000278811.3	LINC00624	8.96	7.52e-18	4e-15	0.39	0.38	Protein quantitative trait loci;	chr1:147352450	chr1:147258885~147517875:-
LGG	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-8.96	7.53e-18	4e-15	-0.51	-0.38	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
LGG	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	8.96	7.59e-18	4.03e-15	0.57	0.38	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
LGG	cis	rs5742933	0.557	rs1233276	ENSG00000253559.1	OSGEPL1-AS1	-8.96	7.62e-18	4.05e-15	-0.49	-0.38	Ferritin levels;	chr2:189820056	chr2:189762704~189765556:+
LGG	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-8.96	7.66e-18	4.07e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
LGG	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-8.96	7.67e-18	4.07e-15	-0.31	-0.38	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
LGG	cis	rs858239	0.539	rs2390757	ENSG00000230042.1	AK3P3	-8.96	7.68e-18	4.08e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23129178~23129841:+
LGG	cis	rs9322193	0.961	rs9767713	ENSG00000216621.7	RP11-244K5.6	8.96	7.7e-18	4.09e-15	0.46	0.38	Lung cancer;	chr6:149588241	chr6:149934527~149936782:+
LGG	cis	rs4281086	0.93	rs12674796	ENSG00000253678.1	RP11-981G7.3	-8.96	7.71e-18	4.09e-15	-0.42	-0.38	Obesity-related traits;	chr8:10480399	chr8:10477491~10479375:-
LGG	cis	rs4819052	0.766	rs4819035	ENSG00000223768.1	LINC00205	-8.96	7.71e-18	4.09e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45293285~45297354:+
LGG	cis	rs67340775	0.834	rs13218875	ENSG00000199851.2	U3	8.96	7.71e-18	4.09e-15	0.94	0.38	Lung cancer in ever smokers;	chr6:27916234	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs67040724	ENSG00000199851.2	U3	8.96	7.71e-18	4.09e-15	0.94	0.38	Depression;	chr6:27937731	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs67662114	ENSG00000199851.2	U3	8.96	7.71e-18	4.09e-15	0.94	0.38	Depression;	chr6:27964523	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs13216117	ENSG00000199851.2	U3	8.96	7.71e-18	4.09e-15	0.94	0.38	Depression;	chr6:27970706	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs36101351	ENSG00000199851.2	U3	8.96	7.71e-18	4.09e-15	0.94	0.38	Depression;	chr6:27975591	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs28360499	ENSG00000199851.2	U3	8.96	7.71e-18	4.09e-15	0.94	0.38	Depression;	chr6:27977618	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs71537572	ENSG00000199851.2	U3	8.96	7.71e-18	4.09e-15	0.94	0.38	Depression;	chr6:28002937	chr6:28015568~28015777:+
LGG	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-8.96	7.73e-18	4.1e-15	-0.47	-0.38	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
LGG	cis	rs9810089	0.843	rs838202	ENSG00000261758.1	RP11-102M11.2	8.96	7.73e-18	4.1e-15	0.41	0.38	Gestational age at birth (child effect);	chr3:136316375	chr3:136752630~136755780:+
LGG	cis	rs9810089	0.843	rs681783	ENSG00000261758.1	RP11-102M11.2	8.96	7.73e-18	4.1e-15	0.41	0.38	Gestational age at birth (child effect);	chr3:136316461	chr3:136752630~136755780:+
LGG	cis	rs227275	0.525	rs223332	ENSG00000230069.3	LRRC37A15P	-8.96	7.73e-18	4.1e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102727274~102730721:-
LGG	cis	rs1707322	0.686	rs61784833	ENSG00000281133.1	AL355480.3	-8.96	7.73e-18	4.1e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45580892~45580996:-
LGG	cis	rs9393777	0.777	rs35984974	ENSG00000216901.1	AL022393.7	8.96	7.74e-18	4.11e-15	0.74	0.38	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28176188~28176674:+
LGG	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-8.96	7.74e-18	4.11e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
LGG	cis	rs858239	0.537	rs10279691	ENSG00000230042.1	AK3P3	-8.96	7.74e-18	4.11e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23129178~23129841:+
LGG	cis	rs2797160	0.651	rs6569436	ENSG00000237742.5	RP11-624M8.1	8.96	7.74e-18	4.11e-15	0.34	0.38	Endometrial cancer;	chr6:125710958	chr6:125578558~125749190:-
LGG	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	-8.96	7.75e-18	4.11e-15	-0.4	-0.38	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
LGG	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	8.96	7.76e-18	4.12e-15	0.44	0.38	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	8.96	7.76e-18	4.12e-15	0.44	0.38	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
LGG	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-8.95	7.79e-18	4.13e-15	-0.42	-0.38	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
LGG	cis	rs2282300	0.637	rs10742240	ENSG00000254532.1	RP11-624D11.2	8.95	7.84e-18	4.16e-15	0.46	0.38	Morning vs. evening chronotype;	chr11:30407891	chr11:30044058~30084343:-
LGG	cis	rs1707322	1	rs1707337	ENSG00000281133.1	AL355480.3	8.95	7.87e-18	4.17e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs1768807	ENSG00000281133.1	AL355480.3	8.95	7.87e-18	4.17e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.721	rs7519900	ENSG00000281133.1	AL355480.3	-8.95	7.9e-18	4.19e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45580892~45580996:-
LGG	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	8.95	7.93e-18	4.2e-15	0.46	0.38	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
LGG	cis	rs1707322	0.963	rs10789484	ENSG00000281133.1	AL355480.3	-8.95	7.98e-18	4.23e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45580892~45580996:-
LGG	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-8.95	7.98e-18	4.23e-15	-0.38	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-8.95	7.98e-18	4.23e-15	-0.38	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
LGG	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	8.95	8e-18	4.24e-15	0.44	0.38	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	8.95	8e-18	4.24e-15	0.44	0.38	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
LGG	cis	rs11148252	0.532	rs9536262	ENSG00000273784.3	RP11-78J21.7	8.95	8.02e-18	4.25e-15	0.45	0.38	Lewy body disease;	chr13:52728939	chr13:52600042~52642542:+
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-8.95	8.06e-18	4.27e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
LGG	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	8.95	8.06e-18	4.27e-15	0.46	0.38	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
LGG	cis	rs6903823	0.508	rs1150726	ENSG00000218016.2	ZNF192P2	-8.95	8.07e-18	4.27e-15	-0.46	-0.38	Pulmonary function;	chr6:28275265	chr6:28188050~28189432:+
LGG	cis	rs7267979	0.668	rs2387977	ENSG00000125804.12	FAM182A	8.95	8.11e-18	4.3e-15	0.45	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:26054655~26086917:+
LGG	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	8.95	8.11e-18	4.3e-15	0.49	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
LGG	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-8.95	8.14e-18	4.31e-15	-0.52	-0.38	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
LGG	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-8.95	8.15e-18	4.32e-15	-0.36	-0.38	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
LGG	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	8.95	8.18e-18	4.33e-15	0.61	0.38	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	8.95	8.18e-18	4.33e-15	0.61	0.38	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.597	rs2412821	ENSG00000249839.1	AC011330.5	-8.95	8.18e-18	4.33e-15	-0.61	-0.38	Lung cancer;	chr15:43864966	chr15:43663654~43684339:-
LGG	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	8.95	8.21e-18	4.35e-15	0.51	0.38	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
LGG	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	8.95	8.21e-18	4.35e-15	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
LGG	cis	rs9532669	0.89	rs7333274	ENSG00000239827.7	SUGT1P3	-8.95	8.26e-18	4.38e-15	-0.4	-0.38	Cervical cancer;	chr13:40862531	chr13:40908159~40921774:-
LGG	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	8.95	8.27e-18	4.38e-15	0.44	0.38	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
LGG	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	8.95	8.28e-18	4.38e-15	0.36	0.38	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
LGG	cis	rs17345786	0.798	rs9817043	ENSG00000244119.1	PDCL3P4	8.95	8.29e-18	4.39e-15	0.31	0.38	Colonoscopy-negative controls vs population controls;	chr3:101563008	chr3:101712472~101713191:+
LGG	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	8.95	8.31e-18	4.4e-15	0.37	0.38	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
LGG	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-8.95	8.32e-18	4.41e-15	-0.38	-0.38	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
LGG	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-8.95	8.33e-18	4.41e-15	-0.52	-0.38	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
LGG	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	8.95	8.34e-18	4.41e-15	0.3	0.38	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	8.95	8.39e-18	4.44e-15	0.5	0.38	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
LGG	cis	rs228614	0.51	rs223311	ENSG00000230069.3	LRRC37A15P	-8.94	8.41e-18	4.45e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102727274~102730721:-
LGG	cis	rs11098499	0.739	rs10031033	ENSG00000249244.1	RP11-548H18.2	8.94	8.43e-18	4.46e-15	0.4	0.38	Corneal astigmatism;	chr4:119230297	chr4:119391831~119395335:-
LGG	cis	rs1707322	0.717	rs3014245	ENSG00000281133.1	AL355480.3	8.94	8.45e-18	4.47e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	8.94	8.46e-18	4.48e-15	0.43	0.38	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
LGG	cis	rs7829975	0.593	rs2921061	ENSG00000253981.4	ALG1L13P	-8.94	8.5e-18	4.49e-15	-0.39	-0.38	Mood instability;	chr8:8460105	chr8:8236003~8244667:-
LGG	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-8.94	8.51e-18	4.5e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
LGG	cis	rs1707322	1	rs10890375	ENSG00000281133.1	AL355480.3	-8.94	8.52e-18	4.51e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs10890377	ENSG00000281133.1	AL355480.3	-8.94	8.52e-18	4.51e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45580892~45580996:-
LGG	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-8.94	8.53e-18	4.51e-15	-0.42	-0.38	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
LGG	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	8.94	8.55e-18	4.52e-15	0.45	0.38	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
LGG	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-8.94	8.55e-18	4.52e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
LGG	cis	rs9322193	0.923	rs9800871	ENSG00000216621.7	RP11-244K5.6	8.94	8.56e-18	4.53e-15	0.46	0.38	Lung cancer;	chr6:149644540	chr6:149934527~149936782:+
LGG	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-8.94	8.56e-18	4.53e-15	-0.45	-0.38	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-8.94	8.56e-18	4.53e-15	-0.45	-0.38	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-8.94	8.56e-18	4.53e-15	-0.45	-0.38	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-8.94	8.56e-18	4.53e-15	-0.45	-0.38	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
LGG	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-8.94	8.56e-18	4.53e-15	-0.45	-0.38	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
LGG	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
LGG	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	8.94	8.56e-18	4.53e-15	0.45	0.38	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
LGG	cis	rs1560104	0.879	rs2865582	ENSG00000274834.1	CTD-3037G24.5	-8.94	8.57e-18	4.53e-15	-0.48	-0.38	Obesity-related traits;	chr16:12623978	chr16:12614451~12614852:+
LGG	cis	rs7267979	0.789	rs1983974	ENSG00000276952.1	RP5-965G21.6	-8.94	8.61e-18	4.55e-15	-0.38	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25284915~25285588:-
LGG	cis	rs17345786	1	rs7641261	ENSG00000256628.3	ZBTB11-AS1	8.94	8.61e-18	4.55e-15	0.48	0.38	Colonoscopy-negative controls vs population controls;	chr3:101560162	chr3:101676475~101679217:+
LGG	cis	rs1707322	1	rs11211205	ENSG00000281133.1	AL355480.3	-8.94	8.61e-18	4.55e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs7547189	ENSG00000281133.1	AL355480.3	-8.94	8.62e-18	4.56e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs7547284	ENSG00000281133.1	AL355480.3	-8.94	8.62e-18	4.56e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45580892~45580996:-
LGG	cis	rs1075265	0.564	rs2111851	ENSG00000233266.1	HMGB1P31	8.94	8.63e-18	4.56e-15	0.5	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53655030	chr2:54051334~54051760:+
LGG	cis	rs893363	0.621	rs14165	ENSG00000271916.1	RP11-884K10.6	-8.94	8.64e-18	4.56e-15	-0.48	-0.38	Axial length;	chr3:53813381	chr3:53797764~53798019:-
LGG	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	8.94	8.65e-18	4.57e-15	0.69	0.38	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	8.94	8.65e-18	4.57e-15	0.69	0.38	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	8.94	8.65e-18	4.57e-15	0.69	0.38	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	8.94	8.65e-18	4.57e-15	0.69	0.38	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
LGG	cis	rs4281086	0.932	rs7838089	ENSG00000253678.1	RP11-981G7.3	8.94	8.7e-18	4.6e-15	0.41	0.38	Obesity-related traits;	chr8:10489141	chr8:10477491~10479375:-
LGG	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-8.94	8.7e-18	4.6e-15	-0.45	-0.38	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-8.94	8.7e-18	4.6e-15	-0.45	-0.38	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-8.94	8.7e-18	4.6e-15	-0.45	-0.38	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
LGG	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	8.94	8.7e-18	4.6e-15	0.45	0.38	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
LGG	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	8.94	8.74e-18	4.62e-15	0.5	0.38	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
LGG	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	8.94	8.75e-18	4.62e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
LGG	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	8.94	8.76e-18	4.63e-15	0.47	0.38	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
LGG	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-8.94	8.8e-18	4.65e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-8.94	8.8e-18	4.65e-15	-0.45	-0.38	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
LGG	cis	rs227275	0.556	rs4235407	ENSG00000230069.3	LRRC37A15P	-8.94	8.83e-18	4.66e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs17215211	ENSG00000230069.3	LRRC37A15P	-8.94	8.9e-18	4.7e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102727274~102730721:-
LGG	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	8.94	8.93e-18	4.71e-15	0.45	0.38	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
LGG	cis	rs7267979	1	rs2474777	ENSG00000125804.12	FAM182A	-8.94	8.94e-18	4.72e-15	-0.47	-0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:26054655~26086917:+
LGG	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	8.94	8.95e-18	4.73e-15	0.93	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	8.94	8.96e-18	4.73e-15	0.94	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	8.94	8.96e-18	4.73e-15	0.94	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	8.94	8.96e-18	4.73e-15	0.94	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	8.94	8.96e-18	4.73e-15	0.94	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
LGG	cis	rs858239	0.6	rs4321896	ENSG00000230042.1	AK3P3	-8.94	9e-18	4.75e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23129178~23129841:+
LGG	cis	rs6496932	1	rs12917518	ENSG00000218052.5	ADAMTS7P4	8.94	9.01e-18	4.75e-15	0.56	0.38	Central corneal thickness;Corneal structure;	chr15:85284018	chr15:85255369~85330334:-
LGG	cis	rs6496932	1	rs28374025	ENSG00000218052.5	ADAMTS7P4	8.94	9.01e-18	4.75e-15	0.56	0.38	Central corneal thickness;Corneal structure;	chr15:85284107	chr15:85255369~85330334:-
LGG	cis	rs9322193	0.923	rs9968911	ENSG00000216621.7	RP11-244K5.6	8.94	9.03e-18	4.76e-15	0.46	0.38	Lung cancer;	chr6:149657419	chr6:149934527~149936782:+
LGG	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	8.94	9.03e-18	4.76e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
LGG	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-8.94	9.05e-18	4.77e-15	-0.45	-0.38	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
LGG	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-8.94	9.05e-18	4.77e-15	-0.41	-0.38	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
LGG	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-8.94	9.05e-18	4.78e-15	-0.46	-0.38	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
LGG	cis	rs1707322	0.721	rs4660314	ENSG00000281133.1	AL355480.3	-8.94	9.06e-18	4.78e-15	-0.47	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45580892~45580996:-
LGG	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	8.93	9.09e-18	4.8e-15	0.58	0.38	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
LGG	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	8.93	9.12e-18	4.81e-15	0.62	0.38	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
LGG	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	8.93	9.12e-18	4.81e-15	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
LGG	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-8.93	9.13e-18	4.82e-15	-0.48	-0.38	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
LGG	cis	rs9532669	0.926	rs9566582	ENSG00000239827.7	SUGT1P3	-8.93	9.13e-18	4.82e-15	-0.41	-0.38	Cervical cancer;	chr13:40852121	chr13:40908159~40921774:-
LGG	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-8.93	9.16e-18	4.83e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-8.93	9.16e-18	4.83e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
LGG	cis	rs9322193	0.887	rs3734295	ENSG00000216621.7	RP11-244K5.6	8.93	9.2e-18	4.85e-15	0.47	0.38	Lung cancer;	chr6:149593917	chr6:149934527~149936782:+
LGG	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-8.93	9.2e-18	4.85e-15	-0.86	-0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
LGG	cis	rs5742933	1	rs5743061	ENSG00000273240.1	RP11-455J20.3	8.93	9.23e-18	4.87e-15	0.46	0.38	Ferritin levels;	chr2:189829540	chr2:189763859~189764456:-
LGG	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-8.93	9.24e-18	4.87e-15	-0.48	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
LGG	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	8.93	9.25e-18	4.87e-15	0.46	0.38	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	8.93	9.25e-18	4.87e-15	0.46	0.38	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
LGG	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	8.93	9.25e-18	4.87e-15	0.46	0.38	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
LGG	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-8.93	9.29e-18	4.89e-15	-0.46	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
LGG	cis	rs3096299	0.838	rs3102384	ENSG00000274627.1	RP11-104N10.2	8.93	9.3e-18	4.9e-15	0.33	0.38	Multiple myeloma (IgH translocation);	chr16:89345253	chr16:89516797~89522217:+
LGG	cis	rs17772222	0.917	rs61984684	ENSG00000222990.1	RNU4-22P	8.93	9.34e-18	4.92e-15	0.5	0.38	Coronary artery calcification;	chr14:88559104	chr14:88513498~88513663:+
LGG	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-8.93	9.37e-18	4.93e-15	-0.33	-0.38	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
LGG	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	8.93	9.38e-18	4.94e-15	0.45	0.38	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	8.93	9.38e-18	4.94e-15	0.45	0.38	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	8.93	9.38e-18	4.94e-15	0.45	0.38	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	8.93	9.38e-18	4.94e-15	0.45	0.38	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
LGG	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	8.93	9.41e-18	4.96e-15	0.55	0.38	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
LGG	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	8.93	9.41e-18	4.96e-15	0.46	0.38	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
LGG	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-8.93	9.42e-18	4.96e-15	-0.51	-0.38	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
LGG	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-8.93	9.46e-18	4.98e-15	-0.42	-0.38	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
LGG	cis	rs6921919	0.583	rs7759191	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs7764737	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs9461458	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.609	rs9468365	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs1361385	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs1416918	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs9468367	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs9461459	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs28360638	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs9468368	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs2041230	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.609	rs1005127	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28015568~28015777:+
LGG	cis	rs853679	0.515	rs4580862	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Depression;	chr6:28399886	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs4357130	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs11755942	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs6907950	ENSG00000199851.2	U3	8.93	9.48e-18	4.99e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28015568~28015777:+
LGG	cis	rs657075	0.697	rs78003854	ENSG00000263597.1	MIR3936	-8.93	9.49e-18	5e-15	-0.65	-0.38	Rheumatoid arthritis;	chr5:132424697	chr5:132365490~132365599:-
LGG	cis	rs657075	0.697	rs34362950	ENSG00000263597.1	MIR3936	-8.93	9.49e-18	5e-15	-0.65	-0.38	Rheumatoid arthritis;	chr5:132430811	chr5:132365490~132365599:-
LGG	cis	rs9532669	0.926	rs2183144	ENSG00000239827.7	SUGT1P3	8.93	9.5e-18	5e-15	0.39	0.38	Cervical cancer;	chr13:40862129	chr13:40908159~40921774:-
LGG	cis	rs4281086	1	rs4268093	ENSG00000253678.1	RP11-981G7.3	-8.93	9.53e-18	5.02e-15	-0.41	-0.38	Obesity-related traits;	chr8:10494720	chr8:10477491~10479375:-
LGG	cis	rs17345786	1	rs55641278	ENSG00000256628.3	ZBTB11-AS1	8.93	9.56e-18	5.03e-15	0.48	0.38	Colonoscopy-negative controls vs population controls;	chr3:101571733	chr3:101676475~101679217:+
LGG	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	8.93	9.59e-18	5.05e-15	0.47	0.38	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
LGG	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-8.93	9.6e-18	5.05e-15	-0.52	-0.38	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
LGG	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-8.93	9.63e-18	5.07e-15	-0.45	-0.38	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
LGG	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	8.93	9.64e-18	5.07e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
LGG	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	8.93	9.64e-18	5.07e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
LGG	cis	rs9532669	0.857	rs9525427	ENSG00000239827.7	SUGT1P3	-8.93	9.68e-18	5.09e-15	-0.4	-0.38	Cervical cancer;	chr13:40918029	chr13:40908159~40921774:-
LGG	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	8.93	9.69e-18	5.09e-15	0.39	0.38	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
LGG	cis	rs893971	0.672	rs13151250	ENSG00000246375.2	RP11-10L7.1	8.93	9.69e-18	5.1e-15	0.46	0.38	Conduct disorder (maternal expressed emotions interaction);	chr4:88301906	chr4:88284942~88331421:+
LGG	cis	rs9532669	0.926	rs9532693	ENSG00000168852.11	TPTE2P5	8.93	9.73e-18	5.12e-15	0.39	0.38	Cervical cancer;	chr13:40980557	chr13:40822296~40921749:-
LGG	cis	rs227275	0.554	rs223316	ENSG00000230069.3	LRRC37A15P	-8.93	9.74e-18	5.12e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102727274~102730721:-
LGG	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-8.93	9.75e-18	5.13e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-8.93	9.75e-18	5.13e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
LGG	cis	rs11722779	0.81	rs223417	ENSG00000230069.3	LRRC37A15P	-8.93	9.75e-18	5.13e-15	-0.37	-0.38	Schizophrenia;	chr4:102810568	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.805	rs223416	ENSG00000230069.3	LRRC37A15P	-8.93	9.75e-18	5.13e-15	-0.37	-0.38	Schizophrenia;	chr4:102810580	chr4:102727274~102730721:-
LGG	cis	rs5742933	1	rs6717922	ENSG00000253559.1	OSGEPL1-AS1	-8.93	9.79e-18	5.15e-15	-0.49	-0.38	Ferritin levels;	chr2:189721497	chr2:189762704~189765556:+
LGG	cis	rs5742933	1	rs4667306	ENSG00000253559.1	OSGEPL1-AS1	-8.93	9.79e-18	5.15e-15	-0.49	-0.38	Ferritin levels;	chr2:189725630	chr2:189762704~189765556:+
LGG	cis	rs5742933	1	rs16831925	ENSG00000253559.1	OSGEPL1-AS1	-8.93	9.79e-18	5.15e-15	-0.49	-0.38	Ferritin levels;	chr2:189731178	chr2:189762704~189765556:+
LGG	cis	rs2274273	0.745	rs56262555	ENSG00000258413.1	RP11-665C16.6	-8.93	9.8e-18	5.15e-15	-0.48	-0.38	Protein biomarker;	chr14:55095244	chr14:55262767~55272075:-
LGG	cis	rs6921919	0.583	rs2071965	ENSG00000218016.2	ZNF192P2	-8.92	9.8e-18	5.15e-15	-0.46	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28188050~28189432:+
LGG	cis	rs8031584	0.505	rs2959036	ENSG00000270015.1	RP11-540B6.6	8.92	9.84e-18	5.17e-15	0.28	0.38	Huntington's disease progression;	chr15:30927539	chr15:30926514~30928407:+
LGG	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	8.92	9.85e-18	5.18e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
LGG	cis	rs482329	0.795	rs623185	ENSG00000228044.2	RP4-781K5.4	8.92	9.86e-18	5.18e-15	0.43	0.38	Life threatening arrhythmia;	chr1:234679249	chr1:234646289~234683176:+
LGG	cis	rs2325036	0.929	rs6549055	ENSG00000239519.1	CADM2-AS1	8.92	9.88e-18	5.19e-15	0.42	0.38	Waist circumference;	chr3:85786757	chr3:85992183~86028007:-
LGG	cis	rs8031584	0.541	rs2959037	ENSG00000270015.1	RP11-540B6.6	8.92	9.89e-18	5.2e-15	0.28	0.38	Huntington's disease progression;	chr15:30925961	chr15:30926514~30928407:+
LGG	cis	rs8031584	0.541	rs2955777	ENSG00000270015.1	RP11-540B6.6	8.92	9.89e-18	5.2e-15	0.28	0.38	Huntington's disease progression;	chr15:30927585	chr15:30926514~30928407:+
LGG	cis	rs853679	0.506	rs1150711	ENSG00000226314.6	ZNF192P1	8.92	9.9e-18	5.2e-15	0.39	0.38	Depression;	chr6:28240757	chr6:28161781~28169594:+
LGG	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	8.92	9.91e-18	5.21e-15	0.5	0.38	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
LGG	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	8.92	9.92e-18	5.22e-15	0.34	0.38	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
LGG	cis	rs62184315	0.575	rs256546	ENSG00000273240.1	RP11-455J20.3	-8.92	9.96e-18	5.24e-15	-0.43	-0.38	Alcohol dependence (age at onset);	chr2:189886437	chr2:189763859~189764456:-
LGG	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-8.92	9.97e-18	5.24e-15	-0.58	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
LGG	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	8.92	9.97e-18	5.24e-15	0.5	0.38	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
LGG	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-8.92	9.98e-18	5.24e-15	-0.45	-0.38	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
LGG	cis	rs17772222	0.917	rs17188046	ENSG00000222990.1	RNU4-22P	8.92	1e-17	5.28e-15	0.49	0.38	Coronary artery calcification;	chr14:88624417	chr14:88513498~88513663:+
LGG	cis	rs11722779	0.903	rs13130741	ENSG00000230069.3	LRRC37A15P	-8.92	1.01e-17	5.28e-15	-0.36	-0.38	Schizophrenia;	chr4:103035799	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	8.92	1.01e-17	5.28e-15	0.44	0.38	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
LGG	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	8.92	1.01e-17	5.28e-15	0.54	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
LGG	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	8.92	1.01e-17	5.29e-15	0.44	0.38	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
LGG	cis	rs1560104	0.833	rs2903044	ENSG00000274834.1	CTD-3037G24.5	-8.92	1.01e-17	5.3e-15	-0.49	-0.38	Obesity-related traits;	chr16:12623535	chr16:12614451~12614852:+
LGG	cis	rs4819052	0.655	rs2330103	ENSG00000215447.6	BX322557.10	-8.92	1.01e-17	5.3e-15	-0.28	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45288052~45291738:+
LGG	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	8.92	1.02e-17	5.35e-15	0.44	0.38	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
LGG	cis	rs10771431	0.817	rs17202253	ENSG00000111788.10	RP11-22B23.1	8.92	1.02e-17	5.36e-15	0.36	0.38	Breast size;	chr12:9209254	chr12:9277235~9313241:+
LGG	cis	rs11148252	0.904	rs3892337	ENSG00000235660.1	LINC00345	-8.92	1.02e-17	5.36e-15	-0.46	-0.38	Lewy body disease;	chr13:52455350	chr13:52484161~52484680:-
LGG	cis	rs11148252	0.904	rs9536079	ENSG00000235660.1	LINC00345	-8.92	1.02e-17	5.36e-15	-0.46	-0.38	Lewy body disease;	chr13:52456430	chr13:52484161~52484680:-
LGG	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	8.92	1.02e-17	5.37e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
LGG	cis	rs9532669	0.889	rs9549302	ENSG00000168852.11	TPTE2P5	8.92	1.02e-17	5.37e-15	0.39	0.38	Cervical cancer;	chr13:40843278	chr13:40822296~40921749:-
LGG	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	8.92	1.02e-17	5.38e-15	0.47	0.38	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
LGG	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	8.92	1.03e-17	5.39e-15	0.61	0.38	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
LGG	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-8.92	1.03e-17	5.39e-15	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
LGG	cis	rs6496932	1	rs6496932	ENSG00000218052.5	ADAMTS7P4	8.92	1.03e-17	5.41e-15	0.56	0.38	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85255369~85330334:-
LGG	cis	rs9987353	0.519	rs11779181	ENSG00000173295.6	FAM86B3P	-8.92	1.03e-17	5.41e-15	-0.41	-0.38	Recombination measurement;	chr8:9205517	chr8:8228595~8244865:+
LGG	cis	rs5742933	1	rs55792400	ENSG00000253559.1	OSGEPL1-AS1	-8.92	1.03e-17	5.41e-15	-0.49	-0.38	Ferritin levels;	chr2:189686708	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.947	rs62185871	ENSG00000253559.1	OSGEPL1-AS1	-8.92	1.03e-17	5.41e-15	-0.49	-0.38	Ferritin levels;	chr2:189686980	chr2:189762704~189765556:+
LGG	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	8.92	1.03e-17	5.42e-15	0.31	0.38	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
LGG	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	8.92	1.03e-17	5.43e-15	0.48	0.38	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
LGG	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	-8.92	1.04e-17	5.45e-15	-0.39	-0.38	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
LGG	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-8.92	1.04e-17	5.47e-15	-0.45	-0.38	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
LGG	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-8.92	1.04e-17	5.47e-15	-0.45	-0.38	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
LGG	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	8.92	1.04e-17	5.47e-15	0.38	0.38	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
LGG	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-8.92	1.05e-17	5.49e-15	-0.52	-0.38	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
LGG	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	8.92	1.05e-17	5.5e-15	0.69	0.38	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	8.92	1.05e-17	5.5e-15	0.69	0.38	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	8.92	1.05e-17	5.5e-15	0.69	0.38	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
LGG	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	8.92	1.05e-17	5.5e-15	0.38	0.38	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
LGG	cis	rs6921919	0.583	rs9468355	ENSG00000199851.2	U3	8.92	1.05e-17	5.5e-15	0.54	0.38	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28015568~28015777:+
LGG	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	8.92	1.05e-17	5.5e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
LGG	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	8.92	1.05e-17	5.51e-15	0.4	0.38	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	8.92	1.05e-17	5.51e-15	0.4	0.38	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	8.92	1.05e-17	5.51e-15	0.4	0.38	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	8.92	1.05e-17	5.51e-15	0.4	0.38	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	8.92	1.05e-17	5.51e-15	0.4	0.38	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
LGG	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-8.92	1.05e-17	5.51e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-8.92	1.05e-17	5.51e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
LGG	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-8.92	1.05e-17	5.51e-15	-0.47	-0.38	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
LGG	cis	rs12935418	0.672	rs78895138	ENSG00000260213.4	RP11-303E16.3	-8.92	1.06e-17	5.53e-15	-0.49	-0.38	Mean corpuscular volume;	chr16:81014820	chr16:81016792~81035759:-
LGG	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-8.92	1.06e-17	5.54e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
LGG	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-8.92	1.06e-17	5.55e-15	-0.46	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
LGG	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	8.92	1.06e-17	5.55e-15	0.49	0.38	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
LGG	cis	rs2412819	0.571	rs678084	ENSG00000249839.1	AC011330.5	8.91	1.06e-17	5.55e-15	0.61	0.38	Lung cancer;	chr15:43828361	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	8.91	1.06e-17	5.55e-15	0.61	0.38	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	8.91	1.06e-17	5.55e-15	0.61	0.38	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	8.91	1.06e-17	5.55e-15	0.61	0.38	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
LGG	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-8.91	1.06e-17	5.55e-15	-0.61	-0.38	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
LGG	cis	rs482329	0.965	rs622339	ENSG00000228044.2	RP4-781K5.4	8.91	1.06e-17	5.56e-15	0.43	0.38	Life threatening arrhythmia;	chr1:234679443	chr1:234646289~234683176:+
LGG	cis	rs4820294	0.516	rs12484441	ENSG00000233360.4	Z83844.1	8.91	1.06e-17	5.57e-15	0.56	0.38	Fat distribution (HIV);	chr22:37701352	chr22:37641832~37658377:-
LGG	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	8.91	1.07e-17	5.58e-15	0.38	0.38	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
LGG	cis	rs227275	0.525	rs13113923	ENSG00000230069.3	LRRC37A15P	-8.91	1.07e-17	5.6e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.844	rs3974602	ENSG00000230069.3	LRRC37A15P	-8.91	1.07e-17	5.62e-15	-0.36	-0.38	Schizophrenia;	chr4:102928840	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.923	rs9689084	ENSG00000216621.7	RP11-244K5.6	8.91	1.07e-17	5.62e-15	0.46	0.38	Lung cancer;	chr6:149639648	chr6:149934527~149936782:+
LGG	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	8.91	1.08e-17	5.64e-15	0.31	0.38	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
LGG	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	8.91	1.08e-17	5.66e-15	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
LGG	cis	rs9322193	0.924	rs9498382	ENSG00000216621.7	RP11-244K5.6	8.91	1.08e-17	5.66e-15	0.46	0.38	Lung cancer;	chr6:149610982	chr6:149934527~149936782:+
LGG	cis	rs9393777	0.92	rs55834529	ENSG00000199851.2	U3	8.91	1.08e-17	5.67e-15	0.99	0.38	Intelligence (multi-trait analysis);	chr6:27104763	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs66462181	ENSG00000199851.2	U3	8.91	1.08e-17	5.67e-15	0.99	0.38	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs35768595	ENSG00000199851.2	U3	8.91	1.08e-17	5.67e-15	0.99	0.38	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28015568~28015777:+
LGG	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-8.91	1.08e-17	5.68e-15	-0.41	-0.38	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
LGG	cis	rs11671005	0.61	rs3816329	ENSG00000269600.1	AC016629.3	-8.91	1.09e-17	5.69e-15	-0.61	-0.38	Mean platelet volume;	chr19:58547326	chr19:58593896~58599355:-
LGG	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-8.91	1.09e-17	5.71e-15	-0.48	-0.38	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
LGG	cis	rs5742933	0.948	rs6434365	ENSG00000253559.1	OSGEPL1-AS1	-8.91	1.09e-17	5.73e-15	-0.49	-0.38	Ferritin levels;	chr2:189707695	chr2:189762704~189765556:+
LGG	cis	rs7302981	0.681	rs706792	ENSG00000272368.2	RP4-605O3.4	8.91	1.1e-17	5.76e-15	0.36	0.38	Systolic blood pressure;	chr12:50073861	chr12:50112197~50165618:+
LGG	cis	rs227275	0.554	rs223454	ENSG00000230069.3	LRRC37A15P	-8.91	1.1e-17	5.77e-15	-0.37	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.923	rs9377230	ENSG00000216621.7	RP11-244K5.6	8.91	1.11e-17	5.79e-15	0.45	0.38	Lung cancer;	chr6:149613607	chr6:149934527~149936782:+
LGG	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-8.91	1.11e-17	5.8e-15	-0.41	-0.38	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
LGG	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	8.91	1.11e-17	5.8e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
LGG	cis	rs4819052	0.655	rs2330102	ENSG00000215447.6	BX322557.10	-8.91	1.11e-17	5.82e-15	-0.28	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45288052~45291738:+
LGG	cis	rs4819052	0.679	rs8132135	ENSG00000215447.6	BX322557.10	-8.91	1.11e-17	5.82e-15	-0.28	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45288052~45291738:+
LGG	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	8.91	1.11e-17	5.83e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
LGG	cis	rs6921919	0.583	rs7740351	ENSG00000218016.2	ZNF192P2	-8.91	1.11e-17	5.83e-15	-0.46	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs16894108	ENSG00000218016.2	ZNF192P2	-8.91	1.11e-17	5.83e-15	-0.46	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28188050~28189432:+
LGG	cis	rs7208859	0.573	rs73267873	ENSG00000266490.1	CTD-2349P21.9	8.91	1.11e-17	5.83e-15	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.561	rs4085382	ENSG00000266490.1	CTD-2349P21.9	8.91	1.11e-17	5.83e-15	0.44	0.38	Body mass index;	chr17:30744184	chr17:30792372~30792833:+
LGG	cis	rs228614	0.536	rs223484	ENSG00000230069.3	LRRC37A15P	-8.91	1.12e-17	5.85e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102727274~102730721:-
LGG	cis	rs1707322	1	rs10158032	ENSG00000281133.1	AL355480.3	-8.91	1.12e-17	5.87e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45580892~45580996:-
LGG	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	8.91	1.12e-17	5.87e-15	0.44	0.38	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
LGG	cis	rs1707322	0.752	rs6678444	ENSG00000281133.1	AL355480.3	-8.91	1.13e-17	5.89e-15	-0.48	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45580892~45580996:-
LGG	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	8.91	1.13e-17	5.9e-15	0.56	0.38	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
LGG	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	8.91	1.13e-17	5.9e-15	0.5	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
LGG	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-8.91	1.13e-17	5.9e-15	-0.45	-0.38	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
LGG	cis	rs9527	0.59	rs12246739	ENSG00000272912.1	RP11-724N1.1	8.91	1.13e-17	5.91e-15	0.43	0.38	Arsenic metabolism;	chr10:103027262	chr10:102914585~102915404:+
LGG	cis	rs9346353	1	rs4706273	ENSG00000219881.1	GAPDHP42	8.91	1.13e-17	5.92e-15	0.36	0.38	Sleep duration;	chr6:69681748	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs12175229	ENSG00000219881.1	GAPDHP42	8.91	1.13e-17	5.92e-15	0.36	0.38	Sleep duration;	chr6:69682100	chr6:69745871~69746851:+
LGG	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-8.91	1.13e-17	5.93e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
LGG	cis	rs1609391	0.561	rs6439675	ENSG00000273486.1	RP11-731C17.2	8.91	1.14e-17	5.95e-15	0.37	0.38	Neuroticism;	chr3:136906594	chr3:136837338~136839021:-
LGG	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-8.91	1.14e-17	5.97e-15	-0.45	-0.38	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
LGG	cis	rs4819052	0.655	rs2330103	ENSG00000223768.1	LINC00205	-8.91	1.14e-17	5.97e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45293285~45297354:+
LGG	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-8.9	1.15e-17	6e-15	-0.51	-0.38	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
LGG	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-8.9	1.15e-17	6.01e-15	-0.45	-0.38	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	8.9	1.15e-17	6.02e-15	0.45	0.38	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
LGG	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	8.9	1.15e-17	6.03e-15	0.62	0.38	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
LGG	cis	rs17772222	0.917	rs2224333	ENSG00000222990.1	RNU4-22P	8.9	1.15e-17	6.03e-15	0.5	0.38	Coronary artery calcification;	chr14:88768748	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs12590826	ENSG00000222990.1	RNU4-22P	8.9	1.15e-17	6.03e-15	0.5	0.38	Coronary artery calcification;	chr14:88769357	chr14:88513498~88513663:+
LGG	cis	rs228614	0.51	rs223358	ENSG00000230069.3	LRRC37A15P	-8.9	1.15e-17	6.03e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102727274~102730721:-
LGG	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	8.9	1.15e-17	6.04e-15	0.45	0.38	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
LGG	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-8.9	1.16e-17	6.04e-15	-0.28	-0.38	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
LGG	cis	rs1275468	0.731	rs1480002	ENSG00000257497.2	RP11-585P4.5	-8.9	1.16e-17	6.04e-15	-0.54	-0.38	Polycystic ovary syndrome;	chr12:75587184	chr12:75483454~75489820:-
LGG	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	-8.9	1.16e-17	6.08e-15	-0.39	-0.38	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
LGG	cis	rs1707322	0.686	rs3014242	ENSG00000281133.1	AL355480.3	8.9	1.16e-17	6.09e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45580892~45580996:-
LGG	cis	rs741668	1	rs2806923	ENSG00000235903.6	CPB2-AS1	-8.9	1.17e-17	6.1e-15	-0.4	-0.38	Cerebrospinal fluid clusterin levels;	chr13:45944435	chr13:46052806~46113332:+
LGG	cis	rs4281086	0.965	rs4289772	ENSG00000253678.1	RP11-981G7.3	-8.9	1.17e-17	6.11e-15	-0.41	-0.38	Obesity-related traits;	chr8:10494383	chr8:10477491~10479375:-
LGG	cis	rs6940638	1	rs12215241	ENSG00000199851.2	U3	8.9	1.17e-17	6.11e-15	0.64	0.38	Intelligence (multi-trait analysis);	chr6:27055302	chr6:28015568~28015777:+
LGG	cis	rs34097030	1	rs34097030	ENSG00000207217.1	SNORA42	-8.9	1.17e-17	6.13e-15	-0.49	-0.38	Reticulocyte fraction of red cells;	chr7:6014758	chr7:6016877~6017011:+
LGG	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-8.9	1.18e-17	6.17e-15	-0.41	-0.38	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
LGG	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	8.9	1.18e-17	6.17e-15	0.49	0.38	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
LGG	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-8.9	1.19e-17	6.19e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
LGG	cis	rs657075	0.639	rs2306772	ENSG00000263597.1	MIR3936	-8.9	1.2e-17	6.24e-15	-0.66	-0.38	Rheumatoid arthritis;	chr5:132340288	chr5:132365490~132365599:-
LGG	cis	rs4281086	0.931	rs7812525	ENSG00000253678.1	RP11-981G7.3	-8.9	1.2e-17	6.27e-15	-0.41	-0.38	Obesity-related traits;	chr8:10521374	chr8:10477491~10479375:-
LGG	cis	rs1707322	1	rs6675222	ENSG00000281133.1	AL355480.3	-8.9	1.2e-17	6.27e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4660895	ENSG00000281133.1	AL355480.3	-8.9	1.2e-17	6.27e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4660318	ENSG00000281133.1	AL355480.3	-8.9	1.2e-17	6.27e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs10890360	ENSG00000281133.1	AL355480.3	-8.9	1.2e-17	6.27e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45580892~45580996:-
LGG	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-8.9	1.2e-17	6.28e-15	-0.45	-0.38	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
LGG	cis	rs6940638	0.956	rs72838268	ENSG00000199851.2	U3	8.9	1.21e-17	6.3e-15	0.64	0.38	Intelligence (multi-trait analysis);	chr6:27053394	chr6:28015568~28015777:+
LGG	cis	rs1075265	0.564	rs2160930	ENSG00000233266.1	HMGB1P31	8.9	1.21e-17	6.31e-15	0.5	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53655390	chr2:54051334~54051760:+
LGG	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	8.9	1.21e-17	6.31e-15	0.46	0.38	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
LGG	cis	rs11148252	0.74	rs9536046	ENSG00000278238.1	RP11-245D16.4	-8.9	1.21e-17	6.32e-15	-0.37	-0.38	Lewy body disease;	chr13:52381764	chr13:52454775~52455331:-
LGG	cis	rs11148252	0.904	rs9568732	ENSG00000235660.1	LINC00345	8.9	1.21e-17	6.33e-15	0.46	0.38	Lewy body disease;	chr13:52419277	chr13:52484161~52484680:-
LGG	cis	rs2921073	0.604	rs2979140	ENSG00000253893.2	FAM85B	-8.9	1.21e-17	6.33e-15	-0.46	-0.38	Parkinson's disease;	chr8:8409692	chr8:8167819~8226614:-
LGG	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	8.9	1.21e-17	6.34e-15	0.44	0.38	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
LGG	cis	rs6921919	0.583	rs6908137	ENSG00000199851.2	U3	8.9	1.21e-17	6.34e-15	0.52	0.38	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28015568~28015777:+
LGG	cis	rs4281086	0.965	rs4531010	ENSG00000253678.1	RP11-981G7.3	8.9	1.22e-17	6.34e-15	0.41	0.38	Obesity-related traits;	chr8:10523618	chr8:10477491~10479375:-
LGG	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-8.9	1.22e-17	6.34e-15	-0.46	-0.38	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
LGG	cis	rs228614	0.536	rs223327	ENSG00000230069.3	LRRC37A15P	-8.9	1.22e-17	6.35e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223326	ENSG00000230069.3	LRRC37A15P	-8.9	1.22e-17	6.35e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102727274~102730721:-
LGG	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	8.9	1.22e-17	6.35e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
LGG	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	8.9	1.22e-17	6.35e-15	0.37	0.38	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
LGG	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-8.9	1.22e-17	6.38e-15	-0.61	-0.38	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
LGG	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-8.9	1.23e-17	6.41e-15	-0.51	-0.38	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
LGG	cis	rs17772222	0.675	rs1099698	ENSG00000258983.2	RP11-507K2.2	-8.9	1.23e-17	6.42e-15	-0.42	-0.38	Coronary artery calcification;	chr14:88414904	chr14:88499334~88515502:+
LGG	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	8.9	1.23e-17	6.43e-15	0.42	0.38	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
LGG	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	8.89	1.24e-17	6.44e-15	0.61	0.38	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
LGG	cis	rs1707322	0.963	rs9787412	ENSG00000281133.1	AL355480.3	-8.89	1.24e-17	6.44e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4660896	ENSG00000281133.1	AL355480.3	-8.89	1.24e-17	6.44e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.928	rs10732844	ENSG00000281133.1	AL355480.3	-8.89	1.24e-17	6.44e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs12133129	ENSG00000281133.1	AL355480.3	-8.89	1.24e-17	6.44e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs4553121	ENSG00000281133.1	AL355480.3	-8.89	1.24e-17	6.44e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs6690652	ENSG00000281133.1	AL355480.3	-8.89	1.24e-17	6.44e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45580892~45580996:-
LGG	cis	rs8062405	0.573	rs11645306	ENSG00000251417.2	RP11-1348G14.4	8.89	1.24e-17	6.46e-15	0.49	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28802743~28817828:+
LGG	cis	rs6519955	0.866	rs9626920	ENSG00000231711.2	LINC00899	-8.89	1.25e-17	6.49e-15	-0.45	-0.38	Dupuytren's disease;	chr22:46033113	chr22:46039907~46044853:-
LGG	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
LGG	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
LGG	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	8.89	1.25e-17	6.53e-15	0.3	0.38	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
LGG	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	8.89	1.25e-17	6.54e-15	0.87	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.796	rs2154594	ENSG00000235689.1	AP000351.13	-8.89	1.26e-17	6.54e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:24006305~24008258:-
LGG	cis	rs4281086	0.932	rs7838337	ENSG00000253678.1	RP11-981G7.3	8.89	1.26e-17	6.55e-15	0.41	0.38	Obesity-related traits;	chr8:10489271	chr8:10477491~10479375:-
LGG	cis	rs4819052	0.634	rs8128636	ENSG00000215447.6	BX322557.10	-8.89	1.26e-17	6.56e-15	-0.28	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45288052~45291738:+
LGG	cis	rs12682352	0.65	rs13265731	ENSG00000173295.6	FAM86B3P	-8.89	1.26e-17	6.56e-15	-0.41	-0.38	Neuroticism;	chr8:8815810	chr8:8228595~8244865:+
LGG	cis	rs2739330	0.732	rs5760175	ENSG00000272787.1	KB-226F1.2	8.89	1.26e-17	6.57e-15	0.41	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23969211~23969873:+
LGG	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	8.89	1.26e-17	6.57e-15	0.44	0.38	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	8.89	1.26e-17	6.57e-15	0.44	0.38	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
LGG	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-8.89	1.26e-17	6.58e-15	-0.41	-0.38	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
LGG	cis	rs12554020	0.892	rs7028729	ENSG00000237385.1	RP11-165J3.5	8.89	1.26e-17	6.58e-15	0.62	0.38	Schizophrenia;	chr9:93443206	chr9:93430342~93431299:-
LGG	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	8.89	1.27e-17	6.6e-15	0.52	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
LGG	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	8.89	1.27e-17	6.6e-15	0.52	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
LGG	cis	rs9322193	0.884	rs2064521	ENSG00000216621.7	RP11-244K5.6	-8.89	1.27e-17	6.6e-15	-0.45	-0.38	Lung cancer;	chr6:149625336	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	8.89	1.27e-17	6.61e-15	0.44	0.38	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	8.89	1.27e-17	6.61e-15	0.44	0.38	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
LGG	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-8.89	1.27e-17	6.64e-15	-0.31	-0.38	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
LGG	cis	rs7829975	0.56	rs17154599	ENSG00000173295.6	FAM86B3P	8.89	1.28e-17	6.65e-15	0.41	0.38	Mood instability;	chr8:8693908	chr8:8228595~8244865:+
LGG	cis	rs2325036	0.75	rs3916054	ENSG00000239519.1	CADM2-AS1	8.89	1.28e-17	6.66e-15	0.43	0.38	Waist circumference;	chr3:85842845	chr3:85992183~86028007:-
LGG	cis	rs1560104	1	rs4780465	ENSG00000274834.1	CTD-3037G24.5	-8.89	1.28e-17	6.67e-15	-0.48	-0.38	Obesity-related traits;	chr16:12613666	chr16:12614451~12614852:+
LGG	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	8.89	1.28e-17	6.68e-15	0.44	0.38	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
LGG	cis	rs858239	0.601	rs7805206	ENSG00000230042.1	AK3P3	-8.89	1.29e-17	6.7e-15	-0.37	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23129178~23129841:+
LGG	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	8.89	1.29e-17	6.72e-15	0.4	0.38	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
LGG	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-8.89	1.29e-17	6.72e-15	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
LGG	cis	rs11722779	0.933	rs7695096	ENSG00000230069.3	LRRC37A15P	-8.89	1.29e-17	6.73e-15	-0.36	-0.38	Schizophrenia;	chr4:103011399	chr4:102727274~102730721:-
LGG	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-8.89	1.29e-17	6.73e-15	-0.53	-0.38	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-8.89	1.29e-17	6.73e-15	-0.51	-0.38	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-8.89	1.29e-17	6.73e-15	-0.51	-0.38	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-8.89	1.29e-17	6.73e-15	-0.51	-0.38	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-8.89	1.29e-17	6.73e-15	-0.51	-0.38	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
LGG	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	8.89	1.3e-17	6.74e-15	0.3	0.38	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
LGG	cis	rs858239	0.536	rs6961109	ENSG00000230042.1	AK3P3	-8.89	1.3e-17	6.76e-15	-0.39	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23129178~23129841:+
LGG	cis	rs9322193	1	rs9377228	ENSG00000216621.7	RP11-244K5.6	8.89	1.3e-17	6.78e-15	0.45	0.38	Lung cancer;	chr6:149600862	chr6:149934527~149936782:+
LGG	cis	rs7786410	1	rs7786410	ENSG00000275875.1	RP11-613E4.5	8.89	1.31e-17	6.83e-15	0.65	0.38	Age-related hearing impairment;	chr7:55854630	chr7:55741525~55741869:+
LGG	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-8.89	1.31e-17	6.83e-15	-0.31	-0.38	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
LGG	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-8.89	1.31e-17	6.83e-15	-0.31	-0.38	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
LGG	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-8.89	1.31e-17	6.84e-15	-0.39	-0.38	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
LGG	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-8.89	1.32e-17	6.89e-15	-0.31	-0.38	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
LGG	cis	rs8037818	1	rs8037102	ENSG00000261064.1	RP11-1000B6.3	-8.89	1.33e-17	6.89e-15	-0.48	-0.38	Obesity-related traits;	chr15:32640449	chr15:32536047~32587613:+
LGG	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-8.89	1.33e-17	6.92e-15	-0.39	-0.38	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-8.89	1.33e-17	6.92e-15	-0.39	-0.38	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
LGG	cis	rs482329	0.895	rs2587539	ENSG00000228044.2	RP4-781K5.4	8.89	1.33e-17	6.93e-15	0.43	0.38	Life threatening arrhythmia;	chr1:234679915	chr1:234646289~234683176:+
LGG	cis	rs6496932	0.503	rs8037726	ENSG00000218052.5	ADAMTS7P4	-8.88	1.34e-17	6.95e-15	-0.57	-0.38	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85255369~85330334:-
LGG	cis	rs228614	0.51	rs223356	ENSG00000230069.3	LRRC37A15P	-8.88	1.34e-17	6.96e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102727274~102730721:-
LGG	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	8.88	1.34e-17	6.97e-15	0.48	0.38	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
LGG	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-8.88	1.35e-17	7e-15	-0.51	-0.38	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
LGG	cis	rs17345786	1	rs3804778	ENSG00000256628.3	ZBTB11-AS1	8.88	1.35e-17	7e-15	0.48	0.38	Colonoscopy-negative controls vs population controls;	chr3:101575728	chr3:101676475~101679217:+
LGG	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-8.88	1.35e-17	7.01e-15	-0.31	-0.38	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
LGG	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-8.88	1.35e-17	7.01e-15	-0.32	-0.38	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
LGG	cis	rs12935418	0.524	rs9933697	ENSG00000260213.4	RP11-303E16.3	-8.88	1.35e-17	7.01e-15	-0.46	-0.38	Mean corpuscular volume;	chr16:80939637	chr16:81016792~81035759:-
LGG	cis	rs6940638	1	rs12215773	ENSG00000199851.2	U3	8.88	1.35e-17	7.01e-15	0.64	0.38	Intelligence (multi-trait analysis);	chr6:27071454	chr6:28015568~28015777:+
LGG	cis	rs2325036	0.75	rs3902500	ENSG00000239519.1	CADM2-AS1	8.88	1.35e-17	7.04e-15	0.43	0.38	Waist circumference;	chr3:85834000	chr3:85992183~86028007:-
LGG	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-8.88	1.37e-17	7.11e-15	-0.31	-0.38	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-8.88	1.37e-17	7.11e-15	-0.31	-0.38	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-8.88	1.37e-17	7.11e-15	-0.31	-0.38	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
LGG	cis	rs3742264	1	rs9567613	ENSG00000235903.6	CPB2-AS1	8.88	1.37e-17	7.12e-15	0.42	0.38	Blood protein levels;	chr13:46075263	chr13:46052806~46113332:+
LGG	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	-8.88	1.37e-17	7.14e-15	-0.38	-0.38	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
LGG	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-8.88	1.38e-17	7.15e-15	-0.41	-0.38	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
LGG	cis	rs6921919	0.583	rs6928771	ENSG00000218016.2	ZNF192P2	-8.88	1.38e-17	7.16e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs6928773	ENSG00000218016.2	ZNF192P2	-8.88	1.38e-17	7.16e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28188050~28189432:+
LGG	cis	rs1707322	0.827	rs6683274	ENSG00000281133.1	AL355480.3	-8.88	1.38e-17	7.16e-15	-0.48	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4660906	ENSG00000281133.1	AL355480.3	-8.88	1.38e-17	7.17e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45580892~45580996:-
LGG	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	8.88	1.38e-17	7.19e-15	0.52	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
LGG	cis	rs6921919	0.583	rs3800328	ENSG00000218016.2	ZNF192P2	-8.88	1.39e-17	7.19e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.609	rs67211468	ENSG00000218016.2	ZNF192P2	-8.88	1.39e-17	7.19e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs35560946	ENSG00000218016.2	ZNF192P2	-8.88	1.39e-17	7.19e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs740622	ENSG00000218016.2	ZNF192P2	-8.88	1.39e-17	7.19e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28188050~28189432:+
LGG	cis	rs2281558	0.583	rs7260957	ENSG00000125804.12	FAM182A	-8.88	1.39e-17	7.21e-15	-0.58	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:26054655~26086917:+
LGG	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	8.88	1.39e-17	7.23e-15	0.4	0.38	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
LGG	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
LGG	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
LGG	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
LGG	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
LGG	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	8.88	1.39e-17	7.23e-15	0.3	0.38	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
LGG	cis	rs1707322	1	rs6682683	ENSG00000281133.1	AL355480.3	-8.88	1.4e-17	7.25e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45580892~45580996:-
LGG	cis	rs2739330	0.76	rs1007888	ENSG00000272787.1	KB-226F1.2	8.88	1.4e-17	7.25e-15	0.4	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23969211~23969873:+
LGG	cis	rs9810089	0.843	rs696081	ENSG00000261758.1	RP11-102M11.2	-8.88	1.4e-17	7.25e-15	-0.4	-0.38	Gestational age at birth (child effect);	chr3:136328347	chr3:136752630~136755780:+
LGG	cis	rs12554020	0.892	rs7025805	ENSG00000237385.1	RP11-165J3.5	-8.88	1.4e-17	7.26e-15	-0.62	-0.38	Schizophrenia;	chr9:93481463	chr9:93430342~93431299:-
LGG	cis	rs9402682	0.77	rs2210366	ENSG00000232876.1	CTA-212D2.2	8.88	1.4e-17	7.26e-15	0.48	0.38	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135094070	chr6:135055033~135060550:+
LGG	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-8.88	1.4e-17	7.27e-15	-0.4	-0.38	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
LGG	cis	rs17807185	0.676	rs4273781	ENSG00000214293.7	APTR	8.88	1.4e-17	7.29e-15	0.37	0.38	Height;	chr7:77671806	chr7:77657660~77696265:-
LGG	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-8.88	1.41e-17	7.31e-15	-0.38	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
LGG	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-8.88	1.41e-17	7.31e-15	-0.47	-0.38	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
LGG	cis	rs1707322	1	rs4524994	ENSG00000281133.1	AL355480.3	-8.88	1.41e-17	7.32e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45580892~45580996:-
LGG	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	8.88	1.42e-17	7.34e-15	0.45	0.38	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
LGG	cis	rs1707322	0.686	rs2991986	ENSG00000281133.1	AL355480.3	8.88	1.42e-17	7.34e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45580892~45580996:-
LGG	cis	rs12935418	0.673	rs2549886	ENSG00000260213.4	RP11-303E16.3	8.88	1.42e-17	7.35e-15	0.48	0.38	Mean corpuscular volume;	chr16:81027627	chr16:81016792~81035759:-
LGG	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-8.88	1.42e-17	7.36e-15	-0.5	-0.38	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
LGG	cis	rs4950322	0.748	rs17360812	ENSG00000278811.3	LINC00624	-8.88	1.42e-17	7.37e-15	-0.38	-0.38	Protein quantitative trait loci;	chr1:147355010	chr1:147258885~147517875:-
LGG	cis	rs397969	0.596	rs17668529	ENSG00000261033.1	RP11-209D14.2	-8.88	1.42e-17	7.38e-15	-0.46	-0.38	Platelet count;	chr17:19996475	chr17:20008051~20009234:-
LGG	cis	rs397969	0.596	rs62066348	ENSG00000261033.1	RP11-209D14.2	-8.88	1.42e-17	7.38e-15	-0.46	-0.38	Platelet count;	chr17:19996600	chr17:20008051~20009234:-
LGG	cis	rs397969	0.57	rs62066349	ENSG00000261033.1	RP11-209D14.2	-8.88	1.42e-17	7.38e-15	-0.46	-0.38	Platelet count;	chr17:19996627	chr17:20008051~20009234:-
LGG	cis	rs397969	0.596	rs62066350	ENSG00000261033.1	RP11-209D14.2	-8.88	1.42e-17	7.38e-15	-0.46	-0.38	Platelet count;	chr17:19996729	chr17:20008051~20009234:-
LGG	cis	rs9322193	0.923	rs9689723	ENSG00000216621.7	RP11-244K5.6	8.88	1.43e-17	7.39e-15	0.45	0.38	Lung cancer;	chr6:149655935	chr6:149934527~149936782:+
LGG	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-8.88	1.43e-17	7.4e-15	-0.58	-0.38	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
LGG	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-8.88	1.43e-17	7.41e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
LGG	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-8.88	1.43e-17	7.41e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-8.88	1.43e-17	7.41e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-8.88	1.43e-17	7.41e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
LGG	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-8.88	1.43e-17	7.41e-15	-0.45	-0.38	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
LGG	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	8.88	1.43e-17	7.41e-15	0.42	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
LGG	cis	rs1707322	1	rs7538978	ENSG00000281133.1	AL355480.3	8.88	1.43e-17	7.42e-15	0.44	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4073847	ENSG00000281133.1	AL355480.3	8.88	1.43e-17	7.43e-15	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45580892~45580996:-
LGG	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	8.88	1.44e-17	7.46e-15	0.3	0.38	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
LGG	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	8.88	1.44e-17	7.46e-15	0.3	0.38	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
LGG	cis	rs17772222	0.917	rs61983300	ENSG00000222990.1	RNU4-22P	8.87	1.44e-17	7.47e-15	0.5	0.38	Coronary artery calcification;	chr14:88754047	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.876	rs78068036	ENSG00000222990.1	RNU4-22P	8.87	1.44e-17	7.47e-15	0.5	0.38	Coronary artery calcification;	chr14:88754817	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs11159868	ENSG00000222990.1	RNU4-22P	8.87	1.44e-17	7.47e-15	0.5	0.38	Coronary artery calcification;	chr14:88760528	chr14:88513498~88513663:+
LGG	cis	rs763567	0.509	rs10919449	ENSG00000271811.1	RP1-79C4.4	8.87	1.45e-17	7.51e-15	0.36	0.38	Tonsillectomy;	chr1:170669517	chr1:170667381~170669425:+
LGG	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	8.87	1.45e-17	7.52e-15	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
LGG	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-8.87	1.45e-17	7.53e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
LGG	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-8.87	1.45e-17	7.53e-15	-0.48	-0.38	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
LGG	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-8.87	1.46e-17	7.54e-15	-0.51	-0.38	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-8.87	1.46e-17	7.54e-15	-0.51	-0.38	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-8.87	1.46e-17	7.54e-15	-0.51	-0.38	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
LGG	cis	rs2282300	0.91	rs528292	ENSG00000242353.1	RP4-710M3.1	8.87	1.46e-17	7.55e-15	0.53	0.38	Morning vs. evening chronotype;	chr11:30368163	chr11:30368148~30368646:+
LGG	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	8.87	1.46e-17	7.56e-15	0.46	0.38	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
LGG	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-8.87	1.46e-17	7.57e-15	-0.99	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
LGG	cis	rs7208859	0.673	rs11652370	ENSG00000266490.1	CTD-2349P21.9	8.87	1.46e-17	7.58e-15	0.44	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30792372~30792833:+
LGG	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	8.87	1.47e-17	7.59e-15	0.46	0.38	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
LGG	cis	rs9393777	0.844	rs28360634	ENSG00000216901.1	AL022393.7	8.87	1.47e-17	7.6e-15	0.84	0.38	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28176188~28176674:+
LGG	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-8.87	1.47e-17	7.61e-15	-0.36	-0.38	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
LGG	cis	rs9527	0.662	rs10786714	ENSG00000272912.1	RP11-724N1.1	-8.87	1.47e-17	7.61e-15	-0.44	-0.38	Arsenic metabolism;	chr10:102838849	chr10:102914585~102915404:+
LGG	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-8.87	1.47e-17	7.62e-15	-0.38	-0.38	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
LGG	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	8.87	1.48e-17	7.65e-15	0.61	0.38	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
LGG	cis	rs2325036	0.75	rs7629375	ENSG00000239519.1	CADM2-AS1	8.87	1.48e-17	7.66e-15	0.43	0.38	Waist circumference;	chr3:85846344	chr3:85992183~86028007:-
LGG	cis	rs2325036	0.714	rs7613695	ENSG00000239519.1	CADM2-AS1	8.87	1.48e-17	7.66e-15	0.43	0.38	Waist circumference;	chr3:85848507	chr3:85992183~86028007:-
LGG	cis	rs9346353	0.9	rs9364053	ENSG00000219881.1	GAPDHP42	8.87	1.48e-17	7.67e-15	0.36	0.38	Sleep duration;	chr6:69725874	chr6:69745871~69746851:+
LGG	cis	rs6545883	0.542	rs10177225	ENSG00000273302.1	RP11-493E12.2	-8.87	1.49e-17	7.69e-15	-0.33	-0.38	Tuberculosis;	chr2:61367363	chr2:61199979~61200769:+
LGG	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	8.87	1.49e-17	7.7e-15	0.4	0.38	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
LGG	cis	rs9987353	0.518	rs4841110	ENSG00000173295.6	FAM86B3P	-8.87	1.49e-17	7.7e-15	-0.4	-0.38	Recombination measurement;	chr8:9228513	chr8:8228595~8244865:+
LGG	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	8.87	1.49e-17	7.7e-15	0.3	0.38	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	8.87	1.49e-17	7.7e-15	0.3	0.38	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
LGG	cis	rs9532669	0.926	rs2324748	ENSG00000168852.11	TPTE2P5	8.87	1.49e-17	7.73e-15	0.38	0.38	Cervical cancer;	chr13:40989452	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs4245311	ENSG00000168852.11	TPTE2P5	8.87	1.49e-17	7.73e-15	0.38	0.38	Cervical cancer;	chr13:40990003	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs9594473	ENSG00000168852.11	TPTE2P5	8.87	1.49e-17	7.73e-15	0.38	0.38	Cervical cancer;	chr13:40997997	chr13:40822296~40921749:-
LGG	cis	rs944990	0.576	rs3901421	ENSG00000227603.1	RP11-165J3.6	8.87	1.5e-17	7.77e-15	0.38	0.38	Body mass index;	chr9:93442256	chr9:93435332~93437121:-
LGG	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-8.87	1.5e-17	7.78e-15	-0.58	-0.38	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
LGG	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	8.87	1.51e-17	7.81e-15	0.46	0.38	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
LGG	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-8.87	1.51e-17	7.83e-15	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
LGG	cis	rs10946940	0.632	rs9366698	ENSG00000216901.1	AL022393.7	8.87	1.51e-17	7.83e-15	0.52	0.38	Systemic lupus erythematosus;	chr6:27704256	chr6:28176188~28176674:+
LGG	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	8.87	1.51e-17	7.83e-15	0.37	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
LGG	cis	rs853679	0.546	rs493161	ENSG00000199851.2	U3	8.87	1.52e-17	7.84e-15	0.82	0.38	Depression;	chr6:27882936	chr6:28015568~28015777:+
LGG	cis	rs12935418	0.673	rs2602428	ENSG00000260213.4	RP11-303E16.3	8.87	1.52e-17	7.86e-15	0.48	0.38	Mean corpuscular volume;	chr16:81028566	chr16:81016792~81035759:-
LGG	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-8.87	1.52e-17	7.87e-15	-0.33	-0.38	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
LGG	cis	rs2282300	0.956	rs1717773	ENSG00000242353.1	RP4-710M3.1	-8.87	1.52e-17	7.88e-15	-0.53	-0.38	Morning vs. evening chronotype;	chr11:30361607	chr11:30368148~30368646:+
LGG	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	8.87	1.52e-17	7.88e-15	0.62	0.38	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
LGG	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-8.87	1.52e-17	7.89e-15	-0.51	-0.38	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
LGG	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	8.87	1.53e-17	7.93e-15	0.38	0.38	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
LGG	cis	rs2287838	0.967	rs11085425	ENSG00000267289.1	CTD-2623N2.11	-8.87	1.54e-17	7.97e-15	-0.41	-0.38	Sleep duration;	chr19:9867979	chr19:9834079~9835013:-
LGG	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-8.87	1.54e-17	7.98e-15	-0.47	-0.38	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
LGG	cis	rs7124681	0.584	rs1471712	ENSG00000280615.1	Y_RNA	-8.87	1.55e-17	7.99e-15	-0.45	-0.38	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47890598	chr11:47614898~47614994:-
LGG	cis	rs1707322	1	rs7532204	ENSG00000281133.1	AL355480.3	8.87	1.55e-17	8e-15	0.44	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45580892~45580996:-
LGG	cis	rs7291412	0.54	rs9627391	ENSG00000231711.2	LINC00899	8.87	1.55e-17	8.01e-15	0.46	0.38	Dupuytren's disease;Subjective well-being;	chr22:46051217	chr22:46039907~46044853:-
LGG	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	8.87	1.56e-17	8.04e-15	0.46	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
LGG	cis	rs12682352	0.602	rs635594	ENSG00000173295.6	FAM86B3P	8.86	1.56e-17	8.08e-15	0.4	0.38	Neuroticism;	chr8:8755877	chr8:8228595~8244865:+
LGG	cis	rs4819052	0.679	rs2838859	ENSG00000215447.6	BX322557.10	-8.86	1.57e-17	8.13e-15	-0.28	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45288052~45291738:+
LGG	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	8.86	1.57e-17	8.14e-15	0.39	0.38	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
LGG	cis	rs62184315	0.536	rs5742926	ENSG00000273240.1	RP11-455J20.3	-8.86	1.58e-17	8.14e-15	-0.55	-0.38	Alcohol dependence (age at onset);	chr2:189784079	chr2:189763859~189764456:-
LGG	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	8.86	1.58e-17	8.16e-15	0.56	0.38	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
LGG	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	8.86	1.58e-17	8.18e-15	0.61	0.38	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
LGG	cis	rs454217	0.765	rs392929	ENSG00000277851.1	RP11-756G20.1	8.86	1.59e-17	8.2e-15	0.38	0.38	Smoking quantity;	chr12:92338016	chr12:92247756~92363832:-
LGG	cis	rs6940638	1	rs6940638	ENSG00000199851.2	U3	8.86	1.59e-17	8.23e-15	0.64	0.38	Intelligence (multi-trait analysis);	chr6:27078471	chr6:28015568~28015777:+
LGG	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	8.86	1.59e-17	8.24e-15	0.47	0.38	Axial length;	chr3:53815483	chr3:53797764~53798019:-
LGG	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-8.86	1.6e-17	8.24e-15	-0.49	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
LGG	cis	rs1707322	1	rs10890355	ENSG00000281133.1	AL355480.3	-8.86	1.6e-17	8.25e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211204	ENSG00000281133.1	AL355480.3	-8.86	1.6e-17	8.25e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45580892~45580996:-
LGG	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	8.86	1.6e-17	8.25e-15	0.46	0.38	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
LGG	cis	rs9346353	0.966	rs2045444	ENSG00000219881.1	GAPDHP42	8.86	1.6e-17	8.25e-15	0.36	0.38	Sleep duration;	chr6:69688170	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs2125022	ENSG00000219881.1	GAPDHP42	8.86	1.6e-17	8.25e-15	0.36	0.38	Sleep duration;	chr6:69689008	chr6:69745871~69746851:+
LGG	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	8.86	1.6e-17	8.26e-15	0.56	0.38	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
LGG	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	8.86	1.6e-17	8.26e-15	0.46	0.38	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
LGG	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	8.86	1.6e-17	8.26e-15	0.46	0.38	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	8.86	1.6e-17	8.27e-15	0.49	0.38	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
LGG	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	8.86	1.6e-17	8.28e-15	0.58	0.38	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
LGG	cis	rs9987353	0.566	rs6998368	ENSG00000173295.6	FAM86B3P	8.86	1.61e-17	8.31e-15	0.41	0.38	Recombination measurement;	chr8:9212778	chr8:8228595~8244865:+
LGG	cis	rs17772222	0.701	rs453112	ENSG00000258983.2	RP11-507K2.2	-8.86	1.61e-17	8.32e-15	-0.43	-0.38	Coronary artery calcification;	chr14:88392657	chr14:88499334~88515502:+
LGG	cis	rs2325036	0.929	rs9836755	ENSG00000239519.1	CADM2-AS1	-8.86	1.61e-17	8.33e-15	-0.42	-0.38	Waist circumference;	chr3:85790221	chr3:85992183~86028007:-
LGG	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-8.86	1.61e-17	8.33e-15	-0.48	-0.38	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
LGG	cis	rs1185460	0.967	rs1784460	ENSG00000272186.1	RP11-110I1.13	8.86	1.61e-17	8.33e-15	0.36	0.38	Coronary artery disease;	chr11:119067660	chr11:119067374~119067698:-
LGG	cis	rs6921919	0.583	rs4254981	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.525	rs6929825	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs35599905	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs1124131	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs6899389	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs6922374	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs6899603	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs6922429	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs6922169	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.559	rs13210866	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.609	rs36018474	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs13201726	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs2027361	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs4642462	ENSG00000218016.2	ZNF192P2	-8.86	1.62e-17	8.34e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28188050~28189432:+
LGG	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-8.86	1.62e-17	8.34e-15	-0.48	-0.38	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
LGG	cis	rs858239	0.601	rs28673077	ENSG00000230042.1	AK3P3	-8.86	1.62e-17	8.35e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23129178~23129841:+
LGG	cis	rs6003958	1	rs6003958	ENSG00000231271.1	AP000350.8	-8.86	1.62e-17	8.35e-15	-0.58	-0.38	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23949918~23954042:+
LGG	cis	rs5760092	0.755	rs6003959	ENSG00000231271.1	AP000350.8	-8.86	1.62e-17	8.35e-15	-0.58	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23949918~23954042:+
LGG	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	8.86	1.63e-17	8.4e-15	0.4	0.38	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
LGG	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-8.86	1.63e-17	8.4e-15	-0.39	-0.38	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
LGG	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	8.86	1.63e-17	8.41e-15	0.44	0.38	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
LGG	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-8.86	1.64e-17	8.46e-15	-0.39	-0.38	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
LGG	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-8.86	1.64e-17	8.46e-15	-0.39	-0.38	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
LGG	cis	rs9532669	0.926	rs11147823	ENSG00000239827.7	SUGT1P3	8.86	1.64e-17	8.47e-15	0.39	0.38	Cervical cancer;	chr13:40878138	chr13:40908159~40921774:-
LGG	cis	rs1707322	1	rs11211217	ENSG00000281133.1	AL355480.3	-8.86	1.64e-17	8.48e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45580892~45580996:-
LGG	cis	rs2282300	0.956	rs2685286	ENSG00000242353.1	RP4-710M3.1	-8.86	1.65e-17	8.49e-15	-0.53	-0.38	Morning vs. evening chronotype;	chr11:30360041	chr11:30368148~30368646:+
LGG	cis	rs9322193	1	rs58189451	ENSG00000216621.7	RP11-244K5.6	8.86	1.65e-17	8.52e-15	0.46	0.38	Lung cancer;	chr6:149600252	chr6:149934527~149936782:+
LGG	cis	rs7302981	0.719	rs836189	ENSG00000272368.2	RP4-605O3.4	8.86	1.65e-17	8.52e-15	0.37	0.38	Systolic blood pressure;	chr12:50067715	chr12:50112197~50165618:+
LGG	cis	rs858239	0.508	rs10242104	ENSG00000230042.1	AK3P3	-8.86	1.65e-17	8.52e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23129178~23129841:+
LGG	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	8.86	1.66e-17	8.55e-15	0.44	0.38	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
LGG	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-8.86	1.66e-17	8.56e-15	-0.47	-0.38	Depression;	chr6:28103220	chr6:28115628~28116551:+
LGG	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	8.86	1.66e-17	8.56e-15	0.48	0.38	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
LGG	cis	rs6545883	0.507	rs6545855	ENSG00000273302.1	RP11-493E12.2	-8.86	1.67e-17	8.59e-15	-0.33	-0.38	Tuberculosis;	chr2:61305725	chr2:61199979~61200769:+
LGG	cis	rs1275468	0.731	rs1480001	ENSG00000257497.2	RP11-585P4.5	-8.86	1.67e-17	8.6e-15	-0.53	-0.38	Polycystic ovary syndrome;	chr12:75586939	chr12:75483454~75489820:-
LGG	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-8.86	1.67e-17	8.6e-15	-0.37	-0.38	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
LGG	cis	rs9532669	0.7	rs9525406	ENSG00000168852.11	TPTE2P5	8.86	1.67e-17	8.61e-15	0.39	0.38	Cervical cancer;	chr13:40860812	chr13:40822296~40921749:-
LGG	cis	rs9322193	0.923	rs9688861	ENSG00000216621.7	RP11-244K5.6	8.86	1.67e-17	8.61e-15	0.45	0.38	Lung cancer;	chr6:149637924	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs7740278	ENSG00000216621.7	RP11-244K5.6	8.86	1.67e-17	8.61e-15	0.45	0.38	Lung cancer;	chr6:149640116	chr6:149934527~149936782:+
LGG	cis	rs853679	0.76	rs11962305	ENSG00000226314.6	ZNF192P1	8.86	1.68e-17	8.66e-15	0.48	0.38	Depression;	chr6:28232159	chr6:28161781~28169594:+
LGG	cis	rs9875589	0.957	rs6778731	ENSG00000233121.1	VN1R20P	8.85	1.68e-17	8.67e-15	0.38	0.38	Ovarian reserve;	chr3:13906007	chr3:13926813~13927778:+
LGG	cis	rs17772222	0.63	rs2778936	ENSG00000258983.2	RP11-507K2.2	-8.85	1.69e-17	8.69e-15	-0.42	-0.38	Coronary artery calcification;	chr14:88505959	chr14:88499334~88515502:+
LGG	cis	rs62184315	0.638	rs12475694	ENSG00000273240.1	RP11-455J20.3	8.85	1.69e-17	8.69e-15	0.42	0.38	Alcohol dependence (age at onset);	chr2:189907882	chr2:189763859~189764456:-
LGG	cis	rs6997458	0.742	rs955007	ENSG00000253549.4	RP11-317J10.2	8.85	1.69e-17	8.72e-15	0.3	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85458166	chr8:85441851~85464915:-
LGG	cis	rs35851103	0.6	rs4841662	ENSG00000255556.2	RP11-351I21.6	-8.85	1.69e-17	8.72e-15	-0.45	-0.38	Neuroticism;	chr8:11986249	chr8:12378679~12380265:-
LGG	cis	rs11722779	0.935	rs11938650	ENSG00000230069.3	LRRC37A15P	-8.85	1.69e-17	8.72e-15	-0.36	-0.38	Schizophrenia;	chr4:103021639	chr4:102727274~102730721:-
LGG	cis	rs7829975	0.56	rs6994131	ENSG00000173295.6	FAM86B3P	8.85	1.7e-17	8.74e-15	0.41	0.38	Mood instability;	chr8:8693448	chr8:8228595~8244865:+
LGG	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-8.85	1.7e-17	8.74e-15	-0.3	-0.38	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	8.85	1.7e-17	8.75e-15	0.43	0.38	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
LGG	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	8.85	1.7e-17	8.76e-15	0.39	0.38	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
LGG	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	-8.85	1.7e-17	8.77e-15	-0.39	-0.38	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
LGG	cis	rs853679	0.76	rs9393910	ENSG00000226314.6	ZNF192P1	8.85	1.7e-17	8.78e-15	0.48	0.38	Depression;	chr6:28240414	chr6:28161781~28169594:+
LGG	cis	rs853679	0.76	rs9368563	ENSG00000226314.6	ZNF192P1	8.85	1.7e-17	8.78e-15	0.48	0.38	Depression;	chr6:28240780	chr6:28161781~28169594:+
LGG	cis	rs853679	0.76	rs9295768	ENSG00000226314.6	ZNF192P1	8.85	1.7e-17	8.78e-15	0.48	0.38	Depression;	chr6:28241324	chr6:28161781~28169594:+
LGG	cis	rs853679	0.699	rs9468318	ENSG00000226314.6	ZNF192P1	8.85	1.7e-17	8.78e-15	0.48	0.38	Depression;	chr6:28241753	chr6:28161781~28169594:+
LGG	cis	rs6997458	0.785	rs6996345	ENSG00000253549.4	RP11-317J10.2	8.85	1.7e-17	8.78e-15	0.3	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85418846	chr8:85441851~85464915:-
LGG	cis	rs6997458	0.774	rs6984619	ENSG00000253549.4	RP11-317J10.2	8.85	1.7e-17	8.78e-15	0.3	0.38	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85419149	chr8:85441851~85464915:-
LGG	cis	rs11148252	0.904	rs9526927	ENSG00000235660.1	LINC00345	-8.85	1.73e-17	8.89e-15	-0.46	-0.38	Lewy body disease;	chr13:52477492	chr13:52484161~52484680:-
LGG	cis	rs2325036	0.75	rs6549058	ENSG00000239519.1	CADM2-AS1	8.85	1.73e-17	8.9e-15	0.43	0.38	Waist circumference;	chr3:85828954	chr3:85992183~86028007:-
LGG	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	8.85	1.73e-17	8.93e-15	0.43	0.38	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
LGG	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	8.85	1.74e-17	8.94e-15	0.46	0.38	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
LGG	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	8.85	1.74e-17	8.96e-15	0.43	0.38	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
LGG	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	8.85	1.74e-17	8.96e-15	0.45	0.38	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	8.85	1.74e-17	8.96e-15	0.45	0.38	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
LGG	cis	rs858239	0.508	rs2390754	ENSG00000230042.1	AK3P3	-8.85	1.74e-17	8.96e-15	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23129178~23129841:+
LGG	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	-8.85	1.74e-17	8.97e-15	-0.38	-0.38	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
LGG	cis	rs1609391	0.561	rs9817967	ENSG00000273486.1	RP11-731C17.2	8.85	1.76e-17	9.05e-15	0.37	0.38	Neuroticism;	chr3:136910648	chr3:136837338~136839021:-
LGG	cis	rs1609391	0.543	rs9859810	ENSG00000273486.1	RP11-731C17.2	8.85	1.76e-17	9.05e-15	0.37	0.38	Neuroticism;	chr3:136911144	chr3:136837338~136839021:-
LGG	cis	rs1609391	0.543	rs9828009	ENSG00000273486.1	RP11-731C17.2	8.85	1.76e-17	9.05e-15	0.37	0.38	Neuroticism;	chr3:136912433	chr3:136837338~136839021:-
LGG	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	8.85	1.76e-17	9.07e-15	0.3	0.38	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
LGG	cis	rs17772222	0.917	rs8021690	ENSG00000222990.1	RNU4-22P	8.85	1.77e-17	9.09e-15	0.5	0.38	Coronary artery calcification;	chr14:88717806	chr14:88513498~88513663:+
LGG	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
LGG	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	8.85	1.77e-17	9.09e-15	0.64	0.38	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
LGG	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	8.85	1.77e-17	9.1e-15	0.45	0.38	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	8.85	1.77e-17	9.1e-15	0.45	0.38	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
LGG	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	8.85	1.77e-17	9.1e-15	0.44	0.38	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
LGG	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	8.85	1.77e-17	9.12e-15	0.45	0.38	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
LGG	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	8.85	1.78e-17	9.14e-15	0.36	0.38	Breast size;	chr12:9206399	chr12:9277235~9313241:+
LGG	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	8.85	1.78e-17	9.17e-15	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
LGG	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	8.85	1.78e-17	9.17e-15	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
LGG	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	8.85	1.78e-17	9.17e-15	0.45	0.38	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
LGG	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	8.85	1.79e-17	9.18e-15	0.63	0.38	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
LGG	cis	rs228614	0.51	rs223472	ENSG00000230069.3	LRRC37A15P	-8.85	1.79e-17	9.18e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223405	ENSG00000230069.3	LRRC37A15P	-8.85	1.79e-17	9.2e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102727274~102730721:-
LGG	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	8.85	1.79e-17	9.21e-15	0.45	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
LGG	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-8.85	1.79e-17	9.22e-15	-0.39	-0.38	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
LGG	cis	rs4281086	0.864	rs13280674	ENSG00000253678.1	RP11-981G7.3	8.85	1.8e-17	9.23e-15	0.4	0.38	Obesity-related traits;	chr8:10488450	chr8:10477491~10479375:-
LGG	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-8.85	1.8e-17	9.24e-15	-0.33	-0.38	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
LGG	cis	rs4820294	0.547	rs62236743	ENSG00000233360.4	Z83844.1	8.85	1.8e-17	9.24e-15	0.55	0.38	Fat distribution (HIV);	chr22:37700046	chr22:37641832~37658377:-
LGG	cis	rs4820294	0.516	rs12627973	ENSG00000233360.4	Z83844.1	8.85	1.8e-17	9.24e-15	0.55	0.38	Fat distribution (HIV);	chr22:37700690	chr22:37641832~37658377:-
LGG	cis	rs228614	0.51	rs223400	ENSG00000230069.3	LRRC37A15P	-8.85	1.8e-17	9.26e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102727274~102730721:-
LGG	cis	rs228614	0.536	rs223420	ENSG00000230069.3	LRRC37A15P	-8.85	1.8e-17	9.26e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102727274~102730721:-
LGG	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-8.85	1.8e-17	9.27e-15	-0.45	-0.38	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
LGG	cis	rs1707322	0.835	rs946525	ENSG00000281133.1	AL355480.3	8.85	1.8e-17	9.27e-15	0.44	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs946524	ENSG00000281133.1	AL355480.3	8.85	1.8e-17	9.27e-15	0.44	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4660336	ENSG00000281133.1	AL355480.3	8.85	1.8e-17	9.27e-15	0.44	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211248	ENSG00000281133.1	AL355480.3	-8.85	1.81e-17	9.29e-15	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45580892~45580996:-
LGG	cis	rs853679	0.76	rs9357067	ENSG00000226314.6	ZNF192P1	8.85	1.81e-17	9.3e-15	0.48	0.38	Depression;	chr6:28242515	chr6:28161781~28169594:+
LGG	cis	rs853679	0.76	rs967005	ENSG00000226314.6	ZNF192P1	8.85	1.81e-17	9.3e-15	0.48	0.38	Depression;	chr6:28242910	chr6:28161781~28169594:+
LGG	cis	rs228614	0.51	rs223410	ENSG00000230069.3	LRRC37A15P	-8.85	1.81e-17	9.32e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102727274~102730721:-
LGG	cis	rs1609391	0.543	rs6800690	ENSG00000273486.1	RP11-731C17.2	8.85	1.81e-17	9.32e-15	0.37	0.38	Neuroticism;	chr3:136904184	chr3:136837338~136839021:-
LGG	cis	rs1609391	0.543	rs7651085	ENSG00000273486.1	RP11-731C17.2	8.85	1.81e-17	9.32e-15	0.37	0.38	Neuroticism;	chr3:136906497	chr3:136837338~136839021:-
LGG	cis	rs1609391	0.543	rs6761993	ENSG00000273486.1	RP11-731C17.2	8.85	1.81e-17	9.32e-15	0.37	0.38	Neuroticism;	chr3:136907060	chr3:136837338~136839021:-
LGG	cis	rs6921919	0.583	rs740621	ENSG00000218016.2	ZNF192P2	-8.84	1.82e-17	9.33e-15	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28188050~28189432:+
LGG	cis	rs9875589	0.957	rs1433358	ENSG00000233121.1	VN1R20P	8.84	1.83e-17	9.38e-15	0.38	0.38	Ovarian reserve;	chr3:13902365	chr3:13926813~13927778:+
LGG	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-8.84	1.83e-17	9.39e-15	-0.76	-0.38	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
LGG	cis	rs482329	0.965	rs476875	ENSG00000228044.2	RP4-781K5.4	8.84	1.83e-17	9.4e-15	0.43	0.38	Life threatening arrhythmia;	chr1:234680253	chr1:234646289~234683176:+
LGG	cis	rs2287838	0.967	rs3786694	ENSG00000267289.1	CTD-2623N2.11	-8.84	1.83e-17	9.41e-15	-0.41	-0.38	Sleep duration;	chr19:9844665	chr19:9834079~9835013:-
LGG	cis	rs2287838	1	rs2287838	ENSG00000267289.1	CTD-2623N2.11	-8.84	1.83e-17	9.41e-15	-0.41	-0.38	Sleep duration;	chr19:9848338	chr19:9834079~9835013:-
LGG	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	8.84	1.83e-17	9.42e-15	0.45	0.38	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
LGG	cis	rs77204473	0.744	rs74882651	ENSG00000254851.1	RP11-109L13.1	8.84	1.84e-17	9.43e-15	0.92	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117114475	chr11:117135528~117138582:+
LGG	cis	rs8081395	0.729	rs12453125	ENSG00000266992.1	DHX40P1	-8.84	1.84e-17	9.44e-15	-0.48	-0.38	White blood cell count;	chr17:59968715	chr17:59976009~60002384:-
LGG	cis	rs9810089	0.843	rs650326	ENSG00000261758.1	RP11-102M11.2	8.84	1.84e-17	9.44e-15	0.4	0.38	Gestational age at birth (child effect);	chr3:136318865	chr3:136752630~136755780:+
LGG	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	8.84	1.84e-17	9.46e-15	0.37	0.38	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	8.84	1.84e-17	9.46e-15	0.37	0.38	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	8.84	1.84e-17	9.46e-15	0.37	0.38	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	8.84	1.84e-17	9.46e-15	0.37	0.38	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
LGG	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-8.84	1.85e-17	9.49e-15	-0.44	-0.38	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-8.84	1.85e-17	9.49e-15	-0.44	-0.38	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
LGG	cis	rs12554020	1	rs7048853	ENSG00000237385.1	RP11-165J3.5	8.84	1.85e-17	9.51e-15	0.59	0.38	Schizophrenia;	chr9:93490896	chr9:93430342~93431299:-
LGG	cis	rs227275	0.556	rs223449	ENSG00000230069.3	LRRC37A15P	-8.84	1.86e-17	9.56e-15	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223447	ENSG00000230069.3	LRRC37A15P	-8.84	1.86e-17	9.56e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223446	ENSG00000230069.3	LRRC37A15P	-8.84	1.86e-17	9.56e-15	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102727274~102730721:-
LGG	cis	rs17772222	0.876	rs61983303	ENSG00000222990.1	RNU4-22P	8.84	1.86e-17	9.57e-15	0.5	0.38	Coronary artery calcification;	chr14:88764459	chr14:88513498~88513663:+
LGG	cis	rs62103177	0.564	rs1864529	ENSG00000261126.6	RP11-795F19.1	-8.84	1.87e-17	9.6e-15	-0.44	-0.38	Opioid sensitivity;	chr18:79988975	chr18:80046900~80095482:+
LGG	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	8.84	1.87e-17	9.6e-15	0.45	0.38	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
LGG	cis	rs7302981	0.719	rs836188	ENSG00000272368.2	RP4-605O3.4	8.84	1.89e-17	9.69e-15	0.36	0.38	Systolic blood pressure;	chr12:50067569	chr12:50112197~50165618:+
LGG	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-8.84	1.89e-17	9.7e-15	-0.39	-0.38	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-8.84	1.89e-17	9.7e-15	-0.39	-0.38	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
LGG	cis	rs6545883	0.524	rs2694619	ENSG00000273302.1	RP11-493E12.2	-8.84	1.89e-17	9.71e-15	-0.32	-0.38	Tuberculosis;	chr2:61309766	chr2:61199979~61200769:+
LGG	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-8.84	1.89e-17	9.72e-15	-0.44	-0.38	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
LGG	cis	rs9532669	0.89	rs35073784	ENSG00000168852.11	TPTE2P5	8.84	1.89e-17	9.72e-15	0.38	0.38	Cervical cancer;	chr13:40993428	chr13:40822296~40921749:-
LGG	cis	rs11722779	0.873	rs223346	ENSG00000230069.3	LRRC37A15P	-8.84	1.9e-17	9.73e-15	-0.36	-0.38	Schizophrenia;	chr4:102859339	chr4:102727274~102730721:-
LGG	cis	rs8062405	0.573	rs8045689	ENSG00000271623.1	RP11-435I10.5	8.84	1.9e-17	9.76e-15	0.49	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28364700~28365333:+
LGG	cis	rs8062405	0.573	rs7187575	ENSG00000271623.1	RP11-435I10.5	8.84	1.9e-17	9.76e-15	0.49	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28364700~28365333:+
LGG	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	8.84	1.9e-17	9.76e-15	0.44	0.38	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
LGG	cis	rs11722779	0.815	rs223347	ENSG00000230069.3	LRRC37A15P	-8.84	1.91e-17	9.82e-15	-0.36	-0.38	Schizophrenia;	chr4:102858815	chr4:102727274~102730721:-
LGG	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	8.84	1.92e-17	9.82e-15	0.46	0.38	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
LGG	cis	rs11148252	0.774	rs6561666	ENSG00000235660.1	LINC00345	-8.84	1.92e-17	9.82e-15	-0.46	-0.38	Lewy body disease;	chr13:52355910	chr13:52484161~52484680:-
LGG	cis	rs17772222	0.917	rs58550317	ENSG00000222990.1	RNU4-22P	8.84	1.92e-17	9.84e-15	0.49	0.38	Coronary artery calcification;	chr14:88775243	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs61982733	ENSG00000222990.1	RNU4-22P	8.84	1.92e-17	9.84e-15	0.49	0.38	Coronary artery calcification;	chr14:88776244	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs2145120	ENSG00000222990.1	RNU4-22P	8.84	1.92e-17	9.84e-15	0.49	0.38	Coronary artery calcification;	chr14:88777699	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs57889459	ENSG00000222990.1	RNU4-22P	8.84	1.92e-17	9.85e-15	0.49	0.38	Coronary artery calcification;	chr14:88770820	chr14:88513498~88513663:+
LGG	cis	rs7267979	0.873	rs6037062	ENSG00000276952.1	RP5-965G21.6	8.84	1.92e-17	9.85e-15	0.37	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25284915~25285588:-
LGG	cis	rs5742933	1	rs3791767	ENSG00000253559.1	OSGEPL1-AS1	8.84	1.92e-17	9.87e-15	0.48	0.38	Ferritin levels;	chr2:189775189	chr2:189762704~189765556:+
LGG	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-8.84	1.93e-17	9.89e-15	-0.4	-0.38	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
LGG	cis	rs9322193	0.923	rs9766037	ENSG00000216621.7	RP11-244K5.6	8.84	1.94e-17	9.92e-15	0.45	0.38	Lung cancer;	chr6:149616921	chr6:149934527~149936782:+
LGG	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-8.84	1.94e-17	9.93e-15	-0.45	-0.38	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
LGG	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	8.84	1.94e-17	9.93e-15	0.43	0.38	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
LGG	cis	rs12073837	0.5	rs4143772	ENSG00000257551.1	HLX-AS1	-8.84	1.94e-17	9.94e-15	-0.46	-0.38	F-cell distribution;	chr1:220815004	chr1:220832763~220880140:-
LGG	cis	rs6967414	0.605	rs7786706	ENSG00000187953.9	PMS2CL	-8.84	1.94e-17	9.95e-15	-0.4	-0.38	Hematocrit;Hemoglobin concentration;	chr7:6707636	chr7:6710128~6753862:+
LGG	cis	rs77204473	0.744	rs12420361	ENSG00000254851.1	RP11-109L13.1	8.84	1.94e-17	9.96e-15	0.92	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117123072	chr11:117135528~117138582:+
LGG	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	8.84	1.95e-17	9.98e-15	0.56	0.38	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	8.84	1.95e-17	9.99e-15	0.92	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
LGG	cis	rs228614	0.51	rs223451	ENSG00000230069.3	LRRC37A15P	-8.84	1.95e-17	1e-14	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102727274~102730721:-
LGG	cis	rs228614	0.51	rs223450	ENSG00000230069.3	LRRC37A15P	-8.84	1.95e-17	1e-14	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102727274~102730721:-
LGG	cis	rs10771431	0.817	rs10843149	ENSG00000111788.10	RP11-22B23.1	8.84	1.96e-17	1e-14	0.35	0.38	Breast size;	chr12:9209471	chr12:9277235~9313241:+
LGG	cis	rs853679	0.76	rs11967137	ENSG00000226314.6	ZNF192P1	8.84	1.96e-17	1e-14	0.48	0.38	Depression;	chr6:28231986	chr6:28161781~28169594:+
LGG	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	8.84	1.96e-17	1e-14	0.44	0.38	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
LGG	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-8.83	1.97e-17	1.01e-14	-0.3	-0.38	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-8.83	1.97e-17	1.01e-14	-0.3	-0.38	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-8.83	1.97e-17	1.01e-14	-0.3	-0.38	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
LGG	cis	rs17772222	0.917	rs77382318	ENSG00000222990.1	RNU4-22P	8.83	1.98e-17	1.02e-14	0.47	0.38	Coronary artery calcification;	chr14:88355785	chr14:88513498~88513663:+
LGG	cis	rs9346353	0.966	rs72910810	ENSG00000219881.1	GAPDHP42	8.83	1.99e-17	1.02e-14	0.36	0.38	Sleep duration;	chr6:69727154	chr6:69745871~69746851:+
LGG	cis	rs2292342	1	rs3745734	ENSG00000232871.7	SEC1P	-8.83	2e-17	1.02e-14	-0.63	-0.38	Elevated serum carcinoembryonic antigen levels;	chr19:48631131	chr19:48638071~48682245:+
LGG	cis	rs2292342	1	rs28540190	ENSG00000232871.7	SEC1P	-8.83	2e-17	1.02e-14	-0.63	-0.38	Elevated serum carcinoembryonic antigen levels;	chr19:48631786	chr19:48638071~48682245:+
LGG	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	8.83	2e-17	1.02e-14	0.91	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	8.83	2e-17	1.03e-14	0.5	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
LGG	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	8.83	2e-17	1.03e-14	0.37	0.38	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
LGG	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-8.83	2.01e-17	1.03e-14	-0.36	-0.38	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
LGG	cis	rs1707322	1	rs7553924	ENSG00000281133.1	AL355480.3	-8.83	2.02e-17	1.03e-14	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4641257	ENSG00000281133.1	AL355480.3	-8.83	2.02e-17	1.03e-14	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs6693336	ENSG00000281133.1	AL355480.3	-8.83	2.02e-17	1.03e-14	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45580892~45580996:-
LGG	cis	rs893363	0.517	rs6445606	ENSG00000271916.1	RP11-884K10.6	-8.83	2.02e-17	1.03e-14	-0.48	-0.38	Axial length;	chr3:53822023	chr3:53797764~53798019:-
LGG	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	8.83	2.02e-17	1.03e-14	0.39	0.38	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
LGG	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	8.83	2.02e-17	1.03e-14	0.86	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
LGG	cis	rs571497	0.756	rs560634	ENSG00000268297.1	CLEC4GP1	8.83	2.02e-17	1.03e-14	0.51	0.38	Monocyte count;	chr19:7767067	chr19:7787549~7790621:+
LGG	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-8.83	2.03e-17	1.04e-14	-0.3	-0.38	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-8.83	2.03e-17	1.04e-14	-0.3	-0.38	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
LGG	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-8.83	2.03e-17	1.04e-14	-0.51	-0.38	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-8.83	2.03e-17	1.04e-14	-0.51	-0.38	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-8.83	2.03e-17	1.04e-14	-0.51	-0.38	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
LGG	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	8.83	2.03e-17	1.04e-14	0.4	0.38	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
LGG	cis	rs4713118	0.513	rs149944	ENSG00000218016.2	ZNF192P2	-8.83	2.04e-17	1.04e-14	-0.48	-0.38	Parkinson's disease;	chr6:28035040	chr6:28188050~28189432:+
LGG	cis	rs17772222	0.917	rs61986670	ENSG00000222990.1	RNU4-22P	8.83	2.04e-17	1.04e-14	0.5	0.38	Coronary artery calcification;	chr14:88730875	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs61986671	ENSG00000222990.1	RNU4-22P	8.83	2.04e-17	1.04e-14	0.5	0.38	Coronary artery calcification;	chr14:88732917	chr14:88513498~88513663:+
LGG	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-8.83	2.04e-17	1.04e-14	-0.36	-0.38	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
LGG	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
LGG	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	8.83	2.05e-17	1.05e-14	0.45	0.38	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
LGG	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	8.83	2.05e-17	1.05e-14	0.64	0.38	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	8.83	2.05e-17	1.05e-14	0.64	0.38	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	8.83	2.05e-17	1.05e-14	0.64	0.38	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	8.83	2.05e-17	1.05e-14	0.64	0.38	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	8.83	2.05e-17	1.05e-14	0.64	0.38	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	8.83	2.05e-17	1.05e-14	0.64	0.38	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
LGG	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-8.83	2.05e-17	1.05e-14	-0.3	-0.38	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-8.83	2.05e-17	1.05e-14	-0.3	-0.38	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	8.83	2.05e-17	1.05e-14	0.43	0.38	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	8.83	2.05e-17	1.05e-14	0.43	0.38	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
LGG	cis	rs9810089	0.843	rs1279086	ENSG00000261758.1	RP11-102M11.2	8.83	2.05e-17	1.05e-14	0.4	0.38	Gestational age at birth (child effect);	chr3:136319732	chr3:136752630~136755780:+
LGG	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	8.83	2.06e-17	1.05e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	8.83	2.06e-17	1.05e-14	0.49	0.38	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
LGG	cis	rs7829975	0.577	rs17684466	ENSG00000173295.6	FAM86B3P	8.83	2.06e-17	1.05e-14	0.41	0.38	Mood instability;	chr8:8687723	chr8:8228595~8244865:+
LGG	cis	rs9987353	0.544	rs2929470	ENSG00000173295.6	FAM86B3P	8.83	2.06e-17	1.05e-14	0.39	0.38	Recombination measurement;	chr8:9204980	chr8:8228595~8244865:+
LGG	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-8.83	2.06e-17	1.05e-14	-0.52	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
LGG	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-8.83	2.06e-17	1.05e-14	-0.34	-0.38	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
LGG	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-8.83	2.06e-17	1.05e-14	-0.4	-0.38	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
LGG	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	8.83	2.07e-17	1.06e-14	0.39	0.38	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
LGG	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	8.83	2.07e-17	1.06e-14	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
LGG	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	8.83	2.08e-17	1.06e-14	0.4	0.38	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
LGG	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	8.83	2.08e-17	1.06e-14	0.4	0.38	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
LGG	cis	rs7124681	0.584	rs11039448	ENSG00000280615.1	Y_RNA	-8.83	2.08e-17	1.06e-14	-0.45	-0.38	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47896864	chr11:47614898~47614994:-
LGG	cis	rs2282300	0.956	rs594937	ENSG00000242353.1	RP4-710M3.1	8.83	2.08e-17	1.06e-14	0.53	0.38	Morning vs. evening chronotype;	chr11:30368585	chr11:30368148~30368646:+
LGG	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	8.83	2.08e-17	1.06e-14	0.54	0.38	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
LGG	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	8.83	2.09e-17	1.07e-14	0.56	0.38	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
LGG	cis	rs227275	0.556	rs4455413	ENSG00000230069.3	LRRC37A15P	-8.83	2.09e-17	1.07e-14	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102727274~102730721:-
LGG	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-8.83	2.1e-17	1.07e-14	-0.47	-0.38	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
LGG	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	8.83	2.1e-17	1.07e-14	0.45	0.38	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
LGG	cis	rs11722779	0.844	rs10003326	ENSG00000230069.3	LRRC37A15P	-8.83	2.1e-17	1.07e-14	-0.36	-0.38	Schizophrenia;	chr4:102948193	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.787	rs6533040	ENSG00000230069.3	LRRC37A15P	-8.83	2.1e-17	1.07e-14	-0.36	-0.38	Schizophrenia;	chr4:102951421	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs223398	ENSG00000230069.3	LRRC37A15P	-8.83	2.1e-17	1.07e-14	-0.36	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102727274~102730721:-
LGG	cis	rs17772222	0.917	rs61986669	ENSG00000222990.1	RNU4-22P	8.83	2.1e-17	1.07e-14	0.5	0.38	Coronary artery calcification;	chr14:88727121	chr14:88513498~88513663:+
LGG	cis	rs7829975	0.577	rs940030	ENSG00000173295.6	FAM86B3P	8.83	2.11e-17	1.08e-14	0.41	0.38	Mood instability;	chr8:8689418	chr8:8228595~8244865:+
LGG	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-8.83	2.11e-17	1.08e-14	-0.47	-0.38	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
LGG	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	8.83	2.11e-17	1.08e-14	0.3	0.38	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
LGG	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	8.83	2.11e-17	1.08e-14	0.44	0.38	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
LGG	cis	rs228614	0.536	rs223419	ENSG00000230069.3	LRRC37A15P	-8.83	2.11e-17	1.08e-14	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102727274~102730721:-
LGG	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-8.83	2.12e-17	1.08e-14	-0.76	-0.38	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
LGG	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	8.82	2.12e-17	1.08e-14	0.49	0.38	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
LGG	cis	rs9393777	0.92	rs72839445	ENSG00000199851.2	U3	8.82	2.12e-17	1.08e-14	0.99	0.38	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28015568~28015777:+
LGG	cis	rs2797160	0.651	rs1268092	ENSG00000237742.5	RP11-624M8.1	-8.82	2.13e-17	1.09e-14	-0.34	-0.38	Endometrial cancer;	chr6:125707897	chr6:125578558~125749190:-
LGG	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-8.82	2.13e-17	1.09e-14	-0.48	-0.38	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
LGG	cis	rs8062405	0.573	rs8045689	ENSG00000251417.2	RP11-1348G14.4	8.82	2.13e-17	1.09e-14	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.573	rs7187575	ENSG00000251417.2	RP11-1348G14.4	8.82	2.13e-17	1.09e-14	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28802743~28817828:+
LGG	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	8.82	2.13e-17	1.09e-14	0.39	0.38	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
LGG	cis	rs228614	0.51	rs3774987	ENSG00000230069.3	LRRC37A15P	-8.82	2.13e-17	1.09e-14	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102727274~102730721:-
LGG	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-8.82	2.13e-17	1.09e-14	-0.52	-0.38	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
LGG	cis	rs17772222	0.917	rs1950806	ENSG00000222990.1	RNU4-22P	8.82	2.14e-17	1.09e-14	0.5	0.38	Coronary artery calcification;	chr14:88774412	chr14:88513498~88513663:+
LGG	cis	rs7746199	0.736	rs72845070	ENSG00000199851.2	U3	8.82	2.14e-17	1.09e-14	0.95	0.38	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28015568~28015777:+
LGG	cis	rs4950322	0.515	rs17160050	ENSG00000278811.3	LINC00624	8.82	2.14e-17	1.09e-14	0.36	0.38	Protein quantitative trait loci;	chr1:147255558	chr1:147258885~147517875:-
LGG	cis	rs858239	0.568	rs6970694	ENSG00000230042.1	AK3P3	-8.82	2.14e-17	1.09e-14	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23129178~23129841:+
LGG	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	8.82	2.14e-17	1.09e-14	0.49	0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
LGG	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	8.82	2.15e-17	1.1e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	8.82	2.15e-17	1.1e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	8.82	2.15e-17	1.1e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	8.82	2.15e-17	1.1e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	8.82	2.15e-17	1.1e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	8.82	2.15e-17	1.1e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	8.82	2.15e-17	1.1e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
LGG	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	8.82	2.15e-17	1.1e-14	0.52	0.38	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
LGG	cis	rs7829975	0.511	rs2955578	ENSG00000253981.4	ALG1L13P	-8.82	2.15e-17	1.1e-14	-0.4	-0.38	Mood instability;	chr8:8279561	chr8:8236003~8244667:-
LGG	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-8.82	2.15e-17	1.1e-14	-0.38	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
LGG	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	8.82	2.16e-17	1.1e-14	0.37	0.38	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
LGG	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	8.82	2.16e-17	1.1e-14	0.54	0.38	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
LGG	cis	rs1275468	1	rs1148004	ENSG00000257497.2	RP11-585P4.5	-8.82	2.17e-17	1.1e-14	-0.5	-0.38	Polycystic ovary syndrome;	chr12:75584897	chr12:75483454~75489820:-
LGG	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	8.82	2.17e-17	1.1e-14	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
LGG	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	8.82	2.17e-17	1.1e-14	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
LGG	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-8.82	2.17e-17	1.11e-14	-0.49	-0.38	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
LGG	cis	rs227275	0.554	rs6810668	ENSG00000248971.2	KRT8P46	-8.82	2.17e-17	1.11e-14	-0.39	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102728746~102730171:-
LGG	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-8.82	2.17e-17	1.11e-14	-0.31	-0.38	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
LGG	cis	rs7085104	0.632	rs7096475	ENSG00000272912.1	RP11-724N1.1	-8.82	2.18e-17	1.11e-14	-0.42	-0.38	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102914585~102915404:+
LGG	cis	rs853679	0.76	rs2299029	ENSG00000226314.6	ZNF192P1	8.82	2.18e-17	1.11e-14	0.47	0.38	Depression;	chr6:28231053	chr6:28161781~28169594:+
LGG	cis	rs9532669	0.926	rs6560963	ENSG00000239827.7	SUGT1P3	-8.82	2.18e-17	1.11e-14	-0.4	-0.38	Cervical cancer;	chr13:40871126	chr13:40908159~40921774:-
LGG	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	8.82	2.19e-17	1.11e-14	0.58	0.38	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	8.82	2.19e-17	1.11e-14	0.58	0.38	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
LGG	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-8.82	2.19e-17	1.12e-14	-0.46	-0.38	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
LGG	cis	rs858239	0.6	rs6461692	ENSG00000230042.1	AK3P3	-8.82	2.19e-17	1.12e-14	-0.38	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23129178~23129841:+
LGG	cis	rs10276381	0.786	rs10272155	ENSG00000234336.5	JAZF1-AS1	-8.82	2.2e-17	1.12e-14	-0.48	-0.38	Crohn's disease;	chr7:28207370	chr7:28180322~28243917:+
LGG	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	8.82	2.2e-17	1.12e-14	0.95	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
LGG	cis	rs6051080	1	rs6051080	ENSG00000250090.1	RP13-401N8.3	-8.82	2.2e-17	1.12e-14	-0.46	-0.38	Colorectal or endometrial cancer;	chr20:25995038	chr20:25835985~25836832:-
LGG	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	8.82	2.2e-17	1.12e-14	0.9	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
LGG	cis	rs853679	0.882	rs9393908	ENSG00000226314.6	ZNF192P1	8.82	2.2e-17	1.12e-14	0.58	0.38	Depression;	chr6:28223052	chr6:28161781~28169594:+
LGG	cis	rs853679	0.882	rs9366717	ENSG00000226314.6	ZNF192P1	8.82	2.2e-17	1.12e-14	0.58	0.38	Depression;	chr6:28223279	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.525	rs11760133	ENSG00000218016.2	ZNF192P2	-8.82	2.21e-17	1.12e-14	-0.45	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28188050~28189432:+
LGG	cis	rs17772222	0.917	rs17188228	ENSG00000222990.1	RNU4-22P	8.82	2.21e-17	1.12e-14	0.49	0.38	Coronary artery calcification;	chr14:88738921	chr14:88513498~88513663:+
LGG	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	8.82	2.22e-17	1.13e-14	0.44	0.38	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	8.82	2.22e-17	1.13e-14	0.44	0.38	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	8.82	2.22e-17	1.13e-14	0.44	0.38	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
LGG	cis	rs9875589	0.957	rs6768050	ENSG00000233121.1	VN1R20P	8.82	2.24e-17	1.14e-14	0.38	0.38	Ovarian reserve;	chr3:13888993	chr3:13926813~13927778:+
LGG	cis	rs1707322	1	rs11211219	ENSG00000281133.1	AL355480.3	-8.82	2.24e-17	1.14e-14	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211222	ENSG00000281133.1	AL355480.3	-8.82	2.24e-17	1.14e-14	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45580892~45580996:-
LGG	cis	rs6921919	0.562	rs13198809	ENSG00000199851.2	U3	8.82	2.25e-17	1.14e-14	0.95	0.38	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28015568~28015777:+
LGG	cis	rs228614	0.51	rs223455	ENSG00000230069.3	LRRC37A15P	-8.82	2.25e-17	1.14e-14	-0.36	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102727274~102730721:-
LGG	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	8.82	2.25e-17	1.14e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	8.82	2.25e-17	1.14e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	8.82	2.25e-17	1.14e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	8.82	2.25e-17	1.14e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	8.82	2.25e-17	1.14e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	8.82	2.25e-17	1.14e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	8.82	2.25e-17	1.14e-14	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
LGG	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	8.82	2.25e-17	1.15e-14	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
LGG	cis	rs7829975	0.56	rs56094035	ENSG00000173295.6	FAM86B3P	8.82	2.26e-17	1.15e-14	0.41	0.38	Mood instability;	chr8:8694112	chr8:8228595~8244865:+
LGG	cis	rs7829975	0.539	rs4841012	ENSG00000173295.6	FAM86B3P	8.82	2.26e-17	1.15e-14	0.41	0.38	Mood instability;	chr8:8694200	chr8:8228595~8244865:+
LGG	cis	rs7829975	0.56	rs4841013	ENSG00000173295.6	FAM86B3P	8.82	2.26e-17	1.15e-14	0.41	0.38	Mood instability;	chr8:8694503	chr8:8228595~8244865:+
LGG	cis	rs1707322	0.89	rs2297883	ENSG00000281133.1	AL355480.3	8.82	2.26e-17	1.15e-14	0.44	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs1707338	ENSG00000281133.1	AL355480.3	8.82	2.26e-17	1.15e-14	0.44	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45580892~45580996:-
LGG	cis	rs6545883	0.501	rs935860	ENSG00000273302.1	RP11-493E12.2	8.82	2.26e-17	1.15e-14	0.33	0.38	Tuberculosis;	chr2:61179426	chr2:61199979~61200769:+
LGG	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	8.82	2.26e-17	1.15e-14	0.33	0.38	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
LGG	cis	rs7208859	0.673	rs2470251	ENSG00000266490.1	CTD-2349P21.9	8.82	2.27e-17	1.15e-14	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs56846352	ENSG00000266490.1	CTD-2349P21.9	8.82	2.27e-17	1.15e-14	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs7211776	ENSG00000266490.1	CTD-2349P21.9	8.82	2.27e-17	1.15e-14	0.43	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30792372~30792833:+
LGG	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	8.82	2.27e-17	1.16e-14	0.41	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
LGG	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	8.82	2.28e-17	1.16e-14	0.44	0.38	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
LGG	cis	rs9810089	0.843	rs518972	ENSG00000261758.1	RP11-102M11.2	8.82	2.28e-17	1.16e-14	0.4	0.38	Gestational age at birth (child effect);	chr3:136320426	chr3:136752630~136755780:+
LGG	cis	rs11992162	0.967	rs7461062	ENSG00000227888.4	FAM66A	8.81	2.29e-17	1.17e-14	0.45	0.38	Monocyte count;	chr8:11974439	chr8:12362019~12388296:+
LGG	cis	rs1707322	1	rs10890350	ENSG00000281133.1	AL355480.3	-8.81	2.3e-17	1.17e-14	-0.45	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45580892~45580996:-
LGG	cis	rs375066	0.935	rs417699	ENSG00000267191.1	RP11-15A1.2	-8.81	2.3e-17	1.17e-14	-0.38	-0.38	Breast cancer;	chr19:43913423	chr19:43902001~43926545:+
LGG	cis	rs4950322	0.515	rs11239954	ENSG00000278811.3	LINC00624	8.81	2.31e-17	1.18e-14	0.36	0.38	Protein quantitative trait loci;	chr1:147246045	chr1:147258885~147517875:-
LGG	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	8.81	2.32e-17	1.18e-14	0.39	0.38	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
LGG	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-8.81	2.32e-17	1.18e-14	-0.48	-0.38	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
LGG	cis	rs7211079	0.719	rs2289535	ENSG00000279259.1	RP11-334C17.3	8.81	2.33e-17	1.18e-14	0.39	0.38	Myocardial infarction;	chr17:80137650	chr17:80147250~80148596:+
LGG	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	8.81	2.33e-17	1.18e-14	0.45	0.38	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
LGG	cis	rs2797160	0.714	rs1777220	ENSG00000237742.5	RP11-624M8.1	8.81	2.34e-17	1.19e-14	0.35	0.38	Endometrial cancer;	chr6:125701456	chr6:125578558~125749190:-
LGG	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-8.81	2.35e-17	1.19e-14	-0.51	-0.38	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
LGG	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	8.81	2.36e-17	1.2e-14	0.49	0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
LGG	cis	rs35425515	0.706	rs4919069	ENSG00000234855.1	SLIT1-AS1	-8.81	2.36e-17	1.2e-14	-0.63	-0.38	Bipolar disorder;	chr10:97101327	chr10:97102756~97103747:+
LGG	cis	rs10771431	0.738	rs11049697	ENSG00000111788.10	RP11-22B23.1	8.81	2.38e-17	1.21e-14	0.36	0.38	Breast size;	chr12:9232743	chr12:9277235~9313241:+
LGG	cis	rs1949733	0.958	rs2631731	ENSG00000205959.3	RP11-689P11.2	-8.81	2.38e-17	1.21e-14	-0.35	-0.38	Response to antineoplastic agents;	chr4:8428090	chr4:8482270~8512610:+
LGG	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	8.81	2.38e-17	1.21e-14	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	8.81	2.38e-17	1.21e-14	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
LGG	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-8.81	2.39e-17	1.21e-14	-0.35	-0.38	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
LGG	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	8.81	2.4e-17	1.22e-14	0.45	0.38	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
LGG	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-8.81	2.4e-17	1.22e-14	-0.49	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
LGG	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-8.81	2.4e-17	1.22e-14	-0.49	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
LGG	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	8.81	2.41e-17	1.22e-14	0.41	0.38	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
LGG	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-8.81	2.41e-17	1.22e-14	-0.39	-0.38	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
LGG	cis	rs1707322	1	rs785478	ENSG00000281133.1	AL355480.3	8.81	2.42e-17	1.23e-14	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45580892~45580996:-
LGG	cis	rs848490	0.508	rs6975810	ENSG00000214293.7	APTR	8.81	2.43e-17	1.23e-14	0.36	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659701	chr7:77657660~77696265:-
LGG	cis	rs9346353	1	rs8180599	ENSG00000219881.1	GAPDHP42	8.81	2.43e-17	1.23e-14	0.36	0.38	Sleep duration;	chr6:69759480	chr6:69745871~69746851:+
LGG	cis	rs853679	0.567	rs7774981	ENSG00000218016.2	ZNF192P2	-8.81	2.43e-17	1.23e-14	-0.48	-0.37	Depression;	chr6:28379133	chr6:28188050~28189432:+
LGG	cis	rs853679	0.567	rs7754960	ENSG00000218016.2	ZNF192P2	-8.81	2.43e-17	1.23e-14	-0.48	-0.37	Depression;	chr6:28379168	chr6:28188050~28189432:+
LGG	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	8.81	2.43e-17	1.23e-14	0.45	0.37	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	8.81	2.43e-17	1.23e-14	0.45	0.37	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	8.81	2.43e-17	1.23e-14	0.45	0.37	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	8.81	2.43e-17	1.23e-14	0.45	0.37	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
LGG	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	8.81	2.43e-17	1.23e-14	0.45	0.37	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
LGG	cis	rs1560104	0.879	rs2865581	ENSG00000274834.1	CTD-3037G24.5	-8.81	2.44e-17	1.24e-14	-0.48	-0.37	Obesity-related traits;	chr16:12623770	chr16:12614451~12614852:+
LGG	cis	rs7247513	0.658	rs4804728	ENSG00000213290.4	PGK1P2	-8.81	2.44e-17	1.24e-14	-0.41	-0.37	Bipolar disorder;	chr19:12642114	chr19:12559571~12561105:+
LGG	cis	rs4950322	0.57	rs79810882	ENSG00000278811.3	LINC00624	8.81	2.45e-17	1.24e-14	0.37	0.37	Protein quantitative trait loci;	chr1:147235575	chr1:147258885~147517875:-
LGG	cis	rs4713118	0.513	rs149989	ENSG00000218016.2	ZNF192P2	-8.81	2.46e-17	1.25e-14	-0.48	-0.37	Parkinson's disease;	chr6:28030406	chr6:28188050~28189432:+
LGG	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-8.81	2.47e-17	1.25e-14	-0.52	-0.37	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
LGG	cis	rs1707322	0.896	rs946528	ENSG00000281133.1	AL355480.3	8.8	2.48e-17	1.26e-14	0.45	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45580892~45580996:-
LGG	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-8.8	2.48e-17	1.26e-14	-0.33	-0.37	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
LGG	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	8.8	2.49e-17	1.26e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
LGG	cis	rs11992162	0.933	rs10108075	ENSG00000227888.4	FAM66A	8.8	2.49e-17	1.26e-14	0.45	0.37	Monocyte count;	chr8:11974570	chr8:12362019~12388296:+
LGG	cis	rs6997458	0.742	rs2307075	ENSG00000253549.4	RP11-317J10.2	8.8	2.52e-17	1.28e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85475999	chr8:85441851~85464915:-
LGG	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-8.8	2.53e-17	1.28e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-8.8	2.53e-17	1.28e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-8.8	2.53e-17	1.28e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
LGG	cis	rs6903823	0.508	rs1150718	ENSG00000218016.2	ZNF192P2	-8.8	2.53e-17	1.28e-14	-0.45	-0.37	Pulmonary function;	chr6:28289170	chr6:28188050~28189432:+
LGG	cis	rs6903823	0.508	rs1233660	ENSG00000218016.2	ZNF192P2	-8.8	2.53e-17	1.28e-14	-0.45	-0.37	Pulmonary function;	chr6:28292472	chr6:28188050~28189432:+
LGG	cis	rs6903823	0.508	rs1778484	ENSG00000218016.2	ZNF192P2	-8.8	2.53e-17	1.28e-14	-0.45	-0.37	Pulmonary function;	chr6:28273021	chr6:28188050~28189432:+
LGG	cis	rs11148252	0.508	rs6561671	ENSG00000278238.1	RP11-245D16.4	-8.8	2.53e-17	1.28e-14	-0.35	-0.37	Lewy body disease;	chr13:52608179	chr13:52454775~52455331:-
LGG	cis	rs9346353	0.966	rs9354885	ENSG00000219881.1	GAPDHP42	8.8	2.55e-17	1.29e-14	0.36	0.37	Sleep duration;	chr6:69740983	chr6:69745871~69746851:+
LGG	cis	rs17345786	0.798	rs4257518	ENSG00000244119.1	PDCL3P4	-8.8	2.55e-17	1.29e-14	-0.3	-0.37	Colonoscopy-negative controls vs population controls;	chr3:101562865	chr3:101712472~101713191:+
LGG	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	-8.8	2.55e-17	1.29e-14	-0.39	-0.37	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
LGG	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-8.8	2.56e-17	1.29e-14	-0.48	-0.37	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-8.8	2.56e-17	1.29e-14	-0.48	-0.37	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
LGG	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-8.8	2.56e-17	1.3e-14	-0.58	-0.37	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
LGG	cis	rs9322193	0.887	rs11155662	ENSG00000216621.7	RP11-244K5.6	8.8	2.56e-17	1.3e-14	0.46	0.37	Lung cancer;	chr6:149592731	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	8.8	2.56e-17	1.3e-14	0.44	0.37	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
LGG	cis	rs11051970	0.559	rs2270786	ENSG00000274964.1	RP11-817I4.1	-8.8	2.56e-17	1.3e-14	-0.41	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32337830	chr12:32339368~32340724:+
LGG	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	8.8	2.57e-17	1.3e-14	0.88	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
LGG	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-8.8	2.57e-17	1.3e-14	-0.47	-0.37	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
LGG	cis	rs6558530	0.777	rs3812477	ENSG00000253982.1	CTD-2336O2.1	8.8	2.58e-17	1.3e-14	0.4	0.37	Systolic blood pressure;	chr8:1786286	chr8:1761990~1764502:-
LGG	cis	rs4281086	0.931	rs6601478	ENSG00000253678.1	RP11-981G7.3	-8.8	2.58e-17	1.31e-14	-0.41	-0.37	Obesity-related traits;	chr8:10505879	chr8:10477491~10479375:-
LGG	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-8.8	2.58e-17	1.31e-14	-0.47	-0.37	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
LGG	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-8.8	2.58e-17	1.31e-14	-0.51	-0.37	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
LGG	cis	rs4713118	0.513	rs149941	ENSG00000218016.2	ZNF192P2	-8.8	2.6e-17	1.32e-14	-0.48	-0.37	Parkinson's disease;	chr6:28033255	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs149942	ENSG00000218016.2	ZNF192P2	-8.8	2.6e-17	1.32e-14	-0.48	-0.37	Parkinson's disease;	chr6:28033832	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs149945	ENSG00000218016.2	ZNF192P2	-8.8	2.6e-17	1.32e-14	-0.48	-0.37	Parkinson's disease;	chr6:28035075	chr6:28188050~28189432:+
LGG	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	8.8	2.61e-17	1.32e-14	0.31	0.37	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
LGG	cis	rs17772222	0.74	rs10150311	ENSG00000222990.1	RNU4-22P	8.8	2.61e-17	1.32e-14	0.44	0.37	Coronary artery calcification;	chr14:88510128	chr14:88513498~88513663:+
LGG	cis	rs853679	0.546	rs34676049	ENSG00000216901.1	AL022393.7	8.8	2.62e-17	1.32e-14	0.85	0.37	Depression;	chr6:28485841	chr6:28176188~28176674:+
LGG	cis	rs17772222	0.874	rs78077739	ENSG00000222990.1	RNU4-22P	8.8	2.62e-17	1.33e-14	0.49	0.37	Coronary artery calcification;	chr14:88741176	chr14:88513498~88513663:+
LGG	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-8.8	2.63e-17	1.33e-14	-0.45	-0.37	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
LGG	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	8.8	2.63e-17	1.33e-14	0.3	0.37	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
LGG	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	8.8	2.63e-17	1.33e-14	0.3	0.37	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
LGG	cis	rs482329	0.719	rs605957	ENSG00000228044.2	RP4-781K5.4	8.8	2.63e-17	1.33e-14	0.42	0.37	Life threatening arrhythmia;	chr1:234672761	chr1:234646289~234683176:+
LGG	cis	rs227275	0.525	rs1080081	ENSG00000230069.3	LRRC37A15P	-8.8	2.63e-17	1.33e-14	-0.36	-0.37	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102727274~102730721:-
LGG	cis	rs227275	0.525	rs4699049	ENSG00000230069.3	LRRC37A15P	-8.8	2.63e-17	1.33e-14	-0.36	-0.37	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102727274~102730721:-
LGG	cis	rs1707322	1	rs11211243	ENSG00000281133.1	AL355480.3	-8.8	2.64e-17	1.34e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211244	ENSG00000281133.1	AL355480.3	-8.8	2.64e-17	1.34e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4660903	ENSG00000281133.1	AL355480.3	-8.8	2.64e-17	1.34e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45580892~45580996:-
LGG	cis	rs1609391	0.543	rs1347209	ENSG00000273486.1	RP11-731C17.2	8.8	2.64e-17	1.34e-14	0.37	0.37	Neuroticism;	chr3:136907855	chr3:136837338~136839021:-
LGG	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-8.8	2.65e-17	1.34e-14	-0.3	-0.37	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
LGG	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-8.8	2.65e-17	1.34e-14	-0.36	-0.37	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
LGG	cis	rs2739330	0.828	rs5760108	ENSG00000235689.1	AP000351.13	8.8	2.65e-17	1.34e-14	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:24006305~24008258:-
LGG	cis	rs482329	0.719	rs534978	ENSG00000228044.2	RP4-781K5.4	8.8	2.65e-17	1.34e-14	0.42	0.37	Life threatening arrhythmia;	chr1:234672526	chr1:234646289~234683176:+
LGG	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-8.79	2.67e-17	1.35e-14	-0.37	-0.37	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
LGG	cis	rs7829975	0.539	rs71537846	ENSG00000173295.6	FAM86B3P	8.79	2.67e-17	1.35e-14	0.41	0.37	Mood instability;	chr8:8684610	chr8:8228595~8244865:+
LGG	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-8.79	2.67e-17	1.35e-14	-0.48	-0.37	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
LGG	cis	rs6997458	0.742	rs1908075	ENSG00000253549.4	RP11-317J10.2	8.79	2.67e-17	1.35e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434567	chr8:85441851~85464915:-
LGG	cis	rs6997458	0.742	rs11985733	ENSG00000253549.4	RP11-317J10.2	8.79	2.67e-17	1.35e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434845	chr8:85441851~85464915:-
LGG	cis	rs6997458	0.742	rs11985029	ENSG00000253549.4	RP11-317J10.2	8.79	2.67e-17	1.35e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434887	chr8:85441851~85464915:-
LGG	cis	rs657075	0.511	rs4705943	ENSG00000233006.5	AC034220.3	-8.79	2.67e-17	1.35e-14	-0.51	-0.37	Rheumatoid arthritis;	chr5:132419312	chr5:132311285~132369916:-
LGG	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	8.79	2.67e-17	1.35e-14	0.3	0.37	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
LGG	cis	rs482329	0.93	rs1660559	ENSG00000228044.2	RP4-781K5.4	8.79	2.67e-17	1.35e-14	0.42	0.37	Life threatening arrhythmia;	chr1:234683298	chr1:234646289~234683176:+
LGG	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	-8.79	2.68e-17	1.35e-14	-0.38	-0.37	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
LGG	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	8.79	2.69e-17	1.36e-14	0.45	0.37	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
LGG	cis	rs10759883	0.539	rs2296858	ENSG00000175611.10	LINC00476	8.79	2.69e-17	1.36e-14	0.51	0.37	Nicotine dependence;	chr9:96041126	chr9:95759231~95875977:-
LGG	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	8.79	2.72e-17	1.37e-14	0.49	0.37	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
LGG	cis	rs9346353	0.868	rs9354883	ENSG00000219881.1	GAPDHP42	8.79	2.72e-17	1.37e-14	0.37	0.37	Sleep duration;	chr6:69724367	chr6:69745871~69746851:+
LGG	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-8.79	2.72e-17	1.37e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
LGG	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	8.79	2.72e-17	1.38e-14	0.88	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
LGG	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	8.79	2.73e-17	1.38e-14	0.61	0.37	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
LGG	cis	rs11148252	0.904	rs9568734	ENSG00000235660.1	LINC00345	-8.79	2.73e-17	1.38e-14	-0.46	-0.37	Lewy body disease;	chr13:52430087	chr13:52484161~52484680:-
LGG	cis	rs11148252	0.904	rs7990581	ENSG00000235660.1	LINC00345	-8.79	2.73e-17	1.38e-14	-0.46	-0.37	Lewy body disease;	chr13:52445298	chr13:52484161~52484680:-
LGG	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	8.79	2.73e-17	1.38e-14	0.3	0.37	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
LGG	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	-8.79	2.73e-17	1.38e-14	-0.38	-0.37	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
LGG	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	-8.79	2.73e-17	1.38e-14	-0.38	-0.37	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
LGG	cis	rs2980439	0.557	rs2976876	ENSG00000253981.4	ALG1L13P	-8.79	2.74e-17	1.38e-14	-0.39	-0.37	Neuroticism;	chr8:8461340	chr8:8236003~8244667:-
LGG	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	8.79	2.74e-17	1.38e-14	0.49	0.37	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
LGG	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-8.79	2.74e-17	1.38e-14	-0.49	-0.37	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
LGG	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-8.79	2.74e-17	1.38e-14	-0.49	-0.37	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
LGG	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-8.79	2.74e-17	1.38e-14	-0.49	-0.37	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
LGG	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-8.79	2.74e-17	1.38e-14	-0.49	-0.37	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
LGG	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-8.79	2.76e-17	1.39e-14	-0.52	-0.37	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
LGG	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	8.79	2.78e-17	1.4e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	8.79	2.78e-17	1.4e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
LGG	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-8.79	2.78e-17	1.4e-14	-0.49	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
LGG	cis	rs9393777	0.92	rs67859638	ENSG00000216901.1	AL022393.7	8.79	2.78e-17	1.4e-14	0.85	0.37	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs58616630	ENSG00000216901.1	AL022393.7	8.79	2.78e-17	1.4e-14	0.85	0.37	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.736	rs34573979	ENSG00000216901.1	AL022393.7	8.79	2.78e-17	1.4e-14	0.85	0.37	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28176188~28176674:+
LGG	cis	rs9810089	0.706	rs521746	ENSG00000261758.1	RP11-102M11.2	-8.79	2.78e-17	1.4e-14	-0.4	-0.37	Gestational age at birth (child effect);	chr3:136385078	chr3:136752630~136755780:+
LGG	cis	rs9532669	0.926	rs9532654	ENSG00000239827.7	SUGT1P3	-8.79	2.79e-17	1.41e-14	-0.39	-0.37	Cervical cancer;	chr13:40909812	chr13:40908159~40921774:-
LGG	cis	rs12554020	0.579	rs79056932	ENSG00000227603.1	RP11-165J3.6	8.79	2.79e-17	1.41e-14	0.7	0.37	Schizophrenia;	chr9:93585431	chr9:93435332~93437121:-
LGG	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	8.79	2.8e-17	1.41e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
LGG	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	8.79	2.8e-17	1.41e-14	0.5	0.37	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
LGG	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-8.79	2.8e-17	1.41e-14	-0.5	-0.37	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
LGG	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-8.79	2.81e-17	1.42e-14	-0.45	-0.37	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
LGG	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-8.79	2.81e-17	1.42e-14	-0.42	-0.37	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
LGG	cis	rs6997458	0.652	rs7827051	ENSG00000253549.4	RP11-317J10.2	8.79	2.81e-17	1.42e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85425619	chr8:85441851~85464915:-
LGG	cis	rs6997458	0.742	rs7841178	ENSG00000253549.4	RP11-317J10.2	-8.79	2.81e-17	1.42e-14	-0.3	-0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85425690	chr8:85441851~85464915:-
LGG	cis	rs8031584	0.56	rs1056118	ENSG00000270015.1	RP11-540B6.6	8.79	2.82e-17	1.42e-14	0.27	0.37	Huntington's disease progression;	chr15:30911583	chr15:30926514~30928407:+
LGG	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	8.79	2.83e-17	1.43e-14	0.44	0.37	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
LGG	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	8.79	2.83e-17	1.43e-14	0.45	0.37	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	8.79	2.83e-17	1.43e-14	0.45	0.37	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
LGG	cis	rs17772222	0.701	rs376698	ENSG00000258983.2	RP11-507K2.2	-8.79	2.84e-17	1.43e-14	-0.42	-0.37	Coronary artery calcification;	chr14:88391886	chr14:88499334~88515502:+
LGG	cis	rs6921919	0.583	rs7764722	ENSG00000199851.2	U3	8.79	2.84e-17	1.43e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28015568~28015777:+
LGG	cis	rs7208859	0.673	rs9912122	ENSG00000266490.1	CTD-2349P21.9	8.79	2.85e-17	1.44e-14	0.43	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30792372~30792833:+
LGG	cis	rs6997458	0.742	rs10091566	ENSG00000253549.4	RP11-317J10.2	8.79	2.85e-17	1.44e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85429330	chr8:85441851~85464915:-
LGG	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	8.79	2.86e-17	1.44e-14	0.51	0.37	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
LGG	cis	rs8062405	0.573	rs7140	ENSG00000251417.2	RP11-1348G14.4	8.79	2.86e-17	1.44e-14	0.48	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28802743~28817828:+
LGG	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	8.79	2.86e-17	1.44e-14	0.39	0.37	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
LGG	cis	rs9987353	0.519	rs2929465	ENSG00000173295.6	FAM86B3P	8.79	2.87e-17	1.45e-14	0.4	0.37	Recombination measurement;	chr8:9206492	chr8:8228595~8244865:+
LGG	cis	rs10916248	0.559	rs56023673	ENSG00000232628.4	RP11-365O16.3	8.79	2.87e-17	1.45e-14	0.6	0.37	QT interval (drug interaction);	chr1:224180821	chr1:224208747~224213279:-
LGG	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-8.78	2.88e-17	1.45e-14	-0.38	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-8.78	2.88e-17	1.45e-14	-0.38	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
LGG	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-8.78	2.88e-17	1.45e-14	-0.47	-0.37	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
LGG	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-8.78	2.88e-17	1.45e-14	-0.47	-0.37	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
LGG	cis	rs2075466	0.508	rs75637175	ENSG00000267077.1	RP11-127I20.5	8.78	2.89e-17	1.46e-14	0.53	0.37	Colonoscopy-negative controls vs population controls;	chr16:4898387	chr16:4795265~4796532:-
LGG	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-8.78	2.89e-17	1.46e-14	-0.49	-0.37	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
LGG	cis	rs7829975	0.577	rs79495969	ENSG00000173295.6	FAM86B3P	8.78	2.9e-17	1.46e-14	0.41	0.37	Mood instability;	chr8:8687740	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	8.78	2.91e-17	1.47e-14	0.44	0.37	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
LGG	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	8.78	2.92e-17	1.47e-14	0.4	0.37	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
LGG	cis	rs2325036	0.929	rs9876664	ENSG00000239519.1	CADM2-AS1	8.78	2.92e-17	1.47e-14	0.41	0.37	Waist circumference;	chr3:85757163	chr3:85992183~86028007:-
LGG	cis	rs5742933	0.557	rs1233276	ENSG00000273240.1	RP11-455J20.3	-8.78	2.93e-17	1.47e-14	-0.48	-0.37	Ferritin levels;	chr2:189820056	chr2:189763859~189764456:-
LGG	cis	rs853679	0.723	rs9366718	ENSG00000226314.6	ZNF192P1	8.78	2.93e-17	1.48e-14	0.47	0.37	Depression;	chr6:28237724	chr6:28161781~28169594:+
LGG	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-8.78	2.93e-17	1.48e-14	-0.33	-0.37	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
LGG	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-8.78	2.93e-17	1.48e-14	-0.36	-0.37	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
LGG	cis	rs482329	0.719	rs610843	ENSG00000228044.2	RP4-781K5.4	8.78	2.94e-17	1.48e-14	0.42	0.37	Life threatening arrhythmia;	chr1:234666662	chr1:234646289~234683176:+
LGG	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	8.78	2.94e-17	1.48e-14	0.39	0.37	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
LGG	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-8.78	2.95e-17	1.48e-14	-0.44	-0.37	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
LGG	cis	rs1707322	0.963	rs11211202	ENSG00000281133.1	AL355480.3	-8.78	2.95e-17	1.48e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45580892~45580996:-
LGG	cis	rs9532669	0.929	rs9532601	ENSG00000168852.11	TPTE2P5	8.78	2.95e-17	1.48e-14	0.38	0.37	Cervical cancer;	chr13:40861086	chr13:40822296~40921749:-
LGG	cis	rs853679	0.567	rs3799499	ENSG00000218016.2	ZNF192P2	-8.78	2.95e-17	1.48e-14	-0.48	-0.37	Depression;	chr6:28386473	chr6:28188050~28189432:+
LGG	cis	rs853679	0.567	rs2232427	ENSG00000218016.2	ZNF192P2	-8.78	2.95e-17	1.48e-14	-0.48	-0.37	Depression;	chr6:28391932	chr6:28188050~28189432:+
LGG	cis	rs853679	0.567	rs1005126	ENSG00000218016.2	ZNF192P2	-8.78	2.95e-17	1.48e-14	-0.48	-0.37	Depression;	chr6:28399846	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.789	rs1119211	ENSG00000218016.2	ZNF192P2	8.78	2.95e-17	1.49e-14	0.49	0.37	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28188050~28189432:+
LGG	cis	rs7267979	0.844	rs869358	ENSG00000276952.1	RP5-965G21.6	-8.78	2.96e-17	1.49e-14	-0.37	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25284915~25285588:-
LGG	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	8.78	2.99e-17	1.5e-14	0.4	0.37	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
LGG	cis	rs6921919	0.789	rs13210258	ENSG00000218016.2	ZNF192P2	-8.78	2.99e-17	1.51e-14	-0.49	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28188050~28189432:+
LGG	cis	rs1707322	1	rs4660889	ENSG00000281133.1	AL355480.3	-8.78	2.99e-17	1.51e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45580892~45580996:-
LGG	cis	rs62184315	0.58	rs62185872	ENSG00000273240.1	RP11-455J20.3	-8.78	3.01e-17	1.51e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189690033	chr2:189763859~189764456:-
LGG	cis	rs1949733	1	rs1880023	ENSG00000205959.3	RP11-689P11.2	8.78	3.01e-17	1.51e-14	0.34	0.37	Response to antineoplastic agents;	chr4:8479104	chr4:8482270~8512610:+
LGG	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	8.78	3.02e-17	1.52e-14	0.54	0.37	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
LGG	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-8.78	3.03e-17	1.53e-14	-0.58	-0.37	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
LGG	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	8.78	3.04e-17	1.53e-14	0.3	0.37	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
LGG	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-8.78	3.04e-17	1.53e-14	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
LGG	cis	rs1707322	0.964	rs7546237	ENSG00000281133.1	AL355480.3	-8.78	3.05e-17	1.53e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45580892~45580996:-
LGG	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-8.78	3.05e-17	1.53e-14	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
LGG	cis	rs9346353	0.933	rs9346327	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69671451	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.931	rs9346328	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69672247	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs9354877	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69673335	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.902	rs3214021	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69676428	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.864	rs3816563	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69676761	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs6455338	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69677201	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs6455339	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69677268	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs9364047	ENSG00000219881.1	GAPDHP42	8.78	3.05e-17	1.53e-14	0.36	0.37	Sleep duration;	chr6:69678460	chr6:69745871~69746851:+
LGG	cis	rs11722779	0.844	rs223345	ENSG00000230069.3	LRRC37A15P	-8.78	3.05e-17	1.54e-14	-0.36	-0.37	Schizophrenia;	chr4:102859366	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.873	rs223344	ENSG00000230069.3	LRRC37A15P	-8.78	3.05e-17	1.54e-14	-0.36	-0.37	Schizophrenia;	chr4:102859765	chr4:102727274~102730721:-
LGG	cis	rs11722779	0.775	rs223341	ENSG00000230069.3	LRRC37A15P	-8.78	3.05e-17	1.54e-14	-0.36	-0.37	Schizophrenia;	chr4:102862343	chr4:102727274~102730721:-
LGG	cis	rs35425515	0.706	rs1490688	ENSG00000234855.1	SLIT1-AS1	-8.78	3.06e-17	1.54e-14	-0.62	-0.37	Bipolar disorder;	chr10:97100717	chr10:97102756~97103747:+
LGG	cis	rs9527	0.59	rs7073323	ENSG00000272912.1	RP11-724N1.1	-8.78	3.06e-17	1.54e-14	-0.44	-0.37	Arsenic metabolism;	chr10:103037666	chr10:102914585~102915404:+
LGG	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-8.78	3.06e-17	1.54e-14	-0.49	-0.37	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
LGG	cis	rs2281558	0.517	rs16987966	ENSG00000125804.12	FAM182A	-8.78	3.07e-17	1.54e-14	-0.58	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25662778	chr20:26054655~26086917:+
LGG	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	8.78	3.07e-17	1.54e-14	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
LGG	cis	rs9810089	0.708	rs619605	ENSG00000261758.1	RP11-102M11.2	8.78	3.07e-17	1.55e-14	0.4	0.37	Gestational age at birth (child effect);	chr3:136368170	chr3:136752630~136755780:+
LGG	cis	rs9346353	0.931	rs9364051	ENSG00000219881.1	GAPDHP42	8.78	3.09e-17	1.55e-14	0.36	0.37	Sleep duration;	chr6:69711720	chr6:69745871~69746851:+
LGG	cis	rs12554020	0.681	rs78792144	ENSG00000227603.1	RP11-165J3.6	8.78	3.09e-17	1.56e-14	0.7	0.37	Schizophrenia;	chr9:93583725	chr9:93435332~93437121:-
LGG	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-8.78	3.1e-17	1.56e-14	-0.36	-0.37	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
LGG	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	8.78	3.1e-17	1.56e-14	0.43	0.37	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
LGG	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	8.78	3.1e-17	1.56e-14	0.39	0.37	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	8.78	3.1e-17	1.56e-14	0.39	0.37	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
LGG	cis	rs9346353	0.966	rs4516910	ENSG00000219881.1	GAPDHP42	8.77	3.11e-17	1.56e-14	0.36	0.37	Sleep duration;	chr6:69700271	chr6:69745871~69746851:+
LGG	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	8.77	3.12e-17	1.57e-14	0.44	0.37	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
LGG	cis	rs3742264	0.656	rs4941537	ENSG00000235903.6	CPB2-AS1	8.77	3.13e-17	1.57e-14	0.39	0.37	Blood protein levels;	chr13:45968441	chr13:46052806~46113332:+
LGG	cis	rs6496932	0.909	rs74024818	ENSG00000218052.5	ADAMTS7P4	8.77	3.18e-17	1.6e-14	0.58	0.37	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85255369~85330334:-
LGG	cis	rs6519955	0.86	rs8136098	ENSG00000231711.2	LINC00899	8.77	3.18e-17	1.6e-14	0.44	0.37	Dupuytren's disease;	chr22:46029766	chr22:46039907~46044853:-
LGG	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	8.77	3.19e-17	1.6e-14	0.45	0.37	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
LGG	cis	rs3020264	0.579	rs1256	ENSG00000271743.1	CTD-2541M15.3	-8.77	3.19e-17	1.6e-14	-0.44	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6615835	chr8:6615604~6617198:-
LGG	cis	rs9532669	0.926	rs9525438	ENSG00000168852.11	TPTE2P5	8.77	3.22e-17	1.62e-14	0.38	0.37	Cervical cancer;	chr13:40964123	chr13:40822296~40921749:-
LGG	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	8.77	3.22e-17	1.62e-14	0.46	0.37	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
LGG	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	8.77	3.22e-17	1.62e-14	0.46	0.37	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
LGG	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-8.77	3.23e-17	1.62e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
LGG	cis	rs6921919	0.609	rs9461455	ENSG00000226314.6	ZNF192P1	8.77	3.23e-17	1.62e-14	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28161781~28169594:+
LGG	cis	rs858239	0.669	rs1618339	ENSG00000230042.1	AK3P3	-8.77	3.24e-17	1.62e-14	-0.38	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs6975852	ENSG00000230042.1	AK3P3	-8.77	3.24e-17	1.63e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23129178~23129841:+
LGG	cis	rs6921919	0.583	rs2071965	ENSG00000199851.2	U3	8.77	3.24e-17	1.63e-14	0.52	0.37	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28015568~28015777:+
LGG	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-8.77	3.24e-17	1.63e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
LGG	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	8.77	3.25e-17	1.63e-14	0.45	0.37	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
LGG	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-8.77	3.26e-17	1.63e-14	-0.56	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
LGG	cis	rs4281086	0.965	rs4473997	ENSG00000253678.1	RP11-981G7.3	8.77	3.26e-17	1.64e-14	0.41	0.37	Obesity-related traits;	chr8:10514738	chr8:10477491~10479375:-
LGG	cis	rs8042680	0.522	rs10775251	ENSG00000214432.8	AC068831.10	-8.77	3.26e-17	1.64e-14	-0.39	-0.37	Type 2 diabetes;	chr15:91011195	chr15:91022619~91036611:+
LGG	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	8.77	3.26e-17	1.64e-14	0.44	0.37	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
LGG	cis	rs2980439	0.783	rs2948305	ENSG00000253981.4	ALG1L13P	-8.77	3.26e-17	1.64e-14	-0.4	-0.37	Neuroticism;	chr8:8241055	chr8:8236003~8244667:-
LGG	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-8.77	3.26e-17	1.64e-14	-0.36	-0.37	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
LGG	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-8.77	3.27e-17	1.64e-14	-0.46	-0.37	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
LGG	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	8.77	3.27e-17	1.64e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	8.77	3.27e-17	1.64e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
LGG	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	8.77	3.28e-17	1.65e-14	0.46	0.37	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
LGG	cis	rs227275	0.556	rs7676765	ENSG00000230069.3	LRRC37A15P	8.77	3.28e-17	1.65e-14	0.35	0.37	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102727274~102730721:-
LGG	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-8.77	3.28e-17	1.65e-14	-0.49	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
LGG	cis	rs2980439	0.556	rs2921059	ENSG00000253981.4	ALG1L13P	-8.77	3.29e-17	1.65e-14	-0.39	-0.37	Neuroticism;	chr8:8460377	chr8:8236003~8244667:-
LGG	cis	rs482329	0.623	rs2770366	ENSG00000228044.2	RP4-781K5.4	8.77	3.29e-17	1.65e-14	0.42	0.37	Life threatening arrhythmia;	chr1:234665153	chr1:234646289~234683176:+
LGG	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	8.77	3.3e-17	1.66e-14	0.43	0.37	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
LGG	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	8.77	3.31e-17	1.66e-14	0.39	0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
LGG	cis	rs7302981	0.719	rs835592	ENSG00000272368.2	RP4-605O3.4	8.77	3.32e-17	1.66e-14	0.37	0.37	Systolic blood pressure;	chr12:50067048	chr12:50112197~50165618:+
LGG	cis	rs4819052	0.679	rs2236450	ENSG00000215447.6	BX322557.10	-8.77	3.32e-17	1.67e-14	-0.28	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45288052~45291738:+
LGG	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-8.77	3.33e-17	1.67e-14	-0.92	-0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
LGG	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	8.77	3.33e-17	1.67e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
LGG	cis	rs9532669	0.889	rs7333447	ENSG00000168852.11	TPTE2P5	8.77	3.33e-17	1.67e-14	0.38	0.37	Cervical cancer;	chr13:40917586	chr13:40822296~40921749:-
LGG	cis	rs853679	0.567	rs13196606	ENSG00000218016.2	ZNF192P2	-8.77	3.33e-17	1.67e-14	-0.47	-0.37	Depression;	chr6:28402301	chr6:28188050~28189432:+
LGG	cis	rs1609391	0.561	rs9289523	ENSG00000273486.1	RP11-731C17.2	8.77	3.34e-17	1.67e-14	0.37	0.37	Neuroticism;	chr3:136916747	chr3:136837338~136839021:-
LGG	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-8.77	3.35e-17	1.68e-14	-0.43	-0.37	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
LGG	cis	rs17345786	0.798	rs9817043	ENSG00000256628.3	ZBTB11-AS1	8.77	3.35e-17	1.68e-14	0.44	0.37	Colonoscopy-negative controls vs population controls;	chr3:101563008	chr3:101676475~101679217:+
LGG	cis	rs853679	0.538	rs13199081	ENSG00000218016.2	ZNF192P2	-8.76	3.36e-17	1.68e-14	-0.48	-0.37	Depression;	chr6:28364057	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.583	rs4254981	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.525	rs6929825	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs35599905	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs1124131	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs6899389	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs6922374	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs6899603	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs6922429	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs6922169	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.559	rs13210866	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.609	rs36018474	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs13201726	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs2027361	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs4642462	ENSG00000199851.2	U3	8.76	3.36e-17	1.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28015568~28015777:+
LGG	cis	rs1707322	1	rs11211235	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.893	rs9919275	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211236	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4660328	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.928	rs61785614	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs9793167	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211237	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs11211238	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4460583	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs4459051	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs11211239	ENSG00000281133.1	AL355480.3	-8.76	3.36e-17	1.69e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45580892~45580996:-
LGG	cis	rs6921919	0.789	rs6456814	ENSG00000218016.2	ZNF192P2	-8.76	3.37e-17	1.69e-14	-0.49	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28188050~28189432:+
LGG	cis	rs6496932	1	rs35156762	ENSG00000218052.5	ADAMTS7P4	8.76	3.38e-17	1.69e-14	0.56	0.37	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85255369~85330334:-
LGG	cis	rs9393777	0.841	rs34332556	ENSG00000199851.2	U3	8.76	3.39e-17	1.7e-14	0.91	0.37	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28015568~28015777:+
LGG	cis	rs10771431	0.713	rs17794353	ENSG00000111788.10	RP11-22B23.1	-8.76	3.39e-17	1.7e-14	-0.35	-0.37	Breast size;	chr12:9209187	chr12:9277235~9313241:+
LGG	cis	rs1707322	1	rs6671754	ENSG00000281133.1	AL355480.3	-8.76	3.4e-17	1.7e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.963	rs6666763	ENSG00000281133.1	AL355480.3	-8.76	3.4e-17	1.7e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs4489497	ENSG00000281133.1	AL355480.3	-8.76	3.4e-17	1.7e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45580892~45580996:-
LGG	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-8.76	3.41e-17	1.71e-14	-0.47	-0.37	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
LGG	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-8.76	3.41e-17	1.71e-14	-0.46	-0.37	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
LGG	cis	rs62184315	0.536	rs62185897	ENSG00000273240.1	RP11-455J20.3	-8.76	3.41e-17	1.71e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189721279	chr2:189763859~189764456:-
LGG	cis	rs2739330	0.828	rs5751770	ENSG00000235689.1	AP000351.13	8.76	3.42e-17	1.71e-14	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:24006305~24008258:-
LGG	cis	rs35851103	0.627	rs6601644	ENSG00000255556.2	RP11-351I21.6	8.76	3.42e-17	1.71e-14	0.45	0.37	Neuroticism;	chr8:11989569	chr8:12378679~12380265:-
LGG	cis	rs9346353	1	rs9364054	ENSG00000219881.1	GAPDHP42	8.76	3.42e-17	1.71e-14	0.36	0.37	Sleep duration;	chr6:69736857	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs45559535	ENSG00000219881.1	GAPDHP42	8.76	3.42e-17	1.71e-14	0.36	0.37	Sleep duration;	chr6:69738101	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs12661224	ENSG00000219881.1	GAPDHP42	8.76	3.42e-17	1.71e-14	0.36	0.37	Sleep duration;	chr6:69738141	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346343	ENSG00000219881.1	GAPDHP42	8.76	3.42e-17	1.71e-14	0.36	0.37	Sleep duration;	chr6:69745132	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs2881080	ENSG00000219881.1	GAPDHP42	8.76	3.42e-17	1.71e-14	0.36	0.37	Sleep duration;	chr6:69750280	chr6:69745871~69746851:+
LGG	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	8.76	3.42e-17	1.71e-14	0.37	0.37	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
LGG	cis	rs741668	1	rs741668	ENSG00000235903.6	CPB2-AS1	-8.76	3.42e-17	1.72e-14	-0.4	-0.37	Cerebrospinal fluid clusterin levels;	chr13:45942333	chr13:46052806~46113332:+
LGG	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	8.76	3.43e-17	1.72e-14	0.43	0.37	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
LGG	cis	rs9532669	0.926	rs9566582	ENSG00000168852.11	TPTE2P5	8.76	3.43e-17	1.72e-14	0.39	0.37	Cervical cancer;	chr13:40852121	chr13:40822296~40921749:-
LGG	cis	rs6997458	0.713	rs1543852	ENSG00000253549.4	RP11-317J10.2	8.76	3.43e-17	1.72e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85440529	chr8:85441851~85464915:-
LGG	cis	rs858239	0.539	rs10254544	ENSG00000230042.1	AK3P3	-8.76	3.44e-17	1.72e-14	-0.4	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23129178~23129841:+
LGG	cis	rs2281558	0.837	rs67676850	ENSG00000125804.12	FAM182A	-8.76	3.44e-17	1.72e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:26054655~26086917:+
LGG	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-8.76	3.45e-17	1.73e-14	-0.36	-0.37	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
LGG	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	8.76	3.5e-17	1.75e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	8.76	3.5e-17	1.75e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	8.76	3.5e-17	1.75e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	8.76	3.5e-17	1.75e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
LGG	cis	rs10276381	0.901	rs73300638	ENSG00000234336.5	JAZF1-AS1	-8.76	3.5e-17	1.75e-14	-0.49	-0.37	Crohn's disease;	chr7:28147725	chr7:28180322~28243917:+
LGG	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-8.76	3.51e-17	1.76e-14	-0.35	-0.37	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
LGG	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	8.76	3.53e-17	1.77e-14	0.31	0.37	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
LGG	cis	rs9527	0.615	rs11191401	ENSG00000272912.1	RP11-724N1.1	-8.76	3.54e-17	1.77e-14	-0.44	-0.37	Arsenic metabolism;	chr10:102813646	chr10:102914585~102915404:+
LGG	cis	rs1609391	0.543	rs2117009	ENSG00000273486.1	RP11-731C17.2	-8.76	3.54e-17	1.77e-14	-0.37	-0.37	Neuroticism;	chr3:136914729	chr3:136837338~136839021:-
LGG	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-8.76	3.54e-17	1.77e-14	-0.44	-0.37	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
LGG	cis	rs9532669	0.926	rs7331435	ENSG00000239827.7	SUGT1P3	8.76	3.56e-17	1.78e-14	0.39	0.37	Cervical cancer;	chr13:40862396	chr13:40908159~40921774:-
LGG	cis	rs6921919	0.583	rs9468355	ENSG00000280107.1	AL022393.9	-8.76	3.57e-17	1.79e-14	-0.39	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28170845~28172521:+
LGG	cis	rs2281558	0.876	rs6115135	ENSG00000125804.12	FAM182A	-8.76	3.58e-17	1.79e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299242	chr20:26054655~26086917:+
LGG	cis	rs17772222	0.917	rs12589982	ENSG00000222990.1	RNU4-22P	8.76	3.58e-17	1.79e-14	0.49	0.37	Coronary artery calcification;	chr14:88716861	chr14:88513498~88513663:+
LGG	cis	rs9346353	1	rs9351772	ENSG00000219881.1	GAPDHP42	8.76	3.59e-17	1.79e-14	0.36	0.37	Sleep duration;	chr6:69718308	chr6:69745871~69746851:+
LGG	cis	rs17772222	0.793	rs7143853	ENSG00000222990.1	RNU4-22P	8.76	3.59e-17	1.8e-14	0.49	0.37	Coronary artery calcification;	chr14:88578477	chr14:88513498~88513663:+
LGG	cis	rs6921919	0.583	rs9468370	ENSG00000226314.6	ZNF192P1	8.76	3.59e-17	1.8e-14	0.38	0.37	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28161781~28169594:+
LGG	cis	rs7826238	0.524	rs2921055	ENSG00000253981.4	ALG1L13P	-8.76	3.6e-17	1.8e-14	-0.38	-0.37	Systolic blood pressure;	chr8:8461832	chr8:8236003~8244667:-
LGG	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	8.76	3.6e-17	1.8e-14	0.4	0.37	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
LGG	cis	rs9346353	0.966	rs3823078	ENSG00000219881.1	GAPDHP42	8.76	3.6e-17	1.8e-14	0.36	0.37	Sleep duration;	chr6:69678859	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346336	ENSG00000219881.1	GAPDHP42	8.76	3.61e-17	1.8e-14	0.35	0.37	Sleep duration;	chr6:69720795	chr6:69745871~69746851:+
LGG	cis	rs1707322	0.685	rs56177313	ENSG00000281133.1	AL355480.3	-8.76	3.61e-17	1.81e-14	-0.46	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45580892~45580996:-
LGG	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	8.76	3.62e-17	1.81e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
LGG	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	8.75	3.62e-17	1.81e-14	0.36	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
LGG	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	8.75	3.63e-17	1.81e-14	0.56	0.37	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
LGG	cis	rs9346353	0.966	rs9360397	ENSG00000219881.1	GAPDHP42	-8.75	3.63e-17	1.82e-14	-0.36	-0.37	Sleep duration;	chr6:69678130	chr6:69745871~69746851:+
LGG	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	8.75	3.64e-17	1.82e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	8.75	3.64e-17	1.82e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	8.75	3.64e-17	1.82e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	8.75	3.64e-17	1.82e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	8.75	3.64e-17	1.82e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	8.75	3.64e-17	1.82e-14	0.86	0.37	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
LGG	cis	rs7829975	0.577	rs940032	ENSG00000173295.6	FAM86B3P	8.75	3.64e-17	1.82e-14	0.41	0.37	Mood instability;	chr8:8688833	chr8:8228595~8244865:+
LGG	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	8.75	3.64e-17	1.82e-14	0.43	0.37	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
LGG	cis	rs853679	0.607	rs34788973	ENSG00000199851.2	U3	8.75	3.66e-17	1.83e-14	0.91	0.37	Depression;	chr6:27911422	chr6:28015568~28015777:+
LGG	cis	rs853679	0.607	rs61742093	ENSG00000199851.2	U3	8.75	3.66e-17	1.83e-14	0.91	0.37	Depression;	chr6:27912204	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	8.75	3.67e-17	1.83e-14	0.43	0.37	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	8.75	3.67e-17	1.83e-14	0.43	0.37	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
LGG	cis	rs17772222	1	rs79579293	ENSG00000222990.1	RNU4-22P	8.75	3.68e-17	1.84e-14	0.47	0.37	Coronary artery calcification;	chr14:88355724	chr14:88513498~88513663:+
LGG	cis	rs2980439	0.557	rs2921056	ENSG00000253981.4	ALG1L13P	-8.75	3.69e-17	1.84e-14	-0.38	-0.37	Neuroticism;	chr8:8461672	chr8:8236003~8244667:-
LGG	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	8.75	3.7e-17	1.85e-14	0.42	0.37	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
LGG	cis	rs950776	0.72	rs11633223	ENSG00000261762.1	RP11-650L12.2	8.75	3.7e-17	1.85e-14	0.48	0.37	Sudden cardiac arrest;	chr15:78643134	chr15:78589123~78591276:-
LGG	cis	rs17772222	0.917	rs61984736	ENSG00000222990.1	RNU4-22P	8.75	3.7e-17	1.85e-14	0.5	0.37	Coronary artery calcification;	chr14:88626359	chr14:88513498~88513663:+
LGG	cis	rs9393777	0.92	rs34953377	ENSG00000199851.2	U3	8.75	3.71e-17	1.85e-14	0.91	0.37	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.778	rs66841633	ENSG00000199851.2	U3	8.75	3.71e-17	1.85e-14	0.91	0.37	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.841	rs13191474	ENSG00000199851.2	U3	8.75	3.71e-17	1.85e-14	0.91	0.37	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs41269265	ENSG00000199851.2	U3	8.75	3.71e-17	1.85e-14	0.91	0.37	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28015568~28015777:+
LGG	cis	rs657075	0.55	rs1468199	ENSG00000233006.5	AC034220.3	-8.75	3.72e-17	1.86e-14	-0.52	-0.37	Rheumatoid arthritis;	chr5:132421320	chr5:132311285~132369916:-
LGG	cis	rs2253762	0.645	rs11200366	ENSG00000276742.1	RP11-500G22.4	-8.75	3.72e-17	1.86e-14	-0.51	-0.37	Breast cancer;	chr10:122044170	chr10:121956782~121957098:+
LGG	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	8.75	3.73e-17	1.86e-14	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
LGG	cis	rs17772222	0.74	rs3783885	ENSG00000222990.1	RNU4-22P	8.75	3.73e-17	1.86e-14	0.45	0.37	Coronary artery calcification;	chr14:88510714	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs11159857	ENSG00000222990.1	RNU4-22P	8.75	3.73e-17	1.86e-14	0.45	0.37	Coronary artery calcification;	chr14:88510796	chr14:88513498~88513663:+
LGG	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-8.75	3.74e-17	1.87e-14	-0.36	-0.37	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
LGG	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-8.75	3.74e-17	1.87e-14	-0.36	-0.37	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
LGG	cis	rs8042680	0.688	rs2386584	ENSG00000214432.8	AC068831.10	-8.75	3.74e-17	1.87e-14	-0.39	-0.37	Type 2 diabetes;	chr15:90996342	chr15:91022619~91036611:+
LGG	cis	rs1707322	0.717	rs3014237	ENSG00000281133.1	AL355480.3	8.75	3.75e-17	1.87e-14	0.46	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45580892~45580996:-
LGG	cis	rs853679	0.546	rs200948	ENSG00000216901.1	AL022393.7	8.75	3.76e-17	1.88e-14	0.72	0.37	Depression;	chr6:27867494	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs200950	ENSG00000216901.1	AL022393.7	8.75	3.76e-17	1.88e-14	0.72	0.37	Depression;	chr6:27867994	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs200952	ENSG00000216901.1	AL022393.7	8.75	3.76e-17	1.88e-14	0.72	0.37	Depression;	chr6:27869198	chr6:28176188~28176674:+
LGG	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	8.75	3.77e-17	1.88e-14	0.48	0.37	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
LGG	cis	rs6921919	0.638	rs7772827	ENSG00000226314.6	ZNF192P1	8.75	3.78e-17	1.89e-14	0.4	0.37	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28161781~28169594:+
LGG	cis	rs564343	0.765	rs1558974	ENSG00000255320.1	RP11-755F10.1	8.75	3.79e-17	1.89e-14	0.48	0.37	Obesity (early onset extreme);	chr11:66110303	chr11:66244840~66246239:-
LGG	cis	rs5742933	1	rs12622902	ENSG00000253559.1	OSGEPL1-AS1	-8.75	3.79e-17	1.89e-14	-0.49	-0.37	Ferritin levels;	chr2:189776263	chr2:189762704~189765556:+
LGG	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-8.75	3.79e-17	1.89e-14	-0.45	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
LGG	cis	rs7849270	0.842	rs12237274	ENSG00000268707.1	RP11-247A12.7	-8.75	3.81e-17	1.9e-14	-0.43	-0.37	Blood metabolite ratios;	chr9:129169441	chr9:129170434~129170940:+
LGG	cis	rs4950322	0.515	rs11239958	ENSG00000278811.3	LINC00624	8.75	3.82e-17	1.9e-14	0.36	0.37	Protein quantitative trait loci;	chr1:147247454	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.515	rs12060046	ENSG00000278811.3	LINC00624	8.75	3.82e-17	1.9e-14	0.36	0.37	Protein quantitative trait loci;	chr1:147249278	chr1:147258885~147517875:-
LGG	cis	rs2281558	0.833	rs6115202	ENSG00000125804.12	FAM182A	8.75	3.82e-17	1.9e-14	0.5	0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:26054655~26086917:+
LGG	cis	rs1707322	1	rs4539075	ENSG00000281133.1	AL355480.3	-8.75	3.82e-17	1.91e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45580892~45580996:-
LGG	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	8.75	3.83e-17	1.91e-14	0.32	0.37	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
LGG	cis	rs853679	0.546	rs200989	ENSG00000199851.2	U3	8.75	3.86e-17	1.93e-14	0.81	0.37	Depression;	chr6:27848664	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs200989	ENSG00000216901.1	AL022393.7	8.75	3.87e-17	1.93e-14	0.72	0.37	Depression;	chr6:27848664	chr6:28176188~28176674:+
LGG	cis	rs35425515	0.706	rs2279510	ENSG00000234855.1	SLIT1-AS1	8.75	3.87e-17	1.93e-14	0.63	0.37	Bipolar disorder;	chr10:97103432	chr10:97102756~97103747:+
LGG	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-8.75	3.88e-17	1.93e-14	-0.46	-0.37	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
LGG	cis	rs1949733	1	rs2631740	ENSG00000205959.3	RP11-689P11.2	8.75	3.88e-17	1.94e-14	0.34	0.37	Response to antineoplastic agents;	chr4:8482379	chr4:8482270~8512610:+
LGG	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-8.75	3.9e-17	1.95e-14	-0.49	-0.37	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
LGG	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	8.74	3.91e-17	1.95e-14	0.54	0.37	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
LGG	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	8.74	3.91e-17	1.95e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
LGG	cis	rs17772222	0.682	rs1152377	ENSG00000258983.2	RP11-507K2.2	-8.74	3.93e-17	1.96e-14	-0.42	-0.37	Coronary artery calcification;	chr14:88496243	chr14:88499334~88515502:+
LGG	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	8.74	3.94e-17	1.97e-14	0.43	0.37	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	8.74	3.94e-17	1.97e-14	0.43	0.37	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	8.74	3.94e-17	1.97e-14	0.43	0.37	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	8.74	3.94e-17	1.97e-14	0.43	0.37	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	8.74	3.94e-17	1.97e-14	0.43	0.37	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	8.74	3.94e-17	1.97e-14	0.43	0.37	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	8.74	3.94e-17	1.97e-14	0.43	0.37	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs9766004	ENSG00000216621.7	RP11-244K5.6	8.74	3.94e-17	1.97e-14	0.44	0.37	Lung cancer;	chr6:149754363	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-8.74	3.96e-17	1.97e-14	-0.44	-0.37	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
LGG	cis	rs6496932	0.503	rs10520588	ENSG00000218052.5	ADAMTS7P4	-8.74	3.97e-17	1.98e-14	-0.54	-0.37	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85255369~85330334:-
LGG	cis	rs6496932	0.503	rs2086756	ENSG00000218052.5	ADAMTS7P4	-8.74	3.97e-17	1.98e-14	-0.54	-0.37	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85255369~85330334:-
LGG	cis	rs3020264	0.669	rs7005662	ENSG00000271743.1	CTD-2541M15.3	8.74	3.98e-17	1.99e-14	0.45	0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6619105	chr8:6615604~6617198:-
LGG	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	8.74	3.99e-17	1.99e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
LGG	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	8.74	3.99e-17	1.99e-14	0.44	0.37	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
LGG	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	8.74	3.99e-17	1.99e-14	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
LGG	cis	rs889122	0.765	rs10425422	ENSG00000267289.1	CTD-2623N2.11	8.74	3.99e-17	1.99e-14	0.47	0.37	Menarche (age at onset);	chr19:9872345	chr19:9834079~9835013:-
LGG	cis	rs889122	0.684	rs1978453	ENSG00000267289.1	CTD-2623N2.11	8.74	3.99e-17	1.99e-14	0.47	0.37	Menarche (age at onset);	chr19:9872769	chr19:9834079~9835013:-
LGG	cis	rs889122	0.729	rs10413248	ENSG00000267289.1	CTD-2623N2.11	8.74	3.99e-17	1.99e-14	0.47	0.37	Menarche (age at onset);	chr19:9873420	chr19:9834079~9835013:-
LGG	cis	rs7523050	0.643	rs12752417	ENSG00000203897.3	SPATA42	8.74	3.99e-17	1.99e-14	0.69	0.37	Fat distribution (HIV);	chr1:108858017	chr1:108857217~108858524:+
LGG	cis	rs12682352	0.602	rs13260419	ENSG00000173295.6	FAM86B3P	-8.74	4.01e-17	2e-14	-0.4	-0.37	Neuroticism;	chr8:8817666	chr8:8228595~8244865:+
LGG	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	8.74	4.01e-17	2e-14	0.37	0.37	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
LGG	cis	rs2281558	0.583	rs11087526	ENSG00000125804.12	FAM182A	-8.74	4.02e-17	2e-14	-0.58	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25667380	chr20:26054655~26086917:+
LGG	cis	rs227275	0.556	rs28367331	ENSG00000230069.3	LRRC37A15P	-8.74	4.02e-17	2e-14	-0.36	-0.37	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102727274~102730721:-
LGG	cis	rs8062405	0.573	rs6565300	ENSG00000271623.1	RP11-435I10.5	-8.74	4.03e-17	2.01e-14	-0.49	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28364700~28365333:+
LGG	cis	rs6496932	1	rs34434405	ENSG00000218052.5	ADAMTS7P4	8.74	4.04e-17	2.01e-14	0.55	0.37	Central corneal thickness;Corneal structure;	chr15:85281437	chr15:85255369~85330334:-
LGG	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	8.74	4.04e-17	2.01e-14	0.45	0.37	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
LGG	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	8.74	4.05e-17	2.02e-14	0.4	0.37	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
LGG	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	8.74	4.06e-17	2.02e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	8.74	4.06e-17	2.02e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	8.74	4.06e-17	2.02e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
LGG	cis	rs1707322	0.964	rs1707339	ENSG00000281133.1	AL355480.3	8.74	4.07e-17	2.03e-14	0.44	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs1768818	ENSG00000281133.1	AL355480.3	8.74	4.07e-17	2.03e-14	0.44	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs1768817	ENSG00000281133.1	AL355480.3	8.74	4.07e-17	2.03e-14	0.44	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs785470	ENSG00000281133.1	AL355480.3	8.74	4.07e-17	2.03e-14	0.44	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45580892~45580996:-
LGG	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-8.74	4.08e-17	2.03e-14	-0.44	-0.37	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
LGG	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	8.74	4.08e-17	2.03e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	8.74	4.08e-17	2.03e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	8.74	4.08e-17	2.03e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	8.74	4.08e-17	2.03e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	8.74	4.08e-17	2.03e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	8.74	4.08e-17	2.03e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	8.74	4.08e-17	2.03e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
LGG	cis	rs4281086	0.931	rs7846328	ENSG00000253678.1	RP11-981G7.3	-8.74	4.09e-17	2.04e-14	-0.4	-0.37	Obesity-related traits;	chr8:10520975	chr8:10477491~10479375:-
LGG	cis	rs858239	0.539	rs10247268	ENSG00000230042.1	AK3P3	-8.74	4.09e-17	2.04e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs6461694	ENSG00000230042.1	AK3P3	-8.74	4.09e-17	2.04e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23129178~23129841:+
LGG	cis	rs858239	0.508	rs7805071	ENSG00000230042.1	AK3P3	-8.74	4.09e-17	2.04e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23129178~23129841:+
LGG	cis	rs858239	0.508	rs7805085	ENSG00000230042.1	AK3P3	-8.74	4.09e-17	2.04e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23129178~23129841:+
LGG	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	8.74	4.11e-17	2.05e-14	0.55	0.37	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	8.74	4.11e-17	2.05e-14	0.55	0.37	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	8.74	4.12e-17	2.05e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
LGG	cis	rs7247513	0.79	rs17476839	ENSG00000213290.4	PGK1P2	8.74	4.14e-17	2.06e-14	0.4	0.37	Bipolar disorder;	chr19:12651969	chr19:12559571~12561105:+
LGG	cis	rs482329	0.93	rs620462	ENSG00000228044.2	RP4-781K5.4	8.74	4.14e-17	2.06e-14	0.42	0.37	Life threatening arrhythmia;	chr1:234682676	chr1:234646289~234683176:+
LGG	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	8.74	4.15e-17	2.07e-14	0.63	0.37	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
LGG	cis	rs858239	0.536	rs6956974	ENSG00000230042.1	AK3P3	8.74	4.16e-17	2.07e-14	0.39	0.37	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs4559148	ENSG00000230042.1	AK3P3	-8.74	4.18e-17	2.08e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23129178~23129841:+
LGG	cis	rs858239	0.539	rs4377861	ENSG00000230042.1	AK3P3	-8.74	4.18e-17	2.08e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23129178~23129841:+
LGG	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-8.74	4.18e-17	2.08e-14	-0.49	-0.37	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
LGG	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	8.74	4.19e-17	2.08e-14	0.43	0.37	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
LGG	cis	rs9346353	1	rs62408999	ENSG00000219881.1	GAPDHP42	8.74	4.19e-17	2.08e-14	0.36	0.37	Sleep duration;	chr6:69762768	chr6:69745871~69746851:+
LGG	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	8.74	4.19e-17	2.08e-14	0.55	0.37	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
LGG	cis	rs853679	0.546	rs200954	ENSG00000216901.1	AL022393.7	8.74	4.19e-17	2.08e-14	0.72	0.37	Depression;	chr6:27870986	chr6:28176188~28176674:+
LGG	cis	rs2281558	0.876	rs6107025	ENSG00000125804.12	FAM182A	-8.74	4.19e-17	2.08e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299244	chr20:26054655~26086917:+
LGG	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	8.74	4.21e-17	2.09e-14	0.4	0.37	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
LGG	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	8.73	4.22e-17	2.1e-14	0.43	0.37	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	8.73	4.22e-17	2.1e-14	0.43	0.37	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
LGG	cis	rs2412819	0.52	rs17727763	ENSG00000249839.1	AC011330.5	-8.73	4.24e-17	2.11e-14	-0.66	-0.37	Lung cancer;	chr15:43623873	chr15:43663654~43684339:-
LGG	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	8.73	4.25e-17	2.11e-14	0.55	0.37	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
LGG	cis	rs853679	0.546	rs175597	ENSG00000199851.2	U3	8.73	4.25e-17	2.11e-14	0.81	0.37	Depression;	chr6:27842848	chr6:28015568~28015777:+
LGG	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	8.73	4.25e-17	2.11e-14	0.31	0.37	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
LGG	cis	rs7746199	0.736	rs13195636	ENSG00000216901.1	AL022393.7	8.73	4.26e-17	2.12e-14	0.85	0.37	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28176188~28176674:+
LGG	cis	rs1707322	0.927	rs11211194	ENSG00000281133.1	AL355480.3	-8.73	4.26e-17	2.12e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45580892~45580996:-
LGG	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-8.73	4.28e-17	2.13e-14	-0.38	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
LGG	cis	rs7302981	0.746	rs836177	ENSG00000272368.2	RP4-605O3.4	8.73	4.29e-17	2.13e-14	0.36	0.37	Systolic blood pressure;	chr12:50098038	chr12:50112197~50165618:+
LGG	cis	rs853679	0.546	rs175597	ENSG00000216901.1	AL022393.7	8.73	4.29e-17	2.13e-14	0.72	0.37	Depression;	chr6:27842848	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.926	rs11147831	ENSG00000168852.11	TPTE2P5	8.73	4.31e-17	2.14e-14	0.38	0.37	Cervical cancer;	chr13:40978593	chr13:40822296~40921749:-
LGG	cis	rs1949733	1	rs2631745	ENSG00000205959.3	RP11-689P11.2	8.73	4.33e-17	2.15e-14	0.34	0.37	Response to antineoplastic agents;	chr4:8488803	chr4:8482270~8512610:+
LGG	cis	rs17772222	1	rs17698817	ENSG00000222990.1	RNU4-22P	8.73	4.33e-17	2.15e-14	0.48	0.37	Coronary artery calcification;	chr14:88356632	chr14:88513498~88513663:+
LGG	cis	rs1830074	1	rs1830074	ENSG00000187953.9	PMS2CL	-8.73	4.35e-17	2.16e-14	-0.33	-0.37	Body mass index;	chr7:6679043	chr7:6710128~6753862:+
LGG	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	8.73	4.37e-17	2.17e-14	0.36	0.37	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
LGG	cis	rs853679	0.546	rs35353359	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28356601	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs35017208	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28377505	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs13213152	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28381921	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs36092177	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28390030	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs13213986	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28390232	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs2232429	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28391855	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs2232426	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28392882	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs34546986	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28394532	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs34871267	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28396455	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs2232423	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28398374	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs35883476	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28400731	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.673	rs13201681	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.778	rs67381177	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28015568~28015777:+
LGG	cis	rs138024639	1	rs138024639	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Breast cancer;	chr6:28468244	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs55690788	ENSG00000199851.2	U3	8.73	4.38e-17	2.18e-14	0.94	0.37	Depression;	chr6:28468368	chr6:28015568~28015777:+
LGG	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	8.73	4.4e-17	2.18e-14	0.44	0.37	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
LGG	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-8.73	4.4e-17	2.19e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-8.73	4.4e-17	2.19e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
LGG	cis	rs5742933	1	rs12619808	ENSG00000253559.1	OSGEPL1-AS1	-8.73	4.4e-17	2.19e-14	-0.49	-0.37	Ferritin levels;	chr2:189776458	chr2:189762704~189765556:+
LGG	cis	rs2287838	0.967	rs12610468	ENSG00000267289.1	CTD-2623N2.11	-8.73	4.41e-17	2.19e-14	-0.41	-0.37	Sleep duration;	chr19:9878794	chr19:9834079~9835013:-
LGG	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-8.73	4.44e-17	2.2e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-8.73	4.44e-17	2.2e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
LGG	cis	rs893971	0.643	rs17789621	ENSG00000246375.2	RP11-10L7.1	8.73	4.46e-17	2.21e-14	0.45	0.37	Conduct disorder (maternal expressed emotions interaction);	chr4:88305969	chr4:88284942~88331421:+
LGG	cis	rs228614	0.509	rs223486	ENSG00000230069.3	LRRC37A15P	-8.73	4.47e-17	2.22e-14	-0.35	-0.37	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102727274~102730721:-
LGG	cis	rs227275	0.556	rs11731885	ENSG00000248971.2	KRT8P46	-8.73	4.49e-17	2.23e-14	-0.38	-0.37	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102728746~102730171:-
LGG	cis	rs9322193	0.924	rs9322189	ENSG00000216621.7	RP11-244K5.6	8.73	4.49e-17	2.23e-14	0.45	0.37	Lung cancer;	chr6:149588797	chr6:149934527~149936782:+
LGG	cis	rs10208649	0.611	rs1974771	ENSG00000272156.1	RP11-477N3.1	8.73	4.5e-17	2.23e-14	0.64	0.37	Body mass index;	chr2:54051406	chr2:54082554~54085066:+
LGG	cis	rs853679	0.546	rs200995	ENSG00000199851.2	U3	-8.73	4.51e-17	2.24e-14	-0.79	-0.37	Depression;	chr6:27845916	chr6:28015568~28015777:+
LGG	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	8.73	4.51e-17	2.24e-14	0.38	0.37	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
LGG	cis	rs950776	0.667	rs57728226	ENSG00000261762.1	RP11-650L12.2	8.73	4.53e-17	2.24e-14	0.48	0.37	Sudden cardiac arrest;	chr15:78637008	chr15:78589123~78591276:-
LGG	cis	rs9595066	0.627	rs9562536	ENSG00000230731.2	RP11-478K15.6	8.73	4.53e-17	2.24e-14	0.59	0.37	Schizophrenia;	chr13:44157452	chr13:44234118~44243192:-
LGG	cis	rs9393777	0.92	rs35120058	ENSG00000216901.1	AL022393.7	8.73	4.53e-17	2.25e-14	0.81	0.37	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28176188~28176674:+
LGG	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-8.72	4.56e-17	2.26e-14	-0.49	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
LGG	cis	rs9393777	0.92	rs35120058	ENSG00000199851.2	U3	8.72	4.56e-17	2.26e-14	0.91	0.37	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28015568~28015777:+
LGG	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-8.72	4.56e-17	2.26e-14	-0.38	-0.37	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
LGG	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-8.72	4.57e-17	2.26e-14	-0.37	-0.37	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
LGG	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	8.72	4.57e-17	2.26e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	8.72	4.57e-17	2.26e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	8.72	4.57e-17	2.26e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	8.72	4.57e-17	2.26e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
LGG	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	8.72	4.57e-17	2.26e-14	0.37	0.37	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
LGG	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	-8.72	4.57e-17	2.27e-14	-0.39	-0.37	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
LGG	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	8.72	4.57e-17	2.27e-14	0.45	0.37	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
LGG	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-8.72	4.58e-17	2.27e-14	-0.41	-0.37	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
LGG	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-8.72	4.58e-17	2.27e-14	-0.49	-0.37	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
LGG	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	8.72	4.58e-17	2.27e-14	0.46	0.37	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
LGG	cis	rs9322193	0.884	rs11155675	ENSG00000216621.7	RP11-244K5.6	8.72	4.59e-17	2.27e-14	0.47	0.37	Lung cancer;	chr6:149742883	chr6:149934527~149936782:+
LGG	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	8.72	4.59e-17	2.27e-14	0.45	0.37	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
LGG	cis	rs5742933	1	rs4666783	ENSG00000253559.1	OSGEPL1-AS1	-8.72	4.62e-17	2.29e-14	-0.46	-0.37	Ferritin levels;	chr2:189748254	chr2:189762704~189765556:+
LGG	cis	rs6921919	0.515	rs1339898	ENSG00000199851.2	U3	8.72	4.64e-17	2.3e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28015568~28015777:+
LGG	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-8.72	4.65e-17	2.3e-14	-0.38	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
LGG	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	8.72	4.65e-17	2.3e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	8.72	4.65e-17	2.3e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
LGG	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	8.72	4.66e-17	2.31e-14	0.45	0.37	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
LGG	cis	rs4950322	0.515	rs76327075	ENSG00000278811.3	LINC00624	8.72	4.66e-17	2.31e-14	0.36	0.37	Protein quantitative trait loci;	chr1:147246319	chr1:147258885~147517875:-
LGG	cis	rs17772222	0.917	rs1956406	ENSG00000222990.1	RNU4-22P	8.72	4.66e-17	2.31e-14	0.49	0.37	Coronary artery calcification;	chr14:88749711	chr14:88513498~88513663:+
LGG	cis	rs7829975	0.557	rs7816427	ENSG00000173295.6	FAM86B3P	8.72	4.67e-17	2.31e-14	0.41	0.37	Mood instability;	chr8:8688374	chr8:8228595~8244865:+
LGG	cis	rs66823261	0.741	rs7841786	ENSG00000223508.5	RPL23AP53	8.72	4.67e-17	2.31e-14	0.41	0.37	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:213186~232231:-
LGG	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	8.72	4.68e-17	2.32e-14	0.5	0.37	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
LGG	cis	rs9346353	1	rs9346339	ENSG00000219881.1	GAPDHP42	8.72	4.68e-17	2.32e-14	0.35	0.37	Sleep duration;	chr6:69734238	chr6:69745871~69746851:+
LGG	cis	rs34119086	1	rs34119086	ENSG00000199851.2	U3	8.72	4.69e-17	2.32e-14	0.94	0.37	Breast cancer;	chr6:28594471	chr6:28015568~28015777:+
LGG	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	8.72	4.7e-17	2.33e-14	0.39	0.37	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
LGG	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	8.72	4.72e-17	2.33e-14	0.55	0.37	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
LGG	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	8.72	4.72e-17	2.34e-14	0.45	0.37	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
LGG	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	8.72	4.74e-17	2.34e-14	0.45	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
LGG	cis	rs9393777	0.92	rs13195040	ENSG00000216901.1	AL022393.7	-8.72	4.74e-17	2.34e-14	-0.8	-0.37	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28176188~28176674:+
LGG	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	8.72	4.75e-17	2.35e-14	0.37	0.37	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
LGG	cis	rs17807185	0.653	rs9641271	ENSG00000214293.7	APTR	8.72	4.75e-17	2.35e-14	0.36	0.37	Height;	chr7:77668098	chr7:77657660~77696265:-
LGG	cis	rs4281086	0.775	rs7835667	ENSG00000253678.1	RP11-981G7.3	8.72	4.75e-17	2.35e-14	0.41	0.37	Obesity-related traits;	chr8:10524161	chr8:10477491~10479375:-
LGG	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	8.72	4.77e-17	2.36e-14	0.57	0.37	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
LGG	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	8.72	4.77e-17	2.36e-14	0.43	0.37	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
LGG	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	-8.72	4.78e-17	2.36e-14	-0.4	-0.37	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
LGG	cis	rs651907	0.535	rs13085776	ENSG00000256628.3	ZBTB11-AS1	8.72	4.78e-17	2.36e-14	0.47	0.37	Colorectal cancer;	chr3:101786663	chr3:101676475~101679217:+
LGG	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	8.72	4.78e-17	2.37e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	8.72	4.78e-17	2.37e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	8.72	4.78e-17	2.37e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	8.72	4.78e-17	2.37e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
LGG	cis	rs6903823	0.508	rs1150721	ENSG00000218016.2	ZNF192P2	-8.72	4.82e-17	2.38e-14	-0.45	-0.37	Pulmonary function;	chr6:28287263	chr6:28188050~28189432:+
LGG	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	8.72	4.82e-17	2.38e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
LGG	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	-8.72	4.82e-17	2.39e-14	-0.37	-0.37	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
LGG	cis	rs853679	0.546	rs200948	ENSG00000199851.2	U3	8.72	4.83e-17	2.39e-14	0.81	0.37	Depression;	chr6:27867494	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs200950	ENSG00000199851.2	U3	8.72	4.83e-17	2.39e-14	0.81	0.37	Depression;	chr6:27867994	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs200952	ENSG00000199851.2	U3	8.72	4.83e-17	2.39e-14	0.81	0.37	Depression;	chr6:27869198	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs3800328	ENSG00000199851.2	U3	8.72	4.83e-17	2.39e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.609	rs67211468	ENSG00000199851.2	U3	8.72	4.83e-17	2.39e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs35560946	ENSG00000199851.2	U3	8.72	4.83e-17	2.39e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs740622	ENSG00000199851.2	U3	8.72	4.83e-17	2.39e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	8.72	4.83e-17	2.39e-14	0.43	0.37	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
LGG	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-8.72	4.84e-17	2.39e-14	-0.49	-0.37	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
LGG	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
LGG	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	8.72	4.84e-17	2.39e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
LGG	cis	rs6921919	0.583	rs7740351	ENSG00000199851.2	U3	8.72	4.85e-17	2.4e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs16894108	ENSG00000199851.2	U3	8.72	4.85e-17	2.4e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28015568~28015777:+
LGG	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	8.72	4.86e-17	2.4e-14	0.25	0.37	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
LGG	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-8.72	4.87e-17	2.41e-14	-0.35	-0.37	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
LGG	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-8.72	4.87e-17	2.41e-14	-0.48	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
LGG	cis	rs893971	0.643	rs7677533	ENSG00000246375.2	RP11-10L7.1	8.72	4.88e-17	2.41e-14	0.45	0.37	Conduct disorder (maternal expressed emotions interaction);	chr4:88306766	chr4:88284942~88331421:+
LGG	cis	rs2075466	0.588	rs111618721	ENSG00000267077.1	RP11-127I20.5	8.72	4.88e-17	2.41e-14	0.52	0.37	Colonoscopy-negative controls vs population controls;	chr16:4827865	chr16:4795265~4796532:-
LGG	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	8.72	4.89e-17	2.42e-14	0.39	0.37	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
LGG	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	8.71	4.91e-17	2.43e-14	0.43	0.37	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
LGG	cis	rs228614	0.51	rs223452	ENSG00000230069.3	LRRC37A15P	-8.71	4.93e-17	2.44e-14	-0.35	-0.37	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102727274~102730721:-
LGG	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	8.71	4.94e-17	2.44e-14	0.43	0.37	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
LGG	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-8.71	4.94e-17	2.44e-14	-0.46	-0.37	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.533	rs35900578	ENSG00000253893.2	FAM85B	-8.71	4.95e-17	2.45e-14	-0.46	-0.37	Mood instability;	chr8:8862003	chr8:8167819~8226614:-
LGG	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	-8.71	4.95e-17	2.45e-14	-0.4	-0.37	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
LGG	cis	rs1949733	1	rs1949733	ENSG00000205959.3	RP11-689P11.2	8.71	4.96e-17	2.45e-14	0.34	0.37	Response to antineoplastic agents;	chr4:8501632	chr4:8482270~8512610:+
LGG	cis	rs944990	0.557	rs10821155	ENSG00000227603.1	RP11-165J3.6	8.71	4.96e-17	2.45e-14	0.38	0.37	Body mass index;	chr9:93541996	chr9:93435332~93437121:-
LGG	cis	rs12899811	0.512	rs7164916	ENSG00000214432.8	AC068831.10	-8.71	4.96e-17	2.45e-14	-0.38	-0.37	Type 2 diabetes;	chr15:91018216	chr15:91022619~91036611:+
LGG	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	8.71	5e-17	2.47e-14	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
LGG	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-8.71	5e-17	2.47e-14	-0.51	-0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
LGG	cis	rs9810089	0.749	rs664088	ENSG00000261758.1	RP11-102M11.2	8.71	5e-17	2.47e-14	0.4	0.37	Gestational age at birth (child effect);	chr3:136318144	chr3:136752630~136755780:+
LGG	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	8.71	5e-17	2.47e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	8.71	5e-17	2.47e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
LGG	cis	rs1707322	0.686	rs2050376	ENSG00000281133.1	AL355480.3	-8.71	5.02e-17	2.48e-14	-0.48	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45580892~45580996:-
LGG	cis	rs2287838	0.967	rs11669872	ENSG00000267289.1	CTD-2623N2.11	-8.71	5.02e-17	2.48e-14	-0.41	-0.37	Sleep duration;	chr19:9875848	chr19:9834079~9835013:-
LGG	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	8.71	5.02e-17	2.48e-14	0.73	0.37	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
LGG	cis	rs1707322	1	rs785469	ENSG00000281133.1	AL355480.3	8.71	5.04e-17	2.49e-14	0.44	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs785468	ENSG00000281133.1	AL355480.3	8.71	5.04e-17	2.49e-14	0.44	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45580892~45580996:-
LGG	cis	rs6997458	0.713	rs703	ENSG00000253549.4	RP11-317J10.2	8.71	5.04e-17	2.49e-14	0.3	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85477174	chr8:85441851~85464915:-
LGG	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-8.71	5.05e-17	2.49e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
LGG	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	8.71	5.06e-17	2.5e-14	0.39	0.37	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
LGG	cis	rs6081541	0.689	rs723768	ENSG00000179447.2	RP5-1027G4.3	-8.71	5.06e-17	2.5e-14	-0.45	-0.37	Psychosis (atypical);	chr20:19234998	chr20:19242302~19284596:-
LGG	cis	rs6545883	0.524	rs2694618	ENSG00000273302.1	RP11-493E12.2	8.71	5.06e-17	2.5e-14	0.32	0.37	Tuberculosis;	chr2:61309849	chr2:61199979~61200769:+
LGG	cis	rs9532669	0.926	rs4942007	ENSG00000239827.7	SUGT1P3	-8.71	5.07e-17	2.5e-14	-0.4	-0.37	Cervical cancer;	chr13:40871887	chr13:40908159~40921774:-
LGG	cis	rs1707322	0.752	rs11488313	ENSG00000281133.1	AL355480.3	-8.71	5.1e-17	2.52e-14	-0.47	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45580892~45580996:-
LGG	cis	rs9810089	1	rs9810089	ENSG00000261758.1	RP11-102M11.2	-8.71	5.14e-17	2.53e-14	-0.4	-0.37	Gestational age at birth (child effect);	chr3:136088767	chr3:136752630~136755780:+
LGG	cis	rs9810089	1	rs1278493	ENSG00000261758.1	RP11-102M11.2	-8.71	5.14e-17	2.53e-14	-0.4	-0.37	Gestational age at birth (child effect);	chr3:136095167	chr3:136752630~136755780:+
LGG	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-8.71	5.14e-17	2.53e-14	-0.38	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
LGG	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	8.71	5.15e-17	2.54e-14	0.38	0.37	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
LGG	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	8.71	5.15e-17	2.54e-14	0.5	0.37	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
LGG	cis	rs498872	1	rs498872	ENSG00000255239.1	AP002954.6	8.71	5.15e-17	2.54e-14	0.47	0.37	Glioma;	chr11:118606652	chr11:118688039~118690600:-
LGG	cis	rs9876781	0.874	rs56298324	ENSG00000244380.1	RP11-24C3.2	-8.71	5.16e-17	2.54e-14	-0.47	-0.37	Longevity;	chr3:48393626	chr3:48440352~48446656:-
LGG	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	8.71	5.17e-17	2.55e-14	0.61	0.37	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
LGG	cis	rs9987353	0.519	rs13276350	ENSG00000173295.6	FAM86B3P	8.71	5.17e-17	2.55e-14	0.4	0.37	Recombination measurement;	chr8:9205647	chr8:8228595~8244865:+
LGG	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-8.71	5.18e-17	2.56e-14	-0.49	-0.37	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
LGG	cis	rs6496932	1	rs35796484	ENSG00000218052.5	ADAMTS7P4	8.71	5.21e-17	2.57e-14	0.56	0.37	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85255369~85330334:-
LGG	cis	rs62184315	0.629	rs5743072	ENSG00000253559.1	OSGEPL1-AS1	-8.71	5.23e-17	2.58e-14	-0.51	-0.37	Alcohol dependence (age at onset);	chr2:189832198	chr2:189762704~189765556:+
LGG	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	8.71	5.24e-17	2.58e-14	0.45	0.37	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
LGG	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-8.71	5.25e-17	2.59e-14	-0.45	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
LGG	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	8.71	5.26e-17	2.59e-14	0.63	0.37	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
LGG	cis	rs1707322	1	rs4390216	ENSG00000281133.1	AL355480.3	-8.71	5.27e-17	2.6e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.964	rs10437063	ENSG00000281133.1	AL355480.3	-8.71	5.27e-17	2.6e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs6676982	ENSG00000281133.1	AL355480.3	-8.71	5.27e-17	2.6e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45580892~45580996:-
LGG	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-8.71	5.27e-17	2.6e-14	-0.49	-0.37	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
LGG	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	8.71	5.28e-17	2.6e-14	0.45	0.37	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
LGG	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	8.71	5.28e-17	2.6e-14	0.44	0.37	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
LGG	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	8.71	5.29e-17	2.61e-14	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
LGG	cis	rs9346353	1	rs9294851	ENSG00000219881.1	GAPDHP42	-8.7	5.3e-17	2.61e-14	-0.36	-0.37	Sleep duration;	chr6:69747737	chr6:69745871~69746851:+
LGG	cis	rs893363	0.61	rs893362	ENSG00000271916.1	RP11-884K10.6	-8.7	5.32e-17	2.62e-14	-0.46	-0.37	Axial length;	chr3:53813767	chr3:53797764~53798019:-
LGG	cis	rs6545883	0.524	rs17482440	ENSG00000273302.1	RP11-493E12.2	-8.7	5.33e-17	2.63e-14	-0.32	-0.37	Tuberculosis;	chr2:61321722	chr2:61199979~61200769:+
LGG	cis	rs733592	0.507	rs7299704	ENSG00000258273.1	RP11-370I10.4	-8.7	5.33e-17	2.63e-14	-0.45	-0.37	Plateletcrit;	chr12:48050705	chr12:48333755~48333901:-
LGG	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	8.7	5.33e-17	2.63e-14	0.3	0.37	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
LGG	cis	rs17772222	0.917	rs61986664	ENSG00000222990.1	RNU4-22P	8.7	5.35e-17	2.64e-14	0.49	0.37	Coronary artery calcification;	chr14:88711251	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.876	rs61986665	ENSG00000222990.1	RNU4-22P	8.7	5.35e-17	2.64e-14	0.49	0.37	Coronary artery calcification;	chr14:88711354	chr14:88513498~88513663:+
LGG	cis	rs2281558	0.837	rs56238023	ENSG00000125804.12	FAM182A	-8.7	5.35e-17	2.64e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:26054655~26086917:+
LGG	cis	rs2281558	0.833	rs55792313	ENSG00000125804.12	FAM182A	-8.7	5.35e-17	2.64e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25540619	chr20:26054655~26086917:+
LGG	cis	rs2281558	0.833	rs12480853	ENSG00000125804.12	FAM182A	-8.7	5.35e-17	2.64e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25542323	chr20:26054655~26086917:+
LGG	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	8.7	5.36e-17	2.64e-14	0.46	0.37	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
LGG	cis	rs853679	0.546	rs200954	ENSG00000199851.2	U3	8.7	5.37e-17	2.65e-14	0.81	0.37	Depression;	chr6:27870986	chr6:28015568~28015777:+
LGG	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	8.7	5.38e-17	2.65e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	8.7	5.38e-17	2.65e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	8.7	5.38e-17	2.65e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	8.7	5.38e-17	2.65e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	8.7	5.38e-17	2.65e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	8.7	5.38e-17	2.65e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	8.7	5.38e-17	2.65e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
LGG	cis	rs1538970	0.504	rs3790585	ENSG00000280836.1	AL355480.1	-8.7	5.39e-17	2.66e-14	-0.58	-0.37	Platelet count;	chr1:45557684	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	8.7	5.39e-17	2.66e-14	0.44	0.37	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
LGG	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	8.7	5.39e-17	2.66e-14	0.39	0.37	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
LGG	cis	rs6545883	0.507	rs62149712	ENSG00000273302.1	RP11-493E12.2	-8.7	5.4e-17	2.66e-14	-0.32	-0.37	Tuberculosis;	chr2:61374137	chr2:61199979~61200769:+
LGG	cis	rs7247513	0.797	rs3815914	ENSG00000213290.4	PGK1P2	-8.7	5.43e-17	2.67e-14	-0.4	-0.37	Bipolar disorder;	chr19:12649850	chr19:12559571~12561105:+
LGG	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	8.7	5.43e-17	2.67e-14	0.49	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
LGG	cis	rs6921919	0.583	rs6928771	ENSG00000199851.2	U3	8.7	5.44e-17	2.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs6928773	ENSG00000199851.2	U3	8.7	5.44e-17	2.68e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28015568~28015777:+
LGG	cis	rs8062405	0.573	rs11645306	ENSG00000271623.1	RP11-435I10.5	8.7	5.47e-17	2.69e-14	0.49	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28364700~28365333:+
LGG	cis	rs9346353	1	rs4707289	ENSG00000219881.1	GAPDHP42	8.7	5.48e-17	2.7e-14	0.35	0.37	Sleep duration;	chr6:69681696	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs1457494	ENSG00000219881.1	GAPDHP42	8.7	5.48e-17	2.7e-14	0.35	0.37	Sleep duration;	chr6:69682283	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs1457493	ENSG00000219881.1	GAPDHP42	8.7	5.48e-17	2.7e-14	0.35	0.37	Sleep duration;	chr6:69682733	chr6:69745871~69746851:+
LGG	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	8.7	5.48e-17	2.7e-14	0.67	0.37	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	8.7	5.48e-17	2.7e-14	0.67	0.37	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	8.7	5.48e-17	2.7e-14	0.67	0.37	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
LGG	cis	rs9875589	0.794	rs2117039	ENSG00000233121.1	VN1R20P	8.7	5.48e-17	2.7e-14	0.37	0.37	Ovarian reserve;	chr3:13921833	chr3:13926813~13927778:+
LGG	cis	rs2281558	0.876	rs12625157	ENSG00000125804.12	FAM182A	-8.7	5.48e-17	2.7e-14	-0.49	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:26054655~26086917:+
LGG	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	8.7	5.51e-17	2.71e-14	0.43	0.37	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
LGG	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	8.7	5.52e-17	2.72e-14	0.32	0.37	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
LGG	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	8.7	5.52e-17	2.72e-14	0.32	0.37	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
LGG	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	8.7	5.52e-17	2.72e-14	0.32	0.37	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
LGG	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	8.7	5.52e-17	2.72e-14	0.32	0.37	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
LGG	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	8.7	5.55e-17	2.73e-14	0.57	0.37	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	8.7	5.55e-17	2.73e-14	0.57	0.37	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	8.7	5.56e-17	2.73e-14	0.52	0.37	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
LGG	cis	rs17772222	0.917	rs8018755	ENSG00000222990.1	RNU4-22P	8.7	5.6e-17	2.75e-14	0.49	0.37	Coronary artery calcification;	chr14:88714249	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs8018630	ENSG00000222990.1	RNU4-22P	8.7	5.6e-17	2.75e-14	0.49	0.37	Coronary artery calcification;	chr14:88714250	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.917	rs8020072	ENSG00000222990.1	RNU4-22P	8.7	5.6e-17	2.75e-14	0.49	0.37	Coronary artery calcification;	chr14:88714332	chr14:88513498~88513663:+
LGG	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-8.7	5.6e-17	2.76e-14	-0.35	-0.37	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
LGG	cis	rs10276381	0.786	rs10281102	ENSG00000234336.5	JAZF1-AS1	-8.7	5.61e-17	2.76e-14	-0.47	-0.37	Crohn's disease;	chr7:28203854	chr7:28180322~28243917:+
LGG	cis	rs763567	0.967	rs736791	ENSG00000271811.1	RP1-79C4.4	-8.7	5.63e-17	2.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170617174	chr1:170667381~170669425:+
LGG	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-8.7	5.63e-17	2.77e-14	-0.47	-0.37	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
LGG	cis	rs9346353	1	rs9354888	ENSG00000219881.1	GAPDHP42	8.7	5.65e-17	2.78e-14	0.35	0.37	Sleep duration;	chr6:69768176	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.931	rs2168713	ENSG00000219881.1	GAPDHP42	8.7	5.65e-17	2.78e-14	0.35	0.37	Sleep duration;	chr6:69768739	chr6:69745871~69746851:+
LGG	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-8.7	5.66e-17	2.78e-14	-0.31	-0.37	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
LGG	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	8.7	5.67e-17	2.79e-14	0.43	0.37	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
LGG	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	8.7	5.68e-17	2.79e-14	0.49	0.37	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
LGG	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	8.7	5.68e-17	2.79e-14	0.49	0.37	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
LGG	cis	rs1609391	0.543	rs9881139	ENSG00000273486.1	RP11-731C17.2	8.7	5.7e-17	2.8e-14	0.36	0.37	Neuroticism;	chr3:136915198	chr3:136837338~136839021:-
LGG	cis	rs6940638	0.956	rs3922717	ENSG00000199851.2	U3	8.7	5.7e-17	2.8e-14	0.6	0.37	Intelligence (multi-trait analysis);	chr6:27063145	chr6:28015568~28015777:+
LGG	cis	rs6940638	0.956	rs13207365	ENSG00000199851.2	U3	8.7	5.7e-17	2.8e-14	0.6	0.37	Intelligence (multi-trait analysis);	chr6:27063201	chr6:28015568~28015777:+
LGG	cis	rs6940638	0.956	rs12203454	ENSG00000199851.2	U3	8.7	5.7e-17	2.8e-14	0.6	0.37	Intelligence (multi-trait analysis);	chr6:27063321	chr6:28015568~28015777:+
LGG	cis	rs6940638	1	rs12204280	ENSG00000199851.2	U3	8.7	5.7e-17	2.8e-14	0.6	0.37	Intelligence (multi-trait analysis);	chr6:27065325	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.583	rs16894060	ENSG00000280107.1	AL022393.9	-8.7	5.71e-17	2.8e-14	-0.38	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28170845~28172521:+
LGG	cis	rs11148252	0.904	rs7321964	ENSG00000235660.1	LINC00345	-8.69	5.72e-17	2.81e-14	-0.46	-0.37	Lewy body disease;	chr13:52466687	chr13:52484161~52484680:-
LGG	cis	rs7474896	0.583	rs11011341	ENSG00000226578.1	RP11-258F22.1	-8.69	5.73e-17	2.82e-14	-0.47	-0.37	Obesity (extreme);	chr10:37709572	chr10:37775371~37784131:-
LGG	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-8.69	5.74e-17	2.82e-14	-0.31	-0.37	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
LGG	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-8.69	5.74e-17	2.82e-14	-0.43	-0.37	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
LGG	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	8.69	5.75e-17	2.82e-14	0.54	0.37	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
LGG	cis	rs6903823	0.508	rs1150724	ENSG00000218016.2	ZNF192P2	-8.69	5.75e-17	2.83e-14	-0.45	-0.37	Pulmonary function;	chr6:28282459	chr6:28188050~28189432:+
LGG	cis	rs17772222	0.917	rs17260408	ENSG00000222990.1	RNU4-22P	8.69	5.76e-17	2.83e-14	0.49	0.37	Coronary artery calcification;	chr14:88715464	chr14:88513498~88513663:+
LGG	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	8.69	5.76e-17	2.83e-14	0.37	0.37	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
LGG	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	8.69	5.78e-17	2.84e-14	0.6	0.37	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
LGG	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	8.69	5.8e-17	2.85e-14	0.46	0.37	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
LGG	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-8.69	5.81e-17	2.85e-14	-0.37	-0.37	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
LGG	cis	rs6921919	0.583	rs740621	ENSG00000199851.2	U3	8.69	5.81e-17	2.86e-14	0.51	0.37	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28015568~28015777:+
LGG	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-8.69	5.82e-17	2.86e-14	-0.49	-0.37	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
LGG	cis	rs6496932	0.503	rs4842882	ENSG00000218052.5	ADAMTS7P4	-8.69	5.83e-17	2.86e-14	-0.53	-0.37	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85255369~85330334:-
LGG	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	8.69	5.83e-17	2.86e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
LGG	cis	rs6921919	0.551	rs13201753	ENSG00000226314.6	ZNF192P1	8.69	5.83e-17	2.87e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28161781~28169594:+
LGG	cis	rs9346353	1	rs3799105	ENSG00000219881.1	GAPDHP42	8.69	5.84e-17	2.87e-14	0.35	0.37	Sleep duration;	chr6:69694389	chr6:69745871~69746851:+
LGG	cis	rs950776	0.745	rs36045869	ENSG00000261762.1	RP11-650L12.2	8.69	5.84e-17	2.87e-14	0.48	0.37	Sudden cardiac arrest;	chr15:78637156	chr15:78589123~78591276:-
LGG	cis	rs9393777	0.92	rs34953377	ENSG00000216901.1	AL022393.7	8.69	5.85e-17	2.87e-14	0.81	0.37	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.778	rs66841633	ENSG00000216901.1	AL022393.7	8.69	5.85e-17	2.87e-14	0.81	0.37	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.841	rs13191474	ENSG00000216901.1	AL022393.7	8.69	5.85e-17	2.87e-14	0.81	0.37	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.92	rs41269265	ENSG00000216901.1	AL022393.7	8.69	5.85e-17	2.87e-14	0.81	0.37	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	8.69	5.85e-17	2.87e-14	0.43	0.37	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
LGG	cis	rs2281558	0.876	rs2274890	ENSG00000125804.12	FAM182A	-8.69	5.85e-17	2.87e-14	-0.49	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:26054655~26086917:+
LGG	cis	rs6940638	0.956	rs12190473	ENSG00000199851.2	U3	8.69	5.86e-17	2.88e-14	0.6	0.37	Intelligence (multi-trait analysis);	chr6:27056908	chr6:28015568~28015777:+
LGG	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-8.69	5.87e-17	2.88e-14	-0.51	-0.37	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
LGG	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-8.69	5.88e-17	2.89e-14	-0.33	-0.37	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
LGG	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-8.69	5.89e-17	2.89e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
LGG	cis	rs875971	0.825	rs59466412	ENSG00000222364.1	RNU6-96P	8.69	5.9e-17	2.9e-14	0.45	0.37	Aortic root size;	chr7:66100371	chr7:66395191~66395286:+
LGG	cis	rs6921919	0.638	rs9468344	ENSG00000280107.1	AL022393.9	-8.69	5.91e-17	2.9e-14	-0.39	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28170845~28172521:+
LGG	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	8.69	5.91e-17	2.9e-14	0.44	0.37	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
LGG	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-8.69	5.92e-17	2.91e-14	-0.57	-0.37	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
LGG	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	8.69	5.95e-17	2.92e-14	0.37	0.37	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
LGG	cis	rs853679	0.546	rs493161	ENSG00000216901.1	AL022393.7	8.69	5.96e-17	2.92e-14	0.72	0.37	Depression;	chr6:27882936	chr6:28176188~28176674:+
LGG	cis	rs7267979	0.714	rs6132825	ENSG00000276952.1	RP5-965G21.6	8.69	5.97e-17	2.93e-14	0.36	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:25284915~25285588:-
LGG	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	8.69	5.97e-17	2.93e-14	0.54	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
LGG	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-8.69	5.99e-17	2.94e-14	-0.54	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
LGG	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	8.69	5.99e-17	2.94e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
LGG	cis	rs9987353	0.62	rs34455383	ENSG00000173295.6	FAM86B3P	8.69	6e-17	2.94e-14	0.42	0.37	Recombination measurement;	chr8:9208948	chr8:8228595~8244865:+
LGG	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	8.69	6.01e-17	2.95e-14	0.46	0.37	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
LGG	cis	rs17772222	0.876	rs12587598	ENSG00000222990.1	RNU4-22P	8.69	6.02e-17	2.95e-14	0.48	0.37	Coronary artery calcification;	chr14:88729474	chr14:88513498~88513663:+
LGG	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	8.69	6.04e-17	2.96e-14	0.57	0.37	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
LGG	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	8.69	6.04e-17	2.96e-14	0.46	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
LGG	cis	rs9393777	0.841	rs67092078	ENSG00000199851.2	U3	8.69	6.06e-17	2.97e-14	0.92	0.37	Intelligence (multi-trait analysis);	chr6:27086993	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.764	rs35565446	ENSG00000199851.2	U3	8.69	6.06e-17	2.97e-14	0.92	0.37	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.777	rs56114371	ENSG00000199851.2	U3	8.69	6.06e-17	2.97e-14	0.92	0.37	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28015568~28015777:+
LGG	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	8.69	6.06e-17	2.97e-14	0.37	0.37	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
LGG	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	8.69	6.07e-17	2.98e-14	0.39	0.37	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
LGG	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-8.69	6.07e-17	2.98e-14	-0.31	-0.37	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
LGG	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-8.69	6.08e-17	2.98e-14	-0.44	-0.37	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
LGG	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-8.69	6.1e-17	2.99e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
LGG	cis	rs1560104	1	rs1560104	ENSG00000274834.1	CTD-3037G24.5	-8.69	6.1e-17	2.99e-14	-0.47	-0.37	Obesity-related traits;	chr16:12614351	chr16:12614451~12614852:+
LGG	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	8.69	6.11e-17	3e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
LGG	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	8.69	6.12e-17	3e-14	0.49	0.37	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
LGG	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	8.69	6.12e-17	3e-14	0.44	0.37	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
LGG	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-8.69	6.12e-17	3e-14	-0.35	-0.37	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
LGG	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	8.69	6.12e-17	3e-14	0.43	0.37	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
LGG	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	8.69	6.12e-17	3e-14	0.54	0.37	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
LGG	cis	rs6940638	0.956	rs12199218	ENSG00000199851.2	U3	8.68	6.17e-17	3.03e-14	0.61	0.37	Intelligence (multi-trait analysis);	chr6:27057502	chr6:28015568~28015777:+
LGG	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	8.68	6.17e-17	3.03e-14	0.46	0.37	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
LGG	cis	rs17772222	0.74	rs11845147	ENSG00000222990.1	RNU4-22P	8.68	6.18e-17	3.03e-14	0.45	0.37	Coronary artery calcification;	chr14:88502804	chr14:88513498~88513663:+
LGG	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-8.68	6.18e-17	3.03e-14	-0.51	-0.37	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
LGG	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-8.68	6.19e-17	3.03e-14	-0.48	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
LGG	cis	rs9532669	0.889	rs9549302	ENSG00000239827.7	SUGT1P3	-8.68	6.2e-17	3.04e-14	-0.4	-0.37	Cervical cancer;	chr13:40843278	chr13:40908159~40921774:-
LGG	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-8.68	6.21e-17	3.04e-14	-0.31	-0.37	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
LGG	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-8.68	6.22e-17	3.05e-14	-0.49	-0.37	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
LGG	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-8.68	6.22e-17	3.05e-14	-0.56	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
LGG	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-8.68	6.23e-17	3.05e-14	-0.49	-0.37	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
LGG	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-8.68	6.23e-17	3.05e-14	-0.49	-0.37	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
LGG	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-8.68	6.23e-17	3.05e-14	-0.49	-0.37	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
LGG	cis	rs9346353	1	rs9360399	ENSG00000219881.1	GAPDHP42	8.68	6.25e-17	3.06e-14	0.35	0.37	Sleep duration;	chr6:69718605	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.9	rs9346337	ENSG00000219881.1	GAPDHP42	8.68	6.25e-17	3.06e-14	0.35	0.37	Sleep duration;	chr6:69733991	chr6:69745871~69746851:+
LGG	cis	rs6545883	0.507	rs10169662	ENSG00000273302.1	RP11-493E12.2	-8.68	6.26e-17	3.07e-14	-0.32	-0.37	Tuberculosis;	chr2:61280801	chr2:61199979~61200769:+
LGG	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	-8.68	6.28e-17	3.07e-14	-0.37	-0.37	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
LGG	cis	rs950776	0.72	rs11637890	ENSG00000261762.1	RP11-650L12.2	-8.68	6.28e-17	3.08e-14	-0.48	-0.37	Sudden cardiac arrest;	chr15:78643077	chr15:78589123~78591276:-
LGG	cis	rs4713118	0.506	rs9366697	ENSG00000199851.2	U3	8.68	6.29e-17	3.08e-14	0.49	0.37	Parkinson's disease;	chr6:27665239	chr6:28015568~28015777:+
LGG	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-8.68	6.31e-17	3.09e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
LGG	cis	rs2251666	0.514	rs75256268	ENSG00000267077.1	RP11-127I20.5	8.68	6.35e-17	3.11e-14	0.52	0.37	Cancer;	chr16:4830907	chr16:4795265~4796532:-
LGG	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	8.68	6.36e-17	3.12e-14	0.44	0.37	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
LGG	cis	rs12444795	0.675	rs74003567	ENSG00000267077.1	RP11-127I20.5	8.68	6.37e-17	3.12e-14	0.55	0.37	Cancer;	chr16:4903054	chr16:4795265~4796532:-
LGG	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-8.68	6.37e-17	3.12e-14	-0.56	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-8.68	6.37e-17	3.12e-14	-0.56	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
LGG	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	8.68	6.38e-17	3.12e-14	0.86	0.37	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
LGG	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-8.68	6.4e-17	3.13e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
LGG	cis	rs1949733	1	rs2631758	ENSG00000205959.3	RP11-689P11.2	8.68	6.4e-17	3.13e-14	0.34	0.37	Response to antineoplastic agents;	chr4:8493577	chr4:8482270~8512610:+
LGG	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-8.68	6.4e-17	3.13e-14	-0.46	-0.37	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
LGG	cis	rs7291412	0.929	rs7289457	ENSG00000231711.2	LINC00899	8.68	6.4e-17	3.13e-14	0.46	0.37	Dupuytren's disease;Subjective well-being;	chr22:46060723	chr22:46039907~46044853:-
LGG	cis	rs62184315	0.536	rs56137655	ENSG00000273240.1	RP11-455J20.3	-8.68	6.41e-17	3.14e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189675844	chr2:189763859~189764456:-
LGG	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	8.68	6.42e-17	3.14e-14	0.58	0.37	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
LGG	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-8.68	6.43e-17	3.15e-14	-0.35	-0.37	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
LGG	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-8.68	6.43e-17	3.15e-14	-0.35	-0.37	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
LGG	cis	rs9393777	0.841	rs34332556	ENSG00000216901.1	AL022393.7	8.68	6.44e-17	3.15e-14	0.81	0.37	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28176188~28176674:+
LGG	cis	rs9346353	0.838	rs9346338	ENSG00000219881.1	GAPDHP42	8.68	6.44e-17	3.15e-14	0.35	0.37	Sleep duration;	chr6:69733996	chr6:69745871~69746851:+
LGG	cis	rs853679	0.527	rs853693	ENSG00000199851.2	U3	8.68	6.5e-17	3.18e-14	0.52	0.37	Depression;	chr6:28314871	chr6:28015568~28015777:+
LGG	cis	rs2013441	0.813	rs4925088	ENSG00000230528.6	NOS2P3	-8.68	6.5e-17	3.18e-14	-0.33	-0.37	Obesity-related traits;	chr17:20146031	chr17:20436337~20447249:+
LGG	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	8.68	6.5e-17	3.18e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	8.68	6.5e-17	3.18e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
LGG	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	8.68	6.51e-17	3.18e-14	0.51	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
LGG	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-8.68	6.52e-17	3.19e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
LGG	cis	rs7927771	0.524	rs10838784	ENSG00000280615.1	Y_RNA	8.68	6.53e-17	3.19e-14	0.44	0.37	Subjective well-being;	chr11:47860789	chr11:47614898~47614994:-
LGG	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	8.68	6.53e-17	3.2e-14	0.43	0.37	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
LGG	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-8.68	6.54e-17	3.2e-14	-0.61	-0.37	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
LGG	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-8.68	6.55e-17	3.2e-14	-0.31	-0.37	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
LGG	cis	rs35851103	0.627	rs58602899	ENSG00000255556.2	RP11-351I21.6	8.68	6.56e-17	3.21e-14	0.45	0.37	Neuroticism;	chr8:11991324	chr8:12378679~12380265:-
LGG	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	8.68	6.61e-17	3.23e-14	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
LGG	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	8.68	6.65e-17	3.25e-14	0.45	0.37	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
LGG	cis	rs7474896	0.583	rs4934898	ENSG00000226578.1	RP11-258F22.1	-8.67	6.65e-17	3.25e-14	-0.48	-0.37	Obesity (extreme);	chr10:37701467	chr10:37775371~37784131:-
LGG	cis	rs6545883	0.524	rs811871	ENSG00000273302.1	RP11-493E12.2	-8.67	6.68e-17	3.26e-14	-0.32	-0.37	Tuberculosis;	chr2:61350814	chr2:61199979~61200769:+
LGG	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	8.67	6.74e-17	3.29e-14	0.51	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
LGG	cis	rs8042680	0.955	rs2034084	ENSG00000214432.8	AC068831.10	-8.67	6.74e-17	3.29e-14	-0.38	-0.37	Type 2 diabetes;	chr15:90963509	chr15:91022619~91036611:+
LGG	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-8.67	6.76e-17	3.3e-14	-0.45	-0.37	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
LGG	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-8.67	6.78e-17	3.31e-14	-0.49	-0.37	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
LGG	cis	rs9876781	1	rs4858793	ENSG00000244380.1	RP11-24C3.2	-8.67	6.79e-17	3.31e-14	-0.46	-0.37	Longevity;	chr3:48373517	chr3:48440352~48446656:-
LGG	cis	rs12073837	0.5	rs4143772	ENSG00000238078.1	LINC01352	-8.67	6.81e-17	3.33e-14	-0.47	-0.37	F-cell distribution;	chr1:220815004	chr1:220829255~220832429:+
LGG	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-8.67	6.81e-17	3.33e-14	-0.49	-0.37	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
LGG	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	8.67	6.82e-17	3.33e-14	0.43	0.37	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
LGG	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-8.67	6.84e-17	3.34e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-8.67	6.84e-17	3.34e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-8.67	6.84e-17	3.34e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-8.67	6.84e-17	3.34e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-8.67	6.84e-17	3.34e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-8.67	6.84e-17	3.34e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
LGG	cis	rs12554020	0.786	rs78547192	ENSG00000227603.1	RP11-165J3.6	8.67	6.87e-17	3.35e-14	0.7	0.37	Schizophrenia;	chr9:93597221	chr9:93435332~93437121:-
LGG	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-8.67	6.88e-17	3.35e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-8.67	6.88e-17	3.35e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
LGG	cis	rs1707322	1	rs785465	ENSG00000281133.1	AL355480.3	-8.67	6.89e-17	3.36e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45580892~45580996:-
LGG	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	8.67	6.91e-17	3.37e-14	0.32	0.37	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
LGG	cis	rs6921919	0.638	rs9468344	ENSG00000218016.2	ZNF192P2	-8.67	6.93e-17	3.38e-14	-0.46	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28188050~28189432:+
LGG	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	8.67	6.93e-17	3.38e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	8.67	6.93e-17	3.38e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	8.67	6.93e-17	3.38e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	8.67	6.93e-17	3.38e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	8.67	6.93e-17	3.38e-14	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
LGG	cis	rs9346353	1	rs3799106	ENSG00000219881.1	GAPDHP42	8.67	6.94e-17	3.38e-14	0.35	0.37	Sleep duration;	chr6:69694872	chr6:69745871~69746851:+
LGG	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	8.67	6.95e-17	3.39e-14	0.47	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
LGG	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-8.67	6.95e-17	3.39e-14	-0.84	-0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
LGG	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	8.67	6.96e-17	3.39e-14	0.35	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
LGG	cis	rs6802315	0.863	rs2364921	ENSG00000272247.1	RP11-379F4.9	-8.67	6.97e-17	3.4e-14	-0.42	-0.37	Periodontitis (CDC/AAP);	chr3:158804674	chr3:158801257~158801935:-
LGG	cis	rs9532669	0.89	rs11619117	ENSG00000239827.7	SUGT1P3	-8.67	6.97e-17	3.4e-14	-0.38	-0.37	Cervical cancer;	chr13:40880020	chr13:40908159~40921774:-
LGG	cis	rs17597773	0.527	rs1537806	ENSG00000238078.1	LINC01352	-8.67	6.97e-17	3.4e-14	-0.46	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910880	chr1:220829255~220832429:+
LGG	cis	rs2251666	0.514	rs17630889	ENSG00000267077.1	RP11-127I20.5	8.67	6.98e-17	3.4e-14	0.52	0.37	Cancer;	chr16:4831208	chr16:4795265~4796532:-
LGG	cis	rs9346353	0.932	rs9364049	ENSG00000219881.1	GAPDHP42	8.67	7.02e-17	3.42e-14	0.35	0.37	Sleep duration;	chr6:69695189	chr6:69745871~69746851:+
LGG	cis	rs1949733	1	rs1916326	ENSG00000205959.3	RP11-689P11.2	8.67	7.02e-17	3.42e-14	0.34	0.37	Response to antineoplastic agents;	chr4:8498296	chr4:8482270~8512610:+
LGG	cis	rs1949733	1	rs6837429	ENSG00000205959.3	RP11-689P11.2	-8.67	7.02e-17	3.42e-14	-0.34	-0.37	Response to antineoplastic agents;	chr4:8500647	chr4:8482270~8512610:+
LGG	cis	rs1949733	1	rs6447875	ENSG00000205959.3	RP11-689P11.2	-8.67	7.02e-17	3.42e-14	-0.34	-0.37	Response to antineoplastic agents;	chr4:8501479	chr4:8482270~8512610:+
LGG	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	8.67	7.04e-17	3.43e-14	0.53	0.37	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-8.67	7.04e-17	3.43e-14	-0.43	-0.37	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
LGG	cis	rs77204473	0.744	rs12421425	ENSG00000254851.1	RP11-109L13.1	8.67	7.07e-17	3.45e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117131244	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	8.67	7.07e-17	3.45e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	8.67	7.07e-17	3.45e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	8.67	7.07e-17	3.45e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	8.67	7.07e-17	3.45e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.683	rs113281309	ENSG00000216621.7	RP11-244K5.6	8.67	7.08e-17	3.45e-14	0.44	0.37	Lung cancer;	chr6:149787289	chr6:149934527~149936782:+
LGG	cis	rs17345786	0.798	rs1609159	ENSG00000244119.1	PDCL3P4	8.67	7.09e-17	3.45e-14	0.3	0.37	Colonoscopy-negative controls vs population controls;	chr3:101557058	chr3:101712472~101713191:+
LGG	cis	rs9346353	0.966	rs4706272	ENSG00000219881.1	GAPDHP42	8.67	7.12e-17	3.47e-14	0.35	0.37	Sleep duration;	chr6:69680391	chr6:69745871~69746851:+
LGG	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-8.67	7.14e-17	3.48e-14	-0.46	-0.37	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
LGG	cis	rs35934224	0.891	rs73148965	ENSG00000232926.1	AC000078.5	8.67	7.14e-17	3.48e-14	0.46	0.37	Glaucoma (primary open-angle);	chr22:19885412	chr22:19887289~19887970:+
LGG	cis	rs7474896	0.526	rs1208716	ENSG00000226578.1	RP11-258F22.1	-8.67	7.15e-17	3.48e-14	-0.5	-0.37	Obesity (extreme);	chr10:37800345	chr10:37775371~37784131:-
LGG	cis	rs7474896	0.559	rs1212108	ENSG00000226578.1	RP11-258F22.1	-8.67	7.15e-17	3.48e-14	-0.5	-0.37	Obesity (extreme);	chr10:37805394	chr10:37775371~37784131:-
LGG	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	8.66	7.17e-17	3.49e-14	0.57	0.37	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
LGG	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	8.66	7.17e-17	3.49e-14	0.37	0.37	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
LGG	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	8.66	7.17e-17	3.49e-14	0.37	0.37	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
LGG	cis	rs9322193	0.923	rs10872645	ENSG00000216621.7	RP11-244K5.6	8.66	7.19e-17	3.5e-14	0.44	0.37	Lung cancer;	chr6:149742840	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs12211511	ENSG00000216621.7	RP11-244K5.6	8.66	7.19e-17	3.5e-14	0.44	0.37	Lung cancer;	chr6:149745206	chr6:149934527~149936782:+
LGG	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	8.66	7.2e-17	3.51e-14	0.44	0.37	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
LGG	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	8.66	7.2e-17	3.51e-14	0.44	0.37	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
LGG	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	8.66	7.2e-17	3.51e-14	0.44	0.37	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
LGG	cis	rs1420956	0.967	rs9955609	ENSG00000264151.4	RP11-739N10.1	8.66	7.22e-17	3.51e-14	0.46	0.37	Obesity-related traits;	chr18:27582895	chr18:27336379~27595164:-
LGG	cis	rs7208859	0.573	rs8078182	ENSG00000266490.1	CTD-2349P21.9	8.66	7.22e-17	3.52e-14	0.43	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30792372~30792833:+
LGG	cis	rs7829975	0.511	rs2948286	ENSG00000253981.4	ALG1L13P	-8.66	7.23e-17	3.52e-14	-0.39	-0.37	Mood instability;	chr8:8272638	chr8:8236003~8244667:-
LGG	cis	rs7247513	0.79	rs8112964	ENSG00000213290.4	PGK1P2	-8.66	7.25e-17	3.53e-14	-0.4	-0.37	Bipolar disorder;	chr19:12641359	chr19:12559571~12561105:+
LGG	cis	rs7927771	0.524	rs10838782	ENSG00000280615.1	Y_RNA	8.66	7.25e-17	3.53e-14	0.45	0.37	Subjective well-being;	chr11:47856248	chr11:47614898~47614994:-
LGG	cis	rs9532669	0.926	rs9532690	ENSG00000168852.11	TPTE2P5	8.66	7.28e-17	3.55e-14	0.37	0.37	Cervical cancer;	chr13:40968654	chr13:40822296~40921749:-
LGG	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	8.66	7.29e-17	3.55e-14	0.49	0.37	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
LGG	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-8.66	7.29e-17	3.55e-14	-0.32	-0.37	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
LGG	cis	rs8042680	0.688	rs4244883	ENSG00000214432.8	AC068831.10	-8.66	7.3e-17	3.55e-14	-0.39	-0.37	Type 2 diabetes;	chr15:91003267	chr15:91022619~91036611:+
LGG	cis	rs17772222	0.74	rs10143744	ENSG00000222990.1	RNU4-22P	8.66	7.31e-17	3.56e-14	0.44	0.37	Coronary artery calcification;	chr14:88508073	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs1999177	ENSG00000222990.1	RNU4-22P	8.66	7.31e-17	3.56e-14	0.44	0.37	Coronary artery calcification;	chr14:88508298	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs1999176	ENSG00000222990.1	RNU4-22P	8.66	7.31e-17	3.56e-14	0.44	0.37	Coronary artery calcification;	chr14:88508371	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs1864746	ENSG00000222990.1	RNU4-22P	8.66	7.31e-17	3.56e-14	0.44	0.37	Coronary artery calcification;	chr14:88508455	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs1864747	ENSG00000222990.1	RNU4-22P	8.66	7.31e-17	3.56e-14	0.44	0.37	Coronary artery calcification;	chr14:88508523	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs7151164	ENSG00000222990.1	RNU4-22P	8.66	7.31e-17	3.56e-14	0.44	0.37	Coronary artery calcification;	chr14:88509329	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs12433026	ENSG00000222990.1	RNU4-22P	8.66	7.31e-17	3.56e-14	0.44	0.37	Coronary artery calcification;	chr14:88509495	chr14:88513498~88513663:+
LGG	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-8.66	7.32e-17	3.56e-14	-0.45	-0.37	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
LGG	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-8.66	7.32e-17	3.56e-14	-0.45	-0.37	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	8.66	7.32e-17	3.56e-14	0.43	0.37	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
LGG	cis	rs8042680	0.688	rs11073964	ENSG00000214432.8	AC068831.10	-8.66	7.34e-17	3.57e-14	-0.39	-0.37	Type 2 diabetes;	chr15:91000531	chr15:91022619~91036611:+
LGG	cis	rs62184315	0.536	rs62185874	ENSG00000273240.1	RP11-455J20.3	-8.66	7.35e-17	3.58e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189704288	chr2:189763859~189764456:-
LGG	cis	rs12554020	0.786	rs6479482	ENSG00000237385.1	RP11-165J3.5	8.66	7.35e-17	3.58e-14	0.61	0.37	Schizophrenia;	chr9:93435814	chr9:93430342~93431299:-
LGG	cis	rs763567	0.967	rs1952675	ENSG00000271811.1	RP1-79C4.4	-8.66	7.4e-17	3.6e-14	-0.36	-0.37	Tonsillectomy;	chr1:170613434	chr1:170667381~170669425:+
LGG	cis	rs763567	0.967	rs6690642	ENSG00000271811.1	RP1-79C4.4	-8.66	7.4e-17	3.6e-14	-0.36	-0.37	Tonsillectomy;	chr1:170614803	chr1:170667381~170669425:+
LGG	cis	rs812925	0.537	rs10208769	ENSG00000273302.1	RP11-493E12.2	-8.66	7.42e-17	3.61e-14	-0.32	-0.37	Immature fraction of reticulocytes;	chr2:61378479	chr2:61199979~61200769:+
LGG	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	8.66	7.43e-17	3.61e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	8.66	7.43e-17	3.61e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	8.66	7.43e-17	3.61e-14	0.43	0.37	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
LGG	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-8.66	7.43e-17	3.61e-14	-0.46	-0.37	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
LGG	cis	rs5742933	0.69	rs62183656	ENSG00000273240.1	RP11-455J20.3	-8.66	7.44e-17	3.62e-14	-0.55	-0.37	Ferritin levels;	chr2:189669387	chr2:189763859~189764456:-
LGG	cis	rs5742933	0.69	rs62183658	ENSG00000273240.1	RP11-455J20.3	-8.66	7.44e-17	3.62e-14	-0.55	-0.37	Ferritin levels;	chr2:189669491	chr2:189763859~189764456:-
LGG	cis	rs4820294	0.516	rs12627943	ENSG00000233360.4	Z83844.1	8.66	7.45e-17	3.62e-14	0.54	0.37	Fat distribution (HIV);	chr22:37700327	chr22:37641832~37658377:-
LGG	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	8.66	7.48e-17	3.64e-14	0.43	0.37	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
LGG	cis	rs889122	0.765	rs62105756	ENSG00000267289.1	CTD-2623N2.11	8.66	7.49e-17	3.64e-14	0.47	0.37	Menarche (age at onset);	chr19:9863257	chr19:9834079~9835013:-
LGG	cis	rs7474896	0.583	rs10827817	ENSG00000226578.1	RP11-258F22.1	-8.66	7.51e-17	3.65e-14	-0.47	-0.37	Obesity (extreme);	chr10:37709046	chr10:37775371~37784131:-
LGG	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	8.66	7.52e-17	3.65e-14	0.43	0.37	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
LGG	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	8.66	7.52e-17	3.66e-14	0.37	0.37	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	8.66	7.52e-17	3.66e-14	0.37	0.37	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	8.66	7.52e-17	3.66e-14	0.37	0.37	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	8.66	7.52e-17	3.66e-14	0.37	0.37	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	8.66	7.52e-17	3.66e-14	0.37	0.37	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
LGG	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-8.66	7.57e-17	3.68e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
LGG	cis	rs6545883	0.524	rs778159	ENSG00000273302.1	RP11-493E12.2	-8.66	7.59e-17	3.69e-14	-0.32	-0.37	Tuberculosis;	chr2:61329609	chr2:61199979~61200769:+
LGG	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	8.66	7.6e-17	3.69e-14	0.43	0.37	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
LGG	cis	rs6496932	0.503	rs7170370	ENSG00000218052.5	ADAMTS7P4	-8.66	7.61e-17	3.7e-14	-0.53	-0.37	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85255369~85330334:-
LGG	cis	rs62184315	0.536	rs2278591	ENSG00000273240.1	RP11-455J20.3	-8.66	7.61e-17	3.7e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189755778	chr2:189763859~189764456:-
LGG	cis	rs62184315	0.536	rs16831972	ENSG00000273240.1	RP11-455J20.3	-8.66	7.61e-17	3.7e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189756707	chr2:189763859~189764456:-
LGG	cis	rs10276381	0.786	rs740261	ENSG00000234336.5	JAZF1-AS1	-8.66	7.63e-17	3.71e-14	-0.48	-0.37	Crohn's disease;	chr7:28201657	chr7:28180322~28243917:+
LGG	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-8.66	7.64e-17	3.71e-14	-0.37	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-8.66	7.64e-17	3.71e-14	-0.37	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
LGG	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-8.66	7.64e-17	3.71e-14	-0.37	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
LGG	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-8.66	7.67e-17	3.73e-14	-0.38	-0.37	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
LGG	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	8.66	7.67e-17	3.73e-14	0.39	0.37	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
LGG	cis	rs9346353	0.838	rs3799099	ENSG00000219881.1	GAPDHP42	8.66	7.7e-17	3.74e-14	0.35	0.37	Sleep duration;	chr6:69688402	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs12662629	ENSG00000219881.1	GAPDHP42	8.66	7.7e-17	3.74e-14	0.35	0.37	Sleep duration;	chr6:69691950	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs9354879	ENSG00000219881.1	GAPDHP42	8.66	7.7e-17	3.74e-14	0.35	0.37	Sleep duration;	chr6:69691963	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs3799100	ENSG00000219881.1	GAPDHP42	8.66	7.7e-17	3.74e-14	0.35	0.37	Sleep duration;	chr6:69692311	chr6:69745871~69746851:+
LGG	cis	rs17772222	0.876	rs58655091	ENSG00000222990.1	RNU4-22P	8.66	7.71e-17	3.74e-14	0.49	0.37	Coronary artery calcification;	chr14:88748567	chr14:88513498~88513663:+
LGG	cis	rs763567	0.967	rs10919444	ENSG00000271811.1	RP1-79C4.4	-8.66	7.73e-17	3.75e-14	-0.36	-0.37	Tonsillectomy;	chr1:170612493	chr1:170667381~170669425:+
LGG	cis	rs17772222	0.917	rs12588535	ENSG00000222990.1	RNU4-22P	8.66	7.73e-17	3.75e-14	0.49	0.37	Coronary artery calcification;	chr14:88781900	chr14:88513498~88513663:+
LGG	cis	rs6496932	0.503	rs7176605	ENSG00000218052.5	ADAMTS7P4	-8.65	7.74e-17	3.76e-14	-0.53	-0.37	Central corneal thickness;Corneal structure;	chr15:85443491	chr15:85255369~85330334:-
LGG	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	8.65	7.77e-17	3.77e-14	0.51	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
LGG	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	8.65	7.78e-17	3.78e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	8.65	7.78e-17	3.78e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
LGG	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	8.65	7.78e-17	3.78e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
LGG	cis	rs853679	0.607	rs200489	ENSG00000216901.1	AL022393.7	8.65	7.81e-17	3.79e-14	0.71	0.37	Depression;	chr6:27830479	chr6:28176188~28176674:+
LGG	cis	rs2075466	0.588	rs17832589	ENSG00000267077.1	RP11-127I20.5	-8.65	7.82e-17	3.8e-14	-0.51	-0.37	Colonoscopy-negative controls vs population controls;	chr16:4828587	chr16:4795265~4796532:-
LGG	cis	rs45509595	0.822	rs200484	ENSG00000216901.1	AL022393.7	8.65	7.83e-17	3.8e-14	0.7	0.37	Breast cancer;	chr6:27807896	chr6:28176188~28176674:+
LGG	cis	rs1949733	1	rs2140337	ENSG00000205959.3	RP11-689P11.2	-8.65	7.83e-17	3.8e-14	-0.34	-0.37	Response to antineoplastic agents;	chr4:8500385	chr4:8482270~8512610:+
LGG	cis	rs4713118	0.513	rs6915987	ENSG00000216901.1	AL022393.7	-8.65	7.83e-17	3.8e-14	-0.43	-0.37	Parkinson's disease;	chr6:27547997	chr6:28176188~28176674:+
LGG	cis	rs944990	0.576	rs6479484	ENSG00000227603.1	RP11-165J3.6	8.65	7.84e-17	3.81e-14	0.37	0.37	Body mass index;	chr9:93454288	chr9:93435332~93437121:-
LGG	cis	rs733592	0.56	rs2158515	ENSG00000258273.1	RP11-370I10.4	8.65	7.84e-17	3.81e-14	0.44	0.37	Plateletcrit;	chr12:48113885	chr12:48333755~48333901:-
LGG	cis	rs6940638	0.956	rs36048693	ENSG00000199851.2	U3	8.65	7.85e-17	3.81e-14	0.6	0.37	Intelligence (multi-trait analysis);	chr6:27064932	chr6:28015568~28015777:+
LGG	cis	rs858239	0.665	rs6964665	ENSG00000230042.1	AK3P3	-8.65	7.85e-17	3.81e-14	-0.38	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23129178~23129841:+
LGG	cis	rs5742933	1	rs2289404	ENSG00000253559.1	OSGEPL1-AS1	-8.65	7.88e-17	3.82e-14	-0.48	-0.37	Ferritin levels;	chr2:189771288	chr2:189762704~189765556:+
LGG	cis	rs2253762	0.609	rs10887057	ENSG00000276742.1	RP11-500G22.4	8.65	7.89e-17	3.83e-14	0.51	0.37	Breast cancer;	chr10:122043799	chr10:121956782~121957098:+
LGG	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	8.65	7.89e-17	3.83e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
LGG	cis	rs7500321	1	rs7500321	ENSG00000271623.1	RP11-435I10.5	8.65	7.9e-17	3.83e-14	0.49	0.37	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28364700~28365333:+
LGG	cis	rs375066	0.935	rs368089	ENSG00000267191.1	RP11-15A1.2	-8.65	7.92e-17	3.84e-14	-0.39	-0.37	Breast cancer;	chr19:43894932	chr19:43902001~43926545:+
LGG	cis	rs73081554	0.611	rs4681852	ENSG00000272360.1	RP11-359I18.5	-8.65	7.92e-17	3.84e-14	-0.6	-0.37	Rheumatoid arthritis;	chr3:58423446	chr3:58490830~58491291:-
LGG	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-8.65	7.95e-17	3.86e-14	-0.37	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
LGG	cis	rs889122	0.765	rs16996255	ENSG00000267289.1	CTD-2623N2.11	8.65	7.95e-17	3.86e-14	0.48	0.37	Menarche (age at onset);	chr19:9872134	chr19:9834079~9835013:-
LGG	cis	rs950776	0.714	rs3743073	ENSG00000261762.1	RP11-650L12.2	-8.65	7.98e-17	3.87e-14	-0.47	-0.37	Sudden cardiac arrest;	chr15:78617197	chr15:78589123~78591276:-
LGG	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-8.65	7.99e-17	3.87e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
LGG	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-8.65	8.03e-17	3.89e-14	-0.49	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
LGG	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-8.65	8.03e-17	3.89e-14	-0.49	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
LGG	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	8.65	8.03e-17	3.9e-14	0.44	0.37	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
LGG	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	8.65	8.05e-17	3.91e-14	0.32	0.37	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
LGG	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	8.65	8.05e-17	3.91e-14	0.44	0.37	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
LGG	cis	rs7247513	0.701	rs8107642	ENSG00000213290.4	PGK1P2	-8.65	8.07e-17	3.91e-14	-0.4	-0.37	Bipolar disorder;	chr19:12655556	chr19:12559571~12561105:+
LGG	cis	rs7500321	1	rs7500321	ENSG00000251417.2	RP11-1348G14.4	8.65	8.09e-17	3.92e-14	0.48	0.37	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28802743~28817828:+
LGG	cis	rs9532669	0.75	rs9532598	ENSG00000168852.11	TPTE2P5	8.65	8.09e-17	3.92e-14	0.38	0.37	Cervical cancer;	chr13:40860627	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.611	rs9532599	ENSG00000168852.11	TPTE2P5	8.65	8.09e-17	3.92e-14	0.38	0.37	Cervical cancer;	chr13:40860633	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.571	rs9525405	ENSG00000168852.11	TPTE2P5	8.65	8.09e-17	3.92e-14	0.38	0.37	Cervical cancer;	chr13:40860638	chr13:40822296~40921749:-
LGG	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	8.65	8.09e-17	3.92e-14	0.49	0.37	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
LGG	cis	rs651907	0.737	rs9844218	ENSG00000244119.1	PDCL3P4	-8.65	8.09e-17	3.93e-14	-0.3	-0.37	Colorectal cancer;	chr3:101866139	chr3:101712472~101713191:+
LGG	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	8.65	8.13e-17	3.94e-14	0.45	0.37	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
LGG	cis	rs9322193	0.887	rs4870139	ENSG00000216906.2	RP11-350J20.9	8.65	8.14e-17	3.95e-14	0.44	0.37	Lung cancer;	chr6:149575182	chr6:149904243~149906418:+
LGG	cis	rs11148252	0.74	rs9596648	ENSG00000278238.1	RP11-245D16.4	8.65	8.14e-17	3.95e-14	0.36	0.37	Lewy body disease;	chr13:52360434	chr13:52454775~52455331:-
LGG	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-8.65	8.16e-17	3.95e-14	-0.36	-0.37	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
LGG	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	8.65	8.23e-17	3.99e-14	0.44	0.37	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
LGG	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-8.65	8.24e-17	3.99e-14	-0.56	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
LGG	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	8.65	8.24e-17	3.99e-14	0.63	0.37	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
LGG	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-8.65	8.24e-17	4e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
LGG	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	8.65	8.28e-17	4.01e-14	0.44	0.37	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
LGG	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-8.65	8.28e-17	4.01e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-8.65	8.28e-17	4.01e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
LGG	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	8.65	8.31e-17	4.03e-14	0.57	0.37	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
LGG	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-8.65	8.33e-17	4.03e-14	-0.51	-0.37	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
LGG	cis	rs9346353	0.966	rs3799104	ENSG00000219881.1	GAPDHP42	8.65	8.34e-17	4.04e-14	0.35	0.37	Sleep duration;	chr6:69693847	chr6:69745871~69746851:+
LGG	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	8.64	8.35e-17	4.05e-14	0.3	0.37	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
LGG	cis	rs889122	0.68	rs1077220	ENSG00000267289.1	CTD-2623N2.11	-8.64	8.36e-17	4.05e-14	-0.46	-0.37	Menarche (age at onset);	chr19:9836241	chr19:9834079~9835013:-
LGG	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	8.64	8.36e-17	4.05e-14	0.54	0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
LGG	cis	rs4281086	0.965	rs10105841	ENSG00000253678.1	RP11-981G7.3	-8.64	8.36e-17	4.05e-14	-0.4	-0.37	Obesity-related traits;	chr8:10523316	chr8:10477491~10479375:-
LGG	cis	rs1707322	1	rs12077974	ENSG00000281133.1	AL355480.3	-8.64	8.42e-17	4.08e-14	-0.46	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45580892~45580996:-
LGG	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	8.64	8.42e-17	4.08e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	8.64	8.42e-17	4.08e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
LGG	cis	rs8062405	0.573	rs7140	ENSG00000271623.1	RP11-435I10.5	8.64	8.43e-17	4.09e-14	0.49	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28364700~28365333:+
LGG	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	8.64	8.45e-17	4.09e-14	0.39	0.37	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
LGG	cis	rs7927771	0.507	rs10838754	ENSG00000280615.1	Y_RNA	8.64	8.5e-17	4.12e-14	0.44	0.37	Subjective well-being;	chr11:47736980	chr11:47614898~47614994:-
LGG	cis	rs950776	0.714	rs3743074	ENSG00000261762.1	RP11-650L12.2	-8.64	8.5e-17	4.12e-14	-0.47	-0.37	Sudden cardiac arrest;	chr15:78617138	chr15:78589123~78591276:-
LGG	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-8.64	8.55e-17	4.14e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
LGG	cis	rs1949733	1	rs2688233	ENSG00000205959.3	RP11-689P11.2	-8.64	8.58e-17	4.15e-14	-0.34	-0.37	Response to antineoplastic agents;	chr4:8490158	chr4:8482270~8512610:+
LGG	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	8.64	8.65e-17	4.18e-14	0.6	0.37	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
LGG	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	8.64	8.65e-17	4.18e-14	0.6	0.37	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
LGG	cis	rs45509595	0.841	rs9368531	ENSG00000216901.1	AL022393.7	8.64	8.67e-17	4.19e-14	0.7	0.37	Breast cancer;	chr6:27814094	chr6:28176188~28176674:+
LGG	cis	rs45509595	0.749	rs401763	ENSG00000216901.1	AL022393.7	8.64	8.67e-17	4.19e-14	0.7	0.37	Breast cancer;	chr6:27814750	chr6:28176188~28176674:+
LGG	cis	rs45509595	0.659	rs390764	ENSG00000216901.1	AL022393.7	8.64	8.67e-17	4.19e-14	0.7	0.37	Breast cancer;	chr6:27814757	chr6:28176188~28176674:+
LGG	cis	rs45509595	0.841	rs401754	ENSG00000216901.1	AL022393.7	8.64	8.67e-17	4.19e-14	0.7	0.37	Breast cancer;	chr6:27814760	chr6:28176188~28176674:+
LGG	cis	rs45509595	0.841	rs2747054	ENSG00000216901.1	AL022393.7	8.64	8.67e-17	4.19e-14	0.7	0.37	Breast cancer;	chr6:27815581	chr6:28176188~28176674:+
LGG	cis	rs45509595	0.841	rs200501	ENSG00000216901.1	AL022393.7	8.64	8.67e-17	4.19e-14	0.7	0.37	Breast cancer;	chr6:27821164	chr6:28176188~28176674:+
LGG	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-8.64	8.71e-17	4.21e-14	-0.37	-0.37	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
LGG	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-8.64	8.73e-17	4.22e-14	-0.4	-0.37	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
LGG	cis	rs853679	0.76	rs9468317	ENSG00000226314.6	ZNF192P1	8.64	8.74e-17	4.23e-14	0.46	0.37	Depression;	chr6:28230678	chr6:28161781~28169594:+
LGG	cis	rs812925	0.533	rs60997156	ENSG00000273302.1	RP11-493E12.2	8.64	8.75e-17	4.23e-14	0.33	0.37	Immature fraction of reticulocytes;	chr2:61169404	chr2:61199979~61200769:+
LGG	cis	rs812925	0.533	rs35507645	ENSG00000273302.1	RP11-493E12.2	8.64	8.75e-17	4.23e-14	0.33	0.37	Immature fraction of reticulocytes;	chr2:61169631	chr2:61199979~61200769:+
LGG	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-8.64	8.78e-17	4.25e-14	-0.48	-0.37	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
LGG	cis	rs9532669	0.926	rs2324747	ENSG00000168852.11	TPTE2P5	8.64	8.79e-17	4.25e-14	0.38	0.37	Cervical cancer;	chr13:40988883	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs9525439	ENSG00000168852.11	TPTE2P5	8.64	8.79e-17	4.25e-14	0.38	0.37	Cervical cancer;	chr13:40992645	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.89	rs1543589	ENSG00000168852.11	TPTE2P5	8.64	8.79e-17	4.25e-14	0.38	0.37	Cervical cancer;	chr13:40999064	chr13:40822296~40921749:-
LGG	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-8.64	8.84e-17	4.27e-14	-0.38	-0.37	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
LGG	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-8.64	8.85e-17	4.28e-14	-0.49	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
LGG	cis	rs2281558	0.793	rs6115227	ENSG00000125804.12	FAM182A	-8.64	8.86e-17	4.28e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610741	chr20:26054655~26086917:+
LGG	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-8.64	8.88e-17	4.29e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
LGG	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-8.64	8.88e-17	4.29e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
LGG	cis	rs853679	0.567	rs6905380	ENSG00000218016.2	ZNF192P2	-8.64	8.89e-17	4.3e-14	-0.47	-0.37	Depression;	chr6:28407125	chr6:28188050~28189432:+
LGG	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	8.64	8.89e-17	4.3e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
LGG	cis	rs1707322	1	rs946527	ENSG00000281133.1	AL355480.3	-8.64	8.9e-17	4.3e-14	-0.42	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45580892~45580996:-
LGG	cis	rs2739330	0.828	rs2330635	ENSG00000235689.1	AP000351.13	8.63	9.04e-17	4.37e-14	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:24006305~24008258:-
LGG	cis	rs12682352	0.602	rs11783966	ENSG00000173295.6	FAM86B3P	8.63	9.05e-17	4.37e-14	0.39	0.37	Neuroticism;	chr8:8807637	chr8:8228595~8244865:+
LGG	cis	rs6921919	0.515	rs1558205	ENSG00000199851.2	U3	-8.63	9.06e-17	4.37e-14	-0.5	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28015568~28015777:+
LGG	cis	rs1949733	1	rs1357481	ENSG00000205959.3	RP11-689P11.2	-8.63	9.13e-17	4.41e-14	-0.34	-0.37	Response to antineoplastic agents;	chr4:8494494	chr4:8482270~8512610:+
LGG	cis	rs1707322	1	rs4660905	ENSG00000281133.1	AL355480.3	8.63	9.13e-17	4.41e-14	0.44	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45580892~45580996:-
LGG	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-8.63	9.15e-17	4.42e-14	-0.48	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
LGG	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	8.63	9.19e-17	4.44e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
LGG	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	8.63	9.19e-17	4.44e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
LGG	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	8.63	9.19e-17	4.44e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
LGG	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-8.63	9.19e-17	4.44e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
LGG	cis	rs17772222	0.696	rs28666030	ENSG00000222990.1	RNU4-22P	8.63	9.2e-17	4.44e-14	0.45	0.37	Coronary artery calcification;	chr14:88511463	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs28493481	ENSG00000222990.1	RNU4-22P	8.63	9.2e-17	4.44e-14	0.45	0.37	Coronary artery calcification;	chr14:88511491	chr14:88513498~88513663:+
LGG	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	8.63	9.2e-17	4.44e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
LGG	cis	rs35160687	0.644	rs11687392	ENSG00000273080.1	RP11-301O19.1	-8.63	9.25e-17	4.46e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86275540	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs1863058	ENSG00000273080.1	RP11-301O19.1	-8.63	9.25e-17	4.46e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86282144	chr2:86195590~86196049:+
LGG	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-8.63	9.27e-17	4.47e-14	-0.37	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
LGG	cis	rs12682352	0.579	rs7006589	ENSG00000173295.6	FAM86B3P	-8.63	9.29e-17	4.48e-14	-0.39	-0.37	Neuroticism;	chr8:8810976	chr8:8228595~8244865:+
LGG	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	8.63	9.32e-17	4.5e-14	0.41	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
LGG	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-8.63	9.34e-17	4.5e-14	-0.44	-0.37	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
LGG	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	8.63	9.37e-17	4.52e-14	0.61	0.37	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
LGG	cis	rs1707322	0.821	rs11211182	ENSG00000281133.1	AL355480.3	-8.63	9.39e-17	4.53e-14	-0.48	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45580892~45580996:-
LGG	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	8.63	9.4e-17	4.53e-14	0.88	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
LGG	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	8.63	9.42e-17	4.54e-14	0.44	0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
LGG	cis	rs1949733	1	rs868105	ENSG00000205959.3	RP11-689P11.2	8.63	9.45e-17	4.56e-14	0.33	0.37	Response to antineoplastic agents;	chr4:8499303	chr4:8482270~8512610:+
LGG	cis	rs6545883	0.524	rs7561697	ENSG00000273302.1	RP11-493E12.2	-8.63	9.48e-17	4.57e-14	-0.32	-0.37	Tuberculosis;	chr2:61292030	chr2:61199979~61200769:+
LGG	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	8.63	9.49e-17	4.58e-14	0.49	0.37	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
LGG	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-8.63	9.5e-17	4.58e-14	-0.39	-0.37	Height;	chr2:231490121	chr2:231508426~231514339:-
LGG	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-8.63	9.5e-17	4.58e-14	-0.39	-0.37	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
LGG	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-8.63	9.52e-17	4.59e-14	-0.58	-0.37	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
LGG	cis	rs56114371	0.568	rs200468	ENSG00000216901.1	AL022393.7	8.63	9.52e-17	4.59e-14	0.52	0.37	Breast cancer;	chr6:27790076	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	8.63	9.56e-17	4.61e-14	0.43	0.37	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	8.63	9.56e-17	4.61e-14	0.43	0.37	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
LGG	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	8.63	9.59e-17	4.62e-14	0.64	0.37	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
LGG	cis	rs9810089	1	rs1279831	ENSG00000261758.1	RP11-102M11.2	8.63	9.63e-17	4.64e-14	0.39	0.37	Gestational age at birth (child effect);	chr3:136214422	chr3:136752630~136755780:+
LGG	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-8.63	9.66e-17	4.65e-14	-0.37	-0.37	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
LGG	cis	rs763567	1	rs6677540	ENSG00000271811.1	RP1-79C4.4	-8.63	9.67e-17	4.66e-14	-0.36	-0.37	Tonsillectomy;	chr1:170614370	chr1:170667381~170669425:+
LGG	cis	rs893971	0.611	rs1595911	ENSG00000246375.2	RP11-10L7.1	8.63	9.68e-17	4.67e-14	0.45	0.37	Conduct disorder (maternal expressed emotions interaction);	chr4:88311273	chr4:88284942~88331421:+
LGG	cis	rs9987353	0.544	rs2929469	ENSG00000173295.6	FAM86B3P	-8.62	9.72e-17	4.68e-14	-0.39	-0.37	Recombination measurement;	chr8:9205146	chr8:8228595~8244865:+
LGG	cis	rs9346353	1	rs7757883	ENSG00000219881.1	GAPDHP42	8.62	9.72e-17	4.69e-14	0.36	0.37	Sleep duration;	chr6:69735444	chr6:69745871~69746851:+
LGG	cis	rs1949733	0.959	rs2688242	ENSG00000205959.3	RP11-689P11.2	-8.62	9.75e-17	4.7e-14	-0.34	-0.37	Response to antineoplastic agents;	chr4:8428216	chr4:8482270~8512610:+
LGG	cis	rs35160687	0.644	rs9309635	ENSG00000273080.1	RP11-301O19.1	8.62	9.76e-17	4.7e-14	0.39	0.37	Night sleep phenotypes;	chr2:86272279	chr2:86195590~86196049:+
LGG	cis	rs9322193	0.884	rs9371201	ENSG00000216621.7	RP11-244K5.6	8.62	9.77e-17	4.71e-14	0.47	0.37	Lung cancer;	chr6:149823865	chr6:149934527~149936782:+
LGG	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-8.62	9.79e-17	4.71e-14	-0.48	-0.37	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
LGG	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-8.62	9.79e-17	4.71e-14	-0.48	-0.37	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
LGG	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-8.62	9.8e-17	4.72e-14	-0.48	-0.37	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
LGG	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-8.62	9.86e-17	4.75e-14	-0.56	-0.37	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
LGG	cis	rs1707322	1	rs34444543	ENSG00000281133.1	AL355480.3	-8.62	9.88e-17	4.76e-14	-0.44	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45580892~45580996:-
LGG	cis	rs200972	1	rs200972	ENSG00000280107.1	AL022393.9	-8.62	9.89e-17	4.76e-14	-0.37	-0.37	Urinary tract infection frequency;	chr6:27891059	chr6:28170845~28172521:+
LGG	cis	rs763567	1	rs12755237	ENSG00000271811.1	RP1-79C4.4	-8.62	9.9e-17	4.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170599573	chr1:170667381~170669425:+
LGG	cis	rs763567	1	rs12742164	ENSG00000271811.1	RP1-79C4.4	-8.62	9.9e-17	4.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170599755	chr1:170667381~170669425:+
LGG	cis	rs763567	1	rs3903239	ENSG00000271811.1	RP1-79C4.4	-8.62	9.9e-17	4.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170600176	chr1:170667381~170669425:+
LGG	cis	rs763567	1	rs12760630	ENSG00000271811.1	RP1-79C4.4	-8.62	9.9e-17	4.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170600548	chr1:170667381~170669425:+
LGG	cis	rs763567	0.967	rs7412231	ENSG00000271811.1	RP1-79C4.4	-8.62	9.9e-17	4.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170601358	chr1:170667381~170669425:+
LGG	cis	rs763567	1	rs10919437	ENSG00000271811.1	RP1-79C4.4	-8.62	9.9e-17	4.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170603805	chr1:170667381~170669425:+
LGG	cis	rs763567	1	rs2206062	ENSG00000271811.1	RP1-79C4.4	-8.62	9.9e-17	4.77e-14	-0.36	-0.37	Tonsillectomy;	chr1:170606966	chr1:170667381~170669425:+
LGG	cis	rs11098499	0.954	rs6857105	ENSG00000250412.1	KLHL2P1	8.62	9.92e-17	4.78e-14	0.43	0.37	Corneal astigmatism;	chr4:119301143	chr4:119334329~119378233:+
LGG	cis	rs7824557	0.592	rs2572371	ENSG00000184608.7	FAM167A-AS1	-8.62	9.94e-17	4.78e-14	-0.3	-0.37	Retinal vascular caliber;	chr8:11366284	chr8:11368402~11438658:+
LGG	cis	rs4295623	0.531	rs2898295	ENSG00000227888.4	FAM66A	-8.62	9.95e-17	4.79e-14	-0.44	-0.37	Morning vs. evening chronotype;	chr8:11738460	chr8:12362019~12388296:+
LGG	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-8.62	9.99e-17	4.81e-14	-0.45	-0.37	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
LGG	cis	rs35160687	0.644	rs10165626	ENSG00000273080.1	RP11-301O19.1	-8.62	1e-16	4.82e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86309584	chr2:86195590~86196049:+
LGG	cis	rs227275	0.556	rs724447	ENSG00000248971.2	KRT8P46	8.62	1e-16	4.82e-14	0.38	0.37	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102728746~102730171:-
LGG	cis	rs9393777	0.844	rs72839477	ENSG00000216901.1	AL022393.7	8.62	1e-16	4.83e-14	0.84	0.37	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28176188~28176674:+
LGG	cis	rs7267979	0.816	rs3746337	ENSG00000276952.1	RP5-965G21.6	8.62	1e-16	4.84e-14	0.37	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25284915~25285588:-
LGG	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	8.62	1.01e-16	4.87e-14	0.37	0.37	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
LGG	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	8.62	1.01e-16	4.87e-14	0.43	0.37	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
LGG	cis	rs2408955	0.715	rs1793957	ENSG00000258273.1	RP11-370I10.4	-8.62	1.01e-16	4.88e-14	-0.46	-0.37	Glycated hemoglobin levels;	chr12:47999041	chr12:48333755~48333901:-
LGG	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-8.62	1.02e-16	4.89e-14	-0.35	-0.37	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-8.62	1.02e-16	4.89e-14	-0.35	-0.37	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
LGG	cis	rs62184315	0.536	rs62183659	ENSG00000273240.1	RP11-455J20.3	-8.62	1.02e-16	4.9e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189672131	chr2:189763859~189764456:-
LGG	cis	rs62184315	0.536	rs62185869	ENSG00000273240.1	RP11-455J20.3	-8.62	1.02e-16	4.9e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189672330	chr2:189763859~189764456:-
LGG	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	8.62	1.02e-16	4.9e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	8.62	1.02e-16	4.9e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
LGG	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	8.62	1.02e-16	4.9e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
LGG	cis	rs4950322	0.542	rs56080828	ENSG00000278811.3	LINC00624	8.62	1.02e-16	4.91e-14	0.36	0.37	Protein quantitative trait loci;	chr1:147183447	chr1:147258885~147517875:-
LGG	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	8.62	1.02e-16	4.92e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	8.62	1.02e-16	4.92e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	8.62	1.02e-16	4.92e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	8.62	1.02e-16	4.92e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	8.62	1.02e-16	4.92e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	8.62	1.02e-16	4.92e-14	0.58	0.37	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
LGG	cis	rs11148252	0.846	rs13431	ENSG00000235660.1	LINC00345	-8.62	1.03e-16	4.93e-14	-0.45	-0.37	Lewy body disease;	chr13:52413342	chr13:52484161~52484680:-
LGG	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	8.62	1.03e-16	4.94e-14	0.45	0.37	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
LGG	cis	rs9346353	1	rs2305837	ENSG00000219881.1	GAPDHP42	8.62	1.03e-16	4.94e-14	0.35	0.37	Sleep duration;	chr6:69713847	chr6:69745871~69746851:+
LGG	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	8.62	1.04e-16	4.99e-14	0.39	0.37	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
LGG	cis	rs2739330	0.76	rs5751761	ENSG00000272787.1	KB-226F1.2	-8.62	1.04e-16	4.99e-14	-0.39	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23969211~23969873:+
LGG	cis	rs4819052	0.565	rs35776291	ENSG00000215447.6	BX322557.10	-8.62	1.04e-16	5e-14	-0.27	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45288052~45291738:+
LGG	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	8.62	1.04e-16	5.01e-14	0.24	0.37	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
LGG	cis	rs6997458	0.712	rs9987281	ENSG00000253549.4	RP11-317J10.2	-8.62	1.05e-16	5.03e-14	-0.29	-0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85436601	chr8:85441851~85464915:-
LGG	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	8.61	1.05e-16	5.03e-14	0.46	0.37	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-8.61	1.05e-16	5.03e-14	-0.46	-0.37	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-8.61	1.05e-16	5.03e-14	-0.46	-0.37	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-8.61	1.05e-16	5.03e-14	-0.46	-0.37	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-8.61	1.05e-16	5.03e-14	-0.46	-0.37	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
LGG	cis	rs9322193	0.962	rs9322220	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149782897	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs10214845	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149783124	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9767122	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149783553	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs1413654	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149783956	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9688809	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149787920	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9689242	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149787970	chr6:149934527~149936782:+
LGG	cis	rs9322193	1	rs9767077	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149788479	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9688938	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149788941	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9688940	ENSG00000216621.7	RP11-244K5.6	8.61	1.05e-16	5.05e-14	0.44	0.37	Lung cancer;	chr6:149788977	chr6:149934527~149936782:+
LGG	cis	rs1707322	1	rs11211200	ENSG00000281133.1	AL355480.3	-8.61	1.05e-16	5.05e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45580892~45580996:-
LGG	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	8.61	1.05e-16	5.05e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
LGG	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-8.61	1.05e-16	5.06e-14	-0.51	-0.37	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
LGG	cis	rs8081395	0.603	rs1292047	ENSG00000266992.1	DHX40P1	8.61	1.05e-16	5.07e-14	0.49	0.37	White blood cell count;	chr17:59877805	chr17:59976009~60002384:-
LGG	cis	rs2797160	0.837	rs1739364	ENSG00000237742.5	RP11-624M8.1	-8.61	1.05e-16	5.07e-14	-0.35	-0.37	Endometrial cancer;	chr6:125701237	chr6:125578558~125749190:-
LGG	cis	rs853679	0.546	rs200977	ENSG00000216901.1	AL022393.7	8.61	1.06e-16	5.08e-14	0.72	0.37	Depression;	chr6:27886523	chr6:28176188~28176674:+
LGG	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-8.61	1.06e-16	5.08e-14	-0.46	-0.37	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-8.61	1.06e-16	5.08e-14	-0.46	-0.37	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	8.61	1.06e-16	5.08e-14	0.46	0.37	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
LGG	cis	rs9346353	0.966	rs2290710	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69738646	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs1993481	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69739519	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs9364056	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69740696	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.931	rs6909708	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69742509	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs6904680	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69743957	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs6938478	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69747294	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs4707343	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69747929	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.932	rs7743613	ENSG00000219881.1	GAPDHP42	8.61	1.06e-16	5.09e-14	0.35	0.37	Sleep duration;	chr6:69754096	chr6:69745871~69746851:+
LGG	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-8.61	1.06e-16	5.1e-14	-0.3	-0.37	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
LGG	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	8.61	1.07e-16	5.12e-14	0.38	0.37	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
LGG	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-8.61	1.07e-16	5.12e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-8.61	1.07e-16	5.12e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-8.61	1.07e-16	5.12e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-8.61	1.07e-16	5.12e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
LGG	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	8.61	1.07e-16	5.12e-14	0.39	0.37	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
LGG	cis	rs77204473	1	rs77204473	ENSG00000254851.1	RP11-109L13.1	8.61	1.07e-16	5.13e-14	0.93	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934348	chr11:117135528~117138582:+
LGG	cis	rs4713118	0.55	rs9368527	ENSG00000199851.2	U3	8.61	1.07e-16	5.14e-14	0.5	0.37	Parkinson's disease;	chr6:27711666	chr6:28015568~28015777:+
LGG	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-8.61	1.07e-16	5.16e-14	-0.32	-0.37	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
LGG	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	8.61	1.08e-16	5.17e-14	0.39	0.37	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
LGG	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-8.61	1.08e-16	5.19e-14	-0.38	-0.37	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-8.61	1.08e-16	5.19e-14	-0.38	-0.37	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
LGG	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	8.61	1.08e-16	5.2e-14	0.38	0.37	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
LGG	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	8.61	1.08e-16	5.2e-14	0.39	0.37	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
LGG	cis	rs12554020	1	rs59582399	ENSG00000237385.1	RP11-165J3.5	8.61	1.08e-16	5.2e-14	0.57	0.37	Schizophrenia;	chr9:93523881	chr9:93430342~93431299:-
LGG	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-8.61	1.09e-16	5.21e-14	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
LGG	cis	rs6600671	0.764	rs6600673	ENSG00000223345.3	HIST2H2BA	8.61	1.09e-16	5.22e-14	0.38	0.37	Hip geometry;	chr1:121426988	chr1:121108210~121117257:-
LGG	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-8.61	1.09e-16	5.23e-14	-0.3	-0.37	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
LGG	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-8.61	1.09e-16	5.24e-14	-0.37	-0.37	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
LGG	cis	rs9527	0.545	rs35756290	ENSG00000272912.1	RP11-724N1.1	-8.61	1.09e-16	5.24e-14	-0.43	-0.37	Arsenic metabolism;	chr10:102825815	chr10:102914585~102915404:+
LGG	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-8.61	1.09e-16	5.25e-14	-0.48	-0.37	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-8.61	1.09e-16	5.25e-14	-0.48	-0.37	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
LGG	cis	rs35160687	0.623	rs4832263	ENSG00000273080.1	RP11-301O19.1	-8.61	1.1e-16	5.27e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86258034	chr2:86195590~86196049:+
LGG	cis	rs9810089	0.967	rs10935177	ENSG00000261758.1	RP11-102M11.2	-8.61	1.1e-16	5.27e-14	-0.39	-0.37	Gestational age at birth (child effect);	chr3:136132235	chr3:136752630~136755780:+
LGG	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	8.61	1.11e-16	5.31e-14	0.3	0.37	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
LGG	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	8.61	1.11e-16	5.31e-14	0.45	0.37	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
LGG	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	8.61	1.11e-16	5.31e-14	0.45	0.37	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	8.61	1.11e-16	5.31e-14	0.45	0.37	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
LGG	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	8.61	1.11e-16	5.31e-14	0.39	0.37	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
LGG	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	8.61	1.11e-16	5.34e-14	0.5	0.37	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
LGG	cis	rs6496932	0.503	rs10220820	ENSG00000218052.5	ADAMTS7P4	-8.61	1.11e-16	5.34e-14	-0.52	-0.37	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85255369~85330334:-
LGG	cis	rs9393777	0.92	rs13195040	ENSG00000199851.2	U3	-8.61	1.12e-16	5.36e-14	-0.89	-0.37	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28015568~28015777:+
LGG	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	8.61	1.12e-16	5.36e-14	0.45	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
LGG	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-8.61	1.12e-16	5.37e-14	-0.47	-0.37	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
LGG	cis	rs35160687	0.623	rs11689971	ENSG00000273080.1	RP11-301O19.1	-8.61	1.12e-16	5.38e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86247348	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.623	rs11127021	ENSG00000273080.1	RP11-301O19.1	-8.61	1.12e-16	5.38e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86247796	chr2:86195590~86196049:+
LGG	cis	rs2075466	0.513	rs11553876	ENSG00000267077.1	RP11-127I20.5	8.61	1.13e-16	5.4e-14	0.54	0.37	Colonoscopy-negative controls vs population controls;	chr16:4799704	chr16:4795265~4796532:-
LGG	cis	rs733592	0.507	rs3825403	ENSG00000258273.1	RP11-370I10.4	8.61	1.13e-16	5.4e-14	0.44	0.37	Plateletcrit;	chr12:48063376	chr12:48333755~48333901:-
LGG	cis	rs17597773	0.527	rs2484698	ENSG00000238078.1	LINC01352	8.6	1.13e-16	5.41e-14	0.47	0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220829255~220832429:+
LGG	cis	rs73081554	0.611	rs4681851	ENSG00000272360.1	RP11-359I18.5	-8.6	1.13e-16	5.41e-14	-0.6	-0.37	Rheumatoid arthritis;	chr3:58410164	chr3:58490830~58491291:-
LGG	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	8.6	1.14e-16	5.46e-14	0.46	0.37	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
LGG	cis	rs1707322	1	rs785480	ENSG00000281133.1	AL355480.3	-8.6	1.14e-16	5.47e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45580892~45580996:-
LGG	cis	rs853679	0.657	rs1778483	ENSG00000218016.2	ZNF192P2	-8.6	1.15e-16	5.48e-14	-0.45	-0.37	Depression;	chr6:28273214	chr6:28188050~28189432:+
LGG	cis	rs853679	0.657	rs1778482	ENSG00000218016.2	ZNF192P2	-8.6	1.15e-16	5.48e-14	-0.45	-0.37	Depression;	chr6:28273215	chr6:28188050~28189432:+
LGG	cis	rs9532669	0.926	rs4254182	ENSG00000239827.7	SUGT1P3	-8.6	1.15e-16	5.5e-14	-0.4	-0.37	Cervical cancer;	chr13:40879120	chr13:40908159~40921774:-
LGG	cis	rs9346353	1	rs59510607	ENSG00000219881.1	GAPDHP42	8.6	1.15e-16	5.51e-14	0.35	0.37	Sleep duration;	chr6:69773091	chr6:69745871~69746851:+
LGG	cis	rs733592	0.507	rs7138917	ENSG00000258273.1	RP11-370I10.4	8.6	1.15e-16	5.52e-14	0.44	0.37	Plateletcrit;	chr12:48061472	chr12:48333755~48333901:-
LGG	cis	rs9876781	0.563	rs4858821	ENSG00000244380.1	RP11-24C3.2	-8.6	1.15e-16	5.52e-14	-0.47	-0.37	Longevity;	chr3:48512515	chr3:48440352~48446656:-
LGG	cis	rs7927771	0.524	rs2290851	ENSG00000280615.1	Y_RNA	-8.6	1.16e-16	5.54e-14	-0.44	-0.37	Subjective well-being;	chr11:47731818	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs4752865	ENSG00000280615.1	Y_RNA	-8.6	1.16e-16	5.54e-14	-0.44	-0.37	Subjective well-being;	chr11:47738289	chr11:47614898~47614994:-
LGG	cis	rs5742933	1	rs5743052	ENSG00000253559.1	OSGEPL1-AS1	-8.6	1.16e-16	5.55e-14	-0.47	-0.37	Ferritin levels;	chr2:189824558	chr2:189762704~189765556:+
LGG	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	8.6	1.16e-16	5.57e-14	0.45	0.37	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
LGG	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	8.6	1.17e-16	5.58e-14	0.56	0.37	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	8.6	1.17e-16	5.58e-14	0.56	0.37	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	8.6	1.17e-16	5.58e-14	0.56	0.37	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
LGG	cis	rs1420956	0.967	rs9957578	ENSG00000264151.4	RP11-739N10.1	8.6	1.17e-16	5.58e-14	0.46	0.37	Obesity-related traits;	chr18:27610172	chr18:27336379~27595164:-
LGG	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	8.6	1.17e-16	5.59e-14	0.31	0.37	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
LGG	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	8.6	1.17e-16	5.6e-14	0.43	0.37	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
LGG	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-8.6	1.17e-16	5.62e-14	-0.43	-0.37	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
LGG	cis	rs35160687	0.644	rs11676515	ENSG00000273080.1	RP11-301O19.1	-8.6	1.18e-16	5.63e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86268934	chr2:86195590~86196049:+
LGG	cis	rs4143844	0.609	rs11632560	ENSG00000259251.2	RP11-643M14.1	8.6	1.18e-16	5.65e-14	0.62	0.37	Bipolar disorder and schizophrenia;	chr15:62009299	chr15:62060503~62062434:+
LGG	cis	rs7927771	0.542	rs7122217	ENSG00000280615.1	Y_RNA	-8.6	1.18e-16	5.65e-14	-0.44	-0.37	Subjective well-being;	chr11:47756368	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs12421563	ENSG00000280615.1	Y_RNA	-8.6	1.18e-16	5.65e-14	-0.44	-0.37	Subjective well-being;	chr11:47758670	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10742820	ENSG00000280615.1	Y_RNA	-8.6	1.18e-16	5.65e-14	-0.44	-0.37	Subjective well-being;	chr11:47759505	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7124396	ENSG00000280615.1	Y_RNA	-8.6	1.18e-16	5.65e-14	-0.44	-0.37	Subjective well-being;	chr11:47765882	chr11:47614898~47614994:-
LGG	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	8.6	1.18e-16	5.65e-14	0.46	0.37	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
LGG	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	8.6	1.19e-16	5.67e-14	0.43	0.37	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
LGG	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	8.6	1.19e-16	5.67e-14	0.42	0.37	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
LGG	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	8.6	1.19e-16	5.68e-14	0.37	0.37	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
LGG	cis	rs9346353	1	rs3778242	ENSG00000219881.1	GAPDHP42	8.6	1.19e-16	5.68e-14	0.35	0.37	Sleep duration;	chr6:69757024	chr6:69745871~69746851:+
LGG	cis	rs11148252	0.74	rs9596642	ENSG00000278238.1	RP11-245D16.4	8.6	1.19e-16	5.69e-14	0.36	0.37	Lewy body disease;	chr13:52326744	chr13:52454775~52455331:-
LGG	cis	rs454217	0.715	rs400708	ENSG00000277851.1	RP11-756G20.1	8.6	1.19e-16	5.69e-14	0.37	0.37	Smoking quantity;	chr12:92320502	chr12:92247756~92363832:-
LGG	cis	rs9810089	0.967	rs7372313	ENSG00000261758.1	RP11-102M11.2	8.6	1.19e-16	5.7e-14	0.39	0.37	Gestational age at birth (child effect);	chr3:136154116	chr3:136752630~136755780:+
LGG	cis	rs62184315	0.536	rs62184265	ENSG00000273240.1	RP11-455J20.3	-8.6	1.2e-16	5.74e-14	-0.55	-0.37	Alcohol dependence (age at onset);	chr2:189756231	chr2:189763859~189764456:-
LGG	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-8.6	1.2e-16	5.75e-14	-0.37	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
LGG	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	8.6	1.21e-16	5.76e-14	0.45	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
LGG	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	8.6	1.21e-16	5.76e-14	0.45	0.37	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
LGG	cis	rs17772222	0.74	rs10138002	ENSG00000222990.1	RNU4-22P	-8.6	1.21e-16	5.77e-14	-0.44	-0.37	Coronary artery calcification;	chr14:88510071	chr14:88513498~88513663:+
LGG	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-8.6	1.21e-16	5.77e-14	-0.6	-0.37	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
LGG	cis	rs3096299	0.646	rs918722	ENSG00000274627.1	RP11-104N10.2	8.6	1.21e-16	5.79e-14	0.33	0.37	Multiple myeloma (IgH translocation);	chr16:89348673	chr16:89516797~89522217:+
LGG	cis	rs62184315	0.536	rs5742985	ENSG00000273240.1	RP11-455J20.3	-8.6	1.21e-16	5.8e-14	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189796383	chr2:189763859~189764456:-
LGG	cis	rs5742933	1	rs62184283	ENSG00000253559.1	OSGEPL1-AS1	-8.6	1.21e-16	5.8e-14	-0.48	-0.37	Ferritin levels;	chr2:189801179	chr2:189762704~189765556:+
LGG	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-8.6	1.22e-16	5.81e-14	-0.45	-0.37	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
LGG	cis	rs1707322	0.927	rs6690386	ENSG00000281133.1	AL355480.3	-8.59	1.22e-16	5.83e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45580892~45580996:-
LGG	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-8.59	1.22e-16	5.83e-14	-0.44	-0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
LGG	cis	rs9346353	1	rs59459704	ENSG00000219881.1	GAPDHP42	8.59	1.22e-16	5.83e-14	0.35	0.37	Sleep duration;	chr6:69714693	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.932	rs9342767	ENSG00000219881.1	GAPDHP42	8.59	1.22e-16	5.83e-14	0.35	0.37	Sleep duration;	chr6:69715673	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.898	rs9354882	ENSG00000219881.1	GAPDHP42	8.59	1.22e-16	5.83e-14	0.35	0.37	Sleep duration;	chr6:69716396	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346352	ENSG00000219881.1	GAPDHP42	8.59	1.23e-16	5.86e-14	0.35	0.37	Sleep duration;	chr6:69780028	chr6:69745871~69746851:+
LGG	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-8.59	1.23e-16	5.87e-14	-0.46	-0.37	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
LGG	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-8.59	1.23e-16	5.87e-14	-0.46	-0.37	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
LGG	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	8.59	1.23e-16	5.88e-14	0.38	0.37	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
LGG	cis	rs9532669	0.926	rs9562254	ENSG00000168852.11	TPTE2P5	-8.59	1.23e-16	5.89e-14	-0.38	-0.37	Cervical cancer;	chr13:40960902	chr13:40822296~40921749:-
LGG	cis	rs9532669	0.926	rs7329302	ENSG00000168852.11	TPTE2P5	-8.59	1.23e-16	5.89e-14	-0.38	-0.37	Cervical cancer;	chr13:40962396	chr13:40822296~40921749:-
LGG	cis	rs9987353	0.589	rs1053036	ENSG00000173295.6	FAM86B3P	8.59	1.24e-16	5.9e-14	0.39	0.37	Recombination measurement;	chr8:9202567	chr8:8228595~8244865:+
LGG	cis	rs8042680	0.522	rs8026678	ENSG00000214432.8	AC068831.10	-8.59	1.24e-16	5.94e-14	-0.38	-0.37	Type 2 diabetes;	chr15:91018775	chr15:91022619~91036611:+
LGG	cis	rs9532669	0.926	rs9532691	ENSG00000168852.11	TPTE2P5	-8.59	1.26e-16	6e-14	-0.37	-0.37	Cervical cancer;	chr13:40969358	chr13:40822296~40921749:-
LGG	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-8.59	1.26e-16	6.02e-14	-0.43	-0.37	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-8.59	1.26e-16	6.02e-14	-0.43	-0.37	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
LGG	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-8.59	1.26e-16	6.02e-14	-0.43	-0.37	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
LGG	cis	rs9346353	1	rs1993483	ENSG00000219881.1	GAPDHP42	8.59	1.26e-16	6.02e-14	0.35	0.37	Sleep duration;	chr6:69743684	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346344	ENSG00000219881.1	GAPDHP42	8.59	1.26e-16	6.02e-14	0.35	0.37	Sleep duration;	chr6:69748638	chr6:69745871~69746851:+
LGG	cis	rs11148252	0.846	rs1056335	ENSG00000235660.1	LINC00345	-8.59	1.26e-16	6.02e-14	-0.45	-0.37	Lewy body disease;	chr13:52415728	chr13:52484161~52484680:-
LGG	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-8.59	1.27e-16	6.04e-14	-0.44	-0.37	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
LGG	cis	rs9346353	0.966	rs3799117	ENSG00000219881.1	GAPDHP42	8.59	1.27e-16	6.04e-14	0.35	0.37	Sleep duration;	chr6:69740531	chr6:69745871~69746851:+
LGG	cis	rs6545883	0.56	rs11677775	ENSG00000273302.1	RP11-493E12.2	-8.59	1.27e-16	6.04e-14	-0.32	-0.37	Tuberculosis;	chr2:61275975	chr2:61199979~61200769:+
LGG	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	8.59	1.27e-16	6.05e-14	0.48	0.37	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
LGG	cis	rs1023500	0.505	rs2143139	ENSG00000227370.1	RP4-669P10.19	8.59	1.27e-16	6.05e-14	0.33	0.37	Schizophrenia;	chr22:42218395	chr22:42132543~42132998:+
LGG	cis	rs11148252	0.846	rs7985262	ENSG00000235660.1	LINC00345	-8.59	1.27e-16	6.06e-14	-0.45	-0.37	Lewy body disease;	chr13:52423026	chr13:52484161~52484680:-
LGG	cis	rs11148252	0.846	rs4886077	ENSG00000235660.1	LINC00345	-8.59	1.27e-16	6.06e-14	-0.45	-0.37	Lewy body disease;	chr13:52424562	chr13:52484161~52484680:-
LGG	cis	rs11148252	0.846	rs8001624	ENSG00000235660.1	LINC00345	-8.59	1.27e-16	6.06e-14	-0.45	-0.37	Lewy body disease;	chr13:52428860	chr13:52484161~52484680:-
LGG	cis	rs11148252	0.744	rs4884354	ENSG00000235660.1	LINC00345	-8.59	1.27e-16	6.06e-14	-0.45	-0.37	Lewy body disease;	chr13:52443339	chr13:52484161~52484680:-
LGG	cis	rs7927771	0.524	rs7116346	ENSG00000280615.1	Y_RNA	-8.59	1.28e-16	6.08e-14	-0.43	-0.37	Subjective well-being;	chr11:47862328	chr11:47614898~47614994:-
LGG	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-8.59	1.28e-16	6.08e-14	-0.46	-0.37	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
LGG	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	8.59	1.28e-16	6.1e-14	0.58	0.37	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	8.59	1.28e-16	6.1e-14	0.58	0.37	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
LGG	cis	rs172166	0.769	rs149965	ENSG00000218016.2	ZNF192P2	-8.59	1.28e-16	6.11e-14	-0.48	-0.37	Cardiac Troponin-T levels;	chr6:28050911	chr6:28188050~28189432:+
LGG	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	8.59	1.28e-16	6.11e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	8.59	1.28e-16	6.11e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
LGG	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-8.59	1.28e-16	6.12e-14	-0.46	-0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
LGG	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-8.59	1.29e-16	6.13e-14	-0.24	-0.37	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
LGG	cis	rs2412819	0.545	rs654276	ENSG00000249839.1	AC011330.5	8.59	1.29e-16	6.14e-14	0.63	0.37	Lung cancer;	chr15:43798656	chr15:43663654~43684339:-
LGG	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	8.59	1.29e-16	6.14e-14	0.56	0.37	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
LGG	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-8.59	1.29e-16	6.14e-14	-0.5	-0.37	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-8.59	1.29e-16	6.14e-14	-0.5	-0.37	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-8.59	1.29e-16	6.14e-14	-0.5	-0.37	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
LGG	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	8.59	1.29e-16	6.15e-14	0.44	0.37	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
LGG	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-8.59	1.29e-16	6.16e-14	-0.47	-0.37	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
LGG	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-8.59	1.29e-16	6.17e-14	-0.44	-0.37	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
LGG	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-8.59	1.3e-16	6.17e-14	-0.46	-0.37	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
LGG	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-8.59	1.3e-16	6.18e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
LGG	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-8.59	1.3e-16	6.19e-14	-0.38	-0.37	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-8.59	1.3e-16	6.19e-14	-0.38	-0.37	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
LGG	cis	rs111649495	1	rs111649495	ENSG00000250928.1	CTB-161M19.2	-8.59	1.3e-16	6.19e-14	-0.66	-0.37	Response to amphetamines;	chr5:119020720	chr5:119011471~119012056:+
LGG	cis	rs9322193	0.923	rs9371486	ENSG00000216621.7	RP11-244K5.6	8.59	1.31e-16	6.21e-14	0.47	0.37	Lung cancer;	chr6:149832090	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	8.59	1.31e-16	6.23e-14	0.43	0.37	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
LGG	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	8.59	1.31e-16	6.23e-14	0.32	0.37	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
LGG	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	8.59	1.31e-16	6.23e-14	0.32	0.37	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
LGG	cis	rs5742933	1	rs3791773	ENSG00000253559.1	OSGEPL1-AS1	-8.58	1.32e-16	6.27e-14	-0.47	-0.37	Ferritin levels;	chr2:189817906	chr2:189762704~189765556:+
LGG	cis	rs9322193	0.886	rs9767555	ENSG00000216621.7	RP11-244K5.6	8.58	1.32e-16	6.27e-14	0.45	0.37	Lung cancer;	chr6:149647022	chr6:149934527~149936782:+
LGG	cis	rs7927771	0.524	rs7122182	ENSG00000280615.1	Y_RNA	-8.58	1.33e-16	6.31e-14	-0.44	-0.37	Subjective well-being;	chr11:47821581	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs4752798	ENSG00000280615.1	Y_RNA	-8.58	1.33e-16	6.31e-14	-0.43	-0.37	Subjective well-being;	chr11:47864812	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7118747	ENSG00000280615.1	Y_RNA	-8.58	1.33e-16	6.31e-14	-0.43	-0.37	Subjective well-being;	chr11:47867993	chr11:47614898~47614994:-
LGG	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	8.58	1.33e-16	6.32e-14	0.54	0.37	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
LGG	cis	rs11168351	0.591	rs4258439	ENSG00000258273.1	RP11-370I10.4	8.58	1.33e-16	6.32e-14	0.44	0.37	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48333755~48333901:-
LGG	cis	rs733592	0.507	rs10747529	ENSG00000258273.1	RP11-370I10.4	8.58	1.33e-16	6.32e-14	0.44	0.37	Plateletcrit;	chr12:48079586	chr12:48333755~48333901:-
LGG	cis	rs733592	0.507	rs56129148	ENSG00000258273.1	RP11-370I10.4	8.58	1.33e-16	6.32e-14	0.44	0.37	Plateletcrit;	chr12:48091747	chr12:48333755~48333901:-
LGG	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-8.58	1.33e-16	6.33e-14	-0.48	-0.37	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
LGG	cis	rs7927771	0.507	rs10838759	ENSG00000280615.1	Y_RNA	8.58	1.33e-16	6.34e-14	0.44	0.37	Subjective well-being;	chr11:47763795	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs11039377	ENSG00000280615.1	Y_RNA	8.58	1.33e-16	6.34e-14	0.44	0.37	Subjective well-being;	chr11:47768224	chr11:47614898~47614994:-
LGG	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-8.58	1.33e-16	6.34e-14	-0.39	-0.37	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
LGG	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-8.58	1.33e-16	6.35e-14	-0.47	-0.37	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-8.58	1.33e-16	6.35e-14	-0.47	-0.37	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
LGG	cis	rs9346353	1	rs9346333	ENSG00000219881.1	GAPDHP42	8.58	1.34e-16	6.36e-14	0.35	0.37	Sleep duration;	chr6:69716587	chr6:69745871~69746851:+
LGG	cis	rs2281558	0.754	rs73597824	ENSG00000125804.12	FAM182A	-8.58	1.34e-16	6.36e-14	-0.5	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610841	chr20:26054655~26086917:+
LGG	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
LGG	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
LGG	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
LGG	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	8.58	1.34e-16	6.38e-14	0.43	0.37	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
LGG	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	8.58	1.34e-16	6.38e-14	0.25	0.37	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
LGG	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-8.58	1.35e-16	6.4e-14	-0.36	-0.37	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
LGG	cis	rs7927771	0.524	rs754434	ENSG00000280615.1	Y_RNA	8.58	1.35e-16	6.4e-14	0.44	0.37	Subjective well-being;	chr11:47792728	chr11:47614898~47614994:-
LGG	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	8.58	1.35e-16	6.42e-14	0.39	0.37	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
LGG	cis	rs848490	0.546	rs7384722	ENSG00000214293.7	APTR	8.58	1.35e-16	6.43e-14	0.35	0.37	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77646106	chr7:77657660~77696265:-
LGG	cis	rs9595066	0.627	rs4942287	ENSG00000230731.2	RP11-478K15.6	-8.58	1.36e-16	6.48e-14	-0.58	-0.37	Schizophrenia;	chr13:44160560	chr13:44234118~44243192:-
LGG	cis	rs9346353	0.966	rs4707359	ENSG00000219881.1	GAPDHP42	8.58	1.36e-16	6.48e-14	0.35	0.37	Sleep duration;	chr6:69761436	chr6:69745871~69746851:+
LGG	cis	rs7927771	0.542	rs7102205	ENSG00000280615.1	Y_RNA	8.58	1.37e-16	6.5e-14	0.44	0.37	Subjective well-being;	chr11:47723822	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs11039431	ENSG00000280615.1	Y_RNA	8.58	1.37e-16	6.5e-14	0.44	0.37	Subjective well-being;	chr11:47850460	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.507	rs11039432	ENSG00000280615.1	Y_RNA	8.58	1.37e-16	6.5e-14	0.44	0.37	Subjective well-being;	chr11:47851775	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs2170815	ENSG00000280615.1	Y_RNA	8.58	1.37e-16	6.5e-14	0.44	0.37	Subjective well-being;	chr11:47854358	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7929725	ENSG00000280615.1	Y_RNA	8.58	1.37e-16	6.5e-14	0.44	0.37	Subjective well-being;	chr11:47860188	chr11:47614898~47614994:-
LGG	cis	rs9987353	0.519	rs11779181	ENSG00000253893.2	FAM85B	-8.58	1.37e-16	6.5e-14	-0.45	-0.37	Recombination measurement;	chr8:9205517	chr8:8167819~8226614:-
LGG	cis	rs1707322	1	rs12124847	ENSG00000281133.1	AL355480.3	-8.58	1.37e-16	6.52e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45580892~45580996:-
LGG	cis	rs35160687	0.712	rs1863057	ENSG00000273080.1	RP11-301O19.1	-8.58	1.38e-16	6.56e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86274978	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.623	rs1863060	ENSG00000273080.1	RP11-301O19.1	-8.58	1.38e-16	6.56e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86284333	chr2:86195590~86196049:+
LGG	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-8.58	1.38e-16	6.56e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-8.58	1.38e-16	6.56e-14	-0.5	-0.37	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
LGG	cis	rs7927771	0.524	rs7101597	ENSG00000280615.1	Y_RNA	8.58	1.38e-16	6.57e-14	0.44	0.37	Subjective well-being;	chr11:47776365	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs11039392	ENSG00000280615.1	Y_RNA	8.58	1.38e-16	6.57e-14	0.44	0.37	Subjective well-being;	chr11:47777201	chr11:47614898~47614994:-
LGG	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-8.58	1.38e-16	6.57e-14	-0.38	-0.37	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
LGG	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-8.58	1.38e-16	6.57e-14	-0.38	-0.37	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
LGG	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-8.58	1.38e-16	6.57e-14	-0.38	-0.37	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
LGG	cis	rs7746199	0.736	rs72845070	ENSG00000216901.1	AL022393.7	8.58	1.39e-16	6.58e-14	0.83	0.37	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28176188~28176674:+
LGG	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	8.58	1.39e-16	6.61e-14	0.52	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
LGG	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	8.58	1.39e-16	6.61e-14	0.52	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
LGG	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-8.58	1.4e-16	6.65e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
LGG	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	8.58	1.4e-16	6.66e-14	0.45	0.37	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
LGG	cis	rs7927771	0.524	rs1563821	ENSG00000280615.1	Y_RNA	8.58	1.4e-16	6.66e-14	0.44	0.37	Subjective well-being;	chr11:47735016	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs6485773	ENSG00000280615.1	Y_RNA	8.58	1.4e-16	6.66e-14	0.44	0.37	Subjective well-being;	chr11:47741957	chr11:47614898~47614994:-
LGG	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	8.58	1.41e-16	6.67e-14	0.48	0.37	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
LGG	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-8.58	1.41e-16	6.68e-14	-0.43	-0.37	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-8.58	1.41e-16	6.68e-14	-0.43	-0.37	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
LGG	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	8.58	1.41e-16	6.68e-14	0.57	0.37	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
LGG	cis	rs6997458	0.606	rs1493302	ENSG00000253549.4	RP11-317J10.2	8.58	1.41e-16	6.69e-14	0.29	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85437051	chr8:85441851~85464915:-
LGG	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-8.58	1.41e-16	6.69e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
LGG	cis	rs7107356	1	rs7107356	ENSG00000280615.1	Y_RNA	8.58	1.41e-16	6.7e-14	0.44	0.37	Neuroticism (multi-trait analysis);Neuroticism;	chr11:47654618	chr11:47614898~47614994:-
LGG	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	8.57	1.42e-16	6.72e-14	0.45	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
LGG	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	8.57	1.42e-16	6.72e-14	0.45	0.37	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
LGG	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	8.57	1.42e-16	6.73e-14	0.32	0.37	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
LGG	cis	rs4950322	0.542	rs4950384	ENSG00000278811.3	LINC00624	8.57	1.43e-16	6.77e-14	0.35	0.37	Protein quantitative trait loci;	chr1:147177310	chr1:147258885~147517875:-
LGG	cis	rs1061377	0.513	rs6840214	ENSG00000249685.1	RP11-360F5.3	-8.57	1.43e-16	6.78e-14	-0.5	-0.37	Uric acid levels;	chr4:39118999	chr4:39133913~39135608:+
LGG	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	8.57	1.43e-16	6.79e-14	0.45	0.37	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
LGG	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	8.57	1.43e-16	6.8e-14	0.46	0.37	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
LGG	cis	rs9813712	0.526	rs62281641	ENSG00000228252.7	COL6A4P2	-8.57	1.43e-16	6.8e-14	-0.42	-0.37	Response to amphetamines;	chr3:130235668	chr3:130212823~130273806:+
LGG	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	8.57	1.43e-16	6.81e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
LGG	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-8.57	1.44e-16	6.82e-14	-0.51	-0.37	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
LGG	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-8.57	1.44e-16	6.83e-14	-0.38	-0.37	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
LGG	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-8.57	1.44e-16	6.83e-14	-0.38	-0.37	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
LGG	cis	rs7124681	0.565	rs2904127	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47795738	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs11039402	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47804538	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs6485786	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47815856	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs11039415	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47824262	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7110300	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47826890	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs9633830	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47827918	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs11039419	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47829802	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10838777	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47839402	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10458915	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47842840	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10742824	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47843290	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.542	rs10769300	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47844008	chr11:47614898~47614994:-
LGG	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-8.57	1.44e-16	6.83e-14	-0.48	-0.37	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-8.57	1.44e-16	6.83e-14	-0.48	-0.37	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
LGG	cis	rs7927771	0.524	rs7932703	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47748384	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10838758	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47749924	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7929014	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47754731	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.542	rs7108479	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47759908	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10838760	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47764862	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7111576	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47765893	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.507	rs7111606	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47765986	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs61895760	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47772986	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10838763	ENSG00000280615.1	Y_RNA	8.57	1.44e-16	6.83e-14	0.44	0.37	Subjective well-being;	chr11:47773250	chr11:47614898~47614994:-
LGG	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-8.57	1.44e-16	6.83e-14	-0.43	-0.37	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-8.57	1.44e-16	6.83e-14	-0.43	-0.37	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-8.57	1.44e-16	6.83e-14	-0.43	-0.37	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
LGG	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-8.57	1.44e-16	6.83e-14	-0.43	-0.37	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-8.57	1.44e-16	6.83e-14	-0.43	-0.37	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
LGG	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	8.57	1.44e-16	6.84e-14	0.9	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.923	rs9479810	ENSG00000216621.7	RP11-244K5.6	8.57	1.45e-16	6.86e-14	0.43	0.37	Lung cancer;	chr6:149751359	chr6:149934527~149936782:+
LGG	cis	rs7950696	1	rs7950696	ENSG00000280615.1	Y_RNA	8.57	1.45e-16	6.87e-14	0.44	0.37	Platelet count;	chr11:47459981	chr11:47614898~47614994:-
LGG	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	8.57	1.45e-16	6.88e-14	0.46	0.37	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
LGG	cis	rs4950322	0.542	rs3766520	ENSG00000278811.3	LINC00624	8.57	1.45e-16	6.89e-14	0.36	0.37	Protein quantitative trait loci;	chr1:147214658	chr1:147258885~147517875:-
LGG	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-8.57	1.46e-16	6.9e-14	-0.27	-0.37	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
LGG	cis	rs7124681	0.584	rs7950674	ENSG00000280615.1	Y_RNA	8.57	1.46e-16	6.91e-14	0.44	0.37	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47849465	chr11:47614898~47614994:-
LGG	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-8.57	1.46e-16	6.92e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
LGG	cis	rs9987353	0.566	rs6998368	ENSG00000253893.2	FAM85B	8.57	1.46e-16	6.93e-14	0.46	0.37	Recombination measurement;	chr8:9212778	chr8:8167819~8226614:-
LGG	cis	rs62184315	0.536	rs5743047	ENSG00000273240.1	RP11-455J20.3	8.57	1.46e-16	6.93e-14	0.54	0.37	Alcohol dependence (age at onset);	chr2:189819942	chr2:189763859~189764456:-
LGG	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-8.57	1.47e-16	6.95e-14	-0.39	-0.37	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
LGG	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-8.57	1.47e-16	6.97e-14	-0.46	-0.37	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
LGG	cis	rs9346353	0.966	rs1457492	ENSG00000219881.1	GAPDHP42	8.57	1.47e-16	6.99e-14	0.35	0.37	Sleep duration;	chr6:69706974	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs6902295	ENSG00000219881.1	GAPDHP42	8.57	1.47e-16	6.99e-14	0.35	0.37	Sleep duration;	chr6:69711356	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs7743876	ENSG00000219881.1	GAPDHP42	8.57	1.47e-16	6.99e-14	0.35	0.37	Sleep duration;	chr6:69706538	chr6:69745871~69746851:+
LGG	cis	rs8062405	0.573	rs6565300	ENSG00000251417.2	RP11-1348G14.4	-8.57	1.48e-16	7.01e-14	-0.47	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28802743~28817828:+
LGG	cis	rs7474896	0.559	rs1735641	ENSG00000226578.1	RP11-258F22.1	8.57	1.48e-16	7.01e-14	0.49	0.37	Obesity (extreme);	chr10:37895924	chr10:37775371~37784131:-
LGG	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-8.57	1.48e-16	7.02e-14	-0.4	-0.37	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
LGG	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-8.57	1.48e-16	7.02e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-8.57	1.48e-16	7.02e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-8.57	1.48e-16	7.02e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-8.57	1.48e-16	7.02e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-8.57	1.48e-16	7.02e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-8.57	1.48e-16	7.02e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-8.57	1.48e-16	7.02e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
LGG	cis	rs9346353	0.966	rs7742087	ENSG00000219881.1	GAPDHP42	8.57	1.48e-16	7.03e-14	0.35	0.37	Sleep duration;	chr6:69702650	chr6:69745871~69746851:+
LGG	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-8.57	1.49e-16	7.03e-14	-0.46	-0.37	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-8.57	1.49e-16	7.03e-14	-0.46	-0.37	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-8.57	1.49e-16	7.03e-14	-0.46	-0.37	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
LGG	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-8.57	1.49e-16	7.03e-14	-0.46	-0.37	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
LGG	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-8.57	1.49e-16	7.06e-14	-0.37	-0.37	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
LGG	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-8.57	1.49e-16	7.06e-14	-0.37	-0.37	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
LGG	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-8.57	1.49e-16	7.07e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
LGG	cis	rs9346353	1	rs16868145	ENSG00000219881.1	GAPDHP42	8.57	1.5e-16	7.1e-14	0.35	0.37	Sleep duration;	chr6:69751770	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs7739633	ENSG00000219881.1	GAPDHP42	8.57	1.5e-16	7.1e-14	0.35	0.37	Sleep duration;	chr6:69753307	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs7738792	ENSG00000219881.1	GAPDHP42	8.57	1.5e-16	7.1e-14	0.35	0.37	Sleep duration;	chr6:69753525	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346346	ENSG00000219881.1	GAPDHP42	8.57	1.5e-16	7.1e-14	0.35	0.37	Sleep duration;	chr6:69754064	chr6:69745871~69746851:+
LGG	cis	rs7927771	0.524	rs7114813	ENSG00000280615.1	Y_RNA	8.57	1.5e-16	7.1e-14	0.44	0.37	Subjective well-being;	chr11:47779549	chr11:47614898~47614994:-
LGG	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-8.57	1.5e-16	7.11e-14	-0.43	-0.37	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
LGG	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-8.57	1.5e-16	7.11e-14	-0.47	-0.37	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-8.57	1.5e-16	7.11e-14	-0.47	-0.37	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
LGG	cis	rs853679	0.546	rs34295134	ENSG00000216901.1	AL022393.7	8.57	1.51e-16	7.13e-14	0.7	0.37	Depression;	chr6:27860373	chr6:28176188~28176674:+
LGG	cis	rs12444795	0.805	rs76087945	ENSG00000267077.1	RP11-127I20.5	8.57	1.51e-16	7.13e-14	0.53	0.37	Cancer;	chr16:4899439	chr16:4795265~4796532:-
LGG	cis	rs35160687	0.644	rs4832264	ENSG00000273080.1	RP11-301O19.1	-8.57	1.51e-16	7.13e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86259711	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.623	rs13005014	ENSG00000273080.1	RP11-301O19.1	-8.57	1.51e-16	7.13e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86260093	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs4832265	ENSG00000273080.1	RP11-301O19.1	-8.57	1.51e-16	7.13e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86261142	chr2:86195590~86196049:+
LGG	cis	rs62184315	0.536	rs2289405	ENSG00000273240.1	RP11-455J20.3	-8.57	1.51e-16	7.15e-14	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189771313	chr2:189763859~189764456:-
LGG	cis	rs2739330	0.731	rs5751792	ENSG00000272787.1	KB-226F1.2	8.57	1.51e-16	7.15e-14	0.39	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23969211~23969873:+
LGG	cis	rs9322193	0.962	rs9688412	ENSG00000216621.7	RP11-244K5.6	-8.57	1.51e-16	7.16e-14	-0.43	-0.37	Lung cancer;	chr6:149803147	chr6:149934527~149936782:+
LGG	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	8.57	1.51e-16	7.17e-14	0.37	0.37	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
LGG	cis	rs9346353	1	rs2125023	ENSG00000219881.1	GAPDHP42	8.57	1.51e-16	7.17e-14	0.35	0.37	Sleep duration;	chr6:69790098	chr6:69745871~69746851:+
LGG	cis	rs13191038	1	rs13191038	ENSG00000199851.2	U3	8.57	1.52e-16	7.18e-14	0.93	0.37	Urinary tract infection frequency;	chr6:28515140	chr6:28015568~28015777:+
LGG	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	8.57	1.52e-16	7.18e-14	0.37	0.37	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
LGG	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	8.57	1.52e-16	7.19e-14	0.61	0.37	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
LGG	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	8.57	1.52e-16	7.19e-14	0.56	0.37	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
LGG	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-8.57	1.52e-16	7.2e-14	-0.49	-0.37	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
LGG	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-8.57	1.52e-16	7.21e-14	-0.5	-0.37	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
LGG	cis	rs7208859	0.623	rs55724095	ENSG00000266490.1	CTD-2349P21.9	8.57	1.52e-16	7.22e-14	0.46	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73271869	ENSG00000266490.1	CTD-2349P21.9	8.56	1.53e-16	7.22e-14	0.46	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73271872	ENSG00000266490.1	CTD-2349P21.9	8.56	1.53e-16	7.22e-14	0.46	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30792372~30792833:+
LGG	cis	rs9322193	0.962	rs2065664	ENSG00000216621.7	RP11-244K5.6	8.56	1.53e-16	7.23e-14	0.44	0.37	Lung cancer;	chr6:149762485	chr6:149934527~149936782:+
LGG	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-8.56	1.53e-16	7.23e-14	-0.43	-0.37	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
LGG	cis	rs11098499	0.526	rs10026625	ENSG00000249244.1	RP11-548H18.2	8.56	1.53e-16	7.23e-14	0.39	0.37	Corneal astigmatism;	chr4:119358981	chr4:119391831~119395335:-
LGG	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	8.56	1.53e-16	7.24e-14	0.49	0.37	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
LGG	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	8.56	1.53e-16	7.24e-14	0.49	0.37	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
LGG	cis	rs62184315	0.536	rs56324258	ENSG00000273240.1	RP11-455J20.3	-8.56	1.53e-16	7.24e-14	-0.54	-0.37	Alcohol dependence (age at onset);	chr2:189811589	chr2:189763859~189764456:-
LGG	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-8.56	1.53e-16	7.25e-14	-0.31	-0.37	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
LGG	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-8.56	1.53e-16	7.25e-14	-0.31	-0.37	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
LGG	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-8.56	1.53e-16	7.25e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
LGG	cis	rs4143844	0.737	rs35984535	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61912747	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs11071640	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61918305	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs12907567	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61922408	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs34853395	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61923024	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs77585482	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61925442	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs62009109	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61927032	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs11637967	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61928417	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs34486946	ENSG00000259251.2	RP11-643M14.1	8.56	1.53e-16	7.25e-14	0.61	0.37	Bipolar disorder and schizophrenia;	chr15:61929355	chr15:62060503~62062434:+
LGG	cis	rs56804039	1	rs67180327	ENSG00000173295.6	FAM86B3P	8.56	1.53e-16	7.25e-14	0.44	0.37	Cervical cancer;	chr8:8523244	chr8:8228595~8244865:+
LGG	cis	rs56804039	1	rs67611618	ENSG00000173295.6	FAM86B3P	8.56	1.53e-16	7.25e-14	0.44	0.37	Cervical cancer;	chr8:8523429	chr8:8228595~8244865:+
LGG	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	8.56	1.54e-16	7.27e-14	0.32	0.37	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
LGG	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-8.56	1.54e-16	7.29e-14	-0.37	-0.37	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
LGG	cis	rs7927771	0.542	rs3886262	ENSG00000280615.1	Y_RNA	8.56	1.54e-16	7.29e-14	0.44	0.37	Subjective well-being;	chr11:47795458	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7123952	ENSG00000280615.1	Y_RNA	8.56	1.54e-16	7.3e-14	0.44	0.37	Subjective well-being;	chr11:47830505	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10838775	ENSG00000280615.1	Y_RNA	8.56	1.54e-16	7.3e-14	0.44	0.37	Subjective well-being;	chr11:47834830	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs3816605	ENSG00000280615.1	Y_RNA	8.56	1.54e-16	7.3e-14	0.44	0.37	Subjective well-being;	chr11:47835701	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10769299	ENSG00000280615.1	Y_RNA	8.56	1.54e-16	7.3e-14	0.44	0.37	Subjective well-being;	chr11:47843608	chr11:47614898~47614994:-
LGG	cis	rs9346353	0.966	rs9354887	ENSG00000219881.1	GAPDHP42	8.56	1.55e-16	7.31e-14	0.35	0.37	Sleep duration;	chr6:69753617	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9360401	ENSG00000219881.1	GAPDHP42	8.56	1.55e-16	7.31e-14	0.35	0.37	Sleep duration;	chr6:69754063	chr6:69745871~69746851:+
LGG	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	8.56	1.55e-16	7.33e-14	0.44	0.37	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
LGG	cis	rs651907	0.737	rs9844218	ENSG00000256628.3	ZBTB11-AS1	-8.56	1.55e-16	7.33e-14	-0.43	-0.37	Colorectal cancer;	chr3:101866139	chr3:101676475~101679217:+
LGG	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-8.56	1.55e-16	7.33e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
LGG	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	-8.56	1.55e-16	7.34e-14	-0.38	-0.37	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
LGG	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-8.56	1.55e-16	7.35e-14	-0.38	-0.37	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
LGG	cis	rs657075	0.697	rs13179900	ENSG00000263597.1	MIR3936	8.56	1.56e-16	7.39e-14	0.61	0.37	Rheumatoid arthritis;	chr5:132311897	chr5:132365490~132365599:-
LGG	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-8.56	1.56e-16	7.39e-14	-0.28	-0.37	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
LGG	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	8.56	1.57e-16	7.42e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
LGG	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-8.56	1.57e-16	7.43e-14	-0.51	-0.37	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
LGG	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	8.56	1.57e-16	7.43e-14	0.35	0.37	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
LGG	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	8.56	1.57e-16	7.43e-14	0.61	0.37	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
LGG	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-8.56	1.58e-16	7.46e-14	-0.48	-0.37	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
LGG	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-8.56	1.58e-16	7.49e-14	-0.46	-0.37	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
LGG	cis	rs454217	0.74	rs373627	ENSG00000277851.1	RP11-756G20.1	8.56	1.59e-16	7.51e-14	0.37	0.37	Smoking quantity;	chr12:92325837	chr12:92247756~92363832:-
LGG	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-8.56	1.59e-16	7.54e-14	-0.37	-0.37	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
LGG	cis	rs853679	0.527	rs853693	ENSG00000218016.2	ZNF192P2	-8.56	1.6e-16	7.54e-14	-0.45	-0.37	Depression;	chr6:28314871	chr6:28188050~28189432:+
LGG	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	8.56	1.6e-16	7.55e-14	0.39	0.37	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
LGG	cis	rs1707322	1	rs4074225	ENSG00000281133.1	AL355480.3	-8.56	1.6e-16	7.55e-14	-0.45	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45580892~45580996:-
LGG	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	8.56	1.6e-16	7.55e-14	0.48	0.37	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
LGG	cis	rs853679	0.527	rs853693	ENSG00000226314.6	ZNF192P1	8.56	1.6e-16	7.55e-14	0.38	0.37	Depression;	chr6:28314871	chr6:28161781~28169594:+
LGG	cis	rs5742933	1	rs5742933	ENSG00000253559.1	OSGEPL1-AS1	-8.56	1.6e-16	7.56e-14	-0.47	-0.37	Ferritin levels;	chr2:189784590	chr2:189762704~189765556:+
LGG	cis	rs812925	0.515	rs1177308	ENSG00000273302.1	RP11-493E12.2	8.56	1.6e-16	7.56e-14	0.33	0.37	Immature fraction of reticulocytes;	chr2:61160119	chr2:61199979~61200769:+
LGG	cis	rs812925	0.553	rs1177307	ENSG00000273302.1	RP11-493E12.2	8.56	1.6e-16	7.56e-14	0.33	0.37	Immature fraction of reticulocytes;	chr2:61160253	chr2:61199979~61200769:+
LGG	cis	rs812925	0.512	rs1729674	ENSG00000273302.1	RP11-493E12.2	8.56	1.6e-16	7.56e-14	0.33	0.37	Immature fraction of reticulocytes;	chr2:61162602	chr2:61199979~61200769:+
LGG	cis	rs11098499	0.909	rs1546504	ENSG00000250412.1	KLHL2P1	8.56	1.61e-16	7.6e-14	0.42	0.37	Corneal astigmatism;	chr4:119320024	chr4:119334329~119378233:+
LGG	cis	rs17772222	0.682	rs2274736	ENSG00000222990.1	RNU4-22P	8.56	1.61e-16	7.6e-14	0.43	0.37	Coronary artery calcification;	chr14:88472308	chr14:88513498~88513663:+
LGG	cis	rs7124681	0.584	rs4752792	ENSG00000280615.1	Y_RNA	-8.56	1.61e-16	7.61e-14	-0.43	-0.37	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47794150	chr11:47614898~47614994:-
LGG	cis	rs6997458	0.742	rs13269441	ENSG00000253549.4	RP11-317J10.2	8.56	1.61e-16	7.61e-14	0.29	0.37	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85418406	chr8:85441851~85464915:-
LGG	cis	rs858239	0.669	rs10950940	ENSG00000230042.1	AK3P3	8.56	1.62e-16	7.63e-14	0.38	0.37	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23129178~23129841:+
LGG	cis	rs11992162	0.967	rs4841661	ENSG00000227888.4	FAM66A	8.56	1.62e-16	7.63e-14	0.44	0.37	Monocyte count;	chr8:11975260	chr8:12362019~12388296:+
LGG	cis	rs6921919	0.525	rs11760133	ENSG00000226314.6	ZNF192P1	8.56	1.62e-16	7.64e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28161781~28169594:+
LGG	cis	rs7523050	0.643	rs34801874	ENSG00000203897.3	SPATA42	-8.56	1.62e-16	7.64e-14	-0.62	-0.37	Fat distribution (HIV);	chr1:108861760	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs35860016	ENSG00000203897.3	SPATA42	-8.56	1.62e-16	7.64e-14	-0.62	-0.37	Fat distribution (HIV);	chr1:108862017	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs35050241	ENSG00000203897.3	SPATA42	-8.56	1.62e-16	7.64e-14	-0.62	-0.37	Fat distribution (HIV);	chr1:108862254	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs35526993	ENSG00000203897.3	SPATA42	-8.56	1.62e-16	7.64e-14	-0.62	-0.37	Fat distribution (HIV);	chr1:108862485	chr1:108857217~108858524:+
LGG	cis	rs17772222	0.74	rs4594187	ENSG00000222990.1	RNU4-22P	8.56	1.63e-16	7.69e-14	0.45	0.37	Coronary artery calcification;	chr14:88511071	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs4514599	ENSG00000222990.1	RNU4-22P	8.56	1.63e-16	7.69e-14	0.45	0.37	Coronary artery calcification;	chr14:88511083	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs61975276	ENSG00000222990.1	RNU4-22P	8.56	1.63e-16	7.69e-14	0.45	0.37	Coronary artery calcification;	chr14:88511193	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs61975277	ENSG00000222990.1	RNU4-22P	8.56	1.63e-16	7.69e-14	0.45	0.37	Coronary artery calcification;	chr14:88511202	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs61984675	ENSG00000222990.1	RNU4-22P	8.56	1.63e-16	7.69e-14	0.45	0.37	Coronary artery calcification;	chr14:88511236	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs73317739	ENSG00000222990.1	RNU4-22P	8.56	1.63e-16	7.69e-14	0.45	0.37	Coronary artery calcification;	chr14:88511400	chr14:88513498~88513663:+
LGG	cis	rs9346353	1	rs9364058	ENSG00000219881.1	GAPDHP42	8.56	1.63e-16	7.7e-14	0.35	0.37	Sleep duration;	chr6:69764863	chr6:69745871~69746851:+
LGG	cis	rs5742933	0.69	rs62183657	ENSG00000273240.1	RP11-455J20.3	-8.56	1.64e-16	7.72e-14	-0.5	-0.37	Ferritin levels;	chr2:189669448	chr2:189763859~189764456:-
LGG	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-8.56	1.64e-16	7.73e-14	-0.38	-0.37	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-8.56	1.64e-16	7.73e-14	-0.38	-0.37	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
LGG	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-8.56	1.64e-16	7.73e-14	-0.48	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
LGG	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-8.56	1.64e-16	7.74e-14	-0.27	-0.37	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
LGG	cis	rs9346353	1	rs3778244	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69774846	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs9346350	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69775780	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.932	rs9346351	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69775959	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs10945188	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69778583	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs9351775	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69779495	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9342774	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69779517	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs1563607	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69787623	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs9360404	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69788823	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs1902654	ENSG00000219881.1	GAPDHP42	8.56	1.64e-16	7.75e-14	0.35	0.37	Sleep duration;	chr6:69789212	chr6:69745871~69746851:+
LGG	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	8.56	1.64e-16	7.75e-14	0.56	0.37	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
LGG	cis	rs5742933	1	rs5743032	ENSG00000253559.1	OSGEPL1-AS1	-8.56	1.64e-16	7.75e-14	-0.47	-0.37	Ferritin levels;	chr2:189814077	chr2:189762704~189765556:+
LGG	cis	rs9987353	0.522	rs2929466	ENSG00000173295.6	FAM86B3P	8.55	1.65e-16	7.77e-14	0.39	0.37	Recombination measurement;	chr8:9206389	chr8:8228595~8244865:+
LGG	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	8.55	1.65e-16	7.78e-14	0.47	0.37	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
LGG	cis	rs11722779	0.935	rs3857200	ENSG00000248971.2	KRT8P46	-8.55	1.65e-16	7.8e-14	-0.38	-0.37	Schizophrenia;	chr4:103001864	chr4:102728746~102730171:-
LGG	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-8.55	1.66e-16	7.81e-14	-0.48	-0.37	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
LGG	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-8.55	1.66e-16	7.83e-14	-0.47	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
LGG	cis	rs6921919	0.583	rs16894060	ENSG00000226314.6	ZNF192P1	8.55	1.66e-16	7.83e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28161781~28169594:+
LGG	cis	rs812925	0.512	rs7558954	ENSG00000273302.1	RP11-493E12.2	8.55	1.66e-16	7.83e-14	0.33	0.37	Immature fraction of reticulocytes;	chr2:61157771	chr2:61199979~61200769:+
LGG	cis	rs7927771	0.524	rs12226431	ENSG00000280615.1	Y_RNA	8.55	1.67e-16	7.85e-14	0.44	0.37	Subjective well-being;	chr11:47784304	chr11:47614898~47614994:-
LGG	cis	rs6496932	0.503	rs7170085	ENSG00000218052.5	ADAMTS7P4	-8.55	1.67e-16	7.87e-14	-0.55	-0.37	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85255369~85330334:-
LGG	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	8.55	1.67e-16	7.88e-14	0.55	0.37	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	8.55	1.67e-16	7.88e-14	0.55	0.37	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	8.55	1.67e-16	7.88e-14	0.55	0.37	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	8.55	1.67e-16	7.88e-14	0.55	0.37	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
LGG	cis	rs3020264	0.962	rs1974946	ENSG00000271743.1	CTD-2541M15.3	-8.55	1.67e-16	7.89e-14	-0.43	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631266	chr8:6615604~6617198:-
LGG	cis	rs7927771	0.524	rs10838769	ENSG00000280615.1	Y_RNA	-8.55	1.68e-16	7.91e-14	-0.43	-0.37	Subjective well-being;	chr11:47803781	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10838771	ENSG00000280615.1	Y_RNA	-8.55	1.68e-16	7.91e-14	-0.43	-0.37	Subjective well-being;	chr11:47809780	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs1563820	ENSG00000280615.1	Y_RNA	-8.55	1.68e-16	7.91e-14	-0.43	-0.37	Subjective well-being;	chr11:47811846	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs4752796	ENSG00000280615.1	Y_RNA	-8.55	1.68e-16	7.91e-14	-0.43	-0.37	Subjective well-being;	chr11:47820310	chr11:47614898~47614994:-
LGG	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	8.55	1.68e-16	7.93e-14	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
LGG	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-8.55	1.69e-16	7.96e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-8.55	1.69e-16	7.96e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-8.55	1.69e-16	7.96e-14	-0.49	-0.37	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
LGG	cis	rs17772222	0.74	rs4390529	ENSG00000222990.1	RNU4-22P	8.55	1.69e-16	7.97e-14	0.45	0.37	Coronary artery calcification;	chr14:88510853	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.771	rs4516145	ENSG00000222990.1	RNU4-22P	8.55	1.69e-16	7.97e-14	0.45	0.37	Coronary artery calcification;	chr14:88510953	chr14:88513498~88513663:+
LGG	cis	rs10276381	0.786	rs28430601	ENSG00000234336.5	JAZF1-AS1	-8.55	1.7e-16	8e-14	-0.48	-0.37	Crohn's disease;	chr7:28199192	chr7:28180322~28243917:+
LGG	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	8.55	1.7e-16	8.01e-14	0.55	0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
LGG	cis	rs9859260	0.925	rs3761717	ENSG00000231464.1	AC024937.4	8.55	1.7e-16	8.01e-14	0.45	0.37	Mean corpuscular volume;	chr3:196071076	chr3:195996738~195998233:+
LGG	cis	rs733592	0.524	rs10875741	ENSG00000258273.1	RP11-370I10.4	8.55	1.7e-16	8.03e-14	0.44	0.37	Plateletcrit;	chr12:48099139	chr12:48333755~48333901:-
LGG	cis	rs733592	0.507	rs7304428	ENSG00000258273.1	RP11-370I10.4	8.55	1.7e-16	8.03e-14	0.44	0.37	Plateletcrit;	chr12:48100492	chr12:48333755~48333901:-
LGG	cis	rs733592	0.524	rs10875744	ENSG00000258273.1	RP11-370I10.4	-8.55	1.7e-16	8.03e-14	-0.44	-0.37	Plateletcrit;	chr12:48104657	chr12:48333755~48333901:-
LGG	cis	rs9346353	0.966	rs4706283	ENSG00000219881.1	GAPDHP42	8.55	1.71e-16	8.04e-14	0.35	0.37	Sleep duration;	chr6:69708963	chr6:69745871~69746851:+
LGG	cis	rs17772222	0.682	rs28482235	ENSG00000222990.1	RNU4-22P	8.55	1.71e-16	8.04e-14	0.44	0.37	Coronary artery calcification;	chr14:88472857	chr14:88513498~88513663:+
LGG	cis	rs35160687	0.623	rs7569654	ENSG00000273080.1	RP11-301O19.1	-8.55	1.71e-16	8.08e-14	-0.38	-0.37	Night sleep phenotypes;	chr2:86250899	chr2:86195590~86196049:+
LGG	cis	rs4950322	0.542	rs28381210	ENSG00000278811.3	LINC00624	8.55	1.72e-16	8.09e-14	0.35	0.37	Protein quantitative trait loci;	chr1:147201925	chr1:147258885~147517875:-
LGG	cis	rs62103177	0.535	rs34299914	ENSG00000261126.6	RP11-795F19.1	8.55	1.73e-16	8.14e-14	0.43	0.37	Opioid sensitivity;	chr18:80191353	chr18:80046900~80095482:+
LGG	cis	rs4143844	1	rs34173668	ENSG00000259251.2	RP11-643M14.1	8.55	1.73e-16	8.15e-14	0.6	0.37	Bipolar disorder and schizophrenia;	chr15:62013385	chr15:62060503~62062434:+
LGG	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-8.55	1.73e-16	8.15e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-8.55	1.73e-16	8.15e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-8.55	1.73e-16	8.15e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-8.55	1.73e-16	8.15e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-8.55	1.73e-16	8.15e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	8.55	1.73e-16	8.15e-14	0.55	0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-8.55	1.73e-16	8.15e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-8.55	1.73e-16	8.15e-14	-0.55	-0.37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
LGG	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	8.55	1.74e-16	8.18e-14	0.92	0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
LGG	cis	rs62263923	0.505	rs7644190	ENSG00000239519.1	CADM2-AS1	8.55	1.74e-16	8.18e-14	0.41	0.37	Educational attainment (years of education);	chr3:85856268	chr3:85992183~86028007:-
LGG	cis	rs6921919	0.583	rs1054372	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs9468354	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs7773051	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs12697938	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs13437294	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.609	rs9468357	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs34513104	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs9461456	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.525	rs9468360	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs16894021	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs11751693	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs7749736	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.525	rs9468361	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs7775132	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs3734563	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs1591913	ENSG00000226314.6	ZNF192P1	8.55	1.74e-16	8.18e-14	0.37	0.37	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28161781~28169594:+
LGG	cis	rs9595066	0.548	rs9562537	ENSG00000230731.2	RP11-478K15.6	8.55	1.74e-16	8.18e-14	0.59	0.37	Schizophrenia;	chr13:44181651	chr13:44234118~44243192:-
LGG	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	8.55	1.74e-16	8.2e-14	0.45	0.37	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
LGG	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-8.55	1.75e-16	8.21e-14	-0.37	-0.37	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
LGG	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-8.55	1.75e-16	8.23e-14	-0.3	-0.37	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
LGG	cis	rs1707322	1	rs11211232	ENSG00000281133.1	AL355480.3	-8.55	1.75e-16	8.24e-14	-0.43	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45580892~45580996:-
LGG	cis	rs35934224	1	rs35934224	ENSG00000232926.1	AC000078.5	8.55	1.75e-16	8.25e-14	0.43	0.37	Glaucoma (primary open-angle);	chr22:19885122	chr22:19887289~19887970:+
LGG	cis	rs11992162	0.967	rs10088415	ENSG00000227888.4	FAM66A	-8.55	1.76e-16	8.26e-14	-0.43	-0.37	Monocyte count;	chr8:11973316	chr8:12362019~12388296:+
LGG	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-8.55	1.76e-16	8.29e-14	-0.37	-0.37	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
LGG	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	8.55	1.77e-16	8.31e-14	0.63	0.37	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
LGG	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	8.55	1.77e-16	8.31e-14	0.63	0.37	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
LGG	cis	rs9322193	0.962	rs35443312	ENSG00000216621.7	RP11-244K5.6	8.55	1.77e-16	8.34e-14	0.43	0.37	Lung cancer;	chr6:149670625	chr6:149934527~149936782:+
LGG	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	8.55	1.77e-16	8.34e-14	0.52	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
LGG	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-8.54	1.77e-16	8.34e-14	-0.43	-0.37	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
LGG	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	8.54	1.78e-16	8.36e-14	0.45	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs56146117	ENSG00000266490.1	CTD-2349P21.9	8.54	1.78e-16	8.36e-14	0.45	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.568	rs9907834	ENSG00000266490.1	CTD-2349P21.9	8.54	1.78e-16	8.36e-14	0.45	0.37	Body mass index;	chr17:30826995	chr17:30792372~30792833:+
LGG	cis	rs858239	0.699	rs858260	ENSG00000230042.1	AK3P3	-8.54	1.78e-16	8.36e-14	-0.38	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23129178~23129841:+
LGG	cis	rs17826219	0.568	rs9903854	ENSG00000266490.1	CTD-2349P21.9	8.54	1.78e-16	8.37e-14	0.45	0.37	Body mass index;	chr17:30826980	chr17:30792372~30792833:+
LGG	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	8.54	1.78e-16	8.37e-14	0.43	0.37	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
LGG	cis	rs10946940	0.965	rs4713112	ENSG00000199851.2	U3	-8.54	1.79e-16	8.4e-14	-0.48	-0.37	Systemic lupus erythematosus;	chr6:27549054	chr6:28015568~28015777:+
LGG	cis	rs9346353	1	rs9360405	ENSG00000219881.1	GAPDHP42	8.54	1.79e-16	8.4e-14	0.35	0.37	Sleep duration;	chr6:69793620	chr6:69745871~69746851:+
LGG	cis	rs4713118	0.513	rs149962	ENSG00000218016.2	ZNF192P2	-8.54	1.79e-16	8.41e-14	-0.48	-0.37	Parkinson's disease;	chr6:28048140	chr6:28188050~28189432:+
LGG	cis	rs12682352	0.602	rs1473029	ENSG00000173295.6	FAM86B3P	-8.54	1.79e-16	8.43e-14	-0.39	-0.37	Neuroticism;	chr8:8811407	chr8:8228595~8244865:+
LGG	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-8.54	1.8e-16	8.45e-14	-0.49	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
LGG	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-8.54	1.8e-16	8.47e-14	-0.39	-0.37	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
LGG	cis	rs7302981	0.51	rs860698	ENSG00000272368.2	RP4-605O3.4	8.54	1.8e-16	8.47e-14	0.35	0.37	Systolic blood pressure;	chr12:50092539	chr12:50112197~50165618:+
LGG	cis	rs3020264	0.55	rs2515557	ENSG00000271743.1	CTD-2541M15.3	-8.54	1.8e-16	8.47e-14	-0.44	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6617592	chr8:6615604~6617198:-
LGG	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-8.54	1.8e-16	8.47e-14	-0.46	-0.37	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
LGG	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-8.54	1.81e-16	8.51e-14	-0.53	-0.37	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
LGG	cis	rs35160687	0.623	rs35408390	ENSG00000273080.1	RP11-301O19.1	-8.54	1.81e-16	8.52e-14	-0.39	-0.37	Night sleep phenotypes;	chr2:86244659	chr2:86195590~86196049:+
LGG	cis	rs2980439	0.818	rs2948300	ENSG00000253981.4	ALG1L13P	-8.54	1.81e-16	8.53e-14	-0.37	-0.37	Neuroticism;	chr8:8248986	chr8:8236003~8244667:-
LGG	cis	rs858239	0.73	rs858279	ENSG00000230042.1	AK3P3	-8.54	1.84e-16	8.63e-14	-0.38	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23129178~23129841:+
LGG	cis	rs17345786	0.798	rs1609159	ENSG00000256628.3	ZBTB11-AS1	8.54	1.84e-16	8.63e-14	0.43	0.37	Colonoscopy-negative controls vs population controls;	chr3:101557058	chr3:101676475~101679217:+
LGG	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-8.54	1.84e-16	8.65e-14	-0.46	-0.37	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
LGG	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-8.54	1.84e-16	8.65e-14	-0.51	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
LGG	cis	rs9875589	0.915	rs9835402	ENSG00000233121.1	VN1R20P	8.54	1.85e-16	8.69e-14	0.37	0.37	Ovarian reserve;	chr3:13912899	chr3:13926813~13927778:+
LGG	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	8.54	1.85e-16	8.7e-14	0.46	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
LGG	cis	rs6539247	0.583	rs880297	ENSG00000257890.1	RP11-114F10.2	-8.54	1.87e-16	8.78e-14	-0.44	-0.37	Attention function in attention deficit hyperactive disorder;	chr12:106049488	chr12:106050961~106058254:-
LGG	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	8.54	1.88e-16	8.82e-14	0.43	0.37	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
LGG	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-8.54	1.88e-16	8.85e-14	-0.48	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
LGG	cis	rs763567	1	rs1928715	ENSG00000271811.1	RP1-79C4.4	-8.54	1.88e-16	8.85e-14	-0.36	-0.37	Tonsillectomy;	chr1:170598296	chr1:170667381~170669425:+
LGG	cis	rs7829975	0.523	rs9644774	ENSG00000173295.6	FAM86B3P	8.54	1.89e-16	8.86e-14	0.41	0.37	Mood instability;	chr8:8702322	chr8:8228595~8244865:+
LGG	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	8.54	1.89e-16	8.87e-14	0.42	0.37	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
LGG	cis	rs5742933	0.69	rs6726636	ENSG00000273240.1	RP11-455J20.3	-8.54	1.89e-16	8.89e-14	-0.51	-0.37	Ferritin levels;	chr2:189653095	chr2:189763859~189764456:-
LGG	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-8.54	1.89e-16	8.89e-14	-0.38	-0.37	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-8.54	1.9e-16	8.9e-14	-0.46	-0.37	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
LGG	cis	rs9322193	0.884	rs10872647	ENSG00000216621.7	RP11-244K5.6	8.54	1.9e-16	8.93e-14	0.46	0.37	Lung cancer;	chr6:149758687	chr6:149934527~149936782:+
LGG	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	8.54	1.91e-16	8.95e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	8.54	1.91e-16	8.95e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	8.54	1.91e-16	8.95e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	8.54	1.91e-16	8.95e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	8.54	1.91e-16	8.95e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
LGG	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	8.53	1.91e-16	8.98e-14	0.5	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
LGG	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-8.53	1.92e-16	9.02e-14	-0.46	-0.36	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-8.53	1.92e-16	9.02e-14	-0.46	-0.36	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-8.53	1.92e-16	9.02e-14	-0.46	-0.36	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-8.53	1.92e-16	9.02e-14	-0.46	-0.36	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-8.53	1.92e-16	9.02e-14	-0.46	-0.36	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-8.53	1.92e-16	9.02e-14	-0.46	-0.36	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
LGG	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-8.53	1.92e-16	9.02e-14	-0.48	-0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
LGG	cis	rs1420956	0.905	rs1030096	ENSG00000264151.4	RP11-739N10.1	8.53	1.93e-16	9.04e-14	0.45	0.36	Obesity-related traits;	chr18:27578304	chr18:27336379~27595164:-
LGG	cis	rs6003958	1	rs6003958	ENSG00000235689.1	AP000351.13	-8.53	1.93e-16	9.05e-14	-0.51	-0.36	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:24006305~24008258:-
LGG	cis	rs5760092	0.755	rs6003959	ENSG00000235689.1	AP000351.13	-8.53	1.93e-16	9.05e-14	-0.51	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:24006305~24008258:-
LGG	cis	rs9346353	1	rs12525951	ENSG00000219881.1	GAPDHP42	8.53	1.94e-16	9.08e-14	0.35	0.36	Sleep duration;	chr6:69766837	chr6:69745871~69746851:+
LGG	cis	rs741668	1	rs17067467	ENSG00000235903.6	CPB2-AS1	8.53	1.94e-16	9.09e-14	0.39	0.36	Cerebrospinal fluid clusterin levels;	chr13:45943774	chr13:46052806~46113332:+
LGG	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-8.53	1.94e-16	9.1e-14	-0.43	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
LGG	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	8.53	1.94e-16	9.1e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	8.53	1.94e-16	9.1e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	8.53	1.94e-16	9.1e-14	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
LGG	cis	rs9859260	1	rs11718657	ENSG00000231464.1	AC024937.4	8.53	1.95e-16	9.14e-14	0.45	0.36	Mean corpuscular volume;	chr3:196070682	chr3:195996738~195998233:+
LGG	cis	rs9859260	0.961	rs11185506	ENSG00000231464.1	AC024937.4	8.53	1.95e-16	9.14e-14	0.45	0.36	Mean corpuscular volume;	chr3:196070705	chr3:195996738~195998233:+
LGG	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	8.53	1.95e-16	9.16e-14	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
LGG	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	8.53	1.96e-16	9.17e-14	0.44	0.36	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
LGG	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-8.53	1.96e-16	9.17e-14	-0.48	-0.36	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
LGG	cis	rs893971	0.643	rs9998450	ENSG00000246375.2	RP11-10L7.1	8.53	1.96e-16	9.19e-14	0.44	0.36	Conduct disorder (maternal expressed emotions interaction);	chr4:88309973	chr4:88284942~88331421:+
LGG	cis	rs893971	0.643	rs28884607	ENSG00000246375.2	RP11-10L7.1	8.53	1.96e-16	9.19e-14	0.44	0.36	Conduct disorder (maternal expressed emotions interaction);	chr4:88310671	chr4:88284942~88331421:+
LGG	cis	rs17772222	0.74	rs61975278	ENSG00000222990.1	RNU4-22P	8.53	1.97e-16	9.23e-14	0.45	0.36	Coronary artery calcification;	chr14:88511223	chr14:88513498~88513663:+
LGG	cis	rs6545883	0.507	rs4672427	ENSG00000273302.1	RP11-493E12.2	-8.53	1.97e-16	9.24e-14	-0.31	-0.36	Tuberculosis;	chr2:61242115	chr2:61199979~61200769:+
LGG	cis	rs9346353	1	rs9346335	ENSG00000219881.1	GAPDHP42	8.53	1.97e-16	9.25e-14	0.35	0.36	Sleep duration;	chr6:69717533	chr6:69745871~69746851:+
LGG	cis	rs5742933	0.696	rs17271246	ENSG00000273240.1	RP11-455J20.3	-8.53	1.98e-16	9.27e-14	-0.54	-0.36	Ferritin levels;	chr2:189781481	chr2:189763859~189764456:-
LGG	cis	rs12554020	0.786	rs7035657	ENSG00000237385.1	RP11-165J3.5	-8.53	1.98e-16	9.28e-14	-0.59	-0.36	Schizophrenia;	chr9:93434769	chr9:93430342~93431299:-
LGG	cis	rs12554020	0.786	rs7036984	ENSG00000237385.1	RP11-165J3.5	8.53	1.98e-16	9.28e-14	0.59	0.36	Schizophrenia;	chr9:93438258	chr9:93430342~93431299:-
LGG	cis	rs1185460	0.967	rs1784461	ENSG00000272186.1	RP11-110I1.13	-8.53	1.99e-16	9.3e-14	-0.35	-0.36	Coronary artery disease;	chr11:119067274	chr11:119067374~119067698:-
LGG	cis	rs9875589	0.628	rs62234602	ENSG00000233121.1	VN1R20P	8.53	1.99e-16	9.31e-14	0.37	0.36	Ovarian reserve;	chr3:13960670	chr3:13926813~13927778:+
LGG	cis	rs8042680	0.522	rs12595616	ENSG00000214432.8	AC068831.10	8.53	1.99e-16	9.31e-14	0.37	0.36	Type 2 diabetes;	chr15:91020283	chr15:91022619~91036611:+
LGG	cis	rs10946940	0.864	rs13201411	ENSG00000199851.2	U3	-8.53	1.99e-16	9.31e-14	-0.49	-0.36	Systemic lupus erythematosus;	chr6:27530438	chr6:28015568~28015777:+
LGG	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	8.53	1.99e-16	9.32e-14	0.65	0.36	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
LGG	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-8.53	1.99e-16	9.32e-14	-0.37	-0.36	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
LGG	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	8.53	1.99e-16	9.32e-14	0.45	0.36	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
LGG	cis	rs7208859	0.673	rs73271887	ENSG00000266490.1	CTD-2349P21.9	8.53	1.99e-16	9.32e-14	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs80355557	ENSG00000266490.1	CTD-2349P21.9	8.53	1.99e-16	9.34e-14	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9911173	ENSG00000266490.1	CTD-2349P21.9	8.53	1.99e-16	9.34e-14	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30792372~30792833:+
LGG	cis	rs4143844	0.867	rs34257602	ENSG00000259251.2	RP11-643M14.1	8.53	1.99e-16	9.34e-14	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61993548	chr15:62060503~62062434:+
LGG	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	8.53	2e-16	9.37e-14	0.43	0.36	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
LGG	cis	rs35160687	0.623	rs11127019	ENSG00000273080.1	RP11-301O19.1	-8.53	2e-16	9.37e-14	-0.38	-0.36	Night sleep phenotypes;	chr2:86240495	chr2:86195590~86196049:+
LGG	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-8.53	2e-16	9.38e-14	-0.44	-0.36	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
LGG	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-8.53	2.01e-16	9.42e-14	-0.3	-0.36	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
LGG	cis	rs950776	0.745	rs3743075	ENSG00000261762.1	RP11-650L12.2	-8.53	2.02e-16	9.44e-14	-0.47	-0.36	Sudden cardiac arrest;	chr15:78617110	chr15:78589123~78591276:-
LGG	cis	rs3096299	0.809	rs3096325	ENSG00000274627.1	RP11-104N10.2	8.53	2.02e-16	9.46e-14	0.32	0.36	Multiple myeloma (IgH translocation);	chr16:89355270	chr16:89516797~89522217:+
LGG	cis	rs9322193	0.884	rs11155679	ENSG00000216621.7	RP11-244K5.6	8.53	2.02e-16	9.46e-14	0.46	0.36	Lung cancer;	chr6:149758881	chr6:149934527~149936782:+
LGG	cis	rs35857674	0.5	rs17758599	ENSG00000253484.1	RP11-109P6.2	8.53	2.02e-16	9.48e-14	0.36	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50034142	chr8:49817586~49820944:-
LGG	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.53	2.03e-16	9.49e-14	-0.38	-0.36	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
LGG	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.53	2.03e-16	9.49e-14	-0.38	-0.36	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
LGG	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.53	2.03e-16	9.49e-14	-0.38	-0.36	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
LGG	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.53	2.03e-16	9.49e-14	-0.38	-0.36	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
LGG	cis	rs6545883	0.507	rs12478192	ENSG00000273302.1	RP11-493E12.2	-8.53	2.03e-16	9.49e-14	-0.31	-0.36	Tuberculosis;	chr2:61364040	chr2:61199979~61200769:+
LGG	cis	rs6545883	0.524	rs12992614	ENSG00000273302.1	RP11-493E12.2	-8.53	2.03e-16	9.49e-14	-0.31	-0.36	Tuberculosis;	chr2:61365941	chr2:61199979~61200769:+
LGG	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-8.53	2.03e-16	9.52e-14	-0.43	-0.36	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
LGG	cis	rs35160687	0.644	rs1863056	ENSG00000273080.1	RP11-301O19.1	-8.53	2.03e-16	9.53e-14	-0.38	-0.36	Night sleep phenotypes;	chr2:86264122	chr2:86195590~86196049:+
LGG	cis	rs4950322	0.57	rs72691004	ENSG00000278811.3	LINC00624	8.53	2.05e-16	9.58e-14	0.35	0.36	Protein quantitative trait loci;	chr1:147234309	chr1:147258885~147517875:-
LGG	cis	rs17597773	0.527	rs2484699	ENSG00000238078.1	LINC01352	-8.53	2.05e-16	9.58e-14	-0.45	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910410	chr1:220829255~220832429:+
LGG	cis	rs6921919	0.848	rs9468350	ENSG00000218016.2	ZNF192P2	-8.53	2.05e-16	9.59e-14	-0.48	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28188050~28189432:+
LGG	cis	rs1555322	1	rs2425027	ENSG00000126005.14	MMP24-AS1	-8.53	2.05e-16	9.59e-14	-0.55	-0.36	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35216462~35278131:-
LGG	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-8.52	2.06e-16	9.64e-14	-0.42	-0.36	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
LGG	cis	rs17772222	0.74	rs10138139	ENSG00000222990.1	RNU4-22P	8.52	2.06e-16	9.65e-14	0.43	0.36	Coronary artery calcification;	chr14:88510027	chr14:88513498~88513663:+
LGG	cis	rs9346353	1	rs921972	ENSG00000219881.1	GAPDHP42	8.52	2.07e-16	9.69e-14	0.35	0.36	Sleep duration;	chr6:69699985	chr6:69745871~69746851:+
LGG	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	-8.52	2.07e-16	9.7e-14	-0.37	-0.36	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
LGG	cis	rs1023500	0.551	rs2301521	ENSG00000227370.1	RP4-669P10.19	8.52	2.07e-16	9.7e-14	0.33	0.36	Schizophrenia;	chr22:42027106	chr22:42132543~42132998:+
LGG	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-8.52	2.07e-16	9.7e-14	-0.35	-0.36	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
LGG	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	8.52	2.08e-16	9.71e-14	0.48	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
LGG	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-8.52	2.08e-16	9.74e-14	-0.3	-0.36	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
LGG	cis	rs9346353	1	rs67438720	ENSG00000219881.1	GAPDHP42	8.52	2.09e-16	9.77e-14	0.35	0.36	Sleep duration;	chr6:69765359	chr6:69745871~69746851:+
LGG	cis	rs35160687	0.644	rs11127024	ENSG00000273080.1	RP11-301O19.1	-8.52	2.09e-16	9.77e-14	-0.38	-0.36	Night sleep phenotypes;	chr2:86278330	chr2:86195590~86196049:+
LGG	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-8.52	2.09e-16	9.78e-14	-0.42	-0.36	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
LGG	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	8.52	2.1e-16	9.81e-14	0.52	0.36	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
LGG	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	8.52	2.11e-16	9.85e-14	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
LGG	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	8.52	2.11e-16	9.85e-14	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
LGG	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	8.52	2.11e-16	9.85e-14	0.9	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
LGG	cis	rs9346353	1	rs4348273	ENSG00000219881.1	GAPDHP42	8.52	2.11e-16	9.87e-14	0.35	0.36	Sleep duration;	chr6:69763203	chr6:69745871~69746851:+
LGG	cis	rs1023500	0.596	rs133350	ENSG00000227370.1	RP4-669P10.19	8.52	2.11e-16	9.88e-14	0.33	0.36	Schizophrenia;	chr22:42033045	chr22:42132543~42132998:+
LGG	cis	rs454217	0.714	rs395142	ENSG00000277851.1	RP11-756G20.1	-8.52	2.12e-16	9.9e-14	-0.37	-0.36	Smoking quantity;	chr12:92341860	chr12:92247756~92363832:-
LGG	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	8.52	2.12e-16	9.9e-14	0.25	0.36	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
LGG	cis	rs9532669	0.926	rs12428966	ENSG00000239827.7	SUGT1P3	-8.52	2.12e-16	9.9e-14	-0.38	-0.36	Cervical cancer;	chr13:40876552	chr13:40908159~40921774:-
LGG	cis	rs6921919	0.583	rs6908137	ENSG00000226314.6	ZNF192P1	8.52	2.13e-16	9.94e-14	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28161781~28169594:+
LGG	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	8.52	2.13e-16	9.95e-14	0.56	0.36	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	8.52	2.13e-16	9.95e-14	0.56	0.36	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
LGG	cis	rs4950322	0.57	rs4593887	ENSG00000278811.3	LINC00624	8.52	2.13e-16	9.97e-14	0.35	0.36	Protein quantitative trait loci;	chr1:147234246	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.748	rs17356680	ENSG00000278811.3	LINC00624	8.52	2.13e-16	9.98e-14	0.37	0.36	Protein quantitative trait loci;	chr1:147354934	chr1:147258885~147517875:-
LGG	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-8.52	2.14e-16	9.98e-14	-0.3	-0.36	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
LGG	cis	rs375066	0.935	rs425221	ENSG00000267191.1	RP11-15A1.2	8.52	2.14e-16	9.99e-14	0.38	0.36	Breast cancer;	chr19:43914392	chr19:43902001~43926545:+
LGG	cis	rs944990	0.64	rs10821131	ENSG00000227603.1	RP11-165J3.6	8.52	2.14e-16	1e-13	0.37	0.36	Body mass index;	chr9:93466540	chr9:93435332~93437121:-
LGG	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-8.52	2.14e-16	1e-13	-0.3	-0.36	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
LGG	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	8.52	2.15e-16	1e-13	0.43	0.36	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
LGG	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-8.52	2.15e-16	1.01e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
LGG	cis	rs1555322	1	rs1555322	ENSG00000126005.14	MMP24-AS1	-8.52	2.16e-16	1.01e-13	-0.54	-0.36	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35216462~35278131:-
LGG	cis	rs6545883	0.507	rs2442025	ENSG00000273302.1	RP11-493E12.2	-8.52	2.16e-16	1.01e-13	-0.32	-0.36	Tuberculosis;	chr2:61344310	chr2:61199979~61200769:+
LGG	cis	rs6545883	0.524	rs2593631	ENSG00000273302.1	RP11-493E12.2	-8.52	2.16e-16	1.01e-13	-0.32	-0.36	Tuberculosis;	chr2:61345151	chr2:61199979~61200769:+
LGG	cis	rs6545883	0.542	rs2593628	ENSG00000273302.1	RP11-493E12.2	-8.52	2.16e-16	1.01e-13	-0.32	-0.36	Tuberculosis;	chr2:61346152	chr2:61199979~61200769:+
LGG	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	-8.52	2.17e-16	1.01e-13	-0.38	-0.36	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
LGG	cis	rs11992162	1	rs11994417	ENSG00000227888.4	FAM66A	8.52	2.17e-16	1.01e-13	0.44	0.36	Monocyte count;	chr8:11975753	chr8:12362019~12388296:+
LGG	cis	rs6496932	0.913	rs34896088	ENSG00000218052.5	ADAMTS7P4	8.52	2.18e-16	1.02e-13	0.54	0.36	Central corneal thickness;Corneal structure;	chr15:85278393	chr15:85255369~85330334:-
LGG	cis	rs2075466	0.514	rs3747614	ENSG00000267077.1	RP11-127I20.5	-8.52	2.18e-16	1.02e-13	-0.51	-0.36	Colonoscopy-negative controls vs population controls;	chr16:4858666	chr16:4795265~4796532:-
LGG	cis	rs9322193	0.923	rs12175504	ENSG00000216621.7	RP11-244K5.6	8.52	2.18e-16	1.02e-13	0.43	0.36	Lung cancer;	chr6:149664079	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs62439843	ENSG00000216621.7	RP11-244K5.6	8.52	2.18e-16	1.02e-13	0.43	0.36	Lung cancer;	chr6:149676521	chr6:149934527~149936782:+
LGG	cis	rs5742933	1	rs1317751	ENSG00000253559.1	OSGEPL1-AS1	-8.52	2.18e-16	1.02e-13	-0.47	-0.36	Ferritin levels;	chr2:189807898	chr2:189762704~189765556:+
LGG	cis	rs5742933	1	rs3791770	ENSG00000253559.1	OSGEPL1-AS1	-8.52	2.18e-16	1.02e-13	-0.47	-0.36	Ferritin levels;	chr2:189809109	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.948	rs62184286	ENSG00000253559.1	OSGEPL1-AS1	-8.52	2.18e-16	1.02e-13	-0.47	-0.36	Ferritin levels;	chr2:189812147	chr2:189762704~189765556:+
LGG	cis	rs4143844	0.867	rs34997975	ENSG00000259251.2	RP11-643M14.1	8.52	2.19e-16	1.02e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61929987	chr15:62060503~62062434:+
LGG	cis	rs4950322	0.542	rs3766519	ENSG00000278811.3	LINC00624	8.52	2.19e-16	1.02e-13	0.35	0.36	Protein quantitative trait loci;	chr1:147214802	chr1:147258885~147517875:-
LGG	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-8.52	2.19e-16	1.02e-13	-0.3	-0.36	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
LGG	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-8.52	2.2e-16	1.03e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
LGG	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	8.52	2.2e-16	1.03e-13	0.42	0.36	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
LGG	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	8.52	2.21e-16	1.03e-13	0.46	0.36	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
LGG	cis	rs944990	0.576	rs3933795	ENSG00000227603.1	RP11-165J3.6	8.52	2.21e-16	1.03e-13	0.37	0.36	Body mass index;	chr9:93423391	chr9:93435332~93437121:-
LGG	cis	rs7247513	0.759	rs73002392	ENSG00000213290.4	PGK1P2	-8.52	2.21e-16	1.03e-13	-0.4	-0.36	Bipolar disorder;	chr19:12657577	chr19:12559571~12561105:+
LGG	cis	rs11992162	0.967	rs7836456	ENSG00000227888.4	FAM66A	8.52	2.21e-16	1.03e-13	0.43	0.36	Monocyte count;	chr8:11971666	chr8:12362019~12388296:+
LGG	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-8.52	2.21e-16	1.03e-13	-0.39	-0.36	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
LGG	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-8.52	2.21e-16	1.03e-13	-0.46	-0.36	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
LGG	cis	rs7829975	0.628	rs1109618	ENSG00000173295.6	FAM86B3P	8.52	2.22e-16	1.04e-13	0.39	0.36	Mood instability;	chr8:8713854	chr8:8228595~8244865:+
LGG	cis	rs6539247	0.583	rs1808691	ENSG00000257890.1	RP11-114F10.2	-8.51	2.22e-16	1.04e-13	-0.44	-0.36	Attention function in attention deficit hyperactive disorder;	chr12:106059741	chr12:106050961~106058254:-
LGG	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-8.51	2.24e-16	1.05e-13	-0.43	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
LGG	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-8.51	2.24e-16	1.05e-13	-0.43	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
LGG	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-8.51	2.24e-16	1.05e-13	-0.48	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-8.51	2.24e-16	1.05e-13	-0.48	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
LGG	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-8.51	2.25e-16	1.05e-13	-0.39	-0.36	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
LGG	cis	rs4281086	1	rs4281086	ENSG00000253678.1	RP11-981G7.3	8.51	2.25e-16	1.05e-13	0.39	0.36	Obesity-related traits;	chr8:10494798	chr8:10477491~10479375:-
LGG	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	8.51	2.25e-16	1.05e-13	0.45	0.36	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
LGG	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	8.51	2.25e-16	1.05e-13	0.34	0.36	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
LGG	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-8.51	2.26e-16	1.05e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
LGG	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	8.51	2.26e-16	1.05e-13	0.39	0.36	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-8.51	2.26e-16	1.05e-13	-0.39	-0.36	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-8.51	2.26e-16	1.05e-13	-0.39	-0.36	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
LGG	cis	rs1707322	1	rs1707322	ENSG00000281133.1	AL355480.3	-8.51	2.27e-16	1.06e-13	-0.43	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45580892~45580996:-
LGG	cis	rs4950322	0.634	rs4950415	ENSG00000278811.3	LINC00624	8.51	2.27e-16	1.06e-13	0.36	0.36	Protein quantitative trait loci;	chr1:147350951	chr1:147258885~147517875:-
LGG	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-8.51	2.27e-16	1.06e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
LGG	cis	rs6921919	0.583	rs7759191	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs7764737	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs9461458	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.609	rs9468365	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs1361385	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs1416918	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs9468367	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs9461459	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs28360638	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs9468368	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs2041230	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.609	rs1005127	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28161781~28169594:+
LGG	cis	rs853679	0.515	rs4580862	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Depression;	chr6:28399886	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs4357130	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs11755942	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs6907950	ENSG00000226314.6	ZNF192P1	8.51	2.28e-16	1.06e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28161781~28169594:+
LGG	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
LGG	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-8.51	2.28e-16	1.06e-13	-0.39	-0.36	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
LGG	cis	rs7474896	0.583	rs11011347	ENSG00000226578.1	RP11-258F22.1	-8.51	2.28e-16	1.06e-13	-0.48	-0.36	Obesity (extreme);	chr10:37730336	chr10:37775371~37784131:-
LGG	cis	rs9532669	0.89	rs9532627	ENSG00000239827.7	SUGT1P3	-8.51	2.28e-16	1.06e-13	-0.4	-0.36	Cervical cancer;	chr13:40874811	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9532689	ENSG00000168852.11	TPTE2P5	8.51	2.28e-16	1.06e-13	0.37	0.36	Cervical cancer;	chr13:40957990	chr13:40822296~40921749:-
LGG	cis	rs10946940	0.965	rs10946935	ENSG00000199851.2	U3	-8.51	2.29e-16	1.07e-13	-0.49	-0.36	Systemic lupus erythematosus;	chr6:27533566	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.638	rs2108926	ENSG00000218016.2	ZNF192P2	-8.51	2.29e-16	1.07e-13	-0.46	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28188050~28189432:+
LGG	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-8.51	2.29e-16	1.07e-13	-0.64	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
LGG	cis	rs7829975	1	rs7829975	ENSG00000253981.4	ALG1L13P	8.51	2.3e-16	1.07e-13	0.38	0.36	Mood instability;	chr8:8690607	chr8:8236003~8244667:-
LGG	cis	rs67340775	0.541	rs200979	ENSG00000226314.6	ZNF192P1	8.51	2.31e-16	1.07e-13	0.51	0.36	Lung cancer in ever smokers;	chr6:27884579	chr6:28161781~28169594:+
LGG	cis	rs67340775	0.541	rs200975	ENSG00000226314.6	ZNF192P1	8.51	2.31e-16	1.07e-13	0.51	0.36	Lung cancer in ever smokers;	chr6:27887847	chr6:28161781~28169594:+
LGG	cis	rs67340775	0.541	rs200974	ENSG00000226314.6	ZNF192P1	8.51	2.31e-16	1.07e-13	0.51	0.36	Lung cancer in ever smokers;	chr6:27888067	chr6:28161781~28169594:+
LGG	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	8.51	2.31e-16	1.07e-13	0.43	0.36	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
LGG	cis	rs4718428	0.705	rs13227468	ENSG00000232546.1	RP11-458F8.1	-8.51	2.31e-16	1.08e-13	-0.35	-0.36	Corneal structure;	chr7:66968576	chr7:66848496~66858136:+
LGG	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	8.51	2.31e-16	1.08e-13	0.36	0.36	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
LGG	cis	rs853679	0.546	rs34676049	ENSG00000199851.2	U3	8.51	2.31e-16	1.08e-13	0.93	0.36	Depression;	chr6:28485841	chr6:28015568~28015777:+
LGG	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	8.51	2.31e-16	1.08e-13	0.35	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
LGG	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-8.51	2.32e-16	1.08e-13	-0.48	-0.36	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
LGG	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-8.51	2.32e-16	1.08e-13	-0.46	-0.36	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-8.51	2.32e-16	1.08e-13	-0.46	-0.36	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
LGG	cis	rs7520050	0.898	rs4660885	ENSG00000280836.1	AL355480.1	8.51	2.32e-16	1.08e-13	0.39	0.36	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45581219~45581321:-
LGG	cis	rs9376098	0.825	rs6922541	ENSG00000232876.1	CTA-212D2.2	-8.51	2.33e-16	1.08e-13	-0.43	-0.36	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161681	chr6:135055033~135060550:+
LGG	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	8.51	2.33e-16	1.08e-13	0.36	0.36	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
LGG	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	8.51	2.33e-16	1.08e-13	0.36	0.36	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
LGG	cis	rs4713118	0.619	rs200486	ENSG00000216901.1	AL022393.7	8.51	2.33e-16	1.08e-13	0.52	0.36	Parkinson's disease;	chr6:27811728	chr6:28176188~28176674:+
LGG	cis	rs1185460	0.967	rs1784302	ENSG00000272186.1	RP11-110I1.13	-8.51	2.33e-16	1.09e-13	-0.35	-0.36	Coronary artery disease;	chr11:119070247	chr11:119067374~119067698:-
LGG	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-8.51	2.34e-16	1.09e-13	-0.3	-0.36	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
LGG	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-8.51	2.35e-16	1.09e-13	-0.37	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
LGG	cis	rs200972	1	rs200972	ENSG00000218016.2	ZNF192P2	-8.51	2.36e-16	1.1e-13	-0.44	-0.36	Urinary tract infection frequency;	chr6:27891059	chr6:28188050~28189432:+
LGG	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	8.51	2.36e-16	1.1e-13	0.48	0.36	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
LGG	cis	rs1185460	0.967	rs1184902	ENSG00000272186.1	RP11-110I1.13	-8.51	2.36e-16	1.1e-13	-0.35	-0.36	Coronary artery disease;	chr11:119074627	chr11:119067374~119067698:-
LGG	cis	rs9322193	0.962	rs35031906	ENSG00000216621.7	RP11-244K5.6	8.51	2.36e-16	1.1e-13	0.43	0.36	Lung cancer;	chr6:149677438	chr6:149934527~149936782:+
LGG	cis	rs853679	0.546	rs200996	ENSG00000216901.1	AL022393.7	8.51	2.37e-16	1.1e-13	0.68	0.36	Depression;	chr6:27844050	chr6:28176188~28176674:+
LGG	cis	rs893971	0.643	rs6532063	ENSG00000246375.2	RP11-10L7.1	8.51	2.38e-16	1.11e-13	0.44	0.36	Conduct disorder (maternal expressed emotions interaction);	chr4:88310803	chr4:88284942~88331421:+
LGG	cis	rs2739330	0.828	rs2877178	ENSG00000235689.1	AP000351.13	8.51	2.38e-16	1.11e-13	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:24006305~24008258:-
LGG	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-8.51	2.38e-16	1.11e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
LGG	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	8.51	2.39e-16	1.11e-13	0.42	0.36	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
LGG	cis	rs3096299	0.584	rs3114889	ENSG00000274627.1	RP11-104N10.2	8.51	2.39e-16	1.11e-13	0.32	0.36	Multiple myeloma (IgH translocation);	chr16:89349097	chr16:89516797~89522217:+
LGG	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-8.5	2.39e-16	1.11e-13	-0.46	-0.36	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
LGG	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-8.5	2.39e-16	1.11e-13	-0.46	-0.36	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
LGG	cis	rs4143844	0.867	rs957348	ENSG00000259251.2	RP11-643M14.1	8.5	2.4e-16	1.12e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61935700	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs35523559	ENSG00000259251.2	RP11-643M14.1	8.5	2.4e-16	1.12e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61936571	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.609	rs34234705	ENSG00000259251.2	RP11-643M14.1	8.5	2.4e-16	1.12e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61938475	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs36004142	ENSG00000259251.2	RP11-643M14.1	8.5	2.4e-16	1.12e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61940042	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs12905103	ENSG00000259251.2	RP11-643M14.1	8.5	2.4e-16	1.12e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61940083	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs12905403	ENSG00000259251.2	RP11-643M14.1	8.5	2.4e-16	1.12e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61940109	chr15:62060503~62062434:+
LGG	cis	rs11148252	0.74	rs9596643	ENSG00000278238.1	RP11-245D16.4	8.5	2.42e-16	1.12e-13	0.35	0.36	Lewy body disease;	chr13:52338245	chr13:52454775~52455331:-
LGG	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	8.5	2.42e-16	1.12e-13	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
LGG	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-8.5	2.42e-16	1.12e-13	-0.42	-0.36	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
LGG	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	8.5	2.42e-16	1.13e-13	0.5	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
LGG	cis	rs853679	0.546	rs200995	ENSG00000216901.1	AL022393.7	-8.5	2.43e-16	1.13e-13	-0.68	-0.36	Depression;	chr6:27845916	chr6:28176188~28176674:+
LGG	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-8.5	2.44e-16	1.13e-13	-0.43	-0.36	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
LGG	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	8.5	2.44e-16	1.13e-13	0.48	0.36	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
LGG	cis	rs9393777	0.844	rs28360634	ENSG00000199851.2	U3	8.5	2.45e-16	1.14e-13	0.91	0.36	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28015568~28015777:+
LGG	cis	rs62184315	0.536	rs62183651	ENSG00000273240.1	RP11-455J20.3	-8.5	2.45e-16	1.14e-13	-0.54	-0.36	Alcohol dependence (age at onset);	chr2:189647251	chr2:189763859~189764456:-
LGG	cis	rs62184315	0.536	rs62183652	ENSG00000273240.1	RP11-455J20.3	-8.5	2.45e-16	1.14e-13	-0.54	-0.36	Alcohol dependence (age at onset);	chr2:189648877	chr2:189763859~189764456:-
LGG	cis	rs62184315	0.536	rs62183653	ENSG00000273240.1	RP11-455J20.3	-8.5	2.45e-16	1.14e-13	-0.54	-0.36	Alcohol dependence (age at onset);	chr2:189650099	chr2:189763859~189764456:-
LGG	cis	rs62184315	0.536	rs72920421	ENSG00000273240.1	RP11-455J20.3	-8.5	2.45e-16	1.14e-13	-0.54	-0.36	Alcohol dependence (age at onset);	chr2:189650292	chr2:189763859~189764456:-
LGG	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-8.5	2.45e-16	1.14e-13	-0.27	-0.36	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
LGG	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-8.5	2.46e-16	1.14e-13	-0.55	-0.36	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
LGG	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-8.5	2.46e-16	1.14e-13	-0.36	-0.36	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
LGG	cis	rs6081541	0.689	rs6081546	ENSG00000179447.2	RP5-1027G4.3	-8.5	2.46e-16	1.14e-13	-0.44	-0.36	Psychosis (atypical);	chr20:19240785	chr20:19242302~19284596:-
LGG	cis	rs4143844	0.867	rs62006964	ENSG00000259251.2	RP11-643M14.1	8.5	2.47e-16	1.15e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61995424	chr15:62060503~62062434:+
LGG	cis	rs3096299	0.585	rs3114881	ENSG00000274627.1	RP11-104N10.2	8.5	2.48e-16	1.15e-13	0.32	0.36	Multiple myeloma (IgH translocation);	chr16:89356224	chr16:89516797~89522217:+
LGG	cis	rs4295623	0.585	rs34421088	ENSG00000227888.4	FAM66A	-8.5	2.48e-16	1.15e-13	-0.44	-0.36	Morning vs. evening chronotype;	chr8:11731533	chr8:12362019~12388296:+
LGG	cis	rs763567	0.81	rs638704	ENSG00000271811.1	RP1-79C4.4	8.5	2.48e-16	1.15e-13	0.36	0.36	Tonsillectomy;	chr1:170629046	chr1:170667381~170669425:+
LGG	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-8.5	2.48e-16	1.15e-13	-0.5	-0.36	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
LGG	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	-8.5	2.49e-16	1.15e-13	-0.37	-0.36	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
LGG	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	8.5	2.49e-16	1.16e-13	0.63	0.36	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
LGG	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-8.5	2.51e-16	1.17e-13	-0.37	-0.36	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
LGG	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-8.5	2.51e-16	1.17e-13	-0.37	-0.36	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
LGG	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	8.5	2.51e-16	1.17e-13	0.48	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
LGG	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-8.5	2.51e-16	1.17e-13	-0.41	-0.36	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
LGG	cis	rs11098499	0.909	rs11723839	ENSG00000250412.1	KLHL2P1	8.5	2.52e-16	1.17e-13	0.42	0.36	Corneal astigmatism;	chr4:119378518	chr4:119334329~119378233:+
LGG	cis	rs7474896	0.559	rs1735629	ENSG00000226578.1	RP11-258F22.1	8.5	2.52e-16	1.17e-13	0.48	0.36	Obesity (extreme);	chr10:37889381	chr10:37775371~37784131:-
LGG	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-8.5	2.52e-16	1.17e-13	-0.41	-0.36	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
LGG	cis	rs17772222	0.74	rs7160647	ENSG00000222990.1	RNU4-22P	8.5	2.52e-16	1.17e-13	0.43	0.36	Coronary artery calcification;	chr14:88507340	chr14:88513498~88513663:+
LGG	cis	rs853679	0.882	rs9380069	ENSG00000226314.6	ZNF192P1	8.5	2.52e-16	1.17e-13	0.53	0.36	Depression;	chr6:28235522	chr6:28161781~28169594:+
LGG	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	8.5	2.53e-16	1.17e-13	0.29	0.36	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
LGG	cis	rs2911132	0.564	rs1057569	ENSG00000248734.2	CTD-2260A17.1	8.5	2.54e-16	1.18e-13	0.43	0.36	Urate levels (BMI interaction);	chr5:96773906	chr5:96784777~96785999:+
LGG	cis	rs2911132	0.511	rs7063	ENSG00000248734.2	CTD-2260A17.1	8.5	2.54e-16	1.18e-13	0.43	0.36	Urate levels (BMI interaction);	chr5:96774507	chr5:96784777~96785999:+
LGG	cis	rs7927771	0.507	rs12366244	ENSG00000280615.1	Y_RNA	8.5	2.54e-16	1.18e-13	0.44	0.36	Subjective well-being;	chr11:47860578	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7933896	ENSG00000280615.1	Y_RNA	8.5	2.54e-16	1.18e-13	0.44	0.36	Subjective well-being;	chr11:47861230	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7943464	ENSG00000280615.1	Y_RNA	8.5	2.54e-16	1.18e-13	0.44	0.36	Subjective well-being;	chr11:47865087	chr11:47614898~47614994:-
LGG	cis	rs7124681	0.546	rs7941399	ENSG00000280615.1	Y_RNA	8.5	2.54e-16	1.18e-13	0.44	0.36	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47868869	chr11:47614898~47614994:-
LGG	cis	rs6496932	0.503	rs7164354	ENSG00000218052.5	ADAMTS7P4	-8.5	2.55e-16	1.18e-13	-0.54	-0.36	Central corneal thickness;Corneal structure;	chr15:85405217	chr15:85255369~85330334:-
LGG	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-8.5	2.55e-16	1.18e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
LGG	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	-8.5	2.55e-16	1.18e-13	-0.37	-0.36	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
LGG	cis	rs4295623	0.504	rs11250160	ENSG00000227888.4	FAM66A	-8.5	2.56e-16	1.19e-13	-0.43	-0.36	Morning vs. evening chronotype;	chr8:11735208	chr8:12362019~12388296:+
LGG	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-8.5	2.56e-16	1.19e-13	-0.48	-0.36	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
LGG	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-8.5	2.56e-16	1.19e-13	-0.48	-0.36	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
LGG	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	8.5	2.56e-16	1.19e-13	0.4	0.36	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
LGG	cis	rs853679	0.607	rs200489	ENSG00000199851.2	U3	8.5	2.56e-16	1.19e-13	0.78	0.36	Depression;	chr6:27830479	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149897	ENSG00000218016.2	ZNF192P2	-8.5	2.57e-16	1.19e-13	-0.47	-0.36	Parkinson's disease;	chr6:28038872	chr6:28188050~28189432:+
LGG	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-8.5	2.57e-16	1.19e-13	-0.44	-0.36	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
LGG	cis	rs5742933	0.69	rs16831821	ENSG00000273240.1	RP11-455J20.3	-8.49	2.58e-16	1.2e-13	-0.54	-0.36	Ferritin levels;	chr2:189641087	chr2:189763859~189764456:-
LGG	cis	rs9322193	0.884	rs10872648	ENSG00000216621.7	RP11-244K5.6	8.49	2.58e-16	1.2e-13	0.46	0.36	Lung cancer;	chr6:149758699	chr6:149934527~149936782:+
LGG	cis	rs4950322	0.542	rs17159924	ENSG00000278811.3	LINC00624	8.49	2.58e-16	1.2e-13	0.35	0.36	Protein quantitative trait loci;	chr1:147199463	chr1:147258885~147517875:-
LGG	cis	rs1185460	0.967	rs1784459	ENSG00000272186.1	RP11-110I1.13	-8.49	2.59e-16	1.2e-13	-0.35	-0.36	Coronary artery disease;	chr11:119067677	chr11:119067374~119067698:-
LGG	cis	rs1185460	0.967	rs1786684	ENSG00000272186.1	RP11-110I1.13	-8.49	2.59e-16	1.2e-13	-0.35	-0.36	Coronary artery disease;	chr11:119067724	chr11:119067374~119067698:-
LGG	cis	rs1387259	0.64	rs10783243	ENSG00000258273.1	RP11-370I10.4	8.49	2.6e-16	1.21e-13	0.42	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48333755~48333901:-
LGG	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	8.49	2.6e-16	1.21e-13	0.43	0.36	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
LGG	cis	rs853679	0.567	rs13209596	ENSG00000218016.2	ZNF192P2	-8.49	2.6e-16	1.21e-13	-0.46	-0.36	Depression;	chr6:28428413	chr6:28188050~28189432:+
LGG	cis	rs853679	0.567	rs9969098	ENSG00000218016.2	ZNF192P2	-8.49	2.6e-16	1.21e-13	-0.46	-0.36	Depression;	chr6:28430971	chr6:28188050~28189432:+
LGG	cis	rs853679	0.567	rs7740429	ENSG00000218016.2	ZNF192P2	-8.49	2.6e-16	1.21e-13	-0.46	-0.36	Depression;	chr6:28431469	chr6:28188050~28189432:+
LGG	cis	rs853679	0.567	rs16894106	ENSG00000218016.2	ZNF192P2	-8.49	2.6e-16	1.21e-13	-0.46	-0.36	Depression;	chr6:28432562	chr6:28188050~28189432:+
LGG	cis	rs17772222	0.653	rs1346996	ENSG00000222990.1	RNU4-22P	8.49	2.61e-16	1.21e-13	0.43	0.36	Coronary artery calcification;	chr14:88507174	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs7160471	ENSG00000222990.1	RNU4-22P	8.49	2.61e-16	1.21e-13	0.43	0.36	Coronary artery calcification;	chr14:88507241	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.74	rs9323830	ENSG00000222990.1	RNU4-22P	8.49	2.61e-16	1.21e-13	0.43	0.36	Coronary artery calcification;	chr14:88507260	chr14:88513498~88513663:+
LGG	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-8.49	2.61e-16	1.21e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
LGG	cis	rs227275	0.525	rs11097796	ENSG00000248971.2	KRT8P46	-8.49	2.61e-16	1.21e-13	-0.38	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs11097797	ENSG00000248971.2	KRT8P46	-8.49	2.61e-16	1.21e-13	-0.38	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs13117110	ENSG00000248971.2	KRT8P46	-8.49	2.61e-16	1.21e-13	-0.38	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs13144033	ENSG00000248971.2	KRT8P46	-8.49	2.61e-16	1.21e-13	-0.38	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs10029073	ENSG00000248971.2	KRT8P46	-8.49	2.61e-16	1.21e-13	-0.38	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs724446	ENSG00000248971.2	KRT8P46	-8.49	2.61e-16	1.21e-13	-0.38	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102728746~102730171:-
LGG	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-8.49	2.62e-16	1.21e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-8.49	2.62e-16	1.21e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
LGG	cis	rs11992162	0.967	rs4840601	ENSG00000227888.4	FAM66A	8.49	2.62e-16	1.21e-13	0.43	0.36	Monocyte count;	chr8:11971221	chr8:12362019~12388296:+
LGG	cis	rs600231	0.623	rs3015966	ENSG00000245532.5	NEAT1	8.49	2.63e-16	1.22e-13	0.25	0.36	Bone mineral density;	chr11:65450118	chr11:65422774~65445540:+
LGG	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-8.49	2.63e-16	1.22e-13	-0.43	-0.36	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
LGG	cis	rs6061231	0.834	rs2427311	ENSG00000273619.1	RP5-908M14.9	-8.49	2.64e-16	1.22e-13	-0.27	-0.36	Colorectal cancer;	chr20:62395067	chr20:62386303~62386970:-
LGG	cis	rs6545883	0.507	rs4411680	ENSG00000273302.1	RP11-493E12.2	-8.49	2.64e-16	1.22e-13	-0.31	-0.36	Tuberculosis;	chr2:61356970	chr2:61199979~61200769:+
LGG	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	8.49	2.64e-16	1.22e-13	0.43	0.36	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
LGG	cis	rs7208859	0.673	rs9915139	ENSG00000266490.1	CTD-2349P21.9	8.49	2.64e-16	1.22e-13	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30792372~30792833:+
LGG	cis	rs6496932	0.865	rs10520600	ENSG00000218052.5	ADAMTS7P4	8.49	2.65e-16	1.22e-13	0.57	0.36	Central corneal thickness;Corneal structure;	chr15:85365171	chr15:85255369~85330334:-
LGG	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-8.49	2.65e-16	1.23e-13	-0.6	-0.36	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
LGG	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-8.49	2.66e-16	1.23e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
LGG	cis	rs1707322	1	rs6661500	ENSG00000281133.1	AL355480.3	-8.49	2.66e-16	1.23e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45580892~45580996:-
LGG	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	8.49	2.66e-16	1.23e-13	0.48	0.36	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
LGG	cis	rs11220082	0.602	rs10893383	ENSG00000254671.2	STT3A-AS1	-8.49	2.66e-16	1.23e-13	-0.45	-0.36	Schizophrenia;	chr11:125466237	chr11:125570284~125592568:-
LGG	cis	rs6921919	0.638	rs1416920	ENSG00000218016.2	ZNF192P2	-8.49	2.66e-16	1.23e-13	-0.46	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.525	rs1361386	ENSG00000218016.2	ZNF192P2	-8.49	2.66e-16	1.23e-13	-0.46	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28188050~28189432:+
LGG	cis	rs6921919	0.638	rs6456815	ENSG00000218016.2	ZNF192P2	-8.49	2.66e-16	1.23e-13	-0.46	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28188050~28189432:+
LGG	cis	rs4143844	1	rs62006969	ENSG00000259251.2	RP11-643M14.1	8.49	2.67e-16	1.23e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:62001213	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs11634077	ENSG00000259251.2	RP11-643M14.1	8.49	2.67e-16	1.23e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:62001376	chr15:62060503~62062434:+
LGG	cis	rs1185460	0.967	rs1786685	ENSG00000272186.1	RP11-110I1.13	-8.49	2.67e-16	1.24e-13	-0.35	-0.36	Coronary artery disease;	chr11:119068246	chr11:119067374~119067698:-
LGG	cis	rs11992162	0.967	rs10108320	ENSG00000227888.4	FAM66A	-8.49	2.67e-16	1.24e-13	-0.43	-0.36	Monocyte count;	chr8:11974754	chr8:12362019~12388296:+
LGG	cis	rs56804039	1	rs58361948	ENSG00000173295.6	FAM86B3P	8.49	2.68e-16	1.24e-13	0.44	0.36	Cervical cancer;	chr8:8523485	chr8:8228595~8244865:+
LGG	cis	rs1061377	0.608	rs35168672	ENSG00000249207.1	RP11-360F5.1	-8.49	2.68e-16	1.24e-13	-0.4	-0.36	Uric acid levels;	chr4:39078902	chr4:39112677~39126818:-
LGG	cis	rs4713118	0.513	rs149959	ENSG00000218016.2	ZNF192P2	-8.49	2.69e-16	1.24e-13	-0.47	-0.36	Parkinson's disease;	chr6:28046076	chr6:28188050~28189432:+
LGG	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-8.49	2.7e-16	1.25e-13	-0.41	-0.36	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
LGG	cis	rs7474896	0.583	rs10740950	ENSG00000226578.1	RP11-258F22.1	-8.49	2.7e-16	1.25e-13	-0.47	-0.36	Obesity (extreme);	chr10:37714568	chr10:37775371~37784131:-
LGG	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-8.49	2.7e-16	1.25e-13	-0.3	-0.36	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
LGG	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-8.49	2.7e-16	1.25e-13	-0.3	-0.36	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
LGG	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	8.49	2.71e-16	1.25e-13	0.38	0.36	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
LGG	cis	rs1949733	1	rs3103072	ENSG00000205959.3	RP11-689P11.2	8.49	2.71e-16	1.25e-13	0.33	0.36	Response to antineoplastic agents;	chr4:8506704	chr4:8482270~8512610:+
LGG	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	8.49	2.72e-16	1.26e-13	0.34	0.36	Breast size;	chr12:9205627	chr12:9277235~9313241:+
LGG	cis	rs4143844	0.867	rs11631273	ENSG00000259251.2	RP11-643M14.1	8.49	2.72e-16	1.26e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61985871	chr15:62060503~62062434:+
LGG	cis	rs11098499	0.954	rs59394118	ENSG00000250412.1	KLHL2P1	8.49	2.72e-16	1.26e-13	0.42	0.36	Corneal astigmatism;	chr4:119374396	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.865	rs9996417	ENSG00000250412.1	KLHL2P1	8.49	2.72e-16	1.26e-13	0.42	0.36	Corneal astigmatism;	chr4:119374707	chr4:119334329~119378233:+
LGG	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-8.49	2.73e-16	1.26e-13	-0.43	-0.36	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
LGG	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	8.49	2.73e-16	1.26e-13	0.38	0.36	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
LGG	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-8.49	2.73e-16	1.26e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
LGG	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-8.49	2.74e-16	1.26e-13	-0.47	-0.36	Height;	chr14:75119585	chr14:75011269~75012851:-
LGG	cis	rs9595066	0.667	rs3809350	ENSG00000230731.2	RP11-478K15.6	8.49	2.74e-16	1.27e-13	0.59	0.36	Schizophrenia;	chr13:44162043	chr13:44234118~44243192:-
LGG	cis	rs9346353	1	rs7762400	ENSG00000219881.1	GAPDHP42	8.49	2.76e-16	1.27e-13	0.34	0.36	Sleep duration;	chr6:69735742	chr6:69745871~69746851:+
LGG	cis	rs11098499	0.865	rs4507344	ENSG00000250412.1	KLHL2P1	8.49	2.77e-16	1.28e-13	0.42	0.36	Corneal astigmatism;	chr4:119386330	chr4:119334329~119378233:+
LGG	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	8.49	2.77e-16	1.28e-13	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	8.49	2.77e-16	1.28e-13	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
LGG	cis	rs4950322	0.58	rs2083720	ENSG00000278811.3	LINC00624	8.49	2.77e-16	1.28e-13	0.35	0.36	Protein quantitative trait loci;	chr1:147122296	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.58	rs72706441	ENSG00000278811.3	LINC00624	8.49	2.77e-16	1.28e-13	0.35	0.36	Protein quantitative trait loci;	chr1:147122601	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.547	rs17355509	ENSG00000278811.3	LINC00624	8.49	2.77e-16	1.28e-13	0.35	0.36	Protein quantitative trait loci;	chr1:147123139	chr1:147258885~147517875:-
LGG	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-8.49	2.78e-16	1.28e-13	-0.55	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
LGG	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	8.49	2.78e-16	1.28e-13	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
LGG	cis	rs1949733	1	rs3103099	ENSG00000205959.3	RP11-689P11.2	8.48	2.78e-16	1.28e-13	0.35	0.36	Response to antineoplastic agents;	chr4:8509840	chr4:8482270~8512610:+
LGG	cis	rs56804039	1	rs59620654	ENSG00000173295.6	FAM86B3P	8.48	2.79e-16	1.29e-13	0.44	0.36	Cervical cancer;	chr8:8525122	chr8:8228595~8244865:+
LGG	cis	rs1949733	1	rs2688223	ENSG00000205959.3	RP11-689P11.2	-8.48	2.79e-16	1.29e-13	-0.33	-0.36	Response to antineoplastic agents;	chr4:8469671	chr4:8482270~8512610:+
LGG	cis	rs11148252	0.574	rs3742297	ENSG00000198384.8	TPTE2P3	-8.48	2.79e-16	1.29e-13	-0.32	-0.36	Lewy body disease;	chr13:52703932	chr13:52522632~52586906:+
LGG	cis	rs11148252	0.574	rs9536247	ENSG00000198384.8	TPTE2P3	-8.48	2.79e-16	1.29e-13	-0.32	-0.36	Lewy body disease;	chr13:52705407	chr13:52522632~52586906:+
LGG	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	8.48	2.8e-16	1.29e-13	0.42	0.36	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
LGG	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	8.48	2.8e-16	1.29e-13	0.42	0.36	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
LGG	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	8.48	2.81e-16	1.3e-13	0.29	0.36	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
LGG	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	8.48	2.81e-16	1.3e-13	0.29	0.36	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
LGG	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	8.48	2.81e-16	1.3e-13	0.29	0.36	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
LGG	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	8.48	2.81e-16	1.3e-13	0.29	0.36	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
LGG	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-8.48	2.81e-16	1.3e-13	-0.43	-0.36	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
LGG	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	8.48	2.81e-16	1.3e-13	0.36	0.36	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
LGG	cis	rs4143844	0.867	rs11629900	ENSG00000259251.2	RP11-643M14.1	8.48	2.81e-16	1.3e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61954938	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs12915585	ENSG00000259251.2	RP11-643M14.1	8.48	2.81e-16	1.3e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61962693	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs34646089	ENSG00000259251.2	RP11-643M14.1	8.48	2.81e-16	1.3e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61978298	chr15:62060503~62062434:+
LGG	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	8.48	2.83e-16	1.31e-13	0.38	0.36	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
LGG	cis	rs9719620	0.74	rs4731793	ENSG00000236753.4	MKLN1-AS	-8.48	2.84e-16	1.31e-13	-0.38	-0.36	Male-pattern baldness;	chr7:131310104	chr7:131309744~131328222:-
LGG	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	8.48	2.87e-16	1.32e-13	0.35	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
LGG	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	8.48	2.87e-16	1.33e-13	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
LGG	cis	rs11098499	0.954	rs12506546	ENSG00000250412.1	KLHL2P1	8.48	2.87e-16	1.33e-13	0.42	0.36	Corneal astigmatism;	chr4:119380463	chr4:119334329~119378233:+
LGG	cis	rs7829975	0.508	rs4841006	ENSG00000173295.6	FAM86B3P	8.48	2.88e-16	1.33e-13	0.38	0.36	Mood instability;	chr8:8643964	chr8:8228595~8244865:+
LGG	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	8.48	2.88e-16	1.33e-13	0.63	0.36	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
LGG	cis	rs1930961	0.85	rs5996945	ENSG00000272942.1	CTA-246H3.12	8.48	2.88e-16	1.33e-13	0.56	0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25434324~25435070:-
LGG	cis	rs5760092	0.755	rs11090298	ENSG00000235689.1	AP000351.13	-8.48	2.89e-16	1.34e-13	-0.51	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:24006305~24008258:-
LGG	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	8.48	2.89e-16	1.34e-13	0.43	0.36	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
LGG	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	8.48	2.89e-16	1.34e-13	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
LGG	cis	rs4713118	0.513	rs156739	ENSG00000218016.2	ZNF192P2	-8.48	2.9e-16	1.34e-13	-0.47	-0.36	Parkinson's disease;	chr6:28045632	chr6:28188050~28189432:+
LGG	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	8.48	2.91e-16	1.34e-13	0.41	0.36	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
LGG	cis	rs9346353	1	rs9354890	ENSG00000219881.1	GAPDHP42	8.48	2.91e-16	1.34e-13	0.35	0.36	Sleep duration;	chr6:69794404	chr6:69745871~69746851:+
LGG	cis	rs11098499	0.618	rs28491261	ENSG00000250412.1	KLHL2P1	8.48	2.91e-16	1.34e-13	0.42	0.36	Corneal astigmatism;	chr4:119373745	chr4:119334329~119378233:+
LGG	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-8.48	2.93e-16	1.35e-13	-0.5	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
LGG	cis	rs6496932	0.503	rs11074205	ENSG00000218052.5	ADAMTS7P4	-8.48	2.94e-16	1.35e-13	-0.54	-0.36	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85255369~85330334:-
LGG	cis	rs9322193	0.887	rs3777949	ENSG00000216621.7	RP11-244K5.6	8.48	2.94e-16	1.36e-13	0.44	0.36	Lung cancer;	chr6:149596021	chr6:149934527~149936782:+
LGG	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-8.48	2.95e-16	1.36e-13	-0.83	-0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
LGG	cis	rs7927771	0.524	rs10838774	ENSG00000280615.1	Y_RNA	8.48	2.96e-16	1.36e-13	0.44	0.36	Subjective well-being;	chr11:47834562	chr11:47614898~47614994:-
LGG	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	8.48	2.96e-16	1.37e-13	0.42	0.36	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
LGG	cis	rs5742933	1	rs1550388	ENSG00000253559.1	OSGEPL1-AS1	8.48	2.98e-16	1.37e-13	0.47	0.36	Ferritin levels;	chr2:189739054	chr2:189762704~189765556:+
LGG	cis	rs35934224	0.542	rs8139091	ENSG00000232926.1	AC000078.5	8.48	2.98e-16	1.38e-13	0.34	0.36	Glaucoma (primary open-angle);	chr22:19857760	chr22:19887289~19887970:+
LGG	cis	rs7474896	0.583	rs12776092	ENSG00000226578.1	RP11-258F22.1	-8.48	2.99e-16	1.38e-13	-0.48	-0.36	Obesity (extreme);	chr10:37726867	chr10:37775371~37784131:-
LGG	cis	rs4143844	1	rs34424197	ENSG00000259251.2	RP11-643M14.1	8.48	2.99e-16	1.38e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61996620	chr15:62060503~62062434:+
LGG	cis	rs4713118	0.669	rs200997	ENSG00000226314.6	ZNF192P1	8.48	2.99e-16	1.38e-13	0.36	0.36	Parkinson's disease;	chr6:27844037	chr6:28161781~28169594:+
LGG	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-8.48	2.99e-16	1.38e-13	-0.45	-0.36	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-8.48	2.99e-16	1.38e-13	-0.45	-0.36	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
LGG	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-8.47	3.01e-16	1.39e-13	-0.46	-0.36	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-8.47	3.01e-16	1.39e-13	-0.46	-0.36	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
LGG	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	8.47	3.01e-16	1.39e-13	0.53	0.36	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
LGG	cis	rs867371	0.929	rs1501371	ENSG00000278603.1	RP13-608F4.5	8.47	3.02e-16	1.39e-13	0.46	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472203~82472426:+
LGG	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-8.47	3.02e-16	1.39e-13	-0.49	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
LGG	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	8.47	3.02e-16	1.39e-13	0.48	0.36	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
LGG	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-8.47	3.02e-16	1.39e-13	-0.43	-0.36	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-8.47	3.02e-16	1.39e-13	-0.43	-0.36	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
LGG	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-8.47	3.02e-16	1.39e-13	-0.43	-0.36	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
LGG	cis	rs227275	0.556	rs10015289	ENSG00000248971.2	KRT8P46	-8.47	3.02e-16	1.39e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs6852141	ENSG00000248971.2	KRT8P46	-8.47	3.02e-16	1.39e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102728746~102730171:-
LGG	cis	rs228614	0.509	rs4455415	ENSG00000248971.2	KRT8P46	-8.47	3.02e-16	1.39e-13	-0.37	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102728746~102730171:-
LGG	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	8.47	3.04e-16	1.4e-13	0.3	0.36	Breast cancer;	chr11:750849	chr11:781645~782105:+
LGG	cis	rs9532669	0.926	rs7799	ENSG00000239827.7	SUGT1P3	-8.47	3.04e-16	1.4e-13	-0.38	-0.36	Cervical cancer;	chr13:40958916	chr13:40908159~40921774:-
LGG	cis	rs2898290	0.5	rs11998678	ENSG00000227888.4	FAM66A	-8.47	3.04e-16	1.4e-13	-0.43	-0.36	Systolic blood pressure;	chr8:11972641	chr8:12362019~12388296:+
LGG	cis	rs6545883	0.524	rs12713435	ENSG00000273302.1	RP11-493E12.2	-8.47	3.05e-16	1.4e-13	-0.31	-0.36	Tuberculosis;	chr2:61272654	chr2:61199979~61200769:+
LGG	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	8.47	3.05e-16	1.41e-13	0.38	0.36	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
LGG	cis	rs7208859	0.623	rs9906957	ENSG00000266490.1	CTD-2349P21.9	8.47	3.05e-16	1.41e-13	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30792372~30792833:+
LGG	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	8.47	3.06e-16	1.41e-13	0.31	0.36	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
LGG	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-8.47	3.07e-16	1.41e-13	-0.36	-0.36	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
LGG	cis	rs62184315	0.52	rs62184268	ENSG00000273240.1	RP11-455J20.3	-8.47	3.07e-16	1.42e-13	-0.54	-0.36	Alcohol dependence (age at onset);	chr2:189767451	chr2:189763859~189764456:-
LGG	cis	rs17772222	0.74	rs7143642	ENSG00000222990.1	RNU4-22P	8.47	3.08e-16	1.42e-13	0.43	0.36	Coronary artery calcification;	chr14:88507616	chr14:88513498~88513663:+
LGG	cis	rs1707322	0.963	rs1768815	ENSG00000281133.1	AL355480.3	8.47	3.08e-16	1.42e-13	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45580892~45580996:-
LGG	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	8.47	3.1e-16	1.43e-13	0.34	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
LGG	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	8.47	3.1e-16	1.43e-13	0.43	0.36	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
LGG	cis	rs7927771	0.524	rs6485763	ENSG00000280615.1	Y_RNA	8.47	3.1e-16	1.43e-13	0.43	0.36	Subjective well-being;	chr11:47605750	chr11:47614898~47614994:-
LGG	cis	rs6545883	0.507	rs2123111	ENSG00000273302.1	RP11-493E12.2	-8.47	3.11e-16	1.43e-13	-0.31	-0.36	Tuberculosis;	chr2:61223319	chr2:61199979~61200769:+
LGG	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-8.47	3.11e-16	1.43e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
LGG	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-8.47	3.11e-16	1.43e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
LGG	cis	rs10946940	0.896	rs12208078	ENSG00000199851.2	U3	-8.47	3.11e-16	1.43e-13	-0.48	-0.36	Systemic lupus erythematosus;	chr6:27530802	chr6:28015568~28015777:+
LGG	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-8.47	3.12e-16	1.44e-13	-0.47	-0.36	Height;	chr14:75022929	chr14:75011269~75012851:-
LGG	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	8.47	3.12e-16	1.44e-13	0.42	0.36	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	8.47	3.12e-16	1.44e-13	0.42	0.36	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
LGG	cis	rs853679	0.538	rs13199081	ENSG00000226314.6	ZNF192P1	8.47	3.12e-16	1.44e-13	0.39	0.36	Depression;	chr6:28364057	chr6:28161781~28169594:+
LGG	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-8.47	3.12e-16	1.44e-13	-0.36	-0.36	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
LGG	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-8.47	3.13e-16	1.44e-13	-0.49	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
LGG	cis	rs9532669	0.926	rs4942007	ENSG00000168852.11	TPTE2P5	8.47	3.13e-16	1.44e-13	0.38	0.36	Cervical cancer;	chr13:40871887	chr13:40822296~40921749:-
LGG	cis	rs7829975	0.545	rs13261926	ENSG00000173295.6	FAM86B3P	8.47	3.13e-16	1.44e-13	0.4	0.36	Mood instability;	chr8:8694100	chr8:8228595~8244865:+
LGG	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-8.47	3.13e-16	1.44e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
LGG	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	8.47	3.13e-16	1.44e-13	0.42	0.36	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
LGG	cis	rs4143844	0.867	rs11629598	ENSG00000259251.2	RP11-643M14.1	8.47	3.13e-16	1.44e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61950998	chr15:62060503~62062434:+
LGG	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	8.47	3.14e-16	1.44e-13	0.53	0.36	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
LGG	cis	rs62103177	0.535	rs62101568	ENSG00000261126.6	RP11-795F19.1	8.47	3.14e-16	1.45e-13	0.43	0.36	Opioid sensitivity;	chr18:80176788	chr18:80046900~80095482:+
LGG	cis	rs4143844	1	rs34556569	ENSG00000259251.2	RP11-643M14.1	8.47	3.14e-16	1.45e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61989619	chr15:62060503~62062434:+
LGG	cis	rs9987353	0.519	rs13276350	ENSG00000253893.2	FAM85B	8.47	3.15e-16	1.45e-13	0.45	0.36	Recombination measurement;	chr8:9205647	chr8:8167819~8226614:-
LGG	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-8.47	3.15e-16	1.45e-13	-0.38	-0.36	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
LGG	cis	rs4143844	0.867	rs62007764	ENSG00000259251.2	RP11-643M14.1	8.47	3.15e-16	1.45e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61948855	chr15:62060503~62062434:+
LGG	cis	rs763567	1	rs2022372	ENSG00000271811.1	RP1-79C4.4	-8.47	3.16e-16	1.45e-13	-0.36	-0.36	Tonsillectomy;	chr1:170620769	chr1:170667381~170669425:+
LGG	cis	rs763567	0.967	rs1234274	ENSG00000271811.1	RP1-79C4.4	8.47	3.16e-16	1.45e-13	0.36	0.36	Tonsillectomy;	chr1:170627232	chr1:170667381~170669425:+
LGG	cis	rs9346353	1	rs9351776	ENSG00000219881.1	GAPDHP42	8.47	3.18e-16	1.46e-13	0.34	0.36	Sleep duration;	chr6:69794229	chr6:69745871~69746851:+
LGG	cis	rs77204473	1	rs17120177	ENSG00000254851.1	RP11-109L13.1	8.47	3.19e-16	1.47e-13	0.9	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116956653	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	8.47	3.2e-16	1.47e-13	0.83	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	8.47	3.2e-16	1.47e-13	0.83	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
LGG	cis	rs1023500	0.505	rs134886	ENSG00000227370.1	RP4-669P10.19	-8.47	3.21e-16	1.48e-13	-0.31	-0.36	Schizophrenia;	chr22:42277850	chr22:42132543~42132998:+
LGG	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	8.46	3.23e-16	1.48e-13	0.46	0.36	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
LGG	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	8.46	3.23e-16	1.49e-13	0.48	0.36	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
LGG	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-8.46	3.25e-16	1.49e-13	-0.54	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
LGG	cis	rs4713118	0.513	rs9368547	ENSG00000218016.2	ZNF192P2	-8.46	3.25e-16	1.49e-13	-0.47	-0.36	Parkinson's disease;	chr6:28060289	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs183244	ENSG00000218016.2	ZNF192P2	-8.46	3.25e-16	1.49e-13	-0.47	-0.36	Parkinson's disease;	chr6:28064060	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs149950	ENSG00000218016.2	ZNF192P2	-8.46	3.25e-16	1.49e-13	-0.47	-0.36	Parkinson's disease;	chr6:28065261	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs149951	ENSG00000218016.2	ZNF192P2	-8.46	3.25e-16	1.49e-13	-0.47	-0.36	Parkinson's disease;	chr6:28065309	chr6:28188050~28189432:+
LGG	cis	rs7291412	1	rs7291412	ENSG00000231711.2	LINC00899	8.46	3.25e-16	1.5e-13	0.45	0.36	Dupuytren's disease;Subjective well-being;	chr22:46063252	chr22:46039907~46044853:-
LGG	cis	rs6558530	0.863	rs4595147	ENSG00000253982.1	CTD-2336O2.1	8.46	3.26e-16	1.5e-13	0.36	0.36	Systolic blood pressure;	chr8:1755403	chr8:1761990~1764502:-
LGG	cis	rs172166	0.694	rs536704	ENSG00000218016.2	ZNF192P2	-8.46	3.26e-16	1.5e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28124825	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs156734	ENSG00000218016.2	ZNF192P2	-8.46	3.26e-16	1.5e-13	-0.47	-0.36	Parkinson's disease;	chr6:28039579	chr6:28188050~28189432:+
LGG	cis	rs2739330	0.828	rs2154593	ENSG00000235689.1	AP000351.13	8.46	3.27e-16	1.5e-13	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:24006305~24008258:-
LGG	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-8.46	3.28e-16	1.51e-13	-0.46	-0.36	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
LGG	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-8.46	3.28e-16	1.51e-13	-0.45	-0.36	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
LGG	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	8.46	3.28e-16	1.51e-13	0.42	0.36	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	8.46	3.28e-16	1.51e-13	0.42	0.36	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	8.46	3.28e-16	1.51e-13	0.42	0.36	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
LGG	cis	rs9532669	0.963	rs9532681	ENSG00000239827.7	SUGT1P3	-8.46	3.28e-16	1.51e-13	-0.39	-0.36	Cervical cancer;	chr13:40951633	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs4516083	ENSG00000239827.7	SUGT1P3	-8.46	3.28e-16	1.51e-13	-0.39	-0.36	Cervical cancer;	chr13:40951783	chr13:40908159~40921774:-
LGG	cis	rs4713118	0.513	rs149958	ENSG00000218016.2	ZNF192P2	-8.46	3.3e-16	1.52e-13	-0.47	-0.36	Parkinson's disease;	chr6:28045839	chr6:28188050~28189432:+
LGG	cis	rs4713118	0.513	rs156738	ENSG00000218016.2	ZNF192P2	-8.46	3.3e-16	1.52e-13	-0.47	-0.36	Parkinson's disease;	chr6:28046247	chr6:28188050~28189432:+
LGG	cis	rs9346353	0.932	rs9351774	ENSG00000219881.1	GAPDHP42	8.46	3.31e-16	1.52e-13	0.34	0.36	Sleep duration;	chr6:69770260	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346348	ENSG00000219881.1	GAPDHP42	8.46	3.31e-16	1.52e-13	0.34	0.36	Sleep duration;	chr6:69773059	chr6:69745871~69746851:+
LGG	cis	rs7520050	0.807	rs28844317	ENSG00000280836.1	AL355480.1	-8.46	3.31e-16	1.52e-13	-0.39	-0.36	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45581219~45581321:-
LGG	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-8.46	3.31e-16	1.52e-13	-0.37	-0.36	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
LGG	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	8.46	3.32e-16	1.52e-13	0.42	0.36	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
LGG	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	8.46	3.32e-16	1.52e-13	0.42	0.36	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
LGG	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-8.46	3.32e-16	1.53e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
LGG	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-8.46	3.32e-16	1.53e-13	-0.46	-0.36	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
LGG	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-8.46	3.32e-16	1.53e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
LGG	cis	rs7520050	0.807	rs6429576	ENSG00000280836.1	AL355480.1	-8.46	3.33e-16	1.53e-13	-0.39	-0.36	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45581219~45581321:-
LGG	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-8.46	3.33e-16	1.53e-13	-0.36	-0.36	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
LGG	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	8.46	3.33e-16	1.53e-13	0.34	0.36	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
LGG	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-8.46	3.35e-16	1.54e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
LGG	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-8.46	3.35e-16	1.54e-13	-0.39	-0.36	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
LGG	cis	rs35425515	0.764	rs4919070	ENSG00000234855.1	SLIT1-AS1	8.46	3.35e-16	1.54e-13	0.62	0.36	Bipolar disorder;	chr10:97104512	chr10:97102756~97103747:+
LGG	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	8.46	3.35e-16	1.54e-13	0.34	0.36	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
LGG	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-8.46	3.35e-16	1.54e-13	-0.48	-0.36	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
LGG	cis	rs9859260	1	rs9990392	ENSG00000231464.1	AC024937.4	8.46	3.36e-16	1.54e-13	0.44	0.36	Mean corpuscular volume;	chr3:196071651	chr3:195996738~195998233:+
LGG	cis	rs1707322	0.752	rs11211145	ENSG00000281133.1	AL355480.3	-8.46	3.36e-16	1.54e-13	-0.48	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45580892~45580996:-
LGG	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	8.46	3.36e-16	1.54e-13	0.62	0.36	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
LGG	cis	rs6921919	0.525	rs16894095	ENSG00000218016.2	ZNF192P2	-8.46	3.36e-16	1.54e-13	-0.44	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28188050~28189432:+
LGG	cis	rs11992162	0.967	rs10112888	ENSG00000227888.4	FAM66A	8.46	3.36e-16	1.54e-13	0.43	0.36	Monocyte count;	chr8:11972699	chr8:12362019~12388296:+
LGG	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-8.46	3.37e-16	1.55e-13	-0.42	-0.36	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
LGG	cis	rs11098499	0.909	rs10020034	ENSG00000250412.1	KLHL2P1	8.46	3.38e-16	1.55e-13	0.42	0.36	Corneal astigmatism;	chr4:119373176	chr4:119334329~119378233:+
LGG	cis	rs1707322	1	rs4134387	ENSG00000281133.1	AL355480.3	-8.46	3.38e-16	1.55e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45580892~45580996:-
LGG	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-8.46	3.38e-16	1.55e-13	-0.48	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
LGG	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-8.46	3.38e-16	1.55e-13	-0.48	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
LGG	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	8.46	3.38e-16	1.55e-13	0.42	0.36	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	8.46	3.38e-16	1.55e-13	0.42	0.36	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	8.46	3.38e-16	1.55e-13	0.42	0.36	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
LGG	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	8.46	3.38e-16	1.55e-13	0.42	0.36	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
LGG	cis	rs4143844	0.867	rs12912477	ENSG00000259251.2	RP11-643M14.1	8.46	3.39e-16	1.55e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61949909	chr15:62060503~62062434:+
LGG	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-8.46	3.39e-16	1.56e-13	-0.36	-0.36	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
LGG	cis	rs12682352	0.602	rs6988939	ENSG00000173295.6	FAM86B3P	-8.46	3.4e-16	1.56e-13	-0.39	-0.36	Neuroticism;	chr8:8809406	chr8:8228595~8244865:+
LGG	cis	rs1023500	0.505	rs134888	ENSG00000227370.1	RP4-669P10.19	8.46	3.4e-16	1.56e-13	0.31	0.36	Schizophrenia;	chr22:42278275	chr22:42132543~42132998:+
LGG	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-8.46	3.4e-16	1.56e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
LGG	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-8.46	3.4e-16	1.56e-13	-0.38	-0.36	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
LGG	cis	rs8042680	0.621	rs12899811	ENSG00000214432.8	AC068831.10	-8.46	3.42e-16	1.57e-13	-0.38	-0.36	Type 2 diabetes;	chr15:91000846	chr15:91022619~91036611:+
LGG	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	8.46	3.43e-16	1.57e-13	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	8.46	3.43e-16	1.57e-13	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
LGG	cis	rs7824557	0.614	rs2736286	ENSG00000184608.7	FAM167A-AS1	8.46	3.44e-16	1.58e-13	0.3	0.36	Retinal vascular caliber;	chr8:11369595	chr8:11368402~11438658:+
LGG	cis	rs56804039	1	rs7017341	ENSG00000173295.6	FAM86B3P	8.46	3.44e-16	1.58e-13	0.44	0.36	Cervical cancer;	chr8:8524154	chr8:8228595~8244865:+
LGG	cis	rs56804039	1	rs11780966	ENSG00000173295.6	FAM86B3P	8.46	3.44e-16	1.58e-13	0.44	0.36	Cervical cancer;	chr8:8525886	chr8:8228595~8244865:+
LGG	cis	rs56804039	1	rs34154295	ENSG00000173295.6	FAM86B3P	8.46	3.44e-16	1.58e-13	0.44	0.36	Cervical cancer;	chr8:8525967	chr8:8228595~8244865:+
LGG	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-8.46	3.45e-16	1.58e-13	-0.43	-0.36	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
LGG	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-8.46	3.46e-16	1.59e-13	-0.48	-0.36	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
LGG	cis	rs7267979	0.649	rs2500406	ENSG00000125804.12	FAM182A	8.46	3.46e-16	1.59e-13	0.47	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:26054655~26086917:+
LGG	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-8.46	3.47e-16	1.59e-13	-0.46	-0.36	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
LGG	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-8.46	3.47e-16	1.59e-13	-0.46	-0.36	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
LGG	cis	rs11148252	0.553	rs9536236	ENSG00000198384.8	TPTE2P3	-8.45	3.47e-16	1.59e-13	-0.33	-0.36	Lewy body disease;	chr13:52680877	chr13:52522632~52586906:+
LGG	cis	rs9322193	0.926	rs9766562	ENSG00000216621.7	RP11-244K5.6	8.45	3.48e-16	1.59e-13	0.43	0.36	Lung cancer;	chr6:149788709	chr6:149934527~149936782:+
LGG	cis	rs4143844	0.867	rs978141	ENSG00000259251.2	RP11-643M14.1	8.45	3.48e-16	1.59e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61974584	chr15:62060503~62062434:+
LGG	cis	rs1185460	0.967	rs1177563	ENSG00000272186.1	RP11-110I1.13	-8.45	3.48e-16	1.6e-13	-0.36	-0.36	Coronary artery disease;	chr11:119078373	chr11:119067374~119067698:-
LGG	cis	rs9527	0.662	rs4919686	ENSG00000272912.1	RP11-724N1.1	-8.45	3.49e-16	1.6e-13	-0.42	-0.36	Arsenic metabolism;	chr10:102832492	chr10:102914585~102915404:+
LGG	cis	rs4713118	0.588	rs200994	ENSG00000226314.6	ZNF192P1	-8.45	3.5e-16	1.6e-13	-0.41	-0.36	Parkinson's disease;	chr6:27846035	chr6:28161781~28169594:+
LGG	cis	rs7119038	0.818	rs4936444	ENSG00000255239.1	AP002954.6	8.45	3.5e-16	1.61e-13	0.52	0.36	Sjögren's syndrome;	chr11:118872629	chr11:118688039~118690600:-
LGG	cis	rs7474896	0.583	rs34185758	ENSG00000226578.1	RP11-258F22.1	-8.45	3.51e-16	1.61e-13	-0.48	-0.36	Obesity (extreme);	chr10:37701926	chr10:37775371~37784131:-
LGG	cis	rs4143844	1	rs62007791	ENSG00000259251.2	RP11-643M14.1	8.45	3.52e-16	1.61e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61992487	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs35259011	ENSG00000259251.2	RP11-643M14.1	8.45	3.52e-16	1.61e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61993260	chr15:62060503~62062434:+
LGG	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	8.45	3.53e-16	1.62e-13	0.38	0.36	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
LGG	cis	rs12073837	0.5	rs11118610	ENSG00000257551.1	HLX-AS1	-8.45	3.54e-16	1.62e-13	-0.44	-0.36	F-cell distribution;	chr1:220816744	chr1:220832763~220880140:-
LGG	cis	rs67340775	0.541	rs200965	ENSG00000226314.6	ZNF192P1	8.45	3.55e-16	1.62e-13	0.5	0.36	Lung cancer in ever smokers;	chr6:27898606	chr6:28161781~28169594:+
LGG	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-8.45	3.57e-16	1.63e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-8.45	3.57e-16	1.63e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
LGG	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-8.45	3.57e-16	1.64e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-8.45	3.57e-16	1.64e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-8.45	3.57e-16	1.64e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
LGG	cis	rs7219021	0.705	rs962273	ENSG00000248278.1	SUMO2P17	8.45	3.58e-16	1.64e-13	0.43	0.36	Schizophrenia or bipolar disorder;	chr17:48900991	chr17:48874860~48908983:-
LGG	cis	rs1185460	0.967	rs4454730	ENSG00000272186.1	RP11-110I1.13	-8.45	3.59e-16	1.64e-13	-0.35	-0.36	Coronary artery disease;	chr11:119066733	chr11:119067374~119067698:-
LGG	cis	rs7124681	0.585	rs10838773	ENSG00000280615.1	Y_RNA	8.45	3.59e-16	1.64e-13	0.44	0.36	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47812794	chr11:47614898~47614994:-
LGG	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-8.45	3.59e-16	1.65e-13	-0.38	-0.36	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-8.45	3.59e-16	1.65e-13	-0.38	-0.36	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
LGG	cis	rs2075466	0.514	rs79392591	ENSG00000267077.1	RP11-127I20.5	8.45	3.62e-16	1.66e-13	0.51	0.36	Colonoscopy-negative controls vs population controls;	chr16:4849246	chr16:4795265~4796532:-
LGG	cis	rs6496932	0.865	rs4842874	ENSG00000218052.5	ADAMTS7P4	8.45	3.63e-16	1.66e-13	0.56	0.36	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85255369~85330334:-
LGG	cis	rs7520050	0.778	rs2934857	ENSG00000280836.1	AL355480.1	-8.45	3.64e-16	1.67e-13	-0.42	-0.36	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45581219~45581321:-
LGG	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	8.45	3.65e-16	1.67e-13	0.42	0.36	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	8.45	3.67e-16	1.68e-13	0.43	0.36	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
LGG	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-8.45	3.67e-16	1.68e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
LGG	cis	rs11148252	0.774	rs7334583	ENSG00000235660.1	LINC00345	8.45	3.68e-16	1.68e-13	0.44	0.36	Lewy body disease;	chr13:52356217	chr13:52484161~52484680:-
LGG	cis	rs1949733	1	rs3103071	ENSG00000205959.3	RP11-689P11.2	8.45	3.69e-16	1.69e-13	0.33	0.36	Response to antineoplastic agents;	chr4:8506852	chr4:8482270~8512610:+
LGG	cis	rs454217	0.74	rs430709	ENSG00000277851.1	RP11-756G20.1	8.45	3.7e-16	1.69e-13	0.36	0.36	Smoking quantity;	chr12:92325836	chr12:92247756~92363832:-
LGG	cis	rs6545883	0.507	rs59981505	ENSG00000273302.1	RP11-493E12.2	-8.45	3.7e-16	1.69e-13	-0.31	-0.36	Tuberculosis;	chr2:61353394	chr2:61199979~61200769:+
LGG	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-8.45	3.71e-16	1.7e-13	-0.38	-0.36	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
LGG	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	8.45	3.72e-16	1.7e-13	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
LGG	cis	rs11220082	0.666	rs7103665	ENSG00000254671.2	STT3A-AS1	-8.45	3.72e-16	1.7e-13	-0.44	-0.36	Schizophrenia;	chr11:125472998	chr11:125570284~125592568:-
LGG	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	8.45	3.73e-16	1.7e-13	0.47	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
LGG	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	8.44	3.77e-16	1.73e-13	0.38	0.36	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
LGG	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-8.44	3.78e-16	1.73e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-8.44	3.78e-16	1.73e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-8.44	3.78e-16	1.73e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
LGG	cis	rs11148252	0.74	rs7983971	ENSG00000278238.1	RP11-245D16.4	-8.44	3.78e-16	1.73e-13	-0.36	-0.36	Lewy body disease;	chr13:52216565	chr13:52454775~52455331:-
LGG	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	8.44	3.8e-16	1.74e-13	0.37	0.36	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	8.44	3.8e-16	1.74e-13	0.37	0.36	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
LGG	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-8.44	3.8e-16	1.74e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-8.44	3.8e-16	1.74e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
LGG	cis	rs2739330	0.796	rs5760106	ENSG00000235689.1	AP000351.13	-8.44	3.81e-16	1.74e-13	-0.42	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:24006305~24008258:-
LGG	cis	rs11148252	0.819	rs7336679	ENSG00000235660.1	LINC00345	-8.44	3.82e-16	1.74e-13	-0.44	-0.36	Lewy body disease;	chr13:52469198	chr13:52484161~52484680:-
LGG	cis	rs4713118	0.581	rs200504	ENSG00000216901.1	AL022393.7	8.44	3.83e-16	1.75e-13	0.51	0.36	Parkinson's disease;	chr6:27818042	chr6:28176188~28176674:+
LGG	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	8.44	3.83e-16	1.75e-13	0.42	0.36	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
LGG	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	8.44	3.84e-16	1.75e-13	0.45	0.36	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	8.44	3.84e-16	1.75e-13	0.45	0.36	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
LGG	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	8.44	3.84e-16	1.75e-13	0.45	0.36	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
LGG	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	8.44	3.84e-16	1.75e-13	0.43	0.36	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
LGG	cis	rs6921919	0.697	rs6942030	ENSG00000280107.1	AL022393.9	-8.44	3.84e-16	1.75e-13	-0.39	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28170845~28172521:+
LGG	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-8.44	3.84e-16	1.76e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
LGG	cis	rs56804039	1	rs6986470	ENSG00000173295.6	FAM86B3P	8.44	3.84e-16	1.76e-13	0.44	0.36	Cervical cancer;	chr8:8523920	chr8:8228595~8244865:+
LGG	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	8.44	3.85e-16	1.76e-13	0.43	0.36	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
LGG	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	8.44	3.85e-16	1.76e-13	0.49	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
LGG	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-8.44	3.85e-16	1.76e-13	-0.45	-0.36	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
LGG	cis	rs11098499	0.954	rs10006525	ENSG00000250412.1	KLHL2P1	8.44	3.85e-16	1.76e-13	0.41	0.36	Corneal astigmatism;	chr4:119487776	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs17005535	ENSG00000250412.1	KLHL2P1	8.44	3.85e-16	1.76e-13	0.41	0.36	Corneal astigmatism;	chr4:119490407	chr4:119334329~119378233:+
LGG	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	8.44	3.85e-16	1.76e-13	0.58	0.36	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
LGG	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	8.44	3.85e-16	1.76e-13	0.43	0.36	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
LGG	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	8.44	3.86e-16	1.76e-13	0.62	0.36	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
LGG	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	8.44	3.87e-16	1.77e-13	0.37	0.36	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
LGG	cis	rs12682352	0.605	rs60707155	ENSG00000173295.6	FAM86B3P	-8.44	3.88e-16	1.77e-13	-0.4	-0.36	Neuroticism;	chr8:8866905	chr8:8228595~8244865:+
LGG	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-8.44	3.88e-16	1.77e-13	-0.42	-0.36	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
LGG	cis	rs4143844	1	rs34042779	ENSG00000259251.2	RP11-643M14.1	8.44	3.89e-16	1.78e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61990899	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs12901735	ENSG00000259251.2	RP11-643M14.1	8.44	3.9e-16	1.78e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61951360	chr15:62060503~62062434:+
LGG	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	8.44	3.9e-16	1.78e-13	0.48	0.36	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
LGG	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.44	3.91e-16	1.78e-13	-0.37	-0.36	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
LGG	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.44	3.91e-16	1.78e-13	-0.37	-0.36	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
LGG	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.44	3.91e-16	1.78e-13	-0.37	-0.36	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
LGG	cis	rs10946940	0.965	rs6910838	ENSG00000199851.2	U3	-8.44	3.91e-16	1.79e-13	-0.48	-0.36	Systemic lupus erythematosus;	chr6:27547740	chr6:28015568~28015777:+
LGG	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-8.44	3.91e-16	1.79e-13	-0.48	-0.36	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
LGG	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-8.44	3.91e-16	1.79e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
LGG	cis	rs9346353	1	rs12173563	ENSG00000219881.1	GAPDHP42	8.44	3.92e-16	1.79e-13	0.34	0.36	Sleep duration;	chr6:69773300	chr6:69745871~69746851:+
LGG	cis	rs7208859	0.673	rs9898858	ENSG00000266490.1	CTD-2349P21.9	8.44	3.94e-16	1.8e-13	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs55658077	ENSG00000266490.1	CTD-2349P21.9	8.44	3.94e-16	1.8e-13	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30792372~30792833:+
LGG	cis	rs26528	0.584	rs153103	ENSG00000271623.1	RP11-435I10.5	8.44	3.94e-16	1.8e-13	0.43	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28364700~28365333:+
LGG	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-8.44	3.94e-16	1.8e-13	-0.46	-0.36	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
LGG	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-8.44	3.94e-16	1.8e-13	-0.46	-0.36	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
LGG	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	8.44	3.95e-16	1.8e-13	0.49	0.36	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
LGG	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	8.44	3.95e-16	1.8e-13	0.49	0.36	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
LGG	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-8.44	3.95e-16	1.8e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-8.44	3.95e-16	1.8e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
LGG	cis	rs1185460	0.967	rs4545564	ENSG00000272186.1	RP11-110I1.13	-8.44	3.97e-16	1.81e-13	-0.35	-0.36	Coronary artery disease;	chr11:119066807	chr11:119067374~119067698:-
LGG	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-8.44	4e-16	1.82e-13	-0.42	-0.36	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
LGG	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-8.44	4.01e-16	1.83e-13	-0.42	-0.36	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
LGG	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-8.44	4.01e-16	1.83e-13	-0.92	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
LGG	cis	rs17772222	0.74	rs10138309	ENSG00000222990.1	RNU4-22P	8.44	4.01e-16	1.83e-13	0.43	0.36	Coronary artery calcification;	chr14:88510352	chr14:88513498~88513663:+
LGG	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-8.44	4.02e-16	1.83e-13	-0.43	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-8.44	4.02e-16	1.83e-13	-0.43	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
LGG	cis	rs6921919	0.697	rs758398	ENSG00000218016.2	ZNF192P2	-8.44	4.02e-16	1.83e-13	-0.45	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28188050~28189432:+
LGG	cis	rs6545883	0.507	rs12617371	ENSG00000273302.1	RP11-493E12.2	-8.44	4.03e-16	1.84e-13	-0.31	-0.36	Tuberculosis;	chr2:61341999	chr2:61199979~61200769:+
LGG	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-8.43	4.07e-16	1.86e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
LGG	cis	rs11220082	0.644	rs34435097	ENSG00000254671.2	STT3A-AS1	-8.43	4.07e-16	1.86e-13	-0.45	-0.36	Schizophrenia;	chr11:125469075	chr11:125570284~125592568:-
LGG	cis	rs172166	0.694	rs203876	ENSG00000218016.2	ZNF192P2	-8.43	4.09e-16	1.86e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28078895	chr6:28188050~28189432:+
LGG	cis	rs172166	0.694	rs203877	ENSG00000218016.2	ZNF192P2	-8.43	4.09e-16	1.86e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28080846	chr6:28188050~28189432:+
LGG	cis	rs11098499	0.954	rs10006706	ENSG00000250412.1	KLHL2P1	8.43	4.1e-16	1.87e-13	0.42	0.36	Corneal astigmatism;	chr4:119487997	chr4:119334329~119378233:+
LGG	cis	rs1707322	0.721	rs11211181	ENSG00000281133.1	AL355480.3	-8.43	4.1e-16	1.87e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45580892~45580996:-
LGG	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-8.43	4.1e-16	1.87e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
LGG	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-8.43	4.1e-16	1.87e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
LGG	cis	rs858239	0.539	rs10270695	ENSG00000230042.1	AK3P3	8.43	4.11e-16	1.87e-13	0.38	0.36	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23129178~23129841:+
LGG	cis	rs2739330	0.752	rs2330634	ENSG00000235689.1	AP000351.13	8.43	4.11e-16	1.87e-13	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:24006305~24008258:-
LGG	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	8.43	4.12e-16	1.88e-13	0.4	0.36	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
LGG	cis	rs9346353	1	rs1563609	ENSG00000219881.1	GAPDHP42	8.43	4.12e-16	1.88e-13	0.35	0.36	Sleep duration;	chr6:69787766	chr6:69745871~69746851:+
LGG	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-8.43	4.12e-16	1.88e-13	-0.49	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
LGG	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-8.43	4.12e-16	1.88e-13	-0.49	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
LGG	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	8.43	4.12e-16	1.88e-13	0.37	0.36	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
LGG	cis	rs9393777	0.72	rs56401801	ENSG00000216901.1	AL022393.7	8.43	4.13e-16	1.88e-13	0.82	0.36	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28176188~28176674:+
LGG	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-8.43	4.13e-16	1.88e-13	-0.3	-0.36	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
LGG	cis	rs9322193	0.923	rs7753812	ENSG00000216621.7	RP11-244K5.6	8.43	4.14e-16	1.89e-13	0.43	0.36	Lung cancer;	chr6:149690150	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs12195866	ENSG00000216621.7	RP11-244K5.6	8.43	4.14e-16	1.89e-13	0.43	0.36	Lung cancer;	chr6:149693334	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9285524	ENSG00000216621.7	RP11-244K5.6	8.43	4.14e-16	1.89e-13	0.43	0.36	Lung cancer;	chr6:149694122	chr6:149934527~149936782:+
LGG	cis	rs4713118	0.513	rs149972	ENSG00000218016.2	ZNF192P2	-8.43	4.15e-16	1.89e-13	-0.47	-0.36	Parkinson's disease;	chr6:28015449	chr6:28188050~28189432:+
LGG	cis	rs9322193	0.962	rs3763162	ENSG00000216621.7	RP11-244K5.6	-8.43	4.15e-16	1.89e-13	-0.43	-0.36	Lung cancer;	chr6:149819674	chr6:149934527~149936782:+
LGG	cis	rs4713118	0.513	rs202908	ENSG00000218016.2	ZNF192P2	-8.43	4.15e-16	1.89e-13	-0.47	-0.36	Parkinson's disease;	chr6:28043773	chr6:28188050~28189432:+
LGG	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	8.43	4.16e-16	1.89e-13	0.56	0.36	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	8.43	4.16e-16	1.89e-13	0.56	0.36	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	8.43	4.16e-16	1.89e-13	0.56	0.36	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
LGG	cis	rs6496932	1	rs11638110	ENSG00000218052.5	ADAMTS7P4	8.43	4.18e-16	1.9e-13	0.55	0.36	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85255369~85330334:-
LGG	cis	rs17772222	0.636	rs10484010	ENSG00000222990.1	RNU4-22P	8.43	4.19e-16	1.91e-13	0.48	0.36	Coronary artery calcification;	chr14:88831944	chr14:88513498~88513663:+
LGG	cis	rs9859260	0.961	rs34221479	ENSG00000231464.1	AC024937.4	8.43	4.19e-16	1.91e-13	0.44	0.36	Mean corpuscular volume;	chr3:196071729	chr3:195996738~195998233:+
LGG	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	8.43	4.21e-16	1.91e-13	0.37	0.36	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	8.43	4.21e-16	1.91e-13	0.37	0.36	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	8.43	4.21e-16	1.91e-13	0.37	0.36	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	8.43	4.21e-16	1.91e-13	0.37	0.36	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
LGG	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-8.43	4.23e-16	1.92e-13	-0.43	-0.36	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
LGG	cis	rs853679	0.527	rs213228	ENSG00000226314.6	ZNF192P1	8.43	4.25e-16	1.93e-13	0.36	0.36	Depression;	chr6:28363475	chr6:28161781~28169594:+
LGG	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-8.43	4.26e-16	1.94e-13	-0.38	-0.36	Height;	chr2:231549981	chr2:231508426~231514339:-
LGG	cis	rs11051970	0.797	rs4540912	ENSG00000274964.1	RP11-817I4.1	-8.43	4.27e-16	1.94e-13	-0.36	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32314259	chr12:32339368~32340724:+
LGG	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	8.43	4.29e-16	1.95e-13	0.39	0.36	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
LGG	cis	rs812925	0.537	rs2463097	ENSG00000273302.1	RP11-493E12.2	-8.43	4.29e-16	1.95e-13	-0.31	-0.36	Immature fraction of reticulocytes;	chr2:61387166	chr2:61199979~61200769:+
LGG	cis	rs4143844	0.867	rs71411468	ENSG00000259251.2	RP11-643M14.1	8.43	4.29e-16	1.95e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61894514	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs36056548	ENSG00000259251.2	RP11-643M14.1	8.43	4.29e-16	1.95e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61904187	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs12907534	ENSG00000259251.2	RP11-643M14.1	8.43	4.29e-16	1.95e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61908396	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs35607089	ENSG00000259251.2	RP11-643M14.1	8.43	4.29e-16	1.95e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61909573	chr15:62060503~62062434:+
LGG	cis	rs45509595	0.822	rs200484	ENSG00000199851.2	U3	8.43	4.29e-16	1.95e-13	0.77	0.36	Breast cancer;	chr6:27807896	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs200981	ENSG00000216901.1	AL022393.7	8.43	4.31e-16	1.96e-13	0.68	0.36	Depression;	chr6:27865396	chr6:28176188~28176674:+
LGG	cis	rs853679	0.546	rs200953	ENSG00000216901.1	AL022393.7	8.43	4.31e-16	1.96e-13	0.68	0.36	Depression;	chr6:27869489	chr6:28176188~28176674:+
LGG	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-8.43	4.31e-16	1.96e-13	-0.36	-0.36	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
LGG	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	8.43	4.31e-16	1.96e-13	0.45	0.36	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
LGG	cis	rs1707322	1	rs10789485	ENSG00000281133.1	AL355480.3	-8.43	4.32e-16	1.96e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45580892~45580996:-
LGG	cis	rs4819052	0.766	rs4819035	ENSG00000215447.6	BX322557.10	-8.43	4.32e-16	1.96e-13	-0.31	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45288052~45291738:+
LGG	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	8.43	4.32e-16	1.96e-13	0.29	0.36	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
LGG	cis	rs1560104	0.597	rs11075126	ENSG00000274834.1	CTD-3037G24.5	8.43	4.32e-16	1.96e-13	0.45	0.36	Obesity-related traits;	chr16:12613117	chr16:12614451~12614852:+
LGG	cis	rs853679	0.546	rs200990	ENSG00000216901.1	AL022393.7	8.43	4.34e-16	1.97e-13	0.67	0.36	Depression;	chr6:27848045	chr6:28176188~28176674:+
LGG	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	8.42	4.35e-16	1.98e-13	0.29	0.36	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
LGG	cis	rs763567	0.933	rs588837	ENSG00000271811.1	RP1-79C4.4	8.42	4.35e-16	1.98e-13	0.35	0.36	Tonsillectomy;	chr1:170653968	chr1:170667381~170669425:+
LGG	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	8.42	4.35e-16	1.98e-13	0.49	0.36	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
LGG	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-8.42	4.36e-16	1.98e-13	-0.46	-0.36	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
LGG	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-8.42	4.36e-16	1.98e-13	-0.46	-0.36	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
LGG	cis	rs4143844	1	rs12905264	ENSG00000259251.2	RP11-643M14.1	8.42	4.36e-16	1.98e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:61994464	chr15:62060503~62062434:+
LGG	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	8.42	4.36e-16	1.98e-13	0.49	0.36	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
LGG	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	8.42	4.36e-16	1.98e-13	0.49	0.36	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
LGG	cis	rs6558530	0.698	rs7015858	ENSG00000253982.1	CTD-2336O2.1	8.42	4.36e-16	1.98e-13	0.38	0.36	Systolic blood pressure;	chr8:1776141	chr8:1761990~1764502:-
LGG	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	8.42	4.36e-16	1.98e-13	0.53	0.36	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
LGG	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	8.42	4.36e-16	1.98e-13	0.53	0.36	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
LGG	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-8.42	4.37e-16	1.98e-13	-0.38	-0.36	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
LGG	cis	rs1185460	0.967	rs1786141	ENSG00000272186.1	RP11-110I1.13	-8.42	4.37e-16	1.99e-13	-0.35	-0.36	Coronary artery disease;	chr11:119067604	chr11:119067374~119067698:-
LGG	cis	rs2412819	0.545	rs35822148	ENSG00000249839.1	AC011330.5	-8.42	4.39e-16	1.99e-13	-0.65	-0.36	Lung cancer;	chr15:43808084	chr15:43663654~43684339:-
LGG	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	8.42	4.39e-16	1.99e-13	0.36	0.36	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
LGG	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-8.42	4.39e-16	1.99e-13	-0.36	-0.36	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
LGG	cis	rs6921919	0.583	rs9468355	ENSG00000226314.6	ZNF192P1	8.42	4.4e-16	2e-13	0.37	0.36	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28161781~28169594:+
LGG	cis	rs6545883	0.524	rs2463101	ENSG00000273302.1	RP11-493E12.2	-8.42	4.4e-16	2e-13	-0.31	-0.36	Tuberculosis;	chr2:61347287	chr2:61199979~61200769:+
LGG	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	8.42	4.41e-16	2e-13	0.36	0.36	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
LGG	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	8.42	4.43e-16	2.01e-13	0.45	0.36	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
LGG	cis	rs8135665	0.625	rs8142185	ENSG00000233739.1	RP5-1039K5.13	8.42	4.43e-16	2.01e-13	0.41	0.36	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38055073	chr22:38057180~38073940:-
LGG	cis	rs763567	1	rs61217505	ENSG00000271811.1	RP1-79C4.4	-8.42	4.45e-16	2.02e-13	-0.35	-0.36	Tonsillectomy;	chr1:170604117	chr1:170667381~170669425:+
LGG	cis	rs6940116	1	rs6940116	ENSG00000216901.1	AL022393.7	8.42	4.46e-16	2.02e-13	0.55	0.36	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28176188~28176674:+
LGG	cis	rs56804039	1	rs56804039	ENSG00000173295.6	FAM86B3P	8.42	4.49e-16	2.04e-13	0.44	0.36	Cervical cancer;	chr8:8523519	chr8:8228595~8244865:+
LGG	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-8.42	4.5e-16	2.04e-13	-0.48	-0.36	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
LGG	cis	rs9346353	0.932	rs9342773	ENSG00000219881.1	GAPDHP42	-8.42	4.5e-16	2.04e-13	-0.34	-0.36	Sleep duration;	chr6:69769880	chr6:69745871~69746851:+
LGG	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	8.42	4.52e-16	2.05e-13	0.29	0.36	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
LGG	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	8.42	4.56e-16	2.07e-13	0.49	0.36	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
LGG	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	8.42	4.57e-16	2.07e-13	0.37	0.36	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
LGG	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-8.42	4.58e-16	2.08e-13	-0.3	-0.36	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
LGG	cis	rs7474896	0.559	rs10740949	ENSG00000226578.1	RP11-258F22.1	-8.42	4.58e-16	2.08e-13	-0.46	-0.36	Obesity (extreme);	chr10:37689507	chr10:37775371~37784131:-
LGG	cis	rs763567	0.845	rs492804	ENSG00000271811.1	RP1-79C4.4	8.42	4.58e-16	2.08e-13	0.35	0.36	Tonsillectomy;	chr1:170643121	chr1:170667381~170669425:+
LGG	cis	rs763567	0.904	rs544478	ENSG00000271811.1	RP1-79C4.4	8.42	4.58e-16	2.08e-13	0.35	0.36	Tonsillectomy;	chr1:170644901	chr1:170667381~170669425:+
LGG	cis	rs763567	0.967	rs593560	ENSG00000271811.1	RP1-79C4.4	8.42	4.58e-16	2.08e-13	0.35	0.36	Tonsillectomy;	chr1:170646776	chr1:170667381~170669425:+
LGG	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-8.42	4.59e-16	2.08e-13	-0.37	-0.36	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-8.42	4.59e-16	2.08e-13	-0.37	-0.36	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
LGG	cis	rs17772222	0.682	rs28711639	ENSG00000222990.1	RNU4-22P	8.42	4.59e-16	2.08e-13	0.43	0.36	Coronary artery calcification;	chr14:88482277	chr14:88513498~88513663:+
LGG	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-8.42	4.59e-16	2.08e-13	-0.48	-0.36	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
LGG	cis	rs17772222	0.74	rs11847417	ENSG00000222990.1	RNU4-22P	-8.42	4.6e-16	2.09e-13	-0.43	-0.36	Coronary artery calcification;	chr14:88510606	chr14:88513498~88513663:+
LGG	cis	rs7219021	0.743	rs575556	ENSG00000248278.1	SUMO2P17	8.42	4.61e-16	2.09e-13	0.42	0.36	Schizophrenia or bipolar disorder;	chr17:48780125	chr17:48874860~48908983:-
LGG	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-8.42	4.61e-16	2.09e-13	-0.34	-0.36	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
LGG	cis	rs763567	0.585	rs553905	ENSG00000271811.1	RP1-79C4.4	-8.42	4.61e-16	2.09e-13	-0.34	-0.36	Tonsillectomy;	chr1:170611336	chr1:170667381~170669425:+
LGG	cis	rs56804039	1	rs11777086	ENSG00000173295.6	FAM86B3P	8.42	4.61e-16	2.09e-13	0.44	0.36	Cervical cancer;	chr8:8526969	chr8:8228595~8244865:+
LGG	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-8.42	4.62e-16	2.1e-13	-0.47	-0.36	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
LGG	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-8.42	4.62e-16	2.1e-13	-0.47	-0.36	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
LGG	cis	rs1707322	1	rs10890376	ENSG00000281133.1	AL355480.3	-8.42	4.63e-16	2.1e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45580892~45580996:-
LGG	cis	rs2638953	0.962	rs7303747	ENSG00000278733.1	RP11-425D17.1	-8.42	4.64e-16	2.1e-13	-0.45	-0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28241969	chr12:28185625~28186190:-
LGG	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-8.42	4.66e-16	2.11e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
LGG	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-8.42	4.66e-16	2.11e-13	-0.37	-0.36	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-8.42	4.66e-16	2.11e-13	-0.37	-0.36	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
LGG	cis	rs9346353	1	rs6920280	ENSG00000219881.1	GAPDHP42	8.42	4.67e-16	2.11e-13	0.34	0.36	Sleep duration;	chr6:69779250	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs3799119	ENSG00000219881.1	GAPDHP42	8.42	4.67e-16	2.11e-13	0.34	0.36	Sleep duration;	chr6:69783977	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9364061	ENSG00000219881.1	GAPDHP42	8.42	4.67e-16	2.11e-13	0.34	0.36	Sleep duration;	chr6:69785485	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs7752533	ENSG00000219881.1	GAPDHP42	8.42	4.67e-16	2.11e-13	0.34	0.36	Sleep duration;	chr6:69786109	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.9	rs2125024	ENSG00000219881.1	GAPDHP42	8.42	4.67e-16	2.11e-13	0.34	0.36	Sleep duration;	chr6:69790228	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs2305838	ENSG00000219881.1	GAPDHP42	8.42	4.67e-16	2.11e-13	0.34	0.36	Sleep duration;	chr6:69790559	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs2305839	ENSG00000219881.1	GAPDHP42	8.42	4.67e-16	2.11e-13	0.34	0.36	Sleep duration;	chr6:69790571	chr6:69745871~69746851:+
LGG	cis	rs2797160	0.904	rs1612274	ENSG00000237742.5	RP11-624M8.1	8.42	4.67e-16	2.12e-13	0.34	0.36	Endometrial cancer;	chr6:125693761	chr6:125578558~125749190:-
LGG	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-8.42	4.67e-16	2.12e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
LGG	cis	rs6496932	0.865	rs4843049	ENSG00000218052.5	ADAMTS7P4	8.42	4.67e-16	2.12e-13	0.55	0.36	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85255369~85330334:-
LGG	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-8.42	4.68e-16	2.12e-13	-0.36	-0.36	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
LGG	cis	rs375066	0.935	rs397913	ENSG00000267191.1	RP11-15A1.2	8.42	4.68e-16	2.12e-13	0.37	0.36	Breast cancer;	chr19:43894788	chr19:43902001~43926545:+
LGG	cis	rs71403859	0.57	rs76231867	ENSG00000260886.1	TAT-AS1	8.41	4.68e-16	2.12e-13	0.67	0.36	Post bronchodilator FEV1;	chr16:71416023	chr16:71565789~71578187:+
LGG	cis	rs71403859	0.57	rs78972826	ENSG00000260886.1	TAT-AS1	8.41	4.68e-16	2.12e-13	0.67	0.36	Post bronchodilator FEV1;	chr16:71420361	chr16:71565789~71578187:+
LGG	cis	rs17345786	0.906	rs11708616	ENSG00000256628.3	ZBTB11-AS1	8.41	4.69e-16	2.13e-13	0.45	0.36	Colonoscopy-negative controls vs population controls;	chr3:101512887	chr3:101676475~101679217:+
LGG	cis	rs7474896	0.583	rs1208770	ENSG00000226578.1	RP11-258F22.1	-8.41	4.71e-16	2.13e-13	-0.48	-0.36	Obesity (extreme);	chr10:37755755	chr10:37775371~37784131:-
LGG	cis	rs7474896	0.526	rs1742235	ENSG00000226578.1	RP11-258F22.1	-8.41	4.71e-16	2.13e-13	-0.48	-0.36	Obesity (extreme);	chr10:37763328	chr10:37775371~37784131:-
LGG	cis	rs7474896	0.559	rs1208779	ENSG00000226578.1	RP11-258F22.1	-8.41	4.71e-16	2.13e-13	-0.48	-0.36	Obesity (extreme);	chr10:37788801	chr10:37775371~37784131:-
LGG	cis	rs7829975	0.533	rs13274028	ENSG00000173295.6	FAM86B3P	-8.41	4.71e-16	2.13e-13	-0.39	-0.36	Mood instability;	chr8:8871683	chr8:8228595~8244865:+
LGG	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-8.41	4.72e-16	2.14e-13	-0.36	-0.36	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
LGG	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	8.41	4.73e-16	2.14e-13	0.27	0.36	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
LGG	cis	rs6545883	0.56	rs11677776	ENSG00000273302.1	RP11-493E12.2	-8.41	4.74e-16	2.14e-13	-0.31	-0.36	Tuberculosis;	chr2:61275978	chr2:61199979~61200769:+
LGG	cis	rs45509595	0.841	rs9368531	ENSG00000199851.2	U3	8.41	4.74e-16	2.15e-13	0.77	0.36	Breast cancer;	chr6:27814094	chr6:28015568~28015777:+
LGG	cis	rs45509595	0.749	rs401763	ENSG00000199851.2	U3	8.41	4.74e-16	2.15e-13	0.77	0.36	Breast cancer;	chr6:27814750	chr6:28015568~28015777:+
LGG	cis	rs45509595	0.659	rs390764	ENSG00000199851.2	U3	8.41	4.74e-16	2.15e-13	0.77	0.36	Breast cancer;	chr6:27814757	chr6:28015568~28015777:+
LGG	cis	rs45509595	0.841	rs401754	ENSG00000199851.2	U3	8.41	4.74e-16	2.15e-13	0.77	0.36	Breast cancer;	chr6:27814760	chr6:28015568~28015777:+
LGG	cis	rs45509595	0.841	rs2747054	ENSG00000199851.2	U3	8.41	4.74e-16	2.15e-13	0.77	0.36	Breast cancer;	chr6:27815581	chr6:28015568~28015777:+
LGG	cis	rs45509595	0.841	rs200501	ENSG00000199851.2	U3	8.41	4.74e-16	2.15e-13	0.77	0.36	Breast cancer;	chr6:27821164	chr6:28015568~28015777:+
LGG	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	8.41	4.74e-16	2.15e-13	0.45	0.36	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
LGG	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	8.41	4.75e-16	2.15e-13	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
LGG	cis	rs7927771	0.524	rs2242081	ENSG00000280615.1	Y_RNA	8.41	4.77e-16	2.16e-13	0.42	0.36	Subjective well-being;	chr11:47478715	chr11:47614898~47614994:-
LGG	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-8.41	4.78e-16	2.16e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
LGG	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	8.41	4.79e-16	2.17e-13	0.36	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
LGG	cis	rs227275	0.525	rs3974485	ENSG00000248971.2	KRT8P46	-8.41	4.81e-16	2.17e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs7688940	ENSG00000248971.2	KRT8P46	-8.41	4.81e-16	2.17e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102728746~102730171:-
LGG	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-8.41	4.81e-16	2.18e-13	-0.45	-0.36	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
LGG	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	8.41	4.81e-16	2.18e-13	0.54	0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
LGG	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	8.41	4.81e-16	2.18e-13	0.37	0.36	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
LGG	cis	rs227275	0.525	rs6533052	ENSG00000248971.2	KRT8P46	-8.41	4.82e-16	2.18e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102728746~102730171:-
LGG	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	8.41	4.83e-16	2.19e-13	0.39	0.36	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
LGG	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	8.41	4.84e-16	2.19e-13	0.53	0.36	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	8.41	4.84e-16	2.19e-13	0.53	0.36	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
LGG	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	8.41	4.84e-16	2.19e-13	0.44	0.36	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
LGG	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	8.41	4.85e-16	2.19e-13	0.24	0.36	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
LGG	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	8.41	4.85e-16	2.2e-13	0.53	0.36	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	8.41	4.85e-16	2.2e-13	0.53	0.36	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
LGG	cis	rs853679	0.607	rs201002	ENSG00000216901.1	AL022393.7	8.41	4.86e-16	2.2e-13	0.67	0.36	Depression;	chr6:27840414	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.89	rs9532627	ENSG00000168852.11	TPTE2P5	8.41	4.87e-16	2.2e-13	0.38	0.36	Cervical cancer;	chr13:40874811	chr13:40822296~40921749:-
LGG	cis	rs6061231	0.505	rs62199217	ENSG00000273619.1	RP5-908M14.9	-8.41	4.87e-16	2.2e-13	-0.3	-0.36	Colorectal cancer;	chr20:62354483	chr20:62386303~62386970:-
LGG	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-8.41	4.88e-16	2.21e-13	-0.43	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
LGG	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-8.41	4.88e-16	2.21e-13	-0.38	-0.36	Height;	chr2:231553603	chr2:231508426~231514339:-
LGG	cis	rs11992162	0.967	rs11250185	ENSG00000227888.4	FAM66A	8.41	4.88e-16	2.21e-13	0.44	0.36	Monocyte count;	chr8:11975614	chr8:12362019~12388296:+
LGG	cis	rs11992162	1	rs12334769	ENSG00000227888.4	FAM66A	8.41	4.88e-16	2.21e-13	0.44	0.36	Monocyte count;	chr8:11975652	chr8:12362019~12388296:+
LGG	cis	rs5742933	1	rs5742998	ENSG00000253559.1	OSGEPL1-AS1	-8.41	4.88e-16	2.21e-13	-0.47	-0.36	Ferritin levels;	chr2:189799626	chr2:189762704~189765556:+
LGG	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-8.41	4.89e-16	2.21e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
LGG	cis	rs1555322	0.53	rs6060341	ENSG00000269202.1	RP4-614O4.12	8.41	4.89e-16	2.21e-13	0.4	0.36	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35201747~35203288:-
LGG	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-8.41	4.9e-16	2.22e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
LGG	cis	rs454217	0.846	rs427600	ENSG00000277851.1	RP11-756G20.1	8.41	4.91e-16	2.22e-13	0.37	0.36	Smoking quantity;	chr12:92326886	chr12:92247756~92363832:-
LGG	cis	rs454217	0.818	rs1661031	ENSG00000277851.1	RP11-756G20.1	8.41	4.91e-16	2.22e-13	0.37	0.36	Smoking quantity;	chr12:92328010	chr12:92247756~92363832:-
LGG	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	8.41	4.92e-16	2.22e-13	0.35	0.36	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
LGG	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-8.41	4.92e-16	2.22e-13	-0.47	-0.36	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
LGG	cis	rs11098499	0.954	rs10034623	ENSG00000250412.1	KLHL2P1	8.41	4.94e-16	2.23e-13	0.41	0.36	Corneal astigmatism;	chr4:119476674	chr4:119334329~119378233:+
LGG	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-8.41	4.94e-16	2.23e-13	-0.36	-0.36	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
LGG	cis	rs11220082	0.644	rs61917855	ENSG00000254671.2	STT3A-AS1	-8.41	4.94e-16	2.23e-13	-0.44	-0.36	Schizophrenia;	chr11:125473652	chr11:125570284~125592568:-
LGG	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-8.41	4.96e-16	2.24e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
LGG	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-8.41	4.96e-16	2.24e-13	-0.38	-0.36	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
LGG	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	8.41	4.96e-16	2.24e-13	0.44	0.36	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
LGG	cis	rs35851103	0.506	rs4841659	ENSG00000227888.4	FAM66A	8.41	4.97e-16	2.24e-13	0.43	0.36	Neuroticism;	chr8:11970691	chr8:12362019~12388296:+
LGG	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-8.41	4.97e-16	2.25e-13	-0.49	-0.36	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-8.41	4.97e-16	2.25e-13	-0.49	-0.36	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
LGG	cis	rs2638953	0.886	rs10492369	ENSG00000278733.1	RP11-425D17.1	8.41	4.99e-16	2.25e-13	0.45	0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172185	chr12:28185625~28186190:-
LGG	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-8.41	4.99e-16	2.25e-13	-0.37	-0.36	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
LGG	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-8.41	4.99e-16	2.26e-13	-0.48	-0.36	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
LGG	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	8.41	4.99e-16	2.26e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	8.41	4.99e-16	2.26e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
LGG	cis	rs4713118	0.715	rs200480	ENSG00000226314.6	ZNF192P1	8.41	5e-16	2.26e-13	0.35	0.36	Parkinson's disease;	chr6:27805886	chr6:28161781~28169594:+
LGG	cis	rs763567	0.967	rs654461	ENSG00000271811.1	RP1-79C4.4	8.41	5e-16	2.26e-13	0.35	0.36	Tonsillectomy;	chr1:170644709	chr1:170667381~170669425:+
LGG	cis	rs763567	0.933	rs567328	ENSG00000271811.1	RP1-79C4.4	8.41	5e-16	2.26e-13	0.35	0.36	Tonsillectomy;	chr1:170644728	chr1:170667381~170669425:+
LGG	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-8.41	5e-16	2.26e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
LGG	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-8.41	5.02e-16	2.27e-13	-0.38	-0.36	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
LGG	cis	rs7124681	0.584	rs12226590	ENSG00000280615.1	Y_RNA	8.41	5.02e-16	2.27e-13	0.43	0.36	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47550256	chr11:47614898~47614994:-
LGG	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-8.41	5.03e-16	2.27e-13	-0.45	-0.36	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
LGG	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	8.41	5.03e-16	2.27e-13	0.67	0.36	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
LGG	cis	rs17772222	0.755	rs12435019	ENSG00000258983.2	RP11-507K2.2	8.41	5.04e-16	2.27e-13	0.4	0.36	Coronary artery calcification;	chr14:88365074	chr14:88499334~88515502:+
LGG	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	8.4	5.04e-16	2.28e-13	0.24	0.36	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
LGG	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-8.4	5.04e-16	2.28e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
LGG	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-8.4	5.04e-16	2.28e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
LGG	cis	rs7772486	0.686	rs9376961	ENSG00000270638.1	RP3-466P17.1	8.4	5.04e-16	2.28e-13	0.24	0.36	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145735570~145737218:+
LGG	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-8.4	5.05e-16	2.28e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
LGG	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-8.4	5.05e-16	2.28e-13	-0.42	-0.36	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
LGG	cis	rs7208859	0.623	rs9899692	ENSG00000266490.1	CTD-2349P21.9	8.4	5.06e-16	2.28e-13	0.45	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30792372~30792833:+
LGG	cis	rs9393777	0.92	rs13207689	ENSG00000216901.1	AL022393.7	8.4	5.1e-16	2.3e-13	0.81	0.36	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.92	rs13196692	ENSG00000216901.1	AL022393.7	8.4	5.1e-16	2.3e-13	0.81	0.36	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.92	rs34150729	ENSG00000216901.1	AL022393.7	8.4	5.1e-16	2.3e-13	0.81	0.36	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.92	rs13191227	ENSG00000216901.1	AL022393.7	8.4	5.1e-16	2.3e-13	0.81	0.36	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28176188~28176674:+
LGG	cis	rs454217	0.846	rs413415	ENSG00000277851.1	RP11-756G20.1	8.4	5.1e-16	2.3e-13	0.37	0.36	Smoking quantity;	chr12:92327115	chr12:92247756~92363832:-
LGG	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-8.4	5.1e-16	2.3e-13	-0.38	-0.36	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
LGG	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	8.4	5.11e-16	2.31e-13	0.52	0.36	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
LGG	cis	rs7474896	0.559	rs1208645	ENSG00000226578.1	RP11-258F22.1	8.4	5.11e-16	2.31e-13	0.48	0.36	Obesity (extreme);	chr10:37843159	chr10:37775371~37784131:-
LGG	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-8.4	5.12e-16	2.31e-13	-0.34	-0.36	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
LGG	cis	rs1949733	1	rs6858542	ENSG00000205959.3	RP11-689P11.2	8.4	5.13e-16	2.32e-13	0.34	0.36	Response to antineoplastic agents;	chr4:8509820	chr4:8482270~8512610:+
LGG	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	8.4	5.13e-16	2.32e-13	0.58	0.36	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
LGG	cis	rs7746199	0.736	rs6904596	ENSG00000199851.2	U3	8.4	5.13e-16	2.32e-13	0.84	0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28015568~28015777:+
LGG	cis	rs7927771	0.524	rs10838740	ENSG00000280615.1	Y_RNA	8.4	5.14e-16	2.32e-13	0.43	0.36	Subjective well-being;	chr11:47658428	chr11:47614898~47614994:-
LGG	cis	rs1555322	0.53	rs2275275	ENSG00000269202.1	RP4-614O4.12	-8.4	5.14e-16	2.32e-13	-0.4	-0.36	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35201747~35203288:-
LGG	cis	rs11220082	0.666	rs12789687	ENSG00000254671.2	STT3A-AS1	-8.4	5.14e-16	2.32e-13	-0.44	-0.36	Schizophrenia;	chr11:125461254	chr11:125570284~125592568:-
LGG	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	8.4	5.18e-16	2.34e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
LGG	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-8.4	5.19e-16	2.34e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-8.4	5.19e-16	2.34e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-8.4	5.19e-16	2.34e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-8.4	5.19e-16	2.34e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-8.4	5.19e-16	2.34e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-8.4	5.19e-16	2.34e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
LGG	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	8.4	5.21e-16	2.35e-13	0.44	0.36	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
LGG	cis	rs11098499	0.863	rs3822192	ENSG00000250412.1	KLHL2P1	8.4	5.22e-16	2.36e-13	0.42	0.36	Corneal astigmatism;	chr4:119524565	chr4:119334329~119378233:+
LGG	cis	rs6921919	0.583	rs6928771	ENSG00000226314.6	ZNF192P1	8.4	5.22e-16	2.36e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs6928773	ENSG00000226314.6	ZNF192P1	8.4	5.22e-16	2.36e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28161781~28169594:+
LGG	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	8.4	5.24e-16	2.36e-13	0.64	0.36	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
LGG	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	8.4	5.24e-16	2.36e-13	0.38	0.36	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
LGG	cis	rs6496932	0.865	rs4842879	ENSG00000218052.5	ADAMTS7P4	8.4	5.25e-16	2.37e-13	0.58	0.36	Central corneal thickness;Corneal structure;	chr15:85381657	chr15:85255369~85330334:-
LGG	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-8.4	5.25e-16	2.37e-13	-0.48	-0.36	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
LGG	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-8.4	5.27e-16	2.37e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
LGG	cis	rs1185460	0.967	rs1168568	ENSG00000272186.1	RP11-110I1.13	-8.4	5.28e-16	2.38e-13	-0.35	-0.36	Coronary artery disease;	chr11:119079089	chr11:119067374~119067698:-
LGG	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-8.4	5.28e-16	2.38e-13	-0.46	-0.36	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
LGG	cis	rs9810089	0.692	rs589092	ENSG00000261758.1	RP11-102M11.2	-8.4	5.28e-16	2.38e-13	-0.38	-0.36	Gestational age at birth (child effect);	chr3:136260856	chr3:136752630~136755780:+
LGG	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	8.4	5.29e-16	2.38e-13	0.37	0.36	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
LGG	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-8.4	5.3e-16	2.39e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
LGG	cis	rs11098499	0.909	rs28884220	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119386056	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs28793658	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119386059	chr4:119334329~119378233:+
LGG	cis	rs1707322	1	rs12403666	ENSG00000281133.1	AL355480.3	-8.4	5.31e-16	2.39e-13	-0.43	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45580892~45580996:-
LGG	cis	rs11098499	0.954	rs59866101	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119375436	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.618	rs6858383	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119375617	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.697	rs6832410	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119375645	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.865	rs1112817	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119376645	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.779	rs10016060	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119377257	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs10005644	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119377322	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.697	rs10016448	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119377690	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.657	rs9996569	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119377849	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.908	rs11729050	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119378911	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs28429722	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119378938	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs10014845	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119379922	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.779	rs7674500	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119382438	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.697	rs4373140	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119386543	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs13113483	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119387884	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.542	rs10440343	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119388632	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs28668716	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119388720	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.542	rs7677836	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119389483	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs10002083	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119389997	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs10024844	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119390373	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs4345162	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119391804	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.657	rs4463052	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119392103	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.697	rs4560394	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119392280	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs13151285	ENSG00000250412.1	KLHL2P1	8.4	5.31e-16	2.39e-13	0.42	0.36	Corneal astigmatism;	chr4:119393586	chr4:119334329~119378233:+
LGG	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-8.4	5.32e-16	2.39e-13	-0.36	-0.36	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
LGG	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	8.4	5.32e-16	2.39e-13	0.3	0.36	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
LGG	cis	rs4713118	0.614	rs9380007	ENSG00000199851.2	U3	8.4	5.32e-16	2.39e-13	0.49	0.36	Parkinson's disease;	chr6:27692729	chr6:28015568~28015777:+
LGG	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	8.4	5.32e-16	2.4e-13	0.58	0.36	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
LGG	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	8.4	5.34e-16	2.4e-13	0.64	0.36	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
LGG	cis	rs9388451	0.657	rs4895799	ENSG00000237742.5	RP11-624M8.1	-8.4	5.34e-16	2.4e-13	-0.32	-0.36	Brugada syndrome;	chr6:125731583	chr6:125578558~125749190:-
LGG	cis	rs7520050	0.807	rs28647556	ENSG00000280836.1	AL355480.1	-8.4	5.36e-16	2.41e-13	-0.38	-0.36	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.807	rs4274104	ENSG00000280836.1	AL355480.1	-8.4	5.37e-16	2.42e-13	-0.38	-0.36	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45581219~45581321:-
LGG	cis	rs4713118	0.513	rs149975	ENSG00000218016.2	ZNF192P2	-8.4	5.37e-16	2.42e-13	-0.47	-0.36	Parkinson's disease;	chr6:28018562	chr6:28188050~28189432:+
LGG	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	8.4	5.38e-16	2.42e-13	0.48	0.36	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
LGG	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	8.4	5.38e-16	2.42e-13	0.48	0.36	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
LGG	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	8.4	5.38e-16	2.42e-13	0.48	0.36	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
LGG	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	8.4	5.38e-16	2.42e-13	0.48	0.36	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
LGG	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	8.4	5.38e-16	2.42e-13	0.48	0.36	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
LGG	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	8.4	5.38e-16	2.42e-13	0.48	0.36	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
LGG	cis	rs763567	0.967	rs473832	ENSG00000271811.1	RP1-79C4.4	8.4	5.38e-16	2.42e-13	0.35	0.36	Tonsillectomy;	chr1:170640049	chr1:170667381~170669425:+
LGG	cis	rs13287066	0.692	rs4563950	ENSG00000227603.1	RP11-165J3.6	8.4	5.39e-16	2.43e-13	0.36	0.36	Intelligence (multi-trait analysis);	chr9:93405359	chr9:93435332~93437121:-
LGG	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	8.4	5.4e-16	2.43e-13	0.39	0.36	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
LGG	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-8.4	5.4e-16	2.43e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
LGG	cis	rs853679	0.585	rs201004	ENSG00000216901.1	AL022393.7	8.4	5.4e-16	2.43e-13	0.51	0.36	Depression;	chr6:27837156	chr6:28176188~28176674:+
LGG	cis	rs853679	0.585	rs201001	ENSG00000216901.1	AL022393.7	8.4	5.4e-16	2.43e-13	0.51	0.36	Depression;	chr6:27841121	chr6:28176188~28176674:+
LGG	cis	rs853679	0.585	rs201000	ENSG00000216901.1	AL022393.7	8.4	5.4e-16	2.43e-13	0.51	0.36	Depression;	chr6:27841381	chr6:28176188~28176674:+
LGG	cis	rs1023500	0.551	rs133379	ENSG00000227370.1	RP4-669P10.19	8.4	5.42e-16	2.44e-13	0.32	0.36	Schizophrenia;	chr22:42072531	chr22:42132543~42132998:+
LGG	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	8.39	5.44e-16	2.45e-13	0.42	0.36	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	8.39	5.44e-16	2.45e-13	0.42	0.36	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
LGG	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	8.39	5.44e-16	2.45e-13	0.48	0.36	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
LGG	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-8.39	5.44e-16	2.45e-13	-0.39	-0.36	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-8.39	5.44e-16	2.45e-13	-0.39	-0.36	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
LGG	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-8.39	5.44e-16	2.45e-13	-0.41	-0.36	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
LGG	cis	rs9346353	1	rs3752787	ENSG00000219881.1	GAPDHP42	8.39	5.46e-16	2.46e-13	0.34	0.36	Sleep duration;	chr6:69796603	chr6:69745871~69746851:+
LGG	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-8.39	5.48e-16	2.46e-13	-0.36	-0.36	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-8.39	5.48e-16	2.46e-13	-0.36	-0.36	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
LGG	cis	rs12682352	0.602	rs6993494	ENSG00000173295.6	FAM86B3P	-8.39	5.48e-16	2.46e-13	-0.38	-0.36	Neuroticism;	chr8:8809934	chr8:8228595~8244865:+
LGG	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-8.39	5.49e-16	2.47e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
LGG	cis	rs4713118	0.911	rs9295746	ENSG00000226314.6	ZNF192P1	8.39	5.49e-16	2.47e-13	0.4	0.36	Parkinson's disease;	chr6:27762285	chr6:28161781~28169594:+
LGG	cis	rs11722779	0.933	rs7695096	ENSG00000248971.2	KRT8P46	-8.39	5.5e-16	2.48e-13	-0.38	-0.36	Schizophrenia;	chr4:103011399	chr4:102728746~102730171:-
LGG	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	8.39	5.51e-16	2.48e-13	0.47	0.36	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
LGG	cis	rs11220082	0.666	rs12223186	ENSG00000254671.2	STT3A-AS1	-8.39	5.51e-16	2.48e-13	-0.44	-0.36	Schizophrenia;	chr11:125461743	chr11:125570284~125592568:-
LGG	cis	rs149866169	1	rs149866169	ENSG00000216901.1	AL022393.7	8.39	5.51e-16	2.48e-13	0.76	0.36	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.668	rs7749305	ENSG00000216901.1	AL022393.7	8.39	5.51e-16	2.48e-13	0.76	0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28176188~28176674:+
LGG	cis	rs7746199	0.668	rs34864796	ENSG00000216901.1	AL022393.7	8.39	5.51e-16	2.48e-13	0.76	0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28176188~28176674:+
LGG	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-8.39	5.51e-16	2.48e-13	-0.48	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
LGG	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-8.39	5.51e-16	2.48e-13	-0.48	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
LGG	cis	rs12682352	0.602	rs28399241	ENSG00000173295.6	FAM86B3P	-8.39	5.51e-16	2.48e-13	-0.38	-0.36	Neuroticism;	chr8:8805705	chr8:8228595~8244865:+
LGG	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	8.39	5.52e-16	2.48e-13	0.41	0.36	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	8.39	5.52e-16	2.48e-13	0.41	0.36	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
LGG	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-8.39	5.52e-16	2.48e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
LGG	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-8.39	5.52e-16	2.48e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
LGG	cis	rs9719620	0.834	rs4731786	ENSG00000236753.4	MKLN1-AS	-8.39	5.53e-16	2.49e-13	-0.37	-0.36	Male-pattern baldness;	chr7:131301579	chr7:131309744~131328222:-
LGG	cis	rs9346353	1	rs7775172	ENSG00000219881.1	GAPDHP42	8.39	5.53e-16	2.49e-13	0.34	0.36	Sleep duration;	chr6:69755811	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346354	ENSG00000219881.1	GAPDHP42	8.39	5.53e-16	2.49e-13	0.34	0.36	Sleep duration;	chr6:69780636	chr6:69745871~69746851:+
LGG	cis	rs7189233	0.955	rs11540358	ENSG00000279344.1	RP11-44F14.7	8.39	5.53e-16	2.49e-13	0.35	0.36	Intelligence (multi-trait analysis);	chr16:53470031	chr16:53478957~53481550:-
LGG	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	8.39	5.54e-16	2.49e-13	0.42	0.36	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
LGG	cis	rs1707322	0.963	rs4630155	ENSG00000281133.1	AL355480.3	-8.39	5.54e-16	2.49e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45580892~45580996:-
LGG	cis	rs12608544	1	rs12608544	ENSG00000232871.7	SEC1P	-8.39	5.55e-16	2.5e-13	-0.64	-0.36	Elevated serum carcinoembryonic antigen levels;	chr19:48633394	chr19:48638071~48682245:+
LGG	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-8.39	5.56e-16	2.5e-13	-0.37	-0.36	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
LGG	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-8.39	5.57e-16	2.5e-13	-0.44	-0.36	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
LGG	cis	rs6921919	0.583	rs7764722	ENSG00000226314.6	ZNF192P1	8.39	5.57e-16	2.51e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28161781~28169594:+
LGG	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-8.39	5.58e-16	2.51e-13	-0.38	-0.36	Height;	chr2:231551270	chr2:231508426~231514339:-
LGG	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	-8.39	5.6e-16	2.51e-13	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
LGG	cis	rs11098499	0.779	rs7699346	ENSG00000250412.1	KLHL2P1	8.39	5.6e-16	2.52e-13	0.42	0.36	Corneal astigmatism;	chr4:119389387	chr4:119334329~119378233:+
LGG	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-8.39	5.6e-16	2.52e-13	-0.42	-0.36	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
LGG	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-8.39	5.63e-16	2.53e-13	-0.34	-0.36	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
LGG	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-8.39	5.63e-16	2.53e-13	-0.34	-0.36	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
LGG	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-8.39	5.63e-16	2.53e-13	-0.34	-0.36	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
LGG	cis	rs853679	0.567	rs13196606	ENSG00000226314.6	ZNF192P1	8.39	5.64e-16	2.53e-13	0.38	0.36	Depression;	chr6:28402301	chr6:28161781~28169594:+
LGG	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-8.39	5.65e-16	2.54e-13	-0.46	-0.36	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
LGG	cis	rs1153858	1	rs11858495	ENSG00000259433.2	CTD-2651B20.4	8.39	5.66e-16	2.54e-13	0.41	0.36	Homoarginine levels;	chr15:45345464	chr15:45330209~45332634:-
LGG	cis	rs853679	0.546	rs200996	ENSG00000199851.2	U3	8.39	5.68e-16	2.55e-13	0.76	0.36	Depression;	chr6:27844050	chr6:28015568~28015777:+
LGG	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	8.39	5.69e-16	2.56e-13	0.42	0.36	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
LGG	cis	rs7219021	0.674	rs4793990	ENSG00000248278.1	SUMO2P17	8.39	5.73e-16	2.57e-13	0.43	0.36	Schizophrenia or bipolar disorder;	chr17:48883398	chr17:48874860~48908983:-
LGG	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-8.39	5.73e-16	2.57e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-8.39	5.73e-16	2.57e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-8.39	5.73e-16	2.57e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	8.39	5.73e-16	2.57e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
LGG	cis	rs11148252	0.711	rs61957304	ENSG00000235660.1	LINC00345	-8.39	5.74e-16	2.57e-13	-0.45	-0.36	Lewy body disease;	chr13:52224288	chr13:52484161~52484680:-
LGG	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	8.39	5.75e-16	2.58e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
LGG	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	8.39	5.75e-16	2.58e-13	0.45	0.36	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
LGG	cis	rs17772222	0.597	rs17700296	ENSG00000222990.1	RNU4-22P	8.39	5.75e-16	2.58e-13	0.47	0.36	Coronary artery calcification;	chr14:88840976	chr14:88513498~88513663:+
LGG	cis	rs2653165	1	rs2653165	ENSG00000272865.1	RP11-561I11.4	8.39	5.75e-16	2.58e-13	0.46	0.36	Response to cytadine analogues (cytosine arabinoside);	chr1:242202980	chr1:242147514~242209129:+
LGG	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	8.39	5.75e-16	2.58e-13	0.48	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
LGG	cis	rs2739330	0.761	rs5760176	ENSG00000272787.1	KB-226F1.2	-8.39	5.75e-16	2.58e-13	-0.39	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23969211~23969873:+
LGG	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	8.39	5.75e-16	2.58e-13	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	8.39	5.75e-16	2.58e-13	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
LGG	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-8.39	5.76e-16	2.58e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
LGG	cis	rs6997458	0.742	rs20571	ENSG00000253549.4	RP11-317J10.2	8.39	5.76e-16	2.58e-13	0.29	0.36	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85439768	chr8:85441851~85464915:-
LGG	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-8.39	5.76e-16	2.59e-13	-0.45	-0.36	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
LGG	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-8.39	5.77e-16	2.59e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
LGG	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-8.39	5.77e-16	2.59e-13	-0.48	-0.36	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
LGG	cis	rs172166	0.694	rs1225716	ENSG00000218016.2	ZNF192P2	-8.39	5.78e-16	2.59e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28145968	chr6:28188050~28189432:+
LGG	cis	rs7927771	0.507	rs1483988	ENSG00000280615.1	Y_RNA	8.39	5.78e-16	2.59e-13	0.43	0.36	Subjective well-being;	chr11:47877478	chr11:47614898~47614994:-
LGG	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	8.39	5.78e-16	2.59e-13	0.38	0.36	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	8.39	5.78e-16	2.59e-13	0.38	0.36	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	8.39	5.78e-16	2.59e-13	0.38	0.36	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	8.39	5.78e-16	2.59e-13	0.38	0.36	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
LGG	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-8.39	5.79e-16	2.6e-13	-0.49	-0.36	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
LGG	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-8.39	5.8e-16	2.6e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-8.39	5.8e-16	2.6e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-8.39	5.8e-16	2.6e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-8.39	5.8e-16	2.6e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-8.39	5.8e-16	2.6e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
LGG	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-8.39	5.8e-16	2.6e-13	-0.46	-0.36	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
LGG	cis	rs172166	0.694	rs2791332	ENSG00000218016.2	ZNF192P2	-8.39	5.82e-16	2.61e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28141010	chr6:28188050~28189432:+
LGG	cis	rs10246939	0.505	rs6967189	ENSG00000261570.1	RP11-744I24.2	-8.39	5.82e-16	2.61e-13	-0.45	-0.36	Bitter taste perception;	chr7:141826220	chr7:141529203~141551304:-
LGG	cis	rs10946940	0.965	rs6456799	ENSG00000199851.2	U3	-8.39	5.82e-16	2.61e-13	-0.48	-0.36	Systemic lupus erythematosus;	chr6:27605757	chr6:28015568~28015777:+
LGG	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-8.39	5.83e-16	2.62e-13	-0.54	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
LGG	cis	rs11098499	0.954	rs12508504	ENSG00000250412.1	KLHL2P1	8.39	5.84e-16	2.62e-13	0.41	0.36	Corneal astigmatism;	chr4:119489452	chr4:119334329~119378233:+
LGG	cis	rs7829975	0.501	rs4840353	ENSG00000173295.6	FAM86B3P	8.38	5.84e-16	2.62e-13	0.4	0.36	Mood instability;	chr8:8723060	chr8:8228595~8244865:+
LGG	cis	rs889122	0.765	rs889162	ENSG00000267289.1	CTD-2623N2.11	8.38	5.85e-16	2.62e-13	0.47	0.36	Menarche (age at onset);	chr19:9841240	chr19:9834079~9835013:-
LGG	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-8.38	5.86e-16	2.63e-13	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
LGG	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-8.38	5.87e-16	2.63e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
LGG	cis	rs812925	0.511	rs11886950	ENSG00000273302.1	RP11-493E12.2	8.38	5.88e-16	2.63e-13	0.32	0.36	Immature fraction of reticulocytes;	chr2:61172182	chr2:61199979~61200769:+
LGG	cis	rs17772222	0.682	rs2297129	ENSG00000222990.1	RNU4-22P	8.38	5.88e-16	2.64e-13	0.43	0.36	Coronary artery calcification;	chr14:88469581	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.682	rs61542857	ENSG00000222990.1	RNU4-22P	8.38	5.88e-16	2.64e-13	0.43	0.36	Coronary artery calcification;	chr14:88470358	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.637	rs7161660	ENSG00000222990.1	RNU4-22P	8.38	5.88e-16	2.64e-13	0.43	0.36	Coronary artery calcification;	chr14:88471832	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.682	rs7141363	ENSG00000222990.1	RNU4-22P	8.38	5.88e-16	2.64e-13	0.43	0.36	Coronary artery calcification;	chr14:88471879	chr14:88513498~88513663:+
LGG	cis	rs1707322	0.963	rs6429581	ENSG00000281133.1	AL355480.3	-8.38	5.89e-16	2.64e-13	-0.43	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45580892~45580996:-
LGG	cis	rs11098499	0.863	rs10030660	ENSG00000250412.1	KLHL2P1	8.38	5.89e-16	2.64e-13	0.42	0.36	Corneal astigmatism;	chr4:119515549	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs13149407	ENSG00000250412.1	KLHL2P1	8.38	5.89e-16	2.64e-13	0.42	0.36	Corneal astigmatism;	chr4:119516670	chr4:119334329~119378233:+
LGG	cis	rs1707322	0.963	rs12076580	ENSG00000281133.1	AL355480.3	-8.38	5.92e-16	2.65e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45580892~45580996:-
LGG	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-8.38	5.93e-16	2.66e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
LGG	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-8.38	5.93e-16	2.66e-13	-0.37	-0.36	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
LGG	cis	rs1061377	0.513	rs2566166	ENSG00000249685.1	RP11-360F5.3	-8.38	5.93e-16	2.66e-13	-0.48	-0.36	Uric acid levels;	chr4:39148404	chr4:39133913~39135608:+
LGG	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	8.38	5.98e-16	2.68e-13	0.51	0.36	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
LGG	cis	rs11148252	0.967	rs11618716	ENSG00000235660.1	LINC00345	8.38	5.98e-16	2.68e-13	0.43	0.36	Lewy body disease;	chr13:52472701	chr13:52484161~52484680:-
LGG	cis	rs9322193	0.962	rs13215691	ENSG00000216621.7	RP11-244K5.6	8.38	5.98e-16	2.68e-13	0.43	0.36	Lung cancer;	chr6:149792666	chr6:149934527~149936782:+
LGG	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	8.38	5.99e-16	2.68e-13	0.43	0.36	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
LGG	cis	rs227275	0.556	rs9999303	ENSG00000248971.2	KRT8P46	-8.38	6e-16	2.69e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs6853193	ENSG00000248971.2	KRT8P46	-8.38	6e-16	2.69e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102728746~102730171:-
LGG	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	8.38	6e-16	2.69e-13	0.45	0.36	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
LGG	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-8.38	6e-16	2.69e-13	-0.54	-0.36	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
LGG	cis	rs7124681	0.565	rs2203712	ENSG00000280615.1	Y_RNA	8.38	6.01e-16	2.69e-13	0.42	0.36	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47513412	chr11:47614898~47614994:-
LGG	cis	rs433598	0.53	rs5012617	ENSG00000260762.1	ACSM5P1	-8.38	6.02e-16	2.7e-13	-0.45	-0.36	Schizophrenia;	chr16:20551424	chr16:20586550~20607107:-
LGG	cis	rs4143844	1	rs11071644	ENSG00000259251.2	RP11-643M14.1	8.38	6.04e-16	2.7e-13	0.59	0.36	Bipolar disorder and schizophrenia;	chr15:61969565	chr15:62060503~62062434:+
LGG	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-8.38	6.05e-16	2.71e-13	-0.49	-0.36	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
LGG	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	8.38	6.05e-16	2.71e-13	0.31	0.36	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
LGG	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-8.38	6.06e-16	2.71e-13	-0.48	-0.36	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
LGG	cis	rs9532669	0.926	rs7799	ENSG00000168852.11	TPTE2P5	8.38	6.07e-16	2.72e-13	0.36	0.36	Cervical cancer;	chr13:40958916	chr13:40822296~40921749:-
LGG	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	8.38	6.08e-16	2.72e-13	0.49	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
LGG	cis	rs7219021	0.705	rs1962412	ENSG00000248278.1	SUMO2P17	8.38	6.11e-16	2.74e-13	0.43	0.36	Schizophrenia or bipolar disorder;	chr17:48892897	chr17:48874860~48908983:-
LGG	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-8.38	6.12e-16	2.74e-13	-0.43	-0.36	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
LGG	cis	rs11098499	0.954	rs10017371	ENSG00000250412.1	KLHL2P1	8.38	6.12e-16	2.74e-13	0.42	0.36	Corneal astigmatism;	chr4:119372621	chr4:119334329~119378233:+
LGG	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-8.38	6.13e-16	2.74e-13	-0.36	-0.36	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
LGG	cis	rs7189233	0.955	rs60420081	ENSG00000279344.1	RP11-44F14.7	8.38	6.13e-16	2.75e-13	0.34	0.36	Intelligence (multi-trait analysis);	chr16:53486892	chr16:53478957~53481550:-
LGG	cis	rs1555322	0.53	rs932562	ENSG00000269202.1	RP4-614O4.12	-8.38	6.14e-16	2.75e-13	-0.4	-0.36	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35201747~35203288:-
LGG	cis	rs227275	0.556	rs12508069	ENSG00000248971.2	KRT8P46	-8.38	6.15e-16	2.75e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102728746~102730171:-
LGG	cis	rs227275	0.527	rs12500379	ENSG00000248971.2	KRT8P46	-8.38	6.15e-16	2.75e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102728746~102730171:-
LGG	cis	rs7927771	0.524	rs10742814	ENSG00000280615.1	Y_RNA	8.38	6.17e-16	2.76e-13	0.42	0.36	Subjective well-being;	chr11:47532785	chr11:47614898~47614994:-
LGG	cis	rs172166	0.694	rs203893	ENSG00000218016.2	ZNF192P2	-8.38	6.18e-16	2.76e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28094288	chr6:28188050~28189432:+
LGG	cis	rs172166	0.652	rs476167	ENSG00000218016.2	ZNF192P2	-8.38	6.18e-16	2.76e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28098110	chr6:28188050~28189432:+
LGG	cis	rs172166	0.694	rs203892	ENSG00000218016.2	ZNF192P2	-8.38	6.18e-16	2.76e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28099418	chr6:28188050~28189432:+
LGG	cis	rs172166	0.611	rs203883	ENSG00000218016.2	ZNF192P2	-8.38	6.18e-16	2.76e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28110578	chr6:28188050~28189432:+
LGG	cis	rs10246939	0.505	rs12703409	ENSG00000261570.1	RP11-744I24.2	-8.38	6.19e-16	2.77e-13	-0.45	-0.36	Bitter taste perception;	chr7:141812058	chr7:141529203~141551304:-
LGG	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-8.38	6.2e-16	2.77e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
LGG	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-8.38	6.2e-16	2.77e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
LGG	cis	rs1707322	1	rs10789486	ENSG00000281133.1	AL355480.3	-8.38	6.2e-16	2.78e-13	-0.42	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45580892~45580996:-
LGG	cis	rs6496932	0.774	rs12901648	ENSG00000218052.5	ADAMTS7P4	-8.38	6.21e-16	2.78e-13	-0.57	-0.36	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:85255369~85330334:-
LGG	cis	rs812925	0.537	rs10196146	ENSG00000273302.1	RP11-493E12.2	-8.38	6.22e-16	2.78e-13	-0.31	-0.36	Immature fraction of reticulocytes;	chr2:61378244	chr2:61199979~61200769:+
LGG	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-8.38	6.24e-16	2.79e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
LGG	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	8.38	6.25e-16	2.79e-13	0.64	0.36	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
LGG	cis	rs2251666	0.533	rs73517042	ENSG00000267077.1	RP11-127I20.5	8.38	6.25e-16	2.8e-13	0.42	0.36	Cancer;	chr16:4851687	chr16:4795265~4796532:-
LGG	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	8.38	6.27e-16	2.8e-13	0.48	0.36	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
LGG	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-8.38	6.27e-16	2.8e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
LGG	cis	rs9346353	0.966	rs4706296	ENSG00000219881.1	GAPDHP42	8.38	6.28e-16	2.81e-13	0.35	0.36	Sleep duration;	chr6:69805318	chr6:69745871~69746851:+
LGG	cis	rs75920871	0.528	rs7950093	ENSG00000254851.1	RP11-109L13.1	8.37	6.31e-16	2.82e-13	0.52	0.36	Subjective well-being;	chr11:117092803	chr11:117135528~117138582:+
LGG	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-8.37	6.31e-16	2.82e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
LGG	cis	rs4713118	0.525	rs9357042	ENSG00000199851.2	U3	8.37	6.32e-16	2.83e-13	0.48	0.36	Parkinson's disease;	chr6:27615016	chr6:28015568~28015777:+
LGG	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	8.37	6.33e-16	2.83e-13	0.38	0.36	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
LGG	cis	rs1707322	1	rs11211223	ENSG00000281133.1	AL355480.3	-8.37	6.33e-16	2.83e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45580892~45580996:-
LGG	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	8.37	6.33e-16	2.83e-13	0.41	0.36	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	8.37	6.33e-16	2.83e-13	0.41	0.36	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	8.37	6.33e-16	2.83e-13	0.41	0.36	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	8.37	6.33e-16	2.83e-13	0.41	0.36	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	8.37	6.33e-16	2.83e-13	0.41	0.36	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
LGG	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-8.37	6.35e-16	2.84e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
LGG	cis	rs7474896	0.515	rs688608	ENSG00000226578.1	RP11-258F22.1	8.37	6.36e-16	2.84e-13	0.49	0.36	Obesity (extreme);	chr10:38042696	chr10:37775371~37784131:-
LGG	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-8.37	6.36e-16	2.84e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
LGG	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	8.37	6.36e-16	2.84e-13	0.64	0.36	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	8.37	6.36e-16	2.84e-13	0.64	0.36	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	8.37	6.36e-16	2.84e-13	0.64	0.36	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-8.37	6.36e-16	2.84e-13	-0.64	-0.36	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
LGG	cis	rs2075466	0.514	rs111431826	ENSG00000267077.1	RP11-127I20.5	8.37	6.36e-16	2.84e-13	0.5	0.36	Colonoscopy-negative controls vs population controls;	chr16:4857111	chr16:4795265~4796532:-
LGG	cis	rs2075466	0.514	rs112861583	ENSG00000267077.1	RP11-127I20.5	8.37	6.36e-16	2.84e-13	0.5	0.36	Colonoscopy-negative controls vs population controls;	chr16:4857124	chr16:4795265~4796532:-
LGG	cis	rs2075466	0.514	rs17770918	ENSG00000267077.1	RP11-127I20.5	8.37	6.36e-16	2.84e-13	0.5	0.36	Colonoscopy-negative controls vs population controls;	chr16:4859622	chr16:4795265~4796532:-
LGG	cis	rs1275468	0.724	rs1611928	ENSG00000257497.2	RP11-585P4.5	-8.37	6.38e-16	2.85e-13	-0.5	-0.36	Polycystic ovary syndrome;	chr12:75561705	chr12:75483454~75489820:-
LGG	cis	rs6496932	0.874	rs2003294	ENSG00000218052.5	ADAMTS7P4	8.37	6.39e-16	2.86e-13	0.52	0.36	Central corneal thickness;Corneal structure;	chr15:85274141	chr15:85255369~85330334:-
LGG	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-8.37	6.4e-16	2.86e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
LGG	cis	rs9346353	0.966	rs9364060	ENSG00000219881.1	GAPDHP42	8.37	6.43e-16	2.87e-13	0.34	0.36	Sleep duration;	chr6:69775970	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs68181489	ENSG00000219881.1	GAPDHP42	8.37	6.43e-16	2.87e-13	0.34	0.36	Sleep duration;	chr6:69777135	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9354889	ENSG00000219881.1	GAPDHP42	8.37	6.43e-16	2.87e-13	0.34	0.36	Sleep duration;	chr6:69777409	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs9346353	ENSG00000219881.1	GAPDHP42	8.37	6.43e-16	2.87e-13	0.34	0.36	Sleep duration;	chr6:69780619	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs59738216	ENSG00000219881.1	GAPDHP42	8.37	6.43e-16	2.87e-13	0.34	0.36	Sleep duration;	chr6:69782284	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs3799120	ENSG00000219881.1	GAPDHP42	8.37	6.43e-16	2.87e-13	0.34	0.36	Sleep duration;	chr6:69786820	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs12662657	ENSG00000219881.1	GAPDHP42	8.37	6.43e-16	2.87e-13	0.34	0.36	Sleep duration;	chr6:69787321	chr6:69745871~69746851:+
LGG	cis	rs9322193	0.923	rs12174035	ENSG00000216621.7	RP11-244K5.6	8.37	6.43e-16	2.87e-13	0.42	0.36	Lung cancer;	chr6:149763311	chr6:149934527~149936782:+
LGG	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-8.37	6.45e-16	2.88e-13	-0.6	-0.36	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
LGG	cis	rs11992162	0.967	rs7461062	ENSG00000255556.2	RP11-351I21.6	8.37	6.45e-16	2.88e-13	0.43	0.36	Monocyte count;	chr8:11974439	chr8:12378679~12380265:-
LGG	cis	rs853679	0.567	rs7774981	ENSG00000280107.1	AL022393.9	-8.37	6.46e-16	2.88e-13	-0.39	-0.36	Depression;	chr6:28379133	chr6:28170845~28172521:+
LGG	cis	rs853679	0.567	rs7754960	ENSG00000280107.1	AL022393.9	-8.37	6.46e-16	2.88e-13	-0.39	-0.36	Depression;	chr6:28379168	chr6:28170845~28172521:+
LGG	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	8.37	6.48e-16	2.89e-13	0.49	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
LGG	cis	rs11992162	1	rs7460395	ENSG00000227888.4	FAM66A	8.37	6.49e-16	2.9e-13	0.43	0.36	Monocyte count;	chr8:11977866	chr8:12362019~12388296:+
LGG	cis	rs454217	0.846	rs428699	ENSG00000277851.1	RP11-756G20.1	8.37	6.49e-16	2.9e-13	0.36	0.36	Smoking quantity;	chr12:92334822	chr12:92247756~92363832:-
LGG	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-8.37	6.49e-16	2.9e-13	-0.45	-0.36	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
LGG	cis	rs7927771	0.524	rs10838732	ENSG00000280615.1	Y_RNA	8.37	6.5e-16	2.9e-13	0.42	0.36	Subjective well-being;	chr11:47586388	chr11:47614898~47614994:-
LGG	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	8.37	6.5e-16	2.9e-13	0.37	0.36	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	8.37	6.5e-16	2.9e-13	0.37	0.36	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	8.37	6.5e-16	2.9e-13	0.37	0.36	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	8.37	6.5e-16	2.9e-13	0.37	0.36	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	8.37	6.5e-16	2.9e-13	0.37	0.36	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	8.37	6.5e-16	2.9e-13	0.37	0.36	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	8.37	6.5e-16	2.9e-13	0.37	0.36	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
LGG	cis	rs7219021	0.674	rs11656939	ENSG00000248278.1	SUMO2P17	-8.37	6.51e-16	2.91e-13	-0.43	-0.36	Schizophrenia or bipolar disorder;	chr17:48887044	chr17:48874860~48908983:-
LGG	cis	rs11148252	0.574	rs73186430	ENSG00000198384.8	TPTE2P3	-8.37	6.52e-16	2.91e-13	-0.32	-0.36	Lewy body disease;	chr13:52658756	chr13:52522632~52586906:+
LGG	cis	rs9532669	0.926	rs9532657	ENSG00000239827.7	SUGT1P3	8.37	6.53e-16	2.91e-13	0.37	0.36	Cervical cancer;	chr13:40918208	chr13:40908159~40921774:-
LGG	cis	rs35934224	0.783	rs7288061	ENSG00000232926.1	AC000078.5	8.37	6.53e-16	2.91e-13	0.42	0.36	Glaucoma (primary open-angle);	chr22:19876716	chr22:19887289~19887970:+
LGG	cis	rs35934224	0.783	rs7287073	ENSG00000232926.1	AC000078.5	8.37	6.53e-16	2.91e-13	0.42	0.36	Glaucoma (primary open-angle);	chr22:19876812	chr22:19887289~19887970:+
LGG	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
LGG	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-8.37	6.53e-16	2.91e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
LGG	cis	rs7824557	0.547	rs2736287	ENSG00000184608.7	FAM167A-AS1	8.37	6.54e-16	2.92e-13	0.3	0.36	Retinal vascular caliber;	chr8:11370497	chr8:11368402~11438658:+
LGG	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	8.37	6.54e-16	2.92e-13	0.46	0.36	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
LGG	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-8.37	6.54e-16	2.92e-13	-0.42	-0.36	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
LGG	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-8.37	6.55e-16	2.92e-13	-0.36	-0.36	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
LGG	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-8.37	6.55e-16	2.92e-13	-0.36	-0.36	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
LGG	cis	rs9346353	1	rs4707392	ENSG00000219881.1	GAPDHP42	8.37	6.55e-16	2.92e-13	0.35	0.36	Sleep duration;	chr6:69803934	chr6:69745871~69746851:+
LGG	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-8.37	6.55e-16	2.92e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-8.37	6.55e-16	2.92e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-8.37	6.55e-16	2.92e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-8.37	6.55e-16	2.92e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-8.37	6.55e-16	2.92e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-8.37	6.55e-16	2.92e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-8.37	6.55e-16	2.92e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
LGG	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-8.37	6.55e-16	2.92e-13	-0.42	-0.36	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
LGG	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	8.37	6.56e-16	2.93e-13	0.55	0.36	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
LGG	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-8.37	6.57e-16	2.93e-13	-0.54	-0.36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
LGG	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-8.37	6.58e-16	2.94e-13	-0.32	-0.36	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
LGG	cis	rs9532669	0.926	rs9562254	ENSG00000239827.7	SUGT1P3	8.37	6.58e-16	2.94e-13	0.38	0.36	Cervical cancer;	chr13:40960902	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7329302	ENSG00000239827.7	SUGT1P3	8.37	6.58e-16	2.94e-13	0.38	0.36	Cervical cancer;	chr13:40962396	chr13:40908159~40921774:-
LGG	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	8.37	6.59e-16	2.94e-13	0.42	0.36	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
LGG	cis	rs35160687	0.644	rs1863061	ENSG00000273080.1	RP11-301O19.1	-8.37	6.61e-16	2.95e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86285784	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs4832272	ENSG00000273080.1	RP11-301O19.1	-8.37	6.61e-16	2.95e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86289088	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs57270703	ENSG00000273080.1	RP11-301O19.1	-8.37	6.61e-16	2.95e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86289750	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs2113615	ENSG00000273080.1	RP11-301O19.1	-8.37	6.62e-16	2.95e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86290479	chr2:86195590~86196049:+
LGG	cis	rs6657613	0.628	rs761423	ENSG00000186715.9	MST1L	8.37	6.63e-16	2.96e-13	0.33	0.36	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16754910~16770237:-
LGG	cis	rs889122	0.659	rs62106799	ENSG00000267289.1	CTD-2623N2.11	8.37	6.64e-16	2.96e-13	0.48	0.36	Menarche (age at onset);	chr19:9874359	chr19:9834079~9835013:-
LGG	cis	rs9532669	0.889	rs1989252	ENSG00000168852.11	TPTE2P5	-8.37	6.65e-16	2.96e-13	-0.37	-0.36	Cervical cancer;	chr13:40911532	chr13:40822296~40921749:-
LGG	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	8.37	6.65e-16	2.97e-13	0.31	0.36	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
LGG	cis	rs454217	0.846	rs418571	ENSG00000277851.1	RP11-756G20.1	8.37	6.66e-16	2.97e-13	0.36	0.36	Smoking quantity;	chr12:92330380	chr12:92247756~92363832:-
LGG	cis	rs848490	0.762	rs7796089	ENSG00000214293.7	APTR	8.37	6.67e-16	2.97e-13	0.37	0.36	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77882781	chr7:77657660~77696265:-
LGG	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-8.37	6.67e-16	2.98e-13	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
LGG	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-8.37	6.69e-16	2.98e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
LGG	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	8.37	6.73e-16	3e-13	0.55	0.36	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	8.37	6.73e-16	3e-13	0.55	0.36	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
LGG	cis	rs11148252	0.712	rs61957257	ENSG00000235660.1	LINC00345	-8.37	6.73e-16	3e-13	-0.45	-0.36	Lewy body disease;	chr13:52195567	chr13:52484161~52484680:-
LGG	cis	rs763567	0.9	rs473133	ENSG00000271811.1	RP1-79C4.4	8.37	6.75e-16	3.01e-13	0.36	0.36	Tonsillectomy;	chr1:170666938	chr1:170667381~170669425:+
LGG	cis	rs7241530	0.585	rs34901621	ENSG00000266213.1	RP11-100K18.1	-8.37	6.76e-16	3.01e-13	-0.43	-0.36	Educational attainment (years of education);	chr18:78131116	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.585	rs35890268	ENSG00000266213.1	RP11-100K18.1	-8.37	6.76e-16	3.01e-13	-0.43	-0.36	Educational attainment (years of education);	chr18:78131169	chr18:78137223~78140887:+
LGG	cis	rs189798	0.807	rs330905	ENSG00000253893.2	FAM85B	-8.36	6.78e-16	3.02e-13	-0.47	-0.36	Myopia (pathological);	chr8:9136041	chr8:8167819~8226614:-
LGG	cis	rs7241530	0.56	rs12956768	ENSG00000266213.1	RP11-100K18.1	-8.36	6.79e-16	3.03e-13	-0.42	-0.36	Educational attainment (years of education);	chr18:78130937	chr18:78137223~78140887:+
LGG	cis	rs6545883	0.507	rs34668697	ENSG00000273302.1	RP11-493E12.2	-8.36	6.8e-16	3.03e-13	-0.31	-0.36	Tuberculosis;	chr2:61341214	chr2:61199979~61200769:+
LGG	cis	rs35934224	0.783	rs7288170	ENSG00000232926.1	AC000078.5	8.36	6.81e-16	3.03e-13	0.39	0.36	Glaucoma (primary open-angle);	chr22:19876729	chr22:19887289~19887970:+
LGG	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	8.36	6.83e-16	3.04e-13	0.64	0.36	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
LGG	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	8.36	6.83e-16	3.04e-13	0.31	0.36	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
LGG	cis	rs11098499	0.954	rs6849171	ENSG00000250412.1	KLHL2P1	8.36	6.84e-16	3.05e-13	0.41	0.36	Corneal astigmatism;	chr4:119488394	chr4:119334329~119378233:+
LGG	cis	rs6921919	0.638	rs1416920	ENSG00000226314.6	ZNF192P1	8.36	6.84e-16	3.05e-13	0.38	0.36	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.525	rs1361386	ENSG00000226314.6	ZNF192P1	8.36	6.84e-16	3.05e-13	0.38	0.36	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.638	rs6456815	ENSG00000226314.6	ZNF192P1	8.36	6.84e-16	3.05e-13	0.38	0.36	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.779	rs10011097	ENSG00000250412.1	KLHL2P1	8.36	6.85e-16	3.05e-13	0.41	0.36	Corneal astigmatism;	chr4:119389204	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs7437420	ENSG00000250412.1	KLHL2P1	8.36	6.85e-16	3.05e-13	0.41	0.36	Corneal astigmatism;	chr4:119391748	chr4:119334329~119378233:+
LGG	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-8.36	6.86e-16	3.06e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
LGG	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-8.36	6.86e-16	3.06e-13	-0.45	-0.36	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
LGG	cis	rs9322193	0.962	rs9505974	ENSG00000216621.7	RP11-244K5.6	8.36	6.87e-16	3.06e-13	0.42	0.36	Lung cancer;	chr6:149779294	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.926	rs9689036	ENSG00000216621.7	RP11-244K5.6	8.36	6.87e-16	3.06e-13	0.42	0.36	Lung cancer;	chr6:149780563	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9322218	ENSG00000216621.7	RP11-244K5.6	8.36	6.87e-16	3.06e-13	0.42	0.36	Lung cancer;	chr6:149782183	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9322219	ENSG00000216621.7	RP11-244K5.6	8.36	6.87e-16	3.06e-13	0.42	0.36	Lung cancer;	chr6:149782263	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9322223	ENSG00000216621.7	RP11-244K5.6	8.36	6.87e-16	3.06e-13	0.42	0.36	Lung cancer;	chr6:149801509	chr6:149934527~149936782:+
LGG	cis	rs6921919	0.583	rs2071965	ENSG00000226314.6	ZNF192P1	8.36	6.88e-16	3.06e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28161781~28169594:+
LGG	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-8.36	6.88e-16	3.06e-13	-0.49	-0.36	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
LGG	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-8.36	6.88e-16	3.07e-13	-0.39	-0.36	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
LGG	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	8.36	6.89e-16	3.07e-13	0.43	0.36	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
LGG	cis	rs812925	0.537	rs778153	ENSG00000273302.1	RP11-493E12.2	-8.36	6.89e-16	3.07e-13	-0.31	-0.36	Immature fraction of reticulocytes;	chr2:61381517	chr2:61199979~61200769:+
LGG	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-8.36	6.9e-16	3.07e-13	-0.47	-0.36	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
LGG	cis	rs11098499	0.954	rs4309825	ENSG00000250412.1	KLHL2P1	-8.36	6.9e-16	3.07e-13	-0.41	-0.36	Corneal astigmatism;	chr4:119393726	chr4:119334329~119378233:+
LGG	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-8.36	6.93e-16	3.08e-13	-0.54	-0.36	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
LGG	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-8.36	6.93e-16	3.08e-13	-0.54	-0.36	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
LGG	cis	rs56114371	0.777	rs200483	ENSG00000216901.1	AL022393.7	8.36	6.94e-16	3.09e-13	0.67	0.36	Breast cancer;	chr6:27807046	chr6:28176188~28176674:+
LGG	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	8.36	6.96e-16	3.1e-13	0.65	0.36	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
LGG	cis	rs17772222	0.636	rs3850390	ENSG00000222990.1	RNU4-22P	8.36	6.96e-16	3.1e-13	0.47	0.36	Coronary artery calcification;	chr14:88829185	chr14:88513498~88513663:+
LGG	cis	rs9346353	1	rs9354891	ENSG00000219881.1	GAPDHP42	8.36	6.97e-16	3.1e-13	0.34	0.36	Sleep duration;	chr6:69795125	chr6:69745871~69746851:+
LGG	cis	rs227275	0.525	rs13150426	ENSG00000248971.2	KRT8P46	-8.36	6.99e-16	3.11e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs28445579	ENSG00000248971.2	KRT8P46	-8.36	7.01e-16	3.12e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102728746~102730171:-
LGG	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	8.36	7.01e-16	3.12e-13	0.47	0.36	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
LGG	cis	rs35425515	0.706	rs4917756	ENSG00000234855.1	SLIT1-AS1	8.36	7.02e-16	3.13e-13	0.64	0.36	Bipolar disorder;	chr10:97115651	chr10:97102756~97103747:+
LGG	cis	rs11051970	0.559	rs60162504	ENSG00000274964.1	RP11-817I4.1	-8.36	7.05e-16	3.14e-13	-0.41	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32320687	chr12:32339368~32340724:+
LGG	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-8.36	7.06e-16	3.14e-13	-0.32	-0.36	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
LGG	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	8.36	7.06e-16	3.14e-13	0.66	0.36	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
LGG	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-8.36	7.08e-16	3.15e-13	-0.43	-0.36	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
LGG	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-8.36	7.09e-16	3.15e-13	-0.5	-0.36	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
LGG	cis	rs7474896	0.583	rs12783272	ENSG00000226578.1	RP11-258F22.1	-8.36	7.09e-16	3.15e-13	-0.49	-0.36	Obesity (extreme);	chr10:37735957	chr10:37775371~37784131:-
LGG	cis	rs7241530	0.585	rs7233393	ENSG00000266213.1	RP11-100K18.1	-8.36	7.09e-16	3.16e-13	-0.43	-0.36	Educational attainment (years of education);	chr18:78128229	chr18:78137223~78140887:+
LGG	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-8.36	7.15e-16	3.18e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
LGG	cis	rs12682352	0.602	rs4841044	ENSG00000173295.6	FAM86B3P	8.36	7.16e-16	3.18e-13	0.38	0.36	Neuroticism;	chr8:8807430	chr8:8228595~8244865:+
LGG	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	8.36	7.16e-16	3.19e-13	0.37	0.36	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
LGG	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-8.36	7.17e-16	3.19e-13	-0.46	-0.36	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
LGG	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-8.36	7.18e-16	3.19e-13	-0.32	-0.36	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
LGG	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-8.36	7.18e-16	3.19e-13	-0.32	-0.36	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
LGG	cis	rs10946940	0.93	rs12215012	ENSG00000199851.2	U3	-8.36	7.23e-16	3.21e-13	-0.48	-0.36	Systemic lupus erythematosus;	chr6:27539715	chr6:28015568~28015777:+
LGG	cis	rs6921919	0.697	rs6942030	ENSG00000218016.2	ZNF192P2	-8.36	7.23e-16	3.21e-13	-0.45	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28188050~28189432:+
LGG	cis	rs812925	0.537	rs778146	ENSG00000273302.1	RP11-493E12.2	-8.36	7.24e-16	3.22e-13	-0.31	-0.36	Immature fraction of reticulocytes;	chr2:61379340	chr2:61199979~61200769:+
LGG	cis	rs1707322	0.964	rs12067716	ENSG00000281133.1	AL355480.3	-8.36	7.25e-16	3.22e-13	-0.43	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45580892~45580996:-
LGG	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-8.36	7.27e-16	3.23e-13	-0.47	-0.36	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
LGG	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-8.36	7.27e-16	3.23e-13	-0.47	-0.36	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
LGG	cis	rs11098499	0.954	rs3733520	ENSG00000250412.1	KLHL2P1	8.36	7.28e-16	3.24e-13	0.41	0.36	Corneal astigmatism;	chr4:119502325	chr4:119334329~119378233:+
LGG	cis	rs1707322	1	rs10890365	ENSG00000281133.1	AL355480.3	-8.36	7.28e-16	3.24e-13	-0.43	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45580892~45580996:-
LGG	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	8.35	7.29e-16	3.24e-13	0.53	0.36	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
LGG	cis	rs4689592	0.503	rs3857180	ENSG00000245468.3	RP11-367J11.3	-8.35	7.3e-16	3.24e-13	-0.44	-0.36	Monocyte percentage of white cells;	chr4:7072172	chr4:7094571~7103385:-
LGG	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-8.35	7.32e-16	3.25e-13	-0.44	-0.36	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
LGG	cis	rs9346353	1	rs3752790	ENSG00000219881.1	GAPDHP42	8.35	7.34e-16	3.26e-13	0.34	0.36	Sleep duration;	chr6:69797241	chr6:69745871~69746851:+
LGG	cis	rs10946940	0.632	rs9366698	ENSG00000199851.2	U3	8.35	7.34e-16	3.26e-13	0.55	0.36	Systemic lupus erythematosus;	chr6:27704256	chr6:28015568~28015777:+
LGG	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	8.35	7.34e-16	3.26e-13	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
LGG	cis	rs9987353	0.566	rs34389718	ENSG00000253893.2	FAM85B	8.35	7.37e-16	3.28e-13	0.45	0.36	Recombination measurement;	chr8:9208015	chr8:8167819~8226614:-
LGG	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	8.35	7.39e-16	3.28e-13	0.3	0.36	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
LGG	cis	rs1420956	1	rs8097226	ENSG00000264151.4	RP11-739N10.1	8.35	7.39e-16	3.28e-13	0.45	0.36	Obesity-related traits;	chr18:27585537	chr18:27336379~27595164:-
LGG	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	8.35	7.4e-16	3.29e-13	0.24	0.36	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
LGG	cis	rs7546	0.529	rs966062	ENSG00000267077.1	RP11-127I20.5	8.35	7.42e-16	3.3e-13	0.41	0.36	Cancer;	chr16:4857429	chr16:4795265~4796532:-
LGG	cis	rs9532669	0.889	rs7339089	ENSG00000239827.7	SUGT1P3	-8.35	7.42e-16	3.3e-13	-0.39	-0.36	Cervical cancer;	chr13:40863790	chr13:40908159~40921774:-
LGG	cis	rs56804039	1	rs17616779	ENSG00000173295.6	FAM86B3P	-8.35	7.44e-16	3.3e-13	-0.43	-0.36	Cervical cancer;	chr8:8524864	chr8:8228595~8244865:+
LGG	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	8.35	7.44e-16	3.3e-13	0.36	0.36	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	8.35	7.44e-16	3.3e-13	0.36	0.36	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
LGG	cis	rs440932	1	rs378974	ENSG00000173295.6	FAM86B3P	-8.35	7.45e-16	3.31e-13	-0.41	-0.36	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8228595~8244865:+
LGG	cis	rs45509595	0.841	rs200485	ENSG00000216901.1	AL022393.7	8.35	7.46e-16	3.31e-13	0.67	0.36	Breast cancer;	chr6:27807919	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-8.35	7.47e-16	3.32e-13	-0.47	-0.36	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
LGG	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-8.35	7.49e-16	3.33e-13	-0.36	-0.36	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
LGG	cis	rs1420956	1	rs1420956	ENSG00000264151.4	RP11-739N10.1	8.35	7.5e-16	3.33e-13	0.45	0.36	Obesity-related traits;	chr18:27587981	chr18:27336379~27595164:-
LGG	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-8.35	7.51e-16	3.33e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
LGG	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	8.35	7.51e-16	3.34e-13	0.44	0.36	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
LGG	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-8.35	7.52e-16	3.34e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
LGG	cis	rs867371	0.929	rs7173852	ENSG00000278603.1	RP13-608F4.5	8.35	7.53e-16	3.34e-13	0.45	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472203~82472426:+
LGG	cis	rs17772222	0.74	rs10150986	ENSG00000222990.1	RNU4-22P	8.35	7.54e-16	3.35e-13	0.44	0.36	Coronary artery calcification;	chr14:88517326	chr14:88513498~88513663:+
LGG	cis	rs13287066	0.692	rs10761225	ENSG00000227603.1	RP11-165J3.6	8.35	7.56e-16	3.36e-13	0.36	0.36	Intelligence (multi-trait analysis);	chr9:93404358	chr9:93435332~93437121:-
LGG	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-8.35	7.57e-16	3.36e-13	-0.37	-0.36	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-8.35	7.57e-16	3.36e-13	-0.37	-0.36	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-8.35	7.57e-16	3.36e-13	-0.37	-0.36	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-8.35	7.57e-16	3.36e-13	-0.37	-0.36	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-8.35	7.57e-16	3.36e-13	-0.37	-0.36	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
LGG	cis	rs853679	0.567	rs16894091	ENSG00000218016.2	ZNF192P2	8.35	7.6e-16	3.37e-13	0.45	0.36	Depression;	chr6:28422360	chr6:28188050~28189432:+
LGG	cis	rs4143844	0.867	rs12916410	ENSG00000259251.2	RP11-643M14.1	8.35	7.6e-16	3.37e-13	0.6	0.36	Bipolar disorder and schizophrenia;	chr15:62010687	chr15:62060503~62062434:+
LGG	cis	rs11168351	0.517	rs10875754	ENSG00000258273.1	RP11-370I10.4	-8.35	7.61e-16	3.38e-13	-0.44	-0.36	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48333755~48333901:-
LGG	cis	rs11098499	0.954	rs10006877	ENSG00000250412.1	KLHL2P1	8.35	7.61e-16	3.38e-13	0.41	0.36	Corneal astigmatism;	chr4:119321638	chr4:119334329~119378233:+
LGG	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-8.35	7.61e-16	3.38e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
LGG	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	8.35	7.62e-16	3.38e-13	0.31	0.36	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
LGG	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-8.35	7.64e-16	3.39e-13	-0.53	-0.36	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
LGG	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	8.35	7.64e-16	3.39e-13	0.43	0.36	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
LGG	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-8.35	7.65e-16	3.4e-13	-0.42	-0.36	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
LGG	cis	rs853679	0.546	rs34295134	ENSG00000199851.2	U3	8.35	7.65e-16	3.4e-13	0.77	0.36	Depression;	chr6:27860373	chr6:28015568~28015777:+
LGG	cis	rs17772222	0.727	rs3179969	ENSG00000222990.1	RNU4-22P	8.35	7.68e-16	3.4e-13	0.42	0.36	Coronary artery calcification;	chr14:88396185	chr14:88513498~88513663:+
LGG	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	8.35	7.68e-16	3.41e-13	0.38	0.36	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
LGG	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	8.35	7.68e-16	3.41e-13	0.39	0.36	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
LGG	cis	rs227275	0.525	rs11737544	ENSG00000248971.2	KRT8P46	-8.35	7.68e-16	3.41e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102728746~102730171:-
LGG	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	8.35	7.69e-16	3.41e-13	0.64	0.36	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	8.35	7.69e-16	3.41e-13	0.64	0.36	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	8.35	7.69e-16	3.41e-13	0.64	0.36	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	8.35	7.69e-16	3.41e-13	0.64	0.36	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
LGG	cis	rs9393777	0.92	rs34071253	ENSG00000216901.1	AL022393.7	8.35	7.7e-16	3.41e-13	0.75	0.36	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.92	rs35716472	ENSG00000216901.1	AL022393.7	8.35	7.7e-16	3.41e-13	0.75	0.36	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28176188~28176674:+
LGG	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	8.35	7.7e-16	3.41e-13	0.4	0.36	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
LGG	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	8.35	7.74e-16	3.43e-13	0.43	0.36	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
LGG	cis	rs7746199	0.736	rs6904596	ENSG00000216901.1	AL022393.7	8.35	7.79e-16	3.46e-13	0.74	0.36	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28176188~28176674:+
LGG	cis	rs17772222	0.63	rs7146241	ENSG00000258983.2	RP11-507K2.2	-8.34	7.89e-16	3.49e-13	-0.4	-0.36	Coronary artery calcification;	chr14:88551622	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.63	rs930181	ENSG00000258983.2	RP11-507K2.2	-8.34	7.89e-16	3.49e-13	-0.4	-0.36	Coronary artery calcification;	chr14:88552364	chr14:88499334~88515502:+
LGG	cis	rs853679	0.882	rs4713140	ENSG00000226314.6	ZNF192P1	8.34	7.92e-16	3.51e-13	0.53	0.36	Depression;	chr6:28129415	chr6:28161781~28169594:+
LGG	cis	rs2832077	0.527	rs2776210	ENSG00000232855.5	AF131217.1	-8.34	7.93e-16	3.51e-13	-0.42	-0.36	Cognitive test performance;	chr21:28896236	chr21:28439346~28674848:-
LGG	cis	rs853679	0.546	rs483143	ENSG00000216901.1	AL022393.7	8.34	7.93e-16	3.52e-13	0.66	0.36	Depression;	chr6:27878966	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	8.34	7.95e-16	3.52e-13	0.44	0.36	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
LGG	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	8.34	7.96e-16	3.52e-13	0.57	0.36	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
LGG	cis	rs9527	0.535	rs4917999	ENSG00000272912.1	RP11-724N1.1	8.34	7.98e-16	3.53e-13	0.42	0.36	Arsenic metabolism;	chr10:103203294	chr10:102914585~102915404:+
LGG	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	8.34	7.98e-16	3.54e-13	0.36	0.36	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	8.34	7.98e-16	3.54e-13	0.36	0.36	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
LGG	cis	rs9532669	0.926	rs4254182	ENSG00000168852.11	TPTE2P5	8.34	7.99e-16	3.54e-13	0.37	0.36	Cervical cancer;	chr13:40879120	chr13:40822296~40921749:-
LGG	cis	rs35425515	0.706	rs78295680	ENSG00000234855.1	SLIT1-AS1	8.34	7.99e-16	3.54e-13	0.64	0.36	Bipolar disorder;	chr10:97109374	chr10:97102756~97103747:+
LGG	cis	rs35425515	0.706	rs34113615	ENSG00000234855.1	SLIT1-AS1	8.34	7.99e-16	3.54e-13	0.64	0.36	Bipolar disorder;	chr10:97109837	chr10:97102756~97103747:+
LGG	cis	rs1061377	0.513	rs2711994	ENSG00000249685.1	RP11-360F5.3	-8.34	8e-16	3.54e-13	-0.49	-0.36	Uric acid levels;	chr4:39148121	chr4:39133913~39135608:+
LGG	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	8.34	8e-16	3.55e-13	0.71	0.36	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
LGG	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-8.34	8.02e-16	3.55e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-8.34	8.02e-16	3.55e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
LGG	cis	rs62184315	0.536	rs16831873	ENSG00000253559.1	OSGEPL1-AS1	-8.34	8.02e-16	3.55e-13	-0.54	-0.36	Alcohol dependence (age at onset);	chr2:189692172	chr2:189762704~189765556:+
LGG	cis	rs4713118	0.513	rs1225591	ENSG00000218016.2	ZNF192P2	-8.34	8.02e-16	3.55e-13	-0.48	-0.36	Parkinson's disease;	chr6:28180974	chr6:28188050~28189432:+
LGG	cis	rs8135665	0.6	rs8142379	ENSG00000233739.1	RP5-1039K5.13	8.34	8.02e-16	3.55e-13	0.4	0.36	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38054964	chr22:38057180~38073940:-
LGG	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	8.34	8.05e-16	3.56e-13	0.36	0.36	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
LGG	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	8.34	8.06e-16	3.57e-13	0.48	0.36	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
LGG	cis	rs9532669	0.889	rs1989252	ENSG00000239827.7	SUGT1P3	8.34	8.09e-16	3.58e-13	0.39	0.36	Cervical cancer;	chr13:40911532	chr13:40908159~40921774:-
LGG	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-8.34	8.1e-16	3.59e-13	-0.65	-0.36	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
LGG	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-8.34	8.1e-16	3.59e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-8.34	8.1e-16	3.59e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-8.34	8.1e-16	3.59e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-8.34	8.1e-16	3.59e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-8.34	8.1e-16	3.59e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
LGG	cis	rs1707322	0.963	rs4508055	ENSG00000281133.1	AL355480.3	-8.34	8.1e-16	3.59e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45580892~45580996:-
LGG	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	8.34	8.15e-16	3.61e-13	0.64	0.36	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	8.34	8.15e-16	3.61e-13	0.64	0.36	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	8.34	8.15e-16	3.61e-13	0.64	0.36	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
LGG	cis	rs62184315	0.536	rs56137655	ENSG00000253559.1	OSGEPL1-AS1	-8.34	8.15e-16	3.61e-13	-0.54	-0.36	Alcohol dependence (age at onset);	chr2:189675844	chr2:189762704~189765556:+
LGG	cis	rs172166	0.694	rs188105	ENSG00000218016.2	ZNF192P2	-8.34	8.16e-16	3.61e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28103615	chr6:28188050~28189432:+
LGG	cis	rs172166	0.611	rs203882	ENSG00000218016.2	ZNF192P2	-8.34	8.16e-16	3.61e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28110724	chr6:28188050~28189432:+
LGG	cis	rs172166	0.694	rs1770131	ENSG00000218016.2	ZNF192P2	-8.34	8.16e-16	3.61e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28118635	chr6:28188050~28189432:+
LGG	cis	rs172166	0.694	rs1631552	ENSG00000218016.2	ZNF192P2	-8.34	8.16e-16	3.61e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28121921	chr6:28188050~28189432:+
LGG	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-8.34	8.17e-16	3.61e-13	-0.38	-0.36	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
LGG	cis	rs7429990	0.895	rs35790549	ENSG00000229759.1	MRPS18AP1	8.34	8.17e-16	3.61e-13	0.45	0.36	Educational attainment (years of education);	chr3:48029998	chr3:48256350~48256938:-
LGG	cis	rs853679	0.567	rs3799499	ENSG00000280107.1	AL022393.9	-8.34	8.2e-16	3.63e-13	-0.38	-0.36	Depression;	chr6:28386473	chr6:28170845~28172521:+
LGG	cis	rs853679	0.567	rs2232427	ENSG00000280107.1	AL022393.9	-8.34	8.2e-16	3.63e-13	-0.38	-0.36	Depression;	chr6:28391932	chr6:28170845~28172521:+
LGG	cis	rs853679	0.567	rs1005126	ENSG00000280107.1	AL022393.9	-8.34	8.2e-16	3.63e-13	-0.38	-0.36	Depression;	chr6:28399846	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.583	rs4254981	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.525	rs6929825	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs35599905	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs1124131	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs6899389	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs6922374	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs6899603	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs6922429	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs6922169	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.559	rs13210866	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.609	rs36018474	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs13201726	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs2027361	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs4642462	ENSG00000226314.6	ZNF192P1	8.34	8.22e-16	3.64e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28161781~28169594:+
LGG	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8.34	8.24e-16	3.64e-13	-0.37	-0.36	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
LGG	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	8.34	8.24e-16	3.64e-13	0.42	0.36	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
LGG	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-8.34	8.24e-16	3.64e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
LGG	cis	rs13287066	0.692	rs72743489	ENSG00000227603.1	RP11-165J3.6	8.34	8.26e-16	3.66e-13	0.36	0.36	Intelligence (multi-trait analysis);	chr9:93406201	chr9:93435332~93437121:-
LGG	cis	rs7189233	0.911	rs8057808	ENSG00000279344.1	RP11-44F14.7	8.34	8.29e-16	3.66e-13	0.35	0.36	Intelligence (multi-trait analysis);	chr16:53486701	chr16:53478957~53481550:-
LGG	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-8.34	8.29e-16	3.67e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
LGG	cis	rs9322193	0.962	rs2275046	ENSG00000216621.7	RP11-244K5.6	8.34	8.29e-16	3.67e-13	0.43	0.36	Lung cancer;	chr6:149835865	chr6:149934527~149936782:+
LGG	cis	rs3096299	0.838	rs3096319	ENSG00000274627.1	RP11-104N10.2	8.34	8.31e-16	3.67e-13	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89516797~89522217:+
LGG	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	8.34	8.32e-16	3.68e-13	0.36	0.36	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
LGG	cis	rs12554020	0.579	rs76025942	ENSG00000227603.1	RP11-165J3.6	8.34	8.33e-16	3.68e-13	0.68	0.36	Schizophrenia;	chr9:93605618	chr9:93435332~93437121:-
LGG	cis	rs10429558	0.609	rs76290025	ENSG00000227603.1	RP11-165J3.6	8.34	8.33e-16	3.68e-13	0.68	0.36	Neuroticism;	chr9:93608100	chr9:93435332~93437121:-
LGG	cis	rs11992186	0.597	rs77717027	ENSG00000173295.6	FAM86B3P	8.34	8.36e-16	3.7e-13	0.39	0.36	Neuroticism;	chr8:8734122	chr8:8228595~8244865:+
LGG	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	8.34	8.38e-16	3.7e-13	0.45	0.36	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
LGG	cis	rs172166	0.694	rs9295760	ENSG00000218016.2	ZNF192P2	-8.34	8.39e-16	3.71e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28179607	chr6:28188050~28189432:+
LGG	cis	rs1560104	0.5	rs11075127	ENSG00000274834.1	CTD-3037G24.5	8.34	8.42e-16	3.72e-13	0.44	0.36	Obesity-related traits;	chr16:12620700	chr16:12614451~12614852:+
LGG	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-8.34	8.44e-16	3.73e-13	-0.44	-0.36	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
LGG	cis	rs11098499	0.863	rs10019674	ENSG00000250412.1	KLHL2P1	-8.34	8.45e-16	3.73e-13	-0.42	-0.36	Corneal astigmatism;	chr4:119522334	chr4:119334329~119378233:+
LGG	cis	rs35857674	0.5	rs62515375	ENSG00000253484.1	RP11-109P6.2	-8.33	8.5e-16	3.76e-13	-0.35	-0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50037379	chr8:49817586~49820944:-
LGG	cis	rs5742933	0.69	rs62183656	ENSG00000253559.1	OSGEPL1-AS1	-8.33	8.52e-16	3.76e-13	-0.54	-0.36	Ferritin levels;	chr2:189669387	chr2:189762704~189765556:+
LGG	cis	rs5742933	0.69	rs62183658	ENSG00000253559.1	OSGEPL1-AS1	-8.33	8.52e-16	3.76e-13	-0.54	-0.36	Ferritin levels;	chr2:189669491	chr2:189762704~189765556:+
LGG	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-8.33	8.52e-16	3.77e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-8.33	8.52e-16	3.77e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-8.33	8.52e-16	3.77e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-8.33	8.52e-16	3.77e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
LGG	cis	rs1023500	0.573	rs13057094	ENSG00000227370.1	RP4-669P10.19	8.33	8.59e-16	3.79e-13	0.32	0.36	Schizophrenia;	chr22:42074313	chr22:42132543~42132998:+
LGG	cis	rs1061377	0.513	rs2712000	ENSG00000249685.1	RP11-360F5.3	8.33	8.61e-16	3.8e-13	0.49	0.36	Uric acid levels;	chr4:39135462	chr4:39133913~39135608:+
LGG	cis	rs7241530	0.61	rs58651431	ENSG00000266213.1	RP11-100K18.1	-8.33	8.63e-16	3.81e-13	-0.42	-0.36	Educational attainment (years of education);	chr18:78131656	chr18:78137223~78140887:+
LGG	cis	rs763567	0.935	rs1234275	ENSG00000271811.1	RP1-79C4.4	-8.33	8.64e-16	3.82e-13	-0.35	-0.36	Tonsillectomy;	chr1:170627117	chr1:170667381~170669425:+
LGG	cis	rs35160687	0.644	rs2367232	ENSG00000273080.1	RP11-301O19.1	-8.33	8.65e-16	3.82e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86314368	chr2:86195590~86196049:+
LGG	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-8.33	8.69e-16	3.84e-13	-0.47	-0.36	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
LGG	cis	rs2832077	0.527	rs1048546	ENSG00000232855.5	AF131217.1	8.33	8.71e-16	3.84e-13	0.42	0.36	Cognitive test performance;	chr21:28872555	chr21:28439346~28674848:-
LGG	cis	rs4143844	0.867	rs11638455	ENSG00000259251.2	RP11-643M14.1	8.33	8.75e-16	3.86e-13	0.62	0.36	Bipolar disorder and schizophrenia;	chr15:61870969	chr15:62060503~62062434:+
LGG	cis	rs35160687	0.644	rs17738058	ENSG00000273080.1	RP11-301O19.1	-8.33	8.76e-16	3.87e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86286080	chr2:86195590~86196049:+
LGG	cis	rs228614	0.51	rs170565	ENSG00000248971.2	KRT8P46	-8.33	8.78e-16	3.88e-13	-0.38	-0.36	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102728746~102730171:-
LGG	cis	rs433598	0.567	rs5012618	ENSG00000260762.1	ACSM5P1	-8.33	8.82e-16	3.89e-13	-0.45	-0.36	Schizophrenia;	chr16:20551415	chr16:20586550~20607107:-
LGG	cis	rs2251666	0.514	rs2271135	ENSG00000267077.1	RP11-127I20.5	8.33	8.83e-16	3.9e-13	0.5	0.36	Cancer;	chr16:4879391	chr16:4795265~4796532:-
LGG	cis	rs6081541	0.622	rs6035257	ENSG00000179447.2	RP5-1027G4.3	8.33	8.84e-16	3.9e-13	0.43	0.36	Psychosis (atypical);	chr20:19224067	chr20:19242302~19284596:-
LGG	cis	rs6081541	0.622	rs6035259	ENSG00000179447.2	RP5-1027G4.3	8.33	8.84e-16	3.9e-13	0.43	0.36	Psychosis (atypical);	chr20:19225349	chr20:19242302~19284596:-
LGG	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-8.33	8.85e-16	3.9e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
LGG	cis	rs17772222	0.917	rs17260415	ENSG00000222990.1	RNU4-22P	8.33	8.89e-16	3.92e-13	0.48	0.36	Coronary artery calcification;	chr14:88745629	chr14:88513498~88513663:+
LGG	cis	rs9532669	0.926	rs9532689	ENSG00000239827.7	SUGT1P3	-8.33	8.9e-16	3.93e-13	-0.38	-0.36	Cervical cancer;	chr13:40957990	chr13:40908159~40921774:-
LGG	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	8.33	8.91e-16	3.93e-13	0.45	0.36	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
LGG	cis	rs2799081	1	rs2799081	ENSG00000226314.6	ZNF192P1	8.33	8.91e-16	3.93e-13	0.37	0.36	Myopia;	chr6:28302807	chr6:28161781~28169594:+
LGG	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	8.33	8.94e-16	3.94e-13	0.54	0.36	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	8.33	8.94e-16	3.94e-13	0.54	0.36	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
LGG	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	8.33	8.97e-16	3.95e-13	0.41	0.36	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
LGG	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-8.33	8.98e-16	3.96e-13	-0.46	-0.36	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
LGG	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	8.33	8.99e-16	3.96e-13	0.48	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
LGG	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	8.33	8.99e-16	3.97e-13	0.32	0.36	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
LGG	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	-8.33	9e-16	3.97e-13	-0.38	-0.36	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
LGG	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	8.33	9e-16	3.97e-13	0.35	0.36	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
LGG	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-8.33	9.02e-16	3.98e-13	-0.36	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
LGG	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	8.33	9.03e-16	3.98e-13	0.42	0.36	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
LGG	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-8.33	9.03e-16	3.98e-13	-0.36	-0.36	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
LGG	cis	rs1023500	0.596	rs5758562	ENSG00000227370.1	RP4-669P10.19	8.33	9.06e-16	4e-13	0.33	0.36	Schizophrenia;	chr22:42052234	chr22:42132543~42132998:+
LGG	cis	rs1023500	0.596	rs5751209	ENSG00000227370.1	RP4-669P10.19	8.33	9.06e-16	4e-13	0.33	0.36	Schizophrenia;	chr22:42055599	chr22:42132543~42132998:+
LGG	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	8.33	9.07e-16	4e-13	0.45	0.36	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
LGG	cis	rs11148252	0.508	rs11148260	ENSG00000278238.1	RP11-245D16.4	-8.33	9.07e-16	4e-13	-0.33	-0.36	Lewy body disease;	chr13:52588508	chr13:52454775~52455331:-
LGG	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-8.33	9.07e-16	4e-13	-0.37	-0.36	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
LGG	cis	rs35160687	0.644	rs4610056	ENSG00000273080.1	RP11-301O19.1	-8.33	9.09e-16	4.01e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86326127	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs7595785	ENSG00000273080.1	RP11-301O19.1	-8.33	9.09e-16	4.01e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86329282	chr2:86195590~86196049:+
LGG	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-8.32	9.1e-16	4.01e-13	-0.54	-0.36	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
LGG	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-8.32	9.12e-16	4.02e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
LGG	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-8.32	9.12e-16	4.02e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
LGG	cis	rs1555322	0.53	rs6060347	ENSG00000269202.1	RP4-614O4.12	-8.32	9.13e-16	4.02e-13	-0.39	-0.36	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35201747~35203288:-
LGG	cis	rs6921919	0.583	rs7740351	ENSG00000226314.6	ZNF192P1	8.32	9.13e-16	4.02e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs16894108	ENSG00000226314.6	ZNF192P1	8.32	9.13e-16	4.02e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28161781~28169594:+
LGG	cis	rs7474896	0.609	rs11011336	ENSG00000226578.1	RP11-258F22.1	-8.32	9.14e-16	4.03e-13	-0.45	-0.36	Obesity (extreme);	chr10:37696388	chr10:37775371~37784131:-
LGG	cis	rs5742933	1	rs3762545	ENSG00000253559.1	OSGEPL1-AS1	-8.32	9.15e-16	4.03e-13	-0.46	-0.36	Ferritin levels;	chr2:189790835	chr2:189762704~189765556:+
LGG	cis	rs1555322	0.53	rs2425047	ENSG00000269202.1	RP4-614O4.12	8.32	9.16e-16	4.04e-13	0.39	0.36	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35201747~35203288:-
LGG	cis	rs893363	0.559	rs877484	ENSG00000271916.1	RP11-884K10.6	8.32	9.18e-16	4.04e-13	0.41	0.36	Axial length;	chr3:53812897	chr3:53797764~53798019:-
LGG	cis	rs35934224	0.783	rs45465601	ENSG00000232926.1	AC000078.5	8.32	9.18e-16	4.04e-13	0.39	0.36	Glaucoma (primary open-angle);	chr22:19881155	chr22:19887289~19887970:+
LGG	cis	rs4281086	0.833	rs6601483	ENSG00000253678.1	RP11-981G7.3	8.32	9.19e-16	4.05e-13	0.39	0.36	Obesity-related traits;	chr8:10538544	chr8:10477491~10479375:-
LGG	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	8.32	9.19e-16	4.05e-13	0.41	0.36	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
LGG	cis	rs7927771	0.542	rs6485775	ENSG00000280615.1	Y_RNA	-8.32	9.2e-16	4.05e-13	-0.43	-0.36	Subjective well-being;	chr11:47751966	chr11:47614898~47614994:-
LGG	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-8.32	9.21e-16	4.06e-13	-0.47	-0.36	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
LGG	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	8.32	9.21e-16	4.06e-13	0.45	0.36	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
LGG	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	8.32	9.21e-16	4.06e-13	0.45	0.36	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
LGG	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-8.32	9.23e-16	4.06e-13	-0.4	-0.36	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
LGG	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	8.32	9.26e-16	4.08e-13	0.87	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
LGG	cis	rs72615157	0.628	rs7801070	ENSG00000242294.5	STAG3L5P	8.32	9.26e-16	4.08e-13	0.24	0.36	Lung function (FEV1/FVC);	chr7:100249524	chr7:100336079~100351900:+
LGG	cis	rs1707322	0.789	rs7540578	ENSG00000281133.1	AL355480.3	-8.32	9.27e-16	4.08e-13	-0.42	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45580892~45580996:-
LGG	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	8.32	9.27e-16	4.08e-13	0.64	0.36	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
LGG	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	8.32	9.27e-16	4.08e-13	0.64	0.36	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
LGG	cis	rs17772222	0.682	rs10132554	ENSG00000222990.1	RNU4-22P	8.32	9.27e-16	4.08e-13	0.42	0.36	Coronary artery calcification;	chr14:88473090	chr14:88513498~88513663:+
LGG	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	8.32	9.29e-16	4.09e-13	0.41	0.36	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
LGG	cis	rs8135665	0.6	rs8139025	ENSG00000233739.1	RP5-1039K5.13	8.32	9.3e-16	4.1e-13	0.4	0.36	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38054874	chr22:38057180~38073940:-
LGG	cis	rs6545883	0.524	rs4599092	ENSG00000273302.1	RP11-493E12.2	-8.32	9.31e-16	4.1e-13	-0.31	-0.36	Tuberculosis;	chr2:61271833	chr2:61199979~61200769:+
LGG	cis	rs853679	0.567	rs7774981	ENSG00000226314.6	ZNF192P1	8.32	9.35e-16	4.12e-13	0.38	0.36	Depression;	chr6:28379133	chr6:28161781~28169594:+
LGG	cis	rs853679	0.567	rs7754960	ENSG00000226314.6	ZNF192P1	8.32	9.35e-16	4.12e-13	0.38	0.36	Depression;	chr6:28379168	chr6:28161781~28169594:+
LGG	cis	rs35934224	0.783	rs7286104	ENSG00000232926.1	AC000078.5	8.32	9.35e-16	4.12e-13	0.39	0.36	Glaucoma (primary open-angle);	chr22:19873703	chr22:19887289~19887970:+
LGG	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-8.32	9.35e-16	4.12e-13	-0.45	-0.36	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
LGG	cis	rs853679	0.538	rs13199081	ENSG00000280107.1	AL022393.9	-8.32	9.39e-16	4.13e-13	-0.38	-0.36	Depression;	chr6:28364057	chr6:28170845~28172521:+
LGG	cis	rs7927771	0.524	rs7939420	ENSG00000280615.1	Y_RNA	-8.32	9.39e-16	4.14e-13	-0.42	-0.36	Subjective well-being;	chr11:47702386	chr11:47614898~47614994:-
LGG	cis	rs3020736	0.5	rs7292241	ENSG00000227370.1	RP4-669P10.19	-8.32	9.4e-16	4.14e-13	-0.31	-0.36	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42132543~42132998:+
LGG	cis	rs3020736	0.5	rs5996111	ENSG00000227370.1	RP4-669P10.19	-8.32	9.4e-16	4.14e-13	-0.31	-0.36	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42132543~42132998:+
LGG	cis	rs1023500	0.573	rs133381	ENSG00000227370.1	RP4-669P10.19	8.32	9.4e-16	4.14e-13	0.31	0.36	Schizophrenia;	chr22:42074604	chr22:42132543~42132998:+
LGG	cis	rs7302981	0.667	rs1362984	ENSG00000272368.2	RP4-605O3.4	-8.32	9.43e-16	4.15e-13	-0.35	-0.36	Systolic blood pressure;	chr12:50206201	chr12:50112197~50165618:+
LGG	cis	rs4143844	0.867	rs12901055	ENSG00000259251.2	RP11-643M14.1	8.32	9.44e-16	4.16e-13	0.62	0.36	Bipolar disorder and schizophrenia;	chr15:61880708	chr15:62060503~62062434:+
LGG	cis	rs9393777	0.92	rs72839445	ENSG00000216901.1	AL022393.7	8.32	9.45e-16	4.16e-13	0.84	0.36	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28176188~28176674:+
LGG	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	8.32	9.46e-16	4.17e-13	0.36	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
LGG	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	8.32	9.49e-16	4.18e-13	0.61	0.36	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
LGG	cis	rs950776	1	rs950776	ENSG00000261762.1	RP11-650L12.2	8.32	9.5e-16	4.18e-13	0.46	0.36	Sudden cardiac arrest;	chr15:78633676	chr15:78589123~78591276:-
LGG	cis	rs6921919	0.583	rs740621	ENSG00000226314.6	ZNF192P1	8.32	9.5e-16	4.18e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.863	rs34868248	ENSG00000250412.1	KLHL2P1	8.32	9.52e-16	4.19e-13	0.41	0.36	Corneal astigmatism;	chr4:119521275	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs3733525	ENSG00000250412.1	KLHL2P1	8.32	9.52e-16	4.19e-13	0.41	0.36	Corneal astigmatism;	chr4:119525893	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs3775847	ENSG00000250412.1	KLHL2P1	8.32	9.52e-16	4.19e-13	0.41	0.36	Corneal astigmatism;	chr4:119526487	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs3775848	ENSG00000250412.1	KLHL2P1	8.32	9.52e-16	4.19e-13	0.41	0.36	Corneal astigmatism;	chr4:119526569	chr4:119334329~119378233:+
LGG	cis	rs17772222	0.63	rs10873392	ENSG00000258983.2	RP11-507K2.2	-8.32	9.53e-16	4.19e-13	-0.4	-0.36	Coronary artery calcification;	chr14:88545124	chr14:88499334~88515502:+
LGG	cis	rs9300255	0.739	rs1402275	ENSG00000235423.7	RP11-282O18.3	8.32	9.54e-16	4.2e-13	0.4	0.36	Neutrophil percentage of white cells;	chr12:123266348	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.739	rs10846491	ENSG00000235423.7	RP11-282O18.3	8.32	9.54e-16	4.2e-13	0.4	0.36	Neutrophil percentage of white cells;	chr12:123268945	chr12:123252030~123261483:-
LGG	cis	rs7241530	0.536	rs34738964	ENSG00000266213.1	RP11-100K18.1	-8.32	9.55e-16	4.2e-13	-0.42	-0.36	Educational attainment (years of education);	chr18:78131259	chr18:78137223~78140887:+
LGG	cis	rs853679	0.567	rs3799499	ENSG00000226314.6	ZNF192P1	8.32	9.57e-16	4.21e-13	0.38	0.36	Depression;	chr6:28386473	chr6:28161781~28169594:+
LGG	cis	rs853679	0.567	rs2232427	ENSG00000226314.6	ZNF192P1	8.32	9.57e-16	4.21e-13	0.38	0.36	Depression;	chr6:28391932	chr6:28161781~28169594:+
LGG	cis	rs853679	0.567	rs1005126	ENSG00000226314.6	ZNF192P1	8.32	9.57e-16	4.21e-13	0.38	0.36	Depression;	chr6:28399846	chr6:28161781~28169594:+
LGG	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	8.32	9.6e-16	4.22e-13	0.61	0.36	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
LGG	cis	rs56114371	0.777	rs200483	ENSG00000199851.2	U3	8.32	9.62e-16	4.23e-13	0.75	0.36	Breast cancer;	chr6:27807046	chr6:28015568~28015777:+
LGG	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-8.32	9.62e-16	4.23e-13	-0.46	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-8.32	9.63e-16	4.24e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
LGG	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-8.32	9.63e-16	4.24e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-8.32	9.63e-16	4.24e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-8.32	9.63e-16	4.24e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
LGG	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-8.32	9.63e-16	4.24e-13	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
LGG	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	8.32	9.63e-16	4.24e-13	0.35	0.36	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
LGG	cis	rs17345786	0.861	rs11707689	ENSG00000256628.3	ZBTB11-AS1	8.32	9.66e-16	4.25e-13	0.46	0.36	Colonoscopy-negative controls vs population controls;	chr3:101367631	chr3:101676475~101679217:+
LGG	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	8.32	9.68e-16	4.26e-13	0.37	0.36	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
LGG	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	8.32	9.68e-16	4.26e-13	0.37	0.36	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	8.32	9.68e-16	4.26e-13	0.37	0.36	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
LGG	cis	rs12554020	0.892	rs3815563	ENSG00000237385.1	RP11-165J3.5	8.32	9.69e-16	4.26e-13	0.56	0.36	Schizophrenia;	chr9:93450864	chr9:93430342~93431299:-
LGG	cis	rs12554020	1	rs7853605	ENSG00000237385.1	RP11-165J3.5	8.32	9.69e-16	4.26e-13	0.56	0.36	Schizophrenia;	chr9:93451247	chr9:93430342~93431299:-
LGG	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-8.32	9.71e-16	4.27e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
LGG	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	8.32	9.72e-16	4.28e-13	0.37	0.36	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
LGG	cis	rs7824557	0.651	rs6601582	ENSG00000184608.7	FAM167A-AS1	-8.32	9.73e-16	4.28e-13	-0.3	-0.36	Retinal vascular caliber;	chr8:11349858	chr8:11368402~11438658:+
LGG	cis	rs8067545	0.603	rs10083830	ENSG00000230528.6	NOS2P3	-8.32	9.74e-16	4.28e-13	-0.34	-0.36	Schizophrenia;	chr17:20062570	chr17:20436337~20447249:+
LGG	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-8.32	9.75e-16	4.29e-13	-0.37	-0.36	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
LGG	cis	rs11992186	0.597	rs11781841	ENSG00000173295.6	FAM86B3P	8.31	9.8e-16	4.31e-13	0.39	0.36	Neuroticism;	chr8:8737753	chr8:8228595~8244865:+
LGG	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-8.31	9.8e-16	4.31e-13	-0.48	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
LGG	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-8.31	9.82e-16	4.32e-13	-0.45	-0.36	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
LGG	cis	rs1023500	0.505	rs134885	ENSG00000227370.1	RP4-669P10.19	8.31	9.82e-16	4.32e-13	0.31	0.36	Schizophrenia;	chr22:42277805	chr22:42132543~42132998:+
LGG	cis	rs7474896	0.609	rs1830612	ENSG00000226578.1	RP11-258F22.1	-8.31	9.83e-16	4.32e-13	-0.46	-0.36	Obesity (extreme);	chr10:37710955	chr10:37775371~37784131:-
LGG	cis	rs9322193	0.962	rs12175575	ENSG00000216621.7	RP11-244K5.6	8.31	9.88e-16	4.34e-13	0.42	0.36	Lung cancer;	chr6:149763351	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs4869966	ENSG00000216621.7	RP11-244K5.6	8.31	9.88e-16	4.34e-13	0.42	0.36	Lung cancer;	chr6:149763714	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs1112730	ENSG00000216621.7	RP11-244K5.6	8.31	9.88e-16	4.34e-13	0.42	0.36	Lung cancer;	chr6:149766383	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs1112729	ENSG00000216621.7	RP11-244K5.6	8.31	9.88e-16	4.34e-13	0.42	0.36	Lung cancer;	chr6:149766491	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs10452626	ENSG00000216621.7	RP11-244K5.6	8.31	9.88e-16	4.34e-13	0.42	0.36	Lung cancer;	chr6:149767481	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs62441303	ENSG00000216621.7	RP11-244K5.6	8.31	9.88e-16	4.34e-13	0.42	0.36	Lung cancer;	chr6:149767547	chr6:149934527~149936782:+
LGG	cis	rs2075466	0.514	rs75588955	ENSG00000267077.1	RP11-127I20.5	8.31	9.93e-16	4.36e-13	0.51	0.36	Colonoscopy-negative controls vs population controls;	chr16:4849393	chr16:4795265~4796532:-
LGG	cis	rs2075466	0.514	rs76214824	ENSG00000267077.1	RP11-127I20.5	8.31	9.93e-16	4.36e-13	0.51	0.36	Colonoscopy-negative controls vs population controls;	chr16:4850238	chr16:4795265~4796532:-
LGG	cis	rs227275	0.525	rs4699046	ENSG00000248971.2	KRT8P46	-8.31	9.99e-16	4.39e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs4699047	ENSG00000248971.2	KRT8P46	-8.31	9.99e-16	4.39e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs28778380	ENSG00000248971.2	KRT8P46	-8.31	9.99e-16	4.39e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102728746~102730171:-
LGG	cis	rs1560104	0.536	rs11075131	ENSG00000274834.1	CTD-3037G24.5	8.31	1e-15	4.41e-13	0.45	0.36	Obesity-related traits;	chr16:12623130	chr16:12614451~12614852:+
LGG	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-8.31	1e-15	4.41e-13	-0.43	-0.36	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
LGG	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-8.31	1e-15	4.41e-13	-0.32	-0.36	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
LGG	cis	rs11148252	0.774	rs7993748	ENSG00000235660.1	LINC00345	-8.31	1.01e-15	4.42e-13	-0.44	-0.36	Lewy body disease;	chr13:52367496	chr13:52484161~52484680:-
LGG	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	8.31	1.01e-15	4.42e-13	0.32	0.36	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
LGG	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	8.31	1.01e-15	4.42e-13	0.32	0.36	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
LGG	cis	rs9393777	0.92	rs34071253	ENSG00000199851.2	U3	8.31	1.01e-15	4.43e-13	0.84	0.36	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28015568~28015777:+
LGG	cis	rs9393777	0.92	rs35716472	ENSG00000199851.2	U3	8.31	1.01e-15	4.43e-13	0.84	0.36	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28015568~28015777:+
LGG	cis	rs4713118	0.513	rs149955	ENSG00000218016.2	ZNF192P2	-8.31	1.01e-15	4.44e-13	-0.47	-0.36	Parkinson's disease;	chr6:28068447	chr6:28188050~28189432:+
LGG	cis	rs45509595	0.841	rs370155	ENSG00000216901.1	AL022393.7	8.31	1.01e-15	4.44e-13	0.66	0.36	Breast cancer;	chr6:27814253	chr6:28176188~28176674:+
LGG	cis	rs1275468	1	rs1148005	ENSG00000257497.2	RP11-585P4.5	-8.31	1.01e-15	4.45e-13	-0.46	-0.36	Polycystic ovary syndrome;	chr12:75584733	chr12:75483454~75489820:-
LGG	cis	rs4713118	0.512	rs2622319	ENSG00000218016.2	ZNF192P2	-8.31	1.01e-15	4.45e-13	-0.47	-0.36	Parkinson's disease;	chr6:28152623	chr6:28188050~28189432:+
LGG	cis	rs172166	0.694	rs1150666	ENSG00000218016.2	ZNF192P2	-8.31	1.01e-15	4.45e-13	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28156150	chr6:28188050~28189432:+
LGG	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	8.31	1.02e-15	4.46e-13	0.3	0.36	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
LGG	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-8.31	1.02e-15	4.47e-13	-0.26	-0.36	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
LGG	cis	rs9322193	0.926	rs3805751	ENSG00000216621.7	RP11-244K5.6	8.31	1.02e-15	4.47e-13	0.42	0.36	Lung cancer;	chr6:149791193	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs10872656	ENSG00000216621.7	RP11-244K5.6	8.31	1.02e-15	4.47e-13	0.42	0.36	Lung cancer;	chr6:149799444	chr6:149934527~149936782:+
LGG	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	8.31	1.02e-15	4.48e-13	0.42	0.36	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
LGG	cis	rs7219021	0.739	rs3760451	ENSG00000248278.1	SUMO2P17	-8.31	1.02e-15	4.48e-13	-0.43	-0.36	Schizophrenia or bipolar disorder;	chr17:48891815	chr17:48874860~48908983:-
LGG	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	8.31	1.02e-15	4.48e-13	0.42	0.36	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
LGG	cis	rs7241530	0.585	rs12956095	ENSG00000266213.1	RP11-100K18.1	-8.31	1.02e-15	4.49e-13	-0.42	-0.36	Educational attainment (years of education);	chr18:78130645	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.585	rs12964467	ENSG00000266213.1	RP11-100K18.1	-8.31	1.02e-15	4.49e-13	-0.42	-0.36	Educational attainment (years of education);	chr18:78130849	chr18:78137223~78140887:+
LGG	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	8.31	1.02e-15	4.49e-13	0.44	0.36	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	8.31	1.02e-15	4.49e-13	0.44	0.36	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
LGG	cis	rs1707322	0.964	rs785508	ENSG00000281133.1	AL355480.3	8.31	1.02e-15	4.5e-13	0.43	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.964	rs785509	ENSG00000281133.1	AL355480.3	8.31	1.02e-15	4.5e-13	0.43	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45580892~45580996:-
LGG	cis	rs7189233	0.955	rs7184800	ENSG00000279344.1	RP11-44F14.7	8.31	1.03e-15	4.5e-13	0.35	0.36	Intelligence (multi-trait analysis);	chr16:53475219	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.955	rs16952242	ENSG00000279344.1	RP11-44F14.7	8.31	1.03e-15	4.52e-13	0.34	0.36	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53478957~53481550:-
LGG	cis	rs6921919	0.638	rs2108926	ENSG00000226314.6	ZNF192P1	8.31	1.03e-15	4.53e-13	0.38	0.36	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28161781~28169594:+
LGG	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-8.31	1.03e-15	4.53e-13	-0.42	-0.36	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
LGG	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-8.31	1.03e-15	4.54e-13	-0.44	-0.36	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	8.31	1.03e-15	4.54e-13	0.44	0.36	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-8.31	1.03e-15	4.54e-13	-0.44	-0.36	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
LGG	cis	rs4714902	0.623	rs3734208	ENSG00000231769.2	RP1-8B1.4	-8.31	1.03e-15	4.54e-13	-0.38	-0.36	Colonoscopy-negative controls vs population controls;	chr6:46130021	chr6:46097093~46129706:-
LGG	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	8.31	1.04e-15	4.55e-13	0.54	0.36	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
LGG	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-8.31	1.04e-15	4.56e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
LGG	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-8.31	1.04e-15	4.56e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
LGG	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-8.31	1.04e-15	4.56e-13	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-8.31	1.04e-15	4.56e-13	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-8.31	1.04e-15	4.56e-13	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
LGG	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-8.31	1.04e-15	4.56e-13	-0.45	-0.36	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
LGG	cis	rs7267979	0.744	rs6050464	ENSG00000276952.1	RP5-965G21.6	8.31	1.04e-15	4.57e-13	0.35	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25284915~25285588:-
LGG	cis	rs35160687	0.644	rs4832274	ENSG00000273080.1	RP11-301O19.1	-8.31	1.04e-15	4.57e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86301961	chr2:86195590~86196049:+
LGG	cis	rs3020736	0.5	rs6002597	ENSG00000227370.1	RP4-669P10.19	-8.31	1.04e-15	4.58e-13	-0.31	-0.36	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42132543~42132998:+
LGG	cis	rs3020736	0.5	rs6002603	ENSG00000227370.1	RP4-669P10.19	-8.31	1.04e-15	4.58e-13	-0.31	-0.36	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42132543~42132998:+
LGG	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-8.31	1.04e-15	4.58e-13	-0.3	-0.36	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
LGG	cis	rs2292342	0.85	rs2301139	ENSG00000232871.7	SEC1P	-8.31	1.05e-15	4.59e-13	-0.65	-0.36	Elevated serum carcinoembryonic antigen levels;	chr19:48630504	chr19:48638071~48682245:+
LGG	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-8.31	1.05e-15	4.59e-13	-0.39	-0.36	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
LGG	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-8.31	1.05e-15	4.59e-13	-0.39	-0.36	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
LGG	cis	rs11098499	0.954	rs1546505	ENSG00000250412.1	KLHL2P1	8.31	1.05e-15	4.6e-13	0.42	0.36	Corneal astigmatism;	chr4:119320069	chr4:119334329~119378233:+
LGG	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-8.31	1.05e-15	4.6e-13	-0.81	-0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
LGG	cis	rs3096299	0.589	rs3114898	ENSG00000274627.1	RP11-104N10.2	8.31	1.05e-15	4.6e-13	0.3	0.36	Multiple myeloma (IgH translocation);	chr16:89325907	chr16:89516797~89522217:+
LGG	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	8.31	1.05e-15	4.6e-13	0.37	0.36	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
LGG	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	8.31	1.05e-15	4.61e-13	0.34	0.36	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
LGG	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-8.31	1.05e-15	4.61e-13	-0.47	-0.36	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
LGG	cis	rs7523050	0.73	rs7519107	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108856745	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs7519293	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108856921	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs7522324	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108857022	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs7551142	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108857088	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs7551313	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108857259	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs12736534	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108857312	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs12741194	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108857768	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs12741359	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108857867	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs34367763	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108858183	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs35662800	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108858194	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs17621851	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108858213	chr1:108857217~108858524:+
LGG	cis	rs7523050	0.643	rs34920128	ENSG00000203897.3	SPATA42	-8.31	1.05e-15	4.61e-13	-0.62	-0.36	Fat distribution (HIV);	chr1:108858267	chr1:108857217~108858524:+
LGG	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-8.3	1.05e-15	4.62e-13	-0.44	-0.36	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
LGG	cis	rs1420956	0.905	rs1420958	ENSG00000264151.4	RP11-739N10.1	-8.3	1.06e-15	4.63e-13	-0.47	-0.36	Obesity-related traits;	chr18:27583826	chr18:27336379~27595164:-
LGG	cis	rs9346353	1	rs4418153	ENSG00000219881.1	GAPDHP42	8.3	1.06e-15	4.64e-13	0.35	0.36	Sleep duration;	chr6:69802787	chr6:69745871~69746851:+
LGG	cis	rs9346353	1	rs4304126	ENSG00000219881.1	GAPDHP42	8.3	1.06e-15	4.64e-13	0.35	0.36	Sleep duration;	chr6:69802875	chr6:69745871~69746851:+
LGG	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-8.3	1.06e-15	4.64e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
LGG	cis	rs9532669	0.926	rs2324742	ENSG00000239827.7	SUGT1P3	-8.3	1.06e-15	4.65e-13	-0.38	-0.36	Cervical cancer;	chr13:40919059	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.857	rs9594455	ENSG00000239827.7	SUGT1P3	-8.3	1.06e-15	4.65e-13	-0.38	-0.36	Cervical cancer;	chr13:40919452	chr13:40908159~40921774:-
LGG	cis	rs6921919	0.583	rs3800328	ENSG00000226314.6	ZNF192P1	8.3	1.07e-15	4.68e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.609	rs67211468	ENSG00000226314.6	ZNF192P1	8.3	1.07e-15	4.68e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs35560946	ENSG00000226314.6	ZNF192P1	8.3	1.07e-15	4.68e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.583	rs740622	ENSG00000226314.6	ZNF192P1	8.3	1.07e-15	4.68e-13	0.36	0.36	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.909	rs79026312	ENSG00000250412.1	KLHL2P1	8.3	1.07e-15	4.68e-13	0.41	0.36	Corneal astigmatism;	chr4:119519522	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs35111518	ENSG00000250412.1	KLHL2P1	8.3	1.07e-15	4.68e-13	0.41	0.36	Corneal astigmatism;	chr4:119519527	chr4:119334329~119378233:+
LGG	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	8.3	1.07e-15	4.68e-13	0.61	0.36	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
LGG	cis	rs11148252	0.904	rs9568732	ENSG00000278238.1	RP11-245D16.4	8.3	1.07e-15	4.68e-13	0.34	0.36	Lewy body disease;	chr13:52419277	chr13:52454775~52455331:-
LGG	cis	rs7824557	0.591	rs2736283	ENSG00000184608.7	FAM167A-AS1	8.3	1.07e-15	4.69e-13	0.3	0.36	Retinal vascular caliber;	chr8:11368401	chr8:11368402~11438658:+
LGG	cis	rs4143844	1	rs11629645	ENSG00000259251.2	RP11-643M14.1	8.3	1.07e-15	4.69e-13	0.59	0.36	Bipolar disorder and schizophrenia;	chr15:62014275	chr15:62060503~62062434:+
LGG	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	8.3	1.07e-15	4.69e-13	0.45	0.36	Height;	chr14:75017109	chr14:75011269~75012851:-
LGG	cis	rs9322193	0.923	rs14314	ENSG00000216621.7	RP11-244K5.6	8.3	1.07e-15	4.7e-13	0.42	0.36	Lung cancer;	chr6:149820395	chr6:149934527~149936782:+
LGG	cis	rs9300255	0.602	rs1716167	ENSG00000235423.7	RP11-282O18.3	-8.3	1.08e-15	4.74e-13	-0.39	-0.36	Neutrophil percentage of white cells;	chr12:123166615	chr12:123252030~123261483:-
LGG	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	8.3	1.09e-15	4.76e-13	0.46	0.36	Height;	chr14:75172868	chr14:75011269~75012851:-
LGG	cis	rs11992162	0.933	rs10108075	ENSG00000255556.2	RP11-351I21.6	8.3	1.09e-15	4.76e-13	0.43	0.36	Monocyte count;	chr8:11974570	chr8:12378679~12380265:-
LGG	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	8.3	1.09e-15	4.77e-13	0.37	0.36	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
LGG	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	8.3	1.09e-15	4.77e-13	0.54	0.36	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
LGG	cis	rs7980687	0.574	rs10744149	ENSG00000235423.7	RP11-282O18.3	8.3	1.09e-15	4.77e-13	0.4	0.36	Head circumference (infant);Educational attainment;Height;	chr12:123223943	chr12:123252030~123261483:-
LGG	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-8.3	1.09e-15	4.78e-13	-0.48	-0.36	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
LGG	cis	rs1023500	0.506	rs6002625	ENSG00000227370.1	RP4-669P10.19	-8.3	1.09e-15	4.78e-13	-0.32	-0.36	Schizophrenia;	chr22:42121685	chr22:42132543~42132998:+
LGG	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	8.3	1.09e-15	4.8e-13	0.41	0.36	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
LGG	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	8.3	1.09e-15	4.8e-13	0.41	0.36	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
LGG	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	-8.3	1.1e-15	4.8e-13	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
LGG	cis	rs7241530	0.585	rs67507908	ENSG00000266213.1	RP11-100K18.1	-8.3	1.1e-15	4.81e-13	-0.42	-0.36	Educational attainment (years of education);	chr18:78131447	chr18:78137223~78140887:+
LGG	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-8.3	1.1e-15	4.82e-13	-0.49	-0.36	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
LGG	cis	rs853679	0.546	rs200490	ENSG00000216901.1	AL022393.7	8.3	1.1e-15	4.82e-13	0.66	0.36	Depression;	chr6:27829157	chr6:28176188~28176674:+
LGG	cis	rs11098499	0.69	rs34818745	ENSG00000250412.1	KLHL2P1	8.3	1.1e-15	4.84e-13	0.41	0.36	Corneal astigmatism;	chr4:119335900	chr4:119334329~119378233:+
LGG	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	8.3	1.11e-15	4.84e-13	0.64	0.36	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
LGG	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	8.3	1.11e-15	4.87e-13	0.31	0.36	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
LGG	cis	rs9532669	0.89	rs4941999	ENSG00000168852.11	TPTE2P5	8.3	1.11e-15	4.87e-13	0.38	0.36	Cervical cancer;	chr13:40859926	chr13:40822296~40921749:-
LGG	cis	rs454217	0.846	rs381966	ENSG00000277851.1	RP11-756G20.1	8.3	1.11e-15	4.87e-13	0.36	0.36	Smoking quantity;	chr12:92335913	chr12:92247756~92363832:-
LGG	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-8.3	1.12e-15	4.88e-13	-0.28	-0.36	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
LGG	cis	rs4295623	0.585	rs13259242	ENSG00000227888.4	FAM66A	-8.3	1.12e-15	4.88e-13	-0.43	-0.36	Morning vs. evening chronotype;	chr8:11735524	chr8:12362019~12388296:+
LGG	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	8.3	1.12e-15	4.89e-13	0.47	0.36	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
LGG	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	8.3	1.12e-15	4.89e-13	0.45	0.36	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
LGG	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	8.3	1.12e-15	4.89e-13	0.45	0.36	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
LGG	cis	rs17772222	0.682	rs3783889	ENSG00000222990.1	RNU4-22P	8.3	1.12e-15	4.9e-13	0.42	0.36	Coronary artery calcification;	chr14:88475637	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.637	rs879932	ENSG00000222990.1	RNU4-22P	8.3	1.12e-15	4.9e-13	0.42	0.36	Coronary artery calcification;	chr14:88479247	chr14:88513498~88513663:+
LGG	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	8.3	1.12e-15	4.9e-13	0.52	0.36	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
LGG	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	8.3	1.12e-15	4.9e-13	0.52	0.36	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
LGG	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-8.3	1.13e-15	4.94e-13	-0.42	-0.36	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
LGG	cis	rs1023500	0.505	rs134889	ENSG00000227370.1	RP4-669P10.19	8.3	1.13e-15	4.94e-13	0.31	0.36	Schizophrenia;	chr22:42278344	chr22:42132543~42132998:+
LGG	cis	rs11098499	0.954	rs10008392	ENSG00000250412.1	KLHL2P1	8.3	1.13e-15	4.94e-13	0.41	0.36	Corneal astigmatism;	chr4:119397684	chr4:119334329~119378233:+
LGG	cis	rs17345786	0.906	rs59359251	ENSG00000256628.3	ZBTB11-AS1	8.3	1.13e-15	4.94e-13	0.45	0.36	Colonoscopy-negative controls vs population controls;	chr3:101427518	chr3:101676475~101679217:+
LGG	cis	rs17345786	0.906	rs55710435	ENSG00000256628.3	ZBTB11-AS1	8.3	1.13e-15	4.94e-13	0.45	0.36	Colonoscopy-negative controls vs population controls;	chr3:101461486	chr3:101676475~101679217:+
LGG	cis	rs17345786	0.906	rs72944107	ENSG00000256628.3	ZBTB11-AS1	8.3	1.13e-15	4.94e-13	0.45	0.36	Colonoscopy-negative controls vs population controls;	chr3:101478346	chr3:101676475~101679217:+
LGG	cis	rs7474896	0.583	rs7071147	ENSG00000226578.1	RP11-258F22.1	-8.3	1.13e-15	4.96e-13	-0.46	-0.36	Obesity (extreme);	chr10:37714448	chr10:37775371~37784131:-
LGG	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-8.3	1.13e-15	4.96e-13	-0.37	-0.36	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
LGG	cis	rs11039216	1	rs11039216	ENSG00000280615.1	Y_RNA	8.29	1.14e-15	4.98e-13	0.42	0.36	Neuroticism;	chr11:47385041	chr11:47614898~47614994:-
LGG	cis	rs12073837	0.5	rs11118610	ENSG00000238078.1	LINC01352	-8.29	1.14e-15	4.98e-13	-0.45	-0.36	F-cell distribution;	chr1:220816744	chr1:220829255~220832429:+
LGG	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	8.29	1.14e-15	4.98e-13	0.42	0.36	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
LGG	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	8.29	1.14e-15	4.98e-13	0.44	0.36	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
LGG	cis	rs673078	0.607	rs7974375	ENSG00000275759.1	RP11-131L12.3	-8.29	1.14e-15	4.98e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118147893	chr12:118428281~118428870:+
LGG	cis	rs35934224	0.843	rs34175429	ENSG00000232926.1	AC000078.5	8.29	1.14e-15	4.99e-13	0.4	0.36	Glaucoma (primary open-angle);	chr22:19879753	chr22:19887289~19887970:+
LGG	cis	rs454217	0.818	rs381750	ENSG00000277851.1	RP11-756G20.1	8.29	1.15e-15	5.02e-13	0.36	0.36	Smoking quantity;	chr12:92323106	chr12:92247756~92363832:-
LGG	cis	rs454217	0.846	rs1661029	ENSG00000277851.1	RP11-756G20.1	8.29	1.15e-15	5.02e-13	0.36	0.36	Smoking quantity;	chr12:92324197	chr12:92247756~92363832:-
LGG	cis	rs7189233	0.955	rs72801817	ENSG00000279344.1	RP11-44F14.7	8.29	1.15e-15	5.02e-13	0.34	0.36	Intelligence (multi-trait analysis);	chr16:53440656	chr16:53478957~53481550:-
LGG	cis	rs17345786	0.906	rs72940399	ENSG00000256628.3	ZBTB11-AS1	8.29	1.15e-15	5.04e-13	0.45	0.36	Colonoscopy-negative controls vs population controls;	chr3:101403731	chr3:101676475~101679217:+
LGG	cis	rs9890032	0.934	rs3760318	ENSG00000266490.1	CTD-2349P21.9	8.29	1.15e-15	5.04e-13	0.29	0.36	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30792372~30792833:+
LGG	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-8.29	1.15e-15	5.04e-13	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
LGG	cis	rs11148252	0.846	rs9379	ENSG00000235660.1	LINC00345	-8.29	1.16e-15	5.06e-13	-0.43	-0.36	Lewy body disease;	chr13:52476344	chr13:52484161~52484680:-
LGG	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	-8.29	1.16e-15	5.06e-13	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
LGG	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-8.29	1.16e-15	5.06e-13	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
LGG	cis	rs11148252	0.5	rs342768	ENSG00000273784.3	RP11-78J21.7	-8.29	1.16e-15	5.07e-13	-0.39	-0.36	Lewy body disease;	chr13:52634747	chr13:52600042~52642542:+
LGG	cis	rs72615157	0.645	rs11771660	ENSG00000242294.5	STAG3L5P	8.29	1.16e-15	5.07e-13	0.24	0.36	Lung function (FEV1/FVC);	chr7:100253646	chr7:100336079~100351900:+
LGG	cis	rs8042680	0.522	rs1867225	ENSG00000214432.8	AC068831.10	-8.29	1.16e-15	5.08e-13	-0.37	-0.36	Type 2 diabetes;	chr15:91020599	chr15:91022619~91036611:+
LGG	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	8.29	1.16e-15	5.08e-13	0.42	0.36	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
LGG	cis	rs7005380	0.62	rs7462302	ENSG00000245330.4	KB-1471A8.1	8.29	1.16e-15	5.08e-13	0.4	0.36	Interstitial lung disease;	chr8:119905531	chr8:119867419~119874488:-
LGG	cis	rs1275468	1	rs1148000	ENSG00000257497.2	RP11-585P4.5	-8.29	1.16e-15	5.08e-13	-0.46	-0.36	Polycystic ovary syndrome;	chr12:75542521	chr12:75483454~75489820:-
LGG	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-8.29	1.16e-15	5.09e-13	-0.42	-0.36	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-8.29	1.16e-15	5.09e-13	-0.42	-0.36	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
LGG	cis	rs11123170	0.569	rs1049137	ENSG00000274877.1	RP11-65I12.1	-8.29	1.16e-15	5.09e-13	-0.5	-0.36	Renal function-related traits (BUN);	chr2:113217533	chr2:113237595~113240825:+
LGG	cis	rs1707322	1	rs4660334	ENSG00000281133.1	AL355480.3	-8.29	1.17e-15	5.09e-13	-0.43	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45580892~45580996:-
LGG	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-8.29	1.17e-15	5.1e-13	-0.36	-0.36	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
LGG	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	8.29	1.17e-15	5.1e-13	0.47	0.36	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
LGG	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-8.29	1.17e-15	5.11e-13	-0.37	-0.36	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
LGG	cis	rs3096299	0.754	rs3096320	ENSG00000274627.1	RP11-104N10.2	8.29	1.17e-15	5.13e-13	0.31	0.36	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89516797~89522217:+
LGG	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	8.29	1.17e-15	5.13e-13	0.47	0.36	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
LGG	cis	rs889122	0.729	rs16996141	ENSG00000267289.1	CTD-2623N2.11	8.29	1.18e-15	5.14e-13	0.47	0.36	Menarche (age at onset);	chr19:9855016	chr19:9834079~9835013:-
LGG	cis	rs9532669	0.926	rs4942014	ENSG00000168852.11	TPTE2P5	8.29	1.18e-15	5.14e-13	0.36	0.36	Cervical cancer;	chr13:40966366	chr13:40822296~40921749:-
LGG	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	8.29	1.18e-15	5.15e-13	0.38	0.36	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
LGG	cis	rs4713118	0.628	rs12179134	ENSG00000216901.1	AL022393.7	8.29	1.18e-15	5.16e-13	0.53	0.36	Parkinson's disease;	chr6:27707690	chr6:28176188~28176674:+
LGG	cis	rs9322193	0.962	rs9765929	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149769680	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.736	rs10457851	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149775216	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.886	rs10872652	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149775303	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.886	rs17672976	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149776207	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs2184369	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149776681	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs2342861	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149777561	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.926	rs2342860	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149777641	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs10872653	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149778907	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	8.29	1.18e-15	5.17e-13	0.44	0.36	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
LGG	cis	rs9322193	0.962	rs62441335	ENSG00000216621.7	RP11-244K5.6	8.29	1.18e-15	5.17e-13	0.42	0.36	Lung cancer;	chr6:149792658	chr6:149934527~149936782:+
LGG	cis	rs11148252	0.74	rs9536052	ENSG00000235660.1	LINC00345	8.29	1.18e-15	5.17e-13	0.43	0.36	Lewy body disease;	chr13:52386574	chr13:52484161~52484680:-
LGG	cis	rs6921919	0.697	rs6942030	ENSG00000226314.6	ZNF192P1	8.29	1.19e-15	5.18e-13	0.38	0.36	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28161781~28169594:+
LGG	cis	rs879620	1	rs879620	ENSG00000262185.1	RP11-462G12.1	8.29	1.19e-15	5.18e-13	0.45	0.36	Hip circumference;Body mass index;	chr16:3965728	chr16:3947609~3950444:-
LGG	cis	rs2739330	0.796	rs1006771	ENSG00000272787.1	KB-226F1.2	8.29	1.19e-15	5.18e-13	0.39	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23969211~23969873:+
LGG	cis	rs71537559	1	rs71537559	ENSG00000199851.2	U3	8.29	1.19e-15	5.18e-13	0.88	0.36	Squamous cell lung carcinoma;	chr6:27342000	chr6:28015568~28015777:+
LGG	cis	rs8180040	0.966	rs2062278	ENSG00000271161.1	BOLA2P2	8.29	1.19e-15	5.18e-13	0.33	0.36	Colorectal cancer;	chr3:47375271	chr3:47499841~47500407:+
LGG	cis	rs7302981	0.746	rs2272391	ENSG00000272368.2	RP4-605O3.4	-8.29	1.19e-15	5.19e-13	-0.34	-0.36	Systolic blood pressure;	chr12:50077847	chr12:50112197~50165618:+
LGG	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-8.29	1.19e-15	5.19e-13	-0.31	-0.36	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
LGG	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	8.29	1.19e-15	5.2e-13	0.44	0.36	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
LGG	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	8.29	1.2e-15	5.22e-13	0.47	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
LGG	cis	rs4295623	0.553	rs34962960	ENSG00000227888.4	FAM66A	-8.29	1.2e-15	5.22e-13	-0.43	-0.36	Morning vs. evening chronotype;	chr8:11737088	chr8:12362019~12388296:+
LGG	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	8.29	1.2e-15	5.22e-13	0.41	0.36	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
LGG	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-8.29	1.2e-15	5.22e-13	-0.45	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
LGG	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-8.29	1.2e-15	5.22e-13	-0.37	-0.36	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
LGG	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	8.29	1.2e-15	5.24e-13	0.4	0.36	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
LGG	cis	rs17772222	0.63	rs1344747	ENSG00000258983.2	RP11-507K2.2	-8.29	1.2e-15	5.25e-13	-0.39	-0.36	Coronary artery calcification;	chr14:88548091	chr14:88499334~88515502:+
LGG	cis	rs4143844	0.867	rs11639286	ENSG00000259251.2	RP11-643M14.1	8.29	1.2e-15	5.26e-13	0.58	0.36	Bipolar disorder and schizophrenia;	chr15:62024397	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs34958705	ENSG00000259251.2	RP11-643M14.1	8.29	1.2e-15	5.26e-13	0.58	0.36	Bipolar disorder and schizophrenia;	chr15:62024558	chr15:62060503~62062434:+
LGG	cis	rs7927771	0.524	rs11039345	ENSG00000280615.1	Y_RNA	8.29	1.21e-15	5.26e-13	0.43	0.36	Subjective well-being;	chr11:47698676	chr11:47614898~47614994:-
LGG	cis	rs812925	0.502	rs778150	ENSG00000273302.1	RP11-493E12.2	-8.29	1.21e-15	5.26e-13	-0.31	-0.36	Immature fraction of reticulocytes;	chr2:61381237	chr2:61199979~61200769:+
LGG	cis	rs853679	0.567	rs6905380	ENSG00000280107.1	AL022393.9	-8.29	1.21e-15	5.27e-13	-0.38	-0.36	Depression;	chr6:28407125	chr6:28170845~28172521:+
LGG	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-8.29	1.21e-15	5.27e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
LGG	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	8.29	1.21e-15	5.27e-13	0.31	0.36	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
LGG	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	8.29	1.21e-15	5.27e-13	0.31	0.36	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
LGG	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	8.29	1.21e-15	5.27e-13	0.31	0.36	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
LGG	cis	rs7181230	1	rs9972424	ENSG00000275636.1	RP11-521C20.5	8.29	1.21e-15	5.28e-13	0.38	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:40078892~40079347:+
LGG	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	8.29	1.21e-15	5.28e-13	0.44	0.36	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
LGG	cis	rs7267979	0.714	rs1555329	ENSG00000276952.1	RP5-965G21.6	8.29	1.21e-15	5.28e-13	0.35	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25284915~25285588:-
LGG	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	8.29	1.21e-15	5.29e-13	0.54	0.36	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
LGG	cis	rs812925	0.537	rs2593620	ENSG00000273302.1	RP11-493E12.2	-8.29	1.21e-15	5.29e-13	-0.31	-0.36	Immature fraction of reticulocytes;	chr2:61386126	chr2:61199979~61200769:+
LGG	cis	rs11098499	0.863	rs12508173	ENSG00000250412.1	KLHL2P1	8.29	1.21e-15	5.3e-13	0.41	0.36	Corneal astigmatism;	chr4:119397371	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.908	rs12504149	ENSG00000250412.1	KLHL2P1	8.29	1.21e-15	5.3e-13	0.41	0.36	Corneal astigmatism;	chr4:119397422	chr4:119334329~119378233:+
LGG	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-8.29	1.22e-15	5.31e-13	-0.45	-0.36	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
LGG	cis	rs9816784	0.525	rs555412	ENSG00000231464.1	AC024937.4	8.29	1.22e-15	5.31e-13	0.45	0.36	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195996738~195998233:+
LGG	cis	rs9816784	0.525	rs422772	ENSG00000231464.1	AC024937.4	8.29	1.22e-15	5.31e-13	0.45	0.36	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195996738~195998233:+
LGG	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-8.29	1.22e-15	5.31e-13	-0.47	-0.36	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
LGG	cis	rs9532669	0.963	rs9566607	ENSG00000168852.11	TPTE2P5	-8.29	1.22e-15	5.32e-13	-0.4	-0.36	Cervical cancer;	chr13:40921788	chr13:40822296~40921749:-
LGG	cis	rs56804039	0.895	rs11776995	ENSG00000173295.6	FAM86B3P	8.29	1.22e-15	5.32e-13	0.44	0.36	Cervical cancer;	chr8:8528037	chr8:8228595~8244865:+
LGG	cis	rs7267979	0.714	rs6115107	ENSG00000276952.1	RP5-965G21.6	8.28	1.22e-15	5.34e-13	0.35	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25284915~25285588:-
LGG	cis	rs3764021	0.527	rs2114870	ENSG00000256594.6	RP11-705C15.2	8.28	1.23e-15	5.35e-13	0.36	0.36	Type 1 diabetes;	chr12:9670544	chr12:9633419~9658412:+
LGG	cis	rs227275	0.525	rs2086499	ENSG00000248971.2	KRT8P46	-8.28	1.23e-15	5.36e-13	-0.37	-0.36	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102728746~102730171:-
LGG	cis	rs1707322	1	rs1707317	ENSG00000281133.1	AL355480.3	8.28	1.23e-15	5.37e-13	0.42	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45580892~45580996:-
LGG	cis	rs9987353	0.566	rs34491841	ENSG00000253893.2	FAM85B	8.28	1.24e-15	5.4e-13	0.45	0.36	Recombination measurement;	chr8:9208000	chr8:8167819~8226614:-
LGG	cis	rs453301	0.624	rs2915251	ENSG00000253893.2	FAM85B	-8.28	1.24e-15	5.41e-13	-0.45	-0.36	Joint mobility (Beighton score);	chr8:9009901	chr8:8167819~8226614:-
LGG	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-8.28	1.24e-15	5.42e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
LGG	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-8.28	1.24e-15	5.42e-13	-0.45	-0.36	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
LGG	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-8.28	1.24e-15	5.42e-13	-0.61	-0.36	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
LGG	cis	rs9532669	0.819	rs9532652	ENSG00000168852.11	TPTE2P5	8.28	1.24e-15	5.42e-13	0.4	0.36	Cervical cancer;	chr13:40903300	chr13:40822296~40921749:-
LGG	cis	rs1707322	0.827	rs6694302	ENSG00000281133.1	AL355480.3	-8.28	1.24e-15	5.43e-13	-0.44	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45580892~45580996:-
LGG	cis	rs7241530	0.56	rs35810817	ENSG00000266213.1	RP11-100K18.1	-8.28	1.24e-15	5.43e-13	-0.43	-0.36	Educational attainment (years of education);	chr18:78131249	chr18:78137223~78140887:+
LGG	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	8.28	1.25e-15	5.44e-13	0.44	0.36	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
LGG	cis	rs7474896	0.583	rs1735621	ENSG00000226578.1	RP11-258F22.1	8.28	1.25e-15	5.44e-13	0.47	0.36	Obesity (extreme);	chr10:37878795	chr10:37775371~37784131:-
LGG	cis	rs853679	1	rs7740487	ENSG00000226314.6	ZNF192P1	8.28	1.25e-15	5.44e-13	0.5	0.36	Depression;	chr6:28248708	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.505	rs75122014	ENSG00000250412.1	KLHL2P1	8.28	1.25e-15	5.46e-13	0.41	0.36	Corneal astigmatism;	chr4:119441271	chr4:119334329~119378233:+
LGG	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-8.28	1.25e-15	5.46e-13	-0.45	-0.36	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
LGG	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-8.28	1.26e-15	5.47e-13	-0.28	-0.36	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-8.28	1.26e-15	5.47e-13	-0.28	-0.36	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
LGG	cis	rs11220082	0.666	rs35203305	ENSG00000254671.2	STT3A-AS1	-8.28	1.26e-15	5.48e-13	-0.43	-0.36	Schizophrenia;	chr11:125468987	chr11:125570284~125592568:-
LGG	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	8.28	1.26e-15	5.48e-13	0.39	0.36	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	8.28	1.26e-15	5.48e-13	0.39	0.36	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
LGG	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-8.28	1.26e-15	5.48e-13	-0.45	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
LGG	cis	rs7474896	0.583	rs10764144	ENSG00000226578.1	RP11-258F22.1	-8.28	1.27e-15	5.51e-13	-0.44	-0.36	Obesity (extreme);	chr10:37686804	chr10:37775371~37784131:-
LGG	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-8.28	1.27e-15	5.52e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
LGG	cis	rs2075466	0.51	rs8060738	ENSG00000267077.1	RP11-127I20.5	8.28	1.27e-15	5.52e-13	0.51	0.36	Colonoscopy-negative controls vs population controls;	chr16:4889115	chr16:4795265~4796532:-
LGG	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	8.28	1.27e-15	5.54e-13	0.55	0.36	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
LGG	cis	rs9322193	0.632	rs3828700	ENSG00000216621.7	RP11-244K5.6	8.28	1.27e-15	5.54e-13	0.42	0.36	Lung cancer;	chr6:149791033	chr6:149934527~149936782:+
LGG	cis	rs35160687	0.644	rs36079379	ENSG00000273080.1	RP11-301O19.1	-8.28	1.27e-15	5.54e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86318837	chr2:86195590~86196049:+
LGG	cis	rs35160687	0.644	rs4832276	ENSG00000273080.1	RP11-301O19.1	8.28	1.27e-15	5.54e-13	0.38	0.36	Night sleep phenotypes;	chr2:86317895	chr2:86195590~86196049:+
LGG	cis	rs17772222	0.63	rs12436642	ENSG00000258983.2	RP11-507K2.2	-8.28	1.27e-15	5.54e-13	-0.39	-0.36	Coronary artery calcification;	chr14:88559032	chr14:88499334~88515502:+
LGG	cis	rs4143844	0.867	rs11629559	ENSG00000259251.2	RP11-643M14.1	8.28	1.27e-15	5.55e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61871348	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs17303887	ENSG00000259251.2	RP11-643M14.1	8.28	1.27e-15	5.55e-13	0.61	0.36	Bipolar disorder and schizophrenia;	chr15:61873354	chr15:62060503~62062434:+
LGG	cis	rs1185460	0.967	rs1307145	ENSG00000272186.1	RP11-110I1.13	-8.28	1.28e-15	5.59e-13	-0.35	-0.36	Coronary artery disease;	chr11:119079507	chr11:119067374~119067698:-
LGG	cis	rs9322193	0.923	rs11155683	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149779341	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs9372044	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149780867	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs11155685	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149781649	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9689269	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149791861	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs4816	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149793609	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.926	rs952166	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149798774	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs952165	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149798900	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.926	rs9285525	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149801253	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs6914319	ENSG00000216621.7	RP11-244K5.6	8.28	1.28e-15	5.59e-13	0.42	0.36	Lung cancer;	chr6:149806304	chr6:149934527~149936782:+
LGG	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	8.28	1.29e-15	5.6e-13	0.61	0.36	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
LGG	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	8.28	1.29e-15	5.6e-13	0.54	0.36	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
LGG	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	8.28	1.29e-15	5.6e-13	0.6	0.36	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
LGG	cis	rs4281086	0.804	rs7839763	ENSG00000253678.1	RP11-981G7.3	8.28	1.29e-15	5.61e-13	0.39	0.36	Obesity-related traits;	chr8:10532011	chr8:10477491~10479375:-
LGG	cis	rs9300255	0.699	rs11057204	ENSG00000235423.7	RP11-282O18.3	8.28	1.29e-15	5.62e-13	0.4	0.36	Neutrophil percentage of white cells;	chr12:123241280	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.62	rs7313483	ENSG00000235423.7	RP11-282O18.3	8.28	1.29e-15	5.62e-13	0.4	0.36	Neutrophil percentage of white cells;	chr12:123242287	chr12:123252030~123261483:-
LGG	cis	rs9532669	0.963	rs2324739	ENSG00000239827.7	SUGT1P3	-8.28	1.29e-15	5.62e-13	-0.38	-0.36	Cervical cancer;	chr13:40925479	chr13:40908159~40921774:-
LGG	cis	rs11148252	0.574	rs61958118	ENSG00000198384.8	TPTE2P3	-8.28	1.29e-15	5.63e-13	-0.32	-0.36	Lewy body disease;	chr13:52596091	chr13:52522632~52586906:+
LGG	cis	rs1949733	0.958	rs3103069	ENSG00000205959.3	RP11-689P11.2	8.28	1.29e-15	5.63e-13	0.33	0.36	Response to antineoplastic agents;	chr4:8507724	chr4:8482270~8512610:+
LGG	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	8.28	1.3e-15	5.64e-13	0.44	0.36	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
LGG	cis	rs128738	0.505	rs13190293	ENSG00000233006.5	AC034220.3	-8.28	1.3e-15	5.64e-13	-0.43	-0.36	Giant cell arteritis;	chr5:132231233	chr5:132311285~132369916:-
LGG	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-8.28	1.3e-15	5.65e-13	-0.47	-0.36	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
LGG	cis	rs66887589	0.592	rs11731571	ENSG00000249244.1	RP11-548H18.2	8.28	1.3e-15	5.66e-13	0.36	0.36	Diastolic blood pressure;	chr4:119300030	chr4:119391831~119395335:-
LGG	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-8.28	1.3e-15	5.66e-13	-0.48	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
LGG	cis	rs7927771	0.524	rs7942074	ENSG00000280615.1	Y_RNA	8.28	1.31e-15	5.68e-13	0.42	0.36	Subjective well-being;	chr11:47698957	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs12785949	ENSG00000280615.1	Y_RNA	8.28	1.31e-15	5.68e-13	0.42	0.36	Subjective well-being;	chr11:47708218	chr11:47614898~47614994:-
LGG	cis	rs9322193	0.884	rs1125	ENSG00000216621.7	RP11-244K5.6	8.28	1.31e-15	5.68e-13	0.47	0.36	Lung cancer;	chr6:149658280	chr6:149934527~149936782:+
LGG	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-8.28	1.31e-15	5.68e-13	-0.38	-0.36	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
LGG	cis	rs1707322	0.964	rs1768802	ENSG00000281133.1	AL355480.3	8.28	1.31e-15	5.7e-13	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs1588663	ENSG00000281133.1	AL355480.3	8.28	1.31e-15	5.7e-13	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs1768801	ENSG00000281133.1	AL355480.3	8.28	1.31e-15	5.7e-13	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs1768800	ENSG00000281133.1	AL355480.3	8.28	1.31e-15	5.7e-13	0.44	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45580892~45580996:-
LGG	cis	rs11098499	0.908	rs2017057	ENSG00000250412.1	KLHL2P1	8.28	1.31e-15	5.7e-13	0.41	0.36	Corneal astigmatism;	chr4:119336556	chr4:119334329~119378233:+
LGG	cis	rs71403859	0.502	rs8053720	ENSG00000260886.1	TAT-AS1	8.28	1.31e-15	5.71e-13	0.66	0.36	Post bronchodilator FEV1;	chr16:71422239	chr16:71565789~71578187:+
LGG	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	8.27	1.32e-15	5.73e-13	0.53	0.36	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
LGG	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-8.27	1.32e-15	5.73e-13	-0.48	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-8.27	1.32e-15	5.73e-13	-0.48	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
LGG	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-8.27	1.32e-15	5.76e-13	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
LGG	cis	rs67340775	0.541	rs200968	ENSG00000226314.6	ZNF192P1	8.27	1.33e-15	5.77e-13	0.49	0.36	Lung cancer in ever smokers;	chr6:27891790	chr6:28161781~28169594:+
LGG	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	8.27	1.33e-15	5.78e-13	0.36	0.36	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
LGG	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-8.27	1.33e-15	5.78e-13	-0.47	-0.36	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
LGG	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	8.27	1.33e-15	5.78e-13	0.45	0.36	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
LGG	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	8.27	1.34e-15	5.82e-13	0.47	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	8.27	1.34e-15	5.82e-13	0.47	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	8.27	1.34e-15	5.82e-13	0.47	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
LGG	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	8.27	1.34e-15	5.82e-13	0.38	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
LGG	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-8.27	1.34e-15	5.83e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-8.27	1.34e-15	5.83e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-8.27	1.34e-15	5.83e-13	-0.47	-0.36	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
LGG	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-8.27	1.34e-15	5.84e-13	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
LGG	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-8.27	1.35e-15	5.86e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
LGG	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	8.27	1.35e-15	5.86e-13	0.43	0.36	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.886	rs9718079	ENSG00000216621.7	RP11-244K5.6	8.27	1.35e-15	5.86e-13	0.43	0.36	Lung cancer;	chr6:149645947	chr6:149934527~149936782:+
LGG	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-8.27	1.35e-15	5.87e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
LGG	cis	rs1560104	0.536	rs12446050	ENSG00000274834.1	CTD-3037G24.5	-8.27	1.35e-15	5.87e-13	-0.44	-0.36	Obesity-related traits;	chr16:12621408	chr16:12614451~12614852:+
LGG	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-8.27	1.35e-15	5.88e-13	-0.47	-0.36	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
LGG	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	8.27	1.35e-15	5.88e-13	0.69	0.36	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
LGG	cis	rs1275468	1	rs1679381	ENSG00000257497.2	RP11-585P4.5	-8.27	1.36e-15	5.89e-13	-0.46	-0.36	Polycystic ovary syndrome;	chr12:75552344	chr12:75483454~75489820:-
LGG	cis	rs763567	0.9	rs525489	ENSG00000271811.1	RP1-79C4.4	8.27	1.36e-15	5.89e-13	0.35	0.36	Tonsillectomy;	chr1:170665861	chr1:170667381~170669425:+
LGG	cis	rs763567	0.835	rs503706	ENSG00000271811.1	RP1-79C4.4	8.27	1.36e-15	5.89e-13	0.35	0.36	Tonsillectomy;	chr1:170665943	chr1:170667381~170669425:+
LGG	cis	rs35160687	0.644	rs4832036	ENSG00000273080.1	RP11-301O19.1	-8.27	1.36e-15	5.9e-13	-0.38	-0.36	Night sleep phenotypes;	chr2:86324179	chr2:86195590~86196049:+
LGG	cis	rs2638953	0.924	rs11049416	ENSG00000278733.1	RP11-425D17.1	8.27	1.36e-15	5.9e-13	0.44	0.36	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28185625~28186190:-
LGG	cis	rs9322193	0.962	rs3805753	ENSG00000216621.7	RP11-244K5.6	8.27	1.36e-15	5.91e-13	0.42	0.36	Lung cancer;	chr6:149795662	chr6:149934527~149936782:+
LGG	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	8.27	1.37e-15	5.93e-13	0.61	0.36	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
LGG	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	8.27	1.37e-15	5.95e-13	0.49	0.36	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
LGG	cis	rs11098499	0.954	rs6822679	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119481547	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs4577559	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119482888	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs7656252	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119483113	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.865	rs28845498	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119484031	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.865	rs28753180	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119484212	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs56270433	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119484875	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs7681544	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119490100	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs11940028	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119490752	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs11935596	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119491302	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs12507964	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119491906	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs11098530	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119491999	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs6834796	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119493538	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs11734241	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119495717	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs28685688	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119499179	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs7687843	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119500056	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs2306455	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119500814	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs10031483	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119501481	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs10031665	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119501697	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs3733523	ENSG00000250412.1	KLHL2P1	8.27	1.37e-15	5.95e-13	0.41	0.36	Corneal astigmatism;	chr4:119502564	chr4:119334329~119378233:+
LGG	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-8.27	1.37e-15	5.95e-13	-0.42	-0.36	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
LGG	cis	rs657075	0.595	rs57750646	ENSG00000263597.1	MIR3936	-8.27	1.37e-15	5.96e-13	-0.59	-0.36	Rheumatoid arthritis;	chr5:132344571	chr5:132365490~132365599:-
LGG	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-8.27	1.37e-15	5.97e-13	-0.37	-0.36	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
LGG	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-8.27	1.38e-15	5.98e-13	-0.45	-0.36	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
LGG	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	8.27	1.39e-15	6.02e-13	0.44	0.36	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
LGG	cis	rs9532669	0.889	rs6560964	ENSG00000239827.7	SUGT1P3	-8.27	1.39e-15	6.02e-13	-0.37	-0.36	Cervical cancer;	chr13:40871132	chr13:40908159~40921774:-
LGG	cis	rs997295	0.535	rs11632776	ENSG00000270964.1	RP11-502I4.3	-8.27	1.39e-15	6.04e-13	-0.37	-0.35	Motion sickness;	chr15:67560307	chr15:67541072~67542604:-
LGG	cis	rs5742933	0.69	rs62183657	ENSG00000253559.1	OSGEPL1-AS1	-8.27	1.39e-15	6.04e-13	-0.49	-0.35	Ferritin levels;	chr2:189669448	chr2:189762704~189765556:+
LGG	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-8.27	1.4e-15	6.06e-13	-0.47	-0.35	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-8.27	1.4e-15	6.06e-13	-0.5	-0.35	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
LGG	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-8.27	1.4e-15	6.08e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
LGG	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-8.27	1.4e-15	6.08e-13	-0.42	-0.35	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
LGG	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	8.27	1.4e-15	6.08e-13	0.54	0.35	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
LGG	cis	rs7005380	0.62	rs13282901	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119881561	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs13260088	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119886525	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs10955940	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119890246	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10103058	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119890830	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs13257316	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119891494	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.58	rs12681623	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119891616	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10107251	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119892108	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10094458	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119892448	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10094587	ENSG00000245330.4	KB-1471A8.1	8.27	1.4e-15	6.08e-13	0.4	0.35	Interstitial lung disease;	chr8:119892560	chr8:119867419~119874488:-
LGG	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-8.27	1.4e-15	6.09e-13	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-8.27	1.4e-15	6.09e-13	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-8.27	1.4e-15	6.09e-13	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-8.27	1.4e-15	6.09e-13	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
LGG	cis	rs454217	0.846	rs1948656	ENSG00000277851.1	RP11-756G20.1	8.27	1.4e-15	6.09e-13	0.36	0.35	Smoking quantity;	chr12:92337508	chr12:92247756~92363832:-
LGG	cis	rs7219021	0.55	rs35929648	ENSG00000248278.1	SUMO2P17	8.27	1.41e-15	6.1e-13	0.42	0.35	Schizophrenia or bipolar disorder;	chr17:48925181	chr17:48874860~48908983:-
LGG	cis	rs9346353	0.966	rs9342777	ENSG00000219881.1	GAPDHP42	8.27	1.41e-15	6.11e-13	0.34	0.35	Sleep duration;	chr6:69803267	chr6:69745871~69746851:+
LGG	cis	rs7005380	0.62	rs13265367	ENSG00000245330.4	KB-1471A8.1	8.27	1.41e-15	6.11e-13	0.4	0.35	Interstitial lung disease;	chr8:119891769	chr8:119867419~119874488:-
LGG	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-8.27	1.41e-15	6.12e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-8.27	1.41e-15	6.12e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
LGG	cis	rs7309	0.622	rs4664395	ENSG00000227403.1	AC009299.3	-8.27	1.41e-15	6.12e-13	-0.47	-0.35	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161044790	chr2:161244739~161249050:+
LGG	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-8.26	1.41e-15	6.13e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-8.26	1.41e-15	6.13e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
LGG	cis	rs11098499	0.863	rs7699064	ENSG00000250412.1	KLHL2P1	-8.26	1.42e-15	6.14e-13	-0.41	-0.35	Corneal astigmatism;	chr4:119507154	chr4:119334329~119378233:+
LGG	cis	rs1707322	0.963	rs12145287	ENSG00000281133.1	AL355480.3	-8.26	1.42e-15	6.14e-13	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45580892~45580996:-
LGG	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-8.26	1.42e-15	6.14e-13	-0.26	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
LGG	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-8.26	1.42e-15	6.14e-13	-0.26	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
LGG	cis	rs35857674	0.5	rs203960	ENSG00000253484.1	RP11-109P6.2	-8.26	1.42e-15	6.15e-13	-0.35	-0.35	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50052015	chr8:49817586~49820944:-
LGG	cis	rs7119038	0.818	rs6421571	ENSG00000255239.1	AP002954.6	8.26	1.42e-15	6.15e-13	0.51	0.35	Sjögren's syndrome;	chr11:118873063	chr11:118688039~118690600:-
LGG	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-8.26	1.42e-15	6.15e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-8.26	1.42e-15	6.15e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-8.26	1.42e-15	6.15e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-8.26	1.42e-15	6.15e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-8.26	1.42e-15	6.15e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-8.26	1.42e-15	6.15e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-8.26	1.42e-15	6.15e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
LGG	cis	rs4143844	0.867	rs34589937	ENSG00000259251.2	RP11-643M14.1	8.26	1.42e-15	6.15e-13	0.61	0.35	Bipolar disorder and schizophrenia;	chr15:61876196	chr15:62060503~62062434:+
LGG	cis	rs7241530	0.585	rs35772443	ENSG00000266213.1	RP11-100K18.1	-8.26	1.42e-15	6.15e-13	-0.42	-0.35	Educational attainment (years of education);	chr18:78131302	chr18:78137223~78140887:+
LGG	cis	rs9393777	0.72	rs56401801	ENSG00000199851.2	U3	8.26	1.43e-15	6.2e-13	0.9	0.35	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28015568~28015777:+
LGG	cis	rs11098499	0.954	rs28572238	ENSG00000250412.1	KLHL2P1	8.26	1.44e-15	6.22e-13	0.41	0.35	Corneal astigmatism;	chr4:119395531	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs28714195	ENSG00000250412.1	KLHL2P1	8.26	1.44e-15	6.22e-13	0.41	0.35	Corneal astigmatism;	chr4:119395795	chr4:119334329~119378233:+
LGG	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	8.26	1.44e-15	6.22e-13	0.36	0.35	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
LGG	cis	rs1555322	0.53	rs2425049	ENSG00000269202.1	RP4-614O4.12	-8.26	1.44e-15	6.22e-13	-0.38	-0.35	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35201747~35203288:-
LGG	cis	rs741668	0.929	rs9595404	ENSG00000235903.6	CPB2-AS1	8.26	1.44e-15	6.23e-13	0.39	0.35	Cerebrospinal fluid clusterin levels;	chr13:45940621	chr13:46052806~46113332:+
LGG	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	8.26	1.44e-15	6.23e-13	0.4	0.35	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
LGG	cis	rs11148252	0.774	rs9596649	ENSG00000235660.1	LINC00345	8.26	1.45e-15	6.26e-13	0.44	0.35	Lewy body disease;	chr13:52360475	chr13:52484161~52484680:-
LGG	cis	rs62184315	0.58	rs62185872	ENSG00000253559.1	OSGEPL1-AS1	-8.26	1.45e-15	6.26e-13	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189690033	chr2:189762704~189765556:+
LGG	cis	rs812925	0.502	rs2053750	ENSG00000273302.1	RP11-493E12.2	-8.26	1.45e-15	6.27e-13	-0.31	-0.35	Immature fraction of reticulocytes;	chr2:61429138	chr2:61199979~61200769:+
LGG	cis	rs9346353	0.932	rs9354892	ENSG00000219881.1	GAPDHP42	8.26	1.45e-15	6.27e-13	0.34	0.35	Sleep duration;	chr6:69801890	chr6:69745871~69746851:+
LGG	cis	rs35934224	0.891	rs13054713	ENSG00000232926.1	AC000078.5	8.26	1.45e-15	6.27e-13	0.41	0.35	Glaucoma (primary open-angle);	chr22:19880391	chr22:19887289~19887970:+
LGG	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-8.26	1.45e-15	6.27e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
LGG	cis	rs375066	0.935	rs406968	ENSG00000267191.1	RP11-15A1.2	-8.26	1.45e-15	6.28e-13	-0.37	-0.35	Breast cancer;	chr19:43914191	chr19:43902001~43926545:+
LGG	cis	rs853679	0.567	rs13196606	ENSG00000280107.1	AL022393.9	-8.26	1.45e-15	6.28e-13	-0.38	-0.35	Depression;	chr6:28402301	chr6:28170845~28172521:+
LGG	cis	rs35934224	0.783	rs16984299	ENSG00000232926.1	AC000078.5	-8.26	1.45e-15	6.28e-13	-0.38	-0.35	Glaucoma (primary open-angle);	chr22:19876070	chr22:19887289~19887970:+
LGG	cis	rs227275	0.525	rs4623004	ENSG00000248971.2	KRT8P46	-8.26	1.45e-15	6.28e-13	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102728746~102730171:-
LGG	cis	rs145729347	1	rs145729347	ENSG00000255250.1	CTD-2005H7.2	8.26	1.45e-15	6.29e-13	0.49	0.35	Lung function (FEV1);	chr11:86731691	chr11:86727355~86765265:+
LGG	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-8.26	1.46e-15	6.31e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-8.26	1.46e-15	6.31e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-8.26	1.46e-15	6.31e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-8.26	1.46e-15	6.31e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-8.26	1.46e-15	6.31e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-8.26	1.46e-15	6.31e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-8.26	1.46e-15	6.31e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
LGG	cis	rs375066	0.935	rs388706	ENSG00000267191.1	RP11-15A1.2	-8.26	1.46e-15	6.32e-13	-0.37	-0.35	Breast cancer;	chr19:43914541	chr19:43902001~43926545:+
LGG	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	8.26	1.46e-15	6.33e-13	0.24	0.35	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
LGG	cis	rs9987353	0.589	rs1053036	ENSG00000253893.2	FAM85B	8.26	1.46e-15	6.33e-13	0.44	0.35	Recombination measurement;	chr8:9202567	chr8:8167819~8226614:-
LGG	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-8.26	1.46e-15	6.34e-13	-0.36	-0.35	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
LGG	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-8.26	1.47e-15	6.36e-13	-0.48	-0.35	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
LGG	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-8.26	1.47e-15	6.36e-13	-0.48	-0.35	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
LGG	cis	rs848490	0.656	rs55714086	ENSG00000214293.7	APTR	8.26	1.47e-15	6.36e-13	0.35	0.35	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77807168	chr7:77657660~77696265:-
LGG	cis	rs1707322	1	rs12097761	ENSG00000281133.1	AL355480.3	-8.26	1.47e-15	6.36e-13	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45580892~45580996:-
LGG	cis	rs2638953	0.924	rs12320545	ENSG00000278733.1	RP11-425D17.1	8.26	1.47e-15	6.38e-13	0.44	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28248047	chr12:28185625~28186190:-
LGG	cis	rs12893668	0.543	rs1799796	ENSG00000269940.1	RP11-73M18.7	8.26	1.47e-15	6.38e-13	0.41	0.35	Reticulocyte count;	chr14:103699590	chr14:103694560~103695170:+
LGG	cis	rs12893668	0.514	rs3212090	ENSG00000269940.1	RP11-73M18.7	8.26	1.47e-15	6.38e-13	0.41	0.35	Reticulocyte count;	chr14:103702526	chr14:103694560~103695170:+
LGG	cis	rs2933343	0.553	rs789212	ENSG00000231305.3	RP11-723O4.2	8.26	1.48e-15	6.41e-13	0.36	0.35	IgG glycosylation;	chr3:128968069	chr3:128861313~128871540:-
LGG	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-8.26	1.48e-15	6.42e-13	-0.44	-0.35	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
LGG	cis	rs6997458	0.742	rs10111039	ENSG00000253549.4	RP11-317J10.2	8.26	1.48e-15	6.42e-13	0.28	0.35	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85484427	chr8:85441851~85464915:-
LGG	cis	rs910316	0.763	rs175016	ENSG00000279594.1	RP11-950C14.10	-8.26	1.48e-15	6.42e-13	-0.45	-0.35	Height;	chr14:74992930	chr14:75011269~75012851:-
LGG	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-8.26	1.48e-15	6.43e-13	-0.42	-0.35	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
LGG	cis	rs56114371	0.53	rs2056923	ENSG00000216901.1	AL022393.7	8.26	1.49e-15	6.43e-13	0.54	0.35	Breast cancer;	chr6:27722160	chr6:28176188~28176674:+
LGG	cis	rs17772222	0.63	rs4904454	ENSG00000258983.2	RP11-507K2.2	-8.26	1.49e-15	6.45e-13	-0.4	-0.35	Coronary artery calcification;	chr14:88537777	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.63	rs2033418	ENSG00000258983.2	RP11-507K2.2	-8.26	1.49e-15	6.45e-13	-0.4	-0.35	Coronary artery calcification;	chr14:88539331	chr14:88499334~88515502:+
LGG	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-8.26	1.49e-15	6.46e-13	-0.38	-0.35	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
LGG	cis	rs7267979	0.586	rs6050445	ENSG00000125804.12	FAM182A	-8.26	1.5e-15	6.5e-13	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:26054655~26086917:+
LGG	cis	rs7241530	0.56	rs12959612	ENSG00000266213.1	RP11-100K18.1	-8.26	1.51e-15	6.51e-13	-0.42	-0.35	Educational attainment (years of education);	chr18:78134165	chr18:78137223~78140887:+
LGG	cis	rs35934224	0.831	rs13057374	ENSG00000232926.1	AC000078.5	8.26	1.51e-15	6.52e-13	0.39	0.35	Glaucoma (primary open-angle);	chr22:19883574	chr22:19887289~19887970:+
LGG	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-8.26	1.51e-15	6.54e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-8.26	1.51e-15	6.54e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
LGG	cis	rs375066	0.868	rs378112	ENSG00000267191.1	RP11-15A1.2	-8.26	1.51e-15	6.54e-13	-0.37	-0.35	Breast cancer;	chr19:43917777	chr19:43902001~43926545:+
LGG	cis	rs375066	0.868	rs378109	ENSG00000267191.1	RP11-15A1.2	-8.26	1.51e-15	6.54e-13	-0.37	-0.35	Breast cancer;	chr19:43917785	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs450308	ENSG00000267191.1	RP11-15A1.2	-8.26	1.51e-15	6.54e-13	-0.37	-0.35	Breast cancer;	chr19:43918206	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs424729	ENSG00000267191.1	RP11-15A1.2	-8.26	1.51e-15	6.54e-13	-0.37	-0.35	Breast cancer;	chr19:43918650	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs423320	ENSG00000267191.1	RP11-15A1.2	-8.26	1.51e-15	6.54e-13	-0.37	-0.35	Breast cancer;	chr19:43918830	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs423752	ENSG00000267191.1	RP11-15A1.2	-8.26	1.51e-15	6.54e-13	-0.37	-0.35	Breast cancer;	chr19:43919043	chr19:43902001~43926545:+
LGG	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-8.26	1.51e-15	6.55e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
LGG	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-8.26	1.51e-15	6.55e-13	-0.44	-0.35	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
LGG	cis	rs10946940	0.897	rs6456801	ENSG00000199851.2	U3	8.26	1.52e-15	6.56e-13	0.47	0.35	Systemic lupus erythematosus;	chr6:27657753	chr6:28015568~28015777:+
LGG	cis	rs11148252	0.846	rs7333451	ENSG00000235660.1	LINC00345	-8.26	1.52e-15	6.56e-13	-0.43	-0.35	Lewy body disease;	chr13:52473574	chr13:52484161~52484680:-
LGG	cis	rs7829975	0.535	rs4841005	ENSG00000173295.6	FAM86B3P	8.26	1.52e-15	6.57e-13	0.37	0.35	Mood instability;	chr8:8643720	chr8:8228595~8244865:+
LGG	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-8.26	1.52e-15	6.57e-13	-0.42	-0.35	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
LGG	cis	rs9322193	0.962	rs9397022	ENSG00000216621.7	RP11-244K5.6	8.26	1.52e-15	6.57e-13	0.42	0.35	Lung cancer;	chr6:149812052	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9397357	ENSG00000216621.7	RP11-244K5.6	8.26	1.52e-15	6.57e-13	0.42	0.35	Lung cancer;	chr6:149812465	chr6:149934527~149936782:+
LGG	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	8.25	1.52e-15	6.58e-13	0.35	0.35	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
LGG	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	8.25	1.53e-15	6.61e-13	0.46	0.35	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
LGG	cis	rs9322193	0.886	rs4039600	ENSG00000216621.7	RP11-244K5.6	8.25	1.53e-15	6.62e-13	0.43	0.35	Lung cancer;	chr6:149576319	chr6:149934527~149936782:+
LGG	cis	rs7241530	0.585	rs35569163	ENSG00000266213.1	RP11-100K18.1	-8.25	1.53e-15	6.62e-13	-0.42	-0.35	Educational attainment (years of education);	chr18:78130441	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.536	rs34361461	ENSG00000266213.1	RP11-100K18.1	-8.25	1.53e-15	6.62e-13	-0.42	-0.35	Educational attainment (years of education);	chr18:78130482	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.585	rs12970672	ENSG00000266213.1	RP11-100K18.1	-8.25	1.53e-15	6.62e-13	-0.42	-0.35	Educational attainment (years of education);	chr18:78130525	chr18:78137223~78140887:+
LGG	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	8.25	1.53e-15	6.62e-13	0.48	0.35	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
LGG	cis	rs6921919	0.697	rs12180820	ENSG00000226314.6	ZNF192P1	-8.25	1.53e-15	6.63e-13	-0.37	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28161781~28169594:+
LGG	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-8.25	1.54e-15	6.65e-13	-0.41	-0.35	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
LGG	cis	rs375066	0.967	rs436249	ENSG00000267191.1	RP11-15A1.2	-8.25	1.54e-15	6.65e-13	-0.37	-0.35	Breast cancer;	chr19:43895413	chr19:43902001~43926545:+
LGG	cis	rs7005380	0.62	rs13249122	ENSG00000245330.4	KB-1471A8.1	8.25	1.55e-15	6.69e-13	0.4	0.35	Interstitial lung disease;	chr8:119893679	chr8:119867419~119874488:-
LGG	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-8.25	1.55e-15	6.7e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
LGG	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-8.25	1.56e-15	6.73e-13	-0.46	-0.35	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
LGG	cis	rs11098499	0.954	rs17006190	ENSG00000250412.1	KLHL2P1	8.25	1.56e-15	6.74e-13	0.41	0.35	Corneal astigmatism;	chr4:119497683	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs3733519	ENSG00000250412.1	KLHL2P1	8.25	1.56e-15	6.74e-13	0.41	0.35	Corneal astigmatism;	chr4:119502293	chr4:119334329~119378233:+
LGG	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	8.25	1.56e-15	6.74e-13	0.61	0.35	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
LGG	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	8.25	1.56e-15	6.74e-13	0.61	0.35	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
LGG	cis	rs7927771	0.725	rs11570094	ENSG00000280615.1	Y_RNA	8.25	1.56e-15	6.76e-13	0.45	0.35	Subjective well-being;	chr11:47338155	chr11:47614898~47614994:-
LGG	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-8.25	1.56e-15	6.76e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
LGG	cis	rs7267979	0.714	rs3787082	ENSG00000276952.1	RP5-965G21.6	8.25	1.57e-15	6.76e-13	0.35	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25284915~25285588:-
LGG	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	8.25	1.57e-15	6.77e-13	0.31	0.35	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
LGG	cis	rs1560104	0.576	rs7202727	ENSG00000274834.1	CTD-3037G24.5	8.25	1.57e-15	6.78e-13	0.44	0.35	Obesity-related traits;	chr16:12614087	chr16:12614451~12614852:+
LGG	cis	rs853679	1	rs68141011	ENSG00000226314.6	ZNF192P1	8.25	1.57e-15	6.79e-13	0.49	0.35	Depression;	chr6:28250019	chr6:28161781~28169594:+
LGG	cis	rs853679	1	rs13200462	ENSG00000226314.6	ZNF192P1	8.25	1.57e-15	6.79e-13	0.49	0.35	Depression;	chr6:28250421	chr6:28161781~28169594:+
LGG	cis	rs11971779	0.68	rs4732379	ENSG00000273391.1	RP11-634H22.1	8.25	1.57e-15	6.79e-13	0.37	0.35	Diisocyanate-induced asthma;	chr7:139438068	chr7:139359032~139359566:-
LGG	cis	rs6061231	0.505	rs13037253	ENSG00000273619.1	RP5-908M14.9	-8.25	1.58e-15	6.8e-13	-0.29	-0.35	Colorectal cancer;	chr20:62353668	chr20:62386303~62386970:-
LGG	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-8.25	1.58e-15	6.81e-13	-0.47	-0.35	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
LGG	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-8.25	1.58e-15	6.81e-13	-0.47	-0.35	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
LGG	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-8.25	1.58e-15	6.81e-13	-0.47	-0.35	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
LGG	cis	rs10973956	0.706	rs13294677	ENSG00000273036.2	FAM95C	-8.25	1.58e-15	6.81e-13	-0.38	-0.35	Tourette's syndrome or obsessive-compulsive disorder;	chr9:38643132	chr9:38540567~38545372:-
LGG	cis	rs11098499	0.863	rs10013305	ENSG00000250412.1	KLHL2P1	8.25	1.58e-15	6.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119529269	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs3775849	ENSG00000250412.1	KLHL2P1	8.25	1.58e-15	6.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119529753	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.818	rs7688802	ENSG00000250412.1	KLHL2P1	8.25	1.58e-15	6.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119530513	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs7695620	ENSG00000250412.1	KLHL2P1	8.25	1.58e-15	6.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119531621	chr4:119334329~119378233:+
LGG	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	8.25	1.58e-15	6.82e-13	0.55	0.35	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
LGG	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-8.25	1.58e-15	6.83e-13	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
LGG	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	8.25	1.58e-15	6.84e-13	0.48	0.35	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
LGG	cis	rs11148252	0.774	rs9536066	ENSG00000235660.1	LINC00345	-8.25	1.59e-15	6.85e-13	-0.43	-0.35	Lewy body disease;	chr13:52409846	chr13:52484161~52484680:-
LGG	cis	rs9322193	0.923	rs9322197	ENSG00000216621.7	RP11-244K5.6	8.25	1.59e-15	6.85e-13	0.42	0.35	Lung cancer;	chr6:149622577	chr6:149934527~149936782:+
LGG	cis	rs848490	0.674	rs6971555	ENSG00000214293.7	APTR	8.25	1.59e-15	6.86e-13	0.35	0.35	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777422	chr7:77657660~77696265:-
LGG	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-8.25	1.6e-15	6.89e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-8.25	1.6e-15	6.89e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
LGG	cis	rs35934224	0.891	rs33997573	ENSG00000232926.1	AC000078.5	8.25	1.6e-15	6.91e-13	0.41	0.35	Glaucoma (primary open-angle);	chr22:19881428	chr22:19887289~19887970:+
LGG	cis	rs812925	0.519	rs10199672	ENSG00000273302.1	RP11-493E12.2	-8.25	1.6e-15	6.92e-13	-0.31	-0.35	Immature fraction of reticulocytes;	chr2:61400499	chr2:61199979~61200769:+
LGG	cis	rs1707322	0.963	rs10789478	ENSG00000281133.1	AL355480.3	-8.25	1.61e-15	6.93e-13	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45580892~45580996:-
LGG	cis	rs997295	0.592	rs8026627	ENSG00000270964.1	RP11-502I4.3	8.25	1.61e-15	6.94e-13	0.36	0.35	Motion sickness;	chr15:67477968	chr15:67541072~67542604:-
LGG	cis	rs34864796	0.547	rs200476	ENSG00000216901.1	AL022393.7	8.25	1.61e-15	6.94e-13	0.5	0.35	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28176188~28176674:+
LGG	cis	rs56114371	0.53	rs169262	ENSG00000216901.1	AL022393.7	8.25	1.61e-15	6.94e-13	0.5	0.35	Breast cancer;	chr6:27803112	chr6:28176188~28176674:+
LGG	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-8.25	1.61e-15	6.94e-13	-0.37	-0.35	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
LGG	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-8.25	1.61e-15	6.94e-13	-0.46	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
LGG	cis	rs1707322	0.638	rs1416706	ENSG00000280836.1	AL355480.1	8.25	1.61e-15	6.95e-13	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45581219~45581321:-
LGG	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	8.25	1.61e-15	6.95e-13	0.45	0.35	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
LGG	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	8.25	1.61e-15	6.95e-13	0.45	0.35	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
LGG	cis	rs11098499	0.954	rs878373	ENSG00000250412.1	KLHL2P1	8.25	1.61e-15	6.96e-13	0.41	0.35	Corneal astigmatism;	chr4:119316329	chr4:119334329~119378233:+
LGG	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-8.25	1.61e-15	6.96e-13	-0.45	-0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
LGG	cis	rs6997458	0.785	rs1389247	ENSG00000253549.4	RP11-317J10.2	8.25	1.62e-15	6.97e-13	0.29	0.35	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85410354	chr8:85441851~85464915:-
LGG	cis	rs7005380	0.62	rs6987580	ENSG00000245330.4	KB-1471A8.1	-8.25	1.62e-15	6.97e-13	-0.4	-0.35	Interstitial lung disease;	chr8:119898140	chr8:119867419~119874488:-
LGG	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-8.25	1.62e-15	6.98e-13	-0.43	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
LGG	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	8.25	1.62e-15	6.99e-13	0.4	0.35	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	8.25	1.62e-15	6.99e-13	0.4	0.35	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	8.25	1.62e-15	6.99e-13	0.4	0.35	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	8.25	1.62e-15	6.99e-13	0.4	0.35	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	8.25	1.62e-15	6.99e-13	0.4	0.35	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	8.25	1.62e-15	6.99e-13	0.4	0.35	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	8.25	1.62e-15	6.99e-13	0.4	0.35	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
LGG	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	8.25	1.62e-15	7e-13	0.42	0.35	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
LGG	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	8.25	1.63e-15	7.02e-13	0.48	0.35	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
LGG	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	8.25	1.63e-15	7.02e-13	0.48	0.35	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
LGG	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	8.25	1.63e-15	7.02e-13	0.73	0.35	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	8.25	1.63e-15	7.02e-13	0.73	0.35	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	8.25	1.63e-15	7.02e-13	0.73	0.35	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
LGG	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	8.25	1.63e-15	7.04e-13	0.44	0.35	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
LGG	cis	rs35934224	0.783	rs5993849	ENSG00000232926.1	AC000078.5	8.25	1.63e-15	7.04e-13	0.39	0.35	Glaucoma (primary open-angle);	chr22:19878671	chr22:19887289~19887970:+
LGG	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-8.25	1.63e-15	7.04e-13	-0.45	-0.35	Height;	chr14:74997592	chr14:75011269~75012851:-
LGG	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-8.25	1.63e-15	7.04e-13	-0.45	-0.35	Height;	chr14:74998335	chr14:75011269~75012851:-
LGG	cis	rs910316	0.763	rs175047	ENSG00000279594.1	RP11-950C14.10	-8.25	1.63e-15	7.05e-13	-0.45	-0.35	Height;	chr14:75012336	chr14:75011269~75012851:-
LGG	cis	rs35934224	0.843	rs1139795	ENSG00000232926.1	AC000078.5	8.25	1.63e-15	7.05e-13	0.39	0.35	Glaucoma (primary open-angle);	chr22:19880248	chr22:19887289~19887970:+
LGG	cis	rs17345786	0.906	rs56171035	ENSG00000256628.3	ZBTB11-AS1	8.24	1.64e-15	7.06e-13	0.45	0.35	Colonoscopy-negative controls vs population controls;	chr3:101392264	chr3:101676475~101679217:+
LGG	cis	rs2832077	0.527	rs11088095	ENSG00000232855.5	AF131217.1	8.24	1.65e-15	7.11e-13	0.41	0.35	Cognitive test performance;	chr21:28850866	chr21:28439346~28674848:-
LGG	cis	rs2832077	0.527	rs2142375	ENSG00000232855.5	AF131217.1	8.24	1.65e-15	7.11e-13	0.41	0.35	Cognitive test performance;	chr21:28851420	chr21:28439346~28674848:-
LGG	cis	rs2832077	0.527	rs9980449	ENSG00000232855.5	AF131217.1	8.24	1.65e-15	7.11e-13	0.41	0.35	Cognitive test performance;	chr21:28852567	chr21:28439346~28674848:-
LGG	cis	rs2832077	0.527	rs59730679	ENSG00000232855.5	AF131217.1	8.24	1.65e-15	7.11e-13	0.41	0.35	Cognitive test performance;	chr21:28853922	chr21:28439346~28674848:-
LGG	cis	rs2832077	0.527	rs2832116	ENSG00000232855.5	AF131217.1	8.24	1.65e-15	7.11e-13	0.41	0.35	Cognitive test performance;	chr21:28856046	chr21:28439346~28674848:-
LGG	cis	rs9376098	0.79	rs6903653	ENSG00000232876.1	CTA-212D2.2	-8.24	1.65e-15	7.11e-13	-0.42	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135171396	chr6:135055033~135060550:+
LGG	cis	rs11671005	0.504	rs3794963	ENSG00000269600.1	AC016629.3	8.24	1.66e-15	7.14e-13	0.46	0.35	Mean platelet volume;	chr19:58559684	chr19:58593896~58599355:-
LGG	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	8.24	1.66e-15	7.15e-13	0.37	0.35	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	8.24	1.66e-15	7.15e-13	0.38	0.35	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
LGG	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-8.24	1.66e-15	7.15e-13	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
LGG	cis	rs944990	0.538	rs10115234	ENSG00000227603.1	RP11-165J3.6	-8.24	1.66e-15	7.16e-13	-0.35	-0.35	Body mass index;	chr9:93538990	chr9:93435332~93437121:-
LGG	cis	rs7474896	0.537	rs1208683	ENSG00000226578.1	RP11-258F22.1	8.24	1.67e-15	7.17e-13	0.47	0.35	Obesity (extreme);	chr10:37804795	chr10:37775371~37784131:-
LGG	cis	rs1707322	1	rs785510	ENSG00000281133.1	AL355480.3	8.24	1.67e-15	7.18e-13	0.43	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45580892~45580996:-
LGG	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	8.24	1.67e-15	7.18e-13	0.47	0.35	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
LGG	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-8.24	1.67e-15	7.19e-13	-0.36	-0.35	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
LGG	cis	rs11148252	0.624	rs6561682	ENSG00000278238.1	RP11-245D16.4	8.24	1.67e-15	7.19e-13	0.36	0.35	Lewy body disease;	chr13:52692162	chr13:52454775~52455331:-
LGG	cis	rs5760092	0.755	rs4585126	ENSG00000235689.1	AP000351.13	-8.24	1.67e-15	7.21e-13	-0.49	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:24006305~24008258:-
LGG	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-8.24	1.67e-15	7.21e-13	-0.45	-0.35	Height;	chr14:75002852	chr14:75011269~75012851:-
LGG	cis	rs11722779	0.903	rs6830193	ENSG00000248971.2	KRT8P46	-8.24	1.67e-15	7.21e-13	-0.36	-0.35	Schizophrenia;	chr4:102955457	chr4:102728746~102730171:-
LGG	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	8.24	1.68e-15	7.24e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
LGG	cis	rs11039131	0.629	rs67871383	ENSG00000280615.1	Y_RNA	-8.24	1.68e-15	7.25e-13	-0.46	-0.35	Schizophrenia;	chr11:47314287	chr11:47614898~47614994:-
LGG	cis	rs7241530	0.61	rs12966809	ENSG00000266213.1	RP11-100K18.1	-8.24	1.69e-15	7.29e-13	-0.42	-0.35	Educational attainment (years of education);	chr18:78134211	chr18:78137223~78140887:+
LGG	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	8.24	1.7e-15	7.31e-13	0.31	0.35	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
LGG	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-8.24	1.7e-15	7.33e-13	-0.45	-0.35	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
LGG	cis	rs2797160	0.684	rs1832937	ENSG00000237742.5	RP11-624M8.1	8.24	1.7e-15	7.33e-13	0.33	0.35	Endometrial cancer;	chr6:125664788	chr6:125578558~125749190:-
LGG	cis	rs11992162	0.967	rs11250185	ENSG00000255556.2	RP11-351I21.6	8.24	1.71e-15	7.36e-13	0.43	0.35	Monocyte count;	chr8:11975614	chr8:12378679~12380265:-
LGG	cis	rs11992162	1	rs12334769	ENSG00000255556.2	RP11-351I21.6	8.24	1.71e-15	7.36e-13	0.43	0.35	Monocyte count;	chr8:11975652	chr8:12378679~12380265:-
LGG	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-8.24	1.71e-15	7.36e-13	-0.44	-0.35	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
LGG	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	8.24	1.71e-15	7.37e-13	0.24	0.35	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
LGG	cis	rs950169	0.84	rs62019457	ENSG00000259295.5	CSPG4P12	8.24	1.71e-15	7.38e-13	0.49	0.35	Schizophrenia;	chr15:84558911	chr15:85191438~85213905:+
LGG	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	8.24	1.71e-15	7.38e-13	0.49	0.35	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
LGG	cis	rs10946940	0.93	rs10807029	ENSG00000199851.2	U3	-8.24	1.72e-15	7.39e-13	-0.47	-0.35	Systemic lupus erythematosus;	chr6:27605684	chr6:28015568~28015777:+
LGG	cis	rs9322193	0.962	rs3763163	ENSG00000216621.7	RP11-244K5.6	8.24	1.72e-15	7.4e-13	0.41	0.35	Lung cancer;	chr6:149819770	chr6:149934527~149936782:+
LGG	cis	rs10246939	0.505	rs6967189	ENSG00000261797.1	RP11-744I24.3	-8.24	1.72e-15	7.42e-13	-0.42	-0.35	Bitter taste perception;	chr7:141826220	chr7:141512698~141513183:-
LGG	cis	rs453301	0.598	rs1025395	ENSG00000173295.6	FAM86B3P	-8.24	1.72e-15	7.42e-13	-0.37	-0.35	Joint mobility (Beighton score);	chr8:8979093	chr8:8228595~8244865:+
LGG	cis	rs11098499	0.863	rs1552095	ENSG00000250412.1	KLHL2P1	8.24	1.73e-15	7.43e-13	0.41	0.35	Corneal astigmatism;	chr4:119539151	chr4:119334329~119378233:+
LGG	cis	rs7474896	0.583	rs10827818	ENSG00000226578.1	RP11-258F22.1	-8.24	1.73e-15	7.43e-13	-0.46	-0.35	Obesity (extreme);	chr10:37711928	chr10:37775371~37784131:-
LGG	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-8.24	1.73e-15	7.45e-13	-0.45	-0.35	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
LGG	cis	rs17772222	0.682	rs8017689	ENSG00000222990.1	RNU4-22P	8.24	1.73e-15	7.45e-13	0.42	0.35	Coronary artery calcification;	chr14:88483442	chr14:88513498~88513663:+
LGG	cis	rs17772222	0.682	rs28371093	ENSG00000222990.1	RNU4-22P	8.24	1.73e-15	7.45e-13	0.42	0.35	Coronary artery calcification;	chr14:88486112	chr14:88513498~88513663:+
LGG	cis	rs227275	0.525	rs4698874	ENSG00000248971.2	KRT8P46	-8.24	1.73e-15	7.46e-13	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102728746~102730171:-
LGG	cis	rs7824557	0.592	rs920044	ENSG00000184608.7	FAM167A-AS1	-8.24	1.73e-15	7.47e-13	-0.3	-0.35	Retinal vascular caliber;	chr8:11366804	chr8:11368402~11438658:+
LGG	cis	rs7189233	0.955	rs72801853	ENSG00000279344.1	RP11-44F14.7	8.24	1.74e-15	7.5e-13	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53482912	chr16:53478957~53481550:-
LGG	cis	rs853679	0.567	rs16894091	ENSG00000226314.6	ZNF192P1	-8.24	1.75e-15	7.52e-13	-0.38	-0.35	Depression;	chr6:28422360	chr6:28161781~28169594:+
LGG	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-8.24	1.75e-15	7.53e-13	-0.46	-0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
LGG	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-8.24	1.75e-15	7.53e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-8.24	1.75e-15	7.53e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
LGG	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-8.24	1.75e-15	7.53e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-8.24	1.75e-15	7.53e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-8.24	1.75e-15	7.53e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-8.24	1.75e-15	7.53e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
LGG	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-8.24	1.75e-15	7.54e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
LGG	cis	rs172166	0.694	rs203884	ENSG00000218016.2	ZNF192P2	-8.24	1.75e-15	7.54e-13	-0.47	-0.35	Cardiac Troponin-T levels;	chr6:28109596	chr6:28188050~28189432:+
LGG	cis	rs651907	0.617	rs797776	ENSG00000244119.1	PDCL3P4	8.24	1.75e-15	7.54e-13	0.28	0.35	Colorectal cancer;	chr3:101891399	chr3:101712472~101713191:+
LGG	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	8.24	1.75e-15	7.54e-13	0.59	0.35	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
LGG	cis	rs9532669	0.926	rs2875421	ENSG00000239827.7	SUGT1P3	-8.24	1.75e-15	7.54e-13	-0.37	-0.35	Cervical cancer;	chr13:40936536	chr13:40908159~40921774:-
LGG	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-8.24	1.76e-15	7.55e-13	-0.46	-0.35	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
LGG	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-8.24	1.76e-15	7.56e-13	-0.53	-0.35	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
LGG	cis	rs1707322	0.964	rs6697830	ENSG00000281133.1	AL355480.3	-8.24	1.76e-15	7.56e-13	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs12060274	ENSG00000281133.1	AL355480.3	-8.24	1.76e-15	7.56e-13	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.896	rs785512	ENSG00000281133.1	AL355480.3	8.24	1.76e-15	7.56e-13	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45580892~45580996:-
LGG	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	8.24	1.76e-15	7.57e-13	0.42	0.35	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
LGG	cis	rs9322193	0.736	rs3828701	ENSG00000216621.7	RP11-244K5.6	8.23	1.77e-15	7.59e-13	0.42	0.35	Lung cancer;	chr6:149791063	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.736	rs3805750	ENSG00000216621.7	RP11-244K5.6	8.23	1.77e-15	7.59e-13	0.42	0.35	Lung cancer;	chr6:149791065	chr6:149934527~149936782:+
LGG	cis	rs375066	0.935	rs408549	ENSG00000267191.1	RP11-15A1.2	-8.23	1.77e-15	7.59e-13	-0.36	-0.35	Breast cancer;	chr19:43921467	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs398388	ENSG00000267191.1	RP11-15A1.2	-8.23	1.77e-15	7.59e-13	-0.36	-0.35	Breast cancer;	chr19:43921530	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs403137	ENSG00000267191.1	RP11-15A1.2	-8.23	1.77e-15	7.59e-13	-0.36	-0.35	Breast cancer;	chr19:43923474	chr19:43902001~43926545:+
LGG	cis	rs375066	0.869	rs379785	ENSG00000267191.1	RP11-15A1.2	-8.23	1.77e-15	7.59e-13	-0.36	-0.35	Breast cancer;	chr19:43923949	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs428505	ENSG00000267191.1	RP11-15A1.2	-8.23	1.77e-15	7.59e-13	-0.36	-0.35	Breast cancer;	chr19:43924759	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs367741	ENSG00000267191.1	RP11-15A1.2	-8.23	1.77e-15	7.59e-13	-0.36	-0.35	Breast cancer;	chr19:43925028	chr19:43902001~43926545:+
LGG	cis	rs893363	0.522	rs11130381	ENSG00000271916.1	RP11-884K10.6	-8.23	1.77e-15	7.6e-13	-0.42	-0.35	Axial length;	chr3:53815978	chr3:53797764~53798019:-
LGG	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-8.23	1.77e-15	7.61e-13	-0.32	-0.35	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
LGG	cis	rs11971779	0.68	rs7785903	ENSG00000273391.1	RP11-634H22.1	8.23	1.77e-15	7.62e-13	0.37	0.35	Diisocyanate-induced asthma;	chr7:139437897	chr7:139359032~139359566:-
LGG	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-8.23	1.77e-15	7.62e-13	-0.46	-0.35	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
LGG	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-8.23	1.78e-15	7.64e-13	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
LGG	cis	rs8064029	0.892	rs62036114	ENSG00000267077.1	RP11-127I20.5	8.23	1.78e-15	7.65e-13	0.6	0.35	Cancer;	chr16:4830826	chr16:4795265~4796532:-
LGG	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-8.23	1.78e-15	7.66e-13	-0.35	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
LGG	cis	rs9322193	0.961	rs9027	ENSG00000216621.7	RP11-244K5.6	8.23	1.78e-15	7.67e-13	0.42	0.35	Lung cancer;	chr6:149594921	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs3805748	ENSG00000216621.7	RP11-244K5.6	8.23	1.79e-15	7.7e-13	0.42	0.35	Lung cancer;	chr6:149772542	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.886	rs12525871	ENSG00000216621.7	RP11-244K5.6	8.23	1.79e-15	7.7e-13	0.42	0.35	Lung cancer;	chr6:149775882	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs9322206	ENSG00000216621.7	RP11-244K5.6	8.23	1.79e-15	7.7e-13	0.42	0.35	Lung cancer;	chr6:149641481	chr6:149934527~149936782:+
LGG	cis	rs2739330	0.892	rs5751776	ENSG00000272787.1	KB-226F1.2	8.23	1.79e-15	7.71e-13	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23969211~23969873:+
LGG	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	8.23	1.8e-15	7.74e-13	0.52	0.35	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
LGG	cis	rs7772486	0.79	rs9485024	ENSG00000270638.1	RP3-466P17.1	-8.23	1.8e-15	7.74e-13	-0.23	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145735570~145737218:+
LGG	cis	rs17345786	0.861	rs11711808	ENSG00000256628.3	ZBTB11-AS1	8.23	1.8e-15	7.74e-13	0.45	0.35	Colonoscopy-negative controls vs population controls;	chr3:101516257	chr3:101676475~101679217:+
LGG	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-8.23	1.8e-15	7.75e-13	-0.35	-0.35	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
LGG	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	8.23	1.8e-15	7.75e-13	0.64	0.35	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
LGG	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-8.23	1.8e-15	7.75e-13	-0.47	-0.35	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
LGG	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	8.23	1.8e-15	7.75e-13	0.34	0.35	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
LGG	cis	rs35934224	0.891	rs5993850	ENSG00000232926.1	AC000078.5	8.23	1.81e-15	7.76e-13	0.39	0.35	Glaucoma (primary open-angle);	chr22:19882180	chr22:19887289~19887970:+
LGG	cis	rs35934224	0.891	rs8141451	ENSG00000232926.1	AC000078.5	8.23	1.81e-15	7.76e-13	0.39	0.35	Glaucoma (primary open-angle);	chr22:19882513	chr22:19887289~19887970:+
LGG	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	8.23	1.81e-15	7.78e-13	0.38	0.35	Height;	chr2:231516534	chr2:231508426~231514339:-
LGG	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-8.23	1.81e-15	7.78e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
LGG	cis	rs227275	0.525	rs2866417	ENSG00000248971.2	KRT8P46	-8.23	1.82e-15	7.81e-13	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102728746~102730171:-
LGG	cis	rs8067545	0.512	rs34726000	ENSG00000261033.1	RP11-209D14.2	-8.23	1.83e-15	7.85e-13	-0.42	-0.35	Schizophrenia;	chr17:19984508	chr17:20008051~20009234:-
LGG	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	8.23	1.83e-15	7.85e-13	0.35	0.35	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
LGG	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	8.23	1.83e-15	7.85e-13	0.35	0.35	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
LGG	cis	rs227275	0.525	rs7685399	ENSG00000248971.2	KRT8P46	-8.23	1.83e-15	7.85e-13	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs1383733	ENSG00000248971.2	KRT8P46	-8.23	1.83e-15	7.85e-13	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102728746~102730171:-
LGG	cis	rs9532669	0.89	rs2324738	ENSG00000239827.7	SUGT1P3	-8.23	1.83e-15	7.85e-13	-0.37	-0.35	Cervical cancer;	chr13:40925242	chr13:40908159~40921774:-
LGG	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-8.23	1.83e-15	7.85e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
LGG	cis	rs9322193	0.926	rs9383546	ENSG00000216621.7	RP11-244K5.6	8.23	1.83e-15	7.87e-13	0.42	0.35	Lung cancer;	chr6:149822743	chr6:149934527~149936782:+
LGG	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-8.23	1.84e-15	7.89e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
LGG	cis	rs11098499	0.954	rs12502423	ENSG00000250412.1	KLHL2P1	8.23	1.84e-15	7.89e-13	0.41	0.35	Corneal astigmatism;	chr4:119503017	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs1480939	ENSG00000250412.1	KLHL2P1	8.23	1.84e-15	7.91e-13	0.41	0.35	Corneal astigmatism;	chr4:119535772	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs1480940	ENSG00000250412.1	KLHL2P1	8.23	1.84e-15	7.91e-13	0.41	0.35	Corneal astigmatism;	chr4:119536527	chr4:119334329~119378233:+
LGG	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	8.23	1.84e-15	7.91e-13	0.36	0.35	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
LGG	cis	rs2638953	0.924	rs11049418	ENSG00000278733.1	RP11-425D17.1	-8.23	1.84e-15	7.92e-13	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192154	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs12367188	ENSG00000278733.1	RP11-425D17.1	-8.23	1.84e-15	7.92e-13	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192511	chr12:28185625~28186190:-
LGG	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	8.23	1.85e-15	7.93e-13	0.65	0.35	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
LGG	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-8.23	1.85e-15	7.94e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
LGG	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	8.23	1.85e-15	7.94e-13	0.49	0.35	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
LGG	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	8.23	1.85e-15	7.96e-13	0.36	0.35	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
LGG	cis	rs812925	0.555	rs12616433	ENSG00000273302.1	RP11-493E12.2	8.23	1.86e-15	7.97e-13	0.31	0.35	Immature fraction of reticulocytes;	chr2:61469353	chr2:61199979~61200769:+
LGG	cis	rs853679	0.607	rs201002	ENSG00000199851.2	U3	8.23	1.86e-15	7.98e-13	0.74	0.35	Depression;	chr6:27840414	chr6:28015568~28015777:+
LGG	cis	rs853679	1	rs735765	ENSG00000226314.6	ZNF192P1	8.23	1.86e-15	7.98e-13	0.51	0.35	Depression;	chr6:28202519	chr6:28161781~28169594:+
LGG	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-8.23	1.86e-15	8e-13	-0.48	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
LGG	cis	rs7119038	0.818	rs4936441	ENSG00000255239.1	AP002954.6	8.23	1.87e-15	8.03e-13	0.52	0.35	Sjögren's syndrome;	chr11:118854951	chr11:118688039~118690600:-
LGG	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	8.23	1.89e-15	8.11e-13	0.35	0.35	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
LGG	cis	rs4143844	0.867	rs11637606	ENSG00000259251.2	RP11-643M14.1	-8.23	1.89e-15	8.12e-13	-0.58	-0.35	Bipolar disorder and schizophrenia;	chr15:61912515	chr15:62060503~62062434:+
LGG	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	8.22	1.9e-15	8.13e-13	0.72	0.35	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
LGG	cis	rs2299587	0.58	rs2427739	ENSG00000254054.2	RP11-156K13.3	-8.22	1.9e-15	8.14e-13	-0.72	-0.35	Economic and political preferences;	chr8:18014320	chr8:17905756~17907887:+
LGG	cis	rs11098499	0.863	rs3775841	ENSG00000250412.1	KLHL2P1	8.22	1.91e-15	8.17e-13	0.41	0.35	Corneal astigmatism;	chr4:119504622	chr4:119334329~119378233:+
LGG	cis	rs6921919	0.789	rs11970439	ENSG00000218016.2	ZNF192P2	-8.22	1.91e-15	8.18e-13	-0.46	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28188050~28189432:+
LGG	cis	rs853679	0.567	rs13209596	ENSG00000280107.1	AL022393.9	-8.22	1.91e-15	8.18e-13	-0.38	-0.35	Depression;	chr6:28428413	chr6:28170845~28172521:+
LGG	cis	rs853679	0.567	rs9969098	ENSG00000280107.1	AL022393.9	-8.22	1.91e-15	8.18e-13	-0.38	-0.35	Depression;	chr6:28430971	chr6:28170845~28172521:+
LGG	cis	rs853679	0.567	rs7740429	ENSG00000280107.1	AL022393.9	-8.22	1.91e-15	8.18e-13	-0.38	-0.35	Depression;	chr6:28431469	chr6:28170845~28172521:+
LGG	cis	rs853679	0.567	rs16894106	ENSG00000280107.1	AL022393.9	-8.22	1.91e-15	8.18e-13	-0.38	-0.35	Depression;	chr6:28432562	chr6:28170845~28172521:+
LGG	cis	rs7005380	0.62	rs10955941	ENSG00000245330.4	KB-1471A8.1	8.22	1.91e-15	8.19e-13	0.39	0.35	Interstitial lung disease;	chr8:119891271	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10094455	ENSG00000245330.4	KB-1471A8.1	8.22	1.91e-15	8.19e-13	0.39	0.35	Interstitial lung disease;	chr8:119892436	chr8:119867419~119874488:-
LGG	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	8.22	1.91e-15	8.19e-13	0.49	0.35	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
LGG	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	8.22	1.92e-15	8.21e-13	0.43	0.35	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
LGG	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	8.22	1.92e-15	8.21e-13	0.43	0.35	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
LGG	cis	rs375066	1	rs375066	ENSG00000267191.1	RP11-15A1.2	-8.22	1.92e-15	8.22e-13	-0.37	-0.35	Breast cancer;	chr19:43919418	chr19:43902001~43926545:+
LGG	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	8.22	1.92e-15	8.22e-13	0.39	0.35	Temperament;	chr17:13996939	chr17:14024514~14025488:+
LGG	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-8.22	1.92e-15	8.22e-13	-0.72	-0.35	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-8.22	1.92e-15	8.22e-13	-0.72	-0.35	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-8.22	1.92e-15	8.22e-13	-0.72	-0.35	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-8.22	1.92e-15	8.22e-13	-0.72	-0.35	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
LGG	cis	rs1707322	0.964	rs7512395	ENSG00000281133.1	AL355480.3	-8.22	1.92e-15	8.25e-13	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45580892~45580996:-
LGG	cis	rs7829975	0.539	rs883647	ENSG00000173295.6	FAM86B3P	8.22	1.93e-15	8.25e-13	0.39	0.35	Mood instability;	chr8:8712214	chr8:8228595~8244865:+
LGG	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-8.22	1.93e-15	8.27e-13	-0.47	-0.35	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
LGG	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	8.22	1.93e-15	8.29e-13	0.44	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
LGG	cis	rs853679	1	rs2799077	ENSG00000226314.6	ZNF192P1	8.22	1.93e-15	8.29e-13	0.49	0.35	Depression;	chr6:28266819	chr6:28161781~28169594:+
LGG	cis	rs6921919	0.638	rs2108926	ENSG00000280107.1	AL022393.9	-8.22	1.94e-15	8.3e-13	-0.38	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28170845~28172521:+
LGG	cis	rs2325036	0.501	rs17023388	ENSG00000239519.1	CADM2-AS1	8.22	1.94e-15	8.33e-13	0.48	0.35	Waist circumference;	chr3:85828030	chr3:85992183~86028007:-
LGG	cis	rs997295	0.57	rs17241808	ENSG00000270964.1	RP11-502I4.3	-8.22	1.94e-15	8.33e-13	-0.37	-0.35	Motion sickness;	chr15:67600454	chr15:67541072~67542604:-
LGG	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	8.22	1.95e-15	8.33e-13	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
LGG	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-8.22	1.95e-15	8.35e-13	-0.34	-0.35	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
LGG	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	8.22	1.96e-15	8.38e-13	0.24	0.35	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
LGG	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-8.22	1.96e-15	8.38e-13	-0.31	-0.35	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
LGG	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-8.22	1.96e-15	8.39e-13	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-8.22	1.96e-15	8.39e-13	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-8.22	1.96e-15	8.39e-13	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
LGG	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-8.22	1.97e-15	8.42e-13	-0.35	-0.35	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-8.22	1.97e-15	8.42e-13	-0.35	-0.35	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
LGG	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-8.22	1.98e-15	8.47e-13	-0.39	-0.35	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
LGG	cis	rs9532669	0.89	rs2149570	ENSG00000239827.7	SUGT1P3	-8.22	1.98e-15	8.5e-13	-0.39	-0.35	Cervical cancer;	chr13:40858533	chr13:40908159~40921774:-
LGG	cis	rs17772222	0.655	rs10150594	ENSG00000222990.1	RNU4-22P	8.22	1.98e-15	8.5e-13	0.42	0.35	Coronary artery calcification;	chr14:88489613	chr14:88513498~88513663:+
LGG	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-8.22	1.99e-15	8.51e-13	-0.41	-0.35	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
LGG	cis	rs1707322	0.827	rs12125508	ENSG00000281133.1	AL355480.3	-8.22	1.99e-15	8.53e-13	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45580892~45580996:-
LGG	cis	rs7267979	0.549	rs6138537	ENSG00000276952.1	RP5-965G21.6	8.22	1.99e-15	8.53e-13	0.36	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25203830	chr20:25284915~25285588:-
LGG	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-8.22	1.99e-15	8.54e-13	-0.46	-0.35	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
LGG	cis	rs2638953	0.924	rs11049467	ENSG00000278733.1	RP11-425D17.1	-8.22	1.99e-15	8.54e-13	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215602	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049468	ENSG00000278733.1	RP11-425D17.1	-8.22	1.99e-15	8.54e-13	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215684	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049469	ENSG00000278733.1	RP11-425D17.1	-8.22	1.99e-15	8.54e-13	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28216729	chr12:28185625~28186190:-
LGG	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-8.22	2e-15	8.55e-13	-0.41	-0.35	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-8.22	2e-15	8.55e-13	-0.41	-0.35	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-8.22	2e-15	8.55e-13	-0.41	-0.35	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-8.22	2e-15	8.55e-13	-0.41	-0.35	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
LGG	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-8.22	2e-15	8.55e-13	-0.41	-0.35	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
LGG	cis	rs10946940	0.965	rs6915266	ENSG00000199851.2	U3	-8.22	2e-15	8.56e-13	-0.47	-0.35	Systemic lupus erythematosus;	chr6:27560864	chr6:28015568~28015777:+
LGG	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
LGG	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	8.22	2e-15	8.56e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
LGG	cis	rs4927850	1	rs6799572	ENSG00000242086.7	LINC00969	8.22	2e-15	8.57e-13	0.32	0.35	Pancreatic cancer;	chr3:196013537	chr3:195658062~195739964:+
LGG	cis	rs7241530	0.585	rs12956802	ENSG00000266213.1	RP11-100K18.1	-8.22	2.01e-15	8.6e-13	-0.42	-0.35	Educational attainment (years of education);	chr18:78131002	chr18:78137223~78140887:+
LGG	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	8.22	2.01e-15	8.6e-13	0.52	0.35	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
LGG	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-8.22	2.02e-15	8.63e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-8.22	2.02e-15	8.63e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-8.22	2.02e-15	8.63e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
LGG	cis	rs7267979	0.586	rs11087505	ENSG00000125804.12	FAM182A	-8.22	2.02e-15	8.65e-13	-0.44	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:26054655~26086917:+
LGG	cis	rs1329650	1	rs1329650	ENSG00000228701.1	TNKS2-AS1	8.22	2.03e-15	8.69e-13	0.44	0.35	Smoking behavior;	chr10:91588363	chr10:91782839~91798291:-
LGG	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	8.21	2.04e-15	8.74e-13	0.37	0.35	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	8.21	2.04e-15	8.74e-13	0.37	0.35	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	8.21	2.04e-15	8.74e-13	0.37	0.35	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	8.21	2.04e-15	8.74e-13	0.37	0.35	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	8.21	2.04e-15	8.74e-13	0.37	0.35	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	8.21	2.04e-15	8.74e-13	0.37	0.35	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
LGG	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-8.21	2.04e-15	8.74e-13	-0.43	-0.35	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-8.21	2.04e-15	8.74e-13	-0.43	-0.35	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
LGG	cis	rs17772222	0.63	rs12437422	ENSG00000258983.2	RP11-507K2.2	-8.21	2.04e-15	8.74e-13	-0.4	-0.35	Coronary artery calcification;	chr14:88529621	chr14:88499334~88515502:+
LGG	cis	rs17772222	0.605	rs4899955	ENSG00000258983.2	RP11-507K2.2	-8.21	2.04e-15	8.74e-13	-0.4	-0.35	Coronary artery calcification;	chr14:88530381	chr14:88499334~88515502:+
LGG	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	8.21	2.05e-15	8.75e-13	0.65	0.35	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
LGG	cis	rs1275468	1	rs1275469	ENSG00000257497.2	RP11-585P4.5	-8.21	2.05e-15	8.75e-13	-0.46	-0.35	Polycystic ovary syndrome;	chr12:75541450	chr12:75483454~75489820:-
LGG	cis	rs812925	0.502	rs13028833	ENSG00000273302.1	RP11-493E12.2	-8.21	2.05e-15	8.75e-13	-0.3	-0.35	Immature fraction of reticulocytes;	chr2:61417194	chr2:61199979~61200769:+
LGG	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-8.21	2.05e-15	8.77e-13	-0.48	-0.35	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
LGG	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	8.21	2.06e-15	8.79e-13	0.45	0.35	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
LGG	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	8.21	2.06e-15	8.8e-13	0.34	0.35	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
LGG	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	8.21	2.06e-15	8.81e-13	0.73	0.35	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	8.21	2.06e-15	8.81e-13	0.73	0.35	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	8.21	2.06e-15	8.81e-13	0.73	0.35	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	8.21	2.06e-15	8.81e-13	0.73	0.35	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	8.21	2.06e-15	8.81e-13	0.73	0.35	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
LGG	cis	rs227275	0.525	rs7698608	ENSG00000248971.2	KRT8P46	-8.21	2.07e-15	8.83e-13	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102728746~102730171:-
LGG	cis	rs11098499	0.863	rs3775845	ENSG00000250412.1	KLHL2P1	8.21	2.07e-15	8.83e-13	0.41	0.35	Corneal astigmatism;	chr4:119511292	chr4:119334329~119378233:+
LGG	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	8.21	2.07e-15	8.83e-13	0.33	0.35	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
LGG	cis	rs2274273	0.743	rs7161656	ENSG00000258413.1	RP11-665C16.6	-8.21	2.07e-15	8.84e-13	-0.44	-0.35	Protein biomarker;	chr14:55057812	chr14:55262767~55272075:-
LGG	cis	rs17772222	0.682	rs4904452	ENSG00000258983.2	RP11-507K2.2	-8.21	2.07e-15	8.85e-13	-0.4	-0.35	Coronary artery calcification;	chr14:88517329	chr14:88499334~88515502:+
LGG	cis	rs4281086	0.833	rs6601481	ENSG00000253678.1	RP11-981G7.3	8.21	2.07e-15	8.87e-13	0.39	0.35	Obesity-related traits;	chr8:10531972	chr8:10477491~10479375:-
LGG	cis	rs7241530	0.61	rs34543415	ENSG00000266213.1	RP11-100K18.1	-8.21	2.07e-15	8.87e-13	-0.43	-0.35	Educational attainment (years of education);	chr18:78131645	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs34094237	ENSG00000266213.1	RP11-100K18.1	-8.21	2.07e-15	8.87e-13	-0.43	-0.35	Educational attainment (years of education);	chr18:78131662	chr18:78137223~78140887:+
LGG	cis	rs11098499	0.865	rs11722183	ENSG00000250412.1	KLHL2P1	8.21	2.07e-15	8.87e-13	0.4	0.35	Corneal astigmatism;	chr4:119359442	chr4:119334329~119378233:+
LGG	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-8.21	2.08e-15	8.87e-13	-0.7	-0.35	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
LGG	cis	rs1560104	0.597	rs4780468	ENSG00000274834.1	CTD-3037G24.5	8.21	2.08e-15	8.89e-13	0.44	0.35	Obesity-related traits;	chr16:12620390	chr16:12614451~12614852:+
LGG	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	8.21	2.08e-15	8.9e-13	0.35	0.35	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	8.21	2.08e-15	8.9e-13	0.35	0.35	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	8.21	2.08e-15	8.9e-13	0.35	0.35	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
LGG	cis	rs11722779	0.935	rs7681629	ENSG00000248971.2	KRT8P46	-8.21	2.08e-15	8.9e-13	-0.36	-0.35	Schizophrenia;	chr4:102974407	chr4:102728746~102730171:-
LGG	cis	rs9990333	0.544	rs11915082	ENSG00000231464.1	AC024937.4	8.21	2.09e-15	8.91e-13	0.45	0.35	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195996738~195998233:+
LGG	cis	rs10246939	0.505	rs12703409	ENSG00000261797.1	RP11-744I24.3	-8.21	2.09e-15	8.92e-13	-0.42	-0.35	Bitter taste perception;	chr7:141812058	chr7:141512698~141513183:-
LGG	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-8.21	2.09e-15	8.92e-13	-0.43	-0.35	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
LGG	cis	rs7160336	0.738	rs11849883	ENSG00000258586.1	RP5-1021I20.2	8.21	2.09e-15	8.92e-13	0.44	0.35	Blood protein levels;	chr14:74010633	chr14:73822559~73830135:-
LGG	cis	rs1275468	0.731	rs2652022	ENSG00000257497.2	RP11-585P4.5	-8.21	2.09e-15	8.92e-13	-0.49	-0.35	Polycystic ovary syndrome;	chr12:75586771	chr12:75483454~75489820:-
LGG	cis	rs11722779	0.844	rs17033381	ENSG00000248971.2	KRT8P46	-8.21	2.09e-15	8.93e-13	-0.36	-0.35	Schizophrenia;	chr4:102974952	chr4:102728746~102730171:-
LGG	cis	rs11992162	1	rs11784499	ENSG00000227888.4	FAM66A	8.21	2.09e-15	8.93e-13	0.43	0.35	Monocyte count;	chr8:11977030	chr8:12362019~12388296:+
LGG	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-8.21	2.09e-15	8.94e-13	-0.59	-0.35	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
LGG	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	8.21	2.09e-15	8.94e-13	0.35	0.35	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
LGG	cis	rs35851103	0.506	rs4841659	ENSG00000255556.2	RP11-351I21.6	8.21	2.1e-15	8.96e-13	0.43	0.35	Neuroticism;	chr8:11970691	chr8:12378679~12380265:-
LGG	cis	rs7302981	0.692	rs1979702	ENSG00000272368.2	RP4-605O3.4	-8.21	2.1e-15	8.97e-13	-0.34	-0.35	Systolic blood pressure;	chr12:50068864	chr12:50112197~50165618:+
LGG	cis	rs4143844	0.867	rs34796280	ENSG00000259251.2	RP11-643M14.1	8.21	2.1e-15	8.98e-13	0.59	0.35	Bipolar disorder and schizophrenia;	chr15:61893680	chr15:62060503~62062434:+
LGG	cis	rs227275	0.556	rs4699044	ENSG00000248971.2	KRT8P46	-8.21	2.1e-15	8.98e-13	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs4699045	ENSG00000248971.2	KRT8P46	-8.21	2.1e-15	8.98e-13	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102728746~102730171:-
LGG	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	8.21	2.11e-15	9e-13	0.52	0.35	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
LGG	cis	rs9300255	0.51	rs1790086	ENSG00000235423.7	RP11-282O18.3	8.21	2.11e-15	9e-13	0.4	0.35	Neutrophil percentage of white cells;	chr12:123187971	chr12:123252030~123261483:-
LGG	cis	rs7208859	0.615	rs216462	ENSG00000266490.1	CTD-2349P21.9	-8.21	2.11e-15	9.01e-13	-0.45	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30792372~30792833:+
LGG	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	8.21	2.11e-15	9.02e-13	0.31	0.35	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
LGG	cis	rs812925	0.519	rs2694638	ENSG00000273302.1	RP11-493E12.2	-8.21	2.11e-15	9.03e-13	-0.31	-0.35	Immature fraction of reticulocytes;	chr2:61408228	chr2:61199979~61200769:+
LGG	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	8.21	2.12e-15	9.06e-13	0.46	0.35	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
LGG	cis	rs128738	0.5	rs6875603	ENSG00000233006.5	AC034220.3	-8.21	2.12e-15	9.07e-13	-0.42	-0.35	Giant cell arteritis;	chr5:132229697	chr5:132311285~132369916:-
LGG	cis	rs13287066	0.692	rs7020852	ENSG00000227603.1	RP11-165J3.6	8.21	2.13e-15	9.08e-13	0.36	0.35	Intelligence (multi-trait analysis);	chr9:93400978	chr9:93435332~93437121:-
LGG	cis	rs11992186	0.57	rs17628941	ENSG00000173295.6	FAM86B3P	8.21	2.13e-15	9.09e-13	0.39	0.35	Neuroticism;	chr8:8730024	chr8:8228595~8244865:+
LGG	cis	rs4714902	0.655	rs1047153	ENSG00000231769.2	RP1-8B1.4	-8.21	2.13e-15	9.1e-13	-0.38	-0.35	Colonoscopy-negative controls vs population controls;	chr6:46161008	chr6:46097093~46129706:-
LGG	cis	rs10946940	0.965	rs6921256	ENSG00000199851.2	U3	8.21	2.13e-15	9.11e-13	0.47	0.35	Systemic lupus erythematosus;	chr6:27619739	chr6:28015568~28015777:+
LGG	cis	rs17772222	0.682	rs2401751	ENSG00000222990.1	RNU4-22P	-8.21	2.13e-15	9.11e-13	-0.42	-0.35	Coronary artery calcification;	chr14:88480278	chr14:88513498~88513663:+
LGG	cis	rs375066	0.868	rs370190	ENSG00000267191.1	RP11-15A1.2	-8.21	2.14e-15	9.12e-13	-0.37	-0.35	Breast cancer;	chr19:43920102	chr19:43902001~43926545:+
LGG	cis	rs375066	0.935	rs413093	ENSG00000267191.1	RP11-15A1.2	-8.21	2.14e-15	9.12e-13	-0.37	-0.35	Breast cancer;	chr19:43922113	chr19:43902001~43926545:+
LGG	cis	rs17345786	0.906	rs11710016	ENSG00000256628.3	ZBTB11-AS1	-8.21	2.14e-15	9.15e-13	-0.45	-0.35	Colonoscopy-negative controls vs population controls;	chr3:101401186	chr3:101676475~101679217:+
LGG	cis	rs1707322	0.821	rs10749857	ENSG00000281133.1	AL355480.3	-8.21	2.15e-15	9.19e-13	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45580892~45580996:-
LGG	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	8.21	2.16e-15	9.22e-13	0.52	0.35	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
LGG	cis	rs853679	1	rs9986596	ENSG00000226314.6	ZNF192P1	8.21	2.16e-15	9.22e-13	0.49	0.35	Depression;	chr6:28251883	chr6:28161781~28169594:+
LGG	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	8.21	2.16e-15	9.24e-13	0.52	0.35	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
LGG	cis	rs228614	0.51	rs223397	ENSG00000248971.2	KRT8P46	-8.21	2.17e-15	9.24e-13	-0.37	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102728746~102730171:-
LGG	cis	rs4143844	0.867	rs11629741	ENSG00000259251.2	RP11-643M14.1	8.21	2.17e-15	9.24e-13	0.59	0.35	Bipolar disorder and schizophrenia;	chr15:61892783	chr15:62060503~62062434:+
LGG	cis	rs11098499	0.58	rs12509234	ENSG00000250412.1	KLHL2P1	8.21	2.17e-15	9.24e-13	0.41	0.35	Corneal astigmatism;	chr4:119398279	chr4:119334329~119378233:+
LGG	cis	rs9322193	1	rs9377229	ENSG00000216621.7	RP11-244K5.6	8.21	2.17e-15	9.25e-13	0.42	0.35	Lung cancer;	chr6:149607655	chr6:149934527~149936782:+
LGG	cis	rs9300255	0.568	rs1790108	ENSG00000235423.7	RP11-282O18.3	8.21	2.17e-15	9.26e-13	0.39	0.35	Neutrophil percentage of white cells;	chr12:123152294	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.51	rs1790109	ENSG00000235423.7	RP11-282O18.3	8.21	2.17e-15	9.26e-13	0.39	0.35	Neutrophil percentage of white cells;	chr12:123153205	chr12:123252030~123261483:-
LGG	cis	rs7219021	0.739	rs1973404	ENSG00000248278.1	SUMO2P17	-8.21	2.17e-15	9.26e-13	-0.42	-0.35	Schizophrenia or bipolar disorder;	chr17:48890530	chr17:48874860~48908983:-
LGG	cis	rs4950322	0.58	rs972368	ENSG00000278811.3	LINC00624	8.21	2.18e-15	9.31e-13	0.34	0.35	Protein quantitative trait loci;	chr1:147111142	chr1:147258885~147517875:-
LGG	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	8.21	2.19e-15	9.33e-13	0.45	0.35	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
LGG	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	8.21	2.19e-15	9.34e-13	0.36	0.35	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
LGG	cis	rs9322193	0.884	rs2095375	ENSG00000216621.7	RP11-244K5.6	8.21	2.19e-15	9.34e-13	0.42	0.35	Lung cancer;	chr6:149807037	chr6:149934527~149936782:+
LGG	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-8.21	2.19e-15	9.35e-13	-0.41	-0.35	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
LGG	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-8.2	2.19e-15	9.35e-13	-0.35	-0.35	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
LGG	cis	rs651907	0.712	rs796410	ENSG00000244119.1	PDCL3P4	8.2	2.19e-15	9.36e-13	0.28	0.35	Colorectal cancer;	chr3:101891345	chr3:101712472~101713191:+
LGG	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-8.2	2.2e-15	9.37e-13	-0.37	-0.35	Height;	chr2:231541633	chr2:231508426~231514339:-
LGG	cis	rs1707322	0.826	rs10890349	ENSG00000281133.1	AL355480.3	-8.2	2.2e-15	9.38e-13	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.758	rs10789474	ENSG00000281133.1	AL355480.3	-8.2	2.2e-15	9.38e-13	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45580892~45580996:-
LGG	cis	rs8067545	0.64	rs10083840	ENSG00000230528.6	NOS2P3	-8.2	2.2e-15	9.39e-13	-0.33	-0.35	Schizophrenia;	chr17:20062659	chr17:20436337~20447249:+
LGG	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	8.2	2.21e-15	9.41e-13	0.39	0.35	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	8.2	2.21e-15	9.41e-13	0.39	0.35	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
LGG	cis	rs1707322	1	rs9429186	ENSG00000281133.1	AL355480.3	8.2	2.21e-15	9.43e-13	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs785506	ENSG00000281133.1	AL355480.3	8.2	2.21e-15	9.43e-13	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45580892~45580996:-
LGG	cis	rs35934224	0.831	rs1044732	ENSG00000232926.1	AC000078.5	8.2	2.21e-15	9.44e-13	0.41	0.35	Glaucoma (primary open-angle);	chr22:19875619	chr22:19887289~19887970:+
LGG	cis	rs11051970	0.592	rs7132235	ENSG00000274964.1	RP11-817I4.1	-8.2	2.21e-15	9.44e-13	-0.38	-0.35	Response to tocilizumab in rheumatoid arthritis;	chr12:32383369	chr12:32339368~32340724:+
LGG	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-8.2	2.21e-15	9.44e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
LGG	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-8.2	2.22e-15	9.47e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
LGG	cis	rs1061377	0.513	rs2566162	ENSG00000249685.1	RP11-360F5.3	8.2	2.22e-15	9.48e-13	0.48	0.35	Uric acid levels;	chr4:39126453	chr4:39133913~39135608:+
LGG	cis	rs12554020	0.792	rs11975	ENSG00000237385.1	RP11-165J3.5	8.2	2.23e-15	9.49e-13	0.58	0.35	Schizophrenia;	chr9:93565409	chr9:93430342~93431299:-
LGG	cis	rs1707322	1	rs6677777	ENSG00000281133.1	AL355480.3	-8.2	2.23e-15	9.51e-13	-0.44	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45580892~45580996:-
LGG	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	8.2	2.23e-15	9.52e-13	0.58	0.35	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
LGG	cis	rs7241530	0.585	rs12967211	ENSG00000266213.1	RP11-100K18.1	8.2	2.23e-15	9.52e-13	0.41	0.35	Educational attainment (years of education);	chr18:78130753	chr18:78137223~78140887:+
LGG	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	8.2	2.23e-15	9.52e-13	0.31	0.35	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
LGG	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	8.2	2.23e-15	9.52e-13	0.31	0.35	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
LGG	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	8.2	2.23e-15	9.52e-13	0.73	0.35	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
LGG	cis	rs7927771	0.524	rs11039329	ENSG00000280615.1	Y_RNA	8.2	2.23e-15	9.52e-13	0.42	0.35	Subjective well-being;	chr11:47663356	chr11:47614898~47614994:-
LGG	cis	rs11098499	0.954	rs9998585	ENSG00000250412.1	KLHL2P1	8.2	2.24e-15	9.54e-13	0.41	0.35	Corneal astigmatism;	chr4:119475647	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs6842762	ENSG00000250412.1	KLHL2P1	8.2	2.24e-15	9.54e-13	0.41	0.35	Corneal astigmatism;	chr4:119477081	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.908	rs11098527	ENSG00000250412.1	KLHL2P1	8.2	2.24e-15	9.54e-13	0.41	0.35	Corneal astigmatism;	chr4:119478751	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs10518328	ENSG00000250412.1	KLHL2P1	8.2	2.24e-15	9.54e-13	0.41	0.35	Corneal astigmatism;	chr4:119480624	chr4:119334329~119378233:+
LGG	cis	rs17772222	0.839	rs2274735	ENSG00000222990.1	RNU4-22P	8.2	2.24e-15	9.54e-13	0.41	0.35	Coronary artery calcification;	chr14:88505414	chr14:88513498~88513663:+
LGG	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-8.2	2.24e-15	9.56e-13	-0.41	-0.35	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
LGG	cis	rs2638953	0.886	rs11049393	ENSG00000278733.1	RP11-425D17.1	-8.2	2.24e-15	9.56e-13	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170273	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049410	ENSG00000278733.1	RP11-425D17.1	-8.2	2.24e-15	9.56e-13	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183438	chr12:28185625~28186190:-
LGG	cis	rs4714902	0.655	rs9395156	ENSG00000231769.2	RP1-8B1.4	-8.2	2.24e-15	9.56e-13	-0.38	-0.35	Colonoscopy-negative controls vs population controls;	chr6:46116234	chr6:46097093~46129706:-
LGG	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	8.2	2.25e-15	9.57e-13	0.54	0.35	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
LGG	cis	rs6921919	0.697	rs758398	ENSG00000280107.1	AL022393.9	-8.2	2.25e-15	9.57e-13	-0.37	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28170845~28172521:+
LGG	cis	rs7189233	0.955	rs7189726	ENSG00000279344.1	RP11-44F14.7	8.2	2.25e-15	9.59e-13	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53463862	chr16:53478957~53481550:-
LGG	cis	rs8135665	0.6	rs6519096	ENSG00000233739.1	RP5-1039K5.13	8.2	2.25e-15	9.6e-13	0.4	0.35	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38055382	chr22:38057180~38073940:-
LGG	cis	rs11098499	0.909	rs2127821	ENSG00000250412.1	KLHL2P1	8.2	2.25e-15	9.6e-13	0.41	0.35	Corneal astigmatism;	chr4:119473380	chr4:119334329~119378233:+
LGG	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	8.2	2.26e-15	9.61e-13	0.43	0.35	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
LGG	cis	rs1930961	1	rs1930961	ENSG00000272942.1	CTA-246H3.12	-8.2	2.26e-15	9.62e-13	-0.52	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25434324~25435070:-
LGG	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-8.2	2.26e-15	9.62e-13	-0.72	-0.35	Gout;	chr7:66654674	chr7:66654538~66669855:+
LGG	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-8.2	2.26e-15	9.62e-13	-0.72	-0.35	Gout;	chr7:66661502	chr7:66654538~66669855:+
LGG	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-8.2	2.27e-15	9.66e-13	-0.5	-0.35	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
LGG	cis	rs2075466	0.514	rs77491748	ENSG00000267077.1	RP11-127I20.5	8.2	2.27e-15	9.69e-13	0.49	0.35	Colonoscopy-negative controls vs population controls;	chr16:4839368	chr16:4795265~4796532:-
LGG	cis	rs2075466	0.514	rs12444795	ENSG00000267077.1	RP11-127I20.5	8.2	2.27e-15	9.69e-13	0.49	0.35	Colonoscopy-negative controls vs population controls;	chr16:4840065	chr16:4795265~4796532:-
LGG	cis	rs7824557	0.591	rs2043510	ENSG00000184608.7	FAM167A-AS1	8.2	2.28e-15	9.7e-13	0.3	0.35	Retinal vascular caliber;	chr8:11367659	chr8:11368402~11438658:+
LGG	cis	rs4714902	0.655	rs993632	ENSG00000231769.2	RP1-8B1.4	-8.2	2.28e-15	9.72e-13	-0.38	-0.35	Colonoscopy-negative controls vs population controls;	chr6:46118520	chr6:46097093~46129706:-
LGG	cis	rs848490	0.615	rs2428939	ENSG00000214293.7	APTR	-8.2	2.29e-15	9.75e-13	-0.35	-0.35	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77932977	chr7:77657660~77696265:-
LGG	cis	rs62184315	0.536	rs62183651	ENSG00000253559.1	OSGEPL1-AS1	-8.2	2.29e-15	9.76e-13	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189647251	chr2:189762704~189765556:+
LGG	cis	rs62184315	0.536	rs62183652	ENSG00000253559.1	OSGEPL1-AS1	-8.2	2.29e-15	9.76e-13	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189648877	chr2:189762704~189765556:+
LGG	cis	rs62184315	0.536	rs62183653	ENSG00000253559.1	OSGEPL1-AS1	-8.2	2.29e-15	9.76e-13	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189650099	chr2:189762704~189765556:+
LGG	cis	rs62184315	0.536	rs72920421	ENSG00000253559.1	OSGEPL1-AS1	-8.2	2.29e-15	9.76e-13	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189650292	chr2:189762704~189765556:+
LGG	cis	rs1707322	0.785	rs10890348	ENSG00000281133.1	AL355480.3	-8.2	2.29e-15	9.76e-13	-0.45	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs10890382	ENSG00000281133.1	AL355480.3	-8.2	2.29e-15	9.76e-13	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45580892~45580996:-
LGG	cis	rs2877649	0.51	rs10129168	ENSG00000258744.1	RP11-80A15.1	-8.2	2.3e-15	9.8e-13	-0.78	-0.35	Smooth-surface caries;	chr14:24436858	chr14:24501594~24508688:+
LGG	cis	rs2877649	0.51	rs73593291	ENSG00000258744.1	RP11-80A15.1	-8.2	2.3e-15	9.8e-13	-0.78	-0.35	Smooth-surface caries;	chr14:24436888	chr14:24501594~24508688:+
LGG	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-8.2	2.3e-15	9.8e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
LGG	cis	rs11098499	0.863	rs3775843	ENSG00000250412.1	KLHL2P1	8.2	2.3e-15	9.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119506689	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs3775844	ENSG00000250412.1	KLHL2P1	8.2	2.3e-15	9.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119506878	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs7664986	ENSG00000250412.1	KLHL2P1	8.2	2.3e-15	9.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119508797	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.818	rs10008791	ENSG00000250412.1	KLHL2P1	8.2	2.3e-15	9.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119510314	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs11736416	ENSG00000250412.1	KLHL2P1	8.2	2.3e-15	9.81e-13	0.41	0.35	Corneal astigmatism;	chr4:119510506	chr4:119334329~119378233:+
LGG	cis	rs7189233	1	rs7194519	ENSG00000279344.1	RP11-44F14.7	8.2	2.31e-15	9.84e-13	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53501364	chr16:53478957~53481550:-
LGG	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-8.2	2.31e-15	9.84e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-8.2	2.31e-15	9.84e-13	-0.47	-0.35	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
LGG	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-8.2	2.31e-15	9.85e-13	-0.45	-0.35	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
LGG	cis	rs4950322	0.802	rs72694705	ENSG00000278811.3	LINC00624	8.2	2.32e-15	9.86e-13	0.35	0.35	Protein quantitative trait loci;	chr1:147362313	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.857	rs55790545	ENSG00000278811.3	LINC00624	8.2	2.32e-15	9.86e-13	0.35	0.35	Protein quantitative trait loci;	chr1:147366649	chr1:147258885~147517875:-
LGG	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-8.2	2.32e-15	9.87e-13	-0.28	-0.35	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
LGG	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-8.2	2.32e-15	9.87e-13	-0.47	-0.35	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
LGG	cis	rs1275468	1	rs1148003	ENSG00000257497.2	RP11-585P4.5	-8.2	2.32e-15	9.88e-13	-0.47	-0.35	Polycystic ovary syndrome;	chr12:75585216	chr12:75483454~75489820:-
LGG	cis	rs9532669	0.926	rs9532659	ENSG00000239827.7	SUGT1P3	-8.2	2.32e-15	9.89e-13	-0.37	-0.35	Cervical cancer;	chr13:40920380	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.89	rs9594457	ENSG00000239827.7	SUGT1P3	-8.2	2.32e-15	9.89e-13	-0.37	-0.35	Cervical cancer;	chr13:40920439	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9594458	ENSG00000239827.7	SUGT1P3	-8.2	2.32e-15	9.89e-13	-0.37	-0.35	Cervical cancer;	chr13:40920448	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs9590562	ENSG00000239827.7	SUGT1P3	-8.2	2.32e-15	9.89e-13	-0.37	-0.35	Cervical cancer;	chr13:40920503	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.963	rs12857052	ENSG00000239827.7	SUGT1P3	-8.2	2.32e-15	9.89e-13	-0.37	-0.35	Cervical cancer;	chr13:40920831	chr13:40908159~40921774:-
LGG	cis	rs6496932	0.913	rs4843037	ENSG00000218052.5	ADAMTS7P4	8.2	2.33e-15	9.89e-13	0.52	0.35	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:85255369~85330334:-
LGG	cis	rs11148252	0.716	rs3803262	ENSG00000235660.1	LINC00345	-8.2	2.33e-15	9.9e-13	-0.43	-0.35	Lewy body disease;	chr13:52462263	chr13:52484161~52484680:-
LGG	cis	rs1949733	0.917	rs10461079	ENSG00000205959.3	RP11-689P11.2	8.2	2.33e-15	9.91e-13	0.33	0.35	Response to antineoplastic agents;	chr4:8390997	chr4:8482270~8512610:+
LGG	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	8.2	2.34e-15	9.96e-13	0.38	0.35	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
LGG	cis	rs9322193	0.962	rs9689447	ENSG00000216621.7	RP11-244K5.6	8.2	2.34e-15	9.96e-13	0.42	0.35	Lung cancer;	chr6:149789350	chr6:149934527~149936782:+
LGG	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-8.2	2.34e-15	9.97e-13	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
LGG	cis	rs4713118	0.911	rs9461406	ENSG00000226314.6	ZNF192P1	-8.2	2.35e-15	9.99e-13	-0.39	-0.35	Parkinson's disease;	chr6:27751985	chr6:28161781~28169594:+
LGG	cis	rs227275	0.525	rs7672319	ENSG00000248971.2	KRT8P46	-8.2	2.35e-15	1e-12	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs6533051	ENSG00000248971.2	KRT8P46	-8.2	2.35e-15	1e-12	-0.37	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102728746~102730171:-
LGG	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-8.19	2.36e-15	1e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
LGG	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-8.19	2.36e-15	1e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
LGG	cis	rs812925	0.519	rs2922089	ENSG00000273302.1	RP11-493E12.2	-8.19	2.37e-15	1.01e-12	-0.3	-0.35	Immature fraction of reticulocytes;	chr2:61397994	chr2:61199979~61200769:+
LGG	cis	rs812925	0.519	rs2694627	ENSG00000273302.1	RP11-493E12.2	-8.19	2.37e-15	1.01e-12	-0.3	-0.35	Immature fraction of reticulocytes;	chr2:61398371	chr2:61199979~61200769:+
LGG	cis	rs7772486	0.754	rs6570708	ENSG00000270638.1	RP3-466P17.1	-8.19	2.37e-15	1.01e-12	-0.23	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145735570~145737218:+
LGG	cis	rs56114371	0.777	rs200482	ENSG00000216901.1	AL022393.7	8.19	2.37e-15	1.01e-12	0.65	0.35	Breast cancer;	chr6:27806126	chr6:28176188~28176674:+
LGG	cis	rs10208649	0.656	rs74693460	ENSG00000272156.1	RP11-477N3.1	8.19	2.38e-15	1.01e-12	0.67	0.35	Body mass index;	chr2:54071471	chr2:54082554~54085066:+
LGG	cis	rs4950322	0.857	rs7522219	ENSG00000278811.3	LINC00624	8.19	2.39e-15	1.01e-12	0.35	0.35	Protein quantitative trait loci;	chr1:147366904	chr1:147258885~147517875:-
LGG	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-8.19	2.4e-15	1.02e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
LGG	cis	rs6452524	0.904	rs10076056	ENSG00000248112.1	RP11-78C3.1	-8.19	2.4e-15	1.02e-12	-0.48	-0.35	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:82919376~82921119:-
LGG	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	8.19	2.4e-15	1.02e-12	0.52	0.35	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
LGG	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	8.19	2.4e-15	1.02e-12	0.52	0.35	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
LGG	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	8.19	2.4e-15	1.02e-12	0.36	0.35	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
LGG	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-8.19	2.41e-15	1.02e-12	-0.47	-0.35	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
LGG	cis	rs62184315	0.575	rs256546	ENSG00000253559.1	OSGEPL1-AS1	-8.19	2.41e-15	1.02e-12	-0.4	-0.35	Alcohol dependence (age at onset);	chr2:189886437	chr2:189762704~189765556:+
LGG	cis	rs7189233	0.955	rs8044205	ENSG00000279344.1	RP11-44F14.7	8.19	2.41e-15	1.03e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53481181	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.955	rs8058684	ENSG00000279344.1	RP11-44F14.7	8.19	2.41e-15	1.03e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53481206	chr16:53478957~53481550:-
LGG	cis	rs7189233	0.911	rs72801854	ENSG00000279344.1	RP11-44F14.7	8.19	2.41e-15	1.03e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53483330	chr16:53478957~53481550:-
LGG	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	8.19	2.42e-15	1.03e-12	0.73	0.35	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
LGG	cis	rs2075466	0.514	rs78766103	ENSG00000267077.1	RP11-127I20.5	8.19	2.43e-15	1.03e-12	0.49	0.35	Colonoscopy-negative controls vs population controls;	chr16:4848251	chr16:4795265~4796532:-
LGG	cis	rs4143844	1	rs34017665	ENSG00000259251.2	RP11-643M14.1	8.19	2.44e-15	1.04e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62027008	chr15:62060503~62062434:+
LGG	cis	rs6921919	0.848	rs56131013	ENSG00000218016.2	ZNF192P2	-8.19	2.44e-15	1.04e-12	-0.46	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28188050~28189432:+
LGG	cis	rs2797160	0.904	rs1739370	ENSG00000237742.5	RP11-624M8.1	8.19	2.45e-15	1.04e-12	0.33	0.35	Endometrial cancer;	chr6:125690085	chr6:125578558~125749190:-
LGG	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	8.19	2.46e-15	1.04e-12	0.35	0.35	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	8.19	2.46e-15	1.04e-12	0.35	0.35	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	8.19	2.46e-15	1.04e-12	0.35	0.35	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
LGG	cis	rs227275	0.525	rs6533050	ENSG00000248971.2	KRT8P46	-8.19	2.46e-15	1.05e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs10032234	ENSG00000248971.2	KRT8P46	-8.19	2.46e-15	1.05e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs28845922	ENSG00000248971.2	KRT8P46	-8.19	2.46e-15	1.05e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102728746~102730171:-
LGG	cis	rs228614	0.517	rs3886722	ENSG00000248971.2	KRT8P46	-8.19	2.46e-15	1.05e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102728746~102730171:-
LGG	cis	rs879620	0.89	rs2601781	ENSG00000262185.1	RP11-462G12.1	-8.19	2.46e-15	1.05e-12	-0.45	-0.35	Hip circumference;Body mass index;	chr16:3967391	chr16:3947609~3950444:-
LGG	cis	rs7189233	1	rs62048520	ENSG00000279344.1	RP11-44F14.7	8.19	2.46e-15	1.05e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53457183	chr16:53478957~53481550:-
LGG	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-8.19	2.47e-15	1.05e-12	-0.47	-0.35	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
LGG	cis	rs9300255	0.602	rs1727315	ENSG00000235423.7	RP11-282O18.3	-8.19	2.47e-15	1.05e-12	-0.39	-0.35	Neutrophil percentage of white cells;	chr12:123154383	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.568	rs1627724	ENSG00000235423.7	RP11-282O18.3	8.19	2.47e-15	1.05e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123154033	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.537	rs1618679	ENSG00000235423.7	RP11-282O18.3	8.19	2.47e-15	1.05e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123166167	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.568	rs1621194	ENSG00000235423.7	RP11-282O18.3	8.19	2.47e-15	1.05e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123166471	chr12:123252030~123261483:-
LGG	cis	rs11018904	0.817	rs11606060	ENSG00000280385.1	AP000648.5	-8.19	2.48e-15	1.05e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr11:90195429	chr11:90193614~90198120:+
LGG	cis	rs11018904	0.906	rs11603498	ENSG00000280385.1	AP000648.5	-8.19	2.48e-15	1.05e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr11:90195615	chr11:90193614~90198120:+
LGG	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	8.19	2.48e-15	1.05e-12	0.72	0.35	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
LGG	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	8.19	2.48e-15	1.05e-12	0.72	0.35	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
LGG	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-8.19	2.48e-15	1.05e-12	-0.4	-0.35	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
LGG	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-8.19	2.48e-15	1.05e-12	-0.4	-0.35	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
LGG	cis	rs4938330	0.739	rs11216266	ENSG00000254851.1	RP11-109L13.1	8.19	2.48e-15	1.05e-12	0.5	0.35	Blood protein levels;	chr11:117079434	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.748	rs7106662	ENSG00000254851.1	RP11-109L13.1	8.19	2.48e-15	1.05e-12	0.5	0.35	Subjective well-being;	chr11:117080669	chr11:117135528~117138582:+
LGG	cis	rs4950322	0.857	rs72693002	ENSG00000278811.3	LINC00624	8.19	2.48e-15	1.06e-12	0.35	0.35	Protein quantitative trait loci;	chr1:147357593	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.857	rs72694703	ENSG00000278811.3	LINC00624	8.19	2.48e-15	1.06e-12	0.35	0.35	Protein quantitative trait loci;	chr1:147358427	chr1:147258885~147517875:-
LGG	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-8.19	2.49e-15	1.06e-12	-0.5	-0.35	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
LGG	cis	rs2638953	0.889	rs11049538	ENSG00000278733.1	RP11-425D17.1	-8.19	2.49e-15	1.06e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335801	chr12:28185625~28186190:-
LGG	cis	rs4713118	0.866	rs9468217	ENSG00000226314.6	ZNF192P1	8.19	2.49e-15	1.06e-12	0.39	0.35	Parkinson's disease;	chr6:27758688	chr6:28161781~28169594:+
LGG	cis	rs5742933	0.696	rs6748102	ENSG00000273240.1	RP11-455J20.3	-8.19	2.49e-15	1.06e-12	-0.54	-0.35	Ferritin levels;	chr2:189760786	chr2:189763859~189764456:-
LGG	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-8.19	2.49e-15	1.06e-12	-0.45	-0.35	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
LGG	cis	rs227275	0.525	rs3974604	ENSG00000248971.2	KRT8P46	-8.19	2.5e-15	1.06e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102728746~102730171:-
LGG	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-8.19	2.5e-15	1.06e-12	-0.28	-0.35	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-8.19	2.5e-15	1.06e-12	-0.28	-0.35	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
LGG	cis	rs11051970	0.559	rs56670459	ENSG00000274964.1	RP11-817I4.1	-8.19	2.5e-15	1.06e-12	-0.39	-0.35	Response to tocilizumab in rheumatoid arthritis;	chr12:32390391	chr12:32339368~32340724:+
LGG	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-8.19	2.51e-15	1.06e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
LGG	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-8.19	2.51e-15	1.06e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-8.19	2.51e-15	1.06e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
LGG	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-8.19	2.51e-15	1.07e-12	-0.37	-0.35	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
LGG	cis	rs11098499	0.909	rs11723757	ENSG00000250412.1	KLHL2P1	8.19	2.51e-15	1.07e-12	0.41	0.35	Corneal astigmatism;	chr4:119378514	chr4:119334329~119378233:+
LGG	cis	rs7241530	0.585	rs11872676	ENSG00000266213.1	RP11-100K18.1	-8.19	2.51e-15	1.07e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78132288	chr18:78137223~78140887:+
LGG	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-8.19	2.51e-15	1.07e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
LGG	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-8.19	2.51e-15	1.07e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
LGG	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-8.19	2.51e-15	1.07e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
LGG	cis	rs12468226	0.938	rs13392645	ENSG00000273456.1	RP11-686O6.2	8.19	2.52e-15	1.07e-12	0.34	0.35	Urate levels;	chr2:202270116	chr2:202374932~202375604:-
LGG	cis	rs1707322	0.964	rs10890358	ENSG00000281133.1	AL355480.3	-8.19	2.52e-15	1.07e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45580892~45580996:-
LGG	cis	rs9300255	0.602	rs1790116	ENSG00000235423.7	RP11-282O18.3	8.19	2.53e-15	1.07e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123133997	chr12:123252030~123261483:-
LGG	cis	rs5743077	1	rs5743077	ENSG00000273240.1	RP11-455J20.3	-8.19	2.53e-15	1.07e-12	-0.52	-0.35	Iron status biomarkers (ferritin levels);	chr2:189832613	chr2:189763859~189764456:-
LGG	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-8.18	2.54e-15	1.08e-12	-0.47	-0.35	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
LGG	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	8.18	2.54e-15	1.08e-12	0.36	0.35	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
LGG	cis	rs950169	0.84	rs12905223	ENSG00000259295.5	CSPG4P12	8.18	2.54e-15	1.08e-12	0.49	0.35	Schizophrenia;	chr15:84571037	chr15:85191438~85213905:+
LGG	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	8.18	2.55e-15	1.08e-12	0.24	0.35	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
LGG	cis	rs7267979	0.816	rs1044573	ENSG00000276952.1	RP5-965G21.6	8.18	2.55e-15	1.08e-12	0.35	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25284915~25285588:-
LGG	cis	rs4713118	0.869	rs4713121	ENSG00000226314.6	ZNF192P1	8.18	2.55e-15	1.08e-12	0.39	0.35	Parkinson's disease;	chr6:27754285	chr6:28161781~28169594:+
LGG	cis	rs9532669	0.926	rs9532690	ENSG00000239827.7	SUGT1P3	-8.18	2.55e-15	1.08e-12	-0.37	-0.35	Cervical cancer;	chr13:40968654	chr13:40908159~40921774:-
LGG	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	8.18	2.56e-15	1.08e-12	0.4	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
LGG	cis	rs3020264	0.59	rs2515561	ENSG00000271743.1	CTD-2541M15.3	-8.18	2.56e-15	1.09e-12	-0.41	-0.35	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6633454	chr8:6615604~6617198:-
LGG	cis	rs11098499	0.909	rs1546502	ENSG00000250412.1	KLHL2P1	8.18	2.56e-15	1.09e-12	0.41	0.35	Corneal astigmatism;	chr4:119314743	chr4:119334329~119378233:+
LGG	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	8.18	2.57e-15	1.09e-12	0.35	0.35	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
LGG	cis	rs9322193	1	rs9322193	ENSG00000216621.7	RP11-244K5.6	8.18	2.57e-15	1.09e-12	0.42	0.35	Lung cancer;	chr6:149598007	chr6:149934527~149936782:+
LGG	cis	rs2638953	0.924	rs11049454	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204755	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs10843134	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205710	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs1824768	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206530	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.886	rs11049465	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28212086	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs7980441	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28214748	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.886	rs11049470	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28221449	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs10843140	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227273	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049472	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28229772	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.888	rs2061760	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28234492	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.886	rs11049474	ENSG00000278733.1	RP11-425D17.1	-8.18	2.57e-15	1.09e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28235512	chr12:28185625~28186190:-
LGG	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	8.18	2.57e-15	1.09e-12	0.35	0.35	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	8.18	2.57e-15	1.09e-12	0.35	0.35	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
LGG	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-8.18	2.58e-15	1.09e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
LGG	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-8.18	2.58e-15	1.1e-12	-0.36	-0.35	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
LGG	cis	rs7267979	0.586	rs6037057	ENSG00000125804.12	FAM182A	-8.18	2.59e-15	1.1e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:26054655~26086917:+
LGG	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	8.18	2.59e-15	1.1e-12	0.43	0.35	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	8.18	2.59e-15	1.1e-12	0.43	0.35	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
LGG	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	8.18	2.59e-15	1.1e-12	0.3	0.35	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
LGG	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	8.18	2.6e-15	1.1e-12	0.43	0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
LGG	cis	rs11098499	0.863	rs3822190	ENSG00000250412.1	KLHL2P1	8.18	2.6e-15	1.1e-12	0.4	0.35	Corneal astigmatism;	chr4:119506943	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs3822191	ENSG00000250412.1	KLHL2P1	8.18	2.6e-15	1.1e-12	0.4	0.35	Corneal astigmatism;	chr4:119506946	chr4:119334329~119378233:+
LGG	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	8.18	2.6e-15	1.1e-12	0.47	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
LGG	cis	rs853679	0.607	rs67998226	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28270281	chr6:28161781~28169594:+
LGG	cis	rs853679	0.607	rs34878803	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28282402	chr6:28161781~28169594:+
LGG	cis	rs853679	0.607	rs34396849	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28283178	chr6:28161781~28169594:+
LGG	cis	rs853679	0.607	rs13211507	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28289600	chr6:28161781~28169594:+
LGG	cis	rs853679	0.607	rs34691223	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28290431	chr6:28161781~28169594:+
LGG	cis	rs853679	0.607	rs34950484	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28310911	chr6:28161781~28169594:+
LGG	cis	rs853679	0.607	rs34661125	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28314117	chr6:28161781~28169594:+
LGG	cis	rs853679	0.607	rs13190888	ENSG00000226314.6	ZNF192P1	8.18	2.6e-15	1.1e-12	0.63	0.35	Depression;	chr6:28318208	chr6:28161781~28169594:+
LGG	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-8.18	2.6e-15	1.1e-12	-0.49	-0.35	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
LGG	cis	rs3764021	0.527	rs11052423	ENSG00000256594.6	RP11-705C15.2	-8.18	2.61e-15	1.11e-12	-0.36	-0.35	Type 1 diabetes;	chr12:9687442	chr12:9633419~9658412:+
LGG	cis	rs11098499	0.954	rs11729521	ENSG00000250412.1	KLHL2P1	8.18	2.61e-15	1.11e-12	0.4	0.35	Corneal astigmatism;	chr4:119495633	chr4:119334329~119378233:+
LGG	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-8.18	2.61e-15	1.11e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
LGG	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	8.18	2.62e-15	1.11e-12	0.42	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
LGG	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-8.18	2.62e-15	1.11e-12	-0.47	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
LGG	cis	rs1707322	1	rs2458400	ENSG00000281133.1	AL355480.3	8.18	2.62e-15	1.11e-12	0.43	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45580892~45580996:-
LGG	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-8.18	2.62e-15	1.11e-12	-0.7	-0.35	Gout;	chr7:66671562	chr7:66654538~66669855:+
LGG	cis	rs454217	0.846	rs1661024	ENSG00000277851.1	RP11-756G20.1	8.18	2.62e-15	1.11e-12	0.36	0.35	Smoking quantity;	chr12:92330771	chr12:92247756~92363832:-
LGG	cis	rs858239	0.699	rs955187	ENSG00000230042.1	AK3P3	8.18	2.63e-15	1.11e-12	0.36	0.35	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23129178~23129841:+
LGG	cis	rs7241530	0.61	rs61530283	ENSG00000266213.1	RP11-100K18.1	-8.18	2.63e-15	1.11e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78131789	chr18:78137223~78140887:+
LGG	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	8.18	2.63e-15	1.12e-12	0.47	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
LGG	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	8.18	2.63e-15	1.12e-12	0.47	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
LGG	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	8.18	2.63e-15	1.12e-12	0.47	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
LGG	cis	rs853679	1	rs6901575	ENSG00000226314.6	ZNF192P1	8.18	2.64e-15	1.12e-12	0.49	0.35	Depression;	chr6:28283207	chr6:28161781~28169594:+
LGG	cis	rs12554020	0.892	rs7870210	ENSG00000237385.1	RP11-165J3.5	8.18	2.64e-15	1.12e-12	0.58	0.35	Schizophrenia;	chr9:93569534	chr9:93430342~93431299:-
LGG	cis	rs12554020	0.892	rs7860098	ENSG00000237385.1	RP11-165J3.5	8.18	2.64e-15	1.12e-12	0.58	0.35	Schizophrenia;	chr9:93569562	chr9:93430342~93431299:-
LGG	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-8.18	2.64e-15	1.12e-12	-0.37	-0.35	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
LGG	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-8.18	2.65e-15	1.12e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-8.18	2.65e-15	1.12e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
LGG	cis	rs11098499	0.863	rs12502389	ENSG00000250412.1	KLHL2P1	8.18	2.65e-15	1.12e-12	0.41	0.35	Corneal astigmatism;	chr4:119533036	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.821	rs3775852	ENSG00000250412.1	KLHL2P1	8.18	2.65e-15	1.12e-12	0.41	0.35	Corneal astigmatism;	chr4:119533401	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.82	rs6534140	ENSG00000250412.1	KLHL2P1	8.18	2.65e-15	1.12e-12	0.41	0.35	Corneal astigmatism;	chr4:119534156	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs7657849	ENSG00000250412.1	KLHL2P1	8.18	2.65e-15	1.12e-12	0.41	0.35	Corneal astigmatism;	chr4:119534339	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs10034450	ENSG00000250412.1	KLHL2P1	8.18	2.65e-15	1.12e-12	0.41	0.35	Corneal astigmatism;	chr4:119534494	chr4:119334329~119378233:+
LGG	cis	rs227275	0.555	rs223403	ENSG00000248971.2	KRT8P46	-8.18	2.65e-15	1.12e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102728746~102730171:-
LGG	cis	rs66823261	0.778	rs2906332	ENSG00000223508.5	RPL23AP53	8.18	2.66e-15	1.13e-12	0.39	0.35	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:213186~232231:-
LGG	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	8.18	2.66e-15	1.13e-12	0.51	0.35	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
LGG	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	8.18	2.66e-15	1.13e-12	0.41	0.35	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
LGG	cis	rs7219021	0.634	rs9905428	ENSG00000248278.1	SUMO2P17	-8.18	2.66e-15	1.13e-12	-0.42	-0.35	Schizophrenia or bipolar disorder;	chr17:48871347	chr17:48874860~48908983:-
LGG	cis	rs2638953	0.853	rs10843179	ENSG00000278733.1	RP11-425D17.1	8.18	2.67e-15	1.13e-12	0.43	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28185625~28186190:-
LGG	cis	rs1707322	1	rs4660335	ENSG00000281133.1	AL355480.3	-8.18	2.67e-15	1.13e-12	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.827	rs10890347	ENSG00000281133.1	AL355480.3	8.18	2.67e-15	1.13e-12	0.47	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45580892~45580996:-
LGG	cis	rs1949733	1	rs3103067	ENSG00000205959.3	RP11-689P11.2	-8.18	2.67e-15	1.13e-12	-0.32	-0.35	Response to antineoplastic agents;	chr4:8509496	chr4:8482270~8512610:+
LGG	cis	rs6921919	0.848	rs6903652	ENSG00000218016.2	ZNF192P2	-8.18	2.68e-15	1.13e-12	-0.46	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28188050~28189432:+
LGG	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-8.18	2.68e-15	1.13e-12	-0.45	-0.35	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
LGG	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-8.18	2.68e-15	1.14e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
LGG	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-8.18	2.68e-15	1.14e-12	-0.47	-0.35	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
LGG	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	8.18	2.69e-15	1.14e-12	0.49	0.35	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
LGG	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	8.18	2.69e-15	1.14e-12	0.49	0.35	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
LGG	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	8.18	2.69e-15	1.14e-12	0.49	0.35	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
LGG	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-8.18	2.69e-15	1.14e-12	-0.48	-0.35	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
LGG	cis	rs10973956	0.744	rs10973954	ENSG00000273036.2	FAM95C	-8.18	2.69e-15	1.14e-12	-0.37	-0.35	Tourette's syndrome or obsessive-compulsive disorder;	chr9:38644424	chr9:38540567~38545372:-
LGG	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-8.18	2.7e-15	1.14e-12	-0.36	-0.35	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
LGG	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	8.18	2.7e-15	1.14e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
LGG	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	8.18	2.7e-15	1.14e-12	0.44	0.35	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
LGG	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	8.18	2.7e-15	1.14e-12	0.41	0.35	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
LGG	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-8.18	2.7e-15	1.14e-12	-0.46	-0.35	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
LGG	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-8.18	2.7e-15	1.14e-12	-0.41	-0.35	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
LGG	cis	rs7267979	0.586	rs1007707	ENSG00000125804.12	FAM182A	-8.18	2.71e-15	1.15e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:26054655~26086917:+
LGG	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	8.18	2.71e-15	1.15e-12	0.42	0.35	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
LGG	cis	rs2933343	0.533	rs13086121	ENSG00000231305.3	RP11-723O4.2	8.18	2.72e-15	1.15e-12	0.36	0.35	IgG glycosylation;	chr3:128985447	chr3:128861313~128871540:-
LGG	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	8.18	2.72e-15	1.15e-12	0.36	0.35	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
LGG	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	8.18	2.72e-15	1.15e-12	0.46	0.35	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
LGG	cis	rs6545883	0.558	rs7587389	ENSG00000273302.1	RP11-493E12.2	-8.18	2.72e-15	1.15e-12	-0.3	-0.35	Tuberculosis;	chr2:61422656	chr2:61199979~61200769:+
LGG	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	8.17	2.73e-15	1.15e-12	0.24	0.35	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
LGG	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-8.17	2.73e-15	1.15e-12	-0.41	-0.35	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-8.17	2.73e-15	1.15e-12	-0.41	-0.35	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
LGG	cis	rs4143844	0.867	rs12902859	ENSG00000259251.2	RP11-643M14.1	8.17	2.73e-15	1.16e-12	0.61	0.35	Bipolar disorder and schizophrenia;	chr15:61884966	chr15:62060503~62062434:+
LGG	cis	rs853679	1	rs11965538	ENSG00000226314.6	ZNF192P1	8.17	2.74e-15	1.16e-12	0.49	0.35	Depression;	chr6:28272137	chr6:28161781~28169594:+
LGG	cis	rs853679	0.882	rs2743555	ENSG00000226314.6	ZNF192P1	8.17	2.74e-15	1.16e-12	0.49	0.35	Depression;	chr6:28273304	chr6:28161781~28169594:+
LGG	cis	rs853679	1	rs1419183	ENSG00000226314.6	ZNF192P1	8.17	2.74e-15	1.16e-12	0.49	0.35	Depression;	chr6:28275017	chr6:28161781~28169594:+
LGG	cis	rs853679	1	rs1679732	ENSG00000226314.6	ZNF192P1	-8.17	2.74e-15	1.16e-12	-0.49	-0.35	Depression;	chr6:28253486	chr6:28161781~28169594:+
LGG	cis	rs853679	1	rs1679709	ENSG00000226314.6	ZNF192P1	-8.17	2.74e-15	1.16e-12	-0.49	-0.35	Depression;	chr6:28260564	chr6:28161781~28169594:+
LGG	cis	rs853679	1	rs1778511	ENSG00000226314.6	ZNF192P1	-8.17	2.74e-15	1.16e-12	-0.49	-0.35	Depression;	chr6:28261633	chr6:28161781~28169594:+
LGG	cis	rs853679	1	rs1778508	ENSG00000226314.6	ZNF192P1	-8.17	2.74e-15	1.16e-12	-0.49	-0.35	Depression;	chr6:28262103	chr6:28161781~28169594:+
LGG	cis	rs11148252	0.967	rs4286007	ENSG00000235660.1	LINC00345	-8.17	2.74e-15	1.16e-12	-0.43	-0.35	Lewy body disease;	chr13:52448383	chr13:52484161~52484680:-
LGG	cis	rs1707322	1	rs10789479	ENSG00000281133.1	AL355480.3	-8.17	2.74e-15	1.16e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45580892~45580996:-
LGG	cis	rs1056107	0.671	rs7875332	ENSG00000259953.1	RP11-4O1.2	-8.17	2.74e-15	1.16e-12	-0.37	-0.35	Colorectal cancer;	chr9:112165255	chr9:112032555~112037730:-
LGG	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	8.17	2.75e-15	1.16e-12	0.48	0.35	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
LGG	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-8.17	2.76e-15	1.17e-12	-0.54	-0.35	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
LGG	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-8.17	2.76e-15	1.17e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
LGG	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-8.17	2.76e-15	1.17e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-8.17	2.76e-15	1.17e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
LGG	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-8.17	2.78e-15	1.17e-12	-0.71	-0.35	Gout;	chr7:66679692	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	8.17	2.78e-15	1.17e-12	0.71	0.35	Gout;	chr7:66682070	chr7:66654538~66669855:+
LGG	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	8.17	2.78e-15	1.17e-12	0.71	0.35	Gout;	chr7:66682162	chr7:66654538~66669855:+
LGG	cis	rs7181230	0.961	rs7183977	ENSG00000275636.1	RP11-521C20.5	-8.17	2.78e-15	1.17e-12	-0.38	-0.35	Dehydroepiandrosterone sulphate levels;	chr15:40084891	chr15:40078892~40079347:+
LGG	cis	rs1707322	1	rs4606257	ENSG00000281133.1	AL355480.3	-8.17	2.78e-15	1.18e-12	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45580892~45580996:-
LGG	cis	rs7005380	0.62	rs13250594	ENSG00000245330.4	KB-1471A8.1	8.17	2.78e-15	1.18e-12	0.39	0.35	Interstitial lung disease;	chr8:119894151	chr8:119867419~119874488:-
LGG	cis	rs11098499	0.954	rs12505469	ENSG00000250412.1	KLHL2P1	8.17	2.78e-15	1.18e-12	0.4	0.35	Corneal astigmatism;	chr4:119328430	chr4:119334329~119378233:+
LGG	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	8.17	2.79e-15	1.18e-12	0.36	0.35	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
LGG	cis	rs397969	0.596	rs12450857	ENSG00000261033.1	RP11-209D14.2	-8.17	2.8e-15	1.18e-12	-0.43	-0.35	Platelet count;	chr17:19991935	chr17:20008051~20009234:-
LGG	cis	rs2075466	0.514	rs76407180	ENSG00000267077.1	RP11-127I20.5	8.17	2.8e-15	1.18e-12	0.49	0.35	Colonoscopy-negative controls vs population controls;	chr16:4848528	chr16:4795265~4796532:-
LGG	cis	rs12444795	0.853	rs77120311	ENSG00000267077.1	RP11-127I20.5	8.17	2.8e-15	1.18e-12	0.49	0.35	Cancer;	chr16:4848635	chr16:4795265~4796532:-
LGG	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-8.17	2.81e-15	1.19e-12	-0.48	-0.35	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-8.17	2.81e-15	1.19e-12	-0.48	-0.35	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
LGG	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-8.17	2.81e-15	1.19e-12	-0.48	-0.35	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
LGG	cis	rs9300255	0.679	rs4759409	ENSG00000235423.7	RP11-282O18.3	8.17	2.81e-15	1.19e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123235038	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.679	rs10772998	ENSG00000235423.7	RP11-282O18.3	8.17	2.81e-15	1.19e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123236630	chr12:123252030~123261483:-
LGG	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	8.17	2.81e-15	1.19e-12	0.43	0.35	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
LGG	cis	rs1707322	1	rs7539800	ENSG00000281133.1	AL355480.3	8.17	2.82e-15	1.19e-12	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45580892~45580996:-
LGG	cis	rs6997458	0.839	rs1390712	ENSG00000253549.4	RP11-317J10.2	8.17	2.82e-15	1.19e-12	0.29	0.35	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85395020	chr8:85441851~85464915:-
LGG	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-8.17	2.82e-15	1.19e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
LGG	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-8.17	2.82e-15	1.19e-12	-0.43	-0.35	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
LGG	cis	rs7241530	0.61	rs7241666	ENSG00000266213.1	RP11-100K18.1	-8.17	2.82e-15	1.19e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78132405	chr18:78137223~78140887:+
LGG	cis	rs7826238	0.543	rs2976908	ENSG00000253893.2	FAM85B	-8.17	2.82e-15	1.19e-12	-0.43	-0.35	Systolic blood pressure;	chr8:8488264	chr8:8167819~8226614:-
LGG	cis	rs9322193	0.884	rs2342858	ENSG00000216621.7	RP11-244K5.6	8.17	2.83e-15	1.19e-12	0.42	0.35	Lung cancer;	chr6:149805967	chr6:149934527~149936782:+
LGG	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-8.17	2.83e-15	1.2e-12	-0.28	-0.35	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
LGG	cis	rs11098499	0.863	rs10004484	ENSG00000250412.1	KLHL2P1	8.17	2.84e-15	1.2e-12	0.4	0.35	Corneal astigmatism;	chr4:119521273	chr4:119334329~119378233:+
LGG	cis	rs3096299	0.702	rs2086825	ENSG00000274627.1	RP11-104N10.2	8.17	2.84e-15	1.2e-12	0.3	0.35	Multiple myeloma (IgH translocation);	chr16:89405134	chr16:89516797~89522217:+
LGG	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-8.17	2.84e-15	1.2e-12	-0.44	-0.35	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
LGG	cis	rs11148252	0.904	rs3892337	ENSG00000278238.1	RP11-245D16.4	-8.17	2.84e-15	1.2e-12	-0.33	-0.35	Lewy body disease;	chr13:52455350	chr13:52454775~52455331:-
LGG	cis	rs11148252	0.904	rs9536079	ENSG00000278238.1	RP11-245D16.4	-8.17	2.84e-15	1.2e-12	-0.33	-0.35	Lewy body disease;	chr13:52456430	chr13:52454775~52455331:-
LGG	cis	rs11098499	0.954	rs10008459	ENSG00000250412.1	KLHL2P1	8.17	2.84e-15	1.2e-12	0.4	0.35	Corneal astigmatism;	chr4:119473076	chr4:119334329~119378233:+
LGG	cis	rs7241530	0.61	rs7239715	ENSG00000266213.1	RP11-100K18.1	-8.17	2.85e-15	1.2e-12	-0.43	-0.35	Educational attainment (years of education);	chr18:78133061	chr18:78137223~78140887:+
LGG	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	8.17	2.85e-15	1.2e-12	0.45	0.35	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
LGG	cis	rs8062405	0.757	rs2411453	ENSG00000251417.2	RP11-1348G14.4	8.17	2.85e-15	1.2e-12	0.41	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28802743~28817828:+
LGG	cis	rs5742933	0.51	rs10182631	ENSG00000273240.1	RP11-455J20.3	-8.17	2.85e-15	1.2e-12	-0.49	-0.35	Ferritin levels;	chr2:189635233	chr2:189763859~189764456:-
LGG	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	8.17	2.85e-15	1.2e-12	0.36	0.35	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
LGG	cis	rs997295	0.57	rs737226	ENSG00000270964.1	RP11-502I4.3	-8.17	2.86e-15	1.21e-12	-0.37	-0.35	Motion sickness;	chr15:67548435	chr15:67541072~67542604:-
LGG	cis	rs997295	0.57	rs11632574	ENSG00000270964.1	RP11-502I4.3	-8.17	2.86e-15	1.21e-12	-0.37	-0.35	Motion sickness;	chr15:67560067	chr15:67541072~67542604:-
LGG	cis	rs853679	0.546	rs483143	ENSG00000199851.2	U3	8.17	2.86e-15	1.21e-12	0.73	0.35	Depression;	chr6:27878966	chr6:28015568~28015777:+
LGG	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	8.17	2.87e-15	1.21e-12	0.31	0.35	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
LGG	cis	rs9322193	0.962	rs6899661	ENSG00000216621.7	RP11-244K5.6	8.17	2.87e-15	1.21e-12	0.42	0.35	Lung cancer;	chr6:149818093	chr6:149934527~149936782:+
LGG	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	8.17	2.87e-15	1.21e-12	0.34	0.35	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
LGG	cis	rs4143844	1	rs17271291	ENSG00000259251.2	RP11-643M14.1	8.17	2.87e-15	1.21e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:61982818	chr15:62060503~62062434:+
LGG	cis	rs9322193	0.923	rs1984111	ENSG00000216621.7	RP11-244K5.6	8.17	2.88e-15	1.21e-12	0.41	0.35	Lung cancer;	chr6:149831720	chr6:149934527~149936782:+
LGG	cis	rs7267979	0.78	rs2500413	ENSG00000276952.1	RP5-965G21.6	8.17	2.88e-15	1.21e-12	0.35	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25284915~25285588:-
LGG	cis	rs7267979	0.714	rs2474763	ENSG00000276952.1	RP5-965G21.6	8.17	2.88e-15	1.21e-12	0.35	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25284915~25285588:-
LGG	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	8.17	2.88e-15	1.22e-12	0.72	0.35	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
LGG	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-8.17	2.88e-15	1.22e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
LGG	cis	rs7824557	0.591	rs2572452	ENSG00000184608.7	FAM167A-AS1	8.17	2.88e-15	1.22e-12	0.3	0.35	Retinal vascular caliber;	chr8:11370745	chr8:11368402~11438658:+
LGG	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	8.17	2.89e-15	1.22e-12	0.44	0.35	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
LGG	cis	rs375066	0.935	rs396973	ENSG00000267191.1	RP11-15A1.2	8.17	2.89e-15	1.22e-12	0.37	0.35	Breast cancer;	chr19:43895154	chr19:43902001~43926545:+
LGG	cis	rs1707322	1	rs10890353	ENSG00000281133.1	AL355480.3	-8.17	2.89e-15	1.22e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45580892~45580996:-
LGG	cis	rs6921919	0.638	rs1416920	ENSG00000280107.1	AL022393.9	-8.17	2.89e-15	1.22e-12	-0.37	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.525	rs1361386	ENSG00000280107.1	AL022393.9	-8.17	2.89e-15	1.22e-12	-0.37	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28170845~28172521:+
LGG	cis	rs6921919	0.638	rs6456815	ENSG00000280107.1	AL022393.9	-8.17	2.89e-15	1.22e-12	-0.37	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28170845~28172521:+
LGG	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-8.17	2.89e-15	1.22e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
LGG	cis	rs228614	0.51	rs223452	ENSG00000248971.2	KRT8P46	-8.17	2.9e-15	1.23e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102728746~102730171:-
LGG	cis	rs4143844	0.867	rs12901036	ENSG00000259251.2	RP11-643M14.1	8.17	2.9e-15	1.23e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:61977797	chr15:62060503~62062434:+
LGG	cis	rs12935418	0.616	rs56299740	ENSG00000260213.4	RP11-303E16.3	-8.17	2.91e-15	1.23e-12	-0.49	-0.35	Mean corpuscular volume;	chr16:80930272	chr16:81016792~81035759:-
LGG	cis	rs1560104	0.597	rs4781297	ENSG00000274834.1	CTD-3037G24.5	8.17	2.91e-15	1.23e-12	0.43	0.35	Obesity-related traits;	chr16:12613347	chr16:12614451~12614852:+
LGG	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-8.17	2.92e-15	1.23e-12	-0.47	-0.35	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
LGG	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-8.17	2.92e-15	1.23e-12	-0.42	-0.35	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
LGG	cis	rs7005380	0.62	rs28669275	ENSG00000245330.4	KB-1471A8.1	8.17	2.93e-15	1.24e-12	0.39	0.35	Interstitial lung disease;	chr8:119889713	chr8:119867419~119874488:-
LGG	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	8.17	2.93e-15	1.24e-12	0.5	0.35	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.528	rs10082609	ENSG00000254851.1	RP11-109L13.1	8.16	2.94e-15	1.24e-12	0.5	0.35	Subjective well-being;	chr11:117078358	chr11:117135528~117138582:+
LGG	cis	rs4266144	0.926	rs4368453	ENSG00000244515.1	KRT18P34	-8.16	2.94e-15	1.24e-12	-0.39	-0.35	Coronary artery disease;	chr3:157134352	chr3:157162663~157163932:-
LGG	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-8.16	2.94e-15	1.24e-12	-0.41	-0.35	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
LGG	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-8.16	2.94e-15	1.24e-12	-0.41	-0.35	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
LGG	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-8.16	2.94e-15	1.24e-12	-0.47	-0.35	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
LGG	cis	rs6921919	0.848	rs6903823	ENSG00000218016.2	ZNF192P2	-8.16	2.95e-15	1.24e-12	-0.46	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28188050~28189432:+
LGG	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	-8.16	2.95e-15	1.24e-12	-0.38	-0.35	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
LGG	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	-8.16	2.95e-15	1.24e-12	-0.38	-0.35	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
LGG	cis	rs12554020	0.786	rs60076242	ENSG00000237385.1	RP11-165J3.5	8.16	2.96e-15	1.25e-12	0.58	0.35	Schizophrenia;	chr9:93571634	chr9:93430342~93431299:-
LGG	cis	rs12554020	0.786	rs10429558	ENSG00000237385.1	RP11-165J3.5	8.16	2.96e-15	1.25e-12	0.58	0.35	Schizophrenia;	chr9:93574508	chr9:93430342~93431299:-
LGG	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-8.16	2.96e-15	1.25e-12	-0.47	-0.35	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
LGG	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-8.16	2.96e-15	1.25e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
LGG	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-8.16	2.96e-15	1.25e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
LGG	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-8.16	2.97e-15	1.25e-12	-0.51	-0.35	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
LGG	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	8.16	2.98e-15	1.25e-12	0.48	0.35	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
LGG	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-8.16	2.99e-15	1.26e-12	-0.3	-0.35	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
LGG	cis	rs10973956	0.706	rs1890109	ENSG00000273036.2	FAM95C	-8.16	3e-15	1.26e-12	-0.36	-0.35	Tourette's syndrome or obsessive-compulsive disorder;	chr9:38643999	chr9:38540567~38545372:-
LGG	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-8.16	3e-15	1.26e-12	-0.4	-0.35	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
LGG	cis	rs9875589	1	rs9875589	ENSG00000233121.1	VN1R20P	8.16	3.01e-15	1.27e-12	0.35	0.35	Ovarian reserve;	chr3:13919660	chr3:13926813~13927778:+
LGG	cis	rs7709377	0.723	rs10076543	ENSG00000212457.1	RNU6-644P	-8.16	3.01e-15	1.27e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116180438	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10076547	ENSG00000212457.1	RNU6-644P	-8.16	3.01e-15	1.27e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116180474	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10076548	ENSG00000212457.1	RNU6-644P	-8.16	3.01e-15	1.27e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116180479	chr5:116188455~116188552:-
LGG	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	8.16	3.01e-15	1.27e-12	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
LGG	cis	rs7119038	0.865	rs4938573	ENSG00000255239.1	AP002954.6	8.16	3.03e-15	1.28e-12	0.51	0.35	Sjögren's syndrome;	chr11:118871133	chr11:118688039~118690600:-
LGG	cis	rs9532669	0.963	rs9562238	ENSG00000239827.7	SUGT1P3	-8.16	3.04e-15	1.28e-12	-0.37	-0.35	Cervical cancer;	chr13:40924785	chr13:40908159~40921774:-
LGG	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-8.16	3.04e-15	1.28e-12	-0.44	-0.35	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
LGG	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	8.16	3.04e-15	1.28e-12	0.24	0.35	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
LGG	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	8.16	3.05e-15	1.28e-12	0.47	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
LGG	cis	rs4713118	0.615	rs9348772	ENSG00000216901.1	AL022393.7	8.16	3.06e-15	1.29e-12	0.43	0.35	Parkinson's disease;	chr6:27688311	chr6:28176188~28176674:+
LGG	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	8.16	3.06e-15	1.29e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
LGG	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	8.16	3.06e-15	1.29e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
LGG	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	8.16	3.07e-15	1.29e-12	0.44	0.35	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
LGG	cis	rs62184315	0.536	rs62185897	ENSG00000253559.1	OSGEPL1-AS1	-8.16	3.07e-15	1.29e-12	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189721279	chr2:189762704~189765556:+
LGG	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-8.16	3.08e-15	1.3e-12	-0.47	-0.35	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
LGG	cis	rs5742933	0.69	rs6726636	ENSG00000253559.1	OSGEPL1-AS1	-8.16	3.08e-15	1.3e-12	-0.49	-0.35	Ferritin levels;	chr2:189653095	chr2:189762704~189765556:+
LGG	cis	rs4714902	0.655	rs995563	ENSG00000231769.2	RP1-8B1.4	-8.16	3.09e-15	1.3e-12	-0.38	-0.35	Colonoscopy-negative controls vs population controls;	chr6:46115200	chr6:46097093~46129706:-
LGG	cis	rs11722779	0.844	rs10003326	ENSG00000248971.2	KRT8P46	-8.16	3.09e-15	1.3e-12	-0.36	-0.35	Schizophrenia;	chr4:102948193	chr4:102728746~102730171:-
LGG	cis	rs11722779	0.787	rs6533040	ENSG00000248971.2	KRT8P46	-8.16	3.09e-15	1.3e-12	-0.36	-0.35	Schizophrenia;	chr4:102951421	chr4:102728746~102730171:-
LGG	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	8.16	3.09e-15	1.3e-12	0.36	0.35	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
LGG	cis	rs2638953	0.853	rs11049656	ENSG00000278733.1	RP11-425D17.1	-8.16	3.09e-15	1.3e-12	-0.41	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481705	chr12:28185625~28186190:-
LGG	cis	rs7267979	0.549	rs11698185	ENSG00000125804.12	FAM182A	-8.16	3.1e-15	1.3e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:26054655~26086917:+
LGG	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-8.16	3.1e-15	1.3e-12	-0.46	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
LGG	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	8.16	3.11e-15	1.31e-12	0.7	0.35	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
LGG	cis	rs227275	0.556	rs4455413	ENSG00000248971.2	KRT8P46	-8.16	3.12e-15	1.31e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102728746~102730171:-
LGG	cis	rs454217	0.846	rs337663	ENSG00000277851.1	RP11-756G20.1	-8.16	3.12e-15	1.31e-12	-0.36	-0.35	Smoking quantity;	chr12:92311428	chr12:92247756~92363832:-
LGG	cis	rs1930961	1	rs6004668	ENSG00000272942.1	CTA-246H3.12	8.16	3.12e-15	1.31e-12	0.52	0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25434324~25435070:-
LGG	cis	rs10946940	1	rs10946940	ENSG00000199851.2	U3	-8.16	3.13e-15	1.32e-12	-0.46	-0.35	Systemic lupus erythematosus;	chr6:27592808	chr6:28015568~28015777:+
LGG	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-8.16	3.13e-15	1.32e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
LGG	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-8.16	3.14e-15	1.32e-12	-0.47	-0.35	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-8.16	3.14e-15	1.32e-12	-0.47	-0.35	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-8.16	3.14e-15	1.32e-12	-0.47	-0.35	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
LGG	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-8.16	3.14e-15	1.32e-12	-0.47	-0.35	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
LGG	cis	rs2281558	0.917	rs3787080	ENSG00000125804.12	FAM182A	-8.16	3.14e-15	1.32e-12	-0.47	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25251968	chr20:26054655~26086917:+
LGG	cis	rs2797160	1	rs1739377	ENSG00000237742.5	RP11-624M8.1	8.16	3.15e-15	1.32e-12	0.32	0.35	Endometrial cancer;	chr6:125691090	chr6:125578558~125749190:-
LGG	cis	rs11051970	0.592	rs12227991	ENSG00000274964.1	RP11-817I4.1	-8.15	3.16e-15	1.33e-12	-0.38	-0.35	Response to tocilizumab in rheumatoid arthritis;	chr12:32387111	chr12:32339368~32340724:+
LGG	cis	rs11051970	0.559	rs11051973	ENSG00000274964.1	RP11-817I4.1	-8.15	3.16e-15	1.33e-12	-0.38	-0.35	Response to tocilizumab in rheumatoid arthritis;	chr12:32388978	chr12:32339368~32340724:+
LGG	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	8.15	3.17e-15	1.33e-12	0.52	0.35	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
LGG	cis	rs7241530	0.61	rs57729653	ENSG00000266213.1	RP11-100K18.1	-8.15	3.18e-15	1.34e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78131593	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs59421856	ENSG00000266213.1	RP11-100K18.1	-8.15	3.18e-15	1.34e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78131599	chr18:78137223~78140887:+
LGG	cis	rs8180040	0.966	rs3736177	ENSG00000271161.1	BOLA2P2	-8.15	3.19e-15	1.34e-12	-0.32	-0.35	Colorectal cancer;	chr3:47409921	chr3:47499841~47500407:+
LGG	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	8.15	3.19e-15	1.34e-12	0.43	0.35	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
LGG	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	8.15	3.2e-15	1.35e-12	0.43	0.35	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
LGG	cis	rs9322193	0.884	rs11155689	ENSG00000216621.7	RP11-244K5.6	8.15	3.2e-15	1.35e-12	0.42	0.35	Lung cancer;	chr6:149808470	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs2342857	ENSG00000216621.7	RP11-244K5.6	8.15	3.2e-15	1.35e-12	0.42	0.35	Lung cancer;	chr6:149809537	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.884	rs933055	ENSG00000216621.7	RP11-244K5.6	8.15	3.2e-15	1.35e-12	0.42	0.35	Lung cancer;	chr6:149809701	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs4869731	ENSG00000216621.7	RP11-244K5.6	8.15	3.2e-15	1.35e-12	0.42	0.35	Lung cancer;	chr6:149810072	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.962	rs7745915	ENSG00000216621.7	RP11-244K5.6	8.15	3.21e-15	1.35e-12	0.42	0.35	Lung cancer;	chr6:149834111	chr6:149934527~149936782:+
LGG	cis	rs853679	0.546	rs13214023	ENSG00000199851.2	U3	-8.15	3.22e-15	1.35e-12	-0.78	-0.35	Depression;	chr6:28364364	chr6:28015568~28015777:+
LGG	cis	rs17772222	0.63	rs8017811	ENSG00000258983.2	RP11-507K2.2	-8.15	3.22e-15	1.35e-12	-0.39	-0.35	Coronary artery calcification;	chr14:88534559	chr14:88499334~88515502:+
LGG	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-8.15	3.22e-15	1.35e-12	-0.47	-0.35	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
LGG	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	8.15	3.22e-15	1.35e-12	0.32	0.35	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
LGG	cis	rs7829975	0.742	rs7832968	ENSG00000253981.4	ALG1L13P	-8.15	3.23e-15	1.36e-12	-0.36	-0.35	Mood instability;	chr8:8795379	chr8:8236003~8244667:-
LGG	cis	rs12073837	0.5	rs2807845	ENSG00000238078.1	LINC01352	-8.15	3.23e-15	1.36e-12	-0.44	-0.35	F-cell distribution;	chr1:220822945	chr1:220829255~220832429:+
LGG	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-8.15	3.24e-15	1.36e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-8.15	3.24e-15	1.36e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-8.15	3.24e-15	1.36e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-8.15	3.24e-15	1.36e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
LGG	cis	rs910316	0.763	rs1548807	ENSG00000279594.1	RP11-950C14.10	8.15	3.24e-15	1.36e-12	0.45	0.35	Height;	chr14:75012879	chr14:75011269~75012851:-
LGG	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-8.15	3.24e-15	1.36e-12	-0.44	-0.35	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
LGG	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	8.15	3.24e-15	1.36e-12	0.24	0.35	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
LGG	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	8.15	3.24e-15	1.36e-12	0.24	0.35	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
LGG	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	8.15	3.24e-15	1.36e-12	0.24	0.35	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
LGG	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-8.15	3.24e-15	1.36e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
LGG	cis	rs12468226	0.938	rs55681656	ENSG00000273456.1	RP11-686O6.2	8.15	3.24e-15	1.36e-12	0.35	0.35	Urate levels;	chr2:202319041	chr2:202374932~202375604:-
LGG	cis	rs75920871	0.528	rs7109649	ENSG00000254851.1	RP11-109L13.1	8.15	3.25e-15	1.36e-12	0.5	0.35	Subjective well-being;	chr11:117072828	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.528	rs1531706	ENSG00000254851.1	RP11-109L13.1	8.15	3.25e-15	1.36e-12	0.5	0.35	Subjective well-being;	chr11:117073236	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.528	rs1531707	ENSG00000254851.1	RP11-109L13.1	8.15	3.25e-15	1.36e-12	0.5	0.35	Subjective well-being;	chr11:117073996	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.528	rs12274388	ENSG00000254851.1	RP11-109L13.1	8.15	3.25e-15	1.36e-12	0.5	0.35	Subjective well-being;	chr11:117075522	chr11:117135528~117138582:+
LGG	cis	rs75920871	0.528	rs7484045	ENSG00000254851.1	RP11-109L13.1	8.15	3.25e-15	1.36e-12	0.5	0.35	Subjective well-being;	chr11:117076174	chr11:117135528~117138582:+
LGG	cis	rs9300255	0.537	rs1727334	ENSG00000235423.7	RP11-282O18.3	8.15	3.26e-15	1.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123229689	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.639	rs941306	ENSG00000235423.7	RP11-282O18.3	8.15	3.26e-15	1.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123230566	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs941305	ENSG00000235423.7	RP11-282O18.3	8.15	3.26e-15	1.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123230719	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.639	rs1716171	ENSG00000235423.7	RP11-282O18.3	8.15	3.26e-15	1.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123231829	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.569	rs1716170	ENSG00000235423.7	RP11-282O18.3	8.15	3.26e-15	1.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123231966	chr12:123252030~123261483:-
LGG	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	8.15	3.27e-15	1.37e-12	0.24	0.35	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
LGG	cis	rs4143844	1	rs12913358	ENSG00000259251.2	RP11-643M14.1	8.15	3.27e-15	1.37e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62032293	chr15:62060503~62062434:+
LGG	cis	rs11722779	0.935	rs6533046	ENSG00000248971.2	KRT8P46	-8.15	3.27e-15	1.37e-12	-0.36	-0.35	Schizophrenia;	chr4:102965917	chr4:102728746~102730171:-
LGG	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	8.15	3.28e-15	1.38e-12	0.5	0.35	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
LGG	cis	rs2797160	1	rs1612249	ENSG00000237742.5	RP11-624M8.1	8.15	3.29e-15	1.38e-12	0.32	0.35	Endometrial cancer;	chr6:125693770	chr6:125578558~125749190:-
LGG	cis	rs11148252	0.74	rs9536046	ENSG00000235660.1	LINC00345	-8.15	3.29e-15	1.38e-12	-0.43	-0.35	Lewy body disease;	chr13:52381764	chr13:52484161~52484680:-
LGG	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	8.15	3.29e-15	1.38e-12	0.81	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
LGG	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	8.15	3.29e-15	1.38e-12	0.34	0.35	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
LGG	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	8.15	3.29e-15	1.38e-12	0.34	0.35	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
LGG	cis	rs897984	0.542	rs4468641	ENSG00000260911.2	RP11-196G11.2	8.15	3.29e-15	1.38e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31085555	chr16:31043150~31049868:+
LGG	cis	rs879620	0.929	rs2238435	ENSG00000262185.1	RP11-462G12.1	-8.15	3.29e-15	1.38e-12	-0.44	-0.35	Hip circumference;Body mass index;	chr16:3964281	chr16:3947609~3950444:-
LGG	cis	rs453301	0.562	rs1038248	ENSG00000173295.6	FAM86B3P	8.15	3.3e-15	1.38e-12	0.36	0.35	Joint mobility (Beighton score);	chr8:9183348	chr8:8228595~8244865:+
LGG	cis	rs228614	0.51	rs223349	ENSG00000248971.2	KRT8P46	-8.15	3.3e-15	1.38e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102728746~102730171:-
LGG	cis	rs17772222	0.682	rs1864744	ENSG00000222990.1	RNU4-22P	-8.15	3.3e-15	1.38e-12	-0.42	-0.35	Coronary artery calcification;	chr14:88484662	chr14:88513498~88513663:+
LGG	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-8.15	3.31e-15	1.39e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
LGG	cis	rs2797160	1	rs1739378	ENSG00000237742.5	RP11-624M8.1	8.15	3.31e-15	1.39e-12	0.32	0.35	Endometrial cancer;	chr6:125691116	chr6:125578558~125749190:-
LGG	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-8.15	3.32e-15	1.39e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
LGG	cis	rs4143844	0.609	rs62007453	ENSG00000259251.2	RP11-643M14.1	8.15	3.32e-15	1.39e-12	0.59	0.35	Bipolar disorder and schizophrenia;	chr15:62062061	chr15:62060503~62062434:+
LGG	cis	rs9322193	0.962	rs1413655	ENSG00000216621.7	RP11-244K5.6	8.15	3.32e-15	1.39e-12	0.41	0.35	Lung cancer;	chr6:149821815	chr6:149934527~149936782:+
LGG	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-8.15	3.32e-15	1.4e-12	-0.36	-0.35	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
LGG	cis	rs6921919	0.697	rs12180820	ENSG00000218016.2	ZNF192P2	8.15	3.32e-15	1.4e-12	0.43	0.35	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28188050~28189432:+
LGG	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-8.15	3.33e-15	1.4e-12	-0.48	-0.35	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
LGG	cis	rs9322193	0.962	rs9688750	ENSG00000216621.7	RP11-244K5.6	8.15	3.34e-15	1.4e-12	0.42	0.35	Lung cancer;	chr6:149657633	chr6:149934527~149936782:+
LGG	cis	rs10790268	1	rs10790268	ENSG00000255239.1	AP002954.6	8.15	3.34e-15	1.4e-12	0.51	0.35	Rheumatoid arthritis;	chr11:118858682	chr11:118688039~118690600:-
LGG	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-8.15	3.35e-15	1.4e-12	-0.83	-0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
LGG	cis	rs7826238	0.502	rs10503377	ENSG00000173295.6	FAM86B3P	-8.15	3.36e-15	1.41e-12	-0.39	-0.35	Systolic blood pressure;	chr8:8520912	chr8:8228595~8244865:+
LGG	cis	rs3764021	0.527	rs10844380	ENSG00000256594.6	RP11-705C15.2	8.15	3.36e-15	1.41e-12	0.36	0.35	Type 1 diabetes;	chr12:9670678	chr12:9633419~9658412:+
LGG	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-8.15	3.36e-15	1.41e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
LGG	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	8.15	3.36e-15	1.41e-12	0.43	0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
LGG	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	8.15	3.36e-15	1.41e-12	0.43	0.35	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
LGG	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-8.15	3.36e-15	1.41e-12	-0.44	-0.35	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
LGG	cis	rs1707322	0.964	rs785483	ENSG00000281133.1	AL355480.3	8.15	3.37e-15	1.41e-12	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45580892~45580996:-
LGG	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	8.15	3.37e-15	1.41e-12	0.43	0.35	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
LGG	cis	rs11992162	0.967	rs4841661	ENSG00000255556.2	RP11-351I21.6	8.15	3.37e-15	1.41e-12	0.43	0.35	Monocyte count;	chr8:11975260	chr8:12378679~12380265:-
LGG	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.38e-15	1.42e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.38e-15	1.42e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.38e-15	1.42e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.38e-15	1.42e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.38e-15	1.42e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.38e-15	1.42e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.38e-15	1.42e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
LGG	cis	rs7267979	0.586	rs6050429	ENSG00000125804.12	FAM182A	-8.15	3.38e-15	1.42e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.586	rs6050431	ENSG00000125804.12	FAM182A	-8.15	3.38e-15	1.42e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.586	rs6050432	ENSG00000125804.12	FAM182A	-8.15	3.38e-15	1.42e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:26054655~26086917:+
LGG	cis	rs11098499	0.954	rs1022145	ENSG00000250412.1	KLHL2P1	8.15	3.38e-15	1.42e-12	0.41	0.35	Corneal astigmatism;	chr4:119309824	chr4:119334329~119378233:+
LGG	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	8.15	3.39e-15	1.42e-12	0.36	0.35	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
LGG	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	8.15	3.39e-15	1.42e-12	0.36	0.35	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
LGG	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	8.15	3.39e-15	1.42e-12	0.36	0.35	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
LGG	cis	rs11098499	0.954	rs3733524	ENSG00000250412.1	KLHL2P1	8.14	3.39e-15	1.42e-12	0.41	0.35	Corneal astigmatism;	chr4:119502574	chr4:119334329~119378233:+
LGG	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-8.14	3.4e-15	1.42e-12	-0.33	-0.35	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
LGG	cis	rs881375	0.501	rs10739591	ENSG00000226752.6	PSMD5-AS1	-8.14	3.41e-15	1.43e-12	-0.51	-0.35	Rheumatoid arthritis;	chr9:121123450	chr9:120824828~120854385:+
LGG	cis	rs2638953	0.79	rs11049653	ENSG00000278733.1	RP11-425D17.1	-8.14	3.41e-15	1.43e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28479882	chr12:28185625~28186190:-
LGG	cis	rs2797160	0.904	rs1777197	ENSG00000237742.5	RP11-624M8.1	8.14	3.42e-15	1.43e-12	0.32	0.35	Endometrial cancer;	chr6:125686255	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.904	rs1739366	ENSG00000237742.5	RP11-624M8.1	8.14	3.42e-15	1.43e-12	0.32	0.35	Endometrial cancer;	chr6:125686263	chr6:125578558~125749190:-
LGG	cis	rs7267979	0.586	rs6050439	ENSG00000125804.12	FAM182A	-8.14	3.42e-15	1.43e-12	-0.42	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:26054655~26086917:+
LGG	cis	rs128738	0.5	rs743563	ENSG00000233006.5	AC034220.3	-8.14	3.43e-15	1.44e-12	-0.42	-0.35	Giant cell arteritis;	chr5:132233713	chr5:132311285~132369916:-
LGG	cis	rs1275468	0.731	rs1383098	ENSG00000257497.2	RP11-585P4.5	-8.14	3.43e-15	1.44e-12	-0.49	-0.35	Polycystic ovary syndrome;	chr12:75588107	chr12:75483454~75489820:-
LGG	cis	rs7189233	0.955	rs72801821	ENSG00000279344.1	RP11-44F14.7	8.14	3.43e-15	1.44e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr16:53445740	chr16:53478957~53481550:-
LGG	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-8.14	3.44e-15	1.44e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-8.14	3.44e-15	1.44e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-8.14	3.44e-15	1.44e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-8.14	3.44e-15	1.44e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
LGG	cis	rs2933343	0.818	rs6764681	ENSG00000231305.3	RP11-723O4.2	-8.14	3.44e-15	1.44e-12	-0.38	-0.35	IgG glycosylation;	chr3:128849537	chr3:128861313~128871540:-
LGG	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-8.14	3.44e-15	1.44e-12	-0.37	-0.35	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
LGG	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-8.14	3.44e-15	1.44e-12	-0.47	-0.35	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
LGG	cis	rs2877649	0.51	rs10083379	ENSG00000258744.1	RP11-80A15.1	-8.14	3.44e-15	1.44e-12	-0.78	-0.35	Smooth-surface caries;	chr14:24438856	chr14:24501594~24508688:+
LGG	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-8.14	3.44e-15	1.44e-12	-0.36	-0.35	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
LGG	cis	rs2638953	0.924	rs1841962	ENSG00000278733.1	RP11-425D17.1	8.14	3.44e-15	1.44e-12	0.42	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28220919	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs7969582	ENSG00000278733.1	RP11-425D17.1	8.14	3.44e-15	1.44e-12	0.42	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28236725	chr12:28185625~28186190:-
LGG	cis	rs62184315	0.638	rs12475694	ENSG00000253559.1	OSGEPL1-AS1	8.14	3.45e-15	1.44e-12	0.4	0.35	Alcohol dependence (age at onset);	chr2:189907882	chr2:189762704~189765556:+
LGG	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	8.14	3.45e-15	1.44e-12	0.41	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
LGG	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	8.14	3.45e-15	1.44e-12	0.4	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
LGG	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-8.14	3.45e-15	1.45e-12	-0.32	-0.35	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
LGG	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	8.14	3.46e-15	1.45e-12	0.44	0.35	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
LGG	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-8.14	3.47e-15	1.45e-12	-0.39	-0.35	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
LGG	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	8.14	3.48e-15	1.46e-12	0.3	0.35	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
LGG	cis	rs35160687	0.644	rs11680025	ENSG00000273080.1	RP11-301O19.1	-8.14	3.5e-15	1.46e-12	-0.37	-0.35	Night sleep phenotypes;	chr2:86318215	chr2:86195590~86196049:+
LGG	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-8.14	3.5e-15	1.47e-12	-0.44	-0.35	Height;	chr14:75022243	chr14:75011269~75012851:-
LGG	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-8.14	3.5e-15	1.47e-12	-0.46	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
LGG	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	8.14	3.5e-15	1.47e-12	0.34	0.35	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
LGG	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-8.14	3.5e-15	1.47e-12	-0.39	-0.35	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
LGG	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-8.14	3.5e-15	1.47e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
LGG	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-8.14	3.51e-15	1.47e-12	-0.24	-0.35	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
LGG	cis	rs11098499	0.954	rs11722872	ENSG00000250412.1	KLHL2P1	8.14	3.52e-15	1.47e-12	0.41	0.35	Corneal astigmatism;	chr4:119311875	chr4:119334329~119378233:+
LGG	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	-8.14	3.55e-15	1.48e-12	-0.36	-0.35	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
LGG	cis	rs1707322	1	rs3922887	ENSG00000281133.1	AL355480.3	-8.14	3.55e-15	1.49e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs3922886	ENSG00000281133.1	AL355480.3	-8.14	3.55e-15	1.49e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45580892~45580996:-
LGG	cis	rs2638953	0.853	rs10506037	ENSG00000278733.1	RP11-425D17.1	-8.14	3.55e-15	1.49e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28185625~28186190:-
LGG	cis	rs997295	0.57	rs72747462	ENSG00000270964.1	RP11-502I4.3	-8.14	3.56e-15	1.49e-12	-0.37	-0.35	Motion sickness;	chr15:67526200	chr15:67541072~67542604:-
LGG	cis	rs997295	0.57	rs72747464	ENSG00000270964.1	RP11-502I4.3	-8.14	3.56e-15	1.49e-12	-0.37	-0.35	Motion sickness;	chr15:67526202	chr15:67541072~67542604:-
LGG	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	8.14	3.56e-15	1.49e-12	0.24	0.35	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
LGG	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	8.14	3.56e-15	1.49e-12	0.23	0.35	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
LGG	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	8.14	3.58e-15	1.5e-12	0.44	0.35	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
LGG	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	8.14	3.58e-15	1.5e-12	0.34	0.35	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
LGG	cis	rs3742264	0.925	rs1087	ENSG00000235903.6	CPB2-AS1	8.14	3.59e-15	1.5e-12	0.38	0.35	Blood protein levels;	chr13:46053304	chr13:46052806~46113332:+
LGG	cis	rs11671005	0.61	rs4756	ENSG00000269600.1	AC016629.3	-8.14	3.59e-15	1.5e-12	-0.48	-0.35	Mean platelet volume;	chr19:58563286	chr19:58593896~58599355:-
LGG	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	8.14	3.6e-15	1.51e-12	0.53	0.35	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
LGG	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-8.14	3.6e-15	1.51e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
LGG	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-8.14	3.6e-15	1.51e-12	-0.46	-0.35	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
LGG	cis	rs7267979	0.586	rs6083776	ENSG00000125804.12	FAM182A	-8.14	3.6e-15	1.51e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:26054655~26086917:+
LGG	cis	rs7267979	0.586	rs1473695	ENSG00000125804.12	FAM182A	-8.14	3.6e-15	1.51e-12	-0.43	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:26054655~26086917:+
LGG	cis	rs2980439	0.807	rs2980438	ENSG00000253981.4	ALG1L13P	-8.14	3.61e-15	1.51e-12	-0.36	-0.35	Neuroticism;	chr8:8237303	chr8:8236003~8244667:-
LGG	cis	rs7119038	0.865	rs4936443	ENSG00000255239.1	AP002954.6	8.14	3.61e-15	1.51e-12	0.5	0.35	Sjögren's syndrome;	chr11:118870155	chr11:118688039~118690600:-
LGG	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-8.14	3.62e-15	1.51e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
LGG	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	8.14	3.62e-15	1.51e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
LGG	cis	rs1707322	0.865	rs785501	ENSG00000281133.1	AL355480.3	8.14	3.63e-15	1.52e-12	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.929	rs785500	ENSG00000281133.1	AL355480.3	8.14	3.63e-15	1.52e-12	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45580892~45580996:-
LGG	cis	rs7267979	0.744	rs6050463	ENSG00000276952.1	RP5-965G21.6	8.14	3.64e-15	1.52e-12	0.35	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25284915~25285588:-
LGG	cis	rs4950322	0.58	rs4950371	ENSG00000278811.3	LINC00624	8.13	3.65e-15	1.52e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147114243	chr1:147258885~147517875:-
LGG	cis	rs4143844	0.867	rs11637599	ENSG00000259251.2	RP11-643M14.1	8.13	3.65e-15	1.52e-12	0.59	0.35	Bipolar disorder and schizophrenia;	chr15:62058866	chr15:62060503~62062434:+
LGG	cis	rs17345786	0.906	rs58835747	ENSG00000256628.3	ZBTB11-AS1	8.13	3.65e-15	1.53e-12	0.45	0.35	Colonoscopy-negative controls vs population controls;	chr3:101524790	chr3:101676475~101679217:+
LGG	cis	rs853679	0.546	rs200990	ENSG00000199851.2	U3	8.13	3.65e-15	1.53e-12	0.73	0.35	Depression;	chr6:27848045	chr6:28015568~28015777:+
LGG	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	8.13	3.67e-15	1.53e-12	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	8.13	3.67e-15	1.53e-12	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
LGG	cis	rs62184315	0.536	rs62183659	ENSG00000253559.1	OSGEPL1-AS1	-8.13	3.67e-15	1.53e-12	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189672131	chr2:189762704~189765556:+
LGG	cis	rs62184315	0.536	rs62185869	ENSG00000253559.1	OSGEPL1-AS1	-8.13	3.67e-15	1.53e-12	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189672330	chr2:189762704~189765556:+
LGG	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-8.13	3.67e-15	1.54e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
LGG	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-8.13	3.67e-15	1.54e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
LGG	cis	rs11098499	0.954	rs6849561	ENSG00000250412.1	KLHL2P1	-8.13	3.67e-15	1.54e-12	-0.41	-0.35	Corneal astigmatism;	chr4:119488539	chr4:119334329~119378233:+
LGG	cis	rs7267979	0.816	rs6115094	ENSG00000276952.1	RP5-965G21.6	8.13	3.68e-15	1.54e-12	0.35	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25284915~25285588:-
LGG	cis	rs5742933	0.69	rs16831821	ENSG00000253559.1	OSGEPL1-AS1	-8.13	3.68e-15	1.54e-12	-0.53	-0.35	Ferritin levels;	chr2:189641087	chr2:189762704~189765556:+
LGG	cis	rs4950322	0.58	rs17359629	ENSG00000278811.3	LINC00624	8.13	3.68e-15	1.54e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147121537	chr1:147258885~147517875:-
LGG	cis	rs2281558	1	rs2281558	ENSG00000125804.12	FAM182A	-8.13	3.68e-15	1.54e-12	-0.47	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25259553	chr20:26054655~26086917:+
LGG	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-8.13	3.68e-15	1.54e-12	-0.48	-0.35	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
LGG	cis	rs9719620	0.9	rs4731788	ENSG00000236753.4	MKLN1-AS	-8.13	3.69e-15	1.54e-12	-0.37	-0.35	Male-pattern baldness;	chr7:131302207	chr7:131309744~131328222:-
LGG	cis	rs6496932	0.913	rs7403354	ENSG00000218052.5	ADAMTS7P4	8.13	3.69e-15	1.54e-12	0.51	0.35	Central corneal thickness;Corneal structure;	chr15:85277624	chr15:85255369~85330334:-
LGG	cis	rs889122	0.68	rs4804459	ENSG00000267289.1	CTD-2623N2.11	-8.13	3.69e-15	1.54e-12	-0.46	-0.35	Menarche (age at onset);	chr19:9834111	chr19:9834079~9835013:-
LGG	cis	rs7241530	0.61	rs57260166	ENSG00000266213.1	RP11-100K18.1	-8.13	3.69e-15	1.54e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78134041	chr18:78137223~78140887:+
LGG	cis	rs11971779	0.527	rs1076349	ENSG00000273391.1	RP11-634H22.1	8.13	3.7e-15	1.55e-12	0.37	0.35	Diisocyanate-induced asthma;	chr7:139441748	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.65	rs4732380	ENSG00000273391.1	RP11-634H22.1	8.13	3.7e-15	1.55e-12	0.37	0.35	Diisocyanate-induced asthma;	chr7:139442113	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.715	rs6467853	ENSG00000273391.1	RP11-634H22.1	8.13	3.7e-15	1.55e-12	0.37	0.35	Diisocyanate-induced asthma;	chr7:139442281	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.715	rs6467854	ENSG00000273391.1	RP11-634H22.1	8.13	3.7e-15	1.55e-12	0.37	0.35	Diisocyanate-induced asthma;	chr7:139442337	chr7:139359032~139359566:-
LGG	cis	rs11098499	0.954	rs7436506	ENSG00000250412.1	KLHL2P1	8.13	3.7e-15	1.55e-12	0.4	0.35	Corneal astigmatism;	chr4:119472614	chr4:119334329~119378233:+
LGG	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66692349	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66693433	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66694214	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66701371	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66702658	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66706390	chr7:66654538~66669855:+
LGG	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66710076	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66715944	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66721259	chr7:66654538~66669855:+
LGG	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-8.13	3.7e-15	1.55e-12	-0.71	-0.35	Gout;	chr7:66732812	chr7:66654538~66669855:+
LGG	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	-8.13	3.72e-15	1.55e-12	-0.5	-0.35	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
LGG	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	8.13	3.72e-15	1.55e-12	0.4	0.35	Height;	chr6:109347707	chr6:109382795~109383666:+
LGG	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-8.13	3.72e-15	1.55e-12	-0.43	-0.35	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
LGG	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-8.13	3.73e-15	1.56e-12	-0.47	-0.35	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
LGG	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-8.13	3.74e-15	1.56e-12	-0.36	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
LGG	cis	rs8135665	0.6	rs6519097	ENSG00000233739.1	RP5-1039K5.13	8.13	3.75e-15	1.56e-12	0.4	0.35	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38055458	chr22:38057180~38073940:-
LGG	cis	rs9300255	0.602	rs1727314	ENSG00000235423.7	RP11-282O18.3	8.13	3.75e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123156117	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.537	rs2682429	ENSG00000235423.7	RP11-282O18.3	8.13	3.75e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123158408	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs2851438	ENSG00000235423.7	RP11-282O18.3	8.13	3.75e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123159142	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.568	rs1047158	ENSG00000235423.7	RP11-282O18.3	8.13	3.75e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123159509	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs1051431	ENSG00000235423.7	RP11-282O18.3	8.13	3.75e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123161256	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs1727296	ENSG00000235423.7	RP11-282O18.3	8.13	3.75e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123163178	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs1716165	ENSG00000235423.7	RP11-282O18.3	8.13	3.75e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123164334	chr12:123252030~123261483:-
LGG	cis	rs2797160	0.935	rs12717178	ENSG00000237742.5	RP11-624M8.1	8.13	3.76e-15	1.57e-12	0.32	0.35	Endometrial cancer;	chr6:125695353	chr6:125578558~125749190:-
LGG	cis	rs9300255	0.602	rs1727316	ENSG00000235423.7	RP11-282O18.3	8.13	3.76e-15	1.57e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123134056	chr12:123252030~123261483:-
LGG	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-8.13	3.76e-15	1.57e-12	-0.36	-0.35	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
LGG	cis	rs2797160	0.935	rs1739379	ENSG00000237742.5	RP11-624M8.1	8.13	3.77e-15	1.57e-12	0.32	0.35	Endometrial cancer;	chr6:125691447	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1739380	ENSG00000237742.5	RP11-624M8.1	8.13	3.77e-15	1.57e-12	0.32	0.35	Endometrial cancer;	chr6:125691712	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1630556	ENSG00000237742.5	RP11-624M8.1	8.13	3.77e-15	1.57e-12	0.32	0.35	Endometrial cancer;	chr6:125692009	chr6:125578558~125749190:-
LGG	cis	rs4714902	0.655	rs7766019	ENSG00000231769.2	RP1-8B1.4	-8.13	3.78e-15	1.58e-12	-0.38	-0.35	Colonoscopy-negative controls vs population controls;	chr6:46115830	chr6:46097093~46129706:-
LGG	cis	rs7189233	0.956	rs62048486	ENSG00000279344.1	RP11-44F14.7	8.13	3.78e-15	1.58e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr16:53414427	chr16:53478957~53481550:-
LGG	cis	rs11220082	0.627	rs34912904	ENSG00000254671.2	STT3A-AS1	-8.13	3.78e-15	1.58e-12	-0.43	-0.35	Schizophrenia;	chr11:125475460	chr11:125570284~125592568:-
LGG	cis	rs9322193	0.884	rs9688858	ENSG00000216621.7	RP11-244K5.6	8.13	3.79e-15	1.58e-12	0.42	0.35	Lung cancer;	chr6:149637911	chr6:149934527~149936782:+
LGG	cis	rs8031584	0.958	rs34909055	ENSG00000270015.1	RP11-540B6.6	-8.13	3.79e-15	1.58e-12	-0.26	-0.35	Huntington's disease progression;	chr15:30991967	chr15:30926514~30928407:+
LGG	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	8.13	3.8e-15	1.58e-12	0.48	0.35	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
LGG	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	8.13	3.8e-15	1.58e-12	0.41	0.35	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
LGG	cis	rs12936587	0.583	rs9783803	ENSG00000223979.2	SMCR2	8.13	3.8e-15	1.58e-12	0.34	0.35	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17649583	chr17:17674026~17677688:-
LGG	cis	rs11098499	0.863	rs13134665	ENSG00000250412.1	KLHL2P1	8.13	3.82e-15	1.59e-12	0.4	0.35	Corneal astigmatism;	chr4:119505275	chr4:119334329~119378233:+
LGG	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-8.13	3.83e-15	1.6e-12	-0.28	-0.35	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
LGG	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	8.13	3.83e-15	1.6e-12	0.45	0.35	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
LGG	cis	rs227275	0.554	rs9307281	ENSG00000248971.2	KRT8P46	-8.13	3.84e-15	1.6e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102728746~102730171:-
LGG	cis	rs11722779	0.903	rs6533037	ENSG00000248971.2	KRT8P46	-8.13	3.84e-15	1.6e-12	-0.36	-0.35	Schizophrenia;	chr4:102935865	chr4:102728746~102730171:-
LGG	cis	rs11722779	0.903	rs4530634	ENSG00000248971.2	KRT8P46	-8.13	3.84e-15	1.6e-12	-0.36	-0.35	Schizophrenia;	chr4:102937924	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs7676943	ENSG00000248971.2	KRT8P46	-8.13	3.84e-15	1.6e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs6419160	ENSG00000248971.2	KRT8P46	-8.13	3.84e-15	1.6e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102728746~102730171:-
LGG	cis	rs11722779	0.838	rs3974494	ENSG00000248971.2	KRT8P46	-8.13	3.84e-15	1.6e-12	-0.36	-0.35	Schizophrenia;	chr4:102945323	chr4:102728746~102730171:-
LGG	cis	rs7241530	0.536	rs34231010	ENSG00000266213.1	RP11-100K18.1	-8.13	3.84e-15	1.6e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78131275	chr18:78137223~78140887:+
LGG	cis	rs748404	0.589	rs62020616	ENSG00000249839.1	AC011330.5	-8.13	3.84e-15	1.6e-12	-0.54	-0.35	Lung cancer;	chr15:43558554	chr15:43663654~43684339:-
LGG	cis	rs748404	0.626	rs60367691	ENSG00000249839.1	AC011330.5	-8.13	3.84e-15	1.6e-12	-0.54	-0.35	Lung cancer;	chr15:43559201	chr15:43663654~43684339:-
LGG	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-8.13	3.84e-15	1.6e-12	-0.3	-0.35	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
LGG	cis	rs12468226	0.938	rs55668474	ENSG00000273456.1	RP11-686O6.2	8.13	3.84e-15	1.6e-12	0.34	0.35	Urate levels;	chr2:202265559	chr2:202374932~202375604:-
LGG	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-8.13	3.85e-15	1.6e-12	-0.28	-0.35	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
LGG	cis	rs11722779	0.873	rs6533041	ENSG00000248971.2	KRT8P46	-8.13	3.85e-15	1.61e-12	-0.36	-0.35	Schizophrenia;	chr4:102951615	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs4698867	ENSG00000248971.2	KRT8P46	-8.13	3.85e-15	1.61e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102728746~102730171:-
LGG	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	8.13	3.86e-15	1.61e-12	0.6	0.35	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
LGG	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	8.13	3.86e-15	1.61e-12	0.6	0.35	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
LGG	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	8.13	3.86e-15	1.61e-12	0.24	0.35	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
LGG	cis	rs11722779	0.935	rs3857199	ENSG00000248971.2	KRT8P46	-8.13	3.86e-15	1.61e-12	-0.36	-0.35	Schizophrenia;	chr4:102957991	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs5028609	ENSG00000248971.2	KRT8P46	-8.13	3.86e-15	1.61e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs6815540	ENSG00000248971.2	KRT8P46	-8.13	3.86e-15	1.61e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs7663876	ENSG00000248971.2	KRT8P46	-8.13	3.86e-15	1.61e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102728746~102730171:-
LGG	cis	rs9322193	0.962	rs4552	ENSG00000216621.7	RP11-244K5.6	8.13	3.87e-15	1.61e-12	0.42	0.35	Lung cancer;	chr6:149811183	chr6:149934527~149936782:+
LGG	cis	rs73222236	0.71	rs7620314	ENSG00000261758.1	RP11-102M11.2	-8.13	3.87e-15	1.61e-12	-0.36	-0.35	Coronary artery disease;	chr3:136413863	chr3:136752630~136755780:+
LGG	cis	rs227275	0.556	rs6842179	ENSG00000248971.2	KRT8P46	-8.13	3.88e-15	1.62e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102728746~102730171:-
LGG	cis	rs879620	1	rs2531995	ENSG00000262185.1	RP11-462G12.1	-8.13	3.88e-15	1.62e-12	-0.44	-0.35	Hip circumference;Body mass index;	chr16:3963466	chr16:3947609~3950444:-
LGG	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-8.13	3.88e-15	1.62e-12	-0.41	-0.35	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
LGG	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-8.13	3.89e-15	1.62e-12	-0.4	-0.35	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
LGG	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-8.13	3.89e-15	1.62e-12	-0.4	-0.35	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
LGG	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-8.13	3.89e-15	1.62e-12	-0.4	-0.35	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
LGG	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-8.13	3.89e-15	1.62e-12	-0.4	-0.35	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
LGG	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-8.13	3.89e-15	1.62e-12	-0.4	-0.35	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
LGG	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	8.13	3.9e-15	1.62e-12	0.33	0.35	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
LGG	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-8.13	3.9e-15	1.62e-12	-0.39	-0.35	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
LGG	cis	rs2797160	1	rs1832979	ENSG00000237742.5	RP11-624M8.1	-8.13	3.9e-15	1.63e-12	-0.32	-0.35	Endometrial cancer;	chr6:125676290	chr6:125578558~125749190:-
LGG	cis	rs9322193	0.962	rs2151912	ENSG00000216621.7	RP11-244K5.6	8.13	3.9e-15	1.63e-12	0.41	0.35	Lung cancer;	chr6:149831772	chr6:149934527~149936782:+
LGG	cis	rs9300255	0.739	rs11057210	ENSG00000235423.7	RP11-282O18.3	8.13	3.91e-15	1.63e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123249252	chr12:123252030~123261483:-
LGG	cis	rs2797160	1	rs1739348	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125693427	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1739349	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125693838	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.967	rs1578793	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125693911	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1578794	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125694323	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs6927161	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125694808	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs6904992	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125694857	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs13328298	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125695434	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs6933302	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125695805	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs6933471	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125695883	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.967	rs6910786	ENSG00000237742.5	RP11-624M8.1	8.13	3.92e-15	1.63e-12	0.32	0.35	Endometrial cancer;	chr6:125695995	chr6:125578558~125749190:-
LGG	cis	rs2877649	0.623	rs3742521	ENSG00000258744.1	RP11-80A15.1	-8.13	3.92e-15	1.63e-12	-0.77	-0.35	Smooth-surface caries;	chr14:24437309	chr14:24501594~24508688:+
LGG	cis	rs2877649	0.623	rs3742522	ENSG00000258744.1	RP11-80A15.1	-8.13	3.92e-15	1.63e-12	-0.77	-0.35	Smooth-surface caries;	chr14:24437328	chr14:24501594~24508688:+
LGG	cis	rs2877649	0.51	rs17103743	ENSG00000258744.1	RP11-80A15.1	-8.13	3.92e-15	1.63e-12	-0.77	-0.35	Smooth-surface caries;	chr14:24438346	chr14:24501594~24508688:+
LGG	cis	rs2877649	0.51	rs73593299	ENSG00000258744.1	RP11-80A15.1	-8.13	3.92e-15	1.63e-12	-0.77	-0.35	Smooth-surface caries;	chr14:24438440	chr14:24501594~24508688:+
LGG	cis	rs2074193	1	rs2074193	ENSG00000257906.1	RP1-90J4.1	-8.12	3.92e-15	1.63e-12	-0.37	-0.35	Migraine with aura;	chr12:47377646	chr12:47415008~47420179:+
LGG	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-8.12	3.92e-15	1.63e-12	-0.36	-0.35	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
LGG	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	8.12	3.92e-15	1.63e-12	0.3	0.35	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
LGG	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	8.12	3.92e-15	1.63e-12	0.3	0.35	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
LGG	cis	rs8180040	0.966	rs12486969	ENSG00000271161.1	BOLA2P2	-8.12	3.93e-15	1.64e-12	-0.32	-0.35	Colorectal cancer;	chr3:47387513	chr3:47499841~47500407:+
LGG	cis	rs8180040	0.966	rs56351005	ENSG00000271161.1	BOLA2P2	-8.12	3.93e-15	1.64e-12	-0.32	-0.35	Colorectal cancer;	chr3:47388696	chr3:47499841~47500407:+
LGG	cis	rs9322193	0.962	rs17673294	ENSG00000216621.7	RP11-244K5.6	8.12	3.93e-15	1.64e-12	0.42	0.35	Lung cancer;	chr6:149813857	chr6:149934527~149936782:+
LGG	cis	rs227275	0.525	rs13113923	ENSG00000248971.2	KRT8P46	-8.12	3.94e-15	1.64e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102728746~102730171:-
LGG	cis	rs733592	0.723	rs10875766	ENSG00000258273.1	RP11-370I10.4	-8.12	3.95e-15	1.64e-12	-0.44	-0.35	Plateletcrit;	chr12:48199797	chr12:48333755~48333901:-
LGG	cis	rs4143844	1	rs35119291	ENSG00000259251.2	RP11-643M14.1	8.12	3.95e-15	1.64e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62042007	chr15:62060503~62062434:+
LGG	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-8.12	3.95e-15	1.65e-12	-0.38	-0.35	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
LGG	cis	rs4143844	0.867	rs17303915	ENSG00000259251.2	RP11-643M14.1	8.12	3.95e-15	1.65e-12	0.61	0.35	Bipolar disorder and schizophrenia;	chr15:61882695	chr15:62060503~62062434:+
LGG	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	8.12	3.95e-15	1.65e-12	0.46	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
LGG	cis	rs11722779	0.844	rs3974602	ENSG00000248971.2	KRT8P46	-8.12	3.95e-15	1.65e-12	-0.36	-0.35	Schizophrenia;	chr4:102928840	chr4:102728746~102730171:-
LGG	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	8.12	3.96e-15	1.65e-12	0.31	0.35	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
LGG	cis	rs2638953	0.962	rs11049530	ENSG00000278733.1	RP11-425D17.1	-8.12	3.96e-15	1.65e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322220	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049531	ENSG00000278733.1	RP11-425D17.1	-8.12	3.96e-15	1.65e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322797	chr12:28185625~28186190:-
LGG	cis	rs2638953	1	rs11049532	ENSG00000278733.1	RP11-425D17.1	-8.12	3.96e-15	1.65e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28323979	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.925	rs10843154	ENSG00000278733.1	RP11-425D17.1	-8.12	3.96e-15	1.65e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28326824	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.889	rs10843155	ENSG00000278733.1	RP11-425D17.1	-8.12	3.96e-15	1.65e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28334920	chr12:28185625~28186190:-
LGG	cis	rs1707322	1	rs34694458	ENSG00000281133.1	AL355480.3	-8.12	3.96e-15	1.65e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45580892~45580996:-
LGG	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	8.12	3.97e-15	1.65e-12	0.41	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
LGG	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-8.12	3.97e-15	1.65e-12	-0.46	-0.35	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
LGG	cis	rs853679	0.567	rs13209596	ENSG00000226314.6	ZNF192P1	8.12	3.97e-15	1.65e-12	0.37	0.35	Depression;	chr6:28428413	chr6:28161781~28169594:+
LGG	cis	rs853679	0.567	rs9969098	ENSG00000226314.6	ZNF192P1	8.12	3.97e-15	1.65e-12	0.37	0.35	Depression;	chr6:28430971	chr6:28161781~28169594:+
LGG	cis	rs853679	0.567	rs7740429	ENSG00000226314.6	ZNF192P1	8.12	3.97e-15	1.65e-12	0.37	0.35	Depression;	chr6:28431469	chr6:28161781~28169594:+
LGG	cis	rs853679	0.567	rs16894106	ENSG00000226314.6	ZNF192P1	8.12	3.97e-15	1.65e-12	0.37	0.35	Depression;	chr6:28432562	chr6:28161781~28169594:+
LGG	cis	rs7829975	0.542	rs7844374	ENSG00000253893.2	FAM85B	8.12	3.97e-15	1.65e-12	0.43	0.35	Mood instability;	chr8:8941174	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.606	rs6601274	ENSG00000253893.2	FAM85B	8.12	3.97e-15	1.65e-12	0.43	0.35	Mood instability;	chr8:8941549	chr8:8167819~8226614:-
LGG	cis	rs10946940	0.965	rs62401383	ENSG00000199851.2	U3	-8.12	3.97e-15	1.65e-12	-0.46	-0.35	Systemic lupus erythematosus;	chr6:27596768	chr6:28015568~28015777:+
LGG	cis	rs2797160	0.602	rs4897150	ENSG00000237742.5	RP11-624M8.1	-8.12	3.97e-15	1.65e-12	-0.32	-0.35	Endometrial cancer;	chr6:125664394	chr6:125578558~125749190:-
LGG	cis	rs11148252	0.904	rs9526927	ENSG00000278238.1	RP11-245D16.4	-8.12	3.98e-15	1.65e-12	-0.33	-0.35	Lewy body disease;	chr13:52477492	chr13:52454775~52455331:-
LGG	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	8.12	3.98e-15	1.66e-12	0.4	0.35	Height;	chr6:109346560	chr6:109382795~109383666:+
LGG	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-8.12	3.98e-15	1.66e-12	-0.47	-0.35	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
LGG	cis	rs62184315	0.536	rs5742926	ENSG00000253559.1	OSGEPL1-AS1	-8.12	3.98e-15	1.66e-12	-0.51	-0.35	Alcohol dependence (age at onset);	chr2:189784079	chr2:189762704~189765556:+
LGG	cis	rs12468226	0.938	rs7568159	ENSG00000273456.1	RP11-686O6.2	8.12	3.98e-15	1.66e-12	0.34	0.35	Urate levels;	chr2:202286226	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs58834901	ENSG00000273456.1	RP11-686O6.2	8.12	3.98e-15	1.66e-12	0.34	0.35	Urate levels;	chr2:202288169	chr2:202374932~202375604:-
LGG	cis	rs12468226	0.938	rs6753044	ENSG00000273456.1	RP11-686O6.2	8.12	3.98e-15	1.66e-12	0.34	0.35	Urate levels;	chr2:202300710	chr2:202374932~202375604:-
LGG	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
LGG	cis	rs2797160	1	rs1739347	ENSG00000237742.5	RP11-624M8.1	8.12	3.99e-15	1.66e-12	0.32	0.35	Endometrial cancer;	chr6:125693011	chr6:125578558~125749190:-
LGG	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	8.12	3.99e-15	1.66e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
LGG	cis	rs7241530	0.61	rs7235050	ENSG00000266213.1	RP11-100K18.1	-8.12	3.99e-15	1.66e-12	-0.43	-0.35	Educational attainment (years of education);	chr18:78133094	chr18:78137223~78140887:+
LGG	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
LGG	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-8.12	3.99e-15	1.66e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
LGG	cis	rs2638953	0.925	rs11049567	ENSG00000278733.1	RP11-425D17.1	8.12	4e-15	1.67e-12	0.43	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28385502	chr12:28185625~28186190:-
LGG	cis	rs8180040	0.966	rs11705957	ENSG00000271161.1	BOLA2P2	-8.12	4.01e-15	1.67e-12	-0.32	-0.35	Colorectal cancer;	chr3:47401772	chr3:47499841~47500407:+
LGG	cis	rs75920871	0.528	rs7935913	ENSG00000254851.1	RP11-109L13.1	-8.12	4.01e-15	1.67e-12	-0.5	-0.35	Subjective well-being;	chr11:117073632	chr11:117135528~117138582:+
LGG	cis	rs1329650	1	rs10881926	ENSG00000228701.1	TNKS2-AS1	-8.12	4.02e-15	1.67e-12	-0.44	-0.35	Smoking behavior;	chr10:91584497	chr10:91782839~91798291:-
LGG	cis	rs17345786	0.906	rs72946021	ENSG00000256628.3	ZBTB11-AS1	8.12	4.03e-15	1.67e-12	0.45	0.35	Colonoscopy-negative controls vs population controls;	chr3:101531164	chr3:101676475~101679217:+
LGG	cis	rs2797160	1	rs1739354	ENSG00000237742.5	RP11-624M8.1	8.12	4.03e-15	1.68e-12	0.32	0.35	Endometrial cancer;	chr6:125696662	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.967	rs1739355	ENSG00000237742.5	RP11-624M8.1	8.12	4.03e-15	1.68e-12	0.32	0.35	Endometrial cancer;	chr6:125696968	chr6:125578558~125749190:-
LGG	cis	rs228614	0.51	rs223435	ENSG00000248971.2	KRT8P46	-8.12	4.03e-15	1.68e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223434	ENSG00000248971.2	KRT8P46	-8.12	4.03e-15	1.68e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs223426	ENSG00000248971.2	KRT8P46	-8.12	4.03e-15	1.68e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102728746~102730171:-
LGG	cis	rs227275	0.554	rs223425	ENSG00000248971.2	KRT8P46	-8.12	4.03e-15	1.68e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102728746~102730171:-
LGG	cis	rs228614	0.536	rs223418	ENSG00000248971.2	KRT8P46	-8.12	4.03e-15	1.68e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223415	ENSG00000248971.2	KRT8P46	-8.12	4.03e-15	1.68e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102728746~102730171:-
LGG	cis	rs3808502	0.503	rs2061830	ENSG00000255556.2	RP11-351I21.6	8.12	4.04e-15	1.68e-12	0.41	0.35	Neuroticism;	chr8:11539948	chr8:12378679~12380265:-
LGG	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-8.12	4.04e-15	1.68e-12	-0.45	-0.35	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
LGG	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	8.12	4.05e-15	1.68e-12	0.44	0.35	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
LGG	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	8.12	4.05e-15	1.68e-12	0.64	0.35	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
LGG	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	8.12	4.05e-15	1.68e-12	0.45	0.35	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
LGG	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	8.12	4.06e-15	1.69e-12	0.7	0.35	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
LGG	cis	rs227275	0.555	rs223402	ENSG00000248971.2	KRT8P46	-8.12	4.06e-15	1.69e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223392	ENSG00000248971.2	KRT8P46	-8.12	4.06e-15	1.69e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102728746~102730171:-
LGG	cis	rs227275	0.554	rs223390	ENSG00000248971.2	KRT8P46	-8.12	4.06e-15	1.69e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102728746~102730171:-
LGG	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-8.12	4.06e-15	1.69e-12	-0.41	-0.35	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
LGG	cis	rs600231	0.708	rs682845	ENSG00000245532.5	NEAT1	8.12	4.07e-15	1.69e-12	0.24	0.35	Bone mineral density;	chr11:65486730	chr11:65422774~65445540:+
LGG	cis	rs7474896	0.559	rs1779075	ENSG00000226578.1	RP11-258F22.1	8.12	4.07e-15	1.69e-12	0.47	0.35	Obesity (extreme);	chr10:37878602	chr10:37775371~37784131:-
LGG	cis	rs7474896	0.559	rs2753880	ENSG00000226578.1	RP11-258F22.1	8.12	4.07e-15	1.69e-12	0.47	0.35	Obesity (extreme);	chr10:37884410	chr10:37775371~37784131:-
LGG	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	8.12	4.07e-15	1.69e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
LGG	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-8.12	4.08e-15	1.7e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
LGG	cis	rs12073837	0.5	rs2807845	ENSG00000257551.1	HLX-AS1	-8.12	4.08e-15	1.7e-12	-0.42	-0.35	F-cell distribution;	chr1:220822945	chr1:220832763~220880140:-
LGG	cis	rs7927771	0.56	rs4752858	ENSG00000280615.1	Y_RNA	-8.12	4.08e-15	1.7e-12	-0.41	-0.35	Subjective well-being;	chr11:47664277	chr11:47614898~47614994:-
LGG	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-8.12	4.09e-15	1.7e-12	-0.36	-0.35	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
LGG	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	8.12	4.1e-15	1.7e-12	0.34	0.35	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
LGG	cis	rs6921919	0.848	rs9468350	ENSG00000280107.1	AL022393.9	-8.12	4.1e-15	1.7e-12	-0.39	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28170845~28172521:+
LGG	cis	rs1707322	1	rs1622208	ENSG00000281133.1	AL355480.3	8.12	4.1e-15	1.7e-12	0.42	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45580892~45580996:-
LGG	cis	rs9376098	1	rs9376098	ENSG00000232876.1	CTA-212D2.2	-8.12	4.1e-15	1.7e-12	-0.41	-0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135178322	chr6:135055033~135060550:+
LGG	cis	rs11148252	0.904	rs9568734	ENSG00000278238.1	RP11-245D16.4	-8.12	4.1e-15	1.71e-12	-0.33	-0.35	Lewy body disease;	chr13:52430087	chr13:52454775~52455331:-
LGG	cis	rs11148252	0.904	rs7990581	ENSG00000278238.1	RP11-245D16.4	-8.12	4.1e-15	1.71e-12	-0.33	-0.35	Lewy body disease;	chr13:52445298	chr13:52454775~52455331:-
LGG	cis	rs7474896	0.583	rs11011346	ENSG00000226578.1	RP11-258F22.1	-8.12	4.11e-15	1.71e-12	-0.48	-0.35	Obesity (extreme);	chr10:37720555	chr10:37775371~37784131:-
LGG	cis	rs7267979	0.549	rs6138536	ENSG00000125804.12	FAM182A	-8.12	4.11e-15	1.71e-12	-0.42	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:26054655~26086917:+
LGG	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	8.12	4.11e-15	1.71e-12	0.3	0.35	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
LGG	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	8.12	4.11e-15	1.71e-12	0.3	0.35	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
LGG	cis	rs17772222	0.682	rs7142053	ENSG00000222990.1	RNU4-22P	8.12	4.11e-15	1.71e-12	0.42	0.35	Coronary artery calcification;	chr14:88511594	chr14:88513498~88513663:+
LGG	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-8.12	4.12e-15	1.71e-12	-0.46	-0.35	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
LGG	cis	rs1707322	1	rs6672115	ENSG00000281133.1	AL355480.3	-8.12	4.12e-15	1.71e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45580892~45580996:-
LGG	cis	rs4143844	0.867	rs12185103	ENSG00000259251.2	RP11-643M14.1	8.12	4.12e-15	1.71e-12	0.6	0.35	Bipolar disorder and schizophrenia;	chr15:61889092	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs35559361	ENSG00000259251.2	RP11-643M14.1	8.12	4.12e-15	1.71e-12	0.6	0.35	Bipolar disorder and schizophrenia;	chr15:61891318	chr15:62060503~62062434:+
LGG	cis	rs2933343	0.553	rs35979399	ENSG00000231305.3	RP11-723O4.2	8.12	4.13e-15	1.71e-12	0.36	0.35	IgG glycosylation;	chr3:128978470	chr3:128861313~128871540:-
LGG	cis	rs2933343	0.533	rs11915889	ENSG00000231305.3	RP11-723O4.2	8.12	4.13e-15	1.71e-12	0.36	0.35	IgG glycosylation;	chr3:128982023	chr3:128861313~128871540:-
LGG	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	8.12	4.13e-15	1.71e-12	0.4	0.35	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
LGG	cis	rs7267979	0.586	rs1007708	ENSG00000125804.12	FAM182A	-8.12	4.13e-15	1.71e-12	-0.42	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:26054655~26086917:+
LGG	cis	rs2638953	0.853	rs11049670	ENSG00000278733.1	RP11-425D17.1	8.12	4.13e-15	1.72e-12	0.42	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28499342	chr12:28185625~28186190:-
LGG	cis	rs10246939	0.543	rs994809	ENSG00000261570.1	RP11-744I24.2	-8.12	4.14e-15	1.72e-12	-0.45	-0.35	Bitter taste perception;	chr7:141911485	chr7:141529203~141551304:-
LGG	cis	rs1023500	0.551	rs133355	ENSG00000227370.1	RP4-669P10.19	8.12	4.15e-15	1.72e-12	0.31	0.35	Schizophrenia;	chr22:42044281	chr22:42132543~42132998:+
LGG	cis	rs12554020	0.892	rs6479494	ENSG00000237385.1	RP11-165J3.5	-8.12	4.15e-15	1.72e-12	-0.58	-0.35	Schizophrenia;	chr9:93568217	chr9:93430342~93431299:-
LGG	cis	rs11148252	0.74	rs9596643	ENSG00000235660.1	LINC00345	8.12	4.15e-15	1.72e-12	0.43	0.35	Lewy body disease;	chr13:52338245	chr13:52484161~52484680:-
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	8.12	4.16e-15	1.73e-12	0.49	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
LGG	cis	rs6657613	0.68	rs7545499	ENSG00000186715.9	MST1L	8.12	4.16e-15	1.73e-12	0.32	0.35	Hip circumference adjusted for BMI;	chr1:17048193	chr1:16754910~16770237:-
LGG	cis	rs2877649	0.51	rs10083509	ENSG00000258744.1	RP11-80A15.1	8.12	4.17e-15	1.73e-12	0.77	0.35	Smooth-surface caries;	chr14:24438841	chr14:24501594~24508688:+
LGG	cis	rs12935418	0.583	rs80181133	ENSG00000260213.4	RP11-303E16.3	-8.12	4.19e-15	1.74e-12	-0.48	-0.35	Mean corpuscular volume;	chr16:80934053	chr16:81016792~81035759:-
LGG	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-8.12	4.19e-15	1.74e-12	-0.42	-0.35	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
LGG	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-8.12	4.19e-15	1.74e-12	-0.31	-0.35	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
LGG	cis	rs1707322	1	rs7531911	ENSG00000281133.1	AL355480.3	-8.12	4.19e-15	1.74e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs10890359	ENSG00000281133.1	AL355480.3	-8.12	4.19e-15	1.74e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45580892~45580996:-
LGG	cis	rs35934224	0.783	rs7285948	ENSG00000232926.1	AC000078.5	8.12	4.19e-15	1.74e-12	0.38	0.35	Glaucoma (primary open-angle);	chr22:19873604	chr22:19887289~19887970:+
LGG	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-8.12	4.19e-15	1.74e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
LGG	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-8.12	4.19e-15	1.74e-12	-0.36	-0.35	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
LGG	cis	rs35857674	0.5	rs203932	ENSG00000253484.1	RP11-109P6.2	8.12	4.21e-15	1.75e-12	0.35	0.35	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50076101	chr8:49817586~49820944:-
LGG	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	8.11	4.21e-15	1.75e-12	0.36	0.35	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
LGG	cis	rs11098499	0.954	rs1480931	ENSG00000250412.1	KLHL2P1	8.11	4.21e-15	1.75e-12	0.4	0.35	Corneal astigmatism;	chr4:119474654	chr4:119334329~119378233:+
LGG	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-8.11	4.22e-15	1.75e-12	-0.46	-0.35	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
LGG	cis	rs7219021	0.705	rs7207087	ENSG00000248278.1	SUMO2P17	8.11	4.22e-15	1.75e-12	0.41	0.35	Schizophrenia or bipolar disorder;	chr17:48840591	chr17:48874860~48908983:-
LGG	cis	rs7003550	0.507	rs6577889	ENSG00000253433.1	NCRNA00250	-8.11	4.23e-15	1.76e-12	-0.43	-0.35	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134838304	chr8:134838069~134842637:+
LGG	cis	rs7119038	0.73	rs10790269	ENSG00000255239.1	AP002954.6	8.11	4.24e-15	1.76e-12	0.5	0.35	Sjögren's syndrome;	chr11:118858747	chr11:118688039~118690600:-
LGG	cis	rs35425515	0.706	rs17112405	ENSG00000234855.1	SLIT1-AS1	8.11	4.24e-15	1.76e-12	0.6	0.35	Bipolar disorder;	chr10:97103060	chr10:97102756~97103747:+
LGG	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-8.11	4.25e-15	1.76e-12	-0.47	-0.35	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
LGG	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-8.11	4.25e-15	1.76e-12	-0.87	-0.35	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
LGG	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-8.11	4.27e-15	1.77e-12	-0.47	-0.35	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
LGG	cis	rs9859260	0.71	rs41298097	ENSG00000242086.7	LINC00969	-8.11	4.28e-15	1.77e-12	-0.31	-0.35	Mean corpuscular volume;	chr3:196052284	chr3:195658062~195739964:+
LGG	cis	rs858239	0.669	rs12539467	ENSG00000230042.1	AK3P3	-8.11	4.28e-15	1.77e-12	-0.36	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23129178~23129841:+
LGG	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-8.11	4.28e-15	1.78e-12	-0.42	-0.35	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
LGG	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-8.11	4.28e-15	1.78e-12	-0.42	-0.35	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
LGG	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-8.11	4.28e-15	1.78e-12	-0.42	-0.35	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
LGG	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-8.11	4.28e-15	1.78e-12	-0.42	-0.35	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
LGG	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-8.11	4.29e-15	1.78e-12	-0.38	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
LGG	cis	rs3764021	0.506	rs11052372	ENSG00000256594.6	RP11-705C15.2	8.11	4.29e-15	1.78e-12	0.36	0.35	Type 1 diabetes;	chr12:9679363	chr12:9633419~9658412:+
LGG	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-8.11	4.29e-15	1.78e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-8.11	4.3e-15	1.78e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
LGG	cis	rs228614	0.51	rs223353	ENSG00000248971.2	KRT8P46	-8.11	4.32e-15	1.79e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223352	ENSG00000248971.2	KRT8P46	-8.11	4.32e-15	1.79e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102728746~102730171:-
LGG	cis	rs2797160	1	rs2797161	ENSG00000237742.5	RP11-624M8.1	8.11	4.32e-15	1.79e-12	0.32	0.35	Endometrial cancer;	chr6:125689643	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2747723	ENSG00000237742.5	RP11-624M8.1	8.11	4.32e-15	1.79e-12	0.32	0.35	Endometrial cancer;	chr6:125689644	chr6:125578558~125749190:-
LGG	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-8.11	4.33e-15	1.79e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-8.11	4.33e-15	1.79e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
LGG	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-8.11	4.33e-15	1.79e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
LGG	cis	rs7829975	0.502	rs11785183	ENSG00000173295.6	FAM86B3P	8.11	4.35e-15	1.8e-12	0.39	0.35	Mood instability;	chr8:8708447	chr8:8228595~8244865:+
LGG	cis	rs7819412	0.511	rs10108511	ENSG00000255556.2	RP11-351I21.6	-8.11	4.35e-15	1.8e-12	-0.43	-0.35	Triglycerides;	chr8:11578007	chr8:12378679~12380265:-
LGG	cis	rs8180040	0.966	rs12636851	ENSG00000271161.1	BOLA2P2	8.11	4.35e-15	1.81e-12	0.32	0.35	Colorectal cancer;	chr3:47422077	chr3:47499841~47500407:+
LGG	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	8.11	4.35e-15	1.81e-12	0.31	0.35	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
LGG	cis	rs2638953	0.777	rs11049689	ENSG00000278733.1	RP11-425D17.1	-8.11	4.35e-15	1.81e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28519177	chr12:28185625~28186190:-
LGG	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	8.11	4.36e-15	1.81e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
LGG	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	8.11	4.36e-15	1.81e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
LGG	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	8.11	4.36e-15	1.81e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
LGG	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	8.11	4.36e-15	1.81e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
LGG	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	8.11	4.36e-15	1.81e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
LGG	cis	rs7241530	0.61	rs7231480	ENSG00000266213.1	RP11-100K18.1	-8.11	4.36e-15	1.81e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78133067	chr18:78137223~78140887:+
LGG	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	8.11	4.37e-15	1.81e-12	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
LGG	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-8.11	4.37e-15	1.81e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
LGG	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-8.11	4.37e-15	1.81e-12	-0.44	-0.35	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
LGG	cis	rs6921919	0.789	rs6912584	ENSG00000218016.2	ZNF192P2	-8.11	4.37e-15	1.81e-12	-0.45	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28188050~28189432:+
LGG	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	8.11	4.37e-15	1.81e-12	0.24	0.35	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
LGG	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-8.11	4.38e-15	1.81e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
LGG	cis	rs7474896	0.515	rs675628	ENSG00000226578.1	RP11-258F22.1	8.11	4.38e-15	1.82e-12	0.47	0.35	Obesity (extreme);	chr10:38016403	chr10:37775371~37784131:-
LGG	cis	rs7474896	0.515	rs594594	ENSG00000226578.1	RP11-258F22.1	8.11	4.38e-15	1.82e-12	0.47	0.35	Obesity (extreme);	chr10:38018795	chr10:37775371~37784131:-
LGG	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-8.11	4.39e-15	1.82e-12	-0.42	-0.35	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
LGG	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	8.11	4.39e-15	1.82e-12	0.24	0.35	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
LGG	cis	rs4714902	0.655	rs9472701	ENSG00000231769.2	RP1-8B1.4	-8.11	4.4e-15	1.82e-12	-0.37	-0.35	Colonoscopy-negative controls vs population controls;	chr6:46148712	chr6:46097093~46129706:-
LGG	cis	rs7241530	0.61	rs12455126	ENSG00000266213.1	RP11-100K18.1	-8.11	4.4e-15	1.82e-12	-0.41	-0.35	Educational attainment (years of education);	chr18:78133273	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs12457297	ENSG00000266213.1	RP11-100K18.1	-8.11	4.4e-15	1.82e-12	-0.41	-0.35	Educational attainment (years of education);	chr18:78133680	chr18:78137223~78140887:+
LGG	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	8.11	4.4e-15	1.82e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
LGG	cis	rs454217	0.846	rs2119575	ENSG00000277851.1	RP11-756G20.1	8.11	4.42e-15	1.83e-12	0.35	0.35	Smoking quantity;	chr12:92309812	chr12:92247756~92363832:-
LGG	cis	rs7241530	0.585	rs12455145	ENSG00000266213.1	RP11-100K18.1	-8.11	4.42e-15	1.83e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78133361	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs12455186	ENSG00000266213.1	RP11-100K18.1	-8.11	4.42e-15	1.83e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78133586	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs12455840	ENSG00000266213.1	RP11-100K18.1	-8.11	4.42e-15	1.83e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78133593	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs12454279	ENSG00000266213.1	RP11-100K18.1	-8.11	4.42e-15	1.83e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78133785	chr18:78137223~78140887:+
LGG	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-8.11	4.42e-15	1.83e-12	-0.75	-0.35	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
LGG	cis	rs62184315	0.536	rs62185874	ENSG00000253559.1	OSGEPL1-AS1	-8.11	4.43e-15	1.84e-12	-0.53	-0.35	Alcohol dependence (age at onset);	chr2:189704288	chr2:189762704~189765556:+
LGG	cis	rs11148252	0.74	rs7983971	ENSG00000235660.1	LINC00345	-8.11	4.44e-15	1.84e-12	-0.44	-0.35	Lewy body disease;	chr13:52216565	chr13:52484161~52484680:-
LGG	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	8.11	4.44e-15	1.84e-12	0.7	0.35	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-8.11	4.44e-15	1.84e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
LGG	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-8.11	4.44e-15	1.84e-12	-0.36	-0.35	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
LGG	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	8.11	4.45e-15	1.84e-12	0.59	0.35	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
LGG	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-8.11	4.45e-15	1.84e-12	-0.45	-0.35	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
LGG	cis	rs11148252	0.774	rs56033750	ENSG00000235660.1	LINC00345	-8.11	4.45e-15	1.84e-12	-0.43	-0.35	Lewy body disease;	chr13:52173143	chr13:52484161~52484680:-
LGG	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	8.11	4.46e-15	1.85e-12	0.57	0.35	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
LGG	cis	rs11098499	0.909	rs10014719	ENSG00000250412.1	KLHL2P1	8.11	4.46e-15	1.85e-12	0.41	0.35	Corneal astigmatism;	chr4:119399560	chr4:119334329~119378233:+
LGG	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	8.11	4.47e-15	1.85e-12	0.35	0.35	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
LGG	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	8.11	4.47e-15	1.85e-12	0.31	0.35	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
LGG	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-8.11	4.49e-15	1.86e-12	-0.36	-0.35	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
LGG	cis	rs733592	0.599	rs12819124	ENSG00000258273.1	RP11-370I10.4	-8.11	4.5e-15	1.86e-12	-0.41	-0.35	Plateletcrit;	chr12:48015271	chr12:48333755~48333901:-
LGG	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	8.11	4.51e-15	1.87e-12	0.41	0.35	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
LGG	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-8.1	4.53e-15	1.88e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
LGG	cis	rs11148252	0.846	rs7323666	ENSG00000235660.1	LINC00345	-8.1	4.53e-15	1.88e-12	-0.43	-0.35	Lewy body disease;	chr13:52431923	chr13:52484161~52484680:-
LGG	cis	rs1275468	0.689	rs1795382	ENSG00000257497.2	RP11-585P4.5	-8.1	4.54e-15	1.88e-12	-0.48	-0.35	Polycystic ovary syndrome;	chr12:75586113	chr12:75483454~75489820:-
LGG	cis	rs1707322	1	rs4660332	ENSG00000281133.1	AL355480.3	-8.1	4.54e-15	1.88e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45580892~45580996:-
LGG	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-8.1	4.54e-15	1.88e-12	-0.28	-0.35	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
LGG	cis	rs9388451	0.591	rs1268792	ENSG00000237742.5	RP11-624M8.1	8.1	4.55e-15	1.88e-12	0.31	0.35	Brugada syndrome;	chr6:125720978	chr6:125578558~125749190:-
LGG	cis	rs11098499	0.863	rs1155576	ENSG00000250412.1	KLHL2P1	8.1	4.55e-15	1.89e-12	0.4	0.35	Corneal astigmatism;	chr4:119529004	chr4:119334329~119378233:+
LGG	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
LGG	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
LGG	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-8.1	4.56e-15	1.89e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
LGG	cis	rs12554020	0.892	rs6479487	ENSG00000237385.1	RP11-165J3.5	8.1	4.57e-15	1.89e-12	0.54	0.35	Schizophrenia;	chr9:93475091	chr9:93430342~93431299:-
LGG	cis	rs9322193	0.962	rs6903998	ENSG00000216621.7	RP11-244K5.6	8.1	4.57e-15	1.89e-12	0.41	0.35	Lung cancer;	chr6:149831357	chr6:149934527~149936782:+
LGG	cis	rs10246939	0.505	rs10952508	ENSG00000261570.1	RP11-744I24.2	-8.1	4.57e-15	1.89e-12	-0.44	-0.35	Bitter taste perception;	chr7:141879415	chr7:141529203~141551304:-
LGG	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-8.1	4.57e-15	1.89e-12	-0.36	-0.35	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
LGG	cis	rs10973956	1	rs10973956	ENSG00000273036.2	FAM95C	-8.1	4.59e-15	1.9e-12	-0.38	-0.35	Tourette's syndrome or obsessive-compulsive disorder;	chr9:38645058	chr9:38540567~38545372:-
LGG	cis	rs227275	0.525	rs223462	ENSG00000248971.2	KRT8P46	-8.1	4.59e-15	1.9e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102728746~102730171:-
LGG	cis	rs7829975	0.846	rs11779061	ENSG00000253981.4	ALG1L13P	8.1	4.59e-15	1.9e-12	0.37	0.35	Mood instability;	chr8:8691922	chr8:8236003~8244667:-
LGG	cis	rs12935418	0.616	rs62054241	ENSG00000260213.4	RP11-303E16.3	-8.1	4.6e-15	1.9e-12	-0.46	-0.35	Mean corpuscular volume;	chr16:80970716	chr16:81016792~81035759:-
LGG	cis	rs35934224	0.771	rs34820460	ENSG00000232926.1	AC000078.5	8.1	4.6e-15	1.91e-12	0.39	0.35	Glaucoma (primary open-angle);	chr22:19881687	chr22:19887289~19887970:+
LGG	cis	rs11159086	0.938	rs11623040	ENSG00000259005.1	RP3-449M8.6	8.1	4.61e-15	1.91e-12	0.6	0.35	Advanced glycation end-product levels;	chr14:74496743	chr14:74474007~74474864:-
LGG	cis	rs433598	0.567	rs9928241	ENSG00000260762.1	ACSM5P1	8.1	4.61e-15	1.91e-12	0.44	0.35	Schizophrenia;	chr16:20595045	chr16:20586550~20607107:-
LGG	cis	rs11220082	0.666	rs12224788	ENSG00000254671.2	STT3A-AS1	-8.1	4.62e-15	1.91e-12	-0.43	-0.35	Schizophrenia;	chr11:125459165	chr11:125570284~125592568:-
LGG	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	8.1	4.63e-15	1.91e-12	0.25	0.35	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
LGG	cis	rs853679	0.546	rs200981	ENSG00000199851.2	U3	8.1	4.63e-15	1.91e-12	0.73	0.35	Depression;	chr6:27865396	chr6:28015568~28015777:+
LGG	cis	rs853679	0.546	rs200953	ENSG00000199851.2	U3	8.1	4.63e-15	1.91e-12	0.73	0.35	Depression;	chr6:27869489	chr6:28015568~28015777:+
LGG	cis	rs7474896	0.515	rs2738203	ENSG00000226578.1	RP11-258F22.1	8.1	4.65e-15	1.92e-12	0.48	0.35	Obesity (extreme);	chr10:37988668	chr10:37775371~37784131:-
LGG	cis	rs66887589	0.72	rs11724758	ENSG00000249244.1	RP11-548H18.2	8.1	4.66e-15	1.93e-12	0.35	0.35	Diastolic blood pressure;	chr4:119318723	chr4:119391831~119395335:-
LGG	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	8.1	4.66e-15	1.93e-12	0.41	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
LGG	cis	rs4950322	0.58	rs7514970	ENSG00000278811.3	LINC00624	8.1	4.66e-15	1.93e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147120516	chr1:147258885~147517875:-
LGG	cis	rs2638953	0.925	rs11049563	ENSG00000278733.1	RP11-425D17.1	-8.1	4.66e-15	1.93e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28376041	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs61920565	ENSG00000278733.1	RP11-425D17.1	-8.1	4.66e-15	1.93e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28377192	chr12:28185625~28186190:-
LGG	cis	rs1707322	1	rs12097799	ENSG00000281133.1	AL355480.3	-8.1	4.66e-15	1.93e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45580892~45580996:-
LGG	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	8.1	4.66e-15	1.93e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
LGG	cis	rs10411161	1	rs8106929	ENSG00000269483.1	AC006272.1	8.1	4.67e-15	1.93e-12	0.5	0.35	Breast cancer;	chr19:51865214	chr19:51839924~51843324:-
LGG	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-8.1	4.67e-15	1.93e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
LGG	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	8.1	4.67e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
LGG	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	8.1	4.67e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	8.1	4.67e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	8.1	4.67e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
LGG	cis	rs11722779	0.935	rs7676736	ENSG00000248971.2	KRT8P46	-8.1	4.67e-15	1.93e-12	-0.36	-0.35	Schizophrenia;	chr4:103016729	chr4:102728746~102730171:-
LGG	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	8.1	4.68e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	8.1	4.68e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	8.1	4.68e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
LGG	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	8.1	4.68e-15	1.93e-12	0.28	0.35	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
LGG	cis	rs4143844	1	rs12909386	ENSG00000259251.2	RP11-643M14.1	8.1	4.68e-15	1.94e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62040700	chr15:62060503~62062434:+
LGG	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	8.1	4.68e-15	1.94e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	8.1	4.68e-15	1.94e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	8.1	4.68e-15	1.94e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	8.1	4.68e-15	1.94e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	8.1	4.68e-15	1.94e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	8.1	4.68e-15	1.94e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	8.1	4.68e-15	1.94e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-8.1	4.68e-15	1.94e-12	-0.36	-0.35	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
LGG	cis	rs11098499	0.908	rs1002152	ENSG00000250412.1	KLHL2P1	8.1	4.68e-15	1.94e-12	0.4	0.35	Corneal astigmatism;	chr4:119352232	chr4:119334329~119378233:+
LGG	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	8.1	4.69e-15	1.94e-12	0.42	0.35	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
LGG	cis	rs8064029	0.655	rs77468976	ENSG00000267077.1	RP11-127I20.5	8.1	4.71e-15	1.95e-12	0.6	0.35	Cancer;	chr16:4819249	chr16:4795265~4796532:-
LGG	cis	rs9393777	0.841	rs13207082	ENSG00000199851.2	U3	8.1	4.71e-15	1.95e-12	0.79	0.35	Intelligence (multi-trait analysis);	chr6:27283600	chr6:28015568~28015777:+
LGG	cis	rs997295	0.57	rs7172298	ENSG00000270964.1	RP11-502I4.3	-8.1	4.71e-15	1.95e-12	-0.36	-0.35	Motion sickness;	chr15:67580645	chr15:67541072~67542604:-
LGG	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-8.1	4.73e-15	1.95e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
LGG	cis	rs7709377	0.68	rs6879075	ENSG00000212457.1	RNU6-644P	-8.1	4.73e-15	1.95e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116181844	chr5:116188455~116188552:-
LGG	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	8.1	4.73e-15	1.95e-12	0.4	0.35	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
LGG	cis	rs10246939	0.505	rs13236432	ENSG00000261797.1	RP11-744I24.3	-8.1	4.73e-15	1.95e-12	-0.41	-0.35	Bitter taste perception;	chr7:141850980	chr7:141512698~141513183:-
LGG	cis	rs8067545	0.64	rs17759083	ENSG00000230528.6	NOS2P3	-8.1	4.75e-15	1.96e-12	-0.33	-0.35	Schizophrenia;	chr17:20060292	chr17:20436337~20447249:+
LGG	cis	rs228614	0.51	rs50034	ENSG00000248971.2	KRT8P46	-8.1	4.76e-15	1.96e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs223380	ENSG00000248971.2	KRT8P46	-8.1	4.76e-15	1.96e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs223379	ENSG00000248971.2	KRT8P46	-8.1	4.76e-15	1.96e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102728746~102730171:-
LGG	cis	rs228614	0.536	rs223375	ENSG00000248971.2	KRT8P46	-8.1	4.76e-15	1.96e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102728746~102730171:-
LGG	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	8.1	4.76e-15	1.97e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
LGG	cis	rs149313	1	rs149313	ENSG00000248734.2	CTD-2260A17.1	-8.1	4.76e-15	1.97e-12	-0.35	-0.35	Blood protein levels;	chr5:96734501	chr5:96784777~96785999:+
LGG	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	8.1	4.77e-15	1.97e-12	0.49	0.35	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
LGG	cis	rs7824557	0.591	rs2736282	ENSG00000184608.7	FAM167A-AS1	-8.1	4.77e-15	1.97e-12	-0.29	-0.35	Retinal vascular caliber;	chr8:11367971	chr8:11368402~11438658:+
LGG	cis	rs11992162	1	rs7460395	ENSG00000255556.2	RP11-351I21.6	8.1	4.78e-15	1.97e-12	0.42	0.35	Monocyte count;	chr8:11977866	chr8:12378679~12380265:-
LGG	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	8.1	4.78e-15	1.97e-12	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
LGG	cis	rs2797160	1	rs1935774	ENSG00000237742.5	RP11-624M8.1	8.1	4.79e-15	1.98e-12	0.32	0.35	Endometrial cancer;	chr6:125675515	chr6:125578558~125749190:-
LGG	cis	rs1707322	0.928	rs7527244	ENSG00000281133.1	AL355480.3	-8.1	4.79e-15	1.98e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45580892~45580996:-
LGG	cis	rs9719620	0.967	rs4731794	ENSG00000236753.4	MKLN1-AS	8.1	4.79e-15	1.98e-12	0.36	0.35	Male-pattern baldness;	chr7:131323577	chr7:131309744~131328222:-
LGG	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-8.1	4.79e-15	1.98e-12	-0.71	-0.35	Gout;	chr7:66693028	chr7:66654538~66669855:+
LGG	cis	rs1707322	1	rs785467	ENSG00000281133.1	AL355480.3	8.1	4.79e-15	1.98e-12	0.42	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45580892~45580996:-
LGG	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	8.1	4.79e-15	1.98e-12	0.4	0.35	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
LGG	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-8.1	4.8e-15	1.98e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
LGG	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	8.1	4.8e-15	1.98e-12	0.44	0.35	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
LGG	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	8.1	4.8e-15	1.98e-12	0.44	0.35	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
LGG	cis	rs77204473	0.793	rs543819	ENSG00000254851.1	RP11-109L13.1	8.1	4.8e-15	1.98e-12	0.77	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116879357	chr11:117135528~117138582:+
LGG	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-8.1	4.8e-15	1.98e-12	-0.41	-0.35	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
LGG	cis	rs2797160	1	rs1739374	ENSG00000237742.5	RP11-624M8.1	8.1	4.81e-15	1.98e-12	0.32	0.35	Endometrial cancer;	chr6:125690679	chr6:125578558~125749190:-
LGG	cis	rs997295	0.57	rs7170299	ENSG00000270964.1	RP11-502I4.3	-8.1	4.81e-15	1.99e-12	-0.36	-0.35	Motion sickness;	chr15:67580380	chr15:67541072~67542604:-
LGG	cis	rs9322193	0.962	rs4869730	ENSG00000216621.7	RP11-244K5.6	8.1	4.82e-15	1.99e-12	0.41	0.35	Lung cancer;	chr6:149808187	chr6:149934527~149936782:+
LGG	cis	rs9322193	0.923	rs2151913	ENSG00000216621.7	RP11-244K5.6	8.1	4.82e-15	1.99e-12	0.41	0.35	Lung cancer;	chr6:149809506	chr6:149934527~149936782:+
LGG	cis	rs1555322	1	rs2425032	ENSG00000126005.14	MMP24-AS1	-8.1	4.82e-15	1.99e-12	-0.53	-0.35	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35216462~35278131:-
LGG	cis	rs1555322	1	rs2425034	ENSG00000126005.14	MMP24-AS1	-8.1	4.82e-15	1.99e-12	-0.53	-0.35	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35216462~35278131:-
LGG	cis	rs1555322	0.858	rs2425035	ENSG00000126005.14	MMP24-AS1	-8.1	4.82e-15	1.99e-12	-0.53	-0.35	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35216462~35278131:-
LGG	cis	rs1555322	1	rs2425036	ENSG00000126005.14	MMP24-AS1	-8.1	4.82e-15	1.99e-12	-0.53	-0.35	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35216462~35278131:-
LGG	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	8.1	4.82e-15	1.99e-12	0.28	0.35	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
LGG	cis	rs9300255	0.544	rs10772995	ENSG00000235423.7	RP11-282O18.3	8.1	4.83e-15	1.99e-12	0.4	0.35	Neutrophil percentage of white cells;	chr12:123187214	chr12:123252030~123261483:-
LGG	cis	rs2797160	1	rs2211420	ENSG00000237742.5	RP11-624M8.1	-8.1	4.84e-15	2e-12	-0.32	-0.35	Endometrial cancer;	chr6:125674403	chr6:125578558~125749190:-
LGG	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-8.1	4.84e-15	2e-12	-0.46	-0.35	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
LGG	cis	rs997295	0.57	rs28730805	ENSG00000270964.1	RP11-502I4.3	-8.1	4.85e-15	2e-12	-0.36	-0.35	Motion sickness;	chr15:67587080	chr15:67541072~67542604:-
LGG	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-8.1	4.85e-15	2e-12	-0.46	-0.35	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
LGG	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-8.1	4.85e-15	2e-12	-0.46	-0.35	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
LGG	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-8.1	4.85e-15	2e-12	-0.46	-0.35	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
LGG	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-8.1	4.86e-15	2.01e-12	-0.48	-0.35	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
LGG	cis	rs950169	0.922	rs62028133	ENSG00000259295.5	CSPG4P12	8.1	4.86e-15	2.01e-12	0.48	0.35	Schizophrenia;	chr15:84250623	chr15:85191438~85213905:+
LGG	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-8.09	4.87e-15	2.01e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
LGG	cis	rs1560104	0.536	rs34480785	ENSG00000274834.1	CTD-3037G24.5	8.09	4.89e-15	2.02e-12	0.44	0.35	Obesity-related traits;	chr16:12624032	chr16:12614451~12614852:+
LGG	cis	rs11018904	0.817	rs11601793	ENSG00000280385.1	AP000648.5	-8.09	4.89e-15	2.02e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr11:90213186	chr11:90193614~90198120:+
LGG	cis	rs11148252	0.508	rs6561671	ENSG00000273784.3	RP11-78J21.7	-8.09	4.9e-15	2.02e-12	-0.38	-0.35	Lewy body disease;	chr13:52608179	chr13:52600042~52642542:+
LGG	cis	rs4718428	0.576	rs12698546	ENSG00000232546.1	RP11-458F8.1	-8.09	4.9e-15	2.02e-12	-0.34	-0.35	Corneal structure;	chr7:66801919	chr7:66848496~66858136:+
LGG	cis	rs1023500	0.551	rs2854837	ENSG00000227370.1	RP4-669P10.19	8.09	4.9e-15	2.02e-12	0.31	0.35	Schizophrenia;	chr22:42062477	chr22:42132543~42132998:+
LGG	cis	rs2638953	0.962	rs11049541	ENSG00000278733.1	RP11-425D17.1	-8.09	4.9e-15	2.02e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341781	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.889	rs11049543	ENSG00000278733.1	RP11-425D17.1	-8.09	4.9e-15	2.02e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342124	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049544	ENSG00000278733.1	RP11-425D17.1	-8.09	4.9e-15	2.02e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342348	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.889	rs10843157	ENSG00000278733.1	RP11-425D17.1	-8.09	4.9e-15	2.02e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346417	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049548	ENSG00000278733.1	RP11-425D17.1	-8.09	4.9e-15	2.02e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28350789	chr12:28185625~28186190:-
LGG	cis	rs4950322	0.542	rs115179956	ENSG00000278811.3	LINC00624	8.09	4.91e-15	2.02e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147172620	chr1:147258885~147517875:-
LGG	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-8.09	4.91e-15	2.03e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
LGG	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-8.09	4.91e-15	2.03e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
LGG	cis	rs812925	0.537	rs10865324	ENSG00000273302.1	RP11-493E12.2	-8.09	4.91e-15	2.03e-12	-0.3	-0.35	Immature fraction of reticulocytes;	chr2:61394172	chr2:61199979~61200769:+
LGG	cis	rs1023500	0.596	rs133369	ENSG00000227370.1	RP4-669P10.19	8.09	4.93e-15	2.03e-12	0.3	0.35	Schizophrenia;	chr22:42067810	chr22:42132543~42132998:+
LGG	cis	rs11098499	0.908	rs7696649	ENSG00000250412.1	KLHL2P1	8.09	4.94e-15	2.04e-12	0.41	0.35	Corneal astigmatism;	chr4:119401022	chr4:119334329~119378233:+
LGG	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	8.09	4.94e-15	2.04e-12	0.31	0.35	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
LGG	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	8.09	4.96e-15	2.04e-12	0.24	0.35	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
LGG	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-8.09	4.97e-15	2.05e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
LGG	cis	rs128738	0.5	rs60168911	ENSG00000233006.5	AC034220.3	-8.09	4.97e-15	2.05e-12	-0.42	-0.35	Giant cell arteritis;	chr5:132229767	chr5:132311285~132369916:-
LGG	cis	rs6964833	0.935	rs7795281	ENSG00000277053.3	GTF2IP1	-8.09	4.98e-15	2.05e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74708523	chr7:75185385~75237696:-
LGG	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-8.09	4.99e-15	2.06e-12	-0.46	-0.35	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
LGG	cis	rs9346353	0.966	rs4706271	ENSG00000219881.1	GAPDHP42	8.09	5e-15	2.06e-12	0.34	0.35	Sleep duration;	chr6:69680240	chr6:69745871~69746851:+
LGG	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-8.09	5e-15	2.06e-12	-0.36	-0.35	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
LGG	cis	rs11723261	0.513	rs2353623	ENSG00000211553.1	AC253576.2	-8.09	5e-15	2.06e-12	-0.5	-0.35	Immune response to smallpox vaccine (IL-6);	chr4:95673	chr4:136461~136568:+
LGG	cis	rs12936587	0.568	rs4925062	ENSG00000223979.2	SMCR2	8.09	5.02e-15	2.07e-12	0.34	0.35	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17647452	chr17:17674026~17677688:-
LGG	cis	rs17345786	0.861	rs74768235	ENSG00000256628.3	ZBTB11-AS1	8.09	5.02e-15	2.07e-12	0.45	0.35	Colonoscopy-negative controls vs population controls;	chr3:101423977	chr3:101676475~101679217:+
LGG	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	8.09	5.03e-15	2.07e-12	0.28	0.35	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
LGG	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	8.09	5.03e-15	2.07e-12	0.28	0.35	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
LGG	cis	rs7119038	0.818	rs4938572	ENSG00000255239.1	AP002954.6	8.09	5.03e-15	2.07e-12	0.5	0.35	Sjögren's syndrome;	chr11:118870222	chr11:118688039~118690600:-
LGG	cis	rs7688540	0.68	rs77762064	ENSG00000275426.1	CH17-262A2.1	8.09	5.04e-15	2.08e-12	0.45	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:281154	chr4:149738~150317:+
LGG	cis	rs2638953	0.962	rs61920564	ENSG00000278733.1	RP11-425D17.1	-8.09	5.06e-15	2.08e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357000	chr12:28185625~28186190:-
LGG	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	8.09	5.07e-15	2.09e-12	0.35	0.35	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
LGG	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	8.09	5.07e-15	2.09e-12	0.44	0.35	Height;	chr14:74990535	chr14:75011269~75012851:-
LGG	cis	rs17772222	0.597	rs17700521	ENSG00000222990.1	RNU4-22P	8.09	5.09e-15	2.09e-12	0.45	0.35	Coronary artery calcification;	chr14:88849531	chr14:88513498~88513663:+
LGG	cis	rs9300255	0.602	rs1727306	ENSG00000235423.7	RP11-282O18.3	8.09	5.09e-15	2.1e-12	0.4	0.35	Neutrophil percentage of white cells;	chr12:123181148	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.512	rs2851436	ENSG00000235423.7	RP11-282O18.3	8.09	5.09e-15	2.1e-12	0.4	0.35	Neutrophil percentage of white cells;	chr12:123182807	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.544	rs1716157	ENSG00000235423.7	RP11-282O18.3	8.09	5.09e-15	2.1e-12	0.4	0.35	Neutrophil percentage of white cells;	chr12:123185926	chr12:123252030~123261483:-
LGG	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	8.09	5.1e-15	2.1e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
LGG	cis	rs7085104	0.513	rs619824	ENSG00000272912.1	RP11-724N1.1	-8.09	5.1e-15	2.1e-12	-0.38	-0.35	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102914585~102915404:+
LGG	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	8.09	5.11e-15	2.1e-12	0.59	0.35	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
LGG	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	8.09	5.11e-15	2.1e-12	0.59	0.35	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
LGG	cis	rs4950322	0.542	rs17159914	ENSG00000278811.3	LINC00624	-8.09	5.11e-15	2.11e-12	-0.33	-0.35	Protein quantitative trait loci;	chr1:147183226	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.542	rs4950382	ENSG00000278811.3	LINC00624	8.09	5.11e-15	2.11e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147176645	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.542	rs2883434	ENSG00000278811.3	LINC00624	8.09	5.11e-15	2.11e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147177505	chr1:147258885~147517875:-
LGG	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-8.09	5.12e-15	2.11e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
LGG	cis	rs9300255	0.602	rs1716168	ENSG00000235423.7	RP11-282O18.3	-8.09	5.12e-15	2.11e-12	-0.38	-0.35	Neutrophil percentage of white cells;	chr12:123167419	chr12:123252030~123261483:-
LGG	cis	rs9813712	0.597	rs10934931	ENSG00000228252.7	COL6A4P2	-8.09	5.13e-15	2.11e-12	-0.39	-0.35	Response to amphetamines;	chr3:130261365	chr3:130212823~130273806:+
LGG	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-8.09	5.13e-15	2.11e-12	-0.68	-0.35	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
LGG	cis	rs7208859	0.673	rs11655623	ENSG00000266490.1	CTD-2349P21.9	8.09	5.14e-15	2.11e-12	0.43	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30792372~30792833:+
LGG	cis	rs9532669	0.963	rs7989303	ENSG00000239827.7	SUGT1P3	-8.09	5.16e-15	2.12e-12	-0.37	-0.35	Cervical cancer;	chr13:40950087	chr13:40908159~40921774:-
LGG	cis	rs11148252	0.74	rs3803264	ENSG00000235660.1	LINC00345	8.09	5.17e-15	2.13e-12	0.43	0.35	Lewy body disease;	chr13:52397758	chr13:52484161~52484680:-
LGG	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-8.09	5.19e-15	2.14e-12	-0.47	-0.35	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
LGG	cis	rs6964833	0.935	rs7795282	ENSG00000277053.3	GTF2IP1	-8.09	5.21e-15	2.14e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74708526	chr7:75185385~75237696:-
LGG	cis	rs9322193	0.962	rs1889473	ENSG00000216621.7	RP11-244K5.6	8.09	5.22e-15	2.15e-12	0.41	0.35	Lung cancer;	chr6:149825485	chr6:149934527~149936782:+
LGG	cis	rs5760092	0.627	rs6519489	ENSG00000250470.1	AP000351.3	-8.09	5.22e-15	2.15e-12	-0.58	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23976904~23977585:-
LGG	cis	rs9719620	0.834	rs4731787	ENSG00000236753.4	MKLN1-AS	8.09	5.23e-15	2.15e-12	0.35	0.35	Male-pattern baldness;	chr7:131301629	chr7:131309744~131328222:-
LGG	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-8.08	5.25e-15	2.16e-12	-0.37	-0.35	Depression;	chr6:28226851	chr6:28115628~28116551:+
LGG	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-8.08	5.26e-15	2.16e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
LGG	cis	rs597539	0.69	rs659465	ENSG00000250508.1	RP11-757G1.6	-8.08	5.27e-15	2.17e-12	-0.47	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68851496	chr11:68870664~68874542:+
LGG	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	-8.08	5.28e-15	2.17e-12	-0.49	-0.35	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
LGG	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-8.08	5.29e-15	2.17e-12	-0.42	-0.35	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
LGG	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	8.08	5.3e-15	2.18e-12	0.35	0.35	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
LGG	cis	rs1023500	0.505	rs134891	ENSG00000227370.1	RP4-669P10.19	8.08	5.31e-15	2.18e-12	0.3	0.35	Schizophrenia;	chr22:42279876	chr22:42132543~42132998:+
LGG	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	8.08	5.31e-15	2.19e-12	0.24	0.35	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
LGG	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-8.08	5.32e-15	2.19e-12	-0.43	-0.35	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
LGG	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-8.08	5.32e-15	2.19e-12	-0.36	-0.35	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
LGG	cis	rs11098499	0.865	rs11098513	ENSG00000250412.1	KLHL2P1	8.08	5.33e-15	2.19e-12	0.4	0.35	Corneal astigmatism;	chr4:119394920	chr4:119334329~119378233:+
LGG	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-8.08	5.33e-15	2.19e-12	-0.46	-0.35	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
LGG	cis	rs7474896	0.526	rs1208633	ENSG00000226578.1	RP11-258F22.1	8.08	5.34e-15	2.19e-12	0.46	0.35	Obesity (extreme);	chr10:37867945	chr10:37775371~37784131:-
LGG	cis	rs2638953	0.962	rs11494780	ENSG00000278733.1	RP11-425D17.1	-8.08	5.35e-15	2.2e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28402269	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049574	ENSG00000278733.1	RP11-425D17.1	-8.08	5.35e-15	2.2e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28406130	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs10506033	ENSG00000278733.1	RP11-425D17.1	-8.08	5.35e-15	2.2e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415032	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049586	ENSG00000278733.1	RP11-425D17.1	-8.08	5.35e-15	2.2e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418028	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049588	ENSG00000278733.1	RP11-425D17.1	-8.08	5.35e-15	2.2e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418628	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.925	rs10843166	ENSG00000278733.1	RP11-425D17.1	-8.08	5.35e-15	2.2e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28422811	chr12:28185625~28186190:-
LGG	cis	rs9859260	0.925	rs2300775	ENSG00000231464.1	AC024937.4	8.08	5.35e-15	2.2e-12	0.43	0.35	Mean corpuscular volume;	chr3:196066468	chr3:195996738~195998233:+
LGG	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-8.08	5.35e-15	2.2e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
LGG	cis	rs1420956	1	rs8091034	ENSG00000264151.4	RP11-739N10.1	8.08	5.35e-15	2.2e-12	0.44	0.35	Obesity-related traits;	chr18:27596486	chr18:27336379~27595164:-
LGG	cis	rs4950322	0.547	rs6660507	ENSG00000278811.3	LINC00624	8.08	5.36e-15	2.2e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147148574	chr1:147258885~147517875:-
LGG	cis	rs1275468	1	rs17115231	ENSG00000257497.2	RP11-585P4.5	-8.08	5.38e-15	2.21e-12	-0.45	-0.35	Polycystic ovary syndrome;	chr12:75539895	chr12:75483454~75489820:-
LGG	cis	rs7005380	0.62	rs13259990	ENSG00000245330.4	KB-1471A8.1	8.08	5.38e-15	2.21e-12	0.39	0.35	Interstitial lung disease;	chr8:119894943	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs13260933	ENSG00000245330.4	KB-1471A8.1	8.08	5.38e-15	2.21e-12	0.39	0.35	Interstitial lung disease;	chr8:119895010	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs13261304	ENSG00000245330.4	KB-1471A8.1	8.08	5.38e-15	2.21e-12	0.39	0.35	Interstitial lung disease;	chr8:119895180	chr8:119867419~119874488:-
LGG	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-8.08	5.39e-15	2.22e-12	-0.47	-0.35	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
LGG	cis	rs2325036	0.558	rs2325035	ENSG00000239519.1	CADM2-AS1	8.08	5.39e-15	2.22e-12	0.45	0.35	Waist circumference;	chr3:85762083	chr3:85992183~86028007:-
LGG	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	8.08	5.41e-15	2.22e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
LGG	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-8.08	5.41e-15	2.22e-12	-0.56	-0.35	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
LGG	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	8.08	5.41e-15	2.22e-12	0.56	0.35	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
LGG	cis	rs4143844	1	rs12917339	ENSG00000259251.2	RP11-643M14.1	8.08	5.42e-15	2.23e-12	0.56	0.35	Bipolar disorder and schizophrenia;	chr15:62054591	chr15:62060503~62062434:+
LGG	cis	rs453301	0.538	rs7830804	ENSG00000173295.6	FAM86B3P	8.08	5.43e-15	2.23e-12	0.38	0.35	Joint mobility (Beighton score);	chr8:9113252	chr8:8228595~8244865:+
LGG	cis	rs9859260	0.961	rs2300780	ENSG00000231464.1	AC024937.4	8.08	5.44e-15	2.23e-12	0.43	0.35	Mean corpuscular volume;	chr3:196063420	chr3:195996738~195998233:+
LGG	cis	rs9859260	1	rs2300778	ENSG00000231464.1	AC024937.4	8.08	5.44e-15	2.23e-12	0.43	0.35	Mean corpuscular volume;	chr3:196063866	chr3:195996738~195998233:+
LGG	cis	rs9859260	1	rs2300777	ENSG00000231464.1	AC024937.4	8.08	5.44e-15	2.23e-12	0.43	0.35	Mean corpuscular volume;	chr3:196063940	chr3:195996738~195998233:+
LGG	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-8.08	5.44e-15	2.24e-12	-0.36	-0.35	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
LGG	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	8.08	5.45e-15	2.24e-12	0.7	0.35	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
LGG	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	8.08	5.45e-15	2.24e-12	0.7	0.35	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
LGG	cis	rs1275468	0.731	rs3912214	ENSG00000257497.2	RP11-585P4.5	-8.08	5.45e-15	2.24e-12	-0.49	-0.35	Polycystic ovary syndrome;	chr12:75550245	chr12:75483454~75489820:-
LGG	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-8.08	5.45e-15	2.24e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
LGG	cis	rs2877649	0.51	rs10083368	ENSG00000258744.1	RP11-80A15.1	-8.08	5.45e-15	2.24e-12	-0.77	-0.35	Smooth-surface caries;	chr14:24438978	chr14:24501594~24508688:+
LGG	cis	rs2877649	0.51	rs10083369	ENSG00000258744.1	RP11-80A15.1	-8.08	5.45e-15	2.24e-12	-0.77	-0.35	Smooth-surface caries;	chr14:24439005	chr14:24501594~24508688:+
LGG	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	8.08	5.46e-15	2.24e-12	0.7	0.35	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
LGG	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-8.08	5.47e-15	2.25e-12	-0.49	-0.35	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
LGG	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-8.08	5.47e-15	2.25e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
LGG	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	8.08	5.5e-15	2.26e-12	0.71	0.35	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-8.08	5.5e-15	2.26e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	8.08	5.5e-15	2.26e-12	0.71	0.35	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	8.08	5.5e-15	2.26e-12	0.71	0.35	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	8.08	5.5e-15	2.26e-12	0.71	0.35	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	8.08	5.5e-15	2.26e-12	0.71	0.35	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	8.08	5.5e-15	2.26e-12	0.71	0.35	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
LGG	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-8.08	5.5e-15	2.26e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
LGG	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-8.08	5.5e-15	2.26e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
LGG	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-8.08	5.51e-15	2.26e-12	-0.23	-0.35	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
LGG	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-8.08	5.52e-15	2.27e-12	-0.36	-0.35	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
LGG	cis	rs11148252	0.967	rs11620062	ENSG00000235660.1	LINC00345	-8.08	5.54e-15	2.27e-12	-0.42	-0.35	Lewy body disease;	chr13:52419891	chr13:52484161~52484680:-
LGG	cis	rs2638953	0.815	rs11049696	ENSG00000278733.1	RP11-425D17.1	-8.08	5.54e-15	2.27e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28528922	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.815	rs11049709	ENSG00000278733.1	RP11-425D17.1	-8.08	5.54e-15	2.27e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28545099	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.782	rs11049710	ENSG00000278733.1	RP11-425D17.1	-8.08	5.54e-15	2.27e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28546231	chr12:28185625~28186190:-
LGG	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	8.08	5.54e-15	2.27e-12	0.7	0.35	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
LGG	cis	rs7181230	1	rs11638521	ENSG00000275636.1	RP11-521C20.5	-8.08	5.55e-15	2.28e-12	-0.37	-0.35	Dehydroepiandrosterone sulphate levels;	chr15:40068113	chr15:40078892~40079347:+
LGG	cis	rs4950322	0.58	rs2014106	ENSG00000278811.3	LINC00624	8.08	5.57e-15	2.29e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147118499	chr1:147258885~147517875:-
LGG	cis	rs4950322	0.58	rs17355474	ENSG00000278811.3	LINC00624	8.08	5.57e-15	2.29e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147120541	chr1:147258885~147517875:-
LGG	cis	rs7709377	0.723	rs62384210	ENSG00000212457.1	RNU6-644P	-8.08	5.57e-15	2.29e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116178945	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs1567338	ENSG00000212457.1	RNU6-644P	-8.08	5.57e-15	2.29e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116179257	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10076480	ENSG00000212457.1	RNU6-644P	-8.08	5.57e-15	2.29e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116180295	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs6878871	ENSG00000212457.1	RNU6-644P	-8.08	5.57e-15	2.29e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116181702	chr5:116188455~116188552:-
LGG	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-8.08	5.59e-15	2.3e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
LGG	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	8.08	5.61e-15	2.3e-12	0.35	0.35	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
LGG	cis	rs2832077	0.527	rs2705690	ENSG00000232855.5	AF131217.1	-8.08	5.62e-15	2.31e-12	-0.41	-0.35	Cognitive test performance;	chr21:28866923	chr21:28439346~28674848:-
LGG	cis	rs2832077	0.527	rs2250141	ENSG00000232855.5	AF131217.1	-8.08	5.62e-15	2.31e-12	-0.41	-0.35	Cognitive test performance;	chr21:28869662	chr21:28439346~28674848:-
LGG	cis	rs12554020	0.892	rs12341488	ENSG00000237385.1	RP11-165J3.5	8.07	5.63e-15	2.31e-12	0.57	0.35	Schizophrenia;	chr9:93568889	chr9:93430342~93431299:-
LGG	cis	rs1560104	0.597	rs735819	ENSG00000274834.1	CTD-3037G24.5	-8.07	5.63e-15	2.31e-12	-0.42	-0.35	Obesity-related traits;	chr16:12618370	chr16:12614451~12614852:+
LGG	cis	rs17345786	0.861	rs17402964	ENSG00000256628.3	ZBTB11-AS1	8.07	5.63e-15	2.31e-12	0.44	0.35	Colonoscopy-negative controls vs population controls;	chr3:101349101	chr3:101676475~101679217:+
LGG	cis	rs6921919	1	rs6922111	ENSG00000218016.2	ZNF192P2	-8.07	5.64e-15	2.31e-12	-0.47	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28188050~28189432:+
LGG	cis	rs1707322	1	rs785486	ENSG00000281133.1	AL355480.3	8.07	5.64e-15	2.32e-12	0.44	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45580892~45580996:-
LGG	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	8.07	5.65e-15	2.32e-12	0.46	0.35	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
LGG	cis	rs12935418	0.616	rs62054239	ENSG00000260213.4	RP11-303E16.3	-8.07	5.66e-15	2.32e-12	-0.46	-0.35	Mean corpuscular volume;	chr16:80966287	chr16:81016792~81035759:-
LGG	cis	rs1707322	0.964	rs796773	ENSG00000281133.1	AL355480.3	8.07	5.66e-15	2.32e-12	0.43	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45580892~45580996:-
LGG	cis	rs1707322	0.896	rs785518	ENSG00000281133.1	AL355480.3	8.07	5.66e-15	2.32e-12	0.43	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs785519	ENSG00000281133.1	AL355480.3	8.07	5.66e-15	2.32e-12	0.43	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45580892~45580996:-
LGG	cis	rs9532669	0.926	rs2039119	ENSG00000239827.7	SUGT1P3	8.07	5.66e-15	2.32e-12	0.36	0.35	Cervical cancer;	chr13:40872432	chr13:40908159~40921774:-
LGG	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-8.07	5.69e-15	2.34e-12	-0.42	-0.35	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
LGG	cis	rs9300255	0.698	rs4759416	ENSG00000235423.7	RP11-282O18.3	8.07	5.7e-15	2.34e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123261810	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.739	rs4759417	ENSG00000235423.7	RP11-282O18.3	8.07	5.7e-15	2.34e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123261963	chr12:123252030~123261483:-
LGG	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-8.07	5.7e-15	2.34e-12	-0.41	-0.35	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
LGG	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-8.07	5.72e-15	2.34e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-8.07	5.72e-15	2.35e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
LGG	cis	rs7189233	1	rs16952251	ENSG00000279344.1	RP11-44F14.7	8.07	5.72e-15	2.35e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr16:53449226	chr16:53478957~53481550:-
LGG	cis	rs7219021	0.705	rs67174000	ENSG00000248278.1	SUMO2P17	-8.07	5.73e-15	2.35e-12	-0.41	-0.35	Schizophrenia or bipolar disorder;	chr17:48905018	chr17:48874860~48908983:-
LGG	cis	rs7219021	0.705	rs28635466	ENSG00000248278.1	SUMO2P17	-8.07	5.73e-15	2.35e-12	-0.41	-0.35	Schizophrenia or bipolar disorder;	chr17:48906458	chr17:48874860~48908983:-
LGG	cis	rs397969	0.596	rs9901294	ENSG00000261033.1	RP11-209D14.2	-8.07	5.73e-15	2.35e-12	-0.41	-0.35	Platelet count;	chr17:19985188	chr17:20008051~20009234:-
LGG	cis	rs7189233	0.956	rs62048478	ENSG00000279344.1	RP11-44F14.7	8.07	5.75e-15	2.36e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr16:53395268	chr16:53478957~53481550:-
LGG	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	8.07	5.75e-15	2.36e-12	0.35	0.35	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
LGG	cis	rs2797160	0.905	rs1418641	ENSG00000237742.5	RP11-624M8.1	-8.07	5.76e-15	2.36e-12	-0.32	-0.35	Endometrial cancer;	chr6:125678708	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.905	rs1418640	ENSG00000237742.5	RP11-624M8.1	-8.07	5.76e-15	2.36e-12	-0.32	-0.35	Endometrial cancer;	chr6:125678720	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1418639	ENSG00000237742.5	RP11-624M8.1	-8.07	5.76e-15	2.36e-12	-0.32	-0.35	Endometrial cancer;	chr6:125678794	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs4895798	ENSG00000237742.5	RP11-624M8.1	-8.07	5.76e-15	2.36e-12	-0.32	-0.35	Endometrial cancer;	chr6:125679016	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.967	rs8180614	ENSG00000237742.5	RP11-624M8.1	-8.07	5.76e-15	2.36e-12	-0.32	-0.35	Endometrial cancer;	chr6:125679453	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.935	rs60515555	ENSG00000237742.5	RP11-624M8.1	-8.07	5.76e-15	2.36e-12	-0.32	-0.35	Endometrial cancer;	chr6:125679492	chr6:125578558~125749190:-
LGG	cis	rs11098499	0.863	rs1383533	ENSG00000250412.1	KLHL2P1	8.07	5.76e-15	2.36e-12	0.4	0.35	Corneal astigmatism;	chr4:119513421	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs2291185	ENSG00000250412.1	KLHL2P1	8.07	5.76e-15	2.36e-12	0.4	0.35	Corneal astigmatism;	chr4:119513678	chr4:119334329~119378233:+
LGG	cis	rs12554020	0.786	rs6479495	ENSG00000237385.1	RP11-165J3.5	8.07	5.78e-15	2.37e-12	0.58	0.35	Schizophrenia;	chr9:93572320	chr9:93430342~93431299:-
LGG	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-8.07	5.79e-15	2.37e-12	-0.65	-0.35	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
LGG	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	8.07	5.8e-15	2.38e-12	0.36	0.35	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	8.07	5.8e-15	2.38e-12	0.36	0.35	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	8.07	5.8e-15	2.38e-12	0.36	0.35	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
LGG	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-8.07	5.8e-15	2.38e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
LGG	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	8.07	5.8e-15	2.38e-12	0.35	0.35	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
LGG	cis	rs9300255	0.739	rs1980252	ENSG00000235423.7	RP11-282O18.3	8.07	5.8e-15	2.38e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123260631	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.739	rs2337934	ENSG00000235423.7	RP11-282O18.3	8.07	5.8e-15	2.38e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123260812	chr12:123252030~123261483:-
LGG	cis	rs2638953	0.924	rs7957382	ENSG00000278733.1	RP11-425D17.1	8.07	5.8e-15	2.38e-12	0.42	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28185625~28186190:-
LGG	cis	rs881375	0.502	rs4837811	ENSG00000226752.6	PSMD5-AS1	-8.07	5.81e-15	2.38e-12	-0.5	-0.35	Rheumatoid arthritis;	chr9:121139316	chr9:120824828~120854385:+
LGG	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	8.07	5.81e-15	2.38e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	8.07	5.81e-15	2.38e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
LGG	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-8.07	5.82e-15	2.38e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
LGG	cis	rs2638953	0.924	rs11049569	ENSG00000278733.1	RP11-425D17.1	-8.07	5.82e-15	2.38e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28386823	chr12:28185625~28186190:-
LGG	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-8.07	5.82e-15	2.38e-12	-0.7	-0.35	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
LGG	cis	rs4295623	0.553	rs11250163	ENSG00000227888.4	FAM66A	8.07	5.83e-15	2.39e-12	0.42	0.35	Morning vs. evening chronotype;	chr8:11738928	chr8:12362019~12388296:+
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000272787.1	KB-226F1.2	8.07	5.84e-15	2.39e-12	0.37	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23969211~23969873:+
LGG	cis	rs228614	0.536	rs223419	ENSG00000248971.2	KRT8P46	-8.07	5.84e-15	2.39e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102728746~102730171:-
LGG	cis	rs4713118	0.513	rs149954	ENSG00000218016.2	ZNF192P2	-8.07	5.85e-15	2.39e-12	-0.46	-0.35	Parkinson's disease;	chr6:28067468	chr6:28188050~28189432:+
LGG	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-8.07	5.85e-15	2.4e-12	-0.39	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
LGG	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	8.07	5.85e-15	2.4e-12	0.42	0.35	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
LGG	cis	rs853679	0.567	rs6905380	ENSG00000226314.6	ZNF192P1	8.07	5.85e-15	2.4e-12	0.37	0.35	Depression;	chr6:28407125	chr6:28161781~28169594:+
LGG	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	8.07	5.87e-15	2.4e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
LGG	cis	rs228614	0.51	rs3774987	ENSG00000248971.2	KRT8P46	-8.07	5.87e-15	2.4e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102728746~102730171:-
LGG	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	8.07	5.88e-15	2.41e-12	0.46	0.35	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
LGG	cis	rs227275	0.556	rs223398	ENSG00000248971.2	KRT8P46	-8.07	5.88e-15	2.41e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102728746~102730171:-
LGG	cis	rs1707322	0.964	rs6675259	ENSG00000281133.1	AL355480.3	8.07	5.9e-15	2.41e-12	0.41	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45580892~45580996:-
LGG	cis	rs10246939	0.505	rs13236432	ENSG00000261570.1	RP11-744I24.2	-8.07	5.94e-15	2.43e-12	-0.43	-0.35	Bitter taste perception;	chr7:141850980	chr7:141529203~141551304:-
LGG	cis	rs12935418	0.616	rs718954	ENSG00000260213.4	RP11-303E16.3	-8.07	5.94e-15	2.43e-12	-0.46	-0.35	Mean corpuscular volume;	chr16:80953219	chr16:81016792~81035759:-
LGG	cis	rs1552244	0.882	rs67631672	ENSG00000180385.7	EMC3-AS1	8.07	5.95e-15	2.43e-12	0.38	0.35	Alzheimer's disease;	chr3:9963084	chr3:9986893~10006990:+
LGG	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-8.07	5.96e-15	2.44e-12	-0.28	-0.35	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
LGG	cis	rs11098499	0.779	rs80242894	ENSG00000250412.1	KLHL2P1	8.07	5.97e-15	2.44e-12	0.4	0.35	Corneal astigmatism;	chr4:119454597	chr4:119334329~119378233:+
LGG	cis	rs9346353	0.762	rs57913618	ENSG00000219881.1	GAPDHP42	8.07	5.98e-15	2.45e-12	0.33	0.35	Sleep duration;	chr6:69786498	chr6:69745871~69746851:+
LGG	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-8.07	5.99e-15	2.45e-12	-0.46	-0.35	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
LGG	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	8.07	5.99e-15	2.45e-12	0.35	0.35	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
LGG	cis	rs7005380	0.62	rs7387264	ENSG00000245330.4	KB-1471A8.1	8.07	6e-15	2.46e-12	0.39	0.35	Interstitial lung disease;	chr8:119913758	chr8:119867419~119874488:-
LGG	cis	rs9532669	0.963	rs3736953	ENSG00000239827.7	SUGT1P3	-8.07	6.01e-15	2.46e-12	-0.37	-0.35	Cervical cancer;	chr13:40951450	chr13:40908159~40921774:-
LGG	cis	rs7241530	0.636	rs12456531	ENSG00000266213.1	RP11-100K18.1	-8.07	6.02e-15	2.46e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78139668	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs12455089	ENSG00000266213.1	RP11-100K18.1	-8.07	6.02e-15	2.46e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78139708	chr18:78137223~78140887:+
LGG	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-8.07	6.02e-15	2.46e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
LGG	cis	rs2797160	1	rs2747717	ENSG00000237742.5	RP11-624M8.1	8.07	6.02e-15	2.46e-12	0.32	0.35	Endometrial cancer;	chr6:125687289	chr6:125578558~125749190:-
LGG	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-8.06	6.04e-15	2.47e-12	-0.36	-0.35	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
LGG	cis	rs67340775	0.541	rs169287	ENSG00000226314.6	ZNF192P1	8.06	6.05e-15	2.48e-12	0.48	0.35	Lung cancer in ever smokers;	chr6:27886982	chr6:28161781~28169594:+
LGG	cis	rs4927850	1	rs6799572	ENSG00000207650.1	MIR570	8.06	6.05e-15	2.48e-12	0.34	0.35	Pancreatic cancer;	chr3:196013537	chr3:195699401~195699497:+
LGG	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	-8.06	6.05e-15	2.48e-12	-0.49	-0.35	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
LGG	cis	rs910316	0.763	rs4556	ENSG00000279594.1	RP11-950C14.10	8.06	6.1e-15	2.5e-12	0.44	0.35	Height;	chr14:75009368	chr14:75011269~75012851:-
LGG	cis	rs910316	0.789	rs12894419	ENSG00000279594.1	RP11-950C14.10	8.06	6.1e-15	2.5e-12	0.44	0.35	Height;	chr14:75005099	chr14:75011269~75012851:-
LGG	cis	rs1799810	0.739	rs13030284	ENSG00000236682.1	AC068282.3	8.06	6.13e-15	2.51e-12	0.45	0.35	Self-rated health;	chr2:127401143	chr2:127389130~127400580:+
LGG	cis	rs1707322	0.789	rs10789473	ENSG00000281133.1	AL355480.3	-8.06	6.14e-15	2.51e-12	-0.43	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45580892~45580996:-
LGG	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-8.06	6.14e-15	2.51e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-8.06	6.14e-15	2.51e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-8.06	6.14e-15	2.51e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
LGG	cis	rs651907	0.64	rs771574	ENSG00000256628.3	ZBTB11-AS1	8.06	6.18e-15	2.53e-12	0.4	0.35	Colorectal cancer;	chr3:101901838	chr3:101676475~101679217:+
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	8.06	6.19e-15	2.53e-12	0.48	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
LGG	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	8.06	6.2e-15	2.53e-12	0.29	0.35	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
LGG	cis	rs35857674	0.5	rs203930	ENSG00000253484.1	RP11-109P6.2	-8.06	6.2e-15	2.53e-12	-0.34	-0.35	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50076277	chr8:49817586~49820944:-
LGG	cis	rs11971779	0.588	rs2003531	ENSG00000273391.1	RP11-634H22.1	8.06	6.2e-15	2.54e-12	0.37	0.35	Diisocyanate-induced asthma;	chr7:139441832	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.715	rs6467856	ENSG00000273391.1	RP11-634H22.1	8.06	6.2e-15	2.54e-12	0.37	0.35	Diisocyanate-induced asthma;	chr7:139442553	chr7:139359032~139359566:-
LGG	cis	rs7189233	1	rs7189819	ENSG00000279344.1	RP11-44F14.7	8.06	6.21e-15	2.54e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr16:53502433	chr16:53478957~53481550:-
LGG	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-8.06	6.21e-15	2.54e-12	-0.33	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
LGG	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-8.06	6.21e-15	2.54e-12	-0.53	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
LGG	cis	rs10246939	0.543	rs7802271	ENSG00000261570.1	RP11-744I24.2	-8.06	6.23e-15	2.55e-12	-0.45	-0.35	Bitter taste perception;	chr7:141909624	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.52	rs7782886	ENSG00000261570.1	RP11-744I24.2	-8.06	6.23e-15	2.55e-12	-0.45	-0.35	Bitter taste perception;	chr7:141909958	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.543	rs994808	ENSG00000261570.1	RP11-744I24.2	-8.06	6.23e-15	2.55e-12	-0.45	-0.35	Bitter taste perception;	chr7:141911091	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.543	rs7808421	ENSG00000261570.1	RP11-744I24.2	-8.06	6.23e-15	2.55e-12	-0.45	-0.35	Bitter taste perception;	chr7:141911592	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.543	rs7789123	ENSG00000261570.1	RP11-744I24.2	-8.06	6.23e-15	2.55e-12	-0.45	-0.35	Bitter taste perception;	chr7:141911699	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.543	rs11767119	ENSG00000261570.1	RP11-744I24.2	-8.06	6.23e-15	2.55e-12	-0.45	-0.35	Bitter taste perception;	chr7:141912316	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.543	rs11769089	ENSG00000261570.1	RP11-744I24.2	-8.06	6.23e-15	2.55e-12	-0.45	-0.35	Bitter taste perception;	chr7:141914310	chr7:141529203~141551304:-
LGG	cis	rs7709377	0.671	rs10478287	ENSG00000212457.1	RNU6-644P	-8.06	6.23e-15	2.55e-12	-0.52	-0.35	Metabolite levels  (X-11787);	chr5:116160471	chr5:116188455~116188552:-
LGG	cis	rs950776	0.706	rs11636753	ENSG00000261762.1	RP11-650L12.2	8.06	6.23e-15	2.55e-12	0.45	0.35	Sudden cardiac arrest;	chr15:78636604	chr15:78589123~78591276:-
LGG	cis	rs2638953	0.962	rs10843159	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354597	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049550	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28358591	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049552	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361466	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049553	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361611	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049554	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28362819	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs12371222	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28363245	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049555	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28364919	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049556	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28365626	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049558	ENSG00000278733.1	RP11-425D17.1	-8.06	6.23e-15	2.55e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28371438	chr12:28185625~28186190:-
LGG	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	8.06	6.24e-15	2.55e-12	0.41	0.35	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
LGG	cis	rs11722779	0.658	rs6533044	ENSG00000248971.2	KRT8P46	-8.06	6.25e-15	2.55e-12	-0.36	-0.35	Schizophrenia;	chr4:102965261	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223356	ENSG00000248971.2	KRT8P46	-8.06	6.25e-15	2.55e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102728746~102730171:-
LGG	cis	rs1560104	0.619	rs3829519	ENSG00000274834.1	CTD-3037G24.5	8.06	6.25e-15	2.55e-12	0.43	0.35	Obesity-related traits;	chr16:12614854	chr16:12614451~12614852:+
LGG	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-8.06	6.25e-15	2.55e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-8.06	6.25e-15	2.55e-12	-0.35	-0.35	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
LGG	cis	rs454217	0.791	rs337650	ENSG00000277851.1	RP11-756G20.1	8.06	6.27e-15	2.56e-12	0.35	0.35	Smoking quantity;	chr12:92309130	chr12:92247756~92363832:-
LGG	cis	rs228614	0.536	rs223437	ENSG00000248971.2	KRT8P46	-8.06	6.28e-15	2.57e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102728746~102730171:-
LGG	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-8.06	6.28e-15	2.57e-12	-0.36	-0.35	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
LGG	cis	rs7119038	0.865	rs7951740	ENSG00000255239.1	AP002954.6	8.06	6.29e-15	2.57e-12	0.5	0.35	Sjögren's syndrome;	chr11:118869709	chr11:118688039~118690600:-
LGG	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	8.06	6.29e-15	2.57e-12	0.35	0.35	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
LGG	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	8.06	6.29e-15	2.57e-12	0.35	0.35	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
LGG	cis	rs11148252	0.74	rs9526914	ENSG00000235660.1	LINC00345	-8.06	6.29e-15	2.57e-12	-0.43	-0.35	Lewy body disease;	chr13:52402165	chr13:52484161~52484680:-
LGG	cis	rs6997458	0.785	rs2548281	ENSG00000253549.4	RP11-317J10.2	8.06	6.3e-15	2.57e-12	0.28	0.35	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85398547	chr8:85441851~85464915:-
LGG	cis	rs7520050	0.833	rs1085242	ENSG00000280836.1	AL355480.1	8.06	6.31e-15	2.58e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.966	rs1768803	ENSG00000280836.1	AL355480.1	8.06	6.31e-15	2.58e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.966	rs4660910	ENSG00000280836.1	AL355480.1	8.06	6.31e-15	2.58e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45581219~45581321:-
LGG	cis	rs2832077	0.527	rs9981922	ENSG00000232855.5	AF131217.1	8.06	6.32e-15	2.58e-12	0.4	0.35	Cognitive test performance;	chr21:28840396	chr21:28439346~28674848:-
LGG	cis	rs76076331	0.517	rs1734367	ENSG00000271952.1	RP11-245G13.2	8.06	6.32e-15	2.58e-12	0.5	0.35	Educational attainment (college completion);Educational attainment (years of education);	chr2:10838036	chr2:10878269~10885118:+
LGG	cis	rs12554020	0.786	rs7857183	ENSG00000237385.1	RP11-165J3.5	8.06	6.32e-15	2.58e-12	0.57	0.35	Schizophrenia;	chr9:93569762	chr9:93430342~93431299:-
LGG	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-8.06	6.33e-15	2.59e-12	-0.42	-0.35	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
LGG	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	8.06	6.35e-15	2.59e-12	0.8	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
LGG	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	8.06	6.35e-15	2.59e-12	0.41	0.35	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
LGG	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-8.06	6.35e-15	2.59e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-8.06	6.35e-15	2.59e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-8.06	6.35e-15	2.59e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
LGG	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-8.06	6.36e-15	2.6e-12	-0.41	-0.35	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
LGG	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-8.06	6.38e-15	2.6e-12	-0.47	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
LGG	cis	rs2797160	1	rs1954361	ENSG00000237742.5	RP11-624M8.1	-8.06	6.38e-15	2.6e-12	-0.32	-0.35	Endometrial cancer;	chr6:125680277	chr6:125578558~125749190:-
LGG	cis	rs228614	0.51	rs223445	ENSG00000248971.2	KRT8P46	-8.06	6.38e-15	2.61e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223443	ENSG00000248971.2	KRT8P46	-8.06	6.38e-15	2.61e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102728746~102730171:-
LGG	cis	rs7520050	0.966	rs1085243	ENSG00000280836.1	AL355480.1	8.06	6.4e-15	2.61e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.931	rs1707333	ENSG00000280836.1	AL355480.1	8.06	6.4e-15	2.61e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45581219~45581321:-
LGG	cis	rs2653165	0.893	rs316825	ENSG00000272865.1	RP11-561I11.4	8.06	6.41e-15	2.62e-12	0.45	0.35	Response to cytadine analogues (cytosine arabinoside);	chr1:242198475	chr1:242147514~242209129:+
LGG	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	8.06	6.42e-15	2.62e-12	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
LGG	cis	rs2797160	0.967	rs1954360	ENSG00000237742.5	RP11-624M8.1	-8.06	6.43e-15	2.62e-12	-0.32	-0.35	Endometrial cancer;	chr6:125679918	chr6:125578558~125749190:-
LGG	cis	rs35934224	0.783	rs34545894	ENSG00000232926.1	AC000078.5	8.06	6.43e-15	2.63e-12	0.38	0.35	Glaucoma (primary open-angle);	chr22:19870419	chr22:19887289~19887970:+
LGG	cis	rs848490	0.722	rs4729772	ENSG00000214293.7	APTR	8.06	6.46e-15	2.63e-12	0.34	0.35	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77826582	chr7:77657660~77696265:-
LGG	cis	rs2281636	0.723	rs11190245	ENSG00000233690.1	EBAG9P1	8.06	6.46e-15	2.64e-12	0.33	0.35	Obesity-related traits;	chr10:99691502	chr10:99697407~99697949:-
LGG	cis	rs35934224	0.783	rs7290770	ENSG00000232926.1	AC000078.5	8.06	6.46e-15	2.64e-12	0.41	0.35	Glaucoma (primary open-angle);	chr22:19873638	chr22:19887289~19887970:+
LGG	cis	rs1023500	0.505	rs134878	ENSG00000227370.1	RP4-669P10.19	8.06	6.49e-15	2.65e-12	0.31	0.35	Schizophrenia;	chr22:42267868	chr22:42132543~42132998:+
LGG	cis	rs6921919	0.697	rs758398	ENSG00000226314.6	ZNF192P1	8.06	6.49e-15	2.65e-12	0.37	0.35	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.954	rs6847248	ENSG00000250412.1	KLHL2P1	8.05	6.5e-15	2.65e-12	0.42	0.35	Corneal astigmatism;	chr4:119304800	chr4:119334329~119378233:+
LGG	cis	rs35425515	0.706	rs12770870	ENSG00000234855.1	SLIT1-AS1	-8.05	6.5e-15	2.65e-12	-0.6	-0.35	Bipolar disorder;	chr10:97103804	chr10:97102756~97103747:+
LGG	cis	rs2638953	0.853	rs11049668	ENSG00000278733.1	RP11-425D17.1	-8.05	6.53e-15	2.66e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497680	chr12:28185625~28186190:-
LGG	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.05	6.53e-15	2.66e-12	-0.36	-0.35	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
LGG	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-8.05	6.54e-15	2.67e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-8.05	6.54e-15	2.67e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-8.05	6.54e-15	2.67e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-8.05	6.54e-15	2.67e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
LGG	cis	rs17345786	0.667	rs7622940	ENSG00000244119.1	PDCL3P4	8.05	6.54e-15	2.67e-12	0.29	0.35	Colonoscopy-negative controls vs population controls;	chr3:101414311	chr3:101712472~101713191:+
LGG	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-8.05	6.57e-15	2.68e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
LGG	cis	rs853679	0.513	rs9468296	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28145952	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs4711164	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28147378	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs4711165	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28147406	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs4713148	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28148143	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9348794	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28149979	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9295758	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28152885	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs17774663	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28153120	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9468298	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28154567	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9295759	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28156691	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9348796	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28158424	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs11552219	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28159056	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9380058	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28159666	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9357065	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28161802	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9357066	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28162053	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9393898	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28162598	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9368556	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28163375	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9368557	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28163759	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9380059	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28164580	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9380060	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28164825	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs35227624	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28164948	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9380061	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28165025	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9368558	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28165528	chr6:28053228~28054165:-
LGG	cis	rs4713118	0.587	rs9393899	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Parkinson's disease;	chr6:28165750	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs4713150	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28168434	chr6:28053228~28054165:-
LGG	cis	rs4713118	0.527	rs4713151	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Parkinson's disease;	chr6:28168578	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9393901	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28169019	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs3173443	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28169249	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs4713152	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28169676	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9348797	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28169755	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9380062	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28169791	chr6:28053228~28054165:-
LGG	cis	rs853679	0.542	rs9380063	ENSG00000182477.5	OR2B8P	8.05	6.57e-15	2.68e-12	0.5	0.35	Depression;	chr6:28170075	chr6:28053228~28054165:-
LGG	cis	rs2638953	0.962	rs11049539	ENSG00000278733.1	RP11-425D17.1	-8.05	6.58e-15	2.69e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335953	chr12:28185625~28186190:-
LGG	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	8.05	6.59e-15	2.69e-12	0.24	0.35	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
LGG	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-8.05	6.59e-15	2.69e-12	-0.41	-0.35	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
LGG	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-8.05	6.59e-15	2.69e-12	-0.41	-0.35	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
LGG	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-8.05	6.6e-15	2.69e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
LGG	cis	rs11992162	1	rs11994417	ENSG00000255556.2	RP11-351I21.6	8.05	6.6e-15	2.69e-12	0.42	0.35	Monocyte count;	chr8:11975753	chr8:12378679~12380265:-
LGG	cis	rs1552244	0.882	rs7636817	ENSG00000180385.7	EMC3-AS1	8.05	6.61e-15	2.7e-12	0.39	0.35	Alzheimer's disease;	chr3:9973192	chr3:9986893~10006990:+
LGG	cis	rs11971779	0.68	rs7808740	ENSG00000273391.1	RP11-634H22.1	8.05	6.61e-15	2.7e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139344209	chr7:139359032~139359566:-
LGG	cis	rs7119038	0.865	rs10892299	ENSG00000255239.1	AP002954.6	-8.05	6.61e-15	2.7e-12	-0.5	-0.35	Sjögren's syndrome;	chr11:118856134	chr11:118688039~118690600:-
LGG	cis	rs2638953	0.924	rs11049478	ENSG00000278733.1	RP11-425D17.1	-8.05	6.62e-15	2.7e-12	-0.44	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244827	chr12:28185625~28186190:-
LGG	cis	rs228614	0.51	rs223463	ENSG00000248971.2	KRT8P46	-8.05	6.62e-15	2.7e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102728746~102730171:-
LGG	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-8.05	6.62e-15	2.7e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
LGG	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.05	6.63e-15	2.7e-12	-0.36	-0.35	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
LGG	cis	rs758324	0.732	rs128738	ENSG00000233006.5	AC034220.3	-8.05	6.63e-15	2.7e-12	-0.42	-0.35	Alzheimer's disease in APOE e4- carriers;	chr5:132205182	chr5:132311285~132369916:-
LGG	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-8.05	6.64e-15	2.7e-12	-0.47	-0.35	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
LGG	cis	rs11148252	0.74	rs9596642	ENSG00000235660.1	LINC00345	8.05	6.64e-15	2.71e-12	0.43	0.35	Lewy body disease;	chr13:52326744	chr13:52484161~52484680:-
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	8.05	6.64e-15	2.71e-12	0.49	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
LGG	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	8.05	6.65e-15	2.71e-12	0.34	0.35	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
LGG	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	8.05	6.65e-15	2.71e-12	0.48	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
LGG	cis	rs2797160	1	rs1777183	ENSG00000237742.5	RP11-624M8.1	8.05	6.65e-15	2.71e-12	0.31	0.35	Endometrial cancer;	chr6:125690849	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1739375	ENSG00000237742.5	RP11-624M8.1	8.05	6.65e-15	2.71e-12	0.31	0.35	Endometrial cancer;	chr6:125690867	chr6:125578558~125749190:-
LGG	cis	rs9322193	0.962	rs7818	ENSG00000216621.7	RP11-244K5.6	8.05	6.66e-15	2.71e-12	0.41	0.35	Lung cancer;	chr6:149810956	chr6:149934527~149936782:+
LGG	cis	rs6964833	1	rs3846966	ENSG00000277053.3	GTF2IP1	-8.05	6.66e-15	2.72e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74698811	chr7:75185385~75237696:-
LGG	cis	rs812925	0.512	rs1177309	ENSG00000273302.1	RP11-493E12.2	8.05	6.67e-15	2.72e-12	0.31	0.35	Immature fraction of reticulocytes;	chr2:61158113	chr2:61199979~61200769:+
LGG	cis	rs758324	0.687	rs154484	ENSG00000233006.5	AC034220.3	-8.05	6.68e-15	2.72e-12	-0.42	-0.35	Alzheimer's disease in APOE e4- carriers;	chr5:132214749	chr5:132311285~132369916:-
LGG	cis	rs11673344	0.536	rs62108291	ENSG00000267422.1	CTD-2554C21.1	8.05	6.68e-15	2.72e-12	0.36	0.35	Obesity-related traits;	chr19:37659457	chr19:37779686~37792865:+
LGG	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	8.05	6.69e-15	2.73e-12	0.35	0.35	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
LGG	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	8.05	6.7e-15	2.73e-12	0.81	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
LGG	cis	rs172166	0.637	rs1233691	ENSG00000218016.2	ZNF192P2	-8.05	6.7e-15	2.73e-12	-0.45	-0.35	Cardiac Troponin-T levels;	chr6:28186119	chr6:28188050~28189432:+
LGG	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-8.05	6.7e-15	2.73e-12	-0.49	-0.35	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
LGG	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-8.05	6.71e-15	2.73e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
LGG	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	8.05	6.71e-15	2.74e-12	0.31	0.35	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
LGG	cis	rs17772222	0.63	rs7141608	ENSG00000258983.2	RP11-507K2.2	-8.05	6.72e-15	2.74e-12	-0.39	-0.35	Coronary artery calcification;	chr14:88514045	chr14:88499334~88515502:+
LGG	cis	rs881375	0.501	rs10156413	ENSG00000226752.6	PSMD5-AS1	-8.05	6.73e-15	2.74e-12	-0.5	-0.35	Rheumatoid arthritis;	chr9:121105504	chr9:120824828~120854385:+
LGG	cis	rs7005380	0.62	rs7387694	ENSG00000245330.4	KB-1471A8.1	8.05	6.73e-15	2.74e-12	0.38	0.35	Interstitial lung disease;	chr8:119885261	chr8:119867419~119874488:-
LGG	cis	rs1560104	0.597	rs4781300	ENSG00000274834.1	CTD-3037G24.5	8.05	6.73e-15	2.74e-12	0.42	0.35	Obesity-related traits;	chr16:12613866	chr16:12614451~12614852:+
LGG	cis	rs2638953	0.853	rs17433981	ENSG00000278733.1	RP11-425D17.1	-8.05	6.74e-15	2.75e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28393634	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs12366617	ENSG00000278733.1	RP11-425D17.1	-8.05	6.74e-15	2.75e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28395726	chr12:28185625~28186190:-
LGG	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	8.05	6.75e-15	2.75e-12	0.33	0.35	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
LGG	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	8.05	6.75e-15	2.75e-12	0.33	0.35	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
LGG	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	8.05	6.75e-15	2.75e-12	0.33	0.35	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
LGG	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	8.05	6.76e-15	2.75e-12	0.46	0.35	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
LGG	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	8.05	6.76e-15	2.75e-12	0.46	0.35	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
LGG	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	8.05	6.76e-15	2.75e-12	0.46	0.35	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
LGG	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-8.05	6.76e-15	2.75e-12	-0.46	-0.35	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
LGG	cis	rs4143844	0.867	rs35324423	ENSG00000259251.2	RP11-643M14.1	8.05	6.78e-15	2.76e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62019946	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs4143845	ENSG00000259251.2	RP11-643M14.1	8.05	6.78e-15	2.76e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62020894	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs36126734	ENSG00000259251.2	RP11-643M14.1	8.05	6.78e-15	2.76e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62022710	chr15:62060503~62062434:+
LGG	cis	rs4143844	0.867	rs34088392	ENSG00000259251.2	RP11-643M14.1	8.05	6.78e-15	2.76e-12	0.57	0.35	Bipolar disorder and schizophrenia;	chr15:62022843	chr15:62060503~62062434:+
LGG	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-8.05	6.79e-15	2.77e-12	-0.26	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
LGG	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	8.05	6.81e-15	2.77e-12	0.43	0.35	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
LGG	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-8.05	6.81e-15	2.77e-12	-0.36	-0.35	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
LGG	cis	rs7241530	0.61	rs7230650	ENSG00000266213.1	RP11-100K18.1	-8.05	6.82e-15	2.78e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78132679	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs7235552	ENSG00000266213.1	RP11-100K18.1	-8.05	6.82e-15	2.78e-12	-0.42	-0.35	Educational attainment (years of education);	chr18:78132776	chr18:78137223~78140887:+
LGG	cis	rs2797160	1	rs1418951	ENSG00000237742.5	RP11-624M8.1	-8.05	6.82e-15	2.78e-12	-0.32	-0.35	Endometrial cancer;	chr6:125675039	chr6:125578558~125749190:-
LGG	cis	rs4986172	0.539	rs12603813	ENSG00000267288.2	RP13-890H12.2	-8.05	6.84e-15	2.78e-12	-0.46	-0.35	Height;	chr17:45119217	chr17:45168800~45171584:-
LGG	cis	rs1023500	0.505	rs134874	ENSG00000227370.1	RP4-669P10.19	8.05	6.84e-15	2.78e-12	0.3	0.35	Schizophrenia;	chr22:42265138	chr22:42132543~42132998:+
LGG	cis	rs7709377	0.672	rs10059989	ENSG00000212457.1	RNU6-644P	-8.05	6.84e-15	2.79e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116146778	chr5:116188455~116188552:-
LGG	cis	rs2797160	1	rs1832980	ENSG00000237742.5	RP11-624M8.1	-8.05	6.85e-15	2.79e-12	-0.32	-0.35	Endometrial cancer;	chr6:125676298	chr6:125578558~125749190:-
LGG	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	8.05	6.85e-15	2.79e-12	0.45	0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
LGG	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	8.05	6.87e-15	2.8e-12	0.35	0.35	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
LGG	cis	rs910316	0.763	rs12588981	ENSG00000279594.1	RP11-950C14.10	8.05	6.88e-15	2.8e-12	0.44	0.35	Height;	chr14:74993858	chr14:75011269~75012851:-
LGG	cis	rs11098499	0.908	rs9995234	ENSG00000250412.1	KLHL2P1	8.05	6.88e-15	2.8e-12	0.41	0.35	Corneal astigmatism;	chr4:119400672	chr4:119334329~119378233:+
LGG	cis	rs7474896	0.537	rs2505255	ENSG00000226578.1	RP11-258F22.1	-8.05	6.88e-15	2.8e-12	-0.47	-0.35	Obesity (extreme);	chr10:38070714	chr10:37775371~37784131:-
LGG	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	8.05	6.89e-15	2.8e-12	0.43	0.35	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
LGG	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-8.05	6.94e-15	2.82e-12	-0.37	-0.35	Depression;	chr6:28229408	chr6:28115628~28116551:+
LGG	cis	rs1560104	0.597	rs881667	ENSG00000274834.1	CTD-3037G24.5	8.05	6.94e-15	2.82e-12	0.42	0.35	Obesity-related traits;	chr16:12618569	chr16:12614451~12614852:+
LGG	cis	rs8180040	0.966	rs7651762	ENSG00000271161.1	BOLA2P2	-8.05	6.94e-15	2.82e-12	-0.32	-0.35	Colorectal cancer;	chr3:47428994	chr3:47499841~47500407:+
LGG	cis	rs8180040	0.966	rs6792461	ENSG00000271161.1	BOLA2P2	-8.05	6.94e-15	2.82e-12	-0.32	-0.35	Colorectal cancer;	chr3:47431678	chr3:47499841~47500407:+
LGG	cis	rs172166	0.637	rs1225592	ENSG00000218016.2	ZNF192P2	-8.05	6.94e-15	2.82e-12	-0.45	-0.35	Cardiac Troponin-T levels;	chr6:28182464	chr6:28188050~28189432:+
LGG	cis	rs172166	0.637	rs1225595	ENSG00000218016.2	ZNF192P2	-8.05	6.94e-15	2.82e-12	-0.45	-0.35	Cardiac Troponin-T levels;	chr6:28183562	chr6:28188050~28189432:+
LGG	cis	rs853679	0.517	rs4713146	ENSG00000182477.5	OR2B8P	8.05	6.95e-15	2.83e-12	0.5	0.35	Depression;	chr6:28143758	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9393894	ENSG00000182477.5	OR2B8P	8.05	6.95e-15	2.83e-12	0.5	0.35	Depression;	chr6:28144784	chr6:28053228~28054165:-
LGG	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	8.05	6.95e-15	2.83e-12	0.49	0.35	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
LGG	cis	rs10246939	0.543	rs11765106	ENSG00000261570.1	RP11-744I24.2	-8.05	6.96e-15	2.83e-12	-0.45	-0.35	Bitter taste perception;	chr7:141902676	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.543	rs11767947	ENSG00000261570.1	RP11-744I24.2	-8.05	6.96e-15	2.83e-12	-0.45	-0.35	Bitter taste perception;	chr7:141912821	chr7:141529203~141551304:-
LGG	cis	rs10246939	0.543	rs11765974	ENSG00000261570.1	RP11-744I24.2	-8.05	6.96e-15	2.83e-12	-0.45	-0.35	Bitter taste perception;	chr7:141914390	chr7:141529203~141551304:-
LGG	cis	rs9322193	0.962	rs9478848	ENSG00000216621.7	RP11-244K5.6	8.05	6.96e-15	2.83e-12	0.41	0.35	Lung cancer;	chr6:149825080	chr6:149934527~149936782:+
LGG	cis	rs11018904	0.906	rs35129016	ENSG00000280385.1	AP000648.5	-8.05	6.96e-15	2.83e-12	-0.44	-0.35	Intelligence (multi-trait analysis);	chr11:90215521	chr11:90193614~90198120:+
LGG	cis	rs7927771	0.524	rs12362318	ENSG00000280615.1	Y_RNA	8.05	6.97e-15	2.84e-12	0.41	0.35	Subjective well-being;	chr11:47661119	chr11:47614898~47614994:-
LGG	cis	rs7267979	0.668	rs2387977	ENSG00000276952.1	RP5-965G21.6	-8.05	6.97e-15	2.84e-12	-0.34	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:25284915~25285588:-
LGG	cis	rs853679	0.517	rs9283884	ENSG00000182477.5	OR2B8P	-8.04	7e-15	2.85e-12	-0.51	-0.35	Depression;	chr6:28167882	chr6:28053228~28054165:-
LGG	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-8.04	7.02e-15	2.85e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
LGG	cis	rs7709377	0.723	rs1396486	ENSG00000212457.1	RNU6-644P	8.04	7.04e-15	2.86e-12	0.5	0.35	Metabolite levels  (X-11787);	chr5:116176844	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7720518	ENSG00000212457.1	RNU6-644P	-8.04	7.04e-15	2.86e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116177106	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7702975	ENSG00000212457.1	RNU6-644P	-8.04	7.04e-15	2.86e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116177123	chr5:116188455~116188552:-
LGG	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-8.04	7.05e-15	2.87e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-8.04	7.05e-15	2.87e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-8.04	7.05e-15	2.87e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
LGG	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-8.04	7.05e-15	2.87e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
LGG	cis	rs227275	0.556	rs7676765	ENSG00000248971.2	KRT8P46	8.04	7.07e-15	2.87e-12	0.35	0.35	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102728746~102730171:-
LGG	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	8.04	7.08e-15	2.88e-12	0.36	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
LGG	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	8.04	7.09e-15	2.88e-12	0.72	0.35	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
LGG	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-8.04	7.11e-15	2.89e-12	-0.46	-0.35	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
LGG	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-8.04	7.11e-15	2.89e-12	-0.46	-0.35	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
LGG	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	8.04	7.11e-15	2.89e-12	0.42	0.35	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
LGG	cis	rs12935418	0.616	rs12444054	ENSG00000260213.4	RP11-303E16.3	-8.04	7.11e-15	2.89e-12	-0.48	-0.35	Mean corpuscular volume;	chr16:80930320	chr16:81016792~81035759:-
LGG	cis	rs858239	0.73	rs858290	ENSG00000230042.1	AK3P3	-8.04	7.12e-15	2.89e-12	-0.35	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23129178~23129841:+
LGG	cis	rs858239	0.73	rs858289	ENSG00000230042.1	AK3P3	-8.04	7.12e-15	2.89e-12	-0.35	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23129178~23129841:+
LGG	cis	rs4950322	0.542	rs1932977	ENSG00000278811.3	LINC00624	8.04	7.12e-15	2.89e-12	0.33	0.35	Protein quantitative trait loci;	chr1:147217371	chr1:147258885~147517875:-
LGG	cis	rs9376098	0.825	rs6569999	ENSG00000232876.1	CTA-212D2.2	8.04	7.12e-15	2.89e-12	0.4	0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161428	chr6:135055033~135060550:+
LGG	cis	rs7927771	0.524	rs7107792	ENSG00000280615.1	Y_RNA	8.04	7.13e-15	2.9e-12	0.41	0.35	Subjective well-being;	chr11:47647697	chr11:47614898~47614994:-
LGG	cis	rs7829975	0.501	rs74345345	ENSG00000173295.6	FAM86B3P	8.04	7.13e-15	2.9e-12	0.39	0.35	Mood instability;	chr8:8720925	chr8:8228595~8244865:+
LGG	cis	rs758324	0.732	rs159903	ENSG00000233006.5	AC034220.3	8.04	7.13e-15	2.9e-12	0.42	0.35	Alzheimer's disease in APOE e4- carriers;	chr5:132204360	chr5:132311285~132369916:-
LGG	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	8.04	7.14e-15	2.9e-12	0.41	0.35	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
LGG	cis	rs1153858	0.848	rs9806699	ENSG00000259433.2	CTD-2651B20.4	-8.04	7.14e-15	2.9e-12	-0.41	-0.35	Homoarginine levels;	chr15:45448194	chr15:45330209~45332634:-
LGG	cis	rs62103177	0.564	rs55867755	ENSG00000261126.6	RP11-795F19.1	8.04	7.15e-15	2.91e-12	0.4	0.35	Opioid sensitivity;	chr18:79963434	chr18:80046900~80095482:+
LGG	cis	rs62103177	0.564	rs59188178	ENSG00000261126.6	RP11-795F19.1	8.04	7.15e-15	2.91e-12	0.4	0.35	Opioid sensitivity;	chr18:79963435	chr18:80046900~80095482:+
LGG	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	8.04	7.17e-15	2.91e-12	0.46	0.35	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
LGG	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	8.04	7.17e-15	2.91e-12	0.44	0.35	Height;	chr14:75159339	chr14:75011269~75012851:-
LGG	cis	rs11148252	0.716	rs2760772	ENSG00000278238.1	RP11-245D16.4	-8.04	7.18e-15	2.92e-12	-0.34	-0.35	Lewy body disease;	chr13:52206238	chr13:52454775~52455331:-
LGG	cis	rs2797160	0.967	rs1777224	ENSG00000237742.5	RP11-624M8.1	8.04	7.18e-15	2.92e-12	0.32	0.35	Endometrial cancer;	chr6:125698381	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1739357	ENSG00000237742.5	RP11-624M8.1	8.04	7.18e-15	2.92e-12	0.32	0.35	Endometrial cancer;	chr6:125698509	chr6:125578558~125749190:-
LGG	cis	rs600231	0.623	rs587080	ENSG00000245532.5	NEAT1	8.04	7.19e-15	2.92e-12	0.24	0.35	Bone mineral density;	chr11:65486329	chr11:65422774~65445540:+
LGG	cis	rs7829975	0.846	rs6601724	ENSG00000253981.4	ALG1L13P	8.04	7.19e-15	2.92e-12	0.36	0.35	Mood instability;	chr8:8687362	chr8:8236003~8244667:-
LGG	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-8.04	7.2e-15	2.92e-12	-0.44	-0.35	Height;	chr14:75163675	chr14:75011269~75012851:-
LGG	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-8.04	7.2e-15	2.93e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
LGG	cis	rs7927771	0.524	rs4539273	ENSG00000280615.1	Y_RNA	-8.04	7.22e-15	2.93e-12	-0.41	-0.35	Subjective well-being;	chr11:47673147	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs12286721	ENSG00000280615.1	Y_RNA	-8.04	7.22e-15	2.93e-12	-0.41	-0.35	Subjective well-being;	chr11:47679976	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs4752860	ENSG00000280615.1	Y_RNA	-8.04	7.22e-15	2.93e-12	-0.41	-0.35	Subjective well-being;	chr11:47683463	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.542	rs11039336	ENSG00000280615.1	Y_RNA	-8.04	7.22e-15	2.93e-12	-0.41	-0.35	Subjective well-being;	chr11:47684589	chr11:47614898~47614994:-
LGG	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-8.04	7.23e-15	2.94e-12	-0.35	-0.35	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
LGG	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-8.04	7.25e-15	2.95e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
LGG	cis	rs6921919	0.697	rs12180820	ENSG00000280107.1	AL022393.9	8.04	7.26e-15	2.95e-12	0.36	0.35	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28170845~28172521:+
LGG	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-8.04	7.26e-15	2.95e-12	-0.65	-0.35	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-8.04	7.26e-15	2.95e-12	-0.65	-0.35	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-8.04	7.26e-15	2.95e-12	-0.65	-0.35	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
LGG	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-8.04	7.26e-15	2.95e-12	-0.65	-0.35	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-8.04	7.26e-15	2.95e-12	-0.65	-0.35	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-8.04	7.26e-15	2.95e-12	-0.65	-0.35	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
LGG	cis	rs228614	0.51	rs223378	ENSG00000248971.2	KRT8P46	-8.04	7.27e-15	2.95e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102728746~102730171:-
LGG	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-8.04	7.28e-15	2.95e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
LGG	cis	rs7520050	0.966	rs1707340	ENSG00000280836.1	AL355480.1	8.04	7.28e-15	2.95e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45581219~45581321:-
LGG	cis	rs7520050	1	rs785473	ENSG00000280836.1	AL355480.1	8.04	7.28e-15	2.95e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.931	rs785472	ENSG00000280836.1	AL355480.1	8.04	7.28e-15	2.95e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45581219~45581321:-
LGG	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-8.04	7.28e-15	2.96e-12	-0.44	-0.35	Height;	chr14:75166305	chr14:75011269~75012851:-
LGG	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-8.04	7.28e-15	2.96e-12	-0.44	-0.35	Height;	chr14:75170264	chr14:75011269~75012851:-
LGG	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-8.04	7.28e-15	2.96e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
LGG	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	8.04	7.3e-15	2.96e-12	0.43	0.35	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
LGG	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	8.04	7.3e-15	2.96e-12	0.43	0.35	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
LGG	cis	rs228614	0.51	rs223410	ENSG00000248971.2	KRT8P46	-8.04	7.32e-15	2.97e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs150893	ENSG00000248971.2	KRT8P46	8.04	7.33e-15	2.98e-12	0.37	0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102728746~102730171:-
LGG	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-8.04	7.33e-15	2.98e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
LGG	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	8.04	7.33e-15	2.98e-12	0.35	0.35	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
LGG	cis	rs5760092	0.755	rs11090298	ENSG00000250470.1	AP000351.3	-8.04	7.34e-15	2.98e-12	-0.58	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23976904~23977585:-
LGG	cis	rs1408799	0.679	rs1326790	ENSG00000235448.1	LURAP1L-AS1	8.04	7.35e-15	2.98e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12761169	chr9:12700100~12814345:-
LGG	cis	rs1408799	0.679	rs1326791	ENSG00000235448.1	LURAP1L-AS1	8.04	7.35e-15	2.98e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12761301	chr9:12700100~12814345:-
LGG	cis	rs1408799	0.704	rs1326792	ENSG00000235448.1	LURAP1L-AS1	8.04	7.35e-15	2.98e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12761361	chr9:12700100~12814345:-
LGG	cis	rs7927771	0.524	rs7933184	ENSG00000280615.1	Y_RNA	8.04	7.35e-15	2.98e-12	0.41	0.35	Subjective well-being;	chr11:47660850	chr11:47614898~47614994:-
LGG	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-8.04	7.35e-15	2.99e-12	-0.37	-0.35	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
LGG	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-8.04	7.36e-15	2.99e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-8.04	7.36e-15	2.99e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
LGG	cis	rs228614	0.51	rs223400	ENSG00000248971.2	KRT8P46	-8.04	7.37e-15	2.99e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102728746~102730171:-
LGG	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-8.04	7.37e-15	2.99e-12	-0.45	-0.35	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
LGG	cis	rs34381861	0.52	rs74382390	ENSG00000260886.1	TAT-AS1	8.04	7.37e-15	2.99e-12	0.62	0.35	Post bronchodilator FEV1;	chr16:71424623	chr16:71565789~71578187:+
LGG	cis	rs2638953	0.853	rs11049635	ENSG00000278733.1	RP11-425D17.1	-8.04	7.37e-15	2.99e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28185625~28186190:-
LGG	cis	rs6997458	0.813	rs3758078	ENSG00000253549.4	RP11-317J10.2	8.04	7.38e-15	3e-12	0.28	0.35	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85462435	chr8:85441851~85464915:-
LGG	cis	rs4295623	0.585	rs13259242	ENSG00000255556.2	RP11-351I21.6	-8.04	7.42e-15	3.01e-12	-0.42	-0.35	Morning vs. evening chronotype;	chr8:11735524	chr8:12378679~12380265:-
LGG	cis	rs1408799	0.704	rs1326788	ENSG00000235448.1	LURAP1L-AS1	8.04	7.42e-15	3.01e-12	0.35	0.35	Eye color;Blue vs. green eyes;	chr9:12759782	chr9:12700100~12814345:-
LGG	cis	rs1408799	0.704	rs1326789	ENSG00000235448.1	LURAP1L-AS1	8.04	7.42e-15	3.01e-12	0.35	0.35	Eye color;Blue vs. green eyes;	chr9:12759839	chr9:12700100~12814345:-
LGG	cis	rs228614	0.536	rs223420	ENSG00000248971.2	KRT8P46	-8.04	7.43e-15	3.02e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102728746~102730171:-
LGG	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-8.04	7.44e-15	3.02e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
LGG	cis	rs454217	0.773	rs518009	ENSG00000277851.1	RP11-756G20.1	8.04	7.44e-15	3.02e-12	0.36	0.35	Smoking quantity;	chr12:92339730	chr12:92247756~92363832:-
LGG	cis	rs8180040	0.966	rs1872164	ENSG00000271161.1	BOLA2P2	-8.04	7.48e-15	3.04e-12	-0.32	-0.35	Colorectal cancer;	chr3:47373610	chr3:47499841~47500407:+
LGG	cis	rs6496932	0.874	rs11074061	ENSG00000218052.5	ADAMTS7P4	8.04	7.49e-15	3.04e-12	0.52	0.35	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:85255369~85330334:-
LGG	cis	rs7927771	0.524	rs7107922	ENSG00000280615.1	Y_RNA	8.04	7.49e-15	3.04e-12	0.41	0.35	Subjective well-being;	chr11:47647737	chr11:47614898~47614994:-
LGG	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-8.03	7.5e-15	3.04e-12	-0.36	-0.35	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
LGG	cis	rs7119038	0.607	rs12365699	ENSG00000255239.1	AP002954.6	-8.03	7.5e-15	3.04e-12	-0.52	-0.35	Sjögren's syndrome;	chr11:118872577	chr11:118688039~118690600:-
LGG	cis	rs853679	0.517	rs4713135	ENSG00000182477.5	OR2B8P	8.03	7.54e-15	3.06e-12	0.5	0.35	Depression;	chr6:28071808	chr6:28053228~28054165:-
LGG	cis	rs9859260	0.744	rs539816	ENSG00000242086.7	LINC00969	-8.03	7.55e-15	3.06e-12	-0.3	-0.35	Mean corpuscular volume;	chr3:196057205	chr3:195658062~195739964:+
LGG	cis	rs9859260	0.744	rs492349	ENSG00000242086.7	LINC00969	-8.03	7.55e-15	3.06e-12	-0.3	-0.35	Mean corpuscular volume;	chr3:196057321	chr3:195658062~195739964:+
LGG	cis	rs9859260	0.744	rs492288	ENSG00000242086.7	LINC00969	-8.03	7.55e-15	3.06e-12	-0.3	-0.35	Mean corpuscular volume;	chr3:196057339	chr3:195658062~195739964:+
LGG	cis	rs2797160	1	rs1739367	ENSG00000237742.5	RP11-624M8.1	-8.03	7.55e-15	3.06e-12	-0.32	-0.35	Endometrial cancer;	chr6:125683574	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2747724	ENSG00000237742.5	RP11-624M8.1	-8.03	7.55e-15	3.06e-12	-0.32	-0.35	Endometrial cancer;	chr6:125683789	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2797154	ENSG00000237742.5	RP11-624M8.1	-8.03	7.55e-15	3.06e-12	-0.32	-0.35	Endometrial cancer;	chr6:125684051	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1739352	ENSG00000237742.5	RP11-624M8.1	-8.03	7.55e-15	3.06e-12	-0.32	-0.35	Endometrial cancer;	chr6:125684164	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs983543	ENSG00000237742.5	RP11-624M8.1	-8.03	7.55e-15	3.06e-12	-0.32	-0.35	Endometrial cancer;	chr6:125684621	chr6:125578558~125749190:-
LGG	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	-8.03	7.56e-15	3.06e-12	-0.36	-0.35	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
LGG	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-8.03	7.56e-15	3.06e-12	-0.43	-0.35	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
LGG	cis	rs9859260	0.744	rs3933	ENSG00000242086.7	LINC00969	-8.03	7.56e-15	3.06e-12	-0.3	-0.35	Mean corpuscular volume;	chr3:196058126	chr3:195658062~195739964:+
LGG	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	8.03	7.56e-15	3.07e-12	0.71	0.35	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	8.03	7.56e-15	3.07e-12	0.71	0.35	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-8.03	7.56e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-8.03	7.56e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-8.03	7.56e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-8.03	7.56e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-8.03	7.56e-15	3.07e-12	-0.71	-0.35	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
LGG	cis	rs7520050	0.778	rs3014216	ENSG00000280836.1	AL355480.1	-8.03	7.58e-15	3.07e-12	-0.39	-0.35	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45581219~45581321:-
LGG	cis	rs440932	0.887	rs398801	ENSG00000173295.6	FAM86B3P	8.03	7.58e-15	3.07e-12	0.39	0.35	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8228595~8244865:+
LGG	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	8.03	7.61e-15	3.09e-12	0.43	0.35	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
LGG	cis	rs950169	0.723	rs17589320	ENSG00000259295.5	CSPG4P12	8.03	7.62e-15	3.09e-12	0.48	0.35	Schizophrenia;	chr15:84251244	chr15:85191438~85213905:+
LGG	cis	rs1408799	0.654	rs7025842	ENSG00000235448.1	LURAP1L-AS1	8.03	7.63e-15	3.09e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12760648	chr9:12700100~12814345:-
LGG	cis	rs1408799	0.679	rs7025953	ENSG00000235448.1	LURAP1L-AS1	8.03	7.63e-15	3.09e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12760719	chr9:12700100~12814345:-
LGG	cis	rs1408799	0.679	rs7025771	ENSG00000235448.1	LURAP1L-AS1	8.03	7.63e-15	3.09e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12760763	chr9:12700100~12814345:-
LGG	cis	rs1408799	0.607	rs7025678	ENSG00000235448.1	LURAP1L-AS1	8.03	7.63e-15	3.09e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12760789	chr9:12700100~12814345:-
LGG	cis	rs1408799	0.679	rs7025914	ENSG00000235448.1	LURAP1L-AS1	8.03	7.63e-15	3.09e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12760885	chr9:12700100~12814345:-
LGG	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-8.03	7.63e-15	3.09e-12	-0.44	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
LGG	cis	rs6997458	0.785	rs7016369	ENSG00000253549.4	RP11-317J10.2	-8.03	7.65e-15	3.1e-12	-0.28	-0.35	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85456040	chr8:85441851~85464915:-
LGG	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-8.03	7.65e-15	3.1e-12	-0.52	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
LGG	cis	rs11722779	0.935	rs3974481	ENSG00000248971.2	KRT8P46	-8.03	7.66e-15	3.1e-12	-0.36	-0.35	Schizophrenia;	chr4:102956834	chr4:102728746~102730171:-
LGG	cis	rs11148252	0.74	rs9596648	ENSG00000235660.1	LINC00345	8.03	7.67e-15	3.11e-12	0.43	0.35	Lewy body disease;	chr13:52360434	chr13:52484161~52484680:-
LGG	cis	rs62184315	0.536	rs2278591	ENSG00000253559.1	OSGEPL1-AS1	-8.03	7.67e-15	3.11e-12	-0.52	-0.35	Alcohol dependence (age at onset);	chr2:189755778	chr2:189762704~189765556:+
LGG	cis	rs62184315	0.536	rs16831972	ENSG00000253559.1	OSGEPL1-AS1	-8.03	7.67e-15	3.11e-12	-0.52	-0.35	Alcohol dependence (age at onset);	chr2:189756707	chr2:189762704~189765556:+
LGG	cis	rs17772222	0.606	rs449338	ENSG00000258983.2	RP11-507K2.2	-8.03	7.68e-15	3.11e-12	-0.38	-0.35	Coronary artery calcification;	chr14:88411690	chr14:88499334~88515502:+
LGG	cis	rs11098499	0.908	rs7695996	ENSG00000250412.1	KLHL2P1	8.03	7.68e-15	3.11e-12	0.4	0.35	Corneal astigmatism;	chr4:119400878	chr4:119334329~119378233:+
LGG	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	8.03	7.69e-15	3.11e-12	0.41	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
LGG	cis	rs1150668	0.768	rs1150716	ENSG00000270326.1	RP5-874C20.6	-8.03	7.69e-15	3.12e-12	-0.44	-0.35	Pubertal anthropometrics;	chr6:28294921	chr6:28319660~28319852:-
LGG	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	8.03	7.69e-15	3.12e-12	0.24	0.35	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
LGG	cis	rs12899811	0.53	rs11073967	ENSG00000214432.8	AC068831.10	-8.03	7.71e-15	3.12e-12	-0.36	-0.35	Type 2 diabetes;	chr15:91022574	chr15:91022619~91036611:+
LGG	cis	rs9393777	0.764	rs35565446	ENSG00000216901.1	AL022393.7	8.03	7.72e-15	3.13e-12	0.76	0.35	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28176188~28176674:+
LGG	cis	rs9393777	0.777	rs56114371	ENSG00000216901.1	AL022393.7	8.03	7.72e-15	3.13e-12	0.76	0.35	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28176188~28176674:+
LGG	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-8.03	7.75e-15	3.14e-12	-0.36	-0.35	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
LGG	cis	rs12893668	0.572	rs2273175	ENSG00000269940.1	RP11-73M18.7	8.03	7.75e-15	3.14e-12	0.39	0.35	Reticulocyte count;	chr14:103693804	chr14:103694560~103695170:+
LGG	cis	rs7824557	0.628	rs7820301	ENSG00000184608.7	FAM167A-AS1	-8.03	7.76e-15	3.14e-12	-0.29	-0.35	Retinal vascular caliber;	chr8:11371163	chr8:11368402~11438658:+
LGG	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-8.03	7.76e-15	3.14e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-8.03	7.76e-15	3.14e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
LGG	cis	rs997295	0.57	rs60066681	ENSG00000270964.1	RP11-502I4.3	-8.03	7.77e-15	3.15e-12	-0.36	-0.35	Motion sickness;	chr15:67515738	chr15:67541072~67542604:-
LGG	cis	rs9300255	0.51	rs1727323	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123214243	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs1716160	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123215678	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.569	rs1727320	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123215929	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs1790131	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123216463	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.544	rs1790130	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123216723	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs2682431	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123218679	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs2851450	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123218954	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.537	rs1790101	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123220297	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.568	rs1790102	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123220343	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs1626899	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123223516	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs10846486	ENSG00000235423.7	RP11-282O18.3	8.03	7.78e-15	3.15e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123225380	chr12:123252030~123261483:-
LGG	cis	rs853679	0.505	rs200992	ENSG00000216901.1	AL022393.7	8.03	7.82e-15	3.17e-12	0.67	0.35	Depression;	chr6:27846899	chr6:28176188~28176674:+
LGG	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-8.03	7.83e-15	3.17e-12	-0.36	-0.35	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
LGG	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	8.03	7.83e-15	3.17e-12	0.4	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
LGG	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-8.03	7.84e-15	3.17e-12	-0.3	-0.35	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
LGG	cis	rs7189233	1	rs7189233	ENSG00000279344.1	RP11-44F14.7	8.03	7.86e-15	3.18e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr16:53421471	chr16:53478957~53481550:-
LGG	cis	rs2638953	0.924	rs10492368	ENSG00000278733.1	RP11-425D17.1	-8.03	7.86e-15	3.18e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28185625~28186190:-
LGG	cis	rs1560104	0.556	rs59670495	ENSG00000274834.1	CTD-3037G24.5	8.03	7.87e-15	3.19e-12	0.43	0.35	Obesity-related traits;	chr16:12617241	chr16:12614451~12614852:+
LGG	cis	rs228614	0.51	rs223358	ENSG00000248971.2	KRT8P46	-8.03	7.9e-15	3.2e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102728746~102730171:-
LGG	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-8.03	7.91e-15	3.2e-12	-0.45	-0.35	Height;	chr14:75170656	chr14:75011269~75012851:-
LGG	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	8.03	7.92e-15	3.2e-12	0.63	0.35	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
LGG	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	8.03	7.92e-15	3.2e-12	0.63	0.35	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
LGG	cis	rs11992162	1	rs11784499	ENSG00000255556.2	RP11-351I21.6	8.03	7.93e-15	3.21e-12	0.42	0.35	Monocyte count;	chr8:11977030	chr8:12378679~12380265:-
LGG	cis	rs7005380	0.62	rs7388508	ENSG00000245330.4	KB-1471A8.1	8.03	7.96e-15	3.22e-12	0.39	0.35	Interstitial lung disease;	chr8:119913913	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs1607624	ENSG00000245330.4	KB-1471A8.1	8.03	7.96e-15	3.22e-12	0.39	0.35	Interstitial lung disease;	chr8:119917049	chr8:119867419~119874488:-
LGG	cis	rs12893668	0.572	rs1606	ENSG00000269940.1	RP11-73M18.7	8.03	7.96e-15	3.22e-12	0.4	0.35	Reticulocyte count;	chr14:103694944	chr14:103694560~103695170:+
LGG	cis	rs6921919	0.789	rs1119211	ENSG00000280107.1	AL022393.9	8.03	7.97e-15	3.22e-12	0.38	0.35	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28170845~28172521:+
LGG	cis	rs2638953	0.85	rs11049428	ENSG00000278733.1	RP11-425D17.1	-8.03	7.97e-15	3.22e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194267	chr12:28185625~28186190:-
LGG	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-8.03	7.97e-15	3.23e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-8.03	7.97e-15	3.23e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
LGG	cis	rs7160336	0.738	rs35579176	ENSG00000258586.1	RP5-1021I20.2	8.03	7.98e-15	3.23e-12	0.42	0.35	Blood protein levels;	chr14:74013601	chr14:73822559~73830135:-
LGG	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-8.03	7.98e-15	3.23e-12	-0.4	-0.35	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
LGG	cis	rs66887589	0.72	rs2036858	ENSG00000249244.1	RP11-548H18.2	8.03	7.98e-15	3.23e-12	0.35	0.35	Diastolic blood pressure;	chr4:119328082	chr4:119391831~119395335:-
LGG	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-8.03	8e-15	3.24e-12	-0.23	-0.35	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
LGG	cis	rs12935418	0.83	rs7195459	ENSG00000260213.4	RP11-303E16.3	-8.03	8.01e-15	3.24e-12	-0.53	-0.35	Mean corpuscular volume;	chr16:81016376	chr16:81016792~81035759:-
LGG	cis	rs35934224	0.783	rs34462686	ENSG00000232926.1	AC000078.5	8.03	8.02e-15	3.24e-12	0.38	0.35	Glaucoma (primary open-angle);	chr22:19872394	chr22:19887289~19887970:+
LGG	cis	rs35934224	0.783	rs34143881	ENSG00000232926.1	AC000078.5	8.03	8.02e-15	3.24e-12	0.38	0.35	Glaucoma (primary open-angle);	chr22:19872570	chr22:19887289~19887970:+
LGG	cis	rs35934224	0.783	rs35969236	ENSG00000232926.1	AC000078.5	8.03	8.02e-15	3.24e-12	0.38	0.35	Glaucoma (primary open-angle);	chr22:19872832	chr22:19887289~19887970:+
LGG	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-8.03	8.03e-15	3.25e-12	-0.46	-0.35	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
LGG	cis	rs11018904	0.861	rs12786959	ENSG00000280385.1	AP000648.5	-8.03	8.03e-15	3.25e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr11:90210508	chr11:90193614~90198120:+
LGG	cis	rs11018904	0.861	rs12787117	ENSG00000280385.1	AP000648.5	-8.03	8.03e-15	3.25e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr11:90210513	chr11:90193614~90198120:+
LGG	cis	rs7302981	0.746	rs836172	ENSG00000272368.2	RP4-605O3.4	8.02	8.08e-15	3.27e-12	0.33	0.35	Systolic blood pressure;	chr12:50096316	chr12:50112197~50165618:+
LGG	cis	rs2797160	1	rs1777222	ENSG00000237742.5	RP11-624M8.1	8.02	8.11e-15	3.28e-12	0.31	0.35	Endometrial cancer;	chr6:125699884	chr6:125578558~125749190:-
LGG	cis	rs9300255	0.602	rs1716164	ENSG00000235423.7	RP11-282O18.3	8.02	8.13e-15	3.29e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123179113	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.568	rs1727300	ENSG00000235423.7	RP11-282O18.3	8.02	8.13e-15	3.29e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123179658	chr12:123252030~123261483:-
LGG	cis	rs11098499	0.779	rs28495013	ENSG00000250412.1	KLHL2P1	8.02	8.14e-15	3.29e-12	0.4	0.35	Corneal astigmatism;	chr4:119454676	chr4:119334329~119378233:+
LGG	cis	rs12935418	0.616	rs62054238	ENSG00000260213.4	RP11-303E16.3	-8.02	8.15e-15	3.29e-12	-0.46	-0.35	Mean corpuscular volume;	chr16:80965753	chr16:81016792~81035759:-
LGG	cis	rs2638953	0.853	rs11049643	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471581	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.777	rs11049644	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471724	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049645	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28472615	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs10843184	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473339	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.815	rs61920658	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475519	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs12367657	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475816	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.815	rs11049654	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28480502	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049657	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481746	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049659	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482147	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs1355475	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482398	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs1918418	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483789	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs1511550	ENSG00000278733.1	RP11-425D17.1	-8.02	8.16e-15	3.3e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28484182	chr12:28185625~28186190:-
LGG	cis	rs853679	0.517	rs9393895	ENSG00000182477.5	OR2B8P	8.02	8.17e-15	3.3e-12	0.5	0.35	Depression;	chr6:28159843	chr6:28053228~28054165:-
LGG	cis	rs812925	0.537	rs778139	ENSG00000273302.1	RP11-493E12.2	-8.02	8.17e-15	3.3e-12	-0.29	-0.35	Immature fraction of reticulocytes;	chr2:61457429	chr2:61199979~61200769:+
LGG	cis	rs7576126	0.563	rs1807337	ENSG00000204929.10	AC074391.1	-8.02	8.17e-15	3.3e-12	-0.34	-0.35	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65436711~66084639:+
LGG	cis	rs2726040	0.902	rs33957528	ENSG00000271623.1	RP11-435I10.5	8.02	8.19e-15	3.31e-12	0.41	0.35	Hip circumference;	chr16:28296619	chr16:28364700~28365333:+
LGG	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	8.02	8.2e-15	3.31e-12	0.35	0.35	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
LGG	cis	rs600231	0.708	rs602838	ENSG00000245532.5	NEAT1	8.02	8.21e-15	3.32e-12	0.24	0.35	Bone mineral density;	chr11:65485776	chr11:65422774~65445540:+
LGG	cis	rs11603023	0.805	rs687190	ENSG00000255176.1	AP002954.3	-8.02	8.22e-15	3.32e-12	-0.26	-0.35	Cholesterol, total;	chr11:118671674	chr11:118636620~118638097:+
LGG	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	8.02	8.22e-15	3.32e-12	0.4	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
LGG	cis	rs9322193	0.651	rs9322188	ENSG00000216621.7	RP11-244K5.6	-8.02	8.23e-15	3.32e-12	-0.41	-0.35	Lung cancer;	chr6:149588355	chr6:149934527~149936782:+
LGG	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-8.02	8.24e-15	3.33e-12	-0.45	-0.35	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
LGG	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-8.02	8.24e-15	3.33e-12	-0.45	-0.35	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
LGG	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	8.02	8.25e-15	3.33e-12	0.35	0.35	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
LGG	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	8.02	8.26e-15	3.34e-12	0.41	0.35	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
LGG	cis	rs2832077	0.527	rs2738953	ENSG00000232855.5	AF131217.1	-8.02	8.26e-15	3.34e-12	-0.41	-0.35	Cognitive test performance;	chr21:28866041	chr21:28439346~28674848:-
LGG	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	8.02	8.26e-15	3.34e-12	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
LGG	cis	rs1552244	0.882	rs6443276	ENSG00000180385.7	EMC3-AS1	8.02	8.26e-15	3.34e-12	0.38	0.35	Alzheimer's disease;	chr3:9967221	chr3:9986893~10006990:+
LGG	cis	rs172166	0.637	rs1233708	ENSG00000218016.2	ZNF192P2	-8.02	8.26e-15	3.34e-12	-0.45	-0.35	Cardiac Troponin-T levels;	chr6:28205441	chr6:28188050~28189432:+
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000272787.1	KB-226F1.2	8.02	8.27e-15	3.34e-12	0.37	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23969211~23969873:+
LGG	cis	rs758324	0.687	rs156023	ENSG00000233006.5	AC034220.3	-8.02	8.27e-15	3.34e-12	-0.42	-0.35	Alzheimer's disease in APOE e4- carriers;	chr5:132209475	chr5:132311285~132369916:-
LGG	cis	rs8067545	0.532	rs12943904	ENSG00000230528.6	NOS2P3	-8.02	8.27e-15	3.34e-12	-0.36	-0.35	Schizophrenia;	chr17:20104254	chr17:20436337~20447249:+
LGG	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	8.02	8.28e-15	3.35e-12	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
LGG	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	8.02	8.31e-15	3.35e-12	0.4	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
LGG	cis	rs9300255	0.739	rs1969354	ENSG00000235423.7	RP11-282O18.3	8.02	8.33e-15	3.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123257229	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.739	rs1533703	ENSG00000235423.7	RP11-282O18.3	8.02	8.33e-15	3.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123257546	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.739	rs4759371	ENSG00000235423.7	RP11-282O18.3	8.02	8.33e-15	3.37e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123258016	chr12:123252030~123261483:-
LGG	cis	rs63406760	1	rs63406760	ENSG00000235423.7	RP11-282O18.3	8.02	8.33e-15	3.37e-12	0.39	0.35	Allergic disease (asthma, hay fever or eczema);	chr12:123258146	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.739	rs4759415	ENSG00000235423.7	RP11-282O18.3	-8.02	8.33e-15	3.37e-12	-0.39	-0.35	Neutrophil percentage of white cells;	chr12:123259127	chr12:123252030~123261483:-
LGG	cis	rs8180040	0.966	rs60369822	ENSG00000271161.1	BOLA2P2	-8.02	8.35e-15	3.37e-12	-0.32	-0.35	Colorectal cancer;	chr3:47438245	chr3:47499841~47500407:+
LGG	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	8.02	8.35e-15	3.37e-12	0.43	0.35	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.807	rs519019	ENSG00000253981.4	ALG1L13P	8.02	8.35e-15	3.37e-12	0.36	0.35	Mood instability;	chr8:8737594	chr8:8236003~8244667:-
LGG	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-8.02	8.35e-15	3.37e-12	-0.45	-0.35	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
LGG	cis	rs12893668	0.572	rs11846404	ENSG00000269940.1	RP11-73M18.7	8.02	8.36e-15	3.37e-12	0.39	0.35	Reticulocyte count;	chr14:103689771	chr14:103694560~103695170:+
LGG	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-8.02	8.38e-15	3.38e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
LGG	cis	rs11992162	0.967	rs10108320	ENSG00000255556.2	RP11-351I21.6	-8.02	8.39e-15	3.39e-12	-0.42	-0.35	Monocyte count;	chr8:11974754	chr8:12378679~12380265:-
LGG	cis	rs853679	0.517	rs12332979	ENSG00000182477.5	OR2B8P	8.02	8.39e-15	3.39e-12	0.5	0.35	Depression;	chr6:28173770	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs67878650	ENSG00000182477.5	OR2B8P	8.02	8.39e-15	3.39e-12	0.5	0.35	Depression;	chr6:28174809	chr6:28053228~28054165:-
LGG	cis	rs853679	0.569	rs9348798	ENSG00000182477.5	OR2B8P	8.02	8.39e-15	3.39e-12	0.5	0.35	Depression;	chr6:28175233	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9380065	ENSG00000182477.5	OR2B8P	8.02	8.39e-15	3.39e-12	0.5	0.35	Depression;	chr6:28176973	chr6:28053228~28054165:-
LGG	cis	rs7005380	0.6	rs4871772	ENSG00000245330.4	KB-1471A8.1	8.02	8.46e-15	3.41e-12	0.39	0.35	Interstitial lung disease;	chr8:119895655	chr8:119867419~119874488:-
LGG	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-8.02	8.46e-15	3.42e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
LGG	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-8.02	8.46e-15	3.42e-12	-0.46	-0.35	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
LGG	cis	rs11098499	0.909	rs71614422	ENSG00000250412.1	KLHL2P1	8.02	8.47e-15	3.42e-12	0.4	0.35	Corneal astigmatism;	chr4:119438185	chr4:119334329~119378233:+
LGG	cis	rs6997458	0.785	rs2432083	ENSG00000253549.4	RP11-317J10.2	8.02	8.47e-15	3.42e-12	0.28	0.35	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85428379	chr8:85441851~85464915:-
LGG	cis	rs12935418	0.616	rs11864367	ENSG00000260213.4	RP11-303E16.3	-8.02	8.48e-15	3.42e-12	-0.46	-0.35	Mean corpuscular volume;	chr16:80967882	chr16:81016792~81035759:-
LGG	cis	rs35934224	0.783	rs12159647	ENSG00000232926.1	AC000078.5	8.02	8.49e-15	3.43e-12	0.38	0.35	Glaucoma (primary open-angle);	chr22:19873052	chr22:19887289~19887970:+
LGG	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-8.02	8.51e-15	3.43e-12	-0.44	-0.35	Migraine;	chr4:56851192	chr4:56960927~56961373:-
LGG	cis	rs1930961	1	rs760554	ENSG00000272942.1	CTA-246H3.12	-8.02	8.52e-15	3.44e-12	-0.52	-0.35	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25434324~25435070:-
LGG	cis	rs375066	0.901	rs1978723	ENSG00000267191.1	RP11-15A1.2	8.02	8.52e-15	3.44e-12	0.36	0.35	Breast cancer;	chr19:43879648	chr19:43902001~43926545:+
LGG	cis	rs1056107	0.731	rs10114892	ENSG00000259953.1	RP11-4O1.2	8.02	8.53e-15	3.44e-12	0.37	0.35	Colorectal cancer;	chr9:112173696	chr9:112032555~112037730:-
LGG	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-8.02	8.53e-15	3.44e-12	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
LGG	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-8.02	8.54e-15	3.45e-12	-0.46	-0.35	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
LGG	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-8.02	8.57e-15	3.46e-12	-0.27	-0.35	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
LGG	cis	rs10055631	0.5	rs706702	ENSG00000229666.1	MAST4-AS1	8.02	8.57e-15	3.46e-12	0.4	0.35	Coronary artery disease;	chr5:67009622	chr5:67001383~67003953:-
LGG	cis	rs4295623	0.553	rs34962960	ENSG00000255556.2	RP11-351I21.6	-8.02	8.58e-15	3.46e-12	-0.42	-0.35	Morning vs. evening chronotype;	chr8:11737088	chr8:12378679~12380265:-
LGG	cis	rs853679	0.517	rs868987	ENSG00000182477.5	OR2B8P	-8.02	8.6e-15	3.47e-12	-0.5	-0.35	Depression;	chr6:28142370	chr6:28053228~28054165:-
LGG	cis	rs12935418	0.616	rs8045512	ENSG00000260213.4	RP11-303E16.3	-8.02	8.6e-15	3.47e-12	-0.46	-0.35	Mean corpuscular volume;	chr16:80952410	chr16:81016792~81035759:-
LGG	cis	rs597539	0.727	rs632984	ENSG00000250508.1	RP11-757G1.6	-8.02	8.61e-15	3.47e-12	-0.47	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68852803	chr11:68870664~68874542:+
LGG	cis	rs11603023	0.874	rs613243	ENSG00000255176.1	AP002954.3	-8.02	8.62e-15	3.48e-12	-0.25	-0.35	Cholesterol, total;	chr11:118643304	chr11:118636620~118638097:+
LGG	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	8.02	8.63e-15	3.48e-12	0.35	0.35	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
LGG	cis	rs7005380	0.62	rs7002839	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.48e-12	0.39	0.35	Interstitial lung disease;	chr8:119906508	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs7006905	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.48e-12	0.39	0.35	Interstitial lung disease;	chr8:119906683	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs4871012	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119895734	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs4871013	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119895750	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs13281299	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119897253	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs7832923	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119897540	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6469861	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119897673	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6469863	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119897910	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6469864	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119897985	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6988011	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119898298	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs35272074	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119898543	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs10103660	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119898547	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs6993797	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119899405	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs13257252	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119899993	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10093230	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119900606	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs13279398	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119902030	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs13277947	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119902192	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs13277992	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119902287	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs13253140	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119902668	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs11777705	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119902992	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs12681402	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119903622	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs7461290	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119904154	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.58	rs4073560	ENSG00000245330.4	KB-1471A8.1	8.02	8.64e-15	3.49e-12	0.39	0.35	Interstitial lung disease;	chr8:119905148	chr8:119867419~119874488:-
LGG	cis	rs944990	0.597	rs10821162	ENSG00000227603.1	RP11-165J3.6	8.02	8.65e-15	3.49e-12	0.36	0.35	Body mass index;	chr9:93579042	chr9:93435332~93437121:-
LGG	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-8.02	8.65e-15	3.49e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
LGG	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-8.01	8.65e-15	3.49e-12	-0.42	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
LGG	cis	rs228614	0.51	rs223459	ENSG00000248971.2	KRT8P46	-8.01	8.66e-15	3.49e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102728746~102730171:-
LGG	cis	rs11671005	0.504	rs3794964	ENSG00000269600.1	AC016629.3	-8.01	8.66e-15	3.49e-12	-0.47	-0.35	Mean platelet volume;	chr19:58559549	chr19:58593896~58599355:-
LGG	cis	rs1275468	0.954	rs6582292	ENSG00000257497.2	RP11-585P4.5	8.01	8.67e-15	3.49e-12	0.45	0.35	Polycystic ovary syndrome;	chr12:75539175	chr12:75483454~75489820:-
LGG	cis	rs1150668	0.799	rs7206	ENSG00000270326.1	RP5-874C20.6	-8.01	8.7e-15	3.51e-12	-0.44	-0.35	Pubertal anthropometrics;	chr6:28233360	chr6:28319660~28319852:-
LGG	cis	rs1408799	0.679	rs10491743	ENSG00000235448.1	LURAP1L-AS1	8.01	8.7e-15	3.51e-12	0.36	0.35	Eye color;Blue vs. green eyes;	chr9:12760921	chr9:12700100~12814345:-
LGG	cis	rs227275	0.588	rs223458	ENSG00000248971.2	KRT8P46	-8.01	8.71e-15	3.51e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102728746~102730171:-
LGG	cis	rs4143844	0.655	rs35633657	ENSG00000259251.2	RP11-643M14.1	8.01	8.71e-15	3.51e-12	0.56	0.35	Bipolar disorder and schizophrenia;	chr15:61977739	chr15:62060503~62062434:+
LGG	cis	rs1707322	1	rs6429588	ENSG00000281133.1	AL355480.3	-8.01	8.72e-15	3.52e-12	-0.42	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45580892~45580996:-
LGG	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	8.01	8.72e-15	3.52e-12	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
LGG	cis	rs9300255	0.51	rs1790133	ENSG00000235423.7	RP11-282O18.3	8.01	8.73e-15	3.52e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123213971	chr12:123252030~123261483:-
LGG	cis	rs35934224	0.783	rs13056219	ENSG00000232926.1	AC000078.5	8.01	8.74e-15	3.52e-12	0.41	0.35	Glaucoma (primary open-angle);	chr22:19873323	chr22:19887289~19887970:+
LGG	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-8.01	8.74e-15	3.52e-12	-0.72	-0.35	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
LGG	cis	rs11098499	0.954	rs2389802	ENSG00000250412.1	KLHL2P1	8.01	8.75e-15	3.52e-12	0.4	0.35	Corneal astigmatism;	chr4:119404577	chr4:119334329~119378233:+
LGG	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	8.01	8.75e-15	3.53e-12	0.47	0.35	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
LGG	cis	rs11971779	0.553	rs36002669	ENSG00000273391.1	RP11-634H22.1	8.01	8.76e-15	3.53e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139428415	chr7:139359032~139359566:-
LGG	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-8.01	8.76e-15	3.53e-12	-0.44	-0.35	Migraine;	chr4:56850720	chr4:56960927~56961373:-
LGG	cis	rs7124681	0.528	rs74608150	ENSG00000280615.1	Y_RNA	8.01	8.78e-15	3.54e-12	0.41	0.35	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47674662	chr11:47614898~47614994:-
LGG	cis	rs3764021	0.527	rs10844427	ENSG00000256594.6	RP11-705C15.2	8.01	8.83e-15	3.56e-12	0.35	0.35	Type 1 diabetes;	chr12:9681798	chr12:9633419~9658412:+
LGG	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-8.01	8.84e-15	3.56e-12	-0.45	-0.35	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
LGG	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-8.01	8.84e-15	3.56e-12	-0.45	-0.35	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
LGG	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-8.01	8.84e-15	3.56e-12	-0.45	-0.35	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
LGG	cis	rs7829975	0.66	rs10093926	ENSG00000253981.4	ALG1L13P	8.01	8.84e-15	3.56e-12	0.37	0.35	Mood instability;	chr8:8691510	chr8:8236003~8244667:-
LGG	cis	rs7520050	0.966	rs6675726	ENSG00000280836.1	AL355480.1	8.01	8.85e-15	3.57e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-8.01	8.86e-15	3.57e-12	-0.37	-0.35	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
LGG	cis	rs9300255	0.602	rs1790095	ENSG00000235423.7	RP11-282O18.3	8.01	8.88e-15	3.58e-12	0.39	0.35	Neutrophil percentage of white cells;	chr12:123196675	chr12:123252030~123261483:-
LGG	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-8.01	8.88e-15	3.58e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
LGG	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-8.01	8.88e-15	3.58e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
LGG	cis	rs858239	0.633	rs858300	ENSG00000230042.1	AK3P3	-8.01	8.9e-15	3.59e-12	-0.35	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23129178~23129841:+
LGG	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-8.01	8.91e-15	3.59e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
LGG	cis	rs11971779	0.616	rs10269683	ENSG00000273391.1	RP11-634H22.1	8.01	8.92e-15	3.59e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139416122	chr7:139359032~139359566:-
LGG	cis	rs9532669	0.963	rs1056835	ENSG00000239827.7	SUGT1P3	-8.01	8.94e-15	3.6e-12	-0.37	-0.35	Cervical cancer;	chr13:40932585	chr13:40908159~40921774:-
LGG	cis	rs227275	0.556	rs3886723	ENSG00000248971.2	KRT8P46	-8.01	8.95e-15	3.6e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102728746~102730171:-
LGG	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-8.01	8.95e-15	3.6e-12	-0.45	-0.35	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
LGG	cis	rs2638953	0.815	rs61922546	ENSG00000278733.1	RP11-425D17.1	-8.01	8.95e-15	3.6e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28524632	chr12:28185625~28186190:-
LGG	cis	rs11722779	0.838	rs4533776	ENSG00000248971.2	KRT8P46	-8.01	8.96e-15	3.61e-12	-0.36	-0.35	Schizophrenia;	chr4:102912732	chr4:102728746~102730171:-
LGG	cis	rs228614	0.514	rs59550147	ENSG00000248971.2	KRT8P46	-8.01	8.96e-15	3.61e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs3974608	ENSG00000248971.2	KRT8P46	-8.01	8.96e-15	3.61e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102728746~102730171:-
LGG	cis	rs7520050	0.966	rs785520	ENSG00000280836.1	AL355480.1	8.01	8.96e-15	3.61e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45581219~45581321:-
LGG	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-8.01	8.98e-15	3.61e-12	-0.4	-0.35	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
LGG	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	8.01	9e-15	3.62e-12	0.36	0.35	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
LGG	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-8.01	9e-15	3.62e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
LGG	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	8.01	9.01e-15	3.63e-12	0.43	0.35	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
LGG	cis	rs128738	0.5	rs28667882	ENSG00000233006.5	AC034220.3	-8.01	9.03e-15	3.63e-12	-0.41	-0.35	Giant cell arteritis;	chr5:132232420	chr5:132311285~132369916:-
LGG	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	8.01	9.03e-15	3.63e-12	0.46	0.35	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
LGG	cis	rs10435719	0.867	rs6999030	ENSG00000255556.2	RP11-351I21.6	8.01	9.03e-15	3.63e-12	0.43	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:12378679~12380265:-
LGG	cis	rs9532669	0.889	rs7333447	ENSG00000239827.7	SUGT1P3	-8.01	9.03e-15	3.64e-12	-0.37	-0.35	Cervical cancer;	chr13:40917586	chr13:40908159~40921774:-
LGG	cis	rs8177876	0.686	rs2602402	ENSG00000260213.4	RP11-303E16.3	-8.01	9.08e-15	3.65e-12	-0.58	-0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052725	chr16:81016792~81035759:-
LGG	cis	rs7520050	0.966	rs1768816	ENSG00000280836.1	AL355480.1	8.01	9.08e-15	3.65e-12	0.37	0.35	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45581219~45581321:-
LGG	cis	rs9859260	0.71	rs34906439	ENSG00000242086.7	LINC00969	-8.01	9.08e-15	3.65e-12	-0.3	-0.35	Mean corpuscular volume;	chr3:196052835	chr3:195658062~195739964:+
LGG	cis	rs9532669	0.89	rs9532676	ENSG00000239827.7	SUGT1P3	-8.01	9.08e-15	3.65e-12	-0.36	-0.35	Cervical cancer;	chr13:40935626	chr13:40908159~40921774:-
LGG	cis	rs72615157	0.645	rs76281814	ENSG00000242294.5	STAG3L5P	8.01	9.09e-15	3.66e-12	0.24	0.35	Lung function (FEV1/FVC);	chr7:100248791	chr7:100336079~100351900:+
LGG	cis	rs72615157	0.595	rs112241539	ENSG00000242294.5	STAG3L5P	8.01	9.09e-15	3.66e-12	0.24	0.35	Lung function (FEV1/FVC);	chr7:100249614	chr7:100336079~100351900:+
LGG	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-8.01	9.11e-15	3.66e-12	-0.44	-0.35	Migraine;	chr4:56852087	chr4:56960927~56961373:-
LGG	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	8.01	9.12e-15	3.67e-12	0.34	0.35	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
LGG	cis	rs7829975	0.51	rs2979160	ENSG00000253981.4	ALG1L13P	-8.01	9.15e-15	3.68e-12	-0.36	-0.35	Mood instability;	chr8:8450156	chr8:8236003~8244667:-
LGG	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-8.01	9.15e-15	3.68e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-8.01	9.15e-15	3.68e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-8.01	9.15e-15	3.68e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-8.01	9.15e-15	3.68e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
LGG	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	8.01	9.17e-15	3.69e-12	0.24	0.35	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
LGG	cis	rs7829975	0.51	rs2921073	ENSG00000253981.4	ALG1L13P	-8.01	9.19e-15	3.69e-12	-0.36	-0.35	Mood instability;	chr8:8450133	chr8:8236003~8244667:-
LGG	cis	rs7181230	1	rs28620926	ENSG00000275636.1	RP11-521C20.5	8.01	9.19e-15	3.7e-12	0.37	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:40078892~40079347:+
LGG	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-8.01	9.2e-15	3.7e-12	-0.46	-0.35	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
LGG	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	8.01	9.2e-15	3.7e-12	0.36	0.35	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
LGG	cis	rs2638953	0.925	rs11049598	ENSG00000278733.1	RP11-425D17.1	-8.01	9.21e-15	3.7e-12	-0.43	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28436160	chr12:28185625~28186190:-
LGG	cis	rs1408799	0.772	rs10756406	ENSG00000235448.1	LURAP1L-AS1	-8.01	9.21e-15	3.71e-12	-0.35	-0.35	Eye color;Blue vs. green eyes;	chr9:12748588	chr9:12700100~12814345:-
LGG	cis	rs1949733	0.656	rs2688243	ENSG00000205959.3	RP11-689P11.2	-8.01	9.22e-15	3.71e-12	-0.3	-0.35	Response to antineoplastic agents;	chr4:8434559	chr4:8482270~8512610:+
LGG	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-8.01	9.23e-15	3.71e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-8.01	9.23e-15	3.71e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-8.01	9.23e-15	3.71e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-8.01	9.23e-15	3.71e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-8.01	9.23e-15	3.71e-12	-0.31	-0.35	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
LGG	cis	rs6921919	0.515	rs1339898	ENSG00000226314.6	ZNF192P1	8.01	9.23e-15	3.71e-12	0.34	0.35	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28161781~28169594:+
LGG	cis	rs227275	0.556	rs223449	ENSG00000248971.2	KRT8P46	-8.01	9.24e-15	3.71e-12	-0.36	-0.35	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223447	ENSG00000248971.2	KRT8P46	-8.01	9.24e-15	3.71e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223446	ENSG00000248971.2	KRT8P46	-8.01	9.24e-15	3.71e-12	-0.36	-0.35	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102728746~102730171:-
LGG	cis	rs9300255	0.602	rs1790126	ENSG00000235423.7	RP11-282O18.3	8.01	9.26e-15	3.72e-12	0.38	0.35	Neutrophil percentage of white cells;	chr12:123199016	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.537	rs1716182	ENSG00000235423.7	RP11-282O18.3	8.01	9.26e-15	3.72e-12	0.38	0.35	Neutrophil percentage of white cells;	chr12:123201580	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs1402274	ENSG00000235423.7	RP11-282O18.3	8.01	9.26e-15	3.72e-12	0.38	0.35	Neutrophil percentage of white cells;	chr12:123201677	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs11057192	ENSG00000235423.7	RP11-282O18.3	8.01	9.26e-15	3.72e-12	0.38	0.35	Neutrophil percentage of white cells;	chr12:123208873	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs2682434	ENSG00000235423.7	RP11-282O18.3	8.01	9.26e-15	3.72e-12	0.38	0.35	Neutrophil percentage of white cells;	chr12:123210177	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs4372492	ENSG00000235423.7	RP11-282O18.3	8.01	9.26e-15	3.72e-12	0.38	0.35	Neutrophil percentage of white cells;	chr12:123212810	chr12:123252030~123261483:-
LGG	cis	rs7980687	0.627	rs1727325	ENSG00000235423.7	RP11-282O18.3	8.01	9.26e-15	3.72e-12	0.38	0.35	Head circumference (infant);Educational attainment;Height;	chr12:123213785	chr12:123252030~123261483:-
LGG	cis	rs5760092	0.618	rs4461358	ENSG00000250470.1	AP000351.3	-8.01	9.27e-15	3.72e-12	-0.54	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23976904~23977585:-
LGG	cis	rs7927771	0.524	rs3758655	ENSG00000280615.1	Y_RNA	8.01	9.28e-15	3.73e-12	0.41	0.35	Subjective well-being;	chr11:47682391	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs7936948	ENSG00000280615.1	Y_RNA	8.01	9.28e-15	3.73e-12	0.41	0.35	Subjective well-being;	chr11:47682648	chr11:47614898~47614994:-
LGG	cis	rs7927771	0.524	rs10838746	ENSG00000280615.1	Y_RNA	8.01	9.28e-15	3.73e-12	0.41	0.35	Subjective well-being;	chr11:47684739	chr11:47614898~47614994:-
LGG	cis	rs7124681	0.584	rs10769285	ENSG00000280615.1	Y_RNA	8.01	9.28e-15	3.73e-12	0.41	0.35	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47687660	chr11:47614898~47614994:-
LGG	cis	rs11018904	0.906	rs36177012	ENSG00000280385.1	AP000648.5	-8	9.31e-15	3.74e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90193614~90198120:+
LGG	cis	rs11018904	0.906	rs7925507	ENSG00000280385.1	AP000648.5	-8	9.31e-15	3.74e-12	-0.43	-0.35	Intelligence (multi-trait analysis);	chr11:90206978	chr11:90193614~90198120:+
LGG	cis	rs763567	0.605	rs647438	ENSG00000271811.1	RP1-79C4.4	-8	9.31e-15	3.74e-12	-0.32	-0.35	Tonsillectomy;	chr1:170608094	chr1:170667381~170669425:+
LGG	cis	rs7824557	0.614	rs7816606	ENSG00000184608.7	FAM167A-AS1	-8	9.33e-15	3.75e-12	-0.29	-0.35	Retinal vascular caliber;	chr8:11348093	chr8:11368402~11438658:+
LGG	cis	rs10435719	0.902	rs12681142	ENSG00000255556.2	RP11-351I21.6	8	9.33e-15	3.75e-12	0.43	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:12378679~12380265:-
LGG	cis	rs9532669	0.963	rs1571116	ENSG00000239827.7	SUGT1P3	-8	9.34e-15	3.75e-12	-0.36	-0.35	Cervical cancer;	chr13:40929765	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.963	rs9532673	ENSG00000239827.7	SUGT1P3	-8	9.34e-15	3.75e-12	-0.36	-0.35	Cervical cancer;	chr13:40930412	chr13:40908159~40921774:-
LGG	cis	rs6964833	1	rs35203738	ENSG00000277053.3	GTF2IP1	-8	9.34e-15	3.75e-12	-0.4	-0.35	Menarche (age at onset);	chr7:74690864	chr7:75185385~75237696:-
LGG	cis	rs2638953	0.924	rs12368652	ENSG00000278733.1	RP11-425D17.1	-8	9.35e-15	3.75e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049392	ENSG00000278733.1	RP11-425D17.1	-8	9.35e-15	3.75e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049394	ENSG00000278733.1	RP11-425D17.1	-8	9.35e-15	3.75e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.886	rs11049395	ENSG00000278733.1	RP11-425D17.1	-8	9.35e-15	3.75e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.886	rs11049397	ENSG00000278733.1	RP11-425D17.1	-8	9.35e-15	3.75e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049398	ENSG00000278733.1	RP11-425D17.1	-8	9.35e-15	3.75e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.924	rs11049399	ENSG00000278733.1	RP11-425D17.1	-8	9.35e-15	3.75e-12	-0.42	-0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28185625~28186190:-
LGG	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-8	9.35e-15	3.75e-12	-0.38	-0.35	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
LGG	cis	rs7709377	0.628	rs6883424	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116165182	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.672	rs7727695	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116165779	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7727528	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116165802	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7709844	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116165851	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7727974	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116165887	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs3902887	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116166255	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10077113	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116166475	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10069865	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116167021	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs28812579	ENSG00000212457.1	RNU6-644P	-8	9.36e-15	3.76e-12	-0.5	-0.35	Metabolite levels  (X-11787);	chr5:116167282	chr5:116188455~116188552:-
LGG	cis	rs45509595	0.841	rs200485	ENSG00000199851.2	U3	8	9.38e-15	3.77e-12	0.72	0.35	Breast cancer;	chr6:27807919	chr6:28015568~28015777:+
LGG	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	8	9.38e-15	3.77e-12	0.39	0.35	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
LGG	cis	rs2638953	0.888	rs1871152	ENSG00000278733.1	RP11-425D17.1	8	9.39e-15	3.77e-12	0.41	0.35	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28226893	chr12:28185625~28186190:-
LGG	cis	rs7302981	0.746	rs646782	ENSG00000272368.2	RP4-605O3.4	8	9.4e-15	3.77e-12	0.33	0.35	Systolic blood pressure;	chr12:50088428	chr12:50112197~50165618:+
LGG	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-8	9.41e-15	3.78e-12	-0.53	-0.35	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
LGG	cis	rs1023500	0.573	rs133377	ENSG00000227370.1	RP4-669P10.19	8	9.42e-15	3.78e-12	0.3	0.35	Schizophrenia;	chr22:42070946	chr22:42132543~42132998:+
LGG	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	8	9.43e-15	3.79e-12	0.4	0.35	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
LGG	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-8	9.44e-15	3.79e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
LGG	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-8	9.44e-15	3.79e-12	-0.4	-0.35	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
LGG	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	8	9.46e-15	3.8e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-8	9.49e-15	3.81e-12	-0.36	-0.34	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
LGG	cis	rs7005380	0.6	rs13267652	ENSG00000245330.4	KB-1471A8.1	8	9.49e-15	3.81e-12	0.39	0.34	Interstitial lung disease;	chr8:119878346	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs13275528	ENSG00000245330.4	KB-1471A8.1	8	9.49e-15	3.81e-12	0.39	0.34	Interstitial lung disease;	chr8:119878617	chr8:119867419~119874488:-
LGG	cis	rs11603023	0.874	rs483598	ENSG00000255176.1	AP002954.3	-8	9.51e-15	3.82e-12	-0.25	-0.34	Cholesterol, total;	chr11:118638950	chr11:118636620~118638097:+
LGG	cis	rs11148252	0.532	rs9526975	ENSG00000278238.1	RP11-245D16.4	-8	9.52e-15	3.82e-12	-0.34	-0.34	Lewy body disease;	chr13:52681669	chr13:52454775~52455331:-
LGG	cis	rs934734	0.509	rs12185577	ENSG00000204929.10	AC074391.1	-8	9.52e-15	3.82e-12	-0.34	-0.34	Rheumatoid arthritis;	chr2:65432354	chr2:65436711~66084639:+
LGG	cis	rs11671005	0.504	rs7257669	ENSG00000269600.1	AC016629.3	-8	9.54e-15	3.83e-12	-0.48	-0.34	Mean platelet volume;	chr19:58553572	chr19:58593896~58599355:-
LGG	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-8	9.55e-15	3.83e-12	-0.47	-0.34	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
LGG	cis	rs9719620	0.967	rs17815356	ENSG00000236753.4	MKLN1-AS	-8	9.55e-15	3.83e-12	-0.36	-0.34	Male-pattern baldness;	chr7:131324425	chr7:131309744~131328222:-
LGG	cis	rs11992162	0.636	rs11250182	ENSG00000227888.4	FAM66A	-8	9.56e-15	3.84e-12	-0.42	-0.34	Monocyte count;	chr8:11950067	chr8:12362019~12388296:+
LGG	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-8	9.57e-15	3.84e-12	-0.4	-0.34	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
LGG	cis	rs7189233	1	rs62048544	ENSG00000279344.1	RP11-44F14.7	8	9.58e-15	3.84e-12	0.33	0.34	Intelligence (multi-trait analysis);	chr16:53503829	chr16:53478957~53481550:-
LGG	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	8	9.59e-15	3.85e-12	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
LGG	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	8	9.6e-15	3.85e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
LGG	cis	rs9719620	0.9	rs11978923	ENSG00000236753.4	MKLN1-AS	-8	9.6e-15	3.85e-12	-0.36	-0.34	Male-pattern baldness;	chr7:131323684	chr7:131309744~131328222:-
LGG	cis	rs227275	0.554	rs223466	ENSG00000248971.2	KRT8P46	-8	9.6e-15	3.85e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102728746~102730171:-
LGG	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-8	9.63e-15	3.86e-12	-0.38	-0.34	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
LGG	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	8	9.64e-15	3.87e-12	0.44	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
LGG	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	8	9.64e-15	3.87e-12	0.43	0.34	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
LGG	cis	rs812925	0.893	rs778160	ENSG00000273302.1	RP11-493E12.2	8	9.66e-15	3.88e-12	0.34	0.34	Immature fraction of reticulocytes;	chr2:61330029	chr2:61199979~61200769:+
LGG	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	8	9.67e-15	3.88e-12	0.35	0.34	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
LGG	cis	rs853679	0.517	rs9393896	ENSG00000182477.5	OR2B8P	8	9.69e-15	3.89e-12	0.5	0.34	Depression;	chr6:28159925	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9393897	ENSG00000182477.5	OR2B8P	8	9.69e-15	3.89e-12	0.5	0.34	Depression;	chr6:28159932	chr6:28053228~28054165:-
LGG	cis	rs7267979	0.816	rs8115257	ENSG00000276952.1	RP5-965G21.6	8	9.69e-15	3.89e-12	0.35	0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25284915~25285588:-
LGG	cis	rs7927771	0.524	rs7943213	ENSG00000280615.1	Y_RNA	8	9.71e-15	3.9e-12	0.41	0.34	Subjective well-being;	chr11:47693972	chr11:47614898~47614994:-
LGG	cis	rs7709377	0.638	rs9326995	ENSG00000212457.1	RNU6-644P	-8	9.72e-15	3.9e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116171971	chr5:116188455~116188552:-
LGG	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	8	9.73e-15	3.9e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	8	9.73e-15	3.9e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
LGG	cis	rs2287838	0.668	rs12979274	ENSG00000267289.1	CTD-2623N2.11	8	9.74e-15	3.91e-12	0.37	0.34	Sleep duration;	chr19:9890249	chr19:9834079~9835013:-
LGG	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-8	9.74e-15	3.91e-12	-0.42	-0.34	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
LGG	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-8	9.75e-15	3.91e-12	-0.38	-0.34	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-8	9.75e-15	3.91e-12	-0.38	-0.34	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-8	9.75e-15	3.91e-12	-0.38	-0.34	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-8	9.75e-15	3.91e-12	-0.38	-0.34	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-8	9.75e-15	3.91e-12	-0.38	-0.34	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
LGG	cis	rs12935418	0.83	rs7188549	ENSG00000260213.4	RP11-303E16.3	-8	9.75e-15	3.91e-12	-0.53	-0.34	Mean corpuscular volume;	chr16:81016371	chr16:81016792~81035759:-
LGG	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-8	9.77e-15	3.92e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-8	9.77e-15	3.92e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-8	9.77e-15	3.92e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-8	9.77e-15	3.92e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000235689.1	AP000351.13	8	9.77e-15	3.92e-12	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:24006305~24008258:-
LGG	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	8	9.77e-15	3.92e-12	0.33	0.34	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
LGG	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	8	9.77e-15	3.92e-12	0.33	0.34	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
LGG	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-8	9.78e-15	3.92e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
LGG	cis	rs997295	0.513	rs11635495	ENSG00000270964.1	RP11-502I4.3	-8	9.79e-15	3.93e-12	-0.36	-0.34	Motion sickness;	chr15:67512344	chr15:67541072~67542604:-
LGG	cis	rs2638953	0.962	rs3825246	ENSG00000278733.1	RP11-425D17.1	-8	9.8e-15	3.93e-12	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310186	chr12:28185625~28186190:-
LGG	cis	rs7005380	0.62	rs13275524	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119908701	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs6469867	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119909172	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.58	rs6469868	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119909601	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.606	rs6469869	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119909696	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6469870	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119909773	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6469871	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119909839	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs6469872	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119910007	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs7015470	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119910101	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6995139	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119910157	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10217077	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119910943	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs939242	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119912030	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.6	rs939241	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119912297	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs10216503	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119912843	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs7824545	ENSG00000245330.4	KB-1471A8.1	8	9.8e-15	3.93e-12	0.39	0.34	Interstitial lung disease;	chr8:119913381	chr8:119867419~119874488:-
LGG	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	8	9.81e-15	3.93e-12	0.4	0.34	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	8	9.81e-15	3.93e-12	0.4	0.34	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	8	9.81e-15	3.93e-12	0.4	0.34	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
LGG	cis	rs494526	0.874	rs11198760	ENSG00000229272.1	RP11-498J9.2	-8	9.84e-15	3.94e-12	-0.41	-0.34	Alcoholic chronic pancreatitis;	chr10:119081666	chr10:119003536~119003884:-
LGG	cis	rs4714902	0.655	rs9367235	ENSG00000231769.2	RP1-8B1.4	-8	9.85e-15	3.95e-12	-0.37	-0.34	Colonoscopy-negative controls vs population controls;	chr6:46142260	chr6:46097093~46129706:-
LGG	cis	rs375066	0.935	rs388685	ENSG00000267191.1	RP11-15A1.2	-8	9.85e-15	3.95e-12	-0.37	-0.34	Breast cancer;	chr19:43914528	chr19:43902001~43926545:+
LGG	cis	rs17772222	0.675	rs845758	ENSG00000258983.2	RP11-507K2.2	-8	9.85e-15	3.95e-12	-0.38	-0.34	Coronary artery calcification;	chr14:88433746	chr14:88499334~88515502:+
LGG	cis	rs1560104	0.549	rs7201160	ENSG00000274834.1	CTD-3037G24.5	8	9.87e-15	3.95e-12	0.43	0.34	Obesity-related traits;	chr16:12614022	chr16:12614451~12614852:+
LGG	cis	rs1560104	0.597	rs4781299	ENSG00000274834.1	CTD-3037G24.5	8	9.91e-15	3.97e-12	0.42	0.34	Obesity-related traits;	chr16:12613756	chr16:12614451~12614852:+
LGG	cis	rs9300255	0.602	rs1716172	ENSG00000235423.7	RP11-282O18.3	8	9.96e-15	3.99e-12	0.39	0.34	Neutrophil percentage of white cells;	chr12:123228165	chr12:123252030~123261483:-
LGG	cis	rs9300255	0.602	rs2510885	ENSG00000235423.7	RP11-282O18.3	8	9.96e-15	3.99e-12	0.38	0.34	Neutrophil percentage of white cells;	chr12:123130266	chr12:123252030~123261483:-
LGG	cis	rs7005380	0.62	rs7459671	ENSG00000245330.4	KB-1471A8.1	7.99	9.98e-15	4e-12	0.39	0.34	Interstitial lung disease;	chr8:119896646	chr8:119867419~119874488:-
LGG	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-7.99	9.98e-15	4e-12	-0.43	-0.34	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
LGG	cis	rs1560104	0.597	rs12162027	ENSG00000274834.1	CTD-3037G24.5	7.99	9.99e-15	4e-12	0.42	0.34	Obesity-related traits;	chr16:12616235	chr16:12614451~12614852:+
LGG	cis	rs35857674	0.5	rs203623	ENSG00000253484.1	RP11-109P6.2	-7.99	1e-14	4.01e-12	-0.34	-0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50110941	chr8:49817586~49820944:-
LGG	cis	rs1185460	0.967	rs1177562	ENSG00000272186.1	RP11-110I1.13	-7.99	1e-14	4.01e-12	-0.34	-0.34	Coronary artery disease;	chr11:119078621	chr11:119067374~119067698:-
LGG	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-7.99	1.01e-14	4.03e-12	-0.46	-0.34	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
LGG	cis	rs2638953	0.853	rs10843185	ENSG00000278733.1	RP11-425D17.1	-7.99	1.01e-14	4.03e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473778	chr12:28185625~28186190:-
LGG	cis	rs6921919	0.789	rs13210258	ENSG00000280107.1	AL022393.9	-7.99	1.01e-14	4.04e-12	-0.38	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28170845~28172521:+
LGG	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	7.99	1.01e-14	4.04e-12	0.71	0.34	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
LGG	cis	rs35934224	0.783	rs9754418	ENSG00000232926.1	AC000078.5	7.99	1.01e-14	4.04e-12	0.38	0.34	Glaucoma (primary open-angle);	chr22:19867210	chr22:19887289~19887970:+
LGG	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.04e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
LGG	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-7.99	1.01e-14	4.06e-12	-0.55	-0.34	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
LGG	cis	rs997295	0.592	rs7162320	ENSG00000270964.1	RP11-502I4.3	-7.99	1.01e-14	4.06e-12	-0.35	-0.34	Motion sickness;	chr15:67473700	chr15:67541072~67542604:-
LGG	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	7.99	1.01e-14	4.06e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
LGG	cis	rs7709377	0.723	rs7703124	ENSG00000212457.1	RNU6-644P	-7.99	1.01e-14	4.06e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116177187	chr5:116188455~116188552:-
LGG	cis	rs11098499	0.863	rs6858592	ENSG00000250412.1	KLHL2P1	7.99	1.01e-14	4.06e-12	0.39	0.34	Corneal astigmatism;	chr4:119537537	chr4:119334329~119378233:+
LGG	cis	rs9859260	0.744	rs557527	ENSG00000242086.7	LINC00969	-7.99	1.01e-14	4.06e-12	-0.3	-0.34	Mean corpuscular volume;	chr3:196053838	chr3:195658062~195739964:+
LGG	cis	rs9532669	0.926	rs7322399	ENSG00000239827.7	SUGT1P3	-7.99	1.02e-14	4.06e-12	-0.37	-0.34	Cervical cancer;	chr13:40952511	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs7322097	ENSG00000239827.7	SUGT1P3	-7.99	1.02e-14	4.06e-12	-0.37	-0.34	Cervical cancer;	chr13:40952513	chr13:40908159~40921774:-
LGG	cis	rs2797160	0.967	rs2747718	ENSG00000237742.5	RP11-624M8.1	7.99	1.02e-14	4.06e-12	0.31	0.34	Endometrial cancer;	chr6:125687963	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2747719	ENSG00000237742.5	RP11-624M8.1	7.99	1.02e-14	4.06e-12	0.31	0.34	Endometrial cancer;	chr6:125688068	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2797158	ENSG00000237742.5	RP11-624M8.1	7.99	1.02e-14	4.06e-12	0.31	0.34	Endometrial cancer;	chr6:125688252	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2747720	ENSG00000237742.5	RP11-624M8.1	7.99	1.02e-14	4.06e-12	0.31	0.34	Endometrial cancer;	chr6:125688312	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.967	rs2797159	ENSG00000237742.5	RP11-624M8.1	7.99	1.02e-14	4.06e-12	0.31	0.34	Endometrial cancer;	chr6:125688411	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2747722	ENSG00000237742.5	RP11-624M8.1	7.99	1.02e-14	4.06e-12	0.31	0.34	Endometrial cancer;	chr6:125688483	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs2797160	ENSG00000237742.5	RP11-624M8.1	7.99	1.02e-14	4.06e-12	0.31	0.34	Endometrial cancer;	chr6:125688970	chr6:125578558~125749190:-
LGG	cis	rs7241530	0.61	rs980492	ENSG00000266213.1	RP11-100K18.1	-7.99	1.02e-14	4.07e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78135710	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.569	rs12965699	ENSG00000266213.1	RP11-100K18.1	-7.99	1.02e-14	4.07e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78135741	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs4799266	ENSG00000266213.1	RP11-100K18.1	-7.99	1.02e-14	4.07e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78135923	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs4799267	ENSG00000266213.1	RP11-100K18.1	-7.99	1.02e-14	4.07e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78136178	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs4799268	ENSG00000266213.1	RP11-100K18.1	-7.99	1.02e-14	4.07e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78136184	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs34622862	ENSG00000266213.1	RP11-100K18.1	-7.99	1.02e-14	4.07e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78136444	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.61	rs8098981	ENSG00000266213.1	RP11-100K18.1	-7.99	1.02e-14	4.07e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78136607	chr18:78137223~78140887:+
LGG	cis	rs7005380	0.579	rs7465181	ENSG00000245330.4	KB-1471A8.1	7.99	1.02e-14	4.07e-12	0.39	0.34	Interstitial lung disease;	chr8:119896349	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs7462250	ENSG00000245330.4	KB-1471A8.1	7.99	1.02e-14	4.07e-12	0.39	0.34	Interstitial lung disease;	chr8:119896367	chr8:119867419~119874488:-
LGG	cis	rs7849270	0.76	rs882616	ENSG00000268707.1	RP11-247A12.7	7.99	1.02e-14	4.07e-12	0.41	0.34	Blood metabolite ratios;	chr9:129178586	chr9:129170434~129170940:+
LGG	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-7.99	1.02e-14	4.07e-12	-0.58	-0.34	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
LGG	cis	rs7772486	0.754	rs2328709	ENSG00000270638.1	RP3-466P17.1	-7.99	1.02e-14	4.08e-12	-0.22	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145735570~145737218:+
LGG	cis	rs853679	0.517	rs9468297	ENSG00000182477.5	OR2B8P	7.99	1.02e-14	4.08e-12	0.5	0.34	Depression;	chr6:28151096	chr6:28053228~28054165:-
LGG	cis	rs853679	0.505	rs200992	ENSG00000199851.2	U3	7.99	1.02e-14	4.08e-12	0.75	0.34	Depression;	chr6:27846899	chr6:28015568~28015777:+
LGG	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-7.99	1.02e-14	4.09e-12	-0.4	-0.34	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
LGG	cis	rs6003958	1	rs6003958	ENSG00000250470.1	AP000351.3	-7.99	1.02e-14	4.09e-12	-0.57	-0.34	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23976904~23977585:-
LGG	cis	rs5760092	0.755	rs6003959	ENSG00000250470.1	AP000351.3	-7.99	1.02e-14	4.09e-12	-0.57	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23976904~23977585:-
LGG	cis	rs1329650	1	rs4933206	ENSG00000228701.1	TNKS2-AS1	-7.99	1.02e-14	4.09e-12	-0.45	-0.34	Smoking behavior;	chr10:91578843	chr10:91782839~91798291:-
LGG	cis	rs7520050	0.966	rs9429183	ENSG00000280836.1	AL355480.1	7.99	1.02e-14	4.1e-12	0.37	0.34	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.966	rs785481	ENSG00000280836.1	AL355480.1	7.99	1.03e-14	4.11e-12	0.37	0.34	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45581219~45581321:-
LGG	cis	rs6964833	1	rs2301907	ENSG00000277053.3	GTF2IP1	-7.99	1.03e-14	4.11e-12	-0.4	-0.34	Menarche (age at onset);	chr7:74700517	chr7:75185385~75237696:-
LGG	cis	rs6997458	0.785	rs10907474	ENSG00000253549.4	RP11-317J10.2	7.99	1.03e-14	4.12e-12	0.28	0.34	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85450152	chr8:85441851~85464915:-
LGG	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-7.99	1.03e-14	4.12e-12	-0.28	-0.34	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
LGG	cis	rs10435719	0.718	rs7813935	ENSG00000255556.2	RP11-351I21.6	7.99	1.03e-14	4.12e-12	0.43	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:12378679~12380265:-
LGG	cis	rs853679	0.599	rs149949	ENSG00000226314.6	ZNF192P1	7.99	1.03e-14	4.13e-12	0.53	0.34	Depression;	chr6:28043738	chr6:28161781~28169594:+
LGG	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-7.99	1.03e-14	4.13e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-7.99	1.03e-14	4.13e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
LGG	cis	rs7119038	0.865	rs7117261	ENSG00000255239.1	AP002954.6	7.99	1.04e-14	4.15e-12	0.51	0.34	Sjögren's syndrome;	chr11:118870448	chr11:118688039~118690600:-
LGG	cis	rs56114371	0.777	rs200481	ENSG00000216901.1	AL022393.7	7.99	1.04e-14	4.16e-12	0.64	0.34	Breast cancer;	chr6:27806054	chr6:28176188~28176674:+
LGG	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-7.99	1.04e-14	4.16e-12	-0.32	-0.34	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
LGG	cis	rs9346353	0.966	rs7755173	ENSG00000219881.1	GAPDHP42	7.99	1.04e-14	4.16e-12	0.33	0.34	Sleep duration;	chr6:69804574	chr6:69745871~69746851:+
LGG	cis	rs9346353	0.966	rs7755189	ENSG00000219881.1	GAPDHP42	7.99	1.04e-14	4.16e-12	0.33	0.34	Sleep duration;	chr6:69804604	chr6:69745871~69746851:+
LGG	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-7.99	1.04e-14	4.17e-12	-0.45	-0.34	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
LGG	cis	rs17772222	0.582	rs12050316	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.17e-12	0.38	0.34	Coronary artery calcification;	chr14:88522097	chr14:88499334~88515502:+
LGG	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-7.99	1.04e-14	4.17e-12	-0.32	-0.34	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
LGG	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-7.99	1.04e-14	4.17e-12	-0.37	-0.34	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
LGG	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	7.99	1.04e-14	4.17e-12	0.38	0.34	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
LGG	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	7.99	1.04e-14	4.17e-12	0.43	0.34	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
LGG	cis	rs35934224	0.783	rs7289343	ENSG00000232926.1	AC000078.5	7.99	1.05e-14	4.18e-12	0.38	0.34	Glaucoma (primary open-angle);	chr22:19873467	chr22:19887289~19887970:+
LGG	cis	rs1707322	1	rs1612419	ENSG00000281133.1	AL355480.3	7.99	1.05e-14	4.18e-12	0.42	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45580892~45580996:-
LGG	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	7.99	1.05e-14	4.19e-12	0.47	0.34	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
LGG	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	7.99	1.05e-14	4.19e-12	0.47	0.34	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
LGG	cis	rs6964833	1	rs6967152	ENSG00000277053.3	GTF2IP1	-7.99	1.05e-14	4.19e-12	-0.4	-0.34	Menarche (age at onset);	chr7:74684983	chr7:75185385~75237696:-
LGG	cis	rs1707322	0.929	rs785513	ENSG00000281133.1	AL355480.3	7.99	1.05e-14	4.19e-12	0.43	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45580892~45580996:-
LGG	cis	rs9300255	0.602	rs1727294	ENSG00000235423.7	RP11-282O18.3	7.99	1.05e-14	4.19e-12	0.38	0.34	Neutrophil percentage of white cells;	chr12:123131967	chr12:123252030~123261483:-
LGG	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	7.99	1.05e-14	4.2e-12	0.46	0.34	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
LGG	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-7.99	1.05e-14	4.2e-12	-0.41	-0.34	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
LGG	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	7.99	1.05e-14	4.21e-12	0.44	0.34	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
LGG	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-7.99	1.05e-14	4.21e-12	-0.36	-0.34	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
LGG	cis	rs11098499	0.954	rs6848389	ENSG00000250412.1	KLHL2P1	7.99	1.06e-14	4.22e-12	0.4	0.34	Corneal astigmatism;	chr4:119481467	chr4:119334329~119378233:+
LGG	cis	rs11992162	0.967	rs10112888	ENSG00000255556.2	RP11-351I21.6	7.99	1.06e-14	4.22e-12	0.41	0.34	Monocyte count;	chr8:11972699	chr8:12378679~12380265:-
LGG	cis	rs7189233	0.956	rs62048490	ENSG00000279344.1	RP11-44F14.7	7.99	1.06e-14	4.23e-12	0.33	0.34	Intelligence (multi-trait analysis);	chr16:53422364	chr16:53478957~53481550:-
LGG	cis	rs7189233	1	rs62048491	ENSG00000279344.1	RP11-44F14.7	7.99	1.06e-14	4.23e-12	0.33	0.34	Intelligence (multi-trait analysis);	chr16:53422479	chr16:53478957~53481550:-
LGG	cis	rs2638953	0.924	rs79712894	ENSG00000278733.1	RP11-425D17.1	-7.99	1.06e-14	4.24e-12	-0.44	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239400	chr12:28185625~28186190:-
LGG	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-7.99	1.06e-14	4.24e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
LGG	cis	rs651907	0.64	rs771575	ENSG00000256628.3	ZBTB11-AS1	7.99	1.06e-14	4.24e-12	0.4	0.34	Colorectal cancer;	chr3:101900515	chr3:101676475~101679217:+
LGG	cis	rs2797160	0.904	rs2326292	ENSG00000237742.5	RP11-624M8.1	-7.99	1.06e-14	4.24e-12	-0.32	-0.34	Endometrial cancer;	chr6:125678528	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.935	rs1739372	ENSG00000237742.5	RP11-624M8.1	7.99	1.06e-14	4.24e-12	0.31	0.34	Endometrial cancer;	chr6:125690179	chr6:125578558~125749190:-
LGG	cis	rs2797160	0.967	rs2797162	ENSG00000237742.5	RP11-624M8.1	7.99	1.06e-14	4.24e-12	0.31	0.34	Endometrial cancer;	chr6:125690235	chr6:125578558~125749190:-
LGG	cis	rs1048886	0.938	rs6900840	ENSG00000271967.1	RP11-134K13.4	-7.99	1.06e-14	4.24e-12	-0.38	-0.34	Type 2 diabetes;	chr6:70472101	chr6:70596438~70596980:+
LGG	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-7.99	1.07e-14	4.26e-12	-0.36	-0.34	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
LGG	cis	rs3020736	0.5	rs6002616	ENSG00000227370.1	RP4-669P10.19	-7.99	1.07e-14	4.26e-12	-0.3	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42132543~42132998:+
LGG	cis	rs3020736	0.5	rs7364293	ENSG00000227370.1	RP4-669P10.19	-7.99	1.07e-14	4.26e-12	-0.3	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42132543~42132998:+
LGG	cis	rs7709377	0.68	rs57096658	ENSG00000212457.1	RNU6-644P	-7.99	1.07e-14	4.26e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116178523	chr5:116188455~116188552:-
LGG	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-7.99	1.07e-14	4.26e-12	-0.37	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
LGG	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	7.99	1.07e-14	4.27e-12	0.39	0.34	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
LGG	cis	rs4950322	0.542	rs12046706	ENSG00000278811.3	LINC00624	7.99	1.07e-14	4.27e-12	0.33	0.34	Protein quantitative trait loci;	chr1:147189758	chr1:147258885~147517875:-
LGG	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	7.99	1.07e-14	4.28e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
LGG	cis	rs11098499	0.738	rs34566984	ENSG00000250412.1	KLHL2P1	7.98	1.07e-14	4.28e-12	0.4	0.34	Corneal astigmatism;	chr4:119440115	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs17009122	ENSG00000250412.1	KLHL2P1	7.98	1.07e-14	4.28e-12	0.4	0.34	Corneal astigmatism;	chr4:119441248	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs9685777	ENSG00000250412.1	KLHL2P1	7.98	1.07e-14	4.28e-12	0.4	0.34	Corneal astigmatism;	chr4:119444810	chr4:119334329~119378233:+
LGG	cis	rs4295623	0.816	rs35558975	ENSG00000227888.4	FAM66A	-7.98	1.07e-14	4.29e-12	-0.43	-0.34	Morning vs. evening chronotype;	chr8:11726967	chr8:12362019~12388296:+
LGG	cis	rs1930961	1	rs6004667	ENSG00000272942.1	CTA-246H3.12	7.98	1.07e-14	4.29e-12	0.51	0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25434324~25435070:-
LGG	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	7.98	1.07e-14	4.29e-12	0.43	0.34	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
LGG	cis	rs8180040	0.966	rs922957	ENSG00000271161.1	BOLA2P2	-7.98	1.08e-14	4.3e-12	-0.32	-0.34	Colorectal cancer;	chr3:47380662	chr3:47499841~47500407:+
LGG	cis	rs453301	0.624	rs2979265	ENSG00000173295.6	FAM86B3P	-7.98	1.08e-14	4.3e-12	-0.37	-0.34	Joint mobility (Beighton score);	chr8:9001207	chr8:8228595~8244865:+
LGG	cis	rs2638953	0.821	rs7964793	ENSG00000278733.1	RP11-425D17.1	7.98	1.08e-14	4.3e-12	0.41	0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28298776	chr12:28185625~28186190:-
LGG	cis	rs1048886	0.938	rs6906592	ENSG00000271967.1	RP11-134K13.4	-7.98	1.08e-14	4.3e-12	-0.37	-0.34	Type 2 diabetes;	chr6:70472221	chr6:70596438~70596980:+
LGG	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-7.98	1.08e-14	4.31e-12	-0.27	-0.34	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
LGG	cis	rs17345786	0.906	rs12638137	ENSG00000256628.3	ZBTB11-AS1	7.98	1.08e-14	4.31e-12	0.44	0.34	Colonoscopy-negative controls vs population controls;	chr3:101432120	chr3:101676475~101679217:+
LGG	cis	rs17345786	0.861	rs79181492	ENSG00000256628.3	ZBTB11-AS1	7.98	1.08e-14	4.31e-12	0.44	0.34	Colonoscopy-negative controls vs population controls;	chr3:101497177	chr3:101676475~101679217:+
LGG	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-7.98	1.08e-14	4.31e-12	-0.45	-0.34	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
LGG	cis	rs7709377	0.638	rs7448122	ENSG00000212457.1	RNU6-644P	-7.98	1.08e-14	4.32e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116171470	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.68	rs1876676	ENSG00000212457.1	RNU6-644P	-7.98	1.08e-14	4.32e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116172472	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10478291	ENSG00000212457.1	RNU6-644P	-7.98	1.08e-14	4.32e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116172544	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.68	rs10478292	ENSG00000212457.1	RNU6-644P	-7.98	1.08e-14	4.32e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116172609	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.586	rs7719318	ENSG00000212457.1	RNU6-644P	-7.98	1.08e-14	4.32e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116173122	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7703661	ENSG00000212457.1	RNU6-644P	-7.98	1.08e-14	4.32e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116173292	chr5:116188455~116188552:-
LGG	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	7.98	1.08e-14	4.32e-12	0.33	0.34	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
LGG	cis	rs11098499	0.863	rs7678400	ENSG00000250412.1	KLHL2P1	7.98	1.08e-14	4.32e-12	0.39	0.34	Corneal astigmatism;	chr4:119540802	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs1480936	ENSG00000250412.1	KLHL2P1	7.98	1.08e-14	4.32e-12	0.39	0.34	Corneal astigmatism;	chr4:119541706	chr4:119334329~119378233:+
LGG	cis	rs62184315	0.536	rs2289405	ENSG00000253559.1	OSGEPL1-AS1	-7.98	1.08e-14	4.32e-12	-0.52	-0.34	Alcohol dependence (age at onset);	chr2:189771313	chr2:189762704~189765556:+
LGG	cis	rs11148252	0.967	rs11618716	ENSG00000278238.1	RP11-245D16.4	7.98	1.08e-14	4.33e-12	0.32	0.34	Lewy body disease;	chr13:52472701	chr13:52454775~52455331:-
LGG	cis	rs227275	0.554	rs223314	ENSG00000248971.2	KRT8P46	-7.98	1.09e-14	4.33e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs7254	ENSG00000248971.2	KRT8P46	-7.98	1.09e-14	4.33e-12	-0.36	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102728746~102730171:-
LGG	cis	rs11722779	0.566	rs6822658	ENSG00000248971.2	KRT8P46	-7.98	1.09e-14	4.33e-12	-0.36	-0.34	Schizophrenia;	chr4:102891964	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs6823625	ENSG00000248971.2	KRT8P46	-7.98	1.09e-14	4.33e-12	-0.36	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs6846762	ENSG00000248971.2	KRT8P46	-7.98	1.09e-14	4.33e-12	-0.36	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs4699032	ENSG00000248971.2	KRT8P46	-7.98	1.09e-14	4.33e-12	-0.36	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102728746~102730171:-
LGG	cis	rs7520050	1	rs785511	ENSG00000280836.1	AL355480.1	7.98	1.09e-14	4.34e-12	0.37	0.34	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.966	rs809775	ENSG00000280836.1	AL355480.1	7.98	1.09e-14	4.34e-12	0.37	0.34	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45581219~45581321:-
LGG	cis	rs4714902	0.624	rs9472703	ENSG00000231769.2	RP1-8B1.4	-7.98	1.09e-14	4.34e-12	-0.37	-0.34	Colonoscopy-negative controls vs population controls;	chr6:46150227	chr6:46097093~46129706:-
LGG	cis	rs1707322	1	rs10890380	ENSG00000281133.1	AL355480.3	-7.98	1.09e-14	4.35e-12	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45580892~45580996:-
LGG	cis	rs62184315	0.536	rs5743047	ENSG00000253559.1	OSGEPL1-AS1	7.98	1.09e-14	4.35e-12	0.52	0.34	Alcohol dependence (age at onset);	chr2:189819942	chr2:189762704~189765556:+
LGG	cis	rs7829975	0.774	rs11249893	ENSG00000253981.4	ALG1L13P	-7.98	1.09e-14	4.36e-12	-0.36	-0.34	Mood instability;	chr8:8843341	chr8:8236003~8244667:-
LGG	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-7.98	1.09e-14	4.36e-12	-0.69	-0.34	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
LGG	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-7.98	1.09e-14	4.36e-12	-0.36	-0.34	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
LGG	cis	rs4143844	1	rs35932993	ENSG00000259251.2	RP11-643M14.1	7.98	1.09e-14	4.37e-12	0.56	0.34	Bipolar disorder and schizophrenia;	chr15:62069557	chr15:62060503~62062434:+
LGG	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-7.98	1.1e-14	4.37e-12	-0.7	-0.34	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
LGG	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	-7.98	1.1e-14	4.37e-12	-0.36	-0.34	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
LGG	cis	rs72772090	0.539	rs11742261	ENSG00000248734.2	CTD-2260A17.1	-7.98	1.1e-14	4.38e-12	-0.52	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96831905	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs11748795	ENSG00000248734.2	CTD-2260A17.1	-7.98	1.1e-14	4.38e-12	-0.52	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96832353	chr5:96784777~96785999:+
LGG	cis	rs8031584	0.918	rs34331396	ENSG00000270015.1	RP11-540B6.6	-7.98	1.1e-14	4.38e-12	-0.26	-0.34	Huntington's disease progression;	chr15:30956533	chr15:30926514~30928407:+
LGG	cis	rs9532669	0.963	rs3764056	ENSG00000239827.7	SUGT1P3	-7.98	1.1e-14	4.38e-12	-0.36	-0.34	Cervical cancer;	chr13:40943849	chr13:40908159~40921774:-
LGG	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-7.98	1.1e-14	4.39e-12	-0.46	-0.34	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
LGG	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-7.98	1.1e-14	4.39e-12	-0.27	-0.34	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-7.98	1.1e-14	4.4e-12	-0.27	-0.34	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
LGG	cis	rs7005380	0.62	rs6993375	ENSG00000245330.4	KB-1471A8.1	7.98	1.1e-14	4.4e-12	0.39	0.34	Interstitial lung disease;	chr8:119899390	chr8:119867419~119874488:-
LGG	cis	rs7520050	0.966	rs785464	ENSG00000280836.1	AL355480.1	7.98	1.11e-14	4.41e-12	0.36	0.34	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45581219~45581321:-
LGG	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-7.98	1.11e-14	4.42e-12	-0.54	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
LGG	cis	rs1707322	1	rs10890381	ENSG00000281133.1	AL355480.3	-7.98	1.11e-14	4.43e-12	-0.42	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45580892~45580996:-
LGG	cis	rs11098499	0.863	rs58452170	ENSG00000250412.1	KLHL2P1	7.98	1.11e-14	4.43e-12	0.39	0.34	Corneal astigmatism;	chr4:119538519	chr4:119334329~119378233:+
LGG	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	7.98	1.11e-14	4.44e-12	0.71	0.34	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	7.98	1.11e-14	4.44e-12	0.71	0.34	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	7.98	1.11e-14	4.44e-12	0.71	0.34	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
LGG	cis	rs10946940	0.965	rs9393830	ENSG00000199851.2	U3	7.98	1.11e-14	4.45e-12	0.46	0.34	Systemic lupus erythematosus;	chr6:27619248	chr6:28015568~28015777:+
LGG	cis	rs7927771	0.524	rs7129797	ENSG00000280615.1	Y_RNA	7.98	1.12e-14	4.45e-12	0.41	0.34	Subjective well-being;	chr11:47645615	chr11:47614898~47614994:-
LGG	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-7.98	1.12e-14	4.45e-12	-0.38	-0.34	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
LGG	cis	rs2638953	0.853	rs11614463	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467278	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs10843183	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467775	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11494781	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469166	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049638	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469687	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049639	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469868	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049641	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471160	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049642	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471325	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs12370338	ENSG00000278733.1	RP11-425D17.1	-7.98	1.12e-14	4.46e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28486787	chr12:28185625~28186190:-
LGG	cis	rs228614	0.51	rs223313	ENSG00000248971.2	KRT8P46	-7.98	1.12e-14	4.47e-12	-0.36	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102728746~102730171:-
LGG	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	7.98	1.12e-14	4.48e-12	0.4	0.34	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
LGG	cis	rs6921919	0.525	rs16894095	ENSG00000199851.2	U3	7.98	1.12e-14	4.48e-12	0.48	0.34	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28015568~28015777:+
LGG	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-7.98	1.12e-14	4.48e-12	-0.41	-0.34	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
LGG	cis	rs227275	0.525	rs10028116	ENSG00000248971.2	KRT8P46	-7.98	1.13e-14	4.49e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102728746~102730171:-
LGG	cis	rs7709377	0.671	rs62384715	ENSG00000212457.1	RNU6-644P	-7.98	1.13e-14	4.49e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116120819	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.671	rs6887852	ENSG00000212457.1	RNU6-644P	-7.98	1.13e-14	4.49e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116128903	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.625	rs6874458	ENSG00000212457.1	RNU6-644P	-7.98	1.13e-14	4.49e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116138939	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs58414661	ENSG00000212457.1	RNU6-644P	-7.98	1.13e-14	4.49e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116143512	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.625	rs7709439	ENSG00000212457.1	RNU6-644P	-7.98	1.13e-14	4.49e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116147164	chr5:116188455~116188552:-
LGG	cis	rs11098499	0.954	rs10017543	ENSG00000250412.1	KLHL2P1	7.98	1.13e-14	4.5e-12	0.4	0.34	Corneal astigmatism;	chr4:119400265	chr4:119334329~119378233:+
LGG	cis	rs1023500	0.551	rs2859438	ENSG00000227370.1	RP4-669P10.19	7.98	1.13e-14	4.51e-12	0.3	0.34	Schizophrenia;	chr22:42070976	chr22:42132543~42132998:+
LGG	cis	rs1023500	0.573	rs4822088	ENSG00000227370.1	RP4-669P10.19	7.98	1.13e-14	4.51e-12	0.3	0.34	Schizophrenia;	chr22:42074585	chr22:42132543~42132998:+
LGG	cis	rs1023500	0.573	rs2269524	ENSG00000227370.1	RP4-669P10.19	-7.98	1.13e-14	4.51e-12	-0.3	-0.34	Schizophrenia;	chr22:42079699	chr22:42132543~42132998:+
LGG	cis	rs1023500	0.573	rs6002592	ENSG00000227370.1	RP4-669P10.19	-7.98	1.13e-14	4.51e-12	-0.3	-0.34	Schizophrenia;	chr22:42080750	chr22:42132543~42132998:+
LGG	cis	rs3020736	0.5	rs4147638	ENSG00000227370.1	RP4-669P10.19	-7.98	1.13e-14	4.51e-12	-0.3	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42132543~42132998:+
LGG	cis	rs3020736	0.5	rs6002605	ENSG00000227370.1	RP4-669P10.19	-7.98	1.13e-14	4.51e-12	-0.3	-0.34	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42132543~42132998:+
LGG	cis	rs8042680	0.784	rs6496747	ENSG00000214432.8	AC068831.10	-7.98	1.13e-14	4.51e-12	-0.36	-0.34	Type 2 diabetes;	chr15:90993397	chr15:91022619~91036611:+
LGG	cis	rs2638953	0.888	rs10843189	ENSG00000278733.1	RP11-425D17.1	-7.98	1.13e-14	4.52e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28185625~28186190:-
LGG	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-7.98	1.14e-14	4.52e-12	-0.3	-0.34	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
LGG	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-7.98	1.14e-14	4.53e-12	-0.45	-0.34	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
LGG	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	7.98	1.14e-14	4.53e-12	0.42	0.34	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
LGG	cis	rs7709377	0.723	rs2161321	ENSG00000212457.1	RNU6-644P	-7.98	1.14e-14	4.54e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116216973	chr5:116188455~116188552:-
LGG	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-7.98	1.14e-14	4.54e-12	-0.36	-0.34	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-7.98	1.14e-14	4.54e-12	-0.36	-0.34	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	7.98	1.14e-14	4.54e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
LGG	cis	rs35857674	0.731	rs6988843	ENSG00000253484.1	RP11-109P6.2	-7.98	1.14e-14	4.55e-12	-0.35	-0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50139475	chr8:49817586~49820944:-
LGG	cis	rs7189233	1	rs62048543	ENSG00000279344.1	RP11-44F14.7	7.98	1.14e-14	4.55e-12	0.33	0.34	Intelligence (multi-trait analysis);	chr16:53500712	chr16:53478957~53481550:-
LGG	cis	rs7005380	0.6	rs4871773	ENSG00000245330.4	KB-1471A8.1	7.98	1.14e-14	4.55e-12	0.39	0.34	Interstitial lung disease;	chr8:119895671	chr8:119867419~119874488:-
LGG	cis	rs35934224	0.724	rs16984286	ENSG00000232926.1	AC000078.5	7.98	1.14e-14	4.55e-12	0.38	0.34	Glaucoma (primary open-angle);	chr22:19870591	chr22:19887289~19887970:+
LGG	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	7.98	1.15e-14	4.57e-12	0.24	0.34	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
LGG	cis	rs7160336	0.738	rs7145427	ENSG00000258586.1	RP5-1021I20.2	7.97	1.15e-14	4.58e-12	0.41	0.34	Blood protein levels;	chr14:74016745	chr14:73822559~73830135:-
LGG	cis	rs7829975	0.846	rs7005216	ENSG00000253981.4	ALG1L13P	7.97	1.15e-14	4.59e-12	0.36	0.34	Mood instability;	chr8:8689600	chr8:8236003~8244667:-
LGG	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	7.97	1.16e-14	4.6e-12	0.38	0.34	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
LGG	cis	rs36715	1	rs251386	ENSG00000245937.6	LINC01184	7.97	1.16e-14	4.6e-12	0.41	0.34	Breast cancer;	chr5:128211606	chr5:127940426~128083172:-
LGG	cis	rs853679	0.517	rs9295761	ENSG00000182477.5	OR2B8P	7.97	1.16e-14	4.6e-12	0.5	0.34	Depression;	chr6:28180209	chr6:28053228~28054165:-
LGG	cis	rs812925	0.855	rs6545851	ENSG00000273302.1	RP11-493E12.2	-7.97	1.16e-14	4.62e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61271222	chr2:61199979~61200769:+
LGG	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	7.97	1.16e-14	4.62e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
LGG	cis	rs1930961	1	rs6004673	ENSG00000272942.1	CTA-246H3.12	-7.97	1.16e-14	4.62e-12	-0.51	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25434324~25435070:-
LGG	cis	rs11722779	0.935	rs11938650	ENSG00000248971.2	KRT8P46	-7.97	1.16e-14	4.62e-12	-0.36	-0.34	Schizophrenia;	chr4:103021639	chr4:102728746~102730171:-
LGG	cis	rs853679	0.769	rs7752608	ENSG00000199851.2	U3	7.97	1.16e-14	4.63e-12	0.75	0.34	Depression;	chr6:28333418	chr6:28015568~28015777:+
LGG	cis	rs11098499	0.908	rs28559989	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.63e-12	0.4	0.34	Corneal astigmatism;	chr4:119465472	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs28632018	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.63e-12	0.4	0.34	Corneal astigmatism;	chr4:119465575	chr4:119334329~119378233:+
LGG	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-7.97	1.17e-14	4.64e-12	-0.72	-0.34	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
LGG	cis	rs7005380	0.62	rs6469862	ENSG00000245330.4	KB-1471A8.1	7.97	1.17e-14	4.65e-12	0.39	0.34	Interstitial lung disease;	chr8:119897796	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6469865	ENSG00000245330.4	KB-1471A8.1	7.97	1.17e-14	4.65e-12	0.39	0.34	Interstitial lung disease;	chr8:119897995	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs6989741	ENSG00000245330.4	KB-1471A8.1	7.97	1.17e-14	4.65e-12	0.39	0.34	Interstitial lung disease;	chr8:119899914	chr8:119867419~119874488:-
LGG	cis	rs7005380	0.62	rs9649947	ENSG00000245330.4	KB-1471A8.1	7.97	1.17e-14	4.65e-12	0.39	0.34	Interstitial lung disease;	chr8:119901117	chr8:119867419~119874488:-
LGG	cis	rs9532669	0.926	rs4454835	ENSG00000239827.7	SUGT1P3	-7.97	1.17e-14	4.65e-12	-0.36	-0.34	Cervical cancer;	chr13:40928978	chr13:40908159~40921774:-
LGG	cis	rs7826238	0.543	rs2976908	ENSG00000253981.4	ALG1L13P	-7.97	1.17e-14	4.65e-12	-0.37	-0.34	Systolic blood pressure;	chr8:8488264	chr8:8236003~8244667:-
LGG	cis	rs1930961	1	rs6004662	ENSG00000272942.1	CTA-246H3.12	-7.97	1.17e-14	4.66e-12	-0.52	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25434324~25435070:-
LGG	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	7.97	1.17e-14	4.66e-12	0.52	0.34	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
LGG	cis	rs17772222	0.655	rs7160717	ENSG00000222990.1	RNU4-22P	7.97	1.17e-14	4.66e-12	0.41	0.34	Coronary artery calcification;	chr14:88498232	chr14:88513498~88513663:+
LGG	cis	rs812925	0.855	rs777592	ENSG00000273302.1	RP11-493E12.2	7.97	1.17e-14	4.66e-12	0.33	0.34	Immature fraction of reticulocytes;	chr2:61191208	chr2:61199979~61200769:+
LGG	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-7.97	1.17e-14	4.67e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
LGG	cis	rs9346353	0.966	rs7767789	ENSG00000219881.1	GAPDHP42	7.97	1.17e-14	4.67e-12	0.33	0.34	Sleep duration;	chr6:69804180	chr6:69745871~69746851:+
LGG	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	7.97	1.17e-14	4.67e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	7.97	1.17e-14	4.67e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	7.97	1.17e-14	4.67e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
LGG	cis	rs11098499	0.954	rs6846442	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119405168	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.738	rs34965784	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119440431	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs71614438	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119450097	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs66506550	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119450290	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs7659501	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119450397	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.657	rs71614442	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119458191	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs2892848	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119460186	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.697	rs11941899	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119461603	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.821	rs28665282	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119463031	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.738	rs10026493	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119463039	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs7681214	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119464165	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs17046116	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119466104	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs17046118	ENSG00000250412.1	KLHL2P1	7.97	1.17e-14	4.67e-12	0.4	0.34	Corneal astigmatism;	chr4:119466341	chr4:119334329~119378233:+
LGG	cis	rs12682352	0.605	rs60707155	ENSG00000253893.2	FAM85B	-7.97	1.18e-14	4.68e-12	-0.44	-0.34	Neuroticism;	chr8:8866905	chr8:8167819~8226614:-
LGG	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-7.97	1.18e-14	4.68e-12	-0.48	-0.34	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
LGG	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-7.97	1.18e-14	4.68e-12	-0.56	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
LGG	cis	rs9329221	0.502	rs11777364	ENSG00000261451.1	RP11-981G7.1	7.97	1.18e-14	4.68e-12	0.38	0.34	Neuroticism;	chr8:10431036	chr8:10433672~10438312:+
LGG	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	7.97	1.18e-14	4.68e-12	0.42	0.34	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
LGG	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-7.97	1.18e-14	4.68e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
LGG	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-7.97	1.18e-14	4.68e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
LGG	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-7.97	1.18e-14	4.68e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
LGG	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	7.97	1.18e-14	4.68e-12	0.42	0.34	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
LGG	cis	rs8135665	0.6	rs3948	ENSG00000233739.1	RP5-1039K5.13	7.97	1.18e-14	4.7e-12	0.4	0.34	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38060673	chr22:38057180~38073940:-
LGG	cis	rs11098499	0.909	rs7681978	ENSG00000250412.1	KLHL2P1	7.97	1.18e-14	4.7e-12	0.4	0.34	Corneal astigmatism;	chr4:119462620	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.697	rs28655325	ENSG00000250412.1	KLHL2P1	7.97	1.18e-14	4.7e-12	0.4	0.34	Corneal astigmatism;	chr4:119451844	chr4:119334329~119378233:+
LGG	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-7.97	1.19e-14	4.71e-12	-0.52	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
LGG	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	7.97	1.19e-14	4.71e-12	0.36	0.34	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
LGG	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	7.97	1.19e-14	4.71e-12	0.36	0.34	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
LGG	cis	rs7208859	0.573	rs73277960	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs73277964	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs11652409	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9896095	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs58920731	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs73277984	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs73277986	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs12103588	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.614	rs9914534	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs4131618	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs11658344	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs9900144	ENSG00000266490.1	CTD-2349P21.9	7.97	1.19e-14	4.71e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30792372~30792833:+
LGG	cis	rs1949733	0.585	rs2631768	ENSG00000205959.3	RP11-689P11.2	7.97	1.19e-14	4.71e-12	0.29	0.34	Response to antineoplastic agents;	chr4:8471323	chr4:8482270~8512610:+
LGG	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-7.97	1.19e-14	4.72e-12	-0.27	-0.34	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-7.97	1.19e-14	4.72e-12	-0.27	-0.34	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-7.97	1.19e-14	4.72e-12	-0.27	-0.34	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
LGG	cis	rs2638953	0.707	rs11049711	ENSG00000278733.1	RP11-425D17.1	-7.97	1.19e-14	4.72e-12	-0.4	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28553171	chr12:28185625~28186190:-
LGG	cis	rs1707322	1	rs4298677	ENSG00000281133.1	AL355480.3	-7.97	1.19e-14	4.73e-12	-0.42	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45580892~45580996:-
LGG	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-7.97	1.19e-14	4.74e-12	-0.29	-0.34	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
LGG	cis	rs1707322	1	rs4660331	ENSG00000281133.1	AL355480.3	-7.97	1.19e-14	4.74e-12	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45580892~45580996:-
LGG	cis	rs35934224	0.831	rs8141610	ENSG00000232926.1	AC000078.5	-7.97	1.2e-14	4.77e-12	-0.39	-0.34	Glaucoma (primary open-angle);	chr22:19882624	chr22:19887289~19887970:+
LGG	cis	rs11971779	0.59	rs6467839	ENSG00000273391.1	RP11-634H22.1	7.97	1.21e-14	4.78e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139378044	chr7:139359032~139359566:-
LGG	cis	rs9532669	0.926	rs9532691	ENSG00000239827.7	SUGT1P3	7.97	1.21e-14	4.78e-12	0.36	0.34	Cervical cancer;	chr13:40969358	chr13:40908159~40921774:-
LGG	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	7.97	1.21e-14	4.79e-12	0.27	0.34	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
LGG	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	7.97	1.21e-14	4.79e-12	0.45	0.34	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
LGG	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-7.97	1.21e-14	4.79e-12	-0.5	-0.34	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
LGG	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	7.97	1.21e-14	4.79e-12	0.35	0.34	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
LGG	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	7.97	1.21e-14	4.79e-12	0.35	0.34	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
LGG	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-7.97	1.21e-14	4.8e-12	-0.4	-0.34	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
LGG	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-7.97	1.21e-14	4.81e-12	-0.42	-0.34	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
LGG	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	7.97	1.21e-14	4.81e-12	0.27	0.34	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
LGG	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	7.97	1.21e-14	4.81e-12	0.47	0.34	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
LGG	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-7.97	1.21e-14	4.81e-12	-0.48	-0.34	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
LGG	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-7.97	1.21e-14	4.82e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
LGG	cis	rs2638953	0.962	rs61922977	ENSG00000278733.1	RP11-425D17.1	-7.97	1.21e-14	4.82e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049505	ENSG00000278733.1	RP11-425D17.1	-7.97	1.21e-14	4.82e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049509	ENSG00000278733.1	RP11-425D17.1	-7.97	1.21e-14	4.82e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28185625~28186190:-
LGG	cis	rs228614	0.51	rs4699033	ENSG00000248971.2	KRT8P46	-7.97	1.22e-14	4.82e-12	-0.36	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102728746~102730171:-
LGG	cis	rs1023500	0.596	rs5751204	ENSG00000227370.1	RP4-669P10.19	7.97	1.22e-14	4.82e-12	0.31	0.34	Schizophrenia;	chr22:42037797	chr22:42132543~42132998:+
LGG	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	7.97	1.22e-14	4.83e-12	0.39	0.34	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
LGG	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-7.97	1.22e-14	4.83e-12	-0.44	-0.34	Height;	chr14:75193543	chr14:75011269~75012851:-
LGG	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-7.97	1.22e-14	4.84e-12	-0.46	-0.34	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
LGG	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	7.97	1.22e-14	4.84e-12	0.42	0.34	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
LGG	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	7.97	1.22e-14	4.84e-12	0.42	0.34	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
LGG	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	7.97	1.22e-14	4.84e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
LGG	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	7.97	1.22e-14	4.84e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
LGG	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	7.97	1.22e-14	4.85e-12	0.44	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	7.97	1.22e-14	4.85e-12	0.44	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	7.97	1.22e-14	4.85e-12	0.44	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
LGG	cis	rs9322193	0.962	rs4870048	ENSG00000216621.7	RP11-244K5.6	7.97	1.22e-14	4.85e-12	0.4	0.34	Lung cancer;	chr6:149834324	chr6:149934527~149936782:+
LGG	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-7.97	1.23e-14	4.86e-12	-0.41	-0.34	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
LGG	cis	rs227275	0.556	rs6815526	ENSG00000248971.2	KRT8P46	-7.97	1.23e-14	4.86e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs6824070	ENSG00000248971.2	KRT8P46	-7.97	1.23e-14	4.86e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102728746~102730171:-
LGG	cis	rs11722779	0.935	rs6856176	ENSG00000248971.2	KRT8P46	-7.97	1.23e-14	4.86e-12	-0.36	-0.34	Schizophrenia;	chr4:102902574	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs11722779	ENSG00000248971.2	KRT8P46	-7.97	1.23e-14	4.86e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102728746~102730171:-
LGG	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-7.97	1.23e-14	4.87e-12	-0.7	-0.34	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-7.97	1.23e-14	4.87e-12	-0.7	-0.34	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-7.97	1.23e-14	4.87e-12	-0.7	-0.34	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
LGG	cis	rs11098499	0.954	rs12510138	ENSG00000250412.1	KLHL2P1	7.97	1.23e-14	4.87e-12	0.39	0.34	Corneal astigmatism;	chr4:119502780	chr4:119334329~119378233:+
LGG	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-7.97	1.23e-14	4.87e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
LGG	cis	rs11098499	0.863	rs11098531	ENSG00000250412.1	KLHL2P1	7.97	1.23e-14	4.87e-12	0.39	0.34	Corneal astigmatism;	chr4:119543846	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs28718422	ENSG00000250412.1	KLHL2P1	7.97	1.23e-14	4.87e-12	0.39	0.34	Corneal astigmatism;	chr4:119545149	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.818	rs12498599	ENSG00000250412.1	KLHL2P1	7.97	1.23e-14	4.87e-12	0.39	0.34	Corneal astigmatism;	chr4:119547348	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs10009626	ENSG00000250412.1	KLHL2P1	7.97	1.23e-14	4.87e-12	0.39	0.34	Corneal astigmatism;	chr4:119548850	chr4:119334329~119378233:+
LGG	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	7.97	1.23e-14	4.88e-12	0.45	0.34	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
LGG	cis	rs6997458	0.869	rs11261474	ENSG00000253549.4	RP11-317J10.2	7.97	1.23e-14	4.89e-12	0.28	0.34	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85382421	chr8:85441851~85464915:-
LGG	cis	rs812925	0.793	rs1405490	ENSG00000273302.1	RP11-493E12.2	-7.97	1.23e-14	4.89e-12	-0.34	-0.34	Immature fraction of reticulocytes;	chr2:61332945	chr2:61199979~61200769:+
LGG	cis	rs4295623	0.531	rs2898295	ENSG00000255556.2	RP11-351I21.6	-7.97	1.23e-14	4.89e-12	-0.41	-0.34	Morning vs. evening chronotype;	chr8:11738460	chr8:12378679~12380265:-
LGG	cis	rs1552244	0.882	rs55808392	ENSG00000180385.7	EMC3-AS1	7.97	1.23e-14	4.89e-12	0.39	0.34	Alzheimer's disease;	chr3:10012997	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.882	rs13075842	ENSG00000180385.7	EMC3-AS1	7.97	1.23e-14	4.89e-12	0.39	0.34	Alzheimer's disease;	chr3:10014129	chr3:9986893~10006990:+
LGG	cis	rs910316	0.967	rs8007539	ENSG00000279594.1	RP11-950C14.10	-7.97	1.24e-14	4.89e-12	-0.43	-0.34	Height;	chr14:75198250	chr14:75011269~75012851:-
LGG	cis	rs7927771	0.507	rs7119517	ENSG00000280615.1	Y_RNA	7.97	1.24e-14	4.9e-12	0.41	0.34	Subjective well-being;	chr11:47653764	chr11:47614898~47614994:-
LGG	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	7.96	1.24e-14	4.91e-12	0.43	0.34	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
LGG	cis	rs2877649	0.51	rs10144287	ENSG00000258744.1	RP11-80A15.1	-7.96	1.24e-14	4.91e-12	-0.77	-0.34	Smooth-surface caries;	chr14:24437643	chr14:24501594~24508688:+
LGG	cis	rs5760092	0.627	rs6519489	ENSG00000235689.1	AP000351.13	-7.96	1.24e-14	4.91e-12	-0.48	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:24006305~24008258:-
LGG	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-7.96	1.24e-14	4.92e-12	-0.42	-0.34	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
LGG	cis	rs6921919	0.806	rs213230	ENSG00000218016.2	ZNF192P2	-7.96	1.24e-14	4.92e-12	-0.44	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28188050~28189432:+
LGG	cis	rs1707322	1	rs785498	ENSG00000281133.1	AL355480.3	7.96	1.24e-14	4.92e-12	0.44	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45580892~45580996:-
LGG	cis	rs2638953	0.962	rs11049518	ENSG00000278733.1	RP11-425D17.1	-7.96	1.24e-14	4.93e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28303728	chr12:28185625~28186190:-
LGG	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	7.96	1.24e-14	4.93e-12	0.44	0.34	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
LGG	cis	rs7241530	0.636	rs8085845	ENSG00000266213.1	RP11-100K18.1	-7.96	1.25e-14	4.93e-12	-0.41	-0.34	Educational attainment (years of education);	chr18:78136982	chr18:78137223~78140887:+
LGG	cis	rs227275	0.524	rs223337	ENSG00000248971.2	KRT8P46	-7.96	1.25e-14	4.94e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102728746~102730171:-
LGG	cis	rs11098499	0.954	rs10518331	ENSG00000250412.1	KLHL2P1	7.96	1.25e-14	4.94e-12	0.4	0.34	Corneal astigmatism;	chr4:119402440	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs13133522	ENSG00000250412.1	KLHL2P1	7.96	1.25e-14	4.94e-12	0.4	0.34	Corneal astigmatism;	chr4:119403269	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs35091806	ENSG00000250412.1	KLHL2P1	7.96	1.25e-14	4.94e-12	0.4	0.34	Corneal astigmatism;	chr4:119404374	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs35165976	ENSG00000250412.1	KLHL2P1	7.96	1.25e-14	4.94e-12	0.4	0.34	Corneal astigmatism;	chr4:119404475	chr4:119334329~119378233:+
LGG	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	7.96	1.25e-14	4.96e-12	0.36	0.34	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
LGG	cis	rs228614	0.51	rs223455	ENSG00000248971.2	KRT8P46	-7.96	1.25e-14	4.97e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102728746~102730171:-
LGG	cis	rs2739330	0.796	rs5760097	ENSG00000272787.1	KB-226F1.2	7.96	1.26e-14	4.99e-12	0.36	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23969211~23969873:+
LGG	cis	rs2638953	0.853	rs11049646	ENSG00000278733.1	RP11-425D17.1	-7.96	1.26e-14	4.99e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28476139	chr12:28185625~28186190:-
LGG	cis	rs11992162	0.967	rs7836456	ENSG00000255556.2	RP11-351I21.6	7.96	1.26e-14	4.99e-12	0.41	0.34	Monocyte count;	chr8:11971666	chr8:12378679~12380265:-
LGG	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	7.96	1.26e-14	5e-12	0.34	0.34	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
LGG	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-7.96	1.26e-14	5e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
LGG	cis	rs7824557	0.614	rs10503421	ENSG00000184608.7	FAM167A-AS1	-7.96	1.26e-14	5e-12	-0.29	-0.34	Retinal vascular caliber;	chr8:11363804	chr8:11368402~11438658:+
LGG	cis	rs2251666	0.765	rs17771656	ENSG00000267077.1	RP11-127I20.5	7.96	1.26e-14	5.01e-12	0.42	0.34	Cancer;	chr16:4878256	chr16:4795265~4796532:-
LGG	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	7.96	1.27e-14	5.01e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
LGG	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	7.96	1.27e-14	5.01e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
LGG	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	7.96	1.27e-14	5.01e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
LGG	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	7.96	1.27e-14	5.01e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
LGG	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	7.96	1.27e-14	5.01e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
LGG	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	7.96	1.27e-14	5.01e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
LGG	cis	rs36715	1	rs251213	ENSG00000245937.6	LINC01184	7.96	1.27e-14	5.02e-12	0.41	0.34	Breast cancer;	chr5:128209913	chr5:127940426~128083172:-
LGG	cis	rs36715	1	rs251212	ENSG00000245937.6	LINC01184	7.96	1.27e-14	5.02e-12	0.41	0.34	Breast cancer;	chr5:128210218	chr5:127940426~128083172:-
LGG	cis	rs7005380	0.62	rs10217083	ENSG00000245330.4	KB-1471A8.1	7.96	1.27e-14	5.02e-12	0.39	0.34	Interstitial lung disease;	chr8:119911045	chr8:119867419~119874488:-
LGG	cis	rs812925	0.784	rs6735081	ENSG00000273302.1	RP11-493E12.2	-7.96	1.27e-14	5.03e-12	-0.32	-0.34	Immature fraction of reticulocytes;	chr2:61233582	chr2:61199979~61200769:+
LGG	cis	rs758324	0.687	rs152047	ENSG00000233006.5	AC034220.3	-7.96	1.27e-14	5.03e-12	-0.41	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132213245	chr5:132311285~132369916:-
LGG	cis	rs758324	0.732	rs152056	ENSG00000233006.5	AC034220.3	-7.96	1.27e-14	5.04e-12	-0.41	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132181789	chr5:132311285~132369916:-
LGG	cis	rs1555322	0.53	rs6058224	ENSG00000269202.1	RP4-614O4.12	-7.96	1.27e-14	5.04e-12	-0.37	-0.34	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35201747~35203288:-
LGG	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-7.96	1.27e-14	5.04e-12	-0.44	-0.34	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
LGG	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-7.96	1.27e-14	5.04e-12	-0.44	-0.34	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
LGG	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-7.96	1.27e-14	5.04e-12	-0.44	-0.34	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
LGG	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	7.96	1.28e-14	5.05e-12	0.32	0.34	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
LGG	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	7.96	1.28e-14	5.06e-12	0.43	0.34	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	7.96	1.28e-14	5.06e-12	0.43	0.34	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	7.96	1.28e-14	5.06e-12	0.43	0.34	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
LGG	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	-7.96	1.28e-14	5.06e-12	-0.36	-0.34	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
LGG	cis	rs1048886	0.938	rs9446252	ENSG00000271967.1	RP11-134K13.4	-7.96	1.28e-14	5.06e-12	-0.38	-0.34	Type 2 diabetes;	chr6:70444171	chr6:70596438~70596980:+
LGG	cis	rs1048886	0.938	rs6918393	ENSG00000271967.1	RP11-134K13.4	-7.96	1.28e-14	5.06e-12	-0.38	-0.34	Type 2 diabetes;	chr6:70451613	chr6:70596438~70596980:+
LGG	cis	rs7824557	0.628	rs11777746	ENSG00000184608.7	FAM167A-AS1	-7.96	1.28e-14	5.06e-12	-0.28	-0.34	Retinal vascular caliber;	chr8:11347246	chr8:11368402~11438658:+
LGG	cis	rs228614	0.51	rs223438	ENSG00000248971.2	KRT8P46	7.96	1.28e-14	5.06e-12	0.36	0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102728746~102730171:-
LGG	cis	rs2638953	0.962	rs61922978	ENSG00000278733.1	RP11-425D17.1	-7.96	1.28e-14	5.07e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292075	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs12372448	ENSG00000278733.1	RP11-425D17.1	-7.96	1.28e-14	5.07e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28293956	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.925	rs11049511	ENSG00000278733.1	RP11-425D17.1	-7.96	1.28e-14	5.07e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28294393	chr12:28185625~28186190:-
LGG	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-7.96	1.28e-14	5.07e-12	-0.52	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-7.96	1.28e-14	5.07e-12	-0.52	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
LGG	cis	rs11098499	0.954	rs12499324	ENSG00000250412.1	KLHL2P1	7.96	1.29e-14	5.09e-12	0.4	0.34	Corneal astigmatism;	chr4:119472631	chr4:119334329~119378233:+
LGG	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-7.96	1.29e-14	5.09e-12	-0.3	-0.34	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
LGG	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-7.96	1.29e-14	5.1e-12	-0.72	-0.34	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
LGG	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	7.96	1.29e-14	5.1e-12	0.38	0.34	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	7.96	1.29e-14	5.1e-12	0.38	0.34	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
LGG	cis	rs7208859	0.673	rs9911989	ENSG00000266490.1	CTD-2349P21.9	-7.96	1.29e-14	5.1e-12	-0.43	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30792372~30792833:+
LGG	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	7.96	1.29e-14	5.11e-12	0.36	0.34	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
LGG	cis	rs1185460	0.967	rs2509121	ENSG00000272186.1	RP11-110I1.13	-7.96	1.29e-14	5.12e-12	-0.34	-0.34	Coronary artery disease;	chr11:119057542	chr11:119067374~119067698:-
LGG	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	7.96	1.29e-14	5.12e-12	0.44	0.34	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
LGG	cis	rs1930961	1	rs6004669	ENSG00000272942.1	CTA-246H3.12	-7.96	1.3e-14	5.12e-12	-0.52	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25434324~25435070:-
LGG	cis	rs1930961	1	rs5996946	ENSG00000272942.1	CTA-246H3.12	-7.96	1.3e-14	5.12e-12	-0.52	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25434324~25435070:-
LGG	cis	rs910316	0.967	rs8013444	ENSG00000279594.1	RP11-950C14.10	-7.96	1.3e-14	5.13e-12	-0.43	-0.34	Height;	chr14:75195278	chr14:75011269~75012851:-
LGG	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-7.96	1.3e-14	5.13e-12	-0.27	-0.34	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-7.96	1.3e-14	5.13e-12	-0.27	-0.34	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
LGG	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	7.96	1.3e-14	5.13e-12	0.34	0.34	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
LGG	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	7.96	1.3e-14	5.14e-12	0.36	0.34	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
LGG	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-7.96	1.3e-14	5.15e-12	-0.23	-0.34	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
LGG	cis	rs10740993	0.717	rs1888693	ENSG00000226083.4	SLC39A12-AS1	7.96	1.3e-14	5.15e-12	0.36	0.34	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);	chr10:18151515	chr10:18001786~18010562:-
LGG	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-7.96	1.3e-14	5.15e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
LGG	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-7.96	1.3e-14	5.15e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
LGG	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-7.96	1.3e-14	5.16e-12	-0.49	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
LGG	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	7.96	1.3e-14	5.16e-12	0.35	0.34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
LGG	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	7.96	1.31e-14	5.16e-12	0.27	0.34	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
LGG	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-7.96	1.31e-14	5.19e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
LGG	cis	rs17772222	0.636	rs77528165	ENSG00000222990.1	RNU4-22P	7.96	1.31e-14	5.2e-12	0.45	0.34	Coronary artery calcification;	chr14:88794249	chr14:88513498~88513663:+
LGG	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	7.96	1.31e-14	5.2e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
LGG	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-7.96	1.32e-14	5.21e-12	-0.27	-0.34	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
LGG	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-7.96	1.32e-14	5.21e-12	-0.27	-0.34	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
LGG	cis	rs7005380	0.6	rs13267896	ENSG00000245330.4	KB-1471A8.1	7.96	1.32e-14	5.22e-12	0.38	0.34	Interstitial lung disease;	chr8:119908414	chr8:119867419~119874488:-
LGG	cis	rs8031584	0.918	rs61997140	ENSG00000270015.1	RP11-540B6.6	-7.96	1.32e-14	5.23e-12	-0.26	-0.34	Huntington's disease progression;	chr15:30985109	chr15:30926514~30928407:+
LGG	cis	rs10246939	0.505	rs892354	ENSG00000261797.1	RP11-744I24.3	-7.96	1.32e-14	5.23e-12	-0.4	-0.34	Bitter taste perception;	chr7:141844934	chr7:141512698~141513183:-
LGG	cis	rs1555322	0.53	rs2425053	ENSG00000269202.1	RP4-614O4.12	-7.96	1.32e-14	5.23e-12	-0.37	-0.34	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35201747~35203288:-
LGG	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	7.96	1.33e-14	5.24e-12	0.43	0.34	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
LGG	cis	rs2638953	0.821	rs76265865	ENSG00000278733.1	RP11-425D17.1	-7.95	1.33e-14	5.26e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504107	chr12:28185625~28186190:-
LGG	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	-7.95	1.33e-14	5.26e-12	-0.49	-0.34	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
LGG	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	7.95	1.34e-14	5.28e-12	0.23	0.34	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
LGG	cis	rs12073837	0.5	rs4143772	ENSG00000272823.1	RP11-295M18.6	-7.95	1.34e-14	5.29e-12	-0.42	-0.34	F-cell distribution;	chr1:220815004	chr1:220828676~220829211:-
LGG	cis	rs227275	0.525	rs4596243	ENSG00000248971.2	KRT8P46	-7.95	1.34e-14	5.29e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102728746~102730171:-
LGG	cis	rs4072705	0.967	rs10739651	ENSG00000224020.1	MIR181A2HG	-7.95	1.34e-14	5.29e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124561794	chr9:124658467~124698631:+
LGG	cis	rs12554020	0.786	rs3893381	ENSG00000227603.1	RP11-165J3.6	-7.95	1.34e-14	5.3e-12	-0.6	-0.34	Schizophrenia;	chr9:93519576	chr9:93435332~93437121:-
LGG	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	7.95	1.34e-14	5.3e-12	0.27	0.34	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
LGG	cis	rs8180040	0.934	rs4858811	ENSG00000271161.1	BOLA2P2	-7.95	1.34e-14	5.31e-12	-0.32	-0.34	Colorectal cancer;	chr3:47439034	chr3:47499841~47500407:+
LGG	cis	rs35851103	0.6	rs4841662	ENSG00000227888.4	FAM66A	-7.95	1.35e-14	5.31e-12	-0.41	-0.34	Neuroticism;	chr8:11986249	chr8:12362019~12388296:+
LGG	cis	rs1707322	1	rs785507	ENSG00000281133.1	AL355480.3	7.95	1.35e-14	5.32e-12	0.42	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45580892~45580996:-
LGG	cis	rs11098499	0.954	rs7654587	ENSG00000250412.1	KLHL2P1	7.95	1.35e-14	5.32e-12	0.39	0.34	Corneal astigmatism;	chr4:119467251	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs11098525	ENSG00000250412.1	KLHL2P1	7.95	1.35e-14	5.32e-12	0.39	0.34	Corneal astigmatism;	chr4:119468997	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.821	rs10032151	ENSG00000250412.1	KLHL2P1	7.95	1.35e-14	5.32e-12	0.39	0.34	Corneal astigmatism;	chr4:119470473	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.865	rs10032158	ENSG00000250412.1	KLHL2P1	7.95	1.35e-14	5.32e-12	0.39	0.34	Corneal astigmatism;	chr4:119470477	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs6838814	ENSG00000250412.1	KLHL2P1	7.95	1.35e-14	5.32e-12	0.39	0.34	Corneal astigmatism;	chr4:119471288	chr4:119334329~119378233:+
LGG	cis	rs228614	0.51	rs6830407	ENSG00000248971.2	KRT8P46	-7.95	1.35e-14	5.33e-12	-0.36	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102728746~102730171:-
LGG	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-7.95	1.35e-14	5.33e-12	-0.39	-0.34	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
LGG	cis	rs8042680	1	rs4508401	ENSG00000214432.8	AC068831.10	-7.95	1.35e-14	5.33e-12	-0.35	-0.34	Type 2 diabetes;	chr15:90971491	chr15:91022619~91036611:+
LGG	cis	rs8180040	0.902	rs73081205	ENSG00000271161.1	BOLA2P2	-7.95	1.35e-14	5.34e-12	-0.32	-0.34	Colorectal cancer;	chr3:47476180	chr3:47499841~47500407:+
LGG	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-7.95	1.35e-14	5.35e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
LGG	cis	rs8042680	1	rs6496743	ENSG00000214432.8	AC068831.10	-7.95	1.36e-14	5.35e-12	-0.36	-0.34	Type 2 diabetes;	chr15:90985128	chr15:91022619~91036611:+
LGG	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	7.95	1.36e-14	5.35e-12	0.27	0.34	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-7.95	1.36e-14	5.35e-12	-0.27	-0.34	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
LGG	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-7.95	1.36e-14	5.35e-12	-0.27	-0.34	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
LGG	cis	rs853679	0.599	rs149990	ENSG00000226314.6	ZNF192P1	7.95	1.36e-14	5.35e-12	0.53	0.34	Depression;	chr6:28030480	chr6:28161781~28169594:+
LGG	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-7.95	1.36e-14	5.35e-12	-0.45	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
LGG	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	7.95	1.36e-14	5.35e-12	0.42	0.34	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
LGG	cis	rs10246939	0.543	rs994809	ENSG00000261797.1	RP11-744I24.3	-7.95	1.36e-14	5.37e-12	-0.42	-0.34	Bitter taste perception;	chr7:141911485	chr7:141512698~141513183:-
LGG	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	7.95	1.36e-14	5.37e-12	0.44	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
LGG	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	7.95	1.36e-14	5.37e-12	0.44	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
LGG	cis	rs7709377	0.716	rs55854033	ENSG00000212457.1	RNU6-644P	-7.95	1.36e-14	5.37e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116159888	chr5:116188455~116188552:-
LGG	cis	rs2638953	0.962	rs11049540	ENSG00000278733.1	RP11-425D17.1	-7.95	1.36e-14	5.38e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28337959	chr12:28185625~28186190:-
LGG	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	7.95	1.36e-14	5.38e-12	0.27	0.34	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-7.95	1.37e-14	5.39e-12	-0.27	-0.34	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
LGG	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-7.95	1.37e-14	5.39e-12	-0.27	-0.34	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
LGG	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-7.95	1.37e-14	5.39e-12	-0.27	-0.34	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
LGG	cis	rs763567	0.935	rs639652	ENSG00000271811.1	RP1-79C4.4	7.95	1.37e-14	5.4e-12	0.33	0.34	Tonsillectomy;	chr1:170643732	chr1:170667381~170669425:+
LGG	cis	rs128738	0.5	rs2077380	ENSG00000233006.5	AC034220.3	7.95	1.37e-14	5.41e-12	0.41	0.34	Giant cell arteritis;	chr5:132232924	chr5:132311285~132369916:-
LGG	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-7.95	1.37e-14	5.41e-12	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
LGG	cis	rs55661361	0.532	rs3802902	ENSG00000254941.1	RP11-677M14.5	-7.95	1.38e-14	5.43e-12	-0.34	-0.34	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:124765139	chr11:124807822~124808269:-
LGG	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	7.95	1.38e-14	5.43e-12	0.4	0.34	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
LGG	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	7.95	1.38e-14	5.43e-12	0.4	0.34	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
LGG	cis	rs12893668	0.572	rs7148857	ENSG00000269940.1	RP11-73M18.7	7.95	1.38e-14	5.43e-12	0.39	0.34	Reticulocyte count;	chr14:103676900	chr14:103694560~103695170:+
LGG	cis	rs7829975	0.711	rs4481596	ENSG00000253981.4	ALG1L13P	-7.95	1.38e-14	5.43e-12	-0.35	-0.34	Mood instability;	chr8:8846820	chr8:8236003~8244667:-
LGG	cis	rs17772222	0.638	rs11629164	ENSG00000258983.2	RP11-507K2.2	-7.95	1.38e-14	5.44e-12	-0.39	-0.34	Coronary artery calcification;	chr14:88564740	chr14:88499334~88515502:+
LGG	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	7.95	1.38e-14	5.44e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
LGG	cis	rs11722779	0.901	rs28674656	ENSG00000248971.2	KRT8P46	-7.95	1.38e-14	5.44e-12	-0.35	-0.34	Schizophrenia;	chr4:102944396	chr4:102728746~102730171:-
LGG	cis	rs36715	1	rs181850	ENSG00000245937.6	LINC01184	7.95	1.38e-14	5.45e-12	0.41	0.34	Breast cancer;	chr5:128211795	chr5:127940426~128083172:-
LGG	cis	rs36715	0.953	rs185177	ENSG00000245937.6	LINC01184	7.95	1.38e-14	5.45e-12	0.41	0.34	Breast cancer;	chr5:128212118	chr5:127940426~128083172:-
LGG	cis	rs9532669	0.889	rs7339089	ENSG00000168852.11	TPTE2P5	7.95	1.38e-14	5.46e-12	0.36	0.34	Cervical cancer;	chr13:40863790	chr13:40822296~40921749:-
LGG	cis	rs6921919	0.789	rs6456814	ENSG00000280107.1	AL022393.9	-7.95	1.38e-14	5.46e-12	-0.38	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28170845~28172521:+
LGG	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-7.95	1.38e-14	5.46e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-7.95	1.38e-14	5.46e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
LGG	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	7.95	1.39e-14	5.47e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
LGG	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	7.95	1.39e-14	5.47e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
LGG	cis	rs62184315	0.536	rs56324258	ENSG00000253559.1	OSGEPL1-AS1	-7.95	1.39e-14	5.49e-12	-0.51	-0.34	Alcohol dependence (age at onset);	chr2:189811589	chr2:189762704~189765556:+
LGG	cis	rs7302981	0.667	rs7308692	ENSG00000272368.2	RP4-605O3.4	-7.95	1.4e-14	5.5e-12	-0.33	-0.34	Systolic blood pressure;	chr12:50233871	chr12:50112197~50165618:+
LGG	cis	rs7520050	0.743	rs61789988	ENSG00000280836.1	AL355480.1	7.95	1.4e-14	5.51e-12	0.37	0.34	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45581219~45581321:-
LGG	cis	rs227275	0.525	rs4699037	ENSG00000248971.2	KRT8P46	-7.95	1.4e-14	5.52e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs3857198	ENSG00000248971.2	KRT8P46	-7.95	1.4e-14	5.52e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102728746~102730171:-
LGG	cis	rs227275	0.525	rs4699039	ENSG00000248971.2	KRT8P46	-7.95	1.4e-14	5.52e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102728746~102730171:-
LGG	cis	rs227275	0.556	rs6821173	ENSG00000248971.2	KRT8P46	-7.95	1.4e-14	5.52e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102728746~102730171:-
LGG	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-7.95	1.4e-14	5.53e-12	-0.46	-0.34	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
LGG	cis	rs12893668	0.572	rs11540512	ENSG00000269940.1	RP11-73M18.7	7.95	1.4e-14	5.53e-12	0.39	0.34	Reticulocyte count;	chr14:103681040	chr14:103694560~103695170:+
LGG	cis	rs12893668	0.572	rs35011804	ENSG00000269940.1	RP11-73M18.7	7.95	1.4e-14	5.53e-12	0.39	0.34	Reticulocyte count;	chr14:103685063	chr14:103694560~103695170:+
LGG	cis	rs853679	0.517	rs1904840	ENSG00000182477.5	OR2B8P	7.95	1.4e-14	5.54e-12	0.5	0.34	Depression;	chr6:28140454	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9368555	ENSG00000182477.5	OR2B8P	7.95	1.4e-14	5.54e-12	0.5	0.34	Depression;	chr6:28141189	chr6:28053228~28054165:-
LGG	cis	rs853679	0.517	rs9393893	ENSG00000182477.5	OR2B8P	7.95	1.4e-14	5.54e-12	0.5	0.34	Depression;	chr6:28141484	chr6:28053228~28054165:-
LGG	cis	rs7520050	0.966	rs4073846	ENSG00000280836.1	AL355480.1	-7.95	1.41e-14	5.54e-12	-0.37	-0.34	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45581219~45581321:-
LGG	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-7.95	1.41e-14	5.54e-12	-0.45	-0.34	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
LGG	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-7.95	1.41e-14	5.54e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
LGG	cis	rs12893668	0.572	rs12590968	ENSG00000269940.1	RP11-73M18.7	7.95	1.41e-14	5.54e-12	0.39	0.34	Reticulocyte count;	chr14:103670296	chr14:103694560~103695170:+
LGG	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-7.95	1.41e-14	5.55e-12	-0.42	-0.34	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
LGG	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-7.95	1.41e-14	5.55e-12	-0.39	-0.34	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-7.95	1.41e-14	5.55e-12	-0.39	-0.34	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-7.95	1.41e-14	5.55e-12	-0.39	-0.34	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
LGG	cis	rs9532669	0.853	rs9315795	ENSG00000239827.7	SUGT1P3	-7.95	1.41e-14	5.57e-12	-0.36	-0.34	Cervical cancer;	chr13:40943382	chr13:40908159~40921774:-
LGG	cis	rs950169	0.922	rs11633534	ENSG00000259295.5	CSPG4P12	7.95	1.42e-14	5.59e-12	0.48	0.34	Schizophrenia;	chr15:84581411	chr15:85191438~85213905:+
LGG	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-7.95	1.42e-14	5.6e-12	-0.46	-0.34	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
LGG	cis	rs35857674	0.5	rs203632	ENSG00000253484.1	RP11-109P6.2	-7.95	1.42e-14	5.6e-12	-0.34	-0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50098184	chr8:49817586~49820944:-
LGG	cis	rs11148252	0.508	rs11148260	ENSG00000273784.3	RP11-78J21.7	-7.95	1.43e-14	5.62e-12	-0.37	-0.34	Lewy body disease;	chr13:52588508	chr13:52600042~52642542:+
LGG	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	7.94	1.43e-14	5.62e-12	0.38	0.34	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
LGG	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	7.94	1.43e-14	5.63e-12	0.48	0.34	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
LGG	cis	rs4713118	0.868	rs10484401	ENSG00000226314.6	ZNF192P1	-7.94	1.43e-14	5.63e-12	-0.39	-0.34	Parkinson's disease;	chr6:27778811	chr6:28161781~28169594:+
LGG	cis	rs9532669	0.963	rs4600338	ENSG00000239827.7	SUGT1P3	-7.94	1.43e-14	5.63e-12	-0.36	-0.34	Cervical cancer;	chr13:40925175	chr13:40908159~40921774:-
LGG	cis	rs8180040	0.966	rs11130129	ENSG00000271161.1	BOLA2P2	-7.94	1.43e-14	5.63e-12	-0.32	-0.34	Colorectal cancer;	chr3:47448395	chr3:47499841~47500407:+
LGG	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	-7.94	1.43e-14	5.64e-12	-0.49	-0.34	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
LGG	cis	rs227275	0.556	rs4235407	ENSG00000248971.2	KRT8P46	-7.94	1.43e-14	5.64e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102728746~102730171:-
LGG	cis	rs10246939	0.505	rs34726057	ENSG00000261797.1	RP11-744I24.3	-7.94	1.43e-14	5.64e-12	-0.4	-0.34	Bitter taste perception;	chr7:141832117	chr7:141512698~141513183:-
LGG	cis	rs1150668	0.799	rs1150707	ENSG00000270326.1	RP5-874C20.6	-7.94	1.43e-14	5.65e-12	-0.44	-0.34	Pubertal anthropometrics;	chr6:28229827	chr6:28319660~28319852:-
LGG	cis	rs1150668	0.768	rs1233713	ENSG00000270326.1	RP5-874C20.6	-7.94	1.43e-14	5.65e-12	-0.44	-0.34	Pubertal anthropometrics;	chr6:28230503	chr6:28319660~28319852:-
LGG	cis	rs10246939	0.543	rs7786202	ENSG00000261570.1	RP11-744I24.2	-7.94	1.43e-14	5.65e-12	-0.45	-0.34	Bitter taste perception;	chr7:141906099	chr7:141529203~141551304:-
LGG	cis	rs1930961	1	rs7285549	ENSG00000272942.1	CTA-246H3.12	-7.94	1.44e-14	5.65e-12	-0.52	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25434324~25435070:-
LGG	cis	rs2638953	0.924	rs11049475	ENSG00000278733.1	RP11-425D17.1	-7.94	1.44e-14	5.66e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs3782517	ENSG00000278733.1	RP11-425D17.1	-7.94	1.44e-14	5.67e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310254	chr12:28185625~28186190:-
LGG	cis	rs1061377	0.513	rs2566163	ENSG00000249685.1	RP11-360F5.3	7.94	1.44e-14	5.67e-12	0.48	0.34	Uric acid levels;	chr4:39128345	chr4:39133913~39135608:+
LGG	cis	rs7709377	0.723	rs4921068	ENSG00000212457.1	RNU6-644P	-7.94	1.44e-14	5.68e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116176090	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.68	rs4921069	ENSG00000212457.1	RNU6-644P	-7.94	1.44e-14	5.68e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116176173	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs4921072	ENSG00000212457.1	RNU6-644P	-7.94	1.44e-14	5.68e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116176365	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs1396484	ENSG00000212457.1	RNU6-644P	-7.94	1.44e-14	5.68e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116176499	chr5:116188455~116188552:-
LGG	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	7.94	1.44e-14	5.68e-12	0.36	0.34	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
LGG	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-7.94	1.44e-14	5.68e-12	-0.45	-0.34	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
LGG	cis	rs853679	0.506	rs1150711	ENSG00000270326.1	RP5-874C20.6	-7.94	1.44e-14	5.68e-12	-0.46	-0.34	Depression;	chr6:28240757	chr6:28319660~28319852:-
LGG	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-7.94	1.45e-14	5.69e-12	-0.36	-0.34	Height;	chr2:231543307	chr2:231508426~231514339:-
LGG	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	7.94	1.45e-14	5.69e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
LGG	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	7.94	1.45e-14	5.69e-12	0.41	0.34	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
LGG	cis	rs4568518	0.53	rs10226084	ENSG00000279048.1	RP11-511H23.2	7.94	1.45e-14	5.7e-12	0.3	0.34	Measles;	chr7:17957989	chr7:17940503~17942922:+
LGG	cis	rs2638953	0.962	rs11049485	ENSG00000278733.1	RP11-425D17.1	-7.94	1.45e-14	5.7e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28185625~28186190:-
LGG	cis	rs8180040	0.932	rs62248599	ENSG00000271161.1	BOLA2P2	-7.94	1.45e-14	5.71e-12	-0.32	-0.34	Colorectal cancer;	chr3:47475238	chr3:47499841~47500407:+
LGG	cis	rs8180040	0.966	rs59586735	ENSG00000271161.1	BOLA2P2	-7.94	1.45e-14	5.71e-12	-0.32	-0.34	Colorectal cancer;	chr3:47476835	chr3:47499841~47500407:+
LGG	cis	rs11098499	0.82	rs11737395	ENSG00000250412.1	KLHL2P1	7.94	1.46e-14	5.73e-12	0.39	0.34	Corneal astigmatism;	chr4:119599549	chr4:119334329~119378233:+
LGG	cis	rs36715	1	rs2617621	ENSG00000245937.6	LINC01184	7.94	1.46e-14	5.73e-12	0.41	0.34	Breast cancer;	chr5:128210574	chr5:127940426~128083172:-
LGG	cis	rs853679	1	rs853685	ENSG00000226314.6	ZNF192P1	7.94	1.46e-14	5.74e-12	0.47	0.34	Depression;	chr6:28321008	chr6:28161781~28169594:+
LGG	cis	rs7219021	0.674	rs9904761	ENSG00000248278.1	SUMO2P17	-7.94	1.46e-14	5.75e-12	-0.41	-0.34	Schizophrenia or bipolar disorder;	chr17:48879468	chr17:48874860~48908983:-
LGG	cis	rs8005677	0.649	rs11629120	ENSG00000279656.1	RP11-298I3.6	-7.94	1.46e-14	5.76e-12	-0.43	-0.34	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:23023083~23024217:-
LGG	cis	rs1275468	0.954	rs1148002	ENSG00000257497.2	RP11-585P4.5	7.94	1.46e-14	5.76e-12	0.44	0.34	Polycystic ovary syndrome;	chr12:75539244	chr12:75483454~75489820:-
LGG	cis	rs11992162	0.967	rs4840601	ENSG00000255556.2	RP11-351I21.6	7.94	1.46e-14	5.76e-12	0.41	0.34	Monocyte count;	chr8:11971221	chr8:12378679~12380265:-
LGG	cis	rs1185460	1	rs1784305	ENSG00000272186.1	RP11-110I1.13	-7.94	1.46e-14	5.76e-12	-0.33	-0.34	Coronary artery disease;	chr11:119071338	chr11:119067374~119067698:-
LGG	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	7.94	1.47e-14	5.79e-12	0.44	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
LGG	cis	rs858239	0.698	rs858295	ENSG00000230042.1	AK3P3	-7.94	1.47e-14	5.79e-12	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23129178~23129841:+
LGG	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	7.94	1.47e-14	5.79e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
LGG	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	7.94	1.47e-14	5.8e-12	0.53	0.34	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
LGG	cis	rs2877649	0.51	rs17103735	ENSG00000258744.1	RP11-80A15.1	-7.94	1.48e-14	5.81e-12	-0.8	-0.34	Smooth-surface caries;	chr14:24436961	chr14:24501594~24508688:+
LGG	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	7.94	1.48e-14	5.81e-12	0.33	0.34	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
LGG	cis	rs1707322	1	rs785504	ENSG00000281133.1	AL355480.3	7.94	1.48e-14	5.82e-12	0.43	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45580892~45580996:-
LGG	cis	rs227275	0.525	rs223332	ENSG00000248971.2	KRT8P46	-7.94	1.48e-14	5.83e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102728746~102730171:-
LGG	cis	rs897984	0.609	rs72800847	ENSG00000260911.2	RP11-196G11.2	7.94	1.48e-14	5.84e-12	0.25	0.34	Dementia with Lewy bodies;	chr16:31011318	chr16:31043150~31049868:+
LGG	cis	rs2797160	1	rs6934435	ENSG00000237742.5	RP11-624M8.1	7.94	1.48e-14	5.84e-12	0.31	0.34	Endometrial cancer;	chr6:125696335	chr6:125578558~125749190:-
LGG	cis	rs11098499	0.908	rs71614449	ENSG00000250412.1	KLHL2P1	7.94	1.49e-14	5.84e-12	0.4	0.34	Corneal astigmatism;	chr4:119465900	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs35063680	ENSG00000250412.1	KLHL2P1	7.94	1.49e-14	5.84e-12	0.4	0.34	Corneal astigmatism;	chr4:119465947	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.954	rs34858317	ENSG00000250412.1	KLHL2P1	7.94	1.49e-14	5.84e-12	0.4	0.34	Corneal astigmatism;	chr4:119465955	chr4:119334329~119378233:+
LGG	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	-7.94	1.49e-14	5.85e-12	-0.37	-0.34	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
LGG	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-7.94	1.49e-14	5.86e-12	-0.53	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
LGG	cis	rs12935418	0.616	rs62054213	ENSG00000260213.4	RP11-303E16.3	-7.94	1.49e-14	5.87e-12	-0.46	-0.34	Mean corpuscular volume;	chr16:80934306	chr16:81016792~81035759:-
LGG	cis	rs2638953	0.924	rs11049610	ENSG00000278733.1	RP11-425D17.1	-7.94	1.49e-14	5.87e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28446674	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049611	ENSG00000278733.1	RP11-425D17.1	-7.94	1.49e-14	5.87e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28447311	chr12:28185625~28186190:-
LGG	cis	rs494003	1	rs12287832	ENSG00000255120.4	OVOL1-AS1	-7.94	1.49e-14	5.87e-12	-0.52	-0.34	Systemic lupus erythematosus;	chr11:65786021	chr11:65789051~65790868:-
LGG	cis	rs10246939	0.505	rs34726057	ENSG00000261570.1	RP11-744I24.2	-7.94	1.5e-14	5.88e-12	-0.42	-0.34	Bitter taste perception;	chr7:141832117	chr7:141529203~141551304:-
LGG	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	7.94	1.5e-14	5.88e-12	0.32	0.34	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
LGG	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-7.94	1.5e-14	5.9e-12	-0.41	-0.34	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
LGG	cis	rs8180040	0.966	rs11716763	ENSG00000271161.1	BOLA2P2	-7.94	1.5e-14	5.9e-12	-0.32	-0.34	Colorectal cancer;	chr3:47476776	chr3:47499841~47500407:+
LGG	cis	rs7709377	0.723	rs10057200	ENSG00000212457.1	RNU6-644P	-7.94	1.5e-14	5.91e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116127940	chr5:116188455~116188552:-
LGG	cis	rs10246939	0.505	rs10952508	ENSG00000261797.1	RP11-744I24.3	-7.94	1.5e-14	5.92e-12	-0.41	-0.34	Bitter taste perception;	chr7:141879415	chr7:141512698~141513183:-
LGG	cis	rs763567	0.817	rs598993	ENSG00000271811.1	RP1-79C4.4	7.94	1.51e-14	5.92e-12	0.33	0.34	Tonsillectomy;	chr1:170634981	chr1:170667381~170669425:+
LGG	cis	rs763567	0.935	rs541557	ENSG00000271811.1	RP1-79C4.4	7.94	1.51e-14	5.92e-12	0.33	0.34	Tonsillectomy;	chr1:170635797	chr1:170667381~170669425:+
LGG	cis	rs7208859	0.573	rs11656121	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11650973	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs73263788	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs56085216	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs12949860	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs11650305	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs11654914	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9914271	ENSG00000266490.1	CTD-2349P21.9	7.94	1.51e-14	5.93e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30792372~30792833:+
LGG	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-7.94	1.51e-14	5.94e-12	-0.35	-0.34	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
LGG	cis	rs758324	0.732	rs152051	ENSG00000233006.5	AC034220.3	-7.94	1.51e-14	5.95e-12	-0.41	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132203332	chr5:132311285~132369916:-
LGG	cis	rs11992186	0.597	rs11781841	ENSG00000253893.2	FAM85B	7.94	1.52e-14	5.96e-12	0.43	0.34	Neuroticism;	chr8:8737753	chr8:8167819~8226614:-
LGG	cis	rs13256369	0.511	rs7012395	ENSG00000173295.6	FAM86B3P	7.94	1.52e-14	5.97e-12	0.38	0.34	Obesity-related traits;	chr8:8680499	chr8:8228595~8244865:+
LGG	cis	rs7709377	0.723	rs12515182	ENSG00000212457.1	RNU6-644P	-7.94	1.52e-14	5.97e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116114296	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs12515280	ENSG00000212457.1	RNU6-644P	-7.94	1.52e-14	5.97e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116114604	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs1876672	ENSG00000212457.1	RNU6-644P	-7.94	1.52e-14	5.97e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116114960	chr5:116188455~116188552:-
LGG	cis	rs758324	0.645	rs754127	ENSG00000233006.5	AC034220.3	-7.94	1.52e-14	5.98e-12	-0.4	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132180037	chr5:132311285~132369916:-
LGG	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-7.94	1.52e-14	5.98e-12	-0.5	-0.34	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
LGG	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	7.94	1.52e-14	5.99e-12	0.42	0.34	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
LGG	cis	rs1555322	0.53	rs8122819	ENSG00000269202.1	RP4-614O4.12	-7.94	1.53e-14	5.99e-12	-0.37	-0.34	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35201747~35203288:-
LGG	cis	rs73222236	0.737	rs9854328	ENSG00000261758.1	RP11-102M11.2	-7.94	1.53e-14	6e-12	-0.38	-0.34	Coronary artery disease;	chr3:136350878	chr3:136752630~136755780:+
LGG	cis	rs8180040	0.966	rs11130128	ENSG00000271161.1	BOLA2P2	-7.94	1.53e-14	6.01e-12	-0.32	-0.34	Colorectal cancer;	chr3:47445142	chr3:47499841~47500407:+
LGG	cis	rs8180040	0.966	rs2101247	ENSG00000271161.1	BOLA2P2	-7.94	1.53e-14	6.01e-12	-0.32	-0.34	Colorectal cancer;	chr3:47452813	chr3:47499841~47500407:+
LGG	cis	rs8180040	0.966	rs6792488	ENSG00000271161.1	BOLA2P2	-7.94	1.53e-14	6.01e-12	-0.32	-0.34	Colorectal cancer;	chr3:47461859	chr3:47499841~47500407:+
LGG	cis	rs7208859	0.673	rs75142521	ENSG00000266490.1	CTD-2349P21.9	7.93	1.53e-14	6.02e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30792372~30792833:+
LGG	cis	rs10246939	0.543	rs10952509	ENSG00000261570.1	RP11-744I24.2	-7.93	1.53e-14	6.02e-12	-0.44	-0.34	Bitter taste perception;	chr7:141890884	chr7:141529203~141551304:-
LGG	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-7.93	1.54e-14	6.04e-12	-0.4	-0.34	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-7.93	1.54e-14	6.04e-12	-0.4	-0.34	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-7.93	1.54e-14	6.04e-12	-0.4	-0.34	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	7.93	1.54e-14	6.04e-12	0.4	0.34	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	7.93	1.54e-14	6.04e-12	0.4	0.34	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	7.93	1.54e-14	6.04e-12	0.4	0.34	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	7.93	1.54e-14	6.04e-12	0.4	0.34	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
LGG	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-7.93	1.54e-14	6.04e-12	-0.3	-0.34	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
LGG	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	7.93	1.54e-14	6.04e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
LGG	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	7.93	1.54e-14	6.04e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
LGG	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	7.93	1.54e-14	6.04e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
LGG	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	7.93	1.54e-14	6.04e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
LGG	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	7.93	1.54e-14	6.04e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
LGG	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	7.93	1.54e-14	6.04e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
LGG	cis	rs11723261	0.664	rs4627799	ENSG00000211553.1	AC253576.2	-7.93	1.54e-14	6.04e-12	-0.5	-0.34	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:136461~136568:+
LGG	cis	rs7208859	0.614	rs73265646	ENSG00000266490.1	CTD-2349P21.9	7.93	1.54e-14	6.05e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs58908911	ENSG00000266490.1	CTD-2349P21.9	7.93	1.54e-14	6.05e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30792372~30792833:+
LGG	cis	rs4568518	0.53	rs10269921	ENSG00000279048.1	RP11-511H23.2	7.93	1.54e-14	6.07e-12	0.3	0.34	Measles;	chr7:17958317	chr7:17940503~17942922:+
LGG	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-7.93	1.55e-14	6.07e-12	-0.38	-0.34	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
LGG	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	7.93	1.55e-14	6.08e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
LGG	cis	rs2638953	0.962	rs11049537	ENSG00000278733.1	RP11-425D17.1	-7.93	1.55e-14	6.09e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28331239	chr12:28185625~28186190:-
LGG	cis	rs7709377	0.723	rs61334805	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116178571	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs9687350	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116183319	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs9686231	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116183595	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10054966	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116184499	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7734614	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116184765	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs11954350	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116185644	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs4484468	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116186114	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs6866514	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116186476	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs9686686	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116186836	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs7718483	ENSG00000212457.1	RNU6-644P	-7.93	1.55e-14	6.09e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116188869	chr5:116188455~116188552:-
LGG	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-7.93	1.56e-14	6.11e-12	-0.39	-0.34	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
LGG	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-7.93	1.56e-14	6.12e-12	-0.46	-0.34	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
LGG	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	7.93	1.56e-14	6.13e-12	0.33	0.34	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
LGG	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-7.93	1.56e-14	6.13e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-7.93	1.56e-14	6.13e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-7.93	1.56e-14	6.13e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-7.93	1.56e-14	6.13e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-7.93	1.56e-14	6.13e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-7.93	1.56e-14	6.13e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
LGG	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-7.93	1.56e-14	6.13e-12	-0.4	-0.34	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
LGG	cis	rs2638953	0.924	rs11524516	ENSG00000278733.1	RP11-425D17.1	-7.93	1.56e-14	6.13e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209517	chr12:28185625~28186190:-
LGG	cis	rs227275	0.554	rs223316	ENSG00000248971.2	KRT8P46	-7.93	1.56e-14	6.14e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102728746~102730171:-
LGG	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-7.93	1.57e-14	6.14e-12	-0.3	-0.34	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
LGG	cis	rs9719620	0.802	rs4731784	ENSG00000236753.4	MKLN1-AS	-7.93	1.57e-14	6.15e-12	-0.35	-0.34	Male-pattern baldness;	chr7:131301022	chr7:131309744~131328222:-
LGG	cis	rs9719620	0.834	rs4731785	ENSG00000236753.4	MKLN1-AS	-7.93	1.57e-14	6.15e-12	-0.35	-0.34	Male-pattern baldness;	chr7:131301050	chr7:131309744~131328222:-
LGG	cis	rs10246939	0.505	rs892354	ENSG00000261570.1	RP11-744I24.2	-7.93	1.57e-14	6.15e-12	-0.43	-0.34	Bitter taste perception;	chr7:141844934	chr7:141529203~141551304:-
LGG	cis	rs1552244	0.882	rs13100734	ENSG00000180385.7	EMC3-AS1	7.93	1.57e-14	6.16e-12	0.38	0.34	Alzheimer's disease;	chr3:9981194	chr3:9986893~10006990:+
LGG	cis	rs758324	0.687	rs185616	ENSG00000233006.5	AC034220.3	-7.93	1.57e-14	6.17e-12	-0.41	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132208073	chr5:132311285~132369916:-
LGG	cis	rs600231	0.571	rs10896000	ENSG00000245532.5	NEAT1	7.93	1.57e-14	6.17e-12	0.23	0.34	Bone mineral density;	chr11:65450547	chr11:65422774~65445540:+
LGG	cis	rs12699921	0.933	rs6942635	ENSG00000279048.1	RP11-511H23.2	7.93	1.57e-14	6.17e-12	0.3	0.34	Fibrinogen levels;	chr7:17948242	chr7:17940503~17942922:+
LGG	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-7.93	1.58e-14	6.19e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
LGG	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	7.93	1.58e-14	6.19e-12	0.3	0.34	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
LGG	cis	rs10435719	0.902	rs6601633	ENSG00000255556.2	RP11-351I21.6	-7.93	1.58e-14	6.19e-12	-0.42	-0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:12378679~12380265:-
LGG	cis	rs1150668	0.799	rs2142730	ENSG00000270326.1	RP5-874C20.6	-7.93	1.58e-14	6.19e-12	-0.44	-0.34	Pubertal anthropometrics;	chr6:28298372	chr6:28319660~28319852:-
LGG	cis	rs8062405	0.54	rs193628	ENSG00000251417.2	RP11-1348G14.4	7.93	1.58e-14	6.19e-12	0.38	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28570821	chr16:28802743~28817828:+
LGG	cis	rs1408799	0.732	rs7035500	ENSG00000235448.1	LURAP1L-AS1	7.93	1.58e-14	6.21e-12	0.34	0.34	Eye color;Blue vs. green eyes;	chr9:12750096	chr9:12700100~12814345:-
LGG	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	7.93	1.59e-14	6.22e-12	0.45	0.34	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
LGG	cis	rs10246939	0.543	rs11765106	ENSG00000261797.1	RP11-744I24.3	-7.93	1.59e-14	6.22e-12	-0.42	-0.34	Bitter taste perception;	chr7:141902676	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.543	rs11767947	ENSG00000261797.1	RP11-744I24.3	-7.93	1.59e-14	6.22e-12	-0.42	-0.34	Bitter taste perception;	chr7:141912821	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.543	rs11765974	ENSG00000261797.1	RP11-744I24.3	-7.93	1.59e-14	6.22e-12	-0.42	-0.34	Bitter taste perception;	chr7:141914390	chr7:141512698~141513183:-
LGG	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	7.93	1.59e-14	6.22e-12	0.31	0.34	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
LGG	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	7.93	1.6e-14	6.26e-12	0.38	0.34	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
LGG	cis	rs950169	0.65	rs12902052	ENSG00000259295.5	CSPG4P12	7.93	1.6e-14	6.26e-12	0.48	0.34	Schizophrenia;	chr15:84582607	chr15:85191438~85213905:+
LGG	cis	rs2292342	1	rs11880333	ENSG00000232871.7	SEC1P	-7.93	1.6e-14	6.26e-12	-0.55	-0.34	Elevated serum carcinoembryonic antigen levels;	chr19:48641533	chr19:48638071~48682245:+
LGG	cis	rs11096990	0.964	rs6842390	ENSG00000249685.1	RP11-360F5.3	-7.93	1.6e-14	6.26e-12	-0.42	-0.34	Cognitive function;	chr4:39261862	chr4:39133913~39135608:+
LGG	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	7.93	1.6e-14	6.27e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
LGG	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	7.93	1.6e-14	6.27e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
LGG	cis	rs35857674	0.731	rs9298278	ENSG00000253484.1	RP11-109P6.2	7.93	1.6e-14	6.27e-12	0.34	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50159453	chr8:49817586~49820944:-
LGG	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-7.93	1.6e-14	6.28e-12	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
LGG	cis	rs440932	1	rs365309	ENSG00000173295.6	FAM86B3P	7.93	1.6e-14	6.28e-12	0.39	0.34	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8228595~8244865:+
LGG	cis	rs2638953	0.752	rs11049571	ENSG00000278733.1	RP11-425D17.1	-7.93	1.6e-14	6.29e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390939	chr12:28185625~28186190:-
LGG	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-7.93	1.6e-14	6.29e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
LGG	cis	rs2638953	0.962	rs11049585	ENSG00000278733.1	RP11-425D17.1	-7.93	1.61e-14	6.29e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417957	chr12:28185625~28186190:-
LGG	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-7.93	1.61e-14	6.3e-12	-0.45	-0.34	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
LGG	cis	rs853679	1	rs2799079	ENSG00000226314.6	ZNF192P1	7.93	1.61e-14	6.3e-12	0.47	0.34	Depression;	chr6:28267398	chr6:28161781~28169594:+
LGG	cis	rs4713118	0.506	rs9366697	ENSG00000216901.1	AL022393.7	7.93	1.61e-14	6.3e-12	0.41	0.34	Parkinson's disease;	chr6:27665239	chr6:28176188~28176674:+
LGG	cis	rs9532669	0.963	rs9315794	ENSG00000239827.7	SUGT1P3	-7.93	1.61e-14	6.31e-12	-0.35	-0.34	Cervical cancer;	chr13:40939489	chr13:40908159~40921774:-
LGG	cis	rs4713118	0.868	rs35069907	ENSG00000226314.6	ZNF192P1	7.93	1.61e-14	6.31e-12	0.39	0.34	Parkinson's disease;	chr6:27778913	chr6:28161781~28169594:+
LGG	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-7.93	1.61e-14	6.31e-12	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
LGG	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	7.93	1.61e-14	6.32e-12	0.48	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
LGG	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-7.93	1.61e-14	6.33e-12	-0.44	-0.34	Migraine;	chr4:56853383	chr4:56960927~56961373:-
LGG	cis	rs10181042	0.612	rs1177282	ENSG00000273302.1	RP11-493E12.2	7.93	1.62e-14	6.33e-12	0.31	0.34	Crohn's disease;	chr2:61130642	chr2:61199979~61200769:+
LGG	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-7.93	1.62e-14	6.34e-12	-0.3	-0.34	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
LGG	cis	rs227275	0.525	rs17215211	ENSG00000248971.2	KRT8P46	-7.93	1.62e-14	6.34e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102728746~102730171:-
LGG	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	7.93	1.62e-14	6.35e-12	0.35	0.34	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
LGG	cis	rs10246939	0.543	rs7802271	ENSG00000261797.1	RP11-744I24.3	-7.93	1.62e-14	6.35e-12	-0.42	-0.34	Bitter taste perception;	chr7:141909624	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.52	rs7782886	ENSG00000261797.1	RP11-744I24.3	-7.93	1.62e-14	6.35e-12	-0.42	-0.34	Bitter taste perception;	chr7:141909958	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.543	rs994808	ENSG00000261797.1	RP11-744I24.3	-7.93	1.62e-14	6.35e-12	-0.42	-0.34	Bitter taste perception;	chr7:141911091	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.543	rs7808421	ENSG00000261797.1	RP11-744I24.3	-7.93	1.62e-14	6.35e-12	-0.42	-0.34	Bitter taste perception;	chr7:141911592	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.543	rs7789123	ENSG00000261797.1	RP11-744I24.3	-7.93	1.62e-14	6.35e-12	-0.42	-0.34	Bitter taste perception;	chr7:141911699	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.543	rs11767119	ENSG00000261797.1	RP11-744I24.3	-7.93	1.62e-14	6.35e-12	-0.42	-0.34	Bitter taste perception;	chr7:141912316	chr7:141512698~141513183:-
LGG	cis	rs10246939	0.543	rs11769089	ENSG00000261797.1	RP11-744I24.3	-7.93	1.62e-14	6.35e-12	-0.42	-0.34	Bitter taste perception;	chr7:141914310	chr7:141512698~141513183:-
LGG	cis	rs9532669	0.89	rs2149570	ENSG00000168852.11	TPTE2P5	7.93	1.62e-14	6.35e-12	0.36	0.34	Cervical cancer;	chr13:40858533	chr13:40822296~40921749:-
LGG	cis	rs1908814	0.504	rs7830734	ENSG00000255556.2	RP11-351I21.6	7.93	1.63e-14	6.37e-12	0.43	0.34	Neuroticism;	chr8:11938130	chr8:12378679~12380265:-
LGG	cis	rs11098499	0.863	rs1010740	ENSG00000250412.1	KLHL2P1	-7.93	1.63e-14	6.37e-12	-0.39	-0.34	Corneal astigmatism;	chr4:119542254	chr4:119334329~119378233:+
LGG	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	7.93	1.63e-14	6.37e-12	0.69	0.34	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
LGG	cis	rs1949733	0.816	rs2631746	ENSG00000205959.3	RP11-689P11.2	7.93	1.63e-14	6.38e-12	0.3	0.34	Response to antineoplastic agents;	chr4:8489207	chr4:8482270~8512610:+
LGG	cis	rs12893668	0.572	rs4900591	ENSG00000269940.1	RP11-73M18.7	7.93	1.63e-14	6.38e-12	0.39	0.34	Reticulocyte count;	chr14:103688541	chr14:103694560~103695170:+
LGG	cis	rs934734	0.673	rs7575614	ENSG00000204929.10	AC074391.1	7.93	1.63e-14	6.39e-12	0.33	0.34	Rheumatoid arthritis;	chr2:65462666	chr2:65436711~66084639:+
LGG	cis	rs934734	0.673	rs6742215	ENSG00000204929.10	AC074391.1	7.93	1.63e-14	6.39e-12	0.33	0.34	Rheumatoid arthritis;	chr2:65463362	chr2:65436711~66084639:+
LGG	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-7.93	1.63e-14	6.39e-12	-0.35	-0.34	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
LGG	cis	rs4143844	0.867	rs17271312	ENSG00000259251.2	RP11-643M14.1	7.93	1.63e-14	6.39e-12	0.54	0.34	Bipolar disorder and schizophrenia;	chr15:62044080	chr15:62060503~62062434:+
LGG	cis	rs4143844	1	rs34311301	ENSG00000259251.2	RP11-643M14.1	7.93	1.63e-14	6.39e-12	0.54	0.34	Bipolar disorder and schizophrenia;	chr15:62050356	chr15:62060503~62062434:+
LGG	cis	rs2797160	0.904	rs1777198	ENSG00000237742.5	RP11-624M8.1	7.93	1.63e-14	6.4e-12	0.31	0.34	Endometrial cancer;	chr6:125686270	chr6:125578558~125749190:-
LGG	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-7.93	1.63e-14	6.4e-12	-0.44	-0.34	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
LGG	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	7.93	1.63e-14	6.4e-12	0.48	0.34	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
LGG	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-7.93	1.64e-14	6.4e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
LGG	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-7.93	1.64e-14	6.41e-12	-0.41	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
LGG	cis	rs228614	0.51	rs223470	ENSG00000248971.2	KRT8P46	-7.93	1.64e-14	6.42e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223468	ENSG00000248971.2	KRT8P46	-7.93	1.64e-14	6.42e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223465	ENSG00000248971.2	KRT8P46	-7.93	1.64e-14	6.42e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223464	ENSG00000248971.2	KRT8P46	-7.93	1.64e-14	6.42e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102728746~102730171:-
LGG	cis	rs4714902	0.571	rs5011271	ENSG00000231769.2	RP1-8B1.4	-7.93	1.64e-14	6.42e-12	-0.36	-0.34	Colonoscopy-negative controls vs population controls;	chr6:46174702	chr6:46097093~46129706:-
LGG	cis	rs1707322	1	rs11211190	ENSG00000281133.1	AL355480.3	-7.92	1.65e-14	6.45e-12	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45580892~45580996:-
LGG	cis	rs1707322	1	rs6429580	ENSG00000281133.1	AL355480.3	-7.92	1.65e-14	6.45e-12	-0.41	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45580892~45580996:-
LGG	cis	rs2638953	0.962	rs61922979	ENSG00000278733.1	RP11-425D17.1	-7.92	1.65e-14	6.46e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301218	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049517	ENSG00000278733.1	RP11-425D17.1	-7.92	1.65e-14	6.46e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301627	chr12:28185625~28186190:-
LGG	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	7.92	1.65e-14	6.47e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
LGG	cis	rs4143844	1	rs62007448	ENSG00000259251.2	RP11-643M14.1	7.92	1.65e-14	6.47e-12	0.55	0.34	Bipolar disorder and schizophrenia;	chr15:62036971	chr15:62060503~62062434:+
LGG	cis	rs4143844	1	rs11634312	ENSG00000259251.2	RP11-643M14.1	7.92	1.65e-14	6.47e-12	0.55	0.34	Bipolar disorder and schizophrenia;	chr15:62038868	chr15:62060503~62062434:+
LGG	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	7.92	1.65e-14	6.47e-12	0.4	0.34	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
LGG	cis	rs858239	0.899	rs28458177	ENSG00000230042.1	AK3P3	-7.92	1.65e-14	6.48e-12	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23129178~23129841:+
LGG	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	7.92	1.66e-14	6.48e-12	0.38	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
LGG	cis	rs11098499	0.954	rs13107475	ENSG00000250412.1	KLHL2P1	7.92	1.66e-14	6.48e-12	0.39	0.34	Corneal astigmatism;	chr4:119471856	chr4:119334329~119378233:+
LGG	cis	rs904251	0.523	rs914348	ENSG00000279942.1	RP1-153P14.7	-7.92	1.66e-14	6.49e-12	-0.37	-0.34	Cognitive performance;	chr6:37516953	chr6:37567716~37571460:+
LGG	cis	rs477895	0.838	rs11607007	ENSG00000257086.1	RP11-783K16.13	7.92	1.66e-14	6.49e-12	0.43	0.34	Mean platelet volume;	chr11:64240504	chr11:64246939~64249494:-
LGG	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	7.92	1.66e-14	6.49e-12	0.35	0.34	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
LGG	cis	rs7208859	0.673	rs11656462	ENSG00000266490.1	CTD-2349P21.9	7.92	1.66e-14	6.49e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs11654331	ENSG00000266490.1	CTD-2349P21.9	7.92	1.66e-14	6.49e-12	0.42	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30792372~30792833:+
LGG	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-7.92	1.66e-14	6.49e-12	-0.46	-0.34	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
LGG	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-7.92	1.66e-14	6.51e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
LGG	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-7.92	1.66e-14	6.51e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
LGG	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-7.92	1.66e-14	6.51e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
LGG	cis	rs4714902	0.655	rs7754915	ENSG00000231769.2	RP1-8B1.4	-7.92	1.66e-14	6.51e-12	-0.38	-0.34	Colonoscopy-negative controls vs population controls;	chr6:46129832	chr6:46097093~46129706:-
LGG	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	7.92	1.67e-14	6.53e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
LGG	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	7.92	1.67e-14	6.53e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
LGG	cis	rs2638953	0.925	rs11049491	ENSG00000278733.1	RP11-425D17.1	-7.92	1.67e-14	6.54e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049493	ENSG00000278733.1	RP11-425D17.1	-7.92	1.67e-14	6.54e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049496	ENSG00000278733.1	RP11-425D17.1	-7.92	1.67e-14	6.54e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.889	rs2045887	ENSG00000278733.1	RP11-425D17.1	-7.92	1.67e-14	6.54e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28185625~28186190:-
LGG	cis	rs4950322	0.58	rs7515160	ENSG00000278811.3	LINC00624	7.92	1.67e-14	6.54e-12	0.32	0.34	Protein quantitative trait loci;	chr1:147120714	chr1:147258885~147517875:-
LGG	cis	rs5760092	0.618	rs5996631	ENSG00000235689.1	AP000351.13	-7.92	1.67e-14	6.54e-12	-0.46	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:24006305~24008258:-
LGG	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-7.92	1.67e-14	6.55e-12	-0.41	-0.34	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
LGG	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-7.92	1.67e-14	6.55e-12	-0.41	-0.34	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
LGG	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-7.92	1.67e-14	6.55e-12	-0.41	-0.34	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
LGG	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-7.92	1.67e-14	6.55e-12	-0.41	-0.34	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
LGG	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-7.92	1.67e-14	6.55e-12	-0.41	-0.34	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
LGG	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-7.92	1.68e-14	6.56e-12	-0.71	-0.34	Gout;	chr7:66645053	chr7:66654538~66669855:+
LGG	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	7.92	1.68e-14	6.56e-12	0.39	0.34	Height;	chr6:109391084	chr6:109382795~109383666:+
LGG	cis	rs2638953	0.925	rs11049545	ENSG00000278733.1	RP11-425D17.1	-7.92	1.68e-14	6.56e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28344965	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049547	ENSG00000278733.1	RP11-425D17.1	-7.92	1.68e-14	6.56e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346945	chr12:28185625~28186190:-
LGG	cis	rs35934224	0.783	rs56291622	ENSG00000232926.1	AC000078.5	7.92	1.68e-14	6.57e-12	0.38	0.34	Glaucoma (primary open-angle);	chr22:19871211	chr22:19887289~19887970:+
LGG	cis	rs3096299	0.702	rs2086824	ENSG00000274627.1	RP11-104N10.2	-7.92	1.68e-14	6.57e-12	-0.29	-0.34	Multiple myeloma (IgH translocation);	chr16:89404838	chr16:89516797~89522217:+
LGG	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	-7.92	1.68e-14	6.59e-12	-0.36	-0.34	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
LGG	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-7.92	1.69e-14	6.6e-12	-0.52	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
LGG	cis	rs9494145	0.531	rs9399136	ENSG00000232876.1	CTA-212D2.2	-7.92	1.69e-14	6.6e-12	-0.52	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135081201	chr6:135055033~135060550:+
LGG	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	7.92	1.69e-14	6.61e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
LGG	cis	rs7824557	0.628	rs2572387	ENSG00000184608.7	FAM167A-AS1	-7.92	1.69e-14	6.62e-12	-0.28	-0.34	Retinal vascular caliber;	chr8:11346656	chr8:11368402~11438658:+
LGG	cis	rs454217	0.846	rs337661	ENSG00000277851.1	RP11-756G20.1	7.92	1.7e-14	6.63e-12	0.35	0.34	Smoking quantity;	chr12:92310960	chr12:92247756~92363832:-
LGG	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	7.92	1.7e-14	6.63e-12	0.43	0.34	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
LGG	cis	rs66887589	0.616	rs13113885	ENSG00000249244.1	RP11-548H18.2	7.92	1.7e-14	6.64e-12	0.35	0.34	Diastolic blood pressure;	chr4:119300021	chr4:119391831~119395335:-
LGG	cis	rs10435719	0.834	rs6985792	ENSG00000255556.2	RP11-351I21.6	7.92	1.7e-14	6.64e-12	0.43	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:12378679~12380265:-
LGG	cis	rs10435719	0.902	rs7459545	ENSG00000255556.2	RP11-351I21.6	7.92	1.7e-14	6.66e-12	0.42	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:12378679~12380265:-
LGG	cis	rs10435719	0.902	rs7006538	ENSG00000255556.2	RP11-351I21.6	7.92	1.7e-14	6.66e-12	0.42	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:12378679~12380265:-
LGG	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	7.92	1.7e-14	6.66e-12	0.23	0.34	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
LGG	cis	rs2638953	0.962	rs10506029	ENSG00000278733.1	RP11-425D17.1	-7.92	1.7e-14	6.66e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28320302	chr12:28185625~28186190:-
LGG	cis	rs14165	0.67	rs2359133	ENSG00000271916.1	RP11-884K10.6	7.92	1.71e-14	6.67e-12	0.42	0.34	Refractive error;	chr3:53802715	chr3:53797764~53798019:-
LGG	cis	rs10246939	0.543	rs12538701	ENSG00000261570.1	RP11-744I24.2	-7.92	1.71e-14	6.67e-12	-0.44	-0.34	Bitter taste perception;	chr7:141893634	chr7:141529203~141551304:-
LGG	cis	rs17772222	0.651	rs1950280	ENSG00000258983.2	RP11-507K2.2	-7.92	1.71e-14	6.68e-12	-0.38	-0.34	Coronary artery calcification;	chr14:88366259	chr14:88499334~88515502:+
LGG	cis	rs494003	1	rs11227284	ENSG00000255120.4	OVOL1-AS1	-7.92	1.71e-14	6.68e-12	-0.51	-0.34	Systemic lupus erythematosus;	chr11:65735753	chr11:65789051~65790868:-
LGG	cis	rs494003	1	rs72922733	ENSG00000255120.4	OVOL1-AS1	-7.92	1.71e-14	6.68e-12	-0.51	-0.34	Systemic lupus erythematosus;	chr11:65753275	chr11:65789051~65790868:-
LGG	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	7.92	1.71e-14	6.69e-12	0.35	0.34	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	7.92	1.71e-14	6.69e-12	0.35	0.34	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	7.92	1.71e-14	6.69e-12	0.35	0.34	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	7.92	1.71e-14	6.69e-12	0.35	0.34	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
LGG	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	7.92	1.71e-14	6.69e-12	0.35	0.34	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
LGG	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	7.92	1.71e-14	6.69e-12	0.42	0.34	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
LGG	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	7.92	1.72e-14	6.71e-12	0.38	0.34	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
LGG	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-7.92	1.72e-14	6.72e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
LGG	cis	rs2274273	0.623	rs1187881	ENSG00000258413.1	RP11-665C16.6	7.92	1.72e-14	6.73e-12	0.44	0.34	Protein biomarker;	chr14:55022479	chr14:55262767~55272075:-
LGG	cis	rs34375054	0.66	rs35941060	ENSG00000279233.1	RP11-158L12.4	7.92	1.72e-14	6.73e-12	0.35	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125109699	chr12:125138245~125141711:+
LGG	cis	rs4718428	0.576	rs12698546	ENSG00000273142.1	RP11-458F8.4	-7.92	1.73e-14	6.75e-12	-0.29	-0.34	Corneal structure;	chr7:66801919	chr7:66902857~66906297:+
LGG	cis	rs2638953	0.924	rs11049403	ENSG00000278733.1	RP11-425D17.1	-7.92	1.73e-14	6.76e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28177105	chr12:28185625~28186190:-
LGG	cis	rs1023500	0.552	rs133368	ENSG00000227370.1	RP4-669P10.19	7.92	1.73e-14	6.76e-12	0.3	0.34	Schizophrenia;	chr22:42067685	chr22:42132543~42132998:+
LGG	cis	rs2638953	0.853	rs1355474	ENSG00000278733.1	RP11-425D17.1	-7.92	1.74e-14	6.79e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463599	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs1355473	ENSG00000278733.1	RP11-425D17.1	-7.92	1.74e-14	6.79e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463632	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049636	ENSG00000278733.1	RP11-425D17.1	-7.92	1.74e-14	6.79e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28465728	chr12:28185625~28186190:-
LGG	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-7.92	1.74e-14	6.8e-12	-0.41	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
LGG	cis	rs597539	0.652	rs564849	ENSG00000250508.1	RP11-757G1.6	-7.92	1.74e-14	6.81e-12	-0.45	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68853972	chr11:68870664~68874542:+
LGG	cis	rs1048886	0.938	rs7742044	ENSG00000271967.1	RP11-134K13.4	-7.92	1.74e-14	6.81e-12	-0.37	-0.34	Type 2 diabetes;	chr6:70422491	chr6:70596438~70596980:+
LGG	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-7.92	1.75e-14	6.82e-12	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
LGG	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	-7.92	1.75e-14	6.83e-12	-0.49	-0.34	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
LGG	cis	rs1555322	0.505	rs639763	ENSG00000269202.1	RP4-614O4.12	-7.92	1.75e-14	6.83e-12	-0.4	-0.34	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35201747~35203288:-
LGG	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	7.92	1.75e-14	6.83e-12	0.39	0.34	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
LGG	cis	rs11096990	0.964	rs6831700	ENSG00000249685.1	RP11-360F5.3	7.92	1.75e-14	6.84e-12	0.42	0.34	Cognitive function;	chr4:39255344	chr4:39133913~39135608:+
LGG	cis	rs7160336	0.738	rs66941731	ENSG00000258586.1	RP5-1021I20.2	7.92	1.75e-14	6.84e-12	0.41	0.34	Blood protein levels;	chr14:74026538	chr14:73822559~73830135:-
LGG	cis	rs7829975	0.501	rs4840353	ENSG00000253893.2	FAM85B	7.92	1.75e-14	6.85e-12	0.43	0.34	Mood instability;	chr8:8723060	chr8:8167819~8226614:-
LGG	cis	rs763567	0.933	rs531007	ENSG00000271811.1	RP1-79C4.4	7.92	1.76e-14	6.85e-12	0.33	0.34	Tonsillectomy;	chr1:170649241	chr1:170667381~170669425:+
LGG	cis	rs7005380	0.561	rs7818471	ENSG00000245330.4	KB-1471A8.1	7.92	1.76e-14	6.86e-12	0.38	0.34	Interstitial lung disease;	chr8:119897596	chr8:119867419~119874488:-
LGG	cis	rs6908034	0.882	rs6456259	ENSG00000228412.5	RP4-625H18.2	7.92	1.76e-14	6.87e-12	0.47	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761487	chr6:19802164~19804752:-
LGG	cis	rs1555322	1	rs2425037	ENSG00000126005.14	MMP24-AS1	7.92	1.76e-14	6.87e-12	0.52	0.34	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35216462~35278131:-
LGG	cis	rs4950322	0.518	rs61838936	ENSG00000278811.3	LINC00624	7.92	1.76e-14	6.87e-12	0.33	0.34	Protein quantitative trait loci;	chr1:147098422	chr1:147258885~147517875:-
LGG	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	7.92	1.76e-14	6.87e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
LGG	cis	rs4714902	0.655	rs1048077	ENSG00000231769.2	RP1-8B1.4	7.92	1.76e-14	6.87e-12	0.38	0.34	Colonoscopy-negative controls vs population controls;	chr6:46144652	chr6:46097093~46129706:-
LGG	cis	rs3764021	0.527	rs3764022	ENSG00000256594.6	RP11-705C15.2	7.92	1.76e-14	6.88e-12	0.35	0.34	Type 1 diabetes;	chr12:9680928	chr12:9633419~9658412:+
LGG	cis	rs11098499	0.954	rs2389803	ENSG00000250412.1	KLHL2P1	-7.92	1.76e-14	6.88e-12	-0.39	-0.34	Corneal astigmatism;	chr4:119472356	chr4:119334329~119378233:+
LGG	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	7.92	1.76e-14	6.89e-12	0.42	0.34	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
LGG	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	7.91	1.77e-14	6.89e-12	0.38	0.34	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	7.91	1.77e-14	6.89e-12	0.38	0.34	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	7.91	1.77e-14	6.89e-12	0.38	0.34	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-7.91	1.77e-14	6.89e-12	-0.38	-0.34	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-7.91	1.77e-14	6.89e-12	-0.38	-0.34	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-7.91	1.77e-14	6.89e-12	-0.38	-0.34	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-7.91	1.77e-14	6.89e-12	-0.38	-0.34	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-7.91	1.77e-14	6.89e-12	-0.38	-0.34	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-7.91	1.77e-14	6.89e-12	-0.38	-0.34	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
LGG	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-7.91	1.77e-14	6.89e-12	-0.38	-0.34	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
LGG	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-7.91	1.77e-14	6.89e-12	-0.36	-0.34	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
LGG	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	7.91	1.77e-14	6.9e-12	0.35	0.34	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
LGG	cis	rs34421088	0.56	rs2618434	ENSG00000255556.2	RP11-351I21.6	-7.91	1.77e-14	6.9e-12	-0.41	-0.34	Neuroticism;	chr8:11541356	chr8:12378679~12380265:-
LGG	cis	rs34421088	0.56	rs2245357	ENSG00000255556.2	RP11-351I21.6	-7.91	1.77e-14	6.9e-12	-0.41	-0.34	Neuroticism;	chr8:11541975	chr8:12378679~12380265:-
LGG	cis	rs642803	0.527	rs1647570	ENSG00000255120.4	OVOL1-AS1	7.91	1.77e-14	6.9e-12	0.44	0.34	Urate levels;	chr11:65800785	chr11:65789051~65790868:-
LGG	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	7.91	1.77e-14	6.92e-12	0.52	0.34	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
LGG	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-7.91	1.77e-14	6.92e-12	-0.43	-0.34	Height;	chr14:75023964	chr14:75011269~75012851:-
LGG	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-7.91	1.78e-14	6.93e-12	-0.27	-0.34	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
LGG	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-7.91	1.78e-14	6.93e-12	-0.27	-0.34	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
LGG	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-7.91	1.78e-14	6.93e-12	-0.39	-0.34	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
LGG	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-7.91	1.78e-14	6.94e-12	-0.36	-0.34	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
LGG	cis	rs2638953	0.853	rs11049622	ENSG00000278733.1	RP11-425D17.1	-7.91	1.78e-14	6.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457637	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.888	rs10843177	ENSG00000278733.1	RP11-425D17.1	-7.91	1.78e-14	6.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457737	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs10771428	ENSG00000278733.1	RP11-425D17.1	-7.91	1.78e-14	6.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458070	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs10506035	ENSG00000278733.1	RP11-425D17.1	-7.91	1.78e-14	6.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458159	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.815	rs11049627	ENSG00000278733.1	RP11-425D17.1	-7.91	1.78e-14	6.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459389	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049628	ENSG00000278733.1	RP11-425D17.1	-7.91	1.78e-14	6.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459781	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs11049629	ENSG00000278733.1	RP11-425D17.1	-7.91	1.78e-14	6.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459856	chr12:28185625~28186190:-
LGG	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-7.91	1.79e-14	6.96e-12	-0.49	-0.34	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
LGG	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	7.91	1.79e-14	6.96e-12	0.36	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
LGG	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-7.91	1.79e-14	6.99e-12	-0.4	-0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
LGG	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	7.91	1.8e-14	7.01e-12	0.35	0.34	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
LGG	cis	rs35934224	0.783	rs34675706	ENSG00000232926.1	AC000078.5	7.91	1.8e-14	7.01e-12	0.37	0.34	Glaucoma (primary open-angle);	chr22:19860095	chr22:19887289~19887970:+
LGG	cis	rs35934224	0.74	rs35142928	ENSG00000232926.1	AC000078.5	7.91	1.8e-14	7.01e-12	0.37	0.34	Glaucoma (primary open-angle);	chr22:19860228	chr22:19887289~19887970:+
LGG	cis	rs1552244	0.882	rs17050699	ENSG00000180385.7	EMC3-AS1	7.91	1.8e-14	7.02e-12	0.38	0.34	Alzheimer's disease;	chr3:9995483	chr3:9986893~10006990:+
LGG	cis	rs9393777	0.547	rs2893910	ENSG00000216901.1	AL022393.7	7.91	1.8e-14	7.03e-12	0.51	0.34	Intelligence (multi-trait analysis);	chr6:27315475	chr6:28176188~28176674:+
LGG	cis	rs858239	1	rs858240	ENSG00000230042.1	AK3P3	-7.91	1.81e-14	7.04e-12	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23129178~23129841:+
LGG	cis	rs10246939	0.543	rs12538701	ENSG00000261797.1	RP11-744I24.3	-7.91	1.81e-14	7.04e-12	-0.42	-0.34	Bitter taste perception;	chr7:141893634	chr7:141512698~141513183:-
LGG	cis	rs1707322	0.896	rs809774	ENSG00000281133.1	AL355480.3	7.91	1.81e-14	7.06e-12	0.43	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45580892~45580996:-
LGG	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-7.91	1.81e-14	7.06e-12	-0.3	-0.34	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
LGG	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	7.91	1.81e-14	7.07e-12	0.47	0.34	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
LGG	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	7.91	1.81e-14	7.07e-12	0.47	0.34	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
LGG	cis	rs4143844	0.737	rs11634818	ENSG00000259251.2	RP11-643M14.1	7.91	1.82e-14	7.07e-12	0.55	0.34	Bipolar disorder and schizophrenia;	chr15:62064187	chr15:62060503~62062434:+
LGG	cis	rs5760092	0.618	rs4461358	ENSG00000235689.1	AP000351.13	-7.91	1.82e-14	7.08e-12	-0.45	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:24006305~24008258:-
LGG	cis	rs1908814	0.541	rs7824267	ENSG00000255556.2	RP11-351I21.6	7.91	1.82e-14	7.08e-12	0.42	0.34	Neuroticism;	chr8:11936770	chr8:12378679~12380265:-
LGG	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-7.91	1.82e-14	7.08e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
LGG	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-7.91	1.82e-14	7.09e-12	-0.42	-0.34	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
LGG	cis	rs36715	0.953	rs2546146	ENSG00000245937.6	LINC01184	7.91	1.82e-14	7.11e-12	0.4	0.34	Breast cancer;	chr5:128210847	chr5:127940426~128083172:-
LGG	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-7.91	1.82e-14	7.11e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
LGG	cis	rs7829975	0.782	rs6990746	ENSG00000253981.4	ALG1L13P	7.91	1.82e-14	7.11e-12	0.36	0.34	Mood instability;	chr8:8690301	chr8:8236003~8244667:-
LGG	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-7.91	1.83e-14	7.12e-12	-0.42	-0.34	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
LGG	cis	rs2638953	0.925	rs17432330	ENSG00000278733.1	RP11-425D17.1	-7.91	1.83e-14	7.12e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292336	chr12:28185625~28186190:-
LGG	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	7.91	1.83e-14	7.12e-12	0.42	0.34	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
LGG	cis	rs9990333	0.544	rs73208092	ENSG00000231464.1	AC024937.4	7.91	1.83e-14	7.13e-12	0.43	0.34	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195996738~195998233:+
LGG	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-7.91	1.83e-14	7.14e-12	-0.35	-0.34	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
LGG	cis	rs2638953	0.925	rs11049510	ENSG00000278733.1	RP11-425D17.1	-7.91	1.84e-14	7.16e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290839	chr12:28185625~28186190:-
LGG	cis	rs228614	0.51	rs223451	ENSG00000248971.2	KRT8P46	-7.91	1.84e-14	7.16e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223450	ENSG00000248971.2	KRT8P46	-7.91	1.84e-14	7.16e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102728746~102730171:-
LGG	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-7.91	1.84e-14	7.16e-12	-0.36	-0.34	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
LGG	cis	rs2638953	0.925	rs7312201	ENSG00000278733.1	RP11-425D17.1	-7.91	1.84e-14	7.16e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417885	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs12372172	ENSG00000278733.1	RP11-425D17.1	-7.91	1.84e-14	7.16e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28419945	chr12:28185625~28186190:-
LGG	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-7.91	1.84e-14	7.18e-12	-0.34	-0.34	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
LGG	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-7.91	1.84e-14	7.18e-12	-0.34	-0.34	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
LGG	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-7.91	1.84e-14	7.18e-12	-0.34	-0.34	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
LGG	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-7.91	1.84e-14	7.18e-12	-0.34	-0.34	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
LGG	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
LGG	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	7.91	1.84e-14	7.18e-12	0.38	0.34	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
LGG	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-7.91	1.85e-14	7.19e-12	-0.46	-0.34	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
LGG	cis	rs477895	0.713	rs11600867	ENSG00000257086.1	RP11-783K16.13	7.91	1.85e-14	7.19e-12	0.42	0.34	Mean platelet volume;	chr11:64204580	chr11:64246939~64249494:-
LGG	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-7.91	1.85e-14	7.2e-12	-0.34	-0.34	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
LGG	cis	rs10246939	0.543	rs10952509	ENSG00000261797.1	RP11-744I24.3	-7.91	1.85e-14	7.2e-12	-0.42	-0.34	Bitter taste perception;	chr7:141890884	chr7:141512698~141513183:-
LGG	cis	rs4143844	1	rs4143844	ENSG00000259251.2	RP11-643M14.1	-7.91	1.85e-14	7.2e-12	-0.54	-0.34	Bipolar disorder and schizophrenia;	chr15:62020641	chr15:62060503~62062434:+
LGG	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-7.91	1.85e-14	7.21e-12	-0.27	-0.34	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-7.91	1.85e-14	7.21e-12	-0.27	-0.34	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-7.91	1.85e-14	7.21e-12	-0.27	-0.34	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
LGG	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-7.91	1.85e-14	7.21e-12	-0.27	-0.34	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-7.91	1.85e-14	7.21e-12	-0.27	-0.34	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
LGG	cis	rs11971779	0.68	rs6965212	ENSG00000273391.1	RP11-634H22.1	7.91	1.85e-14	7.22e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139341719	chr7:139359032~139359566:-
LGG	cis	rs7520050	0.966	rs785485	ENSG00000280836.1	AL355480.1	7.91	1.86e-14	7.23e-12	0.37	0.34	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45581219~45581321:-
LGG	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-7.91	1.86e-14	7.23e-12	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
LGG	cis	rs7709377	0.723	rs2416435	ENSG00000212457.1	RNU6-644P	-7.91	1.86e-14	7.23e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116191308	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs11951682	ENSG00000212457.1	RNU6-644P	-7.91	1.86e-14	7.23e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116192036	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs11955144	ENSG00000212457.1	RNU6-644P	-7.91	1.86e-14	7.23e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116192078	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs2416436	ENSG00000212457.1	RNU6-644P	-7.91	1.86e-14	7.23e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116192767	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.597	rs7721510	ENSG00000212457.1	RNU6-644P	-7.91	1.86e-14	7.23e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116194598	chr5:116188455~116188552:-
LGG	cis	rs7772486	0.754	rs697054	ENSG00000270638.1	RP3-466P17.1	7.91	1.86e-14	7.23e-12	0.22	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145735570~145737218:+
LGG	cis	rs858239	1	rs199347	ENSG00000230042.1	AK3P3	-7.91	1.86e-14	7.24e-12	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23129178~23129841:+
LGG	cis	rs227275	0.527	rs223338	ENSG00000248971.2	KRT8P46	-7.91	1.86e-14	7.25e-12	-0.35	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102728746~102730171:-
LGG	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	7.91	1.86e-14	7.26e-12	0.27	0.34	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
LGG	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	7.26e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-7.91	1.87e-14	7.26e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
LGG	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	7.91	1.87e-14	7.27e-12	0.35	0.34	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
LGG	cis	rs1056107	0.763	rs10115594	ENSG00000259953.1	RP11-4O1.2	7.91	1.87e-14	7.27e-12	0.36	0.34	Colorectal cancer;	chr9:112174198	chr9:112032555~112037730:-
LGG	cis	rs12893668	0.572	rs4906350	ENSG00000269940.1	RP11-73M18.7	7.91	1.87e-14	7.29e-12	0.39	0.34	Reticulocyte count;	chr14:103645457	chr14:103694560~103695170:+
LGG	cis	rs2638953	0.962	rs10506032	ENSG00000278733.1	RP11-425D17.1	-7.91	1.88e-14	7.3e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28384177	chr12:28185625~28186190:-
LGG	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-7.91	1.88e-14	7.3e-12	-0.46	-0.34	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
LGG	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-7.91	1.88e-14	7.31e-12	-0.39	-0.34	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
LGG	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	7.91	1.88e-14	7.31e-12	0.58	0.34	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
LGG	cis	rs858239	0.665	rs858306	ENSG00000230042.1	AK3P3	-7.91	1.88e-14	7.32e-12	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23129178~23129841:+
LGG	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	7.91	1.89e-14	7.33e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
LGG	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	7.9	1.9e-14	7.37e-12	0.39	0.34	Height;	chr6:109374782	chr6:109382795~109383666:+
LGG	cis	rs997295	0.556	rs10468041	ENSG00000270964.1	RP11-502I4.3	-7.9	1.9e-14	7.37e-12	-0.35	-0.34	Motion sickness;	chr15:67480865	chr15:67541072~67542604:-
LGG	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-7.9	1.9e-14	7.37e-12	-0.27	-0.34	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	7.9	1.9e-14	7.37e-12	0.27	0.34	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
LGG	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	7.9	1.9e-14	7.37e-12	0.27	0.34	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	7.9	1.9e-14	7.37e-12	0.27	0.34	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
LGG	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	7.9	1.9e-14	7.37e-12	0.27	0.34	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	7.9	1.9e-14	7.37e-12	0.27	0.34	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
LGG	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	7.9	1.9e-14	7.38e-12	0.4	0.34	Height;	chr6:109424139	chr6:109382795~109383666:+
LGG	cis	rs12893668	0.572	rs4900590	ENSG00000269940.1	RP11-73M18.7	7.9	1.9e-14	7.39e-12	0.39	0.34	Reticulocyte count;	chr14:103680084	chr14:103694560~103695170:+
LGG	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	7.9	1.9e-14	7.39e-12	0.22	0.34	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
LGG	cis	rs7208859	0.673	rs9895684	ENSG00000266490.1	CTD-2349P21.9	7.9	1.91e-14	7.41e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30792372~30792833:+
LGG	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	7.9	1.91e-14	7.41e-12	0.7	0.34	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	7.9	1.91e-14	7.41e-12	0.7	0.34	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
LGG	cis	rs2638953	0.962	rs11049524	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28311956	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049525	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313227	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs12371974	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313969	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049526	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28314751	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049527	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317667	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.925	rs11049528	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317914	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs10843152	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319090	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs10843153	ENSG00000278733.1	RP11-425D17.1	-7.9	1.91e-14	7.42e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319168	chr12:28185625~28186190:-
LGG	cis	rs228614	0.543	rs223330	ENSG00000248971.2	KRT8P46	-7.9	1.91e-14	7.42e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223329	ENSG00000248971.2	KRT8P46	-7.9	1.91e-14	7.42e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102728746~102730171:-
LGG	cis	rs228614	0.51	rs223324	ENSG00000248971.2	KRT8P46	-7.9	1.91e-14	7.42e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102728746~102730171:-
LGG	cis	rs4266144	1	rs12487629	ENSG00000244515.1	KRT18P34	-7.9	1.92e-14	7.44e-12	-0.38	-0.34	Coronary artery disease;	chr3:157134416	chr3:157162663~157163932:-
LGG	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	7.9	1.92e-14	7.45e-12	0.29	0.34	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
LGG	cis	rs1023500	0.596	rs133352	ENSG00000227370.1	RP4-669P10.19	7.9	1.92e-14	7.46e-12	0.3	0.34	Schizophrenia;	chr22:42038018	chr22:42132543~42132998:+
LGG	cis	rs7824557	0.592	rs2736280	ENSG00000184608.7	FAM167A-AS1	-7.9	1.92e-14	7.46e-12	-0.29	-0.34	Retinal vascular caliber;	chr8:11365513	chr8:11368402~11438658:+
LGG	cis	rs10246939	0.505	rs9640203	ENSG00000261797.1	RP11-744I24.3	-7.9	1.92e-14	7.46e-12	-0.4	-0.34	Bitter taste perception;	chr7:141844295	chr7:141512698~141513183:-
LGG	cis	rs2676071	0.638	rs2251110	ENSG00000259446.4	RP11-489D6.2	7.9	1.93e-14	7.48e-12	0.32	0.34	Periodontitis (Mean PAL);	chr15:33306336	chr15:33303657~33310659:-
LGG	cis	rs858239	0.899	rs1881203	ENSG00000230042.1	AK3P3	-7.9	1.93e-14	7.49e-12	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23129178~23129841:+
LGG	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	7.9	1.93e-14	7.5e-12	0.22	0.34	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
LGG	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	7.9	1.93e-14	7.5e-12	0.38	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
LGG	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	7.9	1.93e-14	7.5e-12	0.45	0.34	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
LGG	cis	rs8135665	0.6	rs3026682	ENSG00000233739.1	RP5-1039K5.13	7.9	1.93e-14	7.51e-12	0.4	0.34	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38056475	chr22:38057180~38073940:-
LGG	cis	rs950169	0.84	rs72748702	ENSG00000259295.5	CSPG4P12	7.9	1.93e-14	7.51e-12	0.47	0.34	Schizophrenia;	chr15:84246494	chr15:85191438~85213905:+
LGG	cis	rs950169	0.922	rs4338765	ENSG00000259295.5	CSPG4P12	7.9	1.93e-14	7.51e-12	0.47	0.34	Schizophrenia;	chr15:84248084	chr15:85191438~85213905:+
LGG	cis	rs35934224	0.783	rs58195087	ENSG00000232926.1	AC000078.5	7.9	1.94e-14	7.52e-12	0.37	0.34	Glaucoma (primary open-angle);	chr22:19871024	chr22:19887289~19887970:+
LGG	cis	rs11992162	0.591	rs35657308	ENSG00000227888.4	FAM66A	-7.9	1.94e-14	7.54e-12	-0.42	-0.34	Monocyte count;	chr8:11946893	chr8:12362019~12388296:+
LGG	cis	rs9329221	0.508	rs6601455	ENSG00000253678.1	RP11-981G7.3	7.9	1.94e-14	7.54e-12	0.4	0.34	Neuroticism;	chr8:10415916	chr8:10477491~10479375:-
LGG	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-7.9	1.94e-14	7.54e-12	-0.35	-0.34	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
LGG	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	7.9	1.94e-14	7.55e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
LGG	cis	rs35857674	0.5	rs203939	ENSG00000253484.1	RP11-109P6.2	-7.9	1.94e-14	7.55e-12	-0.34	-0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50073566	chr8:49817586~49820944:-
LGG	cis	rs897984	0.647	rs7203999	ENSG00000260911.2	RP11-196G11.2	-7.9	1.94e-14	7.55e-12	-0.24	-0.34	Dementia with Lewy bodies;	chr16:31006233	chr16:31043150~31049868:+
LGG	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	7.9	1.94e-14	7.55e-12	0.4	0.34	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
LGG	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-7.9	1.95e-14	7.56e-12	-0.43	-0.34	Height;	chr14:75191310	chr14:75011269~75012851:-
LGG	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-7.9	1.95e-14	7.57e-12	-0.45	-0.34	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
LGG	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-7.9	1.95e-14	7.57e-12	-0.45	-0.34	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
LGG	cis	rs7709377	0.723	rs4921067	ENSG00000212457.1	RNU6-644P	-7.9	1.95e-14	7.58e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116175968	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.671	rs10069565	ENSG00000212457.1	RNU6-644P	-7.9	1.95e-14	7.58e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116139132	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10057462	ENSG00000212457.1	RNU6-644P	-7.9	1.95e-14	7.58e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116141976	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs59447269	ENSG00000212457.1	RNU6-644P	-7.9	1.95e-14	7.58e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116146182	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.672	rs10059719	ENSG00000212457.1	RNU6-644P	-7.9	1.95e-14	7.58e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116146345	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10059969	ENSG00000212457.1	RNU6-644P	-7.9	1.95e-14	7.58e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116146579	chr5:116188455~116188552:-
LGG	cis	rs858239	0.72	rs10227559	ENSG00000230042.1	AK3P3	-7.9	1.95e-14	7.59e-12	-0.37	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23129178~23129841:+
LGG	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	7.9	1.96e-14	7.6e-12	0.38	0.34	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
LGG	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-7.9	1.96e-14	7.61e-12	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
LGG	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-7.9	1.96e-14	7.62e-12	-0.27	-0.34	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
LGG	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	7.9	1.96e-14	7.62e-12	0.39	0.34	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
LGG	cis	rs853679	1	rs853694	ENSG00000226314.6	ZNF192P1	7.9	1.97e-14	7.63e-12	0.46	0.34	Depression;	chr6:28311323	chr6:28161781~28169594:+
LGG	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	-7.9	1.97e-14	7.63e-12	-0.35	-0.34	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
LGG	cis	rs12073837	0.5	rs11118610	ENSG00000272823.1	RP11-295M18.6	-7.9	1.97e-14	7.64e-12	-0.42	-0.34	F-cell distribution;	chr1:220816744	chr1:220828676~220829211:-
LGG	cis	rs8135665	0.625	rs34385006	ENSG00000233739.1	RP5-1039K5.13	7.9	1.97e-14	7.64e-12	0.38	0.34	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38054284	chr22:38057180~38073940:-
LGG	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-7.9	1.97e-14	7.65e-12	-0.52	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
LGG	cis	rs7189233	0.955	rs8054299	ENSG00000279344.1	RP11-44F14.7	-7.9	1.97e-14	7.65e-12	-0.35	-0.34	Intelligence (multi-trait analysis);	chr16:53464743	chr16:53478957~53481550:-
LGG	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-7.9	1.97e-14	7.66e-12	-0.3	-0.34	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs12498539	ENSG00000250412.1	KLHL2P1	7.9	1.98e-14	7.67e-12	0.39	0.34	Corneal astigmatism;	chr4:119547215	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.863	rs3822194	ENSG00000250412.1	KLHL2P1	7.9	1.98e-14	7.67e-12	0.39	0.34	Corneal astigmatism;	chr4:119550493	chr4:119334329~119378233:+
LGG	cis	rs7241530	0.595	rs36084769	ENSG00000266213.1	RP11-100K18.1	-7.9	1.98e-14	7.67e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78139991	chr18:78137223~78140887:+
LGG	cis	rs9532669	0.963	rs4941391	ENSG00000239827.7	SUGT1P3	-7.9	1.98e-14	7.68e-12	-0.35	-0.34	Cervical cancer;	chr13:40939787	chr13:40908159~40921774:-
LGG	cis	rs228614	0.51	rs223311	ENSG00000248971.2	KRT8P46	-7.9	1.98e-14	7.69e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102728746~102730171:-
LGG	cis	rs2797160	1	rs6910933	ENSG00000237742.5	RP11-624M8.1	7.9	1.98e-14	7.7e-12	0.31	0.34	Endometrial cancer;	chr6:125696009	chr6:125578558~125749190:-
LGG	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-7.9	1.99e-14	7.71e-12	-0.46	-0.34	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
LGG	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-7.9	1.99e-14	7.71e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-7.9	1.99e-14	7.71e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
LGG	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-7.9	1.99e-14	7.71e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-7.9	1.99e-14	7.71e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
LGG	cis	rs4143844	1	rs12148573	ENSG00000259251.2	RP11-643M14.1	7.9	1.99e-14	7.73e-12	0.54	0.34	Bipolar disorder and schizophrenia;	chr15:62051994	chr15:62060503~62062434:+
LGG	cis	rs4143844	1	rs75520981	ENSG00000259251.2	RP11-643M14.1	7.9	1.99e-14	7.73e-12	0.54	0.34	Bipolar disorder and schizophrenia;	chr15:62052478	chr15:62060503~62062434:+
LGG	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	7.9	1.99e-14	7.74e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
LGG	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-7.9	1.99e-14	7.74e-12	-0.57	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
LGG	cis	rs2797160	1	rs1739362	ENSG00000237742.5	RP11-624M8.1	7.9	1.99e-14	7.74e-12	0.31	0.34	Endometrial cancer;	chr6:125699557	chr6:125578558~125749190:-
LGG	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-7.9	1.99e-14	7.74e-12	-0.65	-0.34	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-7.9	1.99e-14	7.74e-12	-0.65	-0.34	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-7.9	1.99e-14	7.74e-12	-0.65	-0.34	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-7.9	1.99e-14	7.74e-12	-0.65	-0.34	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
LGG	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-7.9	1.99e-14	7.74e-12	-0.65	-0.34	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-7.9	1.99e-14	7.74e-12	-0.65	-0.34	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
LGG	cis	rs189798	1	rs189798	ENSG00000253893.2	FAM85B	7.9	2e-14	7.74e-12	0.44	0.34	Myopia (pathological);	chr8:9133067	chr8:8167819~8226614:-
LGG	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	7.9	2e-14	7.74e-12	0.38	0.34	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
LGG	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-7.9	2e-14	7.76e-12	-0.46	-0.34	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
LGG	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-7.9	2e-14	7.76e-12	-0.46	-0.34	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
LGG	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-7.9	2e-14	7.76e-12	-0.46	-0.34	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
LGG	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-7.9	2e-14	7.76e-12	-0.46	-0.34	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
LGG	cis	rs6967414	0.786	rs9639026	ENSG00000187953.9	PMS2CL	-7.9	2e-14	7.77e-12	-0.45	-0.34	Hematocrit;Hemoglobin concentration;	chr7:6707105	chr7:6710128~6753862:+
LGG	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-7.9	2e-14	7.77e-12	-0.39	-0.34	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
LGG	cis	rs2797160	0.967	rs1739358	ENSG00000237742.5	RP11-624M8.1	7.9	2.01e-14	7.78e-12	0.31	0.34	Endometrial cancer;	chr6:125698590	chr6:125578558~125749190:-
LGG	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-7.9	2.01e-14	7.79e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
LGG	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-7.9	2.01e-14	7.79e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
LGG	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-7.9	2.01e-14	7.8e-12	-0.37	-0.34	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
LGG	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-7.9	2.01e-14	7.8e-12	-0.37	-0.34	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
LGG	cis	rs9532669	0.926	rs9532678	ENSG00000239827.7	SUGT1P3	-7.9	2.01e-14	7.8e-12	-0.35	-0.34	Cervical cancer;	chr13:40941862	chr13:40908159~40921774:-
LGG	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	7.9	2.02e-14	7.82e-12	0.4	0.34	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
LGG	cis	rs7241530	0.636	rs11875760	ENSG00000266213.1	RP11-100K18.1	-7.9	2.02e-14	7.84e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78137285	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.636	rs11873523	ENSG00000266213.1	RP11-100K18.1	-7.9	2.02e-14	7.84e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78137751	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.636	rs12961788	ENSG00000266213.1	RP11-100K18.1	-7.9	2.02e-14	7.84e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78137998	chr18:78137223~78140887:+
LGG	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-7.9	2.02e-14	7.84e-12	-0.3	-0.34	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
LGG	cis	rs2412819	0.571	rs514255	ENSG00000249839.1	AC011330.5	-7.9	2.02e-14	7.84e-12	-0.56	-0.34	Lung cancer;	chr15:43893134	chr15:43663654~43684339:-
LGG	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	7.9	2.02e-14	7.84e-12	0.36	0.34	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
LGG	cis	rs858239	0.932	rs858272	ENSG00000230042.1	AK3P3	-7.9	2.02e-14	7.85e-12	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23129178~23129841:+
LGG	cis	rs2282300	0.739	rs1765139	ENSG00000242353.1	RP4-710M3.1	-7.9	2.03e-14	7.86e-12	-0.47	-0.34	Morning vs. evening chronotype;	chr11:30332178	chr11:30368148~30368646:+
LGG	cis	rs6163	0.508	rs12776506	ENSG00000272912.1	RP11-724N1.1	-7.9	2.03e-14	7.87e-12	-0.4	-0.34	Waist circumference;Hip circumference;	chr10:102773071	chr10:102914585~102915404:+
LGG	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-7.9	2.03e-14	7.88e-12	-0.41	-0.34	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
LGG	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-7.9	2.03e-14	7.88e-12	-0.41	-0.34	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
LGG	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-7.89	2.03e-14	7.88e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
LGG	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-7.89	2.04e-14	7.89e-12	-0.44	-0.34	Migraine;	chr4:56852029	chr4:56960927~56961373:-
LGG	cis	rs2797160	1	rs1777226	ENSG00000237742.5	RP11-624M8.1	7.89	2.04e-14	7.89e-12	0.31	0.34	Endometrial cancer;	chr6:125696545	chr6:125578558~125749190:-
LGG	cis	rs2797160	1	rs1777225	ENSG00000237742.5	RP11-624M8.1	7.89	2.04e-14	7.89e-12	0.31	0.34	Endometrial cancer;	chr6:125697124	chr6:125578558~125749190:-
LGG	cis	rs440932	1	rs440932	ENSG00000173295.6	FAM86B3P	-7.89	2.04e-14	7.9e-12	-0.39	-0.34	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8228595~8244865:+
LGG	cis	rs11992162	0.591	rs4240678	ENSG00000227888.4	FAM66A	-7.89	2.04e-14	7.91e-12	-0.42	-0.34	Monocyte count;	chr8:11944917	chr8:12362019~12388296:+
LGG	cis	rs7241530	0.61	rs7226819	ENSG00000266213.1	RP11-100K18.1	-7.89	2.04e-14	7.92e-12	-0.4	-0.34	Educational attainment (years of education);	chr18:78132508	chr18:78137223~78140887:+
LGG	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-7.89	2.05e-14	7.93e-12	-0.3	-0.34	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
LGG	cis	rs1555322	1	rs2425041	ENSG00000126005.14	MMP24-AS1	-7.89	2.05e-14	7.93e-12	-0.55	-0.34	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35216462~35278131:-
LGG	cis	rs2638953	0.962	rs2172299	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.93e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049503	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.93e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs61922974	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.93e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28185625~28186190:-
LGG	cis	rs4950322	0.518	rs55697094	ENSG00000278811.3	LINC00624	7.89	2.05e-14	7.95e-12	0.32	0.34	Protein quantitative trait loci;	chr1:147121205	chr1:147258885~147517875:-
LGG	cis	rs35934224	0.783	rs28360650	ENSG00000232926.1	AC000078.5	7.89	2.05e-14	7.96e-12	0.37	0.34	Glaucoma (primary open-angle);	chr22:19869538	chr22:19887289~19887970:+
LGG	cis	rs2638953	0.853	rs11049632	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461130	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.777	rs11049681	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508722	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.815	rs11049683	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.815	rs10843193	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.741	rs10843194	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510237	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs7485676	ENSG00000278733.1	RP11-425D17.1	-7.89	2.05e-14	7.96e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28185625~28186190:-
LGG	cis	rs12444795	0.755	rs741692	ENSG00000267077.1	RP11-127I20.5	7.89	2.06e-14	7.98e-12	0.46	0.34	Cancer;	chr16:4812424	chr16:4795265~4796532:-
LGG	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-7.89	2.06e-14	7.98e-12	-0.27	-0.34	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-7.89	2.06e-14	7.98e-12	-0.27	-0.34	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
LGG	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	7.89	2.06e-14	7.98e-12	0.27	0.34	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
LGG	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	7.89	2.06e-14	7.98e-12	0.27	0.34	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
LGG	cis	rs2638953	0.962	rs11049495	ENSG00000278733.1	RP11-425D17.1	-7.89	2.06e-14	7.98e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.853	rs3782515	ENSG00000278733.1	RP11-425D17.1	-7.89	2.06e-14	7.99e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310511	chr12:28185625~28186190:-
LGG	cis	rs7709377	0.723	rs4921078	ENSG00000212457.1	RNU6-644P	-7.89	2.06e-14	7.99e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116197368	chr5:116188455~116188552:-
LGG	cis	rs7208859	0.673	rs79541516	ENSG00000266490.1	CTD-2349P21.9	7.89	2.06e-14	8e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30792372~30792833:+
LGG	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	7.89	2.07e-14	8e-12	0.41	0.34	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
LGG	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-7.89	2.07e-14	8.01e-12	-0.46	-0.34	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
LGG	cis	rs67340775	0.541	rs200964	ENSG00000226314.6	ZNF192P1	7.89	2.07e-14	8.02e-12	0.46	0.34	Lung cancer in ever smokers;	chr6:27899165	chr6:28161781~28169594:+
LGG	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	7.89	2.08e-14	8.04e-12	0.28	0.34	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
LGG	cis	rs7709377	0.723	rs10073199	ENSG00000212457.1	RNU6-644P	-7.89	2.08e-14	8.05e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116173722	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10073157	ENSG00000212457.1	RNU6-644P	-7.89	2.08e-14	8.05e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116173809	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.638	rs1113909	ENSG00000212457.1	RNU6-644P	-7.89	2.08e-14	8.05e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116174014	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10058275	ENSG00000212457.1	RNU6-644P	-7.89	2.08e-14	8.05e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116174104	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs11952310	ENSG00000212457.1	RNU6-644P	-7.89	2.08e-14	8.05e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116175256	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10055145	ENSG00000212457.1	RNU6-644P	-7.89	2.08e-14	8.05e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116175667	chr5:116188455~116188552:-
LGG	cis	rs7709377	0.723	rs10062295	ENSG00000212457.1	RNU6-644P	-7.89	2.08e-14	8.05e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116175749	chr5:116188455~116188552:-
LGG	cis	rs4714902	0.688	rs4496799	ENSG00000231769.2	RP1-8B1.4	-7.89	2.08e-14	8.05e-12	-0.36	-0.34	Colonoscopy-negative controls vs population controls;	chr6:46102670	chr6:46097093~46129706:-
LGG	cis	rs4714902	0.688	rs13210417	ENSG00000231769.2	RP1-8B1.4	-7.89	2.08e-14	8.05e-12	-0.36	-0.34	Colonoscopy-negative controls vs population controls;	chr6:46106406	chr6:46097093~46129706:-
LGG	cis	rs7927771	0.524	rs10838739	ENSG00000280615.1	Y_RNA	-7.89	2.08e-14	8.06e-12	-0.41	-0.34	Subjective well-being;	chr11:47651191	chr11:47614898~47614994:-
LGG	cis	rs172166	0.637	rs1225597	ENSG00000218016.2	ZNF192P2	-7.89	2.08e-14	8.07e-12	-0.44	-0.34	Cardiac Troponin-T levels;	chr6:28194309	chr6:28188050~28189432:+
LGG	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-7.89	2.08e-14	8.07e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
LGG	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	7.89	2.09e-14	8.09e-12	0.38	0.34	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
LGG	cis	rs34421088	0.559	rs12386974	ENSG00000255556.2	RP11-351I21.6	7.89	2.09e-14	8.09e-12	0.41	0.34	Neuroticism;	chr8:11543119	chr8:12378679~12380265:-
LGG	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	7.89	2.09e-14	8.1e-12	0.35	0.34	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
LGG	cis	rs12935418	0.616	rs11859567	ENSG00000260213.4	RP11-303E16.3	-7.89	2.09e-14	8.1e-12	-0.46	-0.34	Mean corpuscular volume;	chr16:80935951	chr16:81016792~81035759:-
LGG	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-7.89	2.09e-14	8.11e-12	-0.4	-0.34	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
LGG	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-7.89	2.1e-14	8.14e-12	-0.46	-0.34	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
LGG	cis	rs2638953	0.925	rs11049549	ENSG00000278733.1	RP11-425D17.1	-7.89	2.11e-14	8.15e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357808	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs10843158	ENSG00000278733.1	RP11-425D17.1	7.89	2.11e-14	8.15e-12	0.42	0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354259	chr12:28185625~28186190:-
LGG	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-7.89	2.11e-14	8.16e-12	-0.44	-0.34	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
LGG	cis	rs2638953	0.962	rs10843143	ENSG00000278733.1	RP11-425D17.1	-7.89	2.11e-14	8.16e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28253484	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs11049488	ENSG00000278733.1	RP11-425D17.1	-7.89	2.11e-14	8.16e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259439	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs57618147	ENSG00000278733.1	RP11-425D17.1	-7.89	2.11e-14	8.16e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259902	chr12:28185625~28186190:-
LGG	cis	rs934734	0.532	rs6546151	ENSG00000204929.10	AC074391.1	-7.89	2.11e-14	8.17e-12	-0.33	-0.34	Rheumatoid arthritis;	chr2:65449449	chr2:65436711~66084639:+
LGG	cis	rs36715	0.868	rs251387	ENSG00000245937.6	LINC01184	7.89	2.11e-14	8.17e-12	0.4	0.34	Breast cancer;	chr5:128211488	chr5:127940426~128083172:-
LGG	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	7.89	2.11e-14	8.18e-12	0.29	0.34	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
LGG	cis	rs2638953	0.924	rs10843139	ENSG00000278733.1	RP11-425D17.1	-7.89	2.11e-14	8.18e-12	-0.43	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227160	chr12:28185625~28186190:-
LGG	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	7.89	2.11e-14	8.18e-12	0.41	0.34	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
LGG	cis	rs858239	0.738	rs7807879	ENSG00000230042.1	AK3P3	-7.89	2.12e-14	8.2e-12	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23129178~23129841:+
LGG	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-7.89	2.12e-14	8.2e-12	-0.45	-0.34	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
LGG	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-7.89	2.12e-14	8.21e-12	-0.23	-0.34	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
LGG	cis	rs12495178	0.578	rs1448609	ENSG00000239519.1	CADM2-AS1	7.89	2.12e-14	8.21e-12	0.45	0.34	Body mass index;	chr3:85803919	chr3:85992183~86028007:-
LGG	cis	rs72615157	0.716	rs75779608	ENSG00000242294.5	STAG3L5P	7.89	2.12e-14	8.21e-12	0.24	0.34	Lung function (FEV1/FVC);	chr7:100171334	chr7:100336079~100351900:+
LGG	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	7.89	2.12e-14	8.22e-12	0.39	0.34	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
LGG	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	7.89	2.12e-14	8.22e-12	0.39	0.34	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
LGG	cis	rs17772222	0.56	rs3742681	ENSG00000258983.2	RP11-507K2.2	-7.89	2.13e-14	8.22e-12	-0.38	-0.34	Coronary artery calcification;	chr14:88554903	chr14:88499334~88515502:+
LGG	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-7.89	2.13e-14	8.23e-12	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
LGG	cis	rs910316	0.737	rs2098251	ENSG00000279594.1	RP11-950C14.10	7.89	2.13e-14	8.24e-12	0.43	0.34	Height;	chr14:75025993	chr14:75011269~75012851:-
LGG	cis	rs910316	0.664	rs2098252	ENSG00000279594.1	RP11-950C14.10	7.89	2.13e-14	8.24e-12	0.43	0.34	Height;	chr14:75026029	chr14:75011269~75012851:-
LGG	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-7.89	2.13e-14	8.25e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
LGG	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-7.89	2.14e-14	8.26e-12	-0.44	-0.34	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
LGG	cis	rs11722779	0.873	rs223346	ENSG00000248971.2	KRT8P46	-7.89	2.14e-14	8.26e-12	-0.35	-0.34	Schizophrenia;	chr4:102859339	chr4:102728746~102730171:-
LGG	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	7.89	2.14e-14	8.27e-12	0.35	0.34	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
LGG	cis	rs11722779	0.815	rs223347	ENSG00000248971.2	KRT8P46	-7.89	2.14e-14	8.29e-12	-0.35	-0.34	Schizophrenia;	chr4:102858815	chr4:102728746~102730171:-
LGG	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-7.89	2.15e-14	8.3e-12	-0.45	-0.34	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
LGG	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-7.89	2.15e-14	8.3e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-7.89	2.15e-14	8.3e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
LGG	cis	rs8180040	0.966	rs17784882	ENSG00000271161.1	BOLA2P2	-7.89	2.15e-14	8.31e-12	-0.32	-0.34	Colorectal cancer;	chr3:47502513	chr3:47499841~47500407:+
LGG	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-7.89	2.15e-14	8.31e-12	-0.22	-0.34	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
LGG	cis	rs2638953	0.779	rs61920241	ENSG00000278733.1	RP11-425D17.1	-7.89	2.15e-14	8.32e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28185625~28186190:-
LGG	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	7.89	2.15e-14	8.32e-12	0.4	0.34	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
LGG	cis	rs1555322	1	rs2425031	ENSG00000126005.14	MMP24-AS1	-7.89	2.15e-14	8.32e-12	-0.5	-0.34	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35216462~35278131:-
LGG	cis	rs7829975	0.509	rs2945269	ENSG00000253981.4	ALG1L13P	-7.89	2.15e-14	8.33e-12	-0.35	-0.34	Mood instability;	chr8:8258056	chr8:8236003~8244667:-
LGG	cis	rs7520050	0.966	rs785488	ENSG00000280836.1	AL355480.1	7.89	2.16e-14	8.33e-12	0.36	0.34	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45581219~45581321:-
LGG	cis	rs7520050	0.966	rs785489	ENSG00000280836.1	AL355480.1	7.89	2.16e-14	8.33e-12	0.36	0.34	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45581219~45581321:-
LGG	cis	rs7241530	0.595	rs35856696	ENSG00000266213.1	RP11-100K18.1	-7.89	2.16e-14	8.33e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78138218	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.636	rs34068602	ENSG00000266213.1	RP11-100K18.1	-7.89	2.16e-14	8.33e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78138236	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.636	rs35311649	ENSG00000266213.1	RP11-100K18.1	-7.89	2.16e-14	8.33e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78138456	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.636	rs4799270	ENSG00000266213.1	RP11-100K18.1	-7.89	2.16e-14	8.33e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78138528	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.636	rs4799271	ENSG00000266213.1	RP11-100K18.1	-7.89	2.16e-14	8.33e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78138539	chr18:78137223~78140887:+
LGG	cis	rs7241530	0.636	rs4799273	ENSG00000266213.1	RP11-100K18.1	-7.89	2.16e-14	8.33e-12	-0.42	-0.34	Educational attainment (years of education);	chr18:78138963	chr18:78137223~78140887:+
LGG	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-7.89	2.16e-14	8.33e-12	-0.43	-0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
LGG	cis	rs858239	0.806	rs10268610	ENSG00000230042.1	AK3P3	-7.89	2.16e-14	8.35e-12	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23129178~23129841:+
LGG	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-7.89	2.16e-14	8.35e-12	-0.4	-0.34	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
LGG	cis	rs2797160	0.967	rs2226158	ENSG00000237742.5	RP11-624M8.1	-7.89	2.16e-14	8.35e-12	-0.31	-0.34	Endometrial cancer;	chr6:125674321	chr6:125578558~125749190:-
LGG	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-7.89	2.16e-14	8.35e-12	-0.39	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
LGG	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	7.89	2.16e-14	8.36e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
LGG	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	7.89	2.17e-14	8.37e-12	0.43	0.34	Height;	chr14:75127136	chr14:75011269~75012851:-
LGG	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	7.89	2.17e-14	8.37e-12	0.43	0.34	Height;	chr14:75127199	chr14:75011269~75012851:-
LGG	cis	rs2638953	0.962	rs79708115	ENSG00000278733.1	RP11-425D17.1	-7.89	2.17e-14	8.37e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28440784	chr12:28185625~28186190:-
LGG	cis	rs2638953	0.962	rs10506034	ENSG00000278733.1	RP11-425D17.1	-7.89	2.17e-14	8.37e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28442363	chr12:28185625~28186190:-
LGG	cis	rs7208859	0.673	rs11080135	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9894876	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs73277967	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs60020217	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.573	rs73277974	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs73277978	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30792372~30792833:+
LGG	cis	rs17826219	0.706	rs9905827	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Body mass index;	chr17:30865150	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11657391	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs58089675	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs73263755	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9899349	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.623	rs11652358	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs11656845	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9891179	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30792372~30792833:+
LGG	cis	rs7208859	0.673	rs9891413	ENSG00000266490.1	CTD-2349P21.9	7.89	2.17e-14	8.37e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30792372~30792833:+
LGG	cis	rs6997458	0.785	rs931505	ENSG00000253549.4	RP11-317J10.2	7.89	2.17e-14	8.37e-12	0.28	0.34	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85436014	chr8:85441851~85464915:-
LGG	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-7.89	2.17e-14	8.38e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
LGG	cis	rs7772486	0.754	rs697053	ENSG00000270638.1	RP3-466P17.1	-7.89	2.17e-14	8.38e-12	-0.22	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145735570~145737218:+
LGG	cis	rs7829975	0.84	rs555617	ENSG00000253981.4	ALG1L13P	7.89	2.17e-14	8.39e-12	0.35	0.34	Mood instability;	chr8:8735335	chr8:8236003~8244667:-
LGG	cis	rs11018904	0.906	rs12793836	ENSG00000280385.1	AP000648.5	-7.89	2.18e-14	8.41e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90193614~90198120:+
LGG	cis	rs2638953	0.924	rs11049507	ENSG00000278733.1	RP11-425D17.1	-7.89	2.18e-14	8.41e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28289554	chr12:28185625~28186190:-
LGG	cis	rs11148252	0.904	rs7321964	ENSG00000278238.1	RP11-245D16.4	-7.89	2.18e-14	8.41e-12	-0.33	-0.34	Lewy body disease;	chr13:52466687	chr13:52454775~52455331:-
LGG	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-7.89	2.18e-14	8.42e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
LGG	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	7.88	2.19e-14	8.44e-12	0.33	0.34	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
LGG	cis	rs11603023	0.874	rs577396	ENSG00000255176.1	AP002954.3	-7.88	2.19e-14	8.44e-12	-0.25	-0.34	Cholesterol, total;	chr11:118628753	chr11:118636620~118638097:+
LGG	cis	rs11603023	0.874	rs11216934	ENSG00000255176.1	AP002954.3	-7.88	2.19e-14	8.44e-12	-0.25	-0.34	Cholesterol, total;	chr11:118630742	chr11:118636620~118638097:+
LGG	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	7.88	2.19e-14	8.46e-12	0.35	0.34	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
LGG	cis	rs228614	0.536	rs223477	ENSG00000248971.2	KRT8P46	-7.88	2.19e-14	8.46e-12	-0.35	-0.34	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102728746~102730171:-
LGG	cis	rs4295623	0.789	rs12541318	ENSG00000227888.4	FAM66A	-7.88	2.19e-14	8.47e-12	-0.42	-0.34	Morning vs. evening chronotype;	chr8:11737461	chr8:12362019~12388296:+
LGG	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-7.88	2.2e-14	8.47e-12	-0.41	-0.34	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
LGG	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	-7.88	2.2e-14	8.48e-12	-0.35	-0.34	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
LGG	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	7.88	2.2e-14	8.49e-12	0.4	0.34	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
LGG	cis	rs4143844	0.867	rs17303894	ENSG00000259251.2	RP11-643M14.1	7.88	2.2e-14	8.5e-12	0.58	0.34	Bipolar disorder and schizophrenia;	chr15:61873378	chr15:62060503~62062434:+
LGG	cis	rs227275	0.554	rs223454	ENSG00000248971.2	KRT8P46	-7.88	2.2e-14	8.51e-12	-0.36	-0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102728746~102730171:-
LGG	cis	rs9876781	0.624	rs12491849	ENSG00000244380.1	RP11-24C3.2	7.88	2.21e-14	8.53e-12	0.44	0.34	Longevity;	chr3:48489975	chr3:48440352~48446656:-
LGG	cis	rs1930961	1	rs760555	ENSG00000272942.1	CTA-246H3.12	-7.88	2.22e-14	8.55e-12	-0.52	-0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25434324~25435070:-
LGG	cis	rs62184315	0.536	rs62184265	ENSG00000253559.1	OSGEPL1-AS1	-7.88	2.22e-14	8.57e-12	-0.51	-0.34	Alcohol dependence (age at onset);	chr2:189756231	chr2:189762704~189765556:+
LGG	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-7.88	2.22e-14	8.57e-12	-0.34	-0.34	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
LGG	cis	rs12893668	0.603	rs12896171	ENSG00000269940.1	RP11-73M18.7	7.88	2.22e-14	8.57e-12	0.39	0.34	Reticulocyte count;	chr14:103669629	chr14:103694560~103695170:+
LGG	cis	rs1150668	0.799	rs9301	ENSG00000270326.1	RP5-874C20.6	-7.88	2.22e-14	8.58e-12	-0.43	-0.34	Pubertal anthropometrics;	chr6:28324929	chr6:28319660~28319852:-
LGG	cis	rs1150668	0.799	rs853684	ENSG00000270326.1	RP5-874C20.6	-7.88	2.22e-14	8.58e-12	-0.43	-0.34	Pubertal anthropometrics;	chr6:28326773	chr6:28319660~28319852:-
LGG	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	7.88	2.23e-14	8.59e-12	0.23	0.34	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
LGG	cis	rs7709377	0.723	rs9942399	ENSG00000212457.1	RNU6-644P	-7.88	2.23e-14	8.61e-12	-0.49	-0.34	Metabolite levels  (X-11787);	chr5:116140285	chr5:116188455~116188552:-
LGG	cis	rs397969	0.596	rs17668529	ENSG00000230528.6	NOS2P3	-7.88	2.24e-14	8.62e-12	-0.35	-0.34	Platelet count;	chr17:19996475	chr17:20436337~20447249:+
LGG	cis	rs397969	0.596	rs62066348	ENSG00000230528.6	NOS2P3	-7.88	2.24e-14	8.62e-12	-0.35	-0.34	Platelet count;	chr17:19996600	chr17:20436337~20447249:+
LGG	cis	rs397969	0.57	rs62066349	ENSG00000230528.6	NOS2P3	-7.88	2.24e-14	8.62e-12	-0.35	-0.34	Platelet count;	chr17:19996627	chr17:20436337~20447249:+
LGG	cis	rs397969	0.596	rs62066350	ENSG00000230528.6	NOS2P3	-7.88	2.24e-14	8.62e-12	-0.35	-0.34	Platelet count;	chr17:19996729	chr17:20436337~20447249:+
LGG	cis	rs1757171	0.542	rs1757186	ENSG00000279942.1	RP1-153P14.7	-7.88	2.24e-14	8.63e-12	-0.37	-0.34	Cognitive performance;	chr6:37516335	chr6:37567716~37571460:+
LGG	cis	rs997295	0.592	rs2899724	ENSG00000270964.1	RP11-502I4.3	-7.88	2.24e-14	8.64e-12	-0.35	-0.34	Motion sickness;	chr15:67468470	chr15:67541072~67542604:-
LGG	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-7.88	2.24e-14	8.65e-12	-0.3	-0.34	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
LGG	cis	rs9376098	1	rs1040441	ENSG00000232876.1	CTA-212D2.2	-7.88	2.25e-14	8.65e-12	-0.4	-0.34	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135172740	chr6:135055033~135060550:+
LGG	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	7.88	2.25e-14	8.66e-12	0.35	0.34	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
LGG	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-7.88	2.25e-14	8.66e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
LGG	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-7.88	2.25e-14	8.66e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
LGG	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-7.88	2.25e-14	8.68e-12	-0.24	-0.34	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
LGG	cis	rs1023500	0.573	rs133382	ENSG00000227370.1	RP4-669P10.19	7.88	2.25e-14	8.68e-12	0.29	0.34	Schizophrenia;	chr22:42075770	chr22:42132543~42132998:+
LGG	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	7.88	2.25e-14	8.69e-12	0.4	0.34	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
LGG	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	7.88	2.25e-14	8.69e-12	0.4	0.34	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
LGG	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-7.88	2.25e-14	8.69e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
LGG	cis	rs11098499	0.908	rs28499576	ENSG00000250412.1	KLHL2P1	7.88	2.26e-14	8.71e-12	0.39	0.34	Corneal astigmatism;	chr4:119465522	chr4:119334329~119378233:+
LGG	cis	rs1555322	0.872	rs2425033	ENSG00000126005.14	MMP24-AS1	-7.88	2.26e-14	8.71e-12	-0.47	-0.34	Attention deficit hyperactivity disorder;	chr20:35267823	chr20:35216462~35278131:-
LGG	cis	rs7772486	0.754	rs857881	ENSG00000270638.1	RP3-466P17.1	-7.88	2.26e-14	8.71e-12	-0.22	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145735570~145737218:+
LGG	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	7.88	2.27e-14	8.73e-12	0.4	0.34	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
LGG	cis	rs11098499	0.738	rs28408407	ENSG00000250412.1	KLHL2P1	7.88	2.27e-14	8.74e-12	0.39	0.34	Corneal astigmatism;	chr4:119454875	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs1809406	ENSG00000250412.1	KLHL2P1	7.88	2.27e-14	8.74e-12	0.39	0.34	Corneal astigmatism;	chr4:119455967	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.865	rs2389809	ENSG00000250412.1	KLHL2P1	7.88	2.27e-14	8.74e-12	0.39	0.34	Corneal astigmatism;	chr4:119456244	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.909	rs9994810	ENSG00000250412.1	KLHL2P1	7.88	2.27e-14	8.74e-12	0.39	0.34	Corneal astigmatism;	chr4:119460435	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.697	rs10020027	ENSG00000250412.1	KLHL2P1	7.88	2.27e-14	8.74e-12	0.39	0.34	Corneal astigmatism;	chr4:119460724	chr4:119334329~119378233:+
LGG	cis	rs11098499	0.779	rs7356491	ENSG00000250412.1	KLHL2P1	7.88	2.27e-14	8.74e-12	0.39	0.34	Corneal astigmatism;	chr4:119460819	chr4:119334329~119378233:+
LGG	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-7.88	2.27e-14	8.75e-12	-0.36	-0.34	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
LGG	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-7.88	2.27e-14	8.75e-12	-0.65	-0.34	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
LGG	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-7.88	2.27e-14	8.75e-12	-0.39	-0.34	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
LGG	cis	rs189798	0.807	rs12785	ENSG00000253893.2	FAM85B	-7.88	2.28e-14	8.77e-12	-0.45	-0.34	Myopia (pathological);	chr8:9137426	chr8:8167819~8226614:-
LGG	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	7.88	2.28e-14	8.78e-12	0.65	0.34	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
LGG	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-7.88	2.28e-14	8.78e-12	-0.65	-0.34	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
LGG	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-7.88	2.28e-14	8.78e-12	-0.65	-0.34	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
LGG	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	7.88	2.28e-14	8.79e-12	0.44	0.34	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
LGG	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-7.88	2.28e-14	8.79e-12	-0.23	-0.34	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
LGG	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-7.88	2.29e-14	8.81e-12	-0.69	-0.34	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
LGG	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-7.88	2.29e-14	8.81e-12	-0.69	-0.34	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
LGG	cis	rs758324	0.628	rs2073506	ENSG00000233006.5	AC034220.3	-7.88	2.29e-14	8.81e-12	-0.53	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132059045	chr5:132311285~132369916:-
LGG	cis	rs7824557	0.547	rs2572391	ENSG00000184608.7	FAM167A-AS1	7.88	2.29e-14	8.82e-12	0.29	0.34	Retinal vascular caliber;	chr8:11378105	chr8:11368402~11438658:+
LGG	cis	rs853679	0.567	rs16894091	ENSG00000280107.1	AL022393.9	7.88	2.29e-14	8.82e-12	0.36	0.34	Depression;	chr6:28422360	chr6:28170845~28172521:+
LGG	cis	rs12893668	0.572	rs4906356	ENSG00000269940.1	RP11-73M18.7	7.88	2.29e-14	8.83e-12	0.39	0.34	Reticulocyte count;	chr14:103672364	chr14:103694560~103695170:+
LGG	cis	rs7709377	0.723	rs4608961	ENSG00000212457.1	RNU6-644P	-7.88	2.3e-14	8.84e-12	-0.5	-0.34	Metabolite levels  (X-11787);	chr5:116184305	chr5:116188455~116188552:-
LGG	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	7.88	2.3e-14	8.85e-12	0.38	0.34	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
LGG	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-7.88	2.3e-14	8.87e-12	-0.71	-0.34	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
LGG	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-7.88	2.3e-14	8.87e-12	-0.71	-0.34	Gout;	chr7:66642037	chr7:66654538~66669855:+
LGG	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	7.88	2.31e-14	8.9e-12	0.4	0.34	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
LGG	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	7.88	2.31e-14	8.9e-12	0.4	0.34	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
LGG	cis	rs7189233	0.91	rs3809634	ENSG00000279344.1	RP11-44F14.7	7.88	2.31e-14	8.9e-12	0.32	0.34	Intelligence (multi-trait analysis);	chr16:53504245	chr16:53478957~53481550:-
LGG	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-7.88	2.32e-14	8.92e-12	-0.39	-0.34	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
LGG	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-7.88	2.32e-14	8.95e-12	-0.39	-0.34	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
LGG	cis	rs2638953	0.744	rs11049426	ENSG00000278733.1	RP11-425D17.1	-7.88	2.32e-14	8.95e-12	-0.41	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193573	chr12:28185625~28186190:-
LGG	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-7.88	2.32e-14	8.95e-12	-0.46	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
LGG	cis	rs35857674	0.731	rs4873408	ENSG00000253484.1	RP11-109P6.2	-7.88	2.33e-14	8.96e-12	-0.34	-0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50143781	chr8:49817586~49820944:-
LGG	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
LGG	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
LGG	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
LGG	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
LGG	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
LGG	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
LGG	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
LGG	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-7.88	2.33e-14	8.96e-12	-0.46	-0.34	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
LGG	cis	rs9532669	0.963	rs4343141	ENSG00000239827.7	SUGT1P3	-7.88	2.33e-14	8.98e-12	-0.35	-0.34	Cervical cancer;	chr13:40940497	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.963	rs3887418	ENSG00000239827.7	SUGT1P3	-7.88	2.33e-14	8.98e-12	-0.35	-0.34	Cervical cancer;	chr13:40940560	chr13:40908159~40921774:-
LGG	cis	rs9532669	0.926	rs1056820	ENSG00000239827.7	SUGT1P3	-7.88	2.33e-14	8.98e-12	-0.35	-0.34	Cervical cancer;	chr13:40941150	chr13:40908159~40921774:-
LGG	cis	rs11098499	0.863	rs6534139	ENSG00000250412.1	KLHL2P1	-7.88	2.34e-14	8.99e-12	-0.39	-0.34	Corneal astigmatism;	chr4:119528301	chr4:119334329~119378233:+
LGG	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-7.88	2.34e-14	8.99e-12	-0.22	-0.34	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
LGG	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-7.88	2.34e-14	8.99e-12	-0.72	-0.34	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
LGG	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-7.88	2.34e-14	8.99e-12	-0.35	-0.34	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
LGG	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	7.88	2.34e-14	9.01e-12	0.27	0.34	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
LGG	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	7.87	2.35e-14	9.03e-12	0.65	0.34	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
LGG	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	7.87	2.35e-14	9.05e-12	0.42	0.34	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
LGG	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-7.87	2.35e-14	9.05e-12	-0.36	-0.34	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
LGG	cis	rs7208859	0.673	rs1347359	ENSG00000266490.1	CTD-2349P21.9	7.87	2.35e-14	9.05e-12	0.4	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30792372~30792833:+
LGG	cis	rs934734	0.673	rs754110	ENSG00000204929.10	AC074391.1	7.87	2.35e-14	9.06e-12	0.33	0.34	Rheumatoid arthritis;	chr2:65464626	chr2:65436711~66084639:+
LGG	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-7.87	2.36e-14	9.08e-12	-0.46	-0.34	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
LGG	cis	rs2976388	0.647	rs13272904	ENSG00000253741.1	CTD-2292P10.4	-7.87	2.37e-14	9.1e-12	-0.35	-0.34	Urinary tract infection frequency;	chr8:142701196	chr8:142702252~142726973:-
LGG	cis	rs35857674	0.5	rs203626	ENSG00000253484.1	RP11-109P6.2	-7.87	2.37e-14	9.12e-12	-0.34	-0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr8:50104928	chr8:49817586~49820944:-
LGG	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	7.87	2.37e-14	9.13e-12	0.68	0.34	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
LGG	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-7.87	2.38e-14	9.13e-12	-0.43	-0.34	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
LGG	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-7.87	2.38e-14	9.15e-12	-0.37	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
LGG	cis	rs812925	0.784	rs1177304	ENSG00000273302.1	RP11-493E12.2	7.87	2.38e-14	9.15e-12	0.33	0.34	Immature fraction of reticulocytes;	chr2:61161029	chr2:61199979~61200769:+
LGG	cis	rs1555322	0.932	rs6060321	ENSG00000126005.14	MMP24-AS1	-7.87	2.38e-14	9.15e-12	-0.49	-0.34	Attention deficit hyperactivity disorder;	chr20:35245978	chr20:35216462~35278131:-
LGG	cis	rs2282300	0.739	rs1631451	ENSG00000242353.1	RP4-710M3.1	-7.87	2.39e-14	9.18e-12	-0.48	-0.34	Morning vs. evening chronotype;	chr11:30327586	chr11:30368148~30368646:+
LGG	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	7.87	2.39e-14	9.19e-12	0.4	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
LGG	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	7.87	2.39e-14	9.2e-12	0.4	0.34	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
LGG	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	7.87	2.39e-14	9.2e-12	0.4	0.34	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
LGG	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-7.87	2.4e-14	9.21e-12	-0.46	-0.34	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
LGG	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-7.87	2.4e-14	9.22e-12	-0.36	-0.34	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-7.87	2.4e-14	9.22e-12	-0.36	-0.34	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-7.87	2.4e-14	9.22e-12	-0.36	-0.34	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-7.87	2.4e-14	9.22e-12	-0.36	-0.34	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
LGG	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-7.87	2.4e-14	9.22e-12	-0.36	-0.34	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
LGG	cis	rs62103177	0.568	rs2365388	ENSG00000261126.6	RP11-795F19.1	7.87	2.41e-14	9.24e-12	0.42	0.34	Opioid sensitivity;	chr18:80215819	chr18:80046900~80095482:+
LGG	cis	rs2797160	0.935	rs6940748	ENSG00000237742.5	RP11-624M8.1	-7.87	2.42e-14	9.28e-12	-0.31	-0.34	Endometrial cancer;	chr6:125672934	chr6:125578558~125749190:-
LGG	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-7.87	2.43e-14	9.33e-12	-0.44	-0.34	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
LGG	cis	rs2933343	0.553	rs789212	ENSG00000261159.1	RP11-723O4.9	7.87	2.43e-14	9.34e-12	0.32	0.34	IgG glycosylation;	chr3:128968069	chr3:128859716~128860526:-
LGG	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	7.87	2.43e-14	9.34e-12	0.42	0.34	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
LGG	cis	rs2638953	0.962	rs716687	ENSG00000278733.1	RP11-425D17.1	-7.87	2.44e-14	9.38e-12	-0.42	-0.34	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28185625~28186190:-
LGG	cis	rs7709377	0.671	rs1508873	ENSG00000212457.1	RNU6-644P	7.87	2.44e-14	9.39e-12	0.49	0.34	Metabolite levels  (X-11787);	chr5:116157916	chr5:116188455~116188552:-
LGG	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-7.87	2.45e-14	9.39e-12	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
LGG	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-7.87	2.45e-14	9.39e-12	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
LGG	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-7.87	2.45e-14	9.39e-12	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
LGG	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-7.87	2.45e-14	9.39e-12	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
LGG	cis	rs858239	0.636	rs7808488	ENSG00000230042.1	AK3P3	-7.87	2.45e-14	9.4e-12	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23129178~23129841:+
LGG	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-7.87	2.45e-14	9.42e-12	-0.31	-0.34	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
LGG	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-7.87	2.45e-14	9.42e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
LGG	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-7.87	2.45e-14	9.42e-12	-0.45	-0.34	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
LGG	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP1